[{"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-65-74", "title": "Preliminary Results of Induction Bio-Chemotherapy followed by Intensity-modulated Radiotherapy for Advanced Nasopharyngeal Carcinoma", "keywords": "Nasopharyngeal carcinoma;Induction chemotherapy;Cetuximab;Radiotherapy \u9f3b\u54bd\u764c;\u8a98\u5c0e\u5316\u7642;\u723e\u5fc5\u5f97\u8212;\u653e\u5c04\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u665a\u671f\u9f3b\u54bd\u764c\u60a3\u8005\u63a5\u53d7\u8a98\u5c0e\u5316\u7642\u5408\u4f75\u6a19\u9776\u6cbb\u7642\uff0c\u96a8\u5f8c\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u7642\u7684\u7642\u6548\u548c\u6bd2\u6027\u3002\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u9304\u65b0\u8a3a\u65b7\u7684\u7b2c\u4e09\u3001\u56db\u671f\u9f3b\u54bd\u764c\u60a3\u800525\u540d\uff0c\u63a5\u53d7\u8a98\u5c0e\u5316\u7642\u5408\u4f75\u6a19\u9776\u6cbb\u7642\uff0c\u96a8\u5f8c\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u7642\u3002\u8a98\u5c0e\u5316\u7642\u70baP-FL\u4e8c\u85e5\u806f\u5408\u8655\u65b9\uff08\u9806\u9251\u52a05-\u6c1f\u5c3f\u5627\u5576\uff0c17\u4f8b\uff09\u3001\u6216\u4e09\u85e5\u806f\u5408\u8655\u65b9P-FL-G\uff08P-FL\u52a0\u5065\u64c7\uff0c7\u4f8b\uff09\u6216P-FL-D\uff08P-FL\u52a0\u6b50\u6d32\u7d2b\u6749\u9187\uff0c\u4e00\u4f8b\uff09\uff0c\u6bcf\u9031\u4e00\u7a2e\u5316\u85e5\u5171\u7d6610-12\u9031\u3002\u5728\u8a98\u5c0e\u5316\u7642\u671f\u9593\u540c\u6642\u7d66\u723e\u5fc5\u5f97\u8212\uff08Cetuximab\uff09400 mg/m^2\u7b2c1\u5929\uff0c\u7136\u5f8c\u6bcf\u9031\u7d66250 mg/m^2\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u7642\u5291\u91cf\u70ba\u5de8\u89c0\u816b\u7624\u9ad4\u7a4d\u7d66\u4e8870 Gy/35\u5206\u6b21\uff08T1-3\u4e4b\u75c5\u60a3\uff09\uff0c74 Gy/37\u5206\u6b21\u621676.8 Gy/64\u5206\u6b21\uff08\u6bcf\u6b211.2 Gy\uff0c\u4e00\u5929\u7167\u5c04\u4e8c\u6b21\uff0cT4\u816b\u7624\u75c5\u60a3\uff09\u3002\u7d50\u679c\uff1a\u75c5\u4eba\u7684\u4e2d\u4f4d\u6578\u5e74\u9f61\u70ba44\u6b72\uff1b\u7537\u6027/\u5973\u6027= 19/6\uff1b\u75c5\u4eba\u4e00\u822c\u72c0\u6cc1ECOG 0/1=13/12\uff1b\u81e8\u5e8a\u5206\u671f\u7b2c\u4e09/\u56db\u671f= 12/13\uff0c\u75c5\u7406\u985e\u578b\uff08WHO\u5206\u578b\uff09IIa/IIb = 12/13\u3002\u6240\u6709\u60a3\u8005\u5c0d\u8a98\u5c0e\u5316\u7642\u5408\u4f75\u6a19\u9776\u6cbb\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u7b2c3\u7d1a\u6bd2\u6027\u53cd\u61c9\u53ea\u67098.0%\u767d\u8840\u7403\u4f4e\u4e0b\u548c40.0%\u76ae\u75b9\uff0c\u6c92\u6709\u767c\u751f\u7b2c4\u7d1a\u6bd2\u6027\u53cd\u61c9\u3002\u8a98\u5c0e\u5316\u7642\u5408\u4f75\u6a19\u9776\u6cbb\u7642\u5f8c\uff0c\u8a55\u4f30\u7642\u6548\u670952.0%\u5b8c\u5168\u7de9\u89e3\u7387\u548c48.0\uff05\u90e8\u5206\u7de9\u89e3\u7387\u300224\u4f8b\u75c5\u60a3\u65bc\u653e\u5c04\u6cbb\u7642\u524d\uff0c\u63a5\u53d7\u9f3b\u54bd\u816b\u7624\u91cd\u5207\u7247\uff0c\u670913\u540d\uff0854.2%\uff09\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u764c\u7d30\u80de\u3002\u5f8c\u7e8c\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u7642\u4e5f\u9032\u884c\u9806\u5229\uff0c\u7e3d\u6cbb\u7642\u5929\u6578\u4ecb\u65bc45-53\u5929\uff08\u4e2d\u4f4d\u657849\u5929\uff09\u3002\u7d93\u4e2d\u4f4d\u8ffd\u8e6421\u500b\u6708\u5f8c\uff0c\u6709\u56db\u4f8b\u767c\u751f\u9060\u8655\u8f49\u79fb\uff0c\u4e8c\u5e74\u7e3d\u5b58\u6d3b\u7387\u3001\u539f\u767c\u53ca\u9838\u90e8\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u3001\u9060\u8655\u8f49\u79fb\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u5206\u5225\u70ba100%\u3001100%\u3001\u548c80%\u3002\u7d50\u8ad6\uff1a\u8a98\u5c0e\u5316\u7642\u5408\u4f75\u723e\u5fc5\u5f97\u8212\u6a19\u9776\u6cbb\u7642\uff0c\u96a8\u5f8c\u5f37\u5ea6\u8abf\u63a7\u653e\u7642\uff0c\u5c0d\u665a\u671f\u9f3b\u54bd\u764c\u662f\u4e00\u7a2e\u9ad8\u5ea6\u6709\u6548\u4e14\u4f4e\u6bd2\u6027\u7684\u6cbb\u7642\u65b9\u6848\u3002", "e": "Purpose: To investigate the efficacy and toxicity of induction bio-chemotherapy followed by intensity-modulated radiotherapy (IMRT) for advanced nasopharyngeal carcinoma (NPC) patients. Materials and Methods: Twenty-five patients with previously untreated, stage III/IV NPC received induction bio-chemotherapy followed by IMRT. Induction chemotherapy consists of weekly P-FL (cisplatin + 5-fluorouracil) doublet (n= 17) or a triplet of P-FL-G (P-FL + gemcitabine, n= 7) or P-FL-D (P-FL + docetaxel, n= 1) for a total of 10-12 weeks. Cetuximab 400 mg/m^2 day 1, then 250 mg/m^2 were administered every week. IMRT 70 Gy/35 fractions were delivered to T1-3 lesions and 74 Gy/37 fractions or 76.8 Gy/64 fractions to the T4 tumor. Results: Baseline characteristics are median age= 44 year-old; male/female= 19/6; performance status ECOG 0/1= 13/12; stage III/IV= 12/13, and pathological type (WHO) IIa/IIb= 12/13. All patients tolerated induction bio-chemotherapy very well. Grade 3 toxicity included leucopenia (8.0%) and skin rashes (40.0%). There was no grade 4 toxicity. After induction bio-chemotherapy, we obtained 52.0% complete response rate and 48.0% partial response rate. Thirteen of 24 (54.2%) patients who received re-biopsy of the nasopharynx before IMRT were reported as no viable tumor. IMRT was performed smoothly with a median treatment time of 49 days (range 45-53). After a median follow-up of 21 months, we observed 4 treatment failures, all in distant sites. The 2-year rates overall survival, locoregional failure-free and distant failure-free survivals were 100%, 100%, and 80%, respectively. Conclusion: Induction chemotherapy plus concurrent weekly cetuximab followed by IMRT is a highly effective protocol with very low toxicity in advanced NPC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-75-86", "title": "\u65e9\u671f\u5de6\u5074\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u81ea\u5275\u53f3\u5074\u8eba\u59ff\u52e2\u4e4b\u7d93\u9a57\u5206\u4eab", "keywords": "\u81ea\u5275\u53f3\u5074\u8eba\u59ff\u52e2;\u7167\u91ce\u5167\u6700\u5927\u5fc3\u81df\u8ddd\u96e2;\u7167\u91ce\u5167\u6700\u5927\u5fc3\u81df\u9577\u5ea6;\u7167\u91ce\u4e2d\u5fc3\u80ba\u8ddd\u96e2 Homemade immobilization device for right decubitus position;Maximum Heart Distance (MHD);Maximum Heart Length (MHL);Central Lung Distance (CLD)", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u81ea\u5275\u53f3\u5074\u8eba\u59ff\u52e2\u8207\u4e00\u822c\u50b3\u7d71\u6cbb\u7642\u5e73\u8eba\u59ff\u52e2\u4e4b\u5fc3\u81df\u548c\u80ba\u81df\u5291\u91cf\uff0c\u4f86\u8a55\u4f30\u81ea\u5275\u56fa\u5b9a\u88dd\u7f6e\u4e4b\u53f3\u5074\u8eba\u59ff\u52e2\uff0c\u5c0d\u65bc\u65e9\u671f\u5de6\u5074\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u4e4b\u6548\u76ca\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u96c6\u7d50\u4e8c\u5341\u4e00\u4f4d\u548c\u4fe1\u6cbb\u764c\u4e2d\u5fc3\u91ab\u9662\u65e9\u671f\u5de6\u5074\u4e73\u764c\u75c5\u4eba\u7684\u8cc7\u8a0a\u7d50\u679c\uff0c\u4f9d\u64da\u816b\u7624\u5e8a\u7684\u90e8\u4f4d\u5206\u985e\uff0c\u53ef\u5206\u70ba8\u500b\u4e0a\u5167\u5074\uff08UIQ\uff09\u30015\u500b\u4e0a\u5916\u5074\uff08UOQ\uff09\u30014\u500b\u4e2d\u5fc3\u90e8\u4f4d\uff08Center\uff09\u30012\u500b\u4e0b\u5167\u5074\uff08LIQ\uff09\u82072\u500b\u4e0b\u5916\u5074\uff08LOQ\uff09\u3002\u6bcf\u4f4d\u75c5\u4eba\u7686\u6536\u53d6\u53f3\u5074\u8eba\u59ff\u52e2\u8207\u5e73\u8eba\u59ff\u52e2\u4e4b\u5169\u7d44\u5f71\u50cf\u3002\u5c0d\u65bc\u53f3\u5074\u8eba\u59ff\u52e2\uff0c\u4f7f\u7528\u81ea\u88fd\u4e8c\u5341\u5ea6\u50be\u659c\u4e4b\u767c\u6ce1\u5291\u6a21\u5177\uff08alpha cradle\uff09\u53ca\u81ea\u88fd\u8173\u90e8\u56fa\u5b9a\u8a2d\u5099\uff1b\u5c0d\u65bc\u5e73\u8eba\u59ff\u52e2\uff0c\u4f7f\u7528\u4e00\u822c\u6cbb\u7642\u4e4b\u6a21\u5177\uff0c\u75c5\u4eba\u96d9\u624b\u7686\u4e0a\u8209\uff0c\u982d\u8f49\u5411\u975e\u6cbb\u7642\u4e4b\u5c0d\u5074\u65b9\u5411\u3002\u5728\u76f8\u540c\u4e4b\u8a08\u756b\u9776\u9ad4\u7a4d\u5305\u8986\u7a0b\u5ea6\u4e0b\uff0c\u7d93\u7531(1)\u4e73\u623f\u9ad4\u7a4d(2)\u7167\u91ce\u5167\u6700\u5927\u5fc3\u81df\u8ddd\u96e2\uff08MHD\uff09\uff1b(3)\u7167\u91ce\u5167\u6700\u5927\u5fc3\u81df\u9577\u5ea6\uff08MHL\uff09\uff1b(4)\u7167\u91ce\u4e2d\u5fc3\u80ba\u8ddd\u96e2\uff08CLD\uff09\uff1b(5)\u816b\u7624\u5340\u57df\u7b49\u65b9\u9762\uff0c\u63a2\u8a0e\u5fc3\u81df\u5291\u91cf\uff08V_5, V_(10), V_(25)\u53ca\u5e73\u5747\u5291\u91cf\uff09\u8207\u80ba\u90e8\u5291\u91cf\uff08V_5, V_(10), V_(20)\u53ca\u5e73\u5747\u5291\u91cf\uff09\u4e4b\u5dee\u7570\uff0c\u8a55\u4f30\u81ea\u5275\u53f3\u5074\u8eba\u59ff\u52e2\u76f8\u8f03\u65bc\u4e00\u822c\u50b3\u7d71\u5e73\u8eba\u59ff\u52e2\u4e4b\u512a\u7f3a\u9ede\u3002\u7d50\u679c\uff1a\u5fc3\u81df\u5291\u91cf\u8207\u4e73\u623f\u9ad4\u7a4d\u6c92\u6709\u76f8\u95dc\u806f\u6027\uff1b\u4f46\u96a8\u8457\u53f3\u5074\u8eba\u59ff\u52e2\uff0cMHD\u3001MHL\u6e1b\u5c11\uff0c\u5fc3\u81df\u5291\u91cf\u7686\u6709\u6e1b\u5c11\u4e4b\u73fe\u8c61\uff0c\u5e73\u5747\u5291\u91cf\u6700\u5927\u53ef\u6e1b\u5c11\u7d0448.2%\u00b114.0%\u4e4b\u6bd4\u7387\uff0cV_5\u53ef\u6e1b\u5c117.6%\u00b16.0%\uff0cV_(10)\u53ef\u6e1b\u5c114.2%\u00b12.4%\uff0cV_(25)\u53ef\u6e1b\u5c111.9%\u00b11.3%\u3002\u7136\u800c\uff0c\u4e26\u975e\u6240\u6709\u4e4b\u53f3\u5074\u8eba\u59ff\u52e2\u76f8\u8f03\u65bc\u5e73\u8eba\u59ff\u52e2\uff0c\u5176CLD\u503c\u7686\u6703\u6e1b\u5c0f\uff0c\u6545\u53f3\u5074\u8eba\u59ff\u52e2\u80ba\u90e8\u5291\u91cf\u4e0d\u4e00\u5b9a\u6703\u6e1b\u5c11\u3002\u816b\u7624\u5340\u57df\u5728\u4e0b\u5167\u5074\uff08LIQ\uff09\u90e8\u4f4d\uff0c\u96a8\u53f3\u5074\u8eba\u59ff\u52e2\uff0c\u5fc3\u81df\u5e73\u5747\u5291\u91cf\u8207V_5\u3001V_(10)\u3001V_(25)\u90fd\u80fd\u66f4\u6709\u6548\u5730\u6e1b\u5c11\uff1b\u4e0a\u5074\u90e8\u4f4d\uff08UIQ, UOQ\uff09\u5fc3\u81df\u5291\u91cf\u4e4bV_(10)\u3001V_(25)\u8f03\u4f4e\uff1b\u816b\u7624\u5728\u4e2d\u592e\u5340\u57df\u4f4d\u7f6e\uff08Central\uff09\u4e4b\u75c5\u4eba\uff0c\u5176\u53f3\u5074\u8eba\u59ff\u52e2\u80ba\u90e8\u5291\u91cf\u53cd\u800c\u8f03\u5e73\u8eba\u59ff\u52e2\u589e\u52a0\uff0c\u4f46\u589e\u52a0\u5e45\u5ea6\u4e0d\u591a\uff0c\u5e73\u5747\u5291\u91cf\u589e\u52a016.4\u5398\u683c\u96f7\uff08cGy\uff09\uff0c\u9ad4\u7a4d-\u5291\u91cf\u56e0\u5b50\u589e\u52a0\u57281%\u7bc4\u570d\u5167\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u81ea\u88fd\u4e4b\u53f3\u5074\u8eba\u59ff\u52e2\u80fd\u6709\u6548\u964d\u4f4e\u5fc3\u81df\u4e4b\u5291\u91cf\uff0c\u73fe\u4eca\u5df2\u666e\u904d\u4f7f\u7528\u65bc\u548c\u4fe1\u6cbb\u764c\u4e2d\u5fc3\u91ab\u9662\uff0c\u65e9\u671f\u5de6\u5074\u4e73\u764c\u75c5\u4eba\u4e4b\u8853\u5f8c\u5168\u4e73\u653e\u5c04\u6cbb\u7642\u3002", "e": "Purpose: To evaluate the effectiveness of homemade immobilization equipment of right decubitus position for left breast cancer treatment by comparing the heart and lung doses of right decubitus position with those of supine position. Materials and Methods: Twenty-one early-stage left breast cancer patients of Koo Foundation Sun Yat-Sen Cancer Center (KFSYSCC) were collected in this study. Based on the location of the tumor bed, 8 Upper Inner Quadrant (UIQ), 5 Upper Outer Quadrant (UOQ), 4 Central, 2 Lower Inner Quadrant (LIQ) and 2 Lower Outer Quadrant (LOQ) sites were classified. Two sets of CT images (right decubitus and supine position) were acquired. Homemade alpha-cradle with 20 degrees tilt and homemade immobilization device of legs were used for the right decubitus position while the routine treatment position with both arms raised and head turned to the opposite side of treatment side was set for the supine position. Heart dose (V_5, V_(10), V_(25) and mean dose) and lung dose (V_5, V_(10), V_(20) and mean dose) of right decubitus position were compared with those of supine position by using parameters of breast volume, Maximum Heart Distance (MHD), Maximum Heart Length (MHL) and Central Lung Distance (CLD) in the same condition of Planning Target Volume (PTV) coverage. Results: There was no correlation between breast volume and heart dose. Heart dose could be decreased by using right decubitus position because of decreased MHD and MHL. Under this condition, the maximum decreased mean heart dose, V_5, V_(10) and V_(25) were 48.2% \u00b1 14.0%, 7.6% \u00b1 6.0%, 4.2% \u00b1 2.4% and 1.9% \u00b1 1.3%, respectively. CLD was not always decreased in the right decubitus position compared to the supine position. Therefore, lung dose was not always decreased by using the right decubitus position. Heart dose was decreased effectively for tumor in the LIQ. Heart dose for tumor in the UIQ or UOQ was lower than that in other position. For tumor in the Central position, lung dose was a little bit increased by using the right decubitus position. The mean dose of lung was increased 16.4 cGy and the Dose-Volume value was increased within 1%. Conclusion: Heart dose can be decreased effectively by using right decubitus position. Homemade immobilization equipment for right decubitus position is now routinely used for early-stage left breast cancer treatment at KFSYSCC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-87-96", "title": "\u6bd4\u8f03\u5171\u5e73\u9762\u8207\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u6280\u8853\u7528\u65bc\u809d\u9580\u975c\u8108\u8840\u6813\u4e4b\u809d\u764c\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u8a55\u4f30", "keywords": "\u809d\u9580\u975c\u8108\u8840\u6813;\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u6280\u8853 Portal vein thrombosis;Noncoplanar volume modulated arc therapy (Noncoplanar VMAT)", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\uff0c\u4e3b\u8981\u662f\u63a2\u8a0e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff0c\u8207\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff0c\u5728\u6cbb\u7642\u809d\u9580\u975c\u8108\u8840\u6813\u809d\u764c\u75c5\u60a3\u7684\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u5206\u4f48\u4e4b\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u9078\u53d67 \u4f4d\u809d\u9580\u975c\u8108\u8840\u6813\u809d\u764c\u75c5\u60a3\uff0c\u9032\u884c\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\uff0c\u8207\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u88fd\u4f5c\uff0c\u6cbb\u7642\u6b21\u657825\u6b21\uff0c\u91ab\u56d1\u5291\u91cf\u70ba50 Gy\u3002\u6240\u6709\u6cbb\u7642\u8a08\u756b\u4e4b\u5291\u91cf\u8a55\u4f30\u53c3\u6578\uff0c\u4f8b\u5982\uff1a\u5747\u52fb\u5ea6\u6307\u6a19\u53ca\u9806\u5f62\u5ea6\u6307\u6a19\uff0c\u5747\u6b78\u4e00\u5316\u5230100%\u7684\u91ab\u56d1\u5291\u91cf\u53ef\u4ee5\u5305\u898695%\u7684\u6cbb\u7642\u8a08\u756b\u9776\u9ad4\u7a4d\u3002\u5371\u53ca\u5668\u5b98\u5982\u810a\u9ad3\u3001\u814e\u81df\u3001\u5c0f\u8178\u53ca\u6b63\u5e38\u809d\u81df\u7d44\u7e54\u4e4b\u5291\u91cf\uff0c\u5247\u85c9\u7531\u9b4f\u514b\u751f\u7b26\u865f\u7b49\u7d1a\u6aa2\u5b9a\u9032\u884c\u7d71\u8a08\u5206\u6790\u3002\u7d50\u679c\uff1a\u5171\u5e73\u9762\u8207\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b\u5e73\u5747\u9806\u5f62\u5ea6\u6307\u6a19\u5206\u5225\u70ba0.809\u00b10.059\u548c0.847\u00b10.043\uff0c\u800c\u5e73\u5747\u5747\u52fb\u5ea6\u6307\u6a19\u5206\u5225\u70ba1.041\u00b10.007\u548c1.047\u00b10.008\uff0c\u7d71\u8a08\u7d50\u679c\u986f\u793a\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u5728\u9806\u5f62\u5ea6\u6307\u6a19\u53ca\u5747\u52fb\u5ea6\u6307\u6a19\uff0c\u4e26\u7121\u986f\u8457\u4e4b\u5dee\u7570\u3002\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e2d\u810a\u9ad3\u6700\u5927\u5291\u91cf\u503c\u3001\u5de6\u5074\u814e\u81df\u4e4b\u5e73\u5747\u5291\u91cf\u4ee5\u53ca\u6b63\u5e38\u809d\u81df\u7d44\u7e54\u4e4bV_5\u3001V_(10)\u3001V_(20)\u3001V_(30)\u3001V_(40)\u3001V_(50)\u5747\u7565\u4f4e\u65bc\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\uff0c\u4f46\u662f\u7d71\u8a08\u4e0a\u4e26\u7121\u986f\u8457\u4e4b\u5dee\u7570\u3002\u6b63\u5e38\u809d\u81df\u7d44\u7e54\u4e4b\u5e73\u5747\u5291\u91cf\uff0c\u7531\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b17.15\u00b15.00 Gy\u986f\u8457\u964d\u4f4e\u81f3\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b16.01\u00b14.93 Gy\uff08p= 0.018\uff09\u3002\u53f3\u5074\u814e\u81df\u4e4b\u5e73\u5747\u5291\u91cf\uff0c\u7531\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b4.89\u00b13.07 Gy\u986f\u8457\u964d\u4f4e\u81f3\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b3.55\u00b12.30 Gy\uff08p= 0.018\uff09\uff0c\u800c\u53f3\u5074\u814e\u81dfV_(18)\u4e4b\u9ad4\u7a4d\u4ea6\u7531\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b3.57\u00b15.88%\u986f\u8457\u964d\u4f4e\u81f3\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b0.93\u00b12.44%\uff08p= 0.043\uff09\u3002\u7d50\u8ad6\uff1a\u975e\u5171\u5e73\u9762\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u6280\u8853\uff0c\u61c9\u7528\u65bc\u809d\u9580\u975c\u8108\u8840\u6813\u4e4b\u809d\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\u8a08\u756b\u88fd\u4f5c\u6642\uff0c\u5728\u76f8\u540c\u4e4b\u6cbb\u7642\u8a08\u756b\u9776\u9ad4\u7a4d\u4e4b\u5291\u91cf\u5305\u8986\u5ea6\u3001\u5291\u91cf\u5747\u52fb\u5ea6\u4ee5\u53ca\u5291\u91cf\u9806\u5f62\u5ea6\u4e0b\uff0c\u5176\u53ef\u4ee5\u964d\u4f4e\u6b63\u5e38\u809d\u81df\u7d44\u7e54\u4e4b\u5e73\u5747\u5291\u91cf\uff0c\u4ee5\u53ca\u53f3\u5074\u814e\u81df\u4e4b\u5e73\u5747\u5291\u91cf\u53caV_(18)\u4e4b\u9ad4\u7a4d\u3002", "e": "Purpose: To evaluate the dosimetric differences between coplanar and noncoplanar volume modulated arc therapy (VMAT) treatment plans for patients with hepatocellular carcinoma with portal vein tumor thrombosis. Materials and Method: Both coplanar and noncoplanar VMAT plans of seven patients with HCC and PVT were designed with a prescribed dose 50 Gy in 25 fractions. The plan quality indexes, such as dose conformity and dose homogeneity, would be calculate in the same dose coverage of 100% prescribed dose covered 95% PTV. The doses of spinal cord, kidney, small bowel and normal liver (whole liver minus CTV) would be collect and analyzed by Wilcoxon signed-rank test. Results : The average conformity of coplanar and noncoplanar VMAT plans were 0.809 \u00b1 0.059 and 0.847 \u00b1 0.043, and the average homogeneity were 1.041 \u00b1 0.007 and 1.047 \u00b1 0.008. There were no significant difference in both conformity and homogeneity between two plan sets. The maximal dose in spinal cord and small bowel, and mean dose in left side kidney, and V_5, V_(10), V_(20), V_(30), V_(40), V_(50) of normal liver in noncoplanar VMAT plans were slightly lower than that in coplanar plans, but without significant difference. The mean dose of normal liver were significantly decreased from 17.15 \u00b1 5.00 Gy in coplanar VMAT plans to 16.01 \u00b1 4.93 Gy in noncoplanar VMAT plans. (p= 0.018) The mean dose of right side kidney were significantly decreased from 4.89 \u00b1 3.07 Gy in coplanar VMAT plans to 3.55 \u00b1 2.30 Gy in noncoplanar VMAT plans (p= 0.018), and V_(18) of right side kidney were significantly decreased from 3.57 \u00b1 5.88% in coplanar VMAT plans to 0.93 \u00b1 2.44% in noncoplanar VMAT plans (p= 0.043). Conclusions: The noncoplanar VMAT plans used in treatments of HCC patients with PVT may decrease mean dose of normal liver and mean dose and V_(18) of right side kidney in similar PTV dose coverage, homogeneity and conformity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-97-109", "title": "\u4e09\u7a2e\u4e0d\u540c\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u5168\u8166\u53ca\u810a\u9ad3\u7167\u5c04\u8a98\u767c\u4e8c\u6b21\u764c\u75c7\u5371\u96aa\u5ea6\u5206\u6790", "keywords": "\u5168\u8166\u810a\u9ad3\u7167\u5c04;\u5668\u5b98\u7b49\u6548\u5291\u91cf;\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6 Cranio-spinal irradiation;Organ equivalent dose;Excess absolute risk;Secondary cancer risk", "c": "\u7814\u7a76\u76ee\u7684\uff1a\u6bd4\u8f03\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08three dimension conformal radiation therapy, 3D-CRT\uff09\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08intensity modulation radiation therapy, IMRT\uff09\u53ca\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\uff08volumetric-modulated arc therapy, VMAT\uff09\u4e09\u7a2e\u6cbb\u7642\u6280\u8853\u5229\u7528\u5668\u5b98\u7b49\u6548\u5291\u91cf\uff08organ equivalent dose, OED\uff09\u5206\u6790\u5efa\u7acb\u4e8c\u6b21\u764c\u75c7\u7684\u98a8\u96aa\u8a55\u4f30\u6a21\u578b\uff0c\u4ee5\u5f97\u5230\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\uff08Excess absolute risk, EAR\uff09\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9078\u53d62010\u5e743\u6708\u81f32016\u5e742\u6708\u9593\u63a5\u53d7\u5168\u8166\u810a\u9ad3\u7167\u5c04\uff08craniospinal irradiation, CSI\uff09\u6cbb\u7642\u7684\u4e94\u4f4d\u75c5\u60a3\u505a\u70ba\u7814\u7a76\u5c0d\u8c61\u3002\u898f\u52833D-CRT\u3001IMRT\u53caVMAT\u4e09\u7a2e\u4e0d\u540c\u4e4b\u6cbb\u7642\u8a08\u756b\uff0c\u5c07\u6cbb\u7642\u8a08\u756b\u6240\u5f97\u4e4b\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716\uff08dose-volume histogram, DVH\uff09\u8cc7\u6599\u8f38\u51fa\uff0c\u57f7\u884c\u5668\u5b98\u7b49\u6548\u5291\u91cf\uff08OED\uff09\u4e4b\u53c3\u6578\u8a08\u7b97\uff0c\u5efa\u7acb\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\uff08EAR\uff09\u4e4b\u4e09\u7a2e\u6a21\u578b\uff0c\u7528\u4ee5\u8a55\u4f30\u56e0\u653e\u5c04\u6cbb\u7642\u6240\u8a98\u767c\u4e4b\u4e8c\u6b21\u764c\u75c7\u6a5f\u7387\u3002\u7d50\u679c\uff1aVMAT\u8f033D-CRT\u53caIMRT\u986f\u8457\u7684\u6e1b\u5c11\u7279\u5b9a\u5371\u6025\u5668\u5b98\u4e4b\u5e73\u5747\u5291\u91cf\u3002\u5728\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\uff08EAR\uff09\u8a55\u4f30\u7d50\u679c\u4e2d\u986f\u793a\uff0c\u5728\u5168\u8166\u810a\u9ad3\u7167\u5c04\u4e2d\u5f15\u8d77\u5c0f\u8178\uff08small intestine\uff09\u4e8c\u6b21\u764c\u75c7\u4e4b\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\u70ba\u6bcf\u842c\u4eba\u4e2d\u5927\u65bc50\u4eba\uff0c\u5176\u4e2d\u4ee53D-CRT\u4e4b\u6cbb\u7642\u6280\u8853\u8a55\u4f30\u7d50\u679c\u70ba\u6700\u9ad8\uff1b\u80ba\u90e8\uff08Lungs\uff09\u4e8c\u6b21\u764c\u75c7\u4e4b\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\u70ba\u6bcf\u842c\u4eba\u4e2d\u5927\u65bc30\u4eba\uff0c\u4ee5VMAT\u4e4b\u6cbb\u7642\u6280\u8853\u8a55\u4f30\u7d50\u679c\u70ba\u6700\u9ad8\u3002\u5728\u809d\u81df\u53ca\u53e3\u8154\u4e8c\u6b21\u764c\u75c7\u4e4b\u984d\u5916\u7d55\u5c0d\u5371\u96aa\u5ea6\u70ba\u6bcf\u842c\u4eba\u4e2d\u5c0f\u65bc10\u4eba\u4ee5\u5167\uff0c\u6a5f\u7387\u6975\u4f4e\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u70ba\u9996\u7bc7\u91dd\u5c0d\u5168\u8166\u810a\u9ad3\u7167\u5c04\uff08CSI\uff09\u4e09\u7a2e\u4e0d\u540c\u4e4b\u6280\u8853\u9032\u884c\u5291\u91cf\u5b78\u4e4b\u5dee\u7570\u6bd4\u8f03\uff0c\u4e26\u5efa\u7acb\u53f0\u7063\u672c\u5730\u63a5\u53d7CSI\u653e\u5c04\u6cbb\u7642\u60a3\u8005\u4e8c\u6b21\u764c\u75c7\u5371\u96aa\u5ea6\u53c3\u6578\uff0c\u63d0\u4f9b\u81e8\u5e8a\u6cbb\u7642\u898f\u5283\u4e4b\u4e8c\u6b21\u764c\u75c7\u5371\u96aa\u5ea6\u53c3\u8003\u6307\u6a19\u3002", "e": "Purpose: To compare the secondary cancer risk (SCR) in cranio-spinal irradiation for three radiotherapy-planning techniques, namely, three dimension conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT). The SCRmodel was established by usingthe organ equivalent dose (OED) to calculate the value of extra absolute risk (EAR). Materials & Methods: In total five patients were included who underwent cranio-spinal irradiation between March 2010 and February 2016 in our hospital. Three different treatment plans were created including 3D-CRT, IMRT and VMAT. The dose-volume histogram (DVH) obtained was used to calculate OED and SCR. Three SCR models established can be utilized to evaluate secondary cancer risks after cranio-spinal irradiation. Results: The highest EAR value in small intestine was greater than 50 for 3D-CRT; as well as in lung was greater than 30 (per 10,000/per year) for VMAT. However, the EAR values in liver and oral cavity were less than 10 (per 10,000/per year) for the three techniques. Conclusion: This is the first study to establish the EAR parameters and evaluation of SCRs by three radiotherapy-planning techniques in cranio-spinal irradiation in Taiwan. The result can be used as a clinical reference for evaluating secondary malignancy risks after radiation therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-111-120", "title": "\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u8207\u7167\u91ce\u5167\u7167\u91ce\u6280\u8853\u904b\u7528\u65bc\u5168\u8166\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u5206\u4f48", "keywords": "\u5168\u8166\u653e\u5c04\u6cbb\u7642\u6280\u8853;\u7167\u91ce\u5167\u7167\u91ce\u6280\u8853;\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642 Whole brain radiation therapy (WBRT);Field-in-field technique;Volume modulated arc therapy (VMAT)", "c": "\u76ee\u7684\uff1a\u764c\u75c7\u8166\u8f49\u79fb\u75c5\u4eba\u5728\u9032\u884c\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u7642\u6642\uff0c\u50b3\u7d71\u4e0a\u4f7f\u7528\u6cbb\u7642\u6642\u9593\u8f03\u77ed\u8207\u7bc0\u7701\u88fd\u4f5c\u6cbb\u7642\u8a08\u5283\u6642\u9593\u4e4b\u96d9\u5074\u5411\u7167\u91ce\u5c0d\u7167\u4e4b\u6280\u8853\uff08bilateral field, BF\uff09\uff0c\u4f46\u7c21\u55ae\u4e14\u7c97\u7cd9\u7684\u6cbb\u7642\u8a08\u5283\u4e4b\u5291\u91cf\u5747\u52fb\u5ea6\u8207\u5291\u91cf\u9806\u5f62\u5ea6\u5747\u4e0d\u4f73\uff0c\u53ef\u80fd\u589e\u52a0\u6b63\u5e38\u7d44\u7e54\u7684\u526f\u4f5c\u7528\u3002\u7136\u800c\u96a8\u8457\u79d1\u6280\u9032\u6b65\uff0c\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u904b\u7b97\u901f\u5ea6\u52a0\u5feb\u53ca\u7167\u91ce\u5167\u7167\u91ce\u6280\u8853\u6cbb\u7642\uff08field-in-field, FIF\uff09\u8207\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff08volumetric modulated arc therapy, VMAT\uff09\u7b49\u6280\u8853\u7684\u767c\u5c55\uff0c\u61c9\u8a72\u91cd\u65b0\u8003\u616e\u80fd\u589e\u9032\u6cbb\u7642\u54c1\u8cea\u4e4b\u5168\u8166\u7167\u5c04\u6280\u8853\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u91dd\u5c0d\u5341\u4f4d\u75c5\u60a3\u5206\u5225\u88fd\u4f5c\u96d9\u5074\u5411\u7167\u91ce\uff08BF\uff09\u3001\u7167\u91ce\u5167\u7167\u91ce\uff08FIF\uff09\u3001\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff08VMAT\uff09\u7b49\u6cbb\u7642\u8a08\u5283\uff0c\u6240\u6709\u6cbb\u7642\u8a08\u5283\u4e4b\u7e3d\u91ab\u56d1\u5291\u91cf\u5747\u70ba30 Gy\u820712\u5206\u6b21\uff0c\u4e14\u6b78\u4e00\u5316\u81f3\u76f8\u540c\u7684\u816b\u7624\u5305\u8986\u5ea6\u8a08\u7b97\u51fa\u7e3d\u9ad4\u6700\u5927\u5291\u91cf\u503c\u3001\u5291\u91cf\u9806\u5f62\u5ea6\u8207\u5291\u91cf\u5747\u52fb\u5ea6\u3002\u6240\u6709\u5668\u5b98\u5291\u91cf\u5747\u6b78\u4e00\u81f32 Gy\u55ae\u6b21\u5291\u91cf\u4e4b\u751f\u7269\u5291\u91cf\uff0c\u4e26\u4ee5\u7121\u6bcd\u6578\u6aa2\u5b9a\u9032\u884c\u7d71\u8a08\u5206\u6790\u3002\u7d50\u679c\uff1aBF\u3001FIF\u8207VMAT\u6cbb\u7642\u8a08\u756b\u5e73\u5747\u7684\u6700\u5927\u5291\u91cf\u767e\u5206\u6bd4\uff08\u6b78\u4e00\u5316\u81f3\u91ab\u56d1\u5291\u91cf\uff09\u5206\u5225\u70ba113.28% \u00b1 1.62%\u3001108.33% \u00b1 1.16%\u8207110.53% \u00b1 0.25%\uff1b\u5e73\u5747\u7684\u5291\u91cf\u9806\u5f62\u5ea6\u5206\u5225\u70ba0.633 \u00b1 0.033\u30010.664 \u00b1 0.023\u82070.853 \u00b1 0.011\uff0c\u5e73\u5747\u7684\u5291\u91cf\u5747\u52fb\u5ea6\u5206\u5225\u70ba0.552 \u00b1 0.166\u30010.841 \u00b1 0.150\u82070.284 \u00b1 0.086\u3002VMAT\u6cbb\u7642\u8a08\u756b\u6709\u8f03\u4f73\u7684\u5291\u91cf\u9806\u5f62\u5ea6\uff0c\u6240\u4ee5\u986f\u8457\u964d\u4f4e\u9776\u5340\u5916\u5371\u53ca\u5668\u5b98\u5291\u91cf\uff0c\u5982\u9838\u690e\u3001\u8996\u795e\u7d93\u3001\u553e\u6db2\u817a\u3001\u5167\u8033\u8207\u5f8c\u8166\u6753\u76ae\u819a\uff1b\u7136\u800c\u8f03\u5dee\u7684\u5291\u91cf\u5747\u52fb\u5ea6\u4e5f\u4f7f\u5f97\u9776\u5340\u5167\u5371\u53ca\u5668\u5b98\u5291\u91cf\uff08\u5982\u8166\u5e79\u3001\u6d77\u99ac\u56de\u8207\u8996\u4ea4\u53c9\uff09\u6709\u4e9b\u5fae\u63d0\u9ad8\u3002\u7d50\u8ad6\uff1aFIF\u6cbb\u7642\u8a08\u5283\u6709\u6700\u4f4e\u7684\u6700\u5927\u5291\u91cf\u767e\u5206\u6bd4\u53ca\u6700\u4f73\u7684\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u6545FIF\u6cbb\u7642\u8a08\u5283\u53ef\u5b8c\u5168\u53d6\u4ee3BF\u6cbb\u7642\u8a08\u5283\u4ee5\u589e\u9032\u5168\u8166\u7167\u5c04\u6cbb\u7642\u54c1\u8cea\u3002VMAT\u6cbb\u7642\u8a08\u5283\u6709\u6700\u4f73\u7684\u5291\u91cf\u9806\u5f62\u5ea6\u53ef\u964d\u4f4e\u9776\u5340\u5916\u5371\u53ca\u5668\u5b98\u5291\u91cf\uff0c\u5291\u91cf\u5747\u52fb\u5ea6\u7a0d\u5dee\u3002\u7121\u8ad6FIF\u6216VMAT\u6280\u8853\u5747\u53ef\u4f5c\u70ba\u589e\u9032\u8166\u8f49\u79fb\u75c5\u4eba\u751f\u6d3b\u54c1\u8cea\u7684\u6cbb\u7642\u9078\u64c7\u3002", "e": "Purpose: Cancer patients with intracranial metastasis were traditionally treated with bilateral-field (BF) technique for whole brain radiation therapy (WBRT). Planning BF is simple and saves both treatment and planning time. However, the relatively crude method suffers from lack of dose conformity and homogeneity. These two factors may increase the complications of normal tissue and hair loss. However, with current improved techniques, the rapid development of therapeutic planning systems and the development of new treatment technologies such as volume modulated arc therapy (VMAT), and field-in-field (FIF) techniques, the treatment quality of whole brain irradiation should be reconsidered. Materials and Methods: The contours of whole brain PTV and the critical organs of ten patients were determined by one radiation oncologist and checked by another one. Bilateral- fields whole brain treatment plans were created. At the same time, a pair of sub-fields from the BF plans were modified to MLCs to create FIF plans. All BF, FIF and VMAT plans for each patient had a prescribed dose of 30 Gy in 12 fractions. The global maximum dose, dose comformity, and dose homogeneity were calculated to the same level as the tumor coverage. All organ doses were normalized to a single biological equivalent dose of 2 Gy fractions. All data was analyzed with non-parametric statistics. Results: The average maximal doses (normalized to the prescribed dose) of BF, FIF and VMAT plans were 113.28% \u00b1 1.62% (mean \u00b1 std), 108.33% \u00b1 1.16% and 110.53% \u00b1 0.25%. The mean conformity of BF, FIF and VMAT plans were 0.633 \u00b1 0.033, 0.664 \u00b1 0.023 and 0.853 \u00b1 0.011. The mean homogeneity of BF, FIF and VMAT plans were 0.552 \u00b1 0.166, 0.841 \u00b1 0.150 and 0.284 \u00b1 0.086. The VMAT regimen had a better dose conformity and therefore significantly reduced organ damage at the critical organs, such as spinal cord, optic nerve, parotid glands, cochleae, and posterior scalp. However, poor dose homogeneity also compromised organ dose endpoints (such as the brainstem, hippocampus and optic chiasm) with slightly elevated doses. Conclusions: The FIF treatment plan has the lowest percentage of maximum dose and the best dose homogeneity, so the FIF treatment plan could completely replace the BF treatment plan to improve the quality of whole-brain irradiation treatment. The better dose conformity for the VMAT treatment plan reduces organ complications outside the target area with somewhat worse homogeneity. Both FIF or VMAT can be used as a treatment option to improve the quality of life of patients with brain metastases."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-121-128", "title": "\u63a2\u8a0e\u76f4\u7dda\u52a0\u901f\u5668\u5168\u9ad4\u7a4d\u5f27\u5f62\u8abf\u63a7\u6cbb\u7642\u5728\u907f\u6d77\u99ac\u8ff4\u7684\u5168\u8166\u653e\u5c04\u6cbb\u7642\u8a08\u756b", "keywords": "\u8166\u8f49\u79fb;\u907f\u6d77\u99ac\u8ff4\u5168\u8166\u653e\u5c04\u6cbb\u7642\u6280\u8853;\u6cbb\u7642\u8a08\u756b;\u5747\u52fb\u6027\u6307\u6a19;\u9806\u5f62\u6027\u6307\u6a19 Brain metastasis;Hippocampus-sparing whole brain radiotherapy;Treatment plan;Homogeneity index;Conformity index", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u75c5\u4eba\u63a5\u53d7\u907f\u6d77\u99ac\u8ff4\uff08hippocampal-sparing\uff09\u4e4b\u5168\u8166\u653e\u5c04\u6cbb\u7642\uff0c\u6bd4\u8f03\u5171\u5e73\u9762\uff08coplanar\uff09\u8207\u975e\u5171\u5e73\u9762\uff08non-coplanar\uff09\u5169\u7a2e\u6cbb\u7642\u8a08\u5283\uff0c\u6bd4\u8f03\u5169\u7a2e\u8a08\u5283\u4e4b\u5291\u91cf\u5206\u5e03\u7684\u512a\u52a3\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u8490\u96c6\u5728\u5357\u90e8\u67d0\u91ab\u9662\u653e\u5c04\u816b\u7624\u90e8\u9580\u65bc2016\u5e74\u81f32017\u5e74\u9593\uff0c9\u4f4d\u7b26\u5408\u7be9\u9078\u689d\u4ef6\u7684\u8166\u90e8\u8f49\u79fb\u816b\u7624\u75c5\u4eba\uff0c\u63a5\u53d7\u907f\u6d77\u99ac\u8ff4\u4e4b\u5168\u8166\u653e\u5c04\u6cbb\u7642\u3002\u4f7f\u7528\u7684\u653e\u5c04\u6cbb\u7642\u6280\u8853\u70ba\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Volumetric-Modulated Arc Therapy\uff09\uff0c\u9032\u884c\u5169\u7a2e\u4e0d\u540c\u6cbb\u7642\u8a08\u756b\u7684\u5206\u6790\u6bd4\u8f03\u3002\u6bcf\u4f4d\u75c5\u4eba\u7686\u63a5\u53d7\u982d\u90e8\u4fef\u89d2\u70ba30\u5ea6\u6cbb\u7642\u5b9a\u4f4d\uff0c\u7136\u5f8c\u9032\u884c\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u3002\u5229\u7528\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\uff08Philip Pinnacle Planning System, Version 9.2\uff09\uff0c\u6bd4\u8f03\u5171\u5e73\u9762\u8207\u975e\u5171\u5e73\u9762\u5169\u7a2e\u4e0d\u540c\u6cbb\u7642\u8a08\u756b\uff0c\u5728\u5747\u52fb\u6027\u6307\u6a19\uff08homogeneity index\uff09\uff0c\u9806\u5f62\u6027\u6307\u6a19\uff08conformity index\uff09\uff0c\u53ca\u5404\u500b\u5371\u96aa\u5668\u5b98\uff08organs at risk ,OAR\uff09\u7684\u5dee\u7570\u53ca\u512a\u7570\u6027\u3002\u7d50\u679c\uff1a\u6839\u64da\u672c\u7814\u7a76\u7684\u7d50\u679c\u6240\u986f\u793a\uff0c\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u4e0d\u8ad6\u662f\u5728\u8a08\u756b\u9776\u9ad4\u7a4d\uff08planning target volume, PTV\uff09\u6216\u6d77\u99ac\u8ff4\u6240\u63a5\u53d7\u5230\u7684\u5291\u91cf\uff0c\u7686\u7b26\u5408\u7f8e\u570b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u7814\u7a76\u7fa4\uff08Radiation Therapy Oncology Group\uff09\u7b2c0933\u865f\u7684\u5404\u5291\u91cf\u9650\u5236\u503c\u3002\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u5728\u5168\u8166\u7684PTV \u4e2d\u7684\u5747\u52fb\u6027\u53ca\u9806\u5f62\u6027\u6307\u6a19\u7684\u6bd4\u8f03\uff0c\u975e\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u7686\u6bd4\u5171\u5e73\u9762\u8a08\u756b\u66f4\u4f73\uff0c\u9054\u7d71\u8a08\u4e0a\u7686\u6709\u986f\u8457\u7684\u5dee\u7570\uff08p\uff1c 0.05\uff09\u3002\u975e\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u4e2d\u65bc\u5169\u5074\u6d77\u99ac\u8ff4\u4e2d\u592e\u8166\u7d44\u7e54\u4e4bPTV\u7684D_(2%)\u3001D_(98%)\u8207\u5e73\u5747\u5291\u91cf\uff0c\u8f03\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u512a\u7570\uff0c\u9054\u7d71\u8a08\u4e0a\u986f\u8457\u5dee\u7570\uff08p\uff1c 0.05\uff09\u3002\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u5728\u6d77\u99ac\u8ff4\u8207\u907f\u6d77\u99ac\u8ff4\u5340\u6240\u63a5\u53d7\u7684\u6700\u5927\u5291\u91cf\uff0c\u5247\u7121\u986f\u8457\u7684\u5dee\u7570\uff08p\uff1e 0.05\uff09\u3002\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u5c0d\u65bc\u5176\u9918\u7684OAR\uff0c\u5247\u7121\u986f\u8457\u7684\u5dee\u7570\uff08p\uff1e 0.05\uff09\u3002\u5728\u6cbb\u7642\u6642\u9593\u7684\u6bd4\u8f03\uff0c\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u8f03\u975e\u5171\u5e73\u9762\u8a08\u756b\u6240\u9700\u6cbb\u7642\u6642\u9593\u8f03\u77ed\uff0c\u9054\u7d71\u8a08\u986f\u8457\u5dee\u7570\uff08p\uff1c 0.05\uff09\u3002\u7d50\u8ad6\uff1a\u975e\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u6bd4\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u5f97\u5230\u8f03\u4f73\u7684\u6cbb\u7642\u8a08\u756b\u7d50\u679c\u3002\u96d6\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u7686\u53ef\u6709\u6548\u964d\u4f4e\u6d77\u99ac\u8ff4\u7684\u5291\u91cf\u3002\u4f46\u975e\u5171\u5e73\u9762\u6cbb\u7642\u8a08\u756b\u6240\u9700\u7684\u6cbb\u7642\u6642\u9593\u8f03\u9577\uff0c\u53ef\u80fd\u5c0e\u81f4\u75c5\u4eba\u4e0d\u8212\u9069\u6216\u56e0\u6b64\u9020\u6210\u5167\u90e8\u4f4d\u79fb\u8207\u64fa\u4f4d\u8aa4\u5dee\uff0c\u5247\u662f\u9700\u9032\u4e00\u6b65\u9700\u8981\u63a2\u8a0e\u7684\u81e8\u5e8a\u8ab2\u984c\u3002", "e": "Purpose: To Investigate the coplanar and non-coplanar treatment plan in hippocampal-sparing whole brain radiotherapy. Materials and Methods: In this study, we enrolled nine indicated patients with brain metastasis to receive hippocampal-sparing whole brain radiotherapy in regional hospital in Southern Taiwan from 2016 to 2017. We conducted to compare two different treatment plans using the technique of volumetric modulated arc therapy. All patients were fixed with head mask and set up a head flexion angle of 30\u00b0, and then received computed tomography simulation. We analyzed the coplanar and non-coplanar treatment plan using therapy planning system (Philip Pinnacle Planning System Version 9.2). Dose constraints were set equally to compare homogeneity index and conformity index of the planning target volume (PTV), and organs at risk (OAR), including the hippocampus, eyes, lens, and optic nerves. Results: The results show two treatment plan all conform the dose-limited guideline of Radiotherapy Therapy Oncology Group 0933. The homogeneity and conformal index of two treatment plans, non-coplanar plan is better than coplanar plan (p\uff1c0.05). The dose distribution of D_(2%), D_(98%), and D_(mean) of PTV between bilateral hippocampus, non-coplanar plan is more homogenous than coplanar counterpart and achieve statistical significance (p\uff1c 0.05). The dose of two plans in both hippocampus and hippocampus avoidance region is similar (p\uff1e 0.05). Other OAR in both two plans was also similar (p\uff1e 0.05). However, treatment time of the coplanar plan can be significantly shorter than the non-coplanar plan (p\uff1c 0.05). Conclusions: Our study concluded the non-coplanar plan is better than the coplanar plan. However, longer therapy time is needed in non-coplanar plan. Whether the longer therapy time might lead to patient's discomfort, then result to internal shift and set-up error. Ongoing study need to be further explored clinically."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-129-137", "title": "\u63a2\u8a0e\u87ba\u65cb\u65b7\u5c64\u52a0\u901f\u5668\uff08helical TomoTherapy\u00ae\uff09\u5728\u653e\u5c04\u6cbb\u7642\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u56e0\u7d20", "keywords": "\u64fa\u4f4d\u8aa4\u5dee;\u8a08\u756b\u9776\u9ad4\u7a4d;\u5b89\u5168\u908a\u7de3;\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u87ba\u65cb\u65b7\u5c64\u52a0\u901f\u5668 Setup error;Planning target volume;Safety margin;Image-guided radiotherapy;Helical TomoTherapy\u00ae", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u87ba\u65cb\u65b7\u5c64\u52a0\u901f\u5668\u653e\u5c04\u6cbb\u7642\uff0c\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u7684\u6cbb\u7642\u76f8\u95dc\u56e0\u7d20\u3002\u5728\u81e8\u5e8a\u6cbb\u7642\u56e0\u64fa\u4f4d\u8aa4\u5dee\uff0c\u4e26\u5efa\u8b70\u8a08\u756b\u9776\u9ad4\u7a4d\uff08planning target volume, PTV\uff09\u6240\u9700\u589e\u52a0\u4e4b\u5b89\u5168\u908a\u7de3\u503c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6587\u737b\u6307\u51fa\u53ef\u80fd\u5f71\u97ff\u75c5\u4eba\u6cbb\u7642\u64fa\u4f4d\u8aa4\u5dee\u7684\u76f8\u95dc\u56e0\u7d20\uff0c\u5305\u62ec\u7cfb\u7d71\u8aa4\u5dee\uff08\u03a3\uff09\u548c\u96a8\u6a5f\u8aa4\u5dee\uff08\u03c3\uff09\u3002\u5f71\u97ff\u03c3\u7684\u56e0\u7d20\uff0c\u5305\u62ec\u75c5\u4eba\u5e74\u9f61\uff0c\u6027\u5225\uff0c\u816b\u7624\u4f4d\u7f6e\uff0c\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08body mass index, BMI\uff09\uff0c\u9ad4\u91cd\u6e1b\u8f15\uff0c\u816b\u7624\u5206\u671f\uff0c\u53ca\u816b\u7624\u8f49\u79fb\u7b49\u56e0\u7d20\u3002\u672c\u7814\u7a76\u6536\u96c6\u53f0\u7063\u5357\u90e8\u67d0\u5340\u57df\u91ab\u9662\u653e\u5c04\u6cbb\u7642\u90e8\u95802013\u81f32016\u5e74\uff0c\u5171138\u4f4d\u764c\u75c7\u75c5\u4eba\u63a5\u53d7\u87ba\u65cb\u65b7\u5c64\u52a0\u901f\u5668\u6cbb\u7642\u3002\u6cbb\u7642\u524d\u4ee5\u767e\u842c\u4f0f\u7279\uff08megavoltage\uff09\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u5b9a\u4f4d\uff0c\u57f7\u884c\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff08image-guided radiation therapy, IGRT\uff09\u3002\u7e3d\u5171\u6536\u96c6\u6cbb\u7642\u671f\u9593\u5404\u5206\u6b21\u6cbb\u76424081\u7d44\u5f71\u50cf\u9032\u884c\u64fa\u4f4d\u8aa4\u5dee\u5206\u6790\u3002\u8a08\u7b97\u6bcf\u4f4d\u75c5\u4eba\u6cbb\u7642\u671f\u9593X, Y, Z\u4e09\u8ef8\u4f4d\u79fb\uff0c\u4e09\u7dad\u7a7a\u9593\uff083D\uff09\u5411\u91cf\uff0c\u53caY\u8ef8\uff08roll\uff09\u65cb\u8f49\u7684\u64fa\u4f4d\u8aa4\u5dee\u5e73\u5747\u503c\uff0c\u53ca\u6a19\u6e96\u5dee\u3002\u5229\u7528\u6587\u737b\u516c\u5f0f\u8a08\u7b97\u5f97\u51fa\u03a3\u548c\u03c3\u6578\u503c\u3002\u5206\u6790\u5f71\u97ff\u75c5\u4eba\u6cbb\u7642X, Y, Z\u4e09\u8ef8\uff0c3D\u5411\u91cf\uff0c\u53caroll\u65cb\u8f49\u7684\u64fa\u4f4d\u8aa4\u5dee\u7684\u56e0\u7d20\u3002\u53c3\u8003van Herk\u5b78\u8005\u63d0\u51fa\u516c\u5f0f\uff082.5\u03a3+0.7\u03c3\uff09\u6f14\u7b97\uff0c\u5f97\u51fa\u65bc\u81e8\u5e8a\u6cbb\u7642PTV\u6240\u9700\u5efa\u8b70\u589e\u52a0\u5b89\u5168\u908a\u7de3\u503c\u3002\u7d50\u679c\uff1a\u7814\u7a76\u6cbb\u7642\u671f\u9593\u5f71\u97ffX\uff0cY\uff0cZ\u4e09\u8ef8\uff0c3D\u5411\u91cf\uff0c\u53caroll\u65cb\u8f49\u7684\u64fa\u4f4d\u8aa4\u5dee\u5e73\u5747\u4f4d\u79fb\u503c\uff0c\u767c\u73fe\u8207\u75c5\u4eba\u5e74\u9f61\uff08p= 0.05\uff09\uff0c\u816b\u7624\u4f4d\u7f6e\uff08p\uff1c 0.001\uff09\uff0c\u53caBMI\uff08p\uff1c 0.001\uff09\uff0c\u9054\u7d71\u8a08\u986f\u8457\u5dee\u7570\u6027\u3002\u55ae\u8b8a\u9805\u8ff4\u6b78\u5206\u6790\u5f71\u97ff3D\u5411\u91cf\u64fa\u4f4d\u8aa4\u5dee\u7684\u56e0\u7d20\uff0c\u767c\u73fe\u816b\u7624\u4f4d\u7f6e\uff0c\u9ad4\u91cd\u6e1b\u8f15\uff0c\u816b\u7624\u671f\u5225\uff0c\u9054\u7d71\u8a08\u986f\u8457\u5dee\u7570\u6027\u3002\u53e6\u55ae\u8b8a\u9805\u8ff4\u6b78\u5206\u6790\u5f71\u97ffroll\u65cb\u8f49\u7684\u64fa\u4f4d\u8aa4\u5dee\u7684\u56e0\u7d20\uff0c\u986f\u793a\u53ea\u6709\u816b\u7624\u4f4d\u7f6e\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u56e0\u7d20\uff0c\u9054\u7d71\u8a08\u986f\u8457\u5dee\u7570\u6027\u3002\u7d93\u591a\u8b8a\u9805\u8ff4\u6b78\u9010\u6b65\u7be9\u9078\u5206\u6790\uff0c\u767c\u73fe\u53ea\u6709\u816b\u7624\u4f4d\u7f6e\u9054\u7d71\u8a08\u986f\u8457\u5dee\u7570\u6027\uff08p\uff1c0.001\uff09\u3002\u7d93\u8a08\u7b97PTV\u6240\u9700\u5efa\u8b70\u589e\u52a0X\uff0cY\uff0cZ\u4e09\u8ef8\u5b89\u5168\u908a\u7de3\u503c\uff0c\u5728\u80f8\u90e8\uff0c\u8179\u90e8\uff0c\u9aa8\u76c6\u90e8\u548c\u524d\u5217\u817a\u816b\u7624\u9700\u89815-11 mm\uff0c\u800c70-89\u6b72\u5e74\u9f61\u5c64\u53caBMI \u226525\u5b89\u5168\u908a\u7de3\u5efa\u8b70\u503c\u5206\u5225\u70ba6-8 mm\u53ca5-6 mm\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u767c\u73fe\u87ba\u65cb\u65b7\u5c64\u52a0\u901f\u5668\u6cbb\u7642\u671f\u9593\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u7684\u91cd\u8981\u56e0\u7d20\u70ba\u75c5\u4eba\u5e74\u9f61\u3001\u816b\u7624\u4f4d\u7f6e\u53caBMI\u3002PTV\u5b89\u5168\u908a\u7de3\u5efa\u8b70\u503c\uff0c\u9700\u91dd\u5c0d\u9019\u4e9b\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u56e0\u7d20\uff0c\u6709\u4e0d\u540c\u7684\u6cbb\u7642\u5b89\u5168\u908a\u7de3\u5efa\u8b70\u503c\u3002\u63d0\u4f9b\u505a\u70ba\u87ba\u65cb\u65b7\u5c64\u6cbb\u7642\u5668\u7684\u81e8\u5e8a\u6cbb\u7642\u7684\u53c3\u8003\u3002", "e": "Objective: We investigate treatment-related factors to affect setup errors during the course in radiotherapy using helical TomoTherapy\u00ae and recommend required safety margins for planning target volume (PTV) clinically. Materials and Methods: The literature indicates that may affect setup errors including systematic error (\u03a3) and random error (\u03c3). The factors to impact \u03c3 in radiotherapy may be caused by age of patient, gender, tumor site, body mass index (BMI), weight loss, cancer stage, and the status whether metastasis. In the study, we collected a total of 138 patients who received helical TomoTherapy\u00ae from 2013 to 2016 at a regional hospital in southern Taiwan. All patients received megavoltage computed tomography for daily therapy position checkup. A total of 4081 sets of images were collected for analysis of setup error. We calculate means, standard deviations of daily setup error of each patient in three axis directions (X, Y, Z-axis), three dimensional (3D) vector, and Y-axis (roll) rotation during the treatment. Then \u03a3 and \u03c3 are derived from adopted equations in the literature. In the study we analyzed which to factors to influence setup error during treatment. The formula (2.5\u03a3+0.7\u03c3) by the author van Herk et al. is proposed to recommend safety margin of PTV clinically. Results: The factors significantly affect daily setup error in X, Y, Z-axis, 3D vector, and Y-axis (roll) rotation were in groups of patient\u2019s age (p= 0.05), tumor sites (p\uff1c 0.001), and BMI (p\uff1c 0.001). Single regression analysis in factors to affect 3D vector setup error, we found tumor sites, weight loss, and tumor stage to achieve statistical significance. Another single regression analysis in factors to affect Y-axis (roll) rotation setup error, we disclosed only tumor site to achieve statistical significance. After multiple regression model, we concluded tumor site is the only factor to influence setup error significantly (p\uff1c 0.001). In the study, we recommended wider safety margins of PTV are 5-11 mm in X, Y, Z- axes in chest, abdomen, pelvis, and prostate tumors. The safety margins are 5-8 mm and 5-6 mm in the age group of 70-89 and the BMI \u226525 respectively. Conclusion: The important factors to affect setup error are age of patient, tumor site, and BMI. In this study, we recommend the safety margin in PTV should be individualized based on these setup error factors in the clinical practice of helical TomoTherapy\u00ae."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-139-150", "title": "Comparison of the gross target volume of lung cancer based on three dimensional CT and four dimensional CT in stereotactic body radiation therapy", "keywords": "Stereotactic body radiation therapy (SBRT);Four-dimensional computed tomography (4DCT);Lung cancer \u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u6cbb\u7642;\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u5f71\u50cf;\u80ba\u764c", "c": "\u76ee\u7684\uff1a\u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u6cbb\u7642\u662f\u4e00\u7a2e\u5ee3\u6cdb\u61c9\u7528\u5728\u5c40\u90e8\u80ba\u816b\u7624\u7684\u6cbb\u7642\u6280\u8853\uff0c\u800c\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u53ef\u63d0\u4f9b\u80ba\u816b\u7624\u5728\u75c5\u4eba\u9ad4\u5167\u96a8\u547c\u5438\u79fb\u52d5\u7684\u6709\u6548\u5de5\u5177\u3002\u672c\u7814\u7a76\u76ee\u7684\u65e8\u5728\u5206\u6790\u672c\u9662\u5229\u7528\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u5728\u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u6cbb\u7642\u53ef\u63d0\u4f9b\u7684\u6709\u6548\u8cc7\u8a0a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6db5\u84cb\u81ea2008\u5e749\u6708\u81f32016\u5e743\u6708\u5728\u672c\u9662\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u7dda\u6cbb\u7642\u768440\u4f4d\u539f\u767c\u6027\u6216\u8f49\u79fb\u80ba\u816b\u7624\u75c5\u4eba\u3002\u6240\u6709\u75c5\u4eba\u7686\u6709\u57f7\u884c\u4e09\u7dad\u53ca\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u4e26\u7531\u5176\u4e2d\u5f71\u50cf\u7522\u751f\u5169\u7a2eGTV\uff08GTV_(3D)\u8207GTV_(4D)\uff09\u3002\u7d00\u9304\u4e26\u6bd4\u8f03\u500b\u5225GTV\u4e4b\u9ad4\u7a4d\u3001\u5ea7\u6a19\u8207\u5176\u4ed6\u816b\u7624\u9776\u9ad4\u7a4d\u5206\u6790\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u4ee5\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u5206\u6790\u53ef\u77e5\u816b\u7624\u79fb\u52d5\u5e45\u5ea6\u4ee5\u75c5\u4eba\u982d\u8173\u65b9\u5411\u6700\u70ba\u986f\u8457\uff0c\u5e73\u5747\u79fb\u52d5\u7d50\u679c\u5728\u75c5\u4eba\u524d\u5f8c\u3001\u5de6\u53f3\u53ca\u982d\u8173\u65b9\u5411\u5206\u5225\u70ba0.24 cm\uff08median 0.20 cm, range 0-0.90 cm\uff09\u30010.15cm\uff08median 0.10 cm, range 0-0.40 cm\uff09\u53ca0.65 cm\uff08median 0.40 cm, range 0.10-2.70 cm\uff09\u3002\u5206\u6790\u79fb\u52d5\u5e45\u5ea6\u8207\u816b\u7624\u4f4d\u7f6e\u95dc\u4fc2\u767c\u73fe\uff0c\u5176\u500b\u5225\u5e73\u5747\u79fb\u52d5\u5411\u91cf\u5728\u4e0a\u3001\u4e2d\u8207\u4e0b\u80ba\u8449\u5206\u5225\u70ba0.44\u00b10.21 cm, 0.73\u00b10.45 cm\u82071.35\u00b10.81 cm\u3002\u7d50\u679c\u986f\u793a\u4f4d\u65bc\u4e0b\u80ba\u8449\u816b\u7624\u5177\u6709\u6700\u5927\u79fb\u52d5\u5e45\u5ea6\uff0c\u4e26\u4e14\u5728\u982d\u8173\u65b9\u5411\u6700\u70ba\u986f\u8457\u3002MI\u8207DI\u6578\u503c\u5728\u4e0b\u80ba\u8449\u816b\u7624\u660e\u986f\u5927\u65bc\u4e2d\u4e0a\u80ba\u8449\u816b\u7624\u3002\u800c\u5206\u6790\u500b\u5225\u79fb\u52d5\u9810\u6e2c\u56e0\u5b50\u767c\u73fe\uff0c\u79fb\u52d5\u5e45\u5ea6\u50c5\u8207\u816b\u7624\u5728\u80ba\u8449\u4f4d\u7f6e\u5177\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u986f\u8457\u76f8\u95dc\u6027\u3002\u7d50\u8ad6\uff1a\u547c\u5438\u5f15\u8d77\u7684\u816b\u7624\u4f4d\u79fb\u5728\u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u662f\u6975\u70ba\u91cd\u8981\u7684\u8003\u91cf\u3002\u5229\u7528\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u53ef\u63d0\u4f9b\u6709\u6548\u7684\u81e8\u5e8a\u8a08\u756b\u9776\u9ad4\u7a4d\u53c3\u8003\u8cc7\u8a0a\u3002\u6839\u64daAAPM Task Group 76\u5831\u544a\u5efa\u8b70\u5c0d\u7167\u672c\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u547c\u5438\u8abf\u63a7\u6280\u8853\u5c0d\u65bc\u4e2d\u4e0b\u80ba\u8449\u816b\u7624\u6709\u5176\u5fc5\u8981\u6027\u3002\u4e14\u816b\u7624\u5728\u9ad4\u5167\u4f4d\u79fb\u70ba\u975e\u5747\u5411\u6027\uff08anisotropic\uff09\uff0c\u982d\u8173\u65b9\u5411\u7684\u4f4d\u79fb\u91cf\u986f\u7136\u5927\u65bc\u5176\u4ed6\u5169\u500b\u65b9\u5411\u3002\u4f4d\u65bc\u4e0b\u80ba\u8449\u7684\u816b\u7624\u7279\u5225\u662f\u8207\u6a6b\u8188\u819c\u76f8\u9023\u8005\uff0c\u5176\u79fb\u52d5\u5e45\u5ea6\u660e\u986f\u5927\u65bc\u4e2d\u4e0a\u80ba\u8449\u816b\u7624\u3002\u56e0\u6b64\u5c0d\u65bc\u8003\u91cf\u75c5\u4eba\u9ad4\u5167\u4f4d\u79fb\u5c0d\u816b\u7624\u4f4d\u7f6e\u5f71\u97ff\u6642\uff0c\u52a0\u4e0a\u975e\u5747\u5411\u6027\u7684\u75c5\u4eba\u9ad4\u5167\u4f4d\u79fb\u7bc4\u570d\u624d\u80fd\u6b63\u78ba\u5c07\u5291\u91cf\u96c6\u4e2d\u5728\u816b\u7624\u4e26\u6e1b\u5c11\u6b63\u5e38\u7d44\u7e54\u63a5\u53d7\u5230\u7684\u5291\u91cf\u3002\u7279\u5225\u662f\u5c0d\u65bc\u63a5\u53d7\u9ad8\u5291\u91cf\u4f4e\u5206\u6b21\u7684\u7acb\u9ad4\u5b9a\u4f4d\u8ec0\u9ad4\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u800c\u8a00\uff0c\u53ef\u6709\u6548\u8a55\u4f30\u816b\u7624\u79fb\u52d5\u76844DCT\u662f\u5fc5\u8981\u7684\u5de5\u5177\u3002", "e": "Purpose: Stereotactic body radiation therapy (SBRT) is widely used as therapy for localized lung cancer or metastases. Four-dimensional computed tomography (4DCT) is the most common technique used to estimate the internal motion of lung cancer tumors. The purpose of this study was to observe tumor motion with 4DCT image in SBRT patients. Materials and Methods: This study was a retrospective analysis. From September 2008 to March 2016; forty patients with proven pathology for lung cancer or pulmonary metastasis, treated with stereotactic body radiotherapy were included in this study. All patients underwent three dimensional (3D) and four dimensional (4D) CT scans. GTV_(3D) and GTV_(4D) were created from 3D and 4DCT scanning, respectively. The volume, position and other tumor parameters, included matching index (MI) and degree of inclusion (DI) between GTV_(3D) and GTV_(4D) were also compared in this study. Results: The tumor motion measured by comparison of different 4DCT phases was highest for the CC direction (mean 0.65 cm, median 0.40 cm, range 0.10 - 2.70 cm). The next highest was for the AP direction (mean 0.24 cm, median 0.20 mm, range 0 - 0.90 cm) then the LR direction (mean 0.15 cm, median 0.10 cm, range 0 - 0.40 cm). The mean motion vector was 0.44 \u00b1 0.21 cm, 0.73 \u00b1 0.45 cm and 1.35 \u00b1 0.81 cm in upper, middle and lower lobes, respectively. This shows that tumors located in the lower lobe of the lung exhibited the greatest amount of motion, and the magnitude was usually greatest along the CC axis. The MI and DI in the lower lobe was significantly different from the upper and middle lobes (p \uff1c 0.05). No clinical or anatomic factors were identified as being related to the magnitude of the tumor excursion, except for lobe location (p= 0.005). Conclusion: Respiration induced tumor motion is an important issue in high precision SBRT. Using 4DCT information can greatly improve the target definition for lung cancer. The respiratory management technique is necessary for middle and lower lung lobes tumors in our study according to The AAPM Task Group 76 report [11]. The tumor motion in all patients was anisotropic, the amplitude was significantly larger in the CC direction than in AP and LR directions. To avoid the target missing and reduce the normal tissue irradiated. The anisotropic margins of ITV were more appropriate than isotropic margin in lung tumor. The tumor movement in lower lobe tumors is obviously greater than in the upper and middle lobes, especially where tumors are adhered to the chest wall and diaphragm. The greater margin in the CC direction especially for lower lobe tumors should be added. To account the internal motions which arise from breathing, the 4DCT is necessary for lung tumor especially in SBRT patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201806-201808270001-201808270001-151-159", "title": "Outcomes of Stereotactic Ablative Radiotherapy in the Treatment of Sarcoma Pulmonary Metastases: Case Reports", "keywords": "Sarcoma;Pulmonary metastasis;Stereotactic ablative radiotherapy;Treatment response \u60e1\u6027\u8089\u7624;\u80ba\u8f49\u79fb;\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642;\u6cbb\u7642\u53cd\u61c9", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u70ba\u63a2\u8a0e\u96fb\u8166\u5200\u9032\u884c\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\uff0c\u7528\u65bc\u60e1\u6027\u8089\u7624\u80ba\u8f49\u79fb\u7684\u6cbb\u7642\u53cd\u61c9\u53ca\u526f\u4f5c\u7528\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u91dd\u5c0d\u60e1\u6027\u8089\u7624\u60a3\u8005\uff0c\u5206\u6790\u80ba\u90e8\u7684\u8f49\u79fb\u75c5\u7076\u81f3\u672c\u79d1\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u7684\u6548\u679c\u3002\u816b\u7624\u7684\u6cbb\u7642\u53cd\u61c9\u900f\u904e\u8ffd\u8e64\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff0c\u4ee52009\u5e74\u7684RECIST\u6e96\u5247\u9032\u884c\u8a55\u4f30\u3002\u6bd2\u526f\u4f5c\u7528\u5247\u900f\u904e\u5b9a\u671f\u7684\u9580\u8a3a\uff0c\u4ee5\u75c5\u53f2\u8a62\u554f\u548c\u8eab\u9ad4\u6aa2\u67e5\u7684\u65b9\u5f0f\u8ffd\u8e64\uff0c\u4e26\u6839\u64daRTOG\u653e\u5c04\u50b7\u5bb3\u7b49\u7d1a\u6a19\u6e96\u9032\u884c\u8a18\u9304\u3002\u5404\u500b\u75c5\u4eba\u8ffd\u8e64\u7684\u6642\u9593\u7d04\u4e00\u5230\u4e09\u5e74\u3002\u7d50\u679c\uff1a\u4e09\u4f4d\u75c5\u4eba\u7e3d\u5171\u6709\u4e03\u500b\u80ba\u90e8\u8f49\u79fb\u75c5\u7076\u3002\u5728\u9032\u884c\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u4e09\u500b\u6708\uff0c\u5176\u4e2d\u4e00\u500b\u75c5\u7076\u5b8c\u5168\u6d88\u5931\uff08complete response\uff09\uff0c\u4e00\u500b\u75c5\u7076\u90e8\u5206\u7e2e\u5c0f\uff08partial response\uff09\u3002\u53e6\u5916\u56db\u500b\u75c5\u7076\u7dad\u6301\u7a69\u5b9a\u7684\u72c0\u614b\uff08no change\uff09\u3002\u53ea\u6709\u4e00\u500b\u75c5\u7076\u60e1\u5316\uff08progressive disease\uff09\u3002\u6b64\u5916\u5728\u672c\u7814\u7a76\u671f\u9593\uff0c\u6c92\u6709\u89c0\u5bdf\u5230\u4efb\u4f55\u6bd2\u6027\u526f\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u4e0d\u9069\u5408\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\uff0c\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u80ba\u90e8\u8f49\u79fb\u7684\u60e1\u6027\u8089\u7624\uff0c\u662f\u4e00\u500b\u53ef\u4ee5\u8003\u616e\u7684\u66ff\u4ee3\u65b9\u6848\u3002", "e": "Introduction: Based on recently published studies, surgical resection of pulmonary metastatic nodules may improve the prognosis for sarcoma patients. Here, we try to report the safety and efficacy of stereotactic ablative radiotherapy (SABR) as a local treatment for pulmonary metastatic sarcoma. Case report: The present report demonstrated sarcoma patients who were treated for pulmonary metastatic lesions using the CyberKnife\u00ae radiosurgery system. There were a total of three patients with seven lesions. In the first 3 months post SABR, one lesion was complete response, another was partial response, 4 lesions was stable disease and only 1 lesion was progressive disease. Overall survival for each patient was 11, 19 and 35 months from lung metastasis diagnosis, respectively. No high grade toxicity was observed at the time of analysis. Discussion: The present report demonstrated that SABR may be an acceptable alternative option for pulmonary metastatic sarcoma in patients in whom surgery is contraindicated. However, more patients are required for statistical analysis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-1-12", "title": "PRETREATMENT LYMPHOCYTE COUNT AS PROGNOSTIC FACTOR IN PATIENTS WITH HEAD-AND-NECK CANCER", "keywords": "Head-and-neck cancer;Prognosis;Lymphocyte count;Radiotherapy \u982d\u9838\u764c;\u9810\u5f8c;\u6dcb\u5df4\u7403;\u653e\u5c04\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4e3b\u8981\u63a2\u8a0e\u6cbb\u7642\u524d\u6dcb\u5df4\u7684\u6578\u91cf\u662f\u5426\u6703\u5f71\u97ff\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u5c04\u6cbb\u7642\u7684\u982d\u9838\u764c\u60a3\u8005\u9810\u5f8c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u56de\u6eaf\u6536\u9304610\u4f4d\u65bc\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u63a5\u53d7\u904e\u6839\u6cbb\u6027\u653e\u7642\u4e4b\u982d\u9838\u764c\u75c5\u60a3\u3002\u6574\u9ad4\u8ffd\u8e64\u7684\u4e2d\u4f4d\u6642\u9593\u9577\u5ea6\u70ba5.13\u5e74\u3002\u6839\u64da\u7642\u7a0b\u524d\u6dcb\u5df4\u7403\u6578\u91cf\u7684\u591a\u5be1\uff08\uff1c 1,885 cells/\u03bcL vs. \u2265 1,885 cells/\u03bcL\uff09\u5206\u7fa4\u5f8c\uff0c\u9032\u884c\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u63a7\u5236\u7387\u3001\u5340\u57df\u63a7\u5236\u7387\u53ca\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u7684\u5206\u6790\u3002\u7d50\u679c\uff1a\u6cbb\u7642\u524d\u7684\u6dcb\u5df4\u7403\u6578\u91cf\u7684\u4e2d\u4f4d\u6578\u70ba 1,885 cells/\u03bcL\uff08\u7bc4\u570d\uff1a285-5341\uff09\u3002\u76f8\u5c0d\u65bc\u6cbb\u7642\u524d\u6709\u8f03\u5c11\u6dcb\u5df4\u7403\u7684\u7fa4\u9ad4\uff0c\u8f03\u591a\u6dcb\u5df4\u7403\u7684\u65cf\u7fa4\u6709\u986f\u8457\u8f03\u9ad8\u7684\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08BMI\uff09\u3001\u8f03\u9ad8\u6bd4\u7387\u5438\u7159\u53ca\u559d\u9152\u8005\u3002\u5728\u7d93\u904e\u591a\u8b8a\u91cf\u5206\u6790\u5f8c\uff0c\u6cbb\u7642\u524d\u6709\u8f03\u591a\u6dcb\u5df4\u7403\u7684\u7fa4\u9ad4\u6bd4\u8d77\u8f03\u5c11\u7684\u4e00\u65b9\uff0c\u5728\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u4e0a\u6709\u7d71\u8a08\u5b78\u4e0a\u986f\u8457\u8f03\u4f73\u7684\u8868\u73fe\u3002\u5728\u5c40\u90e8\u53ca\u5340\u57df\u816b\u7624\u63a7\u5236\u7387\u4e0a\uff0c\u5247\u7121\u89c0\u5bdf\u5230\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u89c0\u5bdf\u5230\u5728\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u7642\u7684\u982d\u9838\u764c\u60a3\u8005\uff0c\u6cbb\u7642\u524d\u6709\u8f03\u591a\u6dcb\u5df4\u7403\u80fd\u6709\u8f03\u4f73\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387", "e": "Purpose: The aim of this study was to investigate the relationship between the pretreatment lymphocyte count (preT LC) and clinical outcomes in patients with head-and-neck cancer treated with chemoradiation (CRT) or radiotherapy (RT) Materials and Methods: All 610 patients with newly diagnosed head-and-neck cancer who were treated by CCRT or RT were retrospectively reviewed. The median follow-up duration was 5.13 years. Overall survival (OS), local recurrence-free survival (LFS), regional recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were analyzed by preT LC, with a cutoff of 1885 cells/\u03bcL. (\uff1c 1,885 cells/\u03bcL vs. \u2265 1,885 cells/\u03bcL) Results: The preT median lymphocyte count was 1,885 cells/\u03bcL (range: 285-5341). Patients in higher preT LC group was characterized by higher BMI (p = 0.023), more smoker (p \uff1c 0.001), and more drinker (p = 0.043). On multivariate analysis, patients with higher preT LC were statistically significantly associated with better OS and DMFS than those with lower preT LC. There was no significant difference between preT LC groups in terms of LFS and RFS. Conclusions: Our data demonstrates that higher preT LC was independently associated with better DMFS and OS for patients with head-and-neck cancer treated with CRT or RT"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-13-20", "title": "IONIZING RADIATION-INDUCED CANCER STEMNESS GENE EXPRESSI ON IS REGULATED BY MATRI X NANOTOPOGRAPHY", "keywords": "Nanotopography;Extracellular matrix;Cancer stemness;Ionizing radiation \u5948\u7c73\u8868\u9762\u7d50\u69cb;\u7d30\u80de\u5916\u9593\u8cea;\u764c\u5e79\u7d30\u80de\u7279\u6027;\u6e38\u96e2\u8f3b\u5c04", "c": "\u524d\u8a00\uff1a\u8fd1\u5e74\u7814\u7a76\u767c\u73fe\u7d30\u80de\u5916\u9593\u8cea\u8207\u7d30\u80de\u63a5\u89f8\u9762\u7684\u5948\u7c73\u8868\u9762\u7d50\u69cb\u662f\u5f71\u97ff\u7d30\u80de\u751f\u7269\u5b78\u7684\u91cd\u8981\u7279\u6027\uff0c\u4f46\u662f\u6b64\u985e\u7d50\u69cb\u56e0\u7d20\u662f\u5426\u5f71\u97ff\u764c\u7d30\u80de\u5c0d\u6e38\u96e2\u8f3b\u5c04\u7684\u53cd\u61c9\u4ecd\u5c6c\u672a\u77e5\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u8b93\u809d\u764c\u6216\u9c57\u72c0\u4e0a\u76ae\u764c\u7d30\u80de\u8cbc\u9644\u5728\u5177\u7279\u5b9a\u5948\u7c73\u7d50\u69cb\u7684\u805a\u5df1\u5167\u916f\u8868\u9762\uff0c\u5728\u986f\u5fae\u93e1\u4e0b\u89c0\u5bdf\u7403\u9ad4\u5f62\u6210\uff0c\u4e26\u5229\u7528\u5b9a\u91cf\u805a\u5408\u9176\u9023\u9396\u53cd\u61c9\u6e2c\u91cf\u6e38\u96e2\u8f3b\u5c04\u8a98\u5c0e\u764c\u7d30\u80de\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\uff08Sox2, Nanog, Oct3/4\uff09\u7684\u8868\u73fe\u3002\u7d50\u679c\uff1a\u7814\u7a76\u7d50\u679c\u767c\u73fe\u6e38\u96e2\u8f3b\u5c04\u53ef\u8a98\u5c0e\u809d\u764c\u8868\u73fe\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\u3002\u82e5\u5c07\u809d\u764c\u7d30\u80de\u682aJ5\u7a2e\u690d\u5728\u5747\u52fb\u5206\u6563\u5948\u7c73\u5b54\u8868\u9762\uff0c\u5247\u6b64\u73fe\u8c61\u660e\u986f\u88ab\u6291\u5236\u3002\u82e5\u5c07\u809d\u764c\u7d30\u80de\u682aJ5\u7a2e\u690d\u5728\u5948\u7c73\u5c3a\u5ea6\u8fd1\u5747\u52fb\u5206\u6563\u5948\u7c73\u5b54\u8868\u9762\uff0c\u5247\u6e38\u96e2\u8f3b\u5c04\u4ecd\u53ef\u8a98\u5c0e\u809d\u764c\u7d30\u80de\u8868\u73fe\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\u3002\u5948\u7c73\u7d50\u69cb\u5c0d\u6e38\u96e2\u8f3b\u5c04\u8a98\u5c0e\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\u8868\u73fe\u7684\u5f71\u97ff\uff0c\u4ea6\u5728\u53e6\u4e00\u9c57\u72c0\u4e0a\u76ae\u764c\u7d30\u80de\u682a\u7372\u5f97\u8b49\u5be6\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u63d0\u4f9b\u5be6\u9a57\u8b49\u64da\uff0c\u986f\u793a\u6e38\u96e2\u8f3b\u5c04\u8a98\u5c0e\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\u8868\u73fe\u7684\u904e\u7a0b\u53d7\u7d30\u80de\u8cbc\u9644\u8868\u9762\u7684\u5948\u7c73\u7d50\u69cb\u6240\u8abf\u63a7\u3002Integrin\u8a0a\u606f\u50b3\u905e\u8207\u764c\u5e79\u7d30\u80de\u7279\u6027\u57fa\u56e0\u8868\u73fe\u4e4b\u9593\u7684\u5206\u5b50\u4e92\u52d5\u6a5f\u5236\uff0c\u4ee5\u53ca\u5728\u653e\u5c04\u816b\u7624\u751f\u7269\u5b78\u7684\u61c9\u7528\u503c\u5f97\u5f8c\u7e8c\u63a2\u8a0e\u3002", "e": "Introduction: Recent studies have revealed that nanoscale structure (nanotopography) of extracellular matrix is an important regulator of cell biology. However, it remains unknown whether nanotopography regulates cancer cell behaviors upon exposure to ionizing radiation (IR). Materials and Methods: Hepatoma cell lines and a squamous cell carcinoma cell line were cultured on nanopatterned polycaprolactone surfaces and were irradiated. Sphere formation was counted and expression of cancer stemness-related genes (Sox2, Nanog and Oct3/4) was measured with quantitative polymerase chain reaction. Results: In this study, we showed that IR induced expression of stemness genes including Sox2, Nanog and Oct3/4 in several cancer cell lines. Growing J5 hepatoma cells on a square lattice of evenly-spaced nanopits made of polycaprolactone attenuates cancer stemness genes expression induced by IR. Growing J5 cells on a near-square lattice of nanopits has smaller effects on IR-induced cancer stemness genes expression. The phenomenon was reproducible in another cell line derived from squamous cell carcinoma. Conclusions: We provided experimental evidence that radiation-induced expression of cancer stemness genes in cancer cells is regulated by nanotopography of the attaching surface. Further research is warranted to analyze molecular interaction between integrin signaling and cancer stemness, as well as the implications for cancer radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-21-32", "title": "\u6574\u5408\u591a\u5957\u653e\u5c04\u816b\u7624\u8207\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\u4ee5\u5be6\u73fe\u75c5\u6b77\u96fb\u5b50\u5316", "keywords": "\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71;\u96fb\u5b50\u75c5\u6b77;\u6cbb\u7642\u54c1\u8cea\u8207\u5b89\u5168 Radiation Oncology Information Systems (ROIS);Electronic medical records;Treatment quality and safety", "c": "\u76ee\u7684\uff1a\u4ee5\u53d6\u4ee3\u7d19\u672c\u75c5\u6b77\u70ba\u76ee\u6a19\uff0c\u5efa\u69cb\u6574\u5408\u5f0f\u653e\u5c04\u6cbb\u7642\u96fb\u5b50\u75c5\u6b77\u7cfb\u7d71\uff08Radiation Therapy Electronic Medical Record\uff0cRTEMR\uff09\uff0c\u4e26\u5206\u5225\u8207\u672c\u79d1\u4f86\u81ea\u4e09\u5bb6\u4f9b\u61c9\u5546\u3001\u9ad8\u7570\u8cea\u6027\u7684\u4e09\u5957\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71\uff08Radiation Oncology Information Systems, ROIS\uff09\uff1aARIA/VARiS\u3001MOSAIQ\u3001Tomotherapy\u9023\u7d50\uff0c\u4ee5\u5373\u6642\u53d6\u5f97\u6cbb\u7642\u7d00\u9304\uff1b\u4ea6\u8207\u5168\u9662\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\u4ea4\u6d41\u8cc7\u6599\uff0c\u53ef\u53d6\u5f97\u75c5\u4eba\u57fa\u672c\u8cc7\u6599\u8207\u6700\u65b0\u9580\u4f4f\u9662\u52d5\u5411\uff0c\u4ea6\u63d0\u4f9b\u6700\u65b0\u6cbb\u7642\u9032\u5ea6\u4f9b\u5176\u4ed6\u90e8\u9580\u53c3\u8003\uff0c\u4e0d\u53d7\u6cbb\u7642\u8a2d\u5099\u5ee0\u724c\u7684\u9650\u5236\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c0dROIS\u4e4b\u8cc7\u6599\u5eab\u9032\u884c\u5256\u6790\uff0c\u4e26\u53ec\u958b\u6703\u8b70\uff0c\u8a0e\u8ad6\u5404\u7d44\u5de5\u4f5c\u4eba\u54e1\u9700\u6c42\u5f8c\uff0c\u7e7c\u627f\u672c\u79d1\u820a\u6709\u4e4b\u55ae\u4e00\u4f7f\u7528\u8005\u3001\u55ae\u6a5f\u7248\u4e4b\u7ba1\u7406\u8edf\u9ad4\uff0c\u9032\u884c\u958b\u767c\u3002RTEMR\u4f7f\u7528\u7db2\u9801\u4ecb\u9762\uff0c\u514d\u5b89\u88dd\uff0c\u6613\u66f4\u65b0\uff0c\u53ef\u8de8\u5e73\u53f0\u4f7f\u7528\u3002\u5373\u6642\u6cbb\u7642\u9032\u5ea6\u7684\u67e5\u8a62\uff0c\u53ef\u540c\u6642\u4ee5\u6cbb\u7642\u8a08\u756b\u53c3\u8003\u9ede\u4e4b\u7d2f\u7a4d\u5291\u91cf\u3001\u53ca\u91ab\u5e2b\u6a19\u9776\u90e8\u4f4d\u8655\u65b9\u7b49\u5169\u7a2e\u65b9\u5f0f\u5448\u73fe\u3002\u7d50\u679c\uff1aRTEMR\u53ef\u4f9d\u767b\u5165\u8eab\u5206\u986f\u793a\u4e0d\u540c\u529f\u80fd\uff0c\u53e6\u6709\u75c5\u4eba\u81ea\u52a9\u5831\u5230\u7cfb\u7d71\uff0c\u5de5\u4f5c\u4eba\u54e1\u53ef\u638c\u63e1\u75c5\u4eba\u52d5\u614b\u3002\u91ab\u5e2b\u8207\u6cbb\u7642\u6a5f\u75c5\u4eba\u540d\u55ae\u53ef\u986f\u793a\u75c5\u4eba\u662f\u5426\u5df2\u5831\u5230\u3001\u5df2\u6cbb\u7642\uff0c\u4ee5\u53ca\u4ea4\u73ed\u6ce8\u610f\u4e8b\u9805\u3002\u653e\u5c04\u6cbb\u7642\u6458\u8981\u81ea\u52d5\u5b8c\u6210\u4ee5\u53ca\u7522\u51fa\u5404\u5f0f\u884c\u653f\u5831\u8868\uff0c\u4ea6\u70baRTEMR\u7684\u91cd\u8981\u61c9\u7528\u3002\u7d50\u8ad6\uff1aRTEMR\u5df2\u660e\u986f\u589e\u52a0\u653e\u5c04\u6cbb\u7642\u90e8\u9580\u7684\u4f5c\u696d\u6548\u7387\uff0c\u964d\u4f4e\u758f\u6f0f\u7684\u98a8\u96aa\uff1b\u672a\u4f86\u8207\u5168\u9662\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\u8207\u764c\u75c7\u8cc7\u8a0a\u7cfb\u7d71\u66f4\u7dca\u5bc6\u7684\u6574\u5408\uff0c\u5c07\u66f4\u986f\u8457\u63d0\u5347\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u3002", "e": "Purpose: To replace paper medical records, we constructed an integrated Radiation Therapy Electronic Medical Record (RTEMR) system, and connected it to heterogeneous Radiation Oncology Information Systems (ROIS) from three independent vendors in our department - ARIA/VARiS, MOSAIQ and Tomotherapy - to acquire real-time treatment records. In addition, data exchange between RTEMR and Health Information System (HIS) allowed RTEMR to get patients' basic data and inpatient/outpatient status from HIS, and medical personnel in other departments can access the most updated information about radiotherapy progress, regardless of treatment unit. Materials and Methods: After analyzing the database structure of ROIS, and meeting with multidisciplinary staff in our department, RTEMR underwent development, as a successor of our original single-user standalone management software. The web-based interface of RTEMR has several advantages: installation-free, ease-of-update and cross-platform. The system provides the real-time treatment progress in terms of cumulative dose and fractions to plans' reference points or physician prescribed target volume. Results: RTEMR can display different functions according to user's login identity. Self-serve checkin system can help our staff to keep track of patients' current state. Patient lists for doctors and treatment machine can show check-in status, treatment status, and special notes. Other important applications of RTEMR are auto-generation of radiation therapy treatment summary and several routine reports for administrative purpose. Conclusion: RTEMR can increase the efficiency and decrease the risk of near miss in clinical work. Further integration with health information system and cancer information system will improve the quality of radiation therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-33-42", "title": "\u63d0\u5347\u982d\u9838\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e4b\u80a9\u8180\u4f4d\u7f6e\u518d\u73fe\u6027\uff1a\u904b\u7528\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0", "keywords": "\u5c0e\u822a\u5f0f\u87ba\u65cb\u5200;\u80a9\u8180\u4f4d\u79fb;\u54c1\u7ba1\u5708;\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0 TomoTherapy;Shoulder displacement;Quality Control Circle (QCC);Plan-Do-Check-Action;(PDCA)", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u982d\u9838\u764c\u60a3\u8005\uff0c\u6703\u88fd\u4f5c\u982d\u9838\u90e8\u56fa\u5b9a\u9762\u5177\uff08Head and Neck immobilization Mask\uff09\uff0c\u4f46\u80a9\u8180\u7684\u4f4d\u7f6e\u5f80\u5f80\u6c92\u6709\u56fa\u5b9a\u6027\u3002\u81e8\u5e8a\u4f7f\u7528\u5c0e\u822a\u5f0f\u87ba\u65cb\u5200\uff08TomoTherapy\uff09\u6cbb\u7642\uff0c\u9032\u884c\u5f71\u50cf\u5c0e\u822a\u6bd4\u5c0d\u6642\uff0c\u767c\u73fe\u80a9\u8180\u4f4d\u7f6e\u8207\u539f\u59cb\u6cbb\u7642\u8a08\u5283\u4f4d\u7f6e\u4e0d\u540c\u3002\u672c\u7814\u7a76\u5e0c\u671b\u85c9\u7531\u54c1\u7ba1\u5708\uff08Quality Control Circle, QCC\uff09\u4e4b\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0\uff08Plan-Do-Check-Action, PDCA\uff09\uff0c\u627e\u51fa\u5408\u9069\u6539\u5584\u5c0d\u7b56\uff0c\u63d0\u5347\u982d\u9838\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e4b\u80a9\u8180\u4f4d\u7f6e\u518d\u73fe\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65bc2014\u5e743\u6708\u81f312\u6708\u671f\u9593\u5171\u6536\u96c6\u4e86184\u4eba\u6b21\uff0c\u4f7f\u7528\u5c0e\u822a\u5f0f\u87ba\u65cb\u5200\u57f7\u884c\u6cbb\u7642\u982d\u9838\u764c\u75c5\u60a3\u4e4b\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff08MVCT\uff09\u3002\u4ee5\u56de\u6eaf\u7684\u65b9\u5f0f\uff0c\u5206\u6790\u60a3\u8005\u6cbb\u7642\u524d\u64fa\u4f4d\u4e4b\u80a9\u8180\u4f4d\u79fb\uff0c\u505a\u70ba\u6539\u5584\u524d\u8cc7\u6599\u4e4b\u4f9d\u64da\u3002\u4e26\u65bc2014\u5e741\u67081\u65e5\u81f312\u670831\u65e5\uff0c\u904b\u7528\u54c1\u7ba1\u5708\u4e4b\u624b\u6cd5\uff0c\u9032\u884c\u300c\u63d0\u5347\u982d\u9838\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e4b\u80a9\u8180\u4f4d\u7f6e\u518d\u73fe\u6027\u300d\u54c1\u8cea\u6539\u5584\u6d3b\u52d5\u3002\u7d50\u679c\uff1a\u5169\u5074\u80a9\u8180\u5c0f\u65bc5 mm\u4f4d\u79fb\u7387\uff0c\u7531\u6539\u5584\u524d\u768458.69 %\u63d0\u5347\u81f394.44 %\u3002\u5169\u5074\u80a9\u8180\u5927\u65bc10 mm\u4f4d\u79fb\u7387\uff0c\u7531\u6539\u5584\u524d\u768411.05 % \u964d\u4f4e\u81f30 %\u3002\u4e26\u6301\u7e8c\u6027\u7684\u8ffd\u8e64\u5176\u6548\u679c\u78ba\u8a8d\uff0c\u4e5f\u986f\u793a\u80fd\u6301\u7e8c\u7dad\u6301\u9ad8\u65bc\u76ee\u6a19\u503c\uff0c\u56e0\u6b64\u8db3\u4ee5\u4ee3\u8868\u6b64\u6b21\u54c1\u8cea\u6539\u5584\u4e4b\u5c0d\u7b56\uff0c\u80fd\u63d0\u5347\u982d\u9838\u764c\u60a3\u8005\u4e4b\u80a9\u8180\u4f4d\u7f6e\u518d\u73fe\u6027\u3002\u7d50\u8ad6\uff1a\u904b\u7528\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0\uff0c\u80fd\u6709\u6548\u767c\u73fe\u554f\u984c\u3001\u6539\u5584\u554f\u984c\uff0c\u4e26\u89e3\u6c7a\u554f\u984c\u8207\u5efa\u7acb\u4f5c\u696d\u6a19\u6e96\u5316\u3002\u6b64\u6b21\u54c1\u8cea\u6539\u5584\u4e4b\u5c0d\u7b56\uff0c\u88fd\u4f5c\u51fa\u53ef\u9069\u7528\u65bc\u4e0d\u540c\u75c5\u60a3\u624b\u62c9\u4f4d\u7f6e\u9577\u5ea6\uff0c\u80fd\u56fa\u5b9a\u8207\u91cf\u5316\u80a9\u8180\u4f4d\u7f6e\u4e4b\u80a9\u8180\u56fa\u5b9a\u5668\uff08shoulder retractor\uff09\uff0c\u63d0\u9ad8\u982d\u9838\u764c\u75c5\u60a3\u80a9\u8180\u4f4d\u7f6e\u518d\u73fe\u6027\u3002", "e": "Purpose: While delivering radiation beam to a head and neck cancer patient, a thermoplastic mask is used to fix the position of head and neck region to ensure the reproducibility of head and neck posture during the whole treatment process. However, the location of the shoulders is not accurate according to comparison of image navigation in the clinical treatment. In this study, we hoped to improve the shoulder position reproducibility of patients undergoing radiotherapy for head and neck cancer by using the plan-do-check-action (PDCA) of quality control circle (QCC). Material and Method: From February 2014 to December 2014 in TomoTherapy. Daily shoulder position variation relative to treatment isocenter was quantified using MVCT-based bony alignment for 184 images with head and neck patients. Shoulder position variation was evaluated with daily CT scans from an MVCT scan. From January 1, 2014 to December 31, 2014, We use of quality control of the way, to improve the shoulder position reproducibility of patients undergoing radiotherapy for head and neck cancer Results: The shoulder displacement less than 5 mm rate was 58.69% at the beginning. The rate of \uff1c 5 mm shoulder displacement was 90% after intervention. The shoulder less than 10 mm displacement rate was 88.95%. The displacement was 100% \uff1c10 mm after intervention for improvement. It was found that the result of plan-do-check-action (PDCA) of quality control circle (QCC) could be maintained after keeping track of the shoulder displacement. Conclusion: The application of quality control circle can effectively identify problems, improve the problem, and solve the problem and the establish of Standard Operating Procedures (SOP). The shoulder retractor can be applied to different patients with hand-pull position, and can be quantified the shoulder position to achieve higher reproducibility of the head and neck cancer shoulder position."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-43-47", "title": "\u5229\u7528\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u6bd4\u8f03\u5169\u7a2e\u6a21\u5177\u4f7f\u7528\u5728\u809d\u764c\u75c5\u60a3\u7684\u56fa\u5b9a\u6548\u7387", "keywords": "\u809d\u81df\u816b\u7624;\u6a21\u5177;\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64 Hepatocellular carcinoma;Mold;Cone beam computed tomography (CBCT)", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u70ba\u56de\u6eaf\u6027\u7814\u7a76\uff0c\u6bd4\u8f03\u767c\u6ce1\u5291\u6a21\u5177\uff08\u03b1-cradle\uff09\u548c\u5168\u8eab\u56fa\u5b9a\u5668\u642d\u914d\u771f\u7a7a\u5305\uff08vacuum bag\uff09\u5c0d\u65bc\u809d\u764c\u75c5\u60a3\u7684\u653e\u5c04\u6cbb\u7642\u7684\u56fa\u5b9a\u6548\u679c\u3002\u540c\u6642\u8a08\u7b97\u51fa\u8a08\u756b\u9776\u9ad4\u7a4d\uff08planning target volume, PTV\uff09\u6240\u9700\u7684\u5b89\u5168\u7bc4\u570d\uff08safe margin\uff09\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2014\u5e741\u67081\u65e5\u59cb\u81f32015\u5e7412\u670831\u65e5\u6b62\uff0c\u6536\u96c6\u672c\u79d1\u7b26\u5408\u6536\u6848\u689d\u4ef6\u7684\u6240\u6709\u809d\u764c\u75c5\u4eba\uff0c\u5728\u6cbb\u7642\u524d\u57f7\u884c\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u651d\u5f71\uff08cone beam computed tomography, CBCT\uff09\u5f8c\u7684\u4f4d\u79fb\u7d50\u679c\u3002\u6839\u64daCBCT\u4e09\u7dad\u5404\u8ef8\uff08X\u3001Y\u3001Z\uff09\u4f4d\u79fb\u6578\u503c\u8a08\u7b97\u5206\u6790\uff0c\u5f97\u5230\u5e73\u5747\u8aa4\u5dee\uff08overall mean\uff0cM\uff09\u3001\u7cfb\u7d71\u8aa4\u5dee\u7684\u6a19\u6e96\u5dee\uff08system error\uff0c\u03a3\uff09\u3001\u96a8\u6a5f\u8aa4\u5dee\u7684\u6a19\u6e96\u5dee\uff08random error\uff0c\u03c3\uff09\u7b49\u6578\u503c\u3002\u4e26\u5229\u75282.5\u03a3+0.7\u03c3\uff0c\u8a08\u7b97\u51fa\u8a08\u756b\u9776\u9ad4\u7a4d\u6240\u9700\u7684\u5b89\u5168\u7bc4\u570d\u3002\u7d50\u679c\uff1a\u767c\u6ce1\u5291\u7d44\u8207\u56fa\u5b9a\u5668\u642d\u914d\u771f\u7a7a\u5305\u7d44\u5728 X\u3001Y\u3001Z\u8ef8\u7684\u4f4d\u79fb\u5e73\u5747\u503c\u8207\u6a19\u6e96\u5dee\u70ba0.4\u00b11.8\u548c0.3\u00b11.8\uff0cp = 0.83\uff1b0.6\u00b12.6\u548c0.2\u00b12.5\uff0cp = 0.52\uff1b-0.6\u00b12.0\u548c0\u00b11.5\uff0cp = 0.15\uff0c\u55ae\u4f4d\u70ba\u6beb\u7c73\uff08mm\uff09\u3002\u5728\u4f7f\u7528\u767c\u6ce1\u5291\u56fa\u5b9a\u5668\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u8a08\u756b\u9776\u9ad4\u7a4d\u5728X\u8ef8\u9700\u589e\u52a05.7 mm\uff0cY\u8ef88.7 mm\uff0cZ\u8ef86.8 mm\u7684\u5b89\u5168\u7bc4\u570d\uff1b\u5728\u4f7f\u7528\u5168\u8eab\u56fa\u5b9a\u5668\u642d\u914d\u771f\u7a7a\u5305\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u8a08\u756b\u9776\u9ad4\u7a4d\u5728X\u8ef8\u9700\u589e\u52a06.1 mm\uff0cY\u8ef89.3 mm\uff0cZ\u8ef85.4 mm\u7684\u5b89\u5168\u7bc4\u570d\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u7d50\u679c\u986f\u793a\u5169\u7a2e\u56fa\u5b9a\u5668\u7684\u56fa\u5b9a\u6548\u7387\u4e26\u7121\u986f\u8457\u5dee\u7570\u3002\u5c0d\u65bc\u809d\u764c\u75c5\u4eba\uff0c\u5efa\u8b70\u8a08\u756b\u9776\u9ad4\u7a4d\u5728X\u8ef8\u9700\u589e\u52a07 mm\uff0cY\u8ef810 mm\uff0cZ\u8ef87 mm\u7684\u5b89\u5168\u7bc4\u570d\u3002", "e": "Purpose: The aim of this study was to compare the positioning reproducibility of \u03b1-cradle and vacuum bag for patients with hepatocellular carcinoma via cone beam computed tomography (CBCT). Safe margins for planning target volume (PTV) were also measured. Methods and Materials: From January 1, 2014 to December 31, 2015, CBCT data of 68 patients with hepatocellular carcinoma were collected. For patient positioning, \u03b1-cradle was used until October 2014. Vacuum bag with abdominal compression was used since October 2014. Patients were imaged before treatment to ascertain inter-fraction motion. Overall mean (M), standard deviation of system error (\u03a3) and standard deviation of random error (\u03c3) were used to compare the positioning reproducibility. Safe margins for PTV were derived from the equation: 2.5\u03a3+0.7\u03c3. Results: There were 35 patients in \u03b1-cradle group and 33 patients in vacuum bag group. The overall means and standard deviations of the X, Y, and Z axes in \u03b1-cradle group and in vacuum bag group were 0.4 \u00b1 1.8 mm and 0.3 \u00b1 1.8 mm (p = 0.82), 0.6 \u00b1 2.6 mm and 0.2 \u00b12.5 mm (p = 0.52), -0.6 \u00b1 2.0 mm and 0 \u00b1 1.5 mm (p = 0.15), respectively. The PTV safe margins in the X, Y, and Z axes of \u03b1-cradle group were 5.7 mm, 8.7 mm and 6.8 mm, respectively. The PTV safe margins in the X, Y, and Z axes of vacuum bag group were 6.1 mm, 9.3 mm and 5.4 mm, respectively. Conclusions: There was no significant difference of positioning reproducibility between \u03b1-cradle and vacuum bag. For patients with hepatocellular carcinoma, the PTV safe margins in the X, Y, and Z axes were 7 mm, 10 mm and 7 mm, respectively."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-49-57", "title": "\u4e73\u764c\u75c5\u60a3\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71\u65bc\u6df1\u5438\u6c23\u9589\u6c23\u8207\u81ea\u7136\u547c\u5438\u4e0b\u4e4b\u5f71\u50cf\u5c0e\u5f15\u8aa4\u5dee\u63a2\u8a0e", "keywords": "\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71;\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u9310\u5f62\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u7cfb\u7d71 Active breathing coordinator system (ABC system);Image guided radiation therapy (IGRT);Cone-beam computed tomography (CBCT)", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e2d\uff0c\u4e73\u764c\u75c5\u60a3\u547c\u5438\u6642\u6703\u9020\u6210\u5be6\u969b\u7167\u5c04\u5230\u9ad4\u5167\u7684\u5291\u91cf\u5206\u5e03\u4e0d\u5982\u9810\u671f\u3002\u56e0\u6b64\u5728\u6cbb\u7642\u6642\uff0c\u6703\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71\uff08Active Breathing Coordinator system, ABC system\uff09\uff0c\u4e26\u642d\u914d\u6bcf\u65e5\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff08image guided radiation therapy, IGRT\uff09\u63a7\u5236\u75c5\u60a3\u7684\u547c\u5438\u904b\u52d5\u3002\u672c\u7814\u7a76\u5728\u75c5\u60a3\u6cbb\u7642\u524d\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u88dd\u7f6e\u642d\u914d\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\u64f7\u53d6\u75c5\u60a3\u81ea\u7136\u547c\u5438\uff08free breathing, FB\uff09\u53ca\u6df1\u5438\u6c23\u9589\u6c23\uff08deep inspiration breath hold radiotherapy, DIBH\uff09\u72c0\u614b\u4e0b\u4e4b\u5f71\u50cf\uff0c\u5206\u5225\u8207\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\uff08computed tomography simulator, CT-simulator\uff09\u6642\u5f71\u50cf\u6bd4\u8f03\u5169\u8005\u9593\u7684\u64fa\u4f4d\u8aa4\u5dee\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u96c610\u4f4d\u642d\u914d\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71\u9032\u884c\u653e\u5c04\u6cbb\u7642\u7684\u4e73\u764c\u75c5\u60a3\uff0c\u653e\u5c04\u6cbb\u7642\u8655\u65b9\u5291\u91cf\u70ba5040 cGy\u5206\u4f5c28\u6b21\u7d66\u4e88\uff0c\u9032\u884c\u6bcf\u65e5\u4e00\u6b21\u7684\u6cbb\u7642\u3002\u5728\u6bcf\u6b21\u57f7\u884c\u6cbb\u7642\u524d\uff0c\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\u4e26\u642d\u914d\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71\uff0c\u6291\u5236\u75c5\u60a3\u547c\u5438\u64f7\u53d6\u4e00\u7d44\u6df1\u5438\u6c23\u9589\u6c23\u72c0\u614b\u4e0b\u4e4b\u5f71\u50cf\uff0c\u723e\u5f8c\u8acb\u75c5\u60a3\u81ea\u7136\u547c\u5438\uff0c\u64f7\u53d6\u4e00\u7d44\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\u4e4b\u5f71\u50cf\uff0c\u5171\u6536\u96c6280\u7d44DIBH\u53ca280\u7d44FB\u5f71\u50cf\uff0c\u5206\u5225\u8207\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\u6642\u7684\u5f71\u50cf\u878d\u5408\uff0c\u4ee5\u8edf\u7d44\u7e54\u70ba\u6a19\u6e96\u4e0b\uff0c\u6bd4\u8f03\u5169\u7a2e\u547c\u5438\u72c0\u614b\u4e0b\u7684\u64fa\u4f4d\u8aa4\u5dee\u503c\uff08setup errors\uff09\u3002\u7d50\u679c\uff1a\u5728R/L\u8ef8\u5411\u4e2d\uff0c\u67093\u4f4d\u75c5\u60a3\uff08\u75c5\u60a31\u30014\u30017\uff09\u65bc\u6df1\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u6bd4\u5728\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u5927\uff1b\u53cd\u4e4b\u67096\u4f4d\u75c5\u60a3\uff08\u75c5\u60a32\u30015\u30016\u30018\u30019\u300110\uff09\u65bc\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u6bd4\u5728\u6df1\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u5927\uff0c\u75c5\u60a33\u5728\u5169\u7a2e\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u76f8\u4f3c\u7121\u6cd5\u5340\u5206\u3002\u5728S/I\u8ef8\u5411\u4e2d\u67098\u4f4d\u75c5\u60a3\uff08\u75c5\u60a31\u30013\u30014\u30016\u30017\u30018\u30019\u300110\uff09\u65bc\u6df1\u5438\u6c23\u9589\u6c23\u72c0\u614b\u4e0b\uff0c\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u6bd4\u5728\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u5927\uff1b\u53cd\u4e4b\u67092\u4f4d\u75c5\u60a3\uff08\u75c5\u60a32\u30015\uff09\u65bc\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\uff0c\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u6bd4\u5728\u6df1\u5438\u547c\u9589\u6c23\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u5927\u3002\u5728A/P\u8ef8\u5411\u4e2d10\u4f4d\u75c5\u60a3\u65bc\u81ea\u7136\u547c\u5438\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u7686\u6bd4\u5728\u6df1\u5438\u547c\u9589\u6c23\u72c0\u614b\u4e0b\u6240\u5f97\u5e73\u5747\u8aa4\u5dee\u503c\u5927\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u7cfb\u7d71\u9032\u884c\u6df1\u5438\u6c23\u9589\u6c23\u5f8c\uff0c\u518d\u64f7\u53d6\u5f71\u50cf\u6bd4\u8d77\u81ea\u7136\u547c\u5438\u5f8c\u518d\u64f7\u53d6\u5f71\u50cf\uff0c\u53ef\u4ee5\u589e\u52a0A/P\u8ef8\u5411\u7684\u6e96\u78ba\u6027\uff0c\u4f46\u662f\u82e5\u9032\u884c\u6df1\u5438\u6c23\u9589\u6c23\u5f8c\u518d\u64f7\u53d6\u5f71\u50cf\u6642\uff0c\u6bcf\u4e00\u6b21\u9589\u6c23\u6642\u5438\u6c23\u91cf\u4e0d\u4e00\u81f4\uff0c\u53cd\u800c\u53ef\u80fd\u6703\u589e\u52a0\u5176\u4ed6\u5169\u8ef8\u5411\u7684\u5e73\u5747\u8aa4\u5dee\u503c\u3002\u672a\u4f86\u82e5\u767c\u5c55\u51fa\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u6280\u8853\u6642\uff0c\u80fd\u56fa\u5b9a\u6df1\u5438\u6c23\u9589\u6c23\u6642\u7684\u5438\u5165\u6c23\u9ad4\u91cf\uff0c\u4e26\u4f7f\u7528\u65bc\u689d\u4ef6\u826f\u597d\u7684\u75c5\u60a3\u8eab\u4e0a\uff0c\u76f8\u8f03\u65bc\u5728\u81ea\u7136\u547c\u5438\u4e0b\u64f7\u53d6\u5f71\u50cf\uff0c\u53ef\u4ee5\u5927\u5e45\u6e1b\u4f4e\u5e73\u5747\u8aa4\u5dee\u503c\u4e14\u64f7\u53d6\u4e4b\u5f71\u50cf\u66f4\u5177\u6709\u53c3\u8003\u50f9\u503c\u3002", "e": "Purpose: To evaluate the effect of set-up errors in breast cancer patients receiving breast irradiation using Active Breathing Coordinator system (ABC system) with deep inspiration breath hold (DIBH) or free breathing (FB). Patients and Methods: We retrospectively estimated set-up errors in ten breast cancer patients receiving breast irradiation using ABC system with DIBH (DIBH) or FB. Daily image guided radiation therapy (IGRT) would be practiced for getting images in DIBH during deep inspiratory using ABC system and FB. In comparison with initial images in soft tissue windows from computed tomography simulator (CT-simulator), we have 280 images in DIBH and FB, respectively. Results: There were 3 patients during DIBH and 7 patients during FB having significant set-up errors in the orientation of right to left (R/L). In the orientation of superior to inferior (S/I), there were 8 patients during DIBH and 2 patients during FB having significant set-up error. Ten patients during during FB having significant set-up error in the orientation of anterior to posterior (A/P). Conclusions: ABC system with DIBH could reduced the set-up errors in the orientation of A/P, but not R/L and S/I."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201803-201804100001-201804100001-59-63", "title": "VULVAR PAGE", "keywords": "Vulvar Paget", "c": "\u4e73\u623f\u4ee5\u5916\u7684\u4f69\u5409\u7279\u6c0f\u75c7\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u8868\u76ae\u817a\u764c\uff0c\u591a\u898b\u65bc\u6c57\u817a\u8c50\u5bcc\u7684\u5340\u57df\u3002\u7d0460%\u7684\u4e73\u623f\u4ee5\u5916\u7684\u4f69\u5409\u7279\u6c0f\u75c7\u767c\u751f\u65bc\u5916\u9670\u90e8\uff0c\u800c\u5916\u9670\u90e8\u4f69\u5409\u7279\u6c0f\u75c7\u7d04\u5360\u5916\u9670\u90e8\u60e1\u6027\u816b\u7624\u76841%\u3002\u4e00\u4f4d95 017\uff12\uff10\uff11\u6b72\u7684\u5973\u6027\u65bc\u904e\u53bb\u5169\u5e74\u591a\u7684\u671f\u9593\uff0c\u98fd\u53d7\u5916\u9670\u90e8\u7d05\u816b\u3001\u7d50\u75c2\u3001\u6ef2\u6db2\u7684\u56f0\u64fe\uff0c\u5728\u672c\u9662\u76ae\u819a\u79d1\u9580\u8a3a\u6642\u4e5f\u5728\u5916\u9670\u90e8\u767c\u73fe\u4e00\u9846\u4e00\u516c\u5206\u5927\u7684\u7d50\u7bc0\u3002\u7d93\u5207\u7247\u5f8c\u8b49\u5be6\u70ba\u4f69\u5409\u7279\u6c0f\u75c7\u3002\u8003\u616e\u5230\u5979\u9ad8\u9f61\u53ca\u7368\u5c45\u7684\u72c0\u6cc1\uff0c\u6c7a\u5b9a\u4e0d\u4ee5\u624b\u8853\u5207\u9664\u800c\u63a1\u653e\u5c04\u6cbb\u7642\u3002\u539f\u8a02\u4ee56 MeV\u96fb\u5b50\u81f3\u5c11\u7167\u5c0425\u6b21\u81f350 Gy\u5291\u91cf\u3002\u4f46\u56e0\u653e\u5c04\u6027\u76ae\u819a\u708e\u800c\u65bc20 Gy\u6642\u4e2d\u6b62\u3002\u6539\u63a1imiquimod 5%\u4e73\u818f\u6cbb\u7642\uff0c\u6bcf\u5169\u65e5\u5857\u62b9\u65bc\u75c5\u7076\u53ca\u5176\u908a\u7de3\u5916\u52a02\u516c\u5206\u4e4b\u7bc4\u570d\u3002\u4e09\u9031\u5f8c\u5df2\u898b\u5230\u75c5\u7076\u660e\u986f\u7e2e\u5c0f\u3002\u5f8c\u56e0\u5979\u884c\u52d5\u4e0d\u4fbf\u800c\u672a\u524d\u4f86\u63a5\u53d7\u6cbb\u7642\uff0c\u7642\u7a0b\u50c5\u7dad\u6301\u5171\u4e94\u9031\u3002\u516d\u500b\u6708\u5f8c\u56de\u8a3a\uff0c\u539f\u672c\u7684\u7d50\u7bc0\u5df2\u6d88\u5931\uff0c\u5927\u90e8\u5206\u75c5\u7076\u4e5f\u5747\u6d88\u5931\uff0c\u4f46\u4ecd\u6709\u90e8\u5206\u7d05\u8272\u6591\u584a\u7591\u4f3c\u6b98\u5b58\u816b\u7624\u3002", "e": "Extramammary Paget's disease (PD) is a rare intraepithelial adenocarcinoma, which is most commonly seen in areas rich in apocrine glands. About 60% of extramammary PD were observed in the vulva. Vulvar PD accounts for 1% of vulvar cancers. A 95 years old female patient suffered from erythema, crusting, and increased maceration over the vulvar area for more than two years. A nodule about 1 cm in diameter had also been noted at the time she visited the dermatology department at our hospital. The biopsy showed the tumor cells are positive for CK7, which is supportive for Paget\u2019s disease. In consideration of her old age and poor family support, surgical resection is not feasible. She was referred to the radiation oncology department for radiotherapy. The initial treatment plan was to irradiate the focal region plus 2 cm margin with 6MeV electron to a total dose of 50 Gy in 25 fractions. However, the treatment was early terminated at 20 Gy due to painful grade III dermatitis. In search of appropriate alternative treatment, 5% imiquimod cream was chosen due to its relatively mild possible adverse effects. The cream was applied on the lesions and up to 2 cm outside their visible margins every other day. After three weeks of topical cream treatment, at least partial response had been observed. She lost of follow-up after 5 weeks of treatment. After repetitively calling her for follow-up, she showed up 6 months later. There were still some suspicious skin lesions although the previously noted nodule was completely gone and most of the patchy lesions were remitted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-261-268", "title": "COMPARISON OF ACUTE TOXICITIES AND TREATMENT TOLERANCE BETWEEN TRI-WEEKLY HIGH-DOSE AND WEEKLY LOW-DOSE CISPLATIN DURING CONCURRENT CHEMORADIOTHERAPY FOR HEAD AND NECK CANCER PATIENTS", "keywords": "Head and neck cancer;Concurrent chemoradiotherapy;Cisplatin \u982d\u9838\u764c;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u9806\u9251", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u982d\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u4f7f\u7528\u4e09\u9031\u4e00\u6b21\u9ad8\u5291\u91cf\u548c\u6bcf\u9031\u4e00\u6b21\u4f4e\u5291\u91cf\u9806\u9251\u4e4b\u6025\u6027\u53cd\u61c9\u8207\u8010\u53d7\u5ea6\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2014\u5e7410\u6708\u81f32015\u5e7412\u6708\u5171\u670961\u4f4d\u7b26\u5408\u672c\u7814\u7a76\u689d\u4ef6\u4e4b\u982d\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642\uff0c\u540c\u6b65\u5316\u7642\u5206\u70ba\u4e09\u9031\u4e00\u6b21\u9ad8\u5291\u91cf\uff08100 mg/m^2\uff09\u9806\u9251\uff08\u7c21\u7a31P100 Q3W\u7d44\uff0c31\u4f8b\uff09\u6216\u6bcf\u9031\u4e00\u6b21\u4f4e\u5291\u91cf\uff0830 mg/m^2\uff09\u9806\u9251\uff08\u7c21\u7a31P30 QW\u7d44\uff0c30\u4f8b\uff09\uff0c\u5169\u7d44\u63a5\u53d7\u4e00\u6a23\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u91dd\u5c0d\u9776\u5340\u7d66\u4e88\u5291\u91cf 60-70 Gy/6-7\u9031\uff0c\u5206\u6790\u6cbb\u7642\u671f\u9593\u4e4b\u6025\u6027\u53cd\u61c9\u3001\u80fd\u7d66\u4e88\u7684\u7d2f\u7a4d\u9806\u9251\u5291\u91cf\u3001\u5e73\u5747\u9806\u9251\u5291\u91cf\u5f37\u5ea6\u53ca\u653e\u7642\u7e3d\u6cbb\u7642\u6642\u9593\u9577\u77ed\u3002\u7d50\u679c\uff1a\u5169\u7d44\u75c5\u4eba\u7279\u5fb5\u7686\u985e\u4f3c\uff0c\u7121\u7d71\u8a08\u986f\u8457\u5dee\u7570\u3002P100 Q3W\u7d44\u75c5\u4eba\u6709\u8f03\u9ad8\u6bd4\u4f8b\u4e4b\u4e09/\u56db\u7d1a\u767d\u8840\u7403 \u4f4e\u4e0b\uff0825.8% vs. 3.3%, p= 0.014\uff09\uff0c\u5176\u4ed6\u4e09/\u56db\u7d1a\u6025\u6027\u53cd\u61c9\u5169\u7d44\u76f8\u4f3c\uff0c\u5305\u542b\u55dc\u4e2d\u6027\u7403\u964d\u4f4e\uff0816.1% vs. 3.3%, p= 0.095\uff09\u3001\u8ca7\u8840\uff080% vs. 3.3%, p= 0.311\uff09\u3001\u8840\u5c0f\u677f\u4f4e\u4e0b\uff080% vs. 0%, p= 1.000\uff09\u3001\u53e3\u8154\u9ecf\u819c\u708e\uff0835.5% vs. 23.3%, p= 0.300\uff09\u548c\u76ae\u819a\u53cd\u61c9\uff080% vs. 10.0%, p= 0.073\uff09\u3002P100 Q3W\u7d44\u75c5\u4eba\u4e5f\u6709\u8f03\u9ad8\u6bd4\u4f8b\u4e4b\u4e00/\u4e8c\u7d1a\u808c\u9178\u9150\u5347\u9ad8\uff0841.9% vs. 16.7%, p= 0.032\uff09\u3002\u5169\u7d44\u75c5\u4eba\u5e73\u5747\u63a5\u53d7\u7d2f\u7a4d\u9806\u9251\u5291\u91cf\u70ba219.4 \u00b1 47.7 mg/m^2\uff08P100 Q3W\u7d44\uff09\u548c80 \u00b1 39.8 mg/m^2\uff08P30 QW\u7d44\uff09\uff08p= 0.001\uff09\u3002\u5e73\u5747\u9806 \u9251\u5291\u91cf\u5f37\u5ea6\u70ba30.9 \u00b1 2.9 mg/m^2/week\uff08P100 Q3W\u7d44\uff09\u548c28.4 \u00b1 2.6 mg/m^2/week\uff08P30 QW\u7d44\uff09\uff08p= 0.001\uff09\u3002\u5b8c\u6210\u653e\u7642\u6240\u9700\u5e73\u5747\u6642\u9593\uff0c\u5169\u7d44\u6c92\u6709\u5dee\u7570\uff0850\u5929vs.49\u5929\uff0cp= 0.424\uff09\u3002\u7d50\u8ad6\uff1a\u982d\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u6642\uff0c\u63a1\u7528\u4e09\u9031\u4e00\u6b21\u9ad8\u5291\u91cf\u9806\u9251\u6bd4\u4f7f\u7528\u4e00\u9031\u4e00\u6b21\u4f4e\u5291\u91cf\u9806\u9251\uff0c\u80fd\u7d66\u4e88\u8f03\u9ad8\u9806\u9251\u7d2f\u7a4d\u7e3d\u5291\u91cf\uff0c\u4f46\u4e5f\u4f34\u96a8\u6709\u8f03\u9ad8\u4e09/\u56db\u7d1a\u4ee5\u4e0a\u767d\u8840\u7403/\u55dc\u4e2d\u6027\u7403\u4f4e\u4e0b\u548c\u4e00/\u4e8c\u7d1a\u808c\u9178\u9150\u5347\u9ad8\u526f\u4f5c\u7528\u3002", "e": "Purpose : To compare the acute toxicity and treatment compliance of tri-weekly highdose cisplatin with weekly low-dose cisplatin during concurrent chemoradiotherapy (CCRT) in head and neck cancer patients. Materials and Methods : From October 2014 to December 2015, a total of 61 head and neck cancer patients who had received CCRT were enrolled. All patients received intensity-modulated radiation therapy (IMRT) with 60-70 Gy in 6 to 7 weeks to the target region. Concurrent chemotherapy consisted of either tri-weekly cisplatin 100 mg/m^2 (P100 Q3W, n= 31) or weekly cisplatin 30 mg/m^2 (P30 QW, n= 30). The primary endpoint was acute toxicity during CCRT. The secondary endpoints were the accumulative cisplatin dose, cisplatin dose intensity, and overall treatment period of radiotherapy. Results : The baseline patient characteristics of both studies were similar between both arms. Patients who received P100 Q3W group had a higher rate of Gr 3/4 leucopenia (25.8% vs. 3.3%, p= 0.014) than those who received P30 QW. Other Gr 3/4 toxicities were similar in both arms, including neutropenia (16.1% vs. 3.3%, p= 0.095), anemia (0% vs. 3.3%, p= 0.311), thrombocytopenia (0% vs. 0%, p= 1.000), mucositis (35.5% vs. 23.3%, p= 0.300) and skin reaction (0% vs. 10.0%, p= 0.073). There was no Gr 3/4 serum creatinine elevation in either arm, however more mild grade (Gr 1/2) creatinine elevation was observed in patients who received P100 Q3W (41.9% vs. 16.7%, p= 0.032). The mean accumulative cisplatin dose delivery in the P100 Q3W group and the P30 QW group was 219.4 \u00b1 47.7 mg/m^2 and 181.0 \u00b1 38.9 mg/m^2 (p= 0.001), respectively. The mean dose intensity in P100 Q3W group was 30.9 \u00b1 2.9 mg/m2/week, and 28.4 \u00b1 2.6 mg/m^2/week in the P30 QW group (p= 0.001). The mean overall treatment period of radiotherapy was similar in both groups (50.0 vs. 49.0 days, p= 0.424). Conclusion : The P100 Q3W schedule delivered a significantly higher accumulative cisplatin dose than the P30 QW, but had a higher incidence of severe leucopenia/ neutropenia along with a mild degree of serum creatinine elevation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-269-278", "title": "A SINGLE INSTITUTION CASE SERIES OF PATIENTS WITH NK/T-CELL LYMPHOMA", "keywords": "Lymphoma;Prognosis;NK/T cell lymphoma;Prognostic factors;Survival;Natural Killer/T-cell lymphoma prognostic index (NKPI) \u6dcb\u5df4\u764c;\u9810\u5f8c;NK/T\u7d30\u80de\u6dcb\u5df4\u764c;\u9810\u5f8c\u56e0\u5b50;\u751f\u5b58;NK/T\u7d30\u80de\u9810\u5f8c\u6307\u6578\uff08NKPI\uff09", "c": "\u76ee\u7684\uff1a\u56de\u9867\u672c\u9662\u6cbb\u7642NK/T\u7d30\u80de\u6dcb\u5df4\u764c\u4e4b\u6210\u679c\uff0c\u4e26\u91d0\u6e05\u9810\u5f8c\u56e0\u5b50\u5c0d\u6574\u9ad4\u5b58\u6d3b\u3001\u75be\u75c5\u9032\u5c55\u3001\u8207\u5c40\u90e8\u63a7\u5236\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u91dd\u5c0d\u672c\u96622000-2014\u5e74\u6cbb\u7642\u4e4b\u6240\u6709NK/T\u7d30\u80de\u6dcb\u5df4\u764c\u75c5\u4eba\u505a\u4e00\u56de\u6eaf\u6027\u75c5\u6b77\u5206\u6790\u3002\u75c5\u4eba\u81f3\u5c11\u9700\u5728\u672c\u9662\u63a5\u53d7\u4e00\u7dda\u7684\u6cbb\u7642\u3002\u6211\u5011\u5f9e\u75c5\u6b77\u8cc7\u6599\u4e2d\u63d0\u53d6\u75c5\u4eba\u57fa\u672c\u8cc7\u8a0a\u3001\u76f8\u95dc\u91ab\u7642\u8a18\u9304\u3001\u6cbb\u7642\u7d30\u7bc0\uff0c\u8207\u5176\u6cbb\u7642\u6210\u679c\u3002\u7d71\u8a08\u65b9\u9762\uff0c\u6211\u5011\u63a1\u7528Kaplan-Meier\u6cd5\u4f30\u7b97\u6574\u9ad4\u5b58\u6d3b\u3001\u7121\u9032\u5c55\u5b58\u6d3b\u3001\u8207\u7121\u5c40\u90e8\u5340\u57df\u5fa9\u767c\u5b58\u6d3b\uff0c\u4e26\u4ee5Cox\u6bd4\u4f8b\u98a8\u96aa\u6a21\u5f0f\u5206\u6790\u9810\u5f8c\u56e0\u5b50\u5c0d\u6cbb\u7642\u6210\u679c\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u7814\u7a76\u7e3d\u8a08\u6536\u930421\u4f4d\u75c5\u4eba\uff0c\u5176\u4e2d12\uff0857%\uff09\u4f4d\u5206\u671f\u70ba\u7b2cI-II\u671f\u30019\uff0843%\uff09\u4f4d\u70ba\u7b2cIV\u671f\u3002\u6240\u6709\u75c5\u4eba\u4e4b\u4e2d\u4f4d\u6574\u9ad4\u5b58\u6d3b\u70ba2\u5e74\u3002\u65e9\u671f\u75c5\u4eba\u4e4b\u4e2d\u4f4d\u5b58\u6d3b\uff083.8\u5e74\uff09\u986f\u8457\u8f03\u665a\u671f\u75c5\u4eba\u70ba\u9577\uff082.5\u500b\u6708\uff09\u3002\u5728\u65e9\u671f\u75c5\u4eba\u4e2d\uff0cNK/T\u6dcb\u5df4\u764c\u9810\u5f8c\u6307\u6a19\uff08NKPI\uff09\u8207\u6574\u9ad4\u5b58\u6d3b\u6709\u986f\u8457\u76f8\u95dc\uff1b\u6709\u6dcb\u5df4\u7d50\u4fb5\u72af\u7684\u75c5\u4eba\uff0c\u5176\u5c40\u90e8\u5fa9\u767c\u7684\u6a5f\u7387\u6709\u8f03\u4f4e\u7684\u8da8\u52e2\uff08P= 0.05, HR= 0.17\uff09\u3002\u7d50\u8ad6\uff1a\u8207\u904e\u53bb\u6587\u737b\u5831\u544a\u76f8\u4eff\uff0cNK/T\u7d30\u80de\u6dcb\u5df4\u764c\u7684\u8868\u73fe\u76f8\u7576\u60e1\u6027\uff0c\u5176\u9810\u5f8c\u4e0d\u751a\u7406\u60f3\u3002\u63d0\u9ad8\u672a\u4f86\u6cbb\u7642\u6210\u6548\u7684\u7b56\u7565\u5305\u542b\uff1a\u78ba\u5be6\u627e\u51fa\u9ad8\u98a8\u96aa\u7684\u65cf\u7fa4\u3001\u4f7f\u7528\u8f03\u65b0\u7684\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u3001\u6216\u63d0\u9ad8\u653e\u5c04\u7dda\u5291\u91cf\u3002", "e": "Purpose: We aim to review treatment outcomes at our institution and evaluate prognostic factors that influence overall survival, progression, and local recurrence. Material and Methods: We conducted a retrospective chart review of all patients with NK/T-cell lymphoma treated from 2000-2014 at our institution. Patients must have received at least one line of therapy. Baseline characteristics and treatment information were extracted from medical records. We employed the Kaplan-Meier product limit method to estimate loco-regional recurrence-free survival (LRFS), progression-free survival (PFS) and overall survival (OS). Cox proportional hazards models were used to assess significance of prognostic factors on treatment outcomes. Results: A total of 21 patients were included, of which 12 (57%) were stage I-II, while the other 9 (43%) were stage IV. Median overall survival for all patients was 2 years. Median survival was significantly longer for stage I-II (3.8 years) than stage IV (2.5 months). In early stage patients, the Natural Killer/T-Cell Lymphoma Prognostic Index (NKPI) was associated with overall survival; patients with clinically positive lymph nodes had a trend towards lower risk of local recurrence (P= 0.05, HR= 0.17). Conclusions: Treatment outcomes of NK/T-cell lymphoma suggest an aggressive pattern and poor outcome, comparable with reports in the literature. Identification of high-risk subgroups and aggressive treatment with modern chemotherapeutic agents, and/or radiotherapy dose escalation may be warranted to improve treatment outcomes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-279-291", "title": "THE RISK OF CANCER IN PATIENTS WITH KELOID AND THE ASSOCIATION WITH RADIOTHERAPY", "keywords": "Keloid;Radiotherapy;Cancer \u87f9\u8db3\u816b;\u653e\u5c04\u6cbb\u7642;\u764c\u75c7", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u87f9\u8db3\u816b\u60a3\u8005\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa\u4ee5\u53ca\u6b64\u65cf\u7fa4\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u81f4\u764c\u98a8\u96aa\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u5065\u4fdd\u8cc7\u6599\u5eab\u8490\u96c61997\u5e74\u81f32011\u5e74\u4e4b\u9593\u65b0\u8a3a\u65b7\u4e4b\u87f9\u8db3\u816b\u75c5\u60a3\uff0c\u75c5\u60a3\u5fc5\u9808\u70ba\u4e8c\u5341\u6b72\u4ee5\u4e0a\u4e14\u904e\u53bb\u7121\u764c\u75c7\u8a3a\u65b7\u3002\u4ee5\u6a19\u6e96\u5316\u767c\u751f\u7387\u6bd4\uff08standardized incidence ratio, SIR\uff09\uff0c\u8a55\u4f30\u87f9\u8db3\u816b\u75c5\u60a3\u7f79\u60a3\u764c\u75c7\u4e4b\u98a8\u96aa\uff0c\u540c\u6642\u4e5f\u8a55\u4f30\u4f7f\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u87f9\u8db3\u816b\u662f\u5426\u589e\u52a0\u7f79\u764c\u98a8\u96aa\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u7e3d\u5171\u8490\u96c6\u4e8618,646\u4f4d\u87f9\u8db3\u816b\u75c5\u60a3\uff0c\u8ffd\u8e64\u671f\u4e2d\u4f4d\u6578\u70ba5.6\u5e74\uff0c\u5171\u6709338\u4f4d\u75c5\u4eba\u7f79\u60a3\u764c\u75c7\u3002\u87f9\u8db3\u816b\u75c5\u60a3\u4e4b\u5168\u764c\u75c7\u6a19\u6e96\u5316\u767c\u751f\u7387\u6bd4\u7a0d\u9ad8\u65bc\u4e00\u822c\u65cf\u7fa4\uff08SIR 1.12, 95%\u4fe1\u8cf4\u5340\u9593 1.00-1.24, p= 0.049\uff09\uff0c\u7279\u5225\u662f\u5728\u5973\u6027\uff08SIR 1.22, 95%\u4fe1\u8cf4\u5340\u9593 1.06-1.40, p= 0.006\uff09\u3002\u91dd\u5c0d\u55ae\u4e00\u764c\u75c7\uff0c\u87f9\u8db3\u816b\u75c5\u60a3\u7f79\u60a3\u9aa8\u9abc\u53ca\u8edf\u7d44\u7e54\u764c\u75c7\u4e4b\u98a8\u96aa\u986f\u8457\u63d0\u5347\uff08SIR 3.84, 95%\u4fe1\u8cf4\u5340\u95931.99-6.71, p\uff1c 0.001\uff09\u3002\u5728\u6240\u6709\u87f9\u8db3\u816b\u75c5\u60a3\u4e2d\uff0c\u53ea\u670922\u4f4d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u56e0\u6a23\u672c\u6578\u904e\u5c11\u800c\u7121\u6cd5\u6e96\u78ba\u7684\u8a55\u4f30\u5176\u7f79\u764c\u98a8\u96aa\u3002\u7d50\u8ad6\uff1a\u87f9\u8db3\u816b\u75c5\u60a3\u76f8\u8f03\u65bc\u4e00\u822c\u65cf\u7fa4\u6709\u8f03\u9ad8\u7684\u7f79\u764c\u98a8\u96aa\uff0c\u7279\u5225\u662f\u9aa8\u9abc\u53ca\u8edf\u7d44\u7e54\u764c\u75c7\u3002\u87f9\u8db3\u816b\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u4eba\u6578\u5f88\u5c11\uff0c\u56e0\u6b64\u7121\u6cd5\u9032\u4e00\u6b65\u8a55\u4f30\u653e\u5c04\u6cbb\u7642\u5f15\u8d77\u7684\u764c\u75c7\u98a8\u96aa\uff0c\u4f46\u4e5f\u8868\u793a\u76ee\u524d\u5728\u53f0\u7063\uff0c\u653e\u5c04\u6cbb\u7642\u65bc\u87f9\u8db3\u816b\u6cbb\u7642\u7684\u4f7f\u7528\u7387\u4ecd\u504f\u4f4e\u3002", "e": "Background: To evaluate the cancer risk in keloid patients and the risk of radiation-associated malignancy in keloid patients who received radiotherapyy (RT) in a population-based study. Materials and Methods: Patients with newly diagnosed keloid who were aged 20 years or above and had no antecedent cancers between 1997 and 2011 were recruited from Taiwan National Health Insurance Research Database. We used standardized incidence ratios (SIRs) to calculate the cancer incidence for keloid patients and also for the subgroup of patients who received RT for keloid. Results: A total of 18,646 keloid patients were enrolled. During a median follow-up time of 5.6 years, 338 patients developed cancers. The overall risk of cancer was slightly increased in keloid cohort (SIR 1.12, 95% confidence interval [CI] 1.00-1.24, p= 0.049), especially in women (SIR 1.22, 95% CI 1.06-1.40, p= 0.006). For specific cancer type, the risk of bone and soft tissue sarcoma was significantly elevated (SIR 3.84, 95% CI 1.99-6.71, p\uff1c 0.001). In the keloid cohort, only 22 (0.12%) patients received RT for keloid treatment. The cancer risk in this subgroup (SIR 2.34, 95% CI 0.28-8.46) cannot be estimated precisely as a consequence of lack of power. Conclusion: Keloids may be associated with an elevated cancer risk, especially for bone and soft tissue sarcoma. The risk of radiation-induced cancers cannot be estimated because the number of keloid patients who received RT is scarce; however, it implies that RT might be underused for treatment of keloids in Taiwan."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-293-301", "title": "\u958b\u767cMOSAIQ\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71\u7684\u7db2\u9801\u4ecb\u9762", "keywords": "MOSAIQ;\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71;\u7db2\u9801\u4ecb\u9762 MOSAIQ;Radiation Oncology Information System;Web Interface", "c": "\u76ee\u7684\uff1a\u900f\u904e\u7db2\u8def\u670d\u52d9\u7684\u5f62\u5f0f\u662f\u6700\u7c21\u55ae\u6709\u6548\u5411\u7528\u6236\u5448\u73fe\u8cc7\u8a0a\u7684\u65b9\u5f0f\uff0c\u56e0\u6b64\u6211\u5011\u958b\u767c\u4e86MOSAIQ\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71\u7684\u7db2\u9801\u4ecb\u9762\uff08MQweb\uff09\uff0c\u7528\u6236\u53ea\u9700\u4f7f\u7528\u7db2\u9801\u700f\u89bd\u5668\uff0c\u5c31\u53ef\u4ee5\u900f\u904e\u9019\u500bMQweb\u7372\u53d6\u6700\u5373\u6642\u7684\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u958b\u653e\u539f\u59cb\u78bc\u7684\u514d\u8cbb\u8edf\u9ad4\u5957\u4ef6\u5efa\u7f6e\u51fa\u4e00\u500b\u7db2\u9801\u4f3a\u670d\u5668\uff0c\u5728\u7db2\u9801\u4f3a\u670d\u5668\u4e0a\u57f7\u884c\u7684PHP\u7a0b\u5f0f\u76f4\u63a5\u9023\u7d50\u5230MOSAIQ\u8cc7\u6599\u5eab\uff0c\u4ee5\u7d50\u69cb\u5316\u67e5\u8a62\u8a9e\u8a00\uff08Structured Query Language, SQL\uff09\u9032\u884c\u67e5\u8a62\uff0c\u53d6\u56de\u8cc7\u6599\u5f8c\u518d\u986f\u793a\u5728\u7528\u6236\u7aef\u7684\u7db2\u9801\u700f\u89bd\u5668\u3002\u7d50\u679c\uff1a\u63d0\u4f9b\u5169\u500b\u5b8c\u6574\u53ef\u57f7\u884c\u7684\u539f\u59cb\u7a0b\u5f0f\u78bc\u4f5c\u70ba\u7bc4\u4f8b\uff0c\u8aaa\u660e\u5982\u4f55\u5be6\u73fe\u986f\u793a\u67d0\u4e00\u4f4d\u75c5\u60a3\u7684\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u8207\u90e8\u4f4d\u6458\u8981\uff08Dose Site Summary\uff09\u53ca\u986f\u793a\u7576\u65e5\u79d1\u5167\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u6392\u7a0b\u540d\u55ae\uff08Schedule\uff09\uff0c\u8b93\u8b80\u8005\u53ef\u4ee5\u5b8c\u6574\u91cd\u73fe\u6211\u5011\u7684\u7814\u7a76\u7d50\u679c\u3002\u7d50\u8ad6\uff1a\u91ab\u7642\u4eba\u54e1\u53ef\u4ee5\u900f\u904eMQweb\u9019\u500b\u7c21\u55ae\u6613\u7528\u4e14\u5bb9\u6613\u5ba2\u88fd\u5316\u7684\u7db2\u9801\u4ecb\u9762\uff0c\u5f9eMOSAIQ\u8cc7\u6599\u5eab\u7372\u53d6\u5291\u91cf\u3001\u90e8\u4f4d\u53ca\u6392\u7a0b\u7b49\u91cd\u8981\u7684\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\uff0c\u6d41\u66a2\u5730\u91dd\u5c0d\u75c5\u60a3\u8cc7\u8a0a\u9032\u884c\u6e9d\u901a\uff0c\u9032\u800c\u63d0\u5347\u5de5\u4f5c\u6548\u7387\u3002", "e": "Purpose: An online site is the most simple and effective way to present information to users. Therefore, we have developed a web interface for the MOSAIQ Radiation Oncology Information System, the MQweb. Users just need to use a web browser to obtain real-time patient radiotherapy information via the MQweb. Materials and Methods: We built a web server using an open-source free software package. The PHP programs executed on the web server were connected directly to the MOSAIQ database, and retrieved the data using the Structured Query Language (SQL), and then displayed the data in the client\u2019s web browser. Results: We provided two complete source code examples of how to display the dose site summary and the radiotherapy schedule. Consequently, readers can fully reproduce the results of our study. Conclusion: Medical staff can access the user-friendly and easy-to-customize MQweb to obtain important radiotherapy information such as dose, site and schedule from the MOSAIQ database, communicate easily with the patient, and improve productivity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-303-313", "title": "THE DIFFERENCES BETWEEN EPI AND 4D-CBCT IN EVALUATING INTER-FRACTION SETUP ERRORS FOR BREAST CANCER RADIOTHERAPY", "keywords": "Breast cancer;Image-guided radiotherapy (IGRT);Electronic portal image (EPI);4-dimensional cone-beam computerized tomography (4D-CBCT);Setup error \u4e73\u764c;\u5f71\u50cf\u5c0e\u5f15;\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u7cfb\u7d71;\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64;\u64fa\u4f4d\u8aa4\u5dee", "c": "\u76ee\u7684\uff1a\u73fe\u4eca\u5c0d\u65bc\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u904b\u7528\u65bc\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u7684\u89d2\u8272\uff0c\u76f8\u8f03\u65bc\u50b3\u7d71\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u7cfb\u7d71\uff0c\u662f\u5426\u80fd\u5e36\u4f86\u66f4\u591a\u7684\u76ca\u8655\u4ecd\u4e0d\u78ba\u5b9a\u3002\u672c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u70ba\u6bd4\u8f03\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u8207\u50b3\u7d71\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u65bc\u5075\u6e2c\u64fa\u4f4d\u7684\u7cfb\u7d71\u53ca\u96a8\u6a5f\u8aa4\u5dee\u4e4b\u5dee\u7570\u3002\u6b21\u8981\u76ee\u7684\u70ba\u5206\u6790\u5404\u7a2e\u75c5\u4eba\u76f8\u95dc\u56e0\u5b50\u5c0d\u65bc\u64fa\u4f4d\u8aa4\u5dee\u662f\u5426\u6709\u986f\u8457\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u897f\u51432013\u81f32016\u5e74\u672c\u7814\u7a76\u5171\u7d0d\u516517\u4f4d\u4e73\u764c\u8853\u5f8c\u7684\u60a3\u8005\uff1b\u6bcf\u4f4d\u60a3\u8005\u65bc\u982d\u5341\u6b21\u653e\u5c04\u6cbb\u7642\u524d\uff0c\u63a5\u53d7\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u8207\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u9019\u5169\u7a2e\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\u6821\u6b63\uff0c\u7531\u91ab\u5e2b\u7576\u5834\u8a18\u9304\u5169\u7a2e\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\uff0c\u8a55\u4f30\u6240\u5f97\u5230\u7684\u4e09\u8ef8\u8aa4\u5dee\u6578\u64da\uff08\u5305\u542b\u5de6\u53f3\u3001\u982d\u8173\u53ca\u524d\u5f8c\u65b9\u5411\uff09\uff0c\u4e26\u4f9d\u64da\u5404\u8ef8\u6578\u64da\u8a08\u7b97\u51fa\u4e0d\u540c\u5f71\u50cf\u5c0e\u5f15\u689d\u4ef6\u4e0b\u64fa\u4f4d\u4e4b\u5e73\u5747\u8aa4\u5dee\u3001\u7cfb\u7d71\u6027\u8aa4\u5dee\uff08\u03a3\uff09\u53ca\u96a8\u6a5f\u8aa4\u5dee\uff08\u03c3\uff09\u3002\u7406\u60f3\u7684PTV\u908a\u754c\u662f\u4ee5van Herk\u516c\u5f0f\u4f86\u8a08\u7b97\uff0c\u9032\u4e00\u6b65\u518d\u6bd4\u8f03\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u8207\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\uff0c\u9019\u5169\u7a2e\u5c0e\u5f15\u6280\u8853\u4e0b\u6240\u6e2c\u5f97\u4e4b\u4e09\u8ef8\u7684\u7cfb\u7d71\u8aa4\u5dee\u53ca\u96a8\u6a5f\u8aa4\u5dee\u662f\u5426\u6709\u7d71\u8a08\u4e0a\u7684\u5dee\u7570\uff1b\u540c\u6642\u5206\u6790\u75c5\u4eba\u76f8\u95dc\u56e0\u5b50\u5c0d\u64fa\u4f4d\u8aa4\u5dee\u7684\u5f71\u97ff\u6027\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5171\u5206\u6790170\u7d44\u96fb\u5b50\u5f0f\u9a57\u8b49\u7cfb\u7d71\u5f71\u50cf\u53ca170\u7d44\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u3002\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u8207\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u7684\u64fa\u4f4d\u8aa4\u5dee\u5e73\u5747\u503c\uff08mm\uff09\u53ca\u6a19\u6e96\u5dee\uff08mm\uff09\u5206\u5225\u70ba\uff1a\u5de6\u53f3\u65b9\u5411-0.24 \u00b1 0.73\u30010.02 \u00b1 1.17\uff1b\u982d\u8173\u65b9\u54110.75 \u00b1 1.40\u30011.54 \u00b1 1.78\uff1b\u524d\u5f8c\u65b9\u54110.27 \u00b1 1.10\u3001-0.15 \u00b1 1.32\u3002\u5206\u6790\u767c\u73fe\uff1a\u5169\u8005\u7684\u64fa\u4f4d\u8aa4\u5dee\u65bc\u5de6\u53f3\u53ca\u524d\u5f8c\u65b9\u5411\u5747\u7121\u986f\u8457\u5dee\u7570\uff1b\u7136\u800c\u5169\u8005\u982d\u8173\u65b9\u5411\u7684\u7cfb\u7d71\u8aa4\u5dee\u6709\u986f\u8457\u5dee\u7570\uff081.40 mm vs. 1.78 mm; p= 0.005\uff09\u3002\u5169\u7a2e\u5f71\u50cf\u5c0e\u5f15\u65b9\u6cd5\u6240\u63a8\u4f30\u7684\u6700\u4f73\u8a08\u756b\u9776\u9ad4\u7a4d\u908a\u754c\uff08mm\uff09\uff0c\u5206\u5225\u662fEPI\uff1a\u5de6\u53f3\u65b9\u54112.63\u3001\u982d\u8173\u65b9\u54116.09\u3001\u524d\u5f8c\u65b9\u54113.85\uff1b4D-CBCT\uff1a\u5de6\u53f3\u65b9\u54113.85\u3001\u982d\u8173\u65b9\u54116.68\u3001\u524d\u5f8c\u65b9\u54114.34\u3002\u7d93\u904e\u5206\u6790\uff0c\u6c92\u6709\u7279\u5b9a\u7684\u75c5\u4eba\u76f8\u95dc\u56e0\u5b50\u8207\u64fa\u4f4d\u8aa4\u5dee\u6709\u986f\u8457\u95dc\u806f\u6027\u3002\u7d50\u8ad6\uff1a\u6b64\u7814\u7a76\u767c\u73fe\uff0c\u82e5\u4f7f\u7528\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u4f5c\u70ba\u4e73\u764c\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u5f71\u50cf\u5c0e\u5f15\uff0c\u8207\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u76f8\u6bd4\uff0c\u9700\u7279\u5225\u6ce8\u610f\u96fb\u5b50\u5f0f\u5f71\u50cf\u9a57\u8b49\u6703\u660e\u986f\u4f4e\u4f30\u982d\u8173\u65b9\u5411\u7684\u7cfb\u7d71\u8aa4\u5dee\uff0c\u4e14\u5176\u65bc\u5404\u8ef8\u5411\u6240\u63a8\u4f30\u51fa\u7684\u8a08\u756b\u9776\u9ad4\u7a4d\u908a\u754c\u5747\u8f03\u7a84\u3002\u56e0\u6b64\u6211\u5011\u5efa\u8b70\uff0c\u81e8\u5e8a\u5be6\u52d9\u4e0a\u61c9\u8a72\u63a1\u7528\u56db\u7dad\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u6240\u8a08\u7b97\u51fa\u7684\u6700\u4f73\u8a08\u756b\u9776\u9ad4\u7a4d\u908a\u754c\u8f03\u70ba\u9069\u7576\u3002", "e": "Purpose: There remains uncertainty whether utilization of 4-dimensional cone-beam computerized tomography (4D-CBCT) has additional benefit over electronic portal image (EPI) in breast radiotherapy. The primary goal of this study was to compare the differences between EPI and 4D-CBCT in evaluating setup errors for breast cancer patients. The secondary aim was to assess the relationship between patient-related factors and setup errors. Materials & Methods: A prospective study with a total of 17 post-operative breast cancer patients was conducted between July 2013 and May 2016. All patients received two kinds of image-guided methods, EPI and 4D-CBCT, before each treatment in the first ten fractions of radiation. The translations in left-right (LR), superior-inferior (SI) and anterior-posterior (AP) directions under different image-guided techniques were measured by physicians on-line. Group systematic (\u03a3) and random errors (\u03c3) for each axis of EPI and 4D-CBCT were calculated. The optimal PTV margins were computed based on van Herk's formula. Differences in daily positioning errors were examined using Wilcoxon singed-ranks test to compare the results between EPI and 4D-CBCT. The Mann-Whitney U-test was used to distinguish the significance between the setup errors and the following patient-related factors: age, height, weight, BMI, laterality of breast cancer and the chest ratio of maximal anterior-posterior to lateral diameter measured from simulation images. Results: The total serial images were 170 EPIs and 170 4D-CBCTs. The mean (mm) and standard deviation (mm) of setup errors of EPI and 4D-CBCT were -0.24 \u00b1 0.73 and 0.02 \u00b1 1.17 in LR direction; 0.75 \u00b1 1.40 and 1.54 \u00b1 1.78 in SI direction; 0.27 \u00b1 1.10 and -0.15 \u00b1 1.32 in AP direction, respectively. The systemic (\u03a3) and random errors (\u03c3) for 4D-CBCT (\u03a3_(LR)= 1.17 mm, \u03a3_(AP)= 1.32 mm and \u03c3_(LR)= 1.32 mm, \u03c3_(AP)= 1.49 mm) and EPI (\u03a3_(LR)= 0.73 mm, \u03a3_(AP)= 1.10 mm and \u03c3_(LR)= 1.15 mm, \u03c3_(AP)= 1.57 mm) were not significant difference in the LR and AP directions. In the SI direction, the systemic setup errors were significantly different between EPI vs. 4D-CBCT (1.40 mm vs. 1.78 mm; p= 0.005). The calculated PTV margins (mm) measured by EPI and 4D-CBCT were 2.63 and 3.85 in LR direction; 6.09 and 6.68 in SI direction; 3.85 and 4.34 in AP direction, respectively. None of the patient-related factors have conclusive influence on these setup errors. Conclusion : This study found that EPI would significantly underestimate the setup errors in the SI direction compared to 4D-CBCT, which in-turn generates a narrower PTV margin by van Herk's formula. Thus we should be careful when using EPI for correction of inter-fraction setup errors in the SI direction of breast cancer patients. We suggest applying the optimal PTV margins calculated from the 4D-CBCT method for clinical application."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-315-322", "title": "\u5229\u7528\u56db\u7dad\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5206\u6790\u809d\u81df\u53ca\u80ba\u90e8\u816b\u7624\u547c\u5438\u4f4d\u79fb\u5f71\u97ff\u56e0\u5b50\u4e4b\u7814\u7a76", "keywords": "\u56db\u7dad\u96fb\u8166\u65b7\u5c64;\u547c\u5438\u76e3\u6e2c;\u80ba\u90e8\u816b\u7624;\u809d\u81df\u816b\u7624 Four dimensional computed tomography (4D CT);Respiratory gating;Pulmonary tumor;Hepatic tumor", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u904b\u7528\u56db\u7dad\u96fb\u8166\u65b7\u5c64\uff08four dimensional computed tomography, 4D CT\uff09\u64f7\u53d6\u75c5\u4eba\u5728\u4e0d\u540c\u547c\u5438\u76f8\u4f4d\u7684\u65b7\u5c64\u5f71\u50cf\uff0c\u4e26\u6536\u96c6\u75c5\u4eba\u8179\u570d\u548c\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08body mass index, BMI\uff09\u8cc7\u8a0a\uff0c\u5206\u6790\u547c\u5438\u5c0d\u65bc\u816b\u7624\u4f4d\u79fb\u7a0b\u5ea6\u7684\u5f71\u97ff\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9078\u64c710\u4f4d\u539f\u767c\u6027\u80ba\u764c\u6216\u80ba\u8f49\u79fb\uff0c8\u4f4d\u809d\u764c\u6216\u809d\u81df\u8f49\u79fb\u75c5\u4eba\uff0c\u6536\u96c6\u75c5\u4eba\u7684BMI\u53ca\u8179\u570d\u8cc7\u6599\u3002\u6bcf\u4f4d\u75c5\u60a3\u53d6\u5f97\u4e00\u7d44\u6b63\u5e38\u547c\u5438\u7684CT\u5f71\u50cf\uff0c\u63a5\u8457\u6383\u63cf\u53e6\u4e00\u7d444D CT\u4e26\u91cd\u7d44\u51fa\u6700\u5927\u5bc6\u5ea6\u6295\u5f71\u5f71\u50cf\uff08Maximum Intensity Projection, MIP\uff09\uff0c\u4ee5\u6b64\u5169\u7d44\u5f71\u50cf\u5206\u5225\u754c\u5b9a\u51fa\u816b\u7624\u7bc4\u570d\uff08CTV_(NB)\u548cCTV_(MIP)\uff09\uff0c\u8a08\u7b97\u51fa\u5169\u8005\u4e4b\u9593\u7684\u9ad4\u7a4d\u5dee\u7570\u767e\u5206\u6bd4\uff08V_(diff)\uff09\uff0c\u4ee5V_(diff)\u505a\u70ba\u56e0\u547c\u5438\u9020\u6210\u7684\u816b\u7624\u79fb\u52d5\u7bc4\u570d\u6307\u6a19\uff0c\u4e4b\u5f8c\u4f7f\u7528SPSS\u8edf\u9ad4\u9032\u884c\u7dda\u6027\u8ff4\u6b78\u5206\u6790\u3002\u7d50\u679c\uff1a\u5c0d\u80ba\u81df\u816b\u7624\u75c5\u4eba\u4f86\u8aaa\uff0cV_(diff)\u548cBMI\u8207\u8179\u570d\u4e4b\u9593\u7121\u76f8\u95dc\u6027\u3002\u809d\u81df\u816b\u7624\u75c5\u4eba\u7fa4\u7d44\u5247\u767c\u73feV_(diff)\u548cBMI\u5448\u986f\u8457\u76f8\u95dc\u6027\u800c\u8179\u570d\u5247\u7121\uff0c\u8868\u793aBMI\u662f\u547c\u5438\u5c0d\u65bc\u809d\u81df\u816b\u7624\u4f4d\u79fb\u7a0b\u5ea6\u7684\u5f71\u97ff\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5f97\u77e5BMI\u8207\u8179\u570d\u5c0d\u80ba\u90e8\u816b\u7624\u7684\u75c5\u4eba\u7684\u816b\u7624\u4f4d\u79fb\u7121\u76f8\u95dc\u6027\uff0c\u4f46\u5728\u809d\u81df\u816b\u7624\u7684\u75c5\u4eba\u5247\u986f\u793a\u51fa\u76f8\u95dc\u6027\uff1b\u809d\u81df\u816b\u7624\u7684\u75c5\u4eba\u5728\u6b63\u5e38\u547c\u5438\u7684\u60c5\u6cc1\u4e0b\uff0cBMI\u548cV_(diff)\u4e4b\u9593\u5448\u73fe\u53cd\u5411\u7684\u95dc\u4fc2\uff0cBMI\u8d8a\u9ad8\u5247V_(diff)\u8d8a\u4f4e\u3002\u63a8\u6e2c\u6b64\u95dc\u4fc2\u662f\u56e0\u70ba\u809d\u81df\u816b\u7624\u4f4d\u65bc\u8179\u90e8\u6a6b\u9694\u9644\u8fd1\uff0c\u6a6b\u8188\u819c\u79fb\u52d5\u5e45\u5ea6\u6703\u53d7\u5230\u75c5\u4eba\u7684\u80d6\u7626\u5f71\u97ff\uff0c\u80d6\u7684\u4eba\u5176\u6a6b\u9694\u819c\u79fb\u52d5\u5e45\u5ea6\u8f03\u5c0f\u3002\u5728\u81e8\u5e8a\u4e0a\u53ef\u6839\u64da\u75c5\u4eba\u9ad4\u578b\u4f86\u9078\u64c7\u9069\u7576\u7684\u547c\u5438\u63a7\u5236\u53ca\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose : To analyze the correlation between body mass index (BMI) and respiration-induced tumor motion, and waist circumference and respiration-induced tumor motion by using different respiratory phases from four dimensional computed tomography (4D-CT) Materials and Methods : Ten patients with primary lung cancer or metastatic lung lesion, and eight patients with primary hepatic cancer or metastatic hepatic lesion who received radiotherapy (RT) during Dec. 2014 to Nov. 2015 were included in this study. Data of BMI and waist circumference for each patient were collected. Images from free breathing CT scans and MIP images from 4D-CT scans were obtained for each patient and used for delineating CTV_(NB) and CTV_(MIP), respectively. We calculated the percentage of volume difference (V_(diff)) between CTV_(NB) and CTV_(MIP). Linear regression analysis between V_(diff) and BMI, and V_(diff) and waist circumference were performed by using Statistical Package for Social Sciences (SPSS) 19 (SPSS Inc., Chicago, IL) . Results : For patients with pulmonary tumor, there was no correlation between V_(diff) and BMI, and between V_(diff) and waist circumference. For patients with hepatic tumor, our study showed a significant correlation between V_(diff) and BMI, but no correlation between V_(diff) and waist circumference. According to the correlation analysis in our study, BMI was a factor influencing the magnitude of respiration-induced hepatic tumor motion. Conclusion : Our study showed that there was a significant correlation between V_(diff) and BMI for patients with hepatic tumor. We speculate that the small V_(diff) for patients with hepatic tumor and high BMI was caused by the tumor location which near the diaphragm, and the magnitude of diaphragm motion was easily influenced by the BMI. Therefore, we could design appropriate treatment techniques for breathing control according to the BMI of the patient."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-323-333", "title": "\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u6a5f\u4ee5\u4e0d\u540c\u5c04\u675f\u963b\u64cb\u65b9\u5f0f\u6cbb\u7642\u809d\u816b\u7624\u4e4b\u5291\u91cf\u5b78\u8a55\u4f30", "keywords": "\u96fb\u8166\u65b7\u5c64\u6cbb\u7642;\u809d\u7d30\u80de\u764c;\u5c04\u675f\u963b\u64cb;\u6cbb\u7642\u8a08\u5283\u5291\u91cf\u9a57\u8b49 Tomotherapy;Hepatocellular carcinoma;Block;Delivery quality assurance", "c": "\u76ee\u7684\uff1a\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u70ba\u4e00\u7a2e\u65cb\u9032\u5f0f\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff0c\u85c9\u7531\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u642d\u914d\u6cbb\u7642\u5e8a\u7684\u9023\u7e8c\u79fb\u52d5\u4f86\u9054\u5230\u9ad8\u5ea6\u9806\u578b\u7684\u5291\u91cf\u5206\u4f48\uff0c\u672c\u5be6\u9a57\u7684\u76ee\u7684\u70ba\u809d\u816b\u7624\u4f7f\u7528\u4e0d\u540c\u5c04\u675f\u963b\u64cb\u65b9\u5f0f\u6240\u5448\u73fe\u7684\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u6bd4\u8f03\u8207\u5291\u91cf\u9a57\u8b49\u6e96\u78ba\u5ea6\u4e4b\u8a55\u4f30\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u6b21\u5be6\u9a57\u662f\u5229\u7528\u56de\u6eaf\u6027\u7684\u65b9\u5f0f\u9078\u53d610\u4f4d\u809d\u816b\u7624\u75c5\u4eba\u4e4b\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u91cd\u65b0\u57f7\u884c\u6cbb\u7642\u8a08\u5283\uff0c\u6bcf\u4f4d\u75c5\u4eba\u5206\u5225\u4f7f\u7528None\uff08without block\uff09\u3001Directional block\u53caComplete block\uff0c\u4f86\u9650\u5236\u5c04\u675f\u9032\u51fa\u7684\u89d2\u5ea6\uff0c\u4ee5\u4fdd\u8b77\u9130\u8fd1\u7684\u5668\u5b98\u3002\u6cbb\u7642\u8a08\u5283\u5291\u91cf\u9a57\u8b49\u4f7f\u7528Exradin A1SL\u6e38\u96e2\u8154\u91cf\u6e2c\u7d55\u5c0d\u9ede\u5291\u91cf\u53ca\u4f7f\u7528EBT3\u5e95\u7247\u4f86\u505a\u4e8c\u7dad\u76f8\u5c0d\u5291\u91cf\u4e4b\u91cf\u6e2c\u3002\u7d50\u679c\uff1a\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u986f\u793a\u6c92\u6709\u4f7f\u7528\u4efb\u4f55\u5c04\u675f\u963b\u64cb\u7684\u6cbb\u7642\u8a08\u5283\u80fd\u63d0\u4f9b\u8f03\u4f73\u7684\u8a08\u5283\u9776\u9ad4\u7a4d\u5305\u8986\u53ca\u5291\u91cf\u9806\u578b\u5ea6\u8207\u5747\u52fb\u5ea6\uff0c\u6cbb\u7642\u8a08\u5283\u5e73\u5747\u76e3\u6e2c\u55ae\u4f4d\uff08monitor unit, MU\uff09\u6578none\uff08without block\uff09\u3001directional block \u53cacomplete block\u4f9d\u5e8f\u70ba3338.1\u30013871.7\u30014761.4 MU\uff0c\u5e73\u5747\u6cbb\u7642\u6642\u9593\u70ba237.26\u3001273.64\u3001334.29\u79d2\uff0c\u6b63\u5e38\u809d\u7d44\u7e54\u7684V5\u4f9d\u5e8f\u70ba81.8%\u300171.8%\u300157.5%\uff0c\u5176\u4ed6\u9130\u8fd1\u5371\u6025\u5668\u5b98\u80c3\u3001\u5341\u4e8c\u6307\u8178\u3001\u814e\u81df\u3001\u5c0f\u8178\u3001\u810a\u690e\u7684\u5291\u91cf\u90fd\u9060\u4f4e\u65bc\u5291\u91cf\u9650\u5236\uff0c\u6cbb\u7642\u8a08\u5283\u9a57\u8b49\u7d50\u679c\u5728\u9ede\u5291\u91cf\u7686\u7b26\u5408\u00b13%\u7684\u57fa\u6e96\u5167\uff0c\u4e8c\u7dad\u76f8\u5c0d\u5291\u91cf\u4e4b\u4f3d\u508c\u901a\u904e\u7387\u5206\u5225\u70ba96.7\u00b12.2%\u300195.8\u00b12.8%\u300194.6\u00b13.8%\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u5c04\u675f\u963b\u64cbdirectional block\u80fd\u63d0\u4f9b\u4e0d\u932f\u7684\u816b\u7624\u5291\u91cf\u9806\u578b\u5ea6\u8207\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u4e5f\u986f\u8457\u5730\u6e1b\u5c11\u6b63\u5e38\u809d\u7d44\u7e54\u6240\u63a5\u53d7\u5230\u7684\u5291\u91cf\uff0c\u6cbb\u7642\u6642\u9593\u589e\u52a0\u7684\u6bd4\u4f8b\u7d04\u6bd4without block\u589e\u52a015%\uff0c\u5c0d\u65bc\u6574\u9ad4\u7684\u6cbb\u7642\u6642\u9593\u589e\u52a0\u4e0d\u591a\uff0c\u5728\u5291\u91cf\u9a57\u8b49\u7684\u7d50\u679c\u4e0d\u8ad6\u5728\u7d55\u5c0d\u9ede\u5291\u91cf\u8207\u5e73\u9762\u5291\u91cf\u7684\u91cf\u6e2c\u8207\u6cbb\u7642\u8a08\u5283\u7684\u7d50\u679c\u4e00\u81f4\u6027\u7686\u5f88\u9ad8\uff0cdirectional block \u5c0d\u65bc\u6162\u6027\u809d\u708e\u5e36\u539f\u809d\u816b\u7624\u7684\u75c5\u4eba\u63d0\u4f9b\u4e00\u500b\u53ef\u9078\u64c7\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose : Helical tomotherapy (HT) is a intensity-modulated radiotherapy treatment (IMRT) delivery system that achieves high dose conformality by multileaf collimator motion during treatment. The goal of this study was to evaluate the plan quality and delivery accuracy of the Hi-Art system with different plan parameters for the treatment of hepatocellular carcinoma. Materials and Methods: A total of 10 cases were analyzed in this study. Three HT treatments plans were generated for each case in the setting of without block, directional block and complete block respectively to adequately treat the planning target volume and spare the organ at risk. Patient delivery quality assurance (DQA) is an essential task to ensure the accuracy of doses delivered to the patients. The absolute point dose was measured with an Exradin A1SL ion chamber and Tomoelectrometer (Standard Imaging, Middleton, WI) which can be positioned anywhere along the central axis of the phantom, and Gafchromic EBT3 films were placed in the coronal orientation to acquire the planar representations of dose distribution. The measurements were analyzed using the gamma evaluation with the 3% dose and 3 mm distance criteria. Results: The results demonstrate that without block was capable of providing more uniform target doses. The conformation number and homogeneity index of plans without block were better than directional block and complete block. The average MUs was 3338.1, 3871.7, 4761.4 MU, and the delivery times was 237.3, 273.6, 334.3 seconds respectively. The V_5 values for the normal liver was 81.8%, 71.8%, 57.5%. All of the cases passed the 3% point dose difference criteria. The 3% / 3 mm average gamma passing rate was 96.7 \u00b1 2.2%, 95.8 \u00b1 2.8%, 94.6 \u00b1 3.8% for without block, directional block and complete block respectively. Conclusions: The results of this study had demonstrated that the three types of plans can be delivered accurately based on their own QA standards. The major advantage of directional block is to reduce the low dose region of normal liver and just increased approximately 15% of delivery time. The directional block can provide a good choice to the HCC patients with chronic hepatitis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-335-348", "title": "THE EFFECT OF RADIOTHERAPY ON THE OUTCOME OF PRIMARY GLIOSARCOMA: A CLINICAL STUDY OF THREE CASES AND A LITERATURE REVIEW", "keywords": "Gliosarcoma;Radiotherapy;Metastasis;High-grade glioma;Taiwan \u795e\u7d93\u81a0\u8cea\u8089\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u8f49\u79fb;\u9ad8\u5ea6\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624;\u53f0\u7063", "c": "\u539f\u767c\u6027\u795e\u7d93\u81a0\u8cea\u8089\u7624\uff08gliosarcoma, GS\uff09\u662f\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u7684\u7f55\u898b\u539f\u767c\u816b\u7624\uff0c\u662f\u4e00\u7a2e\u7368\u7279\u7684\u9ad8\u5ea6\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\uff0c\u540c\u6642\u64c1\u6709\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u8207\u8089\u7624\u7684\u5206\u5316\u30022016\u5e74\u4e16\u754c\u885b\u751f\u7d44\u7e54\u5728\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u816b\u7624\u5206\u985e\u4e2d\u5c07GS\u6b78\u985e\u70ba\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\uff08glioblastoma\uff09\u7684\u4e9e\u578b\uff0c\u7686\u70ba\u7b2c\u56db\u7d1a\u7684\u60e1\u6027\u8166\u7624\u3002\u7531\u65bcGS\u76f8\u7576\u7f55\u898b\uff0c\u6700\u4f73\u7642\u6cd5\u76ee\u524d\u4ecd\u4e0d\u660e\u78ba\uff0c\u81e8\u5e8a\u6cbb\u7642\u4e0a\u591a\u9075\u5faa\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u5728\u6700\u5927\u7bc4\u570d\u624b\u8853\u5207\u9664\u5f8c\uff0c\u642d\u914dtemozolomide\u5316\u7642\u4f75\u540c\u6b65\u653e\u5c04\u6cbb\u7642\u3002\u672c\u5831\u544a\u4ecb\u7d39\u4e86\u4e09\u4f4d\u7d93\u7531\u75c5\u7406\u78ba\u8a3a\u7684GS\u6848\u4f8b\uff0c\u5206\u6790\u5176\u81e8\u5e8a\u7279\u5fb5\uff0c\u6cbb\u7642\u904e\u7a0b\uff0c\u653e\u5c04\u6cbb\u7642\u53ca\u5176\u7642\u6548\u3002\u4e09\u540dGS\u60a3\u8005\uff0c\u6709\u5169\u540d\u7537\u6027\u548c\u4e00\u540d\u5973\u6027\uff0c\u4e2d\u4f4d\u5e74\u9f61\u70ba61\u6b72\uff0c\u816b\u7624\u5168\u90e8\u767c\u751f\u5728\u5929\u5e55\u4e0a\u5340\u57df\u3002\u5169\u4f8b\u60a3\u8005\u6709\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u8f49\u79fb\u81f3\u5c0d\u5074\u6216\u5176\u4ed6\u8166\u8449\uff0c\u53e6\u4e00\u4f8b\u5728\u8a3a\u65b7\u6642\u5373\u6709\u5ee3\u6cdb\u7684\u8166\u810a\u819c\u8f49\u79fb\uff0c\u5176\u4e2d\u4e00\u4f8b\u767c\u751f\u80ba\u548c\u80f8\u819c\u7684\u9871\u5916\u8f49\u79fb\u3002\u6240\u6709\u60a3\u8005\u5747\u63a5\u53d7\u50b3\u7d71\u5206\u6b21\u6216\u4f4e\u5206\u6b21\u9ad8\u5291\u91cf\u7684\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u76ee\u6a19\u8166\u816b\u7624\u9ad4\u7a4d\u7684\u7e3d\u653e\u5c04\u5291\u91cf\u9054\u523050\u81f360 Gy\uff08\u7bc4\u570d50.4\u81f359.4 Gy\uff09\u3002\u6211\u5011\u7684\u7814\u7a76\u7d50\u679c\u6307\u51fa\u624b\u8853\u5f8c\u5c40\u90e8\u653e\u7642\u53ef\u4ee5\u9054\u5230\u8166\u816b\u7624\u5c40\u90e8\u63a7\u5236\u6216\u7de9\u89e3\u6548\u679c\uff0c\u4e26\u4e14\u6c92\u6709\u660e\u986f\u7684\u653e\u7642\u526f\u4f5c\u7528\u3002\u4e09\u540d\u75c5\u4f8b\u5b58\u6d3b\u671f\u70ba8\u81f323\u500b\u6708\uff0c\u5b58\u6d3b\u671f\u4e2d\u4f4d\u657817\u500b\u6708\u3002\u7531\u65bcGS\u7684\u7368\u7279\u81e8\u5e8a\u548c\u6cbb\u7642\u7279\u5fb5\u76f8\u7576\u503c\u5f97\u7814\u7a76\uff0c\u6211\u5011\u5728Medline\u8490\u96c6\u53f0\u7063\u548c\u4e16\u754c\u5404\u5730\u7684GS\u60a3\u8005\u6587\u737b\u5831\u544a\u9032\u884c\u6574\u7406\u53ca\u6587\u737b\u56de\u9867\u3002", "e": "Primary gliosarcoma (GS) is a rare primary tumor of the central nervous system (CNS), and a unique entity among high-grade glioma, composed of both malignant glial and sarcomatous differentiations. The 2016 WHO classification of central nervous tumors classified GS as a grade IV astrocytic neoplasm and a variant of glioblastoma. Due to the rarity of GS, the optimal therapy is not well defined, and the clinical therapies for GS are usually in accordance with glioblastoma guidelines by the mode of maximal surgical resection followed by chemo-radiotherapy with temozolomide. This report describes three rare pathologically confirmed cases of GS in our hospital and analyzes the distinct clinical features, treatment course with more focus on radiotherapy, and their outcome. In our three GS patients, two males and one female with a median age of 61, the main tumors all occurred in the supra-tentorial brain. Two cases are presented with CNS metastasis to different cerebral lobes, and one case with widespread leptomeninges at initial diagnosis. Extra-cranial metastasis is also exhibited in the lungs and pleura during the clinical course. All patients received postoperative radiation therapy with conventional fractionation or hypofractionation regimen. The total radiation dose to the involved brain tumor bed (planning target volume) reached 50 - 60 Gy (range 50.4 to 59.4 Gy). Our results support the role of local radiotherapy after surgery, and the local control effect can be achieved or palliated without obvious side effects. Our cases survived 8 to 23 months with a median survival of 17 months. To highlight the unique clinical features of GS, we conduct a literature review of the reported clinical case series of GS patients in Taiwan and the world using Medline."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201712-201804110002-201804110002-349-355", "title": "METACHRONOUS BILATERAL SQUAMOUS CELL CARCINOMA OF THE EXTERNAL AUDITORY CANAL: A CASE REPORT", "keywords": "External auditory canal;Squamous cell carcinoma;Bilateral;Risk factor \u5916\u8033\u9053;\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c;\u96d9\u5074;\u98a8\u96aa\u56e0\u5b50", "c": "\u5916\u8033\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u662f\u4e00\u500b\u7f55\u898b\u7684\u764c\u75c7\uff0c\u5176\u6e90\u65bc\u5916\u8033\u4e26\u4fb5\u72af\u5468\u906d\u7d44\u7e54\u3002\u5176\u767c\u751f\u7387\u4f30\u8a08\u5728\u6bcf\u767e\u842c\u4eba\u53e3\u4e2d\u6709\u4e00\u5230\u516d\u4eba\u3002\u800c\u96d9\u5074\u7684\u5916\u8033\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u5247\u66f4\u662f\u6975\u70ba\u7f55\u898b\u3002\u56e0\u70ba\u8a72\u75be\u75c5\u7684\u7a00\u6709\u6027\uff0c\u81f3\u4eca\u5c0d\u65bc\u5b83\u7684\u81f4\u75c5\u6a5f\u8f49\u4ecd\u7121\u6cd5\u5b8c\u5168\u4e86\u89e3\uff1b\u4e0d\u904e\u5df2\u7d93\u6709\u5e7e\u500b\u6613\u81f4\u56e0\u5b50\u88ab\u63d0\u51fa\u4f86\u8a0e\u8ad6\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u500b\u60a3\u6709\u7570\u6642\u6027\u96d9\u5074\u5916\u8033\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u5973\u6027\uff0c\u5728\u624b\u8853\u5207\u5207\u9664\u5f8c\u8f14\u4ee5\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u500b\u6848\u3002\u9019\u662f\u672c\u9662\u7b2c\u4e00\u500b\u96d9\u5074\u5916\u8033\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u6848\u4f8b\u3002", "e": "Squamous cell carcinoma (SCC) of the external auditory canal (EAC) is a rare malignancy which arises from the external ear and invades to surrounding tissues. The incidence has been estimated at between 1 and 6 cases per million in the general population. Furthermore, bilateral external auditory canal squamous cell carcinoma is an extremely rare disease. Due to the extreme rarity of bilateral external auditory canal SCC, there is still a lack of complete research of its pathogenesis; however, a variety of predisposing factors have been described. We report the case of a female who had metachronous bilateral SCC of EAC treated by surgical excision followed by adjuvant radiotherapy (RT). To our knowledge, this case is the first bilateral SCC of the external auditory canal reported in our hospital."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-175-185", "title": "CyberKnife Radiosurgery for Refractory Trigeminal Neuralgia: A Single Institutional Experience", "keywords": "CyberKnife;Radiosurgery;Trigeminal neuralgia \u96fb\u8166\u5200;\u653e\u5c04\u7dda\u624b\u8853;\u4e09\u53c9\u795e\u7d93\u75db", "c": "\u76ee\u7684\uff1a\u9019\u7bc7\u6587\u7ae0\u7684\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u96fb\u8166\u5200\u653e\u5c04\u7dda\u624b\u8853\u7528\u65bc\u6cbb\u7642\u96e3\u6cbb\u578b\u4e09\u53c9\u795e\u7d93\u75db\u7684\u5b89\u5168\u6027\u3001\u529f\u6548\u3001\u548c\u526f\u4f5c\u7528\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728 2009 \u5e74 3 \u6708\u81f3 2014 \u5e74 10 \u6708\u4e4b\u9593\uff0c\u6709 22 \u4f4d\u60a3\u6709\u5178\u578b\u4e09\u53c9\u795e\u7d93\u75db\u7684\u75c5\u4eba\uff0c\u5c0d\u65bc\u4e4b\u524d\u7684\u85e5\u7269\u6216\u624b\u8853\u6cbb\u7642\u7121\u6548\uff0c\u5728\u6211\u5011\u7684\u96fb\u8166\u5200\u4e2d\u5fc3\u63a5\u53d7\u6cbb\u7642\u3002\u96fb\u8166\u5200\u653e\u5c04\u7dda\u624b\u8853\u7684\u5291\u91cf\uff08\u7bc4\u570d\uff1a60-65 Gy\uff09\u7d66\u4e88\u5728\u4e09\u53c9\u795e\u7d93\u6839\u548c\u8166\u5e79\u8ddd\u96e2 3 mm \u7684\u5730\u65b9\u3002\u653e\u5c04\u7dda\u5728\u8166\u5e79\u7684\u5291\u91cf\u88ab\u9650\u5236\u5728\u6700\u5927\u5291\u91cf\u7684\u767e\u5206\u4e4b 50 \u6216\u5c0f\u65bc 40 Gy\u3002\u6cbb\u7642\u7684\u7d50\u679c\u7d93\u7531\u96fb\u8a71\u8a62\u554f\u6216\u662f\u5b9a\u671f\u9580\u8a3a\u8ffd\u8e64\u4f86\u8a55\u4f30\u3002\u6cbb\u7642\u7684\u53cd\u61c9\u5247\u4f7f\u7528\u5305\u542b\u6709 Barrow Neurologic Institute (BNI) \u75bc\u75db\u548c\u81c9\u9ebb\u5206\u6578\u7684\u554f\u5377\u4f86\u8868\u793a\u3002\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f 36 \u500b\u6708\u3002\u5168\u90e8\u7684\u75c5\u4eba\u5c0d\u65bc\u96fb\u8166\u5200\u653e\u5c04\u7dda\u624b\u8853\u90fd\u6709\u6548\u679c\uff0c\u53ef\u4ee5\u5f9e\u4ed6\u5011\u6539\u5584\u7684 BNI \u5206\u6578\u4f86\u8b49\u660e\u3002\u75bc\u75db\u6700\u521d\u6539\u5584\u7684\u6642\u9593\u4e2d\u4f4d\u6578\u662f 7 \u5929\uff0c\u75bc\u75db\u6700\u5927\u6539\u5584\u7684\u6642\u9593\u4e2d\u4f4d\u6578\u662f 2\u500b\u6708\u3002\u5728\u6700\u5f8c\u8ffd\u8e64\u7684\u6642\u5019\uff0c\u6709 13 \u500b\u75c5\u4eba\uff0859%\uff09\u5b8c\u5168\u6c92\u6709\u4efb\u4f55\u75bc\u75db\uff08BNI I\uff09\uff1b3 \u500b\u75c5\u4eba\uff0814%\uff09\u5076\u723e\u611f\u5230\u75bc\u75db\u4f46\u662f\u4e0d\u9700\u8981\u85e5\u7269\uff08BNI II\uff09\uff1b6 \u500b\u75c5\u4eba\uff0827%\uff09\u6709\u4e2d\u5ea6\u75bc\u75db\u4e0d\u904e\u85e5\u7269\u80fd\u5920\u63a7\u5236\uff08BNIIII\uff09\u30025 \u500b\u75c5\u4eba\uff0823%\uff09\u5b8c\u5168\u6c92\u6709\u81c9\u9ebb\uff1b13 \u500b\u75c5\u4eba\uff0859%\uff09\u6709\u8f15\u5fae\u7684\u81c9\u9ebb\uff1b2 \u500b\u75c5\u4eba\uff089%\uff09\u6709\u7a0d\u5fae\u60f1\u4eba\u7684\u81c9\u9ebb\uff1b2 \u500b\u75c5\u4eba\uff089%\uff09\u6709\u975e\u5e38\u60f1\u4eba\u7684\u9ebb\u3002\u53ea\u6709 1 \u500b\u75c5\u4eba\uff084.5%\uff09\u7684\u75bc\u75db\u5fa9\u767c\u81f3\u96fb\u8166\u5200\u653e\u5c04\u7dda\u624b\u8853\u524d\u7684\u72c0\u614b\u3002\u548c\u5176\u4ed6\u7684\u6587\u737b\u76f8\u6bd4\uff0c\u6b64\u7bc7\u7814\u7a76\u986f\u793a\u8655\u65b9\u5291\u91cf\u8d8a\u9ad8\u8207\u6cbb\u7642\u5f8c\u8d8a\u9ebb\u548c\u6cbb\u7642\u6548\u679c\u4e26\u7121\u95dc\u9023\u3002\u7d50\u8ad6\uff1a\u96fb\u8166\u5200\u653e\u5c04\u7dda\u624b\u8853\u5c0d\u65bc\u96e3\u6cbb\u578b\u4e09\u53c9\u795e\u7d93\u75db\u662f\u4e00\u9805\u6709\u6548\u7684\u6cbb\u7642\u3002\u5728\u6211\u5011\u7684\u75c5\u4eba\u4e2d\uff0c\u5b83\u63d0\u4f9b\u4e86\u9ad8\u6bd4\u4f8b\u7684\u75bc\u75db\u63a7\u5236\uff0c\u65e9\u671f\u75bc\u75db\u7de9\u89e3\uff0c\u548c\u5f88\u5c11\u7684\u4f75\u767c\u75c7\u3002", "e": "Purpose : The purpose of this article is to evaluate the safety, efficacy, and side effects encountered in treating refractory trigeminal neuralgia (TN) using the CyberKnife radiosurgery (CKRS). Materials and Methods : Between March 2009 and October 2014, 22 patients with classical TN, refractory to previous medical or surgical treatments, received treatment at our CyberKnife center. The prescription dose of CKRS (range: 60-65 Gy) was delivered to the involved trigeminal nerve root entry zone with a 3-mm gap from the brainstem. Radiation dose to the brainstem was limited to 50% of the maximum dose or no more than 40 Gy. Treatment outcomes were assessed through telephone inquiries and scheduled follow-up visits. Treatment responses were addressed in a standard questionnaire containing the Barrow Neurologic Institute (BNI) pain score and facial numbness score. Results : The median duration of follow-up was 36 months. All patients responded to CKRS, as demonstrated by an improvement in their BNI pain scores. Median time to initial onset of pain relief was 7 days, and to maximal pain relief was 2 months. At the last follow-up, 13 patients (59%) were free from any pain (BNI I); 3 patients (14%) had occasional pain and no need of medication (BNI II), and 6 patients (27%) had moderate pain which was adequately controlled with medications (BNI III). Facial numbness was absent (BNI I) in 5 patients (23%), mild (BNI II) in 13 patients (59%), somewhat bothersome (BNI III) in 2 patients (9%), and very bothersome (BNI IV) in 2 patients (9%). Only 1 patient (4.5%) experienced pain relapse to the pre-CKRS status. Compared with other literatures, higher prescription doses and increased posttreatment numbness were not associated with better outcomes in this study. Conclusions : CKRS is an effective therapy for refractory trigeminal neuralgia. It provided high rates of pain control, early onset of pain relief, and few complications in our cohort."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-187-195", "title": "\u982d\u9838\u764c\u653e\u5c04\u6cbb\u7642\u4e2d\u4f7f\u7528\u4e0d\u540c\u56fa\u5b9a\u5668\u5c0d\u65bc\u80a9\u90e8\u7a69\u5b9a\u6027\u7684\u63a2\u8a0e", "keywords": "\u982d\u9838\u80a9\u6a21\u5177;\u64fa\u4f4d\u8aa4\u5dee;\u80a9\u90e8\u4f4d\u79fb Head and shoulder mask;Positioning error;Shoulder displacement", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u8a55\u4f30\u80a9\u90e8\u4f4d\u79fb\u91cf\u5c0d\u982d\u9838\u764c\u75c5\u60a3\u9838\u90e8\u5291\u91cf\u7684\u5f71\u97ff\uff0c\u4e26\u5728\u81e8\u5e8a\u4e0a\u89c0\u5bdf\u80a9\u90e8\u4f4d\u7f6e\u7684\u518d\u73fe\u6027\u8207\u7a69\u5b9a\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5206\u6210\u5047\u9ad4\u5be6\u9a57\u8207\u81e8\u5e8a\u5206\u6790\u5169\u90e8\u5206\uff0c\u5148\u7528\u5047\u9ad4\u6a21\u64ec\u4e0d\u540c\u7684\u80a9\u90e8\u4f4d\u79fb\u91cf\uff0c\u5206\u6790\u76f8\u5c0d\u65bc\u539f\u59cb\u6cbb\u7642\u8a08\u756b\u4e2d\u5c0d\u9838\u90e8\u5291\u91cf\u7684\u5f71\u97ff\u3002\u518d\u7d93\u672c\u9662\u4eba\u9ad4\u8a66\u9a57\u59d4\u54e1\u6703\u8a31\u53ef\u4e0b\uff0c\u81ea2010 \u5e745 \u6708\u81f32012 \u5e7412 \u6708222 \u4f4d\u75c5\u60a3\u5206\u6210\u982d\u9838\u6a21\u5177\uff08head mask, HM\uff09\u3001\u982d\u9838\u6a21\u5177\u52a0\u80a9\u727d\u5f15\u5668\uff08head mask+shoulder tractor, HM+T\uff09\uff1b\u982d\u9838\u80a9\u6a21\u5177\uff08head shoulder mask, HSM\uff09\u53ca\u982d\u9838\u80a9\u6a21\u5177\u52a0\u80a9\u727d\u5f15\u5668\uff08head shoulder mask+shoulder tractor, HSM+T\uff09\u56db\u500b\u65cf\u7fa4\uff0c\u6cbb\u7642\u6642\u7d93\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u4fee\u6b63\u64fa\u4f4d\u8aa4\u5dee\u5f8c\uff0c\u4ee5\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u8a18\u9304\u6bcf\u9031\u4e00\u6b21\u6cbb\u7642\u524d\u80a9\u90e8\u4f4d\u7f6e\uff08inter-fraction\uff09\u7684\u518d\u73fe\u6027\u548c\u6cbb\u7642\u904e\u7a0b\u4e2d\uff08intra-fraction\uff09\u7684\u7a69\u5b9a\u6027\u4f86\u5206\u6790\u81e8\u5e8a\u4e0a\u7684\u610f\u7fa9\u3002\u7d50\u679c\uff1a\u5047\u9ad4\u4f9d\u5e8f\u589e\u52a0\u80a9\u90e8\u9ad8\u5ea6 0 cm\u30011 cm\u30012 cm\u30013 cm\uff0c\u9838\u90e8\u5291\u91cf\u7684\u8b8a\u5316\u5728\u5291\u91cf\u767e\u5206\u6bd4D100\u53caD95 \u5206\u5225\u70ba102%\u300197.5%\u300194.4%\u300191.2% \u53ca 103%\u300199.3%\u300195%\u300192.5%\uff1b\u9ad4\u7a4d\u767e\u5206\u6bd4V100 \u53caV95 \u5206\u5225\u70ba97.4%\u300187.5%\u300152.2%\u300131.2% \u53ca99.5%\u300199%\u300190%\u300175.8%\u3002\u53ef\u77e5\u9838\u90e8\u5291\u91cf\u6703\u96a8\u8457\u80a9\u90e8\u4f4d\u79fb\u91cf\u8b8a\u5316\u800c\u7522\u751f\u5dee\u7570\u3002\u7528HM\u3001HM+T\u3001HSM\u3001HSM+T \u56db\u7a2e\u6a21\u5177\u4f86\u63a2\u8a0e\u5c0d\u65bc\u80a9\u90e8\u7684\u76f8\u95dc\u5f71\u97ff\u6027\uff0c\u5176\u4e2dinter-fraction \u518d\u73fe\u6027\u76843D vector \u503c\u5206\u5225\u662f\u53f3\u80a911.6\u00b14.1 mm\u300110.1\u00b14.1mm\u30015.5\u00b12.0 mm\u30015.6\u00b12.6 mm\uff1b\u5de6\u80a99.7\u00b13.3 mm\u300110.9\u00b13.9 mm\u30015.3\u00b11.9 mm\u30015.9\u00b12.3mm\u3002intra-fraction \u7a69\u5b9a\u6027\u76843D vector \u503c\uff08mm\uff09\u5206\u5225\u662f\u53f3\u80a94.4\u00b12.6 mm\u30014.3\u00b11.5 mm\u30012.2\u00b10.8 mm\u30012.9\u00b11.3 mm\uff1b\u5de6\u80a93.9\u00b11.8 mm\u30014.1\u00b11.3 mm\u30012.1\u00b11.1 mm\u30013.1\u00b11.5 mm\u3002\u7d50\u8ad6\uff1a\u80a9\u90e8\u4f4d\u7f6e\u7684\u6539\u8b8a\u78ba\u5be6\u6703\u5f71\u97ff\u653e\u5c04\u6cbb\u7642\u6642\u982d\u9838\u764c\u75c5\u60a3\u7684\u9838\u90e8\u5291\u91cf\u5206\u5e03\u5747\u52fb\u6027\uff0cHSM \u6a21\u5177\u4e0d\u8ad6\u662f\u518d\u73fe\u6027\u6216\u662f\u7a69\u5b9a\u6027\u90fd\u512a\u65bc\u5176\u4ed6\u6a21\u5177\uff0c\u62c9\u80a9\u727d\u5f15\u5668\u4e26\u7121\u89c0\u5bdf\u5230\u727d\u5f15\u5668\u7684\u52a9\u76ca\u3002\u5efa\u8b70\u6a21\u5177\u56fa\u5b9a\u5b9c\u9078\u64c7\u53ef\u4ee5\u964d\u4f4e\u80a9\u90e8\u4f4d\u79fb\u91cf\u7684\u6a21\u5177\uff0c\u4ee5\u7dad\u6301\u653e\u5c04\u6cbb\u7642\u6642\u7684\u518d\u73fe\u6027\u8207\u7a69\u5b9a\u6027\u3002", "e": "Purpose : This study evaluated the impact of the shoulder displacement in head and neck cancer and observed the reproducibility and stability of the shoulder position in clinical practice. Materials and Methods : This study was divided into the experimental and clinical parts. The experimental displacement of shoulder was evaluated with the Rando phantom. From May 2010 to Dec 2012, four mold groups of 222 patients were HM (head mask), HM + T (head mask with tractor), HSM (head shoulder mask), and HSM + T (head shoulder mask with shoulder tractor) after IRB approval. Setup error was corrected by image-guided system before treatment. Recording to the shoulder displacement error values before and after treatment were determined once a week by cone-beam computed tomography (CBCT). Results : After gradual increasing the shoulder height with 0 cm, 1 cm, 2 cm, 3 cm, the neck dose measured by Rando phantom are 102%, 97.5%, 94.4%, 91.2% and 103%, 99.3% , 95%, 92.5% in D100 and D95, and are 97.4%, 87.5%, 52.2%, 31.2% and 99.5%, 99%, 90%, 75.8% in V100 and V95, respectively. The neck dose is related to the displacement of shoulder. The reproducibility and stability of right and left shoulders displacement were determined as 3D vector during head and neck cancer radiation therapy. The results of right and left shoulders are 11.6\u00b14.1 mm, 10.1\u00b14.1 mm, 5.5\u00b12.0 mm, 5.6\u00b12.6 mm and 3.9\u00b11.8 mm, 4.1\u00b11.3 mm, 2.1\u00b11.1 mm, 3.1\u00b11.5 mm. Conclusion : Compared to HM or HM + T, HSM was more superior. It was recommended that the mold should be chosen approximately to reduce the shoulder displacement and to maintain the stability and reproducibility of radiation therapy. Using a suitable mold can reduce the displacement."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-197-205", "title": "Risk of ocular complications following radiation therapy in head and neck cancer patients: A nationwide retrospective population-based cohort study", "keywords": "Ocular complications;Radiation therapy;Head and neck cancer;National Health Insurance Research Database \u773c\u775b\u4f75\u767c\u75c7;\u653e\u5c04\u6cbb\u7642;\u982d\u9838\u764c;\u5065\u4fdd\u8cc7\u6599\u5eab", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u982d\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7522\u751f\u773c\u775b\u4f75\u767c\u75c7\u7684\u98a8\u96aa\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5f9e 1997 \u5e74\u81f3 2010 \u5e74\u81ea\u53f0\u7063\u5065\u4fdd\u8cc7\u6599\u5eab\u4e2d\uff0c\u627e\u51fa\u982d\u9838\u764c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u5171 2,733 \u4f4d\uff0c\u672a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u5171 375 \u4f4d\u3002\u8ffd\u8e64\u505c\u6b62\u6642\u9593\u70ba\u767c\u751f\u773c\u775b\u4f75\u767c\u75c7\uff08\u767d\u5167\u969c\u3001\u9752\u5149\u773c\u3001\u8996\u7db2\u819c\u75c5\u8b8a\uff09\u6216 2010 \u5e74 12 \u6708 31 \u65e5\u3002\u7d50\u679c\uff1a\u6821\u6b63\u53ef\u80fd\u5f71\u97ff\u7d50\u679c\u7684\u56e0\u5b50\u5f8c\uff0c\u982d\u9838\u764c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u6bd4\u672a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u7522\u751f\u773c\u775b\u4f75\u767c\u75c7\u7684\u98a8\u96aa\u70ba 2.45 \u500d\uff08HR; 2.451, 95% CI = 1.087\uff0d6.895\uff09\u3002\u7576\u8ffd\u8e64\u6642\u9593\u8d85\u904e 36 \u500b\u6708\uff0c\u982d\u9838\u764c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u6bd4\u672a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u7522\u751f\u773c\u775b\u4f75\u767c\u75c7\u7684\u98a8\u96aa\u70ba 2.581 \u500d\uff08adjusted HR =2.581, 95% CI = 1.256\uff0d5.493\uff09\u3002\u982d\u9838\u764c\u539f\u767c\u90e8\u4f4d\u4ee5\u9f3b\u54bd\u764c\u548c\u53e3\u8154\u764c\u5c45\u591a\uff1b\u7522\u751f\u7684\u773c\u775b\u4f75\u767c\u75c7\u4ee5\u8996\u7db2\u819c\u75c5\u8b8a\u548c\u767d\u5167\u969c\u5c45\u591a\u3002\u7d50\u8ad6\uff1a\u5728\u53f0\u7063\u7684\u982d\u9838\u764c\u75c5\u4eba\uff0c\u653e\u5c04\u6cbb\u7642\u8207\u4e4b\u5f8c\u7522\u751f\u7684\u773c\u775b\u4f75\u767c\u75c7\u5169\u8005\u6709\u76f8\u95dc\u806f\u6027\uff1b\u653e\u5c04\u816b\u7624\u79d1\u91ab\u5e2b\u5c0d\u6b64\u76f8\u95dc\u806f\u6027\u8981\u63d0\u9ad8\u8b66\u89ba\u3002", "e": "Purpose : To examine the risk of ocular complications following radiotherapy in head and neck cancer patients. Materials and Methods : We identified a radiotherapy cohort (n= 2,733) and a control cohort (n= 375) in the National Health Insurance Research Database from 1997 to 2010. The follow-up period was terminated upon developing ocular complications (ICD-9-CM 361, 362, 363, 365, 366) or on December 31, 2010. Results : After adjusting for the confounding factors of the study, the radiotherapy cohort had a higher adjusted hazard ratio (HR; 2.451, 95% CI = 1.087\uff0d6.895) of developing ocular complications than did the control cohort. The radiotherapy cohort was associated with a significantly higher risk of developing ocular complications compared with the control cohort when the follow-up period was longer than 36 months (adjusted HR = 2.581, 95% CI = 1.256\uff0d5.493). Primary head and neck tumors are mostly located in the nasopharynx and oral cavity. The most common associated ocular complications were retinopathy and cataracts. Conclusions : Patients who receive radiotherapy for head and neck cancer might be at higher risk for developing ocular complications in Taiwan. Radiation oncologists should pay more attention to this association."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-207-218", "title": "Radiotherapy for the Treatment of Intracranial Solitary Fibrous Tumor", "keywords": "Solitary fibrous tumor;Hemangiopericytoma;Intracranial tumor;Radiotherapy \u55ae\u767c\u6027\u7e96\u7dad\u7624;\u8840\u7ba1\u5916\u76ae\u816b\u7624;\u9871\u5167\u816b\u7624;\u653e\u5c04\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u55ae\u767c\u6027\u7e96\u7dad\u7624\uff08solitary fibrous tumor; SFT\uff09\u662f\u4e00\u985e\u7f55\u898b\u7684\u9593\u8cea\u816b\u7624\uff0c\u5b83\u5305\u62ec\u4e86\u5148\u524d\u7a31\u70ba\u8840\u7ba1\u5916\u76ae\u7d30\u80de\u7624\uff08hemangiopericytoma; HPC\uff09\u7684\u816b\u7624\u3002\u672c\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u662f\u5728\u65bc\u8a55\u4f30\u55ae\u767c\u6027\u7e96\u7dad\u7624\uff08\u4ee5\u53ca\u8840\u7ba1\u5916\u76ae\u816b\u7624\uff09\u7684\u81e8\u5e8a\u7279\u5fb5\uff0c\u75c5\u7406\u7d44\u7e54\u7279\u5fb5\u4ee5\u53ca\u672c\u9662\u653e\u5c04\u6cbb\u7642\u7684\u7d93\u9a57\u8207\u6cbb\u7642\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u57282002\u81f32016\u5e74\u9593\u5e74\u9593\uff0c\u5171\u670918\u4f4d\u75c5\u4eba\u65bc\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u9871\u5167\u55ae\u767c\u6027\u7e96\u7dad\u7624\u7684\u6cbb\u7642\u3002\u9019\u5169\u7a2e\u540d\u7a31\uff08SFT\u548cHPC\uff09\u5728\u904e\u53bb\u88ab\u8a8d\u70ba\u662f\u5404\u81ea\u7368\u7acb\u7684\u75be\u75c5\uff0c\u73fe\u5728\u56e0\u70ba\u5b83\u5011\u6709\u4e00\u4e9b\u5171\u901a\u7684\u7279\u6b8a\u57fa\u56e0\u88ab\u767c\u73fe\uff0c\u6839\u64da2016\u5e74\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71WHO\u7684\u65b0\u7248\u5206\u985e\uff0c\u5b83\u5011\u73fe\u5728\u88ab\u8a8d\u70ba\u662f\u540c\u4e00\u7a2e\u985e\u7684\u75be\u75c5\u3002\u70ba\u4e86\u5206\u6790\u9810\u5f8c\u56e0\u5b50\uff0c\u6211\u5011\u5c07\u4e8c\u7d1a\u7684\u7684\u8840\u7ba1\u5916\u76ae\u7d30\u80de\u7624\u4e8c\u7d1a\u55ae\u767c\u6027\u7e96\u7dad\u7624\u6b78\u985e\u70ba\u4e00\u7d44\uff0c\u4e26\u5c07\u5206\u5316\u4e0d\u826f\u8840\u7ba1\u5916\u76ae\u7d30\u80de\u7624\u8207\u4e09\u7d1a\u55ae\u767c\u6027\u7e96\u7dad\u7624\u6b78\u985e\u81f3\u70ba\u4e00\u7d44\u3002\u75c5\u4eba\u7684\u81e8\u5e8a\u8207\u75c5\u7406\u8cc7\u6599\u4ee5\u53ca\u653e\u5c04\u6cbb\u7642\u8cc7\u6599\u63a1\u81ea\u75c5\u6b77\u8a18\u9304\u8207\u6cbb\u7642\u8a18\u9304\u3002\u653e\u5c04\u6cbb\u7642\u6280\u8853\u5305\u62ec\u50b3\u7d71\u5206\u6b21\u5291\u91cf\u7684\u9ad4\u5916\u7167\u5c04\u8207\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u653e\u5c04\u6cbb\u7642\u7cfb\u7d71\u5305\u62ecVarian Medical System\u4ee5\u53caBrainLab\u7cfb\u7d71\u3002\u7d50\u679c\uff1a\u95dc\u65bc\u624b\u8853\u5207\u9664\u7684\u7a0b\u5ea6\uff0c14\u4f4d\u75c5\u4eba\u63a5\u53d7\u5168\u90e8\u5207\u9664\uff08gross total resection\uff09\uff0877.8%\uff09\uff0c\u4ee5\u53ca\u53e6\u59164\u70ba\u75c5\u4eba\u63a5\u53d7\u4e86\u90e8\u5206\u5207\u9664\uff08subtotal resection\uff09\uff0822.2%\uff09\u3002\u5341\u4f4d\u75c5\u4eba\u5728\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u63a5\u53d7\u904e\u4e00\u6b21\u5916\u79d1\u624b\u8853\uff0c\u6709\u56db\u4f4d\u5728\u653e\u5c04\u6cbb\u7642\u9322\u63a5\u53d7\u904e\u5169\u6b21\u624b\u8853\uff0c\u800c\u5176\u4ed6\u56db\u4f4d\u5247\u63a5\u53d7\u904e\u591a\u6b21\u624b\u8853\uff083-4 \u6b21\uff09\u3002\u6240\u6709\u75c5\u4eba\u5728\u624b\u8853\u5f8c\u90fd\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d12\u4f4d\u662f\u63a5\u53d7\u5206\u6b21\u653e\u5c04\u6cbb\u7642\uff0c\u800c\u53e66\u4f4d\u662f\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u5c0d\u65bc\u5206\u6b21\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u653e\u5c04\u5291\u91cf\u4e2d\u4f4d\u6578\u662f55.5 Gy\uff08\u7bc4\u570d30-60 Gy\uff09\uff0c\u800c\u5c0d\u65bc\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7684\u75c5\u4eba\uff0c\u653e\u5c04\u5291\u91cf\u4e2d\u4f4d\u6578\u662f16 Gy\uff08\u7bc4\u570d15 -16 Gy\uff09\u3002\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u9776\u5340\u9ad4\u7a4d\uff0c\u5c0d\u65bc\u5206\u6b21\u6cbb\u7642\u7684\u75c5\u60a3\u6cbb\u7642\u9776\u5340\u9ad4\u7a4d\u4e2d\u4f4d\u6578\u662f 123.8 \u7acb\u65b9\u516c\u5206\uff08\u7bc4\u570d49.1-237.0\uff09\uff0c\u800c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u5247\u662f5.84\u7acb\u65b9\u516c\u5206\uff08\u7bc4\u570d 3.5-29.24\uff09\u3002\u7814\u7a76\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba73.6\u500b\u6708\uff0c\u4e94\u5e74\u8207\u5341\u5e74\u7e3d\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba70.5%\u820747.0%\u3002\u6709\u5c40\u90e8\u9871\u5167\u5fa9\u767c\u7684\u75c5\u4eba\u67093\u4eba\uff0c\u9871\u5916\u9060\u7aef\u8f49\u79fb\u7684\u75c5\u4eba\u67094\u4f4d\uff0c\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u662f90.9%\u3002\u75c5\u7406\u5206\u985e\u4e0a\uff0c\u4e8c\u7d1a\u816b\u7624\uff08n= 9\uff09\u7684\u9060\u7aef\u8f49\u79fb\u6a5f\u7387\u8f03\u4f4e\uff0c\u4e94\u5e74\u7684\u7121\u9060\u7aef\u8f49\u79fb\u7387\u662f100%\uff0c\u76f8\u8f03\u65bc\u4e09\u7d1a\u816b\u7624\uff08n= 9\uff09\u768440.0%\uff08p= 0.02\uff09\u3002\u53e6\u5916\u7121\u75c5\u60e1\u5316\u7387\u65b9\u9762\u4e5f\u986f\u793a\u4e8c\u7d1a\u816b\u7624\u6a5f\u7387\u5177\u6709\u8f03\u4f4e\u7684\u4e00\u500b\u8da8\u52e2\uff0c\u4e8c\u7d1a\u816b\u7624\u4e94\u5e74\u7121\u75c5\u60e1\u5316\u7387 83.3%\u76f8\u8f03\u65bc\u4e09\u7d1a\u816b\u7624\u7684 34.3%\uff08p= 0.09\uff09\u3002\u56e0\u70ba\u75be\u75c5\u7f55\u898b\u4ee5\u53ca\u500b\u6848\u6578\u5c11\u7684\u95dc\u4fc2\uff0c\u624b\u8853\u5207\u9664\u7684\u7a0b\u5ea6\u8207\u7e3d\u9ad4\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u63a7\u5236\u7387\u3001\u7121\u75c5\u60e1\u5316\u7387\u90fd\u7121\u95dc\u3002\u7d50\u8ad6\uff1a\u624b\u8853\u6cbb\u7642\u662f\u55ae\u767c\u6027\u7e96\u7dad\u7624\u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\uff0c\u800c\u653e\u5c04\u6cbb\u7642\u63d0\u4f9b\u826f\u597d\u4e14\u5b89\u5168\u7684\u63a7\u5236\u7387\u3002\u75c5\u7406\u7684\u5206\u7d1a\u662f\u4e00\u500b\u986f\u8457\u7684\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose : Solitary fibrous tumor (SFT) is a rare mesenchymal tumor, encompassing tumor previously termed hemangiopericytoma (HPC). The aim of this study is to evaluate both histopathological and clinical factors of intracranial SFT, including tumors previously classified as HPC, and offer an analysis of treatment outcomes based on our experience. Materials & Methods : Between 2002 and 2016, 18 patients with intracranial SFT receiving radiotherapy at our hospital were eligible for this study. Hemangiopericytoma was grouped with grade II SFT, and anaplastic hemangiopericytoma was grouped with grade III SFT since they share similar genetic patterns and clinical prognosis. Clinicopathological and radiotherapy data were extracted from patient\u2019s medical record. Radiotherapy was administered by either conventional fractionated radiotherapy or stereotactic radiosurgery. The planning system includes Varian Medical System and BrainLab system. Results : Reviewing operative records, gross total resection was performed in 14 (77.8%) cases, while the remaining 4 (22.2%) cases had subtotal resection. All patients underwent postoperative RT. Before radiation therapy at our department, ten patients received one operation for SFT, four patients received two operations and the other four patients received more than two operations. Twelve patients received conventional fractionated radiotherapy and 6 received stereotactic radiosurgery. The median dose is 55.5 Gy (range 30 \uff0d 60 Gy) for fractionated RT and 16 Gy (range 15 \uff0d 16 Gy) for SRS. The median target volume for patients who received fractionated radiotherapy was 123.8 cm^3 (49.1 \uff0d 237.0 cm^3) and 5.84 cm^3 (range 3.5 \uff0d 29.24 cm^3) for those who received stereotactic radiosurgery. Median follow-up time was 73.6 months. Five and 10 years overall survival rates were 70.5%, and 47.0%, respectively. Tumors reoccurred as intracranial recurrence only (n= 3), and extracranial metastasis alone (n= 4). Local control rate at 5 years was 90.9%. The 5-year metastasis-free rate was 100.0% for grade II (n= 9) tumors and 40.0% for grade III tumors (n= 9) (p= 0.02). There was a trend toward improved progression-free rate in low-grade tumors, with a 5-year progression-free rate of 83.3% for grade II, and 34.3% for grade III tumors (p= 0.09). There was no significant difference for overall survival, progression free rate or local control rates by extent of surgery in this study. Conclusion : For patients with intracranial SFTs, resection remains the initial treatment and postoperative radiotherapy provides an effective and safe adjuvant management option. Histological grading is the most significant prognostic factor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-219-228", "title": "Clinical Outcomes of Advanced Stage Urothelial Carcinoma of the Renal Pelvis or Ureter After Adjuvant Radiotherapy", "keywords": "Radiation therapy;Transitional cell carcinoma (TCC);Upper tract urothelial carcinoma (UTUC) \u653e\u5c04\u6cbb\u7642;\u79fb\u5f62\u4e0a\u76ae\u7d30\u80de\u764c;\u6ccc\u5c3f\u4e0a\u76ae\u764c", "c": "\u76ee\u7684\uff1a\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u5728\u8853\u5f8c\u665a\u671f\u4e0a\u6ccc\u5c3f\u9053\u764c\u75c7\u7684\u89d2\u8272\u76ee\u524d\u5c1a\u672a\u660e\u77ad\u3002\u672c\u7bc7\u56de\u6eaf\u6027\u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u4e00\u91ab\u5b78\u4e2d\u5fc3\u7684\u665a\u671f\u4e0a\u6ccc\u5c3f\u9053\u764c\u75c7\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5\u8207\u6cbb\u7642\u6210\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6536\u96c6\u81ea\u897f\u5143 2006 \u5e74\u5230 2015 \u5e74\u9593\uff0c\u65bc\u6211\u5011\u91ab\u9662\u8a3a\u65b7\u70ba\u665a\u671f\u4e0a\u6ccc\u5c3f\u9053\u764c\u75c7\u4e26\u63a5\u53d7\u6cbb\u7652\u6027\u624b\u8853\u8207\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\u3002\u672c\u7814\u7a76\u63a1\u56de\u6eaf\u6027\u75c5\u6b77\u5206\u6790\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5\u3001\u6cbb\u7642\u3001\u526f\u4f5c\u7528\u4ee5\u53ca\u6cbb\u7642\u6210\u679c\u3002\u6240\u6709\u75c5\u4eba\u63a5\u53d7\u7684\u653e\u5c04\u6cbb\u7642\u5747\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u3002\u75c5\u4eba\u63a5\u53d7\u5316\u7642\u8207\u5426\u5247\u6191\u81e8\u5e8a\u91ab\u5e2b\u5224\u65b7\u3002\u6211\u5011\u4f7f\u7528 Kaplan-Meier \u5b58\u6d3b\u5206\u6790\u65b9\u6cd5\u4f86\u4f30\u8a08\u5404\u9805\u5b58\u6d3b\u7387\uff0c\u5305\u542b\u4e86\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\u3001\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\uff08LRFS\uff09\u3001\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\uff08DMFS\uff09\u4ee5\u53ca\u7121\u8180\u80f1\u5fa9\u767c\u5b58\u6d3b\u7387\uff08BRFS\uff09\u3002\u53e6\u5916\u5206\u6790\u4e26\u6bd4\u8f03\u55ae\u7368\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u6709\u5408\u4f75\u5316\u7642\u7684\u75c5\u4eba\uff0c\u5176\u75be\u75c5\u7684\u5fa9\u767c\u4ee5\u53ca\u526f\u4f5c\u7528\u7684\u5dee\u5225\u3002\u7d50\u679c\uff1a\u5171 20 \u4f4d\u75c5\u4eba\u7d0d\u5165\u8ffd\u8e64\u5206\u6790\u3002\u6240\u6709\u75c5\u4eba\u5747\u63a5\u53d7\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u7684\u6cbb\u7642\u6280\u8853\u3002\u6cbb\u7642\u5291\u91cf\u4ecb\u65bc 45.0 \u81f3 64.8 Gy\uff0c\u4e2d\u4f4d\u6578\u70ba 50.4 Gy\u3002\u4e2d\u4f4d\u8ffd\u8e64\u671f\u9593\u70ba 2.67 \u5e74\u3002\u6240\u6709\u75c5\u4eba\u4e09\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3001\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u53ca\u7121\u8180\u80f1\u5fa9\u767c\u5b58\u6d3b\u7387\u5206\u5225\u70ba 65.8%\u300181.5%\u300173.3%\u300192.3%\u3002\u6211\u5011\u767c\u73fe\u75c5\u4eba\u4f34\u96a8\u8853\u5f8c\u7684\u816b\u7624\u7d30\u80de\u6b98\u7559\u6216\u63a5\u8fd1\u624b\u8853\u7d44\u7e54\u908a\u7de3\uff08positive or close surgical margin\uff09\u6709\u8f03\u5dee\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff08p= .001\uff09\u3002\u6b21\u5206\u6790\u55ae\u7368\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u6709\u5408\u4f75\u5316\u7642\u7684\u75c5\u4eba\uff0c\u5176\u75be\u75c5\u7684\u5fa9\u767c\u53ca\u5b58\u6d3b\u5206\u6790\u65bc\u7d71\u8a08\u4e0a\u6c92\u6709\u986f\u8457\u7684\u5dee\u5225\u3002\u6c92\u6709\u75c5\u4eba\u7d00\u9304\u52303\u7d1a\u6216\u4ee5\u4e0a\u7684\u6025\u6027\u6cbb\u7642\u526f\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u8f14\u52a9\u6027\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6280\u8853\u7684\u6cbb\u7642\u5c0d\u65bc\u665a\u671f\u4e0a\u6ccc\u5c3f\u9053\u764c\u75c7\u4e26\u63a5\u53d7\u6cbb\u7652\u6027\u624b\u8853\u7684\u75c5\u4eba\uff0c\u5728\u672c\u91ab\u9662\u7684\u6cbb\u7642\u6210\u679c\u8207\u5176\u4ed6\u7814\u7a76\u662f\u76f8\u7576\u7684\u3002\u4e14\u75c5\u4eba\u7684\u9806\u5f9e\u5ea6\u548c\u526f\u4f5c\u7528\u7686\u5728\u5408\u7406\u4e14\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\u3002\u81f3\u65bc\u8f14\u52a9\u6027\u5316\u7642\u7684\u597d\u8655\uff0c\u9700\u8981\u9032\u4e00\u6b65\u7684\u524d\u77bb\u6027\u81e8\u5e8a\u5206\u6790\u624d\u5f97\u4ee5\u95e1\u660e\u3002", "e": "Purpose : The role of adjuvant radiotherapy after curative surgery to advanced stage urothelial carcinoma (transitional cell carcinoma) of the renal pelvis or ureter has not been proven in large randomized controlled trials. The purpose of this study is to review the outcomes and toxicities of adjuvant radiotherapy for advanced stage upper tract urothelial carcinoma (UTUC) of the renal pelvis or ureter in our single institution. Materials and Methods : We collected the patients with the diagnosis of UTUC of the renal pelvis or ureter, who received nephroureterectomy with bladder cuff resection (NUR+BCR) and adjuvant radiotherapy (RT) in our institution from 2006 to 2015. Clinicopathologic features, treatment modalities, toxicities and outcome variables were retrospectively reviewed. Adjuvant RT was given with intensity modulated radiotherapy (IMRT) technique for all the patients. Systemic chemotherapy (C/T) was administered at the physician\u2019s discretion of medical oncologists. The Kaplan-Meier method was used to estimate overall survival (OS), locoregional recurrence-free survival (LRFS), distant-metastasis-free survival (DMFS) and bladder-recurrence-free survival (BRFS). A subgroup analysis of treatment toxicities and failure pattern between the RT-alone group and C/T-combined group were also performed. Results : Twenty patients were eligible for the final analysis. All the patients received curative surgery and adjuvant radiotherapy with IMRT technique. Median dose of RT was 50.4 Gy (range 45.0 to 64.8 Gy). Median follow-up time was 2.67 years. The estimated 3-year OS, LRFS, DMFS and BRFS were 65.8%, 81.5%, 73.3% and 92.3%. We found that the patients with positive or close surgical margins had inferior overall survival (p= .001). No significant difference could be demonstrated in survival outcome between the groups with or without C/T administration. None of the patients experienced grade 3 or higher acute toxicities in our study. Conclusions : Adjuvant radiotherapy with IMRT technique after curative surgery for advanced stage UTUC patients achieved a comparable outcome with acceptable patient compliance and adverse events in our institution. The benefit of chemotherapy needs further elucidation through novel prospective studies."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-229-237", "title": "\u904b\u7528\u5167\u90e8\u7db2\u8def\u5efa\u69cb\u4e4b\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u8207\u6392\u7a0b\u7cfb\u7d71", "keywords": "\u653e\u5c04\u6cbb\u7642;\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71;\u6392\u7a0b Radiotherapy;Oncology Information System;Scheduling", "c": "\u76ee\u7684\uff1a\u7ba1\u7406\u653e\u5c04\u816b\u7624\u75c5\u4eba\u8cc7\u6599\u3001\u78ba\u4fdd\u75c5\u6b77\u5b8c\u6574\u3001\u53ca\u75c5\u4eba\u4e4b\u6392\u7a0b\u662f\u76f8\u7576\u91cd\u8981\u4f46\u8cbb\u529b\u7684\u5de5\u4f5c\u3002\u6211\u5011\u5229\u7528\u9662\u5167\u7db2\u8def\u767c\u5c55\u4e26\u5efa\u69cb\u4e86\u4e00\u5957\u653e\u5c04\u816b\u7624\u90e8\u9580\u5c08\u7528\u7684\u8cc7\u8a0a\u8207\u6392\u7a0b\u7cfb\u7d71\u4f86\u8f14\u52a9\u9019\u4e9b\u5de5\u4f5c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5efa\u69cb\u4e86\u4ee5\u7db2\u9801\u70ba\u57fa\u790e\u4e4b\u8cc7\u8a0a\u7cfb\u7d71\uff0c\u53ef\u8a18\u9304\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u81e8\u5e8a\u6240\u9700\u5404\u9805\u8cc7\u6599\u65bc\u8cc7\u6599\u5eab\u4e2d\u3002\u6b64\u7cfb\u7d71\u53ef\u52d5\u614b\u986f\u793a\u6cbb\u7642\u4e2d\u75c5\u4eba\u3001\u7b49\u5f85\u4e2d\u75c5\u4eba\u3001\u672a\u5b8c\u6210\u75c5\u6b77\u3001\u672a\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u6458\u8981\u7b49\u8b8a\u5316\u3002\u7cfb\u7d71\u540c\u6642\u4ea6\u8207\u653e\u5c04\u6cbb\u7642\u521d\u59cb\u75c5\u6b77\u3001\u91ab\u7642\u5f71\u50cf\u7cfb\u7d71\u3001\u53ca\u96fb\u5b50\u75c5\u6b77\u8207\u6aa2\u9a57\u7cfb\u7d71\u505a\u9023\u7d50\uff0c\u4e26\u9644\u5e36\u6709\u6392\u7a0b\u4e4b\u529f\u80fd\u3002\u7d50\u679c\uff1a\u6b64\u7cfb\u7d71\u65bc 2007 \u5e74 9 \u6708\u4e0a\u7dda\u4e4b\u5f8c\uff0c\u81f3\u4eca\u5df2\u6709\u8d85\u904e 15,000 \u7b46\u8cc7\u6599\u5b58\u5728\u7cfb\u7d71\u5167\u3002\u51e1\u53ef\u9023\u63a5\u9662\u5167\u7db2\u8def\u4e4b\u7bc0\u9ede\uff0c\u767b\u5165\u5f8c\u7686\u53ef\u5b58\u53d6\u672c\u7cfb\u7d71\u3002\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u8207\u6392\u7a0b\u7cfb\u7d71\u53ef\u4f9d\u5404\u4f7f\u7528\u8005\u6b0a\u9650\u986f\u793a\u4e0d\u540c\u756b\u9762\uff0c\u5404\u91ab\u5e2b\u4e4b\u75c5\u4eba\u52d5\u614b\u4e00\u76ee\u77ad\u7136\uff0c\u79d1\u90e8\u5de5\u4f5c\u4eba\u54e1\u5247\u53ef\u4ee5\u8f15\u6613\u8abf\u6574\u6392\u7a0b\u3002\u672c\u7cfb\u7d71\u66f4\u53ef\u4ee5\u532f\u51fa\u5404\u91ab\u5e2b\u6216\u5168\u79d1\u6240\u6709\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u7684\u8cc7\u6599\uff0c\u53ef\u7d71\u8a08\u5206\u6790\u75be\u75c5\u5206\u4f48\u3001\u6cbb\u7642\u4eba\u6578\u3001\u6a5f\u5668\u4f7f\u7528\u72c0\u6cc1\uff0c\u4f9b\u79d1\u90e8\u4e3b\u7ba1\u505a\u70ba\u7ba1\u7406\u53c3\u8003\u3002\u914d\u5408\u4f7f\u7528\u8005\u7684\u9700\u6c42\uff0c\u8fd1\u5e74\u5167\u66f4\u9678\u7e8c\u9023\u7d50\u764c\u75c7\u4e2d\u5fc3\u5b50\u7cfb\u7d71\u3001\u4e26\u589e\u52a0\u4f4f\u9662\u91ab\u5e2b\u75c5\u6b77\u8986\u6838\u8207\u6279\u6539\u529f\u80fd\u3002\u7d50\u8ad6\uff1a\u5229\u7528\u5167\u90e8\u7db2\u8def\u6240\u5efa\u69cb\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u548c\u6392\u7a0b\u8cc7\u8a0a\u7684\u8cc7\u6599\u5eab\uff0c\u65b9\u4fbf\u79d1\u90e8\u7684\u904b\u4f5c\uff0c\u8b93\u91ab\u5e2b\u53ef\u4ee5\u8ffd\u8e64\u75c5\u4eba\u76ee\u524d\u7684\u52d5\u5411\uff0c\u4e5f\u65b9\u4fbf\u7ba1\u7406\u8005\u7684\u7ba1\u7406\u3002\u6b64\u5916\uff0c\u80fd\u5920\u8207\u91ab\u9662\u5176\u4ed6\u7cfb\u7d71\u9023\u7d50\u4e26\u8207\u6642\u4ff1\u9032\u65b0\u589e\u529f\u80fd\u4ea6\u70ba\u672c\u7cfb\u7d71\u4e4b\u4e00\u5927\u7279\u8272\u3002", "e": "Purpose : Effective management of patient data, timely completion of records, and patient scheduling issues are important but tedious tasks. We developed and implemented a web-based oncology information system to facilitate management of patient records and task scheduling. Material and Methods: We developed a web-based interface and underlying database aimed to facilitate capture of patient-related information. This system dynamically presents patients currently on-treatment and patients on the waiting list, and also keeps track of due medical records. Integration with imaging, lab, and electronic medical record systems allows rapid physician access to relevant data. Scheduling capability was also implemented. Results : Since implementation of the system in September 2007, the database now contains over 15,000 entries. This system can be used anywhere in the hospital with Intranet access. Data is displayed according to defined privileges: physicians can easily access patient medical data, while departmental staff handles scheduling at ease. Department-wide patient demographics, patient throughput, and machine usage statistics generated by this system provides invaluable insight to aid management. Recently, several new features, including integration with Cancer Center subsystems and the ability to review residents' notes have been added to meet user needs. Conclusions: We implemented a web-based system tailored to radiation oncology workflow. This system allows physicians to keep track of patient status and provides administrative insight. The ability to progressively incorporate new functions is a highlight feature of our system."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-239-245", "title": "\u4f7f\u7528\u5bec\u80fd\u91cf\u4e2d\u5b50\u5075\u6aa2\u5668\u8a55\u4f30\u6a19\u9776\u771f\u5149\u5200\u7cfb\u7d71\u4e4b\u4e2d\u5b50\u5468\u570d\u7b49\u6548\u5291\u91cf", "keywords": "\u4e2d\u5b50\u5468\u570d\u7b49\u6548\u5291\u91cf;\u7121\u5c04\u675f\u6574\u5e73\u6ffe\u7247;\u5bec\u80fd\u91cf\u4e2d\u5b50\u5075\u6aa2\u5668 Neutron ambient dose equivalent;Flattening filter-free;Wide energy neutron detection instrument (WENDI-II)", "c": "\u76ee\u7684\uff1a\u6a19\u9776\u771f\u5149\u5200\uff08Varian TrueBeam\uff09\u7cfb\u7d71\u662f\u65b0\u4e00\u4ee3\u7684\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u7576\u9ad8\u80fd\uff38\u5149\uff08\uff1e 10 MV\uff09\u8207\u9ad8\u539f\u5b50\u5e8f\u7684\u7d44\u4ef6\u4f5c\u7528\u6642\u6703\u7522\u751f\u4e2d\u5b50\uff0c\u9019\u4e9b\u7d44\u4ef6\u53ef\u80fd\u662f\u6574\u5e73\u6ffe\u7247\uff08flattening filter, FF\uff09\u6216\u6e96\u76f4\u5100\uff0c\u6a19\u9776\u771f\u5149\u5200\u7cfb\u7d71\u8a2d\u8a08\u6210\u53ef\u64cd\u4f5c\u5728\u50b3\u7d71\u7684\u6709\u6574\u5e73\u6ffe\u7247\uff08flattening filter, FF\uff09\u6a21\u5f0f\uff0c\u6216\u65b0\u578b\u7684\u7121\u5c04\u675f\u6574\u5e73\u6ffe\u7247\uff08flattening filter free, FFF\uff09\u6a21\u5f0f\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u91dd\u5c0d Varian TrueBeam \u7cfb\u7d71\u65bc FF \u8207FFF \u5169\u7a2e\u6a21\u5f0f\u4e0b\uff0c\u4f7f\u7528\u5bec\u80fd\u91cf\u4e2d\u5b50\u5075\u6aa2\u5668\u8a55\u4f30\u4e2d\u5b50\u88ab\u8a98\u767c\u5f8c\u6240\u9020\u6210\u7684\u4e2d\u5b50\u5468\u570d\u7b49\u6548\u5291\u91cf\uff0cH*(10)\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528 10 MV \u7684 X \u5149\u5c04\u7dda\u65bc FF \u8207 FFF \u5169\u7a2e\u6a21\u5f0f\u4e0b\u9032\u884c\u7167\u5c04\uff0c\u6b64\u6642\u7684\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u548c\u6b21\u8981\u6e96\u76f4\u5100\u70ba\u5b8c\u5168\u95dc\u9589\u7684\u72c0\u614b\u3002\u5291\u91cf\u4ea4\u4ed8\u7684\u901f\u7387\u5728 FF \u6a21\u5f0f\u8207 FFF \u6a21\u5f0f\u4e0b\u5206\u5225\u70ba 600 MU/min \u82072400 MU/min\u3002H*(10) \u7684\u91cf\u6e2c\u662f\u5c07 WENDI-II \u5075\u6aa2\u5668\u7f6e\u65bc\u5c04\u675f\u4e2d\u5fc3\u9ede\u3001\u8ddd\u5c04\u675f\u4e2d\u5fc3\u9ede\u5171\u5e73\u9762\u65b9\u5411\uff08\u00b1X \u8ef8\uff09\u8207\u6b63\u4ea4\u5e73\u9762\u65b9\u5411\uff08-Y \u8ef8\uff09\u7b49\u4e09\u500b\u65b9\u5411\u5e73\u9762\u7684 50 cm \u548c 100 cm \u8655\uff0c\u53ca\u6cbb\u7642\u5ba4\u8ff7\u5bae\u8d70\u9053\u5165\u53e3\u8207\u51fa\u53e3\u7b49\u4f4d\u7f6e\u9032\u884c\u8a55\u4f30\uff0c\u6240\u6709\u4f4d\u7f6e\u6240\u6e2c\u5f97\u7684 H*(10) \u662f\u5728 200 MU \u7684\u7167\u5c04\u689d\u4ef6\u4e0b\u9032\u884c\u8a55\u4f30\u3002\u7d50\u679c\uff1a\u7576\u96a8\u8457\u9060\u96e2\u5c04\u675f\u4e2d\u5fc3\uff0c\u4e2d\u5b50\u5468\u570d\u7b49\u6548\u5291\u91cf\u6703\u96a8\u4e4b\u964d\u4f4e\uff0c\u4e14\u4e2d\u5b50\u7684\u5206\u4f48\u4e26\u975e\u5c0d\u7a31\u7684\uff0c\u4e2d\u5b50\u7522\u751f\u91cf\u5728\uff38\u5149\u5c04\u675f\u884c\u7d93\u65b9\u5411\u4e0a\u662f\u8f03\u9ad8\u7684\u3002\u7576\u7531 FF \u6a21\u5f0f\u6539\u6210 FFF \u6a21\u5f0f\u6642\uff0c\u5c04\u675f\u4e2d\u5fc3\u9ede\u9644\u8fd1\u4f4d\u7f6e\u7684H*(10) \u5c07\u7531 92.5 \u03bcSv \u964d\u4f4e\u81f3 30.8 \u03bcSv\uff0c\u800c\u5728\u8ff7\u9053\u7684 H*(10) \u5c07\u964d\u4f4e\u81f3 6.71 \u03bcSv\u3002\u7d50\u8ad6\uff1aTrueBeam \u7cfb\u7d71\u7684 FFF \u6a21\u5f0f\u53ef\u4ee5\u964d\u4f4e\u4e2d\u5b50\u5291\u91cf\u7684\u7522\u751f\uff0c\u800c\u7814\u7a76\u7684\u6578\u64da\u7d50\u679c\u4e5f\u5229\u65bc\u5f8c\u7e8c\u8a55\u4f3010 MV \u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7684\u5de5\u4f5c\u4eba\u54e1\u5291\u91cf\u53ca\u8f3b\u5c04\u9632\u8b77\u8a08\u756b\u7684\u53c3\u8003\u6e96\u5247\u3002", "e": "Purpose : The Varian TrueBeam system is a modern radiotherapy unit. Undesired neutrons are produced by the interaction of high-energy (\uff1e10 MV) photons with high-Z components such as the flattening filter (FF) and jaws. The new design of the Varian TrueBeam system enables the linac to be operated in the flattening-filter-free (FFF) mode, as well as in the FF mode. Therefore, the aim of this study was to evaluate the neutron ambient dose equivalent, H*(10), around the TrueBeam linac in the FF and FFF modes by using a wide energy neutron detection instrument (WENDI-II). Materials and Methods : Ten-megavolt X-ray beams were used in the FF and FFF modes, with the jaws and multileaf collimators fully closed. The dose delivery rates were set to 600 MU/min in the FF mode and 2400 MU/min in the FFF mode. The H*(10) was measured using the WENDI-II located at the isocenter, 50 and 100 cm away from the isocenter, and at the entrance and exit of the maze. The dose delivery was set to 200 MU. Result : The H*(10) was proportional to the monitor unit and declined with increasing distance to the isocenter. The distribution of scattered neutrons did not appear to be isotropic; the H*(10) was somewhat higher in the gun-target direction. The neutron ambient dose equivalent in the FFF mode was 30.8 \u03bcSv, lower than the 92.5 \u03bcSv detected in the FF mode. In the FFF mode, the neutron ambient dose equivalent in the maze decreased to 6.71 \u03bcSv. Conclusion : Operating the TrueBeam system in the FFF mode greatly decreases the level of undesired neutrons. It also corresponds to a reduction in activation within the treatment vault and subsequent exposure to patients and radiotherapists."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-247-254", "title": "Long-term follow-up after intensity-modulated radiation therapy in extramedullary plasmacytoma of pancreas: a case report", "keywords": "Extramedullary plasmacytoma;Pancreas;Intensity-modulated radiation therapy (IMRT) \u9ad3\u5916\u6f3f\u7d30\u80de\u7624;\u80f0\u81df;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642", "c": "\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u975e\u5e38\u7684\u7f55\u898b\u3002\u6700\u5e38\u898b\u7684\u81e8\u5e8a\u75c7\u72c0\u662f\u963b\u585e\u6027\u9ec3\u75b8\uff0c\u7b2c\u4e8c\u5e38\u898b\u7684\u75c7\u72c0\u662f\u8179\u75db\u3002\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u6709\u767e\u5206\u4e4b\u516b\u5341\u4f4d\u65bc\u80f0\u81df\u982d\u90e8\uff0c\u53e6\u5916\u767e\u5206\u4e4b\u4e8c\u5341\u4f4d\u65bc\u80f0\u81df\u9ad4\u8207\u80f0\u81df\u5c3e\u90e8\u3002\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u5728\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u88e1\u7684\u7279\u5fb5\u662f\u591a\u8449\u5be6\u8cea\u4f4e\u5bc6\u5ea6\u816b\u7624\uff0c\u7d93\u975c\u8108\u6ce8\u5c04\u986f\u5f71\u5291\u5f8c\u6703\u6709\u5747\u8cea\u986f\u5f71\u589e\u5f37\u3002\u85c9\u7531\u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u6307\u5f15\u7d30\u91dd\u62bd\u5438\u6280\u8853\u88ab\u8b49\u5be6\u662f\u7528\u4f86\u7372\u5f97\u80f0\u81df\u816b\u7624\u7d30\u80de\u5b78\u78ba\u5207\u8a3a\u65b7\u6700\u6709\u6548\u7684\u65b9\u6cd5\u3002\u81f3\u4eca\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u4ecd\u7136\u6c92\u6709\u4e00\u500b\u6a19\u6e96\u7684\u6cbb\u7642\u65b9\u91dd\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642\u8207\u7e5e\u9053\u624b\u8853\uff0c\u55ae\u7368\u6216\u5408\u4f75\u4f7f\u7528\u90fd\u66fe\u7d93\u88ab\u5831\u544a\u904e\u3002\u7531\u65bc\u6f3f\u7d30\u80de\u7624\u5c0d\u653e\u5c04\u7dda\u76f8\u7576\u654f\u611f\uff0c\u56e0\u6b64\u6709\u88ab\u5efa\u8b70\u662f\u53ef\u7528\u4f86\u6cbb\u7642\u6f3f\u7d30\u80de\u7624\u7684\u9078\u9805\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u88ab\u7528\u4f86\u6cbb\u7642\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u7684\u76f8\u95dc\u8cc7\u6599\u975e\u5e38\u7a00\u5c11\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u4ee5\u628a\u816b\u7624\u5305\u8986\u7684\u5f88\u597d\uff0c\u4e5f\u53ef\u628a\u5468\u570d\u91cd\u8981\u5668\u5b98\u7684\u653e\u5c04\u7dda\u5291\u91cf\u964d\u5230\u6700\u4f4e\u3002\u6211\u5011\u5831\u544a\u4e00\u500b\u80f0\u81df\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u7684\u500b\u6848\uff0c\u662f\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u9019\u4f4d\u75c5\u60a3\u6cbb\u7642\u5f8c\u7d93\u904e\u4e94\u5e74\u4ee5\u4e0a\u7684\u9577\u671f\u8ffd\u8e64\uff0c\u4ecd\u7136\u5b58\u6d3b\u4e14\u6c92\u6709\u5fa9\u767c\u7684\u73fe\u8c61\u3002", "e": "Extramedullary plasmacytoma (EMP) of the pancreas is very rare. Obstructive jaundice is by far the commonest symptom, followed by abdominal pain. About 80% of pancreatic EMPs are located in the head of the pancreas, whilst the remaining 20% are found in the body and/or the tail of the organ. The computed tomography (CT) appearance of pancreatic EMP is typically described as a multilobular solid hypodense mass with homogeneous intravenous contrast enhancement. Endoscopic ultrasonography (EUS)-fine needle aspiration (FNA) has been proven as the most effective means for making a definitive cytological diagnosis of a pancreatic mass. To date, a standardized treatment for EMPs of the pancreas has not been established. Radiotherapy, chemotherapy, and bypass procedures either alone or in combination have been described. Owing to the highly radiosensitive nature of plasma cell tumors, radiotherapy has been suggested as the treatment of choice. There is scarce information about results of intensity-modulated radiation therapy (IMRT) for the treatment of EMP of the pancreas. IMRT can deliver adequate target coverage while minimizing the dose to critical organs. We report a case of EMP of the pancreas treated with IMRT. Our patient remains alive and without recurrence at long-term follow-up (more than five years)."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201709-201710050001-201710050001-255-259", "title": "Intra-arterial Concurrent Chemo-Radiation Therapy (IACCRT ) for non-operative mouth floor cancer: A case report", "keywords": "Mouth floor cancer, Intra-arterial concurrent chemo-radiation therapy\n(IACCRT), Quality of life, Disease-free survival \u53e3\u5e95\u764c\u3001\u540c\u6b65\u52d5\u8108\u704c\u6ce8\u5316\u653e\u7642\u3001\u751f\u6d3b\u54c1\u8cea\u3001\u7121\u75c5\u751f\u5b58\u671f", "c": "\u665a\u671f\u53e3\u5e95\u764c\u7684\u6cbb\u7642\uff0c\u4e00\u822c\u662f\u624b\u8853\u5207\u9664\u8f14\u4ee5\u624b\u8853\u90e8\u4f4d\u548c\u5340\u57df\u6dcb\u5df4\u7d50\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5118\u7ba1\u7d93\u904e\n\u591a\u5c08\u79d1\u6cbb\u7642\uff0c\u8a72\u75be\u75c5\u9810\u5f8c\u5728\u904e\u53bb\u4ecd\u662f\u4e0d\u4f73\u3002\u6b64\u5916\uff0c\u5c07\u624b\u8853\u5c0d\u529f\u80fd\u548c\u5916\u89c0\u4e0a\u7684\u5f71\u97ff\uff0c\u964d\u5230\u6700\u4f4e\u4ecd\n\u7136\u662f\u500b\u6311\u6230\u3002\u540c\u6b65\u52d5\u8108\u704c\u6ce8\u5316\u653e\u7642\u65bc\u982d\u9838\u764c\u7684\u89d2\u8272\u4ecd\u7136\u662f\u6709\u722d\u8ad6\u7684\u3002\u6211\u5011\u5831\u544a\u9019\u7a2e\u8907\u5408\u6cbb\u7642\u65b9\n\u5f0f\u5728\u4e00\u500b 46 \u6b72\u7537\u6027\u53e3\u5e95\u764c\u7684\u6709\u6548\u6027\u8207\u53ef\u884c\u6027\uff0c\u4ee5\u4f5c\u70ba\u4e00\u500b\u975e\u624b\u8853\u6cbb\u7642\u7684\u66ff\u4ee3\u6027\u9078\u9805\u30029 \u5e74\u8ffd\u8e64\n\u4e0b\uff0c\u60a3\u8005\u4ecd\u4fdd\u6709\u7d55\u4f73\u7684\u751f\u6d3b\u54c1\u8cea\uff0c\u5916\u89c0\u8207\u7121\u75c5\u751f\u5b58\u671f\u3002", "e": "Locally advanced mouth floor cancer is generally treated with resection combined\nwith adjuvant radiation therapy of the primary tumor bed and regional nodes. Despite\naggressive multi-modality therapy, the disease outcomes have remained poor. To\npreserve function and a cosmetic effect, surgery remains a challenge. The role of\nintra-arterial concurrent chemo-radiation therapy in the multimodality treatment of head\nand neck cancer is still controversial. We report our experience of the effectiveness and\nfeasibility of this combination as an alternative non-surgical choice of treatment for a 46\nyear old male with cT2N1M0 mouth floor cancer. The patient had an excellent quality of\nlife, cosmetic appearance and disease-free survival after 9-year follow up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-85-95", "title": "SITES OF SKULL BASE INVASION AS PREDICTORS OF INTRACRANIAL EXTENSION IN NASOPHARYNGEAL CARCINOMA AND ITS IMPACT ON THE TREATMENT OUTCOME", "keywords": "Intracranial involvement;Magnetic resonance imaging;Nasopharyngeal carcinoma;Skull base invasion;Survival \u8166\u5167\u8513\u5ef6;\u78c1\u632f\u651d\u5f71;\u9f3b\u54bd\u764c;\u9871\u5e95\u4fb5\u72af;\u5b58\u6d3b\u7387", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9f3b\u54bd\u764c\u75c5\u4eba\u9871\u5e95\u4fb5\u72af\u5c0d\u9810\u5f8c\u7684\u5f71\u97ff\u548c\u8207\u8166\u5167\u8513\u5ef6\u4e4b\u76f8\u95dc\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5305\u62ec\u9023\u7e8c812\u4f4d\u7d93\u7d44\u7e54\u8a3a\u65b7\u70ba\u9f3b\u54bd\u764c\uff0c\u4e26\u4ee5\u96fb\u8166\u65b7\u5c64\u53ca\u78c1\u632f\u651d\u5f71\u9032\u884c\u539f\u767c\u816b\u7624\u8513\u5ef6\u4e4b\u8a55\u4f30\u3002\u6240\u6709\u5f71\u50cf\u5747\u7d93\u91cd\u65b0\u6aa2\u8996\uff0c\u8a55\u4f30\u75c5\u4eba\u5f71\u50cf\u7684\u8166\u5167\u8513\u5ef6\u8207\u9871\u5e95\u4fb5\u72af\u72c0\u6cc1\u3002\u7d50\u679c\uff1a\u5375\u5713\u5b54\u3001\u9873\u9aa8\u5ca9\u90e8\u3001\u8776\u9aa8\u659c\u5761\u548c\u7ffc\u816d\u7aa9\u4e4b\u816b\u7624\u4fb5\u72af\u8207\u8166\u5167\u8513\u5ef6\u76f8\u95dc\u3002\u9871\u5e95\u4fb5\u72af\u4e4b\u90e8\u4f4d\u6578\u76ee\u591a\u5c11\u6709\u660e\u986f\u4e0d\u540c\u4e4b\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3002\u5375\u5713\u5b54\u3001\u9873\u9aa8\u5ca9\u90e8\u548c\u7ffc\u816d\u7aa9\u4e4b\u816b\u7624\u4fb5\u72af\u4e5f\u540c\u6642\u5f71\u97ff\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3002\u7d50\u8ad6\uff1a\u5305\u62ec\u5375\u5713\u5b54\u3001\u9873\u9aa8\u5ca9\u90e8\u3001\u8776\u9aa8\u659c\u5761\u548c\u7ffc\u816d\u7aa9\u7684\u9871\u5e95\u4fb5\u72af\u70ba\u9f3b\u54bd\u764c\u4f75\u8166\u5167\u8513\u5ef6\u4e4b\u826f\u597d\u9810\u6e2c\u56e0\u5b50\uff0c\u9664\u4e86\u8776\u9aa8\u659c\u5761\u5916\u4e4b\u5176\u9918\u4e09\u8005\u4e5f\u6703\u5f71\u97ff\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3002", "e": "Purpose: To evaluate the influence of skull base abnormality on prognosis and correlation with intracranial invasion in nasopharyngeal carcinoma (NPC) patients. Materials and Methods: Total 812 consecutive patients with histologically confirmed NPC who underwent staging computerized tomography and magnetic resonance imaging for evaluation of primary tumor extension were enrolled in this study. All radiologic images were reviewed and assessed for intracranial extension and skull base invasion. Results: Tumor invasion of the foramen ovale, petrous portion of the temporal bone, clivus and the pterygopalatine fossa associated with intracranial involvement. The number in site of skull base lesions showed significant differences in local failure-free survival. Foramen ovale, petrous portion of the temporal bone and pterygopalatine fossa involvement also showed impact on local failure-free survival. Conclusions: Involvement of the skull base such as foramen ovale, petrous portion of the temporal bone, clivus, and pterygopalatine fossa could be good predictors of intracranial involvement in NPC and all except clivus affected local failure-free survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-97-106", "title": "\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642\u904b\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u98df\u9053\u764c\u60a3\u8005\u4e4b\u7642\u6548\uff0d\u55ae\u4e00\u6a5f\u69cb\u56de\u6eaf\u6027\u5206\u6790", "keywords": "\u98df\u9053\u764c;\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642;\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Definitive concurrent chemoradiotherapy (CCRT);Helical tomotherapy;Intensity Modulation Radiation Therapy (IMRT)", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u5206\u6790\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642\uff0c\u904b\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\uff0c\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u5c0d\u98df\u9053\u764c\u75c5\u4eba\u7684\u6cbb\u7642\u6548\u679c\u8207\u526f\u4f5c\u7528\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a2007\u81f32012\u5e74\u9593\uff0c\u5171\u670967\u4f4d\u98df\u9053\u764c\u75c5\u4eba\u63a5\u53d7\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642\uff0c\u5176\u4e2d34\u4f4d\u4f7f\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\uff0c33\u4f4d\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3002\u672c\u7814\u7a76\u900f\u904e\u8a55\u4f30\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u63a7\u5236\u7387\u8207\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u7684\u6cbb\u7642\u6548\u679c\uff0c\u4ee5\u53ca\u526f\u4f5c\u7528\u653e\u5c04\u6027\u80ba\u708e\u767c\u751f\u7387\u3001\u80ba\u90e8\u53ca\u5fc3\u81df\u7684\u5291\u91cf\u5206\u5e03\u72c0\u6cc1\uff0c\u6bd4\u8f03\u4e0d\u540c\u98df\u9053\u764c\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u512a\u52a3\u3002\u526f\u4f5c\u7528\u7684\u8a55\u4f30\u65b9\u6cd5\u70ba\u5e38\u898b\u4e0d\u826f\u4e8b\u4ef6\u8a55\u50f9\u6a19\u6e96\u7b2c3\u7248\uff08CTCAE version 3.0\uff09\u3002\u7d50\u679c\uff1a\u5168\u90e8\u75c5\u4eba\u7684\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba12.1\u500b\u6708\uff0c\u6574\u9ad4\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u657815\u500b\u6708\u3002\u6bd4\u8f03\u4f7f\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u6574\u9ad4\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u70ba15\u500b\u6708vs. 13.4\u500b\u6708\uff0c1\u5e74\u30012\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba69% vs. 60.6%\u300129.8% vs. 26.7%\uff08p = 0.48\uff09\uff1b1\u5e74\u30012\u5e74\u7121\u75be\u75c5\u5b58\u6d3b\u738738.4% vs. 29.2%\u300121.3% vs. 16.7%\uff08p = 0.63\uff09\uff1b1\u5e74\u30012\u5e74\u5c40\u90e8\u63a7\u5236\u738749.3% vs. 48.7%\u300132.9% vs. 39.0%\uff08p = 0.75\uff09\uff1b1\u5e74\u30012\u5e74\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u738776.5% vs. 61.4%\u300168.8% vs. 39.8%\uff08p = 0.046\uff09\u3002\u4f7f\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5c0d\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u4e26\u6c92\u6709\u986f\u8457\u7684\u5dee\u7570\uff0c\u4f46\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u7d44\u75c5\u4eba\u7684\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u8f03\u597d\u3002\u6bd4\u8f03\u6cbb\u7642\u5291\u91cf\u5927\u65bc50\u683c\u96f7\uff08Gy\uff09\u7684\u75c5\u4eba\uff0c\u5176\u5c40\u90e8\u63a7\u5236\u7387\u548c50 Gy\u4ee5\u4e0b\u7684\u75c5\u4eba\u7121\u986f\u8457\u5dee\u7570\uff08p = 0.25\uff09\u3002\u4f7f\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u53ef\u964d\u4f4e\u526f\u4f5c\u7528\u653e\u5c04\u6027\u80ba\u708e\u7684\u767c\u751f\u7387\uff082.9% vs. 21.2%\uff0cp = 0.027\uff09\uff0c\u4e3b\u8981\u5dee\u7570\u70ba\u80ba\u90e8\u5291\u91cf\u5206\u5e03V20\uff1a21.9% vs. 25.7%\uff08p = 0.03\uff09\u660e\u986f\u8f03\u4f4e\uff0c\u5e73\u5747\u80ba\u90e8\u5291\u91cf\u70ba14.8 Gy vs. 15.3 Gy\uff08p = 0.47\uff09\u3002\u53e6\u5916\uff0c\u4f7f\u7528\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u7d44\u7684\u5fc3\u81df\u5291\u91cf\u5206\u5e03\u512a\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0cV30\u70ba27.8% vs. 39.6%\uff08p = 0.02\uff09\u9054\u5230\u986f\u8457\u5dee\u7570\uff0c\u5e73\u5747\u5fc3\u81df\u5291\u91cf\u70ba22 Gy vs. 26.3 Gy\uff08p = 0.096\uff09\u3002\u7d50\u8ad6\uff1a\u55ae\u4e00\u6a5f\u69cb\u56de\u6eaf\u6027\u5206\u6790\u98df\u9053\u764c\u75c5\u60a3\u63a5\u53d7\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642\u7684\u8cc7\u6599\u986f\u793a\uff0c\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u76f8\u6bd4\uff0c\u5f71\u50cf\u5c0e\u822a\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u53ef\u76f8\u6bd4\u64ec\uff0c\u4f46\u80fd\u6e1b\u5c11\u5fc3\u81df\u53ca\u80ba\u90e8\u7684\u5291\u91cf\uff0c\u964d\u4f4e\u653e\u5c04\u6027\u80ba\u708e\u7684\u767c\u751f\u7387\u3002", "e": "Purpose: To retrospectively review the treatment outcome of esophageal cancer in single institution, and compare the efficacy and toxicity of helical tomotherapy with step-and-shoot Intensity Modulation Radiation Therapy (IMRT). Materials and Methods: Between 2007 and 2012, 67 consecutive patients with locally advanced esophageal cancer, cT2-4N0-3M0, received definitive CCRT. The radiotherapy was delivered with helical tomotherapy in 34 patients, and with step-and-shoot IMRT in 33 patients. We evaluated the outcomes of overall survival rate (OS), disease-free survival rate (DFS), local control rate (LC), distant metastasis-free survival rate (DMFS), toxicity of radiation pneumonitis incidence, and dose distributions to lung and heart. The grading of toxicity was evaluated using CTCAE version 3.0. Result: The median follow-up was 12.1 months. The median overall survival among all patients was 15 months. The treatment outcomes between tomotherapy and step-and-shoot IMRT revealed median OS time 15 months vs. 13.4 months\uff1b1 year\u30012 year OS rates were 69% vs. 60.6%\u300129.8% vs. 26.7% (p = 0.48)\uff1b1 year\u30012 year DFS rates were 38.4% vs. 29.2%\u300121.3% vs. 16.7% (p = 0.63)\uff1b1 year\u30012 year LC rates were 49.3% vs. 48.7%\u300132.9% vs. 39.0% (p = 0.75)\uff1b1 year\u30012 year DMFS rates were 76.5% vs. 61.4%\u300168.8% vs. 39.8% (p = 0.046). No significant differences in OS, DFS, and LC rates were found between tomotherapy and IMRT. There was no significant difference in LC rate with higher radiation dose (\uff1e 50 Gy vs. \u226650 Gy). The patients using tomotherapy had less incidence of radiation pneumonitis (2.9%) than IMRT (21.2%\uff1bp = 0.027), and favorable dose distribution to lung with V20\uff1a21.9% vs. 25.7% (p = 0.03), and mean lung dose 14.8 Gy vs. 15.3 Gy (p = 0.47) compared with IMRT. There was also better dose distribution to heart in tomotherapy which V30 was 27.8% vs. 39.6% (p = 0.02), and mean heart dose was 22 Gy vs. 26.3 Gy (p = 0.096). Conclusion: In our retrospective analysis at single institution, CCRT using tomotherapy for esophageal cancer could reduce dose to normal organs including lung and heart, and reduce incidence of radiation pneumonitis when compared with step-and-shoot IMRT. The treatment outcomes in OS, DFS, and LC rates were similar."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-107-118", "title": "DOSIMETRIC COMPARISON AMONG HELICAL TOMOTHERAPY, INTENSITY-MODULATED RADIOTHERAPY AND TANGENTIAL FIELD-IN-FIELD FOR BILATERAL BREAST CANCER", "keywords": "Bilateral breast cancer;Adjuvant irradiation \u96d9\u5074\u4e73\u623f\u764c;\u6839\u6cbb\u6027\u653e\u5c04\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u70ba\u87ba\u65cb\u5200\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8207\u76f8\u5207\u7167\u91ce\u4e2d\u7167\u91ce\u7528\u65bc\u96d9\u5074\u4e73\u623f\u764c\u75c7\u6cbb\u7642\u4e4b\u5291\u91cf\u5dee\u7570\u5206\u6790\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u662f\u63a1\u7528\u56de\u6eaf\u6027\u65b9\u5f0f\u64f7\u53d6\u672c\u79d1\u5df2\u6cbb\u7642\u904e\u768410\u540d\u4e73\u764c\u60a3\u8005\uff0c\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5f8c\uff0c\u81f3\u672c\u79d1\u63a5\u53d7\u5f8c\u7e8c\u653e\u5c04\u6cbb\u7642\uff0c\u75c5\u7406\u671f\u662f pT1\u223cT2\u3002\u6bcf\u4f4d\u75c5\u4eba\u90fd\u63a5\u53d7\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u6cbb\u7642\u898f\u5283\uff0c\u5206\u5225\u4ee5\u4e09\u7a2e\u6cbb\u7642\u6280\u8853\uff1a\u87ba\u65cb\u5200\u6cbb\u7642\uff08Tomotherapy\uff09\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u548c\u76f8\u5207\u7167\u91ce\u4e2d\u7167\u91ce\uff08tangential field-in-field, FIF\uff09\u5206\u6790\uff0c\u4e26\u6bd4\u8f03\u5404\u6280\u8853\u5c0d\u6cbb\u7642\u9ad4\u7a4d\u7684\u5291\u91cf\u3001\u5747\u52fb\u5ea6\u6307\u6a19\uff08Homogeneity index, HI\uff09\u3001\u9806\u884c\u5ea6\u6307\u6a19\uff08Conformity index, CI\uff09\u548c\u91cd\u8981\u5668\u5b98\u7684\u5291\u91cf\u3002\u7d50\u679c\uff1a\u76f8\u8f03\u65bcIMRT\u548cFIF\uff0cTomotherapy\u65bc\u5fc3\u81df\u5e73\u5747\u5291\u91cf\u5448\u73fe\u6700\u4f4e\uff08tomotherapy = 3.67 Gy\uff0cIMRT = 4.51 Gy and FIF = 4.84 Gy\uff1bp \uff1c 0.05\uff09\u3002\u540c\u6642\uff0c\u6bd4\u8d77IMRT\u548cFIF\uff0cTomotherapy\u5728\u964d\u4f4e\u5de6\u5074\u8207\u53f3\u5074\u80ba\u90e8\u7684\u5e73\u5747\u5291\u91cf\u66f4\u512a\uff08\u53f3\u5074\u80ba\u5e73\u5747\u5291\u91cf\u70ba6.44\uff0c9.08 and 10.03 Gy for Tomotherapy\uff0cIMRT\u548cFIF\uff1bp \uff1c 0.05\uff1b\u5de6\u5074\u80ba\u90e8\u5e73\u5747\u5291\u91cf\uff1a6.33, 7.85 and 8.64 Gy for Tomotherapy\uff0cIMRT\u548cFIF\uff1bp = 0.002\uff09\u3002\u800c\u5728\u51a0\u72c0\u52d5\u8108\u548c\u5de6\u524d\u4e0b\u884c\u52d5\u8108\u7684\u5e73\u5747\u5291\u91cf\u70baTomotherapy = 12.07\u548c19.41 Gy\uff0cIMRT = 16.99\u548c27.86 Gy\uff0cFIF = 19.24\u548c30.94 Gy\u3002\u4ee5\u53ca\u5de6\u5074\u548c\u53f3\u5074\u4e73\u623f\u7684\u9806\u884c\u5ea6\u6307\u6a19\uff08Conformity index, CI\uff09\u70baTomotherapy =1.08 \u00b1 0.01\u548c1.07 \u00b1 0.02\uff0cIMRT = 1.07 \u00b1 0.02\u548c1.08 \u00b1 0.01\uff0cFIF = 1.12 \u00b1 0.03 and 1.11 \u00b1 0.01\u8207\u5747\u52fb\u5ea6\u6307\u6a19\uff08Homogeneity index, HI\uff09\u70baTomotherapy = 1.36 \u00b1 0.08\u548c1.53 \u00b1 0.46\uff0cIMRT = 1.65 \u00b1 0.44\u548c1.51 \u00b1 0.26\uff0cFIF = 1.82 \u00b1 0.51\u548c1.78 \u00b1 0.32\u3002\u7d50\u8ad6\uff1a\u87ba\u65cb\u5200\u6cbb\u7642\uff0c\u5728\u5fc3\u81df\u8207\u80ba\u90e8\u548c\u51a0\u72c0\u52d5\u8108\u5448\u73fe\u7684\u5291\u91cf\u662f\u8f03\u4f4e\u7684\uff0c\u8868\u793a\u6b64\u6cbb\u7642\u6280\u8853\u5728\u96d9\u5074\u4e73\u623f\u764c\u75c7\u6cbb\u7642\u662f\u6709\u5e6b\u52a9\u7684\u3002", "e": "Purpose: This study compared the treatment efficacy of tomotherapy, intensity-modulated radiotherapy (IMRT) and tangential field in field (FIF) for bilateral breast cancer. Materials and Methods: We enrolled 10 patients with breast cancer in this study. All patients had early stage breast cancer (pTis, T1, or T2). A total dose of 5040 cGy was administered for adjuvant breast irradiation with IMRT and tomotherapy for each patient in the treatment planning system. In this study, we compared the treatment efficacy of tangential field-in-field (FIF), IMRT and tomotherapy for bilateral breast cancer. We analyzed the bilateral whole-breast dose coverage, conformity and homogeneity indices, and dose-volume constraints of normal tissues (the right and left lungs and heart). Results: Tomotherapy was more efficient than IMRT and FIF, exhibiting significant improvements in reducing the volume of normal tissues (heart mean doses: tomotherapy = 3.67 Gy, IMRT = 4.51 Gy and FIF = 4.84 Gy; p \uff1c 0.05). Moreover, tomotherapy required a lower mean lung dose (right lung mean dose = 6.44, 9.08 and 10.03 Gy for tomotherapy, IMRT and FIF, respectively; p \uff1c 0.05; left lung mean dose = 6.33, 7.85 and 8.64 Gy for tomotherapy, IMRT and FIF, respectively; p = 0.0002). We also showed the mean doses of coronary artery and left anterior descending artery (LAD): tomotherapy = 12.07 and 19.41 Gy, IMRT = 16.99 and 27.86 Gy, FIF = 19.24 and 30.94 Gy, respectively. The conformity indices (V_(95%)/V_(PTV)) of the right and left breasts were 1.08 \u00b1 0.01 and 1.07 \u00b1 0.02 for tomotherapy, respectively, and 1.07 \u00b1 0.02 and 1.08 \u00b1 0.01 for IMRT, and 1.12 \u00b1 0.03 and 1.11 \u00b1 0.01, respectively, in FIF respectively. Moreover, the homogeneity indices of the right and left breasts were 1.36 \u00b1 0.08 and 1.53 \u00b1 0.46 for tomotherapy, respectively, and 1.65 \u00b1 0.44 and 1.51 \u00b1 0.26 for IMRT, respectively and 1.82 \u00b1 0.51 and 1.78 \u00b1 0.32, respectively, in FIF. Conclusion: Tomotherapy significantly reduced the dose volume of the heart and mean dose for the lungs and coronary vessels. However, long-term follow-up is warranted to ensure low normal tissue toxicity in these patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-119-127", "title": "HYPOTHESIS: DOES \uff02AUTOPHAGY PARADOX\uff02 STRATEGY TO STANDARD THERAPY OF GLIOBLASTOMA MULTIFORME GAIN BENEFIT?", "keywords": "Glioblastoma multiforme;Radiotherapy;Rapamycin;Hydroxychloroquine;Autophagy \u591a\u5f62\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642;Rapamycin;Hydroxychloroquine;\u81ea\u566c\u4f5c\u7528", "c": "\u591a\u5f62\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\uff08GBM\uff09\u662f\u6700\u60e1\u6027\u7684\u539f\u767c\u8166\u7624\u3002\u76ee\u524d\u7684\u6a19\u6e96\u6cbb\u7642\u70ba\u624b\u8853\u52a0\u4e0a\u8f14\u52a9\u6027\u7684\u653e\u5c04\u53ca\u5316\u5b78\u6cbb\u7642\uff08temozolomide\uff09\uff0c\u7136\u800c\u6b64\u75be\u75c5\u9810\u5f8c\u4ecd\u662f\u6975\u5dee\u3002\u6709\u9451\u65bc\u6b64\uff0c\u5404\u5f0f\u65b0\u578b\u7684\u85e5\u7269\u6cbb\u7642\u4e43\u84ec\u52c3\u767c\u5c55\u3002\u540c\u6642\u52a0\u4e0a\u4fc3\u9032\u81ea\u566c\u4f5c\u7528\u7684\u85e5\u7269\uff1asirolimus\uff08Rapamycin\uff09\uff0c\u8207\u5176\u6291\u5236\u85e5\u7269hydroxychloroquine\uff08HCQ, CQ\uff09\u53ef\u4ee5\u7834\u58de\u764c\u75c7\u7d30\u80de\u5f9e\u816b\u7624\u5fae\u74b0\u5883\u7372\u53d6\u80fd\u91cf\u7684\u5e73\u8861\u3002\u9019\u500b\u6cbb\u7642\u7b56\u7565\u88ab\u7a31\u70ba\u201c\u81ea\u566c\u4f5c\u7528\u7684\u6096\u8ad6\u201d\u3002\u6b64\u65b9\u6cd5\u5df2\u7d93\u5728\u4e0d\u540c\u7684\u764c\u75c7\u767c\u73fe\u6709\u9006\u8f49\u85e5\u7269\u6297\u85e5\u6027\u7684\u6548\u679c\u3002\u7d30\u80de\u5be6\u9a57\u767c\u73feGBM\u81ea\u566c\u4f5c\u7528\u4e0d\u9ad8\uff0c\u56e0\u800c\u9700\u8981\u5927\u91cf\u4f9d\u8cf4\u816b\u7624\u5fae\u74b0\u5883\u4f9b\u7d66\u80fd\u91cf\u6210\u9577\u3002\u6839\u64da\u6587\u737b\u63a2\u7d22\u8207\u81e8\u5e8a\u7d93\u9a57\uff0c\u6211\u5011\u5047\u8a2d\u5728\u50b3\u7d71\u5316\u653e\u7642\u52a0\u4e0a\u81ea\u566c\u4f5c\u7528\u8abf\u63a7\u7684\u85e5\u7269\u5c0d\u65bc\u591a\u5f62\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\u7684\u6cbb\u7642\u662f\u6709\u52a9\u76ca\u7684\u3002", "e": "Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Combined surgery, adjuvant radiotherapy (RT), and temozolomide (TMZ) is the standard treatment of care, but the outcome is still grave. Thus, novel therapeutic targets are actively researched in translational studies. Modulation of autophagy by simultaneous administration of the inducer, sirolimus (Rapamycin), and the inhibitor, hydroxychloroquine (HCQ), breaks the vicious cycle of energy supply from the tumor microenvironment (TME) to cancer cells. This strategy was called the \uff02autophagy paradox\uff02. It has been applied to a variety of cancers to reverse drug resistance. A line of evidences including GBM are characterized by low autophagy capacity and highly dependent on the help of TME to provide energy source and biochemical building blocks for tumor growth and survival. Based on literature review and our experience, we hypothesize that add-on \uff02autophagy paradox\uff02 strategy to standard RT-TMZ will be advantageous to GBM treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-129-140", "title": "\u591a\u8449\u6e96\u76f4\u5100\u7cfb\u7d71\u6027\u8aa4\u5dee\u5c0d\u65bcVMAT\u5291\u91cf\u5206\u4f48\u7684\u5f71\u97ff\u5206\u6790", "keywords": "\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642;\u591a\u8449\u6e96\u76f4\u5100;\u52a0\u99ac\u6307\u6a19\u5206\u6790;\u7b49\u6548\u5747\u52fb\u5291\u91cf Volumetric-modulation arc therapy (VMAT);Multileaf collimator (MLC);Gamma index analysis;Equivalent uniform dose", "c": "\u76ee\u7684\uff1a\u4e86\u89e3\u591a\u8449\u6e96\u76f4\u5100\uff08MLC\uff09\u7cfb\u7d71\u6027\u8aa4\u5dee\u5c0d\u65bc\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff08VMAT\uff09\u5728\u5291\u91cf\u5206\u4f48\u548c\u751f\u7269\u5291\u91cf\u53c3\u6578\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5AAPM TG-119\u5831\u544a\u70ba\u4f9d\u64da\uff0c\u672c\u7814\u7a76\u88fd\u4f5c\u4e86\u4e94\u500bVMAT\u6cbb\u7642\u8a08\u756b\uff08\u591a\u9846\u816b\u7624\u3001\u651d\u8b77\u817a\u816b\u7624\u3001\u982d\u90e8\u816b\u7624\u3001\u5bec\u9b06C\u5f62\u816b\u7624\u4ee5\u53ca\u56b4\u683cC\u5f62\u816b\u7624\uff09\u3002\u5404\u6cbb\u7642\u8a08\u756b\u4e2d\u52a0\u5165\u5169\u500b\u65b9\u5411\uff08+ open, - close\uff09\u56db\u7a2e\u7a0b\u5ea6\u7684\u7cfb\u7d71\u6027\u8aa4\u5dee\u503c\uff08\u00b10.5 mm, \u00b11 mm, \u00b12 mm, \u00b13 mm\uff09\u3002\u5206\u5225\u4ee5\u5404\u8a08\u756b\u5728\u5206\u6790\u95be\u503c\u70ba3%/3 mm\u82072%/2 mm\u7684\u52a0\u99ac\u6307\u6a19\u5206\u6790\uff08gamma index analysis\uff09\u7d50\u679c\u53ca\u9776\u9ad4\u7a4d\u548c\u5371\u6025\u5668\u5b98\u7684\u7b49\u6548\u5747\u52fb\u5291\u91cf\uff08equivalent uniform dose\uff09\u8a08\u7b97\u7d50\u679c\u4f86\u8a55\u4f30MLC\u7cfb\u7d71\u6027\u8aa4\u5dee\u5c0d\u65bc\u5291\u91cf\u5206\u4f48\u548c\u751f\u7269\u5291\u91cf\u53c3\u6578\u7684\u5f71\u97ff\u7a0b\u5ea6\u3002\u7d50\u679c\uff1a\u6bcf\u55ae\u4f4dMLC\u7cfb\u7d71\u6027\u8aa4\u5dee\uff08mm\uff09\u5728open\u65b9\u5411\u5c0d\u65bc\u52a0\u99ac\u6307\u6a19\u5206\u6790\u95be\u503c\u57283 mm/3%\u548c2 mm/2%\u7684\u7d50\u679c\u5f71\u97ff\u5206\u5225\u70ba-11.69%\u53ca-18.44%\uff0c\u800c\u5728close\u65b9\u5411\u5247\u5206\u5225\u70ba-9.73%\u548c-15.30%\u3002\u82e5\u8981\u9054\u621090%\u4ee5\u4e0a\u7684\u52a0\u99ac\u6307\u6a19\u901a\u904e\u7387\uff0c\u5728\u95be\u503c\u70ba3 mm/3%\u548c2 mm/2%\u6642\u53ef\u5141\u8a31\u7684\u8aa4\u5dee\u5bb9\u8a31\u503c\u5728open\u65b9\u5411\u5206\u5225\u70ba0.86 mm\u53ca0.54 mm\uff0c\u800c\u5728close\u65b9\u5411\u5247\u5206\u5225\u70ba1.03 mm\u548c0.65 mm\u3002\u6bcf\u55ae\u4f4dMLC\u7cfb\u7d71\u6027\u8aa4\u5dee\uff08mm\uff09\u5c0d\u65bc\u9776\u9ad4\u7a4d\u53ca\u5371\u6025\u5668\u5b98EUD\u7684\u5dee\u7570\u767e\u5206\u6bd4\u5206\u5225\u70ba6.30%\u548c5.20%\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5efa\u8b70\u7684MLC\u7cfb\u7d71\u6027\u8aa4\u5dee\u5bb9\u8a31\u503c\u70ba1 mm\uff0c\u548cTG 142\u7684\u5efa\u8b70\u76f8\u540c\u3002\u653e\u5c04\u6cbb\u7642\u4e2d\u5fc3\u9700\u5177\u6709\u5b8c\u5584\u7684MLC\u54c1\u8cea\u4fdd\u8b49\u8a08\u756b\uff0c\u4ee5\u78ba\u4fdd\u75c5\u60a3\u7372\u5f97\u6b63\u78ba\u7684\u8655\u65b9\u5291\u91cf\u53ca\u907f\u514d\u56b4\u91cd\u7684\u4f75\u767c\u75c7\u7522\u751f\u3002", "e": "Purpose: The purpose of this study was to understand the consequence of MLC systematic errors on the VMAT technique in the dose distribution. Material and Methods: Five VMAT treatment plans (multiTumor, Prostate, Head, C_loose_plan, and C_strict_plan) followed TG-119 instructions were created. MLC systematic errors were simulated for error magnitudes of \u00b10.5 mm, \u00b11 mm, \u00b12 mm, and \u00b13 mm in X1 bank (+ open, - close). The 3 mm/3% and 2 mm/2% gamma index analysis and PTVs and OARs equivalent uniform dose (EUD) were used to evaluate the impact of MLC systematic errors on the dose distribution and the biological dose parameter. Materials and Methods: In total 97 patients with breast cancer were included, they were treated with hybrid intensity-modulated radiotherapy (Hybrid IMRT) for 50.4 Gy in 28 fractions. Patients were evaluated at three months after treatment through the observation of the change of chest computed tomography image. The final endpoint of complication was according to Arriagada's classification. Patients with grade 1+ change on CT images were defined as a complication of radiation pneumonitis. We evaluated the correlation of radiation pneumonitis and mean ipsilateral lung dose. We established LKB NTCP model through calculated the equivalent uniform dose (EUD) of ipsilateral lung and validated the model performance. The NTCP model was mainly used to investigate the dose-response curve for complications of radiation pneumonitis and provided dose parameters to prevent complication of endemic breast cancer patients. Result: The average 3 mm/3% and 2 mm/2% gamma index passing rate was decreased by 11.69% per mm and 18.44% per mm in the open direction and 9.73% per mm and 15.30% per mm in the close direction. The tolerance of MLC systematic errors to achieve \uff1e 90% criteria for 3%/3 mm and 2 mm/2% gamma analysis was 0.86 mm and 0.54 mm in the open direction and 1.03 mm and 0.65 mm in the close direction. The impact of average EUD difference on PTVs and OARs was 6.30% per mm and 5.20% per mm. Conclusion: The present study suggested that the tolerance of systemic MLC errors was 1mm. Radiation treatment centers should have adequate MLC quality assurance program to ensure clinical outcomes and avoid serious complications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-141-150", "title": "\u87ba\u65cb\u5200\u975c\u614b\u5f0f\u7167\u91ce\u5bec\u5ea6\u8207\u8abf\u8b8a\u56e0\u5b50\u53c3\u6578\u8a2d\u5b9a\u5c0d\u653e\u5c04\u6cbb\u7642\u9f3b\u54bd\u764c\u5f71\u97ff\uff1a\u4f96\u9053\u5047\u9ad4\u7814\u7a76", "keywords": "\u87ba\u65cb\u5200;\u7167\u91ce\u5bec\u5ea6;\u8abf\u8b8a\u56e0\u5b50\u6578\u503c;\u9f3b\u54bd\u764c Tomotherapy;Field width;Modulation factor;Nasopharyngeal cancer", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u76ee\u7684\u5728\u63a2\u8a0e\u87ba\u65cb\u5200\uff08Tomotherapy\uff09\u57f7\u884c\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u512a\u5316\u6f14\u7b97\uff0c\u8a2d\u5b9a\u4e0d\u540c\u975c\u614b\u5f0f\u7167\u91ce\u5bec\u5ea6\uff08field width, FW\uff09\u8207\u4e0d\u540c\u8abf\u8b8a\u56e0\u5b50\uff08modulation factor, MF\uff09\u53c3\u6578\u8a2d\u5b9a\uff0c\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u9f3b\u54bd\u764c\u5404\u5371\u6025\u5668\u5b98\uff08organs at risk, OAR\uff09\u5291\u91cf\u8207\u6cbb\u7642\u6642\u9593\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f9d\u64da\u9f3b\u54bd\u764c\u75c5\u4f8b\u816b\u7624\u4f4d\u7f6e\uff0c\u5047\u60f3\u898f\u5283\u8a08\u5283\u9776\u9ad4\u7a4d\uff08PTV\uff09\u8207\u5371\u6025\u5668\u5b98\u5728\u4f96\u9053\u5047\u9ad4\uff08Rando phantom\uff09\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e0a\u3002\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u512a\u5316\u6f14\u7b97\u8a2d\u5b9a\u4e0d\u540c\u975c\u614b\u5f0f\u7167\u91ce\u5bec\u5ea6\uff081.0 cm\u30012.5 cm\u548c5.0 cm\uff09\u642d\u914d\u4e0d\u540c\u8abf\u8b8a\u56e0\u5b50\u6578\u503c\uff081.0\u81f35.0\uff0c\u6bcf\u6578\u503c\u9593\u96940.2\uff09\u7d44\u5408\uff0c\u5171\u8a2d\u8a0863\u500b\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u3002\u7d50\u679c\uff1a\u975c\u614b\u5f0f\u7167\u91ce\u5bec\u5ea6\u5927\u5c0f\u8a2d\u5b9a\u5c0d\u65bc\u5404\u5371\u6025\u5668\u5b98\u5291\u91cf\u5f71\u97ff\u6709\u986f\u8457\u6027\u5dee\u7570\uff08p \uff1c 0.0001\uff09\u3002\u5728\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u5404\u7fa4\u7d44\u4e2d\uff08\u7167\u91ce\u5bec\u5ea61.0 cm\u30012.5 cm\u548c5.0 cm\uff09\uff0c\u5176\u8abf\u8b8a\u56e0\u5b50\u6578\u503c\u8a2d\u5b9a\u5206\u5225\u5c0f\u65bc\u7b49\u65bc1.8\uff0c\u5de6\u53f3\u5169\u5074\u816e\u817a\u5e73\u5747\u5291\u91cf\u6703\u8d85\u904e26 Gy\u8010\u53d7\u5291\u91cf\u9650\u5236\u6a19\u6e96\uff1b\u800c\u8a2d\u5b9a\u70ba1.0\u6642\uff0c\u810a\u9ad3\u795e\u7d93\u8207\u8166\u5e79\u6700\u5927\u5291\u91cf\u6703\u5206\u5225\u8d85\u904e45 Gy\u820754 Gy\u8010\u53d7\u5291\u91cf\u9650\u5236\u6a19\u6e96\u3002\u7167\u91ce\u5bec\u5ea6\u5927\u5c0f\u6703\u5f71\u97ff\u6cbb\u7642\u6642\u9593\uff0c1.0 cm\u30012.5 cm\u548c5.0 cm\u5404\u7fa4\u7d44\u4e2d\u6240\u9700\u7684\u7167\u5c04\u5e73\u5747\u6642\u9593\u5206\u5225\u70ba1036\u79d2\u3001440\u79d2\u548c249\u79d2\u3002\u7be9\u9078\u51fa27\u500b\u6cbb\u7642\u8a08\u5283\u57f7\u884c\u5291\u91cf\u9a57\u8b49\uff0c\u6240\u91cf\u6e2c\u7684\u9ede\u5291\u91cf\u7686\u5728\u00b13%\u5167\uff1b\u4e8c\u7dad\u5291\u91cf\u5206\u4f48\u4e4b\u03b3\u6307\u6a19\uff083%/3 mm\uff09\u901a\u904e\u7387\u4ecb\u65bc90.1%\uff5e92.3%\u4e4b\u9593\u3002\u7d50\u8ad6\uff1a\u5728\u81e8\u5e8a\u4e0a\u82e5\u512a\u5148\u8003\u616e\u964d\u4f4e\u5371\u6025\u5668\u5b98\u5291\u91cf\uff0c\u512a\u5316\u6f14\u7b97\u7684\u53c3\u6578\u5efa\u8b70\u70ba\u8a2d\u5b9a\u7167\u91ce\u5bec\u5ea61\u516c\u5206\u642d\u914d\u8abf\u8b8a\u56e0\u5b502.8\uff0c\u5176\u6b21\u70ba\u7167\u91ce\u5bec\u5ea62.5\u516c\u5206\u642d\u914d\u8abf\u8b8a\u56e0\u5b503.4\uff0c\u4f46\u7167\u91ce\u5bec\u5ea6\u8d8a\u5c0f\u6240\u9700\u6cbb\u7642\u6642\u9593\u5c31\u8d8a\u9577\u3002\u82e5\u8003\u616e\u81e8\u5e8a\u75c5\u60a3\u7121\u6cd5\u9577\u6642\u9593\u4e45\u8eba\u6642\uff0c\u53ef\u4ee5\u9078\u64c7\u7167\u91ce\u5bec\u5ea65\u516c\u5206\u642d\u914d\u8abf\u8b8a\u56e0\u5b50\u6578\u503c\u70ba3.6\u3002", "e": "Purpose: To study the influence of the static field width (FW) and modulation factor (MF) on the organs at risk (OAR) dose and treatment time of nasopharyngeal cancer by Tomotherapy. Materials and Methods: CT scan of RANDO phantom were used to prepare the radiotherapy treatment plan. Planning target volume and the organs at risk (OAR) corresponding to nasopharyngeal cancer were contoured in the CT scan. 63 Tomotherapy plans with the same parameter setting (importance and penalty) were obtained with static FW value including 1 cm, 2.5 cm, and 5 cm, combined with the different value of MF (range of 1.0-5.0 with step 0.2). Result: Treatment plan with different FW resulted a significant difference in the OAR dose (p \uff1c 0.0001). For each computer plan group (FW 1 cm, 2.5 cm and 5 cm), average dose of the parotid gland was higher than the limit value (26 Gy) when the MF value is less than or equal to 1.8. When the MF value was set at 1.0, the maximum dose of spinal cord and brain stem were higher than OAR limits (45 Gy and 54 Gy, respectively). The treatment time with different FW (1, 2.5 and 5 cm) were 1036, 440, 249 seconds, respectively. In the 27 selected quality assurance (QA) plans, the measured dose point was within \u00b1 3%. The gamma pass percentage (3%/ 3 mm) was between 90.1% and 92.3%. Conclusion: The clinical priority to reduce absorbed dose of critical organ, optimized algorithm with MF 2.8 plus a FW 1cm combination were suggested. The second choice combination was MF 3.4 plus FW 2.5 cm. However, small field width will significantly increase treatment time. Considering some patient could not lie down for too long, treatment time could be shortened with combination of MF 3.6 plus FW 5 cm."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-151-159", "title": "SUCCESSFUL TREATMENT OF A HYPOPHARYNGEAL LYMPHOEPITHELIAL CARCINOMA (LEC) PATIENT - A CASE REPORT AND LITERATURE REVIEW", "keywords": "Hypopharyngeal cancer;Lymphoepithelial carcinoma;Concurrent chemo-radiotherapy \u4e0b\u54bd\u764c;\u6dcb\u5df4\u4e0a\u76ae\u764c;\u5408\u4f75\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642", "c": "\u524d\u8a00\uff1a\u4e0b\u54bd\u90e8\u4e4b\u6dcb\u5df4\u4e0a\u76ae\u764c\u70ba\u4e00\u7a2e\u7f55\u898b\u7684\u764c\u75c7\uff0c\u6b64\u985e\u764c\u75c7\u7684\u7d30\u80de\u578b\u614b\u591a\u767c\u751f\u65bc\u9f3b\u54bd\u90e8\u3002\u6dcb\u5df4\u4e0a\u76ae\u764c\u4e3b\u8981\u7531\u5206\u5316\u4e0d\u826f\u578b\u7684\u672a\u89d2\u5316\u9c57\u72c0\u7d30\u80de\u7d44\u6210\uff0c\u4e26\u540c\u6642\u6709\u660e\u986f\u7684\u6dcb\u5df4\u6d78\u6f64\u3002\u5728\u7d44\u7e54\u75c5\u7406\u5b78\u548c\u672a\u5206\u5316\u672a\u89d2\u5316\u9f3b\u54bd\u764c\u975e\u5e38\u76f8\u8fd1\u3002\u4e0d\u540c\u7684\u662f\u4e0b\u54bd\u90e8\u4e4b\u6dcb\u5df4\u4e0a\u76ae\u764c\u4e26\u4e0d\u50cf\u5927\u591a\u6578\u7684\u9f3b\u54bd\u764c\u4e00\u822c\uff0c\u8207EB\u75c5\u6bd2\u6709\u5bc6\u5207\u7684\u76f8\u95dc\u6027\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u540d71\u6b72\u7684\u7537\u6027\uff0c\u57282014\u5e74\u76848\u6708\u88ab\u8a3a\u65b7\u51fa\u4e0b\u54bd\u90e8\u4e4b\u6dcb\u5df4\u4e0a\u76ae\u764c\uff0c\u4e26\u5728\u4e4b\u5f8c\u7dca\u63a5\u8457\u63a5\u53d7\u5408\u4f75\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5728\u6cbb\u7642\u7d50\u675f\u56db\u500b\u6708\u5f8c\uff0c\u6839\u64da\u5f71\u50cf\u5b78\u4e0a\u7684\u8ffd\u8e64\u53ef\u767c\u73fe\u816b\u7624\u9054\u5230\u90e8\u5206\u6709\u6548\uff1b\u800c\u5728\u4e5d\u500b\u6708\u5f8c\uff0c\u5f71\u50cf\u5b78\u4e0a\u7684\u8ffd\u8e64\u767c\u73fe\u816b\u7624\u9054\u5230\u5b8c\u5168\u6709\u6548\u3002\u8a0e\u8ad6\uff1a\u5728\u9019\u500b\u7f55\u898b\u7684\u665a\u671f\u4e0b\u54bd\u90e8\u4e4b\u6dcb\u5df4\u4e0a\u76ae\u764c\u75c5\u4eba\u8eab\u4e0a\uff0c\u4e3b\u7a0b\u6027\u5408\u4f75\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5728\u5230\u76ee\u524d\u70ba\u6b62\u7684\u5341\u4e94\u500b\u6708\u4e2d\uff0c\u8ffd\u8e64\u767c\u73fe\u6709\u4e0d\u932f\u7684\u6cbb\u7642\u6548\u679c\u3002\u4e0d\u904e\u4ecd\u9700\u8981\u66f4\u591a\u7684\u6848\u4f8b\u624d\u80fd\u6c7a\u5b9a\u51fa\u6700\u9069\u7576\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Introduction: Lymphoepithelial carcinoma (LEC), mostly seen in the nasopharynx, is a rare cancer of the hypopharynx. LEC is characterized by an undifferentiated non-keratinizing squamous cell carcinoma with a significant lymphocytic infiltration, and is histopathologically similar to non-keratinizing, undifferentiated nasopharyngeal carcinomas (NPC), but is less associated with the Epstein-Barr virus (EBV). Case report: In this study, we report the diagnosis and treatment by concurrent chemoradiotherapy (CCRT) of a 71-year-old male hypopharyngeal LEC patient in Aug 2014. The patient completed the CCRT treatment course. In the follow-up image survey half a year after treatment, a partial tumor response was noted. Further, complete regression was achieved in the following image survey 9 months after treatment. Discussion: In this rare case of advanced stage, non-EBV related hypopharyngeal LEC, a good response to definitive CCRT was achieved within the 15-month follow-up period. However, more patients are required to define the optimal treatment for hypopharyngeal LEC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-161-166", "title": "SUCCESSFUL TREATMENT OF TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH STEREOTACTIC ABLATIVE RADIOTHERAPY FOR RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION: A CASE REPORT", "keywords": "Hepatocellular carcinoma;Liver transplantation;Transarterial chemoembolization;Stereotactic ablative radiotherapy;Stereotactic body radiotherapy \u809d\u764c;\u809d\u81df\u79fb\u690d;\u7d93\u5c0e\u7ba1\u52d5\u8108\u5316\u5b78\u6813\u585e;\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642;\u8eab\u9ad4\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642", "c": "\u6211\u5011\u5831\u544a\u4e00\u500b\u7f55\u898b\u809d\u81df\u79fb\u690d\u5f8c\u518d\u5fa9\u767c\u4e4b\u809d\u764c\u500b\u6848\uff1a\u4e00\u540d69\u6b72\u539f\u767c\u809d\u764c\u7537\u6027\u56e0\u6813\u585e\u6548\u679c\u4e0d\u4f73\uff0c\u5728\u4e0d\u7b26\u5408\u7c73\u862d\u898f\u7d04\uff08Milan criteria\uff09\u689d\u4ef6\u4e0b\u63a5\u53d7\u539f\u4f4d\u809d\u81df\u79fb\u690d\u3002\u79fb\u690d\u5f8c16\u500b\u6708\u4e4b\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u986f\u793a\u809d\u81df\u690d\u9ad4\u51fa\u73fe\u5169\u8655\u5fa9\u767c\u75c5\u7076\uff0c\u75c5\u4eba\u56e0\u6b64\u63a5\u53d7\u7d93\u5c0e\u7ba1\u52d5\u8108\u5316\u5b78\u6813\u585e\u53ca\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u4e4b\u5408\u4f75\u7642\u6cd5\u3002\u75c5\u4eba\u5c0d\u6b64\u6cbb\u7642\u65b9\u5f0f\u8010\u53d7\u826f\u597d\uff0c\u5728\u6cbb\u7642\u7d50\u675f\u5f8c\u8ffd\u8e64\u768428\u500b\u6708\u4e2d\u4e26\u7121\u51fa\u73fe\u4efb\u4f55\u6025\u6027\u6216\u6162\u6027\u4e4b\u526f\u4f5c\u7528\u3002\u5f8c\u7e8c\u8ffd\u8e64\u7684\u5f71\u50cf\u6aa2\u67e5\u986f\u793a\u6cbb\u7642\u90e8\u4f4d\u5b8c\u5168\u7de9\u89e3\u4e14\u7121\u5fa9\u767c\u8de1\u8c61\u3002\u6b64\u500b\u6848\u5831\u544a\u986f\u793a\uff0c\u5728\u809d\u81df\u79fb\u690d\u5f8c\u65bc\u809d\u690d\u9ad4\u5fa9\u767c\u4e4b\u75c5\u4eba\uff0c\u4f75\u7528\u7d93\u5c0e\u7ba1\u52d5\u8108\u5316\u5b78\u6813\u585e\u53ca\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\uff0c\u53ef\u80fd\u6539\u5584\u5c40\u90e8\u816b\u7624\u63a7\u5236\u53ca\u75c5\u4eba\u5b58\u6d3b\u3002", "e": "We describe a rare case of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT). A 69-year-old male underwent orthotopic LT for primary HCC outside of Milan criteria due to incomplete embolization. Sixteen months after LT, contrast-enhanced computed tomography (CT) showed two recurrent tumors in the liver graft. The patient underwent combined TACE and stereotactic ablative radiotherapy (SABR) to treat the recurrent lesions. Twenty-eight months after completion of combined treatment, the patient is doing well without experiencing any acute or chronic adverse effect. Surveillance images demonstrated complete regression and no evidence of recurrence. This case suggests that this dual-modality treatment in the post-transplant setting may help to improve local control and potentially survival in those recipients who develop recurrent HCC within the liver graft."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201706-201707100005-201707100005-167-173", "title": "\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u65bc\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\uff1a\u6848\u4f8b\u5831\u544a", "keywords": "\u55c5\u795e\u7d93\u6bcd\u7d30\u80de;\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Esthesioneuroblastoma;Volumetric modulated arc therapy (VMAT)", "c": "\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\uff08esthesioneuroblastoma, ENB\uff09\u662f\u57281924\u5e74\u9996\u5148\u7531Berger\u7b49\u4eba\u63cf\u8ff0\u7684\u55c5\u7c98\u819c\u7684\u4e00\u7a2e\u7f55\u898b\u7684\u4fb5\u8972\u6027\u816b\u7624\u3002\u50b3\u7d71\u4e0aENB\u53ef\u4ee5\u900f\u904e\u6839\u6cbb\u6027\u624b\u8853\uff0c\u653e\u5c04\u6cbb\u7642\u548c\u5316\u7642\u4f86\u6cbb\u7642\u3002\u7136\u800c\uff0c\u9019\u7a2e\u7f55\u898b\u7684\u816b\u7624\u5177\u6709\u9ad8\u5fa9\u767c\u548c\u6b7b\u4ea1\u7387\uff0c\u6839\u64da\u7814\u7a76\u986f\u793a\uff0c\u8207\u55ae\u4e00\u5f62\u5f0f\u6cbb\u7642\u76f8\u6bd4\uff0c\u624b\u8853\u5f8c\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u53ef\u63d0\u4f9b\u66f4\u9577\u7684\u7e3d\u751f\u5b58\u671f\u3002\u56e0\u6b64\u672c\u7bc7\u6848\u4f8b\u5831\u544a\u63d0\u51fa\u4f7f\u7528\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08volumetric modulated arc therapy, VMAT\uff09RapidArc\u6210\u529f\u6cbb\u7642ENB\u7684\u6848\u4f8b\u3002\u4e00\u540d72\u6b72\u7684\u7537\u6027\u60a3\u8005\u4e3b\u8a34\uff0c\u572810\u5e74\u671f\u9593\u9f3b\u8154\u5076\u723e\u6703\u6709\u4e00\u4e9b\u9ec3\u7d05\u8272\u7684\u5206\u6ccc\u7269\u3002\u6700\u8fd11\u500b\u6708\uff0c\u6709\u54b3\u55fd\u3001\u9f3b\u585e\u3001\u55c5\u89ba\u55aa\u5931\u548c\u81bf\u6027\u9f3b\u6f0f\u7684\u75c7\u72c0\u30022013\u5e743\u67084\u65e5MRI\u986f\u793a\uff0c\u65bc\u53f3\u9871\u524d\u7aa9\u767c\u73fe\u6709\u4e0048 x 40 x 44 mm\u786c\u819c\u5916\u816b\u7624\u4e26\u4fb5\u72af\u5230\u53f3\u7be9\u7ac7\uff0c\u9838\u90e8\u6dcb\u5df4\u7d50\u7121\u986f\u8457\u816b\u5927\u3002\u75c5\u4eba\u88ab\u8a3a\u65b7\u70baKadish\u5206\u671fC\uff0cHyams\u5206\u7d1a\u2162\u7684ENB\u3002\u4f7f\u7528RapidArc\u6cbb\u76427000 cGy\u7684\u7d2f\u7a4d\u5291\u91cf\u5f8c\uff0c\u8ffd\u8e6439\u500b\u6708\u60a3\u8005\u4ecd\u7121\u75c5\u5b58\u6d3b\u3002", "e": "Esthesioneuroblastoma (ENB) is a rare aggressive tumor of the olfactory mucosa which was first described by Berger et al. in 1924. ENB has been traditionally treated with radical surgery, radiotherapy and/or chemotherapy. Nevertheless, these rare tumors are still associated with high rates of tumor recurrence and mortality. Studies have shown that surgery with postoperative radiotherapy offers a longer overall survival when compared with single modality treatment. We present an advanced case of ENB who was successfully treated with RapidArc (VMAT) technique. A 72 year-old male Taiwanese farmer was seen at the ENT outpatient clinic complaining of productive cough, nasal obstruction, loss of smell sensation and purulent rhinorrhea for 1 month, the patient also complained of yellow to reddish nasal discharge for 10 years. MRI on 2013/03/04 revealed a strongly enhanced right anterior cranial fossa epidural mass (48 x 40 x 44 mm) with a cystic component invading the right ethmoid sinus. No significant neck lymphadenopathy was noted. The patient was diagnosed as Kadish stage C, Hyams grade III ENB. Treatment consisted of giving a cumulative dose of 7000 cGy using the RapidArc technique concurrently with cisplatin and etoposide. The patient is still disease-free 39 months after CCRT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-1-11", "title": "TREATMENT OUTCOME IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER RECEIVING ADJUVANT CHEMORADIOTHERAPY", "keywords": "Gastric cancer;Adjuvant chemotherapy;Adjuvant chemoradiotherapy \u80c3\u764c;\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642;\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u4f75\u5316\u5b78\u6cbb\u7642", "c": "\u80cc\u666f\u53ca\u7814\u7a76\u76ee\u7684\uff1a\u5728\u5c40\u90e8\u4fb5\u8972\u6027\u80c3\u764c\u75c5\u4eba\u9032\u884c\u6cbb\u7652\u6027\u624b\u8853\u5207\u9664\u4f75\u7b2c\u4e8c\u578b\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\u5f8c\u52a0\u4e0a\u8f14\u52a9\u5316\u7642\u8207\u653e\u5c04\u7dda\u7642\u6cd5\u7684\u597d\u8655\u4ecd\u7136\u672a\u5b9a\u8ad6\u3002\u672c\u7814\u7a76\u91dd\u5c0d\u7b2c\u4e8c\u671f\u81f3\u7b2c\u4e09\u671f\u80c3\u764c\u75c5\u4eba\u4e26\u63a5\u53d7\u6cbb\u7652\u6027\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u5408\u4f75\u5316\u7642\uff0c\u9032\u884c\u6cbb\u7642\u7d50\u679c\u7684\u5206\u6790\u3002\u8a66\u9a57\u8a2d\u8a08\u8207\u65b9\u6cd5\uff1a\u5728\u897f\u5143 2006 \u5e74\u81f3 2013 \u5e74\uff0c\u5171 71 \u4f4d\u80c3\u764c\u75c5\u4eba\u63a5\u53d7\u4e86\u80c3\u764c\u5207\u9664\u624b\u8853\u4f75\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7686\u4f9d\u7167 AJCC \u7b2c\u4e03\u7248\u5206\u671f\u3002\u5176\u4e2d\uff0c\u7e3d\u5171\u6536\u9304 40 \u4f4d\u75c5\u60a3\uff0c\u75c5\u7406\u5206\u671f\u7b2c\u4e8c\u81f3\u4e09\u671f\uff0c\u7686\u63a5\u53d7\u6cbb\u7652\u6027\u80c3\u764c\u5207\u9664\u624b\u8853\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\u3002\u5176\u4e2d 38 \u4f4d\u75c5\u60a3\u63a5\u53d7\u7b2c\u4e8c\u578b\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\u3002\u653e\u5c04\u7dda\u5291\u91cf\u70ba 45 Gy\u3001\u653e\u5c04\u6cbb\u7642\u7684\u7bc4\u570d\u5305\u62ec tumor bed\u3001\u5269\u9918\u80c3\u90e8\u8207\u9130\u8fd1\u6dcb\u5df4\u5340\u57df\u3002\u5316\u7642\u63a1\u7528\u9251\u91d1\u985e\u85e5\u7269\u3001\u6c1f\u5c3f\u5627\u5576\u985e\u85e5\u7269\u8207\u8449\u9178\u985e\u85e5\u7269\u3002\u7814\u7a76\u76ee\u7684\u70ba\u6574\u9ad4\u5b58\u6d3b\u7387\uff08overall survival\uff09\u3001\u7121\u60e1\u5316\u5b58\u6d3b\u671f\uff08progression-free survival\uff09\uff0c\u7686\u4f7f\u7528\u5b58\u6d3b\u5206\u6790\uff08Kaplan-Meier\uff09\u4f5c\u8a08\u7b97\uff0c\u4e26\u4f7f\u7528\u5c0d\u6578\u7b49\u7d1a\u6aa2\u5b9a\uff08log-rank\uff09\u8207 cox \u6bd4\u4f8b\u98a8\u96aa\u6a21\u5f0f\u627e\u51fa\u5371\u96aa\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u5728 22.8 \u500b\u6708\uff08\u7bc4\u570d 3.2-76.5\uff09\u8ffd\u8e64\u4e4b\u5f8c\uff0c30 \u500b\u75c5\u4eba\u6b7b\u4ea1\u300234 \u500b\u75c5\u60a3\u6709\u5fa9\u767c\u7522\u751f\uff08\u9060\u7aef\u8f49\u79fb 29 \u4f4d\u3001\u5c40\u90e8\u5fa9\u767c 11 \u4f4d\u3001\u5340\u57df\u6027\u5fa9\u767c 10 \u4f4d\uff09\u300224 \u4f4d\u75c5\u60a3\u6709\u7b2c\u4e8c\u7d1a\u4ee5\u4e0a\u6025\u6027\u8178\u80c3\u9053\u526f\u4f5c\u7528\u6216\u8840\u6db2\u6027\u526f\u4f5c\u7528\u3002\u5728\u8f14\u52a9\u6cbb\u7642\u7684\u904e\u7a0b\u4e2d\u6709\u4e09\u4f4d\u75c5\u60a3\u56e0\u4f4e\u767d\u8840\u7403\u6027\u767c\u71d2\u6b7b\u4ea1\u3002\u591a\u8b8a\u56e0\u5206\u6790\u4e2d\uff0c\u816b\u7624\u5206\u671f\uff08T-stage\uff09\u8207\u6dcb\u5df4\u4fb5\u72af\u7a0b\u5ea6\uff08N-stage\uff09\u5206\u5225\u70ba\u6574\u9ad4\u5b58\u6d3b\u7387\u8207\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u4e4b\u9810\u6e2c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5728\u7b2c\u4e8c\u8207\u7b2c\u4e09\u671f\u5c40\u90e8\u4fb5\u8972\u6027\u80c3\u817a\u764c\u75c5\u4eba\uff0c\u8981\u4f7f\u7528\u5316\u7642\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u524d\uff0c\u5fc5\u9808\u512a\u5148\u8003\u616e\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u3002\u816b\u7624\u5206\u671f\uff08T-stage\uff09\u8207\u6dcb\u5df4\u4fb5\u72af\u7a0b\u5ea6\uff08N-stage\uff09\u5206\u5225\u70ba\u6574\u9ad4\u5b58\u6d3b\u7387\u8207\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u4e4b\u9810\u6e2c\u56e0\u5b50\u3002\u76ee\u524d\u4ecd\u9700\u66f4\u591a\u7684\u524d\u77bb\u6027\u7814\u7a76\u4f86\u6c7a\u5b9a\u6700\u4f73\u7684\u6cbb\u7642\u8a08\u756b\u8207\u6c7a\u5b9a\u9069\u5408\u7684\u75c5\u4eba\u65cf\u7fa4\u3002", "e": "Background : The benefits of adjuvant chemoradiotherapy (CRT) for patients with locally advanced gastric cancer after D2 lymph node dissection remain debatable. This study investigated the treatment outcome in patients with stage II-III gastric cancer receiving curative resection plus adjuvant chemoradiotherapy (CRT). Method : Between January 2006 and December 2013, 71 patients who underwent radiotherapy with a diagnosis of gastric adenocarcinoma were registered. Tumors were staged according to the American Joint Committee on Cancer criteria (AJCC) version 7.0. Forty patients who had stage II and III disease undergoing curative resection were included in this analysis. Of them, 38 patients (95%) received D2 lymph node dissection. The RT field included tumor bed, remnant stomach, and regional lymph nodes with a standard prescribed dose of 45 Gy. Concurrent chemotherapy consisted of cisplatin, 5-fluorouracil and leucovorin, or fluorouracil plus leucovorin. The study endpoints were overall survival (OS) and progression-free survival (PFS), both of which were calculated using the Kaplan\u2013Meier method. The log-rank test and Cox regression analysis were performed to examine the effects of explanatory variables on OS and PFS. Result : 30 patients died in the median follow-up duration of 22.8 months (range, 3.2 ~ 76.5), Thirty-four (80%) experienced recurrent disease (distant metastasis in 29, local relapse in 11, regional recurrence in 10). Twenty-four patients had grade 2 or above acute gastrointestinal or hematological toxicities. Three patients (8%) died from neutropenic infection during the adjuvant CRT. Multivariate analyses showed pathological T4b stage [P = .02, HR = 2.51, 95% CI = 1.16\u20135.46] and pathological N3b stage [P = .008, HR = 2.61, 95% CI = 1.28\u20135.32] were the independent prognostic factors for OS and PFS, respectively. Conclusion : In stage II-III gastric cancer patients receiving adjuvant CRT, treatmentrelated toxicities were the major concerns. Pathological T4b was the independent prognostic factor for OS, whereas N3b for PFS. A multi-institutional trial is recommended to optimize the treatment strategy and patient selection."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-13-23", "title": "FACTORS ASSOCIATED WITH RADIOGRAPHIC RESPONSE AND OVERALL SURVIVAL AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN TUMOR THROMBOSIS", "keywords": "Hepatocellular carcinoma;Portal vein tumor thrombosis;Stereotactic ablative radiotherapy;Stereotactic body radiotherapy;Treatment response \u809d\u764c;\u9580\u975c\u8108\u816b\u7624\u6813\u585e;\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642;\u5168\u8eab\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642;\u6cbb\u7642\u53cd\u61c9", "c": "\u524d\u8a00\uff1a\u809d\u764c\u75c5\u4eba\u5982\u6709\u5408\u4f75\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u5b58\u6d3b\u7387\u76f8\u7576\u5dee\u3002\u8fd1\u5e74\u4f86\u8a31\u591a\u8b49\u64da\u652f\u6301\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u53ef\u7576\u4f5c\u809d\u764c\u75c5\u4eba\u6cbb\u7642\u9078\u64c7\uff0c\u4f46\u662f\u6975\u5c11\u6587\u737b\u5831\u5c0e\u95dc\u65bc\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u4f7f\u7528\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7d50\u679c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u56de\u6eaf\u6027\u7684\u65b9\u5f0f\uff0c\u7be9\u9078\u897f\u5143 2008 \u5e74\u81f3 2013 \u5e74\u65bc\u672c\u90e8\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u4e4b 42 \u4f4d\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u75c5\u4eba\uff0c\u672c\u90e8\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\u4e4b\u57f7\u884c\u662f\u4f7f\u7528\u96fb\u8166\u5200\u5f71\u50cf\u5c0e\u5f15\u7acb\u9ad4\u653e\u5c04\u624b\u8853\u7cfb\u7d71\uff08Cyberknife image-guided radiosurgery system (AccurayInc., Sunnyvale, CA)\uff09\u3002\u6240\u6709\u75c5\u60a3\u63a5\u53d7\u4e4b\u5e73\u5747\u5291\u91cf\u70ba 42.5 Gy, \u6bcf\u6b21\u7167\u5c04 5-12.5 Gy\u3002\u81e8\u5e8a\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u56e0\u5b50\u7686\u6703\u8a73\u7d30\u8a18\u9304\uff0c\u5305\u62ec\u5e74\u9f61\u3001\u7f8e\u570b\u6771\u5cb8\u764c\u75c7\u81e8\u5e8a\u7814\u7a76\u5408\u4f5c\u7d44\u7e54\uff08Eastern Cooperative Oncology Group\uff09\u9ad4\u80fd\u72c0\u614b\u3001\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6578\u503c\u3001Child-Pugh score\u3001Cancer of the Liver Italian Program (CLIP) score\u3001\u6709\u7121\u809d\u5916\u8f49\u79fb\uff08extrahepatic metastasis (EM)\uff09\u7b49\u7b49\u3002\u6cbb\u7642\u5f8c\u6703\u4f9d\u64da\u8ffd\u8e64\u7684\u5f71\u50cf\u8a55\u4f30\u816b\u7624\u53cd\u61c9\uff0c\u5f71\u50cf\u4e0a\u816b\u7624\u53cd\u61c9\u4e4b\u8a55\u4f30\u662f\u4f9d\u64da Response Evaluation Criteria in Solid Tumors (RECIST) \u6b64\u4e00\u6e96\u5247\u3002\u5b58\u6d3b\u7387\u7684\u5206\u6790\u662f\u4f7f\u7528 Kaplan-Meier \u6cd5\u3002\u9810\u5f8c\u56e0\u5b50\u7684\u5206\u6790\u5247\u662f\u4f7f\u7528 Cox \u6bd4\u4f8b\u98a8\u96aa\u6a21\u5f0f\u3002\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba 7.8 \u500b\u6708\uff0c\u5171\u6709 38 \u540d\u75c5\u60a3\u6b7b\u4ea1\uff0c\u4e2d\u4f4d\u6578\u5b58\u6d3b\u671f\u70ba 8.6 \u500b\u6708\uff0c\u7b2c\u4e00\u5e74\u53ca\u7b2c\u4e8c\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u662f 31.4%\u53ca 14.1%\u30029 \u540d\u75c5\u60a3\u5728\u9084\u6c92\u63a5\u53d7\u6cbb\u7642\u5f8c\u7b2c\u4e00\u6b21\u5f71\u50cf\u8ffd\u8e64\u5373\u6b7b\u4ea1\u3002\u5728\u6709\u63a5\u53d7\u4efb\u4f55\u4e00\u6b21\u6cbb\u7642\u5f8c\u5f71\u50cf\u5b78\u8a55\u4f30\u7684\u75c5\u60a3\u7576\u4e2d\uff0c\u816b\u7624\u5b8c\u5168\u53cd\u61c9\u7387\uff08complete response\uff09\u662f 3%\uff0c\u90e8\u5206\u53cd\u61c9\u7387\uff08partial response\uff09 \u662f 55%\uff0c\u75be\u75c5\u7a69\u5b9a\u7387\uff08stable disease\uff09\u662f 39.1%\uff0c\u800c\u75c5\u60c5\u60e1\u5316\u7387\uff08disease progression\uff09\u662f 3%\u30029 \u540d\uff0821%\uff09\u75c5\u60a3\u9580\u975c\u8108\u6709\u88ab\u6253\u901a\u4e14\u6709\u63a5\u53d7\u5f8c\u7e8c\u809d\u52d5\u8108\u5316\u5b78\u6813\u585e\u7642\u6cd5\uff08transarterial chemoembolization\uff09\u3002\u55ae\u8b8a\u91cf\u5206\u6790\u767c\u73fe Child-Pugh A (vs. B & C, HR = 0.470, p = 0.049)\u3001CLIP score \u2264 3 (vs. \uff1e 3, HR = 0.468, p = 0.046) \u4ee5\u53ca\u7121\u809d\u5916\u8f49\u79fb\uff08vs. presence of EM, HR = 0.497, p = 0.035\uff09\u7684\u60a3\u8005\u6703\u6709\u8f03\u4f73\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u591a\u8b8a\u91cf\u5206\u6790\u5247\u767c\u73fe\u7121\u809d\u5916\u8f49\u79fb\uff08vs. presence of EM, HR = 0.340, p = 0.015\uff09\u662f\u552f\u4e00\u6709\u7d71\u8a08\u5b78\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u7acb\u9ad4\u5b9a\u4f4d\u6d88\u878d\u653e\u5c04\u6cbb\u7642\uff0c\u662f\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u75c5\u60a3\u7684\u4e00\u500b\u6cbb\u7642\u9078\u64c7\uff1b\u7121\u809d\u5916\u8f49\u79fb\u662f\u552f\u4e00\u53ef\u4ee5\u9810\u6e2c\u8f03\u4f73\u6574\u9ad4\u5b58\u6d3b\u7684\u7368\u7acb\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Introduction : Survival of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) is poor. While stereotactic ablative radiotherapy (SABR) has emerged as a treatment option for HCC, there are limited data on treatment outcomes and associated prognostic factors focusing on PVTT patients. Methods and Materials : Between 2008 and 2013, 42 HCC patients with PVTT underwent SABR using a Cyberknife radiosurgery system in our institute. The mean radiation dose was 42.5 Gy, 5\u201312.5 Gy per fraction. We collected clinical and treatment-related factors including age, Eastern Cooperative Oncology Group (ECOG) performance status, \u03b1-fetoprotein (AFP) level, Child-Pugh score, Cancer of the Liver Italian Program (CLIP) score, presence of extrahepatic metastasis (EM), and equivalent dose in 2 Gy fractions (EQD2). The patients were assessed for radiographic response and survival outcome. Image response was evaluated with Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Overall survival (OS) was calculated using the Kaplan-Meier test. Prognostic factors were evaluated using a Cox regression model. Results : At the last follow up, 38 patients had died. The median survival was 8.6 months, with 1-year and 2-year OS rates of 31.4% and 14.1%, respectively. Nine patients died before imaging studies for response evaluation could be performed. In those who had radiographic response evaluation, 3% had a complete response, 55% a partial response, 39% stable disease, and 3% disease progression. Nine (21%) patients had portal vein re-canalization and then received transarterial chemoembolization (TACE). In univariate analysis, Child-Pugh A (vs. B & C, HR = 0.470, p = 0.049), CLIP score \u2264 3 (vs. \uff1e 3, HR = 0.468, p = 0.046), and absence of EM (vs. presence of EM, HR = 0.497, p = 0.035) were associated with a higher OS rate. Multivariate analysis showed that only an absence of EM (vs. presence of EM, HR = 0.340, p = 0.015) was a significant prognostic indicator. Conclusions : SABR is an option for HCC patients with PVTT. Absence of EM is the only independent prognostic factor for better OS. A future large-scale study to identify strict patient selection criterion may maximize the benefits of SABR."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-25-34", "title": "\u4e73\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u767c\u751f\u653e\u5c04\u6027\u80ba\u708e\u4e4b\u840a\u66fc\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u6a21\u578b\u53c3\u6578\u5206\u6790", "keywords": "\u4e73\u764c;\u653e\u5c04\u6027\u80ba\u708e;LKB\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u9810\u6e2c\u6a21\u578b Breast cancer;Radiation pneumonitis;Lyman Kutcher-Burman normal tissue complication probability", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4e73\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u5176\u540c\u5074\u80ba\u81df\u5291\u91cf\u8207\u653e\u5c04\u6027\u80ba\u708e\u4f75\u767c\u75c7\uff08radiation pneumonitis, RP\uff09\u4e4b\u5f71\u97ff\uff0c\u672c\u7814\u7a76\u5efa\u7acb\u840a\u66fc Lyman Kutcher-Burman\uff08LKB\uff09\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\uff08Normal Tissue Complication Probability, NTCP\uff09\u6a21\u578b\uff0c\u5206\u6790\u4f75\u767c\u75c7\u5c0d\u61c9\u4e4b\u76f8\u95dc\u5291\u91cf\u95dc\u4fc2\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u91dd\u5c0d97\u4f4d\u4e73\u764c\u60a3\u8005\uff0c\u4f7f\u7528\u6df7\u5408\u578b\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08hybrid intensitymodulated radiotherapy, Hybrid IMRT\uff09\u9032\u884c50.4 Gy\u517128\u6b21\u7684\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u3002\u60a3\u8005\u65bc\u653e\u5c04\u6cbb\u7642\u5f8c\u4e09\u500b\u6708\u9032\u884c\u4f75\u767c\u75c7\u8a55\u4f30\uff0c\u6700\u7d42\u4f75\u767c\u75c7\u5b9a\u7fa9\u6839\u64daArriagada\u5206\u7d1a\u6a19\u6e96\uff0c\u4e3b\u8981\u89c0\u5bdf\u80f8\u8154\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u8b8a\u5316\uff0c\u60a3\u8005\u65bc CT \u5f71\u50cf\u4e2d\u6709\u7b2c\u4e00\u7d1a\u4ee5\u4e0a\u80ba\u708e\u4f75\u767c\u75c7\u4e4b\u5f71\u50cf\u8b8a\u5316\uff0c\u5b9a\u7fa9\u70ba\u5177\u6709\u653e\u5c04\u6027\u80ba\u708e\u4f75\u767c\u75c7\u3002\u7d93\u904e\u540c\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u8207\u653e\u5c04\u6027\u80ba\u708e\u4f75\u767c\u75c7\u76f8\u95dc\u6027\u8a55\u4f30\u5f8c\uff0c\u8a08\u7b97\u60a3\u8005\u540c\u5074\u80ba\u81df\u4e4b\u7b49\u6548\u5747\u52fb\u5291\u91cf\uff08equivalent uniform dose, EUD\uff09\uff0c\u5efa\u7acb LKB NTCP \u9810\u6e2c\u6a21\u578b\uff0c\u540c\u6642\u9032\u884c\u6a21\u578b\u9810\u6e2c\u6548\u529b\u8a55\u4f30\u6aa2\u5b9a\u3002NTCP \u9810\u6e2c\u6a21\u578b\u4e3b\u8981\u7528\u4ee5\u63a2\u8a0e\u5291\u91cf\u5c0d\u65bc\u653e\u5c04\u6027\u80ba\u708e\u4f75\u767c\u75c7\u4e4bS \u578b\u53cd\u61c9\u66f2\u7dda\uff08sigmoid curve\uff09\uff0c\u5efa\u7acb\u672c\u5730\u4e73\u764c\u60a3\u8005\u4f75\u767c\u75c7\u767c\u751f\u7387\u4e4b\u5291\u91cf\u53c3\u6578\u3002\u7d50\u679c\uff1a\u540c\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u8207\u653e\u5c04\u6027\u80ba\u708e\u4f75\u767c\u75c7\u5177\u6709\u7d71\u8a08\u986f\u8457\u6027\uff0c\u5efa\u7acb\u540c\u5074\u80ba\u81df\u5291\u91cf\u4e4bLKB NTCP \u6a21\u578b\u53c3\u6578\uff1a50% \u4f75\u767c\u75c7\u767c\u751f\u7387\u6240\u5c0d\u61c9\u7684\u540c\u5074\u80ba\u81df\u5291\u91cf TD50 = 21.26 Gy\uff0895% CI, 19.78 - 22.97\uff09\uff0c\u659c\u7387\u53c3\u6578 m = 0.32\uff0895% CI, 0.19 - 0.81\uff09\uff0c\u6a21\u578b\u4e4b\u53d7\u6e2c\u8005\u7279\u5fb5\u4e4b\u66f2\u7dda\u4e0b\u9762\u7a4d\uff08area under the receiver operating characteristic curve, AUC\uff09\u70ba 0.65\uff0c\u4e14\u901a\u904e\u767d\u6c0f\u5f97\u5206\u6578\u3001Hosmer-Lemeshow test \u53ca\u6821\u6e96\u66f2\u7dda\u4e4b\u6a21\u578b\u6548\u80fd\u8a55\u4f30\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5efa\u7acb\u4e73\u764c\u653e\u5c04\u6027\u80ba\u708e Lyman Kutcher-Burman\uff08LKB\uff09\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u6a21\u578b\uff0c\u5b9a\u7fa9\u672c\u5730\u60a3\u8005\u4e4b\u76f8\u95dc\u6a21\u578b\u53c3\u6578\uff0c\u53ef\u61c9\u7528\u65bc\u4e73\u764c\u60a3\u8005\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u8a55\u4f30\uff0c\u907f\u514d\u7522\u751f\u653e\u5c04\u6027\u80ba\u708e\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u5f8c\u4e4b\u751f\u6d3b\u54c1\u8cea\u3002", "e": "Purpose : To investigate the correlation of the ipsilateral lung dose and radiation pneumonitis of breast cancer after radiotherapy, we established Lyman Lyman Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model to study the corresponding dose of complication. Materials and Methods : In total 97 patients with breast cancer were included, they were treated with hybrid intensity-modulated radiotherapy (Hybrid IMRT) for 50.4 Gy in 28 fractions. Patients were evaluated at three months after treatment through the observation of the change of chest computed tomography image. The final endpoint of complication was according to Arriagada\u2019s classification. Patients with grade 1+ change on CT images were defined as a complication of radiation pneumonitis. We evaluated the correlation of radiation pneumonitis and mean ipsilateral lung dose. We established LKB NTCP model through calculated the equivalent uniform dose (EUD) of ipsilateral lung and validated the model performance. The NTCP model was mainly used to investigate the dose-response curve for complications of radiation pneumonitis and provided dose parameters to prevent complication of endemic breast cancer patients. Result : Radiation pneumonitis was significantly correlated with mean ipsilateral lung dose. The fitted LKB NTCP parameters were: TD50 = 21.26 Gy (95% CI, 19.78 - 22.97), m = 0.32 (95% CI, 0.19 - 0.81). The area under the receiver operating characteristic curve (AUC) of the NTCP model was 0.65. The model was passing through model performance validations, including Brier score, Hosmer- Lemeshow test and the calibration curve. Conclusion : We established Lyman Kutcher Burman normal tissue complication probability model for breast cancer radiation pneumonitis in this study, and defined the correlated parameters for endemic patients. We can apply these parameters to breast cancer radiation treatment planning evaluation, avoid radiation pneumonitis, and improve the patients\u2019 quality of life after radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-35-47", "title": "STEREOTACTIC BODY RADIATION THERAPY FOR HUGE HEPATOCELLULAR CARCINOMA: DOSIMETRIC COMPARISON OF 3D CONFORMAL RADIOTHERAPY, INTENSITY-MODULATED RADIOTHERAPY AND CYBERKNIFE", "keywords": "3D-conformal radiotherapy;Intensity-modulated radiotherapy (IMRT);Cyberknife \u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u96fb\u8166\u5200", "c": "\u524d\u8a00\uff1a\u6b64\u7bc7\u56de\u6eaf\u6027\u7814\u7a76\u7684\u76ee\u7684\u662f\u70ba\u4e86\u6bd4\u8f03\u8ec0\u9ad4\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff08SBRT\uff09\u61c9\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff083DCRT\uff09\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u8207\u96fb\u8166\u5200\uff08Cyberknife\uff09\u65bc\u53f3\u5074\u5de8\u5927\u809d\u764c\uff08\u2265 10 cm\uff09\u6cbb\u7642\u6642\u5176\u5291\u91cf\u5206\u5e03\u7684\u5dee\u7570\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u7be9\u907810\u540d\u63a5\u53d7\u96fb\u8166\u5200\u8ec0\u9ad4\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u53f3\u5074\u5de8\u5927\u809d\u764c\u60a3\u8005\uff08\u2265 10 cm\uff09\uff0c\u5229\u7528\u4e09\u7a2e\u6cbb\u7642\u6280\u8853\uff0c\u5305\u542b\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff083DCRT\uff09\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u8207\u96fb\u8166\u5200\uff08Cyberknife\uff09\uff0c\u4ee5\u7e3d\u529140 Gy\u52065\u6b21\u6cbb\u7642\uff0c\u6bd4\u8f03\u5176\u5291\u91cf\u5206\u5e03\u7684\u5dee\u7570\u6027\u3002\u70ba\u4f7f\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a\uff08RILD\uff09\u4e4b\u98a8\u96aa\u70ba \u22645%\uff0c\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u9700\u7b26\u5408 \u2265 700 cc \u7684\u6b63\u5e38\u809d\u81df\u9ad4\u7a4d\u5176\u5291\u91cf\u9700 \u2264 15 Gy\u3002\u9664\u816b\u7624\u8986\u84cb\u7387\u4e4b\u5916\uff0c\u5176\u4ed6\u5291\u91cf\u5206\u5e03\u7684\u5206\u6790\u9805\u76ee\u9084\u5305\u62ec\uff1a\u5291\u91cf\u9806\u5f62\u7387\uff08Conformityindex\uff09\uff0c\u5291\u91cf\u540c\u8cea\u7387\uff08Homogeneity index\uff09\uff0c\u6700\u9ad8\u9ede\u5291\u91cf\uff08Dmax\uff09\u3002\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\uff0c\u4e09\u500b\u6280\u8853\u90fd\u53ef\u9054\u5230\u4e0d\u932f\u7684\u8986\u84cb\u816b\u7624\u9ad4\u7a4d\uff08GTV\uff09\uff0c\u96fb\u8166\u5200\u7684\u8a08\u5283\u6a19\u9776\u9ad4\u7a4d\u8986\u84cb\u7387\u512a\u65bc\u5176\u4ed6\u5169\u7a2e\u6280\u8853\uff08p \uff1c 0.0544\uff09\uff1b\u800c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u5291\u91cf\u9806\u5f62\u7387\u986f\u8457\u4f4e\u65bc\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u96fb\u8166\u5200\uff08p \uff1c 0.0082\uff09\u3002\u5728\u5291\u91cf\u540c\u8cea\u7387\u8207\u6700\u9ad8\u9ede\u5291\u91cf\u65b9\u9762\uff0c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u986f\u8457\u4f4e\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8207\u96fb\u8166\u5200\uff08p \uff1c 0.0001\uff09\u3002\u7d50\u8ad6\uff1a\u96fb\u8166\u5200\u8ec0\u9ad4\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u53ef\u70ba\u65bc\u53f3\u5074\u5de8\u5927\u809d\u764c\u60a3\u8005\u63d0\u4f9b\u809d\u764c\u6cbb\u7642\u7684\u53e6\u4e00\u500b\u9078\u9805\uff0c\u96d6\u7136\u816b\u7624\u8986\u84cb\u7387\u8ddf\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e26\u7121\u660e\u986f\u5dee\u7570\uff0c\u4e14\u5291\u91cf\u9806\u5f62\u7387\u8207\u540c\u8cea\u7387\u4e26\u7121\u512a\u65bc\u5176\u4ed6\u5169\u7a2e\u6280\u8853\u3002\u4e0d\u904e\u96fb\u8166\u5200\u7684\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u6cbb\u7642\u8207\u5176\u4ed6\u8ec0\u9ad4\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u65b9\u5f0f\u76f8\u8f03\u4e4b\u4e0b\uff0c\u66f4\u80fd\u7cbe\u78ba\u6bd4\u5c0d\u76ee\u6a19\u800c\u9054\u5230\u5b9a\u4f4d\u512a\u52e2\uff0c\u75c5\u60a3\u4e5f\u4e0d\u6703\u56e0\u8179\u90e8\u58d3\u8feb\u88dd\u7f6e\u6216\u547c\u5438\u8abf\u63a7\u800c\u5728\u6cbb\u7642\u4e2d\u6709\u6240\u4e0d\u9069\u3002", "e": "Introduction : To compare stereotactic body radiation therapy (SBRT) of three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) and Cyberknife for huge hepatocellular carcinoma (\u226510 cm) using dosimetric analysis. Methods and Materials : Ten patients with huge hepatocellular carcinoma (HCC) of the right liver lobe treated with Cyberknife SBRT were enrolled in this study. The dosimetric values for 3D-CRT, IMRT and Cyberknife were calculated for total doses of 40 Gy / 5 fx. Treatments were individualized on the basis of the effective liver volume irradiated maintaining \u2264 5 % risk of radiation-induced liver disease (V15 Gy to \u2264 700 ml normal liver volume). Other parameters included the conformal index (CI), homogeneity index (HI) and hot spot (Dmax) for the planning target volume (PTV). Results : The GTV was covered adequately by all techniques PTV coverage of Cyberknife was comparable to 3D-CRT and IMRT (p= 0.0544); CI of IMRT were significantly lower than 3D-CRT and Cyberknife (p=0.0082). While HI and Dmax were significantly lower with 3D-CRT than with IMRT and Cyberknife (p= 0.0001). Conclusions : SBRT with Cyberknife provided an option for huge HCC in the right lobe although tumor coverage compared with 3D-CRT or IMRT was of borderline significance. IMRT and 3D-CRT resulted in a more conformal and homogenous plan than Cyberknife. And in terms of organ sparing, 3D-CRT was the most effective in the sparing of non-liver organs. However, Cyberknife had the advantage for accurate target localization by real time tracking as compared with other SBRT modalities and eliminated the discomfort of abdominal compression or respiratory control used in other SBRT techniques."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-49-56", "title": "\u4f7f\u7528\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ec\u96fb\u8166\u5200\u6cbb\u7642\u6a5f\u6700\u4f73\u5316\u4e4b\u96fb\u5b50\u5165\u5c04\u53c3\u6578\u8207\u8a08\u7b97\u6548\u7387", "keywords": "\u96fb\u8166\u5200;\u8499\u5730\u5361\u7f85\u6a21\u64ec\u65b9\u6cd5 Cyberknife;Monte Carlo simulation", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u70ba\u61c9\u7528\u8499\u5730\u5361\u7f85\u4f86\u6a21\u64ec\u4e09\u8ecd\u7e3d\u91ab\u9662\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u4e2d\u5fc3\u6240\u4f7f\u7528\u7684\u96fb\u8166\u5200\u7cfb\u7d71 \uff08G3 Cyberknife system, Accuray Inc., Sunnyvale, CA\uff09\u6a5f\u982d\u7684\u7d50\u69cb\uff0c\u5229\u7528\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u66f2\u7dda\u8207 \u5074\u5411\u5291\u91cf\u5256\u9762\u66f2\u7dda\u4e4b\u6e2c\u91cf\u503c\u8207\u8499\u5730\u5361\u7f85\u6a21\u64ec\u5f97\u5230\u4e4b\u7d50\u679c\u9032\u884c\u6bd4\u8f03\uff0c\u51fa\u6700\u4f73\u5316\u4e4b\u5165\u5c04\u96fb\u5b50\u53c3\u6578\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7814\u7a76\u4e2d\u61c9\u7528\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0fBEAMnrc09 \u4f86\u5efa\u7acb\u4e4b\u6a5f\u982d\u6a21\u7d44\u8a2d\u5b9a\u8207\u5c04\u6e90\u53c3\u6578\uff0c\u518d\u5c07 \u6b64\u6a5f\u982d\u6a21\u7d44\u5c04\u6e90\u8f38\u5165DOSXYZnrc09 \u7a0b\u5f0f\u8a08\u7b97\u6c34\u5047\u9ad4\u767e\u5206\u6df1\u5ea6\u5291\u91cf\uff08percentage depth dose\uff09\u3001\u5074\u5411\u5291\u91cf\u66f2\u7dda\uff08lateral profile\uff09\u53ca\u5291\u91cf\u8f38\u51fa\u56e0\u5b50\u4e26\u8207\u5be6\u969b\u91cf\u6e2c\u503c\u505a\u6bd4\u5c0d\u3002 \u7d50\u679c\uff1a\u7814\u7a76\u4e2d\u4ee5\u6700\u4f73\u5316\u4e4b\u96fb\u5b50\u521d\u59cb\u53c3\u6578\u6240\u8a08\u7b97\u4e4b\u7d50\u679c\u8207\u5be6\u969b\u91cf\u6e2c\u7d50\u679c\u505a\u6bd4\u8f03\uff0c\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u7684 \u5dee\u7570\u7d04 1%\uff0c80% \u7167\u91ce\u5bec\u5ea6\u5167\u4e4b\u6a21\u64ec\u5256\u9762\u5291\u91cf\u5206\u4f48\u4e5f\u8207\u6e2c\u91cf\u7d50\u679c\u53ea\u6709 1.5% \u7684\u5291\u91cf\u5dee\u7570\u3002\u5169\u5074\u5728 20% \u53ca 80% \u5291\u91cf\u8655\u6a21\u64ec\u8207\u6e2c\u91cf\u7684\u8ddd\u96e2\u5dee\u7570\u5728 0.5 mm \u4ee5\u5167\u3002\u5728\u5291\u91cf\u8f38\u51fa\u56e0\u5b50\u7684\u90e8\u5206\uff0c\u6700\u5c0f\u7684\u4e09 \u500b\u6e96\u76f4\u5100\u5dee\u7570\u70ba 2.8%-5%\uff0c\u4e3b\u8981\u539f\u56e0\u70ba\u6240\u4f7f\u7528\u7684 diode detector \u6750\u8cea\u4ecd\u7136\u70ba\u975e\u7d44\u7e54\u7b49\u6548\uff0c\u6240\u4ee5\u6703 \u6709\u9ad8\u4f30\u7684\u72c0\u6cc1\u3002 \u7d50\u8ad6\uff1a\u4ee5\u6700\u4f73\u5316\u7684\u6a21\u64ec\u53c3\u6578\u6240\u5f97\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7d50\u679c\u8207\u5be6\u9a57\u7d50\u679c\u662f\u543b\u5408\u7684\u3002\u800c\u5728\u6a21\u64ec\u7684\u904e\u7a0b\u4e2d\u9700\u8981 \u82b1\u8cbb\u5927\u91cf\u7684\u5617\u8a66\u932f\u8aa4\u7684\u65b9\u5f0f\u4f86\u5f97\u5230\u6700\u4f73\u5316\u53c3\u6578\uff0c\u4f46\u5728\u6b64\u7814\u7a76\u4e2d\u5229\u7528\u4e86\u4e00\u4e9b\u65b9\u6cd5\u6e1b\u5c11\u7684\u6a21\u64ec\u7684\u6642 \u9593\uff0c\u53ef\u63d0\u4f9b\u65e5\u5f8c\u6a21\u64ec\u96fb\u8166\u5200\u5100\u5668\u6642\u4f7f\u7528\u3002", "e": "Purpose : The study aims to optimize the initial parameters and calculating efficiency in Monte Carlo simulation for Cyberknife G3 system. Materials and Methods : BEAM09 Monte Carlo codes were applied in this study. The BEAMnrc code was used to simulate the treatment head and generate the phase space files. The DOSXYZnrc code was used to calculate the depth dose curves (percentage depth dose, PDD), lateral profiles and the output factors. Mean energy and the FWHMR were used to determine initial electron parameters. For calculating dose in the region of interest, the use of smaller voxel size may increase the calculation time; conversely, the adaption of larger voxel size may cause a higher partial volume effect. This study aims to investigate the optimal voxel size for dose calculation in a water phantom to achieve reasonable simulation efficiency and an acceptable accuracy. The K\u03b1 method was used for the optimization by comparing the differences between diode measurement data and MC simulations in PDDs and profiles. Disagreement between simulation and measurement were evaluated through the dose differences of PDDs from depths of 1.5 to 20 cm, and the lateral profiles of 80% field width. Distance to agreement (DTA) at lateral positions of 20% to 80% dose profiles of penumbra region were also used for the comparisons. Result : For the efficiency of dose calculation, setting the voxel size equal to one tenth of field width would produce optimal simulation efficiency and acceptable accuracy. According to these parameters, the dose differences of the PDDs were about 1% from depths of 1.5 to 20 cm, the dose differences for lateral profiles within 80% field width were also within 1.5%, and the disagreements of DTA were less than 0.5 mm. The discrepancies of output factor were from 2.8 to 5% for the three smallest cones, which were possibly caused by the effect of electron scattering at the metallic parts of the detector shielding. Conclusion : For Monte Carlo simulations of LINAC and dose calculations, it is important to accurately determine the initial electron beam. These parameters, mean energy and FWHM of incidence electron, have been determined by matching the calculated dose with the measured dose through a trial and error process. This study also applied some methods to increase simulation efficiency which could be the reference of future research."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-57-65", "title": "SUCCESSFUL TREATMENT OF AN AFP-PRODUCING PANCREATIC CANCER PATIENT", "keywords": "Alpha-fetoprotein-producing pancreatic cancer;Pancreatic adenocarcinoma;Concurrent chemo-radiotherapy \u7522\u751f\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u4e4b\u80f0\u81df\u764c;\u80f0\u817a\u764c;\u5408\u4f75\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642", "c": "\u524d\u8a00\uff1a\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u662f\u4e00\u7a2e\u7531\u80ce\u5152\u7684\u809d\u81df\u3001\u5375\u9ec3\u56ca\u548c\u90e8\u5206\u6d88\u5316\u9053\u7d30\u80de\u6240\u88fd\u9020\u7684\u8840\u6f3f\u86cb\u767d\uff0c\u4e26\u4e14\u540c\u6642\u662f\u4e00\u7a2e\u5e38\u7528\u65bc\u809d\u7d30\u80de\u764c\u7684\u816b\u7624\u6a19\u8a8c\u3002\u7136\u800c\u4e26\u4e0d\u53ea\u6709\u809d\u7d30\u80de\u764c\u6703\u5c0e\u81f4\u8840\u6db2\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6fc3\u5ea6\u4e0a\u5347\uff0c\u5728\u67d0\u4e9b\u7f55\u898b\u7684\u764c\u75c7\u4e5f\u6703\u5c0e\u81f4\uff0c\u6bd4\u65b9\u8aaa\u751f\u6b96\u7d30\u80de\u7624\uff1b\u800c\u5728\u67d0\u4e9b\u66f4\u7f55\u898b\u7684\u60c5\u6cc1\u4e0b\uff0c\u6703\u56e0\u80f0\u81df\u764c\u3001\u80c3\u764c\u3001\u5927\u8178\u764c\u6216\u80ba\u764c\u5c0e\u81f4\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6fc3\u5ea6\u4e0a\u5347\u3002\u80f0\u81df\u764c\u5c0e\u81f4\u8840\u6db2\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6fc3\u5ea6\u4e0a\u5347\u7684\u6bd4\u4f8b\uff0c\u6839\u64da\u7814\u7a76\u5831\u544a\u6307\u51fa\u5927\u6982\u5728 2.1%\u5230 24%\u4e4b\u9593\u3002\u5927\u90e8\u5206\u7522\u751f\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u4e4b\u80f0\u81df\u764c\u662f\u5b69\u7ae5\u7684\u80f0\u6bcd\u7d30\u80de\u7624\u6216\u662f\u80f0\u81df\u817a\u80de\u7d30\u80de\u764c\u3002\u7522\u751f\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u4e4b\u80f0\u81df\u764c\u75c5\u4eba\u5e73\u5747\u5e74\u9f61\u7d04\u70ba\u4e94\u5341\u6b72\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u4f4d\u7f79\u60a3\u7522\u751f\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u4e4b\u80f0\u81df\u7ba1\u817a\u764c\u7684 64 \u6b72\u7537\u6027\uff0c\u5728 2011 \u5e74\u7684\u5e74\u4e2d\u88ab\u8a3a\u65b7\u51fa\uff0c\u4e26\u5728\u4e4b\u5f8c\u7dca\u63a5\u8457\u63a5\u53d7\u8fd1\u5168\u80f0\u5207\u9664\u8853\u3001\u65bc 10 \u6708\u5408\u4f75\u8f14\u52a9\u6027\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5728\u6cbb\u7642\u7d50\u675f\u7684\u56db\u5e74\u5f8c\uff0c\u6839\u64da\u5f71\u50cf\u5b78\u4e0a\u7684\u8ffd\u8e64\u767c\u73fe\u6c92\u6709\u5c40\u90e8\u6216\u6dcb\u5df4\u5f15\u6d41\u5340\u5fa9\u767c\u3002\u8840\u6db2\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6fc3\u5ea6\u5728\u958b\u59cb\u6cbb\u7642\u5f8c\u5373\u4e0b\u964d\uff0c\u4e26\u5728\u4e4b\u5f8c\u6bcf\u4e09\u500b\u6708\u7684\u8840\u6db2\u5831\u544a\u4e2d\u7dad\u6301\u5728 2 ng/ml\u5de6\u53f3\u3002\u8a0e\u8ad6\uff1a\u5728\u9019\u500b\u7f55\u898b\u7684\u7b2c 1b \u671f\u7522\u751f\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u4e4b\u80f0\u81df\u7ba1\u817a\u764c\u75c5\u4eba\u8eab\u4e0a\uff0c\u75c5\u60a3\u63a5\u53d7\u8fd1\u5168\u80f0\u5207\u9664\u8853\uff0c\u53ca\u5f8c\u7e8c\u7d66\u4e88\u8f14\u52a9\u6027\u5408\u4f75\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u5728\u5230\u76ee\u524d\u70ba\u6b62\u7684\u56db\u5e74\u4e2d\uff0c\u8ffd\u8e64\u767c\u73fe\u6709\u4e0d\u932f\u7684\u6cbb\u7642\u6548\u679c\uff1b\u9019\u53ef\u80fd\u662f\u56e0\u70ba\u65e9\u671f\u8a3a\u65b7\u65e9\u671f\u6cbb\u7642\u3002\u4e0d\u904e\u6211\u5011\u4ecd\u9700\u8981\u66f4\u591a\u7684\u6848\u4f8b\u624d\u80fd\u6c7a\u5b9a\u51fa\u6700\u9069\u7576\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Introduction : Alpha-fetoprotein (AFP), a plasma protein produced by the fetal hepatocytes, yolk sac cells and some fetal gastrointestinal cells, is the tumor marker mostly used for the screening of hepatocellular carcinoma (HCC). However, AFP is not only elevated in HCC, but also in some rare cancers, such as germ cell tumors and, even more rarely, in AFP-producing pancreatic, gastric, colon and lung cancers. The incidence of elevated serum levels of AFP in pancreatic carcinomas has been reported to be 2.1%\u201324.0%. Most of the AFP-producing pancreatic cancers are pancreatoblastomas occurring in children or acinar cell carcinomas. The mean age of AFP-producing pancreatic cancers was among 50 years old. Case report : We reported a 64y/o male, with AFP-producing pancreatic cancer, ductal adenocarcinoma, diagnosed and treated by near total pancreatectomy and adjuvant concurrent chemo-radiotherapy (CCRT) in Oct. 2011. The patient completed the treatment course of CCRT. There was neither local nor regional recurrence in the image survey, during the 4 years follow-up. The AFP level decreased after CCRT treatment course started, and the AFP level was around 2 ng/ml thereafter, confirmed by the quarterly laboratory examinations. Discussion : In this reported rare case of, ductal adenocarcinoma, stage Ib, good treatment response was achieved with near total pancreatectomy and adjuvant CCRT in the four years follow-up so far, without any severe side effect. However, this may benefit from the early detection and early treatment. More patients were warranted to define the optimal treatment for AFP-producing pancreatic cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-67-75", "title": "ESOPHAGOPERICARDIAL FISTULA AND PURULENT PERICARDITIS CAUSING CARDIAC TAMPONADE DURING CONCURRENT CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: A CASE REPORT", "keywords": "Esophagopericardial fistula;Esophageal cancer;Chemoradiotherapy \u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1;\u98df\u9053\u764c;\u653e\u5316\u7642", "c": "\u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1\u65bc\u98df\u9053\u764c\u662f\u975e\u5e38\u7f55\u898b\u7684\u4f75\u767c\u75c7\uff0c\u6b7b\u4ea1\u7387\u6975\u9ad8\u3002\u672c\u500b\u6848\u70ba\u98df\u9053\u764c\u653e\u5316\u7642\u4e2d\u4f75\u767c\u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1\u5408\u4f75\u5316\u81bf\u6027\u5fc3\u5305\u819c\u708e\u53ca\u5fc3\u5305\u586b\u585e\u3002\u4e00\u540d 54 \u6b72\u7684\u7537\u5b50\u88ab\u78ba\u8a3a\u70ba\u7b2c\u4e09\u671f\u4e4b\u4e2d\u6bb5\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\uff0c\u63a5\u53d7\u6839\u6cbb\u6027\u540c\u6b65\u653e\u5316\u7642\uff0c\u4ed6\u7d2f\u7a4d\u63a5\u53d7 28 Gy \u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u81f3\u98df\u9053\u8207\u80c3\u9031\u908a\u6dcb\u5df4\u7d50\u816b\u7624\uff0c\u4e26\u5408\u4f75\u4e00\u500b\u7642\u7a0b\u4e4b\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u75c5\u60a3\u56e0\u56b4\u91cd\u75b2\u52de\u3001\u541e\u56a5\u56f0\u96e3\u53ca\u80f8\u58c1\u75bc\u75db\u4e2d\u65b7\u6cbb\u7642\u3002\u4e09\u5929\u5f8c\u75c5\u60a3\u767c\u751f\u865b\u6c57\u4e26\u65bc\u6d74\u5ba4\u6688\u53a5\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u4e2d\u5ea6\u5fc3\u5305\u819c\u7a4d\u6db2\uff0c\u96fb\u8166\u65b7\u5c64\u986f\u793a\u6c23\u6ce1\u7a4d\u6db2\u4f4d\u65bc\u6cbb\u7642\u524d\u4e4b\u98df\u9053\u816b\u7624\u90e8\u4f4d\u4e26\u6709\u5fc3\u5305\u819c\u7a4d\u6c34\uff0c\u81e8\u5e8a\u8a3a\u65b7\u70ba\u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1\uff0c\u75c5\u60a3\u7dca\u6025\u63a5\u53d7\u5fc3\u5305\u7a7f\u523a\u53ca\u5f15\u6d41\uff0c\u4e26\u65bd\u6253\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u8a72\u60a3\u8005\u65bc\u4f4f\u9662 18 \u65e5\u5f8c\u75c5\u60c5\u7a69\u5b9a\u51fa\u9662\u3002\u6211\u5011\u61f7\u7591\u672c\u500b\u6848\u56e0\u98df\u9053\u816b\u7624\u4e4b\u524d\u58c1\u7dca\u8cbc\u5de6\u5fc3\u623f\u5305\u819c\uff0c\u56e0\u816b\u7624\u7e2e\u5c0f\u5408\u4f75\u767c\u708e\u53ca\u6f70\u760d\u5c0e\u81f4\u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1\u3002\u98df\u9053\u5fc3\u5305\u819c\u763b\u7ba1\u5408\u4f75\u5316\u81bf\u6027\u5fc3\u5305\u708e\u662f\u4e00\u7a2e\u6025\u75c7\uff0c\u5982\u679c\u5ef6\u9072\u8a3a\u65b7\u548c\u6cbb\u7642\u53ef\u5c0e\u81f4\u6b7b\u4ea1\u3002\u56e0\u70ba\u98df\u9053\u5fc3\u5305\u819c\u7ba1\u7684\u67d0\u4e9b\u75c7\u72c0\u985e\u4f3c\u98df\u9053\u764c\u63a5\u53d7\u653e\u5316\u7642\u4e4b\u526f\u4f5c\u7528\uff0c\u91ab\u5e2b\u9664\u975e\u4fdd\u6301\u9ad8\u5ea6\u8b66\u89ba\uff0c\u5426\u5247\u5f88\u53ef\u80fd\u6703\u88ab\u5ffd\u8996\uff0c\u6545\u5728\u4e2d\u4e0b\u6bb5\u98df\u9053\u816b\u7624\u4e4b\u524d\u58c1\u7dca\u8cbc\u5fc3\u5305\u819c\u4e4b\u500b\u6848\uff0c\u75c5\u60a3\u5728\u63a5\u53d7\u653e\u5316\u7642\u671f\u9593\u6216\u7d50\u675f\u5f8c\uff0c\u6211\u5011\u90fd\u61c9\u6ce8\u610f\u6b64\u4f75\u767c\u75c7\u7684\u53ef\u80fd\u6027\u3002", "e": "Esophagopericardial fistula (EPF) secondary to esophageal cancer is a rare complication with high mortality rate. Here, we present a case of esophageal cancer patient who developed EPF and purulent pericarditis with cardiac tamponade during the course of concurrent chemoradiotherapy. A 54-year-old man who was diagnosed with squamous cell carcinoma of middle to low third esophagus staged as cT3N1M0 underwent concurrent chemoradiotherapy with radical intent. He received a cumulative radiotherapy dose of 28 Gy in 14 fractions to the esophageal tumor and perigastric lymphadenopathy using intensity modulated radiotherapy and one course of concomitant chemotherapy using cisplatin + infusional 5-fluorouracil. There was a treatment break of 3 days due to severe fatigue, dysphagia, and chest wall pain. He was brought to our emergency department due to cold sweating and syncope at the bathroom. Echocardiography revealed small ventricular size due to moderate pericardial effusion. Computed tomography showed encapsulated fluid collection with air bubbles over mediastinum adjacent to the previous tumor site and pericardial effusion. Under the impression of EPF and purulent pericarditis with cardiac tamponade, pericardiocentesis, pigtail tube drainage and antibiotic were instituted. The patient was discharged from hospital on the day 18 with a stable condition. We assume that the EPF observed in this patient may be caused by the location of middle to lower thoracic esophageal tumor, and the anterior wall closed to pericardium of the left atrium, tumor shrinkage combined chronic inflammation and through and through ulcerated esophageal tumor to the pericardium. EPF with purulent pericarditis is an acute and fulminant disease that has high mortality rate if delayed diagnosed and treated. Because some of the symptoms of EPF formation mimic those discomfort arising from esophageal cancer and chemoradiotherapy, it will go unnoticed unless a high index of suspicion has been placed. In the case of the lower third thoracic esophageal tumor and anterior wall close to the pericardium, we should maintain a high index of suspicion of this life-threatening complication during and after chemoradiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201703-201704190026-201704190026-77-84", "title": "CARDIAC METASTASIS DUE TO ORAL CAVITY CANCER PRESENTING AS HEART FAILURE", "keywords": "Cardiac metastasis;Oral cavity cancer;Immuno-suppression therapy \u5fc3\u81df\u8f49\u79fb;\u53e3\u8154\u764c;\u514d\u75ab\u6291\u5236\u6cbb\u7642", "c": "\u60e1\u6027\u816b\u7624\u51fa\u73fe\u5fc3\u81df\u8f49\u79fb\u662f\u76f8\u7576\u7f55\u898b\u7684\uff0c\u5118\u7ba1\u904e\u53bb\u66fe\u6709\u982d\u9838\u764c\u8f49\u79fb\u5230\u5fc3\u81df\u4e4b\u5831\u5c0e\uff0c\u4f46\u4ecd\u4ee5\u80ba\u764c\u9020\u6210\u5fc3\u81df\u8f49\u79fb\u6700\u70ba\u5e38\u898b\u3002\u6b64\u75c5\u4f8b\u5831\u544a\u70ba 50 \u6b72\u7537\u6027\u56e0\u809d\u786c\u5316\u63a5\u53d7\u89aa\u5c6c\u6d3b\u9ad4\u809d\u81df\u79fb\u690d\uff0c\u4e26\u65bc\u809d\u81df\u79fb\u690d\u5f8c\u63a5\u53d7\u514d\u75ab\u6291\u5236\u5291 tacrolimus \u4ee5\u9810\u9632\u5668\u5b98\u6392\u65a5\u53cd\u61c9\u3002\u60a3\u8005\u5f8c\u7e8c\u767c\u73fe\u7f79\u60a3\u820c\u764c\uff0c\u65bc\u63a5\u53d7\u5168\u820c\u5207\u9664\u53ca\u96d9\u9838\u6dcb\u5df4\u64f4\u6e05\u624b\u8853\u5f8c\uff0c\u958b\u59cb\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u3002\u7576\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u70ba26 Gy \u6642\uff0c\u60a3\u8005\u51fa\u73fe\u547c\u5438\u6025\u4fc3\u3001\u51b7\u6c57\u53ca\u5fc3\u60b8\u7b49\u75c7\u72c0\u3002\u5fc3\u81df\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u651d\u5f71\u986f\u793a\u51a0\u72c0\u52d5\u8108\u901a\u66a2\uff0c\u4f46\u5fc3\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u53f3\u5fc3\u5ba4\u51fa\u73fe\u816b\u584a\u4f34\u96a8\u8840\u6d41\u963b\u6eef\uff0c\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u4e5f\u986f\u793a\u53f3\u5fc3\u5ba4\u51fa\u73fe\u58de\u6b7b\u6027\u816b\u584a\u3002\u6211\u5011\u91dd\u5c0d\u670d\u7528\u514d\u75ab\u6291\u5236\u5291\u8207\u764c\u75c7\u767c\u751f\u9032\u884c\u6587\u737b\u63a2\u8a0e\uff0c\u6b64\u75c5\u4f8b\u5831\u544a\u986f\u793a\u670d\u7528\u514d\u75ab\u6291\u5236\u5291\u4e4b\u764c\u75c7\u75c5\u60a3\u53ef\u80fd\u9020\u6210\u7f55\u898b\u4e4b\u5fc3\u81df\u8f49\u79fb\u3002", "e": "Cardiac metastasis from head and neck cancer is rarely seen, while a lung primary would be the most common original anatomic site of cardiac metastasis. A 50-year-old man with the underlying disease of Child C liver cirrhosis underwent a liver transplantation on February 19, 2014 and took tacrolimus for prevention of graft rejection. However, a mass over right tongue border was found by the patient himself at the end of February, 2014. The patient then underwent total glossectomy and right modified radical neck dissection on June 26, 2014. Pathology report showed squamous cell carcinoma of oral tongue, pT4aN2cM0, stage IVA. Postoperative radiation therapy was started on July 22, 2014. However, the patient developed shortness of breath, cold sweating and tachycardia on August 8, 2014 after a cumulative radiation dose of 26 Gy. Coronary arteriogram showed patent coronary arteries. However, echocardiogram found a tumor mass on the right ventricle of the heart with partial cardiac flow obstruction. Chest computer tomography (CT) also showed a necrotic soft tissue mass on right ventricle of the heart, the symptom exacerbated in following two weeks. He was finally transferred for hospice care on August 25, 2014. The patient passed away on August 27, 2014. The immuno-suppressive drugs for rejection prevention may be associated with the occurrence of rare cardiac metastasis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-219-228", "title": "CRANIAL NERVE INVOLVEMENT IN NASOPHARYNGEAL CARCINOMA PATIENTS TREATED WITH INTENSITY-MODULATED RADIOTHERAPY: A SINGLE INSTITUTIONAL EXPERIENCE", "keywords": "Cranial nerve involvement;Nasopharyngeal carcinoma (NPC);Intensity-modulated radiotherapy (IMRT) \u8166\u795e\u7d93\u4fb5\u72af;\u9f3b\u54bd\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u5206\u6790\u4f75\u6709\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u9f3b\u54bd\u764c\u60a3\u8005\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u4e4b\u9810\u5f8c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u6eaf\u6027\u8ffd\u8e64 2007 \u5230 2013 \u5e74\u9593\uff0c230 \u4f4d\u9f3b\u54bd\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d\u6709\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u60a3\u8005\u5360 22 \u4f4d\uff0c\u539f\u767c\u816b\u7624\u53ca\u6dcb\u5df4\u7d50\u967d\u6027\u90e8\u4f4d\u7d66\u4e88 69.96 \u81f3 70 Gy\uff0c\u986f\u5fae\u4fb5\u72af\u8655\u7d66\u4e88 59.4\u81f3 63 Gy\uff0c\u7121\u4fb5\u72af\u8655\u5247\u7d66\u4e88 54.45 \u81f3 56 Gy\u3002\u4e8c\u5341\u4e8c\u4f4d\u6709\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u60a3\u8005\u6709\u4e8c\u5341\u4e00\u4f4d\u6709\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\u7d50\u679c\uff1a\u6709\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u60a3\u8005\u5360\u4e86 9.6%\uff0c\u6700\u5e38\u5f71\u97ff\u5230\u7684\u8166\u795e\u7d93\u70ba\u7b2c\u4e94\u5c0d\uff0859.1%\uff09\u53ca\u7b2c\u516d\u5c0d\uff0845.5%\uff09\u3002\u6700\u666e\u904d\u7684\u75c7\u72c0\u70ba\u773c\u775b\u7684\u795e\u7d93\u75c7\u72c0\uff0868.2%\uff09\uff0c\u7b2c\u4e8c\u70ba\u984f\u9762\u9ebb\u75fa\u75db\uff0845.5%\uff09\u30023 \u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\u3001\u5c40\u90e8\u63a7\u5236\u7387\uff08LRFS\uff09\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\uff08DFS\uff09\u70ba 79.2%\u300182.9%\u53ca 50.0%\u3002\u6bd4\u8f03\u6b21\u5206\u7d44\u7684\u9810\u5f8c\uff0c\u6cbb\u7642\u524d\u75c7\u72c0\u5c0f\u65bc\u4e09\u500b\u6708\u8ddf\u8d85\u904e\u4e09\u500b\u6708\u6bd4\u8f03\u6709\u8f03\u4f73\u7684 OS\uff08100% vs. 43.7%, p =0.016\uff09 \u53ca DFS\uff0877.8% vs. 12.5%, p = 0.014\uff09\u3002\u6cbb\u7642\u5f8c\u795e\u7d93\u5b78\u75c7\u72c0\u5b8c\u5168\u6062\u5fa9\u5728 DFS \u4e0a\u96d6\u7121\u986f\u8457\u5dee\u7570\uff0c\u4f46\u5448\u73fe\u7565\u4f73\u7684\u8da8\u52e2\uff08100.0% vs. 30.0%, p = 0.071\uff09\u3002\u81e8\u5e8a\u75c7\u72c0\u8a3a\u65b7\u6216\u5f71\u50cf\u8a3a\u65b7\uff1b\u53ca\u55ae\u4e00\u8166\u795e\u7d93\u4fb5\u72af\u6216\u591a\u91cd\u8166\u795e\u7d93\u4fb5\u72af\u5c0d\u9810\u5f8c\u4e26\u7121\u986f\u8457\u7684\u5dee\u7570\u3002\u6cbb\u7642\u5f8c\u6240\u6709\u75c5\u4eba\u76ee\u524d\u6c92\u6709\u767c\u751f\u8166\u58de\u6b7b\u7684\u526f\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u6cbb\u7642\u524d\u75c7\u72c0\u5c0f\u65bc\u4e09\u500b\u6708\u8ddf\u8d85\u904e\u4e09\u500b\u6708\u5c0d\u65bc\u6709\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u9f3b\u54bd\u764c\u60a3\u8005 OS \u53ca DFS \u662f\u986f\u8457\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6cbb\u7642\u5f8c\u795e\u7d93\u5b78\u75c7\u72c0\u7684\u5b8c\u5168\u6062\u5fa9\u5c0d\u65bc DFS \u96d6\u4e0d\u662f\u986f\u8457\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u4f46\u6709\u7565\u4f73\u7684\u8da8\u52e2\u3002\u4f46\u6709 CN \u4fb5\u72af\u7684\u591a\u5be1\u53ca\u8a3a\u65b7\u65b9\u5f0f\uff08\u81e8\u5e8a\u6216\u5f71\u50cf\uff09\u5c0d\u65bc\u8166\u795e\u7d93\u4fb5\u72af\u4e4b\u9f3b\u54bd\u764c\u60a3\u8005\u7684\u9810\u5f8c\u7686\u7121\u986f\u8457\u5f71\u97ff\u3002", "e": "Background : This study evaluated cranial nerve (CN) involvement and the outcomes of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT). Method : This study recruited 230 patients with histologically proven NPC without metastasis who were treated with IMRT at our institution between 2007 and 2013. Twenty-two patients had CN involvement. The primary tumor and involved lymph nodes were prescribed 69.96-70 Gy, the microscopic areas were prescribed 59.4-63 Gy, and clinically negative neck regions were prescribed 54.45-56 Gy in 33\u201335 fractions. Twenty-one patients with CN involvement received RT combined with chemotherapy. Result : The incidence of CN involvement was 9.6%. The most commonly involved CNs were the trigeminal (59.1%) and abducens nerves (45.5%), with the most commonly presenting symptoms being neuroophthalmic manifestations (68.2%), followed by facial numbness or pain (45.5%). The 3-year overall survival (OS), local relapse-free survival (LRFS), and disease-free survival (DFS) rates were 79.2%, 82.9%, and 50.0% respectively. Significant differences were observed in the 3-year OS rate (100% vs 43.7%, p = 0.016) and DFS (77.8% vs. 12.5%, p = 0.014) between patients with pretreatment neurological symptoms that presented for less than 3 months and more than 3 months. Patients with complete recovery of neurological symptoms after treatment tended to exhibit higher 3-year DFS (100% vs. 30.0%, p = 0.071). Single or multiple CN involvement and clinically or radiologically diagnosed CN involvement were not prognosticators for NPC patients with CN involvement. No temporal lobe necrosis was noted as the late effect. Conclusion : The pretreatment duration of neurological symptoms is a significant prognostic factor for the OS and DFS of NPC patients with CN palsy. Patients with a complete neurological response after treatment tend to exhibit higher DFS (p = 0.071). However, the outcome of NPC patients with CN palsy is not affected by the extensive involvement of CN lesions or the mode of diagnosis, either clinical or radiological."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-229-236", "title": "LONG-TERM OUTCOMES OF HIGH-DOSE-RATE BRACHYTHERAPY PLUS EXTERNAL-BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER", "keywords": "Prostate cancer;HDR-brachytherapy;Radiotherapy \u651d\u8b77\u817a\u764c;\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642", "c": "\u76ee\u7684\uff1a\u5831\u544a\u4ee5\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\uff08high-dose-rate brachytherapy, HDR-BT\uff09\u52a0\u4e0a\u9ad4\u5916\u5c04\u675f\u653e\u7642\uff08external beam radiotherapy, EBRT\uff09\u5c0d\u4fb7\u9650\u6027\u651d\u8b77\u817a\u764c\uff08localized prostate cancer\uff09\u7684\u9577\u671f\u6cbb\u7642\u6210\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u9304\u4e86 121 \u4f4d\u4ee5 HDR-BT \u52a0\u4e0a EBRT \u6cbb\u7642\u7684 T1c \u81f3 T3b \u671f\u651d\u8b77\u817a\u764c\u75c5\u4eba\u3002HDR-BT \u5291\u91cf\u5171 16.5 Gy\uff0c\u65bc\u9ad4\u5916\u5c04\u675f\u653e\u7642\u524d\u5169\u9031\uff0c\u5206\u4e09\u6b21\u65bc\u4e8c\u5341\u56db\u5c0f\u6642\u5167\u7d66\u4e88\u3002\u9ad4\u5916\u5c04\u675f\u653e\u764250.4 Gy \u7167\u5c04\u65bc\u651d\u8b77\u817a\u548c\u5132\u7cbe\u56ca\u3002\u82e5\u75c5\u4eba\u5e74\u7d00\u5c0f\u65bc 75 \u6b72\u4e26\u4e14\u6dcb\u5df4\u8f49\u79fb\u98a8\u96aa\u5927\u65bc 15%\uff0c\u5247\u8d77\u59cb\u768445 Gy/ 25 \u6b21\u6db5\u84cb\u5168\u9aa8\u76c6\u8154\u3002\u7d50\u679c\uff1a\u767e\u5206\u4e4b\u56db\u5341\u4e5d\u7684\u75c5\u4eba\u5c6c\u65bc\u9ad8\u98a8\u96aa\uff08T3a \u6216 Gleason \u5206\u6578 8-10 \u6216 PSA \u5927\u65bc 20 ng/ml\uff09\u6216\u975e\u5e38\u9ad8\u98a8\u96aa\uff08T3b\uff09\u65cf\u7fa4\u3002\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\u70ba 125 \u500b\u6708\uff08\u7bc4\u570d\uff1a22-168 \u500b\u6708\uff09\u3002\u516b\u5e74\u7684\u7684\u751f\u5316\u63a7\u5236\u7387\uff08biochemical control rate\uff09\u70ba 80%\uff08\u5c0d\u65bc\u4f4e\u3001\u4e2d\u3001\u9ad8\u3001\u975e\u5e38\u9ad8\u98a8\u96aa\u65cf\u7fa4\u7684\u75c5\u4eba\uff0c\u5176\u6578\u5b57\u5247\u5206\u5225\u70ba 100%\uff0c90%\uff0c71%\u548c 20%\uff09\u6709\u5169\u4f4d\u75c5\u4eba\u5728\u9ad4\u5916\u5c04\u675f\u653e\u7642\u7d50\u675f\u5f8c\u5f88\u4e45\uff08108 \u548c 129 \u500b\u6708\uff09\u624d\u7522\u751f\u751f\u5316\u4e0a\u7684\u5931\u6557\uff08biochemical failure\uff09\u3002\u516b\u5e74\u7684\u7e3d\u9ad4\u5b58\u6d3b\u7387\uff08Overall Survival\uff09\u548c\u764c\u75c7\u7279\u5b9a\u5b58\u6d3b\u7387\uff08cancer-specific survival\uff09\u5206\u5225\u70ba 91%\u548c 99%\u3002\u6709\u516d\u4f4d\u75c5\u4eba\uff085%\uff09\u56e0\u8840\u5c3f\u5c0e\u81f4\u7684\u6025\u6027\u5c3f\u6eef\u7559\uff08acute urinary retention\uff09\u7522\u751f\u7b2c\u4e09\u7d1a\u7684\u63d2\u91dd\u76f8\u95dc\uff08implant-related\uff09\u6025\u6027\u526f\u4f5c\u7528\u3002\u80c3\u8178\u9053\uff08gastrointestinal\uff09\u7684\u6162\u6027\u526f\u4f5c\u7528\u4e26\u4e0d\u986f\u8457\uff0c\u4f46\u6709\u4e03\u4f4d\u75c5\u4eba\uff086%\uff09\u56e0\u5c3f\u9053\u72f9\u7a84\uff08urinary stricture\uff09\u548c\u56b4\u91cd\u8840\u5c3f\uff08severe hematuria\uff09\u800c\u88ab\u6b78\u70ba\u7b2c\u4e09\u7d1a\u7684\u6ccc\u5c3f\u9053\uff08genitourinary\uff09\u526f\u4f5c\u7528\u3002\u5168\u9aa8\u76c6\u8154\u7167\u5c04\u6703\u589e\u52a0\u80c3\u8178\u9053\u7684\u6025\u6027\u526f\u4f5c\u7528\u4f46\u975e\u6162\u6027\u526f\u4f5c\u7528\u3002\u5728 83 \u4f4d\u6cbb\u7642\u524d\u6027\u529f\u80fd\u826f\u597d\u7684\u75c5\u4eba\uff0c\u6709 30%\u5728\u6cbb\u7642\u5f8c\u4e94\u5e74\u4ecd\u4fdd\u6709\u5176\u6027\u80fd\u529b\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc T1c \u81f3 T3a \u7684\u651d\u8b77\u817a\u764c\u75c5\u4eba\uff0cHDR-BT \u642d\u914d EBRT \u53ef\u9054\u5230\u6eff\u610f\u7684\u9577\u671f\u751f\u5316\u63a7\u5236\u7387\u4e26\u53ef\u63a5\u53d7\u7684\u526f\u4f5c\u7528\u7d50\u679c\u3002", "e": "Purpose : To report 8-year long-term outcomes for localized prostate cancer patients treated with the combination of high-dose-rate brachytherapy (HDR-BT) and external beam radiotherapy (EBRT). Materials and Methods : One hundred and twenty-one Stage T1c to T3b prostate cancer patients treated with HDR-BT plus EBRT were included. An HDR dose of 16.5 Gy in 3 fractions over 24 hours was given 2 weeks before EBRT. An EBRT dose of 50.4 Gy was administered to the prostate and seminal vesicles. Younger patients (aged under 75 years) with greater than 15% risk of nodal metastasis received whole-pelvis RT (45 Gy in 25 fractions) as part of EBRT. Results : Forty-nine percent of patients belonged to the high-risk (T3a or Gleason score 8\u201310 or prostate specific antigen greater than 20 ng/mL) or very-high-risk (T3b) groups. After a median follow-up of 125 months (range, 22-168 months), 8-year biochemical control rate was 80% (100%, 90%, 71%, and 20% respectively, for patients in the low, intermediate, high, and very-high-risk groups). Biochemical failure was noted in 25 patients. Two patients experienced late biochemical failure (108 and 129 months after EBRT). 8-year overall and cancer-specific survivals were 91% and 99%. Six patients (5%) had grade 3 implant-related acute urinary retention due to hematuria. Chronic gastrointestinal (GI) toxicities were limited, but 7 (6%) patients had episodes of grade 3 chronic genitourinary (GU) toxicities, including urethral stricture and severe hematuria. Whole-pelvis EBRT is a major contributing factor to acute but not to chronic GI toxicities. Among 84 patients with pretreatment sexual potency, 30% retained potency at 5 years. Conclusion : HDR-BT plus EBRT can achieve satisfactory long-term biochemical control with acceptable complications for T1c-T3a prostate cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-237-247", "title": "PRELIMINARY RESULTS OF PREOPERATIVE CHEMORADIATION THERAPY FOR CERVICAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH LARYNX PRESERVATION", "keywords": "Preoperative chemoradiotherapy;Cervical esophageal cancer;Larynx preservation \u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u9838\u90e8\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c;\u5589\u90e8\u4fdd\u7559\u624b\u8853", "c": "\u76ee\u7684\uff1a\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u624b\u8853\u5df2\u88ab\u5ee3\u6cdb\u904b\u7528\u65bc\u6cbb\u7642\u5c40\u90e8\u665a\u671f\u975e\u9838\u90e8\u98df\u9053\u764c\u3002\u672c\u7814\u7a76\u76ee\u7684\u5728\u65bc\u91dd\u5c0d\u9838\u90e8\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\uff0c\u8a55\u4f30\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5589\u90e8\u4fdd\u7559\u624b\u8853\u4e4b\u53ef\u884c\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5206\u6790 11 \u540d\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5589\u90e8\u4fdd\u7559\u624b\u8853\u4e4b\u9838\u90e8\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u60a3\u8005\u3002\u4ee5\u540c\u6b65\u6574\u5408\u52a0\u5f37\u7167\u5c04\u6280\u8853\u7d66\u4e88 48 Gy \u81f3\u816b\u7624\u9776\u5340\uff0c43.2 Gy \u81f3\u6f5b\u5728\u9ad8\u98a8\u96aa\u5340\uff0c\u540c\u6642\u7d66\u4e88 cisplatin \u5316\u5b78\u6cbb\u7642\u3002\u85c9\u7531\u8a55\u4f30\u526f\u4f5c\u7528\uff0c\u5f71\u50cf\u8b8a\u5316\u8207\u75c5\u7406\u53cd\u61c9\u4f86\u8a55\u4f30\u5176\u521d\u6b65\u7642\u6548\u3002\u7d50\u679c\uff1a\u5171\u8a08 10 \u540d\u75c5\u60a3\u5b8c\u6210\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff0c\u800c\u6709 1 \u540d\u75c5\u60a3\u65bc\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u4e2d\u56e0\u70ba\u5438\u5165\u6027\u80ba\u708e\u53ca\u6557\u8840\u75c7\u5c0e\u81f4\u6b7b\u4ea1\u3002\u5b8c\u6210\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u4e2d\uff0c8 \u540d\u63a5\u53d7\u98df\u9053\u816b\u7624\u5207\u9664\u624b\u8853\u3002\u624b\u8853\u5f8c\uff0c4 \u540d\u60a3\u8005\uff0850%\uff09\u75c5\u7406 T \u5206\u671f\u6539\u5584\uff0c1 \u540d\u60a3\u8005(12.5%) \u9054\u5230\u75c5\u7406\u5b8c\u5168\u7de9\u89e3\u30027 \u540d\u60a3\u8005\uff0887.5%\uff09\u4fdd\u7559\u5589\u90e8\uff0c\u4e14 6 \u540d\u60a3\u8005\uff0875%\uff09\u9054\u5230\u624b\u8853\u5207\u53e3\u908a\u7de3\u9670\u6027\u3002\u56e0\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5c0e\u81f4\u7684\u56b4\u91cd\u6025\u6027\u526f\u4f5c\u7528\uff0c\u5206\u5225\u70ba\u5206\u671f 3 \u7d1a\u54b3\u55fd\uff081 \u540d\uff0c10%\uff09\u53ca\u5206\u671f 3 \u7d1a\u8ca7\u8840\uff081 \u540d\uff0c10%\uff09\u3002\u6839\u64da\u5916\u79d1\u91ab\u5e2b\u5171\u8b58\uff0c\u80fd\u63a5\u53d7\u5589\u90e8\u4fdd\u7559\u624b\u8853\u7684\u5206\u754c\u9ede\u70ba\u98df\u9053\u816b\u7624\u8ddd\u96e2\u5589\u90e8\u5927\u65bc 2 \u516c\u5206\u3002\u7d50\u8ad6\uff1a\u9838\u90e8\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u60a3\u8005\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u9032\u884c\u5589\u90e8\u4fdd\u7559\u624b\u8853\u662f\u53ef\u884c\u7684\u3002\u672a\u4f86\u662f\u5426\u80fd\u5c07\u591a\u91cd\u6a21\u5f0f\u6cbb\u7642\u904b\u7528\u65bc\u9838\u90e8\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u75c5\u60a3\u4ee5\u6539\u5584\u816b\u7624\u63a7\u5236\u7387\u53ca\u751f\u6d3b\u54c1\u8cea\uff0c\u53ef\u5c07\u672c\u7814\u7a76\u7684\u521d\u6b65\u7d50\u679c\u4f5c\u70ba\u81e8\u5e8a\u9a57\u8b49\u4e4b\u53c3\u8003\u3002", "e": "Purpose : Preoperative concurrent chemoradiotherapy (CCRT) followed by surgery has been widely accepted for treating locally advanced esophageal cancer except cervical esophageal cancer. This study aimed to evaluate the feasibility of preoperative CCRT followed by surgery for cervical esophageal squamous cell carcinoma (SCC) with intent to preserve the larynx. Materials & Methods : From August 2013 to August 2015, 11 patients with cervical esophageal SCC scheduled to receive preoperative CCRT with surgery were retrospectively analyzed. The gross tumor and involved lymphadenopathies were delivered with 48 Gy and 43.2 Gy to subclinical mucosal/submucosal disease and regional lymphatic basin in 24 fractions by simultaneously integrated boost (SIB) planning through intensity modulated radiation therapy (IMRT) or Tomotherapy. Chemotherapy with weekly cisplatin 30 mg/m^2 was administered during radiation therapy (RT) course. Side effects grading was according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0). The image assessment and pathological responses were recorded and graded. Results : Among all 11 patients, ten of them had received the planned CCRT completely and one was dead due to aspiration pneumonia and sepsis during CCRT course. Of the 10 patients who completed preoperative CCRT, 8 patients of them have received esophagectomy. The pathological T down-staging was noted in 4 patients (50%) and pathological complete response (pCR) was achieved in 1 patient (12.5%). Seven of these 8 patients (87.5%) preserved the larynx and 6 patients (75%) achieved negative surgical margins (R0 resection). The most severe acute toxicities from CCRT were grade 3 cough (n=1, 10%) and grade 3 anemia (n=1, 10%). According to chest surgeons\u2019 consensus, the cut-off point for larynx-preserving surgery after CCRT for cervical esophageal cancer could be 2-cm distance from esophageal tumor to larynx. Conclusion : Preoperative CCRT followed by larynx-sparing surgery is feasible in cervical esophageal SCC. The preliminary results can be used as a reference for further clinical validation of multimodality therapy in cervical esophageal SCC with intent to improve tumor control and quality of life."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-249-257", "title": "\u61c9\u7528\u5168\u570b\u8cc7\u6599\u5eab\u53ca\u50be\u5411\u5206\u6578\u914d\u5c0d\u63a2\u8a0e\u53f0\u7063\u5730\u5340\u5168\u4e73\u5207\u9664\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u5728N1\u75c5\u4eba\u7684\u89d2\u8272", "keywords": "\u4e73\u764c;\u653e\u5c04\u6cbb\u7642;\u5168\u4e73\u623f\u5207\u9664 Breast cancer;Radiotherapy;Mastectomy", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u53f0\u7063 N1 \u4e73\u764c\u75c5\u4eba\u9032\u884c\u5168\u4e73\u623f\u5207\u9664\u5f8c\u653e\u5c04\u6cbb\u7642\u662f\u5426\u5f71\u97ff\u75c5\u4eba\u7684\u9810\u5f8c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6536\u96c6\u5168\u570b\u764c\u75c7\u767b\u8a18\u3001\u5168\u6c11\u5065\u4fdd\u53ca\u6b7b\u4ea1\u6a94\u8cc7\u6599\uff0c\u897f\u5143 2004-2009 \u5e74\u65b0\u767b\u8a18\u7684\u4e73\u764c\u75c5\u4eba\uff0c\u9078\u53d6\u65e9\u671f\u4e73\u764c\uff08T1-2\uff09\u4e26\u6709 N1 \u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u7684\u75c5\u4eba\u5171 6,257 \u4f4d\uff0c\u5728\u63a5\u53d7\u4e73\u623f\u5168\u5207\u9664\u624b\u8853\u5f8c\uff08Post-mastectomy\uff09\uff0c\u5c07\u6709\u7121\u653e\u5c04\u7dda\u6cbb\u7642\uff08post-mastectomy radiotherapy, PMRT\uff09\u7d93\u50be\u5411\u5206\u6578\u914d\u5c0d\uff08propensity score matching, PSM\uff09\u5f8c\uff0c\u5206\u6790\u5176\u751f\u5b58\u7387\u4ee5\u53ca\u8a55\u4f30\u5176\u5371\u96aa\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u5728\u6240\u9078\u65cf\u7fa4\u4e2d\uff0c\u5168\u4e73\u5207\u9664\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7d44\u75c5\u4eba\u5171 2,866\uff0846%\uff09\u4eba\uff0c\u7121\u653e\u5c04\u6cbb\u7642\u7d44\u51713,391\uff0854%\uff09\uff0c\u7d93\u50be\u5411\u5206\u6578\u914d\u5c0d\u5f8c\uff0c\u5169\u7d44\u5206\u5225\u70ba 2,267\uff0850%\uff09\u4eba\u3002\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u7684\u75c5\u4eba\u6bd4\u6c92\u6709\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u6709\u8f03\u4f73\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff08Overall survival, 5 year 92.0% vs. 90.7%; 8 year87.9% vs. 81.5%, p= 0.001\uff09\u8207\u7121\u75c5\u5b58\u6d3b\u7387\uff08Disease-free survival, 5 year 79.3% vs. 74.8%\uff0c8year 74.2% vs. 65.8%, p= 0.0002\uff09\u3002\u800c\u5728\u5371\u96aa\u56e0\u5b50\u8a55\u4f30\u4e2d\uff0c\u6dcb\u5df4\u7d50\u4fb5\u72af\u6578\u76ee\u8207\u75c5\u7406 T2\uff0c\u6b64\u5169\u7a2e\u5371\u96aa\u56e0\u5b50\uff0c\u5728\u6574\u9ad4\u5b58\u6d3b\u7387\uff08Overall survival\uff09 \u4ee5\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\uff08Disease-free survival\uff09\u9054\u5230\u7d71\u8a08\u986f\u8457\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u6b64\u6b21\u7814\u7a76\u5229\u7528\u764c\u767b\u8cc7\u6599\u5eab\u5206\u6790 N1 \u75c5\u4eba\u63a5\u53d7\u5168\u4e73\u5207\u9664\u624b\u8853\u5f8c\u4e4b\u653e\u5c04\u6cbb\u7642\uff0c\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u6709\u8f03\u4f73\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\uff0c\u800c\u816b\u7624\u5927\u5c0f\u548c\u6dcb\u5df4\u7d50\u4fb5\u72af\u6578\u76ee\u70ba\u5f71\u97ff\u5b58\u6d3b\u4e4b\u56e0\u5b50\uff0c\u552f\u6b64\u7814\u7a76\u672a\u5206\u6790\u5c40\u90e8\u6dcb\u5df4\u7d50\u7167\u5c04\u4e4b\u7bc4\u570d\uff0c\u65e5\u5f8c\u53ef\u671b\u9032\u4e00\u6b65\u518d\u5206\u6790\u3002", "e": "Purpose : The application of post-mastectomy radiotherapy (PMRT) in N1 breast cancer patients is still no consensus according to the St. Gallen meeting in 2015. The aim of this study is to investigate the impact of PMRT on survivals in N1 breast cancer patients. Materials and Methods : Data were obtained from the cancer registry database and national health insurance claim data in Taiwan. We selected early breast cancer (T1-T2) and N1 lymph node metastasis patient treated with and without PMRT. Total 6,257 patients diagnosed between 2004 and 2009 were identified. We compared overall survival and disease-free survival between patients with and without PMRT. Propensity score matching and sensitivity analysis were performed. Result : We identified 2,866 (46%) patients with PMRT and 3,391 (54%) patients without PMRT. After the propensity score matching, 2,267 patients for each group were included in the analysis. The PMRT group showed significantly better overall survival and disease-free survival. Sensitivity analysis showed that pathology T2 stage and numbers of lymph node involved were statistically associated with poorer outcomes. Conclusion : Our study suggests that N1 breast cancer patients with PMRT have better overall survival and disease-free survival than those patients without PMRT after risk factors adjusted by the propensity score matching in the nationwide population-based study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-259-268", "title": "\u904b\u7528\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0\u7e2e\u77ed\u59d1\u606f\u6027\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u4e4b\u7b49\u5019\u6642\u9593", "keywords": "\u59d1\u606f\u6027\u653e\u5c04\u6cbb\u7642;\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0;\u6a19\u6e96\u5316\u6d41\u7a0b;\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\u7cfb\u7d71;\u7b49\u5019\u6642\u9593 Palliative radiotherapy;Plan-Do-Check-Action (PDCA) management cycle;Standard operation procedure;Oncology information system;Waiting time", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u65bc\u764c\u75c7\u6cbb\u7642\u4e2d\u626e\u6f14\u8457\u76f8\u7576\u91cd\u8981\u7684\u89d2\u8272\uff0c\u5927\u7d0440% \u4e4b\u60a3\u8005\u662f\u63a5\u53d7\u59d1\u606f\u653e\u5c04\u6cbb\u7642\uff0c\u5e38\u6703\u6709\u6642\u9593\u7684\u7dca\u8feb\u6027\u3002\u5982\u4f55\u7e2e\u77ed\u653e\u5c04\u6cbb\u7642\u4f5c\u696d\u6642\u9593\uff0c\u662f\u63a8\u52d5\u91ab\u7642\u670d\u52d9\u54c1\u8cea\u6975\u70ba\u91cd\u8996\u7684\u4e00\u74b0\u3002\u672c\u7814\u7a76\u5e0c\u671b\u900f\u904e\u904b\u7528\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0\u5efa\u7acb\u6a19\u6e96\u5316\u6d41\u7a0b\u4e26\u6574\u5408\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\u7cfb\u7d71\uff0c\u7e2e\u77ed\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u7684\u7b49\u5f85\u6cbb\u7642\u6642\u9593\uff0c\u6539\u5584\u91ab\u7642\u670d\u52d9\u54c1\u8cea\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65bc2012 \u5e746 \u67084 \u65e5\u81f32012 \u5e746 \u670829 \u65e5\uff0c\u5171\u670926 \u4eba\u6b21\u63a5\u53d7\u7dca\u6025\u653e\u5c04\u6cbb\u7642\uff0c\u4f9d\u5236\u5b9a\u300c\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u524d\u7f6e\u4f5c\u696d\u6642\u9593\u767b\u8a18\u8868\u300d\uff0c\u91dd\u5c0d\u6bcf\u4e00\u4f4d\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u75c5\u4eba\u4e4b\u524d\u7f6e\u4f5c\u696d\u6642\u9593\u8a18\u9304\uff0c\u4f5c\u70ba\u6539\u5584\u524d\u6578\u64da\u6536\u96c6\u3002\u4e26\u65bc2012 \u5e748 \u67081 \u65e5\u81f39 \u670830 \u65e5\u671f\u9593\uff0c\u5229\u7528\u54c1\u7ba1\u5708\u4e4b\u624b\u6cd5\uff0c\u9032\u884c\u5c0d\u7b56\u5be6\u65bd\u6539\u5584\u540c\u6642\uff0c\u6536\u96c6\u6b64\u671f\u9593\u517153 \u4eba\u6b21\u63a5\u53d7\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u7f6e\u4f5c\u696d\u6642\u9593\u8a18\u9304\uff0c\u4f5c\u70ba\u6539\u5584\u5f8c\u6578\u64da\u6536\u96c6\u3002\u7d50\u679c\uff1a\u5728\u4ecb\u5165\u63aa\u65bd\u524d\uff0c\u7d50\u675f\u6a21\u578b\u66a8\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\u4f5c\u696d\u5230\u653e\u5c04\u6cbb\u7642\u958b\u59cb\u4e4b\u9593\u7684\u5e73\u5747\u7d04\u7b49\u5019\u6642\u9593\u70ba48.00 \u5206\u9418\u3002\u800c\u5728\u9032\u884c\u5c0d\u7b56\u5be6\u65bd\u6539\u5584\u671f\u9593\uff0c\u800c\u5176\u5e73\u5747\u7d04\u7b49\u5019\u6642\u9593\u964d\u70ba 28.47 \u5206\u9418\uff08p \uff1c 0.001\uff09\u3002\u7d50\u8ad6\uff1a\u904b\u7528\u54c1\u8cea\u7ba1\u7406\u5faa\u74b0\u53ef\u6709\u6548\u7e2e\u77ed\u75c5\u4eba\u63a5\u53d7\u7dca\u6025\u653e\u5c04\u6cbb\u7642\u7684\u7b49\u5019\u6642\u9593\uff0c\u4f7f\u75c5\u4eba\u6e1b\u5c11\u4e0d\u9069\u611f\u53ca\u4e0d\u4fe1\u4efb\u611f\u3002\u4e26\u7dad\u6301\u6cbb\u7642\u6392\u7a0b\u7684\u6d41\u66a2\u6027\uff0c\u66f4\u6709\u6548\u7387\u7684\u7ba1\u63a7\u5404\u9805\u6392\u7a0b\u6642\u9593\uff0c\u907f\u514d\u56e0\u6642\u9593\u5ef6\u9072\u9020\u6210\u75c5\u4eba\u53ca\u5bb6\u5c6c\u62b1\u6028\u3002", "e": "Purpose : Radiotherapy plays an important role for cancer treatment. About 40% patients undergo palliative radiotherapy, which is usually emergent. How to shorten the proceeding time for radiotherapy is an important part to promote quality of medical service. We built a standard operation procedure to integrate the oncology information system for the emergent radiotherapy using Plan-Do-Check-Action (PDCA) management cycle. These procedures can shorten the waiting time of emergent radiotherapy and improve the quality of medical service. Materials and Methods : Twenty six patients underwent emergent radiotherapy from June 4, 2012 to June 29, 2012. According to the time-registry table before emergent radiotherapy, we checked the initial proceeding time of each patient for collecting pre-intervention data. Within duration of PDCA management cycle for improvement, fifty three patients were enrolled from August 1, 2012 to September 30, 2012. Proceeding time of each patient was also recorded after intervention. Result : The average waiting time between completion of CT simulation and starting of radiotherapy was 48.00 minute before the intervention. The time was reduced to 28.47 minute (p\uff1c 0.001) during intervention for improvement. Conclusion : Using PDCA management cycle can shorten the waiting time of emergent radiotherapy. It may let patients less unconformtable, keep schedule smoothing and effective before treatment, and avoid complain of patients and families due to waiting."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-269-275", "title": "\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u61c9\u7528\u65bc\u51dd\u81a0\u5291\u91cf\u8a08\u4e4b\u6383\u63cf\u53c3\u6578\u8a2d\u5b9a\u63a2\u8a0e", "keywords": "\u7570\u4e19\u57fa\u4e19\u70ef\u91af\u80fa\u51dd\u81a0\u5291\u91cf\u8a08;\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100;\u5f71\u50cf\u96dc\u8a0a N-isopropyl-acrylamide gel dosimeter (NIPAM gel dosimeter);Computer tomography scanner;Image noise", "c": "\u76ee\u7684\uff1a\u8fd1\u5e74\u4f86\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u88ab\u5ee3\u6cdb\u7684\u61c9\u7528\u5728\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u5f71\u50cf\u8cc7\u8a0a\u8a08\u8b80\u3002\u7136\u800c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u53c3\u6578\u7684\u8a2d\u5b9a\u6703\u5f71\u97ff\u5230\u5f71\u50cf\u4e2d\u96dc\u8a0a\uff0c\u9032\u800c\u5f71\u97ff\u5230\u5291\u91cf\u89e3\u6790\u5ea6\uff0c\u56e0\u6b64\u672c\u7814\u7a76\u76ee\u7684\u662f\u8a55\u4f30\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u4f5c\u70ba NIPAM \u51dd\u81a0\u5291\u91cf\u8a08\u8a08\u8b80\u5de5\u5177\u6642\u5176\u6700\u9069\u5316\u7684\u6383\u63cf\u53c3\u6578\uff0c\u4ee5\u964d\u4f4e\u51dd\u81a0\u5f71\u50cf\u96dc\u8a0a\uff0c\u63d0\u9ad8\u8a0a\u96dc\u6bd4\uff0c\u589e\u52a0\u51dd\u81a0\u5291\u91cf\u8a08\u81e8\u5e8a\u4e0a\u4e4b\u5be6\u7528\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u5f71\u50cf\u64f7\u53d6\u662f\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\uff0c\u4e26\u5229\u7528\u4e0d\u540c\u7684\u6383\u63cf\u53c3\u6578\u4f86\u5c0d\u51dd\u81a0\u4f5c\u5f71\u50cf\u64f7\u53d6\uff0c\u800c\u6383\u63cf\u53c3\u6578\u662f\u5f7c\u6b64\u7368\u7acb\u7684\u8b8a\u5316\uff0c\u4ee5\u53bb\u8a55\u4f30\u6bcf\u500b\u7368\u7acb\u53c3\u6578\u5c0d\u65bc\u5f71\u50cf\u96dc\u8a0a\u7684\u5f71\u97ff\u3002\u7d50\u679c\uff1a\u7576\u7ba1\u96fb\u6d41\u589e\u52a0\u6642\uff0c\u5f71\u50cf\u96dc\u8a0a\u4e5f\u96a8\u4e4b\u4e0b\u964d\uff0c\u7576\u7ba1\u96fb\u58d3\u5728 80 kVp \u3001120 kVp \u3001140 kVp \u60c5\u5f62\u4e0b\uff0c\u800c\u7ba1\u96fb\u6d41\u7531 100 mA \u63d0\u5347\u81f3 230 mA \u6642\uff0c\u5176\u5f71\u50cf\u96dc\u8a0a\u5206\u5225\u53ef\u964d\u4f4e 59.3% \u300164.1% \u53ca 60.7%\u3002\u540c\u6a23\u4e4b\u60c5\u5f62\uff0c\u8f03\u9ad8\u7684\u7ba1\u96fb\u58d3\u53ef\u7372\u5f97\u8f03\u5c0f\u7684\u5f71\u50cf\u96dc\u8a0a\u3002\u800c\u5207\u9762\u539a\u5ea6 5 mm \u4e0b\uff0c\u7ba1\u96fb\u58d3\u5f9e 80 kVp \u63d0\u9ad8\u5230 140kVp \u6642\uff0c\u96dc\u8a0a\u53ef\u964d\u4f4e 52.4%\uff1b\u800c\u5207\u9762\u539a\u5ea6\u70ba 10 mm \u6642\uff0c\u5247\u53ef\u964d\u4f4e 55.0%\u3002\u7d50\u8ad6\uff1a\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u4f5c\u70ba\u51dd\u81a0\u5291\u91cf\u8a08\u4e4b\u8cc7\u8a0a\u8a08\u8b80\u6642\uff0c\u6383\u63cf\u53c3\u6578\u7684\u8a2d\u5b9a\u9700\u5728\u7ba1\u7403\u71b1\u8ca0\u8377\u53ca\u5f71\u50cf\u96dc\u8a0a\u4e4b\u964d\u4f4e\u9593\u4f5c\u4e00\u5e73\u8861\u53ca\u6700\u9069\u5316\u4e4b\u8003\u91cf\u3002\u672c\u7814\u7a76\u6240\u5efa\u8b70\u6700\u9069\u5316\u4e4b\u8a2d\u5b9a\u70ba\u7ba1\u96fb\u58d3 120 kVp \u3001\u7ba1\u96fb\u6d41 200 mA\uff0c\u800c\u5207\u9762\u539a\u5ea6\u7684\u9078\u64c7\u5247\u4f9d\u4e0d\u540c\u72c0\u6cc1\u4f86\u9078\u5b9a\u3002\u6700\u9069\u5316\u6383\u63cf\u53c3\u6578\u7684\u8a2d\u5b9a\u53ef\u4ee5\u964d\u4f4e\u5f71\u50cf\u96dc\u8a0a\u5c0d\u65bc\u51dd\u81a0\u5291\u91cf\u89e3\u6790\u5ea6\u4e0a\u7684\u5e72\u64fe\uff0c\u4ee5\u589e\u52a0\u51dd\u81a0\u5291\u91cf\u8a08\u81e8\u5e8a\u5291\u91cf\u8a55\u4f30\u4e0a\u7684\u6b63\u78ba\u6027\u3002", "e": "Purpose : In recent years, computed tomography scanners are widely used in the gel dosimeter for reading of the image information. However, the scanning parameter settings of computed tomography scanners will affect the image noise, thereby affecting the dose resolution. Therefore the aim of this study is to evaluate the optimal scanning parameters of the CT scanner as the reading tool applied in NIPAM gel dosimeter to reduce the gel image noise, improve signal to noise ratio and increase availability of gel dosimeter in the clinical. Materials and Methods : Computer tomography scanner was applied to capture image in the gel dosimeter. Different scanning parameters were used to capture gel images. Scanning parameters changed independently from each other in order to evaluate the image noise affected by each individual parameter. Result : When the tube current was increased, the image noise would reduce. If the tube voltage was 80 kVp, 120 kVp, 140 kVp, and tube current increased from 100 mA to 230 mA, it can reduce the image noise to 59.3%, 64.1% and 60.7 %, respectively. In the same case, smaller image noise was obtained in the higher tube voltage. If the tube voltage was increased from 80 kVp to 140 kVp with 5 mm slice thickness, the noise can be reduced 52.4%. When the slice thickness was changed to 10 mm, the noise can be reduced 55.0%. Conclusion and Discussion : While the computer tomography scanner was used in the gel dosimeter for reading of the image information, the scanning parameters settings were needed to compromise for balancing and optimizing between tube head loading and the decreasing of the image noise. The tube voltage of 120 kVp and tube current of 200 mA are recommended for the optimizing settings by this study but the slice thickness is selected according to different conditions. Optimizing scanning parameter settings can reduce image noise affecting the interference resolution of the gel dosimeter in order to increase the accuracy of gel dosimeter in the clinical dose assessment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-277-284", "title": "SALVAGE CONCURRENT CHEMORADIATION THERAPY STABILIZES PROGRESSION OF RECURRENT INTIMAL SARCOMA OF THE LEFT ATRIUM: A CASE REPORT", "keywords": "Concurrent chemoradiation therapy (CCRT);Intimal sarcoma recurrence \u540c\u6b65\u653e\u5316\u7642;\u5fa9\u767c\u6027\u5167\u819c\u8089\u7624", "c": "\u5167\u819c\u8089\u7624\u662f\u7f55\u898b\u7684\u539f\u767c\u6027\u5fc3\u81df\u816b\u7624\u3002\u91dd\u5c0d\u65b0\u8a3a\u65b7\u7684\u5167\u819c\u8089\u7624\uff0c\u76ee\u524d\u7684\u6a19\u6e96\u6cbb\u7642\u70ba\u624b\u8853\u5207\u9664\uff0c\u800c\u91dd\u5c0d\u5c40\u90e8\u5fa9\u767c\u7684\u5167\u819c\u8089\u7624\uff0c\u5176\u6700\u4f73\u6cbb\u7642\u7b56\u7565\u5c1a\u672a\u6709\u5b9a\u8ad6\u3002\u672c\u6587\u5831\u544a\u4e00\u4f8b\u5de6\u5fc3\u623f\u5167\u819c\u8089\u7624\u5c40\u90e8\u5fa9\u767c\u75c5\u4f8b\uff0c\u60a3\u8005\u5728\u5fa9\u767c\u5f8c\u4f75\u7528\u5316\u5b78\u6cbb\u7642\u8207\u540c\u6b65\u653e\u5316\u7642\u800c\u5f97\u5230\u75be\u75c5\u63a7\u5236\uff0c\u7531\u521d\u8a3a\u65b7\u8fc4\u4eca\u5b58\u6d3b\u5df2\u905448 \u500b\u6708\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5728\u81fa\u7063\u5df2\u76f8\u7576\u666e\u53ca\uff0c\u91dd\u5c0d\u7121\u6cd5\u624b\u8853\u5207\u9664\u7684\u5fc3\u81df\u816b\u7624\uff0c\u6216\u53ef\u8003\u616e\u4ee5\u6b64\u6280\u8853\u914d\u5408\u5316\u7642\u7a4d\u6975\u9032\u884c\u5c40\u90e8\u6cbb\u7642\u3002", "e": "Intimal sarcoma is a rare primary malignancy of the heart. While surgery is the mainstay of curative treatment for newly diagnosed disease, the role of radiation for local recurrence remains elusive. Here we report a case with locally recurrent intimal sarcoma of the heart in the left atrium. Recurrence has been successfully stabilized with sandwich treatment. The patient survived for more than 48 months since the initial diagnosis and is still alive at the time of manuscript preparation. As intensity modulated radiation therapy is becoming widely accessible in Taiwan, there is an unmet need to document outcome and side effect profiles from aggressive CCRT to primary and recurrent cardiac malignancy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-285-290", "title": "TREATMENT OUTCOMES OF RADIOTHERAPY FOR PRIMARY INTRACRANIAL OSTEOSARCOMA", "keywords": "Intracranial osteosarcoma;Radiotherapy;Metachronous recurrence \u9871\u5167\u9aa8\u8089\u7624;\u653e\u5c04\u6cbb\u7642;\u7570\u6642\u6027\u5fa9\u767c", "c": "\u539f\u767c\u6027\u9871\u5167\u9aa8\u8089\u7624\uff08Primary intracranial osteodarcoma, PIOS\uff09\u662f\u4e00\u500b\u81e8\u5e8a\u4e0a\u975e\u5e38\u7f55\u898b\u7684\u75be\u75c5\uff0c\u50c5\u5c11\u6578\u75c5\u4f8b\u66fe\u7d93\u5728\u6587\u737b\u4e2d\u88ab\u5831\u544a\u3002\u7531\u65bc\u5176\u7f55\u898b\u6027\uff0c\u5c0d\u65bc\u5176\u6839\u6cbb\u6027\u6cbb\u7642\u65b9\u5f0f\u3001\u8f14\u52a9\u6cbb\u7642\u4e4b\u89d2\u8272\u3001\u4ee5\u53ca\u6cbb\u7642\u5f8c\u8ffd\u8e64\u7684\u65b9\u5f0f\u4e26\u6c92\u6709\u4e00\u5b9a\u7684\u6a19\u6e96\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f4d 59 \u6b72\u5973\u6027\u4e4b PIOS \u75c5\u60a3\uff0c\u5176\u521d\u59cb\u6cbb\u7642\u5305\u62ec\u4e86\u6839\u9664\u6027\u624b\u8853\uff0c\u4ee5\u53ca\u8853\u5f8c 60 Gy \u4e4b\u539f\u767c\u90e8\u4f4d\u7684\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u3002\u6cbb\u7642\u5f8c\u5176\u5c40\u90e8\u63a7\u5236\u6548\u679c\u826f\u597d\u4e26\u7121\u5c40\u90e8\u5fa9\u767c\u73fe\u8c61\uff0c\u4f46\u5728\u624b\u8853 4 \u500b\u6708\u5f8c\u537b\u5728\u9871\u5167\u767c\u751f\u7570\u6642\u6027\u975e\u5c40\u90e8\u5fa9\u767c\u3002\u5fa9\u767c\u5f8c\u6211\u5011\u518d\u6b21\u5b89\u6392\u6839\u9664\u6027\u624b\u8853\u4e26\u8f14\u4ee5\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u3002\u7531\u6211\u5011\u7684\u7d93\u9a57\u770b\u4f86\uff0c\u6839\u9664\u6027\u624b\u8853\u4e26\u8f14\u4ee5\u5c40\u90e8\u88dc\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u662f\u4e00\u500b\u5c0d\u65bc PIOS \u6709\u6548\u7684\u5c40\u90e8\u63a7\u5236\u6cbb\u7642\u6a21\u5f0f\uff0c\u4f46\u5c0d\u65bc\u6b64\u75be\u75c5\u4e4b\u75c5\u60a3\uff0c\u9808\u6ce8\u610f\u5176\u975e\u5c40\u90e8\u7570\u6642\u6027\u9871\u5167\u5fa9\u767c\u4e4b\u53ef\u80fd\u3002", "e": "Primary intracranial osteosarcoma (PIOS) is a rare intracranial malignancy, only a few case reports have been published in the literature. The curative treatment, the role of adjuvant treatment, and follow-up protocol is not well standardized due to its rarity. We present a 59-year-old woman with PIOS treated with radical surgery followed by adjuvant radiotherapy (RT) to the tumor bed for 60 Gy. Good local control was achieved but she experienced metachronous recurrence 4 months after the initial surgery. A second course of treatment was carried out for her recurrence tumor as radical surgical removal and second course adjuvant RT. The treatment including radical surgery and adjuvant RT seems to be effective for local control but cautions should be taken for possible aggressive metachronous recurrence."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201612-201701240025-201701240025-291-296", "title": "POSTOPERATIVE RADIOTHERAPY FOR CARCINOSARCOMA ARISING FROM PAROTID MIXED TUMOR : A CASE REPORT AND REVIEW OF THE LITERATURE", "keywords": "Carcinosarcoma;Malignant mixed tumor;Parotid gland \u764c\u8089\u7624;\u60e1\u6027\u6df7\u5408\u816b\u7624;\u8033\u4e0b\u817a", "c": "\u8033\u4e0b\u817a\u764c\u8089\u7624\u662f\u76f8\u7576\u7f55\u898b\u7684\u553e\u6db2\u817a\u60e1\u6027\u816b\u7624\uff0c\u5927\u591a\u6578\u75c5\u4f8b\u5747\u6e90\u81ea\u65bc\u5148\u524d\u5b58\u5728\u7684\u826f\u6027\u553e\u6db2\u817a\u6df7\u5408\u7624\u3002\u764c\u8089\u7624\u56e0\u70ba\u5177\u6709\u5f88\u9ad8\u7684\u5c40\u90e8\u5fa9\u767c\u8207\u9060\u7aef\u8f49\u79fb\u6a5f\u7387\uff0c\u56e0\u6b64\u88ab\u8996\u70ba\u9ad8\u60e1\u6027\u5ea6\u4e4b\u60e1\u6027\u816b\u7624\u3002\u6b64\u75c5\u4f8b\u5831\u544a\u70ba56 \u6b72\u5973\u6027\u56e0\u5148\u524d\u8033\u4e0b\u817a\u591a\u578b\u6027\u817a\u7624\u8f49\u5316\u70ba\u8033\u4e0b\u817a\u764c\u8089\u7624\u3002\u60a3\u8005\u9996\u5148\u5448\u73fe\u5de6\u5074\u8033\u4e0b\u817a\u5feb\u901f\u9577\u5927\u4e4b\u58d3\u75db\u6027\u816b\u584a\uff0c\u4f46\u7121\u984f\u9762\u795e\u7d93\u9ebb\u75fa\u4e4b\u75c7\u72c0\u8207\u5fb5\u5019\u3002\u65bc\u5916\u9662\u982d\u9838\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5de6\u5074\u8033\u4e0b\u817a\u816b\u584a\u4f46\u7121\u9838\u90e8\u6dcb\u5df4\u816b\u5927\u3002\u6b64\u75c5\u60a3\u65bc\u672c\u9662\u63a5\u53d7\u5de6\u5074\u8033\u4e0b\u817a\u5207\u9664\u8853\u4e26\u4fdd\u7559\u984f\u9762\u795e\u7d93\u529f\u80fd\u3002\u75c5\u7406\u5831\u544a\u8b49\u5be6\u70ba\u6e90\u81ea\u8033\u4e0b\u817a\u591a\u578b\u6027\u817a\u7624\u4e4b\u764c\u8089\u7624\u3002\u75c5\u60a3\u5f8c\u7e8c\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0866 \u6208\u96f7\uff09\u53ca\u5b9a\u671f\u9580\u8a3a\u8ffd\u8e64\u6aa2\u67e5\u3002\u7d93\u904e65 \u500b\u6708\u9580\u8a3a\u8ffd\u8e64\u6b64\u75c5\u60a3\u4ecd\u5448\u73fe\u7121\u75c5\u5b58\u6d3b\u3002", "e": "Carcinosarcoma, a true malignant mixed tumor, is rarely seen in the parotid glands. The majority of cases arise from existing benign mixed tumors. Carcinosarcoma is considered an aggressive malignancy with a high probability of local recurrence and distant metastases. We report a case of carcinosarcoma arising from a parotid mixed tumor (pleomorphic adenoma) in a 56-year-old female. Initially, the disease presented as a progressively enlarged mass with local tenderness in the left parotid gland. Clinically, there were no symptoms or signs of facial nerve palsy. Contrast-enhanced computed tomography (CT) performed at a different hospital revealed a tumor (4.1 \u00d7 3 \u00d7 2.5 cm) in the left parotid gland without any enlarged cervical lymphadenopathies. Subsequently, the patient underwent a left total parotidectomy with full preservation of the left facial nerve. The pathology report revealed carcinosarcoma arising from the mixed tumor. After surgery, the patient received adjuvant radiotherapy (66 Gy/33 fractions). She was regularly followed up at our outpatient clinic with routine physical examinations and imaging studies. The patient remained alive with no evidence of disease during the 65-month follow up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-145-152", "title": "EVALUATION OF SETUP ERRORS IN PROSTATE CANCER WITH CONE BEAM COMPUTERIZED TOMOGRAPHY", "keywords": "\u653e\u5c04\u6cbb\u7642;\u524d\u5217\u817a\u764c;\u5f71\u50cf\u5c0e\u5f15;\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64;\u64fa\u4f4d\u8aa4\u5dee Radiotherapy;Prostate cancer;Image-guided radiotherapy (IGRT);Cone beam computerized tomography (CBCT);Setup error", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u70ba\u524d\u5217\u817a\u764c\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u60a3\u4ee5\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\uff08CBCT\uff09\u4f86\u91cf\u6e2c\u64fa\u4f4d\u7684\u7cfb\u7d71\u53ca\u96a8\u6a5f\u8aa4\u5dee\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5305\u542b\u6709\u6839\u6cbb\u6027\u53ca\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6b21\u8981\u76ee\u7684\u70ba\u8a55\u4f30\u662f\u5426\u6709\u81e8\u5e8a\u76f8\u95dc\u56e0\u5b50\u6703\u5f71\u97ff\u64fa\u4f4d\u8aa4\u5dee\u7684\u5927\u5c0f\uff0c\u4e26\u8a08\u7b97\u82e5\u6c92\u6709\u4f7f\u7528CBCT\u5f71\u50cf\u5c0e\u5f15\u6642\u7684\u6700\u9069\u5b9c\u8a08\u756b\u9776\u9ad4\u7a4d\u7684\u7bc4\u570d\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5305\u542b\u6839\u6cbb\u6027\u53ca\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u81ea\u897f\u51432011\u81f32015\u5e74\u672c\u7814\u7a76\u5171\u7d0d\u516559\u4f4d\u524d\u5217\u817a\u764c\u75c7\u60a3\u8005\uff1b\u6bcf\u4f4d\u60a3\u8005\u81f3\u5c11\u63a5\u53d7\u4e94\u6b21\u4ee5\u4e0a\u7684CBCT\u5f71\u50cf\u5c0e\u5f15\u6821\u6b63\u3002\u75c5\u60a3\u5728\u57f7\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u524d\u5148\u63a5\u53d7CBCT\u6383\u7784\uff0c\u4e26\u7531\u81e8\u5e8a\u91ab\u5e2b\u5224\u8b80\u64fa\u4f4d\u8aa4\u5dee\u4e4b\u4f4d\u79fb\u6578\u64da\u3002\u6211\u5011\u5c07\u8aa4\u5dee\u4f4d\u79fb\u8ef8\u5411\u5b9a\u7fa9\u70ba\uff1aX\u8ef8\uff08\u5de6\u53f3\u5074\uff09\u3001Y\u8ef8\uff08\u982d\u8173\u5074\uff09\u53caZ\u8ef8\uff08\u80f8\u80cc\u5074\uff09\u3002\u6839\u64da\u5404\u8ef8\u5411\u6578\u64da\u4f86\u8a08\u7b97\u64fa\u4f4d\u4e4b\u5e73\u5747\u8aa4\u5dee\u3001\u7cfb\u7d71\u6027\u8aa4\u5dee\uff08\u03a3\uff09\u53ca\u96a8\u6a5f\u8aa4\u5dee\uff08\u03c3\uff09\uff0c\u4e26\u4ee5\u8b8a\u7570\u6578\u5206\u6790\uff08ANOVA\uff09\u53caT\u6aa2\u5b9a\u8a55\u4f30\u5404\u81e8\u5e8a\u76f8\u95dc\u56e0\u5b50\u8207\u64fa\u4f4d\u8aa4\u5dee\u4e4b\u9593\u7684\u95dc\u806f\u6027\u3002\u7121\u5f71\u50cf\u5c0e\u5f15\u4e4b\u6700\u4f73\u8a08\u756b\u9776\u9ad4\u7a4d\u7684\u589e\u52a0\u8ddd\u96e2\u5247\u85c9\u7531Van Herk\u516c\u5f0f\u8a08\u7b97\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5171\u5206\u67901595\u7d44\u5f71\u50cf\u5c0e\u5f15\u4e4b\u5f71\u50cf\u3002\u4e09\u8ef8\u7684\u64fa\u4f4d\u5e73\u5747\u8aa4\u5dee\u3001\u7cfb\u7d71\u6027\u8aa4\u5dee\uff08\u03a3\uff09\u53ca\u96a8\u6a5f\u8aa4\u5dee\uff08\u03c3\uff09\u5206\u5225\u70ba\uff1aX\u8ef80.37 mm\u30011.92 mm\u30012.50 mm\uff1bY\u8ef80.29 mm\u30011.33 mm\u30012.00 mm\uff1b\u53caZ\u8ef80.58 mm\u30011.59 mm\u30012.45 mm\u3002\u81e8\u5e8a\u76f8\u95dc\u56e0\u5b50\u7684\u5404\u4e2d\u503c\u6578\u70ba\u5e74\u9f6174\u6b72\u3001\u8eab\u9ad8165\u516c\u5206\u3001\u9ad4\u91cd69.1\u516c\u65a4\u3001\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08BMI\uff0925.5 kg/m^2\u3001\u524d\u5217\u817a\u9ad4\u7a4d45.9 ml\u3002\u5176\u4ed6\u56e0\u5b50\u6709\u81e8\u5e8a\u6216\u75c5\u7406\u5206\u671f\u3001\u6cbb\u7642\u76ee\u7684\u53ca\u76f4\u8178\u64f4\u5f35\u7b49\u3002\u7d93\u5206\u6790\u767c\u73fe\u76f4\u8178\u64f4\u5f35\u8207\u5426\u6703\u986f\u8457\u5f71\u97ffZ\u8ef8\u65b9\u5411\u4e4b\u96a8\u6a5f\u8aa4\u5dee\uff08p=0.013\uff09\u3002X\u3001Y\u3001Z\u4e09\u8ef8\u4e4b\u6700\u4f73\u8a08\u756b\u9776\u9ad4\u7a4d\u7bc4\u570d\u5247\u5206\u5225\u70ba6.6 mm\u30014.7 mm\u53ca5.7 mm\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u4e4b\u4e09\u8ef8\u5411\u7684\u7cfb\u7d71\u53ca\u96a8\u6a5f\u8aa4\u5dee\u8207\u5148\u524d\u6587\u737b\u6bd4\u8f03\uff0c\u6709\u985e\u4f3c\u4e4b\u7d50\u679c\uff0c\u4e14\u96fb\u8166\u65b7\u5c64\u5b9a\u4f4d\u6642\u76f4\u8178\u7684\u64f4\u5f35\u8207\u5426\u6703\u5f71\u97ff\u80f8\u80cc\u5074\u7684\u64fa\u4f4d\u8aa4\u5dee\u3002\u5728\u672a\u57f7\u884cCBCT\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u60c5\u6cc1\u4e0b\uff0c\u6700\u4f73\u7684\u8a08\u756b\u9776\u9ad4\u7a4d\u7bc4\u570d\u81f3\u5c11\u70ba4.7\u81f36.6 mm\u3002", "e": "Purpose: The primary goal of this study is to measure the systemic and random errors in prostatic cancer patients receiving definitive and adjuvant radiotherapy with cone beam computerized tomography (CBCT). The secondary aim is to evaluate the clinical factors that may affect these setup errors, and to determine the optimal planning target volume (PTV) margins for patients without using CBCT. Materials & Methods: From 2011 to 2015, we retrospectively reviewed 59 patients who underwent at least five sessions of definitive or adjuvant radiotherapy with CBCT. All the images were obtained prior to treatment. All the setup corrections were determined by physicians. The definitions of axis was X in left-right, Y in superior-inferior and Z in anterior-posterior. The overall mean error, systemic error (\u03a3) and random error (\u03c3) were calculated for each axis. We used ANOVA and Student t-test models to evaluate the significance among various clinical factors and the setup errors. The optimal PTV margins without image-guided radiotherapy (IGRT) were calculated based on Van Herk Formula. Results: In total, 1595 sets of images were obtained from this study. The mean error (mm), \u03a3 (mm) and \u03c3 (mm) were 0.37, 1.92, 2.50 in X; 0.29, 1.33, 2.00 in Y; and 0.58, 1.59, 2.45 in Z axis, respectively. The median value of various clinical factors were 74 years of age, 165 cm in height, 69.1 kg in weight, BMI of 25.5 kg/m^2 and 45.9 ml of prostate volume. Other clinical factors such as clinical / pathological stage, definitive or adjuvant treatment and distension of rectum were also analyzed. The rectal distension affected the random error in direction Z significantly (p= 0.013). The optimal PTV margins without CBCT were 6.6, 4.7 and 5.7 mm in directions X, Y and Z, respectively. Conclusion: The dimensions of systemic and random errors in various axes were similar to previous studies. Rectal distension can influence anterior-posterior setup errors. The optimal PTV margins should be at least 4.7 ~ 6.6 mm to overcome the daily setup uncertainties without CBCT corrections."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-153-162", "title": "REPEAT IRRADIATION OF RECURRENT HEPATOCELLULAR CARCINOMA - A SINGLE INSTITUTE EXPERIENCE", "keywords": "\u809d\u764c;Sunitinib;\u653e\u5c04\u6cbb\u7642 Hepatocellular carcinoma;Sunitinib;Radiotherapy", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u70ba\u76ee\u524d\u6cbb\u7642\u5c40\u90e8\u6027\u809d\u764c\u4e4b\u91cd\u8981\u65b9\u5f0f\uff0c\u4f46\u662f\u5c0d\u65bc\u518d\u6b21\u653e\u5c04\u6cbb\u7642\u4ecd\u5c11\u6709\u8457\u58a8\u3002\u7531\u65bc\u809d\u764c\u70ba\u591a\u767c\u6027\u75be\u75c5\uff0c\u7576\u5176\u4ed6\u7684\u6cbb\u7642\u65b9\u5f0f\u90fd\u7528\u76e1\u6642\uff0c\u6211\u5011\u4ecd\u9808\u8003\u616e\u518d\u6b21\u653e\u7642\u7684\u53ef\u80fd\u6027\u3002\u672c\u6587\u4e43\u5c0d\u65bc\u672c\u9662\u63a5\u53d7\u4e8c\u6b21\u653e\u7642\u8005\u7684\u809d\u764c\u6240\u4f5c\u7684\u56de\u6eaf\u6027\u5206\u6790\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e2003\u81f32013\u4e4b\u9593\uff0c\u5171\u670919\u4f4d\u809d\u764c\u5fa9\u767c\u60a3\u8005\uff08\u7537\uff0f\u5973=17\uff0f2\uff1b\u5e74\u9f61\u4e2d\u4f4d\u6578\uff1a64.4\u6b72\uff09\u65bc\u672c\u9662\u63a5\u53d7\u7b2c\u4e8c\u6b21\u653e\u5c04\u6cbb\u7642\uff0c\u7576\u4e2d\u65bc\u524d\u6b21\u6cbb\u7642\u90e8\u4f4d\u5fa9\u767c\u8005\u70ba8\u4f4d\uff0c\u5728\u653e\u5c04\u90e8\u4f4d\u4e4b\u5916\u5fa9\u767c\u8005\u70ba11\u4f4d\u3002\u5176\u4e3b\u8981\u6536\u6848\u689d\u4ef6\u70ba\u6b63\u5e38\u809d\u9ad4\u7a4d\u8d85\u904e700\u6beb\u5347\u3002\u5728\u7b2c\u4e8c\u6b21\u6cbb\u7642\u7684\u90e8\u4f4d\u4e2d\uff0c\u5e73\u5747\u5291\u91cf\u70ba47.5Gy\uff0c\u800c\u90e8\u5206\u6cbb\u7642\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u4ee5\u53ca\u6301\u7e8c\u6027\u4e4b\u8840\u7ba1\u751f\u6210\u6291\u5236\u85e5\u7269\u3002\u672c\u7814\u7a76\u4ee5\u55ae\u8b8a\u9805\u5206\u6790\u7528\u65bc\u627e\u51fa\u53ef\u80fd\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u5728\u901919\u500b\u75c5\u4eba\u4e2d\uff0c\u67094\u4f4d\u9054\u5230\u816b\u7624\u5b8c\u5168\u53cd\u61c9\uff0c\u67096\u4f4d\u9054\u5230\u816b\u7624\u90e8\u5206\u53cd\u61c9\u3002\u6240\u6709\u75c5\u60a3\u7684\u4e2d\u4f4d\u6578\u7e3d\u5b58\u6d3b\u671f\u70ba10.3\u6708\uff0c\u4e00\u5e74\u53ca\u4e8c\u5e74\u7e3d\u5b58\u6d3b\u7387\u5206\u5225\u70ba47%\u4ee5\u53ca26%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u5169\u6b21\u653e\u5c04\u6cbb\u7642\u671f\u9593\u8f03\u9577\u8005\uff08\uff1e 6.2\u6708\uff09\u4ee5\u53ca\u5408\u4f75\u4f7f\u7528\u6297\u8840\u7ba1\u65b0\u751f\u85e5\u7269\u8005\u4e4b\u7e3d\u5b58\u6d3b\u671f\u6709\u986f\u8457\u5dee\u7570\u3002\u5728\u7814\u7a76\u7684\u7fa4\u7d44\u4e2d\uff0c\u50c511%\u60a3\u8005\u767c\u751f\u653e\u5c04\u6027\u809d\u708e\u3002\u7d50\u8ad6\uff1a\u5728\u4e0d\u8d85\u904e\u91cd\u8981\u5668\u5b98\u5291\u91cf\u9650\u5236\u7684\u60c5\u6cc1\u4e0b\uff0c\u4ee5\u7b2c\u4e8c\u6b21\u7684\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u5fa9\u767c\u6027\u7684\u809d\u764c\u662f\u53ef\u884c\u7684\u3002\u5169\u6b21\u653e\u5c04\u6cbb\u7642\u671f\u9593\u8d85\u904e6.2\u6708\u8005\u6709\u8f03\u9577\u7684\u5e73\u5747\u5b58\u6d3b\u671f\uff0c\u800c\u4f7f\u7528\u6297\u8840\u7ba1\u65b0\u751f\u85e5\u7269\u53ef\u986f\u8457\u7684\u5ef6\u9577\u5b58\u6d3b\u671f\u3002", "e": "Purpose: Radiotherapy is recognized as an effective local treatment for hepatocellular carcinoma, but limited evidence exists for its efficacy in repeat liver irradiation. When other treatment modalities have been exhausted, repeat irradiation may be the only option. A single institution experience of repeat irradiation of hepatocellular carcinoma is reported here. Materials and Methods: Between 2003 and 2013, 19 patients (M/F = 17/2; median age = 64.4 years) with recurrent hepatocellular carcinoma (8 in-field and 11 out-field) and having had previous radiotherapy, were treated with repeat irradiation. The primary eligibility criteria for selecting these patients for repeat liver irradiation was normal liver volume greater than 700 mL. The median equivalent dose in 2 Gy (EQD2) delivered to tumors was 47.5 Gy (range: 30-71 Gy). A proportion of patients had concurrent and maintenance angiogenic blockades. Univariate analyses were used to identify statistically significant prognostic factors. Results: Among the 19 patients, complete response was achieved in 4 patients, and partial response in 6. The median overall survival for the entire series was 10.3 months. Overall survival rates at 1 and 2 years were 47% and 26% respectively. The presence of either longer treatment intervals between radiotherapies (\uff1e 6.2 months) or use of angiogenic blockades was associated with longer overall survival on univariate analysis. The incidence of radiation induced liver injury was 11%. Conclusions: Repeat hepatic irradiation is possible where the necessary dosimetric parameters can be met. Patients with longer intervals between radiotherapies may achieve longer survival rates in comparison to those without. Survival benefit is attainable with concomitant and maintenance angiogenic blockades."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-163-174", "title": "\u4f7f\u7528\u9644\u81ea\u52d5\u63a1\u6a23\u5323\u4e4b\u9ad8\u5206\u5b50\u934d\u8986\u77f3\u82f1\u6676\u9ad4\u5fae\u5929\u5e73\u69cb\u7bc9\u514d\u75ab\u53cd\u61c9\u578b\u816b\u7624\u80da\u80ce\u6297\u539f\u751f\u7269\u611f\u6e2c\u5668", "keywords": "\u78c1\u632f\u5c0e\u822a\u805a\u7126\u8d85\u97f3\u6ce2\u71b1\u6cbb\u7642;\u65e5\u5e38\u54c1\u8cea\u78ba\u4fdd;\u4f4d\u7f6e\u7a69\u5b9a\u6027 Biosensor;Quartz crystal microbalance (QCM);Poly-parylene quartz crystal microbalance (pQCM)", "c": "\u76ee\u7684\uff1a\u60e1\u6027\u816b\u7624\u5c45103\u5e74\u5ea6\u570b\u4eba\u5341\u5927\u6b7b\u56e0\u4e4b\u9996\u4f4d\uff0c\u5176\u4e2d\uff0c\u7d50\u8178\u76f4\u8178\u764c\u3001\u80c3\u764c\u3001\u8207\u98df\u9053\u764c\u7b49\u6d88\u5316\u9053\u764c\u75c7\uff0c\u5206\u4f54\u7b2c\u4e09\u4f4d\u3001\u7b2c\u4e03\u4f4d\u8207\u7b2c\u4e5d\u4f4d\u3002\u816b\u7624\u80da\u80ce\u6297\u539f\uff08CEA\uff09\u662f\u4eba\u985e\u6d88\u5316\u9053\u764c\u75c7\u7684\u816b\u7624\u6a19\u8a18\uff0c\u88ab\u5ee3\u6cdb\u61c9\u7528\u65bc\u6d88\u5316\u9053\u764c\u75c7\u4e4b\u7be9\u6aa2\uff0c\u76ee\u524d\u591a\u63a1\u7528\u514d\u75ab\u5206\u6790\u6cd5\u9032\u884c\u6aa2\u6e2c\uff0c\u4f46\u662f\u6aa2\u6e2c\u904e\u7a0b\u9700\u8017\u66422-3\u5c0f\u6642\u3002\u56e0\u6b64\uff0c\u672c\u7814\u7a76\u64ec\u958b\u767c\u53ef\u5373\u6642\u6aa2\u6e2c\u816b\u7624\u80da\u80ce\u6297\u539f\u4e4b\u514d\u75ab\u53cd\u61c9\u578b\u751f\u7269\u611f\u6e2c\u5668\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u751f\u7269\u611f\u6e2c\u5206\u6790\u6280\u8853\u88ab\u8b7d\u70ba\u4e8c\u5341\u4e00\u4e16\u7d00\u5206\u6790\u53ca\u7be9\u6aa2\u79d1\u6280\u4e4b\u65b0\u5bf5\uff0c\u4fc2\u7531\u6297\u9ad4\u3001\u9175\u7d20\u7b49\u751f\u7269\u8b58\u5225\u6027\u6750\u6599\uff0c\u914d\u5408\u5fae\u8cea\u91cf\u5929\u5e73\u3001\u96fb\u5316\u5b78\u96fb\u6975\u7b49\u5404\u7a2e\u8a0a\u865f\u8f49\u63db\u5668\u7d44\u5408\u800c\u6210\u3002\u672c\u7814\u7a76\u5229\u7528\u816b\u7624\u80da\u80ce\u6297\u539f\u55ae\u682a\u6297\u9ad4\u5c0d\u816b\u7624\u80da\u80ce\u6297\u539f\u4e4b\u9ad8\u5ea6\u5c08\u4e00\u6027\u8207\u89aa\u548c\u6027\uff0c\u914d\u5408\u5177\u5099\u9ad8\u5b89\u5b9a\u6027\u3001\u9ad8\u654f\u611f\u5ea6\u3001\u5373\u6642\u8f38\u51fa\u3001\u91cd\u8907\u4f7f\u7528\u7b49\u591a\u9805\u512a\u9ede\u4e4b\u77f3\u82f1\u6676\u9ad4\u5fae\u8cea\u91cf\u5929\u5e73\uff08quartz crystal microbalance, QCM\uff09\u5143\u4ef6\u4f5c\u70ba\u8a0a\u865f\u8f49\u63db\u5668\uff0c\u540c\u6642\u914d\u5408\u81ea\u884c\u958b\u767c\u4e4b\u81ea\u52d5\u63a1\u6a23\u88dd\u7f6e\u4ee5\u53ca\u4ee5\u805a\u5c0d\u4e8c\u7532\u82ef\uff08poly-parylene\uff09\u5c0dQCM\u5143\u4ef6\u9032\u884c\u8868\u9762\u934d\u8986\u88fd\u6210pQCM\u4e4b\u6280\u8853\uff0c\u5171\u540c\u7d44\u5408\u69cb\u6210\u80fd\u5920\u5373\u6642\u6aa2\u6e2c\u816b\u7624\u80da\u80ce\u6297\u539f\u6fc3\u5ea6\u4ee5\u4fbf\u5373\u6642\u7be9\u6aa2\u6d88\u5316\u9053\u764c\u75c7\u4e4b\u514d\u75ab\u53cd\u61c9\u578b\u816b\u7624\u80da\u80ce\u6297\u539f\u751f\u7269\u611f\u6e2c\u5668\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5c07\u816b\u7624\u80da\u80ce\u6297\u539f\u55ae\u682a\u6297\u9ad4\u56fa\u5b9a\u5728pQCM\u5143\u4ef6\u8868\u9762\u69cb\u6210\u7684\u816b\u7624\u80da\u80ce\u6297\u539f\u611f\u6e2c\u5668\uff0c\u5c0d\u6eb6\u89e3\u5728PBS\u7de9\u885d\u6db2\u5206\u5225\u914d\u88fd\u62100.5\u30012.5\u300125\u4ee5\u53ca200 ng/ml\u6fc3\u5ea6\u4e4b\u816b\u7624\u80da\u80ce\u6297\u539f\u6a19\u6e96\u6a23\u54c1\u6eb6\u6db2\u9032\u884c\u6aa2\u6e2c\uff0c\u5c0d\u65bc\u4f4e\u6fc3\u5ea6\uff080.5 ng/ml\uff09\u53ca\u9ad8\u6fc3\u5ea6\uff08200 ng/ml\uff09\u6a23\u54c1\uff0c\u50c5\u5206\u5225\u9700\u66425\u5206\u9418\u53ca\u5c11\u65bc10\u5206\u9418\u5373\u53ef\u5b8c\u6210\u6aa2\u6e2c\u64cd\u4f5c\uff1b\u57288\u5929\u5167\u91cd\u8907\u9032\u884c16\u6b21\u6aa2\u6e2c\u64cd\u4f5c\uff0c\u76f8\u5c0d\u632f\u983b\u79fb\u5dee\u90fd\u80fd\u5920\u7dad\u6301\u572895% \u4ee5\u4e0a\uff0c\u986f\u793a\u5176\u5177\u5099\u64cd\u4f5c\u5b89\u5b9a\u6027\u3002\u76f8\u5c0d\u65bc\u816b\u7624\u80da\u80ce\u6297\u539f\u6a23\u54c1\uff0c\u5c0d\u6fc3\u5ea6\u540c\u6a23\u70ba25 ng/ml\u4e4b\u542b\u9435\u86cb\u767d\uff08ferritin\uff09\u4ee5\u53ca\u7532\u578b\u80ce\u5152\u86cb\u767d\uff08\u03b1-fetoprotein\uff09\uff0c\u50c5\u5206\u5225\u67093.9% \u53ca4.6%\u4e4b\u61c9\u7b54\u5f37\u5ea6\uff08responsiveness\uff09\uff1b\u5c0d\u540c\u6642\u5305\u542b\u6fc3\u5ea6\u5206\u5225\u70ba25 ng/ml\u4e4b\u542b\u9435\u86cb\u767d\u8207\u7532\u578b\u80ce\u5152\u86cb\u767d\u4e4b25 ng/ml\u816b\u7624\u80da\u80ce\u6297\u539f\u6a23\u54c1\uff0c\u6aa2\u6e2c\u6578\u64da\u50c5\u6bd4\u55ae\u7368\u5c0d25 ng/ml\u816b\u7624\u80da\u80ce\u6297\u539f\u6a23\u54c1\u4e4b\u61c9\u7b54\uff08responsiveness\uff09\u589e\u52a06.5%\uff0c\u8b49\u5be6\u5176\u5177\u5099\u512a\u7570\u5c08\u4e00\u6027\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u672c\u7814\u7a76\u9664\u53ef\u5b8c\u6210\u672c\u8ad6\u6587\u4e4b\u816b\u7624\u80da\u80ce\u6297\u539f\u611f\u6e2c\u5668\u4e4b\u958b\u767c\u5916\uff0c\u6240\u5efa\u7acb\u4e4b\u7cfb\u7d71\u6280\u8853\u4ea6\u53ef\u61c9\u7528\u65bc\u5176\u4ed6\u816b\u7624\u6a19\u8a18\u751f\u7269\u611f\u6e2c\u5668\u4e4b\u958b\u767c\uff0c\u4e26\u53ef\u66f4\u9032\u4e00\u6b65\u767c\u5c55\u53ef\u540c\u6642\u6aa2\u6e2c\u591a\u9805\u816b\u7624\u6a19\u8a18\u4e4b\u96c6\u7a4d\u5f0f\u591a\u529f\u80fd\u764c\u75c7\u7be9\u6aa2\u7cfb\u7d71\uff0c\u5c0d\u65bc\u764c\u75c7\u4e4b\u65e9\u671f\u767c\u73fe\u63d0\u4f9b\u91cd\u8981\u8ca2\u737b\u3002", "e": "Purpose : This study aims at developing an immune-biosensor that can detect carcinoembryonic antigens (CEAs) in real time. Malignant tumors were the top cause of death in Taiwan in 2014. Among the GI tract cancer deaths, colorectal cancer, gastric cancer, and esophageal cancer ranked third, seventh, and ninth. CEAs are the tumor biomarkers used when screening for human GI tract cancers. At present, immunoassays are the most widely used screening method. However, they are extremely time-consuming and require approximately 2-3 h per test. Thus, the present study is aimed at developing an immune-biosensor that can perform real-time CEA detection. Materials and Methods : Biosensor analysis technologies are fast becoming the preferred technology for analysis and screening in the 21st century. Such technologies operate by combining biometric materials, such as antibodies and enzymes, and various signal converters, such as microbalances or electrochemical electrodes. In the present study, a quartz crystal microbalance (QCM), with advantages of high stability, high sensitivity, real-time output, and reusability, was coated with polypropylene and equipped with a self-developed auto-sampling device to create a novel polypropylene-coated quartz crystal microbalance with auto-sampling (pQCM). The pQCM was then combined with CEA-related antibodies (high specificity and affinity to CEAs) to develop an immuno-biosensor that can instantaneously measure CEA concentrations, thereby creating an effective means to instantly screen for gastrointestinal cancers. Result : CEA-related monoclonal antibodies were adhered to the surface of the pQCM to create a CEA sensor. Four standard sample solutions were prepared by dissolving 0.2, 2.5, 25, and 200 ng/ml of CEA into phosphate buffered saline solution. The CEA sensor was then used to test the standard sample solutions. The samples with the lowest (0.5 ng/ml) and highest (200 ng/ml) CEA concentrations required only 5 and 10 min to complete testing, respectively. Tests were repeated 16 times over 8 days. Results indicated that the relative vibration frequency shift was maintained at 95% or higher, suggesting that the results achieved excellent operational stability. For comparison, samples prepared with 25 ng/ml of ferritin and \u03b1-fetoprotein only achieved a responsiveness of 3.9% and 4.6%, respectively. Subsequently, the test results of the 25 ng/ml CEA samples separately prepared with the 25 ng/ml of ferritin and \u03b1-fetoprotein showed an increase in responsiveness of only 6.5% compared to those of the pure 25 ng/ml CEA sample, confirming the excellent specificity of the proposed biosensor. Discussion : The proposed CEA sensor satisfies the requirements of the present study; in addition, the systems technology established in the present study can be applied to developing biosensors for multiple cancer biomarkers or even a cumulative and multifunctional cancer screening system, greatly benefiting the early identification of cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-175-181", "title": "\u4f7f\u7528\u8abf\u6574\u53c3\u6578\u8a2d\u8a08\u4e4b\u87ba\u65cb\u5200\u6cbb\u7642\u6280\u8853\u65bc\u5de6\u5074\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u4e4b\u53ef\u884c\u6027\u7814\u7a76\uff1a\u8207\u6df7\u548c\u5f0f\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u6280\u8853\u4e4b\u6bd4\u8f03", "keywords": "\u87ba\u65cb\u5200\u6cbb\u7642\u6280\u8853;\u6df7\u548c\u5f0f\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u6280\u8853;\u5747\u52fb\u5ea6\u6307\u6a19 TomoTherapy;Hybrid-IMRT;Homogeneity index", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u76ee\u7684\u662f\u671f\u671b\u5728\u4f7f\u7528\u963b\u64cb\u53c3\u6578\u8a2d\u8a08\u8207\u512a\u5316\u87ba\u8ddd\u4e4b\u87ba\u65cb\u5200\u653e\u5c04\u6cbb\u7642\u6280\u8853\u65bc\u5de6\u5074\u4e73\u764c\u7684\u75c5\u75c7\u7684\u540c\u6642\uff0c\u5371\u6025\u5668\u5b98\u5291\u91cf\u6bd4\u8d77\u50b3\u7d71\u4e73\u764c\u5c0d\u7167\u6280\u8853\u80fd\u7372\u5f97\u6709\u6548\u7684\u964d\u4f4e\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u662f\u63a2\u8a0e\u5de6\u5074\u4e73\u764c\u60a3\u8005\u505a\u87ba\u65cb\u5200\u6cbb\u7642\u8a08\u5283\u6642\u53c3\u8003An-Cheng Shiau 2014\u4e4b\u9650\u5236\u963b\u64cb\u53c3\u6578\u8a2d\u5b9a\u4e26\u642d\u914d\u512a\u5316\u87ba\u8ddd\u8a2d\u5b9a\uff0c\u76ee\u7684\u662f\u671f\u671b\u9054\u5230\u8f03\u4f73\u7684\u9806\u884c\u5ea6\u4e26\u4e14\u964d\u4f4e\u9644\u8fd1\u5371\u6025\u5668\u5b98\u5291\u91cf\u3002\u9996\u5148\uff0c\u9700\u5148\u5f97\u77e5\u5b9a\u4f4d\u4e2d\u5fc3\u4f4d\u7f6e\u8207\u5be6\u969b\u6cbb\u7642\u9776\u9ad4\u7a4d\u4e4b\u4f4d\u7f6e\u4e2d\u8ef8\u504f\u5dee\u8ddd\u96e2\uff0c\u518d\u53c3\u8003Mingli Chen 2011\u7684\u8868\u683c\u627e\u5230\u5408\u9069\u7684\u87ba\u8ddd\u3002\u63a5\u8457\uff0c\u5728\u8a2d\u8a08\u597d\u5b8c\u5168\u963b\u64cb\u5716\u5340\u8207\u65b9\u5411\u6027\u963b\u64cb\u5716\u5340\u7684\u8a08\u5283\u5957\u7528\u5148\u524d\u67e5\u8868\u5f97\u77e5\u7684\u87ba\u8ddd\u3002\u963b\u64cb\u5716\u5340\u7684\u8a2d\u8a08\u4ecd\u9808\u8003\u91cf\u8207\u9776\u9ad4\u7a4d\u7684\u8ddd\u96e2\uff0c\u53e6\u5916\u53c3\u8003Strydhorst 2011\u63d0\u51fa\u7684\u5efa\u8b70\uff0c\u9700\u8981\u518d\u7e6a\u88fd\u865b\u64ecbolus\uff0c\u76ee\u7684\u662f\u8003\u91cf\u5230\u547c\u5438\u9020\u6210\u4f4d\u79fb\u7684\u5f71\u97ff\u3002\u6df7\u548c\u5f0f\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u8a08\u5283\u662f\u5229\u7528\u5169\u500b\u50b3\u7d71\u5207\u7dda\u7167\u91ce\u5c04\u675f\u4f5480%\u8655\u65b9\u5291\u91cf\uff0c\u518d\u52a0\u4e0a\u5169\u500b\u5f37\u5ea6\u8abf\u63a7\u5c04\u5c04\u675f\u7576\u4f5c\u8f14\u52a9\u5c04\u675f\u4f5420%\u8655\u65b9\u5291\u91cf\uff0c\u8655\u65b9\u5291\u91cf\u662f50Gy\u520625\u6b21\u7167\u5c04\u3002\u53e6\u5916\uff0c\u5728\u80ba\u90e8\u5668\u5b98\u8207\u5fc3\u81df\u5291\u91cf\uff0c\u5c07\u8a55\u4f30\u5728\u5207\u7dda\u5c0d\u7167\u4e4b\u7167\u91ce\u5167\u5c04\u675f\u773c\u5167\u7684\u7167\u91ce\u5fc3\u81df\u9ad4\u7a4d\u8207\u7167\u91ce\u80ba\u90e8\u9ad4\u7a4d\u3002\u7d50\u679c\uff1a\u6700\u5927\u7167\u91ce\u5fc3\u81df\u9ad4\u7a4d\u8207\u7167\u91ce\u80ba\u90e8\u9ad4\u7a4d\u5206\u5225\u662f15.49 cc\u548c88.8 cc\uff0c\u76f8\u8f03\u65bc\u6df7\u548c\u5f0f\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u8a08\u5283\uff0c\u512a\u5316\u9650\u5236\u6027\u87ba\u65cb\u5200\u6cbb\u7642\u8a08\u5283\u53ef\u63d0\u9ad8\u9776\u9ad4\u7a4d\u5167\u7684\u6700\u4f4e\u5291\u91cf\uff0839.16\u00b14.958Gy vs. 30.56\u00b19.478Gy\uff09\uff0c\u4ee5\u53ca\u63d0\u5347\u5747\u52fb\u5ea6\u6307\u6a19\uff08HI=PTVm95%-PTVm107%\uff09\uff080.9888\u00b10.0054 vs. 0.9690\u00b10.0138\uff09\uff0c\u9806\u884c\u5ea6\u6307\u6a19\uff08Conformity index, CI\uff09\uff081.5892\u00b10.2998 vs. 1.6286\u00b10.2526\uff09\u4e0d\u5206\u8ed2\u8f0a\u3002\u53e6\u5916\uff0c\u512a\u5316\u9650\u5236\u6027\u87ba\u65cb\u5200\u6cbb\u7642\u8a08\u5283\uff0c\u6bd4\u8d77\u50b3\u7d71\u6df7\u548c\u5f0f\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u8a08\u5283\uff0c\u5728\u5fc3\u81df\u7684\u5e73\u5747\u5291\u91cf\u662f\u964d\u4f4e\u4e8618.38%\uff082.72\u00b12.214Gy vs. 2.22\u00b11.872Gy\uff09\uff1b\u5728\u5de6\u80ba\u90e8\u7684\u5e73\u5747\u5291\u91cf\u964d\u4f4e\u4e8613.74%\uff085.75\u00b10.848Gy vs. 4.96\u00b11.352Gy\uff09\u3002\u7d50\u8ad6\uff1a\u512a\u5316\u9650\u5236\u6027\u87ba\u65cb\u5200\u6cbb\u7642\u6280\u8853\uff0c\u5728\u5fc3\u81df\u8207\u80ba\u90e8\u5668\u5b98\u5448\u73fe\u7684\u5291\u91cf\u662f\u8f03\u4f4e\u7684\uff0c\u9019\u662f\u56e0\u70ba\u6b64\u6280\u8853\u5728\u8a08\u5283\u904e\u7a0b\u4e2d\u6709\u66f4\u591a\u53ef\u8abf\u6574\u7684\u7a7a\u9593\u3002\u76f8\u4fe1\u87ba\u65cb\u5200\u6cbb\u7642\u6280\u8853\u7684\u7814\u7a76\uff0c\u5728\u5de6\u5074\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u662f\u6709\u5e6b\u52a9\u7684\u3002", "e": "Purpose : In order to reduce heart and ipsilateral lung dose, a modified TomoTherapy planning technique for left-sided breast was introduced and compared to Hybrid-IMRT technique. Materials and Methods: A modified TomoTherapy planning technique was designed for left-sided breast cancer patients. It was based on the Limited-TomoTherapy planning technique but applying optimal pitches to achieve better conformity and lower heart and ipsilateral lung dose. First, the optimized off-axis distance was determined. Then the optimal pitches were chosen according to the optimized off-axis distance. The last step was applying optimal pitches with the Limited- TomoTherapy planning technique, which employed several artificial contours such as the Complete-block, Directional-block for near PTV area and the virtual bolus, in the optimized process of the left-sided breast TomoTherpy planning. Hybrid-IMRT plans were designed by tangential-fields and IMRT fields combined. The prescription dose was 50 Gy in 25 fractions to PTV. The lung and heart dose volume were measured and analyzed in Beam's-eye-view of tangential-fields with in-field heart volume and in-field lung volume. Result: The maximum volumes of in-field heart volume and in-field lung volume were 15.49 cc and 88.8 cc, respectively. Comparing to the Hybrid-IMRT technique, the modified TomoTherapy planning technique increased the minimal dose of PTV (39.16\u00b14.958 Gy vs. 30.56\u00b19.478 Gy), the homogeneity index (HI= PTV_(m95%)-PTV_(m107%)) was better (0.9888 \u00b1 0.0054 vs. 0.9690 \u00b1 0.0138) and conformity index (CI= V_(95%)/PTV_(95%)) was no obvious difference (1.5892\u00b10.2998 vs. 1.6286\u00b10.2526). The D_(mean) of heart in modified planning technique was under 18.38% than in the Hybrid-IMRT technique (2.22 \u00b1 1.872 Gy vs. 2.72 \u00b1 2.214 Gy). The D_(mean) of Lt lung was under 13.74% in modified planning technique than in the Hybrid-IMRT technique (4.96 \u00b1 1.352 Gy vs. 5.75 \u00b1 0.848 Gy). Discussion and Conclusions: The modified planning technique showed better dose reduction in heart and lung, due to its more flexibility in the optimized planning process. It should be useful in left-sided breast treatment with TomoTherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-183-190", "title": "\u653e\u5c04\u6cbb\u7642\u4e8c\u7dad\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u7d50\u679c\u8207\u6548\u76ca\u5206\u6790", "keywords": "\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;On-Board Imager\uff08OBI\uff09;\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49 Image-guided radiation therapy (IGRT);On-board imager (OBI);Daily QualityAssurance", "c": "\u76ee\u7684\uff1a\u5f71\u50cf\u5c0e\u5f15\u5df2\u662f\u653e\u5c04\u6cbb\u7642\u4e2d\u8209\u8db3\u8f15\u91cd\u7684\u6280\u8853\uff0c\u8981\u78ba\u4fdd\u5f71\u50cf\u5c0e\u5f15\u7d50\u679c\u6e96\u78ba\uff0c\u8a73\u5be6\u7684\u54c1\u8cea\u4fdd\u8b49\uff08Quality Assurance, QA\uff09\u4f5c\u696d\u4e0d\u53ef\u7f3a\u5c11\uff0c\u6545\u53c3\u8003\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5b78\u6703\uff08American Association of Physicists in Medicine, AAPM\uff09142\u865f\u5de5\u4f5c\u5831\u544a\u5efa\u8b70\uff0c\u9032\u884c\u672c\u79d1\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u3002\u672c\u7814\u7a76\u5206\u6790\u76f8\u95dc\u7d50\u679c\u53ca\u6548\u76ca\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u76f4\u7dda\u52a0\u901f\u5668\u8207\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u70baVarian Trilogy On Board Imager\uff08OBI\uff09\u7cfb\u7d71\uff0c\u54c1\u4fdd\u4f7f\u7528\u5047\u9ad4\u70baIsocenter Cube Assy\uff08Varian TM 55150000 isocenter Cube tool\uff09\u3002\u7531\u540c\u4e00\u4f4d\u91ab\u4e8b\u653e\u5c04\u5e2b\u57f7\u884c40\u6b21\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u6bcf\u65e5\u54c1\u4fdd\u4f5c\u696d\uff0c\u9805\u76ee\u6709\u78b0\u649e\u9023\u9396\uff08Collision interlocks\uff09\u3001\u5f71\u50cf\u8207\u6cbb\u7642\u4e2d\u5fc3\u9ede\u91cd\u5408\uff08Imaging and treatment coordinate coincidence\uff09\u8207\u6cbb\u7642\u5e8a\u4f4d\u79fb\u6e96\u78ba\u6027\uff08Positioning\uff09\u54c1\u4fdd\u4f5c\u696d\u3002\u91dd\u5c0d\u6cbb\u7642\u5e8a\u4f4d\u79fb\u6e96\u78ba\u6027\uff0c\u672c\u7814\u7a76\u57f7\u884c\u65b9\u6cd5\u4e00\u70ba\u5224\u8b80\u65b9\u683c\u7d19\u4e0a\u4f4d\u79fb\u7684\u8ddd\u96e2\uff08\u65b9\u683c\u7d19\u76ee\u8996\u6aa2\u6e2c\uff09\u3001\u65b9\u6cd5\u4e8c\u70ba\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u62cd\u651d\u6b63\u4ea4\u7247\u5224\u8b80\u5c0f\u9435\u7403\uff08Ball Bullet, BB\uff09\u4e2d\u5fc3\u9ede\u5dee\u7570\uff08BB\u5f71\u50cf\u5206\u6790\u6aa2\u6e2c\uff09\u3001\u65b9\u6cd5\u4e09\u70ba\u89c0\u5bdfBB\u8207\u96f7\u5c04\u4ea4\u6703\u60c5\u5f62\uff08BB\u76ee\u8996\u6aa2\u6e2c\uff09\u7684\u4e09\u7a2e\u54c1\u4fdd\u4f5c\u696d\u65b9\u5f0f\u63a2\u8a0e\u5176\u5dee\u7570\uff0c\u4e26\u7d00\u9304\u82b1\u8cbb\u7684\u6642\u9593\u3002\u7d50\u679c\uff1a\u4e00\u3001\u78b0\u649e\u9023\u9396\u6e2c\u8a66\u5168\u6578\u901a\u904e\u3002\u4e8c\u3001\u5f71\u50cf\u8207\u6cbb\u7642\u4e2d\u5fc3\u9ede\u91cd\u5408\u54c1\u4fdd\u7d50\u679c\u7686\u70ba\u5bb9\u8a31\u8aa4\u5dee\u4e4b\u5167\u3002\u4e09\u3001\u6cbb\u7642\u5e8a\u4f4d\u79fb\u6e96\u78ba\u6027\u4e09\u7a2e\u65b9\u6cd5\u7d50\u679c\u7686\u70ba\u5bb9\u8a31\u8aa4\u5dee\u4e4b\u5167\u3002\u6bd4\u8f03\u6cbb\u7642\u5e8a\u4f4d\u79fb\u6e96\u78ba\u6027\u54c1\u4fdd\u4f5c\u696d\u4e4b\u65b9\u683c\u7d19\u76ee\u8996\u8207BB\u5f71\u50cf\u5206\u6790\u6aa2\u6e2c\u7684X\u3001Y\u3001Z\u8ef8\u8207\u4e09\u8ef8\u7e3d\u4f4d\u79fb\u8aa4\u5dee\u6c92\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u5dee\u7570\uff0cP\u503c\u5206\u5225\u662f0.229\u30011\u30010.867\u82070.196\u3002\u6bd4\u8f03\u54c1\u4fdd\u6cbb\u7642\u5e8a\u4f4d\u79fb\u6e96\u78ba\u6027\u4e09\u7a2e\u65b9\u6cd5\u4e4b\u6642\u9593\u82b1\u8cbb\u5e73\u5747\u503c\uff0cBB\u5f71\u50cf\u5206\u6790\u6bd4\u65b9\u683c\u7d19\u76ee\u8996\u6aa2\u6e2c\u591a0.4\u79d2\uff0c\u65b9\u683c\u7d19\u76ee\u8996\u6bd4BB\u76ee\u8996\u6aa2\u6e2c\u591a\u51fa17.6\u79d2\u3002\u65b9\u683c\u7d19\u76ee\u8996\u8207BB\u5f71\u50cf\u5206\u6790\u6aa2\u6e2c\u6c92\u6709\u986f\u8457\u5dee\u7570\uff08P\uff1e0.05\uff09\uff1b\u65b9\u683c\u7d19\u76ee\u8996\u8207BB\u76ee\u8996\u6aa2\u6e2c\u6709\u986f\u8457\u5dee\u7570\uff08P=0.00012\uff09\uff1bBB\u5f71\u50cf\u5206\u6790\u8207 BB\u76ee\u8996\u6aa2\u6e2c\u6709\u986f\u8457\u5dee\u7570\uff08P=0.00006\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u8a66\u4f5c\u4e4b\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u53ef\u7528\u65bcOBI\u8207\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u5099\uff08Electronic Portal Imaging Device, EPID\uff09\uff0c\u54c1\u4fdd\u6d41\u7a0b\u4e0d\u7e41\u8907\uff0c\u5efa\u8b70\u653e\u5c04\u816b\u7624\u79d1\u90e8\u9580\u61c9\u5efa\u7acb\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\uff0c\u78ba\u4fdd\u75c5\u4eba\u6cbb\u7642\u7684\u6e96\u78ba\u6027\u8207\u5b89\u5168\u6027\u3002", "e": "Purpose : Image-guided radiation therapy is an important irradiating technique. To ensure the accuracy of image guidance, it is essential to conduct daily quality assurance (QA). According to Report No. 142 of the American Association of Physicists in Medicine, we developed daily quality assurance for a two-dimensional image-guided system. This study reports our results and benefit analysis. Materials and Methods : Our image-guided linear accelerator was Varian Trilogy with On-Board Imager (OBI) system. The QA phantom was Isocenter Cube Assay (Varian TM55150000 isocenter Cube tool). A qualified radiation technologist executed 40 daily QAs for our two-dimensional image-guided system. QA items included collision interlocks, imaging and treatment coordinate coincidence and positioning tests. To ensure the correct position of the treatment couch, we performed three QA methods. First, we interpreted the displacement on a graph paper visually. Second, we identified the displacement of Ball Bullet (BB) on the center of the image-guided system by using orthogonal films (BB image analysis and detection). Third, we calculated the difference between BB and the intersection of laser lines (visual inspection of BB). We compared these three QA methods, including the time cost. Result : All collision interlocks tests had positive results. All imaging and treatment coordinates and positioning test results were within the range of allowable errors. Comparing the first two methods of position testing, no statistically significant difference was detected between them (P values in X-Y-Z three axes and total error, 0.229, 1, 0.867 and 0.196, respectively). Comparing the mean time taken for couch positioning among the three QA methods, the BB image analysis and detection took 0.4 seconds longer than the visual inspection of graph paper. The visual inspection of graph paper took 17.6 second longer than the visual inspection of BB. There was no statistically significant difference between the visual inspection of graph paper and BB image analysis and detection (P\uff1e 0.05). However, statistically significant differences were detected both (1) between the visual inspection of graph paper and the visual inspection of BB (P = 0.00012), and (2) between the BB image analysis and the visual inspection of BB (P = 0.00006). Conclusion : Our QA methods ensure the quality of two-dimensional image-guided radiation therapy in both Electronic Portal Imaging Device (EPID) and OBI systems. The QA procedures are easy to implement. To ensure the accuracy of radiotherapy, establishing QA procedures for image-guided systems is strongly recommended."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-191-203", "title": "ORAL CANCER PATIENT WITH AN UNRESECTABLE LUNG OLIGOMETASTASIS SUCCESSFULLY TREATED BY STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR ) WITH SIMULTANEOUSLY INTEGRATED INNER-ESCALATED BOOST (SIEB ): A CASE REPORT", "keywords": "\u5be1\u91cf\u8f49\u79fb;\u7acb\u9ad4\u5b9a\u4f4d\u71d2\u707c\u6027\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u816b\u7624\u5167\u589e\u91cf\u653e\u5c04\u6cbb\u7642;\u53e3\u8154\u764c Oligometastasis;Stereotactic ablative radiotherapy (SABR);Simultaneously Integrated Inner-Escalated Boost (SIEB);Oral cancer", "c": "\u53e3\u8154\u764c\u662f\u53f0\u7063\u5e38\u898b\u7684\u982d\u9838\u764c\u4e4b\u4e00\uff0c\u5927\u90e8\u5206\u5728\u521d\u8a3a\u65b7\u6642\u70ba\u5c40\u90e8\u6027\u75be\u75c5\u3002\u5373\u4f7f\u75be\u75c5\u9032\u5c55\u5230\u5f8c\u671f\uff0c\u9060\u7aef\u8f49\u79fb\u7684\u6bd4\u4f8b\u4ecd\u7136\u4e0d\u591a\u3002\u5728\u904e\u53bb\u4e00\u65e6\u764c\u75c7\u75c5\u4eba\u6709\u4e86\u9060\u7aef\u8f49\u79fb\uff0c\u5373\u4f7f\u8f49\u79fb\u7684\u6578\u91cf\u5c11\u6216\u9ad4\u7a4d\u5f88\u5c0f\uff08\u5be1\u91cf\u8f49\u79fb\uff09\u4ecd\u88ab\u8a8d\u70ba\u662f\u7121\u6cd5\u6cbb\u7652\u7684\u75be\u75c5\u3002\u56e0\u6b64\u9019\u985e\u75c5\u4eba\u5927\u90e8\u5206\u63a5\u53d7\u7de9\u548c\u6cbb\u7642\u3002\u7136\u800c\u6709\u8a31\u591a\u7684\u6587\u737b\u986f\u793a\u5728\u63a5\u53d7\u7a4d\u6975\u7684\u6cbb\u7642\u60c5\u6cc1\u4e0b\uff0c\u5be1\u91cf\u8f49\u79fb\u7684\u764c\u75c7\u75c5\u4eba\u6bd4\u8d77\u7030\u6f2b\u6027\u8f49\u79fb\uff0c\u53ef\u4ee5\u6709\u8f03\u9577\u7684\u7121\u75be\u75c5\u5b58\u6d3b\u671f\uff0c\u9019\u4e9b\u8b49\u64da\u986f\u793a\u5be1\u91cf\u8f49\u79fb\u7684\u764c\u75c7\u662f\u6709\u671b\u6cbb\u7652\uff0c\u800c\u4e0d\u662f\u5b8c\u5168\u7121\u6cd5\u6cbb\u7652\u7684\u75be\u75c5\u3002\u9019\u4e9b\u73fe\u8c61\u5728\u5f88\u591a\u4e0d\u540c\u7a2e\u985e\u764c\u75c7\u4e0a\u7686\u6709\u88ab\u89c0\u5bdf\u5230\uff0c\u5305\u542b\u5927\u8178\u76f4\u8178\u764c\u3001\u9ed1\u8272\u7d20\u7624\u3001\u5b50\u5bae\u5167\u819c\u764c\u7b49\u3002\u7136\u800c\u53e3\u8154\u764c\u88ab\u5831\u544a\u7684\u8cc7\u6599\u5f88\u5c11\u3002\u56e0\u6b64\u672c\u6587\u5831\u544a\u4e00\u4f4d\u53e3\u8154\u764c\u75c5\u4eba\uff0c\u5408\u4f75\u7121\u6cd5\u5207\u9664\u7684\u80ba\u55ae\u9846\u8f49\u79fb\u75c5\u7076\uff0c\u63a5\u53d7\u300c\u7acb\u9ad4\u5b9a\u4f4d\u71d2\u707c\u6027\u300d\u53ca\u300c\u540c\u6b65\u816b\u7624\u5167\u589e\u91cf\u300d\u653e\u5c04\u6cbb\u7642\u3002\u5728\u6cbb\u7642\u5b8c\u6210\u7684\u56db\u500b\u6708\u5f8c\u816b\u7624\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u3002\u800c\u4e14\u5728\u6700\u5f8c\u4e00\u6b21\u56de\u8a3a\u8ffd\u8e64\u6642\uff08\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u5169\u5e74\u5f8c\uff09\uff0c\u75c5\u4eba\u7684\u982d\u9838\u90e8\u53ca\u80ba\u90e8\u5340\u57df\u7686\u6c92\u6709\u6b98\u5b58\u7684\u816b\u7624\u3002", "e": "Oral cancer, one common subtype of head and neck cancers in Taiwan, mainly presented as a locoregional disease at diagnosis. Even in its late course, distant metastasis is still rare. Previously, once cancer patients with distant metastasis - even in limited number or small size (i.e., oligometastasis) - were considered as having an \uff02incurable\uff02 disease. Thus, palliative treatments were recommended. However, several lines of evidence showed that while applying aggressive managements, most oligometastatic cancer patients demonstrated a durable disease-free survival when compared with those patients with disseminated metastases. This observation implicated that oligometastasis may be a 'potentially curable,' rather than \uff02incurable\uff02 disease status. This phenomenon has been observed in several types of cancers, such as colorectal cancer, melanoma, and endometrium cancer. But, few data were reported in oral cancer. Herein, we presented an oral cancer patient with an un-resectable pulmonary oligometastasis. Stereotactic ablative radiotherapy (SABR) was given in conjunction with Simultaneous Integrated Inner-Escalated Boost (SIEB) technique. Four months after SABR/SIEB, complete response was observed. Moreover, no evidence of cancer disease was noted in both lung and head-and-neck region till the last follow-up (two years after RT)."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-205-212", "title": "A CASE OF HEPATOCELLULAR CARCINOMA WITH TUMOR THROMBUS EXTENDING FROM THE INFERIOR VENA CAVA TOWARDS THE RIGHT ATRIUM SHOWS COMPLETE RESPONSE AFTER COMBINED TREATMENT WITH RADIATION THERAPY AND SORAFENIB", "keywords": "\u809d\u7d30\u80de\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;sorafenib Hepatocellular carcinoma;Radiation therapy;Sorafenib", "c": "\u672c\u6587\u5831\u544a\u4e00\u809d\u764c\u60a3\u8005\u56e0\u5408\u4f75\u4e0b\u8154\u975c\u8108\u53ca\u53f3\u5fc3\u623f\u816b\u7624\u6813\u585e\u800c\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u9019\u540d55\u6b72C\u578b\u809d\u708e\u60a3\u8005\uff0c\u65bc\u78ba\u8a3a\u809d\u764c\u6642\u5373\u767c\u73fe\u540c\u6642\u5408\u4f75\u4e0b\u8154\u975c\u8108\u53ca\u53f3\u5fc3\u623f\u816b\u7624\u6813\u585e\u3002\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf35Gy\u520615\u6b21\uff0c\u540c\u6642\u670d\u7528\u6a19\u9776\u85e5\u7269Sorafenib\u3002\u5f8c\u7e8c\u5f71\u50cf\u8ffd\u8e64\u767c\u73fe\u816b\u7624\u6813\u585e\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u6548\u679c\u3002", "e": "We report a case of advanced hepatocellular carcinoma (HCC) with tumor thrombosis extending from the inferior vena cava (IVC) towards the right atrium (RA) treated by radiation therapy (RT) and targeted therapy with sorafenib. A 55-year old man who had been a hepatitis C carrier eventually developed liver cirrhosis and primary HCC. Tumor thrombosis spanning across the IVC and the RA was noted at initial diagnosis. He received RT with 37.5 Gy in 15 fractions in addition to concurrent and sequential sorafenib therapy. Follow-up imaging studies showed complete response of IVC and RA thrombus."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201609-201609290001-201609290001-213-217", "title": "RADIOTHERAPY FOR AMELOBLASTOMA: A CASE REPORT AND LITERATURE REVIEW", "keywords": "\u9020\u91c9\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642 Ameloblastoma;Radiotherapy", "c": "\u9020\u91c9\u7d30\u80de\u7624\u662f\u500b\u8868\u76ae\u884d\u751f\u3001\u975e\u529f\u80fd\u6027\u7684\u816b\u7624\uff0c\u767c\u75c5\u5e74\u9f61\u5e73\u5747\u70ba30\u523040\u6b72\uff0c\u7121\u6027\u5225\u5dee\u7570\u3002\u8a72\u816b\u7624\u81e8\u5e8a\u75c7\u72c0\u901a\u5e38\u7121\u75db\u800c\u6c92\u6709\u660e\u986f\u75c7\u72c0\u3002\u75be\u75c5\u4e3b\u8981\u7d93\u7531\u5f71\u50cf\u5b78\u8a3a\u65b7\u5f8c\u900f\u904e\u53d6\u5f97\u75c5\u7406\u7d44\u7e54\u4f86\u78ba\u8a3a\u3002\u6cbb\u7642\u65b9\u5f0f\u4ee5\u816b\u7624\u5207\u9664\u5408\u4f75\u91cd\u5efa\u624b\u8853\u70ba\u4e3b\u3002\u91dd\u5c0d\u81e8\u5e8a\u7121\u6cd5\u624b\u8853\u6216\u62d2\u7d55\u624b\u8853\u4e4b\u6cbb\u7642\u65b9\u6cd5\u5247\u5c1a\u672a\u6709\u660e\u78ba\u5171\u8b58\u3002\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u589e\u52a0\u816b\u7624\u5c40\u90e8\u63a7\u5236\u7684\u6a5f\u6703\u3002\u672c\u75c5\u4f8b\u5831\u544a\u70ba\u4e00\u4f4d50\u6b72\u60a3\u8005\u56e0\u524d\u5074\u4e0b\u984e\u7121\u75db\u6027\u816b\u7624\u524d\u4f86\u5c31\u8a3a\u3002\u7d44\u7e54\u75c5\u7406\u5b78\u8a3a\u65b7\u70ba\u9020\u91c9\u7d30\u80de\u7624\u3002\u60a3\u8005\u62d2\u7d55\u63a5\u53d7\u624b\u8853\u3002\u5b89\u6392\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff083D-CRT\uff0960Gy\u6cbb\u7642\u4e09\u5341\u6b21\u5f8c\uff0c\u8ffd\u8e64\u516d\u5e74\u4ecd\u7121\u5fa9\u767c\u3002", "e": "Ameloblastoma is an epithelial origin, nonfunctional neoplasm. The patients are equal in gender and reported to have mean age between 30 to 40 years old. The clinical manifestations of this tumor are generally painless without obvious symptoms or signs. The disease is tentatively diagnosed by imaging study, and is confirmed histologically. The main treatment for ameloblastoma is tumor resection with or without reconstruction surgery. The optimal treatment options for clinically inoperable disease or refusal of operation are not defined. Radiotherapy is able to increase the likelihood of local control. The 50-year-old patient visited our hospital due to painless mass over his anterior mandible. Histologic examination showed ameloblastoma. The patient refused operation. Radiotherpy with 60 Gy in 30 fractions by three-dimensional conformal radiation therapy (3D-CRT) was delivered. After 6-year follow-up, there was no local recurrence."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-85-97", "title": "TREATMENT OUTCOMES OF NEOADJUVANT CCRT IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER -A SINGLE INSTITUTIONAL REPORT", "keywords": "\u8853\u524d\u540c\u6b65\u5316\u653e\u7642;\u76f4\u8178\u764c;\u6cbb\u7642\u6210\u6548 Neoadjuvant concurrent chemoradiotherapy;Rectal cancer;Treatment outcomes", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\u60a3\u8005\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u653e\u7642\u4e4b\u6cbb\u7642\u6210\u6548\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u9867\u672c\u9662\u81ea\u897f\u51432006\u5e74\u81f32013\u5e74\u9593\uff0c\u65b0\u8a3a\u65b7\u4e4b\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\uff0c\u4e14\u65bc\u624b\u8853\u524d\u63a5\u53d7\u540c\u6b65\u5316\u653e\u7642\u7684\u75c5\u4f8b\u3002\u6392\u9664\u8a3a\u65b7\u6642\u5df2\u6709\u8f49\u79fb\u53ca\u6700\u7d42\u6c92\u6709\u5728\u672c\u9662\u63a5\u53d7\u624b\u8853\u8005\u3002\u653e\u7642\u7e3d\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba5040cGy\uff0c\u5e38\u7528\u7684\u540c\u6b65\u5316\u7642\u85e5\u7269\u70baCapecitabine\u6216Tegafur & Uracil\u3002\u8853\u524d\u653e\u5316\u7642\u7d50\u675f\u81f3\u624b\u8853\u9593\u9694\u6642\u9593\u4e2d\u4f4d\u6578\u70ba8\u5468\u3002\u4f7f\u7528Kaplan-Meier\u65b9\u6cd5\u5206\u6790\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\u3001\u764c\u75c7\u5b58\u6d3b\u7387\uff08CSS\uff09\u3001\u9aa8\u76c6\u8154\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\uff08PRFS\uff09\u3001\u8207\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\uff08DMFS\uff09\u3002\u4e26\u5206\u6790\u5f71\u97ff\u75c5\u7406\u5b8c\u5168\u7de9\u89e3\u7387\uff08pCR\uff09\u4e4b\u56e0\u5b50\u53ca\u4e0d\u540c\u624b\u8853\u65b9\u5f0f\u7684\u9810\u5f8c\u3002\u7d50\u679c\uff1a166\u4f4d\u75c5\u4eba\u88ab\u7d0d\u5165\u672c\u7814\u7a76\uff0c\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba3.03\u5e74\u30025\u5e74\u7684OS\u548cCSS\u5206\u5225\u70ba73%\u53ca78%\u3002\u7121\u9aa8\u76c6\u8154\u5fa9\u767c\u548c\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u5206\u5225\u70ba2.6\u5e74\u53ca2.2\u5e74\u3002\u75c5\u7406\u5b8c\u5168\u7de9\u89e3\u7387\u70ba11.45%\u3002\u5316\u7642\u85e5\u7269\u4e4b\u9078\u64c7\u5c0d\u5b58\u6d3b\u7387\u53ca\u75c5\u7406\u5b8c\u5168\u7de9\u89e3\u7387\u7121\u986f\u8457\u5f71\u97ff\u3002\u75c5\u60a3\u63a5\u53d7\u809b\u9580\u4fdd\u7559\u624b\u8853\u4e4b\u6bd4\u4f8b\u70ba77%\uff0c\u5728\u8ddd\u96e2anal verge\u5c0f\u65bc5 cm\u30015\u523010 cm\u3001\u8207\u8d85\u904e10 cm\u4e4b\u60a3\u8005\uff0c\u63a5\u53d7\u809b\u9580\u4fdd\u7559\u624b\u8853\u7684\u6bd4\u4f8b\u5206\u5225\u70ba59%\u300187%\u3001100%\u3002\u8179\u8154\u93e1\u8207\u50b3\u7d71\u958b\u8179\u624b\u8853\u4e4b\u6bd4\u8f03\u986f\u793a\uff1a\u63a5\u53d7\u8179\u8154\u93e1\u624b\u8853\u4e4b\u60a3\u8005\u6709\u8f03\u5c11\u7684\u9aa8\u76c6\u8154\u5167\u5fa9\u767c\uff0811.1% v.s 25.6%, p= .036\uff09\uff0c\u8f03\u5c11\u7684\u8853\u4e2d\u5931\u8840\u91cf\uff08174 cc v.s 309 cc, p= .012\uff09\uff0c\u53ca\u8f03\u77ed\u7684\u4f4f\u9662\u5929\u6578\uff088 days v.s 13 days, p= .000\uff09\u3002\u5728\u5b58\u6d3b\u5206\u6790\u65b9\u9762\uff0cOS\u3001CSS\u3001PRFS\u53caDMFS\u65bc\u63a5\u53d7\u5169\u7a2e\u8853\u5f0f\u4e4b\u75c5\u4eba\u9593\uff0c\u7686\u7121\u7d71\u8a08\u4e0a\u986f\u8457\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u8853\u524d\u540c\u6b65\u5316\u653e\u7642\u70ba\u6cbb\u7642\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\u60a3\u8005\u4e4b\u6709\u6548\u65b9\u6cd5\u3002Capecitabine\u8207Tegafur & Uracil\u9019\u5169\u7a2e\u85e5\u7269\u5747\u53ef\u5408\u4f75\u8853\u524d\u653e\u5c04\u7dda\u6cbb\u7642\u4f7f\u7528\u3002\u5167\u8996\u93e1\u816b\u7624\u5207\u9664\u624b\u8853\u8207\u958b\u8179\u816b\u7624\u5207\u9664\u624b\u8853\u76f8\u8f03\u6709\u76f8\u540c\u7684\u6cbb\u7642\u6210\u679c\u4f46\u76f8\u5c0d\u8f03\u4f4e\u7684\u624b\u8853\u4f75\u767c\u75c7\u3002", "e": "Introduction : The purpose of this study is to evaluate preliminary outcomes in locally advanced rectal cancer patients who underwent neoadjuvant concurrent chemoradiotherapy (CCRT). Material and Method : From 2006 to 2013, 166 patients with newly diagnosed clinical stage II or III rectal cancer who received neoadjuvant CCRT were identified (cT2- 3=155, cT4=11, cN+=93). All of them received external beam radiotherapy (EBRT) with median dose of 5040 cGy (4400 - 5400 cGy). The regimens of chemotherapy combined with radiation were Capecitabine (47%), Tegafur & Uracil (40%) and others. Median duration from the end of neoadjuvant CCRT to surgery was 56 days (21 - 173 days). All radical surgery were done in a total mesorectal excision (TME) fashion. The end points of this study included overall survival (OS), cancer-specific survival (CSS), pelvic recurrence-free survival (PRFS), and distant metastasis-free survival (DMFS). We also analyzed factors associated with pathological complete response (pCR) and outcomes between different surgical procedures. Result : After a median follow-up duration of 3.03 years (0.22 - 8.16 years), 5-year OS rate was 73%, 5-year CSS rate was 78%, median PRFS was 2.6 \u00b1 2 years, and median DMFS was 2.2 \u00b1 2 years. There were no differences in OS (p= .776) and CSS (p= .717) between patients receiving Capecitabine or Tegafur & Uracil combined with radiation. We achieved pCR rate of 11.45%, and ratio of receiving anal-preservation surgery was 77% (59%, 87%, 100% for lower third, middle third, and upper third tumor, respectively). In subgroup analysis, laparoscopic surgery group had lower pelvic recurrence rate (11.1% v.s 25.6%, p= .036), less intra-operative blood loss (mean, 174 cc v.s 309 cc, p= .012), and shorter hospital stay (mean, 8 days v.s 13 days, p= .000). The 5-year OS rate was 78% for laparoscopic surgery group and 59% for open surgery group respectively (p = .126), the 5-year CSS rate was 80% and 72% (p= .572), median PRFS was 2.2 years and 4.6 years (p= .672), and median DMFS was 2 years and 3.5 years (p= .549). Conclusion : Neoadjuvant CCRT followed by surgery is a feasible way to treat locally advanced rectal cancer, and the 5-year OS rate was 73% in the current study. Capecitabine and Tegafur & Uracil are reasonable choices as concurrent regimens. Laparoscopic surgery is recommended due to lower surgical morbidities and noninferiority of outcomes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-99-106", "title": "FORMULATION AND VALIDATION OF A SURROGATE ESTIMATE FOR THE INTERVAL BETWEEN SURGERY AND ADJUVANT RADIOTHERAPY IN PATIENTS WITH MALIGNANT BRAIN TUMORS BASED ON THE NATIONAL HEALTH INSURANCE DATABASE", "keywords": "\u885b\u751f\u798f\u5229\u8cc7\u6599\u5eab;\u5168\u6c11\u5065\u5eb7\u4fdd\u96aa;\u653e\u5c04\u6cbb\u7642;\u9593\u9694\u6642\u8ddd Health and welfare database;National health insurance;Radiotherapy;Time interval", "c": "\u76ee\u7684\uff1a\u57282011\u5e741\u67081\u65e5\u524d\uff0c\u5168\u6c11\u5065\u5eb7\u4fdd\u96aa\u8cc7\u6599\uff0c\u4e26\u672a\u8a18\u9304\u624b\u8853\u6216\u653e\u5c04\u6cbb\u7642\u4e4b\u57f7\u884c\u65e5\u671f\uff0c\u56e0\u800c\u4f7f\u6b63\u78ba\u7684\u6cbb\u7642\u9593\u9694\u6642\u8ddd\u4e4b\u8a08\u7b97\u53d7\u5230\u9650\u5236\u3002\u6211\u5011\u7684\u76ee\u7684\u662f\u63a8\u5c0e\u4e26\u9a57\u8b49\u624b\u8853\u8207\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u4e4b\u9593\u9694\u6642\u8ddd\u7684\u66ff\u4ee3\u4f30\u8a08\u65b9\u6cd5\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u81ea\u5168\u6c11\u5065\u5eb7\u4fdd\u96aa\u8cc7\u6599\u5eab\u4e2d\u63d0\u53d6\u4e26\u56de\u6eaf\u5206\u6790\u65bc2011\u5e741\u67081\u65e5\u81f32012\u5e7412\u670831\u65e5\u671f\u9593\u88ab\u8a3a\u65b7\u70ba\u60e1\u6027\u8166\u7624\u4e26\u63a5\u53d7\u624b\u8853\u8207\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u4e4b\u500b\u6848\u3002\u624b\u8853\u8207\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u9593\u9694\u6642\u8ddd\u4e4b\u66ff\u4ee3\u4f30\u8a08\u503c\uff0c\u4fc2\u4f9d\u64da\u9580\u8a3a\u5c31\u91ab\u65e5\u671f\u53ca\u4f4f\u9662\u9996\u65e5\u8a08\u7b97\u5f97\u5230\u3002\u5229\u7528\u6700\u4f73\u914d\u9069\u7dda\u6027\u8ff4\u6b78\uff0c\u4ee5\u624b\u8853\u8207\u653e\u5c04\u6cbb\u7642\u57f7\u884c\u65e5\u671f\u8a08\u7b97\u4e4b\u6b63\u78ba\u9593\u9694\u6642\u8ddd\u70ba\u57fa\u6e96\uff0c\u4ee5\u9a57\u8b49\u8a72\u66ff\u4ee3\u4f30\u8a08\u503c\u3002\u7d50\u679c\uff1a\u6839\u64da ICD-9\u8a3a\u65b7\u78bc\uff0c1,527\u4f8b\u500b\u6848\u88ab\u5b9a\u7fa9\u70ba\u60e1\u6027\u8166\u7624\u8a3a\u65b7\u3002\u5176\u4e2d394\u4f8b\u500b\u6848\u56e0\u5b58\u5728\u5176\u4ed6\u764c\u75c7\u8a3a\u65b7\u800c\u88ab\u6392\u9664\u3002\u5728\u5269\u9918\u76841,133\u4f8b\u500b\u6848\u4e2d\uff0c463\u4f8b\u63a5\u53d7\u8166\u7624\u5207\u9664\u624b\u8853\u4f75\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u7684\u500b\u6848\u88ab\u5206\u6790\u3002\u624b\u8853\u8207\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u9593\u9694\u6642\u8ddd\u4e4b\u66ff\u4ee3\u4f30\u8a08\u503c\u8207\u6b63\u78ba\u503c\u9593\u7684\u76f8\u95dc\u6027\u4f73\uff0c\u659c\u7387\u70ba1.0076\uff0cR^2\u7b49\u65bc0.8633\u4e14y\u622a\u8ddd\u63a5\u8fd1-1\u3002\u85c9\u7531\u6392\u9664\u9593\u9694\u6642\u8ddd\u5c0f\u65bc\u6216\u7b49\u65bc 0\u4e4b\u500b\u6848\uff0c\u672c\u4f30\u8a08\u65b9\u6cd5\u53ef\u9032\u4e00\u6b65\u6700\u4f73\u5316\u81f3R^2\u7b49\u65bc0.9809\u800c\u659c\u7387\u70ba0.9951\u4e14y\u622a\u8ddd\u63a5\u8fd15\u3002\u7d50\u8ad6\uff1a\u6211\u5011\u63d0\u51fa\u4e86\u624b\u8853\u8207\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u9593\u9694\u6642\u8ddd\u4e4b\u66ff\u4ee3\u4f30\u8a08\u65b9\u6cd5\u4e26\u9a57\u8b49\u4e4b\u3002\u6b64\u7814\u7a76\u63d0\u4f9b\u4e00\u53ef\u80fd\u65b9\u6cd5\uff0c\u7528\u4ee5\u514b\u670d2011\u5e741\u67081\u65e5\u524d\u5168\u6c11\u5065\u5eb7\u4fdd\u96aa\u8cc7\u6599\u65e5\u671f\u8cc7\u8a0a\u4e0d\u5145\u5206\u6240\u9020\u6210\u7684\u9650\u5236\uff0c\u4f7f\u5f97\u5728\u9032\u884c\u624b\u8853\u8207\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u9593\u9694\u6642\u8ddd\u5c0d\u764c\u75c7\u9810\u5f8c\u5f71\u97ff\u7684\u76f8\u95dc\u7814\u7a76\u6642\uff0c\u53ef\u4ee5\u5145\u5206\u5229\u7528\u885b\u751f\u798f\u5229\u8cc7\u6599\u5eab\u4e2d\u5927\u591a\u6578\u7684\u5168\u6c11\u5065\u5eb7\u4fdd\u96aa\u8cc7\u6599\u9032\u884c\u8f03\u5927\u898f\u6a21\u7684\u7814\u7a76\u3002", "e": "Purpose : The date of surgery or radiotherapy (RT) was not recorded in the National Health Insurance database until Jan. 1, 2011, which limits the calculation of the exact time interval between treatments. Our purpose is to formulate and validate a surrogate estimate for the time interval between surgery and adjuvant RT. Materials and Methods: Information of patients with malignant brain tumors diagnosed and treated with surgery and adjuvant RT between Jan. 1, 2011 and Dec. 31, 2012 was obtained from the National Health Insurance (NHI) database and retrospectively analyzed. The surrogate estimate for the interval between surgery and RT was formulated according to the date of outpatient visits and the first date of hospitalization. Surrogate estimate of the interval was validated with the exact interval calculated by the later coded dates of surgery and RT from the database, using the best-fitting linear regression. Results: 1,527 cases of malignant brain tumors were defined according to ICD-9 diagnosis code. 394 cases were excluded for the presence of other cancer diagnoses. Among the remaining 1,133 cases, 463 cases receiving both brain tumor excision and adjuvant RT were analyzed. Surrogate estimate of time intervals and exact time intervals correlate well with a slope of 1.0076, a y-intercept close to -1 day, and an R2 of 0.8633. The calculation is further improved to an R2 of 0.9809 with a slope of 0.9951 and a y-intercept close to 5 days, by excluding cases with surrogate estimates of an interval smaller or equal to 0. Conclusion: Our validated surrogate estimate of the interval between surgery and adjuvant RT provides a possible method to overcome the limitation of inadequate date information before Jan. 1, 2011, and therefore enables the application of most of the data from the Health and Welfare Database for research regarding the effect of RT delay on cancer outcomes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-107-114", "title": "\u81e8\u5e8a\u78c1\u632f\u5c0e\u822a\u805a\u7126\u8d85\u97f3\u6ce2\u7cfb\u7d71\u7684\u4f4d\u7f6e\u7a69\u5b9a\u6027\u5206\u6790\uff1a\u4e00\u5e74\u7684\u7d93\u9a57", "keywords": "\u78c1\u632f\u5c0e\u822a\u805a\u7126\u8d85\u97f3\u6ce2\u71b1\u6cbb\u7642;\u65e5\u5e38\u54c1\u8cea\u78ba\u4fdd;\u4f4d\u7f6e\u7a69\u5b9a\u6027 MRI-guided focused ultrasound surgery (MRgFUS);Daily Quality Assurance (DQA);Position stability", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u4ecb\u7d39\u8d85\u97f3\u6ce2\u71b1\u6cbb\u7642\u5100\uff0c\u61c9\u7528\u65bc\u9aa8\u8f49\u79fb\u75bc\u75db\u6240\u9700\u4e4b\u76f8\u95dc\u8a2d\u5099\uff0c\u5206\u4eab\u8d85\u97f3\u6ce2\u805a\u7126\u4f4d\u7f6e\u6821\u6b63\u7a0b\u5e8f\u7b49\u7d93\u9a57\uff0c\u4e26\u6839\u64da\u76ee\u524d\u5df2\u57f7\u884c\u4e4b\u6848\u4f8b\uff0c\u63d0\u4f9b\u6821\u6b63\u6578\u64da\u7684\u6a19\u6e96\u8207\u5efa\u8b70\u5bb9\u8a31\u503c\u3002\u76fc\u80fd\u85c9\u6b64\u7d93\u9a57\u5efa\u7acb\u9a57\u8b49\u8d85\u97f3\u6ce2\u805a\u7126\u4f4d\u7f6e\u6e96\u78ba\u6027\u4e4b\u4f5c\u696d\u7a0b\u5e8f\uff0c\u4ee5\u63d0\u4f9b\u75c5\u60a3\u66f4\u5177\u54c1\u8cea\u7684\u6cbb\u7642\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7bc7\u7814\u7a76\u4f7f\u7528\u65bc\u81fa\u5317\u91ab\u5b78\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u6240\u6536\u96c6\u768431\u500b\u6848\u4f8b\u4e4b\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\uff08Daily Quality Assurance, DQA\uff09\u8cc7\u6599\uff0c\u4e26\u6bd4\u8f03\u5176\u5728\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\u524d\u5f8c\uff0c\u8d85\u97f3\u6ce2\u805a\u7126\u9ede\u8207\u6b63\u78ba\u5347\u6eab\u9ede\u9593\u7684\u5dee\u8ddd\u3002\u78c1\u632f\u5c0e\u822a\u8d85\u97f3\u6ce2\u71b1\u6cbb\u7642\uff0c\u662f\u5229\u7528\u6838\u78c1\u5171\u632f\u5f71\u50cf\u5b9a\u4f4d\u8f49\u79fb\u6027\u9aa8\u816b\u7624\u4f4d\u7f6e\uff0c\u642d\u914d\u8d85\u97f3\u6ce2\u805a\u7126\u52a0\u71b1\u6280\u8853\uff0c\u4f7f\u8d85\u97f3\u6ce2\u5c07\u80fd\u91cf\u50b3\u9054\u5230\u9aa8\u982d\u75bc\u75db\u5340\u57df\uff0c\u52a0\u71b1\u81f360\u2103\u4ee5\u4e0a\uff0c\u4ee5\u71b1\u6d88\u878d\u7834\u58de\u9aa8\u982d\u75db\u695a\u8868\u9762\u4e4b\u611f\u89ba\u795e\u7d93\uff0c\u9054\u5230\u75bc\u75db\u63a7\u5236\u7684\u76ee\u7684\u3002\u6b64\u4e00\u6cbb\u7642\u65b9\u5f0f\u7684\u4e3b\u8981\u512a\u9ede\u70ba\u975e\u4fb5\u5165\u6027\u3001\u975e\u8f3b\u5c04\u7dda\u7684\u55ae\u6b21\u7642\u7a0b\u5373\u53ef\u9054\u6210\u6301\u4e45\u6027\u7684\u75bc\u75db\u7de9\u89e3\u3002\u7d50\u679c\uff1a\u7814\u7a76\u986f\u793a\u7d93\u904e\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\u7a0b\u5e8f\uff0c\u53ef\u4ee5\u6709\u6548\u7684\u6e1b\u5c11\u805a\u7126\u9ede\u8207\u6b63\u78ba\u6eab\u5ea6\u9ede\u4e4b\u5dee\u8ddd\uff0c\u5176p-value\u7686\uff1c0.01\uff0c\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u986f\u8457\u5dee\u7570\uff0c\u4e1495%\u4fe1\u8cf4\u5340\u9593\u75311.73\u00b10.43 mm\u964d\u70ba0.43\u00b10.12 mm\u3002\u7d50\u8ad6\uff1a\u7e3d\u7d50\u4e0a\u8ff0\u7d93\u9a57\u53ef\u77e5\u9032\u884c\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\uff0c\u53ef\u4fdd\u8b49\u6cbb\u7642\u7684\u6e96\u78ba\u6027\u8207\u5b89\u5168\u6027\uff0c\u4e14\u805a\u7126\u9ede\u8207\u6b63\u78ba\u5347\u6eab\u9ede\u7684\u8aa4\u5dee\u53ef\u4ee5\u660e\u986f\u7684\u6e1b\u5c11\u3002\u6545\u5728\u57f7\u884c\u78c1\u632f\u5c0e\u822a\u805a\u7126\u8d85\u97f3\u6ce2\u71b1\u6cbb\u7642\u7684\u6bcf\u65e5\u54c1\u8cea\u4fdd\u8b49\u7a0b\u5e8f\u6642\uff0c\u5efa\u8b70\u8981\u505a\u5230\u4f7f\u805a\u7126\u9ede\u8207\u6b63\u78ba\u6eab\u5ea6\u9ede\u7684\u5dee\u8ddd\u5c0f\u65bc1 mm\uff0c\u53ef\u5927\u5e45\u63d0\u9ad8\u6cbb\u7642\u6642\u7684\u7cbe\u78ba\u5ea6\u3002", "e": "Purpose : We developed a quality assurance protocol for treating painful bone metastasis with a Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) system. The system delivers ultrasonic energy to heat the MR-delineated metastatic bone target up to 60 degrees Celsius and ablate periosteal nerve fibers for sustained pain control. In this protocol, equipments, calibration procedures, and recommended tolerance are reported. Materials and Methods : In this research, we measured sonication-induced temperature change in a homogenous phantom before and after Daily Quality Assurance (DQA) procedure performed in thirty-one treatment sessions in a single institute. Distances between ultrasonic focus and the spot with highest temperature (Focusing Error, FE) in the phantom were measured with magnetic resonance thermography. Result : DQA procedure effectively decrease FE (Pre-DQA group: 1.73\u00b10.43 mm, DQA group: 0.43\u00b10.12 mm, p-value\uff1c0.01). Discussion : A comprehensive DQA procedure decreases focusing error and therefore guarantees treatment accuracy. It may translate into better patient safety and avoid unplanned heating of adjacent critical structures. We recommend that a FE of less than 1 mm should be achieved with DQA procedure before starting a MRgFUS treatment session."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-115-122", "title": "\u4f7f\u7528CIRS\u6210\u4eba\u5047\u9ad4\u8207\u91d1\u6c27\u534a\u5834\u6548\u96fb\u6676\u9ad4\u8a55\u4f30\u4e73\u764c\u75c5\u60a3\u4f7f\u7528\u7167\u91ce\u4e2d\u7167\u91ce\u6cbb\u7642\u6280\u8853\u8207\u6df7\u5408\u5f37\u5ea6\u63a7\u6cbb\u7642\u6280\u8853\u5291\u91cf\u7684\u5dee\u7570\u6027", "keywords": "\u91d1\u6c27\u534a\u5834\u6548\u96fb\u6676\u9ad4\u5291\u91cf\u8a08;\u7167\u91ce\u4e2d\u7167\u91ce\u653e\u5c04\u6cbb\u7642;\u6df7\u5408\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Metal Oxide Semiconductor Field Effect Transistor dosimeters (MOSFET);Field-infield radiotherapy;Hybrid-intensity modulated radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u524d\u77bb\u6027\u4e4b\u7814\u7a76\uff0c\u4e3b\u8981\u5229\u7528CIRS\u6210\u4eba\u5047\u9ad4\u8207\u91d1\u6c27\u534a\u5834\u6548\u96fb\u6676\u9ad4\uff08MOSFET\uff09\u5291\u91cf\u8a08\uff0c\u53bb\u8a55\u4f30\u4e73\u764c\u75c5\u60a3\u4f7f\u7528\u5169\u4e0d\u540c\u6cbb\u7642\u8a08\u5283\u65b9\u5f0f\uff0c\u5176\u8868\u9762\u5291\u91cf\u8207\u5167\u90e8\u5291\u91cf\u7684\u5dee\u7570\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4f7f\u7528MOSFET\u5291\u91cf\u8a08\u4f5c\u70ba\u5291\u91cf\u91cf\u6e2c\u5de5\u5177\uff0c\u4e26\u5229\u7528CIRS\u5047\u9ad4\u8207\u4e73\u623f\u5047\u9ad4\u4f86\u6a21\u64ec\u771f\u5be6\u4e73\u764c\u75c5\u60a3\u3002\u5728\u53d6\u5f97\u5047\u9ad4\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\u5f71\u50cf\u5f8c\uff0c\u5c07\u5f71\u50cf\u50b3\u81f3\u8a08\u5283\u7cfb\u7d71\u88fd\u4f5c\u7167\u91ce\u4e2d\u7167\u91ce\uff08Field in Field, FIF\uff09\u8207\u6df7\u5408\u5f37\u5ea6\u8abf\u63a7\uff08Hybrid-IMRT\uff09\u6cbb\u7642\u8a08\u5283\uff0c\u518d\u5229\u7528\u76f4\u7dda\u52a0\u901f\u5668\u6536\u96c6MOSFET\u5291\u91cf\u8a08\u6240\u91cf\u6e2c\u7684\u5291\u91cf\u6578\u64da\uff0c\u4e5f\u540c\u6642\u6536\u96c6\u8a08\u5283\u7cfb\u7d71\u4e0a\u7684\u5291\u91cf\u6578\u64da\uff0c\u518d\u91dd\u5c0d\u6536\u96c6\u5230\u7684\u6578\u64da\u7d50\u679c\u4f5c\u6bd4\u8f03\u3002\u7d50\u679c\uff1a\u8868\u9762\u5291\u91cf\u6e2c\u91cf\u9ede1~20\u6578\u64da\u7d50\u679c\u5728\u55ae\u6b21\u8655\u65b9\u5291\u91cf\u70ba180 cGy\u6642\uff0cFIF\u6578\u503c\u5e73\u5747\u70ba142.8 \u00b1 2.74 cGy\uff0cHybrid-IMRT\u7684\u6578\u503c\u5e73\u5747\u70ba136.3 \u00b1 1.98 cGy\uff0c\u5167\u90e8\u5291\u91cf\u6e2c\u91cf\u9ede\u6578\u64da\u7d50\u679c\u986f\u793a\uff0cFIF\u76845\u500b\u6e2c\u91cf\u9ede\u5291\u91cf\u5e73\u5747\u503c\u70ba202.3 \u00b1 2.01 cGy\uff0cHybrid-IMRT\u76845\u500b\u6e2c\u91cf\u9ede\u5291\u91cf\u5e73\u5747\u503c\u70ba194.3 \u00b1 2.64 cGy\uff0c\u53e6\u4e00\u65b9\u9762\uff0c\u5728\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u4e0a\uff0c\u6240\u5f97\u5230\u7684\u6578\u64da\u7d50\u679c\u986f\u793aFIF\u5e73\u5747\u5291\u91cf\u70ba195.5 \u00b1 9.7 cGy\uff0cHybrid-IMRT\u5e73\u5747\u5291\u91cf\u70ba187.6 \u00b1 5.7 cGy\uff0cFIF V_(95)\u70ba97.5%\uff0cHybrid-IMRT V_(95)\u70ba97.9%\uff0cFIF\u6b63\u5e38\u80ba\u90e8\u7d44\u7e54\u5291\u91cfV_5\u70ba0.84%\uff0cHybrid-IMRT \u6b63\u5e38\u80ba\u90e8\u7d44\u7e54\u5291\u91cfV_5\u70ba4.13%\uff0cFIF 110%\u9ad8\u5291\u91cf\u5340\u57df\u7684\u9ad4\u7a4d\u70ba107 cm^3\uff0cHybrid-IMRT 110%\u9ad8\u5291\u91cf\u5340\u57df\u7684\u9ad4\u7a4d\u70ba0.8 cm^3\uff0c\u6b64\u5916\uff0c\u7531\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u986f\u793a\uff0c\u8868\u9762\u5291\u91cf\u6e2c\u91cf\u9ede1~20\u6578\u64da\u7684\u7d50\u679c\uff0cFIF\u7684\u6578\u503c\u5e73\u5747\u70ba117.1 \u00b1 8.1 cGy\uff0c\u800cHybrid-IMRT\u7684\u6578\u503c\u5e73\u5747\u70ba113.5 \u00b1 7.9 cGy\uff0c\u5167\u90e8\u5291\u91cf\u6e2c\u91cf\u9ede\u6578\u64da\uff0c\u7d50\u679c\u5247\u986f\u793aFIF\u76845\u500b\u6e2c\u91cf\u9ede\u5291\u91cf\u5e73\u5747\u503c\u70ba202.3 \u00b1 0.37 cGy\uff0c\u800cHybrid-IMRT\u76845\u500b\u6e2c\u91cf\u9ede\u5291\u91cf\u5e73\u5747\u503c\u70ba189.7 \u00b1 0.15 cGy\u3002\u7d50\u8ad6\uff1a\u7531\u672c\u5be6\u9a57\u5f97\u77e5Hybrid-IMRT\u6bd4\u8d77FIF\u7684\u65b9\u5f0f\u53ef\u4ee5\u6539\u5584\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u8f03\u4f4e\u4e4b\u8868\u9762\u5291\u91cf\u53ef\u4f7f\u75c5\u60a3\u5728\u6cbb\u7642\u904e\u7a0b\u7576\u4e2d\u80fd\u6709\u8f03\u8f15\u5fae\u7684\u76ae\u819a\u53cd\u61c9\uff0c\u53e6\u5916\u505a\u8a08\u5283\u6240\u9700\u6642\u9593\u4e5f\u8f03\u77ed\uff0c\u5c0d\u81e8\u5e8a\u7269\u7406\u5e2b\u800c\u8a00\u662f\u8f03\u6709\u6548\u7387\u7684\u8a08\u5283\u65b9\u5f0f\u3002", "e": "Purpose : This prospective study used the Computed Imaging Reference System (CIRS) phantom and Metal Oxide Semiconductor Field Effect Transistor (MOSFET) dosimeters to evaluate internal dose and surface dose differences between two different types of treatment plans in radiotherapy for breast cancer patients. Materials and Methods : In this study, we used MOSFET dosimeters as a measurement tool. To simulate the real breast cancer patients, we used CIRS phantom to make prosthesis. After CT simulation, images were transmitted to the Pinnacle planning system, and then field-in-field (FIF) and hybridintensity modulated radiotherapy (IMRT) treatment plans were conducted. Irradiation through a linear accelerator to collect dose data by MOSFET dosimeters. The dose data calculated by the Pinnacle planning system were also collected. We compared the dosimetry differences between FIF and hybrid- IMRT techniques. Result : The mean measured surface dose from 1 to 20 points, in a single dose of prescription 180 cGy, was 142.8 \u00b1 2.74 cGy and 136.3 \u00b1 1.98 cGy for FIF and Hybrid-IMRT technique, respectively. The mean measured internal dose from 5 internal dose points was 202.3 \u00b1 2.01 cGy and 194.3 \u00b1 2.64 cGy for FIF and Hybrid-IMRT technique, respectively. On the other hand, treatment planning system revealed that the mean dose for FIF and Hybrid-IMRT technique was 195.5 \u00b1 9.7 cGy and 187.6 \u00b1 5.7 cGy, respectively. The V95 for FIF and Hybrid-IMRT technique was 97.5% and 97.9%, respectively. Normal lung tissue dose V5 for FIF and Hybrid-IMRT technique was 0.84% and 4.13%, respectively. The 110% volume of high-dose region for FIF and Hybrid-IMRT technique was 107 cm^3 and 0.8 cm^3, respectively. In addition, treatment planning system showed that the mean surface dose of 1 to 20 points was 117.1 \u00b1 8.1 cGy and 113.5 \u00b1 7.9 cGy for FIF and Hybrid-IMRT technique, respectively; the mean internal dose of five measurement points FIF dose was 202.3 \u00b1 0.37 cGy and 189.7 \u00b1 0.15 cGy for FIF and Hybrid-IMRT technique, respectively. Conclusions : Our study suggested that compared to FIF, Hybrid-IMRT technique can improve dose uniformity and decrease surface dose, and lower skin reactions can be expected. Furthermore, shorter time is required for Hybrid-IMRT plan, which is more efficient in terms of the program approach."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-123-128", "title": "\u5229\u7528\u540c\u6b65\u5316\u653e\u7642\u6cbb\u7642\u98df\u9053\u985e\u6dcb\u5df4\u4e0a\u76ae\u764c\uff0d\u75c5\u4f8b\u5831\u544a", "keywords": "\u6dcb\u5df4\u4e0a\u76ae\u764c;EB\u75c5\u6bd2;\u98df\u9053;\u540c\u6b65\u5316\u653e\u7642 Lymphoepithelioma;Epstein-Barr virus;Esophagus;Concurrent chemoradiotherapy", "c": "\u539f\u767c\u6027\u98df\u9053\u985e\u6dcb\u5df4\u4e0a\u76ae\u764c\uff08LELC\uff09\u662f\u4e00\u7a2e\u975e\u5e38\u7f55\u898b\u7684\u75be\u75c5\uff0c\u5728\u91ab\u5b78\u6587\u737b\u53ea\u670929\u4f8b\u5831\u5c0e\u7684\u6848\u4f8b\u3002\u6b64\u816b\u7624\u7684\u7279\u5fb5\u662f\u672a\u5206\u5316\u7d30\u80de\u6df7\u5408\u6709\u7dfb\u5bc6\u7684\u6dcb\u5df4\u7d30\u80de\u6d78\u6f64\uff0c\u5728\u591a\u6578\u6587\u737b\u5831\u544a\u4e2d\u6307\u51fa\u548cEBV\u7684DNA\u76f8\u95dc\u3002\u5728\u672c\u7bc7\u5831\u544a\u4e2d\u63d0\u51fa\u4e00\u540d52\u6b72\u7684\u7537\u6027\u60a3\u8005\u88ab\u8a3a\u65b7\u70ba\u7b2c\u56db\u671f\uff08cT3N2M1\uff09\u98df\u9053\u4e2d\u4e0b\u6bb5LELC\uff0c\u5230\u9662\u6642\u4e3b\u8a34\u67093\u500b\u661f\u671f\u7684\u6642\u9593\u541e\u56a5\u56f0\u96e3\u3002\u8a72\u60a3\u8005\u5229\u7528\u540c\u6b65\u5316\u7642\u548c\u653e\u5c04\u6cbb\u7642\uff08CCRT\uff09\u6cbb\u7642\u6210\u529f\u3002\u6cbb\u7642\u5f8c12\u500b\u6708\u5c0d\u98df\u9053\u518d\u9032\u884c\u4e00\u6b21\u5207\u7247\u986f\u793a\u816b\u7624\u5b8c\u5168\u7de9\u89e3\uff0c\u8ffd\u8e6424\u500b\u6708\u75c5\u60a3\u4ecd\u7136\u5b58\u6d3b\u4e14\u6c92\u6709\u5fa9\u767c\uff0c\u76ee\u524d\u4ecd\u7e7c\u7e8c\u9580\u8a3a\u8ffd\u8e64\u3002", "e": "Primary lymphoepithelioma like carcinoma (LELC) of the esophagus is a very rare disease; only 29 cases were reported in the medical literature. This type of tumor is characterized by undifferentiated cells mixed with dense lymphocytic infiltration. Here we would like to present a 52 year old male patient who was diagnosed with stage IV (cT3N2M1) LELC of the middle to lower esophagus. The patient's chief complaint was dysphagia of 3 weeks duration. The patient was successfully treated with concurrent chemotherapy (PF4 regimen) and radiotherapy (5040 cGy). A repeat esophageal biopsy done 12 months after concurrent chemoradiation therapy (CCRT) revealed no evidence of tumor. This patient is alive and disease-free 24 months after CCRT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-129-135", "title": "CARCINOSARCOMA EX PLEOMORPHIC ADENOMA OF THE PAROTID GLAND: A CASE REPORT", "keywords": "\u4e0a\u76ae\u8089\u7624;\u591a\u578b\u6027\u817a\u7624;\u816e\u817a;\u653e\u5c04\u7dda\u6cbb\u7642 Carcinosarcoma;Pleomorphic adenoma;Parotid gland;Radiotherapy", "c": "\u816e\u817a\u7684\u591a\u5f62\u6027\u817a\u7624\u662f\u553e\u6db2\u817a\u4e2d\u6700\u5e38\u898b\u7684\u826f\u6027\u816b\u7624\uff0c\u5176\u4e2d\u6709\u975e\u5e38\u5c11\u6578\u6703\u8f49\u8b8a\u70ba\u60e1\u6027\u816b\u7624\uff0c\u800c\u8f49\u8b8a\u70ba\u60e1\u6027\u816b\u7624\u4e2d\uff0c\u8f49\u5316\u70ba\u4e0a\u76ae\u8089\u7624\u662f\u975e\u5e38\u7f55\u898b\u7684\u6848\u4f8b\u3002\u4e0a\u76ae\u8089\u7624\u9867\u540d\u601d\u7fa9\u662f\u540c\u6642\u5177\u5099\u4e0a\u76ae\u764c\uff0c\u4ee5\u53ca\u8089\u7624\u7684\u7279\u5fb5\u3002\u5728\u904e\u53bb\u6587\u737b\u5831\u5c0e\u4e2d\u500b\u6848\u6578\u76f8\u7576\u4f4e\uff0c\u4e26\u4e14\u6c92\u6709\u4e00\u81f4\u7684\u6cbb\u7642\u65b9\u91dd\u3002\u624b\u8853\u5207\u9664\u4ecd\u662f\u76ee\u524d\u6cbb\u7642\u7684\u4e3b\u8981\u65b9\u5f0f\uff0c\u800c\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5247\u53ef\u4ee5\u589e\u9032\u5176\u5c40\u90e8\u63a7\u5236\u7387\u3002\u672c\u7bc7\u75c5\u6b77\u5831\u544a\u63d0\u51fa\u4e00\u4f4d45\u6b72\u7537\u6027\uff0c\u5728\u63a5\u53d7\u5169\u6b21\u5207\u9664\u53f3\u5074\u816e\u817a\u591a\u578b\u6027\u817a\u7624\u4e4b\u5f8c\uff0c\u5fa9\u767c\u4e86\u591a\u578b\u6027\u817a\u7624\u5408\u4f75\u4e0a\u76ae\u8089\u7624\u3002\u6211\u5011\u7d66\u4e88\u624b\u8853\u8868\u6dfa\u816e\u817a\u5207\u9664\u4e4b\u5f8c\uff0c\u8853\u5f8c\u57f7\u884c\u4e86\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f7f\u7528\u6bcf\u5468cisplatin\u7684\u8f38\u6ce8\u4ee5\u53ca66 Gy\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u75c5\u4eba\u8ffd\u8e6430\u5468\uff0c\u60c5\u6cc1\u826f\u597d\uff0c\u6c92\u6709\u5fa9\u767c\u6216\u8f49\u79fb\u7684\u73fe\u8c61\u3002", "e": "Pleomorphic adenoma of the parotid gland is the most common tumor of the salivary glands. Although very rare, this tumor can undergo malignant transformation, resulting in carcinosarcoma ex pleomorphic adenoma, which possesses the characteristics of both carcinoma and sarcoma. In the literature, the number of such cases is very low and the treatment outcomes are varied. Surgery remains the primary local treatment. Radiotherapy may be added to enhance local-regional control. Here, we present a 45-year-old male who underwent surgical removal of pleomorphic adenoma of the right parotid gland twice. He was eventually diagnosed with carcinosarcoma ex pleomorphic adenoma. Treatment consisted of superficial parotidectomy and adjuvant concurrent chemoradiation with weekly cisplatin and a radiation dose of 66 Gy. After 30 weeks of follow-up, no disease recurrence or distant metastasis was observed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201606-201608040002-201608040002-137-143", "title": "THE ESSENTIAL ROLE OF TOTAL NEURO-AXIS SURVEY IN A MEDULLOBLASTOMA PATIENT WITH POSTOPERATIVE QUADRIPLEGIA: A CASE REPORT", "keywords": "\u9ad3\u6bcd\u7d30\u80de\u7624;\u56db\u80a2\u7671\u7613;\u653e\u5c04\u6cbb\u7642 Medulloblastoma;Quadriplegia;Radiotherapy", "c": "\u9ad3\u6bcd\u7d30\u80de\u7624\u5927\u90e8\u5206\u9577\u81ea\u9871\u5f8c\u7aa9\uff0c\u7d04\u4f5415%-20%\u7684\u5152\u7ae5\u4e2d\u6a1e\u6027\u795e\u7d93\u816b\u7624\u3002\u624b\u8853\u662f\u9ad3\u6bcd\u7d30\u80de\u7624\u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\u3002\u81e8\u5e8a\u4e0a\uff0c\u624b\u8853\u5f8c\u767c\u751f\u56db\u80a2\u7671\u7613\u7684\u60c5\u6cc1\u975e\u5e38\u5c11\u898b\u3002\u672c\u6587\u5831\u544a\u4e00\u4f4d\u65bc\u8853\u5f8c\u767c\u751f\u56db\u80a2\u7671\u7613\u7684\u9ad3\u6bcd\u7d30\u80de\u7624\u75c5\u60a3\uff0c\u4e00\u958b\u59cb\u6b64\u60c5\u6cc1\u88ab\u8a8d\u70ba\u662f\u7121\u6cd5\u6cbb\u7652\u7684\u8853\u5f8c\u75c5\u767c\u75c7\u3002\u7136\u800c\u5728\u8a73\u7d30\u7684\u5f71\u50cf\u5224\u8b80\u5f8c\uff0c\u6211\u5011\u65bcT2W\u6838\u78c1\u5171\u632f\u5f71\u50cf\u4e0a\u770b\u5230\u7b2c6\u7bc0\u9838\u690e\u6709\u90e8\u5206\u7684\u8a0a\u865f\u589e\u52a0\uff0c\u7121\u6cd5\u5b8c\u5168\u6392\u9664\u816b\u7624\u6d78\u6f64\u7684\u53ef\u80fd\u6027\u3002\u5728\u8207\u75c5\u4eba\u7684\u5bb6\u5c6c\u8a73\u7d30\u8a0e\u8ad6\u6cbb\u7642\u7684\u597d\u8655\u53ca\u58de\u8655\u5f8c\uff0c\u75c5\u4eba\u63a5\u53d7\u4e86\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u5728\u6cbb\u7642\u5f8c\u81e8\u5e8a\u75c7\u72c0\u5f97\u5230\u986f\u8457\u5730\u6539\u5584\u3002\u6b64\u75c5\u4f8b\u63d0\u9192\u6211\u5011\u5728\u5408\u4f75\u6709\u816b\u7624\u76f8\u95dc\u795e\u7d93\u5b78\u75c7\u72c0\u7684\u9ad3\u6bcd\u7d30\u80de\u7624\u75c5\u4eba\u8eab\u4e0a\uff0c\u653e\u5c04\u6cbb\u7642\u626e\u6f14\u4e86\u91cd\u8981\u7684\u89d2\u8272\u3002", "e": "Medulloblastoma, mainly arising from the posterior cranial fossa, accounts for 15%-20% of pediatric central nerve system (CNS) tumors. Surgical resection is the major treatment modality used to manage medulloblastoma. Clinically, very few patients develop quadriplegia after surgery. We report a case of medulloblastoma patient developing quadriplegia postoperatively which was initially thought to be secondary to surgery but was later found to due to leptomeningeal carcinomatosis of the cervical spine. Postoperative radiotherapy significantly improved the patient's symptoms. The positive outcome in this patient is a reminder of the pivotal role radiotherapy plays in the management of cancer-related neurologic dysfunction in medulloblastoma patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-1-11", "title": "ANALYSIS OF PROGNOSTIC FACTORS OF ORAL CAVITY SQUAMOUS CELL CARCINOMA PATIENTS RECEIVING SURGERY", "keywords": "\u53e3\u8154\u9c57\u72c0\u4e0a\u76ae\u764c;\u9810\u5f8c\u56e0\u5b50;\u624b\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u6cbb\u7642;\u5c40\u90e8\u63a7\u5236\u7387;\u7e3d\u9ad4\u5b58\u6d3b\u7387;\u7121\u75c5\u5b58\u6d3b\u7387 Oral cavity squamous cell carcinoma;Prognostic factor;Adjuvant radiation therapy;Locoregional control rate;Overall survival rate;Disease-free survival rate", "c": "\u76ee\u7684\uff1a\u53e3\u8154\u9c57\u72c0\u4e0a\u76ae\u764c\u7684\u75c5\u4eba\u5728\u8853\u5f8c\u5982\u679c\u767c\u73fe\u5b58\u5728\u4e00\u4e9b\u4e0d\u597d\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u88ab\u5efa\u8b70\u8981\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u6216\u662f\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c\u624b\u8853\u5207\u9664\u7684\u908a\u7de3\u6709\u816b\u7624\u7d30\u80de\u548c\u6dcb\u5df4\u7d50\u819c\u5916\u4fb5\u72af\u662f\u666e\u904d\u88ab\u8a8d\u53ef\u7684\u4e3b\u8981\u4e0d\u826f\u9810\u5f8c\u56e0\u5b50\uff0c\u9664\u6b64\u4e4b\u5916\uff0c\u76ee\u524d\u5c0d\u5176\u4ed6\u8f03\u6b21\u8981\u7684\u5371\u96aa\u56e0\u5b50\u4e26\u7121\u5171\u901a\u7684\u5b9a\u8ad6\u3002\u5728\u9019\u7bc7\u7814 \u7a76\u4e2d\uff0c\u6211\u5011\u8a66\u8457\u5206\u8fa8\u51fa\u6b21\u8981\u7684\u5371\u96aa\u56e0\u5b50\u4e26\u4e14\u63d0\u4f9b\u76f8\u5c0d\u61c9\u6cbb\u7642\u7684\u5efa\u8b70\u3002\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u672c\u7bc7\u56de\u6714\u6027\u6536\u9304\u4e86\u5f9e 2002\u5e741\u6708\u8d77\u81f3 2013\u5e7412\u6708\u6b62\uff0c567\u4f4d\u53e3\u8154\u9c57\u72c0\u4e0a\u76ae\u764c\u63a5\u53d7\u624b\u8853\u5168\u5207\u9664\u7684\u75c5\u4eba\u3002\u4ee5Kaplan-Meier\u5206\u6790\u6cd5\u5206\u6790\u4e94\u5e74\u816b\u7624\u5c40\u90e8\u63a7\u5236\u3001\u7121\u75c5\u5b58\u6d3b\u3001\u548c\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u7528\u55ae\u8b8a\u9805\u548c\u591a\u8b8a\u9805\u5206\u6790\u4ee5\u5206\u8fa8\u51fa\u6709\u95dc\u5c40\u90e8\u63a7\u5236\u3001\u7121\u75c5\u5b58\u6d3b\u3001\u548c\u6574\u9ad4\u5b58\u6d3b\u7387\u3002Cox\u56de\u6b78\u5206\u6790 \u6cd5\u70ba\u591a\u8b8a\u9805\u4e4b\u5206\u6790\u6cd5\u3002\u7d50\u679c\uff1a\u8ffd\u8e64\u671f\u4e2d\u4f4d\u6578\u70ba3.5\u5e74\uff080.2\u81f312.5\u5e74\uff09\uff0c\u75c5\u4eba\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba54\u6b72\uff0828\u81f379\u6b72\uff09\u3002\u5176\u4e94\u5e74\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387 I\u3001II\u3001III\u3001IVa\u3001IVb\u5404\u671f\u5225\u4f9d\u5e8f\u70ba79.7%\u300170.8%\u300165.8%\u300149.0%\u300117.7%\u3002\u5176\u4e94\u5e74\u4e4b\u7121\u75c5\u5b58\u6d3b\u7387I\u3001II\u3001III\u3001IVa\u3001IVb\u5404\u671f\u5225\u5206\u5225\u4f9d\u5e8f\u70ba 65.8%\u3001 63.8%\u300161.5%\u300139.9%\u3001 30.1%\u3002\u5176\u4e94\u5e74\u4e4b\u5c40\u90e8\u63a7\u5236\u7387I\u3001II\u3001III\u3001IVa\u3001IVb\u5404\u671f\u5225\u5206\u5225\u4f9d\u5e8f\u70ba 77.6%\u300177.6%\u300176%\u300167.8%\u300142.5%\u3002\u75c5\u7406\u671f\u5225\u3001\u816b\u7624\u4fb5\u72af\u6dcb\u5df4\u7d50\u3001\u6dcb\u5df4\u7d50\u819c\u5916\u4fb5\u72af\u3001\u816b\u7624\u4fb5\u72af\u6df1\u5ea6\u3001\u6dcb\u5df4\u548c\u795e\u7d93 \u5468\u570d\u7684\u4fb5\u72af\u3001\u816b\u7624\u5206\u5316\u7a0b\u5ea6\u7686\u70ba\u4e94\u5e74\u816b\u7624\u5c40\u90e8\u63a7\u5236\u3001\u7121\u75c5\u5b58\u6d3b\u3001\u548c\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6b64\u5916\uff0c\u5e74\u9f61\u548c\u6cbb\u7642\u65b9\u5f0f\u662f\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5e74\u9f61\u3001\u65e5\u5e38\u9ad4\u80fd\u72c0\u614b\u3001\u8840\u7ba1\u5468\u570d\u4fb5\u72af\u3001\u6cbb\u7642\u65b9\u5f0f\u70ba\u4e94\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u6263\u9664\u624b\u8853\u5207\u7de3\u6709\u816b\u7624\u7d30\u80de\u548c\u6dcb\u5df4\u7d50\u819c\u5916\u4fb5\u72af\u7684\u75c5\u4eba\uff0c\u5206\u6790\u542b\u6709\u4ee5\u4e0a\u7684\u5176\u4ed6\u6b21\u8981\u98a8\u96aa\u56e0\u5b50\u4e2d\u5169\u7a2e\u4ee5\u4e0a\u7684\u75c5\u4eba\u5171\u6709203\u4f4d\uff0c\u5728\u63a5\u53d7\u8853\u5f8c\u81f3\u5c1160 Gy\u7684\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u6709\u610f\u7fa9\u7684\u63d0\u5347\u75c5\u4eba\u7684\u4e94\u5e74\u816b\u7624\u5c40\u90e8\u63a7\u5236\uff0876.2% v.s 68.6%, p= 0.027\uff09\u3001\u7121\u75c5\u5b58\u6d3b\uff0856.1% v.s 44.1%, p= 0.05\uff09\u3001\u548c\u7e3d\u9ad4\u5b58\u6d3b\u7387\uff0863.9% v.s 50.4%, p= 0.021\uff09\u3002\u7d50\u8ad6\uff1a\u9664\u4e86\u624b\u8853\u5207\u7de3\u6709\u816b\u7624\u7d30\u80de\u548c\u6dcb\u5df4\u7d50\u819c\u5916\u4fb5\u72af\u4ee5\u5916\uff0c\u53e3\u8154\u9c57\u72c0\u4e0a\u76ae\u764c\u7684\u6b21\u8981\u9810\u5f8c\u4e0d\u4f73\u7684\u56e0\u5b50\u5305\u542b\u75c5\u7406\u671f\u5225T\u7b2c\u56db\u671f\u3001\u816b\u7624\u4fb5\u72af\u6dcb\u5df4\u7d50\u3001\u816b\u7624\u4fb5\u72af\u6df1\u5ea6\u4e00\u516c\u5206\u4ee5\u4e0a\u3001\u816b\u7624\u7d30\u80de\u8f03\u5dee\u7684\u5206\u5316\u3001\u548c\u6dcb\u5df4\u8840\u7ba1\u795e\u7d93\u5468\u570d\u7684\u4fb5\u72af\u3002\u6709\u81f3\u5c11\u5169\u9805\u6b21\u8981\u56e0\u5b50\u7684\u75c5\u4eba\u61c9\u8a72\u63a5\u53d7\u624b\u8853\u5f8c\u81f3\u5c1160 Gy\u4e4b\u653e\u5c04\u6cbb\u7642\u3002", "e": "Purpose : Patients with oral cavity squamous cell carcinoma (OSCC) undergoing surgery were recommended to receive adjuvant radiotherapy (RT) with or without chemotherapy if there are unfavorable prognostic factors. Positive surgical margin and extracapsular extension (ECE) of lymph node were well-known major prognostic factors and adjuvant concurrent chemoradiotherapy (CCRT) was suggested for patients with these factors. However, the managements of patients with other risk factors were still debatable. In this study, we tried to recognize the minor risk factors and provide adjuvant treatment suggestions. Materials and Methods : From January 2002 to December 2013, 567 OSCC patients receiving radical surgery were retrospectively reviewed. Five-year locoregional control (LRC), disease free survival (DFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. Univariate and multivariate analyses were used to identify the risk factors for LRC, DFS, and OS. Cox regression model was used for multivariate analyses. Results : The median follow-up time was 3.5 years (range: 0.2\u201312.5 years). The median age of the patients was 54 years old (range 28 to 79 years). The 5-year OS rate for stage I, II, III, IVa, IVb patients were 79.7%, 70.8%, 65.8%, 49.0%, and 17.7%, respectively. The 5-year DFS rate for stage I, II, III, IVa, IVb patients were 65.8%, 63.8%, 61.5%, 39.9% and 30.1%, respectively. The 5-year LRC rate for stage I, II, III, IVa, IVb patients were 77.6%, 77.6%, 76%, 67.8% and 42.5%, respectively. The pathological T-classification, pathological N-classification, ECE, pathological tumor depth, lymphatic invasion, perineural invasion, histology grading were prognostic factors for 5-year LRC, DFS and OS. Moreover, age and treatment modalities were prognostic factors for 5-year OS and age, performance status, vascular invasion and treatment modalities were prognostic factors for 5-year DFS, respectively. In subgroup analysis, 203 patients with at least two of poor prognostic factors and without positive margin nor ECE receiving RT with radiation dose at least 60 Gy showed better 5-year LRC (76.2% v.s 68.6%, p= 0.027) and DFS (56.1% v.s 44.1%, p= 0.05) and OS (63.9% v.s 50.4%, p= 0.021) than those without adjuvant RT or receiving RT with radiation dose less than 60 Gy. Conclusions : In addition to ECE and positive margin, pathological T-classification T4a/T4b, pathological positive node, pathological tumor depth \u2267 10 mm, lymphatic invasion, vascular invasion, perineural invasion and poorly differentiated grading were poor prognostic factors for LRC and survival outcomes for OSCC patients. Patients with two or more poor prognostic factors should receive radiotherapy with radiation dose at least 60 Gy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-13-20", "title": "PROGNOSTIC FACTORS AND OUTCOMES OF POSTOPERATIVE RADIOTHERAPY FOR MALIGNANT GLIOMAS: A SINGLE-INSTITUTION EXPERIENCE", "keywords": "\u653e\u5c04\u6cbb\u7642;\u672a\u5206\u5316\u6027\u661f\u72c0\u7d30\u80de\u7624;\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624 Radiotherapy;Anaplastic astrocytoma;Glioblastoma", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u60e1\u6027\u8166\u7624\u75c5\u60a3\u8853\u5f8c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u6210\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u9867\u81ea\u897f\u51432007\u5e744\u6708\u81f32014\u5e7410\u6708\u9593\uff0c\u56e0\u70ba\u60e1\u6027\u8166\u7624\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u3002\u75c5\u4eba\u4e4b\u81e8\u5e8a\u8868\u73fe\u3001\u624b\u8853\u5207\u9664\u72c0\u614b\u3001\u5f71\u50cf\u7279\u5fb5\u8207\u6574\u9ad4\u5b58\u6d3b\uff08overall survival\uff09\u90fd\u88ab\u6aa2\u8996\u8207\u5206\u6790\u3002\u7d50\u679c\uff1a\u517134\u4f4d\u75c5\u4eba\u88ab\u7d0d\u5165\u672c\u7814\u7a76\u3002\u5176\u4e2d13\u4f4d\u75c5\u4eba\uff0838%\uff09\u88ab\u8a3a\u65b7\u70ba\u672a\u5206\u5316\u6027\u661f\u72c0\u7d30\u80de\u7624\uff0c21\u4f4d\u75c5\u4eba\uff0862%\uff09\u88ab\u8a3a\u65b7\u70ba\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u3002\u8ffd\u8e64\u671f\u7684\u4e2d\u4f4d\u6578\u70ba14\u500b\u6708\uff08\u7bc4\u570d\u5f9e4\u523046\u500b\u6708\uff09\u3002\u5168\u90e8\u75c5\u4eba\u6574\u9ad4\u5b58\u6d3b\u7684\u4e2d\u4f4d\u6578\u70ba14.3\u500b\u6708\uff08\u7bc4\u570d\u5f9e3.8\u523045.7\u500b\u6708\uff09\u3002\u672a\u5206\u5316\u6027\u661f\u72c0\u7d30\u80de\u7624\u548c\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u4e4b\u6574\u9ad4\u5b58\u6d3b\u4e2d\u4f4d\u6578\u5206\u5225\u70ba15.2\u548c12.3\u500b\u6708\uff08p= 0.0355\uff09\u3002\u5728\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de \u7624\u7684\u75c5\u4eba\u7576\u4e2d\uff0c\u7b2c\u4e00\u7d44\u75c5\u60a3\uff08\u816b\u7624\u5207\u9664\u5927\u65bc50%\uff09\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u8f03\u7b2c\u4e8c\u7d44\u75c5\u60a3\uff08\u816b\u7624\u5207\u9664\u5c0f\u65bc50%\uff09\u70ba\u9ad8\uff08p=0.0225\uff09\u3002\u7d50\u8ad6\uff1a\u5176\u4ed6\u7d71\u8a08\u8cc7\u6599\u76f8\u6bd4\uff0c\u6211\u5011\u7684\u7814\u7a76\u7d50\u679c\u986f\u793a\uff1a\u91dd\u5c0d\u60e1\u6027\u8166\u7624\u75c5\u60a3\u7684\u6cbb\u7642\u6211\u5011\u6709\u76f8\u4f3c\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u800c\u624b\u8853\u5207\u9664\u816b\u7624\u7684\u7a0b\u5ea6\u5728\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u4e2d\u5360\u6709\u91cd\u8981\u7684\u89d2\u8272\u3002", "e": "Purpose : To investigate the prognostic factors and treatment outcomes of patients with malignant gliomas treated with postoperative radiotherapy. Material and Methods : We retrospectively reviewed the medical records of patients with malignant gliomas who received postoperative radiotherapy in our department between April 2007 and October 2014. Clinical characteristics, surgical resection status, and image findings of these patients were reviewed and analyzed. The primary endpoint was overall survival (OS). Results : Thirty-four patients were included in the study. Thirteen patients (38%) were diagnosed with anaplastic astrocytoma (AA) and 21 patients (62%) with glioblastoma (GBM). The median follow-up time was 14 months (range: 4\u201346 months). The median OS for all patients was 14.3 months (range: 3.8\u201345.7 months). The median OS of patients with AA and those with GBM were 15.2 and 12.3 months, respectively (p = 0.0355). In patients with GBM, group 1 (tumor resected more than 50%) had better OS than group 2 (tumor resected less than 50%, p = 0.0225). Conclusions : Our results showed similar OS to published articles. Surgical resection status was demonstrated to be an important prognostic factor for OS in patients with GBM."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-21-29", "title": "INTERRUPTED DEEP INSPIRATION WITH RESPIRATORY GATING (IDIRG): A NOVEL RADIOTHERAPY TECHNIQUE DESIGNED FOR LEFT BREAST CANCER PATIENTS NEEDING NODAL IRRADIATION AND NOT TOLERATING DEEP INSPIRATION BREATH HOLD (DIBH)", "keywords": "\u4e73\u764c;\u653e\u5c04\u6cbb\u7642;\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7 Breast cancer;Radiotherapy;Interrupted deep inspiration with respiratory gating", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u6211\u5011\u4f9d\u64da\u6df1\u5438\u6c23\u9589\u6c23\u6cd5\uff0c\u6240\u4fee\u6539\u8a2d\u8a08\u51fa\u7684\u653e\u5c04\u6cbb\u7642\u65b0\u65b9\u6cd5--\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\uff0c\u6bd4\u8d77\u50b3\u7d71\u81ea\u7531\u547c\u5438\u6cd5\uff0c\u662f\u5426\u80fd\u6e1b\u5c11\u9700\u8981\u6dcb\u5df4\u7d50\u7167\u5c04\uff0c\u4f46\u4e0d\u80fd\u914d\u5408\u6df1\u5438\u6c23\u9589\u6c23\u6cd5\u7684\u5de6\u5074\u4e73\u764c\u75c5\u60a3\u7684\u5de6\u5074\u80ba\u81df\u548c\u5fc3\u81df\u5291\u91cf\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7e3d\u5171\u5341\u4e8c\u4f4d\u8853\u5f8c\u9700\u8981\u6dcb\u5df4\u7d50\u7167\u5c04\u7684\u5de6\u5074\u4e73\u764c\u75c5\u60a3\u88ab\u8a55\u4f30\uff0c\u5176\u4e2d\u4e94\u4f4d\u63a5\u53d7\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\u6cd5\u3001\u4e03\u4f4d\u4f7f\u7528\u50b3\u7d71\u81ea\u7531\u547c\u5438\u6cd5\u3002\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\u6cd5\u6700\u4e0d\u540c\u7684\u5730\u65b9\u5728\u65bc\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\uff0c\u5305\u62ec\u4f7f\u7528\u74e6\u91cc\u5b89\u5373\u6642\u4f4d\u7f6e\u7ba1\u7406\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u8abf\u63a7\u7cfb\u7d71\uff0c\u76e3\u6e2c\u75c5\u4eba\u6240\u88fd\u9020\u51fa\u9023\u7e8c\u4e14\u9593\u65b7\u7684\u6df1\u5438\u6c23\uff0c\u4ee5\u53ca\u4f7f\u7528\u8ef8\u5411\u96fb\u8166\u65b7\u5c64\u800c\u975e\u4e00\u822c\u5e38\u7528\u7684\u87ba\u65cb\u96fb\u8166\u65b7\u5c64\u3002\u76ee\u6a19\u7e6a\u756b\u5305 \u62ec\u5de6\u5074\u5168\u4e73\u3001\u5de6\u5074\u80f8\u58c1\u3001\u5c40\u90e8\u6dcb\u5df4\u7d50\u53ef\u80fd\u5305\u542b\u5167\u4e73\u6dcb\u5df4\u7d50\u3002\u6cbb\u7642\u8a08\u756b\u4f7f\u7528\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u8a08\u756b\u88fd\u4f5c\u3002\u7d50\u679c\uff1a\u6bd4\u8f03\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\u6cd5\u548c\u50b3\u7d71\u81ea\u7531\u547c\u5438\u6cd5\u6642\uff0c\u76ee\u6a19\u9ad4\u7e3e\uff08855.85 \u6beb\u5347\u6bd4836.83\u6beb\u5347\uff0cP\u503c0.740\uff09\u3001\u76ee\u6a19\u5305\u8986\u7387\uff0897.41%\u6bd496.99%\uff0cP\u503c0.728\uff09\u548c\u6700\u9ad8\u5291\u91cf\u5340\uff08113.33%\u6bd4114.42%\uff0cP\u503c0.128\uff09\u6c92\u6709\u7d71\u8a08\u986f\u8457\u5dee\u7570\u3002\u81f3\u65bc\u5de6\u5074\u80ba\u81df\u548c\u5fc3\u81df\u7684\u76e3\u6e2c\u7d42\u9ede\uff0c\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\u6cd5\u6709\u986f\u8457\u8f03\u5927\u7684\u7e3d\u80ba\u9ad4\u7a4d\uff083465.33\u6beb\u5347\u6bd4 2065.14\u6beb\u5347\uff0cP\u503c\u5c0f\u65bc0.001\uff09\u9020\u6210\u8f03\u5c11\u537b\u6c92\u6709\u9054\u5230\u7d71\u8a08\u986f\u8457\u7684\u5de6\u80ba\u5291\u91cf\uff0820 Gy\u9ad4\u7a4d\uff1a27.92% \u6bd430.11%\uff0cP\u503c0.156\uff1b10 Gy\u9ad4\u7a4d\uff1a47.42%\u6bd451.08%\uff0cP\u503c0.199\uff09\uff0c\u4ee5\u53ca\u986f\u8457\u6e1b\u5c11\u7684\u5fc3\u81df\u5291\u91cf\u5305\u62ec\u5168\u5fc3\u81df\uff0825 Gy\u9ad4\u7a4d\uff1a4.77% \u6bd4 17.09%\uff0cP\u503c0.012\uff1b\u5e73\u5747\u5291\u91cf\uff1a10.78 Gy\u6bd415.71 Gy\uff0cP\u503c0.016\uff09\u548c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u679d\uff08\u524d\u767e\u5206\u4e4b\u5341\u5291\u91cf\uff1a31.80 Gy\u6bd450.41 Gy\uff0cP\u503c0.004\uff1b\u5e73\u5747\u5291\u91cf\uff1a24.46 Gy\u6bd4 43.64 Gy\uff0cP\u503c\u5c0f\u65bc0.001\uff09\u3002\u7d50\u8ad6\uff1a\u9593\u65b7\u6027\u6df1\u5438\u6c23\u642d\u914d\u547c\u5438\u8abf\u63a7\u6cd5\uff0c\u70ba\u6211\u5011\u70ba\u9700\u8981\u6dcb\u5df4\u7d50\u7167\u5c04\uff0c\u4f46\u4e0d\u80fd\u914d\u5408\u6df1\u5438\u6c23\u9589\u6c23\u6cd5\u7684\u5de6\u5074\u4e73\u764c\u75c5\u60a3\u6240\u8a2d\u8a08\u51fa\u7684\u653e\u5c04\u6cbb\u7642\u65b0\u65b9\u6cd5\uff0c\u6bd4\u8d77\u50b3\u7d71\u81ea\u7531\u547c\u5438\u6cd5\uff0c\u5b83\u53ef\u4ee5\u63d0\u4f9b\u64f4\u5f35\u7684\u80ba\u81df\u9ad4\u7a4d\uff0c\u9032\u800c\u6e1b\u5c11\u548c\u9577\u671f\u5fc3\u56e0\u6027\u6b7b\u4ea1\u76f8\u61c9\u5c0d\u7684\u5fc3\u81df\u5291\u91cf\u3002", "e": "Purpose : To assess if the novel radiotherapy technique named interrupted deep inspiration with respiratory gating (IDIRG) modified from deep inspiration breath hold (DIBH) can reduce left pulmonary and cardiac dose compared to traditional free breath method (FB) in left breast cancer patients needing nodal irradiation and not tolerating DIBH. Materials and Methods : Twelve postoperative left breast cancer patients needing nodal irradiation were evaluated. Five used IDIRG technique and seven used the traditional FB method. The IDIRG method differs most from FB technique during the CT-simulation phase. Patients were asked to take interrupted deep inspiration breaths monitored by the Varian Real-time Position Management Respiratory Gating System (RPM). Axial CT was applied instead of routinely used Helical CT. Target delineation included the whole left breast, left chest wall, and regional lymph nodes with or without internal mamillary nodes. Treatment planning was made using volumetric modulated arc technique. Result : There was no statistically significant difference in IDIRG and FB in respect to target volume (855.85 ml vs 836.83 ml, p= 0.740), target coverage (97.41% vs 96.99%, p =0.728), and hotspot (113.33% vs 114.42%, p= 0.128). In terms of left pulmonary and cardiac endpoints, IDIRG showed significantly larger total lung volume (3465.33ml vs 2065.14ml, p \uff1c0.001) which translated into a lesser, but not statistically significant, left pulmonary dose (V20: 27.92% vs 30.11%, p= 0.156; V10: 47.42% vs 51.08%, p= 0.199), and significant reduction in cardiac dose including heart (V25: 4.77% vs 17.09%, p= 0.012; mean dose: 10.78 Gy vs 15.71 Gy, p= 0.016) and left anterior descending coronary artery (LAD) (D10: 31.80 Gy vs 50.41 Gy, p= 0.004; mean dose: 24.46 Gy vs 43.64 Gy, p\uff1c 0.001). Conclusions : IDIRG, a novel radiotherapy technique designed for patients with left breast cancer needing nodal irradiation and not tolerating DIBH, can provide expanded lung volume to reduce cardiac dose, corresponding to lower long-term cardiac mortality compared to the traditional FB method."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-31-45", "title": "\u5168\u570b\u653e\u5c04\u6cbb\u7642\u7cfb\u7d71\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u57f7\u884c\u73fe\u6cc1\u5be6\u6e2c\u7814\u7a76\u5831\u544a", "keywords": "\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u4fdd\u8b49;\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668 Radiotherapy;Quality assurance for radiation therapy;Medical linear accelerator", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4f9d\u64da\u81ea\u6c11\u570b94\u5e747\u67081\u65e5\u8d77\u8a02\u5b9a\u7684\u300c\u8f3b\u5c04\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u6a19\u6e96\u300d\u91dd\u5c0d\u653e\u5c04\u6cbb\u7642\u8a2d\u5099\u6240\u898f\u7bc4\u7684\u9805\u76ee\uff0c\u85c9\u7531\u66f8\u9762\u8cc7\u6599\u8490\u96c6\u53ca\u73fe\u5834\u5be6\u5730\u8a2a\u67e5\uff0c\u5efa\u7acb\u5168\u570b\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u6e96\u78ba\u6027\u8207\u4f5c\u696d\u54c1\u8cea\u7ba1\u63a7\u7a0b\u5ea6\u7684\u8cc7\u6599\u5eab\uff0c\u4ee5\u6aa2\u8996\u63a8\u884c\u300c\u8f3b\u5c04\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u6a19\u6e96\u300d\u7684\u6210\u6548\uff0c\u540c\u6642\u4f5c\u70ba\u7cbe\u9032\u6b64\u4f5c\u696d\u6a19\u6e96\u7684\u91cd\u8981\u53c3\u8003\uff0c\u4e26\u5354\u52a9\u81e8\u5e8a\u55ae\u4f4d\u63d0\u6607\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u53ca\u6280\u8853\u6c34\u5e73\uff0c\u5f37\u5316\u8f3b\u5c04\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u898f\u7bc4\u7684\u5b8c \u6574\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u66f8\u9762\u5be9\u67e5\u53ca\u73fe\u5834\u8a2a\u67e5\u7684\u65b9\u5f0f\u57f7\u884c\u54c1\u4fdd\u6821\u9a57\u67e5\u6838\u5de5\u4f5c\uff0c\u7e3d\u8a08\u6536\u96c676\u5bb6\u653e\u5c04\u6cbb\u7642\u81e8\u5e8a\u55ae\u4f4d\uff0c135\u53f0\u76f4\u7dda\u52a0\u901f\u5668\uff0c8\u53f0\u52a0\u99ac\u5200\uff0c38\u53f0\u8fd1\u63a5\u6cbb\u7642\u6a5f\uff0c18\u53f0\u87ba\u65cb\u6cbb\u7642\u6a5f\uff0c5\u53f0\u96fb\u8166\u5200\u7684\u8a2d\u5099\u8207\u54c1\u4fdd\u6821\u9a57\u8cc7\u6599\uff0c\u540c\u6642\u5b8c\u6210\u6240\u6709\u8a2d\u5099\u7684\u54c1\u4fdd\u9805\u76ee\u73fe\u5834\u8a2a\u67e5\u3002\u5404\u8a2d\u5099\u54c1\u4fdd\u4f5c\u696d\u7684\u65b9\u6cd5\uff0c\u5291\u91cf\u6821\u9a57\u7684\u8a2d\u5099\u8207\u6d41\u7a0b\u7b49\u90fd\u8acb\u4f5c\u696d\u57f7\u884c\u55ae\u4f4d\u63d0\u4f9b\u5b8c\u6574\u7684\u8cc7\u6599\u4f5c\u70ba\u66f8\u9762\u5be9\u67e5\u53ca\u73fe\u5834\u8a2a\u67e5\u7684\u53c3\u8003\u3002\u73fe\u5834 \u8a2a\u67e5\u5247\u5c0d\u6240\u6709\u54c1\u4fdd\u4f5c\u696d\u7684\u5be6\u969b\u60c5\u5f62\u4f5c\u8a73\u76e1\u7684\u77ad\u89e3\u3002\u7d9c\u5408\u6574\u7406\u5206\u6790\u5168\u570b\u6cbb\u7642\u8a2d\u5099\u7684\u54c1\u4fdd\u6821\u9a57\u8cc7\u6599\uff0c\u5efa\u7acb\u5305\u62ec\u6cbb\u7642\u8a2d\u5099\u7279\u6027\u6578\u64da\u3001\u5291\u91cf\u91cf\u6e2c\u5100\u5668\u7279\u6027\u6578\u64da\u3001\u5291\u91cf\u6821\u9a57\u65b9\u6cd5\u8207\u6e96\u78ba\u6027\u5206\u6790\u8cc7\u6599\u3001\u91ab\u7642\u55ae\u4f4d\u53ca\u4eba\u54e1\u72c0\u6cc1\u8207\u54c1\u4fdd\u4f5c\u696d\u57f7\u884c\u7684\u5206\u6790\u8cc7\u6599\u7b49\u7684\u8cc7\u6599\u5eab\uff0c\u4f5c\u70ba\u63a8\u884c\u54c1\u4fdd\u4f5c\u696d\u91cd\u8981\u53c3\u8003\u8cc7\u6599\u53ca\u672a\u4f86\u7cbe\u9032\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u653f\u7b56\u4e4b\u4f9d\u64da\u3002\u7d50\u679c\uff1a\u672c\u8a08\u756b\u57f7\u884c\u7684\u6240\u6709\u54c1\u4fdd\u9805\u76ee\uff0c\u85c9\u7531\u8cc7\u6599\u6536\u96c6\u8207\u8a0e\u8ad6\u4fee\u6539\u5f8c\uff0c\u73fe\u5834\u67e5\u6838\u7d50\u679c\u5728\u4f9d\u5faa\u81e8\u5e8a\u55ae\u4f4d\u6240\u5236\u8a02\u7684\u7a0b\u5e8f\u66f8\u57f7\u884c\u4e0b\uff0c\u5176\u7d50\u679c\u7686\u7b26\u5408\u300c\u8f3b\u5c04\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u6a19\u6e96\u300d\u7684\u898f\u5b9a\u3002\u8a0e\u8ad6\uff1a\u57fa\u65bc\u7cbe\u9032\u54c1\u4fdd\u4f5c\u696d\u54c1\u8cea\u7684\u76ee\u7684\u63d0\u51fa\u4e0b\u5217\u5efa\u8b70\uff1a1.\u8a2d\u5099\u4f7f\u7528\u55ae\u4f4d\u61c9\u5efa\u7acb\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50\uff0c\u9032\u4e00\u6b65\u63d0\u6607\u5291\u91cf\u6821\u9a57\u7684\u6e96\u78ba\u6027\u30022.\u5c04\u675f\u5e73\u5766\u6027\u61c9\u5efa\u7acb\u9069\u7576\u57fa\u6e96\u503c\uff0c\u4ee5\u66f4\u6709\u6548\u7684\u9054\u5230\u76e3\u63a7\u5c04\u675f\u54c1 \u8cea\u7684\u76ee\u7684\u30023.\u5c04\u675f\u5e73\u5766\u6027\u53ca\u5c0d\u7a31\u6027\u7684\u8a08\u7b97\u61c9\u4f7f\u7528\u300c\u8f3b\u5c04\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u6a19\u6e96\u300d\u7a0b\u5e8f\u66f8\u6240\u8f09\u7684\u516c\u5f0f\u30024.\u542b\u653e\u5c04\u6027\u7269\u8cea\u4e4b\u9059\u63a7\u5f8c\u8377\u5f0f\u8fd1\u63a5\u6cbb\u7642\u8a2d\u5099\u4e4b\u8f3b\u5c04\u6e90\u5f37\u5ea6\u6821\u9a57\uff0c\u5efa\u8b70\u61c9\u4fee\u6539\u8aa4\u5dee\u5bb9\u8a31\u503c\u30025.\u653e\u5c04\u6cbb\u7642\u8a2d\u5099\u5291\u91cf\u6821\u9a57\u4f7f\u7528\u7684\u8b70\u5b9a\u66f8\uff0c\u61c9\u4f9d\u7167\u5167\u9644\u7684\u5de5\u4f5c\u8868\uff08worksheet\uff09\u5efa\u7acb\u5b8c\u6574\u7684\u7d19\u672c\u8868\u683c \u6578\u64da\u8cc7\u6599\uff0c\u907f\u514d\u76f4\u63a5\u6216\u552f\u4e00\u4f7f\u7528excel\u61c9\u7528\u7a0b\u5f0f\u5de5\u5177\u3002", "e": "Purpose : Based on the \uff02medical radiation exposure quality assurance standards\uff02, with on-site visits to the radiation therapy departments, a national database for the accuracy and quality control of dosimetry in radiotherapy were established. This database can serve as a basis for reviewing the effects of the quality assurance standards for medical radiation exposure and improving quality assurance policies related to medical radiation exposure. In addition, the database can serve as a reference for clinical units seeking to enhance the quality of technologies used in radiotherapy and to strengthen the integrity of quality assurance measures related to medical radiation exposure. Materials and Methods : There are totally 204 radiotherapy equipments, including 135 linac, 8 gamma knife, 38 brachytherapy system, 18 Tomotherapy, and 5 Cyberknife, currently used in Taiwan. Methods of QA procedure, equipments of dose calibration will be ask to provide for on site inspection. Site visits will give a more detailed understanding of the actual situation of all quality assurance operations, and for dose output, beam energy and beam flatness and symmetry, actual measurement will be performed on site. Analyze the QA data from this study, including treatment equipment characteristics, characteristics of dose measurement instruments, the variations from the dose calibration methods, medical units and personnel statuses which will be an important reference for the improving of quality assurance in radiation therapy. Results : after data survey and parameter corrections, the results of on-site check for the QA items executed in this study are all fit the criteria of the \uff02radiation exposure of medical quality assurance standards\uff02 Discussion : To improve the quality assurance procedures, we offer the following recommendations: 1. phantom dose conversion factor should be established, if the phantom is not used in the protocol, hence to further enhance the accuracy of dose calibration; 2. an appropriate reference level of beam flatness and symmetry should be established for monitoring the beam quality more effectively. 3. beam flatness and symmetry shall be calculated using the same formula list in the AEC published program of \uff02radiation exposure of medical quality assurance standards\uff02. 4. the calibration criteria of brachytherapy source activity should be revised. 5. the data worksheet of dose calibration should be established fully according to the enclosed data worksheet in the protocol, should avoid direct or sole use of excel application tools."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-47-54", "title": "\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u5f27\u5f62\u908a\u7de3\u504f\u79fb\u4fee\u6b63\u5c0d\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u5f71\u97ff", "keywords": "\u591a\u8449\u5f0f\u6e96\u76f4\u5100;\u5f27\u5f62\u908a\u7de3\u504f\u79fb;\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u54c1\u8cea\u4fdd\u8b49 Multileaf collimator (MLC);Rounded leaf end offset (RLO);Volumetric modulated arc radiotherapy (VMAT);Quality assurance (QA)", "c": "\u76ee\u7684\uff1aPhilips Pinnacle^3\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u63d0\u4f9b\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u8449\u7247\u5f27\u5f62\u908a\u7de3\u504f\u79fb\uff08rounded leaf offset, RLO\uff09\u4fee\u6b63\u53c3\u6578\uff0c\u53ef\u4fee\u6b63\u8449\u7247\u4f4d\u7f6e\u8207\u8f3b\u5c04\u7167\u91ce\u908a\u7de3\u4f4d\u7f6e\u4e4b\u5dee\u7570\u3002\u672c\u5be6\u9a57\u5c07\u91cf\u6e2cRLO\u4fee\u6b63\u91cf\u5f8c\uff0c\u5c07\u6b64\u53c3\u6578\u8f38\u5165\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\uff0c\u85c9\u6b64\u4fee\u6b63\u5f8c\u8449\u7247\u4f4d\u7f6e\u5f8c\u91cd\u65b0\u8a08\u7b97\u81e8\u5e8a\u4f7f\u7528\u4e4b\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 \uff08VMAT\uff09\u8a08\u756b\u5291\u91cf\u5206\u5e03\uff0c\u4e26\u8a55\u4f30\u7d50\u679c\u662f\u5426\u6539\u5584\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u5305\u62ec\u5169\u90e8\u4efd\uff1a\uff081\uff09\u8449\u7247\u5f27\u5f62\u908a\u7de3\u504f\u79fb\u4fee\u6b63\u6e2c\u91cf\uff1a\u5229\u7528\u5291\u91cf\u7cfb\u7d71\u6e2c\u91cf\u4e0d\u540c\u8449\u7247\u7167\u91ce\u8a2d\u5b9a\u4e0b\uff0c\u5176\u8f3b\u5c04\u7167\u91ce\u908a\u7de3\u4f4d\u7f6e\uff0c\u85c9\u4ee5\u8a55\u4f30\u5169\u8005\u9593\u7684\u5dee\u7570\uff1b\uff082\uff09\u8449\u7247\u504f\u79fb\u91cf\u8abf\u6574\u5f8c\u4e4b\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u8a55\u4f30\uff1a\u4ee5\u6e2c\u91cf\u4e4bRLO\u4fee\u6b63\u53c3\u6578\u8f38\u5165\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5f8c\uff0c\u8a08\u7b97\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u5206\u5e03\uff0c\u6b64\u8a08\u7b97\u7d50\u679c\u5c07\u8207\u5be6\u969b\u5229\u7528\u5291\u91cf\u6e2c\u91cf\u7cfb\u7d71\u5728\u5047\u9ad4\u4e2d\u91cf\u6e2c\u5230\u7684\u7d50\u679c\u6bd4\u8f03\u3002\u7d50\u679c\uff1a\u504f\u79fb\u91cf\u6e2c\u91cf\u7d50\u679c\u986f\u793a\uff0c\u5728\u8449\u7247\u4f4d\u7f6e\u8d8a\u904e\u4e2d\u5fc3\u5c04\u675f\u8ef8\u5176RLO\u4ecb\u65bc-0.205 mm\u81f3-0.658 mm\uff0c\u9664\u4e86\u5728\u8449\u7247\u4f4d\u7f6e-10 cm\u8655\u6642RLO\u8207\u9810\u8a2d\u503c\u5dee\u7570\u7d04\u70ba1.6 mm\u4ee5\u5916\uff0c\u5728-8 cm \u81f30 cm\u4e4bRLO\u8207\u9810\u8a2d\u503c\u5dee\u7570\u5c0f\u65bc1 mm\u3002\u800c\u4e2d\u5fc3\u5c04\u675f\u8ef8\u4e0a\u6e2c\u91cf\u5230\u7684\u4fee\u6b63\u9805\u70ba0.538 mm\uff0c\u5176\u9918\u5728\u8449\u7247\u4f4d\u7f6e \u75312 cm\u81f318 cm\u4e4b\u4fee\u6b63\u91cf\u5247\u4ecb\u65bc0.655 mm \u81f3-1.061 mm\u3002\u7d93\u904eRLO \u8abf\u6574\u5f8c\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71 \u8a08\u7b97\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u7686\u6bd4\u9810\u8a2dRLO \u8a08\u7b97\u51fa\u7684\u7d50\u679c\u4f86\u7684\u4f4e\u3002\u53e6\u5916\uff0c\u5be6\u6e2c5 \u500b\u6cbb\u7642\u8a08\u756b\u4e4b\u5291 \u91cf\u5206\u5e03\u5f8c\uff0c\u986f\u793a\u4fee\u6b63\u5f8c\u7684\u9ede\u5291\u91cf\u6bd4\u672a\u4fee\u6b63\u6240\u8a08\u7b97\u51fa\u7684\u7d50\u679c\u8f03\u63a5\u8fd1\u5be6\u6e2c\u503c\uff0c\u5176\u8aa4\u5dee\u6e1b\u5c11\u7d041.6%\u81f33.4%\uff1b\u800c\u5229\u7528\u4e8c\u7dad\u9663\u5217\u5f0f\u6e38\u96e2\u8154\u6e2c\u91cf\u5291\u91cf\u5206\u5e03\u7d50\u679c\u5176\u52a0\u99ac\u6307\u6a19\u57283% / 3 mm \u6a19\u6e96\u4e0b\u4ecb\u65bc94.4%\u81f398.2%\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u4ee5\u4e0a\u8ff0\u65b9\u5f0f\u91cf\u6e2c\u672c\u79d1RLO\u4fee\u6b63\u503c\uff0c\u7531\u7d50\u679c\u53ef\u770b\u5230\u8207\u539f\u9810\u8a2d\u503c\u6709\u660e\u986f\u5dee\u7570\uff0c\u7d93\u6b64\u65b9\u6cd5 \u8abf\u6574\u5f8c\u7684RLO\u4fee\u6b63\u503c\u53ef\u63d0\u5347\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8a08\u7b97\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5206\u5e03\u7684\u6e96\u78ba\u5ea6\uff0c\u5982\u6b64\u4e5f\u53ef\u78ba\u4fdd\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u6642\u6cbb\u7642\u54c1\u8cea\u7684\u4fdd\u8b49\u3002", "e": "Purpose : The purpose of the Rounded Leaf Offset (RLO) table was to take into account the differences between planning leaf positions and actual radiation leaf edges. Most users utilize the default RLO table supplied by the vendor. Our goal was to improve the dosimetric accuracy in Volumetric Modulated Arc Therapy (VMAT) by applying the measured RLO parameters. Materials and Methods : This study consists of two parts: (1)The radiation leaf edges at various positions were measured with ion chamber dosimetry system. The results were compared with the default table in the Treatment Planning System (TPS). (2) Five VMAT clinical plans were used to evaluate the overall dosimetric effects of RLO table. An ion chamber in a solid water phantom was used to determine the absolute dose at a reference point for each plan. The 2D dose distributions were measured with a 2D-Array dosimetry system. Results : The RLO measurements showed that the offsets were between -0.205 mm and 0.658 mm when the leaf positions crossed the central axis of the beam. The differences between the default and measured RLO values were less than 1 mm when the leaf positions were in the range of -8 cm and 0 cm, but at -10 cm position the difference was 1.6 mm. At the central beam axis, the measured correction was 0.538 mm and the others were in range of 0.655 mm and -1.061 mm for the leaf positions at 2 cm to 18 cm. After the modification of RLO table, the TPS calculated doses for the VMAT plans were lower than those calculated with default RLO table. Also, based on the measurements of 5 VMAT plans, the point doses improved about 1.6% to 3.4%, and the 2D dose distributions using 3% / 3 mm Gamma test achieved 94.4% to 98.2% passing rate. Conclusions : This study established the RLO correction values in our department. We found the default RLO values are obviously inaccurate for our machine. This adjustment of RLO table improves the dose calculation accuracy of TPS, in the meantime, ensures the quality of patients\u2019treatments."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-55-65", "title": "\u7b46\u5c04\u675f\u5377\u7a4d\u548c\u975e\u5747\u5411\u89e3\u6790\u6f14\u7b97\u6cd5\u8a55\u4f30\u5728\u4e0d\u540c\u5291\u91cf\u8a08\u7b97\u9694\u9ede\u4e0b\u8868\u9762 \u5291\u91cf\u8a08\u7b97\u503c\u8207\u6e2c\u91cf\u503c\u4e4b\u5047\u9ad4\u7814\u7a76", "keywords": "\u8868\u9762\u5291\u91cf;\u7b46\u5c04\u675f\u5377\u7a4d\u6f14\u7b97\u6cd5;\u975e\u5747\u5411\u89e3\u6790\u6f14\u7b97\u6cd5;\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247 Surface dose;Pencil Beam Convolution;Analytical Anisotropic Algorithm;Ultrathin TLD;Gafchromic film", "c": "\u76ee\u7684\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u5229\u7528\u7b46\u5c04\u675f\u5377\u7a4d\u6f14\u7b97\u6cd5\uff08Pencil Beam Convolution, PBC\uff09\u548c\u975e\u5747\u5411\u89e3\u6790\u6f14\u7b97\u6cd5\uff08Analytical Anisotropic Algorithm, AAA\uff09\u8a08\u7b97\u982d\u9838\u764c\u75c5\u4eba\u8abf\u5f37\u653e\u5c04\u6cbb\u7642\u4e4b\u76ae\u819a\u5291\u91cf\uff0c\u52a0\u4e0a\u5047\u9ad4 \u6e2c\u91cf\u5f8c\u8a55\u4f30\u982d\u9838\u764c\u75c5\u4eba\u5728\u6cbb\u7642\u8a08\u756b\u4e2d\u7684\u76ae\u819a\u5291\u91cf\u8a08\u7b97\u503c\u7684\u53ef\u4fe1\u5ea6\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u63a1\u7528\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u4f86\u505a\u70ba\u91cf\u6e2c\u5de5\u5177\uff0c\u5728IMRT head/ neck phantom \u548c anthropomorphic Rando phantom\u6e2c\u91cf\u6a21\u64ec\u7684\u9838\u90e8\u6dcb\u5df4\u5340\u7684\u8868\u9762\u5291\u91cf\uff0c\u5229\u7528Eclipse version10.0\u5167\u5169\u7a2e\u4e0d\u540c\u7684\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u6f14\u7b97\u6cd5\uff08PBC\u548cAAA\uff09\u88fd\u4f5c\u8655\u65b9\u5291\u91cf\u70ba180 cGy\u76847\u500b\u7167\u91ce\u6cbb\u7642\u8a08\u756b\uff0c\u9032\u884c\u6b64\u5169\u7a2e\u91cf\u6e2c\u5de5\u5177\u7d55\u5c0d\u5291\u91cf\u4e4b\u6e2c\u91cf\u3002 \u7d50\u679c\uff1a\u672c\u5be6\u9a57\u4e4b\u8584\u7247\u578b TLD \u8b8a\u7570\u4fc2\u6578\u57283%\u4ee5\u5167\uff0c\u8a08\u8b80\u503c\u8207\u7d66\u4e88\u5291\u91cf\u9593\u5448\u73fe\u826f\u597d\u7dda\u6027\u95dc\u4fc2\uff1b \u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u6821\u6b63\u5340\u7dda\u4e0a\u6bcf\u500b\u9ede\u4e4b\u8b8a\u7570\u4fc2\u6578\u57281%\u4ee5\u5167\uff1b\u8a08\u7b97\u9694\u9ede\u9593\u8ddd\u8a2d\u5b9a\u70ba 2.5 mm\u6642\uff0c IMRT head/neck phantom\u53f3\u5074\u8868\u9762\u5291\u91cf\u7684\u8a08\u7b97\u503c\u8207EBT2 film\u8207\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u5e73\u5747\u503c\u4e4b\u8aa4 \u5dee\uff0cPBC\u548cAAA\u70ba 13.02%\u300110.73%\u548c-4.54%\u3001-6.48%\u4ee5\u53ca\u5de6\u5074\u70ba -12.52%\u3001-10.06%\u548c-4.58%\u3001-1.9%\uff1banthropomorphic Rando\u00ae phantom\u53f3\u5074\u8868\u9762\u5291\u91cf\u7684\u8a08\u7b97\u503c\u8207EBT2 film\u8207\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u5e73\u5747\u503c\u4e4b\u8aa4\u5dee\uff0cPBC\u548cAAA\u70ba-0.99%\u3001-2.26%\u548c0.64%\u3001-0.64%\u4ee5\u53ca\u5de6\u5074\u70ba-7.68%\u3001-12.47%\u548c2.9%\u3001-2.44%\uff1b\u7576\u8a08\u7b97\u9694\u9ede\u9593\u8ddd\u8a2d\u5b9a\u70ba 2.5 mm\u6642\uff0cAAA\u6709\u8f03\u7a69\u5b9a\u7684\u8a08\u7b97\u503c\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u7531\u672c\u5be6\u9a57\u5f97\u77e5\uff0c\u5169\u8005\u6f14\u7b97\u6cd5\u96d6\u7136\u7686\u7121\u6cd5\u6e96\u78ba\u8a08\u7b97\u8868\u9762\u5291\u91cf\uff0c\u4f46\u662fAAA\u4ecd\u7136\u6bd4\u8f03\u63a5\u8fd1\u91cf\u6e2c\u503c\u800c\u4e14\u6709\u8f03\u7a69\u5b9a\u7684\u6578\u503c\uff0c\u672a\u4f86\u672c\u7814\u7a76\u5c07\u627e\u51fa\u66f4\u6e96\u78ba\u7684\u6f14\u7b97\u6cd5\u4e26\u5c0d\u8f2a\u5ed3\u505a\u4fee\u6b63\u5f8c\u627e\u51fa\u76f4\u63a5\u5229\u7528\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5c31\u53ef\u4ee5\u63a8\u4f30\u76ae\u819a\u5291\u91cf\u7684\u65b9\u5f0f\uff0c\u4ee5\u78ba\u5be6\u627e\u51fa\u9020\u6210\u75c5\u4eba\u76ae\u819a\u53cd\u61c9\u7684\u5291\u91cf\u8a55\u4f30\u503c\u3002", "e": "Purpose : Pencil Beam Convolution (PBC) and Analytical Anisotropic Algorithm (AAA) were used to calculate the surface dose of simulated phantoms for head-and-neck patients treated with intensitymodulated radiation therapy. These were also used to evaluate the reliability of calculated results for the skin dose in vivo head-and-neck patients. Materials and Methods : This experiment adopted 0.1 mm ultrathin thermoluminescent dosimeters (ultrathin TLD) and ISP Gafchromic EBT2 film as measurement tools. The surface doses at hypothetical neck lymphatic regions were measured. Seven-field IMRT plans with a prescribed dose of 180 cGy were designed using an Eclipse (version10.0) treatment planning system where both PBC and AAA were implemented. These two different measurement tools were used to measure the absolute dose when calculated algorithms used different grid sizes. Result : In this experiment the variance coefficient of ultrathin TLD was within 3%. The reading values and delivered doses were in a good linear relationship. The points on calibration curve of Gafchromic film were within 1%. Using grid size of 2.5 mm, the errors between calculated values (PBC and AAA) and the mean surface measured doses for EBT2 film and ultrathin TLD were 13.02%, 10.73% and -4.54%, -6.48% on right side and -12.52%, -10.06% and -4.58%, -1.9% on left side neck of IMRT head/neck phantom, respectively. The errors between calculated values (PBC and AAA) and the mean surface measured doses for EBT2 film and ultrathin TLD were -0.99%, -2.26% and 0.64%, -0.64% on right side and -7.68%, -12.47% and 2.9%, -2.44% on left side neck of anthropomorphic Rando\u00ae phantom, respectively. Thus, AAA had more stable calculated results and performance than PBC using a grid size of 2.5 mm. Conclusion and Discussion : From the experimental results, neither algorithm was precise in calculating the surface dose. However, AAA was closer to the measured dose and its performance was stable. Future research will evaluate the most precise algorithm and modify the contours of the body to evaluate the skin dose. The treatment planning system can then be used directly to calculate patients\u2019 skin dose indeed affecting the skin reaction."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-67-76", "title": "RADIOTHERAPY OF RECURRENT FIBROMATOSIS IN GARDNER SYNDROME: REPORT OF TWO CASES IN A FAMILY", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u7e96\u7dad\u7624\u75c5;\u985e\u7d50\u7de0\u7e54\u7624;\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4 Radiotherapy;Fibromatosis;Desmoid tumor;Gardner syndrome", "c": "\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u6709\u4e09\u7a2e\u4e3b\u8981\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u5206\u5225\u662f\u5927\u8178\u606f\u8089\u75c5\u3001\u76ae\u819a\u6216\u8edf\u7d44\u7e54\u7684\u9593\u8cea\u7d30\u80de\u816b\u7624\u3001\u53ca\u9aa8\u7624\u3002\u6b64\u75c7\u5019\u7fa4\u7684\u767c\u75c5\u662f\u4ee5\u67d3\u8272\u9ad4\u986f\u6027\u907a\u50b3\uff0c\u7d71\u8a08\u4e0a\u60a3\u8005\u7684\u5b50\u5973\u7d04\u6709\u4e00\u534a\u90fd\u6703\u53d7\u5f71\u97ff\u3002\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u53ef\u8996\u70ba\u5bb6\u65cf\u6027\u7d50\u76f4\u8178\u606f\u8089\u7d9c\u5408\u75c7\uff08familial adenomatous polyposis[FAP]\uff09\u7684\u4e00\u7a2e\u8b8a\u578b\uff0c\u5169\u8005\u90fd\u662f\u6e90\u81ea\u65bcFAP\u57fa\u56e0\u8b8a\u7570\u7684\u907a\u50b3\u6027\u75be\u75c5\u3002\u56e0\u6b64\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u6709\u591a\u6a23\u5728\u5927\u8178\u5916\u7684\u75c7\u72c0\u8868\u73fe\uff0c\u76ee\u524d\u8a8d\u70ba\u662f\u56e0\u70ba\u57fa\u56e0\u4e0d\u540c\u7684\u5916\u986f\u7387\u8868\u73fe\u6240\u81f4\u3002\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u6613\u7522\u751f\u816b\u7624\u6709\u9aa8\u7624\u3001\u8868\u76ae\u6a23 \u56ca\u816b\u3001\u8102\u80aa\u7624\u3001\u7e96\u7dad\u7624\u3001\u795e\u7d93\u7e96\u7dad\u7624\u3001\u76ae\u819a\u8272\u7d20\u75c5\u8b8a\u3001\u53ca\u7e96\u7dad\u7624\u75c5\uff08fibromatosis\uff09\u7b49\u4e0d\u540c\u816b\u7624\u75c5\u8b8a\u3002\u6587\u737b\u4e0a\u53c8\u7a31\u6df1\u90e8\u7e96\u7dad\u7624\u75c5\u70ba\u985e\u7d50\u7de0\u7e54\u7624\uff08desmoid tumor\uff09\u6216\u4fb5\u8972\u6027\uff08aggressive\uff09\u7e96\u7dad\u7624\u75c5\u3002\u5728\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u75c5\u60a3\u7684\u767c\u751f\u6bd4\u7387\u7d04\u57283-5%\u3002\u7e96\u7dad\u7624\u75c5\u7684\u6cbb\u7642\u9069\u61c9\u75c7\u662f\u5728\u65bc\u9020\u6210\u81e8\u5e8a\u75c7\u72c0\u3001\u7834\u58de\u5468\u570d\u7d44\u7e54\u529f\u80fd\u3001\u6216\u662f\u5f71\u97ff\u7f8e\u89c0\u7684\u6642\u624d\u9700\u6cbb\u7642\u3002\u624b\u8853\u5207\u9664\u662f\u6700\u5e38\u63a1\u53d6\u7684\u521d\u6b65\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u662f\u5373\u4f7f\u5927\u7bc4\u570d\u624b\u8853\u5207\u9664\uff0c\u8853\u5f8c\u4ecd\u5e38\u6703\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u554f\u984c\u3002\u5c0d\u65bc\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u5f15\u8d77\u4e4b\u7e96\u7dad\u7624\u75c5\uff0c\u65bc\u5fa9\u767c\u6216\u7121\u6cd5\u5207\u9664\u6642\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u53ef\u8003\u616e\u7684\u6551\u63f4\u6027\u6cbb\u7642\u3002\u6211\u5011\u63d0\u51fa\u5169\u4f4d\u7f55\u898b\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u4f75\u7e96\u7dad\u7624\u75c5\u7684\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7d93\u9a57\u3002\u5169\u4f4d\u90fd\u662f\u8853\u5f8c \u518d\u5fa9\u767c\uff0c\u9020\u6210\u81e8\u5e8a\u4e0d\u9069\u75c7\u72c0\uff0c\u4e26\u4e14\u5f71\u97ff\u751f\u6d3b\u54c1\u8cea\u53ca\u5bb9\u8c8c\u7f8e\u89c0\u3002\u7d66\u4e88\u4e94\u81f3\u516d\u5468\u7684\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf50\u81f354Gy\uff0c\u4ee5\u6bcf\u6b211.8\u81f32Gy\u5206\u6b21\u5291\u91cf\u3002\u5728\u4e00\u5e74\u4ee5\u4e0a\u81e8\u5e8a\u8ffd\u8e64\uff0c\u7e96\u7dad\u7624\u75c5\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u6548\u679c\u826f\u597d\uff0c\u816b\u7624\u6301\u7e8c\u7e2e\u5c0f\u3002\u5c0d\u65bc\u81e8\u5e8a\u75bc\u75db\u548c\u5bb9\u8c8c\u90fd\u6709\u986f\u8457\u7684\u6539\u5584\u3002\u75c5\u4eba\u6cbb\u7642\u526f\u4f5c\u7528\u8f15\u5fae\uff0c\u53ea\u7522\u751f\u6025\u6027\u653e\u5c04\u526f\u4f5c\u7528\u53cd\u61c9\u7684\u7b2c\u4e00\u7d1a\u76ae\u819a\u708e\uff0c\u53e3\u8154\u708e\u53ca\u53e3\u4e7e\u53cd\u61c9\u3002\u6211\u5011\u7684\u521d\u6b65\u6cbb\u7642\u7d93\u9a57\u986f\u793a\uff0c\u5c0d\u65bc\u5fa9\u767c\u6216\u7121\u6cd5\u5207\u9664\u52a0\u5fb7\u7d0d\u75c7\u5019\u7fa4\u5f15\u8d77\u826f\u6027\u7e96\u7dad\u7624\u75c5\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u5f88\u597d\u7684\u6551\u63f4\u6027\u6cbb\u7642\u3002", "e": "The triad of colonic polyposis, mesenchymal tumors of the skin or soft tissues, and osteomas, is known as Gardner syndrome (GS). This syndrome is inherited as an autosomal-dominant trait that occurs in approximately half of the children of afflicted parents. GS is the variant of familial adenomatous polyposis (FAP), and shares the same genetic disorder as FAP. The fact that GS is associated with extra-colonic manifestations may be the result of a variable penetrance of a common genetic mutation. GS may present osteomas of the bones, sebaceous or epidermoid cysts, fibromas, neurofibromas, lipomas, pigmented skin lesions, or fibromatosis. The deep fibromatosis is most commonly referred to as a desmoid tumor or aggressive fibromatosis in the literature, and appears in only approximately 3-5% of affected individuals with GS. Treatment of fibromatosis is indicated only when it causes clinical symptoms, dysfunction of adjacent structures, or aesthetic concerns. Surgical excision is generally advised first; however, there may be local recurrence even following a wide resection. Local radiotherapy could be used in un-resectable or recurrent fibromatosis for symptoms alleviation. We present two rare cases of GS in a family with recurrent fibromatosis after repeated excision. The tumor caused clinical symptoms, affected daily life and had negative aesthetic effects. A 50-54 Gy radiation dose in 1.8-2 Gy fractions was delivered to the involved tumor region in a 5-6 week course. Fibromatosis responded to radiotherapy, and the tumor regressed during serial follow-ups for more than a year. Radiation therapy achieved satisfactory results in local control and cosmetic outcome. The pain and disfiguration could all be ameliorated. Treatment was well tolerated, with only Grade 1 radiation dermatitis, mucositis, and xerostomia using the acute radiation morbidity scoring criteria. Our results support that radiotherapy could be used as salvage therapy for such recurrent benign tumors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201603-201604200021-201604200021-77-83", "title": "TRACHEAL ADENOID CYSTIC CARCINOMA: POST-OP ERATIVE CHEMORADIOTHERAPY \u2013 A CASE REPORT", "keywords": "\u6c23\u7ba1\u764c;\u817a\u6a23\u56ca\u6027\u764c;\u540c\u6b65\u653e\u5c04\u7dda\u6cbb\u7642\u4f75\u5316\u5b78\u6cbb\u7642 Trachea cancer;Adenoid cystic carcinoma;Concurrent chemoradiotherapy", "c": "\u539f\u767c\u6027\u6c23\u7ba1\u764c\u662f\u4e00\u500b\u7f55\u898b\u7684\u75be\u75c5\uff0c\u767c\u751f\u7387\u5728\u6bcf\u5e74\u65b0\u767c\u751f\u7684\u764c\u75c7\u4e2d\u7d04\u4f540.1\u20130.4%\uff0c\u817a\u6a23\u56ca\u6027\u764c\u5247\u662f\u7d44\u7e54\u5b78\u5206\u985e\u4e2d\u6392\u540d\u7b2c\u4e8c\u5e38\u898b\u7684\u6c23\u7ba1\u764c\u3002\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u624b\u8853\uff0c\u800c\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u4e5f\u6709\u8b49\u64da\u986f\u793a\u5c0d\u7121\u75be\u75c5\u5b58\u6d3b\u671f\u9084\u6709\u6574\u9ad4\u5b58\u6d3b\u7387\u6709\u5e6b\u52a9\uff0c\u7136\u800c\u56e0\u70ba\u767c\u751f\u7387\u4f4e\uff0c\u76ee\u524d\u4e26\u6c92\u6709\u91dd\u5c0d\u8853\u5f8c \u908a\u7de3\u63a5\u8fd1\u800c\u9032\u884c\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u81e8\u5e8a\u5be6\u9a57\u3002\u6211\u5011\u5728\u9019\u908a\u63d0\u51fa\u4e00\u500b\u4e4b\u524d\u6709\u53f3\u5074\u9ecf\u6db2\u6027\u4e73\u764c\u75c5\u53f2\u768452\u6b72\u5973\u6027\u817a\u6a23\u56ca\u6027\u764c\u75c5\u4f8b\u3002\u5728\u6700\u521d\u7684\u624b\u8853\u5f8c\uff0c\u75c5\u60a3\u56e0\u70ba\u624b\u8853\u908a\u7de3\u816b\u7624\u6b98\u7559\u800c\u63a5\u53d7\u4e86\u5f8c\u7e8c\u7684\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7d66\u8207\u516d\u9031\u7684\u653e\u5c04\u7dda\u6cbb\u764260 Gy\u4ee5\u53caCisplatin 30 mg/m^2\u5316\u5b78\u6cbb\u7642\u3002\u75c5\u60a3\u8853\u5f8c\u5728\u6211\u5011\u7684\u9580\u8a3a\u8ffd\u8e64\u4e86\u4e00\u5e74\uff0c\u9664\u4e86\u5de6\u8072\u5e36\u9ebb\u75f9\u9020\u6210\u7684\u8072\u97f3\u5fae\u5f31\u4ee5\u5916\u4e26\u6c92\u6709\u770b\u5230\u5176\u4ed6\u7684\u526f\u4f5c\u7528\uff0c\u75c5\u60a3\u7684\u767c\u97f3\u529f\u80fd\u4e5f\u5728\u8072\u5e36\u6ce8\u5c04hyaluronic acid\u5f8c\u5f97\u5230\u6539\u5584\u3002\u6211\u5011\u5f97\u5230\u7684\u7d50\u8ad6\u662f\u8853\u5f8c\u8f14\u52a9\u540c\u6b65\u653e\u5c04\u7dda\u6cbb\u7642\u4f75\u5316\u5b78\u6cbb\u7642\u6216\u8a31\u662f\u4e00\u500b\u6cbb\u7642\u6c23\u7ba1\u817a\u6a23\u56ca\u6027\u764c\u5f88\u597d\u7684\u65b9\u5f0f\u3002", "e": "Primary tracheal cancer is a rare disease entity which represents 0.1-0.4% of all newly diagnosed cancers every year. Adenoid cystic carcinoma is the second most common histological type of tracheal cancer. The primary treatment modality is surgical excision. Post-operative radiotherapy also shows benefit in disease-free survival and overall survival. However, there were no randomized trials for post-operative chemoradiotherapy in patients with close margin due to its low incidence. Here, we present a 52-year-old female adenoid cystic carcinoma patient with a history of right breast mucinous carcinoma. After primary surgical resection, the patient received adjuvant concurrent chemoradiotherapy due to positive margin. Radiotherapy 60 Gy together with weekly cisplatin 30 mg/m^2 were delivered within six weeks. The patient was followed at our outpatient clinic for 1 more year after the initial surgery. No severe complications were found except for a persistant weak voice due to left vocal cord palsy. The patient's phonation improved after intracordal hyaluronic acid injection. We concluded that postoperative adjuvant concurrent chemoradiotherapy (CCRT) may be a good treatment modality for tracheal adenoid cystic carcinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-255-266", "title": "MicroRNA-17-5p Regulation of Apoptosis-Related Protein Expressions in Oral Squam ous Cell Ca rcinoma Cells Is Related to Betel Quid Chewing", "keywords": "\u5fae\u6838\u91a3\u6838\u917817-5p;\u653e\u5c04\u7dda;OC3\u7d30\u80de;p53\u86cb\u767d MicroRNA (miR)-17-5p;Radiation;Oral carcinoma 3 (OC3) cells;Tumor protein p53", "c": "\u524d\u8a00\uff1a\u5728\u53f0\u7063\u53e3\u8154\u764c\u8207\u56bc\u98df\u6ab3\u6994\u662f\u6709\u76f8\u95dc\u7684\uff0c\u653e\u5c04\u6cbb\u7642\u662f\u5176\u4e2d\u91cd\u8981\u7684\u4e00\u7a2e\u6cbb\u7642\u65b9\u5f0f\u3002\u904e\u53bb\u7684\u7814\u7a76\u8b49\u5be6\u5fae\u6838\u91a3\u6838\u917817-5p\uff08microRNAs 17-5p\uff1bmiR 17-5p\uff0c\u4e00\u7a2eRNA\u7684\u5206\u5b50\uff09\u5728\u7d93\u7531\u653e\u5c04\u7dda\u7167\u5c04\u904e\u5f8c\u7684\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\uff08\u9577\u671f\u56bc\u98df\u6ab3\u6994\u4f46\u4e0d\u62bd\u83f8\u4e4b\u53e3\u8154\u9c57\u72c0\u7d30\u80de\u764c\u4e4b\u7d30\u80de\u682a\uff09\u4e4b\u4e2d\u6703\u8868\u73fe\u51fa\u4f86\uff0c\u9084\u767c\u73femiR 17-5p\u6703\u6291\u5236\u4e0b\u6e38\u86cb\u767dp21\u7684\u8868\u73fe\u4e26\u589e\u52a0\u653e\u5c04\u7dda\u7684\u654f\u611f\u5ea6\u3002\u672c\u7bc7\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u5229\u7528\u4e86\u6578\u7d44\u4eba\u985e\u51cb\u4ea1\u86cb\u767d\u91d0\u6e05\u4e86\u76f8\u95dc\u86cb\u767d\u5c0d\u65bc\u5fae\u6838\u91a3\u6838\u917817-5p\u7684\u8abf\u63a7\u3002\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u7d30\u80de\u6eb6\u89e3\u7522\u7269\u5747\u4f86\u81ea\u65bc\u5177\u6709\u5c0f\u5e72\u64feRNA\u6216\u5fae\u6838\u91a3\u6838\u917817-5p\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\uff0c\u4e26\u5206\u6790\u5176\u51cb\u4ea1\u86cb\u767d\u7684\u8868\u73fe\u3002\u5fae\u6838\u91a3\u6838\u917817-5p\u76f8\u95dc\u4e4b\u51cb\u4ea1\u86cb\u767d\u6703\u518d\u5229\u7528\u897f\u65b9\u58a8\u9ede\u6cd5Westernblotting\u4f86\u78ba\u8a8d\u3002\u5229\u7528\u653e\u5c04\u7dda\u7167\u5c04\u7121p53\u548c\u6709\u9ad8\u5ea6\u7684p53\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\uff0c\u518d\u63a5\u53d7\u7898\u5316\u8207\u6d41\u5f0f\u7d30\u80de\u5100\u7684\u6aa2\u9a57\u3002\u7d50\u679c\uff1a\u4f7f\u7528\u4eba\u985e\u51cb\u4ea1\u86cb\u767d\u7d44\uff08R&D Systems; catalog # ARY009\uff09\uff0c\u6211\u5011\u89c0\u5bdf\u5230\u5728\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u7684\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\u4e2d\uff0c\u5728\u5fae\u6838\u91a3\u6838\u917817-5p\u76f8\u5c0d\u53cd\u7fa9\u5be1\u6838\u7518\u9178\u6216\u63a7\u5236\u7d44\u5be1\u6838\u7518\u9178\u7684\u8abf\u63a7\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\u4e0b\u670935\u7a2e\u51cb\u4ea1\u86cb\u767d\u5177\u6709\u5176\u76f8\u5c0d\u61c9\u7684\u53cd\u61c9\u3002\u5176\u4e2d\u4e00\u4e9b\u86cb\u767d\u8cea\uff0c\u5305\u62ecp21, p53, TNF RI,FADD, cIAP-1, HIF-1\u03b1,\u8207TRAIL R1\uff0c\u9019\u4e9b\u6a21\u7d44\u7684\u589e\u5f37\u8207\u6e1b\u5f31\u8868\u73fe\u65b9\u5f0f\u8207\u4f7f\u7528\u897f\u65b9\u58a8\u9ede\u6cd5\u78ba\u8a8d\u5f8c\u662f\u76f8\u540c\u7684\u3002\u65bc\u6b64\u6211\u5011\u66f4\u9032\u4e00\u6b65\u91d0\u6e05p53\u5728\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\u7d93\u653e\u5c04\u7dda\u7167\u5c04\u904e\u5f8c\u7684\u89d2\u8272\uff0c\u6211\u5011\u5c07p53\u904e\u5ea6\u8868\u73fe\uff0c\u8b49\u5be6\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\u4e2dp53\u7684\u8868\u73fe\u589e\u52a0\u6703\u963b\u65b7\u764c\u7d30\u80de\u9032\u5165G2/M\u5468\u671f\u7684\u6548\u679c\u662f\u986f\u8457\u7684\u3002\u7d50\u8ad6\uff1a\u5728\u9c57\u72c0\u764c\u7d30\u80deOC3\u4e2d\uff0c\u51cb\u4ea1\u86cb\u767dp21\u3001p53\u3001TNF RI\u3001FADD\u3001cIAP-1\u3001HIF-1\u03b1\u548cTRAIL R1\u8868\u73fe\u662f\u6703\u53d7\u5230\u5fae\u6838\u91a3\u6838\u9178 17-5p \u8abf\u63a7\u7684\u3002\u5c0d\u65bc\u9c57\u72c0\u764c\u7d30\u80de\u682aOC3\u4e2d\uff0c\u8abf\u63a7\u4fc3\u9032p53\u86cb\u767d\u8868\u73fe\uff0c\u5c0d\u65bc\u56e0\u56bc\u98df\u6ab3\u6994\u5f15\u8d77\u7684\u53e3\u8154\u764c\u7d30\u80de\u653e\u5c04\u7dda\u654f\u611f\u5ea6\u7684\u8abf\u7bc0\u662f\u6709\u5f71\u97ff\u7684\u3002", "e": "Background and purpose : Betel nut chewing is associated with oral cavity cancer in Taiwan. Radiotherapy is one of the therapeutic approaches. Our previous study demonstrated that microRNA (miR)-17-5p (one of the miR-17-92 polycistronic miRNAs) was enhanced in the irradiated OC3 cancer cell line (which was established from oral squamous cell carcinoma in a long-term betel nut chewer who did not smoke), and miR-17-5p was also found to inhibit downstream protein p21 expression and induce radiosensitivity. In this study, we used a human apoptosis protein array to clarify which apoptosis-related proteins are modulated by miR-17-5p. Materials and Methods : Total cell lysates from OC3 cells with control small interfering (si)RNA or miR-17-5p were used to analyze apoptosis-related proteins. A specific miR- 17-5p effector apoptosis-related protein was confirmed by Western blotting. To confirm the role of p53 in irradiated OC-3 cells, OC3 cells without or with a p53-overexpressing clone were irradiated and examined by propidium iodide staining and flow cytometry. Results : Using a human apoptosis protein array analysis (R&D Systems; catalog # ARY009), we simultaneously detected the relative expressions of 35 apoptosis-related proteins in OC3 cells that were treated with an miR-17-5p antisense oligonucleotide (AS-ODN) or a control ODN. Several proteins, including p21, p53, TNF RI, FADD, cIAP-1, HIF-1\u03b1, and TRAIL R1, were found to be up- or downregulated by miR-17-5p in OC3 cells; their expression patterns were also confirmed by Western blotting. We further clarified the role of p53 in irradiated OC3 cells, using a p53 overexpression strategy, and results revealed that enhancement of p53 expression significantly enhanced radiation-induced G2/M arrest of OC3 cells. Conclusions : miR-17-5p regulated the apoptosis-related proteins of p21, p53, TNF RI, FADD, cIAP-1, HIF-1\u03b1, and TRAIL R1 in OC3 cells; interestingly, its effect on p53 protein expression contributed to modulating the cell cycle arrest of OC3 cells."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-267-274", "title": "The role of radioTherapy in The TreaTmenT of hepaTocellular carcinoma wiTh inferior vena cava Tumor Thrombosis", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u809d\u7d30\u80de\u764c;\u4e0b\u8154\u975c\u8108 Radiotherapy;Hepatocellular carcinoma;Inferior vena cava", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u653e\u5c04\u7dda\u6cbb\u7642\u61c9\u7528\u65bc\u809d\u7d30\u80de\u764c\u5408\u4f75\u4e0b\u8154\u975c\u8108\u816b\u7624\u6813\u585e\u4e4b\u6210\u6548\uff0c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\u65b9\u6cd5\uff1a\u65bc 2006\u5e74\u81f32009\u5e74\u9593\uff0c\u517122\u4f4d\u809d\u7d30\u80de\u764c\u5408\u4f75\u4e0b\u8154\u975c\u8108\u816b\u7624\u6813\u585e\u4e4b\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u5291\u91cf\u70ba 60 Gy\uff0c\u520630\u6b21\u7d66\u4e88\u3002\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\u3002\u7d50\u679c\uff1a\u67097\u4f4d\u75c5\u60a3\u9054\u5230\u5b8c\u5168\u53cd\u61c9\uff0c6\u4f4d\u75c5\u60a3\u9054\u5230\u90e8\u5206\u53cd\u61c9\u3002\u6574\u9ad41\u5e74\u5b58\u6d3b\u7387\u70ba40.9%\uff0c2\u5e74\u5b58\u6d3b\u7387\u70ba22.7%\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba8\u500b\u6708\u3002\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u7522\u751f\u5ba2\u89c0\u53cd\u61c9\uff08\u5305\u62ec\u5b8c\u5168\u53cd\u61c9\u53ca\u90e8\u5206\u53cd\u61c9\uff09\u70ba\u552f\u4e00\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u6709\u5ba2\u89c0\u53cd\u61c9\u4e4b\u75c5\u60a3\u4e4b1\u5e74\u5b58\u6d3b\u7387\u70ba53.8%\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba16.9\u500b\u6708\u3002\u7121\u5ba2\u89c0\u53cd\u61c9\u4e4b\u75c5\u60a3\u4e4b1\u5e74\u5b58\u6d3b\u7387\u70ba 22.2%\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba4.7\u500b\u6708\uff08p= 0.004\uff09\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u809d\u7d30\u80de\u764c\u5408\u4f75\u4e0b\u8154\u975c\u8108\u816b\u7624\u6813\u585e\u4e4b\u75c5\u60a3\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u4ee5\u626e\u6f14\u7de9\u89e3\u6cbb\u7642\u7684\u89d2\u8272\u3002", "e": "Purpose : To evaluate the role of radiotherapy in treatment of hepatocellular carcinoma (HCC) with inferior vena cava tumor thrombosis (IVCTT) and the prognostic factors for overall survival. Materials and Methods : Twenty-two patients with HCC and IVCTT referred for radiotherapy between 2006 and 2009 were retrospectively reviewed. A total of 60 Gy in 30 daily fractions was delivered with intensity-modulated radiotherapy techniques. Patient-related and treatment-related factors were analyzed to evaluate their prognostic significance for overall survival rate. Results : Complete response was noted in 7 patients and partial response in 6 patients. The 1-year, 2-year overall survival rates were 40.9 %, 22.7% and the median survival was 8 months for the entire cohort of patients. Objective response (complete or partial response) to radiotherapy was the only prognostic factor for overall survival. For patients with objective response to radiotherapy, the median survival was 16.9 months and the 1-year overall survival rate was 53.8%, compared to 4.7 months and 22.2% of those without objective response (p =0.004). Conclusions : Our results showed that radiotherapy achieved a high objective response rate and prolonged survival in patients with HCC and IVCTT. Patients with response to radiotherapy have favorable prognosis than their counterpart. Radiotherapy could be considered as an effective palliative treatment option for patients with HCC and IVCTT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-275-284", "title": "Preliminary outcome on toxicities and biochemical control of image-guided radiotheraPy in intermediateto high-risk Prostate cancer", "keywords": "\u651d\u8b77\u817a\u764c;\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u7dda\u6cbb\u7642;\u651d\u8b77\u817a\u7279\u7570\u6297\u539f Prostate cancer;Image-guided radiotherapy (IGRT);Prostate specific antigen (PSA)", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4e2d\u9ad8\u98a8\u96aa\u5ea6\u651d\u8b77\u817a\u764c\u75c5\u4eba\u63a5\u53d7\u87ba\u65cb\u5200\u6216\u92b3\u901f\u5200\u4e4b\u5f71\u50cf\u5c0e\u5f15\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u751f\u5316\u7121\u5fa9\u767c\u7387\u53ca\u6cbb\u7642\u526f\u4f5c\u7528\u4e4b\u521d\u6b65\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a2008\u5e744\u6708\u81f32012\u5e7410\u6708\uff0c\u517172\u4f4d\u6709\u4e2d\u9ad8\u98a8\u96aa\u5ea6\u651d\u8b77\u817a\u764c\u4e14\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u75c5\u60a3\u65bc\u672c\u79d1\u63a5\u53d7\u5f71\u50cf\u5c0e\u5f15\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3002\u5e74\u9f61\u7bc4\u570d\u4ecb\u65bc58\u81f389\u6b72\uff0c\u5e73\u5747\u5e74\u9f61\u70ba73\u6b72\u300223\u4f4d\u70ba\u4e2d\u98a8\u96aa\u5ea6\uff0c49\u4f4d\u70ba\u9ad8\u98a8\u96aa\u5ea6\u3002\u5206\u5225\u670951\u4f4d\u63a5\u53d7\u87ba\u65cb\u5200\u6cbb\u7642\uff0c21\u4f4d\u63a5\u53d7\u92b3\u901f\u5200\u6cbb\u7642\u3002\u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u7684\u5e73\u5747\u5291\u91cf\u70ba74 Gy\u300220\u4f4d\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u800c\u670952\u4f4d\u63a5\u53d7\u653e\u5c04\u7dda\u5408\u4f75\u8cc0\u723e\u8499\u6cbb\u7642\u3002\u751f\u7269\u5316\u5b78\u5931\u6557\u7684\u81e8\u5e8a\u5b9a\u7fa9\u662f\u63a1\u7528\u8840\u6db2\u4e2d\u6e2c\u5f97\u7684\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u503c\u5927\u65bc\u6700\u4f4e\u503c\u52a02 ng/mL\u3002\u6cbb\u7642\u5f8c\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u6700\u4f4e\u503c\u4ee50.2 ng/mL\u70ba\u95be\u503c\u6216\u4ee5\u51fa\u73fe\u66ab\u6642\u6027\u53cd\u5347\u524d\u6700\u4f4e\u503c\u70ba\u6a19\u6e96\u3002\u6cbb\u7642\u526f\u4f5c\u7528\u4f9d\u7167\u5e38\u898b\u4e0d\u826f\u4e8b\u4ef6\u8a55\u50f9\u6a19\u6e96\u7b2c\u4e09\u7248\uff08CTCAE v.3.0\uff09\u4f86\u8a55\u4f30\u3002\u7d50\u679c\uff1a\u5e73\u5747\u8ffd\u8e64\u6642\u959328\u500b\u6708\u30024\u4f4d\u75c5\u60a3\u6709\u751f\u7269\u5316\u5b78\u5931\u6557\u3002\u5728\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u63a5\u53d7\u653e\u5c04\u7dda\u5408\u4f75\u8cc0\u723e\u8499\u6cbb\u7642\u7684\u5169\u7fa4\u75c5\u60a3\u4e2d\uff0c\u653e\u5c04\u6cbb\u7642\u5f8c\u5230\u9054\u6700\u4f4e\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u503c\u7684\u6642\u9593\u5206\u5225\u70ba15.58\u53ca5.73\u500b\u6708\uff08p = 0.001\uff09\u3002\u6240\u6709\u75c5\u60a3\u7684\u653e\u5c04\u7dda\u7642\u7a0b\u7686\u7121\u4e2d\u65b7\u300243\u4f4d\u75c5\u4eba\uff0859.7%\uff09\u7522\u751f\u6025\u6027\u7b2c\u4e00\u7d1a\u6ccc\u5c3f\u9053\u75c7\u72c0\uff0c4\u4f4d\u75c5\u4eba\uff085.6%\uff09\u7522\u751f\u6025\u6027\u7b2c\u4e8c\u7d1a\u6ccc\u5c3f\u9053\u75c7\u72c0\uff0c\u7121\u75c5\u4eba\u6709\u6025\u6027\u7b2c\u4e09\u7d1a\u4ee5\u4e0a\u6ccc\u5c3f\u9053\u75c7\u72c0\u300225\u4f4d\u75c5\u4eba\uff0834.7%\uff09\u7522\u751f\u6025\u6027\u7b2c\u4e00\u7d1a\u8178\u80c3\u9053\u75c7\u72c0\uff0c\u7121\u75c5\u4eba\u6709\u6025\u6027\u7b2c\u4e8c\u7d1a\u4ee5\u4e0a\u8178\u80c3\u9053\u75c7\u72c0\u3002\u5169\u4f4d\u75c5\u60a3\u5728\u653e\u5c04\u6cbb\u764220\u500b\u6708\u5f8c\u5de6\u53f3\u88ab\u8a3a\u65b7\u51fa\u6709\u653e\u5c04\u6cbb\u7642\u5f8c\u76f4\u8178\u708e\u3002\u7d50\u8ad6\uff1a\u5f71\u50cf\u5c0e\u5f15\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u91dd\u5c0d\u4e2d\u9ad8\u98a8\u96aa\u5ea6\u651d\u8b77\u817a\u764c\u75c5\u4eba\u70ba\u4e00\u7a2e\u6709\u6548\u4e14\u6613\u63a5\u53d7\u7684\u6cbb\u7642\u3002\u800c\u6211\u5011\u4e5f\u89c0\u5bdf\u5230\u653e\u5c04\u7dda\u5408\u4f75\u8cc0\u723e\u8499\u6cbb\u7642\u7684\u9019\u7fa4\u75c5\u60a3\u4e2d\uff0c\u6709\u6bd4\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u66f4\u597d\u7684\u751f\u7269\u5316\u5b78\u63a7\u5236\u7387\u3002\u7136\u800c\u5c1a\u9808\u8981\u66f4\u9577\u7684\u8ffd\u8e64\u6642\u9593\u4ee5\u6bd4\u8f03\u7d50\u679c\u3002", "e": "Purpose: To evaluate the preliminary outcome of curative image-guided radiotherapy (IGRT) with Helical Tomotherapy or RapidArc for patients with intermediate- to highrisk prostate cancer. Materials and Methods: Between April 2008 and October 2012, 72 patients with pathologically proven prostate adenocarcinoma were included. Age ranged from 58 to 89 with mean age of 73 years. Twenty-three patients were intermediate-risk group and 49 were high-risk group. Fifty-one and 21 patients were treated with Helical Tomotherapy and RapidArc respectively. The mean radiation dose was 74 Gy. Twenty patients were treated with external beam radiation therapy alone (EBRT-only group) and 52 were treated with EBRT plus androgen deprivation therapy (EBRT-ADT group). The biochemical failure was defined by a rise of 2 ng/mL or more above the nadir prostate specific antigen (PSA). The nadir was defined as lowest PSA value preceding a given threshold of 0.2 ng/mL or as absolutely lowest PSA before the transient bounce. Toxicities were assessed and documented in agreement with the Common Terminology Criteria for Adverse Events version 3 (CTCAE v.3.0). Results: With the mean follow-up period of 28 months, four patients (5%, 4/72) had biochemical failure. The mean time interval to achieve the nadir PSA (TnPSA) in the EBRT-only group and EBRT-ADT group were 15.58 months and 5.73 months respectively (p = 0.001). All patients tolerated IGRT without any interruption. The patients exhibited grades 1 and 2 levels of acute genitourinary toxicities at 59.7% (43/72) and 5.6% (4/72). Grade 1 acute gastrointestinal toxicity was 34.7% (25/72). As for late toxicity, two patients developed grade 2 radiation proctitis 20 months after EBRT. Conclusion : IGRT for patients with intermediate- to high-risk prostate cancer was an effective and well-tolerated treatment. The EBRT-ADT group had better biochemical control than the EBRT-only group. Longer follow-up period was necessary."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-285-296", "title": "Evaluation of thE dosimEtric and radiobiological impacts on prostatE cancEr patiEnts of daily imagE-guidEd volumEtric modulatEd arc thErapy", "keywords": "\u5f27\u65cb\u5200;\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u6383\u63cf;\u7b49\u50f9\u5747\u52fb\u5291\u91cf;\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387 Volumetric modulated arc therapy (VMAT);Cone-beam computed tomography (CBCT);Equivalent uniform dose (EUD);Normal tissue complication probability (NTCP)", "c": "\u76ee\u7684\uff1a\u5c0d\u65bc\u6cbb\u7642\u651d\u8b77\u817a\u764c\u7684\u75c5\u60a3\uff0c\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\u88ab\u8a8d\u70ba\u53ef\u4ee5\u964d\u4f4e\u526f\u4f5c\u7528\u4e26\u6539\u5584\u9810\u5f8c\u3002\u672c\u7814\u7a76\u5229\u7528\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u6a21\u64ec\u6709\u7121\u5f71\u50cf\u5c0e\u5f15\u4e0b\u4e4b\u5291\u91cf\u5206\u5e03\uff0c\u4ee5\u8a55\u4f30\u5169\u8005\u5291\u91cf\u5b78\u4e0a\u7684\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u8490\u96c6\u4e8610\u500b\u4f7f\u7528\u5f27\u65cb\u5200\u6cbb\u7642\u651d\u8b77\u817a\u764c\u75c5\u60a3\uff0c\u6bcf\u500b\u75c5\u60a3\u7684\u8a08\u5283\u9776\u9ad4\u7a4d\u90fd\u662f\u4ee5\u81e8\u5e8a\u6a19\u9776\u9ad4\u7a4d\u5411\u5404\u500b\u65b9\u5411\u589e\u52a05 mm\u6240\u5f97\u5230\u7684\uff0c\u6211\u5011\u4f9d\u7167\u6bcf\u65e5\u6cbb\u7642\u524d\u57f7\u884c\u5f71\u50cf\u5c0e\u5f15\u6240\u5f97\u5230\u7684\u64fa\u4f4d\u8aa4\u5dee\u79fb\u52d5\u9019\u4e9b\u75c5\u4eba\u7684\u539f\u59cb\u6cbb\u7642\u8a08\u756b\u4e2d\u7167\u5c04\u4e4b\u4e2d\u5fc3\u9ede\u4ee5\u6a21\u64ec\u6c92\u6709\u5f71\u50cf\u5c0e\u5f15\u4e0b\u7684\u5291\u91cf\u5206\u5e03\uff0c\u63a5\u8457\u4ee5\u5291\u91cf\u5b78\u6307\u6a19\uff08dosimetric index\uff09\u6bd4\u8f03\u539f\u5291\u91cf\u5206\u5e03\u8207\u6a21\u64ec\u7121\u5f71\u50cf\u5c0e\u5f15\u5291\u91cf\u5206\u5e03\u4e4b\u5dee\u7570\uff0c\u6700\u5f8c\u8a08\u7b97\u7b49\u50f9\u5747\u52fb\u5291\u91cf\uff08equivalent uniform dose\uff09\u4ee5\u53ca\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\uff08normal tissue complicationprobability\uff09\u4ee5\u8a55\u4f30\u65bc\u751f\u7269\u6548\u61c9\u4e0a\u4e4b\u5f71\u97ff\u3002\u7d50\u679c\uff1a\u64fa\u4f4d\u7684\u7cfb\u7d71\u8aa4\u5dee\uff08\u03a3\uff09\u4ee5\u53ca\u96a8\u6a5f\u8aa4\u5dee\uff08\u03c3\uff09\u65bc\u5de6\u53f3\uff08LR\uff09\u3001\u4e0a\u4e0b\uff08SI\uff09\u3001\u524d\u5f8c\uff08AP\uff09\u65b9\u5411\u5404\u70ba0\u03a3 LR= 1.4 mm, \u03c3 LR= 1.95 mm, \u03a3 SI= 3.22 mm, \u03c3 SI= 2.46 mm, \u03a3 AP= 3.17 mm\u4ee5\u53ca\u03c3 AP=2.79 mm\u3002\u5728\u6a21\u64ec\u7121\u5f71\u50cf\u5c0e\u5f15\u7684\u60c5\u6cc1\u4e0b\uff0c\u81e8\u5e8a\u6a19\u9776\u9ad4\u7a4d\u7684\u5291\u91cf\u8986\u84cb\u7387\u8f03\u5dee\uff08V100%: 99.99% vs.92.37%, p \uff1c 0.05 and V95%: 100% vs. 99.46%, p \uff1c 0.05\uff09\u4e14\u7b49\u50f9\u5747\u52fb\u5291\u91cf\u4ea6\u8f03\u4f4e\uff0876.8 Gy vs. 75.4Gy, p \uff1c 0.05\uff09\u3002\u76f4\u8178\u4ee5\u53ca\u8180\u80f1\u7684\u5291\u91cf\u5b78\u6307\u6a19\u3001\u7b49\u50f9\u5747\u52fb\u5291\u91cf\u4ee5\u53ca\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u7686\u7121\u660e\u986f\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u5728\u4ee5\u651d\u8b77\u817a\u52a05 mm\u4f5c\u70ba\u8a08\u756b\u6a19\u9776\u9ad4\u7a4d\u7684\u72c0\u6cc1\u4e0b\uff0c\u4f7f\u7528\u5f27\u65cb\u5200\u642d\u914d\u5f71\u50cf\u5c0e\u5f15\u6cbb\u7642\u651d\u8b77\u817a\u764c\u53ef\u4ee5\u964d\u4f4e\u64fa\u4f4d\u8aa4\u5dee\uff0c\u4e26\u907f\u514d\u56e0\u8aa4\u5dee\u9020\u6210\u81e8\u5e8a\u6a19\u9776\u9ad4\u7a4d\u5291\u91cf\u4f4e\u65bc\u9810\u671f\u4e4b\u60c5\u6cc1\uff0c\u4e0d\u904e\u5c0d\u65bc\u76f4\u8178\u53ca\u8180\u80f1\u4e4b\u5291\u91cf\u548c\u751f\u7269\u6548\u61c9\uff0c\u4e26\u7121\u660e\u986f\u5dee\u7570\u3002", "e": "Purpose: Image-guided radiation therapy (IGRT) was suggested to improve outcomes and reduce toxicity for localized prostate cancer treatment. We generated virtual treatment plans to evaluate the dosimetric impacts with and without IGRT. Materials and Methods: Daily position setup errors from 10 patients treated with volumetric modulated arc therapy (VMAT) were acquired with cone-beam computed tomography (CBCT). A margin of 5 mm was added to the clinical target volume (CTV) to generate a planned target volume (PTV). We shifted the isocenters in the planning system with errors, fraction by fraction, to simulate the situation without IGRT. Dosimetric indices were compared between the initial plans (pretreatment CT plans) and the shifted plans. Radiobiological evaluations of an equivalent uniform dose (EUD) and normal tissue complication probability (NTCP) were also performed. Results : The system errors (\u03a3) and random errors (\u03c3) in the left-right (LR), superiorinferior (SI), and anterior-posterior (AP) directions were \u03a3 LR=1.4 mm, \u03c3 LR= 1.95 mm, \u03a3 SI =3.22 mm, \u03c3 SI = 2.46 mm, \u03a3 AP=3.17 mm and \u03c3 AP = 2.79 mm. Coverage of the CTV for 100% and 95% of the prescribed doses were lower in the shifted plans (V100%: 99.99% vs. 92.37%, p \uff1c 0.05 and V95%: 100% vs. 99.46%, p \uff1c 0.05). There was no difference in the dosimetric indices for the bladder and rectum. The EUD value of the CTV was also lower in the shifted plan (76.8 Gy vs. 75.4 Gy, p \uff1c 0.05). The EUD and NTCP for the bladder and rectum did not statistically differ. Conclusions: Using CBCT-acquired VMAT for treating prostate cancer not only shortened the treatment time but also decreased the setup uncertainty. In the setting of reducing the PTV margin to 5 mm, the dose to the prostate was compromised without IGRT but the estimated toxicity to the rectum and bladder exhibited no difference."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-297-306", "title": "\u61c9\u7528NIPAM\u51dd\u81a0\u5291\u91cf\u8a08\u5728\u547c\u5438\u904b\u52d5\u4e0b\u9a57\u8b49\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u7684\u53ef\u884c\u6027\u7814\u7a76", "keywords": "\u4e09\u7dad\u5291\u91cf\u5206\u4f48;\u5291\u91cf\u9a57\u8b49;NIPAM\u51dd\u81a0\u5291\u91cf\u8a08;\u5291\u91cf\u66f2\u7dda Three-dimensional dose distribution;Dose verification;NIPAM gel dosimeters;Dose curve", "c": "\u76ee\u7684\uff1a\u5229\u7528NIPAM\u51dd\u81a0\u5291\u91cf\u8a08\u9032\u884c\u547c\u5438\u60c5\u6cc1\u4e0b\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u9a57\u8b49\u7684\u53ef\u884c\u6027\u8a55\u4f30\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4f7f\u7528\u6821\u6b63\u8a66\u7ba1\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u5206\u5225\u8a2d\u7f6e\u65bc\u81ea\u884c\u8a2d\u8a08\u7684\u6a21\u64ec\u80f8\u90e8\u547c\u5438\u904b\u52d5\u7684\u53ef\u79fb\u52d5\u8a2d\u5099\u4e0a\u9032\u884c\u5be6\u9a57\u3002\u6821\u6b63\u7ba1\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u904b\u52d5\u53c3\u6578\u70ba\uff1a\u00b11 cm\u982d\u8173\u5411\u4f4d\u79fb\uff08\u7e3d\u95772 cm\uff09\uff0c\u6bcf4\u79d2\u4f86\u56de\u4e00\u6b21\u3002\u7167\u5c04\u524d\u6821\u6b63\u7ba1\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u7d93\u7531CT simulator\u53d6\u7684CT\u5f71\u50cf\uff0c\u7531Varian\u7684Eclipse\u8a08\u5283\u7cfb\u7d71\u5b8c\u6210\u6cbb\u7642\u8a08\u756b\u53ca\u8a08\u7b97MU\u503c\u3002NIPAM\u51dd\u81a0\u6821\u6b63\u7ba1\u70ba\u4e00\u73bb\u7483\u8a66\u7ba1\uff0c\u4f7f\u7528Varian iX\u76f4\u7dda\u52a0\u901f\u5668\u7167\u5c04\uff0c\u7167\u5c04\u5291\u91cf\u5206\u5225\u70ba0\u30011\u30012\u30015\u30018\u300110 Gy\uff086 MV\u5149\u5b50\uff09\u3002\u7136\u5f8c\u9032\u884cMRI\u6383\u63cf\uff0c\u53d6\u5f97\u6bcf\u500b\u6821\u6b63\u7ba1\u7167\u5c04\u5f8c\u6240\u7372\u5f97MRI\u7684T2\u503c\u4e26\u5c07\u5176\u8f49\u63db\u70baR2\u503c\uff0c\u7e6a\u88fd\u5291\u91cf\u6821\u6b63\u66f2\u7dda\u3002\u53e6\u5916\uff0c\u5c07\u5713\u67f1\u578b\u7a7a\u74f6\u5167\u586b\u5145NIPAM\u51dd\u81a0\uff0c\u4f7f\u7528Varian iX\u76f4\u7dda\u52a0\u901f\u5668\u57f7\u884cbilateral tangential forward field-infieldIMRT\u6cbb\u7642\u8a08\u756b\uff0c\u7167\u5c04\u5291\u91cf5.4 Gy\uff086 MV\u5149\u5b50\uff09\u3002\u7136\u5f8c\u9032\u884cMRI\u6383\u63cf\uff0c\u4f7f\u7528MATLAB\u8edf\u4ef6\u9032\u884c\u5206\u6790\u6bd4\u8f03\uff0c\u8a55\u4f30\u6cbb\u7642\u8a08\u756b\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u5291\u91cf\u66f2\u7dda\u7684\u8b8a\u5316\u3002\u7d50\u679c\uff1a\u6821\u6b63\u7d50\u679c\u9748\u654f\u5ea6\u70ba 0.1353 s-1/Gy\uff0c\u5291\u91cf\u66f2\u7dda\u7684\u76f8\u95dc\u4fc2\u6578\uff08correlation coefficient, R2\uff09\u70ba0.9952\u3002\u8ef8\u5411\u5207\u9762\u6bd4\u8f03\u6cbb\u7642\u8a08\u5283\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u5291\u91cf\u5206\u4f48\uff0c\u572870%\u81f380%\u7684\u5291\u91cf\u66f2\u7dda\u6709\u8f03\u9ad8\u543b\u5408\u5ea6\u3002\u77e2\u72c0\u9762\u548c\u51a0\u72c0\u9762\u6cbb\u7642\u8a08\u756b\u548c\u51dd\u81a0\u5291\u91cf\u8a08\u7684\u4f4e\u5291\u91cf\u5340\uff08\uff1c 60%\u5291\u91cf\u66f2\u7dda\uff09\u5176\u5291\u91cf\u66f2\u7dda\u9762\u7a4d\u5927\u65bc\u6cbb\u7642\u8a08\u756b\u9762\u7a4d\u3002\u6b64\u5916\uff0c\u9ad8\u5291\u91cf\u7684\u5340\u57df\u4e2d\u7684\u6cbb\u8a08\u7642\u8a08\u5283\u7684\u9762\u7a4d\u6bd4\u51dd\u81a0\u5291\u91cf\u5291\u91cf\u66f2\u7dda\u9762\u7a4d\u5927\u3002\u7d50\u8ad6\uff1a\u672c\u6a21\u51dd\u5be6\u9a57\u8b49\u660e\u4e86NIPAM\u51dd\u81a0\u5291\u91cf\u8a08\u642d\u914d\u53ef\u79fb\u52d5\u8a2d\u5099\u6240\u53d6\u5f97\u4e09\u7dad\u5291\u91cf\u5206\u4f48\u8b8a\u5316\u8207\u6cbb\u7642\u8a08\u756b\u8a08\u7b97\u503c\u662f\u4e00\u81f4\uff0c\u56e0\u6b64\u4f7f\u7528NIPAM\u51dd\u81a0\u5291\u91cf\u8a08\u4f86\u9a57\u8b49\u547c\u5438\u60c5\u6cc1\u4e0b\u7684\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u662f\u53ef\u884c\u7684\u3002", "e": "Purpose: Evaluation of NIPAM gel dosimeter under respiratory motion to verify radiotherapy treatment plan. Materials and Methods: We used a self-designed NIPAM gel dosimeter and a set of NIPAM gel calibration tubes to perform the experiment. The calibration tubes and gel dosimeter were set on a movable device which simulated respiratory movement of the chest. The movement parameters of the calibration tubes and the gel dosimeter were: \u00b110 mm cephalic and caudal displacement (20 mm in total), and a period of 4 seconds. Correction and gel dosimeter before irradiation CT images were taken by CT simulator. The calibration tube was made by filling NIPAM gel into a test tube. For each calibration tube, a specific radiation dose of 0,1, 2, 5, 8,10 Gy (6 MV photon) was given respectively by a Varian iX Linear accelerator. MRI scan was then performed to each calibration tube after irradiation and the T2 value obtained was converted to R2 value before a calibration curve was plotted. Another cylinder was also filled with NIPAM gel. A treatment plan of bilateral tangential forward field-in-field IMRT was done by Varian Eclipse planning system. The gel dosimeter was then irradiated up to 5.4 Gy (6 MV photon) with Varian iX linear accelerator using the treatment plan generated by the treatment planning system. A MRI scan was then performed, and the image data was than analyzed with MATLAB to evaluate dose curve change between the treatment plan and the gel dosimeter. Results: The sensitivity of the calibration gel dosimeter was 0.1353 s^(-1)/Gy. The correlation coefficient (R^2) of the calibration curve was 0.9952. In axial sections, when comparing dose distribution of the treatment plan and the gel dosimeter, 70% and 80% isodose curves were in high concordance. In sagittal and coronal views, the area of low dose region (\uff1c 60% isodose curves) in the gel dosimeter was larger than that of the treatment plan. In addition, the area of high dose region in the treatment plan was larger than that of the gel dosimeter. Conclusion: We demonstrated three-dimensional dose distribution of the NIPAM gel dosimeter with respiratory motion, had high concordance with that of the calculated treatment plan. Therefore using NIPAM gel dosimeter to verify radiotherapy treatment plan with respiratory motion is feasible."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-307-314", "title": "\u904b\u7528\u7db2\u8def\u61c9\u7528\u7de8\u7a0b\u4ecb\u9762\u6574\u5408\u5404\u653e\u5c04\u6cbb\u7642\u5100\u4e26\u9023\u7d50\u91ab\u9662\u8cc7\u8a0a\u7cfb\u7d71", "keywords": "\u96fb\u5b50\u75c5\u6b77;\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71;\u8a18\u9304\u66a8\u9a57\u8b49\u7cfb\u7d71 Electronic medical records;Radiation oncology information system;Records and verify systems", "c": "\u76ee\u7684\uff1a\u5efa\u7f6e\u4e00\u7db2\u9801\u61c9\u7528\u7de8\u7a0b\u4ecb\u9762\u4ee5\u6574\u5408\u653e\u5c04\u816b\u7624\u90e8\u9580\u73fe\u5b58\u4e0d\u540c\u5ee0\u724c\u653e\u5c04\u6cbb\u7642\u5100\u4e4b\u6cbb\u7642\u8a18\u9304\uff0c\u4e26\u61c9\u7528\u65bc\u653e\u5c04\u816b\u7624\u96fb\u5b50\u75c5\u6b77\u5316\u8207\u91ab\u9662\u5167\u73fe\u884c\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\u4e4b\u9023\u7d50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u7814\u7a76\u5256\u6790\u4e09\u5957\u5546\u7528\u8a18\u9304\u66a8\u9a57\u8b49\u7cfb\u7d71\u4e4b\u7d50\u69cb\u548c\u6b04\u4f4d\u4e26\u6253\u9020\u4e00\u7db2\u8def\u61c9\u7528\u7de8\u7a0b\u4ecb\u9762\uff0c\u5176\u5305\u542b\u529f\u80fd\u5982\u4e0b\uff1a1.\u900f\u904ePHP\u548c\u6a19\u6e96SQL\u8a9e\u8a00\u5c07\u6240\u9700\u6b04\u4f4d\u8cc7\u6599\u7531\u8a18\u9304\u66a8\u9a57\u8b49\u7cfb\u7d71\u8cc7\u6599\u5eab\u4e2d\u53d6\u56de\uff0c2.\u5c07\u53d6\u56de\u8cc7\u8a0a\u6574\u7406\u4e26\u91cd\u65b0\u7de8\u6392\uff0c3.\u75c5\u4eba\u4e4b\u6cbb\u7642\u8a18\u9304\u900f\u904eJSON\u683c\u5f0f\u50b3\u56de\u81f3\u91ab\u9662\u7cfb\u7d71\u3002\u6211\u5011\u7d71\u8a08\u4f7f\u7528\u6b64\u7cfb\u7d71\u3001\u5546\u7528\u8edf\u9ad4\u3001\u7d19\u672c\u75c5\u6b77\u4f86\u67e5\u8a6220\u4f4d\u75c5\u60a3\u4e4b\u6cbb\u7642\u8a18\u9304\u6240\u8cbb\u6642\u9593\uff0c\u4ee5\u8a55\u4f30\u6b64\u7cfb\u7d71\u5e36\u4f86\u4e4b\u6548\u76ca\u3002\u7d50\u679c\uff1a\u6b64\u7cfb\u7d71\u7368\u7acb\u904b\u4f5c\u5728\u4e0d\u5f71\u97ff\u73fe\u5b58\u653e\u5c04\u6cbb\u7642\u5de5\u4f5c\u6d41\u7a0b\u4e4b\u4e0b\uff0c\u53ef\u9054\u5230\u8207\u91ab\u9662\u7cfb\u7d71\u9593\u8cc7\u8a0a\u4ea4\u63db\uff0c\u4efb\u4f55\u5177\u5099\u6b0a\u9650\u7684\u4f7f\u7528\u8005\uff0c\u7686\u53ef\u4ee5\u5728\u4efb\u610f\u6642\u9593\u3001\u5728\u91ab\u9662\u5404\u500b\u89d2\u843d\uff0c\u900f\u904e\u4e92\u52d5\u5f0f\u7db2\u9801\uff0c\u67e5\u8a62\u75c5\u60a3\u5373\u6642\u6cbb\u7642\u8a18\u9304\uff0c\u7bc0\u7701\u7d19\u672c\u75c5\u6b77\u7684\u904b\u9001\u53ca\u4eba\u70ba\u9375\u5165\u8cc7\u6599\u7684\u8aa4\u5dee\u3002\u8207\u8abf\u95b1\u7d19\u672c\u75c5\u6b77\uff08\u6642\u9593\uff1a927 \u00b1 2541\u79d2\uff09\u3001\u5206\u5225\u9032\u5165\u5404\u5546\u7528\u8edf\u9ad4\u67e5\u8a62\uff08\u6642\u9593\uff1a17.1 \u00b1 16.2\u79d2\uff09\u76f8\u6bd4\uff0c\u6b64\u7cfb\u7d71\uff08\u6642\u9593\uff1a1.08 \u00b1 0.56\u79d2\uff09\u4e5f\u986f\u8457\u7684\u6e1b\u5c11\u6cbb\u7642\u8a18\u9304\u67e5\u8a62\u6642\u9593\u3002\u7d50\u8ad6\uff1a\u6b64\u7cfb\u7d71\u81ea\u52d5\u5316\u6574\u5408\u4e86\u4e0d\u540c\u5ee0\u724c\u6cbb\u7642\u5100\u5668\u7684\u6cbb\u7642\u8a18\u9304\uff0c\u6253\u7834\u4e86\u6642\u9593\u3001\u5730\u57df\u548c\u5ee0\u724c\u7cfb\u7d71\u7684\u85e9\u7c6c\uff0c\u5c0d\u653e\u5c04\u6cbb\u7642\u75c5\u6b77\u5168\u9762\u96fb\u5b50\u5316\u53ca\u96fb\u5b50\u5316\u7ba1\u7406\u6709\u6975\u5927\u5e6b\u52a9\uff0c\u4e5f\u7bc0\u7701\u4f7f\u7528\u8005\u67e5\u8a62\u6cbb\u7642\u8a18\u9304\u6642\u9593\u3002", "e": "Purpose: The purpose of this study was to develop a web application programming interface to integrate records and verify systems of various vendors and help bridging hospital information system and electronic radiotherapy medical record. Materials and Methods: The structure and fields of three commercial records and verify systems were identified and studied. A web application programming interface was implemented to perform the following three tasks: 1. Pre-defined fields were queried from each database using PHP and standard SQL language, 2. The retrieved data were rearranged and consolidated to fulfill clinical needs, 3. The patients' treatment histories were summarized and exported to hospital information system via JSON format. The performance of the web API, commercial applications, and with manual transfer of paper charts were measured by analysis of query time for twenty patients. Results: The system has been transparently incorporated into our radiation treatment planning workflow. The website-based database interface has allowed authorized users with minimal training to extract patient's daily treatment from the database anytime and anywhere in the hospital. The query time significantly decreased using this system. Conclusions : The web application programming interface can integrate patient's treatment data from different commercial treatment machines and export to hospital information system. The application breakthrough the vendor's limitation, and is helpful in developing radiotherapy electronic medical records. Acknowledgement : This study was supported in part by the grant of Center of Excellence for Cancer Research, No. MOHW104-TDU-B-211-124-001."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-315-321", "title": "IntraoperatIve radIotherapy of extrahepatIc cholangIocarcInoma- a case report", "keywords": "\u809d\u5916\u81bd\u7ba1\u764c;\u624b\u8853\u5207\u9664;\u624b\u8853\u4e2d\u653e\u5c04\u7dda\u6cbb\u7642 Extrahepatic cholangiocarcinoma;Respectability;Intraoperative radiotherapy", "c": "\u81bd\u7ba1\u764c\u662f\u4e00\u500b\u5b58\u6d3b\u9810\u5f8c\u4e0d\u597d\u7684\u5168\u4e16\u754c\u6027\u816b\u7624\uff0c\u8207\u5168\u4e16\u754c10-15%\u7684\u76db\u884c\u7387\u76f8\u6bd4\uff0c\u53f0\u70632012\u5e74\u764c\u75c7\u5831\u544a\u6307\u51fa\uff0c\u81bd\u7ba1\u764c\u5728\u6240\u6709\u7684\u809d\u81bd\u764c\u75c7\u4e2d\u6240\u4f54\u6bd4\u7387\u7d04\u67097.5%\u3002\u800c\u5728\u5176\u4ed6\u7814\u7a76\u5831\u544a\u4e2d\uff0c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u7d04\u70ba20-30%\u3002\u5982\u679c\u75c5\u60a3\u80fd\u5920\u958b\u5200\u7684\u8a71\uff0c\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f\u5c31\u662f\u624b\u8853\u3002\u5c0d\u5927\u90e8\u4efd\u7684\u75c5\u4eba\u4f86\u8aaa\uff0c\u56e0\u70ba\u8907\u96dc\u7684\u5927\u5c0f\u8840\u7ba1\u5206\u4f48\u9084\u6709\u65c1\u908a\u7684\u91cd\u8981\u5668\u5b98\u5f71\u97ff\uff0c\u5f88\u96e3\u9054\u5230\u5b8c\u5168\u5207\u9664\uff0c\u56e0\u6b64\uff0c\u8853\u4e2d\u6216\u662f\u8853\u5f8c\u7684\u8f14\u52a9\u6027\u6cbb\u7642\u7684\u89d2\u8272\u5c0d\u764c\u75c7\u6cbb\u7652\u5c31\u66f4\u52a0\u91cd\u8981\u3002\u5728\u809d\u5916\u81bd\u7ba1\u764c\u7684\u6cbb\u7642\u6587\u737b\u4e2d\uff0c\u5df2\u4f7f\u7528\u624b\u8853\u4e2d\u653e\u5c04\u7dda\u6cbb\u7642\u4f86\u6e1b\u5c11\u5176\u4ed6\u66f4\u4fb5\u5165\u6027\u6cbb\u7642\u7684\u5291\u91cf\u3001\u6e1b\u5c11\u526f\u4f5c\u7528\u4ee5\u589e\u52a0\u5c40\u90e8\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u3002\u6211\u5011\u63d0\u51fa\u4e00\u500b78\u6b72\u7684\u7537\u6027\u809d\u5916\u81bd\u7ba1\u764c\u7684\u75c5\u60a3\u7684\u75c5\u4f8b\u3002\u9019\u500b\u75c5\u60a3\u5728\u624b\u8853\u4e2d\u816b\u7624\u5207\u9664\u5f8c\u4f7f\u752820 Gy\u7684\u624b\u8853\u5167\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4e26\u4e14\u4e4b\u5f8c\u4e26\u6c92\u6709\u9032\u4e00\u6b65\u7684\u5316\u5b78\u6cbb\u7642\u548c\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u5728\u8ffd\u8e646\u500b\u6708\u4e4b\u5f8c\u4e26\u7121\u660e\u986f\u526f\u4f5c\u7528\u6216\u816b\u7624\u5fa9\u767c\u60c5\u5f62\u3002\u624b\u8853\u4e2d\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5c0d\u53ef\u4ee5\u624b\u8853\u4e26\u4e14\u7121\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\u7684\u809d\u5916\u81bd\u7ba1\u764c\u75c5\u4eba\uff0c\u4e5f\u8a31\u662f\u5b89\u5168\u4e14\u5408\u9069\u7684\u6cbb\u7642\uff0c\u540c\u6642\u9700\u9577\u671f\u8ffd\u8e64\u665a\u671f\u526f\u4f5c\u7528\u548c\u6cbb\u7642\u7d50\u679c\u3002", "e": "Cholangiocarcinoma is a malignant neoplasm with a poor survival worldwide. In the 2012 cancer registration report showed a prevalence rate about 7.5% of all hepatobiliary malignancy in Taiwan whereas it was 10 - 15% in the world. The overall 5-year survival rate is only 20 - 30% in literature. Surgical resection is the mainstay treatment for operable patients. However, complete microscopic (R0) resection is difficult to achieve due to the complicated distribution of vessel network and close surrounding normal organs. Thus, the role of post-operative adjuvant radiotherapy is important but normal tissue radiation tolerance remains a critical issue. By using intraoperative radiaotherapy (IORT), the target lesion could be irradiated with single high-dose fraction while avoiding surrounding tissues. Here, we presented a 78-year-old male with extrahepatic cholangiocarcinoma without regional lymphadenopathy. IORT with 20 Gy via a portable kilovoltage x-ray generator was delivered in operative room after removal of tumor and surrounding tissues. The pathology report showed close surgical margin and no regional lymph node metastasis. No further adjuvant external beam radiotherapy or chemotherapy was given due to none of major risk factor and old age. After 6-month follow up, no evidence of recurrence and complication was noted. We conclude that IORT might be a safe radiotherapy modality for patients with resectable extrahepatic cholangiocarcinoma. The long term follow up for evaluation of late toxicity and treatment outcome is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201512-201601220002-201601220002-323-331", "title": "RadiotheRapy of extRauteRine endometRial StRomal SaRcoma: two caSeS RepoRt", "keywords": "\u5b50\u5bae\u9ad4\u5916\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Extrauterine endometrial stromal sarcoma;Radiotherapy", "c": "\u524d\u8a00\uff1a\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\u70ba\u5c11\u898b\u7684\u5b50\u5bae\u9ad4\u60e1\u6027\u816b\u7624\u3002\u6e90\u767c\u65bc\u5b50\u5bae\u5916\u5982\u9670\u9053\u548c\u9aa8\u76c6\u8154\u7684\u75c5\u4f8b\u5247\u9bae\u5c11\u88ab\u5831\u544a\u3002\u5b50\u5bae\u9ad4\u5916\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\u4e3b\u8981\u6cbb\u7642\u4ee5\u624b\u8853\u5207\u9664\u70ba\u4e3b\uff0c\u800c\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u89d2\u8272\u4ecd\u4e0d\u660e\u78ba\u3002\u6211\u5011\u671f\u671b\u767c\u5c55\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u4f4e\u60e1\u6027\u5ea6\u4e4b\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\uff0c\u7279\u5225\u65bc\u6cbb\u7642\u5b50\u5bae\u9ad4\u5916\u4e4b\u75c5\u7076\u3002\u4ee5\u4e0b\u63d0\u51fa\u5169\u4f4d\u75c5\u60a3\u5831\u544a\uff0c\u7b2c\u4e00\u4f8b\u70ba\u624b\u8853\u5207\u9664\u52a0\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u65bc\u539f\u767c\u9670\u9053\u8655\u816b\u7624\uff0c\u7b2c\u4e8c\u4f8b\u70ba\u539f\u767c\u65bc\u9aa8\u76c6\u8154\u5167\u4e26\u4f7f\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u7b2c\u4e00\u4f8b\u75c5\u4f8b\u5831\u544a\uff1a39\u6b72\u5973\u6027\uff0c\u75c7\u72c0\u8868\u73fe\u70ba\u5927\u91cf\u9670\u9053\u51fa\u8840\uff0c\u6aa2\u67e5\u767c\u73fe\u9670\u9053\u58c1\u9760\u8fd1\u5b50\u5bae\u9838\u958b\u53e3\u6709\u4e00\u606f\u8089\u72c0\u816b\u7624\u3002\u7d93\u624b\u8853\u5207\u9664\u5f8c\u75c5\u7406\u5831\u544a\u70ba\u4f4e\u60e1\u6027\u5ea6\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\u3002\u8853\u5f8c\u8f14\u52a9\u6027\u6cbb\u7642\u4f7f\u7528\u9ad4\u5916\u7167\u5c04\u5291\u91cf 50.4 Gy\u5206\u5225\u7167\u5c0428\u6b21\uff0c\u52a0\u4e0a2\u6b21\u8fd1\u63a5\u6cbb\u7642\u6bcf\u6b21\u5291\u91cf\u70ba3 Gy\u3002\u7b2c\u4e8c\u4f8b\u75c5\u4f8b\uff1a59\u6b72\u5973\u6027\uff0c\u5728\u75c5\u60a345\u6b72\u6642\u56e0\u5b50\u5bae\u58c1\u5167\u5e73\u6ed1\u808c\u7624\u63a5\u53d7\u5b50\u5bae\u5375\u5de2\u5207\u9664\u8853\u3002\u75c5\u60a3\u73fe\u56e0\u5e7e\u5929\u4f86\u7684\u4e0b\u8179\u75bc\u75db\u548c\u7121\u5c3f\u800c\u6c42\u8a3a\u3002\u7d93\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5f8c\uff0c\u5831\u544a\u986f\u793a\u51fa\u5927\u5c0f8 x 5 cm\u7684\u8edf\u7d44\u7e54\u816b\u584a\uff0c\u4f4d\u65bc\u9aa8\u76c6\u8154\u9130\u8fd1\u5de6\u5074\u8180\u80f1\u4e09\u89d2\u548c\u8f38\u5c3f\u7ba1\u8655\uff0c\u4e26\u4e14\u4fb5\u72af\u81f3\u9670\u9053\u7a79\u7abf\u9802\u3002\u5207\u7247\u5831\u544a\u70ba\u4f4e\u60e1\u6027\u5ea6\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\u3002\u6b64\u75c5\u60a3\u672a\u63a5\u53d7\u624b\u8853\u800c\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5291\u91cf\u70ba72 Gy\u5206\u5225\u7167\u5c0440\u6b21\u3002\u7d50\u8ad6\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u6709\u8f03\u4f4e\u7684\u5fa9\u767c\u7387\u3002\u5c0d\u65bc\u63d0\u9ad8\u5b58\u6d3b\u7387\u537b\u4ecd\u6709\u722d\u8b70\u6027\u3002\u7136\u800c\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u4ecd\u53ef\u7528\u65bc\u4e0d\u9069\u5408\u624b\u8853\u7684\u75c5\u60a3\u3002\u6211\u5011\u7684\u5169\u4f4d\u75c5\u4f8b\u5206\u5225\u57281\u5e74\u820712\u5e74\u8ffd\u8e64\u6642\u9593\u5167\u90fd\u986f\u793a\u7121\u5fa9\u767c\u3002\u4f46\u662f\u53d7\u9650\u65bc\u8f03\u5c11\u7684\u75c5\u4f8b\u6578\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u65bc\u5b50\u5bae\u9ad4\u5916\u5167\u819c\u57fa\u8cea\u60e1\u6027\u816b\u7624\u7684\u6548\u7528\u4ecd\u9700\u8981\u9032\u4e00\u6b65\u7684\u7814\u7a76\u4f86\u78ba\u8a8d\u3002", "e": "Background : Endometrial stromal sarcoma (ESS) is a rare malignant tumor of the uterus. Few extrauterine ESS cases arising in vagina and pelvic cavity were reported. The main treatment for extrauterine ESS is surgical resection; however the role of radiotherapy in extrauterine ESS remained unclear. We aimed to explore the value of radiotherapy treating low-grade endometrial stromal sarcoma (LGESS), especially in extrauterine. We presented one case of extrauterine LGESS arising in vaginal wall with surgical treatment and adjuvant radiotherapy and the second case arising from pelvic cavity treated with tumor-directed radiotherapy alone. Case Presentation : Case 1: A 39-year-old woman presented with symptom of excessive vaginal bleeding. A polyp tumor protruding from the vagina wall near cervical os was found on speculum examination. She underwent surgical removal of the mass. The microscopic examination revealed LGESS. Adjuvant radiotherapy was performed using external beam radiotherapy (EBRT) with a dose of 50.4 Gy in 28 fractions and brachytherapy with a dose of 3 Gy x 2 fractions. Case 2: A 59-year-old woman had a past history of abdominal total hysterectomy with bilateral salpingo-oophorectomy due to intramural leiomyoma at age 45 years. She presented with progressive lower abdominal pain and anuria for days. Contrast-enhanced CT scan showed a 8x5 cm soft tissue mass over left pelvic cavity close to trigone of urinary bladder and left ureter, with involvement of vaginal vault apex. Biopsy revealed LGESS. She received tumor-directed radiotherapy with a dose of 72 Gy in 40 fractions without surgical resection. Conclusions: Radiotherapy provide lower recurrence rate, but the result of overall survival was still in controversy. It can be considered in patients who are unsuitable for surgical resection. Our 2 cases had no evidence of recurrence in 1 year and 12 years of follows-up. Because of the paucity of extrauterine ESS, further investigation is needed to determine the benefit of radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-163-170", "title": "A Single Institute", "keywords": "\u817a\u6a23\u56ca\u72c0\u764c;\u547c\u5438\u9053;\u653e\u5c04\u6cbb\u7642 Adenoid cystic carcinoma;Respiratory tract;Radiotherapy", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u6bd4\u8f03\u6e90\u767c\u65bc\u4e0a\u4e0b\u547c\u5438\u9053\u7684\u817a\u6a23\u56ca\u72c0\u4e0a\u76ae\u764c\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u8ffd\u8e64\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u6eaf\u6027\u8ffd\u8e641987\u52302012\u5e74\u4e4b\u9593\uff0c12\u4f4d\u78ba\u5b9a\u8a3a\u65b7\u70ba\u547c\u5438\u9053\u817a\u6a23\u56ca\u72c0\u4e0a\u76ae\u764c\u7684\u75c5\u4eba\u3002\u5f9e\u75c5\u6b77\u4e2d\u53d6\u5f97\u624b\u8853\u7684\u65b9\u5f0f\u8207\u653e\u5c04\u6cbb\u7642\u7684\u5167\u5bb9\uff0c\u4e26\u4e14\u6bd4\u8f03\u5176\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\uff0c\u8207\u7121\u9032\u5c55\u5b58\u6d3b\u7387\uff08PFS\uff09\u3002\u7d50\u679c\uff1a\u5728\u4e0a\u4e0b\u547c\u5438\u9053\u7684\u6bd4\u8f03\u4e2d\uff0c\u4e0d\u8ad6\u662f\u6574\u9ad4\u5b58\u6d3b\uff08p=0.177\uff09\u6216\u7121\u9032\u5c55\u5b58\u6d3b\uff08p=0.264\uff09\u90fd\u6c92\u6709\u986f\u8457\u7684\u5dee\u7570\u3002\u7136\u800c\u7576\u6bd4\u8f03\u500b\u6848\u63a5\u53d7\u624b\u8853\u5207\u9664\u8207\u5426\u8207\u5b58\u6d3b\u7684\u95dc\u4fc2\u6642\uff0c\u6709\u63a5\u53d7\u624b\u8853\u8005\u4e0d\u8ad6\u5728\u6574\u9ad4\u5b58\u6d3b\uff08p=0.005\uff09\u6216\u7121\u9032\u5c55\u5b58\u6d3b\u7387\uff08p=0.016\uff09\uff0c\u90fd\u512a\u65bc\u672a\u63a5\u53d7\u624b\u8853\u8005\u3002\u7d50\u8ad6\uff1a\u547c\u5438\u9053\u817a\u6a23\u56ca\u72c0\u764c\u7684\u767c\u90e8\u4f4d\u4e0d\u5f71\u97ff\u5176\u9810\u5f8c\uff0c\u7136\u800c\u539f\u767c\u816b\u7624\u662f\u5426\u63a5\u53d7\u624b\u8853\u5247\u6703\u5f71\u97ff\u9810\u5f8c\u3002", "e": "Purpose: To report the treatment outcome of the adenoid cystic carcinoma (ACC) of the respiratory tract. Materials and Methods: Twelve ACC patients diagnosed between 1987 and 2012 were retrospectively reviewed. Surgical resection and radiotherapy status were obtained from medical records. Overall survival (OS) and progression free survival (PFS) were analyzed using the Kaplan-Meier method. Results: There was no statistical difference in OS (p=0.177) and PFS (p=0.264) of the upper and lower airway ACCs. However, there was a significantly better OS (p=0.005) and PFS (p=0.016) in patients that received surgical excision. Conclusions: The primary site does not affect the prognosis of ACCs. Surgical intervention plays a critical role in the management of ACCs."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-171-185", "title": "Comparison of Dosimetry for Left Anterior Descending Coronary Artery in Left Breast Irradiation by Intensity-Modulated and 3-Dimentional Conformal Radiotherapy", "keywords": "\u5de6\u5074\u4e73\u764c;\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642;\u51a0\u72c0\u52d5\u8108;\u653e\u5c04\u7dda\u6cbb\u7642 Left breast cancer;Intensity-modulated radiotherapy;Coronary artery;Radiation therapy", "c": "\u76ee\u7684\uff1a\u6b64\u7bc7\u56de\u6eaf\u6027\u7814\u7a76\u7684\u76ee\u7684\u662f\u70ba\u4e86\u6bd4\u8f03\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\uff08LAD\uff09\u4ee5\u53ca\u91cd\u8981\u5668\u5b98\u5728\u5de6\u5074\u4e73\u764c\u60a3\u8005\u63a5\u53d7\u8853\u5f8c\u5168\u4e73\u623f\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u4ee5\u53ca\u50b3\u7d71\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff083DCRT\uff09\u6642\uff0c\u5291\u91cf\u5206\u5e03\u4e0a\u7684\u5dee\u7570\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u7be9\u907814\u540d\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4e4b\u5de6\u5074\u4e73\u764c\u60a3\u8005\uff0c\u5176\u4e2d9\u540d\u63a5\u53d7\u5168\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\uff1b5\u540d\u63a5\u53d7\u5168\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u53ca\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u6b645\u540d\u75c5\u60a3\u6211\u5011\u53ea\u6bd4\u8f03\u5168\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u7684\u90e8\u5206\u3002\u56e0\u6b64\u6211\u5011\u6bd4\u8f03\u50b3\u7d71\u9806\u5f62\u6cbb\u7642\u548c\u5169\u7a2e\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5206\u5e03\u4e0a\u7684\u5dee\u7570\u6027\uff08\u5176\u4e2d\u4e00\u7a2e\u6c92\u6709\u4f7f\u7528\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\uff0c\u53e6\u4e00\u7a2e\u5247\u6709\uff09\uff0c\u4e26\u5206\u67903\u500b\u7d44\u5225\u9593\u7684\u5291\u91cf\u5206\u5e03\uff0c\u5206\u5225\u547d\u540d\u70ba\uff1a\u76f8\u5207\u7167\u91ce\u7d44\uff08tangential field, TF\uff09\uff0cIMRT\u7121\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u7d44\uff08non-LAD constraint, NLC\uff09\u548cIMRT\u4f7f\u7528\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u7d44\uff08use LAD constraint, LC\uff09\u3002\u5291\u91cf\u5206\u5e03\u7684\u5206\u6790\u9805\u76ee\u5305\u62ec\uff1a\u5291\u91cf\u9806\u5f62\u7387\uff08conformity index\uff09\uff0c\u5291\u91cf\u540c\u8cea\u7387\uff08homogeneity index\uff09\uff0c\u4ee5\u53ca\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\uff0c\u5fc3\u81df\u548c\u5de6\u5074\u80ba\u81df\u7684\u5291\u91cf\uff0d\u9ad4\u7a4d\u5716\uff08dose-volume histogram, DVH\uff09\u3002\u4f7f\u7528\u91cd\u8907\u6027\u6e2c\u91cfANOVA\u4ee5\u53caBonferroni post hoc test\u8a55\u4f30\u5168\u4e73\u623f\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u4ee5\u53ca\u50b3\u7d71\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\uff0c\u5fc3\u81df\u548c\u5de6\u5074\u80ba\u81df\u7684\u5291\u91cf\u5206\u5e03\u662f\u5426\u6709\u986f\u8457\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1aIMRT\u5c0d\u65bc\u5291\u91cf\u540c\u8cea\u7387\u548c\u5291\u91cf\u9806\u5f62\u7387\u7684\u6539\u5584\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u7684\u5dee\u7570\uff08p\uff1c0.0001\uff09\u3002\u6211\u5011\u767c\u73fe\u4f7f\u7528IMRT\u6642\uff0c\u82e5\u6709\u4f7f\u7528\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u689d\u4ef6\u6642\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4eLAD\u5e73\u5747\u63a5\u53d7\u5291\u91cf\uff0cV20 Gy\u9ad4\u7a4d\u767e\u5206\u6bd4\uff0cV30 Gy\u9ad4\u7a4d\u767e\u5206\u6bd4\u548cLAD area\uff08\u7531LAD\u5728\u5404\u65b9\u5411\u52a01\u516c\u5206\u5f62\u6210\uff09\u5e73\u5747\u63a5\u53d7\u5291\u91cf\uff08p\u503c\u5206\u5225\u70ba\uff1c0.0001, \uff1c0.0001, 0.004, \uff1c0.0001\uff09\uff0c\u4f46\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u76f8\u8f03\u65bc\u50b3\u7d71\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6703\u660e\u986f\u589e\u52a0LAD V5 Gy\u9ad4\u7a4d\u767e\u5206\u6bd4\uff08p\u503c\uff1c0.05\uff09\u3002\u4f46LAD Dmax\u5728\u4e09\u7d44\u9593\u5247\u7121\u660e\u986f\u5dee\u7570\u3002\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u6703\u4f7f\u5fc3\u81df\u5e73\u5747\u63a5\u53d7\u5291\u91cf\uff0c\u5de6\u5074\u80ba\u81df\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u548cV5 Gy\u9ad4\u7a4d\u767e\u5206\u6bd4\u660e\u986f\u9ad8\u65bc\u50b3\u7d71\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff083DCRT\uff09\uff08p\u503c\u7686\uff1c0.0001\uff09\uff0c\u4e14\u65bc\u5169\u500bIMRT\u7d44\u5225\u9593\u7121\u986f\u8457\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u63d0\u4f9b\u8f03\u4f73\u7684\u5291\u91cf\u540c\u8cea\u7387\u4ee5\u53ca\u5291\u91cf\u9806\u5f62\u7387\u3002\u82e5\u9700\u4f7f\u7528IMRT\u6cbb\u7642\u60a3\u8005\uff0c\u5247\u5efa\u8b70\u4f7f\u7528\u9069\u7576\u7684\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u689d\u4ef6\uff08\u5728\u6b64\u7bc7\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u4f7f\u7528\u7684\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u689d\u4ef6\u70baV20 Gy\u9ad4\u7a4d\u767e\u5206\u6bd4\u5c0f\u65bc50%\uff09\uff0c\u4ee5\u671f\u6e1b\u5c11\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u9ad8\u5291\u91cf\u5206\u5e03\u7684\u5340\u57df\u3002\u4f46IMRT\u6703\u660e\u986f\u589e\u52a0\u4f4e\u5291\u91cf\u5206\u4f48\u7684\u5340\u57df\uff0c\u56e0\u6b64\u4f7f\u7528IMRT\u9808\u8b39\u614e\u8a55\u4f30\u6b64\u98a8\u96aa\u3002\u672a\u4f86\u9700\u8981\u66f4\u6df1\u5165\u7684\u7814\u7a76\u4ee5\u671f\u80fd\u6709\u66f4\u8da8\u7406\u60f3\u7684\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5291\u91cf\u9650\u5236\u689d\u4ef6\u3002", "e": "Purpose: The intent of this study was to compare the dosimetry of the left anterior descending coronary artery (LAD) and organs at risk (OARs) in left breast cancer patients in two treatment techniques, intensity-modulated radiation therapy (IMRT) and 3-dimentional conformal radiotherapy (3DCRT). Materials and Methods: Fourteen patients with left breast cancer who had received post-operative radiotherapy (RT) to the breast between October 2012 and November 2013 were enrolled in the study. All patients were irradiated with 6- or 10-MV photon beams using 3-dimentional conformal tangential technique to the left whole breast. For dosimetric comparison, two sets of six-field IMRT plans, with or without LAD constraint of V20 Gy\uff1c50%, on each patient were performed. These three RT plans were named tangential field (TF), non-LAD constraint (NLC) and LAD constraint (LC), respectively. Five patients also received supraclavicular fossa (SCF) irradiation, but only whole breast dosimetry parameters were analyzed. The conformity index (CI), homogeneity index (HI) and dose-volume histogram (DVH) for the LAD, heart and ipsilateral lung were calculated for analysis. Repeated measures of one-way ANOVA with Bonferroni post hoc test (software SPSS 21.0) was used for statistics. Results: For the 14 patients given left breast irradiation, there was an obvious statistical benefit for HI (average 12.67%) and CI (average 92.95%) by IMRT (both p\uff1c0.0001). According to the data, it was found that an LAD mean dose (Dmean), V20 Gy, V30 Gy and LAD area mean dose (LAD of 10 mm in all directions) were reduced by using the LC arm (average 20.28 Gy, 41.19%, 29.60% and 21.46 Gy, respectively) if using IMRT technique (all p\uff1c0.05). However, there was no statistical difference between TF and LC arms (p\uff1e0.05). Additionally, although the low dose bath (LAD V5 Gy average 82.81%) was a drawback in IMRT (p\uff1c0.05), the LC arm was still better than the NLC arm if the LAD constraint was used (p=0.013). There was no statistical significance between the 3 arms in regard to LAD maximum dose (Dmax) (3-arm average 47.21 Gy). 3DCRT had lower heart Dmean (average 3.77 Gy), ipsilateral lung Dmean (average 7.14 Gy) and V5 Gy (average 19.21%) than with IMRT (average 6.10 Gy, 9.31 Gy and 38.57%, respectively) (all p\uff1c0.0001), and there was no statistical difference between IMRT arms (p\uff1e0.05). Conclusion: In the light of our dosimetric data, IMRT may offer much better HI and CI than conventional tangential-field RT. In order to decrease the high-dose area of LAD, we had to select an appropriate LAD constraint (in this study, LAD V20 Gy \uff1c50% was used), if IMRT planning was done. IMRT technique results in a low dose bath (V5 Gy) and we should use this treatment option carefully. Further investigation for LAD constraint is needed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-187-197", "title": "Preliminary Results of Helical Tomotherapy for Non-metastatic Prostate Cancer", "keywords": "\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u76f4\u8178\u708e;\u8180\u80f1\u708e;\u5c0e\u822a\u87ba\u65cb\u5200 Image-guided radiotherapy;Proctitis;Cystitis;Helical tomotherapy", "c": "\u76ee\u7684\uff1a\u767c\u8868\u55ae\u4e00\u91ab\u5b78\u4e2d\u5fc3\u4f7f\u7528\u5c0e\u822a\u87ba\u65cb\u5200\u6cbb\u7642\u975e\u8f49\u79fb\u6027\u651d\u8b77\u817a\u764c\u4e4b\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2006\u5e7412\u6708\u81f32013\u5e746\u6708\uff0c\u517185\u4f4d\u651d\u8b77\u817a\u764c\u75c5\u4eba\u63a5\u53d7\u5f71\u50cf\u5c0e\u5f15\u5c0e\u822a\u87ba\u65cb\u5200\u6cbb\u7642\u3002\u6bcf\u65e5\u4f7f\u7528MVCT\u5f71\u50cf\u5c0e\u5f15\u4ee5\u6e1b\u5c11\u5c0d\u4f4d\u8aa4\u5dee\u3002\u751f\u5316\u63a7\u5236\u5931\u6557\u63a1\u7528Pheonix\u5b9a\u7fa9\uff0c\u526f\u4f5c\u7528\u7684\u5206\u7d1a\u6839\u64daCTCAE 4.0\u7248\u672c\u3002\u7d50\u679c\uff1a\u4e2d\u4f4d\u8ffd\u8e64\u671f\u70ba41\u500b\u6708\uff0c\u4e2d\u4f4d\u653e\u5c04\u5291\u91cf\u81f3\u651d\u8b77\u817a\u70ba76 Gy\u3002\u6240\u6709\u75c5\u4eba\u4e2d\u670954%\u70ba\u9ad8\u98a8\u96aa\u7fa4\u3002\u56db\u5e74\u751f\u5316\u63a7\u5236\u7387\u70ba93.3%\uff0c\u6240\u6709\u4e2d\u4f4e\u98a8\u96aa\u7fa4\u7684\u75c5\u4eba\u7686\u63a7\u5236\u826f\u597d\uff0c\u9ad8\u98a8\u96aa\u7684\u75c5\u4eba\u67096\u4f4d\u751f\u5316\u5931\u6557\uff0c\u5176\u4e2d2\u4f4d\u4f75\u767c\u9aa8\u982d\u8f49\u79fb\u3002\u6cbb\u7642\u671f\u9593\uff0c\u50c5\u5206\u5225\u67094.7%\u53ca9.4%\u7684\u75c5\u4eba\u51fa\u73fe\u7b2c\u4e8c\u7d1a\u7684\u8178\u80c3\u9053\u548c\u6ccc\u5c3f\u9053\u6025\u6027\u526f\u4f5c\u7528\u3002\u5927\u65bc\u7b2c\u4e8c\u7d1a\u7684\u6162\u6027\u526f\u4f5c\u7528\u7d2f\u7a4d\u767c\u751f\u7387\uff0c\u5305\u542b\u51fa\u8840\u6027\u76f4\u8178\u764c\u3001\u51fa\u8840\u6027\u8180\u80f1\u708e\u548c\u5c3f\u9053\u72f9\u7a84\u5247\u5206\u5225\u70ba8.2%\u30014.7%\u53ca4.7%\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u651d\u8b77\u817a\u764c\u4e4b\u75c5\u4eba\uff0c\u4f7f\u7528\u5c0e\u822a\u87ba\u65cb\u5200\u4e4b\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff0c\u5728\u6211\u5011\u7684\u77ed\u671f\u8ffd\u8e64\u4e0b\u6709\u826f\u597d\u7684\u751f\u5316\u63a7\u5236\u3002\u6cbb\u7642\u76f8\u95dc\u7684\u526f\u4f5c\u7528\u662f\u53ef\u63a5\u53d7\u7684\u3002", "e": "Purpose: We report the results of non-metastatic prostate cancer patients treated by helical tomotherapy (HT) in a single institution. Materials and Methods: From December 2006 to June 2013, eighty-five prostate cancer patients receiving image-guided radiation therapy (IGRT) with HT were enrolled in this study. Mega-voltage computed tomography was performed to minimize geographic miss and setup error. The Phoenix definition was used to define biochemical failure. Toxicities were recorded based on Common Terminology Criteria for Adverse Events, version 4.0. Results: The median follow-up interval was 41 months (range, 8-96 months). The median radiation dose delivered was 76 Gy to the whole prostate. Fifty-four percent of patients were in the high-risk category. The 4-year biochemical control rate was 93.3%. All of the patients attributed to the low- and intermediate-risk groups had good biochemical control (n=39). For high-risk group, only 13% (6/46) patients had biochemical failure, and 2 of them also developed bony metastases. During treatment, only 4.7% and 9.4% of the patients experienced grade 2 acute gastrointestinal and genitourinary toxicities, respectively. No grade 3 or 4 acute toxicity was observed. The cumulative incidence of late toxicities of grade 2 or above hemorrhagic proctitis, hemorrhagic cystitis and urethral stricture were 8.2%, 4.7% and 4.7%, respectively. Conclusion: For prostate cancer patients, IGRT with HT results an excellent biochemical control in our limited follow-up period. The treatment-related toxicities were acceptable."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-199-209", "title": "Patient-specific CBCT Number Corrections for Cone Beam CT-based Dose Calculations", "keywords": "\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64;\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642 Cone beam CT (CBCT);Image-guided radiation therapy (IGRT)", "c": "\u76ee\u7684\uff1a\u64b0\u5beb\u7a0b\u5f0f\u4fee\u6b63\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u6578\u503c\uff0c\u4e26\u65bc\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u8a08\u7b97\u6b64\u91cd\u5efa\u5f71\u50cf\u5c0e\u5f15\u5f71\u50cf\uff0c\u4ee5\u6b64\u8a55\u4f30\u6b64\u7a0b\u5f0f\u4fee\u6b63\u4e4b\u91cd\u5efa\u5f71\u50cf\u7528\u4ee5\u8a08\u7b97\u75c5\u60a3\u6bcf\u65e5\u771f\u5be6\u63a5\u53d7\u5291\u91cf\u7684\u53ef\u884c\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u5f71\u50cf\u8207\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u53d6\u5f97\u591a\u8655\u76f8\u540c\u4f4d\u7f6e\u5708\u9078\u5340\u57df\u4e4b\u96fb\u8166\u65b7\u5c64\u6578\u503c\uff0c\u5982\uff1a\u7a7a\u6c23\u3001\u7d44\u7e54\u3001\u8102\u80aa\u8207\u9aa8\u982d\u3002\u85c9\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u5f71\u50cf\u4e4b\u6578\u503c\uff0d\u5bc6\u5ea6\u5c0d\u61c9\u8868\u627e\u51fa\u8a72\u5708\u9078\u5340\u57df\u4e4b\u5bc6\u5ea6\uff0c\u4e26\u4f9d\u6b64\u5bc6\u5ea6\u91cd\u65b0\u5efa\u7acb\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u5f71\u50cf\u4e4b\u6578\u503c\uff0d\u5bc6\u5ea6\u5c0d\u61c9\u8868\u8207\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e4b\u6578\u503c\uff0d\u5bc6\u5ea6\u5c0d\u61c9\u8868\u5169\u8005\u7684\u7dda\u6027\u8ff4\u6b78\u65b9\u7a0b\u5f0f\u3002\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e4b\u6578\u503c\u4f9d\u64da\u5176\u7dda\u6027\u8ff4\u6b78\u65b9\u7a0b\u5f0f\u6c42\u5f97\u8f49\u63db\u543b\u5408\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u5f71\u50cf\u7dda\u6027\u8ff4\u6b78\u65b9\u7a0b\u5f0f\u4e4b\u6578\u503c\u3002\u7136\u800c\uff0c\u9310\u72c0\u5c04\u675f\u5f71\u50cf\u4e4b\u8996\u91ce\u7bc4\u570d\uff08FOV\uff09\u53d7\u5230\u6383\u63cf\u689d\u4ef6\u6240\u9650\u5236\uff0c\u90e8\u4efd\u7d44\u7e54\u56e0\u800c\u672a\u5305\u542b\u65bc\u9310\u72c0\u5c04\u675f\u5f71\u50cf\u4e4b\u4e2d\u3002\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u5f71\u50cf\u88dc\u8db3\u9310\u72c0\u5c04\u675f\u5f71\u50cf\u8996\u91ce\u7bc4\u570d\uff08FOV\uff09\u5916\u7684\u5f71\u50cf\u4ee5\u63d0\u4f9b\u771f\u5be6\u7684\u8870\u6e1b\u8207\u6563\u5c04\u689d\u4ef6\u3002\u4f7f\u7528\u5747\u8cea\u5047\u9ad4\u3001\u4eba\u5f62\u975e\u5747\u8cea\u5047\u9ad4\u8207\u5341\u4e8c\u4f4d\u75c5\u60a3\u5f71\u50cf\uff0c\u900f\u904e\u6b64\u7a0b\u5f0f\u4fee\u6b63\u5f8c\u4e4b\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u65bc\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u91cd\u65b0\u8a08\u7b97\uff0c\u4ee5\u8a55\u4f30\u7576\u65e5\u6cbb\u7642\u5291\u91cf\u8207\u8a08\u756b\u898f\u5283\u4e4b\u6e96\u78ba\u6027\u8207\u5dee\u7570\u3002\u7d50\u679c\uff1a\u7d93\u904e\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u7684\u8a08\u7b97\uff0c\u5176\u5169\u8005\u9ede\u5291\u91cf\u5dee\u7570\u65bc6 MV\u7d50\u679c\u70ba0.71%\uff08SD=1.73%\uff09\uff0c10MV\u5dee\u7570\u7d50\u679c\u70ba0.49%\uff08SD=1.39%\uff09\u3002\u5e73\u9762Gamma index\u6bd4\u5c0d\u7d50\u679c\uff0c6 MV\u901a\u904e\u738797.46%\uff08SD= 4.08%\uff09\uff0c10 MV\u901a\u904e\u7387 99.32%\uff08SD=0.90%\uff09\u3002\u70ba\u6c42\u81e8\u5e8a\u61c9\u7528\u9a57\u8b49\uff0c\u6311\u9078\u5f62\u8b8a\u8f03\u5c0f\u4e4b\u75c5\u60a3\uff0c\u8a08\u756b\u9776\u9ad4\u7a4dD95%\u7684\u5291\u91cf\u5dee\u7570\u7d50\u679c\u70ba0.48%\uff08SD=1.19%\uff09\uff0c\u8a08\u756b\u9776\u9ad4\u7a4d\u7684\u8655\u65b9\u5291\u91cf\u5305\u8986\u6027\u5dee\u7570\u70ba0.36%\uff08SD =1.69%\uff09\uff0c\u8a08\u5283\u9776\u9ad4\u7a4d\u4e4b\u4e00\u5e73\u9762Gamma index\u6bd4\u5c0d\u7d50\u679c\u901a\u904e\u738798.06%\uff08SD=1.66%\uff09\u3002\u7d50\u8ad6\uff1a\u6b64\u7a0b\u5f0f\u5229\u7528\u500b\u5225\u75c5\u60a3\u5f71\u50cf\u4fee\u6b63\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u6578\u503c\uff0c\u7528\u4ee5\u91cd\u5efa\u75c5\u60a3\u6bcf\u65e5\u771f\u5be6\u63a5\u53d7\u5291\u91cf\u6709\u5176\u81e8\u5e8a\u8a55\u4f30\u53c3\u8003\u7684\u53ef\u884c\u6027\u3002", "e": "Background and Purpose: We develop an in-house program to correct computed tomography (CT) numbers of cone beam CT (CBCT) images and to recalculate modified CBCT images by using treatment planning system (TPS) software to evaluate actual patient doses. Material and Methods: Mean CT numbers were determined for planning CT and CBCT for the same selected regions of air, tissue, and bone. Based on CT-density tables for the planning CT, the density of CBCT could be determined for a selected volume. After generating linear regression equations for both the CT-density table and the CBCT-density table, the CT numbers for CBCT could be modified to fit the planning CT-density table. The field of view (FOV) boundaries in the corrected CBCT images were identified and merged with the planning CT images to provide real scatter and attenuation data. Images of 2 phantoms and 12 patients were used to verify the accuracy of corrected CBCT doses. Results: Based on Pinnacle TPS calculations, the differences in point dose between CBCT and CT images in the phantom study were 0.71% (SD=1.73%) at 6 MV, and 0.49% (SD=1.39%) at 10 MV. The 2D passing rates for a gamma index were 97.46% (SD=4.08%) at 6 MV, and 99.32% (SD=0.90%) at 10 MV. The dose difference of D95% was 0.48%\u00b11.19%. The difference in planning target volume (PTV) coverage of the prescribed dose was 0.36%\u00b11.69%, and the 2D passing rate without threshold was 98.06%\u00b11.66%. Conclusion: Patient-specific correction of daily CBCT images can be used for reconstructing daily dose distribution and is practicable for radiotherapy treatment and clinical evaluations."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-211-219", "title": "\u5291\u91cf\u7387\u8a2d\u5b9a\u5c0d\u4f7f\u7528\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u8a08\u7b97\u7d50\u679c\u4e4b\u5f71\u97ff", "keywords": "\u5291\u91cf\u7387;\u92b3\u901f\u5200;\u6a5f\u982d\u65cb\u8f49\u901f\u5ea6 Dose rate setting;RapidArc;Gantry speed", "c": "\u76ee\u7684\uff1a\u92b3\u901f\u5200\uff08RapidArc\uff09\u653e\u5c04\u6cbb\u7642\u662f\u5229\u7528\u65cb\u8f49\u81c2\uff08gantry\uff09\u5728\u65cb\u8f49\u7684\u540c\u6642\uff0c\u85c9\u7531\u6539\u8b8a\u591a\u8449\u5f0f\u6e96\u76f4\u5100\uff08multi-leaves collimator; MLC\uff09\u8449\u7247\u7684\u4f4d\u7f6e\u3001\u7167\u91ce\u5167\u7684\u8f3b\u5c04\u5291\u91cf\u7387\u4ee5\u53cagantry\u65cb\u8f49\u901f\u5ea6\uff0c\u4ee5\u9054\u5230\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u76ee\u7684\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u4e3b\u8981\u63a2\u8a0e\u4f7f\u7528\u92b3\u901f\u5200\u6280\u8853\u4f5c\u8a08\u756b\u512a\u5316\u6642\uff0c\u4e0d\u540c\u5291\u91cf\u7387\u8a2d\u5b9a\u9020\u6210\u8a08\u756b\u57f7\u884c\u6642\u5291\u91cf\u7387\u8b8a\u5316\u53ca\u6a5f\u982d\u65cb\u8f49\u901f\u5ea6\u7684\u76f8\u4e92\u5f71\u97ff\u95dc\u4fc2\u3002\u4e14\u63a2\u8a0e\u5176\u5c0d\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u54c1\u8cea\u53ca\u8a08\u756b\u54c1\u4fdd\u7d50\u679c\u7684\u5f71\u97ff\uff0c\u5e0c\u671b\u627e\u51fa\u5728\u505a\u8a08\u756b\u512a\u5316\u6642\uff0c\u76f8\u5c0d\u9069\u7576\u7684\u6a5f\u5668\u5291\u91cf\u7387\u689d\u4ef6\u8a2d\u5b9a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u63a1\u56de\u6eaf\u6027\u65b9\u5f0f\u9078\u53d6\u672c\u79d1\u60a3\u8005\u8cc7\u6599\u5eab\u4e2d\u7684\u982d\u9838\u764c3\u540d\u3001\u98df\u9053\u764c\u60a3\u80055\u540d\u53ca\u651d\u8b77\u817a\u764c\u60a3\u80055\u540d\u7e3d\u517113\u540d\u60a3\u8005\u3002\u9032\u884c\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u7684\u512a\u5316\u904e\u7a0b\u6642\uff0c\u5291\u91cf\u7387\u8a2d\u5b9a\u70ba100\u3001200\u3001300\u3001400\u3001500\u53ca600 MU/min\u7b49\u516d\u7a2e\u4e0d\u540c\u5291\u91cf\u7387\u91cd\u65b0\u57f7\u884c\u6cbb\u7642\u8a08\u756b\u512a\u5316\u3002\u6240\u6709\u60a3\u8005\u5728\u9032\u884c\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u7684\u512a\u5316\u904e\u7a0b\u4e2d\uff0c\u5c0d\u6cbb\u7642\u8a08\u756b\u9776\u9ad4\u7a4d\uff08planning target volume; PTV\uff09\u548c\u5404\u5371\u6025\u5668\u5b98\uff08organ at risk; OAR\uff09\u4f7f\u7528\u76f8\u540c\u7684\u5291\u91cf\u9650\u5236\uff08dose constraint\uff09\u53ca\u8a08\u756b\u512a\u5316\u512a\u5148\u6b0a\uff08optimization priority\uff09\u4ee5\u6e1b\u5c11\u5f71\u97ff\u7d50\u679c\u7684\u8b8a\u7570\u6027\u3002\u8a55\u4f30\u5291\u91cf\u7387\u8a2d\u5b9a\u5404\u8a08\u5283\u5728\u816b\u7624\u5747\u52fb\u6027\u3001\u9806\u5f62\u5ea6\u4ee5\u53ca\u5371\u6025\u5668\u5b98\u6240\u63a5\u53d7\u7684\u5291\u91cf\uff0c\u4e14\u6bd4\u8f03MU\u6578\u3001\u5c04\u675f\u7d66\u4e88\u6642\u9593\u4ee5\u53ca\u8a08\u5283\u54c1\u4fdd\u7d50\u679c\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u7d50\u679c\u5f97\u77e5\u53d7\u9650\u65bc\u6a23\u672c\u6578\u4e0d\u8db3\u4e26\u7121\u76f8\u7576\u7684\u8b49\u64da\u6216\u8da8\u52e2\u986f\u793a\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u8207\u4e0d\u540c\u5291\u91cf\u7387\u7684\u76f8\u95dc\u6027\uff1b\u8a2d\u5b9a\u9ad8\u5291\u91cf\u7387\u5728\u8a08\u756b\u512a\u5316\u6642\u6703\u4ee5\u6700\u5927\u6a5f\u5668\u65cb\u8f49\u901f\u7387\u70ba\u4e3b\u8981\u8003\u91cf\uff0c\u56e0\u6b64\u5291\u91cf\u8f38\u51fa\u8b8a\u5316\u8207\u6a5f\u5668\u65cb\u8f49\u901f\u5ea6\u76f8\u4e92\u8abf\u7bc0\u7684\u5f48\u6027\u8f03\u5927\uff1b\u65cb\u8f49\u89d2\u5ea6\u5708\u6578\u8d8a\u591a\uff0c\u53ef\u8abf\u6574\u7a7a\u9593\u4e5f\u8f03\u591a\uff1b\u9ad8\u5291\u91cf\u7387\u7e2e\u77ed\u8f03\u591a\u7684\u6cbb\u7642\u6642\u9593\uff0c\u4f46\u4e0d\u7d55\u5c0d\u5c40\u9650\u65bc\u6700\u9ad8\u5291\u91cf\u7387\uff08600 MU/min\uff09\u6642\u3002\u7d50\u8ad6\uff1a\u5728\u57f7\u884c\u92b3\u901f\u5200\u653e\u5c04\u6cbb\u7642\u6280\u8853\u6642\uff0c\u96d6\u7136\u8a08\u756b\u512a\u5316\u6f14\u7b97\u6cd5\u672c\u8eab\u7684\u8907\u96dc\u6027\u4e14\u53d7\u9650\u65bc\u75c5\u60a3\u6578\u4e0d\u8db3\uff0c\u4f46\u4ecd\u53ef\u77e5\u9ad8\u5291\u91cf\u7387\u6709\u597d\u7684\u6a5f\u5668\u65cb\u8f49\u901f\u5ea6\u8207\u5291\u91cf\u7387\u76f8\u4e92\u8abf\u6574\u7684\u5f48\u6027\u53ca\u5728\u6e1b\u5c11\u6cbb\u7642\u6642\u9593\u4e0a\u6709\u76f8\u7576\u7684\u512a\u52e2\u3002", "e": "Purpose: RapidArc is the latest VMAT technique of radiotherapy delivery, varying multi-leaves collimator (MLC) shape, dose rate and gantry speed simultaneously during gantry rotation. The purpose of this study is to evaluate the interplay of dose rate setting and gantry speed during RapidArc optimization, and analyzing treatment planning and plan verify results to find out the most suitable dose rate setting. Materials and Methods: Thirteen patients included three head and neck, five esophageal and prostate patients were selected to re-optimize the treatment plan of RapidArc by setting six different dose rate (100, 200, 300, 400, 500 and 600 MU/min). All re-optimized plans used the same dose constraint and priority for planned target volume and critical organ. Compare the results of the homogeneity index (HI) and conformal index (CI) in the tumor, the dose received by critical organs, monitor unit numbers, delivery time and plan verified by setting different dose rate. Result: All plans results showed that there was no evidence and trend toward improved plan quality for clinical case was observed with any dose rate. When setting high dose rate, gantry maximal speed was the main consideration then it was more flexible in modulating gantry speed and dose rate and using more arcs in plan also did. The main advantage of setting high dose rate was saving total treatment time. But not mean that it must be setting the maximum dose rate (600 MU/min). Conclusion: RapidArc plan was complex and limited by amounts of cases in this study, but high dose rate had high dynamic range in gantry speed modulation. No doubt high dose rate could reduce total treatment time."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-221-230", "title": "\u5efa\u7acb\u653e\u5c04\u6027\u816b\u7624\u96fb\u5b50\u75c5\u6b77\u7cfb\u7d71\u4e4b\u7814\u7a76", "keywords": "\u653e\u5c04\u816b\u7624;\u96fb\u5b50\u75c5\u6b77;\u764c\u767b\u7cfb\u7d71 Radiation oncology;Electronic medical records;Cancer registry system", "c": "\u76ee\u7684\uff1a\u75c5\u6b77\u96fb\u5b50\u5316\u5df2\u70ba\u5fc5\u7136\u8da8\u52e2\uff0c\u4f46\u53f0\u7063\u653e\u5c04\u816b\u7624\u5c08\u79d1\u7684\u75c5\u6b77\u7cfb\u7d71\u5927\u591a\u7368\u7acb\u65bc\u91ab\u9662\u8cc7\u8a0a\u7cfb\u7d71\uff08hospital information system, HIS\uff09\u4e4b\u5916\uff0c\u6216\u8207\u91ab\u9662\u8cc7\u8a0a\u7cfb\u7d71\u672a\u540c\u6b65\u9023\u7d50\uff0c\u5b58\u5728\u764c\u75c5\u5718\u968a\u6210\u54e1\u4e0d\u6613\u53d6\u5f97\u672c\u5c08\u79d1\u8cc7\u8a0a\u7b49\u554f\u984c\u3002\u56e0\u6b64\uff0c\u672c\u7814\u7a76\u76ee\u7684\u70ba\u5efa\u7acb\u8207HIS\u7cfb\u7d71\u53ca\u653e\u816b\u764c\u767b\u8cc7\u6599\u5eab\u6574\u5408\u7684\u653e\u816b\u5c08\u79d1\u5404\u9805\u75c5\u6b77\u7684\u96fb\u5b50\u75c5\u6b77\u7cfb\u7d71\uff0c\u517c\u9867\u8cc7\u8a0a\u7684\u6b63\u78ba\u6027\u3001\u6548\u7387\u6027\u3001\u5b89\u5168\u6027\u3001\u5373\u6642\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u78ba\u5b9a\u5404\u9805\u5c08\u79d1\u75c5\u6b77\u8cc7\u8a0a\u9700\u6c42\u3001\u79d1\u5167\u4f5c\u696d\u6d41\u7a0b\u3001\u53ca\u820a\u6709\u764c\u767b\u4f5c\u696d\u529f\u80fd\uff0c\u5728Java 2 Enterprise Edition\u67b6\u69cb\u904b\u7528JAVA\u8207WEB\u7db2\u9801\u6280\u8853\uff0c\u958b\u767c\u653e\u5c04\u816b\u7624\u79d1\u96fb\u5b50\u75c5\u6b77\u7cfb\u7d71\u3002\u8003\u91cf\u653e\u816b\u79d1\u6cbb\u7642\u75c5\u6b77\u5404\u6b04\u4f4d\u5be6\u969b\u5132\u5b58\u7684\u7279\u6027\u3001\u672a\u4f86\u7d71\u8a08\u5206\u6790\u9700\u6c42\uff0c\u5c07\u8cc7\u6599\u5b9a\u7fa9\u6210\u4e0d\u540c\u683c\u5f0f\u4fdd\u5b58\u3002\u4e26\u4ee5\u53cd\u5411\u5de5\u7a0b\uff08Reverse engineering\uff09\u6982\u5ff5\uff0c\u5c07\u539f\u6709\u55ae\u6a5f\u7248\u764c\u767b\u4f5c\u696d\u91cd\u65b0\u5efa\u7f5d\u70ba\u8207\u672c\u9662\u91ab\u7642\u7cfb\u7d71\u6574\u5408\u4e4bweb\u7248\uff0c\u8cc7\u6599\u4ea6\u532f\u5165\u4e26\u8f49\u63db\u76f8\u5bb9\u65bc\u65b0\u7cfb\u7d71\u4e2d\uff0c\u4ee5\u9054\u5230\u7dda\u4e0a\u6574\u5408\u64cd\u4f5c\u8207\u5373\u6642\u67e5\u8a62\u7684\u76ee\u6a19\u3002\u7d50\u679c\uff1a\u5b8c\u6210\u5404\u9805\u653e\u816b\u96fb\u5b50\u75c5\u6b77\u5305\u62ec\u6709\uff1a\u521d\u59cb\u75c5\u6b77\u3001\u75c5\u7a0b\u7d00\u9304\u526f\u4f5c\u7528\u8868\u3001\u8fd1\u63a5\u6cbb\u7642\u7d00\u9304\u3001\u653e\u5c04\u6cbb\u7642\u6458\u8981\u7d00\u9304\u53ca\u653e\u816b\u764c\u767b\u8cc7\u6599\u5eab\u3002\u8207HIS\u6574\u5408\u53ca\u8cc7\u6599\u5171\u4eab\uff0c\u53ef\u5927\u5e45\u6e1b\u5c11\u81e8\u5e8a\u91ab\u5e2b\u66f8\u5beb\u75c5\u6b77\u6642\u9593\u8207\u91cd\u8907\u8f38\u5165\u9020\u6210\u7684\u932f\u8aa4\uff0c\u4e26\u5f37\u5316\u5c0d\u5176\u4ed6\u764c\u75c7\u5718\u968a\u6210\u54e1\u7684\u8cc7\u8a0a\u5373\u6642\u6027\u8207\u900f\u660e\u6027\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u8a2d\u8a08\u7684\u653e\u816b\u96fb\u5b50\u75c5\u6b77\u7cfb\u7d71\uff0c\u9664\u53ef\u6e1b\u5c11\u5c08\u79d1\u75c5\u6b77\u66f8\u5beb\u6642\u9593\uff0c\u4ea6\u53ef\u5efa\u7acb\u5305\u542b\u5b8c\u6574\u75c5\u53f2\u53ca\u5176\u4ed6\u764c\u75c5\u8cc7\u8a0a\u7684\u8cc7\u6599\u5eab\u4ee5\u4f9b\u672a\u4f86\u7814\u7a76\u4f7f\u7528\uff1b\u56e0\u61c9\u672a\u4f86\u75c5\u6b77\u653f\u7b56\u7684\u6539\u8b8a\u4e5f\u66f4\u5177\u5f48\u6027\u3002", "e": "Purpose: Electronic medical records (EMR) have become indispensable. However, most medical records systems for radiation oncology in Taiwan are independent from hospital information systems (HIS), or asynchronous with HIS. It is difficult to gather information on radiation oncology for other members of cancer treatment team. Therefore, the aim of this study is to build an EMR system, which integrates with both HIS and the cancer registry database, to achieve efficient, safe, instant transfer of information. Materials & Methods: The needs of radiation oncology medical records, the existing processes, and the functions of the cancer registry system were identified first. By applying Java and web technology under J2EE architecture, we developed an electronic medical records system. Considering the characteristics of information storage and the need for future statistical analysis, we defined the information in the notes as different forms. We built a web-based version of the cancer registry system integrated with HIS, using the concept of reverse engineering. The data from the previous cancer registry system was imported and converted to be compatible with the new system to achieve the goal of online operation and real-time search. Results: The electronic medical records system included initial notes, acute radiation morbidity records, brachytherapy notes, complete notes, and a cancer registry database. By integrating with the HIS and sharing the information, we can reduce the time and possible mistakes clinicians spend on medical records and repeated inputing. The instant transparency for other members of the cancer treatment team are improved by the system as well. Conclusions: The electronic medical records designed by this study not only reduce documentation time, but also build a database containing complete patient history and other cancer information for retrospective study or clinical trial. It is also more flexible in response to changes in medical records policy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-231-238", "title": "Radiotherapy for Large Liver Hemangioma: Report on Four Cases and Review of Literature", "keywords": "\u809d\u81df\u8840\u7ba1\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Hepatic hemangioma;Radiotherapy", "c": "\u524d\u8a00\uff1a\u8840\u7ba1\u7624\u662f\u6700\u5e38\u898b\u7684\u826f\u6027\u809d\u816b\u7624\u4e14\u5927\u591a\u6578\u662f\u7121\u75c7\u72c0\u7684\u3002\u5c0d\u65bc\u4f34\u96a8\u8457\u75c7\u72c0\u7684\u8840\u7ba1\u7624\uff0c\u624b\u8853\u5207\u9664\u662f\u5e38\u898b\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u7136\u800c\u5c0d\u65bc\u7121\u6cd5\u624b\u8853\u5207\u9664\u7684\u809d\u8840\u7ba1\u7624\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u76f8\u5c0d\u65bc\u7d93\u52d5\u8108\u6813\u585e\u8853\u537b\u70ba\u4e0d\u5e38\u898b\u7684\u6cbb\u7642\u9078\u64c7\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u56db\u4f4d\u75c5\u4f8b\u63a1\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u809d\u8840\u7ba1\u7624\u4e26\u4f5c\u6587\u737b\u56de\u9867\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u672c\u6587\u63a1\u7528\u56de\u6eaf\u6027\u5206\u6790\uff0c\u56db\u4f4d\u75c5\u4f8b\u5831\u544a\u7686\u70ba\u5973\u6027\uff0c\u5e74\u9f61\u70ba50\u81f361\u6b72\u3002\u6240\u6709\u75c5\u4eba\u90fd\u6709\u53f3\u4e0a\u8179\u75bc\u75db\u4ee5\u53ca\u8179\u8139\u7684\u75c7\u72c0\u3002\u4e00\u4f4d\u75c5\u4eba\u70ba\u624b\u8853\u5f8c\u6578\u5e74\u5f8c\u5fa9\u767c\u809d\u8840\u7ba1\u7624\u3002\u5176\u9918\u4e09\u4f4d\u70ba\u7d93\u5c0e\u7ba1\u809d\u52d5\u8108\u6813\u585e\u8853\u5f8c\u75c7\u72c0\u7121\u660e\u986f\u6539\u5584\u3002\u7167\u5c04\u5291\u91cf\u70ba50\u523059.4\u683c\u96f7\u5206\u5225\u7167\u5c0420\u523033\u6b21\uff0c\u51714\u52307\u9031\u3002\u5728\u6700\u65b0\u7684\u8ffd\u8e64\u4e2d\uff0c\u6240\u6709\u7684\u75c5\u4eba\u7686\u7121\u75c7\u72c0\uff0c\u4e14\u809d\u8840\u7ba1\u7624\u9ad4\u7a4d\u7e2e\u5c0f\u6bd4\u4f8b\u5f9e80.8%\u523098.0%\uff0c\u7121\u4efb\u4f55\u76f8\u95dc\u526f\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u7528\u65bc\u4f34\u96a8\u8457\u75c7\u72c0\u7684\u809d\u81df\u8840\u7ba1\u7624\uff0c\u4e14\u6cbb\u7642\u7d50\u679c\u826f\u597d\u3002", "e": "Background: Hemangioma is the most common benign liver tumor, and mostly asymptomatic. For symptomatic hemangioma, surgical resection is the most common treatment. In unresectable hemangiomas, one of the alternative managements is radiotherapy, a relatively uncommon choice compared to transcatheter arterial embolization. We present our experience of four cases of liver hemangioma treated with fractionated radiotherapy and reviewed the literatures. Case Presentation: A total of four female patients, aged between 50 to 61 years, were retrospectively analyzed. They presented with symptoms of right upper quadrant pain and abdominal fullness. One patient had recurrent liver hemangioma years after liver resection. The other three received transcatheter arterial embolization to hemangioma with limited improvement in symptoms. All patients received radiotherapy with a total dose of 50-59.4 Gy in 20-33 fractions over a 4-7 week period. At the latest follow-up, the regression rate for these liver hemangiomas was 80.8% to 98.0% without radiation-associated adverse effects and the patients remained symptom-free. Conclusions: Radiotherapy is a feasible treatment for symptomatic liver hemangioma with good outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201509-201510230025-201510230025-239-247", "title": "Palliative Radiotherapy for the Extensive Skin Metastasis of Breast Cancer: A Case Report and Review of the Literature", "keywords": "\u4e73\u764c;\u76ae\u819a\u8f49\u79fb;\u653e\u5c04\u6cbb\u7642;\u59d1\u606f\u6027 Breast cancer;Skin metastasis;Radiotherapy;Palliation", "c": "\u4e73\u764c\u662f\u53f0\u7063\u5a66\u5973\u6b7b\u4ea1\u7387\u7b2c\u56db\u4f4d\u4e4b\u764c\u75c7\uff0c\u4e14\u8f03\u6613\u64f4\u6563\u81f3\u9aa8\u9abc\u3001\u809d\u81df\u3001\u80ba\u81df\u4ee5\u53ca\u8166\u90e8\u3002\u7136\u800c\uff0c\u76ae\u819a\u4e4b\u8f49\u79fb\u537b\u4ee3\u8868\u8457\u8f03\u4e0d\u826f\u7684\u9810\u5f8c\u3002\u672c\u6587\u5c07\u5831\u544a\u4e0042\u6b72\u5973\u6027\u4e73\u764c\u75c5\u60a3\u65bc\u7d50\u675f\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u5f8c17\u500b\u6708\u96a8\u5373\u53cd\u8986\u767c\u751f\u76ae\u819a\u8f49\u79fb\u7684\u6848\u4f8b\u3002\u6b64\u6848\u4f8b\u5728\u5316\u5b78\u6cbb\u7642\u63a7\u5236\u5931\u6557\u5f8c\u63a5\u53d7\u4e86\u87ba\u65cb\u5200\u4f5c\u70ba\u59d1\u606f\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u4f46\u6cbb\u7642\u6210\u679c\u53ea\u7372\u5f97\u4e86\u90e8\u5206\u7684\u53cd\u61c9\u4e14\u6709\u76f8\u7576\u7684\u526f\u4f5c\u7528\u3002\u59d1\u606f\u6027\u653e\u5c04\u6cbb\u7642\u4e5f\u8a31\u53ef\u4ee5\u4f5c\u70ba\u4e73\u764c\u75c5\u60a3\u75c5\u76ae\u819a\u8f49\u79fb\u7684\u6cbb\u7642\u9078\u64c7\u4e4b\u4e00\uff0c\u4f46\u5c0d\u65bc\u60a3\u8005\u5be6\u8cea\u52a9\u76ca\u8207\u50b7\u5bb3\u9593\u4ecd\u61c9\u4ed4\u7d30\u6b0a\u8861\u3002\u672c\u6587\u91dd\u5c0d\u6848\u4f8b\u7684\u6cbb\u7642\u904e\u7a0b\u52a0\u4ee5\u8a73\u8ff0\uff0c\u4e26\u4e14\u56de\u9867\u76f8\u95dc\u6587\u737b\u3002", "e": "We report a 42-year-old Taiwanese woman with recurrent skin metastasis who presented with extensive forebreast, and abdominal skin metastasis approximately 17 months after initial adjuvant radiotherapy. The patient was treated with Helical Tomo-Therapy at a total dose of 50 Gy given in 2 Gy per fraction per day. Skin metastases in this case showed only partial response to radiotherapy, and new metastatic lesions developed during the treatment. Radiotherapy might be considered as a palliative treatment option for the skin metastasis of breast cancer. The treatment course of this case is described and previous reports are reviewed in this article."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-89-101", "title": "Postoperative Radiotherapy with or without Concurrent Chemotherapy for Salivary Gland Carcinomas", "keywords": "\u553e\u6db2\u817a\u764c;\u540c\u6b65\u653e\u5316\u7642;\u817a\u6a23\u56ca\u72c0\u764c;\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642 Salivary gland carcinoma;Chemoradiotherapy;Adenoid cystic carcinoma;Postoperative radiotherapy", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u65bc\u553e\u6db2\u817a\u764c\u75c5\u60a3\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u89d2\u8272\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6b64\u7bc7\u56de\u6eaf\u6027\u7814\u7a76\u6536\u7d0d\u65bc2001\u5e74\u81f32011\u5e74\u9593\u65bc\u672c\u9662\u63a5\u53d7\u6cbb\u7642\u4e4b167\u4f4d\u553e\u6db2\u817a\u764c\u75c5\u60a3\u3002\u6240\u6709\u5165\u6848\u75c5\u60a3\u7686\u63a5\u53d7\u6839\u6cbb\u6027\u624b\u8853\u8207\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d\u517174\u4f4d\u75c5\u60a3\u63a5\u53d7\u624b\u8853\u5f8c\u540c\u6b65\u653e\u5316\u7642\u3002\u5169\u7d44\u75c5\u60a3\u4e4b\u653e\u7642\u4e2d\u4f4d\u6578\u7167\u5c04\u5291\u91cf\u5747\u70ba66 Gy\uff0c\u800c\u9251\u91d1\u985e\u5316\u7642\u85e5\u70ba\u6700\u5e38\u4f7f\u7528\u4e4b\u540c\u6b65\u5316\u7642\u85e5\u7269\u3002\u7d50\u679c\uff1a\u7814\u7a76\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba5.4\u5e74\uff0c\u63a5\u53d7\u540c\u6b65\u653e\u5316\u7642\u4e4b\u75c5\u60a3\u6709\u8f03\u591a\u75c5\u7406\u98a8\u96aa\u56e0\u5b50\u8207\u8f03\u56b4\u91cd\u4e4b\u764c\u75c7\u671f\u5225\uff0c\u7136\u800c\u7121\u8ad6\u91dd\u5c0d\u65e9\u671f\u6216\u665a\u671f\u75c5\u60a3\u5169\u7d44\u4e4b\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u3001\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u8207\u7e3d\u5b58\u6d3b\u7387\u7686\u7121\u7d71\u8a08\u4e0a\u4e4b\u986f\u8457\u5dee\u7570\uff1b\u6b64\u5916\uff0c\u5c0d\u65bc\u817a\u6a23\u56ca\u72c0\u764c\u4e4b\u75c5\u60a3\uff0c\u63a5\u53d7\u8853\u5f8c\u540c\u6b65\u653e\u5316\u7642\u75c5\u60a3\u4e4b\u4e94\u5e74\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u70ba100%\uff0c\u8f03\u8853\u5f8c\u55ae\u7d14\u653e\u7642\u75c5\u60a3\uff0881%\uff09\u6709\u7d71\u8a08\u4e0a\u6539\u5584\u4e4b\u8da8\u52e2\uff08P=.057\uff09\u3002\u5728\u6b21\u65cf\u7fa4\u5206\u6790\u4e2d\uff0c\u5c0d\u65bc\u817a\u6a23\u56ca\u72c0\u764c\u5408\u4f75\u624b\u8853\u908a\u7de3\u967d\u6027\uff08P=.022\uff09\u6216\u6cbf\u795e\u7d93\u4fb5\u72af\uff08P=.043\uff09\u4e4b\u75c5\u60a3\uff0c\u8853\u5f8c\u540c\u6b65\u653e\u5316\u7642\u986f\u8457\u63d0\u5347\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u3002\u5728\u6574\u7d44\u7814\u7a76\u65cf\u7fa4\u4e2d\uff0c\u4e3b\u8981\u7684\u816b\u7624\u5fa9\u767c\u5f62\u5f0f\u70ba\u9060\u7aef\u8f49\u79fb\u3002\u7d50\u8ad6\uff1a\u8853\u5f8c\u653e\u7642\u4e2d\u65bd\u4e88\u540c\u6b65\u5316\u7642\u53ef\u80fd\u53ef\u6539\u5584\u817a\u6a23\u56ca\u72c0\u764c\u75c5\u60a3\u5408\u4f75\u624b\u8853\u908a\u7de3\u967d\u6027\u6216\u6cbf\u795e\u7d93\u4fb5\u72af\u4e4b\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u3002\u5728\u591a\u65b9\u4ecb\u5165\u6cbb\u7642\u4e0b\u9060\u7aef\u8f49\u79fb\u4ecd\u662f\u553e\u6db2\u817a\u764c\u6cbb\u7642\u4e0a\u4e4b\u6700\u5927\u969c\u7919\u3002", "e": "Purpose: To investigate the potential value of concurrent chemotherapy in patients with salivary gland carcinomas treated with postoperative radiotherapy (PORT). Materials and Methods: This retrospective review included 167 consecutive patients with major and minor salivary gland carcinomas from 2001 to 2011. All were treated with curative surgery followed by PORT (n=93) or postoperative chemoradiotherapy (POCRT) (n=74). The median cumulative radiation doses were 66 Gy for both groups, and cisplatin-based concurrent chemotherapies were the most commonly used regimens. Results: The median follow-up was 5.4 years for survivors. Although patients receiving POCRT possessed more adverse pathological prognosticators and higher cancer stages, there were no statistical differences in locoregional control (LRC), diseasefree survival (DFS), and overall survival (OS) between the PORT and POCRT groups according to early or advanced stage. However, a trend towards LRC improvement was observed in patients with adenoid cystic carcinoma (ACC) undergoing POCRT, with 100% 5-year LRC compared with 81% for those treated with PORT (P=.057). In subgroup analyses, POCRT provided significant LRC advantages over PORT for ACC patients who also exhibited positive surgical margins (P=.022) or perineural invasion (P=.043). The predominant pattern of failure for the entire cohort was distant metastasis. Conclusions: Adding concurrent chemotherapy to postoperative radiotherapy might be most beneficial in terms of LRC for salivary gland ACC patients with positive surgical margins or perineural invasion. Distant metastasis remains problematic despite multimodal intervention."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-103-111", "title": "Frameless Fractionated Stereotactic Radiosurgery for Acoustic Neuromas: A Single-Institution Experience", "keywords": "\u807d\u795e\u7d93\u7624;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u653e\u5c04\u7dda\u6cbb\u7642 Acoustic neuroma;Stereotactic radiosurgery;Radiotherapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u807d\u795e\u7d93\u7624\u7684\u75c5\u4eba\u63a5\u53d7\u7121\u6846\u5f0f\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u5f8c\u7684\u816b\u7624\u63a7\u5236\u7387\u3001\u807d\u529b\u4fdd\u5b58\u7387\u3001\u53ca\u526f\u4f5c\u7528\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u6eaf\u6027\u5206\u6790\u5f9e2009\u5e74\u52302012\u5e74\u671f\u9593\uff0c57\u4f4d\u7f79\u60a3\u807d\u795e\u7d93\u7624\u7e3d\u517163\u8655\u75c5\u7076\uff0c\u63a5\u53d7\u7121\u6846\u5f0f\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u7684\u75c5\u4f8b\u7d00\u9304\u3002\u7e3d\u6cbb\u7642\u5291\u91cf\u5404\u5225\u70ba18 Gy\u81f330 Gy\uff0c\u5206\u62103\u6b21\u81f35\u6b21\u7642\u7a0b\u3002\u6211\u5011\u5229\u7528\u6838\u78c1\u5171\u632f\u986f\u5f71\u5f71\u50cf\u5b9a\u671f\u8ffd\u8e64\u4ee5\u8a55\u4f30\u816b\u7624\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u4e26\u5229\u7528Gardner-Robertson scale\u4f86\u8ffd\u8e64\u807d\u529b\u3002\u6b64\u5916\u4ea6\u65bc\u75c5\u60a3\u56de\u8a3a\u6642\u7531\u75c5\u60a3\u4e3b\u89c0\u5224\u65b7\u5176\u807d\u529b\u53ca\u5176\u4ed6\u75c7\u72c0\u7684\u8b8a\u5316\u3002\u7d50\u679c\uff1a\u7d93\u904e\u4e2d\u4f4d\u503c29.1\u500b\u6708\u7684\u8ffd\u8e64\u6642\u9593\uff0c\u4e8c\u5e74\u53ca\u4e09\u5e74\u7684\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba94.8%\u53ca89.3%\u3002\u5176\u4e2d13\u4f4d\u75c5\u60a3\u65bc\u6cbb\u7642\u524d\u4fdd\u6709\u6709\u7528\u807d\u529b\u4e14\u6cbb\u7642\u5f8c\u6709\u5b9a\u671f\u63a5\u53d7\u807d\u529b\u6e2c\u9a57\uff0c\u7d93\u904e\u4e2d\u4f4d\u503c30.8\u500b\u6708\u8ffd\u8e64\uff0c\u5176\u7d50\u679c\u986f\u793a\u6cbb\u7642\u5f8c\u807d\u529b\u4fdd\u7559\u7387\u70ba88.2%\u3002\u800c57\u4f4d\u75c5\u60a3\u4e2d\u50c5\u67096\u4f4d\u65bc\u6cbb\u7642\u5f8c\u767c\u751f3\u81f34\u5ea6\u7684\u6c34\u8166\u75c7\u3001\u8166\u6c34\u816b\uff0c\u53ca\u982d\u75db\u7b49\u526f\u4f5c\u7528\u9700\u63a5\u53d7\u85e5\u7269\u6216\u624b\u8853\u8655\u7406\u3002\u7d50\u8ad6\uff1a\u8207\u904e\u53bb\u6709\u95dc\u807d\u795e\u7d93\u7624\u63a5\u53d7\u624b\u8853\u3001\u50b3\u7d71\u7acb\u9ad4\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u6216\u4f3d\u508c\u5200\u70ba\u57fa\u790e\u7684\u7acb\u9ad4\u653e\u5c04\u624b\u8853\u6cbb\u7642\u7684\u6587\u737b\u6bd4\u8f03\uff0c\u4f7f\u7528\u7121\u6846\u5f0f\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u807d\u795e\u7d93\u7624\u53ef\u4ee5\u7372\u5f97\u826f\u597d\u7684\u816b\u7624\u5c40\u90e8\u63a7\u5236\u7387\u53ca\u807d\u529b\u4fdd\u7559\u7387\uff0c\u4e14\u6cbb\u7642\u76f8\u95dc\u7684\u526f\u4f5c\u7528\u767c\u751f\u7387\u4ea6\u5728\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\u3002", "e": "Objective: To evaluate tumor control, hearing preservation, and complication rates after frameless fractionated stereotactic radiosurgery (FSRS) in patients with acoustic neuromas (ANs). Methods: Fifty-seven patients with 63 ANs treated with FSRS at Chi-Mei Medical Center from 2009 to 2012 were retrospectively analyzed. The radiation dose ranged from 18 Gy to 30 Gy in 3 to 5 fractions. To evaluate local control rate, we arranged brain MRI with contrast enhancement at regular intervals. Hearing ability was also assessed using the Gardner-Robertson scale. Additionally, subjective change of hearing was rated at regular OPD follow-ups. Results: With a median follow-up of 29.1 months (range 3.6-54.1), actuarial local control rate was 94.8% after 2 years and 89.3% after 3 years. Of the 13 patients with serviceable hearing and with audiograms, the hearing preservation rate was 88.2% at a median follow-up of 30.8 months. Among the 57 treated patients, 6 developed complications including grade 3 to 4 hydrocephalus, perifocal edema, and headache that needed medical or surgical intervention after treatment. Conclusion: Frameless fractionated SRS treatment of AN demonstrates good results for tumor control, hearing preservation rate, and acceptable rates of radiation related toxicity as compared to literature on study series on surgery, conventional stereotactic radiotherapy, and Gamma-knife based stereotactic radiosurgery, yet longer follow-up will be needed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-113-120", "title": "Outcome of Gemcitabine Based Chemoradiation for Loco-Regional Cholangiocarcinoma", "keywords": "\u81bd\u9053\u764c;\u653e\u5c04\u6cbb\u7642 Cholangiocarcinoma;Gemcitabine;Radiotherapy", "c": "\u76ee\u7684\uff1a\u76ee\u524d\u81bd\u9053\u764c\u7684\u6cbb\u7642\u4ecd\u4ee5\u624b\u8853\u70ba\u4e3b\uff0c\u800c\u540c\u6b65\u5316\u653e\u7642\u6cbb\u7642\u5247\u7528\u65bc\u8853\u5f8c\u4e4b\u8f14\u52a9\u6027\u6cbb\u7642\uff0c\u6216\u5728\u7121\u6cd5\u624b\u8853\u5207\u9664\u75c5\u7076\u4e4b\u75c5\u60a3\u3002\u6587\u737b\u4e2d\u6240\u8a18\u8f09\u4e4b\u540c\u6b65\u5316\u653e\u7642\u7642\u6cd5\u4ecd\u4ee5flourauracil\u70ba\u4e3b\uff0c\u4ee5gemcitabine\u9032\u884c\u6cbb\u7642\u8005\u8457\u58a8\u4e0d\u591a\u3002\u672c\u6587\u4e43\u5c0d\u65bc\u672c\u9662\u63a5\u53d7gemcitabine\u884c\u540c\u6b65\u5316\u653e\u7642\u75c5\u4eba\u9032\u884c\u56de\u6eaf\u6027\u5206\u6790\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e2004\u5e744\u6708\u81f32012\u5e7412\u6708\uff0c\u5171\u670926\u4f4d\u65b0\u8a3a\u65b7\u81bd\u7ba1\u764c\u75c5\u60a3\uff08\u7537\uff0f\u5973=17\uff0f9\uff1b\u5e74\u9f61\u4e2d\u4f4d\u6578\uff1a66\u6b72\uff09\u65bc\u672c\u9662\u63a5\u53d7\u4ee5gemcitabine\u70ba\u4e3b\u7684\u6839\u6cbb\u6027\u540c\u6b65\u5316\u653e\u7642\u3002\u7576\u4e2d22\u4f4d\u75c5\u60a3\u9ad4\u80fd\u72c0\u614b\u70baECOG 0-1\u30014\u4f4d\u70baECOG 2\uff0c9\u4f4d\u6709\u6dcb\u5df4\u8f49\u79fb\u75c5\u7076\u300117\u4f4d\u7121\u6dcb\u5df4\u8f49\u79fb\u75c5\u7076\u3002Gemcitabine\u4f7f\u7528\u5291\u91cf\u70ba\u6bcf\u9031\u6216\u9694\u9031 400 mg\uff0fm2\uff0c\u653e\u5c04\u7dda\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba52.0 Gy\uff0840\uff0d72.1 Gy\uff09\u3002\u4ee5\u55ae\u8b8a\u9805\u53ca\u591a\u8b8a\u9805\u5206\u6790\u627e\u51fa\u53ef\u80fd\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u6240\u6709\u75c5\u60a3\u7684\u5e73\u5747\u5b58\u6d3b\u671f\u70ba13.2\u6708\uff0c\u4e00\u5e74\u53ca\u4e8c\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba53%\u4ee5\u53ca8%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u9ad4\u80fd\u72c0\u614b\u70baECOG 0-1\u8005\u8f03ECOG 2\u8005\u4e4b\u5b58\u6d3b\u671f\u5b58\u5728\u986f\u8457\u5dee\u7570\uff0816.9\u6708vs. 1.5\u6708\uff0cp=0.045\uff09\u3002\u5e74\u9f61\uff08\uff1c 66\u6b72\uff09\u96d6\u7136\u5c0d\u5e73\u5747\u5b58\u6d3b\u671f\u6709\u6b63\u9762\u5f71\u97ff\uff0c\u4f46\u672a\u9054\u986f\u8457\u7d71\u8a08\u5dee\u7570\uff0828.0\u6708vs.4.8\u6708\uff0cp=0.055\uff09\u3002\u5728\u816b\u7624\u5340\u5fa9\u767c\u8005\u5171\u516b\u4f4d\uff0c\u5176\u4e2d\u4e8c\u4f4d\u70ba\u55ae\u7d14\u816b\u7624\u5fa9\u767c\u3002\u56e0\u6cbb\u7642\u526f\u4f5c\u7528\u6b7b\u4ea1\u8005\u5171\u5169\u4f4d\u3002\u7d50\u8ad6\uff1a\u4ee5gemcitabine\u9032\u884c\u81bd\u9053\u7ba1\u764c\u7684\u540c\u6b65\u5316\u653e\u7642\u662f\u53ef\u884c\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u53ef\u505a\u70ba\u624b\u8853\u4e4b\u5916\u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\u3002\u9ad4\u80fd\u72c0\u614b\u826f\u597d\u7684\u75c5\u4eba\u61c9\u53ef\u7531\u672c\u6cbb\u7642\u5f97\u5230\u8f03\u9577\u7684\u751f\u5b58\u671f\u3002", "e": "Purpose: Surgery remains the primary treatment of cholangiocarcinoma, with concurrent chemoradiation (CCRT) reserved for adjuvant treatment or as primary treatment for unresectable disease. However, the experience has been limited to flourauracilbased chemoradiation. A retrospective analysis of gemcitabine based CCRT as primary treatment for loco-regional cholangiocarcinoma in our institute was performed. Materials and Methods: Between April, 2004 and December, 2012, 26 patients (M/F=17/9; median age=66years) with cholangiocarcinoma (14 intrahepatic primary and 12 perihilar or extrahepatic primary) were treated with curative intent at our department. Baseline performance status based on Eastern Cooperative Oncology Group (ECOG) was 0-1 in 22 patients and 2 in 4 patients. Nine had regional extension of the diseases (defined as metastasis in either regional or para-aortic lymph nodes), whereas 17 had localized (T1-4N0M0) disease. The median equivalent dose in 2 Gy (EQD2) was 52.0 Gy (range: 40-72.1 Gy). Concurrent chemotherapy was low dose gemcitabine at 400 mg/m2 given weekly to biweekly. Both univariateand multivariate analyses were used to identify statistically significant prognostic factors. Results: The median survival of the entire cohort was 13.2 months. Survival rates at 1 and 2 year were 53% and 8% respectively. Patients of better performance status (ECOG 0-1) had improved median survival in comparison to those who of poorer baseline performance status (ECOG 2) (16.9 months vs. 1.5 months, p=0.045) on univariate analysis. Younger age (\uff1c 66 years) trended towards improved median survival (28.0 months vs. 4.8 months, p=0.055). There was eight local failures, two of which were isolated local failures. There were two treatment-related deaths. Conclusions: Outcome of low dose gemcitabine CCRT for cholangiocarcinoma seems promising. Those with better baseline performance status are most likely to benefit from this treatment. Definitive gemcitabine based CCRT for loco-regional cholangiocarcinoma may be an alternative to primary surgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-121-127", "title": "\u7c21\u4ecb\u61c9\u7528\u5065\u5eb7\u7167\u8b77\u7814\u7a76\u65bc\u653e\u5c04\u816b\u7624\u5b78\uff0d\u4ee5\u8cc7\u6599\u5eab\u5206\u6790\u70ba\u4f8b", "keywords": "\u5065\u5eb7\u7167\u8b77\u7814\u7a76;\u6bd4\u8f03\u6548\u76ca\u7814\u7a76;\u8cc7\u6599\u5eab\u5206\u6790 Health services research;Comparative effectiveness research;Database analysis", "c": "\u672c\u6587\u4e3b\u8981\u7c21\u4ecb\u8aaa\u660eHealth Services Research\uff08HSR\uff09\u53caComparative Effectiveness Research\uff08CER\uff09\u5169\u7a2e\u7814\u7a76\u985e\u578b\uff0c\u4ecb\u7d39\u5176\u7814\u7a76\u7684\u5de5\u5177\u8207\u65b9\u6cd5\uff0c\u7279\u5225\u8457\u91cd\u65bc\u8cc7\u6599\u5eab\u5206\u6790\uff0c\u4e26\u63d0\u51fa\u500b\u4eba\u7684\u5fc3\u5f97\u8207\u7d93\u9a57\uff0c\u63d0\u4f9b\u6709\u8208\u8da3\u7684\u8b80\u8005\u82e5\u5e72\u5be6\u52d9\u95b1\u8b80\u8207\u7814\u7a76\u5efa\u8b70\u3002", "e": "This review provided a concise introduction regarding applying health services research/ comparative effectiveness analysis in radiation oncology in Taiwan. Research methodology was introduced and personal experiences were provided, especially focused on database analysis. Finally, some suggestions regarding reading and research in this field were provided."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-129-138", "title": "\u61c9\u7528EBT3\u81ea\u986f\u5e95\u7247\u57f7\u884cVarian Millennium 120-leaf\u591a\u8449\u6e96\u76f4\u5100\u7684\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d", "keywords": "\u591a\u8449\u6e96\u76f4\u5100;\u54c1\u8cea\u4fdd\u8b49;\u81ea\u986f\u5e95\u7247 Multileaf collimator;Quality assurance;Film", "c": "\u76ee\u7684\uff1a\u6839\u64da\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5b78\u6703\u7b2c142\u865f\u5831\u544a\u5efa\u8b70\uff0c\u5229\u7528EBT3\u81ea\u986f\u5e95\u7247\u57f7\u884cVarian Millennium120-Leaf\u591a\u8449\u6e96\u76f4\u5100\u7684\u4f8b\u884c\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u63a1\u7528\u7b2c\u4e09\u4ee3EBT\u81ea\u986f\u5e95\u7247\u6536\u96c6Varian Millennium 120-Leaf\u591a\u8449\u6e96\u76f4\u5100\u7684\u4f8b\u884c\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u7684\u5f71\u50cf\uff0c\u4f7f\u7528PIPS pro\u8edf\u9ad4\u5206\u6790\u91cf\u5316\u5176\u8aa4\u5dee\u503c\u4e26\u5efa\u7acb\u5176\u591a\u8449\u6e96\u76f4\u5100\u54c1\u4fdd\u57fa\u6e96\u503c\u3002\u54c1\u8cea\u4fdd\u8b49\u65bd\u4f5c\u9805\u76ee\u5305\u62ec\u6bcf\u6708\u54c1\u8cea\u4fdd\u8b49\uff0c\u9805\u76ee\u6709\u5149\u7167\u91ce\u8207\u8f3b\u5c04\u7167\u91ce\u543b\u5408\u5ea6\u3001\u5099\u7528\u6e96\u76f4\u5100\u8a2d\u5b9a\u3001\u8449\u7247\u9077\u79fb\u901f\u5ea6\u3001\u8449\u7247\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u3002\u6bcf\u5e74\u54c1\u8cea\u4fdd\u8b49\uff0c\u9805\u76ee\u6709\u5149\u7167\u91ce\u8207\u8f3b\u5c04\u7167\u91ce\u543b\u5408\u5ea6\u3001\u8449\u7247\u8f3b\u5c04\u4e2d\u5fc3\u9ede\u6e2c\u8a66\u3001\u8449\u7247\u4f4d\u7f6e\u518d\u73fe\u6027\u53ca\u8449\u7247\u7a7f\u900f\u7387\u3002\u672c\u7814\u7a76\u4f9d\u7167\u591a\u8449\u6e96\u76f4\u5100\u54c1\u4fdd\u7684\u8981\u6c42\uff0c\u5c0d\u65bc\u7167\u5c04EBT3\u81ea\u986f\u5e95\u7247\u7684\u6b65\u9a5f\u3001\u66dd\u5149\u689d\u4ef6\u8207\u8a2d\u8a08\u7684\u54c1\u4fdd\u7167\u5c04\u6a21\u7d44\u63d0\u4f9b\u53ef\u884c\u7684\u5efa\u8b70\u3002\u7d50\u679c\uff1a\u5404\u9805\u591a\u8449\u6e96\u76f4\u5100\u54c1\u4fdd\u7d50\u679c\u90fd\u7b26\u5408\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5b78\u6703\u7b2c142\u865f\u5831\u544a\u7684\u8981\u6c42\uff0c\u9019\u7d50\u679c\u53ea\u9650\u65bc\u8a72\u90e8\u76f4\u7dda\u52a0\u901f\u5668\u914d\u7f6eVarian Millennium 120-Leaf\u591a\u8449\u6e96\u76f4\u5100\u3002\u6578\u9805\u591a\u8449\u6e96\u76f4\u5100\u54c1\u4fdd\u6e2c\u91cf\u503c\u90fd\u80fd\u8207\u76f4\u7dda\u52a0\u901f\u5668\u9a57\u6536\u6642\u7684\u57fa\u6e96\u503c\u76f8\u543b\u5408\u3002\u53ea\u8981\u6709\u9069\u7576\u7684\u8edf\u9ad4\u8207\u65b9\u6cd5\uff0cEBT3\u81ea\u986f\u5e95\u7247\u80fd\u5920\u6eff\u8db3\u591a\u8449\u6e96\u76f4\u5100\u7684\u4f8b\u884c\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u3002\u7d50\u8ad6\uff1a\u9805\u76ee\u4e2d\u7684\u8449\u7247\u8f3b\u5c04\u4e2d\u5fc3\u9ede\u6e2c\u8a66\u6703\u8207\u76f4\u7dda\u52a0\u901f\u5668\u54c1\u8cea\u4fdd\u8b49\u4e2d\u7684\u6e96\u76f4\u5100\u8f3b\u5c04\u4e2d\u5fc3\u9ede\u6e2c\u8a66\u4e00\u81f4.\uff0c\u7531\u65bcVarian Millennium 120-Leaf\u7684\u591a\u8449\u6e96\u76f4\u5100\u8207\u6e96\u76f4\u5100\u4f4d\u65bc\u76f8\u540c\u6a5f\u982d\u4f46\u53ea\u662f\u4e0a\u4e0b\u5c64\u4f4d\u7f6e\u4e0d\u540c\u3002\u8449\u7247\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u6703\u56e0\u91cd\u529b\u7684\u5f71\u97ff\u96a8\u8457\u6a5f\u982d\u89d2\u5ea6\u7684\u8b8a\u5316\u5448\u73fe\u4e0d\u540c\u7d50\u679c\u3002", "e": "Purpose: Follow recommendation of AAPM report no.142; applying EBT3 film to process routine quality assurance for Varian Millennium 120-Leaf multileaf collimator. Materials and Methods: The study was designed the specific pattern for MLC quality assurance and acquired the images by EBT3 film. The commercial software can be analyzing the images scanned from EBT3 film and creating reference values. The monthly QA items was included setting versus radiation field for two patterns\u3001travel speed and leaf position accuracy. The items for annual QA was consisted of MLC transmission for all energies, leaf position repeatability, MLC spoke shot, coincidence of light field and x-ray field and IMRT testing for segment and sliding window. The paper was described particularly for the QA procedure, method of exposed film and specific testing pattern. Results: The results of quality assurance for Varian Millennium 120-Leaf were satisfied with criteria which were recorded on AAPM report no.142. The QA reference values were only available for this specific MLC on this linear accelerator. The paper is presenting the QA procedure of Varian Millennium 120-Leaf MLC using EBT3 film and appropriate software. Discussions: Several MLC QA reference values could be consist with record on customer acceptance procedure document. Due to MLC was installed lower level than collimator but on same gantry head. The result of MLC spoke shot could be same with collimator spoke shot. The accuracy of leaf position must be varying with gantry angle causing gravity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-139-146", "title": "\u4f7f\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\u4ee5\u53ca\u4e0d\u898f\u5247\u9ad4\u8868\u88dc\u511f\u5668\u65bc\u4e73\u764c\u75c5\u4eba\u653e\u5c04\u6cbb\u7642\u4e4b\u5047\u9ad4\u76ae\u819a\u5291\u91cf\u91cf\u6e2c", "keywords": "\u76ae\u819a\u5291\u91cf;\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247 Skin dose;Ultrathin TLD;Gafchromic EBT film", "c": "\u76ee\u7684\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u5229\u7528\u5047\u9ad4\u6e2c\u91cf\u4e73\u764c\u75c5\u4eba\u653e\u5c04\u6cbb\u7642\u4e4b\u8868\u9762\u5291\u91cf\uff0c\u4ee5\u53ca\u8a55\u4f30\u4e73\u764c\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u91cf\u6e2c\u5de5\u5177\u7684\u53ef\u4fe1\u5ea6\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u63a1\u7528\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u4f86\u505a\u70ba\u91cf\u6e2c\u5de5\u5177\uff0c\u4e26\u5206\u5225\u5c0d\u5176\u7279\u6027\u505a\u7814\u7a76\uff1b\u4f7f\u7528\u64ec\u4eba\u5047\u9ad4\uff08anthropomorphic Rando phantom\uff09\u6a21\u64ec\u6e2c\u91cf\u81ea\u88fd\u4e73\u623f\u7684\u8868\u9762\u5291\u91cf\uff0c\u5229\u7528Eclipse\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u88fd\u4f5c\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\uff08Field-in-Field, FIF\uff09\u548c\u4e0d\u898f\u5247\u9ad4\u8868\u88dc\u511f\u5668\uff08Irregular surface compensator, ISC\uff09\u7684\u5169\u7a2e\u6280\u8853\u4f5c\u70ba\u6cbb\u7642\u7684\u65b9\u6cd5\u4f86\u505a\u5291\u91cf\u5206\u6790\uff0c\u8655\u65b9\u5291\u91cf\u70ba180 cGy\u3002\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u4e4b\u8584\u7247\u578bTLD\u8b8a\u7570\u4fc2\u6578\u57283%\u4ee5\u5167\uff0c\u8a08\u8b80\u503c\u8207\u7d66\u4e88\u5291\u91cf\u9593\u5448\u73fe\u826f\u597d\u7dda\u6027\u95dc\u4fc2\uff1b\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u6821\u6b63\u5340\u7dda\u4e0a\u6bcf\u500b\u9ede\u4e4b\u8b8a\u7570\u4fc2\u6578\u57281%\u4ee5\u5167\uff0c\u6574\u9ad4\u6821\u6b63\u66f2\u7dda\u5448\u73fe\u7a69\u5b9a\u7684\u95dc\u4fc2\uff1bFIF\u548cISC\u5229\u7528EBT film\u548c\u8584\u7247\u578bTLD\u5169\u7a2e\u91cf\u6e2c\u5de5\u5177\u6e2c\u91cf\u7684\u8868\u9762\u5291\u91cf\u5e73\u5747\u503c\u5206\u5225\u70ba108.74 \u00b1 14.86 cGy\u3001107.35 \u00b1 15.93 cGy\u548c103.19 \u00b1 12.91 cGy\u3001102.09 \u00b1 10.02 cGy\uff1bEBT film\u548c\u8584\u7247\u578bTLD\u5169\u7a2e\u91cf\u6e2c\u5de5\u5177\u5728FIF\u7684\u7167\u5c04\u65b9\u5f0f\u4e2d\u6e2c\u91cf\u81ea\u88fd\u4e73\u623f\u5167\u5074\u3001\u4e2d\u9593\u3001\u5916\u5074\u3001\u4e0a\u5074\u3001\u4e0b\u5074\u548c\u5168\u90e8\u7684\u5291\u91cf\u8aa4\u5dee\u5206\u5225\u70ba5.17%\u3001-3.45%\u30011.58%\u30011.27%\u3001-0.55%\u548c1.3%\uff1bEBT film\u548c\u8584\u7247\u578bTLD\u5169\u7a2e\u91cf\u6e2c\u5de5\u5177\u5728ISC\u7684\u7167\u5c04\u65b9\u5f0f\u4e2d\u6e2c\u91cf\u81ea\u88fd\u4e73\u623f\u5167\u5074\u3001\u4e2d\u9593\u3001\u5916\u5074\u3001\u4e0a\u5074\u3001\u4e0b\u5074\u548c\u5168\u90e8\u7684\u5291\u91cf\u8aa4\u5dee\u5206\u5225\u70ba1.86%\u30012.94%\u30018.3%\u3001-3.44%\u3001-5%\u548c1.08%\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u7531\u672c\u5be6\u9a57\u5f97\u77e5\uff0c\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u9069\u5408\u7528\u4f86\u4f5c\u70ba\u4e73\u764c\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u7684\u91cf\u6e2c\u5de5\u5177\uff0c\u672a\u4f86\u672c\u7814\u7a76\u5c07\u7d71\u8a08\u81e8\u5e8a\u4e0a\u4eba\u9ad4\u51fa\u73fe\u76ae\u819a\u53cd\u61c9\u6642\u5be6\u969b\u63a5\u53d7\u7684\u5291\u91cf\uff0c\u4ee5\u671f\u6e2c\u91cf\u5230\u6700\u6e96\u78ba\u7684\u76ae\u819a\u5291\u91cf\u4e26\u8a55\u4f30\u81e8\u5e8a\u4e0d\u540c\u76ae\u819a\u53cd\u61c9\u6642\u7684\u76ae\u819a\u6bd2\u6027\uff0c\u78ba\u5be6\u627e\u51fa\u9020\u6210\u75c5\u4eba\u76ae\u819a\u53cd\u61c9\u7684\u5291\u91cf\u8a55\u4f30\u503c\u3002", "e": "Purpose: This reasearch was focused on the measured surface dose of the simulated phantom for breast cancer patients treated with field-in-field (FIF) and irregular surface compensator (ISC) and the reliable measured tools to evaluate the skin dose of breast cancer patients. Materials and Methods: This experiment adopted 0.1mm ultrathin thermoluminescent dosimeters (ultrathin TLD) and ISP Gafchromic EBT film as the measured tool to establish the characteristics. Superficial doses of home-made breast on anthropomorphic Rando phantom were measured. FIF and ISC plans with a prescribed dose of 180 cGy were designed on this phantom using an Eclipse treatment planning system and using two measured tools to measure the absolute surface dose. Result: In this experiment the variance coefficient of TLD film was within 3%. The reading values and delivered doses were in a good linear relationship. The points on calibration curve of Gafchromic film were within 1% and in a stable performance. Mean surface measured doses of FIF and ISC with the EBT film and TLD film were 108.74 \u00b1 14.86 cGy, 107.35 \u00b1 15.93 cGy and 103.19 \u00b1 12.91 cGy, 102.09 \u00b1 10.02 cGy, respectively. The error between EBT film and TLD film for the inner, middle, outer, upper, lower regions of home-made breast and the total mean dose of FIF was 5.17%, -3.45%, 1.58%, 1.27%, -0.55% and 1.3%, respectively; the error between EBT film and TLD film for the inner, middle, outer, upper, lower regions of home-made breast and the total mean dose of ISC was 1.86%, 2.94%, 8.3%, -3.44%, -5% and 1.08%, respectively. Conclusion and Discussion: From the experimental results, ultrathin TLD and EBT film can be adopted as the measured tools for surface dose of breast cancer patients. The future work for this research could gather statistics of the skin reactions indeed affected by the skin dose received from radiation for clinical applications. To evaluate severity of skin reaction and measure most accurate skin dose, and this data can be used references for skin reaction gradings."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-147-152", "title": "Metastatic Adenocarcinoma Mimicking Primary Breast Cancer- A Case Report and Review of the Literature", "keywords": "\u8f49\u79fb\u6027\u4e73\u764c;\u6a21\u4eff\u6027\u4e73\u764c;\u76f4\u8178\u764c Metastatic breast cancer;Mimicking breast cancer;Rectal cancer", "c": "\u6b64\u4efd\u500b\u6848\u5831\u544a\u70ba\u4e00\u500b50\u6b72\u5973\u6027\u7f79\u60a3\u8f49\u79fb\u6027\u4e73\u623f\u60e1\u6027\u816b\u7624\u5408\u4f75\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\u3002\u75c5\u4eba\u7684\u81e8\u5e8a\u8868\u73fe\u3001\u5f71\u50cf\u5b78\u6aa2\u67e5\u53ca\u75c5\u7406\u7d44\u7e54\u5207\u7247\u6aa2\u9a57\u5f8c\uff0c\u521d\u6b65\u61f7\u7591\u662f\u539f\u767c\u6027\u4e73\u764c\uff0c\u4f46\u7d93\u624b\u8853\u5207\u9664\u53ca\u6bd4\u5c0d\u904e\u53bb\u75c5\u53f2\u8207\u4ee5\u5f80\u7d44\u7e54\u67d3\u8272\u5f8c\uff0c\u78ba\u8a8d\u662f\u8f49\u79fb\u6027\u817a\u764c\u3002\u6211\u5011\u7684\u5047\u8aaa\u662f\u539f\u767c\u65bc\u76f4\u8178\u764c\u7684\u8f49\u79fb\u6027\u764c\u7d30\u80de\uff0c\u5148\u8f49\u79fb\u81f3\u4e73\u623f\uff0c\u7136\u5f8c\u518d\u4f9d\u5e8f\u8f49\u79fb\u81f3\u5c40\u90e8\u814b\u4e0b\u6dcb\u5df4\u7d50\u3002", "e": "We report a 50-year-old female who had metastatic adenocarcinoma of the breast which mimicked a primary breast cancer with regional lymph nodes metastases. The clinical presentation and histologic findings were similar to primary invasive ductal carcinoma of the breast. We hypothesize that the origin was adenocarcinoma of the rectum which metastasized to the breast and then seeded in the ipsilateral axillary nodes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-153-158", "title": "Verrucous Carcinoma of the Renal Pelvis and Ureter: A Case Report in Taiwan", "keywords": "\u75a3\u72c0\u764c;\u814e\u76c2;\u8f38\u5c3f\u7ba1;\u653e\u5c04\u6cbb\u7642 Verrucous carcinoma;Renal pelvis;Ureter;Radiotherapy", "c": "\u75a3\u72c0\u764c\u662f\u4e00\u7a2e\u826f\u597d\u5206\u5316\u7684\u9c57\u72c0\u7d30\u80de\u764c\uff0c\u4e5f\u662f\u4e00\u7a2e\u5f88\u5c11\u51fa\u73fe\u9060\u7aef\u8f49\u79fb\u7684\u4f4e\u5ea6\u60e1\u6027\u816b\u7624\u3002\u6839\u64da\u904e\u53bb\u5831\u544a\u7684\u75c5\u4f8b\u4e2d\uff0c\u5b83\u7684\u767c\u751f\u53ef\u80fd\u662f\u56e0\u7d50\u77f3\u7684\u51fa\u73fe\u9020\u6210\u6162\u6027\u767c\u708e\u548c\u5916\u50b7\u6027\u7684\u523a\u6fc0\uff0c\u9019\u6a23\u7684\u6a5f\u5236\u5c07\u4fc3\u9032\u4e0a\u534a\u90e8\u6ccc\u5c3f\u9053\u75a3\u72c0\u764c\u7684\u767c\u5c55\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f8b\u767c\u751f\u5728\u53f3\u5074\u814e\u76c2\u8207\u8f38\u5c3f\u7ba1\u7684\u75a3\u72c0\u764c\uff0c\u9019\u6a23\u7684\u816b\u7624\u9020\u6210\u56b4\u91cd\u7684\u6ccc\u5c3f\u9053\u963b\u585e\u3002\u624b\u8853\u6cbb\u7642\u662f\u4e3b\u8981\u6cbb\u7642\u6a21\u5f0f\u3002\u9019\u4f4d\u75c5\u60a3\u63a5\u53d7\u814e\u76c2\u53ca\u8f38\u5c3f\u7ba1\u5207\u9664\u624b\u8853\u3002\u6b64\u5916\u56e0\u70ba\u5728\u986f\u5fae\u93e1\u88e1\u770b\u5230\u6b98\u7559\u816b\u7624\u5728\u8f38\u5c3f\u7ba1\u5207\u53e3\u7aef\u90e8\uff0c\u8a72\u75c5\u60a3\u4e5f\u63a5\u53d7\u4e86\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u3002", "e": "Verrucous carcinoma (VC) is a well differentiated squamous cell carcinoma that is a low-grade malignancy and rarely presents with distant metastasis. According to previously reported cases, it is possible that the presence of calculi may cause chronic inflammation and traumatic irritation; this mechanism seems to promote the development of VC in the upper part of urinary tract. We present a case of verrucous carcinoma of the right renal pelvis and right ureter. Such tumors may cause severe urinary tract obstruction. Surgical treatment is the main modality of therapy. This patient received nephro-ureterectomy. Furthermore, because a microscopic residual tumor was found at the cut end of ureter, the patient also received adjuvant radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201506-201507020031-201507020031-159-162", "title": "Carotid Stenosis after Radiotherapy for NasopharyngealCarcinoma: Case report and review of literature", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u9838\u52d5\u8108\u72f9\u7a84 Nasopharyngeal cancer;Radiotherapy;Carotid stenosis", "c": "\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u9838\u52d5\u8108\u72f9\u7a84\u88ab\u8a8d\u70ba\u662f\u982d\u9838\u90e8\u764c\u75c7\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7f55\u898b\u4f75\u767c\u75c7\u3002\u60a3\u8005\u53ef\u80fd\u51fa\u73fe\u5404\u7a2e\u75c7\u72c0\uff0c\u5982\u77ed\u66ab\u6027\u8166\u7f3a\u8840\u767c\u4f5c\uff0c\u7a81\u767c\u6027\u9ed1\u8499\u6216\u4e2d\u98a8\u3002\u7136\u800c\uff0c\u5728\u6b64\u4f75\u767c\u75c7\u4e0b\uff0c\u51fa\u73fe\u808c\u9663\u6523\u75c7\u72c0\u5c1a\u672a\u88ab\u5831\u544a\u904e\u3002\u6211\u5011\u63cf\u8ff0\u4e00\u4f4d33\u6b72\u7684\u7537\u5b50\u7f79\u60a3\u9f3b\u54bd\u764ccT1N1M0\u7b2c\u4e00\u671f\uff0c\u65bc\u63a5\u53d7\u653e\u5c04\u7dda70Gy\u5408\u4f75Erbitux\u5316\u5b78\u6cbb\u7642\u5f8c\u5169\u5e74\u534a\uff0c\u767c\u751f\u5de6\u9838\u90e8\u808c\u9663\u6523\u3002\u78c1\u5171\u632f\u8840\u7ba1\u9020\u5f71\uff08MRA\uff09\u986f\u793a\u6709\u5de6\u5074\u8fd1\u7aef\u5167\u9838\u52d5\u8108\u5927\u7d0460%\u7684\u72f9\u7a84\u3002\u4ed6\u672a\u63a5\u53d7\u4efb\u4f55\u91dd\u5c0d\u9838\u52d5\u8108\u72f9\u7a84\u7684\u4fb5\u5165\u6027\u6cbb\u7642\uff0c\u76ee\u524d\u5176\u5de6\u9838\u90e8\u808c\u9663\u6523\u5728\u6bcf\u5e74\u63a5\u53d7\u5c40\u90e8\u8089\u6bd2\u687f\u83cc\u7d20\u6ce8\u5c04\u5f8c\uff0c\u8fd1\u4e09\u5e74\u7686\u7372\u5f97\u826f\u597d\u63a7\u5236\u3002", "e": "Carotid stenosis after radiotherapy has been recognized as a complication of external irradiation to the head and neck resulting from treatment for cancer. However, myoclonus is seldom found. We report on a 33-year-old man diagnosed with nasopharyngeal cancer (NPC) cT1N1M0. He had undergone concurrent chemo-radiotherapy (CCRT) with Cetuximab (Erbitux) and curative radiotherapy (RT) with a dose of 7000cGy in 33 fractions. He developed a myoclonic jerk in the left neck 2.5 years after CCRT. Magnetic resonance angiography (MRA) revealed roughly 60% stenosis of the left proximal internal carotid artery. He did not receive any invasive intervention for carotid stenosis and the neck myoclonus was well controlled by an annual local Botox injection for 3 years."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-1-12", "title": "Outcomes and Prognosis of Radiation Therapy in Locoregional Recurrent Breast Cancer after Mastectomy", "keywords": "\u653e\u5c04\u6cbb\u7642;\u4e73\u764c;\u5c40\u90e8\u5fa9\u767c;\u9810\u5f8c Radiation therapy;Breast neoplasms;Locoregional recurrence;Prognosis", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4e73\u623f\u5207\u9664\u8853\u5f8c\u5c40\u90e8\u5fa9\u767c\u4e4b\u4e73\u764c\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u6210\u679c\uff0c\u4e26\u63a2\u8a0e\u5f71\u97ff\u5b58\u6d3b\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u9867\u81ea\u897f\u51431989\u81f32009\u5e74\u9593\uff0c\u56e0\u4e73\u623f\u5207\u9664\u8853\u5f8c\u5c40\u90e8\u5fa9\u767c\uff0c\u800c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u4e73\u764c\u60a3\u8005\u4e4b\u75c5\u6b77\uff0c\u6392\u9664\u904e\u53bb\u66fe\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u53ca\u5c40\u90e8\u5fa9\u767c\u524d\u5df2\u6709\u9060\u8655\u8f49\u79fb\u8005\uff0c\u4f46\u6709\u540c\u6b65\u9060\u8655\u8f49\u79fb\u7684\u60a3\u8005\u4ecd\u7d0d\u5165\u672c\u7814\u7a76\uff0c\u9032\u800c\u5206\u6790\u6cbb\u7642\u6210\u679c\u8207\u81e8\u5e8a\u75c5\u7406\u4e4b\u76f8\u95dc\u9810\u5f8c\u56e0\u5b50\u3002\u4f7f\u7528Kaplan-Meier\u5b58\u6d3b\u5206\u6790\u65b9\u6cd5\u4f86\u4f30\u8a08\u5c40\u90e8\u5fa9\u767c\u7121\u9032\u5c55\u5b58\u6d3b\u7387\uff08LRPFS\uff09\u3001\u7121\u9060\u8655\u8f49\u79fb\u5b58\u6d3b\u7387\uff08DMPFS\uff09\u3001\u548c\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\uff0c\u53e6\u5916\u4f7f\u7528Cox\u6bd4\u4f8b\u98a8\u96aa\u6a21\u5f0f\uff0c\u4f86\u8a55\u4f30\u9019\u4e9b\u81e8\u5e8a\u75c5\u7406\u53c3\u6578\u7684\u9810\u5f8c\u610f\u7fa9\u3002\u7d50\u679c\uff1a155\u4f4d\u75c5\u60a3\u88ab\u7d0d\u5165\u672c\u7814\u7a76\uff0c\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba9.8\u5e74\u300231\u4f4d\uff0820%\uff09\u60a3\u8005\u5728\u5c40\u90e8\u5fa9\u767c\u8a3a\u65b7\u6642\u6709\u540c\u6b65\u9060\u8655\u8f49\u79fb\uff0c\u800c124\u4f4d\uff0880%\uff09\u60a3\u8005\u5247\u50c5\u6709\u5c40\u90e8\u5fa9\u767c\u800c\u7121\u9060\u8655\u8f49\u79fb\u3002\u6709\u540c\u6b65\u9060\u8655\u8f49\u79fb\u60a3\u8005\u548c\u7121\u9060\u8655\u8f49\u79fb\u60a3\u8005\u7684OS\u4e2d\u4f4d\u6578\uff0c\u5206\u5225\u70ba1.6\u548c4.2\u5e74\u9593\uff08P= 0.001\uff09\uff0c\u4f46\u5169\u7d44\u9593\u7684LRPFS\u7121\u5dee\u7570\uff08P= 0.33\uff09\u3002\u5c0d\u5176\u4e2d124\u4f8b\u7121\u9060\u8655\u8f49\u79fb\u7684\u60a3\u8005\uff0c5\u5e74\u7684LRPFS\uff0cDMFS\u548cOS\u5206\u5225\u70ba\uff1a58.9%\uff0c35.4%\u548c46%\uff0c\u4e14\u5f8c\u7e8c\u670983\u4f4d\uff0867%\uff09\u75c5\u4eba\u767c\u751f\u764c\u75c7\u9060\u7aef\u8f49\u79fb\u3002\u80f8\u58c1\u5fa9\u767c\u7684\u60a3\u8005\u6709\u986f\u8457\u8f03\u597d\u7684\u5b58\u6d3b\uff0c\u6bd4\u5b64\u7acb\u6dcb\u5df4\u817a\u5fa9\u767c\u6216\u591a\u500b\u90e8\u4f4d\u5fa9\u767c\u8005\u597d\uff08\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba56.3% vs. 39.8% vs. 27.8%\uff0cP=0.04\uff09\u3002\u5c0d\u9019\u7fa4\u7121\u9060\u8655\u8f49\u79fb\u7684\u60a3\u8005\uff0c\u591a\u8b8a\u6578\u5206\u6790\u986f\u793a\uff0c\u5c40\u90e8\u5fa9\u767c\u7684\u90e8\u4f4d\u548c\u816b\u7624\u7684\u6700\u521d\u5206\u671f\u662f\u5f71\u97ffLRPFS\u7684\u986f\u8457\u9810\u5f8c\u56e0\u5b50\uff1b\u800c\u7a4d\u6975\u7684\u5c40\u90e8\u6cbb\u7642\uff08\u5305\u62ec\u624b\u8853\u548c\u653e\u5c04\u6cbb\u7642\uff09\u3001\u816b\u7624\u7684\u6700\u521d\u5206\u671f\u548c\u633d\u6551\u6027\u5168\u8eab\u6cbb\u7642\u662f\u5f71\u97ffOS\u7684\u986f\u8457\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5c40\u90e8\u5fa9\u767c\u4e73\u764c\u6709\u9ad8\u98a8\u96aa\u6613\u9060\u8655\u8f49\u79fb\uff0c\u7a4d\u6975\u7684\u5c40\u90e8\u6cbb\u7642\u548c\u5168\u8eab\u6027\u6cbb\u7642\u53ef\u4ee5\u8b93\u90e8\u4efd\u6bd4\u4f8b\u7684\u60a3\u8005\u9054\u5230\u9577\u671f\u7684\u5b58\u6d3b\u3002", "e": "Purpose: To analyze the treatment outcomes of radiation therapy (RT) in breast cancer patients who developed locoregional recurrence (LRR) after initial treatment with mastectomy, and to investigate the prognostic factors influencing survival. Materials and Methods: We retrospectively reviewed medical records of breast cancer patients who received RT for post-mastectomy LRR in our hospital from 1989 to 2009. Patients who had previous RT and distant metastasis before LRR were excluded, but patients with synchronous distant metastasis were included in this study. Clinicopathologic parameters and outcomes were analyzed. Kaplan-Meier method was used to estimate local recurrence progression-free survival (LRPFS), distant metastasis -free survival (DMFS) and overall survival (OS). Cox proportional hazards models were utilized to assess the prognostic significance of these clinicopathologic parameters on survival. Results: One hundred and fifty-five patients were included in the study. Median followup time was 9.8 years. Thirty-one (20.0%) patients had synchronous metastasis at the diagnosis of LRR, while 124 (80%) patients had not. The median OS for patients with and without synchronous metastasis were 1.6 and 4.2 years, respectively (P= 0.001), but there was no difference on LRPFS between these two groups (P= 0.33). Among the 124 patients without synchronous metastasis, the 5-year LRPFS, DMFS and OS for were 58.9%, 35.4% and 46%, respectively. Eighty-three patients (67%) subsequently developed distant metastases. Patients with chest wall recurrence had a significantly better 5-year OS than patients with isolated LN or multiple sites recurrences (56.3% vs. 39.8% vs. 27.8%, P= 0.04). Multivariate analysis for patients without synchronous metastasis revealed that sites of LRR and initial stage were significant prognostic factors for LRPFS, while aggressive local therapy (including surgery and RT), initial stage and salvage systemic therapy were significant prognostic factors affecting OS. Conclusions: Locoregional recurrent breast cancer carries a high risk of distant metastasis. Use of aggressive local therapy and systemic therapy can achieve good survival outcomes in a substantial proportion of patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-13-23", "title": "Evaluation of Dose to Heart and Left Anterior Descending Coronary Artery during Left Breast Irradiation", "keywords": "\u5de6\u5074\u4e73\u764c;\u51a0\u72c0\u52d5\u8108;\u653e\u5c04\u7dda\u6cbb\u7642 Left breast cancer;Coronary artery;Radiotherapy", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u5206\u6790\u5de6\u5074\u4e73\u764c\u75c5\u4eba\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u5fc3\u81df\u548c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u7167\u5c04\u5291\u91cf\u53ca\u63a2\u8a0e\u964d\u4f4e\u5176\u7167\u5c04\u5291\u91cf\u7684\u53ef\u80fd\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u7be9\u907821\u540d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u5de6\u5074\u4e73\u764c\u60a3\u8005\uff0c\u5176\u4e2d14\u540d\u63a5\u53d7\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\uff0c7\u540d\u63a5\u53d7\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u53ca\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3002\u6240\u6709\u75c5\u4eba\u7684\u5fc3\u81df\u548c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u63a5\u53d7\u5291\u91cf\u90fd\u4ee5\u5291\u91cf\uff0d\u9ad4\u7a4d\u5716\uff08dose-volume histogram, DVH\uff09\u4f5c\u5206\u6790\uff0c\u4ee5\u76ae\u723e\u905c\u7a4d\u5dee\u76f8\u95dc\u4fc2\u6578\u8a55\u4f30\u5fc3\u81df\u548c\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u63a5\u53d7\u5291\u91cf\u7684\u76f8\u95dc\u6027\uff0c\u4ee5t-test\u8a55\u4f30\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u8207\u5426\u5c0d\u65bc\u5fc3\u81df\u548c\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u63a5\u53d7\u5291\u91cf\u662f\u5426\u6709\u986f\u8457\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u6574\u9ad4\u60a3\u8005\u7684\u5fc3\u81df\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba4.04 Gy\uff08\u7bc4\u570d\u70ba1.75-11.15 Gy\uff09\uff0c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba21.29 Gy\uff08\u7bc4\u570d\u70ba 6.99-35.28 Gy\uff09\uff0c\u5e73\u5747\u6700\u5927\u63a5\u53d7\u5291\u91cf\u70ba 54.31 Gy\uff08\u7bc4\u570d\u70ba50.55-58.42 Gy\uff09\uff0c\u5fc3\u81df\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u548c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5e73\u5747\u5291\u91cf\u6709\u9ad8\u5ea6\u7684\u95dc\u806f\u6027\uff08r= 0.80, p\uff1c0.01\uff09\uff1b\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u5e73\u5747\u5291\u91cf\u548c\u5728\u7167\u91ce\u5167\u4e4b\u9ad4\u7a4d\u6709\u9ad8\u5ea6\u95dc\u806f\u6027\uff08r= 0.94, p\uff1c 0.0001\uff09\uff0c\u67097\u540d\u60a3\u8005\u540c\u6642\u63a5\u53d7\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u53ca\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u5fc3\u81df\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba4.15 Gy\uff08\u7bc4\u570d\u70ba 2.58-8.9 Gy\uff09\uff0c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba 22.08 Gy\uff08\u7bc4\u570d\u70ba 16.57-35.28 Gy\uff09\uff0c\u5e73\u5747\u6700\u5927\u63a5\u53d7\u5291\u91cf\u70ba 55.71 Gy\uff08\u7bc4\u570d\u70ba 52.99-58.42 Gy\uff09\uff1b\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u5c0d\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba 21.93 Gy\uff08\u7bc4\u570d\u70ba16.49-35.21 Gy\uff09\uff0c\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5c0d\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u70ba 0.15 Gy\uff08\u7bc4\u570d\u70ba 0.05-0.35 Gy\uff09\uff0c\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u6709\u7121\u9396\u9aa8\u4e0a\u7aa9\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u5fc3\u81df\u53ca\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u7121\u660e\u986f\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u63a5\u53d7\u63a5\u53d7\u5de6\u5074\u4e73\u623f\u76f8\u5207\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u63a5\u53d7\u5291\u91cf\u548c\u7167\u91ce\u5167\u4e4b\u9ad4\u7a4d\u6709\u9ad8\u5ea6\u6b63\u76f8\u95dc\uff1b\u5fc3\u81df\u5e73\u5747\u5291\u91cf\u548c\u5de6\u51a0\u72c0\u52d5\u8108\u524d\u964d\u652f\u7684\u5e73\u5747\u63a5\u53d7\u5291\u91cf\u6709\u9ad8\u5ea6\u7684\u76f8\u95dc\u6027\uff0c\u800c\u4e14\u5de6\u51a0\u72c0\u52d5\u8108\u5728\u96fb\u8166\u65b7\u5c64\u4e0d\u4e00\u5b9a\u6709\u826f\u597d\u4e4b\u986f\u50cf\uff0c\u56e0\u6b64\u6211\u5011\u5efa\u8b70\u505a\u6cbb\u7642\u8a08\u5283\u6642\uff0c\u82e5\u662f\u75c5\u4eba\u7684\u5de6\u51a0\u72c0\u52d5\u8108\u5728\u96fb\u8166\u65b7\u5c64\u4e0a\u96e3\u4ee5\u8fa8\u8a8d\uff0c\u53ef\u4ee5\u9650\u5236\u5fc3\u81df\u5e73\u5747\u63a5\u53d7\u4e4b\u5291\u91cf\uff0c\u4ee5\u9054\u5230\u964d\u4f4e\u5de6\u51a0\u72c0\u52d5\u8108\u5291\u91cf\u7684\u76ee\u7684\u3002", "e": "Purpose: The aim of this retrospective study is to quantify dose irradiated to the heart and the left anterior descending coronary artery (LADCA) in left breast cancer patients treated with adjuvant breast radiotherapy and analyse the probable causes of high dose to the heart and LADCA. Methods and Materials: Twenty-one consecutive patients with left-sided breast cancer who underwent adjuvant radiotherapy to the breast between August 2012 and October 2013 are enrolled in our study. All patients were irradiated with 6- or 10-MV tangential beams to the breast and seven patients of them also received supraclavicular fossa (SCF) irradiation with IMRT technique. For each dose plan, dose-volume histograms (DVHs) for the heart and LADCA were calculated and analyzed. Pearson correlation coefficient was calculated to assess the relationship between average heart D_(mean) (mean dose), LAD D_(mean) and LAD_(max) (maximum dose) and between LAD D_(mean) and volume of LADCA in the radiation fields (i.e., it received \uff1e25 Gy). Student's t test was used to assess the statistical significance of differences in radiation dose to LADCA and heart between patients who received SCF IMRT or not. Results: For the 21 patients given left breast irradiation, the average mean [range] dose was 4.04 [1.75-11.15] Gy to the heart and 21.29 [6.99-35.28] Gy to the LADCA, and the average maximum dose was 54.31 [50.55-58.42] Gy to the LADCA. There is significant correlation between D_(mean) to the heart and LADCA (r= 0.80, p \uff1c 0.01). The D_(mean) to LADCA was postulated to increase 3.44 Gy for each increase of 1 Gy in the mean radiation dose delivered to the heart in our study. There is significant correlation between Dmean to LADCA and the volume of LAD in the radiation fields (i.e., it received \uff1e25 Gy) (r= 0.94, p\uff1c 0.0001). The D_(mean) to LADCA was postulated to increase 0.77 Gy for each increase of 1 ml of LADCA volume in the radiation field. For 7 patients who received left-tangential radiotherapy and SCF IMRT, the average mean dose was 4.15 [2.58-8.9] Gy to the heart and 21.93 [16.49-35.21] Gy to the LADCA, and the average maximum dose was 55.21 [52.63-57.79] Gy to the LADCA. SCF IMRT contributed to average mean dose 0.15 [0.05-0.35] Gy and average maximum dose 0.43 [0.15-0.68] Gy to the LADCA. There is no significant difference in Dmean to the LADCA and heart between patients who received SCF IMRT or not (p= 0.38, p= 0.45, respectively). Conclusion: For patients receiving left-tangential radiotherapy, the higher Dmean to the LADCA was strongly correlated to the larger volume of LADCA in the radiation fields. There is significant correlation between D_(mean) to the heart and LADCA. The patients with the higher mean heart dose had the higher mean LADCA dose. We may suggest to limit mean dose to LADCA by avoiding volume of LADCA in the treatment fields if well visualized LADCA on CT scan or limiting the mean heart dose to lower mean LADCA dose if poor visualization of LADCA on CT scan."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-25-39", "title": "\u71df\u990a\u7167\u6703\u8207\u75c5\u60a3\u885b\u6559\u662f\u982d\u9838\u90e8\u816b\u7624\u75c5\u60a3\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u6700\u91cd\u8981\u7684\u4ecb\u5165\u63aa\u65bd", "keywords": "\u6703\u8ac7\u885b\u6559;\u71df\u990a\u7167\u6703;\u653e\u5c04\u7dda\u6cbb\u7642;\u982d\u9838\u764c;\u6cbb\u7642\u5b8c\u6210\u7387 Patient instructions;Nutritional consultation;Radiation therapy;Head and neck cancer;Completion of radiation therapy", "c": "\u7814\u7a76\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u70ba\u982d\u9838\u764c\u75c5\u60a3\u9664\u4e86\u5916\u79d1\u624b\u8853\u3001\u5316\u5b78\u6cbb\u7642\u5916\u7684\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u6709\u4e9b\u75c5\u60a3\u56e0\u4e2d\u65b7\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u800c\u5f71\u97ff\u4e86\u6cbb\u7642\u6548\u679c\u3002\u672c\u7814\u7a76\u70ba\u56de\u9867\u6027\u63a2\u8a0e\u672c\u79d1\u982d\u9838\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u4e2d\u65b7\u56e0\u7d20\uff0c\u4ee5\u63d0\u4f9b\u8b77\u7406\u4eba\u54e1\u6539\u5584\u653e\u5c04\u6cbb\u7642\u8b77\u7406\u54c1\u8cea\u4e4b\u53c3\u8003\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u79d1\u81ea2013\u5e741\u67081\u65e5\u8d77\u81f32013\u5e746\u670830\u65e5\u6b62\uff0c\u91dd\u5c0d\u6b64\u671f\u9593\u56de\u9867\u982d\u9838\u764c\u521d\u8a3a\u60a3\u8005\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\uff0c\u9032\u884c\u75c5\u60a3\u500b\u4eba\u5c6c\u6027\u3001\u81e8\u5e8a\u72c0\u6cc1\u8207\u8b77\u7406\u4ecb\u5165\u63aa\u65bd\u8207\u653e\u5c04\u6cbb\u7642\u5b8c\u6210\u7642\u7a0b\u76f8\u95dc\u6027\u4e4b\u5206\u6790\uff0c\u4ee5\u63a5\u53d7\u8a08\u756b\u5291\u91cf90%\u5b9a\u7fa9\u70ba\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u3002\u5229\u7528Chi-square test\u8a55\u4f30\u75c5\u60a3\u4e0d\u540c\u56e0\u5b50\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7684\u6bd4\u4f8b\uff0c\u4e26\u4ee5Logistic regression\u8a55\u4f30\u5f71\u97ff\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u7684\u7368\u7acb\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u5171\u6709203\u4f4d\u982d\u9838\u764c\u75c5\u60a3\u65bc\u672c\u79d1\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c174\u4eba\uff0885.7%\uff09\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\uff0c\u5728Chi-square test\u4e2d\uff0c\u75c5\u60a3\u500b\u4eba\u5c6c\u6027\u4e2d\u7121\u9060\u7aef\u8f49\u79fb\uff08p= 0.024\uff09\u53ca\u7121\u6162\u6027\u75c5\uff08p= 0.044\uff09\u8005\u6709\u8f03\u4f73\u4e4b\u6cbb\u7642\u5b8c\u6210\u7387\u3002\u5728\u4ecb\u5165\u63aa\u65bd\u65b9\u9762\u75c5\u60a3\u63a5\u53d7\u71df\u990a\u7167\u6703\uff08p\uff1c0.001\uff09\u548c\u6703\u8ac7\u885b\u6559\uff08p\uff1c0.001\uff09\uff0c\u53ca\u81ea\u8cbb\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff08p= 0.004\uff09\u8005\u4ea6\u6709\u8f03\u4f73\u4e4b\u6cbb\u7642\u5b8c\u6210\u7387\u3002\u5728Logistic regression \u4e2d\uff0c\u75c5\u60a3\u65e5\u5e38\u751f\u6d3b\u72c0\u614b\uff08Eastern Cooperative Oncology Group\ufe50ECOG\uff09\u512a\u65bc\u7b49\u65bc1\uff08p= 0.049\uff09\u3001\u7121\u9060\u7aef\u8f49\u79fb\uff08p= 0.032\uff09\u3001\u66fe\u63a5\u53d7\u6703\u8ac7\u885b\u6559\uff08p= 0.004\uff09\u53ca\u71df\u990a\u5e2b\u7167\u6703\uff08p= 0.004\uff09\u70ba\u8207\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u6709\u95dc\u4e4b\u7368\u7acb\u56e0\u5b50\uff0c\u5176\u4e2d\u53c8\u4ee5\u71df\u990a\u7167\u6703\u53ca\u6703\u8ac7\u885b\u6559\u70ba\u6700\u986f\u8457\u4e4b\u7368\u7acb\u56e0\u5b50\uff0c\u5176\u6a5f\u7387\u6bd4\u503c\u5206\u5225\u70ba8.902\u8207 8.012\u3002\u63a5\u53d7\u71df\u990a\u7167\u6703\u3001\u885b\u6559\u6703\u8ac7\u548c\u81ea\u8cbb\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\u4e09\u8005\u7686\u4e92\u76f8\u95dc\u806f\uff0c\u4e14\u5176\u6cbb\u7642\u5b8c\u6210\u7387\u8f03\u9ad8\u3002\u75c5\u60a3\u4e2d\u65b7\u6cbb\u7642\u6700\u5e38\u898b\u7684\u539f\u56e0\u662f\u7121\u6cd5\u5fcd\u53d7\u53ca\u5bb3\u6015\u526f\u4f5c\u7528\uff0c\u4f5448.3%\uff0814/29\uff09\uff0c\u5176\u6b21\u70ba\u75c5\u60c5\u56b4\u91cd\u8eab\u9ad4\u865b\u5f31\uff0c\u4f5434.5%\uff0810/29\uff09\u3002\u7d50\u8ad6\uff1a\u7531\u672c\u7814\u7a76\u986f\u793a\u7d50\u679c\uff0c\u982d\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u71df\u990a\u7167\u6703\u53ca\u6703\u8ac7\u885b\u6559\u70ba\u6cbb\u7642\u5b8c\u6210\u7387\u4e0a\u70ba\u91cd\u8981\u4e4b\u5f71\u97ff\u56e0\u5b50\u3002\u56e0\u6b64\u85c9\u7531\u4ecb\u5165\u63aa\u65bd\uff0d\u71df\u990a\u7167\u6703\u8207\u5c08\u696d\u653e\u5c04\u816b\u7624\u79d1\u8b77\u7406\u5e2b\u6703\u8ac7\u885b\u6559\uff0c\u53ef\u6539\u5584\u75c5\u60a3\u6cbb\u7642\u7684\u9806\u5f9e\u6027\u9032\u800c\u63d0\u9ad8\u6cbb\u7642\u5b8c\u6210\u7387\u3002", "e": "Purpose: Radiation therapy is the major treatment modality in head and neck cancer other than surgical intervention, Some patients did not complete the radiation therapy course that in turn compromise the treatment response. In this study, we retrospectively reviewed the clinical and interventional factors that affect the completion of radiation therapy, and help to improve the quality of nursing care in radiation therapy. Materials & Methods: From January 1 to June 30 in 2013, total 203 patients with head and neck cancer were referred to our radiation therapy department were reviewed. The completion of radiation therapy is defined as 90% of planned radiation dose was delivered. The association between the completion of radiation therapy and their personal characteristics, clinical status and nursing interventions were analyzed. Chi-square test was used for evaluate the proportion of complete treatment in different factors and Logistic regression was applied to define independent factors for completion of radiation therapy. Results: There were 203 head and neck cancer patients received radiation therapy enrolled in this study. Total 174 patients (85.7%) had completed the radiation therapy course. In Chi-square test, the patients who were without distant metastases (p= 0.024) and without chronic systematic disease (p= 0.044) had higher completion rate. For interventional factors, patients who accepted patient instructions (p\uff1c 0.001), nutritional consultation (P\uff1c 0.001) and image-guided radiation therapy by self-paid (p= 0.004) were also had a better completion rate for radiation therapy course. In Logistic regression, Eastern Cooperative Oncology Group (ECOG) performance status less or equal to 1 (p= 0.049), without distant metastases (p= 0.032), patients who had conselling of patient instructions (p= 0.004) and nutritional consultation (P= 0.004) were the independent factors for completion of radiation therapy course. Nutritional consultation and patient instructions were the most significant independent factors for completion of radiation therapy, and the odd ratio were 8.902 and 8.012, respectively. Nutritional consultation, patient instructions and image-guided radiation therapy by self-paid are interrelated with a higher completion rate of radiation therapy course. The most common reasons for interruption of radiation therapy were intolerante to and anxious of the treatment complications in 48.3% (14/29) patients, following by sickness and weakness in 34.5% (10/29) patients. Conclusion: Nutritional consultation and patient instructions are the most significant interventional factors for the completion of radiation therapy course in head and neck cancer. The compliance of radiation therapy in head and neck cancer patients may be improved via the intervention of nutritional consultation and patient instructions."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-41-50", "title": "\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cfNIPAM\u51dd\u81a0\u5291\u91cf\u5206\u5e03", "keywords": "\u805a\u5408\u7269\u51dd\u81a0;\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100;\u03b3\u6e2c\u8a66 Polymer gel;Computed tomography;Gamma test", "c": "\u76ee\u7684\uff1a\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u51dd\u81a0\u5291\u91cf\u5206\u5e03\u81e8\u5e8a\u5be6\u7528\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u76f4\u7dda\u52a0\u901f\u5668\uff08Varian Clinic iX\uff0c\u7f8e\u570b\uff09\u4f5c\u70ba\u5c04\u6e90\uff0c\u7167\u5c04NIPAM\u805a\u5408\u7269\u51dd\u81a0\u5291\u91cf\u8a08\uff0c\u51dd\u81a0\u805a\u5408\u53cd\u61c9\u5b8c\u6210\u5f8c\u4f7f\u7528 X-ray\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\uff08HiSpeed GE\uff0c\u7f8e\u570b\uff09\u64f7\u53d6\u5207\u9762\u51dd\u81a0\u5f71\u50cf\uff0c\u5229\u7528Matlab\uff08The MathWorks, Natick, MA, USA\uff09\u8edf\u9ad4\u5206\u6790\u51dd\u81a0\u4e4b\u5207\u9762\u5f71\u50cf\uff0c\u6bd4\u8f03\u6cbb\u7642\u8a08\u756b\u8207NIPAM\u51dd\u81a0\u5291\u91cf\u8a08\u4e4b\u03b3\u6e2c\u8a66\u3002\u7d50\u679c\uff1a\u7d50\u679c\u5448\u73fe\u4f7f\u7528\u591a\u5f35CT image\u8a08\u7b97\u5f71\u50cf\u5e73\u5747CT\u503c\uff0c\u53ef\u4ee5\u5927\u5e45\u964d\u4f4eCT\u96dc\u8a0a\uff0c\u642d\u914d\u5229\u7528\u805a\u5408\u7269\u51dd\u81a0\u672a\u7167\u5c04\u7576\u80cc\u666f\u5f71\u50cf\uff08Background image\uff09\u6e1b\u8d05\u5f8c\uff0c\u7b2c\u4e00\u6b21\u5be6\u9a57\u7d50\u679c\u74b0\u72c0\u5047\u5f71\u6d88\u5931\u03b3\u6e2c\u8a66\u753168.40%\u63d0\u5347\u81f3 95.02%\u901a\u904e\u7387\u3002\u7b2c\u4e8c\u6b21\u5be6\u9a57\u7d50\u679c\u5f97\u5230\u8207TPS\u66f4\u70ba\u76f8\u8fd1\u51dd\u81a0\u5291\u91cf\u5206\u5e03\uff0c\u03b3\u6e2c\u8a66\u7684\u5206\u6790\u7d50\u679c\u70ba97.57%\u901a\u904e\u7387\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u8a72\u7d50\u679c\u8868\u660eX-ray\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u662f\u53ef\u4ee5\u61c9\u7528\u65bc\u81e8\u5e8a\u805a\u5408\u7269\u51dd\u81a0\u5291\u91cf\u9a57\u8b49\u8a08\u8b80\u5de5\u5177\u4e0a\u3002", "e": "Objectives: Using computed tomography (CT) scanning to evaluate the clinical applicability of intensity modulated gel dosimeter based on the dose distribution. Materials and Approaches: A Clinac iX linear accelerator (Varian, USA) was adopted as the radiation source to irradiate an N-isopropylacrylamide (NIPAM) polymer gel dosimetry. After the polymerization reaction, the gel was scanned using a HiSpeed CT scanner (GE, USA), and sliced images of the gel were analyzed using Matlab (MathWorks, Natick, MA, USA). Next, the gamma test obtained for the treatment plan and the NIPAM polymer gel were compared. Results: The results indicated that using numerous CT images to calculate the mean CT numbers of the images can substantially reduce CT noise. In addition, when the polymer gel was unilluminated and background subtraction occurred, the ring artifacts produced in the first experiment disappeared. Furthermore, the gamma test increased from 68.40% to 95.02% pass rate. The gel dose distribution yielded in the second experiment was similar to that of the treatment plan system, and the obtained gamma test was 97.57% pass rate. Discussion and Conclusion: The results showed that X-ray CT scanning can be applied to clinical polymer gel dosimeters."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-51-61", "title": "From Impossible to Feasible- A Dosimetric Study Comparing Four Different Treatment Techniques in a Lung Cancer Patient Presenting with Diffuse Pleural Seeding", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642;\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u87ba\u65cb\u653e\u5c04\u6cbb\u7642;\u80ba\u764c Intensity-modulated radiation therapy (IMRT);Volumetric-modulate arc therapy (VMAT);Three dimensional conformal radiotherapy (3D-CRT);Helical Tomotherapy (HT);Lung Cancer", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u56db\u7a2e\u4e0d\u540c\u76f4\u7dda\u52a0\u901f\u5668\u653e\u5c04\u6cbb\u7642\u8a2d\u5099\u7528\u65bc\u80ba\u764c\u75c5\u4eba\u5408\u4f75\u7030\u6f2b\u6027\u808b\u819c\u8f49\u79fb\u59d1\u606f\u6027\u6cbb\u7642\u6642\u7684\u5291\u91cf\u5206\u4f48\u53ca\u53ef\u884c\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee56 MV\u7684X\u5149\u53ca\u9069\u7576\u7684\u6700\u4f73\u5316\u689d\u4ef6\uff0c\u5206\u5225\u91dd\u5c0d\u540c\u4e00\u4f4d\u808b\u819c\u8f49\u79fb\u7684\u75c5\u60a3\u7522\u51fa\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u53ca\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u7b49\u56db\u7a2e\u4e0d\u540c\u7684\u6cbb\u7642\u8a08\u756b\u3002\u7d66\u4e88\u8a08\u756b\u9776\u5340\uff08PTV\uff09\u7684\u7e3d\u5291\u91cf\u70ba50 Gy\uff0c\u5171\u520620\u6b21\u7167\u5c04\uff0c\u4e26\u4f7f\u7528\u5291\u91cf- \u9ad4\u7a4d\u76f4\u65b9\u5716\uff08DVH\uff09\u3001\u9806\u5f62\u6307\u6578\uff08CI\uff09\u3001\u5747\u52fb\u5ea6\u6307\u6578\uff08HI\uff09\u7b49\u5de5\u5177\u4f86\u8a55\u4f30\u8a08\u756b\u9776\u5340\u53ca\u5371\u6025\u5668\u5b98\u7684\u5291\u91cf\u5206\u4f48\u3002\u7d50\u679c\uff1a\u6574\u9ad4\u800c\u8a00\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u53ca\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u53ef\u9054\u6210\u7684\u8a08\u756b\u9776\u5340\u5291\u91cf\u5206\u4f48\u76f8\u7576\u3002\u56db\u7a2e\u6280\u8853\u80fd\u5305\u898698%\u8a08\u756b\u9776\u5340\u9ad4\u7a4d\u7684\u5291\u91cf\u5747\u8d85\u904e48.5 Gy\u3002\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u5177\u6709\u6700\u9ad8\u7684\u9806\u5f62\u6307\u6578\u548c\u6700\u4f4e\u7684\u5747\u52fb\u5ea6\u6307\u6578\uff0c\u800c\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u6700\u5927\u5291\u91cf\uff0858 Gy\uff09\u548c\u5305\u89862%\u8a08\u756b\u9776\u5340\u9ad4\u7a4d\u7684\u5291\u91cf\uff0856.82 Gy\uff09\u6700\u9ad8\u3002\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u540c\u5074\u80ba\u63a5\u53d745 Gy\u7684\u9ad4\u7a4d\u6700\u5c0f\uff0845%\uff09\uff0c\u540c\u5074\u80ba\u90e8\u7684\u5e73\u5747\u5291\u91cf\uff0845 Gy\uff09\u4e5f\u6700\u4f4e\u3002\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u5c0d\u5074\u80ba\u63a5\u53d718 Gy\u7684\u9ad4\u7a4d\uff080%\uff09\u548c\u5c0d\u5074\u80ba\u90e8\u7684\u5e73\u5747\u5291\u91cf\uff081.14 Gy\uff09\u6700\u4f4e\u3002\u5168\u80ba\u90e8\u7684\u7d2f\u7a4d\u5291\u91cf\uff08integral dose\uff09\u7684\u5927\u5c0f\u9806\u5e8f\u70ba\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff1e\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\uff1e\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff1e\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3002\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u7d66\u4e88\u7684\u76e3\u6e2c\u55ae\u4f4d\uff08Monitor Unit\uff09\u91cf\u6700\u591a\uff0c\u7e3d\u6cbb\u7642\u6642\u9593\u4e5f\u6700\u9577\u3002\u7d50\u8ad6\uff1a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u548c\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u5747\u53ef\u9054\u523095% \u4ee5\u4e0a\u7684\u8a08\u756b\u9776\u5340\u5305\u8986\u7387\uff0c\u548c\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u76f8\u6bd4\uff0c\u5c0d\u5371\u6025\u5668\u5b98\u7684\u4fdd\u8b77\u8f03\u4f73\uff0c\u7136\u800c\uff0c\u6709\u4e9b\u6b63\u5e38\u7d44\u7e54\u63a5\u53d7\u5230\u4e2d\u4f4e\u5291\u91cf\u7684\u9ad4\u7a4d\u6703\u8f03\u5927\uff0c\u800c\u4f7f\u5f97\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u548c\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u5177\u6709\u8f03\u9ad8\u7684\u7d2f\u7a4d\u5291\u91cf\u3002\u8981\u5224\u65b7\u90a3\u4e00\u7a2e\u6280\u8853\u8f03\u4f73\u4ecd\u9700\u8981\u81e8\u5e8a\u4e0a\u7684\u95dc\u806f\u3002", "e": "Purpose: To investigate the performance and feasibilities of four different linac-based radiation therapy devices in palliating a lung adenocarcinoma patient presenting with diffuse pleural seeding and intractable pain. Patients and Methods: Treatment plans were generated for three dimensional conformal radiotherapy (3D-CRT), Intensity-modulated radiation therapy (IMRT), Volumetric- modulated arc therapy (VMAT) and Helical Tomotherapy (HT) using 6 MV photon beam with adequate optimization criteria. The total prescribed dose to planning target volume (PTV) was 50 Gy in 20 fractions. Dose distributions to PTV and organs at risk (OAR) were compared using dose-volume histograms (DVHs), conformity indexes (CIs), and homogeneity indexes (HIs). Results: In general, IMRT, VMAT and HT all resulted in comparable PTV coverage. The D98 of all four techniques were all greater than 48.5 Gy. HT had the highest CI (0.982) and the lowest HI (0.035), whereas 3D-CRT had the highest D2% (56.82 Gy) and Dmax (58 Gy). HT had the lowest ipsilateral lung V45 (55%) and ipsilateral mean lung dose (45 Gy). 3D-CRT had the lowest contralateral lung V18 (0%) and contralateral mean lung dose (1.14 Gy). The integral dose (L.Gy) for total lung tissue was VMAT \uff1e HT \uff1e IMRT \uff1e 3D-CRT. HT delivered the most monitor units (MUs) and needed the longest treatment time. Conclusion: IMRT, VMAT and HT all could attain over 95% PTV coverage and had superior OAR sparing compared to 3D-CRT. However, larger volumes of some healthy tissues (especially contralateral lung) received low-to-intermediate doses, which contributed to a higher integral dose in VMAT, HT and IMRT. The superiority of one technique over another needed further clinical correlation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-63-69", "title": "\u9080\u8acb\u4e73\u764c\u75c5\u4eba\u53c3\u8207\u653e\u5c04\u6cbb\u7642\u885b\u6559\u6210\u6548\u554f\u5377\u8abf\u67e5\u6642\u53ef\u5426\u514d\u9664\u75c5\u4eba\u7c3d\u7f72\u77e5\u60c5\u540c\u610f\u66f8", "keywords": "\u653e\u5c04\u6cbb\u7642;\u885b\u6559\u6210\u6548;\u554f\u5377\u8abf\u67e5;\u77e5\u60c5\u540c\u610f Radiation therapy;The efectiveness of health education;Questionnaires;Informed consent", "c": "\u76ee\u7684\uff1a\u7576\u7814\u7a76\u4eba\u54e1\u9080\u8acb\u4e73\u764c\u75c5\u4eba\u53c3\u8207\u653e\u5c04\u6cbb\u7642\u885b\u6559\u6210\u6548\u554f\u5377\u8abf\u67e5\u6642\uff0c\u6709\u4e9b\u91ab\u9662\u7684\u4eba\u9ad4\u8a66\u9a57\u59d4\u54e1\u6703\u3001\u70ba\u4e86\u4fdd\u8b77\u75c5\u4eba\u6b0a\u76ca\uff0c\u6703\u8981\u6c42\u7814\u7a76\u8005\u5fc5\u9808\u5148\u5411\u75c5\u4eba\u8aaa\u660e\u7814\u7a76\u5167\u5bb9\u4e26\u8acb\u75c5\u4eba\u7c3d\u7f72\u540c\u610f\u66f8\u4e4b\u5f8c\uff0c\u65b9\u53ef\u9032\u884c\u7814\u7a76\u8abf\u67e5\u3002\u7136\u800c\u5728\u5be6\u52d9\u4e0a\uff0c\u611f\u89ba\u8a31\u591a\u75c5\u4eba\u9858\u610f\u63a5\u53d7\u9080\u8acb\u3001\u586b\u5beb\u554f\u5377\uff0c\u4f46\u662f\u5c0d\u65bc\u7c3d\u7f72\u540c\u610f\u66f8\u5247\u4e0d\u751a\u6a02\u610f\u3002\u672c\u7814\u7a76\u5c07\u63a2\u8a0e\uff1a\u4e00\u3001\u7a76\u7adf\u6709\u591a\u5c11\u6bd4\u4f8b\u7684\u53d7\u8a2a\u8005\u4e0d\u9858\u610f\u7c3d\u7f72\u540c\u610f\u66f8\u3002\u4e8c\u3001\u7576\u554f\u5377\u8abf\u67e5\u4ee5\u533f\u540d\u65b9\u5f0f\u9032\u884c\u3001\u4e0d\u6d89\u53ca\u75c5\u4eba\u96b1\u79c1\u53ca\u91ab\u7642\u6b0a\u76ca\u6642\uff0c\u53ef\u5426\u514d\u53d6\u5f97\u53d7\u8a2a\u8005\u540c\u610f\u66f8\u3002\u4e09\u3001\u7576\u53d7\u8a2a\u8005\u5c07\u554f\u5377\u5e36\u56de\u5bb6\u586b\u5beb\u3001\u4e4b\u5f8c\u81ea\u884c\u7e73\u56de\uff0c\u5982\u6b64\u53ef\u5426\u8996\u70ba\u81ea\u9858\u53d7\u8a2a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5206\u56db\u500b\u968e\u6bb5\u5c07\u554f\u5377\u767c\u7d66\u75c5\u4eba\uff0c\u6bcf\u500b\u968e\u6bb5\u767c\u653e\u65b9\u5f0f\u7a0d\u6709\u4e0d\u540c\uff0c\u7528\u4ee5\u8fa8\u5225\u4e0d\u540c\u77e5\u60c5\u540c\u610f\u904e\u7a0b\u662f\u5426\u5f71\u97ff\u554f\u5377\u56de\u6536\u7387\u3001\u672a\u7c3d\u7f72\u540c\u610f\u66f8\u6bd4\u7387\u53ca\u7121\u6548\u554f\u5377\u7387\u3002\u7d50\u679c\uff1a\u9664\u4e86\u7b2c\u4e00\u968e\u6bb5\uff08\u8acb\u75c5\u4eba\u7c3d\u7f72\u540c\u610f\u66f8\uff09\uff0c\u5176\u9918\u4e8c\u3001\u4e09\u3001\u56db\u968e\u6bb5\uff08\u7531\u75c5\u4eba\u81ea\u4e3b\u6c7a\u5b9a\uff09\u7686\u67092~3\u6210\u53d7\u8a2a\u8005\u672a\u7c3d\u7f72\u540c\u610f\u66f8\u3002\u7b2c\u4e8c\u968e\u6bb5\u77e5\u60c5\u540c\u610f\u904e\u7a0b\u7c21\u7565\uff0c\u6545\u554f\u5377\u56de\u6536\u7387\u6700\u4f4e\u3002\u7b2c\u4e00\u3001\u4e09\u968e\u6bb5\u96d6\u7136\u77e5\u60c5\u540c\u610f\u904e\u7a0b\u8a73\u7d30\u4f46\u7121\u6548\u554f\u5377\u7387\u9ad8\u3002\u7b2c\u56db\u968e\u6bb5\u77e5\u60c5\u540c\u610f\u904e\u7a0b\u6700\u5b8c\u5584\uff0c\u6545\u554f\u5377\u56de\u6536\u7387\u9ad8\u4e14\u7121\u6548\u554f\u5377\u7387\u6700\u4f4e\u3002\u7d50\u8ad6\uff1a\u4e00\u3001\u7576\u75c5\u4eba\u5728\u81ea\u4e3b\u6b0a\u7684\u60c5\u6cc1\u4e0b\uff0c\u78ba\u67092~3\u6210\u7684\u53d7\u8a2a\u8005\u4e0d\u9858\u610f\u5728\u540c\u610f\u66f8\u4e0a\u7c3d\u540d\u3002\u4e8c\u3001\u7576\u533f\u540d\u554f\u5377\u4e0d\u6d89\u53ca\u75c5\u4eba\u96b1\u79c1\u53ca\u91ab\u7642\u6b0a\u76ca\u6642\uff0c\u61c9\u53ef\u63a1\u7528\u8aaa\u660e\u66f8\u544a\u77e5\uff08\u4e0d\u9808\u7c3d\u540d\u70ba\u8b49\uff09\u4ee5\u514d\u75c5\u4eba\u70ba\u96e3\u3002\u4e09\u3001\u7576\u53d7\u8a2a\u8005\u5c07\u554f\u5377\u5e36\u56de\u53bb\u586b\u5beb\u3001\u4e4b\u5f8c\u81ea\u52d5\u7e73\u56de\uff0c\u5373\u53ef\u8996\u70ba\u81ea\u9858\u53d7\u8a2a\u3002", "e": "Objective: As patients with breast cancer are recruited to participate in a survey on the effectiveness of health education in radiotherapy, the IRB of some hospitals will, to protect the patient's interest, ask the investigators to explain the survey to the patient and ask the patient to sign an informed consent form before the questionnaire can be distributed. In practice, however, some patients would like to participate in the survey and answer the questionnaire but may be unwilling to sign the consent form. This study was designed to investigate: (1) The proportion of participants unwilling to sign the consent form. (2) If the questionnaire was anonymous and didn't involve patient's privacy and medical interests, can the consent form be waived? (3) If the patient takes the questionnaire home, answers it, and returns to the investigators, can this be regarded as a voluntary response? Materials and Methods: The questionnaires were distributed to patients in four different groups consecutively. The informed consent process of these groups were designed to differ a little so as to identify their effects on the response rate, the rate of unsigned consent form, and the invalid questionnaire rate. Results: Except the first group (asking the patient to sign the consent form), the other groups (at the patient\u2019s discretion) had about 20 to 30% of the respondents who declined to sign the consent form. In the second group, the informed consent process was too simplistic; hence it had the lowest response rate. In the first and the third groups, the informed consent process was more elaborate, but the invalid rate was high. In the fourth group, the informed consent process was the most complete, as a result, the response rate was high and the invalid rate was the lowest. Conclusion: (1) At the patient's discretion, about 20 to 30 percent of the respondents declined to sign the consent form. (2) If an anonymous questionnaire does not involve patient's privacy and medical interests, instructions may be used instead (without requiring a signature as evidence) lest the patient feel uneasy. (3) If a participant takes the questionnaire home, answers it, and returns to the investigator, this may be regarded as a voluntary response."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-71-81", "title": "Stereotactic Radiosurgery for Cerebral Dural Arteriovenous Fistulas: A Case Report and Review of the Literatures", "keywords": "\u8166\u819c\u52d5\u975c\u8108\u763b\u7ba1;\u640f\u52d5\u6027\u8033\u9cf4;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u76f4\u7dda\u52a0\u901f\u5668 Dural arteriovenous fistulas (DAVFs);Pulsatile tinnitus;Stereotactic radiosurgery;Linear accelerator", "c": "\u8166\u819c\u52d5\u975c\u8108\u763b\u7ba1\u7d04\u5360\u9871\u5167\u8840\u7ba1\u7578\u5f62\u7684 10-15%\uff0c\u5176\u6cbb\u7642\u9700\u8981\u591a\u5c08\u79d1\u5718\u968a\u53c3\u8207\uff0c\u5305\u542b\u624b\u8853\uff0c\u8840\u7ba1\u6813\u585e\u53ca\u653e\u5c04\u624b\u8853\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f8b52\u6b72\u5973\u6027\uff0c\u56e0\u5de6\u8033\u767c\u751f\u640f\u52d5\u6027\u8033\u9cf4\u4e09\u500b\u6708\uff0c\u4e14\u5c0d\u85e5\u7269\u6cbb\u7642\u7121\u6548\uff0c\u63a5\u53d7\u8840\u7ba1\u651d\u5f71\u5f8c\u767c\u73fe\u70ba\u5de6\u5074\u4e59\u72c0\u975c\u8108\u7ac7\u4e4b\u8166\u819c\u52d5\u975c\u8108\u763b\u7ba1\u6240\u81f4\uff0c\u5176\u763b\u7ba1\u6c92\u6709\u767c\u751f\u8166\u76ae\u8cea\u975c\u8108\u56de\u6d41\u3002\u6b64\u75c5\u4f8b\u56e0\u4e0d\u9069\u5408\u624b\u8853\u53ca\u8840\u7ba1\u6813\u585e\uff0c\u6545\u88ab\u8f49\u4ecb\u81f3\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u6211\u5011\u4f7f\u7528\u71b1\u5851\u5f62\u9762\u5177\u56fa\u5b9a\u75c5\u4eba\uff0c\u800c\u5f8c\u75c5\u4eba\u63a5\u53d7\u7d30\u5207\u4e4b\u6838\u78c1\u5171\u632f\uff08\u6709\u6253\u986f\u5f71\u5291\uff09\u53ca\u96fb\u8166\u65b7\u5c64\u651d\u5f71\uff08\u4e0d\u6253\u986f\u5f71\u5291\uff09\u3002\u5229\u7528\u8207\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u878d\u5408\u4e4b\u6838\u78c1\u5171\u632f\u5f71\u50cf\u756b\u51fa\u4e0d\u6b63\u5e38\u4e4b\u8840\u7ba1\u8207\u763b\u7ba1\u3002\u653e\u5c04\u624b\u8853\u4e4b\u524d\uff0c\u6211\u5011\u4ee5\u5373\u6642X\u5149\u5f71\u50cf\uff08on-board imager\uff09\u53d62D\u5f71\u50cf\u53ca\u9310\u675f\u96fb\u8166\u65b7\u5c64\uff08conebeam CT images\uff09\u9032\u884c\u5f71\u50cf\u5c0e\u5f15\uff0c\u4ee5\u6821\u6b63\u64fa\u4f4d\u8aa4\u5dee\u3002\u653e\u5c04\u5291\u91cf\u7531\u914d\u5099\u52d5\u614b\u591a\u8449\u6e96\u76f4\u5100\u4e4b\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u4e94\u500b\u975e\u5171\u9762\u5f27\u5f62\u5c04\u675f\u7d66\u4e8820 Gy\uff0c\u6700\u9ad8\u5291\u91cf\u70ba21.9 Gy\u3002\u75c5\u4eba\u4e4b\u640f\u52d5\u6027\u8033\u9cf4\u7d04\u65bc\u653e\u5c04\u624b\u8853\u5f8c\u5169\u500b\u6708\u6642\u5b8c\u5168\u6d88\u5931\uff0c\u800c\u65bc\u653e\u5c04\u624b\u8853\u5f8c\u4e09\u53ca\u4e5d\u500b\u6708\u8ffd\u8e64\u4e4b\u6838\u78c1\u5171\u632f\u5f71\u50cf\u53ca\u4e00\u5e74\u5f8c\u8ffd\u8e64\u4e4b\u8840\u7ba1\u651d\u5f71\u767c\u73fe\u8166\u819c\u52d5\u975c\u8108\u763b\u7ba1\u5df2\u5b8c\u5168\u963b\u585e\uff0c\u4e14\u75c5\u7076\u5468\u908a\u7121\u53ef\u898b\u7684\u5f71\u50cf\u8b8a\u5316\uff1b\u653e\u5c04\u624b\u8853\u5f8c\u4e00\u5e74\u6642\u4ea6\u7121\u526f\u4f5c\u7528\u4e4b\u5831\u544a\u3002", "e": "Dural arteriovenous fistulas (DAVFs) account for approximately 10% to 15% of intracranial vascular malformations. The current management of cerebral DAVFs includes a multimodal approach involving surgery, endovascular therapy, and stereotactic radiosurgery (SRS). A 52 years-old female suffered from progressive pulsatile tinnitus of left ear for about 3 months and her symptoms didn\u2019t response to medical treatment. Her angiography showed numerous DAVFs without cortical venous reflux in left sigmoid sinus. She was referred to Radiation Oncology clinic for SRS, because surgery or endovascular therapy was not recommended. A thermoplastic mask was done for patient fixation. Then, the patient underwent a thin-sliced contrast-enhanced MRI exam with contrast enhancement and CT simulation without contrast enhancement. Abnormal fistulas and vessel were contoured on MRI images which were fused with CT images. Before SRS, pairs of orthogonal films and cone beam CT images which obtained by on-board imager were used for image guidance. Radiation dose was delivered with dynamic multileaf collimator in five non-coplanar arcs by a linear accelerator. The prescription dose was 20 Gy and the maximal dose was 21.9 Gy. The symptom of pulsatile tinnitus had been improved gradually since SRS and completely disappeared at about 2 months after SRS. Follow-up MRI at 3 and 9 months and angiography at 1 year after SRS suggested complete obliteration of DAVFs. No radiation-induced change at the perimeter of the lesion was observed by MRI or other chronic toxicity was reported at 1 year after SRS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201503-201504100025-201504100025-83-88", "title": "Successful Treatment of Adult Type Granulosa Cell Tumor of the Ovary - A Case Report and the Literature Review", "keywords": "\u6210\u4eba\u578b;\u9846\u7c92\u5c64\u7d30\u80de\u7624;\u5375\u5de2 Adult type;Granulosa cell tumor;Ovary", "c": "\u524d\u8a00\uff1a\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u5728\u5206\u985e\u4e0a\u5c6c\u65bc\u6027\u7d22\u9593\u8cea\u7d30\u80de\uff0c\u7d04\u4f54\u5375\u5de2\u816b\u7624\u76842-5%\u3002\u5176\u4e2d\u6210\u4eba\u578b\u4f54\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u768495%\u4e4b\u591a\uff0c\u597d\u767c\u572850\u523055\u6b72\u7684\u5973\u6027\u3002\u816b\u7624\u5206\u671f\u662f\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u7b2c\u4e00\u671f\u7684\u5341\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba84-95%\uff0c\u7b2c\u4e8c\u671f\u70ba50-65%\uff0c\u7b2c\u4e09\u53ca\u7b2c\u56db\u671f\u70ba0-22%\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u500b56\u6b72\u7684\u5973\u6027\uff0c\u56e0\u70ba\u5de6\u5074\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u5728\u81e8\u5e8a\u5206\u671f\u81f3\u5c11\u6709\u7b2c\u4e09\u671f\uff0c\u6240\u4ee5\u65bc\u897f\u51432002\u5e742\u670823\u65e5\u63a5\u53d7\u6e1b\u7a4d\u624b\u8853\u3002\u8853\u5f8c\uff0c\u5979\u63a5\u53d7\u4ee5\u64b2\u7d2f\u60e1\u6ce8\u5c04\u5291\uff08Bleomycin\uff09\u3001\u9806\u9251\uff08Cisplatin\uff09\u8207\u4f9d\u6258\u6cca\u7519\uff08Etoposide\uff09\u70ba\u8655\u65b9\u7684\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u5171\u56db\u500b\u7642\u7a0b\u3002\u63a5\u8457\u63a5\u53d7\u8f14\u52a9\u6027\u5168\u8179\u8154\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u764221\u6b21\uff0c\u5291\u91cf\u70ba25.2 Gy\u3002\u5b8c\u6210\u4e4b\u5f8c\uff0c\u518d\u63a5\u53d7\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u764211\u6b21\uff0c\u5291\u91cf\u70ba19.8 Gy\u3002\u81ea\u7d50\u675f\u7642\u7a0b\u81f3\u4eca\uff0c\u5979\u90fd\u898f\u5247\u5728\u672c\u9662\u8ffd\u8e64\uff0c\u4e14\u6c92\u6709\u4efb\u4f55\u816b\u7624\u5fa9\u767c\u6216\u75be\u75c5\u7e7c\u7e8c\u9032\u5c55\u7684\u73fe\u8c61\u3002\u8a0e\u8ad6\uff1a\u81f3\u4eca\u5c0d\u65bc\u60a3\u6709\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u7684\u75c5\u4eba\u4ecd\u7136\u6c92\u6709\u6a19\u6e96\u548c\u516c\u8a8d\u660e\u78ba\u6709\u6548\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u7279\u5225\u662f\u7b2c\u4e09\u56db\u671f\uff0c\u6216\u662f\u5fa9\u767c\u4ee5\u5f8c\u7121\u6cd5\u958b\u5200\u7684\u60a3\u8005\u3002\u9762\u5c0d\u9019\u500b\u75be\u75c5\uff0c\u901a\u5e38\u624b\u8853\u5207\u9664\u662f\u7b2c\u4e00\u7dda\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u5728\u5316\u5b78\u6cbb\u7642\u65b9\u9762\uff0c\u4ee5\u9806\u9251\u70ba\u4e3b\u7684\u8655\u65b9\u9078\u64c7\u81f3\u4eca\u4e5f\u672a\u80fd\u6709\u6e05\u695a\u7684\u6307\u5f15\u3002\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u89d2\u8272\u4e5f\u6c92\u6709\u78ba\u5b9a\u3002\u8fd1\u671f\uff0c\u6709\u4e00\u7bc7\u7814\u7a76\u6307\u51fa\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u6709\u52a9\u65bc\u6cbb\u7642\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u3002\u6709\u53e6\u4e00\u7bc7\u7814\u7a76\u6307\u51fa\u7de9\u548c\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u7de9\u89e3\u75c5\u4eba\u7684\u75c7\u72c0\u6709\u6b63\u9762\u7684\u5e6b\u52a9\u3002\u56e0\u6b64\uff0c\u6211\u5011\u5efa\u8b70\u5728\u7279\u5b9a\u7684\u5375\u5de2\u9846\u7c92\u5c64\u7d30\u80de\u7624\u60a3\u8005\u4e0a\uff0c\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u61c9\u53ef\u6539\u5584\u9810\u5f8c\u3002", "e": "Introduction: Granulosa cell tumor (GCT) of the ovary is classified as a sex cord stromal tumor, representing approximately 2-5% of ovarian neoplasms, and adult type accounts 95% of all GCTs, usually occurs in women during 50-55 years old. The most important prognostic factor of this tumor is stage, with 10-year overall survival of 84-95% for stage I tumors, decreasing to 50-65% for stage II tumors, and to 0-22% for stage III and IV disease. Case report: A 56-year-old woman with left side ovarian granulosa cell tumor, at least clinical FIGO stage IIIa, underwent debulking operation on February 23rd, 2002. After surgery, she received four cycles adjuvant chemotherapy with the regimen of Bleomycin, Cisplatin and Etoposide. Then she received postoperative whole-abdomen and pelvis irradiation. The dose was given 2520 cGy in 21 fractions with liver and kidney shielding. After whole-abdomen and pelvis irradiation, she received pelvis boost with the dose of 1980 cGy in 11 fractions. Since then, she was regularly followed at our hospital until now without any signs of tumor recurrence nor tumor progression. Discussion: Until now there is no standard and proven treatment for GCT patients, especially when they suffered from advanced-stage or recurrent unresectable tumors. Complete tumor resection should be considered as the primary treatment. The optimal choice of combination platinum-based chemotherapy is still not well-defined. The role of adjuvant radiation therapy remains controversial. We suggested that adjuvant RT for patients with GCT might improve outcomes in selected patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-257-265", "title": "Second Primary Malignancies after Definitive Radiotherapy for Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c;\u7b2c\u4e8c\u539f\u767c\u764c\u75c7;\u653e\u5c04\u7dda\u6cbb\u7642 Nasopharyngeal carcinoma;Second primary malignancy;Radiation therapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u65bc\u672c\u9662\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u7642\u4e4b\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u6cbb\u7642\u5f8c\u7522\u751f\u7b2c\u4e8c\u539f\u767c\u6027\u764c\u75c7\u7684\u7279\u5fb5\u4ee5\u53ca\u5b58\u6d3b\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1984\u5e741\u6708\u81f32010\u5e748\u6708\uff0c\u67092208\u4f8b\u75c5\u4eba\u7d93\u75c5\u7406\u5207\u7247\u78ba\u8a3a\u70ba\u9f3b\u54bd\u764c\u4e14\u65bc\u672c\u79d1\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u5c04\u6cbb\u7642\uff08\u00b1\u5316\u7642\uff09\uff0c\u5176\u4e2d\u5171\u670958\u4f8b\u65bc\u6cbb\u7642\u5f8c\u7522\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u3002\u6211\u5011\u4ed4\u7d30\u700f\u89bd\u75c5\u6b77\u7d00\u9304\u3001\u653e\u7642\u7d00\u9304\u3001\u5f71\u50cf\u8cc7\u6599\uff0c\u5206\u6790\u5176\u81e8\u5e8a\u7279\u8272\u3001\u6cbb\u7642\u7d93\u904e\u3001\u5b58\u6d3b\u72c0\u6cc1\u3002\u7d50\u679c\uff1a\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u7c97\u767c\u751f\u7387\u70ba2.6%\uff0c\u7d2f\u7a4d\u767c\u751f\u7387\u65bc\u4e94\u5e74\u3001\u5341\u5e74\u3001\u5341\u4e94\u5e74\u3001\u4e8c\u5341\u5e74\u3001\u4e8c\u5341\u4e94\u5e74\u5206\u5225\u70ba1.5%\u30014.7%\u30015.6%\u30019.2%\u300114%\u3002\u982d\u9838\u764c\u70ba\u6700\u5e38\u898b\u7684\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\uff0829.3%\uff09\uff0c\u5176\u6b21\u70ba\u80ba\u764c\uff0819.0%\uff09\u3001\u5927\u8178\u76f4\u8178\uff0812.1%\uff09\u53ca\u5973\u6027\u4e73\u764c\uff0812.1%\uff09\u3002\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u70ba3\u5e74\uff08\u7bc4\u570d1\u6708-10.9\u5e74\uff09\u3002\u6240\u6709\u75c5\u4eba\u7684\u5169\u5e74\u3001\u4e94\u5e74\u3001\u5341\u5e74\u5b58\u6d3b\u5206\u5225\u70ba52.3%\u300129.5%\u300111.8%\u3002\u4e73\u764c\u4ee5\u53ca\u5927\u8178\u76f4\u8178\u764c\u60a3\u8005\u76f8\u8f03\u65bc\u982d\u9838\u764c\u3001\u80ba\u764c\u3001\u4ee5\u53ca\u809d\u81bd\u8178\u80c3\u764c\u60a3\u8005\u6709\u8f03\u597d\u7684\u9810\u5f8c\uff08\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u738756.3% vs. 15.8%,p=0.0029\uff09\u7d50\u8ad6\uff1a\u9f3b\u54bd\u764c\u75c5\u60a3\u653e\u7642\u5f8c\u767c\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u4e4b\u7d2f\u7a4d\u76db\u884c\u7387\u96a8\u8457\u8ffd\u8e64\u6642\u9593\u589e\u52a0\u800c\u589e\u52a0\u3002\u597d\u767c\u8655\u4ee5\u982d\u9838\u90e8\u764c\u75c7\u6700\u5e38\u898b\uff1b\u6cbb\u7642\u5f8c\u4ee5\u5927\u8178\u76f4\u8178\u4ee5\u53ca\u5973\u6027\u4e73\u764c\u5b58\u6d3b\u7387\u6700\u597d\u3002", "e": "Purpose: To investigate the clinical features and survival outcomes of second primary malignancies (SPM) in nasopharyngeal carcinoma (NPC) after definitive radiotherapy. Materials and Methods: From January 1984 to August 2010, a total of 2208 patients with pathologically-proven NPC who received curative radiotherapy with or without chemotherapy were screened for the occurrence of SPM. Fifty-eight patients were eligible for the final analysis. We reviewed hospital charts, radiotherapy records and diagnostic imaging studies thoroughly and analyzed the clinical characteristics, treatment courses, and survival outcomes. Results: The overall incidence of SPM in this study was 2.6% (58/2208). The cumulative incidences at 5 years, 10 years, 15 years, 20 years, and 25 years were 1.5%, 4.7%, 5.6%, 9.2%, and 14%, respectively. Head and neck (H&N) was the most common site of SPM (29.3%), followed by the lung (19.0%), colon/rectum (12.1%) and female breast (12.1%). The median survival after diagnosis of SPM was 3 years (range, 1 month-10.9 years). The 2-year, 5-year, and 10-year survival rates after SPM diagnosis were 52.3%, 29.5%, and 11.8%, respectively. Patients with SPM arising from the breast/ colon/rectum had better survival than those with SPM arising from the H&N/lung/liverpancreas- stomach (5-year OS rates, 56.3% vs. 15.8%, p=0.0029). Conclusion: The cumulative incidence of SPM in NPC patients after definitive radiotherapy increased over time. Head and neck cancer is the most common site of SPM. Patients with SPM of colon/rectum and female breast had the best survival outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-267-276", "title": "Reirradiation in Patients with Recurrent or Residual Esophageal Cancer after Concurrent Chemoradiotherapy or Radiotherapy", "keywords": "\u98df\u9053\u764c;\u5fa9\u767c;\u6b98\u9918\u816b\u7624;\u518d\u5ea6\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Relapse;Residual tumor;Reirradiation", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u66fe\u7d93\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u98df\u9053\u764c\u75c5\u60a3\uff0c\u82e5\u6709\u5fa9\u767c\u6216\u6b98\u9918\u816b\u7624\u518d\u5ea6\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u9810\u5f8c\u8a55\u4f30\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e2007\u81f32010\u5e74\u9593\uff0c\u517138\u4f4d\u98df\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u66fe\u7d93\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u5fa9\u767c\u6216\u6709\u6b98\u9918\u816b\u7624\u7684\u75c5\u60a3\u9032\u5165\u5206\u6790\uff0c\u5176\u4e2d24\u4f4d\u518d\u5ea6\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff08\u65cf\u7fa4A\uff09\uff0818\u4f4d\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c6\u4f4d\u7121\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff09\uff08\u653e\u5c04\u7dda\u65b9\u6cd5\u5305\u542b18\u4f4d\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u53ca6\u4f4d\u63a5\u53d7\u98df\u9053\u8154\u5167\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\uff09\uff0c\u5269\u991814\u4f4d\uff08\u65cf\u7fa4B\uff09\u50c5\u63a5\u53d7\u55ae\u7d14\u5316\u5b78\u6cbb\u7642\u6216\u652f\u6301\u6027\u7167\u9867\u3002\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba\u7814\u7a76\u7684\u521d\u6b65\u7d42\u9ede\uff0c\u7d71\u8a08\u65b9\u6cd5\u4f7f\u7528Kaplain-Meier\u65b9\u6cd5\uff0c\u5169\u65cf\u7fa4\u4e4b\u9593\u6bd4\u8f03\u4f7f\u7528log-rank\u6e2c\u8a66\u53cacoxregression\u4f86\u6aa2\u6e2c\u5dee\u7570\u3002\u7d50\u679c\uff1a\u5728\u8ffd\u8e64\u4e2d\u4f4d\u657814.4\u500b\u6708\u5f8c\uff08\u7bc4\u570d\u57281.7\u523068.6\u500b\u6708\uff09\uff0c\u670929\u4f4d\u75c5\u4eba\u6b7b\u4ea1\u3002\u6574\u9ad4\u75c5\u4eba\u5b58\u6d3b\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f10.6 \u00b1 1.8\u500b\u6708\uff0c\u7136\u800c\u5728\u65cf\u7fa4A\u5b58\u6d3b\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f13.7 \u00b1 2.3\uff0c\u65cf\u7fa4B\u5b58\u6d3b\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f4.38 \u00b1 0.9\u500b\u6708(p=0.001)\u3002\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\u6709\u63a5\u53d7\u518d\u5ea6\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\u4e5f\u6bd4\u672a\u63a5\u53d7\u518d\u5ea6\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u6709\u66f4\u9577\u7684\u5b58\u6d3b\u6642\u9593(HR=0.30, 95% C.I. 0.10~0.89, p=0.031)\u3002\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7814\u7a76\u8a8d\u70ba\u5c0d\u65bc\u6709\u5fa9\u767c\u6216\u6b98\u9918\u98df\u9053\u816b\u7624\u7684\u75c5\u4eba\uff0c\u518d\u5ea6\u653e\u5c04\u6cbb\u7642\u53ef\u80fd\u662f\u6709\u5e6b\u52a9\u7684\u3002\u672a\u4f86\u9700\u8981\u66f4\u591a\u7684\u7814\u7a76\u53bb\u5206\u6790\u627e\u51fa\u9069\u5408\u518d\u5ea6\u653e\u5c04\u6cbb\u7642\u7684\u5fa9\u767c\u98df\u9053\u816b\u7624\u75c5\u4eba\u3002", "e": "Introduction: The purpose of this study was to evaluate the treatment outcomes following reirradiation (re-RT) with or without chemotherapy in patients with recurrent or residual esophageal cancer after primary definitive concurrent chemoradiotherapy (CCRT) or radiotherapy (RT). Materials and Methods: From 2007 to 2010, 38 patients with recurrent or residual esophageal cancer who had received definitive CCRT or RT were analyzed. The pathology of all patients was squamous cell carcinoma. Among these patients, 24 received re-RT (group A). Eighteen of these patients received re-RT combined with chemotherapy and 6 received re-RT alone. External-beam radiotherapy was administered to 18 patients and intraluminal brachytherapy to 6 patients. The remaining 14 patients (group B) were treated using chemotherapy or provided supportive care. The study endpoint was to identify overall survival (OS). These rates were calculated using the Kaplan-Meier method. The log-rank test and Cox regression were performed to compare the variables. Results: After a median follow-up duration of 14.4 months (range, 1.7-68.6), 29 patients were dead. The median OS time for the entire cohort was 10.6 \u00b1 1.8 months, whereas the OS for group A and B was 13.7 \u00b1 2.3 months and 4.38 \u00b1 0.9 months respectively (P=.001). According to the multivariate analysis, patients received re-RT had a longer OS than those without re-RT. (hazard ratio=0.30, 95% Confidence Interval 0.10-0.89, P=.031). Conclusion: Our study results indicate that re-RT might be feasible in patients with recurrent or residual esophageal cancer who had received previous CCRT or RT. Further studies are required to identify those who will be benefited from re-RT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-277-284", "title": "Clinicopathologic Features and Radiation Therapy for Metaplastic Carcinoma of the Breast", "keywords": "\u8f49\u5316\u578b\u4e73\u764c;\u653e\u5c04\u6cbb\u7642;\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5;\u81e8\u5e8a\u6cbb\u7642\u6210\u679c Metaplastic carcinoma of the breast;Radiation therapy;Clinicopathologic features;Clinical Outcome", "c": "\u76ee\u7684\uff1a\u8f49\u5316\u578b\u4e73\u764c\uff08MCB\uff09\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u4e73\u764c\u4e9e\u578b\uff0c\u5176\u7279\u5fb5\u5728\u65bc\u816b\u7624\u540c\u6642\u6709\u4e0a\u76ae\u548c\u9593\u8cea\u7d30\u80de\u7684\u7d44\u7e54\u5b78\u6210\u5206\u5b58\u5728\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u6b64\u4e00\u65cf\u7fa4\u75c5\u4eba\u7684\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5\u548c\u63a5\u53d7\u653e\u5c04\u7dda\u7dda\u6cbb\u7642\u7684\u6210\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7814\u7a76\u5728\u6211\u5011\u91ab\u9662\u63a5\u53d7\u4ee5\u6cbb\u7652\u70ba\u76ee\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u4e14\u7121\u9060\u8655\u8f49\u79fb\u7684MCB\u75c5\u4eba\uff0c\u6536\u96c6\u5176\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5\u4e26\u5206\u6790\u5176\u6cbb\u7642\u7d50\u679c\uff0c\u6211\u5011\u63a1\u7528Kaplan-Meier\u7d71\u8a08\u65b9\u6cd5\u4f86\u5206\u6790\u9019\u7fa4\u75c5\u4eba\u7684\u7121\u75c5\u5b58\u6d3b\u7387\uff08DFS\uff09\u53ca\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\u3002\u7d50\u679c\uff1a\u81ea\u897f\u51431996\u81f32012\u5e74\u9593\uff0c\u7b26\u5408\u7d0d\u5165\u689d\u4ef6\u7684\u75c5\u4eba\u670912\u4f4d\u3002\u60a3\u8005\u5e74\u9f61\u4ecb\u65bc29\u81f366\u6b72\uff08\u4e2d\u4f4d\u6578\u70ba48\uff09\uff0c\u539f\u767c\u816b\u7624\u5927\u5c0f\u4e2d\u4f4d\u6578\u70ba5.3\u516c\u5206\uff08\u7bc4\u570d1.2-19\uff09\uff0c\u7121\u6dcb\u5df4\u7d50\u8f49\u79fb\u8005\u67099\u4f4d\u75c5\u4eba\uff0875%\uff09\uff0c\u572810\u4f4d\u5df2\u77e5\u53d7\u9ad4\u72c0\u6cc1\u7684\u75c5\u4eba\u4e2d\uff0c9\u540d\u60a3\u8005\u6709\u4e09\u9670\u6027\u7684\u816b\u7624\uff08\u5373ER\u9670\u6027\u3001PR\u9670\u6027\u548cHER2\u9670\u6027\uff09\uff0c9\u4f4d\u60a3\u8005\u63a5\u53d7\u5168\u4e73\u623f\u5207\u9664\u8853\uff0c3\u540d\u60a3\u8005\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u3002\u653e\u5c04\u7dda\u7684\u5291\u91cf\u5f9e50-66Gy\u4e0d\u7b49\uff08\u4e2d\u4f4d\u657860Gy\uff09\uff0c\u6cbb\u7642\u5f8c\u6c92\u6709\u75c5\u4eba\u5c40\u90e8\u5fa9\u767c\u3002\u7121\u75c5\u5b58\u6d3b\u7684\u4e2d\u4f4d\u6578\u70ba4.2\u5e74\uff0c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba52.5%\u3002\u7d50\u8ad6\uff1a\u6211\u5011\u7814\u7a76\u986f\u793a\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u662fMCB\u60a3\u8005\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7684\u4e00\u7a2e\u975e\u5e38\u6709\u6548\u7684\u8f14\u52a9\u6cbb\u7642\u3002", "e": "Purpose: Metaplastic carcinoma of the breast (MCB) is a rare subtype of breast cancer and characterized by the histologic presence of two or more cellular types of epithelial and mesenchymal components. The purpose of the study is to review the clinicopathologic features and outcomes of MCB treated with radiation therapy (RT) at our institution. Materials and Methods: Patients with MCB of the breast who did not have distant metastasis at diagnosis and received curative-intent RT at our institution were identified. Clinicopathologic features were collected and outcomes were analyzed. We used Kaplan-Meier statistic method to estimate local control, disease-free survival (DFS) and overall survival (OS) in these patients. Results: From 1996 to 2012, twelve MCB patients who met the inclusion criteria were enrolled. Patient age ranged from 29 to 66 years (mean, 48). The median tumor size was 5.3 cm (range, 1.2-19). Nine patients (75%) were nodal negative. Triple negative tumors (ie, ER negative, PR negative and HER2 negative) were found in 9 of 12 patients (75%). Nine patients received mastectomy while 3 patients underwent breast conserving surgery. RT dose ranged from 50-66 Gy (mean, 60). No patient developed local recurrence after RT. The median DFS was 4.2 years. Overall survival was 52.5% at 5 years. Conclusions: Our findings suggest adjuvant RT is a very effective adjuvant treatment on local tumor control for patients with MCB."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-285-294", "title": "Application of a Spacer Medial to the Left Parotid Gland to Improve Dosimetry for Head and Neck Radiotherapy-A Swine Model", "keywords": "\u9694\u96e2\u7269;\u816e\u817a;\u653e\u5c04\u7dda\u6cbb\u7642;\u5291\u91cf\u53c3\u6578 Spacer;Parotid gland;Radiotherapy;Dosimetry", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u982d\u9838\u764c\u4e4b\u91cd\u8981\u7642\u6cd5\u3002\u56e0\u9130\u8fd1\u9776\u9ad4\u7a4d\uff0c\u816e\u817a\u3001\u981c\u4e0b\u817a\u8207\u5c0f\u553e\u6db2\u817a\u7d93\u5e38\u6703\u63a5\u53d7\u5230\u653e\u5c04\u7dda\u7167\u5c04\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\u7684\u9032\u6b65\u5927\u5e45\u5ea6\u5730\u6e1b\u5c11\u4e86\u6b63\u5e38\u7d44\u7e54\u7684\u5291\u91cf\u5206\u4f48\uff0c\u7136\u800c\u816e\u817a\u4ecd\u6703\u63a5\u53d7\u5230\u9ad8\u5291\u91cf\u653e\u5c04\u7dda\uff0c\u9032\u800c\u5f15\u8d77\u76f8\u95dc\u7684\u4f75\u767c\u75c7\u2500\u53e3\u4e7e\u75c7\u3002\u672c\u7814\u7a76\u900f\u904e\u65bc\u5de6\u5074\u816e\u817a\u5167\u5074\u7f6e\u5165\u4e00\u9694\u96e2\u7269\uff0c\u85c9\u6b64\u9694\u958b\u9776\u9ad4\u7a4d\u8207\u816e\u817a\uff0c\u671f\u671b\u6e1b\u5c11\u816e\u817a\u7684\u653e\u5c04\u7dda\u5291\u91cf\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u4ee5\u6700\u4f4e\u50b7\u5bb3\u624b\u8853\u65b9\u5f0f\u5728\u5be6\u9a57\u8c6c\u7684\u5de6\u5074\u816e\u817a\u5167\u5074\u88fd\u9020\u4e00\u7a7a\u8154\uff0c\u518d\u7f6e\u5165\u4e00\u500b\u9694\u96e2\u7269\u4e26\u7e2b\u5408\u56fa\u5b9a\u3002\u4ee5\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5b9a\u4f4d\u6a5f\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\uff0c\u9032\u884c\u6a21\u64ec\u53ef\u898b\u816b\u7624\u3001\u9ad8\u98a8\u96aa\u81e8\u5e8a\u9776\u9ad4\u7a4d\u8207\u816e\u817a\u7b49\u5176\u4ed6\u6b63\u5e38\u7d44\u7e54\u7684\u5291\u91cf\u5206\u4f48\u5206\u6790\u3002\u4e4b\u5f8c\u4ee5\u914d\u5c0dt\u6aa2\u5b9a\u9032\u884c\u7d71\u8a08\u5206\u6790\uff0c\u6bd4\u8f03\u5728\u816e\u817a\u5167\u5074\u7f6e\u5165\u9694\u96e2\u7269\u524d\u5f8c\u6240\u9020\u6210\u7684\u5404\u5291\u91cf\u53c3\u6578\u4e0a\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u5728\u624b\u8853\u524d\u5f8c\u4e4b\u6a21\u64ec\u53ef\u898b\u816b\u7624\u8a08\u756b\u9776\u9ad4\u7a4d\uff08PTV_(70)\uff1a70 Gy\uff0c\u4e00\u6b212 Gy\uff09\u8207\u9ad8\u98a8\u96aa\u9776\u5340\u57df\uff08PTV_(63)\uff1a63 Gy\uff09\u7684\u8a08\u756b\u9776\u9ad4\u7a4d\u6709\u76f8\u4f3c\u7684\u5305\u8986\u6027\u8207\u9806\u578b\u6027\u4e4b\u57fa\u790e\u4e0b\uff0c\u672c\u7814\u7a76\u8b49\u5be6\u4e86\u816e\u817a\u7684\u653e\u5c04\u7dda\u5291\u91cf\u53ef\u56e0\u7f6e\u5165\u9694\u96e2\u7269\u800c\u5927\u5e45\u6e1b\u5c11\u3002\u624b\u8853\u9032\u884c\u524d\uff0c\u5de6\u5074\u8207\u53f3\u5074\u816e\u817a\u7684\u5e73\u5747\u5291\u91cf\u5206\u5225\u70ba2808 \u00b1 205cGy\u82072901 \u00b1 189 cGy\u3002\u5728\u5de6\u5074\u7684\u816e\u817a\u5167\u5074\u7f6e\u5165\u4e00\u9694\u96e2\u7269\u5f8c\uff0c\u5de6\u5074\u8207\u53f3\u5074\u816e\u817a\u7684\u5e73\u5747\u5291\u91cf\u5206\u5225\u70ba2027 \u00b1 364 cGy\u82072972 \u00b1 114 cGy\u3002\u5728\u540c\u5074\uff08\u5de6\u5074\uff09\u816e\u817a\u5167\u5074\u7f6e\u5165\u9694\u96e2\u7269\u6703\u4f7f\u5f97\u5291\u91cf\u6709\u986f\u8457\u5dee\u7570\uff08p=0.003\uff09\uff0c\u4f46\u4e0d\u5f71\u97ff\u5c0d\u5074\uff08\u53f3\u5074\uff09\u553e\u6db2\u817a\u7684\u5291\u91cf\uff08p=0.36\uff09\u3002\u7d50\u8ad6\uff1a\u85c9\u7531\u7f6e\u5165\u9694\u96e2\u7269\u9694\u96e2\u816e\u817a\u8207\u9776\u9ad4\u7a4d\uff0c\u6211\u5011\u767c\u5c55\u51fa\u4e00\u5957\u53ef\u5927\u5e45\u6e1b\u5c11\u816e\u817a\u5291\u91cf\u5206\u4f48\u7684\u5be6\u9a57\u6a21\u5f0f\uff0c\u5f80\u5f8c\u9700\u9032\u4e00\u6b65\u9a57\u8b49\u52d5\u7269\u816e\u817a\u9577\u671f\u8207\u77ed\u671f\u529f\u80fd\u4e4b\u5f71\u97ff\u3002", "e": "Purpose: Radiation therapy is an important treatment method for head and neck cancer. The parotid gland, submandibular gland and minor salivary gland are often irradiated due to being adjacent to the target volumes. Although advancing radiotherapy techniques have reduced the dose of radiation to normal tissues and toxicity, the radiation dose distributed to the parotid gland remains high, causing a considerable amount of xerostomia. The aim of this study is to reduce the dose of radiation to the left parotid gland by inserting a spacer into the medial parotid space and separating it from the target volume. Materials and Methods: A minimally invasive procedure was developed to create a space medial to the left parotid gland in experimental swine, and a spacer was inserted into this space. A computed tomography simulator and radiation therapy planning system was used to analyze the distribution of the radiation dose to the putative gross disease, high risk clinical target volume, and parotid glands. Statistics obtained by using a paired t test were used to compare the dosimetry parameters with or without the insertion of the spacer. Results: The dose of radiation to the parotid glands was found to be significantly reduced by the demand for a similar coverage and conformity of the putative target volume for the gross disease (PTV 70 Gy) and high risk nodal region (PTV 63 Gy) with 2 Gy per fraction. Before the space was created, the left and right parotid glands were estimated to receive a mean dose of 2808 \u00b1 205 cGy and 2901 \u00b1 189 cGy, respectively. After the spacer was inserted into the left medial parotid gland space, the left and right parotid glands were estimated to receive a mean dose of 2027 \u00b1 364 cGy and 2972 \u00b1 114 cGy respectively. Therefore, the spacer had made a significant difference in the dose to the ipsilateral (left) parotid gland (p=0.003) without affecting the contralateral (right) one (p=0.36). Conclusion: An experimental model was developed by using spacers to create a space between the left parotid gland and the target volume, which markedly reduced the dose to the left parotid gland. Both short and long term functional assays for parotid damage in animals is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-295-304", "title": "\u904b\u7528\u55ae\u9375\u89e3\u6c7a\u65b9\u6848\u6574\u5408\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71(MOSAIQ)\u8207\u91ab\u9662\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71", "keywords": "\u96fb\u5b50\u75c5\u6b77;\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71;\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u7cfb\u7d71 Electronic medical record;Health information system;Radiation oncology information system", "c": "\u76ee\u7684\uff1a\u96d6\u7136\u5e02\u5834\u4e0a\u6709\u4e00\u4e9b\u653e\u5c04\u816b\u7624\u8cc7\u8a0a\u8207\u5de5\u4f5c\u7ba1\u7406\u7cfb\u7d71\u53ef\u4f9b\u9078\u7528\uff08\u4f8b\u5982\uff0cElekta\u516c\u53f8\u7684MOSAIQ\uff09\uff0c\u4f46\u9019\u985e\u8cc7\u8a0a\u7cfb\u7d71\u5f80\u5f80\u662f\u91dd\u5c0d\u653e\u5c04\u816b\u7624\u5c08\u696d\u9818\u57df\u8a2d\u8a08\u7684\uff0c\u5728\u53f0\u7063\u76f8\u7576\u96e3\u4ee5\u548c\u91ab\u9662\u5167\u73fe\u884c\u7684\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71healthin formation system(HIS)\u9032\u884c\u6574\u5408\u3002\u56e0\u6b64\uff0c\u6211\u5011\u63d0\u51fa\u4e86\u80fd\u5920\u6574\u5408\u9019\u5169\u500b\u4e0d\u540c\u8cc7\u8a0a\u7cfb\u7d71\u7684\u55ae\u9375\u5f0f\u89e3\u6c7a\u65b9\u6848One-Touch Solution(OTS)\uff0c\u4e0d\u8ad6\u4f55\u6642\u4f55\u5730\u90fd\u80fd\u8b93\u91ab\u5e2b\u900f\u904e\u9019\u500b\u6574\u5408\u7cfb\u7d71\u7372\u53d6\u6700\u5373\u6642\u7684\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5148\u78ba\u8a8d\u79d1\u5167\u73fe\u884c\u7684\u5de5\u4f5c\u6d41\u7a0b\uff0c\u91d0\u6e05\u91ab\u9662HIS\u548c\u653e\u5c04\u816b\u7624\u79d1\u5167MOSAIQ\u4e4b\u9593\u8cc7\u8a0a\u7684\u50b3\u905e\u60c5\u5f62\uff0c\u63a5\u8457\u904b\u7528\u4ee5\u4e0b\u6578\u500b\u8cc7\u8a0a\u6280\u8853\u5efa\u7f6e\u4e86\u80fd\u5920\u6574\u5408\u9019\u5169\u500b\u4e0d\u540c\u8cc7\u8a0a\u7cfb\u7d71\u7684\u55ae\u9375\u5f0f\u89e3\u6c7a\u65b9\u6848\uff0c\u5305\u62ecHL7\u8a0a\u606f\u4ea4\u63db\u3001SQL\u67e5\u8a62\u548c\u52d5\u614b\u7db2\u9801\u3002OTS\u5141\u8a31\u7d93\u904e\u9a57\u8b49\u7684\u7528\u6236\u4f7f\u7528\u5df2\u6388\u6b0a\u7684\u96fb\u8166\u5de5\u4f5c\u7ad9\u6216\u79fb\u52d5\u88dd\u7f6e\uff0c\u4ee5\u6700\u76f4\u89c0\u7c21\u6613\u4e14\u5feb\u901f\u7684\u65b9\u5f0f\uff0c\u4f86\u7372\u53d6\u75c5\u60a3\u7684\u653e\u5c04\u6cbb\u7642\u5373\u6642\u8cc7\u8a0a\uff0c\u4f8b\u5982\uff1a\u6cbb\u7642\u90e8\u4f4d\u3001\u5291\u91cf\u8207\u6b21\u6578\u3001\u6cbb\u7642\u8d77\u8a16\u65e5\u671f\u7b49\u3002\u7d50\u679c\uff1aOTS\u6210\u529f\u5be6\u73fe\u4e86\u53ea\u6309\u4e00\u9375\u5c31\u53ef\u5b8c\u6210MOSAIQ\u8207\u91ab\u9662HIS\u9593\u7684\u8cc7\u6599\u4ea4\u63db\uff0c\u65b9\u4fbf\u6bcf\u65e5\u81e8\u5e8a\u5de5\u4f5c\u4f7f\u7528\u3002\u5f9e\u4f7f\u7528\u8005\u7372\u53d6\u75c5\u60a3\u7684\u5373\u6642\u653e\u5c04\u6cbb\u7642\u8cc7\u8a0a\uff0c\u7136\u5f8c\u8a18\u9304\u5728\u91ab\u9662HIS\u6240\u9700\u7684\u5e73\u5747\u6642\u9593\uff0c\u76f8\u8f03\u65bc\u76f4\u63a5\u5728MOSAIQ\u67e5\u8a62\u768412.7\u79d2\u8207\u4eba\u5de5\u50b3\u9001\u7d19\u672c\u75c5\u6b77\u768447.1\u79d2\uff0c\u900f\u904eOTS\u7684\u6574\u5408\u53ef\u4ee5\u986f\u8457\u5730\u6e1b\u5c11\u5230\u53ea\u97001\u79d2\u5b8c\u6210\uff08\u5169\u7d44\u6bd4\u8f03\u7686\u662fP\uff1c0.05\uff09\u3002\u7d50\u8ad6\uff1aOTS\u53ef\u4ee5\u4f7f\u653e\u5c04\u6cbb\u7642\u7684\u8cc7\u6599\u5728\u4e0d\u540c\u7684\u8cc7\u8a0a\u7ba1\u7406\u7cfb\u7d71\u4e4b\u9593\u4ea4\u63db\u8b8a\u5f97\u66f4\u52a0\u5bb9\u6613\uff0c\u4e26\u7d13\u7de9\u653e\u5c04\u816b\u7624\u79d1\u91ab\u5e2b\u7684\u91cd\u8907\u6027\u4e8b\u52d9\uff0c\u8b93\u91ab\u5e2b\u80fd\u6709\u591a\u9ede\u6642\u9593\u8457\u91cd\u65bc\u5176\u4ed6\u66f4\u91cd\u8981\u7684\u91ab\u7642\u5de5\u4f5c\uff0c\u9032\u800c\u63d0\u5347\u653e\u5c04\u6cbb\u7642\u7684\u54c1\u8cea\u8207\u5b89\u5168\u3002", "e": "Purpose: While a variety of information and practice management systems are available (e.g., MOSAIQ from Elekta), these information systems are specific to radiation oncology and are quite difficult to integrate with existing hospital Health Information System (HIS) in Taiwan. A one-touch solution to integrate diverse information systems was proposed to readily access radiotherapy information in real time wherever and whenever needed. Materials and Methods: First, we identified all existing processes and the distribution of information between HIS in the hospital and MOSAIQ in the department of radiation oncology. Then a one-touch solution (OTS) was implemented using several information technologies, including HL7 message exchange, SQL query, and dynamic web pages. It allowed authenticated users to obtain the radiotherapy information such as treatment sites, dose and fractions, and start/end date of radiotherapy on authorized computer workstations or mobile devices in an intuitive and rapid way. Results: The ability to exchange data between MOSAIQ and hospital HIS with just one touch was successfully implemented for daily clinical use. The mean time for users to retrieve up-to-date radiotherapy information for each patient and record it in hospital HIS was significantly decreased to 1 sec with OTS compared to 12.7 sec with searching data in MOSAIQ and 47.1 sec with manual transfer of paper charts (p\uff1c0.05 for both comparisons). Conclusion: OTS can facilitate the exchange of radiotherapy data between different information systems. It can free up radiation oncologists from doing repetitive tasks, and allow them to focus on other important tasks to improve the quality and safety of radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-305-315", "title": "\u524d\u5217\u817a\u764c\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\u64fa\u4f4d\u8aa4\u5dee\u4e4b\u5291\u91cf\u8a55\u4f30", "keywords": "\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u5168\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642;\u64fa\u4f4d\u8aa4\u5dee;\u81e8\u5e8a\u9776\u9ad4\u7a4d;\u8a08\u756b\u9776\u9ad4\u7a4d Image-guided radiation therapy (IGRT);Volumetric modulated arc therapy (VMAT);Set-up errors;Clinical target volume (CTV);Planning target volume (PTV)", "c": "\u76ee\u7684\uff1a\u524d\u5217\u817a\u764c\u653e\u5c04\u6cbb\u7642\uff0c\u6cbb\u7642\u9593\uff08inter-fraction\uff09\u7684\u5668\u5b98\u8b8a\u52d5\u548c\u5f62\u8b8a\uff0c\u6703\u9020\u6210\u6bcf\u5929\u6cbb\u7642\u5291\u91cf\u4e4b\u6539\u8b8a\u3002\u672c\u7814\u7a76\u61c9\u7528\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff08imaged-guided radiation therapy, IGRT\uff09\u4e4b\u96e2\u7dda\u91cd\u65b0\u8a08\u7b97\u5291\u91cf\u548c\u7dda\u4e0a\u91cd\u65b0\u6821\u6b63\u64fa\u4f4d\u4e4b\u65b9\u5f0f\u4f86\u57f7\u884c\u5168\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\uff08volumetric modulated arctherapy, VMAT\uff09\uff0c\u8a55\u4f30\u64fa\u4f4d\u8aa4\u5dee\uff08set-uperror\uff09\u5c0d\u81e8\u5e8a\u9776\u9ad4\u7a4d\uff08clinicaltarget volume, CTV\uff09\u3001\u8a08\u756b\u9776\u9ad4\u7a4d\uff08planning target volume, PTV\uff09\u5305\u8986\u7387\u548c\u5468\u570d\u5371\u6025\u5668\u5b98\uff08organat risk\uff09\u4e4b\u5291\u91cf\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u70ba\u56de\u6eaf\u6027\u5be6\u9a57\uff0c\u6642\u9593\u70ba\u897f\u51432011\u5e745\u6708\u81f32013\u5e744\u6708\uff0c\u6536\u96c612\u4f4d\u524d\u5217\u817a\u764c\u75c5\u60a3\uff0c\u61c9\u7528Elekta Synergy X-ray cone beam computed tomography system\u57f7\u884c\u6821\u6b63\u9776\u9ad4\u7a4d\u5b9a\u4f4d\u4e4b\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff0c\u7e3d\u6cbb\u7642\u5291\u91cf\u70ba75.6Gy\u3002IGRT\u8f14\u4ee5VMAT\uff0c\u64f7\u53d6\u6bcf\u5206\u6b21\u7684\u7a7a\u9593\u5ea7\u6a19\u4e4b\u518d\u8a08\u7b97\u5291\u91cf\u5f8c\uff0c\u4ee5Python\u7a0b\u5f0f\u52a0\u7e3d\u3002CTV\u3001PTV\u4e4b\u5305\u8986\u7387\u548c\u5468\u570d\u5371\u6025\u5668\u5b98\u4e4b\u5291\u91cf\u662f\u88ab\u91cd\u65b0\u8a55\u4f30\u7684\uff0c\u56e0\u5be6\u969b\u4e4b\u7d55\u5c0d\u5291\u91cf\u662f\u91cd\u65b0\u8a08\u7b97\u3001\u5806\u758a\u5728\u6bcf\u5206\u6b21\u4e4b\u7a7a\u9593\u5ea7\u6a19\u4e0a\uff0c\u8207\u539f\u59cb\u8a08\u756b\u505a\u6bd4\u64ec\u3002\u7d50\u679c\uff1a\u6240\u6709\u75c5\u60a3\u7684\u5e73\u5747\u4f4d\u79fb\u8aa4\u5dee\u5728\u5de6\u53f3\u3001\u982d\u5c3e\u3001\u524d\u5f8c\u5404\u70ba\uff1a2mm\u00b11mm\u30013mm\u00b13mm\u30014mm\u00b13mm\u3002\u7cfb\u7d71\u8aa4\u5dee\u5728\u5de6\u53f3\u3001\u982d\u5c3e\u3001\u524d\u5f8c\u5404\u70ba\uff1a0.8mm\u30012.0mm\u30011.6mm\u3002\u96a8\u6a5f\u8aa4\u5dee\u5728\u5de6\u53f3\u3001\u982d\u5c3e\u3001\u524d\u5f8c\u5206\u5225\u70ba\uff1a1.2mm\u30011.7mm\u30012.1mm\u3002\u91cd\u65b0\u8a08\u7b97\u4e4bCTV\u5291\u91cf\u5305\u8986\u7387\u7531100%\u964d\u81f396%\u3001PTV\u5305\u8986\u7387\u753197.5%\u964d\u81f386.9%\uff0c\u5468\u570d\u5371\u6025\u5668\u5b98\uff0c\u5728\u7d71\u8a08\u4e0a\u5247\u4e0d\u5177\u986f\u8457\u4e4b\u6539\u8b8a\u3002\u6545\u5f71\u50cf\u5c0e\u5f15\u662f\u5fc5\u9808\u7684\uff0c\u96d6\u7136CTV\u5291\u91cf\u5305\u8986\u7387\u7531100%\u964d\u81f396%\uff0c\u4f46PTV\u5305\u8986\u7387\u753197.5%\u964d\u81f386.9%\uff0c\u9054\u7d71\u8a08\u4e0a\u4e4b\u986f\u8457\u6539\u8b8a\u3002\u7d50\u8ad6\uff1aIGRT\u5c0d\u524d\u5217\u817a\u764c\u8f14\u4ee5VMAT\u662f\u6709\u76ca\u7684\uff0c\u4e0d\u50c5\u80fd\u964d\u4f4e\u6bcf\u5206\u6b21\u9593\u4e4b\u64fa\u4f4d\u8aa4\u5dee\u3002\u5c0d\u65bc\u5371\u6025\u5668\u5b98\u548c\u816b\u7624\u4e4b\u5177\u9ad4\u5291\u91cf\uff0c\u66f4\u80fd\u7cbe\u78ba\u8a55\u4f30\uff0c\u4e26\u7372\u5f97\u66f4\u4f73\u4e4b\u816b\u7624\u63a7\u5236\u7387\u8207\u8f03\u5c11\u4e4b\u4f75\u767c\u75c7\uff0c\u4e5f\u671f\u671b\u5728\u672a\u4f86\u88e1\uff0c\u80fd\u6709\u66f4\u65b0\u7684\u96a8\u6a5f\u81e8\u5e8a\u8a66\u9a57\u9a57\u8b49\u3002", "e": "Purpose: In prostate radiation therapy, inter-fractional organ motion/deformation has posed significant challenges on reliable daily dose delivery. To evaluate the set-up errors and dose impact at clinical target volume (CTV), planning target volume (PTV) coverage and critical organ with cone beam computed tomography (CBCT), image-guided radiation therapy (IGRT), volumetric modulated arc therapy (VMAT); off-line re-optimization and online re-positioning have been used clinically. Materials and Methods: Between 2011 and 2013, 12 patients with prostate cancer were treated with IGRT to a dose of 75.6 Gy with daily correction of the target position based on Elekta Synergy X-ray cone beam computed tomography system, image-guided radiation therapy practiced with VMAT. We captured each space coordinates in every fraction with dose redistribution to form a new dose distribution with the Pyton software. The real dose with recalculation and stacking with new three dimensional coordinates from each fraction were compared with initial plan. The dose at CTV, PTV coverage and critical organ were reevaluated. Results: The average shift of ML (medial-lateral), CC (cranio-caudal) and AP (anterior-posterior) were 2 mm\u00b11 mm, 3 mm\u00b13 mm and 4 mm\u00b13 mm. The calculated systematic errors in ML, AP and CC direction were 0.8 mm, 2.0 mm and 1.6 mm. The calculated random errors in ML, AP and CC direction were 1.22 mm, 1.7 mm and 2.1 mm. The coverage of CTV and PTV with recalculation were significantly decreased from 100% to 96% and 97.5% to 86.9% respectively. There was no statistical difference in the dose to organ at risk. IGRT will be necessary in our study. Though CTV coverage decrease from 100% to 96%, but the PTV coverage decrease from 97.5% to 86.9% reaching statistical significance. Conclusions: IGRT would be beneficial for prostate cancer treatment with VMAT really. CBCT image guide VMAT in radiotherapy to prostate cancer not only shortened the treatment time but also decreased the uncertainty of set-up within each fraction. The specific dose to critical organs and tumor would be more exact compared with radiotherapy without IGRT. The less side effect and better tumor control might be expected in the future after proof of new randomized clinical trial."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-317-326", "title": "\u4ee5\u79fb\u4f4d\u53ca\u6578\u5b78\u65b9\u6cd5\u63d0\u5347PTW 2D Array\u5728\u653e\u5c04\u6cbb\u7642\u9a57\u8b49\u89e3\u6790\u5ea6\u4e4b\u7814\u7a76", "keywords": "\u5291\u91cf\u9a57\u8b49;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u4e8c\u7dad\u9663\u5217\u7cfb\u7d71 Quality assurance (QA);Intensity modulated radiotherapy (IMRT);2D-Array system", "c": "\u76ee\u7684\uff1a\u5728\u73fe\u6709PTW-seven29 2D-Array\u5de5\u5177\u4e0b\uff0c\u5229\u7528\u591a\u6b21\u79fb\u4f4d\u4e26\u7d50\u5408\u6578\u5b78\u7406\u8ad6\uff0c\u7d66\u51fa\u4e00\u898f\u5247\u6027\u4e14\u6709\u6548\u5730\u589e\u52a0\u6e2c\u91cf\u89e3\u6790\u5ea6\u7684\u65b9\u6cd5\uff0c\u4e26\u5be6\u969b\u548c\u6cbb\u7642\u8a08\u756b\u7684\u6578\u503c\u505a\u6bd4\u8f03\uff0c\u63a2\u8a0e2D Array\u7528\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(intensity modulated radiotherapy, IMRT)\u5291\u91cf\u9a57\u8b49\u7684\u53ef\u884c\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1aPTW-seven29 2D Array\u70ba\u6e2c\u91cf\u5de5\u5177\uff0c\u4e26\u4f7f\u752815\u7247PTW-RW3 Slab Phantoms\u5728\u96fb\u8166\u65b7\u5c64(computed tomography, CT)\u6383\u63cf\u5f71\u50cf\u4f86\u505a\u5291\u91cf\u5206\u5e03\u7684\u6a21\u64ec\u8a08\u7b97\uff0c\u5c04\u6e90\u5230\u56fa\u614b\u5047\u9ad4(solid phantom)\u8868\u9762\u7684\u8ddd\u96e2(SSD)\u70ba95 cm\uff0c\u8868\u9762\u4e0b5 cm\u7684\u4e8c\u7dad\u5291\u91cf\u5206\u5e03\u7576\u4f5c\u6578\u503c\u53c3\u8003\u503c\u3002\u4e26\u7d00\u9304\u4e0d\u540c\u79fb\u4f4d\u4e0b\u7684\u5be6\u969b\u6e2c\u91cf\u7d50\u679c\uff0c\u5229\u7528\u6578\u5b78\u539f\u7406\u7d44\u5408\u91cf\u6e2c\u6578\u503c\uff0c\u4ee5\u5f97\u5230\u4e0d\u540c\u7406\u8ad6\u89e3\u6790\u5ea6\u7684\u5206\u5e03\uff0c\u4e26\u8a0e\u8ad6\u5229\u7528\u4f4e\u7406\u8ad6\u89e3\u6790\u5ea6\u6e2c\u91cf\u7d50\u679c\u9810\u6e2c\u9ad8\u7406\u8ad6\u89e3\u6790\u5ea6\u7684\u6e2c\u91cf\u503c\u548c\u5be6\u969b\u6e2c\u91cf\u503c\u9593\u7684\u95dc\u4fc2\uff0c\u4e26\u548c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71(treatment planning system, TPS)\u8a08\u7b97\u7d50\u679c\u505aGamma index\u6bd4\u8f03\u3002\u7d50\u679c\uff1a\u6211\u5011\u767c\u73fe\u5229\u7528\u591a\u6b21\u79fb\u4f4d\u78ba\u5be6\u80fd\u6709\u6548\u589e\u52a0\u5291\u91cf\u5206\u5e03\u7684\u91cf\u6e2c\u89e3\u6790\u5ea6\uff0c\u4e14\u7406\u8ad6\u89e3\u6790\u5ea6\u548c\u7e3d\u91cf\u6e2c\u6b21\u6578\u662f\u6210\u6b63\u6bd4\u7684\u95dc\u4fc2\uff0c\u4e5f\u5c31\u662f\u5047\u5982\u8981\u7372\u5f974\u500d\u7406\u8ad6\u89e3\u6790\u5ea6\uff0c\u5247\u7e3d\u6e2c\u91cf\u6b21\u6578\u70ba4\u6b21\uff0c\u9032\u4e00\u6b65\u548c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u7684\u8a08\u7b97\u7d50\u679c\u505aGamma index\u6bd4\u8f03\u5f8c\uff0c\u8a8d\u70ba\u5229\u7528\u79fb\u4f4d4\u6b21\u6e2c\u91cf\u662f\u6700\u6709\u6548\u7387\u4e14\u53ef\u5f97\u5230\u8fd1\u4f3c\u65bc\u6cbb\u7642\u8a08\u756b\u76842\u7dad\u5291\u91cf\u5206\u5e03\uff0c\u7576\u7136\u5728\u6642\u9593\u5145\u8db3\u4e0b\uff0c\u79fb\u4f4d8\u6b21\u4f86\u505a\u6e2c\u91cf\uff0c\u80fd\u5f97\u5230\u8f03\u597d\u7684\u7d50\u679c\uff0c\u4f46\u53d7\u9650\u6e38\u96e2\u8154\u7684\u6709\u9650\u9ad4\u7a4d\uff0c\u5176\u6539\u5584\u6709\u9650\u3002\u7d50\u8ad6\uff1a\u5229\u7528\u7d44\u5408\u591a\u6b21\u79fb\u4f4d2D-Array\u6e2c\u91cf\u7684\u65b9\u5f0f\uff0c\u78ba\u5be6\u80fd\u6709\u6548\u589e\u52a0\u6e2c\u91cf\u7684\u89e3\u6790\u5ea6\u4e26\u8868\u73fe\u51fa\u771f\u5be6\u5291\u91cf\u5206\u5e03\uff0c\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u5291\u91cf\u9a57\u8b49\u4e0a\uff0c\u63d0\u4f9b\u4e86\u53e6\u4e00\u500b\u53ef\u884c\u7684\u65b9\u6cd5\u3002", "e": "Purpose : To investigate the feasibility of using PTW 2D-Array detecting system in IMRT dosimetric quality assurance, we propose a mathematical and efficient method. The method uses the multiple acquisition sequence to increase the resolution. Then the measured results and calculated results are analyzed and compared. Materials and Methods: We use PTW-seven29 2D Array as the detecting system and PTW-RW3 Slab Phantom as solid phantom. With 15 cm-thickness solid phantom and CT images, the dosimetric distribution is calculated by the treatment planning system (TPS). The phantom source surface distance (SSD) is 95 cm and the 2D distribution at the 5 cm depth is as the calculated result. By combining the measured results in different acquisition sequence, we can get the dosimetric distribution in different theory resolution. The relation between the low-resolution and high-resolution results is analyzed. In advance we combine the calculated result to get the Gamma index in different theory resolution. Results: We find that using the multiple acquisition sequence really increases the measured resolution in the 2D-Array detecting system. And the number of measuring times is direct ratio to the theoretic resolution. For example combining the four-times measures in different position can get the fourfold-theory resolution. In comparing the measured results with calculated results, the fourfold-theory resolution is the most efficient and passes the Gamma index test. However using eightfold-theory resolution is better but needs more time in quality assurance. Conclusions: We find that using the multiple acquisition sequence in the 2D-Array detecting system increases the measuring resolution and really is feasible in dosimetric quality assurance."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201412-201501060029-201501060029-327-331", "title": "A Case of Aortoesophageal Fistula Following Concurrent Chemoradiotherapy of Esophageal Cancer", "keywords": "\u4e3b\u52d5\u8108\u5167\u5957\u819c\u652f\u67b6;\u52a0\u5229\u6c0f\u4e09\u5408\u75c7;\u653e\u5c04\u7dda\u6cbb\u7642;\u7d93\u5c0e\u7ba1\u52d5\u8108\u6813\u585e Aortic endografting;Chiari", "c": "\u6211\u5011\u5831\u544a\u4e00\u4f4d\u4e94\u5341\u6b72\u7537\u6027\u7d93\u8a3a\u65b7\u70ba\u4e2d\u6bb5\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u7684\u60a3\u8005\uff0c\u5728\u63a5\u53d7\u540c\u6b65\u653e\u5316\u7642\u5f8c\u767c\u751f\u7f55\u898b\u4f46\u537b\u81f4\u547d\u7684\u98df\u9053\u52d5\u8108\u763b\u7ba1\u4f75\u767c\u75c7\u3002\u653e\u5c04\u6cbb\u7642\u4e43\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u65b9\u5f0f\uff0c\u7e3d\u8a08\u91cf\u70ba50.4 Gy\uff0c\u5206\u621028\u6b21\u7d66\u4e88\u3002\u6cbb\u7642\u7d50\u675f\u4e00\u500b\u6708\u5f8c\uff0c\u75c5\u60a3\u7a81\u767c\u5927\u91cf\u7684\u5410\u8840\u53ca\u4f4e\u5bb9\u6027\u4f11\u514b\uff0c\u7531\u65bc\u51fa\u8840\u7121\u6cd5\u63a7\u5236\uff0c\u5b89\u6392\u4e86\u8840\u7ba1\u651d\u5f71\uff0c\u5e0c\u671b\u85c9\u7531\u52d5\u8108\u6813\u585e\u6b62\u8840\uff0c\u5728\u986f\u5f71\u5291\u6e2c\u8a66\u671f\u770b\u5230\u4e86\u986f\u5f71\u5291\u6d41\u5165\u98df\u9053\uff0c\u9ad8\u5ea6\u61f7\u7591\u6709\u4e3b\u52d5\u8108\u5f13\u4e0b\u65b9\u7684\u98df\u9053\u52d5\u8108\u763b\u7ba1\u3002\u4f46\u7531\u65bc\u6c92\u6709\u627e\u5230\u660e\u78ba\u7684\u4f9b\u8840\u52d5\u8108\u5206\u652f\uff0c\u8840\u7ba1\u6813\u585e\u4e26\u672a\u9032\u884c\uff0c\u75c5\u4eba\u6539\u63a5\u53d7\u7dca\u6025\u7684\u4e3b\u52d5\u8108\u5167\u5957\u819c\u652f\u67b6\u624b\u8853\uff0c\u4e4b\u5f8c\u751f\u547d\u5fb5\u8c61\u6f38\u8da8\u7a69\u5b9a\u3002\u7136\u800c\uff0c\u75c5\u4eba\u5728\u79fb\u9664\u547c\u5438\u5668\u4e09\u5929\u5f8c\u51fa\u73fe\u4e86\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4\u4e14\u6b7b\u4ea1\u3002\u7531\u65bc\u4e3b\u52d5\u8108\u6709\u5f37\u97cc\u7684\u808c\u8089\u5c64\uff0c\u6211\u5011\u4e0d\u8a8d\u70ba\u4e2d\u7b49\u7684\u653e\u5c04\u7dda\u5291\u91cf\u6703\u76f4\u63a5\u9020\u6210\u6b64\u4f75\u767c\u75c7\uff0c\u53ef\u80fd\u75c5\u4eba\u5728\u63a5\u53d7\u5b8c\u653e\u5316\u7642\u5f8c\uff0c\u541e\u56a5\u56f0\u96e3\u6539\u5584\u800c\u5403\u4e86\u8f03\u5805\u786c\u7684\u98df\u7269\uff1b\u53e6\u5916\u5728\u6cbb\u7642\u4e2d\u5b89\u6392\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff0c\u986f\u793a\u7591\u4f3c\u816b\u7624\u4fb5\u72af\u81f3\u4e3b\u52d5\u8108\u5916\u58c1\uff0c\u7d9c\u5408\u4e0a\u8ff0\u56e0\u7d20\u9020\u6210\u76f8\u5c0d\u8f03\u8106\u5f31\u7684\u98df\u9053\u58c1\u548c\u4e3b\u52d5\u8108\u9593\u7684\u763b\u7ba1\u3002\u7531\u65bc\u6b64\u4f75\u767c\u75c7\u5f88\u5c11\uff0c\u7121\u6cd5\u7531\u904e\u53bb\u6848\u4f8b\u53bb\u6b78\u7d0d\u5206\u6790\u4e3b\u52d5\u8108\u7684\u95be\u503c\u5291\u91cf\u3002\u7136\u800c\uff0c\u6211\u5011\u4ecd\u9700\u4e86\u89e3\u9019\u81f4\u547d\u6027\u6975\u9ad8\u7684\u4f75\u767c\u75c7\u4e26\u4e14\u5728\u6cbb\u7642\u524d\u544a\u77e5\u75c5\u4eba\u3002", "e": "Aortoesophageal fistula (AEF) is a rare but lethal condition. Here, we present a case of AEF following concurrent chemoradiotherapy (CCRT). A 50-year-old man was diagnosed with squamous cell carcinoma of the middle third esophagus and was treated by CCRT with a total dose of 50.4 Gy in 28 fractions using IMRT. AEF developed within 1 month after completion of CCRT, with a presentation of massive hematemesis and hypovolemic shock. For uncontrolled bleeding, angiography for transcatheter arterial embolization was arranged. A subarcuate AEF was highly suspected with contrast flow along the esophagus noted in the contrast test series. No definite feeding arterial branch of the hemorrhagic lesion could be recognized, thus an embolizing procedure was not performed. Then he received emergent descending aortic endografting for AEF. His hemodynamic status and oxygenation became relatively stable. However, the patient developed acute respiratory distress syndrome and passed away three days later. The aorta consists of strong muscular layer, and we do not believe the moderate dose of radiotherapy alone induced such rare complication. We are inclined to assume that solid food induced a penetrating ulcer of the esophagus and thoracic aorta after improvement of dysphagia. Owing to the rare occurrence, it is hard to set a tolerance dose threshold to the aorta in treating tumors adjacent to it. Nevertheless, we still should keep in mind the possibility of this rare complication with substantial mortality and inform patients before beginning radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-155-174", "title": "Preliminary Outcome of Definitive Radical Radiotherapy for Adenocarcinoma of Prostate in an Era of Intensity-Modulated Radiotherapy: Experience of 564 Patients in a Medical Center in Taiwan", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u651d\u8b77\u817a\u764c;\u81e8\u5e8a\u7d50\u679c Intensity modulated radiotherapy (IMRT);Adenocarcinoma of prostate;Clinical outcome", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u5831\u544a\u672c\u9662\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u6642\u4ee3\uff0c\u4f7f\u7528\u4e3b\u7a0b\uff08definitive\uff09\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5728\u651d\u8b77\u817a\u817a\u764c\u7684\u521d\u6b65\u7642\u6548\u53ca\u6cbb\u7642\u6bd2\u6027\u7d50\u679c\uff0c\u4e26\u5206\u6790\u53ef\u80fd\u7684\u5f71\u97ff\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u57282003-2010\u5e74\u9593\uff0c\u9023\u7e8c564\u4f4d\u7121\u9060\u7aef\u8f49\u79fb\u7684\u651d\u8b77\u817a\u817a\u764c\u75c5\u4eba\uff0c\u5728\u672c\u9662\u5b8c\u6210\u4e3b\u7a0b\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u3002\u56de\u6eaf\u5206\u6790\u8ffd\u8e64\u4e2d\u4f4d\u6578\u70ba63\u500b\u6708\u3002\u5728CT\u6216MRI\u4e0a\uff0c\u6c92\u6709\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\uff08N0\uff09\u7684542\u4eba\u4e2d\uff0c\u4f9d\u7f8e\u570b\u570b\u5bb6\u7d9c\u5408\u764c\u75c7\u7db2\u7d61\uff08National Cancer Comprehensive Network, NCCN\uff09\u98a8\u96aa\u7fa4\u7d44\u70ba\u4f4e\u3001\u4e2d\u3001\u9ad8\u3001\u548c\u975e\u5e38\u9ad8\u98a8\u96aa\u7d44\u7684\u75c5\u4eba\uff0c\u5206\u5225\u670997\uff0817.2%\uff09\u3001181\uff0832.1%\uff09\u3001214\uff0837.9%\uff09\u3001\u548c50\uff088.9%\uff09\u4eba\u3002\u53e6\u5916\u670922\uff083.9%\uff09\u4eba\uff0c\u5728CT\u6216MRI\u4e0a\uff0c\u5224\u65b7\u6709\u5c40\u90e8\u7684\u6dcb\u5df4\u8f49\u79fb\uff08N1\uff09\u3002\u8655\u65b9\u5291\u91cf\u7684\u4e2d\u4f4d\u6578\u70ba78 Gy\u3002\u5728\u672c\u9662\u63a5\u53d7\u904e\u96c4\u6027\u7d20\u6291\u5236\u7642\u6cd5\uff08Androgren Deprivation Therapy, ADT\uff09\u6709453\u4eba\uff0880.3%\uff09\uff0c\u5176\u4e2d62\u4eba\uff0811%\uff09\u63a5\u53d7\u8d85\u904e\u5169\u5e74\u7684\u8f14\u52a9\u6027ADT\u3002\u7d50\u679c\uff1a\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\uff08OS\uff09\u70ba90.3%\uff0c\u4e94\u5e74\u75be\u75c5\u7279\u5b9a\u5b58\u6d3b\u7387\uff08DSS\uff09\u70ba97.9%\uff0c\u4e94\u5e74\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\uff08DMFS\uff09\u70ba94.1%\u3002\u4e94\u5e74\u7121\u751f\u5316\u5931\u6557\u5b58\u6d3b\u7387\uff08Biochemical Failure Free Survival, BFFS\uff09\u70ba87.1%\uff0c\u5728NCCN\u4f4e\u3001\u4e2d\u3001\u9ad8\u3001\u548c\u975e\u5e38\u9ad8\u98a8\u96aa\u7fa4\u7d44\u7684\u75c5\u4eba\uff0c\u5206\u5225\u70ba98.2%, 94.6%, 81.2%\u548c75.7%\uff0c\u5728N1\u7d44\u5247\u70ba49.9%\u3002\u9ad8\u548c\u975e\u5e38\u9ad8\u98a8\u96aa\u7d44\u7684BFFS\u9810\u5f8c\uff0c\u9700\u8981MRI\u624d\u80fd\u986f\u8457\u5340\u5206\u3002\u591a\u8b8a\u6578Cox\u8ff4\u6b78\u5206\u6790\u767c\u73fe\uff0c\u8f03\u9ad8\u7684\u816b\u7624\u5c40\u90e8\u4fb5\u72af\u98a8\u96aa\u5206\u7d44\uff08risk group\uff09\u3001Gleason\u5206\u6578\u98a8\u96aa\u5206\u7d44\u3001\u521d\u59cbPSA\u503c\u98a8\u96aa\u5206\u7d44\u3001\u548c\u5e74\u9f6180\u6b72\u4ee5\u4e0a\uff0c\u70ba\u986f\u8457\u7684BFFS\u98a8\u96aa\u56e0\u5b50\u3002\u9aa8\u76c6\u6dcb\u5df4\u7167\u5c04\u6703\u589e\u52a0\u6025\u6027\u8178\u80c3\u9053\uff08GI\uff09\u6bd2\u6027\uff0c\u6bd4\u503c\u6bd4\u70ba1.486\uff0895%\u4fe1\u8cf4\u5340\u9593\uff1a1.059-2.086\uff09\u3002\u5728\u4e09\u7d1a\u4ee5\u4e0a\u7684\u5ef6\u9072\u6bd2\u6027\u65b9\u9762\uff0c\u6ccc\u5c3f\u9053\uff08GU\uff09\u670923\u4f4d\uff084.1%\uff09\uff0cGI\u670933\u4f4d\uff085.9%\uff09\u75c5\u4eba\u3002\u5728\u6700\u5f8c\u4e00\u6b21\u8a2a\u67e5\u4ecd\u6709\u4e09\u7d1a\u4ee5\u4e0a\u5ef6\u9072\u6bd2\u6027\u8005\uff0cGU\u67094\u4f4d\uff080.7%\uff09\uff0cGI\u67091\u4f4d\uff080.2%\uff09\u3002\u591a\u8b8a\u6578\u5206\u6790\u767c\u73fe\uff0c\u76f4\u8178\u5291\u91cf\uff1e 48 Gy\u662f\u5f71\u97ff\u51fa\u8840\u552f\u4e00\u986f\u8457\u7684\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u521d\u6b65\u5224\u65b7\u672c\u9662\u7642\u6548\uff0c\u8207\u6587\u737b\u4e2d\u4f7f\u7528IMRT\u7684\u7d50\u679c\u76f8\u7576\u3002\u8f03\u9ad8\u98a8\u96aa\u5206\u7d44\u7684\u816b\u7624\u5c40\u90e8\u4fb5\u72af\u3001Gleason\u5206\u6578\u3001\u548c\u521d\u59cbPSA\u503c\u3001\u4ee5\u53ca\u5e74\u9f6180\u6b72\u4ee5\u4e0a\uff0c\u70ba\u986f\u8457\u7684BFFS\u98a8\u96aa\u56e0\u5b50\u3002\u9aa8\u76c6\u6dcb\u5df4\u7167\u5c04\u7565\u70ba\u589e\u52a0\u6025\u6027GI\u6bd2\u6027\u3002\u5728\u9810\u5f8c\u5224\u65b7\u4e0a\uff0cMRI\u8f03CT\u6b63\u78ba\u3002\u76f4\u8178\u51fa\u8840\u8207\u9ad8\u5291\u91cf\u6709\u95dc\u3002", "e": "Purpose : We here report the preliminary treatment and toxicity outcome of definitive radical radiotherapy for patients with adenocarcinoma of prostate in an era of intensity modulated radiotherapy (IMRT) in our institution and analyze the possible prognostic factors. Materials and Methods : During 2003 and 2010, 564 consecutive patients with adenocarcinoma of prostate receiving radical definitive radiotherapy in our institution were retrospectively reviewed with a median follow-up of 63 months. Among the 542 patients without evident lymphadenopathy (N0) on CT or MRI, there were 97 (17.2%), 181 (32.1%), 214 (37.9%), and 50 (8.9%) in low, intermediate, high, and very high risk groups respectively, based on the National Comprehensive Cancer Network (NCCN) risk classification criteria. Another 22 (3.9%) patients showed regional lymphadenopathy (N1). Median prescription dose was 78 Gy. There were 453 (80.3%) patients receiving androgen deprivation therapy (ADT). Among them, 62 (11.1%) received adjuvant ADT for more than 2 years. Results : The 5-year overall survival (OS), disease specific survival (DSS), distant metastasis free survival (DMFS) and biochemical failure free survival (BFFS) of all patients were 90.3%, 97.9%, 94%, and 87.1% respectively. The 5-year BFFS were 98.2%, 94.6%, 81.2%, and 75.7% for patients of low, intermediate, high, and very high risk groups, respectively. For patients with N1 disease, the 5-year BFFS was down to 49.9%. The difference of BFFS between patients of high and very high risk groups was significant only in those who had MRI for staging. Multivariate Cox regression analysis showed that T-stage, Gleason score, and initial PSA risk groups, and age of 80 or older were significant risk factors of BFFS. Pelvic irradiation significantly increased acute GI toxicity with odds ratio of 1.486 (95% confidence interval 1.059-2.086). Grade 3 or more late toxicity was noted in 23 patients (4.1%) in GU system and 33 patients (5.9%) in GI system. Only 4 (0.7%) patients had persistent GU toxicity and 1 (0.2%) had persistent GI toxicity at the last follow-up date. Multivariate Cox regression showed the mean dose to rectum above 48 Gy to be the only significant factor for late GI bleeding. Conclusions : The treatment outcome of our institution was comparable to published results of IMRT. The higher risk groups of T stage, Gleason score, initial PSA, and age of 80 or older, were significant risk factors for BFFS. Pelvic irradiation modestly increased acute GI toxicity. MRI was more accurate for BFFS prognosis. Late GI bleeding was associated with a mean dose above 48 Gy to the rectum."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-175-190", "title": "Treatment Outcome in Women with Operable HER 2-Positive Breast Cancer: A single Institutional Report", "keywords": "\u4eba\u985e\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u7b2c\u4e8c\u578b\u63a5\u53d7\u5668\uff08HER-2\uff09;\u8f14\u52a9\u6027\u8cc0\u764c\u5e73;\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb;\u9810\u5f8c\u56e0\u5b50;\u4e73\u764c Human epidermal growth factor receptor 2 (HER-2);Adjuvant trastuzumab;Central nervous system metastasis;Prognostic factors;Breast cancer", "c": "\u76ee\u7684\uff1a\u8a31\u591a\u7814\u7a76\u767c\u73fe\uff0c\u8cc0\u764c\u5e73\u6cbb\u7642\u5c0d\u4eba\u985e\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u7b2c\u4e8c\u578b\u63a5\u53d7\u5668\u967d\u6027\u4e4b\u4e73\u764c\u60a3\u8005\u6709\u5e6b\u52a9\uff0c\u4f46\u662f\u589e\u52a0\u8166\u90e8\u8f49\u79fb\u4e4b\u6a5f\u6703\uff0c\u6211\u5011\u5831\u544a\u6211\u5011\u6a5f\u69cb\u4ee5\u8cc0\u764c\u5e73\u6cbb\u7642\u53ef\u958b\u5200\u4e4b\u4eba\u985e\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u7b2c\u4e8c\u578b\u63a5\u53d7\u5668\u967d\u6027\u4e73\u764c\u60a3\u8005\uff0c\u5176\u6cbb\u7642\u6210\u6548\u53ca\u6cbb\u7642\u5931\u6557\u4e4b\u8868\u73fe\uff1b\u6b64\u5916\u5c08\u6ce8\u5728\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u8f49\u79fb\u4e4b\u767c\u884c\u7387\u53ca\u80fd\u9810\u6e2c\u6709\u8f03\u9ad8\u6a5f\u6703\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u8f49\u79fb\u75c5\u4eba\u4e4b\u56e0\u5b50\u3002\u65b9\u6cd5\u53ca\u6750\u6599\uff1a\u6211\u5011\u56de\u6714\u6027\u5206\u6790243\u4f4d\u53ef\u958b\u5200\u4e4b\u4eba\u985e\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u7b2c\u4e8c\u578b\u63a5\u53d7\u5668\u967d\u6027\u4e4b\u5973\u59d3\u4e73\u764c\u60a3\u8005\uff0c\u60a3\u8005\u65bc2002\u5e746\u6708\u81f32011\u5e7412\u6708\u671f\u9593\u5728\u6211\u5011\u91ab\u9662\u8a3a\u65b7\u53ca\u6cbb\u7642\u3002\u6240\u6709\u75c5\u4eba\u4e4b\u816b\u7624\u7686\u5927\u65bc2\u516c\u5206\u6216\u8005\u6709\u6dcb\u5df4\u8f49\u79fb\uff0c\u4e14\u63a5\u53d7\u8853\u5f8canthracycline\u70ba\u4e3b\u4e4b\u5316\u5b78\u85e5\u7269\u6cbb\u7642\u5408\u4f75\u6216\u6c92\u6709\u63a5\u53d7\u8cc0\u764c\u5e73\u3002\u8ddf\u64da\u8ffd\u8e64\u4e2d\u51fa\u73fe\u4e4b\u81e8\u5e8a\u75c7\u72c0\u52a0\u4e0a\u795e\u7d93\u5f71\u50cf\u4e4b\u6aa2\u67e5\u8a3a\u65b7\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u8f49\u79fb\u3002\u6211\u5011\u4f30\u7b97\u7121\u4e8b\u4ef6\u5b58\u6d3b\u7387\uff0c\u6574\u9ad4\u5b58\u6d3b\u7387\uff0c\u4ee5\u53ca\u7121\u8166\u8f49\u79fb\u5b58\u6d3b\u7387\uff1b\u4e26\u8a55\u4f30\u81e8\u5e8a\u53ca\u75c5\u7406\u56e0\u5b50\u5c0d\u9810\u5f8c\u4e4b\u5f71\u97ff\u3002\u6211\u5011\u4e5f\u5206\u6790\u9810\u6e2c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u8f49\u79fb\u4e4b\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u7d9363.57\u500b\u6708\u7684\u8ffd\u8e64\uff0c\u6574\u9ad4\u4e4b5\u5e74\u7121\u4e8b\u4ef6\u5b58\u6d3b\u7387\uff0c\u6574\u9ad4\u5b58\u6d3b\u7387\uff0c\u53ca\u7121\u8166\u8f49\u79fb\u5b58\u6d3b\u7387\u5206\u5225\u70ba72%\u300185%\u548c92%\u300260\u500b\u4e8b\u4ef6\u4e2d\u670943\u500b\u662f\u9060\u7aef\u8f49\u79fb\uff0871.7%\uff09\uff0c\u662f\u6cbb\u7642\u5931\u6557\u7684\u4e3b\u56e0\u3002\u6839\u64da\u4e0d\u540c\u4e8b\u4ef6\u985e\u578b\u8a08\u7b97\u4e4b5\u5e74\u7d2f\u7a4d\u767c\u751f\u7387\u5206\u5225\u70ba\uff1a\u5c40\u90e8\u5fa9\u767c4.7%\uff0c\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb2.57%\uff0c\u975e\u4e2d\u6a1e\u795e\u7d93\u4e4b\u9060\u7aef\u8f49\u79fb15.83%\uff0c\u7b2c\u4e8c\u539f\u767c\u816b\u76241.46%\uff0c\u53ca\u975e\u816b\u7624\u5f15\u8d77\u4e4b\u6b7b\u4ea10.4%\u3002\u6240\u6709\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb\u4e2d\uff0c\u5176\u4e2d\u67096\u4f4d\u662f\u7b2c\u4e00\u500b\u6cbb\u7642\u5931\u6557\u7684\u5730\u65b9\uff0c\u5176\u4e2d10\u4f4d\u767c\u751f\u5728\u5176\u4ed6\u8f49\u79fb\u4e4b\u5f8c\u3002\u672a\u63a5\u53d7\u8f14\u52a9\u6027\u8cc0\u764c\u5e73\u6cbb\u7642\uff0c\u8d85\u904e9\u9846\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u53ca\u771f\u76ae\u5c64\u4fb5\u72af\u5728\u55ae\u4e00\u6216\u591a\u8b8a\u6578\u5206\u6790\u7686\u9810\u6e2c\u8f03\u5dee\u4e4b\u7121\u4e8b\u4ef6\u5b58\u6d3b\u7387\uff08p=0.001, \uff1c 0.001, 0.042\uff09\uff0c\u9019\u4e9b\u56e0\u5b50\u540c\u6a23\u53ef\u9810\u6e2c\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u7121\u767c\u73fe\u7279\u5225\u4e4b\u56e0\u5b50\u53ef\u4f9b\u9810\u6e2c\u4ee5\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb\u70ba\u7b2c\u4e00\u8868\u73fe\u4e4b\u8f49\u79fb\uff085\u5e74\u7d2f\u7a4d\u767c\u751f\u7387\u5728\u63a5\u53d7\u6216\u672a\u63a5\u53d7\u8cc0\u764c\u5e73\u4e4b\u75c5\u4eba\u70ba1.86%\u53ca3.02%, p=0.633\uff09\u3002\u8d85\u904e9\u9846\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u6dcb\u5df4\u8840\u7ba1\u4fb5\u72af\uff0c\u53ca\u816b\u7624\u5206\u5316\u7b49\u7d1a\u8f03\u9ad8\u6703\u6709\u8f03\u5dee\u4e4b\u7121\u8166\u8f49\u79fb\u5b58\u6d3b\u7387\uff08p= 0.043, \uff1c 0.001, \uff1c 0.001\uff09\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u8f14\u52a9\u6027\u8cc0\u764c\u5e73\u6539\u5584\u7b2c\u4e8c\u3001\u4e09\u671f\u5177\u4eba\u985e\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u7b2c\u4e8c\u578b\u63a5\u53d7\u5668\u967d\u6027\u4e4b\u4e73\u764c\u60a3\u8005\u4e4b\u7121\u4e8b\u4ef6\u5b58\u6d3b\u7387\u53ca\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u6211\u5011\u7684\u6578\u64da\u986f\u793a\u4f7f\u7528\u8f14\u52a9\u6027\u8cc0\u764c\u5e73\u4e26\u672a\u589e\u52a0\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb\u4e4b\u6a5f\u7387\u3002\u75c5\u4eba\u6709\u8d85\u904e9\u9846\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u6dcb\u5df4\u8840\u7ba1\u4fb5\u72af\uff0c\u53ca\u816b\u7624\u5206\u5316\u7b49\u7d1a\u8f03\u9ad8\u7b49\u56e0\u5b50\u53ef\u8003\u616e\u65bc\u8ffd\u8e64\u6642\u52a0\u4e0a\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5\u3002\u4e0d\u904e\u4ecd\u9700\u66f4\u5927\u578b\u7814\u7a76\u4e4b\u6578\u64da\u4f86\u6c7a\u5b9a\u54ea\u4e9b\u75c5\u4eba\u662f\u8f03\u5bb9\u6613\u767c\u751f\u4e2d\u6a1e\u795e\u7d93\u8f49\u79fb\u3002", "e": "Purpose: Women with HER-2 overexpressing breast carcinoma benefit from trastuzumab-based systemic therapy despite the awareness of increasing risk of brain failure from this treatment modality among several studies. We report the treatment outcome and patterns of failure in women with operable HER2-positive breast cancer using trastuzumab as adjuvant setting at our institution, furthermore, focus on the incidence of central nervous system failure and the predictors for those with high risk of developing CNS relapse. Method and Material: We retrospectively identified 243 women with HER2-positive operable breast cancer diagnosed and treated at our institution between June 2002 and December 2011. All patients with tumor size more than two centimeters or any positive lymph node received adjuvant anthracycline-based chemotherapy with or without trastuzumab. Central nervous system failure was recognized through clinical symptoms and neuro-images during follow up. We estimated the event - free survival (EFS), overall survival (OS), and brain-metastasis free survival (BMFS) using Kaplan-Meier method, and performed cox-proportional hazards models to assess the impact of clinical-pathologic parameters on EFS, OS. The covariates for predicting CNS relapse either as first site or as sequential event during follow up were also analyzed. Results: With median follow up of 63.57 months (range 8.8~132.4months) of entire cohort, the five year event-free survival rate, overall survival rate, and brain-metastasis free survival was 72%, 85%, and 92%, respectively. Forty-three of sixty first events (71.7%) were distal relapse which remained the main failure type of our cohort. The five year cumulative incidence of different first events, included loco-regional recurrence, CNS relapse, distal non-CNS relapse, second primary, and non-cancer death, were 4.7%, 2.57%, 15.83%, 1.46%, and 0.4%. Central nervous system failure either as first site of recurrence or as a sequential event was noted in six and ten women. No adjuvant trastuzumab, positive lymph node number more than nine, and dermis involvement significantly predicted poorer event free survival on uni-and-multivariate analysis(p= 0.001, \uff1c 0.001, 0.042, respectively). These factors also translated in predicting overall survival. No significant predictor was noted for the occurrence of CNS relapse as first site (5-year cumulative incidence: 1.86% and 3.02% in patients with or without adjuvant trastuzumab, p= 0.633). The negatively prognostic factors for brain-metastasis free survival were positive lymph node number more than nine, lymphovascular invasion, and high grade tumor (p= 0.043, \uff1c0.001, and \uff1c0.001, respectively). Conclusion: Using adjuvant trastuzumab improves event-free survival and overall survival in women with stage II /III HER2-positive breast cancer. The development of CNS relapse did not increase in our patients receiving trastuzumab based adjuvant therapy. Brain image as part of follow up might be considered, especially for those with positive lymph node number more than nine, high grade tumor, and with lymphovascular invasion. Larger prospective data or data from published randomized trials is needed for determining patients with high risks of developing CNS relapse."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-191-199", "title": "Fractionated Stereotactic Radiotherapy for Choroidal Melanoma", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642;\u8108\u7d61\u819c\u9ed1\u8272\u7d20\u7624;\u8996\u529b\u4fdd\u7559 Choroidal melanoma;Stereotactic radiotherapy;Visual acuity preservation", "c": "\u76ee\u6a19\uff1a\u96d6\u7136\u8108\u7d61\u819c\u9ed1\u8272\u7d20\u7624\u662f\u6700\u5e38\u898b\u7684\u773c\u775b\u539f\u767c\u60e1\u6027\u816b\u7624\uff0c\u4f46\u662f\u5728\u53f0\u7063\u4ecd\u662f\u8f03\u70ba\u7f55\u898b\u7684\u75be\u75c5\u3002\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u5e0c\u671b\u80fd\u5920\u4e86\u89e3\u4f7f\u7528\u7acb\u9ad4\u5b9a\u4f4d\u5be1\u5206\u6b21\u5149\u5b50\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u6b64\u75be\u75c5\u7684\u6cbb\u7642\u6548\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2009\u52302012\u5e74\uff0c\u5171\u67096\u4f4d\u8108\u7d61\u819c\u9ed1\u8272\u7d20\u7624\u7684\u75c5\u60a3\u62d2\u7d55\u63a5\u53d7\u773c\u7403\u6458\u9664\u624b\u8853\u4e26\u4e14\u4f7f\u7528\u76f4\u7dda\u52a0\u901f\u5668\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u9ad4\u5916\u7167\u5c04\u6cbb\u7642\u3002\u7e3d\u5291\u91cf\u70ba50 Gy\u4e26\u5206\u70ba5\u6b21\u9032\u884c\u3002\u6240\u6709\u7684\u75c5\u60a3\u65bc\u653e\u5c04\u6cbb\u7642\u524d\u4ee5\u53ca\u6cbb\u7642\u5f8c\u8ffd\u8e64\u7686\u9700\u8981\u63a5\u53d7\u773c\u79d1\u8a73\u7d30\u7684\u6aa2\u67e5\uff0c\u5305\u62ec\uff1a\u8996\u529b\u4ee5\u53ca\u773c\u5e95\u93e1\u6aa2\u67e5\u3002\u6b64\u5916\uff0c\u96fb\u8166\u65b7\u5c64\u4e5f\u6703\u5728\u6cbb\u7642\u5f8c\u7528\u65bc\u8ffd\u8e64\u816b\u7624\u7684\u6cbb\u7642\u6548\u679c\u53cd\u61c9\u3002\u7d50\u679c\uff1a\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u4e00\u5171\u4e09\u4f4d\u75c5\u60a3\u6709\u4e2d\u578b\u7684\u816b\u7624\uff0c\u53e6\u5916\u4e09\u4f4d\u64c1\u6709\u5927\u578b\u7684\u816b\u7624\u3002\u816b\u7624\u9ad8\u5ea6\u7684\u4e2d\u4f4d\u6578\u70ba9.3 mm\uff0c\u5e95\u90e8\u76f4\u5f91\u4e2d\u4f4d\u6578\u70ba13.4 mm\uff0c\u4ee5\u53ca\u9ad4\u7a4d\u4e2d\u4f4d\u6578\u70ba0.94\u7acb\u65b9\u516c\u5206\u3002\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba29\u500b\u6708\uff0c\u4e09\u5e74\u7684\u5c40\u90e8\u63a7\u5236\u3001\u9060\u7aef\u8f49\u79fb\u63a7\u5236\u4ee5\u53ca\u6574\u9ad4\u5b58\u6d3b\u7387\u7686\u70ba100%\u3002\u6709\u4e00\u4f4d\u75c5\u60a3\u5728\u63a5\u53d7\u6cbb\u7642\u768425\u500b\u6708\u5f8c\uff0c\u56e0\u70ba\u6cbb\u7642\u5f8c\u7522\u751f\u7684\u65b0\u751f\u8840\u7ba1\u578b\u9752\u5149\u773c\u800c\u63a5\u53d7\u773c\u7403\u6458\u9664\u624b\u8853\u3002\u5728\u56db\u4f4d\u6cbb\u7642\u524d\u8996\u529b\u5927\u65bc0.1\u7684\u75c5\u60a3\u4e2d\uff0c\u6709\u4e09\u4f4d\u4ecd\u7136\u80fd\u5920\u5728\u6cbb\u7642\u5f8c\u4fdd\u7559\u8996\u529b\u3002\u5176\u4e2d\u6709\u4e00\u4f4d34\u6b72\u7684\u75c5\u60a3\u65bc\u63a5\u53d7\u6cbb\u764224\u500b\u6708\u5f8c\uff0c\u767c\u751f\u4e86\u767d\u5167\u969c\u7684\u60c5\u6cc1\u5f71\u97ff\u8996\u529b\uff0c\u4e26\u4e14\u5728\u63a5\u53d7\u4e86\u4eba\u5de5\u6c34\u6676\u9ad4\u7f6e\u63db\u624b\u8853\u5f8c\u6062\u5fa9\u4e86\u90e8\u5206\u7684\u8996\u529b\u3002\u7d50\u8ad6\uff1a\u6b64\u7814\u7a76\u986f\u793a\u7e3d\u5291\u91cf\u70ba50 Gy\u5206\u70ba5\u6b21\u7684\u7acb\u9ad4\u5b9a\u4f4d\u5be1\u5206\u6b21\u5149\u5b50\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u8108\u7d61\u819c\u9ed1\u8272\u7d20\u7624\u6709\u8457\u826f\u597d\u7684\u5c40\u90e8\u63a7\u5236\u7387\u3002\u4fdd\u7559\u8996\u529b\u4ee5\u53ca\u6e1b\u5c11\u653e\u5c04\u6cbb\u7642\u5f15\u8d77\u7684\u65b0\u751f\u8840\u7ba1\u578b\u9752\u5149\u773c\u662f\u6211\u5011\u4ecd\u820a\u9700\u8981\u5728\u672a\u4f86\u52aa\u529b\u7684\u76ee\u6a19\u3002", "e": "Purpose/Objectives: Although choroidal melanoma is a relatively rare disease in Taiwan, this study aimed to investigate the feasibility of using linear accelerator based hypofractionated stereotactic radiotherapy (SRT) for choroidal melanoma. Materials and Methods: From 2009 to 2012, 6 patients with choroidal melanoma were treated for a total dose of 50 Gy in 5 fractions with SRT. All patients underwent image studies (CT or MRI) and ophthalmologic examination, including visual acuity, funduscopy and ultrasound, before and regularly after treatment. In this study, three patients had medium-sized tumors (tumor height \u2264 10 mm and tumor base \u2264 16 mm) and the other three had large-sized tumors (tumor height \uff1e10 mm or tumor base \uff1e16 mm). Results: With a median follow-up duration of 29 months, the 3-year local control, distant metastasis free and overall survival were all 100%. One patient had enucleation due to the development of radiation-induced neovascular glaucoma after 25 months. In addition, one patient developed a cataract after 24 months and received an intraocular lens implant. Among the four patients with pre-treatment visual acuity \uff1e0.1(VA), VA was preserved in 3 patients. Conclusions: Our study supports the theory that hypofractionated SRT with 50Gy applied in five fractions seems to be sufficient to obtain good tumor control. More efforts should be made to reduce the radiation-induced neovascular glaucoma and preserve visual acuity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-201-209", "title": "\u9f3b\u54bd\u764c\u75c5\u4eba\u7d93\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u53ca\u526f\u4f5c\u7528\u4e4b\u8b8a\u5316", "keywords": "\u526f\u4f5c\u7528;\u6982\u5316\u4f30\u8a08\u65b9\u7a0b\u5f0f;\u9f3b\u54bd\u764c;\u751f\u6d3b\u54c1\u8cea Complication;Generalized estimating equation;Nasopharyngeal carcinoma;Quality of life", "c": "\u76ee\u7684\uff1a\u63cf\u8ff0\u9f3b\u54bd\u764c\u75c5\u4eba\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u53ca\u526f\u4f5c\u7528\u7684\u8b8a\u5316\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7e3d\u5171\u6709\u5169\u6a5f\u69cb288\u4f4d\u9f3b\u54bd\u764c\u60a3\u8005\u88ab\u9080\u8acb\u53c3\u8207\u7814\u7a76\u3002\u6240\u6709\u75c5\u4eba\u5747\u7b26\u5408\u9f3b\u54bd\u90e8\u63a5\u53d7\u653e\u5c04\u5291\u91cf\u4e0d\u4f4e\u65bc70 Gy\u3001\u9838\u90e8\u63a5\u53d7\u653e\u5c04\u5291\u91cf\u4e0d\u4f4e\u65bc50 Gy\u3002\u65bc\u6cbb\u7642\u524d\u3001\u6cbb\u7642\u7d50\u675f\u3001\u6cbb\u7642\u7d50\u675f\u5f8c1\u30013\u30016\u300112\u300118\u548c24\u500b\u6708\uff0c\u4f7f\u7528\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08European Organization for Research and Treatment of Cancer, EORTC\uff09\u7684EORTC QLQ-C30\u53caEORTC QLQ-H&N35\u91cf\u8868\u8a55\u4f30\u5176\u5065\u5eb7\u76f8\u95dc\u7684\u751f\u6d3b\u54c1\u8cea\u53ca\u526f\u4f5c\u7528\u3002\u4ee5\u6982\u5316\u4f30\u8a08\u65b9\u7a0b\u5f0f\uff08generalized estimating equation\uff09\u5206\u6790\u6642\u9593\u3001\u75c5\u4eba\u500b\u4eba\u56e0\u7d20\u3001\u75be\u75c5\u8207\u6cbb\u7642\u76f8\u95dc\u8b8a\u9805\u5c0d\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u53ca\u526f\u4f5c\u7528\u4e4b\u5f71\u97ff\u6548\u679c\u3002\u7d50\u679c\uff1a\u8207\u6cbb\u7642\u524d\u76f8\u8f03\uff0c\u9f3b\u54bd\u764c\u65bc\u6cbb\u7642\u7d50\u675f\u6642\u4e4b\u6574\u9ad4\u751f\u6d3b\u54c1\u8cea\u8207\u529f\u80fd\u72c0\u6cc1\u6700\u5dee\u3002\u6574\u9ad4\u751f\u6d3b\u54c1\u8cea\u65bc\u6cbb\u7642\u7d50\u675f\u5f8c1\u500b\u6708\u5373\u8fc5\u901f\u6062\u5fa9\u4e14\u7a69\u5b9a\u589e\u52a0\uff0c\u7136\u800c\u75c5\u4eba\u7684\u6574\u9ad4\u529f\u80fd\u72c0\u6cc1\uff0c\u5247\u76f4\u81f3\u653e\u5c04\u6cbb\u7642\u5f8c12\u500b\u6708\u624d\u6062\u5fa9\uff0c\u5f62\u6210\u5ef6\u9072\u6548\u61c9\u3002\u4e3b\u8981\u526f\u4f5c\u7528\u7684\u6e1b\u7de9\u5448\u73fe\u5f88\u5927\u5dee\u7570\uff1a\u8aaa\u8a71\u554f\u984c\u65bc\u6cbb\u7642\u5f8c12\u500b\u6708\u7de9\u89e3\uff0c\u75bc\u75db\u8207\u5f35\u5634\u554f\u984c\u5206\u5225\u65bc18\u53ca24\u500b\u6708\u6e1b\u7de9\uff0c\u90e8\u5206\u526f\u4f5c\u7528\u5982\u53e3\u4e7e\u3001\u553e\u6db2\u9ecf\u7a20\u53ca\u541e\u56a5\u554f\u984c\u76f4\u81f3\u6cbb\u7642\u5f8c24\u500b\u6708\u4ecd\u7136\u8f03\u6cbb\u7642\u524d\u70ba\u9ad8\u3002\u7d50\u8ad6\uff1a\u653e\u5c04\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u8207\u526f\u4f5c\u7528\u5448\u73fe\u5f88\u5927\u5dee\u7570\u4e14\u8207\u6642\u9593\u76f8\u95dc\u3002\u672c\u7814\u7a76\u53ef\u5e6b\u52a9\u81e8\u5e8a\u91ab\u5e2b\u8a55\u4f30\u6cbb\u7642\u76f8\u95dc\u4e4b\u526f\u4f5c\u7528\u98a8\u96aa\uff0c\u4e26\u5c0d\u5176\u63d0\u4f9b\u9f3b\u54bd\u764c\u75c5\u4eba\u6cbb\u7642\u5f8c\u7684\u5fa9\u5065\u3001\u5fc3\u7406\u8aee\u5546\u53ca\u885b\u6559\u7167\u8b77\u6709\u6240\u52a9\u76ca\u3002", "e": "Purpose: To describe the change of quality of life (QoL) and complications in patients with nasopharyngeal carcinoma (NPC) after treatment. Materials and Methods: Total 288 NPC patients in two institutions were invited to participate; all the patients received radiation doses of at least 70 Gy to the nasopharynx and at least 50 Gy to the neck. Health-related QoL and complications of the patients were evaluated by the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the EORTC head and neck module (QLQ-H&N35) before treatment, end of treatment, and 1, 3, 6, 12, 18 and 24 months after treatment. The effects of time, demographic, disease-related and treatmentrelated variables to QoL and complications were analyzed by the generalized estimating equation. Results: Comparing to pre-treatment, the NPC patients had the worst global QoL and functional status after completion of radiotherapy. The global QoL status improved rapidly at 1 month post-treatment and increased steadily, however, the global functional status had a delayed effect that patient recovered until 12 months after radiotherapy. The alleviations of the major complications were quite different. Speech problem was resolved at 12 months after treatment, pain at 18 months, the problem of open mouth at 24 months, but some complications such as dry mouth, sticky saliva and difficult swallowing still persist even 24 months after treatment. Conclusion: The QoL and complications show wide variations and time dependent. Our study can aid clinical physicians in assessing the risk of complications related to treatment, and help them in providing rehabilitation, consultation and supportive care to NPC patients after completion of treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-211-221", "title": "Treating Intact Cervical Cancer with Intensity-Modulated Radiotherapy: Maximized Bladder-Filling Change and Tumor Extent Are Associated with Organ Motion", "keywords": "\u5b50\u5bae\u9838\u764c;\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5668\u5b98\u79fb\u52d5 Cervical cancer;Delta volume of bladder;IMRT;Organ motion", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5b50\u5bae\u9838\u764c\u75c5\u4eba\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4f5c\u70ba\u6839\u9664\u6027\u6cbb\u7642\u6642\uff0c\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u5c0d\u65bc\u76ee\u6a19\u5668\u5b98\u79fb\u52d5\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9023\u7e8c22\u4f4d\u5b50\u5bae\u9838\u764c\u75c5\u4eba\uff08FIGO\u5206\u671fIB-IVB\uff09\u63a5\u53d7\u9aa8\u76c6\u8154\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e26\u7d0d\u5165\u5206\u6790\u3002\u6bcf\u4f4d\u75c5\u4eba\u7686\u63a5\u53d7\u5169\u7d44\u6cbb\u7642\u8a08\u756b\u7528\u96fb\u8166\u65b7\u5c64\uff0c\u4e00\u7d44\u70ba\u6f32\u5c3f\u72c0\u614b\uff0c\u53e6\u4e00\u7d44\u70ba\u6392\u5c3f\u72c0\u614b\u3002\u653e\u5c04\u6cbb\u7642\u4e4b\u76ee\u6a19\u8207\u6b63\u5e38\u7d44\u7e54\u52fe\u52d2\u53c3\u7167\u8a3a\u65b7\u7528\u6838\u78c1\u5171\u632f\u8207\u6700\u65b0\u81e8\u5e8a\u6307\u5f15\uff0c\u5206\u5225\u5728\u5169\u7d44\u6cbb\u7642\u8a08\u756b\u96fb\u8166\u65b7\u5c64\u4e0a\u5b8c\u6210\u3002\u5176\u4e2d\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\uff08DVB\uff09\u5b9a\u7fa9\u70ba\u6f32\u5c3f\u53ca\u6392\u5c3f\u5f8c\u5169\u7d44\u96fb\u8166\u65b7\u5c64\u4e0a\u7684\u8180\u80f1\u9ad4\u7a4d\u5dee\u7570\u3002\u5b50\u5bae\u9838\u816b\u7624\u53ca\u5b50\u5bae\u9ad4\u7684\u5e7e\u4f55\u4e2d\u5fc3\uff08centroid position\uff09\u5728\u5169\u7d44\u96fb\u8166\u65b7\u5c64\u4e0a\u7d93\u7531\u6cbb\u7642\u8a08\u5283\u8edf\u9ad4\u904b\u7b97\u6c7a\u5b9a\u3002\u6211\u5011\u89c0\u5bdf\u5b50\u5bae\u9838\u816b\u7624\u53ca\u5b50\u5bae\u9ad4\u7684\u5e7e\u4f55\u4e2d\u5fc3\u5728\u5169\u7d44\u96fb\u8166\u65b7\u5c64\u4e0a\u7684\u79fb\u52d5\uff0c\u4e26\u5c0d\u5176\u8207\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u7684\u95dc\u4fc2\u9032\u884c\u5206\u6790\u3002\u7d50\u679c\uff1a\u7d93\u6bd4\u8f03\u8180\u80f1\u6f32\u5c3f\u53ca\u6392\u5c3f\u7684\u5169\u7d44\u96fb\u8166\u65b7\u5c64\uff0c\u5b50\u5bae\u9838\u816b\u7624\u53ca\u5b50\u5bae\u9ad4\u4e4b\u5e7e\u4f55\u4e2d\u5fc3\u5728\u982d\u8173\u8ef8\u5411\u4e0a\u6709\u986f\u8457\u7684\u79fb\u52d5\uff0c\u4e14\u79fb\u52d5\u8ddd\u96e2\u7684\u591a\u5be1\u8207\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u70ba\u986f\u8457\u7684\u6b63\u7dda\u6027\u95dc\u4fc2\uff08adjusted R2= 0.49, p=0.0005\uff09\u3002\u5176\u4e2d8\u4f4d\u75c5\u4eba\u5176\u5b50\u5bae\u9838\u816b\u7624\u4fb5\u72af\u5b50\u5bae\u9ad4\u5c0f\u65bc\u4e00\u534a\u8005\uff0c\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u8207\u5e7e\u4f55\u4e2d\u5fc3\u79fb\u52d5\u8ddd\u96e2\u7684\u6b63\u5411\u7dda\u6027\u95dc\u4fc2\u6700\u70ba\u660e\u986f\uff08adjusted R2 = 0.61, p= 0.0008\uff09\uff1b\u800c\u5c0d\u65bc\u816b\u7624\u9ad4\u7a4d\u8f03\u5927\uff0c\u4fb5\u72af\u8d85\u904e\u5b50\u5bae\u9ad4\u7a4d\u8d85\u904e\u4e00\u534a\u4e4b\u75c5\u4eba\uff0c\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u8207\u5e7e\u4f55\u4e2d\u5fc3\u79fb\u52d5\u8ddd\u96e2\u7684\u95dc\u4fc2\u5247\u4e0d\u986f\u8457\u3002\u82e5\u5b50\u5bae\u70ba\u524d\u50be\u72c0\u614b\uff0c\u5247\u5b50\u5bae\u9838\u816b\u7624\u8207\u5b50\u5bae\u9ad4\u79fb\u52d5\u7684\u8ddd\u96e2\u548c\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u5448\u73fe\u6b63\u5411\u7dda\u6027\u95dc\u4fc2\uff08adjusted R2 = 0.40, p= 0.022\uff09\uff0c\u82e5\u5b50\u5bae\u5f8c\u50be\uff0c\u5247\u6b64\u7dda\u6027\u95dc\u4fc2\u4e0d\u986f\u8457\u3002\u7d93\u8003\u91cf\u75c5\u60a3\u5e74\u9f61\u3001\u75be\u75c5\u5206\u671f\u8207\u5b50\u5bae\u4f4d\u7f6e\uff08\u524d\u50be\u6216\u5f8c\u50be\uff09\u7b49\u56e0\u7d20\u4f5c\u591a\u5143\u56de\u6b78\u5f8c\uff0c\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u53ca\u816b\u7624\u5927\u5c0f\u70ba\u9810\u6e2c\u5b50\u5bae\u9838\u816b\u7624\u53ca\u5b50\u5bae\u9ad4\u4e2d\u5fc3\u79fb\u52d5\u7684\u9810\u6e2c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5728\u6b64\u5b50\u5bae\u9838\u764c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u7814\u7a76\u4e2d\uff0c\u6700\u5927\u8180\u80f1\u9ad4\u7a4d\u8b8a\u5316\u91cf\u53ca\u816b\u7624\u5927\u5c0f\u8207\u5b50\u5bae\u9838\u816b\u7624\u53ca\u5b50\u5bae\u9ad4\u5728\u982d\u8173\u65b9\u5411\u4e0a\u7684\u79fb\u52d5\u5177\u986f\u8457\u95dc\u806f\u3002", "e": "Introduction: The aim of the present study is to evaluate the impact of bladder filling on uterus-cervix mobility in patients with cervical cancer and an intact uterus treated by intensity-modulated radiotherapy (IMRT). Methods and Materials: Twenty-two consecutive women with cervical cancer (FIGO stage IB-IVB) receiving pelvic IMRT were selected for analysis. Two series of treatment planning CT scans, one with a full bladder and the other with an empty bladder, were acquired. The target volumes and normal tissues were contoured on each CT scan according to the updated guidelines and staging MRI. We determined the centroid positions of the cervical tumor and uterus, then correlated the centroid displacement to the delta volume of the bladder (DVB; defined as the volume difference between full and empty urinary bladders; the maximized bladder filling change). Results: A significant mobility of the uterus-cervix according to bladder filling was observed on the superior-inferior axis only. For all patients, displacement of the uteruscervix on the superior-inferior axis was significantly correlated with the DVB (adjusted R2= 0.49, p= 0.0005). Among 8 patients with cervical tumor invading less than onehalf of the uterus, the target displacement affected by DVB was well-described by linear regression (adjusted R2= 0.61, p= 0.0008). For those with bulky tumor extent, the correlation between target displacement and DVB was much less apparent. For patients have anteverted uterus (n= 11), the DVB was associated with cervix-uterus motion on superior-inferior axis (adjusted R2 =0.40, p= 0.022), while for those with retroverted or tip-up uterus, there was no significant correlation. After a multivariate linear regression analysis, DVB and tumor extent were significantly correlated with uterus-cervix motion. Conclusion: The maximized bladder filling change (DVB), and tumor extent, were significantly correlated with uterus-cervix centroid displacement on the superiorinferior axis of cervical cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-233-234", "title": "Predictive Factors for Brain Metastases in Early-Stage Non-Small Cell Lung Cancer", "keywords": "\u65e9\u671f;\u975e\u5c0f\u7d30\u80de\u80ba\u764c;\u8166\u8f49\u79fb;\u9810\u6e2c\u56e0\u5b50 Early-stage;Non-small cell lung cancer;Brain metastases;Predictive factors", "c": "\u76ee\u7684\uff1a\u8166\u90e8\u8f49\u79fb\u5728\u5c40\u90e8\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u70ba\u6700\u5e38\u898b\u7684\u9060\u7aef\u8f49\u79fb\uff0c\u6839\u64da\u4e4b\u524d\u7684\u7814\u7a76\u5927\u7d04\u670922%\uff5e55%\u7684\u5c40\u90e8\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u5f8c\u6703\u6709\u8166\u90e8\u7684\u8f49\u79fb\u3002\u4f46\u662f\u91dd\u5c0d\u65e9\u671f\u7684\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u5c0d\u6b64\u76f8\u95dc\u7684\u7814\u7a76\u4e26\u4e0d\u591a\u3002\u56e0\u6b64\uff0c\u672c\u7bc7\u6587\u7ae0\u4e3b\u8981\u76ee\u5730\u70ba\u63a2\u8a0e\u65e9\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u8166\u90e8\u8f49\u79fb\u7684\u6a5f\u7387\u548c\u5371\u96aa\u56e0\u5b50\u5206\u6790\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u96c6\u4e86\u5f9e2007\u5e741\u6708\u52302012\u5e746\u6708\u65bc\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u8a3a\u65b7\u70ba\u81e8\u5e8a\u5206\u671fT1\uff5e2\uff0cN0\uff5e1\uff0cM0\u7684\u75c5\u4eba\uff0c\u4e26\u518d\u4f9d\u4e0b\u5217\u689d\u4ef6\u4f5c\u9069\u7576\u7684\u6392\u9664\uff1a1\u3001\u75c5\u4eba\u8a3a\u65b7\u5f8c\u6c92\u6709\u5728\u672c\u9662\u7e7c\u7e8c\u8ffd\u7e31\u6cbb\u7642\u3001\u8cc7\u6599\u4e0d\u8db3\u6216\u662f\u8ffd\u8e64\u6642\u9593\u5c0f\u65bc3\u500b\u6708\uff1b2\u3001\u6839\u64da\u75c5\u4eba\u7684\u75c5\u6b77\u8a18\u9304\uff0c\u75c5\u4eba\u6709\u5169\u7a2e\u4ee5\u4e0a\u7684\u764c\u75c7\u8a3a\u65b7\uff1b3\u3001\u75c5\u4eba\u6709\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u4e26\u4e14\u75c5\u7406\u5206\u671f\u7684T \uff1e 2\u6216N \uff1e 1\u3002\u7d93\u904e\u7be9\u9078\u5f8c\u7684\u75c5\u4eba\uff0c\u4f9d\u5176\u75c5\u6b77\u8cc7\u6599\u5c07\u8a3a\u65b7\u5e74\u9f61\u3001\u6027\u5225\u3001\u7d30\u80de\u7d44\u7e54\u578b\u614b\u3001\u7d44\u7e54\u60e1\u6027\u5ea6\u5206\u7d1a\u3001T\u671f\u5225\u3001N\u671f\u5225\u3001\u75c5\u7076\u6240\u5728\u7684\u80ba\u8449\u3001\u65e5\u5e38\u9ad4\u80fd\u72c0\u614b\u548c\u75c5\u4eba\u6240\u63a5\u53d7\u7684\u6cbb\u7642\u7b49\u56e0\u5b50\u4f5c\u55ae\u8b8a\u9805\u548c\u591a\u8b8a\u9805\u5206\u6790\u5176\u8207\u4e4b\u5f8c\u8166\u90e8\u8f49\u79fb\u7684\u76f8\u95dc\u6027\u3002\u7d50\u679c\uff1a\u81ea2007\u5e741\u6708\u81f32012\u5e746\u6708\uff0c\u7e3d\u5171\u6709260\u4f4d\u65e9\u671f\u80ba\u764c\u7684\u75c5\u4eba\u5728\u6211\u5011\u91ab\u9662\u88ab\u8a3a\u65b7\uff0c\u7d93\u904e\u6392\u9664\u689d\u4ef6\u7684\u7be9\u9078\u5f8c\uff0c\u5171\u6709177\u4f4d\u75c5\u4eba\u7684\u76f8\u95dc\u56e0\u5b50\u88ab\u5c0b\u627e\u51fa\u4f86\u4e26\u52a0\u4ee5\u5206\u6790\u3002\u5728\u672c\u7bc7\u7814\u7a76\u7576\u4e2d\uff0c\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u70ba28.4\u500b\u6708\uff083\uff5e74\u500b\u6708\uff09\u3002\u7e3d\u5171\u670918\u4f4d\u75c5\u5728\u5728\u8ffd\u8e64\u5176\u9593\u767c\u73fe\u6709\u8166\u90e8\u8f49\u79fb\u30025\u5e74\u7684\u8166\u90e8\u8f49\u79fb\u7d2f\u7a4d\u98a8\u96aa\u70ba19%\u3002\u5f9e\u8a3a\u65b7\u5230\u767c\u73fe\u75c5\u4eba\u8166\u90e8\u8f49\u79fb\u7684\u4e2d\u4f4d\u6642\u9593\u70ba17.8\u500b\u6708\uff081.8\uff5e60.6\u500b\u6708\uff09\uff0c\u6709\u8166\u90e8\u8f49\u79fb\u7684\u75c5\u4eba\u4e4b\u4e2d\u4f4d\u8a3a\u65b7\u5e74\u9f61\u70ba69.5\u6b72\u3002\u5728\u55ae\u8b8a\u9805\u548c\u591a\u8b8a\u9805\u5206\u6790\u6240\u5f97\u4e4b\u7d50\u679c\u4e2d\uff0cT2\u671f\u5225\u548c\u662f\u5426\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u7686\u548c\u8166\u90e8\u8f49\u79fb\u6709\u660e\u986f\u7684\u76f8\u95dc\u3002\u53e6\u5916\uff0c\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u5e74\u9f61\uff08\uff1e60\u6b72\uff09\u548c\u8166\u90e8\u8f49\u79fb\u53ef\u80fd\u6709\u76f8\u95dc\u6027\uff08p= 0.053\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7bc7\u7814\u7a76\u767c\u73fe\uff0c\u91dd\u5c0d\u65e9\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u75c5\u4eba\uff0c5\u5e74\u7684\u8166\u90e8\u8f49\u79fb\u7d2f\u7a4d\u98a8\u96aa\u70ba19%\u3002T2\u5206\u671f\u548c\u662f\u5426\u6709\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u548c\u4e4b\u5f8c\u7684\u8166\u90e8\u8f49\u79fb\u6709\u660e\u986f\u7684\u76f8\u95dc\u6027\u3002", "e": "Purpose: The risk of developing brain metastases in locally advanced non-small cell lung cancer (NSCLC) is approximately 22%-55% and has been discussed in many studies. However the risk for patients with early stage NSCLC is less defined. The purpose of this study is to evaluate the risk factors of developing brain metastases in early stage NSCLC. Materials and Methods: Patients diagnosed with early stage (clinical T1-2, N0-1, M0) NSCLC in our institution from Jan, 2007 to Jun, 2012 were surveyed. Exclusion criteria were (1) patients who did not received regular follow up at our hospital or those with missing data or who had a follow up time \uff1c 3 months. (2) Double cancer (3) pathological \uff1eT2 or \uff1eN1 disease. Factors such as age at diagnosis, gender, cell type, histological grade, T stage, N stage, different pulmonary lobe, performance status and treatment modality were reviewed from their chart records and analyzed using Kaplan-Meier and Cox regression to estimate the association and significance with brain metastases. Results: From Jan, 2007 to Jun, 2012, 260 patients were diagnosed with early stage NSCLC. Eighty three patients were excluded and 177 were enrolled in this study. The median follow up time of all the patients was 28.4 months (range, 3-74 months). Brain metastases were identified in 18 patients. The 5-year risk of developing brain metastases was 19%. The median time from diagnosis to brain metastases was 17.8 months (range, 1.8-60.6 months) and the median age at diagnosis was 69.5 years. In univariate and multivariate analysis, stage (T2) and surgery status (without surgery) had strong associations with developing brain metastases (p= 0.007 and 0.001 in univariate, p= 0.028 and 0.007 in multivariate respectively). Age (\uff1e60 y/o) showed a trend towards association with brain metastases in multivariate analysis (p= 0.053). Conclusions: Our results showed that the 5-year risk of developing brain metastases was 19% in early stage NSCLC. Tumor stage (T2) and surgery status (without surgery) were significant predictors for brain metastases."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-235-242", "title": "\u5149\u5b50\u5c04\u675f\u4e0b\u4f7f\u7528\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u7248\u65bc\u4e0d\u540c\u7167\u91ce\u5927\u5c0f\u53ca\u6a5f\u982d\u5165\u5c04\u89d2\u5ea6\u4e4b\u8870\u6e1b\u6548\u61c9", "keywords": "\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f;\u8870\u6e1b\u6548\u61c9;\u7167\u91ce;\u6a5f\u982d\u89d2\u5ea6 Carbon Fiber Respiratory Control Board (CFRCB);Attenuation effects;Field size;Gantry angle", "c": "\u76ee\u7684\uff1a\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u53ef\u7528\u4f86\u6291\u5236\u56e0\u75c5\u4eba\u547c\u5438\u8d77\u4f0f\u9020\u6210\u4e4b\u5668\u5b98\u79fb\u52d5\uff0c\u7136\u800c\u82e5\u5176\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u5c04\u675f\u4e4b\u8870\u6e1b\u904e\u5927\uff0c\u5728\u75c5\u60a3\u5c0d\u4f4d\u6642\u82e5\u6709\u8aa4\u5dee\uff0c\u5c07\u6703\u5927\u5e45\u5f71\u97ff\u6cbb\u7642\u4e4b\u5291\u91cf\u6e96\u78ba\u6027\u3002\u672c\u7814\u7a76\u4e4b\u4e3b\u8981\u76ee\u7684\u70ba\u8a55\u4f30\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u5c04\u675f\u4e4b\u8870\u6e1b\u6548\u61c9\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u85c9\u7531\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u7684CT\u503c\u4f86\u9810\u6e2c\u5176\u5404\u500b\u7d50\u69cb\u4e4b\u96fb\u5b50\u5bc6\u5ea6\u6975\u53ef\u80fd\u9020\u6210\u7684\u8870\u6e1b\u7a0b\u5ea6\u3002\u4f7f\u7528Varian iX\u76f4\u7dda\u52a0\u901f\u5668\u6e2c\u91cf\u57286 MV\u53ca10 MV\u5149\u5b50\u5c04\u675f\u4e0b\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u5728\u4e0d\u540c\u6a5f\u982d\u5165\u5c04\u89d2\u5ea6\u7684\u8870\u6e1b\u56e0\u5b50\u3002\u6e2c\u91cf\u6642\u4f7f\u7528\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u76f4\u63a5\u52a0\u58d3\u56fa\u614b\u6c34\u5047\u9ad4\uff0c\u7f6e\u5165PTW 0.6cc\u8fb2\u592b\u578b\u6e38\u96e2\u8154\u6e2c\u91cf\u4e0d\u540c\u7167\u91ce\u5927\u5c0f\u4e4b\u8870\u6e1b\u56e0\u5b50\uff0c\u4e26\u7528\u6210\u5c0dt\u6aa2\u5b9a\u9032\u884c\u5206\u6790\u3002\u5229\u7528Gafchromic EBT3\u8edf\u7247\u91cf\u6e2c\u4e8c\u7dad\u7684\u52a0\u58d3\u7d44\u4ef6\u8870\u6e1b\u3002\u7d50\u679c\uff1a\u5728\u56fa\u614b\u6c34\u5047\u9ad4\u7684\u91cf\u6e2c\u4e2d\uff0c\u6a5f\u982d\u89d2\u5ea6300\u5ea6\u81f360\u5ea6\u5e7e\u4e4e\u6c92\u6709\u8870\u6e1b\uff1b\u5728\u6a5f\u982d\u89d2\u5ea6165\u5ea6\u81f3195\u5ea6\u6642\uff0c\u5c0f\u7167\u91ce\u5728\u4e0d\u540c\u5149\u5b50\u80fd\u91cf\u7684\u5e73\u5747\u8870\u6e1b\u7d04\u70ba25.17%\u53ca20.21%\uff086 MV\u53ca10 MV\uff09\uff0c\u5927\u7167\u91ce\u7684\u5e73\u5747\u8870\u6e1b\u7d04\u70ba23.53%\u53ca19.20%\uff1b\u5728\u5176\u4ed6\u6a5f\u982d\u5165\u5c04\u89d2\u5ea6\u6642\uff0c\u5c0f\u7167\u91ce\u7684\u5e73\u5747\u8870\u6e1b\u7d04\u70ba9.51%\u53ca7.31%\uff0c\u5927\u7167\u91ce\u7684\u5e73\u5747\u8870\u6e1b\u7d04\u70ba8.57%\u53ca6.84%\u3002\u7121\u8ad6\u662f\u5927\u7167\u91ce\u6216\u9ad8\u80fd\u91cf\uff0c\u5176\u8870\u6e1b\u56e0\u5b50\u90fd\u6709\u986f\u8457\u964d\u4f4e\uff08p\uff1c 0.01\uff09\u3002\u7d50\u8ad6\uff1a\u8870\u6e1b\u6548\u61c9\u6703\u96a8\u8457\u5149\u5b50\u80fd\u91cf\u589e\u52a0\u8207\u7167\u91ce\u589e\u52a0\u800c\u96a8\u4e4b\u6e1b\u5c11\u3002\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u80fd\u5920\u6709\u6548\u5730\u4e26\u8f03\u8212\u9069\u5730\u6e1b\u5c11\u547c\u5438\u9020\u6210\u7684\u5668\u5b98\u4f4d\u79fb\uff0c\u4f46\u9084\u662f\u8981\u9867\u616e\u53ef\u80fd\u9020\u6210\u7684\u8870\u6e1b\u6548\u61c9\u3002\u82e5\u816b\u7624\u6070\u5de7\u88ab\u78b3\u7e96\u547c\u5438\u8abf\u63a7\u677f\u906e\u853d\uff0c\u61c9\u76e1\u91cf\u907f\u514d\u4f7f\u7528\u8abf\u63a7\u677f\uff0c\u6216\u4ee5\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8a08\u7b97\u5176\u8870\u6e1b\u6548\u61c9\u3002", "e": "Purpose: The Carbon Fiber Respiratory Control Board (CFRCB) (Blessing-Cathay Corp.) was used to suppress the organ motions due to respiratory. The attenuation effects of CFRCB will affect the dose accuracy in radiation treatment plans. The purpose of this study is to evaluate the attenuation effects with different measurement field sizes and gantry angle due to the Carbon Fiber Respiratory Control Board. Materials and Methods: The CT numbers of CFRCB would be analyzed to predict the electron density and attenuation of each components. The attenuation factors of CFRCB were measured with rotated gantry angles in 6 MV and 10 MV using a Varian iX Linac machine. In the measurements, the CFRCB compressed from anterior (gantry= 180\u00b0) to the center of plastic water phantoms. A PTW 30013 0.6cc farmer chamber was placed in plastic water phantoms and measured with different field sizes. The attenuation factors would be calculated and compared between different field sizes and photon energy with paired t-test. The Gafchromic EBT3 films replaced the farmer chamber to perform the attenuation of the compressor in 2D. Results: In phantom attenuation measurements, there were no attenuation effects in gantry angle 300\u00b0 to 60\u00b0 (posterior). In gantry angle 165\u00b0 to 195\u00b0 (anterior), the mean attenuations were 25.17% vs 20.21% (in 6 MV vs 10 MV) in smaller field size 10 x 10 cm^2, and 23.53% vs 19.20% in larger field size. In the other gantry angles, the mean attenuations were 9.51% vs 7.31% (in 6 MV vs 10 MV) in smaller field size, and 8.57% vs 6.84% in larger field size. In larger field size and higher photon energy, the attenuation factors were significantly decrease (p\uff1c 0.01).The largest attenuation of the compressor was in diameter 1cm of beam center, that is the position of the screw. The attenuation due to the respiratory suppression plate was lower than the attenuation of the screw, but it should also be concerned. Conclusions: The attenuation effects were decrease when measured with higher energy, larger field size. Therefore, CFRCB can control and decrease the respiratory motions efficiently and comfortably, but the attenuation effect should be considered. When the tumor targets are blocked by CFRCB, the CFRCB should not be used in treatment or the attenuation effects must be calculated by the planning system."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-243-248", "title": "A Case of Squamous Cell Carcinoma Arising from Presacral (Retrorectal) Epidermoid Cyst", "keywords": "\u85a6\u690e\u524d\u816b\u7624;\u8868\u76ae\u56ca\u816b;\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c;\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642 Presacral tumor;Epidermoid cyst;Squamous cell carcinoma;Adjuvant radiotherapy", "c": "\u751f\u65bc\u85a6\u690e\u524d\u7a7a\u9593\u7684\u8868\u76ae\u56ca\u816b\u662f\u4e00\u7a2e\u5c11\u898b\u7684\u5148\u5929\u75c5\u7076\u3002\u8868\u76ae\u56ca\u816b\u5167\u6709\u60e1\u6027\u816b\u7624\u7d30\u80de\u66f4\u662f\u6975\u70ba\u7f55\u898b\u3002\u7d93\u904e\u6587\u737b\u7684\u641c\u5c0b\uff0c\u76f8\u540c\u7684\u6848\u4f8b\u76ee\u524d\u53ea\u6709\u4e00\u7bc7\u82f1\u6587\u7684\u5f71\u50cf\u5831\u544a\u8207\u56db\u7bc7\u65e5\u6587\u7684\u500b\u6848\u5831\u544a\u66fe\u88ab\u767c\u8868\u3002\u5728\u6b64\u6211\u5011\u5831\u544a\u4e86\u4e00\u540d\u516d\u5341\u4e8c\u6b72\u7684\u5973\u6027\uff0c\u7d93\u904e\u6aa2\u67e5\u5f8c\u88ab\u8a3a\u65b7\u65bc\u85a6\u690e\u524d\u7a7a\u9593\u6709\u4e00\u56ca\u816b\u3002\u9019\u540d\u60a3\u8005\u63a5\u53d7\u4e86Kraske\u6c0f\u624b\u8853\u4ee5\u79fb\u9664\u56ca\u816b\u816b\u584a\u3002\u75c5\u7406\u6aa2\u67e5\u767c\u73fe\u5167\u542b\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u7d30\u80de\u3002\u56e0\u70ba\u816b\u584a\u5728\u8853\u4e2d\u7834\u88c2\u4e86\uff0c\u60a3\u8005\u63a5\u8457\u63a5\u53d7\u4e86\u8853\u5f8c\u7684\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5291\u91cf\u662f\u4e94\u5341\u6208\u96f7\uff0f\u4e8c\u5341\u4e94\u5206\u6b21\u3002\u7d93\u904e\u4e86\u4e00\u5e74\u7684\u8ffd\u8e64\uff0c\u60a3\u8005\u4e26\u6c92\u6709\u816b\u7624\u5fa9\u767c\u7684\u8de1\u8c61\u3002", "e": "Epidermoid cyst of the presacral space is a rare congenital lesion. Cases of malignance arising from the lesion are extremely rare. After searching the literature, there are only 1 image report in English literature (PubMed) and 4 cases reports in Japanese literature of the disease. Here we report a 62-year-old female who was diagnosed with presacral cyst before surgery. Wide excision of the cystic tumor by Kraske's operation was performed. The pathology showed squamous cell carcinoma. Because of tumor rapture during operation, adjuvant radiotherapy 50 Gray/ 25 fractions was performed. After 1 year follow up, there is no evidence of disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201409-201409250087-201409250087-249-256", "title": "A Case of Intractable Pain Arising from Buttock Malignant Peripheral Nerve Sheath Tumor with Nerve Compression", "keywords": "\u75bc\u75db;\u60e1\u6027\u5468\u908a\u795e\u7d93\u9ad3\u9798\u816b\u7624;\u795e\u7d93\u7e96\u7dad\u8089\u7624 Pain;Malignant peripheral nerve sheath tumor (MPNST);Malignant schwannoma", "c": "\u60e1\u6027\u5468\u908a\u795e\u7d93\u9ad3\u9798\u816b\u7624\u901a\u5e38\u4f86\u6e90\u65bc\u81c0\u90e8\u548c\u4e0b\u80a2\u5750\u9aa8\u795e\u7d93\u5468\u570d\u9644\u8fd1\u7684\u795e\u7d93\u7d30\u80de\u3002\u5f80\u5f80\u8207\u75bc\u75db\u548c\u611f\u89ba\u9072\u920d\u6709\u95dc\uff0c\u800c\u7576\u58d3\u8feb\u5230\u76f8\u95dc\u7684\u795e\u7d93\u6642\u6703\u767c\u5c55\u6210\u9811\u56fa\u6027\u80a2\u9ad4\u75bc\u75db\u3002\u5728\u9019\u4efd\u75c5\u4f8b\u5831\u544a\u4e2d\uff0c\u6211\u5011\u63d0\u51fa\u4e86\u4e00\u500b\u4e0d\u5e38\u898b\u7684\u5de6\u81c0\u90e8\u60e1\u6027\u5468\u908a\u795e\u7d93\u9798\u816b\u7624\u7684\u500b\u6848\uff0c\u4e14\u4e00\u958b\u59cb\u4f34\u96a8\u6709\u9032\u884c\u6027\u611f\u89ba\u9072\u920d\u548c\u9ebb\u6728\u7b49\u75c7\u72c0\u5728\u5de6\u5927\u817f\u5f8c\u5074\u3002\u96d6\u7136\u75c5\u60a3\u63a5\u53d7\u4e86\u5de6\u5074\u4e0b\u80a2\u80a2\u9ad4\u4fdd\u7559\u624b\u8853\u8207\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u548c\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u9019\u4e9b\u816b\u7624\u4ecd\u7136\u7121\u60c5\u5730\u5feb\u901f\u6210\u9577\u3002\u7136\u5f8c\uff0c\u60e1\u6027\u5468\u908a\u795e\u7d93\u9ad3\u9798\u816b\u7624\u58d3\u8feb\u5230\u75c5\u4eba\u5de6\u5074\u5750\u9aa8\u795e\u7d93\u4e26\u9020\u6210\u9811\u56fa\u6027\u80a2\u9ad4\u75bc\u75db\u3002\u6700\u5f8c\u75c5\u4eba\u56e0\u70ba\u60e1\u75c5\u9ad4\u8cea\u800c\u5f80\u751f\u3002", "e": "Malignant peripheral nerve sheath tumor usually originates from peripheral nerve cells of sciatic nerves in the buttock and lower extremities. It often is associated with pain and dysesthesia, and develops intractable limb pain when compressing the associated nerve. In this report, we present an unusual left buttock malignant peripheral nerve sheath tumor case with progressive hypoesthesia and numbness over the posterior aspect of left thigh in the beginning. Though he had undergone limb-sparing resection with adjuvant radiation therapy and chemotherapy, this tumor progressed quickly and relentlessly. Finally, the malignant peripheral nerve sheath tumor compressed the left sciatic nerve and developed intractable limb pain, and the patient passed away with cachexia."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-77-87", "title": "Hemoglobin Level during Chemoradiation Therapy Predicts Treatment Outcome in Nasopharyngeal Cancer", "keywords": "\u9f3b\u54bd\u764c;\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642;\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u8ca7\u8840 Nasopharyngeal cancer;Induction chemotherapy;Chemoradiation therapy;Anemia", "c": "\u76ee\u7684\uff1a\u672c\u6587\u7814\u7a76\u9f3b\u54bd\u764c\u65bc\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u671f\u9593\u4e4b\u8840\u7d05\u7d20\u503c\u8207\u6cbb\u7642\u5f8c\u5b58\u6d3b\u7387\u4e4b\u95dc\u806f\u6027\u3002\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u57282006\u5e7412\u6708\u81f32010\u5e743\u6708\u671f\u9593\uff0c\u7d0d\u5165\u975e\u9060\u7aef\u8f49\u79fb\u4e4b\u9f3b\u54bd\u764c\u60a3\u8005\u3002\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u9776\u9ad4\u7a4d\u4e4b\u539f\u767c\u816b\u7624\u8207\u967d\u6027\u6dcb\u5df4\u7d50\u7d66\u4e8870 Gy\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\uff0c\u4ee51.8 Gy\u81f32.0 Gy\u5206\u6b21\u7d66\u4e88\u3002\u5927\u90e8\u4efd\u75c5\u4eba\uff0879.7%\uff09\u63a5\u53d7\u540c\u6b65cisplatin-based\u5316\u5b78\u6cbb\u7642\uff0c\u90e8\u4efd\u75c5\u4eba\u4e26\u63a5\u53d7\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u3002\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642EP-HDFL\uff0c\u5305\u542bEpirubicin\u3001Cisplatin\u30015-FU\u548cLeucovorin\u3002\u540c\u6b65\u5316\u7642PFL\uff0c\u5305\u542bCisplatin\u30015-FU\u548cLeucovorin\u3002\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u4e14\uff0f\u6216\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u671f\u9593\uff0c\u6bcf\u9031\u7686\u6e2c\u91cf\u8840\u7d05\u7d20\u503c\u4ee5\u8a55\u4f30\u8840\u6db2\u5b78\u6548\u61c9\u3002\u7d50\u679c\uff1a\u7e3d\u8a0864\u4f4d\u75c5\u60a3\u88ab\u7d0d\u5165\uff0c\u8ffd\u7e31\u671f\u4e2d\u4f4d\u6578\u70ba56\u500b\u6708\u3002AJCC\u5206\u671f\u7b2c\u4e09\u671f\u548c\u7b2c\u56db\u671f\u6709\u8f03\u5dee\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff0c\u5206\u5225\u70ba88.5%\u548c58.3%\u3002\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u4e2d\u7b2c\u4e8c\u7d1a\u8ca7\u8840\uff0c\u8207\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u4e2d\u7b2c\u4e09\u7d1a\u8ca7\u8840\uff0c\u7686\u8207\u8f03\u5dee\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u76f8\u95dc\uff0c\u5206\u5225\u70ba50.0%\u548c50.0%\u3002\u5728\u672c\u7814\u7a76\u4e2d\u4e26\u7121\u767c\u751f\u7b2c\u56db\u6216\u7b2c\u4e94\u7d1a\u8ca7\u8840\u3002\u8ca7\u8840\u7522\u751f\u7684\u6548\u61c9\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\u8da8\u65bc\u986f\u8457\u3002\u7d50\u8ad6\uff1a\u9664\u4e86AJCC\u5206\u671f\uff0c\u5728\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u4e14\uff0f\u6216\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u671f\u9593\u6bcf\u9031\u6e2c\u91cf\u4e4b\u8840\u7d05\u7d20\u503c\uff0c\u70ba\u6f5b\u5728\u7684\u9577\u671f\u6cbb\u7642\u9810\u5f8c\u6307\u6a19\u3002", "e": "Purpose: The aim of the study is to investigate the correlation between hemoglobin level during chemoradiation therapy and overall survival in nasopharyngeal cancer. Materials and Methods: Between December 2006 and March 2010, patients with nonmetastatic nasopharyngeal cancer were enrolled. Radiation consisted of at least 70 Gy to the planning target volumes of primary tumor plus any positive nodal disease using 1.8 Gy to 2.0 Gy per fraction. Most patients (79.7%) received concurrent cisplatinbased chemotherapy with or without induction chemotherapy. Induction chemotherapy regimens, EP-HDFL, consisted of Epirubicin, Cisplatin, 5-FU, and Leucovorin. Concurrent chemotherapy, PFL, consisted of Cisplatin, 5-FU, and Leucovorin. Weekly hemoglobin levels during induction chemotherapy and/or concurrent chemoradiation therapy were checked for evaluation of hematological effects. Results: Total 64 patients were enrolled with a median follow-up of 56 months. AJCC stage III and IV predicted worse 5-year overall survival rates, 88.5% and 58.3%, respectively. Both grade 2 anemia in induction chemotherapy and grade 3 anemia in concurrent chemotherapy correlated with worse 5-year overall survival rates, 50.0% and 50.0%, respectively. No grade 4 or 5 anemia occurred in this study. The effect of anemia had a trend toward significance in univariate analysis. Conclusion: Besides AJCC staging, weekly hemoglobin levels during induction chemotherapy and/or concurrent chemoradiation therapy is a potentially clinical predictor of long-term treatment outcome in nasopharyngeal cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-89-100", "title": "A Retrospective Comparison of Treatment Results among GBM Patients Treated with Different Radiotherapy Protocols", "keywords": "\u653e\u5c04\u6cbb\u7642;\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624;\u5e1d\u76df\u591a Radiotherapy;Glioblastoma multiforme (GBM);Temozolomide", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u8853\u5f8c\u7d93\u4e0d\u540c\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1995\u5e742\u6708\u81f32012\u5e749\u6708\uff0c\u5171\u5206\u679065\u4f4d\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u75c5\u60a3\u7d93\u624b\u8853\u5207\u9664\u5f8c\u63a5\u53d7\u4e0d\u540c\u4e4b\u8f14\u52a9\u6027\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u7b2c\u4e00\u7d44\u75c5\u60a3\uff0827\u4f4d\uff09\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u76426000 cGy/30\u6b21\u7167\u5c04\u5408\u4f75\u5e1d\u76df\u591a\u53ca\u8f14\u52a9\u6027\u5e1d\u76df\u591a\u7642\u7a0b\uff08\u5408\u4f75\u4f7f\u7528\u5291\u91cf\u70ba\u6bcf\u65e575 mg/m^2 BSA,\u670d\u7528\u671f\u9593\u70ba\u653e\u5c04\u6cbb\u7642\u7b2c\u4e00\u5929\u81f3\u6700\u5f8c\u4e00\u5929;\u8f14\u52a9\u5291\u91cf\u70ba\u6bcf\u65e5150\u81f3200 mg/m^2 BSA\uff0c\u9023\u7e8c\u670d\u75285\u5929\u4f11\u606f23\u5929\u70ba\u4e00\u500b\u5faa\u74b0\uff0c\u670d\u7528\u81f3\u75c5\u60a3\u767c\u751f\u6b7b\u4ea1\u6216\u60e1\u5316\uff09\uff1b\u7b2c\u4e8c\u7d44\u75c5\u60a3\uff0824\u4f4d\uff09\u50c5\u63a5\u53d76660-7000 cGy/33-35\u6b21\u7167\u5c04\u4e4b\u8853\u5f8c\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u7121\u5316\u5b78\u6cbb\u7642\u4ecb\u5165\uff1b\u7b2c\u4e09\u7d44\u75c5\u60a3\uff0814\u4f4d\uff09\u63a5\u53d7\u7167\u91ce\u5167\u518d\u7167\u5c04\u4e4b\u8853\u5f8c\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff08\u6bcf\u65e5\u65bc\u5927\u7167\u91ce\u7167\u5c04180 cGy\uff0c\u518d\u6e1b\u5c0f\u7167\u91ce\u7167\u5c0470 cGy\uff0c\u5171\u7167\u5c0425-26\u65e5\uff0c\u9054\u7e3d\u5291\u91cf6250-6500 cGy\uff0c\u7121\u5316\u5b78\u6cbb\u7642\u4ecb\u5165\u3002\u7814\u7a76\u7d42\u9ede\u70ba\u6574\u9ad4\u5b58\u6d3b\u671f\uff08overall survival\uff09\u3002\u7d50\u679c\uff1a\u8ffd\u8e64\u671f\u7684\u4e2d\u4f4d\u6578\u70ba13.6\u500b\u6708\u300265\u4f4d\u75c5\u60a3\u4e4b\u6574\u9ad4\u5b58\u6d3b\u671f\u4e2d\u4f4d\u6578\u53ca\u5fa9\u767c\u6642\u9593\u4e2d\u4f4d\u6578\u70ba13.3\u53ca8.2\u500b\u6708\u3002\u7b2c\u4e00\u7d44\u3001\u7b2c\u4e8c\u7d44\u53ca\u7b2c\u4e09\u7d44\u75c5\u60a3\u4e4b\u6574\u9ad4\u5b58\u6d3b\u671f\u4e2d\u4f4d\u6578\u5206\u5225\u70ba19.9\u300112.6\u820710.4\u500b\u6708\u3002\u5176\u4e2d\u7b2c\u4e00\u7d44\u75c5\u60a3\u7684\u6574\u9ad4\u5b58\u6d3b\u671f\u8f03\u9577\uff0c\u8207\u7b2c\u4e8c\u3001\u4e09\u7d44\u7d50\u679c\u76f8\u8f03\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u986f\u8457\u5dee\u7570\u3002\u75be\u75c5\u7121\u60e1\u5316\u5b58\u6d3b\u671f\uff08progression-free survival\uff09\u7684\u4e2d\u4f4d\u6578\u65bc\u4e09\u7d44\u75c5\u60a3\u9593\u4e26\u7121\u986f\u8457\u5dee\u7570\u3002\u75c5\u60a3\u9ad4\u80fd\u72c0\u614b\u3001\u624b\u8853\u662f\u5426\u5b8c\u5168\u5207\u9664\u816b\u7624\u53ca\u8853\u5f8c\u8f14\u52a9\u6027\u6cbb\u7642\u65b9\u6cd5\u662f\u6574\u9ad4\u5b58\u6d3b\u671f\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u672c\u56de\u6eaf\u6027\u7814\u7a76\u767c\u73fe\u75c5\u60a3\u9ad4\u80fd\u72c0\u614b\u3001\u624b\u8853\u662f\u5426\u5b8c\u5168\u5207\u9664\u816b\u7624\u53ca\u8853\u5f8c\u8f14\u52a9\u6027\u6cbb\u7642\u65b9\u6cd5\u662f\u5f71\u97ff\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u5b58\u6d3b\u671f\u7684\u91cd\u8981\u56e0\u5b50\u3002\u75c5\u60a3\u9ad4\u80fd\u72c0\u614b\u4f73\u3001\u624b\u8853\u5207\u9664\u4e7e\u6de8\u53ca\u63a5\u53d7\u8853\u5f8c\u5c40\u90e8\u653e\u5c04\u6cbb\u76426000 cGy/30\u6b21\u7167\u5c04\u5408\u4f75\u5e1d\u76df\u591a\u53ca\u8f14\u52a9\u6027\u5e1d\u76df\u591a\u7642\u7a0b\uff0c\u53ef\u9054\u5230\u826f\u597d\u7684\u6574\u9ad4\u5b58\u6d3b\u671f\u3002", "e": "Purpose: To compare the treatment results of different radiotherapy protocols for glioblastoma multiforme (GBM). Materials and Methods: Between February 1995 and September 2012, 65 patients with GBM who treated with maximal surgical resection, followed by different external radiotherapy (RT) protocols were evaluated retrospectively. 27 patients (group 1) had received CCRT (concurrent chemoradiotherapy) with temozolomide (TMZ) administered orally at 75 mg/m^2 body surface area (BSA) daily from the first to the last day with local RT (6000 cGy/30 fractions), followed by adjuvant TMZ (150 to 200 mg/m^2 BSA, 5-day dosing and 23 days non-treatment) till the patient's death or progressive disease occurred. 24 patients (group 2) had received adjuvant RT alone with 6660-7000 cGy/33-35 fractions. 14 patients (group 3) had received field-in-field (FIF) boost protocol with RT consisted of daily fractions of 180 cGy to brain tumor site, followed by subsequently 70 cGy (total 250 cGy daily) to reduced field of tumor bed with a total dose of 6250-6500 cGy without other chemotherapy permission. The primary endpoint was overall survival (OS). Results: Median follow-up was 13.6 months (range, 3.6-67.1 months). Median OS and time to progression for 65 patients were 13.3 and 8.2 months, respectively. Median OS of group 1, 2 and 3 were 19.9, 12.6 and 10.4 months, respectively. The group 1 had significantly better OS than both group 2 (p = 0.03) and group 3 (p = 0.04). No significant difference in OS of group 2 and 3 (p = 0.06). Median progression free survival (PFS) did not differ significantly among group 1, 2 and 3 (median PFS: 9.8, 7.2 and 9.7 months, respectively; group 1 vs 2, group 2 vs 3, and group 3 vs 1, p = 0.09, 0.90 and 0.80, respectively). Patient ECOG PS (Eastern Cooperative Oncology Group performance status), GTR (gross tumor resection) or not and RT protocol were significantly correlated with overall survival on both univariate and multivariate analysis. Conclusions: Three independent predictors of survival were identified in our studies: ECOG PS, GTR or not and RT protocol. When independent prognostic factors were examined, advantageous median OS was found out for the patients whose ECOG PS were \u2264 2 and who had GTR, followed by TMZ during and after conventional RT (6000 cGy/30 fractions)."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-101-109", "title": "Image-Guided Stereotactic Radiosurgery Using Volumetric Modulated Arc Therapy for Arteriovenous Malformation of the Brain: Experiences of a Single Institution", "keywords": "\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62;\u5f71\u50cf\u5c0e\u822a;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u5f27\u5f62\u8abf\u63a7 Brain AVM;Image-guided;Stereotactic radiosurgery;Volumetric modulated arc therapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4ee5\u5f27\u5f62\u8abf\u63a7\u4e4b\u5f71\u50cf\u5c0e\u822a\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u4e4b\u6210\u6548\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u9867\u7814\u7a76\u65bc2010\u5e743\u6708\u81f32012\u5e7411\u6708\u671f\u9593\uff0c\u5206\u6790\u63a5\u53d7\u5f71\u50cf\u5c0e\u822a\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u4e4b\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u60a3\u8005\u3002\u5171\u670920\u4f4d\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u7684\u75c5\u60a3\u63a5\u53d7\u6cbb\u7642\u3002\u4ed6\u5011\u7684\u8a3a\u65b7\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba40\u6b72\uff0c14\u4f4d\u75c5\u60a3\u70ba\u7537\u6027\uff0870%\uff09\uff0c6\u4f4d\u75c5\u60a3\u70ba\u5973\u6027\uff0830%\uff09\u30025\u4f4d\u75c5\u60a3\u6709\u63a5\u53d7\u904e\u624b\u8853\uff0c2\u4f4d\u75c5\u60a3\u6709\u63a5\u53d7\u904e\u8840\u7ba1\u6813\u585e\uff0c\u55ae\u7d14\u89c0\u5bdf\u7642\u6cd5\u4e26\u6c92\u6709\u7528\u5728\u4efb\u4f55\u75c5\u60a3\u8eab\u4e0a\u3002\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u5291\u91cf\u7684\u4e2d\u4f4d\u6578\u70ba18 Gy\uff0c\u6cbb\u7642\u5340\u57df\u9ad4\u7a4d\u4e2d\u4f4d\u6578\u70ba3.6 c.c\u3002\u7d50\u679c\uff1a\u8ffd\u8e64\u671f\u9593\u4e2d\u4f4d\u6578\u70ba11.8\u500b\u6708\u3002\u63a5\u53d7\u6cbb\u7642\u4e4b\u5f8c\uff0c\u5176\u4e2d\u67094\u4f4d\u60a3\u8005\uff0820%\uff09\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u5b8c\u5168\u6d88\u9000\uff0c8\u4f4d\u60a3\u8005\uff0840%\uff09\u90e8\u5206\u6d88\u9000\uff0c\u5176\u99188\u4f4d\u60a3\u8005\uff0840%\uff09\u5247\u70ba\u7a69\u5b9a\u75be\u75c5\u72c0\u614b\u3002\u4e00\u5e74\u3001\u5169\u5e74\u3001\u4e09\u5e74\u7684\u6d88\u9000\u7387\u5206\u5225\u70ba40%\u300155%\u820760%\u3002\u7d50\u8ad6\uff1a\u4ee5\u5f27\u5f62\u8abf\u63a7\u4e4b\u5f71\u50cf\u5c0e\u822a\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u4e4b\u6210\u6548\uff0c\u5728\u8ffd\u8e64\u671f\u9593\u4e2d\u4f4d\u6578\u70ba11.8\u500b\u6708\u4e4b\u5f8c\uff0c\u53ef\u9054\u6574\u9ad460%\u4e4b\u6d88\u9000\u7387\u3002\u800c\u4e00\u5e74\u3001\u5169\u5e74\u3001\u4e09\u5e74\u7684\u6d88\u9000\u7387\u5247\u5206\u5225\u70ba40%\u300155%\u820760%\u3002\u60a3\u8005\u5fc5\u9700\u63a5\u53d7\u66f4\u9577\u6642\u9593\u7684\u8ffd\u8e64\u4ee5\u7372\u81f4\u66f4\u7cbe\u78ba\u7684\u6cbb\u7642\u6210\u6548\u5206\u6790\u3002", "e": "Purpose: To evaluate the therapeutic effects of brain arteriovenous malformation (AVM) treated with image-guided stereotactic radiosurgery using volumetric modulated arc therapy. Material and Methods: From March 2010 through November 2012, there were 20 patients with brain AVM treated with image-guided stereotactic radiosurgery in our institution. The median age at diagnosis was 40 years (ranged from 9 to 74 years). Fourteen patients were male (70%) and 6 were female (30%). Among all these 20 patients, 5 patients (25%) had previous surgery of craniotomy with excision, and 2 patients (10%) received previous endovascular embolization. No patients had been managed with observation only at the time of diagnosis. The median dose of stereotactic radiosurgery was 18 Gy (ranged from 12 to 20 Gy). The median clinical target volume was 3.6 c.c (ranged from 1.5 to 15.5 c.c). Results: The median follow-up period was 11.8 months (ranged from 4.7 to 35.4 months). Four patients (20%) had complete obliteration, 8 patients (40%) had partial obliteration, while 8 patients (40%) had stable diseases after treatments. The actuarial 1-year, 2-year and 3-year obliteration rates were 40%, 55% and 60%, respectively. Conclusion: The therapeutic effects of brain AVM treated with image-guided stereotactic radiosurgery using volumetric modulated arc therapy achieved 60% of both complete and partial obliteration rate within the median follow-up period of 11.8 months. The actuarial 1-year, 2-year and 3-year obliteration rates were 40%, 55% and 60%, respectively. The long-term follow-up duration should be warranted to evaluate the further treatment results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-111-119", "title": "Radiotherapy for Intracranial Germinoma: Treatment Modalities and Clinical Outcome", "keywords": "\u751f\u6b96\u7d30\u80de\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u5168\u8166\u810a\u9ad3\u7167\u5c04;\u5168\u8166\u5ba4 Germinoma;Radiotherapy;Chemotherapy;Craniospinal irradiation;Whole-ventricle", "c": "\u76ee\u7684\uff1a\u6211\u5011\u7528\u56de\u6eaf\u6027\u5206\u6790\u9871\u5167\u751f\u6b96\u7d30\u80de\u7624\u7684\u81e8\u5e8a\u75c5\u7406\u7279\u5fb5\uff0c\u6cbb\u7642\u65b9\u5f0f\u5305\u62ec\u55ae\u7d14\u653e\u5c04\u7dda\u6cbb\u7642\uff08RT\uff09\uff0c\u53ca\u5f15\u5c0e\u5f0f\u5316\u5b78\u6cbb\u7642\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff08CRT\uff09\u53ca\u5176\u81e8\u5e8a\u9810\u5f8c\u3002\u7814\u7a76\u65b9\u6cd5\u8207\u6750\u6599\uff1a\u65bc2006\u5e74\u52302012\u5e74\uff0c\u7e3d\u5171\u6536\u930420\u4f4d\u7d93\u75c5\u7406\u7d44\u7e54\u78ba\u8a8d\uff0c\u4e26\u5728\u672c\u9662\u63a5\u53d7\u6cbb\u7642\u4e26\u6709\u8ffd\u8e64\u8cc7\u6599\u7684\u9871\u5167\u751f\u6b96\u7d30\u80de\u7624\u7684\u75c5\u4eba\u3002\u5176\u4e2d16\u4f4d\u75c5\u4eba\u63a5\u53d7\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u7dda\u6cbb\u7642\uff08CRT\uff09\uff0c4\u4f4d\u75c5\u4eba\u63a5\u53d7\u55ae\u7d14\u653e\u5c04\u7dda\u6cbb\u7642\uff08RT\uff09\u3002\u5c0d\u65bc\u63a5\u53d7CRT\u7684\u75c5\u4eba\uff0c\u4ed6\u5011\u5148\u63a5\u53d71\u52305\u500b\u7642\u7a0b\u7684\u5f15\u5c0e\u5f0f\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\uff08\u5168\u8166\u5ba4\u6216\u662f\u816b\u7624\u5340\u57df\uff09\u6216\u8005\u662f\u5168\u8166\u810a\u9ad3\u7167\u5c04\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5291\u91cf\u8207\u7167\u91ce\u5927\u5c0f\u56e0\u816b\u7624\u4f4d\u7f6e\uff0c\u816b\u7624\u5c0d\u65bc\u5316\u5b78\u6cbb\u7642\u4e4b\u53cd\u61c9\u548c\u810a\u9ad3\u53d7\u4fb5\u72af\u4e4b\u72c0\u614b\u800c\u5b9a\u3002\u572820\u4f4d\u75c5\u4eba\u4e2d\uff0c\u670913\u4f4d\u75c5\u4eba\u63a1\u7528\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\u9032\u884c\u6cbb\u7642\uff0c\u5176\u4ed67\u4f4d\u63a5\u53d7\u5168\u8166\u810a\u9ad3\u7167\u5c04\u7684\u75c5\u4eba\uff0c\u5247\u63a1\u7528\u87ba\u65cb\u5200\u6cbb\u7642\u6280\u8853\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5305\u62ec18\u4f4d\u7537\u6027\u82072\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba14\u6b72\uff0c\u7bc4\u570d\u70ba7\u81f329\u6b72\u3002\u8ffd\u8e64\u6642\u9593\u5e73\u5747\u4e2d\u4f4d\u6578\u70ba34\u500b\u6708\uff0c\u51763\u5e74\u7684\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba90%\uff0c\u800c\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba100%\u3002\u5c0d\u65bc\u55ae\u7d14\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u5168\u8166\u810a\u9ad3\u7167\u5c04\u5291\u91cf\u70ba30.6\u683c\u96f7\uff08Gy\uff09\uff0c\u6bcf\u65e5\u7167\u5c041.8\u683c\u96f7\uff0c\u82e5\u7121\u8166\u810a\u9ad3\u7167\u5c04\u6642\uff0c\u5168\u8166\u5ba4\u53ca\u8166\u4e0b\u817a\u795e\u7d93\u90e8\u7167\u5c04\u5291\u91cf\u70ba30\u683c\u96f7\uff0c\u6bcf\u65e5\u7167\u5c042\u683c\u96f7\uff0c\u518d\u91dd\u5c0d\u816b\u7624\u5340\u57df\u52a0\u5f37\u5291\u91cf\u5230\u4e2d\u4f4d\u6578\u5291\u91cf50\u683c\u96f7\uff0846.5-50.4\u683c\u96f7\uff09\u3002\u800c\u5c0d\u65bc\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u7642\u7684\u75c5\u4eba\uff0c\u5168\u8166\u810a\u9ad3\u7167\u5c04\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba24\u683c\u96f7\uff0821.6-30.6\u683c\u96f7\uff09\uff0c\u6bcf\u65e5\u63a5\u53d71.5\u81f31.8\u683c\u96f7\uff0c\u4e4b\u5f8c\u518d\u91dd\u5c0d\u816b\u7624\u5340\u57df\u52a0\u5f37\u5291\u91cf\u5230\u4e2d\u4f4d\u5291\u91cf45\u683c\u96f7\uff0824-50.4\u683c\u96f7\uff09\u3002\u55ae\u7d14\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\u4e2d\u6c92\u6709\u5fa9\u767c\u7684\u60c5\u6cc1\uff0c\u7136\u800c2\u4f4d\u63a5\u53d7\u5316\u653e\u7642\u4f46\u6c92\u6709\u63a5\u53d7\u5168\u8166\u810a\u9ad3\u7167\u5c04\u7684\u75c5\u4eba\u5247\u767c\u751f\u810a\u690e\u5340\u57df\u5fa9\u767c\u3002\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7814\u7a76\u6210\u679c\u986f\u793a\u5c0d\u65bc\u9871\u5167\u751f\u6b96\u7d30\u80de\u7624\u800c\u8a00\uff0c\u4e0d\u8ad6\u75c5\u60a3\u8166\u810a\u9ad3\u6db2\u662f\u5426\u6e2c\u5f97\u03b2-HCG\uff0c\u524d\u5c0e\u5f0f\u5316\u7642\u642d\u914d\u8f03\u5c11\u5291\u91cf\u53ca\u8f03\u5c0f\u7167\u5c04\u7bc4\u570d\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7686\u53ef\u9054\u5230\u826f\u597d\u7684\u75be\u75c5\u63a7\u5236\u8207\u9810\u5f8c\u3002", "e": "Purpose: We retrospectively analyzed the clinicopathologic features and treatment modalities, including radiotherapy (RT) alone and induction chemotherapy followed by RT (CRT), and the clinical outcomes of intracranial germinoma. Methods and Materials: A total of 20 patients diagnosed with tissue-confirmed intracranial germinoma between 2006 and 2012 and available follow-up data were included in this study. Sixteen patients underwent CRT and 4 underwent RT alone. CRT involved one to five cycles of upfront chemotherapy followed by limited-field (whole ventricle plus primary tumor boost) or extended-field RT (craniospinal irradiation [CSI] followed by limited-field), for which the RT field and dose depended on the tumor location, response to chemotherapy, and metastatic status. Among them, 13 patients received limited or extended-field RT with 3-dimensional (3D) conformal radiotherapy (3D-CRT), and 7 patients received CSI accompanied by helical tomotherapy. Results: This study consisted of 18 male and 2 female patients, with a median age of 14 years (7-29 y). After a median follow-up of 34 months, the 3-year disease-free survival rate and overall survival (OS) rate were 90% and 100%, respectively. For the RT alone group, the CSI was delivered with a tumor dose of 30.6 Gy in fractions of 1.8 Gy/d, whole-ventricle and neurohypophysis involved administering 30 Gy in fractions of 2 Gy/d if no CSI was used. Finally, the tumor was boosted to receive a total median dose of 50 Gy (46.5-50.4 Gy), whereas for the CRT group, the entire brain and/or spine received a median of 24 Gy (21.6-30.6 Gy) in fractions of 1.5-1.8 Gy/d, and the tumor was boosted to a total median dose of 45 Gy (24-50.4 Gy). No recurrences developed in patients treated using extended RT; however, 2 patients treated with CRT, but not with CSI, developed spinal relapse. Conclusion: Our results indicate that induction chemotherapy accompanied by dosereduced and volume-reduced RT resulted in effective disease control and prognosis for intracranial germinoma, including \u03b2-HCG secreting germinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-121-129", "title": "\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624\u61c9\u7528\u92b3\u901f\u5200\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u4e4b\u6bd4\u8f03", "keywords": "\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624;\u92b3\u901f\u5200;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Malignant pleural mesothelioma (MPM);RapidArc;Intensity-modulated radiotherapy (IMRT)", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u60e1\u6027\u80f8\u819c\u9593\u76ae\u7624\uff08Malignant Pleural Mesothelioma, MPM\uff09\u61c9\u7528\u92b3\u901f\u5200\uff08RapidArc\uff09\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08Intensity-modulated Radiotherapy, IMRT\uff09\u6cbb\u7642\u8a08\u5283\u7684\u7d50\u679c\u9032\u884c\u6bd4\u8f03\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u672c\u79d1\u4e8c\u4f8bMPM\u7684\u75c5\u60a3\u5206\u5225\u57f7\u884cRapidArc\u4ee5\u53caIMRT\u6cbb\u7642\u8a08\u5283\u512a\u5316\u7684\u7a0b\u5e8f\uff0c\u518d\u5c0d\u8a08\u5283\u7d50\u679c\u9032\u884c\u816b\u7624\u9ad8\u5291\u91cf\u8986\u84cb\u7387\u3001\u6b63\u5e38\u5668\u5b98\u63a5\u53d7\u5291\u91cf\u3001\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u53ca\u6cbb\u7642\u6642\u9593\u4ee5\u53ca\u6cbb\u7642\u8a08\u5283\u54c1\u8cea\u4fdd\u8b49\u7d50\u679c\u5206\u6790\uff0c\u6bd4\u8f03\u4e8c\u7a2e\u4e0d\u540c\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1aCTV\u6700\u5927\u5291\u91cf\u7684\u90e8\u4efdIMRT\u548cRapidArc\u5206\u5225\u662f65.78 Gy\u300167.09 Gy\uff0cRapidArc\u7565\u9ad8\u65bcIMRT\u3002COIN\u4ee5\u53caHI\u8a08\u7b97\u7d50\u679c\u5247\u662fRapidArc\u512a\u65bcIMRT\u3002\u5468\u908a\u7684\u6b63\u5e38\u5668\u5b98\u6240\u63a5\u53d7\u7684\u5291\u91cf\u90fd\u53ef\u4ee5\u7b26\u5408\u6cbb\u7642\u8a08\u5283\u7684\u9650\u5236\uff0c\u4f46\u662fRapidArc\u7684\u8868\u73fe\u4e00\u822c\u90fd\u512a\u65bcIMRT\u3002\u6cbb\u7642\u8a08\u5283MU\u5e73\u5747\u503c\u5206\u5225\u70ba1799 \u00b1 367\u4ee5\u53ca828 \u00b1 24.75\uff0cIMRT\u660e\u986f\u9ad8\u65bcRapidArc\u5927\u7d04\u4e8c\u500d\u7684\u91cf\u3002\u4e8c\u4f8bIMRT\u75c5\u60a3\u5b8c\u6210\u6cbb\u7642\u6240\u9700\u7684\u6642\u9593\u5e73\u5747\u70ba11.96 \u00b1 1.0\u5206\u9418\uff0cRapidArc\u5b8c\u6210\u6cbb\u7642\u6240\u9700\u7684\u6642\u9593\u5e73\u5747\u70ba4.0 \u00b1 0.71\u5206\u9418\u3002MatriXX QA\u6e2c\u91cf\u7d50\u679c\uff0c\u5728\u8ddd\u96e23 mm\u548c\u5291\u91cf3%\u8aa4\u5dee\u7684\u95be\u503c\u4e4b\u4e0bIMRT\u548cRapidArc\u6cbb\u7642\u8a08\u5283\u8207\u6e2c\u91cf\u503c\u6bd4\u5c0d\u7684\u4f3d\u78bc\u503c\u901a\u904e\u7387\u5206\u5225\u70ba91.06%\u4ee5\u53ca92.65%\u3002\u7d50\u8ad6\uff1a\u5229\u7528\u5927\u7bc4\u570d\u7167\u91ce\u6cbb\u7642MPM\u7684\u75c5\u60a3\uff0cRapidArc\u6cbb\u7642\u6280\u8853\u53ef\u4ee5\u63d0\u4f9b\u5f88\u597d\u7684\u816b\u7624\u9ad8\u5291\u91cf\u8986\u84cb\u7387\uff0c\u540c\u6642\u964d\u4f4e\u6b63\u5e38\u5668\u5b98\u63a5\u53d7\u7684\u8f3b\u5c04\u5291\u91cf\uff0c\u548cIMRT\u6bd4\u8f03\u4e5f\u53ef\u4ee5\u6e1b\u5c11\u6cbb\u7642\u6240\u9700\u7684MU\u548c\u82b1\u8cbb\u7684\u6642\u9593\u905450%\u4ee5\u4e0a\uff0c\u53ef\u4ee5\u9810\u9632\u7e7c\u767c\u6027\u816b\u7624\u7684\u53ef\u80fd\u6027\u4ee5\u53ca\u6bcf\u5929\u6cbb\u7642\u4e2d\u4e0d\u81ea\u4e3b\u904b\u52d5\u6240\u9020\u6210\u7684\u8aa4\u5dee\u3002", "e": "Purpose: A treatment planning study comparing volumetric arc modulation with RapidArc and intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma (MPM). Materials and Methods: For both IMRT and RapidArc, the dose calculations and optimizations were performed using the Eclipse treatment planning system. The plans for IMRT with nine fixed beams were compared against four partial arcs with a single isocenter. All plans were optimized for 6 MV photon beams. The dose prescription was 60 Gy to the planning target volume. For organs at risk, the mean and maximum doses were constrained and additional objectives were set on various volume thresholds. The monitor units (MUs) and delivery time were scored to measure the treatment efficiency. The treatment planning dosimetry scored delivery to the calculation agreement with the passing rate of gamma index. Results: RapidArc and IMRT provided equivalent coverage, the average of maximum dose of CTV for IMRT and RapidArc were 65.78 Gy, 67.09 Gy, respectively. The conformity index (COIN) and homogeneity index (HI) of RapidArc were better than IMRT. Both techniques accomplished objectives on organs at risk with a tendency of RA to improve sparing. The number of MUs was 828 \u00b1 24.75 for RapidArc and 1799 \u00b1 367 for IMRT. Treatment plan delivery time was 4.0 \u00b1 0.71 min for RapidArc and 11.96 \u00b1 1.0 min for IMRT. The agreement between planning and measurement showed the passing rate of gamma index for IMRT of 91.06% and for RapidArc of 92.65%. Conclusion: Compared with IMRT, RapidArc treatment technique can provide similar target coverage and better dose sparing to the organs at risks for MPM patients. RapidArc can also reduce the treatment MU and treatment time more than 50% to prevent the possibility of secondary tumors and uncertainty from daily treatment of involuntary movement."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-131-140", "title": "\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u6a5f\u7167\u91ce\u5bec\u5ea6\u8207\u87ba\u8ddd\u53c3\u6578\u8a2d\u5b9a\u5c0d\u6cbb\u7642\u8a08\u756b\u7684\u5f71\u97ff\uff1a\u5047\u9ad4\u5be6\u9a57", "keywords": "\u96fb\u8166\u65b7\u5c64\u6cbb\u7642;\u87ba\u8ddd;\u6f23\u6ce2\u6548\u61c9;\u653e\u5c04\u6cbb\u7642\u8a08\u756b Tomotherapy;Pitch;Ripple effect;Radiotherapy plan", "c": "\u76ee\u7684\uff1a\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u6a5f\uff08Tomotherapy\u00ae\uff09\u4ee5\u65cb\u9032\uff08helical\uff09\u65b9\u5f0f\u50b3\u905e\u5291\u91cf\uff0c\u56e0\u6b64\u7167\u91ce\u5bec\u5ea6\uff08field width\uff09\u8207\u87ba\u8ddd\uff08pitch\uff09\u5169\u500b\u53c3\u6578\u7684\u8a2d\u5b9a\uff0c\u6703\u5c0d\u6cbb\u7642\u8a08\u756b\u7684\u7d50\u679c\u7522\u751f\u4e00\u5b9a\u4e4b\u5f71\u97ff\u3002\u672c\u5be6\u9a57\u76ee\u7684\u5728\u6bd4\u8f03\u4e0d\u540c\u7684\u7167\u91ce\u5bec\u5ea6\u8207\u87ba\u8ddd\u8a2d\u5b9a\uff0c\u5728\u5747\u52fb\u5047\u9ad4\u4e2d\u5c0d\u6cbb\u7642\u8a08\u756b\u7d50\u679c\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u53d6\u5f97\u5713\u67f1\u578b\u56fa\u614b\u6c34\u5047\u9ad4\uff08Med Cal, Verona, WI\uff09\u4e4b\u65b7\u5c64\u5f71\u50cf\u3002\u7e6a\u88fd\u9776\u9ad4\u7a4d\u8207\u5371\u6025\u5668\u5b98\u8f2a\u5ed3\u3001\u57f7\u884c\u76f8\u540c\u7684\u6700\u4f73\u5316\u758a\u4ee3\u6b21\u6578\u8207\u76f8\u540c\u7684\u9776\u9ad4\u7a4d\u8207\u5371\u6025\u5668\u5b98\u6b0a\u91cd\uff0c\u50c5\u8a2d\u5b9a\u4e0d\u540c\u7167\u91ce\u5bec\u5ea6\uff085 cm\u30012.5 cm\u30011 cm\uff09\u53ca\u87ba\u8ddd\u53c3\u6578\uff080.2\u30010.4\u30010.6\u30010.8\uff09\u3002\u6bd4\u8f03\u6574\u9ad4\u6642\u9593\u3001\u9776\u9ad4\u7a4d\u4e4b\u5747\u52fb\u6307\u6a19\u8207\u982d\u8173\u5411\u4e4b\u6f23\u6ce2\u6548\u61c9\uff08ripple effect\uff09\u4ee5\u53ca\u5371\u6025\u5668\u5b98\u63a5\u53d7\u7684\u5291\u91cf\u3002\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\u7576\u6a5f\u982d\u65cb\u8f49\u4e00\u5708\u6240\u82b1\u9031\u671f\u5927\u65bc\u6700\u5feb\u9031\u671f\u6642\uff0c\u7167\u5c04\u6642\u9593\u8207\u87ba\u8ddd\u503c\u7121\u95dc\u800c\u8207\u7167\u91ce\u5bec\u5ea6 \u6709\u95dc\uff0c5 cm\u30012.5 cm\u30011 cm\u6240\u9700\u7684\u7167\u5c04\u6642\u9593\u6bd4\u503c\u7d04\u70ba1:1.8:4\u3002\u7576\u87ba\u8ddd\u592a\u5c0f\uff0c\u4f7f\u5f97\u6a5f\u982d\u65cb\u8f49\u9031\u671f\u5c0f\u65bc15\u79d2\u6642\uff0c\u70ba\u914d\u5408\u6a5f\u5668\u6700\u5feb\u9031\u671f\u7684\u9650\u5236\uff0c\u65cb\u8f49\u9031\u671f\u6703\u5ef6\u9577\u70ba\u6a5f\u982d\u7684\u6700\u5feb\u9031\u671f\uff0c\u4f7f\u7167\u5c04\u6642\u9593\u589e\u9577\u3002\u7167\u91ce\u5bec\u5ea6\u6108\u5927\u982d\u8173\u5411\u5291\u91cf\u534a\u5f71\u5340\u6108\u5927\u3002\u87ba\u8ddd\u8a2d\u5b9a0.6\u6642\u9776\u9ad4\u7a4d\u5167\u6709\u660e\u986f\u7684\u6f23\u6ce2\u6548\u61c9\uff0c\u6b64\u6642\u9776\u9ad4\u7a4d\u7684\u5747\u52fb\u5ea6\u6700\u5dee\u3002\u9776\u9ad4\u7a4d\u9806\u5f62\u5ea6\u5728\u6a6b\u5207\u9762\u4e0a\u4e26\u7121\u660e\u986f\u5dee\u7570\uff0c\u7167\u91ce\u5bec\u5ea6\u6108\u5c0f\u5728\u7167\u91ce\u908a\u7de3\u982d\u8173\u5411\u7684\u5291\u91cf\u68af\u5ea6\u6108\u5927\u3002\u5c0f\u7167\u91ce\u5bec\u5ea6\u8207\u5c0f\u87ba\u8ddd\u5c0d\u5371\u6025\u5668\u5b98\u7684\u4fdd\u8b77\u6700\u4f73\u3002\u53e6\u5747\u52fb\u5047\u9ad4\u5167\uff0c\u843d\u5728AP\u65b9\u5411\u7684\u5371\u6025\u5668\u5b98\u63a5\u53d7\u7684\u5e73\u5747\u5291\u91cf\u6bd4\u5074\u5411\u9ad8\u3002\u8a0e\u8ad6\uff1a\u7531\u7d50\u679c\u53ef\u5f97\u7167\u5c04\u6642\u9593\u8207\u7167\u91ce\u5bec\u5ea6\u6709\u660e\u986f\u76f8\u95dc\uff0c\u82e5\u4ee5\u6cbb\u7642\u6642\u9593\u70ba\u4e3b\uff0c\u53ef\u8003\u616e\u7528\u5927\u7167\u91ce\u5bec\u5ea6\u642d\u914d\u5c0f\u87ba\u8ddd\uff0c\u4f46\u4f4d\u65bc\u9776\u9ad4\u7a4d\u5916\u5074\u982d\u8173\u5411\u5340\u57df\u7684\u5291\u91cf\u6703\u589e\u52a0\u3002\u82e5\u4ee5\u8a08\u756b\u54c1\u8cea\u70ba\u4e3b\uff0c\u5247\u4f7f\u7528\u5c0f\u7167\u91ce\u5bec\u5ea6\u8207\u5c0f\u87ba\u8ddd\uff0c\u4f46\u6cbb\u7642\u6642\u9593\u6703\u589e\u52a0\u3002", "e": "Purpose: Field width (FW) and pitch factor (PF) are parameters that influence the quality of treatment plans and beam-on times in Tomotherapy that delivers helical radiation therapy. This study examines the relationship between these parameters and their influence on the quality of treatment plan. Material and Method: Target volumes and organ at risk (OAR) volumes were delineated on a computerized tomography of a cylindrical chess phantom. Maintaining the weightings of each volume, treatment plans were optimized with a different combination of planning parameters (FW = 5, 2,5, 1 cm. PF = 0.2, 0.4, 0.6, 0.8). Each plan was analyzed for dose distribution, treatment time, homogeneity index, conformity index and ripple effect. Result: For revolutions lasting between 15 and 60 seconds, the increase in treatment time correlated with decreasing field width. The ratio between treatment time with different field widths, when treatment time at 5 cm was 1, 1.8 and 4 times at widths of 2.5 cm and 1 cm respectively. Where change in pitch factor was did not result in change in treatment time. For revolutions under 15 seconds, smaller pitch denotes longer treatment time. The dimension of penumbra increased with increasing width. At pitch factor 0.6, the ripple effect was evident and the homogeneity index was at its worst. Transversely, conformity indices differed non-significantly. Longitudinally, the dose gradient increased with decreasing field width. Doses to OARs were minimized at small pitch and field width. OARs in longitudinal direction had higher median dose. Conclusion: Change in field width could lead to change in treatment time. Treatment time could be shortened with combination of large field width and the pitch value, at expense of increased dose to longitudinal directions. Combination of small field width and small pitch yielded better planning quality, and increase in treatment time."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-141-145", "title": "Adjuvant Radiotherapy for Recurrent Mucoepidermoid Carcinoma of the Orbit: A Case Report and Review of Literature", "keywords": "\u9ecf\u6db2\u8868\u76ae\u6a23\u764c;\u87ba\u65cb\u5200;\u773c\u7736 Mucoepidermoid Carcinoma;TomoTherapy;Orbit", "c": "\u9ecf\u6db2\u8868\u76ae\u6a23\u764c\u4e26\u975e\u5e38\u898b\u7684\u773c\u7736\u90e8\u4f4d\u816b\u7624\u3002\u672c\u6587\u5c07\u5831\u544a\u4e0062\u6b72\u7537\u6027\u60a3\u773c\u7403\u51f8\u51fa\u90548\u5e74\u4e4b\u4e45\u7684\u6848\u4f8b\u3002\u6b64\u6848\u4f8b\u63a5\u53d7\u816b\u7624\u5207\u9664\u4e26\u7d93\u7531\u75c5\u7406\u7d44\u7e54\u8b49\u5be6\u70ba\u9ecf\u6db2\u8868\u76ae\u6a23\u764c\u3002\u56e0\u70ba\u75c5\u4f8b\u6578\u5c11\uff0c\u6211\u5011\u96e3\u4ee5\u754c\u5b9a\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u7684\u89d2\u8272\u3002\u9019\u500b\u6848\u4f8b\u56e0\u70ba\u816b\u7624\u53cd\u8986\u5fa9\u767c\u800c\u63a5\u53d7\u4e86\u591a\u6b21\u7684\u624b\u8853\u5207\u9664\u3002\u6b64\u6848\u4f8b\u5f8c\u4f86\u63a5\u53d7\u4e86\u87ba\u65cb\u5200\u4f5c\u70ba\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\uff0c\u4e14\u7d93\u5f71\u50cf\u5b78\u8ffd\u8e642\u5e74\u89c0\u5bdf\u5230\u7a69\u5b9a\u7684\u816b\u7624\u63a7\u5236\u3002\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u63d0\u4f9b\u773c\u7736\u5fa9\u767c\u6027\u9ecf\u6db2\u8868\u76ae\u6a23\u764c\u75c5\u60a3\u6cbb\u7642\u9078\u64c7\u3002\u672c\u6587\u91dd\u5c0d\u6848\u4f8b\u7684\u6cbb\u7642\u904e\u7a0b\u52a0\u4ee5\u8a0e\u8ad6\uff0c\u4e26\u4e14\u56de\u9867\u76f8\u95dc\u6587\u737b\u3002", "e": "Mucoepidermoid carcinoma of the orbit is an uncommon neoplasm. We report a 62-year-old Taiwanese man developed a painless proptosis for 8 years. He underwent tumor resection. By histopathology, mucoepidermoid carcinoma was diagnosed. Owing to the rare incidence, the role of adjuvant radiotherapy (RT) in the disease control has not been defined. Several episodes of recurrence developed despite repeated surgery in this case. The patient was treated with the adjuvant TomoTherapy afterwards. The results at 2 years image follow up revealed stationary tumor volume state after treatment. Therefore, adjuvant RT could be an option of treatment for recurrent mucoepidermoid carcinoma arising from the eye following surgery. Treatment decision making of this case is discussed and previous reports are reviewed in this article."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201406-201407070026-201407070026-147-153", "title": "Primary Small Cell Carcinoma of the Ureter-A Case Report and Review of the Literature", "keywords": "\u80ba\u5916;\u5c0f\u7d30\u80de\u764c;\u8f38\u5c3f\u7ba1 Extrapulmonary;Small cell carcinoma;Ureter", "c": "\u524d\u8a00\uff1a\u5c0f\u7d30\u80de\u764c\u901a\u5e38\u8d77\u6e90\u65bc\u80ba\u5167\uff0c\u4f46\u4e5f\u53ef\u4ee5\u8d77\u6e90\u65bc\u80ba\u5916\u7684\u8a31\u591a\u4f4d\u7f6e\u4e0a\u3002\u80ba\u5916\u7684\u5c0f\u7d30\u80de\u764c\u5f88\u5c11\u898b\uff0c\u53ea\u4f54\u4e86\u6240\u6709\u5c0f\u7d30\u80de\u764c\u7684\u5343\u5206\u4e4b\u4e00\u5230\u56db\uff0c\u800c\u4e14\u539f\u767c\u5728\u975e\u5e38\u591a\u6a23\u7684\u5668\u5b98\u4e0a\u3002\u6ccc\u5c3f\u7cfb\u7d71\u7684\u5c0f\u7d30\u80de\u764c\u6700\u5e38\u898b\u5728\u8180\u80f1\uff0c\u8d77\u6e90\u65bc\u8f38\u5c3f\u7ba1\u66f4\u662f\u6975\u70ba\u7f55\u898b\u3002\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u500b\u4e94\u5341\u516d\u6b72\u7684\u7537\u6027\uff0c\u56e0\u70ba\u5169\u500b\u6708\u524d\u958b\u59cb\u6709\u53f3\u8179\u5074\u75db\u800c\u4f86\u4f4f\u9662\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u5728\u53f3\u5074\u9aa8\u76c6\u8154\uff0c\u767c\u73fe\u8d77\u6e90\u65bc\u53f3\u5074\u8f38\u5c3f\u7ba1\u7684\u6d78\u6f64\u6027\u7684\u816b\u7624\uff0c\u7d048.5 cm x 7.6cm\u5927\uff0c\u4f34\u96a8\u8457\u56b4\u91cd\u7684\u53f3\u5074\u6c34\u814e\u4ee5\u53ca\u53f3\u5074\u8f38\u5c3f\u7ba1\u7a4d\u6c34\u3002\u75c5\u4eba\u63a5\u53d7\u4e86\u4e09\u500b\u7642\u7a0b\uff0c\u914d\u65b9\u70ba\u9806\u9251\u8207\u5065\u64c7\u7684\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u63a5\u8457\u63a5\u53d7\u53f3\u5074\u624b\u8f14\u52a9\u5f0f\u5f8c\u8179\u8154\u93e1\u814e\u8f38\u5c3f\u7ba1\u5207\u9664\u8853\u3002\u8853\u5f8c\u52a0\u505a\u8f14\u52a9\u6027\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3002\u5316\u5b78\u6cbb\u7642\u7684\u90e8\u4efd\u70ba\u4e09\u500b\u7642\u7a0b\u7684\u9806\u9251\uff08Cisplatin\uff09\u8207\u4f9d\u6258\u6cca\u7519\uff08Etoposide\uff09\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u90e8\u4efd\u5728\u816b\u7624\u539f\u767c\u75c5\u7076\u8655\u7d66\u4e8864.8 Gy\u3002\u8a0e\u8ad6\uff1a\u539f\u767c\u8f38\u5c3f\u7ba1\u5c0f\u7d30\u80de\u764c\u6700\u5e38\u898b\u7684\u75c7\u72c0\u662f\u8089\u773c\u6027\u8840\u5c3f\u8207\u8179\u5074\u75bc\u75db\u3002\u800c\u6b64\u75be\u75c5\u7684\u5206\u671f\u4f9d\u64da\u5c0f\u7d30\u80de\u80ba\u764c\u3002\u539f\u767c\u8f38\u5c3f\u7ba1\u5c0f\u7d30\u80de\u764c\u7684\u6cbb\u7642\u76ee\u524d\u4ecd\u6c92\u6709\u5b8c\u6574\u5efa\u7acb\u3002\u5118\u7ba1\u6709\u8f14\u52a9\u6027\u6cbb\u7642\uff0c\u5927\u90e8\u4efd\u7684\u75c5\u4eba\u5f8c\u4f86\u90fd\u6709\u9060\u7aef\u8f49\u79fb\u4e14\u9810\u5f8c\u4e0d\u597d\u3002\u70ba\u4e86\u6539\u5584\u9810\u5f8c\uff0c\u7a4d\u6975\u7684\u6cbb\u7642\u662f\u9700\u8981\u7684\uff0c\u4f46\u662f\u8981\u8003\u616e\u5230\u75c5\u4eba\u7684\u8010\u53d7\u6027\u3002", "e": "Introduction: Small cell carcinoma usually arises in the lung but can also originate in a wide range of extrapulmonary sites. Extrapulmonary small cell carcinoma is rare, encompassing approximately 0.1-0.4 percent of all small cell carcinomas, and has been described in a variety of organs. Small cell carcinoma of the genitourinary tract is often found in the urinary bladder, and is extremely rare in the ureter. Case report: A 56-year-old man was admitted with a two-month history of the right flank pain. An abdominal computed tomography demonstrated an infiltrative mass lesion with size of about 8.5 \u00d7 7.6 cm in the right pelvis, arising from the right ureter, with severe right hydronephrosis and hydroureter. The patient received neoadjuvant chemotherapy with cisplatin and gemcitabine for 3 cycles, followed by right side hand-assisted retroneoscopic nephroureterectomy. Then adjuvant concurrent chemo-radiotherapy was given. The chemotherapy regimens were cisplatin and etoposide for 3 cycles. The irradiation course consisted of 64.8 Gy/36 fractions to the tumor bed. Discussion: The most common symptoms of this disease are gross hematuria and flank pain. The staging of this disease is according to small cell carcinoma of the lung. The treatment of ureter small cell carcinoma is not well established. Despite adjuvant chemotherapy or radiotherapy, most patients develop metastatic disease resulting in poor prognosis of this disease. Aggressive treatment is warranted to improve the outcome. However, the tolerance of the patients is still needed to be considered."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-1-12", "title": "Preliminary Results of Biochemical Outcomes, Survival and Toxicity in Patients Treated with Intensity-Modulated Radiation Therapy for Localized Prostate Cancer", "keywords": "\u651d\u8b77\u817a\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642;\u751f\u5316\u7121\u5fa9\u767c\u5b58\u6d3b\u7387 Prostate cancer;IMRT;Biochemical relapse-free survival", "c": "\u76ee\u7684\uff1a\u5c40\u9650\u6027\u4e14\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u651d\u8b77\u817a\u764c\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u521d\u6b65\u7684\u751f\u5316\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u3001\u5b58\u6d3b\u7387\u53ca\u6cbb\u7642\u526f\u4f5c\u7528\u7684\u7d50\u679c\u5831\u544a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a2003\u5e7412\u6708\u81f32012\u5e743\u6708\uff0c\u517187\u4f4d\u6709\u5c40\u9650\u6027\u4e14\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u651d\u8b77\u817a\u764c\u75c5\u60a3\u65bc\u672c\u79d1\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6cbb\u7642\u8a08\u5283\u5229\u7528\u9006\u7b97\u5f0f\u96fb\u8166\u8a08\u5283\u7cfb\u7d71\u642d\u914d\u52d5\u614b\u591a\u8449\u578b\u6e96\u76f4\u5100\u3002\u75c5\u4eba\u662f\u4f9d\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u8cc7\u8a0a\u7db2\uff08NCCN\uff09\u7684\u651d\u8b77\u817a\u764c\u671f\u5225\u5206\u985e\u3002\u751f\u7269\u5316\u5b78\u5931\u6557\u7684\u81e8\u5e8a\u5b9a\u7fa9\u662f\u63a1\u75282005\u5e74RTOG-ASTRO\u9cf3\u51f0\u57ce\u6703\u8b70\u4e2d\u6240\u9054\u6210\u4e4b\u5171\u8b58\uff0d\u8840\u6db2\u4e2d\u6e2c\u5f97\u7684\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u503c\u5927\u65bc\u6700\u4f4e\u503c\u52a02 ng/mL\u3002\u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u7684\u5291\u91cf\u4ecb\u65bc61\u820778.4\u845b\u96f7\u3002\u6cbb\u7642\u5f8c\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u503c\u662f41\u500b\u6708\uff08\u7bc4\u570d\u4ecb\u65bc10\u5230105\u500b\u6708\uff09\u3002\u7d50\u679c\uff1a\u4e09\u5e74\u7684\u751f\u5316\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u5c0d\u65bc\u4f4e\u5371\u96aa\u7fa4\u3001\u4e2d\u5371\u96aa\u7fa4\u3001\u9ad8\u5371\u96aa\u7fa4\u3001\u975e\u5e38\u9ad8\u5371\u96aa\u7fa4\u5206\u5225\u662f100%\u3001100%\u300176.3%\u300188.5%\u3002\u4e09\u5e74\u548c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u662f92%\u820780%\u300225\u4f4d\u75c5\u4eba\uff0828.7%\uff09\u7522\u751f\u6025\u6027\u7b2c\u4e8c\u7d1a\u8178\u80c3\u9053\u526f\u4f5c\u7528\uff0c\u7121\u75c5\u4eba\u6709\u6025\u6027\u7b2c\u4e09\u7d1a\u4ee5\u4e0a\u7684\u8178\u80c3\u9053\u75c7\u72c0\u300219\u4f4d\u75c5\u4eba\uff0821.8%\uff09\u7522\u751f\u6025\u6027\u7b2c\u4e8c\u7d1a\u6ccc\u5c3f\u9053\u75c7\u72c0\uff0c\u800c\u6709\u4e00\u4f4d\u75c5\u4eba\u51fa\u73fe\u5c3f\u6eef\u7559\u73fe\u8c61\uff08\u7b2c\u4e09\u7d1a\u4ee5\u4e0a\u6ccc\u5c3f\u9053\u526f\u4f5c\u7528\uff09\u3002\u6c92\u6709\u75c5\u4eba\u7522\u751f\u6162\u6027\u7b2c\u4e8c\u7d1a\u4ee5\u4e0a\u8178\u80c3\u9053\u526f\u4f5c\u7528\u3002\u53ea\u6709\u4e09\u4f4d\u75c5\u4eba\uff083.5%\uff09\u51fa\u73fe\u6162\u6027\u7b2c\u4e8c\u7d1a\u6ccc\u5c3f\u9053\u75c7\u72c0\uff0c\u4f46\u7121\u75c5\u4eba\u7522\u751f\u6162\u6027\u7b2c\u4e09\u7d1a\u4ee5\u4e0a\u6ccc\u5c3f\u9053\u526f\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u5f9e\u6211\u5011\u7684\u7d50\u679c\u4f86\u770b\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u662f\u651d\u8b77\u817a\u764c\u75c5\u4eba\u53ef\u884c\u7684\u81e8\u5e8a\u6cbb\u7642\u65b9\u5f0f\u3002\u521d\u6b65\u7684\u751f\u5316\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u8207\u5176\u4ed6\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u6587\u737b\u76f8\u7576\uff0c\u4e14\u4f34\u96a8\u5c11\u6578\u7684\u6025\u6027\u548c\u6162\u6027\u6cbb\u7642\u526f\u4f5c\u7528\u3002\u57fa\u65bc\u9019\u6709\u5229\u7684\u7d50\u679c\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u5df2\u6210\u70ba\u672c\u79d1\u6cbb\u7642\u5c40\u9650\u6027\u4e14\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u651d\u8b77\u817a\u764c\u7684\u6a19\u6e96\u6a21\u5f0f\u3002", "e": "Purpose: To report preliminary biochemical outcomes, survival and toxicity for patients with localized prostate cancer treated with intensity-modulated radiotherapy (IMRT).Materials and Methods: Between December 2003 and March 2012, eighty-seven patients with clinically localized prostate cancer were treated with IMRT at our institution. Treatment was planned using an inverse-planning method. The beam intensity profiles were delivered by dynamic multileaf collimation. Patients were stratified by prognostic risk groups based on National Comprehensive Cancer Network (NCCN) risk classification criteria. Biochemical failure was defined using the 2005 ASTRO Phoenix consensus definition of the nadir prostate-specific antigen (PSA) concentration plus 2 ng/mL. Prescribed dose ranged from 61-78.4 Gy. The median follow-up time was 41 months (range: 10-105 months).Results : The 3-year actuarial biochemical relapse-free survival rates for low, intermediate, high, and very high risk group patients were 100%, 100%, 76.3%, and 88.5%, respectively. The 3- and 5-year actuarial overall survival rates were 92% and 80%. Twenty-five patients (28.7%) developed acute Grade 2 GI toxicity, and no patient experienced acute Grade 3 or greater rectal symptoms. Nineteen patients (21.8%) developed acute Grade 2 genitourinary (GU) symptoms, and one experienced Grade 3 or higher GU toxicity. No patient developed late Grade 2 or greater rectal toxicity. Only three patients (3.5%) experienced late Grade 2 GU toxicity. No late Grade 3 or greater GU complications have been observed.Conclusions: Our data demonstrate the feasibility of IMRT in the treatment of localized prostate cancer. Acute and late rectal toxicities are minimal. Short-term biochemical controls are comparable to published results of IMRT. Based on this favorable outcome, IMRT has become the standard treatment for localized prostate cancer at our institution."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-13-20", "title": "A Two-Year Experience of Using Moderate Deep Inspiration Breath-Hold for Patients with Early-Stage Breast Cancer and Dosimetric Comparison", "keywords": "\u9069\u5ea6\u6df1\u5438\u6c23\u547c\u5438\u8abf\u63a7;\u4e3b\u52d5\u547c\u5438\u8abf\u63a7;\u65e9\u671f\u4e73\u764c Moderate deep inspiration breath-hold;Active breathing control;Early stage breast cancer", "c": "\u76ee\u7684\uff1a\u6211\u5011\u5831\u544a\u4f7f\u7528\u9069\u5ea6\u6df1\u5438\u6c23\u547c\u5438\u8abf\u63a7\u6280\u8853\u65bc\u65e9\u671f\u4e73\u764c\u60a3\u8005\u7684\u5169\u5e74\u7d93\u9a57\u4e26\u5206\u6790\u6bd4\u8f03\u5291\u91cf\uff0c\u85c9\u4ee5\u8a55\u4f30\u6b64\u6280\u8853\u65bc\u5fc3\u81df\u3001\u80ba\u81df\u8207\u809d\u81df\u63a5\u53d7\u5291\u91cf\u6e1b\u5c11\u7684\u52a9\u76ca\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u9867\u5206\u6790\u65bc2010\u5e747\u6708\u81f32012\u5e747\u6708\u671f\u9593\u63a5\u53d7\u6cbb\u7642\u7684\u6240\u6709\u65b0\u8a3a\u65b7\u65e9\u671f\u4e73\u764c\u75c5\u60a3\uff0c\u5305\u62ec\u539f\u4f4d\u764c\u3001\u7b2c\u4e00\u671f\u8207\u7b2c\u4e8c\u671f\u75c5\u60a3\u3002\u6b64\u7814\u7a76\u7e3d\u8a08\u670981\u4f4d\u75c5\u60a3\uff0c\u5176\u4e2d24\u4f4d\u63a5\u53d7\u9069\u5ea6\u6df1\u5438\u6c23\u547c\u5438\u8abf\u63a7\u6280\u8853\uff0c\u53e6\u591657\u4f4d\u5247\u63a1\u7528\u81ea\u7136\u547c\u5438\u3002\u5c07\u5169\u7d44\u75c5\u60a3\u505a\u5291\u91cf\u5206\u6790\u4e26\u6bd4\u8f03\u5fc3\u81df\u3001\u80ba\u81df\u8207\u809d\u81df\u6240\u63a5\u53d7\u653e\u5c04\u5291\u91cf\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u6709\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u6280\u8853\u8207\u81ea\u7136\u547c\u5438\u7684\u5169\u7d44\u75c5\u60a3\uff0c\u7d93\u904e\u5206\u6790\u5f8c\u767c\u73fe\u4ee5\u4e0b\u56e0\u5b50\u4e26\u7121\u5dee\u7570\uff1a\u764c\u75c7\u5206\u671f\u5206\u5e03\u3001\u816b\u7624\u90e8\u4f4d\u5206\u5e03\u3001\u5e74\u9f61\u5206\u5e03\u3001\u81e8\u5e8a\u9776\u5340\u7684\u5291\u91cf\u5305\u8986\u7387\u3001\u81e8\u5e8a\u9776\u9ad4\u7a4d\u3001\u5fc3\u81df\u9ad4\u7a4d\u8207\u809d\u81df\u9ad4\u7a4d\u300281\u4f4d\u6240\u6709\u75c5\u60a3\u7d93\u5206\u6790\u5f8c\u767c\u73fe\u6709\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u6280\u8853\u7684\u75c5\u60a3\u76f8\u8f03\u65bc\u81ea\u7136\u547c\u5438\u7684\u75c5\u60a3\uff0c\u6709\u660e\u986f\u8f03\u4f4e\u7684\u55ae\u5074\u80ba\u81dfV10\u3001\u55ae\u5074\u80ba\u81dfV20\u3001\u55ae\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u3001\u5169\u5074\u80ba\u81dfV10\u3001\u5169\u5074\u80ba\u81dfV20\u3001\u5169\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u3001\u809d\u81dfV30\u8207\u809d\u81df\u5e73\u5747\u5291\u91cf\u3002\u82e5\u91dd\u5c0d37\u4f4d\u5de6\u5074\u4e73\u764c\u75c5\u60a3\u9032\u884c\u5206\u6790\uff0c\u767c\u73fe\u6709\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u6280\u8853\u7684\u75c5\u60a3\u76f8\u8f03\u65bc\u81ea\u7136\u547c\u5438\u7684\u75c5\u60a3\uff0c\u6709\u660e\u986f\u8f03\u4f4e\u7684\u55ae\u5074\u80ba\u81dfV10\u3001\u55ae\u5074\u80ba\u81dfV20\u3001\u55ae\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u3001\u5fc3\u81dfV30\u3001\u5fc3\u81dfV40\u3001\u5fc3\u81df\u5e73\u5747\u5291\u91cf\u8207\u809d\u81df\u5e73\u5747\u5291\u91cf\u3002\u82e5\u91dd\u5c0d44\u4f4d\u53f3\u5074\u4e73\u764c\u75c5\u60a3\u9032\u884c\u5206\u6790\uff0c\u767c\u73fe\u6709\u4f7f\u7528\u4e3b\u52d5\u547c\u5438\u8abf\u63a7\u6280\u8853\u7684\u75c5\u60a3\u76f8\u8f03\u65bc\u81ea\u7136\u547c\u5438\u7684\u75c5\u60a3\uff0c\u6709\u660e\u986f\u8f03\u4f4e\u7684\u55ae\u5074\u80ba\u81dfV20\u3001\u55ae\u5074\u80ba\u81df\u5e73\u5747\u5291\u91cf\u3001\u5fc3\u81df\u5e73\u5747\u5291\u91cf\u3001\u809d\u81dfV30\u8207\u809d\u81df\u5e73\u5747\u5291\u91cf\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u9069\u5ea6\u6df1\u5438\u6c23\u547c\u5438\u8abf\u63a7\u6280\u8853\u65bc\u65e9\u671f\u4e73\u764c\u60a3\u8005\u4e0d\u4f46\u53ef\u4ee5\u964d\u4f4e\u5fc3\u81df\u653e\u5c04\u7dda\u5291\u91cf\uff0c\u4ea6\u53ef\u964d\u4f4e\u80ba\u81df\u8207\u809d\u81df\u5291\u91cf\u3002\u56e0\u6b64\u5e38\u898f\u5730\u4f7f\u7528\u9069\u5ea6\u6df1\u5438\u6c23\u547c\u5438\u8abf\u63a7\u6280\u8853\u53ef\u671b\u5e6b\u5fd9\u6e1b\u5c11\u653e\u5c04\u7dda\u5c0d\u65bc\u5fc3\u81df\u3001\u80ba\u81df\u8207\u809d\u81df\u7684\u6bd2\u6027\u3002", "e": "Purpose: We present our two-year experience of using moderate deep inspiration breath-hold (mDIBH) with an active breathing control (ABC) device for patients with early-stage breast cancer and dosimetric comparison to evaluate the benefit of mDIBH on the heart, lung, and liver.Materials and Methods: We retrospectively reviewed all patients with newly diagnosed breast cancer and having clinical stage Tis, I, or II disease treated between November 2010 and July 2012. Among the 81 patients included in this study, 24 patients were treated with mDIBH and 57 patients were treated with free breathing. Dosimetric analysis was performed to compare dose distribution in the heart, lung, and liver between the two treatment groups.Results: There was no significant difference in the distribution of stage, tumor site, age, clinical target volume (CTV) V50 and volume of CTV, heart, and liver between the non-ABC and ABC group. For all 81 patients, there was a significantly lower ipsilateral lung V10, ipsilateral lung V20, mean ipsilateral lung dose, whole lung V10, whole lung V20, mean whole lung dose, liver V30, and mean liver dose in the ABC group. For 37 patients with a left-sided breast tumor, significantly lower ipsilateral lung V10, ipsilateral lung V20, mean ipsilateral lung dose, heart V30, heart V40, mean heart dose, and mean liver dose were observed in the ABC group. For 44 patients with a right-sided breast tumor, significantly lower ipsilateral lung V20, mean ipsilateral lung dose, mean heart dose, liver V30, and mean liver dose were observed in the ABC group.Conclusions: For early-stage breast cancer patients, mDIBH reduces not only the heart dose but also the lung and liver doses. The routine integration of mDIBH using an ABC device may decrease radiation-induced toxicity in the heart, lung, and liver."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-21-30", "title": "Impact of the Body-Mass Factors on Set-up Displacement in Patients Treated with Pelvic Irradiation for Gynecological Cancer with Daily On-Line Image Guidance", "keywords": "\u5a66\u764c;\u8a2d\u5b9a\u8aa4\u5dee;\u5f71\u50cf\u5c0e\u5f15;\u8eab\u9ad4\u76f8\u95dc\u5f15\u5b50 Gynecological cancer;Setup displacement;Image-guided radiotherapy;Body-mass factors", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u63a2\u8a0e\u5206\u6790\u5a66\u764c\u60a3\u8005\u7684\u8eab\u9ad4\u76f8\u95dc\u56e0\u5b50\u5c0d\u65bc\u9aa8\u76c6\u8154\u653e\u5c04\u6cbb\u7642\u6642\u4e4b\u6cbb\u7642\u4f4d\u7f6e\u8a2d\u5b9a\u8aa4\u5dee\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u6536\u96c6\u4e8622\u4f4d\u56e0\u5b50\u5bae\u9838\u764c\u6216\u5b50\u5bae\u5167\u819c\u764c\u800c\u63a5\u53d7\u9aa8\u76c6\u8154\u5f37\u5ea6\u8abf\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u7684\u8eab\u9ad4\u76f8\u95dc\u56e0\u5b50\uff0c\u5305\u62ec\u9ad4\u91cd\u3001\u8eab\u9ad8\u3001\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08BMI\uff09\u3001\u8170\u570d\u3001\u8170\u5f91\u3001\u81c0\u570d\u3001\u81c0\u5f91\uff1a\u4e26\u53d6\u5f97\u9019\u4e9b\u75c5\u60a3\u5728\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\uff08IGRT\uff09\u4e0b\u89c0\u5bdf\u5230\u4e4b\u6bcf\u65e5\u5373\u6642\u5f71\u50cf\uff08OBI\uff09\u7684\u6cbb\u7642\u4f4d\u7f6e\u8a2d\u5b9a\u6821\u6b63\u6578\u503c\uff0c\u9019\u4e9b\u6578\u503c\u5305\u62ec\u4e86\u4e0a\u4e0b\u3001\u524d\u5f8c\u3001\u5de6\u53f3\u3001\u6cbb\u7642\u5e8a\u65cb\u8f49\u7b49\u56db\u7a2e\u65b9\u5411\u7684\u7cfb\u7d71\u8aa4\u5dee\u548c\u96a8\u6a5f\u8aa4\u5dee\u3002\u6211\u5011\u5c07\u9019\u4e9b\u75c5\u4eba\u7684\u8eab\u9ad4\u76f8\u95dc\u56e0\u5b50\u4e4b\u4e2d\u4f4d\u6578\u7576\u4f5c\u5207\u5272\u9ede\uff0c\u4f7f\u7528Mann-Whitney U\u6aa2\u5b9a\u6cd5\u4f86\u5206\u6790\u9019\u4e9b\u56e0\u5b50\u5c0d\u6cbb\u7642\u4f4d\u7f6e\u8a2d\u5b9a\u8aa4\u5dee\u6240\u9020\u6210\u7684\u5f71\u97ff\u3002\u7d50\u679c\uff1a\u4e0a\u4e0b\u3001\u524d\u5f8c\u3001\u5de6\u53f3\u65b9\u5411\u7684\u7cfb\u7d71\u8aa4\u5dee\u548c\u96a8\u6a5f\u8aa4\u5dee\u5206\u5225\u662f2.8\u516c\u91d0\u30012.6\u516c\u91d0\u30012.4\u516c\u91d0\u4ee5\u53ca1.7\u516c\u91d0\u30011.4\u516c\u91d0\u30011.3\u516c\u91d0\u3002\u65cb\u8f49\u89d2\u5ea6\u7684\u7cfb\u7d71\u8aa4\u5dee\u548c\u96a8\u6a5f\u8aa4\u5dee\u5206\u5225\u662f0.33\u548c0.25\u5ea6\u3002\u8f03\u5927\u7684\u8170\u570d\u8207\u8f03\u5927\u7684\u4e0a\u4e0b\uff0d\u7cfb\u7d71\u8aa4\u5dee\uff08p = 0.02\uff09\u53ca\u65cb\u8f49\uff0d\u96a8\u6a5f\u8aa4\u5dee\uff08p = 0.013\uff09\u6709\u6b63\u76f8\u95dc\u3002\u8f03\u5927\u7684\u81c0\u570d\u5c0e\u81f4\u8f03\u5927\u7684\u4e0a\u4e0b\uff0d\u96a8\u6a5f\u8aa4\u5dee\uff08p = 0.045\uff09\u8207\u65cb\u8f49\uff0d\u96a8\u6a5f\u8aa4\u5dee\uff08p = 0.018\uff09\u3002\u8f03\u5927\u7684\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\u5f15\u8d77\u8f03\u5927\u7684\u65cb\u8f49\uff0d\u96a8\u6a5f\u8aa4\u5dee\uff08p = 0.006\uff09\u3002\u8f03\u9ad8\u7684\u8eab\u9ad8\u5c0e\u81f4\u8f03\u5927\u7684\u524d\u5f8c\uff0d\u7cfb\u7d71\u8aa4\u5dee\uff08p = 0.036\uff09\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u64c1\u6709\u8170\u570d\u5927\u65bc80.5\u516c\u5206\u3001\u6216\u81c0\u570d\u5927\u65bc88.5\u516c\u5206\u3001\u6216\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\u5927\u65bc22.1\u7684\u5a66\u764c\u75c5\u4eba\uff0c\u6211\u5011\u5efa\u8b70\u4f7f\u7528\u5373\u6642\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\u4ee5\u6e1b\u5c11\u6cbb\u7642\u4f4d\u7f6e\u7684\u8a2d\u5b9a\u8aa4\u5dee\u3002", "e": "Purpose: This study was to determine the impact of the body-mass factors on magnitude of setup displacements in patients treated with pelvic intensity modulated radiotherapy (IMRT) for gynecological cancer.Methods: Using the alignment data of daily on-line On Board Imaging (OBI) from image-guided radiotherapy (IGRT), the clinical data of 22 patients treated with pelvic IMRT for cervical or endometrial cancer was analyzed. Body-mass factors included body weight, body height, body mass index (BMI), waist circumference, waist thickness, hip circumference and hip thickness. Setup displacements for each patient were assessed by four components: namely systemic error (SE), and random error (RE), through three translational directions and couch rotation (CR). The median values for the body-mass factors were used as cutoff points to divide the groups. The Mann-Whitney U test was conducted to assess the predictive role of these factors for the set-up errors.Results: Population SE and RE were 2.8 mm, 2.6 mm, 2.4 mm and 1.7 mm, 1.4 mm, 1.3 mm in the superior-inferior (SI), anterior-posterior (AP) and medial-lateral (ML) directions, respectively. The SE and RE for rotation (CR) was 0.33 and 0.25 degree. Larger waist circumference (WC) was significantly correlated with greater SI-SE (p = 0.02), and CR-RE (p = 0.013), whereas larger hip circumference (HC) with greater SI-RE (p = 0.045), and CR-RE (p = 0.018). Higher BMI was associated with greater, CR-RE (p = 0.006). Body height correlated with AP-SE (p = 0.036).Conclusions: To reduce setup displacements in women with gynecological cancer requiring pelvic IMRT, the use of on-line IGRT should be recommended for those who have a WC \uff1e 80.5 cm or a HC \uff1e 88.8 cm, or a BMI \uff1e22.1 Kg/m^2."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-31-41", "title": "Speculation of Intrafractional Motion Errors in Patients with Prostate Cancer during Pelvis RapidArc Radiotherapy", "keywords": "\u6cbb\u7642\u4e2d;\u9aa8\u76c6;\u651d\u8b77\u817a\u764c;\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64;\u92b3\u901f\u5200 Intrafractional motion;Pelvis;Prostate cancer;Cone beam CT (CBCT);RapidArc", "c": "\u76ee\u7684\uff1a\u5206\u6790\u651d\u8b77\u817a\u764c\u75c5\u60a3\u63a5\u53d7\u9aa8\u76c6\u92b3\u901f\u5200\uff08RapidArc\uff09\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u6cbb\u7642\u4e2d\u7684\u79fb\u52d5\u8aa4\u5dee\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5171\u6536\u7d0d18\u4f4d\u63a5\u53d7\u9aa8\u76c6\u92b3\u901f\u5200\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u96fb\u8166\u5200\uff08Cyberknife\uff09\u52a0\u5f37\u5291\u91cf\u7684\u9ad8\u5371\u96aa\u7fa4\u651d\u8b77\u817a\u764c\u75c5\u60a3\u3002\u6cbb\u7642\u671f\u9593\u7684\u524d\u4e09\u6b21\u6cbb\u7642\u65e5\uff0c\u75c5\u60a3\u8eba\u5e8a\u5f8c\u505a\u7b2c\u4e00\u6b21\u7684\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff08kV cone beam computerized tomography\uff09\uff0c\u4e26\u5229\u7528\u5176\u4f86\u8207\u6cbb\u7642\u8a08\u756b\u7684\u81e8\u5e8a\u816b\u7624\u9ad4\u7a4d\u7bc4\u570d\uff08CTV\uff09\u6bd4\u5c0d\uff0c\u77ef\u6b63\u64fa\u4f4d\u8aa4\u5dee\u3002\u63a5\u8457\u5728\u77ef\u6b63\u5f8c\u653e\u5c04\u6cbb\u7642\u524d\u8207\u653e\u5c04\u6cbb\u7642\u5f8c\u505a\u7b2c\u4e8c\u6b21\u8207\u7b2c\u4e09\u6b21\u7684\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u3002\u5229\u7528\u9019\u4e9b\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u6bd4\u5c0d\uff0c\u7d00\u9304\u51fa\u6cbb\u7642\u524d\u5f8c\u7684\u4e09\u500b\u8ef8\uff08\u5de6\u53f3\uff0d\u4e0a\u4e0b\uff0d\u524d\u5f8c\uff09\u7684\u4f4d\u79fb\u8aa4\u5dee\u3002\u7d50\u679c\uff1a\u5728\u6cbb\u7642\u6642\u9593\u77ed\uff08\u7d04\u4e09\u5206\u9418\uff09\u7684\u92b3\u901f\u5200\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e0b\uff0c\u6cbb\u7642\u524d\u5f8cresidual systemic\u548crandom errors\u662f\u8f03\u5c0f\u7684\u3002\u5229\u7528\u7b2c\u4e8c\u6b21\u8207\u7b2c\u4e09\u6b21\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64\uff08\u5206\u5225\u70ba\u6cbb\u7642\u524d\u8207\u6cbb\u7642\u5f8c\uff09\u5f71\u50cf\u6bd4\u5c0d\uff0c\u6cbb\u7642\u4e2d\u8aa4\u5dee\uff08mean \u00b1 SD\uff09\u5728\u4e09\u500b\u8ef8\uff08\u5de6\u53f3\uff0d\u4e0a\u4e0b\uff0d\u524d\u5f8c\uff09\u5206\u5225\u70ba-0.4 \u00b1 0.8, -0.2 \u00b1 1.0, 0.1 \u00b1 0.8 mm\uff0c\u9664\u4e86\u5de6\u53f3\u65b9\u5411\uff0c\u5176\u9918\u7121\u7d71\u8a08\u4e0a\u986f\u8457\u5dee\u7570\u3002\u53e6\u5916\u5229\u7528\u9019\u4e9b\u8aa4\u5dee\u503c\uff0c\u5728\u5169\u500b\u4e0d\u540c\u516c\u5f0f\uff08linear\u8207quadrature margin\uff09\u8a08\u7b97\u4e0b\uff0c\u5176\u81e8\u5e8a\u816b\u7624\u9ad4\u7a4d\uff08CTV\uff09\u5f62\u6210\u816b\u7624\u6cbb\u7642\u9ad4\u7a4d\uff08PTV\uff09\u7684\u7bc4\u570d\u5404\u70ba3.6, 4.4, 4.5 mm\uff1b2.5, 3.2, 3.3 mm\uff08\u5de6\u53f3\uff0d\u4e0a\u4e0b\uff0d\u524d\u5f8c\uff09\u3002\u7d50\u8ad6\uff1a\u651d\u8b77\u817a\u764c\u75c5\u60a3\u63a5\u53d7\u9aa8\u76c6\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u5229\u7528\u8f03\u5feb\u901f\u7684\u92b3\u901f\u5200\u653e\u5c04\u6cbb\u7642\u642d\u914d\u9310\u72c0\u653e\u5c04\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u4f5c\u70ba\u6cbb\u7642\u524d\u77ef\u6b63\uff0c\u5176\u6cbb\u7642\u4e2d\u7684\u9aa8\u76c6\u79fb\u52d5\u662f\u6bd4\u8f03\u5c11\u7684\u3002\u672c\u7bc7\u6240\u89c0\u5bdf\u7684\u9019\u4e9b\u8aa4\u5dee\u7d93\u9a57\uff0c\u53ef\u4ee5\u7528\u4f86\u63d0\u5347\u65e5\u5f8c\u653e\u5c04\u6cbb\u7642\u6e96\u78ba\u6027\u7684\u53c3\u8003\u3002", "e": "Purpose: To evaluate the intrafractional motion errors in patient with prostate cancer received pelvis irradiation during RapidArc radiotherapy.Materials and Methods: A total of eighteen high risk group prostate cancer patients were treated prostate and pelvis lymph nodes by RapidArc radiotherapy then boost dose by Cyberknife. All patients had kV cone beam computerized tomography (CBCT) scans in their first three fractions of treatment. During these treatments, the CBCT scans were registered to planning CT simulation images as reference to perform registration procedure based on soft tissue windows matched with clinical tumor volume (CTV). The errors of isocenter position were corrected by couch shifted. The second and third CBCT images were immediately acquired before and after RapidArc treatment. These errors of isocenter position on the left-right (LR), superior\u2013inferior (SI) and anterior\u2013posterior (AP) directions were analyzed retrospectively.Results: Under RapidArc technique with a shortened treatment delivery time (about 3 min), the residual systemic and random errors in pre and post-radiation treatment revealed limited. Based on the paired 2^(nd) and 3^(rd) CBCT images, the intrafractional errors (mean \u00b1 SD) in LR-SI-AP directions were -0.4 \u00b1 0.8, -0.2 \u00b1 1.0, 0.1 \u00b1 0.8 mm. No intrafractional error differences in three axes, except borderline significant in LR direction (p= 0.046). Isotropic planning margins created with the linear addition of internal margin to clinical tumor volume was respectively 3.6, 4.4, 4.5 mm in LR-SI-AP axes and 2.5, 3.2, 3.3 mm if generated with quadrature addition.Conclusion: Use of the faster RapidArc technique with accurate kV CBCT images online verification for prostate cancer pelvis radiotherapy, the intrafractional motion errors were limited. These speculated intrafractional errors could be applied to improve the accuracy of radiation delivery and a smaller PTV margin might be adopted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-43-53", "title": "Evaluation the Interfractional dose Difference Using Cone-beam CT in Prostate Patients", "keywords": "\u651d\u8b77\u817a\u764c;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642;\u9310\u9ad4\u9ad4\u7a4d\u96fb\u8166\u65b7\u5c64\u5f71\u50cf Prostate;SBRT (stereotactic body radiation therapy);CBCT (cone beam computed tomography)", "c": "\u76ee\u7684\uff1a\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u4e00\u7a2e\u53ef\u7cbe\u6e96\u4e14\u6709\u6548\u9054\u5230\u4f4e\u5206\u6b21\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u65b9\u5f0f\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u65e8\u5728\u5229\u7528\u9310\u9ad4\u9ad4\u7a4d\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff0c\u9032\u884c\u5291\u91cf\u91cd\u5efa\u4e26\u8a55\u4f30\u5176\u816b\u7624\u5305\u8986\u6027\u8207\u6b63\u5e38\u7d44\u7e54\u7684\u5291\u91cf\u5206\u5e03\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u6587\u5229\u75283\u4f4d\u65e9\u671f\u524d\u5217\u817a\u764c\u75c5\u4eba\u70ba\u7814\u7a76\u5c0d\u8c61\u3002\u6bcf\u4f4d\u75c5\u4eba\u5728\u6cbb\u7642\u524d\u5148\u63a5\u53d7\u91d1\u5c6c\u6a19\u8a8c\u7269\u7684\u690d\u5165\u3002\u5b9a\u4f4d\u8207\u6cbb\u7642\u6642\u75c5\u4eba\u90fd\u63a5\u53d7\u7279\u6b8a\u7684\u76f4\u8178\u8207\u8180\u80f1\u4e8b\u524d\u6e96\u5099\u5de5\u4f5c\u3002\u5728\u6bcf\u6b21\u6cbb\u7642\u4e4b\u524d\u75c5\u4eba\u6703\u5148\u63a5\u53d7\u4ee5\u91d1\u5c6c\u690d\u5165\u7269\u70ba\u5c0d\u4f4d\u4f9d\u64da\u7684\u6b63\u4ea4X\u5149\u5f71\u50cf\uff0c\u518d\u63a5\u8457\u4ee5\u8edf\u7d44\u7e54\u70ba\u5c0d\u4f4d\u4f9d\u64da\u7684\u9310\u9ad4\u9ad4\u7a4d\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u3002\u6cbb\u7642\u7e3d\u5291\u91cf\u70ba37.5 Gy\u52065\u500b\u5206\u6b21\u7d66\u4e88\u3002\u6cbb\u7642\u8a08\u756b\u9808\u6eff\u8db395%\u7684\u816b\u7624\u9ad4\u7a4d\u9808\u5305\u898695%\u7684\u8655\u65b9\u5291\u91cf\u3002\u7d50\u679c\uff1a\u4ee5\u8edf\u7d44\u7e54\u70ba\u5c0d\u4f4d\u4f9d\u64da\u7684\u9310\u9ad4\u9ad4\u7a4d\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u689d\u4ef6\u4e0b\uff0c\u6240\u6709\u75c5\u4eba\u7684\u8a08\u756b\u7686\u53ef\u9054\u523095%\u7684\u816b\u7624\u9ad4\u7a4d\u5305\u898695%\u7684\u8655\u65b9\u5291\u91cf\u3002\u4ee5\u91d1\u5c6c\u690d\u5165\u7269\u70ba\u5c0d\u4f4d\u4f9d\u64da\u7684\u6b63\u4ea4X\u5149\u5f71\u50cf\u689d\u4ef6\u4e0b\uff0c\u53ea\u670986%\u7684\u75c5\u4eba\u8a08\u756b\u53ef\u9054\u523095%\u7684\u816b\u7624\u9ad4\u7a4d\u5305\u898695%\u7684\u8655\u65b9\u5291\u91cf\u3002\u6b63\u5e38\u7d44\u7e54\u65b9\u9762\uff0c86.66%\u7684\u75c5\u4eba\u8a08\u756b\u5176\u8180\u80f1\u5291\u91cf\u53ef\u9054\u5230V50\u5c11\u65bc50%\uff1b60%\u7684\u75c5\u4eba\u8a08\u756b\u53ef\u9054\u5230V100\u5c11\u65bc5 cc\u300286.66 %\u7684\u75c5\u4eba\u8a08\u756b\u5176\u76f4\u8178\u5291\u91cf\u53ef\u9054\u5230V50\u5c11\u65bc50%\uff1b94%\u7684\u75c5\u4eba\u8a08\u756b\u5176\u76f4\u8178\u5291\u91cf\u53ef\u9054\u5230V80\u5c11\u65bc20%\uff1b60% \u7684\u75c5\u4eba\u8a08\u756b\u5176\u76f4\u8178\u5291\u91cf\u53ef\u9054\u5230V90\u5c11\u65bc10%\uff1b60%\u7684\u75c5\u4eba\u8a08\u756b\u5176\u76f4\u8178\u5291\u91cf\u53ef\u9054\u5230V100\u5c11\u65bc5%\u3002\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793a\u9310\u9ad4\u9ad4\u7a4d\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u53ef\u63d0\u4f9b\u6b63\u78ba\u7684\u75c5\u4eba\u5c0d\u4f4d\u8cc7\u8a0a\uff0c\u96d6\u7136\u5c0d\u65bc\u75c5\u4eba\u5728\u5b9a\u4f4d\u8207\u6cbb\u7642\u6642\u7686\u914d\u5408\u8180\u80f1\u8207\u76f4\u8178\u7684\u7279\u6b8a\u6e96\u5099\uff0c\u4f46\u4ecd\u7121\u6cd5\u6709\u6548\u6e1b\u5c11\u5176\u9ad4\u7a4d\u8b8a\u5316\u56e0\u800c\u53cd\u61c9\u5728\u5291\u91cf\u7684\u8b8a\u7570\u6027\u4e0a\u3002\u5728\u672a\u4f86\u6211\u5011\u5e0c\u671b\u53ef\u4ee5\u589e\u52a0\u6a23\u672c\u6578\u4ee5\u63d0\u4f9b\u66f4\u5ba2\u89c0\u8207\u986f\u8457\u7684\u7d50\u679c\u3002", "e": "Purposes: Stereotactic body radiation therapy (SBRT) is a method for the precise and efficient administration of hypofractionated radiotherapy. The aim of this study was to utilize the cone beam computed tomography (CBCT) scans acquired before treatment for dose reconstruction and hereby to assess target volume coverage during prostate SBRT.Materials and Methods: Three patients with early stage prostate cancer were included in this study. All patients had implanted two golden fiducial markers under transrectal ultrasound for image-guided localization. The rectum and bladder in-house preparation protocols were used in this study. Before each treatment, the patient was first set up with a pair of orthogonal kilovoltage (kV) portal images based on fiducial markers and subsequently adjusted to the treatment position with CBCT for soft tissue alignment. A CBCT image set acquired prior to each treatment for patient positioning was employed for the dose reconstruction calculation. The prescription dose was 37.5 Gy in 5 fractions. The criterion of plan is to satisfy at least the 95% of prescription dose to cover 95% of PTV (V95 greater than 95%).Results: All the patients can meet the V95 greater than 95% criterion if we corrected the patient position base on CBCT image. There was only 86% of all fractions can meet the V95 greater than 95% when the patient position was corrected with kV portal images. For bladder, 86.66% and 60% of all fractions could meet the criteria of V50 of bladder less than 50%, and V100 less than 5 c.c respectively. For rectum, 86.66%, 94%, 60%, and 60% of all fractions could meet the criteria of V50 of rectum less than 50%, V80 less than 20%, V90 less than 10%, and V100 less than 5% respectively. Furthermore, there are less than 5cc of rectum receiving 100% of dose for all cases.Conclusion: The correct dose delivered to the correct location is the most important goal of radiation therapy especially for SBRT. The tighter margin than other conventional treatment was applied to this study. Our results show the CBCT registration provides the opportunity to improve the dose delivery accuracy. Although the dose and volume variations of bladder and rectum still cannot be controlled well even if we used in house special protocols in this study. In conclusion, the margin apply to this study is sufficient to achieve the PTV coverage if applying CBCT base on soft tissue matching for patient position registration. We plan to expend our sample size to get more statistically significant results in near future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-55-61", "title": "\u4ee5\u5f71\u50cf\u81ea\u52d5\u5316\u8abf\u6574\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\u7684\u7a97\u5bec\u548c\u7a97\u4f4d\u7684\u7814\u7a76", "keywords": "\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668;\u96fb\u8166\u65b7\u5c64;\u5c0d\u6bd4\u5ea6 Iterative Filter;CT;Contrast", "c": "\u76ee\u7684\uff1a\u5728\u6bd4\u8f03\u624b\u52d5\u8abf\u6574\u548c\u81ea\u52d5\u5316\u8abf\u6574\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u7684\u7a97\u5bec\u548c\u7a97\u4f4d\uff08Window and Level, WL\uff09\u5c0d\u9310\u72c0\u5c04\u675f\u96fb\u8166\u65b7\u5c64\uff08Cone Beam Computed Tomography, CBCT\uff09\u5f71\u50cf\u4e2d\u6750\u8cea\u7684\u8fa8\u8b58\u5ea6\u7684\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u8a2d\u5099\u70baElekta Synergy\u76f4\u7dda\u52a0\u901f\u5668\u7684CBCT\u5f71\u50cfXVI\uff0c\u6e2c\u91cf\u5047\u9ad4\u70baCatphan phantom CTP404\u3002\u7d93\u7531\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\uff08Iterative Filter\uff09\u5206\u6790\u4e0d\u540c\u6750\u8cea\u5728\u87a2\u5e55\u4e0a\u6240\u986f\u793a\u7684\u7070\u968e\uff0c\u4ee5\u8fa8\u8b58\u5047\u9ad4\u5167\u805a\u82ef\u4e59\u70ef\uff08Polystyrene, C8H8, PS\uff09\u8207\u58d3\u514b\u529b\uff08Acrylic\uff09\u6750\u8cea\uff0c\u540c\u6642\u6bd4\u8f03\u624b\u52d5WL\u8abf\u6574\u548c\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1aPS\u6750\u8cea\u5728\u8996\u89ba\u4e0a\u5df2\u53ef\u4ee5\u8fa8\u8b58\uff0c\u6240\u4ee5\u5728\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u7684P\u503c\uff081.0 x 10^(-13)\uff09\u8207\u624b\u52d5WL\u7684P\u503c\uff082.5 x 10^(-12)\uff09\u90fd\u5f88\u5c0f\u3002\u800c\u58d3\u514b\u529b\u6750\u8cea\u5728\u8996\u89ba\u4e0a\u8fa8\u8b58\u5ea6\u4e0d\u4f73\uff0c\u5728\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u7684P\u503c\uff086.88 x 10^(-6)\uff09\u660e\u986f\u512a\u65bc\u624b\u52d5\u8abf\u6574WL\u7684P\u503c\uff080.026\uff09\uff0c\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u5728\u7d71\u8a08\u4e0a\u6709\u8f03\u4f73\u7684\u8fa8\u8b58\u5ea6\u3002\u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u4e2d\u767c\u73fe\uff0c\u4eba\u5de5\u624b\u52d5\u4e4bWL\u4e26\u7121\u6cd5\u6539\u5584\u5f71\u50cf\u54c1\u8cea\u3002\u672c\u7814\u7a76\u65b9\u6cd5\u5177\u6709\u9ad8\u901a\u4e4b\u300c\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u300d\uff0c\u80fd\u5feb\u901f\u5c07\u9078\u53d6\u5340\u57df\u7684\u5f71\u50cf\u8abf\u6574\u5230\u6700\u4f73\uff0c\u4e0d\u6703\u56e0\u500b\u4eba\u7d93\u9a57\u800c\u6709\u5dee\u7570\u3002\u5c0d\u65bc\u4e0d\u6613\u9451\u5225\u7684\u5340\u57df\uff0c\u6b64\u6ffe\u6ce2\u5668\u8a2d\u8a08\u5728\u7d71\u8a08\u4e0a\u5f71\u50cf\u6709\u66f4\u597d\u7684\u8fa8\u8b58\u5ea6\u3002\u672c\u7814\u7a76\u7684\u7d50\u679c\u986f\u793a\u300c\u8fed\u4ee3\u5f0f\u6ffe\u6ce2\u5668\u300d\u5728\u4e0d\u72a7\u7272\u5f71\u50cf\u54c1\u8cea\u751a\u81f3\u6709\u6539\u5584\u4e0b\uff0c\u63d0\u4f9b\u66f4\u9069\u5207\u7684\u81ea\u52d5WL\u4f86\u6eff\u8db3\u8996\u89ba\u8fa8\u8b58\u6027\u3002\u672a\u4f86\u5e0c\u671b\u5c07\u6b64\u6280\u8853\u61c9\u7528\u65bc\u4e0d\u6613\u88ab\u9451\u5225\u7684\u81e8\u5e8a\u91ab\u5b78\u5f71\u50cf\u3002", "e": "Purpose: The purpose of this study is to identify the difference in the window and level of the CBCT (Cone Beam Computed Tomography) image between manual adjustment and Iterative Filter. By Iterative Filter, the best contrast image is displayed immediately and the identification of the material in the CBCT is improved.Materials and Methods: The instrument used in this study is the CBCT image XVI of the Elerkta Synergy linear. Catphan phantom CTP 404 is the material being measured. The gray scale on the monitor is analyzed through Iterative Filter to identify Polystyrene, C8H8, PS and Acrylic in the specimen. The gray scale of different materials showed on the monitor can be analyzed and Iterative Filter, the sesult is also compare with manual adjustment.Results: PS material can be identified visually; therefore, the P value of the Iterative Filter (1.0 \u00d7 10^(-13)) and the P value of the manual adjustment (2.5 \u00d7 10^(-12)) are trivial. However, because it is more difficult to identify the Acrylic material in the image, the P value of the Iterative Filter (6.88 \u00d7 10^(-6)) is significantly better than the P value of the manual adjustment (0.026). The Iterative Filter has better identification.Conclusion: In this study, the manual adjustment to the window and level can not improve the quality of the image. The approach in this study using the Iterative Filter can perfect the chosen image immediately. The image quality in window-level and identification can be improved Iterative Filter Statistic Method and has a better result than that of manual adjustment. The Iterative Filter provides adequate identification and the improvement in the image quality."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-63-70", "title": "Long-Term Survival after Induction Therapy Followed by Concurrent Target-Radiotherapy of an Unresectable Stage IIIB Non-Small Cell Lung Cancer Patient: Case Report", "keywords": "\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e09\u671fB\u671f\u7121\u6cd5\u958b\u5200\u7684\u75c5\u60a3;\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642;\u540c\u6b65\u9032\u884c\u5316\u5b78\u653e\u5c04\u6cbb\u7642 Unresectable locally advanced NSCLC;Induction chemotherapy;Target-radiotherapy", "c": "\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e09\u671f\u4e0d\u80fd\u958b\u5200\u8005\u7684\u4e09\u5e74\u5b58\u6d3b\u7387\u53ea\u6709\u767e\u5206\u4e4b\u516b\uff0c\u76ee\u524d\u6cbb\u7642\u7684\u4e3b\u6d41\u662f\u540c\u6b65\u9032\u884c\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff08concurrent chemoradiotherapy\uff09\u3002\u81f3\u65bc\u662f\u5426\u52a0\u5165\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\uff08induction chemotherapy\uff09\u5247\u672a\u6709\u5b9a\u8ad6\u3002\u540c\u6b65\u9032\u884c\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u526f\u4f5c\u7528\u5927\uff0c\u56e0\u6b64\u75c5\u4eba\u5fc5\u9808\u6709\u597d\u7684\u8eab\u9ad4\u72c0\u6cc1\u8207\u80ba\u529f\u80fd\u624d\u9069\u5408\u9032\u884c\uff0c\u75c5\u60a3\u82e5\u5c0d\u5316\u5b78\u6cbb\u7642\u53cd\u61c9\u4e0d\u597d\uff0c\u5373\u4f7f\u52a0\u5f37\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u9664\u4e86\u589e\u52a0\u526f\u4f5c\u7528\u5916\uff0c\u4e5f\u7121\u6cd5\u963b\u6b62\u9060\u8655\u8f49\u79fb\u7684\u53ef\u80fd\u6027\u800c\u5931\u53bb\u75ca\u7652\u7684\u6a5f\u6703\u3002\u6839\u64da\u4e0b\u54bd\u5589\u764c\u6cbb\u7642\u7684\u7d93\u9a57\uff0c\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u7684\u53cd\u61c9\uff0c\u53ef\u4ee5\u9810\u6e2c\u63a5\u7e8c\u7684\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u9810\u5f8c\u3002\u6a19\u9776\u85e5\u7269\u827e\u745e\u838e\uff08iressa\uff09\u5c0d\u6771\u65b9\u4eba\u7684\u7368\u7279\u7642\u6548\u5df2\u53cd\u61c9\u5728\u8a31\u591a\u81e8\u5e8a\u8a66\u9a57\uff0c\u9577\u671f\u4f7f\u7528\u7684\u526f\u4f5c\u7528\u4e5f\u9060\u4f4e\u65bc\u50b3\u7d71\u5316\u5b78\u6cbb\u7642\u85e5\u7269\uff0c\u5728\u9032\u884c\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u6642\u4e5f\u4e0d\u9808\u6e1b\u91cf\u3002\u5728\u6b64\u6211\u5011\u5831\u544a\u4e00\u4f4dcT43M0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e09\u671fB\u671f\u7121\u6cd5\u958b\u5200\u7684\u75c5\u60a3\uff0c\u5728\u7d93\u904e\u5169\u7dda\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u5931\u6557\u5f8c\uff0c\u63a5\u53d7\u53e3\u670d\u827e\u745e\u838e\u6cbb\u7642\u4e26\u4e14\u5728\u80f8\u90e8X\u5149\u7247\u6aa2\u67e5\u9054\u5230\u816b\u7624\u5168\u6d88\u7684\u53cd\u61c9\u3002\u75c5\u60a3\u5728\u6301\u7e8c\u53e3\u670d\u827e\u745e\u838e\u7684\u60c5\u6cc1\u4e0b\u63a5\u7e8c\u540c\u6b65\u653e\u5c04\u6cbb\u7642\uff0c\u6cbb\u7642\u7d50\u675f\u5f8c\u6b63\u5b50\u651d\u5f71\u986f\u793a\u816b\u7624\u5b8c\u5168\u6d88\u5931\u3002\u6574\u9ad4\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u63a5\u8fd1\u56db\u5e74\uff0c\u7121\u75c5\u5b58\u6d3b\u671f\u5927\u7d04\u5169\u5e74\uff0c\u75c5\u60a3\u4e4b\u5f8c\u56e0\u816b\u7624\u5fa9\u767c\uff0c\u5408\u4f75\u5438\u5165\u6027\u80ba\u708e\u65bc2011\u5e74\u6b7b\u4ea1\uff0c\u4f46\u662f\u6b64\u7a2e\u6cbb\u7642\u65b9\u5f0f\u5927\u5927\u5ef6\u9577\u75c5\u4eba\u7684\u5b58\u6d3b\u3002\u6211\u5011\u8a8d\u70ba\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e09\u671fB\u671f\u4e0d\u80fd\u958b\u5200\u7684\u75c5\u60a3\u61c9\u8a72\u5148\u63a5\u53d7\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u82e5\u816b\u7624\u6709\u8b8a\u5c0f\uff0c\u518d\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff0c\u6703\u6709\u6bd4\u8f03\u9577\u7684\u7121\u75c5\u5b58\u6d3b\u671f\u751a\u81f3\u75ca\u7652\u3002", "e": "Concurrent chemoradiotherapy (CCRT) is the standard therapy for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). CCRT is usually associated with various levels of complications due to the dosage of either chemotherapy regimen or radiation; therefore, only patients with good performance status were qualified for this aggressive treatment. Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is well tolerated compared with most chemotherapy regimens in treating NSCLC patients, and there is no need to decrease the dosage of gefitinib when combined with radiotherapy. Induction chemotherapy, although not recommended in the treatment strategy for patients with unresectable NSCLC, may be appropriate for select patients who are most likely to benefit from subsequent CCRT. In this case, we report on an unresectable stage IIIB NSCLC patient, who had failed to two lines of chemotherapy, received gefitinib followed by concurrent target-radiotherapy with complete remission and long-term disease free survival for 2 years. We suggest that patients with unresectable NSCLC should be initially considered to receive induction chemotherapy or target therapy and plan further treatment such as radiotherapy or surgery according to the response."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201403-201404020031-201404020031-71-76", "title": "Salivary Duct Carcinoma of Submandibular Gland: A Case Report in Taiwan", "keywords": "\u553e\u6db2\u817a\u7ba1\u9053\u764c;\u9837\u4e0b\u817a;\u4eba\u985e\u4e0a\u76ae\u7d30\u80de\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u56682 Salivary duct carcinoma;Submandibular gland;HER-2/neu", "c": "\u553e\u6db2\u817a\u7ba1\u9053\u764c\u662f\u4e00\u7a2e\u7f55\u898b\u4e14\u9ad8\u5ea6\u60e1\u6027\u7684\u816b\u7624\uff0c\u5b83\u7684\u7d44\u7e54\u5f62\u614b\u7279\u5fb5\u8207\u4e73\u817a\u7ba1\u9053\u764c\u76f8\u4f3c\uff0c\u751a\u81f3\u6709\u4eba\u985e\u4e0a\u76ae\u7d30\u80de\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u56682\u81f4\u764c\u57fa\u56e0\uff08HER2/neu oncogene\uff09\u7684\u904e\u5ea6\u8868\u73fe\u3002\u9019\u7a2e\u75be\u75c5\u7684\u9810\u5f8c\u5f88\u5dee\uff0c\u5728\u8a3a\u65b7\u5f8c\u4e94\u5e74\u5167\u7684\u6b7b\u4ea1\u7387\u8d85\u904e60%\uff0c\u6587\u737b\u4e0a\u9019\u7a2e\u75be\u75c5\u8a3a\u65b7\u7684\u5e73\u5747\u5e74\u9f61\u5e7e\u4e4e\u90fd\u5927\u65bc\u516d\u5341\u6b72\u3002\u6211\u5011\u5831\u544a\u4e00\u500b\u56db\u5341\u4e00\u6b72\u7537\u6027\u7f79\u60a3\u53f3\u5074\u9837\u4e0b\u817a\u553e\u6db2\u817a\u7ba1\u9053\u764c\uff0c\u63a5\u53d7\u816b\u7624\u5207\u9664\u3001\u540c\u5074\u9838\u90e8\u6dcb\u5df4\u7d50\u5ed3\u6e05\u624b\u8853\u3001\u8853\u5f8c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642\u3002\u5b8c\u6210\u6cbb\u7642\u5f8c6\u500b\u6708\u7121\u5fa9\u767c\u6216\u8f49\u79fb\u3002", "e": "Salivary duct carcinoma (SDC) is one of the rarest and aggressive malignant neoplasms of salivary gland tumors. It is characterized by histomorphologic features reminiscent of the ductal carcinoma of breast, even with HER-2/neu oncoprotein overexpression. The prognosis is poor; more than 60% of patients will die within 5 years after diagnosis. The average age of diagnosis is more than 60 in literatures. Here, we reported a 41-year-old male with SDC of right submandibular gland. He received tumor excision, ipsilateral modified neck dissection, postoperative adjuvant chemotherapy and radiotherapy. The patient is alive without evidence of recurrence or metastases 6 months after completing therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-243-252", "title": "Definitive Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: High Dose versus Standard Dose Radiation Therapy", "keywords": "\u98df\u9053\u764c;\u540c\u6b65\u653e\u5316\u7642;\u653e\u5c04\u5291\u91cf Esophageal cancer;Concurrent chemoradiotherapy;Radiation dose", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u5206\u6790\u540c\u6b65\u653e\u5316\u7642\u7528\u65bc\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u53ca\u6bd4\u8f03\u4e0d\u540c\u653e\u5c04\u5291\u91cf\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5305\u62ec2007\u5e741\u6708\u81f32010\u5e7412\u6708\u65bc\u672c\u9662\u8a3a\u65b7\u70ba\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u7684109\u4f8b\u60a3\u8005\uff0c\u81e8\u5e8a\u5206\u671fT2-4\u3001N0-1\u3001M0-1\u3001II-IV\u671f\u7121\u6cd5\u4ee5\u624b\u8853\u5207\u9664\u7684\u98df\u9053\u764c\u75c5\u60a3\u5747\u63a5\u53d7\u540c\u6b65\u653e\u5316\u7642\u70ba\u4e3b\u8981\u6cbb\u7642\u65b9\u6cd5\uff0c\u653e\u5c04\u6cbb\u7642\u70ba\u6bcf\u6b211.8-2.0 Gy\uff0c\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u70ba\u975c\u8108\u6ef4\u6ce8cisplatin\u70ba\u4e3b\u7684\u914d\u65b91\u81f32\u500b\u9031\u671f\uff0c\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4f7f\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u6240\u6709\u75c5\u60a3\u63a5\u53d7\u653e\u7642\u5291\u91cf\u4e4b\u4e2d\u4f4d\u6578\u70ba56 Gy\uff08\u7bc4\u570d\u70ba45-70 Gy\uff09\uff0c\u5206\u5225\u6bd4\u8f03\u9ad8\u5291\u91cf\u7d44\uff0856\u81f370 Gy\uff0c55\u4f8b\uff09\u53ca\u6a19\u6e96\u5291\u91cf\u7d44\uff0845\u81f355.8 Gy\uff0c54\u4f8b\uff09\u75c5\u60a3\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3002\u5b58\u6d3b\u7387\u66f2\u7dda\u4ee5Kaplan-Meier\u53caCox regression\u6cd5\u8a08\u7b97\u3002\u7d50\u679c\uff1a\u9ad8\u5291\u91cf\u7d44\u548c\u6a19\u6e96\u5291\u91cf\u7d44\u4e4b\u5169\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba38.0%\u548c23.2%\u3002\u81e8\u5e8a\u5206\u671f\u7b2cII\uff0cIII\uff0cIV\u671f\u4e4b\u5169\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba57.9%\u300132.8%\u300120.1%\u3002\u55ae\u8b8a\u9805\u5206\u6790\u986f\u793a\u9ad8\u5291\u91cf\u653e\u7642\uff08\u226756 Gy\uff09\u3001T\u5206\u671f\u3001M\u5206\u671f\u53ca\u81e8\u5e8a\u671f\u5225\u986f\u8457\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u7387\uff08p=0.013\uff0c0.016\uff0c0.012\uff0c0.010\uff09\u3002\u591a\u8b8a\u9805\u5206\u6790\u767c\u73fe\u9ad8\u5291\u91cf\u653e\u7642\uff08\u226756 Gy\uff09\u8207\u81e8\u5e8aII-III\u671f\u70ba\u5177\u5f71\u97ff\u529b\u7684\u8f03\u4f73\u6574\u9ad4\u5b58\u6d3b\u7387\u9810\u5f8c\u56e0\u5b50\uff08p=0.030\uff0c0.015\uff09\u3002\u572849\u4f8b\u7121\u9060\u7aef\u8f49\u79fb\u75c5\u60a3\u4e4b\u55ae\u8b8a\u9805\u53ca\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u9ad8\u5291\u91cf\u653e\u7642\u4ecd\u70ba\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\uff08p=0.020\uff0cp=0.003\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\u8f03\u9ad8\u7684\u653e\u7642\u5291\u91cf\uff08\u226756 Gy\uff09\u7528\u65bc\u63a5\u53d7\u540c\u6b65\u653e\u5316\u7642\u4e4b\u98df\u9053\u9c57\u72c0\u7d30\u80de\u764c\u75c5\u60a3\u53ef\u986f\u8457\u6539\u5584\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u5c40\u90e8\u5fa9\u767c\u5b58\u6d3b\u7387\u3002\u672a\u4f86\u9700\u8981\u9032\u4e00\u6b65\u7684\u96a8\u6a5f\u81e8\u5e8a\u7814\u7a76\u4ee5\u78ba\u8a8d\u4f7f\u7528\u9806\u884c\u653e\u5c04\u6cbb\u7642\u6280\u8853\u7d66\u4e88\u8f03\u9ad8\u653e\u7642\u5291\u91cf\u5f8c\u4e4b\u7642\u6548\u8207\u5f71\u97ff\u3002", "e": "Purpose: To analyze the treatment results and compare overall survival rate after definitive concurrent chemoradiotherapy (CCRT) with different doses of radiotherapy for esophageal squamous cell carcinoma (ESCC) in a retrospective study. Materials and Methods: This study included 109 patients with histologically confirmed ESCC at Taipei Veterans General Hospital between January 2007 and December 2010. The median age at diagnosis of the patients was 62 years old (range, 34-89 years). Patients who were clinically staged as T2-4, N0-1, M0-1, stage II-IV ESCC received definitive CCRT as the primary treatment, with radiotherapy at 1.8-2.0 Gy per fraction and concurrent infusional cisplatin-based chemotherapy for 1-2 cycles. Radiotherapy was delivered by three-dimensional conformal radiation therapy (3DCRT) or intensity modulated radiation therapy (IMRT) technique, with a median dose of 56 Gy (range, 45-70 Gy). The overall survival (OS) rates and local recurrence free survival (LRFS) rates were compared between high radiation dose (56-70 Gy, n= 55) group and standard radiation dose (45-55.8 Gy, n= 54) group. Survival analysis was done with the Kaplan-Meier method and Cox regression model.Results: Two-year overall survival rate of the high-dose and standard-dose group was 38.0% and 23.2%, respectively. The 2-year OS rate of stage II, III, and IV was 57.9%, 32.8%, and 20.1%, respectively. Univariate analysis revealed that high dose radiation (\u226756 Gy), T classification, M classification, and clinical stage significantly affected overall survival (p= 0.013, 0.016, 0.012, and 0.010, respectively). Multivariate analysis showed that high dose radiation \u226756 Gy (p= 0.030) and clinical stage II-III (p= 0.015) were significant predictors of better OS. In the univariate and multivariate analyses of the patients with M0 disease (n= 49), high dose radiation also has a remarkable impact on LRFS (p= 0.020, 0.003, respectively). Conclusion: Our study showed that higher radiation dose (\u226756 Gy) significantly improved OS and LRFS in patients with unresectable ESCC who underwent definitive CCRT using 3DCRT or IMRT techniques. Further randomized clinical studies are required to clarify the benefits and side effects of escalated radiation dose in the setting of modern conformal radiotherapy techniques."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-253-260", "title": "Long-Term Outcome of Radiotherapy for Mucoepidermoid Carcinoma of the Head and Neck Region", "keywords": "\u9ecf\u6db2\u4e0a\u76ae\u6a23\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Mucoepidermoid carcinoma;Radiotherapy;Prognostic factor", "c": "\u76ee\u7684\uff1a\u5206\u6790\u8853\u5f8c\u6216\u76f4\u63a5\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u982d\u9838\u90e8\u9ecf\u6db2\u4e0a\u76ae\u6a23\u764c\u75c5\u4eba\u4e4b\u9577\u671f\u6cbb\u7642\u6548\u679c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1984\u5e746\u6708\u52302009\u5e745\u6708\uff0c\u670937\u4f4d\u4e4b\u524d\u672a\u63a5\u53d7\u904e\u6cbb\u7642\uff0c\u65bc\u8853\u5f8c\u6216\u76f4\u63a5\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u81f3\u5c1150 Gy\u7684\u982d\u9838\u90e8\u9ecf\u6db2\u4e0a\u76ae\u6a23\u764c\u75c5\u4eba\u88ab\u7d0d\u5165\u9019\u500b\u7814\u7a76\u3002\u9019\u500b\u7814\u7a76\u5206\u6790\u81e8\u5e8a\u53ca\u75c5\u7406\u56e0\u5b50\u53ca\u5b58\u6d3b\u7387\u7684\u95dc\u806f\u6027\u3002\u7d50\u679c\uff1a5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca5\u5e74\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba85.5%\u53ca83.2%\u3002\u55ae\u8b8a\u9805\u5206\u6790\u986f\u793a\u6027\u5225\uff08P=0.0005\uff09\u3001\u5e74\u7d00\uff08P=0.0008\uff09\u3001\u624b\u8853\u5207\u7de3\uff08P=0.0031\uff09\u3001\u6cbb\u7642\u65b9\u5f0f\uff08P=0.0045\uff09\u3001\u539f\u767c\u816b\u7624\u90e8\u4f4d\uff08P=0.0307\uff09\u3001\u53ca\u7d30\u80de\u5b78\u5f62\u614b\uff08P=0.0328\uff09\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u6709\u986f\u8457\u5f71\u97ff\u3002\u5176\u4e2d\uff0c\u6cbb\u7642\u65b9\u5f0f\uff08P=0.0014\uff09\uff0c\u624b\u8853\u5207\u7de3\uff08P=0.0086\uff09\u53ca\u6027\u5225\uff08P=0.0175\uff09\u4e5f\u662f\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u7684\u91cd\u8981\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u55ae\u8b8a\u9805\u5206\u6790\u986f\u793a\uff0c\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u800c\u8a00\uff0c\u5973\u6027\u6027\u5225\uff0c\u4e7e\u6de8\u7684\u624b\u8853\u5207\u7de3\u53ca\u6cbb\u7642\u65b9\u5f0f\u70ba\u624b\u8853\u52a0\u4e0a\u653e\u5c04\u7dda\u6cbb\u7642\u7686\u662f\u8f03\u597d\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u800c\u8001\u5e74\u4eba\uff0c\u975e\u816e\u817a\u816b\u7624\uff0c\u53ca\u7d30\u80de\u5b78\u9ad8\u60e1\u6027\u5ea6\u816b\u7624\u5247\u6709\u8f03\u5dee\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002", "e": "Purpose: To analyze the long-term treatment outcome and various prognostic factors in patients with mucoepidermoid carcinoma (MEC) arising from the head and neck region treated by radiotherapy with or without surgery.Materials and Methods: Thirty-seven patients with previously untreated MEC in the head and neck region who received at least 50 Gy of radiotherapy with or without precedent surgery from June 1984 to May 2009 were enrolled in this study. The relationship between clinical and pathologic characteristics and survival rate was investigatedResults: The 5-year overall survival (OS) and disease-free survival (DFS) rates were 85.5% and 83.2% respectively. Univariate analysis of OS demonstrated that the parameters which significantly affected survival were the gender (P=0.0005), age (P=0.0008), surgical margin (P=0.0031), treatment modality (P=0.0045), primary tumor site (P=0.0307), and histological grade (P=0.0328). The treatment modality (P=0.0014), surgical margin (P=0.0086), and gender (P=0.0175) were predictive factors of DFSConclusion: In univariate analysis, female gender, free surgical margins, and treatment by surgery plus radiotherapy were favorable prognostic factors in predicting both OS and DFS. Older age, non-parotid origin, and high grade tumor indicated worse OS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-261-270", "title": "Solitary Extramedullary Plasmacytoma of the Head and Neck: Treatment Outcome in 6 Patients and a Review of Literature", "keywords": "\u9ad3\u5916\u6f3f\u7d30\u80de\u7624;\u982d\u9838\u90e8\u816b\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Extramedullary plasmacytoma;Head and neck;Radiotherapy", "c": "\u76ee\u7684\uff1a\u982d\u9838\u90e8\u7684\u9aa8\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u662f\u4e00\u7a2e\u5f88\u5c11\u898b\u7684\u75be\u75c5\u3002\u672c\u7bc7\u56de\u9867\u4e86\u5728\u6211\u5011\u91ab\u9662\u7f79\u60a3\u6b64\u75be\u75c5\u60a3\u8005\u7684\u6cbb\u7642\u4ee5\u53ca\u9810\u5f8c\u3002\u65b9\u6cd5\u8207\u6750\u6599\uff1a\u516d\u540d\u60a3\u8005\uff08\u56db\u540d\u7537\u6027\u8207\u5169\u540d\u5973\u6027\uff09\u5728\u897f\u51431980\u5e74\u82072010\u5e74\u9593\u65bc\u672c\u9662\u88ab\u8a3a\u65b7\u70ba\u982d\u9838\u90e8\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u3002\u60a3\u8005\u5011\u7684\u4e2d\u4f4d\u8a3a\u65b7\u5e74\u9f61\u70ba64\u6b72\uff08\u7bc4\u570d\u70ba54\u523079\u6b72\uff09\u3002\u5176\u4e2d\u6709\u5169\u540d\u60a3\u8005\u53ea\u63a5\u53d7\u624b\u8853\u6cbb\u7642\uff1b\u5169\u540d\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff1b\u53e6\u5916\u5169\u540d\u5247\u63a5\u53d7\u4e86\u624b\u8853\u4ee5\u53ca\u8853\u5f8c\u7684\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7e3d\u5291\u91cf\u90fd\u572850 Gy\u4e0a\u4e0b\u3002\u7d50\u679c\uff1a\u6240\u6709\u60a3\u8005\u7684\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\u70ba5\u5e74\u3002\u816b\u7624\u539f\u767c\u90e8\u4f4d\u70ba\u9f3b\u8154\uff082\u540d\uff09\u3001\u9f3b\u7ac7\uff082\u540d\uff09\u3001\u53e3\u54bd\uff081\u540d\uff09\u4ee5\u53ca\u9f3b\u54bd\uff081\u540d\uff09\u3002\u5169\u540d\u53ea\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u7684\u60a3\u8005\u5f8c\u4f86\u90fd\u51fa\u73fe\u5c40\u90e8\u5fa9\u767c\u7684\u73fe\u8c61\uff0c\u5176\u4e2d\u4e00\u540d\u5728\u7d93\u904e\u7b2c\u4e8c\u6b21\u624b\u8853\u5f8c\u5c31\u5f97\u5230\u4e86\u63a7\u5236\u3002\u6709\u5169\u540d\u60a3\u8005\u63a5\u53d7\u624b\u8853\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u53e6\u5916\u5169\u540d\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u60a3\u8005\u4e4b\u5f8c\u90fd\u6c92\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u73fe\u8c61\uff0c\u4f46\u662f\u5206\u5225\u65bc\u76ae\u819a\u4ee5\u53ca\u5176\u4ed6\u9aa8\u9abc\u90e8\u4f4d\u51fa\u73fe\u4e86\u9060\u7aef\u8f49\u79fb\u75be\u75c5\u3002\u5728\u8ffd\u8e64\u671f\u9593\u6c92\u6709\u60a3\u8005\u9032\u5c55\u6210\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002\u6240\u6709\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u60a3\u8005\u90fd\u6c92\u6709\u660e\u986f\u4e14\u56b4\u91cd\u7684\u5f8c\u907a\u75c7\u3002\u9019\u516d\u540d\u60a3\u8005\u4e2d\u6709\u4e00\u540d\u56e0\u70ba\u6b64\u75be\u75c5\u800c\u6b7b\u4ea1\u3002\u7d50\u8ad6\uff1a\u56db\u540d\u7f79\u60a3\u982d\u9838\u90e8\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u7684\u60a3\u8005\u5728\u63a5\u53d7\u55ae\u7368\u6216\u8f14\u52a9\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u5728\u5c40\u90e8\u90fd\u5f97\u5230\u4e86\u826f\u597d\u7684\u63a7\u5236\uff0c\u4f46\u662f\u5176\u4e2d\u5169\u540d\u60a3\u8005\u4e4b\u5f8c\u51fa\u73fe\u4e86\u9060\u7aef\u8f49\u79fb\u7684\u75c5\u7076\u3002\u6839\u64da\u9019\u4e9b\u500b\u6848\u8207\u6587\u737b\u56de\u9867\u7684\u7d50\u679c\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u982d\u9838\u90e8\u9ad3\u5916\u6f3f\u7d30\u80de\u7624\u53ef\u70ba\u5b89\u5168\u4e14\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: Solitary extramedullary plasmacytoma of the head and neck (EMPHN) is a rare disease. The objective of this study was to review the treatment results of EMPHN patients in a single institution in TaiwanMethods and Materials: The cases of 6 patients (4 males and 2 females) diagnosed at our hospital with EMPHN between 1980 and 2010 were reviewed. The median age of the patients was 64 years (range, 54-79 years). Two patients underwent surgery alone, 2 patients underwent radiotherapy alone, and 2 patients underwent surgery and adjuvant radiotherapy. The dose of radiotherapy was 50-50.4 grays (Gy) in 25-28 fractions.Results: The median follow-up duration was 5 years. The primary tumor sites were the nasal cavity (2), paranasal sinuses (2), oropharynx (1), and nasopharynx (1). Local recurrence was observed in 2 patients who underwent surgery alone and local control was achieved in 1 after salvage surgery (no evidence of disease after salvage surgery in the follow up 3 years period). Local control was achieved in 2 patients treated with surgery and adjuvant radiotherapy. Distant metastasis to the skin and bone without evidence of local recurrence was observed in 2 patients treated with radiotherapy alone. None of the patients progressed to multiple myeloma during follow-up evaluations and no severe radiotherapy-related morbidity was observed. One patient who treated with surgery alone died from recurrent EMPHN within the follow-up duration.Conclusions: Local control of the tumor in the primary site was achieved in 4 patients with EMPHN who underwent radiotherapy alone or adjuvant, although 2 of these patients presented with distant metastasis. According to the review of literature and our results, radiotherapy might be safe and effective for local control of EMPHN."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-271-280", "title": "\u9f3b\u54bd\u764c\u4e8c\u6b21\u5b9a\u4f4d\u8a08\u5283\u4e2d\u816b\u7624\u53ca\u816e\u817a\u9ad4\u7a4d\u8b8a\u5316\u7684\u81e8\u5e8a\u52d5\u614b\u7814\u7a76", "keywords": "\u9f3b\u54bd\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u816e\u817a;\u4e0b\u9837\u817a Nasopharyngeal Carcinoma;Intensity Modulated Radiotherapy;Parotid Gland;Submandibular Gland", "c": "Objective: To investigate the changes of the tumor and salivary gland volumes in intensity modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) through 2nd phase of computed tomography (CT) treatment planning.Materials and Methods: Thirty-eight patients with nasopharyngeal carcinoma were enrolled in this study, the primary tumor and neck lymph nodes were treated by IMRT; and formed the plan1 (DVH1), re-planning CT with same position after twenty-two radiation treatments formed the plan2 (DVH2). All target volumes and organs at risk were outlined by the same physician. The physical objective and dose constraints were optimized with same criteria. The data obtained from CT treatment planning and DVH were analyzed. The volumes, weights, and outline changes in the transverse diameter of CT images varied between before and after treatments.Results: Patient weight, volumes of tumors and salivary glands decreased remarkably during radiotherapy. The average weight decreased by 2.97% (2.33 kg, range 1.5~3.7 kg). Compared Plan 1 with Plan 2, the parotid glands was significantly reduced by 15.67% (10.83 cc, 95% CI: range 7.45~14.21 cc), submandibular glands 15.83% (3.39 cc, 95% CI: range 2.14~4.65 cc), GTV decreased 15.49% (3.83 cc, 95% CI: range 2.36~5.30 cc), and GTV-LN decreased 41.81% (15.12 cc, 95% CI: range 8.66~21.57 cc). The transverse diameter of head and neck CT images reduced by average of 0.32 ~ 0.89 cm (1.93%~6.04%), especially at the transverse diameter in the level of 3 cm above the set-up center (0.89 cm). The GTV volume on average shrank 2.23 cc and 6.91 cc as comparing T1-3 with T4 disease (p = 0.0013); The GTV-LN volume shrank on average 8.59 cc, 38.93 cc (P\uff1c 0.0001) as comparing N1-2 with N3 disease. The transverse diameter changes of head and neck contours were correlated significantly with N stage and body weight loss.Conclusion: For NPC patients treated with IMRT, weight loss, volume reduction of salivary gland, and body contour change are common. The salivary glands on average reduced volume by 15% and GTV-LN by 40% after one-month treatment. The transverse diameter of head and neck regions could decrease up to 0.89 cm. We recommend repeat simulation after one-month of radiotherapy in order to reduce the dose to the normal organs and avoid missing treatment targets.", "e": "Objective: To investigate the changes of the tumor and salivary gland volumes in intensity modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) through 2nd phase of computed tomography (CT) treatment planning.Materials and Methods: Thirty-eight patients with nasopharyngeal carcinoma were enrolled in this study, the primary tumor and neck lymph nodes were treated by IMRT; and formed the plan1 (DVH1), re-planning CT with same position after twenty-two radiation treatments formed the plan2 (DVH2). All target volumes and organs at risk were outlined by the same physician. The physical objective and dose constraints were optimized with same criteria. The data obtained from CT treatment planning and DVH were analyzed. The volumes, weights, and outline changes in the transverse diameter of CT images varied between before and after treatments.Results: Patient weight, volumes of tumors and salivary glands decreased remarkably during radiotherapy. The average weight decreased by 2.97% (2.33 kg, range 1.5~3.7 kg). Compared Plan 1 with Plan 2, the parotid glands was significantly reduced by 15.67% (10.83 cc, 95% CI: range 7.45~14.21 cc), submandibular glands 15.83% (3.39 cc, 95% CI: range 2.14~4.65 cc), GTV decreased 15.49% (3.83 cc, 95% CI: range 2.36~5.30 cc), and GTV-LN decreased 41.81% (15.12 cc, 95% CI: range 8.66~21.57 cc). The transverse diameter of head and neck CT images reduced by average of 0.32 ~ 0.89 cm (1.93%~6.04%), especially at the transverse diameter in the level of 3 cm above the set-up center (0.89 cm). The GTV volume on average shrank 2.23 cc and 6.91 cc as comparing T1-3 with T4 disease (p = 0.0013); The GTV-LN volume shrank on average 8.59 cc, 38.93 cc (P\uff1c 0.0001) as comparing N1-2 with N3 disease. The transverse diameter changes of head and neck contours were correlated significantly with N stage and body weight loss.Conclusion: For NPC patients treated with IMRT, weight loss, volume reduction of salivary gland, and body contour change are common. The salivary glands on average reduced volume by 15% and GTV-LN by 40% after one-month treatment. The transverse diameter of head and neck regions could decrease up to 0.89 cm. We recommend repeat simulation after one-month of radiotherapy in order to reduce the dose to the normal organs and avoid missing treatment targets."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-281-292", "title": "\u52a0\u99ac\u5200\u8207\u96fb\u8166\u5200\u61c9\u7528\u65bc\u52d5\u975c\u8108\u7578\u5f62\u6cbb\u7642\u4e4b\u81e8\u5e8a\u8a55\u4f30\u6bd4\u8f03\u8207\u5291\u91cf\u5dee\u7570\u5206\u6790", "keywords": "\u52a0\u99ac\u5200;\u96fb\u8166\u5200;\u52d5\u975c\u8108\u7578\u5f62 Gamma Knife;CyberKnife;Arteriovenous malfomations", "c": "\u76ee\u7684\uff1a\u5206\u6790\u6bd4\u8f03\u52a0\u99ac\u5200\uff08Gamma Knife\u00ae\uff09\u8207\u96fb\u8166\u5200\uff08CyberKnife\u00ae\uff09\u5169\u7a2e\u653e\u5c04\u624b\u8853\u8a2d\u5099\uff0c\u61c9\u7528\u65bc\u52d5\u975c\u8108\u7578\u5f62\uff08Arteriovenous malformations, AVMs\uff09\u75c5\u4f8b\u4e4b\u6cbb\u7642\u6642\uff0c\u5176\u5169\u8005\u56e0\u81e8\u5e8a\u6cbb\u7642\u904b\u7528\u6280\u8853\u53ca\u6a5f\u68b0\u7d50\u69cb\u8fe5\u7570\uff0c\u6240\u9020\u6210\u5291\u91cf\u5206\u4f48\u7684\u8b8a\u5316\u60c5\u5f62\uff1b\u4e26\u63a2\u8a0e\u8207\u8a55\u4f30\u6b64\u5291\u91cf\u5206\u4f48\u7684\u7279\u6027\u65bc\u81e8\u5e8a\u6cbb\u7642\u61c9\u7528\u4e0a\u4e4b\u5dee\u7570\u53ca\u5176\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9078\u64c710\u4f4d\u63a5\u53d7\u904e\u96fb\u8166\u5200\u6cbb\u7642\u7684AVM\u60a3\u8005\uff0c\u55ae\u6b21\u8655\u65b9\u5291\u91cf\u70ba20\uff0d25 Gy\uff0c\u53d6\u5f97\u5176\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u3002\u6b64\u5916\uff0c\u5c07\u96fb\u8166\u5200\u6cbb\u7642\u8a08\u756b\u7684CT\u5f71\u50cf\u3001\u9776\u9ad4\u7a4d\u8207\u5468\u908a\u5371\u6025\u5668\u5b98\u8f2a\u5ed3\u6a94\u6848\uff0c\u81ea\u96fb\u8166\u5200\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8f38\u51fa\u5f8c\uff0c\u8f49\u8f38\u5165\u52a0\u99ac\u5200\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\uff0c\u4f9d\u76f8\u540c\u8655\u65b9\u5291\u91cf\uff0c\u5b8c\u6210\u52a0\u99ac\u5200\u7684\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u3002\u6bd4\u8f0310\u4f4d\u75c5\u60a3\u7684\u96fb\u8166\u5200\u8207\u52a0\u99ac\u5200\u6cbb\u7642\u8a08\u756b\u7684\u5291\u91cf\u9806\u5f62\u5ea6\u3001\u5291\u91cf\u68af\u5ea6\u8207\u5291\u91cf\u7570\u8cea\u6027\u6307\u6a19\uff0c10\u300112 Gy\u6240\u6db5\u84cb\u7bc4\u570d\u4e4b\u9ad4\u7a4d\uff0c\u8166\u5e79\u7684\u6700\u5927\u5291\u91cf\u4ee5\u53ca\u7167\u5c04\u7684\u6642\u9593\u3002\u5728\u7d71\u8a08\u5206\u6790\u7684\u90e8\u5206\uff0c\u5291\u91cf\u9806\u5f62\u5ea6\u8207\u5291\u91cf\u68af\u5ea6\u6307\u6a19\uff0c10\u300112 Gy\u6240\u6db5\u84cb\u7bc4\u570d\u4e4b\u9ad4\u7a4d\u7684\u6bd4\u8f03\u662f\u4ee5Paired Samples t-test\u4f86\u57f7\u884c\uff0c\u6c42\u53d6p\u503c\u5f8c\u8a55\u4f30\u5169\u7a2e\u6cbb\u7642\u8a08\u756b\u5728\u6240\u6bd4\u8f03\u4e4b\u9805\u76ee\u662f\u5426\u5b58\u5728\u8457\u986f\u8457\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u52a0\u99ac\u5200\u8207\u96fb\u8166\u5200\u7684\u5291\u91cf\u9806\u5f62\u5ea6\u6307\u6a19\u7d71\u8a08\u503c\u5206\u5225\u70ba0.626 \u00b1 0.106\u53ca0.795 \u00b1 0.087\uff0cp=0.004\u3002\u52a0\u99ac\u5200\u8207\u96fb\u8166\u5200\u7684\u5291\u91cf\u68af\u5ea6\u6307\u6a19\u7d71\u8a08\u503c\u5206\u5225\u70ba3.082 \u00b1 0.369\u53ca6.071 \u00b1 1.698\uff0cp=0.001\u3002\u52a0\u99ac\u5200\u8207\u96fb\u8166\u5200\u7684\u5291\u91cf\u7570\u8cea\u6027\u6307\u6a19\u5206\u5225\u70ba0.723 \u00b1 0.055\u53ca0.275 \u00b1 0.045\u300210\u820712 Gy\u5291\u91cf\u9ad4\u7a4d\u7684\u7d71\u8a08\u5206\u6790p\u503c\u5206\u5225\u70ba0.025\u82070.022\u30023\u4f4dAVM\u4f4d\u7f6e\u9130\u8fd1\u8166\u5e79\u7684\u75c5\u4f8b\uff0c\u5728\u8166\u5e79\u7d44\u7e541 c.c.\u9ad4\u7a4d\u5291\u91cf\u8207\u8166\u5e79\u6700\u5927\u5291\u91cf\u6bd4\u8f03\uff0c\u52a0\u99ac\u5200\u7686\u5c0f\u65bc\u96fb\u8166\u5200\u3002\u5728\u6548\u80fd\u7684\u6bd4\u8f03\u4e0a\uff0c\u96fb\u8166\u5200\u6240\u9700\u7684\u7167\u5c04\u6642\u9593\u5247\u8f03\u77ed\u3002\u7d50\u8ad6\uff1a\u96fb\u8166\u5200\u56e0\u70ba\u4f7f\u7528\u9006\u5411\u5f0f\u6cbb\u7642\u8a08\u756b\u4e14\u5f62\u6210\u985e\u4f3c\u5f37\u5ea6\u8abf\u63a7\u7684\u529f\u80fd\uff0c\u56e0\u6b64\u8f03\u6613\u6c42\u5f97\u8f03\u4f73\u7684\u5291\u91cf\u9806\u5f62\u5ea6\u3002\u5728\u5468\u908a\u6b63\u5e38\u7d44\u7e54\u5291\u91cf\u8c41\u514d\u7684\u90e8\u5206\uff0c\u5247\u662f\u52a0\u99ac\u5200\u6709\u8f03\u4f73\u7684\u8868\u73fe\uff0c\u53ef\u9810\u671f\u52a0\u99ac\u5200\u53ef\u4f7f\u6b63\u5e38\u8166\u7d44\u7e54\u8207\u9130\u8fd1\u4e4b\u5371\u6025\u5668\u5b98\u5f97\u5230\u8f03\u4f73\u7684\u4fdd\u8b77\u3002", "e": "Purpose: To analyze and compare the dose distribution characteristic of two radiosurgery treatment devices of Gamma Knife\u00ae(GK) and Cyber Knife\u00ae(CK), in treating arteriovenous malformations (AVMs) and the influence on their clinical application.Material and Method: Ten AVM patients treated with CK of prescribed dose of 20-25 Gy in single fraction were evaluated. Each treatment plan CT images including the contours of the target and the surrounding critical organs were exported and loaded into the GK treatment planning system. GK treatment plan using the same prescribed radiation dose were generated. Dosimetric comparison of the two treatment devices including the conformity, gradient and heterogeneity index, volume of brain tissue covered by 10 Gy and 12 Gy, maximum dose of brain stem and the beam on time. Paired Samples t-test was used to statistical analyze and compare the conformal and gradient index, the dose coverage volume of 10 Gy and 12 Gy in both plans for significance (p value)Result: The conformal index was 0.626 \u00b1 0.106 and 0.795 \u00b1 0.087 in GK and CK, respectively (p = 0.004). The gradient index was 3.082 \u00b1 0.369 and 6.071 \u00b1 1.698 in GK and CK, respectively (p = 0.001). The heterogeneity index was 0.723 \u00b1 0.055 and 0.275 \u00b1 0.045 in GK and CK, respectively. The difference of coverage volume of 10 Gy and 12 Gy were significant (p = 0.025 and 0.022, respectively). For the 3 cases with AVM location adjacent \u03c9the brainstem, the dose of 1 c.c. and maximum dose of brain stem in GK plan were less than CK. CK had better treatment efficiency due to shorter beam on time.Conclusion: Cyber Knife using inverse treatment planning similar to intensity modulated function had better dose conformity. Gamma Knife should have better normal brain tissue and critical organs protection due to sharp dose fall-off gradient."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-293-305", "title": "A Planning Study for Feasibility of Applying Volumetric-Modulated Arc Therapy for Locally Advanced Head and Neck Cancer", "keywords": "\u5291\u91cf\u5b78\u6bd4\u8f03;\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u982d\u9838\u764c Dosimetric comparison;Volumetric-modulated arc therapy (VMAT);Intensity-modulated radiotherapy (IMRT);Head and neck cancer", "c": "Purpose: The aim of this study was to investigate the feasibility of applying VMAT for HNC patients in daily practice by comparing volumetric-modulated arc therapy (VMAT) with intensity-modulated radiation therapy (IMRT) for patients with locally advanced head-and-neck cancer (HNC) with regard to the dosimetric parameters and efficiency of delivery.Material & Method: Nine locally advanced HNC patients on either an IMRT or VMAT treatment plan were selected for this study. Another corresponding plan using an alternative technique was generated for comparison. We applied an adaptive strategy with a simultaneous integrated boost (SIB) technique in all radiation therapy protocols, including an initial plan and a reduced plan with acquisition of CT images about 4 weeks later. The Philips Pinnacle\u00b3\u00ae Planning System v. 9.0 was adopted for designing all treatment plans. Dosimetric parameters compared between VMAT and IMRT plans included target coverage, dose conformity, dose homogeneity, organs at risk (OAR) sparing, monitor units (MUs) and treatment delivery time.Result: The average number of arc used in the VMAT plan was 2.07 and the number of fields per IMRT plan was 6.5. The VMAT and IMRT plans had similar PTV coverage (V100% \uff1e 98% and \uff1e 96%, respectively). There was no significant difference between VMAT and IMRT in conformity (CI= 1.73 and 1.63, respectively, p= 0.546), homogeneity of PTV-H (HI= 1.08 and 1.07, respectively, p= 0.387), PTV-M (HI = 1.10 and 1.10, respectively, p= 0.891) and PTV-L (HI = 1.13 and 1.12, respectively, p= 0.369). There were similar dose-volume histogram distributions between these two techniques for most of OARs. No significant difference existed in performance of parotid sparing by using these two techniques. Compared to IMRT, VMAT technique significantly reduced the MUs by 16.1% (757.0 versus 635.4 MUs, p= 0.011) and the average treatment time by 4.2 minutes (8.7 versus 4.5 minutes, p \uff1c 0.001).Conclusion: This study demonstrated that equally clinical acceptable dose distributions can be achieved in both VMAT and IMRT techniques for HNC. In addition, VMAT provided faster delivery time and lower executed monitor units. Therefore, it is feasible to apply VMAT for HNC for improving the efficiency without compromising the quality of planning dosimetry.", "e": "Purpose: The aim of this study was to investigate the feasibility of applying VMAT for HNC patients in daily practice by comparing volumetric-modulated arc therapy (VMAT) with intensity-modulated radiation therapy (IMRT) for patients with locally advanced head-and-neck cancer (HNC) with regard to the dosimetric parameters and efficiency of delivery.Material & Method: Nine locally advanced HNC patients on either an IMRT or VMAT treatment plan were selected for this study. Another corresponding plan using an alternative technique was generated for comparison. We applied an adaptive strategy with a simultaneous integrated boost (SIB) technique in all radiation therapy protocols, including an initial plan and a reduced plan with acquisition of CT images about 4 weeks later. The Philips Pinnacle\u00b3\u00ae Planning System v. 9.0 was adopted for designing all treatment plans. Dosimetric parameters compared between VMAT and IMRT plans included target coverage, dose conformity, dose homogeneity, organs at risk (OAR) sparing, monitor units (MUs) and treatment delivery time.Result: The average number of arc used in the VMAT plan was 2.07 and the number of fields per IMRT plan was 6.5. The VMAT and IMRT plans had similar PTV coverage (V100% \uff1e 98% and \uff1e 96%, respectively). There was no significant difference between VMAT and IMRT in conformity (CI= 1.73 and 1.63, respectively, p= 0.546), homogeneity of PTV-H (HI= 1.08 and 1.07, respectively, p= 0.387), PTV-M (HI = 1.10 and 1.10, respectively, p= 0.891) and PTV-L (HI = 1.13 and 1.12, respectively, p= 0.369). There were similar dose-volume histogram distributions between these two techniques for most of OARs. No significant difference existed in performance of parotid sparing by using these two techniques. Compared to IMRT, VMAT technique significantly reduced the MUs by 16.1% (757.0 versus 635.4 MUs, p= 0.011) and the average treatment time by 4.2 minutes (8.7 versus 4.5 minutes, p \uff1c 0.001).Conclusion: This study demonstrated that equally clinical acceptable dose distributions can be achieved in both VMAT and IMRT techniques for HNC. In addition, VMAT provided faster delivery time and lower executed monitor units. Therefore, it is feasible to apply VMAT for HNC for improving the efficiency without compromising the quality of planning dosimetry."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-307-314", "title": "Merkel Cell Carcinoma of Lower Extremity: A Case Report and Review of the Literatures", "keywords": "\u9ed8\u514b\u7d30\u80de\u764c;\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624;\u653e\u5c04\u6cbb\u7642 Merkel cell carcinoma;Neuroendocrine carcinoma;Radiotherapy", "c": "\u9ed8\u514b\u7d30\u80de\u764c\u662f\u7f55\u898b\u7684\uff0c\u540c\u6642\u5177\u6709\u9ad8\u5ea6\u4fb5\u8972\u6027\u53ca\u81f4\u547d\u6027\u7684\u76ae\u819a\u60e1\u6027\u816b\u7624\uff0c\u901a\u5e38\u4ee5\u8001\u5e74\u4eba\u53ca\u514d\u75ab\u529f\u80fd\u7f3a\u640d\u7684\u60a3\u8005\u8f03\u6613\u767c\u751f\u3002\u6211\u5011\u5728\u6b64\u63d0\u51fa\u4e00\u4f4d\u53f3\u5927\u817f\u610f\u5916\u767c\u73fe\u9ed8\u514b\u7d30\u80de\u764c\u4e4b\u7537\u6027\u75c5\u60a3\u53ca\u5176\u6cbb\u7642\u7d93\u9a57\u3002\u6b64\u75c5\u60a3\u63a5\u53d7\u816b\u7624\u5ee3\u6cdb\u5207\u9664\u5f8c\uff0c\u7d93\u7531\u7d30\u80de\u89d2\u8cea\u86cb\u767d20\uff08CK 20\uff09\u4e4b\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\uff0c\u8b49\u5be6\u70ba\u9ed8\u514b\u7d30\u80de\u764c\u3002\u5f71\u50cf\u6aa2\u67e5\u5305\u542b\uff1a\u53f3\u817f\u3001\u80f8\u8154\u3001\u8179\u8154\u53ca\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u5747\u986f\u793a\u7121\u5340\u57df\u6dcb\u5df4\u7bc0\u4fb5\u72af\u6216\u9060\u7aef\u81df\u5668\u8f49\u79fb\u3002\u56e0\u70ba\u81e8\u5e8a\u4e0a\u7121\u6dcb\u5df4\u4fb5\u72af\uff08cN0\uff09\u8b49\u64da\u4e14\u5148\u524d\u816b\u7624\u5ee3\u6cdb\u5207\u9664\u986f\u793a\u7121\u6b98\u5b58\u816b\u7624\uff0c\u6b64\u75c5\u60a3\u4e26\u672a\u63a5\u53d7\u54e8\u5175\u6dcb\u5df4\u7d50\u5207\u7247\u6aa2\u67e5\u3002\u75c5\u60a3\u5f8c\u7e8c\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u539f\u767c\u816b\u7624\u90e8\u4f4d\u53ca\u53f3\u9f20\u8e4a\u6dcb\u5df4\u5f15\u6d41\u5340\u57df\u5206\u5225\u63a5\u53d759.4\u53ca54\u683c\u96f7\u4e4b\u5149\u5b50\u7167\u5c04\u3002\u5728\u653e\u5c04\u6cbb\u7642\u5373\u5c07\u7d50\u675f\u524d\u50c5\u51fa\u73fe\u4e7e\u6027\u76ae\u819a\u812b\u5c51\u4e4b\u6025\u6027\u53cd\u61c9\uff0c\u4e26\u65bc\u5f8c\u7e8c\u9580\u8a3a\u8ffd\u8e64\u671f\u9593\u9010\u6f38\u5fa9\u539f\u3002\u75c5\u60a3\u5728\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\u534a\u5e74\u5167\uff0c\u6bcf\u6708\u56de\u8a3a\u63a5\u53d7\u7406\u5b78\u6aa2\u67e5\u53ca\u5b9a\u671f\u5f71\u50cf\u8ffd\u8e64\uff0c\u96a8\u5f8c\u6539\u70ba\u6bcf\u5b63\u5b9a\u671f\u56de\u8a3a\u8ffd\u8e64\u3002\u8ffd\u8e64\u81f3\u4eca\u5df2\u905434\u500b\u6708\u4e14\u7121\u5fa9\u767c\u8de1\u8c61\u3002\u7531\u65bc\u9ed8\u514b\u7d30\u80de\u764c\u7f3a\u4e4f\u524d\u77bb\u6027\u4e4b\u96a8\u6a5f\u81e8\u5e8a\u8a66\u9a57\u8cc7\u6599\uff0c\u56e0\u6b64\u6700\u7406\u60f3\u7684\u6cbb\u7642\u65b9\u5f0f\u4ecd\u7121\u5b9a\u8ad6\u3002NCCN\u6307\u5f15\u5efa\u8b70\u6240\u6709\u75c5\u60a3\u7686\u9700\u63a5\u53d7\u54e8\u5175\u6dcb\u5df4\u7d50\u5207\u7247\u6aa2\u67e5\uff0c\u4ee5\u6c42\u5f97\u6b63\u78ba\u4e4b\u764c\u75c7\u5206\u671f\uff0c\u904e\u53bb\u6574\u5408\u5206\u6790\u4e5f\u8b49\u5be6\u8853\u5f8c\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u53ef\u964d\u4f4e\u5c40\u90e8\u53ca\u5340\u57df\u816b\u7624\u5fa9\u767c\u3002", "e": "Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma of the skin, and most commonly seen in the elderly and immunocompromised patients. This is a case report describing our experience with MCC in a male patient who incidentally found a nodule over his right lower thigh. MCC was confirmed by positive cytokeratin 20 expressions in immunohistochemical staining after tumor wide excision. Image studies, including right leg CT, chest mediastinum CT and abdomen to pelvis CT, showed neither regional lymph node involvement nor visceral organ metastases. Due to clinical N0 and prior local excision with free margin, sentinel lymph node biopsy is not performed. The patient received postoperative photon beam RT with 59.4 Gy and 54 Gy to primary tumor bed with 5 cm margin and regional inguinal lymphatic area, respectively. Dry skin desquamation was noted near completion of adjuvant radiotherapy but recovered during follow-up. The patient underwent regular OPD follow-up monthly in the first six months after adjuvant RT and quarterly thereafter. The patient kept disease-free 34 months postoperatively. As no prospective randomized studies exist, the optimum treatment of this disease is limited. Sentinel lymph node biopsy was recommended by NCCN for accurate staging, previous meta-analysis demonstrates local adjuvant RT after complete excision reduced local and regional recurrence."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201312-201312260034-201312260034-315-321", "title": "Unusual Oligometastases of Distant Nodes as the Initial Relapse Site of Uterine Sarcoma: A Case Report", "keywords": "\u5b50\u5bae\u8089\u7624;\u5c0e\u822a\u87ba\u65cb\u5200;\u5f71\u50cf\u5c0e\u822a\u653e\u5c04\u6280\u8853;\u9396\u9aa8\u4e0a\u7aa9\u8f49\u79fb Endometrial stromal sarcoma;Helical tomotherapy;Image-guided radiotherapy;Supraclavicular metastases", "c": "\u201c\u672a\u5206\u5316\u201d\u5b50\u5bae\u8089\u7624\uff0c\u201c\u9ad8\u60e1\u6027\u5ea6\u201d\u5b50\u5bae\u5167\u819c\u57fa\u8cea\u8089\u7624\uff08ESS\uff09\uff0c\u662f\u7a2e\u5c11\u898b\u4e14\u9810\u5f8c\u4e0d\u4f73\u7684\u60e1\u6027\u816b\u7624\u3002\u4e00\u4f4d48\u6b72\u5973\u6027\u5728\u672c\u9662\u8a3a\u65b7\u70ba\u201c\u672a\u5206\u5316\u201d\u5b50\u5bae\u8089\u7624\uff0c\u7d93\u904e\u624b\u8853\u8207\u8f14\u52a9\u6027\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\uff0c\u5728\u7b2c\u4e94\u500b\u6708\u8207\u7b2c\u4e5d\u500b\u6708\u5206\u5225\u767c\u751f\u5de6\u5074\u9396\u9aa8\u4e0a\u7aa9\u8207\u5de6\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002\u5de6\u5074\u9396\u9aa8\u4e0a\u7aa9\u4e4b\u6dcb\u5df4\u7d50\u7d66\u8207\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u3002\u800c\u5de6\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u5247\u65bd\u4ee5\u6dcb\u5df4\u7d50\u6458\u9664\u8853\u4e26\u8ffd\u52a0\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u60a3\u8005\u6cbb\u7642\u81f3\u4eca\u5df2\u9054\u4e94\u5e74\uff0c\u76ee\u524d\u4ecd\u7121\u764c\u75c7\u800c\u5b58\u6d3b\u3002\u5de6\u5074\u9396\u9aa8\u4e0a\u7aa9\u66a8\u814b\u4e0b\u6dcb\u5df4\u8f49\u79fb\u5c0d\u201c\u672a\u5206\u5316\u201d\u5b50\u5bae\u8089\u7624\u4e43\u70ba\u7f55\u898b\u6848\u4f8b\uff0c\u7e31\u4f7f\u75c5\u4eba\u767c\u751f\u9060\u7aef\u5be1\u8f49\u79fb\uff0c\u6b64\u985e\u60a3\u8005\uff0c\u82e5\u7d93\u7a4d\u6975\u653e\u5c04\u7dda\u6cbb\u7642\u4ecd\u80fd\u6709\u6548\u5ef6\u9577\u75c5\u60a3\u5b58\u6d3b\u6642\u9593\u3002", "e": "\u201dUndifferentiated\u201d uterine sarcoma, or \u201dhigh-grade\u201d endometrial stromal sarcoma (ESS), is a rare neoplasm characterized by early visceral organ dissemination and poor prognosis. We present a case of a 48-year-old woman with \u201dundifferentiated\u201d uterine sarcoma. She was treated and staged by surgery with adjuvant pelvic irradiation. Metastases of left supraclavicular fossa (SCF) and axillary nodes developed 5 and 9 months after the surgery. Salvage radiotherapy alone was delivered to left SCF region. Furthermore, axillary nodal dissection followed by local radiotherapy was done for left axillary Iymphadenopathies. She is alive without evidence of disease and doing well 64 months after the diagnosis of uterine sarcoma. In conclusion, isolated SCF and axillary lymph node metastases are unusual sites of relapse for \u201dundifferentiated\u201d uterine sarcoma. Aggressive radiotherapy with or without surgery may achieve longer survival for such patients with oligometastases of distant nodes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-159-169", "title": "Clinical-Pathologic Features and Outcomes of Radiation Therapy in a Large Cohort of Patients with Operable Breast Cancer", "keywords": "\u653e\u5c04\u6cbb\u7642;\u4e73\u764c;\u81e8\u5e8a\u6cbb\u7642\u6210\u679c Radiation therapy;Breast neoplasms;Clinical outcome", "c": "Purpose: To evaluate our relative large institutional experience of the clinical-pathologic features and outcomes of radiation therapy in patients with operable primary breast cancer.Materials and Methods: We reviewed 1,623 consecutive patients with operable breast cancers which received complete course of adjuvant radiation therapy at our institution between 1988 and 2009. All patients underwent either mastectomy or breast conserving surgery (BCS) as part of their treatment. Clinical-pathologic and outcome parameters were analyzed. Kaplan-Meier product limit method was used to estimate loco-regional recurrence-free survival (LRFS), metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS). Cox proportional hazards models were performed to assess the prognostic significance of these clinicalpathologic parameters on LRFS.Results: The median follow-up was 6.1 years (range, 2.3 months - 23.0 years). Among these 1623 patients, a total of 83 (5.1%) patients developed loco-regional recurrences, which occurred at 4.7 months to 12.5 years (mean, 2.0 years) after surgery. The 5-year LRFS, MFS, DFS and OS were 95.1%, 83.5%, 79.8%, 85.4% respectively for the entire cohort. Multivariate analyses showed that patients with advanced T stage, nodes positive, HER2 positive or triple negative tumors (ie, ER negative, PR negative and HER2 negative) had poor prognosis on LRFS (all P \uff1c 0.05). For 39 patients with initial stage IV breast cancer and receiving post-operation adjuvant radiotherapy, the 5-year loco-regional control rate was 89.9%.Conclusions: Our results are consistent with others that radiation therapy is a very effective adjuvant treatment on loco-regional control in breast cancer patients. Triplenegative and HER2-positive profiles are prognostic markers for loco-regional recurrence. Aggressive local therapy improves local control in metastatic breast cancer.", "e": "Purpose: To evaluate our relative large institutional experience of the clinical-pathologic features and outcomes of radiation therapy in patients with operable primary breast cancer.Materials and Methods: We reviewed 1,623 consecutive patients with operable breast cancers which received complete course of adjuvant radiation therapy at our institution between 1988 and 2009. All patients underwent either mastectomy or breast conserving surgery (BCS) as part of their treatment. Clinical-pathologic and outcome parameters were analyzed. Kaplan-Meier product limit method was used to estimate loco-regional recurrence-free survival (LRFS), metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS). Cox proportional hazards models were performed to assess the prognostic significance of these clinicalpathologic parameters on LRFS.Results: The median follow-up was 6.1 years (range, 2.3 months - 23.0 years). Among these 1623 patients, a total of 83 (5.1%) patients developed loco-regional recurrences, which occurred at 4.7 months to 12.5 years (mean, 2.0 years) after surgery. The 5-year LRFS, MFS, DFS and OS were 95.1%, 83.5%, 79.8%, 85.4% respectively for the entire cohort. Multivariate analyses showed that patients with advanced T stage, nodes positive, HER2 positive or triple negative tumors (ie, ER negative, PR negative and HER2 negative) had poor prognosis on LRFS (all P \uff1c 0.05). For 39 patients with initial stage IV breast cancer and receiving post-operation adjuvant radiotherapy, the 5-year loco-regional control rate was 89.9%.Conclusions: Our results are consistent with others that radiation therapy is a very effective adjuvant treatment on loco-regional control in breast cancer patients. Triplenegative and HER2-positive profiles are prognostic markers for loco-regional recurrence. Aggressive local therapy improves local control in metastatic breast cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-171-178", "title": "Treatment Outcome of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma in Our Institution", "keywords": "\u98df\u9053\u764c;\u8853\u524d\u540c\u6b65\u653e\u5c04\u8207\u5316\u7642\u6cbb\u7642;\u816b\u7624\u6e1b\u5c11\u7a0b\u5ea6 Esophageal cancer;Neoadjuvant chemoradiotherapy;Tumor regression grade", "c": "Purpose: In this retrospective study, we evaluated the treatment outcome following neoadjuvant chemoradiotherapy for esophageal cancer and the impact of tumor regression and post operative nodal status.Materials and Methods: Sixty-four patients of esophageal cancer treated with neoadjuvant chemoradiotherapy from June, 1999 to April, 2011 were followed retrospectively. Tumor regression grade (TRG), post operative nodal status, pathologic stage, pattern of recurrence and overall survival (OS) of these patients were recorded and analyzed. Disease-free and overall survival rates were calculated with Kaplan-Meier method and group comparisons were based on the log-rank test. Cox regression analysis was the method applied when several factors were assessed simultaneously.Results: Median survival is 24.2 months (range, 3-92 months). Comparing TRG 1 with TRG 2-4, the OS was not significantly different (P = 0.549). When TRG1-2 was compared with TRG3-4, there was a trend of significant difference in OS (P = 0.089). The median survival was 23.6 months in the N- group, compared with 13.5 months in the N+ group (P \uff1c 0.001). In univariate survival analysis, N+ (P \uff1c 0.001) and vascular involvement (P = 0.041) significantly influence survival probabilities. N+ was significantly (P = 0.001) associated with distant metastasis and TRG 3-4 (P = 0.008) with locoregional recurrence. By multivariate analysis, only N+ significantly influence OS (P = 0.004) and vascular involvement (P = 0.658) was not significant.Conclusion: For those who are receiving neoadjuvant chemoradiotherapy, achieving node-negative status is a significant prognostic factor for the outcome. As for histomorphologic tumor regression, it has a less predictive factor.", "e": "Purpose: In this retrospective study, we evaluated the treatment outcome following neoadjuvant chemoradiotherapy for esophageal cancer and the impact of tumor regression and post operative nodal status.Materials and Methods: Sixty-four patients of esophageal cancer treated with neoadjuvant chemoradiotherapy from June, 1999 to April, 2011 were followed retrospectively. Tumor regression grade (TRG), post operative nodal status, pathologic stage, pattern of recurrence and overall survival (OS) of these patients were recorded and analyzed. Disease-free and overall survival rates were calculated with Kaplan-Meier method and group comparisons were based on the log-rank test. Cox regression analysis was the method applied when several factors were assessed simultaneously.Results: Median survival is 24.2 months (range, 3-92 months). Comparing TRG 1 with TRG 2-4, the OS was not significantly different (P = 0.549). When TRG1-2 was compared with TRG3-4, there was a trend of significant difference in OS (P = 0.089). The median survival was 23.6 months in the N- group, compared with 13.5 months in the N+ group (P \uff1c 0.001). In univariate survival analysis, N+ (P \uff1c 0.001) and vascular involvement (P = 0.041) significantly influence survival probabilities. N+ was significantly (P = 0.001) associated with distant metastasis and TRG 3-4 (P = 0.008) with locoregional recurrence. By multivariate analysis, only N+ significantly influence OS (P = 0.004) and vascular involvement (P = 0.658) was not significant.Conclusion: For those who are receiving neoadjuvant chemoradiotherapy, achieving node-negative status is a significant prognostic factor for the outcome. As for histomorphologic tumor regression, it has a less predictive factor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-179-190", "title": "Gamma Knife Perfexion Radiosurgery for Intraocular Tumor-Technique Establishment and Preliminary Results", "keywords": "\u52a0\u99ac\u5200Perfexion;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u624b\u8853;\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624 Leksell Gamma Knife Perfexion;Stereotactic radiosurgery;Uveal melanoma", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u7dda\u624b\u8853\u7528\u65bc\u6cbb\u7642\u773c\u7403\u5167\u816b\u7624\u5c0d\u65bc\u4fdd\u7559\u8996\u529b\u8207\u773c\u7403\u4fdd\u5b58\u4f54\u6709\u91cd\u8981\u7684\u89d2\u8272\uff0c\u8207\u8fd1\u63a5\u6cbb\u7642\u76f8\u6bd4\uff0c\u7528\u65bc\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u75c5\u4eba\uff0c\u653e\u5c04\u7dda\u624b\u8853\u4ea6\u63d0\u4f9b\u4e86\u4e00\u500b\u975e\u4fb5\u5165\u6027\u8207\u55ae\u6b21\u4e4b\u6cbb\u7642\u65b9\u5f0f\u3002\u6b64\u5916\u653e\u5c04\u7dda\u624b\u8853\u4e4b\u9069\u61c9\u75c7\u53ef\u7528\u65bc\u5176\u4ed6\u773c\u7403\u5167\u75be\u75c5\u3002\u6b64\u7bc7\u7814\u7a76\u4e3b\u8981\u70ba\u8a55\u4f30\u65b0\u8a2d\u8a08\u4e4b\u52a0\u99ac\u5200\u6cbb\u7642\u65b9\u6cd5\u53ca\u6d41\u7a0b\uff0c\u7528\u65bc\u773c\u7403\u5167\u816b\u7624\u4e4b\u5b9a\u4f4d\u6e96\u78ba\u6027\u8207\u81e8\u5e8a\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a \u9078\u64c72\u4f4d\u8461\u8404\u819c\u9ed1\u8272\u7d20\u7624\u75c5\u4eba\u82071\u4f4d\u4e73\u764c\u4f75\u773c\u7403\u5167\u8f49\u79fb\u4e4b\u75c5\u4eba\u63a5\u53d7\u52a0\u99ac\u5200\uff08Perfexion\uff09\u6cbb\u7642\u3002\u75c5\u4eba\u5148\u63a5\u53d7\u7403\u5f8c\u9ebb\u9189\uff0c\u4e26\u5c07\u5169\u689d\u773c\u7403\u5916\u808c\u8089\u7e2b\u5408\u56fa\u5b9a\u65bc\u982d\u90e8\u7acb\u9ad4\u5b9a\u4f4d\u6846\u67b6\u4e0a\uff0c\u505a\u70ba\u773c\u7403\u4e4b\u56fa\u5b9a\uff0c\u4e4b\u5f8c\u5b89\u6392\u78c1\u632f\u9020\u5f71\u6383\u63cf\u4ee5\u88fd\u4f5c\u52a0\u99ac\u5200\u8a08\u756b\u3002\u55ae\u6b21\u6cbb\u7642\u8655\u65b9\u5291\u91cf\u70ba25-30 Gy\uff0c\u6cbb\u7642\u8a08\u756b\u9078\u64c750-55%\u7684\u7b49\u5291\u91cf\u66f2\u7dda\u7bc4\u570d\u5305\u8986\u9776\u9ad4\u7a4d\u3002\u75c5\u4eba\u5206\u5225\u65bc\u56fa\u5b9a\u982d\u67b6\u4e4b\u5f8c\uff08CT-1\uff09\uff0c\u6cbb\u7642\u4e4b\u524d\uff08CT-2\uff09\uff0c\u53ca\u6cbb\u7642\u4e4b\u5f8c\uff08CT-3\uff09\u5171\u6703\u6383\u63cf\u4e09\u7d44\u96fb\u8166\u65b7\u5c64\uff0c\u85c9\u6b64\u6bd4\u8f03\u816b\u7624\u4e4b\u9ad4\u7a4d\uff0c\u816b\u7624\u8207\u6c34\u6676\u9ad4\u4e4b\u91cd\u5fc3\u4f4d\u7f6e\u8207\u4f4d\u79fb\uff0c\u4f86\u5206\u6790\u5b9a\u4f4d\u4e4b\u6e96\u78ba\u6027\u3002\u7d50\u679c\uff1a\u773c\u7403\u79fb\u52d5\u5206\u6790\u7d50\u679c\uff0c\u5728\u4e09\u7d44\u96fb\u8166\u65b7\u5c64\u5f71\u50cfCT-1 \u3001CT-2 \u3001CT-3 \u4e0a\uff0c\u816b\u7624\u8207\u6c34\u6676\u9ad4\u4e4b\u91cd\u5fc3\u4f4d\u7f6e\u4f4d\u79fb\u5747\u5c0f\u65bc0.120\u516c\u5398\uff0c\u5728\u7d66\u4e88\u5291\u91cf\u7684\u816b\u7624\u5305\u8986\u7387\u5747\u9ad8\u65bc95%\u3002\u5728\u4e09\u4f4d\u75c5\u4eba\u7684\u8ffd\u8e64\u4e2d\u53ef\u898b\u816b\u7624\u9ad4\u7a4d\u4e4b\u7e2e\u5c0f\u8207\u8996\u7db2\u819c\u525d\u96e2\u4e4b\u6539\u5584\u3002\u7d50\u8ad6\uff1a\u6839\u64da\u672c\u7814\u7a76\u52a0\u99ac\u5200\u624b\u8853\u4e4b\u6cbb\u7642\u65b9\u6cd5\u8207\u6d41\u7a0b\uff0c\u52a0\u99ac\u5200\u904b\u7528\u65bc\u773c\u7403\u5167\u816b\u7624\u6cbb\u7642\u5177\u6709\u9ad8\u6e96\u78ba\u6027\u3002\u52a0\u99ac\u5200\u53ef\u63d0\u4f9b\u773c\u7403\u5167\u816b\u7624\u975e\u4fb5\u5165\u6027\u53ca\u55ae\u6b21\u6cbb\u7642\u4e4b\u5668\u5b98\u4fdd\u7559\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: Radiosurgery plays an important role in treating patients with intraocular tumor and retained visual function aiming at organ-conservation. Gamma knife stereotactic radiosurgery (GKRS) provides a relatively non-invasive and less time-consuming procedure for treating patients with choroidal melanoma comparing with plaque brachytherapy. It also has the potential radiosurgery to provide effective treatment for other ophthalmologic indication. We presented a new treatment protocol using GKRS to treat patient with intraocular tumor and evaluated the safety and precision of GKRS as a primary treatment for intraocular tumor.Methods: Two patients with uveal melanoma and one patient with breast cancer orbital metastasis treated with the Leksell Gamma Knife Perfexion stereotactic radiosurgery in our hospital. Retrobulbar anesthesia following fixation of the treated eye by suturing two extraocular muscles to the stereotactic frame were performed in order to immobilize the eye in the whole treatment procedure. The dose to the tumor margin was 25-30 Gy prescribed at 50-55% isodose line. Contrast-enhanced MRI was used for Gamma Plan dose planning. CT scans were done after eye fixation, immediate before and after the GKRS to confirm the accuracy of tumor localization. We compared tumor volume, tumor and lens gravity point deviation, and tumor coverage in the 3 sets of CT scans to check the precision of immobilization and eye fixation.Results: The eye movement analysis revealed that the gravity point coordination deviation of the tumor and lens between CT-1 and CT-2, or CT-1 and CT-3 was less than 0.120 mm. At least 95% of the tumor volume was covered by the prescription dose in the 3 sets of CT image. After GKRS, tumor shrinkage and serous retinal detachments disappearance were noted by ophthalmoscopy and orbital MRI in two patients. No major complication was found during follow up.Conclusion: GKRS using our treatment protocol is a relatively non-invasive, organconserving, and less time-consuming single fraction treatment for intraocular tumor. Our eye fixation method reveals high accuracy. Larger study with long term follow up is needed to evaluate the dose response result of the patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-191-197", "title": "\u61c9\u7528\u985e\u795e\u7d93\u7db2\u8def\u9810\u6e2c\u9f3b\u54bd\u764c\u75c5\u4eba\u4e4b\u4e94\u5e74\u5b58\u6d3b\u72c0\u614b", "keywords": "\u5b58\u6d3b\u9810\u6e2c;\u9f3b\u54bd\u764c;\u985e\u795e\u7d93\u7db2\u8def Artificial neural networks;Nasopharyngeal carcinoma;Survival prediction", "c": "\u76ee\u7684\uff1a\u61c9\u7528\u985e\u795e\u7d93\u7db2\u8def\u5efa\u7acb\u9f3b\u54bd\u764c\u75c5\u4eba\u9810\u5f8c\u9810\u6e2c\u7cfb\u7d71\uff0c\u63d0\u4f9b\u500b\u4eba\u5316\u7684\u5b58\u6d3b\u72c0\u6cc1\u9810\u6e2c\u8cc7\u8a0a\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u7be9\u90781990\u5e74\u81f32005\u5e74\u9593\u81fa\u7063\u5730\u5340\u67d0\u764c\u75c7\u5c08\u79d1\u91ab\u9662\u81e8\u5e8a\u7814\u7a76\u5ba4\u8cc7\u6599\u5eab\u76841,114\u4f4d\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u9078\u7528\u5e74\u9f61\u3001\u6027\u5225\u3001\u816b\u7624\u671f\u5225\u3001\u539f\u59cb\u816b\u7624\u4fb5\u72af\u7a0b\u5ea6\u3001\u6dcb\u5df4\u7d50\u64f4\u6563\u72c0\u614b\u3001\u75c5\u7406\u7d30\u80de\u5207\u7247\u3001\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u3001\u5316\u5b78\u6cbb\u7642\u65b9\u5f0f\u3001\u4e73\u9178\u812b\u6c2b\u8122\u6307\u6578\u3001\u9e7c\u6027\u78f7\u9178\u8122\u6307\u6578\u3001\u904e\u5f80\u5438\u83f8\u7fd2\u6163\u3001 \u5bb6\u65cf\u764c\u75c7\u75c5\u53f2\u7b49\u5341\u4e8c\u9805\u8b8a\u6578\uff0c\u5254\u9664\u8b8a\u6578\u8cc7\u6599\u6b04\u4f4d\u4e0d\u5168\u800570\u4eba\u4ee5\u53ca60\u4f4d\u9060\u7aef\u8f49\u79fb\u8005\u5f8c\uff0c\u5c07\u6574\u9ad4\u6a23\u672c984\u4eba\u96a8\u6a5f\u6311\u907875%\u70ba\u8a13\u7df4\u6a23\u672c\uff0c\u5efa\u7acb\u985e\u795e\u7d93\u7db2\u8def\u6a21\u578b\u9810\u6e2c\u9f3b\u54bd\u764c\u75c5\u4eba\u4e94\u5e74\u5b58\u6d3b\u72c0\u614b\uff0c\u4e26\u5c0d25%\u6e2c\u8a66\u6a23\u672c\u7684\u9810\u6e2c\u6e96\u78ba\u7387\u3001\u9748\u654f\u5ea6\u3001\u7279\u7570\u5ea6\u548cROC\u66f2\u7dda\u4e0b\u9762\u7a4d\u9032\u884c\u8a55\u4f30\u53ca\u5206\u6790\u3002\u7d50\u679c\uff1a\u6574\u9ad4\u6a23\u672c\u5e73\u5747\u5e74\u9f61\u70ba45.45\u6b72\uff0c\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba77.74%\uff0c\u5229\u7528STATISTICA\u8edf\u9ad4\u4f7f\u7528\u591a\u5c64\u6b21\u985e\u795e\u7d93\u7db2\u8def\u65b9\u5f0f\u5efa\u7acb\u8d77\u6700\u4f73\u5316\u7684\u9810\u6e2c\u6a21\u578b\u70baMLP 34-5-2\uff0c\u5176\u8a13\u7df4\u6548\u80fd\u70ba92.00\uff0c\u6e2c\u8a66\u6548\u80fd\u70ba87.80\u3002\u8207\u539f\u59cb\u75c5\u4eba\u5b58\u6d3b\u72c0\u614b\u8cc7\u6599\u9032\u884c\u6bd4\u5c0d\u5206\u6790\uff0c\u6574\u9ad4\u6a23\u672c\u4e2d\u5c0d\u65bc\u500b\u5225\u75c5\u4eba\u7684\u5b58\u6d3b\u72c0\u614b\u9810\u6e2c\u6e96\u78ba\u7387\u70ba90.96%\uff0c\u9748\u654f\u5ea6\u548c\u7279\u7570\u5ea6\u5206\u5225\u70ba93.73%\u53ca81.28%\uff0cROC\u66f2\u7dda\u4e0b\u9762\u7a4d\u70ba0.95\uff0c\u5982\u679c\u55ae\u4ee5\u6e2c\u8a66\u7d44\u6a23\u672c\u4f86\u770b\uff0c\u5176\u9810\u6e2c\u6e96\u78ba\u7387\u70ba87.80%\uff0c\u9748\u654f\u5ea6\u548c\u7279\u7570\u5ea6\u5206\u5225\u70ba92.23%\u53ca71.70%\uff0cROC\u66f2\u7dda\u4e0b\u9762\u7a4d\u70ba0.88\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u904b\u7528\u985e\u795e\u7d93\u7db2\u8def\u63d0\u4f9b\u4e86\u4e00\u7a2e\u9810\u6e2c\u500b\u5225\u9f3b\u54bd\u764c\u75c5\u4eba\u9810\u5f8c\u7684\u65b9\u6cd5\uff0c\u4f7f\u7528\u5404\u9805\u7d71\u8a08\u6307\u6a19\u8a55\u4f30\u8a72\u985e\u795e\u7d93\u7db2\u8def\u9810\u6e2c\u6a21\u578b\u6548\u80fd\uff0c\u986f\u793a\u9078\u7528\u66f4\u591a\u8f38\u5165\u8b8a\u6578\u8cc7\u6599\u7684\u985e\u795e\u7d93\u7db2\u8def\uff0c\u5728\u9810\u6e2c\u500b\u5225\u9f3b\u54bd\u764c\u75c5\u4eba\u4e94\u5e74\u5b58\u6d3b\u72c0\u614b\u7684\u8868\u73fe\u8f03\u5148\u524d\u7814\u7a76\u70ba\u4f73\uff0c\u4f46\u6b64\u65b9\u6cd5\u662f\u5426\u9069\u7528\u65bc\u5be6\u969b\u81e8\u5e8a\u75c5\u4eba\u4ecd\u6709\u5f85\u9032\u4e00\u6b65\u7684\u8a55\u4f30\u8207\u7814\u7a76\u3002", "e": "Purpose: This study wants to establish a prognostic prediction system by artificial neural network for individual patients with nasopharyngeal carcinoma.Materials and methods: In this study, the dataset are 1,114 patients with nasopharyngeal carcinoma in one cancer center during the year from 1990 to 2005. The chosen variables include age, sex, primary tumor, regional lymph nodes, biopsy, radiotherapy, chemotherapy, lactic dehydrogenase, alkaline phosphatase, smoking, and family history. The final dataset are 984 patients excluding 70 patients with any data columns missing and 60 patients with distant metastasis. Seventy-five percent of 984 patients are randomly selected and classified to training group. An artificial neural network is created by computer software to predict the five-year survival status of patients with nasopharyngeal carcinoma. The performance of prediction models will be evaluated according to parameters such as accuracy, sensitivity, specificity, and the area under receiver operating characteristic curve.Result: The average age of the patients is 45.45 years old, and the five-year overall survival rate is 77.74%. The optimized artificial neural network is MLP 34-5-2 which training performance is 92.00 and test performance is 87.80. Its accuracy is 90.96%, sensitivity is 93.73%, specificity is 81.27%, and area under the ROC curve is 0.95 for all patients. Its accuracy is 87.80%, sensitivity is 92.23%, specificity is 71.70%, and area under the ROC curve is 0.88 for test group.Conclusion: This study shows that the prognostic prediction system established by artificial neural network has the potential to predict the five-year survival status of individual patients with nasopharyngeal carcinoma. With more input data, the performance of prediction models is better than previous researches. But this prognostic prediction system still need further study to prove it could be used for clinical patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-199-209", "title": "\u4f9d\u5faaTG-21\u8b70\u5b9a\u66f8\u6bd4\u8f03\u5404\u578b\u56fa\u614b\u5047\u9ad4\u57f7\u884c\u7d55\u5c0d\u5291\u91cf\u6821\u9a57\u4e4b\u5dee\u7570", "keywords": "TG-21\u8b70\u5b9a\u66f8;\u56fa\u614b\u6c34\u5047\u9ad4;\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50 TG-21 protocol;Solid water phantom;Phantom dose conversion factor", "c": "\u76ee\u7684\uff1a1983\u5e74\u767c\u8868\u7684AAPM TG-21\u9ad8\u80fd\u5c04\u675f\u5291\u91cf\u6821\u9a57\u8b70\u5b9a\u66f8\u5141\u8a31\u4f7f\u7528\u56fa\u614b\u5047\u9ad4\u91cf\u6e2c\u7d55\u5c0d\u5291\u91cf\uff0c\u4f46\u50c5\u63d0\u4f9bAcrylic\uff08Acry\uff09\u8207clear polystyrene\uff08Cpoly\uff09\u5169\u7a2e\u56fa\u614b\u5047\u9ad4\u4e4b\u53c3\u6578\u8cc7\u6599\u3002\u73fe\u4eca\u81e8\u5e8a\u4f7f\u7528\u591a\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\u6821\u9a57\u7d55\u5c0d\u5291\u91cf\uff0c\u7136\u800c\u537b\u4ecd\u4f9d\u5faaTG-21\u8b70\u5b9a\u66f8\u4e4b\u5167\u5bb9\uff0c\u6b64\u64cd\u4f5c\u65b9\u5f0f\u61c9\u7528\u5728\u9ad8\u80fd\u5149\u5b50\u8207\u96fb\u5b50\u5c04\u675f\u6642\u53ef\u80fd\u6703\u5f15\u8d77\u5291\u91cf\u7684\u8aa4\u5dee\u3002\u672c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u5728\u8a08\u7b97\u51fa\u5404\u7a2e\u56fa\u614b\u5047\u9ad4\u4e4b\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50\uff0c\u78ba\u4fdd\u61c9\u7528\u56fa\u614b\u5047\u9ad4\u57f7\u884c\u7d55\u5c0d\u5291\u91cf\u6821\u9a57\u6642\u53ef\u4ee5\u5f97\u5230\u6b63\u78ba\u7684\u6821\u9a57\u7d50\u679c\uff0c\u85c9\u6b64\u7dad\u6301\u653e\u5c04\u6cbb\u7642\u7684\u54c1\u8cea\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f9d\u5faaTG-21\u8b70\u5b9a\u66f8\u4e4b\u5167\u5bb9\u57f7\u884c\u5291\u91cf\u6821\u9a57\u3002\u7814\u7a76\u6bd4\u8f03\u4e4b\u5047\u9ad4\u5305\u62ec\uff1aPlastic Water\uff08PSW\uff09\u3001Standard Grade Solid Water\uff08GSW\uff09\u3001Virtual Water^TM\uff08VSW\uff09\u3001RW3 solid water\uff08RW3\uff09\u8207 White polystyrene phantom\uff08Wpoly\uff09\u7b49\u4e94\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\uff0c\u4ee5\u53caAcry \u8207Cpoly \u5169\u7a2e\u56fa\u614b\u5047\u9ad4\u3002\u5c04\u675f\u80fd\u91cf\u70ba6\u300110\u53ca15 MV\u5149\u5b50\u5c04\u675f\u82076\u30019\u300112\u53ca15 MeV\u96fb\u5b50\u5c04\u675f\uff0c\u5728\u5404\u5c04\u675f\u80fd\u91cf\u689d\u4ef6\u4e0b\uff0c\u5206\u5225\u6bd4\u8f03\u5404\u578b\u56fa\u614b\u5047\u9ad4\u8207\u6c34\u5047\u9ad4\u7d55\u5c0d\u5291\u91cf\u6821\u9a57\u4e4b\u5dee\u7570\u3002\u4e94\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\u4e4b\u5291\u91cf\u6821\u9a57\u8a08\u7b97\u7686\u4ee5\u6c34\u70ba\u4ecb\u8cea\u4e26\u57f7\u884cTG-21\u8b70\u5b9a\u66f8\u4e4b\u53c3\u6578\u67e5\u8868\uff0c\u5176\u4e2dRW3\u8207Wpoly\u518d\u52a0\u4ee5Cpoly\u70ba\u4ecb\u8cea\u57f7\u884c\u53c3\u6578\u67e5\u8868\u3002\u5149\u5b50\u5c04\u675f\u5291\u91cf\u6821\u9a57\u6df1\u5ea6\u8a2d\u5b9a\u65bc5 cm\uff0c\u800c\u96fb\u5b50\u5c04\u675f\u5247\u65bc\u6700\u5927\u5291\u91cf\u6df1\u5ea6\u4f4d\u7f6e\u3002\u5728\u5b8c\u6210\u5404\u578b\u56fa\u614b\u5047\u9ad4\u4e4bTG-21\u67e5\u8868\u5f8c\uff0c\u4e0d\u540c\u80fd\u91cf\u5c04\u675f\u5148\u5f8c\u4f7f\u7528\u6c34\u5047\u9ad4\u8207\u56fa\u614b\u5047\u9ad4\u57f7\u884c\u7d55\u5c0d\u5291\u91cf\u91cf\u6e2c\uff0c\u5206\u6790\u6bd4\u8f03\u5176\u5291\u91cf\u5dee\u7570\u3002\u6b64\u5916\uff0c\u900f\u904e\u5404\u578b\u56fa\u614b\u5047\u9ad4\u8207\u6c34\u5047\u9ad4\u7684\u5291\u91cf\u6bd4\u5c0d\uff0c\u6c42\u5f97\u5404\u578b\u56fa\u614b\u5047\u9ad4\u7684\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50\uff08phantom dose conversion factor, PDCF\uff09\uff0c\u85c9\u4ee5\u4fee\u6b63\u56fa\u614b\u5047\u9ad4\u57f7\u884c\u5291\u91cf\u6821\u9a57\u6642\u7684\u8aa4\u5dee\u3002\u9664\u4e86\u5728\u5291\u91cf\u6821\u9a57\u9ede\u7684\u6bd4\u5c0d\u4e4b\u5916\uff0c\u70ba\u78ba\u8a8d\u56fa\u614b\u6c34\u5047\u9ad4\u5728\u4e0d\u540c\u6df1\u5ea6\u5c0d\u65bc\u5c04\u675f\u8870\u6e1b\u53ca\u6563\u5c04\u7b49\u7279\u6027\u8207\u6c34\u7684\u5dee\u7570\uff0c\u672c\u7814\u7a76\u6e2c\u91cf\u56fa\u614b\u6c34\u5047\u9ad4\u65bc\u5149\u5b50\u5c04\u675f5\uff0c10\u53ca15 cm\u4e4b\u767e\u5206\u6df1\u5ea6\u5291\u91cf\uff08PDD\uff09\u8207\u96fb\u5b50\u5c04\u675fd50\u8207d80\u4e4b\u767e\u5206\u6df1\u5ea6\u6e38\u96e2\u91cf\uff08PDI\uff09\uff0c\u85c9\u4ee5\u9a57\u8b49\u4e0d\u540c\u6df1\u5ea6\u4e0b\u56fa\u614b\u6c34\u5047\u9ad4\u65bc\u5149\u5b50\u53ca\u96fb\u5b50\u5c04\u675f\u4f5c\u7528\u4e0b\uff0c\u76f8\u5c0d\u65bc\u6c34\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u7e3d\u8a08\u4e03\u7a2e\u56fa\u614b\u5047\u9ad4\u5728\u6240\u6709\u9ad8\u80fd\u5149\u5b50\u5c04\u675f\u8207\u6c34\u5047\u9ad4\u6240\u91cf\u6e2c\u4e4b\u7d55\u5c0d\u5291\u91cf\u5dee\u7570\u7686\u5c0f\u65bc1%\u3002PSW\u8207Acry\u5728\u6240\u6709\u96fb\u5b50\u5c04\u675f\u4e0b\u8207\u6c34\u5047\u9ad4\u91cf\u6e2c\u4e4b\u7d55\u5c0d\u5291\u91cf\u5dee\u7570\u5c0f\u65bc1%\uff0c\u800cGSW \u3001 VSW \u3001 RW3 \u3001 Wploy \u3001 Cpoly\u4e4b\u91cf\u6e2c\u5dee\u7570\u5247\u4ecb\u65bc-0.6 ~ -3.6%\u4e4b\u9593\uff0c\u5c0d\u61c9\u6c42\u5f97\u4e4b\u96fb\u5b50\u5c04\u675f\u56fa\u614b\u6c34\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50\u5247\u4ecb\u65bc0.994 ~ 0.964\u4e4b\u9593\u3002\u4e94\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\u5728\u5149\u5b50\u5c04\u675f\u4e0b5\uff0c10\u53ca15 cm\u4e4bPDD\u503c\u8207\u6c34\u5047\u9ad4\u6240\u91cf\u6e2c\u4e4b\u5dee\u7570\u7686\u5c0f\u65bc1.1%\uff1b\u800c\u4e94\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\u5728\u96fb\u5b50\u5c04\u675f\u4e0b\uff0cd50\u8207d80\u6df1\u5ea6\u4e4bPDI\u503c\u8207\u6c34\u5047\u9ad4\u6240\u91cf\u6e2c\u4e4b\u5dee\u7570\u5247\u7686\u57281.5 mm\u4ee5\u4e0b\u3002\u7d50\u8ad6\uff1a\u5728\u5149\u5b50\u5c04\u675f\u4f7f\u7528PSW \u3001 GSW \u3001 VSW \u3001 RW3\u3001 Wpoly\u4e94\u7a2e\u56fa\u614b\u6c34\u5047\u9ad4\u91cf\u6e2c\u7d55\u5c0d\u5291\u91cf\u6642\u7686\u53ef\u8996\u70ba\u6c34\u4ecb\u8cea\uff0c\u56e0\u5176\u5047\u9ad4\u6750\u8cea\u9020\u6210\u7684\u5291\u91cf\u5dee\u7570\u5c0f\u65bc1%\uff1b\u4e14\u5728\u96fb\u5b50\u5c04\u675f\u4f7f\u7528PSW\u5047\u9ad4\u91cf\u6e2c\u7d55\u5c0d\u5291\u91cf\u6642\u4ea6\u53ef\u8996\u70ba\u6c34\uff0c\u5176\u56e0\u5047\u9ad4\u6750\u8cea\u9020\u6210\u7684\u5291\u91cf\u5dee\u7570\u4e5f\u5c0f\u65bc1%\u3002\u800cGSW \u3001 VSW \u3001 RW3\u8207Wpoly\u5047\u9ad4\u5728\u57f7\u884c\u96fb\u5b50\u5c04\u675f\u5291\u91cf\u91cf\u6e2c\u6642\uff0c\u5247\u5efa\u8b70\u5148\u6c42\u51fa\u96fb\u5b50\u5c04\u675f\u4e4b\u5047\u9ad4\u5291\u91cf\u8f49\u63db\u56e0\u5b50\uff0c\u85c9\u4ee5\u4fee\u6b63\u56fa\u614b\u6c34\u5047\u9ad4\u56e0\u6750\u8cea\u6240\u9020\u6210\u7684\u5291\u91cf\u5dee\u7570\u3002", "e": "Purpose: To verify the accuracy of the clinical reference dosimetry according to the TG-21 protocol using seven solid phantoms for high energy photon and electron beams.Materials and Methods: The TG-21 protocol was published in 1983, and then the clinical reference dosimetry can be performed in the solid phantom materials. However, only acrylic and clear polystyrene are supported in TG-21. Reference dosimetry followed by TG-21 but use solid phantoms other than the phantoms supported by this protocol can result uncertainties in absolute dose calibration. Plastic Water\u00ae Phantom Material (PSW), Standard Grade Solid Water\u00ae (GSW), Virtual Water^TM Phantom Materials (VSW), RW3 solid water phantom (RW3), white polystyrene phantom (Wpoly), acrylic phantom (Acry) and clear polystyrene phantom (Cpoly) are enrolled to compare the responses with water for 6, 10 and 15 MV photon beams and 6, 9, 12 and 15 MeV electron beams. For the RW3 and Wpoly, we compare the results using the water and clear polystyrene parameters for clinical absolute dosimetry calculation. Ionization measurements were taken at water equivalent depths of 5 cm and dmax for photon and electron beams, respectively. The phantom dose conversion factor (PDCF) of the absolute dose between solid water phantoms and water at the identical calibration conditions are obtained. Additionally, comparisons for percent depth doses at water equivalent depths of 5, 10, and 15 cm in photon beams, and d50 and d80 in electron beams were performed to verify the different response at different depths.Results: The variations between five solid water phantoms and water for photon beams are all within 1.0%. For PSW and Acry, the variations in electron beams are within 1.0%. However, the variations are -0.6 to -3.6% for 6 to 15 MeV electron beams for GSW, VSW, RW3, Wploy and Cpoly. The PDCF of 0.994~ 0.964 for electron beams are obtained. The variations of PDD (5 cm), PDD (10 cm), PDD (15 cm) between five solid water phantoms and water for photon beams are within 1.1%. The variations of d50 and d80 between five solid water phantoms and water for photon beams are within 1.5 mm.Conclusion: The PSW\u3001GSW\u3001VSW\u3001RW3\u3001Wpoly solid water phantom can be treated as water for 6, 10 and 15 MV photon beams. And the PSW can also be treated as water for electron beams. For electron beam dose calibration, PDCF should be applied for GSW, VSW, RW3 and Wpoly. Phantom response relative to water should be evaluated carefully when TG-21 protocol is used for clinical dose calibration."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-211-226", "title": "\u92a5-192\u8fd1\u63a5\u6cbb\u7642\u5c04\u6e90\u4e4b\u5291\u91cf\u8a08\u7b97\u8207\u6e2c\u91cf\u7814\u7a76", "keywords": "\u8fd1\u63a5\u6cbb\u7642;\u92a5192;\u71b1\u767c\u5149\u5291\u91cf\u8a08 Brachytherapy;192Ir;Thermoluminescent dosimeter (TLD)", "c": "\u76ee\u7684\uff1a\u73fe\u4eca\u7684\u8fd1\u63a5\u6cbb\u7642\u65b9\u5f0f\u5927\u591a\u4ee5\u9ad8\u5291\u91cf\u7387\uff08high dose rate, HDR\uff09\u7684\u9059\u63a7\u5f8c\u8377\u5f0f\u8fd1\u63a5\u6cbb\u7642\uff08remote afterloading brachytherapy\uff09\u70ba\u4e3b\uff0c\u800c\u570b\u5167\u91ab\u9662\u5927\u591a\u63a1\u7528Nucletron\u7684micro-Selectron\u7cfb\u5217\uff0c\u6b64\u7cfb\u5217\u63a1\u7528\u6d3b\u5ea610\u5c45\u79ae(Ci)\u7684\u92a5-192(^192Ir)\u8fd1\u63a5\u6cbb\u7642\u5c04\u6e90\u3002\u8fd1\u63a5\u6cbb\u7642\u7684\u5291\u91cf\u8a08\u7b97\u7686\u4ee5\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u904b\u7b97\uff0c\u8207micro-Selectron\u914d\u5408\u7684\u7cfb\u7d71\u70baPLATO(PLATO Brachytherapy - INSIGHT^TM module system)\uff0cPLATO\u662f\u4e00\u5957\u4ee5TG-43\u4f5c\u8a08\u7b97\u57fa\u790e\u7684\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\uff0c\u70ba\u63a2\u8a0e\u92a5-192\u8fd1\u63a5\u6cbb\u7642\u5c04\u6e90\u7684\u5291\u91cf\u5206\u5e03\uff0c\u672c\u5be6\u9a57\u64ec\u5229\u7528\u71b1\u767c\u5149\u5291\u91cf\u8a08(thermoluminescent dosimeter\uff0c TLD)\u5be6\u6e2c\u8207\u897f\u5f17\u7a4d\u5206(Sievert integral)\u8a08\u7b97\u5169\u7a2e\u65b9\u5f0f\u4f86\u8207TG-43\u7684\u7d50\u679c\u6bd4\u8f03\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5Varian 2100C\u578b\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u4f5c\u70ba\u6a19\u6e96\u5c04\u6e90\u7be9\u9078TLD\uff0c\u5c07\u7be9\u9078\u904e\u7684TLD\u8207needle applicator\u7f6e\u65bc\u7279\u88fd\u6c34\u5047\u9ad4\u4e2d\uff0c\u6e2c\u91cf\u4e0d\u540c\u4f4d\u7f6e\u4e0b\u7684\u5291\u91cf\u503c\uff0c\u53e6\u5916\uff0c\u914d\u5408\u7576\u6642\u7684\u6d3b\u5ea6\u8a08\u7b97\u51faSievert integral\u8207TG-43\u7684\u5291\u91cf\u503c\u3002\u7d50\u679c\uff1aTLD\u7684\u6e2c\u91cf\u503c\u8207TG-43\u7684\u8a08\u7b97\u503c\u7684\u7d50\u679c\uff0c\u8aa4\u5dee\u7686\u57288%\u5167\u3002\u800cSievert integral\u7684\u7d50\u679c\uff0c\u4e0d\u8ad6\u8207TLD\u7684\u6e2c\u91cf\u503c\u6216TG-43\u7684\u8a08\u7b97\u503c\u90fd\u6709\u660e\u986f\u7684\u5dee\u7570\uff0c\u5c24\u5176\u5728\u8d8a\u63a5\u8fd1\u5c04\u6e90\u7684\u4f4d\u7f6e\u8d8a\u986f\u8457\uff0c\u6700\u5927\u8aa4\u5dee\u53ef\u905422%\uff0c\u96a8\u8457\u5f91\u5411\u8ddd\u96e2\u589e\u52a0\uff0cSievert integral\u7684\u8aa4\u5dee\u503c\u6709\u6e1b\u5c11\u7684\u8da8\u52e2\uff0c\u5728\u5f91\u5411\u8ddd\u96e2\u5927\u65bc6 cm\u5f8c\uff0c\u8aa4\u5dee\u6703\u5927\u5e45\u6e1b\u5c11\uff0c\u53ef\u572810%\u4ee5\u5167\u3002\u7d50\u8ad6\uff1a\u5229\u7528TLD\u6e2c\u91cf\u8207TG-43\u7684\u8a08\u7b97\u503c\u7684\u5dee\u7570\u6700\u5927\u70ba8%\uff1b\u4f46Sievert integral\u7684\u7d50\u679c\u8207\u5176\u4ed6\u5169\u8005\u7684\u5dee\u8ddd\u572810-20%\u5de6\u53f3\uff0c\u986f\u793a\u659c\u6563\u5c04\u7684\u8ca2\u737b\u6703\u5c0e\u81f4\u5291\u91cf\u88ab\u4f4e\u4f30\uff0c\u4e14\u659c\u6563\u5c04\u7684\u5f71\u97ff\u6703\u96a8\u8ddd\u96e2\u589e\u52a0\u800c\u6e1b\u5c11\u3002\u5c0d\u65bc\u8fd1\u63a5\u6cbb\u7642\u7279\u6709\u7684\u9661\u5ced\u5291\u91cf\u68af\u5ea6\u8b8a\u5316\uff0c\u9ad4\u7a4d\u5c0f\u7684TLD\u80fd\u63d0\u4f9b\u8f03\u4f73\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\u3002\u53e6\u5916\uff0c\u7531\u8aa4\u5dee\u5206\u6790\u53ef\u77e5\uff0c\u5c04\u6e90\u8207TLD\u7684\u5de6\u53f3\u504f\u79fb\u662f\u672c\u5be6\u9a57\u6700\u5927\u7684\u8aa4\u5dee\u4f86\u6e90\u3002", "e": "Purpose: High dose rate (HDR) remote afterloading brachytherapy is the most common methods used for brachytherapy. Most hospitals in Taiwan used the Nucletron microSelectron system with 10 Ci 192Ir source for brachytherapy. The theory of dose calculation of Nucletron microSelectron system was based on TG-43. The aim of this study was to compare the result of TLD measurement the calculation results using the Sievert integral and TG-43.Material and Method: The TLDs and Varian 2100C LINAC were used to build the calibration curve. The selected TLD and needle applicator were put in the special positions in solid water phantom. The result of measurement was compared with Sievert integral and TG-43.Result: The variation between the result of measurement and calculation with TG-43 are in 8%, but the result of calculation with Sievert integral have large variation up to 22% between the others, especial in the region near source. The differences between three methods were decreased with large radial distances.Conclusion: The variation between the result of measurement and calculation with TG-43 were within 8%. The underestimate of dose for Sievert integral might be due to the oblique scatting, and the influence of oblique scatting would be decreased with the increasing of radial distance. The most contribution of error in this study might be come from the shift of TLD positions and the brachytherapy source position."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-227-234", "title": "Primary Osteosarcoma of the Breast: A Case Report in Taiwan", "keywords": "\u4e73\u623f\u539f\u767c\u6027\u9aa8\u8089\u7624;\u4e73\u623f;\u653e\u5c04\u6cbb\u7642 Osteosarcoma;Breast;Radiotherapy", "c": "\u4e73\u623f\u539f\u767c\u6027\u9aa8\u8089\u7624\u662f\u4e00\u500b\u5c11\u898b\u7684\u9aa8\u9abc\u5916\u9aa8\u8089\u7624\u3002\u56de\u9867\u904e\u53bb\u7684\u6587\u737b\u591a\u70ba\u75c5\u4f8b\u5831\u544a\uff0c\u4e14\u591a\u6578\u5f15\u75281998\u5e74\u7531Silver\u53caTavassoli\u767c\u8868\u7684\u8ffd\u8e6438\u5e74\u670950\u500b\u75c5\u4f8b\u6578\u7684\u7814\u7a76\u3002\u9019\u985e\u816b\u7624\u767c\u751f\u539f\u56e0\u4e0d\u660e\uff0c\u4f46\u53ef\u80fd\u51fa\u73fe\u5728\u653e\u5c04\u6cbb\u7642\u5f8c\u3001\u5916\u50b7\u5f8c\u6216\u4e73\u623f\u690d\u5165\u5916\u4f86\u7570\u7269\u5f8c\uff0c\u4e14\u7121\u7279\u5b9a\u597d\u767c\u5e74\u9f61\u3002\u9019\u985e\u816b\u7624\u70ba\u9ad8\u60e1\u6027\u5ea6\u9810\u5f8c\u4e0d\u4f73\uff0c\u4e14\u6613\u8f49\u79fb\u7684\u816b\u7624\uff0c\u591a\u70ba\u8840\u6db2\u64f4\u6563\uff0c\u5c11\u898b\u6dcb\u5df4\u64f4\u6563\uff0c\u5e38\u898b\u8f49\u79fb\u90e8\u4f4d\u662f\u80ba\u90e8\u3002\u6cbb\u7642\u65b9\u5f0f\u4ecd\u4ee5\u624b\u8853\u5207\u9664\u70ba\u4e3b\uff0c\u5c0d\u65bc\u816b\u7624\u8f49\u79fb\u7684\u75c5\u60a3\uff0c\u624d\u8003\u616e\u5316\u5b78\u6cbb\u7642\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f8b\u4e73\u623f\u539f\u767c\u6027\u9aa8\u8089\u7624\uff0c\u63a5\u53d7\u5de6\u5074\u6539\u826f\u5f0f\u5168\u4e73\u623f\u5207\u9664\u624b\u8853\uff0c\u75c5\u7406\u5207\u7247\u767c\u73fe\u57fa\u90e8\u908a\u7de3\u4ecd\u6b98\u7559\u816b\u7624\uff0c\u56e0\u6b64\u7d66\u4e88\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\uff0c\u96d6\u7136\u672a\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u7684\u60c5\u6cc1\uff0c\u4f46\u5728\u8853\u5f8c\u5341\u4e94\u500b\u6708\u4ecd\u7136\u767c\u751f\u80ba\u90e8\u8f49\u79fb\u3002\u5927\u90e8\u5206\u7684\u75c5\u4f8b\u5831\u544a\u8f03\u5c11\u8ac7\u8ad6\u5230\u653e\u5c04\u6cbb\u7642\uff0c\u5c31\u6b64\u75c5\u4f8b\u800c\u8a00\uff0c\u653e\u5c04\u6cbb\u7642\u53ef\u80fd\u964d\u4f4e\u75be\u75c5\u7684\u5c40\u90e8\u5fa9\u767c\u7387\uff0c\u4f46\u7121\u6cd5\u6539\u5584\u9aa8\u8089\u7624\u7684\u9ad8\u8f49\u79fb\u7387\u3002", "e": "Primary breast osteosarcoma is an aggressive and relatively rare tumour with poor prognosis. It is associated with early recurrence and hematogenous rather than lymphatic spread, most commonly to the lungs. We report a case in a 32-year-old woman who presented with a hard painless lump at left breast of six years duration. Left side nipple sparing mastectomy including axillary lymph node dissection was carried out. The tumor was 10 x 9.5 x 6 cm in size. Histopathology of the nipple sparing mastectomy specimen showed predominantly osteosarcomatous areas. Immunohistochemistry indicated that neoplastic osteoblastic cells of the tumor stained positively for vimentin, but negatively for epithelial markers; which suggested. Immunohistochemistry plays a pivotal role in the diagnosis of this type of tumor. Because there was no evidence of metastasis and residual tumoral cell was present at the base of site of surgery, she received adjuvant radiotherapy and chemotherapy. But she remained disease free at 15 months at which time metastases of bone and lung were diagnosed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201309-201309230006-201309230006-235-242", "title": "High Dose Radiotherapy of an Esophageal Cancer Patient with Cardiac Pacemaker Implantation-A Case Report", "keywords": "\u98df\u9053\u764c;\u5fc3\u81df\u7bc0\u5f8b\u5668;\u653e\u5c04\u6cbb\u7642;\u53f0\u7063 Esophageal cancer;Pacemaker;Radiotherapy;Taiwan", "c": "\u4e00\u4f4d\u690d\u5165\u5fc3\u81df\u7bc0\u5f8b\u5668\u4e4b85\u6b72\u7537\u6027\u75c5\u4eba\u88ab\u8a3a\u65b7\u51fa\u7f79\u60a3\u98df\u9053\u764c\u3002\u7d93\u591a\u5718\u968a\u6703\u8b70\u8a0e\u8ad6\u5f8c\uff0c\u75c5\u4eba\u4e0d\u9069\u5408\u5316\u5b78\u6cbb\u7642\u6216\u624b\u8853\uff0c\u56e0\u6b64\u6c7a\u5b9a\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u3002\u816b\u7624\u4f4d\u7f6e\u76f8\u7576\u63a5\u8fd1\u7bc0\u5f8b\u5668\u7684\u7dda\u8def\uff0c\u6240\u4ee5\uff0c\u5373\u4fbf\u6587\u737b\u5efa\u8b70\u4e0d\u8981\u8b93\u7bc0\u5f8b\u5668\u5438\u6536\u5291\u91cf\u8d85\u904e200 cGy\uff0c\u7bc0\u5f8b\u5668\u4ecd\u7136\u7121\u53ef\u907f\u514d\u5438\u6536\u4e86\u9ad8\u5291\u91cf\u7684\u8f3b\u5c04\u3002\u5728\u653e\u5c04\u816b\u7624\u79d1\u548c\u5fc3\u81df\u5167\u79d1\u7684\u5bc6\u5207\u5408\u4f5c\u4e0b\uff0c\u75c5\u4eba\u9806\u5229\u5b8c\u6210\u4e86\u653e\u5c04\u6cbb\u7642\u3002\u816b\u7624\u7684\u5438\u6536\u5291\u91cf6000 cGy\uff0c\u800c\u7bc0\u5f8b\u5668\u7684\u5438\u6536\u5291\u91cf\u70ba5777 cGy\u3002\u5728\u6cbb\u7642\u7d50\u675f\u5f8c\u4e09\u500b\u6708\u7684\u8ffd\u8e64\uff0c\u816b\u7624\u5b8c\u5168\u6d88\u9664\uff0c\u7bc0\u5f8b\u5668\u4e5f\u7121\u529f\u80fd\u7570\u5e38\u3002\u5c31\u6211\u5011\u6240\u77e5\uff0c\u5728\u53f0\u7063\uff0c\u9019\u662f\u7b2c\u4e00\u500b\u5206\u4eab\u5982\u4f55\u85c9\u7531\u653e\u5c04\u816b\u7624\u79d1\u548c\u5fc3\u81df\u5167\u79d1\u7684\u5bc6\u5207\u5408\u4f5c\uff0c\u5373\u4f7f\u7bc0\u5f8b\u5668\u7121\u53ef\u907f\u514d\u63a5\u53d7\u9ad8\u5291\u91cf\u8f3b\u5c04\uff0c\u4ecd\u53ef\u4ee5\u6210\u529f\u5730\u4ee5\u653e\u5c04\u6cbb\u7642\u4f86\u6cbb\u7642\u764c\u75c7\u75c5\u4eba\u7684\u75c5\u4f8b\u5831\u544a\u3002", "e": "An 85-year-old man who had artificial pacemaker implantation was diagnosed to have esophageal cancer. The patient was ineligible for surgery or chemotherapy as the agreement of multidisciplinary tumor board. So radiotherapy alone was planned. The location of tumor is very close to the lead of pacemaker. Thus, the pacemaker absorbed high dose of radiation inevitably although the published literature strongly suggested that the pacemaker should not be in the direct field or absorb radiation dose higher than 200 cGy. Under close cooperation between the radiation oncologist and the cardiologist, the patient underwent the radiotherapy smoothly. The prescribed dose was 6000 cGy to tumor and 5777 cGy to pacemaker. The tumor got complete remission and no malfunction of pacemaker was noted at three months' follow up. To our knowledge, this is the first case report in Taiwan to demonstrate how to successfully use radiotherapy to treat a cancer patient with pacemaker implantation under the close cooperation of radiation oncologist and cardiologist."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-89-96", "title": "Prognostic Factors after Adjuvant Radiotherapy in Cervical Cancers: A Retrospective Study", "keywords": "\u5b50\u5bae\u9838\u764c;\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Cervical cancer;Adjuvant radiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u6b64\u56de\u6eaf\u6027\u7814\u7a76\u91dd\u5c0d\u63a5\u53d7\u904e\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u5b50\u5bae\u9838\u764c\u60a3\u8005\uff0c\u7814\u7a76\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5f9e2000\u81f32006\u5e74\u65bc\u9ad8\u96c4\u69ae\u6c11\u7e3d\u91ab\u9662\u6536\u9304149\u540d\u63a5\u53d7\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u5b50\u5bae\u9838\u764c\u60a3\u8005\u3002\u5229\u7528\u55ae\u8b8a\u9805\u8207\u591a\u8b8a\u9805\uff0c\u5206\u6790\u5404\u7a2e\u53ef\u80fd\u5f71\u97ff\u5b58\u6d3b\u7387\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u75c5\u60a3\u4e4b\u4e2d\u4f4d\u6578\u5e74\u9f61\u70ba55\u6b72\u3002\u5b50\u5bae\u9838\u764c\u60a3\u8005\u4f9d\u64da\u5206\u671f\uff0cIB\u6709102\u4f4d\uff0cIIA\u670933\u4f4d\uff0cIIB-IVA\u670914\u4f4d\u3002\u5206\u671f\u70baIB\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba75.2%\u53ca65.4%\u3002\u5206\u671f\u70baIIA\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba69.7%\u53ca70.5 %\u3002\u5206\u671f\u70baIIB-IVA\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba66.7%\u53ca50%\u3002\u591a\u8b8a\u9805\u5206\u6790\u986f\u793a\u5b50\u5bae\u65c1\u4fb5\u72af\u4ee5\u53ca\u817a\u764c\u986f\u8457\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u7d50\u8ad6\uff1a\u5b50\u5bae\u65c1\u4fb5\u72af\u4ee5\u53ca\u817a\u764c\u985e\u578b\u7684\u7d44\u7e54\u578b\u614b\u70ba\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u53e6\u5916\uff0c\u5728\u6211\u5011\u7684\u7814\u7a76\u4e2d\uff0c\u8f14\u52a9\u6027\u5316\u7642\u4e26\u4e0d\u80fd\u63d0\u5347\u5b58\u6d3b\u7387\u3002", "e": "Purpose: This retrospective study aimed to investigate the prognostic factors influenced the overall and progression-free survival (PFS) in cervical cancer patients who received radical hysterectomy and Iymphadenectomy and adjuvant radiotherapy.Methods: From 2000 to 2006, there were 149 cervical cancer patients treated with surgery and adjuvant radiotherapy in the Department of Radiation therapy, Kaohsiung Veterans General Hospital, Taiwan. Patient characteristics, treatment characteristics and pathologic factors were analyzed using log rank test. The overall survival (OS) and PFS distribution were calculated by Kaplan-Meier method. Multivariate analysis was performed by the Cox regression model.Result: The median age of this population was 55 years-old (ranged from 25 to 82). There were 102, 33, and 14 patients belonged to FIGO stage 18, IIA and 118 to IVA, respectively. The 5-year OS and PFS were 75.2% and 65.4% in stage 18 cervical cancer, 69.7% and 70.5% in stage IIA cervical cancer, and 66.7% and 50% in stage 118. IVA cervical cancer. In multivariate analysis, the factors of adenocarcinoma (p \uff1c0.05) and parametrial invasion (p \uff1c 0.01) correlated with worse OS and the factors of parametrial invasion (p \uff1c0.01) and age \uff1c60 (p \uff1c0.05) correlated with worse PFS.Conclusion: Parametrial invasion and histology of adenocarcinoma accounted the most important prognostic factors among other clinical and pathological factors in patients receiving adjuvant radiotherapy. Adjuvant chemotherapy didn't achieve better survival in our study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-97-105", "title": "\u87ba\u65cb\u5200\u653e\u5c04\u6cbb\u7642\u5100\u4f4e\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u7b2c\u56db\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u80ba\u5167\u75c5\u7076\uff0d\u55ae\u4e00\u4e2d\u5fc3\u7d93\u9a57\u5206\u4eab", "keywords": "\u80ba\u764c;\u87ba\u65cb\u5200\u653e\u5c04\u6cbb\u7642\u5100;\u4f4e\u5206\u6b21\u653e\u5c04\u6cbb\u7642 Lung cancer;Tomotherapy;Hypofractionated radiotherapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u4ee5\u87ba\u65cb\u5200\u653e\u5c04\u6cbb\u7642\u5100\u4f4e\u5206\u5206\u6b21\u653e\u5c04\u6cbb\u7642\uff08HT, Hypofractionated Tomotherapy\uff09\u7b2c4\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08NSCLC, non-small cell lung cancer\uff09\u80ba\u5167\u75c5\u59d3\u4e4b\u81e8\u5e8a\u7d93\u9a57\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2007\u5e744\u6708\u81f32011\u5e747\u6708\uff0c\u5171\u8a08\u670927\u4f4d\u7b2c4\u671fNSCLC\u60a3\u8005\u63a5\u53d7HT\u6cbb\u7642\u5176\u80ba\u5167\u75c5\u5740\u3002\u6240\u6709\u60a3\u8005\u80ba\u5167\u75c5\u7076\u6578\u76ee\u4e0d\u5927\u65bc5\u500b\uff0c \u4e14\u4efb\u4e00\u75c5\u7076\u4e0d\u5927\u65bc5cm\uff0c\u4e3b\u8981\u5206\u6790\u70ba\u6574\u9ad4\u751f\u5b58\u671f\u3001\u7167\u91ce\u5167\u5fa9\u767c\u4ee5\u53ca\u653e\u5c04\u6027\u80ba\u708e\u4e4b\u767c\u751f\u3002\u60a3\u8005\u6cbb\u7642\u8a08\u756b\u9700\u53c3\u8003\u9ad8\u80fd\u96fb\u8166\u65b7\u5c64\u4e4b\u5f71\u50cf\uff08MVCT, megavoltage computerized tomography\uff09\u3002\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u5206\u6b21\u6578\u4ecb\u65bc9\u81f316\u6b21\uff0c\u4e2d\u4f4d\u6578\u70ba10\u6b21\uff0c\u55ae\u6b21\u5291\u91cf\u5e73\u5747\u6578\u70ba4.7\u00b10.3Gy\uff08\u5e73\u5747\u6578\u00b1\u6a19\u6e96\u5dee\uff09\uff0c\u7e3d\u5291\u91cf\u5e73\u5747\u6578\u70ba48.6\u00b16.8 Gy\u3002\u7d50\u679c\uff1a\u5168\u90e8\u75c5\u4eba\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\uff08median follow up\uff09\u70ba16.1\u6708\uff0c\u8ffd\u8e64\u671f\u5167\u7121\u7167\u91ce\u5167\u5fa9\u767c\u3002\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\uff08median overall survival\uff09\u70ba32.1\u6708\u3002\u60a3\u6709\u80ba\u5916\u8f49\u79fb\u75c5\u7076\uff08EPD\uff0cextrapu lmonary disease\uff09\u4e4b\u60a3\u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u70ba11.2\u6708\uff0c\u7121EPD\u4e4b\u60a3\u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u5247\u70ba38.6\u6708\uff0c\u5169\u8005\u4e4b\u9593\u5177\u6709\u986f\u8457\u5dee\u7570\uff08p\u503c\u7b49\u65bc0.003\uff09\uff0c\u4ee5\u80ba\u5167\u75c5\u7076\u6578\u91cf\u4f5c\u89c0\u5bdf\uff0c\u8f49\u79fb\u75c5\u7076\u6578\u91cf\u5c0f\u65bc3\u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u70ba34.7\u6708\uff0c\u8f49\u79fb\u75c5\u7076\u6578\u91cf\u4ecb\u65bc3\u81f35\u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u5247\u70ba32.1\u6708\uff0c\u5169\u8005\u4e4b\u9593\u7121\u986f\u8457\u5dee\u7570\uff08p\u503c\u7b49\u65bc0.57\uff09\u3002\u80ba\u5167\u75c5\u7076\u7e3d\u9ad4\u7a4d\u5e73\u6600\u6578\u70ba39.18\u00b139.98cm^3\u3002\u80ba\u5e73\u5747\u5291\u91cf\u70ba7.34\u00b13.38 Gy\u3002\u4ee5\u80ba\u5167\u75c5\u7076\u7e3d\u9ad4\u7a4d\u505a\u8a55\u4f30\uff0c\u8f49\u79fb\u75c5\u7076\u7e3d\u9ad4\u7a4d\u5c0f\u65bc\u6216\u7b49\u65bc27.89cm^3\u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u70ba34.7\u6708\uff0c\u8f49\u79fb\u75c5\u7076\u7e3d\u9ad4\u7a4d\u5927\u65bc27.89cm^3 \u8005\uff0c\u5176\u6574\u9ad4\u751f\u5b58\u671f\u4e2d\u4f4d\u6578\u5247\u70ba12.3\u6708\uff0c\u5169\u8005\u4e4b\u9593\u5177\u6709\u5177\u986f\u8457\u5dee\u7570\uff08p\u503c\u7b49\u65bc0.04\uff09\u3002\u51712\u4f4d\u767c\u751f\u7b2c3\u7d1a\u4ee5\u4e0a\u4e4b\u653e\u5c04\u6027\u80ba\u708e\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528HT\u6cbb\u7642\u5c0f\u65bc\u6216\u7b49\u65bc5\u500b\u7b2c4\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u80ba\u5167\u75c5\u7076\uff0c\u53ef\u5f97\u5230\u826f\u597d\u4e4b\u816b\u7624\u5c40\u90e8\u63a7\u5236\u7387\u3002\u6709\u7121\u80ba\u5916\u8f49\u79fb\u75c5\u7076\u4ee5\u53ca\u80ba\u5167\u75c5\u7076\u7e3d\u9ad4\u7a4d\u7686\u70ba\u5f71\u97ff\u6574\u9ad4\u751f\u5b58\u671f\u4e4b\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Introduction : To retrospectively evaluate Hypofractionated Tomotherapy (HT) on the treatment of intrathoracic lesions in patients with stage IV non-small celllung cancer (NSCLC).Material and Methods: Between April 2007 and July 2011, 27 stage IV NSCLC patients were treated with HT for their intrathoracic lesions. The number of intrathocic lesions was \u2266 5 and none of them exceeded 5 cm in greatest dimension. Overall survival, rate of in-field recurrence and incidence of radiation pneumonitis were analyzed. Megavoltage computerized tomography (MVCT) was utilized for tumor contouring. The mean radiation dose per fraction was 4.7\u00b10.3 Gy (mean\u00b1standard deviation) and the number of fractions ranged between 9 and 16 (median: 10 fractions). Total irradiation dose was 48.8\u00b16.8 Gy.Results: The median follow-up period was 16.1 months. There was no in-field failure. The median duration of overall survival was 11.2 months among patients with extrapulmonary disease (EPD) and 38.6 months among patients without EPD (p = 0.03). The median duration of overall survival was 34.7 months among patients with \uff1c 3 intrathoracic GTV s and 32.1 months among patients with 3-5 intrathoracic GTVs (p = 0.57). The aggregated intrathoracic GTV in each patient averaged 39.18\u00b139.98 cm3. The median duration of overall survival was 38.6 months among patients with aggregated intrathoracic GTV \u226627.89 cm^3 and 12.3 months among patients with aggregated intrathothoracic GTV \uff1e 27.89 cm^3 (p= 0.04). Two patients developed grade 3 or greater radiation pneumomhs.Conclusion: HT may be feasible for selected stage IV NSCLC patients with the number of intrathoracic lesions less than or equal to 5. Excellent local control can be anticipated. Presence of EPD and volume of intrathoracic lesions may be significant prognostic factors for overall survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-107-114", "title": "The Impact of Prone Position with Belly-Board Device on Three-Dimensional Conformal Radiotherapy of Prostate Cancer: Decreasing the Rectum Complication Probability", "keywords": "\u651d\u8b77\u817a\u764c;\u4e09\u7dad\u9069\u5f62\u653e\u7642;\u6cbb\u7642\u59ff\u52e2;\u8179\u677f;\u5291\u91cf\u8207\u9ad4\u7a4d\u7684\u76f4\u65b9\u5716 Prostate cancer;Three-dimensional conformal radiotherapy;Treatment position; Belly-board;Dose-Volume Histogram", "c": "\u80cc\u666f\u548c\u76ee\u7684\uff1a\u6bd4\u8f03\u4f7f\u7528Belly board\uff08\u8179\u677f\uff09\u4e4b\u4fef\u81e5\u4f4d\u662f\u5426\u512a\u65bc\u4ef0\u81e5\u4f4d\u5f0f\u651d\u8b77\u817a\u764c\u653e\u7642\uff0c\u4e26\u8a08\u7b97\u76f4\u8178\u7684\u76f4\u5f91\u8b8a\u5316\u3001\u76f4\u8178\u8207\u651d\u8b77\u817a\u9593\u8ddd\u53ca\u8a55\u4f30\u6cbb\u7642\u5291\u91cf\u8207\u9ad4\u7a4d\u76f4\u65b9\u5716\uff08DVH\uff09\u4e4b\u95dc\u4fc2\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a15\u4f8b\u651d\u8b77\u817a\u764c\u60a3\u8005\u5206\u5225\u9032\u884c\u5169\u7d44\u9aa8\u76c6\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u5206\u5225\u662f\u4f7f\u7528Belly board\u4e4b\u4fef\u81e5\u4f4d\u53ca\u6c92\u6709\u56fa\u5b9a\u7684\u4ef0\u81e5\u4f4d\u3002\u6bcf\u500b\u75c5\u4eba\u5728\u5169\u7a2e\u64fa\u4f4d\u4e0b\u7684\u6cbb\u7642\u8a08\u5283\u7686\u4f7f\u75284-field box technique\uff08\u65b9\u76d2\u6cbb\u7642\u6280\u8853\uff09\u4e09\u7dad\u9069\u5f62\u653e\u7642\uff083DCRT\uff09\u3002\u4f7f\u7528Wilcoxon signed-rank test\u4f5c\u7d71\u8a08\u5206\u6790\uff0c\u5206\u6790\u9805\u76ee\u5305\u62ec:\u76f4\u8178\u7684\u5e7e\u4f55\u8b8a\u5316\u3001\u76f4\u8178\u8207\u651d\u8b77\u817a\u9593\u8ddd\u53ca\u91cd\u8981\u5668\u5b98\u7684\u6cbb\u7642\u5291\u91cf\u8207\u9ad4\u7a4d\u76f4\u65b9\u5716\uff08DVH\uff09\u5206\u6790\u3002\u7d50\u679c\uff1a\u60a3\u8005\u65bc\u4fef\u81e5\u59ff\u52e2\u52a0\u8179\u677f\u6cbb\u7642\u76f8\u5c0d\u65bc\u60a3\u8005\u5728\u4ef0\u81e5\u4f4d\u7f6e\u6709\u8f03\u5927\u7684\u76f4\u8178\u524d\u5f8c\u5f91\u548c\u6a6b\u5411\u5f91\u70ba\uff08p\u503c=0.003\u548cp=0.031\uff09\uff0c\u548c\u8f03\u5927\u7684\u651d\u8b77\u817a\u548c\u76f4\u8178\u7684\u4e2d\u5fc3\u9593\u7684\u8ddd\u96e2\uff08p\u503c= 0.002\uff09\u3002\u95dc\u65bcDVHs\u6578\u64da\uff0c\u60a3\u8005\u65bc\u4fef\u81e5\u6cbb\u7642\u5c0e\u81f4\u6cbb\u7642\u90e8\u4f4d\u7684\u76f4\u8178\u9ad4\u7a4d\u8f03\u5927\uff08P=0.015\uff09\uff0c\u610f\u5473\u8457\u8f03\u4f4e\u76f4\u8178\u5291\u91cf\uff08p=0.002\uff09\u548c\u8f03\u5c0f\u7684\u76f4\u8178\u9ad4\u7a4d\u63a5\u53d7\u9ad8\u8f3b\u5c04\u5291\u91cf\uff08p=0.001\uff09\u3002\u7d50\u8ad6\uff1a\u651d\u8b77\u817a\u764c\u75c5\u4eba\u6cbb\u7642\u6642\u4f7f\u7528Belly board\uff08\u8179\u677f\uff09\u4e4b\u4fef\u81e5\u4f4d\u4e4b\u56fa\u5b9a\u65b9\u5f0f\u5c0d\u76f4\u8178\u76f4\u5f91\uff08\u524d\u5f8c\u5411\u53ca\u6a6b\u65b7\u9762\uff09\u90fd\u6709\u986f\u8457\u7684\u589e\u5927\uff08\u76f8\u8f03\u65bc\u4ef0\u81e5\u4f4d\u7684\u56fa\u5b9a\u65b9\u5f0f\uff09\uff0c\u5728\u76f4\u8178\u8207\u651d\u8b77\u817a\u4e2d\u5fc3\u9ede\u9593\u7684\u8ddd\u96e2\u4e5f\u662f\u4f7f\u7528Belly board\uff08\u8179\u677f\uff09\u4e4b\u4fef\u81e5\u4f4d\u4e4b\u56fa\u5b9a\u65b9\u5f0f\u6709\u8f03\u5927\u7684\u8ddd\u96e2\uff0c\u5728\u5291\u91cf\u8207\u9ad4\u7a4d\u7684\u76f4\u65b9\u5716\u4e5f\u986f\u793a\u4f7f\u7528Belly board\uff08\u8179\u677f\uff09\u4e4b\u4fef\u81e5\u4f4d\u4e4b\u56fa\u5b9a\u65b9\u5f0f\u6709\u8f03\u4f4e\u7684\u76f4\u8178\u8f3b\u5c04\u5291\u91cf\u53ef\u4ee5\u964d\u4f4e\u653e\u7642\u5f15\u8d77\u7684\u4f75\u767c\u75c7\u3002", "e": "Backaround and Purpose: To investigate the impact of supine position versus prone position with belly-board on prostate radiotherapy by evaluation the geometric parameter change between internal organs and treatment dose-volume histograms (DVHs).Materials and Methods: Fifteen patients with prostate cancer underwent pelvic CT scan in position of both prone with belly-board device and supine without immobilization. Four-field box three-dimensional conformal radiotherapy (3DCRT) treatment planning was planned for each patient in both positions. Geometric change including diameter of rectum, distant between critical organs and treatment DVHs were investigated. Wilcoxon signed-rank test was used for statistical analysis.Results: Patients in prone treatment position had both larger anterio-posterior diameters and transverse diameter of rectum (p = 0.003 and p = 0.031), and larger distance between the centers of prostate and rectum (p=0.002) than those of patients in supine position. In regard to the DVHs data, prone treatment position resulted in larger rectal volume (p = 0.015), lower mean rectal dose (p = 0.002) and smaller rectal volume receiving high radiation dose (p = 0.001).Conclusions: Patients in prone treatment position with belly-board immobilization had both larger anterio-posterior diameters, transverse diameter of rectum, and larger distance between the centers of prostate and rectum than those of patients in supine position. Prone treatment position with belly-board device can reduce rectum dose, which may in turn decrease the risk of radiation-induced complications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-115-126", "title": "\u8a55\u4f30\u982d\u9838\u90e8\u6a21\u578b\u4f7f\u7528\u7684TIMO\u6795\u8207\u58d3\u514b\u529b\u6795\u5728\u653e\u5c04\u6cbb\u7642\u4e2d\u7684\u518d\u73fe\u6027\u8207\u8212\u9069\u5ea6", "keywords": "\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u982d\u9838\u90e8\u816b\u7624;\u6795\u588a\u8212\u9069\u5ea6;\u518d\u73fe\u6027 Image-guided radiation therapy (IGRT);Head-and-neck tumor;Comfort level;Reproducibility", "c": "Objectives/Hypothesis: To compare setup reproducibility, comfort level and hardness perceived by the patients between two head suports employed in the same immobilization system in head-and neck radiotherapy. Additionally, the relationship between setup accuracy and patient comfort survey was also investigated.Methods: Between March 2011 and February 2012, there were 35 patients undergoing head-and-neck radiotherapy (RT) being recruited and all studied patients received the same immobilization device (a standard thermoplastic head-and-shoulder mask, Type S mask) twice, in which two different head supports were employed. Both a TIMO support and a Silverman support were used to compare setup accuracy/precision with several types of measurement respectively in each studied patient. All patients underwent planning computed tomography (CT). A series of on-board images (OBIs) were taken at the start, during, and by the end of the radiotherapy course in each studied patient. The OBI images were subsequently co-registered and repositioning accuracy was examined by recording displacement including three axes at the isocenter and orthogonal planes. Furthermore, the patients' subjective perception of comfort level, hardness, and preference for selecting between the two head supports were analyzed and compared. Last but not least, we attempted to explore the association between repositioning accuracy represented by several indicators and the patients' subjective perception in terms of comfort level and hardness.Results: A total of 351 OBI data sets were analyzed. Although the absolute difference was quite small between the two head supports (TIMO support vs. Silverman support) with regard to three displacement errors, total vector displacement errors, spine curve, and mandible angle, it was noted that Silverman support was associated with more limited repositioning displacement in the anteroposterior (AP) and medio-lateral (ML) directions (paired t-test, p= 0.011, 0.004, respectively). As the RT course was proceeding, a trend was noted toward a greater variation in both spinal curve and mandible angle, suggesting that reproducibility should be paid more attention when the RT course moves forward. In the comfort survey, perception of hardness was positively correlated with comfort level in both head supports with weak but significant significance (Spearman's correlation coefficient = 0.387, p \uff1c0.001). As for the association between repositioning accuracy and repositioning accuracy and comfort survey, although there was no any correlation between hardness of head supports and repositioning accuracy, comfort level was positively correlated with repositioning displacement in rotation (Pearson's correlation coefficient =0.213, P \uff1c0.001) and total vector displacement error (Pearson's correlation coefficient =0.153, p= 0.006) in Silverman head support only.Conclusions: The results of the current study have demonstrated that the available immobilization system equipped with either TIMO head support or a Silverman head support provides satisfactory and nearIy equivalent repositioning-related outcomes. More limited repositioning displacement is positively associated with more satisfactory perception of comfort level exclusively in the immobilization system equipped with Silverman head support. In the future, we might consider leaving the choice between the two different head supports to the individual patient according to subjective perception of comfort level.", "e": "Objectives/Hypothesis: To compare setup reproducibility, comfort level and hardness perceived by the patients between two head suports employed in the same immobilization system in head-and neck radiotherapy. Additionally, the relationship between setup accuracy and patient comfort survey was also investigated.Methods: Between March 2011 and February 2012, there were 35 patients undergoing head-and-neck radiotherapy (RT) being recruited and all studied patients received the same immobilization device (a standard thermoplastic head-and-shoulder mask, Type S mask) twice, in which two different head supports were employed. Both a TIMO support and a Silverman support were used to compare setup accuracy/precision with several types of measurement respectively in each studied patient. All patients underwent planning computed tomography (CT). A series of on-board images (OBIs) were taken at the start, during, and by the end of the radiotherapy course in each studied patient. The OBI images were subsequently co-registered and repositioning accuracy was examined by recording displacement including three axes at the isocenter and orthogonal planes. Furthermore, the patients' subjective perception of comfort level, hardness, and preference for selecting between the two head supports were analyzed and compared. Last but not least, we attempted to explore the association between repositioning accuracy represented by several indicators and the patients' subjective perception in terms of comfort level and hardness.Results: A total of 351 OBI data sets were analyzed. Although the absolute difference was quite small between the two head supports (TIMO support vs. Silverman support) with regard to three displacement errors, total vector displacement errors, spine curve, and mandible angle, it was noted that Silverman support was associated with more limited repositioning displacement in the anteroposterior (AP) and medio-lateral (ML) directions (paired t-test, p= 0.011, 0.004, respectively). As the RT course was proceeding, a trend was noted toward a greater variation in both spinal curve and mandible angle, suggesting that reproducibility should be paid more attention when the RT course moves forward. In the comfort survey, perception of hardness was positively correlated with comfort level in both head supports with weak but significant significance (Spearman's correlation coefficient = 0.387, p \uff1c0.001). As for the association between repositioning accuracy and repositioning accuracy and comfort survey, although there was no any correlation between hardness of head supports and repositioning accuracy, comfort level was positively correlated with repositioning displacement in rotation (Pearson's correlation coefficient =0.213, P \uff1c0.001) and total vector displacement error (Pearson's correlation coefficient =0.153, p= 0.006) in Silverman head support only.Conclusions: The results of the current study have demonstrated that the available immobilization system equipped with either TIMO head support or a Silverman head support provides satisfactory and nearIy equivalent repositioning-related outcomes. More limited repositioning displacement is positively associated with more satisfactory perception of comfort level exclusively in the immobilization system equipped with Silverman head support. In the future, we might consider leaving the choice between the two different head supports to the individual patient according to subjective perception of comfort level."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-127-134", "title": "\u764c\u75c7\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u904b\u4f5c\u6a21\u5f0f\u8207\u672a\u4f86\u5c55\u671b", "keywords": "\u591a\u5c08\u79d1;\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70;\u764c\u75c7\u8a3a\u7642\u54c1\u8cea Multidisciplinary;Multidisciplinary team conferences;Quality of cancer treatment", "c": "\u764c\u75c7\u8a3a\u7642\u54c1\u8cea\u662f\u6709\u8cf4\u65bc\u591a\u5c08\u79d1\u5718\u968a\u9593\u7684\u5354\u8abf\u3001\u6e9d\u901a\u3001\u5408\u4f5c\u548c\u5354\u4f5c\u3002\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u662f\u4e00\u500b\u7531\u5177\u6709\u764c\u75c7\u8a3a\u7642\u76f8\u95dc\u5c08\u9577\u4e4b\u91ab\u7642\u4eba\u54e1\u7d44\u6210\u7684\u8ad6\u58c7\uff0c\u7528\u4ee5\u8a0e\u8ad6\u764c\u75c7\u75c5\u4eba\u4e4b\u8a3a\u65b7\u3001\u524d\u77bb\u6027\u6cbb\u7642\u5c0d\u9ee8\u548c\u8655\u7f6e\u5efa\u8b70\u53ca\u764c\u75c7\u7167\u8b77\u3002\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u7684\u76ee\u7684\u5728\u65bc\u63d0\u9ad8\u764c\u75c7\u75c5\u60a3\u7684\u7167\u8b77\u54c1\u8cea\u3002\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u672c\u8eab\u7684\u54c1\u8cea\u6539\u5584\u66f4\u70ba\u9700\u8981\u3002\u7136\u800c\uff0c\u570b\u5167\u5c0d\u65bc\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u7684\u81e8\u5e8a\u6a19\u6e96\u898f\u7bc4\u5c1a\u672a\u660e\u78ba\u8a02\u7acb\u3002\u672c\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u63cf\u8ff0\u764c\u75c7\u8a3a\u7642\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u7684\u5b9a\u7fa9\u3001\u5167\u5bb9\u548c\u7d44\u6210\uff0c\u5c0d\u65bc\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u7684\u512a\u9ede\u548c\u4fc3\u9032\u56e0\u7d20\u4e5f\u8a73\u52a0\u8aaa\u660e\u3002\u6b64\u5916\uff0c\u6587\u4e2d\u4e5f\u78ba\u8a8d\u591a\u5c08\u79d1\u5718\u968a\u4e2d\u53c3\u8207\u6210\u54e1\u7684\u89d2\u8272\u548c\u6240\u9700\u8ca0\u8cac\u7684\u8cac\u4efb\uff0c\u4e26\u63a2\u8a0e\u76ee\u524d\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u6240\u9762\u5c0d\u7684\u56f0\u5883\u53ca\u8a0e\u8ad6\u5176\u5c0d\u672a\u4f86\u7684\u5c55\u671b\u3002\u671f\u4f7f\u5982\u6b64\u7d50\u679c\u53ef\u4ee5\u63d0\u9ad8\u6211\u5011\u5c0d\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u91cd\u8981\u6027\u7684\u7406\u89e3\uff0c\u4e26\u6709\u52a9\u65bc\u5236\u5b9a\u6709\u6548\u7684\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u81e8\u5e8a\u6a19\u6e96\u898f\u7bc4\u3002", "e": "Quality of cancer treatment depends on coordination, communication, cooperation and collaboration of multidisciplinary team. Multidisciplinary team conferences are forums for cancer treatment providers to discuss of the diagnosis, prospective treatment policy and recommendation of management, caring and nursing for a cancer patient. The implementation of multidisciplinary team conferences aims for improving the quality of cancer care. Improvement in quality of multidisciplinary team conferences is also required. However, a practice standard of multidisciplinary team conferences is not well-established in Taiwan. In this study, we described the definition, content and composition, advantages and facilitators of multidisciplinary team conferences for cancer patients. Furthermore, the role and responsibility of multidisciplinary team members were identified. In addition, we discussed and explored the dilemmas and further perspectives of multidisciplinary team conferences. Results would enhance our understanding in the impact of the multidisciplinary team conferences. Such information would be useful for developing effective practice standard of multidisciplinary team conferences."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-135-143", "title": "\u7814\u7a76Overshoot Effect\u5c0d\u65bc\u57f7\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u5f71\u97ff\u53ca\u5291\u91cf\u4fee\u6b63", "keywords": "\u5206\u6bb5\u5f0f\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u591a\u64ca\u6548\u61c9;\u5291\u91cf\u7387 Step-and-Shoot Intensity-Modulated Radiation Therapy;Overshoot;Dose Rate", "c": "\u76ee\u7684\uff1a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5df2\u6210\u70ba\u8a31\u591a\u985e\u578b\u7684\u764c\u75c7\u7684\u6a19\u6e96\u8f3b\u5c04\u6cbb\u7642\u6280\u8853\uff0c\u5982\u524d\u5217\u817a\u764c\uff0c\u982d\u9838\u764c\uff0c\u4f46\u57f7\u884c\u5206\u6bb5\u5f0f\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08step-and-shoot intensity modulated radiation therapy, SIMRT\uff09\u6642\uff0c\u7576\u4f7f\u7528\u9ad8\u5291\u91cf\u7387\uff08high dose rate\uff09\u6216\u4f4e\u5340\u6bb5\u5291\u91cf\uff08low dose per segment\uff09\u6642\uff0c\u6703\u6709\u660e\u986f\u5291\u91cf\u4e0d\u6e96\u78ba\u7684\u73fe\u8c61\uff0c\u6b64\u73fe\u8c61\u5728\u7b2c\u4e00\u500b\u5340\u6bb5\uff08segment\uff09\uff0c\u8f3b\u5c04\u5291\u91cf\u6703\u904e\u591a\uff0c\u53ca\u6700\u5f8c\u4e00\u500b\u5340\u6bb5\uff08segment\uff09\u7684\u5291\u91cf\u904e\u5c11\uff0c\u7a31\u4e4b\u70ba\u591a\u64ca\u6548\u61c9\uff08overshoot effect\uff09 \u8207\u5c11\u64ca\u6548\u61c9\uff08undershoot effect\uff09\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u6e2c\u91cf\u591a\u64ca\u6548\u61c9\u5f71\u97ff\u7a0b\u5ea6\uff0c\u4e26\u627e\u51fa\u6821\u6b63\u65b9\u6cd5\uff0c\u6539\u5584\u5176\u5f71\u97ff\uff0c\u4f7f\u5be6\u969b\u7d66\u65bc\u75c5\u4eba\u7684\u5291\u91cf\u8207\u6cbb\u7642\u8a08\u756b\u4e0a\u7684\uff0c\u5169\u8005\u7121\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u9019\u6b21\u7684\u7814\u7a76\u4e2d\u4e3b\u8981\u5206\u70ba\u5169\u5927\u90e8\u5206:\u7b2c\u4e00\u70ba\u5c0d\u65bc\u4e0d\u540c\u5291\u91cf\u7387\uff0c\u7531\u6bcf\u5206\u9418100\u76e3\u6e2c\u55ae\u4f4d\uff08monitor unit, MU\uff09\u81f3\u6bcf\u5206\u941860OMU\uff0c\u4e26\u4f7f\u7528\u4e0d\u540c\u5340\u6bb5\u5291\u91cf\uff08segment dose\uff09\uff0c\u7531\u6bcf\u500b\u5340\u6bb5\u7167\u5c041MU\u81f3\u6bcf\u500b\u5340\u6bb5\u7167\u5c0410MU\uff0c\u5206\u5225\u9032\u884c\u591a\u64ca\uff08Overshoot effect\uff09\u6548\u61c9\u7a0b\u5ea6\u7814\u7a76\uff0c\u7b2c\u4e8c\u4ee5\u963b\u64cb\u4fee\u6b63\uff08Block Correct\uff09\u3001\u4ea4\u932f\u4fee\u6b63\uff08Interiace Correct\uff09\u3001\u7d22\u5f15\u4fee\u6b63\uff08Index Correct\uff09\u4e09\u7a2e\u4fee\u6b63\u6280\u8853\uff0c\u5206\u5225\u904b\u7528\u4e0d\u540c\u5291\u91cf\u7387\u548c\u4e0d\u540c\u5340\u6bb5\u5291\u91cf\u4f86\u91cf\u6e2c\u6bd4\u8f03\u8a0e\u8ad6\uff0c\u9032\u884c\u591a\u64ca\u6548\u61c9\u7a0b\u5ea6\u7814\u7a76\u3002\u7d50\u679c\uff1a\u7814\u7a76\u6e2c\u91cf\u591a\u64ca\u6548\u61c9\u73fe\u8c61\uff0c\u5176\u96a8\u5291\u91cf\u7387\u8d8a\u9ad8\u8d8a\u660e\u986f\u800c\u5340\u6bb5\u5291\u91cf\u8d8a\u4f4e\u8d8a\u986f\u8457\uff0c\u5176\u4e2d\u7576\u91cf\u6e2c\u5340\u6bb5\u5291\u91cf\u70ba1\u76e3\u6e2c\u55ae\u4f4d\uff0f\u5340\u6bb5\uff08MU\uff0fSeg\uff09\u4e14\u8655\u65bc\u5291\u91cf\u7387600\u76e3\u6e2c\u55ae\u4f4d/\u5206\u9418\uff0c\u5176\u591a\u64ca\u73fe\u8c61\u9ad8\u905452.5%\u4ee5\u4e0a\u3002\u800c\u4e09\u7a2e\u4fee\u6b63\u6280\u8853\u5747\u53ef\u9054\u6210\u4fee\u6b63\u6548\u679c\u7d66\u65bc\u6b63\u78ba\u5291\u91cf\u5206\u5e03\u3002\u963b\u64cb\u4fee\u6b63\uff08Block Correct\uff09\u3001\u4ea4\u932f\u4fee\u6b63\uff08Interlace Correct\uff09\u3001\u7d22\u5f15\u4fee\u6b63\uff08Index Correct\uff09\u5206\u5225\u5c07\u5340\u6bb5\u5291\u91cf\u70ba1\u76e3\u6e2c\u55ae\u4f4d\uff0f\u5340\u6bb5\u4e14\u8655\u65bc\u5291\u91cf\u7387600\u76e3\u6e2c\u55ae\u4f4d\uff0f\u5206\u9418\u4e0b\u7684\u591a\u64ca\u6548\u61c9\u73fe\u8c61\u964d\u81f3-1.3%\u30016.6%\u30010.1%\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u627e\u5230\u826f\u597d\u7684\u6821\u6b63\u65b9\u6cd5\uff0c\u53ef\u907f\u514d\u7576\u4f7f\u7528\u5c0f\u76e3\u6e2c\u55ae\u4f4d\u548c\u9ad8\u5291\u91cf\u7387\u4f7f\u7528\u6642\uff0c\u591a\u64ca\u6548\u61c9\u9020\u6210\u7684\u5340\u6bb5\u5291\u91cf\u8aa4\u5dee\uff08segment dose error\uff09\u3002\u4e09\u7a2e\u4fee\u6b63\u65b9\u6cd5\u7684\u6e2c\u91cf\u7d50\u679c\u7686\u986f\u793a\u53ef\u4ee5\u7528\u4f86\u6539\u5584\u5206\u6bb5\u5f0f\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u4e0d\u6e96\u78ba\u3002", "e": "Purpose: Intensity-modulated radiation therapy (IMRT) has become a standard radiation delivery technique for many types of cancers such as prostate, head and neck and breast. The dosage was not precise in step-and-shoot IMRT, while the radiation delivered with higher dose rate or lower dose per segment. The phenomenon is overshoot effect. It causes the higher dose at the first segment and lower dose at the last segment. The purposes are that exam the dosimetric accuracy with overshoot effect, and improve the accuracy with corrections.Materials and Method's: There are two parts in the study. The first part is to exam the overshoot with the dose rates, from 100 MU/min to 600 MU/min, and segment dose, from 1 MU per segment (MUI seg) to 10 MU/seg. The second part is to correct and measure the overshoot effect with block correct, interlace correct and index correct.Result : The overshoot effect cause higher dose at the first segment and lower dose at the last segment with higher dose rate and lower dose per segment. While the dose per segment is 1 MU and the dose rate is 600 MU/min, the dosimetric error is up to 52.5%. The three corrections improved dosimetric accuracy with the overshoot effect. Block correct, interlace correct and index correct reduce the dose from 152.5% to 98.7%, 93.4% and 100.1 %, repectively.Conclusion: Clinically, it is possible to reduce the overshoot effect with with lower dose per segment and higher dose rate. The three corrections improve the dosimetric accuracy for overshoot effect."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-145-150", "title": "Tomotherapy for Cervical Cancer with Bilateral Total Hip Replacement", "keywords": "\u4eba\u5de5\u9ad4\u95dc\u7bc0;\u5b50\u5bae\u9838\u764c;\u91d1\u5c6c\u95dc\u7bc0;\u767e\u842c\u4f0f\u7279\u96fb\u8166\u65b7\u5c64\u6383\u63cf;\u87ba\u65cb\u5200 Hip replacement;Cervical cancer;Metallic prostheses;MVCT;Tomotherapy", "c": "\u96a8\u8457\u9ad8\u9f61\u5316\u793e\u6703\u7684\u4f86\u81e8\uff0c\u5404\u81e8\u5e8a\u5c08\u79d1\u91ab\u5e2b\u5728\u65e5\u5e38\u8a3a\u7642\u7576\u4e2d\uff0c\u5e38\u6703\u63a5\u89f8\u5230\u8207\u65e5\u4ff1\u589e\u7684\u60a3\u8005\u88dd\u6709\u91d1\u5c6c\u4eba\u5de5\u95dc\u7bc0\u3002\u9019\u985e\u91d1\u5c6c\u690d\u5165\u7269\u5728\u4e00\u822c\u96fb\u8166\u65b7\u5c64\u4e4b\u5f71\u50cf\u4e2d\u6703\u9020\u6210\u5e72\u64fe\u5047\u5f71\uff0c\u800c\u7121\u6cd5\u6e05\u695a\u5730\u77ad\u89e3\u75c5\u5973\u58eb\uff1b\u6b64\u5916\uff0c\u56e0\u91d1\u5c6c\u6703\u5e72\u64fe\u78c1\u5834\uff0c\u9019\u4e9b\u75c5\u4eba\u4e5f\u7121\u6cd5\u63a5\u53d7\u78c1\u632f\u6383\u63cf\u3002\u7531\u65bc\u7121\u6cd5\u5f97\u5230\u9019\u4e9b3D\u7cbe\u5bc6\u5f71\u50cf\uff0c\u56e0\u6b64\u5c0d\u653e\u5c04\u6cbb\u7642\u4e2d\u76f8\u95dc\u75c5\u59d3\u8a3a\u65b7\u8207\u8a08\u756b\u7684\u8a2d\u5b9a\u6709\u5f88\u5927\u7684\u59a8\u7919\u3002\u5728\u6b64\u6211\u5011\u5229\u7528Tornotherapy\uff08\u87ba\u65cb\u5200\u5f71\u50cf\u5c0e\u5f15\u6cbb\u7642\u7cfb\u7d71\uff09\u4e4bMVCT\uff08\u767e\u842c\u4f0f\u7279\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff09\uff0c\u4e0d\u4f46\u53ef\u4ee5\u6e1b\u8f15\u4e00\u822c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u7684\u91d1\u5c6c\u5047\u5f71\uff0c\u4f7f\u5f97\u81e8\u5e8a\u91ab\u5e2b\u53ef\u4ee5\u5224\u5225\u75c5\u7076\u6240\u5728\uff0c\u4e26\u5c07\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u4e4b\u5f71\u50cf\u5728\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u96fb\u8166\u7cfb\u7d71\u4e0a\u8207MVCT\u4e4b\u5f71\u50cf\u878d\u5408\uff0c\u53ef\u5f9e\u5c0d\u816b\u7624\u7d30\u80de\u65b0\u9673\u4ee3\u8b1d\u7684\u8a8d\u77e5\uff0c\u7528\u4ee5\u8f14\u52a9\u764c\u75c7\u6cbb\u7642\u8a08\u5283\u3002", "e": "In aging societies, it is common for clinicians to encounter difficulties in discerning pelvic lesions with hindrance from total hip replacement (THR) on computed tomography (CT) scans. For the patient with bilateral metallic hip prostheses, we utilized megavoltage computed tomography (MVCT) to overcome metallic artifacts diagnostically. The obscured lesion in conventional CT scans can be seen via MVCT provided by Tomotherapy. Serial MVCTs were merged with pretreatment positron emission tomography (PET) images sets for target delineation during treatment planning. The application of MVCT provides insights and the feasibility of another therapeutic pathway in patients with metallic implantation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201306-201307240023-201307240023-151-157", "title": "\u5229\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u9ed8\u514b\u7d30\u80de\u764c\u6dcb\u5df4\u817a\u8f49\u79fb\u7684\u75c5\u60a3\uff0d\u75c5\u4f8b\u5831\u544a", "keywords": "\u9ed8\u514b\u7d30\u80de\u764c;\u653e\u5c04\u6cbb\u7642 Merkel Cell Carcinoma (MCC);Radiotherapy", "c": "\u9ed8\u514b\u7d30\u80de\u764c\uff08Merkel cell carcinoma; MCC\uff09\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u539f\u767c\u6027\u76ae\u819a\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624\uff0c\u5176\u9810\u5f8c\u5dee\u5b58\u6d3b\u7387\u4e5f\u4f4e\uff0c\u5728\u7f8e\u570b\u767c\u75c5\u7387\u4f30\u8a083.2\uff5e4.4\u4eba\uff0f\u6bcf\u767e\u842c\u4eba\uff0d\u5e74\u3002\u901a\u5e38MCC\u7684\u75c5\u7a0b\u767c\u5c55\u5feb\u901f\uff0c\u65e9\u671f\u5c40\u90e8\u5fa9\u767c\u548c\u9060\u8655\u8f49\u79fb\u7387\u9ad8\u905425%\uff0cMCC\u597d\u767c\u65bc65\u6b72\u4ee5\u4e0a\u7684\u8001\u4eba\uff0c\u767c\u75c5\u4f4d\u7f6e\u5927\u591a\u70ba\u66b4\u9732\u5728\u967d\u5149\u4e0b\u7684\u982d\u9838\u90e8\u5340\u57df\u7d04\u4f5455%\uff0c40%\u5728\u56db\u80a2\u548c5%\u5728\u8ec0\u5e79\u3002\u5728\u672c\u7bc7\u5831\u544a\u4e2d\u63d0\u51fa\u4e86\u4e00\u540d75\u6b72\u65bc2008\u5e74\u5728\u672c\u9662\u6cbb\u7642pT3bNO stage III\u7684\u524d\u5217\u817a\u764c\uff0c2012\u5e74\u53c8\u5728\u53f3\u5074\u8033\u524d\u5340\u767c\u73feTXN1MO stage IIIB\u7684MCC\u7684\u75c5\u60a3\u3002\u8853\u5f8c\u63a5\u53d7\u5291\u91cf\u70ba61.2 Gy\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u6587\u737b\u56de\u9867\u8868\u793a\u7a4d\u6975\u7684\u5316\u653e\u7642\u53f8\u4ee5\u63d0\u9ad8\u5c40\u90e8\u63a7\u5236\u7387\u548c\u751f\u5b58\u7387\u3002", "e": "Merkel cell carcinoma (MCC) is a rare primary cutaneous tumor of neuroendocrine type associated with a poor prognosis and a low survival rate. It has an estimated age-adjusted incidence of 3.2 to 4.4 per 1,000,000 person-years in the United States. MCC usually has an aggressive course with early locoregional recurrence and high distant metastatic rates of up to 25% in most series. It usually affects elderly people over 65 years of age. It preferably affects areas exposed to the sun: 55% in the head and neck, 40% in the limbs and 5% in the trunk. Here we present a 75 year old case of cT0 pNl cMl stage IV Merkel cell carcinoma of right preauricular area with pT3bNO, stage III prostate cancer. Postoperative radiotherapy was given to the patient for 61.2 Gy. A literature review of MCC indicates that aggressive radiotherapy can have a positive impact on overalllocal control and survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-1-11", "title": "Advanced Thymic Carcinoma: Clinical Experience and Prognostic Factors of 18 Patients", "keywords": "\u80f8\u817a\u764c;\u9810\u5f8c;\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642\u5291\u91cf Thymic carcinoma;Prognosis;Radiotherapy;Radiation dose", "c": "\u76ee\u7684\uff1a\u80f8\u817a\u764c\u662f\u4e00\u500b\u4e0d\u5e38\u898b\u4f46\u81f4\u547d\u7684\u60e1\u6027\u816b\u7624\uff0c\u6211\u5011\u5206\u6790\u4e86\u672c\u9662\u665a\u671f\u80f8\u817a\u764c\u75c5\u4eba\u7684\u6cbb\u7642\u7d50\u679c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e1996\u5e744\u6708\u81f32012\u5e744\u6708\uff0c\u5171\u670918\u4f4d\u65b0\u8a3a\u65b7\u80f8\u817a\u764c\u75c5\u4eba\u65bc\u4e09\u8ecd\u7e3d\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\uff0c\u6211\u5011\u5206\u6790\u5176\u75c5\u7a0b\u8a18\u9304\uff0c\u51719\u4f4d\u63a5\u53d7\u624b\u8853\u6cbb\u7642\uff0c\u5176\u4e2d\u5305\u62ec3\u4f4d\u63a5\u53d7\u8853\u524d\u6cbb\u7642\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c5\u4f4d\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u53ca1\u4f4d\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u30028\u4f4d\u816b\u7624\u7121\u6cd5\u5207\u9664\u6216\u7121\u6cd5\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u6216\u653e\u5c04\u6cbb\u7642\u3002\u67091\u4f4d\u75c5\u4eba\u6c92\u6709\u63a5\u53d7\u764c\u75c7\u6cbb\u7642\u800c\u65bc\u8a3a\u65b7\u5f8c2\u500b\u6708\u6b7b\u4ea1\u3002\u653e\u5c04\u6cbb\u7642\u662f\u63a1\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6216\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff0c\u653e\u5c04\u6cbb\u7642\u7684\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba63  Gy\u3002\u5927\u90e8\u5206\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\uff0893.3%\uff09\u4f7f\u7528\u7684\u85e5\u7269\u5305\u542bcisplatin\u3002\u7d50\u679c\uff1a\u4f9d\u7167Masaoka\u5206\u671f\uff0c\u67097\u4f4d\u75c5\u4eba\u662f\u7b2cIII\u671f\uff0c4\u4f4d\u662fIVA\u671f\uff0c7\u4f4d\u662fIVB\u671f\u3002\u6240\u6709\u75c5\u60a35\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba46.5%\uff0c3\u5e74\u7121\u60e1\u5316\u5b58\u6d3b\u7387\u70ba32.1%\u300217\u4f4d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\uff0c\u51765\u5e74\u7684\u7167\u5c04\u7bc4\u570d\u5167\u816b\u7624\u63a7\u5236\u7387\u70ba80.9%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5927\u65bc65 Gy\u662f\u552f\u4e00\u5c0d\u9810\u5f8c\u6709\u5e6b\u52a9\u7684\u56e0\u5b50\uff0c\u7e3d\u653e\u5c04\u5291\u91cf\u5927\u65bc65 Gy\u53ef\u63d0\u5347\u80f8\u817a\u764c\u75c5\u4eba3\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\uff08100% vs. 13.1%, p= 0.004\uff09\u548c3\u5e74\u7121\u60e1\u5316\u5b58\u6d3b\u7387\uff0847.6% vs. 16%, p= 0.044\uff09\u3002\u5728\u6c92\u6709\u63a5\u53d7\u624b\u8853\u7684\u80f8\u817a\u764c\u75c5\u4eba\uff0c\u63a5\u53d7\u7e3d\u653e\u5c04\u5291\u91cf\u5927\u65bc65 Gy\u5c0d\u5b58\u6d3b\u6709\u597d\u8655\u3002\u7d50\u8ad6\uff1a\u7a4d\u6975\u591a\u7a2e\u65b9\u5f0f\u7684\u6cbb\u7642\u5305\u62ec\u624b\u8853\u3001\u653e\u5c04\u6cbb\u7642\u548c\u5316\u5b78\u6cbb\u7642\u5c0d\u65bc\u665a\u671f\u80f8\u817a\u764c\u75c5\u4eba\u662f\u6709\u5e6b\u52a9\u7684\u3002\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5927\u65bc65 Gy\u53ef\u4ee5\u6539\u5584\u665a\u671f\u80f8\u817a\u764c\u75c5\u4eba\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u548c\u7121\u60e1\u5316\u5b58\u6d3b\u7387\uff0c\u5c24\u5176\u662f\u5728\u6c92\u6709\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\u3002", "e": "Purpose: Thymic carcinoma is an uncommon but lethal malignancy. We analyze the outcomes and prognostic factors of patients with advanced thymic carcinoma treated at a single institution.Materials and Methods: The records of 18 patients with histologically confirmed thymic carcinoma treated between April 1996 and April 2012 at Tri-Service General Hospital were retrospectively reviewed. Surgical resection was performed in 9 patients, including 3 patients who received preoperative therapy and postoperative chemoradiotherapy followed by chemotherapy, 5 who received postoperative chemoradiotherapy followed by chemotherapy and 1 who received postoperative radiotherapy alone. Eight patients had tumor which were unresectable or medically inoperable and underwent chemoradiotherapy followed by chemotherapy or radiotherapy alone. One patient died 2 months after diagnosis without any cancer treatment. Radiotherapy was delivered with three-dimensional conformal radiation therapy, intensity-modulated radiation therapy or stereotactic ablative radiotherapy using Cyberknife (Accuray, Inc., Sunnyvale, CA). The median dose of radiotherapy was 63 Gy. Most (93.3%) of the chemotherapy regimen contained cisplatin.Results: The distribution of Masaoka stage at presentation was III in 7 patients, IVA in 4 patients and IVB in 7 patients. The 5-year overall survival (OS) rate and 3-year progression-free survival (PFS) rate were 46.5% and 32.1%, respectively. The 5-year in-field tumor control rate of 17 patients who underwent radiotherapy was80.9%. Univariate statistical analysis revealed that radiotherapy \u2267 65 Gy was the only statistically significant predictor of outcome. A total radiation dose of \u2267 65 Gy results in improved 3-year OS (100% vs. 13.1%, p= 0.004) and 3-year PFS (47.6% vs. 16%, p=0.044) in patients with thymic carcinoma. The survival benefit of receiving radiotherapy \u2267 65 Gy was apparent in the unresected group of patients with thymic carcinoma.Conclusions: Aggressive multidisciplinary treatments including surgery, radiotherapy, and chemotherapy, are helpful in treating advanced thymic carcinoma. Radiotherapy with dose above 65 Gy may improve the OS and PFS of patients with advanced thymic carcinoma, especially in the unresected group."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-13-22", "title": "Feasibility Study Using Pre-operative Prone-position Volumetric Modulated Arc Therapy and Chemotherapy in Locally Advanced Rectal Cancer", "keywords": "\u76f4\u8178\u764c;\u4fef\u81e5;\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Rectal cancer;Prone position;Volumetric modulated arc therapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u8853\u524d\u4fef\u81e5\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c\u65bc\u5c40\u90e8\u56b4\u91cd\u6027\u76f4\u8178\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\u526f\u4f5c\u7528\u4ee5\u53ca\u521d\u6b65\u6cbb\u7642\u6210\u6548\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u897f\u51432010\u5e74 4\u6708\u81f32010\u5e7410\u6708\uff0c\u5341\u4f4d\u81e8\u5e8a\u5206\u671f\u70ba\u4e8c\u81f3\u56db\u671f\u4e4b\u76f4\u8178\u764c\u75c5\u60a3\u63a5\u53d7\u4e86\u8853\u524d\u4fef\u81e5\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u3002\u6240\u6709\u75c5\u60a3\u7686\u4f7f\u7528\u8179\u677f\uff08belly board\uff09\u4ee5\u53ca\u6f32\u5c3f\u6cbb\u7642\u3002\u6240\u6709\u6cbb\u7642\u8a08\u756b\u7686\u662f45 Gy\u520625\u6b21\u6cbb\u7642\uff0c\u4e26\u4ee5Pinnacle^3 9.0\u8edf\u9ad4\u8a2d\u8a08\u3002\u64fa\u4f4d\u8aa4\u5dee\u4ee5\u81f3\u5c11\u6bcf\u9031\u4e00\u6b21\u7684\u9310\u675f\u96fb\u8166\u65b7\u5c64\uff08cone-beam computed tomography\uff09\u6821\u6b63\u3002\u6cbb\u7642\u4e4b\u526f\u4f5c\u7528\u4ee5Common Terminolo Criteria for Adverse Events v4.0\u4f5c\u70ba\u8a55\u4f30\u5de5\u5177\u3002\u5316\u5b78\u6cbb\u7642\u4e3b\u8981\u4ee55-fluorouracil\u642d\u914doxaliplatin \u6216\u662fmitomycin\u3002\u4e94\u4f4d\u75c5\u60a3\u540c\u6642\u4f7f\u7528\u4e86bevacizumab\u3002\u7d50\u679c\uff1a\u6240\u6709\u7684\u75c5\u4eba\u7686\u5b8c\u6210\u4e86\u8853\u524d\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\uff0c\u4e5f\u90fd\u63a5\u53d7\u4e86\u624b\u8853\u5207\u9664\u3002\u5169\u4f4d\u4f7f\u7528bevacizumab\u7684\u75c5\u4eba\u9054\u5230\u4e86\u75c5\u7406\u5b8c\u5168\u53cd\u61c9\uff08pathological complete response\uff09\u3002\u4e5d\u4f4d\u75c5\u4eba\u9054\u5230\u4e86\u75c5\u7406\u4e0a\u7684\u671f\u5225\u4e0b\u964d\uff08downstaging\uff09\u3002\u53ea\u6709\u4e00\u500b\u75c5\u4eba\u75c5\u7406\u4e0a\u6709\u6dcb\u5df4\u7d50\u7684\u8f49\u79fb\u3002\u6700\u5e38\u898b\u7684\u526f\u4f5c\u7528\u662f\u7b2c\u4e00\u7d1a\u6216\u7b2c\u4e8c\u7d1a\u7684\u809b\u9580\u76ae\u819a\u53cd\u61c9\u6216\u8179\u7009\u3002\u6c92\u6709\u4efb\u4f55\u75c5\u60a3\u6709\u7b2c\u4e09\u7d1a\u6216\u4ee5\u4e0a\u7684\u526f\u4f5c\u7528\u3002\u75c5\u60a3\u7684\u526f\u4f5c\u7528\u548c\u662f\u5426\u4f7f\u7528bevacizumab \u7121\u95dc\u3002\u5e73\u5747\u64fa\u4f4d\u8aa4\u5dee\u5728\u982d\u8173\u3001\u5de6\u53f3\u53ca\u524d\u5f8c\u65b9\u5411\u5206\u5225\u70ba0.24\u516c\u5206\u30010.21\u516c\u5206\u53ca0.37 \u516c\u5206\u3002\u64fa\u4f4d\u8aa4\u5dee\u4e4b\u6a19\u6e96\u5dee\u4e4b\u7bc4\u570d\u5728\u982d\u8173\u3001\u5de6\u53f3\u53ca\u524d\u5f8c\u65b9\u5411\u5206\u5225\u70ba0.09-0.34\u516c\u5206\u30010.06-0.20\u516c\u5206\u53ca0.11-0.52\u516c\u5206\u3002\u7d50\u8ad6\uff1a\u4e0d\u8ad6\u662f\u5426\u5408\u4f75\u4f7f\u7528bevacizumab\uff0c\u8853\u524d\u4fef\u81e5\u5f27\u5f62\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u662f\u53ef\u884c\u4e14\u5b89\u5168\u7684\u3002\u6cbb\u7642\u9020\u6210\u7684\u526f\u4f5c\u7528\u5728\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\uff0c\u6cbb\u7642\u4e4b\u53cd\u61c9\u4e5f\u6709\u4e0d\u932f\u7684\u6210\u6548\u3002\u4fef\u81e5\u59ff\u52e2\u9700\u8981\u591a\u6ce8\u610f\u64fa\u4f4d\u8aa4\u5dee\u7684\u6821\u6b63\u3002", "e": "Purpose: To evaluate the toxicity and treatment response of using volumetric modulated arc therapy (VMAT) and chemotherapy as neoadjvuant concurrent chemoradiotherapy (CCRT) for rectal cancer.Materials and Methods: Ten patients with stage IIA-IV rectal adenocarcinoma who underwent neoadjuvant CCRT using prone-position VMAT from April 2010 to December 2010 were enrolled in this study. All patients were treated on a belly board with a full bladder. All VMAT plans were designed with the Pinnacle3 9.0 planning system with 45 Gy in 25 fractions. Setup errors were corrected using cone-beam computed tomography weekly or more frequently. Treatment toxicities were graded using the Common Terminology Criteria for Adverse Events v4.0. The chemotherapy regimens were 5-fluorouracil-based, combined with oxaliplatin or mitomycin. Five patients received bevacizumab as a part of the chemotherapy regimen.Results: All patients completed neoadjuvant CCRT and received post-CCRT surgical resection. Two had pathological complete response (pCR), and both of these received bevacizumab. Nine of 10 patients had T or N downstaging. Only one patient had pathological nodal involvement. The most common toxicities were grade 1 or 2 anal skin reaction and diarrhea. No patient experienced more than grade 3 toxicity. There was no difference in toxicity between patients with or without bevacizumab. The average displacement in longitudinal, lateral, and vertical directions in the whole group was 0.24 cm, 0.21 cm, and 0.37 cm, respectively. The standard deviation of displacement at longitudinal, lateral, and vertical directions ranged from 0.09-0.34 cm, 0.06-0.20 cm, and 0.11-0.52 cm, respectively.Conclusions: Using VMAT and prone position on a belly board in neoadjuvant CCRT with or without bevacizumab for rectal cancer is feasible and safe. The treatmentrelated toxicity was acceptable and the treatment response was satisfactory. Proneposition technique requires more attention in setup errors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-23-30", "title": "Dosimetric Comparison of Treatment Plans between Intensity-modulated Radiotherapy, Intensity-modulated Arc Therapy and Helical Tomotherapy for Total Scalp Irradiation", "keywords": "\u5168\u982d\u76ae\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u87ba\u65cb\u5149\u5b50\u5200;\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642 Total scalp irradiation;Intensity modulated radiotherapy;Helical tomotherapy;Intensity-modulated arc therapy", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u87ba\u65cb\u5200\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u53ca\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\u61c9\u7528\u5728\u5168\u982d\u76ae\u653e\u5c04\u6cbb\u7642\u6642\u7684\u5291\u91cf\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7814\u7a76\u5c0d\u8c61\u662f\u4e00\u4f4d\u56e0\u60e1\u6027\u8840\u7ba1\u8089\u7624\u63a5\u53d7\u5168\u982d\u76ae\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u3002\u91dd\u5c0d\u6b64\u75c5\u4eba\u7684\u6cbb\u7642\u7bc4\u570d\uff0c\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u548c\u87ba\u65cb\u5200\u4e09\u7a2e\u653e\u5c04\u6280\u8853\u9593\u653e\u5c04\u5291\u91cf\u7684\u8a55\u4f30\u8207\u6bd4\u8f03\u3002\u672c\u7814\u7a76\u4e2d\u6cbb\u7642\u8a08\u756b\u65bd\u4e88\u9776\u9ad4\u7a4d\u4e4b\u653e\u5c04\u5291\u91cf\u70ba50 Gy\uff0c\u7814\u7a76\u9805\u76ee\u5305\u62ec\u6bd4\u8f03\u4e09\u7a2e\u6cbb\u7642\u6280\u8853\u9593\u8a08\u756b\u7684\u9776\u9ad4\u7a4d\u5291\u91cf\u7684\u9806\u884c\u6307\u6578\u3001\u8166\u8207\u6c34\u6676\u9ad4\u5291\u91cf\u3001\u653e\u5c04\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u4ee5\u53ca\u7e3d\u6cbb\u7642\u6642\u9593\u3002\u6700\u5f8c\u4f7f\u7528\u985e\u4f3c\u7d50\u69cb\u7684\u5be6\u9a57\u5047\u9ad4\u9a57\u8b49\u5176\u8207\u81e8\u5e8a\u6cbb\u7642\u8a08\u756b\u7d50\u679c\u7684\u5dee\u7570\u3002\u7d50\u679c\uff1a\u8a08\u756b\u7684\u9776\u9ad4\u7a4d\u4e4b\u8986\u84cb\u56e0\u5b50\u8207\u5747\u8cea\u6307\u6578\u65bc\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u6280\u8853\u70ba0.99 / 1.04\u3001\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u70ba0.95 / 1.14\u3001\u87ba\u65cb\u5200\u70ba0.98 / 1.07\uff0c\u800c\u4e09\u7a2e\u6280\u8853\u7684\u9806\u884c\u6307\u6578\u5206\u5225\u70ba0.74\u30010.74\u3001\u82070.69\u3002\u65bc\u5f37\u5ea6\u8abf\u63a7\u6280\u8853\u4e2d\u63a5\u53d7\u9ad8\u65bc30 Gy / 40 Gy\u7684\u6b63\u5e38\u8166\u7d44\u7e54\u6bd4\u7387\u70ba43.8% / 10.4%\uff0c\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u70ba40.7% / 18.5%\uff0c\u87ba\u65cb\u5200\u70ba20.6% / 7.4%\u3002\u96d6\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u6280\u8853\u76f8\u8f03\u65bc\u5f37\u5ea6\u8abf\u63a7\u6280\u8853\u4e26\u7121\u660e\u986f\u7684\u5291\u91cf\u512a\u52e2\uff0c\u4f46\u5176\u512a\u9ede\u70ba\u6709\u8f03\u4f4e\u7684\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u53ca\u8f03\u5c11\u7684\u6cbb\u7642\u6642\u9593\u3002\u5047\u9ad4\u7684\u5291\u91cf\u7814\u7a76\u6bd4\u8f03\u7d50\u679c\u8207\u75c5\u4eba\u7684\u6cbb\u7642\u8a08\u756b\u76f8\u8fd1\u3002\u7d50\u8ad6\uff1a\u5c0d\u65bc\u63a5\u53d7\u5168\u982d\u76ae\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u4e09\u7a2e\u653e\u5c04\u6cbb\u7642\u6280\u8853\u53ef\u4ee5\u9054\u6210\u985e\u4f3c\u7684\u6a19\u9776\u9ad4\u7a4d\u8986\u84cb\u56e0\u5b50\u548c\u5747\u8cea\u6307\u6578\uff0c\u800c\u87ba\u65cb\u5200\u5c0d\u65bc\u6b63\u5e38\u8166\u90e8\u5291\u91cf\u7684\u906e\u853d\u6548\u679c\u512a\u65bc\u5f37\u5ea6\u8abf\u63a7\u5f27\u5f62\u8207\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u6280\u8853\u3002", "e": "Purpose: To compare the dosimetric advantage of helical tomotherapy (HT) over intensity-modulated arc therapy (IMAT) and sliding window intensity-modulated radiation therapy (SW-IMRT) for total scalp irradiation.Methods: Three treatment plans (SW-IMRT, IMAT and HT) were generated for a 73 year-old man with scalp angiosarcoma undergoing IMRT. The doses to the planning target volume (PTV) were 50 Gy. Conformity indexes, doses to the brain and lens, number of monitor units (MU), and treatment times were compared between techniques. Plan verification using a phantom study was also performed to compare the radiation planning results.Results: The coverage factors of the PTV and homogeneous index were 0.99/1.10 for SW-IMRT, 0.95/1.14 for IMAT, and 0.99/1.04 for HT. The conformation numbers for the three plans were 0.74, 0.74, and 0.69, respectively. The proportions of normal brain receiving above 30 Gy/40 Gy were 43.8%/10.4% for IMRT, 40.7%/18.5% for IMAT and 20.6%/7.4% for HT. Although IMAT showed no superior dosimetric advantage over SW-IMRT, a lower number of MUs and a shorter treatment time were needed for IMAT. The phantom study had similar dosimetric results.Conclusion: For patients receiving total scalp irradiation, these three techniques provide comparable target coverage. HT spares the brain better than IMAT and SW-IMRT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-31-40", "title": "\u6a21\u64ec\u982d\u9838\u90e8\u75c5\u4eba\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u76ae\u819a\u5291\u91cf\u4e4b\u5047\u9ad4\u7814\u7a76", "keywords": "\u76ae\u819a\u5291\u91cf;\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247 Skin dose;Ultrathin TLD;Gafchromic film", "c": "\u76ee\u7684\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u5229\u7528\u5047\u9ad4\u6e2c\u91cf\u982d\u9838\u90e8\u75c5\u4eba\u8abf\u5f37\u653e\u5c04\u6cbb\u7642\u4e4b\u76ae\u819a\u5291\u91cf\uff0c\u4ee5\u53ca\u8a55\u4f30\u982d\u9838\u764c\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u91cf\u6e2c\u5de5\u5177\u7684\u53ef\u4fe1\u5ea6\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u63a1\u7528\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u4f86\u505a\u70ba\u91cf\u6e2c\u5de5\u5177\uff0c\u4e26\u5206\u5225\u505a\u5176\u7279\u6027\u7814\u7a76\u4ee5\u53ca\u589e\u5efa\u5340\u7684\u6e2c\u91cf\uff1b\u5728IMRT head/neck phantom\u548canthropomorphic Rando phantom\u6e2c\u91cf\u6a21\u64ec\u7684\u9838\u90e8\u6dcb\u5df4\u5340\u7684\u8868\u9762\u5291\u91cf\uff0c\u5229\u7528\u6b64\u5169\u7a2e\u4e0d\u540c\u7684\u5047\u9ad4\u4ee5\u53caEclipse\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u88fd\u4f5c\u8655\u65b9\u5291\u91cf\u70ba180 cGy\u76847\u500b\u7167\u91ce\u6cbb\u7642\u8a08\u756b\uff0c\u9032\u884c\u6b64\u5169\u7a2e\u91cf\u6e2c\u5de5\u5177\u7d55\u5c0d\u5291\u91cf\u4e4b\u6e2c\u91cf\u3002\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u4e4b\u8584\u7247\u578bTLD\u8b8a\u7570\u4fc2\u6578\u5728 3%\u4ee5\u5167\uff0c\u8a08\u8b80\u503c\u8207\u7d66\u4e88\u5291\u91cf\u9593\u5448\u73fe\u826f\u597d\u7dda\u6027\u95dc\u4fc2\uff1b\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\uff08EBT film\uff09\u6821\u6b63\u5340\u7dda\u4e0a\u6bcf\u500b\u9ede\u4e4b\u8b8a\u7570\u4fc2\u6578\u57281%\u4ee5\u5167\uff0c\u6574\u9ad4\u6821\u6b63\u66f2\u7dda\u5448\u73fe\u7a69\u5b9a\u7684\u95dc\u4fc2\uff1b\u8584\u7247\u578bTLD\u8207EBT film\u7684\u91cf\u6e2c\u503c\uff0c\u5728\u5047\u9ad4\u6a21\u64ec\u65b9\u9762\uff08\u816b\u7624\u8f2a\u5ed3\u5167\u7e2e3 mm\uff09\uff0c\u5169\u8005\u8868\u9762\u5291\u91cf\u7684\u5e73\u5747\u91cf\u6e2c\u503c\u8aa4\u5dee\u5c0f\u65bc5%\uff0c\u7576Prescribed Dose\uff08Dp\uff09\u70ba180 cGy\u6642IMRT head/neck phantom\u8868\u9762\u5291\u91cf\u7684\u53f3\u5074\u91cf\u6e2c\u503c\uff0cEBT film \u7684\u91cf\u6e2c\u7d50\u679c\u70ba93.25 cGy\u5230104.66 cGy\u4e4b\u9593\uff1b\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u7d50\u679c\u70ba93.99 cGy\u5230103.72 cGy\u4e4b\u9593\uff1b\u5de6\u5074\u91cf\u6e2c\u503c\uff0cEBT film\u7684\u91cf\u6e2c\u7d50\u679c\u70ba99.57 cGy\u5230113.91 cGy\u4e4b\u9593\uff0c\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u7d50\u679c\u70ba99.77 cGy\u5230116.85 cGy\u4e4b\u9593\u3002Rando\u00ae phantom\u8868\u9762\u5291\u91cf\u7684\u53f3\u5074\u91cf\u6e2c\u503c\uff0cEBT film\u7684\u91cf\u6e2c\u7d50\u679c\u70ba99.39 cGy\u5230122.49 cGy\u4e4b\u9593\uff1b\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u7d50\u679c\u70ba104.43 cGy\u5230120.97 cGy\u4e4b\u9593\u5de6\u5074\u91cf\u6e2c\u503c\uff0cEBT film\u7684\u91cf\u6e2c\u7d50\u679c\u70ba114.54cGy\u5230125.02 cGy\u4e4b\u9593\uff0c\u8584\u7247\u578bTLD\u7684\u91cf\u6e2c\u7d50\u679c\u70ba113.15 cGy\u5230 121.80cGy\u4e4b\u9593\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u7531\u672c\u5be6\u9a57\u5f97\u77e5\uff0c\u8584\u7247\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u9069\u5408\u7528\u4f86\u4f5c\u70ba\u8868\u9762\u5291\u91cf\u7684\u91cf\u6e2c\u5de5\u5177\uff0c\u672a\u4f86\u672c\u7814\u7a76\u5c07\u7d71\u8a08\u81e8\u5e8a\u4e0a\u4eba\u9ad4\u51fa\u73fe\u76ae\u819a\u53cd\u61c9\u6642\u5be6\u969b\u63a5\u53d7\u7684\u5291\u91cf\uff0c\u4ee5\u671f\u6e2c\u91cf\u5230\u6700\u6e96\u78ba\u7684\u76ae\u819a\u5291\u91cf\u4e26\u8a55\u4f30\u81e8\u5e8a\u4e0d\u540c\u76ae\u819a\u53cd\u61c9\u6642\u7684\u76ae\u819a\u6bd2\u6027\uff0c\u78ba\u5be6\u627e\u51fa\u9020\u6210\u75c5\u4eba\u76ae\u819a\u53cd\u61c9\u7684\u5291\u91cf\u8a55\u4f30\u503c\u3002", "e": "Purpose: This research was focused on the skin dose of simulated phantoms for head-and-neck patients treated with radiation and the reliability of measured tool for the skin dose in vivo of the headand-neck patients.Materials and Methods: This experiment adopted 0.1 mm ultrathin thermoluminescent dosimeters (ultrathin TLD) and ISP Gafchromic EBT film as the measured tool to establish the characteristics and buildup region. Superficial doses at hypothetical neck lymphatic regions were measured with IMRT head/neck phantom and anthropomorphic Rando phantom. Seven-field IMRT plans with a prescribed dose of 180 cGy were designed using an Eclipse treatment planning system. Two different geometric phantoms were used to measure the absolute dose for two measured tools.Result: In this experiment the variance coefficient of ultrathin TLD was within 3%. The reading values and delivered doses were in a good linear relationship. The points on calibration curve of Gafchromic film were within 1% and in a stable performance. The mean surface measured doses for simulated phantoms with tumor 3 mm shrinkage within 5%. The mean surface measured doses for EBT film and ultrathin TLD with a prescribed dose of 180 cGy were 93.25 cGy~104.66 cGy and 93.99 cGy~103.72 cGy on right side neck of IMRT head/neck phantom, 99.57 cGy~113.91 cGy and 99.77 cGy~116.85 cGy on left side neck of IMRT head/neck phantom, respectively. The mean surface measured doses for EBT film and ultrathin TLD were 99.39 cGy~122.49 cGy and 104.43 cGy~120.97 cGy on right side neck of Rando\u00ae phantom, 114.54 cGy~125.02 cGy and 113.15 cGy~121.80 cGy on left side neck of Rando\u00ae phantom, respectively.Conclusion and Discussion: From the experimental results, ultrathin TLD and EBT film can be adopted as the measured tools for surface dose. The future work for this research could gather statistics of the skin reactions indeed affected by the skin dose received from radiation for clinical applications. To evaluate severity of skin reaction and measure most accurate skin dose, and this data can be used references for skin reaction gradings."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-41-48", "title": "PTW 2D-Array\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u53ca\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u6cbb\u7642\u5291\u91cf\u9a57\u8b49\u4e4b\u7d93\u9a57\u5206\u4eab", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853;\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853;\u89d2\u5ea6\u4f9d\u5b58\u6027 Intensity-modulated radiation therapy;Volumetric Modulated Arc Therapy;Angular dependences", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u4e3b\u8981\u76ee\u7684\u662f\u5728\u8a55\u4f30\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Intensity-modulated radiation therapy; IMRT\uff09\u548c\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Volumetric Modulated Arc Therapy; VMAT\uff09\u4e4b\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u7d66\u4e88\u6e96\u78ba\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u5177\u6709729\u500b\u6e38\u96e2\u8154\u4e4bPTW 2D-ARRAY\u548cOctavius\u5047\u9ad4\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Intensity-modulated radiation therapy; IMRT\uff09\u53ca\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Volumetric Modulated Arc Therapy; VMAT\uff09\u4e4b\u4e8c\u7dad\u5291\u91cf\u5206\u5e03\u91cf\u6e2c\u3002\u8fb2\u592b\u578b\u6e38\u96e2\u8154\u548c\u56fa\u614b\u6c34\u5047\u9ad4\u4e4b\u5291\u91cf\u9a57\u8b49\u7cfb\u7d71\u5247\u7528\u4f86\u91cf\u6e2c\u55ae\u9ede\u4e4b\u7d55\u5c0d\u5291\u91cf\u3002\u5728\u672c\u7814\u7a76\u4e2d\u9078\u53d6\u4e8619\u500b\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u53ca8\u500b\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u4e4b\u6cbb\u7642\u8a08\u5283\u9032\u884c\u5291\u91cf\u91cf\u6e2c\uff0c\u5176\u4e2d\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u5747\u5728\u65cb\u8f49\u81c2\u89d2\u5ea6\u70ba0\u5ea6\u6642\u9032\u884c\u5291\u91cf\u91cf\u6e2c\u5206\u6790\uff0c\u800c\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u5247\u63a1\u7528\u5176\u539f\u4f86\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u89d2\u5ea6\u9032\u884c\u5291\u91cf\u91cf\u6e2c\u5be6\u9a57\u3002\u4f46\u662f\uff0c\u7531\u65bcPTW 2D-ARRAY\u6709\u89d2\u5ea6\u4f9d\u5b58\u6027\u4e4b\u554f\u984c\u5b58\u5728\uff0c\u56e0\u6b64\u91dd\u5c0d\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u800c\u8a00\uff0c\u5728\u9032\u884c\u4e8c\u7dad\u5291\u91cf\u5206\u6790\u6642\uff0c\u5fc5\u9808\u7d66\u4e88\u4e00\u5291\u91cf\u4fee\u6b63\u56e0\u5b50\u3002\u4e8c\u7dad\u5291\u91cf\u5206\u5e03\u4e4b\u8a55\u4f30\u65b9\u6cd5\u63a1\u7528Gamma-index method\uff0c\u4f7f\u7528\u4e4b\u8a55\u4f30\u6a19\u6e96\u5291\u91cf\u8aa4\u5dee\u5c0f\u65bc3%\u4e14\u8ddd\u96e2\u8aa4\u5dee\u5c0f\u65bc3\u6beb\u7c73\u3002\u7d50\u679c\uff1a\u5728\u65cb\u8f49\u81c2\u89d2\u5ea6\u4ecb\u65bc90\u5ea6\u81f3270\u5ea6\u4e4b\u9593\u6642PTW 2D-ARRAY\u6703\u6709\u660e\u986f\u4e4b\u89d2\u5ea6\u4f9d\u5b58\u6027\u5b58\u5728\uff0c\u5c24\u5176\u662f\u5728\u89d2\u5ea6\u70ba90\u5ea6\u548c270\u5ea6\u6642\u66f4\u70ba\u660e\u986f\uff0c\u800c\u6b64\u6642\u5165\u5c04\u89d2\u5ea6\u8207\u91cf\u6e2c\u5e73\u9762\u5e73\u884c\u3002\u5be6\u9a57\u7d50\u679c\u986f\u793a\uff0c\u7576\u65cb\u8f49\u81c2\u89d2\u5ea6\u70ba90\u5ea6\u548c270\u5ea6\u6642\uff0c6 MV\u5149\u5b50\u5c04\u675f\u4e4b\u52a0\u99ac\u56e0\u5b50\uff08gamma factor\uff09\u5206\u5225\u70ba 13.1%\u548c22.3%\uff0c\u800c10 MV\u5149\u5b50\u5c04\u675f\u4e4b\u52a0\u99ac\u56e0\u5b50\uff08gamma factor\uff09\u5206\u5225\u70ba 31.7%\u548c 37.2%\u3002\u9ede\u5291\u91cf\u4e4b\u91cf\u6e2c\u7d50\u679c\uff0c\u6240\u670927\u500b\u75c5\u60a3\u4e4b\u9ede\u5291\u91cf\u5e73\u5747\u8aa4\u5dee\u5206\u6790\u7d50\u679c\u70ba -1.0%\u00b11.0%\u3002\u4e8c\u7dad\u5291\u91cf\u9a57\u8b49\u5206\u6790\u7d50\u679c\uff0c19\u500b\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u6cbb\u7642\u8a08\u5283\u4e4b\u5e73\u5747\u52a0\u99ac\u56e0\u5b50\uff08mean gamma factor\uff09\u70ba 98.3%\u00b12.1%\uff0c\u800c8\u500b\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u4e4b\u6cbb\u7642\u8a08\u5283\u5728\u7d66\u4e88\u89d2\u5ea6\u4f9d\u5b58\u6027\u6821\u6b63\u56e0\u5b50\u4fee\u6b63\u5f8c\u4e4b\u5e73\u5747\u52a0\u99ac\u56e0\u5b50\uff08mean gamma factor\uff09\u70ba 95.6\u00b12.6%\uff0c\u800c\u4fee\u6b63\u56e0\u5b50\u4ecb\u65bc 1.007\u81f3 1.040\u4e4b\u9593\u3002\u7d50\u8ad6\uff1aPTW 2D-ARRAY\u61c9\u7528\u5728\u91cf\u6e2c\u56fa\u5b9a\u89d2\u5ea6\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u53ef\u9054\u5230\u8f03\u4f73\u7684\u7d50\u679c\uff0c\u4f46\u662f\u5728\u61c9\u7528\u65bc\u6e2c\u91cf\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u5291\u91cf\u6e96\u78ba\u6027\u6642\uff0c\u56e0\u70ba\u6709\u89d2\u5ea6\u4f9d\u5b58\u6027\u4f7f\u5176\u61c9\u7528\u4e0a\u53d7\u5230\u9650\u5236\u3002\u6211\u5011\u5efa\u8b70\u5728\u4f7f\u7528 PTW 2D-ARRAY\u91cf\u6e2c\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u4e8c\u7dad\u5291\u91cf\u5206\u5e03\u6642\uff0c\u5fc5\u9808\u91dd\u5c0d\u6bcf\u500b\u6cbb\u7642\u8a08\u5283\u65bd\u4e88\u89d2\u5ea6\u4f9d\u5b58\u6027\u6821\u6b63\u56e0\u5b50\uff0c\u624d\u80fd\u5f97\u5230\u66f4\u6e96\u78ba\u7684\u6e2c\u91cf\u7d50\u679c\u3002", "e": "Purpose: The purpose of this study was to evaluate the accuracy of dose delivery in IMRT and VMAT.Method and Materials: The PTW 2D-ARRAY consists of 729 vented ionization chambers with a dedicated phantom called Octavius were used to acquire the 2D dose distributions for the IMRT and VMAT plans. One limitation of the PTW 2D-ARRAY is the significant angular dependency, so we had measured the correction factors for VMAT plans. Another dosimetry system consists of a farmer type ion chamber (Wellhofer FC-65P) and solid water phantom was used to measure the selected point dose. Total of 19 IMRT and 8 VMAT plans were included in this study. IMRT plans were verified with perpendicular deliveries at 0 degree gantry angle. VMAT plans were measured with actual treatment arcs, and then the corrections were applied after the measurements. We performed gamma comparison with 3% and 3mm criteria to evaluate the results of all 2D dose maps.Results: The significant angular dependences of PTW 2D-ARRAY were showed at the measured gantry angle between 90 to 270 degrees, especially at both 90 and 270 degrees, which was parallel with the measured plane of PTW 2D-ARRAY. The gamma factors of the gantry angle 90 and 270 were 13.1% and 22.3% for 6 MV photon beam and 31.7% and 37.2% for 10 MV photon beam.The mean point doses variation between each measurements and treatment plans in all IMRT/VMAT QA was -1.0% +/-1.0 % (mean +/- std). The mean gamma factor of IMRT QA was 98.3%+/- 2.1%. And the mean gamma factor in the full-arc VMAT QA was 95.6+/-2.6% after applied acorrection factor range from 1.007 to 1.040. Therefore, the 2D dose maps showed great agreements in all IMRT/VMAT QA.Conclusions: PTW 2D-ARRAY has better performance in static angle IMRT, but has limitations caused by angular dependences in VMAT QA. We suggest a correction factor should be applied to every measured points of 2D dose maps when using PTW 2D-ARRAY for a full-arc VMAT QA."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-49-56", "title": "\u4f7f\u7528\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u5728\u5f27\u5f62\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u9a57\u8b49", "keywords": "\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e;\u52a0\u99ac\u543b\u5408\u6307\u6578;\u5f27\u5f62\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5291\u91cf\u9a57\u8b49 Electronic Portal Imaging Device (EPID);Gamma Agreement Index (GAI);Volumetric Modulated Arc Therapy (VMAT);Dosimetry Verification", "c": "\u76ee\u7684\uff1a\u4f7f\u7528\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\uff08EPID, VARIAN aS-1000\uff09\u8a2d\u5099\uff0c\u914d\u5408 Epiqa \u5291\u91cf\u9a57\u8b49\u8edf\u9ad4\u4f86\u9a57\u8b49\u5f27\u5f62\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u8a08\u756b\u7684\u5291\u91cf\u5206\u5e03\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1aEpiqa\u662f\u4e00\u5957\u57fa\u65bcGLAaS\u7406\u8ad6\u5c07\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u5f71\u50cf\u8f49\u63db\u6210\u5291\u91cf\u5716\uff08dose map\uff09\u7684\u8edf\u9ad4\uff0c\u53ef\u7528\u4f86\u9a57\u8b49\u5f27\u5f62\u5f37\u5ea6\u8abf\u63a7\uff08RapidArc\uff09\u653e\u5c04\u6cbb\u7642\u3002\u5c07\u5291\u91cf\u5f71\u50cf\u8f49\u63db\u70ba\u5291\u91cf\u5716\uff0c\u5fc5\u9700\u900f\u904e\u6821\u6b63\u7684\u7a0b\u5e8f\u53d6\u5f97\u4e0d\u540c\u5927\u5c0f\u958b\u653e\u7167\u91ce\u53ca\u7a7f\u900f\u7167\u91ce\uff08transmission field\uff09\u7684\u5f71\u50cf\uff0c\u4e26\u8f38\u5165\u4f7f\u7528\u6e38\u96e2\u8154\u6e2c\u91cf\u7684\u8f38\u51fa\u56e0\u5b50\u4fc2\u6578\u8868\uff1b\u5efa\u7acb\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u6bcf\u4e00\u500b\u50cf\u7d20\uff08pixel\uff09\u7684\u6821\u6b63\u56e0\u5b50\uff0c\u5c07\u50cf\u7d20\u7684\u8b80\u503c\u8f49\u63db\u70ba\u5728\u6c34\u4e2ddmax\u6df1\u8655\u7684\u5291\u91cf\u3002\u900f\u904e\u9019\u6a23\u7684\u8f49\u63db\uff0c\u53ef\u4ee5\u5c07\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u7684\u6240\u6709\u50cf\u7d20\u8f49\u63db\u6210\u5728\u6c34\u4e2ddmax\u6df1\u5ea6\u8655\u7684\u5e73\u9762\u5291\u91cf\u5206\u5e03\u5716\uff1b\u4fbf\u53ef\u5c07\u6cbb\u7642\u8a08\u756b\u8207\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u5169\u8005\u5291\u91cf\u5206\u5e03\u6bd4\u5c0d\u9032\u800c\u8207\u4e4b\u9a57\u8b49\u3002\u672c\u7814\u7a76\u91dd\u5c0d20\u4f4d\u5f27\u5f62\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6848\u4f8b\u9032\u884c\u5291\u91cf\u9a57\u8b49\uff0c\u5176\u4e2d\u67097 \u4f4d\u651d\u8b77\u817a\u764c\u30012\u4f4d\u4e73\u764c\u30013\u4f4d\u76f4\u8178\u764c\u30014\u4f4d\u9f3b\u54bd\u764c\u82074\u4f4d\u5176\u5b83\u90e8\u4f4d\u3002\u7d50\u679c\uff1a\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u5291\u91cf\u53c3\u6578\u7684\u52a0\u99ac\u503c\uff08Gamma Agreement Index, GAI\uff09\u8a2d\u5b9a\u543b\u5408\u8ddd\u96e2\uff08DTA\uff09\u70ba3\u6beb\u7c73\uff0c\u5291\u91cf\u5dee\u7570\uff08\u0394D\uff093%\u4e0b\uff0c\u75c5\u60a3\u7684\u5e73\u5747GAI[%] \u70ba94.32\u00b13.19\uff0899.06-81.31\uff09\uff0c\u800c\u651d\u8b77\u817a\u764c\u3001\u4e73\u764c\u3001\u76f4\u8178\u764c\u3001\u9f3b\u54bd\u764c\u8207\u5176\u5b83\u90e8\u4f4d\u7684\u5e73\u5747GAI[%]\u5206\u5225\u70ba93.62\u00b14.03\uff0899.06-81.31\uff09\u300197.43\u00b11.14\uff0898.86-96.24\uff09\u300192.96\u00b12.51\uff0897.19-89.01\uff09\u300194.98\u00b12.31\uff0897.64-89.09\uff09 \u820794.95\u00b12.48\uff0898.9-90.76\uff09\uff0c\u4e73\u764c\u7684GAI[%]\u5448\u73fe\u8f03\u597d\u7684\u7d50\u679c\uff08\u6700\u4f4e\u503c\u9054\u523096.24\uff09\uff0c\u5176\u4e2d\u651d\u8b77\u817a\u764c\u76841\u4f4d\u60a3\u8005\u57283\u500bArc\u4e2d\uff0c\u67092\u500bArc\u7684GAI[%]\u503c\u572890%\u4ee5\u4e0b\u3002\u7d50\u8ad6\uff1a\u5229\u7528Epiqa\u9019\u5957\u8edf\u9ad4\u9a57\u8b49\u6cbb\u7642\u8a08\u756b\u904b\u7b97\u6240\u5f97\u7684\u5291\u91cf\uff0c\u4f5c\u70ba\u5291\u91cf\u9a57\u8b49\u7684\u5de5\u5177\u662f\u4e00\u7a2e\u7c21\u55ae\u4e14\u53ef\u884c\u7684\u7684\u65b9\u6cd5\uff0c\u5e0c\u671b\u7d2f\u7a4d\u66f4\u591a\u81e8\u5e8a\u7684\u9a57\u8b49\u8cc7\u6599\uff0c\u4f7f\u672a\u4f86\u5291\u91cf\u9a57\u8b49\u7684\u7a0b\u5e8f\u66f4\u52a0\u7406\u60f3\u3002", "e": "Purpose: Verification of dose distributions for RapidArc Volumetric Modulated Arc Therapy (VMAT) treatment plans with Electronic Portal Imaging Device (EPID) and its associated software.Materials and Methods: Epiqa is software to covert the EPID images into dose map based on the GLAaS theory. It can be used to verify the dose distributions for RapidArc therapy. To convert images into dose map, we need to have calibration factors for each pixel to covert the pixel values into dmax dose in water. For the purpose of calibration, a set of integrated images for open and transmission fields of different field sizes are acquired and consequently imported into Epiqa together with the output factor table to establish basic algorithm configuration data. A calibration factor can then be determined for every pixel of EPID images by weighting the contribution of primary and transmitted radiation. The pixel based calibration relates the readout of a pixel to a dose at the depth of dmax in water equivalent homogenous medium. By applying the conversion factors to all pixels of the EPID images, a planar dose distribution at the dmax in water is obtained. A total of 20 patients (70 arcs in total) were included in this study, 7 with prostate cancers, 2 with breast cancer, 4 with rectal cancer, 4 with NPC, and 4 with other sites.Results : The Distance to Agreement (DTA) and the Dose Difference (\u0394D) for The Gamma Agreement Index (GAI) of dosimetry parameters with EPID were set as 3 mm and less than 3% respectively. The average GAI (%) of patients in our study is 94.32 \u00b1 3.19 (99.06-81.31). GAI (%) for prostate cancer, breast cancer, rectal cancer, NPC, and other sites is 93.62 \u00b1 4.03 (99.06-81.31), 97.43 \u00b1 1.14 (98.86-96.24), 92.96 \u00b1 2.51 (97.19-89.01), 94.98 \u00b1 2.31 (97.64-89.09), and 94.95 \u00b1 2.48 (98.9-90.76), respectively. The GAI (%) for breast cancer had a better result, with a lowest value of 96.24. For one of the prostate cancer patient treated with 3 arcs, there are two arcs had a GAI value below 90%.Conclusions: It is an easy and feasible way to apply the EPID with Epiqa software as dosimetry verification tool for VMAT. We will gather more clinical data to come out a better dosimetry verification procedure for VMAT in the near future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-57-63", "title": "\u653e\u5c04\u816b\u7624\u79d1\u9580\u8a3a\u75c5\u60a3\u63a5\u53d7\u8de8\u9662\u5340\u8f49\u4ecb\u4e4b\u610f\u898b\u8abf\u67e5", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u9580\u8a3a\u75c5\u60a3;\u8f49\u4ecb;\u610f\u898b\u8abf\u67e5 Radiotherapy;Outpatient;Referral;Opinion survey", "c": "\u76ee\u7684\uff1a\u67d0\u6559\u5b78\u91ab\u5b78\u4e2d\u5fc3\u7684\u653e\u5c04\u816b\u7624\u79d1\uff0c\u56e0\u70ba\u9580\u8a3a\u6cbb\u7642\u7684\u5f85\u6392\u4eba\u6578\u8d85\u904e\u5176\u6b63\u5e38\u8ca0\u8377\u91cf\uff0c\u70ba\u907f\u514d\u75c5\u60a3\u7b49\u5019\u5c31\u91ab\u7684\u6642\u9593\u5ef6\u5b95\uff0c\u6240\u4ee5\u8f49\u4ecb\u75c5\u60a3\u81f3\u4f4d\u65bc\u9130\u8fd1\u7e23\u5e02\uff0c\u4f46\u64c1\u6709\u76f8\u540c\u6cbb\u7642\u8a2d\u5099\u7684\u5340\u57df\u91ab\u9662\u4ee5\u53ca\u65e9\u5c31\u91ab\u3002\u672c\u7814\u7a76\u5e0c\u671b\u77ad\u89e3\u63a5\u53d7\u8f49\u4ecb\u7684\u75c5\u60a3\u53ca\u5bb6\u5c6c\uff0c\u5c0d\u6b64\u91ab\u7642\u670d\u52d9\u65b9\u5f0f\u7684\u770b\u6cd5\u53ca\u9700\u6c42\uff0c\u4ee5\u4f5c\u70ba\u672a\u4f86\u653e\u5c04\u816b\u7624\u79d1\u91ab\u7642\u54c1\u8cea\u6539\u9032\u7684\u53c3\u8003\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2010\u5e7412\u6708\u81f32012\u5e741\u6708\uff0c\u5171\u8a08\u670965\u540d\u91ab\u5b78\u4e2d\u5fc3\u7684\u75c5\u60a3\u63a5\u53d7\u8f49\u4ecb\u81f3\u5340\u57df\u6559\u5b78\u91ab\u9662\u63a5\u53d7\u9580\u8a3a\u653e\u5c04\u6cbb\u7642\u3002\u672c\u7814\u7a76\u63a1\u81ea\u64ec\u7684\u7d50\u69cb\u5f0f\u554f\u5377\uff0c\u4f9d\u9580\u8a3a\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u7684\u7279\u6027\u8a2d\u8a08\u800c\u6210\uff0c\u5206\u6790\u75c5\u60a3\u9858\u610f\u8f49\u4ecb\u7684\u539f\u56e0\u53ca\u8f49\u4ecb\u5f8c\u7684\u6eff\u610f\u5ea6\u3002\u7d50\u679c\uff1a\u75c5\u60a3\u5728\u6c7a\u5b9a\u662f\u5426\u8981\u63a5\u53d7\u8f49\u4ecb\u7684\u8003\u91cf\u6642\uff0c\u4ee5\u4e0d\u60f3\u62d6\u5ef6\u6cbb\u7642\uff0f\u6216\u56e0\u7b49\u5f85\u800c\u7522\u751f\u7684\u7126\u616e\u70ba\u6700\u91cd\u8981\u56e0\u7d20\uff0856.9%\uff09\uff0c\u5176\u6b21\u662f\u57fa\u65bc\u4fe1\u4efb\u540c\u4e00\u91ab\u7642\u9ad4\u7cfb\u7684\u95dc\u4fc2\u800c\u9858\u610f\u8f49\u4ecb\uff0823%\uff09\uff0c\u518d\u5176\u6b21\u5247\u662f\u56e0\u70ba\u91ab\u9662\u6709\u63d0\u4f9b\u4ea4\u901a\u53ca\u505c\u8eca\u512a\u60e0\uff0820.1%\uff09\u3002\u5176\u4e2d\u6700\u6eff\u610f\u7684\u9805\u76ee\uff0c\u662f\u5c08\u5c6c\u6cbb\u7642\u6642\u6bb5\u7684\u65b9\u4fbf\u6027\uff0855.4%\uff09\uff0c\u5176\u6b21\u662f\u4ea4\u901a\u7684\u4fbf\u5229\uff0833.8%\uff09\uff08\u6709\u514d\u8cbb\u5c08\u8eca\u63a5\u9001\uff09\u3002\u6574\u9ad4\u800c\u8a00\uff0c\u5927\u591a\u6578\u7684\u75c5\u60a3\u662f\u80af\u5b9a\u6b64\u8de8\u9662\u5340\u8f49\u4ecb\u7684\u6a21\u5f0f\uff0c\u5c0d\u5340\u57df\u91ab\u9662\u7684\u91ab\u7642\u670d\u52d9\u54c1\u8cea\u611f\u5230\u6eff\u610f\u7684\u6bd4\u4f8b89.2%\u3002\u7d50\u8ad6\uff1a\u764c\u75c7\u662f\u91cd\u5927\u75be\u75c5\uff0c\u4e0d\u8ad6\u662f\u75c5\u60a3\u672c\u8eab\u6216\u662f\u91ab\u9662\uff0c\u90fd\u5e0c\u671b\u80fd\u5118\u65e9\u5b8c\u6210\u6cbb\u7642\uff1b\u4f46\u82e5\u9047\u5230\u91ab\u7642\u8cc7\u6e90\u7121\u6cd5\u6eff\u8db3\u9700\u6c42\uff0c\u4e0d\u5f97\u4e0d\u8f49\u4ecb\u81f3\u4ed6\u9662\u6642\uff0c\u91ab\u9662\u6709\u8cac\u4efb\u63d0\u4f9b\u59a5\u5584\u898f\u5283\u3002\u540c\u4e00\u91ab\u7642\u9ad4\u7cfb\u5167\u8de8\u9662\u5340\u7684\u8f49\u4ecb\u6a21\u5f0f\uff0c\u512a\u9ede\u662f\u53ef\u4ee5\u78ba\u4fdd\u764c\u75c7\u6cbb\u7642\u8a08\u756b\u7684\u57f7\u884c\u80fd\u505a\u5230\u7121\u7e2b\u63a5\u8ecc\uff0c\u4ee5\u7dad\u6301\u91ab\u7642\u54c1\u8cea\u3002\u85c9\u7531\u6b64\u8abf\u67e5\u77ad\u89e3\u75c5\u60a3\u53ca\u5bb6\u5c6c\u5c31\u91ab\u6642\u7684\u8003\u91cf\u8207\u610f\u898b\uff0c\u53ef\u63d0\u4f9b\u76f8\u95dc\u91ab\u7642\u7d93\u71df\u7ba1\u7406\u653f\u7b56\u5236\u5b9a\u6642\u7684\u53c3\u8003\u3002", "e": "Purpose: Owning to the extended waiting list and the possibility of treatment delay, the department of radiation oncology at a medical center referred its waiting outpatients to another regional hospital which was affiliated to the same health care system and equipped with similar linear accelerator facility, but located across the Taipei basin. The purpose of this study is to survey the opinion and demand of referred patients and their family member to this service mode, and to provide a reference for future quality improvement.Material and Method: Between December 2010 and January 2012, there were 65 patients referred to the regional teaching hospital for radiotherapy. A self-constructed structural questionnaire was designed according to the characteristic of outpatient at department of radiation oncology. Statistical analysis was performed to investigate the consideration and satisfaction with this referral mode.Results : When patient considering to accept trans-hospital referral or not, the most critical factor in decision making was fear of being delayed or the anxiety associated with waiting (56.9%), the second was the confidence in the same health care system (23%), and the third was the convenience in transportation and parking (20.1%). The service patients most satisfied with were the exclusively reserved daily treatment schedule (55.4%), and the free transportation shuttle to and fro the medical center and regional hospital. In general, most patients (89.2%) acknowledged this referral mode and the service quality of this regional hospital.Conclusion: Cancer is a serious disease, and both patients themselves and hospital hope to complete the treatment as soon as possible. In circumstances when medical resources can not meet the needs and referral are suggested, hospital must provide proper arrangement. In spite of transportation across district, referral within the same health care system has advantages in ensuring the execution and consistency of cancer treatment. The considerations and opinions to this referral mode can provide useful reference for medical business management and health policy making."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201303-201304250003-201304250003-65-75", "title": "Gene Sequencing for Selection of Chemotherapy Drugs Combined with Stereotactic Body Radiation Therapy for Stage IV Colon Cancer: A Case Report", "keywords": "\u5927\u8178\u76f4\u8178\u764c;\u57fa\u56e0\u5b9a\u5e8f;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642 Colorectal carcinoma;Gene sequence;SBRT (Stereotactic Body Radiation Therapy);Chemotherapy", "c": "\u6211\u5011\u5831\u544a\u4e00\u540d31\u6b72\u5973\u6027\u8a3a\u65b7\u70ba\u5927\u8178\u764c\u5408\u4f75\u591a\u8655\u80ba\u8f49\u79fb\u500b\u6848\uff1a\u85c9\u7531\u8840\u6db2\u57fa\u56e0\u5b9a\u5e8f\u7d50\u679c\uff0c\u6211\u5011\u6311\u9078\u6700\u5408\u9069\u4e4b\u5316\u7642\u85e5\u7269\u7d44\u5408\uff0c\u4e26\u5728\u6210\u529f\u63a7\u5236\u816b\u7624\u72c0\u6cc1\u5f8c\uff0c\u5c0d\u65bc\u539f\u767c\u90e8\u4f4d\u9032\u884c\u5916\u79d1\u624b\u8853\u5207\u9664\u4e26\u5c0d\u6b98\u9918\u80ba\u90e8\u8f49\u79fb\u816b\u7624\u9032\u884c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7d93\u96fb\u8166\u65b7\u5c64\u6b63\u5b50\u651d\u5f71\u986f\u793a\uff0c\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u3002\u76ee\u524d\u81e8\u5e8a\u4e0a\u96d6\u6709\u6578\u7bc7\u95dc\u65bc\u56de\u6eaf\u6027\u5206\u6790\u57fa\u56e0\u8868\u73fe\u8207\u81e8\u5e8a\u85e5\u7269\u53cd\u61c9\u3001\u751a\u81f3\u9810\u5f8c\u4e4b\u76f8\u95dc\u5b78\u8853\u7814\u7a76\uff0c\u4f46\u662f\u85c9\u7531\u57fa\u56e0\u5b9a\u5e8f\u3001\u6574\u5408\u591a\u7a2e\u57fa\u56e0\u8868\u73fe\u7d50\u679c\u800c\u9078\u64c7\u5316\u7642\u85e5\u7269\u5c1a\u5f85\u66f4\u591a\u7814\u7a76\u3002\u672c\u7bc7\u5c6c\u65bc\u8a66\u9a57\u6027\u7684\u524d\u77bb\u6027\u81e8\u5e8a\u7814\u7a76\u4f86\u8a55\u5b9a\u57fa\u56e0\u5b9a\u5e8f\u8207\u5927\u8178\u764c\u6cbb\u7642\u7684\u81e8\u5e8a\u7d50\u679c\uff0c\u5e0c\u671b\u85c9\u7531\u66f4\u591a\u5f8c\u7e8c\u76f8\u95dc\u7814\u7a76\u53ef\u4ee5\u9054\u6210\u5c07\u4f86\u4f9d\u7167\u500b\u4eba\u4e0d\u540c\u57fa\u56e0\u7d44\u6210\u800c\u9078\u64c7\u6700\u4f73\u7642\u6548\u4e4b\u5316\u7642\u85e5\u7269\u3002", "e": "Gene sequencing may be a feasible means of individualizing cancer treatment. By investigating the correlation between genetic profiles and treatment outcomes of chemotherapy, it may be possible to determine effective treatment strategies according to individual genotypes in cancer patients. Despite great advances in drugs for cancer treatment, treatment outcomes may be improved by analyzing genetic markers that indicate treatment efficacy. We report the treatment for a patient with metastatic colon cancer in which gene sequencing was used for the selection of an effective chemotherapy regimen. In addition, we describe the entire course of treatment, including the combination of surgical resection for local control and radiotherapy to eradicate distant metastases. This is a pilot report of the clinical use of gene sequencing for determining a treatment regimen. Further clinical trials are needed to optimize the personalization of cancer treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-167-179", "title": "Body Weight Loss\u22675% during Radiotherapy Confers a Better Overall Survival in NPC Patients with Pretreatment BMI\u226725", "keywords": "\u9f3b\u54bd\u764c;\u9810\u5f8c;\u9ad4\u91cd\u8b8a\u5316;\u8eab\u9ad4\u8cea\u91cf\u6307\u6578;\u80a5\u80d6;\u653e\u5c04\u6cbb\u7642 Nasopharyngeal carcinoma;Prognosis;Weight change;Body mass index;Obesity;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5c11\u6709\u7814\u7a76\u8a0e\u8ad6\u653e\u5c04\u6cbb\u7642\uff08\u4ee5\u4e0b\u7c21\u7a31\u201c\u653e\u7642\u201d\uff09\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u8b8a\u5316\u5c0d\u5b58\u6d3b\u7387\u4e4b\u5f71\u97ff\u3002\u672c\u6587\u9664\u4e86\u63a2\u8a0e\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u8b8a\u5316\u8207\u9f3b\u54bd\u764c\u75c5\u4eba\u5b58\u6d3b\u7387\u9593\u7684\u76f8\u95dc\u6027\uff0c\u4e5f\u540c\u6642\u8a0e\u8ad6\u653e\u7642\u524d\u8eab\u9ad4\u8cea\u91cf\u6307\u6578\uff08BMI\uff09\u662f\u5426\u5f71\u97ff\u4e0a\u8ff0\u7684\u76f8\u95dc\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u56de\u6eaf\u6536\u93041583\u4f4d\uff0c\u5f9e1995\u81f32007\u5e74\u65bc\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u63a5\u53d7\u904e\u6839\u6cbb\u6027\u653e\u7642\u4e4b\u9f3b\u54bd\u764c\u75c5\u60a3\uff0c\u5206\u5225\u6839\u64da\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u8b8a\u5316\uff08\u22675% vs.\uff1c5%\uff09\u8207\u653e\u7642\u524dBMI\uff08\u226725 VS.\uff1c25\uff09\u5206\u7fa4\u5f8c\uff0c\u9032\u884c\u5b58\u6d3b\u7387\u5206\u6790\uff1b\u6700\u5f8c\u9032\u884c\u5b58\u6d3b\u7387\u7684\u591a\u8b8a\u9805\u5206\u6790\uff0c\u7d0d\u5165\u7d71\u8a08\u5206\u6790\u6a21\u578b\u7684\u95dc\u9375\u6027\u56e0\u5b50\u5305\u62ec\u653e\u7642\u524d\u5f8c\u9ad4\u91cd\u8b8a\u5316\u3001\u653e\u7642\u524dBMI\uff0c\u8207\u5176\u4ed6\u81e8\u5e8a\u76f8\u95dc\u56e0\u5b50\u3002\u7d50\u679c\uff1a\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u4e0b\u964d\u7a0b\u5ea6\u662f\u5426\u8d85\u904e5%\u6703\u53d7\u5230\u75c5\u60a3\u5e74\u9f61\u3001\u5316\u7642\u7d66\u4e88\u8207\u5426\u3001\u653e\u7642\u7642\u7a0b\u7e3d\u5929\u6578\u548c\u6cbb\u7642\u524dBMI\u7684\u5f71\u97ff\u3002\u91dd\u5c0d\u5168\u90e8\u75c5\u4eba\u9032\u884c\u55ae\u8b8a\u9805\u548c\u591a\u8b8a\u9805\u5206\u6790\u6642\uff0c\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u8b8a\u5316\u72c0\u6cc1\u8207\u9f3b\u54bd\u764c\u75c5\u60a3\u5b58\u6d3b\u7387\u4e4b\u9593\u7684\u76f8\u95dc\u6027\u7686\u9054\u7d71\u8a08\u4e0a\u7684\u986f\u8457\u610f\u7fa9\uff1b\u82e5\u9032\u4e00\u6b65\u4f9d\u64da\u653e\u7642\u524dBMI\uff08\u226725\u6216\uff1c25\uff09\u5206\u7fa4\u5f8c\uff0c\u767c\u73fe\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u6e1b\u5c11\u7a0b\u5ea6\u8d85\u904e5%\u5c0d\u5b58\u6d3b\u7387\u4e4b\u6b63\u9762\u5f71\u97ff\u53ea\u51fa\u73fe\u5728BMI\u226725\uff08\u653e\u7642\u524d\u904e\u91cd\u6216\u80a5\u80d6\uff09\u4e4b\u6b21\u65cf\u7fa4\uff0c\u5177\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u610f\u7fa9\uff08p=0.046, log-rank test\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u89c0\u5bdf\u5230\u9f3b\u54bd\u764c\u75c5\u60a3\u4e2d\uff0c\u653e\u7642\u7642\u7a0b\u524d\u5f8c\u9ad4\u91cd\u6e1b\u5c11\u7a0b\u5ea6\u8d85\u904e5%\u8005\u64c1\u6709\u8f03\u4f73\u7684\u5b58\u6d3b\u7387\uff0c\u7279\u5225\u662f\u5728\u653e\u7642\u524dBMI\u226725\u4e4b\u6b21\u65cf\u7fa4\u3002\u95dc\u65bc\u6b64\u73fe\u8c61\u4e4b\u53ef\u80fd\u89e3\u91cb\u5c1a\u9700\u66f4\u6df1\u5165\u7684\u7814\u7a76\uff0c\u5305\u62ec\u5176\u6f5b\u6709\u7684\u751f\u7269\u6a5f\u8f49\u8207\u9f3b\u54bd\u764c\u7684\u5fa9\u767c\u5f62\u614b\u3002", "e": "Objectives/Hypothesis: The association between weight loss during radiotherapy (RT) and patients' survival has not been assessed in patients with nasopharyngeal carcinoma (NPC). This study was aimed to investigate this association and also determine whether pretreatment body mass index (BMI) affects the association between weight loss and overall survival.Methods: 1583 NPC patients diagnosed between 1995 and 2007 undergoing definitive RT were consecutively enrolled. Survival analyses were performed with stratification according to weight change (\u22675% vs.\uff1c5%) and pretreatment BMI (\u226725 vs.\uff1c25) respectively. Cox proportional hazards model was carried out to evaluate the impact of weight change, pretreatment BMI on survival controlling for the other clinically relevant factors.Results: Weight change (\u22675%) during RT is significantly influenced by age, chemotherapy, RT duration and pretreatment BMI. A statistically significant association between the status of weight change and overall survival could be identified both in univariate and multivariate analyses. After further stratification by BMI (\u226725 or\uff1c25), there is a significantly positive impact of weight loss\u22675% on survival particularly among the patients who are overweight or obese (p=0.046, log-rank test).Conclusions: A weight loss\u22675% during RT confers a more favorable overall survival in NPC patients who are initially overweight or obese (BMI\u226725). The explanation for this phenomenon warrants further analyses with regard to locoregional control and underlying biological mechanisms."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-181-188", "title": "\u6bd4\u8f03\u78c1\u632f\u651d\u5f71\u8207\u96fb\u8166\u65b7\u5c64\u5c0d\u9f3b\u54bd\u764c\u9871\u5167\u8513\u5ef6\u4e4b\u5075\u6aa2\u53ca\u5206\u6790\u5c0d\u6cbb\u7642\u6210\u679c\u4e4b\u5f71\u97ff", "keywords": "\u9871\u5167\u8513\u5ef6;\u9f3b\u54bd\u764c;\u5b58\u6d3b\u7387 Intracranial invasion;Nasopharyngeal carcinoma;Survival", "c": "Purpose: To compare magnetic resonance imaging (MRI) and computed tomography (CT) in detecting intracranial extension of the patients with nasopharyngeal carcinoma (NPC) and to analyze the impact on treatment outcome.Materials and Methods: From December 1997 to December 2004, 587 patients with histologically confirmed NPC (Iess than or equal to stage IVA according to American Joint Committee on Cancer, sixth edition) and received therapeutic radiation dose who underwent CT and MRI for evaluation of primary tumor extension. AII o f the images were reviewed and assessed by two physicians independently. Cases with variable interpretation or disagreement between the observers, these images were reevaluated side by side and any discrepancy was resolved by consensus. The kappa test for inter-observer concordance was 0.841 for CT and 0.931 for MRI.Results: The detection rate of intracranial invasion by MRI was 62.7% and that by CT was 15.5% (p\uff1c0.001). The group with no intracranial invasion detected by MRI or CT (group 1) had significantly higher overall survival rate than intracranial invasion detected by MRI but not by CT (group 2, p\uff1c0.001) or intracranial invasion detected by both MRI and CT (group 3, p\uff1c0.001). For group 2 patients, chemotherapy plus radiotherapy had higher overall survival rate than radiotherapy alone (p\uff1c0.001). Group 2 and 3 had the odd ratio of 3.2 and 4.0 comparing to group 1 by Cox regression. According to different treatment modalities, patients treated by radiotherapy alone had odd ratio of 2.6 comparing to chemotherapy plus radiotherapy.Conclusion: MRI owned a higher intracranial invasion detection rate than CT. Patients with intracranial involvement should receive both chemotherapy and radiotherapy in order to improve overall survival, even those with only subtle intracranial invasion.", "e": "Purpose: To compare magnetic resonance imaging (MRI) and computed tomography (CT) in detecting intracranial extension of the patients with nasopharyngeal carcinoma (NPC) and to analyze the impact on treatment outcome.Materials and Methods: From December 1997 to December 2004, 587 patients with histologically confirmed NPC (Iess than or equal to stage IVA according to American Joint Committee on Cancer, sixth edition) and received therapeutic radiation dose who underwent CT and MRI for evaluation of primary tumor extension. AII o f the images were reviewed and assessed by two physicians independently. Cases with variable interpretation or disagreement between the observers, these images were reevaluated side by side and any discrepancy was resolved by consensus. The kappa test for inter-observer concordance was 0.841 for CT and 0.931 for MRI.Results: The detection rate of intracranial invasion by MRI was 62.7% and that by CT was 15.5% (p\uff1c0.001). The group with no intracranial invasion detected by MRI or CT (group 1) had significantly higher overall survival rate than intracranial invasion detected by MRI but not by CT (group 2, p\uff1c0.001) or intracranial invasion detected by both MRI and CT (group 3, p\uff1c0.001). For group 2 patients, chemotherapy plus radiotherapy had higher overall survival rate than radiotherapy alone (p\uff1c0.001). Group 2 and 3 had the odd ratio of 3.2 and 4.0 comparing to group 1 by Cox regression. According to different treatment modalities, patients treated by radiotherapy alone had odd ratio of 2.6 comparing to chemotherapy plus radiotherapy.Conclusion: MRI owned a higher intracranial invasion detection rate than CT. Patients with intracranial involvement should receive both chemotherapy and radiotherapy in order to improve overall survival, even those with only subtle intracranial invasion."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-189-199", "title": "\u907f\u514d\u982d\u9838\u90e8\u764c\u75c7\u653e\u5c04\u6cbb\u7642\u53e3\u4e7e\u75c7\u7684\u6cbb\u7642\u8a08\u5283\u9650\u503c\uff1a\u4f7f\u7528\u751f\u6d3b\u554f\u5377\u8abf\u67e5\u6578\u64da\u8cc7\u6599\u7684QUANTEC\u6e96\u5247\u9a57\u8b49", "keywords": "QUANTEC\u6e96\u5247;\u982d\u9838\u90e8;\u9c57\u72c0\u7d30\u80de\u764c;\u9f3b\u54bd\u764c;\u751f\u6d3b\u54c1\u8cea QUANTEC;Head and neck;Head and neck squamous cell carcinoma;Nasopharyngeal carcinoma;Quality of life", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u91dd\u5c0d\u982d\u9838\u764c\uff08HN\uff09\u75c5\u60a3\uff0c\u5305\u62ec\u982d\u9838\u90e8\u9c57\u72c0\u7d30\u80de\u764c\uff08HNSCC\uff09\u548c\u9f3b\u54bd\u764c\uff08NPC\uff09\u60a3\u8005\uff0c\u9032\u884c\u751f\u6d3b\u54c1\u8cea\uff08QoL\uff09\u554f\u5377\u8abf\u67e5\uff0c\u9a57\u8b49\u81e8\u5e8a\u6b63\u5e38\u7d44\u7e54\u6548\u61c9\u5b9a\u91cf\u5206\u6790\uff08QUANTEC\uff09\u6e96\u5247\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u91dd\u5c0d95\u4f4dNPC\u548c142\u4f4dHNSCC\u60a3\u8005\u7684QoL\u554f\u5377\u8abf\u67e5\u5206\u5225\u9032\u884c\u5206\u6790\uff0c\u4e26\u4f7f\u7528\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08The European Organization for Research and Treatment of Cancer\uff09\u6240\u63d0\u4f9b\u7684\u982d\u9838\u90e8QoL\u554f\u5377\u8abf\u67e5\u7d50\u679c\uff08H&N35\uff09\u4f5c\u70ba\u8a55\u4f30\u7642\u6548\u6307\u6a19\u3002\u8207\u6cbb\u7642\u524d\u6bd4\u8f03\uff0c\u5982\u679c\u53e3\u4e7e\u7684QoL\u7a0b\u5ea6\u88ab\u8a55\u70ba66\u81f3100\u5206\uff0c\u5247\u5b9a\u7fa9\u70ba\u4e2d\u91cd\u5ea6\u53e3\u4e7e\u3002\u4f7f\u7528\u840a\u66fc\u7b49\u4eba\uff08Lyman-Kutcher-Burman\uff09\u6240\u63d0\u51fa\u7684\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u6a21\u578b\uff08NTCP\uff09\u501f\u8ff0\u53e3\u4e7e\u75c7\uff08xerostomia\uff09\u7684\u767c\u751f\u7387\uff0c\u4e26\u7528\u9670\u6027\u9810\u6e2c\u503c\uff08NPVs\uff09\u4f86\u6c7a\u5b9a\u672a\u767c\u751f\u4f75\u767c\u75c7\u7684\u9810\u6e2c\u6e96\u78ba\u7387\u3002\u7d50\u679c\uff1aNTCP\u7684\u64ec\u5408\u53c3\u6578\u8a2d\u5b9a\u57282\u500b\u6642\u9593\u9ede\uff0c\u5206\u5225\u70ba3\u500b\u6708\u6642TD50 =39.8 Gy\u3001m=0.28\uff0c\u4ee5\u53ca12\u500b\u6708\u6642TD50 = 45.2Gy\u3001m=0.24\u3002\u7576\u816e\u817a\u7684\u5e73\u5747\u5291\u91cf\u5c0f\u65bc20\u548c25 Gy\uff0c\u57283\u500b\u6708\u6642\uff0cHN\u5168\u9ad4\u548cHNSCC\u9a57\u8b49\u4e86\u76f8\u4f3c\u7684\u7d50\u679c\uff0cQoL\u554f\u5377\u5206\u6790\u7684\u6578\u64da\u5206\u5225\u986f\u793a\u7d04\u67096%\u548c16%\u7684\u6a5f\u6703\u7522\u751fxerostomia\uff1b\u800c\u572812\u500b\u6708\u6642\uff0cxerostomia\u6a5f\u7387\u5247\u5206\u5225\u7d04\u70ba5%\u548c14%\u3002\u91dd\u5c0dNPC\u60a3\u8005\uff0c\u6578\u64da\u986f\u793a\u57283\u500b\u6708\u6642\u5206\u5225\u7d04\u67090%\u548c33%\uff08NPV\u7d04\u70ba67%\uff09\u7684\u6a5f\u6703\u7522\u751fxerostomia\u3002\u800c\u572812\u500b\u6708\u6642xerostomia\u6a5f\u7387\u7686\u7d04\u70ba0% \uff08NPV \u7d04\u70ba100%\uff09\uff0c\u6b64\u8207HNSCC\u7684\u7d50\u679c\u986f\u8457\u4e0d\u540c\u3002\u7d50\u8ad6\uff1aQoL\u554f\u5377\u5206\u6790\u6578\u64da\u8cc7\u6599\u9a57\u8b49QUANTEC\u6e96\u5247\u7684\u5be6\u7528\u6027\uff0c\u4e26\u5efa\u8b70\u4fee\u6b63\u816e\u817a\u7684QUANTEC\u6e96\u5247\u70ba20/20 Gy\uff0c\u6b64\u6578\u64da\u9069\u7528\u65bcHNSCC\u7684\u81e8\u5e8a\u4f7f\u7528\uff0c\u53ef\u6709\u6548\u5730\u907f\u514dxerostomia\uff0c\u800c\u816e\u817a\u7684QUANTEC\u6e96\u5247\u70ba25 Gy\u5247\u9069\u7528\u65bcNPC\u7684\u60a3\u8005\u3002", "e": "Purpose: To check the clinical normal tissue effects of quantitative analyses in the clinical (QUANTEC) guidelines by using quality of life (QoL) questionnaire dataset on the head and neck (HN) cancers, including head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) patients.Materials and Methods: Questionnaires of QoL for 95 patients with NPC and 142 with HNSCC were analysed, and the European Organization for Research and Treatment of Cancer H&N35 QoL questionnaire was performed as the endpoint assessment. Compared with pre-treatment, the degree of QoL scoring of 66-100 points were defined as moderate to severe xerostomia. We used the Lyman-Kutcher-Burman normal tissue complication probability model (NTCP) to describe the incidence of xerostomia. Negative predictive value (NPV) was used to determine the prediction accuracy of the complications.Results: The fitting parameters of NTCP were set at two time points, for 3-months and 12-month with TD50=39.8 Gy, m=0.28 and TD50= 45.2 Gy, m=0.24, respectively. We found that the parotid gland with the mean doses of less than 20 and 25 Gy in the HN and HNSCC cohorts were verified with similar results at 3 months. Besides, the analysis of the QoL datasets at 3 months showed that about ~6% and ~16% rates of xerostomia, and those at 12 months showed that about ~5% and ~14%, respectively. For patients with NPC, the data showed that about the ~0% and ~33% opportunity respectively to produce xerostomia at 3 months (NPV of approximately 67%). However, both data showed that ~0% (NPV of approximately 100%) at 12 months. There are with significant difference from the results for the HNSCC cohort.Conclusion: The QoL datasets testified the practicality of QUANTEC guidelines. We proposed amendments to the parotid gland QUANTEC 20/20 Gy spared-gland guideline for HNSCC cohort. Moreover, the QUANTEC 25 Gy guideline was applicable to the clinical use of the NPC, which can effectively avoid xerostomia."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-201-212", "title": "Surface-Enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry-mediated Identification of a Biomarker Pattern for Hepatocellular Carcinoma in Taiwanese Patients", "keywords": "\u8a3a\u65b7;\u86cb\u767d\u8cea\u9ad4\u5b78;\u86cb\u767d\u8cea\u6676\u7247;\u8868\u9762\u589e\u5f37\u96f7\u5c04\u812b\u9644\u6e38\u96e2\uff0f\u98db\u884c\u6642\u9593\u8cea\u8b5c;\u809d\u764c Diagnostics;Proteomics;Protein chip;SELDI-TOF-MS;Liver cancer", "c": "\u76ee\u7684\uff1a\u65e9\u671f\u8a3a\u65b7\u809d\u7d30\u80de\u764c\u662f\u975e\u5e38\u91cd\u8981\u7684\uff0c\u4ee5\u4f5c\u70ba\u9632\u6b62\u5176\u767c\u5c55\u6210\u6975\u5177\u7834\u58de\u6027\u8207\u9ad8\u597d\u767c\u7387\u7684\u60e1\u6027\u816b\u7624\u3002\u6240\u4ee5\uff0c\u5982\u4f55\u5728\u809d\u7d30\u80de\u764c\u767c\u5c55\u65e9\u671f\u4fbf\u80fd\u627e\u51fa\u4e00\u8a3a\u65b7\u6a19\u8a18\u4f86\u5340\u5225\u5176\u70ba\u826f\u6027\u6216\u60e1\u6027\u662f\u975e\u5e38\u6709\u5176\u5fc5\u8981\u6027\u3002\u6b64\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u4f7f\u7528SELDI-TOS-MS\u5149\u8b5c\u4f86\u5206\u6790\u53f0\u7063\u809d\u764c\u65cf\u7fa4\u8207\u975e\u809d\u764c\u5065\u5eb7\u65cf\u7fa4\u8840\u6e05\u4e2d\u4e4b\u86cb\u767d\u5716\u8b5c\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u4ee5SELDI\u6676\u7247\u7cfb\u7d71\u53bb\u5075\u6e2c\u53f0\u7063\u4eba\u809d\u764c\u7d30\u80de\u8207\u975e\u809d\u764c\u65cf\u7fa4\u4e4b\u7279\u5b9a\u8840\u6e05\u5167\u86cb\u767d\u578b\u614b\u3002\u5728\u6700\u521d\u65bc\u53f0\u7063\u962e\u7d9c\u5408\u91ab\u9662\u6536\u96c663\u4f4d\u53d7\u6aa2\u8005\u4e4b\u8840\u6e05\u3002\u70ba\u4e86\u78ba\u8a8d\u6f5b\u5728\u6709\u6548\u7528\u7684\u6a19\u8a18\uff0c\u6536\u96c6\u53e6\u4e00\u7d4463\u4f4d\u53f0\u7063\u4eba\u8840\u6e05\u6aa2\u9ad4\u505a\u70ba\u96a8\u6a5f\u6027\u55ae\u76f2\u6709\u6548\u6e2c\u8a66\u3002\u8840\u6e05\u6e2c\u8a66\u7cfb\u7d71\u4f7f\u7528Ciphergen ProteinChip\u00aeSAX2\u77e9\u9663\u7cfb\u5217\uff0c\u4e26\u5229\u7528ProteinChip Reader Model PBS II\u7cfb\u7d71\u5206\u6790\u6676\u7247\u4e0a\u86cb\u767d\u8cea\u3002\u5728\u6676\u7247\u8a08\u8b80\u5f8c\uff0c\u6240\u6709\u6b63\u5e38\u53ca\u816b\u7624\u8840\u6e05\u5716\u8b5c\u90fd\u4ee5\u751f\u7269\u6a19\u8a18\u578b\u614b\u8edf\u9ad4\u6574\u7406\u53ca\u5206\u6790\u5176\u6578\u64da\u53ca\u986f\u793a\u5f62\u614b\u3002\u7d50\u679c\uff1a\u5728\u641c\u5c0b\u5169\u7d4463\u4f4d\u6aa2\u9ad4\u4f5c\u70ba\u5c0d\u7167\u8207\u6548\u529b\u6e2c\u8a66\uff0c\u6211\u5011\u627e\u51fa\u751f\u7269\u6a19\u8a18\u5716\u8b5c\u542b\u6709\u56db\u500b\u8840\u6e05\u86cb\u767d\u6a19\u8a18\u4f4d\u7f6e\u5728m/z:4091\u30015637\u30016840\u82078567\u4e0a\u3002\u6b64\u7814\u7a76\u5efa\u7acb\u4e00\u500b\u4eba\u5de5\u7db2\u8def\u7528\u505a\u809d\u7d30\u80de\u764c\u7684\u9ad8\u7279\u7570\u6027\u8207\u654f\u611f\u5ea6\u4e4b\u5075\u6e2c\u3002\u4e5f\u5c31\u662f\u8aaa\u80fd\u9451\u5b9a\u51fa\u7684\u751f\u7269\u6a19\u8a18\u578b\u614b\uff0c \u53ef\u7528\u4f86\u5340\u5206HCC\u8207\u975eHCC\u7570\u5e38\u65cf\u7fa4\u3002\u4e26\u65bc\u9032\u4e00\u6b65\u5be6\u9a57\u986f\u793a\u51fa\uff0c\u6b64\u751f\u7269\u6a19\u8a18\u578b\u614b\u4e4b\u9748\u654f\u5ea6\u53ca\u7279\u7570\u6027\u53ef\u5404\u81ea\u9054\u523093.33%\u53ca93.93% \u6240\u4ee5\u9019\u6aa2\u9ad4\u53ef\u7528\u4f86\u5206\u6790\u53ca\u767c\u5c55\u4e00\u5340\u5206\u985e\u6027\u8a55\u5206\u7cfb\u7d71\u3002\u7d50\u8ad6\uff1a\u9019\u662f\u9996\u6b21\u4f7f\u7528SELDl-TOF-MS\u8207\u7c21\u8a55\u5206\u7cfb\u7d71\u53bb\u9451\u5b9a\u51fa\u4e00\u7279\u7570\u6027\u751f\u7269\u6a19\u8a18\u6a21\u5f0f\uff0c\u53ef\u6709\u6548\u7387\u53ca\u5176\u610f\u7fa9\u7684\u5f9e\u975e\u809d\u764c\u75c5\u4eba\u65cf\u7fa4\u4e2d\u9451\u5b9a\u51fa\u809d\u764c\u75c5\u4eba\u3002", "e": "Purpose: The early detection of hepatocellular carcinoma (HCC) is of tremendous importance to prevent this devastating and frequently reported cancer. Therefore, it is required to identify novel and specific HCC diagnostic marker(s) to distinguish HCC patients from non-HCC patients at the early stage of HCC development. We employed surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to analyze protein profiles in the serum of Taiwanese HCC and healthy, non-HCC subjects.Materials and Methods: The SELDI-Chip-System was used to determine a specific protein pattern in serum samples obtained from Taiwanese HCC and non-HCC subjects. The initial training group consisted of 63 subjects from whom serum was collected at the Yuan's General Hospital (Taiwan). To validate a potential marker pattern, a second group of 63 Taiwanese subjects was enrolled from whom serum samples were also collected, randomized, and used in a blind validation study. Serum was applied to Ciphergen ProteinChip\u00ae SAX2 Arrays and proteins bound to the chips were analyzed using the ProteinChip Reader Model PBS II. After reading the chips, all profiles of normal and tumor serum were summarized using the Biomarker pattern software to a master pattern followed by analyses using a clustering method and data mining.Results: By recruiting two groups of 63 subjects for training and validation, we identified a biomarker pattern that contained four serum protein markers with m/z of 4091, 5637, 6840, and 8567. This study allowed setting up an artificial network with high specificity and sensitivity for HCC detection. In other words, the identified biomarker pattern was used to classify serum samples of HCC and non-HCC validation group subjects. During the latter experiment, it appeared that the sensitivity and specificity of the pattern was 93.33% and 93.93%, respectively. The specimens were used to analyze and develop a classification scoring system.Conclusions: For the first time, SELDI-TOF-MS combined with a simple scoring system were employed to identify a specific biomarker pattern that allowed to efficiently and significantly distinguish Taiwanese HCC patients from non-HCC patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-213-226", "title": "Intensity-modulated Radiation Therapy in Treating Unknown Primary Head and Neck Cancer: Single Institute Experience", "keywords": "\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u816b\u7624;\u982d\u9838\u90e8\u764c\u75c7;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Unknown primary neoplasm;Head and neck cancer;Intensity modulated radiation therapy", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u7814\u7a76\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e4b\u982d\u9838\u764c\u7d93\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u7d50\u679c\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e2005\u5e74\u81f32010\u5e74\u9593\uff0c\u517114\u4f4d\u8a3a\u65b7\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e4b\u982d\u9838\u90e8\u9e9f\u72c0\u4e0a\u76ae\u764c\u4e4b\u75c5\u4eba\u8f49\u4ecb\u81f3\u672c\u79d1\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3002\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba48\u6b72\uff08\u9593\u8ddd\u70ba33 \u81f367\u6b72\uff09\u3002\u81e8\u5e8aN\u671fN1, N2a, N2b\u53caN3\u5206\u5225\u67091\uff087%\uff09, 3\uff0821%\uff09, 6\uff0843%\uff09\u53ca4\uff0829%\uff09\u4eba\u3002\u5176\u4e2d\u5341\u4e8c\u4f4d\u75c5\u4eba\uff0886%\uff09\u63a5\u53d7\u9838\u90e8\u6dcb\u5df4\u5ed3\u6e05\u8853\uff0c\u5169\u4f4d\u50c5\u63a5\u53d7\u6dcb\u5df4\u5207\u7247\u800c\u5df2\u3002\u6709\u4e94\u4f4d\u75c5\u4eba\uff0836%\uff09\u4e4b\u6dcb\u5df4\u8f49\u79fb\u5230\u4e0b\u9838\u90e8\uff0c\u53e6\u5916\u4e5d\u4f4d\uff0864%\uff09\u75c5\u4eba\u4e4b\u75c5\u7076\u50c5\u4fb7\u9650\u5728\u4e0a\u9838\u90e8\u3002\u6709\u4e94\u4f4d\u75c5\u4eba\u4e4b\u6dcb\u5df4\u7d50\u6709\u56ca\u5916\u64f4\u6563\u4e4b\u60c5\u5f62\u3002\u5728\u63a5\u53d7\u9838\u90e8\u5ed3\u6e05\u8853\u7684\u75c5\u4eba\uff0c\u5728\u5177\u6709\u56ca\u5916\u64f4\u6563\u7684\u7bc4\u5712\u7d66\u4e8866 Gy\u4e4b\u5291\u91cf\uff0c\u6c92\u6709\u56ca\u5916\u64f4\u6563\u8005\u7d66\u4e8860 Gy\u3002\u5c0d\u65bc\u50c5\u63a5\u53d7\u6dcb\u5df4\u5207\u9664\u7684\u4eba\uff0c\u539f\u75c5\u7076\u8655\u5247\u7d66\u4e8870 Gy\u7684\u5291\u91cf\u3002\u6240\u6709\u7684\u75c5\u4eba\uff0c\u5728\u54bd\u8ef8\u63a5\u53d759.4 Gy\uff0c\u800c\u672a\u88ab\u8f49\u79fb\u6dcb\u5df4\u4fb5\u72af\u7684\u4e0b\u9838\u90e8\u5247\u63a5\u53d7\u523050 Gy\u3002\u672c\u7814\u7a76\u7167\u5c04\u4e4b\u54bd\u8ef8\uff0c\u5305\u542b\u9f3b\u54bd\u3001\u53e3\u54bd\u3001\u4e0b\u54bd\u90e8\u4e0a\u65b9\u9ecf\u819c\uff0c\u907f\u958b\u4e86\u8072\u5e36\u53ca\u5176\u5f8c\u4e0b\u65b9\u4e4b\u4e0b\u54bd\u90e8\u9ecf\u819c\u3002\u7d50\u679c\uff1a\u7d93\u904e36.4\u500b\u6708\u7684\u8ffd\u8e64\uff0c\u56db\u4f4d\u75c5\u4eba\uff0821%\uff09\u6709\u9060\u7aef\u8f49\u79fb\u4e26\u4e14\u6b7b\u4ea1\uff0c\u4e09\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u9060\u7aef\u8f49\u79fb\u7121\u75c5\u5b58\u6d3b\u7387\u70ba79%\u3002\u5728\u8ffd\u8e64\u671f\u9593\u6c92\u6709\u539f\u767c\u816b\u7624\u4e4b\u51fa\u73fe\uff0c\u4ea6\u6c92\u6709\u5c40\u90e8\u5fa9\u767c\uff0c\u4e09\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba100%\u3002\u5169\u4f4d\u75c5\u4eba\u6709\u7b2c\u4e8c\u539f\u767c\u816b\u7624\u4e4b\u7522\u751f\uff0c\u4e00\u500b\u5728\u4e0a\u98df\u9053\uff0c\u4e00\u500b\u5728\u53e3\u8154\u9ecf\u819c\u3002\u5728\u4e9e\u7d44\u5206\u6790\u4e0a\uff0c\u7576\u75c5\u4eba\u70ba\u81e8\u5e8aN3\u671f\uff08p=0.036; p=0.016\uff09\u3001\u6dcb\u5df4\u8f49\u79fb\u81f3\u4e0b\u9838\u90e8\uff08p=0.001; p=0.001\uff09\u6216\u5177\u6709\u56ca\u5916\u64f4\u6563\u8005\uff08p=0.003; p=0.007\uff09\uff0c\u6709\u8f03\u4f4e\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u9060\u7aef\u8f49\u79fb\u7121\u75c5\u5b58\u6d3b\u7387\u3002\u5c0d\u65bcN2b\u6216N3\u671f\u75c5\u4eba\uff0c\u50c5\u63a5\u53d7\u6dcb\u5df4\u5207\u9664\u8005\u76f8\u8f03\u65bc\u63a5\u53d7\u6dcb\u5df4\u5ed3\u6e05\u8853\u4e4b\u60a3\u8005\uff0c\u5177\u6709\u8f03\u5dee\u7684\u6574\u9ad4\u6d3b\u7387\uff08p=0.001\uff09\u548c\u9060\u7aef\u8f49\u79fb\u7121\u75c5\u5b58\u6d3b\u7387\uff08p=0.029\uff09\u3002\u5728\u526f\u4f5c\u7528\u65b9\u9762\uff0c\u4e94\u4f4d\u75c5\u4eba\uff0836%\uff09\u6709\u7b2c\u4e09\u7d1a\u6025\u6027\u526f\u4f5c\u7528\uff0c\u5176\u4e2d\u56db\u4f4d\u662f\u53e3\u8154\u9ecf\u819c\u767c\u708e\u6216\u767d\u8840\u7403\u904e\u4f4e\uff0c\u6709\u4e00\u4f4d\u5169\u8005\u90fd\u767c\u751f\u3002\u9019\u4e9b\u75c5\u4eba\u4e2d\uff0c\u6709\u516b\u6210\u7684\u60a3\u8005\u63a5\u53d7\u4e86\u540c\u6b65\u653e\u5316\u7642\u3002\u8ffd\u8e64\u81f3\u76ee\u524d\u70ba\u6b62\uff0c\u6c92\u6709\u7b2c\u4e09\u7d1a\u4ee5\u4e0a\u4e4b\u6162\u6027\u526f\u4f5c\u7528\u7522\u751f\u3002\u7d50\u8ad6\uff1a\u5728\u6211\u5011\u7684\u7d93\u9a57\u4e2d\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e26\u4e14\u9583\u907f\u8072\u5e36\u53ca\u4e0b\u54bd\u4e0b\u534a\u90e8\u4f4d\uff0c\u4e0d\u4f46\u53ef\u4ee5\u964d\u4f4e\u526f\u4f5c\u7528\uff0c\u540c\u6642\u4e0d\u6703\u72a7\u7272\u75be\u75c5\u63a7\u5236\u7387\u3002\u662f\u4e00\u500b\u53ef\u4ee5\u88ab\u7528\u5728\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u982d\u9838\u90e8\u9e9f\u72c0\u4e0a\u76ae\u764c\u75c5\u60a3\u4e0a\u4e4b\u5b89\u5168\u53c8\u6709\u6548\u7684\u6cbb\u7642\u3002\u5c0d\u65bcN3\u671f\u3001\u4e0b\u9838\u90e8\u6dcb\u5df4\u8f49\u79fb\u4ee5\u53ca\u6dcb\u5df4\u5177\u6709\u56ca\u5916\u64f4\u6563\u4e4b\u75c5\u4eba\uff0c\u6709\u8f03\u5dee\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u9060\u7aef\u8f49\u79fb\u7121\u75c5\u5b58\u6d3b\u7387\u3002\u91dd\u5c0d\u9019\u7fa4\u75c5\u4eba\uff0c\u61c9\u767c\u5c55\u66f4\u5f37\u6548\u7684\u6cbb\u7642\u65b9\u91dd\u3002", "e": "Purpose: To retrospectively review the results of patients with metastatic squamous cell carcinoma of the head and neck (SCCHN) from an unknown primary site (UPS) treated with intensity-modulated radiation therapy (IMRT) in a single institute.Methods and Materials: Fourteen male patients with a median age of 48 (range 33 to 67) who presented with unknown primary SCCHN were treated with IMRT with or without cisplatin-based chemotherapy from 2005 to 2010. The number of patients with initial presentation of N1, N2a, N2b and N3 was, 1 (7%), 3 (21%), 6 (43%) and 4 (29%), respectively. Twelve patients (86%) received neck dissections and two had excision biopsies only. Five patients (36%) had metastatic nodes involving both upper and lower neck, where 9 (64%) had nodes limited to the upper neck only. Five (36%) patients presented with extracapsular spread (ECS). Patients undergoing neck dissection were treated with a median dose of 66 Gy to the ECS surgical bed. Those who did not undergo neck dissection were given 60 Gy. For those who had only excision biopsy, 70 Gy was prescribed to the tumor bed and suspected Iymphadenopathy. For all patients, a median dose of 59.4 Gy and 50 Gy was given to the pharyngeal mucosa and uninvolved lower neck, respectively. The irradiated pharyngeal mucosa, included the nasopharynx, oropharynx, surpaglottis and upper hypopharynx, but spared the vocal cords and lower hypopharynx.Results: After a median follow up of 36.4 months, four patients (21%) developed distant metastases and died, yielding a 3-year overall survival rate of 79%. There was no occurrence of the occult primary and no local regional recurrence noted. The control rate was 100%. Two patients had second primary tumors noted over the cervical esophagus and the buccal mucosa. In subgroup analysis, patients with clinical N3 stage, with nodal involvement over the lower neck region and nodes possessing ECS had significantly poorer overall survival and poor distant metastases-free survival rates. In patients with cN2 or cN3 disease, those receiving excision biopsy had a poor overall survival (p=0.001) and distant metastases-free survival (p=0.029) compared to those undergoing neck dissection. There was no grade III chronic toxicity during follow-up.Conclusions: In our experience, IMRT with vocal cords and lower hypopharyngeal sparing can achieve excellent functional outcomes without compromising disease control and may be adopted as a safe and effective treatment for SCCHN of UPS Patients with clinical N3 stage, lower neck involvement and nodes with ECS have significantly poorer overall survival and distant metastases-free survival rates. More intense regimens should be developed for such patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-227-236", "title": "Cyberknife Robotic Radiosurgery for Limited Liver Metastates in Three Fractionation", "keywords": "\u96fb\u8166\u5200;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642;\u809d\u8f49\u79fb Cyberknife;Stereotactic radiosurgery;Liver metastases", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u5f15\u7528\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4ee560 Gy\u5206\u4e09\u5206\u6b21\u6cbb\u7642\u4fb7\u9650\u6027\u809d\u816b\u7624\u8f49\u79fb\u7684\u53ef\u884c\u6027\u8207\u6548\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u6eaf\u6536\u96c62009\u81f32011\u5e74\u3002\u5171\u67097\u4f4d\u7121\u6cd5\u958b\u5200\u5207\u9664\uff0c\u4fb7\u9650\u809d\u8f49\u79fb\u75c5\u60a3\u65bc\u5947\u7f8e\u91ab\u5b78\u4e2d\u5fc3\u653e\u5c04\u7dda\u7624\u90e8\u63a5\u53d7\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u8ffd\u8e64\u6642\u9593\u7bc4\u570d\u5f9e5\uff5e25\u500b\u6708\uff08\u4e2d\u4f4d\u6578\u70ba17\u500b\u6708\uff09\u30024\u4f4d\u75c5\u60a3\u70ba\u55ae\u9846\u816b\u7624\uff0c\u53e63\u4f4d\u70ba\u591a\u9846\u816b\u7624\uff08\u5c11\u65bc3\u9846\uff09\u3002\u6700\u5927\u816b\u7624\u76f4\u5f91\u70ba1.5\uff5e5 cm\uff0c\u539f\u767c\u816b\u7624\u90e8\u4f4d\u70ba\u76f4\u8178\u764c\uff082\uff09\u3001\u80ba\u764c\uff082\uff09\u3001\u80f0\u81df\u764c\uff081\uff09\u3001\u814e\u81df\u764c\uff081\uff09\u3001\u8180\u80f1\u764c\uff081\uff09\u3002\u5e74\u9f61\u7bc4\u570d\u5f9e60\uff5e80\u6b72\u3002\u75c5\u60a3\u63a5\u53d7\u4ee5\u9694\u65e5\u4e09\u5206\u6b21\u7e3d\u5291\u91cf\u70ba60 Gy\u7684\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u8655\u65b9\u5291\u91cf\u70ba75\uff5e80%\u7684\u7b49\u5291\u91cf\u66f2\u7dda\u3002\u7d50\u679c\uff1a\u6cbb\u7642\u5b8c\u75623\u500b\u6708\u5f8c\u4ee5\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u6383\u63cf\u6aa2\u67e5\u986f\u793a3\u4f8b\u75c5\u60a3\u53d6\u5f97\u4e86\u5b8c\u6574\u7de9\u89e3\u30024\u4f8b\u75c5\u60a3\u53d6\u5f97\u4e86\u90e8\u5206\u7de9\u89e3\uff0c6\u500b\u6708\u5f8c\u518d\u4ee5\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u6383\u63cf\u6aa2\u67e5\uff0c\u986f\u793a6\u4f8b\u75c5\u60a3\u5df2\u53d6\u5f97\u4e86\u5b8c\u6574\u7de9\u89e3\u3002\u6cbb\u7642\u4e26\u7121\u56b4\u91cd\u526f\u4f5c\u7528\u7522\u751f\uff0c\u50c5\u67091\u4f8b\u986f\u793a\u4e00\u7d1a\u6025\u6027\u809d\u708e\u8207\u8178\u80c3\u708e\u30021\u5e74\u5b58\u6d3b\u7387\u70ba71.4%\uff0c2\u5e74\u5b58\u6d3b\u7387\u70ba42.8%\u3002\u5b58\u6d3b\u7387\u7bc4\u570d\u70ba6\uff5e25\u500b\u6708\uff08\u4e2d\u4f4d\u657817\u500b\u6708\uff09[95% CI 6.75\uff5e27.26]\uff0c\u7121\u9032\u5c55\u751f\u5b58\u7387\u7bc4\u570d\u70ba5\uff5e25\u500b\u6708\uff08\u4e2d\u4f4d\u65789\u500b\u6708\uff09[95% CI 1.3- 16.7]\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u4ee560 Gy\u5206\u4e09\u5206\u6b21\u6cbb\u7642\u65bc\u7121\u6cd5\u958b\u5200\u5207\u9664\uff0c\u4fb7\u9650\u809d\u8f49\u79fb\u662f\u53ef\u884c\u8207\u6709\u6548\u7684\u3002\u6cbb\u7642\u53ef\u4ee5\u5be6\u73fe\u826f\u597d\u7684\u5c40\u90e8\u5340\u57df\u63a7\u5236\u53ca\u7121\u56b4\u91cd\u526f\u4f5c\u7528\u3002\u96d6\u7136\u6211\u5011\u7684\u6578\u64da\u5efa\u7acb\u9019\u7a2e\u6cbb\u7642\u65b9\u6cd5\u7684\u5b89\u5168\u6027\uff0c\u4f46\u9700\u8981\u66f4\u56b4\u683c\u7684\u81e8\u5e8a\u7814\u7a76\uff0c \u4ee5\u5145\u5206\u8a55\u4f30\u9577\u671f\u7642\u6548\u548c\u53ef\u80fd\u7522\u751f\u7684\u526f\u4f5c\u7528\u3002", "e": "Purpose: To determine the feasibility and efficacy of 60 Gy/3 fractions with Cyberknife image-guided robotic stereotactic radiosurgery for limited liver metastases.Materials and Method: Between 2009 to 2011, a total of 7 patients with inoperable, limited numbers of liver metastases underwent Cyberknife image-guided robotic stereotactic radiosurgery at our center. Follow-up time ranged from 5-25 months (median: 17 mo.). Four patients had a solitary lesion and 3 had small multiple lesions (Iess than 3 nodules), the maximum tumor diameter ranged from 1.5 cm. to 5 cm. Primary tumor sites were rectal cancer (n=2), lung Cancer (n=2), pancreatic cancer (n=1), renal cell cancer (n=1), bladder cancer (n=1). The ages ranged from 60-87 years old. The patients were treated with 60 Gy delivered in 3 fractions given every other day. Isodose value range from 75-80% of the prescribed dose.Results: A follow-up CT-scan of the abdomen done 3 months after Cyberknife image-guided robotic stereotactic radiosurgery showed complete response was attained in 3 patients and partial response in 4 patients. Six months after the treatment all patients achieved a complete tumor response. Only 1 patient shown grade 1 acute liver and gastrointestinal toxicity. No severe complication was attributed to the therapy. The l-and 2-year overall survival rate was 71.4% and 42.8%, respectively. Median survival was 17 months (6-26 months) [95% CI 6.75-27.26], and median progression-free survival was 9 months (5-26 months) [95% CI 1.3-16.7].Conclusion: Cyberknife image-guided robotic stereotactic radiosurgery in 60 Gy/3 fractions for limited liver metastases is feasible and effective. Excellent local control can be achieved with minimal toxicity. While our data established the safety of this treatment, more rigorous clinical studies are needed to fully evaluate long term efficacy and toxicity results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-237-245", "title": "Henschke\u8fd1\u63a5\u6cbb\u7642\u88dd\u7642\u7ba1\u65bc\u5546\u7528\u6cbb\u7642\u8a08\u756b\u8207\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u9593\u7684\u5291\u91cf\u5206\u5e03\u6bd4\u8f03", "keywords": "\u8499\u5730\u5361\u7f85;\u8fd1\u63a5\u6cbb\u7642 Monte Carlo;Henschke applicator", "c": "\u76ee\u7684\uff1aHenschke\u88dd\u7642\u7ba1\u65bc\u8fd1\u63a5\u6cbb\u7642\u9020\u6210\u7684\u5291\u91cf\u64fe\u52d5\uff0c\u5728\u6700\u8fd1\u5e7e\u5e74\u5167\u53d7\u5230\u95dc\u6ce8\uff0c\u70ba\u4e86\u77ad\u89e3\u5291\u91cf\u8a08\u7b97\u6642\u6709\u7121\u542b\u91d1\u5c6c\u906e\u853d\u7269\uff0c\u5c0d\u65bc\u5291\u91cf\u5f71\u97ff\u7a0b\u5ea6\uff0c\u672c\u7814\u7a76\u5c07\u91dd\u5c0d\u65bcIr-192\u5c04\u6e90\u65bc\u6c34\u5047\u9ad4\u4e2d\u7684\u5291\u91cf\u5206\u5e03\uff0c\u6bd4\u8f03\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u53ca\u5546\u7528\u6cbb\u7642\u8a08\u91cf\u7a0b\u5f0f\u5291\u91cf\u5206\u5e03\u7d50\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1aHenschke\u88dd\u7642\u7ba1\u5305\u542b\u5169\u500b\u534a\u7403\u9ad4\u53ca\u4e00\u6839\u5782\u76f4\u7684\u7ba1\u5b50\uff0c\u5728\u6b64\u7814\u7a76\u4e2d\u53ef\uff0cIr-192\u5c04\u6e90\u5c07\u88ab\u5c0e\u5165Henschke\u88dd\u7642\u7ba1\u7684\u4e09\u500b\u901a\u9053\u4e2d\u3002\u5176\u4e2d\u5169\u500b\u505c\u7559\u9ede\u5206\u5225\u4f4d\u65bc\u5169\u500b\u534a\u7403\u9ad4\u5404\u81ea\u7684\u4e2d\u5fc3\uff0c\u7b2c\u4e09\u500b\u505c\u7559\u9ede\u4f4d\u65bc\u6b64\u5169\u500b\u534a\u7403\u9ad4\u4e2d\u5fc3\u9ede\u7684\u4e2d\u9593\uff0c\u6b64\u9ede\u70ba\u8fd1\u63a5\u6cbb\u7642\u8a08\u756b\u53ca\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u7684\u5ea7\u6a19\u4e2d\u5fc3\u4f4d\u7f6e\u3002\u53d6\u5169\u500b\u534a\u7403\u9ad4\u5f80\u5916\u5ef6\u4f380.5\u516c\u5206\u7684\u908a\u754c\u4e0a\u516d\u500b\u9ede\u7684\u5e73\u5747\u5291\u91cf\uff0c\u4f5c\u70ba\u6b78\u4e00\u5316\u7684\u5291\u91cf\u9ede\u3002\u672c\u7814\u7a76\u4f7f\u7528\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u4f5c\u70ba\u5291\u91cf\u5206\u5e03\u7684\u6a21\u64ec\uff0c\u800c\u6b64\u6f14\u7b97\u6cd5\u4ee5\u7db2\u72c0\u7d00\u9304\u9762\uff08mesh tally\uff09\u4f86\u57f7\u884c\u5291\u91cf\u7d50\u679c\u7684\u8f38\u51fa\u8cc7\u6599\u3002\u70ba\u78ba\u4fdd\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u53c3\u6578\u8a2d\u5b9a\u4e4b\u6b63\u78ba\u6027\uff0c\u4e8b\u5148\u5df1\u8207\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5b78\u6703\u7b2c43\u5de5\u4f5c\u5c0f\u7d44\uff08TG-43\uff09\u6240\u516c\u4f48\u7684\u53c3\u6578\u505a\u6bd4\u5c0d\u3002\u7d50\u679c\uff1a\u5728\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u548c\u8fd1\u63a5\u6cbb\u7642\u8a08\u756b\u7684\u5291\u91cf\u5716\u4e2d\u53ef\u4ee5\u660e\u986f\u7684\u89c0\u5bdf\u5230\uff0c\u6709\u7121Henschke\u88dd\u7642\u7ba1\u7684\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u5e03\u7684\u5dee\u7570\uff0c\u7d93\u6b64\u7b49\u5291\u91cf\u66f2\u7dda\u7684\u6bd4\u8f03\u53ef\u4ee5\u77e5\u9053Henschke\u88dd\u7642\u7ba1\u660e\u986f\u9020\u6210\u5291\u91cf\u66f2\u7dda\u5206\u5e03\u7684\u4e0d\u540c\uff0c\u82e5Henschke\u88dd\u7642\u7ba1\u88ab\u7d0d\u5165\u5291\u91cf\u8a08\u7b97\u7684\u8003\u91cf\u6642\uff0c\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u66f2\u7dda\u7531Z\u65b9\u54111.5\u516c\u5206\u5f80\u5ea7\u6a19\u539f\u9ede\u9000\u81f31\u516c\u5206\u8655\u70ba\u8499\u5730\u5361\u7f85\u7b49\u5291\u91cf\u66f2\u7dda300 cGy\u3002\u7d50\u8ad6\uff1aHenschke\u88dd\u7642\u7ba1\u9020\u6210\u7684\u5291\u91cf\u64fe\u52d5\u662f\u6709\u610f\u7fa9\u7684\uff0c\u4f46\u6b64\u64fe\u52d5\u53ea\u80fd\u4ee5\u8499\u5730\u5361\u7f85\u6f14\u7b97\u6cd5\u7684\u5291\u91cf\u5716\u8868\u793a\uff0c\u800c\u8fd1\u63a5\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5291\u91cf\u5716\u7121\u6cd5\u5448\u73fe\u88dd\u7642\u7ba1\u9020\u6210\u7684\u5291\u91cf\u64fe\u52d5\u3002", "e": "Introduction: In recent years, the dose perturbation caused by the Henschke applicator is a major concern in brachytherapy planning system (BPS). To investigate impact of the dose where there is a lack of metal shielding, Monte Carlo simulations, and BPS calculations have been performed for dose assessments in a Plastic Water\u00ae phantom.Material and Methods : A Henschke applicator consists of one tandem and two ovoids. In this study, an 192 Ir source would be driven into all three channels of a Henschke applicator, at the middle of each ovoid, and at the center of two ovoids. For BPS, the origin of the coordinates was set at the middle of two ovoids, as was the Monte Carlo simulation. The dose normalization point was the average dose at six arbitrary points extended to the surface of the ovoids by 5 mm. Monte Carlo N-Particle Transport Code MCNP (X-5 Monte Carlo Team) was used in this study to simulate the dose distribution and output simulation data was recorded by mesh tally. The Monte Carlo set-up parameters had been validated by TG-43 data in a previous report.Results: The isodose distribution with Henschke applicator and without Henschke applicator showed tremendous deviation between Monte Carlo simulation and BPS calculation. This indicated that a Henschke applicator affected the isodose distribution significantly. Compared to the prescription dose area, the simulation isodose curves had a shrinkage of about 0.5 cm, when the metal applicator was considered.Conclusions: The Henschke applicator affected the dose distribution significantly and this could be observed in Monte Carlo simulation, but not in BPS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-247-254", "title": "Adjuvant Radiotherapy for Malignant Solitary Fibrous Tumor of the Pleura-A Case Report", "keywords": "\u60e1\u6027\u55ae\u767c\u6027\u7e96\u7dad\u7624;\u8f14\u52a9\u653e\u5c04\u6cbb\u7642 Malignant solitary fibrous tumor;Adjuvant radiotherapy", "c": "\u55ae\u767c\u6027\u7e96\u7dad\u7624\u4e26\u975e\u5e38\u898b\u80f8\u8154\u816b\u7624\uff0c\u624b\u8853\u5207\u9664\u662f\u76ee\u524d\u7684\u6cbb\u7652\u6027\u6cbb\u7642\u4ee5\u53ca\u63d0\u4f9b\u75c5\u7406\u8a3a\u65b7\uff0c\u56e0\u70ba\u75c5\u4f8b\u6578\u5c11\uff0c\u96e3\u4ee5\u754c\u5b9a\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u7684\u89d2\u8272\u3002\u7136\u800c\u60e1\u6027\u55ae\u767c\u6027\u7e96\u7dad\u7624\u6613\u5fa9\u767c\u4e14\u7652\u5f8c\u8f03\u5dee\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f4d\u60e1\u6027\u55ae\u767c\u6027\u7e96\u7dad\u7624\u75c5\u4eba\uff0c\u5728\u5927\u90e8\u5206\u816b\u7624\u5207\u9664\u5f8c\uff0c \u63a5\u53d7\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u6709\u8d85\u8d8a\u5169\u5e74\u672a\u5fa9\u767c\u4e4b\u7652\u5f8c\u3002\u8f14\u52a9\u653e\u5c04\u6cbb\u7642\u53ef\u63d0\u4f9b\u975e\u5b8c\u6574\u6027\u5207\u9664\u4e4b\u60e1\u6027\u55ae\u767c\u6027\u7e96\u7dad\u7624\u75c5\u60a3\u6cbb\u7642\u9078\u64c7\u3002", "e": "Solitary fibrous tumor of the pleura (SFTP) is an uncommon neoplasm. Surgery is the only curative therapy and provides a definitive diagnosis. Among these patients, malignant SFTP was reported having high recurrent rate and poor prognosis. Because of the rare incidence, the role of radiotherapy (RT) in the management of the disease has not been well defined. We reported a 50-year-old woman with malignant SFTP in the right thorax, which has been living free of disease for more than 2 years after surgery with microscopic residual disease and adjuvant RT. Adjuvant RT could be an option of treatment for microscopically residual disease of malignant SFTP following major surgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201209-201301160032-201301160032-255-261", "title": "Brainstem Cavernoma Treated with Cone-based Stereotactic Radiosurgery", "keywords": "\u8166\u5e79\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u5713\u9310\u5f62\u6e96\u76f4\u5100\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853 Brainstem cavernoma;Stereotactic radiosurgery (SRS);Cone-Based stereotactic radiosurgery", "c": "\u8166\u5e79\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u7684\u6cbb\u7642\u5305\u62ec\u795e\u7d93\u5916\u79d1\u624b\u8853\u548c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u6211\u5011\u5831\u544a\u5169\u4f4d\u8166\u5e79\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u7684\u6848\u4f8b\u63a5\u53d7\u5713\u9310\u5f62\u6e96\u76f4\u5100\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u6848\u4f8b\u4e00\uff1a\u4e00\u4f4d44\u6b72\u5973\u6027\u75c5\u60a3\uff0c\u8166\u5e79\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u5408\u4f75\u53f3\u5074\u6a4b\u8166\u51fa\u8840\u3002\u65bc\u767c\u75c5\u5f8c\u5e7e\u500b\u6708\uff0c\u5979\u9010\u6f38\u6062\u5fa9\u4e86\u795e\u7d93\u529f\u80fd\u3002\u8166\u90e8\u78c1\u632f\u5f71\u50cf\u767c\u73fe\u5de6\u5074\u6a4b\u8166\u53e6\u4e00\u500b\u589e\u751f\u7684\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u3002\u75c5\u60a3\u63a5\u53d7\u76f4\u7dda\u52a0\u901f\u5668\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\uff0c\u8655\u65b9\u5291\u5ba4\u70ba14 Gy\uff0c\u5206\u5169\u6b21\u6cbb\u7642\u3002\u65bc\u63a5\u53d7\u653e\u5c04\u624b\u8853\u5f8c\uff0c\u6c92\u6709\u767c\u73fe\u65b0\u7684\u795e\u7d93\u529f\u80fd\u7f3a\u640d\u3002\u65bc\u8ffd\u8e64\u7684\u8166\u90e8\u78c1\u632f\u5f71\u50cf\u767c\u73fe\uff0c\u5de6\u5074\u6a4b\u8166\u7684\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u9010\u6f38\u7e2e\u5c0f\uff0c\u6c92\u6709\u653e\u5c04\u6cbb\u7642\u76f8\u95dc\u4e4b\u8166\u6c34\u816b\u767c\u751f\u3002\u6848\u4f8b\u4e8c\uff1a\u4e00\u4f4d43\u6b72\u7684\u7537\u6027\u75c5\u60a3\uff0c\u904e\u53bb\u75c5\u53f2\u6709\u5de6\u5074\u773c\u7736\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\uff0c\u65bc1997\u5e74\u63a5\u53d7\u904e\u5916\u79d1\u624b\u8853\u53ca\u653e\u5c04\u6cbb\u7642\u3002\u65bc\u8ffd\u8e64\u6642\u767c\u73fe\u5728\u5074\u7b2c\u56db\u8166\u5ba4\u5c4b\u9802\u74b0\u6c60\u6709\u4e00\u500b0.7\u3000cm\u7684\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u3002\u75c5\u60a3\u63a5\u53d7\u76f4\u7dda\u52a0\u901f\u5668\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\uff0c\u8655\u65b9\u5291\u91cf\u70ba18 Gy\uff0c\u5206\u5169\u6b21\u6cbb\u7642\u3002\u65bc\u8ffd\u8e64\u7684\u8166\u90e8\u78c1\u632f\u5f71\u50cf\u767c\u73fe\uff0c\u6d77\u7dbf\u72c0\u8840\u7ba1\u7624\u8868\u73fe\u51fa\u826f\u597d\u7684\u6cbb\u7642\u53cd\u61c9\u3002", "e": "The treatment of brainstem cavernoma includes neurosurgery and stereotactic radiosurgery (SRS). We reported two cases with brainstem cavernoma treated with linear accelerator (LlNAC) cone-based stereotactic radiosurgery.CASE 1: A 44 year-old female patient survived from brainstem cavernoma with bleeding into right pons. She recovered her neurological function gradually in months. Another growing cavernoma at left pons was noted by magnetic resonance imaging (MRI) of brain. It was treated with cone-based stereotactic radiosurgery. The prescribed radiation dose was 14 Gy in two fractions. No new neurological deficit was noted after radiosurgery. On the regular follow-up of brain MRI, the cavernoma over left pons remitted gradually, and no cerebral edema related to radiosurgery was observed.CASE 2: A 43 year-old male patient with history of left orbital cavernoma status post operation and radiation therapy in 1997 had a 0.7 cm cavernoma at left ambient cistern of the 4th ventricle roof. Cone-based stereotactic radiosurgery was performed. The prescribed radiation dose was 18 Gy in two fractions. On the regular follow-up brain MRI the cavernoma demonstrated very good treatment response."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-81-91", "title": "Evaluation of Lung Volume/Dose in Breast Cancer Irradiation after Modified Radical Mastectomy versus Breast Conservative Surgery", "keywords": "\u4e73\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u80ba\u90e8\u9ad4\u7a4d\uff0f\u5291\u91cf Breast cancer;Radiotherapy;Lung volume/dose", "c": "\u76ee\u7684\uff1a\u6b64\u7bc7\u7814\u7a76\u76ee\u7684\u70ba\u6bd4\u8f03\u6839\u9664\u6027\u5168\u4e73\u5207\u9664\u8207\u4e73\u623f\u4fdd\u5b58\u624b\u8853\u5f8c\u4e73\u764c\u75c5\u60a3\u3001\u63a5\u53d7\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u4e4b\u80ba\u90e8\u63a5\u53d7\u9ad4\u7a4d\uff0f\u5291\u91cf\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2009\u5e747\u6708\u81f32010\u5e7410\u6708\uff0c\u6211\u5011\u6536\u96c6\u4e86116\u4f4d\u8f49\u4ecb\u81f3\u672c\u79d1\u63a5\u53d7\u8f14\u52a9\u6027\u653e\u5c04\u3001\u6cbb\u7642\u7684\u4e73\u764c\u75c5\u614b\u3002\u5176\u4e2d77\u4f4d\u63a5\u53d7\u4e73\u623f\u4fdd\u5b58\u624b\u8853\uff0c39\u4f4d\u63a5\u53d7\u6839\u9664\u6027\u5168\u4e73\u5207\u9664\u3002\u6211\u5011\u4f7f\u7528\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u53bb\u8a55\u4f30\u5728\u4e0d\u540c\u5291\u91cf\u4e0b\u80ba\u90e8\u6240\u63a5\u53d7\u5230\u7684\u9ad4\u7a4d\uff0c\u4e26\u767c\u89ba\u662f\u5426\u6703\u53d7\u624b\u8853\u65b9\u6cd5\u6216\u5176\u4ed6\u56e0\u7d20\u6240\u5f71\u97ff\u3002\u6211\u5011\u5206\u5225\u4f7f\u7528two sample t-test and one-way analysis of variance\u53bb\u57f7\u884c\u55ae\u8b8a\u9805\u8207\u591a\u8b8a\u9805\u7d71\u8a08\u5206\u6790\u3002\u7d50\u679c\uff1a\u55ae\u8b8a\u9805\u7d71\u8a08\u5206\u6790\u986f\u793a\u63a5\u53d7\u4e73\u623f\u4fdd\u5b58\u624b\u8853\u3001\u65e9\u671f\u816b\u7624\u3001\u6216\u6cbb\u7642\u7167\u91ce\u672a\u5305\u62ec\u4e0a\u9396\u9aa8\u5340\u57df\u7684\u75c5\u60a3\u6709\u7d71\u8a08\u5b78\u4e0a\u986f\u8457\u6027\u7684\u8f03\u4f4e\u4e4b\u5e73\u5747\u767e\u5206\u6bd4\u80ba\u90e8\u7167\u5c04\u9ad4\u7a4d\uff0c\u800c\u75c5\u7076\u5074\u5c0d\u5728\u8f03\u9ad8\u5291\u91cf\u4e0b\u7684\u5e73\u5747\u767e\u5206\u6bd4\u80ba\u90e8\u7167\u5c04\u9ad4\u7a4d\u4f3c\u6709\u5f71\u97ff\u3002\u9032\u4e00\u6b65\u591a\u8b8a\u9805\u7d71\u8a08\u5206\u6790\u5247\u986f\u793a\u816b\u7624\u671f\u6578\u4e0d\u518d\u662f\u660e\u986f\u56e0\u5b50\uff0c\u800c\u75c5\u7076\u5074\u8207\u4e0a\u9396\u9aa8\u5340\u57df\u7167\u91ce\u5c0d\u65bc\u5404\u5291\u91cf\u4e0b\u7684\u80ba\u90e8\u9ad4\u7a4d\u662f\u6709\u610f\u7fa9\u7684\u9810\u6e2c\u56e0\u5b50\u3002\u624b\u8853\u65b9\u6cd5\u5c0d\u65bc\u8f03\u9ad8\u5291\u91cf\u4e0b\u7684\u80ba\u90e8\u7167\u5c04\u9ad4\u7a4d\u6709\u5f71\u97ff\u3002\u7d50\u8ad6\uff1a\u6b64\u7bc7\u7814\u7a76\u986f\u793a\u7576\u7d66\u8207\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u63a5\u53d7\u4e73\u623f\u4fdd\u5b58\u624b\u8853\u4e4b\u4e73\u764c\u75c5\u60a3\u6bd4\u5168\u4e73\u5207\u9664\u4e4b\u75c5\u614b\u3001\u53ef\u4ee5\u5f97\u5230\u8f03\u4f4e\u7684\u80ba\u90e8\u7167\u5c04\u5291\u91cf\uff0f\u9ad4\u7a4d\u3002", "e": "Purpose: The aim of this study is to compare irradiated lung volume/dose for breast cancer patients receiving adjuvant radiotherapy after modified radical mastectomy or breast conservative surgery.Materials & Method: Between July 2009 and October 2010, we collected 116 breast cancer patients who were referred to our department for adjuvant radiotherapy. Seventy-seven received breast conservative surgery and 39 received modified radical mastectomy. We used a treatment planning system to estimate the irradiated lung volume at different dose levels and to discover if different surgical methods or any other factors affected irradiated volume. For statistics, we used two sample t-test and one-way analysis of variance to perform the univariate and multivariate analyses, respectively.Results: The results from the univariate analysis showed that patients receiving breast conservative surgery, with earlier stage, or without suprac1avicular coverage had a significantly lower mean percentage of irradiated lung volume compared to patients receiving modified radical mastectomy, with advanced stage, or with supraclavicular coverage. Left side lesion was a borderline factor in predicting the higher mean percentages of lung volumes at higher dose levels. In the multivariate analysis; however, the stage was not a significant factor. On the other hand, lesion side and supraclavicular coverage were statistically significant factors for lung volumes, and surgical methods affected lung volumes at the higher doses.Conclusion: Patients with breast conservative surgery appear to have a lower irradiated lung volume/dose compared to patients with modified radical mastectomy when post-operative adjuvant radiation is indicated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-93-104", "title": "Clinical Characteristics, Image Findings, and Treatment Modalities Associate with Outcomes of Patients with Glioblastoma Multiforme", "keywords": "\u591a\u5f62\u6027\u795e\u7d93\u81a0\u82bd\u7d30\u80de\u7624;\u9810\u5f8c;\u6cbb\u7642\u7d50\u679c;\u53f0\u7063 Glioblastoma multilorme;Prognosis;Treatment outcome;Taiwan", "c": "\u76ee\u7684\uff1a\u5728\u6b64\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u8a55\u4f30\u81e8\u5e8a\u8868\u73fe\u3001\u5f71\u50cf\u7279\u5fb5\u53ca\u6cbb\u7642\u65b9\u5f0f\u662f\u5426\u5f71\u97ff\u591a\u5f62\u6027\u795e\u7d93\u81a0\u82bd\u7d30\u80de\u7624\u75c5\u4eba\u7684\u81e8\u5e8a\u9810\u5f8c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2001\u5e743\u6708\u81f32008\u5e7410\u6708\uff0c\u6211\u5011\u8a55\u4f30114\u4f4d\u5728\u55ae\u4e00\u91ab\u9662\u7d93\u7d44\u7e54\u5b78\u8a3a\u65b7\u70ba\u591a\u5f62\u6027\u795e\u7d93\u81a0\u82bd\u7d30\u80de\u7624\u7684\u75c5\u4eba\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u63a5\u53d7\u816b\u7624\u5168\u5207\u9664\u6216\u5c40\u90e8\u5207\u9664\u3002\u591a\u6578\u75c5\u4eba\u5247\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u6216\u4f75\u7528temozolomide\u3002\u75c5\u4eba\u4e4b\u81e8\u5e8a\u8868\u73fe\u3001\u5f71\u50cf\u7279\u5fb5\u3001\u6cbb\u7642\u65b9\u5f0f\u8207\u6574\u9ad4\u5b58\u6d3b\uff08overall survival, OS\uff09\u90fd\u88ab\u6aa2\u8996\u8207\u5206\u6790\u3002\u7d50\u679c\uff1a\u517135\u4f4d\u75c5\u4eba\u63a5\u53d7\u816b\u7624\u5168\u5207\u9664\u6216\u5c40\u90e8\u5207\u9664\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4f75\u540c\u6b65\u53ca\u8f14\u52a9\u85e5\u7269temozolomide\uff0c55\u4f4d\u75c5\u4eba\u63a5\u53d7\u816b\u7624\u5207\u9664\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u800c24\u4f4d\u75c5\u4eba\u50c5\u63a5\u53d7\u816b\u7624\u5207\u9664\u3002\u5728\u5e73\u5747\u4e2d\u4f4d\u6578\u8ffd\u8e64\u6642\u959340.6\u500b\u6708\u5f8c\uff08\u7bc4\u570d\u5f9e0.3\u81f361.8\u500b\u6708\uff09\uff0c\u75c5\u4eba\u7684\u4e2d\u4f4d\u6578\u6574\u9ad4\u5b58\u6d3b\u6642\u9593\u70ba12.5\u500b\u6708\uff0c\u800cl\u5e74\u53ca2\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5247\u5206\u5225\u70ba50%\u820717.5%\u3002\u63a5\u53d7\u624b\u8853\u5207\u9664\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4f75temozolomide\u4f7f\u7528\u7684\u75c5\u4eba\uff0c\u6bd4\u8d77\u63a5\u53d7\u816b\u7624\u5207\u9664\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u6709\u8f03\u597d\u7684\u4e2d\u4f4d\u6578\u6574\u9ad4\u5b58\u6d3b\u6642\u9593\uff08\u5206\u5225\u70ba19.4\u53ca10.1\u500b\u6708\uff0cp = 0.01\uff09\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\uff0cKarnofsky\u6c0f\u9ad4\u80fd\u8868\u73fe\u72c0\u614b\u4e0d\u4f73\u8005\uff08Kamofsky performance status, KPS\uff09\uff08\u2264 70\uff0cp = 0.036\uff09\u3001\u591a\u91cd\u795e\u7d93\u5b78\u969c\u7919\uff08p = 0.044\uff09\u3001\u8166\u90e8\u591a\u767c\u75c5\u7076\u6216\u80fc\u80dd\u9ad4\u4fb5\u72af\uff08p = 0.003\uff09\u3001\u816b\u7624\u5c40\u90e8\u5207\u9664\uff08p = 0.001\uff09\uff0c\u672a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff08p\uff1c0.001\uff09\u6216\u672a\u4f7f\u7528temozolomide\uff08p = 0.001\uff09\u70ba\u9810\u6e2c\u75c5\u4eba\u6574\u9ad4\u5b58\u6d3b\u4e0d\u826f\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002\u5728\u591a\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u591a\u91cd\u795e\u7d93\u5b78\u969c\u7919\uff08p = 0.008\uff09\u3001\u8166\u90e8\u591a\u767c\u75c5\u7076\u6216\u80fc\u80dd\u9ad4\u4fb5\u72af\uff08p = 0.007\uff09\u3001\u816b\u7624\u5c40\u90e8\u5207\u9664\uff08p = 0.005\uff09\uff0c\u672a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff08p\uff1c0 .001\uff09\u6216\u672a\u4f7f\u7528temozolomide\uff08p = 0.007\uff09\u4ecd\u70ba\u9810\u6e2c\u75c5\u4eba\u6574\u9ad4\u5b58\u6d3b\u4e0d\u826f\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7814\u7a76\u7d50\u679c\u986f\u793a\uff1a\u591a\u91cd\u795e\u7d93\u5b78\u969c\u7919\u3001\u5f71\u50cf\u7279\u5fb5\uff0c\u5c24\u5176\u662f\u8166\u90e8\u591a\u767c\u75c5\u7076\u6216\u80fc\u80dd\u9ad4\u4fb5\u72af\u4ee5\u53ca\u975e\u6574\u5408\u6027\u6cbb\u7642\u70ba\u9810\u6e2c\u6574\u9ad4\u5b58\u6d3b\u4e0d\u826f\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose: In this study, we evaluated the clinical outcomes of glioblastoma multilorme (GBM) patients with their prognostic factors.Materials and Method: From March 2001 through October 2008, we evaluated 114 consecutive patients with histologically confirmed GBM in a single institution. Most patients received tumor resection followed by radiotherapy (RT) with or without temozolomide use, while some received tumor resection alone. Clinical characteristics, image findings, treatment modalities, and overall survival (OS) of these patients were reviewed and analyzed.Results: Thirty-live patients were treated with total or subtotal tumor resection followed by RT with concurrent and adjuvant temozolomide, 55 treated with tumor resection and adjuvant RT, and 24 treated with resection alone. At a median follow-up time of 40.6 months (ranging from 0.3 to 61 .8 months), the median OS for all the patients was 12.5 months, and the one-year and two-year OS rates were 50% and 17.5%, respectively. Patients receiving combined tumor resection with RT and temozolomide had a better median OS than those without temozolomide used (19.4 vs. 10.1 months, p = 0.01). In univariate analysis, poor Karnofsky performance status (KPS) (\u2264 70, P = 0.036), multiple neurologic deficits (p = 0.044), multiple brain lesions or corpus callosum invasion (p = 0.003) , subtotal resection (p = 0.001) , no RT (p \uff1c 0.001) , and no temozolomide (p = 0.001) were significant prognostic factors for predicting poor OS of these patients. In multivariate analysis, multiple neurologic deficits (p = 0.008), multiple brain lesions or corpus callosum invasion (p = 0.007), subtotal resection (p = 0.005), no RT (p \uff1c 0.001), and no temozolomide (p = 0.007) remained independent worse prognostic factors for OS 01 these patients.Conclusion: Our results indicated that multiple neurologic deficits, image findings of corpus callosum invasion or multiple brain lesions, and single modality treatment were important factors for predicting poor prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-105-117", "title": "Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma", "keywords": "\u809d\u764c;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642;\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642 HCC;Stereotactic body radiotherapy;Three-Dimensional conlormal radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u662f\u91dd\u5c0d\u809d\u764c\u75c5\u60a3\u6bd4\u8f03\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u53ca\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u5b58\u6d3b\u7387\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a41\u4f4d\u7121\u6cd5\u5207\u9664\u6216\u5fa9\u767c\u7684\u809d\u764c\u75c5\u4eba\u5206\u7d44\u70ba20\u4f4d\u75c5\u4eba\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff1b\u53e6\u4e00\u7d4421\u4f4d\u75c5\u4eba\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff0c\u5f9e2007\u5e745\u6708\u52302009\u5e745\u6708\u671f\u9593\u75c5\u4eba\u65bc\u4e09\u8ecd\u7e3d\u91ab\u9662\u653e\u5c04\u81e8\u7624\u79d1\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f12\u500b\u6708\uff08\u7bc4\u570d\u57282\u523036\u500b\u6708\uff09\uff0c\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba\u7814\u7a76\u7684\u521d\u6b65\u7d42\u9ede\u3002\u7d50\u679c\uff1a\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u7684\u809d\u764c\u75c5\u60a3\uff0c\u5176\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u5206\u5225\u70ba11\u500b\u6708\u53ca16\u500b\u6708\uff1b\u800c\u4e00\u5e74\u7684\u5b58\u6d3b\u7387\u5206\u5225\u662f42.9%\u53ca70.0%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u3001Okuda\u5206\u671f\u8f03\u65e9\u671f\u3001\u8840\u4e2d\u767d\u86cb\u767d\u8f03\u9ad8\u53ca\u9ec3\u75b8\u6307\u6578\u8f03\u4f4e\u8005\u6709\u8f03\u597d\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff0c\u4e14\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u986f\u8457\u5dee\u7570\u3002\u800cChi1d\u5206\u671f\uff08p=0.074\uff09\u5c0d\u6574\u9ad4\u5b58\u6d3b\u7387\u96d6\u7136\u6c92\u6709\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u986f\u8457\u5dee\u7570\uff0c\u4f46\u9032\u4e00\u6b65\u5206\u6790Chi1d \u5206\u671fA\u7684\u75c5\u4eba\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u6bd4\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6709\u66f4\u597d\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u5728\u591a\u8b8a\u9805\u5206\u6790\u767c\u73fe\u8f03\u65e9\u671f\u7684Okuda\u5206\u671f\u53ca\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u70ba\u8f03\u5177\u5f71\u97ff\u529b\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5f9e\u672c\u7814\u7a76\u5206\u6790\u4e86\u89e3\uff0c\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u6bd4\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6709\u66f4\u597d\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u6211\u5011\u7684\u7814\u7a76\u7d50\u679c\u5efa\u8b70Child\u5206\u671fA\u7684\u75c5\u4eba\u512a\u5148\u8003\u616e\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u80fd\u6709\u66f4\u597d\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u672a\u4f86\u53ef\u9032\u4e00\u6b65\u7814\u7a76\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u53ca\u5206\u6b21\u7684\u5f71\u97ff\u3002", "e": "Purpose: To compare stereotactic body radiotherapy (SBRT) with three-dimensional conformal radiotherapy (3D-CRT) for improving hepatocellullar carcimona (HCC) patient survival rates.Material and Method: Forty-one patients with unresectable or recurrent HCC were divided into one group of 20 patients who received SBRT, and another group of 21 patients who received 3D-CRT. They were treated in the Radiation Oncology Department of the Tri-Service General Hospital from March 2007 to March 2009. The median follow-up time for all patients was 12 months (range 2 to 36 months). Overall survival was the primary end point.Results: For the 3D-CRT and SBRT patient groups, the median survival (MS) was 11 months and 16 months with the 1-year overall survival (OS) of 42.9% and 70.0%, respectively. In the univariate analysis, CyberKnife SBRT (p= 0.019), non-advanced Okuda stage (p= 0.002), serum albumin higher than 3.5g /dl (p= 0.008), and total bilirubin lower than 2.0 mg/dL (p= 0.042) were associated with significantly better OS. Further statistical analyses showed that those patients in Child-Pugh class A who received SBRT had better OS than those who received 3D-CRT (p= 0.047). Multivariate analyses revealed that Okuda stage (p= 0.006). Child-Pugh class (p= 0.042) and technique of RT (p= 0.029) were significant prognostic factors for OS.Conclusions: This study showed that patients who received SBRT had significantly better OS than those who received 3D-CRT. SBRT has the advantage of short overall treatment times compared to 3D-CRT. Our results also suggest that SBRT could be considered first in patients with Child-Pugh class A. Further study is required to define the effects of administered radiation dose and fractionation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-119-129", "title": "Treatment Outcomes for Synchronous or Metachronous Hypopharyngeal/Laryngeal/Oropharyngeal Cancer and Esophageal Cancer", "keywords": "\u4e0b\u54bd;\u53e3\u54bd;\u54bd\u5589;\u98df\u9053 Hypopharynx;Oropharynx;Larynx;Esophagus", "c": "\u76ee\u7684\uff1a\u5448\u73fe\u982d\u9838\u90e8\u4e0a\u76ae\u764c\uff08\u53e3\u54bd\u3001\u54bd\u5589\u53ca\u4e0b\u54bd\u764c\uff09\u4f34\u96a8\u540c\u6642\u6216\u7570\u6642\u767c\u751f\u98df\u9053\u764c\u7684\u75c5\u4eba\uff0c\u8fd1\u5341\u5e74\u4f86\u4e4b\u6cbb\u7642\u7d93\u9a57\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u542b1998\u81f32008\u5e74\uff0c\u7f79\u60a3\u540c\u6642\u6216\u7570\u6642\u767c\u751f\u7684\u53e3\u54bd\u764c\u3001\u54bd\u5589\u6216\u4e0b\u54bd\u764c\u53ca\u98df\u9053\u764c\u7684\u75c5\u4eba\u3002\u540c\u6642\u767c\u751f\u7684\u5b9a\u7fa9\u70ba\u5169\u7a2e\u816b\u7624\u767c\u751f\u7684\u6642\u9593\u5728\u516d\u500b\u6708\u5167\uff0c\u7570\u6642\u767c\u751f\u7684\u5b9a\u7fa9\u662f\u5169\u7a2e\u764c\u75c7\u767c\u751f\u7684\u6642\u9593\u9593\u9694\u5927\u65bc\u516d\u500b\u6708\u3002\u5728\u98df\u9053\u816b\u7624\u7684\u6cbb\u7642\uff0c\u670911\u4f4d\u75c5\u4eba\u6700\u7d42\u6709\u63a5\u53d7\u624b\u8853\u5207\u9664 \u5176\u991822\u4f4d\u75c5\u4eba\u5247\u53ea\u63a5\u53d7\u653e\uff08\u5316\uff09\u7642\u3002\u5728\u982d\u9838\u764c\u6cbb\u7642\u65b9\u9762\uff0c\u670915\u500b\u4eba\u63a5\u53d7\u624b\u8853\u5207\u9664\uff0c\u5176\u991818\u4eba\u53ea\u6709\u63a5\u53d7\u653e\u5316\u7642\u3002\u7d50\u679c\uff1a\u517133\u4f4d\u75c5\u4eba\u6536\u9304\u9032\u672c\u7814\u7a76\uff0c\u5176\u4e2d10\u4eba\u7f79\u60a3\u540c\u6642\u767c\u751f\u7684\u764c\u75c7\uff0c\u5176\u991823\u4eba\u6709\u7570\u6642\u767c\u751f\u7684\u764c\u75c7\u3002\u5728\u672c\u7814\u7a76\u5b58\u6d3b\u75c5\u4eba\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f41.3\u500b\u6708\u3002\u6240\u6709\u75c5\u4eba\u5b58\u6d3b\u6642\u9593\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u5206\u5225\u662f13.6\u53ca9.3\u500b\u6708\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u5c0d\u65bc\u5b58\u6d3b\u6642\u9593\u8207\u7121\u75be\u75c5\u5b58\u6d3b\u6642\u9593\u7684\u826f\u597d\u9810\u5f8c\u56e0\u5b50\u70ba\u65e9\u671f\u7684\u98df\u9053\u764c\u3002\u98df\u9053\u816b\u7624\u7684\u624b\u8853\u5207\u9664\u5728\u9810\u5f8c\u65b9\u9762\u6709\u8f03\u4f73\u7684\u8da8\u52e2\u3002\u7d50\u8ad6\uff1a\u540c\u6642\u6216\u7570\u6642\u767c\u751f\u7684\u53e3\u54bd\u764c\u3001\u54bd\u5589\u6216\u4e0b\u54bd\u764c\u53ca\u98df\u9053\u764c\u5e38\u4f34\u96a8\u8457\u4e0d\u597d\u7684\u6cbb\u7642\u7d50\u679c\u3002\u767c\u73fe\u6642\u70ba\u65e9\u671f\u4e4b\u98df\u9053\u816b\u7624\u80fd\u4f34\u96a8\u8457\u8f03\u4f73\u7684\u9810\u5f8c\u3002\u80fd\u4ee5\u624b\u8853\u6cbb\u7642\u98df\u9053\u816b\u7624\u7684\u75c5\u4eba\uff0c\u5728\u7121\u75be\u75c5\u5b58\u6d3b\u6642\u9593\u4e5f\u6709\u8f03\u4f73\u7684\u7d50\u679c\u3002", "e": "Purpose: To evaluate the treatment of synchronous or metachronous hypopharyngeal / laryngeal / oropharyngeal head and neck cancer (H&N cancer) and esophageal cancer in our institution.Materials and Method: The retrospective study included patients with synchronous or metachronous H&N and esophageal cancer treated at our institution from 1998 to 2008. A synchronous malignancy was defined as a second malignancy diagnosed within 6 months after the initial diagnosis of cancer. A metachronous malignancy was defined as a second malignancy diagnosed more than 6 months after the initial diagnosis of cancer. For the treatment of esophageal cancer, 11 patients underwent surgery with or without neoadjuvant concurrent chemo-radiotherapy (CCRT), and the other 22 patients received definitive radiotherapy with or without concurrent chemotherapy. For the treatment of H&N cancer, 15 patients underwent surgical intervention with or without adjuvant CCRT, and the other 18 patients received definitive CCRT.Result: Our study included 33 patients. Among these patients, 10 presented with synchronous H&N and esophageal cancer, and 23 patients developed metachronous carcinomas. The median age at primary diagnosis was 56.8 years (range: 40.7-79.6 years). The median follow-up time for living patients was 41 .3 months. For the entire group, the median overall survival time (OS) and disease-free survival time (DFS) were 13.6 and 9.3 months, respectively. Univariate analysis revealed that T stage of esophageal cancer (T1/T2 vs. T3/T4) was a significant prognostic factor for OS and DFS (22.5 vs.12.2 months [p=0.041], and 21.3 vs. 8.5 months [p = 0.020], respectively). In the case of synchronous or metachronous esophageal cancer, surgical intervention was associated with a better outcome than radiotherapy, with borderline significance (p = 0.076).Conclusions: Patients with synchronous or metachronous H&N and esophageal cancer had poor outcomes. Those with T1/T2 esophageal cancer had a better chance for survival than those with T3/T4 esophageal cancer. This result implies that the T stage of esophageal cancer is a prognosis-limiting factor. Routine screening for synchronous or metachronous esophageal cancer may facilitate early detection and thereby improve the outcomes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-131-142", "title": "Evaluate the Accuracy of VMAT for Clinical Use the Initial Experience of Smartarc Application", "keywords": "\u5f27\u5f62\u6cbb\u7642;\u65cb\u8f49\u6a5f\u982d\u89d2\u5ea6\u9593\u8ddd;Gafchromic EBT2\u5e95\u7247;\u52a0\u78bc\u6307\u6a19\u901a\u904e\u7387 VMAT;Gantry spacing;Galchromic EBT2 film;Gamma passing rate", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u8a55\u4f30SmartArc\u5167\u4e0d\u540c\u8a08\u7b97\u53c3\u6578\u8a2d\u5b9a\u5c0d\u5f27\u5f62\u6cbb\u7642\u6e96\u78ba\u5ea6\u7684\u5f71\u97ff\uff0c \u6211\u5011\u5e0c\u671b\u80fd\u7531\u6578\u500b\u4e0d\u540c\u60a3\u90e8\u7684\u6cbb\u7642\u8a08\u756b\u4e2d\uff0c\u5206\u5225\u4ee5\u4e0d\u540c\u65cb\u8f49\u6a5f\u982d\u89d2\u5ea6\u9593\u8ddd\u9084\u7b97\u53ca\u662f\u5426\u8003\u91cf\u6cbb\u7642\u5e8a\u8870\u6e1b\u7b49\uff0c\u5be6\u969b\u91cf\u6e2c\u6cbb\u7642\u4e4b\u6e96\u78ba\u5ea6\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5171\u9078\u64c728\u4f8b\u5f27\u5f62\u6cbb\u7642\u75c5\u60a3\uff0c\u5176\u4e2d\u5305\u542b8\u4f8b\u8179\u90e8\uff0f\u9aa8\u76c6\u30016\u4f8b\u55ae\u5074\u982d\u9838\u90e8\u30018\u4f8b\u96d9\u5074\u982d\u9838\u90e8\u53ca6\u4f8b\u651d\u8b77\u817a\u3002\u4f7f\u7528E1ekta Synergy\u76f4\u7dda\u52a0\u901f\u5668\u53caPhilips Pinnacle 9.0\u4e4bSmartArc\u904b\u7b97\u7a0b\u5f0f\u57f7\u884c\u6cbb\u7642\u53ca\u9084\u7b97\uff0c\u5206\u5225\u4ee5\u65cb\u8f49\u6a5f\u982d\u89d2\u5ea6\u9593\u8ddd2\u30013\u30014\u53ca6\u5ea6\u57f7\u884c\u6700\u4f73\u5316\u8a08\u7b97\uff0c\u4e26\u65bc\u6bcf\u7d44\u5f71\u50cf\u52a0\u4e0a\u5bec50 cm\u539a8 mm\u5bc6\u5ea61g\uff0f\u7acb\u65b9\u516c\u5206\u7684\u6a21\u64ec\u6cbb\u7642\u5e8a\u3002\u7167\u5c04\u6642\uff0c\u5047\u9ad4\u5167\u540c\u6642\u64fa\u653e0.125\u7acb\u65b9\u516c\u5206Semif1ex\u6e38\u96e2\u8154\u53caGafchromic EBT2\u5e95\u7247\u3002\u7d50\u679c\uff1a\u65bc\u6240\u6709224\u500b\u6cbb\u7642\u8a08\u756b\u4e2d\u8003\u91cf\u6709\uff0f\u7121\u6cbb\u7642\u5e8a\u5dee\u7570\uff0c\u7b26\u5408\u9ede\u5291\u91cf\u00b13%\u57fa\u6e96\u5167\u4e4b\u6bd4\u7387\u5206\u5225\u70ba99.1%\u53ca94.6%\uff1bEBT2\u5e95\u7247\u7d55\u5c0d\u5291\u91cf\u5206\u4f48\u65bc3%/3 mm\u7684\u52a0\u78bc\u6307\u6a19\u901a\u904e\u7387\uff0c\u4f4e\u65bc95%\u95be\u503c\u6bd4\u7387\u5206\u5225\u70ba5.4%\u53ca11.6% \u3002\u91dd\u5c0d\u81e8\u5e8a\u4f7f\u7528\u53c3\u6578\u8a2d\u5b9a\u689d\u4ef6\uff08\u89d2\u5ea6\u9593\u8ddd3 \u5ea6\u3001\u8003\u91cf\u6cbb\u7642\u5e8a\u8870\u6e1b\uff09\uff0c\u8179\u90e8/\u9aa8\u76c6\u3001\u96d9\u5074\u982d\u9838\u90e8\u3001\u96d9\u5074\u982d\u9838\u90e8\u3001\u651d\u8b77\u817a\u65bc3% / 3 mm\u7684\u52a0\u78bc\u6307\u6a19\u901a\u904e\u7387\u5206\u5225\u70ba98.3\u00b12.3%\u300199.5\u00b10.5%\u300197.6\u00b12.3%\u53ca99.5\u00b10.5%\u3002Kruskal-Wallis H\u6aa2\u5b9a\u986f\u793a2-6\u5ea6\u89d2\u5ea6\u9593\u8ddd\u4e4b\u5291\u91cf\u5be6\u6e2c\u7d50\u679c\uff0c\u4e26\u7121\u986f\u8457\u5dee\u7570\u4e14\u672a\u9054\u8981\u6c42\u6848\u4f8b\u96a8\u6a5f\u767c\u751f\u5728\u4efb\u4f55\u89d2\u5ea6\u9593\u8ddd\uff1bMann-Whitney U\u6aa2\u5b9a\u986f\u793a\uff0c\u651d\u8b77\u817a\u4ee5\u5916\u4e4b\u5176\u4ed6\u60a3\u90e8\u5728\u6709\uff0f\u7121\u6cbb\u7642\u5e8a\u4e4bp\u503c\u4f4e\u65bc\u6216\u63a5\u8fd1\u986f\u8457\u6c34\u6e96\u3002Spearman's correlation coefficient\u66f4\u6307\u51fa\u7167\u5c04MU\u91cf\u53ef\u80fd\u5f71\u97ff\u6cbb\u7642\u6e96\u78ba\u5ea6\uff08p\uff1c0.05\uff09\u4f46\u8207PTV\u5927\u5c0f\u5247\u7121\u76f8\u95dc\u6027\u3002\u7d50\u8ad6\uff1a\u5229\u7528EBT2\u5e95\u7247\u57f7\u884c\u5f27\u5f62\u6cbb\u7642\u524d\u4e4b\u6574\u9ad4\u5291\u91cf\u8a55\u4f30\u78ba\u70ba\u4e00\u53ef\u884c\u65b9\u6cd5\uff0c\u672c\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u96d6\u7136\u5728\u4e0d\u540c\u8a08\u7b97\u53c3\u6578\u8a2d\u5b9a\u4e0b\u6cbb\u7642\u6e96\u78ba\u5ea6\u5dee\u7570\u4e0d\u4e00\uff0c\u4f46\u6574\u9ad4\u4f86\u8aaa\uff0c\u5176\u5291\u91cf\u6e2c\u91cf\u503c\u8207\u8a08\u7b97\u503c\u4e4b\u4e00\u81f4\u6027\u6975\u9ad8\u3002", "e": "Purpose: The goal of this study was to investigate the accuracy of VMAT with different calculation parameters in SmartArc. Dosimetric comparisons of various gantry spacings with and without couch (WC/WOC) insert simulation were evaluated based on statistics.Materials and Method: Twenty-eight VMAT cases were selected in this study, including 8 abdomen/pelvis, 6 one-side HN, 8 two-side HN and 6 prostate. A commercial Elekta Synergy linear accelerator and SmartArc algorithm in Pinnacle^3 9.0 was used. The patients were treated clinically with VMAT using 3\u00b0 gantry spacing and reoptimized using 2\u00b0, 4\u00b0 and 6\u00b0. An 8 mm thick water equivalent contour couch was added under the phantom. The phantom was irradiated with 0.125 cm^3 Semiflex chamber and Gafchromic EBT2 film simultaneously.Results: 99.1% and 94.6% of WC and WOC passed the 3% point dose difference criteria. In absolute dosimetric agreement of EBT2 film, the gamma passing rate of 3%/3 mm for all 224 plans separately were 5.4% for WC and 11.6% for WOC below 95% tolerance level. While using clinical parameters (3\u00b0 gantry spacing, WC), the 3%/3 mm gamma average passing rate was 98.3\u00b12.3%, 99.5\u00b10.5%, 97.6\u00b12.8% and 99.5\u00b10.5% for abdomen/pelvis, one-side HN, two-side HN and prostate respectively Considered with the 2-6\u00b0 gantry spacing, the Kruskal-Wallis H test shows very similar results and failures situations occurred randomly on any gantry spacing. The results 01 with /without couch insert simulation shows the Mann-Whitney U test p-value lower than or close to, the significant level expected for prostate cases. Spearman's correlation coefficient indicates that delivery MU may inlluence the accuracy (p-value \uff1c 0.05) but it's independent of PTV volume.Conclusions: Composite dose measurements performed with EBT2 film are a practicable approach for patient-specific QA of VMAT plans. Film dosimetry in this study has shown good agreement in various parameter settings."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-143-151", "title": "Improvement of Setup Accuracy by Neck-Shoulder Bag during Radiotherapy in Head and Neck Cancer Patients", "keywords": "\u982d\u9838\u764c;\u64fa\u4f4d\u6b63\u78ba\u6027;\u80a9\u9838\u56fa\u5b9a\u588a;\u9838\u690e\u89d2\u5ea6 Head and neck cancer;Setup accuracy;Neck-shoulder bag;Cervical spine angle", "c": "\u76ee\u7684\uff1a\u85c9\u7531\u5206\u6790\u9838\u690e\u593e\u89d2\u65bc\u6cbb\u7642\u904e\u7a0b\u4e2d\u4e4b\u8b8a\u5316\uff0c\u8a55\u4f30\u80a9\u9838\u56fa\u5b9a\u588a\u5c0d\u6cbb\u7642\u64fa\u4f4d\u6b63\u78ba\u6027\u4e4b\u6539\u5584\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2008\u5e743\u6708\u81f32009\u5e743\u6708\uff0c\u5c0766\u540d\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u982d\u9838\u764c\u75c5\u60a3\uff0c\u4f9d\u80a9\u9838\u548c\u6cbb\u7642\u5e8a\u9593\u8ddd\u96e2\u5206\u70ba\u5169\u7d44\uff1a\u8ddd\u96e2\u5c0f\u65bc\u4e09\u516c\u5206\u672a\u4f7f\u7528\u80a9\u9838\u56fa\u5b9a\u588a\u70baA\u7d44\uff0837\u540d\uff09\u3001\u8ddd\u96e2\u5927\u65bc\u4e09\u516c\u5206\u4e14\u4f7f\u7528\u80a9\u9838\u56fa\u5b9a\u588a\u70baB\u7d44\uff0829\u540d\uff09\uff1b\u6b64\u5916\uff0c\u56de\u9867\u5206\u67902007\u5e743\u6708\u81f39\u6708\uff0c31\u540d\u75c5\u60a3\u70ba\u5c0d\u7167\u7d44\uff0c\u8ddd\u96e2\u5c0f\u65bc\u4e09\u516c\u5206\u70baA'\u7d44\uff0815\u540d\uff09\u3001\u8ddd\u96e2\u5927\u65bc\u4e09\u516c\u5206\u70baB\u7d44\uff0816\u540d\uff09\uff0c\u7686\u672a\u4f7f\u7528\u80a9\u9838\u56fa\u5b9a\u588a\u7528\u65bc\u8a55\u4f30\u55ae\u7368\u4f7f\u7528\u71b1\u5851\u6027\u9762\u8ecd\u5176\u9838\u690e\u89d2\u5ea6\u4e4b\u8b8a\u7570\u3002\u5206\u6790\u9838\u690e\u89d2\u5ea6\u70ba\u9838\u690e\u7b2c\u4e8c\u7bc0\u6295\u5f71\u8207\u9838\u690e\u7b2c\u4e94\u7bc0\u5f8c\u7de3\u6295\u5f71\u4e4b\u593e\u89d2\u3002\u5229\u7528Offline Review\u8edf\u9ad4\uff0c\u6536\u96c697\u4f4d\u75c5\u60a3582\u5f35\u5f71\u50cf\uff0c\u91cf\u6e2c\u7b2c\u4e00\u6b21\u6cbb\u7642\u524d\u4e4b\u5343\u4f0f\u5f71\u50cf\u8207\u6bcf\u9031\u62cd\u651d\u4e4b\u5e38\u898f\u7167\u91ce\u9a57\u8b49\u5f71\u50cf\u548c\u53c3\u8003\u5f71\u50cf\u9593\u4e4b\u9838\u690e\u89d2\u5ea6\u5dee\u7570\uff0c\u4e26\u8a18\u9304\u75c5\u60a3\u9ad4\u91cd\u8b8a\u5316\u3001\u6cbb\u7642\u524d\u662f\u5426\u624b\u8853\u5207\u9664\u3001\u80a9\u9838\u548c\u6cbb\u7642\u5e8a\u9593\u8ddd\u96e2\u3001\u662f\u5426\u4f7f\u7528\u80a9\u9838\u56fa\u5b9a\u588a\uff1b\u8cc7\u6599\u4f7f\u7528\u76ae\u723e\u68ee\u76f8\u95dc\u4fc2\u6578\u53caSPSS17\u9032\u884c\u55ae\u8b8a\u6578\u7368\u7acb\u6a23\u672cT\u6aa2\u5b9a\u3002\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u5171\u5206\u6790582\u5f35\u5f71\u50cf\uff1b\u5176\u4e2d\u80a9\u9838\u548c\u6cbb\u7642\u5e8a\u9593\u8ddd\u96e2\u5c0f\u65bc3\u516c\u5206\u4e4bA\u7d44\u9838\u690e\u593e\u89d2\u8b8a\u7570\u70ba0.67\u00b12.58\u5ea6\u548cA'\u7d44\u70ba1.03\u00b13.48\u5ea6\uff08p=0.4840\uff09\uff1b\u800c\u8ddd\u96e2\u5927\u65bc3\u516c\u5206\u4e14\u4f7f\u7528\u80a9\u9838\u90e8\u56fa\u5b9a\u588a\u4e4b8\u7d44\u593e\u89d2\u8b8a\u7570\u70ba0.41\u00b10.66\u5ea6\u800c\u672a\u4f7f\u7528\u4e4bB'\u7d44\u70ba1.52\u00b13.63\u5ea6\uff08p=0.0462\uff09\u3002\u7d71\u8a08\u7d50\u679c\u986f\u793a\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u524d\u63a5\u53d7\u624b\u8853\u6703\u4f7f\u9838\u690e\u593e\u89d2\u8b8a\u7570\u589e\u52a0\uff08p = 0.0436\uff09\uff0c\u800c\u75c5\u60a3\u9ad4\u91cd\u8b8a\u5316\u548c\u9838\u690e\u593e\u89d2\u8b8a\u7570\u9593\u4e0d\u5177\u76f8\u95dc\u6027\uff08r : 0.01 to -0.21\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u7d50\u679c\u986f\u793a\u5c0d\u65bc\u80a9\u9838\u548c\u6cbb\u7642\u5e8a\u9593\u8ddd\u96e2\u5927\u65bc3\u516c\u5206\u4e4b\u75c5\u60a3\uff0c\u4f7f\u7528\u80a9\u9838\u56fa\u5b9a\u588a\u53ef\u964d\u4f4e\u9838\u690e\u593e\u89d2\u8b8a\u7570\uff0c\u63d0\u5347\u6cbb\u7642\u64fa\u4f4d\u6b63\u78ba\u6027\u3002", "e": "Purpose: To study how neck-shoulder bag (NSB) improve the setup accuracy among head and neck cancer patients during radiation therapy (RT) by analyzing the cervical spine curvature difference.Meterials and Method: Between March 2008 and March 2009, sixty-six consecutive head and neck cancer patients received RT with immobilization by thermoplastic mask and hollow-pillow. These 66 patients were divided into two groups. Group A (n = 37) were those with a neck to couch perpendicular distance (NCD) \uff1c 3 cm, measuring at the point just caudal to the hollow-pillow, and the \u03b3 did not use the NSS for neck support Group S (n = 29) were those with NCD equal to or larger than 3 cm, and all of them used NSB during RT. Another cohort of 31 cases treated in the year 2007, not using the NSB was used as the retrospective control group. Among these 31 cases, fifteen have NCD \uff1c 3 cm (Group A') and sixteen cases were 3 cm (Group B'). Patient's cervical spine curvature was quantified by his/her second and fifth cervical vertebrae intersecting angle (cervical spine angle, CSA). It was measured weekly from patient's portal images and simulation films. A small difference between the weekly CSA indicated good setup accuracy. Body weight change, surgery prior to RT, NCD, and whether using a NSB or not were investigated correlating to CSA. Analyses were performed using the Pearson correlation coefficient and SPSS17 for independent univariate t test.Results: A total of 582 portal images were obtained. Patients with NCD \uff1c 3 cm and not using the NSB have a CSA weekly difference of 0.67\u00b12.58\u00b0 for Group A, and 1.03\u00b13.48\u00b0 for Group A' (p = 0.484). Those with NCD \u22653 cm, CSA weekly variation for Group B was 0.41\u00b10.66\u00b0, and was 1.52\u00b13.63\u00b0 for Group B', (p = 0.046). Surgery prior to RT significantly increased the CSA range of difference (p = 0.0436). Body weight change had little to no correlation with CSA variation (r range: 0.01 to -0.21).Conclusions: Our results indicated using NSS in patients with NCD \u22653 cm significantly reduced CSA variation among RT fractionations, thus improved setup accuracy. Patients with NCD \uff1c 3 cm had acceptable setup accuracy in the absence of NSB."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-153-159", "title": "Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Anaplastic Thyroid Cancer", "keywords": "\u672a\u5206\u5316\u578b\u7532\u72c0\u817a\u764c;\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u6574\u5408\u52a0\u91cf\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Anaplastic thyroid cancer;Radiotherapy;Simultaneous integrated boost intensity-modulated radiotherapy", "c": "\u672a\u5206\u5316\u578b\u7532\u72c0\u817a\u764c\u70ba\u4e00\u7f55\u898b\u4e14\u5177\u9ad8\u5ea6\u4fb5\u72af\u6027\u4e4b\u60e1\u6027\u816b\u7624\uff0c\u76ee\u524d\u91ab\u5b78\u754c\u5c0d\u65bc\u6700\u9069\u7576\u4e4b\u6cbb\u7642\u7b56\u7565\u4ecd\u7121\u5171\u8b58\u3002\u56de\u9867\u904e\u53bb\u6587\u737b\u4e2d\u767c\u73fe\uff0c\u5c40\u90e8\u816b\u7624\u6e1b\u7a4d\u624b\u8853\u4e26\u8f14\u4ee5\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u5c0d\u65bc\u5c40\u90e8\u665a\u671f\u4e4b\u672a\u5206\u5316\u578b\u7532\u72c0\u817a\u764c\uff08Anaplastic thyroid cancer, ATC\uff09\u53ef\u63d0\u4f9b\u8f03\u4f73\u4e4b\u5c40\u90e8\u63a7\u5236\u3002\u7136\u800c\uff0c\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u56e0\u5176\u6280\u8853\u4e0a\u4e4b\u9650\u5236\uff0c\u5c0d\u4f4d\u65bc\u6b64\u8655\u4e4b\u816b\u7624\u5728\u6cbb\u7642\u6642\u5f88\u96e3\u9054\u5230\u6709\u6548\u4e14\u5747\u52fb\u4e4b\u7406\u60f3\u5291\u91cf\u5206\u4f48\u3002\u8fd1\u5e74\u4f86\u85c9\u8457\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u9032\u6b65\uff0c\u4f8b\u5982\u7c4d\u7531\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u53ef\u6709\u6548\u6539\u5584\u50b3\u7d71\u6cbb\u7642\u4e4b\u9650\u5236\u3002\u800c\u65bc\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u82e5\u662f\u8f14\u4ee5\u540c\u6b65\u6574\u5408\u52a0\u91cf\u4e4b\u6280\u8853\uff0c\u5247\u53ef\u63d0\u4f9b\u66f4\u4f73\u4e4b\u6574\u9ad4\u5291\u91cf\u5206\u4f48\u8207\u751f\u7269\u6548\u61c9\u3002\u7531\u65bc\u6587\u737b\u4e2d\u4e26\u7121\u95dc\u65bc\u6b64\u7a2e\u6280\u8853\u61c9\u7528\u5728\u5c40\u90e8\u665a\u671fATC\u4e4b\u6210\u679c\uff0c\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f4d\u60a3\u6709\u5c40\u90e8\u665a\u671fATC\u4e4b60\u6b72\u5973\u6027\uff0c\u65bc\u672c\u9662\u884c\u816b\u7624\u6e1b\u7a4d\u624b\u8853\u5f8c\uff0c\u8f14\u4ee5\u540c\u6b65\u6574\u5408\u52a0\u91cf\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u6210\u679c\uff0c\u4e26\u56de\u9867\u76f8\u95dc\u6587\u737b\u3002", "e": "Anaplastic thyroid cancer (ATC) is a rare malignancy with aggressive behavior and dismal outcome; the optimal treatment has not yet been determined. Debulky surgery followed by adjuvant radiotherapy (RT) has been reported to have better local control for locally advanced ATC. However, the technical limitations of conventional RT made it difficult to irradiate a homogenous and effective dose to the thyroid region. Recent advances in RT techniques such as intensity-modulated radiotherapy (IMRT) provided the potential to conquer the limitation. Additionally, IMRT using simultaneous integrated boost technique (SIB-IMRT) further improved the biologic and dosimetric advantages. As no previous literature has reported the use of this technique on locally advanced ATC, we report a 60-year-old female with ATC treated by debulky surgery and SIB-IMRT and review the literatures."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201206-201208130006-201208130006-161-166", "title": "Osteosarcoma after Irradiated Nasopharyngeal Carcinoma: A Case Report", "keywords": "\u9f3b\u54bd\u764c;\u653e\u7642\u6027\u8089\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Nasopharyngeal carcinoma;Radiation-induced sarcoma;Radiotherapy", "c": "\u4e00\u4f4d23\u6b72\u7537\u6027\u75c5\u4eba\u66fe\u56e0\u9f3b\u54bd\u764c\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff0c\u56db\u5e74\u5f8c\u767c\u751f\u5de6\u773c\u7736\u816b\u8139\u548c\u5de6\u773c\u81c9\u4e0b\u8822\uff0c\u78c1\u632f\u9020\u5f71\u767c\u73fe\u5de6\u534a\u908a\u81c9\u6709\u4e0015\u516c\u5206\u5de8\u5927\u816b\u7624\uff0c\u624b\u8853\u5207\u9664\u5f8c\u75c5\u7406\u5316\u9a57\u8b49\u8cea\u70ba\u60e1\u6027\u9aa8\u8089\u7624\uff0c\u6838\u9178\u539f\u4f4d\u96dc\u4ea4\u4e5f\u986f\u793a\u816b\u7624\u7d30\u80de\u70baEB\u75c5\u6bd2\u9670\u6027\uff0c\u653e\u7642\u5f8c\u7167\u5c04\u5340\u57df\u9644\u8fd1\u4e4b\u816b\u7624\u9700\u8003\u616e\u653e\u7642\u5f15\u767c\u8089\u7624\u4e4b\u53ef\u80fd\uff0c\u5373\u4f7f\u6f5b\u4f0f\u671f\u5c0f\u65bc\u4e94\u5e74\u3002", "e": "A 23-year-old man presented with left ptosis and periorbital swelling 4 years after concurrent chemoradiotherapy for his nasopharyngeal carcinoma. MRI revealed a 15 cm tumor in left hemiface. Craniofacial resection 01 the tumor was performed and showed a high-grade osteosarcoma. The tumor cells were negative for Epstein-Barr virus (EBV) by EBV-encoded small RNA in situ hybridization. Radiation-induced sarcoma should be considered in a previously irradiated patient even with relatively short latent period."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-4-12", "title": "Treatment Outcomes of Two Different Pre-Operative Modalities for Patients with Rectal Cancer: A Retrospective Study and the Importance of Major Surgery", "keywords": "\u5b8c\u5168\u7de9\u89e3;\u6a19\u6e96\u624b\u8853;\u8853\u524d\u8f14\u52a9\u6cbb\u7642;\u76f4\u8178\u764c Complete tumor response;Major surgery;Pre-operative;Rectal cancer", "c": "Purpose: The aim of the present study was to evaluate the incidence of complete tumor response (CR) achieved following two different neoadjuvant modalities and the importance of major surgery after neoadjuvant treatment. Materials and Method: Between March 1999 and December 2007, this is retrospective study included 417 patients with newly-diagnosed dissemination-naive rectal cancer, treated with pre-operative short-course radiotherapy (RT) or long-course chemoradiotherapy (CCRT). The status of tumor response was confirmed by biopsy or surgery. Result: Median follow-up was 30.9 months. After neoadjuvant treatment, CR was documented in 5 of 221 patients (2%) in the short-course RT group, and 34 of 198 (17%) in the long-course CCRT group (p \uff1c 0.001). The 5-year overall survival rate was 59% in short-course RT group and 49% in long-course CCRT group respectively. Focusing on the subgroup that was documented to achieve pathological tumor complete response (pCR), the survival benefit was most clear in those who received major surgery after neoadjuvant treatment rather than local excision only. There were more patients receiving merely local excision or observation in CCRT group (n= 50, 25.5%) than in RT alone group (n= 7, 3%). In the subgroup analysis specific to the patients who underwent standard major surgery after neoadjuvant treatment, no statistically significant difference in terms of overall survival was found between these two different neoadjuvant settings (p= 0.657). Conclusions: Subgroup analysis pertaining to patients who actually received major surgery after neoadjuvant treatment showed that there was no significant difference with regard to overall survival rates in these two neoadjuvant settings. The importance of patient compliance and performing major surgery after neoadjuvant treatment was clearly demonstrated in this retrospective study.", "e": "Purpose: The aim of the present study was to evaluate the incidence of complete tumor response (CR) achieved following two different neoadjuvant modalities and the importance of major surgery after neoadjuvant treatment. Materials and Method: Between March 1999 and December 2007, this is retrospective study included 417 patients with newly-diagnosed dissemination-naive rectal cancer, treated with pre-operative short-course radiotherapy (RT) or long-course chemoradiotherapy (CCRT). The status of tumor response was confirmed by biopsy or surgery. Result: Median follow-up was 30.9 months. After neoadjuvant treatment, CR was documented in 5 of 221 patients (2%) in the short-course RT group, and 34 of 198 (17%) in the long-course CCRT group (p \uff1c 0.001). The 5-year overall survival rate was 59% in short-course RT group and 49% in long-course CCRT group respectively. Focusing on the subgroup that was documented to achieve pathological tumor complete response (pCR), the survival benefit was most clear in those who received major surgery after neoadjuvant treatment rather than local excision only. There were more patients receiving merely local excision or observation in CCRT group (n= 50, 25.5%) than in RT alone group (n= 7, 3%). In the subgroup analysis specific to the patients who underwent standard major surgery after neoadjuvant treatment, no statistically significant difference in terms of overall survival was found between these two different neoadjuvant settings (p= 0.657). Conclusions: Subgroup analysis pertaining to patients who actually received major surgery after neoadjuvant treatment showed that there was no significant difference with regard to overall survival rates in these two neoadjuvant settings. The importance of patient compliance and performing major surgery after neoadjuvant treatment was clearly demonstrated in this retrospective study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-14-23", "title": "\u8a55\u4f30\u809d\u764c\u60a3\u8005\u653e\u5c04\u6cbb\u7642\u524d\u5f8c\u71df\u990a\u72c0\u614b\u8207\u5176\u751f\u6d3b\u54c1\u8cea\u4e4b\u63a2\u8a0e", "keywords": "\u809d\u764c;\u71df\u990a\u8a55\u4f30;\u751f\u6d3b\u54c1\u8cea;\u653e\u5c04\u6cbb\u7642 Hepatocellular carcinoma;Nutritional assessment;Quality of life;Radiotherapy", "c": "Purpose: The aims of this study are assessing the nutritional status and quality of life (QoL) in the patients with hepatocellular carcinoma treated by radiotherapy, and discussing the impacts of radiotherapy and nutritional status on QoL. Materails and Methods: From August 2007 to April 2009, one hundred and fifty hepatocellular carcinoma patients treated by radiotherapy at a teaching hospital in central Taiwan were enrolled in this study. Nutritional status and QoL of the patients were assessed by means of the Mini-Nutrition Assessment (MNA) and European Organization for Research and Treatment of Cancer Quality of Life Core-3D (EORTC QLQ-C30) at three different time points: before treatment, end of treatment, and 1 month after treatment.  Results: Forty-two percent patients had the problem of nutritional status before radiotherapy. There was no significant changes in nutritional status of the patient s who received radiotheray (Friedman X^2 = 2.06, p = 0.358). The nutritional status correlated with global health status, all five functioning scales and the most of symptom scales /item at all of the different time points. Using generalized estimating equation, global health status (p \uff1c 0.01), global functioning status (p \uff1c 0.05), the most severe symptoms included fatigue (p \uff1c 0.05), financial difficulty (p \uff1c 0.001 ), and pain ( p \uff1c 0.01) were significantly improved after radiotherapy. The nutritional status o f the patients were strong relationship with global health status (p \uff1c 0.001), global functioning status (p \uff1c 0.001), insomnia (p \uff1c 0.01), fatigue (p \uff1c 0.001), financial difficulty (p \uff1c 0.001), loss of appetite (p \uff1c 0.001) and pain (p \uff1c 0.01). Conclusion: Although the level o f nutritional status of the patients is not effectively increase in a short period, it would be worth to note that the QoL and the most of the major symptoms are significantly improved after the patient s received radiotherapy. Considering, the nutritional status of the patients will directly influence their QoL and the major symptoms. The patients with hepatocellular carcinoma should have to establish nutritional assessment and arrange early nutritional intervention before radiotherapy to get more nutritional support, and in turn to improve the QoL.", "e": "Purpose: The aims of this study are assessing the nutritional status and quality of life (QoL) in the patients with hepatocellular carcinoma treated by radiotherapy, and discussing the impacts of radiotherapy and nutritional status on QoL. Materails and Methods: From August 2007 to April 2009, one hundred and fifty hepatocellular carcinoma patients treated by radiotherapy at a teaching hospital in central Taiwan were enrolled in this study. Nutritional status and QoL of the patients were assessed by means of the Mini-Nutrition Assessment (MNA) and European Organization for Research and Treatment of Cancer Quality of Life Core-3D (EORTC QLQ-C30) at three different time points: before treatment, end of treatment, and 1 month after treatment.  Results: Forty-two percent patients had the problem of nutritional status before radiotherapy. There was no significant changes in nutritional status of the patient s who received radiotheray (Friedman X^2 = 2.06, p = 0.358). The nutritional status correlated with global health status, all five functioning scales and the most of symptom scales /item at all of the different time points. Using generalized estimating equation, global health status (p \uff1c 0.01), global functioning status (p \uff1c 0.05), the most severe symptoms included fatigue (p \uff1c 0.05), financial difficulty (p \uff1c 0.001 ), and pain ( p \uff1c 0.01) were significantly improved after radiotherapy. The nutritional status o f the patients were strong relationship with global health status (p \uff1c 0.001), global functioning status (p \uff1c 0.001), insomnia (p \uff1c 0.01), fatigue (p \uff1c 0.001), financial difficulty (p \uff1c 0.001), loss of appetite (p \uff1c 0.001) and pain (p \uff1c 0.01). Conclusion: Although the level o f nutritional status of the patients is not effectively increase in a short period, it would be worth to note that the QoL and the most of the major symptoms are significantly improved after the patient s received radiotherapy. Considering, the nutritional status of the patients will directly influence their QoL and the major symptoms. The patients with hepatocellular carcinoma should have to establish nutritional assessment and arrange early nutritional intervention before radiotherapy to get more nutritional support, and in turn to improve the QoL."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-24-32", "title": "Prognostic Factors Affecting the Outcome in Glioblastoma Multiforme: A Single Institution Experience", "keywords": "\u8166\u90e8\u816b\u7624;\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u5e1d\u76df\u591a Brain tumor;Glioblastoma multiforme;Radiotherapy;Temozolomide", "c": "\u76ee\u7684\uff1a\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u662f\u767c\u751f\u65bc\u6210\u5e74\u4eba\u6700\u60e1\u6027\u7684\u539f\u767c\u6027\u8166\u816b\u7624\uff0c\u5728\u6b64\u7bc7\u6587\u7ae0\u4e2d\uff0c\u6211\u5011\u5831\u544a\u4e86\u6cbb\u7642\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u7684\u7d93\u9a57\u4e26\u5206\u6790\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1998\u5e744\u6708\u81f32010\u5e748\u6708\uff0c\u5728\u672c\u9662\u670930\u4f8b\u63a5\u53d7\u816b\u7624\u5207\u9664\u548c\u653e\u5c04\u6cbb\u7642\u4e26\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff08\u6216\u7121\uff09\u7684\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u75c5\u4eba\u3002\u5176\u4e2d16\u4f8b\u60a3\u8005\u70ba\u7537\u6027\uff0853%\uff09\uff0c14\u4f8b\u70ba\u5973\u6027\uff0847%\uff09\u3002\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba61\u6b72\u3002\u5728\u65e5\u5e38\u9ad4\u80fd\u72c0\u614b\u65b9\u9762\uff0c\u5361\u5f0f\u91cf\u8868\u5927\u65bc70\u5206\u70ba19\u4f8b\uff0863%\uff09\uff0c\u5c0f\u65bc70\u5206\u70ba11\u4f8b\uff0837%\uff09\u3002\u816b\u7624\u5927\u5c0f\u4e2d\u4f4d\u6578\u70ba5.0\u516c\u5206\u3002\u6240\u6709\u60a3\u8005\u5728\u8853\u5f8c\u5747\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4f75\u5316\u5b78\u6cbb\u7642\uff08\u6216\u7121\uff09\u3002\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba5940 cGy\uff0c\u670913\u4f4d\u75c5\u4eba\uff0843%\uff09\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\u5316\u7642\u8655\u65b9\u85e5\u7269\u5305\u62ecACNU\u3001BCNU\u8207Temozolomide\u3002\u8ffd\u8e64\u671f\u9593\u70ba1.2\u81f349.3\u500b\u6708\uff08\u4e2d\u4f4d\u6578\u70ba10.4\u500b\u6708)\u3002\u7d50\u679c\uff1a\u6cbb\u7642\u7d50\u675f\u5f8c\u67098\u4f4d\u75c5\u4eba\uff0827%\uff09\u6709\u816b\u7624\u6cbb\u7642\u53cd\u61c9\uff0c19\u4f4d\u75c5\u4eba\uff0863%\uff09\u7684\u75be\u75c5\u5448\u73fe\u60e1\u5316\u72c0\u614b\uff0c\u800c3\u4f4d\u75c5\u4eba\uff0810%\uff09\u5247\u70ba\u75be\u75c5\u7a69\u5b9a\u72c0\u614b\u3002\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u70ba10.4\u500b\u6708\u3002\u5728\u6700\u5f8c\u4e00\u6b21\u8ffd\u8e64\u6642\u67095\u4f4d\u75c5\u4eba\uff0817%\uff09\u5b58\u6d3b\uff0c25\u4f4d\u75c5\u4eba\uff0883%\uff09\u6b7b\u4ea1\u3002\u4e00\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba49%\uff0c\u800c2\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba17%\u3002\u65e5\u5e38\u9ad4\u80fd\u72c0\u614b\u662f\u4e00\u500b\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff08p= 0.008, log-rank test\uff1bp= 0.025\uff0cCox proportional hazards model\uff09\u3002\u7d50\u8ad6\uff1a\u5118\u7ba1\u6cbb\u7642\u9032\u6b65\uff0c\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u7684\u9810\u5f8c\u4ecd\u820a\u4e0d\u4f73\uff0c\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\u8207\u5c40\u90e8\u5fa9\u767c\u4ecd\u662f\u5f71\u97ff\u591a\u578b\u6027\u81a0\u72c0\u6bcd\u7d30\u80de\u7624\u9810\u5f8c\u7684\u4e3b\u8981\u56e0\u7d20\u3002\u5fc5\u9808\u8981\u6709\u66f4\u6709\u6548\u7684\u6cbb\u7642\u4ee5\u671f\u6539\u5584\u6cbb\u7642\u7d50\u679c\u8207\u9810\u5f8c\u3002", "e": "Purpose: Glioblastoma multilorme (GBM) is the most malignant primary brain tumor in adults, Here we presented our institution experience of treatment resu1ts in Taiwan GBM patients and analyzed the prognostic factors. Materials and Methods: From Apri1 1998 to August 2010, 30 patients with GBM received tumor excision and radiotherapy with/without chemotherapy in our institution. Sixteen patients were ma1e (53%), and 14 were female (47%). The median age was 61 years. The performances status of Karnofsky Performance Sca1e was \u226570 in 19 patients (63%), and \uff1c70 in 11 patients (37%). The median size of tumor was 5.0 cm. All patients had definitive or post-operative adjuvant radiotherapy with/without chemotherapy. The median total radiation dose was 5940 cGy. Thirteen patients (43%) received chemotherapy. The chemotherapy regimens included ACNU, BCNU and Temozolomide. The follow-up period ranged from 1.2 to 49.3 months (median, 10.4 months) Results: Eight patients (27%) had tumor response after treatments, 19 patients (63%) had progression of disease, and 3 patients (10%) had stable disease. The median survival duration was 10.4 months. Five patients (17%) were alive and 25 patients (83%) were dead at the 1ast 101l0w-up. The 1-year overall surviva1 was 49%, and the 2-year overall survival was 17%. Performance status was a statistically significant factor for overall surviva1 (p= 0.008, log-rank test; p= 0.025, Cox proportiona1 hazards model). Conclusion: Despite recent therapeutic advances, the prognosis of GBM remains poor. Poor response to current therapies and loco-regional recurrence still were the main failure patterns for GBM. A large series of more patients with longer follow-up and more effective treatments is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-34-42", "title": "The Outcome of Intraluminal Brachytherapy Using Iridium 192(IR-192) for Hepatobiliary Cancers with Biliary Tract Obstruction", "keywords": "\u809d\u81bd\u9053\u764c;\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642;\u92a5\uff0d192;\u8154\u5167\u6cbb\u7642 Cholangiocarcinoma;Brachytherapy;Iridium192;Radiotherapy;Obstruction", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5c40\u90e8\u809d\u81bd\u9053\u60e1\u6027\u816b\u7624\u5728\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u5f8c\u4e4b\u6cbb\u7642\u6548\u679c\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2007\u5e743\u6708\u81f32011\u5e743\u6708\uff0c\u670911\u4f4d\u809d\u81bd\u9053\u60e1\u6027\u816b\u7624\u75c5\u60a3\u5176\u764c\u75c7\u671f\u5225\u70baTI\uff5e4\uff0cNO\uff5e1\uff0cM0\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u60a3\u4e4b\u5e74\u9f61\u5206\u4f48\u5f9e46\u6b72\u523079\u6b72\uff0c\u5176\u4e2d\u4f4d\u6578\u70ba68\u6b72\u3002\u75c5\u60a3\u65bc2\uff5e3\u5929\u5167\u63a5\u53d73\uff5e5\u6b21\u9ad8\u5291\u91cf\u7387\u7684\u92a5\uff0d192\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\uff0c\u5e73\u5747\u653e\u5c04\u7dda\u5291\u91cf\u70ba14 Gy\uff089\uff5e17.5 Gy\uff0c3.13 Gy/fraction\uff0cb.i.d.\uff09\u3002\u5176\u4e2d\u516d\u4f4d\u75c5\u60a3\u9664\u4e86\u63a5\u53d7\u8fd1\u63a5\u6cbb\u7642\uff0c\u4e5f\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u5291\u91cf\u7bc4\u570d\u5f9e40 Gy\u81f364.8 Gy\uff0c\u5e73\u5747\u653e\u5c04\u7dda\u5291\u91cf\u70ba44 Gy\u3002\u81ea\u764c\u75c7\u8a3a\u65b7\u8d77\u7b97\u75c5\u60a3\u4e4b\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba10\u500b\u6708\uff081\uff5e28\u500b\u6708\uff09\u3002\u7d50\u679c\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u524d\u7e3d\u81bd\u7d05\u7d20\u5e73\u5747\u70ba9.66 mg/dL\uff081.05\uff5e29.22 mg/dL\uff09;\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u7e3d\u81bd\u7d05\u7d20\u5e73\u5747\u70ba1.73 mg/dL\uff080.27\uff5e4.23 mg/dL\uff09\u3002\u4e09\u4f4d\u809d\u5916\u81bd\u9053\u764c\u75c5\u60a3\u4e4b\u5b58\u6d3b\u4e2d\u4f4d\u6578\u70ba19\u500b\u6708\uff1b\u4e09\u4f4d\u809d\u5167\u81bd\u9053\u764c\u75c5\u60a3\u4e4b\u5b58\u6d3b\u4e2d\u4f4d\u6578\u70ba9\u500b\u6708\uff1b\u5169\u4f4d\u58fa\u8179\u4e73\u982d\u764c\u75c5\u60a3\u4e4b\u5b58\u6d3b\u4e2d\u4f4d\u6578\u70ba22\u500b\u6708\uff1b\u5169\u4f4d\u809d\u764c\u75c5\u614b\u4e4b\u5b58\u6d3b\u4e2d\u4f4d\u6578\u70ba5\u500b\u6708\uff1b\u4e00\u4f4d\u81bd\u56ca\u764c\u75c5\u614b\u3001\u4e4b\u5b58\u6d3b15\u500b\u6708\u3002\u7d50\u8ad6\uff1a\u5c40\u90e8\u809d\u81bd\u9053\u60e1\u6027\u816b\u7624\u75c5\u60a3\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u6709\u52a9\u65bc\u89e3\u9664\u963b\u585e\u6027\u9ec3\u75b8\u3002", "e": "Purpose: To investigate the outcome of intraluminal brachytherapy (ILBT) using Iridium 192 (Ir-192) for hepatobiliary cancers with biliary tract obstruction. Materials and Methods: The clinical data of eleven patients with hepatobiliary malignancies (clinical stage as Tl-4, NO-1, MO) were collected from March 2007 to March 2011. AII of them had biliary obstruction caused by hepatobiliary cancers. The age at the initial diagnosis ranged from 46 to 79 years with a median of 68 years. AII patients received three to five fractions of high dose-rate Ir-192 ILBT (twice a day, for two to three days) with mean dose 01 14 Gy (9-17.5 Gy, 3.13 Gy/fraction, b.i.d.) and 6 of them also received external beam radiotherapy (EBRT) with mean dose of 44 Gy (40-64.8 Gy, 2 Gy/fraction/day). The median follow-up time from initial diagnosis was 10 months (1-28 months). Results: The mean value of pre-RT total bilirubin was 9.66 mg/dL (1.05-29.22 mg/dL) and that of post-RT was 1.73 mg/dL (0.27-4.23 mg/dL). The median survival time was 19 months for three patients with extra-hepatic cholangiocarcinoma, 9 months for three patients with intra-hepatic cholangiocarcinoma, 22 months for two patients with ampulla of Vater cancer and 5 months for those with hepatocellular carcinoma. The only single patient with gall bladder cancer survived 15 months. Conclusion: Ir-192 intraluminal brachytherapy is a feasible treatment option to relieve biliary tract obstruction and improve bile drainage for patients with hepatobiliary cancers."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-44-52", "title": "Tomotherapy for Craniospinal Irradiation: Dosimetric Comparison between Techniques", "keywords": "\u5168\u8166\u53ca\u810a\u9ad3\u7167\u5c04;\u87ba\u65cb\u5149\u5b50\u5200;\u653e\u5c04\u7dda\u6cbb\u7642 Craniospinal irradiation;TomoTherapy;Radiotherapy", "c": "Purpose: The aim of this study is to compare dosimetric parameters of TomoTherapy (Tomo) and 3D conformal radiotherapy (3D CRT) for craniospinal irradiation (CSI). Materials & Methods: Three patients requiring CSI treatments were enrolled. All patients were adult males and treated in the supine position. Computed tomography (CT) scans with 10mm slice thickness were acquired for both the 3D CRT and Tomo plans. The prescribed dosage of the planning target volume (PTV) was 32 Gy. Dose homogeneity index (DHI), conformal index (CI), and physical parameters were used to compare the differences between the two treatment modalities. Results: The V95% (volume of receiving at least 95% of prescribed dose) of planning target volume-brain (PTV-B) was 100% for six plans. The mean V95% of planning target volume-spine (PTV-S) were 98.7% and 100% for 3D CRT and Tomo plans, respectively. The mean Dmax (maximal dose) of PTV-B was higher on 3D CRT than on Tomo (37.4 Gy/117% vs. 33.6 Gy/105%). The mean Dmax of PTV-S on 3D CRT was much higher than that on Tomo (50.8 Gy/159% vs. 33 Gy/103%). The mean DHI of PTV-B showed significant differences between CRT (1.17) and Tomo (1 .05), p= 0.009. The dose distribution of PTV-S planned by Tomo was more homogenous than that planned by 3D CRT (mean DHI 1.03 vs. 1.59, p= 0.0047). There were no significant differences in the mean CI of PTV-B on CRT (0.76) and Tomo (0.74), p\uff1e 0.05. The mean CI of PTV-S of Tomo was better than that of 3D CRT (0.47 vs. 0.2, p\uff1c 0.05). There were decreases in all Dmax of organs at risk (OARs) in the Tomo group except for bilateral kidneys (Tomo vs. 3D CRT: 14.8 Gy vs. 3.8 Gy). Conclusion: Tomo is simpler than linear accelerator for CSI because there is no junction between treatment fields. The dosimetric parameters of DHI and CI are superior in the Tomo group. Decreased OAR dose via Tomo may be helpful for minimizing the long-term latent effect.", "e": "Purpose: The aim of this study is to compare dosimetric parameters of TomoTherapy (Tomo) and 3D conformal radiotherapy (3D CRT) for craniospinal irradiation (CSI). Materials & Methods: Three patients requiring CSI treatments were enrolled. All patients were adult males and treated in the supine position. Computed tomography (CT) scans with 10mm slice thickness were acquired for both the 3D CRT and Tomo plans. The prescribed dosage of the planning target volume (PTV) was 32 Gy. Dose homogeneity index (DHI), conformal index (CI), and physical parameters were used to compare the differences between the two treatment modalities. Results: The V95% (volume of receiving at least 95% of prescribed dose) of planning target volume-brain (PTV-B) was 100% for six plans. The mean V95% of planning target volume-spine (PTV-S) were 98.7% and 100% for 3D CRT and Tomo plans, respectively. The mean Dmax (maximal dose) of PTV-B was higher on 3D CRT than on Tomo (37.4 Gy/117% vs. 33.6 Gy/105%). The mean Dmax of PTV-S on 3D CRT was much higher than that on Tomo (50.8 Gy/159% vs. 33 Gy/103%). The mean DHI of PTV-B showed significant differences between CRT (1.17) and Tomo (1 .05), p= 0.009. The dose distribution of PTV-S planned by Tomo was more homogenous than that planned by 3D CRT (mean DHI 1.03 vs. 1.59, p= 0.0047). There were no significant differences in the mean CI of PTV-B on CRT (0.76) and Tomo (0.74), p\uff1e 0.05. The mean CI of PTV-S of Tomo was better than that of 3D CRT (0.47 vs. 0.2, p\uff1c 0.05). There were decreases in all Dmax of organs at risk (OARs) in the Tomo group except for bilateral kidneys (Tomo vs. 3D CRT: 14.8 Gy vs. 3.8 Gy). Conclusion: Tomo is simpler than linear accelerator for CSI because there is no junction between treatment fields. The dosimetric parameters of DHI and CI are superior in the Tomo group. Decreased OAR dose via Tomo may be helpful for minimizing the long-term latent effect."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-54-64", "title": "\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u6bd4\u8f03\u8207\u5291\u91cf\u9a57\u8b49\u65bc\u982d\u9838\u764c\u75c5\u4f8b\u4e4b\u7814\u7a76", "keywords": "\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u5f37\u63a7\u653e\u5c04\u6cbb\u7642;Gafchromic EBT2\u5e95\u7247 Volumetric modulated arc therapy;Intensity modulated radiotherapy;Gafchromic EBT2 film", "c": "\u76ee\u7684\uff1a\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u70ba\u76ee\u524d\u653e\u5c04\u6cbb\u7642\u4e2d\u8f03\u65b0\u4e4b\u6280\u8853\uff0c\u900f\u904e\u672c\u7814\u7a76\u4e86\u89e3\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u5f37\u5ea6\u5f37\u63a7\u653e\u5c04\u6cbb\u7642\u5728\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u4e0a\u8207\u6cbb\u7642\u6548\u7387\u4e0a\u4e4b\u5dee\u7570\uff0c\u4e26\u4e14\u900f\u904e\u5291\u91cf\u9a57\u8b49\u8a55\u4f30\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5206\u5e03\u4e4b\u6e96\u78ba\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81e8\u5e8a\u4e0a\u5341\u4f4d\u982d\u9838\u764c\u60a3\u8005\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8207\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u8a08\u756b\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4f7f\u7528Pinnacle^3 9.0\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u4e4b\u76f4\u63a5\u6a5f\u68b0\u53c3\u6578\u6700\u4f73\u5316\u7522\u751f\u4e5d\u500b\u5c04\u675f\u7167\u91ce\uff0c\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u4f7f\u7528Pinnacle^3 9.0 Smart Arc\u6700\u4f73\u5316\u7522\u751f\u5169\u500b\u5168\u5f27\u5f62\u5c04\u675f\uff0c\u5169\u8005\u7686\u4ee5Elekta AXESSE\u76f4\u7dda\u52a0\u901f\u5668\u70ba\u6cbb\u7642\u8a08\u756b\u8a08\u7b97\u57fa\u6e96\uff1bVMAT\u6cbb\u7642\u8a08\u756b\u4f7f\u7528Wellhofer cc01\u6e38\u96e2\u8154\u57f7\u884c\u9ede\u5291\u91cf\u9a57\u8b49\u4e26\u4f7f\u7528ISP\uff08international specialty products Wayne\uff0cNJ\uff09\u516c\u53f8\u6240\u767c\u5c55\u4e4b\u81ea\u986f\u5f71\u5e95\u7247Gafchromic EBT2\u5e95\u7247\u8207\u9a57\u8b49\u8edf\u9ad4FilmQA\u4f86\u5206\u6790\u9762\u5291\u91cf\u5206\u5e03\u3002\u7d50\u679c\uff1a\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u8207\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5728\u6cbb\u7642\u8a08\u756b\u4e2d\u8a08\u756b\u9776\u9ad4\u7a4dV95\u4e26\u7121\u660e\u986f\u5dee\u7570\uff0c\u5371\u6025\u5668\u5b98\u65bc\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u5247\u6709\u8f03\u5c11\u7684\u5291\u91cf\uff1b\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u9ede\u5291\u91cf\u5e73\u5747\u8aa4\u5dee\u70ba2.43%\uff081.6%\uff0d3.2%\uff09\uff0c\u9762\u5291\u91cfgamma\u503c\u5e73\u5747\u70ba97.38%\uff0896.7%\uff0d98.2%\uff09\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u85c9\u7531\u672c\u7814\u7a76\u53ef\u4ee5\u4e86\u89e3\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u5728\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u4e4b\u8868\u73fe\u4ee5\u53ca\u5291\u91cf\u9a57\u8b49\u4e4b\u6e96\u78ba\u6027\uff1b\u52d5\u614b\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u53ef\u7dad\u6301\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u4e0b\uff0c\u540c\u6642\u6cbb\u7642\u6642\u9593\u4e4b\u82b1\u8cbb\u6bd4\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u53ef\u5e73\u5747\u6e1b\u5c1156%\u4e14\u8f38\u51fa\u76e3\u6e2c\u55ae\u4f4d\u5e73\u5747\u6e1b\u5c1120%\u3002", "e": "Purpose: Volumetric modulated arc therapy (VMAT) is a relatively new technology of radiation therapy. The objective of this study is to compare VMAT with fixed field intensity modulated radiotherapy (IMRT) in term s of plan quality, delivery efficiency, and to assess the dose distribution by dose verification of the accuracy of VMAT. Materials and Methods: Ten clinical cases of head and neck cancer were evaluated in this study. IMRT plans were developed using direct machine parameter optimization in the Pinnacle^3 V9.0 treatment planning system, VMAT plans were generated using Smart Arc in the Pinnacle^3 V9.0. ITMRT and VMAT plans were delivered using Elekta AXESSE. Treatment plan quality assurance for VMAT was performed using the Wellhofer cc01 ion chamber and Gafchromic EBT2 film system. Results: The PTV V95 is no significant difference between VMAT and IMRT. Normal tissue sparing was improved using VMAT as compared with IMRT. The verification of VMAT dose point average error and average gamma was 2.43% (1.6%-3.2%) and 97.38% (96.7%-98.2%). Dicussion and Conclusion: VMAT treatment plans can be delivered accurately based on dose verification. VMAT has the potential to significantly reduce 56% treatment time and 20% monitor unit compared with IMRT, with no sacrifice in quality of plan."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-66-75", "title": "Sensitizing Effect of Berberine on Radiation-Induced Cytotoxicity in Human Liver Cancer Cells", "keywords": "\u9ec3\u84ee\u7d20;\u7d30\u80de\u51cb\u4ea1;\u653e\u5c04\u7dda\u654f\u611f\u6027 Berberine;Apoptosis;Radiosensitivity", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u9ec3\u84ee\u7d20\u5c0d\u65bc\u653e\u5c04\u7dda\u9020\u6210\u4eba\u985e\u809d\u764c\u7d30\u80de\u7684\u6b7b\u4ea1\u662f\u5426\u6709\u589e\u654f\u4f5c\u7528\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528\u4eba\u985e\u809d\u764c\u7d30\u80de\u682aHep3B\uff0c\u6bd4\u8f03\u4ee5\u653e\u5c04\u7dda\u6216\u653e\u5c04\u7dda\u5408\u4f75\u9ec3\u84ee\u7d20\u5c0d\u65bcHep3B\u7d30\u80de\u6b7b\u4ea1\u7684\u5f71\u97ff\uff0c\u5229\u7528MTT assay\u5206\u6790\u7d30\u80de\u7684\u5b58\u6d3b\uff0c\u4ee5DAPI stain\u8a08\u7b97\u7d30\u80de\u6838\u5167DNA\u6fc3\u67d3\u7684\u6578\u76ee\uff0c\u800cflow cytometry\u5206\u6790\u5b9a\u91cf\u7d30\u80de\u7684\u51cb\u4ea1\uff0cwestern blot\u5206\u6790\u8207\u7d30\u80de\u51cb\u4ea1\u76f8\u95dc\u86cb\u767d\u7684\u8868\u73fe\u3002\u7d50\u679c\uff1a\u653e\u5c04\u7dda\u4e3b\u8981\u8a98\u5c0eHep3B\u7d30\u80de\u7684\u51cb\u4ea1\uff0c\u8207\u653e\u5c04\u5291\u91cf\u6210\u6b63\u76f8\u95dc\u3002\u6bd4\u8f03\u55ae\u7368\u653e\u5c04\u7dda\u7167\u5c0410Gy\u8207\u5408\u4f7510Gy\u7684\u653e\u5c04\u7dda\u53ca10\u03bcM\u9ec3\u84ee\u7d20\u5169\u7d44\u7d30\u80de\uff0c\u6d41\u5f0f\u7d30\u80de\u5100\u986f\u793a\u7d30\u80de\u51cb\u4ea1\u7684\u6bd4\u4f8b\u81ea15.3%\u63d0\u5347\u81f347.2%\u3002\u8207\u7d30\u80de\u51cb\u4ea1\u76f8\u95dc\u7684\u86cb\u767d\u5982cytochrome c\u3001Bax\u3001p-JNK\u3001cleaved caspase-3\u8868\u73fe\u91cf\u589e\u52a0\uff0c\u76f8\u53cd\u5730\uff0c\u6297\u51cb\u4ea1\u86cb\u767d\u5982Bcl-2\u8207Akt\u7684\u8868\u73fe\u5247\u964d\u4f4e\u3002\u7d50\u8ad6\uff1a\u4e0a\u8ff0\u7d50\u679c\u8b49\u5be6\u9ec3\u84ee\u7d20\u80fd\u63d0\u5347\u653e\u5c04\u7dda\u6bd2\u6bbaHep3B\u7d30\u80de\u7684\u6548\u679c\uff0c\u5176\u5206\u5b50\u8abf\u63a7\u6a5f\u8f49\u63a8\u6e2c\u53ef\u80fd\u662f\u900f\u904e\u6d3b\u5316JNK\u8207\u6291\u5236Akt\u8a0a\u606f\u50b3\u5c0e\u9014\u5f91\uff0c\u9019\u90e8\u5206\u6709\u5f85\u9032\u4e00\u6b65\u5be6\u9a57\u8b49\u5be6\u3002", "e": "Purpose: To study the sensitizing effect of berberine on radiation-induced cytotoxicity in human liver cancer cells. Materials and Methods: Berberine, an isoquinoline alkaloid, was used in combination with radiotherapy to treat a human liver cancer cell line, Hep3B. The cells were irradiated with the indicated single dose of 10Gy with or without berberine (10\u03bcM) and cell viability was analyzed on MTT(3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl- tetrazolium bromide) assay. DAPI(4',6-diamidino-2-phenylindole)staining was used to detect the apoptosis and acridine orange was used to detect presence of acidic organelles formation. The morphology of the cells was observed under fluorescence microscope and apoptosis was quantified by flow cytometry. The expressions of apoptosis-related proteins such as cytochrome c, cleaved caspase-3, Bax, p-JNK, Bcl-2 and Akt were analyzed on Western blot. Results: Radiation induced apoptotic cell death of Hep3B cells in a dose-dependent manner. The ratio of apoptotic cells increased from 15.3% in Hep3B treated with irradiation alone to 47.2% in Hep3B cells treated with irradiation in combination with berberine. Western blot analysis demonstrated increased expressions of apoptosis-related proteins, such as cytochrome c, Bax, p-JNK, and cleaved caspase-3, and decreased expressions of phosphorylated Akt and Bcl-2. Conclusion: Berberine enhances radiation-induced cytotoxicity in Hep3B cells most likely by activation of JNK and suppression of Akt."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201203-201204230001-201204230001-76-83", "title": "\u653e\u5c04\u7dda\u6cbb\u7642\u8cc7\u8a0a\u6574\u5408", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u8cc7\u6599\u6574\u5408;HIS;PACS Radiation oncology;Data management;HIS;PACS", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u816b\u7624\u79d1\u7684\u6cbb\u7642\u8cc7\u6599\u4e00\u5411\u4ee5\u79d1\u5167\u7d19\u672c\u5b58\u6a94\u70ba\u4e3b\u3002\u82e5\u8981\u7d71\u5408\u5169\u9662\u5340\u7684\u75c5\u60a3\u8cc7\u6599\uff0c\u5247\u9700\u8981\u4e00\u500b\u96d9\u908a\u6574\u5408\u7cfb\u7d71\u4ee5\u5229\u65bc\u75c5\u4eba\u8cc7\u6599\u50b3\u905e\u3002\u540c\u6642\uff0c\u76ee\u524d\u764c\u75c7\u6cbb\u7642\u8da8\u65bc\u591a\u79d1\u91ab\u7642\u6574\u5408\u6a21\u5f0f\u3002\u7d71\u5408\u6027\u764c\u75c7\u60a3\u8005\u8cc7\u6599\u7684\u7cfb\u7d71\u5efa\u7acb\u53ef\u4ee5\u5354\u52a9\u75c5\u60a3\u8cc7\u8a0a\u6574\u5408\uff0c\u52a0\u5f37\u6cbb\u7642\u54c1\u8cea\u3002\u672c\u6587\u4e2d\uff0c\u6211\u5011\u6b32\u7814\u767c\u6574\u5408\u6027\u7cfb\u7d71\u4ee5\u7b26\u5408\u4e0a\u8ff0\u76ee\u7684\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5404\u5206\u9662\u5340\u5df2\u901a\u7528\u7684\u7cfb\u7d71\u5305\u62ec\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\uff08HIS\uff09\u3001\u5f71\u50cf\u64f7\u53d6\u53ca\u50b3\u8f38\u7cfb\u7d71\uff08PACS\uff09\uff0c\u9084\u6709\u75c5\u6458\u7cfb\u7d71\u3002\u6211\u5011\u5728\u75c5\u6458\u7cfb\u7d71\u4e0a\u5efa\u7f6e\u653e\u5c04\u7dda\u6cbb\u7642\u65b0\u75c5\u4eba\u8a55\u4f30\u8a18\u9304\uff0c\u4e26\u4e14\u5728HIS\u7cfb\u7d71\u4e0a\u6839\u64da\u53f0\u7063\u764c\u75c7\u767b\u8a18\u8cc7\u6599\u5eab\u6240\u9700\u8cc7\u6599\u5efa\u7acb\u653e\u5c04\u7dda\u6cbb\u7642\u7d00\u9304\u6458\u8981\u3002\u6b64\u5916\u5c07\u6cbb\u7642\u7cfb\u7d71\u4e0a\u7684\u8a08\u756b\u5716\u8f49\u6210\u91ab\u7642\u6578\u4f4d\u5f71\u50cf\u50b3\u8f38\u5354\u5b9a\uff08DICOM\uff09\u6a94\u6848\u4e0a\u50b3PACS\u3002\u7d50\u679c\uff1a\u53c3\u8207\u540c\u4e00\u60a3\u8005\u6cbb\u7642\u7684\u91ab\u5e2b\u53ef\u4ee5\u900f\u904e\u4e0a\u8ff0\u7cfb\u7d71\u7684\u8cc7\u6599\u4e86\u89e3\u653e\u5c04\u7dda\u6cbb\u7642\u9032\u884c\u6642\u7684\u8a55\u4f30\u3001\u6cbb\u7642\u8a08\u756b\uff0c\u4ee5\u53ca\u6700\u7d42\u57f7\u884c\u60c5\u6cc1\u3002\u6b64\u7cfb\u7d71\u540c\u6642\u4e5f\u63d0\u4f9b\u764c\u75c7\u767b\u8a18\u76f8\u95dc\u8cc7\u8a0a\u4ee5\u6536\u9304\u8cc7\u6599\u3002\u6b64\u5916\uff0c\u75c5\u60a3\u4e5f\u53ef\u4ee5\u900f\u904e\u4e0a\u8ff0\u7cfb\u7d71\u66f4\u52a0\u4e86\u89e3\u81ea\u5df1\u6240\u63a5\u53d7\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u7d30\u7bc0\u7b49\u8cc7\u8a0a\u7d50\u8ad6\uff1a\u81ea\u900f\u904e\u9023\u7d50\u653e\u5c04\u816b\u7624\u79d1\u5167\u7684\u96fb\u5b50\u8cc7\u8a0a\u3001HIS\u3001\u4ee5\u53caPACS\u53ef\u4ee5\u63d0\u4f9b\u60a3\u8005\u6574\u5408\u6027\u7684\u6cbb\u7642\u8cc7\u8a0a\uff0c\u4e0d\u50c5\u50c5\u65b9\u4fbf\u91ab\u5e2b\u4e4b\u9593\u7684\u91ab\u5b78\u8a0e\u8ad6\uff0c\u66f4\u80fd\u5920\u589e\u9032\u91ab\u5e2b\u8207\u75c5\u60a3\u4e4b\u9593\u7684\u6e9d\u901a\u8207\u95dc\u4fc2\u3002", "e": "Purpose: Multiple treatment sites of one radiation oncology department need an integrated system to assure the effectiveness of patient information communication. A patient centered union data-base was needed to improve the quality of multimodality treatment. We tried to create a system to meet these necessities. Materials and Methods: The previous intranet information system was system was modified. We set up a database to restore radiation oncology completion information at HIS, and another data-base to restore initial notes from radiation oncology in the hospital\u2019s previous summarized system. All the items from radiation completion notes followed the Taiwan Cancer Database to facilitate data collection. Also, the images from the planning system were transformed to DICOM and sent on to PACS. Results: Physicians involved in a patient\u2019s treatment comprehend the evaluation, treatment planning, and final treatment of radiotherapy via above systems. The systems provide sufficient relative information for the Taiwan Cancer Database collection. In addition, detailed information from radiation therapy can be revealed to the patient through the images on PACS. Conclusion: The connection of radiation electronic management data system, HIS, and PACS provide integrated information on cancer patient treatment. The information facilitates the communication not only between physicians, but also between physician and patient."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-3-11", "title": "Prognostic Factors Analysis of Lung Cancer Patients with Brain Metastasis after Whole Brain Irradiation", "keywords": "\u80ba\u764c;\u8166\u8f49\u79fb;\u9810\u5f8c\u56e0\u5b50;\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u7642 Lung cancer;Brain metastasis;Prognostic factor;Whole brain radiotherapy", "c": "Purpose: Brain metastases occur commonly in patients with lung cancer. The aim of this study is to evaluate survival outcome and prognostic factors of whole brain radiotherapy (WBRT) for lung cancer patients with brain metastases.Patients and Methods: We retrospectively reviewed the medical records of 386 lung cancer patients with brain metastases who received WBRT between January 2001 and December 2008. The end-point was overall survival (OS). Several potential prognostic factors were studied: age, gender, histology, performance status, number of brain metastases, prior therapy of lung cancer, dose schedule, and presence of extracranial metastases.Results: No patient was lost to follow-up. 374 patients died with disease and 12 patients were alive. OS ranged from 2 weeks to 40 months (median 4.7 months). In the univariate analysis, better survival was observed in age \uff1c 65 years old (p\uff1c0.0001), female gender (p\uff1c0.0001), good performance status (p= 0.0201) and absence of extracranial metastases (p= 0.0226). In the multivariate analysis, age \uff1c 65 years old (p\uff1c0.001), female gender (p\uff1c0.001), good performance status (p= 0.014), absence of extracranial metastases (p\uff1c0.001) and absence of prior therapy of lung caner (p= 0.003) were favorable factors.Conclusion: The survival outcome for lung cancer patients with brain metastasis after WBRT was poor. Age \uff1c 65 years old, female gender, good performance status, absence of extracranial metastases and absence of prior therapy of lung caner were favorable prognostic factors.[Therapeut Radiol Oncol 2011; 18(4): 265-273]", "e": "Purpose: Brain metastases occur commonly in patients with lung cancer. The aim of this study is to evaluate survival outcome and prognostic factors of whole brain radiotherapy (WBRT) for lung cancer patients with brain metastases.Patients and Methods: We retrospectively reviewed the medical records of 386 lung cancer patients with brain metastases who received WBRT between January 2001 and December 2008. The end-point was overall survival (OS). Several potential prognostic factors were studied: age, gender, histology, performance status, number of brain metastases, prior therapy of lung cancer, dose schedule, and presence of extracranial metastases.Results: No patient was lost to follow-up. 374 patients died with disease and 12 patients were alive. OS ranged from 2 weeks to 40 months (median 4.7 months). In the univariate analysis, better survival was observed in age \uff1c 65 years old (p\uff1c0.0001), female gender (p\uff1c0.0001), good performance status (p= 0.0201) and absence of extracranial metastases (p= 0.0226). In the multivariate analysis, age \uff1c 65 years old (p\uff1c0.001), female gender (p\uff1c0.001), good performance status (p= 0.014), absence of extracranial metastases (p\uff1c0.001) and absence of prior therapy of lung caner (p= 0.003) were favorable factors.Conclusion: The survival outcome for lung cancer patients with brain metastasis after WBRT was poor. Age \uff1c 65 years old, female gender, good performance status, absence of extracranial metastases and absence of prior therapy of lung caner were favorable prognostic factors.[Therapeut Radiol Oncol 2011; 18(4): 265-273]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-12-23", "title": "Treatment Results and Prognostic Factors of FIGO Stage III and IVA Cervical Cancer Treated with Concurrent Chemoradiotherapy", "keywords": "\u5b50\u5bae\u9838\u764c;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Cervical carcinoma;Concurrent chemoradiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u7d71\u8a08\u5c40\u90e8\u665a\u671f\u9c57\u72c0\u7d30\u80de\u5b50\u5bae\u9838\u764c\u60a3\u8005\uff0c\u5728\u672c\u9662\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u7d50\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u5206\u6790\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1999\u5e741\u6708\u52302008\u5e7412\u6708\u7e3d\u5171106\u4f4d\u88ab\u8a3a\u65b7\u70baFIGO III\uff0dIVa\u671f\u5b50\u5bae\u9838\u764c\u75c5\u60a3\uff0c\u5728\u672c\u9662\u63a5\u53d7\u904e\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3002\u5176\u4e2d\u670993\u4f4d\uff0887.7%\uff09\u70ba\u9c57\u72c0\u7d30\u80de\u764c\u60a3\u8005\u505a\u70ba\u672c\u6b21\u56de\u6eaf\u6027\u5206\u6790\u7684\u5c0d\u8c61\u3002\u5b58\u6d3b\u7387\u662f\u4ee5Kaplan-Meier method\u8a08\u7b97\uff0c\u55ae\u4e00\u8b8a\u6578\u5206\u6790\u662f\u63a1\u7528log\uff0drank test\uff0c\u800c\u591a\u8b8a\u6578\u5206\u6790\u662f\u63a1\u7528Cox proportional hazards model\u3002\u7d50\u679c\uff1a\u75c5\u4eba\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba55\u6b72\uff08\u7bc4\u570d\u4ecb\u65bc34\u81f386\u6b72\uff09\uff0c\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba57.05\u500b\u6708\uff08\u7bc4\u570d\u4ecb\u65bc4.57\uff0d137.3\u500b\u6708\uff09\u30025\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba63.4%\uff0c5\u5e74\u7684\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u548c\u9060\u8655\u8f49\u79fb\u63a7\u5236\u7387\u5206\u5225\u70ba61.3% and 57.0%\u300234\u500b\u75c5\u60a3\uff0836.6%\uff09\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u6216\u9060\u8655\u8f49\u79fb\uff1a9\u500b\u75c5\u60a3\u7522\u751f\u5c40\u90e8\u5fa9\u767c\uff0c25\u500b\u75c5\u60a3\u7522\u751f\u9060\u8655\u8f49\u79fb\uff0c\u5176\u4e2d\u67091\u75c5\u60a3\u540c\u6642\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u73fe\u8c61\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u751f\u6d3b\u529f\u80fd\u72c0\u614b\uff08ECOG performance status\uff09\u3001\u816b\u7624\u5927\u5c0f\uff08\u5927\u65bc4cm\uff09\u3001\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u9c57\u72c0\u7d30\u80de\u764c\u6297\u539f\u503c\u4ecd\u5347\u9ad8\uff08elevated serum SCC-Ag after CCRT\uff09\u3001\u6cbb\u7642\u524d\u8840\u7d05\u7d20\u4f4e\u4e0b\u8207\u76c6\u6dcb\u5df4\u8f49\u79fb\u5c0d\u65bc5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u548c\u9060\u8655\u8f49\u79fb\u63a7\u5236\u7387\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5728\u591a\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u751f\u6d3b\u529f\u80fd\u72c0\u614b\u8207\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u9c57\u72c0\u7d30\u80de\u764c\u6297\u539f\u503c\u4ecd\u5347\u9ad8\u5c0d\u65bc5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u548c\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\uff1b\u751f\u6d3b\u529f\u80fd\u72c0\u614b\u3001\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u9c57\u72c0\u7d30\u80de\u764c\u6297\u539f\u503c\u4ecd\u5347\u9ad8\u8207\u816b\u7624\u5927\u65bc4\u516c\u5206\u5c0d\u65bc5\u5e74\u9060\u8655\u8f49\u79fb\u63a7\u5236\u7387\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u5728\u6b64\u7814\u7a76\u4e2d\uff0c\u75c5\u60a3\u7684\u751f\u6d3b\u529f\u80fd\u72c0\u614b\u8f03\u5dee\u3001\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u9c57\u72c0\u7d30\u80de\u764c\u6297\u539f\u503c\u4ecd\u5347\u9ad8\u8207\u816b\u7624\u5927\u65bc4cm\uff0c\u5176\u9810\u5f8c\u8f03\u5dee\uff0c\u5c0d\u65bc\u9019\u4e9b\u75c5\u4eba\u53ef\u4ee5\u8003\u616e\u7d66\u4e88\u66f4\u7a4d\u6975\u7684\u6cbb\u7642\u3002[\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b782011\uff1b18(4)\uff1a275-286]", "e": "Purpose: To investigate the overall survival, local control and distant control of patients with locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy (CCRT). We analyze the prognostic factors affecting their outcomes.Materials and Methods: We conducted a retrospective analysis of 106 patients with FIGO stage III-IVa carcinoma of the cervix treated with CCRT between January 1999 and December 2008 in our institution. Ninety-three patients with squamous cell carcinoma (87.7%). Survival estimations were analyzed using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model.Results: The median age at diagnosis was 55 years (range: 34-86 years). The median follow-up period was 57.05 months (range: 4.57-137.3 months) respectively. The 5-year overall survival (OS) rate was 63.4%, and 5-year local control (LC) and distant control (DC) rates of 61.3% and 57.0%, respectively. Thirty-four of 93 patients (36.6%) were diagnosed with recurrence or distant metastasis at the follow-up time. Twenty-five patients (26.8%) had distant failure, of which 24 had only distant metastasis, one patient had both distant and loco-regional recurrence, and the remaining 9 patients recurred locoregionally.ECOG performance status, tumor size, pelvic lymphadenopathy, pre-treatment hemoglobin and elevated serum SCC level after CCRT were significantly correlated with 5-year OS, LC and DC by univariate analysis. The ECOG performance status and elevated serum SCC after CCRT are significant prognostic factors for 5-year OS and LC rate. The performance status, tumor size (\uff1e4 cm) and elevated serum SCC level after CCRT were significant for 5-year DC rate by multivariate analysis.Conclusions: The patient with poor ECOG performance status, bulky tumor (\uff1e4cm) and elevated serum SCC after CCRT had worse outcome. More aggressive treatment may be considered for these patients.[Therapeut Radiol Oncol 2011; 18(4): 275-286]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-24-34", "title": "\u91ab\u9662\u670d\u52d9\u54c1\u8cea\u8207\u9867\u5ba2\u50f9\u503c\u5c0d\u65bc\u764c\u60a3\u6eff\u610f\u5ea6\u7684\u95dc\u4fc2\u63a2\u8a0e", "keywords": "\u91ab\u9662\u670d\u52d9\u54c1\u8cea;\u9867\u5ba2\u50f9\u503c;\u764c\u60a3\u6eff\u610f\u5ea6 Medical service quality;Customer value;Cancer patient", "c": "Purpose: The aim of this study is to understand the level of patient's perception toward both hard and soft facilities of medical industry to further discuss the relationship between the \u201dmedical service quality\u201d and the \u201dcustomer value\u201d and its impact on the \u201dcancer patient's satisfaction\u201d and the \u201dcustomer value\u201d, and hopefully to improve the customer loyalty based on the \u201dcustomer oriented\u201d service to achieve the highest goal of sustained management for medical care institutions.Material and Method: This study targeted on the patients who have received the complete radiotherapy at a medical center in northern Taiwan from March 1st 2010 to October 30th 2010. Through structured questionnaire method, the patients aged above 20 regardless of gender and education degree have filled the questionnaires. A total of 550 questionnaires were collected. Based on Pearson correlation analysis, the correlation statistic was conducted.Results: Most of the cancer patients were satisfied with the soft and hard facilities provided by hospital; Cancer patients were also satisfied with the medical workers' professional knowledge and technical proficiency. Further, 346 patients were satisfied with the hospital's efficiency of handling complaints and 384 patients felt it is worth while to pay the medical fees. As a result, 535 (97.3%) of the patients have expressed willingness to go back to the same hospital; 539 patients (98%) have shown willingness to recommend the hospital to their families and friends. 411 patients (74.7%) indicated that they will not choose other hospital even if the registration fee is lower.Discussion: The medical workers' professional knowledge and technical proficiency are correlated with the cancer patients' medical service satisfaction (p\uff1c0.01) and are also correlated with the medical service procedure and the efficiency of handling patients' complaints (p\uff1c0.01). The higher patients' medical service satisfaction is associated with higher rate of returning to the hospital. They are positively correlated (p\uff1c0.003). The overall service from the hospital is positively correlated with the patients' willingness for recommendation. The patients will be more willing to recommend their families and friends to the hospital if they receive higher satisfaction with the hospital's overall medical service. The result is very significant (p\uff1c0.003). When the cancer patients are satisfied with the overall service of the hospital they initially consulted, they will not choose other hospital even if the registration fee is lower. The result is very significant (p\uff1c0.001).[Therapeut Radiol Oncol 2011; 18(4): 287-297]", "e": "Purpose: The aim of this study is to understand the level of patient's perception toward both hard and soft facilities of medical industry to further discuss the relationship between the \u201dmedical service quality\u201d and the \u201dcustomer value\u201d and its impact on the \u201dcancer patient's satisfaction\u201d and the \u201dcustomer value\u201d, and hopefully to improve the customer loyalty based on the \u201dcustomer oriented\u201d service to achieve the highest goal of sustained management for medical care institutions.Material and Method: This study targeted on the patients who have received the complete radiotherapy at a medical center in northern Taiwan from March 1st 2010 to October 30th 2010. Through structured questionnaire method, the patients aged above 20 regardless of gender and education degree have filled the questionnaires. A total of 550 questionnaires were collected. Based on Pearson correlation analysis, the correlation statistic was conducted.Results: Most of the cancer patients were satisfied with the soft and hard facilities provided by hospital; Cancer patients were also satisfied with the medical workers' professional knowledge and technical proficiency. Further, 346 patients were satisfied with the hospital's efficiency of handling complaints and 384 patients felt it is worth while to pay the medical fees. As a result, 535 (97.3%) of the patients have expressed willingness to go back to the same hospital; 539 patients (98%) have shown willingness to recommend the hospital to their families and friends. 411 patients (74.7%) indicated that they will not choose other hospital even if the registration fee is lower.Discussion: The medical workers' professional knowledge and technical proficiency are correlated with the cancer patients' medical service satisfaction (p\uff1c0.01) and are also correlated with the medical service procedure and the efficiency of handling patients' complaints (p\uff1c0.01). The higher patients' medical service satisfaction is associated with higher rate of returning to the hospital. They are positively correlated (p\uff1c0.003). The overall service from the hospital is positively correlated with the patients' willingness for recommendation. The patients will be more willing to recommend their families and friends to the hospital if they receive higher satisfaction with the hospital's overall medical service. The result is very significant (p\uff1c0.003). When the cancer patients are satisfied with the overall service of the hospital they initially consulted, they will not choose other hospital even if the registration fee is lower. The result is very significant (p\uff1c0.001).[Therapeut Radiol Oncol 2011; 18(4): 287-297]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-35-46", "title": "\u809d\u764c\u75c5\u60a3\u71df\u990a\u72c0\u6cc1\u8a55\u4f30\u8207\u751f\u6d3b\u54c1\u8cea\u4e4b\u5206\u6790", "keywords": "\u809d\u764c;\u71df\u990a\u8a55\u4f30;\u751f\u6d3b\u54c1\u8cea Hepatocellular carcinoma;Nutritional assessment;Quality of life", "c": "Purpose: The aims of this study are assessing the nutritional status and quality of life (QoL) in the patients with hepatocellular carcinoma, and analyzing the predictors of QoL.Materials and Methods: From August 2007 to March 2009, three hundred outpatients with hepatocellular carcinoma at the Department of Radiation Oncology, a teaching hospital in central Taiwan consented to participate in this study. The scores of the Mini-Nutrition Assessment (MNA), the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (EORTC QLQ-C30), and the data of routine biochemical tests were collected to evaluate the nutritional status and QoL.Results: Almost half of the patients (45.7%) had problems in nutritional status. The nutritional status of the patients was significantly related with the grade of liver cirrhosis (\u03c7^2 = 21.218, p \uff1c 0.001). The levels of global health status were not well, but the levels of the global functioning status were still satisfied. Analyzing impact of the variables on the QoL, the predictors of global health status were self-nutritional assessment, general nutritional assessment, diet assessment and AFP; general nutritional assessment, diet assessment, self-nutritional assessment, anthropometric assessment and AFP were the predictive factors of global functioning status.Conclusion: The nutritional status is the predictor of global QoL in the patients with hepatocellular carcinoma. Nutritional screening and assessment are necessary for liver cancer patients. In addition, nutritional intervention and support should be beneficial to improve the QoL for those patients.[Therapeut Radiol Oncol 2011; 18(4): 299-310]", "e": "Purpose: The aims of this study are assessing the nutritional status and quality of life (QoL) in the patients with hepatocellular carcinoma, and analyzing the predictors of QoL.Materials and Methods: From August 2007 to March 2009, three hundred outpatients with hepatocellular carcinoma at the Department of Radiation Oncology, a teaching hospital in central Taiwan consented to participate in this study. The scores of the Mini-Nutrition Assessment (MNA), the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (EORTC QLQ-C30), and the data of routine biochemical tests were collected to evaluate the nutritional status and QoL.Results: Almost half of the patients (45.7%) had problems in nutritional status. The nutritional status of the patients was significantly related with the grade of liver cirrhosis (\u03c7^2 = 21.218, p \uff1c 0.001). The levels of global health status were not well, but the levels of the global functioning status were still satisfied. Analyzing impact of the variables on the QoL, the predictors of global health status were self-nutritional assessment, general nutritional assessment, diet assessment and AFP; general nutritional assessment, diet assessment, self-nutritional assessment, anthropometric assessment and AFP were the predictive factors of global functioning status.Conclusion: The nutritional status is the predictor of global QoL in the patients with hepatocellular carcinoma. Nutritional screening and assessment are necessary for liver cancer patients. In addition, nutritional intervention and support should be beneficial to improve the QoL for those patients.[Therapeut Radiol Oncol 2011; 18(4): 299-310]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-47-55", "title": "A Novel Vagina Enhancement Modality Improves Dosimetric Parameters in Pelvic Intensity-modulated Radiotherapy", "keywords": "\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853;\u653e\u5c04\u7dda\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u8a08\u756b;\u8180\u80f1 Vagina enhancement modality;Intensity-modulated radiotherapy;Bladder", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u5b50\u5bae\u9838\u764c\u6216\u5b50\u5bae\u5167\u819c\u764c\u8853\u5f8c\u75c5\u60a3\u4e4b\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\uff0c\u8a55\u4f30\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853\u7684\u53ef\u884c\u6027\u548c\u5176\u8a08\u5283\u5291\u91cf\u4e4b\u5206\u6790\u7d50\u679c\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u91dd\u5c0d20\uff0d70\u6b72\u5b50\u5bae\u9838\u764c\u6216\u5b50\u5bae\u5167\u819c\u764c\u8853\u5f8c\u75c5\u60a3\uff0c\u6bd4\u8f03\u55ae\u7368\u65bc\u9670\u9053\u5167\u653e\u7f6e\u6a19\u8a18\u8207\u653e\u7f6e\u6a19\u8a18\u53ca\u9670\u9053\u986f\u5f71\u8853\u5169\u8005\u4e4b\u9593\u5728\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u7642\u8a08\u756b\u6642\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e0a\u7684\u5dee\u7570\u3002\u8a55\u4f30\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853\u80fd\u5426\u4f7f\u9670\u9053\u9031\u908a\u7d44\u7e54\u66f4\u70ba\u6e05\u695a\uff0c\u4ee5\u53ca\u9032\u884c\u653e\u5c04\u5291\u91cf\u5206\u6790\u3002\u7d50\u679c\uff1a\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853\u53ef\u6709\u6548\u7684\u4f7f\u9670\u9053\u5728\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e0a\u66f4\u70ba\u6e05\u695a\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u5206\u6790\u986f\u793a\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853\u53ef\u6709\u6548\u6e1b\u5c11\u8a08\u756b\u5167\u7684\u9670\u9053\u9ad4\u7a4d\uff0c\u9670\u9053\u548c\u90e8\u5206\u8180\u80f1\u53d7\u5230\u7684\u5e73\u5747\u5291\u91cf\u4e5f\u6709\u6e1b\u5c11\u3002\u6574\u9ad4\u8180\u80f1\u53d7\u5230\u5291\u91cf\u7684\u9ad4\u7a4d\u767e\u5206\u6bd4\uff08V45\uff09\u548c\u90e8\u5206\u8180\u80f1\u53d7\u5230\u5291\u91cf\u7684\u9ad4\u7a4d\u767e\u5206\u6bd4\uff08V45\u3001V50\uff09\u4e5f\u6709\u986f\u8457\u7684\u964d\u4f4e\u3002\u7d50\u8ad6\uff1a\u65b0\u5f62\u5f0f\u9670\u9053\u986f\u5f71\u8853\u5728\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u7684\u61c9\u7528\u53ef\u6e05\u695a\u5b9a\u4f4d\u51fa\u9670\u9053\uff0c\u4e26\u5728\u653e\u5c04\u5291\u91cf\u5206\u6790\u4e0a\u91dd\u5c0d\u8180\u80f1\u53ca\u9670\u9053\u63d0\u4f9b\u986f\u8457\u7684\u6539\u5584\u3002[\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b782011\uff1b18(4)\uff1a311-319]", "e": "Purpose: For the postoperative female pelvis intensity-modulated radiotherapy, contouring target volumes and normal structures around the paravaginal area varies greatly due to lack of landmarks of vaginal lumen. To aid a precise delineation for vaginal lumen, we developed a novel vagina enhancement modality (VEM) and evaluated its feasibility as well as dosimetric impact.Materials and Methods: Postoperative computed tomography (CT) scan simulations with and without VEM were taken for 5 patients with cervical or endometrial carcinoma. For the plans with VEM, cervical clip markers and a jelly-based vaginal contrast were applied before CT-simulations. The clinical target volume (CTV) of paravaginal area below the parametrium was then delineated with a 0.5-cm margin around the visible vaginal lumen. As for the plans without VEM, we applied cervical clip markers only, and the paravaginal CTV was delineated as the interspace between bladder and rectum. The feasibility of VEM was evaluated based on the visualization rate. The difference of vaginal volume contoured was also analyzed. Dosimetric parameters including mean dose and dose-volume histograms were compared between plans with and without VEM.Result: We found that the vaginal lumen was successfully illustrated on CT-simulations with VEM. In RT plans with VEM, dosimetric analysis showed significant decrease in vagina volume, bladder V45, corresponding bladder V45 and V50. The mean dose of vagina and corresponding bladder, which are critically influenced by paravaginal contouring, also showed significant reduction with VEM.Conclusion: The novel vaginal enhancement modality is an effective guide to clearly define the vagina lumen in postoperative female pelvis IMRT with dosimetric improvements particularly in bladder and vagina.[Therapeut Radiol Oncol 2011; 18(4): 311-319]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-56-65", "title": "\u6e96\u76f4\u5100\u89d2\u5ea6\u5c0d\u651d\u8b77\u817a\u764c\u60a3\u8005\u4f7f\u7528\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u8a08\u7b97\u7d50\u679c\u4e4b\u5f71\u97ff", "keywords": "\u6e96\u76f4\u5100\u89d2\u5ea6;\u651d\u8b77\u817a\u764c;\u92b3\u901f\u5200 Collimator angle;Prostate cancer;RapidArc", "c": "\u76ee\u7684\uff1a\u92b3\u901f\u5200\uff08RapidArc\uff09\u653e\u5c04\u6cbb\u7642\u662f\u5229\u7528\u65cb\u8f49\u81c2\uff08gantry\uff09\u5728\u65cb\u8f49\u7684\u540c\u6642\uff0c\u85c9\u7531\u6539\u8b8a\u591a\u8449\u5f0f\u6e96\u76f4\u5100\uff08multi-leaves collimator\uff1bMLC\uff09\u7684\u4f4d\u7f6e\u3001\u7167\u91ce\u5167\u7684\u8f3b\u5c04\u5291\u91cf\u7387\u4ee5\u53cagantry\u65cb\u8f49\u901f\u5ea6\uff0c\u4ee5\u9054\u5230\u9ad4\u7a4d\u8abf\u63a7\u5f27\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u76ee\u7684\u3002\u5176\u4e2d\uff0c\u70ba\u4e86\u6e1b\u5c11tongue and groove effect\u4ee5\u53ca\u63d0\u9ad8\u5291\u91cf\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\uff0c\u6e96\u76f4\u5100\uff08collimator\uff09\u89d2\u5ea6\u6210\u70ba\u512a\u5316\u6cbb\u7642\u8a08\u5283\u7684\u689d\u4ef6\u4e2d\u4e0d\u53ef\u6216\u7f3a\u7684\u4e3b\u8981\u53c3\u6578\u4e4b\u4e00\u3002\u672c\u7814\u7a76\u76ee\u7684\u5373\u70ba\u627e\u51fa\u9069\u5408\u651d\u8b77\u817a\u764c\u60a3\u8005\u4f7f\u7528\u4e4b\u6cbb\u7642\u8a08\u5283\u7684\u6e96\u76f4\u5100\u65cb\u8f49\u89d2\u5ea6\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65bc\u672c\u79d1\u60a3\u8005\u8cc7\u6599\u5eab\u4e2d\u6311\u907815\u4f4d\u651d\u8b77\u817a\u764c\u60a3\u8005\uff0c\u5206\u5225\u9078\u64c715\u5ea6\u300130\u5ea6\u300145\u5ea6\u300160\u5ea6\u300175\u5ea6\u7b495\u7a2e\u4e0d\u540c\u7684\u6e96\u76f4\u5100\u89d2\u5ea6\u91cd\u65b0\u9032\u884c\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u3002\u6240\u6709\u60a3\u8005\u5728\u9032\u884c\u92b3\u901f\u5200\u6cbb\u7642\u8a08\u5283\u7684\u512a\u5316\u904e\u7a0b\u4e2d\uff0c\u5c0d\u816b\u7624\u6cbb\u7642\u9ad4\u7a4d\uff08planning target volume\uff1bPTV\uff09\u548c\u5404\u5371\u6025\u5668\u5b98\uff08organ at risk\uff1bOAR\uff09\u4f7f\u7528\u76f8\u540c\u7684\u5291\u91cf\u9650\u5236\uff08dose constraint\uff09\u53ca\u5668\u5b98\u6b0a\u91cd\uff08priority\uff09\u4ee5\u6e1b\u5c11\u5f71\u97ff\u7d50\u679c\u7684\u8b8a\u7570\u6027\u3002\u539f\u5ee0\u5efa\u8b7045\u5ea6\u70ba\u6700\u4f73\u7684\u6e96\u76f4\u5100\u89d2\u5ea6\uff0c\u56e0\u6b64\u4ee545\u5ea6\u4f5c\u70ba\u6a19\u6e96\uff0c\u6bd4\u8f03\u6539\u8b8a\u6e96\u76f4\u5100\u89d2\u5ea6\u5404\u8a08\u5283\u5728\u816b\u7624\u6700\u5927\u5291\u91cf\u503c\uff08dose maximum\uff1bDmax\uff09\u3001\u5747\u52fb\u6027\uff08homogeneity index\uff1bHI\uff09\u53ca\u9806\u5f62\u5ea6\uff08conformal index\uff1bCI\uff09\u4ee5\u53ca\u5371\u6025\u5668\u5b98\uff08organ at risk\uff1bOAR\uff09\u6240\u63a5\u53d7\u7684\u5291\u91cf\u3002\u7d50\u679c\uff1a\u4ee545\u5ea6\u7576\u4f5c\u6a19\u6e96\u4f86\u9032\u884c\u6bd4\u8f03\uff0c\u6cbb\u7642\u8a08\u5283\u5728\u6e96\u76f4\u5100\u65cb\u8f4915\u5ea6\u300130\u5ea6\u300160\u5ea6\u548c75\u5ea6\u6240\u8a08\u7b97\u7684\u6700\u5927\u5291\u91cf\u503c\u5206\u5225\u6709 20%\uff083\uff0f15\uff09\u300173.3%\uff0811\uff0f15\uff09\u300153.3%\uff088\uff0f15\uff09\u548c 20%\uff083\uff0f15\uff09\u7684\u6bd4\u4f8b\u5c0f\u65bc45\u5ea6\u7684\u6700\u5927\u5291\u91cf\u503c\u3002\u572815\u5ea6\u300130\u5ea6\u300160\u5ea6\u548c75\u5ea6\u5206\u5225\u67096.7%\uff081\uff0f15\uff09\u300146.7%\uff087\uff0f15\uff09\u300140%\uff086\uff0f15\uff09\u548c13.3%\uff082\uff0f15\uff09\u7684\u6bd4\u4f8b\u6709\u8f03\u597d\u7684\u5747\u52fb\u6027\u3002\u800c\u572815\u5ea6\u300130\u5ea6\u300160\u5ea6\u548c75\u5ea6\u5206\u5225\u6709 40%\uff086\uff0f15\uff09\u300160%\uff089\uff0f15\uff09\u300140%\uff086\uff0f15\uff09\u548c 13.3%\uff082\uff0f15\uff09\u7684\u6bd4\u4f8b\u6709\u66f4\u597d\u7684\u9806\u5f62\u5ea6\uff0c\u5c0d\u65bc\u5371\u6025\u5668\u5b98\u6240\u63a5\u53d7\u7684\u5291\u91cf\u90fd\u53ef\u4ee5\u63a7\u5236\u5728\u5291\u91cf\u9650\u5236\u7684\u7bc4\u570d\u5167\u3002\u7d50\u8ad6\uff1a\u5728\u57f7\u884c\u92b3\u901f\u5200\u653e\u5c04\u6cbb\u7642\u6280\u8853\u6642\uff0c\u672c\u7814\u7a76\u7d50\u679c\u986f\u793a\u6e96\u76f4\u5100\u8a2d\u5b9a30\u5ea6\u89d2\u5c0d\u651d\u8b77\u817a\u764c\u7684\u60a3\u8005\u800c\u8a00\uff0c\u548c\u5176\u4ed6\u56db\u7a2e\u4e0d\u540c\u7684\u89d2\u5ea6\u53ef\u4ee5\u5bb9\u6613\u5f97\u5230\u8f03\u597d\u7684\u7d50\u679c\u3002[\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b782011\uff1b18(4)\uff1a321-330]", "e": "Purpose: RapidArc is the latest VMAT technique that treat patient very quickly by optimizing the MLC shape, radiation dose rate, and gantry rotation speed in a single arc radiotherapy. In addition to reduce tongue and groove effect and to raise the spatial resolution of high dose area, collimator angle has become a determining factor for RapidArc optimization. This study try to find the most suitable collimator angle for RapidArc treatment planning system for patients with prostate cancer.Materials and Methods: Fifteen prostate cancer patients were selected to re-optimize the treatment plan of RapidArc. Five different collimator angles (15\u00b0, 30\u00b0, 45\u00b0, 60\u00b0, 75\u00b0) were used while we doing the plans. RapidArc treatment plan optimization, using the same optimization parameters, such as dose constraint and priority for planned target volume and critical organ. The plan of 45 degree of collimator angle was used as the basis of comparison of the maximum dose(Dmax), homogeneity index(HI)and conformal index(CI)in the tumor and the dose received by critical organs.Result: To use the plan of 45 degree of collimator angle as the standard. When collimator rotated 15, 30, 60 and 75 degrees, there were 20% (3/15), 73.3% (11/15), 53.3% (8/15) and 20% (3/15) ratio of the Dmax lower than the Dmax calculated by 45 degree respectively. When collimator rotated 15, 30, 60 and 75 degrees, there were 6.7% (1/15), 46.7% (7/15), 40% (6/15) and 13.3% (2/15) ratio of results got more homogeneous distribution than 45 degree. And when collimator rotated 15, 30, 60 and 75 degrees, there were 40% (6/15), 60% (9/15), 40% (6/15) and 13.3% (2/15) ratio of the results has more conformal distribution. Further more, the dose which accepted by critical organs were all under the dose constraints.Conclusion: In order to reduce the tongue and groove effect and to improve spatial resolution of high dose area, collimator in the treatment process must be rotated. The results of this study show that the 30 degree of the collimator angle for prostate cancer patients has better result compared to another four different angles.[Therapeut Radiol Oncol 2011; 18(4): 321-330]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-66-75", "title": "\u4ee5\u96fb\u5b50\u9a57\u8b49\u5f71\u50cf\u5feb\u901f\u4f30\u6e2c\u5149\u8207\u8f3b\u5c04\u7167\u91ce\u4e00\u81f4\u6027\u3001\u5149\u5b50\u5e73\u5766\u6027\u8207\u5c0d\u7a31\u6027", "keywords": "\u5149\u8207\u8f3b\u5c04\u7167\u91ce\u7684\u4e00\u81f4\u6027;\u5149\u5b50\u5e73\u5766\u6027;\u5149\u5b50\u5c0d\u7a31\u6027;\u96fb\u5b50\u9a57\u8b49\u5f71\u50cf\u88dd\u7f6e Light/radiation field coincidence;Beam flatness;Beam symmetry;EPID", "c": "\u76ee\u7684\uff1a\u4ee5\u96fb\u5b50\u9a57\u8b49\u5f71\u50cf\u5feb\u901f\u4f30\u6e2c\u5149\u8207\u8f3b\u5c04\u7167\u91ce\u4e00\u81f4\u6027\u3001\u5149\u5b50\u5e73\u5766\u6027\u8207\u5c0d\u7a31\u6027\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6240\u4f7f\u7528\u4e4b\u96fb\u5b50\u9a57\u8b49\u5f71\u50cf\uff0c\u5176\u4f86\u6e90\u70baElekta Precise Sli\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u914d\u7f6e\u578b\u865f\u70baPerkin Elmer XRD 1640\u4e4b\u96fb\u5b50\u5f71\u50cf\u9a57\u8b49\u88dd\u7f6e\u6240\u62cd\u651d\u3002\u4ee5\u6240\u9644iViewGT\u8edf\u9ad4\u5c07\u5f71\u50cf\u8f49\u5b58\u70ba16\u4f4d\u5143\u7684\u6a19\u8a18\u5f71\u50cf\u6a94\u6848\u683c\u5f0f\u5f8c\uff0c\u5728\u5de5\u7a0b\u8a08\u7b97\u8edf\u9ad4Matlab\u7248\u672c2008b\u4e2d\uff0c\u64b0\u5beb\u7a0b\u5f0f\u5c0d\u8f38\u51fa\u5f71\u50cf\u9032\u884c\u5206\u6790\u3002\u6211\u5011\u9996\u5148\u6e2c\u91cf\u5728\u4e0d\u540c\u7684\u7167\u5c04\u689d\u4ef6\u4e0b\u6240\u6e2c\u5f97\u4e4b\u8f3b\u5c04\u7167\u91ce\u8207\u5149\u7167\u91ce\u662f\u5426\u543b\u5408\u3002\u63a5\u8457\u518d\u5206\u5225\u8a08\u7b97\u4e0d\u540c\u689d\u4ef6\u4e0b\u7684\u5149\u5b50\u5e73\u5766\u6027\u8207\u5c0d\u7a31\u6027\u3002\u7d50\u679c\uff1a\u6839\u64da\u6211\u5011\u7684\u5be6\u9a57\u7d50\u679c\uff0c\u6e2c\u91cf10\u5f35\u5f71\u50cf\u6c34\u5e73\u8ef8\u8207\u5782\u76f4\u8ef8\u7684\u5149\u8207\u8f3b\u5c04\u7167\u91ce\u7684\u4e00\u81f4\u6027\u3001\u5149\u5b50\u5e73\u5766\u6027\u8207\u5c0d\u7a31\u6027\u50c5\u9700\u82b1\u8cbb0.414\u79d2\u3002\u5176\u5167\u5bb9\u986f\u793a\uff0c\u5149\u8207\u8f3b\u5c04\u7167\u91ce\u4e00\u81f4\u6027\u8207\u5149\u5b50\u5c0d\u7a31\u6027\u4e4b\u6e2c\u91cf\u5168\u6578\u7b26\u5408\u6a19\u6e96\u3002\u4f46\u662f\u5728\u5e73\u5766\u5ea6\u7684\u6e2c\u91cf\u5247\u767c\u73fe\uff0c\u4ee56 MV\u7167\u5c04\u6642\uff0c\u6c34\u5e73\u8ef8\u7167\u91ce\u70ba5 cm\u300110 cm\u300115 cm\u820710 MV\u7167\u5c04\u6642\uff0c\u6c34\u5e73\u8ef8\u7167\u91ce\u70ba5 cm\u5171\u56db\u7d44\u8cc7\u6599\uff0c\u56e0MLC\u8f03\u5927\u7684\u534a\u5f71\u5340\u5c0e\u81f4\u6e2c\u91cf\u7d50\u679c\u8d85\u51fa\u898f\u5b9a\u9650\u503c\u3002\u7d50\u8ad6\uff1a\u76f8\u8f03\u65bc\u5176\u4ed6\u6e2c\u91cf\u5100\u5668\uff0c\u96fb\u5b50\u9a57\u8b49\u5f71\u50cf\u88dd\u7f6e\u4e4b\u89e3\u6790\u5ea6\u70ba1024\u00d71024\uff0c\u7d93\u63db\u7b97\u5f8c\u7d040.25mm\uff0c\u53ef\u4ee5\u5075\u6e2c\u51fa\u5c0f\u7167\u91ce\u7d30\u5fae\u7684\u8b8a\u5316\u3002\u5feb\u901f\u7684\u6e2c\u91cf\u8a08\u7b97\u642d\u914d\u6aa2\u6e2c\u983b\u7387\u7684\u63d0\u9ad8\u53ef\u4ee5\u63d0\u65e9\u767c\u73fe\u554f\u984c\uff0c\u518d\u4f7f\u7528\u66f4\u7cbe\u5bc6\u7684\u5100\u5668\u5982\u6c34\u5047\u9ad4\u7b49\u5100\u5668\u9032\u884c\u66f4\u9032\u4e00\u6b65\u7684\u6e2c\u91cf\u3002[\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b782011\uff1b18(4)\uff1a331-340]", "e": "Purpose: Fast evaluation of light/radiation field coincidence, beam flatness and symmetry measurement by electronic portal image device.Material and Methods: In this study, EPIs was taken by Elekta precise SLi linear accerator equipped with Perkin Elmer XRD 1640 EPID. Images were exported by iView GT software as 16 bits Tagged Image File Format. All images were analyzed by Matlab 2008b. Light/radiation fields coincidence was calculated under different exposure condition. Finally, beam flatness and symmetry of different photon energy and collimator setting were analyzed.Results: According to the experiment results, it takes 0.414 seconds to analyze 10 EPIs with light/radiation field coincidence, beam flatness and symmetry. Each has vertical and horizontal data respectively. All of the results of light/radiation field coincidence and symmetry measurement could meet the standard of tolerance. But the horizontal flatness of 6 MV with 5 cm, 10 cm and 15 cm collimator settings and 10 MV with 5 cm collimator setting exceeded the tolerance level due to larger penumbra of MLC.Conclusion: Compare with other instruments, the resolution of EPID is 1024\u00d71024. It means that each pixel represents 0.25 mm that is suitable for small field analysis. The calculation is fast enough to increase analysis frequency and any abnormality could be uncovered as early as possible.[Therapeut Radiol Oncol 2011; 18(4): 331-340]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201112-201203020008-201203020008-76-80", "title": "Helical Tomotherapy Reduces Pain Efficiently for Circuited Pleural Metastasis of Nasopharyngeal Carcinoma-A Case Report", "keywords": "\u5c0e\u822a\u87ba\u65cb\u5200;\u9f3b\u54bd\u764c;\u808b\u819c\u8f49\u79fb;\u75db Helical tomotherapy;Nasopharyngeal carcinoma;Pleural metastasis;Pain", "c": "\u9f3b\u54bd\u764c\u808b\u819c\u8f49\u79fb\u5e38\u56e0\u816b\u7624\u5f62\u6210\u5713\u67f1\u72c0\u8207\u9130\u8fd1\u5371\u96aa\u5668\u5b98\u800c\u9020\u6210\u6cbb\u7642\u56f0\u96e3\u3002\u5c0e\u822a\u87ba\u65cb\u5200\u662f\u4e00\u65b0\u5f0f\u5f71\u50cf\u5c0e\u822a\u4e4b\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5100\u5668\uff0c\u80fd\u63d0\u4f9b\u9ad8\u9806\u5f62\u5ea6\u816b\u7624\u6cbb\u7642\u8207\u5371\u96aa\u5668\u5b98\u9583\u907f\u4e4b\u529f\u80fd\u3002\u6545\u5c0e\u822a\u87ba\u65cb\u5200\u53ef\u7528\u65bc\u56f0\u96e3\u6cbb\u7642\u4e4b\u816b\u7624\u3002\u4e00\u4f4d38\u6b72\u9f3b\u54bd\u764c\u60a3\u8005\u56e0\u808b\u819c\u8f49\u79fb\u9020\u6210\u5f37\u70c8\u795e\u7d93\u75bc\u75db\u75c7\u72c0\uff0c\u7d93\u5c0e\u822a\u87ba\u65cb\u520036 Gy\u6cbb\u7642\u5f8c\uff0c\u816b\u7624\u9ad4\u7a4d\u5f9e629 ml\u964d\u81f3158 ml\uff0c\u6709\u6548\u964d\u4f4e\u795e\u7d93\u75bc\u75db\u75c7\u72c0\u3002\u75bc\u75db\u6307\u6578\u753110\u964d\u81f30\uff0c\u540c\u6642\u7121\u80ba\u90e8\u526f\u4f5c\u7528\u7522\u751f\u3002\u6545\u82e5\u4ee5\u7de9\u548c\u6cbb\u7642\u70ba\u76ee\u7684\uff0c\u5c0e\u822a\u87ba\u65cb\u5200\u4ea6\u53ef\u5c0d\u7279\u6b8a\u5f62\u72c0\u4e4b\u816b\u7624\u63d0\u4f9b\u6709\u6548\u4e14\u5b89\u5168\u4e4b\u6cbb\u7642\u3002[\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b782011\uff1b18(4)\uff1a341-345]", "e": "Nasopharyngeal carcinoma (NPC) with pleural circulative metastasis is difficult to treat due to the cylinder shape and close critical organs. Helical tomotherapy (HT) is a new type of CT-based rotational intensity modulated radiotherapy with highly conformal dose distributions and critical organs sparing. HT could be helpful in this kind of difficult situation.A 38-year-old male Asian nasopharyngeal carcinoma patient with pleural and liver metastasis was treated. Thirty-six Gy was delivered to bilateral pleural and mediastinum metastatic sites with HT. After HT treatment, pain was controlled by narcotics successfully. Pain scale decreased from 10 to 0. Tumor volume decreased from 629 ml to 158 ml. HT reduced V20 by more than 50% for each lung and reduced the mean lung dose by 22.2% and 33.8% in the right lung and left lung when compared with the IMRT technique, respectively.For palliative treatment, HT provides impressive ability for irregularly shaped metastatic sites and reduces painful sensation successfully.[Therapeut Radiol Oncol 2011; 18(4): 341-345]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-173-180", "title": "Once-Daily and Twice-Daily Radiotherapy without Chemotherapy in the Treatment of Malignant Glioma", "keywords": "\u591a\u5f62\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624;\u9000\u884c\u6027\u661f\u72c0\u7d30\u80de\u7624;\u9ad8\u5206\u6b21\u653e\u5c04\u7dda\u6cbb\u7642 Glioblastoma multiforme;Anaplastic astrocytoma;Hyperfractionated radiotherapy", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u4e00\u65e5\u4e00\u6b21\u6216\u4e00\u65e5\u5169\u6b21\u4e4b\u653e\u5c04\u6cbb\u7642\u672a\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u5c0d\u65bc\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u4e4b\u7642\u6548\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c0d\u65bc48\u4f4d\u672a\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u50c5\u55ae\u7d14\u63a5\u53d7\u5c04\u6cbb\u7642\u4e4b\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u60a3\u8005\uff0c\u9032\u884c\u56de\u6eaf\u6027\u7814\u7a76\u3002\u653e\u5c04\u6cbb\u7642\u5206\u70ba\u4e00\u65e5\u4e00\u6b21\uff08l.8-2 Gy/\u65e5\uff09\u6216\u4e00\u65e5\u5169\u6b21\uff081.2-1.5 Gy\u5169\u6b21\uff0f\u65e5\uff09\u3002\u5176\u4e2d8\u4f4d\u50c5\u63a5\u53d7\u7d44\u7e54\u5207\u7247\u800c\u7121\u816b\u7624\u5207\u9664\uff0c28\u4f4d\u63a5\u53d7\u5c40\u90e8\u5207\u9664\u800c12\u4f4d\u63a5\u53d7\u5b8c\u5168\u5207\u9664\u3002\u5b58\u6d3b\u7387\u5206\u6790\u4f7f\u7528Kaplan and Meier\u65b9\u6cd5\u4f86\u8a08\u7b97\u3002\u548c\u5b58\u6d3b\u7387\u76f8\u95dc\u7684\u55ae\u8b8a\u9805\u5206\u6790\u63a1\u7528log rank test\uff0c\u800c\u591a\u8b8a\u9805\u5206\u6790\u5247\u5229\u7528Cox regression models\u4f86\u9032\u884c\u3002\u7d50\u679c\uff1a\u5b58\u6d3b\u4e2d\u4f4d\u6708\u6578\u70ba13\u500b\u6708\u30022\u4f4d\u75c5\u4eba\u9054\u5230\u5b8c\u5168\u53cd\u61c9\uff0c22\u4f4d\u9054\u90e8\u5206\u53cd\u61c9\uff0c\u53e6\u5916\u768424\u4f4d\u5247\u662f\u7121\u53cd\u61c9\u6216\u75c5\u60c5\u60e1\u5316\u3002\u4e00\u65e5\u5169\u6b21\u4e26\u672a\u6709\u8f03\u597d\u7684\u5b58\u6d3b\u4e2d\u4f4d\u6708\u6578\uff0813 vs. 16.73\u500b\u6708\uff0cp=0.439\uff09\u3002\u5728\u55ae\u8b8a\u9805\u53ca\u591a\u8b8a\u9805\u5206\u6790\u4e2d\u50c5\u767c\u73fe\u5e74\u9f61\u5927\u65bc50\u6b72\u70ba\u6709\u610f\u7fa9\u7684\u8f03\u5dee\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u816b\u7624\u7bc4\u570d\u8d85\u904e\u4e00\u8449\u3001\u7121\u6cd5\u8fd1\u5168\u816b\u7624\u5207\u9664\u3001\u53ca\u751f\u7269\u7b49\u6548\u5291\u91cf\u672a\u905472 GyE\u6709\u8f03\u5dee\u4e4b\u9810\u5f8c\u4f46\u672a\u9054\u7d71\u8a08\u610f\u7fa9\u3002\u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u4e2d\u4e26\u672a\u767c\u73fe\u4e00\u65e5\u5169\u6b21\u7684\u653e\u5c04\u6cbb\u7642\u6709\u8f03\u597d\u7684\u6cbb\u7642\u6210\u679c\u3002\u5c07\u4f86\u4ecd\u9700\u8981\u66f4\u5927\u898f\u6a21\u7684\u7814\u7a76\u4ee5\u78ba\u8a8d\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u6700\u9069\u5408\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Aims and Background: To review if hyperfractionated radiotherapy provides better tumor control over standard radiotherapy for malignant glioma without chemotherapy.Methods: The records of 48 patients with glioblastoma multiforme or anaplastic astrocytoma treated with hyperfractionated/standard radiotherapy were reviewed for survival and prognostic factors analyses. The radiation schedule consisted of standard fractionation (1.8~2 Gy/day) or hyperfractionated fractionation (1.2~1.5 Gy twice/day with at least 6 hours interval), depending on the preference of different physicians. None of them received chemotherapy. Eight patients underwent biopsy only, and 28 patients underwent subtotal resection. The rest 12 patients had gross tumor resection. Survival rates were estimated using the method of Kaplan and Meier. In univariate analyses of survival time, the different variables were compared using the log rank test. Within the framework of Cox regression models, multivariate analysis was performed to differentiate the relationships between variables and their relevance to the survival.Results: No patient was lost to follow-up. Median survival was 13 months (range, 1-158 months). Two patients had complete response after radiotherapy. Twenty-two had partial response. The other 24 had stable disease or progression. The hyperfractionated radiotherapy group didn't show any benefit on survival (13 vs. 16.733 months, p=0.439). Age older than 50 years showed worse prognosis in both univariate and multivariate analyses. Tumor involvement more than one lobe, grossly total resection not achieved, and biologically equivalent dose (assuming \u03b1/\u03b2 ratio=10) (BED10) less than 72 GyE had trends associating with worse prognosis, which were not statistically significant.Conclusion: In our study, patients didn't benefit from hyperfractionated radiotherapy. Due to small patient number, further investigation is warranted to evaluate the benefit and toxicity of hyperfractionated radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-181-192", "title": "Elderly Oropharynx-Hypopharynx Carcinoma Patients: Induction Chemotherapy Plus Chemoradiotherapy Improve Cancer Controls Than Radiotherapy Alone", "keywords": "\u53e3\u54bd\u764c;\u4e0b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u5e74\u9577 Oropharynx carcinoma;Hypopharynx carcinoma;Radiotherapy;Chemotherapy;Elderly", "c": "\u80cc\u666f\uff1a\u672c\u7bc7\u7814\u7a76\u8001\u5e74\u53e3\u54bd\u53ca\u4e0b\u54bd\u764c\u65cf\u7fa4\uff08\u4ee5\u6cbb\u7652\u70ba\u6297\u764c\u76ee\u7684\u4e26\u4e14\u6c92\u6709\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\uff09\uff1a\u63a2\u8a0e\u524d\u5c0e\u6027\u5316\u7642\u5408\u4f75\u540c\u6b65\u5316\u653e\u7642\u8207\u55ae\u7368\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u6548\u679c\u6bd4\u8f03\u3002\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u6eaf\u6536\u96c62003\u81f32007\u5e74\uff0c\u7d44\u7e54\u5b78\u8b49\u5be6\u70ba\u53e3\u54bd\u6216\u4e0b\u54bd\u764c\uff0c\u5e74\u7d00\u8d85\u904e70\u6b72\u4e26\u4e14\u6c92\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba44\u4f4d\u3002\u75c5\u4eba\u5206\u70ba\u5169\u7d44\uff0cA\u7d44\uff08\u524d\u5c0e\u6027\u5316\u7642\u52a0\u4e0a\u540c\u6b65\u5316\u653e\u7642\uff0cn=22\uff09\u548cB\u7d44\uff08\u53ea\u505a\u653e\u5c04\u6cbb\u7642\uff0cn=22\uff09\u3002\u4f9d\u75c5\u4eba\u7684\u816b\u7624\u4f4d\u7f6e\uff0c\u6027\u5225\u53ca\u81e8\u5e8a\u5206\u671f\u5728\u5169\u7d44\u4e2d\u4f7f\u7528\u4e00\u5c0d\u4e00(1:1)\u914d\u5c0d\u5206\u6790\u3002\u7e3d\u5171\u6709\u4e09\u5341\u516d\u4f4d\u7537\u6027\u53ca\u516b\u4f4d\u5973\u6027\u6848\u4f8b\uff0c\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba76\u6b72\uff08\u5206\u4f48\u7bc4\u570d\u70ba70~88\u6b72\uff09\u3002\u5be6\u9a57\u7684\u89c0\u5bdf\u6a19\u7684(end point)\u70ba\u75c5\u4eba\u7684\u5b58\u6d3b\u7387\u53ca\u816b\u7624\u63a7\u5236\u3002\u7d50\u679c\uff1a\u6240\u6709\u75c5\u4eba\u8ffd\u8e64\u7684\u6642\u9593\u4e2d\u4f4d\u6578\u70ba35\u500b\u6708\uff08\u5206\u4f48\u7bc4\u570d\u70ba1~72\u500b\u6708\uff09\u3002\u5728\u7b2c\u4e09\u5e74\uff0cA\u7d44\u5448\u73fe\u6bd4B\u7d44\u66f4\u597d\u7684\u816b\u7624\u63a7\u5236\uff0c\u5728\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\uff0886.4%\u6bd436.4%\uff0cp=0.002\uff09\u53ca\u7121\u75c5\u751f\u5b58\u7387\uff0861.4%\u6bd436.4%\uff0cp=0.035\uff09\u3002\u7136\u800c\uff0c\u5728\u75be\u75c5\u7279\u7570\u751f\u5b58\u7387\u53ca\u7e3d\u751f\u5b58\u7387\u4e0a\uff0c\u5169\u7d44\u6c92\u6709\u986f\u8457\u5dee\u7570\u3002\u53ef\u4ee5\u60f3\u898b\u7684\u662f\uff0cA\u7d44\u6bd4B\u7d44\u6709\u66f4\u591a\u7684\u6cbb\u7642\u526f\u4f5c\u7528\uff08Grade 3~4\u7684\u9ecf\u819c\u708e\uff0c63.6%\u6bd427.3%\uff0cp=0.015\uff09\u3002\u7d50\u8ad6\uff1a\u5c0d\u6c92\u6709\u63a5\u53d7\u624b\u8853\u7684\u8001\u5e74\u53e3\u54bd\u4e0b\u54bd\u764c\u60a3\u8005\u4f86\u8aaa\uff0c\u524d\u5c0e\u6027\u5316\u7642\u5408\u4f75\u540c\u6b65\u5316\u653e\u7642\u6bd4\u8d77\u53ea\u505a\u653e\u5c04\u6cbb\u7642\uff0c\u660e\u986f\u589e\u9032\u816b\u7624\u63a7\u5236\u7387\uff0c\u53ea\u505a\u653e\u5c04\u6cbb\u7642\u61c9\u8a72\u53ea\u9069\u5408\u81e8\u5e8a\u4e0a\u4e0d\u9069\u5408\u505a\u5316\u7642\u7684\u75c5\u4eba\u3002", "e": "Methods: Between 2003 and 2007, we retrospectively included 44 histologically proven oropharynx-hypopharynx carcinoma patients who were aged more than 70 years and treated non-surgically. Two groups were defined: the group A (induction chemotherapy plus CCRT, n=22) and the group B (RT alone, n=22). Patients in the group B were 1:1 match-paired to those in the group A by using three factors: cancer subsite, gender, and clinical stage. Totally, there were 36 males and 8 females, with a median age of 76 years (range, 70-88 years). Patient survival and cancer control were defined as study end points.Background: This study intended to compare treatment results between induction chemotherapy plus chemoradiotherapy (CCRT) and radiotherapy (RT) alone in elderly oropharynx-hypopharynx carcinoma patients who were treated curatively and non-surgically.Results: The median follow-up time for all patients was 35.0 months (range, 1-72 months). At 3 years, the group A demonstrated better cancer controls than the group B, in terms of locoregional control (86.4% versus 36.4%, p=0.002) and disease-free survival (61.4% versus 36.4%, p=0.035). However, no statistically significant differences were found on disease-specific and overall survivals. Not surprisingly, more treatment-related toxicity were observed in the group A than in the group B (grade 3-4 mucositis, 63.6% versus 27.3%, p=0.015).Conclusions: For elderly oropharynx-hypopharynx carcinoma patients treated nonsurgically, induction chemotherapy plus CCRT significantly improves cancer control when compared with RT alone. RT alone should be reserved for patients who are medically contra-indicated to chemotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-193-204", "title": "Clinical Implications of Tumor Volume in Patients with the Base of Tongue Cancer Treated with Definitive Intensity-Modulated Radiotherapy Technique", "keywords": "\u820c\u6839\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50;\u816b\u7624\u9ad4\u7a4d Base of tongue cancer;Intensity-modulated radiotherapy technique;Prognostic factor;Tumor volume", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u820c\u6839\u764c\u75c5\u4eba\u7684\u816b\u7624\u9ad4\u7a4d\u5c0d\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u9810\u5f8c\u7684\u5f71\u97ff\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u56de\u6eaf\u6027\u5206\u6790\u5f9e2003\u5e74\u52302009\u5e74\u671f\u9593\uff0c35\u4f4d\u78ba\u8a3a\u70ba\u81e8\u5e8a\u4e8c\u81f3\u56db\u671f\u9c57\u72c0\u4e0a\u76ae\u764c\u820c\u6839\u764c\u4e14\u63a5\u53d7\u5668\u5b98\u4fdd\u7559\u6cbb\u7642\u75c5\u4eba\u7684\u75c5\u4f8b\u7d00\u9304\u3002\u6240\u6709\u75c5\u4eba\u7686\u5b8c\u6210\u5169\u968e\u6bb5\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u6bcf\u5929\u63a5\u53d7\u4e4b\u653e\u5c04\u5291\u91cf\u70ba1.8 Gy\uff0c\u539f\u767c\u816b\u7624\u8207\u8f49\u79fb\u6027\u6dcb\u5df4\u7d50\u63a5\u53d7\u7684\u7e3d\u5291\u91cf\u4e4b\u4e2d\u4f4d\u503c\u70ba70.2 Gy\uff0c\u9810\u9632\u6027\u9838\u90e8\u6dcb\u5df4\u7684\u5291\u91cf\u4e4b\u4e2d\u4f4d\u503c\u70ba50.4 Gy\u3002\u5176\u4e2d\u768424\u4f4d\u75c5\u4eba\u63a5\u53d7\u5408\u4f75cisplatin\u4e4b\u540c\u6b65\u5316\u5b78\u6cbb\u7642(cisplatin 80-100 mg/\u5e73\u65b9\u516c\u5c3a\uff0c\u653e\u7642\u958b\u59cb\u7684\u7b2c1\u300122\u300143\u5929\uff09\u3002\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u4e4b\u6e2c\u91cf\u8207\u8a08\u7b97\u5206\u5225\u53d6\u81ea\u653e\u5c04\u6cbb\u7642\u524d\u53ca\u6cbb\u7642\u671f\u4e2d\u4e4b\u6a21\u64ec\u651d\u5f71\u5f71\u50cf\u3002\u7d50\u679c\uff1a\u7d93\u904e\u4e2d\u4f4d\u503c18\u500b\u6708\u7684\u8ffd\u8e64\u6642\u9593\uff0c24\u4f4d\u75c5\u4eba(68.5%)\u88ab\u767c\u73fe\u6709\u539f\u767c\u816b\u7624\u6216\u9838\u90e8\u6dcb\u5df4\u4e4b\u5c40\u90e8\u5fa9\u767c\u3002\u6240\u6709\u75c5\u4eba\u4e4b\u5169\u5e74\u764c\u75c7\u76f8\u95dc\u5b58\u6d3b\u7387\u70ba24%\uff0c\u5176\u4e2d\u7b2c\u4e8c\u81f3\u4e09\u671f\u75c5\u4eba\u7684\u764c\u75c7\u76f8\u95dc\u5b58\u6d3b\u7387\u70ba25%\uff0c\u7b2c\u56db\u671f\u75c5\u4eba\u4e4b\u764c\u75c7\u76f8\u95dc\u5b58\u6d3b\u7387\u70ba9% (p=0.13)\u3002\u53e6T2-T3\u816b\u7624\u7684\u5169\u5e74\u539f\u767c\u816b\u7624\u7121\u5fa9\u767c\u7387\u70ba35%\uff0c\u800cT4\u816b\u7624\u7684\u5247\u964d\u81f30\uff05 (p=0.01)\u3002\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u4e4b\u4e2d\u4f4d\u503c\u70ba34.6 mL\uff08\u7bc4\u570d\uff0c8.0\u81f3165 mL\uff09\uff0c\u800c\u6cbb\u7642\u4e2d\u4e4b\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u4e4b\u4e2d\u4f4d\u503c\u70ba9.4-19.4 mL\uff08\u7bc4\u570d\uff0c3.8\u81f379.3 mL\uff09\u3002\u591a\u8b8a\u6578\u5206\u6790\u767c\u73fe\u539f\u767c\u816b\u7624\u5fa9\u767c\u4e4b\u4e0d\u826f\u9810\u5f8c\u56e0\u5b50\u70ba\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u5927\u65bc20 mL \uff08p=0.005\uff0c\u52dd\u7b97\u6bd45.87\uff0c95\uff05\u4fe1\u8cf4\u5340\u95931.29-26.7\uff09\u8207\u653e\u7642\u671f\u4e2d\u816b\u7624\u9ad4\u7a4d\u964d\u4f4e\u6bd4\u7387\u5c0f\u65bc0.4 (p=0.002\uff0c\u52dd\u7b97\u6bd43.74\uff0c95%\u4fe1\u8cf4\u5340\u95931.68~9.73\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5831\u544a\u986f\u793a\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u5c0d\u65bc\u65bd\u884c\u5668\u5b98\u4fdd\u7559\u8853\u4e4b\u820c\u6839\u764c\u75c5\u4eba\u7684\u6cbb\u7642\u6210\u6548\u4e26\u4e0d\u7406\u60f3\uff0c\u5c0d\u65bc\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u5927\u65bc20 mL\u6216\u653e\u7642\u671f\u4e2d\u816b\u7624\u9ad4\u7a4d\u964d\u4f4e\u6bd4\u7387\u5c0f\u65bc0.4\u7684\u75c5\u4eba\uff0c\u5fc5\u9808\u8003\u616e\u4ee5\u66f4\u7a4d\u6975\u7684\u6cbb\u7642\u65b9\u5f0f\u4f86\u63d0\u9ad8\u5c40\u90e8\u816b\u7624\u7684\u63a7\u5236\u7387\uff0c\u5982\u63d0\u9ad8\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u6216\u662f\u5408\u4f75\u6cbb\u7642\u3002", "e": "Purpose: To investigate the impact of tumor volume in patients with the base of tongue (BOT) cancer treated with definitive intensity-modulated radiotherapy technique (IMRT).Materials and Methods: From 2003 to 2009, 35 patients with stage \u2161-\u2163 squamous cell carcinoma of the BOT cancer receiving organ preservation scheme were enrolled in this retrospective analysis. Radiotherapy was performed using a sequential IMRT. All patients received 1.8 Gy daily up to a median total dose 01 70.2 Gy to gross tumors and metastatic Iymph nodes, whereas the area harboring microscopic disease was prescribed with a median dose of 50.4 Gy. Twenty-four patients had concurrent chemotherapy. The regimen consisted of cisplatin (80-100 mg/m^2 on Days 1, 22, 43). Primary tumor volume measurement was derived using separate simulation images for the pretreatment gross tumor volume (pGTV) and the interval gross tumor volume (iGTV).Results: With a median follow-up duration of 18 months, 24 patients (68.5%) were found to have locoregional failures. The 2-year cause-specific survival was for all patients was 24%. The curve could be split into 25% for stage \u2161-\u2162 disease, and 18% for stage \u2163 disease (p=0.29). The 2-year primary relapse-free survival (PRFS) was 35% for patients with T2-T3 disease, and the curve dropped to zero for patients with T4 disease (p=0.01). The pGTV value ranged from 8.1 to 165 mL (median, 34.6 mL), whereas the iGTV ranged from 3.8 to 79.3 mL (median, 19.4 mL). Multivariate analysis showed that there were two predictors for the PRFS: pGTV\u226720ml (p=0.02, hazard ratio=5.87, 95% CI 1.29-26.72) and volume reduction rate (VRR)\uff1c0.4 (p=0.002, hazard ratio 4.33, 95% CI l.71~10.99).Conclusions: This preliminary study shows that IMRT outcome in the BOT cancer patients was unsatisfactory. To optimize the treatment result, an aggressive treatment scheme should be considered for large pretreatment tumor burden or a VRR less than 0.4."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-205-213", "title": "Limited-Stage Small Cell Carcinoma of Esophagus: A Single Institution Experience", "keywords": "\u98df\u9053\u764c;\u5c0f\u7d30\u80de\u764c;\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Small cell carcinoma;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u5c40\u9650\u671f\u98df\u9053\u5c0f\u7d30\u80de\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u9867\u5f9e\u4e00\u4e5d\u516b\u4e94\u5e74\u81f3\u4e8c\u25cb\u25cb\u4e00\u5e74\u671f\u9593\u65bc\u53f0\u5317\u69ae\u6c11\u7e3d\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\u4e4b\u5c40\u9650\u671f\u98df\u9053\u5c0f\u7d30\u80de\u764c\u75c5\u4f8b\uff0c\u5831\u544a\u4e26\u5206\u6790\u5176\u4eba\u53e3\u7d71\u8a08\u5b78\u53ca\u81e8\u5e8a\u8cc7\u6599\uff0c\u4e26\u5206\u5225\u5229\u7528Kaplan-Meier method\u4f86\u8a08\u7b97\u75c5\u60a3\u6574\u9ad4\u5b58\u6d3b\u72c0\u6cc1\u53calog-rank test\u4f86\u6bd4\u8f03\u4e0d\u540c\u65cf\u7fa4\u75c5\u60a3\u5b58\u6d3b\u4e4b\u5dee\u7570\u3002\u7d50\u679c\uff1a\u98df\u9053\u5c0f\u7d30\u80de\u764c\u5360\u8a72\u91ab\u9662\u540c\u6642\u671f\u98df\u9053\u60e1\u6027\u816b\u7624\u76840.89%\u3002\u672c\u7814\u7a76\u5171\u542b\u62ec\u5341\u4e00\u4f4d\u75c5\u4eba\uff0c\u4ed6\u5011\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba70\u6b72\uff0841-82\u6b72\uff09\uff0c\u5176\u4e2d\u516b\u4f4d\u75c5\u60a3\u4e3b\u8981\u816b\u7624\u4f4d\u65bc\u4e2d\u6bb5\u80f8\u90e8\u98df\u9053\u3002\u5728\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba11\u500b\u6708\u7684\u60c5\u6cc1\u4e0b\uff0c\u53ea\u6709\u4e00\u4f4d\u75c5\u60a3\u7121\u75c5\u5b58\u6d3b\uff0c\u5176\u9918\u5341\u4eba\u7686\u56e0\u75be\u75c5\u6216\u6cbb\u7642\u526f\u4f5c\u7528\u6b7b\u4ea1\u3002\u75c5\u60a3\u6574\u9ad4\u5b58\u6d3b\u671f\u4e2d\u4f4d\u6578\u70ba11\u500b\u6708\uff0c\u5176\u4e00\u5e74\u3001\u5169\u5e74\u53ca\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba36%\uff0c18%\u53ca9%\u3002\u5728\u75c5\u60a3\u6700\u5f8c\u8ffd\u8e64\u6216\u6b7b\u4ea1\u7576\u6642\uff0c\u56db\u4f4d\u75c5\u4eba\u6709\u5c40\u90e8\u5fa9\u767c\uff0c\u4e94\u4f4d\u75c5\u4eba\u6709\u5c40\u90e8\u4e26\u9060\u7aef\u5fa9\u767c\u3002\u6b64\u5916\uff0c\u6211\u5011\u89c0\u5bdf\u5230\u5e74\u7d00\u672a\u8d85\u904e\u4e03\u5341\u6b72\u7684\u75c5\u60a3\u3001\u6709\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u60a3\u53ca\u6709\u63a5\u53d7\u5c40\u90e8\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u60a3\u6703\u6709\u8f03\u9577\u7684\u5b58\u6d3b\u3002\u7d50\u8ad6\uff1a\u98df\u9053\u5c0f\u7d30\u80de\u764c\u662f\u4e00\u500b\u76f8\u7576\u60e1\u6027\u4e14\u9810\u5f8c\u4e0d\u597d\u7684\u764c\u75c7\uff0c\u6211\u5011\u5efa\u8b70\u7d66\u4e88\u5c40\u9650\u671f\u98df\u9053\u5c0f\u7d30\u80de\u764c\u75c5\u60a3\u5c40\u90e8\u4f75\u5316\u5b78\u6cbb\u7642\u3002", "e": "Purpose: To analyze the treatment outcome of patients with limited-stage small cell carcinoma (SmCC) of esophagus.Methods: Patients with limited-stage SmCC of esophagus presenting to Taipei Veterans General Hospital between 1985 and 2001 were retrospectively reviewed. Demographic and clinical data were presented and analyzed. We calculated overall survival with the Kaplan-Meier method and compared the survival between different groups with the log-rank test.Results: SmCC of esophagus represented 0.89% of esophageal malignancies in this institution. Eleven (one female and ten male) patients with limited-stage SmCC of esophagus were included in this study. The median age was 70 years (range, 41-82 years). Eight of 11 patients had the main primary neoplasm over the middle third thoracic esophagus. With a median follow-up of 11 months (range, 2-144 months), only one patient remained alive without disease and the other ten patients died of the disease or treatment complication. The median overall survival was 11 months, with survival rates at 1, 2 and 5 years were 36%, 18% and 9%, respectively. At the last follow-up visit or mortality, lour patients had loco-regional failure only and live patients had loco-regional and distant relapse. We observed significantly longer median survival in patients 70 years old or younger (16 months vs. 5 months in patients older than 70 years old, P=0.036), patients receiving chemotherapy (16 months vs. 5 months in patients not receiving chemotherapy, P=0.001), and patients receiving local treatment (radiotherapy or surgery) plus chemotherapy (21 months vs. 6 months in patients not receiving local treatment plus chemotherapy, P=0.003).Conclusions: SmCC of esophagus was an aggressive neoplasm with poor prognosis. We recommend local therapy plus chemotherapy for patients with limited stage SmCC of esophagus."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-215-224", "title": "Update in the Management of Locally Advanced Pancreatic Cancer-Focusing on the Strategy of Induction Chemotherapy Followed by Chemoradiotherapy", "keywords": "\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c;\u5408\u4f75\u591a\u79d1\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642 Locally advanced pancreatic cancer;Combined modality therapy;Chemotherapy;radiotherapy", "c": "\u96d6\u7136\u50c5\u50c5\u4f54\u81fa\u7063\u5168\u90e8\u764c\u75c7\u8a3a\u65b7\u76842%\uff0c\u80f0\u81df\u764c\u537b\u540d\u5217\u81fa\u7063\u5341\u5927\u764c\u75c7\u6b7b\u56e0\uff0c\u4e5f\u662f\u6700\u96e3\u8655\u7406\u7684\u60e1\u6027\u816b\u7624\u4e4b\u4e00\u3002\u5728\u8a3a\u65b7\u521d\u671f\uff0c\u53ea\u670910-15%\u7684\u80f0\u81df\u764c\u662f\u53ef\u5207\u9664\u7684\u3002\u7d04\u670930%\u7684\u80f0\u81df\u764c\u5728\u8a3a\u65b7\u521d\u671f\u96d6\u70ba\u5c40\u90e8\u5c40\u9650\u6027\uff0c\u537b\u7121\u6cd5\u5207\u9664\u3002\u57fa\u65bc\u5c11\u6578\u96a8\u6a5f\u5206\u914d\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff0c\u6211\u5011\u5c0d\u65bc\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u75c5\u60a3\uff0c\u7d66\u4e88\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642\u3002\u6700\u8fd1\u7684\u7d71\u5408\u5206\u6790\u986f\u793a\uff0c\u63a5\u53d7\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u5b58\u6d3b\u671f\uff0c\u512a\u65bc\u50c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u8005\uff1b\u4f46\u8207\u50c5\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u7684\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u75c5\u60a3\u5b58\u6d3b\u671f\uff0c\u4e26\u7121\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u7684\u5dee\u7570\u3002\u7531\u65bc\u985e\u4f3c\u7684\u81e8\u5e8a\u7d50\u679c\u8207\u8f03\u4f4e\u7684\u526f\u4f5c\u7528\uff0c\u8a31\u591a\u81e8\u5e8a\u91ab\u5e2b\u4ee5gemcitabine\u70ba\u4e3b\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u4f5c\u70ba\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u75c5\u60a3\u7684\u6a19\u6e96\u6cbb\u7642\u3002\u7136\u800c\uff0c\u653e\u5c04\u6cbb\u7642\u5728\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u7684\u89d2\u8272\uff0c\u4ecd\u6709\u8a31\u591a\u722d\u8b70\u3002\u672c\u7bc7\u7d9c\u8ad6\u91dd\u5c0d\u653e\u7642\u89d2\u8272\uff0c\u6574\u7406\u76ee\u524d\u5c0d\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u7684\u8655\u7406\u65b9\u5f0f\u3001\u9078\u64c7\u8207\u722d\u8b70\uff0c\u4ee5\u53ca\u672a\u4f86\u767c\u5c55\u65b9\u5411\uff1b\u4e5f\u5c07\u5831\u544a\u6211\u5011\u6700\u8fd1\u5b8c\u6210\u7684\u7b2c\u4e8c\u76f8\u81e8\u5e8a\u8a66\u9a57\u4e2d\u7d50\u679c(TCOG1204)\uff1a\u65bc\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\uff0c\u4ee5\u5f15\u5c0e\u5f0f\u5316\u5b78\u6cbb\u7642\u518d\u7d66\u4e88\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u7b56\u7565\u3002", "e": "Even though pancreatic cancer accounts for only 2% of all cancer diagnoses in Taiwan, it is one of the ten leading causes of cancer death and the most difficult malignancy to manage. Because of the usually late onset symptoms, hall of the patients presented with metastatic disease. Only 10-15% of patients had resectable disease at initial diagnosis. Around 30% of patients present with locally advanced disease that precludes resection. The use of chemoradiotherapy for locally advanced pancreatic cancer (LAPC) is based on few randomized trials. Recent meta-analysis revealed a survival benefit for chemoradiotherapy over radiotherapy alone; however, chemoradiotherapy did not demonstrate significant survival advantage over chemotherapy alone. Because of similar outcome and lower toxicity, gemcitabine based chemotherapy is considered as a standard of care in many clinical situations. However, there is much controversy about the role of radiotherapy in local disease control. This paper reviews the current management options, controversies, and ongoing and future directions for the treatment of LAPC, focusing on the role of radiotherapy. The rationale and results of our phase\u2161 study on LAPC using induction chemotherapy followed by chemoradiation (TCOG1204) will be presented."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-225-231", "title": "\u6539\u5584\u816b\u7624\u5fae\u74b0\u5883\u8207\u653e\u5c04\u654f\u611f\u6027\u7684\u95dc\u4fc2", "keywords": "\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u589e\u654f;\u816b\u7624\u5fae\u74b0\u5883;\u514d\u75ab\u7d30\u80de;\u8840\u7ba1\u65b0\u751f Radiotherapy;Radiosensitization;Tumour microenvironment;Immune cells;Angiogenesis", "c": "\u816b\u7624\u7d30\u80de\u5468\u570d\u7684\u5916\u5728\u74b0\u5883\u6703\u5f71\u97ff\u653e\u5c04\u53cd\u61c9\u7684\u6210\u6548\uff0c\u800c\u5728\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u7684\u5167\u76ae\u7d30\u80de\u548c\u514d\u75ab\u6d78\u6f64\u7d30\u80de\u5247\u662f\u986f\u8457\u5f71\u97ff\u653e\u5c04\u6cbb\u7642\u7d50\u679c\u7684\u5169\u500b\u95dc\u9375\u56e0\u5b50\u4e4b\u4e00\u3002\u5728\u5206\u6b21\u653e\u7642\u4e2d\uff0c\u6703\u5f15\u767cHIF-1\u548cVEGF\u7684\u589e\u52a0\uff0c\u56e0\u800c\u964d\u4f4e\u5206\u6b21\u653e\u7642\u7684\u512a\u52e2\u3002\u53e6\u5916\uff0c\u6297\u8840\u7ba1\u65b0\u751f\u85e5\u7269\u7684\u7642\u6548\u6703\u88ab\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u7684\u5167\u751f\u6027\u8840\u7ba1\u751f\u6210\u524d\u8da8\u7d30\u80de\u6240\u4e2d\u548c\u3002\u9664\u4e86\u8840\u7ba1\u4e4b\u5916\uff0c\u6dcb\u5df4\u7d30\u80de\u4e5f\u5728\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u626e\u6f14\u5f88\u91cd\u8981\u7684\u89d2\u8272\u3002\u514d\u75ab\u7d30\u80de\u7684\u7d44\u6210\u7a2e\u985e\u4e0d\u540c\uff0c\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u7684\u6548\u679c\u4e5f\u6709\u5f88\u5927\u7684\u5f71\u97ff\u3002\u5728\u9019\u7bc7\u6587\u7ae0\u4e2d\uff0c\u6211\u5011\u63a2\u8a0e\u4e86\u6700\u8fd1\u4e00\u4e9b\u91dd\u5c0d\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u514d\u75ab\u7d30\u80de\u91cd\u8981\u6027\u7684\u6587\u737b\u3002\u76ee\u524d\u6b63\u5728\u767c\u5c55\u4e2d\u7684\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u4ee5\u53ca\u514d\u75ab\u6cbb\u7642\u6216\u5176\u4ed6\u8abf\u63a7\u6574\u500b\u816b\u7624\u5fae\u74b0\u5883\u7684\u65b9\u5f0f\uff0c\u6709\u53ef\u80fd\u5728\u4e0d\u4e45\u7684\u5c07\u4f86\u6703\u6709\u8c50\u78a9\u7684\u6210\u679c\u3002", "e": "Radioresponse is influenced by factors extrinsic to cancer cells. Endothelial cells and infiltrating immune cells within the tumour microenvironment are the two components that significantly affect the outcome of radiotherapy. The benefits of fractionated radiotherapy are reduced by up-regulation of hypoxia inducible factor-l\u03b1 (HIF-l\u03b1) and vasculoendothelial growth factor (VEGF). Further, the therapeutic effect of anti-angiogenic agents is counteracted by the mobilization of endogenous proangiogenic cells into the tumour microenvironment. In addition to endothelial cells, immune cells play an important role in the microenvironment that regulates tumour growth and response to therapy. In this review, we highlight some of the recent studies on the importance of immune cells in the microenvironment. The progress in developing combinations of radiotherapy and immunotherapy or other methods for modulation of the tumour immune microenvironment may yield fruitful results in the near future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-233-244", "title": "\u4f7f\u7528\u5ee3\u7fa9\u7b49\u6548\u5747\u52fb\u5291\u91cf(gEUD)\u70ba\u512a\u5316\u57fa\u790e\u7684\u5291\u91cf\u9ad4\u7a4d\u76ee\u6a19\u4e4b\u96d9\u908a\u4e73\u764c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283", "keywords": "\u96d9\u908a\u4e73\u764c;DV-plan;DV-gEUD-plan Bilateral breast cancer BBC;DV-plan;DV-gEUD-plan", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u8a55\u4f30\u5169\u7a2e\u4e0d\u540c\u6a21\u5f0f\uff0d(1)\u4ee5\u5291\u91cf\uff0d\u9ad4\u7a4d\u57fa\u790e\u512a\u5316\u689d\u4ef6\u70ba\u4e3b\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff08DV-based IMRT plan\uff0c\u7c21\u7a31DV-plan\uff09\uff0c(2)\u4ee5DV-based\u512a\u5316\u689d\u4ef6\u70ba\u4e3b\uff0c\u4e26\u4ee5\u5ee3\u7fa9\u7b49\u6548\u5747\u52fb\u5291\u91cf(generalized equilibrium uniform dose, gEUD-based)\u512a\u5316\u689d\u4ef6\u70ba\u8f14\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff08DV-gEUD-based IMRT plan, \u7c21\u7a31DV-gEUD-plan\uff09\u5c0d\u65bc\u96d9\u908a\u4e73\u764c\u75c5\u60a3\u6cbb\u7642\u4e4b\u9593\u7684\u5dee\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u63a1\u75286\u4f4d\u75be\u75c5\u5206\u671f\u70baT2~T4\u7684\u96d9\u908a\u4e73\u764c\u75c5\u60a3\uff0c\u4f7f\u7528Pinnacle^3 (version 8.0 m, Philips, Fitchburg, WI)\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u5206\u5225\u898f\u5283DV-based\u8207DV-gEUD\u8a08\u5283\u9032\u884c\u6bd4\u8f03\uff0c\u4e26\u5728\u914d\u5099\u6709120\u8449\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u7684Varian 21 EX Linac (Varian Medical Systems Milpitas, CA)\u6a5f\u5668\u57f7\u884c\u6cbb\u7642\u3002\u8a08\u5283\u9776\u9ad4\u7a4d(planning target volume, PTV)\u7684\u5291\u91cf\u8655\u65b9\u70ba50.4 Gy\uff0c\u9032\u884c28\u6b21\u7684\u5206\u6b21\u6cbb\u7642\u3002\u5229\u7528\u5291\u91cf\u6307\u6a19\u8a55\u4f30\u91cf\u5316\u8a08\u5283\u7d50\u679c\uff0c\u5305\u62ecPTV\u7684\u9806\u5f62\u6307\u6a19(conformity index, CI)\u3001\u52fb\u7a31\u6307\u6a19(homogeneity Index, HI)\u548c\u816b\u7624\u63a7\u5236\u7387(tumor control probability TCP)\uff1b\u5371\u53ca\u5668\u5b98\uff08\u5305\u62ec\u5fc3\u3001\u80ba\u81d3\uff09\u7684V(\u4e0b\u6a19 20Gy)\u8207V(\u4e0b\u6a19 30Gy)\u9ad4\u7a4d\u3001\u5e73\u5747\u5291\u91cf\u8207\u6b63\u5e38\u7d44\u7e54\u526f\u4f5c\u7528\u767c\u751f\u7387(normal tissue complication probability, NTCP)\u3002\u540c\u6642\uff0c\u8a55\u4f30\u6cbb\u7642\u8a08\u5283\u57f7\u884c\u7684\u6b63\u78ba\u7387\u3002\u7d50\u679c\uff1aDV-\u8207DV-gEUD-plan\u90fd\u80fd\u7b26\u5408PTV\u5305\u8986\u7387\u7684\u8981\u6c42\uff0cPTV\u9806\u5f62\u6307\u6a19\u548c\u52fb\u7a31\u6307\u6a19\u5728\u5169\u8a08\u5283\u8868\u73fe\u76f8\u7576\uff0c\u800cDV-gEUD-plan \u5177\u6709\u6e1b\u5c11\u5371\u53ca\u5668\u5b98\u5291\u91cf\u7684\u512a\u52e2\uff1a\u5fc3\u81df\u3001\u80ba\u81df\u7684\u5e73\u5747\u5291\u91cf\u8207\u80ba\u81dfV(\u4e0b\u6a19 20Gy)\u3001\u5fc3\u81dfV(\u4e0b\u6a19 30Gy)\u5728DV-gEUD-plan\u90fd\u6bd4DV-plan\u4f4e\uff08p\u503c\u5c0f\u65bc0.05\uff09\u3002\u53e6\u5916\u5169\u7a2e\u8a08\u5283Gamma (T(\u4e0b\u6a19 3mm. 3%))\u5206\u6790\u7d50\u679c\u90fd\u670995.5\uff05\u4ee5\u4e0a\u7684\u901a\u904e\u7387\u3002\u7d50\u8ad6\uff1aDV-gEUD-Plan\u7d50\u5408DV-\u8207gEUD-based\u7684\u76ee\u6a19\u51fd\u6578\uff0c\u53ef\u4ee5\u5275\u5efa\u66f4\u597d\u7684\u8a08\u5283\u7d50\u679c\u3002\u9019\u7a2e\u6df7\u5408\u7684\u65b9\u6cd5\uff0c\u53ef\u4ee5\u6e1b\u5c11DV-plan\u8a66\u8aa4\u7684\u6b21\u6578\uff0c\u540c\u6642\u4fdd\u7559gEUD-plan\u6240\u63d0\u4f9b\u7684\u6700\u4f73\u5291\u91cf\u5206\u4f48\u3002", "e": "Purpose: To compare the planning performance between dose-volume-based IMRT plans (DV-based IMRT plan, (DV-plan) ) and DV-plan with generalized equivalent uniform dose (gEUD) optimization (DV-gEUD-based IMRT plan, (DV-gEUD-plan) ) on bilateral breast cancer (BBC).Materials and Methods: Six consecutive BBC patients (staged: T2-T4) were planed using the planning system of the Pinnacle^3 (version 8.0 m, Philips, Fitchburg, WI) to compare the performance of DV-and DV-gEUD plans. The plan was delivered on a Varian 21 EX Linac (Varian Medical Systems, Milpitas, CA) equipped with a 120-leaf multileaf collimator. The prescribed doses were 50.4 Gy/28 fractions to the planned target volume (PTV). The dosimetric parameters used included the conformity index (CI), homogeneity index (HI) and tumor control probability (TCP) for the PTV; and V(subscript 20Gy) and V(subscript 30Gy) for the total lung and heart, respectively; and mean dose, normal tissue complication probability (NTCP) for the both OARs. The planning delivery accuracy was checked.Results: Both techniques fulfilled the objectives on target coverage. A comparable CI and HI of the PTV were observed on both plans. For the OARs, a significantly superior normal tissue sparing was observed in DV-gEUD-plan. The DV-gEUD-plan has smaller mean dose of lung and heart, V(subscript 20Gy) of lung, and V(subscript 30Gy) of heart (p\uff1c0.05) with respect to the DV-plan. Both plans presented a high QA pass rate (\uff1e95.5%) of the T(subscript 3mm. 3%) criterion.Conclusions: A better plan (DV-gEUD-plan) can be obtained through a combination of DV-and gEUD-based objective function, This hybrid approach can reduce the number of trial and error in DV-plan processing while retaining a better dose distribution which gEUD-plan can provide."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-245-254", "title": "Total Body Irradiation with Lateral Treatment Technique Using Water Bags as Tissue Compensators", "keywords": "\u5168\u8eab\u653e\u5c04\u6cbb\u7642;\u6025\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c7;\u5074\u7167\u6280\u8853 Total body irradiation;Acute lymphoblastic leukemia;Lateral technique", "c": "\u76ee\u7684\uff1a\u6539\u5584\u4ef0\u81e5\u5f0f\u5074\u7167\u6280\u8853\u61c9\u7528\u65bc\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u6280\u8853\u7684\u5291\u91cf\u5206\u4f48\u5747\u52fb\u5ea6\uff0c\u4e26\u63a2\u8a0e\u6b64\u6280\u8853\u7684\u518d\u73fe\u6027\u53ca\u80ba\u90e8\u5291\u91cf\u7684\u8a08\u7b97\u548c\u9a57\u8b49\u3002\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u63a1\u7528\u58d3\u514b\u529b\u7bb1\u4f5c\u70ba\u63d0\u4f9b\u60a3\u8005\u4ef0\u81e5\u59ff\u52e2\u7684\u6cbb\u7642\u5e8a\uff0c\u4e26\u65bc\u5176\u9ad4\u8868\u5468\u570d\u7a7a\u9593\u4ee5\u6c34\u888b\u9806\u5f62\u586b\u6eff\u7a7a\u9699\uff0c\u4ee5\u4f5c\u70ba\u7d44\u7e54\u586b\u5145\u7269\u4e4b\u7528\u3002\u6cbb\u7642\u5100\u5668\u9078\u64c7\u80fd\u91cf15 MV\u4e4b\u52a0\u901f\u5668\uff0c\u5c04\u6e90\u81f3\u9ad4\u8868\u8ddd\u96e2\u70ba415 cm\uff0c\u5291\u91cf\u7387\u8abf\u6574\u70ba\u6bcf\u5206\u94185 cGy\u3002\u4e94\u4f4d\u75c5\u60a3\u8005\u63a5\u53d7\u6b64\u9805\u6cbb\u7642\uff0c\u4e26\u5728\u60a3\u8005\u9069\u7576\u7684\u53c3\u8003\u9ede\u4f48\u5efa\u6c1f\u5316\u92f0\u71b1\u9aee\u5149\u5291\u91cf\u8a08\u4ee5\u91cf\u6e2c\u5be6\u969b\u5291\u91cf\u3002\u6cbb\u7642\u5291\u91cf\u70ba\u6bcf\u6b21150 cGy\u3002\u6bcf\u65e5\u5169\u6b21\uff0c\u5171\u5206\u516b\u6b21\uff0c\u7d66\u4e88\u7e3d\u8a08\u91cf1200 cGy\uff1b\u4f46\u80ba\u90e8\u5247\u4ee5\u9069\u7576\u539a\u5ea6\u7684\u925b\u5c4f\u853d\u963b\u64cb\u90e8\u4efd\u5291\u91cf\u4f7f\u4e4b\u4f4e\u65bc960 cGy\u3002\u7d50\u679c\uff1a\u4e94\u4f4d\u75c5\u4eba\u5728\u6240\u6709\u9ad4\u8868\u4f48\u8a2d\u9ede\u5be6\u969b\u6e2c\u5f97\u5291\u91cf\u5747\u53ef\u9054\u5230\u8207\u9810\u5b9a\u503c\u8aa4\u5dee\u65bc\u53ef\u63a5\u53d7\u7bc4\u570d\u5167\uff0c\u5728\u80ba\u90e8\u7684\u5c4f\u853d\u4e5f\u9054\u5230\u6eff\u610f\u7684\u9a57\u8b49\u8207\u518d\u73fe\u6027\u3002\u6574\u500b\u6cbb\u7642\u904e\u7a0b\u53ef\u5728\u4e94\u5341\u5206\u9418\u5167\u5b8c\u6210\u3002\u7d50\u8ad6\uff1a\u4ee5\u4ef0\u81e5\u5f0f\u5074\u7167\u6280\u8853\u61c9\u7528\u65bc\u5168\u8eab\u653e\u5c04\u6cbb\u7642\uff0c\u8f14\u4ee5\u6c34\u888b\u4f5c\u70ba\u7d44\u7e54\u586b\u5145\u7269\uff0c\u9069\u7528\u65bc\u9ad4\u80fd\u72c0\u6cc1\u8f03\u5dee\u6216\u7121\u6cd5\u4e45\u7acb\u652f\u6490\u7684\u60a3\u8005\uff0c\u5176\u5291\u91cf\u5747\u52fb\u5ea6\u4ecd\u5728\u53ef\u63a5\u53d7\u7bc4\u570d\u5167\uff0c\u4e26\u53ef\u5f97\u5230\u66f4\u4f73\u7684\u80ba\u90e8\u5c4f\u853d\u4f4d\u7f6e\u53ca\u6548\u679c\uff0c\u8207\u9069\u7576\u7684\u64cd\u4f5c\u6642\u6548\u3002", "e": "Purpose: To improve dose homogeneity in total body irradiation (TBI) with lateral technique. Dose homogeneity and dosimetry of lung shielding are investigated.Materials and Methods: Five patients, three with acute Iymphocytic leukemia (ALL), one with acute myelocytic leukemia (AML), and one with non-Hodgkin's Iymphoma (NHL), were delivered total body irradiation with lateral technique. An acrylic box was designed for treatment table, and water bags were utilized as tissue compensators to fill the surrounding space, conforming patients' body contours as possible. LiF thermoluminescent dosimeters (TLDs) were positioned along the reference points on the body surface. Treatment dose 1200 cGy, using 15 MV photons with dose rate 5 cGy/minute, divided in 8 fractions within 4 days was prescribed at the midline of the body, while partial lung block was designed to deliver 900 to 960 cGy to the midline of thorax in sum after lung correction calculation. The mean doses of different reference points throughout the body were obtained after calculation of three to four measurements for each patient to investigate dose homogeneity.Results: After application of tissue compensators with water bags thoroughly surrounding the patients, the average dose homogeneity was measured withinacceptable difference from the prescribed dose. Postural stability and reproducibility were satisfied. Treatment duration took about 50 minutes and patients tolerated the procedures well.Conclusion: Though anterioposterior TBI technique is commonly used with regard to better dose uniformity and setup procedures, there is superiority of consistency of lung shielding and patients' comfort to utilize lateral technique for fragile patients, especially when low dose rate is used and treatment duration prolongs. The application of tissue compensators with water bags as an alternative can be easily setup with acceptable dose homogeneity and treatment time."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201109-201109280004-201109280004-255-263", "title": "Carcinoma Showing Thymus-Like Differentiation (Castle) of the Neck: A Case Report and Review of the Literature", "keywords": "\u9838\u90e8\u5448\u80f8\u817a\u6a23\u5206\u5316\u4e0a\u76ae\u7d30\u80de\u764c;\u9838\u90e8\u8edf\u7d44\u7e54;\u653e\u5c04\u7dda\u6cbb\u7642 Carcinoma showing thymus-like differentiation;CASTLE;Soft tissue of neck;Radiotherapy", "c": "\u9838\u90e8\u5448\u80f8\u817a\u6a23\u5206\u5316\u4e0a\u76ae\u7d30\u80de\u764c\u662f\u4e00\u7a2e\u7f55\u898b\uff0c\u767c\u751f\u65bc\u7532\u72c0\u817a\u6216\u662f\u9838\u90e8\u8edf\u7d44\u7e54\u7684\u60e1\u6027\u816b\u7624\u3002\u5b83\u53ef\u4ee5\u85c9\u7531\u7d44\u7e54\u75c5\u7406\u5207\u7247\u4ee5\u53ca\u514d\u75ab\u751f\u5316\u67d3\u8272\u78ba\u8a3a\u3002\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f\u70ba\u624b\u8853\u5207\u9664\u3002\u5b83\u88ab\u8a8d\u70ba\u662f\u4e00\u7a2e\u5c0d\u653e\u5c04\u7dda\u654f\u611f\u7684\u816b\u7624\uff0c\u7136\u800c\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u89d2\u8272\u537b\u4ecd\u4e0d\u660e\u78ba\u3002\u6211\u5011\u63d0\u51fa\u4e00\u500b\u9838\u90e8\u5448\u80f8\u817a\u6a23\u5206\u5316\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u75c5\u4f8b\uff0c\u5176\u539f\u767c\u90e8\u4f4d\u70ba\u9838\u90e8\u8edf\u7d44\u7e54\uff0c\u4e00\u958b\u59cb\u63a5\u53d7\u5916\u79d1\u6cbb\u7642\uff0c\u7136\u800c\u624b\u8853\u908a\u7de3\u5728\u75c5\u7406\u5207\u7247\u4e0b\u96e3\u4ee5\u5224\u5b9a\u3002\u65bc\u8ffd\u8e64\u6642\u4e4b\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u7591\u4f3c\u6b98\u9918\u816b\u7624\u4e4b\u60c5\u5f62\uff0c\u56e0\u6b64\u63a5\u53d7\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u81f32010\u5e7412\u6708\u6700\u5f8c\u4e00\u6b21\u9580\u8a3a\u8ffd\u8e64\u7684\u671f\u9593\uff0c\u4e5f\u5c31\u662f\u8a3a\u65b7\u5f8c47\u500b\u6708\uff0c\u90fd\u6c92\u6709\u5c40\u90e8\u5fa9\u767c\u53ca\u9060\u7aef\u8f49\u79fb\u7684\u60c5\u6cc1\u767c\u751f\u3002", "e": "Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor occurring in the thyroid gland or in the soft tissue of the neck. A definitive diagnosis can be made through histolopathologic examination and immunohistochemical profile. The main treatment modality is surgical excision. It is considered a radiosensitive tumor, however, the role of radiotherapy is uncertain. This is a report on a case of CASTLE of the neck treated with surgery but without adequate margin. A residual tumor was suspected on computed tomogram scan during follow-up, so sequential chemotherapy and radiotherapy were given. No local recurrence or distant metastasis was found 47 months after initial diagnosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-89-96", "title": "Prognostic Factor Affecting the Outcome of Bone Metastasis from Hepatocellular Carcinoma", "keywords": "\u809d\u7d30\u80de\u764c;\u9aa8\u982d\u8f49\u79fb HCC;Bone metastasis", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u662f\u91dd\u5c0d\u809d\u7d30\u80de\u764c\u6709\u9aa8\u982d\u8f49\u79fb\u7684\u60a3\u8005\uff0c\u8a55\u4f30\u4ed6\u5011\u7684\u5b58\u6d3b\u7387\u548c\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1999\u5e746\u6708\u52302005\u5e741\u6708\uff0c\u7e3d\u5171\u670969\u4f4d\u75c5\u4eba\u8a3a\u65b7\u809d\u7d30\u80de\u764c\u64c1\u6709\u9aa8\u982d\u8f49\u79fb\u5728\u6211\u5011\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\u3002\u672c\u7814\u7a76\u5206\u6790\u7684\u8b8a\u56e0\u5305\u62ec\u8a3a\u65b7\u9aa8\u982d\u8f49\u79fb\u6642\u7684\u6027\u5225\u3001\u5e74\u9f61\u3001\u809d\u786c\u5316Child's\u5206\u671f\u3001Okuda\u7cfb\u7d71\u3001\u6cbb\u7642\u9aa8\u982d\u8f49\u79fb\u7684\u65b9\u5f0f\u7b49\u3002\u7d50\u679c\uff1a52\u4f4d(75.4%)\u662f\u7537\u6027\uff0c17\u4f4d(24.6%)\u662f\u5973\u6027\u3002\u8a3a\u65b7\u809d\u764c\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f66\u6b72\u3002\u5728\u5b58\u6d3b\u65b9\u9762\uff0c\u5f9e\u8a3a\u65b7\u9aa8\u982d\u8f49\u79fb\u90a3\u5929\u7b97\u8d77\uff0c\u5b58\u6d3b\u671f\u7684\u4e2d\u4f4d\u6578\u70ba3.06\u500b\u6708\uff0c6\u500b\u6708\u30011\u5e74\u30012\u5e74\u7684\u5b58\u6d3b\u7387(overall survival)\u5206\u5225\u70ba30.43%\uff0c11.59%\u548c5.80%\u3002\u5728\u55ae\u4e00\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u809d\u786c\u5316Child's\u5206\u671f(p=0.0022)\u3001Okuda\u7cfb\u7d71(p=0.0002)\u548c\u75c5\u4eba\u6574\u9ad4\u72c0\u6cc1(p=0.0277)\u90fd\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5728\u591a\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u75c5\u4eba\u6574\u9ad4\u72c0\u6cc1(p=0.003)\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7d50\u8ad6\uff1a\u809d\u7d30\u80de\u764c\u6709\u9aa8\u982d\u8f49\u79fb\u60a3\u8005\u7684\u9810\u5f8c\u4e0d\u4f73\uff0c\u70ba\u4e86\u6539\u5584\u9810\u5f8c\uff0c\u6211\u5011\u9700\u8981\u6536\u96c6\u66f4\u591a\u7684\u60a3\u8005\uff0c\u4e26\u5b89\u6392\u5408\u4f75\u809d\u764c\u5c40\u90e8\u6cbb\u7642\u548c\u5168\u8eab\u7cfb\u7d71\u6cbb\u7642\u7684\u81e8\u5e8a\u8a66\u9a57\u3002", "e": "Purpose: The purpose of this study is to analyze the overall survival rate of patients with bone metastasis from hepatocellular carcinoma (HCC) and prognostic factors affecting their outcomes.Materials and Methods: From June 1999 to January 2005, there were 69 patients with bone metastasis from HCC who were treated at our hospital. The variables, such as gender, age of diagnosis of bone metastasis, Pugh's modification of Child's grading of cirrhosis Okuda staging system, performance status, serum level of \u03b1-fetoprotein at diagnosis of bone metastasis from HCC, methods of treatment for bone metastasis, site of bone metastasis and metastasis to organ other than bones were analyzed about their influence upon prognosis.Results: Fifty-two patients (75.4%) are male and 17 patients (24.6%) are female. The medium age of diagnosis of bone metastasis was 66 years old (range from 31 to 78 years old). The medium survival from diagnosis of bone metastasis was 3.06 months. The 6-month, 1-year and 2-year overall survival rates were 30.43%, 11.59% and 5.80%, respectively. In univariate analysis, Child's grading of cirrhosis (p=0.0022), Okuda staging system (p=0.0002), and performance status (p=0.0277) were statistically significant factors for survival. In multivariate analysis, performance status (p=0.003) was the only significant prognostic factor.Conclusion: The survival of patients with bone metastasis from HCC was poor. To improve the outcome, we should enroll more patients and arrange prospective trial by combination of locoregional and systemic therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-97-110", "title": "Three-Dimensional Conformal Radiotherapy for Unresectable or Post-Operative Residual Biliary Tract Carcinoma", "keywords": "\u653e\u5c04\u6cbb\u7642;\u81bd\u9053\u764c;\u7121\u6cd5\u5207\u9664;\u8853\u5f8c\u6b98\u9918 Radiotherapy;Biliary tract carcinoma;Unresectable;Post-operative residual", "c": "Purpose: To evaluate the efficacy of three-dimensional conformal radiotherapy (3D-CRT) for unresectable or post-operative residual biliary tract carcinoma (BTC).Materials and Methods: From September 1997 to August 2005, twenty-eight patients with localized unresectable (23 patients) or post-operative residual (5 patients) BTC were treated by 3D-CRT. The median radiation dose was 62.0 Gy (21.6-70.0 Gy/1.8-2.5 Gy). Seven patients also underwent chemotherapy. The median follow-up time for all patients was 6.4 months.Results: The median progression-free survival (PFS) was 5.8 months and the 2-year actuarial PFS rate was 10.7%. The median overall survival (OS) was 8.4 months and the 2-year actuarial OS rate was 23.1%. In univariate analysis, both OS and PFS strongly correlate with the performance status, jaundice, radiation dose and serum carbohydrate antigen 19-9 level. The PFS also significantly associates with unresectable tumor status. After multivariate analysis: good performance status (ECOG: 0 or 1) and higher radiation dose (\uff1e50.0 Gy) were two independent prognostic factors which showed for patients with both PFS (p\uff1c0.001 and p=0.046, respectively) and OS (p\uff1c0.001 and p=0.010, respectively). The overall incidence of upper gastrointestinal bleeding in patients without any previous peptic ulcer history was 18.2% and the complications were medically manageable.Conclusions: The study demonstrated that performance status and RT dose are two predictors for outcome in patients treated with 3D-CRT for unresectable or postoperative residual BTC.", "e": "Purpose: To evaluate the efficacy of three-dimensional conformal radiotherapy (3D-CRT) for unresectable or post-operative residual biliary tract carcinoma (BTC).Materials and Methods: From September 1997 to August 2005, twenty-eight patients with localized unresectable (23 patients) or post-operative residual (5 patients) BTC were treated by 3D-CRT. The median radiation dose was 62.0 Gy (21.6-70.0 Gy/1.8-2.5 Gy). Seven patients also underwent chemotherapy. The median follow-up time for all patients was 6.4 months.Results: The median progression-free survival (PFS) was 5.8 months and the 2-year actuarial PFS rate was 10.7%. The median overall survival (OS) was 8.4 months and the 2-year actuarial OS rate was 23.1%. In univariate analysis, both OS and PFS strongly correlate with the performance status, jaundice, radiation dose and serum carbohydrate antigen 19-9 level. The PFS also significantly associates with unresectable tumor status. After multivariate analysis: good performance status (ECOG: 0 or 1) and higher radiation dose (\uff1e50.0 Gy) were two independent prognostic factors which showed for patients with both PFS (p\uff1c0.001 and p=0.046, respectively) and OS (p\uff1c0.001 and p=0.010, respectively). The overall incidence of upper gastrointestinal bleeding in patients without any previous peptic ulcer history was 18.2% and the complications were medically manageable.Conclusions: The study demonstrated that performance status and RT dose are two predictors for outcome in patients treated with 3D-CRT for unresectable or postoperative residual BTC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-111-124", "title": "Early Experience of Stereotactic Body Radiotherapy in Patients with Primary and Metastatic Lung Tumors", "keywords": "\u96fb\u8166\u5200;\u7acb\u9ad4\u5b9a\u4f4d\u9ad4\u90e8\u653e\u5c04\u6cbb\u7642;\u80ba\u816b\u7624;\u653e\u5c04\u6027\u80ba\u708e CyberKnife(superscript \u00ae);Stereotactic body radiotherapy;Lung tumor;Radiation pneumonitis", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4f7f\u7528\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u9ad4\u90e8\u653e\u5c04\u6cbb\u7642(SBRT)\u65bc\u539f\u767c\u6027\u548c\u8f49\u79fb\u6027\u80ba\u816b\u7624\u75c5\u60a3\u4e4b\u81e8\u5e8a\u7d50\u679c\u3002\u65b9\u6cd5\uff1a\u56de\u6eaf\u6027\u63a2\u8a0e\u81ea2005\u5e7411\u6708\u81f32008\u5e746\u6708\u9593\u65bc\u842c\u82b3\u91ab\u9662\u63a5\u53d7SBRT\u4e4b19\u4f4d\u75c5\u60a3\u7684\u91ab\u7642\u8a18\u9304\u3002SBRT\u662f\u904b\u7528\u96fb\u8166\u5200\u4e4b\u816b\u7624\u8ffd\u8e64\u7cfb\u7d71\u4f86\u5be6\u884c\u6cbb\u7642\u3002\u6cbb\u7642\u5f8c\u816b\u7624\u53cd\u61c9\u548c\u76f8\u95dc\u4e4b\u526f\u4f5c\u7528\u662f\u4ee5\u8ffd\u8e64\u5f71\u50cf\u9032\u884c\u8a55\u4f30\u3002\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u5247\u4ee5Common Terminology Criteria for Adverse Events version 3.0\u5206\u7d1a\u4f86\u8a18\u9304\u526f\u4f5c\u7528\u4e4b\u56b4\u91cd\u7a0b\u5ea6\u3002\u7d50\u679c\uff1a\u65bc\u63a5\u53d7\u96fb\u8166\u5200SBRT\u4e4b19\u4f4d\u80ba\u816b\u7624\u75c5\u60a3\uff08\u517147\u9846\u80ba\u816b\u7624\uff09\u4e2d\uff0c8\u4f4d\uff0811\u9846\u816b\u7624\uff09\u70ba\u539f\u767c\uff0c11\u4f4d\uff0836\u9846\u816b\u7624\uff09\u70ba\u8f49\u79fb\u30029\u9846\u816b\u7624\u4f4d\u65bc\u4e2d\u592e\uff0c\u5176\u9918\u4f4d\u65bc\u9031\u908a\u3002\u816b\u7624\u9ad4\u7a4d\u4ecb\u65bc1.1\u81f3110.5\u6beb\u5347\uff08\u4e2d\u4f4d\u6578\uff0c9.5\u6beb\u5347\uff09\u3002\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u4ecb\u65bc22\u81f360Gy\uff0c\u6b78\u4e00\u5316\u65bc76%\u81f385%\u4e4b\u7b49\u5291\u91cf\u66f2\u7dda\uff0c\u52062\u81f34\u6b21\u7d66\u4e88\u3002\u65bc12\u500b\u6708\u4e4b\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\u4e2d\uff0c\u5171\u67093\u4f4d\u75c5\u60a3\u767c\u751f2\u7d1a\u653e\u5c04\u6027\u80ba\u708e\uff0c\u53e6\u67092\u4f4d\u75c5\u60a3\u767c\u751f3\u7d1a\u653e\u5c04\u6027\u80ba\u708e\u3002\u5206\u6790\u5176\u98a8\u96aa\u56e0\u5b50\uff0c\u5973\u6027(p=0.038)\u548c\u4e2d\u592e\u578b\u80ba\u816b\u7624(p=0.042)\u65bc\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\u6709\u7d71\u8a08\u5b78\u4e0a\u4e4b\u5dee\u7570\u3002\u5728\u5169\u4f4d\u70ba\u5fa9\u767c\u4e2d\u592e\u578b\u80ba\u816b\u7624\u4e14\u5148\u524d\u5df1\u63a5\u53d7\u904e\u80ba\u90e8\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u4e4b\u75c5\u60a3\u4e2d\uff0c\u89c0\u5bdf\u5230\u6c23\u7ba1\u98df\u9053\u763a\u7ba1\u53ca\u652f\u6c23\u7ba1\u58de\u6b7b\u4e4b\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u3002\u65bc16\u4f4d\u53ef\u4f9b\u5206\u6790\u5c40\u90e8\u63a7\u5236\u7387\u7684\u75c5\u60a3\u4e2d\uff0c4\u4f4d(25%)\u70bacomplete response\uff0c7\u4f4d(43.8%)\u70bapartial response\uff0c2\u4f4d(12.5%)\u70bastable disease\uff0c3\u4f4d(18.7%)\u70baprogressive disease\u3002\u75c5\u4eba\u4e00\u5e74\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba63%\uff0c\u4e00\u5e74\u4e4b\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387\u70ba84.2%\u3002\u6bd4\u8f03\u539f\u767c\u6027\u548c\u8f49\u79fb\u6027\u80ba\u764c\u4e4b\u4e00\u5e74\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387(87.5% vs. 81.8%, p=0.87)\uff0c\u4ee5\u53ca\u4e2d\u592e\u578b\u548c\u9031\u908a\u578b\u80ba\u816b\u7624\u4e4b\u4e00\u5e74\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387(80% vs. 85.7%, p=0.63)\uff0c\u4e26\u7121\u7d71\u8a08\u5b78\u4e0a\u4e4b\u5dee\u7570\u3002\u7d50\u8ad6\uff1a\u65bc\u6211\u5011\u7684\u65e9\u671f\u7d93\u9a57\u4e2d\uff0c\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u9ad4\u90e8\u653e\u5c04\u6cbb\u7642\u80fd\u6709\u6548\u5c40\u90e8\u63a7\u5236\u539f\u767c\u6027\u548c\u8f49\u79fb\u6027\u80ba\u816b\u7624\uff0c\u7136\u800c\uff0c\u6cbb\u7642\u4e2d\u592e\u578b\u6216\u5148\u524d\u5df1\u7167\u5c04\u904e\u653e\u5c04\u7dda\u4e4b\u5fa9\u767c\u80ba\u816b\u7624\u6642\uff0c\u61c9\u7279\u5225\u8b39\u614e\u4ee5\u907f\u514d\u8f03\u56b4\u91cd\u4e4b\u526f\u4f5c\u7528\u3002", "e": "Purpose: To investigate the clinical outcomes of patients with primary and metastatic lung tumors treated by CyberKnife(superscript \u00ae) (CK) stereotactic body radiotherapy (SBRT).Methods: Between November 2005 and June 2008, we treated 19 patients with SBRT at Taipei Medical University-Wan Fang Hospital. The SBRT was delivered by CK tumor tracking system. Tumor response and treatment-related toxicity were evaluated by follow-up image study. Treatment-related toxicities were scored by Common Terminology Criteria for Adverse Events version 3.0. In this study, we reviewed their medical records retrospectively.Results: We treated 47 lung tumors in 19 patients using CK SBRT. Eleven tumors in 8 patients were primary lung cancer, and 36 tumors in 11 patients were metastatic lung cancer. The locations of 9 tumors were central, whereas the others were peripheral. The tumor volumes were ranged from 1.1 to 110.5 ml (median, 9.5 ml). The radiation doses were ranged from 22 to 60 Gy, given in 2 to 4 fractions. The prescribed doses were normalized at 76% to 85% of the planned isodose. With a median follow-up interval of 12 months, we observed that grade 2 radiation pneumonitis (RP) occurred in 3 patients (1 central; 2 peripheral), whereas we found that grade 3 RP occurred in 2 patients with central lesions. According to the univariate analysis, female (p=0.038) and central lesion (p=0.042) were two predictive factors to the occurrence of grade\u22652 RP. One grade 4 tracheal complication (tracheoesophageal fistula) and one grade 5 bronchial complication (bronchial necrosis) were observed in two patients who had centrally located recurrent tumors and had been previous treated with external beam radiotherapy. Four of the evaluable patients (16 patients) had responded completely (25%), seven exhibited partial response to treatment (43.8%), and two had stable disease (12.5%). Three patients had tumor progression after SBRT (18.7%). The 1-year overall survival (OS) was 63%, and the 1-year local progression-free survival (PFS) was 84.2%. The 1-year local PFS was 87.5% for primary lung cancer and 81.8% for metastatic lung cancer (p=0.87). The 1-year local PFS for central and peripheral lesions was 80% and 85.7%, respectively (p=0.63).Conclusion: Our study showed that SBRT using the CK system was effective for treating primary and metastatic lung tumors, providing better local control and shorter treatment course compared with those treated with conventional fractionated radiotherapy. Our study also showed two predicting factors for RP. Finally, using SBRT to treat centrally located tumor or re-irradiate recurrent tumor require additional caution due to higher risk of having complication. Thus, we suggest that more studies are needed in the future to confirm those findings in this study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-125-135", "title": "Dosimetric Analysis for Sparing the Obturator Nerves Using IMRT Technique for Cervical Cancer", "keywords": "\u9589\u5b54\u795e\u7d93;\u5b50\u5bae\u9838\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Obturator nerve;Cervical carcinoma;Intensity-modulated radiotherapy", "c": "\u76ee\u7684\uff1a\u9589\u5b54\u795e\u7d93\u75c5\u8b8a\u662f\u5b50\u5bae\u9838\u764c\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7684\u665a\u671f\u4f75\u767c\u75c7\u4e4b\u4e00\uff0c\u9589\u5b54\u5167\u7684\u9589\u5b54\u795e\u7d93\u4f4d\u65bc\u9aa8\u76c6\u653e\u5c04\u6cbb\u7642\u4e4b\u9ad8\u5291\u91cf\u7bc4\u570d\uff0c\u85c9\u7531\u754c\u5b9a\u9589\u5b54\u5167\u4e4b\u9589\u5b54\u795e\u7d93\uff0c\u4ee5\u8a55\u4f30\u964d\u4f4e\u9589\u5b54\u795e\u7d93\u5291\u91cf\u4e4b\u6cbb\u7642\u8a08\u756b\u7684\u7d50\u679c\u53ca\u53ef\u884c\u6027\u3002\u6750\u6599\u53ca\u65b9\u6cd5\uff1a10\u4f4d\u5b50\u5bae\u9838\u764c\u75c5\u4eba\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u8cc7\u6599\u4e2d\uff0c\u4f9d\u64da\u6559\u79d1\u66f8\u8cc7\u6599\u5708\u9078\u9589\u5b54\u795e\u7d93\u53ca\u5468\u908a\u7d50\u69cb\uff0c\u5206\u6790\u964d\u4f4e\u9589\u5b54\u795e\u7d93\u653e\u5c04\u6cbb\u7642\u4e2d\u63a5\u53d7\u4e4b\u5291\u91cf\u5c0d\u6cbb\u7642\u8a08\u756b\u53c3\u6578\u7684\u5f71\u97ff\uff0c\u4f8b\u5982\uff1a\u9776\u9ad4\u7a4d\u6216\u5371\u6025\u5668\u5b98\u5291\u91cf\u9ad4\u7a4d\u7d44\u7e54\u5716\u3001\u6700\u9ad8\u5291\u91cf\u3001\u6a19\u7684\u8655\u65b9\u5291\u91cf\u5305\u8986\u5ea6\u53ca\u9806\u5f62\u6307\u6a19\u7b49\u3002\u7d50\u679c\uff1a\u9589\u5b54\u795e\u7d93\u754c\u5b9a\u6307\u5f15\u904b\u7528\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u964d\u4f4e\u9589\u5b54\u795e\u7d93\u5291\u91cf\u7684\u6cbb\u7642\u8a08\u756b\u65bc\u9ad4\u5916\u7167\u5c04\u63a5\u53d7\u4e4b\u6700\u5927\u5291\u91cf\u53ef\u6e1b\u5c11\u905418.3\u00b14.1%\uff0c\u4e26\u4e14\u5c0d\u65bc\u8a08\u5283\u9776\u9ad4\u7a4d\u4e4b\u9806\u5f62\u6307\u6a19\u3001\u5291\u91cf\u5206\u4f48\u53ca\u5371\u6025\u5668\u5b98\u4e4b\u5291\u91cf\u9ad4\u7a4d\u95dc\u4fc2\u65bc\u7d71\u8a08\u4e0a\u4e26\u7121\u660e\u986f\u5f71\u97ff\u3002\u7d50\u8ad6\uff1a\u964d\u4f4e\u9589\u5b54\u795e\u7d93\u5291\u91cf\u7684\u6cbb\u7642\u8a08\u756b\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e2d\u662f\u53ef\u884c\u7684\uff0c\u9664\u53ef\u964d\u4f4e\u9589\u5b54\u5167\u4e4b\u9589\u5b54\u795e\u7d93\u6240\u63a5\u53d7\u5291\u91cf\uff0c\u540c\u6642\u4e0d\u589e\u52a0\u5176\u4ed6\u6b63\u5e38\u5668\u5b98\u5291\u91cf\u53ca\u4e0d\u5f71\u97ff\u816b\u7624\u8655\u65b9\u5291\u91cf\u5305\u8986\u5ea6\u3002", "e": "Purpose: Obturator neuropathy is a late complication of radiotherapy (RT) and chemo-radiation in cervical cancer patients. We studied the feasibility of sparing the obturator nerves in patients receiving intensity-modulated radiotherapy (IMRT) by delineating the obturator nerves in obturator canals near to the high dose region in pelvis irradiation.Materials and Methods: Volumetric computed tomography (CT) images of ten patients with cervical cancers were retrieved. Anatomical orientation of obturator canals were gathered based on published knowledge in textbooks. Target volume of obturator nerves and pertinent normal structures were contoured and reconstructed for IMRT planning. Dosimetric parameters including dose-volume histograms (DVHs), maximal dose, prescription dose coverage and conformal index were compared between plans with and without obturator nerves as organ of avoidance.Result: A guideline for delineation of obturator canals for IMRT on axial contrast CT images was derived. The use of sparing the obturator nerve technique resulted in an average of 18.3\u00b14.1 % decrease in the calculated maximum dose of the obturator nerves (p\uff1c0.05). No significant impact on the conformality and coverage of planning target volume (PTV) of cervical cancer and neither significant dosimetric impact on other critical normal organs in pelvic area.Conclusion: We found that sparing the obturator nerve technique is feasible for patients with cervical cancer and treated with IMRT. The reduction of doses to OBN did not compromise target coverage of tumor and DVHs of other normal organs."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-137-147", "title": "\u8a2d\u8a08\u4e00\u5957\u7279\u6b8a\u91dd\u677f\u53ca\u5e73\u884c\u5b9a\u4f4d\u91cf\u89d2\u5668\u505a\u70ba\u651d\u8b77\u817a\u63d2\u7a2e\u6cbb\u7642\u8f14\u52a9\u5de5\u5177\u7684\u7814\u7a76", "keywords": "\u651d\u8b77\u817a\u63d2\u7a2e\u6cbb\u7642;\u7279\u6b8a\u91dd\u677f;\u5e73\u884c\u5b9a\u4f4d\u91cf\u89d2\u5668;\u6a21\u64ec\u6cbb\u7642 Prostate needle implant;Domed-Cones template;Parallel shift protractor;Brachy therapy pre-simulation", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u8aaa\u660e\u5982\u4f55\u5229\u7528\u81ea\u884c\u8a2d\u8a08\u7684\u7279\u6b8a\u91dd\u677f\u53ca\u5e73\u884c\u5b9a\u4f4d\u91cf\u89d2\u5668\uff0c\u4ee5\u671f\u5728\u651d\u8b77\u817a\u7684\u63d2\u7a2e\u904e\u7a0b\u4e2d\uff0c\u9054\u5230\u65e2\u53ef\u4ee5\u8b93\u91dd\u56fa\u5b9a\u53ca\u659c\u63d2\u7684\u6548\u679c\u3001\u4e14\u53ef\u4ee5\u9810\u5148\u6a21\u64ec\u91dd\u7f6e\u5165\u4eba\u9ad4\u7684\u89d2\u5ea6\u53ca\u91dd\u7f6e\u5165\u7684\u6df1\u5ea6\uff0c\u4ee5\u4fbf\u57f7\u884c\u6700\u4f73\u7684\u63d2\u7a2e\u6cbb\u7642\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u7d50\u5408\u5169\u7247\u9577\u5bec\u5747\u662f7.5\u516c\u5206\uff0c\u539a\u5ea6\u70ba0.5\u516c\u5206\uff0c\u5167\u5074\u6709\u201c\u7897\u7d50\u69cb\u201d\u5f62\u72c0\u7684\u58d3\u514b\u529b\u677f\uff0c\u800c\u5728\u6bcf\u500b\u201c\u7897\u7d50\u69cb\u201d\u5f62\u72c0\u7684\u58d3\u514b\u529b\u677f\u5916\u5074\u5404\u670960\u00ba\u89d2\u7684\u706b\u5c71\u9310\u5408\u6210\u7279\u6b8a\u7684\u91dd\u677f\uff1b\u800c\u5728\u6b64\u5169\u500b\u201c\u7897\u7d50\u69cb\u201d\u6240\u5408\u6210\u7684\u7a7a\u5fc3\u7403\u9ad4\u5167\u5305\u542b\u5169\u74e3\u6709\u5b54\u6d1e\u7684\u534a\u7403\u9ad4\uff1b\u7d50\u679c\u986f\u793a\uff0c\u5728\u651d\u8b77\u817a\u7684\u63d2\u7a2e\u904e\u7a0b\u4e2d\uff0c\u7576\u4f7f\u7528\u6b64\u7a2e\u7279\u6b8a\u91dd\u677f\u6642\uff0c\u53ef\u4ee5\u9054\u5230\u9632\u6b62\u91dd\u5f80\u5167\u6233\uff0c\u53c8\u53ef\u907f\u514d\u91dd\u5f80\u5916\u6ed1\uff0c\u4e14\u53ef\u4ee5\u8b93\u91dd\u4ee5\u50be\u659c\u7684\u89d2\u5ea6\u63d2\u5165\u75c5\u60a3\u9ad4\u5167\u7684\u529f\u80fd\u3002\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u4f7f\u7528\u6b64\u7bc7\u81ea\u884c\u8a2d\u8a08\u7684\u7279\u6b8a\u91dd\u677f\u7684\u540c\u6642\uff0c\u5982\u679c\u518d\u52a0\u4e0a\u5e73\u884c\u5b9a\u4f4d\u91cf\u89d2\u5668\u7684\u8f14\u52a9\u53ca\u91dd\u677f\u56fa\u5b9a\u5668\u7684\u904b\u7528\uff0c\u8db3\u4ee5\u8b93\u651d\u8b77\u817a\u63d2\u7a2e\u6cbb\u7642\u9054\u5230\u6700\u4f73\u7684\u63d2\u7a2e\u6548\u679c\uff1b\u5982\u679c\u4ee5\u6b64\u88dd\u7f6e\u518d\u914d\u5408\u76f4\u8178\u8d85\u97f3\u6ce2\u7684\u4f7f\u7528\uff0c\u4e0d\u4f46\u5728\u651d\u8b77\u817a\u63d2\u7a2e\u6cbb\u7642\u4e0a\uff0c\u751a\u81f3\u5728\u6c38\u4e45\u6027\u7684\u63d2\u7a2e\u6cbb\u7642\u4e0a\u90fd\u53ef\u4ee5\u8b93\u8f3b\u5c04\u5291\u91cf\u9054\u5230\u6700\u4f73\u7684\u5206\u4f48\u3002", "e": "Purpose: Normally, the conventional acrylic board with parallel holes template in prostate needle implant lead disadvantages to be able to tile or rotate when needles need to approach seminal vesicle or to avoid the obstruction of symphysis pubis. In order to overcome the disadvantages of conventional templates, we developed a special template for guiding needles insertion and fixation when practice prostate needle implant.Materials and Methods: Two acrylic board, each with 7.5 cm by 7.5 cm of width, length and 0.5 cm thickness, were drilled a set of domed holes and cones combination placed split balls inside this combination to provide firmly grip and fixation of needles both in tilting and rotation movement. Thirety nine domed-cones combination concentric circles array provide at most thirety nine needles insertion and eight nylon screws screwed tight to compress those thirety nine glass fiber reinforced plastic split balls inside domed-cones combination to support needles fixation. All these materials have been considered the tolerance not to be spoiled under normal sterillizaton condition.Results: A dosimetric measurement with home-made phantom have been developed. The special designed acrylic board domed-cones combination provide needles up to 60\u00b0 rotation flexibility application. Some area that isodose curves couldn't cover in conventional parallel template could be covered now by using this new designed template.Conclusion: This special designed acrylic board domed-cones combination not only provide a reliable way for needles fixation and rotational function, but also provide a superior dose distribution in anterior portion of prostate and well coverage of seminal vesicle."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-149-156", "title": "4D CT\u5f71\u50cf\u65bc\u80ba\u90e8\u816b\u7624\u653e\u5c04\u6cbb\u7642\u7684\u61c9\u7528", "keywords": "\u80ba\u816b\u7624;\u653e\u5c04\u6cbb\u7642;\u56db\u7dad\u96fb\u8166\u65b7\u5c64;\u6700\u5927\u5bc6\u5ea6\u6295\u5f71 Lung tumor;Radiotherapy;4-D CT;Maximum intensity projection MIP", "c": "Purpose: The purpose of this study is to describe our management of the respiration-induced uncertainty by the Maximum Intensity Projection (MIP) of 4-dimensional (4D) CT.Material and Methods: Gross target volumes (GTVs) and planning target volumes (PTVs) were contoured on the images of normal-breathing CT and MIP of 4D CT for 12 patients with primary lung cancer or metastatic lung tumor. The volumes of GTVs and PTVs were compared between the two sets of images by using the paired t-test.Results: The GTVs of MIP images (mean=8.13\u00b19.05 cm^3) were larger than those of normal breathing images (mean=4.74\u00b15.89 cm^3, p=0.04). When applying different safe margins on GTVs to define their PTVs, the PTVs of MIP images (mean=25.28\u00b120.38 cm^3) became smaller than those of normal breathing images (mean 75.04\u00b136.49 cm^3, p=\uff1c0.01). Moreover, in 3 cases whose tumors were located in the lower lung, the PTVs of normal breathing images could not fully cover the GTVs of the MIP images. On the contrary, for tumors above the carina, the differences of target volumes between the two image sets were smaller.Discussion and Conclusion: 4D CT depicts the excursion of a lung tumor and increases the accuracy of the target definition. The 4D CT-based plans can reduce the target volumes to spare more normal tissues compared with conventional plans.", "e": "Purpose: The purpose of this study is to describe our management of the respiration-induced uncertainty by the Maximum Intensity Projection (MIP) of 4-dimensional (4D) CT.Material and Methods: Gross target volumes (GTVs) and planning target volumes (PTVs) were contoured on the images of normal-breathing CT and MIP of 4D CT for 12 patients with primary lung cancer or metastatic lung tumor. The volumes of GTVs and PTVs were compared between the two sets of images by using the paired t-test.Results: The GTVs of MIP images (mean=8.13\u00b19.05 cm^3) were larger than those of normal breathing images (mean=4.74\u00b15.89 cm^3, p=0.04). When applying different safe margins on GTVs to define their PTVs, the PTVs of MIP images (mean=25.28\u00b120.38 cm^3) became smaller than those of normal breathing images (mean 75.04\u00b136.49 cm^3, p=\uff1c0.01). Moreover, in 3 cases whose tumors were located in the lower lung, the PTVs of normal breathing images could not fully cover the GTVs of the MIP images. On the contrary, for tumors above the carina, the differences of target volumes between the two image sets were smaller.Discussion and Conclusion: 4D CT depicts the excursion of a lung tumor and increases the accuracy of the target definition. The 4D CT-based plans can reduce the target volumes to spare more normal tissues compared with conventional plans."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-157-161", "title": "18F-FDG PET/CT Images Produced Stunningly False-Negative Results after Definitive Chemoradiotherapy in Nasopharyngeal Caricinoma-A Case Report", "keywords": "\u9f3b\u54bd\u764c;\u6b63\u5b50\u651d\u5f71;\u64ca\u660f\u6548\u61c9 18-fluoro-2-deoxyglucose positron emission tomography FDG-PET;Nasopharyngeal carcinoma;Stunning effect", "c": "\u6211\u5011\u5831\u544a\u4e86\u4e00\u4f4d45\u6b72\u9f3b\u54bd\u764c\u7537\u6027\uff0c\u63a5\u53d7\u6839\u6cbb\u6027\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u4e09\u500b\u6708\u4e4b\u5f8c\uff0c\u6838\u78c1\u5171\u632f\u7684\u6aa2\u67e5\u986f\u793a\u6709\u591a\u9846\u6b98\u5b58\u9838\u90e8\u6dcb\u5df4\u7d50\uff0c\u53ef\u662f\u6b63\u5b50\u651d\u5f71\u4e26\u7121\u660e\u986f\u6d3b\u6027\u5438\u6536\u3002\u6211\u5011\u5b89\u6392\u4e86\u6539\u826f\u5f0f\u9838\u90e8\u6dcb\u5df4\u5ed3\u6e05\u8853\u4e4b\u5f8c\uff0c\u8b49\u660e\u9838\u90e8\u6dcb\u5df4\u7d50\u662f\u7d93\u7531\u9f3b\u54bd\u8f49\u79fb\u4f86\u7684\u60e1\u6027\u7d30\u80de\u3002\u6b63\u5b50\u651d\u5f71\u5448\u73fe\u5373\u4f7f\u6839\u6cbb\u6027\u6cbb\u7642\u5f8c\u8d85\u904e3\u500b\u6708\uff0c\u4ecd\u53ef\u80fd\u51fa\u73fe\u64ca\u660f\u6548\u61c9\u5f71\u50cf\u3002\u5728\u77ed\u6642\u9593\u7684\u6839\u6cbb\u6027\u6cbb\u7642\u5f8c\uff0c\u529f\u80fd\u6027\u7684\u6aa2\u67e5\u4ecd\u9700\u8b39\u614e\u5c0f\u5fc3\u3002", "e": "We report the case of a 45-year-old man who received definitive chemoradiotherapy for nasopharyngeal carcinoma. Three months after chemoradiotherapy, head-and-neck magnetic resonance imaging (MRI) showed multiple residual lymph nodes with what appeared to be metastases in the neck. However, 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) produced nonspecific findings. We performed a confirmatory modified radical neck dissection; and pathologic examination revealed metastatic carcinoma, consistent with nasopharyngeal origin. The dramatic false-negative results were obtained on FDG-PET images more than 3 months after chemoradiotherapy. We conclude that functional studies need to be interpreted with caution within short intervals after definitive chemoradiotherapy even after 3 months."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201106-201107200009-201107200009-163-170", "title": "Intracranial Hemangiopericytoma: A Case Report and Literatures Review", "keywords": "\u9871\u5167;\u8840\u7ba1\u5916\u76ae\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Intracranial;Hemangiopericytoma;Radiotherapy", "c": "\u8840\u7ba1\u5916\u76ae\u7624\u662f\u4e00\u7a2e\u76f8\u7576\u5c11\u898b\u7684\u8edf\u7d44\u7e54\u816b\u7624\uff0c\u597d\u767c\u90e8\u4f4d\u4ee5\u4e0b\u80a2\uff0c\u5f8c\u8179\u8154\u6216\u9aa8\u76c6\u8154\u4f54\u591a\u6578\uff0c\u800c\u54bd\u5589\u3001\u813e\u81df\u3001\u9aa8\u9abc\u3001\u8166\u819c\u3001\u80f8\u8154\u5247\u662f\u8f03\u5c11\u51fa\u73fe\u7684\u90e8\u4f4d\u3002\u6211\u5011\u5831\u544a\u4e00\u500b35\u6b72\u9871\u5167\u8840\u7ba1\u5916\u76ae\u7624\u7684\u7537\u6027\u75c5\u4f8b\uff0c\u5728\u9871\u9aa8\u5207\u958b\u8853\u8207\u90e8\u4efd\u816b\u7624\u5207\u9664\u5f8c\u63a5\u53d7\u624b\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u4f7f\u7528\u50b3\u7d71\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\u7d66\u4e88\u6b98\u9918\u816b\u7624\u90e8\u4f4d63 Gy/35\u6b21\u7684\u653e\u5c04\u5291\u91cf\u3002\u7d93\u904e10\u5e74\u7684\u8ffd\u8e64\uff0c\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u4e26\u7121\u816b\u7624\u5fa9\u767c\u3002\u9019\u500b\u75c5\u4f8b\u5728\u63a5\u53d7\u624b\u8853\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u7372\u5f97\u9577\u671f\u7684\u816b\u7624\u63a7\u5236\u3002", "e": "Hemangiopericytomas are rare soft tissue tumors that develop mainly in the lower extremities, retroperitoneum or pelvis and rarely occur in the larynx, spleen, bone, meninges or thorax. This case is that of a 35-year-old man with intracranial hemangiopericytoma which was treated with craniotomy and partial removal of tumor. This was followed by post operative radiotherapy using conventional wedge pair technique with total dose of 63 Gy in 35 fractions to the residual tumor. MRI (magnetic resonance image) of brain showed no recurrence or other abnormal finding at a 10-year follow-up. The patient has long-term tumor control after surgery and post-operative radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-1-15", "title": "\u96fb\u8166\u5200\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u7cfb\u7d71\u61c9\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u4e4b\u8a55\u4f30", "keywords": "\u96fb\u8166\u5200;\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u7cfb\u7d71;\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71;\u79fb\u52d5\u5047\u9ad4 CyberKnife;Synchrony respiratory tracking system;Image guide system;Motion phantom", "c": "\u76ee\u7684\uff1a\u9a57\u8b49\u8207\u63a2\u8a0e\u96fb\u8166\u5200\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u7cfb\u7d71\uff0c\u5728\u816b\u7624\u56e0\u547c\u5438\u800c\u9020\u6210\u9031\u671f\u6027\u79fb\u52d5\u4e0b\uff0c\u6cbb\u7642\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u8207\u6cbb\u7642\u7bc4\u570d\u7684\u8b8a\u5316\u60c5\u5f62\uff0c\u8a55\u4f30\u8a72\u7cfb\u7d71\u65bc\u81e8\u5e8a\u6cbb\u7642\u4e0a\u4e4b\u8ca2\u737b\u53ca\u5176\u76f8\u95dc\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528\u5177\u6709\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u529f\u80fd\u7684\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7cfb\u7d71\u3002\u4f7f\u7528\u79fb\u52d5\u5047\u9ad4(Motion phantom)\u6a21\u64ec\u75c5\u60a3\u6cbb\u7642\u4f4d\u7f6e\u56e0\u547c\u5438\u800c\u79fb\u52d5\u60c5\u5f62\u3002\u6b64\u5047\u9ad4\u914d\u7f6e\u4e00\u500b\u7531\u65cb\u8f49\u8ef8\u5e36\u52d5\u4e4b\u5e73\u53f0\uff0c\u53ef\u4f5c\u524d\u5f8c\u65b9\u5411\u904b\u52d5\uff0c\u5e73\u53f0\u4e0a\u53ef\u4f9b\u653e\u7f6e\u5167\u542b\u9a57\u8b49\u7247\u7684\u5168\u7cfb\u7d71\u6e2c\u8a66\u7528\u7403\u578b\u7acb\u65b9\u9ad4\u3002\u9a57\u8b49\u7247\u4f7f\u7528MD-55\u81a0\u7247\uff0c\u6383\u63cf\u9a57\u8b49\u7247\u4f7f\u7528Epson expression 1680\u7a7f\u900f\u5f0f\u5e73\u7248\u6383\u63cf\u5668\u3002\u7a7a\u9593\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u9a57\u8b49\u4e4b\u5206\u6790\u8edf\u9ad4\u70baEnd to End test\u3002\u81e8\u5e8a\u75c5\u60a3\u5291\u91cf\u5206\u4f48\u9a57\u8b49\u4e4b\u5206\u6790\u8edf\u9ad4\u5247\u70baFilm QA\u3002\u7a7a\u9593\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u5206\u6790\u5206\u975c\u614b\u3001\u904b\u52d5\u4e0d\u88dc\u511f\u53ca\u904b\u52d5\u81ea\u52d5\u88dc\u511f\u7b49\u4e09\u7a2e\u689d\u4ef6\u9032\u884c\uff0c\u7531\u5047\u9ad4\u975c\u6b62\u72c0\u614b\u5230\u5047\u9ad4\u79fb\u52d5\u540c\u6642\u555f\u52d5\u6cbb\u7642\u8a2d\u5099\u4f5c\u52d5\u614b\u81ea\u52d5\u88dc\u511f\uff0c\u8a55\u4f30\u96fb\u8166\u5200\u5728\u5404\u7a2e\u60c5\u6cc1\u4e0b\u57f7\u884c\u6cbb\u7642\u8a08\u756b\u6642\u7684\u7a7a\u9593\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u60c5\u5f62\u3002\u5728\u6cbb\u7642\u4f4d\u7f6e\u904b\u52d5\u8aa4\u5dee\u53ca\u52d5\u614b\u81ea\u52d5\u88dc\u511f\u8aa4\u5dee\u7684\u8a55\u4f30\u65b9\u9762\uff0c\u8a2d\u8a08\u4e86\u5169\u500b\u81e8\u5e8a\u72c0\u6cc1\u5be6\u9a57\uff1a\u4e00\u3001\u547c\u5438\u9031\u671f\u4e2d\u4e0d\u540c\u4f4d\u7f6e\uff0c\u4e8c\u3001\u8b8a\u5316\u547c\u5438\u983b\u7387\u53d6\u5b9a\u4f4d\u5f71\u50cf\u4e4b\u6cbb\u7642\u6e96\u78ba\u5ea6\u8a55\u4f30\u3002\u81e8\u5e8a\u5291\u91cf\u9a57\u8b49\u5247\u91dd\u5c0d\u80ba\u90e8\u3001\u809d\u81df\u8207\u651d\u8b77\u817a\u4e09\u500b\u90e8\u4f4d\uff0c\u5404\u9078\u64c7\u4e00\u4f4d\u75c5\u60a3\u4e4b\u96fb\u8166\u6cbb\u7642\u8a08\u756b\uff0c\u4ee5MD-55\u5291\u91cf\u9a57\u8b49\u81a0\u7247\uff0c\u03b3\u6578\u503c\u8a55\u4f30\u65b9\u6cd5(3%, 3 mm)\uff0c\u6bd4\u5c0d\u5728\u816b\u7624\u4e2d\u5fc3\u9ede\u6240\u5728\u7684\u8ef8\u72c0\u5207\u9762(axial)\u53ca\u77e2\u72c0\u5207\u9762(sagittal)\u5291\u91cf\u91cf\u6e2c\u7d50\u679c\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u8a08\u7b97\u7d50\u679c\u4e4b\u5dee\u7570\u3002\n\u7d50\u679c\uff1a\u5047\u9ad4\u975c\u614b\u689d\u4ef6\uff0c\u5e73\u5747\u8aa4\u5dee\u70ba0.42\u00b10.06 mm\u3002\u5047\u9ad4\u9031\u671f\u904b\u52d5\u6642\uff0c\u5728\u547c\u5438\u9031\u671f\u4e0d\u540c\u6642\u9593\u9ede\u53d6\u50cf\u7684\u60c5\u6cc1\u4e0b\uff0c\u904b\u52d5\u4e0d\u6821\u6b63\u88dc\u511f\u8207\u904b\u52d5\u6821\u6b63\u88dc\u511f\u689d\u4ef6\u4e0b\u4e4b\u5e73\u5747\u8aa4\u5dee\u5206\u5225\u70ba7.59\u00b15.14 mm\u82070.35\u00b10.10 mm\uff0cp\u503c\u5c0f\u65bc0.0001\u3002\u5728\u8b8a\u5316\u547c\u5438\u983b\u7387\u7684\u60c5\u6cc1\u4e0b\uff0c\u6bcf\u5206\u941820\u6b21\u8207\u6bcf\u5206\u941815\u6b21\u4e4b\u5e73\u5747\u8aa4\u5dee\u5dee\u8ddd\u50c5\u67090.12 mm\uff0cp\u503c\u70ba0.11\u3002\u81e8\u5e8a\u75c5\u60a3\u5291\u91cf\u9a57\u8b49\uff0c\u80ba\u90e8\u3001\u809d\u81df\u8207\u651d\u8b77\u817a\u4e09\u7d44\u81e8\u5e8a\u75c5\u60a3\u4e4b\u8ef8\u72c0\u5207\u9762\u8207\u77e2\u72c0\u5207\u9762\u4e4b2\u7dad\u5291\u91cf\u9a57\u8b49\uff0c\u03b3\u6578\u503c\u8a55\u4f30\u65b9\u6cd5\u7684\u901a\u904e\u7387\u7686\u9ad8\u65bc99%\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u7684\u5206\u6790\u4e2d\uff0c\u96fb\u8166\u5200\u547c\u5438\u540c\u6b65\u8ffd\u8e64\u7cfb\u7d71\u4e4b\u7a7a\u9593\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u8aa4\u5dee\u5c0f\u65bc0.5 mm\uff0c\u7b26\u5408\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u5c0d\u65bc\u7a7a\u9593\u4f4d\u7f6e\u6e96\u78ba\u5ea6\u4e4b\u8981\u6c42\u3002\u5728\u8655\u7406\u6cbb\u7642\u4f4d\u7f6e\u6703\u56e0\u547c\u5438\u800c\u79fb\u52d5\u7684\u75c5\u60a3\u6642\uff0c\u57f7\u884c\u6b64\u7cfb\u7d71\uff0c\u5c07\u53ef\u5927\u5e45\u6e1b\u5c11\u7167\u5c04\u7684\u7bc4\u570d\uff0c\u6709\u6548\u964d\u4f4e\u6b63\u5e38\u7d44\u7e54\u7684\u50b7\u5bb3\u3002\u5728\u81e8\u5e8a\u75c5\u60a3\u5291\u91cf\u9a57\u8b49\u5be6\u9a57\u4e2d\uff0c\u5291\u91cf\u5206\u4f48\u4e4b\u6e96\u78ba\u6027\u4ea6\u53ef\u5145\u5206\u6eff\u8db3\u81e8\u5e8a\u6cbb\u7642\u7684\u8981\u6c42\u3002\u7136\u800c\u4f7f\u7528\u672c\u7cfb\u7d71\u7684\u6cbb\u7642\u6642\u9593\u5e38\u98081.5~2.5\u5c0f\u6642\uff0c\u6613\u4f7f\u75c5\u60a3\u56e0\u4e45\u8eba\u4e0d\u8010\u800c\u8e81\u52d5\uff0c\u5f71\u97ff\u6cbb\u7642\u4f4d\u7f6e\u7684\u6e96\u78ba\u6027\u3002\u81e8\u5e8a\u61c9\u7528\u6642\uff0c\u61c9\u659f\u914c\u75c5\u60a3\u7684\u7a69\u5b9a\u5ea6\u9069\u7576\u4f7f\u7528\u5373\u6642\u5f71\u50cf\u5c0e\u5f15\u7684\u529f\u80fd\uff0c\u78ba\u4fdd\u6cbb\u7642\u7684\u54c1\u8cea\u3002", "e": "Purpose: To verify the accuracy of CyberKnife(superscript \u00ae) Respiratory Tracking System (SRTS) in tracking the tumor motion during the respiratory cycle and the influence on treatment field; and to evaluate the clinical application of the system.\nMaterials and Methods: The SRTS was a subsystem of the CyberKnife(superscript \u00ae) stereotactic radiosurgery system for respiratory tracking. The motion phantom was used in the respiratory motion experiments, which can imitate regular breathing pattern. The motion phantom contained a motion table and a ball-cube phantom which can hold verification films. We performed the E2E CyberKnife(superscript \u00ae) dose calibration procedure and used MD-55 verification film, flatbed scanner (Epson Expression 1680) and dose analysis software (Film QA) to evaluate the clinical dosimetry and treatment accuracy. The mechanical accuracy of the SRTS was tested and confirmed by three stages of studies including the static phantom, motion phantom and the motion tracking compensation experiments. We also designed two experiments with phantom moved in different phases and frequency of the respiratory cycle to test for the accuracy of the image guide system on motion compensation. The clinical dosimetry verification studies included the lung, liver and prostate cancer patients. The two dimensional dose distribution (sagittal and axial) measured by the MD-55 film was compared with the treatment planning result by a gamma comparison with pass criteria of 3%/3 mm.\nResult: The average positional error for the static stage study was 0.42\u00b10.06 mm. The average targeting error with and without the SRTS tracking compensation in the respiratory cycle was 0.35\u00b10.10 mm and 7.59\u00b15.14 mm, respectively (p\uff1c0.0001). The difference of average targeting error between two respiratory cycles (15/min and 20/min) was 0.12 mm (p=0.11). In the verification of the axial and sagittal 2-D dose distribution of the three clinical cases, they were 99% compatible. Conclusion: The spatial positional error of SRTS was less than 0.5 mm which matched the accuracy requirement of stereotatic radiosurgery. By using the SRTS to track and compensate for the motion of lesions during respiratory cycle, we can significantly minimize the volume of the treatment field and the dose of the surrounding critical structures. The accuracy of dosimetry was also proven by our clinical cases experiments. However, additional positional error will be caused by patient who can not tolerate to the long treatment hours (1.5 to 2.5 hrs)."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-17-26", "title": "Retrospective Analysis of outcomes for Patients with Invasive Thymoma Receiving Surgery with or without Adjuvant Radiotherapy", "keywords": "\u80f8\u817a\u7624;\u624b\u8853;\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Invasive thymoma;Surgery;Adjuvant radiotherapy;Prognostic factor", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u4fb5\u8972\u6027\u80f8\u817a\u7624\u8853\u5f8c\u60a3\u8005\uff0c\u63a2\u8a0e\u76f8\u95dc\u4e4b\u9810\u5f8c\u56e0\u5b50\u8207\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6a21\u5f0f\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5305\u542b63\u4f4d\u4fb5\u8972\u6027\u80f8\u817a\u7624\u60a3\u8005\u3002\u6240\u6709\u75c5\u60a3\u5747\u63a5\u53d7\u624b\u8853\uff0c\u5176\u4e2d49\u4f4d\u75c5\u60a3\u63a5\u53d7\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u7642\u3002\u56de\u9867\u5206\u6790\u75c5\u4eba\u76f8\u95dc\u7279\u5fb5\u5982\u5e74\u9f61\u3001\u6027\u5225\u3001\u80f8\u817a\u7624\u671f\u5225\u3001\u6709\u7121\u91cd\u75c7\u808c\u7121\u529b\u4ee5\u53ca\u6cbb\u7642\u76f8\u95dc\u56e0\u5b50\u5982\u624b\u8853\u5207\u9664\u7a0b\u5ea6\u3001\u653e\u5c04\u7dda\u5291\u91cf\u8207\u7167\u91ce\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u4e4b\u5b58\u6d3b\u7387\u4ee5\u53ca\u7121\u75c5\u4e4b\u5b58\u6d3b\u7387\u5206\u5225\u70ba83%\u53ca81.5%\u3002\u6700\u5e38\u898b\u4e4b\u5fa9\u767c\u4f4d\u7f6e\u70ba\u808b\u819c\u5fa9\u767c\u3002\u55ae\u8b8a\u9805\u5206\u6790\u767c\u73feMosaoka\u671f\u5225\u8207\u624b\u8853\u5207\u9664\u7a0b\u5ea6\u70ba\u91cd\u8981\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u7b2c\u2161\u671f\u8207\u7b2c\u2162/\u2163\u671f\u75c5\u4eba\u4e4b5\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba95.8%\u820771.9%(p=0.06)\u3002\u624b\u8853\u9054\u5230\u5b8c\u5168\u5207\u9664\u76f8\u8f03\u65bc\u986f\u5fae\u93e1\u4e0b\u6216\u5de8\u89c0\u6b98\u5b58\u816b\u7624\u7684\u60a3\u8005\u76845\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba87.3%\u820744.4%(p=0.04)\u3002\u63a5\u53d7\u5927\u7bc4\u570d\u7e31\u8188\u8154\u6216\u7e31\u8188\u8154\u53ca\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7167\u5c04\u7684\u75c5\u4eba\uff0c\u8207\u63a5\u53d7\u5c0f\u7bc4\u570d\u816b\u7624\u5207\u9664\u5468\u570d\u7167\u5c04\u7684\u75c5\u4eba\u57285\u5e74\u7684\u5b58\u6d3b\u7387\u6c92\u6709\u7d71\u8a08\u4e0a\u986f\u8457\u5dee\u7570\uff0c\u5206\u5225\u70ba88%\u820794.7%(p=0.53)\u3002\u5728\u7121\u75c5\u5b58\u6d3b\u7387\u65b9\u9762\uff0c\u672c\u7814\u7a76\u4e26\u672a\u627e\u5230\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u767c\u73fe\u624b\u8853\u5207\u9664\u7a0b\u5ea6\u70ba\u4fb5\u8972\u6027\u80f8\u817a\u7624\u6700\u91cd\u8981\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u9810\u9632\u6027\u7167\u5c04\u7e31\u8188\u8154\u5c0d\u6cbb\u7642\u7d50\u679c\u4e26\u7121\u986f\u8457\u9032\u6b65\u3002", "e": "Purpose: To investigate the prognostic factors associated with outcome in patients with invasive thymoma undergoing surgery with or without adjuvant radiotherapy and strategies for optimal adjuvant radiotherapy.\nMethods and Materials: This retrospective study included 63 patients with invasive thymoma. All patients received surgery and 49 patients underwent adjuvant radiotherapy. Patient characteristics and treatment related parameters were analyzed to correlate with overall survival and disease free survival.\nResults: The 5-year overall survival and disease-free survival rate was 83% and 81.5%, respectively. The most common site of failure is pleural seeding. The univariate analyses showed that Mosaoka stage and extent of surgical resection were important prognostic factors. The 5-year overall survival rate was 95.8 % in stage \u2161 thymoma and 71.9% in stage \u2162/\u2163 thymoma (p=0.06). The 5-year survival rate was 87.3% for those who underwent complete resection compared with 44.4% for those with microscopic or gross residual disease (p=0.04). Patients receiving extended-field or involved-field radiotherapy had similar 5-year overall survival (88% versus 94.7%, p=0.53). In this study, we can not identify significant prognostic factors for disease free survival.\nConclusion: In our study, the extent of resection is important prognostic factor for invasive thymoma. Extensive radiation field covering mediastinum is not associated with better outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-27-36", "title": "The Clinical Outcome of Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer", "keywords": "\u624b\u8853\u524d\u5316\u5b78\u5408\u4f75\u653e\u5c04\u6cbb\u7642;\u76f4\u8178\u764c Neoadjuvant chemoradiotherapy;Rectal cancer", "c": "\u76ee\u7684\uff1a\u5206\u6790\u76f4\u8178\u764c\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u6cbb\u7642\u7684\u9577\u671f\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5206\u6790\u81ea2004\u5e7411\u6708\u52302006\u5e748\u6708\u671f\u9593\uff0c32\u4f4d\u75c5\u7406\u8a3a\u65b7\u70ba\u817a\u764c\u7684\u76f4\u8178\u764c\u75c5\u60a3\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u63a5\u53d7\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u6cbb\u7642\uff0c\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u5291\u91cf\u70ba50.4 Gy\uff0cA\u7d44\u7684\u75c5\u4eba\u5316\u5b78\u85e5\u4f7f\u75285FU\uff0cB\u7d44\u7684\u75c5\u4eba\u5247\u4f7f\u75285FU\u52a0\u4e0a\u53e3\u670dUFUR\u300214\u4f4d\u75c5\u4eba\u70baA\u7d44\uff0c18\u4f4d\u75c5\u4eba\u70baB\u7d44\u3002\u624b\u8853\u5728\u653e\u5c04\u6cbb\u7642\u5f8c4~6\u9031\u9032\u884c\u3002\u672c\u7814\u7a76\u4e3b\u8981\u5206\u6790\u6cbb\u7642\u5f8c\u5206\u671f\u4e0b\u964d\uff0c\u8853\u5f8c\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u4e4b\u764c\u7d30\u80de\uff0c\u53ca\u53ef\u884c\u809b\u9580\u4fdd\u7559\u624b\u8853\u7684\u6bd4\u4f8b\u3002\u5176\u6b21\u5206\u6790\u7e3d\u5b58\u6d3b\u7387\uff0c\u5fa9\u767c\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u3002\n\u7d50\u679c\uff1a\u81ea\u8a3a\u65b7\u5f8c\u958b\u59cb\u8a08\u7b97\uff0c\u7d93\u904e\u4e2d\u4f4d\u657844\u500b\u6708\uff0815~59\u500b\u6708\uff09\u7684\u8ffd\u8e64\uff0c\u75c5\u4eba\u7684\u6cbb\u7642\u5f8c\u5206\u671f\u4e0b\u964d\uff0c\u8853\u5f8c\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u4e4b\u764c\u7d30\u80de\uff0c\u53ca\u809b\u9580\u4fdd\u7559\u624b\u8853\u7387\u5206\u5225\u70ba46.9%,12.5%\u548c72.7%\u3002\u5206\u5225\u4f86\u770b\uff0cA\u7d44\u9054\u5230\u6cbb\u7642\u5f8c\u5206\u671f\u4e0b\u964d\u548c\u8853\u5f8c\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u4e4b\u764c\u7d30\u80de\u70ba35.7%\u548c7.1%\uff1bB\u7d44\u9054\u5230\u6cbb\u7642\u5f8c\u5206\u671f\u4e0b\u964d\u548c\u8853\u5f8c\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u4e4b\u764c\u7d30\u80de\u70ba55.4%\u548c16.7%\u3002\u67094\u4f4d\u9054\u5230\u8853\u5f8c\u75c5\u7406\u5831\u544a\u7121\u5b58\u6d3b\u4e4b\u764c\u7d30\u80de\u4e4b\u75c5\u4eba\u81f3\u7814\u7a76\u7d50\u675f\u70ba\u6b62\u6c92\u6709\u5c40\u90e8\u5fa9\u767c\u548c\u9060\u8655\u8f49\u79fb\u3002\u5168\u90e8\u75c5\u4eba\u7684\u56db\u5e74\u7e3d\u5b58\u6d3b\u7387\u53ca\u5fa9\u767c\u7387\u5206\u5225\u70ba70.3%\u548c9.6%\u3002\u5206\u5225\u4f86\u770b\uff0cA\u7d44\u7684\u5fa9\u767c\u7387\u70ba11.1%\uff0c\u800cB\u7d44\u7684\u5fa9\u767c\u7387\u70ba5.6%\u3002\u5728\u6cbb\u7642\u526f\u4f5c\u7528\u65b9\u9762\uff0cB\u7d44\u6709\u8f03\u5f37\u7684\u8840\u6db2\u526f\u4f5c\u7528\u3002\u800c\u5728\u8178\u80c3\u9053\u7684\u526f\u4f5c\u7528\u65b9\u9762\uff0c\u4e8c\u7d44\u76f8\u4f3c\u3002\u624b\u8853\u76f8\u95dc\u7684\u526f\u4f5c\u7528\u4e8c\u7d44\u4e5f\u662f\u76f8\u4f3c\u3002\n\u7d50\u8ad6\uff1a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u6e1b\u5c11\u8178\u9053\u4e4b\u526f\u4f5c\u7528\u3002\u624b\u8853\u524d\u5316\u5b78\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u53ef\u9054\u5230\u8f03\u9ad8\u7684\u809b\u9580\u4fdd\u7559\u6bd4\u7387\u53ca\u8f03\u4f4e\u7684\u5fa9\u767c\u7387\u3002", "e": "Purpose: To investigate clinical outcome, especially anal sphincter preservation and local recurrence rate, of locally advanced rectal cancer after neoadjuvant chemoradiotherapy.\nMaterials and Methods: From November 2004 to August 2006, a total of 32 patients with adenocarcinoma of rectal cancer, clinical stage T3-4, N0-2, were enrolled in this retrospective study. All patients received neoadjuvant chemoradiotherapy which consisted of intensity-modulated radiotherapy (50.4 Gy) and was concomitant with bolus 5-FU (group A) or bolus 5-FU plus oral UFUR (group B). Fourteen patients were enrolled in group A; 18 patients were categorized as group B. Operation was performed 4~6 weeks thereafter. The primary endpoints were downstaging, pathological complete response (pCR) and sphincter preservation rate. The secondary endpoints were overall survival (OS), local recurrence rate (LRR), and disease-free survival (DFS).\nResults: The median follow-up period for all patients was 44 months from the date of diagnosis, ranging from 15 to 59 months. The downstaging, pCR and sphincter preservation rate of all patients were 46.9%, 12.5% and 72.7%, respectively. There was no significant difference between group A and B in tumor downstaging or pCR. The 4 patients who achieved pathological complete response did not experience local recurrence or distant metastasis at the end of this study. The 4-year OS, LRR and DFS of all patients were 70.3%, 9.6% and 74.5%. No significant difference could be recorded between groups A and B in OS, LRR and DFS. Group B had more significant hematological toxicity. Grade 2 or greater GI toxicity was similar in both groups. Surgery related complications were similar in both groups.\nConclusion: Neoadjuvant chemoradiotherapy using IMRT with concomitant 5-FU based chemotherapy achieved good results for sphincter preservation and local control in locally advanced rectal cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-37-45", "title": "Comparison of Treatment Results of Malignant Astrocytoma after post-op Radiotherapy Alone or post-op Concurrent Chemoradiotherapy plus Adjuvant chemotherapy-Experience in TSGH", "keywords": "\u60e1\u6027\u661f\u72c0\u7d30\u80de\u7624;\u591a\u5f62\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624;\u5e1d\u76df\u591a;\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642;\u9806\u5f62\u653e\u5c04\u6cbb\u7642 Anaplastic astrocytoma;Glioblastoma multiforme;Temozolomide;Radiotherapy;Chemoradiotherapy;Conformal radiation therapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u60e1\u6027\u661f\u72c0\u7d30\u80de\u7624\u8853\u5f8c\u653e\u7642\u6216\u5408\u4f75\u653e\u5316\u7642\u6cbb\u7642\u7d50\u679c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e2002\u5e744\u6708\u81f32007\u5e7412\u6708\uff0c\u5171\u670935\u4f4d\u65b0\u8a3a\u65b7\u60e1\u6027\u661f\u72c0\u7d30\u80de\u7624\u53ca\u591a\u5f62\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u7684\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u5207\u9664\uff0c\u8853\u5f8c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u6216\u540c\u6b65\u653e\u5316\u7642\u3002\u653e\u5c04\u6cbb\u7642\u4f7f\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642(3DCRT)\uff0c\u65bc\u516d\u9031\u5167\u7d66\u4e8860 Gy\u3002\u6211\u5011\u4f7f\u7528\u5f71\u50cf\u7d50\u5408\u7684\u6280\u8853\uff0c\u7d50\u5408\u8853\u524d\u6838\u78c1\u5171\u632f\u53ca\u96fb\u8166\u65b7\u5c64\u5b9a\u4f4d\u7684\u5f71\u50cf\uff0c\u6c7a\u5b9a\u6cbb\u7642\u5340\u57df\u7684\u7bc4\u570d\u3002\u5316\u5b78\u6cbb\u7642\u4f7f\u7528\u5e1d\u76df\u591a\uff0c\u5728\u540c\u6b65\u653e\u5316\u7642\u7684\u904e\u7a0b\uff0c\u5291\u91cf\u70ba\u6bcf\u592975 mg/\u5e73\u65b9\u516c\u5c3a\uff0c\u81f3\u5c11\u4f7f\u752849\u5929\u3002\u653e\u7642\u5f8c\u5316\u7642\uff0c28\u5929\u70ba\u4e00\u500b\u7642\u7a0b\uff0c\u6bcf\u500b\u7642\u7a0b\u524d5\u5929\u63a5\u53d7\u5316\u7642\uff0c\u5291\u91cf\u70ba\u6bcf\u5929150-200 mg/\u5e73\u65b9\u516c\u5c3a\uff0c\u81f3\u5c116\u500b\u7642\u7a0b\u3002\u8ffd\u8e64\u548c\u5b58\u6d3b\u6642\u9593\u7684\u5b9a\u7fa9\u70ba\u5207\u7247\u8a3a\u65b7\u7684\u65e5\u671f\u5230\u78bc\u6b7b\u4ea1\u7684\u65e5\u671f\u3002\u5b58\u6d3b\u7387\u66f2\u7dda\u4ee5Kaplan-Meier\u65b9\u6cd5\u7e6a\u88fd\u3002\n\u7d50\u679c\uff1a\u5e73\u5747\u8ffd\u8e64\u6642\u9593\u70ba19.1\u500b\u6708\u3002\u8ffd\u8e64\u671f\u9593\u5167\uff0c\u517110\u4f4d\u75c5\u4eba\u5b58\u6d3b\uff0c25\u4f4d\u75c5\u4eba\u6b7b\u4ea1\u3002\u6240\u6709\u75c5\u4eba\u7684\u5e73\u5747\u5b58\u6d3b\u7387\u70ba19.1\u500b\u6708\u3002\u4e09\u5e74\u5b58\u6d3b\u7387\uff0c\u5728\u653e\u7642\u9019\u7d44\u70ba14%\uff0c\u653e\u5316\u7642\u9019\u7d44\u70ba43%\uff08p\u503c\uff1d0.002\uff09\u3002\u4e09\u5e74\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\uff0c\u5728\u653e\u7642\u9019\u7d44\u70ba10.6%\uff0c\u653e\u5316\u7642\u9019\u7d44\u70ba13.9%\uff08p\u503c\uff1d0.54\uff09\u3002\u60e1\u6027\n\u661f\u72c0\u7d30\u80de\u7624\u7684\u75c5\u4eba\uff0c\u5b58\u6d3b\u7387\u5728\u653e\u7642\u9019\u7d44\u70ba8.7%\uff0c\u653e\u5316\u7642\u9019\u7d44\u70ba67.9%\uff08p\u503c\uff1d0.001\uff09\u3002\u591a\u5f62\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u7684\u75c5\u4eba\uff0c\u5b58\u6d3b\u7387\u5728\u653e\u7642\u9019\u7d44\u70ba16.3%\uff0c\u653e\u5316\u7642\u9019\u7d44\u70ba23.7%\uff08p\u503c\uff1d0.261\uff09\u3002\u653e\u5c04\u6cbb\u7642\u7167\u91ce\u5167\u7684\u5fa9\u767c\u70ba\u4e3b\u8981\u7684\u5fa9\u767c\u578b\u614b\u3002\u6240\u670935\u4f4d\u75c5\u4eba\u4e2d\uff0c\u670922\u4f4d\u75c5\u4eba\u767c\u751f\u7167\u91ce\u5167\u5fa9\u767c(62.8%)\u3002\u6240\u6709\u7684\u75c5\u4eba\u7686\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u300230\u4f4d\u75c5\u4eba(86%)\u7522\u751fGradeI\u4e2d\u6a1e\u795e\u7d93\u6bd2\u6027\uff1b5\u4f4d\u75c5\u4eba(14%)\u7522\u751fGrade \u2161\u4e2d\u6a1e\u795e\u7d93\u6bd2\u6027\u300221\u4f4d\u63a5\u53d7\u5316\u7642\u7684\u75c5\u4eba\u4e2d\uff0c18\u4f4d\u75c5\u4eba\u5728\u5316\u7642\u904e\u7a0b\u4e2d\u4e26\u6c92\u6709\u4efb\u4f55\u526f\u4f5c\u7528\u7522\u751f\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u60e1\u6027\u661f\u72c0\u7d30\u80de\u7624\u53ca\u591a\u5f62\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u7684\u75c5\u4eba\u624b\u8853\u5207\u9664\u5f8c\uff0c\u8853\u5f8c\u63a5\u53d7\u540c\u6b65\u653e\u5316\u7642\u6709\u7d71\u8a08\u5b78\u4e0a\u5b58\u6d3b\u7387\u7684\u5e6b\u52a9\u800c\u50c5\u6709\u53ef\u63a5\u53d7\u4e4b\u526f\u4f5c\u7528\u3002", "e": "Purpose: To analyze the treatment results of malignant astrocytoma after radiotherapy alone or concurrent chemoradiotherapy plus adjuvant chemotherapy in TSGH.\nMethods and Materials: From April 2002 to December 2007, we identified 35 patients with documented, histologically confirmed, previously untreated glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA). They were treated with surgical resection followed by radiotherapy alone or chemoradiotherapy in our hospital. A total of 60 Gy was given in 6 weeks with 3D conformal RT (3D-CRT). Fusion of planning CT with MRI was routinely used to assist target delineation. We used concomitant temozolomide (75 mg/m^2 daily up to 49 days) followed by up to six cycles of adjuvant temozolomide (150 to 200 mg/m^2 daily for five days, every 28 days). Follow-up and survival times were calculated from the date of diagnosis to the date of last contact or death. Disease-free survival (DFS) and overall survival (OS) were computed by Kaplan-Meier methods.\nResults: The median follow-up was 19.1 months. At the time of analysis, 10 patients were alive, 25 patients had died. The median survival rate was 19.1 months for all patients. The 3-year overall survival rates were 14% and 43% in radiotherapy alone arm and CCRT arm, respectively. (p=0.002). The 3-year progression-free survival rates were 10.6% and 13.9% in radiotherapy alone and CCRT arm, respectively. (p=0.54). In the AA group, the overall survival rates were 8.7% and 67.9% in radiotherapy alone arm and CCRT arm, respectively. (p=0.001). In the GBM group, the overall survival rates were 16.3% and 23.7% in radiotherapy alone and CCRT arm, respectively. (p=0.261). In-field failure was the major cause of failure, among 35 patients, 22 (62.8%) patients had in-field failure. All patients completed radiotherapy courses. Thirty (86%) patients had grade 1 CNS toxicity and 5 (14%) patients had grade 2 CNS toxicity. Among 21 patients who received temozolomide, 18 patients had no obvious side effects during and after chemotherapy.\nConclusions: Addition of adjuvant chemotherapy with temozolomide to radiotherapy for patients with newly diagnosed AA and GBM has statistically significant survival benefit especially for patients of AA with tolerable toxicity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-47-58", "title": "Evaluation of Prostate Cancer Treated with Temporary High Dose Rate Interstitial Brachytherapy and Followed by EBRT", "keywords": "\u651d\u8b77\u817a\u764c;\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642;\u5916\u90e8\u653e\u5c04\u7dda\u6cbb\u7642 Prostate cancer;HDR-brachytherapy;EBRT", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5c40\u90e8\u651d\u8b77\u817a\u764c\u5728\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u8fd1\u63a5\u6cbb\u7642\u8207\u5916\u90e8\u653e\u5c04\u6cbb\u7642\u5f8c\u4e4b\u6cbb\u7642\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2004\u5e742\u6708\u81f32009\u5e742\u6708\uff0c\u670928\u4f4d\u651d\u8b77\u817a\u764c\u75c5\u60a3\u5176\u764c\u75c7\u671f\u5225\u70baT1~3\u3001N0\u3001M0\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u8fd1\u63a5\u6cbb\u7642\u8207\u5916\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u60a3\u65bc\u5169\u5929\u5167\u63a5\u53d7\u4e09\u6b21\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u6cbb\u7642\uff0c\u4e2d\u4f4d\u653e\u5c04\u7dda\u5291\u91cf\u70ba18 Gy(15~21 Gy)\u3002\u75c5\u60a3\u65bc\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u6cbb\u7642\u5f8c2\u81f34\u5468\u958b\u59cb\u63a5\u53d7\u5916\u90e8\u653e\u5c04\u6cbb\u7642\u8207\u5176\u5291\u91cf\u7bc4\u570d\u5f9e50 Gy\u81f370.4 Gy\u3002\n\u7d50\u679c\uff1a\u6709\u4e09\u4f4d\u75c5\u60a3\u65bc\u8ffd\u8e64\u671f\u9593\u5931\u806f\uff0c\u6240\u4ee5\u4e0d\u5217\u5165\u672c\u7bc7\u5206\u6790\u3002\u75c5\u60a3\u4e4b\u5e74\u9f61\u5206\u4f48\u5f9e48\u6b72\u523082\u6b72\uff0c\u5176\u4e2d\u4f4d\u6578\u70ba73\u6b72\u3002\u6cbb\u7642\u524d\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u6307\u6578(PSA)\u4e2d\u4f4d\u6578\u70ba16.3 ng/ml\uff0c(6.2~85.3 ng/ml)\uff1b\u683c\u91cc\u68ee\u5206\u6578(Gleason Score)\u4e4b\u4e2d\u4f4d\u6578\u70ba6\u8207\u5176\u5206\u4f48\u5f9e2\u52309\u300220\u4f4d\u75c5\u60a3(80%)\u5728\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u524d\u6709\u5148\u63a5\u53d7\u6297\u96c4\u6fc0\u7d20\u8377\u723e\u8499\u6cbb\u7642\u3002\u75c5\u60a3\u4e4b\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba30\u500b\u6708\uff0812~66\u500b\u6708\uff09\u3002\u4f9d\u64daPhoenix definition of biochemical failure\uff0c1\u5e74\u82075\u5e74\u7684\u751f\u5316\u63a7\u5236\u7387\u5206\u5225\u70ba96%\u820784%\u30025\u5e74\u5b58\u6d3b\u7387\u70ba100%\u3002\u6709\u4e03\u4f4d\u75c5\u60a3(28%)\u7522\u751f\u7b2c\u4e8c\u7d1a\u653e\u5c04\u7dda\u76f8\u95dc\u4e4b\u6025\u6027\u526f\u4f5c\u7528\u3002\u5169\u4f4d\u75c5\u60a3(8%)\u7522\u751f\u7b2c\u4e8c\u7d1a\u6162\u6027\u526f\u4f5c\u7528\u3002\u4e26\u6c92\u6709\u89c0\u5bdf\u5230\u7b2c\u4e09\u8207\u7b2c\u56db\u7d1a\u526f\u4f5c\u7528\u7684\u7522\u751f\u3002\n\u7d50\u8ad6\uff1a\u5c40\u90e8\u651d\u8b77\u817a\u764c\u75c5\u60a3\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u7d44\u7e54\u63d2\u7a2e\u6cbb\u7642\u8207\u5916\u90e8\u653e\u5c04\u6cbb\u7642\u5f8c\u5176\u75be\u75c5\u63a7\u5236\u662f\u5f88\u660e\u986f\u7684\uff0c\u5176\u7522\u751f\u7684\u526f\u4f5c\u7528\u4e5f\u662f\u5728\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\u3002\u5118\u7ba1\u5982\u6b64\uff0c\u70ba\u4e86\u5f97\u5230\u66f4\u6709\u610f\u7fa9\u7684\u9577\u671f\u75be\u75c5\u63a7\u5236\u7387\uff0c\u5b58\u6d3b\u7387\uff0c\u8207\u526f\u4f5c\u7528\u4e4b\u8a55\u4f30\uff1b\u66f4\u9577\u671f\u7684\u8ffd\u8e64\u8207\u66f4\u591a\u7684\u75c5\u60a3\u6578\u662f\u5fc5\u9808\u7684\u3002", "e": "Purpose: To evaluate the treatment outcome of patients with localized prostate cancer treated with HDR interstitial brachytherapy followed by EBRT.\nMaterials and Methods: From February 2004 to February 2009, 28 prostate cancer patients with cancer staging of T1~3, N0, M0 were treated with HDR interstitial brachytherapy followed by 3-D EBRT. Patient received 3 consecutive HDR-brachytherapy in 2 days with the brachytherapy median dose of 18 Gy (15~21 Gy). EBRT was given 2~4 weeks after the HDR interstitial brachytherapy with dose ranged from 50 Gy to 70.4 Gy.\nResults: Three patients were lost during the follow-up period and therefore were excluded from the analysis. The median age was 73 years old, with a range of 48~82 years old. The median pretreatment PSA value was 16.3 ng/ml, with a range of 6.2~85.3 ng/ml; and the median Gleason Score was 6, with a range of 2~9. Twenty patients (80%) received anti-androgenic hormone therapy prior to radiotherapy. The median follow-up period was 30 months (range 12~66 months). The 1 year and 5 years biochemical control rate was 96% and 84% respectively according to Phoenix definition of biochemical failure. The 5 years overall survival rate was 100%. Seven (28%) patients developed grade \u2161 acute radiation associated side effects. Two (8%) patients had late grade \u2161 toxicity. No Gr \u2162 or Gr \u2163 side effects were observed.\nConclusion: Localized prostate cancer treated with HDR interstitial brachytherapy and EBRT has shown excellent result in disease control with well-acceptable complication rate. However, longer follow-up period and more patients are required for more meaningful long term disease control, survival, and side effect evaluation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-59-67", "title": "\u5229\u7528\u5c04\u675f\u963b\u64cb\u6cd5\u4fee\u6b63\u4e09\u7dad\u6b63\u5b50\u9020\u5f71\u4e4b\u975e\u771f\u5be6\u4e8b\u4ef6\u8ca2\u737b", "keywords": "\u5c04\u675f\u963b\u64cb;\u6563\u5c04\u4e8b\u4ef6;\u96a8\u6a5f\u4e8b\u4ef6 Beam stopper;Scatter event;Random event", "c": "\u76ee\u7684\uff1a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u6383\u63cf\u662f\u5728\u6838\u5b50\u91ab\u5b78\u4e0a\u4e00\u9805\u975e\u4fb5\u8972\u6027\u7684\u6aa2\u67e5\u6280\u8853\uff0c\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u529f\u80fd\u6027\u751f\u7406\u8cc7\u8a0a\u3002\u76ee\u524d\u5e38\u7528\u4e09\u7dad\u64f7\u53d6\u6a21\u5f0f\u4f86\u63d0\u9ad8\u9020\u5f71\u7684\u9748\u654f\u5ea6\uff0c\u4f46\u96a8\u6a5f\u8207\u6563\u5c04\u540c\u7b26\u4e8b\u4ef6\u56e0\u6b64\u63d0\u9ad8\u3002\u4e00\u822c\u96a8\u6a5f\u4e8b\u4ef6\u4fee\u6b63\u662f\u5229\u7528\u5373\u6642\u7684\u5ef6\u9072\u6642\u9593\u7a97\u4fee\u6b63\u6cd5\uff1b\u6563\u5c04\u4e8b\u4ef6\u4fee\u6b63\u662f\u5229\u7528\u55ae\u6b21\u6563\u5c04\u5149\u5b50\u6a21\u64ec\u6cd5\uff0c\u7136\u800c\u4ee5\u4e0a\u4fee\u6b63\u6cd5\u7686\u6709\u7f3a\u5931\u5f71\u97ff\u4fee\u6b63\u5f8c\u7684\u6e96\u78ba\u6027\u3002\u70ba\u6709\u6548\u77ef\u6b63\u6b63\u5b50\u9020\u5f71\u975e\u771f\u5be6\u4e8b\u4ef6\uff0c\u6545\u63d0\u51fa\u5229\u7528\u8499\u5730\u5361\u7f85\u6a21\u64ec\u65cb\u7e5e\u5f0f\u5c04\u675f\u963b\u64cb\u88dd\u7f6e\u4fee\u6b63\u6cd5\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528GATE\u8499\u5730\u5361\u7f85\u8edf\u9ad4\u6a21\u64ecmicroPET R4\u7cfb\u7d71\u4ee5\u53ca\u5c04\u675f\u963b\u64cb\u4fee\u6b63\u6cd5\u3002\u5229\u7528\u5c04\u675f\u963b\u64cb\u88dd\u7f6e\u5728\u4e0d\u540c\u89d2\u5ea6\u4e0b\u5169\u7d44\u6b63\u5f26\u5716\u53d7\u6a94\u584a\u906e\u853d\u4e0b\u7684\u8cc7\u8a0a\uff0c\u4ea4\u53c9\u8a08\u7b97\u51fa\u5176\u975e\u771f\u5be6\u4e8b\u4ef6\u7684\u8ca2\u737b\u91cf\uff0c\u56e0\u975e\u771f\u5be6\u4e8b\u4ef6\u5206\u5e03\u662f\u7de9\u6162\u8b8a\u5316\u51fd\u6578\uff0c\u6240\u4ee5\u53ef\u6839\u64da\u64cb\u584a\u906e\u853d\u90e8\u4efd\u7684\u53d6\u6a23\u9ede\u5229\u7528cubic-spline\u5167\u63d2\u6cd5\u5f97\u5230\u6574\u5f35\u6b63\u5f26\u5716\u4e2d\u975e\u771f\u5be6\u4e8b\u4ef6\u5206\u5e03\u60c5\u5f62\uff0c\u518d\u9032\u884c\u77ef\u6b63\u3002\n\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u7814\u7a76\u512a\u9ede\u5728\u63d0\u51fa\u80fd\u7a97\u7bc4\u570d\u8f03\u5927\u9748\u654f\u5ea6\u63d0\u5347\u7684\u540c\u6642\uff0c\u6383\u63cf\u6642\u9593\u4fdd\u6301\u56fa\u5b9a\uff0c\u5c04\u675f\u4fee\u6b63\u6cd5\u77ef\u6b63\u7684\u975e\u771f\u5be6\u4e8b\u4ef6\u5206\u738731.55%\u8207\u8499\u5730\u5361\u7f85\u975e\u771f\u5be6\u4e8b\u4ef6\u5206\u738729.62%\u7684\u7d50\u679c\u6700\u76f8\u8fd1\uff0c\u800c\u4e14\u77ef\u6b63\u5f8c\u5047\u9ad4\u5340\u57df\u6d3b\u5ea6\u5206\u4f48\u4e5f\u8f03\u63a5\u8fd1\u5be6\u969b\u6d3b\u5ea6\u6bd4\u4f8b\u7684\u5206\u914d\u3002\n\u7d50\u8ad6\uff1a\u65cb\u7e5e\u5f0f\u5c04\u675f\u963b\u64cb\u6cd5\u5728\u4e0d\u984d\u5916\u589e\u52a0\u9020\u5f71\u6383\u63cf\u6642\u9593\u7684\u60c5\u6cc1\u4e0b\uff0c\u5229\u7528\u5c04\u675f\u963b\u64cb\u88dd\u7f6e\u8f49\u63db\u4f4d\u7f6e\u4f86\u63d0\u9ad8\u5be6\u9a57\u53d6\u6a23\u7d50\u679c\uff0c\u77ef\u6b63\u6548\u679c\u63a5\u8fd1\u8499\u5730\u5361\u7f85\u7d50\u679c\u3002\u76f8\u4fe1\u672c\u7814\u7a76\u6240\u63d0\u51fa\u7684\u77ef\u6b63\u6cd5\u662f\u66f4\u9069\u5408\u65bc\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u81e8\u5e8a\u4e0a\u61c9\u7528\u3002", "e": "Purpose: Position Emission Tomography (PET) is a non-invasive technique used in nuclear medicine, which provides physiological information using molecular tracers. As 3D PET data acquisition increases, random and scatter coincidence events increase relevantly. They cause a uniform distribution of background on the image and degrade the accuracy of quantitative analysis. The conventional corrections for random and scatter coincidences are achieved by the delayed window technique and Single Scatter Simulation (SSS) method. However, they increase noise and reduce image accuracy.\nMaterial and Methods: The aim of this study is to examine the feasibility of using a beam stopper (BS) for correcting non-true coincidence events. The BS placed on the line of response (LOR) at two different locations rotating with constant degrees absorbs a particular fraction of the true events. The non-true coincidence, non-blocked at the LORs by each stopper, can be estimated. Assuming that the non-true radiation is a spatially slow-varying distribution, the whole non-true sinogram can be recovered using cubic-spline interpolation from these local measurements. Beam stopper rotated (BSR) reduces the effective sampling distance without increasing the number of the stoppers. In this study, we performed Monte Carlo (MC) simulations for 3-D PET with the GATE software for a cold phantom to conduct the BSR method.\nResult: The estimate of non-true event fraction in a large FOV using BSR method is 31.55% and is close to the result of Monte-Carlo simulation. The activity ratio of region approaches the initial input quantity.\nConclusion: We conclude that the proposed correction method is effective and better than conventional correction schemes without increasing scan time. In sum, the BSR method is a convenient and effective correction for non-true coincidences in 3D PET."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-69-75", "title": "Mailgnant Lymphoma Involving the Prostate: A Case Report", "keywords": "\u60e1\u6027\u6dcb\u5df4\u7624;\u651d\u8b77\u817a;\u514d\u75ab\u7d44\u7e54\u5316\u5b78 Malignant lymphoma;Prostate gland;Immunohistochemistry", "c": "\u767c\u751f\u65bc\u651d\u8b77\u817a\u4e4b\u60e1\u6027\u6dcb\u5df4\u7624\uff0c\u4e0d\u8ad6\u662f\u539f\u767c\u6027\u6216\u7e7c\u767c\u6027\uff0c\u90fd\u662f\u975e\u5e38\u7f55\u898b\u7684\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d74\u6b72\u7537\u6027\u56e0\u6025\u6027\u5c3f\u6eef\u7559\u7684\u75c7\u72c0\u6c42\u91ab\uff0c\u9032\u800c\u88ab\u8a3a\u65b7\u51fa\u7f79\u60a3\u4fb5\u72af\u651d\u8b77\u817a\u764c\u4e4b\u5f4c\u6563\u6027\u60e1\u6027\u6dcb\u5df4\u7624\u3002\u809b\u9580\u6307\u8a3a\u767c\u73fe\u5149\u6ed1\u800c\u6709\u5f48\u6027\u4e4b\u8f15\u5fae\u651d\u8b77\u817a\u80a5\u5927\u3002\u5728\u826f\u6027\u651d\u8b77\u817a\u80a5\u5927\u4e4b\u521d\u6b65\u8a3a\u65b7\u4e4b\u4e0b\uff0c\u75c5\u60a3\u63a5\u53d7\u4e86\u7d93\u5c3f\u9053\u651d\u8b77\u817a\u522e\u9664\u8853\u3002\u75c5\u7406\u5831\u544a\u767c\u73fe\u5145\u6eff\u816b\u7624\u7d30\u80de\u4e4b\u6d78\u6f64\u3002\u7279\u6b8a\u4e4b\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u986f\u793aCD20\u70ba\u967d\u6027\uff0c\u7b26\u5408\u70ba\u60e1\u6027B\u7d30\u80de\u6dcb\u5df4\u7624\u3002\u5168\u8eab\u6027\u6aa2\u67e5\u767c\u73fe\u75be\u75c5\u6563\u4f48\u591a\u5340\u57df\u3002\u80cc\u90e8\u816b\u584a\u5207\u7247\u767c\u73fe\u5ee3\u6cdb\u6d78\u6f64\u4e2d\u5c0f\u975e\u5178\u578b\u6dcb\u5df4\u7d30\u80de\uff0c\u7279\u6b8a\u4e4b\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u986f\u793aCD10\u53caCD20\u70ba\u967d\u6027\uff0c\u8a3a\u65b7\u70ba\u6ffe\u6ce1\u578b\u6dcb\u5df4\u7624\u3002\u75c5\u60a3\u63a5\u53d7\u4e86\u56db\u6b21\u7684rituximab\uff0ccyclophosphamide\uff0cetoposide\uff0cvincristine and prednisone (R-CEOP)\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u816b\u7624\u5f88\u5feb\u5fa9\u767c\u3002\u75c5\u60a3\u518d\u63a5\u53d7\u88dc\u6551\u6027\u5316\u5b78\u6cbb\u7642\u53ca\u4e3b\u52d5\u8108\u65c1\u816b\u5927\u4e4b\u6dcb\u5df4\u7d50\u7684\u653e\u5c04\u6cbb\u7642\u3002\u7531\u65bc\u75c5\u60c5\u60e1\u5316\u75c5\u60a3\u6c92\u80fd\u5b8c\u6210\u5168\u7a0b\u4e4b\u653e\u5c04\u6cbb\u7642\uff0c\u75c5\u60a3\u65bc\u6700\u521d\u8a3a\u65b7\u5f8c\u76849\u500b\u6708\u5e36\u75c5\u6b7b\u4ea1\u3002", "e": "Malignant lymphoma of the prostate gland, either primary or secondary, is rare. We report a 74-year-old male who was diagnosed with disseminated lymphoma including involvement of the prostate gland with the initial presentation of urinary retention. Digital rectal examination revealed mildly enlarged prostate gland with smooth and rubbery consistency. He received transurethral resection of the prostate under the impression of benign prostatic hyperplasia. The pathology found diffused infiltration of atypical lymphoid cells infiltration. The immunohistochemical staining revealed positive for CD20, and consistent with malignant B cell lymphoma. Systemic work-up found that his disease has disseminated many areas. Back mass biopsy showed small to medium atypical lymphoid cells diffused infiltration with immunohistochemical staining for CD3(-), CD5(-), CD10(+), CD20(+), CD23(-), and Cyclin D1(-). The diagnosis of follicular lymphoma was made. The patient received four cycles of chemotherapy with rituximab, cyclophosphamide, etoposide, vincristine and prednisone (R-CEOP). After temporarily partial response, tumor regrowing was noted. Salvage chemotherapy followed by the radiotherapy (RT) to the enlarged paraaortic lymph nodes was given. The patient did not finish the RT course because of exacerbated condition. He died with the disease 9 months after diagnosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-77-81", "title": "Prostate Cancer of a Young Man: A Case Report and Review of Literature", "keywords": "\u651d\u8b77\u817a\u764c;\u5e74\u8f15\u7537\u6027;\u653e\u5c04\u6cbb\u7642 Prostate cancer;Young age;Radiotherapy", "c": "\u651d\u8b77\u817a\u764c\u7684\u767c\u751f\u901a\u5e38\u898b\u65bc\u5e74\u7d00\u8f03\u5927\u7684\u7537\u6027\u75c5\u60a3\u3002\u672c\u6587\u5831\u544a\u4e86\u4e00\u4f4d\u521d\u59cb\u75c7\u72c0\u70ba\u53cd\u8986\u767c\u71d2\u768439\u6b72\u7537\u6027\u651d\u8b77\u817a\u764c\u60a3\u8005\uff0c\u814e\u81df\u8d85\u97f3\u6ce2\u975e\u9810\u671f\u6027\u7684\u767c\u73fe\u8180\u80f1\u816b\u7624\uff0c\u7d93\u5207\u7247\u8b49\u5be6\u70ba\u651d\u8b77\u817a\u764c\u4fb5\u72af\uff0c\u7cfb\u5217\u6aa2\u67e5\u767c\u73fe\u6b64\u75c5\u4eba\u6709\u591a\u8655\u6dcb\u5df4\u7d50\u8f49\u79fb\u8207\u9aa8\u8f49\u79fb\uff0c\u75c5\u60a3\u4e4b\u5f8c\u63a5\u53d7\u8377\u723e\u8499\u6cbb\u7642\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6211\u5011\u4e5f\u56de\u9867\u95dc\u65bc\u5e74\u8f15\u7537\u6027\u651d\u8b77\u817a\u764c\u7684\u6587\u737b\u8cc7\u6599\u3002", "e": "Carcinoma of the prostate is predominantly a tumor of older men. We report a 39-year-old man with prostate cancer, who initially presented as fever off and on for one month. Renal sonography found a urinary bladder mass, and biopsy under cystoscopy showed adenocarcinoma with prostate-specific antigen (PSA) (+). Systemic work-up revealed multiple lymph nodes and bone metastases. The patient was treated with hormone therapy and radiotherapy. We also reviewed the literatures of prostate cancer in young men."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201103-201104160006-201104160006-83-88", "title": "Basal Cell Adenocarcinoma of Parotid Gland: A Case Report in Taiwan", "keywords": "\u8033\u4e0b\u817a\u57fa\u5e95\u7d30\u80de\u817a\u764c;\u8033\u4e0b\u817a Basal cell adenocarcinoma;Parotid gland", "c": "\u57fa\u5e95\u7d30\u80de\u817a\u764c\u662f\u4e00\u500b\u5c11\u898b\u7684\u553e\u6db2\u817a\u60e1\u6027\u816b\u7624\u3002\u9019\u500b\u540d\u7a31\u76f8\u7576\u65b0\uff0c\u57281991\u5e74\u4e16\u754c\u885b\u751f\u7d44\u7e54\u553e\u6db2\u817a\u816b\u7624\u5206\u985e\u7b2c\u4e8c\u7248\u4e2d\u624d\u5c07\u5176\u5217\u5165\u3002\u5927\u90e8\u5206\u7684\u9019\u985e\u816b\u7624\u767c\u751f\u5728\u4e3b\u8981\u553e\u6db2\u817a\uff0c\u70ba\u4f4e\u60e1\u6027\u5ea6\uff0c\u4f46\u6709\u8f03\u9ad8\u7684\u5fa9\u767c\u7387\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f8b\u8033\u4e0b\u817a\u57fa\u5e95\u7d30\u80de\u817a\u764c\uff0c\u63a5\u53d7\u53f3\u5074\u5168\u8033\u4e0b\u817a\u5207\u9664\u53ca\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002", "e": "Basal cell adenocarcinoma (BCAC) is a rare malignant tumor of salivary glands. The entity is relatively new and categorized in the second version of the World Health Organization (WHO) classification of the salivary gland tumors in 1991. Most of these tumors have been reported to occur in the major salivary glands and are considered to be low grade malignancy with a higher recurrence rate. We report a case of BCAC of the parotid gland, which accepted right total parotidectomy and postoperative radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-259-269", "title": "Facility Radiation Oncology Registry Data Standards of Taiwan Cancer Database", "keywords": "\u764c\u75c7\u767b\u8a18;\u8cc7\u6599\u6a19\u6e96;\u653e\u5c04\u6cbb\u7642;\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab Cancer registry;Data standards;Radiation therapy;Taiwan Cancer Database", "c": "\u885b\u751f\u7f72\u570b\u6c11\u5065\u5eb7\u5c40\u65bc2006\u5e74\u4e09\u6708\u53ec\u958b\u9996\u6b21\u5c08\u5bb6\u5171\u8b58\u6703\u8b70\uff0c\u4ee5\u5efa\u7acb\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u3002\u7d93\u904e\u6578\u6b21\u5c08\u5bb6\u5171\u8b58\u6703\u8b70\u5f8c\uff0c\u7b2c\u4e00\u724895\u500b\u6b04\u4f4d\u7684\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u6b63\u5f0f\u5efa\u7acb\uff1b\u800c\u6240\u6709\u53c3\u8207\u5065\u5eb7\u5c40\u764c\u75c7\u54c1\u8cea\u8a8d\u8b49\u7684\u6240\u6709\u91ab\u7642\u9662\u6240\uff0c\u90fd\u5fc5\u9808\u82072007\u5e74\u4e00\u6708\u4e00\u65e5\u8d77\uff0c\u6839\u64da\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u768495\u500b\u6b04\u4f4d\uff0c\u8490\u96c6\u4e26\u7533\u5831\u516d\u5927\u764c\u75c7\u7684\u8cc7\u6599\u3002\n\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u7684\u8cc7\u6599\u683c\u5f0f\u6a19\u6e96\uff0c\u662f\u6839\u64da\u7f8e\u570b\u5916\u79d1\u5b78\u9662(American College of Surgeons)\u7684\u764c\u75c7\u59d4\u54e1\u6703(Commission on Cancer)\u6240\u5efa\u69cb\u7684\u570b\u5bb6\u764c\u75c7\u8cc7\u6599\u9663\uff08National Cancer Data Base\uff0c\u7c21\u7a31NCDB\uff09\u4e4b\uff1b\u898f\u7bc4\u4fee\u8a02\u800c\u6210\u3002\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u8207NCDB\u6700\u5927\u7684\u5dee\u7570\u662f\u95dc\u65bc\u653e\u5c04\u6cbb\u7642\u7684\u6b04\u4f4d\u3002\u70ba\u4e86\u514b\u670dNCDB\u8cc7\u6599\u6a19\u6e96\u8a2d\u8a08\u7684\u7f3a\u5931\uff0c\u5728TCDB\u768420\u500b\u653e\u5c04\u6cbb\u7642\u6b04\u4f4d\u4e2d\uff0c\u4e03\u500b\u6b04\u4f4d\u4f7f\u7528\u4e86\u65b0\u5275\u53ef\u76f8\u52a0\u7684\u4ee3\u78bc\u4f86\u8a18\u9304\u8907\u96dc\u7684\u81e8\u5e8a\u60c5\u5883\u3002\n\u5065\u5eb7\u5c40\u5373\u5c07\u65bc2011\u5e74\u8fa6\u7406\u7b2c\u4e8c\u6b21\u764c\u75c7\u54c1\u8cea\u8a8d\u8b49\u3002\u65b0\u7248\u7684\u764c\u75c7\u54c1\u8cea\u8a8d\u8b49\u5305\u62ec\u91dd\u5c0d\u653e\u5c04\u6cbb\u7642\u7684\u54c1\u8cea\u9805\u76ee\uff0c\u56e0\u6b64\u53f0\u7063\u653e\u5c04\u816b\u7624\u5b78\u6703\u7684\u6703\u54e1\u5fc5\u9808\u719f\u6089\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\u4e2d\u653e\u5c04\u6cbb\u7642\u6b04\u4f4d\u7684\u8cc7\u6599\u6a19\u6e96\u898f\u7bc4\u3002\u672c\u5831\u544a\u7c21\u4ecb\u53f0\u7063\u764c\u75c7\u8cc7\u6599\u5eab\uff0c\u4e26\u8a73\u7d30\u8a0e\u8ad6\u8a72\u8cc7\u6599\u5eab\u4e2d\u653e\u5c04\u6cbb\u7642\u6b04\u4f4d\u7684\u8a2d\u8a08\u7406\u5ff5\u53ca\u512a\u9ede\uff0c\u4ee5\u5354\u52a9\u53f0\u7063\u653e\u5c04\u816b\u7624\u5b78\u6703\u7684\u6703\u54e1\u6e96\u5099\u672a\u4f86\u65b0\u7248\u764c\u75c7\u54c1\u8cea\u8a8d\u8b49\u5de5\u4f5c\u3002", "e": "The Bureau of Health Promotion (BHP) assembled an expert committee to draft Taiwan Cancer Database (TCDB) in March 2006. After several consensus meetings of the expert committee, the first version of TCDB with a total of 95 items was created. Medical Institutes participating in the BHP accreditation of cancer program are required to collect these 95 items of TCDB for the 6 major cancers, started on Jan 1, 2007.\nThe data standards of TCDB are based and modified from the architecture 01 National Cancer Database (NCDB) of Commission on Cancer. The most radical modifications of TCDB from NCDB are the radiation therapy (RT) registry data items. To overcome the deficiency of NCDB RT data standards, seven of the 20 TCDB RT items use an innovative combinable code for complex clinical scenarios.\nWith the coming second BHP accreditation of cancer program with added quality indicators specific for RT in year 2011, the members of the Taiwan Society for Therapeutic Radiology and Oncology should be familiar with the data standard of RT in TCDB. This report introduces the TCDB, focusing on the rationale and advantages of its RT data standards, and helps preparing the accreditation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-271-278", "title": "Rare Malignancies of the Nasopharynx-25-Year Clinical Experience of a Medical Center", "keywords": "\u7f55\u898b\u816b\u7624;\u9f3b\u54bd;\u6cbb\u7642\u6210\u679c Rare malignancy;Nasopharynx;Treatment outcome", "c": "\u76ee\u7684\uff1a\u9f3b\u54bd\u90e8\u7684\u60e1\u6027\u816b\u7624\u8a3a\u65b7\u4e0a\u5927\u591a\u662f\u975e\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u6216\u672a\u5206\u5316\u764c\uff0c\u5176\u4ed6\u75c5\u7406\u578b\u614b\u6975\u70ba\u5c11\u898b\u3002\u6211\u5011\u63a2\u8a0e\u672c\u966225\u5e74\u671f\u9593\u63a5\u53d7\u6cbb\u7642\u7684\u7f55\u898b\u9f3b\u54bd\u90e8\u60e1\u6027\u816b\u7624\u75c5\u4eba\u7684\u81e8\u5e8a\u8868\u73fe\u8207\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1983\u5e74l\u6708\u958b\u59cb\u81f32008\u5e7412\u6708\u70ba\u6b62\uff0c\u7e3d\u5171\u67092113\u500b\u9f3b\u54bd\u90e8\u60e1\u6027\u816b\u7624\u7684\u75c5\u4eba\u767b\u9304\u5728\u672c\u9662\u7684\u653e\u5c04\u6cbb\u7642\u8cc7\u6599\u5eab\uff0c\u50c5\u67097\u4f4d\u75c5\u4eba\u7b26\u5408\u672c\u7bc7\u6587\u7ae0\u7684\u7814\u7a76\u76ee\u7684\u3002\u6211\u5011\u56de\u9867\u6027\u7684\u6aa2\u8996\u9019\u5e7e\u4f4d\u75c5\u4eba\u7684\u75c5\u6b77\u3001\u653e\u5c04\u6cbb\u7642\u7d00\u9304\u8207\u5f71\u50cf\u6aa2\u67e5\u3002\u6211\u5011\u5206\u67907\u9019\u4e9b\u75c5\u4eba\u7684\u81e8\u5e8a\u75c5\u7a0b\u8207\u6cbb\u7642\u7d50\u679c\u3002\u6211\u5011\u6bd4\u8f03\u4e86\u9019\u7fa4\u75c5\u4eba\u7684\u5b58\u6d3b\u8207\u53e6\u4e00\u7fa4\u50b3\u7d71\u9f3b\u54bd\u764c\uff08\u671f\u5225\u2161-\u2163b\uff09\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u7684\u5b58\u6d3b\u3002\n\u7d50\u679c\uff1a\u672c\u9662\u7f55\u898b\u9f3b\u54bd\u90e8\u60e1\u6027\u816b\u7624\u7684\u767c\u751f\u7387\u53ea\u67090.33%\u3002\u75c5\u7406\u8a3a\u65b7\u5171\u67093\u4f4d\u4e0a\u76ae\u6027\u60e1\u6027\u816b\u7624\uff08\u817a\u764c\u3001\u9ecf\u819c\u6027\u4e0a\u76ae\u764c\u3001\u5c0f\u7d30\u80de\u764c\uff09\uff0c3\u4f4d\u6dcb\u5df4\u764c\uff0c1\u4f4d\u6a6b\u7d0b\u808c\u60e1\u6027\u8089\u7624\u3002\u9019\u4e9b\u75c5\u4eba\u7684\u521d\u671f\u81e8\u5e8a\u8868\u73fe\u8207\u50b3\u7d71\u9f3b\u54bd\u764c\u76f8\u4f3c\u3002\u6709\u5169\u4f4d\u75c5\u4eba\u4e00\u958b\u59cb\u88ab\u8a3a\u65b7\u70ba\u50b3\u7d71\u9f3b\u54bd\u764c\uff08\u672a\u5206\u5316\u764c\uff09\uff0c\u76f4\u81f3\u767c\u751f\u9060\u7aef\u8f49\u79fb\u5f8c\uff0c\u8a3a\u65b7\u66f4\u6b63\u70ba\u6dcb\u5df4\u764c\u8207\u6a6b\u7d0b\u808c\u60e1\u6027\u8089\u7624\u3002\u7814\u7a76\u7d44\u75c5\u4eba\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u8207\u75be\u75c5\u7121\u60e1\u5316\u5b58\u6d3b\u7387\u6bd4\u50b3\u7d71\u9f3b\u54bd\u764c\u5dee\uff0c\u5177\u6709\u7d71\u8a08\u986f\u8457\u5dee\u7570\uff08\u5206\u5225\u70ba42.9% vs. 74.8%\uff0cP=0.027\uff1b42.9% vs. 71.7%\uff0cP=0.016\uff09\u3002\n\u7d50\u8ad6\uff1a\u7f55\u898b\u7684\u9f3b\u54bd\u90e8\u60e1\u6027\u816b\u7624\u5305\u62ec\u591a\u7a2e\u4e0d\u540c\u7684\u75c5\u7406\u578b\u614b\u3002\u56e0\u6b64\u8981\u6b63\u78ba\u8a3a\u65b7\u9019\u4e9b\u75c5\u4eba\u5fc5\u9808\u4ef0\u8cf4\u75c5\u7406\u79d1\u91ab\u5e2b\u7684\u9ad8\u5ea6\u61f7\u7591\u3002\u9019\u985e\u75c5\u4eba\u7684\u6cbb\u7642\u6210\u679c\u4f4e\u65bc\u50b3\u7d71\u9f3b\u54bd\u764c\u7684\u75c5\u4eba\u3002", "e": "Purpose: Nasopharyngeal malignancies, other than squamous cell carcinoma and undifferentiated carcinoma, are rare. We investigated the clinical manifestations and treatment outcomes of patients with rare nasopharyngeal malignancies over a 25-year period.\nMaterials and Methods: From January 1983 to December 2008, a total of 2113 patients with nasopharyngeal malignancies were registered in our radiotherapy database. Only seven eligible patients with rare malignancies of the nasopharynx were found. We retrospectively reviewed hospital charts, radiotherapy records, and imaging studies. The clinical courses and final outcomes were analyzed. Survival was compared with another group of patients with stage II-IVb conventional nasopharyngeal carcinoma (NPC). treated by concomitant chemoradiotherapy.\nResults: The incidence of rare nasopharyngeal malignancies was only 0.33%. The pathologic diagnoses were three rare carcinomas (adenocarcinoma, mucoepidermoid carcinoma, and small cell carcinoma), three lymphomas and one rhabdomyosarcoma. The initial manifestations were similar to conventional NPC. Two patients were misdiagnosed with conventional NPC (undifferentiated carcinoma), but this was revised to rhabdomyosarcoma and malignant lymphoma when distant sites relapsed. The overall survival and progression-free survival of the study group were significantly worse than conventional NPC (42.9% vs. 74.8%, P=0.027; 42.9% vs. 71.7%, P=0.016, respectively).\nConclusion: Rare malignancies arising from the nasopharynx consist of several different pathologies. The accurate diagnosis of rare malignancies of the nasopharynx depends on high index of suspicious of pathologist. The treatment outcome is worse than conventional NPC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-279-291", "title": "Treatment Outcome and Prognostic Factors of NK/T-Cell Lymphoma of the Nasal Cavity and Paranasal Sinuses", "keywords": "NK/T\u7d30\u80de\u6dcb\u5df4\u7624;\u9f3b\u8154;\u9f3b\u7ac7;\u9810\u5f8c\u56e0\u5b50 NK/T-cell lymphoma;Nasal cavity;Paranasal sinus;Prognostic factors", "c": "Purpose: The purpose of this study is to evaluate the overall survival of patients with NK/T-cell lymphoma arising from the nasal cavity and paranasal sinus, and to identify prognostic factors that affect clinical outcome.\nMaterials and Methods: The records of 18 patients with primary sinonasal NK/T-cell lymphoma diagnosed and treated in our institution between September 1992 and September 2008 were reviewed. Twelve patients were male, and 6 patients were female. The median age of the patients at the diagnosis was 52 years old (range 28-75 years old). Fourteen patients had loco-regional disease (stage \u2160-\u2161) and 4 patients had systemic disease (stage \u2162-\u2163). A total of 5 patients received chemo therapy (C/T) only, 1 patient received radiotherapy (RT) only, and 12 patients received combination of RT and C/T.\nResults: The median follow up period was 44 months (range from 0.4 months to 16.0 years). Twelve patients (66.7%) achieved complete response (CR) by image study, and then 6 out of the 12 patients had recurrent disease. The 5-year overall survival and 2-year disease-free survival (DFS) rate were 55.2% and 42.2%, respectively. Up front RT resulted in better DFS for 14 patients with stage \u2160/\u2161 disease (2-year DFS: RT vs. C/T: 83.3% vs. 25%, P=0.031). CR was the most potent prognostic factor affecting 5-year overall survival (CR vs. non-CR: 83.3% vs. 0%, P\uff1c0.001) and 2-year DFS (CR vs. non-CR: 48.1% vs. 0%, P\uff1c0.001). The International Prognostic Index score was found to independently influence only the DFS in patients with NK/T-cell lymphoma.\nConclusion: In this study, achievement of a CR is a particularly important determinant of treatment success. In analysis the 14 patients with stage \u2160/\u2161 disease, up front RT had an essential role improvement of DFS.", "e": "Purpose: The purpose of this study is to evaluate the overall survival of patients with NK/T-cell lymphoma arising from the nasal cavity and paranasal sinus, and to identify prognostic factors that affect clinical outcome.\nMaterials and Methods: The records of 18 patients with primary sinonasal NK/T-cell lymphoma diagnosed and treated in our institution between September 1992 and September 2008 were reviewed. Twelve patients were male, and 6 patients were female. The median age of the patients at the diagnosis was 52 years old (range 28-75 years old). Fourteen patients had loco-regional disease (stage \u2160-\u2161) and 4 patients had systemic disease (stage \u2162-\u2163). A total of 5 patients received chemo therapy (C/T) only, 1 patient received radiotherapy (RT) only, and 12 patients received combination of RT and C/T.\nResults: The median follow up period was 44 months (range from 0.4 months to 16.0 years). Twelve patients (66.7%) achieved complete response (CR) by image study, and then 6 out of the 12 patients had recurrent disease. The 5-year overall survival and 2-year disease-free survival (DFS) rate were 55.2% and 42.2%, respectively. Up front RT resulted in better DFS for 14 patients with stage \u2160/\u2161 disease (2-year DFS: RT vs. C/T: 83.3% vs. 25%, P=0.031). CR was the most potent prognostic factor affecting 5-year overall survival (CR vs. non-CR: 83.3% vs. 0%, P\uff1c0.001) and 2-year DFS (CR vs. non-CR: 48.1% vs. 0%, P\uff1c0.001). The International Prognostic Index score was found to independently influence only the DFS in patients with NK/T-cell lymphoma.\nConclusion: In this study, achievement of a CR is a particularly important determinant of treatment success. In analysis the 14 patients with stage \u2160/\u2161 disease, up front RT had an essential role improvement of DFS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-293-301", "title": "Comprehensive Measurement for Total Body Irradiation (TBI)", "keywords": "\u5168\u8eab\u6027\u653e\u5c04\u7167\u5c04;\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u6bd4;\u7d44\u7e54\u8207\u6700\u5927\u5291\u91cf\u6bd4;\u88dc\u511f\u5668\u56e0\u5b50 Total Body Irradiation;PDD;TMR;Compensator factor", "c": "\u76ee\u7684\uff1a\u91cf\u6e2c\u5168\u8eab\u6027\u653e\u5c04\u7167\u5c04(TBI)\u4e4b\u5c04\u675f\u7279\u6027\u8207\u5291\u91cf\u53c3\u6578\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u5206\u70ba\u4e03\u90e8\u5206\u4f86\u63a2\u8a0e\uff1a\u5c04\u675f\u8f38\u51fa\u5291\u91cf\u6bd4\u503c(output ratio)\u3001\u6258\u76e4\u8207\u6563\u5c04\u5c4f\u98a8\u56e0\u5b50(tray and spoiler factors)\u3001\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u6bd4(PDD)\u3001\u7d44\u7e54\u8207\u6700\u5927\u5291\u91cf\u6bd4(TMR)\u3001\u88dc\u511f\u5668\u56e0\u5b50(compensator factor)\u3001\u5c04\u675f\u5256\u9762\u5716(beam profile)\u53ca\u5291\u91cf\u9a57\u8b49\u7b49\uff61\u6240\u6709\u5c04\u675f\u7279\u6027\u53ca\u5291\u91cf\u53c3\u6578\u4e4b\u91cf\u6e2c\u7686\u4f7f\u7528\u897f\u9580\u5b50Primus\u76f4\u7dda\u52a0\u901f\u5668\u516d\u767e\u842c\u4f0f\u7279(MV)\u4e4b\u5149\u5b50\u5c04\u675f\u3002\u91cf\u6e2c\u8a2d\u7f6e\u60c5\u6cc1\u6bd4\u7167\u5be6\u969bTBI\u6cbb\u7642\u6642\u7684\u60c5\u5f62\uff1a\u5728SSD\u70ba480\u516c\u5206\u8655\u653e\u7f6e\u5047\u9ad4\uff0c\u7167\u91ce\u5927\u5c0f\u70ba40\u00d740\u5e73\u65b9\u516c\u5206\uff08\u6b64\u70baSAD 100\u516c\u5206\u8655\u4e4b\u5927\u5c0f\uff09\uff0c\u6e96\u76f4\u5100\u53ca\u65cb\u8f49\u81c2\u7684\u89d2\u5ea6\u5404\u70ba45\u5ea6\u53ca270\u5ea6\u3002\u6b64\u5916\uff0c\u5728\u5047\u9ad4\u524d\u65b9\u9084\u6703\u653e\u7f6e\u4e00\u97621\u516c\u5206\u4e4b\u6563\u5c04\u5c4f\u98a8\u4ee5\u63d0\u9ad8\u8868\u9762\u5291\u91cf\u3002\u672c\u7814\u7a76\u524d\u4e94\u90e8\u5206\u4e4b\u5291\u91cf\u53c3\u6578\u4e3b\u8981\u4f7f\u7528\u8fb2\u592b\u578b\u6e38\u96e2\u8154(Farmer type ion chamber)\u3001\u96fb\u91cf\u8a08(electrometer)\u3001\u5e73\u884c\u677f\u6e38\u96e2\u8154(parallel-plate ion chamber)\u53ca\u805a\u82ef\u4e59\u70ef\u5047\u9ad4(polystyrene phantom)\u7b49\u8a2d\u5099\u4f86\u505a\u91cf\u6e2c\uff1a\u5728\u5c04\u675f\u5256\u9762\u5716\u90e8\u5206\uff1a\u5206\u5225\u5c07\u81a0\u7247(film)\u8cbc\u653e\u5728\u6563\u5c04\u5c4f\u98a8\u4e0a\u6216\u5c07\u6e38\u96e2\u8154\u653e\u5728\u58d3\u514b\u529b\u5047\u9ad4\u5167\u505a\u91cf\u6e2c\uff0c\u9032\u884c\u5169\u8005\u4e4b\u6bd4\u8f03\uff1a\u5291\u91cf\u9a57\u8b49\u90e8\u5206\uff1a\u5728TBI\u6cbb\u7642\u75c5\u4eba\u7684\u540c\u6642\uff0c\u5c07\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD)\u8cbc\u653e\u5728\u75c5\u4eba12\u500b\u4e0d\u540c\u7684\u90e8\u4f4d\u63a5\u6536\u5291\u91cf\uff0c\u4ee5\u8a55\u4f30\u75c5\u4eba\u5be6\u969b\u63a5\u53d7\u5230\u5291\u91cf\u7684\u60c5\u5f62\uff0c\u662f\u5426\u8207\u9802\u671f\u76f8\u7b26\u3002\n\u7d50\u679c\uff1a\u5c04\u675f\u8f38\u51fa\u5291\u91cf\u6bd4\u503c\u8a8d0.0466\uff0c\u6b64\u503c\u8207\u4e00\u822c\u6a19\u6e96\u6821\u6b63\u60c5\u6cc1\u4e0b\u6240\u5f97\u5230\u4e4b\u503c\uff0c\u7d93\u5e73\u65b9\u53cd\u6bd4\u53ca\u7167\u91ce\u56e0\u5b50\u8f49\u63db\u5f8c\u6240\u5f97\u4e4b\u503c\u6975\u70ba\u76f8\u8fd1\u3002\u62d6\u76e4\u56e0\u5b50\u3001\u6563\u5c04\u5c4f\u98a8\u56e0\u5b50\u53ca\u6258\u76e4\u8207\u6563\u5c04\u5c4f\u98a8\u56e0\u5b50\u5206\u5225\u70ba0.949\u30010.982\u53ca0.931\u3002\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u6bd4\u8207\u7d44\u7e54\u8207\u6700\u5927\u5291\u91cf\u6bd4\u7d93\u8f49\u63db\u5f8c\u4e4b\u5dee\u7570\u4ecb\u65bc2%\u7684\u7bc4\u570d\u5167\u3002\u88dc\u511f\u5668\u56e0\u5b50\u5728\u805a\u82ef\u4e59\u70ef\u539a\u5ea6\u4f4e\u65bc13\u516c\u5206\u6642\u7684\u503c\u70ba0.045\uff0c\u800c\u805a\u82ef\u4e59\u70ef\u8207\u925b\u4e4b\u539a\u5ea6\u6bd4\u503c(thickness ratio)\u70ba0.511\u3002\u7531\u81a0\u7247\u8207\u6e38\u96e2\u8154\u6240\u91cf\u5f97\u4e4b\u5c04\u675f\u5256\u9762\u5716\u9817\u70ba\u4e00\u81f4\u3002\u5728\u5291\u91cf\u9a57\u8b49\u90e8\u5206\uff0c\u7531\u71b1\u767c\u5149\u5291\u91cf\u8a08\u6240\u91cf\u5f97\u4e4b\u5291\u91cf\u8207\u8655\u65b9\u5291\u91cf\u76f8\u6bd4\u5dee\u7570\u7d04\u70ba\u00b15%\u3002\n\u7d50\u8ad6\uff1a\u6839\u64da\u4e0a\u8ff0\u91cf\u6e2c\u7d50\u679c\uff0c\u6240\u6709\u8aa4\u5dee\u7686\u57282%\u7684\u7bc4\u570d\u5167\uff08\u5291\u91cf\u9a57\u8b49\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u7684\u7d50\u679c\u9664\u5916\uff09\uff0c\u6545\u672c\u7814\u7a76\u91cf\u6e2c\u5c04\u675f\u7279\u6027\u53ca\u5291\u91cf\u53c3\u6578\u4e4b\u65b9\u6cd5\u662f\u53ef\u884c\u7684\uff0c\u4e14\u6240\u6709\u91cf\u6e2c\u7d50\u679c\u76ee\u524d\u7686\u88ab\u5be6\u969b\u4f7f\u7528\u5728\u81e8\u5e8a\u6cbb\u7642\u4e0a\u9762\u3002", "e": "Purpose: To measure the beam data and dosimetry parameters for Total Body Irradiation (TBI).\nMaterials and Methods: The set of measurements consists of seven items: output ratio, tray and spoiler factors, PDD, TMR, compensator factor, beam profile and dose verification. All measurements were performed on a 6 MV photon beam of Siemens Primus Linac. Experimental setup simulated TBI treatment conditions with SSD at 480 cm, field size at 40\u00d740 cm^2 at SAD 100 cm, and the collimator and gantry angles set to 45\u00b0 and 270\u00b0, respectively. In addition, a 1 cm spoiler screen was placed in front of the phantom to increase the surface dose. The first five items of dosimetry parameters were measured with a Farmer-type ion chamber, an electrometer, a parallel- plate ion chamber and a polystyrene phantom. The beam profile was measured both with films placed on the spoiler screen and with ion chamber in a polystyrene phantom. For dose verification, TLDs were placed at twelve different sites on the patient skin during TBI treatment.\nResults: The output ratio was 0.0466, very close to that obtained under calibration conditions after applying the inverse square correction and output factor correction for TBI treatment conditions. The tray factor, spoiler factor and the combined tray-and- spoiler factor were 0.949, 0.982 and 0.931, respectively. The discrepancy between PDD and TMR was lower than 2 %. The compensator factor was 0.045 for polystyrene thickness up to 13 cm and the thickness ratio of polystyrene to lead was 0.511. Beam profiles measured with films and ion chamber were almost the same. For dose verification, the discrepancies between TLD and prescribed dose were comparable to the intrinsic measurement uncertainty, \u00b15 %.\nConclusion: A comprehensive set of beam data and dosimetry parameters were measured and all ratio discrepancies seen during the study (except TLD part), consistent with those applied clinically, were within 2 % indicating the study viable."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-303-308", "title": "\u975e\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u8207\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u982d\u9838\u90e8\u816b\u7624\u6cbb\u7642\u6280\u8853\u4e4b\u9838\u90e8\u76ae\u819a\u5291\u91cf\u5be6\u6e2c", "keywords": "\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede;\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u9838\u90e8\u76ae\u819a\u5291\u91cf Mono-isocenter;Thermoluminescence Dosimeter TLD;Neck skin dose", "c": "\u76ee\u7684\uff1a\u982d\u9838\u90e8\u816b\u7624\u56e0\u816b\u7624\u4e4b\u578b\u614b\u8207\u6dcb\u5df4\u4e4b\u6d41\u5411\u95dc\u4fc2\uff0c\u5728\u6cbb\u7642\u6642\u5e38\u8003\u616e\u4e0b\u9838\u90e8\u8207\u9396\u9aa8\u4e0a\u7aa9\u6dcb\u5df4\u7d50\u4e4b\u7167\u5c04\uff0c\u5176\u7167\u5c04\u65b9\u6cd5\u591a\u70ba\u524d\u65b9\u55ae\u4e00\u9580\u4e4b\u9810\u9632\u6027\u7167\u5c04\u3002\u7531\u65bc\u73fe\u4eca\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u8207\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u9032\u6b65\uff0c\u982d\u9838\u90e8\u816b\u7624\u653e\u5c04\u6cbb\u7642\u64fa\u4f4d\u65b9\u5f0f\u591a\u63a1\u7528\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede(mono-isocenter)\u4f86\u53d6\u4ee3\u904e\u53bb\u975e\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u7684\u64fa\u4f4d\u65b9\u5f0f\uff0c\u672c\u7814\u7a76\u5373\u8a55\u4f30\u9838\u90e8\u8868\u9762\u5291\u91cf\u56e0\u6280\u8853\u4e0d\u540c\u5176\u76ae\u819a\u5291\u91cf\u4e4b\u8b8a\u5316\u8207\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4ee5\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD-100)\u7f6e\u65bcRT-HUMANOID\u4f3c\u4eba\u5047\u9ad4\u8868\u9762\uff0c\u8a55\u4f30\u4ee5TMR\u516c\u5f0f\u8a08\u7b97\u4e4b\u975e\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u3001\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u8a08\u7b97\u4e4b\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u9019\u5169\u7a2e\u8a08\u7b97\u8207\u64fa\u4f4d\u65b9\u5f0f\u65bc\u982d\u9838\u90e8\u816b\u7624\u6cbb\u7642\u6642\u7684\u9838\u90e8\u76ae\u819a\u5291\u91cf\uff0c\u5e0c\u671b\u80fd\u77ad\u89e3\u5176\u76ae\u819a\u5291\u91cf\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u5be6\u9a57\u767c\u73fe\u4eca\u4f7f\u7528\u7684\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u914d\u5408\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u64fa\u4f4d\u7684\u9838\u90e8\u76ae\u819a\u5291\u91cf\u8f03TMR\u516c\u5f0f\u8207\u975e\u55ae\u4e00\u7b49\u4e2d\u5fc3\u9ede\u64fa\u4f4d\u4e4b\u9838\u90e8\u76ae\u819a\u5291\u91cf\u9ad8\u51fa\u7d046%\u3002\u4f7f\u7528\u76f8\u540c\u4e4b\u64fa\u4f4d\uff08\u975e\u55ae\u4e00\u9ede\u4e2d\u5fc3\u64fa\u4f4d\uff09\uff0c\u4e0d\u540c\u8a08\u7b97\u65b9\u5f0f\uff08TMR\u516c\u5f0f\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u5283\uff09\uff0c\u5247\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7d66\u4e88\u5291\u91cf\u4e4b\u5047\u9ad4\u7684\u9838\u90e8\u76ae\u819a\u5291\u91cf\u8f03TMR\u516c\u5f0f\u8a08\u7b97\u7d66\u4e88\u5291\u91cf\u4e4b\u5047\u9ad4\u7684\u9838\u90e8\u76ae\u819a\u5291\u91cf\u9ad8\u51fa\u7d048%\u3002\n\u7d50\u8ad6\uff1a\u76ae\u819a\u5291\u91cf\u56e0\u6cbb\u7642\u65b9\u5f0f\u6216\u8a08\u7b97\u65b9\u5f0f\u4e0d\u540c\u3001\u5176\u8f38\u51fa\u5291\u91cf\u4e5f\u4e0d\u540c\uff0c\u5229\u7528\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u4f86\u7d66\u4e88\u6cbb\u7642\u8f38\u51fa\u5291\u91cf\u6642\u6703\u6bd4\u5229\u7528TMR\u8a08\u7b97\u7d66\u4e88\u4e4b\u5291\u91cf\u9ad8\uff0c\u56e0\u6b64\u7522\u751f\u8f03\u9ad8\u4e4b\u76ae\u819a\u5291\u91cf\uff0c\u7d71\u8a08\u5b78\u4e0a\u662f\u6709\u610f\u7fa9\u7684\u3002", "e": "Purpose: In radiotherapy of head and neck cancer, regional lympha mode of lower-neck and supraclavicular fossa was taken into the irradiation field because of the tumor type and lymphatic drainage always in high risk. A conventional anterior low-neck and supercalaviculer field was performed regularly during radiotherapy. Owing to the remarkable progressing advances in linear accelerator and treatment planning system, there were a lot of achievement in radiotherapy in recent decades, the patient setup technique of radiotherapy in head and neck cancer have changed from multi-centers technique to mono-isocenter technique.\nMaterials and Methods: Thermoluminescent dosimeters (TLDs) were used to place on RT-HUMANOID phantom to evaluate the skin dose of head and neck field. Multi-centers and monoisocenter techniques were performed in setup with anthropomorphic phantom during the experiment. TMR formula and Pinnacle radiotherapy planning system were used to calculate the output monitor- unit (MU).\nResults: We found that the neck skin doses in mono-isocenter technique was calculated in treatment planning system as 6% higher than multi-centers technique when that of calculated with TMR formula. The neck skin doses of mono-isocenter were 3% higher than that of multi-centers setup technique using the same calculation method (which is Pinnacle radiotherapy planning system). The neck skin doses of Pinnacle radiotherapy planning system were 8% higher than that of TMR formula using the same setup technique (which is multi-centers).\nDiscussions: The calculation methods and the SSD (source-surface distance) might cause the different of the neck skin doses."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-309-315", "title": "Delay Diagnosis of Leptomeningeal Metastasis in Lung Cancer Associated Spinal Cord Compression Presented with Papilledema: A Case Report", "keywords": "\u8996\u4e73\u7a81\u6c34\u816b;\u8edf\u8166\u810a\u819c\u8f49\u79fb;\u9871\u5167\u58d3\u589e\u52a0;\u810a\u9ad3\u58d3\u8feb;\u8166\u6c34\u816b Papilledema;Leptomeningeal metastasis;Increased intracranial pressure;Spinal cord compression;hydrocephalus", "c": "\u4e00\u4f4d46\u6b72\u5973\u6027\uff0c\u5de6\u4e0a\u80ba\u80ba\u817a\u764c\uff0c\u81e8\u5e8a\u671f\u5225\u70baT4N2M1\uff0c\u5408\u4f75\u8170\u690e\u7b2c\u4e00\u7bc0\u4e4b\u810a\u9ad3\u58d3\u8feb\u3002\u81e8\u5e8a\u75c7\u72c0\u8868\u73fe\u53ea\u6709\u8996\u529b\u6a21\u7cca\u8207\u982d\u75db\uff0c\u539f\u56e0\u8b49\u5be6\u70ba\u9871\u5167\u58d3\u589e\u52a0\u5408\u4f75\u5169\u5074\u8996\u4e73\u7a81\u6c34\u816b\u3002\u81e8\u5e8a\u8a55\u4f30\u5305\u542b\u591a\u6b21\u8166\u90e8\u78c1\u5171\u632f\u6383\u63cf\u3001\u8170\u690e\u7a7f\u523a\u8207\u6703\u8a3a\u773c\u79d1\u5c08\u79d1\u91ab\u5e2b\u3002\u5728\u85c9\u52a9\u78c1\u5171\u632f\u6383\u63cf\u5b8c\u6210\u5168\u810a\u9ad3\u6db2\u7cfb\u7d71\uff08\u8166\u8207\u5168\u810a\u9ad3\uff09\u6aa2\u67e5\uff0c\u8a3a\u65b7\u70ba\u8170\u690e\u7b2c\u4e00\u7bc0\u810a\u9ad3\u58d3\u8feb\u6240\u5c0e\u81f4\u3002\u8996\u4e73\u7a81\u6c34\u816b\u8207\u9871\u5167\u58d3\u5728\u5b8c\u6210\u7b2c\u4e00\u7bc0\u8170\u690e\u653e\u5c04\u7dda\u6cbb\u7642\u7372\u5f97\u77ed\u66ab\u6539\u5584\u3002\u4e5d\u500b\u6708\u5f8c\uff0c\u6700\u7d42\u8a3a\u65b7\u70ba\u8edf\u8166\u810a\u819c\u8f49\u79fb\uff0c\u75c5\u56e0\u8207\u8a3a\u65b7\u5c07\u9032\u4e00\u6b65\u8a0e\u8ad6\u3002", "e": "A case of adenocarcinoma of left upper lung, cT4N2M1, with spinal cord compression over Li in a 46-year-old woman is presented. The only clinical symptom was blurred vision and headache, which proved to be caused by increased intracranial pressure (IICP) with bilateral papilledema. Evaluations of IICP were performed including repeated MRI of brain, lumbar puncture and ophthalmologist consultation. After complete survey of the entire CSF system by MRI, the diagnosis of spinal cord compression over Li region was made. After the completion of palliative radiotherapy for the Li cord compression, the symptoms of blurred vision and headache improved transiently. The final diagnosis of leptomeningeal metastasis was established nine months latter. The cause as well as diagnosis is discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-317-322", "title": "Radiotherapy for Genital Extramammary Paget", "keywords": "\u4e73\u623f\u5916\u67cf\u54f2\u5fb7\u6c0f\u75c5;\u6703\u9670\u90e8;\u653e\u5c04\u7dda\u6cbb\u7642 Extramammary Paget", "c": "\u4e73\u623f\u5916\u67cf\u54f2\u5fb7\u6c0f\u75c5(Extramammary Paget's Disease)(EMPD)\u662f\u4e00\u7f55\u898b\u7684\u75be\u75c5\uff0c\u597d\u767c\u5e74\u7d00\u572850\u81f380\u6b72\uff0c\u597d\u767c\u90e8\u4f4d\u5728\u6c57\u817a\u8f03\u767c\u9054\u7684\u5730\u65b9\u5982\u809b\u9580\u5468\u570d\u3001\u9670\u56ca\u3001\u6703\u9670\u8207\u5916\u9670\u90e8\u3002\u81e8\u5e8a\u75c7\u72c0\u5f88\u50cf\u4e73\u982d\u7684\u67cf\u54f2\u5fb7\u6c0f\u75c5\uff0c\u4e3b\u8981\u7684\u75c7\u72c0\u70ba\u6414\u7662\uff0c\u60c5\u6cc1\u8207\u4e00\u822c\u7d30\u83cc\u611f\u67d3\u76f8\u4f3c\uff0c\u5f88\u5bb9\u6613\u88ab\u8aa4\u8a3a\uff0c\u4e00\u958b\u59cb\u5448\u73fe\u754c\u9650\u660e\u986f\u3001\u55ae\u4e00\u812b\u5c51\u6027\u8868\u5c64\u7684\u7d05\u75b9\uff0c\u5e38\u88ab\u7576\u6210\u6162\u6027\u6fd5\u75b9\u6cbb\u7642\uff0c\u5ef6\u8aa4\u6cbb\u7642\u7684\u6642\u6a5f\uff0c\u589e\u52a0\u764c\u75c7\u7d30\u80de\u8f49\u79fb\u7684\u6a5f\u6703\uff0c\u540c\u6642\u6703\u5408\u4f75\u6709\u5176\u4ed6\u9130\u8fd1\u5668\u5b98\u7684\u764c\u75c7\u3002\n\u6cbb\u7642\u50b3\u7d71\u4ee5\u5916\u79d1\u624b\u8853\u5207\u9664\uff0c\u4e00\u822c\u4f86\u8aaa\uff0c\u9810\u5f8c\u826f\u597d\u4f46\u5fa9\u767c\u7387\u9ad8\u3002\u5982\u4f4d\u5728\u89e3\u5256\u4f4d\u7f6e\u8907\u96dc\u7684\u5730\u65b9\u5982\u6703\u9670\u3001\u809b\u9580\u5468\u570d\u7b49\u8655\uff0c\u70ba\u8981\u9054\u6839\u9664\u76ee\u7684\uff0c\u751a\u81f3\u8981\u9700\u8981\u5207\u9664\u809b\u9580\uff0c\u5c0d\u75c5\u4eba\u5fc3\u7406\u8207\u751f\u6d3b\u4e0a\u9020\u6210\u5f88\u5927\u7684\u5f71\u97ff\u4fdd\u5b88\u6027\u6cbb\u7642\u6709\u5c40\u90e8\u5316\u7642\u3001\u5c40\u90e8\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\u6216\u653e\u5c04\u6cbb\u7642\uff0c\u4f46\u90fd\u56e0\u75c5\u4f8b\u4e0d\u591a\uff0c\u7121\u6cd5\u6709\u78ba\u5207\u7684\u5b9a\u8ad6\u3002\u85c9\u7531\u6b64\u6587\u5831\u544a\u4e00\u4f4d\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u4e73\u623f\u5916\u67cf\u54f2\u5fb7\u6c0f\u75c5\u7684\u75c5\u4f8b\uff0c\u4e26\u56de\u9867\u6709\u95dc\u4e73\u623f\u5916\u67cf\u54f2\u5fb7\u6c0f\u75c5\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6587\u737b\uff0c\u63d0\u4f9b\u5927\u5bb6\u5c0d\u6b64\u4e00\u75be\u75c5\u9664\u624b\u8853\u5916\u53e6\u4e00\u6548\u679c\u4e0d\u932f\u7684\u9078\u64c7\u3002", "e": "Extramammary Paget's disease (EMPD) is an uncommon cutaneous adenocarcinoma. It predominantly involves apocrine gland-bearing areas, especially the vulva, scrotum, and perianal areas. In contrast to mammary Paget's disease, extramammary Paget's disease may or may not be associated with internal malignancy. Initially, the lesion is typically erythematous, dry, and raised with pruritus. It later may turn into an eczematoid, crusted, ulcerated, or papillary lesion with pain and bleeding. Patients often give a history of prolonged treatment with topical corticosteroid and antifungal agents before a diagnosis is made by biopsy of the lesion. Extramammary Paget's disease should be highly suspected if a skin lesion fails to clear with topical steroid and antifungal treatment.\nMany different treatment modalities have been reported, including surgery or Mohs micrographic surgery, radiotherapy, chemo-radiotherapy, topical chemotherapy and topical immune modulator. The effectiveness of radiotherapy is generally difficult to ascertain because most of the literatures comprised mostly of individual case reports. We report a case of genital EMPD treated with curative intent radiotherapy and to review relevant literatures of treatment modality except surgery as a first- choice treatment in anogenital EMPD."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201012-201101150003-201101150003-323-330", "title": "\u6c23\u7ba1\u7c97\u964d\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u4e4b\u653e\u5c04\u6cbb\u7642\uff1a\u75c5\u4f8b\u5831\u544a", "keywords": "\u808c\u4e0a\u76ae\u764c;\u60e1\u6027\u808c\u4e0a\u76ae\u7624;\u6c23\u7ba1\u7c97\u9686;\u6c23\u7ba1;\u653e\u5c04\u6cbb\u7642 Myoepithelial carcinoma;Malignant Myoepithelioma MME;Carina;Trachea;Radiotherapy", "c": "Myoepithelial carcinoma\u53c8\u7a31\u70bamalignant myoepithelioma\uff0c\u662f\u4e00\u7a2e\u975e\u5e38\u5c11\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u5927\u7d04\u53ea\u4f54\u6240\u6709\u553e\u6db2\u817a\u816b\u7624\u76841%\u3002MME\u9664\u4e86\u751f\u9577\u5728\u816e\u817a\uff0c\u4e5f\u53ef\u80fd\u767c\u751f\u5728\u5c0f\u553e\u6db2\u817a\u3001\u652f\u6c23\u7ba1\u6216\u4e73\u623f\u3002\u5728\u672c\u7bc7\u7684\u6848\u4f8b\u5831\u544a\u4e2d\u5c07\u8a0e\u8ad6\u4e00\u4f4dMME\u751f\u9577\u5728carina\u7684\u75c5\u4f8b\uff0c\u4e00\u540d55\u6b72\u7537\u6027\u75c5\u60a3\uff0c\u5c31\u8a3a\u6642\u51fa\u73fe\u547c\u5438\u7a98\u8feb\u4f34\u96a8\u8457\u8072\u97f3\u6c99\u555e\uff0c\u5728\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e0a\u767c\u73fe2cm\u83cc\u72c0\u4e0d\u898f\u5247\u7684\u816b\u7624\u963b\u585e\u5169\u5074\u4e3b\u652f\u6c23\u7ba1\uff0c\u4fbf\u7dca\u6025\u57f7\u884c\u6c23\u7ba1\u9020\u53e3\u8853\u53ca\u6c23\u7ba1\u93e1\u5207\u7247\uff0c\u4e26\u5c0d\u6c23\u7ba1\u9686\u7a81\u90e8\u816b\u7624\u7d66\u4e88\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u70ba63 Gy\u5171\u6cbb\u764235\u6b21\u3002\u653e\u5c04\u6cbb\u7642\u5f8c18\u500b\u6708\uff0c\u816b\u7624\u5f97\u5230\u826f\u597d\u7684\u5c40\u90e8\u63a7\u5236\uff0c\u75c5\u60a3\u75c7\u72c0\u4e5f\u7372\u5f97\u6539\u5584\u4e26\u4e14\u79fb\u9664\u6c23\u5207\u7ba1\u3002", "e": "Myopithelial carcinoma or malignant myoepithelioma (MME) is a very rare cancer that account for less than 1% of salivary gland tumor. Outside the parotid, MME may also arise from minor salivary glands, bronchi or breast. In this report we describe a unique case of MME arising from the carina. A 55 year old male patient initially presented with respiratory distress associated with hoarseness. Emergency tracheostomy and bronschoscopic biospy were performed after CT scan revealed a 2 cm fungiform irregular carinal tumor obstructing the bilateral main bronchus. Radiotherapy was given with a total dose of 63 Gy in 35 fractions to the carinal tumor. Good local tumor control was achieved 18 months after radiotherapy, acheiving symptomatic relief and safe removal of tracheostomy tube."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-169-179", "title": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff0c\u4f7f\u7528\u6a19\u9776\u5100\u6216\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u5b9a\u4f4d\u6cbb\u7642\u4e2d\u5fc3\u9ede\u7684\u8aa4\u5dee\u6bd4\u8f03", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642;\u5f71\u50cf\u5c0e\u5f15\u5b9a\u4f4d\u7cfb\u7d71;\u6a19\u9776\u5100\u5b9a\u4f4d\u7cfb\u7d71;\u5b9a\u4f4d\u8aa4\u5dee Stereotactic radiosurgery;Image guided system;Setup error", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5728\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u6280\u8853(stereotactic radiotherapy)\u4e2d\uff0c\u4f7f\u7528\u6a19\u9776\u5100(stereotactic localizer box)\u6216\u662f\u5f71\u50cf\u5c0e\u5f15(image guided system)\u5b9a\u4f4d\u7cfb\u7d71\uff0c\u5c0d\u65bc\u6cbb\u7642\u4e2d\u5fc3\u9ede\u7684\u6e96\u78ba\u5ea6\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u8afe\u529b\u5200(BrainLAB Novalis, Feldkirchen, Germany)\u70ba\u5de5\u5177\uff0c\u5206\u6210\u5169\u500b\u4e3b\u8981\u90e8\u4efd\uff1a\u4e00\u3001\u5c07\u4eba\u982d\u5047\u9ad4\u5206\u5225\u4ee5BrainLAB\u7684headring\u8207mask headring(maskring)\u5169\u7a2e\u56fa\u5b9a\u982d\u90e8\u7684\u6a21\u5177\uff0c\u8f14\u4ee5\u6a19\u9776\u5100\u8207\u5f71\u50cf\u5c0e\u5f15\u5169\u7a2e\u5b9a\u4f4d\u7cfb\u7d71\uff0c\u6a21\u64ec\u81e8\u5e8a\u6cbb\u7642\u904e\u7a0b\uff0c\u6bd4\u8f03\u5169\u7a2e\u5b9a\u4f4d\u7cfb\u7d71\u7684\u6cbb\u7642\u4e2d\u5fc3\u9ede\u4f55\u8005\u6e96\u78ba\u3002\u4e8c\u3001\u57282007\u5e745\u6708\u81f32008\u5e7410\u6708\u4e4b\u9593\uff0c22\u4f4d\u8166\u7624\u75c5\u60a3\u9032\u884c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d8\u4f4d\u9032\u884c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853(stereotactic radiosurgery, SRS)\uff0c14\u4f4d\u9032\u884c\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642(stereotac ticradiotherapy, SRT)\u3002\u6bcf\u4f4d\u75c5\u4eba\u5747\u5148\u7d93\u904e\u6a19\u9776\u5100\u5b9a\u4f4d\u5f8c\uff0c\u518d\u4ee5\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u651d\u5f71\u5b9a\u4f4d\uff0c\u7d00\u9304\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u8edf\u9ad4\u5c0d\u6cbb\u7642\u4e2d\u5fc3\u9ede\u7684\u4f4d\u79fb\u4fee\u6b63\u503c\uff0c\u5206\u6790\u5169\u8005\u4f4d\u79fb\u4fee\u6b63\u503c\u5728\u81e8\u5e8a\u4e0a\u7684\u610f\u7fa9\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u5728\u5047\u9ad4\u5be6\u9a57\u4e2d\uff0c\u4ee5\u5047\u9ad4\u4e2d\u57cb\u5165\u7684\u91dd\u982d\u4f5c\u70ba\u6a19\u6e96\u6cbb\u7642\u4e2d\u5fc3\u9ede\uff0c\u6a19\u9776\u5100\u5448\u73fe\u7684\u8aa4\u5dee\uff1aheadring\u5728A-P\u65b9\u5411\u662f1.0mm\uff1bmaskring\u5728A-P\u8207Lateral\u65b9\u5411\uff0c\u5206\u5225\u662f1.1mm\u82071.0mm\uff1b\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u5448\u73fe\u7684\u8aa4\u5dee\uff1aheadring\u5728A-P\u65b9\u5411\u662f0.6mm\uff1bmaskring\u5728A-P\u8207Lateral\u65b9\u5411\uff0c\u5206\u5225\u662f0.2mm\u82070.4mm\u3002\u56e0\u6b64\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u5b9a\u4f4d\u7684\u6e96\u78ba\u6027\u8f03\u7528\u6a19\u9776\u5100\u5b9a\u4f4d\u7cfb\u7d71\u4f86\u7684\u6e96\u78ba\uff1b\u4f46\u5c0d\u5047\u9ad4\u800c\u8a00\uff0c\u5169\u5b9a\u4f4d\u7cfb\u7d71\u5f7c\u6b64\u7684\u76f8\u5c0d\u5dee\u7570\u5e7e\u8fd1\uff0c\u800c\u4e14\u5c0d\u4f4d\u6e96\u78ba\u6027\u5747\u7b26\u5408\u7acb\u9ad4\u5b9a\u4f4d\u7cfb\u7d71\u5728\u6cbb\u7642\u4e2d\u5fc3\u9ede\u7684\u8aa4\u5dee\u9700\u5c0f\u65bc1mm\u7684\u6a19\u6e96\u3002\n\u81e8\u5e8a\u75c5\u4eba\u6578\u64da\u5728\u5169\u5b9a\u4f4d\u7cfb\u7d71\u5f7c\u6b64\u7684\u76f8\u5c0d\u4f4d\u79fb\u4fee\u6b63\u503c\uff0c\u4ee5headring\u56fa\u5b9a\u8005\uff0c\u5728SRS\u9664\u5728\u982d\u90e8\u524d\u5f8c\u65b9\u5411\u4f4d\u79fb\u4fee\u6b63\u503c\u5fae\u5927\u65bc1mm\u5916\uff0c\u5176\u9918\u6240\u6709\u65b9\u5411\u7684\u4f4d\u79fb\u4fee\u6b63\u503c\u5747\u63a5\u8fd1\u6216\u5c0f\u65bc1mm\u82071\u5ea6\uff0c\u8207\u5047\u9ad4\u5be6\u9a57\u7d50\u679c\u7b26\u5408\uff1b\u800cmaskring\u56fa\u5b9a\u8005\uff0c\u5728SRS\u8207SRT\u7684\u6cbb\u7642\u4e2d\u5fc3\u9ede\u7684\u4f4d\u79fb\u4fee\u6b63\u503c\u5247\u5168\u90e8\u5747\u5c0f\u65bc3mm\u82072\u5ea6\u3002\u8aa4\u5dee\u7522\u751f\u7684\u539f\u56e0\u5728\u6bd4\u8f03\u7cfb\u7d71\u8aa4\u5dee\u3001\u96a8\u6a5f\u8aa4\u5dee\u3001\u518d\u73fe\u6027\u3001\u7a7a\u9593\u5411\u91cf\u53ca\u8207\u5176\u4ed6\u6587\u737b\u5831\u544a\u7684\u4f50\u8b49\u5f8c\uff0c\u7814\u5224\u6a19\u9776\u5100\u5b9a\u4f4d\u6e96\u78ba\u6027\uff0c\u6703\u53d7\u5230\u4e0d\u540c\u6a21\u5177\u56fa\u5b9a\u6548\u679c\u6216\u6cbb\u7642\u5e8a\u4f4d\u7f6e\u7684\u5f71\u97ff\uff0c\u800c\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u56e0\u70ba\u4ee5\u89e3\u5256\u69cb\u9020\u70ba\u57fa\u6e96\u505a\u70ba\u6bd4\u8f03\uff0c\u8f03\u4e0d\u6613\u53d7\u5230\u5916\u5728\u56e0\u7d20\u5f71\u97ff\uff0c\u56e0\u6b64\u4fbf\u7522\u751f\u5169\u8005\u5728\u81e8\u5e8a\u5b9a\u4f4d\u4e0a\u7684\u5dee\u7570\u3002\n\u7d50\u8ad6\uff1a\u70ba\u4e86\u964d\u4f4e\u5b9a\u4f4d\u6642\u7684\u8aa4\u5dee\uff0c\u78ba\u4fdd\u6bcf\u6b21\u6cbb\u7642\u6642\u7684\u6cbb\u7642\u4e2d\u5fc3\u9ede\u8207\u6cbb\u7642\u8a08\u756b\u4e2d\u6cbb\u7642\u4e2d\u5fc3\u9ede\u76f8\u540c\u7684\u6b63\u78ba\u6027\uff0c\u4f7f\u7528maskring\u914d\u5408\u6a19\u9776\u5100\u5b9a\u4f4d\u7cfb\u7d71\u5728\u9700\u8981\u9ad8\u6e96\u78ba\u6027\u7684\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u5efa\u8b70\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u5b9a\u4f4d\u7cfb\u7d71\u3002", "e": "Purpose: The study is to investigate the spatial difference of the treatment center between setup by the stereotactic localizer box and by ExacTrac x-ray verification system in the treatments of stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SRT) for intracranial lesions.\nMaterials and Methods: Between May 2007 to October 2008, 22 patients were enrolled in this study, including 8 patients each treated by single fraction SRS, and 14 other patients treated by SRT. All patients were treated by dedicated Novalis radiosurgery system coupled with ExacTrac image guided system.\nAt first, we performed head phantom test to compare the accuracy of each setup method to predefined isocenter, and then to compare the spatial difference between these two setup methods from patients' data. Due to the software\u2019s limitation, treatment setup can be proceeded only by one method at a time, either by stereotactic localizer box or ExacTrac image guided system, therefore, the phantom and each patient had two treatment plans of the same treatment center. We started to setup by the traditional SRS procedure first, i.e., matching the treatment center in the stereotactic localizer box from the first plan, and then we took two fixed angled oblique radiographs to check the difference between this treatment center and that from the digital reconstructed radiographs of the second treatment plan.\nResults: In phantom's test, the setup error of stereotactic frame box with maskring is 1.1 mm in AP direction, and 1mm in lateral direction, in contrast to 0.2 mm in AP, and 0.4 mm in lateral direction by ExacTrac x-ray verification system. Patients with immobilization using headring had less displacement error, all were smaller than 1 mm or within 1 degree of rotation except in vertical direction. In contrast, immobilization using maskring had larger displacement, but all of them were smaller than 3 mm or within 2 degrees. The setup accuracy of localizer box could be affected by the reproducibility of maskring, and this factor can be corrected in ExacTrac image guided system. Conclusion : For SRS, the setup error is usually required to be within 1 mm for rapid dose fall-off outside of the target, and headring can meet this requirement; maskring, usually used in the SRT, had larger setup error, and this should be taken into account in defining treatment target. The adoption of image guided system for double-check of the treatment center could be beneficial in reducing the setup error, especially in the SRT treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-181-187", "title": "\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u5c0d\u9f3b\u54bd\u764c\u6cbb\u7642\u5728\u7167\u91ce\u5916\u6563\u5c04\u5291\u91cf\u4e4b\u6e2c\u91cf", "keywords": "\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387;\u7167\u91ce\u5916\u7684\u6563\u5c04\u5291\u91cf;\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100;Rando\u4eba\u5f62\u5047\u9ad4 Cancer risks;Out-of-field scatter doses;Helical tomotherapy;Rando phantom", "c": "\u76ee\u7684\uff1a\u5229\u7528Rando\u4eba\u5f62\u5047\u9ad4\u57f7\u884c\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u6e2c\u91cf\u5404\u90e8\u4f4d\u7684\u5668\u5b98\u7167\u91ce\u5916\u53ef\u80fd\u63a5\u53d7\u7684\u6563\u5c04\u5291\u91cf\uff0c\u4e26\u63a2\u8a0e\u8a98\u767c\u53e6\u4e00\u500b\u764c\u75c7\u4e4b\u53ef\u80fd\u6027\u53ca\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c07\u6821\u6b63\u5b8c\u6210\u7684TLD-100H\u6309\u7167\u5404\u4e0d\u540c\u5668\u5b98\u7684\u4f4d\u7f6e\u7f6e\u5165\u65bcRando\u4eba\u5f62\u5047\u9ad4\u4e2d\uff0c\u4ee5\u5be6\u969b\u9f3b\u54bd\u764c\u75c5\u60a3\u6cbb\u7642\u7684\u60c5\u6cc1\uff0c\u5229\u7528\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u4f5c\u7167\u5c04\u53ca\u8a55\u4f30\uff0c\u4e26\u53c3\u914cICRP60\u865f\u5831\u544a\uff0c\u4ee5\u7e3d\u5291\u91cf72Gy\u4f86\u6c42\u5f97\u500b\u5225\u7d44\u7e54\u6216\u5668\u5b98\u7684\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u8207\u7e3d\u9ad4\u640d\u5bb3\u7684\u5371\u96aa\u5ea6\u3002\n\u7d50\u679c\uff1a\u773c\u7403\u6c34\u6676\u9ad4\u7684\u5e73\u5747\u7e3d\u5438\u6536\u5291\u91cf\u70ba3.91Gy\uff0c\u5fc3\u81df\u53ca\u814e\u81df\u5206\u5225\u662f0.49\u53ca0.11Gy\uff0c\u9060\u4f4e\u65bc\u5b83\u5011\u6240\u80fd\u63a5\u53d7\u7684\u8010\u53d7\u5291\u91cf\u3002\u6839\u64daICRP60\u865f\u5831\u544a\uff0c\u98df\u9053\u53ca\u80ba\u90e8\u53ef\u80fd\u67090.7~4.45%\u7684\u5371\u96aa\u5ea6\uff0c\u800c\u5176\u4ed6\u5668\u5b98\u7684\u5371\u96aa\u5ea6\u7d04\u7565\u70ba0.2~0.08%\uff0c\u800c\u5168\u8eab\u6709\u6548\u5291\u91cf\u7d04\u70ba0.52Sv\uff0c\u5176\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u7d04\u70ba2.6%\u3002\n\u7d50\u8ad6\uff1a\u5118\u7ba1\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u5728\u6cbb\u7642\u9f3b\u54bd\u764c\u75c5\u60a3\u6709\u5f88\u9ad8M.U.\u8f38\u51fa\uff0c\u4f46\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u7d50\u679c\u53ca\u6b63\u5e38\u7684\u7d44\u7e54\u8a98\u767c\u7b2c\u4e8c\u500b\u764c\u75c7\u7684\u5371\u96aa\u5ea6\u5f88\u4f4e\u3002\u501f\u6b64\u7814\u7a76\u80fd\u63d0\u4f9b\u7d66\u81e8\u5e8a\u91ab\u5e2b\u5c0d\u65bc\u75c5\u60a3\u65e5\u5f8c\u53ef\u80fd\u8a98\u767c\u7b2c\u4e8c\u500b\u764c\u75c7\u8ffd\u8e64\u7684\u4f9d\u64da\u3002", "e": "Purpose: To study associated cancer risks by measurements from out-of-field scatter doses with IMRT techniques such as helical tomotherapy with the use of an anthropomorphic Rando phantom.\nMaterials and Methods: A commercially available Rando phantom was placed on the treatment couch to simulate the patient treatment delivery under tomotherapy. Various calibrated TLD chips were placed at different anatomical locations for the dosimetry measurements. For nasopharyngeal cancer patient, tomotherapy was generated to deliver the radiation doses for evaluation. The clinical comparison is based on the ICRP-60 risk model analysis of critical organ doses after evaluation of the helical-IMRT techniques using 72Gy dose prescription and optimization criteria.\nResults: Len, heart and kidney received 3.91Gy, 0.49 and 0.11Gy respectively, which were far less than their maximal tolerance dose. According to the data calculation from ICRP Publication No.60 the lung and esophagus have about 0.7~4.45% risks, the risks for others organs were 0.2~0.08%. The whole body dose and fatal cancer probability rate recevied about 0.52Sv and 2.6% respectively.\nConclusion: Despite the overall higher M.U. delivery in tomotherapy, the overall whole body dose is lower risk probability of secondary malignancies induced by low dose radiation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-189-199", "title": "The Outcome of Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck", "keywords": "\u817a\u6a23\u56ca\u72c0\u764c;\u982d\u9838\u90e8;\u653e\u5c04\u6cbb\u7642;\u624b\u8853 Adenoid cystic carcinoma;Head and neck;Radiotherapy;Surgery", "c": "Purpose: To investigate treatment outcome of adenoid cystic carcinoma (ACC) of the head and neck region by surgery plus postoperative radiotherapy.\nMaterials and Methods: From June 1984 to August 2007, a total of 46 patients with ACC of the head and neck were analyzed. There were 23 males and 23 females with a median age of 55 years (range, 16-75). The primary sites included major salivary gland (18), sinonasal region (14), oral cavity (8), lacrimal gland (3), tongue base (2), and larynx (1). The major endpoint was overall survival (OS). The secondary endpoints were local failure-free survival (LFFS), metastasis-free survival (MFS) and cancer-specific survival (CSS).\nResults: After a median follow-up of 157 months, 24 of 46 patients had tumor relapse (7 local, 1 regional, 2 locoregional, 9 distant, 5 local plus distant). The 5-year rates of LFFS, MFS, OS and CSS were 73.1%, 74.0%, 75.3% and 80.1%, respectively. Univariate analysis revealed that female gender, younger age, early stage, good performance status, major salivary gland location and shorter interval between operation and radiotherapy were favorable prognostic factors for OS (P\uff1c0.05). The multivariate analysis revealed that performance status was the only significant prognostic factor that affected overall survival (hazard ratio, 8.47; 95% confidence interval, 1.85-38.64; P=0.006) and cancer-specific survival (hazard ratio, 9.23; 95% confidence interval, 1.63-52.10; P= 0.012).\nConclusion: The treatment outcomes of surgery plus postoperative radiotherapy for ACC of head and neck region were good with a 5-year overall survival rate of 75.3%. Performance status was the most important and independent prognostic factor.", "e": "Purpose: To investigate treatment outcome of adenoid cystic carcinoma (ACC) of the head and neck region by surgery plus postoperative radiotherapy.\nMaterials and Methods: From June 1984 to August 2007, a total of 46 patients with ACC of the head and neck were analyzed. There were 23 males and 23 females with a median age of 55 years (range, 16-75). The primary sites included major salivary gland (18), sinonasal region (14), oral cavity (8), lacrimal gland (3), tongue base (2), and larynx (1). The major endpoint was overall survival (OS). The secondary endpoints were local failure-free survival (LFFS), metastasis-free survival (MFS) and cancer-specific survival (CSS).\nResults: After a median follow-up of 157 months, 24 of 46 patients had tumor relapse (7 local, 1 regional, 2 locoregional, 9 distant, 5 local plus distant). The 5-year rates of LFFS, MFS, OS and CSS were 73.1%, 74.0%, 75.3% and 80.1%, respectively. Univariate analysis revealed that female gender, younger age, early stage, good performance status, major salivary gland location and shorter interval between operation and radiotherapy were favorable prognostic factors for OS (P\uff1c0.05). The multivariate analysis revealed that performance status was the only significant prognostic factor that affected overall survival (hazard ratio, 8.47; 95% confidence interval, 1.85-38.64; P=0.006) and cancer-specific survival (hazard ratio, 9.23; 95% confidence interval, 1.63-52.10; P= 0.012).\nConclusion: The treatment outcomes of surgery plus postoperative radiotherapy for ACC of head and neck region were good with a 5-year overall survival rate of 75.3%. Performance status was the most important and independent prognostic factor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-201-211", "title": "A Single Institute Experience of Radiotherapy for Treatment of Skull Base Chordoma and Literature Review", "keywords": "\u810a\u7d22\u7624;\u9871\u5e95;\u653e\u5c04\u6cbb\u7642 Chordoma;Skull base;Radiotherapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9871\u5e95\u810a\u7d22\u7624\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7d50\u679c\uff0c\u4e26\u5c0d\u6b64\u4e3b\u984c\u9032\u884c\u6587\u737b\u56de\u9867\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c0d\u81ea1984\u5e74\u81f32002\u5e74\uff0c\u65bc\u672c\u9662\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d\u90e8\u4efd\u4ea6\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u4e4b9\u4f4d\u9871\u5e95\u810a\u7d22\u7624\u60a3\u8005\uff0c\u9032\u884c\u56de\u6eaf\u6027\u7814\u7a76\u3002\u8a3a\u65b7\u6642\u4e4b\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba54\u6b72\uff08\u7bc4\u570d\u70ba4-70\u6b72\uff09\u3002\u6cbb\u7642\u7e3d\u5291\u91cf\u7bc4\u570d46-70Gy\uff0c\u4e2d\u4f4d\u6578\u70ba60Gy\u3002\u5b58\u6d3b\u75c5\u60a3\u4e4b\u4e2d\u4f4d\u8ffd\u8e64\u671f\u9593\u70ba94.2\u500b\u6708\uff08\u7bc4\u570d\u70ba24.4-245.2\u500b\u6708\uff09\u3002\n\u7d50\u679c\uff1a9\u4f4d\u60a3\u8005\u4e2d\u67094\u4f4d\u5c40\u90e8\u5fa9\u767c\u30023\u5e74\u53ca5\u5e74\u4e4b\u5c40\u90e8\u63a7\u5236\u7387\u7686\u70ba66.7%\u30023\u5e74\u53ca5\u5e74\u4e4b\u7e3d\u5b58\u6d3b\u7387\u5206\u5225\u70ba88.9%\u53ca63.5%\u30025\u4f4d\u6b7b\u4ea1\u7684\u60a3\u8005\u4e2d\uff0c3\u4f4d\u662f\u56e0\u75be\u75c5\u6216\u6cbb\u7642\u76f8\u95dc\u56e0\u7d20\u30022\u4f4d\u60a3\u8005\u63a5\u53d7\u6cbb\u7642\u5f8c\u816b\u7624\u660e\u986f\u7e2e\u5c0f\u30023\u4f4d\u5206\u5225\u65bc9\uff0c4\u53ca5\u6b72\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u5152\u7ae5\u60a3\u8005\uff0c\u5177\u6709\u76f8\u5c0d\u8f03\u9577\u4e4b\u5b58\u6d3b\u6642\u9593\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7814\u7a76\u986f\u793a\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u53ef\u6539\u5584\u9871\u5e95\u810a\u7d22\u7624\u4e4b\u5c40\u90e8\u63a7\u5236\uff0c\u4f46\u9bae\u80fd\u6cbb\u7652\u7121\u6cd5\u5207\u9664\u6216\u6b98\u9918\u816b\u7624\u91cf\u5927\u4e4b\u75be\u75c5\u3002\u6587\u737b\u986f\u793a\uff0c\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u53ca\u7c92\u5b50\u6cbb\u7642\u6709\u826f\u597d\u6210\u6548\u3002", "e": "Purpose: Clinical results evaluation of patients with skull base chordoma who received radiotherapy and review the literature on this topic.\nMaterials and Methods: Nine patients with skull base chordoma who were treated with external beam radiotherapy with or without surgery between 1984 and 2002 were retrospectively reviewed. The median age at diagnosis was 54 years old (range, 4-70 years old). The prescribed total tumor doses ranging from 46 to 70Gy were delivered with a median dose of 60Gy. The median follow-up of living patients was 94.2 months (range, 25.4-245.2 months).\nResults: Local failure developed in 4 of 9 patients. The local control rates at 3 and 5 years were both 66.7%. The overall survival rates at 3 and 5 years were 88.9% and 63.5%, respectively, with 5 deaths; Three deaths were disease-or treatment-related. Two patients had significant tumor regression after treatment. The 3 pediatric patients who received radiotherapy at ages 9, 4 and 5 years had relatively long overall survivals.\nConclusion: Our study demonstrates that conventional radiotherapy has a positive impact on local tumor control of skull base chordoma, but unresectable or overt residual diseases are rarely cured. In the literature, stereotactic radiosurgery and particle therapy results are promising."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-213-225", "title": "Prognostic Factors Affecting the Outcome of Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy Followed by Surgery", "keywords": "\u76f4\u8178\u764c;\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Rectal cancer;Preoperative chemoradiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u7d71\u8a08\u76f4\u8178\u764c\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\uff0c\u4e26\u4e14\u5206\u6790\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1999\u5e741\u6708\u52302007\u5e748\u6708\uff0c\u670970\u4f4d\u88ab\u8a3a\u65b7\u70ba\u76f4\u8178\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3002\u624b\u8853\u524d\u63a5\u53d7\u5316\u5b78\u6cbb\u7642(5-Fluorouracil+Leucovorin)\u548c\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff08\u5291\u91cf\u7bc4\u570d4140cGy\u81f35940cGy\uff09\u3002\u5728\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u4e4b\u5f8c\uff0c\u6240\u6709\u7684\u75c5\u4eba\u90fd\u6703\u63a5\u53d7\u6839\u9664\u6027\u7684\u624b\u8853\u3002\u8853\u5f0f\u5305\u62ecabdominoperineal resection, low anterior resection \u548cHartmann's procedure\u3002\u6211\u5011\u5206\u6790\u4ee5\u4e0b\u7684\u9810\u5f8c\u56e0\u5b50\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u5f71\u97ff\uff1a\u5e74\u9f61\u3001\u6027\u5225\u3001\u624b\u8853\u524d\u7684\u81e8\u5e8a\u5206\u671f\u3001\u624b\u8853\u5f8c\u7684\u75c5\u7406\u5206\u671f\u3001\u624b\u8853\u5207\u9664\u7684\u816b\u7624\u5927\u5c0f\u3001\u816b\u7624\u8207\u809b\u9580\u53e3\u7684\u8ddd\u96e2\u3002\n\u7d50\u679c\uff1a\u75c5\u4eba\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f60.3\u6b72\uff08\u7bc4\u570d\u4ecb\u65bc28\u81f385\u6b72\uff09\u3002\u670912\u500b\u75c5\u4eba(17.1%)\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c27\u500b\u75c5\u4eba(38.6%)\u767c\u751f\u9060\u8655\u8f49\u79fb\u3002\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u662f42\u500b\u6708\uff08\u7bc4\u570d\u5f9e3\u81f3114\u500b\u6708\uff09\u30021\u5e74\u30013\u5e74\u548c5\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba89.3%\u300152.9%\u53ca36.9%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u624b\u8853\u524d\u7684T\u5206\u671f\u3001\u624b\u8853\u5f8c\u7684N\u5206\u671f\u3001\u4ee5\u53ca\u624b\u8853\u5207\u9664\u7684\u816b\u7624\u5927\u5c0f\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u800c\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u624b\u8853\u524d\u7684T\u5206\u671f\u3001\u624b\u8853\u5f8c\u7684N\u5206\u671f\u3001\u4ee5\u53ca\u624b\u8853\u5207\u9664\u7684\u816b\u7624\u5927\u5c0f\u4ecd\u7136\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u8a8d\u70ba\u7576\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u4e4b\u5f8c\uff0c\u5728\u624b\u8853\u5207\u9664\u7684\u6a19\u672c\u4e2d\uff0c\u5982\u679c\u6dcb\u5df4\u7d50\u6709\u816b\u7624\u7d30\u80de\u7684\u5b58\u5728\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u6709\u91cd\u8981\u7684\u5f71\u97ff\u3002\u800c\u5728\u624b\u8853\u524d\u7684T\u5206\u671f\u548c\u624b\u8853\u6240\u5207\u9664\u7684\u816b\u7624\u5927\u65bc4\u516c\u5206\u4e5f\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u4e0d\u904e\u4ecd\u7136\u9700\u8981\u66f4\u5927\u578b\u7684\u7814\u7a76\u4f86\u78ba\u8a8d\u6211\u5011\u7684\u7d50\u8ad6\u4e26\u4e14\u627e\u51fa\u6700\u9069\u7576\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: The purpose of this study is to investigate the overall survival and local control of patients with rectal cancer scheduled to receive preoperative chemoradiotherapy (CRT). We analyze the prognostic factors affecting their outcomes.\nMaterials and Methods: From January 1999 to August 2007, 70 patients with the diagnosis of rectal cancer treated at our institution were included in this study. The preoperative treatment consisted of chemotherapy (5-Fluorouracil plus Leucovorin) and external-beam radiotherapy (ranged from 4140 cGy to 5940 cGy). After the CRT course, surgical intervention was performed in all of the patients. Surgical procedures included abdominoperineal resection, low anterior resection, and Hartmann's procedure. We analyzed the following factors to evaluate their impact on overall survival: age of diagnosis, gender, clinical T and N stage at initial diagnosis, pathologic T and N stage after surgery, tumor size at surgical resection, and distance of tumor from anal verge.\nResults: The median age of diagnosis of rectal cancer was 60.3 years old (ranged from 28 to 85 years old). Local recurrence occurred in 12 patients (17.1%) and distant metastasis occurred in 27 patients (38.6%). The median follow-up duration was 42 months (ranged from 3 to 114 months). The 1-year, 3-year and 5-year overall survival rates were 89.3%, 52.9% and 36.9%, respectively. In univariate analysis, clinical T stage (p=0.0047), pathologic N stage (p=0.0023), and tumor size at surgical resection (p=0.0009) were statistically significant prognostic factors for overall survival. In multivariate analysis, clinical T stage (p=0.017), pathologic N stage (p=0.004) and tumor size at surgical resection (p\uff1c0.001) were statistically significant prognostic factors for overall survival.\nConclusion: We concluded that the pathological specimens with regional lymph node involvement in the patient receiving preoperative CRT is a strongly prognostic factor for overall survival. Advanced clinical T stage and bulky tumor (\u22654cm) noted at surgical resection are also associated with poor overall survival. Further prospective studies which enroll more patients to evaluate the impact of pathologic lymph node status and to define the optimal management are warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-227-236", "title": "\u764c\u75c7\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u5c0d\u65bc\u670d\u52d9\u54c1\u8cea\u8207\u6eff\u610f\u5ea6\u4e4b\u8abf\u67e5\u7814\u7a76", "keywords": "\u670d\u52d9\u54c1\u8cea;\u6eff\u610f\u5ea6;\u653e\u5c04\u6cbb\u7642 Service quality;Satisfaction;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5f37\u5316\u670d\u52d9\u54c1\u8cea\u9032\u800c\u589e\u52a0\u75c5\u60a3\u4e4b\u6eff\u610f\u5ea6\u662f\u91ab\u7642\u6a5f\u69cb\u4e4b\u8cac\u4efb\u3002\u50b3\u7d71\u670d\u52d9\u54c1\u8cea\u4e4b\u6982\u5ff5\u662f\u5426\u9069\u7528\u65bc\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u764c\u75c7\u75c5\u60a3\u53ca\u5176\u5c0d\u75c5\u60a3\u6eff\u610f\u5ea6\u4e4b\u5f71\u97ff\u662f\u503c\u5f97\u63a2\u8a0e\u4e4b\u8b70\u984c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528\u4f9d\u7814\u7a76\u74b0\u5883\u4fee\u6539\u5f8c\u4e4bSERVQUAL\u4e94\u500b\u670d\u52d9\u54c1\u8cea\u69cb\u9762\u8207\u6eff\u610f\u5ea6\u8abf\u67e5\u91cf\u8868\uff0c\u81ea2007\u5e7411\u6708\u81f32008\u5e743\u6708\u70ba\u6b62\u5c0d203\u4f4d\u63a5\u53d7\u5b8c\u653e\u5c04\u6cbb\u7642\u4e4b\u764c\u75c7\u75c5\u60a3\u9032\u884c\u554f\u5377\u8abf\u67e5\u3002\u9032\u884c\u4fe1\u6548\u5ea6\u6aa2\u6e2c\uff0c\u6536\u96c6\u4eba\u53e3\u5b78\u8207\u81e8\u5e8a\u8b8a\u9805\uff0c\u4e26\u7d71\u8a08\u5206\u6790\u5f71\u97ff\u670d\u52d9\u54c1\u8cea\u8207\u6eff\u610f\u5ea6\u4e4b\u76f8\u95dc\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u91cf\u8868\u5404\u5b50\u984c\u4e4b\u6f0f\u7b54\u7387\u4ecb\u65bc0-1.5%\u3002\u4fe1\u6548\u5ea6\u6aa2\u6e2c\u986f\u793a\u5404\u69cb\u9762Cronbach's \u03b1\u503c\u4ecb\u65bc0.92\u81f30.96\uff08\u5927\u65bc\u9580\u6abb\u503c0.7\uff09\uff0c\u540c\u6642\u5177\u6709\u826f\u597d\u4e4b\u5340\u5225\u8207\u805a\u5408\u6548\u5ea6(discriminate and convergent validity)\u3002\u5728\u4eba\u53e3\u5b78\u8b8a\u9805\u90e8\u5206\uff0c\u986f\u793a\u7d93\u6fdf\u72c0\u6cc1\u6108\u4f73\u8005\u5c0d\u670d\u52d9\u54c1\u8cea\u4e4b\u4fdd\u8b49\u6027(p=0.03)\u53ca\u53cd\u61c9\u6027(p=0.02)\u7d71\u8a08\u4e0a\u5448\u73fe\u6709\u610f\u7fa9\u4e4b\u8f03\u9ad8\u8a55\u50f9\u3002\u81e8\u5e8a\u8b8a\u9805\u90e8\u5206\uff0c\u4e0d\u8ad6\u662f\u770b\u8a3a\u91ab\u5e2b\u5e74\u8cc7\u3001\u764c\u75c7\u671f\u5225\u3001\u653e\u5c04\u6cbb\u7642\u90e8\u4f4d\u3001\u653e\u5c04\u6cbb\u7642\u6280\u8853\u3001\u6216\u653e\u5c04\u6cbb\u7642\u5291\u91cf\uff0c\u5c0d\u4e94\u500b\u670d\u52d9\u54c1\u8cea\u69cb\u9762\u53ca\u6eff\u610f\u5ea6\u4e26\u7121\u4efb\u4f55\u7d71\u8a08\u4e0a\u6709\u610f\u7fa9\u4e4b\u5f71\u97ff\u3002\u591a\u8b8a\u9805\u5206\u6790\u986f\u793a\uff0c\u4e94\u500b\u670d\u52d9\u54c1\u8cea\u69cb\u9762\u4e2d\uff0c\u53cd\u61c9\u6027\u3001\u53ef\u9760\u6027\u8207\u4fdd\u8b49\u6027\u5c0d\u6eff\u610f\u5ea6\u5177\u7d71\u8a08\u4e0a\u6709\u610f\u7fa9\u4e4b\u5f71\u97ff(R^2=0.681)\u3002\n\u7d50\u8ad6\uff1a\u50b3\u7d71\u670d\u52d9\u54c1\u8cea\u4e4b\u6982\u5ff5\u662f\u9069\u7528\u65bc\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u764c\u75c7\u75c5\u60a3\uff0c\u91ab\u7642\u6a5f\u69cb\u85c9\u7531\u63d0\u9ad8\u5176\u91ab\u7642\u4eba\u54e1\u670d\u52d9\u4e4b\u53cd\u61c9\u6027\u3001\u53ef\u9760\u6027\u8207\u4fdd\u8b49\u6027\u53ef\u6709\u6548\u63d0\u5347\u75c5\u60a3\u6eff\u610f\u5ea6\u3002", "e": "Purpose: It is the duty of the medical institutes to increase the patients' satisfaction by improving their service quality. Whether the conventional used concept of service quality could be applied in cancer patients treated by radiotherapy is an issue to be investigated.\nMaterials and Methods: The constructed questionnaire incorporating the five service quality domains based on the environment-adjusted SERVQUAL questionnaire and the questionnaire about satisfaction was completed by 203 cancer patients after finishing the course of radiotherapy from Nov. 2007 to Mar. 2008. The psychometric test of the questionnaire was performed and the collected sociodemographic-and medical-related variables were analyzed for their association with the outcomes of service quality and satisfaction.\nResults: The missing rate of each question ranged 0-1.5%. The psychometric test revealed the value of Cronbach's \u03b1 was adequate (range: 0.92-0.96) for each domain, with excellent results in the discriminate and convergent validity. As regards the sociodemographic variables, only those patients with a higher socioeconomic level were observed to have a significantly better expression in the service quality domain of Assurance (p=0.03) and Reliability (p=0.02). On the contrast, no significant correlation was observed between the variables of the seniority of the attending physicians, cancer stages, radiation sites, radiation techniques, or the radiation doses with the outcomes of the five service quality domains and patients' satisfaction. In the multivariate analysis, we found the service quality domains of Responsiveness, Reliability, and Assurance were significant predictors correlated with patients' satisfaction (R^2=0.681 in the model).\nConclusion: The conventional used concept of service quality could be applied in cancer patients treated by radiotherapy. The medical institutes could increase the patients\u2019 satisfaction by improving their service quality of Responsiveness, Reliability, and Assurance."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-237-243", "title": "Radiation Recall Dermatitis: A Case Report and Review of Literature", "keywords": "\u653e\u5c04\u7dda\u56de\u61b6\u76ae\u819a\u708e;\u5b83\u83ab\u897f\u82ac;5-\u6c1f\u5c3f\u5627\u5576;\u6cdb\u827e\u9ef4\u7d20;\u764c\u5f97\u661f Radiation recall dermatitis;Tamoxifen;5-FU;Eplrubicin;Endoxan", "c": "\u653e\u5c04\u7dda\u56de\u61b6\u76ae\u819a\u708e\u4e26\u975e\u5e38\u898b\u4e4b\u653e\u5c04\u7dda\u53cd\u61c9\u3002\u672c\u6587\u5c07\u5831\u544a\u4e0040\u6b72\u5973\u6027\u4e73\u764c\u6848\u4f8b\u3002\u6b64\u6848\u4f8b\u4f9d\u5e8f\u63a5\u53d7\u624b\u8853\u3001\u8377\u723e\u8499\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u4ee5\u53ca\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u65bc\u5316\u5b78\u6cbb\u7642\u7d50\u675f\u5f8c\u5728\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5340\u57df\u7522\u751f\u7d05\u816b\u4ee5\u53ca\u58d3\u75db\u7684\u8868\u73fe\u3002\u672c\u6587\u91dd\u5c0d\u6b64\u500b\u6848\u7684\u8a3a\u65b7\u904e\u7a0b\u52a0\u4ee5\u8a0e\u8ad6\uff0c\u4e26\u4e14\u56de\u9867\u76f8\u95dc\u6587\u737b\u52a0\u4ee5\u63a2\u8a0e\u3002", "e": "Radiation recall dermatitis is not a common phenomenon. We present a case of 40-year-old female who is a victim of breast cancer. She has received: in the sequence of operation, hormone therapy, radiotherapy, and then chemotherapy. However, swollen skin with pain within previous radiation region was immediately observed after completion of chemotherapy. We have encountered the difficulty to differentiate the cause of the skin change. After further survey and evaluation, radiation recall dermatitis was diagnosed. Previous reports are reviewed and treatment decision making of this case is discussed in this article."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-245-250", "title": "Radiation Therapy for Trichoepithelioma: Case Report", "keywords": "\u6bdb\u9aee\u4e0a\u76ae\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Trichoepithelioma;Radiation therapy", "c": "\u76ee\u7684\uff1a\u6bdb\u9aee\u4e0a\u76ae\u7624\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u6e90\u65bc\u6bdb\u56ca\u7684\u76ae\u819a\u816b\u7624\uff0c\u597d\u767c\u65bc\u982d\u9838\u90e8\u5982\u982d\u76ae\u3001\u984d\u982d\u3001\u9f3b\u5b50\u3001\u81c9\u90e8\u548c\u5507\u90e8\uff0c\u5e38\u5f15\u8d77\u7f8e\u89c0\u4e0a\u7684\u56f0\u64fe\u6216\u662f\u529f\u80fd\u4e0a\u7684\u969c\u7919\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f8b\u591a\u767c\u6027\u6bdb\u9aee\u4e0a\u76ae\u7624\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u986f\u8457\u6cbb\u7642\u6210\u679c\u3002\n\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u540d57\u6b72\u7684\u5a66\u5973\u767c\u73fe\u7f79\u60a3\u8a31\u591a\u6bdb\u9aee\u4e0a\u76ae\u7624\u65bc\u5169\u5074\u7684\u7709\u6bdb\u4e0a\uff0c\u4e09\u5e74\u591a\u4f86\u5979\u63a5\u53d7\u904e\u8a31\u591a\u7a2e\u6cbb\u7642\uff0c\u5305\u62ec\u5857\u62b9\u985e\u56fa\u9187\u53ca\u5176\u4ed6\u4e0d\u660e\u7684\u85e5\u7269\uff1b\u53e3\u670d\u6297\u751f\u7d20\u3001\u51b7\u51cd\u6cbb\u7642\u3001\u78e8\u76ae\u624b\u8853\u53ca\u96f7\u5c04\u6cbb\u7642\u7b49\u7b49\u5747\u7121\u6548\uff0c\u5f8c\u4f86\u5979\u63a5\u53d750Gy 20\u6b21\u76846\u767e\u842c\u96fb\u5b50\u4f0f\u7279\u7684\u96fb\u5b50\u5c04\u7dda\u653e\u5c04\u6cbb\u7642\uff0c\u816b\u7624\u56e0\u6b64\u5f97\u5230\u5b8c\u5168\u7de9\u89e3\uff0c\u6cbb\u7642\u81f3\u4eca\u5df218\u500b\u6708\uff0c\u6c92\u6709\u816b\u7624\u5fa9\u767c\u7684\u8de1\u8c61\u4e14\u5916\u89c0\u6b63\u5e38\uff0c\u6c92\u6709\u7f8e\u89c0\u4e0a\u7684\u56f0\u64fe\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u7d93\u904e\u6cbb\u7642\u5931\u6557\u6216\u662f\u56e0\u6cbb\u7642\u6703\u5f15\u8d77\u7f8e\u89c0\u6216\u662f\u529f\u80fd\u969c\u7919\u7684\u6bdb\u9aee\u4e0a\u76ae\u7624\u800c\u8a00\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u679c\u4e5f\u5f88\u597d\uff0c\u61c9\u662f\u53e6\u4e00\u500b\u9078\u64c7\u3002", "e": "Background: Trichoepithelioma is a rare skin tumor that arises from hair follicles. The most common locations are in the scalp, forehead, nose and upper lip and can cause significant cosmetic and functional impairment. In this study, we report a case of multiple trichoepitheliomas treated by radiation therapy which demonstrated a dramatic response with a significant cosmetic improvement.\nCase: A 57-year-old woman suffered from multiple coalesced lesions of trichoepitheliomas in her bilateral eyebrows for three years. She had received numerous treatments including topical steroid and unknown drugs use, oral antibiotics, cryotherapy, dermabrasion and laser surgery which all had failed. She then received radiation therapy with 50Gy in 20 fractions by 6-MeV electron beams. She is free of tumor in the irradiated area 18 months after treatment with significant cosmetic improvement.\nConclusion: Radiation therapy should be an alternative for patients with trichoepitheliomas who have failed other forms of treatment and those with multiple coalesced lesions that cause significant cosmetic or functional impairment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201009-201008270035-201008270035-251-257", "title": "A Case Report: Urachal Adenocarcinoma", "keywords": "\u81cd\u5c3f\u7ba1\u817a\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u8840\u5c3f Urachal adenocarcinoma;Hematuria;Radiation therapy", "c": "\u81cd\u5c3f\u7ba1\u817a\u7624\u70ba\u4eba\u985e\u80da\u80ce\u767c\u80b2\u671f\u9593\u6240\u6b98\u5b58\u81cd\u5c3f\u7ba1\u8655\uff0c\u662f\u4e00\u7a2e\u975e\u5e38\u7f55\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u53ea\u5360\u6240\u6709\u60e1\u6027\u816b\u7624\u76840.01%\uff0c\u5373\u4f7f\u5c0d\u65bc\u8180\u80f1\u764c\u4e5f\u50c5\u50c5\u53ea\u4f54\u67090.7%\u3002\u540c\u6642\u56e0\u70ba\u5f80\u5f80\u4e0d\u6613\u8a3a\u65b7\u53ca\u9ad8\u60e1\u6027\u5ea6\uff0c\u6240\u4ee5\u5373\u4f7f\u767c\u73fe\u5f8c\uff0c\u5b83\u7684\u9810\u5f8c\u4e5f\u76f8\u7576\u4e0d\u597d\u3002\u9019\u88e1\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f4d\u81cd\u5c3f\u7ba1\u817a\u7624\u7684\u6848\u4f8b\u300244\u6b72\u7684\u5973\u6027\uff0c\u8d77\u521d\u53ea\u662f\u8840\u5c3f\u75c7\u72c0\uff0c\u5f8c\u4f86\u57282008\u5e746\u6708\u65bc\u672c\u9662\u7d93\u5f71\u50cf\u8207\u7d30\u80de\u75c5\u7406\u5207\u7247\uff0c\u8a3a\u65b7\u70ba\u81cd\u5c3f\u7ba1\u817a\u7624\uff0c\u4e4b\u5f8c\u5b89\u6392\u624b\u8853\u5207\u9664\u6cbb\u7642\u3002\u4e26\u5b89\u6392\u5728\u624b\u8853\u4e00\u500b\u6708\u5f8c\uff0c\u958b\u59cb\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u52302009\u5e747\u6708\u7684\u6700\u5f8c\u4e00\u6b21\u9580\u8a3a\u8ffd\u8e64\u671f\u9593\uff0c\u90fd\u6c92\u6709\u816b\u7624\u5c40\u90e8\u5fa9\u767c\u8207\u9060\u8655\u8f49\u79fb\u7684\u60c5\u6cc1\u767c\u751f\uff0c\u5728\u6b64\u4e5f\u63d0\u4f9b\u4e00\u4e9b\u81e8\u5e8a\u4e0a\u7684\u7d93\u9a57\u8207\u6cbb\u7642\u53c3\u8003\u3002", "e": "Urachal adenocarcinoma is an extremely rare neoplasm and usually associated with poor prognosis. We report a case of urachal adenocarcinoma in one 44-year-old woman. She presented painless hematuria. Cystoscopic examination and transurethral biopsy showed an urachal tumor. After undergoing laparoscopic partial cystectomy with lymph nodes dissection, the patient received postoperative radiation therapy. The clinical presentation, radiological, histopathological findings, treatment methods and correlated literature are discussed and reviewed here."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-85-99", "title": "Long-Term Outcomes of Radiotherapy for Primary Pediatric Brain Tumors: Statistics and Strategies of a Single Institute in Taiwan", "keywords": "\u539f\u767c\u5152\u7ae5\u8166\u7624;\u653e\u5c04\u6cbb\u7642;\u5b58\u6d3b\u7387;\u96fb\u5b50\u767b\u9304\u7cfb\u7d71 Primary pediatric brain tumors;Radiotherapy;Survival;Electronic registry system", "c": "\u76ee\u7684\uff1a\u5728\u53f0\u7063\uff0c\u5152\u7ae5\u8166\u7624\u7684\u9577\u671f\u8ffd\u8e64\u5831\u544a\u4ecd\u70ba\u5c11\u898b\uff0c\u6211\u5011\u767c\u5c55\u4e86\u4e00\u5957\u96fb\u5b50\u767b\u9304\u7cfb\u7d71(ERS)\uff0c\u4e26\u4ee5\u4e4b\u5efa\u7acb\u4e86\u4e00\u500b\u5152\u7ae5\u8166\u7624\u8cc7\u6599\u5eab\uff0c\u5176\u4e2d\u5305\u542b\u4e86\u81ea\u897f\u51431975\u5e741\u6708\u8d77\u81f32004\u5e745\u6708\u6b62\u7684986\u4f4d\u5c0f\u65bc18\u6b72\u7684\u5152\u7ae5\u8166\u7624\u75c5\u6b77\uff0c\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u5206\u6790\u5176\u4e2d\u66fe\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684371\u500b\u75c5\u4eba\u5b58\u6d3b\u5206\u6790\u72c0\u6cc1\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u672c\u9662\u539f\u59cb\u764c\u75c7\u767b\u8a18\u8cc7\u6599\u5eab\u4e2d\uff0c\u5171\u8a18\u9304529\u500b\u539f\u767c\u5152\u7ae5\u8166\u7624\u75c5\u4f8b\u66fe\u65bc1975\u5e741\u6708\u81f32004\u5e745\u6708\u63a5\u53d7\u904e\u653e\u5c04\u6cbb\u7642\uff0c\u6211\u5011\u900f\u904e\u8abf\u95b1\u539f\u59cb\u653e\u5c04\u6cbb\u7642\u4e4b\u7d19\u672c\u8cc7\u6599\u4e26\u8a18\u9304\u65bc\u65b0\u5efa\u4e4b\u96fb\u5b50\u767b\u9304\u7cfb\u7d71(ERS)\u4e2d\uff0c\u7e3d\u5171\u6709371\u4f4d\u5177\u5b8c\u6574\u8cc7\u6599(70.1%)\u3002\u4f9d\u7167\u4e0d\u540c\u7684\u5152\u7ae5\u8166\u7624\u5206\u985e\uff0c\u7d71\u8a08\u5176\u7537\u5973\u6bd4\u3001\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u6b7b\u4ea1\u75c5\u4f8b\u6578\u3001\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u6642\u7684\u5e74\u9f61\u3001\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u3001\u548c\u5404\u75be\u75c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u6bd4\u7387\u3002\u4e26\u5206\u6790\u6578\u7a2e\u75be\u75c5\u4e4b\u7e3d\u5b58\u6d3b\u7387(overall survival)\u53ca\u90e8\u5206\u75be\u75c5\u4e4b\u7121\u60e1\u5316\u5b58\u6d3b\u7387(progression-free survival)\u6216\u653e\u5c04\u6cbb\u7642\u5f8c\u7121\u5931\u6557\u5b58\u6d3b\u7387(post-radiotherapy failure-free survival)\u3002\u7d50\u679c\uff1a\u5728371\u500b\u66fe\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u4e2d\uff0c\u9ad3\u6bcd\u7d30\u80de\u7624(medulloblastoma)\u6240\u4f54\u4eba\u6578\u6700\u9ad8(n=93)\uff0c\u5176\u6b21\u4f9d\u5e8f\u662f\u751f\u6b96\u6027\u7d30\u80de\u80da\u82bd\u7624(germinoma; n=59)\uff0c\u661f\u72c0\u7d30\u80de\u7624(astrocytoma, WHO grade \u2161; n=36)\uff0c\u518d\u751f\u4e0d\u826f\u6027\u661f\u72c0\u7d30\u80de\u7624(anaplastic astrocytoma, WHO grade \u2162; n=36)\u548c\u8166\u5e79\u816b\u7624(brain stem tumor, n=29)\u3002\u9ad3\u6bcd\u7d30\u80de\u7624\u3001\u975e\u5178\u578b\u7578\u80ce\uff0f\u985e\u6a6b\u7d0b\u808c\u7d30\u80de\u7624(atypical teratoid/rhabdoid tumor)\u3001\u661f\u72c0\u7d30\u80de\u7624\u3001\u518d\u751f\u4e0d\u826f\u6027\u661f\u72c0\u7d30\u80de\u7624\u3001\u81a0\u8cea\u6bcd\u7d30\u80de\u7624(glioblastoma)\u548c\u751f\u6b96\u6027\u7d30\u80de\u80da\u82bd\u7624\u7b49\u75be\u75c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u6bd4\u7387\u5206\u5225\u70ba70.9%\u300190.4%\u300148.65%\u300180.0%\u300141.0%\u548c78.6%\u3002\u6240\u6709\u75be\u75c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u5f8c\u7684\u7e3d\u6b7b\u4ea1\u7387\u70ba43.93%\u3002\u9ad3\u6bcd\u7d30\u80de\u7624\u3001\u661f\u72c0\u7d30\u80de\u7624\u3001\u518d\u751f\u4e0d\u826f\u6027\u661f\u72c0\u7d30\u80de\u7624\u3001\u548c\u751f\u6b96\u6027\u7d30\u80de\u80da\u82bd\u7624\u7b49\u75be\u75c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u76845\u5e74\u7e3d\u5b58\u6d3b\u7387(overall survival)\u5206\u5225\u70ba81.73%\u300171.49%\u300125.34%\u548c88.94%\u3002\u9ad3\u6bcd\u7d30\u80de\u7624\u76845\u5e74\u7121\u60e1\u5316\u5b58\u6d3b\u7387(progression-free survival)\u662f66.46%\u3002\u975e\u5178\u578b\u7578\u80ce\uff0f\u985e\u6a6b\u7d0b\u808c\u7d30\u80de\u7624\u7684\u4e2d\u9593\u7e3d\u5b58\u6d3b\u7387(median overall survival)\u548c\u4e2d\u9593\u653e\u5c04\u6cbb\u7642\u5f8c\u7121\u5931\u6557\u5b58\u6d3b\u7387(median post-radiotherapy failure-free survival)\u5206\u5225\u70ba17\u500b\u6708\u548c11\u500b\u6708\u3002\u53e6\u5916\uff0c\u67097\u4f4d\u60a3\u8005(1.89%)\u65bc\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\u4e00\u6bb5\u6642\u9593\uff082.8\u81f324\u5e74\uff1b\u4e2d\u4f4d\u657819.7\u5e74\uff09\uff0c\u7f79\u60a3\u53ef\u80fd\u8207\u5148\u524d\u653e\u5c04\u6cbb\u7642\u6709\u95dc\u4e4b\u9871\u5167\u7b2c\u4e8c\u7a2e\u816b\u7624\u3002\n\u7d50\u8ad6\uff1a\u96fb\u5b50\u767b\u9304\u7cfb\u7d71(ERS)\u53ef\u6709\u6548\u4fbf\u5229\u5354\u52a9\u904e\u5f80\u7f55\u898b\u5152\u7ae5\u8166\u7624\u75be\u75c5\u4e4b\u8cc7\u6599\u4fdd\u5b58\u53ca\u76f8\u95dc\u7d71\u8a08\u7684\u5206\u6790\u9032\u884c\uff0c\u672c\u7814\u7a76\u5831\u544a\u4e4b\u6bd4\u7387\u7d71\u8a08\u548c\u5b58\u6d3b\u5206\u6790\u7686\u8207\u904e\u5f80\u6587\u737b\u4e2d\u520a\u8f09\u7684\u6578\u64da\u76f8\u7576\uff0c\u6b64\u5152\u7ae5\u8166\u7624\u8cc7\u6599\u5eab\u503c\u5f97\u7e7c\u7e8c\u904b\u4f5c\uff0c\u671f\u671b\u5c07\u63d0\u4f9b\u76f8\u7576\u591a\u5bf6\u8cb4\u7684\u8cc7\u6599\u7d66\u672a\u4f86\u7684\u7814\u7a76\u4e4b\u9032\u884c\u3002", "e": "Purpose In Taiwan, data regarding the long-term outcomes of radiotherapy for pediatric brain tumors are still rare. We developed an electronic registry system (ERS) that can help to establish a database, which consisted of 986 cases of primary brain tumors in children younger than 18 years of age in Taipei Veterans General Hospital from January 1975 to May 2004. In this study, we focused on the long-term outcomes of 371 available patients treated by radiotherapy.\nMaterials and Methods: In our original cancer registry data, there were 529 pediatric brain tumor patients who underwent radiotherapy between January 1975 and May 2004. However, after reviewing the cases, only 371 cases (70.1%) were fully recorded without missing data. Profiles of radiotherapy for these patients were input into our newly established ERS. The demographic data were analyzed, including classification of tumors, gender distribution, mortality case numbers after radiotherapy, age at treatment, dose profile of radiotherapy, and proportion of patients receiving radiotherapy. For some diseases of interest, overall survival, progression-free survival and postradiotherapy failure-free survival were also analyzed by the Kaplan-Meier method.\nResults: Of the 371 patients receiving radiotherapy, treatment for medulloblastomas is the most common (n=93), followed by germinomas (n=59), astrocytomas (n=36), anaplastic astrocytomas (n=36) and brain stem tumors (n=29). The proportions of patients receiving radiotherapy for medulloblastomas, atypical teratoid/rhabdoid tumors, astrocytomas (grade \u2161), anaplastic astrocytomas, glioblastomas and germinomas were 70.9%, 90.4%, 48.65%, 80.0%, 41.0% and 78.6%, respectively. The pooled mortality rate of all diseases after radiotherapy was 43.93%. The five-year overall survival rates of medulloblastomas, astrocytomas (grade \u2161), anaplastic astrocytomas and germinomas were 81.73%, 71.49%, 25.34% and 88.94%, respectively. The 5-year progression-free survival of medulloblastomas was 66.46%. Additionally, seven patients (1.89%) suffered from radiation-induced secondary tumors after completion of radiotherapy for a period of time (range, 2.8 to 24 years; median, 19.7 years).\nConclusion: An electronic registry system can help to facilitate the statistical analysis for rare pediatric brain tumor data. Our demographic and survival analyses were mostly comparable with those of previous studies. The database of pediatric brain tumors is worthy continuing to provide materials for further studies."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-101-112", "title": "Preliminary Results of Intensity-Modulated Radiotherapy in the Treatment of Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u5316\u5b78\u6cbb\u7642 Nasopharyngeal carcinoma;Intensity-modulated radiotherapy;Concomitant chemotherapy", "c": "\u76ee\u7684\uff1a\u5831\u544a\u6211\u5011\u4ee5\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u9f3b\u54bd\u764c\u4e4b\u521d\u6b65\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65bc2005\u5e745\u6708\u81f32008\u5e747\u6708\u9593\uff0c\u5171\u670958\u4f4d\u9f3b\u54bd\u764c\u60a3\u8005\u65bc\u4f5b\u6559\u6148\u6fdf\u7d9c\u5408\u91ab\u9662\u53f0\u5317\u5206\u9662\u63a5\u53d7\u6cbb\u7652\u6027\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u4eba\u6027\u5225\u70ba17\u4f4d\u5973\u6027\uff0c41\u4f4d\u7537\u6027\uff1b\u4e2d\u4f4d\u5e74\u9f61\u70ba51.5\u6b72\uff08\u7bc4\u570d27\u81f388\u6b72\uff09\u3002\u816b\u7624\u5206\u671f\u70ba\u7b2c\u4e00\u671f3\u4f4d(5%)\u3001\u7b2c\u4e8c\u671f12\u4f4d(21%)\u3001\u7b2c\u4e09\u671f29\u4f4d(50%)\u53ca\u7b2c\u56db\u671f14\u4f4d(24%)\u3002\u7531\u591a\u8449\u6e96\u76f4\u5100\u4ee5\u52d5\u614b\u65b9\u5f0f\u57f7\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u300231\u4f4d\u75c5\u4eba\u63a5\u53d7cisplatin\u53ca5FU\u4e4b\u540c\u6b65\u5316\u5b78\u6cbb\u7642\uff1b17\u4f4d\u75c5\u4eba\u50c5\u63a5\u53d7cisplatin\u300231\u4f4d\u75c5\u4eba\u63a5\u53d7cisplatin\u53ca5FU\u4e4b\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u3002\u539f\u767c\u816b\u7624\u53ca\u8f49\u79fb\u6dcb\u5df4\u7bc0\u4e4b\u6cbb\u7642\u5291\u91cf\u70ba66-72Gy\uff0c\u672a\u6709\u8f49\u79fb\u6dcb\u5df4\u7bc0\u5340\u57df\u4e4b\u6cbb\u7642\u5291\u91cf\u70ba46.8-50Gy\u3002\u6211\u5011\u4ee5Radiation Therapy Oncology Group (RTOG)\u526f\u4f5c\u7528\u5206\u7d1a\u8a18\u9304\u6025\u6027\u53ca\u665a\u671f\u526f\u4f5c\u7528\u3002\u4ee5Kaplan-Meier\u65b9\u6cd5\u8a08\u7b97\u5c40\u90e8\u63a7\u5236\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u53ca\u6dcb\u5df4\u63a7\u5236\u5b58\u6d3b\u7387\u3001\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u53ca\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\n\u7d50\u679c\uff1a\u4e2d\u4f4d\u8ffd\u8e64\u671f\u70ba19.3\u500b\u6708\uff08\u7bc4\u570d7\u81f341\u500b\u6708\uff09\u3002\u5c40\u90e8\u5fa9\u767c\u75c5\u4f8b\u6578\u70ba11\u4f4d\uff0c\u6dcb\u5df4\u5fa9\u767c\u75c5\u4f8b\u6578\u70ba7\u4f4d\uff0c\u9060\u7aef\u8f49\u79fb\u75c5\u4f8b\u6578\u70ba7\u4f4d\uff0c\u5176\u4e2d6\u4f4d\u75c5\u4eba\u5df2\u6b7b\u4ea1\u3002\u4e8c\u5e74\u5c40\u90e8\u63a7\u5236\u5b58\u6d3b\u7387\u70ba78%\u3001\u5c40\u90e8\u53ca\u6dcb\u5df4\u63a7\u5236\u5b58\u6d3b\u7387\u70ba74%\u3001\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u70ba85%\u53ca\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba86%\u3002\u591a\u8b8a\u6578\u5206\u6790\u986f\u793a\uff0c\u816b\u7624\u5206\u671f\u70ba\u552f\u4e00\u5f71\u97ff\u5c40\u90e8\u53ca\u6dcb\u5df4\u5fa9\u767c\u7684\u56e0\u7d20\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5408\u4f75cisplatin\u53ca5FU\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u8207\u50c5\u5408\u4f75\u4f7f\u7528cisplatin\u6709\u76f8\u4f3c\u4e4b\u6cbb\u7642\u7d50\u679c\uff0c\u4f46\u6025\u6027\u526f\u4f5c\u7528\u8f03\u56b4\u91cd\u3002\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5f8c19.3\u500b\u6708\uff08\u4e2d\u4f4d\u6578\uff09\uff0c\u75c5\u60a3\u53e3\u4e7e\u7a0b\u5ea6\u70ba\u7b2c3\u7d1a7%\u3001\u7b2c2\u7d1a41%\u3001\u7b2c1\u7d1a26%\u3001\u7b2c0\u7d1a2%\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u70ba\u4ee5\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u9f3b\u54bd\u764c\u4e4b\u521d\u6b65\u5831\u544a\u3002\u61c9\u8003\u616e\u6bd4\u8f03\u5408\u4f75cisplatin\u53ca5FU\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u8207\u50c5\u5408\u4f75\u4f7f\u7528cisplatin\u4e4b\u5dee\u5225\u3002\u7d2f\u7a4d\u8f03\u591a\u75c5\u4f8b\u6578\u53ca\u8f03\u9577\u4e4b\u8ffd\u8e64\u6642\u9593\u6709\u52a9\u65bc\u78ba\u7acb\u672c\u7814\u7a76\u4e4b\u7d50\u679c\u3002", "e": "Purpose: To report our initial experience with intensity-modulated radiotherapy (IMRT) in the treatment of nasopharyngeal carcinoma (NPC).\nMaterials and Methods: Between May 2005 and July 2008, 58 patients underwent definitive IMRT for NPC in the Buddhist Tzu Chi General Hospital, Taipei Branch. There were 17 females and 41 males, with a median age of 51.5 (range 27-88). The disease was Stage \u2160 in 3 (5%), Stage \u2161 in 12 (21%), Stage \u2162 in 29 (50%), and Stage \u2163 in 14 (24%). IMRT was delivered using a dynamic multileaf collimator. Thirty-one patients received concomitant cisplatin and 5FU, and seventeen patients received concomitant cisplatin. Among them, thirty-one patients received adjuvant cisplatin and 5-FU chemotherapy. The prescribed dose was 66-72 Gy to the gross tumor volume and positive neck nodes, 46.8-50 Gy to the clinically negative neck. Acute and late normal tissue effects were graded according to the Radiation Therapy Oncology Group (RTOG) radiation morbidity scoring criteria. The local control, local-regional control, distant metastasis-free, and the overall survival rates were calculated using the Kaplan-Meier method.\nResults : With a median follow-up of 19.3 months (range 7 to 41 months), there were 11 local recurrences at the primary site. Seven patients failed in the neck. Seven patients developed distant metastases; 6 of these patients died. The 2-year local control, local-regional control, and distant metastases-free rates were 78%, 74%, and 85% respectively. The 2-year overall survival was 86%. With 11 and 13 patents experiencing local and locoregional failure, only stage of disease was a significant predictor by multivariate analysis. IMRT with concomitant cisplatin and 5FU had treatment outcomes similar to IMRT with concomitant cisplatin alone, but this regimen was associated with more severe acute toxicity. At 19.3 months (median) after IMRT, 7% of the patients had Grade 3 xerostomia, 41% had Grade 2, 26% had Grade 1 and 2% had no xerostomia.\nConclusion: Our preliminary results using IMRT for treatment of NPC were reported. Further study to compare concomitant cisplatin and 5FU with cisplatin alone is warranted. A larger case number and longer follow-up time were needed to confirm our preliminary results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-113-123", "title": "The Impact of Dynamic Parotid Volume Changes and Body Weight Loss on Dose Distributions for Patients with Nasopharyngeal Cancer Receiving Intensity-Modulated Radiation Therapy", "keywords": "\u9f3b\u54bd\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u816e\u817a;\u9ad4\u91cd\u6e1b\u8f15;\u653e\u5c04\u6cbb\u7642\u8a08\u756b Nasopharyngeal neoplasm;Intensity-modulated radiotherapy;Parotid gland;Weight loss;Radiotherapy planning", "c": "\u76ee\u7684\uff1a\u5c0d\u65bc\u9f3b\u54bd\u764c\u800c\u8a00\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5df2\u6210\u70ba\u5177\u5c55\u671b\u7684\u65b0\u6cbb\u7642\u65b9\u6cd5\uff0c\u53ef\u4ee5\u63d0\u4f9b\u826f\u597d\u7684\u816b\u7624\u5305\u8986\u4e26\u4e14\u6709\u610f\u7fa9\u7684\u4fdd\u7559\u816e\u817a\u7684\u529f\u80fd\u3002\u672c\u7814\u7a76\u76ee\u7684\u5728\u65bc\u91cf\u5316\u5c0d\u65bc\u986f\u8457\u7684\u9ad4\u91cd\u6e1b\u8f15\u8207\u5426\u5c0d\u816e\u817a\u9ad4\u7a4d\u7684\u7e2e\u5c0f\u7684\u5f71\u97ff\u4ee5\u53ca\u816e\u817a\u9ad4\u7a4d\u7684\u7e2e\u5c0f\u5c0d\u65bc\u816e\u817a\u7684\u5291\u91cf\u5206\u5e03\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2003\u5e742\u6708\u52302005\u5e7410\u6708\uff0c\u5171\u6536\u96c6\u4e8630\u500b\u75c5\u4eba\u300213\u500b\u75c5\u4eba\u6709\u986f\u8457\u7684\u9ad4\u91cd\u6e1b\u8f15\u3002\u5728\u6bcf\u500b\u75c5\u4eba\u63a5\u53d7\u7684\u5291\u91cf\u5230\u905441.4Gy\u523046.8Gy\u7684\u6642\u5019\uff0c\u6703\u8b93\u75c5\u4eba\u518d\u505a\u4e00\u6b21\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\uff0c\u7372\u5f97\u7b2c\u4e8c\u7d44\u7528\u4f86\u505a\u6cbb\u7642\u8a08\u756b\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff0c\u505a\u51fa\u7b2c\u4e8c\u500b\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u8a08\u756b\uff08\u65b0\u6cbb\u7642\u8a08\u756b\uff09\u3002\u53e6\u5916\uff0c\u5728\u5047\u8a2d\u6c92\u6709\u7b2c\u4e8c\u7d44\u7528\u4f86\u505a\u6cbb\u7642\u8a08\u756b\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u7684\u60c5\u5f62\u4e4b\u4e0b\uff0c\u5c0d\u65bc\u539f\u4f86\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\uff0c\u6211\u5011\u4e5f\u6703\u505a\u51fa\u53e6\u4e00\u500b\u6cbb\u7642\u8a08\u756b\uff08\u65b0\u6df7\u5408\u578b\u6cbb\u7642\u8a08\u756b\uff09\u3002\n\u7d50\u679c\uff1a\u75c5\u4eba\u8eab\u9ad4\u8f2a\u5ed3\u7684\u7e2e\u6e1b\u548c\u9ad4\u91cd\u6e1b\u8f15\u6709\u9ad8\u5ea6\u76f8\u95dc\u3002\u4e0d\u7ba1\u9ad4\u91cd\u6709\u7121\u986f\u8457\u7684\u6e1b\u8f15\uff0c\u816e\u817a\u9ad4\u7a4d\u90fd\u6703\u7e2e\u5c0f\u3002\u5728\u6bd4\u8f03\u201c\u65b0\u6cbb\u7642\u8a08\u756b\u201d\u548c\u201c\u65b0\u6df7\u5408\u578b\u6cbb\u7642\u8a08\u756b\u201d\u7684\u5291\u91cf\u5206\u5e03\u4e4b\u5f8c\uff0c\u6211\u5011\u767c\u73fe\u5169\u8005\u5728\u816b\u7624\u76ee\u6a19\u7684\u5305\u8986\u4e0a\u4e26\u6c92\u6709\u986f\u8457\u7684\u5291\u91cf\u5dee\u7570\u3002\u4f46\u662f\u5728\u8166\u5e79\uff0c\u810a\u9ad3\u4ee5\u53ca\u5169\u5074\u7684\u816e\u817a\u5247\u767c\u73fe\u5728\u65b0\u6df7\u5408\u578b\u6cbb\u7642\u8a08\u756b\u6709\u986f\u8457\u7684\u5291\u91cf\u589e\u52a0\u3002\u9032\u4e00\u6b65\u5206\u6790\u767c\u73fe\uff0c\u7576\u75c5\u4eba\u9ad4\u91cd\u6709\u986f\u8457\u7684\u6e1b\u8f15\u6642\uff0c\u810a\u9ad3\uff0c\u8166\u5e79\uff0c\u53f3\u5074\u7684\u816e\u817a\u53ca\u9ad8\u5291\u91cf\u5340\u5728PTVCTV1\u7684\u6bd4\u4f8b\u5247\u6709\u986f\u8457\u589e\u52a0\u3002\u7576\u75c5\u4eba\u9ad4\u91cd\u6c92\u6709\u986f\u8457\u7684\u6e1b\u8f15\u6642\uff0c\u8166\u5e79\u548c\u810a\u9ad3\u7684\u5291\u91cf\u6703\u589e\u52a0\u4f46\u816b\u7624\u7684\u5291\u91cf\u5305\u8986\u4ecd\u662f\u7b26\u5408\u8981\u6c42\u7684\u3002\n\u7d50\u8ad6\uff1a\u816e\u817a\u9ad4\u7a4d\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u904e\u7a0b\u4e2d\u6703\u6709\u986f\u8457\u7684\u7e2e\u5c0f\uff0c\u5373\u4f7f\u75c5\u4eba\u6c92\u6709\u986f\u8457\u7684\u9ad4\u91cd\u6e1b\u8f15\u3002\u5c0d\u65bc\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4f86\u6cbb\u7642\u9f3b\u54bd\u764c\uff0c\u7b2c\u4e8c\u7d44\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4ee5\u53ca\u65b0\u7684\u6cbb\u7642\u8a08\u756b\u662f\u9700\u8981\u7684\u3002", "e": "Background: Intensity-modulated radiation therapy (IMRT) has become the new promising treatment of nasopharyngeal cancer (NPC) in terms of providing excellent tumor coverage with significant sparing of the parotid glands. In this study, we intend to quantify the importance of the volume shrinkage of parotid gland and its influence on the dose distribution of parotid glands among patients with or without significant body weight loss.\nMaterial and Methods: From Feb. 2003 to Oct. 2005, 30 patients with NPC were enrolled into this study. 13 patients suffered from significant body weight loss (\uff1e6% of their origin body weight at the end of the 4th week of the entire RT course). A 2nd plan CT scan images were acquired after every patient had received 41.4 to 46.8 Gy of prescribed dose. A second IMRT plan was generated for the cone-down treatment. However, we also created a 2nd plan (Hybrid 2nd plan) for the 1st CT images to assume if no 2nd plan CT images were available.\nResults: The reductions of body contours are highly correlated with the body weight loss of the patients. The parotid glands decrease in size no matter the patients had significant body weight loss or not. When comparing the dosimetric effects of Hybrid and New 2nd plan, there were no significant dosimetric differences of target coverage. However, increases in the doses of normal tissue such as brainstem, spinal cord, left and right parotid glands were noted. In the subgroup analysis, there were significant increase of spinal cord, brainstem, R't parotid gland doses and hot spots in PTV(subscript CTV1) for patients with significant body weight loss. For patients without significant body weight loss, there were increases of spinal cord and brainstem doses but the target dose coverage remained satisfactory.\nConclusions: We conclude that the volume of parotid glands decreased significantly during the course of IMRT even in patients without significant body weight loss. A 2nd plan CT and a new 2nd IMRT plan based on the new CT scan are needed for the IMRT treatment of NPC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-125-135", "title": "\u5229\u7528\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4f86\u8a55\u4f30\u64fa\u4f4d\u8aa4\u5dee\u5c0d\u65bc\u8a08\u5283\u9776\u9ad4\u7a4d\u5305\u8986\u7387\u7684\u5f71\u97ff", "keywords": "\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642;\u64fa\u4f4d\u8aa4\u5dee;\u8a08\u5283\u9776\u9ad4\u7a4d;\u5668\u5b98\u98a8\u96aa IGRT;setup error;PTV;OAR", "c": "\u76ee\u7684\uff1a\u96a8\u8457\u79d1\u6280\u65e5\u65b0\u6708\u7570\uff0c\u6709\u6108\u4f86\u6108\u591a\u5148\u9032\u7684\u8a2d\u5099\u53ef\u4f9b\u653e\u5c04\u6cbb\u7642\u9818\u57df\u61c9\u7528\uff0c\u672c\u6587\u4e3b\u8981\u85c9\u8457\u5f71\u50cf\u5c0e\u5f15\u7684\u6280\u8853\u4e26\u5229\u7528\u56de\u6eaf\u5206\u6790\u7684\u65b9\u5f0f\uff0c\u8a55\u4f30\u982d\u9838\u764c\u75c5\u4eba\u82e5\u7121\u7d93\u904e\u5f71\u50cf\u5c0e\u5f15\uff0c\u5176\u4f4d\u79fb\u4fee\u6b63\u5c0d\u8a08\u756b\u9776\u9ad4\u7a4d(PTV)\u5305\u8986\u7387\u8207\u5468\u570d\u9130\u8fd1\u6b63\u5e38\u7d44\u7e54\u7684\u9ad4\u7a4d\u88ab\u7167\u5c04\u7387\u7684\u885d\u64ca\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u8afe\u5229\u5200\u76f4\u7dda\u52a0\u901f\u5668\u70ba\u4e8c\u5341\u4f4d\u75c5\u4eba\u9032\u884c\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\uff0c\u5171\u4e09\u767e\u516b\u5341\u516d\u6b21\u7684\u6cbb\u7642\uff0c\u5229\u7528\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\uff08\u4ee5\u4eba\u9ad4\u9aa8\u9abc\u70ba\u4e3b\u914d\u5408\u00d7\u5149\u5f71\u50cf\u878d\u5408\uff09\u6c42\u51fa\u6bcf\u6b21\u64fa\u4f4d\u8aa4\u5dee\u7684\u4f4d\u79fb\u4fee\u6b63\uff0c\u4e26\u4ee5\u5ea7\u6a19\u8ef8\u683c\u5f0f\u91cd\u65b0\u8f38\u5165\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\uff0c\u4f46\u5176\u4ed6\u8a2d\u5b9a\u6cbf\u7528\u820a\u6cbb\u7642\u8a08\u5283\u5f8c\u53d6\u5f97\u65b0\u7684\u6cbb\u7642\u8a08\u5283\u7d50\u679c\uff0c\u5229\u7528\u8a08\u5283\u52a0\u7e3d\u7684\u65b9\u5f0f\uff0c\u8a55\u4f30\u64fa\u4f4d\u8aa4\u5dee\u5c0d\u65bc\u8a08\u5283\u9776\u9ad4\u7a4d\u8207\u6b63\u5e38\u7d44\u7e54\u4e4b\u88ab\u7167\u5c04\u7387\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u6839\u64da\u5be6\u969b\u7684\u6e2c\u91cf\u7d50\u679c\uff0c\u5728\u524d\u5f8c\u8ef8\u4f4d\u7684\u5e73\u5747\u4f4d\u79fb\u4fee\u6b63\u70ba\uff0d0.4\u00b10.9mm\uff0c\u800c\u7cfb\u7d71\u8aa4\u5dee\u6a19\u6e96\u5dee\u8207\u96a8\u6a5f\u8aa4\u5dee\u6a19\u6e96\u5dee\u5206\u5225\u662f0.9mm\u82070.9mm\uff1b\u5728\u4e2d\u5074\u8ef8\u4f4d\u7684\u5e73\u5747\u4f4d\u79fb\u4fee\u6b63\u70ba\uff0d0.4\u00b11.2mm\uff1b\u800c\u7cfb\u7d71\u8aa4\u5dee\u6a19\u6e96\u5dee\u8207\u96a8\u6a5f\u8aa4\u5dee\u6a19\u6e96\u5dee\u5206\u5225\u662f0.7mm\u82070.9mm\uff1b\u5728\u982d\u8173\u8ef8\u4f4d\u7684\u5e73\u5747\u4f4d\u79fb\u4fee\u6b63\u70ba\uff0d0.1\u00b10.7mm\uff0c\u800c\u7cfb\u7d71\u8aa4\u5dee\u6a19\u6e96\u5dee\u8207\u96a8\u6a5f\u8aa4\u5dee\u6a19\u6e96\u5dee\u5247\u5206\u5225\u662f1.2mm\u82071.1mm\u3002\u6574\u9ad4\u75c5\u4eba\u7684\u7a7a\u9593\u5411\u91cf\u4f4d\u79fb\u5c0f\u65bc3mm\u7684\u983b\u7387\u70ba88%\uff0c\u800c\u5e73\u5747\u4f4d\u79fb\u9593\u8ddd\u662f2.1\u00b10.3mm\u3002\u5728\u8166\u90e8\u816b\u7624\u8207\u982d\u9838\u764c\u7684\u75c5\u4eba\u4e4b\u4e2dV90\uff0890%\u5291\u91cf\u66f2\u7dda\u5305\u542b\u7684\u9ad4\u7a4d\uff09\u7684\u932f\u5931\u7387\u5206\u5225\u70ba0.15%\u82070.17%\uff1bV95\uff0895%\u5291\u91cf\u66f2\u7dda\u5305\u542b\u7684\u9ad4\u7a4d\uff09\u7684\u932f\u5931\u7387\u5206\u5225\u70ba0.37%\u82070.39%\uff1b\u50c5\u6709\u5c11\u65bc0.03%\u82070.31%\u7684\u8a08\u5283\u9776\u9ad4\u7a4d\u88ab\u5305\u8986\u5728107%\u7684\u9ad8\u5291\u91cf\u5340\u5167\u3002\u800c\u5728\u5371\u6025\u5668\u5b98\u7684\u9ad4\u7a4d\u88ab\u7167\u5c04\u7387\u7684\u8b8a\u7570\u8a55\u4f30\uff0c\u8166\u90e8\u816b\u7624\u75c5\u4eba\u5de6\u5074\u773c\u775b\u3001\u8166\u5e79\u3001\u53f3\u5074\u773c\u775b\u7684\u5e73\u5747\u5dee\u7570\u662f0.25\u00b11.36%\u30011.18\u00b10.81%\u3001-0.09\u00b11.16%\uff1b\u982d\u9838\u764c\u75c5\u4eba\u7684\u810a\u9ad3\u3001\u5de6\u5074\u816e\u817a\u3001\u53f3\u5074\u816e\u817a\u7684\u5e73\u5747\u5dee\u7570\u5247\u662f-0.22\u00b10.63%\u30010.15\u00b10.77%\u3001-0.21\u00b10.80%\u3002\n\u7d50\u8ad6\uff1a\u5728\u9032\u884c\u6cbb\u7642\u8a08\u756b\u7684\u898f\u5283\u6642\uff0c\u9664\u4e86\u4f9dvan Herk.\u7684\u5efa\u8b70\u5728\u81e8\u5e8a\u9776\u9ad4\u7a4d\u7684\u5916\u7de3\u591a\u52a02.5\u03a3\u00b10.7\u03c3mm\u7684\u5b89\u5168\u9593\u8ddd\u5916\uff0c\u4f9d\u672c\u7814\u7a76\u6240\u793a\uff0c\u50b3\u7d71\u6cbb\u7642\u64fa\u4f4d\u7684\u8aa4\u5dee\u5c0f\u65bc3mm\u7684\u6a5f\u6703\u5927\u7d04\u70ba88%\uff0c\u82e5\u53ef\u914d\u5408\u4f7f\u7528\u5f71\u50cf\u5c0e\u5f15\u6280\u8853\u78ba\u8a8d\u6bcf\u6b21\u7684\u64fa\u4f4d\u7d50\u679c\uff0c\u5247\u53ef\u63a7\u5236\u6bcf\u4e00\u6b21\u6cbb\u7642\u7684\u64fa\u4f4d\u8aa4\u5dee\u4f4e\u65bc3mm\uff0c\u8b93\u7a7a\u9593\u5411\u91cf\u7684\u9593\u8ddd\u7dad\u6301\u57285.2mm\u7684\u7bc4\u570d\u4e4b\u5167\uff0c\u9032\u800c\u76f8\u4fe1\u5be6\u969b\u6cbb\u7642\u6642\u7684\u81e8\u5e8a\u9776\u9ad4\u7a4d\u7684\u5305\u8986\u7387\u8207\u5371\u6025\u5668\u5b98\u9ad4\u7a4d\u88ab\u7167\u5c04\u4e4b\u98a8\u96aa\u8a55\u4f30\u90fd\u5728\u5408\u7406\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\u3002", "e": "Introduction: By using image-guided correction, we analyzed the dose coverage of planning target volume (PTV) and surrounding normal tissues impacted by radiation dose retrospectively. This was done on head and neck (H&N) cancer patients who were not guided by imaging based on the effective treatment results of intensity modulated radiation therapy (IMRT).\nMaterial and Methods : 20 patients underwent image-guided radiotherapy (IGRT) resulted in a total of 386 paired images which were analyzed by software to acquire the correction shifts in three axis, followed by recalculation of a treatment plan system. The effect of PTV and normal tissue irradiation volume were evaluated by plan summation.\nResults: The average correction shift of anterior-posterior (AP), medial-lateral (RL) and cranio-caudal (CC) directions were -0.4\u00b10.9 mm, -0.4\u00b11.2 mm and -0.1\u00b10.7 mm, respectively. The systematic and random errors in AP direction were 0.9 mm and 0.9 mm, in RL direction were 0.7 mm and 0.9 mm, in SI direction were 1.2 mm and 1.1 mm. The average vector shift was 2.1\u00b10.3 mm with 88% probability of being less than 3 mm.\nIn brain and H&N tumor groups, the PTV missing probability of V90 (the volume covered by 90% isodose curve), V95 (the volume covered by 95% isodose curve) and V107 (the volume covered by 107% isodose curve) were 0.15% and 0.17%, 0.37% and 0.39%, 0.03% and 0.31%, respectively. On the other hand, in brain and H&N tumor groups, the probabilities of normal tissue being irradiated were as follows: 0.25\u00b11.36% of left eye, 1.18\u00b10.81% of brain stem, -0.22\u00b10.63% of spinal cord, left 0.15\u00b10.77% of parotid gland, -0.09\u00b11.16% of right eye and -0.21\u00b10.8% of right parotid gland.\nConclusion: The dose coverage of PTV and normal tissue risk can be kept within the acceptable range by adding the safety margin recommended by Marcel van Herk (2.5\u03a3\u00b10.7\u03c3) mm along with the control of the setup error of less than 3 mm and the space vector shift of less than 5.2 mm."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-137-144", "title": "\u4f7f\u7528\u8f3b\u5c04\u8b8a\u8272\u81a0\u7247\u65bc\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49", "keywords": "\u8f3b\u5c04\u8b8a\u8272\u81a0\u7247;\u5361\u6ce2\u897f\u6c0f\u8089\u7624;\u7d44\u7e54\u586b\u5145\u7269;\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49 Gafchromic EBT film;Kaposi", "c": "\u76ee\u7684\uff1a\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u7684\u7279\u6027\u4e3b\u8981\u70ba\u4fb5\u72af\u76ae\u819a\u7d44\u7e54\uff0c\u81e8\u5e8a\u4e0a\u5e38\u4f7f\u7528\u7d44\u7e54\u88dc\u511f\u7269\u589e\u52a0\u8868\u9762\u5291\u91cf\u3002\u6b64\u6b21\u7814\u7a76\u76ee\u7684\u70ba\u8a55\u4f30\u500b\u5225\u4fb5\u72af\u55ae\u8173\u8207\u96d9\u8173\u76ae\u819a\u7684\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u75c5\u4eba\uff0c\u56e0\u4e0d\u540c\u9069\u61c9\u75c7\u800c\u642d\u914d\u5169\u7a2e\u4e0d\u540c\u7d44\u7e54\u88dc\u511f\u7269\uff0c\u4f7f\u7528Gafchromic EBT\u81a0\u7247\u505a\u70ba\u6d3b\u9ad4\u5291\u91cf\u8a08\uff0c\u7d93\u7531\u81e8\u5e8a\u5be6\u6e2c\uff0c\u8a18\u9304\u6bcf\u5929\u5291\u91cf\u8b8a\u5316\u60c5\u5f62\uff0c\u85c9\u4ee5\u4f5c\u70ba\u91ab\u751f\u5ba2\u89c0\u8a55\u4f30\u76ae\u819a\u5291\u91cf\u7684\u4f9d\u64da\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5206\u6210\u5169\u7a2e\u4e0d\u540c\u7684\u6cbb\u7642\u64fa\u4f4d\u65b9\u5f0f\uff0c\u7686\u8cbc\u4e0a2\u00d72\u5e73\u65b9\u516c\u5206\u5927\u5c0f\u7684EBT\u81a0\u7247\uff0c\u7528\u4ee5\u91cf\u6e2c\u76ae\u819a\u5291\u91cf\u3002\u7b2c\u4e00\u7a2e\u70ba\u96d9\u8173\u7686\u9700\u8981\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u96d9\u8173\u4f75\u650f\u7f6e\u65bc\u6c34\u7bb1\u4e2d\uff0c\u4f7f\u7528\u80fd\u91cf10MV\u5149\u5b50\u9032\u884c\u5169\u5074\u5c0d\u7167\uff0c\u55ae\u6b21\u8655\u65b9\u5291\u91cf\u70ba300 cGy\uff0c\u5171\u6cbb\u764212\u6b21\uff1b\u7b2c\u4e8c\u7a2e\u70ba\u50c5\u9700\u55ae\u8173\u5c40\u90e8\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u4f7f\u7528\u767c\u6ce1\u5291\u56fa\u5b9a\u7cfb\u7d71\uff0c\u6dfb\u52a0\u539a\u5ea6\u81f3\u5c113mm\u4ee5\u4e0a\u7684Polyflex \u2161\u7576\u4f5c\u7d44\u7e54\u88dc\u511f\u7269\uff0c\u7167\u5c04\u65b9\u5f0f\u70ba\u4f7f\u75284\u500b\u5165\u5c04\u89d2\u5ea6\u7684\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff0c\u5149\u5b50\u80fd\u91cf\u70ba4MV\uff0c\u55ae\u6b21\u8655\u65b9\u5291\u91cf\u70ba200cGy\uff0c\u9810\u8a08\u6cbb\u764225\u6b21\uff0c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u70baPhilips pinnacle^3v7.6c\u3002\n\u7d50\u679c\uff1a\u96d9\u8173\u7167\u5c04\u4e2d\uff0c12\u500b\u91cf\u6e2c\u9ede\u91cd\u8907\u91cf\u6e2c5\u5929\uff0c\u96d9\u8173\u76ae\u819a\u5e73\u5747\u5291\u91cf\u70ba313.3\u00b115.7cGy\uff1b\u55ae\u8173\u7167\u5c04\u4e2d\uff0c2\u500b\u91cf\u6e2c\u9ede\u91cd\u8907\u91cf\u6e2c10\u5929\uff0cA\u9ede\u8655\u7684\u76ae\u819a\u5e73\u5747\u5291\u91cf\u70ba219.5\u00b14.1 cGy\uff1bB\u9ede\u8655\u7684\u76ae\u819a\u5e73\u5747\u5291\u91cf\u70ba219.0\u00b15.5cGy\uff0c\u6cbb\u7642\u8a08\u756b\u8a08\u7b97\u7d50\u679cA\u9ede\u70ba212.7 cGy\uff0c\u5176\u6e2c\u91cf\u7d50\u679c\u6bd4\u6cbb\u7642\u8a08\u756b\u591a3.2%\uff1b\u800cB\u9ede\u8a08\u7b97\u7d50\u679c\u70ba216.7 cGy\uff0c\u5176\u6e2c\u91cf\u7d50\u679c\u6bd4\u6cbb\u7642\u8a08\u756b\u591a1.1%\u3002\n\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u6587\u4e2d\u4f7f\u7528\u7684\u5169\u7a2e\u8a2d\u7f6e\u65b9\u5f0f\uff0c\u4e0d\u8ad6\u662f\u4f7f\u7528\u6c34\u6216Polyflex \u2161\u7576\u4f5c\u7d44\u7e54\u88dc\u511f\u7269\uff0c\u7d93\u904e\u6d3b\u9ad4\u5291\u91cf\u91cf\u6e2c\uff0c\u8b49\u5be6\u90fd\u53ef\u4ee5\u4f7f\u76ae\u819a\u5f97\u5230\u8db3\u5920\u7684\u5291\u91cf\uff0c\u751a\u81f3\u63a5\u53d7\u5230\u7d04\u9ad8\u65bc\u8655\u65b9\u5291\u91cf10%\u5de6\u53f3\u7684\u503c\uff0c\u63d0\u4f9b\u7d66\u91ab\u5e2b\u4f5c\u70ba\u65e5\u5f8c\u5ba2\u89c0\u8a55\u4f30\u76ae\u819a\u5291\u91cf\u7684\u4f9d\u64da\u3002", "e": "Purpose: Epidemic Kaposi's sarcoma mainly invades skin tissues. In the clinic, we often use bolus to increase the surface dose. To evaluate the patients of epidemic Kaposi's sarcoma who had lesions on either single foot or on both feet skins, Gafchromic EBT film was used as in-vivo dosimetry to compare two different radiotherapy methods and verified the skin doses.\nMaterials and Methods: In these two different treatment methods, we used 2\u00d72 cm^2 size EBT film to measure the skin dose. The first method treated both feet. Two feet were immersed in a water tank and irradiated with 10 MV bilateral photon beam. The total dose of 36 Gy was delivered in 12 fractions. The second method treated only partial single foot, and used the Alpha cradle fixation system. In this study, we used at least 3mm thick Polyflex II as the tissue-compensator. Base on CT images, the treatment site was irradiated with 4 MV photon beams at 4 different angles. The total dose of 50 Gy was delivered in 25 fractions. The treatment planning system used in this study was Philips pinnacle^3 v7.6c.\nResults: In both-feet irradiation case, we chose twelve points and repeated measurement for 5 days. The average skin dose of both feet was 313.3\u00b115.7 cGy. In single foot irradiation case, two measure points were repeated for 10 days. The average skin dose at points A and B were 219.5\u00b14.1 cGy and 219.0\u00b15.5 cGy respectively. The calculation results of treatment planning at A and B points were 212.7 cGy and 216.7 cGy respectively. The measurement results were higher than the treatment planning system by 3.2% and 1.1%.\nConclusions: As shown by the results of this study, either water tank or polyflex II may be used as tissue-compensators. They can provide sufficient doses to the skin tissue. Both methods are available for follow-up evaluation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-145-151", "title": "Small Cell Carcinoma of External Auditory Canal: A Case Report", "keywords": "\u5c0f\u7d30\u80de\u764c;\u80ba\u5916;\u5916\u8033\u9053;\u653e\u5c04\u6cbb\u7642 Small cell carcinoma;Extrapulmonary;External auditory canal;Radiotherapy", "c": "\u80ba\u5916\u5c0f\u7d30\u80de\u764c\u5f88\u5c11\u5728\u982d\u9838\u90e8\u767c\u73fe\uff0c\u6211\u5011\u5831\u544a\u4e00\u500b51\u6b72\u5973\u6027\u7684\u53f3\u5916\u8033\u9053\u5c0f\u7d30\u80de\u764c\u3002\u5ee3\u6cdb\u6027\u5207\u9664\u816b\u7624\u5f8c\uff0c\u53c8\u767c\u73fe\u53f3\u9838\u90e8\u6dcb\u5df4\u7d50\u3002\u5979\u63a5\u53d7\u4e866\u500b\u7642\u7a0b\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u4f7f\u7528\u7684\u85e5\u7269\u662fcisplatin\u548cetoposide\u3002\u65b7\u5c64\u6383\u63cf\u986f\u793a\u6dcb\u5df4\u7d50\u816b\u5927\u5df2\u6d88\u5931\uff0c\u4e14\u539f\u767c\u90e8\u4f4d\u6c92\u6709\u816b\u7624\u5fa9\u767c\u3002\u4e4b\u5f8c\u5979\u518d\u63a5\u53d7\u5c40\u90e8\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u816b\u7624\u5e8a\u7684\u5291\u91cf\u662f60Gy/30\u6b21\uff0c\u5c40\u90e8\u6dcb\u5df4\u7d50\u7684\u5291\u91cf\u662f54Gy/30\u6b21\uff0c\u653e\u5c04\u6cbb\u7642\u5f88\u9806\u5229\u5b8c\u6210\u3002\u7136\u800c\uff0c\u75c5\u4eba\u5728\u653e\u7642\u904e\u7a0b\u4e2d\u767c\u751f\u4e86\u809d\u8f49\u79fb\uff0c\u6700\u5f8c\u8ddd\u96e2\u521d\u8a3a\u65b712\u500b\u6708\u5f8c\u6b7b\u4ea1\u3002\u6211\u5011\u76f8\u4fe1\uff0c\u5c0d\u65bc\u80ba\u5916\u5c0f\u7d30\u80de\u764c\u4f86\u8aaa\uff0c\u96d6\u7136\u653e\u5c04\u6cbb\u7642\u5c0d\u5c40\u90e8\u63a7\u5236\u6709\u5e6b\u52a9\uff0c\u4f46\u662f\u5316\u5b78\u6cbb\u7642\u9084\u662f\u6700\u91cd\u8981\u7684\u3002", "e": "Extrapulmonary small cell carcinoma arising from head and neck is extremely rare. We report a 51-year-old woman with small cell carcinoma of right external auditory canal. A wide excision surgery was performed. Right side neck lymph node metastasis was found after operation. She underwent chemotherapy with 6 courses of cisplatin and etoposide. The posttreatment CT scan of head and neck disclosed complete remission of lymphadenopathy and no local recurrence of primary tumor. Then she received local radiotherapy using IMRT technique with 60 Gy in 30 fractions to tumor bed and 54 Gy in 30 fractions to regional lymphatics. The treatment course of radiation was completed smoothly. However, the patient developed liver metastases during the radiotherapy course and then died 12 months after the initial diagnosis. We believe that although radiotherapy have benefit for local control, chemotherapy is of the most importance for extrapulmonary small cell carcinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-153-159", "title": "Pulmonary Kaposi", "keywords": "\u80ba\u90e8\u5361\u6ce2\u897f\u6c0f\u8089\u7624;\u611b\u6ecb\u75c5;\u8f49\u79fb Pulmonary Kaposi", "c": "\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u662f\u611b\u6ecb\u75c5\u60a3\u8005\u6700\u5e38\u7f79\u60a3\u7684\u816b\u7624\u4e4b\u4e00\uff0c\u7136\u800c\u6b64\u816b\u7624\u7684\u8868\u73fe\u65b9\u5f0f\u901a\u5e38\u4ee5\u76ae\u819a\u4e0a\u4e45\u4e0d\u7652\u7684\u6f70\u760d\u6216\u591a\u8655\u7a81\u8d77\u7684\u76ae\u4e0b\u816b\u7624\u70ba\u4e3b\uff0c\u53ea\u6709\u5728\u514d\u75ab\u529b\u56b4\u91cd\u4f4e\u4e0b\u6642\u624d\u6703\u8f49\u79fb\u5230\u5167\u81df\u3002\u901a\u5e38\u5148\u6709\u76ae\u819a\u4e0a\u7684\u75c7\u72c0\uff0c\u4e4b\u5f8c\u624d\u6703\u767c\u73fe\u5167\u81df\u8f49\u79fb\uff0c\u8f49\u79fb\u5230\u5167\u81df\u7684\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u5176\u81e8\u5e8a\u75c7\u72c0\u5f80\u5f80\u6c92\u6709\u7279\u7570\u6027\u3002\u4ee5\u80ba\u90e8\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u800c\u8a00\uff0c\u5176\u81e8\u5e8a\u8868\u73fe\u5e38\u70ba\u54b3\u55fd\u3001\u54b3\u8840\u3001\u6216\u547c\u5438\u6025\u4fc3\uff0c\u4f46\u9019\u4e9b\u75c7\u72c0\u5728\u4e00\u822c\u80ba\u90e8\u611f\u67d3\u4ea6\u6703\u8868\u73fe\uff0c\u4e0d\u6613\u5340\u5206\u8207\u611f\u67d3\u3002\u9019\u88e1\u6211\u5011\u5831\u5c0e\u4e00\u4f8b\u611b\u6ecb\u75c5\u75c5\u60a3\u57282002\u5e74\u8a3a\u65b7\u611b\u6ecb\u75c5\u5f8c\u6c92\u6709\u898f\u5247\u670d\u85e5\uff0c2007\u5e744\u6708\u958b\u59cb\u6709\u54b3\u55fd\u53ca\u5de6\u4e0b\u80a2\u8272\u7d20\u6c88\u6fb1\u75c7\u72c0\uff0c\u4e00\u958b\u59cb\u8a3a\u65b7\u9593\u8cea\u6027\u80ba\u708e\uff0c\u4ee5\u6297\u751f\u7d20\u53ca\u6297\u611b\u6ecb\u75c5\u85e5\u7269\u6cbb\u7642\u5f8c\uff0c\u80ba\u90e8\u75c7\u72c0\u6539\u5584\u4f46\u6548\u4e0b\u80a2\u8272\u7d20\u6c88\u6fb1\u7bc4\u570d\u6301\u7e8c\u64f4\u5927\u4e14\u5f62\u6210\u6f70\u760d\uff0c\u75c5\u60a3\u63a5\u53d7\u622a\u80a2\u6cbb\u7642\uff0c\u75c5\u7406\u5207\u7247\u6700\u5f8c\u78ba\u5b9a\u8a3a\u65b7\u70ba\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u5408\u4f75\u80ba\u90e8\u8f49\u79fb\uff1b\u4e26\u63a2\u8a0e\u5176\u81f4\u75c5\u6a5f\u8f49\u3001\u8a3a\u65b7\u65b9\u6cd5\u3001\u53ca\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Kaposi's sarcoma is the most common tumor in patients with human immunodeficiency virus (HIV) infection in the form of cutaneous lesion and seldom involved visceral organ except in severe immune deficiency situation. However, the clinical symptom with pulmonary Kaposi's sarcoma is not specific. Physician easily missed the diagnosis if other infection coexisted.\nHere we describe a case who had been diagnosed with HIV infection. The patient developed pulmonary Kaposi's sarcoma proved pathologically 4 years later. A 42 years old man had diagnosis of HIV in 2002 and treated suboptimally with medication in another hospital. Unfortunately, productive cough with whitish sputum and hyperpigmentation macules over left lower leg occurred in April, 2007. Opportunistic pulmonary infection was first diagnosed due to severe immune deficiency situation even though there was no positive finding in the examination. CT guided biopsy had been performed resulting in interstitial pneumonitis initially.\nThe respiratory symptoms improved after prophylactic antibiotics treatment and anti-HIV medication. However, macules over his leg aggravated 2 months later and treated by amputation. Kaposi's sarcoma of left leg was diagnosed according to histologic pattern. After reviewing the previous lung biopsy, AIDS-associated KS of left leg with lung metastasis was finally diagnosed. We also review the liturature to discuss epidemiology, incidence, clinical symptoms, pathogenesis, diagnostic methods and treatments. Concomitant pulmonary infection may underlying pulmonary KS. In addition, the lesions in the lung may be subtle. Physician should be alert of the existence of pulmonary KS and opportunistic infection, especially in patients who had already known to have extrapulmonary KS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201006-201007050078-201007050078-161-167", "title": "Oncocytic Carcinoma of the Submandibular Gland, from Benign to Malignant-A Report on an Unusual Case", "keywords": "\u55dc\u9178\u7d30\u80de\u764c;\u981c\u4e0b\u817a;\u653e\u5c04\u6cbb\u7642 Oncocytic carcinoma;Submandibular gland;Radiotherapy", "c": "\u76ee\u7684\uff1a\u55dc\u9178\u7d30\u80de\u7624\u662f\u4e00\u500b\u975e\u5e38\u7f55\u898b\u7684\u816b\u7624,\u901a\u5e38\u662f\u826f\u6027\u7684\uff0c\u4e00\u822c\u767c\u751f\u5728\u816e\u817a\u3002\u55dc\u9178\u7d30\u80de\u764c\u66f4\u662f\u5c11\u898b\u7684\uff0c\u5176\u4e2d\u5305\u62ec\u5927\u7d04\u53ea\u67095%\u7684\u6240\u6709\u55dc\u9178\u7d30\u80de\u7624\u3002\u5728\u56b4\u8b39\u7684\u5be9\u67e5\uff0c\u4e16\u754c\u6587\u5b78\uff0c\u53ea\u6709\u5c11\u6578\u6848\u4ef6\u7684\u981c\u4e0b\u817a\u55dc\u9178\u7d30\u80de\u764c\u7684\u5831\u5c0e\uff0c\u66f4\u4e0d\u5c0b\u5e38\u7684\u662f\u5b83\u4ee5\u524d\u6240\u7522\u751f\u7684\u826f\u6027\u55dc\u9178\u7d30\u80de\u7624\u3002\u6211\u5011\u63cf\u8ff0\u4e00\u500b\u984d\u5916\u6848\u4ef6\u981c\u4e0b\u817a\u55dc\u9178\u7d30\u80de\u7624\u5411\u60e1\u6027\u8f49\u5316\u8207\u5340\u57df\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002\n\u75c5\u4eba\u8207\u65b9\u6cd5\uff1a\u4e00\u4f8b\u7f55\u898b\u768451\u6b72\u7537\u5b50\u60e1\u6027\u55dc\u9178\u7d30\u80de\u7624\u662f\u3002\u816b\u7624\u88ab\u767c\u73fe\u5728\u5de6\u981c\u4e0b\u817a\u8207\u5340\u57df\u6dcb\u5df4\u7d50\u816b\u5927\u3002\n\u7d50\u679c\u548c\u7d50\u8ad6\uff1a\u55dc\u9178\u7d30\u80de\u764c\u4f3c\u4e4e\u7522\u751f\u65bc\u826f\u6027\u55dc\u9178\u7d30\u80de\uff0c\u6216\u8005\u4e5f\u53ef\u80fd\u662f\u539f\u767c\u816b\u7624\u3002\u982d\u9838\u90e8\u55dc\u9178\u7d30\u80de\u764c\uff0c\u662f\u5426\u5b58\u5728\u8f49\u79fb\uff0c\u800c\u4e0d\u662f\u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u662f\u6700\u91cd\u8981\u7684\u9810\u5f8c\u6307\u6a19\u3002\u6cbb\u7642\u5305\u62ec\u624b\u8853\u5207\u9664\u548c\u653e\u5c04\u6cbb\u7642\uff0c\u4f46\u653e\u5c04\u6cbb\u7642\u7684\u7642\u6548\u4ee5\u53ca\u5316\u7642\u4ecd\u4e0d\u6e05\u695a\u3002", "e": "Purpose: Oncocytomas are very rare tumors that are usually benign and typically occur in the parotid gland. Oncocytic carcinomas are even more uncommon, comprising only approximately 5% of all oncocytomas. In a critical review of the international medical literature, only a few cases of oncocytic carcinoma of submandibular gland were found. Even more unusual was the fact in this case, it arose from a previously benign oncocytoma. We describe this case of submandibular oncocytoma transforming into a malignancy associated with regional lymph node metastases.\nPatient and Methods: A rare case of 51 year-old man with malignant oncocytoma is presented. The tumor was found in the left submandibular gland with regional lymph node enlargement.\nResults and Conclusion: Oncocytic carcinoma appears to arise from benign oncocytomas, or may also arise de novo. In oncocytic carcinoma of the head and neck, the presence of distant, rather than local lymph node, metastasis is the most important prognostic indicator. Therapy consists of surgical resection and radiotherapy but the efficacy of radiotherapy, and chemotherapy are still unclear."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-1-8", "title": "Second Primary Malignancies in Patients with Nasopharyngeal Cancer after Radiotherapy: A 38-Year Follow-Up", "keywords": "\u9f3b\u54bd\u764c;\u7b2c\u4e8c\u539f\u767c\u764c\u75c7;\u653e\u5c04\u6cbb\u7642;\u767c\u751f\u7387 Nasopharyneal cancer;Second primary malignancies;Radiotherapy;Incidence", "c": "\u76ee\u7684\uff1a\u5206\u6790\u672c\u9662\u9f3b\u54bd\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u7522\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u7684\u767c\u751f\u7387\u53ca\u5206\u6790\u53ef\u80fd\u7684\u5371\u96aa\u56e0\u5b50\uff0c\u6211\u5011\u4e5f\u540c\u6642\u5206\u6790\u75c5\u4eba\u5f97\u5230\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u4e4b\u5f8c\u7684\u9810\u5f8c\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e1971\u5e744\u6708\u81f32009\u5e744\u6708\uff0c\u5171\u67091367\u4f4d\u65b0\u8a3a\u65b7\u9f3b\u54bd\u764c\u75c5\u60a3\u65bc\u672c\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d\u7684\u4f4d\u5f97\u5230\u7b2c\u4e09\u539f\u767c\u764c\u75c7\uff0c\u4ed6\u5011\u63a5\u53d7\u4e86\u4e0d\u540c\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u5305\u542b\u55ae\u7d14\u624b\u8853\u6216\u5408\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u6216\u55ae\u7d14\u653e\u5c04\u6cbb\u7642\u3002\u653e\u5c04\u6cbb\u7642\u7684\u6280\u8853\u5305\u542b\u4e86\u50b3\u7d71\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642(3DCRT)\u53ca\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u3002\n\u7ed3\u679c\uff1a\u6700\u5e38\u898b\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u7684\u90e8\u4f4d\u4f9d\u5e8f\u662f\u982d\u9838\u764c\uff0c\u80ba\u764c\uff0c\u809d\u764c\uff0c\u8840\u764c\u53ca\u6dcb\u5df4\u764c\u3002\u5c0d\u6240\u6709\u75c5\u60a3\u800c\u8a00\uff0c\u767c\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u7684\u4e2d\u4f4d\u6578\u6642\u9593\u70ba\u653e\u5c04\u6cbb\u7642\u5f8c94\u500b\u6708\uff0c\u7c97\u767c\u751f\u7387\u70ba3.3%\uff0c\u8ffd\u8e64\u4e8c\u5341\u5e74\u5f8c\u767c\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u7684\u7d2f\u7a4d\u6a5f\u7387\u70ba16.7%\uff0c\u5728\u63a5\u53d7\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u53ca\u5305\u542b\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5169\u7d44\u767c\u751f\u7387\u7684\u6bd4\u8f03\uff0c\u5176\u5dee\u7570\u4e26\u672a\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u610f\u7fa9(p=0.666)\u3002\u5728\u5b58\u6d3b\u7387\u7684\u6bd4\u8f03\u65b9\u9762\uff0c\u55ae\u7368\u9f3b\u54bd\u764c\u6216\u5408\u4f75\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u5169\u7d44\u6bd4\u8f03\u4ea6\u672a\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u610f\u7fa9(p=0.245)\u3002\n\u7ed3\u8bba\uff1a\u982d\u9838\u764c\u662f\u9f3b\u54bd\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u6700\u5e38\u767c\u751f\u7684\u7b2c\u4e8c\u764c\u75c7\u3002\u5c0d\u65bc\u767c\u751f\u7b2c\u4e8c\u539f\u767c\u764c\u75c7\u800c\u8a00\uff0c\u5927\u65bc50\u6b72\u7684\u75c5\u4eba\u8f03\u6613\u767c\u751f\u3002", "e": "Purpose: To define the incidence and risk of the second primary malignancies (SPM) in patients with nasopharyngeal cancer (NPC) post radiotherapy in our hospital. We also analyze their prognosis after the SPM\nMaterials and Method: Between April 1971 and April 2009, 1367 patients were indentified to have NPC after definitive radiotherapy. Of them, 45 patients developed SPM. They received various treatment strategies including surgery with or without adjuvant radiotherapy, concurrent chemoradiotherapy or radiotherapy alone. Radiotherapy technique included conventional radiotherapy, three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT).\nResults: The most common site for a SPM was the head and neck region, lung, liver and leukemia & lymphoma in decreasing order. The median time to development of SPM was 94 months. The crude incidence was 3.3%. The 20-year cumulative rate of development of SPM was 16.7%. Older patient has a higher incidence of 39.1%. The incidence between patients who received conventional radiotherapy and those having 3DCRT or IMRT is not significantly different (p=0.666). There is no significant difference for survival in NPC with or without SPM (p=0.245).\nConclusions: Head and neck cancer is the most common second cancer in NPC patients after radiotherapy. There is a trend to the development of SPM in the older age groups (\uff1e50 years old)"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-9-18", "title": "The Prognostic Factors and Short-Term Outcome of Intensity-Modulated Radiotherapy for Patients with Prostatic Adenocarcinoma", "keywords": "\u651d\u8b77\u817a\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50;\u6cbb\u7642\u7d50\u679c Prostatic adenocarcinoma;IMRT;Prognostic factors;Outcome", "c": "Purpose: We performed this retrospective analysis to evaluate prognostic factors and short-term outcome for patients with prostatic adenocarcinoma receiving definitive intensity-modulated radiotherapy (IMRT).\nMaterial and Method: This study included 142 patients who underwent definitive IMRT at National Taiwan University Hospital between December 2003 and December 2006. The median dose to the clinical target volume was 78 Gy (range: 73.1-82.3 Gy) in daily fractions of 1.91-2.11 Gy. Neoadjuvant hormonal therapy was given to 136 patients, usually starting 1 to 3 months before IMRT. The survival outcome was estimated using Kaplan-Meier method, and univariate and multivariate analyses were made with Log-rank test and Cox regression, respectively, on potential prognostic factors for survival.\nResults: The median follow-up time was 24.3 months. The 2-year overall survival (OS) was 95.4%. The 2-year failure-free survival (FFS), biochemical failure-free survival (BFFS), and distant metastasis-free survival (DMFS) rates for the whole cohort were 87.1%, 85.9%, and 97.6%, respectively. The 2-year FFS and BFFS were adversely influenced by T stage, Gleason score (GS) \uff1e7, and initial PSA (iPSA) serum level \uff1e20 ng/mL. The 2-year DMFS was adversely influenced by T stage, and GS \uff1e7. Multivariate analyses show that T stage is an independent factor for BFFS (p=.040), and FFS (p=.050), and that GS is an independent factor for DMFS (p=.037). Among the 17 patients with biochemical failure, the interval between PSA nadir and biochemical failure correlated significantly with 2-year DMFS (\u22646 months 50.0% vs. \uff1e6 months 84.6%, p=.049). The rate of acute grade 2 gastrointestinal (GI) and genitourinary (GU) toxicities was 16.8% and 14%, respectively. The rate of late grade 2 GI and GU toxicities was 12.6% and 6.3%, respectively. Three patients (2.1%) developed late grade 3 GI toxicities. The use of a rectal balloon significantly reduced\u2265grade 3 late GI toxicity (without balloon it was 7.14% vs. with, 0 %, p=.046).\nConclusion: Patients with prostatic adenocarcinoma undergoing definitive IMRT had T stage, initial PSA, and GS as significant prognostic factors for BFFS and FFS. T stage, GS, and the interval between PSA nadir and biochemical failure were prognostic factors for DMFS.", "e": "Purpose: We performed this retrospective analysis to evaluate prognostic factors and short-term outcome for patients with prostatic adenocarcinoma receiving definitive intensity-modulated radiotherapy (IMRT).\nMaterial and Method: This study included 142 patients who underwent definitive IMRT at National Taiwan University Hospital between December 2003 and December 2006. The median dose to the clinical target volume was 78 Gy (range: 73.1-82.3 Gy) in daily fractions of 1.91-2.11 Gy. Neoadjuvant hormonal therapy was given to 136 patients, usually starting 1 to 3 months before IMRT. The survival outcome was estimated using Kaplan-Meier method, and univariate and multivariate analyses were made with Log-rank test and Cox regression, respectively, on potential prognostic factors for survival.\nResults: The median follow-up time was 24.3 months. The 2-year overall survival (OS) was 95.4%. The 2-year failure-free survival (FFS), biochemical failure-free survival (BFFS), and distant metastasis-free survival (DMFS) rates for the whole cohort were 87.1%, 85.9%, and 97.6%, respectively. The 2-year FFS and BFFS were adversely influenced by T stage, Gleason score (GS) \uff1e7, and initial PSA (iPSA) serum level \uff1e20 ng/mL. The 2-year DMFS was adversely influenced by T stage, and GS \uff1e7. Multivariate analyses show that T stage is an independent factor for BFFS (p=.040), and FFS (p=.050), and that GS is an independent factor for DMFS (p=.037). Among the 17 patients with biochemical failure, the interval between PSA nadir and biochemical failure correlated significantly with 2-year DMFS (\u22646 months 50.0% vs. \uff1e6 months 84.6%, p=.049). The rate of acute grade 2 gastrointestinal (GI) and genitourinary (GU) toxicities was 16.8% and 14%, respectively. The rate of late grade 2 GI and GU toxicities was 12.6% and 6.3%, respectively. Three patients (2.1%) developed late grade 3 GI toxicities. The use of a rectal balloon significantly reduced\u2265grade 3 late GI toxicity (without balloon it was 7.14% vs. with, 0 %, p=.046).\nConclusion: Patients with prostatic adenocarcinoma undergoing definitive IMRT had T stage, initial PSA, and GS as significant prognostic factors for BFFS and FFS. T stage, GS, and the interval between PSA nadir and biochemical failure were prognostic factors for DMFS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-19-28", "title": "\u982d\u9838\u90e8\u75c5\u4eba\u8abf\u5f37\u653e\u5c04\u6cbb\u7642\u76ae\u819a\u5291\u91cf\u4e4b\u521d\u6b65\u7814\u7a76", "keywords": "\u76ae\u819a\u5291\u91cf;\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247 Skin dose;TLD;Gafchromic film", "c": "\u76ee\u7684\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u8a55\u4f30\u982d\u9838\u764c\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u91cf\u6d4b\u5de5\u5177\u7684\u53ef\u4fe1\u5ea6\uff0c\u4ee5\u53ca\u627e\u51fa\u81e8\u5e8a\u4e0a\u8a55\u4f30\u982d\u9838\u75de\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u7684\u53c3\u8003\u6578\u64da\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u63a1\u7528\u71b1\u767c\u5149\u5291\u91cf\u8a08\u3001\u5e73\u884c\u677f\u6e38\u96e2\u8154\u4ee5\u53ca\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u4f86\u4f5c\u70ba\u6e2c\u91cf\u5de5\u5177\uff0c\u4e26\u5206\u5225\u4f5c\u5176\u7279\u6027\u7814\u7a76\u4ee5\u53ca\u589e\u5efa\u5340\u7684\u91cf\u6e2c\uff1b\u816b\u7624\u8f2a\u5ed3\u570b\u9078\u65b9\u9762\uff0c\u5206\u5225\u70ba\u6a19\u9776(target)\u8f2a\u5ed3\u5167\u7e2e\u8868\u9762\u4e0b5mm\u3001\u6a19\u9776\u8f2a\u5ed3\u8207\u8868\u9762\u76f8\u540c\u908a\u7de3\u548c\u7121\u7d93\u904e\u4fee\u6539\u4e4b\u6a19\u9776\u8f2a\u5ed3\u7a81\u51fa\u8868\u9762\u3002\u672c\u7814\u7a76\u7528\u8868\u9762\u5291\u91cf(D0)\u8207\u5782\u76f4\u65bc\u8868\u9762\u5291\u91cf\u9ede\u5207\u7dda\u65b9\u5411\u5f80\u4e0b1\u516c\u5206\u7684\u5291\u91cf(D1)\u4e4b\u6bd4\u503c(D0/D1)\uff0c\u671f\u671b\u53ef\u4ee5\u7528\u6b64\u6bd4\u503c\u6c42\u51fa\u5be6\u969b\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u8b8a\u7570\u4fc2\u6578\u57283%\u4ee5\u5167\uff0c\u8a08\u503c\u8207\u7d66\u4e88\u5291\u91cf\u554f\u5448\u73fe\u826f\u597d\u7dda\u6027\u95dc\u4fc2\uff1b\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u6821\u6b63\u5340\u7dda\u4e0a\u6bcf\u500b\u9ede\u4e4b\u8b8a\u7570\u4fc2\u6578\u57285%\u4ee5\u5167\uff0c\u6574\u9ad4\u6821\u6b63\u66f2\u7dda\u5448\u73fe\u7a69\u5b9a\u7684\u95dc\u4fc2\uff1b\u8f3b\u5c04\u8b8a\u8272\u8edf\u7247\u7684\u91cf\u6e2c\u503c\u8207\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u7684\u8a08\u7b97\u503c\uff0c\u5728\u8ddd\u8868\u9762\u4e0b1\u516c\u5206\u6642\u7684\u8aa4\u5dee\u5c0f\u65bc5%\uff0c\u4e26\u4ee5\u6b64\u9ede\u4f5c\u70ba\u8207\u8868\u9762\u5291\u91cf\u7684\u6bd4\u503c\uff0c\u53ef\u4ee5\u85c9\u7531D0/D1\u6982\u7565\u6c42\u51fa\u76ae\u819a\u5291\u91cf\u3002\u5728\u5047\u9ad4\u6a21\u64ec\u65b9\u9762\uff0c\u7576\u6a19\u9776\u8f2a\u5ed3\u7a81\u51fa\u8868\u9762\u6216\u662f\u6a19\u9776\u8f2a\u5ed3\u8207\u8868\u9762\u76f8\u540c\u908a\u7de3\u6642\uff0c\u5176\u8868\u9762\u5291\u91cf\u6709\u53f8\u80fd\u6703\u9054\u5230D1\u4e4b85%~95%\u4e4b\u9593\uff0c\u800c\u5728\u6a19\u9776\u8f2a\u5ed3\u5167\u7e2e\u8868\u9762\u4e0b4mm\u6642\uff0c\u8868\u9762\u5291\u91cf\u5247\u6709\u53ef\u80fd\u6703\u9054\u5230D1\u4e4b67%~68%\u4e4b\u9593\u3002\n\u7d50\u8ad6\uff1a\u7531\u672c\u5be6\u9a57\u5f97\u77e5\uff0c\u4e0d\u540c\u7684\u816b\u7624\u8f2a\u5ed3\u4ee5\u53ca\u8f2a\u5ed3\u5230\u8868\u9762\u7684\u8ddd\u7684\u78ba\u6703\u5f71\u97ff\u75c5\u4eba\u76ae\u819a\u7167\u5c04\u7684\u5291\u91cf\uff1bD0/D1\u53ef\u61c9\u7528\u65bc\u81e8\u5e8a\u4e0a\u8a55\u4f30\u982d\u9838\u764c\u75c5\u4eba\u76ae\u819a\u5291\u91cf\u7684\u53c3\u8003\u6578\u64da\u3002", "e": "Purpose: This research was focused on the reliability of measured tool for the skin dose in vivo of the head-and-neck patients treated with radiation. To establish the relationship of the dose ratio of the surface and Dmax, and this data can be used as references for c1inical applications.\nMaterials and Method: This experiment adopted Harshaw cylindrical TLD, Markus parallel ion chamber and ISP Gafchromic EBT film as the measured tool to establish the characteristics and buildup region. Target contoured were under the skin surface, equal to the skin surface and over the skin surface respectively. This research will establish the relationship of the dose ratio of the surface (D0) and 1 cm depth from skin (D1) when D1 of the measurement is similar to that calculated by the treatment planning system. D0/D1 is expected to predict the actual absolute received dose.\nResult: In this experiment the variance coefficient of TLD was within 3%. The reading values and delivered doses were in a good linear relationship. The points on calibration curve of Gafchromic film were within 5% and in a stable performance. In additiol1, D1 of Gafchromic film compared to that calculated by the treatment planning system was similar and the errors were all within 5%. Thus, the dose ratio (D0/D1) of the measured surface dose and calculated dose with 1 cm depth from skin could be used to calculate the approximate skin dose. The measured skin dose for most of the head-and-neck patients with the target contoured over or equal to the skin surface was around 85%~95% of D1; whereas with the target contoured 4 mm under the skin surface, the measured skin dose was around 67%-68% of D1.\nConclusion and Discussion: From the experimental results, the proximity of the target contour to the skin indeed affects the skin dose received from radiation treatment. D0/D1, can be used as references for clinical applications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-29-38", "title": "\u865b\u64ec\u5be6\u9ad4\u74b0\u5883\u6574\u5408\u5f71\u50cf\u5c0d\u4f4d\u6a21\u7d44\u5728\u76f4\u7dda\u52a0\u901f\u5668\u7167\u91ce\u5b9a\u4f4d\u898f\u5283\u8207\u9a57\u8b49\u4e4b\u904b\u7528", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642\u8a08\u5283;\u5f71\u50cf\u6821\u6e96\u5c0d\u4f4d;\u865b\u64ec\u5be6\u9ad4\u74b0\u5883;\u9006\u5411\u5de5\u7a0b Radiation treatment planning;Image registration;Virtual simulation environment;Reverse engineering", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u958b\u767c\uff0d\u653e\u5c04\u6cbb\u7642\u7167\u91ce\u5b9a\u4f4d\u898f\u5283\u8207\u9a57\u8b49\u8f14\u52a9\u7cfb\u7d71\uff0c\u5176\u4e2d\u5305\u542b\u865b\u64ec\u5be6\u9ad4\u6a21\u7d44\u53ca\u5f71\u50cf\u6821\u6e96\u5c0d\u4f4d\u6a21\u7d44\u4e26\u4ee5\u591a\u5a92\u9ad4\u4e4b\u4ecb\u9762\u74b0\u5883\u64cd\u4f5c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7cfb\u7d71\u662f\u7d50\u5408\u865b\u64ec\u5be6\u5883\u6280\u8853\u3001\u96fb\u81663D\u5f71\u50cf\u8655\u7406\u4ecb\u9762\u3001\u9006\u5411\u5de5\u7a0b\u53ca\u91ab\u5b78\u6578\u4f4d\u5f71\u50cf\u5c0d\u4f4d\u539f\u7406\u6574\u5408\u69cb\u6210\u7684\u4e00\u5957\u5b9a\u4f4d\u898f\u5283\u9a57\u8b49\u6280\u8853\u4e26\u5c07\u5176\u8207\u76f4\u7dda\u52a0\u901f\u5668\u7d50\u5408\u4f7f\u7528\u3002\u672c\u7814\u7a76\u4fc2\u4f7f\u7528\u5168\u5c3a\u5bf8\u865b\u64ec\u5be6\u5883\u6280\u8853\u4f86\u5efa\u7acb\u653e\u5c04\u816b\u7624\u6cbb\u7642\u5834\u666f\uff0c\u4e26\u4ee5\u4e09\u7dad\u91cd\u69cb\u6280\u8853\u53d6\u5f97\u60a3\u8005\u4eba\u9ad43D\u6578\u4f4d\u5f71\u50cf\u53ca\u6a21\u578b\uff08\u771f\u5be6\u5c3a\u5bf8\uff09\uff0c\u9032\u4e00\u6b65\u7d50\u5408\u653e\u5c04\u6cbb\u7642\u6a21\u64ec\u651d\u5f71\u5ba4\u4e2d\u771f\u5be6\u7684\u5f71\u50cf\u5c0d\u4f4d\u8cc7\u8a0a\uff0c\u63d0\u4f9b\u653e\u5c04\u6cbb\u7642\u81e8\u5e8a\u6cbb\u7642\u4e0a\u6240\u9700\u7684\u4e09\u7dad\u5b9a\u4f4d\u8cc7\u8a0a\uff0c\u63d0\u6607\u7167\u91ce\u5b9a\u4f4d\u9a57\u8b49\u4e4b\u7cbe\u5ea6\u53ca\u65b9\u4fbf\u6027\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u958b\u767c\u4e4b\u6578\u4f4d\u5f71\u50cf\u6821\u6e96\u5c0d\u4f4d(Registration)\u6a21\u7d44\u53ef\u6709\u6548\u7684\u9032\u884c\u5c0d\u4f4d\u8207\u9a57\u8b49\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5efa\u7acb\u4e00\u5957\u7b26\u5408\u771f\u5be6\u5c3a\u5bf8\u6bd4\u4f8b\u4e4b\u653e\u5c04\u6cbb\u7642\u7167\u91ce\u5b9a\u4f4d\u898f\u5283\u8207\u9a57\u8b49\u8f14\u52a9\u7cfb\u7d71\uff0c\u5176\u5177\u5099\u9069\u5408\u91ab\u5e2b\u8853\u524d\u6a21\u64ec\u5b9a\u4f4d\u3001\u6cbb\u7642\u6f14\u7df4\u3001\u53ca\u5f71\u50cf\u5c0d\u4f4d\u9a57\u8b49\u4e4b\u591a\u7a2e\u7528\u9014\uff0c\u9664\u53ef\u63d0\u9ad8\u653e\u5c04\u6cbb\u7642\u4e4b\u6e96\u78ba\u5ea6\uff0c\u4e26\u53ef\u4f5c\u70ba\u81e8\u5e8a\u91ab\u5e2b\u6559\u5b78\u8a13\u7df4\u4e4be\u5316\u8a2d\u5099\u3002", "e": "Purpose: A novel system for radiation treatment planning (RTP) positioning procedure is developed by integrating the full size virtual simulation module and computer aided image registration module operated under multimedia environment to assist the radiation treatment planning positioning procedure.\nMaterials and Method: The novel system is developed by integrating the virtual reality technique, 3D computer image interface, reverse engineering and computer graphics theory. The full size solid virtual objects are reconstructed from CT slides in order to provide the real 3-dimension information to simulate and adjust the difference between the simulator and the linear accelerator.\nResults: The advantage of using this novel system is to provide the adjustment for difference between simulation patient position and treatment patient position\nConclusion: With the assistance of this system, the simulation time will be decreased without sacrificing the accuracy of the positioning. This system developed in this study also can be a useful e-learning tool for c1inical studying and teaching."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-39-45", "title": "Salvage Treatment for Isolated Para-Aortic Lymph Node Recurrence in Cervical Carcinoma after Concurrent Chemoradiotherpy-A Case Report", "keywords": "\u5b50\u5bae\u9838\u764c;\u5408\u4f75\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642;\u62ef\u6551\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u8207\u624b\u8853\u6cbb\u7642 cervical cancer;chemoradiotherapy;salvage radiotherapy and surgery", "c": "\u5728\u6b64\u6211\u5011\u5831\u544a\u4e00\u4f4d70\u6b72\u5a66\u5973\uff0c\u7f79\u60a3\u5b50\u5bae\u9838\u764c\uff0c\u6700\u521d\u5206\u671f\u70baFIGO IIB\uff0c\u904e\u53bb\u66fe\u7d93\u63a5\u53d7\u5408\u4f75\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3002\u7531\u65bc\u8840\u6e05\u4e2d\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u6297\u539f\u6578\u503c\u63d0\u9ad8\uff0c\u6b63\u5b50\u651d\u5f71\u8207\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u4e3b\u52d5\u8108\u6dcb\u5df4\u817a\u8f49\u79fb\u3002\u75c5\u60a3\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff0c\u517162Gy/33\u6b21\uff0c\u540c\u6642\u5408\u4f75\u53e3\u670d\u5316\u5b78\u6cbb\u7642(UFUR)\u3002\u8ffd\u8e64\u5176\u96fb\u8166\u65b7\u5c64\u8207\u6b63\u5b50\u651d\u5f71\u767c\u73fe\u4ecd\u6709\u6b98\u9918\u4e3b\u52d5\u8108\u6dcb\u5df4\u817a\u8f49\u79fb\u3002\u75c5\u60a3\u63a5\u53d7\u53e6\u4e00\u6b21\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u517136Gy/20\u6b21\u3002\u5f8c\u7e8c\u96fb\u8166\u65b7\u5c64\u8207\u6b63\u5b50\u651d\u5f71\u4ecd\u767c\u73fe\u6709\u6b98\u9918\u75c5\u5146\uff0c\u65bc\u662f\u75c5\u60a3\u63a5\u53d7\u624b\u8853\u6e05\u9664\u4e3b\u52d5\u8108\u6dcb\u5df4\u817a\u3002\u75c5\u7406\u5831\u544a\u986f\u793a\u70ba\u8f49\u79fb\u6027\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u3002\n\u6b64\u75c5\u60a3\u3001\u7d93\u904e57\u500b\u6708\u9580\u8a3a\u8ffd\u8e64\u6aa2\u67e5\uff0c\u76ee\u524d\u4e26\u7121\u4efb\u4f55\u5fa9\u767c\u6216\u8f49\u79fb\u8de1\u8c61\u3002", "e": "We herein reported a case of 70-year-old woman with squamous cell carcinoma of uterine cervix, initial FIGO stage IIB. She received concurrent chemoradiotherapy in the past. Elevated serum SCC-antigen level was noted and para-aortic lymph node metastasis was demonstrated by PET scan and abdominal CT scan. Salvage radiotherapy with 62 Gy/33 fractions, intensity modulated radiotherapy technique to the para-aortic lymph node and concomitant UFUR capsules were prescribed. Residual lymph node at the para-aortic area was noted by follow up CT scan and PET scan. Another course of radiotherapy using 36 Gy/20 fractions with intensity modulated radiotherapy technique to the residual lymph node was performed. However, a small residual lymph node was identified by follow up CT scan and PET scan. Salvage surgery with para-aortic lymph node dissection was done later. The pathology showed metastatic squamous cell carcinoma.\nThe patient is still alive without local recurrence or distant metastasis at 57 months' follow up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-47-52", "title": "A Metachronous Gastric Tube Cancer for Esophageal Cancer after Surgical Esophagectomy", "keywords": "\u8907\u6578\u764c;\u91cd\u5efa\u98df\u9053\u80c3\u764c Secondary cancer;Reconstructed gastric tube", "c": "\u98df\u9053\u764c\u7684\u65e9\u671f\u8a3a\u65b7\u8207\u6cbb\u7642\u6280\u8853\u7684\u9032\u6b65\u5ef6\u9577\u4e86\u98df\u9053\u764c\u75c5\u4eba\u7684\u5b58\u6d3b\u671f\uff1b\u56e0\u6b64\u4ee5\u80c3\u4f5c\u91cd\u5efa\u98df\u9053\u4e4b\u7e8c\u767c\u6027\u80c3\u764c\u5c07\u6210\u70ba\u764c\u75c7\u5c08\u5bb6\u4e4b\u7279\u6b8a\u8b70\u984c\u3002\u6211\u5011\u767c\u8868\u4e00\u4f4d\u98df\u9053\u764c\u75c5\u4eba\u63a5\u53d7\u98df\u9053\u5207\u9664\u8853\uff0c\u4e26\u4ee5\u80c3\u4f5c\u91cd\u5efa\u98df\u9053\u9577\u671f\u8ffd\u8e64\u5f8c\u767c\u73fe\u7b2c\u4e8c\u500b\u764c\u75c7\u5728\u98df\u9053\u91cd\u5efa\u7684\u80c3\u5167\u3002\u5916\u79d1\u5207\u9664\u662f\u9019\u7a2e\u7e8c\u767c\u764c\u6cbb\u7642\u4e4b\u9996\u9078\uff1b\u764c\u7684\u65e9\u671f\u8a3a\u65b7\u8207\u5167\u8996\u93e1\u9ecf\u819c\u5207\u9664\u8853\u662f\u7372\u5f97\u826f\u597d\u9810\u5f8c\u7684\u57fa\u672c\u689d\u4ef6\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u5c0d\u7121\u6cd5\u624b\u8853\u3001\u62d2\u7d55\u63a5\u53d7\u624b\u8853\u6216\u9700\u8981\u8853\u5f8c\u8f14\u52a9\u6cbb\u7642\u7684\u75c5\u4eba\u6240\u61c9\u8003\u616e\u7684\u4e00\u7a2e\u6cbb\u7642\u6a21\u5f0f\u3002", "e": "Early detection of esophageal cancer and advance in therapeutic techniques increase the survival of esophageal cancer patients; therefore, reconstructed gastric tube cancer may become a special issue for oncologists. We present a case of esophageal cancer after esophagectomy and gastric tube reconstruction with long-term remission who developed a second cancer in reconstructed gastric tube Surgical intervention is the first priority choice of treatment, and endoscopic mucosal resection (EMR) for early cancer might result in good prognosis. Radiotherapy should be considered for inoperable patients or as an adjuvant mode after surgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-53-59", "title": "Small Cell Carcinoma of the Duodenum: A Case Report", "keywords": "\u5c0f\u7d30\u80de\u764c;\u5341\u4e8c\u6307\u8178;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642 Small cell carcinoma;Duodenum;Concurrent chemoradiation", "c": "\u5341\u4e8c\u6307\u8178\u4e4b\u5c0f\u7d30\u80de\u764c\u662f\u975e\u5e38\u7f55\u898b\u7684\u4e26\u4e14\u6709\u6975\u5dee\u7684\u9810\u5f8c\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d54\u6b72\u5973\u6027\u56e0\u6700\u521d\u8868\u73fe\u8178\u80c3\u9053\u51fa\u8840\u8207\u9ec3\u75b8\u800c\u88ab\u8a3a\u65b7\u51fa\u5341\u4e8c\u6307\u8178\u7684\u5c0f\u7d30\u80de\u764c\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u767c\u73fe\u5728\u5341\u4e8c\u6307\u8178\u7684\u7b2c\u4e8c\u90e8\u5206\u6709\u4e00\u500b\u754c\u7dda\u4e0d\u660e\u7684\u816b\u584a\uff0c\u800c\u5167\u8996\u93e1\u5207\u7247\u7684\u7d44\u7e54\u5b78\u6aa2\u67e5\u986f\u793a\u672a\u5206\u5316\u764c\u3002\u75c5\u60a3\u63a5\u53d7\u4e86Whipple\u624b\u8853\u53ca\u5c40\u90e8\u6dcb\u5df4\u6458\u9664\uff0c\u800c\u75c5\u7406\u5831\u544a\u8868\u73fe\u51fa\u5c0f\u7d30\u80de\u764c\uff0c\u624b\u8853\u6aa2\u9ad4\u908a\u7de3\u4e26\u672a\u6709\u816b\u7624\u4fb5\u72af\uff0c\u4f46\u5c40\u90e8\u6dcb\u5df4\u5247\u88ab\u816b\u7624\u4fb5\u72af\u3002\u8853\u5f8c\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u767c\u73fe\u816b\u7624\u5fa9\u767c\u65bc\u816b\u7624\u5e8a\u8655\u3002\u75c5\u60a3\u63a5\u53d7\u4e86\u88dc\u6551\u6027\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u6cbb\u7642\uff0c\u4f46\u6cbb\u7642\u5f15\u8d77\u7684\u9aa8\u9ad3\u529f\u80fd\u6291\u5236\u9020\u6210\u75c5\u60a3\u7121\u6cd5\u5b8c\u6210\u5168\u7a0b\u7684\u653e\u5c04\u6cbb\u7642\u3002\u96d6\u7136\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u986f\u793a\u826f\u597d\u7684\u88dc\u6551\u6cbb\u7642\u7d50\u679c\uff0c\u816b\u7624\u5f88\u5feb\u53c8\u9577\u5927\u800c\u75c5\u60a3\u4ecd\u65bc\u6700\u521d\u8a3a\u65b7\u5f8c\u768411\u500b\u6708\u5e36\u75c5\u6b7b\u4ea1\u3002", "e": "Small cell carcinoma of the duodenum is an extremely rare disease with grave prognosis. We report a 54-year-old female who was diagnosed with small cell carcinoma in the duodenum with the initial presentation of gastrointestinal bleeding and jaundice. Abdominal computed tomography (CT) disclosed an ill-defined mass over the second part of duodenum and the histology from endoscopic biopsy demonstrated undifferentiated carcinoma. She received Whipple operation with regional lymph nodes (LNs) dissection and the pathology showed small cell carcinoma with clear surgical margins. Regional LNs were as well involved by cancer cells. Postoperative CT revealed recurrent mass at previous surgical bed. She was planned to receive salvage concurrent chemoradiation to control her disease, but treatment induced inadequate bone marrow function hindered patient to complete her full radiation course. Although CT demonstrated good salvage result, tumor enlarged again soon and the patient still died with the disease 11 months after initial diagnosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-201003-201007050077-201007050077-61-70", "title": "Metastatic Adenoid Cystic Carcinoma to the Kidney of the Mouth Floor Origin: A Case Report and Review of the Literature", "keywords": "\u817a\u6a23\u56ca\u72c0\u764c;\u53e3\u8154\u5e95;\u814e\u81df\u8f49\u79fb Adenoid cystic carcinoma;Mouth floor;Renal metastasis", "c": "\u817a\u6a23\u56ca\u72c0\u764c\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u4e09\u5206\u4e4b\u4e00\u5230\u4e00\u534a\u6e90\u81ea\u65bc\u553e\u6db2\u817a\u3002\u5b83\u901a\u5e38\u4ee5\u7121\u75c7\u72c0\u7684\u81e8\u5e8a\u8868\u73fe\u3001\u7368\u7279\u7684\u7de9\u6162\u537b\u7121\u6b62\u76e1\u7684\u751f\u9577\u6a21\u5f0f\u4ee5\u53ca\u6709\u5f88\u9ad8\u7684\u6a5f\u6703\u4fb5\u72af\u795e\u7d93\u4f86\u8868\u73fe\uff0c\u4f46\u6dcb\u5df4\u7684\u8f49\u79fb\u5247\u5f88\u5c11\u898b\u3002\u9060\u7aef\u8f49\u79fb\u53ef\u4ee5\u5728\u5c40\u90e8\u53ca\u5340\u57df\u6c92\u6709\u5fa9\u767c\u7684\u60c5\u5f62\u4e0b\uff0c\u8ddd\u6700\u521d\u6cbb\u7642\u8d85\u904e\u5341\u5e74\u4ee5\u4e0a\u624d\u5fa9\u767c\u3002\u96d6\u7136\u9060\u7aef\u8f49\u79fb\u5230\u80ba\u81df\u3001\u809d\u81df\u4ee5\u53ca\u9aa8\u9abc\u5e38\u767c\u751f\uff0c\u8f49\u79fb\u5230\u814e\u81df\u5247\u4e0d\u5e38\u898b\u3002\u53ea\u6709\u4e00\u5c0f\u90e8\u4efd\u6e90\u81ea\u65bc\u4e73\u623f\u3001\u816e\u817a\u3001\u80ba\u81df\u3001\u6dda\u817a\u3001\u8033\u9053\u548c\u786c\u816d\u7684\u817a\u6a23\u56ca\u72c0\u764c\u8f49\u79fb\u5230\u814e\u81df\u7684\u6848\u4f8b\u66fe\u88ab\u5831\u544a\u904e\u3002\u5c31\u6211\u5011\u6240\u77e5\uff0c\u76ee\u524d\u6587\u737b\u4e0a\u5c1a\u7121\u6e90\u81ea\u65bc\u53e3\u8154\u5e95\u7684\u817a\u6a23\u56ca\u72c0\u764c\u8f49\u79fb\u5230\u814e\u81df\u7684\u6848\u4f8b\u88ab\u5831\u5c0e\u904e\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d\u7684\u6b72\u7684\u7537\u6027\u5728\u624b\u8853\u6cbb\u7642\u53e3\u8154\u5e95\u817a\u6a23\u56ca\u72c0\u764c20\u5e74\u4e4b\u5f8c\uff0c\u767c\u751f\u816b\u7624\u8f49\u79fb\u5230\u814e\u81df\u7684\u6848\u4f8b\uff0c\u4e26\u505a\u6587\u737b\u7684\u56de\u9867\u3002", "e": "Adenoid cystic carcinoma (ACC) is a rare malignant tumor, and one third to half of which arises from the salivary glands. It usually shows remarkably asymptomatic c1inical course, unique slow-growing but relentless pattern and high incidence of perineural invasion whereas lymph nodes metastasis is seldom seen. Distant metastasis can occur without evidence of locoregional failure more than a decade after initial treatment. Although distant metastases to lung, liver and bone develop frequently, metastasize to kidney is uncommon. Only a small number of patients with ACC metastasize to kidney from the breast, parotid gland, lung, lacrimal gland, auditory canal, and hard palate have been reported. To our knowledge, renal involvement from a mouth floor origin has not been reported in the literature. We report a 68-year-old male patient who presented as metastatic adenoid cystic carcinoma to his right kidney 20 years after surgical treatment of ACC of the mouth floor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-165-177-a", "title": "Comparison between Pre-Operative Short Course Radiotherapy and Long Course Chemoradiotherapy in Patients with Locally Advanced Rectal Cancers", "keywords": "\u76f4\u8178\u764c;\u8853\u524d\u653e\u5c04\u6cbb\u7642;\u8853\u524d\u77ed\u671f\u653e\u5c04\u6cbb\u7642;\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642 Rectal cancer;Preoperative radiotherapy;Pre-operative short-course radiotherapy;Concurrent chemoradiotherapy", "c": "\u76ee\u7684\uff1a\u9019\u500b\u7814\u7a76\u7684\u76ee\u7684\u662f\u5206\u6790\u5c0d\u65bc\u4fb5\u8972\u6027\u76f4\u8178\u764c\u7684\u75c5\u60a3\uff0c\u8853\u524d\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\u8207\u9577\u7a0b\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642\uff0c\u662f\u5426\u5c31\u53ef\u5207\u9664\u6027\uff0c\u816b\u7624\u53cd\u61c9\u548c\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u7559\u800c\u8a00\u63d0\u4f9b\u76f8\u8fd1\u7684\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u897f\u51432003\u5e7412\u6708\u81f32008\u5e748\u6708\u671f\u9593\uff0c88\u500b\u4fb5\u8972\u6027\u76f4\u8178\u764c\u7684\u75c5\u60a3\u63a5\u53d7\u8853\u524d5\u00d75 Gy\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u7acb\u5373\u6027\u624b\u8853\u6216\u662f\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff08\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u723250.4 Gy\uff0c\u55ae\u6b21\u5291\u91cf1.8 Gy\uff1b\u540c\u6642\u52a0\u4e0a\u5169\u500b\u7642\u7a0b\u76845-fluorouracil\u548cleucovorin\uff09\u5408\u4f75\u5ef6\u9072\u6027\u624b\u8853\u3002\n\u7d50\u679c\uff1a\u572888\u500b\u4fb5\u8972\u6027\u76f4\u8178\u764c\u7684\u75c5\u60a3\u4e2d\uff0c38\u500b\u63a5\u53d7\u8853\u524d\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\uff0c50\u500b\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3002\u6240\u6709\u75c5\u4eba\u90fd\u6709\u63a5\u53d7\u624b\u8853\u3002\u624b\u8853\u5f8c\u908a\u7de3\u4e7e\u6de8\u7684\u6bd4\u4f8b\u5206\u5225\u662f97%\u548c98%\uff0c\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u7559\u7684\u6bd4\u4f8b\u5206\u5225\u662f100%\u548c98%\u3002\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u6bd4\u63a5\u53d7\u8853\u524d\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u6709\u8f03\u9ad8\u7684\u6bd4\u4f8b\u6709\u816b\u7624\u53cd\u61c9(CCRT 40% vs. SCRT 29%, p=0.28)\u3002\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f19\u500b\u6708\u3002\u5728\u8ffd\u8e64\u671f\u9593\uff0c6\u500b\u75c5\u60a3(7%)\u6709\u5c40\u90e8\u5fa9\u767c\uff0c16\u500b\u75c5\u60a3(18%)\u767c\u751f\u9060\u7aef\u8f49\u79fb\u30022\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5728\u5169\u500b\u65cf\u7fa4\u4e4b\u9593\u4e26\u6c92\u6709\u7d71\u8a08\u4e0a\u7684\u5dee\u7570(SCRT-96.0% vs. CCRT-86.9%, p=0.48)\u3002\u5c31\u7121\u75c5\u5b58\u6d3b\u7387\u800c\u8a00\uff0c\u63a5\u53d7\u8853\u524d\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u6bd4\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u6709\u8f03\u4f73\u76842\u5e74\u7121\u75c5\u5b58\u6d3b\u7387(SCRT-82.4% vs. CCRT-62.4%, p=0.06)\u3002\n\u7d50\u8ad6\uff1a\u5c31\u53ef\u5207\u9664\u6027\u548c\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u7559\u800c\u8a00\uff0c\u5c0d\u65bc\u7b2cII-III\u671f\u7684\u76f4\u8178\u764c\u75c5\u60a3\uff0c\u8853\u524d\u77ed\u7a0b\u653e\u5c04\u6cbb\u7642\u548c\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u63d0\u4f9b\u4e86\u76f8\u8fd1\u7684\u6548\u679c\u3002\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5247\u6709\u8f03\u9ad8\u7684\u816b\u7624\u53cd\u61c9\u6bd4\u4f8b\u3002\u5169\u7a2e\u6cbb\u7642\u65b9\u5f0f\u5c0d\u65bc\u9577\u671f\u7684\u5b58\u6d3b\u7387\u548c\u816b\u7624\u63a7\u5236\u7387\u7684\u6548\u679c\u5247\u9700\u8981\u66f4\u9577\u7684\u8ffd\u8e64\u6642\u9593\u624d\u80fd\u4e86\u89e3\u3002", "e": "Purpose: The aim of this study is to determine whether preoperative short course radiotherapy (SCRT) or long course chemoradiotherapy (CCRT) offers similar results in terms of the resectability, tumor response and sphincter preservation in patients with locally advanced (stage II-III) rectal cancer.\nMaterials and Methods: Between December 2003 and August 2008, 88 patients with rectal adenocarcinoma (clinical staged T3-4N0-2M0) received either SCRT or CCRT were enrolled. In the SCRT group, patients received pre-operative 5\u00d75 Gy with immediate surgery. In the CCRT group, patients received a total dose of 50.4 Gy (1.8 Gy per fraction) concomitantly with two courses of 5-fluorouracil and leucovorin followed by delayed surgery.\nResults: Among the 88 patients, 38 received SCRT and 50 received CCRT. All patients received curative surgery. A R0 resection was performed in 97% and 98% of patients received SCRT and CCRT respectively. Sphincter preservation was achieved in 100% and 98% of patients received SCRT and CCRT respectively. A higher tumor response rate was observed in the CCRT group (downstage 40%) as compared with SCRT group (downstaging 29%). With a median follow-up time of 19 months, local failure developed in 6 of 88 (7%) and distant metastases occurred in 16 of 88 (18%). The 2-year overall survival (OS) are comparable between these two groups (OS: SCRT-96.0% vs. CCRT-86.9%, p=0.48). In terms of disease-free survival (DFS), patients in the SCRT group have borderline significant better 2-year DFS as compared with CCRT group (DFS: SCRT-82.4% vs. CCRT-62.4%, p=0.06).\nConclusion: Pre-operative SCRT and CCRT are equally effective in terms of the resectability and sphincter preservation in stage II-III rectal cancer. A higher tumor response (downstaging and complete tumor response) was noted in the CCRT group. The long term results of overall tumor control and survivals between these two groups still need longer follow-up time to disclose."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-179-194-a", "title": "Radiation Therapy for Advanced Hepatocellular Carcinoma with Hepatic Hilum Involvement and High Bilirubin Level: Better Survival in Decreased Bilirubin after Radiotherapy", "keywords": "\u809d\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u81bd\u7d05\u7d20;\u809d\u9580 Hepatocellular carcinoma;Radiation therapy;Bilirubin;Hepatic hilum", "c": "Purpose: To investigate the efficacy of external beam radiation therapy (EBRT) for hepatocellular carcinoma (HCC) with hepatic hilum (portal vein with or without bile duct) involvement and high bilirubin level (\uff1e3 mg/dl).\nMaterials and Methods: Between May 2001 and August 2007, 41 HCC patients with hepatic hilum involvement and high bilirubin level before EBRT were retrospectively reviewed. The radiation dose was 24 Gy in 5 fractions and the target volume was focused on the tumor involved hepatic hilum. All patients had bilirubin data 2 weeks before EBRT and 1 month after EBRT. The decreased bilirubin (De-Bil) group included patients whose bilirubin after EBRT was lower than bilirubin before EBRT, and the patients in increased bilirubin (In-Bil) group had bilirubin after EBRT equal to or higher than before. The survival times were analyzed by Kaplan-Meier and Cox regression analysis.\nResults: The bilirubin was decreased after EBRT in 48.8% of patients. In all clinical features, there were no significant differences between the De-Bil and In-Bil groups by the chi-square test. The median survival was 4.4 months in the De-Bil group and 1.0 month in the In-Bil group, respectively (p\uff1c0.001). The De-Bil group had significantly better survival than the In-Bil group according to Child-Pugh class, American Joint Committee on Cancer (AJCC) stage, Okuda stage, Cancer of the Liver Italian Program (CLIP) score, and Japan Integrated Staging (JIS) score. In multivariate analysis, the bilirubin change was the most significant factor associated with survival (HR: 34.314, p\uff1c0.001). In treatment response evaluation by follow-up images, the De-Bil group had better response than the In-Bil group in available patients.\nConclusion: Decrease of bilirubin level after EBRT indicates a better survival and is related to a better response in image study. Local EBRT to HCC invading hepatic hilum shows prolonged survival in radiation responsive patients.", "e": "Purpose: To investigate the efficacy of external beam radiation therapy (EBRT) for hepatocellular carcinoma (HCC) with hepatic hilum (portal vein with or without bile duct) involvement and high bilirubin level (\uff1e3 mg/dl).\nMaterials and Methods: Between May 2001 and August 2007, 41 HCC patients with hepatic hilum involvement and high bilirubin level before EBRT were retrospectively reviewed. The radiation dose was 24 Gy in 5 fractions and the target volume was focused on the tumor involved hepatic hilum. All patients had bilirubin data 2 weeks before EBRT and 1 month after EBRT. The decreased bilirubin (De-Bil) group included patients whose bilirubin after EBRT was lower than bilirubin before EBRT, and the patients in increased bilirubin (In-Bil) group had bilirubin after EBRT equal to or higher than before. The survival times were analyzed by Kaplan-Meier and Cox regression analysis.\nResults: The bilirubin was decreased after EBRT in 48.8% of patients. In all clinical features, there were no significant differences between the De-Bil and In-Bil groups by the chi-square test. The median survival was 4.4 months in the De-Bil group and 1.0 month in the In-Bil group, respectively (p\uff1c0.001). The De-Bil group had significantly better survival than the In-Bil group according to Child-Pugh class, American Joint Committee on Cancer (AJCC) stage, Okuda stage, Cancer of the Liver Italian Program (CLIP) score, and Japan Integrated Staging (JIS) score. In multivariate analysis, the bilirubin change was the most significant factor associated with survival (HR: 34.314, p\uff1c0.001). In treatment response evaluation by follow-up images, the De-Bil group had better response than the In-Bil group in available patients.\nConclusion: Decrease of bilirubin level after EBRT indicates a better survival and is related to a better response in image study. Local EBRT to HCC invading hepatic hilum shows prolonged survival in radiation responsive patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-195-201-a", "title": "\u4ee5\u975e\u7b49\u6bd4\u91cd\u56db\u7167\u91ce\u5168\u9aa8\u76c6\u8154\u7167\u5c04\u5c0d\u5a66\u764c\u75c5\u60a3\u5c0f\u8178\u9ad4\u7a4d\u4e4b\u5f71\u97ff", "keywords": "\u8eab\u9ad4\u8cea\u91cf\u6307\u6578;\u5c0f\u8178;\u7b49\u6bd4\u91cd;\u975e\u7b49\u6bd4\u91cd Body mass index;Small-bowel;Equal weighting;Non-equal weighting", "c": "Purpose: To evaluate effect of different beam weighting in 4-field radiotherapy on small-bowel volume in patients with gynecologic malignancies.\nMaterial and Methods: Thirty gynecological patients were enrolled in this study from August 2004 to September 2005. Computed-tomography (CT)-simulations were performed and the small bowel was outlined manually by the physician. Treatment plans with non-equal weighted 4-field technique (AP/ PA 20%/20% and R/L 30%/30%) were done and the dose-volume histograms for small bowel were compared with equal weighted 4-field technique. D50 was defined as the volume difference isodose curve between equal and non-equal weighting technique. D50R was defined as the ratio of D50 to small-bowel volume of equal weighting technique. We tried to correlated D50 or D50R with age and body mass index (BMI) with correlation and multiple linear regression.\nResults: The non-equal weighting technique achieved maximum small-bowel volume reduction at 50% isodose level (p\uff1c0.001). D50 was correlated with age (R=0.623, p\uff1c0.001) and BMI (R=0.610, p\uff1c0.001). D50R was correlated with BMI (R=0.726, p\uff1c0.001). On multiple linear regression, age (p\uff1c0.001) and BMI (p\uff1c0.001) were independent factors of D50. BMI (p\uff1c0.001) was the only independent factor of D50R.\nConclusion: Treatment plans using non-equal-weighted treatment plans with smaller weighting in the antero-posterior direction can reduce small-bowel volume in patients with gynecologic malignancies, especially in those with high BMI.", "e": "Purpose: To evaluate effect of different beam weighting in 4-field radiotherapy on small-bowel volume in patients with gynecologic malignancies.\nMaterial and Methods: Thirty gynecological patients were enrolled in this study from August 2004 to September 2005. Computed-tomography (CT)-simulations were performed and the small bowel was outlined manually by the physician. Treatment plans with non-equal weighted 4-field technique (AP/ PA 20%/20% and R/L 30%/30%) were done and the dose-volume histograms for small bowel were compared with equal weighted 4-field technique. D50 was defined as the volume difference isodose curve between equal and non-equal weighting technique. D50R was defined as the ratio of D50 to small-bowel volume of equal weighting technique. We tried to correlated D50 or D50R with age and body mass index (BMI) with correlation and multiple linear regression.\nResults: The non-equal weighting technique achieved maximum small-bowel volume reduction at 50% isodose level (p\uff1c0.001). D50 was correlated with age (R=0.623, p\uff1c0.001) and BMI (R=0.610, p\uff1c0.001). D50R was correlated with BMI (R=0.726, p\uff1c0.001). On multiple linear regression, age (p\uff1c0.001) and BMI (p\uff1c0.001) were independent factors of D50. BMI (p\uff1c0.001) was the only independent factor of D50R.\nConclusion: Treatment plans using non-equal-weighted treatment plans with smaller weighting in the antero-posterior direction can reduce small-bowel volume in patients with gynecologic malignancies, especially in those with high BMI."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-203-213-a", "title": "\u4e94\u5473\u5b50\u7d20Schisandrin B\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u4e4b\u63a2\u8a0e", "keywords": "\u4e94\u5473\u5b50\u7d20;\u8f3b\u5c04\u4fdd\u8b77;\u6297\u51cb\u4ea1;\u6297\u6c27\u5316 Schisandrin B;Radioprotection;Antiapoptosis;Antioxidation", "c": "Purpose: Schisandrin B (San B), an active component of Schizandra chinensis Baill, has biological activities and pharmacological action including anti-oxidative and hepatoprotective effects. In this present study, we investigated the radioprotective effect of San B and its related mechanism.\nMaterial and Methods: Cytotoxicity of pre-exposure to San B 72 hrs on Chang liver cell was measured by MTT assay. The radiation-induced apoptosis of Chang liver cell pretreated with San B at 40 \u03bcM for 24 hours followed by irradiation 15 Gy was assessed by flow cytometry and Western Blot test. The antioxidative activity of Chang liver cells pretreated with San B 40 \u03bcM for 4 hours followed by irradiation was evaluated by Glutathione Assay Kit.\nResults: A significant increase in mean survival viability (31.4\u00b113.6%) of Chang liver cell irradiated after pre-exposure to San B at 40 \u03bcM was observed as compared to corresponding irradiated alone controls (22.6\u00b19.6%, p\uff1c0.05) by MTT assay. The sub G1 population of Chang liver cells, pretreated with San B at 40 \u03bcM followed by irradiation, was 5% compared to 12% in radiation alone group (p\uff1c0.05). The antioxidative activity of Chang liver cells pretreated with San B 40 \u03bcM followed by irradiation also significantly increased the intracellular glutathione (GSH) levels in comparison with radiation alone group. Furthermore, Western blotting showed that pretreatment with San B 40 \u03bcM significantly down-regulated p53 and Bax, suppressing expression of caspases-9 and caspases-3 after irradiation. However, no effect on the antiapoptotic protein Bcl-2 was found, suggesting that the radioprotective effect of San B is mediated by inhibition of p53-mediated apoptotic pathway.\nConclusion: Our results suggest that San B has a radioprotective effects on Chang liver cells. Its action mechanism involves both elevation of antioxidative activity and inhibition of radiation-induced apoptosis.", "e": "Purpose: Schisandrin B (San B), an active component of Schizandra chinensis Baill, has biological activities and pharmacological action including anti-oxidative and hepatoprotective effects. In this present study, we investigated the radioprotective effect of San B and its related mechanism.\nMaterial and Methods: Cytotoxicity of pre-exposure to San B 72 hrs on Chang liver cell was measured by MTT assay. The radiation-induced apoptosis of Chang liver cell pretreated with San B at 40 \u03bcM for 24 hours followed by irradiation 15 Gy was assessed by flow cytometry and Western Blot test. The antioxidative activity of Chang liver cells pretreated with San B 40 \u03bcM for 4 hours followed by irradiation was evaluated by Glutathione Assay Kit.\nResults: A significant increase in mean survival viability (31.4\u00b113.6%) of Chang liver cell irradiated after pre-exposure to San B at 40 \u03bcM was observed as compared to corresponding irradiated alone controls (22.6\u00b19.6%, p\uff1c0.05) by MTT assay. The sub G1 population of Chang liver cells, pretreated with San B at 40 \u03bcM followed by irradiation, was 5% compared to 12% in radiation alone group (p\uff1c0.05). The antioxidative activity of Chang liver cells pretreated with San B 40 \u03bcM followed by irradiation also significantly increased the intracellular glutathione (GSH) levels in comparison with radiation alone group. Furthermore, Western blotting showed that pretreatment with San B 40 \u03bcM significantly down-regulated p53 and Bax, suppressing expression of caspases-9 and caspases-3 after irradiation. However, no effect on the antiapoptotic protein Bcl-2 was found, suggesting that the radioprotective effect of San B is mediated by inhibition of p53-mediated apoptotic pathway.\nConclusion: Our results suggest that San B has a radioprotective effects on Chang liver cells. Its action mechanism involves both elevation of antioxidative activity and inhibition of radiation-induced apoptosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-215-226-a", "title": "\u653e\u5c04\u6cbb\u7642\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71ARIA(\u4e0b\u6a19 TM)\u5ba2\u88fd\u5316\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u8a18\u9304\u55ae", "keywords": "\u653e\u5c04\u6cbb\u7642\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71;\u6cbb\u7642\u7d00\u9304\u55ae Oncology Information System;Record Sheet", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u9808\u7d93\u91ab\u5e2b\u3001\u7269\u7406\u5e2b\u3001\u5291\u91cf\u5e2b\u3001\u653e\u5c04\u5e2b\u7b49\u4eba\u901a\u529b\u5408\u4f5c\uff0c\u624d\u80fd\u5b8c\u6210\u898f\u5283\u3001\u6e96\u5099\u53ca\u57f7\u884c\u76f4\u7dda\u52a0\u901f\u5668\u3001\u5f71\u50cf\u5c0e\u5f15\u88dd\u7f6e\u3001\u6a21\u64ec\u651d\u5f71\u3001\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u7b49\uff0c\u7531\u65bc\u6b64\u8907\u96dc\u57f7\u884c\u904e\u7a0b\u5e38\u767c\u751f\u6587\u4ef6\u8cc7\u8a0a\u50b3\u905e\u932f\u8aa4\uff0c\u672c\u7814\u7a76\u5c0e\u5165\u96fb\u5b50\u5316\u8f38\u51fa\u653e\u5c04\u6cbb\u7642\u8a18\u9304\u55ae\u65b9\u5f0f\u4ee5\u78ba\u4fdd\u6587\u4ef6\u8cc7\u8a0a\u8207\u8cc7\u6599\u5eab\u5167\u5bb9\u540c\u6b65\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u70ba\u6a19\u699c\u5b8c\u5168\u6574\u5408\u75c5\u60a3\u8cc7\u8a0a\u53ca\u653e\u5c04\u6cbb\u7642\u8a18\u9304\u8207\u5f71\u50cf\u7ba1\u7406\uff0c\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u60c5\u4eba\u6e56\u5206\u9662\u653e\u5c04\u816b\u7624\u79d1\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71(Oncology Information System, OIS) ARIA(\u4e0a\u6a19 TM) (Varian, Palo Alto, USA)\u7ba1\u7406\u76f4\u7dda\u52a0\u901f\u5668(Clinac(\u4e0a\u6a19 \u00ae) iX, Varian, Palo Alto, USA)\u7684\u6cbb\u7642\u57f7\u884c\u8207\u8a18\u9304\u653e\u5c04\u6cbb\u7642\u4f5c\u696d\u3002\u8a72\u7cfb\u7d71\u5c07\u764c\u75c5\u8cc7\u8a0a\u3001\u6392\u7a0b\u8cc7\u8a0a\u3001\u5f71\u50cf\u5206\u6790\u3001\u6cbb\u7642\u8a08\u756b\u3001\u6cbb\u7642\u8f38\u51fa\u7d50\u679c\u7b49\u7686\u5132\u5b58\u65bc\u7121\u7d19\u3001\u7121\u7247\u7684\u55ae\u4e00\u8cc7\u6599\u5eab\u5167\u3002\u672c\u79d1\u81ea2006\u5e743\u6708\u8d77\u81f32008\u5e741\u6708\u5e95\u6b62\u5171675\u4f4d\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\uff0c\u5229\u7528InfoMaker(\u4e0a\u6a19 \u00ae)\u8edf\u9ad4(Sybase, Berkeley, USA)\u6240\u8a2d\u8a08\u7684\u8a18\u9304\u55ae\u5b8c\u6210\u6bcf\u65e5\u653e\u5c04\u6cbb\u7642\u57f7\u884c\u60c5\u5f62\u8a18\u9304\uff0c\u4e26\u78ba\u8a8d\u6bcf\u6b21\u57f7\u884c\u524d\u8a18\u9304\u55ae\u5167\u5bb9\u8f38\u51fa\u662f\u5426\u6b63\u78ba\u3002\n\u7d50\u679c\uff1a\u6bd4\u5c0d675\u4f4d\u75c5\u60a31331\u500b\u6cbb\u7642\u8a08\u5283\u6240\u7522\u751f\u7684\u6cbb\u7642\u7d00\u9304\u55ae\uff0c\u672a\u767c\u751f\u4efb\u4f55\u6cbb\u7642\u7d00\u9304\u55ae\u53c3\u6578\u8207\u52a0\u901f\u5668\u8f38\u51fa\u63a7\u5236\u689d\u4ef6\u4e0d\u543b\u5408\u72c0\u6cc1\uff0c\u56e0\u6b64\u4f7f\u7528\u8a72\u65b9\u5f0f\u8f38\u51fa\u6cbb\u7642\u7d00\u9304\u55ae\u53ef\u907f\u514d\u7d19\u672c\u6587\u4ef6\u6cbb\u7642\u53c3\u6578\u7d00\u9304\u932f\u8aa4\u767c\u751f\u6a5f\u6703\uff0c\u6e1b\u5c11\u5c0d\u653e\u5c04\u6cbb\u7642\u91ab\u7642\u8cc7\u8a0a\u7cfb\u7d71\u6240\u9700\u7684\u54c1\u8cea\u63a7\u7ba1\u6d41\u7a0b\uff0c\u78ba\u4fdd\u75c5\u60a3\u63a5\u53d7\u5b89\u5168\u7684\u653e\u5c04\u6cbb\u7642\u3002", "e": "Purpose: Radiotherapy is a multidisciplinary specialty involving the cooperation of physicians, medical physicists, and therapists. In addition to the use of complex equipment and procedures for the assessment, planning, and delivery of treatment, it is also imperative to guarantee the correct \u201drecord and verify\u201d of all treatment parameters. This study introduces a computer-based method to integrate accelerator therapy with its existing treatment practices.\nMaterial and Method: ARIA(superscript TM) oncology information system (OIS, Varian, Palo Alto, USA) has been used by the Department of Radiation Oncology, Chang Gung Memorial Hospital Lakeview Branch, Keelung to facilitate and ensure the connectivity between radiation delivery devices (Clinac(superscript \u00ae) iX, Varian, Palo Alto, USA) and the \u201drecord and verify\u201d functions. This system integrates information about cancer registration, treatment process, image analyses, treatment planning, and radiation deliveries in a database without paper and film. From Mar 2006 to Jan 2008, 1331 record sheets of 675 patients were established by Infomaker(superscript \u00ae) software (Sybase, Berkeley, USA). The accuracy of the record lists was evaluated.\nResult: Total of the 1331 record lists were found accurately matched with all the treatment parameters. Thus, using the computer-controlled OIS and related software could avoid artificial record mistake, verify processes of quality control, and facilitate and ensure superior radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-227-234-a", "title": "Combination of Induction Chemotherapy, Preoperative Chemoradiation and Surgery for Locally Advanced Gastric Cancer-A Case with Long-Term Control and Testicular Metastasis", "keywords": "\u80c3\u764c;\u8853\u524d\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u776a\u4e38\u8f49\u79fb Stomach neoplasm;Pre-operative chemoradiatherapy;Testicular metastasis", "c": "\u80c3\u764c\u70ba\u4e16\u754c\u4e0a\u764c\u75c7\u76f8\u95dc\u6b7b\u56e0\u6392\u540d\u7b2c\u4e8c\u4f4d\u7684\u764c\u75c7\u3002\u5c0d\u65bc\u5c40\u90e8\u4fb5\u8972\u6027\u80c3\u764c\uff0c\u8853\u5f8c\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u70ba\u73fe\u4eca\u4e4b\u6a19\u6e96\u6cbb\u7642\u3002\u7136\u800c\uff0c\u5c0d\u7121\u6cd5\u5207\u9664\u4e4b\u4fb5\u8972\u6027\u80c3\u764c\uff0c\u81f3\u4eca\u4ecd\u6c92\u6709\u6a19\u6e96\u7684\u6cbb\u7642\u5171\u8b58\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d\u8a3a\u65b7\u6642\u70ba\u7121\u6cd5\u5207\u9664\u4e4b\u5c40\u90e8\u4fb5\u8972\u6027\u80c3\u764c\u75c5\u4eba\uff0c\u5728\u63a5\u53d7\u5148\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u548c\u8853\u524d\u8f14\u52a9\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u518d\u884c\u624b\u8853\u5207\u9664\u53ca\u8853\u5f8c\u8f14\u52a9\u5316\u5b78\u6cbb\u7642\u3002\u75c5\u4eba\u5728\u6cbb\u7642\u904e\u7a0b\u4e2d\u4e26\u7121\u51fa\u73fe\u91cd\u5927\u7684\u526f\u4f5c\u7528\u3002\u9664\u6b64\u4e4b\u5916\uff0c\u5728\u9577\u671f\u8ffd\u8e64\u6642\uff0c\u75c5\u4eba\u767c\u751f\u7f55\u898b\u7684\u80c3\u764c\u776a\u4e38\u8f49\u79fb\u3002\u662f\u6545\uff0c\u7d50\u5408\u5148\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u3001\u8853\u524d\u8f14\u52a9\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u3001\u624b\u8853\u53ca\u8853\u5f8c\u8f14\u52a9\u5316\u5b78\u6cbb\u7642\u5c0d\u5c40\u90e8\u4fb5\u8972\u6027\u80c3\u764c\u6216\u8a31\u70ba\u4e00\u53ef\u884c\u4e4b\u6cbb\u7642\u65b9\u91dd\u3002", "e": "The gastric cancer is the second-leading cause of cancer-related death worldwide. The concurrent chemoradiatherapy (CCRT) using combination of radiotherapy and 5-FU is now a standard treatment modality for locally advanced gastric cancer post-operatively. However, there is no standard management to unresectable advanced gastric cancer yet. We reported a patient with initially unresectable gastric cancer received induction chemotherapy followed by neoadjuvant CCRT, surgical resection and adjuvant chemotherapy. He tolerated well without severe complication. Intriguingly, a rare metastasis over right testis developed after a relative long-term control. It suggests that the combination of induction chemotherapy, neoadjuvant CCRT, surgery and adjuvant chemotherapy might be a feasible treatment strategy for unresectable advanced gastric cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-235-241-a", "title": "Targeted the Target Volume?-A Case Report of Laryngeal Radionecrosis after Conformal Radiotherapy for Early Glottic Carcinoma", "keywords": "\u5589\u90e8\u653e\u5c04\u7dda\u6027\u58de\u6b7b;\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u65e9\u671f\u5589\u764c Laryngeal radionecrosis;Conformal radiotherapy;Early glottic carcinoma", "c": "\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u5df2\u88ab\u5ee3\u6cdb\u63a5\u53d7\u4f5c\u70ba\u60e1\u6027\u816b\u7624\u7684\u6cbb\u7642\uff0c\u7136\u800c\u76ee\u524d\u7684\u5291\u91cf\u8cc7\u6599\u7686\u7531\u5047\u9ad4\u6e2c\u5f97\uff0c\u800c\u975e\u5be6\u969b\u7531\u4eba\u9ad4\u6e2c\u91cf\u3002\u5728\u6b64\u6211\u5011\u5831\u544a\u4e00\u65e9\u671f\u5589\u764c\u75c5\u4eba\u4e4b\u5589\u90e8\u653e\u5c04\u7dda\u6027\u58de\u6b7b\uff0c\u85c9\u7531\u5206\u6790\u75c5\u7406\u8b49\u5be6\u7684\u58de\u6b7b\u7d44\u7e54\u8207\u91cd\u65b0\u5206\u6790\u7576\u521d\u6cbb\u7642\u5291\u91cf\u5206\u5e03\u7684\u95dc\u806f\u6027\uff0c\u4f86\u8aaa\u660e\u4e0a\u8ff0\u6d3b\u9ad4\u6cbb\u7642\u5291\u91cf\u7684\u6982\u5ff5\u3002\u6211\u5011\u7684\u5206\u6790\u986f\u793a\u63a5\u53d7\u8f03\u9ad8\u5291\u91cf\u7684\u653e\u5c04\u6cbb\u7642\u5340\u57df\u8207\u58de\u6b7b\u7d44\u7e54\u9ad4\u7a4d\u4e4b\u9593\u6709\u5bc6\u5207\u76f8\u95dc\uff0c\u6216\u8a31\u53ef\u85c9\u6b64\u8b49\u5be6\u76ee\u524d\u4e3b\u6d41\u7684\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u78ba\u80fd\u9776\u6240\u6b32\u9776\uff0c\u9054\u6210\u5305\u62ec\u816b\u7624\u63a7\u5236\u53ca\u9020\u6210\u653e\u5c04\u7dda\u6027\u58de\u6b7b\u4e4b\u751f\u7269\u6548\u61c9\u3002\u7136\u800c\u6211\u5011\u9700\u8981\u66f4\u591a\u75c5\u4f8b\u7814\u7a76\u4f86\u8b49\u5be6\u6b64\u8ad6\u9ede\uff0c\u672a\u4f86\u53ef\u8003\u616e\u61c9\u7528\u6b64\u7814\u7a76\u6a21\u5f0f\u4f86\u8a55\u4f30\u8a31\u591a\u5148\u9032\u7684\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff0c\u4ee5\u589e\u5f37\u4f7f\u7528\u8005\u78ba\u8a8d\u80fd\u9776\u6240\u6b32\u9776\u7684\u4fe1\u5fc3\u3002", "e": "Although the use of conformal radiotherapy techniques has been extensively accepted for treatment of malignancies, the current dosimetry data were from measurement in phantom, not in human body. Herewith we reported a case of T1 laryngeal cancer suffered from conformal radiotherapy-related laryngeal necrosis. The pathological validation of necrosis and reevaluation of dose distribution were assessed to prove the above concept as for in vivo dosimetry in irradiated patients. Our analysis shows a close correlation of the high dose volume and the necrotic volume, indicating a possible causal relationship. This might provide a proof of concept that conformal radiotherapy in current practice did target the targeted volumes with correlative biological effects including both tumor control and radiation necrosis. However, this conclusion definitely needs more cases to validate it. Further evaluation of more advanced radiotherapy techniques by using this research model could be considered to strengthen our belief in targeting the target volumes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200909-16-3-243-250-a", "title": "Metastatic Choroidal Adenocarcinoma from Lung Cancer: A Case Report and Review of Literature", "keywords": "\u8108\u7d61\u819c;\u80ba\u764c;\u9060\u7aef\u8f49\u79fb Choroid plexus;Lung cancer;Distant metastases", "c": "\u80ba\u764c\u6700\u5e38\u8f49\u79fb\u7684\u4f4d\u7f6e\u70ba\u8166\u53ca\u9aa8\u9abc\u7b49\u90e8\u4f4d\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f4d\u9060\u7aef\u8f49\u79fb\u7684\u80ba\u817a\u764c\u75c5\u4eba\uff0c\u4ee5\u8996\u529b\u6a21\u7cca\u75c7\u72c0\u70ba\u6700\u521d\u8868\u73fe\u3002\u60a3\u8005\u70ba57\u6b72\u5973\u6027\uff0c\u65bc2006\u5e744\u6708\u958b\u59cb\u51fa\u73fe\u8996\u529b\u6a21\u7cca\u7684\u75c7\u72c0\uff0c\u4e26\u7121\u4f34\u96a8\u5176\u4ed6\u4e0d\u9069\u3002\u6b64\u75c7\u72c0\u6301\u7e8c\u4e14\u8d8a\u8da8\u60e1\u5316\uff0c\u60a3\u8005\u81f3\u672c\u9662\u6c42\u8a3a\u5f8c\u7d93\u78c1\u632f\u9020\u5f71\u767c\u73fe\u6709\u816b\u7624\u986f\u5f71\u65bc\u53f3\u773c\u5e95\u3002\u8003\u91cf\u53ef\u80fd\u70ba\u539f\u767c\u6027\u9ed1\u8272\u7d20\u7624\uff0c\u5728\u540c\u5e746\u6708\u505a\u4e86\u773c\u7403\u6458\u9664\u624b\u8853\uff0c\u7d93\u75c5\u7406\u5831\u544a\u8b49\u5be6\u70ba\u8f49\u79fb\u6027\u817a\u764c\uff0c\u518d\u7d93\u80ba\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u5728\u53f3\u4e0a\u80ba\u6709\u4e00\u816b\u7624\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u500b\u773c\u5e95\u8f49\u79fb\u4e4b\u80ba\u764c\u75c5\u4f8b\u4e26\u4ee5\u8996\u529b\u9000\u5316\u70ba\u6700\u521d\u8868\u73fe\uff0c\u540c\u6642\u56de\u9867\u904e\u53bb\u76f8\u95dc\u6587\u737b\u3002", "e": "So far as we know, the most metastatic site in lung cancer is brain and bone. Choroid metastases rarely occur in clinical diagnosis. We report a case of 57 yearold woman presenting as right blurred vision initially. She came to our hospital for further management due to deteriorating vision. Magnetic resonance (MR) revealed a homogeneous enhancing soft tissues mass occupied in the posterior surface of right eye. Under the impression of primary melanoma, enucleation was performed in June fifth, 2006. Pathologic report proved metastatic adenocarcinoma later. Chest computerized tomography (CT) displayed a spiculated mass at RUL and multiple mediastinal lymphadenopathies. Primary adenocarcinoma of lung with choroid metastases was final diagnosed. We also reviewed related literature and emphasized the importance of differentiating diagnosis in choroidal tumor, especially in cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-85-97", "title": "Treatment Outcome and Pattern of Failure in Patients with Hodgkin", "keywords": "\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624;\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642;\u53f0\u7063 Hodgkin", "c": "Purpose: There was little data concerning Hodgkin's lymphoma (HL) treated with combined modality therapy in Taiwanese patients found in the literature. We retrospectively reviewed the treatment outcome and pattern of failure in the HL patients treated with local radiotherapy with or without chemotherapy in a single institution.\nMaterials and Methods: From 1997 to 2007, there were 63 adult HL patients treated in the department of radiation oncology. Radiotherapy treatment field was designed by the same radiation oncologist and tailored to the initially involved (lymphoid) region with or without the first echelon lymphatic. The pattern of failure, event-free survival (EFS), overall survival (OS) and associated prognostic factors were analyzed.\nResults: There were 29 (46%) female and 34 (54%) male patients. Median age was 29 years old. Patients younger than 50 years old showed a much better EFS and OS (5-year EFS 81% and 46% respectively, p 0.004; 5-year OS 85% and 57% respectively, p=0.002). Patients with B symptoms showed an inferior EFS and OS (5-year EFS 43% and 84% respectively, p\uff1c0.001; 5-year OS 56% and 89% respectively, p=0.004). Other significant poor prognostic factors for EFS included the presence of bulky disease (p=0.036) and equal to or more than 4 involved sites (p=0.036). Complete response (CR) to chemotherapy was a better prognostic factor for OS (p=0.035). In this study, favorable early stage HL showed a significant better EFS and OS, whereas unfavorable early stage HL showed a similar EFS and OS as advanced HL (5-year EFS 100%, 59% and 64% respectively, p=0.003; 5-year OS 100%, 65% and 76% respectively, p=0.014). There were 11 cases of relapses after radiotherapy. Out-field failure was the predominant pattern of failure (10/11).\nConclusion: The potentially important risk factors for EFS identified in this analysis were age at diagnosis (\u226550), the presence of B symptoms, the presence of bulky disease, and the number of involved regions (\u22654). The poor prognostic factors for OS were age at diagnosis (\u226550), the presence of B symptoms, and not achieving CR after chemotherapy. The poor 5-year EFS and OS in unfavorable early stage HL suggested a more intensified treatment should be considered.", "e": "Purpose: There was little data concerning Hodgkin's lymphoma (HL) treated with combined modality therapy in Taiwanese patients found in the literature. We retrospectively reviewed the treatment outcome and pattern of failure in the HL patients treated with local radiotherapy with or without chemotherapy in a single institution.\nMaterials and Methods: From 1997 to 2007, there were 63 adult HL patients treated in the department of radiation oncology. Radiotherapy treatment field was designed by the same radiation oncologist and tailored to the initially involved (lymphoid) region with or without the first echelon lymphatic. The pattern of failure, event-free survival (EFS), overall survival (OS) and associated prognostic factors were analyzed.\nResults: There were 29 (46%) female and 34 (54%) male patients. Median age was 29 years old. Patients younger than 50 years old showed a much better EFS and OS (5-year EFS 81% and 46% respectively, p 0.004; 5-year OS 85% and 57% respectively, p=0.002). Patients with B symptoms showed an inferior EFS and OS (5-year EFS 43% and 84% respectively, p\uff1c0.001; 5-year OS 56% and 89% respectively, p=0.004). Other significant poor prognostic factors for EFS included the presence of bulky disease (p=0.036) and equal to or more than 4 involved sites (p=0.036). Complete response (CR) to chemotherapy was a better prognostic factor for OS (p=0.035). In this study, favorable early stage HL showed a significant better EFS and OS, whereas unfavorable early stage HL showed a similar EFS and OS as advanced HL (5-year EFS 100%, 59% and 64% respectively, p=0.003; 5-year OS 100%, 65% and 76% respectively, p=0.014). There were 11 cases of relapses after radiotherapy. Out-field failure was the predominant pattern of failure (10/11).\nConclusion: The potentially important risk factors for EFS identified in this analysis were age at diagnosis (\u226550), the presence of B symptoms, the presence of bulky disease, and the number of involved regions (\u22654). The poor prognostic factors for OS were age at diagnosis (\u226550), the presence of B symptoms, and not achieving CR after chemotherapy. The poor 5-year EFS and OS in unfavorable early stage HL suggested a more intensified treatment should be considered."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-99-108", "title": "Primary Angiosarcoma of the Breast", "keywords": "\u539f\u767c\u6027\u4e73\u623f\u8840\u7ba1\u60e1\u6027\u8089\u7624;\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c Primary angiosarcoma of the breast;Radiotherapy;Prognosis", "c": "\u7c21\u4ecb\uff1a\u539f\u767c\u6027\u7684\u4e73\u623f\u60e1\u6027\u8089\u7624\u4f54\u4e73\u623f\u60e1\u6027\u816b\u7624\u4e2d\u4e0d\u52301%\u7684\u6bd4\u4f8b\u3002\u5728\u4e73\u623f\u7684\u60e1\u6027\u8089\u7624\u4e2d\u6700\u5e38\u898b\u7684\u4fbf\u662f\u8840\u7ba1\u60e1\u6027\u8089\u7624\u3002\u8840\u7ba1\u60e1\u6027\u8089\u7624\u662f\u76f8\u7576\u60e1\u6027\u7684\u816b\u7624\uff0c\u9019\u4e9b\u60e1\u6027\u816b\u7624\u7d30\u80de\u6703\u8868\u73fe\u8840\u7ba1\u5167\u76ae\u7d30\u80de\u7684\u6027\u8cea\u3002\u800c\u9019\u662f\u76f8\u7576\u5c11\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u5230\u76ee\u524d\u70ba\u6b62\u4e26\u6c92\u6709\u76f8\u7576\u6e05\u695a\u7684\u6cbb\u7642\u65b9\u5f0f\u53ca\u9810\u5f8c\u7684\u5224\u65b7\u3002\u5728\u904e\u53bb\u4e8c\u5341\u5e74\u554f\uff0c\u6211\u5011\u91ab\u9662\u50c5\u6709\u5169\u500b\u539f\u767c\u6027\u4e73\u623f\u8840\u7ba1\u60e1\u6027\u8089\u7624\u7684\u6cbb\u7642\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u9019\u88e1\u6211\u5011\u5831\u544a\u5169\u4f4d\u539f\u767c\u6027\u4e73\u623f\u8840\u7ba1\u60e1\u6027\u8089\u7624\u7684\u6848\u4f8b\uff0c\u800c\u9019\u5169\u4f4d\u75c5\u4eba\u7684\u75be\u75c5\u8868\u73fe\u8ddf\u6cbb\u7642\u7b56\u7565\u4e26\u4e0d\u76f8\u540c\u3002\u4e00\u4f4d\u63a5\u53d7\u5168\u4e73\u5207\u9664\u75c5\u8f14\u4ee5\u8853\u5f8c\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u56e0\u70ba\u9019\u4f4d\u75c5\u4eba\u6709\u8457\u8f03\u5927\u7684\u816b\u7624\u9ad4\u7a4d\u3002\u4e00\u4f4d\u53ea\u63a5\u53d7\u5168\u4e73\u5207\u9664\u53ca\u6dcb\u5df4\u7bc0\u6e05\u9664\u8853\u3002\u5169\u4f4d\u75c5\u4eba\u4e2d\u6709\u4e00\u4f4d\u63a5\u53d7\u624b\u8853\u53ca\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u53e6\u4e00\u4f4d\u75c5\u4eba\u53ea\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u8840\u7ba1\u60e1\u6027\u8089\u7624\u7684\u9810\u5f8c\u8ddf\u816b\u7624\u7684\u5927\u5c0f\u3001\u5206\u5316\u7684\u7a0b\u5ea6\u3001\u624b\u8853\u5207\u53e3\u7684\u4fb5\u72af\u8207\u5426\uff0c\u6709\u76f8\u7576\u6700\u91cd\u8981\u7684\u95dc\u4fc2\uff0c\u5c24\u5176\u8ddf\u5c40\u90e8\u5fa9\u767c\u7387\u8ddf\u5b58\u6d3b\u7387\u6709\u95dc\u3002\u5169\u4f4d\u75c5\u4eba\u4e2d\u6709\u4e00\u4f4d\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u56e0\u70ba\u9019\u4f4d\u75c5\u4eba\u6709\u8457\u8f03\u5927\u7684\u816b\u7624\u9ad4\u7a4d\uff0c\u53e6\u4e00\u4f4d\u75c5\u4eba\u53ea\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u3002\u8ffd\u8e64\u4e00\u81f3\u4e09\u5e74\u4e26\u7121\u5fa9\u767c\u7684\u73fe\u8c61\u3002\n\u7d50\u8ad6\uff1a\u6cbb\u7642\u4e73\u623f\u8840\u7ba1\u60e1\u6027\u8089\u7624\u7684\u9996\u9078\u662f\u624b\u8853\u6cbb\u7642\u53ca\u7559\u6709\u9069\u7576\u7684\u5b89\u5168\u7bc4\u570d\uff0c\u6dcb\u5df4\u6e05\u9664\u8853\u4e26\u4e0d\u4e00\u5b9a\u5efa\u8b70\u57f7\u884c\uff0c\u56e0\u70ba\u6dcb\u5df4\u8f49\u79fb\u7684\u6a5f\u6703\u662f\u76f8\u7576\u4f4e\u7684\u3002\u8853\u5f8c\u8f14\u52a9\u6cbb\u7642\u7684\u89d2\u8272\u76ee\u524d\u9084\u4e0d\u5f88\u6e05\u695a\u3002\u800c\u8840\u7ba1\u60e1\u6027\u8089\u7624\u6709\u8457\u76f8\u7576\u9ad8\u7684\u5c40\u90e8\u5fa9\u767c\u7387\uff0c\u56e0\u6b64\u9069\u7576\u7684\u5c40\u90e8\u6cbb\u7642\u53ef\u80fd\u53ef\u4ee5\u52a0\u5f37\u75be\u75c5\u7684\u63a7\u5236\u3002\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642\u53ef\u80fd\u5728\u5b58\u6d3b\u4e0a\u626e\u6f14\u91cd\u8981\u7684\u89d2\u8272\u3002", "e": "Introduction: Primary breast sarcomas are rare tumors that account for less than 1% of primary breast neoplasms. Angiosarcoma is predominantly found in breast sarcomas. Angiosarcoma is an aggressive malignancy in which malignant cells express the properties of endothelial cells. Because of its rarity, the management and outcome of angiosarcoma patients has not been clearly described. In the past 20 years, there have been only two primary breast angiosarcomas treated in our hospital.\nMaterials and Methods: Here we report on two cases of primary breast angiosarcoma with different presentations and treatment strategies. One underwent total mastectomy followed by adjuvant radiotherapy. The other one underwent modified radical mastectomy with axillary lymph node dissection.\nResult: The prognosis for primary breast sarcoma is highly dependent on the tumor size; higher grade and positive margins increase the risk of local recurrence and thus a decreased survival rate. One patient completed the adjuvant radiotherapy in January 2008 because of the larger tumor bed. The other one underwent surgery only due to the fact that the small lesion was still disease-free after almost 3 years.\nConclusion: The treatment of choice for angiosarcoma is surgery with adequate margins. Axillary dissection is not indicated because nodal metastasis is rare. The definitive role of adjuvant therapy remains undetermined. Due to the high locoregional recurrent rate of this disease, local therapy should be optimized with multimodality treatment. Chemotherapy and radiotherapy may play an important role in survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-109-117", "title": "\u653e\u5c04\u6cbb\u7642\u6392\u7a0b\u4e2d\u75c5\u60a3\u5931\u7d04\u56e0\u5b50\u4e4b\u63a2\u8a0e", "keywords": "\u653e\u5c04\u6cbb\u7642;\u5931\u7d04;\u6cbb\u7642\u4f7f\u7528\u7387;\u793e\u6703\u4eba\u53e3\u5b78 Radiotherapy;Miss-appointment;Ireatment utility;Sociodemography", "c": "\u76ee\u7684\uff1a\u75c5\u60a3\u65bc\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u4e2d\uff0c\u5e38\u56e0\u67d0\u4e9b\u539f\u56e0\u800c\u5931\u7d04\uff0c\u6b64\u5f71\u97ff\u4e86\u8a2d\u5099\u4f7f\u7528\u7387\u53ca\u5176\u4ed6\u75c5\u60a3\u5b89\u6392\u7684\u6642\u7a0b\u3002\u57fa\u65bc\u6cbb\u7642\u4f7f\u7528\u6700\u4f73\u5316\u4e4b\u539f\u5247\uff0c\u672c\u7814\u7a76\u63a2\u8a0e\u764c\u75c7\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u4e4b\u5931\u7d04\u5f71\u97ff\u56e0\u5b50\u3002\n\u65b9\u6cd5\uff1a\u524d\u77bb\u5f0f\u7814\u7a76\uff0c\u4ee5\u672c\u9662\u653e\u5c04\u816b\u7624\u79d12006\u5e747-12\u6708\u65b0\u6392\u5165\u7684\u75c5\u60a3\u70ba\u6a23\u672c\u3002\u8cc7\u6599\u6536\u96c6\u5305\u62ec\u75c5\u60a3\u4e4b\u793e\u6703\u4eba\u53e3\u5b78\u8cc7\u6599\u3001\u764c\u75c7\u53ca\u653e\u5c04\u6cbb\u7642\u76f8\u95dc\u8cc7\u6599\u3001\u4ee5\u53ca\u75c5\u60a3\u5931\u7d04\u539f\u56e0\u3002\u5229\u7528\u8907\u5c0d\u6578\u8ff4\u6b78\u5206\u6790\u6cd5\u9032\u884c\u7d71\u8a08\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u5171\u6536\u96c6505\u4f8b\uff0c\u6709\u4e00\u6b21\uff08\u542b\uff09\u4ee5\u4e0a\u5931\u7d04\u8a18\u9304\u7684\u75c5\u60a3\u5171169\u4f8b(3346%)\uff0c\u5931\u7d04\u4eba\u6b21\u5171\u6709330\u4eba\u6b21\uff0c\u75c5\u60a3\u5e73\u5747\u5931\u7d04\u7387\u70ba458\u00b1127%\u3002\u793e\u6703\u4eba\u53e3\u5b78\u8cc7\u6599\u8207\u6cbb\u7642\u76f8\u95dc\u56e0\u5b50\u8b8a\u9805\u4e2d\uff0c\u6211\u5011\u767c\u73fe\u5e74\u6536\u5165100\u842c\u4ee5\u4e0b\u7684\u75c5\u60a3\u6bd4\u5e74\u6536\u5165100\u842c\u4ee5\u4e0a\u7684\u75c5\u60a3\u8f03\u6703\u5931\u7d04(aOR=9.69, 95% CI=1.26-74.37)\u3001\u4f4f\u9662\u7684\u75c5\u60a3\u6bd4\u9580\u8a3a\u7684\u75c5\u60a3(aOR=1.70, 95% CI=1.11-2.62)\u8f03\u6703\u5931\u7d04\u53ca\u6cbb\u7642\u7e3d\u5291\u91cf\u57283000cGy\u4ee5\u4e0b\u6bd43000cGy\u4ee5\u4e0a\u7684\u75c5\u60a3(aOR=2.15, 95% CI=130-356)\u8f03\u6703\u5931\u7d04\u3002\u5931\u7d04\u539f\u56e0\u4ee5\u8eab\u9ad4\u4e0d\u9069\u6700\u591a\u4f5448.5%\u3002\n\u7d50\u8ad6\uff1a\u764c\u75c7\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u671f\u9593\u6709\u4e9b\u56e0\u5b50\u662f\u8207\u5931\u7d04\u76f8\u95dc\u7684\u3002\u6211\u5011\u5efa\u8b70\u63a15%\u904e\u9810\u7d04\u65b9\u6cd5\uff0c\u540c\u6642\u7d93\u7531\u885b\u6559\u3001\u75c5\u60a3\u8aee\u8a62\u5354\u52a9\u4ee5\u53ca\u66f4\u591a\u91ab\u7642\u7167\u8b77\u4f86\u907f\u514d\u75c5\u60a3\u5931\u7d04\u3002", "e": "Objective: For some reasons, cancer patients treated by radiotherapy (RI) experienced miss-appointment, which reduced the utility of treatment machines and affected the appointment schedule of other patients. Io optimize the treatment utility, we investigated the factors associated with patient miss-appointment during RT.\nMethods: We prospectively and consecutively enrolled 505 cancer patients treated at the department of radiation oncology in our hospital from July 1 to December 31 in 2006. The questionnaire concerning the reasons of miss-appointment was documented and the sociodemographic and cancer- related data of patients were reviewed. Logistic regression model was used for multivariate analysis.\nResults: There were 169 cases experiencing at least one miss-appointment during the RT course. The total miss-appointment number was 330, with a miss-appointment rate of 4.58+1.27%. Concerning the sociodemographic and cancer-related factors, we found patients with annual income below 10 million NTD (aOR=9.69, 95% CI=1.26-74.37), in-patients (aOR=1.70, 95% CI=1.11-2.62), and those treated with RI dose below 3000 cGy (aOR = 2.15, 95% CI=1.30-3.56) experienced more miss-appointment rate compared with the counterparts. Feeling ill was the most common (48.5%) reason of miss-appointment.\nConclussion: Some factors were found to be associated with patient miss-appointment during RT. We suggest a 5% over-appointment rate to maximize the treatment utility, and to educate and pay more medical care to patients with a high risk of miss-appointment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-125-134", "title": "\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u5c04\u7dda\u7167\u5c04\u65b0\u6cbb\u7642\u6280\u8853\u7684\u958b\u767c\u53ca\u7814\u7a76", "keywords": "\u5168\u8eab\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642;\u982d\u9802\u53ca\u8173\u5e95;\u65cb\u8f49\u677f;\u76ae\u819a\u764c Total Skin Electron Therapy;Vertex and the soles;Aswirl board;Skin cancer", "c": "\u76ee\u7684\uff1a\u4e00\u822c\u5728\u75c5\u4eba\u505a\u5b8c\u5168\u8eab\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u75c5\u4eba\u7684\u982d\u9802\u53ca\u8173\u5e95\u6703\u6709\u5291\u91cf\u4e0d\u8db3\u7684\u73fe\u8c61\uff1b\u6b64\u6642\u80fd\u5920\u505a\u7684\u5c31\u662f\u63a1\u4e8b\u5f8c\u88dc\u8db3\u5291\u91cf\u7684\u63aa\u65bd\uff1b\u5982\u4f55\u5728\u6cbb\u7642\u904e\u7a0b\u4e2d\uff0c\u540c\u6642\u8b93\u75c5\u4eba\u7684\u982d\u9802\u53ca\u8173\u5e95\u53ca\u5168\u8eab\u90fd\u7d66\u5230\u8db3\u5920\u4e14\u76f8\u540c\u7684\u8f3b\u5c04\u5291\u91cf\u662f\u6b64\u7bc7\u7814\u7a76\u7684\u4e3b\u984c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u9078\u64c7Elekta\u5ee0\u813e\u7684\u76f4\u7dda\u52a0\u901f\u5668\u53ca6MeV\u7684\u96fb\u5b50\u5c04\u675f\u505a\u70ba\u7d66\u4e88\u8f3b\u5c04\u5291\u91cf\u7684\u8a2d\u5099\uff1b\u6cbb\u7642\u5ba4\u5167\u76f4\u7dda\u52a0\u901f\u5668\u7684\u7b49\u4e2d\u5fc3\u65cb\u8f49\u9ede\u5230\u75c5\u4eba\u8868\u9762\u7684\u8ddd\u96e2\u662f350cm\uff0c\u4e26\u4e14\u9078\u64c70.6cm\u7684\u58d3\u514b\u529b\u677f\u653e\u5728\u8ddd\u96e2\u75c5\u4eba\u8868\u976290cm\u8655\uff0c\u505a\u70ba\u96fb\u5b50\u7684\u6563\u5c04\u677f\uff1b\u5be6\u9a57\u904e\u7a0b\u662f\u5148\u627e\u51fa\u5982\u4f55\u8b93\u76f4\u7dda\u52a0\u901f\u5668\u7684\u6a5f\u982d\u6c34\u5e73\u5f80\u4e0a\u6216\u6c34\u5e73\u5f80\u4e0b\u7684\u89d2\u5ea6\u7167\u5c04\u5f8c\u5408\u6210\u4e00\u500b\u53ef\u7528\u5291\u91cf\u5256\u9762\u7167\u91ce\uff0c\u4e4b\u5f8c\u518d\u4ee5\u4e8c\u500b\u65cb\u8f49\u6846\uff0c\u6700\u5916\u6846\u662f\u56fa\u5b9a\u7528\uff0c\u4e2d\u9593\u7684\u6846\u662f\u53ef\u4ee5\u524d\u5f8c\u50be\u659c\u65cb\u8f49\uff0c\u800c\u6700\u5167\u6846\u53f8\u4ee5\u9806\u6642\u91dd\u3001\u9006\u6642\u91dd\u65cb\u8f49\uff0c\u8b93\u75c5\u4eba\u53f8\u4ee5\u5f97\u5230\u8db3\u5920\u4e14\u5747\u52fb\u7684\u96fb\u5b50\u5291\u91cf\u4ee5\u4fbf\u505a\u5168\u8eab\u6027\u7684\u96fb\u5b50\u5c04\u7dda\u7684\u6cbb\u7642\u3002\n\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u7d50\u679c\u986f\u793a\u4ee5\u5728\u7b49\u4e2d\u5fc3\u65cb\u8f49\u9ede\u8655\u7167\u91ce\u70ba40cm\u00d740cm\uff0c\u7576\u52a0\u901f\u5668\u7684\u6a5f\u982d\u6c34\u5e73\u5f80\u4e0a\u53ca\u6c34\u5e73\u5f80\u4e0b\u5404155\u3002\u7684\u7d44\u5408\u7167\u5c04\u6642\uff0c\u6b64\u7d44\u5408\u7167\u91ce\u5728\u75c5\u4eba\u6cbb\u7642\u8868\u9762\u8655\u6703\u6709\u4e00\u500b\u5e73\u5766\u7684\u5291\u91cf\u5256\u9762\uff0c\u6b64\u5256\u9762\u7684\u5291\u91cf\u5747\u52fb\u5ea6\u53ef\u63a7\u5236\u5728\u00b110%\u7684\u7bc4\u570d\u5167\uff1b\u56e0\u4f7f\u7528\u5168\u8eab\u96fb\u5b50\u5c04\u7dda\u65cb\u8f49\u677f\u7684\u95dc\u4fc2\uff0c\u6240\u4ee56MeV\u65bc\u75c5\u4eba\u6cbb\u7642\u8868\u9762\u8655\u7684\u767e\u5206\u6df1\u5ea6\u66f2\u7dda\u6703\u6bd4\u50b3\u7d71\u5782\u76f4\u7167\u5c04\u7684\u7d50\u679c\u6703\u66f4\u5f80\u8868\u6dfa\u8655\u504f\u79fb\uff1bR50\u8b8a\u6210125cm\uff0cE0\u8b8a\u62102.913MeV\uff0cRp\u662f1.75Cm\uff0c\u8f38\u51fa\u5291\u91cf\u7387\u662f0085cGy/min\u3002\n\u7d50\u8ad6\uff1a\u96d6\u7136\u6b64\u6cbb\u7642\u65b9\u5f0f\u770b\u4f3c\u8907\u96dc\uff0c\u4f46\u662f\u75c5\u4eba\u5728\u6574\u500b\u6cbb\u7642\u7684\u4e00\u6b21\u5faa\u74b0\u4e2d\u53ea\u9700\u4e0a\u4e0b\u5167\u6846\u5404\u4e00\u6b21\uff1b\u4e00\u6b21\u662f\u4fef\u81e5\u5728\u5167\u6846\u7db2\u4e0a\uff0c\u53e6\u4e00\u6b21\u662f\u6b63\u8eba\u5728\u5167\u6846\u7db2\u4e0a\uff1b\u5176\u9918\u7684\u59ff\u52e2\u90fd\u53f8\u7531\u50be\u659c\u4e2d\u6846\u53ca\u65cb\u8f49\u5167\u6846\u64fa\u51fa\u5404\u7a2e\u6cbb\u7642\u89d2\u5ea6\u3002\u6b64\u7a2e\u65b9\u6cd5\u7684\u6700\u5927\u512a\u9ede\u662f\u4e0d\u9700\u50cf\u53f2\u4e39\u4f5b\u5927\u5b78\u7684\u6cbb\u7642\u65b9\u5f0f\u9700\u5728\u6cbb\u7642\u5f8c\u88dc\u8db3\u5291\u91cf\u4e0d\u8db3\u4e4b\u8655\uff0c\u800c\u53f8\u4ee5\u540c\u6642\u8b93\u982d\u9802\u53ca\u8173\u5e95\u5728\u540c\u4e00\u6b21\u7684\u6cbb\u7642\u7d50\u675f\u5f8c\u5f97\u5230\u548c\u5168\u8eab\u5176\u9918\u7684\u5340\u57df\u76f8\u540c\u4e14\u5747\u52fb\u7684\u5291\u91cf\u3002", "e": "Purpose: The aim of this study is to present a novel technique in which uniform dose to the whole body as well as the soles and vertex of scalp can be achieved in one electron beam treatment fraction. An experiment was undertaken with a home-made aswirl board that enables the patient to lie in supine or prone position for treatment.\nMaterial and Methods: A 6 MeV nominal electron beam was delivered using Elekta Precise Sli throughout this experiment. The patient is treated at a isocenter to skin distance of 350 cm. The largest field size available at SSD 100 cm is 40x40cm^2 and a high dose rate of 3000 MU min^(-1) was used. A 0.6 cm thick acrylic beam spoiler was placed 90cm away from the surface of the patient to scatter the electron beam for a more homogeneous surface dose. Patients are treated with two groups in prone and supine position by leaning on inner rotational board in prone and supine position, each group can further be separated into two subgroup with tilting and rotation positions for treatment. By incorporating all these seeting on the aswirl board with the optimal gantry angle, the patient will final accumulate compensated dosages on whole body surface.\nResults: One of the gantry beam was directed 15.5\u00b0 upward and the other 15.5\u00b0 downward from the horizontal axis to provide a field size as large as 200 cm in height and 140cm in width. An incline angle of 31.50\u00b0 anteriorly (forward) or posteriorly (backward) of the middle frame and an angle rotated 60\u00b0 clockwise or counterclockwise of the inner frame is found to be most appropriate. The output dose rate for the AB-TSET was 0.085 cGy/mu at SSD 350 cm. The beam characteristics of the AB-TSET depth dose curves were R50=1.25cm, d(subscript max)=0.6 cm E0=2.913 MeV, R(subscript p)=1.75 cm.\nConclusion: The AB-TSET technique presented in this study is able to deliver a uniform dose to the patient\u2019s skin surface as well as to the vertex and the soles all in one time, eliminating the troubles of having to further boost fields for these two regions when using the Stanford Six Field Technique."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-135-142", "title": "Total Marrow Irradiation with Helical Tomotherapy: A Case Report", "keywords": "\u5c0e\u822a\u87ba\u65cb\u5200;\u591a\u767c\u6027\u9aa8\u9ad3\u7624;\u5168\u9aa8\u9ad3\u653e\u5c04\u7dda\u6cbb\u7642 Helical tomotherapy;Multiple Myeloma;Total Bone Marrow Irradiation", "c": "\u4e00\u4f4d\u7b2c\u4e09\u671f\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e4b53\u6b72\u4e9e\u6d32\u5973\u6027\u7d93\u5316\u5b78\u6cbb\u7642\u5f8c\u6c7a\u5b9a\u63a5\u53d7\u81ea\u9ad4\u9aa8\u9ad3\u79fb\u690d\u6cbb\u7642\u3002\u800c\u81ea\u9ad4\u9aa8\u9ad3\u79fb\u690d\u6cbb\u7642\u524d\u5247\u63a5\u53d7\u5168\u9aa8\u9ad3\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6574\u500b\u7642\u7a0b\u4e4b\u5291\u91cf\u5171\u8a08800cGy\u5206\u6210\u56db\u5929\uff0c\u6bcf\u5929\u63a5\u53d7200cGy\u4e4b\u5168\u9aa8\u9ad3\u7167\u5c04\u5291\u91cf\u3002\u63a5\u53d7\u79fb\u690d\u5f8c\uff0c\u6b77\u7d93\u5341\u500b\u591a\u6708\u8ffd\u8e64\uff0c\u7121\u8b49\u64da\u986f\u793a\u5176\u5fa9\u767c\u3002\u5168\u9aa8\u9ad3\u7167\u5c04\u6cbb\u7642\u7642\u7a0b\u4e2d\uff0c\u50c5\u767c\u751f\u7b2c\u4e00\u7d1a\u4e4b\u5641\u5fc3\u53ca\u5614\u5410\u3002\u8207\u904e\u53bb\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u7d93\u9a57\u76f8\u8f03\uff0c\u5168\u9aa8\u9ad3\u653e\u5c04\u7dda\u6cbb\u7642\u8f03\u4e0d\u5177\u6bd2\u6027\u4e14\u53ef\u9054\u76f8\u8fd1\u7684\u6cbb\u7642\u7d50\u679c\u3002\u6574\u500b\u6cbb\u7642\u904e\u7a0b\u5efa\u8b70\u65bc\u6cbb\u7642\u524d\u7d66\u4e88\u6b62\u5410\u5291\u4ee5\u964d\u4f4e\u6cbb\u7642\u4e4b\u526f\u4f5c\u7528\u3002", "e": "A 53-year-old Asian woman with plasma cell myloma with IgG/kappa stage IIIa post chemotherapy was selected for autologous hematopoietic cell transplantation (HCT). Total marrow irradiation (TMI) tomotherapy was planned as a preconditioning regimen of HCT. A total dose of 800 cGy (200 cGy/ fraction) was delivered to the bone marrow. More than 10 months post transplant without evidence of active disease for the patient was noted. Except for Grade 1 nausea and vomiting there were no significantly adverse effects during TMI. The preconditioning regimen for the bone marrow transplant with helical tomotherapy targeting the bone marrow of the whole body is potentially less toxic and as efficacious in the patient. Antiemetics should be prescribed for the whole course of TMI for emesis prevention."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-143-150", "title": "Radiotherapy for Kimura", "keywords": "\u6728\u6751\u6c0f\u75c7;\u653e\u5c04\u7dda\u6cbb\u7642;\u826f\u6027\u75be\u75c5 Kimura", "c": "\u6728\u6751\u6c0f\u75c7\u70ba\u4e00\u7f55\u898b\u75be\u75c5\uff0c\u901a\u5e38\u898b\u65bc\u5e74\u8f15\u4e9e\u6d32\u7537\u6027\u3002\u901a\u5e38\u8868\u73fe\u70ba\u7121\u75db\u9838\u90e8\u816b\u584a\uff0c\u8840\u6db2\u6aa2\u67e5\u5247\u5448\u73fe\u55dc\u9178\u6027\u767d\u8840\u7403\u904e\u591a\u75c7(Eosinophilia)\u53ca\u514d\u75ab\u7403\u86cb\u767dE (Immunoglobulin E, IgE)\u5347\u9ad8\u3002\u672c\u75c5\u662f\u4e00\u7a2e\u826f\u6027\u7684\u6162\u6027\u767c\u708e\u75be\u75c5\uff0c\u4f46\u75c5\u4eba\u537b\u53ef\u80fd\u56e0\u70ba\u5de8\u5927\u7684\u9838\u90e8\u816b\u584a\u7b49\u9020\u6210\u5916\u89c0\u4e0a\u7684\u554f\u984c\u3002\u5916\u79d1\u5207\u9664\u53ca\u985e\u56fa\u9187\u662f\u6cbb\u7642\u7684\u9996\u9078\uff1b\u7136\u800c\u55ae\u7d14\u5207\u9664\u5f80\u5f80\u6613\u65bc\u5fa9\u767c\uff0c\u800c\u985e\u56fa\u9187\u7684\u6548\u679c\u96d6\u597d\uff0c\u537b\u6709\u505c\u85e5\u5f8c\u7acb\u523b\u5fa9\u767c\u3002\u904e\u53bb\u5728\u53f0\u7063\u672a\u6709\u4eba\u5831\u544a\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u679c\u3002\u5728\u6b64\u5831\u544a\u4e09\u4f4d\u75c5\u4eba\u56e0\u6b64\u75c5\u5728\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u6cbb\u7642\u7684\u60c5\u6cc1\u3002\u4e09\u4f4d\u75c5\u4eba\u5728\u6cbb\u7642\u4e2d\u5373\u53ef\u770b\u5230\u816b\u584a\u7e2e\u5c0f\u60c5\u6cc1\uff0c\u9577\u671f\u5c40\u90e8\u63a7\u5236\u7387\u7d04\u70ba50%\u3002\u5728\u6cbb\u7642\u4e2d\u53ca\u9580\u8a3a\u8ffd\u8e64\uff0c\u9019\u4e9b\u75c5\u4eba\u4e2d\u4e26\u6c92\u6709\u660e\u986f\u7684\u526f\u4f5c\u7528\u3002\u4e00\u4f4d\u75c5\u4eba\u5728\u4e03\u5e74\u5f8c\u5fa9\u767c\uff0c\u518d\u6b21\u6cbb\u7642\u4ecd\u7136\u53ef\u89c0\u5bdf\u5230\u660e\u986f\u7642\u6548\u3002\u6839\u64da\u6211\u5011\u7684\u7d93\u9a57\u53ca\u6587\u737b\u56de\u9867\u7684\u7d50\u679c\uff0c\u5728\u7b2c\u4e00\u7dda\u6cbb\u7642\u6216\u5176\u4ed6\u6cbb\u7642\u7121\u6548\u4e4b\u5f8c\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u6975\u70ba\u503c\u5f97\u8003\u616e\u7684\u3002", "e": "Kimura's disease is a rare disease and usually afflicts Oriental population, especially the young gentleman. Patients are commonly presented with painless neck mass, eosinophilia and increased serum immunoglobulin E (IgE) in examination. Although its nature is a chronic inflammation, patients may have disfigurement because of the huge neck mass. Surgical excision and postoperative steroid is the first choice of treatment. However, the local recurrent rate is high after surgery alone, and rapid rebound after discontinuing steroid frequently occurrs even the initial response is good. By our best search, we did not find any report describing the treatment outcome of radiotherapy in Kimura's disease in Taiwan and therefore we reported our experiences in three cases with four times of treatment. Rapid regression was observed during the radiotherapy, and long-term local control rate was 50%. One patient had local relapse seven years after first radiotherapy, and obvious response was noted when re-irradiation was performed. Our limited experiences and literature review suggest radiotherapy should be used in patients whose disease was not controlled by first-line treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-151-156", "title": "Severe Skin Reaction Related to Concurrent Radiotherapy with Sunitinib in Renal Cell Carcinoma-A Case Report", "keywords": "sunitinib;\u814e\u7d30\u80de\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u624b\u8db3\u75c7\u5019\u7fa4 Sunitinib;Renal cell carcinoma;Radiotherapy;Hand foot syndrome", "c": "Sunitinib is a tyrosine kinase inhibitor of both platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors. It has shown great efficacy in metastatic and cytokine refractory advanced renal cell carcinoma. The focus of this article is on its dermatological effect in combination with radiotherapy. In this case report, the patient concurrently received sunitinib and radiotherapy developed severe skin reaction in irradiation field. This type of skin reaction has never been reported in the literature. We hypothesized that the skin reaction in radiation field may be precipitated by sunitinib. Further observation may be warranted while sunitinib is prescribed to RCC patients receiving radiotherapy.", "e": "Sunitinib\u70ba\u4e00\u53ef\u6291\u5236\u8840\u5c0f\u677f\u751f\u9577\u56e0\u5b50(PDGF)\u53ca\u8840\u7ba1\u5167\u76ae\u751f\u9577\u56e0\u5b50(VEGF)\u7684\u9169\u6c28\u9178\u6fc0\u91c5\u6291\u5236\u9f4a\u3002\u5b83\u5c0d\u65bc\u8f49\u79fb\u53ca\u5177\u7d30\u80de\u6fc0\u7d20\u6297\u6027\u4e4b\u814e\u7d30\u80de\u764c\u6709\u986f\u8457\u7684\u6548\u529b\u3002\u6b64\u7bc7\u4e3b\u8981\u76ee\u7684\u70ba\u63a2\u8a0e\u5176\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u4f75\u7528\u6642\u7684\u76ae\u819a\u53cd\u61c9\u3002\u75c5\u60a3\u5728\u4f75\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u8207sunitinib\u6642\u5728\u7167\u91ce\u5167\u7522\u751f\u56b4\u91cd\u7684\u76ae\u819a\u53cd\u61c9\u3002\u6b64\u60c5\u5f62\u5728\u5176\u4ed6\u6587\u737b\u4e2d\u4e26\u672a\u88ab\u63d0\u53ca\u904e\u3002\u6211\u5011\u5047\u8a2d\u7167\u91ce\u5167\u4e4b\u76ae\u819a\u53cd\u61c9\u662f\u56e0sunitinib\u4fc3\u4f7f\u7522\u751f\u7684\u3002\u56e0\u6b64\u7576RCC\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6642\u7d66\u4e88sunitinib\u6642\uff0c\u9032\u4e00\u6b65\u7684\u89c0\u5bdf\u53ef\u80fd\u662f\u5fc5\u9808\u7684\u3002"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200906-200908040050-200908040050-157-163", "title": "Malignant Myoepithelioma of Soft Palate: A Case Report", "keywords": "\u60e1\u6027\u808c\u4e0a\u76ae\u7624;\u8edf\u984e;\u553e\u6db2\u817a\u816b\u7624 Malignant myoepithelioma;soft palate;salivary gland tumor", "c": "\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u70ba\u4e00\u7f55\u898b\u4e4b\u816b\u7624\uff0c\u5927\u90e8\u5206\u767c\u751f\u5728\u816e\u817a\uff0c\u4e14\u4f54\u6240\u6709\u60e1\u6027\u553e\u6db2\u817a\u816b\u7624\u4e0d\u52301%\u3002\u9019\u88e1\u6211\u5011\u5831\u544a\u4e00\u4f4d\u8edf\u984e\u4e4b\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u7684\u75c5\u4f8b\u3002\u4e00\u4f4d36\u6b72\u5973\u6027\uff0c\u6709\u9577\u90544\u5e74\u7684\u8edf\u984e\u7121\u75db\u816b\u584a\u4e4b\u75c5\u53f2\uff0c\u65bc1998\u5e745\u6708\u4f86\u672c\u91ab\u9662\u6c42\u8a3a\uff0c\u7d93\u5207\u7247\u6aa2\u67e5\u521d\u6b65\u8a3a\u65b7\u70ba\u591a\u5f62\u6027\u817a\u7624\u3002\u4e0d\u904e\u65bc1998\u5e749\u6708\u7d93\u816b\u7624\u5207\u9664\u5f8c\u78ba\u5b9a\u8a3a\u65b7\u70ba\u808c\u4e0a\u76ae\u7624\u3002\u65bc2001\u5e74\u767c\u73fe\u53f3\u5074\u981c\u4e0b\u817a\u90e8\u4f4d\u6709\u6dcb\u5df4\u816b\u584a\uff0c\u4e26\u63a5\u53d7\u7d30\u91dd\u62bd\u5438\u7d30\u80de\u5b78\u6aa2\u67e5\uff0c\u7d50\u679c\u8a3a\u65b7\u70ba\u7531\u9f3b\u54bd\u8f49\u79fb\u904e\u4f86\u7684\u672a\u5206\u5316\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u3002\u65bc\u662f\u8a72\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u7dda\u8207\u5316\u5b78\u6cbb\u7642\uff0c\u4e26\u65bc2001\u5e7412\u6708\u6cbb\u7642\u7d50\u675f\u3002\u7d93\u904e\u56db\u500b\u6708\u5f8c\uff0c\u4ecd\u6709\u6b98\u9918\u7684\u6dcb\u5df4\u816b\u584a\uff0c\u7d93\u624b\u8853\u5207\u9664\u5f8c\uff0c\u75c5\u7406\u8a3a\u65b7\u70ba\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u3002\u57282005\u5e741\u6708\u7684\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u767c\u73fe\u4e0a\u981c\u90e8\u9f3b\u7ac7\u8207\u984e\u90e8\u6709\u816b\u7624\uff0c\u7d93\u904e\u624b\u8853\u5207\u9664\u5f8c\uff0c\u78ba\u5b9a\u70ba\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u4e4b\u5fa9\u767c\u3002\u57282007\u5e7410\u6708\u7684\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u767c\u73fe\u4e0a\u981c\u90e8\u9f3b\u7ac7\u6709\u816b\u7624\uff0c\u7d93\u904e\u624b\u8853\u5207\u9664\u5f8c\uff0c\u78ba\u5b9a\u70ba\u5c40\u90e8\u5fa9\u767c\u3002\u8a72\u75c5\u60a3\u65bc\u624b\u8853\u5f8c\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u764228\u6b21\uff0c\u7e3d\u5291\u91cf\u70ba50.4\u683c\u96f7\uff0c\u4e26\u65bc2008\u5e741\u6708\u6cbb\u7642\u7d50\u675f\u3002\u7d93\u904e8\u500b\u6708\u5f8c\uff0c\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u6753\u6703\u53ad\u895e\u90e8\u4f4d\u6709\u816b\u7624\uff0c\u7d93\u904e\u624b\u8853\u5207\u9664\u5f8c\uff0c\u78ba\u5b9a\u70ba\u60e1\u6027\u808c\u4e0a\u76ae\u7624\u4e4b\u5fa9\u767c\u3002\u624b\u8853\u5f8c\u52302009\u5e742\u6708\u7684\u6700\u5f8c\u4e00\u6b21\u9580\u8a3a\u8ffd\u8e64\u671f\u9593\uff0c\u90fd\u6c92\u6709\u767c\u751f\u816b\u7624\u5fa9\u767c\u3002", "e": "Malignant myoepithelioma, a rare tumor mostly located in the parotid gland, accounts for less than 1% of salivary gland neoplasms. Here, we report a case of malignant soft palate myoepithelioma. A 36-year-old woman had a painless mass over the soft palate for 4 years: she first visited our hospital in May 1998; received a biopsy; and was initially diagnosed with pleomorphic adenoma. After local excision of the tumor in September 1998, the myoepithelioma was confirmed. Lymph nodes over the right submandibular area were subsequently identified in 2001. Using fine needle aspiration, undifferentiated squamous cell carcinoma of nasopharyngeal origin was ascertained. The patient underwent a course of concurrent chemoradiotherapy ending in December 2001. Four months later, residual lymph nodes were excised. The tumor cells were diagnosed as malignant myoepithelioma. A CT scan in January 2005 showed a mass lesion in the right maxillary sinus and palate. Wide excision confirmed the diagnosis of recurrent malignant myoepithelioma. A further CT scan in October 2007 showed a mass involving the right maxillary sinus. After wide excision, local recurrence was confirmed. Local radiotherapy in a dose of 50.4 Gy in 28 fractions was initiated and ended in January 2008. Eight months later, a CT scan asserted a mass in the right aryepiglottic fold. After excision, recurrent malignant myoepithelioma was confirmed. This patient was free of the disease in the last OPD follow-up in February 2009."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-1-13-a", "title": "The Effect of Primary Tumor Volume Measured by Mr Imaging on T-Stage, Local Control, and Survival in Patients with Advanced Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c;\u539f\u767c\u816b\u7624;\u6838\u78c1\u5171\u632f Nasopharyngeal carcinoma;Primary tumor volume;Magnetic resonance imaging", "c": "Purpose: To investigate the association of primary tumor volume by magnetic resonance imaging (MRI) with T-stage, and its prognostic influence on patients with advanced nasopharyngeal carcinoma (NPC).\nMaterials and Methods: From February 2000 to May 2002, 69 biopsy-proven NPC; stage \u2162/\u2163 disease, no distant metastasis and with available pre-treatment MRI were retrospectively reviewed. All patients received 10-weekly neoadjuvant chemotherapy followed by conventional fractionated radiotherapy of 70-74 Gy. The minimal follow- up time was 5 years. The primary tumor volume was delineated on the axial slides of T2-weighted images without contrast and calculated by the Eclipse(superscript TM) treatment planning software, Local-failure-free survival (LFFS), distant metastasis-free survival (DMFS), and overall survival (OS) were calculated by the Kaplan-Meier method.\nResults: The primary tumor volume for all patients ranged from 5.46 to 137.40 cm^3 with a median value of 17.12 cm^3 and a mean value of 25.36 cm^3. The primary tumor volume had positive correlation with T-stage. The median volume for T1-2, T3 and T4 tumors were 9.91 cm^3, 13.90 cm^3, and 27.26 cm^3, respectively (p\uff1c0.0001). Five-year LFFS (90.6% vs. 87.1%, p=0.5056), DMFS (65.7% vs. 76.8%,: p-0.3656) and 05 (74.3% vs. 70.1%, p=0.9026) were not statistically different in patients with large : (volume 17 cm^3) and small (volume\u226717 cm^3) primary tumor volume. The results are similar when the cutoff value is changed from the median to the mean values (\u2267and\uff1c25 cm^3). When other cutoff values are used, the differences still don't achieve statistical significance.\nConclusion: The primary tumor volume measured on T2-weighted non-contrast: enhanced MAI had positive correlation with T-staging but did not influence the prognosis of advanced NPC patients receiving neoadjuvant chemotherapy and radiotherapy.", "e": "Purpose: To investigate the association of primary tumor volume by magnetic resonance imaging (MRI) with T-stage, and its prognostic influence on patients with advanced nasopharyngeal carcinoma (NPC).\nMaterials and Methods: From February 2000 to May 2002, 69 biopsy-proven NPC; stage \u2162/\u2163 disease, no distant metastasis and with available pre-treatment MRI were retrospectively reviewed. All patients received 10-weekly neoadjuvant chemotherapy followed by conventional fractionated radiotherapy of 70-74 Gy. The minimal follow- up time was 5 years. The primary tumor volume was delineated on the axial slides of T2-weighted images without contrast and calculated by the Eclipse(superscript TM) treatment planning software, Local-failure-free survival (LFFS), distant metastasis-free survival (DMFS), and overall survival (OS) were calculated by the Kaplan-Meier method.\nResults: The primary tumor volume for all patients ranged from 5.46 to 137.40 cm^3 with a median value of 17.12 cm^3 and a mean value of 25.36 cm^3. The primary tumor volume had positive correlation with T-stage. The median volume for T1-2, T3 and T4 tumors were 9.91 cm^3, 13.90 cm^3, and 27.26 cm^3, respectively (p\uff1c0.0001). Five-year LFFS (90.6% vs. 87.1%, p=0.5056), DMFS (65.7% vs. 76.8%,: p-0.3656) and 05 (74.3% vs. 70.1%, p=0.9026) were not statistically different in patients with large : (volume 17 cm^3) and small (volume\u226717 cm^3) primary tumor volume. The results are similar when the cutoff value is changed from the median to the mean values (\u2267and\uff1c25 cm^3). When other cutoff values are used, the differences still don't achieve statistical significance.\nConclusion: The primary tumor volume measured on T2-weighted non-contrast: enhanced MAI had positive correlation with T-staging but did not influence the prognosis of advanced NPC patients receiving neoadjuvant chemotherapy and radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-15-24-a", "title": "Value of Computed Tomography-Based Tumor Volume as a Predictor of Local Control in Oropharyngeal Cancer after Treatment of Definitive Radiotherapy", "keywords": "\u53e3\u54bd\u764c;\u816b\u7624\u9ad4\u7a4d;\u653e\u5c04\u6cbb\u7642 Oropharyngeal cancer;Primary tumor volume;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u53e3\u54bd\u764c\u75c5\u4eba\u6cbb\u7642\u524d\u816b\u7624\u9ad4\u7a4d\uff0c\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u5c40\u90e8\u63a7\u5236\u7387\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u56de\u6eaf\u6027\u8a55\u4f302002\u5e741\u6708\u52302006\u5e7412\u6708\u671f\u9593\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u768465\u4f4d\u53e3\u54bd\u764c\u75c5\u4eba\uff0c\u5176\u4e2d\u6241\u6843\u7aa9(tonsillar fossa)\u670951\u4f4d\uff0c\u8edf\u984e(soft palate)\u670914\u4f4d\u3002\u6240\u6709\u7684\u75c5\u4eba\u6bcf\u5929\u63a5\u53d71.8 Gy\u7684\u7167\u5c04\uff0c\u7e3d\u5291\u91cf\u9054\u523068.4 Gy\u81f378 Gy\uff08\u5291\u91cf\u4e2d\u4f4d\u657870.2 Gy\uff09\uff0c\u5176\u4e2d54\u4f4d\u75c5\u4eba\u4e5f\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u3002\u672c\u7814\u7a76\u4f7f\u7528\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u53ca\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u4f86\u5206\u5225\u63cf\u7e6a\u8207\u8a08\u7b97\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u3002\u7d71\u8a08\u65b9\u6cd5\u4ee5Kaplan-Meier\u4f86\u5206\u6790\u539f\u8208\u816b\u7624\u63a7\u5236\u7387\uff0c\u518d\u4f7f\u7528Cox's proportional hazard model\u4f86\u9032\u884c\u591a\u8b8a\u6578\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u4e2d\u4f4d\u657826\u500b\u6708\u7684\u8ffd\u8e64\uff086\u81f3\u96d9\u6708\uff09\u3001T1\u548cT2\u7684\u75c5\u4eba\u4e4b3\u5e74\u539f\u767c\u816b\u7624\u63a7\u5236\u7387\u70ba90%\uff0cT3\u548cT4\u7684\u75c5\u4eba\u70ba46%\uff08p\u503c\u507d0.003\uff09\u3002\u91cf\u6e2c\u7684\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u5e73\u5747\u70ba49.33\u6beb\u5347\uff083.17\u81f3242.59\u6beb\u5347\uff09\u3002\u7576\u539f\u767c\u816b\u7624\u9ad4\u7a4d\uff1c30\u6beb\u5347\u6642\uff0c3\u5e74\u539f\u767c\u816b\u7624\u63a7\u5236\u7387\u70ba82%\uff1b\u800c\u7576\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u226730\u6beb\u5347\u6642\uff0c3\u5e74\u4e4b\u539f\u767c\u816b\u7624\u63a7\u5236\u7387\u70ba38%\uff08p\u503c\u70ba0.001\uff09\u3002\u591a\u8b8a\u6578\u5206\u6790\u4e0b\u986f\u793a\u5169\u500b\u8f03\u5dee\u7684\u9810\u5f8c\u56e0\u5b50\uff1a\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u226730\u6beb\u5347\uff08p\u503c\u70ba0007\uff0c\u5371\u96aa\u6bd4\uff1a6.6\uff09\uff0c\u548c\u5e74\u9f61\u226750\u6b72\uff08p\u503c\u70ba0000\uff0c\u5371\u96aa\u6bd4\uff1a10.6\uff09\u3002\n\u7d50\u8ad6\uff1a\u5229\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u524d\u7684\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u8a55\u4f30\u539f\u767c\u816b\u7624\u7684\u9ad4\u7a4d\uff0c\u53ef\u4ee5\u66f4\u6e96\u78ba\u7684\u9810\u6e2c\u53e3\u54bd\u764c\u75c5\u4eba\u7684\u5c40\u90e8\u63a7\u5236\u7387\u3002\u7576\u539f\u767c\u816b\u7624\u9ad4\u7a4d\u5927\u65bc30\u6beb\u5347\u6642\uff0c\u6703\u6709\u8f03\u9ad8\u7684\u539f\u767c\u816b\u7624\u5fa9\u767c\u7684\u53ef\u80fd\u6027\u3002", "e": "Purpose: To investigate the value of pretreatment computed tomography (CT) volumetric analysis for the prediction of primary tumor control in patients with oropharyngeal cancer (OPC) treated by definite radiotherapy (RT), or concurrent chemoradiotherapy.\nMaterials and Methods: From January 2002 through December 2006, 65 patients with OPC were enrolled for this retrospective analysis. The tonsillar fossa was the principal site in 51 cases, whereas the soft palate in 14 patients. All patients received daily dose of 1.8 Gy to a total dose of 68.4 Gy to 78 Gy (median; 70.2 Gy). Concurrent chemotherapy was given to 54 patients. Primary tumor volume (pGTV) was contoured using the CT simulation and the volume was calculated by the planning system. Primary tumor relapse-free survival (PRFS) was calculated using the Kaplan-Meier method, Multivariate analysis was performed using the Cox's proportional hazard model.\nResult: With a median follow-up of 26 months (range, 6-52 months), the 3 year PRFS was 90% for T1-2 disease and 46 % for T3-4 disease (p=0.003). The measured pGTV values ranged from 3.17 to 242.59 ml (mean, 49.33 ml). The 3 year PRFS was 82% for those with pGTV\uff1c30 ml and 38% when pGTV were\u226730 ml (p=0.001): Multivariate analysis of PRFS revealed two poor prognosis factor: pGTV\u226730 ml (p=0.007, Hazard ratio: 6.6), and age\u226750 years old (p=0.000, Hazard ratio: 10.6).\nConclusion: Pretreatment CT-based primary tumor volumes are a strong predictor of local control for OPC treated by definitive RT. Primary tumor volumes\u226730 ml are associated with higher relapse rate."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-25-33-a", "title": "Postoperative Concurrent Chemoradiotherapy for Non-Early Stage Gastric Adenocarcinoma", "keywords": "\u80c3\u817a\u764c;\u8853\u5f8c\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642;\u5b58\u6d3b\u7387 Gastric Adenocarcinoma;Postoperative concurrent chemoradiotherapy;Survival rate", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u80c3\u817a\u764c\u958b\u5200\u5f8c\uff0c\u8ffd\u52a0\u8f14\u52a9\u6027\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u76f4\u81f32002\u5e744\u6708\uff0c\u672c\u9662\u59cb\u91dd\u5c0d\u7b2c\u4e8c\u3001\u4e09\u3001\u56db\u671f\u7121\u9060\u7aef\u8f49\u79fb\uff0c\u53ef\u884c\u6839\u6cbb\u6027\u5207\u9664\u4e4b\u80c3\u817a\u764c\u75c5\u4eba\uff0c\u5efa\u8b70\u75c5\u4eba\u65bc\u63a5\u53d7\u6839\u6cbb\u6027\u624b\u8853\u5fa9\u539f\u5f8c\uff0c\u7d66\u4e88\u8f14\u52a9\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u3002\u53c8\u81f32005\u5e744\u6708\uff0c\u517131\u4f4d\u75c5\u4eba\u63a5\u53d7\u8853\u5f8c\u8f14\u52a9\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u4e4b\u5efa\u8b70\uff0c\u800c\u53e635\u4f4d\u75c5\u4eba\u5247\u53ea\u63a5\u53d7\u6839\u6cbb\u6027\u624b\u8853\u3002\n\u7d50\u679c\uff1a\u591a\u8b8a\u6578\u5206\u6790\u986f\u793a\u75c5\u4eba\u6240\u9078\u64c7\u4e4b\u6cbb\u7642\u65b9\u5f0f\u53ca\u5176\u75be\u75c5\u5206\u671f\u53ca\u5916\u79d1\u5207\u9664\u8853\u5f0f\uff0c\u986f\u8457\u5f71\u97ff\u5b58\u6d3b\u7387\u3002\u5728\u8f14\u52a9\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u9019\u4e00\u7d44\u75c5\u4eba\uff0c\u5176\u4e09\u5e74\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba61.3%\u548c76.4%\uff1b\u800c\u53ea\u63a5\u53d7\u624b\u8853\u7684\u9019\u4e00\u7d44\u75c5\u4eba\uff0c\u5176\u4e09\u5e74\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u5247\u660e\u986f\u8f03\u4f4e\uff0c\u5206\u5225\u70ba40.0%\u548c47.9%\uff08log-rank p\u7686\u5c0f\u65bc0.05\uff09\u3002\u4f46\u5728\u8f14\u52a9\u540c\u6b65\u65bd\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u9019\u4e00\u7d44\u75c5\u4eba\uff0c\u670919.4%\u7684\u75c5\u4eba\u6709\u56b4\u91cd\u4e4b\u6025\u6027\u8178\u80c3\u9053\u526f\u4f5c\u7528\u3002\n\u7d50\u8ad6\uff1a\u4f9d\u6211\u5011\u904e\u53bb\u7684\u7d93\u9a57\uff0c\u65bd\u884c\u904e\u6839\u6cbb\u6027\u624b\u8853\u4e4b\u7b2c\u4e8c\u3001\u4e09\u3001\u56db\u671f\u7121\u9060\u7aef\u8f49\u79fb\u4e4b\u80c3\u817a\u764c\u75c5\u4eba\uff0c\u82e5\u63a5\u53d7\u8f14\u52a9\u4e4b\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642\uff0c\u53ef\u80fd\u660e\u986f\u6539\u5584\u5176\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u3002", "e": "Purpose: To analyze the treatment outcome of adjuvant concurrent chemoradiotherapy for patients with gastric adenocarcinoma.\nMaterial and Method: After April 2002, adjuvant concurrent chemoradiotherapy (CCRT) was suggested for our patients with gastric adenocarcinoma of stage \u2161, \u2162, and \u2163 (MO) after gastrectomy. Until April 2005, thirty-one patients received adjuvant CCRT with median dose of 45 Gy (ranged from 14.4 to 50.4 Gy). The other thirty-five patients in this period had no other treatment after radical surgery.\nResults Multivariate analysis of Cox regression showed the factors of stages, treatment methods, and surgical dissection (D1 or D2) were significant prognostic factors for survival rate. By using Kaplan-Meier methods, the 3-year survival and local control rates in adjuvant CCRT group were 61.3% and 76.4%, and the 3-year survival and local control rates in operation alone group were 40% and 47.9% (significantly lower, log-rank p\uff1c0.05). The most common severe acute toxicity in the adjuvant CCRT group was gastro-intestinal (GI) grade \u2162 complication according to the Radiation Therapy Oncology Group for acute radiation morbidity scoring criteria. Six out of 31 patients with CCRT (19.4%) had the grade \u2162 G1 acute side effect.\nConclusion: Adjuvant CCRT after radical gastrectomy might significantly improve survival and local control in patients with gastric adenocarcinonia of stage \u2161, \u2162, and \u2163 (MO) in our experience."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-35-46-a", "title": "Treatment Results of Esophageal Cancer after Radiotherapy Alone or Concurrent Chemoradiothepapy", "keywords": "\u98df\u9053\u764c;\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642;\u9806\u5f62\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Radiotherapy;Chemoradiotherapy;Conformal radiation therapy", "c": "Purpose: To analyze the treatment results of the patients with esophageal cancer after radiotherapy (RT) alone or concurrent chemoradiotherapy (CCRT) and identify possible prognostic factors.\nMethods and Materials: Between February 1997 and February 2007, we treated 118 patients who had previously untreated esophageal carcinoma using definitive RT alone or CCRT. Fifty-two patients (44.1%) underwent RT alone and 66 patients (55.9%) underwent CCRT. Radiotherapy was delivered with conventional technique in 58 patients, three-dimensional conformal radiation therapy (3DCRT) in 56 patients, and intensity-modulated radiation therapy (IMAT) in 4 patients. The median dose of RT was 59.4 Gy. Survival rates were calculated from the end of the radiotherapy with the Kaplan-Meier method.\nResults: The median follow-up was 4 months for all patients and 25 months for those alive. Ten patients were alive, 102 patients died, and 6 patients were lost to follow-up. The 4-year overall survival of all patients were 8.2%. The 4-year overall survival of the patients in the RT alone and the CORT arm was 2.7% and 13.8%, respectively (p=0.188). The 4-year overall survival rate of stage \u2161, \u2162, and \u2163 Was 9%, 14.6%, and 0%, respectively (p=0.045). There is no survival benefit for patient treated with 3DCRT or IMRT compared with conventional technique. A higher pretreatment hemoglobin (10 gm/dl or more) resulted in a better survival (p=0.001). In multivariate analysis, stage, CCRT, pretreatment hemoglobin, and completion of RT course were significant predictors of survival (p=0.033, 0.046, 0.032, \uff1c0.001, respectively). Adding chemotherapy to radiotherapy did not increase treatment mortality and morbidity. Three-dimensional conformal radiation therapy (3DCRT)/IMRT decreased incidence of radiation pneumonitis compared with conventional technique (p=0.011).\nConclusions: There is a trend for a better survival in the CCRT group and adding chemotherapy did not bring more toxicities. Higher pretreatment hemoglobin, early stage, CCRT, completion of AT course were significant predictors of better survival. New AT technique with 3DCRT/IMRT did not offer survival benefit, but decreased incidence of radiation pneumonitis.", "e": "Purpose: To analyze the treatment results of the patients with esophageal cancer after radiotherapy (RT) alone or concurrent chemoradiotherapy (CCRT) and identify possible prognostic factors.\nMethods and Materials: Between February 1997 and February 2007, we treated 118 patients who had previously untreated esophageal carcinoma using definitive RT alone or CCRT. Fifty-two patients (44.1%) underwent RT alone and 66 patients (55.9%) underwent CCRT. Radiotherapy was delivered with conventional technique in 58 patients, three-dimensional conformal radiation therapy (3DCRT) in 56 patients, and intensity-modulated radiation therapy (IMAT) in 4 patients. The median dose of RT was 59.4 Gy. Survival rates were calculated from the end of the radiotherapy with the Kaplan-Meier method.\nResults: The median follow-up was 4 months for all patients and 25 months for those alive. Ten patients were alive, 102 patients died, and 6 patients were lost to follow-up. The 4-year overall survival of all patients were 8.2%. The 4-year overall survival of the patients in the RT alone and the CORT arm was 2.7% and 13.8%, respectively (p=0.188). The 4-year overall survival rate of stage \u2161, \u2162, and \u2163 Was 9%, 14.6%, and 0%, respectively (p=0.045). There is no survival benefit for patient treated with 3DCRT or IMRT compared with conventional technique. A higher pretreatment hemoglobin (10 gm/dl or more) resulted in a better survival (p=0.001). In multivariate analysis, stage, CCRT, pretreatment hemoglobin, and completion of RT course were significant predictors of survival (p=0.033, 0.046, 0.032, \uff1c0.001, respectively). Adding chemotherapy to radiotherapy did not increase treatment mortality and morbidity. Three-dimensional conformal radiation therapy (3DCRT)/IMRT decreased incidence of radiation pneumonitis compared with conventional technique (p=0.011).\nConclusions: There is a trend for a better survival in the CCRT group and adding chemotherapy did not bring more toxicities. Higher pretreatment hemoglobin, early stage, CCRT, completion of AT course were significant predictors of better survival. New AT technique with 3DCRT/IMRT did not offer survival benefit, but decreased incidence of radiation pneumonitis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-47-53-a", "title": "\u8f3b\u5c04\u751f\u7269\u5be6\u9a57\u7d30\u80de\u7167\u5c04\u4e4b\u5291\u91cf\u5206\u6790", "keywords": "\u7d30\u80de\u7167\u5c04;\u754c\u9762\u5291\u91cf;TLD;\u7b49\u6548\u6469\u5ea6\u4fc2\u6578CET Cell irradiation;Interface does;TLD;GET", "c": "\u76ee\u7684\uff1a\u57fa\u790e\u8f3b\u5c04\u751f\u7269\u5b78\u7684\u7d30\u80de\u7167\u5c04\u5be6\u9a57\u5c0d\u653e\u5c04\u751f\u7269\u5b78\u7684\u767c\u5c55\u5f71\u97ff\u6df1\u9060\uff0c\u5229\u7528\u76f4\u7dda\u52a0\u901f\u5668\u505a\u751f\u7269\u7d30\u80de\u7167\u5c04\u3002\u53d7\u9650\u65bc\u57f9\u990a\u7d30\u80de\u4e4b\u5668\u76bf\u7684\u5e7e\u4f55\u7d50\u69cb\uff0c\u5728\u5291\u91cf\u4e0a\u6709\u76f8\u7576\u591a\u7684\u4e0d\u78ba\u5b9a\u6027\u3002\u5be6\u969b\u4ee5TLO\u91cf\u6e2c\u5404\u7a2e\u7167\u5c04\u689d\u4ef6\u7684\u5291\u91cf\u503c\uff0c\u4ee5\u6c42\u6e96\u78ba\u5730\u63a7\u5236\u5291\u91cf\u7684\u7d66\u4e88\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528ELEKTA SL-18\u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f\u76846 MV\u300110 MV\u5149\u5b50\u5c04\u675f\u53ca10 MeV\u300112 Mev\u300115 Mev\u96fb\u5b50\u5c04\u675f\uff0c\u7167\u91ce\u5927\u5c0f\u8a2d\u5b9a\u5149\u5b50\u5c04\u675f\u70ba20\u00d720\u5e73\u65b9\u516c\u5206\uff0c\u96fb\u5b50\u5c04\u675f\u70ba25\u00d725\u5e73\u65b9\u516c\u5206\u3002\u9078\u64c7\u4e09\u7a2e\u5e38\u7528\u65bc\u8f3b\u5c04\u7167\u5c04\u5be6\u9a57\u7684\u7d30\u80de\u57f9\u990a\u76bf\uff0c\u5be6\u9a57\u7684\u67b6\u8a2d\u4f9d\u7167\u5c04\u675f\u7167\u5c04\u65b9\u5f0f\u5206\u6210AP\u548c\u4ee5\u5169\u90e8\u5206\uff0c\u7686\u4f7f\u7528\u5149\u5b50\u548c\u96fb\u5b50\u5c04\u675f\u3002\u5291\u91cf\u91cf\u6e2c\u4ee5\u539a\u5ea60.1 mm\u7684\u8d85\u8584TLD\u57f7\u884c\u3002\u7d30\u80de\u7167\u5c04\u5be6\u9a57\u7684\u60c5\u6cc1\u985e\u4f3c\u65bc\u9ad4\u5167\u4e0d\u5747\u52fb\u4ecb\u8cea\u5206\u5e03\uff0c\u5291\u91cf\u5206\u5e03\u5728\u6b64\u975e\u5747\u8cea\u7d44\u7dde\u7684\u5f8c\u9762\u5247\u53ef\u4ee5\u5229\u7528\u7b49\u6548\u539a\u5ea6\u4fc2\u6578\u7684\u65b9\u6cd5\u8a55\u4f30\u3002\u5617\u8a66\u5efa\u7acb\u4e0d\u540c\u5f62\u5f0f\u57f9\u990a\u76bf\u3001\u5c04\u675f\u80fd\u91cf\u53ca\u7167\u5c04\u689d\u4ef6\u6240\u9020\u6210\u5291\u91cf\u8a08\u7b97\u503c\u8207\u91cf\u6e2c\u503c\u7684\u95dc\u4fc2\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1aAP\u7167\u5c04\u7684\u60c5\u6cc1\u4e0b\uff0c\u5149\u5b50\u5c04\u675f\u7684\u91cf\u6e2c\u503c\u6709\u9ad8\u65bc\u8a08\u7b97\u503c\u7684\u8da8\u52e2\uff0c6MV\u504f\u9ad8\u7d04\uff1a7%\uff1b10MV\u5247\u70ba5%\uff1b\u96fb\u5b50\u5c04\u675f\u572810 MeV\u300112 MeV\u4e0b\uff0c\u8a08\u7b97\u8207\u91cf\u6e2c\u503c\u76f8\u7576\u543b\u5408\uff0c\u5dee\u7570\u7d04\u5728\u00b13%\u4ee5\u5167\u3002\u4f46\u662f\u572815 MeV\u6642\uff0c\u91cf\u6e2c\u503c\u5247\u7565\u9ad8\u65bc\u8a08\u7b97\u503c\u3002\u65bcPA\u67b6\u8a2d\u6a21\u5f0f\u4e0b\uff0c\u91cf\u6e2c\u503c\u666e\u904d\u5448\u73fe\u4f4e\u65bc\u8a08\u7b97\u503c\uff0c\u5c24\u5176\u80fd\u91cf\u9ad8\u7684\u5149\u5b50\u5c04\u675f\u6216\u7a7a\u8154\u8f03\u5927\u7684\u57f9\u990a\u76bf\u66f4\u70ba\u660e\u986f\u3002\u9ad8\u80fd\u5149\u5b50\u8f03\u96fb\u5b50\u5c04\u6771\u6709\u66f4\u660e\u986f\u7684\u589e\u5efa\u5340\u57df\uff0c\u7576\u5291\u91cf\u8a55\u4f30\u5340\u57df\u843d\u65bc\u589e\u5efa\u5340\uff0c\u5149\u5b50\u5c04\u675f\u53ef\u80fd\u6703\u6709\u8f03\u9ad8\u7684\u5291\u91cf\u4e0d\u78ba\u5b9a\u6027\u3002\u9ad8\u80fd\u96fb\u5b50\u5c04\u675f\uff1b10\u300112\u300115 MeV\u7b49\u7684PDD\u66f2\u7dda\u5728\u6df1\u5ea6\u70ba1cm~3.5cm\u4e4b\u9593\u6642\uff0c\u5448\u73fe\u4e00\u500b\u8f03\u70ba\u5e73\u5766\u7684\u6700\u5927\u5291\u91cf\u5206\u70ba\u5340\u57df\u3002\u5373\u4f7f\u5728\u7a7a\u8154\u539a\u5ea6\u8a55\u4f30\u6e96\u78ba\u6027\u4e0a\u6709\u4e9b\u4e0d\u8db3\uff0c\u4f46\u662f\u56e0\u70ba\u8655\u65bc\u5e73\u5766\u5340\uff0c\u5291\u91cf\u7d66\u4e88\u7684\u8aa4\u5dee\u5c07\u8f03\u5c0f\u3002", "e": "Purpose: Dose analysis is important for biological cell irradiation study. When cell irraiation was performed by using a high energy radiotherapy Linac, the dose uncertainties caused by the inhomogeneity structures of the cell containers make it difficult to estimate the cell dose. In this study, cell doses were measured and analysised for different setup conditions.\nMaterials and Methods: 6 MV, 10 MV photon beams and 10 MeV, 12 MeV, 15 MeV electron beams generated by Electa SL-18 Linac were used in this study. Field sizes of 20\u00d720 cm^2 for photon beams and 25\u00d725 cm^2 for electron beams were designed to have a fully side scatter condition. Dosimetry analyses for AP and PA directions were performed for 86 mm\u00d7l9.5 mm Polystyrene petri dish, 25 cm^2\u00d724.3 mm and 75 cm^2\u00d736.5 mm Tissue Culture Flask. Extra thin TLDs (0.1 mm) were used for dose measurements. The cell irradiation condition is similar to the inhomogeneity distribution in a human body. GET (Coefficient of Equivalent Thickness) is used to evaluation the dose distribution which beyond the inhomogeneity structures. The dose variations for calculation and measurement were analyzed in different setup conditions.\nResults and Discussion: In AP setup, the calculation dose was consistent for electron beams, within 3%, but was under estimated for both of photon beams, maximum variation of 7% in 6 MV and 5% in 10 MV. In PA setup, the calculation doses were under estimated for electron and photon beams, and are more significant for higher photon energy and larger air cavity. The depth dose distribution in buildup region is much sharper for photon beam than electron beam. This behavior makes a smaller dose variation in electron beams than in photon beams when evaluated position is located at the buildup area."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-55-62-a", "title": "\u5229\u7528Sybase InfoMaker\u81eaARIA\u764c\u75c7\u8cc7\u8a0a\u7cfb\u7d71\u8f38\u51fa\u81e8\u5e8a\u4f5c\u696d\u5831\u544a", "keywords": "\u764c\u75c7\u8cc7\u8a0a\u7cfb\u7d71;\u5716\u5f62\u6a21\u5f0f\u7d50\u69cb\u5316\u67e5\u8a62\u8a9e\u8a00;\u8cc7\u8a0a\u8cc7\u6599\u5eab Oncology Information System;Structured Query Language;Information Database", "c": "\u76ee\u7684\uff1a\u4ee5InfoMaker\u8a2d\u8a08\u8f38\u51fa\u6587\u4ef6\uff0c\u89e3\u6c7aARIA\u764c\u75c7\u8cc7\u8a0a\u7cfb\u7d71\u8cc7\u6599\u7d71\u8a08\u53ca\u8f38\u51fa\u554f\u984c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528InfoMaker\u7a0b\u5f0f\uff0c\u4f9d\u7167ARIA\u764c\u75c7\u8cc7\u8a0a\u7cfb\u7d71(ARIA)\u5167\u8cc7\u8a0a\u4f4d\u7f6e\uff0c\u53ca\u8a72\u8cc7\u6599\u5eab\u5167\u8cc7\u6599\u8868\u9593\u76f8\u95dc\u7d44\u6210\u4e4b\u95dc\u806f\u7d50\u69cb\uff0c\u65bc\u5716\u5f62\u6a21\u5f0f\u7d50\u69cb\u5316\u67e5\u7d62\u8a9e\u8a00(SQL)\u4e0b\u91cd\u65b0\u7de8\u8f2f\u8cc7\u6599\u8868\u9593\u7684\u6846\u67b6\u53ca\u8cc7\u8a0a\u5831\u8868\u7de8\u8f2f\uff0c\u4e26\u5c07\u7de8\u8f2f\u5b8c\u6210\u7684\u7d50\u679c\u5831\u8868\uff0c\u8f49\u63db\u6210\u53ef\u65bc\u6240\u6709\u5de5\u4f5c\u7ad9\u7aef\u96fb\u8166\u57f7\u884c\u7684\u53ef\u57f7\u884c\u6a94\u3002\n\u7d50\u679c\uff1a\u5229\u7528InfoMaker\u81ea\u884c\u8a2d\u8a08\u81e8\u5e8a\u4f5c\u696d\u6240\u9700\u5831\u8868\uff0c\u53ef\u81eaARIA\u8cc7\u6599\u5eab\u8f38\u51fa\u8f14\u52a9\u81e8\u5e8a\u4f5c\u696d\u6240\u9700\u7684\u4f5c\u696d\u8868\u55ae\uff0c\u4e14\u53ef\u540c\u6642\u6aa2\u8996\u8f38\u5165\u65bc\u8cc7\u6599\u5eab\u4e2d\u8cc7\u8a0a\u662f\u5426\u6b63\u78ba\u3002\u900f\u904eInfoMaker\u8f38\u51fa\uff0c\u4e5f\u53ef\u907f\u514dARIA\u7121\u6cd5\u76f4\u63a5\u8f38\u51fa\u4e2d\u6587\u7684\u554f\u984c\u3002\u6b64\u5916\uff0c\u900f\u904e\u53ef\u57f7\u884c\u6a94\u7684\u5efa\u7acb\uff0c\u9054\u5230\u65bc\u5404\u5de5\u4f5c\u7ad9\u55ae\u4e00\u9ede\u64ca(one-click)\u8f38\u51fa\u5831\u8868\u7684\u4fbf\u5229\u3002\u56e0\u6b64\uff0cARIA\u9664\u505a\u70ba\u6cbb\u7642\u4f5c\u696d\u4e2d\u8cc7\u8a0a\u50b3\u8f38\u8207\u9a57\u8b49\u5916\uff0c\u4e26\u53ef\u5229\u7528\uff0cInfoMaker\u7de8\u8f2f\u81e8\u5e8a\u4f5c\u696d\u6240\u9700\u5831\u8868\uff0c\u66f4\u9032\u4e00\u6b65\u76f4\u63a5\u8f38\u51fa\u7d71\u8a08\u8868\uff0c\u9032\u884c\u7d71\u8a08\u4f5c\u696d\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u7528\u56deInfoMaker\u8a2d\u8a08\u81e8\u5e8a\u4f5c\u696d\u6240\u9700\u5831\u8868\uff0c\u53ef\u514b\u670d\u8b80\u53d6\u53ca\u8f38\u51faARIA\u5167\u5b58\u8cc7\u6599\u7684\u56f0\u96e3\uff0c\u4e26\u63d0\u4f9b\u5404\u5de5\u4f5c\u7ad9\u7686\u80fd\u9ede\u64ca\u8f38\u51fa\u5831\u8868\u53ca\u5feb\u901f\u7372\u53d6\u7d71\u8a08\u8cc7\u6599\u7684\u4fbf\u5229\uff0c\u514d\u9664\u53e6\u884c\u5efa\u7acb\u7d71\u8a08\u8cc7\u6599\u5eab\u7684\u5de5\u4f5c\uff0c\u986f\u8457\u63d0\u5347\u7cfb\u7d71\u4f7f\u7528\u6548\u7387\u4e26\u6e1b\u5c11\u8cc7\u6599\u8655\u7406\u7684\u5de5\u4f5c\u3002", "e": "Purpose: To explore a resolution to export data of ARIA oncology information (ARIA) system by InfoMaker.\nMaterials and Methods: According to the data Location in the ARIA and Linking structures between each database, we used InfoMaker program to reconstruct and edit new information report and data sheet frame by the Structured Query Language. These reports were further transformed to executive files so that each report can be retrieved at every terminal computer at each work station.\nResults: Through customized report and data sheet by InfoMaker, we could export nearly all information in the ARIA with self-designed format for clinical service. The language output was correct through InfoMaker program, and we could also validate the data. Besides, after transforming those document to executive files, we achieved the convenience such as one-click execution and accessible at all workstation terminals. Through InfoMaker, ARIA could not only manage the radiation therapy information, but also direct export document for clinical service, statistical report, and customized form with extreme convenience.\nConclusion: Customizing documents, reports, and forms by InfoMaker, could overcome the difficulty and error in retrieving data from ARIA. It could also provide the one-click and accessible at every terminals convenience, and avoid the burden of establishing other database or program for exporting or processing data."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-63-67-a", "title": "\u4f7f\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\u4e8e\u4e73\u623f\u4fdd\u7559\u624b\u8853\u764c\u75c5\u60a3\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7d50\u679c", "keywords": "\u76ae\u819a\u53cd\u61c9;\u4e73\u764c\u653e\u5c04\u6cbb\u7642;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642 Skin reaction;Breast radiation therapy;IMRT", "c": "\u76ee\u7684\uff1a\u4f7f\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce(Field-in-Field, FIF)\u4e8e\u4e73\u623f\u4fdd\u7559\u624b\u8853\u764c\u75c5\u60a3\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7d50\u679c\uff0c\u8207\u50b3\u7d71\u4f7f\u7528\u6954\u578b\u6ffe\u7247\u7167\u91ce(wedge-Fields)\u6bd4\u8f03\u3002\u6bd4\u8f03\u9805\u76ee\u5305\u62ec\uff1a\u76ae\u819a\u53cd\u61c9\u3001\u6574\u9ad4\u6700\u5927\u5291\u91cf\u3001\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u53ca\u6cbb\u7642\u6642\u9593\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6536\u96c62006\u5e741\u6708\u81f32007\u5e746\u6708\u5171172\u500b\u75c5\u4eba\uff0c\u5176\u4e2d100\u500b\u75c5\u4eba\u4f7f\u7528wedge field\u6cbb\u7642\u65b9\u5f0f\uff0c72\u500b\u75c5\u4eba\u4f7f\u7528FIF\u6cbb\u7642\u65b9\u5f0f\u3002\u6bcf\u4f4d\u75c5\u4eba\u4e4b\u76ae\u819a\u53cd\u61c9\u6839\u64daRTOG\u5206\u985e\uff0c\u6bcf\u661f\u671f\u505a\u4e00\u6b21\u8a55\u4f30\uff1b\u6574\u9ad4\u6700\u5927\u5291\u91cf(Global maximum dose)\u53ca\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d(Monitor Unit)\u53ef\u7531\u5176\u6cbb\u7642\u8a08\u5283\u4e2d\u7372\u5f97\uff1b\u6cbb\u7642\u6642\u9593\u5b9a\u7fa9\u70ba\u5f9e\u7b2c\u4e00\u500b\u7167\u91ce\u81f3\u6700\u5f8c\u4e00\u500b\u7167\u91ce\u4e4b\u9593\u7684\u6642\u9593\uff0c\u53ef\u7531Lantis\u4e4bRecord & verify System\u4e2d\u6cbb\u7642\u8a18\u9304\u53d6\u5f97\u3002\n\u7d50\u679c\uff1a\u4f7f\u7528wedge field technique\u4e4b100\u4f4d\u75c5\u4eba\u4e2d\u670971 (71%)\u4f4d\u7522\u751fgrade 1\u76ae\u819a\u53cd\u61c9\uff0c5(5%)\u4f4d\u7522\u751fgrade 2\u76ae\u819a\u53cd\u61c9\uff0c\u5e73\u5747\u6574\u9ad4\u6700\u5927\u5291\u91cf\u70ba5582 cGy\uff0c\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u70ba495 MU\uff0c\u6cbb\u7642\u6642\u9593\u7d045\u5206\u937e\u3002\n\u4f7f\u7528FIF\u6cbb\u7642\u4e4b72\u4f4d\u75c5\u4eba\u4e2d\u670925(35%)\u4f4d\u7522\u751fgrade 1\u76ae\u819a\u53cd\u61c9\uff0c\u6ca1\u6709\u4eba\u7522\u751f\u99b4grade 2(0%)\u76ae\u819a\u53cd\u61c91\u5e73\u5747\u6574\u9ad4\u6700\u5927\u5291\u91cf\u70ba5208 cGy\uff0c\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u70ba257 MU\uff0c\u6cbb\u7642\u6642\u9593\u7d043\u5206\u9418\u3002\n\u7528\u7d71\u8a08\u65b9\u6cd5\u5206\u6790\u6b64\u5169\u7a2e\u6280\u8853\u4e4b\u5dee\u7570\uff0c\u5176p\u503c\u7686\u5c0f\u65bc0.001\uff0c\u986f\u793a\u6b64\u5728\u7d71\u8a08\u4e0a\u6709\u610f\u7fa9\u3002\n\u7d50\u8ad6\uff1b\u4f7f\u7528FIF\u4e8e\u4e73\u623f\u4fdd\u7559\u624b\u8853\u764c\u75c5\u60a3\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7d50\u679c\uff0c\u5728\u76ae\u819a\u53cd\u61c9\u4e0a\u5f88\u660e\u986f\u6bd4\u4f7f\u7528wedge-field technique\u5c11\uff0c\u6b64\u5916\uff0c\u75c5\u4eba\u4e4b\u6574\u9ad4\u6700\u5927\u5291\u91cf\u3001\u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\u53ca\u6cbb\u7642\u6642\u9593\u4ea6\u660e\u986f\u6e1b\u5c11\u3002\u5c0d\u65bc\u4e73\u623f\u4fdd\u7559\u624b\u8853\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\uff0cFIF\u662f\u4e00\u6709\u6548\u4e26\u53ef\u884c\u4e4b\u6280\u8853\u3002", "e": "Purpose: To compare the results of breast treatment using the Field-in-Field (FIF) technique and the conventional wedge technique in terms of skin-reaction, global maximum dose, treatment monitor unit and treatment time.\nMaterial and Methods We collected 172 patients treated from January 2006 to June 2007, of which 100 patients used the traditional wedge-field technique, and 72 patients used the FIF method. Using the RTOG classification, the patient skin-reaction was assessed once a week. We also obtained the global maximum dose and the treatment monitor unit from the patient's treatment plan. The treatment time, defined as the time period between the first beam-on to the last beam-off, was obtained from the Record & verify System (Lantis).\nResults: For the 100 patients using traditional wedge, 71 (71%) patients had grade I skin reaction, 5 (5%) patients had grade 2 skin reaction, the averaged global maximum dose was 5,582 cGy, the averaged treatment monitor unit was 495 MU, and the averaged treatment time was approximately 5 minutes.\nFor the 72 patients using the FIF technique, 25 (35%) patients had grade I skin reaction, none had grade 2 (0%) skin reaction, the averaged global maximum dose was 5,208 cGy, the averaged treatment monitor unit was 257 MU, and the averaged treatment time was approximately 3 minutes.\nUsing statistical method to analyze these differences, the p-values were all less than 0.001, indicating the difference is statistically significant. Clinical results of the FIF technique have reduced skin reactions.\nConclusion: The clinical results of breast treatment showed that the FIF method produced less complications in skin reactions compared to the conventional wedge method. Moreover, the FIF technique delivers less global maximum dose, requires less MU and delivery time than the traditional wedge technique. Thus, the FIF technique is a practical and efficient method that is suitable for routine clinical use."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-69-78-a", "title": "Lymphoepithelial Carcinoma of the Sublingual Gland Associated with EBV Infection: A Case Report", "keywords": "\u6dcb\u5df4\u4e0a\u76ae\u764c;\u820c\u4e0b\u817a;EB\u75c5\u6bd2;\u553e\u6db2\u817a Lymphoepithelial carcinoma;The sublingual gland;EBV;Salivary gland", "c": "\u524d\u8a00\uff1a\u6dcb\u5df4\u4e0a\u76ae\u764c(lymphoepithelial carcinoma)\u662f\u672a\u5206\u5316\u764c\u7684\u4e00\u7a2e\uff0c\u662f\u5f9e\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u8f49\u8b8a\u800c\u4f86\u7684\u3002\u5728\u4e3b\u553e\u6db2\u817a\u4e2d\uff0c\u6dcb\u5df4\u4e0a\u76ae\u764c\u662f\u5f88\u5c11\u898b\u7684\uff0c\u5c24\u5176\u662f\u5728\u820c\u4e0b\u817a\uff0c\u5927\u90e8\u5206\u90fd\u662f\u4fb5\u72af\u816e\u817a\u3002\u5728\u683c\u9675\u862d\u5cf6\u7684\u611b\u65af\u57fa\u6469\u4eba\u53ca\u6771\u5357\u4e9e\u7684\u4eba\uff0c\u6709\u8f03\u9ad8\u7684\u76db\u884c\u7387\uff0c\u800c\u4e14\u8ddfEB(Esptein-Barr virus)\u75c5\u6bd2\u7684\u611f\u67d3\u6709\u76f8\u7576\u7684\u95dc\u806f\u3002\u5c31\u6211\u5011\u6240\u77e5\uff0c\u5230\u76ee\u524d\u70ba\u6b62\u4e26\u6c92\u6709\u91ab\u5b78\u5831\u544a\u5831\u5c0e\u904e\u820c\u4e0b\u817a\u7684\u6dcb\u5df4\u4e0a\u76ae\u764c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5831\u544a\u4e86\u7b2c\u4e00\u500b\u820c\u4e0b\u817a\u4e4b\u6dcb\u5df4\u4e0a\u76ae\u764c\uff0c\u767c\u751f\u5728\u4e00\u4f4d37\u6b72\u7684\u53f0\u7063\u7537\u6027\u3002\u4e00\u958b\u59cb\u662f\u4ee5\u4e0b\u9837\u816b\u584a\u4f86\u8868\u73fe\u3002\u6b63\u5b50\u65b7\u5c64\u6383\u63cf\u8b49\u5be6\u9019\u662f\u4e00\u500b\u4fb7\u9650\u5728\u5340\u57df\u7684\u75be\u75c5\uff0c\u53ea\u5f71\u97ff\u5de6\u5074\u7684\u53e3\u8154\u5e95\u90e8\u8ddf\u4e0b\u9837\u6dcb\u5df4\u3002\u540c\u6642\u9f3b\u54bd\u90e8\u4e26\u7121\u4fb5\u72af\u3002\u5728\u8840\u6e05\u5b78\u4e0a\uff0cEBV VCA IgA\u53caIgG\u90fd\u6709\u4e0a\u5347\u3002\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u4e0aLMP-1\u4e5f\u5448\u73fe\u967d\u6027\u53cd\u61c9\u3002\u75c5\u4eba\u5148\u9032\u884c\u6dcb\u5df4\u6458\u9664\u8853\uff0c\u518d\u63a5\u7e8c\u9032\u884c\u653e\u5c04\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u5728\u63a5\u53d7\u5b8c\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u816b\u7624\u5f97\u5230\u5b8c\u5168\u7684\u7de9\u89e3\uff0c\u4e26\u572820\u500b\u6708\u7684\u8ffd\u8e64\u4e0b\uff0c\u6c92\u6709\u767c\u73fe\u75c5\u4eba\u6709\u5fa9\u767c\u6216\u662f\u8f49\u79fb\u7684\u73fe\u8c61\u3002\n\u7d50\u8ad6\uff0c\u553e\u6db2\u817a\u7684\u6dcb\u5df4\u4e0a\u76ae\u764c\u5728\u982d\u9838\u90e8\u7684\u672a\u5206\u5316\u764c\u4e2d\u7684\u9810\u5f8c\u662f\u6bd4\u8f03\u597d\u3002\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u5f97\u5230\u4e00\u500b\u4e0d\u932f\u7684\u5c40\u90e8\u5340\u57df\u7684\u63a7\u5236\u7387\u3002\u56e0\u6b64\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u521d\u671f\u6216\u662f\u624b\u8853\u5f8c\u7684\u75c5\u4eba\u53ef\u4ee5\u63d0\u4f9b\u4e00\u500b\u826f\u597d\u7684\u5c40\u90e8\u5340\u57df\u63a7\u5236\u4e4b\u6cbb\u7642\u3002", "e": "Purpose: Lymphoepithelial carcinoma (LEC) is a subtype of undifferentiated carcinoma, which is originated from squamous cell. Lymphoepithelial carcinoma is a rare tumor of the major salivary gland, especially in sublingual gland. In moat cases, LEC affected the parotid gland. There are high incidences in Greenlandic Eskimos and Southeastern Asians with strongly associated with Epstein-Barr virus infection. To our knowledge, there is no case of LEC in sublingual gland reported in the medical literature.\nMaterials and Methods: We report the first case of LEC of the sublingual tumor of a 37-year-old Taiwanese man. The initial presentation was a mass over the submental area. PET/CT scan showed there was only a locoregional disease, which was limited in the left mouth floor and submental lymph node. Naopharynx was not involved at the same time. Serological studies showed elevated titer of Epstein-Barr virus: capsid antigen IgG and IgA antibodies. Immunohistochemical stain of LMP-1 also showed the positive result. The patient underwent excision and lymphodectomy followed by definite radiotherapy.\nResult: Complete remission of LEC of the sublingual gland was achieved by the definite radiotherpy. The patient remained alive without any recurrence or metastasis after 20-month of follow-up.\nConclusion: LEC of the salivary gland is a radiosensitive disease and has a better prognosis among the undifferentiated carcinoma at the head and neck region. High rates of locoregional control were achieved by radiotherapy. Therefore, radiotherapy is appropriate locoregional therapy for patents in the early stage or after surgical intervention."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200903-16-1-79-84-a", "title": "Physiological Uptake of Soft Tissue in Positron Emission Tomography May Mimic Local Recurrelce of Nasopharyn-Geal Carcinoma: A Case Report", "keywords": "\u6b63\u5b50\u651d\u5f71;\u9f3b\u54bd\u764c;\u5c40\u90e8\u5fa9\u767c PET/CT;Nasopharyngeal carcinoma;Local-regional recurrence", "c": "\u672c\u6587\u5831\u544a\u4e00\u4f8b\u653e\u5c04\u6cbb\u7642\u5f8c\u9f3b\u54bd\u764c\u75c5\u60a3\uff0c\u5176\u8ffd\u8e64\u6aa2\u67e5\u4e4b\u6b63\u5b50\u65b7\u5c64\u651d\u5f71\u986f\u793a\u96d9\u5074\u9838\u90e8\u8edf\u7d44\u7e54\u6709\u660e\u985e\u985e\u5f71\uff0c\u7591\u4f3c\u5c40\u90e8\u5fa9\u767c\uff0c\u5207\u7247\u672a\u767c\u73fe\u764c\u7d30\u80de\u4e14\u8ffd\u8e64\u4e00\u5e74\u672a\u5fa9\u767c\u3002\n\u6b63\u5b50\u65b7\u5c64\u651d\u5f71\u61c9\u7528\u65bc\u816b\u7624\u5b78\u65e5\u76ca\u589e\u52a0\uff0c\u751f\u7406\u6027\u986f\u5f71\u767c\u751f\u5728\u9838\u90e8\u808c\u8089\u3001\u8102\u80aa\u3001\u6241\u6843\u817a\u3001\u5074\u54bd\u7aa9\u6216\u553e\u6db2\u817a\u7b49\u8edf\u7d44\u7e54\u3002\u751f\u7406\u6027\u986f\u5f71\u72c0\u4f3c\u5c40\u90e8\u5fa9\u767c\uff0c\u53ef\u80fd\u9020\u6210\u507d\u967d\u6027\u5224\u8b80\uff0c\u6a19\u6e96\u651d\u53d6\u503c(SUV)\u3001\u986f\u5f71\u5f62\u72c0\u53ca\u5f62\u614b\u4e0a\u4e4b\u653f\u8b8a\u53ef\u5e6b\u52a9\u9451\u5225\u8a3a\u65b7\u3002", "e": "This paper reported a case of post-radiation nasopharyngeal carcinoma whose follow-op positive emission tomography/computed tomography (PET/CT) scan showed physiological uptake in bilateral neck soft tissue. This image pattern mimicked local recurrence. Biopsy revealed no malignant cells. One-year follow-op showed free of recurrence.\nPET/CT scan has been increasingly used in oncology. Physiological uptake may happen n soft tissues of neck such as muscles, fat, tonsils, lateral pharyngeal recess and salivary glands. Physiological uptake may mimic local recurrence and cause false-positive reading. Standard uptake value (SUV), image pattern and morphology change may help in differential diagnosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-257-267-a", "title": "\u9f3b\u54bd\u764c\u75c5\u60a3\u7d93\u653e\u5c04\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u4e4b\u6025\u6027\u8b8a\u5316", "keywords": "\u9f3b\u54bd\u764c;\u751f\u6d3b\u54c1\u8cea;\u653e\u5c04\u6cbb\u7642 Nasopharyngeal carcinoma;Quality of life;Radiotherapy", "c": "Purpose: The aim of this prospective, longitudinal study is to describe the acute changes of quality of life (QoL) and complications in patients with nasopharyngeal carcinoma from the time of diagnosis until 3 months after radiotherapy.\nMaterials and Methods: One hundred and ninety-five nasopharyngeal carcinoma patients in two institutions were invited to participate; all the patients received radiation doses of at least 70 Gy to the nasopharynx and at least 50 Gy to the neck. Health-related QoL and complications of the patients were assessed by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ C-30) and the EORTC head and neck module (QLQ H&N-35) at four different stages: before treatment; end of treatment; and 1 and 3 months after treatment.\nResults: Our data shows that patients have the best overall health status three months after completion of radiotherapy. Patients' condition was significantly better than the time before treatment and at the end of treatment (p\uff1c0.001). Differences in physical function (p=0.003), role function (p\uff1c0.001) and emotional function (p=0.028) were statistically significant at different stages. Symptoms including fatigue (p\uff1c0.001), nausea/vomiting (p\uff1c0.001), pain (p\uff1c0.001), insomnia (p\uff1c0.001), poor appetite (p\uff1c0.001), constipation (p\uff1c0.001) and diarrhea (p=0.035) had statistically significant variations at different stages. In the QLQ H&N-35 module, patients had the worst QoL and complications at the end of treatment, with both factors gradually recovering 3 months after completion of treatment.\nConclusion: As a whole, the QoL and complications show wide variations at different stages. The rapid deterioration of QoL and complications are noted at the end of treatment and improve by degrees at the first 3 months after treatment. In this study, our data may provide information to support clinical physicians in assessing the risk of side effects related to treatment, and help them in providing rehabilitation, mental consultation and supportive care after completion of treatment. The results may also help us to understand the acute changes in QoL after in patients with nasopharyngeal carcinoma after radiotherapy.", "e": "Purpose: The aim of this prospective, longitudinal study is to describe the acute changes of quality of life (QoL) and complications in patients with nasopharyngeal carcinoma from the time of diagnosis until 3 months after radiotherapy.\nMaterials and Methods: One hundred and ninety-five nasopharyngeal carcinoma patients in two institutions were invited to participate; all the patients received radiation doses of at least 70 Gy to the nasopharynx and at least 50 Gy to the neck. Health-related QoL and complications of the patients were assessed by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ C-30) and the EORTC head and neck module (QLQ H&N-35) at four different stages: before treatment; end of treatment; and 1 and 3 months after treatment.\nResults: Our data shows that patients have the best overall health status three months after completion of radiotherapy. Patients' condition was significantly better than the time before treatment and at the end of treatment (p\uff1c0.001). Differences in physical function (p=0.003), role function (p\uff1c0.001) and emotional function (p=0.028) were statistically significant at different stages. Symptoms including fatigue (p\uff1c0.001), nausea/vomiting (p\uff1c0.001), pain (p\uff1c0.001), insomnia (p\uff1c0.001), poor appetite (p\uff1c0.001), constipation (p\uff1c0.001) and diarrhea (p=0.035) had statistically significant variations at different stages. In the QLQ H&N-35 module, patients had the worst QoL and complications at the end of treatment, with both factors gradually recovering 3 months after completion of treatment.\nConclusion: As a whole, the QoL and complications show wide variations at different stages. The rapid deterioration of QoL and complications are noted at the end of treatment and improve by degrees at the first 3 months after treatment. In this study, our data may provide information to support clinical physicians in assessing the risk of side effects related to treatment, and help them in providing rehabilitation, mental consultation and supportive care after completion of treatment. The results may also help us to understand the acute changes in QoL after in patients with nasopharyngeal carcinoma after radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-269-278-a", "title": "Clinical Outcome of Postoperative Intensity-Modulated Radiotherapy for Esophageal Cancer", "keywords": "\u98df\u9053\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Intensity-modulated radiotherapy;Post-operative radiotherapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u98df\u9053\u764c\u8853\u5f8c\u7684\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u81e8\u5e8a\u7d50\u679c\u8207\u5291\u91cf\u5206\u6790\u3002\n\u65b9\u6cd5\u8207\u6750\u6599\uff1a\u4e00\u5171\u670930\u4f4dstage \u2161-\u2163\u80f8\u6bb5\u98df\u9053\u764c\u7684\u75c5\u4eba\u5728\u63a5\u53d7\u6cbb\u7652\u76ee\u7684\u624b\u8853\u4e4b\u5f8c\uff0c\u63a5\u53d7\u4e86\u8853\u5f8c\u7684\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u4eba\u65bc\u8853\u5f8c4-6\u9031\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u800c\u6240\u6709\u7684\u6cbb\u7642\u8a08\u756b\u90fd\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u65b9\u5f0f\u3002\u5176\u4e2d\u67097\u4f4d\u75c5\u4eba\u540c\u6642\u63a5\u53d7\u4e86\u8853\u5f8c\u8f14\u52a9\u5316\u5b78\u6cbb\u7642\u3002\u653e\u5c04\u6cbb\u7642\u4f7f\u75286 MV photo beam\uff0c\u4ee56-7\u500b\u5c04\u675f\u4ee5\u4e0d\u540c\u7684\u7167\u5c04\u89d2\u5ea6\u4f86\u69cb\u6210CTV\u3002CTV\u5305\u542b\u4e86\u6574\u500b\u539f\u80f8\u6bb5\u98df\u9053\u90e8\u4f4d\uff0c\u800c\u7576\u816b\u7624\u4f4d\u65bc\u4e2d\u6bb5\uff0f\u4e0a\u6bb5\u80f8\u90e8\u98df\u9053\u6642\u6703\u5305\u542b\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7d50\uff0c\u800c\u816b\u7624\u4f4d\u65bc\u4e0b1/3\u98df\u9053\u6642\u6703\u5305\u542bceliac\u6dcb\u5df4\u7d50\u3002\u57285-6\u9031\u7684\u6642\u9593\uff0cPTV\u7684\u5291\u91cf\u6703\u7d66\u4e8850-60Gy\u3002\u6211\u5011\u9032\u800c\u8a55\u4f30\u75c5\u4eba\u6cbb\u7642\u7684\u53cd\u61c9\u8207\u4e0d\u826f\u53cd\u61c9\u3002\n\u7d50\u679c\uff1a\u653e\u5c04\u6cbb\u7642\u6240\u5f15\u8d77\u7684\u6025\u6027\u4e0d\u826f\u53cd\u61c9\u76f8\u7576\u8f15\u5fae\uff0c\u800c\u80ba\u90e8\uff0c\u5fc3\u81df\u8207\u810a\u9ad3\u76e1\u91cf\u907f\u958b\u65bc\u7167\u5c04\u7bc4\u570d\uff1b\u5de6\u80ba\u8207\u53f3\u80ba\u6240\u63a5\u53d7\u7684\u5e73\u5747\u5291\u91cf\u5206\u5225\u70ba13.1Gy\u820713.3Gy\u3002\u5de6\u80ba\u8207\u53f3\u80ba\u63a5\u53d7\u8d85\u904e2000cGy\u7684\u9ad4\u7a4d(V20)\u5206\u5225\u70ba19.7%\u820719.8%\u3002\u5fc3\u81df\u6240\u63a5\u53d7\u7684\u5e73\u5747\u5291\u91cf\u70ba22.4Gy\uff0c\u4e14\u63a5\u53d7\u8d85\u904e40Gy\u7684\u9ad4\u7a4d(V40)\u53ea\u67099.8%\u3002\u810a\u9ad3\u6240\u63a5\u53d7\u7684\u6700\u5927\u5291\u91cf\u70ba36.5Gy\uff0c\u76f8\u5c0d\u4f86\u8aaa\u662f\u5341\u5206\u4f4e\u7684\u3002\u5e73\u5747\u7684Conformity index\u70ba0.8\uff0c\u6697\u793a\u6cbb\u7642\u8a08\u756b\u8207\u6cbb\u7642\u6a19\u7684\u7684\u9ad8\u5ea6\u4e00\u81f4\u6027\uff0c\u5e73\u5747\u7684homogeneity index\u70ba0.94\uff0c\u8868\u793a\u6cbb\u7642\u6a19\u7684\u5167\u7684\u5291\u91cf\u5747\u52fb\u5ea6\u9ad8\u3002\u5728\u5e73\u5747\u8ffd\u8e6414\u500b\u6708\u5f8c\uff0c\u67095\u500b\u60a3\u8005\u6709\u5c40\u90e8\u5fa9\u767c\uff0c\u5206\u5e03\u65bcanatomic site(1), supraclavicular region(1), subcarina region(3)\u3002\u5169\u5e74\u7684\u5c40\u90e8\u5fa9\u767c\u7387\u70ba22.4%\uff0c\u800c\u5169\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba45.1%\u3002\u9060\u7aef\u8f49\u79fb\u70ba\u5169\u5e74\u5167\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u3002\n\u7d50\u8ad6\uff1a\u80f8\u6bb5\u98df\u9053\u764c\u8853\u5f8c\u4ee5\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u75286-7\u500b\u5c04\u675f\u6cbb\u7642\u53ef\u4ee5\u6709\u5f88\u597d\u7684\u816b\u7624\u9806\u5f62\u5ea6\u53ca\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u4e14\u53ef\u4ee5\u907f\u958b\u6b63\u5e38\u7684\u7d44\u7e54\u3002\u5c40\u90e8\u63a7\u5236\u7d50\u679c\u5f88\u597d\uff0c\u4e14\u5169\u5e74\u5b58\u6d3b\u7387\u662f\u53ef\u4ee5\u63a5\u53d7\u7684\u3002\u7136\u800c\uff0c\u65e9\u671f\u9060\u7aef\u8f49\u79fb\u4ecd\u7136\u662f\u500b\u6cbb\u7642\u4e0a\u7684\u554f\u984c\u3002\u65b0\u7684\u6cbb\u7642\u65b9\u5f0f\u9084\u9700\u8981\u53bb\u7814\u7a76\u4ee5\u671f\u80fd\u589e\u9032\u81e8\u5e8a\u6cbb\u7642\u7d50\u679c\u3002", "e": "Purpose: To evaluate the clinical outcome and dosimetry analysis of postoperative intensity-modulated radiation therapy (IMRT) for esophageal cancer.\nMaterials and Methods: A total of 30 patients with stage \u2161-\u2163 esophageal cancer were treated with curative surgery followed by postoperative radiotherapy. All postoperative radiotherapy was planned using an intensity-modulated radiotherapy (IMRT) treatment planning system and was administered 4-6 weeks after operation. Seven out of 30 patients received post-radiotherapy adjuvant chemotherapy. Radiation from 6-7 beam angles, which was designed according to specific shape of clinical target volume (CTV), was delivered by a linear accelerator with energy of 6 MV photons. The CTV included the whole esophageal region plus the supraclavicular region for tumors at the upper and middle thoracic portion of the esophagus or celiac region for tumor situated at the lower thoracic portion. A total dose of 50 Gy to 60 Gy was aimed at the PTV over 5 to 6 weeks. Treatment response was evaluated and toxicities were assessed. The organ at risk dose profile was calculated under isocenter dose of 50 Gy.\nResults: Radiotherapy related acute toxicities were mild. Organs at risk such as lungs, heart, and spinal cord were spared from the prescribed doses. The mean doses for right and left lungs were 13.1 Gy and 13.3 Gy, respectively. The lung volume received doses of 2000 cGy or more (V20) for right and left lung was 19.7% and 19.8%, respectively. The mean dose to heart was 22.4 Gy and only 9.8% of heart tissue received a dosage over 40 Gy (V40). For spinal cord, the maximum dose was 36.5 Gy which is relatively low. An average conformity index (CI) of 0.8 implies high treatment conformity to the target. An average homogeneity index (HI) of 0.94 indicated good dose homogeneity within the target. After a mean follow-up of 14 months, 5 local recurrences were found over anastomotic site in 1 patient, supraclavicular region in 1 patient and subcarina region in 3 patients, the local recurrence rate in 2-year period is 22.4%. The 2-year overall survival rate was 45.1%. Distant metastasis is the most important reason for those who died within 2 year period of follow-up.\nConclusion: Postoperative IMRT using 6 to 7 beams has good coverage of the target and high dose homogeneity while decreasing doses to normal tissue. Local control was good with an acceptable 2-year survival rate. However, early distant metastasis remains to be a problem. New approaches are needed to improve the clinical outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-279-287-a", "title": "Adjuvant Chemoradiation for Surgical Resected Gastric Cancer Patients: CGH Experience", "keywords": "\u80c3\u764c;\u8853\u5f8c\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u6025\u6027\u526f\u4f5c\u7528 Gastric cancer;Adjuvant chemoradiation;Acute side effects", "c": "\u76ee\u7684\uff1a\u570b\u5916Intergroup 0116\u96a8\u6a5f\u53d6\u6a23\u7684\u5206\u6790\u5831\u544a\u6307\u51fa\uff0c\u80c3\u764c\u75c5\u60a3\u8853\u5f8c\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u548c\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u589e\u9032\u75c5\u60a3\u4e2d\u4f4d\u5b58\u6d3b\u7387\uff0c\u4e26\u964d\u4f4e\u5c40\u90e8\u5fa9\u767c\u3002\u6211\u5011\u91ab\u9662\u63a1\u7528\u96f7\u540c\u7684\u5316\u7642\u653e\u5c04\u6cbb\u7642\u65b9\u6cd5\u6cbb\u7642\u4e8635\u4f4d\u75c5\u60a3\u3002\u9032\u884c\u4e86\u8ffd\u8e64\u5206\u6790\uff0c\u7d50\u679c\u8207\u5404\u4f4d\u5206\u4eab\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1999\u5e748\u6708\u81f32006\u5e748\u6708\uff0c35\u4f4d\u80c3\u764c\u75c5\u60a3\u5728\u8853\u5f8c\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u548c\u653e\u5c04\u6cbb\u7642\u3002\u65b9\u6cd5\u662fFluorouracil 425mg/\u5e73\u65b9\u516c\u5c3a\u52a0\u4e0aLeucovorin 20mg/\u5e73\u65b9\u516c\u5c3a\u7d935\u5929\u7684\u6ce8\u5c04\uff0c\u4e00\u500b\u6708\u4e4b\u5f8c\uff0c\u63a5\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u548c\u653e\u5c04\u6cbb\u7642(CRT)\uff0c\u653e\u5c04\u6cbb\u7642\u5728\u4e94\u9031\u5167\u7d66\u4e884500cGy\uff0c\u5316\u5b78\u6cbb\u7642\u4ee5\u76f8\u540c\u7684\u85e5\u7269\u5728\u653e\u5c04\u7642\u7a0b\u671f\u9593\u524d4\u5929\u53ca\u6700\u5f8c3\u5929\u7d66\u4e88\u3002\u800c\u4e00\u500b\u6708\u4e4b\u5f8c\uff0c\u518d\u63a5\u5169\u6b21\u6216\u591a\u6b21\u7684\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u5f9e1.6\u500b\u6708\u523071.9\u500b\u6708\uff0c\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\u70ba13.2\u500b\u6708\u3002\u81f32007\u5e745\u6708\u5e95\uff0c57%\u7684\u75c5\u60a3\u4ecd\u7136\u5b58\u6d3b\uff0c\u4e00\u5e74\u53ca\u4e09\u5e74\u7684\u5b58\u6d3b\u7387\u70ba71%\u53ca56%\u3002\u6574\u500b\u6cbb\u7642\u904e\u7a0b\u76f8\u7576\u5b89\u5168\uff0c\u56b4\u91cd\u7684\u526f\u4f5c\u7528\uff08\u7b2c\u4e09\u7d1a\uff09\u53ea\u6709\u5c11\u6578\u3002\u5c40\u90e8\u5fa9\u767c\u7387\u53ea\u67095.6%\uff0c\u800c\u9060\u8655\u5fa9\u767c\u70ba25.7%\u3002\u6bd4\u8f03\u4e0d\u540c\u7d44\u7684\u751f\u5b58\u7387\u767c\u73fe\uff0c\u5728CRT\u4e4b\u5f8c\u63a5\u53d7\u542b\u5169\u6b21\u4ee5\u4e0a\u5316\u7642\u7684\u75c5\u60a3\uff0c\u5176\u751f\u5b58\u7387\u8f03\u5c11\u65bc\u5169\u6b21\u7684\u9ad8\u3002\u4e3b\u8981\u70baSignet ring cell\u7684\u7d44\u7e54\u578b\u614b\u751f\u5b58\u7387\u6bd4\u8d77\u5176\u4ed6\u7d44\u7e54\u578b\u614b\u5dee\uff0c\u7d71\u8a08\u5b78\u4e0a\u662f\u6709\u610f\u7fa9\u7684\u3002\n\u7d50\u8ad6\uff1a\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u548c\u653e\u5c04\u6cbb\u7642\u5c0d\u8853\u5f8c\u7684\u80c3\u764c\u75c5\u60a3\u662f\u5b89\u5168\u53ca\u6709\u5e6b\u52a9\u7684\u3002", "e": "Purpose: The benefits of adjuvant chemoradiation (CRT) after surgical resection for gastric cancer patients has been firmly established since randomized study published by Intergroup 0116 reporting a definite improvement in median survival. We would like to share our experience in a retrospective study of 35 patients in our hospital using a similar regimen.\nMaterials and Methods: From August 1999 to August 2006, 35 patients received postoperative CRT after curative surgical resection. The adjuvant CRT consisted of 425 mg/m^2 of fluorouracil plus 20 mg/m^2 leucovorin for 5 days, and then one month later followed by 4500 cGy of radiotherapy for 5 weeks with fluorouracil and leucovorin on the first 4 and last 3 days of radiotherapy. Two or more 5-day cycles of fluorouracil and leucovorin were given one month after completion of CRT.\nResults: During a median follow up of period of 13.2 months, 57% of patients were alive with free of disease. One year and 3 year overall survival were 71% and 56% respectively. The whole treatment course was well tolerated with a few incidences of severe (grade \u2162) acute side effects and local-regional relapses occurred in 5.7% of patients and 25.7% had distant relapses. Compared survivals between different subgroups, we found patients with primary signet ring cell histology bear a significantly poorer survival than other histological types. Patients who received 2 or more cycles of chemotherapy after CRT did better in overall survival than patients who did less.\nConclusion: Our study found chemoradiation safe and beneficial for gastric cancer patients after curative surgical resection."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-289-300-a", "title": "\u653e\u5c04\u816b\u7624\u764c\u60a3\u63a5\u53d7\u897f\u91ab\u3001\u4e2d\u91ab\u8207\u53e6\u985e\u7642\u6cd5\u7684\u76f8\u95dc\u6027\u8abf\u67e5\u5206\u6790", "keywords": "\u897f\u91ab\u7642\u6cd5;\u4e2d\u91ab\u7642\u6cd5;\u53e6\u985e\u7642\u6cd5 Western medical;Chinese medical;Alternative medical treatment", "c": "Purpose: This study included irradiated cancer patients to explore multivariate correlation factors and current status among Western (WM) Chinese (CM) and Alternative (AM) medical treatment modalities so that one can understand the magnitude of predictors for receiving alternative treatment. From cultural view points, medical staff should try to investigate motivation of herb and alternative modalities of treatment, enhancing communication & instruction to patients to accept most updated medical knowledge which may yield a synergistic effect to traditional orthodoxic medicine.\nMaterials and Methods: Between August 1, 2005 and September 30, 2005, 338 cancer patients irradiated at the department of radiation oncology. Chang Gung Memorial Hospital were retrospectively reviewed with respect to patients' data collected from self-structured questionnaire assisted by nursing staff of the dept. All cases came from different area islandwide and should have completed a full course of RT with a minimum follow-up period of three years.\nResults: Data revealed that the first choice of cancer treatment was WM followed by at least 1 to 2 kind of CM or AM which accounted for 156 (46.1%) patients. Of these, 108 (32%) patients took mainly herb drugs as a major part of treatment by CM. The duration of most alternative treatment was approximately 3 months at an expense of around NT$100000.00. Two hundred and twenty nine (67.8%) cases considered CM or AM having potential for cure of cancer and the information regarding to these type of treatment was mainly from patients' family 194 (57.4%) or relatives 175 (51.8%).\nConclusion: Different age groups yield no significant correlation to the selection of either CM or WM (p\uff1e0.05); Although different educational backgrounds had no specific impact in the choice of CM (p\uff1e0.05) yet effect significantly in the selection of various types of AM (p\uff1c0.011). Patients with educational background equalled to or above college level may predominantly choose a physiologic type of AM (p\uff1c0.01). One hundred and eighty two (53.8%) cases might refer other cancer patients to receive CM. This correlated significantly (p\uff1c0.0005) to the concept of 273 (80.8%) cases that CM have a high potential to completely or partially cure the cancer patients. In addition, 89 (26.4%) cases showed intention to be treated at Mainland China which correlated significantly (p\uff1c0.0003) to the belief that the therapeutic effect of CM is better in Mainland China than in Taiwan.", "e": "Purpose: This study included irradiated cancer patients to explore multivariate correlation factors and current status among Western (WM) Chinese (CM) and Alternative (AM) medical treatment modalities so that one can understand the magnitude of predictors for receiving alternative treatment. From cultural view points, medical staff should try to investigate motivation of herb and alternative modalities of treatment, enhancing communication & instruction to patients to accept most updated medical knowledge which may yield a synergistic effect to traditional orthodoxic medicine.\nMaterials and Methods: Between August 1, 2005 and September 30, 2005, 338 cancer patients irradiated at the department of radiation oncology. Chang Gung Memorial Hospital were retrospectively reviewed with respect to patients' data collected from self-structured questionnaire assisted by nursing staff of the dept. All cases came from different area islandwide and should have completed a full course of RT with a minimum follow-up period of three years.\nResults: Data revealed that the first choice of cancer treatment was WM followed by at least 1 to 2 kind of CM or AM which accounted for 156 (46.1%) patients. Of these, 108 (32%) patients took mainly herb drugs as a major part of treatment by CM. The duration of most alternative treatment was approximately 3 months at an expense of around NT$100000.00. Two hundred and twenty nine (67.8%) cases considered CM or AM having potential for cure of cancer and the information regarding to these type of treatment was mainly from patients' family 194 (57.4%) or relatives 175 (51.8%).\nConclusion: Different age groups yield no significant correlation to the selection of either CM or WM (p\uff1e0.05); Although different educational backgrounds had no specific impact in the choice of CM (p\uff1e0.05) yet effect significantly in the selection of various types of AM (p\uff1c0.011). Patients with educational background equalled to or above college level may predominantly choose a physiologic type of AM (p\uff1c0.01). One hundred and eighty two (53.8%) cases might refer other cancer patients to receive CM. This correlated significantly (p\uff1c0.0005) to the concept of 273 (80.8%) cases that CM have a high potential to completely or partially cure the cancer patients. In addition, 89 (26.4%) cases showed intention to be treated at Mainland China which correlated significantly (p\uff1c0.0003) to the belief that the therapeutic effect of CM is better in Mainland China than in Taiwan."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-301-310-a", "title": "Evaluation of Cyberknife Treatment Planning for Prostate Cancer using the Conformal Index and the Tumor Control Probability", "keywords": "\u816b\u7624\u5305\u8986\u9806\u578b\u5ea6;\u816b\u7624\u63a7\u5236\u6a5f\u7387\u6a21\u5f0f;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u624b\u8853;\u96fb\u8166\u5200 Conformity index;Tumor control probability;Stereotactic radiosurgery;CyberKnife", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u5728\u65bc\u5229\u7528\u5291\u91cf\u5305\u8986\u9806\u578b\u5ea6\u6578\u5b78\u6a21\u578b\uff0c\u5206\u6790\u96fb\u8166\u5200\u653e\u5c04\u6cbb\u7642\u6280\u8853\u8f3b\u7167\u5340\u57df\u5291\u91cf\u8207\u5468\u570d\u5668\u5b98\u9ad4\u7a4d\u5f7c\u6b64\u9593\u9806\u578b\u5ea6\u4e4b\u95dc\u4fc2\u3002\u914d\u5408\u816b\u7624\u63a7\u5236\u6a5f\u7387\u516c\u5f0f\u904b\u7b97\u5206\u6790\u651d\u8b77\u817a\u764c\u7d93\u653e\u5c04\u6cbb\u7642\u5f8c\u816b\u7624\u63a7\u5236\u6a5f\u7387\uff0c\u4ee5\u671f\u66f4\u80fd\u9069\u7528\u65bc\u96fb\u8166\u5200\u6cbb\u7642\u8a08\u756b\u7684\u5206\u6790\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u56de\u6eaf\u6027\u6536\u96c6\u516d\u540d\u651d\u8b77\u817a\u816b\u7624\u60a3\u8005\u63a5\u53d7\u4f4e\u5206\u6b21\u96fb\u8166\u5200\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u3002\u7d66\u4e88\u5291\u91cf\u5206\u5225\u70ba37.5Gy\u5206\u4e94\u6b21\u6cbb\u7642\uff0c42Gy\u5206\u4e94\u6b21\u6cbb\u7642\uff0c\u548c32Gy\u5206\u56db\u6b21\u6cbb\u7642\u3002\u8a08\u7b97\u5291\u91cf\u5305\u8986\u9806\u578b\u5ea6\u53ca\u816b\u7624\u63a7\u5236\u6a5f\u7387\uff0c\u4e26\u5206\u6790\u8a08\u7b97\u7d50\u679c\u4ee5\u4f5c\u70ba\u8a55\u4f30\u96fb\u8166\u5200\u8a08\u756b\u7cfb\u7d71\u7684\u53c3\u8003\u3002\n\u7d50\u679c\uff1a\u96fb\u8166\u5200\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u672c\u8eab\u6240\u63d0\u4f9b\u7684\u5291\u91cf\u5305\u8986\u9806\u578b\u5ea6\u8a08\u7b97\u503c\u5728\u816b\u7624\u63a7\u5236\u6a5f\u7387\u905498.3%\u4ee5\u4e0a\u6642\u5747\u57281.483\u4ee5\u4e0b\u3002\u800c\u7d93\u904e\u4ee5\u9031\u906d\u91cd\u8981\u5668\u5b98\u52a0\u5165\u8003\u91cf\u7684\u6a21\u5f0f\u8a08\u7b97\u5f8c\uff0c\u589e\u52a0\u5291\u91cf\u5305\u8986\u9806\u578b\u5ea6\u7684\u5dee\u7570\u6027\u63d0\u4f9b\u4f5c\u70ba\u6cbb\u7642\u8a08\u756b\u7684\u8a55\u4f30\u3002\n\u7d50\u8ad6\uff1a\u653e\u5c04\u7dda\u624b\u8853\u6cbb\u7642\u8a08\u756b\u7d66\u4e88\u8f03\u9ad8\u7684\u751f\u7269\u7b49\u6548\u5291\u91cf\uff0c\u6545\u9069\u7528\u65bc\u96fb\u8166\u5200\u5291\u91cf\u5305\u8986\u9806\u578b\u5ea6\u6a21\u5f0f\uff0c\u5fc5\u9808\u80fd\u517c\u9867\u5206\u6790\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5340\u6700\u4f73\u7684\u816b\u7624\u9ad4\u7a4d\u5305\u8986\u7279\u6027\uff0c\u548c\u64f4\u6563\u5230\u5468\u570d\u7684\u6b63\u5e38\u7d44\u7e54\u9ad8\u5291\u91cf\u5206\u4f48\u3002\u672c\u6587\u4e2d\u6240\u904b\u7b97\u7684\u6a21\u5f0f\u53ef\u4ee5\u7528\u4f86\u8a55\u4f30\u53ca\u6bd4\u8f03\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u3002", "e": "Purpose: This study was to evaluate the feasibility of dose conformity and tumor control probability calculated for CyberKnife(superscript \u00ae) hypofractionated planning for prostate cancer.\nMaterials and Methods: Six patients with early prostate cancer were included in this retrospective study. They received stereotactic hypofractionation radiotherapy by CyberKnife(superscript \u00ae). The dose prescriptions were 37.5 Gy in 5 fractions, 42 Gy in 5 fractions, or 32 Gy in 4 fractions. Dose conformity was calculated with three parameters: the conformity index (CI), the new conformity index (nCI) and the modified conformal index (mCOIN). A statistical analysis of the tumor control probability (TCP) was also calculated.\nResults: The CI and nCI of the CyberKnife(superscript \u00ae) treatment planning system are all under 1.483. All the calculated TCP values were greater than 98.3%. We added the factors pertaining to the critical organ and obtained the mCOINs. The mCOIN values were listed to compare the quality of treatment plans.\nConclusion: The conformity index value can be used to evaluate the quality of radiosurgery planning. The mCOIN values are also feasible to compare the plans."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-311-322-a", "title": "\u578b\u865fFWT-70-40(M)\u5291\u91cf\u8a08\u61c9\u7528\u65bcBNCT\u8f3b\u5c04\u5834\u7684\u52a0\u99ac\u5291\u91cf\u5ea6\u91cf", "keywords": "\u8f3b\u5c04\u8272\u67d3\u5291\u91cf\u8a08;\u7d9c\u6027\u5291\u91cf\u53cd\u61c9\u4f4e\u9650\u503c;\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642;\u4e2d\u5b50\u52a0\u99ac\u6df7\u5408\u8f3b\u5c04\u5834 Radia-Chromic dye dosimeter RDD;Threshold of linear response;Boron Neutron Capture Therapy BNCT;Neutron and gamma mixed field", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4fc2\u63a7\u8a0e\u578b\u865fFWT-70-40(M)\u5291\u91cf\u8a08\uff0c\u61c9\u7528\u65bc\u4e2d\u5b50\u3001\u52a0\u99ac(n\u3001Y)\u6df7\u5408\u8f3b\u5c04\u5834\u4e2d\u52a0\u99ac\u5291\u91cf\u5ea6\u91cf\u7684\u53ef\u884c\u6027\u53ca\u5176\u5f71\u97ff\u56e0\u7d20\uff0c\u4ee5\u63d0\u4f9b\u4f5c\u70ba\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642(BNCT)\u764c\u75c7\u7684\u53e6\u4e00\u5291\u91cf\u5ea6\u91cf\u5291\u91cf\u8a08\u7684\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6240\u63a2\u8a0e\u5291\u91cf\u8a08\u70baFWT-70\u7cfb\u5217\u7684\u578b\u865fFWT-70-40(M)\u5291\u91cf\u8a08\uff1b\u4e2d\u5b50\u3001\u52a0\u99ac\u6df7\u5408\u8f3b\u5c04\u5834\u70ba\u6e05\u83ef\u5927\u5b78\u539f\u5b50\u79d1\u5b78\u6280\u8853\u767c\u5c55\u4e2d\u5fc3\u984d\u5b9a\u529f\u73872MW\u6c34\u6c60\u5f0f\u6838\u5b50\u53cd\u61c9\u5668(THOR)\u7684BNCT\u7167\u5c04\u6cbb\u7642\u5ba4\u6240\u63d0\u4f9b\uff0c\u52a0\u99ac\u5291\u91cf\u654f\u5ea6\u6821\u6b63\u8f3b\u5c04\u5834\u5247\u70ba\u6e05\u83ef\u5927\u5b78\u539f\u5b50\u79d1\u5b78\u6280\u8853\u767c\u5c55\u4e2d\u5fc3\u6d3b\u5ea61.08 E 15Bq\uff082.919\u842c\u5c45\u91cc\uff09\u9ad8\u5291\u91cf\uff08\u7387\uff09\u923760\u52a0\u99ac\u7167\u5c04\u5be6\u9a57\u5ba4\u3002\uff0c\u5be6\u9a57\u904e\u7a0b\u4fc2\u5229\u75280.69\u7acb\u65b9\u516c\u5206\u6e38\u96e2\u8154\u6a19\u5b9a\u923760\u52a0\u99ac\u7167\u5c04\u5834\u5404\u7167\u5c04\u9ede\u7684\u5291\u91cf\u7387\uff0c\u5c07\u578b\u865fFWT-70-40(M)\u5291\u91cf\u8a08\uff0c\u5206\u5225\u7f6e\u65bc\u5404\u7167\u5c04\u9ede\u7167\u5c04\u4e0d\u540c\u7684\u5291\u91cf\uff0c\u4ee5\u7372\u5f97\u5176\u5c0d\u52a0\u99ac\u7684\u8f3b\u5c04\u654f\u5ea6\u8207\u5291\u91cf\u7dda\u6027\u53cd\u61c9\u7bc4\u570d\uff1b\u53e6\u5c07\u5176\u7f6e\u65bcTHOR\u7210\u5fc3\u63a5\u53d7\u9ad8\u71b1\u4e2d\u5b50\u901a\u91cf\u7167\u5c04\uff0c\u4ee5\u89c0\u5bdf\u5176\u5c0d\u4e2d\u5b50\u901a\u91cf\uff08\u5291\u91cf\uff09\u7167\u5c04\u7684\u8010\u53d7\u5ea6\u3002\n\u7d50\u679c\uff1a\u5be6\u9a57\u7d50\u679c\u986f\u793a\u578b\u865fFWT-70-40(M)\u5291\u91cf\u8a08(1)\u5c0d\u5e73\u5747\u80fd\u91cf1.25MeV\u52a0\u99ac\u7684\u6700\u4f4e\u5291\u91cf\u9650\u503c\u70ba2Gy\uff1a\u6700\u9ad8\u5291\u91cf\u9650\u503c\u70ba7k Gy\u3002(2)\u88ab\u4e2d\u5b50\u6d3b\u5316\u7684\u7522\u7269\u70ba\u920924(24Na)\uff0c\u6b64\u920924\u6d3b\u5316\u7522\u7269\u5728\u76f8\u5c0d\u65bc\u7e3d\u71b1\u4e2d\u5b50\u901a\u91cf3.6E12 nth/\u5e73\u65b9\u516c\u5206\u7684\u4e2d\u5b50\u901a\u91cf\u7167\u5c04\u4e0b\uff0c\u65bc\u5e73\u5747\u58fd\u547d\u6642\u9593\u7522\u751f\u7684\u7d2f\u7a4d\u81ea\u6fc0\u5291\u91cf\u50c51.12\u00b10.12mGy\u3002\n\u7d50\u8ad6\uff1a\u578b\u865fFWT-70-4O(M\uff09\u5291\u91cf\u8a08\u65bcBNCT\u9ad8\u4e2d\u5b50\u901a\u91cf\uff08\u7387\uff09\u8207\u5291\u91cf\uff08\u7387\uff09\u7684\u4e2d\u5b50\u3001\u52a0\u99ac\u6df7\u5408\u8f3b\u5c04\u5834\u6240\u7522\u751f\u7684\u81ea\u6fc0\u5291\u91cf\uff0c\u5c0d\u52a0\u99ac\u5291\u91cf\u5ea6\u91cf\u5e72\u64fe\u53ef\u5ffd\u7565\uff0c\u4e14\u5c0d\u52a0\u99ac\u7684\u6700\u4f4e\u5291\u91cf\u9650\u503c\u70ba2Gy\uff0c\u56e0\u6b64\u9664\u53ef\u61c9\u7528\u65bc\u923760\u52a0\u99ac\u9ad8\u5291\u91cf\uff08\u7387\uff09\u8f3b\u5c04\u5834\u8207\u653e\u5c04\u6cbb\u7642\u7528\u9ad8\u80fd\u91cf\u3001\u9ad8\u5291\u91cf\uff08\u7387\uff09\u96fb\u5b50\u5c04\u675f\u7684\u5291\u91cf\u5ea6\u91cf\u5916\uff0c\u4ea6\u53ef\u61c9\u7528\u65bcBNCT\u7167\u5c04\u6cbb\u7642\u7528\u9ad8\u80fd\u91cf\u3001\u9ad8\u5291\u91cf\uff08\u7387\uff09\u7684\u4e2d\u5b50\u3001\u52a0\u99ac\u6df7\u5408\u8f3b\u5c04\u5834\u7684\u52a0\u99ac\u5291\u91cf\u5ea6\u91cf\u3002", "e": "Purpose: The feasibility of FWT-70-40(M) dosimeter was studied for gamma dose measurement in a neutron and gamma mixed field. Furthermore, it was adopted as another dosimeter to determine the gamma dose in an epithermal neutron beam for Boron Neutron Capture Therapy (BNCT).\nMaterial and Methods: The dosimeter used in this article was FWT-70 series of type FWT-70-40 (M). Using the Co-60 source of 29190 curies, which located in the Nuclear Science and Technology Development Center of National Tsing Hua University, performed calibration of the gamma dose sensitivity. The radiation sensitivity and the range of the linear response were obtained by irradiating the dosimeter with various dose rates and different total dose. Besides, this dosimeter was also irradiated with high neutron flux in the reactor core of the Tsing Hua Open pool Reactor (THOR) to investigate the neutron influence and activation. And then it was adopted as another dosimeter to measure the gamma dose in the BNCT facility at THOR.\nResults: Experimental data show that: (1) the threshold of linear response is 2 Gy, while the up limitation is 7 kGy for average gamma energy of 1.25 MeV; (2) the major product of the neutron activation is Na-24. The accumulated self-exciting dose for Na-24 is only 1.12 mGy during its average life-time for irradiation of total thermal neutron fluence of 3.6E12 nth/cm^2.\nConclusions: Because of the self-exciting dose reduced from neutron activation can be neglected for gamma dose measurement in neutron and gamma mixed field, and the threshold of linear response is 2 Gy, the FWT-70-40 (M) dosimeter not only can be used for high dose rate Co-60 irradiation field and the high energy electron beam for medical purpose, but also can be used for gamma dose measurement in an epithermal neutron beam for boron neutron capture therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-323-330-a", "title": "Moderately Differentiated Neuroendocrine Carcinoma of the Larynx: A Case Report and Review of the Literatures", "keywords": "\u795e\u7d93\u5167\u5206\u6ccc\u764c;\u975e\u5178\u578b\u985e\u764c;\u5589\u764c;\u653e\u5c04\u7dda\u6cbb\u7642 Atypical carcinoid;Moderately differentiated neuroendocrine carcinomas;Larynx tumors;Radiation therapy", "c": "\u5589\u90e8\u7684\u4e2d\u5ea6\u5206\u5316\u795e\u7d93\u5167\u5206\u6ccc\u764c\uff08\u904e\u53bb\u66fe\u88ab\u7a31\u4e4b\u70ba\u975e\u5178\u578b\u985e\u764c\uff09\u662f\u4e00\u7f55\u898b\u7684\u75be\u75c5\uff0c\u81e8\u5e8a\u591a\u4ee5\u8072\u97f3\u6c99\u555e\u8207\u541e\u56a5\u56f0\u96e3\u70ba\u8868\u73fe\u3002\u6b64\u75be\u75c5\u5e38\u6709\u6dcb\u5df4\u53ca\u8840\u7ba1\u6d78\u6f64\uff0c\u4e00\u65e6\u64f4\u6563\u81f3\u9838\u90e8\u6dcb\u5df4\u7bc0\u5f80\u5f80\u8996\u70ba\u4e0d\u826f\u9810\u5f8c\uff0c\u96a8\u4e4b\u5bb9\u6613\u6709\u9060\u7aef\u8f49\u79fb\u800c\u5177\u9ad8\u81f4\u6b7b\u7387\u3002\u624b\u8853\u5207\u9664\u70ba\u591a\u6578\u4eba\u63a1\u53d6\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u81f3\u65bc\u5176\u4ed6\u6cbb\u7642\u5247\u56e0\u75c5\u6b77\u6578\u5c11\u800c\u7121\u6cd5\u6709\u660e\u78ba\u7684\u5171\u8b58\u3002\u4f46\u591a\u6578\u6587\u737b\u8a8d\u70ba\u6b64\u795e\u7d93\u5167\u5206\u6ccc\u764c\u70ba\u4e00\u4fb5\u72af\u6027\u5f37\u7684\u816b\u7624\uff0c\u7a4d\u6975\u7684\u6cbb\u7642\u6c7a\u7b56\uff0c\u4f8b\u5982\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u53ef\u80fd\u53ef\u4ee5\u589e\u52a0\u75c5\u4eba\u5b58\u6d3b\u3002\u7a4d\u6975\u7684\u6cbb\u7642\u6c7a\u7b56\u6709\u8cf4\u65bc\u6b63\u78ba\u8a3a\u65b7\u6b64\u75c5\uff0c\u7136\u800c\u6b64\u75c5\u5728\u75c5\u7406\u5207\u7247\u4e0b\u4e0d\u5bb9\u6613\u8207\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u3001\u526f\u795e\u7d93\u7bc0\u7624\u505a\u5340\u5206\uff0c\u5fc5\u9808\u85c9\u7531\u7279\u6b8a\u67d3\u8272\u5354\u52a9\u78ba\u8a3a\u3002\u6587\u737b\u56de\u9867\u767c\u73fe\uff1a\u904e\u53bb\u7531\u65bc\u5589\u90e8\u795e\u7d93\u5167\u5206\u6ccc\u764c\u5206\u985e\u547d\u540d\u6cd5\u7d0a\u4e82\uff0c\u9020\u6210\u65e9\u671f\u6587\u737b\u6240\u6307\u7684\u300c\u975e\u5178\u578b\u985e\u764c\u300d\u8207\u73fe\u5728\u8a8d\u70ba\u4e4b\u300c\u4e2d\u5ea6\u5206\u5316\u795e\u7d93\u5206\u6ccc\u764c\u300d\u53ef\u80fd\u4e0d\u662f\u540c\u7a2e\u75be\u75c5\uff0c\u6b64\u9ede\u5728\u6587\u737b\u56de\u9867\u8207\u5206\u6790\u5fc5\u9808\u76f8\u7576\u5c0f\u5fc3\u3002\n\u672c\u6587\u5c07\u5831\u544a\u4e00\u4f4d59\u6b72\u7537\u6027\uff0c\u5728\u78ba\u8a3a\u70ba\u5589\u90e8\u4e2d\u5ea6\u5206\u5316\u795e\u7d93\u5167\u5206\u6ccc\u764c\u5f8c\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u8207\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7d93\u904e19\u500b\u6708\u8ffd\u8e64\u4e26\u7121\u4efb\u4f55\u5fa9\u767c\u8b49\u64da\u3002\u8332\u5f8c\u6587\u737b\u56de\u9867\uff0c\u5c07\u63a2\u8a0e\u6b64\u75c5\u4e4b\u5206\u985e\u547d\u540d\u3001\u81e8\u5e8a\u8868\u73fe\u3001\u75c5\u7406\u7279\u5fb5\u3001\u6cbb\u7642\u9810\u5f8c\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u6240\u626e\u6f14\u7684\u89d2\u8272\u3002", "e": "The moderately differentiated neuroendocrine carcinomas (MDNC) are rare tumors in the larynx. Most patients present with hoarseness and dysphagia. Commonly, these tumors have vascular or lymphatic invasion. High mitotic rate, necrosis and nuclear pleomorphism are also frequent. Once patients develop regional or distal metastasis, they usually had high mortality with poor prognosis. Unfortunately, these tumors have high tendency of regional or distal metastases, so MDNC is considered as an aggressive tumor in the larynx. Early diagnosis determines the treatment plan and outcome. Surgical removal is generally advised as the treatment of choice, and radiation therapy may have a benefit in survival.\nWe present a 59-year-old non-smoking man with MDNC of the left supraglottic larynx, cT1N0M0, stage \u2160. The patient received surgical excision (pT1N0M0, stage \u2160) and post-operative radiation therapy (6300 cGy/35 frs). There was no evidence of recurrence for 19 months. Neither dysphasia nor hoarseness was complained. Currently, he had regular follow-up in the out-patient department."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-331-336-a", "title": "A Case of Abdominal Tumor with Unusual Presentation", "keywords": "\u5f8c\u8179\u819c\u816b\u7624;\u6cbb\u7642;\u5408\u4f75\u75c7 Retroperitoneal tumor;Treatment;Complication", "c": "\u8179\u90e8\u816b\u7624\u7684\u81e8\u5e8a\u8868\u5fb5\u5e38\u96a8\u816b\u7624\u6240\u5728\u4f4d\u7f6e\u800c\u7570\uff0c\u5982\u679c\u8868\u5fb5\u70ba\u591a\u6a23\u6027\uff0c\u5e38\u5c0e\u81f3\u9451\u5225\u56f0\u96e3\uff0c\u751a\u81f3\u65bc\u504f\u96e2\u6cbb\u7642\u65b9\u5411\u3002\n\u672c\u75c5\u4f8b\u81e8\u5e8a\u4e0a\u8868\u73fe\u8170\u75e0\u3001\u5de6\u4e0b\u80a2\u6c34\u816b\u9ebb\u6728\u3001\u8179\u8139\u3002\u75c5\u4eba\u5148\u5f8c\u81f3\u5a66\u79d1\u53ca\u9aa8\u79d1\u6c42\u8a3a\uff0c\u4e14\u5206\u5225\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u3002\u56e0\u816b\u7624\u5de8\u5927\u53ea\u80fd\u90e8\u5206\u5207\u9664\u6216\u5207\u7247\uff0c\u6700\u5f8c\u8a3a\u65b7\u70ba\u7578\u80ce\u7624\u8207\u5f8c\u8179\u819c\u6dcb\u5df4\u7624\u3002\u5728\u4f4f\u9662\u8a3a\u65b7\u6cbb\u7642\u904e\u7a0b\u66f2\u6298\u3002\u6cbb\u7642\u63a1\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff0c\u5316\u5b78\u6cbb\u7642\u4f7f\u7528CHOP\u7d44\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7d66\u4e8e\u816b\u7624\u5291\u91cf\u70ba3060cGy\u3002\u816b\u7624\u9664\u5feb\u901f\u6eb6\u89e3\u3001\u81bf\u760d\u5f62\u6210\u5916\u53c8\u767c\u5c55\u763b\u7ba1\u53ca\u7d44\u7e54\u58de\u6b7b\u6027\u808c\u819c\u708e\u3002\u6587\u737b\u4e0a\u6240\u898b\u4e0d\u591a\uff0c\u63d0\u51fa\u4f86\u5831\u544a\u3002", "e": "Tumors originated in retroperitoneum are rare and usually the primary treatment is surgery. We report a case of double tumors, retroperitoneal lymphoma and ovarian teratoma with unusual presentation.\nThe patient presented with low back soreness, lower leg edema and numbness, abdominal fullness. She was treated by the gynecologist, orthopedics and oncologist. She was treated with CHOP regimen chemotherapy combined with radiation 3060 cGy. Rapid tumor lysis was complicated with abscess formation, fistula and necrotizing fasciitis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200812-15-4-337-342-a", "title": "Adenoid Cystic Carcinoma of the Trachea Treated with Post-operative Chemoradiotherapy and Metronomic Chemotherapy: A Case Report", "keywords": "\u817a\u6a23\u56ca\u72c0\u764c;\u7bc0\u62cd\u5f0f\u5316\u5b78\u6cbb\u7642;\u6c23\u7ba1\u764c Adenoid cystic carcinoma;Metronomic chemotherapy;Trachea cancer", "c": "\u6c23\u7ba1\u817a\u6a23\u56ca\u72c0\u764c\u70ba\u4e00\u7a2e\u7f55\u898b\u75be\u75c5\uff0c\u5176\u6cbb\u7642\u662f\u4ee5\u624b\u8853\u70ba\u4e3b\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d\u6c23\u7ba1\u817a\u6a23\u56ca\u72c0\u764c\u768440\u6b72\u7537\u6027\u75c5\u60a3\uff0c\u7d93\u624b\u8853\u3001\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff08\u7e3d\u5291\u91cf\u70ba64.8Gy\uff0c\u4ee536\u5206\u6b21\u7d66\u4e88\uff0c\u540c\u6642\u7d66\u4e88\u6bcf\u9031Cisplatin 30mg/\u5e73\u65b9\u516c\u5c3a\uff09\u53ca\u8f14\u52a9\u5316\u5b78\u6cbb\u7642\uff08\u6bcf\u6708\u7d66\u4e885-Fluorouracil\u53caCisplatin\uff09\u5f8c\uff0c\u77ed\u671f\u5167\u537b\u767c\u73fe\u6709\u5c40\u90e8\u5fa9\u767c\u53ca\u80ba\u90e8\u8f49\u79fb\u7684\u60c5\u5f62\u3002\u7d93\u80ba\u8f49\u79fb\u5207\u9664\u5f8c\uff0c\u958b\u59cb\u4e86\u4ee5Etoposide\u53cacisplatin\u70ba\u57fa\u790e\u7684\u6436\u6551\u6027\u5316\u5b78\u7642\u6cd5\u3002\u4f46\u662f\u7d93\u904e3\u6b21\u6436\u6551\u6027\u5316\u5b78\u7642\u6cd5\u5f8c\uff0c\u75be\u75c5\u4f9d\u820a\u6301\u7e8c\u9032\u5c55\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u7a0d\u5f8c\u537b\u767c\u73fe\u816b\u7624\u5c0d\u4ee5\u53e3\u670dEtoposide\u53caCisplatin\u70ba\u57fa\u790e\u7684\u7bc0\u62cd\u5f0f\u5316\u5b78\u6cbb\u7642\u6709\u826f\u597d\u7684\u53cd\u61c9\uff0c\u4e14\u8ca0\u4f5c\u7528\u4ea6\u4e0d\u5927\u3002\u5728\u9019\u7bc7\u5831\u544a\u4e2d\uff0c\u6211\u5011\u767c\u73fe\u5c0d\u65bc\u653e\u5c04\u7dda\u53ca\u5316\u5b78\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\u7684\u8f49\u79fb\u6027\u6c23\u7ba1\u817a\u6a23\u56ca\u72c0\u764c\uff0c\u7bc0\u62cd\u5f0f\u5316\u5b78\u6cbb\u7642\u6216\u8a31\u662f\u4e00\u500b\u9078\u64c7\u3002", "e": "Adenoid cystic carcinoma (ACC) of the trachea is a rare disease and primarily treated with surgery. Here we report a 40 years-old male patient with ACC of the trachea. He was initially treated with surgery, concurrent chemoradiotherapy (delivered with a total dose of 64.8 Gy in 36 fractions concurrently with weekly cisplatin 30 mg/m^2) and adjuvant chemotherapy (monthly 5-fluorouracil and cisplatin). However, local recurrence and lung metastasis developed within a short period. After pulmonary metastatectomy, salvage chemotherapy with etoposide and cisplatin for 3 cycles were given but the disease kept progressing. Intriguingly, metronomic chemotherapy with oral etoposide and cyclophosphamide showed a good tumor response with minimal adverse effect. We reported that metronomic chemotherapy might be an option for the metastatic ACC of the trachea refractory to radiation and chemotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-167-179-a", "title": "Prognostic Factors Affecting the Outcome of Oropharyngeal Carcinoma", "keywords": "\u53e3\u54bd\u764c;\u6cbb\u7642\u7d50\u679c;\u9810\u5f8c Oropharyngeal carcinoma;Treatment results;Prognostic factors", "c": "\u76ee\u7684\uff1a\u5206\u6790\u53e3\u54bd\u764c\u60a3\u8005\u63a5\u53d7\u6cbb\u7642\u7684\u7d50\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1995\u5e743\u6708\u52302005\u5e749\u6708\uff0c\u6709110\u4f4d\u88ab\u8a3a\u65b7\u70ba\u53e3\u54bd\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u6cbb\u7642\u3002\u5176\u4e2d\u7537\u6027105\u4f4d\uff0c\u5973\u60275\u4f4d\u3002\u75c5\u4eba\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f52\u6b72\uff08\u7bc4\u570d\u4ecb\u65bc30\u81f377\u6b72\uff09\u3002\u670987\u4f4d\u75c5\u4eba(79.1%)\u539f\u767c\u90e8\u4f4d\u70ba\u6241\u6843\u817a\u5340\u57df\uff0c23\u4f4d\u75c5\u4eba(20.9%)\u5247\u70ba\u5176\u4ed6\u90e8\u4f4d\u7684\u53e3\u54bd\u3002\u75c5\u7406\u7d44\u7e54\u578b\u614b\u5206\u4f48\u4e2d\uff0c\u5206\u5225\u670910%\uff0c62.8%\u53ca27.2%\u7684\u75c5\u4eba\u70ba\u826f\u597d\u5206\u5316\uff0c\u4e2d\u5ea6\u5206\u5316\u53ca\u4e0d\u826f\u5206\u5316\u3002\u4ee5AJCC\u5206\u671f\u7cfb\u7d71\u4f86\u8a02\u5b9a\u75c5\u4eba\u7684\u764c\u75c7\u671f\u5225\uff0c8.2%\u7684\u75c5\u4eba\u662fstage \u2161\uff0c7.3%\u7684\u75c5\u4eba\u662fstage \u2162\uff0c69.1%\u53ca15.5%\u7684\u75c5\u4eba\u5206\u5225\u70bastage Iva\u53castage IVb\u3002\u670949\u4f4d\u75c5\u4eba\u63a5\u53d7\u4e86\u5207\u9664\u624b\u8853\uff0c\u5176\u4e2d\u670932\u4f4d\u75c5\u4eba\uff08\u4f54\u5168\u9ad4\u768429%\uff09\u4e26\u63a5\u53d7\u4e86\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u53e6\u591617\u4f4d\u75c5\u4eba\uff08\u4f54\u5168\u9ad4\u768415.5%\uff09\u63a5\u53d7\u4e86\u8f14\u52a9\u6027\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u300217\u4f4d\u75c5\u4eba\uff08\u4f54\u5168\u9ad4\u768415.5%\uff09\u63a5\u53d7\u4e86\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u9084\u670944\u4f4d\u75c5\u4eba\uff08\u4f54\u5168\u9ad4\u768440%\uff09\u63a5\u53d7\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u5f8c\u7684\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u662f17\u500b\u6708\uff08\u7bc4\u570d\u5f9e2.4\u81f3130.2\u500b\u6708\uff09\u3002\u5728\u8ffd\u8e64\u7684\u904e\u7a0b\u4e2d\uff0c39\u4f4d\u75c5\u4eba\u5b58\u6d3b(35.5%)\uff0c71\u4f4d\u75c5\u4eba\u6b7b\u4ea1(64.5%)\u3002\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u5206\u5225\u70ba28.4%\uff0c28.8%\u53ca58.4%\u3002\u82e5\u4ee5\u63a5\u53d7\u6cbb\u7642\u7684\u7d44\u5408\u4f86\u770b\uff0c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5c0d\u63a5\u53d7\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u70ba24.8%\uff0c\u63a5\u53d7\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\u70ba14.1%\uff0c\u63a5\u53d7\u624b\u8853\u5207\u9664\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u70ba36.9%\uff0c\u63a5\u53d7\u624b\u8853\u5207\u9664\u53ca\u8f14\u52a9\u6027\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u70ba45.8%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u6027\u5225\u3001\u539f\u767c\u90e8\u4f4d\u3001\u75c5\u7406\u7d44\u7e54\u578b\u614b\u4ee5\u53ca\u63a5\u53d7\u624b\u8853\u8207\u5426\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u800c\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u63a5\u53d7\u624b\u8853\u662f\u552f\u4e00\u5c0d\u5b58\u6d3b\u7387\u6709\u7d71\u8a08\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u800c\u5c0d\u65bc\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u4f86\u8aaa\uff0c\u63a5\u53d7\u624b\u8853\u4ee5\u53ca\u539f\u767c\u90e8\u4f4d\u662f\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u5f9e\u9019\u7bc7\u8ffd\u6eaf\u6027\u7684\u6587\u7ae0\u4f86\u770b\uff0c\u63a5\u53d7\u624b\u8853\u5c0d\u65bc\u53e3\u54bd\u764c\u7684\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u5340\u57df\u63a7\u5236\u662f\u7d71\u8a08\u4e0a\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u7136\u800c\uff0c\u8fd1\u5e74\u4f86\u96a8\u8457\u653e\u5c04\u6cbb\u7642\u6280\u8853\u7684\u9032\u6b65\u4ee5\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u52a0\u5165\uff0c\u5728\u4e0d\u72a7\u7272\u6cbb\u7642\u7d50\u679c\u7684\u524d\u63d0\u4e0b\uff0c\u5668\u5b98\u4fdd\u5b58\u61c9\u662f\u73fe\u4eca\u6cbb\u7642\u53e3\u54bd\u764c\u7684\u8da8\u52e2\u3002", "e": "Purpose: This retrospective study is to investigate the treatment results and prognostic factors of oropharyngeal carcinoma.\nMaterials and Methods: From March 1995 to September 2005, 110 patients diagnosed as oropharyngeal cancer received treatments in our institution. One hundred and five patients were male (95.5%) and 5 patients were female (4.5%). The median age of diagnosis was 52 year-old (range, 30-77 years). Eighty-seven patients (79.1%) were diagnosed as tonsillar carcinoma, and 23 patients (20.9%) were diagnosed as carcinoma of other oropharyngeal subsites. Histopathologically, well-differentiated, moderately-differentiated and poorly- differentiated carcinoma were 10%, 62.8%, and 27.2%, respectively. Staging classification were 8.2%, 7.3%, 69.1% and 15.5% for stage \u2161, \u2162, IVa, and IVb, respectively. Forty-nine patients were treated with resection of primary tumor with or without neck dissection. Thirty-two of all 110 patients (29.0%) received surgery and adjuvant radiotherapy, 17 patients (15.5%) received surgery and adjuvant chemoradiotherapy. Seventeen patients (15.5%) were treated with radiotherapy alone, and 44 patients (40.0%) were treated with definitive radiotherapy plus chemotherapy.\nResults: The follow-up period ranged from 2.4 to 130.2 months (median, 17 months). During the follow-up period, 39 patients (35.5%) were alive and 71 patients (64.5%) died. Five-year overall survival rate, disease-free survival rate, and loco-regional control rate of oropharyngeal cancer were 28.4%, 28.8%, and 58.4%, respectively. Five-year overall survival rate for the group of RT alone, definitive RT+C/T, OP+ adjuvant RT and OP+ adjuvant CCRT were 24.8%, 14.1%, 36.9%, and 45.8%, respectively. Gender, tumor site, histopathology and surgery significantly predicted survival in univariate analysis. In multivariate analysis, surgery was the only significant predictor for overall and disease-free survival, while tumor site and surgery were the significant predictors for loco-regional control.\nConclusion: Surgery was significantly predicted for loco-regional control and overall survival in this retrospective study. However, improving radiotherapy technique and addition of chemotherapy have changed the practice of oropharyngeal cancer in recent years with organ preservation without compromising the treatment results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-181-188-a", "title": "Comparing Intensity-Modulated Radiation Therapy with Conventional Tangential Technique in Treating Left-Sided Breast Cancer", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5de6\u5074\u4e73\u764c;\u5fc3\u81df\u6548\u61c9 Intensity-modulated radiation therapy;Left-sided breast cancer;Cardiac effect", "c": "Background and purpose: To determine whether or not intensity modulated radiation therapy (IMRT) offers a better treatment plan compared with conventional parallel opposed tangential radiation therapy for the left-sided breast cancer patients.\nMaterials and Methods: Between January 2005 and December 2006, we treated 70 patients who had Tis-2N0M0 left-sided breast cancers and underwent breast conservation surgery with or without chemotherapy. Both IMRT and conventional radiotherapy were planned for every patient. After comparing the radiation dose and volume to the heart and lung, and other dosimetric parameters, we then decided which technique to use for individual patient. Conventional radiotherapy was used for 2 patients and IMRT for 68 patients.\nResults: The mean conformity indexes are 1.47 and 1.08 for conventional radiotherapy and IMRT, respectively (p\uff1c0.05). Radiation dose to the heart, ipsilateral lung, and contralateral lung all can be reduced by 38.7%, 22.9% and 60.9%, respectively, with IMRT. Acute side effects were acceptable. The dose heterogeneity of conventional radiotherapy is greater than IMRT with a large area of cold and hot spots.\nConclusions: For the left-sided breast, IMRT can reduce the irradiation dose to the heart and both lungs. It also offers better conformity index and dose homogeneity. However, IMRT delivers very low dose radiation to a larger volume of normal surrounding tissues.", "e": "Background and purpose: To determine whether or not intensity modulated radiation therapy (IMRT) offers a better treatment plan compared with conventional parallel opposed tangential radiation therapy for the left-sided breast cancer patients.\nMaterials and Methods: Between January 2005 and December 2006, we treated 70 patients who had Tis-2N0M0 left-sided breast cancers and underwent breast conservation surgery with or without chemotherapy. Both IMRT and conventional radiotherapy were planned for every patient. After comparing the radiation dose and volume to the heart and lung, and other dosimetric parameters, we then decided which technique to use for individual patient. Conventional radiotherapy was used for 2 patients and IMRT for 68 patients.\nResults: The mean conformity indexes are 1.47 and 1.08 for conventional radiotherapy and IMRT, respectively (p\uff1c0.05). Radiation dose to the heart, ipsilateral lung, and contralateral lung all can be reduced by 38.7%, 22.9% and 60.9%, respectively, with IMRT. Acute side effects were acceptable. The dose heterogeneity of conventional radiotherapy is greater than IMRT with a large area of cold and hot spots.\nConclusions: For the left-sided breast, IMRT can reduce the irradiation dose to the heart and both lungs. It also offers better conformity index and dose homogeneity. However, IMRT delivers very low dose radiation to a larger volume of normal surrounding tissues."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-189-199-a", "title": "The Comparison of Nodal Stage Determined by Magnetic Resonance Imaging and Clinical Palpation for Nasopharyngeal Carcinoma Patients with Bulky Lymph Node Metastasis", "keywords": "\u9f3b\u54bd\u764c;\u9f90\u5927\u9838\u90e8\u6dcb\u5df4\u7d50;\u5206\u671f;\u6838\u78c1\u5171\u632f Nasopharyngeal carcinoma;Bulky cervical lymph node;Staging;Magnetic resonance imaging", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u63a2\u8a0e\u4f75\u6709\u9f90\u5927\u9838\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\u4ee5\u6838\u78c1\u5171\u632f\u6c7a\u5b9a\u6700\u5927\u6dcb\u5df4\u7d50\u5927\u5c0f\u53caN\u5206\u671f\u662f\u5426\u8f03\u81e8\u5e8a\u89f8\u8a3a\u8207\u75c5\u4eba\u9810\u5f8c\u6709\u66f4\u5f37\u76f8\u95dc\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5408\u683c\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\u6709\u89f8\u8a3a\u5927\u65bc\u6216\u7b49\u65bc6\u516c\u5206\u7684\u9838\u90e8\u6dcb\u5df4\u7d50\u4e26\u63a5\u53d7\u6838\u78c1\u5171\u632f\u4f5c\u70ba\u5206\u671f\u4f9d\u64da\u3002\u6211\u5011\u6392\u9664\u6709\u9060\u7aef\u6216\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7d50\u8f49\u79fb\u7684\u75c5\u4eba\u3002\u81ea1992\u81f32005\u5e74\u5171\u670947\u4f4d\u75c5\u4eba\u7b26\u5408\u689d\u4ef6\u3002\u6bcf\u4f4d\u75c5\u4eba\u7686\u5728\u6bcf\u9031\u8209\u884c\u4e4b\u591a\u5c08\u79d1\u5718\u968a\u6703\u8b70\u4e2d\u7d93\u5171\u8b58\u5f8c\u6c7a\u5b9aN\u5206\u671f\u3002\u75c5\u4eba\u7686\u4f9d\u7167\u91ab\u9662\u6cbb\u7642\u6e96\u5247\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\uff0c\u52a0\u6216\u4e0d\u52a0\u4e0a\u653e\u5c04\u5f8c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u3002\u6211\u5011\u6bd4\u8f03\u6838\u78c1\u5171\u632fN\u5206\u671f\u70baN1\u6216N2\u53caN3a\u7684\u75c5\u4eba\u7684\u5b58\u6d3b\u53ca\u5fa9\u767c\u90e8\u4f4d\u5206\u4f48\u3002\n\u7d50\u679c\uff1a\u6838\u78c1\u5171\u632fN\u5206\u671f\u70baN3a\u7684\u75c5\u4eba\u670922\u4f4d\uff0cN1\u6216N2\u670925\u4f4d\u3002\u7d93\u904e\u4e2d\u4f4d\u657864\u500b\u6708\u7684\u8ffd\u8e64\u5f8c\uff0c\u6838\u78c1\u5171\u632fN3\u7d44\u4e4b\u7121\u75c5\u5b58\u6d3b\u7387(53%)\u8f03N1\u6216N2\u7d44(65%)\u4f4e\uff0c\u4f46\u7121\u7d71\u8a08\u5b78\u4e0a\u610f\u7fa9(p=0.65)\u3002\u6838\u78c1\u5171\u632fN3(\u4e0b\u6a19 a)\u53caN1\u6216N2\u4e4b\u4e94\u5e74\u7e3d\u5b58\u6d3b\u7387\u53ca\u7121\u9060\u7aef\u8f49\u79fb\u5b58\u6d3b\u7387\u5206\u5225\u70ba78%\u6bd477%(p=0.5)\u53ca70%\u6bd465%(p=0.9)\u3002\u5169\u7fa4\u75c5\u4eba\u7684\u5c40\u90e8\u6216\u9060\u7aef\u5fa9\u767c\u90e8\u4f4d\u7684\u6bd4\u4f8b\u76f8\u4f3c\u3002\n\u7d50\u8ad6\uff1a\u4f75\u6709\u9f90\u5927\u9838\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\u4e0d\u8ad6\u6838\u78c1\u5171\u632fN\u5206\u671f\u70ba\u4f55\u7686\u6709\u8f03\u5dee\u7684\u6574\u9ad4\u5b58\u6d3b\u3002\u6211\u5011\u5efa\u8b70\u5982\u679c\u9838\u90e8\u6dcb\u5df4\u7d50\u5728\u6838\u78c1\u5171\u632f\u4e0a\u76f8\u9130\u878d\u5408\u5728\u4e00\u8d77\uff0c\u5b83\u5011\u7684\u5927\u5c0f\u4e0d\u61c9\u5206\u958b\u6e2c\u91cf\u3002\u9019\u4e9b\u75c5\u4eba\u61c9\u7686\u5b9a\u70baN3a\u671f\u3002", "e": "Purpose: This study is to find out whether maximal lymph node size determined by magnetic resonance imaging (MRI) correlates with prognosis better than that determined by clinical palpation for patients with nasopharyngeal carcinoma (NPC) and bulky cervical lymph node metastasis.\nMaterial and Methods: All eligible NPC patients should have cervical lymph node size 6 cm or greater by clinical palpation and use MRI as primary imaging modality. Patients with N3b and distant metastases were excluded from this study. From 1992 to 2005, a total of 47 patients were included. Their MRI nodal stage was determined at weekly multidisciplinary team conference with a consensus. Patients received concurrent chemoradiotherapy with or without adjuvant chemotherapy according to hospital guideline. We compared the survival and failure patterns of MRI N1-2 and MRI N3a patients.\nResults: Twenty-two patients were assigned MRI N3a and 25 MRI N1 or N2. With a median follow up of 64 months, the 5-year disease-free survival rate for MRI N3a group (53%) was lower than MRI N1-2 group (65%) but not statistically significant (p=0.56). The 5-year overall survival and metastasis-free survival of MRI N3a vs MRI N1-2 patients were 78% vs. 77% (p= 0.5) and 70% vs. 65% (p= 0.9), respectively. The failure pattern was similar.\nConclusion: NPC patients with clinical bulky cervical lymph node metastasis have relatively poor survival regardless of MRI N-stage. We recommend that if cervical lymph nodes are confluent together, their sizes determined by MRI should not be measured separately. These patients are best to be staged as N3a disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-201-212-a", "title": "Retrospective Study of the Concurrent Intraarterial Chemo-Radiotherapy for Locally Advanced or al Cancers", "keywords": "\u53e3\u8154\u764c;\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5;\u6ec5\u53ef\u5584\u6ce8\u5c04\u6db2 Oral cancer;IACCRT;Methotrexate", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u65bc\u63a2\u8a0e\u5c40\u90e8\u6027\u665a\u671f\u53e3\u8154\u764c\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5\u7684\u81e8\u5e8a\u7d50\u679c\u53ca\u4f75\u767c\u75c7\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2001\u5e749\u6708\u81f32006\u5e747\u6708\uff0c\u5171\u670930\u4f4d\u5c40\u90e8\u6027\u665a\u671f\u53e3\u8154\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\uff08\u5176\u4e2d22\u4f4d\u764c\u75c7\u5206\u671f\u4e4b\u671f\u5225\u70ba\u7b2c\u56db\u671f\uff1b\u53e6\u59168\u4f4d\u70ba\u7b2c\u4e09\u671f\uff09\u7684\u75c5\u60a3\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5\u3002\u5e74\u9f61\u5206\u4f48\u5f9e32\u6b72\u523063\u6b72\uff08\u4e2d\u4f4d\u6578\u70ba45\u6b72\uff09\u3002\u6bcf\u500b\u75c5\u60a3\u5728\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u540c\u6642\u4e5f\u90fd\u6703\u540c\u6b65\u5730\u63a5\u53d7\u6bcf\u9031\u4e00\u6b2150\u6beb\u514bmethotrexate\u7684\u52d5\u8108\u5316\u5b78\u6cbb\u7642\u3002\u6240\u6709\u75c5\u60a3\u6240\u63a5\u53d7\u7684\u4e2d\u4f4d\u653e\u5c04\u7dda\u5291\u91cf\u70ba64Gy\uff0c\u4e2d\u4f4d\u7684\u8ffd\u8e64\u6642\u9593\u670920\u500b\u6708\uff08\u6700\u77ed\u8ffd\u8e646\u500b\u6708\uff1b\u6700\u9577\u7684\u8ffd\u8e64\u670952\u500b\u6708\uff09\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u5728\u6cbb\u7642\u7d50\u675f\u4e4b\u5f8c\uff0c\u5229\u7528\u81e8\u5e8a\u7684\u7406\u5b78\u6aa2\u67e5\u4ee5\u53ca\u5f71\u50cf\u5b78\u7684\u6aa2\u67e5\uff0c\u4f86\u8a55\u4f30\u75c5\u7076\u5c0d\u6cbb\u7642\u7684\u53cd\u61c9\u6548\u679c\u3002\u7d50\u679c\u767c\u73fe\u670953%\u5728\u6cbb\u7642\u5f8c\u75c5\u7076\u5b8c\u5168\u6d88\u9664\uff1b23%\u7684\u75c5\u4f8b\u75c5\u7076\u70ba\u90e8\u5206\u6d88\u9664\uff1b17%\u7684\u75c5\u7076\u5c0d\u6cbb\u7642\u6c92\u6709\u53cd\u61c9\uff1b7%\u7684\u75c5\u7076\u6cbb\u7642\u5f8c\u75c5\u7076\u6709\u64f4\u5927\u7684\u60c5\u5f62\u3002\u5728\u6cbb\u7642\u671f\u9593\u670933.3%\u7684\u75c5\u60a3\u5c0e\u81f4\u7b2c\u4e09\u7d1a\u7684\u53e3\u8154\u9ecf\u819c\u708e\uff1b26.6%\u7684\u75c5\u60a3\u6709\u7b2c\u4e09\u7d1a\u7684\u541e\u56a5\u56f0\u96e3\uff1b3%\u6709\u7b2c\u4e09\u7d1a\u7684\u767d\u8840\u7403\u4f4e\u4e0b\u75c7\u3002\u4e00\u5e74\u7684\u5b58\u6d3b\u7387\u670960.4%\u3002\u5206\u6790\u7684\u7d50\u679c\uff0c\u6211\u5011\u767c\u73fe\u5728\u6cbb\u7642\u5f8c\u75c5\u7076\u80fd\u5b8c\u5168\u6216\u90e8\u5206\u6d88\u9664\u7684\u75c5\u60a3\u6709\u6bd4\u8f03\u597d\u7684\u5b58\u6d3b\u7387\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u521d\u6b65\u7684\u7d50\u679c\u986f\u793a\u5c40\u90e8\u6027\u665a\u671f\u53e3\u8154\u764c\u63a5\u53d7\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5\u662f\u53ef\u884c\u7684\uff0c\u7279\u5225\u662f\u53e3\u8154\u764c\u4e2d\u7684\u820c\u764c\u53ca\u9f52\u9f66\u764c\u5c0d\u65bc\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5\u6709\u6bd4\u8f03\u597d\u7684\u6cbb\u7642\u6210\u6548\u3002\u5118\u7ba1\u5982\u6b64\uff0c\u540c\u6b65\u653e\u5c04\u7dda\u52d5\u8108\u5316\u5b78\u7642\u6cd5\u5c0d\u65bc\u5c40\u90e8\u6027\u665a\u671f\u53e3\u8154\u764c\u7684\u7642\u6548\uff0c\u9084\u9700\u8981\u66f4\u5927\u578b\u7684\u524d\u77bb\u6027\u7814\u7a76\u4f86\u63a2\u8a0e\u3002", "e": "Purpose: The aim of this study is to investigate the clinical outcomes and complications of intraarterial chemotherapy and concurrent radiation therapy (IACCRT) for locally advanced oral cancers.\nMaterials and Methods: Between September, 2001 and July, 2006, 30 patients with locally advanced oral squamous cell carcinoma (stage \u2163: 22 patients and stage \u2162: 8 patients) received concurrent intraarterial chemo-radiotherapy in our department. The age ranged from 32 year-old to 63 year-old (median, 45 year-old). Each patient received a single bolus of 50 mg of methotrexate intraarterially every week while undergoing irradiation. The median irradiation dose was 64 Gy with 1.8-2.0 Gy daily fractions. The median follow-up period was 20 months (range, 6-52 months).\nResults: The response rate was evaluated by clinical examination and imaging study after IACCRT and the results were as follows: complete response, 53% (16/30); partial response, 23% (7/30); no response, 17% (5/30); progression, 7% (2/30). The major toxicities included grade 3 mucositis (10/30, 33.3%), grade 3 dysphagia (8/30, 26.6%), and grade 3 leukopenia (1/30, 3%). The estimated 1-year survival rate was 60.4%. Patients with complete or partial response were associated with better overall survival by Kaplan Meier survival analysis (log-rank test, p=0.05).\nConclusion: Our preliminary data suggests IACCRT for locally advanced oral cancers is feasible. We have inferred a conclusion from the facts that tongue and gingival cancers have better response to IACCRT than buccal cancer does. Nevertheless, the result was not statistically significant. Further larger prospective study with detailed case selection is necessary."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-213-221-a", "title": "Metronomic Cyclophosphamide Enhances Response of Murine Subcutaneous Melanoma to Radiation", "keywords": "\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u5316\u7642;\u8840\u7ba1\u65b0\u751f;\u5f37\u5316\u4fc2\u6578 Metronomic chemotherapy;Angiogenesis;Enhancement factor", "c": "\u76ee\u7684\uff1a\u8fd1\u671f\u7814\u7a76\u986f\u793a\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u65bd\u8207\u5316\u5b78\u85e5\u7269(metronomic chemotherapy)\u5177\u6709\u6291\u5236\u8840\u7ba1\u65b0\u751f\u4e4b\u529f\u6548\u4e14\u4e0d\u5177\u986f\u8457\u6bd2\u6027\u3002\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u65bd\u8207cyclophosphamide\u5728\u52d5\u7269\u53ca\u4eba\u9ad4\u5be6\u9a57\u4e2d\u986f\u73fe\u6291\u5236\u816b\u7624\u751f\u9577\u3002\u6578\u9805\u7814\u7a76\u986f\u793a\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u6291\u5236\u8840\u7ba1\u65b0\u751f\u53ef\u80fd\u5177\u6709\u52a0\u6210\u6216\u76f8\u52a0\u4e4b\u7642\u6548\uff0c\u6211\u5011\u56e0\u6b64\u6e2c\u8a66\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u65bd\u8207cyclophosphamide\u53ca\u653e\u5c04\u6cbb\u7642\u5c0d\u8001\u9f20\u76ae\u4e0b\u9ed1\u8272\u7d20\u7624\u4e4b\u7642\u6548\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u8001\u9f20\u63a5\u53d7\u76ae\u4e0b\u9ed1\u8272\u7d20\u7624\u6ce8\u5c04\u9694\u65e5\u5728\u98f2\u6c34\u4e2d\u7d66\u4e88cyclophosphamide(0, 6, or 20 mg/kg/day)\u76f4\u5230\u5be6\u9a57\u7d50\u675f\u3002\u816b\u7624\u6ce8\u5c04\u7b2c16\u5929\u6642\uff0c\u8001\u9f20\u63a5\u53d7\u55ae\u4e008Gy\u653e\u5c04\u7dda\u7167\u5c04\uff0c\u6bcf\u9031\u91cf\u6e2c\u816b\u7624\u7684\u5927\u5c0f2\u6b21\u3002\n\u7d50\u679c\uff1a\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u65bd\u8207cyclophosphamide\uff0c\u53ef\u9020\u6210\u986f\u8457\u7684\u816b\u7624\u751f\u9577\u6291\u5236\u6548\u679c\uff0c\u800c\u6cbb\u7642\u5f15\u8d77\u4e4b\u6bd2\u6027\u5247\u4e0d\u660e\u986f\u3002\u55ae\u4e00\u6b21\u6578\u4e4b8Gy\u653e\u5c04\u6cbb\u7642\u6291\u5236\u816b\u7624\u751f\u9577\u800c\u540c\u6642\u65bd\u8207\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0fcyclophosphamide\u5247\u6548\u679c\u66f4\u5f62\u986f\u8457\uff0c\u800c\u63a8\u7b97\u4e4b\u653e\u5c04\u7dda\u5f37\u5316\u4fc2\u6578(enhancementfactor)\u70ba2.4\u3002\n\u7d50\u8ad6\uff1a\u4f4e\u5291\u91cf\u7bc0\u62cd\u5668\u5f0f\u65bd\u8207cyclophosphamide\u7684\u81e8\u5e8a\u6548\u76ca\u503c\u5f97\u9032\u4e00\u6b65\u63a2\u8a0e\uff0c\u5176\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5408\u4f75\u7642\u6548\uff0c\u8207\u5408\u4f75\u4f7f\u7528\u4e4b\u9069\u7576\u5291\u91cf\u53ca\u9806\u5e8f\u4e4b\u5206\u5b50\u6a5f\u5236\u4e5f\u503c\u5f97\u5728\u672a\u4f86\u7684\u7814\u7a76\u4e2d\u91d0\u6e05\u3002", "e": "Purpose: Encouraging results shown in recent literatures have demonstrated that low dose metronomic (LDM) chemotherapy exhibits antiangiogenic property with relatively safe profile. LDM cyclophosphamide has been studied in numerous pre-clinical studies and administrated to cancer patients with some beneficial effect on tumor stabilization. Given that several lines of evidence suggesting a potential synergistic or additive effect of antiangiogenic therapy and radiation, we examined whether the addition of LDM chemotherapy of cyclophosphamide could enhance the response of subcutaneously inoculated melanoma, B16F10, to radiation in a syngenic murine model.\nMaterials and Methods: One day after subcutaneous B16F10 inoculation on the flanks, c57/BL6 mice were given cyclophosphamide at 0, 6, or 20 mg/kg/day through drinking water on a daily basis throughout the whole course of experiment. On 16th day after tumor inoculation, tumors bearing mice, which were given 0 or 6 mg/kg/day were either irradiated with 8 Gy or left untreated. The tumor growths were measured two times per week for evaluation of the effects of various doses of LDM cyclophosphamide alone, radiation alone, or combination of both.\nResults: LDM cyclophosphamide treatment significantly suppressed subcutaneous melanoma growth in a syngenic tumor model without discernible toxicity. Efficacy of LDM cyclophosphamide was demonstrated in a dose-dependent manner. A single fraction of 8 Gy radiation significantly delayed the growth of melanoma and the effect was further enhanced by concomitant administration of LDM cyclophosphamide with an enhancement factor of 2.4.\nConclusion: The clinical benefit of LDM cyclophosphamide may be further tested in clinical trials. It is also of great interests to further evaluate molecular mechanism of radiation and LDM cyclophosphamide combination regarding the dosing schedule and sequence."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-223-231-a", "title": "\u87ba\u65cb\u5f0f\u65b7\u5c64\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8207\u56fa\u5b9a\u89d2\u5ea6\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5728\u80ba\u90e8\u5291\u91cf\u4e0a\u7684\u6bd4\u8f03", "keywords": "\u87ba\u65cb\u5f0f\u65b7\u5c64\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u80ba\u5e73\u5747\u5291\u91cf;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u80ba\u764c Tomotherapy;Mean lung dose;IMRT;Lung cancer", "c": "\u76ee\u7684\uff1a\u672c\u5be6\u9a57\u4e4b\u76ee\u7684\u662f\u63a2\u8a0e\u87ba\u65cb\u5f0f\u65b7\u5c64\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(Tomotherapy)\u662f\u5426\u80fd\u9032\u4e00\u6b65\u5730\u6e1b\u5c11\u80ba\u90e8\u5291\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u9078\u53d68\u4f4d\u80ba\u764c\u75c5\u4eba\uff0c\u5176\u4e2d5\u4f4d\u53ea\u6709\u4e00\u8655\u539f\u767c\u764c\u9700\u8981\u7167\u5c04\uff0c\u5176\u4ed63\u4f4d\u9664\u4e86\u539f\u767c\u764c\u5916\uff0c\u5408\u4f75\u67092\u52303\u8655\u80ba\u90e8\u6dcb\u5df4\u8f49\u79fb\uff0c\u6bcf\u4f4d\u75c5\u4eba\u540c\u6642\u505a\u51fa\u5169\u500b\u6cbb\u7642\u8a08\u756b\uff0c\u5305\u62ecTomotherapy\u8207\u56fa\u5b9a\u65cb\u8f49\u81c2(gantry)\u89d2\u5ea6\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(fixed gantry angle IMRT)\uff0c\u6700\u5f8c\u8a55\u4f30\u5169\u500b\u6cbb\u7642\u8a08\u756b\uff0c\u5728\u96d9\u5074\u6b63\u5e38\u80ba\u3001\u816b\u7624\u540c\u5074\u6b63\u5e38\u80ba\u8207\u5c0d\u5074\u6b63\u5e38\u80ba\u4e4b\u5291\u91cf\u3002\u9664\u80ba\u764c\u539f\u767c\u75c5\u4eba\u5916\uff0c\u80ba\u90e8\u591a\u767c\u6027\u8f49\u79fb\u3001\u4e73\u764c\u8207\u80f8\u9aa8\u8f49\u79fb\u75c5\u4eba\uff0c\u5404\u6709\u4e00\u4f4d\uff0c\u4ee5\u521d\u6b65\u63a2\u8a0e\u80f8\u90e8\u7167\u5c04\u7684\u75c5\u4eba\uff0c\u5728\u5169\u7a2e\u4e0d\u540c\u6cbb\u7642\u6280\u8853\u4e0b\u80ba\u5291\u91cf\u4e4b\u512a\u52a3\u3002\n\u7d50\u679c\uff1a\u57288\u4f4d\u80ba\u764c\u75c5\u4eba\u7684\u6cbb\u7642\u8a08\u756b\u4e2d\uff0cTomotherapy\u5e73\u5747\u53ef\u4ee5\u6e1b\u5c11\u96d9\u5074\u6b63\u5e38\u80ba\u7684\u5e73\u5747\u5291\u91cf4.0%\uff08\u4e2d\u4f4d\u6578\uff0d2.5%\uff0c\u7bc4\u570d\uff0d0.2%~-7.2%\uff0cp=0.006\uff09\uff0c\u82e5\u5206\u70ba\u540c\u5074\u6b63\u5e38\u80ba\u8207\u5c0d\u5074\u6b63\u5e38\u80ba\u4f86\u770b\uff0ctomotherpy\u5e73\u5747\u53ef\u4ee5\u6e1b\u5c11\u540c\u5074\u6b63\u5e38\u80ba\u7d047.7%\u7684\u5e73\u5747\u5291\u91cf\uff08\u4e2d\u4f4d\u6578\uff0d7.6%\uff0c\u7bc4\u570d\uff0d17.8%~-1.0%\uff0cp=0.003\uff09\uff0c\u4f46\u5c0d\u5c0d\u5074\u6b63\u5e38\u80ba\uff0c\u4f7f\u7528Tomotherapy\u4e26\u6c92\u6709\u660e\u986f\u7684\u7d71\u8a08\u610f\u7fa9\uff08\u5e73\u5747\uff0b8.0%\uff0c\u4e2d\u4f4d\u6578\uff0d3.1%\uff0c\u7bc4\u570d\uff0d22.3%~+63.2%\uff0cp=0.20\uff09\u3002\u5c0d\u65bc\u80ba\u90e8\u591a\u767c\u6027\u8f49\u79fb\u3001\u4e73\u764c\u53ca\u80f8\u9aa8\u8f49\u79fb\u7684\u4e09\u4f4d\u75c5\u4eba\uff0cTomotherapy\u6e1b\u5c11\u80ba\u90e8\u5e73\u5747\u5291\u91cf\u905427.3%\u30013.6%\u300110.2%\u3002\n\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u7d93\u904e\u4ed4\u7d30\u7684\u8a08\u756b\u5f8c\uff0c\u5c0d\u65bc\u7167\u5c04\u80ba\u90e8\u7684\u75c5\u4eba\uff0c\u4f7f\u7528Tomotherapy\u6709\u6f5b\u529b\u6e1b\u5c11\u6216\u7dad\u6301\u8207IMRT\u4e00\u6a23\u7684\u96d9\u5074\u6b63\u5e38\u80ba\u8207\u540c\u5074\u6b63\u5e38\u80ba\u7684\u5e73\u5747\u5291\u91cf\uff0c\u4e0d\u904e\u4ecd\u9808\u9032\u4e00\u6b65\u7684\u7814\u7a76\u4f86\u78ba\u8a8d\u3002", "e": "Purpose: The purpose of this experiment is to compare the lung dose between fixed-angle IMRT technique and Tomotherapy. We also explore the possibility to lower the lung dose with Tomotherapy.\nMaterial and Method: Eight patients were selected for this study. Five of them only have one primary tumor. The others have one primary tumor with two or three lymph node metastasis. All of them were both planned by fixed gantry angle IMRT technique and Tomotherapy technique. The dose distributions and the mean dose to ipsilateral, contralateral and both normal lungs were evaluated and compared between two plans. For completeness, we also evaluate the lung mean dose for a sternum metastasis patient, a multiple lung metastasis patient and a breast cancer patient between fixed-angle IMRT technique and Tomotherapy technique.\nResult: By comparing the isodose plan of eight patients, Tomotherapy group has lowered mean dose to both normal lung (4.0% lower in average, median: -2.5%, range: -0.2%~-7.2%, p=0.006) and to ipsilateral normal lung (7.7% lower in average, median: -7.6%, range: -17.8%~-1.0%, p=0.003). But for the contralateral normal lung, Tomotherapy technique doesn\u2019t show the statistically significant superiority than fixed-angle IMRT technique (median: -3.1%, range: -22.3%~+63.2%, p=0.20). For patients with multiple lung metastasis, with sternum metastases and with breast cancer, Tomotherpy can reduce the mean dose for whole normal lung by 27.3%, 3.6% and 10.2% respectively.\nConclusion and Discussion: With carefully planning, the Tomotherapy plan could have the same or lower mean dose of ipsilateral and both normal lungs than fixed-angle IMRT. Tomotherapy may have potential to reduce more mean dose to lung than fixed-angle IMRT. We need further investigation to verify this potential."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-233-240-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u7d9c\u5408\u6cbb\u7642\u8a08\u756b\u4e4b\u6574\u9ad4\u7684\u8a55\u4f30", "keywords": "\u6574\u9ad4\u6cbb\u7642\u8a08\u756b;\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642;\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u5e03;\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716 Composite plan;Cone down plan;IMRT;Isodose distribution;Dose-volume histogram", "c": "\u76ee\u7684\uff1a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u901a\u5e38\u5305\u542b\u5169\u5927\u90e8\u5206\uff1a\u521d\u59cb\u6cbb\u7642\u8a08\u756b\uff0c\u6cbb\u7642\u7bc4\u570d\u6db5\u84cb\u81e8\u5e8a\u4e0a\u53ef\u80fd\u53d7\u816b\u7624\u4fb5\u72af\u4e4b\u81e8\u5e8a\u6a19\u9776\u9ad4\u7a4d(Clinical Target Volume\uff0cCTV)\u53ca\u9031\u908a\u53ef\u80fd\u5177\u5371\u96aa\u6027\u7684\u6dcb\u5df4\u5340\u57df\uff1b\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\uff0c\u91dd\u5c0d\u816b\u7624\u9ad4\u7a4d\u505a\u5c40\u90e8\u7684\u5291\u91cf\u88dc\u5f37\u3002\u672c\u7bc7\u7814\u7a76\u4ee5\u4e0d\u540c\u5291\u91cf\u9650\u5236\u7d44\u5408\u4f86\u8a55\u4f30\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\u7684\u512a\u52a3\uff0c\u4ee5\u53ca\u5c0d\u6574\u9ad4\u6cbb\u7642\u8a08\u5283\u7684\u5f71\u97ff\uff0c\u9650\u5236\u65b9\u5f0f\u5206\u70ba\u5c0d\u521d\u59cb\u8a08\u756b\u6709\u4f9d\u5b58\u6027\u53ca\u7121\u4f9d\u5b58\u6027\u5169\u7a2e\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7bc7\u7814\u7a76\u9078\u53d6\u4e86\u516d\u4f4d\u982d\u9838\u90e8\u764c\u75c7\u7684\u75c5\u4eba\uff0c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u70baPinnacle Version 7.4 (Philips Medical Systems\uff0cMadison\uff0cWI)\u3002\u5169\u7a2e\u5291\u91cf\u9650\u5236\u7684\u6cbb\u7642\u8a08\u756b\u7686\u4ee5\u76f8\u540c\u521d\u59cb\u6cbb\u7642\u8a08\u756b\u70ba\u57fa\u790e\uff0c\u85c9\u7531\u4e0d\u540c\u5291\u91cf\u53c3\u6578\u4f86\u8a55\u4f30\u548c\u5206\u6790\u6cbb\u7642\u8a08\u5283\u7684\u512a\u52a3\u3002\u6cbb\u7642\u8a08\u756b\u4e4b\u5291\u91cf\u8f38\u51fa\u76e3\u6e2c\u55ae\u4f4d(monitor unit\uff0cMU)\u4ea6\u5305\u542b\u5728\u8a55\u4f30\u7684\u7bc4\u570d\u5167\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\uff0c\u521d\u59cb\u6cbb\u7642\u8a08\u756b\u7684\u512a\u52a3\u5c0d\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\u4e4b\u5291\u91cf\u66f2\u7dda\u5206\u5e03\u6709\u986f\u8457\u7684\u5f71\u97ff\u3002\u5c31\u4f9d\u5b58\u6027\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u800c\u8a00\uff0c\u70ba\u9054\u5230\u6574\u9ad4\u5291\u91cf\u5206\u5e03\u7684\u5747\u52fb\u5ea6\uff0c\u5728\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\u4e2d\u6703\u7522\u751f\u6975\u4e0d\u5747\u52fb\u7684\u5291\u91cf\u5206\u5e03\u53caMU\u904e\u9ad8\u7684\u60c5\u5f62\uff1b\u5728\u7121\u4f9d\u5b58\u6027\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u4e2d\uff0c\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\u4e0d\u4f46\u5177\u6709\u826f\u597d\u7684\u5291\u91cf\u5206\u5e03\uff0c\u7e3d\u5291\u91cf\u4e5f\u53ea\u6709\u4e9b\u5fae\u7684\u589e\u52a0\u3002\u7d9c\u89c0\u5176\u7d50\u679c\uff0c\u7121\u4f9d\u5b58\u6027\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u662f\u8f03\u9069\u5408\u7528\u65bc\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\u3002\n\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u6839\u64da\u5169\u7a2e\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u6bd4\u8f03\u5176\u7d50\u679c\uff0c\u7531\u65bc\u7121\u4f9d\u5b58\u6027\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u53ef\u4ee5\u9054\u5230\u5b8c\u6574\u7684\u816b\u7624\u5305\u8986\uff0c\u95dc\u9375\u5668\u5b98\u4ea6\u4e0d\u6703\u63a5\u53d7\u5230\u904e\u591a\u7684\u5291\u91cf\uff0c\u5c0d\u65bc\u751f\u7269\u6548\u61c9\u53ca\u6cbb\u7642\u6548\u679c\u90fd\u80fd\u6709\u5b8c\u6574\u7684\u8a55\u4f30\u3002\u56e0\u6b64\uff0c\u5efa\u8b70\u4f7f\u7528\u7121\u4f9d\u5b58\u6027\u5291\u91cf\u9650\u5236\u65b9\u5f0f\u4f86\u88fd\u4f5c\u5c40\u90e8\u589e\u5f37\u6cbb\u7642\u8a08\u756b\uff0c\u4e26\u4e14\u5be9\u614e\u7684\u8a2d\u5b9a\u95dc\u9375\u5668\u5b98\u7684\u5291\u91cf\u9650\u5236\uff0c\u800c\u5176\u6574\u9ad4\u6cbb\u7642\u8a08\u756b\u5c31\u53ef\u4ee5\u9054\u5230\u9810\u671f\u7684\u6cbb\u7642\u6548\u679c\uff0c\u95dc\u9375\u5668\u5b98\u4ea6\u4e0d\u6703\u8d85\u51fa\u8010\u53d7\u5291\u91cf\u3002", "e": "Purpose: IMRT treatment planning generally includes two parts: initial comprehensive IMRT (C-IMRT) plan to cover the CTV and risky nodal regions and the Cone Down (CD) IMRT plan for gross tumor boost. We try to evaluate the impact of the 2 CD constrain sets, dependent and independent constrain sets in relation to the initial plan on the final composite isodose distribution.\nMaterials and Methods: A total of six IMRT plans with head and neck cancer were performed with the Philip Pinnacle3 Planning System. Two different constrain sets of CD IMRT plan had been done with the same C-IMRT plan for each patient. Isodose distributions, dose-volume histograms (DVHs), and the various dosimetric parameters were generated and calculated for each plans. Comparison was made to evaluate the differences of DVHs and composite isodose distributions of 2 CD constrain sets both superimposed on the initial C-IMRT planning. We also compared the monitor unit (MU) in two CD constrain sets plans.\nResult: Our finding showed that the initial IMRT plan has a great impact on CD IMRT plan. Dependent constrain sets in CD IMRT plan could be negatively influenced by the initial IMRT plan with unacceptable surplus of MUs due to the non-uniform intensity map summarization. The independent constrain sets may not generate an acceptable composite dose distribution since summation of the two acceptable individual intensity maps may not create an optimum composite intensity to meet the final dose criteria. However, taken all consideration together, the independent constrain sets could be adequate for CD IMRT plan.\nConclusion and Discussion: According to the aforementioned planning comparisons, it is perfered to implement the CD IMRT plan without summating the initial IMRT plan. CD IMRT paln with independent constrain sets was prefered over dependent constrain sets because of consistent minimum tumor coverage in the cone down phase, similar tumor coverage, equal critial organ sparing and bioradiological evaluation. The dose constrains defined in the initial IMRT plan has a great effect on the critical organ dose. Analysis of the composite IMRT plan is indispensable."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-241-247-a", "title": "The Experience of Endobronchial Brachytherapy in Lung Cancer", "keywords": "\u6c23\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642;\u80ba\u764c;\u59d1\u606f\u6027\u7642\u6cd5 Endobronchial brachytherapy;Lung cancer;Palliation", "c": "\u76ee\u7684\uff1a\u6c23\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u5c0d\u65bc\u6c23\u7ba1\u5167\u816b\u7624\u963b\u585e\u6216\u6c23\u7ba1\u65c1\u816b\u7624\u58d3\u8feb\u6240\u9020\u6210\u75c7\u72c0\uff0c\u662f\u4e00\u6709\u6548\u7de9\u89e3\u4e4b\u59d1\u606f\u6027\u7642\u6cd5\u3002\u767c\u8868\u6211\u5011\u4f7f\u7528Ir-192\u4e4b\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\u65bc\u80ba\u764c\u75c5\u4eba\u6cbb\u7642\u4e4b\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2000\u5e74\u81f32006\u5e74\uff0c\u7e3d\u5171\u670950\u4f4d\u5c40\u90e8\u56b4\u91cd\u6027\u7684\u80ba\u764c\u60a3\u8005\u65bc\u672c\u79d1\u63a5\u53d7\u9ad8\u5291\u91cf\u7387\u4e4b\u8fd1\u63a5\u6cbb\u7642\u3002\u4f7f\u7528\u6cbb\u7642\u75c5\u4eba\u7684\u6a5f\u5668\u662fVarians VS200\u578b\u865f\uff0c\u4ee5\u53ca\u4f7f\u7528Cadplan BT\u70ba\u6cbb\u7642\u8a08\u5283\u6240\u7528\u4e4b\u96fb\u8166\u8edf\u9ad4\u3002\u7531\u672c\u9662\u7684\u80f8\u8154\u5167\u79d1\u91ab\u751f\u9078\u64c7\u9069\u5408\u63a5\u53d7\u8fd1\u63a5\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u4e26\u8ca0\u8cac\u88dd\u7f6e\u597d\u8fd1\u63a5\u6cbb\u7642\u6642\u6240\u9700\u8981\u4e4b\u6c23\u7ba1\u5167\u7ba1\u3002\u5927\u90e8\u5206\u7684\u75c5\u4eba\u5728\u4e00\u81f3\u4e8c\u9031\u7684\u6642\u9593\u5167\u63a5\u53d7\u4e86\u4e8c\u5230\u4e09\u6b21\u7684\u8fd1\u63a5\u6cbb\u7642\uff0c\u55ae\u6b21\u5291\u91cf\u7684\u7bc4\u570d\u5f9e300 cGy\u52301000 cGy\u3002\u6839\u64da\u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\u3001\u5f71\u50cf\u5b78\u8ffd\u8e64\u3001\u6216\u75c5\u4eba\u7684\u4e3b\u8a34\u4f86\u8a55\u4f30\u6cbb\u7642\u6709\u7121\u7de9\u89e3\u75c7\u72c0\u4e4b\u6548\u76ca\u3002\n\u7d50\u679c\uff1a\u6c23\u7ba1\u5167\u816b\u7624\u963b\u585e\u6216\u6c23\u7ba1\u65c1\u816b\u7624\u58d3\u8feb\u6240\u9020\u6210\u75c7\u72c0\uff0c\u5728\u7d93\u904e\u6c23\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u5f8c\uff0c50\u4f4d\u75c5\u4eba\u4e2d35\u4f4d(70%)\u7372\u5f97\u7de9\u89e3\u3002\u6c92\u6709\u4e09\u7d1a\u6216\u56db\u7d1a\u7684\u7684\u6cbb\u7642\u5f8c\u4f75\u767c\u75c7\u4e4b\u7d00\u9304\u3002\n\u7d50\u8ad6\uff1a\u6c23\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u5c0d\u65bc\u7de9\u89e3\u56e0\u5c40\u90e8\u56b4\u91cd\u6027\u80ba\u764c\u5f15\u8d77\u4e4b\u963b\u585e\u6027\u6216\u58d3\u8feb\u6027\u75c7\u72c0\u662f\u4e00\u7a2e\u6709\u6548\u800c\u5b89\u5168\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: Endobronchial brachytherapy (EBBT) is a useful modality for the palliation of symptoms caused by endobronchial tumor or compression from peribronchial tumor. We report our experience of treating lung cancer patients with Iridium-192 high-dose-rate (HDR) endobronchial brachytherapy (EBBT).\nMaterials and Methods: From 2000 to 2006, 50 patients of advanced lung cancer received HDR-EBBT in our radiation oncology department. These patients were treated with Varians VS200 and treatment plans are based on Cadplan BT. The physicians from Medical Chest selected the patients whom are appropriate for the treatment and responsible for the insertion of endobronchial tube for EBBT. Most patients received 2 to 3 fractions of EBBT in 1-2 weeks. The dose of each fraction ranged from 300 cGy to 1000 cGy. The response of symptomatic relief was assessed with endoscope, radiography and the subjective sensation of these patients.\nResults: Relief of endobronchial tumor-related symptoms and external compression from peribronchial tumor was noted in 35 of 50 patients (70%) treated with EBBT. No grade III-IV complication was observed.\nConclusion: HDR-EBBT is an effective and safe palliative tool in locally advanced lung cancer, with a relatively long duration of symptom palliation and a considerable improvement in the quality of life. There is also significant reduction of endobronchial obstruction."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200809-15-3-249-256-a", "title": "Whole Brain Radiotherapy Followed by Boost to Individual Brain Metastases: A Case Report of Radiotherapy for Disseminated Brain Metastases Using Tomotherapy", "keywords": "\u5168\u8166\u7167\u5c04;\u8f49\u79fb;\u5c0e\u822a\u87ba\u65cb\u5200 Whole brain radiotherapy;Metastases;Tomotherapy", "c": "\u904e\u53bb\u7d93\u9a57\u53ca\u6587\u737b\u5831\u544a\uff0c\u4e26\u672a\u63d0\u53ca\u5c0d\u6563\u4f48\u578b\u8166\u8f49\u79fb\u7684\u75c5\u60a3\u63a1\u53d6\u5168\u8166\u7167\u5c04\u5408\u4f75\u500b\u5225\u764c\u584a\u8ffd\u52a0\u7167\u5c04\u3002\u539f\u56e0\u53ef\u80fd\u5305\u62ec\u6280\u8853\u4e0a\u7684\u56f0\u96e3\uff0c\u7406\u8ad6\u4e0a\u6563\u4f48\u578b\u8166\u8f49\u79fb\u4ee3\u8868\u8457\u6975\u5dee\u7684\u9810\u5f8c\uff0c\u53ca\u8b49\u64da\u7684\u7f3a\u4e4f\u3002\u672c\u75c5\u4f8b\u5831\u544a\u5373\u5728\u5831\u5c0e\u6211\u5011\u5229\u7528\u5c0e\u822a\u87ba\u65cb\u5200\u6cbb\u7642\u4e00\u4f4d\u56e0\u6563\u4f48\u578b\u8166\u8f49\u79fb\uff0840\u500b\u4ee5\u4e0a\u7684\u764c\u584a\uff09\u63a5\u53d7\u7a4d\u6975\u8166\u90e8\u7167\u5c04\u75c5\u60a3\u7684\u7d93\u9a57\u3002\u8a72\u5973\u6027\u70ba\u975e\u5c0f\u7d30\u80de\u764c\u75c5\u60a3\uff0c\u5e74\u9f6144\u6b72\uff0c\u5728\u5316\u7642\u5f8c\u816b\u7624\u7372\u5f97\u6578\u6708\u63a7\u5236\u5f8c\uff0c\u51fa\u73fe\u816b\u7624\u60e1\u5316\u8de1\u8c61\u4e14\u4f75\u767c\u8166\u90e8\u6563\u4f48\u8f49\u79fb\u800c\u5c0e\u81f4\u8166\u58d3\u5347\u9ad8\u75c7\u72c0\u3002\u7531\u65bc\u5176\u8eab\u9ad4\u72c0\u6cc1\u5c1a\u4f73\uff0c\u6545\u63a1\u53d6\u7a4d\u6975\u8166\u90e8\u7167\u5c04\uff0c\u5180\u671b\u80fd\u7d66\u4e88\u8f03\u597d\u7684\u8166\u90e8\u63a7\u5236\uff0c\u80fd\u9806\u5229\u5b8c\u6210\u63f4\u6551\u5316\u7642\u3002\u5728\u7d93\u904e15\u5206\u6b21\u517130 Gy\u7684\u5168\u8166\u7167\u5c04\u5f8c\uff0c\u8166\u90e8\u6c34\u816b\u53ca\u795e\u7d93\u75c7\u72c0\u6709\u660e\u986f\u6539\u5584\u3002\u5168\u8166\u7167\u5c04\u5b8c\u4e09\u5468\u5f8c\u53c8\u63a5\u53d713\u5206\u6b21\u517126 Gy\uff08\u5927\u764c\u584a\uff09\u53ca20 Gy\uff08\u5c0f\u764c\u584a\uff09\u7684\u500b\u5225\u764c\u584a\u7684\u8ffd\u52a0\u7167\u5c04\u3002\u6cbb\u7642\u904e\u7a0b\u9806\u5229\u4e26\u9054\u5230\u6975\u4f73\u7684\u7de9\u89e3\u4f5c\u7528\u4e14\u672a\u9020\u6210\u660e\u986f\u526f\u4f5c\u7528\u3002\u7269\u7406\u5206\u6790\u986f\u793a\u5c0e\u822a\u87ba\u65cb\u5200\u6709\u6975\u4f73\u7684\u96a8\u5f62\u6cbb\u7642\u80fd\u529b\u53ca\u9583\u907f\u91cd\u8981\u6b63\u5e38\u5668\u5b98\u7d50\u69cb\u7684\u80fd\u529b\u3002", "e": "There is no report up to date about treating disseminated brain metastases using whole brain radiotherapy followed by individual tumor boost. Technical difficulty, expected dismal prognosis, and lack of supporting evidences are possible reasons contributing to the lack of attention paid to this matter. This report may be a first on an aggressive brain radiation for symptomatic disseminated brain metastases, more than 40 tumor foci, using tomotherapy. The patient in question is a 44 year-old lady with advanced nonsmall cell lung cancer. Symptomatic disseminated brain metastases concurrent with progression of intrapulmonary disease developed after months of remission achieved by primary chemotherapy. Because of her relative young age and good performance status, an aggressive brain radiation was performed in a hope to deliver a better intracranial control during the period of ensuing salvage chemotherapy. A whole brain radiotherapy (WBRT) of 30 Gy in 15 fractions was delivered first and achieved a good palliative effect of ameliorating her brain edema and reducing the tumor sizes. A sequential tumor boost to all observable tumor foci was delivered three weeks after WBRT to a total dose of 56 Gy for two large masses or 50 Gy for other small masses, respectively, without incurring significant toxicity. The treatment to the patient is quite successful, taking into consideration of its good palliative effects as well as low toxicity. The physic profile showed that tomotherapy is good at delivering a highly conformal therapy to targets while avoiding critical structures, e.g. eyes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-91-100-a", "title": "The Treatment Results of Unknown Primary Head and Neck Cancers without Epstein-Barr Virus Infection", "keywords": "\u982d\u9838\u90e8\u764c\u75c7;\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u764c\u75c7;Epstein-Barr\u75c5\u6bd2 Head and neck cancer;Unknown primary cancer;Epstein-Barr virus", "c": "\u76ee\u7684\uff1a\u9019\u500b\u56de\u6714\u6027\u7684\u7814\u7a76\u76ee\u7684\u5728\u65bc\u5206\u6790\u672a\u611f\u67d3Epstein-Barr\u75c5\u6bd2\u4e4b\u982d\u9838\u90e8\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u764c\u75c7\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u81ea\u897f\u51431993\u5e743\u6708\u81f32002\u5e74\u5341\u6708\u671f\u9593\uff0c\u5171\u670935\u4f4d\u982d\u9838\u90e8\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u764c\u75c7\u75c5\u4eba\u5728\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u6cbb\u7642\uff0c\u6240\u6709\u7684\u75c5\u4eba\u5747\u63a5\u53d7\u6dcb\u5df4\u7bc0\u6216\u9f3b\u54bd\u8154\u7684\u5207\u7247\uff0c\u5176\u4e2d\u670913\u4f4d\u75c5\u4eba\u56e0\u70ba\u9838\u90e8\u6dcb\u5df4\u7d50\u6216\u9f3b\u54bd\u8154\u5207\u7247\u85cf\u6709EB\u75c5\u6bd2\u800c\u88ab\u6392\u9664\u3002\u7e3d\u517122\u4f4d\u7d93\u5207\u7247\u8b49\u5be6\u672a\u611f\u67d3EB\u75c5\u6bd2\u4e4b\u982d\u9838\u90e8\u539f\u767c\u4e0d\u660e\u764c\u75c7\u75c5\u4eba\u88ab\u7d0d\u5165\u9019\u6b21\u7684\u5206\u6790\u300214 (63%)\u4f4d\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u4f75\u8853\u5f8c\u540c\u6b65\u5316\u5b78\u548c\u653e\u5c04\u7dda\u6cbb\u7642\uff087\u4f4d\uff09\u6216\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff087\u4f4d\uff09\u3002\u5176\u9918\u672a\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\u5206\u5225\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u548c\u653e\u5c04\u7dda\u6cbb\u7642\uff083\u4f4d\uff09\u3001\u653e\u5c04\u7dda\u6cbb\u7642\uff083\u4f4d\uff09\u3001\u6216\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff082\u4f4d\uff09\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7e3d\u5291\u91cf\u7bc4\u570d\u5f9e6000\u81f37280 cGy\uff0c\u7e3d\u5291\u91cf\u4e4b\u4e2d\u4f4d\u6578\u70ba6750 cGy\u3002\u6cbb\u7642\u7684\u55ae\u6b21\u5291\u91cf\u70ba180\u6216200 cGy\u4e26\u4e14\u6bcf\u500b\u79ae\u62dc\u6cbb\u76425\u5929\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u4e4b\u4e2d\u4f4d\u6578\u70ba8\u5e74\uff085-14\u5e74\uff09\u3002\u8ffd\u8e64\u671f\u9593\uff0c\u67099\u75c5\u4eba\u4ecd\u7136\u5b58\u6d3b\uff0c13\u4f4d\u6b7b\u4ea1\u30029\u4f4d\u75c5\u4eba\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u6216\u662f\u6cbb\u7642\u5f8c\u4ecd\u662f\u7121\u6cd5\u63a7\u5236\u7684\u9838\u90e8\u816b\u584a\uff0c\u53ea\u67092\u4f4d\u75c5\u4eba\u767c\u751f\u9060\u7aef\u8f49\u79fb\u30023\u5e74\u30015\u5e74\u3001\u548c8\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba50%\u300150%\u548c42%\u3002\u4ee5\u6dcb\u5df4\u7d50\u5206\u671f\u70baN1\u3001N2\u548cN3\u7684\u75c5\u4eba\u51765\u5e74\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba100%\u300144%\u548c33%\uff08P\u503c\u70ba0.019\uff09\u3002\u5728\u591a\u8b8a\u6578\u5206\u6790\u5247\u50c5\u6709\u540c\u6642\u4fb5\u72af\u4e0a\u534a\u90e8\u548c\u4e0b\u534a\u90e8\u9838\u90e8\u5728\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u30023\u5e74\u548c5\u5e74\u4e4b\u5340\u57df\u63a7\u5236\u7387\u5206\u5225\u70ba60%\u548c53%\u3002\u5728N1\u3001N2\u548cN3\u5206\u671f\u51765\u5e74\u4e4b\u5340\u57df\u63a7\u5236\u7387\u5206\u5225\u70ba100%\u300167%\u548c17%\uff08P\u503c\u70ba0.034\uff09\u3002\u5728\u591a\u8b8a\u6578\u5206\u6790\u5247\u50c5\u6709\u540c\u6642\u4fb5\u72af\u4e0a\u534a\u90e8\u548c\u4e0b\u534a\u90e8\u9838\u90e8\u5728\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u3002\u5982\u679c\u75c5\u4eba\u4e00\u958b\u59cb\u5373\u63a5\u53d7\u9838\u90e8\u64f4\u6e05\u8853\uff0c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u548c\u5340\u57df\u63a7\u5236\u7387\u5206\u5225\u70ba64.3%\u548c66.5%\u3002\u76f8\u53cd\u5730\uff0c\u5982\u679c\u4e00\u958b\u59cb\u672a\u63a5\u53d7\u624b\u8853\uff0c\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u548c\u5340\u57df\u63a7\u5236\u7387\u5206\u5225\u964d\u523025%\u548c31%\u3002\u96d6\u7136\u672a\u9054\u5230\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\uff0c\u4f46\u4ecd\u53ef\u767c\u73fe\u4e00\u958b\u59cb\u5c31\u63a5\u53d7\u624b\u8853\u7684\u75c5\u4eba\u5728\u9810\u5f8c\u6709\u8f03\u4f73\u7684\u7d50\u679c\u3002\u5728\u6dcb\u5df4\u7d50\u5206\u671fN3\u7684\u75c5\u4eba\u540c\u6a23\u53ef\u4ee5\u767c\u73fe\u8f03\u4f73\u7684\u7d50\u679c\u3002\n\u7d50\u8ad6\uff1a\u6cbb\u7642\u672a\u611f\u67d3EB\u75c5\u6bd2\u4e4b\u982d\u9838\u90e8\u539f\u767c\u4e0d\u660e\u764c\u75c7\u4e0a\uff0c\u5728\u9838\u90e8\u6dcb\u5df4\u7d50\u7684\u5340\u57df\u63a7\u5236\u662f\u6975\u5bcc\u6311\u6230\u6027\u7684\uff0c\u5728\u6211\u5011\u7684\u7814\u7a76\u4e2d\uff0c\u9019\u7fa4\u75c5\u4eba\u82e5\u4e00\u958b\u59cb\u672a\u63a5\u53d7\u9838\u90e8\u64f4\u6e05\u8853\u6216\u662f\u540c\u6642\u4fb5\u72af\u4e0a\u534a\u90e8\u548c\u4e0b\u534a\u90e8\u9838\u90e8\u5176\u9838\u90e8\u7684\u63a7\u5236\u7387\u662f\u8f03\u5dee\u7684\u3002\u6211\u5011\u5f37\u8abf\u5728\u982d\u9838\u90e8\u539f\u767c\u4e0d\u660e\u7684\u764c\u75c7\u4e0a\u9838\u90e8\u64f4\u6e05\u8853\u6709\u5176\u5fc5\u8981\u6027\uff0c\u5c24\u5176\u5728\u6c92\u6709EB\u75c5\u6bd2\u611f\u67d3\u7684\u75c5\u4eba\u3002", "e": "Purpose: This retrospective study was aimed to analyze the treatment results of unknown primary head and neck cancer without Epstein-Barr virus (EBV) infection.\nMethods and Materials: During the period between March 1993 and October 2002, 35 patients with neck lymph node metastases from unknown primary head and neck cancers were treated at the Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou. Twenty-two of them were eligible for this study, because 13 patients were proven to have EBV infection in their nasopharynx or neck lymph nodes. Fourteen (64%) received surgery and postoperative concurrent chemoradiotherapy (7 patients) or radiotherapy alone (7 patients). Others who did not receive surgery were treated by concurrent chemoradiotherapy (3 patients), radiotherapy (3 patients), or induction chemotherapy with radiotherapy (2 patients). Total prescription dose ranged from 6000 cGy to 7280 cGy with a median of 6750 cGy to Waldeyer's ring and involved neck.\nResults: The median follow-up duration was 8 years (ranged from 5 to 14 years). Nine (41%) patients were alive, and 13 (59%) patients died. Nine (41%) patients had neck recurrence, including four patients with uncontrolled neck mass enlargement. Only 2 patients developed distant metastases. The 3-year, 5-year, and 8-year overall survival were 50%, 50%, and 42%, respectively. The 5-year overall survival for N1, N2, and N3 patients were 100%, 44%, and 33% (P value=0.019), respectively. In multivariant analysis, only both upper and lower neck involvement was a significant predictor for overall survival. The 3-year and 5-year regional control rates were 60% and 53%, respectively. For N1, N2, and N3 diseases, the 5-year regional control rates were 100%, 67%, and 17% (P value=0.034), respectively. In multivariant analysis, only both upper and lower neck involvement reached statistical significance for regional control. If patients initially were treated with neck node dissection, 5-year overall survival and regional control rate were 64% and 67%, respectively. If surgery was not performed initially, 5-year overall survival and regional control rate were 25% and 31%, respectively. Although all statistics did not reach significance, we still found a trend that favor surgery initially group. Better results were also noted in N3 patients.\nConclusion: The treatment for neck nodal control of unknown primary head and neck cancer without EBV infection is challenging. In our present study, this group of patients had poor neck control if neck dissection was not performed initially or both upper and lower neck involvement. Neck dissection is suggested for patients with unknown primary head and neck cancer, especially those without EBV infection."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-101-108-a", "title": "Long-Term Outcome of Postoperative Adjuvant Radiotherapy for Thymoma", "keywords": "\u80f8\u817a\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;Masaoka\u5206\u671f\u7cfb\u7d71 Thymoma;Radiation therapy;Masaoka staging systeml", "c": "\u76ee\u7684\uff1a\u5206\u6790\u80f8\u817a\u7624\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u9577\u671f\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u9078\u64c7\u7d93\u75c5\u7406\u8b49\u5be6\u662f\u80f8\u817a\u7624\u7684\u75c5\u4eba\uff0c\u4e14\u63a5\u53d7\u5207\u9664\u624b\u8853\u53ca40 Gy\u4ee5\u4e0a\u7684\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u81ea1984\u5e7410\u6708\u81f32002\u5e748\u6708\u671f\u9593\uff0c\u672c\u9662\u764c\u75c7\u767b\u8a18\u8cc7\u6599\u5eab\u4e2d\u670938\u4f4d\u7b26\u5408\u689d\u4ef6\u3002\u6211\u5011\u56de\u9867\u4e86\u9019\u4e9b\u75c5\u4eba\u7684\u75c5\u6b77\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u7d00\u9304\u53ca\u6aa2\u67e5\u5f71\u50cf\u3002\u816b\u7624\u7684\u5206\u671f\u662f\u4f9d\u64daMasaoka\u5206\u671f\u7cfb\u7d71\u3002\u9019\u4e9b\u75c5\u4eba\u7684\u4e2d\u4f4d\u6578\u5e74\u9f61\u662f47\u6b72\uff08\u81ea22\u6b72\u523083\u6b72\uff09\uff1b\u7537\u6027\uff0f\u5973\u6027\uff1a26\u4f4d\uff0f12\u4f4d\uff1b\u7b2c\u4e00\u671f\u67094\u4f4d\uff0c\u7b2c\u4e8c\u671f\u670915\u4f4d\uff0c\u7b2c\u4e09\u671f\u670915\u4f4d\uff0c\u7b2c\u56db\u671f\u67094\u4f4d\u3002\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e3b\u8981\u662f\u524d\u5f8c\u76f8\u5c0d\u7167\u91ce\u3001\u6954\u5f62\u6ffe\u677f(wedge pair)\u6216\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\uff0c\u5291\u91cf\u4e2d\u4f4d\u6578\u662f50 Gy\uff0840\u81f368 Gy\uff09\uff0c\u4ee5\u50b3\u7d71\u5206\u6b21\u65b9\u5f0f\u7d66\u4e88\u3002\u6211\u5011\u4f7f\u7528Kaplan-Meier\u7d71\u8a08\u65b9\u5f0f\u4f86\u5206\u6790\u7e3d\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387\u53ca\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u4e2d\u4f4d\u657811\u5e74\u7684\u8ffd\u8e64\uff0c38\u4f4d\u75c5\u4eba\u4e2d\u670913\u4f4d\u75c5\u4eba\u816b\u7624\u5fa9\u767c\uff082\u4f4d\u662f\u5c40\u90e8\u5fa9\u767c\uff0c7\u4f4d\u662f\u9060\u8655\u8f49\u79fb\uff0c4\u4f4d\u662f\u5c40\u90e8\u5fa9\u767c\u5408\u4f75\u9060\u8655\u8f49\u79fb\uff09\u3002\u4e94\u5e74\u7684\u7e3d\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387\u53ca\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u5206\u5225\u662f75.5%\u300182.1%\u548c83.5%\uff1b\u5341\u5e74\u7684\u7e3d\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387\u53ca\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u5206\u5225\u662f51.2%\u300182.1%\u548c56.7%\u3002\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u816b\u7624\u5206\u671f\u548c\u624b\u8853\u5207\u9664\u7bc4\u570d\u5927\u5c0f\u662f\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u7d20\u3002\u5e74\u9f61\u3001\u6027\u5225\u3001\u653e\u5c04\u7dda\u5291\u91cf\u53ca\u662f\u5426\u5408\u4f75\u6709\u91cd\u75c7\u808c\u7121\u529b\u7b49\u56e0\u7d20\u4e26\u4e0d\u5f71\u97ff\u5b58\u6d3b\u7387\u3002\u5728\u665a\u671f\u816b\u7624\uff08\u7b2c\u4e09\u671f\u548c\u7b2c\u56db\u671f\uff09\u7684\u5341\u5e74\u7e3d\u5b58\u6d3b\u7387(24.1% vs. 89.5%, P=0.0010)\u3001\u5341\u5e74\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387(59.9% vs. 100%, P=0.0031)\u53ca\u5341\u5e74\u7121\u8f49\u79fb\u5b58\u6d3b\u7387(29.6% vs. 82.9%, P=0.0084)\u5747\u8f03\u65e9\u671f\u816b\u7624\uff08\u7b2c\u4e00\u671f\u548c\u7b2c\u4e8c\u671f\uff09\u70ba\u5dee\u3002\u6709\u5b8c\u5168\u5207\u9664\u816b\u7624\u7684\u75c5\u4eba\u7684\u5341\u5e74\u7e3d\u5b58\u6d3b\u7387(60.6% vs. 11.3%, P=0.0083)\u3001\u5341\u5e74\u5c40\u90e8\u7121\u75c5\u5b58\u6d3b\u7387(86.4% vs. 53.3%, P=0.1101)\u53ca\u5341\u5e74\u7121\u8f49\u79fb\u5b58\u6d3b\u7387(66.4% vs. 0%, P=0.0002)\u8f03\u53ea\u6709\u90e8\u4efd\u816b\u7624\u5207\u9664\u7684\u75c5\u4eba\u70ba\u4f73\u3002\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u53ea\u6709\u816b\u7624\u5206\u671f\u662f\u5f71\u97ff\u9810\u5f8c\u7684\u56e0\u7d20\u3002\n\u7d50\u8ad6\uff1a\u816b\u7624\u5206\u671f\u548c\u624b\u8853\u5207\u9664\u7bc4\u570d\u5927\u5c0f\u662f\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u7d20\u3002\u8853\u5f8c\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u65e9\u671f\u816b\u7624\u7684\u63a7\u5236\u6709\u5f88\u597d\u7684\u6548\u679c\uff0c\u4f46\u5c0d\u665a\u671f\u816b\u7624\u7684\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\u3002\u5728\u672a\u4f86\u7684\u7814\u7a76\u4e2d\uff0c\u61c9\u8a72\u8003\u616e\u5c0d\u665a\u671f\u816b\u7624\u7684\u75c5\u4eba\u8f14\u52a9\u5316\u5b78\u6cbb\u7642\u3002", "e": "Purpose: To analyze the long-term outcome of postoperative radiotherapy for thymoma.\nMaterials and Methods: Patients with pathological-proven thymoma and receiving surgical resection plus postoperative radiotherapy \ue05e40 Gy were eligible for this retrospective study. From October 1984 to August 2002, 38 eligible patients were obtained from our Cancer Registration Database. We reviewed hospital charts, radiotherapy records and diagnostic imaging studies thoroughly. Tumor staging was defined according to the Masaoka staging system. Baseline characteristics of patients were median age 47 (range 22-83), male/female=26/12, stage \u2160/\u2161/\u2162/\u2163=4/15/15/4. The radiotherapy was delivered by a wedge-pair or 3-D conformal-beam technique with a median dose of 50 Gy (range 40-68 Gy) by conventional fractionation. The end points were overall survival (OS), locoregional disease-free survival (LDFS) and metastasis-free survival (MFS) by the Kaplan-Meier method.\nResults: After a median follow-up of 11 years, 13 of 38 patients had tumor relapse (2 locoregional recurrence, 7 distant metastasis, and 4 locoregional plus distant failure). The 5-year and 10-year of OS, LDFS, and MFS for all patients were 75.5% and 51.2%, 82.1% and 82.1%, and 83.5% and 56.7%, respectively. On univariate analysis, stages and the extent of surgical resection were the most important prognostic factors. Age, gender, radiation dose, and association of myasthenia gravis did not affect the survival significantly. The 10-year OS (24.1% vs. 89.5%, P=0.0010), LDFS (59.9% vs. 100%, P=0.0031), and MFS (29.6% vs. 82.9%, P=0.0084) were significantly lower in patients with advanced-stage (\u2162+\u2163) than in those with early-stage (\u2160+\u2161). Patients with total resection had better 10-year OS (60.6% vs. 11.3%, P=0.0083), LDFS (86.4% vs. 53.3%, P=0.1101), and MFS (66.4% vs. 0%, P=0.0002) than those with subtotal resection. The multivariate analysis revealed that stage was the only significant prognostic factor.\nConclusion: Stages and the extent of surgical resection are the most important prognostic factors. Postoperative adjuvant radiotherapy has good tumor control for earlystage disease but is inadequate for advanced-stage disease. Chemotherapy should be considered for advanced-stage patients in future trials."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-109-117-a", "title": "Clinical Features and Management of Distant Metastases from Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c;\u9060\u7aef\u8f49\u79fb;\u81e8\u5e8a\u8868\u73fe Nasopharyngeal carcinoma;Distant metastasis;Clinical features", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4e3b\u8981\u5728\u63a2\u8a0e\u9f3b\u54bd\u764c\u4f75\u9060\u7aef\u8f49\u79fb\u75c5\u4eba\u4e4b\u81e8\u5e8a\u8868\u73fe\u8207\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1991\u5e743\u6708\u81f32005\u5e749\u6708\uff0c\u7e3d\u5171\u670970\u4f4d\u9f3b\u54bd\u764c\u4f75\u9060\u7aef\u8f49\u79fb\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u6cbb\u7642\uff0c\u5176\u4e2d15\u4f4d\u75c5\u4eba(76%)\u662f\u7537\u6027\uff0c17\u4f4d\u75c5\u4eba(24%)\u662f\u5973\u6027\u3002\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f50\u6b72\uff08\u7bc4\u570d\u81ea17\u81f387\u6b72\uff09\u30025\u4f4d\u75c5\u4eba(7%)\u5728\u75c5\u7406\u5831\u544a\u4e0a\u662f\u5c6c\u65bcWHO type \u2160\uff0c30\u4f4d(43%)\u662fWHO type \u2161\uff0c35\u4f4d(50%)\u662fWHO type \u2162\u3002\u4f9d\u64daAJCC 2002 \u816b\u7624\u5206\u671f\uff0c2\u4f4d\u75c5\u4eba(3%)\u662fT1\uff0c11\u4f4d(15%)\u662fT2\uff0c18\u4f4d(26%)\u662fT3\uff0c39\u4f4d(56%)\u662fT4\u30024\u4f4d\u75c5\u4eba(6%)\u662fN0\uff0c9\u4f4d(13%)\u662fN1\uff0c10\u4f4d(14%)\u662fN2\uff0c47\u4f4d(67%)\u662fN3\u3002\u670916\u4f4d\u75c5\u4eba(23%)\u5728\u5c31\u91ab\u6642\u7121\u9060\u7aef\u8f49\u79fb(M0)\uff0c\u53e6\u591654\u4f4d\u75c5\u4eba(77%)\u5247\u662f\u4e00\u958b\u59cb\u5c31\u5df2\u7d93\u6709\u9060\u7aef\u8f49\u79fb(M1)\u3002\u5728\u6240\u670970\u4f4d\u75c5\u4eba\u7576\u4e2d\uff0c\u670946\u4f4d(66%)\u63a5\u53d7\u4e86\u9f3b\u54bd\u539f\u767c\u90e8\u4f4d\u8207\u9838\u90e8\u6dcb\u5df4\u7d50\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u4e2d\u4f4d\u6578\u662f7380 cGy\u3002\u9060\u7aef\u8f49\u79fb\u7684\u90e8\u4f4d\u5305\u62ec\u9aa8\u8f49\u79fb(54%)\u3001\u809d\u81df\u8f49\u79fb(34%)\u3001\u80ba\u90e8\u8f49\u79fb(24%)\u3001\u8166\u90e8\u8f49\u79fb(6%)\uff0c\u8207\u5176\u4ed6\u90e8\u4f4d\u8f49\u79fb(6%)\u3002\u5c0d\u65bc\u8f49\u79fb\u90e8\u4f4d\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c21\u4f4d\u75c5\u4eba(30%)\u63a5\u53d7\u7de9\u89e3\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c24\u4f4d(34%)\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c5\u4f4d(7%)\u63a5\u53d7\u62ef\u6551\u6027\u624b\u8853\uff0c\u5176\u991826\u4f4d\u75c5\u4eba(37%)\u5247\u662f\u63a5\u53d7\u652f\u6301\u7642\u6cd5\u3002\n\u7d50\u679c\uff1a\u9060\u7aef\u8f49\u79fb\u4e4b\u5f8c\u7684\u5b58\u6d3b\u671f\u9593\u4e2d\u4f4d\u6578\u70ba9.4\u500b\u6708\uff08\u7bc4\u570d\u81ea1\u81f351.3\u500b\u6708\uff09\u3002\u5176\u4e2d\u67099\u4f4d\u75c5\u4eba(13%)\u5b58\u6d3b\u8d85\u904e2\u5e74\u3002\u4ee5Kaplan-Meier \u5b58\u6d3b\u5206\u6790\u4f86\u7d71\u8a08\uff0c\u5e74\u9f61\uff08p\u503c\u70ba0.0388\uff09\u8207\u9060\u7aef\u8f49\u79fb\u90e8\u4f4d\uff08p\u503c\u70ba0.0390\uff09\u70ba\u5f71\u97ff\u51fa\u73fe\u9060\u7aef\u8f49\u79fb\u5f8c\u4e4b\u5b58\u6d3b\u7387\u4e4b\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002\u75c5\u4eba\u82e5\u662f\u5e74\u9f61\u5c0f\u65bc50\u6b72\u6216\u662f\u70ba\u9aa8\u8f49\u79fb\u6216\u662f\u80ba\u90e8\u8f49\u79fb\uff0c\u5247\u6709\u8f03\u9577\u7684\u5b58\u6d3b\u6642\u9593\uff0c\u76f8\u5c0d\u7684\u82e5\u75c5\u4eba\u5e74\u9f61\u5927\u65bc50\u6b72\u6216\u662f\u70ba\u809d\u81df\u8f49\u79fb\u6216\u662f\u8166\u90e8\u8f49\u79fb\uff0c\u5247\u5b58\u6d3b\u6642\u9593\u8f03\u77ed\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u7de9\u89e3\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642\u3001\u62ef\u6551\u6027\u624b\u8853\uff0c\u6216\u662f\u652f\u6301\u7642\u6cd5\u4f86\u6cbb\u7642\u9f3b\u54bd\u764c\u4f75\u9060\u7aef\u8f49\u79fb\u7684\u75c5\u4eba\uff0c\u53ef\u4ee5\u9054\u52309.4\u500b\u6708\u7684\u5b58\u6d3b\u6642\u9593\u3002\u4ee5Kaplan-Meier\u5b58\u6d3b\u5206\u6790\u4f86\u7d71\u8a08\uff0c\u5e74\u9f61\u8207\u9060\u7aef\u8f49\u79fb\u90e8\u4f4d\u70ba\u5f71\u97ff\u51fa\u73fe\u9060\u7aef\u8f49\u79fb\u5f8c\u4e4b\u5b58\u6d3b\u7387\u4e4b\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose: To evaluate the clinical features and the results of patients of nasopharyngeal carcinoma (NPC) with distant metastases.\nMaterials and Methods: This study enrolled 70 patients of NPC development of distant metastases from March 1991 to September 2005. Fifty-three patients (76%) were male, and 17 (24%) were female. The median age of initial diagnosis as NPC was 50 years (ranged from 17 to 87 years). Five patients (7%) were WHO type \u2160 nasopharyngeal carcinoma, 30 (43%) were type \u2161, and 35 (50%) were type \u2162. According to AJCC (American Joint Committee on Cancer) 2002 TNM staging system, 2 patients (3%) were T1, 11 (15%) were T2 (4 were T2a, 7 were T2b), 18 (26%) were T3, and 39 (56%) were T4. Four patients (6%) were N0, 9 (13%) were N1, 10 (14%) were N2, and 47 (67%) were N3 (32 were N3a, 15 were N3b). Sixteen patients (23%) were initially M0, and 54 (77%) were initially M1. Forty-six of all 70 patients (66%) received radiotherapy/concurrent chemoradiotherapy to the primary sites of nasopharynx and neck lymph nodes. The median cumulative irradiation dose was 7380 cGy. The sites of initial distant metastases included bone (54%), liver (34%), lung (24%), brain (6%), and others (6%). Twenty-one patients (30%) received palliative irradiation to sites of distant metastases, 24 (34%) received chemotherapy, 5 (7%) received salvage surgery, and 26 (37%) received supportive care.\nResults: The median duration of survival after distant metastases of all patients was 9.4 months (ranged from 1 to 51.3 months). Nine patients (13%) survived for more than 2 years. In Kaplan-Meier survival evaluation, age (p=0.0388) and metastastic site (p=0.0390) were prognostic factors for survival since distant metastasis. Patients with age less than 50 years or with bone and lung metastases had longer survival, while patients with age larger than 50 years or with liver and brain metastases had shorter survival.\nConclusion: With managements of palliative irradiation, chemotherapy, salvage surgery and supportive care, the median survival was 9.4 months for patients of nasopharyngeal carcinoma developing distant metastases. Age and metastastic site were prognostic factors for survival since distant metastasis with Kaplan-Meier survival evaluation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-119-128-a", "title": "Verification of Patient Setup Error in Tomotherapy through Image Guided Radiation Therapy (IGRT) Procedure", "keywords": "\u5c0e\u822a\u87ba\u65cb\u5f0f\u5149\u5b50\u5200;\u75c5\u60a3\u5b9a\u4f4d\u8aa4\u5dee;\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642 Tomotherapy;Patient setup error;Image-guided radiation therapy IGRT", "c": "\u76ee\u7684\uff1a\u4ee5\u767e\u842c\u4f0f\u7279\u96fb\u8166\u65b7\u5c64\u6383\u63cf(MVCT)\u8a55\u4f30\u5c0e\u822a\u87ba\u65cb\u5f0f\u5149\u5b50\u5200(Tomo Therapy)\u5728\u4e0d\u540c\u6cbb\u7642\u90e8\u4f4d\u7684\u9593\u6b21\u5b9a\u4f4d\u8aa4\u5dee\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u53d6\u6a23\u81ea13\u540d\u9032\u884c\u5c0e\u822a\u87ba\u65cb\u5f0f\u5149\u5b50\u5200\u6cbb\u7642\u7684\u75c5\u4eba\u3002\u5176\u4e2d\u5206\u52257\u4f4d\u662f\u982d\u9838\u90e8\u816b\u7624\uff0c3\u4f4d\u60a3\u90e8\u4f4d\u65bc\u80f8\u8154\u90e8\uff0c\u5176\u4ed63\u4f4d\u5247\u662f\u9aa8\u76c6\u8154\u90e8\u3002\u7368\u7acb\u5206\u6790\u9019\u4e09\u7d44\u75c5\u4eba\u8cc7\u6599\u3002\u4ee5\u6bcf\u65e5\u7684MVCT\u5f71\u50cf\u8207\u521d\u59cb\u4e09\u7dad\u6a21\u64ec\u7684KVCT\u5f71\u50cf\u505a\u6bd4\u8f03\uff0c\u4ee5\u8a55\u4f30\u9593\u6b21\u5b9a\u4f4d\u8aa4\u5dee\u3002\u4ee5\u81ea\u52d5\u8207\u624b\u52d5\u5169\u7a2e\u65b9\u5f0f\u5224\u8b80\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a208\u500b\u982d\u9838\u90e8\u55ae\u65e5MVCT\u6aa2\u6e2c\u503c\uff1a\u5e73\u5747\u8b8a\u4f4d\u6a6b\u5411\u70ba0.3\u00b12.3 mm\uff0c\u7e31\u5411\u70ba0.0\u00b12.6 mm\uff0c\u5782\u76f4\u5411\u70ba2.3\u00b11.8 mm\uff0c\u7e31\u8ef8\u8f49\u52d5\u5e73\u5747\u70ba0.6\u00b10.9 \u5ea6\uff1b80\u500b\u80f8\u8154\u90e8\u55ae\u65e5MVCT\u6aa2\u6e2c\u503c\uff1a\u5e73\u5747\u8b8a\u4f4d\u6a6b\u5411\u70ba-0.4\u00b12.4 mm\uff0c\u7e31\u5411\u70ba-2.6\u00b12.9 mm\uff0c\u5782\u76f4\u5411\u70ba2.5\u00b13.9 mm\uff0c\u7e31\u8ef8\u8f49\u52d5\u5e73\u5747\u70ba0.4\u00b10.5 \u5ea6\uff1b76\u500b\u9aa8\u76c6\u8154\u90e8\u55ae\u65e5MVCT\u6aa2\u6e2c\u5e73\u5747\u503c\uff1a\u8b8a\u4f4d\u6a6b\u5411\u70ba0.3\u00b13.9 mm\uff0c\u7e31\u5411\u70ba-2.4\u00b14.8 mm\uff0c\u5782\u76f4\u5411\u70ba8.3\u00b14.3 mm\uff0c\u7e31\u8ef8\u8f49\u52d5\u5e73\u5747\u70ba0.4\u00b10.3\u5ea6\u3002\u9664\u4e86\uff5a\u65b9\u5411\u4e4b\u5916\uff0c\u8b8a\u4f4d\u7684\u6a21\u5f0f\u5747\u70ba\u96a8\u6a5f\u5206\u5e03\u3002\n\u7d50\u8ad6\uff1a\u9664\u4e86\u9aa8\u76c6\u8154\u90e8\u4f4d\u816b\u7624\u7d44\uff5a\u65b9\u5411\u5916\uff0c\u5206\u6790\u5728\u4e0d\u540c\u90e8\u4f4d\u8207\u5404\u65b9\u5411\u7684\u6578\u64da\uff0c\u81ea\u52d5\u8207\u624b\u52d5\u65b9\u6cd5\u7121\u986f\u8457\u5dee\u7570\u3002", "e": "Purpose: To evaluate the interfraction setup errors in different treatment sites with Tomotherapy by mega-voltage computerized tomography (MVCT).\nMaterials and Methods: This study included 13 patients underwent radiotherapy with Tomotherapy. There were 7, 3 and 3 patients belonged to head and neck cancer, thoracic and pelvis cancer, respectively. These three subgroups were analyzed separately. The interfraction setup errors were evaluated by comparing daily series MVCT with initial simulation KVCT three dimensionally. Both automatic and manual methods were used for determination of these errors.\nResults: For 208 daily MVCT check-up for head and neck tumor, average shift was 0.3\u00b12.3 mm for lateral direction (x), 0.0\u00b12.6 mm for longitudinal direction (y), 2.3\u00b11.8 mm for vertical direction (z), and 0.6\u00b10.9 degree for longitudinal axis (roll) rotation. For 80 daily MVCT check-up for thoracic tumor, average shift was -0.4\u00b12.4 mm for x direction, -2.6\u00b12.9 mm for y-direction, 2.5\u00b13.9 mm for z-direction, and 0.4\u00b10.5 degree for roll axis rotation. For 76 daily MVCT check-up for pelvic tumor, average shift was 0.3\u00b13.9 mm for x direction, -2.4\u00b14.8 mm for y-direction, 8.3\u00b14.3 mm for z-direction, and 0.4\u00b10.3 degree for roll axis rotation. The pattern of shifts showed a random distribution except z direction.\nConclusion: Except from z-direction of pelvic tumor, there was no significant difference between automatic and manual methods among different treatment sites and different direction errors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-129-137-a", "title": "\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ec\u65bc\u81e8\u5e8a\u96fb\u5b50\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u96fb\u5b50\u5c04\u6e90\u9805\u53c3\u6578\u7814\u7a76", "keywords": "\u8499\u5730\u5361\u7f85\u6a21\u64ec;\u5291\u91cf\u8a08\u7b97;OMEGA/BEAM\u7a0b\u5f0f Monte Carlo simulation;Dose calculation;OMEGA/BEAM", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u70ba\u5229\u7528\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ec\u76f4\u7dda\u52a0\u901f\u5668\u6a5f\u982d\uff0c\u4e26\u627e\u51fa\u9069\u7528\u65bcVarian Clinac 21EX 6 MV\u76f4\u7dda\u52a0\u901f\u5668\u6a5f\u982d\u4e4b\u6700\u4f73\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u53c3\u6578\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5229\u7528OMEGA/BEAM\u7a0b\u5f0f\u5c07\u5df1\u77e5\u7684\u8a73\u7d30\u52a0\u901f\u5668\u6a5f\u982d\u5e7e\u4f55\u53c3\u6578\u642d\u914d\u4e0a\u4e0d\u540c\u7684\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u8207\u5176\u5c04\u675f\u5bec\u5ea6\u6a21\u64ecVarian Clinac 21EX 6 MV\u76f4\u7dda\u52a0\u901f\u5668\u6a5f\u982d\uff0c\u4e26\u52a0\u4ee5\u5206\u6790\u5176\u7522\u751f\u4e4b\u5149\u5b50\u5c04\u675f\u5291\u91cf\u5206\u4f48\uff0c\u6700\u5f8c\u8a02\u5b9a\u4e00\u5957\u6700\u4f73\u5316\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u53c3\u6578\u4e4b\u627e\u5c0b\u65b9\u6cd5\u3002\n\u7d50\u679c\uff1a\u5229\u7528\u6700\u4f73\u5316\u4e4b\u96fb\u5b50\u5c04\u675f\u53c3\u6578\uff0c\u8a08\u7b97\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u8207\u5f91\u5411\u5291\u91cf\u5206\u4f48\uff0c\u4e26\u8207\u5be6\u6e2c\u503c\u9032\u884c\u6bd4\u8f03\uff0c\u5176\u767e\u5206\u8aa4\u5dee\u7d04\u5c0f\u65bc2%\uff1b\u5176\u4e2d\uff0c\u65bc\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u65b9\u9762\uff0c\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u5f71\u97ff\u8f03\u5927\uff1b\u800c\u65bc\u5f91\u5411\u5291\u91cf\u5206\u4f48\u65b9\u9762\uff0c\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u8207\u5165\u5c04\u96fb\u5b50\u5c04\u675f\u5bec\u5ea6\u7686\u6709\u5f71\u97ff\u3002\n\u7d50\u8ad6\uff1aOMEGA/BEAM\u7a0b\u5f0f\u6210\u529f\u5efa\u69cb\u51fa\u9069\u7528\u65bcVarian Clinac 21EX\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7cfb\u7d71\u3002\u5229\u7528\u672c\u7814\u7a76\u8a02\u5b9a\u4e4b\u6700\u4f73\u5316\u96fb\u5b50\u53c3\u6578\u627e\u5c0b\u65b9\u6cd5\uff0c\u53ef\u7bc0\u7701\u5927\u91cf\u7684\u53c3\u6578\u6e2c\u8a66\u6642\u9593\u3002", "e": "Purpose: The parameters of electron source term used in Monte Carlo simulation for Varian 21EX 6 MV linac were optimized in this study.\nMaterials and Methods: The detailed geometry of linac head and the parameters of electron source term, i.e., energy and intensity distribution (spot size), were used to simulate the beam output for the Varian 21EX 6 MV photon mode. Calculation results of dose distributions were analyzed to optimize the parameters of electron source term.\nResults: With the optimum parameters for electron source term, less than 2% discrepancies between the measured and calculated results for both PDDs and dose profiles were observed. The PDDs were mostly affected by the incident electron beam energy, while the dose profiles were affected by both the energy and spot size of the incident electron beam.\nConclusion: The OMEGA/BEAM Monte Carlo code was used to calculate the dose distributions for Varian 21EX 6 MV linac. A method was described in this study to optimize the parameters of the electron source term."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-139-147-a", "title": "\u5feb\u901f\u6210\u578b\u6280\u8853\u76f4\u63a5\u88fd\u4f5c\u653e\u5c04\u6cbb\u7642\u586b\u5145\u7269\u4e4b\u6548\u80fd\u8a55\u4f30", "keywords": "\u4eba\u9ad43D\u91cf\u6e2c\u7cfb\u7d71;\u5feb\u901f\u6210\u578b;\u586b\u5145\u7269;\u653e\u5c04\u6cbb\u7642 3D Anthropometric phantom study;Rapid prototyping;Bolus;Radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4fc2\u63a2\u8a0e\u65bc\u4eba\u9ad4\u8868\u9762\u9032\u884c\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u88fd\u4f5c\u5b8c\u5168\u8cbc\u9644\u4eba\u9ad43D\u9069\u5f62\u586b\u5145\u7269\u4e4b\u751f\u6210\u6a21\u7d44\u3002\u5176\u4fc2\u6574\u5408\u9006\u5411\u5de5\u7a0b(Reverse Engineering)\u8207\u4eba\u9ad4\u6578\u4f4d\u6a21\u578b\u7cfb\u7d71\u4e4b3D\u53d6\u50cf\u53ca\u6210\u5f62\u6280\u8853\uff0c\u4f7f\u7528\u5169\u7a2e\u5feb\u901f\u6210\u578b\u6a5f(Rapid Prototyping)\u88fd\u4f5c\u5bc6\u5ea6\u4e0d\u540c\u4e4b\u6750\u6599\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528\u5851\u81a0\u7c89\u672b(PVC)\u81a0\u5408\u53ca\u6db2\u614b\u6a39\u8102(ABS)\u71d2\u7d50\u6210\u578b\u586b\u5145\u7269\uff0c\u4ee5\u7b26\u5408\u500b\u6848\u4e4b\u4eba\u9ad43D\u9069\u5f62\u586b\u5145\u7269(bolus)\u5be6\u9ad4\u3002\u7d50\u679c\uff1a\u672c\u7814\u7a76\u4e4b3D\u9069\u5f62\u586b\u5145\u7269\u53ef\u5b8c\u5168\u8cbc\u9644\u4eba\u9ad4\uff0c\u53ef\u6709\u6548\u6539\u8b8a\u653e\u5c04\u5291\u91cf\u6df1\u5ea6\uff0c\u9032\u800c\u4f7f\u76ae\u819a\u5291\u91cf\u9054\u5230\u8655\u65b9\u5291\u91cf\u3002\n\u7d50\u8ad6\uff1a\u8a723D\u9069\u5f62\u586b\u5145\u7269\u4e4b\u88fd\u7a0b\u7d93\u672c\u7814\u7a76\u4e4b\u57f7\u884c\u53ca\u9a57\u8b49\uff0c\u53ef\u4ee5\u6a19\u6e96\u4f5c\u696d\u7a0b\u5e8f\u751f\u6210\u6a21\u7d44\uff0c\u751f\u6210\u6700\u4f73\u5316\u4e4b3D\u9069\u5f62\u586b\u5145\u7269\u5be6\u9ad4\uff0c\u5e0c\u671b\u5728\u672a\u4f86\u80fd\u63d0\u4f9b\u653e\u5c04\u6cbb\u7642\u8f14\u52a9\u5668\u6750\u53e6\u4e00\u7a2e\u9078\u64c7\u3002", "e": "Purpose: This study shown the 3D total contact bolus of human body can effectively improve the radiation dose of the skin surface during radiotherapy.\nMaterial and Methods: When the 3D total contact bolus of human body be produced, we integrated 3D image and reverse engineering technology to a 3D Anthropometric Phantom Study, and used rapid prototyping technique to produce a 3D total contact bolus entity to the human body.\nResults: We have selected two materials in order to test which one is better for skin dose coverage. According to our study, 3D total contact bolus made by ABS (ACRYLONITRILE-BUTADIENE-STYRENE) can get the correct prescribed dose on skin surface.\nConclusion: The manufacture process of 3D total contact bolus of human body can be an optimized standard operating procedure and it will be a useful tool for radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-149-159-a", "title": "The Efficacy of Radiation Therapy for Keloid and Hypertrrophic Scar: The Experience of Nine Cases", "keywords": "\u7622\u7624;\u80a5\u539a\u75a4\u75d5;\u653e\u5c04\u6cbb\u7642 Keloid;Hypertrophic scar;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5831\u544a\u4e00\u5bb6\u6559\u5b78\u91ab\u9662\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u8853\u5f8c\u7622\u7624\u7684\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u6536\u96c6\u81ea1999\u52302003\u5e74\u5728\u672c\u9662\u57f7\u884c\u7622\u7624\u6216\u80a5\u539a\u75a4\u75d5\u60a3\u8005\u5728\u8853\u5f8c\u9032\u884c\u653e\u7642\u7684\u7d50\u679c\uff0c\u4e26\u5206\u6790\u7576\u4e2d\u53ef\u80fd\u7684\u56e0\u7d20\u3002\n\u7d50\u679c\uff1a\u9019\u6bb5\u671f\u9593\u5171\u6709\u4e5d\u500b\u60a3\u8005\u7684\u6cbb\u7642\u88ab\u89c0\u5bdf\uff0c\u5176\u4e2d\u4e00\u4f4d\u7537\u6027\uff0c\u516b\u4f4d\u5973\u6027\u3002\u4e94\u4f4d\u5c0d\u5176\u7d50\u679c\u611f\u5230\u6eff\u610f\uff0c\u4e8c\u4f4d\u9084\u53ef\u4ee5\uff0c\u4e8c\u4f4d\u611f\u5230\u5931\u671b\u3002\u611f\u5230\u5931\u671b\u7684\u60a3\u8005\u4e2d\uff0c\u4e00\u4f4d\u7684\u7622\u7624\u9577\u6210\u816b\u584a\u72c0\uff0c\u53e6\u4e00\u4f4d\u958b\u5200\u904e\u4e8617\u5929\u624d\u4f86\u653e\u7642\u3002\u611f\u5230\u6eff\u610f\u7684\u60a3\u8005\u4e2d\uff0c\u4e00\u4f4d\u958b\u5200\u904e\u4e866\u5929\u624d\u4f86\u653e\u7642\uff0c\u5176\u4ed6\u5247\u958b\u904e\u52002\u5929\u5167\u5c31\u958b\u59cb\u653e\u7642\u3002\u7e3d\u5171\u4e5d\u500b\u60a3\u8005\u4e2d\uff0c8\u4f4d\u63a5\u53d7\u4e8615 Gy\uff0c\u5206\u4e94\u6b21\u7167\u5c04\u5b8c\u7562\uff1b\u53e6\u4e00\u4f4d\u63a5\u53d7\u4e8612 Gy\uff0c\u5206\u56db\u6b21\u7167\u5c04\u5b8c\u7562\u3002\u7814\u7a76\u671f\u9593\u6c92\u6709\u770b\u5230\u6b21\u767c\u6027\u60e1\u6027\u816b\u7624\u662f\u56e0\u70ba\u653e\u7642\u5f15\u8d77\u7684\u3002\u7d93\u904e\u5206\u6790\u6240\u6709\u7684\u8b8a\u6578\u4e4b\u5f8c\u767c\u73fe\u521d\u59cb\u75c7\u72c0\u6709\u919c\u578b\u554f\u984c\u8005\u548c\u6cbb\u7642\u6eff\u610f\u5ea6\u6709\u76f8\u95dc\uff0c\u4f46\u6c92\u6709\u4e00\u500b\u8b8a\u6578\u548c\u9810\u5f8c\u7d50\u679c\u6709\u95dc\u3002\n\u7d50\u8ad6\uff1a\u5291\u91cf\u572812\u523015 Gy\u9593\uff0c\u52064\u52305\u6b21\u7167\u5c04\uff0c\u5c0d\u7622\u7624\u6216\u80a5\u539a\u75a4\u75d5\u7684\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u662f\u9069\u5b9c\u7684\u3002\u8853\u5f8c\u61c9\u57282-3\u5929\u5167\u5373\u958b\u59cb\u653e\u7642\u3002\u5c31\u7b97\u5728\u6b64\u689d\u4ef6\u4e0b\u653e\u7642\uff0c\u6cbb\u7642\u53cd\u61c9\u4ecd\u53ef\u80fd\u4e0d\u4f73\uff0c\u5c24\u5176\u662f\u5df2\u7d93\u9577\u6210\u816b\u584a\u72c0\u7684\u7622\u7624\u3002", "e": "Purpose: To report the experience of postoperative radiation therapy (RT) for keloid at a teaching hospital.\nMaterial and Methods: We recruited patients with keloid or hypertrophic scar lesions who received excision and postoperative RT from 1999 to 2003 at a teaching hospital. We use 6 MeV electron beam covered with 0.5-1 cm Superflap as bolus to enhance skin dose, and the electron beam margin was designed as 0.5 to 1 cm from re-operative suture line area. All of them were treated with 15 Gy of RT in five fractions in consecutive days, except one who had problems in scheduling the last treatment and received 12 Gy in four fractions. We summarized information on their outcomes and evaluated the possible prognostic factors.\nResults: A total of nine patients were observed during the study period, including one man and eight women. Five of them were satisfied with their outcomes, two had fair outcome, and two felt disappointed. Of the two disappointed patients, one had a gross keloid, and the other had an elapsed time of 17 days between excision and radiation. One of the patients with satisfactory outcome, however, had an elapsed time of 6 days. All the other six patients who had satisfactory or fair outcomes started RT within 2 days after surgery. Eight patients received 15 Gy in five fractions, and one received 12 Gy in four fractions. No second malignancy was observed during the study period. Among all variables evaluated, ugly as the initial symptom was the only significant factor associated with satisfaction, but none was associated with the outcome.\nConclusion: The dose-fractions between 12 and 15 Gy in four or five fractions are feasible in postoperative RT for keloid or hypertrophic scar. Starting the RT within 2 to 3 days should be suggested after excision. Unsatisfactory response is still possible under this timing and dose-fractions, especially for gross lesions."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200806-15-2-161-166-a", "title": "Early-Stage Esophageal Squamous Cell Carcinoma Adjacent to Cirrhosis-Related Varices: A Case Report", "keywords": "\u98df\u9053\u975c\u8108\u66f2\u5f35;\u98df\u9053\u764c;\u653e\u5c04\u6cbb\u7642 Esophageal varices;Esophageal cancer;Radiotherapy", "c": "\u6587\u737b\u5831\u544a\u4e0a\u95dc\u65bc\u672a\u7d93\u6cbb\u7642\u4e4b\u98df\u9053\u975c\u8108\u66f2\u5f35\u5408\u4f75\u5df2\u5b58\u5728\u4e4b\u98df\u9053\u764c\u7684\u7d00\u9304\u76f8\u7576\u5c11\u3002\u5927\u90e8\u5206\u7684\u5831\u544a\u591a\u4ee5\u63a2\u8a0e\u7d93\u5167\u8996\u93e1\u6ce8\u5c04\u786c\u5316\u5291\u7642\u6cd5\u662f\u5426\u5c0e\u81f4\u5f8c\u7e8c\u7684\u98df\u9053\u764c\u70ba\u4e3b\u984c\u3002\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u98df\u9053\u764c\u662f\u5426\u6703\u5f15\u8d77\u7167\u91ce\u5167\u7684\u98df\u9053\u975c\u8108\u66f2\u5f35\u4e4b\u7d50\u69cb\u8b8a\u5316\u800c\u9020\u6210\u5927\u91cf\u51fa\u8840\u7684\u8a0e\u8ad6\u4e5f\u9bae\u5c11\u88ab\u63d0\u53ca\u3002\u6211\u5011\u5728\u6b64\u5831\u544a\u4e00\u4f4d\u5728\u505a\u5167\u8996\u93e1\u5c0b\u627e\u4e0a\u6d88\u5316\u9053\u51fa\u8840\u539f\u56e0\u6642\uff0c\u610f\u5916\u767c\u73fe\u8868\u6dfa\u98df\u9053\u764c\u53ca\u9130\u8fd1\u4e4b\u98df\u9053\u975c\u8108\u66f2\u5f35\u7684\u75c5\u4eba\u3002\u6839\u64da\u6211\u5011\u6240\u6574\u7406\u7684\u6587\u737b\uff0c\u98df\u9053\u764c\u53ca\u98df\u9053\u975c\u8108\u66f2\u5f35\u53ef\u5206\u958b\u6cbb\u7642\u800c\u4e0d\u81f4\u76f8\u4e92\u5f71\u97ff\u3002\u6587\u4e2d\u4e26\u4ecb\u7d39\u591a\u7a2e\u5c0d\u8868\u6dfa\u98df\u9053\u764c\u53ca\u98df\u9053\u975c\u8108\u66f2\u5f35\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u9019\u4f4d\u75c5\u4eba\u5728\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u524d\u5148\u63a5\u53d7\u98df\u9053\u975c\u8108\u66f2\u5f35\u7684\u74b0\u5957\u7d50\u7d2e\u3002\u4ed6\u9806\u5229\u5b8c\u6210\u7642\u7a0b\u5f8c\uff0c\u8ffd\u8e64\u81f3\u4eca\u672a\u6709\u98df\u9053\u764c\u5fa9\u767c\u53ca\u6cbb\u7642\u6240\u5f15\u8d77\u7684\u5408\u4f75\u75c7\u3002", "e": "The presence of cirrhosis-related esophageal varices combined with pre-existed esophageal cancer is rarely documented. Most studies concerned about the possibility that endoscopic injection sclerotherapy (EIS) induces a secondary esophageal cancer. Whether radiotherapy complicates varices bleeding or rupture is seldom mentioned. We present a case of early esophageal cancer accidentally found by panendoscope (PES) for upper gastrointestinal bleeding survey. The tumor was adjacent to one of the esophageal varices. According to the case reports we summarized, varices and the esophageal cancer can be managed separately. Varices can be treated by ligation, sclerotherapy, or photodynamic therapy (PDT). The early esophageal cancer can be treated by PDT, endoscopic resection, radiotherapy, or esophagectomy. In this case, varices ligation was performed prior to radiotherapy. The treatment course finished smoothly. He had kept regular follow-up at our OPD"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-1-8-a", "title": "Prognostic Factors of Local-Regional Recurrence after Breast-Conserving Surgery and Radiation Therapy With/Without Chemotherapy for Early Breast Cancer", "keywords": "\u521d\u671f\u4e73\u764c;\u4e73\u623f\u4fdd\u7559\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642;\u5c40\u90e8\u5fa9\u767c Early breast cancer;Breast-conserving therapy;Radiotherapy;Local-regional recurrence", "c": "\u76ee\u7684\uff1a\u672c\u56de\u6eaf\u6027\u7814\u7a76\u7684\u76ee\u7684\u5728\u65bc\u5831\u544a\u672c\u9662\u521d\u671f\u4e73\u764c\u75c5\u4eba\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u6cbb\u7642\u4e4b\u6210\u679c\uff0c\u4e26\u5206\u6790\u75be\u75c5\u5fa9\u767c\u4e4b\u5371\u96aa\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u9662\u65bc1990\u5e74\u81f32002\u5e74\u9593\u5171\u6709374\u4f4d\u521d\u671f\u4e73\u764c\u75c5\u4eba\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d285\u4f4d(76%)\u4e4b\u5c40\u90e8\u671f\u5225\u70baT\u300189\u4f4d(24%)\u70baT2\uff0c\u670987\u4f4d\u75c5\u4eba(23%)\u540c\u6642\u6709\u814b\u4e0b\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u63a5\u53d7\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\u670928\u4f4d(75%)\u3002\u653e\u5c04\u6cbb\u7642\u7684\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba\u60a3\u5074\u5168\u4e73\u623f\u7d66\u4e8846\u845b\u96f7\u4e4b\u5f8c\u518d\u7d66\u4e88\u5c40\u90e8\u52a0\u5f376\u845b\u96f7\u3002\u5b58\u6d3b\u7387\u7684\u66f2\u7dda\u662f\u4ee5Kaplan-Miere\u65b9\u6cd5\u7e6a\u88fd\uff0c\u540c\u6642\u4ee5Chi-square\u6216Fisher's exact test\u627e\u5c0b\u53ef\u80fd\u7684\u5371\u96aa\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u5728\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u70ba4.2\u5e74\u7684\u60c5\u6cc1\u4e0b\u7e3d\u5171\u67096\u4f4d\u75c5\u4eba\u767c\u751f\u4e86\u5c40\u90e8\u5fa9\u767c(\u5176\u4e2d11\u4f4d\u50c5\u6709\u540c\u5074\u4e73\u623f\u6216\u6dcb\u5df4\u7d50\u5c40\u90e8\u5fa9\u767c\uff0c5\u4f4d\u65bc\u78ba\u8a8d\u5fa9\u767c\u6642\u5408\u4f75\u6709\u9060\u7aef\u8f49\u79fb)\uff1b5\u5e74\u7684\u7121\u75c5\u5b58\u6d3b\u7387\u70ba87.9%\uff0c\u7121\u5c40\u90e8\u5fa9\u767c\u7387\u70ba95%\u3002\u5c40\u90e8\u5fa9\u767c\u7684\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u4e86\uff1a\u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\u6b72\u3001multifocal or multicentric disease\uff08\u591a\u767c\u6027\uff09\u4ee5\u53capositive or close surgical margin\uff08\u624b\u8853\u4e7e\u6de8\u908a\u7de3\u4e0d\u8db3\uff09\u3002\u6240\u670910\u4f4d\u50c5\u6709\u60a3\u5074\u4e73\u623f\u5c40\u90e8\u5fa9\u767c\u7684\u75c5\u4eba\u5728\u63a5\u53d7\u4e86\u4e73\u623f\u6839\u9664\u624b\u8853\u5f8c\u65bc\u6301\u7e8c\u8ffd\u8e64\u4e2d\u5747\u70ba\u7121\u75c5\u5b58\u6d3b\u7684\u72c0\u614b\uff08\u8ffd\u8e64\u6642\u95939~34\u500b\u6708\uff0c\u4e2d\u4f4d\u657860\u500b\u6708\uff09\u3002\n\u7d50\u8ad6\uff1a\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u80fd\u5920\u63d0\u4f9b\u521d\u671f\u4e73\u764c\u75c5\u4eba\u5408\u7406\u7684\u6cbb\u7642\u7d50\u679c\uff0c\u4f46\u662f\u5c0d\u65bc\u75be\u75c5\u5c40\u90e8\u5fa9\u767c\u7684\u9ad8\u5371\u96aa\u7fa4\uff08\u5982\uff1a\u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\u6b72\u3001\u591a\u767c\u6027\u4ee5\u53ca\u624b\u8853\u4e7e\u6de8\u908a\u7de3\u4e0d\u8db3\uff09\u75c5\u4eba\u61c9\u7d66\u4e88\u66f4\u70ba\u5bc6\u96c6\u5730\u8ffd\u8e64\u3002", "e": "Purpose: This retrospective study is to report the results of breast-conserving treatment and analyze the prognostic factors of local-regional recurrence (LRR) of early breast cancer in a single institute.\nMaterials and Methods: Between 1990 and 2002, 374 women of non-metastatic invasive breast cancer received breast-conserving surgery followed by post-operative radiotherapy (RT) with or without chemotherapy at the Koo Foundation Sun Yat-Sen Cancer Center. Of the 374 patients, 285 (76%) had pathologic Ti disease and 89 (24%) T2 disease. Eighty-seven (23%) patients were found to have pathologic involvement of axillary lymph nodes. Two hundred and eighty-one patients (75%) have received adjuvant chemotherapy. The median dose of RT was 46 Gy in 23 fractions to the breast with/without supraclavicular area and internal mammary chain followed by tumor bed boost of 16 Gy. The medical records including pathologic reports were reviewed for analysis of tumor recurrence.\nResults: There were 16 local and/or regional recurrences (11 LRR only; 5 LRR with distant metastasis) after a median follow-up of 4.2 years. The 5-year disease-free, LRR-free and overall survivals were 87.9%, 95% and 94.1% respectively. The risk factors of LRR include age equal to or less than 40 years old, multifocal or multicentric disease, and positive or close surgical margin. All 10 patients with ipsilateral breast tumor recurrence only were still alive without disease after salvage simple mastectomy (range, 9~134 months; median 60 months).\nConclusion: Breast-conserving surgery followed by RT provided excellent local-regional control for early breast cancer. Patients with risk factors of young age, close/positive margin, and multifocal/multicentric disease need to be followed closely."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-9-19-a", "title": "Acute Toxicity of Locally Advanced Pancreatic Carcinoma Treated with Intensity-Modulated Radiotherapy-A Preliminary Report", "keywords": "\u80f0\u81df\u764c;\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642;\u6025\u6027\u526f\u4f5c\u7528 Pancreatic carcinoma;Intensity-modulated radiotherapy;Acute toxicity", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u5728\u8a55\u4f30\u4ee5\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u6cbb\u7642\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u6240\u5f15\u8d77\u4e4b\u8178\u80c3\u3001\u8840\u6db2\u6027\u6025\u6027\u526f\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2001\u5e741\u6708\u81f32005\u5e7412\u6708\u6b62\uff0c\u4e00\u5171\u6709\u4e5d\u4f4d\u7f79\u60a3\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3002\u5176\u4e2d\u6709\u4e94\u4f4d\u5728\u653e\u5c04\u6cbb\u7642\u671f\u9593\u5408\u4f75\u4f7f\u7528\u5316\u5b78\u6cbb\u7642\u3002\u6709\u4e00\u4f4d\u75c5\u4eba\u5728\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\u524d\u5148\u63a5\u53d7\u4e86Whipple\u624b\u8853\uff0c\u9084\u6709\u4e00\u4f4d\u75c5\u4eba\u5728\u6cbb\u7642\u524d\u5148\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\u4e5d\u4f4d\u75c5\u4eba\u4e2d\u6709\u516b\u4f4d\u7f79\u60a3\u7121\u6cd5\u4ee5\u624b\u8853\u5b8c\u5168\u6e05\u9664\u4e4b\u5c40\u90e8\u4fb5\u72af\u6027\u816b\u7624\uff0c\u6709\u4e00\u4f4d\u5247\u662f\u63a5\u53d7\u904e\u624b\u8853\u5207\u9664\u5f8c\u5fa9\u767c\u3002\u56db\u4f4d\u60a3\u8005\u5728\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u524d\u5148\u63a5\u53d7\u4e86\u5c40\u90e8\u50b3\u7d713D\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5269\u4e0b\u7684\u4e94\u4f4d\u5247\u662f\u63a5\u53d7\u5b8c\u6574\u7684\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u4e5d\u4f4d\u75c5\u4eba\u4e2d\uff0c2\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u662f33.3%\uff0c\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u70ba53%\u3002\u4e5d\u4f4d\u75c5\u4eba\u4e2d\u6709\u4e00\u4f4d\u9054\u5230\u5b8c\u5168\u63a7\u5236(complete response)\uff0c\u4e94\u4f4d\u9054\u5230\u90e8\u5206\u63a7\u5236(partial response)\u800c\u6709\u4e09\u4f4d\u7684\u75be\u75c5\u6301\u7e8c\u9032\u5c55(progressive disease)\u3002\u4e5d\u4f4d\u75c5\u4eba\u4e2d\u53ea\u6709\u4e00\u4f4d\u767c\u751f\u7b2c\u4e09\u7d1a\u7684\u6025\u6027\u8178\u80c3\u9053\u526f\u4f5c\u7528\uff1b\u6709\u4e09\u4f4d\u540c\u6642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\u767c\u751f\u4e86\u7b2c\u4e09\u7d1a\u7684\u6025\u6027\u8840\u6db2\u6027\u526f\u4f5c\u7528\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u6210\u529f\u7684\u5b8c\u6210\u4e86\u6cbb\u7642\uff0c\u6c92\u6709\u9700\u8981\u9f3b\u80c3\u7ba1\u7f6e\u5165\u9032\u884c\u71df\u990a\u88dc\u5145\u7684\u75c5\u4eba\u3002\u6709\u56db\u4f4d\u75c5\u4eba\u767c\u751f\u6cbb\u7642\u4e2d\u65b7\u7684\u60c5\u5f62\uff0c\u5e73\u5747\u6cbb\u7642\u4e2d\u65b7\u5929\u6578\u70ba14.5\u5929\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u6216\u672a\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u6cbb\u7642\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u7684\u75c5\u4eba\uff0c\u6240\u89c0\u5bdf\u5230\u7684\u6025\u6027\u8178\u80c3\u6027\u53ca\u8840\u6db2\u6027\u526f\u4f5c\u7528\u4e26\u4e0d\u9ad8\u3002\u9019\u500b\u521d\u6b65\u5831\u544a\u986f\u793a\u5c0d\u65bc\u5c40\u90e8\u4fb5\u72af\u6027\u80f0\u81df\u764c\u7684\u75c5\u4eba\uff0c\u6b64\u4e00\u65b0\u5f0f\u6cbb\u7642\u662f\u53ef\u63a5\u53d7\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: To evaluate the gastrointestinal and hematological toxicity of locally advanced pancreatic carcinoma treated mainly with intensity-modulated radiotherapy (IMRT).\nMaterials and Methods: A total of 9 locally advanced pancreatic carcinoma were treated with IMRT between June 2001 and December 2005. Five received concurrent chemotherapy. One patient received Whipple surgery before local irradiation, and one received chemotherapy prior to local irradiation. One presented with distant bone metastasis prior to radiation therapy. Eight out of nine patients had unresect-able primary and one had recurrent tumor. Four out of nine underwent treatment planning with conventional three-dimensional radiotherapy boost plus IMRT while others received solely IMRT.\nResults: The 2-year expected overall survival was 33.3%. The local regional control rate was 53%. One out of 9 patients achieved complete response, 5 achieved partial response and 3 remained progressive disease. One out of 9 patients developed Grade 3 gastrointestinal toxicity. Three developed Grade 3 hematological toxicity, all with concurrent gemcitabine. No nasal-gastric tube support was needed among all patients. Interruption of treatment was noted within 4 patients with a median of 14.5 days.\nConclusion: In our study, the observed gastrointestinal and hematological toxicity rate was relatively low. This preliminary result showed that patient with locally advanced pancreatic carcinoma tolerated this new treatment approach well."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-21-34-a", "title": "Quality Assurance Schedule and Practical Experience with Helical Tomotherapy", "keywords": "\u54c1\u8cea\u4fdd\u8b49;TG-40;\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100;\u76f4\u7dda\u52a0\u901f\u5668 Quality assurance;TG-40;TomoTherapy;Linear accelerator", "c": "\u76ee\u7684\uff1a\u6211\u5011\u63d0\u51fa\u4e00\u500b\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u7684\u54c1\u8cea\u4fdd\u8b49(QA)\u6392\u7a0b\u4e26\u4e14\u5206\u4eab\u6b64\u4e00\u6700\u5148\u9032\u6a5f\u5668\u7684\u54c1\u8cea\u4fdd\u8b49\u5be6\u969b\u7d93\u9a57\u3002\u5728\u53f0\u7063\uff0c\u6839\u64da\u6e38\u96e2\u8f3b\u5c04\u9632\u8b77\u6cd5\uff08\u7b2c17\u689d\u7b2c\u4e09\u9805\uff09\uff0c\u4f9d\u7167\u91ab\u7642\u66dd\u9732\u54c1\u8cea\u4fdd\u8b49\u4f5c\u696d\u7684\u898f\u5b9a\uff0c\u5728\u4e00\u500b\u653e\u5c04\u6cbb\u7642\u90e8\u9580\u88e1\uff0c\u5fc5\u9808\u70ba\u6bcf\u4e00\u6cbb\u7642\u5100\u5668\u8a02\u5b9a\u54c1\u8cea\u4fdd\u8b49\u8655\u7406\u7a0b\u5e8f\u4f86\u78ba\u4fdd\u6cbb\u7642\u54c1\u8cea\uff0c\u5176\u4e2d\u9808\u5305\u62ec\u6bcf\u5929\u3001\u6bcf\u6708\u3001\u6bcf\u5e74\u4e00\u6b21\u7684\u9805\u76ee\u4e26\u9808\u5b9a\u671f\u5be6\u65bd\u3002\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u65bc2003\u5e74\u5728\u9ea5\u8fea\u905c\u5a01\u5dde\u5927\u5b78\u767c\u5c55\u5f8c\u91cf\u7522\uff1b\u70ba\u63d0\u4f9b\u75c5\u60a3\u9ad8\u54c1\u8cea\u670d\u52d9\uff0c\u6211\u5011\u962e\u7d9c\u5408\u91ab\u9662\u57282006\u5e744\u6708\u5b89\u88dd\u6b64\u4e00\u6700\u5148\u9032\u6a5f\u5668\uff0c\u56e0\u800c\u5728\u5357\u53f0\u7063\u9059\u9059\u9818\u5148\u5176\u4ed6\u91ab\u9662\u3002\u5728\u9019\u9805\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u63d0\u51fa\u5728\u6211\u5011\u90e8\u9580\u5167\u57f7\u884c\u7684\u54c1\u8cea\u4fdd\u8b49\u6392\u7a0b\uff0c\u6b64\u4e00\u6392\u7a0b\u9075\u5faa\u4e86AAPM TG-40\u7684\u539f\u5247\u4f46\u4e5f\u5305\u542b\u4e00\u4e9b\u5d84\u65b0\u7684\u9805\u76ee\uff0c\u53cd\u6620\u51fa\u6b64\u4e00\u6700\u5148\u9032\u6a5f\u5668\u8a2d\u5099\u548c\u50b3\u7d71\u7684\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u9593\u7684\u5dee\u5225\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u64ec\u8a02\u4e86\u4e00\u5957\u9075\u5faaAAPM TG-40\u539f\u5247\u7684\u54c1\u8cea\u4fdd\u8b49\u8655\u7406\u7a0b\u5e8f\uff0c\u6bd4\u8f03\u4e86\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u548cElekta-Precise\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u9593\u7684\u54c1\u8cea\u4fdd\u8b49\u5be6\u65bd\u6548\u7387\uff0c\u5176\u4e2d\u5b8c\u6574\u5730\u5305\u62ec\u4e86\u6bcf\u5929\u3001\u6bcf\u6708\u3001\u6bcf\u5e74\u4e00\u6b21\u7684QA\u9805\u76ee\u3002\u5728\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u65b9\u9762\uff0c\u5176\u54c1\u8cea\u4fdd\u8b49\u8a08\u756b\u7684\u5be6\u65bd\u4f7f\u7528\u4e00\u7279\u5225\u8a2d\u8a08\u88fd\u4f5c\u7684\u52fb\u7a31\u5713\u67f1\u578b\u5be6\u9ad4\u6a21\u64ec\u6c34\u5047\u9ad4\uff0c\u4f86\u4f5c\u4e00\u7cfb\u5217\u7684\u5be6\u969b\u8a18\u9304\u91cf\u6e2c\u3002\u6b64\u5c08\u7528\u6c34\u5047\u9ad4\u662f\u88ab\u5206\u6210\u5169\u534a\u7684\u5713\u67f1\u9ad4\u5176\u76f4\u5f91\u70ba30\u5398\u7c73\u3001\u9577\u70ba18\u5398\u7c73\uff0c\u56e0\u6b64X\u5149\u7247\u53ef\u4ee5\u5728\u4f5c\u5be6\u969b\u8a18\u9304\u91cf\u6e2c\u6642\u88ab\u653e\u5728\u4ed6\u5011\u4e4b\u9593\u3002\u70ba\u4e86\u57f7\u884c\u5291\u91cf\u53c3\u6578\u548c\u4fee\u6b63\u4fc2\u6578\u7684\u91cf\u6e2c\uff0c\u5728\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u65b9\u9762\u4f7f\u7528Standard Imaging\u516c\u53f8\u88fd\u9020\u7684\u4e09\u652fExradin-A1SL\u6e38\u96e2\u8154\u548c\u4e00\u7d44TomoEletrometer\u8a08\u8b80\u5668\uff1b\u800c\u5728Elekta-Precise\u76f4\u7dda\u52a0\u901f\u5668\u4e0a\u4f7f\u7528\u4e86\u4e00\u652f0.6 cc PTW TM30013\u8fb2\u592b\u578b\u6e38\u96e2\u8154\u548cPTW T0008\u96fb\u5b50\u96fb\u91cf\u8a08\u8b80\u5668\u3002\u65bc\u5e74\u5ea6\u5c04\u675f\u54c1\u8cea\u91cf\u6e2c\u65b9\u9762\uff0c\u4f7f\u7528\u4e00\u7d44\u591a\u6a21\u5f0f\u87ba\u65cb\u653e\u5c04\u6cbb\u7642\u5100\u5c08\u7528\u7684\u96fb\u5b50\u96fb\u91cf\u91cf\u6e2c\u7cfb\u7d71(TEMS)\u914d\u5408\u4e00\u5957\u4e8c\u7dad\u5c04\u675f\u5206\u6790\u6383\u63cf\u5100(TomoScanner)\uff0c\u8207\u53e6\u4e00\u5957PTW-Freiburg MP3-S\u5c04\u675f\u5206\u6790\u6c34\u5047\u9ad4\u7cfb\u7d71\uff0c\u4f86\u57f7\u884c\u500b\u5225\u6a5f\u5668\u7684\u5c04\u675f\u52fb\u7a31\u6027\u6578\u64da\u6383\u63cf\u5716(profile)\u91cf\u6e2c\uff0c\u4e26\u6aa2\u6e2c\u5206\u6790\u5c04\u675f\u6578\u64da\u6383\u63cf\u5716\u662f\u5426\u8207\u63a5\u6a5f\u9a57\u6536\u6642\u4e00\u6a23\u3002\n\u7d50\u679c\uff1a\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u7684\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u65b9\u6cd5\u662f\u4e00\u5d84\u65b0\u7684\u89c0\u5ff5\uff0c\u6211\u5011\u5229\u7528\u5c07\u8fd1\u4e00\u5e74\u7684\u5be6\u969b\u6e2c\u91cf\u8cc7\u6599\u7d71\u8a08\uff0c\u53ef\u4ee5\u5f97\u5230\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u9664\u4e86\u5728\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u6642\u9593\u4e0a\u6bd4Elekta-Precise\u76f4\u7dda\u52a0\u901f\u5668\u77ed\u4e14\u6709\u6548\u7387\u5916\uff0c\u5176\u5291\u91cf\u8f38\u51fa\u8aa4\u5dee\u503c\u4ea6\u6bd4Elekta-Precise\u76f4\u7dda\u52a0\u901f\u5668\u4f4e\u3002\u5728\u6bcf\u6708\u54c1\u4fdd\u5be6\u65bd\u6642\u9593\u4e0a\u7d04\u5c112\u5c0f\u6642\u3001\u6bcf\u5e74\u54c1\u4fdd\u5be6\u65bd\u6642\u9593\u7d04\u5c1110\u5c0f\u6642\uff0c\u800c\u5728\u6bcf\u65e5\u54c1\u4fdd\u5be6\u65bd\u6642\u9593\u4e0a\u5247\u7d04\u7565\u76f8\u7576\u3002\u5728\u5291\u91cf\u8f38\u51fa\u7d71\u8a08\u65b9\u9762\uff0c\u6bcf\u65e5\u5291\u91cf\u8f38\u51fa\u8aa4\u5dee\u57281%\u5167\u7684\u7d04\u4f54\u7e3d\u6bd4\u7387\u768475%\uff0c\u8aa4\u5dee\u57281-2%\u4ee5\u5167\u7684\u7d04\u4f5418.75%\uff0c\u8aa4\u5dee\u57282-3%\u4ee5\u5167\u7684\u7d04\u4f546.25%\u3002\u4e14\u5728\u6bcf\u6708\u7684\u5291\u91cf\u8f38\u51fa\u7a69\u5b9a\u6027\u4e0a\u8868\u73fe\u90fd\u57281%\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u7684\u7d50\u8ad6\u53ef\u6b78\u7d0d\u5982\u4e0b\uff1a\u9996\u5148\uff0c\u4f9d\u5be6\u969b\u6e2c\u91cf\u8cc7\u6599\u7d71\u8a08\u7d50\u679c\u5728\u4f8b\u884c\u7684\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u6642\u9593\u4e0a\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u6bd4\u76f4\u7dda\u52a0\u901f\u5668\u8f03\u6709\u6548\u7387\u3002\u518d\u8005\uff0c\u7531\u65bc\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u6a5f\u5668\u7684\u672c\u8cea\u7d50\u69cb\u7279\u6027\uff0c\u6709\u4e9b\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u9805\u76ee\u4e0d\u9808\u5be6\u65bd\uff0c\u5982\u5728\u6a5f\u68b0\u65b9\u9762\u4e0d\u9808\u8981\u505a\u65cb\u8f49\u81c2\u3001\u6cbb\u7642\u5e8a\u3001\u6e96\u76f4\u5100\u4e4b\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u6821\u6b63\u5de5\u4f5c\uff0c\u6240\u4ee5\u5728\u4f8b\u884c\u7684\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u5de5\u4f5c\u4e0a\u8f03\u70ba\u7c21\u55ae\uff1b\u6b64\u5916\u56e0\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u53ea\u6709\u55ae\u4e00\u5149\u5b50\u5c04\u675f(6MV)\uff0c\u800c\u6c92\u6709\u96fb\u5b50\u5c04\u675f\u6240\u4ee5\u5728\u54c1\u8cea\u4fdd\u8b49\u91cf\u6e2c\u4e0a\u4e0d\u9808\u6e2c\u91cf\u96fb\u5b50\u5c04\u675f\uff0c\u56e0\u800c\u7c21\u5316\u8a31\u591a\u7a0b\u5e8f\uff0c\u4f46\u96fb\u5b50\u5c04\u675f\u7684\u7279\u6027\u53ef\u4ee5\u7531\u4e0d\u540c\u7684\u5c0f\u5c04\u675f(beamlet)\u7d44\u5408\u4f86\u9054\u5230\u76f8\u540c\u7684\u6548\u679c\u3002\u7531\u65bc\u591a\u6a21\u5f0f\u87ba\u65cb\u65b7\u5c64\u653e\u5c04\u6cbb\u7642\u5100\u7684\u5be6\u969b\u81e8\u5e8a\u8a18\u9304\u76f8\u5c0d\u8f03\u77ed\uff0c\u6240\u4ee5\u7576\u6709\u66f4\u9032\u4e00\u6b65\u7684\u54c1\u8cea\u4fdd\u8b49\u6e2c\u91cf\u5be6\u969b\u64cd\u4f5c\u7d93\u9a57\u88ab\u7372\u5f97\u5f8c\uff0c\u53ef\u80fd\u767c\u73fe\u6709\u4e00\u4e9b\u54c1\u8cea\u4fdd\u8b49\u9805\u76ee\u61c9\u8a72\u5728\u4e0d\u540c\u7684\u671f\u9593\u88ab\u9069\u6642\u4fee\u6b63\uff0c\u6216\u8005\u9808\u589e\u6dfb\u4e00\u4e9b\u65b0\u7684\u54c1\u8cea\u4fdd\u8b49\u9805\u76ee\u624d\u80fd\u4f7f\u6574\u500b\u54c1\u8cea\u4fdd\u8b49\u6392\u7a0b\u66f4\u81fb\u65bc\u5b8c\u5584\u3002", "e": "Purpose: We present a quality assurance (QA) schedule for the Hi-Art Helical Tomo-Therapy unit and share our QA practical experience with this state-of-the-art machine. According to the Ionizing Radiation Protection Act (Article. 17, item 3), the regulation of medical exposure QA in Taiwan has to include daily, monthly, and annual items in the schedule for every treatment machine in a radiation oncology department. The Hi-Art Helical Tomo-Therapy unit was developed at the University of Wisconsin-Madison in 2003. We installed a new system at Yuan's General Hospital to take the lead in South- Taiwan in April 2006. In this study, we present the QA schedule that is performed in our department, which follows the principles of AAPM TG-40 but contains some novel components, reflecting the differences between the Hi-Art device and conventional linear accelerators.\nMaterials and Methods: We compared the efficiency of the daily, monthly, and annual QA programs in our department with Hi-Art Helical Tomo-Therapy unit and an Elekta-Precise linear accelerator with a standard QA schedule. We followed the principles of AAPM TG-40. For tomotherapy, the QA program included a series of measurements that were recorded in a specially fabricated, cylindrically symmetric Virtual Water phantom. This was designed specifically for commissioning the Helical Tomo-Therapy unit and QA. The phantom is 30cm in diameter, 18cm long, and is divided into two halves, such that film may be placed between them.\nTo perform the measurements of the dosimetry parameters and correction factors, three EXRADIN-A1SL ion chambers and a Standard Imaging-TomoEletrometer were used for the Helical Tomo-Therapy unit, and a 0.6CC PTW TM30013 Farmer chamber with PTW T0008 Eletrometer was used for the Elekta-Precise linear accelerator. For the beam quality measurements, the dedicated TomoTherapy electrometer measurement system (TEMS) along with a two-dimensional radiation beam analyzer (TomoScanner) and a PTW-Freiburg MP3-S therapy beam analyzer water phantom system were performed the scanning for the beam symmetrical profiles assessment for the corresponding machine respectively.\nResults: The lengths of time required for daily QA program was almost the same for the two machines. However, the monthly and annual programs were more efficient for the Hi-Art Helical TomoTherapy, saving 2 hours and 10 hours compared to the Elekta-Precise linear accelerator, respectively. The statistical data collected over the past 10 months show that the time spent for the TomoTherapy was less, and the tolerance value was lower than that of the Elekta-Precise linear accelerator; the output error of daily QA was within \u00b11% for 75% of the data, within \u00b12% for 18.75% of the data, and within +3% for the remaining 6.25% of the data, and the dose output error value for the monthly QA was less than \u00b11%.\nConclusions\uff1a The following conclusions can be drawn from this study. First, the time needed for the QA schedule for the Hi-Art Helical TomoTherapy is less than that required for routine work with a linear accelerator. Due to the TomoTherapy machine intrinsic characteristics, some mechanical items, such as the gantry, the couch angle, the collimator etc., do not need to be checked. Additionally, no electron beam verification is needed but the same beam effect can be formed from the different beamlets of the machine. Nonetheless, Helical TomoTherapy has a relatively short clinical track record and, as further operational experience is gained, it may be found that some QA items will need to be modified and some additional tests may need to be developed for completeness of the QA schedule."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-35-43-a", "title": "Image-Based Study on the Distributions of the Metastatic Cervical Lymph Nodes in Patients with Nasopharyngeal Carcinoma: Kaohsiung Medical University Hospital Experience", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u6dcb\u5df4\u7d50\u75c5\u8b8a Nasopharyngeal carcinoma;Radiotherapy;Lymphadenopathy", "c": "\u76ee\u7684\uff1a\u9019\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u5728\u5617\u8a66\u7528\u81e8\u5e8a\u5f71\u50cf\u4f86\u8a55\u4f30\u9f3b\u54bd\u764c\u60a3\u8005\u7684\u9838\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u60c5\u6cc1\u548c\u4e0d\u540c\u671f\u5225\u7684\u9f3b\u54bd\u764c\u7684CTV\u7bc4\u570d\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u81ea2004\u5e741\u6708\u81f32006\u5e742\u6708\u5171\u6709131\u4f4d\u9f3b\u54bd\u764c\u75c5\u4eba\u5728\u672c\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u56e0\u670917\u4f4d\u75c5\u4eba\u6c92\u6709\u5408\u9069\u7684\u5f71\u50cf\u8cc7\u6599\uff0c\u6240\u4ee5\u7e3d\u5171114\u4f4d\u75c5\u4eba\u9032\u5165\u6b64\u7814\u7a76\u3002\u9019\u4e9b\u60a3\u8005\u90fd\u6709\u63a5\u53d7\u5f9e\u9871\u5e95\u81f3\u9396\u9aa8\u7684\u96fb\u8166\u65b7\u5c64\u6216\u78c1\u632f\u9020\u5f71\u6383\u7784\u3002\u800c\u6dcb\u5df4\u7d50\u7684\u5206\u4f48\u4e5f\u7d93\u7531\u5f71\u50cf\u8a3a\u65b7\u79d1\u8207\u653e\u5c04\u816b\u7624\u79d1\u91ab\u5e2b\u7684\u5171\u540c\u8a55\u4f30\u3002\n\u7d50\u679c\uff1a\u5728\u521d\u8a3a\u6642\uff0c82\u4f4d\u75c5\u4eba(71.9%)\u6709\u9838\u90e8\u6dcb\u5df4\u7d50\u75c5\u8b8a\uff0c32\u4f4d\u75c5\u4eba(28.1%)\u6c92\u6709\u9838\u90e8\u6dcb\u5df4\u7d50\u75c5\u8b8a\u3002\u5728\u6240\u6709\u75c5\u4eba\u4e2d\uff0c\u7d0436.8%\u7684\u75c5\u4eba\u6709\u5169\u5074\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002\u5176\u4e2d82\u4f4d\u6709\u9838\u90e8\u6dcb\u5df4\u7d50\u75c5\u8b8a\u7684\u75c5\u4eba\u4e2d\u7d0451.2%\u6709\u5169\u5074\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002\u81e8\u5e8a\u4e0a\u4e0d\u540c\u5340\u57df\u8f49\u79fb\u6027\u6dcb\u5df4\u7d50\u7684\u5206\u4f48\u5982\u4e0b\uff1alevel IA\u70ba0\uff1blevel IB\u70ba15.9%\uff1blevel IIA\u70ba50.0%\uff1blevel IIB\u70ba89.0%\uff1blevel III\u70ba31.7%\uff1blevel IV\u70ba8.5%\uff1blevel VA\u70ba30.5%\uff1band level VB\u70ba7.3%\u3002\n\u7d50\u8ad6\uff1a\u5728\u53f0\u7063\uff0c\u9f3b\u54bd\u764c\u75c5\u4eba\u65bclevel IIA, IIB, III, and VA \u6dcb\u5df4\u7d50\u6709\u8f03\u9ad8\u7684\u8f49\u79fb\u53ef\u80fd\u6027\u3002\u6b64\u7814\u7a76\u4e2d\uff0c\u4e0b\u9838\u90e8(level IV, VB)\u6dcb\u5df4\u7d50\u75c5\u8b8a\u6a5f\u7387\u76f8\u5c0d\u8f03\u4f4e\uff0c\u6240\u4ee5\u5c0d\u65bc\u65e9\u671f\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u53ef\u4ee5\u7e2e\u6e1b\u4e0b\u9838\u90e8\u7684\u7167\u5c04\u7bc4\u570d\u6216\u662f\u7701\u7565\u9396\u9aa8\u4e0a\u7aa9\u7684\u7167\u5c04\u3002\u7136\u800c\uff0c\u9700\u8981\u66f4\u591a\u524d\u77bb\u6027\u7814\u7a76\u4ee5\u6539\u826f\u9f3b\u54bd\u764c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u7b56\u7565\u3002", "e": "Purpose: The purpose of this study was to evaluate the image-based distributions of cervical nodal metastases of patients with nasopharyngeal carcinoma (NPC) and to define a clinical target volume (CTV) extent according to different stage of NPC.\nMaterials and Methods: We collected 131 patients with NPC who received radiotherapy at the Radiation Oncology Department of KMUH from January, 2004 to February, 2006. Seventeen patients were excluded due to no proper image data and 114 patients were enrolled in our study. These patients had a pretreatment evaluation by contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) from base of skull to clavicle. The nodal distributions were assessed by diagnostic radiologists and radiation oncologist according to the image-based classification.\nResults: Eighty-two patients (71.9%) had cervical lymphadenopathy (LAP) and thirty- two patients (28.1%) had no lymph node metastasis at the initial presentation. A total of 36.8% of patients had bilateral neck nodal metastases. In the patients with LAP, 51.2% of patients had bilateral neck lymph node involvement. The distributions of clinical metastatic lymph nodes per level in patients with cervical lymph node metastases were as follows: level IA: 0; level IB: 15.9%; level IIA: 50.0%; level IIB: 89.0%; level III: 31.7%; level 1V: 8.5%; level VA: 30.5%; and level VB: 7.3%.\nConclusion: In Taiwan, patients with NPC have a high probability of cervical nodal metastases especially in level IIA, IIB, III, and VA. In this study, the metastaic rates of lower neck lymph nodes (level IV and VB) were relatively low. When we design the treatment plan of radiotherapy for NPC, we may consider reducing the field size of lower neck and even omitting the supraclavicular fossa (SCF) irradiation in patients with early stage of NPC. Further clinical prospective studies also need to improve the treatment strategy of NPC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-45-51-a", "title": "\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u514d\u75ab\u7642\u6cd5\uff08\u96fb\u57fa\u56e0\u6cd5\u52a0\u816b\u7624\u5167\u6ce8\u5c04\u6a39\u7a81\u7d30\u80de\uff09\u6cbb\u7642\u6548\u679c\u4e4b\u52d5\u7269\u5be6\u9a57\u521d\u5831", "keywords": "\u6a39\u7a81\u7d30\u80de;\u96fb\u885d\u6cd5;\u514d\u75ab\u7642\u6cd5;\u653e\u5c04\u7dda\u6cbb\u7642 Dendritic cells;Electroporation;Immunotherapy;Radiotherapy", "c": "\u76ee\u7684\uff1a\u6709\u7814\u7a76\u6307\u51fa\uff0c\u816b\u7624\u5167\u6ce8\u5c04\u6a39\u7a81\u7d30\u80de(dendritic cell)\u53ef\u4ee5\u5f15\u767c\u5168\u8eab\u514d\u75ab\u53cd\u61c9\uff0c\u7136\u800c\u816b\u7624\u5167\u7684\u6a39\u7a81\u7d30\u80de\u4e5f\u6703\u56e0\u70ba\u4e0d\u5bb9\u6613\u5b58\u6d3b\u800c\u5f71\u97ff\u5230\u514d\u75ab\u53cd\u61c9\u7684\u6548\u679c\u3002\u56e0\u6b64\u672c\u5be6\u9a57\u5047\u8a2d\u7d66\u4e88\u7b2c\u4e8c\u4ecb\u767d\u8cea\u7d20(IL-2)\u53ca\u9846\u7c92\u7403\u5de8\u566c\u7d30\u80de\u7fa4\u843d\u523a\u6fc0\u56e0\u5b50(GM-CSF)\u80fd\u5920\u5e6b\u52a9\u6a39\u7a81\u7d30\u80de\u7684\u5206\u5316\u6210\u719f\u56e0\u800c\u589e\u52a0\u514d\u75ab\u6cbb\u7642\u7684\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u8a2d\u8a08\u4e00\u500b\u80fd\u6709\u5229\u65bc\u514d\u75ab\u5fae\u74b0\u5883(microenvironment)\u7684\u65b9\u6cd5\uff1a\u5728\u816b\u7624\u8655\u5148\u85c9\u7531\u96fb\u885d\u6cd5(electroporation)\u5c07\u7b2c\u4e8c\u4ecb\u767d\u8cea\u7d20\u53ca\u9846\u7c92\u7403\u5de8\u566c\u7d30\u80de\u7fa4\u843d\u523a\u6fc0\u56e0\u5b50\u7684\u57fa\u56e0\u5e36\u5165\u816b\u7624\u7d30\u80de\u5167\uff0c\u7136\u5f8c\u518d\u628a\u6a39\u7a81\u7d30\u80de\u6ce8\u5165\u816b\u7624\u5167\u3002\u7d93\u7531\u96fb\u57fa\u56e0\u8f49\u6b96(EGT)\u5f8c\u800c\u58de\u6b7b\u7684\u816b\u7624\u7d30\u80de\u6703\u91cb\u51fa\u816b\u7624\u6297\u539f\u7d66\u6a39\u7a81\u7d30\u80de\u800c\u5f15\u767c\u6bd2\u6bbaT\u7d30\u80de(cytotoxic T cells)\u53ca\u6d3b\u5316\u81ea\u7136\u6bba\u624b\u7d30\u80de(NK cells)\u3002\u5728\u672c\u5be6\u9a57\u4e2d\uff0c\u6211\u5011\u4f7f\u7528\u7684\u816b\u7624\u7d30\u80de\u70ba\u8001\u9f20\u8178\u817a\u764c\u7d30\u80de(PSA/CT-26\u7d30\u80de)\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u767c\u73fe\uff0c\u7d93\u904e\u53cd\u8986\u56db\u6b21\u7684\u96d9\u57fa\u56e0\u96fb\u57fa\u56e0\u8f49\u6b96(EGT-L-2/GM-CSF)\u5f8c\uff0c\u518d\u5c07\u6a39\u7a81\u7d30\u80de\u6ce8\u5c04\u5165\u816b\u7624\u5167\u80fd\u660e\u986f\u6291\u5236\u816b\u7624\u751f\u9577\u548c\u5f15\u767c\u5168\u8eab\u6027\u7684\u514d\u75ab\u53cd\u61c9\u3002\u9019\u7a2e\u514d\u75ab\u6cbb\u7642\u7684\u7b56\u7565\u80fd\u5f15\u8d77\u5927\u91cf\u7684T\u7d30\u80de\u816b\u7624\u5167\u6d78\u6f64\uff0c\u66f4\u91cd\u8981\u7684\u662f\uff0c\u514d\u75ab\u6cbb\u7642\u5f8c\u7684\u816b\u7624\u986f\u7136\u7531\u65bc\u5fae\u74b0\u5883\u7684\u6539\u8b8a\uff0c\u5c07\u5927\u5e45\u63d0\u9ad8\u816b\u7624\u7684\u653e\u5c04\u7dda\u654f\u611f\u5ea6\uff0c\u4e14\u7d93\u904e\u7d50\u5408\u514d\u75ab\u6cbb\u7642\u8207\u653e\u7642\u7684\u8001\u9f20\u80fd\u5f15\u767c\u5168\u8eab\u6027\u7684\u514d\u75ab\u53cd\u61c9\uff0c\u9632\u6b62\u5c0d\u5074\u816b\u7624\u63a5\u7a2e\u7684\u6210\u9577\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u672c\u5be6\u9a57\u6211\u5011\u767c\u73fe\uff1a\u5408\u4f75\u514d\u75ab\u7642\u6cd5\u52a0\u653e\u5c04\u7dda\u6cbb\u7642\u9664\u4e86\u80fd\u9054\u5230\u66f4\u597d\u7684\u816b\u7624\u63a7\u5236\u4e4b\u5916\u4e5f\u80fd\u5f15\u767c\u5168\u8eab\u6027\u514d\u75ab\u53cd\u61c9\u800c\u9054\u5230\u9810\u9632\u816b\u7624\u5fa9\u767c\u7684\u6548\u679c\u3002\u800c\u672c\u7814\u7a76\u61c9\u8a72\u7e7c\u7e8c\u9032\u884c\u514d\u75ab\u6a5f\u8f49\u7684\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Purpose: Intra-tumoral (i.t.) injection of dendritic cells (DC) has been demonstrated to be able to evoke the systemic immunological response. Nevertheless, the injected DC are prone to be apoptotic in tumor site. Local secreted IL-2 and GM-CSF help the maturation and functioning of injected DC.\nExperimental Design: We developed a method of creating an immunological favorable microenvironment by in situ electroporation of IL-2 and GM-CSF genes followed by injection of DC at tumor site. Necrotic and apoptotic cells from electrical shock may provide antigen source for DC to promote cross-priming of cytotoxic T cells and activate NK cells. PSA/CT-26 cells was used in this study.\nResults: 4 repeated cycles of double gene EGT plus i.t. DC significantly inhibited the tumor growth and produced systemic immunity. The combination of double gene EGT and DC treatment induced heavy T cell infiltration inside tumor. Mice successfully treated by the combination of immunotherapy & radiotherapy can induce a systemic immunity to prevent the contralateral tumor challenge. Interestingly, the immunological favorable micro-environment established in the tumor site by this protocol created a highly effective condition for subsequent radiotherapy.\nConclusions: Our findings may have clinical implications in achieving better local control and prevention of systemic relapse through the combination of immunotherapy and radiotherapy. Further study for the mechanism is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-53-61-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u982d\u9838\u90e8\u816b\u7624\u8868\u9762\u53ca\u6dfa\u90e8\u5291\u91cf\u4e4b\u91cf\u6e2c\u8207\u5206\u6790", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642;\u589e\u5efa\u5340\u5291\u91cf\u5206\u6790;\u8868\u9762\u5291\u91cf\u91cf\u6e2c;TLD IMRT;Does analyze in build up region;Surface dose;TLD", "c": "\u76ee\u7684\uff1aIMRT\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u4f7f\u7528\u9006\u5411\u5f0f\u8a08\u7b97\u5c04\u675f\u7684\u5f37\u5ea6\u5206\u4f48\uff0c\u5728\u6b64\u6a21\u5f0f\u4e0b\uff0c\u816b\u7624\u53ca\u76f8\u95dc\u5371\u6025\u5668\u5b98\u7684\u6a19\u5b9a\u65b9\u5f0f\u5c07\u5f37\u70c8\u5f71\u97ff\u8a08\u756b\u904b\u7b97\u7684\u7d50\u679c\u3002\u7136\u800c\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5c0d\u9ad4\u8868\u589e\u5efa\u5340\u5291\u91cf\u8a08\u7b97\u7684\u6e96\u78ba\u5ea6\u4ecd\u5b58\u5728\u8457\u8f03\u9ad8\u7684\u4e0d\u78ba\u5b9a\u6027\u3002\u56e0\u6b64\uff0c\u672c\u7814\u7a76\u91dd\u5c0dIMRT\u4e0d\u540c\u7684\u816b\u7624\u6a19\u5b9a\u65b9\u5f0f\uff0c\u91cf\u6e2c\u5176\u8868\u9762\u53ca\u589e\u5efa\u5340\u4e4b\u5291\u91cf\uff0c\u4e26\u4f5c\u6df1\u5165\u4e4b\u5206\u6790\u8207\u63a2\u8a0e\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528Varian 21EX\u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f\u76846MV \u5c04\u675f\uff0c\u642d\u914dVarian Eclipse\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u3002\u4ee5\u76f4\u5f9116cm\u4e4b\u5713\u7403\u5f62\u5047\u9ad4\u4f86\u6a21\u64ec\u982d\u90e8\u3002\u5291\u91cf\u91cf\u6e2c\u4ee5\u539a\u5ea60.1mm\u7684\u8d85\u8584TLD\u57f7\u884c\u3002\u5206\u5225\u91cf\u6e2c\u5047\u9ad4\u4e2d\u5fc3\u622a\u9762\uff0c\u5c04\u675f0\u00b0\u300130\u00b0\u300160\u00b0\u300180\u00b0\u3001330\u00b0\u3001300\u00b0\u53ca280\u00b0\u5728\u6df1\u5ea60\u30013\u53ca6mm\u4e4b\u5291\u91cf\u3002\u816b\u7624\u6a19\u5b9a\u5247\u91dd\u5c0dPTV\u8a2d\u5b9a\u4e09\u7a2e\u5f9e\u9ad4\u8868\u9000\u7e2e\u7684\u65b9\u5f0f\uff1b\u5305\u62ec0\uff0c3\u53ca5mm\uff1b\u5206\u5225\u4ee5\u76f8\u540c\u7684IMRT\u6cbb\u7642\u8a08\u756b\u53c3\u6578\u8a2d\u5b9a\u65b9\u5f0f\uff0c\u57f7\u884c\u5c04\u675f\u5f37\u5ea6\u6700\u4f73\u5316\u904b\u7b97(optimization)\u3002\u5291\u91cf\u8a08\u7b97\u6642\u4e4b\u683c\u9ede\u9593\u8ddd\u70ba2.5mm\uff0c\u4e26\u5206\u5225\u4ee5\u4e0d\u4f5c\u975e\u5747\u8cea\u4fee\u6b63(None)\u53ca\u4ee5Equivalent TAR (ETAR)\uff0c Batho power law (BPL)\u53caModified Batho(MB)\u7b49\u4e0d\u540c\u7684\u975e\u5747\u8cea\u4fee\u6b63\u65b9\u5f0f\u4f5c\u904b\u7b97\u3002\u5617\u8a66\u5efa\u7acb\u6b64\u7cfb\u7d71\u6dfa\u90e8\u5291\u91cf\u8a08\u7b97\u7684\u8a55\u4f30\u53c3\u8003\u3002\n\u7d50\u679c\uff1a\u5c04\u675f\u5f37\u5ea6\u7684\u6700\u4f73\u5316\u904b\u7b97\u65b9\u9762\u5728PTV\u4e0d\u9000\u7e2e\u7684\u60c5\u5f62\u4e0b\uff0c\u6dfa\u90e8\u5340\u57df\u660e\u986f\u5448\u73fe\u8f03\u9ad8\u7684\u5f37\u5ea6\u5206\u4f48\uff0c\u8a08\u7b97\u503c\u8207\u91cf\u6e2c\u503c\u7684\u5dee\u7570\u5728\u6b64\u60c5\u5f62\u4e0b\u4e5f\u6700\u5927\uff0c\u5047\u9ad4\u8868\u9762\u6709\u6700\u591a\u9ad8\u9054\uff0b40%\u53ca\uff0d24%\u7684\u8b8a\u5316\u3002\u9664\u4e86\u5728\u5047\u9ad4\u8868\u976280\u00b0\u53ca280\u00b0\u7684\u91cf\u6e2c\u9ede\u4e4b\u5916\uff0c\u4e0d\u4f5c\u975e\u5747\u8cea\u4fee\u6b63\u53ca\u4e09\u7a2e\u975e\u5747\u8cea\u4fee\u6b63\u6cd5\u7684\u5291\u91cf\u8a08\u7b97\u503c\u5927\u591a\u5448\u73fe\u4f4e\u4f30\u7684\u73fe\u8c61\uff0c\u5c24\u5176\u4ee5ETAR\u4f4e\u4f30\u7684\u60c5\u5f62\u6700\u70ba\u660e\u986f\u3002\u8a08\u7b97\u503c\u5728\u8f03\u6df1\u7684\u4f4d\u7f6e\uff0c\u5dee\u7570\u6709\u9010\u6f38\u7e2e\u5c0f\u7684\u8da8\u52e2\u3002\u57286mm\u6df1\u5ea6BPL\u53caMB\u4fee\u6b63\u6cd5\u7684\u5dee\u7570\u503c\u90fd\u57285%\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5728\u8d8a\u63a5\u8fd1\u8868\u9762\u7684\u5340\u57df\u5176\u5291\u91cf\u8a08\u7b97\u503c\u7684\u5dee\u7570\u8d8a\u5927\u3002\u7576\u816b\u7624\u4fb5\u72af\u81f3\u63a5\u8fd1\u8868\u9762\u6642\uff0c\u9069\u7576\u7684\u8986\u84cb\u7b49\u7d44\u7e54\u586b\u5145\u7269(bolus)\u65b9\u53ef\u6709\u6548\u63d0\u9ad8\u816b\u7624\u6dfa\u90e8\u4f4d\u7f6e\u4e4b\u5291\u91cf\uff0c\u4e26\u4e14\u5f97\u5230\u8f03\u70ba\u6e96\u78ba\u7684\u8a08\u7b97\u6578\u64da\u3002\u82e5\u816b\u7624\u4fb5\u72af\u672a\u53ca\u8868\u9762\uff0c\u70ba\u907f\u514d\u5291\u91cf\u8a08\u7b97\u7684\u4e0d\u78ba\u5b9a\u6027\u9020\u6210\u76ae\u819a\u6548\u61c9\u7684\u767c\u751f\uff0c\u9069\u7576\u7684PTV\u9000\u7e2e\u8655\u7406\u4ecd\u662f\u9700\u8981\u7684\u3002", "e": "Purpose: Dosimetry accuracy in surface and build-up region is inadequate for commercialized treatment planning systems. This uncertainty is more significant for IMRT with inverse treatment planning procedure and may cause a severe skin reaction for head and neck cancer. In this study, various target contouring methods for IMRT planning are used to analyze the dosimetry effects in buildup region.\nMaterials and Methods: 6-MV photon beams generated by Varian 21EX and Varian Eclipse treatment planning system (TPS) are used in this study. A 16cm diameter ball phantom was used for superficial dose measurements. Three different planning target volume (PTV) shrinkage methods (0, 3, 5 mm) were designed for IMRT planning. Plan optimizations are performed with same dose constraint condition. Dose calculations are performed with 2.5 mm grid size and with inhomogeneity correction methods (Equivalent TAR, Batho Power Law and Modified Batho). Extra thin TLDs (0.1 mm) are used for surface and superficial dose measurements. TPS calculated doses in different conditions are compared with the measurement data. A guidance may be established in this issue to assess the method of IMRT target contouring and the estimation of superficial dose from TPS.\nResults: A significant high intensity distribution at superficial area was shown for PTV margin extend to body surface and shrink 0mm. The highest variations between measurements and calculations (+40% to -24%) also existed in this condition and at body surface. Most of the TPS calculation data are under estimated except for points at 80\u00b0 and 280\u00b0 on body surface are over estimated. The under estimation is more significant for ETAR. The variation is reduced for deeper position. At 6mm depth, the variation is within 5% for BPL and MB methods.\nConclusions: The variations are more significant at shallow position. When tumor invasion is close to body surface, a bolus of proper thickness is the method to increase the superficial dose and to have a correct calculation dose. On the other, if superficial area is not a risk area, proper PTV margin shrinkage will be necessary to avoid the skin reaction."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-63-71-a", "title": "\u63a2\u8a0eFWT-70\u7cfb\u5217\u8f3b\u5c04\u8272\u67d3\u5291\u91cf\u8a08\u5c0d\u80fd\u91cf3.2~12.6 MeV\u96fb\u5b50\u5c04\u675f\u7684\u654f\u5ea6\u53cd\u61c9", "keywords": "\u8f3b\u5c04\u8272\u67d3\u5291\u91cf\u8a08;\u7dda\u6027\u5291\u91cf\u53cd\u61c9\u6700\u4f4e\u9650\u503c;\u96fb\u5b50\u5c04\u675f\u80fd\u91cf;\u5291\u91cf\u7387 RDF;Threshold dose for linear response;Election beam energy;Dose rate", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4fc2\u63a2\u8a0e\u8f3b\u5c04\u8272\u67d3(radiochromic dye film; RDF)\u5291\u91cf\u8a08\uff0c\u5c0d\u9ad8\u80fd\u91cf\u96fb\u5b50\u5c04\u675f\u7684\u654f\u5ea6\u53cd\u61c9\uff0c\u4ee5\u4f5c\u70ba\u5ea6\u91cf\u653e\u5c04\u6cbb\u7642\u7528\u96fb\u5b50\u5c04\u675f\u5291\u91cf\u7684\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6240\u63a2\u8a0eRDF\u5291\u91cf\u8a08\uff0c\u70baFWT-70\u7cfb\u5217\u7684\u5169\u7a2e\u4e0d\u540c\u578b\u865fRDF\u5291\u91cf\u8a08\uff1b\u9ad8\u80fd\u91cf\u96fb\u5b50\u5c04\u675f\u70ba\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u6240\u8f38\u51fa\u80fd\u91cf\u70ba6~20MeV\u7684\u96fb\u5b50\u5c04\u675f\u3002\u5be6\u9a57\u904e\u7a0b\u4fc2\u5c07\u4e0d\u540c\u578b\u865fRDF\u5291\u91cf\u8a08\uff0c\u5206\u5225\u7f6e\u65bc\u5404\u4e0d\u540c\u80fd\u91cf\u96fb\u5b50\u5c04\u675f\u5728\u56fa\u614b\u6c34\u5047\u9ad4\u5167\u7684\u6700\u5927\u5291\u91cf\u9ede\u4f4d\u7f6e\uff0c\u63a5\u53d7\u4e0d\u540c\u80fd\u91cf\u3001\u5291\u91cf\u8207\u5291\u91cf\u7387\u7684\u96fb\u5b50\u5c04\u675f\u7167\u5c04\u3002\n\u7d50\u679c\uff1a\u5728FWT-70\u7cfb\u5217\u7684\u5169\u7a2e\u4e0d\u540c\u578b\u865fRDF\u5291\u91cf\u8a08\u4e2d\uff0c(1)\u5c0d\u80fd\u91cf3.2MeV\u96fb\u5b50\u5c04\u675f\u7684\u654f\u5ea6\u53cd\u61c9\u8207\u7dda\u6027\u5291\u91cf\u53cd\u61c9\u7684\u6700\u4f4e\u9650\u503c\u800c\u8a00\uff0c\u4ee5\u578b\u865fFWT-70-40(M)RDF\u5291\u91cf\u8a08\u5c0d\u96fb\u5b50\u5c04\u675f\u654f\u5ea6\u53cd\u61c9\u6700\u9ad8\uff0c\u70ba0.0099 OD/Gy\uff0c\u5176\u7dda\u6027\u5291\u91cf\u53cd\u61c9\u7684\u6700\u4f4e\u9650\u503c\u6700\u4f4e\uff0c\u70ba8Gy\uff1b\u5176\u6b21\u70ba\u578b\u865fFWT-70-83(M)RDF\u5291\u91cf\u8a08\uff0c\u5176\u5c0d\u96fb\u5b50\u5c04\u675f\u654f\u5ea6\u53cd\u61c9\uff0c\u50c5\u70ba0.0015 OD/Gy\uff0c\u7dda\u6027\u5291\u91cf\u53cd\u61c9\u7684\u6700\u4f4e\u9650\u503c\u5247\u70ba20Gy\u3002(2)\u578b\u865fFWT-70-40(M)RDF\u5291\u91cf\u8a08\u5c0d\u4e0d\u540c\u80fd\u91cf\u7684\u96fb\u5b50\u5c04\u675f\u654f\u5ea6\u53cd\u61c9\uff0c\u8207\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u5448\u4f9d\u6043\u6027\u95dc\u4fc2\uff1b\u578b\u865fFWT-70-83(M)RDF\u5291\u91cf\u8a08\uff0c\u5c0d\u4e0d\u540c\u80fd\u91cf\u7684\u96fb\u5b50\u5c04\u675f\u654f\u5ea6\u53cd\u61c9\uff0c\u8207\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u6240\u5448\u73fe\u7684\u4f9d\u6043\u6027\u95dc\u4fc2\uff0c\u4e26\u4e0d\u986f\u8457\u3002(3)\u578b\u865fFWT-70-40(M)RDF\u5291\u91cf\u8a08\u8207\u578b\u865fFWT-70-83(M)RDF\u5291\u91cf\u8a08\uff0c\u5c0d\u4e0d\u540c\u7167\u5c04\u5291\u91cf\u7387\u7684\u96fb\u5b50\u5c04\u675f\u654f\u5ea6\u53cd\u61c9\uff0c\u5747\u96a8\u96fb\u5b50\u5c04\u675f\u7684\u7167\u5c04\u5291\u91cf\u7387\u8b8a\u5316\uff0c\u5448\u4f9d\u6043\u6027\u95dc\u4fc2\u3002\n\u7d50\u8ad6\uff1aFWT-70\u7cfb\u5217\u7684\u578b\u865fFWT-70-40(M)RDF\u5291\u91cf\u8a08\u8207\u578b\u865fFWT-70-83(M)RDF\u5291\u91cf\u8a08\uff0c\u9664\u5747\u53ef\u61c9\u7528\u65bc\u923760\u52a0\u99ac\u9ad8\u5291\u91cf\uff08\u7387\uff09\u8f3b\u5c04\u5834\u7684\u5291\u91cf\u5ea6\u91cf\u5916\uff0c\u4ea6\u53ef\u61c9\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u7528\u9ad8\u80fd\u91cf\u3001\u9ad8\u5291\u91cf\uff08\u7387\uff09\u96fb\u5b50\u5c04\u675f\u7684\u5291\u91cf\u5ea6\u91cf\uff0c\u4f46\u5fc5\u9808\u4f9d\u5176\u578b\u865f\u7684\u4e0d\u540c\uff0c\u5206\u5225\u9032\u884c\u5176\u5c0d\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u8207\u7167\u5c04\u5291\u91cf\u7387\u7684\u654f\u5ea6\u4f9d\u6043\u53cd\u61c9\uff0c\u52a0\u4ee5\u4fee\u6b63\u3002", "e": "Objective: The sensitivity response of radiochromic dye film (RDF) dosimeter with high energy electron beams was studied in this paper. The feasibility of RDF as a dosimeter for measuring the electron beams of a medical accelerator was studied.\nMaterials and Methods: Type FWT-70 series were used as the RDF dosimeter, and the electron beams with 6-20 MeV were from a medical linear accelerator. Various types of RDF dosimeter were placed at the maximum dose position in a solid water phantom, that exposed by various electron beam conditions with different energies, doses, and dose rates.\nResults: In the two different RDF dosimeters of the FWT-70 series: (1) the sensitivity and threshold dose of type FWT-70-40 (M) are 0.0099 OD/Gy and 8 Gy respectively and that of FWT-70-83 (M) RDF are 0.0015 OD/Gy and 20 Gy respectively. (2) FWT-70-40 (M) RDF has higher sensitivity of electron beam energy than Type FWT-70-83 (M). (3) the dose rate dependence of Types FWT-70-40 (M) and FWT-70-83 (M) RDF dosimeters are about 200% and 60%.\nConclusion: In conventional RDF dosimeters of Type FWT-70 series was using for measuring high dose in a gamma radiation field from 60Co. In this paper, we show that it also can be applied in the electron radiation field with high energy, dose and dose rate. However, the type of dosimeter should be well selected and calibrated according to the sensitivity dependence on electron beam energy and dose rate."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200803-15-1-73-78-a", "title": "Jejunal Metastasis from Squamous Cell Carcinoma of the Esophagus Presenting as Intestinal Bleeding", "keywords": "\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c;\u98df\u9053;\u5c0f\u8178\u8f49\u79fb;\u5c0f\u8178\u51fa\u8840;\u653e\u5c04\u7dda\u6cbb\u7642 Squamous cell carcinoma;Esophagus;Small intestinal metastasis;Small intestinal bleeding;Radiotherapy", "c": "\u98df\u9053\u7684\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u5f88\u5c11\u8f49\u79fb\u5230\u5c0f\u8178\u6216\u662f\u8178\u7cfb\u819c\u7684\u6dcb\u5df4\u7d50\u3002\u904e\u53bb\u66fe\u5831\u5c0e\u904e\u7684\u9019\u985e\u75c5\u4f8b\u591a\u534a\u662f\u4ee5\u8178\u963b\u585e\u7684\u75c7\u72c0\u5448\u73fe\u3002\u6211\u5011\u5831\u544a\u7684\u75c5\u4f8b\u5247\u662f\u7b2c\u4e00\u4f8b\u4ee5\u8178\u9053\u51fa\u8840\u70ba\u75c7\u72c0\u4f86\u5448\u73fe\u3002\n\u9019\u4f4d\u4e94\u5341\u56db\u6b72\u7684\u7537\u6027\u7f79\u60a3\u98df\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\uff0c\u4e26\u4e3b\u8a34\u8fd1\u65e5\u6709\u89e3\u9ed1\u4fbf\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u767c\u73fe\u5728\u7a7a\u8178\u8178\u9053\u5167\u6709\u7591\u4f3c\u8f49\u79fb\u7684\u816b\u584a\u3002\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u5c0e\u5f15\u63a1\u6a23\u5207\u7247\u9001\u6aa2\u7684\u7d50\u679c\u78ba\u5b9a\u662f\u8f49\u79fb\u7684\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u3002\u5728\u7d66\u4e8815Gy\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u4ed6\u5df2\u505c\u6b62\u89e3\u9ed1\u4fbf\u3002\u6587\u4e2d\u4e26\u6574\u7406\u6bd4\u8f03\u904e\u53bb\u985e\u4f3c\u75c5\u4f8b\u4e4b\u6cbb\u7642\u65b9\u5f0f\uff0c\u8a0e\u8ad6\u53ef\u80fd\u7684\u8f49\u79fb\u8def\u5f91\uff0c\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u6b62\u8840\u7684\u76f8\u95dc\u6a5f\u5236\u3002", "e": "Small bowel or mesenteric lymph node metastases from esophageal squamous cell carcinomas are rare. When it happens, most reported cases present as intestinal obstruction. The patient we report here suffered from intestinal tumor bleeding associated with metastasis from esophageal squamous cell carcinoma to the jejunum. This, to our knowledge, would be the first case ever reported.\nOur patient was a 54-year old man with squamous cell carcinoma of the esophagus, who had suffered from tarry stool. Abdominal computed tomography (CT) showed a mass occupying the jejunal cavity. The CT-guided biopsy proved that the mass was metastatic squamous cell carcinoma, which had originated from his esophageal cancer. Tumor bleeding came under control after 1500 cGy of radiation. We also review similar published case reports and discuss the routes of metastasis and the possible mechanisms of arresting intestinal bleeding by irradiation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-141-147-a", "title": "Risk Factors for Ipisilateral Breast Tumor Recurrence in Patients with Ductal Carcinoma in Situ Undergoing Wide Excision Alone", "keywords": "\u540c\u5074\u4e73\u623f\u816b\u7624\u5fa9\u767c;\u4e73\u7ba1\u539f\u4f4d\u764c;\u4e73\u623f\u4fdd\u7559\u624b\u8853 Ipsilateral breast tumor recurrence;Ductal carcinoma in situ;Wide excision", "c": "\u76ee\u7684\uff1a\u6211\u5011\u56de\u9867\u672c\u9662\u4e73\u7ba1\u539f\u4f4d\u764c\u4ee5\u4e73\u623f\u4fdd\u7559\u624b\u8853\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u4e26\u5206\u6790\u5176\u540c\u5074\u4e73\u623f\u816b\u7624\u5fa9\u767c\u76f8\u95dc\u7684\u5371\u96aa\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1990\u5e741\u6708\u81f32002\u5e7412\u6708\u9593\uff0c\u65bc\u548c\u4fe1\u6cbb\u764c\u4e2d\u5fc3\u91ab\u9662\u6cbb\u7642\u7684257\u4f4d\u4e73\u7ba1\u539f\u4f4d\u764c\u75c5\u4eba\u4e2d\uff0c\u670947\u4f4d\u53ea\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u4e14\u7121\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4eba\u5217\u5165\u5206\u6790\u3002\u6211\u5011\u63a2\u8a0e\u4e0b\u5217\u5371\u96aa\u56e0\u5b50\uff0c\u5305\u62ec\u816b\u7624\u5927\u5c0f\u3001\u7d30\u80de\u6838\u5206\u5316\u3001\u75c5\u7076\u5207\u9664\u5468\u908a\u5b89\u5168\u8ddd\u96e2\u3001\u75c5\u7076\u7d44\u7e54\u58de\u6b7b\u3001\u7d30\u80de\u6838\u7684\u6709\u7d72\u5206\u88c2\u3001\u591a\u767c\u6027\u816b\u7624\u3001\u8cc0\u723e\u8499\u53d7\u9ad4\u3001\u5e74\u9f61\u3001\u9223\u5316\u9ede\u3001\u518d\u6b21\u5207\u9664\u3001\u5c0d\u5074\u4fb5\u72af\u6027\u764c\u75c7\u3001\u5948\u6c0f\u6307\u6578\u7b49\u7b49\uff0c\u8207\u540c\u5074\u4e73\u623f\u816b\u7624\u5fa9\u767c\u7684\u95dc\u4fc2\u3002\n\u7d50\u679c\uff1a\u65bc\u4e2d\u4f4d\u65785.94\u5e74\u7684\u8ffd\u8e64\u6642\u9593\uff0c\u540c\u5074\u4e73\u623f\u816b\u7624\u5fa9\u767c\u767c\u751f\u65bc6\u4f4d\u75c5\u4eba\uff0c\u5176\u4e2d\u67093\u4f4d\u662f\u4fb5\u72af\u6027\u764c\u75c7\uff0c3\u4f4d\u4ecd\u662f\u4e73\u7ba1\u539f\u4f4d\u764c\u55ae\u3002\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u75c5\u7076\u7d44\u7e54\u58de\u6b7b\u662f\u552f\u4e00\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u7684\u5371\u96aa\u56e0\u5b50\uff0c\u800c\u7d30\u80de\u6838\u5206\u5316\u3001\u7d30\u80de\u6838\u7684\u6709\u7d72\u5206\u88c2\u3001\u5948\u6c0f\u6307\u6578\u22656\uff0c\u5247\u662f\u63a5\u8fd1\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u610f\u7fa9\u3002\u81f3\u65bc\u591a\u55ae\u8b8a\u9805\u5206\u6790\u5247\u672a\u5f97\u5230\u6709\u610f\u7fa9\u7684\u5371\u96aa\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u75c5\u7076\u7d44\u7e54\u58de\u6b7b\u662f\u548c\u540c\u5074\u4e73\u623f\u816b\u7624\u5fa9\u767c\u76f8\u95dc\u7684\u5371\u96aa\u56e0\u5b50\u3002", "e": "Purpose: We review our experience of treating ductal carcinoma in situ (DCIS) patients with wide excision alone and examine risk factors that are associated with ipsilateral breast tumor recurrence (IBTR).\nMaterials and Methods: Between January 1990 and December 2002, 47 out of 257 DCIS patients who were treated with wide excision alone were included in this study. The primary end point of this study was IBTR. Local control rate was calculated by Kaplan-Meier method. Variables including tumor size, nuclear grade, margin status, necrosis, mitosis, multifocal disease, ER/PR status, patient's age, microcalcification, re-excision, contralateral invasive carcinoma, and Van Nuys prognostic index (VNPI) were enrolled for analysis\nResult: With a median follow-up interval of 5.94 years, IBTR developed in 6 patients (12.5%), with 3 invasive carcinomas, and 3 DCIS. Necrosis was the only significant prognostic factor for IBTR (p= 0.0249) by Fisher's exact test. Nuclear grade, VNPI \u2265 6, and mitosis were marginal significant (p= 0.0586, p= 0.0718, and p= 0.0684, respectively). Multivariate analysis failed to identify any significant risk factors.\nConclusion: Necrosis is a significant risk factor for IBRT in patients with DCIS undergoing wide excision alone."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-149-163-a", "title": "Comparison of Altered Fractionation and Conventional Radiotherapy for Primary Central Nervous System Lymphoma", "keywords": "\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71;\u6dcb\u5df4\u816b\u7624;\u653e\u5c04\u6cbb\u7642;\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642 Central nervous system;Lymphoma;Radiation therapy;Altered fractionion", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u6cbb\u7642\u6210\u6548\uff0c\u4e26\u6bd4\u8f03\u50b3\u7d71\u8207\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u6548\u76ca\u8207\u6cbb\u7642\u76f8\u95dc\u6bd2\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1990\u5e741\u6708\u81f32004\u5e7412\u6708\u9593\uff0c44\u4f4d\u7d93\u7531\u75c5\u7406\u5b78\u6216\u81e8\u5e8a\u4e0a\u8a3a\u65b7\u70ba\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7684\u75c5\u4eba\uff0c\u65bc\u53f0\u5317\u69ae\u6c11\u7e3d\u91ab\u9662\u764c\u75c5\u4e2d\u5fc3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u8a08\u670929\u4f4d\u7537\u6027\u820715\u4f4d\u5973\u6027\uff0c\u5e73\u5747\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba64\u6b72\uff08\u7bc4\u570d\uff0c21-80\uff09\u3002\u6240\u6709\u75c5\u60a3\u4f9d\u64da\u5176\u6240\u63a5\u53d7\u7684\u6cbb\u7642\u65b9\u5f0f\u56de\u6eaf\u6027\u5206\u6210\u56db\u7d44\uff1a1)\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\uff08\u6bcf\u6b211.8-2.5\u683c\u96f7\uff0c\u6bcf\u5929\u4e00\u6b21\uff09\uff0c15\u4eba\uff1b2)\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c5\u4eba\uff1b3)\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\uff08\u6bcf\u6b211.2-1.5\u683c\u96f7\uff0c\u6bcf\u5929\u4e8c\u6b21\uff0917\u4eba\uff1b\u4ee5\u53ca4)\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c7\u4eba\u3002\u6240\u6709\u7684\u5316\u5b78\u6cbb\u7642\u7686\u5728\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u7d66\u4e88\uff0c\u5176\u4e2d10\u4f4d\u75c5\u60a3\u63a5\u53d7\u4ee5methotrexate(MTX)\u70ba\u4e3b\u7684\u5316\u5b78\u6cbb\u7642\u3002\u75c5\u60a3\u7684\u6574\u9ad4\u5b58\u6d3b\u7387(overall survival, OS)\u4ee5\u53ca\u7121\u60e1\u5316\u5b58\u6d3b\u7387(progression-free survival, PFS)\u662f\u4ee5Kaplan-Meier\u65b9\u6cd5\u8a08\u7b97\u3002\u5404\u985e\u5225\u8b8a\u9805\u9593\u662f\u4ee5log-rank test\u4f86\u6bd4\u8f03\u3002\n\u7d50\u679c\uff1a\u75c5\u60a3\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u6578\u662f24.3\u500b\u6708\uff08\u7bc4\u570d\uff0c2.7-83.1\uff09\u3002\u5728\u53ef\u4ee5\u8a55\u4f30\u53cd\u61c9\u768439\u4f4d\u75c5\u60a3\u4e2d\uff0c\u5b8c\u5168\u53cd\u61c9\u8005\u670932\u4f4d(82%)\uff0c\u90e8\u5206\u53cd\u61c9\u8005\u67095\u4f4d(13%)\u3002\u7121\u60e1\u5316\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u70ba18.9\u500b\u6708\uff0895%\u4fe1\u8cf4\u5340\u9593\uff0c10-27\uff09\uff0c\u9810\u4f30\u76841\u5e74\u30012\u5e74\u82075\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba61%\u300140%\u820710%\u3002\u6574\u9ad4\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u70ba25.8\u500b\u6708\uff0895%\u4fe1\u8cf4\u5340\u9593\uff0c16-36\uff09\uff0c\u9810\u4f30\u76841\u5e74\u30012\u5e74\u82075\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba75%\u300154%\u820715%\u3002\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u8207\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u5728\u6574\u9ad4\u5b58\u6d3b\u7387\uff08p\u503c\u70ba0.28\uff09\u8207\u7121\u60e1\u5316\u5b58\u6d3b\u7387\uff08p\u503c\u70ba0.14\uff09\u4e0a\u4e26\u6c92\u6709\u986f\u8457\u5dee\u7570\u3002\u55ae\u8b8a\u9805\u5206\u6790\u986f\u793a\u5e74\u9f61\u3001\u8eab\u9ad4\u72c0\u6cc1\uff08Karnofsky\u8868\u73fe\u5206\u6578\uff09\u8207\u662f\u5426\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u4f46\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\u53ea\u6709\u5e74\u9f61\u9054\u5230\u986f\u8457\u6027\u610f\u7fa9\u3002\u5e74\u9f61\u572864\u6b72\u4ee5\u4e0b\u7684\u75c5\u60a3\uff0c\u5176\u6574\u9ad4\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u70ba35.9\u500b\u6708\uff0c\u800c64\u6b72\u621664\u6b72\u4ee5\u4e0a\u7684\u60a3\u8005\uff0c\u5176\u6574\u9ad4\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u53ea\u670918.9\u500b\u6708\uff08p\u503c\u70ba0.011\uff09\u3002Karnofsky\u8868\u73fe\u5206\u6578\u9ad8\u65bc\u6216\u7b49\u65bc70\u5206\u7684\u60a3\u8005\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u4e2d\u4f4d\u6578\u70ba32.2\u500b\u6708\uff0c\u660e\u986f\u512a\u65bcKarnofsky\u8868\u73fe\u5206\u6578\u4f4e\u65bc70\u5206\u60a3\u8005\u768413.1\u500b\u6708\uff08p\u503c\u70ba0.016\uff09\u3002\n\u7d50\u8ad6\uff1a\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u4f7f\u7528\u65bc\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\uff0c\u5c0d\u65bc\u75be\u75c5\u7684\u63a7\u5236\u3001\u75c5\u60a3\u7684\u5b58\u6d3b\u7387\u4e26\u6c92\u6709\u660e\u986f\u7684\u5e6b\u52a9\u3002\u4f7f\u7528\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u53ef\u80fd\u6709\u6bd4\u8f03\u9ad8\u7684\u6a5f\u6703\u7522\u751f\u795e\u7d93\u6bd2\u6027\u3002\u5e74\u9f61\u8207\u8eab\u9ad4\u72c0\u6cc1\u662f\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5c0d\u65bc\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7684\u75c5\u60a3\uff0c\u61c9\u6839\u64da\u5176\u5e74\u9f61\u8207\u8eab\u9ad4\u72c0\u6cc1\u9078\u64c7\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: To assess the treatment outcomes of primary central nervous lymphoma (PCNSL) treated with different radiotherapy (RT) fractionation strategies (conventional fractionation vs. altered fractionated radiotherapy) with or without systemic chemotherapy.\nMaterials and Methods: Between January 1990 and December 2004, 44 patients with PCNSL (pathological or clinical) treated with curative radiotherapy at Taipei Veterans General Hospital were reviewed. There were 29 males and 15 females, with a median age of 64 (range, 21-80). Patients were retrospectively classified into 4 groups: 1) conventional fractionated radiotherapy alone (n=15); 2) combined conventional fractionated radiotherapy with chemotherapy (n=5); 3) altered fractionated radiotherapy (1.2-1.5 Gy per fraction, twice daily) alone (n=17); and 4) altered fractionated radiotherapy with chemotherapy (n=7). All chemotherapy, mostly (n=10) methotrexate (MTX) based regimens, were given before radiotherapy. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier method and subgroups were compared with log-rank test.\nResults: The median follow-up duration was 24.3 months (range, 2.7-83.1 months). Of the evaluable 39 patients, 32 patients (82%) obtained complete response and 5 patients (13%) had partial response. The median PFS was 18.9 months (95% confidence interval [CI], 10-27) with estimated 1-, 2- and 5-year PFS of 61%, 40% and 10%, respectively. The median OS was 25.8 months (95% CI, 16-36) with estimated 1-, 2- and 5-year survival rate of 75%, 54% and 15%, respectively. There was no significant difference in the OS and PFS between groups using conventional RT and altered fractionated RT regardless of chemotherapy (p=0.28 and 0.14, respectively). Age, Karnofsky performance status (KPS) and administration of chemotherapy were important prognostic factors in univariate analysis, but only age at diagnosis remained significant in multivariate model. Median survival was 35.9 months in patients younger than 64 and only 18.9 months in those aged 64 or older (p= 0.011). Patients with KPS \u226570 had a median survival of 32.2 months, which was longer than 13.1 months of patients with KPS \uff1c 70 (p= 0.016).\nConclusions: Altered fractionated radiotherapy is not beneficial in improving survivals of PCNSL. Age and performance status are most important prognostic predictors in PCNSL and should be taken into account in the selection of treatment modalities."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-165-178-a", "title": "Treatment Outcome Following Three-Dimensional Conformal Radiation Therapy for NK/T-Cell Lymphoma of Nasal Cavity: A Single Institute Survey in Taiwan", "keywords": "\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642;NK/T\u7d30\u80de\u6dcb\u5df4\u7624;\u9f3b\u8154;\u6574\u9ad4\u5b58\u6d3b\u7387 Three-dimensional conformal radiotherapy;NK/T-cell lymphoma;Nasal cavity;Overall survival", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9f3b\u8154NK/T\u7d30\u80de\u6dcb\u5df4\u7624\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2000\u5e748\u6708\u81f32005\u5e743\u6708\uff0c\u5171\u670911\u4f4d\u4ee5\u75c5\u7406\u7d44\u7e54\u7279\u5fb5\u548c\u7279\u6b8a\u514d\u75ab\u986f\u578b\u8a3a\u65b7\u70ba\u9f3b\u8154NK/T\u7d30\u80de\u6dcb\u5df4\u7624\u7684\u60a3\u8005\u3002\u5176\u4e2d\u7537\u60275\u4f4d\u5973\u60276\u4f4d\uff0c\u5e74\u9f61\u5206\u4f48\u4ecb\u65bc27\u81f390\u6b72\uff08\u4e2d\u4f4d\u503c\u70ba57\u6b72\uff09\u3002\u67095\u4f4d\u75c5\u4eba\u63a5\u53d74\u52306\u6b21\u7684CHOP\uff08cyclophosphamide\uff0cdoxorubicin\uff0cvincristine\u53caprednisolone\uff09\u6cbb\u7642\uff0c\u96a8\u5f8c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u53e6\u5916\u4e09\u4f4d\u5148\u63a5\u53d73\u6b21\u7684CHOP\u6cbb\u7642\u518d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u800c\u5f8c\u518d\u63a5\u53d73\u6b21\u7684CHOP\u6cbb\u7642\u3002\u6211\u5011\u6392\u9664\u4e86\u5169\u4f4d\u5728\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e2d\u6b7b\u4ea1\u7684\u60a3\u8005\u3002\u800c\u6240\u6709\u7684\u60a3\u8005\u5747\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u6839\u64da\u8a08\u756b\u7d66\u4e8850.4-54.0Gy/28-30\u6b21\u3002\n\u7d50\u679c\uff1a\u4e2d\u4f4d\u6578\u8ffd\u8e64\u671f\u70ba24.9\u500b\u6708\uff08\u7bc4\u570d\u4ecb\u65bc4\u81f375\u500b\u6708\uff09\uff0c\u5176\u4e2d9\u4f4d\u60a3\u8005\u4e2d\u67097\u4eba(78%)\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u3002\u800c\u6574\u9ad42\u5e74\u7684\u5b58\u6d3b\u7387\u70ba79%\u3002\u6709\u5169\u4f4d\u60a3\u8005\u5728\u6cbb\u7642\u5b8c\u6210\u7684\u4e00\u5e74\u5167\u6b7b\u4ea1\u3002\u5169\u5e74\u7684\u5c40\u90e8\u63a7\u5236\u7387\u548c\u7121\u9060\u7aef\u8f49\u79fb\u7387\u5206\u5225\u662f89%\u548c79%\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\u6703\u6709\u4e0d\u826f\u9810\u5f8c\u7684\u81e8\u5e8a\u56e0\u5b50\u5982\u4e0b\uff1a\u8f03\u9ad8\u7684Ann Arbor\u5206\u671f(p=0.005)\uff0cB\u578b\u75c7\u72c0\u7684\u8868\u73fe(p=0.005)\uff0c\u548c\u8f03\u9ad8\u7684International Prognostic Index (IPI)\u5206\u6578(p=0.005)\u3002\u57288\u4f4d\u7b2c\u4e00\u671f\u7684\u60a3\u8005\u4e2d\uff0c7\u4f4d\uff0888%\uff09\u9054\u5230\u816b\u7624\u5b8c\u5168\u7de9\u89e3\uff0c\u6574\u9ad42\u5e74\u5b58\u6d3b\u7387\u70ba88%\u3002\u7531\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u9020\u6210\u7684\u526f\u4f5c\u7528\u662f\u66ab\u6642\u6027\u4e14\u53ef\u63a5\u53d7\u7684\u3002\n\u7d50\u8ad6\uff1a\u5728\u6211\u5011\u7684\u7d93\u9a57\u4e2d\u767c\u73fe\uff0c\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u91dd\u5c0d\u9f3b\u8154NK/T\u7d30\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u6cbb\u7642\u7b56\u7565\u662f\uff1a\u4f7f\u7528\u5927\u65bc50Gy\u7684\u653e\u5c04\u5291\u91cf\uff0c\u5305\u8986\u53ef\u898b\u7684\u816b\u7624/\u816b\u7624\u8853\u5f8c\u7684\u5340\u57df\u52a0\u4e0a\u9069\u7576\u7684\u7bc4\u570d\uff0c\u9019\u6a23\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u5408\u7406\u7684\u3002", "e": "Purpose: To evaluate the treatment outcome following three-dimensional conformal radiotherapy (3D-CRT) for NK/T-cell lymphoma of nasal cavity.\nMaterials and Methods: Between August 2000 and March 2005, 11 patients had NK/T-cell lymphomas of nasal cavity diagnosed by histopathologic characteristics and typical immunophenotype. There were 5 males and 6 females, patients with age ranged from 27 years to 90 years (median, 57 years). Five patients were scheduled to receive 4-6 cycles of CHOP (cyclophosphamide, doxorubicin, vincrinstine and prednisolone) followed by radiotherapy. Three patients received 3 cycles of neo-adjuvant CHOP, radiotherapy, and 3 cycles of CHOP adjuvant. We excluded two patients who were dead during our radiotherapy course. All patients received 3D-CRT. The planned 3D-CRT dose was 50.4-54.0 Gy / 28-30 fractions.\nResults: The median time of follow-up was 24.9 months (range 4 to 75 months). Seven (78%) of nine patients achieved complete remission (CR). The 2-year overall survival (OS) rate was 79%. Two patients expired in the first year. The 2-year local control and distant metastasis-free rates were 89% and 79%, respectively. The clinical factors predicting worse survival in univariate analysis were as follows: advanced Ann Arbor stage (p=0.005), B symptom (p=0.005), and higher International Prognostic Index scores (p=0.005). In the stage IE group, 7 of 8 patients (88%) achieved CR. The 2-year OS rate was 88%. The side effects of 3D-CRT were temporary and acceptable.\nConclusion: In our experience, the treatment policy for NK/T cell lymphoma of nasal cavity using 3D-CRT with greater than 50 Gy to gross tumor/tumor bed plus adequate margin was feasible."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-179-188-a", "title": "The Effect of Hepatoma-Derived Growth Factor, Bcl-2, and Glutathione on Radiation-Induced Apoptosis in Hepatocellular Carcinoma Cell Lines", "keywords": "Bcl-2;GSH;HDGF;\u809d\u764c\u7d30\u80de\u682a Bcl-2;GSH;HDGF;Hepatoma cell line", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u80fd\u66f4\u4e86\u89e3\u7d30\u80de\u5167\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20(HDGF)\u3001glutathione(GSH)\u53caBcl-2\u91cf\u7b49\u56e0\u5b50\u5c0d\u809d\u764c\u7d30\u80de\u4e4b\u653e\u5c04\u654f\u611f\u6027\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9019\u56db\u7a2e\u4e0d\u540c\u5206\u5316\u4e4b\u809d\u764c\u7d30\u80de\u682a\uff0c\u7d9320 Gy\u5291\u91cf\u653e\u5c04\u8655\u7406\u5f8c\uff0c\u7528TUNEL\u87a2\u5149\u67d3\u8272\u3001\u63a5\u8457\u7528\u5171\u7126\u986f\u5fae\u93e1\u4f86\u8a08\u7b97\u7d30\u80de\u51cb\u4ea1\u4e4b\u767e\u5206\u6bd4\u3002\u800c\u672a\u653e\u5c04\u8655\u7406\u764c\u7d30\u80de\u682a\u5167Bcl-2\u86cb\u767d\u53ca\u7d30\u80de\u5167GSH\u7684\u6d3b\u6027\u91cf\u662f\u7528\u4ee5ELISA\u4f86\u5b9a\u91cf\u3002\u800c\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20\u7684\u6e2c\u5b9a\u662f\u4ee5\u6bcf\u7a2e\u7d30\u80de\u5167HDGF/\u03b2-tubulin\u86cb\u767d\u5728Western blot\u4e0a\u7684\u76f8\u5c0d\u5b9a\u91cf\u6bd4\u503c\u8a08\u7b97\u5f97\u5230\uff0c\u518d\u5c07\u4e0a\u500b\u4e09\u53c3\u6578\u8207\u7d30\u80de\u51cb\u4ea1\u4e4b\u767e\u5206\u6bd4\u4f5c\u6bd4\u5c0d\uff0cPearson\u7dda\u6027\u95dc\u4fc2\u88ab\u7528\u4f86\u4f5c\u5176\u95dc\u9023\u6027\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u7d93\u653e\u5c04\u8655\u7406\u4e4bMahlavu\u3001G2\u3001SK\u3001\u53ca3B\u56db\u7a2e\u809d\u764c\u7d30\u80de\u682a\u4e2d\uff0c\u5f15\u8d77\u4e0d\u540c\u7a0b\u5ea6\u4e4b\u7d30\u80de\u51cb\u4ea1\uff0c\u9019\u4e9b\u672a\u653e\u5c04\u8655\u7406\u7d30\u80de\u682a\u4e2dBcl-2\u86cb\u767d\u8868\u73fe\u7684\u91cf\u5206\u5225\u662f419, 204, 58\u53ca22units/mg\uff1bGSH\u7684\u91cf\u5247\u662f95, 247, 70\u53ca177umol/mg\uff1b\u800cHDGF/\u03b2-tubulin\u86cb\u767d\u6bd4\u662f0.827, 0.152, 0.987\u82070.520\u3002GSH\u53caHDGF/\u03b2-tubulin\u86cb\u767d\u6bd4\u4e4b\u9593\u6709\u8ca0\u95dc\u4fc2(R^2=0.994)\uff0c\u800cBcl-2\u4e26\u6c92\u6709\u8207GSH\u53caHDGF\u6709Pearson\u7dda\u6027\u3001\u4e8c\u6b21\u65b9\u3001\u6216\u5176\u5b83\u95dc\u4fc2\u3002\u9664\u4e86Mahlavu\u5916\uff0c\u7d30\u80de\u51cb\u4ea1\u7a0b\u5ea6\u8207HDGF\u67096\u6b63\u5411\u95dc\u4fc2(R^2=0.98)\u3001\u8207GSH\u6709\u9006\u5411\u95dc\u4fc2(R^2=0.993)\u3002\n\u7d50\u8ad6\uff1a\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20\u3001Bcl-2\u3001GSH\u7684\u91cf\u5728\u56db\u7a2e\u4e0d\u540c\u5206\u5316\u4e4b\u809d\u764c\u7d30\u80de\u682a\u5167\u6709\u4e0d\u540c\u8868\u73fe\uff0c\u809d\u764c\u7d30\u80de\u682a\u5167\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20\u7684\u91cf\u53caGSH\u6d3b\u6027\u6709\u5f88\u5f37\u95dc\u4fc2\uff0c\u800c\u809d\u764c\u7d30\u80de\u4e4b\u653e\u5c04\u7d30\u80de\u51cb\u4ea1\u53cd\u61c9\uff0c\u9664Mahlavu\u7d30\u80de\u5916\u8207\u7d30\u80de\u682a\u5167\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20\u7684\u91cf\u53caGSH\u6d3b\u6027\u6709\u5f88\u5f37\u95dc\u4fc2\u3002\u5728Mahlavu\u7d30\u80de\u4e2dBcl-2\u662f\u6240\u6709\u7d30\u80de\u682a\u4e2d\uff0c\u6709\u6700\u8f03\u9ad8\u7684\u8868\u73fe\u4e14\u7d30\u80de\u8f03\u4e0d\u6613\u51cb\u4ea1\uff0c\u5176\u76f8\u4e92\u95dc\u4fc2\u4ecd\u9700\u9032\u4e00\u6b65\u6c42\u8b49\uff0c\u4ee5\u9032\u4e00\u6b65\u4e86\u89e3\u809d\u764c\u7d30\u80de\u751f\u9577\u6fc0\u7d20\u3001GSH\u3001\u53caBcl-2\u5c0d\u816b\u7624\u7d30\u80de\u7d93\u653e\u5c04\u8655\u7406\u5f8c\u7d30\u80de\u51cb\u4ea1\u4e4b\u95dc\u4fc2\uff0c\u751a\u81f3\u6539\u8b8a\u7d30\u80de\u5167\u9019\u4e9b\u86cb\u767d\u7684\u91cf\u4f86\u6539\u5584\u6211\u5011\u6cbb\u7642\u809d\u764c\u7684\u6548\u679c\u3002", "e": "Purpose: To determine the factors affecting the apoptosis of hepatoma cells by irradiation.\nMethods and Materials: The mean percentages of apoptotic cells were determined using confocal microscope after hepatoma cells were irradiated with a single dose of 20 Gy and stained using TUNEL stain. The level of Bcl-2 protein and glutathione (GSH) content in the naive cell lysate was measured using ELISA. The ratio of hepatoma derived growth factor (HDGF)/\u03b2-tubulin of the untreated cells was calculated from the protein band in Western blot gel after densitometer quantization. The Pearson correlation between each paired parameters and the apoptosis were compared and correlation coefficiency was measured for their relationship.\nResults: The expressed factors were listed as 419, 204, 58, and 22 units/mg for Bcl-2 in the tested Mahlavu, Hep G2, Hep SK, and Hep 3B cell lysates. The GSH content were 95, 247, 70, and 177 umol/mg and the HDGF/ beta-tubulin ratio were 0.827, 0.152, 0.987, and 0.520 in those 4 cell lines. The level of HDGF/\u03b2-tubulin was inversely correlated with GSH (R^2=0.994, p=0.0032). However, Bcl-2 amounts did not correlate with GSH or HDGF/\u03b2-tubulin. Linear correlation was also observed between apoptosis and GSH except Mahlavu cell with R2 value of 0.98 (p=0.05). Mahlavu cell, with highest Bcl-2 level, exhibited relatively lower level of apoptosis.\nConclusions: The HDGF, GSH, and Bcl-2 were expressed differently among these four hepatoma cell lines with different level of radiation-induced apoptosis. The HDGF/beta-tubulin level correlated well with GSH activity. HDGF levels in the 4 hepatoma cells correlated with the degree of the radiation-induced apoptosis treated with 20 Gy. However, this differential apoptotic effect among the four different Hepatoma cell lines can not be solely attributed to the amount of GSH or HDGF contents. Highest Bcl-2 concentration was observed in the Mahlavu cell which might rescue the apoptotic effect due to irradiation. Further investigation for the Bcl-2 effect on GSH is necessary to elucidate this relationship to explore the possibility of using the combined pattern of these biomarkers as the prognostic factors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-189-196-a", "title": "Evaluation of the Dose Response of Gafchromic EBT Film for High Energy Photon Beams", "keywords": "EBT\u578b\u81ea\u986f\u5f71\u5e95\u7247;\u9060\u7aef\u7167\u5c04;\u66dd\u9732\u5f8c\u7684\u5149\u5bc6\u5ea6\u8b8a\u5316 EBT film;External beam;Post-exposed density growth", "c": "\u76ee\u7684\uff1a\u81ea\u986f\u5f71\u5e95\u7247\u8fd1\u5e74\u4f86\u5df2\u88ab\u5ee3\u6cdb\u7528\u65bc\u91ab\u5b78\u7269\u7406\u9818\u57df\u4e2d\uff0c\u5b83\u5177\u6709\u8a31\u591a\u512a\u9ede\u5305\u542b\u826f\u597d\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\u3001\u76f8\u7576\u4f4e\u7684\u80fd\u8b5c\u654f\u611f\u5ea6\u3001\u63a5\u8fd1\u7d44\u7e54\u7b49\u6548\u3001\u4e0d\u9700\u7279\u5225\u7684\u6d17\u7247\u8655\u7406\u5373\u53ef\u8a08\u8b80\u3002EBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u662fISP\u7684\u6700\u65b0\u7522\u54c1\uff0c\u4e3b\u8981\u9069\u7528\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u5291\u91cf\u9a57\u8b49\u3002\u672c\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u5373\u5728\u63a2\u8a0eEBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u5c0d\u81e8\u5e8a\u4f7f\u7528\u7684\u9ad8\u80fd\u5149\u5b50\u4e4b\u5291\u91cf\u53cd\u61c9\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4e2d\uff0c\u4ee5ELEKTA Precise LINAC\u4f5c\u8f3b\u5c04\u6e90\uff0c\u5c07EBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u5206\u5225\u66dd\u9732\u5728\u4e0d\u540c\u7684\u5149\u5b50\u80fd\u91cf\u3001\u5291\u91cf\u7387\u3001\u5206\u6b21\u53ca\u5ba4\u5167\u71c8\u5149\u4e0b\u3002\u5728\u66dd\u9732\u5f8c\u4f7f\u7528Radlink Laserport 16 scanner\u53caEpson Perfection 4990 photo scanner\uff0c\u5206\u5225\u4ee5\u7d05\u5149\u3001\u85cd\u5149\u3001\u7da0\u5149\u53ca\u7070\u968e\u4f5c\u70ba\u5149\u6e90\u9032\u884c\u8a08\u8b80\u3002\u4ee5\u8a08\u8b80\u7d50\u679c\u5efa\u7acb\u500b\u5225\u9ad8\u80fd\u5149\u5b50\u7684\u6821\u6b63\u66f2\u7dda\uff0c\u4e26\u8a55\u4f30\u96a8\u6642\u9593\u6539\u8b8a\u7684\u984f\u8272\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\u7121\u8ad6\u5728\u4e0d\u540c\u5206\u6b21\u6216\u5149\u5b50\u80fd\u91cf\u4e0b\uff0cEBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u4e26\u7121\u986f\u8457\u6027\u7684\u5dee\u7570\u5b58\u5728\u3002\u7576\u5291\u91cf\u5c0f\u65bc4 Gy\u6642\uff0c\u4ee5\u7d05\u5149\u70ba\u5149\u6e90\u7684Epson Perfection 4990 photo scanner\u6709\u6700\u9ad8\u7684\u5291\u91cf\u53cd\u61c9\uff1b\u800c\u7576\u5291\u91cf\u5927\u65bc4 Gy\u6642\uff0c\u5247\u4ee5\u7da0\u5149\u70ba\u5149\u6e90\u7684Epson Perfection 4990 photo scanner\u6709\u6700\u9ad8\u7684\u5291\u91cf\u53cd\u61c9\u3002\u800cRadlink Laserport 16 scanner\u7121\u8ad6\u5728\u5291\u91cf\u5927\u65bc\u6216\u5c0f\u65bc4 Gy\u60c5\u5f62\u4e0b\uff0c\u53cd\u61c9\u7686\u70ba\u6700\u4f4e\u3002\u8edf\u7247\u66dd\u9732\u5f8c\u7684\u5149\u5bc6\u5ea6\u8b8a\u5316\u986f\u793a\uff0c\u5728\u66dd\u9732\u5f8c1\u81f35\u5929\u6709\u4e9b\u5fae\u7684\u589e\u52a0\uff1b\u5728\u7b2c6\u5929\u51fa\u73fe\u660e\u986f\u7684\u6e1b\u5c11\u73fe\u8c61\uff1b\u57287\u81f314\u5929\u9593\u5448\u73fe\u7a69\u5b9a\u7684\u72c0\u6cc1\u3002\u9023\u7e8c\u5728\u5ba4\u5167\u71c8\u5149\u4e0b\u66dd\u973224\u5c0f\u6642\u6703\u5c0e\u81f4\u5149\u5bc6\u5ea6\u589e\u52a00.117\uff0c\u7d04\u7b49\u65bc\u63a5\u53d7\u523010cGy\u7684\u8f3b\u5c04\u66dd\u9732\u91cf\u3002\n\u7d50\u8ad6\uff1aEBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u662f\u4e00\u7a2e\u9069\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u7684\u65b0\u578b\u5291\u91cf\u8a08\uff0c\u6211\u5011\u7684\u7d50\u679c\u986f\u793a\uff0c\u5b83\u4e26\u6c92\u6709\u986f\u8457\u6027\u7684\u5206\u6b21\u4f9d\u5b58\u6027\uff0c\u800c\u4e14\u57284MV\u30016MV\u53ca10MV\u4e26\u7121\u660e\u986f\u80fd\u91cf\u4f9d\u5b58\u6027\u5b58\u5728\u3002\u4f46\u662f\u5b83\u5c0d\u65bc\u5ba4\u5167\u71c8\u5149\u7684\u4e0d\u654f\u611f\u6027\u537b\u4e0d\u5982\u6211\u5011\u6240\u9810\u671f\u7684\u597d\u3002\u96d6\u7136\u5982\u6b64\uff0c\u5b83\u4ecd\u9069\u5408\u4f5c\u70ba\u81e8\u5e8a\u5291\u91cf\u8a08\u4f7f\u7528\u3002\u6211\u5011\u5efa\u8b70EBT\u578b\u81ea\u986f\u5f71\u5e95\u7247\u5728\u66dd\u5149\u5f8c\u81f3\u5c11\u61c9\u7b4924\u5c0f\u6642\u518d\u884c\u8a08\u8b80\uff0c\u8a08\u8b80\u6642\u61c9\u4ee5\u7d05\u5149\u505a\u5149\u6e90\u4ee5\u671f\u6709\u8f03\u597d\u7684\u53cd\u61c9\u3002\u800c\u8edf\u7247\u5728\u4e0d\u4f7f\u7528\u7684\u60c5\u5f62\u4e0b\u61c9\u5118\u91cf\u81f3\u65bc\u6697\u8655\u4ee5\u907f\u514d\u4e0d\u5fc5\u8981\u7684\u5e72\u64fe\u7522\u751f\u3002", "e": "Purpose: Radiochromic film has gained increasing popularity in medical applications in recent years. It has several advantageous features, including high spatial resolution, relatively low spectral sensitivity, near tissue equivalence, and it requires no special development procedure. This study aimed to evaluate the response of new type Gafchromic EBT film for high energy photon beams in clinical use. \nMaterial and Methods: The ISP Gafchromic EBT film (prototype A) and ELEKTA Precise LINAC were used in this study. Gafchromic EBT films were exposed to radiation of difference energies, dose rates, fractionation and to the ambient light respectively. After completely being exposed, we scanned the film with Radlink Laserport 16 scanner and Epson Perfection 4990 photo scanner in red, blue, green channel and gray scale respectively. The post-exposure density growth with varied time was also evaluated. The calibration curves for high energy photon beams were established.\nResults: The results showed that the effect of dose fractionation was insignificant, and there is no significant energy dependence on 4MV, 6MV and 10MV photon beams. The response using red light source of Epson scanner against corresponding delivered dose is higher than that of the green, blue channel, gray scale and Radlink LaserPor scanner at doses below 4 Gy. The gray scale model showed the lowest response in all scanners. It is interesting that the green light source would have the highest response when the dose was greater than 4 Gy. The post-exposure density growth test showed a slight increase between 1st to 5th day, at sixth day, an obvious decrease occur, then became stable between 7th to 14th day. However, the net OD was nonlinear with time and dose, continuous exposure to the room light for 24 hours resulted in a density change of about 0.117, which is equivalent to a radiation exposure of about 10 cGy.\nConclusion: Gafchromic EBT film is a new type of film for radiotherapy dosimetry. Its response to different dose rates and dose fractionations were insignificant, but theresults of the effect for room light exposure were not as good ad expected. However, it is still a reliable dosimeter for clinical dosimetry. Our suggestion is to read the film at least 24 hours after irradiation, and scan the films with color scanner in red channel to obtain better response. Furthermore, the film should be kept properly when not in use to avoid other confoundedly influences."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-197-205-a", "title": "\u9f3b\u54bd\u764c\u60a3\u8005\u63a5\u53d7\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a98\u767c\u7b2c\u4e8c\u500b\u764c\u75c7\u4e4b\u98a8\u96aa\u8a55\u4f30", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387;\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u98a8\u96aa Intensity Modulated Radiotherapy IMRT;Fatal cancer probability;Thermoluminescent dosimeters TLDs;Risk", "c": "\u76ee\u7684\uff1a\u5229\u7528\u8f3b\u5c04\u5291\u91cf\u8a08\u4f86\u6e2c\u91cf\u8a55\u4f30\u7576\u9f3b\u54bd\u764c\u75c5\u60a3\u88ab\u57f7\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u6642\uff0c\u75c5\u60a3\u672c\u8eab\u5404\u90e8\u4f4d\u7684\u5668\u5b98\u53ef\u80fd\u63a5\u53d7\u8f03\u9ad8\u7684\u6563\u5c04\u5291\u91cf\uff0c\u662f\u5426\u6709\u8a98\u767c\u53e6\u4e00\u500b\u764c\u75c7\u4e4b\u53ef\u80fd\u6027\u53ca\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9996\u5148\u9808\u5c0d\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f\u76846 MV\u9ad8\u80fdX\u5149\u5c04\u675f\u7684\u80fd\u91cf\u53ca\u5291\u91cf\u8f38\u51fa\u505a\u6821\u6b63\uff0c\u5c071MU\u7684\u5291\u91cf\u8f38\u51fa\u6821\u6b63\u62101 cGy\u7684\u5438\u6536\u5291\u91cf\u3002\u5efa\u7acb\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD-100H)\u7684\u6e96\u78ba\u5ea6\u53ca\u5291\u91cf\u97ff\u61c9\u9748\u654f\u5ea6\uff0c\u5176\u8aa4\u5dee\u9808\u5c0f\u65bc3%\u3002\u5c07TLD-100H\u7f6e\u5165Rando\u4eba\u5f62\u5047\u9ad4\u4e2d\uff0c\u6309\u7167\u5be6\u969b\u6cbb\u7642\u60c5\u6cc1\u7167\u5c04\uff0c\u6e2c\u91cf\u5404\u90e8\u4f4d\u7684\u5e73\u5747\u5438\u6536\u5291\u91cf\uff0c\u53c3\u914cICRP60\u865f\u5831\u544a\uff0c\u6c42\u5f97\u500b\u5225\u7d44\u7e54\u6216\u5668\u5b98\u7684\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u8207\u7e3d\u9ad4\u640d\u5bb3\u7684\u5371\u96aa\u5ea6\u3002\n\u7d50\u679c\uff1a\u6574\u500b\u653e\u5c04\u6cbb\u7642\u7642\u7a0b40\u500b\u5206\u6b21(fraction)\u517172 Gy\u7684\u7e3d\u5291\u91cf\u4e2d\uff0c\u773c\u775b\u6c34\u6676\u9ad4\u63a5\u53d7\u52304.03Gy\uff0c\u5c0d\u8a98\u767c\u767d\u5167\u969c\u53ef\u80fd\u6709\u8f03\u9ad8\u7684\u98a8\u96aa\uff0c\u800c\u5fc3\u81df\u53ca\u814e\u81df\u5206\u5225\u662f0.86\u53ca0.19 Gy\uff0c\u9060\u4f4e\u65bc\u5b83\u5011\u6240\u80fd\u63a5\u53d7\u7684\u8010\u53d7\u5291\u91cf(tolerance dose)\u3002\u6839\u64daICRP60\u865f\u5831\u544a\u5167\u5bb9\u63db\u7b97\uff0c\u80ba\u90e8\u53ca\u98df\u9053\u53ef\u80fd\u67091~7%\u7684\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\uff0c\u8996\u5176\u9760\u8fd1\u6cbb\u7642\u7167\u91ce\u4f4d\u7f6e\u800c\u5b9a\uff0c\u800c\u5176\u4ed6\u5668\u5b98\u7684\u81f4\u6b7b\u764c\u75c5\u6a5f\u7387\u7d04\u7565\u70ba0.04~0.1%\u3002\n\u7d50\u8ad6\uff1a\u8a98\u767c\u764c\u75c7\u7684\u5371\u96aa\u5ea6\u5f88\u4f4e(0.75%)\uff0c\u4f46\u662f\u5c0d\u65bc\u6cbb\u7642\u90e8\u4f4d\u9644\u8fd1\u7684\u7d44\u7e54\u5176\u5371\u96aa\u5ea6\u9084\u662f\u504f\u9ad8\u7684(7%)\uff0c\u53ef\u4ee5\u91dd\u5c0d\u6cbb\u7642\u7167\u91ce\u9760\u8fd1\u5371\u6025\u6216\u8010\u53d7\u5291\u91cf\u8f03\u4f4e\u7684\u5668\u5b98\uff0c\u6216\u8005\u662f\u7e3d\u76e3\u63a7\u55ae\u4f4d(MU)\u6bd4\u8f03\u9ad8\u7684\u6bcf\u500b\u75c5\u4eba\uff0c\u5c24\u5176\u662f\u53ef\u6cbb\u7652(curable)\u7684\u5e74\u8f15\u75c5\u60a3\uff0c\u5728\u5176\u63a5\u53d7\u6574\u500b\u7642\u7a0b\u88e1\u505a\u6b64\u6e2c\u91cf\u8a55\u4f30\u7684\u5de5\u4f5c\uff0c\u4ee5\u505a\u70ba\u8b8a\u66f4\u6cbb\u7642\u8a08\u756b\u6216\u8a2d\u8a08\u7279\u6b8a\u5c4f\u853d\u7269\u4e4b\u4f9d\u64da\u3002", "e": "Purposes: The radiation dosimeters are used to measure the nasopharyngeal cancer (NPC) patients who are treated by the IMRT technique. The organs doses from scatter radiation are measured, and then the risk is evaluated. For stochastic effect, we estimate the risk for these patients to increase the chance of secondary malignancy and other possible late biological effects.\nMaterials and Methods: First of all, we calibrated the energy and output factor for 6 MV x-ray from a linear accelerator (Elekta Precise-Sli). One monitor unit (MU) output was calibrated as 1 cGy. The accuracy and sensitivity of TLD-100H dosimeters were also measured. TLD-100H dosimeters within 3% accuracy were applied in the study. TLD-100H dosimeters were placed in different anatomical positions of the Rando phantom, then the Rando phantom was irradiated the head and neck area as NPC treatment by IMRT technique. The data of different organs doses were obtained separately for each of IMRT irradiation. The tissue fatal cancer probability and total risk were estimated following the ICRP Publication No.60.\nResults: Total radiation dose in the IMRT treatment course was 72 Gy in 40 fractions. Len received 4.03 Gy, which had relatively risks to induce cataract. Heart received 0.86 and kidney received 0.19 Gy, which were far less than their maximal tolerance dose. According to the data calculation from ICRP Publication No.60 the lung and esophagus have about 1~7% fatal cancer probability, which depended on the distance of the position from radiation fields. The fatal cancer probability rate for others organs were 0.04~0.1%.\nConclusion: The overall risks for inducing fatal cancer is about 0.75%, and the risks for the adjacent tissues to the radiation fields are about 7%. However, a long term evaluation for young cancer patients with curable attempt is feasible."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-207-217-a", "title": "Olfactory Neuroblastoma: A Clinical Analysis of 13 Cases", "keywords": "\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624;\u77e5\u89ba\u795e\u7d93\u82bd\u7d30\u80de\u7624;\u653e\u5c04\u7dda\u6cbb\u7642 Olfactory Neuroblastoma;Esthesioneuroblastoma;Radiotherapy", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u60a3\u8005\u4e4b\u6cbb\u7642\u7d50\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u6eaf\u5206\u6790\u81ea1994\u5e743\u6708\u52302005\u5e7410\u6708\uff0c17\u4f4d\u65bc\u672c\u9662\u8a3a\u65b7\u70ba\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u4eba\u3002\u85c9\u7531\u81e8\u5e8a\u75c5\u6b77\u8a18\u9304\u3001\u75c5\u7406\u5831\u544a\u3001\u91ab\u5b78\u5f71\u50cf\u8207\u653e\u5c04\u7dda\u8a18\u9304\u4f86\u6536\u96c6\u75c5\u4eba\u8cc7\u6599\u3001\u6cbb\u7642\u65b9\u5f0f\u7d30\u7bc0\u8207\u8ffd\u8e64\u6cbb\u7642\u7d50\u679c\u3002\u6240\u6709\u75c5\u4eba\u6839\u64daKadish\uff0cDulguerov\u53ca6th AJCC\u4e09\u7a2e\u65b9\u5f0f\u91cd\u5b9a\u75be\u75c5\u5206\u671f\uff0c\u540c\u6642\u4e5f\u4f9dHyams\u5206\u7d1a\u65b9\u5f0f\u91cd\u5b9a\u816b\u7624\u5206\u5316\u7a0b\u5ea6\u3002\n\u7d50\u679c\uff1a\u75c5\u60a3\u5305\u62ec9\u4f4d\u7537\u6027\u82078\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u5206\u5e03\u81ea14\u81f374\u6b72\u3002\u4f9d\u64daKadish\u5206\u671f\uff0c3\u4f4d\u75c5\u60a3\u70baA\u671f\uff0c3\u4f4d\u70baB\u671f\uff0c10\u4f4d\u70baC\u671f\u3002\u6700\u5e38\u898b\u7684\u75c7\u72c0\u70ba\u6d41\u9f3b\u8840\u3002\u5176\u4e2d13\u4f4d\u75c5\u60a3\u65bc\u672c\u9662\u63a5\u53d7\u6cbb\u7642\uff0c\u5728\u7d93\u904e40.3\u6708\u7684\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\uff08\u5e73\u574748.6\u500b\u6708\uff09\uff0c6\u4f4d\u75c5\u4eba\u5b58\u6d3b\u4e14\u7121\u75be\u75c5\uff0c\u53e6\u67094\u4f4d\u75c5\u60a3\u5b58\u6d3b\u4f46\u6709\u816b\u7624\u6b98\u5b58\u3002\u67095\u4f4d\u75c5\u4eba\u5c40\u90e8\u9031\u908a\u75be\u75c5\u63a7\u5236\u5931\u6557\uff0c\u9060\u8655\u8f49\u79fb\u767c\u751f\u57282\u4f4d\u75c5\u60a3\u8eab\u4e0a\u3002\u6574\u9ad4\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba52.5%\uff0c5\u5e74\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba42%\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\uff0c\u552f\u6709\u624b\u8853\u5f8c\u816b\u7624\u6b98\u5b58\u7a0b\u5ea6\u70ba\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50(p=0.021)\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u816b\u7624\u5b8c\u5168\u6458\u9664\u662f\u6700\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5c0d\u65bc\u5373\u4f7f\u63a5\u53d7\u5ee3\u6cdb\u5207\u9664\u624b\u8853\u4ecd\u6709\u6b98\u7559\u7684\u665a\u671f\u75be\u75c5\u60a3\u8005\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7b49\u8f14\u52a9\u6cbb\u7642\u662f\u5fc5\u9700\u7684\u3002\u624b\u8853\u5207\u9664\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u4e00\u6709\u6548\u7684\u6cbb\u7642\u7d44\u5408\uff0c\u53ef\u4ee5\u63d0\u9ad8\u5c40\u90e8\u63a7\u5236\u7387\u3002\u5927\u90e8\u4efd\u7684\u816b\u7624\u5728\u63a5\u53d755-65 Gy\u7684\u5291\u91cf\u5f8c\u5747\u6709\u826f\u597d\u7684\u53cd\u61c9\u3002\u9810\u9632\u6027\u7684\u9838\u90e8\u7167\u5c04\u4e26\u975e\u5e38\u898f\u5fc5\u9700\u3002\u5c40\u90e8\u518d\u767c\u53ef\u4ee5\u5728\u6cbb\u7642\u7d50\u675f\u4e94\u5e74\u5f8c\u767c\u751f\uff0c\u56e0\u6b64\u9577\u671f\u7684\u8ffd\u8e64\u662f\u9700\u8981\u7684\u3002", "e": "Purpose: To analyze treatment outcome and prognostic factors of patients with olfactory neuroblastoma.\nMaterials and Methods: Seventeen patients with pathology-proven olfactory neuroblastoma diagnosed between March 1994 and October 2005 were analyzed retrospectively. Clinical charts, pathology reports, radiology images and radiotherapy records were reviewed. Patients' characteristics, details of treatment modalities and clinical outcome were collected. Sixteen patients were re-staged with three staging system including: Kadish, Dulguerov and the 6th AJCC staging system for nasal cavity and paranasal sinuses. Histo-pathological specimens of 17 patients were reviewed to define the tumor grading using Hyams' four-tier system.\nResults: There were 9 male and 8 female, age ranged from 14 to 74 years old. According to Kadish's classification, there were 3 stage A, 3 stage B and 10 stage C diseases. The most common symptom was epistaxis. Thirteen patients received treatment at our institute. A median follow-up time of 40.3 months (mean: 48.6 months), 6 patients were alive without disease and 4 were alive with disease. Locoregional failure occurred in 5 patients and distant metastases were noted in 2 patients. Five-year overall survival rate was 52.5% and 5-year disease free survival rate was 42%. Degree of surgery was the only significant prognostic factor in univariate analysis (p=0.021).\nConclusion: In this study, surgical intervention to total removal of the tumor was the most significant prognostic factor. Adjuvant treatment such as radiotherapy was needed for advanced diseases, in which residual tumor was notified even after radical surgery. Radiotherapy combined with surgical resection was an effective modality for treatment of olfactory neuroblastoma; this combination could provide excellent local control. Most tumors were response to the initial radiotherapy at the range of 55 to 65 Gy. Elective neck irradiation was not needed routinely. Local recurrence might happen even 5 years later, and long-term follow-up should be mandated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-219-226-a", "title": "Invasive Thymoma with Intracaval and Intracardiac Extension Treatment with Three Dimensional Conformal Radiotherapy: Report of a Case and Review of Literature", "keywords": "\u4fb5\u8972\u6027\u80f8\u817a\u7624;\u5fc3\u81df\u4fb5\u72af;\u4e0a\u8154\u975c\u8108\u4fb5\u72af;\u653e\u5c04\u6cbb\u7642 Invasive thymoma;Intracardiac extension;Intracaval extension;Radiotherapy", "c": "\u80f8\u817a\u7624\u7684\u6cbb\u7642\u662f\u4ee5\u624b\u8853\u70ba\u4e3b\uff0c\u81f3\u65bc\u653e\u5c04\u6cbb\u7642\u4e3b\u8981\u662f\u626e\u6f14\u8f14\u52a9\u6216\u7de9\u89e3\u7684\u89d2\u8272\u3002\u5c0d\u65bc\u5df2\u7d93\u6709\u5fc3\u81df\u53ca\u4e0a\u8154\u975c\u8108\u4fb5\u72af\u7684\u4fb5\u8972\u6027\u80f8\u817a\u7624\uff0c\u624b\u8853\u5207\u9664\u6703\u8b8a\u5f97\u5f88\u56f0\u96e3\u3002\u6240\u4ee5\u7576\u6709\u9019\u7a2e\u60c5\u5f62\u6642\uff0c\u653e\u5c04\u6cbb\u7642\u5247\u6210\u70ba\u6cbb\u7642\u7684\u9996\u9078\u3002\u56e0\u70ba\u80f8\u817a\u7624\u5c0d\u653e\u5c04\u7dda\u662f\u76f8\u5c0d\u654f\u611f\u7684\uff0c\u6240\u4ee5\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u9054\u5230\u6eff\u610f\u7684\u75c7\u72c0\u7de9\u89e3\u53ca\u5c40\u90e8\u63a7\u5236\u7684\u76ee\u7684\u3002\u8fd1\u5e74\u4f86\uff0c\u96a8\u8457\u6cbb\u7642\u6280\u8853\u53ca\u8a2d\u5099\u7684\u9032\u6b65\uff0c\u653e\u5c04\u6cbb\u7642\u7684\u6210\u679c\u4e5f\u96a8\u8457\u63d0\u6607\u3002\u91cd\u8981\u7684\u653e\u5c04\u6cbb\u7642\u6280\u8853\u6539\u9032\uff0c\u5305\u62ec\u6709\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642\u4ee5\u53ca\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u3002\u9019\u4e9b\u6280\u8853\u53ef\u4ee5\u9054\u5230\u589e\u52a0\u816b\u7624\u5291\u91cf\u53ca\u964d\u4f4e\u6b63\u5e38\u7d44\u7e54\u5291\u91cf\u7684\u76ee\u7684\u3002\u6211\u5011\u5831\u544a\u4e00\u500b\u4fb5\u8972\u6027\u80f8\u817a\u7624\u5408\u4f75\u5fc3\u81df\u53ca\u4e0a\u8154\u975c\u8108\u4fb5\u72af\uff0c\u55ae\u7368\u4ee5\u653e\u5c04\u7dda\u4f86\u6cbb\u7642\u4e26\u9054\u5230\u826f\u597d\u7684\u5c40\u90e8\u63a7\u5236\u7684\u6848\u4f8b\u3002", "e": "The main treatment for thymoma is surgery. The role of radiotherapy is adjuvant or palliative treatment. But when the state of thymoma with intracardiac and intracaval invasion occurs, surgery becomes difficult and radiotherapy becomes the first choice of treatment. Thymoma is relatively radiosensitive. Radiotherapy may achieve satisfactory symptom relief and local control. Recently, the improvement of technique and equipment including three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy and stereotactic radiosurgery increases the treatment result of radiotherapy. These techniques increase the tumor dose and decrease the normal tissue dose. We report a case of intracardiac and intracaval invasive thymoma treated with radiotherapy alone and resulted in good local control."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200709-14-3-227-232-a", "title": "Electron Therapy for Periorbital Basal Cell Carcinoma: A Case Report and Review of the Literature", "keywords": "\u57fa\u5e95\u7d30\u80de\u764c;\u773c\u77bc;\u653e\u5c04\u7dda\u6cbb\u7642 Basal cell carcinoma;Eyelid;Radiotherapy", "c": "\u773c\u77bc\u4e4b\u57fa\u5e95\u7d30\u80de\u764c\u70ba\u4e0d\u5e38\u898b\u7684\u76ae\u819a\u764c\u75c7\u75c5\u8b8a\u3002\u800c\u6cbb\u7642\u773c\u77bc\u57fa\u5e95\u7d30\u80de\u764c\u7684\u76ee\u6a19\u9664\u4e86\u816b\u7624\u63a7\u5236\u5916\uff0c\u6cbb\u7642\u5f8c\u7684\u5916\u89c0\u53ca\u529f\u80fd\u7684\u4fdd\u7559\u4e5f\u662f\u5f88\u91cd\u8981\u7684\u3002\u76ee\u524d\u5c0d\u65bc\u773c\u77bc\u57fa\u5e95\u7d30\u80de\u764c\u4e4b\u6cbb\u7642\u65b9\u5f0f\u6709\u8a31\u591a\uff0c\u4f46\u7a76\u7adf\u4f55\u8005\u70ba\u9996\u9078\u65b9\u5f0f\u5247\u672a\u6709\u5b9a\u8ad6\u3002\u6211\u5011\u5831\u544a\u4e86\u4e00\u4f8b77\u6b72\u7684\u773c\u77bc\u57fa\u5e95\u7d30\u80de\u764c\u7537\u6027\u60a3\u8005\uff0c\u55ae\u7368\u4ee56 MeV\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u816b\u7624\u3002\u75c5\u4eba\u7e3d\u5171\u63a5\u53d7\u4e865940 cGy\u7684\u5291\u91cf\u5f8c\uff0c\u816b\u7624\u6d88\u5931\uff0c\u4e26\u5728\u5169\u5e74\u7684\u8ffd\u8e64\u4e2d\u6c92\u6709\u767c\u73fe\u5fa9\u767c\u6216\u662f\u5176\u4ed6\u56b4\u91cd\u7684\u773c\u90e8\u4f75\u767c\u75c7\u3002\u6839\u64da\u6211\u5011\u7684\u7d93\u9a57\u53ca\u6587\u737b\u56de\u9867\uff0c\u76f8\u8f03\u65bc\u624b\u8853\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5728\u5be9\u614e\u7684\u7be9\u9078\u75c5\u4eba\u4e0b\u662f\u4e00\u7a2e\u5b89\u5168\uff0c\u7c21\u55ae\uff0c\u4e14\u53ef\u4ee5\u6e1b\u5c11\u4f4f\u9662\u7684\u6cbb\u7642\uff0c\u5176\u5c40\u90e8\u63a7\u5236\u7387\u53ca\u5c0d\u65bc\u5916\u89c0\uff0c\u529f\u80fd\u7684\u4fdd\u7559\u4ea6\u548c\u624b\u8853\u76f8\u8fd1\u3002", "e": "Basal cell carcinoma (BCC) of the eyelid is a relatively uncommon facial tumor. The goals for treatment are both definitive tumor control and preservation of the functional structures. The roles of radiotherapy and surgery in this regard are controversial. We report a 77-year-old male with a BCC of the eyelid treated by 6 MeV electron beam therapy alone to a total of 5940 cGy in 33 fractions, with an eye shield. The tumor responded well. There was no recurrence or serious ocular complication in 24 months of follow up. With careful patient selection, radiotherapy is a safe, simple alternative to surgery for BCC of the eyelid, yielding good local control and cosmetic results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-63-73-a", "title": "Treatment Results of Hypopharyngeal Cancer based", "keywords": " ", "c": "\u76ee\u7684\uff1a\u5206\u6790\u4e00\u81f3\u56db\u671f\u4e0b\u54bd\u764c\u75c5\u4eba\u63a5\u53d7\u8072\u5e36\u4fdd\u7559\u653e\u5c04\u6cbb\u7642\u4e4b\u6cbb\u7642\u7d50\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea 1996 \u5e74 1 \u6708\u81f3 2005 \u5e74 6 \u6708\uff0c\u5171\u6709 130 \u4f4d\u4e00\u81f3\u56db\u671f\u4e4b\u4e0b\u54bd\u764c\u75c5\u4eba\u5b8c\u6210\u8072\u5e36\u4fdd\u7559\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d 126 \u4f4d\u75c5\u60a3\u7684\u816b\u7624\u6e90\u767c\u90e8\u4f4d\u70ba\u68a8\u72c0\u7ac7\u3002\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u70ba\u6bcf\u65e5 1.8 Gy\uff0c\u7e3d\u5291\u91cf\u5f9e68.4 \u81f3 82.4 Gy\uff08\u4e2d\u4f4d\u503c 70.2 Gy\uff09\uff0c98 \u4f4d\u75c5\u60a3\u63a5\u53d7 cisplatin \u5408\u4f75 5-fluorouracil \u7684\u5316\u5b78\u6cbb\u7642\u3002\u5206\u6790\u9019\u4e9b\u75c5\u4eba\u4e4b\u81e8\u5e8a\u8cc7\u6599\u5f8c\uff0c\u4ee5 Kaplan-Meier \u65b9\u5f0f\u8a08\u7b97\u4e94\u5e74\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u75be\u75c5\u6709\u95dc\u5b58\u6d3b\u7387\u3001\u53ca\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\uff0c\u4e26\u4ee5 Cox\u2019s proportional hazards model \u9032\u884c\u591a\u8b8a\u6578\u5206\u6790\u5c0b\u627e\u9810\u5f8c\u6709\u95dc\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u5f8c\u7684\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u662f 39 \u500b\u6708\uff08\u7bc4\u570d\u5f9e14\u81f3120\u500b\u6708\uff09\u3002\u7b2c\u4e00\u4e8c\u671f\uff0c\u4e09\u671f\uff0c\u56db\u671f\u7684\u75c5\u60a3\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u75be\u75c5\u6709\u95dc\u5b58\u6d3b\u7387\u5206\u5225\u70ba 56%/64%\uff0c30%/43%\uff0c\u53ca 14%/15%\u3002\u800c\u6240\u6709\u75c5\u4eba\uff0c\u7b2c\u4e00\u4e8c\u671f\uff0c\u4e09\u671f\uff0c\u56db\u671f\u75c5\u60a3\u4e4b\u4e94\u5e74\u816b\u7624\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba 34%\uff0c66%\uff0c46%\uff0c18%\uff08p \u503c\u70ba0.004\uff09\u3002\u591a\u8b8a\u6578\u5206\u6790\u7d50\u679c\u986f\u793a\u7b2c\u56db\u671f\u7684\u816b\u7624\u70ba\u5c0e\u81f4\u5c40\u90e8\u5fa9\u767c\u7684\u9810\u5f8c\u56e0\u5b50\uff08p \u503c\u70ba 0.002\uff09\u3002\n\u7d50\u8ad6\uff1a\u7b2c\u4e00\u4e8c\u671f\u4e4b\u4e0b\u54bd\u764c\u75c5\u4eba\u9069\u5408\u63a5\u53d7\u8072\u5e36\u4fdd\u7559\u653e\u5c04\u6cbb\u7642\uff0c\u81f3\u65bc\u7b2c\u4e09\u671f\u75c5\u4eba\u56e0\u534a\u6578\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c\u6240\u4ee5\u8072\u5e36\u4fdd\u7559\u6cbb\u7642\u65b9\u5f0f\u7684\u89d2\u8272\u4ecd\u6709\u5f85\u9032\u4e00\u6b65\u7814\u7a76\u3002\u6b64\u5916\u7b2c\u56db\u671f\u4e4b\u75c5\u60a3\u4ee5\u540c\u6a23\u6cbb\u7642\u65b9\u5f0f\u4e4b\u9810\u5f8c\u8f03\u5dee\uff0c\u61c9\u5408\u4f75\u66f4\u7a4d\u6975\u7684\u6cbb\u7642\u7b56\u7565\u3002", "e": "Purpose : To investigate the prognostic factors for survival and locoregional control in patients with stage I-IV hypopharyngeal cancer (HPC) treated with curative-intent laryngeal preservation radiotherapy (LPRT).\nMaterials and Methods : From January 1996 through June 2005, 130 patients with stage I-IV squamous cell carcinoma of the hypopharynx were enrolled in this retrospective analysis. The pyriform sinus was the principle site of involvement in 126\ncases. All patients received 1.8 Gy daily up to a total dose of 68.4 to 82.4 Gy (median 70.2 Gy). Ninety-eight patients (75.4%) received chemotherapy combined with cisplatin plus 5-fluorouracil (5-FU). Actuarial survival (AS), disease-specific survival (DSS) and local relapse-free survival (LRFS) were calculated, and multivariate analyses were performed using the Cox\u2019s proportional hazards model.\nResults : With a median follow-up duration of 39 months (range 14 to 120 months), the 5-year AS/DSS was 56%/64% for patients with stage I-II disease, 30%/43% for stage III disease, and 14%/15% for those with stage IV disease. The 5-year LRFS rate was 34% for all patients, 66% for patients with stage I-II disease, 46% for stage III disease, and 18% for those with stage IV disease (p = 0.004). Multivariate analyses showed that stage\nIV disease was an independent prognostic factor for local recurrence (p = 0.002).\nConclusions : Patients with stage I-II disease are suitable for LPRT. Indiscriminate use of LPRT for stage III disease is still problematic because nearly half of these patients had\nunsuccessful outcomes. For most patients with stage IV, the treatment results were poor.\nMore aggressive combined modality treatment should be considered."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-75-81-a", "title": "\u665a\u671f\u80f8\u817a\u764c\u7684\u6cbb\u7642\u8207\u9810\u5f8c\u56e0\u5b50", "keywords": " ", "c": "\u76ee\u7684\uff1a\u80f8\u817a\u764c\u70ba\u7f55\u898b\u4e4b\u80f8\u8154\u60e1\u6027\u816b\u7624\uff0c\u767c\u73fe\u6642\u591a\u5df2\u665a\u671f\u4e14\u9810\u5f8c\u4e0d\u4f73\u3002\u672c\u7814\u7a76\u65e8\u5728\u5206\u6790\u665a\u671f\u80f8\u817a\u764c\u75c5\u60a3\u5728\u672c\u9662\u63a5\u53d7\u5404\u7a2e\u6cbb\u7642\u65b9\u5f0f\u7684\u7d50\u679c\u53ca\u5f71\u97ff\u6cbb\u7642\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1992\u81f3 2005\u5e74\uff0c\u5171\u670929\u4f4d\u665a\u671f\u80f8\u817a\u764c\u7684\u75c5\u60a3\u81f3\u672c\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d3\u4f4d\u5931\u53bb\u806f\u7d61\uff0c1\u4f4d\u672a\u5b8c\u6210\u6cbb\u7642\uff0c1\u4f4d\u6709\u96d9\u91cd\u764c\u75c7\u7686\u4e0d\u5217\u5165\u8a0e\u8ad6\u3002\u6cbb\u7642\u65b9\u5f0f\u9664\u653e\u5c04\u7dda\u6cbb\u7642\u5916\uff0c\u6709\u4e9b\u75c5\u60a3\u4e5f\u5408\u4f75\u63a5\u53d7\u816b\u7624\u5207\u9664\u624b\u8853\uff0c\u6216\u8005\u662f cisplatin-based \u7684\u5316\u5b78\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u4ee5\u5206\u6b21\u6cbb\u7642\uff0c\u7528\u50b3\u7d71\u524d\u5f8c\u5c0d\u7167\u3001\u6954\u5f62\u7167\u91ce\u6216\u8005\u662f\u4e09\u7dad\u7acb\u9ad4\u9806\u5f62\u6280\u8853\u4f86\u6cbb\u7642\u539f\u767c\u816b\u7624\u3002\u672c\u7814\u7a76\u5206\u6790\u75c5\u60a3\u7279\u5fb5\u3001\u662f\u5426\u63a5\u53d7\u624b\u8853\u3001\u5316\u5b78\u6cbb\u7642\u3001\u672a\u958b\u5200\u75c5\u60a3\u4e4b\u653e\u5c04\u7dda\u5291\u91cf\u3001\u6cbb\u7642\u6a21\u5f0f\u5c0d\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u5168\u9ad4 24 \u4f4d\u75c5\u60a3\u5176\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f 58 \u6b72\uff0c\u63a5\u53d7\u653e\u5c04\u7dda\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba 54.5 Gy \uff0836~66 Gy\uff09\u3002\u9664 4 \u4f4d\u75c5\u60a3 KPS \u70ba 70\uff0c\u5176\u9918\u7686\u5728 80 \u4ee5\u4e0a\u3002\u5728 24 \u4f4d\u4e2d\u6709 7 \u4f4d\u63a5\u53d7\u624b\u8853\u5207\u9664\uff0c\u6709 9 \u4f4d\u63a5\u53d7cisplatin-based \u7684\u5316\u5b78\u6cbb\u7642\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e0a\u767c\u73fe\u624b\u8853\u5207\u9664\u816b\u7624\u53ef\u4ee5\u589e\u52a0\u5b58\u6d3b\u7387\uff08p= 0.017\uff09\uff0c\u7136\u800c\u662f\u5426\u80fd\u5920\u5b8c\u5168\u5207\u9664\u816b\u7624\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u6709\u7121\u5c0d\u9810\u5f8c\u7121\u95dc\u3002\u4ee5\u591a\u8b8a\u6578\u5206\u6790\u4f86\u770b\uff0c\u624b\u8853\u5207\u9664\u6b64\u56e0\u7d20\u4ecd\u6709\u610f\u7fa9\uff08p= 0.046\uff09\u3002\u6574\u9ad4\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u70ba 26 \u500b\u6708\uff0c\u4e00\u5e74\u5b58\u6d3b\u7387\u70ba78.3%\uff0c\u4e09\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba 15.3%\u3002\u67095\u4eba\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c\u5fa9\u767c\u6642\u9593\u5f9e 2 \u81f3 49 \u500b\u6708\u300222\u540d\u75c5\u60a3\u7684\u5c40\u90e8\u63a7\u5236\u7387\u4e00\u5e74\u70ba 64.6%\uff0c\u5169\u5e74\u70ba 37.7%\u3002\n\u7d50\u8ad6\uff1a\u76ee\u524d\u5c0d\u665a\u671f\u80f8\u817a\u764c\u75c5\u60a3\u7684\u6cbb\u7642\u65b9\u6cd5\u4ecd\u7121\u6709\u6548\u7684\u6574\u5408\u3002\u4f9d\u672c\u6b21\u7814\u7a76\u7d50\u679c\uff0c\u6211\u5011\u767c\u73fe\u816b\u7624\u624b\u8853\u5207\u9664\u70ba\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5c0d\u672a\u80fd\u624b\u8853\u5207\u9664\u4e4b\u75c5\u60a3\u800c\u8a00\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u7684\u5b9a\u4f4d\u5c0d\u75c5\u60a3\u7684\u5e6b\u52a9\u4f9d\u7136\u4e0d\u660e\u3002", "e": "Purpose : Thymic carcinoma is a rare malignant mediastinal tumor. It is usually found at a late stage and the prognosis is poor. This retrospective study reviewed the treatment results of patients with advanced stage thymic carcinoma and analyzed the prognostic factors.\nMaterials and Methods : This retrospective study was to analyze 29 patients with advanced thymic carcinoma who received radiotherapy in our hospital between 1992 and 2005. Because of incomplete course of radiotherapy, lost follow-up, or double cancer, five patients were excluded. The treatment modality included external beam radiotherapy, tumor resection or cisplatin-based chemotherapy.\nFractionated radiotherapy was given in conventional or 3D conformal techniques. The characteristics of patients, receiving tumor resection, chemotherapy, the dose of radiotherapy in inoperable patients and treatment modality were analyzed to find the prognostic factors for overall survival retrospectively.\nResults : The median age was 58 year-old. The median radiotherapy dose of 24 patients was 54.5 Gy. The Karnofsky performance status was 70 for 4 of the patients, and above 80 for the rest. Seven patients received surgical resection, and 9 patients had cisplatin-based chemotherapy. The survival\nrate was improved by receiving surgical resection significantly in univariate analysis (p= 0.017) but not by the completeness of tumor resection, the dose of radiotherapy, or chemotherapy. In multivariate analysis of these factors, only receiving surgical resection still remained to improve the survival rate (p= 0.046). The median overall survival time was 26 months. One-year survival rate was 78.3% and 3-year survival rate was 15.3%. Local recurrence occurred in 5 patients, and the relapse time\nwas from 2 to 49 months. The local control rate of 22 patients at 1 and 2 years was 64.6% and 37.7% respectively.\nConclusion : There is no effective treatment protocol for patients with advance stage thymic carcinoma. In our study, we found tumor resection as an important prognostic factor in advanced stage thymic carcinoma. For unresectable thymic carcinoma, the roles of radiotherapy and chemotherapy\nremain ambiguous."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-83-93-a", "title": "Three-dimentional conformal radiotherapy  with or without oral Thalidomide for advanced hepatocellular carcinoma", "keywords": " ", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u7814\u7a76\u5c0d\u8c61\u70ba\u7121\u6cd5\u63a5\u53d7\u809d\u52d5\u8108\u5316\u5b78\u6813\u585e\u3001\u9152\u7cbe\u6ce8\u5c04\u6216\u8005\u7d93\u6cbb\u7642\u5f8c\u5fa9\u767c\u7684\u809d\u7d30\u80de\u764c\u60a3\u8005\uff0c\u5728\u5176\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u6295\u4e88\u6216\u4e0d\u6295\u4e88\u53e3\u670d\u300c\u6c99\u5229\u7ac7\u9081\u300d\uff0c\u4e26\u6bd4\u8f03\u6cbb\u7642\u6548\u679c\u662f\u5426\u6709\u6240\u5dee\u7570\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u81ea2001\u5e741\u6708\u81f32004\u5e7410\u6708\u9593\uff0c\u5171\u670937\u4f4d\u65bc\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u809d\u7d30\u80de\u764c\u60a3\u8005\u7d0d\u5165\u6b64\u6b21\u7684\u56de\u6eaf\u6027\u7814\u7a76\u3002\u9019\u4e9b\u60a3\u8005\u57281999\u5e745\u6708\u81f32004\u5e749\u6708\u9593\u88ab\u8a3a\u65b7\u70ba\u809d\u7d30\u80de\u764c\u3002\u5176\u4e2d\u67096\u4f4d\u60a3\u8005\u56e0\u70ba\u665a\u671f\u809d\u786c\u5316\uff08Child-Pugh class C\uff09\u4ee5\u53ca2\u4f4d\u56e0\u70ba\u975e\u816b\u7624\u7684\u809d\u81df\u90e8\u4efd\u5c0f\u65bc40%\u800c\u88ab\u6392\u9664\u5728\u5916\u3002\u5728\u9019\u6b21\u7d71\u8a08\u768429\u4f4d\u60a3\u8005\u4e2d\uff0c\u5171\u670917\uff0858.6%\uff09\u4f4d\u60a3\u8005\u540c\u6642\u5408\u4f75\u53e3\u670d\u300c\u6c99\u5229\u7ac7\u9081\u300d\uff08100-200 mg/day\uff09\u3002\u5728\u653e\u5c04\u6cbb\u7642\u6280\u8853\u65b9\u9762\uff0c\u4f7f\u7528\u76f4\u7dda\u52a0\u901f\u56686\u621610\u767e\u842c\u4f0f\u7279\u4e4b\u5149\u5b50\u5c04\u7dda\uff0c\u6bcf\u5929\u5291\u91cf\u70ba 160-180 cGy\uff0c\u7e3d\u5291\u91cf\u70ba 39.6-50.4 Gy\u3002\u7d71\u8a08\u4e26\u5206\u6790\u6cbb\u7642\u53cd\u61c9\u7387\u3001\u5b58\u6d3b\u7387\u4ee5\u53ca\u5176\u5f71\u97ff\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u572829\u4f4d\u60a3\u8005\u4e2d\uff0c17\u4f4d\u6709\u660e\u986f\u7684\u816b\u7624\u7e2e\u5c0f\u53cd\u61c9\uff1b\u6cbb\u7642\u53cd\u61c9\u7387\u70ba59%\u3002\u6839\u64da\u7d71\u8a08\u7d50\u679c\uff0c\u5e74\u7d00\uff08P = 0.022\uff09\u8207\u6709\u7121\u75c5\u6bd2\u6027\u809d\u708e\uff08P=0.026\uff09\u5c0d\u6cbb\u7642\u53cd\u61c9\u7387\u6709\u660e\u986f\u7684\u5f71\u97ff\u3002\u901929\u4f4d\u60a3\u8005\u5f9e\u8a3a\u65b7\u51fa\u809d\u7d30\u80de\u764c\u958b\u59cb\u7b97\u8d77\uff0c\u7b2c1\u3001\u7b2c2\u8207\u7b2c5\u5e74\u7684\u5b58\u6d3b\u7387\u5206\u5225\u70ba 57.5%\u300129.0%\u820710.1%\u3002\u5f9e\u958b\u59cb\u63a5\u53d7\u9806\u884c\u653e\u5c04\u6cbb\u7642\u958b\u59cb\u7b97\u8d77\uff0c\u7b2c6\u3001\u7b2c12\u8207\u7b2c 18 \u500b\u6708\u7684\u5b58\u6d3b\u7387\u5206\u5225\u70ba 50.4%\u300119.7% \u820711.3%\u3002\u6839\u64da\u55ae\u8b8a\u9805\u5206\u6790\uff0c\u8840\u6e05\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\uff08P=0.003\uff09\u8207\u809d\u786c\u5316\uff08P= 0.036\uff09\u5c0d\u65bc\u5b58\u6d3b\u7387\u6709\u986f\u8457\u7684\u5f71\u97ff\u3002\u4f46\u5728\u591a\u8b8a\u9805\u5206\u6790\u7684\u6a21\u5f0f\u4e0b\uff0c\u53ea\u6709\u8840\u6e05\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\uff08P = 0.01\uff09\u4ecd\u5c0d\u5b58\u6d3b\u7387\u6709\u660e\u986f\u7684\u5f71\u97ff\u3002\n\u7d50\u8ad6\uff1a\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u7121\u6cd5\u63a5\u53d7\u809d\u52d5\u8108\u5316\u5b78\u6813\u585e\u3001\u9152\u7cbe\u6ce8\u5c04\u6216\u8005\u7d93\u6cbb\u7642\u5f8c\u5fa9\u767c\u7684\u809d\u7d30\u80de\u764c\u60a3\u8005\u6709\u4e2d\u7b49\u7a0b\u5ea6\u7684\u816b\u7624\u63a7\u5236\u6548\u679c\u3002\u5c31\u77ed\u671f\u751f\u5b58\u7387\u800c\u8a00\uff0c\u5408\u4f75\u53e3\u670d\u300c\u6c99\u5229\u7ac7\u9081\u300d\u53ef\u80fd\u6709\u6539\u5584\u3002\u4f46\u662f\u5426\u53ef\u4ee5\u589e\u52a0\u60a3\u8005\u7684\u751f\u6d3b\u54c1\u8cea\u4ecd\u7136\u9700\u8981\u66f4\u9032\u4e00\u6b65\u7684\u7814\u7a76\u3002\u6b64\u5916\u7d71\u8a08\u767c\u73fe\u8f03\u9ad8\u7684\u8840\u6e05\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\uff08\u5c24\u5176\u5927\u65bc 4000 IU/ml\uff09\u6709\u660e\u986f\u8f03\u5dee\u7684\u751f\u5b58\u7387\u3002\u6211\u5011\u4ecd\u9700\u66f4\u9032\u4e00\u6b65\u3001\u66f4\u56b4\u8b39\u7684\u7814\u7a76\u4f86\u78ba\u8a8d\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u53e3\u670d\u300c\u6c99\u5229\u7ac7\u9081\u300d\u7684\u6548\u679c\u3002", "e": "Purpose : To compare the efficacy and long-term survival rates between the treatments of three-dimensional conformal radiotherapy (3D-CRT) combined with and without thalidomide for advanced hepatocellular carcinoma (HCC) patients for whom\ntransarterial embolization (TAE) or percutaneous ethanol injection therapy (PEIT) was ineffective or unsuitable.\nMaterials and Methods : From January 2001 to October 2004, 37 advanced HCC patients who received 3D-CRT at Mackay Memorial Hospital, Taipei, Taiwan were enrolled in this retrospective study. They were diagnosed as HCC during May 1999 to September 2004. Six patients with Child\u2013Pugh class C and 2 patients with nontumor part of liver below 40% were excluded from this study. Seventeen (58.6%) of 29 patients were given thalidomide (100-200 mg/day) concomitantly with 3D-CRT. All treatments were delivered by means of a linear accelerator using 6 or 10 MV photons.\nRadiotherapy was given 5 days a week with fraction dose of 1.6-1.8 Gy per day. The radiation dose to the target volume ranged from 39.6 to 50.4 Gy (46.8\u00b15.1 Gy). Treatment response, survival rates and factors affecting survival were analyzed.\nResults : Primary tumor responses were observed in 17 (59%) patients. Age (P = 0.022) and viral hepatitis (P = 0.026) significantly influenced the tumor response.\nOverall survival rates form the time of diagnosis of 29 patients at 1, 2 and 5 years were 57.5%, 29.0% and 10.1%, respectively. From the time of starting 3D-CRT, survival rates at 6, 12 and 18 months were 50.4%, 19.7% and 11.3%, respectively. The 1-year survival rate was 26.9% and 7.1% in the combined modality group and 3D-CRT alone group, respectively. On univariate analysis, both alpha-fetoprotein (AFP) level (P = 0.003) and liver cirrhosis (P =0.036) were shown to significantly affect survival. On multivariate analysis, only AFP level (P = 0.001) was shown to significantly affect survival.\nConclusion : 3D-CRT provides a moderate tumor control in hepatoma patients who failed or were unsuitable for TAE/PEIT. Addition of oral thalidomide may have a benefit\non short-term survival rate, indicating that vascular disruptive agent could be an adjunct to radiotherapy. Whether this combination improves quality of life remains to be determined.\nIn addition, higher serum AFP level, especially over 4000 IU/ml, had a signifi-cantly poor survival rate. Further randomized-controlled study is mandatory to identify the efficacy of 3D-CRT combined with thalidomide."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-95-103-a", "title": "Prognositc factor analysis for lung cancer patientswith superior vena cava syndrome treated withradiation therapy", "keywords": " ", "c": "\u76ee\u7684\uff1a\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4\uff08SVC syndrome\uff09\u767e\u5206\u4e4b\u4e5d\u5341\u7531\u60e1\u6027\u816b\u7624\u6240\u5f15\u8d77\u3002\u800c\u5176\u4e2d\u6700\u5e38\u898b\u7684\u539f\u767c\u816b\u7624\u662f\u80ba\u764c\u3002\u5728\u9019\u500b\u56de\u9867\u6027\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u63a2\u8a0e\u4e86\u59d1\u606f\u6027\u653e\u5c04\u6cbb\u7642\u5c0d\u80ba\u764c\u75c5\u60a3\u4f75\u767c\u4e4b\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4\u7684\u6cbb\u7642\u6548\u679c\u4ee5\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e 1996 \u5e74 1 \u6708\u5230 2003 \u5e74 12 \u6708\uff0c\u6211\u5011\u63a5\u53d7\u4e86 92 \u4f4d\u539f\u767c\u6027\u80ba\u764c\u5408\u4f75\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4\u7684\u75c5\u60a3\u7684\u6703\u8a3a\u800c\u9032\u884c\u653e\u5c04\u6cbb\u7642\u3002\u6211\u5011\u56de\u9867\u4e86\u6240\u6709\u75c5\u6b77\u4ee5\u53ca\u653e\u5c04\u6cbb\u7642\u7d00\u9304\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u8ffd\u8e64\u5230\u5176\u6b7b\u4ea1\u3002\u6211\u5011\u904b\u7528 Kaplan-Meier \u5b58\u6d3b\u66f2\u7dda\u4ee5\u53ca log-rank test \u6bd4\u8f03\u5404\u56e0\u5b50\u5c0d\u5b58\u6d3b\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u4e5d\u5341\u4e8c\u4f4d\u75c5\u4eba\u4e2d\u6709 53 \u4f4d\u5b8c\u6210\u7576\u521d\u6240\u8a08\u5283\u7684 30 \u845b\u96f7\u7167\u5c04\u3002\u6240\u6709\u75c5\u60a3\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba 65\u5929\u3002\u7121\u9060\u7aef\u8f49\u79fb\u75c5\u60a3\u76f8\u8f03\u65bc\u9060\u7aef\u8f49\u79fb\u75c5\u60a3\u6709\u8f03\u9577\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\uff08150 vs. 49 \u5929\uff0c p = 0.0038\uff09\u3002\u5b8c\u6210\u7576\u521d\u6240\u8a08\u5283\u7684 30 \u845b\u96f7\u7167\u5c04\u4e4b\u75c5\u60a3\u76f8\u8f03\u65bc\u7121\u6cd5\u5b8c\u6210\u7167\u5c04\u4e4b\u75c5\u60a3\u6709\u8f03\u9577\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\uff08111 vs. 14\u5929\uff0c p= 0.0006\uff09\u3002Karnofsky \u6307\u6578\u5728\u767e\u5206\u4e4b\u4e03\u5341\u4ee5\u4e0a\u7684\u75c5\u60a3\u76f8\u8f03\u65bc\u4f4e\u65bc\u4e03\u5341\u7684\u75c5\u60a3\u6709\u8f03\u9577\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\uff08107 vs. 44 \u5929\uff0cp = 0.0089\uff09\u3002\u6cbb\u7642\u5f8c\u6709\u6e1b\u8f15\u75c7\u72c0\u7684\u75c5\u60a3\u76f8\u8f03\u65bc\u6c92\u6709\u6e1b\u8f15\u6216\u52a0\u91cd\u75c7\u72c0\u7684\u75c5\n\u60a3\u6709\u8f03\u9577\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\uff08113 vs. 15 \u5929\uff0cp = 0.0000\uff09\u3002\u800c\u591a\u8b8a\u7570\u5206\u6790\u986f\u793a\u7121\u9060\u7aef\u8f49\u79fb\u70ba\u986f\u8457\u5f71\u97ff\u5b58\u6d3b\u7684\u9810\u5f8c\u56e0\u5b50\uff08p = 0.019\uff09\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u5206\u6790\u986f\u793a\uff1a\u6c92\u6709\u9060\u7aef\u8f49\u79fb\uff0cKarnofsky \u6307\u6578\u9ad8\u65bc\u6216\u7b49\u65bc 70%\uff0c\u6cbb\u7642\u5f8c\u75c7\u72c0\u6e1b\u8f15\uff0c\u5b8c\u6210\u7576\u521d\u8a08\u5283\u7684\u7642\u7a0b\uff0c\u9019\u56db\u500b\u90fd\u662f\u80ba\u764c\u5408\u4f75\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u60a3\u4e4b\u6b63\u9762\u9810\u5f8c\u56e0\u7d20\u3002", "e": "Purpose : Superior vena cava (SVC) syndrome is associated with malignancy in more than 90% of cases. Among them, lung cancers are the most common primary tumor.\nThe aim of this retrospective study was to investigate prognostic factors in lung cancer patients with SVC syndrome treated with palliative radiation therapy (RT).\nMaterials and Methods : From January 1996 to December 2003, 92 lung cancer patients with SVC syndrome were referred for RT. Clinical charts and RT records were reviewed. All patients were followed up until death. Kaplan-Meier survival curves were\ncalculated and comparisons of different subgroups were made by the log-rank test.\nResults : Fifty-three of 92 patients completed the planned RT (30 Gy). The median overall survival for all patients was 65 days. Patients without distant metastasis at RT had significantly longer median survival than those with distant metastasis at RT (150 vs. 49 days, p = 0.0038). Patients receiving complete RT had significantly longer median survival than those who received incomplete RT (111 vs. 14 days, p= 0.0006).\nPatients with Karnofsky performance scale \uff1e= 70% had significantly longer median survival than those with Karnofsky performance scale \uff1c70% (107 vs. 44 days, p = 0.0089). Patients with symptom relief after RT had significantly longer median survival than those without symptom relief (113 vs. 15 days, p = 0.0000). With multivariate analysis, only distant metastasis was a significant prognostic factor (p = 0.019).\nConclusion : Our analysis showed that no distant metastasis at RT, Karnofsky performance scale \uff1e= 70%, symptom relief after RT, and RT completion were significant favorable prognostic factors for lung cancer patients with SVC syndrome who receivedRT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-105-112-a", "title": "\ufeff\ufeff\ufeff\ufeff\ufeff\ufeff\ufeff\u8a55\u4f30\u4f7f\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\u6280\u8853\u4e8e\u4e73\u623f\u4fdd\u7559\u624b\u8853\u4e73\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642", "keywords": " ", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u5229\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\uff08field-in-field, FIF\uff09\u6280\u8853\u6cbb\u7642\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\uff08breast conservation therapy, BCT \uff09\u4e4b\u4e73\u764c\u75c5\u60a3\u816b\u7624\u4f4d\u7f6e\u4e4b\u5291\u91cf\u5747\u52fb\u6027\u53ca\u6cbb\u7642\u6240\u9700\u6642\u9593\u3002\t \n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528Focus \u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u505aBCT \u4e73\u764c\u75c5\u4eba\u4e4b\u6cbb\u7642\u8a08\u5283\uff0c \u4e26\u4f7f\u7528\u50b3\u7d71\u4e4b\u76f8\u5207\u7167\u91ce\u4f46\u4e0d\u4f7f\u7528\u6954\u578b\u6ffe\u7247\uff0c\u5728\u6b64\u5169\u500b\u76f8\u5207\u7167\u91ce\u4e2d\u5404\u81ea\u518d\u52a0\u4e0a\u5169\u500b\u884d\u751f\u51fa\u4f86\u4e4b\u8f03\u5c0f\u7167\u91ce\u3002\u6b64\u6cbb\u7642\u8a08\u5283\u50b3\u9001\u81f3Siemens\u76f4\u7dda\u52a0\u901f\u5668\u6cbb\u7642\u75c5\u4eba\uff0c\u6b64\u516d\u500b\u7167\u91ce\u53ef\u6392\u6210\u4e00\u500b\u6cbb\u7642\u5e8f\u5217\uff0c \u653e\u5c04\u5e2b\u5728\u64fa\u8a2d\u75c5\u4eba\u5f8c\uff0c\u53ef\u8b93\u6a5f\u5668\u4f9d\u5e8f\u5217\u5730\u4e00\u6b21\u5b8c\u6210\u6cbb\u7642\u3002\u53e6\u5916\u6211\u5011\u4f7f\u7528\u4e8c\u7dad\u9663\u5217Matrixx \u6e2c\u91cf\u7cfb\u7d71\uff0c \u9a57\u8b49\u6b64\u6cbb\u7642\u8a08\u5283\u4e4b\u6e96\u78ba\u6027\uff0c\u505a\u6cd5\u5982\u540c\u4e00\u822c\u505aIMRT \u6642\u4e4b\u9a57\u8b49\u65b9\u5f0f\uff0c\u628a\u6cbb\u7642\u8a08\u5283\u5957\u7528\u5230\u56fa\u9ad4\u5047\u9ad4\u4e0a\uff0c \u5b8c\u6210\u4e00\u500b\u57285.36\u516c\u5206\u6df1\u5ea6\u8655\u4e4b\u5e73\u9762\u5291\u91cf\uff0cMatrixx \u6e2c\u91cf\u7cfb\u7d71\u4ea6\u64fa\u8a2d\u5728\u76f8\u540c\u6df1\u5ea6\u505a\u6e2c\u91cf\uff0c \u5c31\u53ef\u9a57\u8b49\u6cbb\u7642\u8a08\u5283\u4e4b\u6e96\u78ba\u6027\u3002 \n\u7d50\u679c\uff1a\u63a1\u7528\u4ee5\u6b64\u65b9\u5f0f\u6cbb\u7642\u4e4b\u524d10 \u500b\u75c5\u4eba\uff0c\u6bd4\u8f03\u6b64\u65b9\u6cd5\u548c\u50b3\u7d71\u52a0\u6954\u578b\u6ffe\u7247\u4e4b\u7d50\u679c\uff0c\u6574\u9ad4\u6700\u5927\u5291\u91cf\u503c\uff08Global maximum dose \uff09\u5e73\u5747\u964d\u4f4e5% \uff0c \u5927\u65bc105% \u4e4b\u9ad4\u7a4d\u5e73\u5747\u6e1b\u5c1128%\uff0c\u5927\u65bc110% \u4e4b\u9ad4\u7a4d\u5e73\u5747\u6e1b\u5c1170%\uff0c\u5168\u90e8MU\uff08 \u6cbb\u7642\u76e3\u6e2c\u55ae\u4f4d\uff09\u5e73\u5747\u6e1b\u5c1148% \uff0c \u6bcf\u500b\u75c5\u4eba\u6bcf\u6b21\u4e4b\u6cbb\u7642\u6642\u9593\u7d04\u7bc0\u77012\u5206\u9418\u3002\u9019\u5169\u7a2e\u65b9\u6cd5\u4e4b\u524d\u8ff0\u5404\u500b\u7279\u6027\uff0c \u6211\u5011\u505a\u7d71\u8a08\u6bd4\u8f03\uff0cp\u503c\u7686\u5c0f\u65bc0.05\u3002Matrixx \u91cf\u7cfb\u7d71\u548c\u6cbb\u7642\u8a08\u5283\t\u6bd4\u8f03\u4e4b\u7d50\u679c\uff0c \u5728\u6cbb\u7642\u5340\u57df\u5167\u7686\u5c0f\u65bc1.6% \u3002\u6b64\u6280\u8853\u73fe\u5df2\u4f8b\u884c\u7528\u65bcBCT \u4e73\u764c\u75c5\u4eba\u6cbb\u7642\u3002\t \n\u7d50\u8ad6\uff1a\u4f7f\u7528\u7167\u91ce\u4e2d\u4e4b\u7167\u91ce\u4e4b\u6280\u8853\u6cbb\u7642BCT \u4e73\u764c\u75c5\u60a3\uff0c \u53ef\u8b93\u75c5\u4eba\u5f97\u5230\u8f03\u5747\u52fb\u4e4b\u5291\u91cf\u5206\u4f48\uff0c\u4e5f\u53ef\u6e1b\u5c11\ufeff\u6cbb\u7642\u6642\u9593\u53ca\u653e\u5c04\u5e2b\u4e4b\u5de5\u4f5c\u8ca0\u8377\u3002", "e": "Purpose : To develop a Field-in-Field technique for breast treatment, to produce a uniform dose distribution in the treatment volume, and to efficiently implement this technique in the clinic. \t \nMaterial and Methods : Using the Focus planning system, we first employ two tangent fields as in conventional breast treatment technique, but without using the wedge. Based on the dose distribution resulting from these open tangent fields, we create two smaller fields inside each tangent field, to achieve a more uniform dose in the breast volume. The treatment plan including the final six fields are then sent to the treatment database. In the actual treatment, these six fields are properly arranged so that they can be automatically delivered in one sequence without having to enter the treatment room. \t \nIn addition, to verify the accuracy of this technique, we used a 2D detector system to measure the delivered dose distribution in a phantom and compare it with the planned results. \t \nResults : We compared the treatment plans of the first ten patients using this field-in-field technique with those using the conventional technique. The global maximum dose was reduced by about 5%, the volumes receiving at least 105% and 110% doses were reduced by 28% and 70%, respectively. The total MU was also reduced by about 48%. The in-room time of each patient was reduced by 2 minutes. \t \nThe p-values of these comparisons were all less than 0.05. The difference between the measured and \tthe planned doses were less than 1.6% inside the treatment fields. \t \nConclusion : The Field-in-field technique can produce more uniform dose distribution inside the treatment volume for breast treatment. It also reduces the treatment time and lessens the work load for the therapist. This method has been implemented for routine clinical use."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-113-121-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u8868\u9762\u5291\u91cf\u6e2c\u91cf", "keywords": " ", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4e3b\u8981\u8a55\u4f30\u71b1\u767c\u5149\u5291\u91cf\u8a08\u5728\u9ad8\u80fd\u5149\u5b50\u5c04\u675f\u589e\u5efa\u5340\u5291\u91cf\u91cf\u6e2c\u7684\u6e96\u78ba\u6027\uff0c \u4ee5\u5efa\u7acb\u81e8\u5e8a\u4e0a\u91cf\u6e2c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08Intensity Modulated Radiotherapy, IMRT \uff09 \u982d\u9838\u90e8\u75c5\u60a3\u8868\u9762\u5291\u91cf\u4e4b\u8a55\u4f30\u65b9\u6cd5\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4e3b\u8981\u5305\u62ec\u4e09\u500b\u90e8\u4efd\uff1a(1) \u5e73\u884c\u677f\u6e38\u96e2\u8154\u65bc\u5047\u9ad4\u4e2d\u589e\u5efa\u5340\u5291\u91cf\u6e2c\u91cf\uff1b(2) \u71b1\u767c\u5149\u5291\u91cf\u8a08\u65bc\u5047\u9ad4\u4e2d\u589e\u5efa\u5340\u5291\u91cf\u6e2c\u91cf\uff1b(3) \u71b1\u767c\u5149\u5291\u91cf\u8a08\u61c9\u7528\u65bc\u64ec\u4eba\u5f62\u5047\u9ad4\u982d\u9838\u90e8\u8868\u9762\u5291\u91cf\u4e4b\u6e2c\u91cf\u3002\u5be6\u9a57\u4f7f\u7528Varian 21EX \u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f\u76846 MV \u5149\u5b50\u5c04\u675f\u3002\u91cf\u6e2c\u8a2d\u5099\u5305\u62ecMarkus \u6e38\u96e2\u8154\uff0c\u4ee5\u53ca\u539a\u5ea6\u5206\u5225\u70ba0.89 mm\u30010.38 mm \u53ca0.1 mm\u7684\u71b1\u767c\u5149\u5291\u91cf\u8a08\u3002\u5728\u5782\u76f4\u5165\u5c04\u5149\u5b50\u5c04\u675f\u91cf\u6e2c\u65b9\u9762\uff0cMarkus \u6e38\u96e2\u8154\u589e\u5efa\u5340\u5291\u91cf\u91cf\u6e2c\u6578\u64da\uff0c \u5747\u4f5c\u9069\u7576\u4fee\u6b63\uff0c\u4ee5\u5f97\u5230\u8f03\u6e96\u78ba\u7684\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\uff0c\u96a8\u5f8c\u8207\u4e0d\u540c\u539a\u5ea6\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u91cf\u6e2c\u503c\u505a\u8a55\u4f30\u6bd4\u8f03\uff0c\u4ee5\u78ba\u8a8d\u5176\u4e0d\u78ba\u5b9a\u5ea6\u3002\u50be\u659c\u5165\u5c04\u5149\u5b50\u5c04\u675f\u4e4b\u5047\u9ad4\u8868\u9762\u91cf\u6e2c\u65b9\u9762\uff0c\u5247\u4ee50.1mm\u539a\u5ea6\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u8207Markus \u6e38\u96e2\u8154\u9032\u884c\u6e2c\u91cf\u53ca\u8a55\u4f30\u6bd4\u8f03\u3002\u5728\u64ec\u4eba\u5f62\u5047\u9ad4\u982d\u9838\u90e8\u8868\u9762\u5291\u91cf\u7684\u91cf\u6e2c\u65b9\u9762\uff0c \u63a1\u75280.1 mm \u539a\u5ea6\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4e4b\u6e2c\u91cf\u503c\u8207\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u9032\u884c\u6bd4\u8f03\u3002\u7d50\u679c\uff1a\u589e\u5efa\u5340\u5291\u91cf\u91cf\u6e2c\u65b9\u9762\uff0c0.1 mm\u539a\u5ea6\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u4e4b\u6e2c\u91cf\u7d50\u679c\u8207Markus\u6e38\u96e2\u8154\uff08\u7d93\u904e\u4fee\u6b63\u5f8c\u4e4b\u6e2c\u91cf\u503c\uff09\u6709\u8f03\u597d\u7684\u543b\u5408\u5ea6\uff0c\u9069\u7528\u65bc\u81e8\u5e8a\u8868\u9762\u5291\u91cf\u7684\u91cf\u6e2c\u3002\u5be6\u969b\u91cf\u6e2cIMRT \u8868\u9762\u5291\u91cf\u65b9\u9762\uff0c\u6cbb\u7642\u8a08\u5283\u8a08\u7b97\u503c\u8207\u8d85\u8584\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u91cf\u6e2c\u503c\u7684\u6bd4\u8f03\u767c\u73fe\uff0c\u5927\u90e8\u4efd\u8a08\u7b97\u503c\u5728\u8868\u9762\u90e8\u4f4d\u6709\u660e\u986f\u4f4e\u4f30\u7684\u60c5\u5f62\u3002\u8a0e\u8ad6\uff1a\u4e0d\u540c\u539a\u5ea6\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u61c9\u7528\u65bc\u589e\u5efa\u5340\u5291\u91cf\u91cf\u6e2c\u7d50\u679c\u5dee\u7570\u660e\u986f\uff0c\u8d85\u8584\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u9069\u7528\u65bc\u8868\u9762\u5291\u91cf\u6e2c\u91cf\uff0c\u81e8\u5e8a\u4e0a\uff0c\u5176\u6e2c\u91cf\u503c\u53ef\u85c9\u4ee5\u4f5c\u70ba\u6cbb\u7642\u8a08\u5283\u4e4b\u6bd4\u8f03\u53c3\u8003\u3002", "e": "Purpose : The purpose of this study is to evaluate the accuracy of dose measurements in buildup region for high energy photon beams by using the thermoluminescence dosimeters. The method in evaluation of surface dose in intensity modulated radiotherapy for head and neck cancer has also been developed in this study.  Materials and Methods : The measurements included: (1)measurements of buildup dose in phantom by plane-parallel ionization chamber; (2) measurements of buildup dose in phantom by thermoluminescence dosimeters; (3) measurements of surface dose on head and neck Rando phantom by using thermoluminescence dosimeters. Experiments were performed for 6 MV x-ray  beams generated by a Varian 21EX linear accelerator. The instruments included the Markus plane- parallel ionization chamber and thermoluminescence dosimeters with 0.89 mm, 0.38 mm, and 0.1 \t \nmm in thickness, respectively. For normal incident beams, the dose measured in buildup region were corrected with suitable correction equations for plane-parallel ionization chamber and then evaluated the accuracy of the dose measurements in buildup region by using various thickness thermoluminescence dosimeters. The dose at phantom surface for obliquely incident beams were also measured and evaluated by the ultra-thin (0.1 mm) thermoluminescence dosimeters and plane-parallel ionization chamber for small field size (5 cm \u00d7 5 cm). For surface dose on the head and neck Rando phantom, the ultra-thin thermoluminescence dosimeters measurements were compared with the treatment planning system calculations. \t \nResults : The dose measured in buildup region by using the ultra-thin thermoluminescence dosimeters and Markus chamber are in good agreement and the former is suitable for surface dose measurements in clinical application. The underestimation of surface dose was found in treatment planning system  calculation results in comparison with ultra-thin thermoluminescence dosimeters measurements on head and neck Rando phantom. \t \nDiscussion : The dose measured in buildup region is markedly different by using TLDs in different thickness. The ultra-thin TLD is suitable for surface dose measurement, and provides the comparable reference in clinical treatment planning."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-123-130-a", "title": "\ufeffDefinitive RaDiotheRapy foR aneuRysmal Bone Cyst of the", "keywords": " ", "c": "Aneurysmal bone cysts (ABC) are rare, with a benign process, and usually found in children and young adults. Radical surgery was still the main modality of curative treatment. Radiotherapy (RT) has been used as an alternative if an adequate surgical procedure would result in significant morbidity or poor cosmetic results (such as vertebral lesions). In this paper, we present the case in which a huge ABC in the lumbar vertebra  \nwas treated with definitive RT. Images after RT demonstrated a relatively satisfactory response after radiation therapy. The patient had an obvious improvement in neurologic complaints without severe complications in the short-term observation. Furthermore, the role of RT in ABC could be discussed based on our experience and literature review.", "e": "\u52d5\u8108\u7624\u6a23\u9aa8\u56ca\u816b\u662f\u4e00\u7a2e\u7a00\u6709\u7684\u75be\u75c5\uff0c \u901a\u5e38\u4ee5\u826f\u6027\u767c\u5c55\u7684\u75c5\u7a0b\u8868\u73fe\uff0c \u7d93\u5e38\u597d\u767c\u65bc\u5152\u7ae5\u548c\u5c11\u5e74\u3002\t \n\u6839\u6cbb\u6027\u624b\u8853\u4ecd\u662f\u73fe\u4eca\u4e3b\u8981\u7684\u6cbb\u7652\u6027\u7642\u6cd5\u3002\u82e5\u662f\u9069\u5207\u7684\u624b\u8853\u6703\u9020\u6210\u4e86\u986f\u8457\u7684\u75be\u75c5\u50b7\u5bb3\u6216\u4e0d\u826f\u7684\u5916\u89c0\u8b8a\u5316\uff08 \u5982\u690e\u9aa8\u90e8\u4f4d\uff09\uff0c \u653e\u5c04\u7dda\u6cbb\u7642\u5e38\u88ab\u7576\u4f5c\u4e00\u7a2e\u66ff\u4ee3\u6027\u7642\u6cd5\u3002\u5728\u672c\u7bc7\u8ad6\u6587\u4e2d\uff0c \u6211\u5011\u63d0\u51fa\u4e86\u4e00\u500b\u75c5\u4f8b\u4ee5\u78ba\u5207\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u65bc\u8170\u690e\u9aa8\u7684\u5de8\u5927\u52d5\u8108\u7624\u6a23\u9aa8\u56ca\u816b\u3002\u653e\u7642\u5f8c\u7684\u5f8c\u7e8c\u5f71\u50cf\u5b78\u8ffd\u8e64\u8b49\u5be6\u4e86\u76f8\u5c0d\u4ee4\u4eba\u6eff\u610f\u7684\u816b\u7624\u6cbb\u7642\u53cd\u61c9\u3002\u77ed\u671f\u7684\u8ffd\u8e64\u89c0\u5bdf\u671f\u88e1\uff0c \u75c5\u4eba\u4e5f\u7372\u5f97\u660e\u986f\u7684\u795e\u7d93\u5b78\u4e0d\u9069\u7684\u6539\u5584\u4e14\u7121\u56b4\u91cd\u7684\u653e\u7642\u5f8c\u526f\u4f5c\u7528\u3002\u518d\u8005\uff0c \u57fa\u65bc\u6b64\u81e8\u5e8a\u7d93\u9a57\u53ca\u6587\u737b\u56de\u9867\uff0c \u6211\u5011\u66f4\u53ef\u95e1\u660e\u653e\u5c04\u7dda\u6cbb\u7642\u65bc\u52d5\u8108\u7624\u6a23\u9aa8\u56ca\u816b\u7684\u6cbb\u7642\u89d2\u8272\u3002"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200706-14-2-131-140-a", "title": "\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\uff1a \u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7d93\u9a57", "keywords": " ", "c": "\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\uff08olfactory neuroblastoma;ONB \uff09 \u662f\u4e00\u7a2e\u4f86\u81ea\u65bc\u55c5\u9ecf\u819c\u7684\u60e1\u6027\u816b\u7624\uff0c \u4e5f\u662f\u5728\u9f3b\u8154\u4e2d\u5c11\u898b\u7684\u816b\u7624\uff0c \u50b3\u7d71\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u4ee5\u624b\u8853\u9032\u884c\u5207\u9664\uff0c \u7136\u800c\u5e38\u4f34\u96a8\u8457\u9ad8\u5fa9\u767c\u7387\u53ca\u9ad8\u81f4\u6b7b\u7387\u3002\u672c\u6848\u4f8b\u662f\u4ee5\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff08Intensity Modulated Radiation Therapy; IMRT \uff09\u6cbb\u7642ONB \u7684\u5831\u544a\u3002\t \n\u4e00\u540d67 \u6b72\u7537\u6027\u5efa\u7bc9\u5de5\u4eba\u56e0\u53f3\u5074\u81c9\u9830\u53ca\u7259\u9f52\u75bc\u75db\u8d85\u904e\u4e00\u500b\u6708\uff0c \u7d93\u7259\u79d1\u8a3a\u6240\u62d4\u7259\u6cbb\u7642\u5f8c\u53f3\u5074\u81c9\u9830\u75bc\u75db\u4e26\u672a\u6539\u5584\uff0c\u800c\u4e14\u60c5\u6cc1\u6709\u6301\u7e8c\u52a0\u91cd\u7684\u73fe\u8c61\u56e0\u800c\u81f3\u672c\u9662\u6c42\u8a3a\u300293 \u5e745 \u670813 \u65e5\u5b89\u6392\u96fb\u8166\u65b7\u5c64\uff08computed tomography; CT \uff09\u6aa2\u67e5\u767c\u73fe\u5728\u4e0a\u981c\u7ac7\u53f3\u5074\u6709\u4e00\u816b\u584a\uff0c\u4e26\u9020\u6210\u53f3\u5074\u984d\u9aa8\u3001\u7be9\u9aa8\u53ca\u8776\u7ac7\u88ab\u7834\u58de\u3002\u8033\u9f3b\u5589\u79d1\u9032\u884c\u9032\u4e00\u6b65\u7684\u5207\u7247\u6aa2\u67e5\uff0c \u75c5\u7406\u6aa2\u67e5\u5831\u544a\u816b\u584a\u70ba\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\uff0c \u795e\u7d93\u5143\u7279\u7570\u70ef\u9187\u9176\uff08neuron specific enolase stain; NSE \uff09\u67d3\u8272\u70ba\u967d\u6027\u53cd\u61c9\uff0c\u65bc\u662f\u8f49\u4ecb\u81f3\u653e\u5c04\u816b\u7624\u79d1\u9032\u884cIMRT \u6cbb\u7642\u3002\u653e\u5c04\u6cbb\u7642\u81ea93\u5e746\u670830\u65e5\u81f393\u5e748 \u670820\u65e5\u5171\u6cbb\u76426300 cGy\uff0c\u671f\u9593\u5408\u4f752 \u6b2130 mg/M2/\u9031cisplatin \u975c\u8108\u6ce8\u5c04\u7684\u5316\u5b78\u6cbb\u7642\u300293\u5e749\u67089\u65e5CT\u986f\u793a\u5728\u4e0a\u981c\u7ac7\u53f3\u5074\u4ecd\u7136\u6709\u6b98\u7559\u7684\u816b\u7624\uff0c93\u5e7410\u67081\u65e5\u91dd\u5c0d\u6b98\u5b58\u7684\u816b\u7624\u7d66\u4e88\u5c0f\u7bc4\u570dIMRT3300cGy\u52a0\u5f37\u653e\u5c04\u7dda\u5291\u91cf\uff0c \u75c5\u60a3\u5b8c\u6210\u6cbb\u7642\u5f8c\u53f3\u5074\u81c9\u9830\u75bc\u75db\u7684\u554f\u984c\u5df2\u7372\u89e3\u6c7a\u300295 \u5e7412 \u6708CT \u8ffd\u8e64\u6aa2\u67e5\u5728\u984d\u9aa8\u3001\u4e0a\u981c\u7ac7\u3001\u7be9\u9aa8\u53ca\u8776\u7ac7\u7684\u4f4d\u7f6e\u6709\u767c\u708e\u7684\u73fe\u8c61\u4e26\u4f46\u662f\u6c92\u6709\u816b\u7624\u5fa9\u767c\u7684\u8de1\u8c61\u3002\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u5305\u62ec\u9f3b\u6dda\u7ba1\u72f9\u7a84\u3001\u963b\u585e\u6240\u9020\u6210\u7684\u53f3\u773c\u75bc\u75db\u3002\u9f3b\u6dda\u7ba1\u72f9\u7a84\u3001\u963b\u585e\u4ee5\u624b\u8853\u7684\u65b9\u5f0f\u89e3\u9664\u75c7\u72c0\uff0c \u6cbb\u7642\u7d50\u675f15\u500b\u6708\u5f8c\u75c5\u60a3\u96d9\u773c\u8996\u529b\u6709\u8996\u529b\u6e1b\u9000\u7684\u60c5\u5f62\u3002\u76ee\u524d\u5df2\u8ffd\u8e6429 \u500b\u6708\u6c92\u6709\u767c\u73fe\u5fa9\u767c\u53ca\u5176\u4ed6\u7cfb\u7d71\u6027\u7684\u75be\u75c5\u3002\t \n\u5c0d\u65bcONB \u7121\u6cd5\u958b\u5200\u7684\u75c5\u60a3\uff0cIMRT \u5408\u4f75\u6bcf\u9031cisplatin \u5316\u5b78\u6cbb\u7642\u662f\u53e6\u4e00\u7a2e\u53ef\u4ee5\u9078\u64c7\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u56e0\u70baIMRT\u53ef\u4ee5\u7d66\u4e88\u816b\u7624\u6700\u5927\u7684\u653e\u5c04\u7dda\u5291\u91cf\uff0c\u4e26\u4fdd\u8b77\u6b63\u5e38\u7684\u7d44\u7e54\uff0c\u53ef\u4ee5\u5c07\u526f\u4f5c\u7528\u6e1b\u81f3\u6700\u4f4e\u3002\u7136\u800c\uff1b\u4e0d\u5e78\u7684\u662f\u5728\u6cbb\u7642\u7684\u904e\u7a0b\u4e2d\u56e0\u8996\u795e\u7d93\u53d7\u5230\u904e\u9ad8\u8f3b\u5c04\u5291\u91cf\u7167\u5c04\u800c\u5c0d\u75c5\u60a3\u8996\u529b\u9020\u6210\u640d\u50b7\u3002\u56e0\u6b64\u96d6\u7136IMRT \u7684\u6cbb\u7642\u8a08\u756b\u53ef\u4ee5\u6e1b\u5c11\u6b63\u5e38\u7d44\u7e54\u63a5\u53d7\u7684\u5291\u91cf\uff0c \u9084\u662f\u8981\u6ce8\u610f\u6240\u6709\u53ef\u80fd\u5f15\u8d77\u7684\u50b7\u5bb3\u4ee5\u6e1b\u8f15\u6b63\u5e38\u5668\u5b98\u7684\u526f\u4f5c\u7528\u3002", "e": "Olfactory neuroblastoma (ONB) is a rare aggressive tumor of the olfactory mucosa that has been traditionally treated with radical surgical excision. Nevertheless, these rare tumors are still associated with high rates of tumor recurrence and mortality. A novel therapeutic approach using intensity modulated radiotherapy (IMRT) is presented in this report. \t \nWe would like to report a 67 years old construction worker who was referred to our department due to a chief complaint of progressive right cheek pain and right side toothache for 1 month. The patient has been previously seen by a dentist who performed a tooth extraction; however, this did not\u3000resolve his right cheek pain. A CT scan of the paranasal sinuses performed on May 13, 2004 revealed a large enhancing tumor in the right maxillary sinus with right frontal, ethmoid and sphenoid sinuses bone destruction. The patient was referred to the department of ENT for biopsy of the unresectable tumor. The pathologic finding was that of an olfactory neuroblastoma, with the tumor staining positive  for neuron specific enolase. IMRT was given to the patient for a total dose of 6300 cGy (June 30, 2004 to August 20, 2004) concurrently with 2 course of cisplatin iv infusion at 30 mg/m2 per week. \t \nA repeat CT scan on Sept. 9, 2004 revealed a residual enhancing tumor of right maxillary sinus with bone invasion. A very small field IMRT boost for 3300 cGy was then given from Oct. 1, 2004 to Nov. 4, 2004. The patient completed the whole course of radiotherapy smoothly with no treatment\u3000break. A CT scan of the sinus performed on Dec.31, 2006 revealed only frontal, maxillary, ethmoid and sphenoid sinusitis with no evidence of tumor recurrence. Radiation induced right nasolacrimal duct stenosis and obstruction, tearing of the right eye, and decreased vision of both eyes was noted 15 months after IMRT. The stenosis was successfully corrected by surgical ntervention. The patient is still well and alive 29 months after IMRT with no evidence of local recurrence or systemic disease. \t \nIMRT in conjunction with weekly cisplatin should be considered as a treatment option in patients with unresectable olfactory neuroblastoma since this technique can deliver an adequate tumorical dose; however, it is unfortunate that the patient developed significant vision impairment due to the high radiation dose to the optic nerves. Careful IMRT treatment planning is necessary to avoid or\u3000minimize untoward side effects."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-1-10-a", "title": "Rectal Sparing by Balloon Catheter Immobilization during Intensity Modulated Radiation Therapy for Prostate Cancer", "keywords": "\u76f4\u8178\u64f4\u5f35\u6c23\u7403;\u651d\u8b77\u817a\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642;\u4f4d\u79fb\u8aa4\u5dee Rectal balloon;Prostate cancer;Intensity modulated radiation therapy;Inter-fractional displacement", "c": "\u76ee\u7684\uff1a\u9010\u6b65\u589e\u52a0\u651d\u8b77\u817a\u764c\u7684\u653e\u5c04\u7dda\u5291\u91cf\u5c0d\u65bc\u5176\u9810\u5f8c\u6709\u986f\u8457\u7684\u6539\u5584\u3002\u8981\u9054\u5230\u4e00\u500b\u6700\u7406\u60f3\u7684\u6cbb\u7642\u8a08\u756b\uff0c\u5176\u5291\u91cf\u5206\u5e03\u53d7\u9650\u65bc\u5468\u570d\u7684\u6b63\u5e38\u7d44\u7e54\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u63a2\u8a0e\u651d\u8b77\u817a\u764c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642(IMRT)\u6642\uff0c\u4f7f\u7528\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u5b9a\u4f4d\u5c0d\u65bc\u6e1b\u5c11\u76f4\u8178\u5291\u91cf\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2005\u5e746\u6708\u81f38\u6708\uff0c\u5171\u670911\u4f4d\u651d\u8b77\u817a\u764c\u7684\u75c5\u60a3\u5728\u7b2c\u4e00\u6b21\u5b9a\u4f4d\u6642\uff0c\u5206\u5225\u63a5\u53d7\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\uff08\u6c23\u7403\u5167\u6253\u516560ml\u7684\u7a7a\u6c23\uff09\u53ca\u6c92\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u7684\u96fb\u8166\u65b7\u5c64(CT)\u5b9a\u4f4d\u3002\u4e26\u4e14\u5728IMRT\u7642\u7a0b\u7d50\u675f\u6642\u518d\u63a5\u53d7\u4e00\u6b21\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u7684\u96fb\u8166\u65b7\u5c64\u5b9a\u4f4d\u3002\u7531TMS Helax\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u8a2d\u8a08\u51fa\u975c\u614b\u5f0f(step-and-shoot)\u4e94\u65b9\u5411\u5171\u5e73\u9762\u7684IMRT\u6cbb\u7642\u8a08\u756b\u3002\u5206\u5225\u70ba\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u53ca\u6c92\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u88fd\u4f5c\u5169\u500b\u4e0d\u540c\u7684IMRT\u6cbb\u7642\u8a08\u756b\u3002\u81e8\u5e8a\u76ee\u6a19\u5340\u57df(CTV)\u7684\u7d66\u4e88\u5291\u91cf\u90fd\u662f78 Gy\u520639\u6b21\u6bcf\u6b212 Gy\u3002CTV\u662f\u6839\u64da\u75c5\u60a3\u6240\u5c6c\u7684\u5371\u96aa\u7fa4\u5206\u985e\u800c\u8a02\u5b9a\u3002\u8a08\u756b\u76ee\u6a19\u5340\u57df(PTV)95%\u4ee5\u4e0a\u7684\u9ad4\u7a4d\u4e5f\u8981\u9054\u523078Gy\u3002\u6309\u7167\u7d2f\u52a0\u7684\u9ad4\u7a4d\u76f4\u65b9\u5716(DVH)\u5206\u6790\u51faCTV\u3001PTV\u3001\u76f4\u8178\u53ca\u8180\u80f1\u6240\u63a5\u53d7\u7684\u5291\u91cf\u3002\u5206\u6b21\u6cbb\u7642\u9593\u651d\u8b77\u817a\u7684\u4f4d\u79fb\u8aa4\u5dee\u7684\u6e2c\u91cf\u662f\u6bd4\u8f03\u5728\u5169\u6b21\u4e0d\u540c\u7684CT\uff0c\u6700\u9760\u8fd1\u6065\u9aa8\u9802\u7aef\u7684\u90a3\u4e00\u5f35CT\u5f71\u50cf\u4e0a\u6065\u9aa8\u7de3\u5230\u651d\u8b77\u817a\u524d\u7de3\u53ca\u651d\u8b77\u817a\u5f8c\u7de3\u5230\u9aa8\u7684\u8ddd\u96e2\u3002\u7528\u6210\u5c0d\u6a23\u672ct\u6aa2\u5b9a\u8a55\u4f30\u5291\u91cf\u5206\u5e03\u5dee\u7570\u53ca\u5206\u6b21\u6cbb\u7642\u9593\u651d\u8b77\u817a\u7684\u4f4d\u79fb\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u4e2d\u5c6c\u65bcTlcN0M0\u67094\u4f4d\u75c5\u60a3\u3001T2bN0M0\u67094\u4f4d\u75c5\u60a3\uff0cT3bN0M0\u67092\u4f4d\u75c5\u60a3\uff0c\u800cT4N0M0\u67091\u4f4d\u75c5\u60a3\u3002CTV\u53ea\u5305\u542b\u651d\u8b77\u817a\u7684\u67098\u4f4d\u75c5\u60a3\uff0c\u5305\u542b\u651d\u8b77\u817a\u53ca\u5169\u5074\u5132\u7cbe\u56ca\u7684\u67093\u4f4d\u75c5\u60a3\u3002CTV\u6240\u63a5\u53d7\u6700\u4f4e\u5291\u91cf\u7684\u5e73\u5747\u503c\u70ba79Gy\u3002\u5e73\u5747\u7684\u591a\u8449\u6e96\u76f4\u5100\u79fb\u52d5\u7247\u6bb5(segment)\u7684\u6578\u91cf\u5728\u6709\u7f6e\u653e\u53ca\u6c92\u6709\u7f6e\u653e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u7684\u6cbb\u7642\u8a08\u756b\u5206\u5225\u70ba43\u53ca42(P=0.7)\u3002\u6709\u653e\u7f6e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u7684\u6cbb\u7642\u8a08\u756b\u5728\u76f4\u8178\u63a5\u53d7\u9ad8\u5291\u91cf\u7684\u9ad4\u7a4d\u4e0a\u6709\u986f\u8457\u7684\u964d\u4f4e\uff0c\u226765 Gy\u70ba13%\u53ca17% (P=0.007)\uff1b\u226770 Gy\u70ba9%\u53ca13% (P=0.005\u3002\u63a5\u53d7\u226765 Gy\u7684\u8180\u80f1\u9ad4\u7a4d\u5728\u5169\u500b\u6cbb\u7642\u8a08\u756b\u4e2d\u4e26\u6c92\u6709\u986f\u8457\u5dee\u7570\uff0818%\u53ca16%\uff0cP=0.07\uff09\u3002\u651d\u8b77\u817a\u7684\u4f4d\u79fb\u8aa4\u5dee\u5728\u6cbb\u7642\u4e4b\u524d\u53ca\u6cbb\u7642\u7d50\u675f\u6642\u662f\u76f8\u4f3c\u7684\uff0c\u6065\u9aa8\u7de3\u5230\u651d\u8b77\u817a\u524d\u7de3\u7684\u8ddd\u96e2\u70ba0.90cm\u53ca0.96cm (P=06)\uff0c\u651d\u8b77\u817a\u5f8c\u7de3\u5230\u3000\u9aa8\u7684\u8ddd\u96e2\u70ba3.69cm\u53ca3.73cm(P=0.8)\u3002\u6bcf\u4e00\u4f4d\u75c5\u60a3\u90fd\u80fd\u5bb9\u5fcd\u5728\u6574\u500bIMRT\u7684\u7642\u7a0b\u4e2d\u6bcf\u5929\u88ab\u653e\u7f6e\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u3002\u6c92\u6709\u75c5\u60a3\u767c\u751f\u7b2c\u4e09\u7d1a\u6216\u4ee5\u4e0a\u7684\u6025\u6027\u53cd\u61c9\u3002\n\u7d50\u8ad6\uff1a\u651d\u8b77\u817a\u764cIMRT\u6642\uff0c\u6bcf\u5929\u4f7f\u7528\u76f4\u8178\u64f4\u5f35\u6c23\u7403\u5b9a\u4f4d\u662f\u4e00\u500b\u53ef\u884c\u8207\u91cd\u8907\u6027\u9ad8\u7684\u6b65\u9a5f\u3002\u6b64\u65b9\u6cd5\u53ef\u4ee5\u986f\u8457\u6e1b\u5c11\u76f4\u8178\u63a5\u53d7\u9ad8\u5291\u91cf\u7684\u9ad4\u7a4d\u3002\u75c5\u60a3\u7684\u63a5\u53d7\u5ea6\u5f88\u597d\u4e14\u4e0d\u6703\u9020\u6210\u651d\u8b77\u817a\u660e\u986f\u7684\u4f4d\u79fb\u8aa4\u5dee\u3002", "e": "Purpose: Escalating radiotherapy dose results in a substantial improvement in prostate cancer outcome. Obtaining an optimal plan and acceptable dose distribution would be limited by normal critical structures. Our study is to evaluate the effect of rectal balloon immobilization in reducing rectal dose during daily treatment of prostate cancer with intensity modulated radiation therapy (IMRT).\nMaterials and Methods: From June 2005 to August 2005, 11 patients with prostate cancer underwent computed tomography (CT) simulations with and without rectal balloon (filled with 60ml air) before and at the end of IMRT course. TMS Helax treatment planning system was used to generate step-and-shoot five coplanar-field IMRT plans. Plans were separately designed with and without a rectal balloon. The prescription dose to clinical target volume (CTV) was 78 Gy in 39 fractions of 2 Gy each. CTV was determined according to the patients' risk category. The dose to 95% of planning target volume (PTV) was 78 Gy. Cumulative dose-volume histograms (DVHs) were analyzed for the CTV, PTV, rectum, and bladder. Inter-fractional prostate displacement was measured on two separate CT images with the distance between pubic bone rim/sacrum and anterior/posterior borders of prostate, respectively, at the cranial level of pubic symphysis. To assess the dosimetric difference and inter-fractional variation of balloon setup, the paired Student t-test was used.\nResults: Patients included in this study had the TNM stage distribution of T1cN0M0 in 4 patients, T2bN0M0 in 4 patients, T3bN0M0 in 2 patients, and T4N0M0 in 1 patient. CTV was prostate alone in 8 patients and prostate plus bilateral seminal vesicles in 3 patients. Minimum dose to CTV with and without a rectal balloon were both 79 Gy in average. Average segment number in plans with and without a rectal balloon were 43 and 42 (P=0.7), respectively. Plans with a rectal balloon showed a significant reduction in rectal volume fraction at 65 Gy (13% vs 17%, P=0.007), and at 70 Gy (9% vs 13%, P=0.005). Plans with a rectal balloon did not show difference in bladder volume fraction at 65 Gy (18% vs 16%, P=0.07). Inter-fractional prostate positions before and at the end of IMRT were similar in the distance from pubic bone to anterior border (0.90cm vs 0.96cm, P=0.6), and posterior border of prostate to sacrum (3.69cm vs 3.73cm, P=0.8). All patients tolerated their whole IMRT course with daily placement of rectal balloon. There was no grade \u2162 acute toxicity. \nConclusion: Rectal balloon immobilization during daily fractionated IMRT for prostate cancer is a feasible and reproducible procedure. It would be beneficial to reduce high dose to the rectum. The effect of prostate immobilization is acceptable with minimal inter-fractional setup variation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-11-18-a", "title": "The Experience of Total Body Irradiation in Bone Marrow Transplantation Patients Referred to the Chai-Yi Christian Hospital-A Preliminary Report", "keywords": "\u5168\u8eab\u653e\u5c04\u6cbb\u7642;\u9aa8\u9ad3\u79fb\u690d;\u76f4\u7dda\u52a0\u901f\u5668 Total body irradiation;Bone marrow transplantation;Linear accelerator", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u8f49\u81f3\u5609\u7fa9\u57fa\u7763\u6559\u91ab\u9662\u4f86\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u7684\u9aa8\u9ad3\u79fb\u690d\u75c5\u60a3\u7684\u521d\u6b65\u7642\u6548\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e2002\u5e748\u6708\u52302004\u5e748\u6708\u8a08\u670912\u4f4d\u767d\u8840\u75c5\u6216\u6dcb\u5df4\u7624\u8981\u9aa8\u9ad3\u79fb\u690d\u7684\u75c5\u60a3\u88ab\u8f49\u4f86\u5609\u7fa9\u57fa\u7763\u6559\u91ab\u9662\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u3002\u7576\u4e2d\u670910\u4f4d\u5b8c\u6210\u4e86\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\uff0c\u53e6\u5916\u5169\u4f4d\u5247\u53ea\u505a\u5b8c\u4e86\u6a21\u64ec\u5b9a\u4f4d\u3002\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u60a3\u8005\u7576\u4e2d\uff0c9\u4f4d\u63a5\u53d7\u4e861200cGy\uff0c\u57283\u5929\u5167\u52066\u6b21\u7167\u5c04\u5b8c\u7562\uff1b\u9084\u6709\u4e00\u4f4d\u5152\u7ae5\u5247\u63a5\u53d7\u4e861320cGy\uff0c\u57283\u5929\u5167\u52066\u6b21\u7167\u5c04\u5b8c\u7562\u3002\u6211\u5011\u4f7f\u7528\u5f9e\u52a0\u901f\u5668\u5c04\u6e90\u7126\u9ede\u5230\u75c5\u60a3\u4e2d\u8ef8\u7684\u8ddd\u96e2\u70ba600cm\u7684\u6280\u8853\u3002\u7528\u7684\u6a5f\u5668\u662f\u74e6\u91cc\u5b89\u7684\u52a0\u901f\u5668\uff0c6\u767e\u842c\u96fb\u5b50\u4f0f\u7279\u7684\u5149\u5b50\uff0c\u5291\u91cf\u535b\u70ba\u6bcf\u5206\u9418300\u5230400\u76e3\u6e2c\u55ae\u4f4d\u3002\u6240\u6709\u7684\u75c5\u60a3\u90fd\u5728\u90e8\u5206\u6d88\u6bd2\u7684\u689d\u4ef6\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u4f4f\u5728\u672c\u9662\u7684\u9aa8\u9ad3\u79fb\u690d\u75c5\u623f\u3002\u6211\u5011\u5728\u75c5\u60a3\u7684\u80f8\u90e8\u7684\u524d\u5f8c\u9806\u578b\u6bbc\u9396\u4e0a1\u516c\u5206\u7684\u906e\u64cb\u5408\u91d1\uff0c\u4e26\u63a1\u7528\u524d\u5f8c\u65b9\u5411\u7684\u7167\u5c04\u6280\u8853\uff0c\u4e26\u5728\u5165\u5c04\u65b9\u5411\u96e2\u60a3\u8005\u7d0410\u516c\u5206\u8655\u88dd\u7f6e\u4e862\u516c\u5206\u539a\u7684\u58d3\u514b\u529b\u5e73\u677f\u3002\n\u7d50\u679c\uff1a\u52302005\u5e741\u6708\u6b62\uff0c\u5b8c\u6210\u4e86\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u768410\u4f4d\u60a3\u8005\u4e2d\uff0c\u67095\u4f4d\u9084\u5b58\u6d3b\u3002\u5b58\u6d3b\u60a3\u8005\u4e4b\u4e2d\u53ea\u67091\u4f4d\u60a3\u6709\u690d\u5165\u9ad4\u5c0d\u6297\u5bbf\u4e3b\u75be\u75c5\u800c\u6709\u6162\u6027\u7684\u53e3\u8154\u9ecf\u819c\u708e\uff0c\u5176\u4ed6\u7684\u5b58\u6d3b\u60a3\u8005\u5247\u7121\u5fa9\u767c\u6216\u6709\u4f75\u767c\u75c7\u7684\u554f\u984c\uff0c\u7576\u4e2d\u751a\u81f3\u9084\u6709\u4e00\u4f4d\u672a\u5206\u5316\u7684T\u7d30\u80de\u6dcb\u5df4\u7624\u5316\u7642\u5f8c\u53ea\u6709\u90e8\u5206\u7de9\u89e3\u7684\u3002\u57285\u4f4d\u6b7b\u4ea1\u7684\u60a3\u8005\u4e2d\uff0c4\u4f4d\u6c92\u6709\u9054\u5230\u5b8c\u5168\u7684\u7de9\u89e3\u4e26\u5728\u5169\u500b\u6708\u5167\u56e0\u70ba\u690d\u9ad4\u6c92\u9577\u6210\u529f\u3001\u65e9\u671f\u5fa9\u767c\u3001\u8207\u548c\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u7121\u95dc\u7684\u6b21\u767c\u6027\u611f\u67d3\u6b7b\u53bb\u3002\u7576\u4e2d\u9084\u6709\u5169\u4f4d\u9084\u6709\u975c\u8108\u963b\u585e\u6027\u7684\u809d\u75c5\u3002\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u7684\u6b7b\u4ea1\u75c5\u4f8b\u662f\u4e00\u4f4d\u6025\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5\u7684\u60a3\u8005\uff0c\u9aa8\u9ad3\u79fb\u690d\u5f8c3\u500b\u6708\u4ed6\u5f97\u4e86\u9ef4\u83cc\u611f\u67d3\uff0c\u4e4b\u5f8c\u53c8\u6709\u816b\u7624\u5fa9\u767c\uff0c\u4e4b\u5f8c\u6b7b\u65bc15\u5e74\u5f8c\u3002\u53ea\u505a\u5b8c\u6a21\u64ec\u5b9a\u4f4d\u7684\u60a3\u8005\u5247\u56e0\u70ba\u6301\u7e8c\u7684\u5fa9\u767c\u548c\u611f\u67d3\u800c\u7121\u6cd5\u771f\u6b63\u7684\u4f86\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u3002\n\u7ed3\u8ad6\uff1a\u6211\u5011\u7684\u7d50\u679c\u986f\u793a\uff0c\u8207\u65c5\u9014\u6709\u95dc\u7684\u611f\u67d3\u554f\u984c\u5728\u8f49\u4f86\u7684\u9aa8\u9ad3\u79fb\u690d\u505a\u5168\u8eab\u653e\u5c04\u6cbb\u7642\u7684\u60a3\u8005\u7684\u9810\u5f8c\u53c3\u8003\u50f9\u503c\u4e26\u4e0d\u91cd\u8981\u3002\u96d6\u7136\u60a3\u8005\u6578\u5c11\u4e14\u8ffd\u8e64\u6642\u9593\u4e0d\u9577\uff0c\u6211\u5011\u4ecd\u8a8d\u70ba\u521d\u6b65\u7d50\u679c\u53ef\u4ee5\u63a5\u53d7\u3002\u614e\u9078\u5408\u9069\u7684\u60a3\u8005\u6703\u6709\u66f4\u597d\u7684\u7d50\u679c\uff0c\u4f46\u5c0d\u4e4b\u524d\u5316\u7642\u53ea\u6709\u90e8\u5206\u53cd\u61c9\u4e26\u4e0d\u4ee3\u8868\u79fb\u690d\u4e00\u5b9a\u5931\u6557\u3002", "e": "Purpose: The objective of this study is to evaluate the initial treatment outcome of total body irradiation (TBI) in patients with bone marrow transplantation (BMT) who were referred to the Chai-Yi Christian Hospital (CYCH).\nMaterials and Methods: From August 2002 to August 2004, 12 patients of leukemia or lymphoma were referred to the Chai-Yi Christian Hospital for TBI before BMT. Ten received TBI, and the other two received the simulation procedure only. For TBI, nine received 1200 cGy in 6 fractions over three days, and a child received 1320 cGy in 6 fractions over three days. The distance from focus of linear accelerator (LA) to middle abdomen of patients was 600cm. We used 6MeV photon at the dose rates of 300 and 400 monitor unit (MU) per minute with a Varian LA, but without a compensator. All patients were admitted to the BMT ward under partial aseptic environment. We placed a 1cm lung partial block over thermoplastic shell on the patient's chest and applied the APPA projection technique with a 2cm-thick acrylic sheet around 10cm ahead of the patient.\nResults: Of the ten patients who received TBI, five survived till January 2005. Only one patient experienced chronic graft vursus host disease with oral mucositis, and the others had no relapse or complications, including a patient with T-anaplastic cell lymphoma who had only partial remission after the chemotherapy. Of the five expired patients, four failed to achieve complete remission and died within two months due to graft failure, secondary infections not related to TBI, or early relapse. Two of them also had venous occlusive liver disease. The patient who had complete remission was a case of acute lymphoblastic leukemia who acquired fungal infection three months after the BMT followed by the relapse and died 1.5 years later. The two patients who went through simulation alone had persistent relapse, and infection episodes hindered them from receiving TBI.\nConclusion: Our results suggest that infections related to the transportation of patients did not appear to be a key prognostic factor in TBI of BMT patients referred from other hospitals. Although the follow-up time is short and patient number is small, we consider the initial outcome satisfactory. Selection of patients is essential for better result, but partial remission from initial chemotherapy may not necessarily destine to failure."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-19-27-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8154\u5167\u81a0\u7247\u5291\u91cf\u54c1\u8cea\u4fdd\u8b49", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u54c1\u8cea\u4fdd\u8b49;GafChromic EBT\u81a0\u7247;\u53e3\u8154\u5291\u91cf Intensity modulated radiation therapy;Quality assurance;GafChromic EBT film;Oral cavity dosimetry", "c": "\u76ee\u7684\uff1a\u5728\u4f7f\u7528\u65b0\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6280\u8853\u6cbb\u7642\u816b\u7624\u6642\uff0c\u85c9\u7531\u653e\u5c04\u81a0\u7247\u4f86\u505a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u4fdd\u8b49\uff0c\u662f\u975e\u5e38\u91cd\u8981\u7684\u4e00\u9805\u5de5\u4f5c\u3002\u672c\u7814\u7a76\u76ee\u7684\u70ba\u5c0dGafChromic EBT\u81a0\u7247\u9032\u884c\u4e00\u7cfb\u5217\u7684\u7279\u6027\u6e2c\u91cf\u53ca\u6821\u6b63\uff0c\u4e26\u5efa\u7acb\u8a08\u8b80\u7684\u65b9\u5f0f\u8207\u7a0b\u5e8f\uff0c\u6700\u5f8c\u5c07\u81a0\u7247\u653e\u7f6e\u65bc\u53e3\u8154\u764c\u53ca\u820c\u764c\u75c5\u60a3\u53e3\u8154\u88e1\uff0c\u5ea6\u91cf\u5176\u6240\u63a5\u53d7\u4e4b\u8f3b\u5c04\u5291\u91cf\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5728\u7814\u7a76\u7684\u904e\u7a0b\u88e1\uff0c\u5148\u5c0dGafChromic EBT\u81a0\u7247\u9032\u884c\u4e00\u7cfb\u5217\u7684\u7279\u6027\u6e2c\u91cf\u8207\u6821\u6b63\u4e26\u5efa\u7acb\u8a08\u8b80\u7a0b\u5e8f\uff0c\u4e4b\u5f8c\u5c07\u81a0\u7247\u653e\u7f6e\u65bc\u56fa\u614b\u6c34\u5047\u9ad4\u4e4b\u53c3\u8003\u9ede\u8207\u76f4\u63a5\u653e\u7f6e\u5728\u75c5\u4eba\u53e3\u8154\u5167\uff0c\u4f86\u91dd\u5c0d\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6a21\u5f0f\u4e0b\u6e2c\u91cf\u5176\u5291\u91cf\uff0c\u5c07\u5176\u6240\u5f97\u4e4b\u5291\u91cf\u8207\u6cbb\u7642\u8a08\u756b\u4e92\u76f8\u6bd4\u8f03\uff0c\u7d93\u7531\u4f7f\u7528\u9019\u4e00\u7a2e\u53e3\u8154\u8f3b\u5c04\u5291\u91cf\u5ea6\u91cf\u65b9\u6cd5\uff0c\u4f86\u9a57\u8b49\u81e8\u5e8a\u4e0a\u5be6\u969b\u5f97\u5230\u7684\u7167\u5c04\u5291\u91cf\u3002\u7d50\u679c\uff1a\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u5047\u9ad4\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6a21\u5f0f\u7167\u5c04\uff0c\u7686\u4ee5\u975c\u614b\u5f0fstep-and-shoot\u7684\u65b9\u5f0f\u7167\u5c04\u4ee5\u53ca\u4ee5\u5169\u7a2e\u4e0d\u540c\u4e4b\u5e7e\u4f55\u7167\u91ce\u7167\u5c04\u4f86\u6a21\u64ec\u75c5\u4eba\uff0c\u5176\u4e00\u7167\u91ce\u7684\u6e2c\u91cf\u7d50\u679c\u6bd4\u6cbb\u7642\u8a08\u756b\u591a2%\uff0c\u5176\u4e8c\u7167\u91ce\u7684\u6e2c\u91cf\u7d50\u679c\u6bd4\u6cbb\u7642\u8a08\u756b\u5c1137%\u3002\u800c\u5728\u53e3\u8154\u8f3b\u5c04\u6e2c\u91cf\u7d50\u679c\u4e2d\uff0c\u53e3\u8154\u764c\u75c5\u60a3\u6e2c\u91cf\u7d50\u679c\u8207\u6cbb\u7642\u8a08\u756b\u76f8\u6bd4\uff0c\u5176\u5e73\u5747\u8aa4\u5dee\u70ba256%(+0.5%~+53%)\uff0c\u800c\u820c\u764c\u75c5\u60a3\u6e2c\u91cf\u7d50\u679c\u8207\u6cbb\u7642\u8a08\u756b\u76f8\u6bd4\uff0c\u5176\u5e73\u5747\u8aa4\u5dee\u70ba\uff0d526%(-34%~-71%)\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u672c\u5be6\u9a57\u77ad\u89e3GafChromic EBT\u81a0\u7247\u4e4b\u7d50\u69cb\u8207\u7279\u6027\uff0c\u4ee5\u53ca\u5efa\u7acb\u4e00\u5957\u5305\u62ec\u6821\u6b63\u8207\u8a08\u8b80\u7a0b\u5e8f\uff0c\u4e14\u5efa\u8b70\u5728\u4f7f\u7528\u6642\u6240\u61c9\u8a72\u6ce8\u610f\u7684\u4e8b\u9805\uff0c\u4ee5\u964d\u4f4e\u8aa4\u5dee\u7684\u767c\u751f\u3002\u4e26\u85c9\u7531\u76f4\u63a5\u7684\u65b9\u5f0f\uff0c\u5c07\u81a0\u7247\u7f6e\u653e\u65bc\u75c5\u60a3\u53e3\u8154\u5167\u8a08\u8b80\u5176\u5291\u91cf\uff0c\u4ee5\u9054\u5230\u54c1\u8cea\u4fdd\u8b49\u7684\u76ee\u7684\u3002", "e": "Purpose: The intensity modulated radiation therapy (IMRT) quality assurance (QA) by film is a very important job when using the new technique of IMRT to treat tumor. The aim of this study is first to measure the characteristic of the GafChromic EBT film, calibration and establish a procedure of reading, then we do an oral cavity dosimetry for buccal and tongue cancers.\nMaterials and Methods: We use the new developed GafChromic EBT film for oral cavity dosimetry study in this work. First, we measure the characteristic of the film and establish a procedure for reading. Second, we put the film into the solid water phantom's reference point and the patient's oral cavity to do oral cavity dosimetry for IMRT. We have compared the results with treatment planning system. Our oral cavity dosimetry can verify the real tumor dose in clinic situation.\nResults: The measured dosimetry results for solid water phantom are 2% more than treatment planning system in case one, and 3.7% less than treatment planning system in case two. For oral cavity dosimetry, the error is 2.56% for buccal cancer and 5.26% for tongue cancer\nConclusion: By this study, we can understand the structure and characteristic of this newly developed film as well as establish procedure of calibration and readings. In order to reduce error and increase accuracy, we also made suggestions for using this film to do dose measurements. Through patient oral cavity dosimetry, we can achieve the goal of quality assurance."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-29-35-a", "title": "\u4ee5\u4e0d\u540c\u659c\u7167\u6280\u8853\u7167\u5c04\u4e73\u623f\u4e4b\u6bd4\u8f03", "keywords": "\u4e73\u623f\u659c\u5c0d\u7167\u5c04;\u514d\u6c96\u6d17\u5e95\u7247;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u6b63\u7b97\u5f0f\u8abf\u5f37\u653e\u7642;\u6df7\u5408\u578b\u8abf\u5f37\u653e\u7642 Tangential breast irradiation;GAFCROMIC film;Intensity modulated radiotherapy;Forward IMRT;Hybrid IMRT", "c": "\u76ee\u7684\uff1a\u5229\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u4e73\u764c\u75c5\u60a3\u65e9\u5df2\u88ab\u8b49\u5be6\u53f8\u4ee5\u6709\u6548\u6e1b\u4f4e\u5c40\u90e8\u5fa9\u767c\u7387\uff0c\u4f46\u7531\u65bc\u526f\u4f5c\u7528\u592a\u5927\uff0c\u5e38\u4f7f\u5f97\u75c5\u60a3\u62d2\u7d55\u6216\u4e2d\u65b7\u6cbb\u7642\uff0c\u6548\u679c\u56e0\u800c\u5927\u6253\u6298\u6263\u3002\u9020\u6210\u9019\u4e9b\u4f75\u767c\u75c7\u7684\u4e3b\u8981\u539f\u56e0\u662f\u50b3\u7d71\u659c\u5c0d\u7167\u65b9\u5f0f\u7684\u5291\u91cf\u4e0d\u5747\u52fb\u5ea6\u904e\u5927\u6240\u5c0e\u81f4\uff0c\u9019\u500b\u5be6\u9a57\u7684\u76ee\u7684\u5247\u662f\u627e\u51fa\u4e00\u500b\u6700\u9069\u5207\u7684\u6cbb\u7642\u65b9\u5f0f\u4f86\u7167\u5c04\u4e73\u623f\u90e8\u4f4d\uff0c\u5e0c\u671b\u672a\u4f86\u53ef\u5ee3\u6cdb\u61c9\u7528\u65bc\u81e8\u5e8a\u6cbb\u7642\u4e0a\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u9019\u6b21\u7684\u7814\u7a76\u8a55\u4f30\u6578\u7a2e\u4e73\u623f\u659c\u5c0d\u7167\u65b9\u5f0f\uff0c\u5206\u5225\u4ee5\u4e8c\u7a2e\u4e0d\u540c\u7684\u65b9\u5f0f\u4f86\u505a\u6bd4\u8f03\u548c\u63a2\u8a0e\u3002\u7b2c\u4e00\u70ba\u6cbb\u7642\u8a08\u5283\u7d50\u679c\u7684\u6bd4\u8f03\uff0c\u7b2c\u4e8c\u662f\u5229\u7528\u5047\u9ad4\u53ca\u514d\u6c96\u6d17\u5e95\u7247\u9a57\u8b49\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8a08\u7b97\u6e96\u78ba\u5ea6\u53ca\u5404\u6cbb\u7642\u65b9\u5f0f\u57f7\u884c\u7684\u7cbe\u6e96\u5ea6\u7b49\u3002\u4ee5\u4e0b\u56db\u7a2e\u6cbb\u7642\u6280\u8853\u5c07\u5206\u5225\u904b\u7528\u65bc6\u4f4d\u4e73\u764c\u75c5\u60a3\u7684\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u4f86\u57f7\u884c\u6cbb\u7642\u8a08\u5283\uff1a\u50b3\u7d71\u659c\u5c0d\u7167\u3001\u53cd\u7b97\u5f0f\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08\u8abf\u5f37\u653e\u7642\uff09\u659c\u5c0d\u7167\u3001\u6b63\u7b97\u5f0f\u8abf\u5f37\u653e\u7642\u659c\u5c0d\u7167\u3001\u50b3\u7d71\u8207\u8abf\u5f37\u653e\u7642\u7d50\u5408\uff08\u6df7\u5408\u578b\u8abf\u5f37\u653e\u7642\uff09\u659c\u5c0d\u7167\u3002\n\u7d50\u679c\uff1a\u8207\u50b3\u7d71\u659c\u5c0d\u7167\u6bd4\u8f03\uff0c\u6df7\u5408\u578b\u8abf\u5f37\u653e\u7642\u3001\u6b63\u7b97\u5f0f\u8abf\u5f37\u653e\u7642\u8207\u53cd\u7b97\u5f0f\u8abf\u5f37\u653e\u7642\u4e09\u8005\u5747\u53ef\u9054\u6210\u8f03\u4f73\u7684\u5291\u91cf\u5206\u5e03\u3002\u9776\u9ad4\u7a4d\u5916\u7d44\u7e54\u5927\u65bc110%\u7d66\u4e88\u5291\u91cf\u4e4b\u5340\u57df\uff0c\u50b3\u7d71\u659c\u5c0d\u7167\u662f\u6700\u5927\u7684\uff1b\u5fc3\u81df\u5291\u91cf\u5927\u65bc30Gy\u4e4b\u9ad4\u7a4d\u6bd4\u4f8b\uff0c\u4ee5\u53cd\u7b97\u5f0f\u8abf\u5f37\u653e\u7642\u70ba\u6700\u5927\uff1b\u8207\u60a3\u90e8\u540c\u5074\u80ba\u90e8\u5291\u91cf\uff0c\u4ecd\u7136\u4ee5\u53cd\u7b97\u5f0f\u8abf\u5f37\u653e\u7642\u6700\u5927\u3002\u6bd4\u8f03\u5047\u9ad4\u5be6\u6e2c\u8207\u6cbb\u7642\u8a08\u756b\u7684\u7d50\u679c\u986f\u793a\uff0c\u56db\u7a2e\u4e0d\u540c\u7684\u7167\u5c04\u65b9\u5f0f\u90fd\u883b\u7b26\u5408\u7684\uff0c\u4f46\u5728\u5047\u9ad4\u908a\u7de3\u7686\u51fa\u73fe\u5291\u91cf\u9ad8\u4f30\u7684\u60c5\u5f62\u3002\u7d50\u8ad6\u8207\u8a0e\u8ad6\uff1a\u6df7\u5408\u578b\u8abf\u5f37\u653e\u7642\u4e0d\u50c5\u63d0\u5347\u4e86\u9776\u9ad4\u7a4d\u7684\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u66f4\u91cd\u8981\u7684\u662f\u5728\u4e0d\u589e\u52a0\u80ba\u90e8\u5291\u91cf\u7684\u524d\u63d0\u4e0b\uff0c\u5927\u5e45\u6e1b\u5c11\u5468\u570d\u8edf\u7d44\u7e54\u7684\u9ad8\u5291\u91cf\u5340\uff0c\u6b64\u5916\uff0c\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u672c\u6280\u8853\u4e4b\u6cbb\u7642\u8a08\u5283\u53ca\u57f7\u884c\u6cbb\u7642\u6240\u8017\u8cbb\u7684\u6642\u9593\u5e7e\u4e4e\u8207\u50b3\u7d71\u6cbb\u7642\u65b9\u5f0f\u76f8\u7576\uff0c\u4e0d\u81f3\u65bc\u5728\u6a5f\u5668\u6216\u4eba\u529b\u4e0a\u9020\u6210\u984d\u5916\u7684\u8ca0\u64d4\u3002", "e": "Purpose: External-beam radiotherapy for breast cancer has been shown to reduce the local recurrence. The potentially important gains are often offset by side effect. A major contributing factor to these complications is the inhomogeneity of the dose distribution from tangential irradiation. The objective of this study is to find out the optimal method for breast irradiation which would be applied for clinical patient treatment in the future. \nMaterials and Methods: Several treatment techniques for tangential breast irradiation were evaluated in this study. The comparisons include two subjects. First, some clinical relevant factors were compared in the result of planning. Second, we will verify the delivery accuracy and delivery time for all techniques using phantom and GAFCHROMIC film. The following four plan techniques were applied for 6 patients: conventional tangents, Intensity modulated radiotherapy (IMRT) only tangents, forward IMRT tangents, and conventional open plus IMRT tangents (Hybrid IMRT). \nResult: The IMRT only tangents, forward IMRT tangents and Hybrid IMRT achieved dose distributions better than conventional tangents. The volume of tissue outside the planning target volume receiving \uff1e110% of prescribed dose was largest for conventional tangents. Heart volume \uff1e30 Gy was largest for IMRT only tangents. Average total lung volume \uff1e20 Gy was largest for IMRT only tangents too. Compare the result in measurement and calculation. Overall, TPS showed good agreement with the measurement in all techniques. However, it was found that there were significant discrepancies in the surface of the phantom. \nConclusion and Discussion: The hybrid IMRT improve the uniformity of target. The most important is reducing high dose area to the surrounding soft tissue while no increase dose to lung. Besides, planning and treatment time for hybrid techniques is almost the same with conventional technique."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-37-46-a", "title": "\u5718\u9ad4\u885b\u6559\u764c\u75c7\u71df\u990a\u77e5\u8b58\u5c0d\u65bc\u75c5\u60a3\u8207\u5bb6\u5c6c\u4e4b\u6210\u6548\u63a2\u8a0e", "keywords": "\u764c\u75c7;\u71df\u990a\u885b\u6559;\u77e5\u8b58 Cancer;Nutritional education program;Knowledge", "c": "Purpose: The health education program is an important intervention provided by nurses, to help patients in self care and health promotion information or skills. The purpose of this study is to examine the effects of nutritional education program on knowledge and satisfaction of cancer patients and their family.\nMethods: Pre/post-test design was used in one group of subjects this study. A total of 34 subjects were enrolled in this study. We carried out a structural education program regarding nutrition, radiation-related side effects, and appropriate diet for cancer patients in a radiotherapy clinic of medical center in Taiwan.\nResults: The statistical results revealed that the score of knowledge was 8.72 after education program was significantly higher than that of 3.03 at baseline (p\uff1c0.05). The score of knowledge correlated with the educational level. Subjects with the degree of senior high school or higher had a higher score of knowledge. The percentage of satisfaction was 87% after education program, significantly higher than that (80%) at baseline (p\uff1c0.05).\nConclusion: The nutritional education program had significant effects on knowledge and satisfaction of cancer patients and their family.", "e": "Purpose: The health education program is an important intervention provided by nurses, to help patients in self care and health promotion information or skills. The purpose of this study is to examine the effects of nutritional education program on knowledge and satisfaction of cancer patients and their family.\nMethods: Pre/post-test design was used in one group of subjects this study. A total of 34 subjects were enrolled in this study. We carried out a structural education program regarding nutrition, radiation-related side effects, and appropriate diet for cancer patients in a radiotherapy clinic of medical center in Taiwan.\nResults: The statistical results revealed that the score of knowledge was 8.72 after education program was significantly higher than that of 3.03 at baseline (p\uff1c0.05). The score of knowledge correlated with the educational level. Subjects with the degree of senior high school or higher had a higher score of knowledge. The percentage of satisfaction was 87% after education program, significantly higher than that (80%) at baseline (p\uff1c0.05).\nConclusion: The nutritional education program had significant effects on knowledge and satisfaction of cancer patients and their family."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-47-55-a", "title": "Primary Mucosa-Associated Lymphoid Tissue Lymphoma of the Larynx: A Case Report and Literature Review", "keywords": "\u5589\u90e8;\u7c98\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54\u6dcb\u5df4\u7624;\u6162\u6027\u5589\u708e;\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u611f\u67d3 Larynx;MALT lymphoma;chronic laryngitis;H. pylon infection", "c": "\u539f\u767c\u6027\u5589\u7c98\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54\u6dcb\u5df4\u7624\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u539f\u767c\u60e1\u6027\u816b\u7624\uff0c\u5728\u904e\u53bb\u7684\u6587\u737b\u4e2d\uff0c\u50c5\u767c\u8868\u904e15\u500b\u75c5\u4f8b\u3002\u6211\u5011\u5831\u544a\u4e00\u500b\u65e9\u671f\u539f\u767c\u6027\u5589\u7c98\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54\u6dcb\u5df4\u7624\u7684\u75c5\u4f8b\uff0c\u540c\u6642\u4f34\u96a8\u6709\u6162\u6027\u5589\u708e\u53ca\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u611f\u67d3\u3002\u75c5\u60a3\u5728\u5b8c\u6210\u653e\u5c04\u7dda\u6cbb\u7642\u516d\u500b\u6708\u5f8c\uff0c\u767c\u73fe\u5c40\u90e8\u5fa9\u767c\uff0c\u4e4b\u5f8c\u96d6\u7136\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u53ca\u6297CD20\u55ae\u682a\u6297\u9ad4\u7642\u6cd5\uff0c\u5176\u75c5\u60c5\u4e26\u672a\u7372\u5f97\u6709\u6548\u6539\u5584\u3002\u6b64\u75c5\u60a3\u4e4b\u5f8c\u63a5\u53d7\u5168\u5589\u5207\u9664\u624b\u8853\uff0c\u4e14\u9023\u7e8c\u8ffd\u8e6416\u500b\u6708\u4e26\u672a\u518d\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u60c5\u6cc1\u767c\u751f\u3002\u539f\u767c\u6027\u5589\u7c98\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54\u6dcb\u5df4\u7624\u7684\u6cbb\u7642\uff0c\u76ee\u524d\u4ecd\u662f\u81e8\u5e8a\u4e0a\u7684\u4e00\u9805\u6311\u6230\u3002\u56e0\u6b64\u6211\u5011\u56de\u9867\u6587\u737b\u4e2d\u6709\u95dc\u7c98\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54\u6dcb\u5df4\u7624\u4e4b\u81e8\u5e8a\u8868\u73fe\u3001\u75c5\u614b\u751f\u7406\u3001\u6cbb\u7642\u7b56\u7565\u53ca\u9810\u5f8c\uff0c\u4e26\u91dd\u5c0d\u6b64\u4e00\u75c5\u60a3\u6cbb\u7642\u6548\u679c\u4e0d\u5f70\uff0c\u63d0\u51fa\u53ef\u80fd\u7684\u89e3\u91cb\u3002", "e": "Mucosa-associated lymphoid tissue (MALT) lymphoma in the larynx represents a very rare entity in primary malignant tumors and no more than 15 cases have been reported in the literatures. We present a case diagnosed with early stage MALT lymphoma of larynx associated with chronic laryngitis and gastric H. pylon infection. Local relapse was noted six months after radiotherapy. Recurrent disease revealed poor response for chemotherapy and anti-CD20 therapy. Salvage surgery with total laryngectomy was performed. No evidence of disease was observed after 16 months of follow-up. The treatment of primary MALT lymphoma in the larynx remains a challenge. We review the literatures of the clinical features, pathophysiology, treatment modalities and outcomes of MALT lymphoma, and try to explain the poor treatment result of our case."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200703-14-1-57-62-a", "title": "Occult Breast Cancer Presenting as Axillary Nodal Metastases-A Case Report and Review of the Literature", "keywords": "\u96b1\u6027\u4e73\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u814b\u4e0b\u6dcb\u5df4\u7d50\u8f49\u79fb Occult breast cancer;Radiotherapy;Axillary node metastasis", "c": "\u6211\u5011\u5831\u544a\u4e00\u4f4d53\u6b72\u5973\u6027\u75c5\u4eba\u4ee5\u814b\u4e0b\u6dcb\u5df4\u7d50\u8f49\u79fb\u4f86\u8868\u73fe\u539f\u767c\u4f4d\u7f6e\u4e0d\u660e\u7684\u4e73\u764c\u3002\u8d77\u521d\u7684\u75c7\u72c0\u70ba\u53f3\u908a\u814b\u4e0b\u816b\u75db\uff0c\u4f46\u4e73\u623f\u4e26\u6c92\u6709\u89f8\u6478\u5230\u816b\u584a\u3002\u4e73\u623f\u651d\u5f71\u6c92\u6709\u767c\u73fe\u4e73\u623f\u5167\u816b\u584a\uff0c\u53ea\u6709\u5448\u73fe\u53f3\u814b\u4e0b\u591a\u8655\u9ad8\u7dfb\u5bc6\u5ea6\u7684\u6dcb\u5df4\u7d50\u3002\u6b63\u5b50\u6383\u63cf\u6aa2\u67e5\u7d50\u679c\u70ba\u53f3\u908a\u814b\u4e0b\u53ca\u53f3\u908a\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7d50\u967d\u6027\u986f\u5f71\u3002\u7d93\u904e\u7d30\u80de\u7a7f\u523a\u6aa2\u67e5\u5f8c\uff0c\u78ba\u5b9a\u6dcb\u5df4\u817a\u7684\u7d30\u80de\u578b\u614b\u70ba\u8f49\u79fb\u6027\u7684\u817a\u764c\uff0c\u96cc\u6fc0\u7d20\u63a5\u53d7\u9ad4\u8207\u9ec3\u9ad4\u6fc0\u7d20\u63a5\u53d7\u9ad4\u7686\u70ba\u967d\u6027\u3002\u4ee5\u4e0a\u8cc7\u6599\u986f\u793a\u75c5\u4eba\u6709\u539f\u767c\u4f4d\u7f6e\u4e0d\u660e\u4e4b\u4e73\u764c\u3002\u75c5\u4eba\u5728\u63a5\u53d7\u904e\u53f3\u814b\u4e0b\u6dcb\u5df4\u7d50\u6e05\u9664\u624b\u8853\u53ca\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u518d\u7e7c\u7e8c\u63a5\u53d7\u53f3\u4e73\u53ca\u53f3\u9396\u9aa8\u4e0a\u6dcb\u5df4\u5340\u7684\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u4eba\u5728\u6cbb\u7642\u5f8c\u8ffd\u8e64\uff0c\u60c5\u6cc1\u7a69\u5b9a\u3002", "e": "We report a case of a 53-year-old female with occult breast cancer presenting with right axillary lymph nodes metastases. The initial presentation was swelling and pain of right axilla without palpable breast mass. Mammography revealed no mass or microcalcification in breast tissue except multiple hyperdense right axillary lymphadenopathy. Positron-emission tomography scan showed increasing FDG uptake of right axillary and right supuraclavicular lymph nodes. Biopsy of lymph node revealed metastatic carcinoma with positive estrogen receptor and progesterone receptor. These data suggested an occult cancer of the breast with right axillary lymph nodes metastases. The patient received right axillary lymph nodes dissection followed by chemotherapy with lipodox and taxotere. Adjuvant radiotherapy to the right breast and right supraclavicular area was given. The patient is well without evidence of disease after the treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-163-173-a", "title": "Treatment outcome and patterns of failure in breast cancer patients with locoregional recurrence after mastectomy", "keywords": " ", "c": "\ufeff\u76ee\u7684\uff1a\u76ee\u524d\u7814\u7a76\u8b49\u64da\u8a8d\u70ba\uff0c \u7576\u7d93\u4e73\u623f\u5207\u9664\u4e4b\u4e73\u764c\u75c5\u60a3\u767c\u751f\u5c40\u90e8\u5340\u57df\u5fa9\u767c\u6642\uff0c \u901a\u5e38\u8207\u81f4\u75c5\u6027\u548c\u5168\u8eab\u6027\u8f49\u79fb\u6709\u9ad8\u76f8\u95dc\u6027\u3002\u56e0\u6b64\uff0c \u672c\u7814\u7a76\u662f\u5e0c\u671b\u80fd\u91d0\u6e05:\u662f\u5426\u85c9\u7531\u52a0\u5f37\u5c40\u90e8\u6cbb\u7642\uff0c \u53bb\u9032\u4e00\u6b65\u9632\u6b62\u4e73\u764c\t\u518d\u5ea6\u5fa9\u767c\uff0c \u548c\u5168\u8eab\u6027\u8f49\u79fb\uff0c \u4e26\u9032\u800c\u6539\u5584\u5b58\u6d3b\u7387\u3002 \n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u81ea1992 \u5e741 \u6708\u81f32001 \u5e7412 \u6708\u9593\uff0c \u5f9e\u81fa\u5927\u91ab\u9662\u764c\u75c7\u767b\u8a18\u5ba4\u4e4b\u8cc7\u6599\u5eab\u4e2d\uff0c \u7b26\u5408\u7d93\u4e73\u623f\u5168\u5207\u9664\u5f8c\u4e4b\u75c5\u60a3\uff0c \u4e14\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c \u4f46\u540c\u6642\u4e26\u7121\u4f75\u767c\u9060\u8655\u8f49\u79fb\uff0c \u4e26\u7d93\u5c40\u90e8\u6cbb\u7642\u4e4b\u75c5\u60a3\uff0c \u88ab\u9078\u51fa\u56de\u9867\u3002\u540c\u5074\u5c40\u90e8\u5fa9\u767c\u88ab\u5b9a\u7fa9\u70ba\uff1a \u5c40\u90e8\u4e73\u764c\u4e4b\u5fa9\u767c\uff0c \u53ea\u5c40\u9650\u65bc\u540c\u5074\u4e4b\u80f8\u58c1\u3001\u5207\u9664\u5f8c\u4e73\u623f\u4e4b\u75a4\u75d5\u5340\u57df\u3001\u4e0a\u9396\u9aa8\u5340\u57df\u3001\u4e0b\u9396\u9aa8\u5340\u57df\uff0c \u5167\u4e73\u623f\u7b49\u6dcb\u5df4\u5340\u57df\u3002\u82e5\u5fa9\u767c\u5340\u57df\u767c\u751f\u5728\u4e0a\u8ff0\u5340\u57df\u4e4b\u5916\uff0c\u5247\u7a31\u70ba\u9060\u8655\u8f49\u79fb\u3002\u7e3d\u517160 \u4f4d\u75c5\u60a3\uff0c\u5176\u5e73\u5747\u5e74\u9f61\u70ba47 \u6b72\uff0829 \u6b72\u81f375 \u6b72\uff09\uff0c\u9032\u5165\u6b64\u7814\u7a76\u3002\u6700\u5e38\u5fa9\u767c\u4e4b\u5340\u57df\u70ba\u540c\u5074\u4e4b\u80f8\u58c1\u548c\u5207\u9664\u5f8c\u4e73\u623f\u4e4b\u75a4\u75d5\u5340\u57df\uff0c \u6b64\u6bd4\u4f8b\u70ba62%\u3002\u4e0a\u9396\u9aa8\uff0c\u4e0b\u9396\u9aa8\u5340\u57df\u5176\u767c\u751f\u7387\u70ba\n22%\u3002\u800c\u814b\u4e0b\u53ca\u5167\u4e73\u623f\u6dcb\u5df4\u7d50\u4e4b\u767c\u751f\u7387\u70ba16%\u3002\u5176\u4e2d54 \u4f4d\u75c5\u60a3\uff0c\u63a5\u53d7\u5c40\u90e8\u5207\u9664\u5f8c\uff0c \u518d\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u800c\u5176\u4ed66 \u4f4d\u75c5\u60a3\uff0c\u5247\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u4f86\u4f5c\u70ba\u7b2c\u4e00\u7dda\u6cbb\u7642\u3002\u5728\u9019\u4e9b\u75c5\u60a3\u4e2d\uff0c \u670936 \u4f4d\u53ea\u63a5\u53d7\u55ae\u7368\u5c40\u90e8\u5340\u57df\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u800c\u5176\u4ed624 \u4f4d\u5247\u63a5\u53d7\u5c40\u90e8\u6027\u548c\u9078\u64c7\u6027\u5c40\u90e8\u5340\u57df\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\uff08\u6cbb\u7642\u5bb9\u91cf\u5305\u62ec\u540c\u5074\u80f8\u58c1\u548c\u5c40\u90e8\u6dcb\u5df4\u5340\u57df\uff09\u3002\u5176\u4e2d68.3% \u4e4b\u5fa9\u767c\u75c5\u60a3\uff0c\u5247\u63a5\u53d7\u8ffd\u52a0\u6027\u5168\u8eab\u6cbb\u7642\u5982\uff1a \u8cc0\u723e\u8499\u6cbb\u7642\u3001\u6216\u5316\u5b78\u6cbb\u7642\u3001\u6216\u5408\u4f75\u8cc0\u723e\u8499\u548c\u5316\u5b78\u6cbb\u7642\u3002\t \n\u7d50\u679c\uff1a\u75c5\u4eba\u7684\u4e2d\u4f4d\u6578\u8ffd\u8e64\u671f\u70ba51.5 \u500b\u6708\u3002\u540c\u5074\u80f8\u58c1\u5fa9\u767c\u4e4b\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u70ba67%\u3002\u800c\u814b\u4e0b\u3001\u4e0a\u9396\u9aa8\u5340\u57df\u3001\u4e0b\u9396\u9aa8\u5340\u57df\u4e4b\u5fa9\u767c\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u5247\u70ba56%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u7121\u75c5\u5b58\u6d3b\u7387\uff0c\u5728\u80f8\u58c1\u5fa9\u767c\u9019\u7d44\u548c\u80f8\u58c1\u5916\u5fa9\u767c\u9019\u7d44\u5247\u5206\u5225\u70ba56\uff05\u548c52 \uff05 \u3002\u76f8\u5c0d\u65bc\u665a\u671f\u5fa9\u767c\u4e4b\u60a3\u8005\uff08\u7121\u75c5\u4e4b\u6642\u9593\u9593\u9694\u81f3\u5c11\u5169\u5e74\u4ee5\u4e0a\uff09\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u70ba76 \uff05\uff0c\u800c\u65e9\u671f\u5fa9\u767c\u4e4b\u60a3\u8005\uff08 \u7121\u75c5\u4e4b\u6642\u9593\u9593\u9694\u5c0f\u65bc\u6216\u7b49\u65bc\u5169\u5e74\uff09\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u5247\u70ba39\uff05\uff08P \u503c\u7b49\u65bc0.04\uff09\u3002\u76f8\u5c0d\u65bc\u60a3\u8005\u63a5\u53d7\u5c40\u90e8\u5340\u57df\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u9ad8\u5c40\u90e8\u5fa9\u767c\u7387\u70ba22.2%\uff0c\u800c\u63a5\u53d7\u5c40\u90e8\u548c\u9078\u64c7\u5340\u57df\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c\u5176\u5c40\u90e8\u5fa9\u767c\u7387\u5247\u964d\u4f4e\u5f88\u591a\u70ba8.3%\u3002\u76f8\u5c0d\u65bc\u53ea\u63a5\u53d7\u55ae\u7368\u5c40\u90e8\u5340\u57df\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u70ba55\uff05 \u3001\u800c\u7121\u75c5\u5b58\u6d3b\u7387\u70ba48%\uff1b\u800c\u63a5\u53d7\u5c40\u90e8\u6027\u548c\u9078\u64c7\u6027\u5c40\u90e8\u5340\u57df\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u5247\u70ba69 \uff05 \u3001\u800c\u7121\u75c5\u5b58\u6d3b\u7387\u5247\u70ba57%\uff08\u5b58\u6d3b\u7387\uff1aP \u503c\u7b49\u65bc0.21\uff1b\u7121\u75c5\u5b58\u6d3b\u7387\uff1aP \u503c\u7b49\u65bc0.24\uff09\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0c\u60a3\u8005\u63a5\u53d7\u8ffd\u52a0\u6027\u5168\u8eab\u6cbb\u7642\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u5b58\u6d3b\u7387\u70ba64 \uff05\u3001\u800c\u7121\u63a5\u53d7\u8ffd\u52a0\u6027\u5168\u8eab\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4\u5e74\u5b58\u6d3b\u7387\u5247\u70ba43\uff05\uff08P \u503c\u7b49\u65bc0.08 \uff09\u3002\u540c\u6a23\u7684\u3001\u76f8\u5c0d\u65bc\u7121\u63a5\u53d7\u8ffd\u52a0\u6027\u5168\u8eab\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c \u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba33 \uff05\uff0c\u800c\u63a5\u53d7\u8ffd\u52a0\u6027\u5168\u8eab\u6cbb\u7642\u4e4b\u60a3\u8005\uff0c\u5176\u5fa9\u767c\u5f8c\u4e4b4 \u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u5247\u70ba60%\uff08P \u503c\u7b49\u65bc0.38 \uff09\u3002 \n\u7d50\u8ad6\uff1a\u4ecd\u6709\u4e00\u90e8\u4efd\u4e4b\u60a3\u8005\u5728\u7d93\u7a4d\u6975\u5c40\u90e8\u6cbb\u7642\u5f8c\uff0c \u4ecd\u53ef\u4eab\u53d7\u5f88\u597d\u7684\u7e3d\u5b58\u6d3b\u7387\uff0c \u548c\u5f88\u9577\u6642\u9593\u7684\u7121\u75c5\u5b58\u6d3b\u7387\u3002\u56e0\u6b64\uff0c \u5728\u9762\u5c0d\u5168\u4e73\u623f\u5207\u9664\u5f8c\u4e4b\u4e73\u764c\u60a3\u8005\uff0c \u82e5\u767c\u751f\u55ae\u7368\u540c\u5074\u5c40\u90e8\u5fa9\u767c\uff0c \u61c9\u7d66\u4e88\u7a4d\u6975\u5c40\u90e8\t\u6cbb\u7642\uff0c \u4ee5\u63d0\u4f9b\u9069\u7576\u7684\u5c40\u90e8\u63a7\u5236\uff0c \u548c\u9632\u6b62\u7b2c\u4e8c\u5ea6\u8f49\u79fb\u3002", "e": "\ufeffPurpose : Recent data suggest that postmastectomy patients with locoregional recur-rences are frequently associated with considerable morbidity and present with sys-temic failure. The present study sought to clarify the correlation of radical locoregional therapy with the prevention of further local recurrence, secondary spread, and the improvement of survival. \t \nMaterials and Methods : Breast cancer patients who were treated for an isolated postmastectomy locoregional recurrence without simultaneous evidence of distant metastasis were selected from 1992 to 2001. Isolated locoregional recurrence (ILRR) \t \nwas defined as any recurrence of tumor in the ipsilateral chest wall, mastectomy scar, supraclavicular, infraclavicular, axillary, or internal mammary lymph node (LN), with no \t \nother metastasis. A total of 60 patients, with a median age of 47 years (range 29-75 years) were included. The majority of recurrences occurred at the chest wall and around the mastectomy scar (62%). Supra- or infraclavicular LN recurrence represent-\t \ned 22% of all ILRR, and axillary failure represented 16%. Fifty-four patients received irradiation after local tumor excision. Six patients had received radiotherapy as part of their primary treatment. In these cases, the involved-field radiotherapy was given in 36 patients, while 24 patients were treated with both involved-field and elective-field (chest wall and regional lymphatics) locoregional irradiation. Adjuvant systemic therapy con-sisting of either tamoxifen, cytotoxic chemotherapy, or both, along with the recurrent tumor, had been applied in 68.3% of patients. \t \nResults : With a median follow-up of 51.5 months, the 4-year actuarial overall survival (OS) after ILRR was 67% for patients with chest wall recurrence. Patients with either axillary, supra- or infraclavicular- recurrence had a 4-year OS of 56%. The 4-year disease-free survival (DFS) for chest wall recurrence and either axillary, supra- or infra-clavicular- recurrence was 56% and 52%, respectively. Seventy-six percent of patients \t \nwith a disease-free interval of at least 2 years (late relapse) survived 4 years follow-ing ILRR, as compared to 4-year OS of 39% in those with disease-free interval of less than 2 years (early relapse) (P = .04). The incidence of second ILRR was 8.3% with both involved- and elective-field locoregional irradiation as compared to 22.2% with \ufeffinvolved-field irradiation alone. Patients who were treated with both involved-field and \t \nelective-field locoregional irradiation had the 4-year OS of 69%, and the 4-year DFS of 57%, compared to 55% and 48% of those who were treated with involved-field radiation alone (OS, P = .21; DFS, P = .24). Furthermore, 64% patients who had been treated with adjuvant systemic therapy survived 4 years following ILRR, as compared to 43% for those without additional systemic therapy (P = .08). Similarly, recurrent patients \t \nwith adjuvant systemic therapy experienced a 4-year DFS of 60%, compared with 33% for patients without systemic therapy after ILRR (P = .38) Conclusion : A substantial portion of postmastectomy patients with locoregional recur-rence sustain an unexpected long DFS and OS after curative therapy. Therefore, com-prehensive radiotherapy should be used to provide optimal locoregional control and to prevent secondary dissemination in patients with ILRR."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-185-195-a", "title": "\ufeff\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u6dcb\u5df4\u7624\u6cbb\u7642\u7684\u65b0\u9032\u5c55", "keywords": " ", "c": "\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u7684\u6dcb\u5df4\u7624\u4e26\u4e0d\u5e38\u898b\u3002\u904e\u53bb\u7684\u6cbb\u7642\u4ee5\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u7642\u70ba\u4e3b\uff0c \u96a8\u8457\u5316\u5b78\u85e5\u7269\u7684\u767c\u5c55\u53ca\u9577\u671f\u5c0d\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u81e8\u5e8a\u8868\u73fe\u7684\u89c0\u5bdf\u7814\u7a76\uff0c \u5316\u5b78\u6cbb\u7642\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u4f7f\u5f97\u5b58\u6d3b\u7387\u9010\u6f38\u63d0\u5347\uff0c\u4e5f\u6f38\u6210\u70ba\u6cbb\u7642\u7684\u4e3b\u6d41\u3002\u800c\u6cbb\u7642\u5f15\u767c\u4e4b\u665a\u671f\u795e\u7d93\u7cfb\u7d71\u4f75\u767c\u75c7\uff0c\u4f8b\u5982\u8a8d\u77e5\u529f\u80fd\u969c\u7919\u7b49\uff0c\u5728\u8fd1\u4e9b\u5e74\u4e5f\u6f38\u53d7\u5230\u91cd\u8996\u3002\u570b\u969b\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u5408\u4f5c\u7d44\u7e54\u5247\u5236\u5b9a\u8a55\u4f30\u6cbb\u7642\u53cd\u61c9\u7684\u5b9a\u7fa9\u53ca\u6e96\u5247\uff0c\u4ee5\u65b9\u4fbf\u570b\u969b\u9593\u4e4b\u5b78\u8853\u4ea4\u6d41\u53ca\u5408\u4f5c\u3002\u672c\u7bc7\u7814\u7a76\u56de\u98672000-2005 \u5e74\u6709\u95dc\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7684\u6587\u737b\u767c\u73fe\uff0c \u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\u7642\u65b9\u5f0f\u96d6\u4ecd\u672a\u9054\u5171\u8b58\uff0c \u4f46\u591a\u6578\u7814\u7a76\u80af\u5b9a\u4ee5\u5927\u5291\u91cf\u7532\u6c28\u558b\u5464\t\uff08methotrexate \uff09 \u70ba\u4e3b\u7684\u806f\u5408\u5316\u7642\u52a0\u4e0a\u653e\u5c04\u7dda\u6cbb\u7642\u70ba\u76ee\u524d\u6700\u5e38\u7528\u4e14\u8f03\u6709\u6548\u7684\u6cbb\u7642\u6a21\u5f0f\uff0c \u81f3\u65bc\u810a\u9ad3\u8154\u5167\u5316\u5b78\u6cbb\u7642\u7684\u89d2\u8272\u5247\u4ecd\u6709\u722d\u8b70\u3002\u50b3\u7d71\u4e0a\u4ee5\u55ae\u7368\u5168\u8166\u653e\u5c04\u6cbb\u7642\u70ba\u4e3b\u7684\u4f5c\u6cd5\uff0c \u76ee\u524d\u5df2\u6f38\u5f0f\u5fae\u3002\u672a\u4f86\u61c9\u9032\u884c\u8de8\u570b\u5927\u578b\u96a8\u6a5f\u6027\u7814\u7a76\uff0c \u4e26\u5c07\u795e\u7d93\u7cbe\u795e\u529f\u80fd\u8a55\u4f30\u5217\u5165\u8a0e\u8ad6\uff0c \u76f8\u4fe1\u61c9\u80fd\u627e\u51fa\u6700\u4f73\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "\ufeffPrimary central nervous system lymphoma is a rare form of extranodal non-Hodgkin\u2019s lymphoma that is confined to the central nervous system and eye. Whole brain irradiation was the main treatment before 1990. However, Numerous studies examined this disorder in the past 6 years. Novel treatment regimens continue to be studied for newly diagnosed primary central nervous system lymphoma. As overall survival improved, the burden of late neurotoxicity has become more apparent. \t \nNeuropsychological testing of patients treated with hemoradiation shows significant cognitive deficits that can be attributed to whole brain irradiation. The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) has proposed guidelines for the baseline evaluation. In conclusion, the optimal treatment for primary  central nervous system lymphoma remains undefined. The role of intrathecal chemotherapy remains unclear. Whole brain irradiation alone become less popular. The most common and probably effective treatment of newly diagnosed disease should include high-dose methotrexate-based chemotherapy plus radiotherapy at the present status. International large-scale prospective randomized studies including prospective neuropsycholgical test will be needed, as it is impossible to draw conclusions from the \ufeffnonrandomized small series published so far."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-197-204-a", "title": "\ufeff\u96fb\u8166\u5200\u7cfb\u7d71\u9a57\u6536\u6e2c\u8a66\u7a0b\u5e8f", "keywords": " ", "c": "\ufeff\u76ee\u7684\uff1a\u96fb\u8166\u5200\u662f\u4e00\u7a2e\u5f71\u50cf\u5c0e\u5f15\u5f0f\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7cfb\u7d71\u3002\u672c\u7814\u7a76\u7684\u4e3b\u8981\u76ee\u7684\u70ba\u78ba\u8a8d\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u7684\u6e96\u78ba\u6027\u3001\u6a5f\u68b0\u624b\u81c2\u7684\u6e96\u78ba\u6027\u53ca\u5291\u91cf\u7684\u6e96\u78ba\u6027\uff0c \u4ee5\u78ba\u4fdd\u81e8\u5e8a\u6cbb\u7642\u54c1\u8cea\u3002\u540c\u6642\u91cf\u6e2c\u5291\u91cf\u53c3\u6578\u4f5c\u70ba\u81e8\u5e8a\u6cbb\u7642\u8a08\u5283\u7684\u4f9d\u64da\u3002\t \n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u96fb\u8166\u5200\u662f\u7531\u4e00\u500b\u6a5f\u68b0\u624b\u81c2\u53ca\u5169\u7d44kV \u7684X \u2013ray \u5f71\u50cf\u7cfb\u7d71\u6240\u7d44\u6210\u7684\u5f71\u50cf\u5c0e\u5f15\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7cfb\u7d71\u3002\u5c0d\u65bc\u6a5f\u68b0\u624b\u81c2\u4e4b\u6e96\u78ba\u6027\u7684\u78ba\u8a8d\uff0c \u4fc2\u4f9d\u7167\u539f\u5ee0\u63d0\u4f9b\u7684Isopost \u4e4b\u7d05\u5916\u7dda\u4f86\u6e2c\u8a66\u6a5f\u68b0\u624b\u81c2\u7684\u6bcf\u500b\u7167\u5c04\u4f4d\u7f6e\u5728\u4e0d\u540c\u7684SAD \u8ddd\u96e2\u4e0b\u662f\u5426\u8207\u7b49\u4e2d\u5fc3\u9ede\u543b\u5408\u3002\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\uff08Target Locating System \uff09 \u7684\u6e2c\u8a66\u662f\u5c07\u7cfb\u7d71\u5206\u62106 \u7dad\u982d\u9871\u8ffd\u8e64\u6a21\u7d44\uff086D Skull Tracking Mode \uff09 \u82076 \u7dad\u9871\u5916\u6a19\u8a18\u8ffd\u8e64\u6a21\u7d44\uff086D Fiducial Tracking Mode \uff09\uff0c \u4ee5\u5047\u9ad4\u4f86\u78ba\u8a8d\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u7684\u6e96\u78ba\u6027\u3002\u81f3\u65bc\u6574\u9ad4\u96fb\u8166\u5200\u7cfb\u7d71\uff08 \u5305\u62ec\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u3001\u6a5f\u68b0\u624b\u81c2\u3001\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u3001\u52a0\u901f\u5668\u7684\u6240\u6709\u5291\u91cf\u8f38\u51fa\uff09 \u5247\u4ee5End-to-End \u6e2c\u8a66\u65b9\u6cd5\u4f86\u78ba\u8a8d\u5176\u6e96\u78ba\u5ea6\u3002\t \n\u7d50\u679c\uff1a\u6a5f\u68b0\u624b\u81c2\u5728\u4e0d\u540c\u7684SAD \u8ddd\u96e2\u4e0b\uff0c \u6240\u6709\u7167\u5c04\u9ede\u8aa4\u5dee\u90fd\u5c0f\u65bc0.5 mm \uff1b \u81f3\u65bc\u5f71\u50cf\u5c0e\u5f15\u7cfb\u7d71\u7121\u8ad6\u662f6 \u7dad\u982d\u9871\u8ffd\u8e64\u6a21\u7d44\uff086D Skull Tracking Mode \uff09 \u6216\u662f6 \u7dad\u9871\u5916\u6a19\u8a18\u8ffd\u8e64\u6a21\u7d44\uff086D Fiducial Tracking Mode \uff09 \u4e0b\u7684\u8aa4\u5dee\u7686\u5c0f\u65bc1 mm \uff08 \u5305\u542b\u5e73\u79fb\u8ef8\u53ca\u65cb\u8f49\u8ef8\uff09 \u3002\u6700\u5f8c\u6574\u9ad4\u96fb\u8166\u5200\u7cfb\u7d71\u7684\u8a55\u4f30\u5728\u4f7f\u7528end-to-end \u6e2c\u8a66\u5f8c\u5176\u8aa4\u5dee\u503c\u7686\u5c0f\u65bc1 mm \u3002\t \n\u7d50\u8ad6\uff1a\u96fb\u8166\u5200\u7cfb\u7d71\u53ef\u63d0\u4f9b\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u66f4\u7cbe\u78ba\u7684\u6cbb\u7642\u4f4d\u7f6e\uff0c \u540c\u6642\u900f\u904e\u5f71\u50cf\u5c0e\u5f15\u7684\u65b9\u5f0f\u53ef\u78ba\u4fdd\ufeff\u75c5\u4eba\u5728\u6cbb\u7642\u904e\u7a0b\u4e2d\u7684\u79fb\u52d5\u8aa4\u5dee\u843d\u5728\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\u3002", "e": "\ufeffPurpose : To assure the accuracy of image-guided system, robotic arm, and dosimetry for Cyberknife unit and to prepared it for the clinical use. \t \nMethod and Materials : Cyberknife is consisted of one robotic arm with a 6MV Linac and one image guided system with two-sets of X-ray units. It is one of the dedicated equipment for stereotactic radiosurgery. The accuracy of the robotic arm was tested to verify the agreement between the arm positions and the isocenters at various SAD using the Isopost system provided by the manufacture. \t \nThe accuracy of the Target Locating System (TLS) was tested by both 6D skull tracking mode and 6D  fiducial tracking mode using a special phantom. As for the whole Cyberknife system, we applied \u201cEnd- to-End\u201d method, using anthropomorphic phantom and Gafchromic film, to verify its accuracy. \t \nResults : The agreement of robotic arm positions and isocenters at various SAD were within 0.5 mm which is within the tolerance of the manufacture suggested value. For the test results of Target Locating System, the errors (including translation and rotation) are less than 0.5 mm for both tracking modes. \t \nThe end-to-end test results for the entire Cyberknife system are all better than 1 mm. \t \nConclusions : From the results of our Acceptance Tests and Commissioning, the Cyberknife could be used in clinic for radiosurgery procedures. The image-guided function for the unit makes it an accurate and effective radiation treatment modality for radiosurgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-205-215-a", "title": "\ufeff\u5982\u4f55\u4ee5\u65cb\u8f49\u6e96\u76f4\u5100\u7684\u65b9\u5f0f\u4f86\u6539\u5584\u982d\u9838\u90e8\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642", "keywords": " ", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u982d\u9838\u90e8\u764c\u75c7\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u5617\u8a66\u63a1\u7528\u6e96\u76f4\u5100\u65cb\u8f49\u5f0f\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\uff08Collimator Rotated IMRT, CR IMRT \uff09\u4f86\u6539\u5584\u9838\u90e8\u7167\u91ce\u63a5\u5408\u8655\u7684\u5291\u91cf\u5747\u52fb\u5ea6\uff0c \u4e26\u6bd4\u8f03\u8207\u50b3\u7d71IMRT \u65b9\u5f0f\u7684\u5dee\u7570\u6027\u3002\t \n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u9078\u64c710 \u4f4d\u982d\u9838\u90e8\u764c\u75c7\u60a3\u8005\u7684CT \u5f71\u50cf\uff0c\u5206\u5225\u4ee5\u50b3\u7d71\u7684IMRT \u53ca\u65b0\u8a2d\u8a08\u7684CR IMRT\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u9032\u884c\u5206\u6790\uff0c\u4e26\u6bd4\u8f03\u5176\u9806\u5f62\u53c3\u6578\u8207\u5291\u91cf\u5747\u52fb\u5ea6\u7684\u5dee\u7570\u3002CR IMRT \u6cbb\u7642\u65b9\u5f0f\u70ba\u65cb\u8f49\u6e96\u76f4\u5100\u4e5d\u5341\u5ea6\uff0c\u4e3b\u9776\u5340\u53ca\u4e0a\u9838\u90e8\u4ee5\u4e5d\u500b\u7167\u91ce\u6db5\u84cb\uff1b\u9396\u9aa8\u53ca\u4e0b\u9838\u90e8\u7684\u6dcb\u5df4\u7d50\u5247\u4ee5\u4e09\u500b\u7167\u91ce\uff0c\u7167\u91ce\u4e0a\u4e0b\u7de3\u76f8\u63a5\u8655\u5206\u5225\u5448\u968e\u68af\u72c0\u4e92\u76f8\u91cd\u758a\uff0c\u7528\u4ee5\u6e1b\u5c11\u76f8\u63a5\u8655\u5c40\u90e8\u5291\u91cf\u4e0d\u5747\u52fb\u7684\u60c5\u5f62\u3002\u4f9d\u64da\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5e2b\u5b78\u6703TG-40 \u5831\u544a\u7684\u8981\u6c42\uff0c \u6e96\u76f4\u5100\u7684\u8aa4\u5dee\u61c9\u57282\u516c\u91d0\u4ee5\u5167\uff0c\u6240\u4ee5\u672c\u7814\u7a76\u5206\u6790\u7167\u91ce\u63a5\u9130\u8655\u504f\u5dee\u7684\u9593\u9694\uff08gap\uff09\u00b11\u516c\u91d0\u3001\u00b12\u516c\u91d0\uff0c \u91cd\u758a\uff08overlap\uff09\u00b11\u516c\u91d0\u3001\u00b12\u516c\u91d0\u6642\u5c0d\u5291\u91cf\u7684\u5f71\u97ff\u3002X\u5149\u7247\u9a57\u8b49\u4e5f\u65bc\u672c\u7814\u7a76\u9032\u884c\uff0c\u7528\u4ee5\u5206\u6790\u9019\u5169\u7a2e\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u65b9\u5f0f\u5728\u7167\u91ce\u76f8\u63a5\u8655\u7684\u5291\u91cf\u4e0d\u5747\u52fb\u5ea6\u3002\n\u7d50\u679c\uff1a\u50b3\u7d71IMRT\u8207CR IMRT\u5728\u8a08\u5283\u54c1\u8cea\u5206\u6790\u4e0a\uff0c\u5e7e\u4e4e\u9054\u5230\u76f8\u540c\u7684\u9806\u5f62\u53c3\u6578\uff08conformity index \uff09\u548c\u5291\u91cf\u5747\u52fb\u7a0b\u5ea6\uff08homogeneity index \uff09\uff0c\u91cd\u8981\u6b63\u5e38\u5668\u5b98\u7684\u5291\u91cf\u8a55\u4f30\u4e0a\uff0c \u5305\u62ec\u8166\u5e79\u3001\u810a\u9ad3\u3001\u5169\u5074\u553e\u6db2\u817a\u7684\u6700\u5927\u5291\u91cf\u6216\u5e73\u5747\u5291\u91cf\u5747\u5728\u5668\u5b98\u5bb9\u8a31\u5291\u91cf\u7bc4\u570d\u5167\u3002\u4ee5X\u5149\u7247\u5be6\u969b\u7167\u5c04\u9838\u90e8\u76f8\u63a5\u8655\u767c\u73fe\u50b3\u7d71IMRT\u6cbb\u7642\u65b9\u5f0f\u5728\u4e0a\u4e0b\u7de31\u516c\u91d0\u30012\u516c\u91d0\u30014\u516c\u91d0\u8aa4\u5dee\u6642\u76f8\u63a5\u8655\u5291\u91cf\u70ba\u00b112%\u3001\u00b122% \u3001\u00b141%\uff0c\u4ee5CR IMRT \u7684\u6cbb\u7642\u65b9\u5f0f\u5247\u767c\u73fe\u4e0a\u4e0b\u7de31\u516c\u91d0\u30012\u516c\u91d0\u30014\u516c\u91d0\u8aa4\u5dee\u6642\u76f8\u63a5\u8655\u5291\u91cf\u5927\u5e45\u6539\u5584\u70ba\u00b16%\u3001\u00b18%\u3001\u00b112% \u3002 \n\u7d50\u8ad6\uff1aCR IMRT \u5728\u6cbb\u7642\u8a08\u756b\u54c1\u8cea\u5e7e\u4e4e\u8207\u50b3\u7d71IMRT \u76f8\u540c\uff0c \u4e14\u4e0a\u4e0b\u9838\u63a5\u9130\u5340\u7684\u5291\u91cf\u4e0d\u5747\u52fb\u6027\u53ef\u4ee5\u5927\u5e45\ufeff\u6539\u5584\uff0c \u70ba\u4e00\u503c\u5f97\u7528\u4ee5\u6cbb\u7642\u982d\u9838\u90e8\u764c\u75c7\u4e4bIMRT \u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose : To improve dose homogeneity at the neck junction in head-and-neck cancer radiotherapy, we employ a rotating collimator and compare the differences between it and conventional intensity-modulated radiation therapy (IMRT). \t \nMaterials and Methods : CT images for 10 head-and-neck cancer patients previously treated with SIHB technique in our clinic were used for this planning study. We generated a new CR IMRT in each case and compared the differences between the conformity index and homogeneity index. The new planning technique also used beams with equally-spaced gantry angles but only for the neck above the shoulder. We made beams above the shoulder with a slightly lower field border (normally 3 to 5 mm), to have a built-in feathering. Three of the nine beams treated the entire neck, including the lower neck and supraclavicular lymph nodes. Only three beams are required to split and therefore the total number of fields is 12. The AAPM TG-40 recommended an accuracy of field size and jaw symmetry calibration to be within 2 mm. Hence, for an accelerator operating within these guidelines, \t \ntwo abutting fields can overlap or gap up to 2 mm. Field mismatches of \u00b11 mm and \u00b12 mm because of imperfect jaw/MLC calibration were simulated. We used film to measure junction inhomogenity. \t \nResults : The new technique could be used to successfully generate IMRT plans for head and neck cancers. Both conventional IMRT and CR IMRT had almost the same conformity index and \t \nhomogeneity index. Upon evaluating the dose distribution of critical organs, we found all of them were within the tolerance ranges. Film measurements showed that dose inhomogeneities that resulted from 1 mm, 2 mm, 4 mm junction area as jaw/MLC calibration errors were reduced from as large as \u00b112%, \t \n\u00b122%, \u00b141% with the single-isocenter and half-beam (SIHB) technique to less than \u00b16% \u3001\u00b18%, \u00b112% with this newly developed technique. \t \nConclusion : Compared with the conventional SIHB technique, the new technique provides superior dose homogeneity in the abutment region between the supraclavicular and head-and-neck IMRT \t \nfields. With a modulating lower border of fields, the feathering mechanism substantially reduces \ufeffdose inhomogeneities that result from imperfect jaw/MLC calibration."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-217-223-a", "title": "\u9ad8\u80fd\u5149\u5b50\u5c04\u675f\u4e0b\u76f4\u7dda\u52a0\u901f\u5668\u6cbb\u7642\u5e8a\u53ca\u56fa\u5b9a\u6a21\u5177\u5c0d\u6dfa\u5c64\u5291\u91cf\u7684\u5f71\u97ff", "keywords": " ", "c": "\u76ee\u7684\uff1a\u81e8\u5e8a\u4e0a\u7576\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6642\uff0c\u652f\u6490\u53ca\u56fa\u5b9a\u75c5\u7076\u7bc4\u570d\u6240\u9078\u7528\u7684\u6750\u6599\u662f\u5f88\u91cd\u8981\u7684\u3002\u6cbb\u7642\u6642\u82e5\u4f7f\u7528\u5f8c\u524d\u5411\u5c04\u675f\u7167\u91ce\u6642\uff0c\u5149\u5b50\u5c04\u675f\u5fc5\u9808\u7d93\u904e\u76f4\u7dda\u52a0\u901f\u5668\u7684\u6cbb\u7642\u5e8a\u53ca\u56fa\u5b9a\u6a21\u5177\u3002\u7576\u9ad8\u80fd\u5149\u5b50\u5c04\u675f\t\u7a7f\u904e\u6cbb\u7642\u5e8a\u53ca\u56fa\u5b9a\u6a21\u5177\u800c\u8870\u6e1b\u6642\uff0c\u6703\u9020\u6210\u76ae\u819a\u514d\u9664\u6548\u61c9\u964d\u4f4e\u3002\u672c\u7814\u7a76\u662f\u5728\u5448\u73fe\u9ad8\u80fd\u5149\u5b50\u5c04\u675f\u7a7f\u904e\u4e19\u70ef\u6a39\u916f\u6cbb\u7642\u5e8a\u53ca\u56fa\u5b9a\u6a21\u5177\u5f8c\uff0c \u5728\u6cbb\u7642\u7269\u6dfa\u5c64\u5291\u91cf\u7684\u8b8a\u5316\u60c5\u5f62\u3002\t \n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6e2c\u91cf\u6642\u5149\u5b50\u5c04\u675f\u662f\u4ee5180\u5ea6\u7684\u5f8c\u524d\u5411\u5c04\u675f\u7167\u91ce\u5782\u76f4\u5165\u5c04\uff0c\u518d\u4ee5\u6cbb\u7642\u5e8a\u53ca\u771f\u7a7a\u588a\u4e0d\u540c\u7684\u64fa\u8a2d\u65b9\u5f0f\u5206\u5225\u75284\u7a2e\u4e0d\u540c\u7684\u7167\u91ce\u5927\u5c0f\u9032\u884c\u91cf\u6e2c\uff0c \u5206\u5225\u70ba10\u00d710 \u339d2\u300115\u00d715 \u339d2\u300120\u00d720 \u339d2\u53ca25 \u00d725 \u339d2\u3002\t \n\u7d50\u679c\uff1a\u771f\u7a7a\u588a\u7684\u539a\u5ea6\u6108\u539a\u6642\u6dfa\u5c64\u5291\u91cf\u6108\u5927\uff0c\u4e14\u7576\u7167\u91ce\u9762\u7a4d\u6108\u5c0f\u6642\uff0c\u6dfa\u5c64\u5291\u91cf\u589e\u52a0\u7684\u7a0b\u5ea6\u76f8\u5c0d\u5730\u6108\u5927\u3002\u6cbb\u7642\u5e8a\u5c0d\u5291\u91cf\u4e5f\u6709\u986f\u8457\u7684\u5f71\u97ff\uff0c\u5c24\u5176\u662f\u6dfa\u5c64\u5291\u91cf\uff0c\u96a8\u7167\u91ce\u9762\u7a4d\u7684\u6e1b\u5c0f\u5f71\u97ff\u6108\u5927\u300210\u00d710 \u339d2\u7167\u91ce\u6dfa\u5c64\u5291\u91cf\u70ba\u672a\u6709\u6cbb\u7642\u5e8a\u53ca\u771f\u7a7a\u588a\u6642\u540c\u7167\u91ce\u7684191%\uff1b\u572825\u00d725 \u339d2\u7167\u91ce\u6642\u70ba161%\u3002\t \n\u8a0e\u8ad6\uff1a\u6545\u56e0\u6cbb\u7642\u5e8a\u53ca\u4f7f\u7528\u56fa\u5b9a\u6a21\u5177\u9020\u6210\u6dfa\u5c64\u5291\u91cf\u7684\u589e\u52a0\uff0c \u6b64\u985e\u8a2d\u5b9a\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u5f8c\u5c0d\u76ae\u819a\u6240\u9020\u6210\ufeff\u7684\u53ef\u80fd\u50b7\u5bb3\uff0c \u5728\u81e8\u5e8a\u4e0a\u6cbb\u7642\u8a2d\u8a08\u61c9\u4e88\u65bc\u8003\u91cf\u3002", "e": "Purpose : Clinically it is important for patients to have the supporting and the immobilization during radiotherapy. When using a posterior-anterior beam, radiation normally passes through the treatment couch insert of the linear accelerator and the immobilization devices. With high energy photon beam \t \nattenuated by the couch insert and immobilization devices, the skin sparing effect will be reduced. \t \nThis study is to investigate the dosimetric changes in the Superficial layer dose of the treated object after high energy photon beam passes through the treatment couch (Perspex) insert and immobilization devices. \t \nMaterials and Methods : The gantry angle was set as 180\u00b0, so that the posterior-anterior photon beam incidents to the couch insert. Measurements were taken for the different combinations of the couch insert and vacuums with 4 beam sizes: 10 \u00d7 10 cm2, 15 \u00d7 15 cm2, 20 \u00d7 20 cm2, and 25 \u00d7 25 cm2 . \t \nResults : The thicker the vacuum, the larger increase in the Superficial layer dose. The proportion of Superficial layer dose increase was relative larger with smaller field size. There was significant influence of the dose from the couch insert. The magnitude of the influence was relative larger with \t \nsmaller field size. The Superficial layer dose with couch insert was 191% of the one with none of each other at the 10 \u00d7 10 cm2 field size. The Superficial layer dose with couch insert was 161% of the one with none of them at the 25 \u00d7 25 cm2 field size.\nConclusion : The uses of the couch inert and immobilization devices cause the increased Superficial layer dose. Special considerations need to be taken in these conditions for the possible radiation related skin injury. The impact should be incorporated into the treatment design."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200609-13-3-225-229-a", "title": "Malignant melanoma of the rectum: a case report", "keywords": " ", "c": "\u76f4\u8178\u90e8\u4f4d\u4e4b\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u7624\u662f\u4e00\u6975\u7f55\u898b\u4f46\u5feb\u901f\u60e1\u5316\u7684\u75be\u75c5\uff0c\u5373\u4f7f\u63a5\u53d7\u6cbb\u7642\uff0c\u5927\u591a\u6578\u75c5\u4eba\u4ecd\u6b7b\u65bc\u75be\u75c5\u64f4\u6563\uff0c\u80fd\u9577\u671f\u5b58\u6d3b\u7684\u5f88\u5c11\u3002\u5c0d\u65bc\u75be\u75c5\u4fb7\u9650\u65bc\u5c40\u90e8\u6216\u5340\u57df\u7684\u60a3\u8005\uff0c\u624b\u8853\u5207\u9664\u662f\u4e3b\u8981\u6cbb\u7642\u3002\u5927\u591a\u6578\u7684\u7814\u7a76\u986f\u793a\uff1a\u63a5\u53d7\u8179\u90e8\u6703\u9670\u806f\u5408\u5207\u9664\u8853\u7684\u75c5\u4eba\u8207\u63a5\u53d7\u5bec\u908a\u7de3\u5c40\u90e8\u5207\u9664\u7684\u75c5\u4eba\u76f8\u8f03\uff0c\u5728\u5b58\u6d3b\u7387\u4e0a\u4e26\u7121\u5dee\u5225\uff0c\u5118\u7ba1\u8179\u90e8\u6703\u9670\u806f\u5408\u5207\u9664\u8853\u53ef\u4ee5\u9054\u5230\u8f03\u4f73\u7684\u5c40\u90e8\u63a7\u5236\u3002\u67d0\u4e9b\u7814\u7a76\u8005\u63d0\u51fa\u4ee5\u4fdd\u5b88\u6027\u624b\u8853\u5207\u9664\u816b\u7624\uff0c\u5408\u4f75\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u7684\u65b9\u5f0f\uff0c \u4ee5\u671f\u80fd\u540c\u6642\u4fdd\u7559\u5668\u5b98\u529f\u80fd\u8207\u63d0\u5347\u5c40\u90e8\u63a7\u5236\u7387\u3002\t \n\u6211\u5011\u4ee5\u7d93\u809b\u9580\u816b\u7624\u5207\u9664\u8853\uff0c\u52a0\u4e0a\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u91dd\u5c0d\u816b\u7624\u539f\u767c\u90e8\u4f4d\u8207\u9aa8\u76c6\u5340\u57df\u6dcb\u5df4\u7cfb\u7d71\u7167\u5c04\uff0c\u6cbb\u7642\u4e00\u4f4d\u7f79\u60a3\u4e0b\u6bb5\u76f4\u8178\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u7624\u7684\u516d\u5341\u4e03\u6b72\u5973\u6027\u60a3\u8005\u3002\u5f9e\u958b\u59cb\u6cbb\u7642\u81f3\u4eca\u5341\u4e94\u500b\u6708\uff0c\u5979\u8eab\u9ad4\u72c0\u6cc1\u826f\u597d\uff0c \u6392\u4fbf\u529f\u80fd\u6b63\u5e38\uff0c \u4e14\u7121\u816b\u7624\u5fa9\u767c\u73fe\u8c61\u3002", "e": "\ufeffMalignant melanoma of the rectum is a very rare but aggressive malignancy. \t \nLong-term survival is rare as most patients die of disseminated disease regardless of \t \ntreatment. Surgery is the mainstay of treatment for patients with local-regional disease. \t \nMost studies did not show difference in survival between patients who underwent abdominoperineal resection (APR) and those who underwent wide local excision, although APR was noted to result in improved local-regional control rate. Some \t \ninvestigators propose to treat these patients with conservative surgery and adjuvant radiotherapy in an attempt to both preserve the sphincter function and improve local-regional control. \t \nWe managed a 67-year-old female patient with malignant melanoma of the lower rectum with transanal wide excision and postoperative irradiation to the primary tumor site and pelvic regional lymphatics. At present, she is well and continent without evidence of recurrence 15 months after the initial treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-87-94-a", "title": "Prognostic Factors Affecting the Outcome of Endometrial Cancer", "keywords": "\u5b50\u5bae\u5167\u819c\u764c;\u624b\u8853;\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c Endometrial Cancer;Surgery;Radiotherapy;Prognosis", "c": "\u76ee\u7684\uff1a\u5206\u6790\u5b50\u5bae\u5167\u819c\u764c\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u7d50\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1993\u5e748\u6708\u81f32004\u5e744\u6708\uff0c\u670969\u4f4d\u8a3a\u65b7\u70ba\u5b50\u5bae\u5167\u819c\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u6cbb\u7642\u3002\u75c5\u4eba\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f55\u6b72\uff08\u7bc4\u570d\u5f9e34\u81f380\u6b72\uff09\u3002\u4ee5FIGO\u5206\u671f\u7cfb\u7d71\u4f86\u8a02\u5b9a\u75c5\u4eba\u7684\u764c\u75c7\u671f\u5225\uff0c46\u4f4d\u75c5\u4eba(67%)\u662fstage\u2160\uff0c8\u4f4d(12%)\u662fstage \u2161\uff0c12\u4f4d(17%)\u662fstage \u2162\uff0c3\u4f4d(4%)\u662fstage \u2163\u300258\u4f4d\u75c5\u4eba(84%)\u7684\u75c5\u7406\u7d44\u7e54\u7d30\u80de\u578b\u614b\u662f\u5b50\u5bae\u5167\u819c\u817a\u764c\uff0c11\u4f4d(16%)\u5247\u70ba\u5b50\u5bae\u5167\u819c\u817a\u764c\u4ee5\u5916\u7684\u75c5\u7406\u7d30\u80de\u578b\u614b\uff1a\u5728\u6b64\u7576\u4e2d\uff0c4\u4f4d\u662fleiomyoscarcoma\uff0c3\u4f4d\u662fMMMT(malignant mixed mullerian tumor)\uff0c2\u4f4d\u662fpapillary serous carcinoma\uff0c1\u4f4d\u662fclear cell carcinoma\uff0c1\u4f4d\u662fmixed mucinous and small cell carcinoma\u3002\u6240\u670969\u4f4d\u75c5\u4eba\u90fd\u63a5\u53d7\u624b\u8853\u6cbb\u7642\uff0c\u9019\u7576\u4e2d\u670963\u4f4d\u75c5\u4eba(91%)\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u5f8c\u7684\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u6578\u662f38\u500b\u6708\uff08\u7bc4\u570d\u5f9e8\u81f3129\u500b\u6708\uff09\u3002\u5728\u8ffd\u8e64\u7684\u904e\u7a0b\u4e2d\uff0c60\u4f4d\u75c5\u4eba(87%)\u5b58\u6d3b\uff0c9\u4f4d\u75c5\u4eba(13%)\u6b7b\u4ea1\u30023\u4f4d\u75c5\u4eba(4%)\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u60c5\u5f62\u30029\u4f4d\u75c5\u4eba(13%)\u5247\u6709\u9060\u7aef\u8f49\u79fb\u3002\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u662f85%\u3002\u5728\u55ae\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u764c\u75c7\u671f\u5225\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u4f86\u8aaa\u662f\u4e00\u500b\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff08p\u503c\u70ba0.0298\uff09\u3002\u75c5\u7406\u7d44\u7e54\u7d30\u80de\u578b\u614b\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u4f86\u8aaa\u4e5f\u662f\u4e00\u500b\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff08p\u503c\u70ba0.0063\uff09\u3002\u662f\u5426\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u4f86\u8aaa\u662f\u53e6\u4e00\u500b\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff08p\u503c\u70ba0.0469\uff09\u3002\u800c\u5728\u591a\u8b8a\u9805\u5206\u6790\u7576\u4e2d\uff0c\u75c5\u7406\u7d44\u7e54\u7d30\u80de\u578b\u614b\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u4f86\u8aaa\u4ecd\u820a\u662f\u4e00\u500b\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\uff08p\u503c\u70ba0.045\uff09\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u624b\u8853\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u4f86\u6cbb\u7642\u5b50\u5bae\u5167\u819c\u764c\u75c5\u4eba\uff0c\u5728\u672c\u6587\u7814\u7a76\u4e2d\u53ef\u4ee5\u9054\u523085%\u7684\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u3002\u764c\u75c7\u671f\u5225\u3001\u75c5\u7406\u7d44\u7e54\u7d30\u80de\u578b\u614b\u8207\u662f\u5426\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u662f\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\u3002\u672a\u4f86\u9700\u8981\u66f4\u9577\u6642\u9593\u7684\u8ffd\u8e64\u4ee5\u8a55\u4f30\u75c5\u4eba\u7684\u6cbb\u7642\u7d50\u679c\u8207\u9577\u671f\u9810\u5f8c\u3002", "e": "Purpose: To evaluate the prognostic factors and treatment outcomes in patients of endometrial cancer with treatments of surgery followed by radiotherapy.\nMaterials and Methods: From August 1993 to April 2004, there were 69 patients diagnosed as endometrial cancer at our hospital. The median age at diagnosis was 55 years (ranged from 34 to 80 years). According to the FIGO staging system for cancer of the uterine body, 46 patients (67%) were stage \u2160, 8 (12%) were stage \u2161, 12 (17%) were stage \u2162, and 3 (4%) were stage \u2163. Fifty-eight patients (84%) had endometrioid carcinomas and 11 patients (16%) had non-endometrioid carcinomas: 4 were leiomyoscarcomas, 3 were MMMTs (malignant mixed mullerian tumor), 2 were papillary serous carcinomas, 1 was clear cell carcinoma, and 1 was mixed mucinous and small cell carcinoma. All 69 patients underwent surgery. Sixty-three (91%) of these 69 patients received postoperative adjuvant radiotherapy.\nResults: The median follow-up duration was 38 months (ranged from 8 to 129 months). During the follow-up period, 60 patients (87%) were alive, and 9 patients (13%) died. Three patients (4%) had local recurrence. Nine patients (13%) had distant metastases. The actuarial 5-year overall survival rate was 85%. In univariate analysis, stage was a significant prognostic factor for overall survival, favoring early stages (p=0.0298). Pathological cell type was also a prognostic factor for overall survival, favoring cell type of endometrioid carcinoma (p=0.0063). Lymph node metastasis was another significant prognostic factor affecting overall survival, favoring status without lymph node metastasis (p=0.0469). In multivariate analysis, pathological cell type continued to be a significant prognostic factor for overall survival, favoring cell type of endometrioid carcinoma (p=0.045).\nConclusions: The 5-year overall survival rate of 85% was achieved in our report of patients of endometrial cancer treated with surgery followed by radiotherapy. Stage, pathological cell type and lymph node metastasis were significant prognostic factors affecting overall survival based on our study. Longer follow-up of these patients and accrual of more patients are needed to evaluate long-term survival and treatment outcomes."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-95-101-a", "title": "\u6642\u9593\u56e0\u7d20\u5c0d\u982d\u9838\u90e8\u764c\u75c7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u5f71\u97ff", "keywords": "\u982d\u9838\u90e8\u764c\u75c7;\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642;\u6574\u9ad4\u6cbb\u7642\u6642\u9593;\u6cbb\u7642\u4e2d\u65b7\u6642\u9593 Head-and-neck cancer;Postoperative radiotherapy;Overall treatment time;Treatment gap", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u539f\u767c\u6027\u982d\u9838\u90e8\u816b\u7624\u60a3\u8005\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u5404\u9805\u6642\u9593\u56e0\u7d20\u5c0d\u65bc\u5c40\u90e8\u63a7\u5236\u7387\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1996\u81f32004\u5e74\uff0c\u5171\u6709141\u4f4d\u63a5\u53d7\u6839\u9664\u6027\u624b\u8853\u7684\u982d\u9838\u90e8\u764c\u75c7\u75c5\u60a3\uff0c\u81f3\u672c\u79d1\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u3002\u82e5\u662f\u624b\u8853\u5f8c\u56e0\u70ba\u5fa9\u767c\u624d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u6216\u53ea\u63a5\u53d7\u5207\u7247\u6aa2\u67e5\u7684\u75c5\u4eba\u5247\u4e0d\u5305\u62ec\u5728\u5167\u3002\u7167\u5c04\u5291\u91cf\u3001\u6574\u9ad4\u6cbb\u7642\u6642\u9593\u3001\u6cbb\u7642\u524d\u7b49\u5f85\u6642\u9593\u7684\u4e2d\u503c\u5206\u5225\u70ba61.2\u683c\u96f7\uff0c48\u5929\uff0c\u820734\u5929\uff0c\u5176\u4e2d\u6709277%\u7684\u75c5\u4eba\u5728\u6cbb\u7642\u4e2d\u6c92\u6709\u4e2d\u65b7\uff0c\u670920.6%\u7684\u75c5\u4eba\u6cbb\u7642\u4e2d\u65b7\u5927\u65bc5\u5929\u3002\n\u7d50\u679c\uff1a\u6240\u6709\u75c5\u4eba\u8ffd\u8e64\u6642\u9593\u4e2d\u503c\u70ba14\u500b\u6708\uff0c\u7121\u5fa9\u767c\u5b58\u6d3b(recurrence-free Survival)\u6642\u9593\u4e2d\u503c\u70ba34\u500b\u6708\uff0c\u5176\u4e2d\u670961\u4f4d\u75c5\u4eba(43.3%)\u6709\u5fa9\u767c\u7684\u73fe\u8c61\u3002\u4ee5\u55ae\u8b8a\u6578\u5206\u6790\uff0c\u6cbb\u7642\u524d\u7b49\u5f85\u6642\u9593\u5c0f\u65bc\u7b49\u65bc30\u5929\u7684\u75c5\u4eba\u6709\u8f03\u4f73\u7684\u5c40\u90e8\u63a7\u5236\u7387(p=0.0328)\uff0c\u4f46\u662f\u591a\u8b8a\u6578\u5206\u6790\u6c92\u6709\u986f\u8457\u610f\u7fa9\uff1b\u6574\u9ad4\u6cbb\u7642\u6642\u9593\u8207\u6cbb\u7642\u4e2d\u65b7\u6642\u9593\u7684\u9577\u77ed\u5c0d\u5c40\u90e8\u63a7\u5236\u7387\u6c92\u6709\u5f71\u97ff\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u982d\u9838\u90e8\u816b\u7624\u60a3\u8005\u800c\u8a00\uff0c\u6cbb\u7642\u524d\u7b49\u5f85\u6642\u9593\u5927\u65bc30\u5929\u662f\u4e00\u500b\u4e0d\u5229\u56e0\u5b50\uff1b\u96d6\u7136\u5728\u672c\u7814\u7a76\u4e2d\u6574\u9ad4\u6cbb\u7642\u6642\u9593\u8207\u6cbb\u7642\u4e2d\u65b7\u6642\u9593\u4e26\u6c92\u6709\u986f\u8457\u610f\u7fa9\uff0c\u6211\u5011\u4ecd\u61c9\u76e1\u91cf\u7e2e\u77ed\u6cbb\u7642\u524d\u7684\u7b49\u5f85\u6642\u9593\uff0c\u4e26\u907f\u514d\u6cbb\u7642\u4e2d\u65b7\u3002", "e": "Purpose: To study the locoregional tumor control in postoperative radiotherapy of head-and-neck cancer in relation to the duration of the surgery-radiotherapy interval, overall radiation treatment time (OTT), and treatment gap.\nMethods and Materials: This retrospective study included 141 patients with cancer of head and neck, treated with surgery first, followed by postoperative irradiation between 1996 and 2004. The patients who had recurrence before radiotherapy or only received biopsy were not included. The median of the total radiation dose, surgery-radiotherapy interval, and the overall treatment time were 61.2 Gy, 34 days, and 48 days respectively. No interruption during radiotherapy (except for weekend breaks) was found in 27.7% of patients. Twenty point six percent of patients had more than 5 days of gap.\nResults: The median duration of follow-up was 14 months. The median recurrence-free survival time was 34 months. Recurrence developed in 61 patients (43.3%). Increased surgery-radiotherapy interval to more than 30 days was significantly related to a decrease in recurrence-free survival (RFS) (p=0.0328). However, the duration of OTT and treatment gaps did not influence RFS significantly.\nConclusions: In our study, increased surgery-radiotherapy interval to more than 30 days would cause an adverse effect. Although the overall treatment time and treatment gap did not affect RFS significantly, we should do our best to shorten the surgery-radiotherapy interval and avoid the treatment gaps."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-103-116-a", "title": "Transurethral Resection of Bladder Tumors Followed by Radiotherapy with or without Chemotherapy for Bladder Preservation in Patients with Invasive Bladder Transitional Cell Carcinoma: Preliminary Ntuh", "keywords": "\u8180\u80f1\u764c;\u4fdd\u7559\u7642\u6cd5;\u4e09\u5408\u4e00\u6cbb\u7642 Bladder cancer;Preservation;Trimodality therapy", "c": "\u76ee\u7684\uff1a\u6839\u9664\u6027\u8180\u80f1\u5207\u9664\u8853\u662f\u4fb5\u8972\u6027\u8180\u80f1\u8f49\u578b\u7d30\u80de\u764c\u7684\u6a19\u6e96\u6cbb\u7642\u65b9\u5f0f\u3002\u7d93\u5c3f\u9053\u8180\u80f1\u816b\u7624\u5207\u9664\u8853\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u63d0\u4f9b\u8180\u80f1\u5207\u9664\u8853\u4e4b\u5916\uff0c\u4fdd\u7559\u8180\u80f1\u7684\u6cbb\u7642\u9078\u64c7\u3002\u52a0\u4e0a\u524d\u5c0e\u6027\u53ca\u540c\u6642\u6027\u5316\u5b78\u6cbb\u7642\u4e4b\u4e09\u5408\u4e00\u7642\u6cd5\u80fd\u9032\u4e00\u6b65\u6539\u5584\u6cbb\u7642\u6210\u6548\u3002\u672c\u7bc7\u7814\u7a76\u5831\u544a\u5c07\u8a55\u4f30\u4e09\u5408\u4e00\u7642\u6cd5\u7528\u65bc\u8180\u80f1\u4fdd\u7559\u7642\u6cd5\u4e4b\u77ed\u671f\u6210\u6548\u53ca\u6cbb\u7642\u76f8\u95dc\u4e4b\u526f\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u96c62000\u81f32004\u5e74\uff0c37\u4f4d\u7f79\u60a3\u8180\u80f1\u8f49\u578b\u7d30\u80de\u764c\u4e14\u63a5\u53d7\u8180\u80f1\u4fdd\u7559\u7642\u6cd5\u4e4b\u75c5\u4eba\u9032\u884c\u56de\u9867\u5206\u6790\u3002\u5176\u4e2d21\u4f4d\u75c5\u4eba\u53ea\u63a5\u53d7\u7d93\u5c3f\u9053\u8180\u80f1\u816b\u7624\u5207\u9664\u8853\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u3002\u5176\u991816\u4f4d\u75c5\u4eba\u5728\u63a5\u53d7\u7d93\u5c3f\u9053\u8180\u80f1\u816b\u7624\u5207\u9664\u8853\u8207\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u5f8c\u9054\u5230\u5b8c\u5168\u6216\u90e8\u4efd\u7de9\u89e3\u4e4b\u5f8c\uff0c\u63a5\u53d7\u9032\u4e00\u6b65\u4e4b\u653e\u5c04\u6cbb\u7642\u6216\u540c\u6642\u6027\u5316\u5b78\u6cbb\u7642\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u3002\u5728\u4e09\u5408\u4e00\u6cbb\u7642\u7d44\u4e2d\uff0c\u653e\u5c04\u6cbb\u7642\u4e4b\u8a2d\u8a08\u70ba\u6bcf\u5929\u4e00\u6b211.8Gy\uff0c\u6cbb\u7642\u5291\u91cf\u70ba\uff1a\u9aa8\u76c6\u815445Gy\uff0c\u5168\u8180\u80f150.4Gy\uff0c\u816b\u7624\u90e8\u4f4d64.8Gy\u3002\u672a\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u4e4b\u75c5\u4eba\u63a5\u53d7\u4e4b\u6bcf\u5929\u4e00\u6b212.0Gy\u4e4b\u653e\u5c04\u6cbb\u7642\uff0c\u6cbb\u7642\u5291\u91cf\u70ba\uff1a\u9aa8\u76c6\u815440Gy\uff0c\u5168\u8180\u80f160Gy\u3002\u63a5\u53d7\u4e09\u5408\u4e00\u6cbb\u7642\u4e4b\u75c5\u4eba\u5728\u7642\u7a0b\u4e2d\u9808\u63a5\u53d7\u8180\u80f1\u93e1\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u662f\u5426\u6301\u7e8c\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff0c\u5f97\u4ee5\u7e7c\u7e8c\u653e\u5c04\u6cbb\u7642\u4e4b\u7642\u7a0b\u3002\n\u7d50\u679c\uff1a\u4e09\u5408\u4e00\u7642\u6cd5\u7d44\u75c5\u4eba\u4e4b\u4e2d\u4f4d\u5e74\u9f61\u70ba61.8\u6b72\uff0c\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u4e2d\u4f4d\u5e74\u9f61\u70ba76.8\u6b72\u3002\u5168\u9ad4\u75c5\u4eba\u5171\u670930\u4f4d\u7537\u6027\uff0c7\u4f4d\u5973\u6027\u3002\u5728\u4e09\u5408\u4e00\u6cbb\u7642\u7d44\u4e2d\uff0c\u670914\u4f4d\u75c5\u4eba\u5728\u7d93\u5c3f\u9053\u8180\u80f1\u816b\u7624\u5207\u9664\u8853\u8207\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u5f8c\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u3002\u67097\u4f4d\u75c5\u4eba\u767c\u751f\u7b2c\u4e09\u6216\u7b2c\u56db\u7d1a\u6025\u6027\u53cd\u61c9\uff0c\u5176\u4e2d2\u4f4d\u56e0\u6cbb\u7642\u6bd2\u6027\u800c\u6b7b\u4ea1\u3002\u53e6\u59165\u4f4d\u5728\u8abf\u6574\u5316\u5b78\u6cbb\u7642\u8655\u65b9\u5f8c\u7e7c\u7e8c\u5b8c\u6210\u7642\u7a0b\u3002\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u4e2d\u5247\u53ea\u67091\u4f4d\u75c5\u4eba\u767c\u751f\u7b2c\u4e09\u7d1a\u6025\u6027\u53cd\u61c9\u3002\u4e2d\u4f4d\u8ffd\u8e64\u6642\u9593\u5728\u4e09\u5408\u4e00\u7642\u6cd5\u7d44\u70ba14.6\u500b\u6708\uff0c\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u70ba21\u500b\u6708\u3002\u4e00\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u5728\u4e09\u5408\u4e00\u7642\u6cd5\u7d44\u70ba93.3%\uff0c\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u70ba72.0%\uff08p\u503c0.11\uff09\u3002\u4e09\u5408\u4e00\u7642\u6cd5\u7d44\u8207\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7d44\u4e4b\u4e00\u5e74\u9060\u7aef\u8f49\u79fb\u63a7\u5236\u7387\uff0c\u75be\u75c5\u63a7\u5236\u7387\u8207\u5b58\u6d3b\u7387\u5206\u5225\u70ba100%\u820773.3%\uff08p\u503c0.047\uff09\uff0c93.3%\u820762.3%\uff08p\u503c0.05\uff09\uff0c\u4ee5\u53ca87.5%\u820779.8%\uff08p\u503c0.23\uff09\u3002\n\u7d50\u8ad6\uff1a\u5728\u589e\u52a0\u6025\u6027\u53cd\u61c9\u4e4b\u4ee3\u50f9\u4e4b\u4e0b\uff0c\u4e09\u5408\u4e00\u8180\u80f1\u4fdd\u7559\u7642\u6cd5\u63d0\u4f9b\u8f03\u4f73\u4e4b\u9060\u7aef\u8f49\u79fb\u63a7\u5236\u7387\u8207\u50be\u5411\u6709\u8f03\u597d\u7684\u75be\u75c5\u63a7\u5236\u7387\u3002\u672c\u9662\u76ee\u524d\u6240\u4f7f\u7528\u7684\u7642\u7a0b\u4f3c\u4e4e\u5177\u6709\u53ef\u884c\u6027\u4e14\u53ef\u70ba\u591a\u6578\u75c5\u4eba\u6240\u627f\u53d7\u3002\u5728\u6709\u9650\u7684\u77ed\u671f\u4e4b\u8ffd\u8e64\u4e0b\uff0c\u4e09\u5408\u4e00\u8180\u80f1\u4fdd\u7559\u7642\u6cd5\u4e4b\u6210\u6548\u5728\u90e8\u4efd\u75c5\u4eba\u6709\u4ee4\u4eba\u6eff\u610f\u7684\u6210\u679c\u3002\u4f46\u4ecd\u9808\u66f4\u9577\u6642\u9593\u7684\u8ffd\u8e64\u4f86\u78ba\u8a8d\u6b64\u4fdd\u7559\u7642\u6cd5\u7684\u6700\u7d42\u6210\u679c\u3002", "e": "Purpose: Radical cystectomy has been the standard treatment for invasive transitional cell carcinoma (TCC) of urinary bladder. Transurethral resection of bladder tumors (TUR-BT) and radiotherapy (RT) provide an alternative option to cystectomy for organ preservation. The trimodality therapy (TMT) incorporating neoadjuvant and concurrent chemotherapy (CHT) seems to improve the treatment result. This study is to evaluate the short-term outcome and treatment-related toxicity of the TMT for bladder preservation.\nMaterials and Methods: From 2000 to 2004, 37 patients with invasive bladder TCC undergoing bladder preservation therapy were reviewed retrospectively. Among them, 21 patients received radical TUR-BT followed by RT alone. The other 16 patients who had complete response or good partial response after radical TUR-BT and neoadjuvant CHT received further RT or concurrent chemoradiation. The RT protocol was 45Gy to small pelvis field and 50.4Gy to whole bladder, plus tumor bed boost to a total dose of 64.8Gy with daily fraction size of 1.8Gy in the TMT group. Patients in the RT alone group received 60Gy to whole bladder or 40Gy to whole pelvis plus 20Gy boost to whole bladder with daily fraction size of 2.0 Gy. Interval cystoscopy was performed to confirm the status of complete response for continuation of RT in the TMT group.\nResults: The median age was 61.8 in the TMT group and 76.8 in the RT alone group. Thirty patients were male and seven were female. In the TMT group, fourteen patients had complete response after radical TUR-BT and induction CHT. Seven patients (43.7%) in the TMT group had grade 3 or 4 acute toxicity, and two of them died of treatment toxicity. The other five patients completed their treatment course with modification of CHT. In the RT alone group, only one patient (4.7%) had grade 3 acute toxicity. The median follow-up was 14.6 months in the TMT group and 21 months in the RT alone group. In the 14 patients completing TMT, two patients experienced local recurrence and none of 16 patients had distant metastasis. In the RT alone group, eight of 21 patients had local recurrence while 7 patients had distant metastasis. The one-year locoregional control rates were 93.3% in TMT group and 72.0% in RT alone group (p=0.11). The one-year metastasis-free survival, disease-free survival, and overall survival were 100% and 73.3% (p=0.047), 93.3% and 62.3% (p=0.05), and 87.5% and 79.8% (p=0.23), respectively.\nConclusion: At the cost of increased acute toxicity, TMT for bladder preservation provides significant better metastasis-free survival and favorable disease-free survival. Our protocol seems feasible and well tolerated in most patients. With limited follow-up, the result of TMT remains satisfactory in selected patients. Longer observation is needed to confirm the ultimate success of bladder preservation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-117-125-a", "title": "Adjuvant Concurrent Uracil-Tegafur with Leucovorin and Radiotherapy for Locally Advanced Rectal Cancer", "keywords": "\u540c\u6b65\u6027\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642;UFUR;\u4fb5\u72af\u6027\u76f4\u8178\u764c Concurrent chemoradiation therapy CCRT;UFUR;Advanced rectal cancer", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u63a2\u8a0e\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\u624b\u8853\u5f8c\u4f75\u7528Uracil-Tegafur (UFUR)\uff0cLeucovorin (LV)\u53ca\u540c\u6b65\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u7642\u6548\u3001\u6bd2\u6027\u53ca\u5b89\u5168\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2001\u5e742\u6708\u81f32004\u5e7411\u6708\uff0c\u517117\u4f4d\u63a5\u53d7\u540c\u6b65\u6027\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u4f75\u7528UFUR\u8207LV\u7684\u76f4\u8178\u764c\u8853\u5f8c\u7684\u60a3\u8005\u3002\u60a3\u8005\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba54\u6b72\uff08\u5f9e42\u81f386\u6b72\uff09\u3002\u624b\u8853\u7684\u65b9\u5f0f\u53ef\u5206\u70baAPR\u8207RP\u3002\u5728\u6cbb\u7642\u671f\u9593\u6bcf\u5929\u53e3\u670dUFUR\u7684\u5291\u91cf\u70ba200-250mg/m2/day\uff1b\u800cLV\u70ba45-60 mg/day\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u70ba\u6bcf\u65e51.8Gy\uff0c\u5171\u8a08\u7167\u5c0428\u81f333\u6b21\u3002\u5168\u9aa8\u76c6\u7167\u5c04\u517145Gy\uff0c\u4e4b\u5f8c\u518d\u5c0d\u816b\u7624\u5c40\u90e8\u7167\u5c045.4Gy\u81f314.4Gy\u3002\u5316\u5b78\u6cbb\u7642\u5728\u653e\u5c04\u6cbb\u7642\u5f8c\u4ee5\u540c\u6a23\u5291\u91cf\u6301\u7e8c\u4f7f\u7528\u4e00\u5e74\u4ee5\u4e0a\u6216\u81f3\u5fa9\u767c\u70ba\u6b62\u3002\n\u7d50\u679c\uff1a17\u4f4d\u4e2d\uff0c7\u4f4d\u70ba\u7537\u6027\uff0c10\u4f4d\u70ba\u5973\u6027\u30025\u4f4d\u63a5\u53d7APR\u800c12\u4f4d\u63a5\u53d7RP\u300217\u4f4d\u7686\u5c6c\u65bc\u817a\u764c\u300215\u4f4d\u75c5\u7406\u5206\u7d1a\u70ba\u4e2d\u5ea6\u5206\u5316\uff0c2\u4f4d\u70ba\u5206\u5316\u4e0d\u826f\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u4e2d\u4f4d\u6578\u5291\u91cf\u70ba59.4Gy(50.4Gy~59.4Gy)\uff0c\u5e73\u5747\u5291\u91cf\u70ba57.7Gy\u3002\u6cbb\u7642\u671f\u9593\u7121\u4eba\u6b7b\u4ea1\u3002\u4e2d\u4f4d\u6578\u751f\u5b58\u6708\u4efd\u70ba36\u500b\u6708\u3002\u4e09\u5e74\u5b58\u6d3b\u738768%\u3002\u4e09\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba44%\u30024\u4f4d(24%)\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u53ca\u4e09\u5e74\u5c40\u90e8\u5fa9\u767c\u63a7\u5236\u7387\u70ba68%\u30025\u4f4d(29%)\u767c\u751f\u9060\u8655\u8f49\u79fb\u800c\u4e09\u5e74\u9060\u8655\u8f49\u79fb\u63a7\u5236\u7387\u70ba62%\u3002\u672c\u6b21\u7814\u7a76\u4e2d\u6700\u5e38\u767c\u751f\u7684\u526f\u4f5c\u7528\u70ba\u5641\u5fc3\u3001\u5614\u5410\u3001\u75b2\u5026\u3001\u76ae\u819a\u708e\u8207\u8ca7\u8840\u3001\u767d\u8840\u7403\u6e1b\u5c11\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u3002\u6c92\u67094\u7d1a\u4ee5\u4e0a\u7684\u6bd2\u6027\u53cd\u61c9\u30023\u7d1a\u4ee5\u4e0a\u7684\u8179\u7009\u4f5418%\uff1b3\u7d1a\u4ee5\u4e0a\u7684\u75b2\u5026\u4f546%\uff1b3\u7d1a\u4ee5\u4e0a\u7684\u5614\u5410\u4f546%\u4f46\u90fd\u5728\u53ef\u63a5\u53d7\u7684\u7a0b\u5ea6\u3002\u76ae\u819a\u708e\uff0c\u6700\u56b4\u91cd\u70ba2\u7d1a\u7684\u50b7\u5bb3\u30023\u7d1a\u4ee5\u4e0a\u7684\u8ca7\u8840\u53ea\u4f546%\u3002\u6c92\u67093\u7d1a\u4ee5\u4e0a\u7684\u767d\u8840\u7403\u6e1b\u5c11\uff0c\u8840\u5c0f\u677f\u6e1b\u5c11\u7684\u60c5\u5f62\u3002\n\u7d50\u8ad6\uff1a\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\u624b\u8853\u5f8c\u4f75\u7528Uracil-Tegafur (UFUR)\uff0cLV\u53ca\u540c\u6b65\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u63d0\u4f9b\u6709\u6548\u3001\u5b89\u5168\u65b9\u4fbf\u800c\u6bd2\u6027\u5c11\u7684\u6cbb\u7642\u3002\u53ef\u518d\u9032\u884c\u9032\u4e00\u6b65\u7684\u81e8\u5e8a\u96a8\u6a5f\u6027\u8a66\u9a57\u3002", "e": "Purpose: This prospective, nonrandomized study was conducted to test the efficacy and toxicity of adjuvant concurrent chemoradiation therapy (CCRT) using uracil-tegafur (UFUR) and leucovorin (LV) in patients with locally advanced rectal cancer.\nMaterial and Methods: From February 2001 through November 2004, 17 patients with stage II or III rectal adenocarcinoma were enrolled in the study. All underwent curative resection followed by adjuvant CCRT at Mackay Memorial Hospital, Taipei. The median age was 54 (range, 42 to 86) years. The operative procedures were either abdominoperineal resection or a radical proctectomy. Radiotherapy (RT), delivered in 28 to 33 fractions, consisted of 45Gy of whole-pelvis irradiation followed by a 5.4 to 14.4Gy local boost to the tumor bed. A combination of oral UFUR at 200 to 250 mg/m2/day and LV 45 to 60 mg/day was given 7 days a week during the RT course and then for at least one year or until treatment failure, whichever came first.\nResults: Of the 17 patients, 7 were male and 10 were female. Five had undergone APR and 12 RP. The adenocarcinoma was moderately differentiated in 15 poorly differentiated in 2. The median radiation dose was 59.4 (range, 50.4 to 59.4)Gy, with a mean 57.7Gy. None of the patients died during the CCRT course. The median survival for all 17 patients was 36 months, and the 3-year overall survival was 68%. The 3-year disease-free survival rate was 44%. Four patients developed local failure, yielding a 3-year local control rate of 68%. Five patients developed distant metastasis, for a 3-year metastasis-free rate of 62%. The most-common side effects were diarrhea and nausea or vomiting, dermatitis, fatigue, and hematological toxicity consisting of anemia, leucopenia, and thrombocytopenia. No grade 4 toxicity was observed. Three patients had grade 3 diarrhea, and 1 grade 3 fatigue and vomiting, but these were tolerable. None had greater than grade 2 skin toxicity. One patient had grade 3 anemia, but none had grade 3 leucopenia or thrombocytopenia.\nConclusions: Adjuvant CCRT that includes oral UFUR and LV provided acceptable survival and local control rates with acceptable toxicity in patients with locally advanced rectal cancer. A randomized trial of this combined treatment is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-127-133-a", "title": "Side Effects of Amifostine with Concurrent Chemoradiation Therapy for Head and Neck Cancer", "keywords": "Amifostine;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642;\u982d\u9838\u90e8\u764c\u75c7;\u53e3\u4e7e Amifostine;Concurrent chemoradiation therapy;Head and neck cancer;Xerostomia", "c": "\u76ee\u7684\uff1a\u5c0d\u6b63\u5e38\u7d44\u7e54\u7684\u6bd2\u6027\u53cd\u61c9\u4f5c\u7528\u4e00\u76f4\u662f\u540c\u6b65\u6027\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u4e3b\u8981\u9650\u5236\u56e0\u7d20\u3002\u5728\u9019\u6b21\u7684\u7814\u7a76\u88e1\uff0c\u6211\u5011\u8a55\u4f30\u982d\u9838\u90e8\u764c\u75c7\u7684\u60a3\u8005\uff0c\u5c0d\u65bc\u4f7f\u7528amifostine\u5728\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u6642\u7684\u4fdd\u8b77\u6548\u679c\u53ca\u5176\u6bd2\u6027\u3002\n\u75c5\u4eba\u8207\u65b9\u6cd5\uff1a\u81ea2000\u5e746\u6708\u81f32002\u5e7411\u6708\uff0c\u5171\u670916\u4f4d\u982d\u9838\u90e8\u764c\u75c7\u7684\u60a3\u8005\u63a5\u53d7\u540c\u6b65\u6027\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u60a3\u8005\u63a5\u53d7\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u70ba\u6bcf\u65e5180cGy\uff0c\u7bc4\u570d\u5f9e64.8\u81f372.0Gy\u3002\u5316\u5b78\u6cbb\u7642\u70ba\u5728\u653e\u5c04\u7dda\u6cbb\u7642\u671f\u9593\uff0c\u6bcf\u9031\u63a5\u53d7cisplatin (CDDP) 30.0 mg/\u5e73\u65b9\u516c\u5c3a\u3002\u6bcf\u6b21\u653e\u5c04\u7dda\u6cbb\u7642\u524d15\u5206\u9418\uff0c\u7d66\u4e88amifostine (300mg/\u5e73\u65b9\u516c\u5c3a)3\u5206\u9418\u7684\u5feb\u901f\u6ef4\u6ce8\u3002\u60a3\u8005\u6bcf\u500b\u661f\u671f\u8a18\u9304amifostine\u7684\u4fdd\u8b77\u6548\u679c\u53ca\u5176\u6bd2\u6027\u3002\n\u7d50\u679c\uff1a16\u4f4d\u60a3\u8005\u4e2d\uff0c\u67098\u4f4d\u7684\u60a3\u8005\u56e0\u70baamifostine\u6240\u5c0e\u81f4\u7684\u526f\u4f5c\u7528\u800c\u5fc5\u9808\u66ab\u505c\u4f7f\u7528amifostine\u3002\u5176\u4e2d5\u500b\u60a3\u8005\u5fc5\u9808\u5c07\u5291\u91cf\u6e1b\u5230210mg/\u5e73\u65b9\u516c\u5c3a\uff0c3\u4f4d\u505c\u6b62\u7e7c\u7e8c\u4f7f\u7528amifostine\u3002Amifostine\u6240\u5c0e\u81f4\u7684\u526f\u4f5c\u7528\u9020\u62107\u4f4d\u75c5\u4eba\u653e\u5c04\u7dda\u6cbb\u76422\u52307\u5929\u7684\u5ef6\u9072\uff0c\u751a\u81f3\u6709\u4e00\u4f4d\u60a3\u8005\u56e0\u70ba\u56b4\u91cd\u7684\u526f\u4f5c\u7528\u800c\u5fc5\u9808\u505c\u6b62\u6cbb\u7642\u3002\n\u53e3\u4e7e\u3001\u541e\u56a5\u56f0\u96e3\u53ca\u53e3\u8154\u767c\u708e\u7b49\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u526f\u4f5c\u7528\uff0c\u5728\u6240\u6709\u60a3\u8005\u5747\u6709\u89c0\u5bdf\u5230\u3002\u67096\u4f4d\u60a3\u8005\u7522\u751f3\u7d1a\u53e3\u4e7e\u7684\u526f\u4f5c\u7528\u3002\u56b4\u91cd\u76844\u7d1a\u526f\u4f5c\u7528\u767c\u751f\u57281\u4f4d\u60a3\u8005\u8eab\u4e0a\u30021\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba78%\uff0c2\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba60%\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u982d\u9838\u90e8\u60a3\u8005\uff0c\u6bcf\u6b21\u653e\u5c04\u6cbb\u7642\u524d\u7d66\u4e88\u7d93\u7531\u975c\u8108\u8f38\u6ce8\u7684amifostine 300 mg/\u5e73\u65b9\u516c\u5c3a\uff0c\u4f34\u96a8\u56b4\u91cd\u7684\u526f\u4f5c\u7528\u3002\u5efa\u8b70\u8abf\u6574\u8d77\u59cb\u5291\u91cf\u6216\u8005\u6539\u8b8a\u9014\u5f91\u3002", "e": "Objective: Toxicity to normal tissues remains a major treatment-limiting factor in concurrent chemoradiation therapy (CCRT). This study was conducted to evaluate the toxicity of amifostine used along with CCRT to treat head and neck cancer.\nPatients and Methods: The medical records of 16 patients with head and neck cancer treated from June 2001 to November 2003 with CCRT plus amifostine in our department were retrospectively analyzed. The primary tumor was in the nasopharynx in 6, oropharynx in 6, and oral cavity in 4. Radiotherapy (RT) was administered to the primary tumor and regional lymph nodes at a dose of 64.8 to 72Gy over 7 to 8 weeks. Chemotherapy consisted of 6 weekly doses of cisplatin (30 mg/m^2) given approximately\n1 hour prior to RT. A rapid 3-minute intravenous infusion of amifostine, 300 mg/m^2, was given 15 minutes before each RT fraction. All patients were examined at the end of each week. Adverse effects of amifostine were recorded.\nResults: In 8 of the 16 patients (50%), the amifostine therapy had to be discontinued or reduced because of amifostine-related toxicity. The dose was reduced to 210 mg/m^2 in 5 patients and stopped completely in another 3. Amifostine-related adverse effects resulted in delay of RT by 2 to 7 days in 7 of the 16 patients, and RT could not be completed in 1 patient. Long-term amifostine-related toxicity was not observed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-135-146-a", "title": "Radiobiological Characterization of the Epithermal Neutron Beam Produced at the Tsing Hua Open-Pool Reactor (THOR) for BNCT: Comparison with Other BNCT Facilities", "keywords": "\u653e\u5c04\u6cbb\u7642;\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642BNCT;\u76f8\u5c0d\u751f\u7269\u6548\u61c9RBE;\u8f3b\u5c04\u751f\u7269\u7684\u76f8\u4e92\u6bd4\u5c0d;\u8178\u5c0f\u56ca Radiotherapy;Boron Neutron Capture Therapy BNCT;Relative Biological Effectiveness RBE;Radiobiological Intercomparison;Intestinal crypts", "c": "\u76ee\u7684\uff1a\u5728\u6e05\u83ef\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668(THOR)\u7279\u5b9a\u7167\u5c04\u689d\u4ef6\u4e0b\uff0c\u672c\u7814\u7a76\u5229\u7528\u7279\u5b9a\u751f\u7269\u65b9\u6cd5\u4f86\u63a2\u8a0eTHOR\u505a\u70ba\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642(BNCT)\u7528\u9014\u4e4b\u8d85\u71b1\u4e2d\u5b50\u675f\u7684RBE\u503c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6240\u63a1\u7528\u4e4b\u751f\u7269\u65b9\u6cd5\u70ba\u5c0f\u9f20\u9ad4\u5167\u8178\u5c0f\u56ca\u7684\u518d\u751f\u7d30\u80de\uff0c\u5be6\u9a57\u904e\u7a0b\u5c0f\u9f20\u4e26\u672a\u6ce8\u5c04\u542b\u787c\u85e5\u7269\uff0c\u5be6\u9a57\u6240\u5f97\u4e4bRBE\u503c\u5247\u662f\u6bd4\u8f03\u923760\u7167\u5c04\u53caTHOR\u7167\u5c04\u689d\u4ef6\u4e0b\uff08\u7531\u4e0d\u540c\u52a0\u99ac\u53ca\u201c\u975e\u52a0\u99ac\u201d\u8f3b\u5c04\u5291\u91cf\u7d44\u6210\uff09\uff0c\u7522\u751f\u76f8\u540c\u8f3b\u5c04\u751f\u7269\u6548\u61c9\u4e4b\u8f3b\u5c04\u5291\u91cf\u7684\u95dc\u4fc2\u503c\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5728THOR\u5169\u7a2e\u7167\u5c04\u689d\u4ef6\u4e0b\uff0c\u8d85\u71b1\u4e2d\u5b50\u675f\u7684RBE\u503c\u5206\u5225\u70ba1.5\u548c1.9\uff0c\u5176\u4e2d\u52a0\u99ac\u8f3b\u5c04\u5291\u91cf\u6240\u4f54\u7684\u6bd4\u4f8b\u5206\u5225\u70ba75%\u548c70%\u3002\u5047\u8a2d\u52a0\u99ac\u8f3b\u5c04\u7684RBE\u503c\u7b49\u65bc1\uff0c\u5247THOR\u5169\u7a2e\u7167\u5c04\u689d\u4ef6\u4e0b\u4e4b\u201c\u975e\u52a0\u99ac\u201d\u8f3b\u5c04\u7684RBE\u503c\u53ef\u5206\u5225\u6c42\u5f97\u70ba2.9\u548c4.0\u3002\u6bd4\u8f03THOR\u8207\u5168\u4e16\u754c\u5176\u4ed66\u500bBNCT\u8a2d\u65bd\u5728\u76f8\u540c\u5be6\u9a57\u65b9\u6cd5\u4e0b\u6240\u5f97\u7684\u7d50\u679c\u53ef\u4ee5\u767c\u73fe\uff1a\u5373\u4f7f\u5728\u8a2d\u65bd\u7d44\u6210\u53ca\u8f3b\u5c04\u5291\u91cf\u7d44\u5408\u76f8\u985e\u4f3c\u7684\u60c5\u6cc1\u4e0b\uff0c\u5404\u8d85\u71b1\u4e2d\u5b50\u675f\u7684RBE\u503c\u4ea6\u4e0d\u76e1\u76f8\u540c\uff1b\u7136\u800c\uff0c\u4e2d\u5b50\u675fRBE\u503c\u96a8\u8457\u201c\u975e\u52a0\u99ac\u201d\u8f3b\u5c04\u5291\u91cf\u6240\u4f54\u7684\u6bd4\u4f8b\u589e\u52a0\u800c\u5fae\u5e45\u589e\u52a0\u7684\u8da8\u52e2\u5247\u662f\u4e00\u81f4\u3002\u96d6\u7136\u5404\u5be6\u9a57\u8a2d\u65bd\u6240\u63a8\u5f97\u4e4b\u201c\u975e\u52a0\u99ac\u201d\u8f3b\u5c04\u7684RBE\u503c\u4ea6\u5448\u73fe\u6975\u5927\u5dee\u7570\uff0c\u4f46\u5176\u5e73\u5747\u503c3.4\u5247\u8207\u73fe\u884c\u81e8\u5e8a\u61c9\u7528\u4f86\u6c7a\u5b9a\u7e3d\u751f\u7269\u6b0a\u91cd\u5291\u91cf\u7684RBE\u503c\u76f8\u8fd1\u3002\n\u8a0e\u8ad6\u8207\u7d50\u8ad6\uff1a\u6bd4\u8f03THOR\u8207\u4e16\u754c\u4e0a\u5176\u4ed6BNCT\u8a2d\u65bd\u7684\u7d50\u679c\u986f\u793a\uff1a\u6240\u6709\u8a2d\u65bd\u4e4b\u8d85\u71b1\u4e2d\u5b50\u675f\u7684RBE\u503c\u7686\u96a8\u8457\u201c\u975e\u52a0\u99ac\u201d\u8f3b\u5c04\u5291\u91cf\u6240\u4f54\u7684\u6bd4\u4f8b\u589e\u52a0\u800c\u589e\u52a0\uff0c\u7136\u800c\uff0c\u4e0d\u540c\u8a2d\u65bd\u4e4b\u9593\u6240\u5f97\u7684\u7d50\u679c\u5dee\u7570\u9817\u5927\uff0c\u7121\u6cd5\u4ee5\u8a2d\u65bd\u7d44\u6210\u4e0d\u540c\u6216\u6240\u63d0\u4f9b\u7684\u5291\u91cf\u7387\uff08\u53cd\u61c9\u5668\u529f\u7387\uff09\u4e0d\u540c\u4f86\u52a0\u4ee5\u89e3\u91cb\uff0c\u53ef\u80fd\u8981\u5f9e\u6e1b\u5c11\u8f3b\u5c04\u5291\u91cf\u6e2c\u91cf\u7684\u4e0d\u6e96\u5ea6\uff0c\u4e26\u63a1\u53d6\u5171\u901a\u7684\u5291\u91cf\u6e2c\u91cf\u7a0b\u5e8f\uff0c\u4ee5\u78ba\u4fdd\u8f3b\u5c04\u751f\u7269\u6578\u64da\u7684\u4e00\u81f4\u6027\u3002\u7531\u65bc\u672c\u5be6\u9a57\u65b9\u6cd5\u5177\u6709\u53ef\u5168\u9762\u6aa2\u67e5\u7167\u5c04\u7a0b\u5e8f\uff08\u5305\u542b\u5291\u91cf\uff09\u7684\u6027\u8cea\uff0c\u56e0\u6b64\u53ef\u7528\u4f86\u505a\u70ba\u65b0\u8a2d\u65bd\u5efa\u7acb\u6216\u91cd\u5927\u8a2d\u65bd\u5347\u7b49\u7684\u8a55\u4f30\u4f9d\u64da\u3002", "e": "Purpose: To determine the RBE of the BNCT epithermal neutron beam produced at THOR for a reference biological system and reference irradiation conditions.\nMaterials and Methods: Intestinal crypt regeneration in mice was chosen as biological system. No boron compound was administrated. RBE was determined relative to cobalt-60 gamma rays for two irradiation conditions corresponding to different gamma and \u201dnon-gamma\u201d absorbed dose mixtures.\nResults: The RBE(subscript beam) (i.e. considering the beam \u201das it is\u201d, with all dose components and its actual dose rate) was found equal to 1.5 and 1.9 for absorbed dose mixtures comprising 75 and 70% of gamma respectively. Assuming that the RBE of the gamma dose component is equal to unity and deriving the RBE of the non-gamma dose component, RBE(subscript non-\u03b3) values of 2.9 and 4.0 were obtained from the data of the first and second absorbed dose mixture respectively. Comparing the THOR data with those obtained from the same system in 6 other BNCT facilities worldwide, large differences between the RBE(subscript beam) are observed, even when comparing those beam configurations exhibiting similar absorbed dose mixtures. There is, however, a general trend for the RBE(subscript beam) to increase slightly with increasing non-gamma dose component contribution. The derived RBE(subscript non-\u03b3) exhibit also large differences, but average 3.4, which value is close to the one currently apply in clinical practice for determining the \u201dtotal biologically weighted dose\u201d.\nDiscussion and Conclusion: The THOR data as well as those of the other facilities exhibit a certain degree of internal consistency in that the RBE(subscript beam) increases with the non-gamma dose component. However, the RBE differences between institutions appear too large to be explained only by the difference in the composition of the beams and in dose rate (power of the reactor). It is likely that lessening the dosimetric uncertainties and adopting common dosimetric protocols would restore some homogeneity in the radiobiological data. As such experiments constitue an overall check of the irradiation procedure (including dosimetry), they should be undertaken for the commissioning of new installations or on the occasion of any substantial upgrade."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-147-152-a", "title": "Scalp Metastasis from Transitional Cell Carcinoma of Renal Pelvis-A Case Report and Review of the Literature", "keywords": "\u79fb\u5f62\u7d30\u80de\u764c;\u653e\u5c04\u6cbb\u7642;\u76ae\u819a\u8f49\u79fb\u764c Transitional cell carcinoma;Radiation therapy;Skin metastasis", "c": "\u6ccc\u5c3f\u9053\u79fb\u5f62\u7d30\u80de\u764c\u8f49\u79fb\u81f3\u76ae\u819a\u4e4b\u75c5\u4f8b\u4e0d\u591a\u3002\u8180\u80f1\u79fb\u5f62\u7d30\u80de\u764c\u8f49\u79fb\u81f3\u76ae\u819a\u4e4b\u767c\u751f\u7387\u70ba\u767e\u5206\u4e4b\u96f6\u9ede\u4e8c\u81f3\u4e8c\u4e4b\u9593\u3002\u814e\u76c2\u79fb\u5f62\u7d30\u80de\u764c\u8f49\u79fb\u81f3\u76ae\u819a\u4e4b\u767c\u751f\u7387\u4e0d\u660e\u3002\u5927\u90e8\u5206\u76ae\u819a\u8f49\u79fb\u5728\u539f\u767c\u764c\u6cbb\u7642\u5f8c\u534a\u5e74\u81f3\u6578\u5e74\u4e4b\u9593\u767c\u751f\u3002\u76ae\u819a\u8f49\u79fb\u764c\u4e4b\u6cbb\u7642\u6a21\u5f0f\u5305\u62ec\u624b\u8853\uff0c\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u3002\u5316\u5b78\u6cbb\u7642\u5305\u62ecM-VAC\uff08Methrotrexate, Vinblastine, Adriamycin\u53caCisplatin\uff09\u6216Gemcitabine\u3002\u6ccc\u5c3f\u9053\u79fb\u5f62\u7d30\u80de\u764c\u8f49\u79fb\u81f3\u76ae\u819a\u4e4b\u9810\u5f8c\u6975\u5dee\u3002", "e": "It is rare to see skin metastasis originated from the transitional cell carcinoma (TCC) of urinary tract. The incidence of skin metastasis from TCC of urinary bladder generally falls in the range from 0.2 to 2%, however, that of the TCC of renal pelvis metastasis to skin remains unknown. Most of the skin metastases occur at a time period from six months to several years after the diagnosis of the primary tumor. The treatment modalities adapted on the treatment of cutaneous metastasis include surgery, radiation therapy and chemotherapy with M-VAC (methrotrexate, vinblastin, adriamycin and cisplatin) or gemcitabine. We have seen a dismal prognosis on a male patient with skin metastasis from TCC of urinary tract."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200606-13-2-153-162-a", "title": "IMRT for a Malignant Mesothelioma", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642 Radiotherapy;Malignant pleural mesothelioma;IMRT", "c": "\u76ee\u7684\uff1a\u4ee5\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642(IMRT)\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u65bc\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624\u4e4b\u6cbb\u7642\u6548\u679c\u8a55\u4f30\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6b64\u70ba\u4e00\u4f4d65\u6b72\u7537\u6027\u3001\u53f3\u5074\u808b\u819c\u8154\u5167\u6709\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624\u4e4b\u75c5\u60a3\uff0c\u5176\u4e3b\u8a34\u70ba\u54b3\u55fd\u5e36\u6709\u8840\u7d72\u5df2\u67093\u500b\u6708\u3001\u547c\u5438\u77ed\u4fc3\u3001\u9ad4\u91cd\u6e1b\u8f15\u3002\u6b64\u75c5\u60a3\u4e4b\u80f8\u8154X\u5149\u7247\u4e2d\u767c\u73fe\u53f3\u5074\u808b\u819c\u7a4d\u6c34\uff0c\u521d\u5224\u70ba\u80ba\u764c\u3002\u65bc2003\u5e741\u67083\u65e5\u5b89\u6392\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u7784(CT scan)\uff0c\u767c\u73fe\u53f3\u4e0b\u80ba\u9580\u6709\u816b\u584a\u53ca\u80ba\u816b\u8139\u4e0d\u5168\u3002\u6700\u5f8c\u6839\u64daCT\u5f71\u50cf\uff0c\u5224\u70ba\u80ba\u816b\u8139\u4e0d\u5168\u4e4b\u53f3\u4e0b\u5074\u652f\u6c23\u7ba1\u80ba\u764c\uff0c\u4e26\u4e14\u53f3\u5074\u80ba\u7a4d\u6c34\u3002\u65bd\u4e88\u80ba\u7a4d\u6c34\u5f15\u6d41\u5f8c\uff0c\u518d\u505a\u4e00\u6b21\u80f8\u90e8X\u5149\uff0c\u767c\u73fe\u80ba\u808b\u819c\u589e\u539a\u3002\u65bc2003\u5e741\u670817\u65e5\uff0c\u65bd\u4e88\u75c5\u7406\u5207\u7247\uff0c\u5831\u544a\u6307\u51fa\u70ba\u4e0a\u76ae\u578b\u4e4b\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624\uff0cCEA\u67d3\u8272\u5448\u9670\u6027\uff0c\u800cCK\u548cEMA\u67d3\u8272\u5247\u5448\u967d\u6027\u3002TNM\u671f\u5225\u70baT2N1M0\u3002\u96a8\u5373\u5b89\u6392\u75c5\u60a3\u9032\u884c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u7d93GE lightspeed\u96fb\u8166\u65b7\u5c64\u6a5f\uff0c\u53d6\u5f97\u5207\u7247\u539a\u5ea6\u70ba5\u516c\u5398\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u7528\u7684\u5b9a\u4f4dCT\u5f71\u50cf\uff0c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u70baEclipse\u7b2c\u516d\u7248\u3002IMRT\u6cbb\u7642\u90e8\u4f4d\u70ba\u53f3\u5074\u6574\u500b\u80ba\u808b\u819c\uff0c\u7e3d\u5291\u91cf\u70ba64.6\u683c\u96f7\uff0c\u81ea2003\u5e742\u670812\u65e5\u81f34\u670822\u65e5\uff0c\u70ba\u671f61\u5929\uff0c\u517138\u6b21\u3002\u653e\u5c04\u6cbb\u76424\u5929\u524d\uff0c\u75c5\u60a3\u5148\u63a5\u53d7\u4e86\u7684cisplatin 100\u6beb\u514b\u7d93\u975c\u8108\u4e4b\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u4e4b\u5f8c\uff0c\u75c5\u60a3\u5728\u9580\u8a3a\u8ffd\u8e64\u6301\u7e8c\u4e86\u5e7e\u500b\u6708\u3002\u5c04\u7dda\u7dda\u6cbb\u7642\u5f8c\u516d\u500b\u6708\u5167\uff0c\u90fd\u6c92\u6709\u5fa9\u767c\u3002\u8ffd\u8e64\u4e4bCT\u5f71\u50cf\u4e2d\u986f\u51fa\uff0c\u8f15\u5fae\u80ba\u7a4d\u6c34\u53ca\u53f3\u5074\u80ba\u808b\u819c\u8154\u9010\u6f38\u8b8a\u5c0f\u3002\u65bc2003\u5e7410\u6708\u767c\u73fe\u8166\u8f49\u79fb\uff0c2003\u5e7410\u670818\u65e5\u81f32003\u5e7411\u670820\u65e5\uff0c\u7d66\u4e88\u59d1\u606f\u6027\u4e4b\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u70ba42.5\u683c\u96f7\u3002\u8a72\u75c5\u60a3\u65bc2003\u5e7411\u670830\u65e5\u6b7b\u4ea1\u3002\n\u7d50\u8ad6\uff1a\u60e1\u6027\u9593\u76ae\u7d30\u80de\u7624\u5728\u7121\u6cd5\u9032\u884c\u6839\u9664\u6027\u958b\u5200\u624b\u8853(EPP)\u4e4b\u9918\uff0c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4ea6\u70ba\u4e00\u500b\u9078\u64c7\uff0c\u4e26\u4e14\u6c92\u6709\u767c\u751f\u56e0\u9ad8\u5291\u91cf\u7684\u653e\u5c04\u7dda\u800c\u8a98\u767c\u7684\u80ba\u708e\u3002\u6b64\u5916\uff0c\u9808\u8981\u66f4\u591a\u7684\u81e8\u5e8a\u8a66\u9a57\u53bb\u8a55\u4f30\u9019\u65b0\u7684\u6cbb\u7642\u65b9\u6cd5\u4e4b\u6548\u76ca\u3002", "e": "Purpose: To report the use of intensity-modulated radiotherapy (IMRT) combined with chemotherapy in the treatment of a case of a malignant mesothelioma.\nMaterials and Methods: A case of a malignant mesothelioma of the right pleural cavity is reported here. This 65-year-old male patient had an initial complaint of persistent cough with blood-tinged sputum for 3 months, and associated symptoms were progressive shortness of breath and body weight loss. Because the patient's chest x-ray revealed right pleural effusion, the initial impression was lung cancer. A chest CT scan was performed and revealed a right infrahilar mass with atelectasis of the right lower lung, and a small nodular density in the right upper anterior lung segment. The final diagnosis of the CT scan was lung cancer of the right lower bronchus with atelectasis and right pleural effusion. A repeat chest PA after pleural fluid drainage revealed thickening of the right visceral and parietal pleurae. A thoracotomy with a pleural biopsy was performed 2 weeks after the CT scan. The pathology revealed an epithelial-type well-differentiated malignant mesothelioma; CK and EMA stains were positive, while CEA stain was negative. The TNM staging was T2N1M0. Radiotherapy was then arranged for this patient. A CT scan of the entire chest cavity in 5-mm slices was performed prior to radiotherapy for treatment simulation with a GE lightspeed scanner. Radiotherapy treatment planning was done with the Eclipse RTP system, version 6.5. Intensitymodulated radiotherapy (IMRT) was given to the entire right visceral and parietal pleurae for a total dose of 64.6Gy in 38 fractions over a 61-day period from Febuary 12 to April 22, 2003. The patient also received a course of chemotherapy with 100 mg cisplatin iv given 4 days before the start of radiotherapy.\nResults: The patient, who was followed-up in the outpatient clinic every month, had suffered no local recurrence by 6 months after radiotherapy, and a follow-up CT scan showed slight pleural effusion with progressive regression of the right pleural cavity. The patient suffered a brain metastasis in October 2003. Palliative radiotherapy for the entire brain was given from October 18 to November 20, 2003 for a total dose of 42.5Gy. The patient unexpectedly expired on November 30, 2003.\nConclusions: IMRT is an alternative treatment option for a malignant mesothelioma which is otherwise unsuitable for a radical extrapleural pneumonectomy (EPP). No severe radiation-induced pneumonitis was noted even with the high dose of IMRT. More clinical trials are needed to determine the benefit of this new treatment modality."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-1-9-a", "title": "The Role of Radiotherapy in the Treatment of Non-Melanomatous Cancers of the Skin", "keywords": "\u653e\u5c04\u6cbb\u7642;\u975e\u9ed1\u8272\u7d20\u76ae\u819a\u764c;\u9810\u5f8c\u56e0\u5b50 Radiotherapy;Nonmelanoma skin cancer;Prognostic factors", "c": "Purpose: To evaluate the treatment results and analyze the prognostic factors of radiotherapy for skin malignancies.\nMaterials and Methods: From January 1994 to April 2004, 48 patients with malignant skin cancer received a complete course of radiotherapy at Changhua Christian Hospital. There were 22 males and 26 females, between 38 and 94 years old (median: 78 years). The numbers of patients in stage I to IV were 16, 21, 11, and 0, respectively. The subtypes of histology were Squamous cell carcinoma (SCC) in 27 patients (56.3%), and Basal cell carcinoma (BCC) in 21 patients (43.8%). The median tumor size was 3 cm. Tumors location was predominantly at nose (29.2%), scalp (25%), facial (18.8%), extremities (8.3%), ear (6.3%), eyelids (4.2%) and others (8.3%). The median radiation dose and total treatment days were 60 Gy and 48 days.\nResults: The patients were followed up until October 2004. The median duration of follow-up was 26 months (range: 5.8 to 118.8 months). The 5-year overall survival and disease-free survival rate were 56.2% and 37.8%, respectively. Treatment failure included loco-regional relapse (8 patients), and distant metastasis (3 patients). In univariate analysis of variables with log rank test, AJCC stage, histology type and nodal metastasis were the significant prognostic factors (P\uff1c0.05) for overall survival.\nConclusion: Radiotherapy is effective in treatment of skin cancers. Our data indicated that the overall survival, disease-free survival, cosmetic appearance and patient tolerance were good and feasible.", "e": "Purpose: To evaluate the treatment results and analyze the prognostic factors of radiotherapy for skin malignancies.\nMaterials and Methods: From January 1994 to April 2004, 48 patients with malignant skin cancer received a complete course of radiotherapy at Changhua Christian Hospital. There were 22 males and 26 females, between 38 and 94 years old (median: 78 years). The numbers of patients in stage I to IV were 16, 21, 11, and 0, respectively. The subtypes of histology were Squamous cell carcinoma (SCC) in 27 patients (56.3%), and Basal cell carcinoma (BCC) in 21 patients (43.8%). The median tumor size was 3 cm. Tumors location was predominantly at nose (29.2%), scalp (25%), facial (18.8%), extremities (8.3%), ear (6.3%), eyelids (4.2%) and others (8.3%). The median radiation dose and total treatment days were 60 Gy and 48 days.\nResults: The patients were followed up until October 2004. The median duration of follow-up was 26 months (range: 5.8 to 118.8 months). The 5-year overall survival and disease-free survival rate were 56.2% and 37.8%, respectively. Treatment failure included loco-regional relapse (8 patients), and distant metastasis (3 patients). In univariate analysis of variables with log rank test, AJCC stage, histology type and nodal metastasis were the significant prognostic factors (P\uff1c0.05) for overall survival.\nConclusion: Radiotherapy is effective in treatment of skin cancers. Our data indicated that the overall survival, disease-free survival, cosmetic appearance and patient tolerance were good and feasible."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-11-19-a", "title": "The Treatment Result of Adjuvant Chemo-Radiotherapy for Post-Operative Colorectal Cancer", "keywords": "\u5927\u8178\u76f4\u8178\u764c;\u8f14\u52a9\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c Colorectal carcinoma;Adjuvant treatment;Prognosis", "c": "\u76ee\u7684\uff1a\u70ba\u7814\u7a76\u672c\u9662\u7d50\u8178\u76f4\u8178\u764c\u75c5\u4eba\u624b\u8853\u5f8c\u63a5\u53d7\u8f14\u52a9\u6027\u6cbb\u7642\u7d50\u679c\u8207\u5176\u5f71\u97ff\u9810\u5f8c\u56e0\u5b50\u5206\u6790\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1996\u5e74\u81f32003\u5e74\u5171\u56de\u6eaf\u6027\u6536\u96c680\u4f8b\u624b\u8853\u5f8c\u7d50\u8178\u76f4\u8178\u764c\u75c5\u4eba\uff0c\u63a5\u53d7\u5b8c\u6574\u8f14\u52a9\u6027\u6cbb\u7642\u8005\uff0c\u6392\u96646\u4f8b\u539f\u767c\u65bc\u9aa8\u76c6\u8154\u5916\u4e4b\u7d50\u8178\u764c\u53ca\u4e00\u4f8b\u975e\u817a\u764c\uff0c\u53e6\u4e00\u4f8b\u6cbb\u7642\u5f8c\u5373\u672a\u56de\u8a3a\uff1b\u7e3d\u517172\u4f8b\uff0c\u7537\u602750\u4f8b\uff0c\u5973\u602722\u4f8b\uff1b\u5e74\u9f61\u81ea29\u6b72\u81f379\u6b72\uff0c\u5e73\u574756.4\u6b72\uff08\u4e2d\u503c60\u6b72\uff09\uff0c\u5176\u8ffd\u8e64\u671f\u81ea2-106\u500b\u6708\uff08\u4e2d\u503c33\u500b\u6708\uff09\u3002\u75c5\u4eba\u4e4b\u8ffd\u8e64\u5b9a\u671f\u4f5c\u7406\u5b78\u6aa2\u67e5\u3001\u653e\u5c04\u7dda\u6aa2\u67e5\u3001\u8179\u90e8\u8d85\u97f3\u6ce2\u3001\u5927\u8178\u93e1\u6aa2\u67e5\u8207\u816b\u7624\u6a19\u5e5f\u3002\u75be\u75c5\u5206\u671f\u4f9dAJCC\uff08\u7b2c\u516d\u7248\uff09\u5206\u671f\uff0c\u4ee5\u56db\u767e\u842c\u6216\u516d\u767e\u842c\u4f0f\u7279\u9ad8\u80fd\u76f4\u7dda\u52a0\u901f\u5668\u6cbb\u7642\uff0c\u653e\u5c04\u5291\u91cf\u81ea45 Gy\u81f361.2 Gy\uff0c\u6bcf\u6b21\u7167\u5c04\u7d66\u4e88\u5291\u91cf\u70ba1.8-2.0 Gy\u3002\u6cbb\u7642\u65b9\u5f0f\u63a1\u524d\u5f8c\u76f8\u5c0d\u7167\u91ce\u6216\u7bb1\u5f62\u7167\u91ce\uff0c\u6709\u6216\u7121\u8ffd\u52a0\u85a6\u9aa8\u524d\u5340\u7167\u5c04\uff0c\u5316\u5b78\u6cbb\u7642\u4ee55FU\u70ba\u57fa\u672c\u7d44\u5408\u3002\n\u7d50\u679c\uff1a\u7e3d\u517172\u4f8b\u75c5\u4eba\uff0c\u5176\u4e09\u5e74\u53ca\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba68%\u820753%\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba33\u500b\u6708\uff1b\u5176\u4e09\u5e74\u5fa9\u767c\u7387\u70ba15%\u3001\u4e94\u5e74\u70ba17%\uff0c\u81e8\u5e8a\u4e0a\u816b\u7624\u6709\u4fb5\u8972\u8840\u7ba1\u3001\u6dcb\u5df4\u7ba1\u6ef2\u900f\u3001\u795e\u7d93\u65c1\u4fb5\u72af\u7b49\u5f71\u97ff\u75c5\u4eba\u4e4b\u751f\u5b58\u671f\uff0c\u5c24\u5176\u4fb5\u8972\u591a\u8655\u8005\u9810\u5f8c\u5dee(P=0.001)\uff0c\u6cbb\u7642\u524d\u4e4bCEA\u503c\u5927\u65bc20 ng/ml\u4e5f\u662f\u9810\u5f8c\u56e0\u5b50\u3002\u5e74\u9f61\u226450\u6b72\u8005\u8207\u5e74\u9577\u8005\u9810\u5f8c\u4e26\u7121\u5dee\u5225\u3002\n\u7d50\u8ad6\uff1a\u9aa8\u76c6\u8154\u7bc4\u570d\u5167\u4e4b\u7d50\u8178\u76f4\u8178\u764c\u624b\u8853\u5f8c\u52a0\u4e0a\u8f14\u52a9\u6027\u6cbb\u7642\u7d50\u679c\u826f\u597d\u3002\u5916\u79d1\u624b\u8853\u5207\u9664\u6a19\u672c\u5982\u6709\u816b\u7624\u4fb5\u8972\u8840\u7ba1\u3001\u6dcb\u5df4\u7ba1\u6ef2\u900f\u3001\u795e\u7d93\u65c1\u4fb5\u72af\u53ef\u4f5c\u70ba\u9700\u8981\u8f14\u52a9\u6027\u6cbb\u7642\u4e4b\u53c3\u8003\uff0c\u4e14\u5f71\u97ff\u75c5\u4eba\u751f\u5b58\u671f\uff0c\u5e74\u9f61\u4f3c\u975e\u4e0d\u826f\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose: To analyze the treatment result of colorectal cancer post-operative adjuvant chemotherapy and radiotherapy and to evaluate the prognostic factors.\nMaterials and Methods: This is a retrospective study of eighty patients who underwent surgery for colorectal cancer and received post- operative adjuvant chemo-radiotherapy between January 1996 and December 2003. Tumor work-up and follow-up were documented by physical examination, image studies (CT, MRI, sonography), colonoscopy and CEA. The applied TNM staging system was based on the AJCC manual of staging of cancer 6th edition, 2002. The adjuvant radiation was delivered with linear accelerator and the radiation dosage ranged from 45 Gy to 61.2 Gy. The adjuvant chemotherapy was given with 5-FU based regimen. The STATA(superscript TM) computer database and SPSS were used for statistic analysis.\nResult: Of these 72 patients, the mean age was 56.4 years (median 60), the 3- and 5- year overall survival rates were 68 % and 53%, respectively; local control rates were 85% and 83%, respectively; the disease free survival rates were 47% and 41%, respectively. There were 18 patients under age 50 and 54 patients older than age 50. The survival rate for the younger was worse than the older in our study, but without statistic significance (p=0.2618). The resection specimen with blood vessel or lymphovascular permeation, inadequate margin and adjacent organs invasion resulted in a poor prognosis. The pretreatment CEA level more than 20 ng/ml was a significant risk factor for survival after stage was adjusted but not significant for local control or disease control.\nConclusion: For colorectal cancer receiving surgery and post -operative chemotherapy and radiotherapy, the pathologic finding of lymphovascular permeation, blood vessel invasion and unclear margin are of prognostic significance. The pretreatment CEA level more than 20 ng/ml was also a risk factor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-21-31-a", "title": "\u53f0\u7063\u5730\u5340\u6c34\u5438\u6536\u5291\u91cf\u4e4b\u6a19\u6e96\u5efa\u7acb\u8207\u91cf\u6e2c\u6bd4\u5c0d", "keywords": "TG-51;\u5713\u9905\u578b\u77f3\u58a8\u6e38\u96e2\u8154;\u6c34\u5438\u6536\u5291\u91cf;TG-21 TG-51;Pancake graphite ionization chamber;Absorbed dose to water;TG-21", "c": "\u76ee\u7684\uff1a\u56e0\u61c9AAPM TG-51\u8b70\u5b9a\u66f8\u4e4b\u65bd\u884c\uff0c\u6838\u80fd\u7814\u7a76\u6240(INER)\u7814\u88fd\u5713\u9905\u578b\u77f3\u58a8\u6e38\u96e2\u8154\uff0c\u4f5c\u70ba60Co\u6c34\u5438\u6536\u5291\u91cf\u539f\u7d1a\u6821\u6b63\u6a19\u6e96\u3002\u6b64\u5916\uff0cINER\u4ea6\u8207\u570b\u516713\u5bb6\u91ab\u9662\u5408\u4f5c\uff0c\u5206\u5225\u4f9d\u64daAAPM TG-21\u53caTG-51\u8b70\u5b9a\u66f8\uff0c\u91cf\u6e2c6MV\u820710MV\u9ad8\u80fd\u5149\u5b50\u4e4b\u6c34\u5438\u6536\u5291\u91cf\uff0c\u4e26\u5206\u6790\u5728\u4e0d\u540c\u8b70\u5b9a\u66f8\u4e4b\u689d\u4ef6\u4e0b\uff0c\u91cf\u6e2c\u6c34\u5438\u6536\u5291\u91cf\u4e4b\u5dee\u7570\u503c\uff0c\u4ee5\u4f5c\u70ba\u91ab\u9662\u5728\u8f49\u63db\u4e0d\u540c\u8b70\u5b9a\u66f8\u6642\u4e4b\u54c1\u4fdd\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1aINER\u5b8c\u6210\u5713\u9905\u578b\u77f3\u58a8\u6e38\u96e2\u8154\u5404\u9805\u7269\u7406\u53c3\u6578\u8207\u4fee\u6b63\u56e0\u5b50\u4e4b\u8a55\u4f30\u3001\u91cf\u6e2c\uff0c\u518d\u4ee5\u4e09\u652fNE 2571\u6e38\u96e2\u8154\u4f5c\u70ba\u50b3\u905e\u4ef6\uff0c\u8207\u6fb3\u6d32ABPANSA\u570b\u5bb6\u5be6\u9a57\u5ba4\u9032\u884c60Co\u6c34\u5438\u6536\u5291\u91cf\u6a19\u6e96\u4e4b\u96d9\u908a\u6bd4\u5c0d\u3002\u540c\u6642\uff0c\u672c\u5be6\u9a57\u4e5f\u4ee560Co\u7167\u5c04\u5668\u9032\u884c\u91ab\u7528\u6e38\u96e2\u8154\u4e4b\u7a7a\u6c23\u514b\u99ac\u8207\u6c34\u5438\u6536\u5291\u91cf\u6821\u6b63\uff0c\u800c\u91ab\u7528\u52a0\u901f\u5668\u6c34\u5438\u6536\u5291\u91cf\u4e4b\u91cf\u6e2c\u6bd4\u5c0d\u689d\u4ef6\u4fc2\u53c3\u8003TG-51\u8b70\u5b9a\u66f8\uff0c\u9078\u64c7100 cm\u4e4bSSD\u6216SAD\u300110 cm\u00d710 cm\u7167\u91ce\u53ca10 cm\u6821\u6b63\u6df1\u5ea6\u3002\n\u7d50\u679c\uff1aINER\u8207ARPANSA 60Co\u6c34\u5438\u6536\u5291\u91cf\u6a19\u6e96\u4e4b\u6bd4\u5c0d\u5dee\u7570\u57280.3%\u4ee5\u5167\uff0c\u5c0f\u65bc\u7d44\u5408\u6a19\u6e96\u4e0d\u78ba\u5b9a\u5ea6(k=1)\uff0c\u986f\u793a\u96d9\u65b9\u91cf\u6e2c\u7d50\u679c\u5177\u6709\u826f\u597d\u7684\u4e00\u81f4\u6027\u3002\u91dd\u5c0d\u570b\u516713\u5bb6\u6bd4\u5c0d\u55ae\u4f4d\u6240\u4f7f\u7528\u76845\u7a2e\u898f\u683c\u6e38\u96e2\u8154\u800c\u8a00\uff0c60Co\u6c34\u5438\u6536\u5291\u91cf\u8207\u7a7a\u6c23\u514b\u99ac\u6821\u6b63\u4fc2\u6578\u4e4b\u6bd4\u503c\u7bc4\u570d\u70ba1.094\u81f31.105\uff0c\u6240\u6709\u6e38\u96e2\u8154\u4e4b\u6821\u6b63\u4fc2\u6578\u6bd4\u503c\u8207\u5e73\u5747\u9053\u7684\u5dee\u7570\u4e5f\u7dad\u6301\u57280.6%\u4ee5\u5167\u3002\u540c\u6642\uff0c\u5c0d\u65bc\u53c3\u52a0\u6bd4\u5c0d\u4e4b\u91ab\u9662\uff0c\u57286 MV\u820710 MV\u5169\u7a2e\u9ad8\u80fd\u5149\u5b50\u80fd\u91cf\u4e0b\uff0c\u5229\u7528TG-51\u53caTG-21\u8b70\u5b9a\u66f8\u6240\u91cf\u6e2c\u4e4b\u52a0\u901f\u5668\u6c34\u5438\u6536\u5291\u91cf\u5dee\u7570\u5747\u5c0f\u65bc15%\u3002\n\u7d50\u8ad6\uff1a\u91ab\u7528\u52a0\u901f\u5668\u8207\u6e38\u96e2\u8154\u4e4b\u5ee0\u724c\u3001\u69cb\u9020\uff0c\u4e26\u4e0d\u6703\u5f71\u97ff\u4f7f\u7528TG-51\u8207TG-21\u6e2c\u91cf\u6c34\u5438\u6536\u5291\u91cf\u6240\u9020\u6210\u7684\u5dee\u7570\u3002\u7576\u91ab\u9662\u91cf\u6e2c\u7684TG-51/TG-21\u5291\u91cf\u5dee\u7570\u8d85\u904e15%\u6642\uff0c\u5c31\u5fc5\u9808\u91cd\u65b0\u9a57\u8b49\u5728\u5169\u7a2e\u5291\u91cf\u8b70\u5b9a\u66f8\u6240\u4f7f\u7528\u7684\u5404\u9805\u8a08\u7b97\u53c3\u6578\u8207\u91cf\u6e2c\u6578\u64da\u4e4b\u6b63\u78ba\u6027\u3002", "e": "Purpose: In response to the AAPM TG-51 protocol, the Institute of Nuclear Energy Research (INER) fabricated a pancake graphite ionization chamber as the primary standard for the absorbed dose to water in 60Co. Meanwhile, INER cooperated with 13 domestic hospitals in measurements of the absorbed dose to water of 6 MV and 10 MV high-energy photon beams respectively based on the AAPM TG-21 and TG-51 protocols to analyze the dosimetry differences under the two protocols. A quality assurance guide for institutions switching from the TG-21 to TG-51 protocol was suggested based on the comparison results of these two dosimetry protocols.\nMaterial and Methods: INER completed the assessment and measurement of the physical parameters and correction factors of the pancake graphite ionization chamber and then made a bilateral comparison with ARPANSA/Australia for the standards of absorbed dose to water in 60Co by using three NE 2571 ionization chambers as transfer items. Also, INER used a 60Co irradiator in performing chamber calibrations in terms of the air kerma and absorbed dose to water. As to the measurement conditions of the absorbed dose to water for the 6 MV and 10 MV high-energy photon beams, they were based on the AAPM TG-51 protocol at 100 cm SSD (or SAD), 10 cm\u00d710 cm irradiation field and 10 cm calibratoin depth.\nResults: The difference of the INER-ARPANSA bilateral comparison of the standards of the absorbed dose to water in 60Co was within 0.3%, which was less than the combined standard uncertainty (k=1). It showed that both laboratories had good agreement in measurement results. For the 5 types of cavity ionization chambers used by the 13 dosmetic hospitals, the ratios of the absorbed dose to water calibration coefficient against the air kerma calibration coefficient in 60Co were between 1.094 and 1.105, showing similar results within tight limits (envelop of \u00b10.6%), At the same time, for all the 13 participants, the measurement differences of the absorbed dose to water for 6 MV and 10 MV high-energy photon beams based on the TG-21 and TG-51 dosimetry protocols were less than 1.5%.\nConclusions: The manufacturers and structures of medical accelerators and ionization chambers will not cause differences in dose measurement either it was TG-51 or TG-21 protocol that had been used. If an institution determines TG-5 or TG-21 ratios measurably different (\uff1e1.5%) than the values presented in this paper, it should recheck the correctness of calculation parameters and measurement data used in both protocols."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-33-45-a", "title": "Preprocessing Treatment Targeting for Intensity Modulated Radiotherapy Based on Wavelet Segmentation", "keywords": "\u524d\u8655\u7406;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5c0f\u6ce2;\u5207\u5272 Preprocessing;Intensity modulated radiotherapy;Wavelet;Segmentation", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u8981\u7814\u767c\u51fa\u4e00\u500b\u7cbe\u6e96\u7684\u4e09\u7dad\u5f71\u50cf\u5207\u5272\u7e6a\u5716\u65b9\u6cd5\uff0c\u4f86\u6e05\u695a\u5730\u5f37\u5316\u5f71\u50cf\u7684\u6a21\u7cca\u908a\u754c\uff0c\u4e26\u5f15\u7528\u5207\u5272\u7684\u6210\u679c\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u5148\u671f\u816b\u7624\u5b9a\u4f4d\u8655\u7406\uff0c\u5982\u6b64\u53ef\u4ee5\u5b8c\u6210\u91ab\u5e2b\u7d93\u5e38\u6240\u63d0\u7684\u78ba\u4fdd\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u816b\u7624\u5291\u91cf\u63d0\u5347\u7684\u7279\u6027\u4e4b\u8981\u6c42\u76ee\u6a19\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u7531\u65bc\u5c0f\u6ce2\u6280\u8853\u5177\u6709\u591a\u91cd\u5c3a\u5ea6\u8207\u591a\u91cd\u89e3\u6790\u7684\u7279\u6027\uff0c\u4f7f\u5c0f\u6ce2\u65b9\u6cd5\u6beb\u7121\u7591\u554f\u5730\u6210\u70ba\u773e\u6240\u7686\u77e5\u6700\u597d\u7684\u68af\u5ea6\u5207\u5272\u65b9\u6cd5\u4e4b\u4e00\uff0c\u7d93\u7531\u5ef6\u4f38\u6a19\u6e96\u96e2\u6563\u5c0f\u6ce2\u8f49\u63db\u5230\u4e8c\u7dad\u7a7a\u9593\uff0c\u800c\u85c9\u6b64\u6a19\u6e96\u96e2\u6563\u5c0f\u6ce2\u8f49\u63db\u6f14\u7b97\u6cd5\u63a8\u5c55\u51fa\u4e00\u500b\u65b0\u7684\u908a\u754c\u6aa2\u6e2c\u65b9\u6cd5\uff0c\u56e0\u70ba\u5f71\u50cf\u8655\u7406\u7684\u5be6\u969b\u9700\u8981\uff0c\u6211\u5011\u4f7f\u7528\u4e8c\u7dad\u96e2\u6563\u9031\u671f\u5c0f\u6ce2\u8f49\u63db\u4f86\u4ee3\u66ff\u50b3\u7d71\u7684\u4e8c\u7dad\u5c0f\u6ce2\u51fd\u6578\u4f86\u7522\u751f\u4e8c\u7dad\u7684\u908a\u754c\u6aa2\u6e2c\u6ffe\u6ce2\u5668\uff0c\u6700\u5f8c\u5957\u7528\u675c\u6bd4\u5176\u5c0f\u6ce2\u8f49\u63db\u5c0e\u51fa\u5c0f\u6ce2\u906e\u7f69\uff0c\u4f86\u5b8c\u6210\u4e8c\u7dad\u5f71\u50cf\u8655\u7406\u7684\u8ff4\u65cb\u6372\u7a4d\u904b\u7b97\uff0c\u5982\u6b64\u4e00\u4f86\u4f7f\u6211\u5011\u5f97\u4ee5\u4f9d\u4e0d\u540c\u5c3a\u5ea6\u7684\u908a\u7da0\u6aa2\u6e2c\u6ffe\u6ce2\u5668\u4f86\u505a\u5f71\u50cf\u5207\u5272\u3002\u7dda\u6027\u63d2\u88dc\u6cd5\u5247\u8207\u908a\u754c\u9023\u63a5\u8207\u908a\u7de3\u7d30\u7dda\u5316\u6cd5\u5247\u4ea6\u88ab\u4f7f\u7528\u4f86\u5b8c\u6210\u4e09\u7dad\u7684\u63cf\u7e6a\u7d44\u50cf\u3002\u6587\u4e2d\u4f7f\u7528\u4e00\u5f35\u8a2d\u8a08\u6d41\u7a0b\u5716\u4f86\u8aaa\u660e\u6211\u5011\u6240\u63d0\u51fa\u7684\u4e09\u7dad\u6cbb\u7642\u76ee\u6a19\u5b9a\u4f4d\u7684\u5f71\u50cf\u91cd\u7d44\u63cf\u7e6a\u65b9\u6cd5\u4e4b\u6d41\u7a0b\uff0c\u4e26\u4e14\u4f7f\u7528\u4e0d\u540c\u7684\u91ab\u5b78\u5f71\u50cf\u4f86\u9a57\u8b49\u6211\u5011\u6240\u63d0\u65b9\u6cd5\u7684\u59a5\u7576\u6027\u4e26\u5c07\u7d50\u679c\u8207\u50b3\u7d71\u7684\u5340\u57df\u6210\u9577\u5207\u5272\u6cd5\u4f5c\u6bd4\u8f03\uff0c\u4ee5\u5448\u73fe\u6211\u5011\u6240\u63d0\u7684\u65b9\u6cd5\u4e0d\u50c5\u80fd\u9054\u5230\u7406\u60f3\u7684\u6e96\u78ba\u5ea6\u4e26\u767c\u73fe\u6709\u4e00\u4e9b\u5c0d\u672a\u4f86\u91ab\u5b78\u6709\u8da3\u4e14\u5be6\u7528\u7684\u904b\u7528\u3002\n\u7d50\u679c\uff1a\u5728\u9a57\u8b49\u6211\u5011\u65b9\u6cd5\u7684\u5f71\u50cf\u8cc7\u6599\u7576\u4e2d\u6709\u5169\u7d44\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u651d\u5f71\u50cf\u8207\u4e00\u7d44\u6838\u78c1\u5171\u632f\u5f71\u50cf\uff0c\u5176\u4e2d\u7b2c\u4e00\u7d44\u662f\u4eba\u9ad4\u80f8\u8154\u5f71\u50cf\u8cc7\u6599\uff0c\u6211\u5011\u4f7f\u7528\u5b83\u4f86\u5206\u96e2\u53f3\u80ba\uff0c\u7576\u4f5c\u7279\u5fb5\u7684\u8403\u53d6\uff0c\u5728\u5716\u4e09\u3001\u56db\u3001\u4e94\u4e2d\u5448\u73fe\u51fa\u5c0f\u6ce2\u5207\u5272\u7d50\u679c\uff0c\u540c\u6642\u5c07\u5340\u57df\u6210\u9577\u5207\u5272\u7d50\u679c\u63cf\u7e6a\u51fa\u4f86\u4f5c\u70ba\u6bd4\u8f03\uff0c\u800c\u7b2c\u4e8c\u7d44\u5be6\u9a57\u662f\u4e00\u500b\u8166\u4e2d\u60a3\u6709\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u7684\u5973\u6027\u75c5\u60a3\u7684\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u651d\u5f71\u8cc7\u6599\uff0c\u7d50\u679c\u5448\u73fe\u816b\u7624\u7684\u5927\u5c0f\u5f62\u72c0\uff0c\u5728\u8166\u4e2d\u7684\u65b9\u4f4d\u8207\u5b83\u8ddf\u982d\u90e8\u7684\u76f8\u95dc\u4f4d\u7f6e\uff0c\u6211\u5011\u90fd\u53ef\u6e05\u695a\u67e5\u770b\uff0c\u5716\u516d\u3001\u4e03\u4e2d\u6e05\u695a\u5730\u5448\u73fe\u6211\u5011\u5207\u5272\u7684\u6210\u679c\uff0c\u5177\u6709\u63d0\u4f9b\u816b\u7624\u660e\u78ba\u5c3a\u5bf8\u8207\u4f4d\u7f6e\u7684\u80fd\u529b\uff0c\u800c\u7b2c\u4e09\u7d44\u5be6\u9a57\u662f\u6838\u78c1\u5171\u632f\u5f71\u50cf\uff0c\u6211\u5011\u5448\u73fe\u5982\u4f55\u4f7f\u7528\u8457\u8272\u6280\u5de7\u4f86\u5f37\u8abf\u91cd\u8981\u90e8\u4f4d\uff0c\u5728\u5716\u5341(d)\u4e2d\u7684\u4e09\u7dad\u91cd\u7d44\u5f71\u50cf\u986f\u793a\u4f7f\u7528\u4e0d\u540c\u984f\u8272\u4f86\u5f37\u8abf\u8166\u90e8\u8207\u982d\u81da\u4e4b\u9593\u7684\u76f8\u95dc\u4f4d\u7f6e\u3002\u5728\u6240\u6709\u5be6\u9a57\u7576\u4e2d\u4e0d\u50c5\u9054\u5230\u6211\u5011\u60f3\u8981\u7684\u6e96\u78ba\u5ea6\u4e26\u4e14\u7372\u5f97\u52a0\u5165\u900f\u660e\u6548\u679c\u53ef\u4ee5\u65cb\u8f49\u4e0d\u540c\u89d2\u5ea6\u8207\u4f7f\u7528\u4e0d\u540c\u984f\u8272\u4f86\u5f37\u8abf\u91cd\u8981\u90e8\u4f4d\u7684\u4e09\u7dad\u5207\u5272\u5f71\u50cf\uff0c\u7d50\u679c\u53ef\u8b93\u91ab\u5e2b\u66f4\u7cbe\u6e96\u4e14\u6709\u6548\u7387\u7684\u5f9e\u4e8b\u624b\u8853\u6216\u6cbb\u7642\u3002\u539f\u672c\u6709\u4e9b\u9700\u9760\u91ab\u5e2b\u81ea\u884c\u60f3\u50cf\u7d44\u5408\u7684\u4e09\u7dad\u5f71\u50cf\u7d93\u7531\u6b64\u4e00\u65b9\u6cd5\u5207\u5272\u7d44\u50cf\u5f8c\u4fbf\u53ef\u6e05\u695a\u8b58\u5225\uff0c\u5716\u50cf\u7279\u5fb5\u6e05\u695a\u5206\u8fa8\uff0c\u4f4d\u7f6e\u7cbe\u78ba\u5b9a\u7fa9\uff0c\u76f8\u95dc\u4f4d\u7f6e\u95dc\u4fc2\u53ef\u4ee5\u6e05\u695a\u660e\u767d\u3002\u9019\u4e9b\u6280\u8853\u5728\u653e\u5c04\u6cbb\u7642\u4e0a\u90fd\u662f\u76f8\u7576\u91cd\u8981\u7684\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u6240\u63d0\u51fa\u7684\u4e09\u7dad\u6cbb\u7642\u76ee\u6a19\u5b9a\u4f4d\u5207\u5272\u6f14\u7b97\u6cd5\u53ef\u7cbe\u6e96\u6709\u6548\u5730\u5354\u52a9\u91ab\u5e2b\u4f5c\u50b3\u7d71\u6cbb\u7642\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7684\u5c0e\u5f15\uff0c\u6211\u5011\u767c\u73fe\u4e09\u7dad\u5c0f\u6ce2\u5207\u5272\u63cf\u7e6a\u6cd5\u4e0d\u50c5\u9054\u5230\u6211\u5011\u60f3\u8981\u7684\u6e96\u78ba\u6027\u4e26\u4e14\u6703\u5728\u81e8\u5e8a\u91ab\u5b78\u5f71\u50cf\u8655\u7406\u4e2d\u5177\u6709\u76f8\u7576\u5730\u7528\u9014\uff0c\u56e0\u6b64\u6211\u5011\u76f8\u4fe1\u6240\u63d0\u7684\u6f14\u7b97\u6cd5\u5c07\u6703\u5728\u672a\u4f86\u7684\u5f71\u50cf\u5c0e\u5f15\u653e\u5c04\u6cbb\u7642(IGRT)\u8207\u5176\u4ed6\u7684\u91ab\u7642\u61c9\u7528\u4e0a\u626e\u6f14\u76f8\u7576\u91cd\u8981\u7684\u89d2\u8272\u3002", "e": "Purpose: This study aimed to develop an advance precision three-dimensional (3-D) image segmentation algorithm to enhance the blurred edges clearly and then introduce the result onto the intensity modulated radiotherapy (IMRT) for tumor targeting. This will achieve what physicians usually demand that tumor doses escalation characteristics of IMRT.\nMaterials and Methods: No doubt the Wavelet method is well known to be one of the best gradient segmentation methods due to its multi-scale and multi-resolution capabilities. We extend the standard Discrete Wavelet Transform (DWT) into two dimensions. By applying this 2-D DWT algorithm one may develop a new edge detection method. But for practical purposes, we replace the traditional 2-D wavelet functions with a 2-D discrete periodic wavelet transform (2-D DPWT). Finally, by using Daubechies wavelet transform function to form the wavelet masks for convolution operation in image processing, it allows us to detect edges at different scales for segmentation. Linear interpolation and edges linking and thinning algorithm were then used to form 3-D renderings. A proposed algorithm flowchart designed for this precision 3-D treatment targeting was introduced in this paper. Different medical images were used to test the validity of our method. We then compared the results with a traditional region growing segmentation approach to show that our 3-D renderings not only achieved the precision we sought but also has many interesting applications that shall be most useful to the medical practice.\nResults: Two CT scan data and one MRI data of different medical images were used to verify the validity of our proposed method. One CT scan dataset from a human chest was test first to extract the right lung for feature extraction. Its wavelet segmentation result was shown in the Figs. 3, 4, 5 and the region growing method was also shown for comparison. The second dataset was a CT scan of a female patient with a pituitary tumor in her brain. The size and shape of the tumor, its orientation with the brain, and the position relative to the head are all now clearly seen. Figures 6, 7 clearly demonstrated the results of our segmentation capable of providing an outstanding positioning of the tumor. In the third experiment of an MRI data, we demonstrate how colors were used in our 3-D renderings to enhance the important parts. 3-D reconstruction of the brain in a partial skull is shown in Fig. 10 (d) with different colors to emphasize their relative positions. On all examples of medical images we created, not only desired precision had been achieved, we are also able to create rotation of the objects with transparent effects to obtain its 3-D images of different angles. They will allow physicians to conduct surgery or treatment much more accurately and effectively. Many 3-D images physicians usually only compose by imaginations, now all visible under our 3-D processing. Features are now clearly identified, locations pinned down exactly, and relative orientations are now well understood. These are all vital for radiation therapies.\nConclusion: The 3-D targeting segmentation we proposed allows physicians to improve the traditional treatments or IMRT much more accurately and effectively. Our precision 3- D wavelet segmentation rendering shall be very useful in practice for medical images. They will play an important role in image-guided radiotherapy (IGRT) and many other medical applications in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-47-56-a", "title": "\u74e6\u91cc\u5b89\u78b3\u7e96\u7dad\u6cbb\u7642\u5e8a\u4e4b\u8870\u6e1b\u53ca\u5c04\u675f\u8207\u6cbb\u7642\u5e8a\u7684\u5e7e\u4f55\u95dc\u4fc2", "keywords": "\u78b3\u7e96\u7dad\u6cbb\u7642\u5e8a;\u8870\u6e1b;\u652f\u6490\u67b6 Exact couch;Attenuation;Removable accessory rail", "c": "\u524d\u8a00\uff1a\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u4e3b\u8981\u662f\u4ee5\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5f71\u50cf\u4f5c\u70ba\u5291\u91cf\u8a08\u7b97\u53ca\u89d2\u5ea6\u8a2d\u8a08\u7684\u57fa\u790e\uff0c\u4f46\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e26\u672a\u5305\u542b\u6cbb\u7642\u5e8a\uff0c\u7576\u6cbb\u7642\u7167\u91ce\u7d93\u7531\u6cbb\u7642\u5e8a\u4e0b\u65b9\u89d2\u5ea6\u5165\u5c04\u75c5\u60a3\u9ad4\u5167\u6642\uff0c\u75c5\u606f\u5be6\u969b\u63a5\u53d7\u7684\u5291\u91cf\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u6703\u6709\u6240\u5dee\u7570\u3002\u56e0\u6b64\uff0c\u6cbb\u7642\u5e8a\u5c0d\u8f3b\u5c04\u6240\u9020\u6210\u7684\u8870\u6e1b\u662f\u5fc5\u9808\u8a55\u4f30\u7684\u3002\n\u65b9\u6cd5\u8207\u6750\u6599\uff1a\u672c\u7814\u7a76\u662f\u91dd\u5c0dVarian 21EX\u76f4\u7dda\u52a0\u901f\u5668\u6240\u914d\u5099\u4e4b\u78b3\u7e96\u7dad\u6cbb\u7642\u5e8a(Exact Couch)\u9032\u884c\u8870\u6e1b\u6e2c\u91cf\u3002\u5c07\u6e38\u96e2\u8154\u5957\u4e0a\u76f4\u5f916\u516c\u5206\u7684\u589e\u5efa\u5e3d\uff0c\u7f6e\u65bc\u6cbb\u7642\u5e8a\u4e2d\u5fc3\uff0c\u5c04\u6e90\uff0d\u4e2d\u5fc3\u8ef8\u8ddd\u96e2(source-axis distance, SAD)\u70ba100\u516c\u5206\uff0c\u5206\u5225\u4f7f\u75286 MV\u53ca10 MV\u80fd\u91cf\u4e4b\u5149\u5b50\u4ee55\u00d75\u5e73\u65b9\u516c\u5206\uff0c10\u00d710\u5e73\u65b9\u516c\u5206\uff0c15\u00d715\u5e73\u65b9\u516c\u5206\u7167\u91ce\u7167\u5c04\u3002\u5c04\u675f\u89d2\u5ea6\u5247\u662f\u5c07\u65cb\u8f49\u81c2(gantry)\u5f9e0\u00b0\u81f3360\u00b0\u6bcf\u96945\u00b0\u4f5c\u70ba\u5165\u5c04\u89d2\u5ea6\uff0c\u91dd\u5c0d\u6bcf\u500b\u89d2\u5ea6\u6e2c\u91cf3\u6b21\uff0c\u6bcf\u6b21\u7167\u5c04\u5291\u91cf\u70ba50 MU\u3002\u7167\u5c04\u4e00\u5708\u5f8c\u4ee5\u65cb\u8f49\u81c20\u00b0\u70ba\u6e2c\u91cf\u57fa\u6e96\u503c\uff0c\u6c42\u51fa\u5404\u500b\u6e2c\u91cf\u89d2\u5ea6\u7684\u8b80\u503c\u8207\u65cb\u8f49\u81c20\u00b0\u8b80\u503c\u7684\u8870\u6e1b\u767e\u5206\u6bd4\u3002\n\u7d50\u679c\uff1a\u7d93\u5be6\u969b\u6e2c\u91cf\u5f8c\uff0c\u5c04\u675f\u4e2d\u5fc3\u8ef8\u672a\u901a\u904e\u6cbb\u7642\u5e8a\u53ca\u5176\u652f\u6490\u67b6\u8005\uff0c\u8207\u65cb\u8f49\u81c20\u00b0\u8b80\u503c\u76f8\u6bd4\u4e4b\u5dee\u7570\u57280.5%\u5de6\u53f3\uff1b\u901a\u904e\u6cbb\u7642\u5e8a\u4f46\u4e0d\u7d93\u904e\u652f\u6490\u67b6\u8005\uff0c\u8207\u65cb\u8f49\u81c20\u00b0\u8b80\u503c\u76f8\u6bd4\u4e4b\u5dee\u7570\u57281%\u4e4b\u5167\uff1b\u800c\u901a\u904e\u6cbb\u7642\u5e8a\u53ca\u5176\u652f\u6490\u67b6\u8005\uff0c\u8207\u65cb\u8f49\u81c20\u00b0\u8b80\u503c\u76f8\u6bd4\u4e4b\u5dee\u7570\u6709\u516d\u8655\u8870\u6e1b\u8d85\u904e10%\uff0c\u5206\u5225\u572897.5\u00b0\u3001102.5\u00b0\u3001120\u00b0\u3001240\u00b0\u3001257.5\u00b0\u3001262.5\u00b0(IEC scale)\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u5f9e\u6e2c\u91cf\u6578\u64da\u4e2d\u767c\u73fe\uff0c\u5171\u6709\u516d\u8655\u7522\u751f\u8f03\u5927\u7684\u8870\u6e1b\uff0c\u5206\u5225\u70ba\u5169\u908a\u7684\u652f\u6490\u67b6\u7684\u4e0a\u4e0b\u7de3\u53ca\u6cbb\u7642\u5e8a\u908a\u7de3\u6240\u9020\u6210\u3002\u5c04\u675f\u7d93\u904e\u6cbb\u7642\u5e8a\u53ca\u652f\u6490\u67b6\u800c\u53d7\u5230\u8870\u6e1b\u7684\u56e0\u7d20\u4e3b\u8981\u8207\u6cbb\u7642\u5e8a\u8868\u9762\u81f3\u6cbb\u7642\u4e2d\u5fc3\u7684\u8ddd\u96e2\u3001\u6cbb\u7642\u7167\u91ce\u5927\u5c0f\u53ca\u6cbb\u7642\u4e2d\u5fc3\u8207\u6cbb\u7642\u5e8a\u4e4b\u4e2d\u5fc3\u8ddd\u96e2\u6709\u95dc\u3002\u900f\u904e\u4e0a\u8ff0\u4e09\u500b\u56e0\u7d20\u7684\u6578\u503c\uff0c\u914d\u5408\u4e0a\u4e09\u89d2\u51fd\u6578\u8207\u5e7e\u4f55\u95dc\u4fc2\uff0c\u7522\u751f\u53ef\u63a8\u5c0e\u51fa\u6cbb\u7642\u89d2\u5ea6\u8207\u6cbb\u7642\u5e8a\u76f8\u4e92\u95dc\u4fc2\u7684\u65b9\u7a0b\u5f0f\uff0c\u85c9\u7531\u65b9\u7a0b\u5f0f\u4fbf\u53ef\u627e\u51fa\u5c04\u675f\u7167\u91ce\u4e0d\u6703\u901a\u904e\u652f\u6490\u67b6\u7684\u6cbb\u7642\u89d2\u5ea6\u3002", "e": "Purpose: The does calculation of all commercialized treatment planning computer system are based on Computerized Tomography image, but treatment room couch information is not included in CT images, therefore, the delivered does is literally different to the does distribution designed by treatment planning computer system. Especially when radiation beam incident posterially under the treatment couch, the phenomenal of radiation attenuation caused by treatment couch should be studied.\nMaterial and Method: This study was to measure the attenuation caused by carbon fiber Exact couch in Varian 21EX Linear accelerator treatment machine, ion chamber was used to take the radiation does converted to reading with 6 cm build up cap at SAD 100 cm isocentrally setup. Field size was set to be 5 by 5 cm^2, 10 by 10 cm^2,15 by 15 cm^2 with different gantry angle from 0\u00b0 to 360\u00b0 in every 5\u00b0 for 6 MV and 10 MV photon beam.\nResults: According to the experimental measurement results, the electrometer chamber reading of those gantry angle which central axis did not penetrate the couch and the supporter compared to 0\u00b0 gantry angle was within 0.5%, while the attenuation result was within 1% when the radiation penetrate through couch and exclude supporter, and there are six position whose attenuation results are exceed 10% there are at gantry angle 97.5\u00b0, 102.5\u00b0, 122.5\u00b0, 237.5\u00b0, 257.5\u00b0, 262.5\u00b0 IEC scale.\nConclusion: The geometry of radiation beam and supporter were related to distance from treatment isocenter to couch surface in the vertical direction, field size, and shift of the couch to isocenter in the horizontal direction. We can get a gantry angle from the relation avoid the radiation to hit the supporter. Therefore, a set of equation was developed to check if the radiation beam penetrates the couch supporter or not."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-57-65-a", "title": "\u653e\u5c04\u7dda\u5f37\u5ea6\u8abf\u63a7\u6cbb\u7642\u4e0a\u547c\u5438\u904b\u52d5\u4fee\u6b63\u7684\u53ef\u884c\u6027\u7814\u7a76", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u547c\u5438\u904b\u52d5;\u591a\u8449\u6e96\u76f4\u5100 IMRT;Respiration;MLC leaf sequence", "c": "\u76ee\u7684\uff1a\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(intensity modulated radiotherapy; IMRT)\u5229\u7528\u975e\u5747\u52fb\u5f37\u5ea6\u5c04\u675f\uff0c\u53ef\u4ee5\u4e2d\u6e96\u78ba\u7684\u628a\u6240\u9700\u7684\u653e\u5c04\u7dda\u5291\u91cf\u7d66\u5230\u816b\u7624\u9ad4\u7a4d\u4e0a\u3002\u7136\u800c\u6cbb\u7642\u4e2d\u7531\u65bc\u5668\u5b98\u7684\u904b\u52d5\uff0c\u539f\u672c\u9810\u671f\u4e4b\u5291\u91cf\u5206\u5e03\u6703\u6709\u626d\u66f2\u800c\u5931\u771f\u3002\u672c\u7814\u7a76\u4fc2\u91dd\u5c0d\u547c\u5438\u904b\u52d5\uff0c\u767c\u5c55\u547c\u5438\u540c\u6b65\u4e4b\u653e\u5c04\u6cbb\u7642\u6cd5\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u4ee5\u8996\u89ba\u4e0a\u7684\u9031\u671f\u5716\u6848\u4f86\u8a98\u5c0e\u75c5\u4eba\u547c\u5438\uff0c\u4f7f\u5176\u547c\u5438\u9031\u671f\u56fa\u5b9a\u3002\u85c9\u6b64\u543e\u4eba\u53ef\u9810\u6e2c\u6cbb\u7642\u671f\u9593\u75c5\u4eba\u547c\u5438\u7684\u76f8\u4f4d\uff0c\u800c\u5668\u5b98\u7684\u4f4d\u7f6e\u53ef\u7d93\u7531\u900f\u8996\u9810\u5148\u5f97\u77e5\u3002\u4e26\u4e14\u4fee\u6539\u591a\u8449\u6e96\u76f4\u5100(multileaf collimator; MLC)\u7684\u63a7\u5236\u6a94\u6848\uff0c\u4f86\u4fee\u6b63\u5404\u500b\u8449\u7247(leaflet)\u79fb\u52d5\u7684\u901f\u7387\u4ee5\u6539\u8b8a\u5c04\u675f\u65b9\u5411\uff0c\u4f7f\u5c04\u675f\u96a8\u8457\u547c\u5438\u540c\u6b65\u904b\u52d5\uff0c\u5982\u6b64\u4fbf\u53ef\u5c07\u7167\u91ce\u56fa\u5b9a\u5728\u816b\u7624\u4e4b\u4e0a\uff0c\u6e1b\u5c11\u547c\u5438\u904b\u52d5\u6240\u9020\u6210\u5291\u91cf\u5206\u5e03\u7684\u626d\u66f2\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u6211\u5011\u4ee5\u5047\u9ad4\u6a21\u64ec\u547c\u5438\u904b\u52d5\uff0c\u4ee5EDR2\u9a57\u8b49\u7247\u505a\u5291\u91cf\u5206\u5e03\u7684\u6e2c\u91cf\u3002\u7d50\u679c\u986f\u793a\u6539\u8b8aMLC\u7684\u904b\u52d5\u6a21\u5f0f\u53ef\u4ee5\u7528\u4f86\u6e1b\u5c11\u547c\u5438\u904b\u52d5\u6240\u9020\u6210\u7684\u5931\u771f\u3002\u5229\u7528\u9031\u671f\u5716\u6848\u4f86\u8a98\u5c0e\u75c5\u4eba\u547c\u5438\uff0c\u4e5f\u53ef\u9054\u5230\u904b\u52d5\u898f\u5f8b\u5316\u7684\u6548\u679c\u3002\u672c\u65b9\u6cd5\u53ef\u4ee5\u904b\u7528\u5728\u81e8\u5e8a\u4e0a\uff0c\u5b83\u6bd4\u5176\u4ed6\u547c\u5438\u904b\u52d5\u4fee\u6b63\u65b9\u6cd5\u7684\u597d\u8655\u662f\u6cbb\u7642\u6642\u9593\u4e0d\u6703\u5ef6\u9577\u3002\u4e0d\u904e\u5b83\u9700\u8981\u75c5\u4eba\u7684\u5408\u4f5c\uff0c\u4f7f\u5f97\u547c\u5438\u904b\u52d5\u80fd\u5920\u898f\u5f8b\u7684\u9032\u884c\u3002", "e": "Purpose: Intensity modulated radiation therapy (IMRT) utilizes nonuniform beam profile to provide desired radiation dosage to the tumor volume more accurately. However, the problem of intra-fraction organ motion can cause distortion to the desired beam intensities. This study aims to develop a respiration adaptive technique to toggle the problem of respiratory motion in radiation therapy.\nMaterials and Methods: A video cue that shows a cyclic moving pattern is shown to the patient to help adjust his respiratory motion. Once the respiratory motion becomes regular, we can predict his respiratory phase during the treatment. The trajectory of the organ due to the respiratory motion can be obtained from the fluoroscopy study. The trajectory is then used to modify the velocities of MLC leaves so that the radiation field is synchronized with organ motion. Once the beam moves with the respiratory motion, the field size can be fixed on the tumor volume and reduce the distortion of dose distribution due to the organ motion.\nResults and Conclusions: A phantom was built to simulate the respiratory motion. EDR2 films are employed for the measurement of dose distribution. Preliminary results show that modification of MLC can be used to reduce the distortion due to respiration. Visual cue can be used to improve the regularization of respiration. This technique can be applied to clinical cases. The advantage of this Respiration Adaptive IMRT is to eliminate the inaccuracy of the TM field delivery caused from respiration movement without the cost of treatment efficiency. It requires patient's cooperation for regular respiratory motion."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-67-75-a", "title": "\u8a55\u4f30\u50b3\u7d71\u4e8c\u7dad\u6cbb\u7642\u8a08\u5283\u5728\u4e73\u623f\u76f8\u5207\u7167\u5c04\u7684\u5291\u91cf\u5206\u4f48", "keywords": "\u4e73\u764c;\u76f8\u5207\u7167\u5c04;\u6cbb\u7642\u8a08\u5283 Breast cancer;Tangential irradiation;Treatment plan", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u50b3\u7d71\u6a21\u64ec\u5b9a\u4f4d\u6280\u8853(2-D)\u8207\u73fe\u884c\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e09\u7dad\u6cbb\u7642\u6280\u8853(3-D)\u5728\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u4e0a\u7684\u5dee\u7570\uff0c\u4e26\u78ba\u8a8d\u50b3\u7d71\u6a21\u64ec\u5b9a\u4f4d\u6280\u8853\u5728\u4e73\u623f\u76f8\u5207\u7167\u5c04\u6280\u8853\u7684\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1998\u5e7411\u6708\u81f31998\u5e7412\u6708\uff0c\u5341\u4f4d\u5728\u672c\u79d1\u63a5\u53d7\u4e73\u623f\u76f8\u5207\u7167\u5c04\u6cbb\u7642\u7684\u521d\u671f\u4e73\u764c\u75c5\u60a3\u6536\u5165\u5230\u6b64\u7bc7\u7684\u7814\u7a76\u9ad4\u6750\u5167\u3002\u75c5\u60a3\u4f7f\u7528\u767c\u6ce1\u5291\u88fd\u505a\u56fa\u5b9a\u59ff\u52e2\uff0c\u9032\u884c\u50b3\u7d71\u4e73\u623f\u76f8\u5207\u7167\u5c04\u7684\u6a21\u64ec\u651d\u5f71\u64cd\u4f5c\u7a0b\u5e8f\uff0c\u53d6\u5f97\u50b3\u7d712-D\u6cbb\u7642\u6280\u8853\u7684\u53c3\u6578\u3002\u4e4b\u5f8c\uff0c\u75c5\u60a3\u9032\u884c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u4ee5\u64f7\u53d6\u5f71\u50cf\u50b3\u8f38\u81f33-D\u5f71\u50cf\u8f14\u52a9\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u3002\u6bd4\u8f033-D\u5f71\u50cf\u8f14\u52a9\u6cbb\u7642\u8a08\u5283\u5176\u6700\u4f73\u7684\u5291\u91cf\u5206\u4f48\u82072-D\u6cbb\u7642\u53c3\u6578\uff08\u4e2d\u5fc3\u9ede\u3001\u7167\u91ce\u3001\u65cb\u8f49\u81c2\u89d2\u5ea6\u53ca\u6e96\u76f4\u5100\u89d2\u5ea6\u7b49\uff09\u8f38\u5165\u81f33-D\u5f71\u50cf\u8f14\u52a9\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u4e4bDVH\uff0c\u4e26\u8a08\u7b97\u6240\u5f97\u7684\u7167\u5c04\u9ad4\u7a4d\uff08\u5982PTV\u3001\u6b63\u5e38\u7d44\u7e54\u3001\u80ba\u90e8\u8207\u5fc3\u81df\uff09\u3002\n\u7d50\u679c\uff1a\u6b64\u5169\u7a2e\u6280\u8853\u8a08\u7b97\u5176PTV\u7684\u8986\u84cb\u6bd4\u7387\u70ba0.95\u00b10.02\u3002\u5c31\u6b63\u5e38\u7d44\u7e54\uff0c2-D\u572850%\u7684\u5291\u91cf\u66f2\u7dda\u5167\u6709\u8f03\u591a\u7684\u80f8\u58c1\u8edf\u7d44\u7e54\u88ab\u542b\u62ec\uff0c\u4f46\u5169\u8005\u6280\u8853\u4e26\u6c92\u6709\u7522\u751f\u660e\u986f\u5dee\u5225\uff08\u5e73\u5747\u9ad4\u7a4d\u5206\u5225\u70ba2-D 703 ml\u00b1205 ml\u548c3-D 539 ml\u00b1197 ml, t test p=0.146\uff09\u3002\u5c0d\u540c\u5074\u7684\u80ba\u90e8\u800c\u8a00\uff0c\u6709\u76f8\u540c\u7684\u80ba\u90e8\u7167\u5c04\u9ad4\u7a4d\u767e\u5206\u6bd4\uff082-D\u70ba75%\u00b130%\u82073-D\u70ba76%\u00b148%\uff09\u3002\u53e6\u5916\u5de6\u5074\u4e73\u764c\u75c5\u60a3\uff0c\u5fc3\u81df\u63a5\u53d7\u7167\u5c04\u9ad4\u7a4d\u4ea6\u6c92\u6709\u4e0d\u540c\uff082-D\u70ba5.8 ml\u00b14.2 ml, 3-D\u70ba5.4 ml\u00b13.9 ml\uff09\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u8cc7\u6599\u986f\u793a\uff0c\u5169\u7a2e\u6280\u8853\u7121\u8ad6\u5728PTV\u3001\u6b63\u5e38\u7d44\u7e54\u3001\u80ba\u90e8\u8207\u5fc3\u81df\u5176\u5206\u6790\u8cc7\u6599\u7121\u5dee\u5225\u3002\u5728\u6c92\u6709CT\u6a21\u64ec\u651d\u5f71\u6a5f\u7684\u6642\u5f8c\uff0c\u4ee5\u50b3\u7d71\u76842-D\u6a21\u64ec\u651d\u5f71\u4f86\u57f7\u884c\u4e73\u623f\u76f8\u5207\u7167\u5c04\u6280\u8853\u4f86\u57f7\u884c\uff0c\u4ea6\u662f\u4e00\u7a2e\u53ef\u884c\u7684\u9078\u64c7\u3002", "e": "Purpose: To compare the conventional 2-dimensional (2-D) simulation technique with CT- based 3-D planning method, and verify the feasibility of 2-D method for breast tangential irradiation.\nMaterials and Methods: From November to December1998, ten successive patients with early-staged breast cancer were enrolled for this study. After immobilization with alpfa-cradle, patient underwent a conventional simulation-method to get the parameters for 2-D treatment plan. Patient also had a chest CT scan and these images were stored for subsequent 3-D treatment plan. These two treatment planning methods were retrospectively compared with their dose-volume histogram (DVH) of the irradiated targets (PTV normal tissue, lung and heart).\nResults: The PTV covering ratio (2-D vs. 3-D) of these two techniques is 0.95 \u00b1 0.02. For the normal tissue, two-dimensional technique has more chest wall soft tissue included within 50% isodose curve, but there is no significant difference (mean volume 703 ml\u00b1205 ml for 2-D vs. 539 ml\u00b1197 ml for 3-D, t test p=0.146). For the ipsilateral lung tissue, both methods have equivalent irradiated percentage lung volume (7.5%\u00b13.0% for 2-D vs. 7.6%\u00b14.8% for 3-D). For left-sided breast cancer, the average irradiated heart volumes are 5.4 ml\u00b14.2 ml (2-D) versus 5.8 ml\u00b13.9 ml (3-D).\nConclusions: Our analysis shows that both planning methods have equivalent irradiated dose-volume histograms. For circumstances where CT scan simulator is not available, conventional 2-D planning method is an acceptable alternative."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200603-13-1-77-85-a", "title": "Lumbar Spine Chordoma with Bone Metastasis: A Case Report and Literature Review", "keywords": "\u8170\u690e;\u810a\u7d22\u7624;\u9aa8\u8f49\u79fb;\u653e\u5c04\u6cbb\u7642 Lumbar spine;Chordoma;Bone metastasis;Radiotherapy", "c": "\u810a\u7d22\u7624\u662f\u6975\u5c11\u898b\u7684\u60e1\u6027\u816b\u7624\u3002\u5927\u591a\u6578\u810a\u7d22\u7624\u767c\u751f\u5728\u9871\u5e95\u3001\u9838\u690e\u53ca\u85a6\u9aa8\u3002\u6211\u5011\u5831\u544a\u4e00\u5c11\u898b\u539f\u767c\u8170\u690e\u7684\u810a\u7d22\u7624\u3002\u6b64\u75c5\u4f8b\u4e2d\uff0c\u8170\u690e\u8853\u5f8c\u53ca\u653e\u5c04\u7dda\u7167\u5c04\u5169\u5e74\u5f8c\uff0c\u6c92\u6709\u5c40\u90e8\u518d\u767c\u7522\u751f\uff0c\u537b\u8f49\u79fb\u5230\u53f3\u80a9\u80db\u9aa8\u53ca\u5de6\u80a1\u9aa8\u5e79\u3002\u810a\u7d22\u7624\u4e4b\u6cbb\u7642\u4ecd\u662f\u4e00\u500b\u5f88\u5927\u7684\u6311\u6230\u3002\u6211\u5011\u56de\u9867\u6587\u737b\u4e2d\u6709\u95dc\u810a\u7d22\u7624\u4e4b\u81e8\u5e8a\u8868\u73fe\u3001\u75c5\u614b\u751f\u7406\u3001\u6cbb\u7642\u7b56\u7565\u53ca\u9810\u5f8c\uff0c\u4e26\u6574\u7406\u653e\u5c04\u6cbb\u7642\u4e4b\u6700\u65b0\u9032\u5c55\uff0c\u5305\u62ec\u8cea\u5b50\u6cbb\u7642\u53ca\u91cd\u7c92\u5b50\u6cbb\u7642\u5982\u78b3\u96e2\u5b50\u5c0d\u810a\u7d22\u7624\u4e4b\u6cbb\u7642\u6bd4\u8f03\u3002", "e": "Chordomas are rare malignant neoplasms. Most chordomas are found at skull base, sacrum and cervical spine. We present a rare case of chordoma with lumbar spine origin and bone metastasis after operation and radiotherapy. In this case, no local recurrence was found in two years after tumor removal and adjuvant radiotherapy, but metastases to right scapula and left femur shaft were found afterward. Besides, the treatment of chordomas remains a challenge. We review the literatures of the clinical feature, pathophysiology, treatment modalities and prognosis of chordomas, and also the newest advances of radiotherapy, including proton beam radiotherapy (RT) and heavy charged particles RT (carbon ions) for treating chordomas."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-247-256-a", "title": "Treatment Result of Cerebral Arteriovenous Malformations Treated by Linac-Based Stereotactic Radiosurgery", "keywords": "X\u5149\u5200;\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62;\u653e\u5c04\u6cbb\u7642;\u8166\u90e8\u58de\u6b7b Linac stereotactic radiotherapy X-knife;Cerebral arteriovenous malformation AVM;Radiotherapy;Brain necrosis", "c": "\u76ee\u7684\uff1a\u5206\u6790\u672c\u9662\u4f7f\u7528X\u5149\u5200\u6cbb\u7642\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u7684\u6cbb\u7642\u6548\u679c\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u5f9e\u4e00\u4e5d\u4e5d\u516d\u5e74\u5230\u5169\u5343\u96f6\u56db\u5e74\uff0c\u5171\u6709\u4e00\u767e\u4e00\u5341\u4e03\u500b\u8166\u90e8\u75c5\u7076\u60a3\u8005\u65bc\u672c\u9662\u63a5\u53d7\u8166\u90e8X\u5149\u5200\u6cbb\u7642\u3002\u4e2d\u4f4d\u6578\u8ffd\u8e64\u671f\u70ba\u56db\u5341\u4e8c\u500b\u6708\uff08\u7bc4\u570d\uff1a\u516d\u81f3\u4e00\u767e\u96f6\u4e03\u500b\u6708\uff09\u3002\u5176\u4e2d\u5171\u6709\u4e8c\u5341\u516d\u4f4d\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u60a3\u8005\u3002\u4f9d\u6027\u5225\u5206\uff0c\u5171\u6709\u4e03\u4f4d\u5973\u6027\u53ca\u5341\u4e5d\u4f4d\u7537\u6027\u3002\u63a5\u53d7X\u5149\u5200\u6642\u7684\u5e73\u5747\u5e74\u9f61\u70ba\u4e8c\u5341\u4e5d\u6b72\uff08\u7bc4\u570d\uff1a\u516b\u81f3\u4e03\u5341\u4e00\u6b72\uff09\u3002\u4f9dSpetzler-Martin\u5206\u6578\u4f86\u5206\uff0c\u5404\u5225\u70ba\uff1a\u4e5d\u4f4d\u75c5\u4eba\u70ba\u4e00\u5206\uff0c\u4e94\u4f4d\u75c5\u4eba\u70ba\u5169\u5206\uff0c\u56db\u4f4d\u75c5\u4eba\u70ba\u4e09\u5206\u53ca\u516b\u4f4d\u75c5\u4eba\u70ba\u56db\u5206\u3002\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u5e73\u5747\u6a19\u7684\u9ad4\u7a4d\u70ba\u4e03\u9ede\u4e5d\u897f\u897f\u3002\u5e73\u5747\u6a19\u7684\u5468\u908a\u5291\u91cf\u70ba\u5341\u4e09\u683c\u96f7\u3002\n\u7d50\u679c\uff1a\u6c92\u6709\u75c5\u4eba\u65bc\u6536\u6848\u671f\u9593\u6b7b\u4ea1\u3002\u4e8c\u5341\u56db\u4f4d\u75c5\u4eba\u65bcX\u5149\u5200\u5f8c\u6709\u63a5\u53d7\u8166\u90e8\u6838\u78c1\u5171\u632f\u6aa2\u67e5\uff0c\u516b\u4f4d\u6709\u63a5\u53d7\u50b3\u7d71\u8166\u90e8\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\u3002\u7c97\u6cbb\u7652\u7387\u70ba\u767e\u5206\u4e4b\u516d\u5341\u4e8c\u9ede\u4e94(5/8)\u3002X\u5149\u5200\u5f8c\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u65bc\u50b3\u7d71\u8840\u7ba1\u651d\u5f71\u6642\u986f\u73fe\u5b8c\u5168\u963b\u585e\u4e4b\u4e2d\u4f4d\u6642\u9593\u70ba\u516d\u5341\u4e09\u500b\u6708\uff08\u7bc4\u570d\uff1a\u4e09\u5341\u4e09\u81f3\u4e03\u5341\u4e8c\u500b\u6708\uff09\u3002X\u5149\u5200\u524d\u7684\u51fa\u8840\u7387\u70ba\u767e\u5206\u4e4b\u516d\u5341\u4e00\u9ede\u4e94\uff1bX\u5149\u5200\u5f8c\u7684\u51fa\u8840\u7387\u70ba\u767e\u5206\u4e4b\u4e03\u9ede\u4e03\u3002\u5171\u6709\u4e09\u4f4d\u75c5\u4eba\u65bc\u63a5\u53d7X\u5149\u5200\u5f8c\u7522\u751f\u6c38\u4e45\u6027\u8166\u90e8\u58de\u6b7b\u75c7\u72c0\uff08\u767e\u5206\u4e4b\u5341\u4e00\u9ede\u4e94\uff09\u3002\u9019\u4e09\u4f4d\u75c5\u4eba\u7686\u662f\u65e9\u671f\u6cbb\u7642\u7684\u75c5\u60a3\u3002\u5f71\u97ff\u8166\u90e8\u58de\u6b7b\u7684\u5371\u96aa\u56e0\u5b50\u70ba\u6cbb\u7642\u6a19\u7684\u9ad4\u7a4d\u8d85\u904e\u4e03\u897f\u897f\uff08P\u503c\u7b49\u65bc0.002\uff09\u53caX\u5149\u5200\u6700\u5927\u6cbb\u7642\u5b54\u5f91\u5927\u65bc\u4e09\u516c\u5206\uff08P\u503c\u7b49\u65bc0.004\uff09\u3002\n\u7d50\u8ad6\uff1a\u672c\u9662\u4f7f\u7528X\u5149\u5200\u6cbb\u7642\u8166\u90e8\u52d5\u975c\u8108\u7578\u5f62\u7684\u6cbb\u7642\u6548\u679c\u8207\u6587\u737b\u4e0a\u5831\u5c0e\u7d50\u679c\u70ba\u53ef\u6bd4\u8f03\u7684\u3002\u7136\u800c\u672c\u9662\u7684\u6cbb\u7642\u6578\u76ee\u4ecd\u5c11\uff0c\u9700\u65e5\u5f8c\u66f4\u591a\u75c5\u4eba\u6578\u53ca\u66f4\u9577\u4e4b\u8ffd\u8e64\u671f\u4ee5\u4fbf\u7372\u5f97\u66f4\u5f37\u800c\u6709\u529b\u7684\u7d50\u8ad6\u3002", "e": "Introduction: To report our preliminary treatment result of AVMs treated by Linac-based Stereotactic Radiosurgery (X-knife).\nMaterials and Methods: From 1996 to 2004, there were 117 patients treated by X-knife for their brain lesions in this hospital. The median follow-up time was 42 months (range: 6-107 months). These included 26 cerebral AVMs. There were 7 female and 19 male. The mean age at time of SRS was 29 years (range, 8-71 years). For Spetzler-Martin score distribution, there were score 1 (n=9), score 2(n=5), score 3(n=4) and score 4(n=8), respectively. Mean target volume was 7.9 c.c.. Mean peripheral or minimal dose was 13 Gy.\nResults: No patient had died during the study interval. Twenty-four patients had at least one MRI/MRA follow-up and 8 had catheter angiography. The crude rate of cure was 62.5% (5/8). The crude rate of combined total and partial obliteration was 79.2% (19/24). Median time to complete disappearance of the nidus on MRI/MRA was 28 months (range, 1-82). Median time to complete obliteration verified by conventional angiography was 63 months (range, 33-72). Hemorrhage rate before and after radiosurgery were recorded in 61.5% and 7.7%, respectively. Three patients (11.5%) had brain necrosis with permanent neurological defects and all were treated in the early stage in this study. Significant risk factors for brain necrosis showed target volume more than 7c.c. (P=0.002) and maximum cone size more than 3.0 cm (P=0.04).\nConclusion: The results of AVM treated by Linac-based SRS in our institute were comparable with other reported data. However, larger sample size with a longer follow-up is needed for a more conclusive comment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-257-266-a", "title": "Long-Term Results of Stage IB to IIB Cervical Carcinoma Treated by Preoperative Radiotherapy and Surgery", "keywords": "\u5b50\u5bae\u9838\u764c;\u8853\u524d\u653e\u5c04\u6cbb\u7642;\u4fee\u6b63\u578b\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853 Cervical cancer;Preoperative radiotherapy;Extrafascial hysterectomy", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u624b\u8853\u524d\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5b50\u5bae\u5207\u9664\u8853\u5c0d\u65bc\u521d\u671f\u5b50\u5bae\u9838\u764c\u60a3\u8005\u4e4b\u9577\u671f\u6cbb\u7642\u7d50\u679c\u53ca\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1986\u5e747\u6708\u81f31988\u5e7412\u6708\uff0c26\u4f4d\u521d\u671f\u5b50\u5bae\u9838\u764c\u60a3\u8005\uff08\u4f9dFIGO\u5206\u671f13\u4f4d\u70baIB\uff0c10\u4f4d\u70ba\u2161A\uff0c3\u4f4d\u70ba\u2161B\uff09\u63a5\u53d7\u624b\u8853\u524d\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u4fee\u6b63\u578b\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u3002\u75c5\u60a3\u5e74\u9f61\u4e2d\u4f4d\u6578\u70ba49\u6b72\uff08\u4ecb\u65bc35\u81f365\u6b72\uff09\u3002\u816b\u7624\u5927\u5c0f\u4e2d\u4f4d\u6578\u70ba5cm\uff08\u4ecb\u65bc2\u81f37cm\uff09\u3002\u7d44\u7e54\u5b78\u578b\u614b\u5305\u542b\u6709\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\uff0822\u4f4d\u60a3\u8005\uff09\u3001\u817a\u764c\uff082\u4f4d\u60a3\u8005\uff09\u53ca\u5c0f\u7d30\u80de\u764c\uff082\u4f4d\u60a3\u8005\uff09\u3002\u624b\u8853\u524d\u653e\u5c04\u6cbb\u7642\u70ba\u9aa8\u76c6\u8154\u9ad4\u5916\u7167\u5c043600-4500cGy\uff08\u4e2d\u4f4d\u6578\u70ba3700cGy\uff09\uff0c\u56db\u6b21\u5b50\u5bae\u8154\u5167\u6cbb\u7642\u5171\u8a083200cGy\u81f3A\u9ede\u3002\u8fd1\u63a5\u6cbb\u7642\u5f8c\u5169\u9031\u518d\u4ee5\u9ad4\u5916\u8ffd\u52a0\u7167\u5c04\u9aa8\u76c6\u8154\u6dcb\u5df4\u5f15\u6d41\u5340\u57df360-1260cGy\uff08\u4e2d\u4f4d\u6578\u70ba540\u6beb\u683c\u96f7\uff09\u3002\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c4\u81f36\u5468\u63a5\u53d7\u4fee\u6b63\u578b\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u53ca\u5375\u5de2\u8f38\u5375\u7ba1\u5207\u9664\u3002\n\u7d50\u679c\uff1a\u60a3\u8005\u63a5\u53d7\u4fee\u6b63\u578b\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u5f8c\uff0c22\u4f4d\u60a3\u8005\u65bc\u8853\u5f8c\u75c5\u7406\u6aa2\u67e5\u9054\u5230\u816b\u7624\u5b8c\u5168\u7de9\u89e3\uff0c\u4f46\u4ecd\u67092\u4f4d\u60a3\u8005\u65bc\u5b50\u5bae\u9838\u65c1\u7d44\u7e54\u51fa\u73fe\u6b98\u5b58\u816b\u7624\u30026\u4f4d\u60a3\u8005\uff08\u4f5423.1%\uff09\u65bc\u624b\u8853\u5f8c\u51fa\u73fe\u4f75\u767c\u75c7\u3002\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba79.5%\u820784.3%\u3002\u4f9d\u64daCox\u591a\u8b8a\u9805\u5206\u6790\u986f\u793a\uff1a\u63a5\u53d7\u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642(p=0.005)\u3001\u624b\u8853\u5f8c\u5b50\u5bae\u9838\u65c1\u7d44\u7e54\u51fa\u73fe\u6b98\u5b58\u816b\u7624(p=0.007)\u53ca\u60a3\u8005\u5e74\u9f61\u5c0f\u65bc40\u6b72(p=0.017)\u662f\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u4e4b\u9810\u5f8c\u56e0\u7d20\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u521d\u671f\u5b50\u5bae\u9838\u764c\u60a3\u8005\uff0c\u7279\u5225\u662f\u5de8\u5927\u816b\u7624\uff0c\u624b\u8853\u524d\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u4fee\u6b63\u578b\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u53ef\u9054\u5230\u8207\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u6216\u55ae\u7d14\u653e\u5c04\u6cbb\u7642\u76f8\u7576\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\u5c0d\u65bc\u624b\u8853\u5207\u9664\u5f8c\u5b50\u5bae\u9838\u65c1\u7d44\u7e54\u51fa\u73fe\u6b98\u5b58\u816b\u7624\u4e4b\u60a3\u8005\uff0c\u5176\u9810\u5f8c\u8f03\u5dee\u3002", "e": "Purpose: To evaluate the treatment results of preoperative radiotherapy followed by surgery and the prognostic factors in patients with stage IB to IIB cervical carcinoma.\nMaterials and Methods: Between July 1986 and December 1988, twenty-six patients with FIGO stage IB (13 patients), IIA (10 patients) and IIB (3 patients) cervical carcinoma were evaluated and treated at the Tri-Service General Hospital. The median age of the patients was 49 years (range 35-65). The median tumor size was 5 cm (range 2-7). The histological types were squamous cell carcinoma (22 patients), adenocarcinoma (2 patients) and small cell carcinoma (2 patients). Preoperative radiotherapy dose to whole pelvis was 3600-4500 cGy (median 3700 cGy). This was followed by 4 fractions of intracavitary brachytherapy providing 3200 cGy to point A. A boost dose of 360-1260 cGy (median 540 cGy) was given to the parametrial area. All patients underwent extrafascial hysterectomy and bilateral salpingo-oophorectomy 4 to 6 weeks after completion of radiation therapy.\nResults: Twenty-two (84.6%) patients had no residual tumor after hysterectomy, but two patients (7.7%) had parametrial involvement after operation. Complications were observed in 6 (23.1%) patients, all occurred in postoperative period. Five-year overall and disease-free survival was 79.5% and 84.3%, respectively. Cox proportional hazard models demonstrated poor prognostic factors were adjuvant chemotherapy (p=0.005), parametrial involvement after operation (p=0.007) and age below 40 years old (p=0.017).\nConclusions: The results of preoperative radiotherapy and surgery showed as comparable as radical hysterectomy or radiotherapy alone, especially for bulky tumor. Residual parametrial involvement after operation remains poor prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-267-275-a", "title": "Intensity-Modulated Radiotherapy Versus 3-D Tangential Therapy in the Treatment of Left Breast Cancer: A Comparative Planning Study", "keywords": "\u4e73\u764c;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u5fc3\u81df\u81f4\u6b7b\u7387;\u5fc3\u81df\u5291\u91cf Breast cancer;Intensity-modulated radiotherapy;Cardiac mortality;Cardiac dose", "c": "\u76ee\u7684\uff1a\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5f8c\u5408\u4f75\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u5df2\u662f\u65e9\u671f\u4e73\u764c\u7684\u6a19\u6e96\u6cbb\u7642\u7a0b\u5e8f\u3002\u7136\u800c\u56e0\u5b58\u6d3b\u6642\u9593\u5ef6\u9577\uff0c\u6709\u4e9b\u7814\u7a76\u986f\u793a\u5de6\u5074\u4e73\u764c\u75c5\u4eba\u653e\u7642\u5f8c\u6709\u8f03\u9ad8\u7684\u5fc3\u81df\u526f\u4f5c\u7528\u6a5f\u6703\u3002\u91dd\u5c0d\u5de6\u5074\u4e73\u764c\uff0c\u672c\u7bc7\u7814\u7a76\u8a2d\u8a08\u4e09\u7a2e\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff0c\u4e26\u8207\u4e09\u5ea6\u7a7a\u9593\u76f8\u5207\u7167\u91ce\u6cbb\u7642\u8a08\u5283\u4f5c\u6bd4\u8f03\uff0c\u8a55\u4f30\u4e0d\u540c\u7684\u6cbb\u7642\u6280\u8853\u5c0d\u816b\u7624\u7bc4\u570d\u7684\u6db5\u84cb\u53ca\u5fc3\u81df\u4fdd\u8b77\u6548\u61c9\u7684\u5dee\u7570\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u641c\u96c6\u5341\u4f4d\u5de6\u5074\u4e73\u764c\u75c5\u4eba\uff0c\u4e4b\u524d\u4ee5\u4e09\u5ea6\u7a7a\u9593\u76f8\u5207\u7167\u91ce\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u662f50Gy\uff0c\u6cbb\u7642\u6b21\u6578\u662f25\u6b21\u3002\u6240\u6709\u75c5\u4eba\u7d93\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5f8c\uff0c\u63a5\u53d7\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u6cbb\u7642\u898f\u5283\u3002\u6bcf\u4f4d\u75c5\u4eba\u63a5\u53d7\u56db\u7a2e\u6cbb\u7642\u8a08\u5283\u7684\u5206\u6790\uff0c\u8a55\u4f30\u5176\u8a08\u756b\u6cbb\u7642\u9ad4\u7a4d(PTV)\u4ee5\u53ca\u91cd\u8981\u5668\u5b98(OAR)\u7684\u5291\u91cf\uff0d\u9ad4\u7a4d\u5206\u5e03\u5716(DVH)\u3002\u4f7f\u7528\u7684\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u662fEclipse Version 7.1\uff0c\u6cbb\u7642\u5c04\u675f\u662f6MV\u7684X\u5c04\u7dda\uff0c\u5291\u91cf\u7d66\u4e88\u65b9\u5f0f\u662fstep and shoot\u3002\u56db\u7a2e\u6cbb\u7642\u8a08\u756b\u5982\u4e0b\uff1a(1)3-D tangential field (3D)\uff0c(2)2-field tangential IMRT plan(2T)\uff0c(3)2-field optimized IMRT plan(2O)\uff0cand (4)4-field IMRT technique(4I)\u3002\u7d71\u8a08\u5206\u6790\u4e0d\u540c\u8a08\u5283\u9593DVH\u7684\u5dee\u7570\u6027\u662f\u6839\u64daStudent's t-test\u3002\n\u7d50\u679c\uff1a\u56db\u7a2e\u6cbb\u7642\u65b9\u5f0f\u7686\u80fd\u9054\u5230\u985e\u4f3c\u7684PTV\u9ad4\u7a4d\u4e4b\u6db5\u84cb\u5747\u52fb\u5ea6\u3002\u7576\u8a08\u7b973D\u30012T\u30012O\u548c4I\u56db\u7a2e\u8a08\u5283\u4e2d\u4ecb\u65bc\u6cbb\u7642\u5291\u91cf95-107%\u4e4bPTV\u4e4b\u9ad4\u7a4d\u6bd4\u7387(V(\u4e0b\u6a19 95-107%))\u6642\uff0c\u5176\u5e73\u5747\u503c\u5206\u5225\u662f96.1%\u300197.4%\u300196.0%\u548c97.6%\u3002\u800c\u5728\u8a08\u7b97\u5fc3\u81df\u9ad4\u7a4d\u6bd4\u7387\u63a5\u53d7\u5927\u65bc95/80%\u6cbb\u7642\u5291\u91cf\u65b9\u9762\uff0c\u5176\u5e73\u5747\u503c\u5206\u5225\u70ba3.4/7.4%\u30012.5/5.8%\u30011.7/4.5%\u548c1.2/2.9%\u3002\u53e6\u5916\u80ba\u90e8\u9ad4\u7a4d\u63a5\u53d7\u5927\u65bc20Gy\u7684\u5e73\u5747\u503c\u5206\u5225\u662f19.6%\u300117.5%\u300123.9%\u548c19.3%\u30024I\u6cbb\u7642\u8a08\u5283\u986f\u8457\u964d\u4f4e\u5fc3\u81df\u7684\u9ad8\u5291\u91cf\u5340\uff0c\u7136\u800c\u537b\u76f8\u5c0d\u589e\u52a0\u5c0d\u5074\u4e73\u623f\u7684\u5291\u91cf\u3002\u6b64\u5916\uff0c\u7d50\u679c\u986f\u793a\u4f7f\u7528IMRT\u6cbb\u7642\u8a08\u5283\u4e26\u4e0d\u6703\u589e\u52a0\u80ba\u90e8\u5927\u65bc20Gy\u7684\u7167\u5c04\u9ad4\u7a4d\u6216\u5e73\u5747\u5291\u91cf\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u5de6\u5074\u4e73\u764c\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u9808\u8a55\u4f30\u5fc3\u81df\u63a5\u53d7\u8f03\u9ad8\u653e\u5c04\u5291\u91cf\u5f8c\u7684\u526f\u4f5c\u7528\u6a5f\u6703\uff0c\u800c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u63d0\u4f9b\u53e6\u4e00\u7a2e\u9078\u64c7\u3002\u672c\u7bc7\u7814\u7a76\u986f\u793a4-field IMRT\u6280\u8853\u53ef\u9054\u5230\u8207\u76f8\u5207\u7167\u91ce\u76f8\u540c\u7684\u8a08\u756b\u6cbb\u7642\u9ad4\u7a4d\u4e4b\u6db5\u84cb\u5747\u52fb\u5ea6\uff0c\u4e26\u5f97\u5230\u8f03\u4f73\u7684\u5fc3\u81df\u4fdd\u8b77\u6548\u61c9\u3002", "e": "Purpose: Adjuvant radiotherapy is a part of the routine care of patients with early breast cancer. However, a subset of patients with left breast cancer has been shown to be at significant risk of cardiac mortality after longer relapse-free survival. This planning study was designed to assess the efficacy of target coverage and cardiac sparing by three intensity-modulated radiotherapy (IMRT) techniques compared to three-dimensional tangential radiotherapy.\nMaterials and Methods: Treatment planning study was performed retrospectively on 10 selected left-sided breast cancer patients previously treated by three-dimensional tangential radiotherapy with the prescribed dose of 50 Gy in 25 fractions. All patients underwent CT scan following their breast conserving surgery. For each patient, plans were generated and compared using dose volume histograms for planning target volume (PTV) and organs at risk (OAR). Treatment planning was performed using a commercial IMRT system (Eclipse Version 7.1), and the beam fluency was delivered using a step and shoot window leaf sequence and 6-MV beams. Four different radiation techniques were analyzed: (1) 3-dimensional tangential plan (3D), (2) 2-field tangential IMRT plan (2T), (3) 2-field optimized IMRT plan (2O), and (4) 4-field IMRT plan (4I). Doses to the PTV and each OAR were compared using a paired Student's t-test.\nResults: PTV homogeneity was similar for the four techniques. For all patients, the average part of the PTV receiving a dose between 95 and 107% of the prescribed dose was 96.1%, 97.4%, 96.0% and 97.6% for the 3D, 2T, 2O and 4I plans, respectively. The mean proportion of the heart receiving more than 95/80% of the prescribed dose was 3.4/7.4% for 3D, 2.5/5.8% for 2T, 1.7/4.5% for 2O and 1.2/2.9% for 4I techniques, while the mean proportion of lung receiving more than 20 Gy was 19.6%, 17.5%, 23.9% and 19.3% for the four plans, respectively. When compared to 3D plans, the 41 plans significantly reduced the high dose irradiation volume of heart; however, the irradiated doses to the contralateral breast were increased. The use of IMRT techniques did not increase either V20 Gy of lung or the mean left lung doses.\nConclusion: Left breast cancer patients undergoing adjuvant irradiation in which the heart receiving higher dose should be considered for alternation to IMRT plan. Better cardiac sparing effect is achievable with the use of 4-field IMRT technique without compromising target coverage."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-277-283-a", "title": "Palliative Splenic Irradiation for Splenomegaly: Retrospective Review of Experience at the Mackay Memorial Hospital", "keywords": "\u813e\u81df\u653e\u5c04\u6cbb\u7642;\u813e\u81df\u816b\u5927;\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642 Splenic irradiation;Splenomegaly;Palliative radiotherapy", "c": "\u5f15\u8a00\uff1a\u8a31\u591a\u6587\u737b\u6307\u51fa\u813e\u81df\u7684\u653e\u5c04\u6cbb\u7642\u53ef\u7528\u65bc\u6cbb\u7642\u4e00\u4e9b\u8840\u6db2\u816b\u7624\u3002\u813e\u81df\u7684\u653e\u5c04\u6cbb\u7642\u6548\u679c\u826f\u597d\u4e14\u526f\u4f5c\u7528\u5f88\u5c11\uff0c\u76f8\u8f03\u65bc\u4e00\u4e9b\u5167\u79d1\u7642\u6cd5\u5176\u82b1\u8cbb\u4e5f\u8f03\u4f4e\uff0c\u5c0d\u65bc\u7de9\u548c\u813e\u81df\u816b\u5927\u7684\u75c7\u72c0\u6709\u5176\u5b58\u5728\u50f9\u503c\u3002\u6211\u5011\u56de\u9867\u672c\u9662\u7684\u813e\u81df\u653e\u5c04\u6cbb\u7642\u7684\u7d93\u9a57\u4e26\u5206\u6790\u53ca\u8a0e\u8ad6\u5176\u6709\u6548\u7a0b\u5ea6\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u81ea2000\u5e741\u6708\u81f32004\u5e748\u6708\u5171\u670912\u4f4d\u75c5\u60a3\u65bc\u672c\u79d1\u63a5\u53d7\u813e\u81df\u7684\u653e\u5c04\u6cbb\u7642\u3002\u5305\u62ec4\u4f4d\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u75c5\u60a3\u30013\u4f4d\u809d\u786c\u5316\u30012\u4f4d\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u30011\u4f4d\u6025\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5\u30011\u4f4d\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u53ca1\u4f4d\u81ea\u767c\u6027\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u75c5\u4eba\uff0c\u7e3d\u5171\u63a5\u53d718\u500b\u7642\u7a0b\u7684\u653e\u5c04\u6cbb\u7642\u3002\u4f7f\u7528\u9237\uff0d60\u30016\u621615\u767e\u842c\u4f0f\u7279\u4e4b\u5149\u5b50\u5c04\u7dda\uff0c\u4ee5\u524d\u5f8c\u76f8\u5c0d\u7167\u91ce\u7167\u5c04\uff0c\u6bcf\u5929\u5291\u91cf\u70ba50-160cGy\uff0c\u7e3d\u5291\u91cf\u70ba500cGy\u52302400cGy\u3002\n\u7d50\u679c\uff1a\u5171\u67094\u4f4d\u75c5\u60a3\uff083\u4f4d\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u75c5\u60a3\u30011\u4f4d\u81ea\u767c\u6027\u9aa8\u9ad3\u7e96\u7dad\u5316\u7684\u75c5\u4eba\uff09\u53ca7\u500b\u7642\u7a0b\u6709\u826f\u597d\u7642\u6548\u3002\u53e6\u5916\u67096\u4f4d\u75c5\u60a3\uff082\u4f4d\u809d\u786c\u5316\uff0c\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u75c5\u60a3\u3001\u6025\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5\u3001\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u53ca\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u54041\u4f4d\uff09\u53ca9\u500b\u7642\u7a0b\u6709\u90e8\u4efd\u7684\u7642\u6548\u3002\u67092\u4f4d\u75c5\u60a3\u5c0d\u65bc\u6cbb\u7642\u6c92\u6709\u7642\u6548\uff0c\u5176\u8a3a\u65b7\u5206\u5225\u70ba\u809d\u786c\u5316\u53ca\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u3002\n\u7d50\u8ad6\uff1a\u813e\u81df\u7684\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u6e1b\u8f15\u56e0\u8840\u6db2\u816b\u7624\u53ca\u81ea\u767c\u6027\u9aa8\u9ad3\u7e96\u7dad\u5316\u6240\u9020\u6210\u7684\u813e\u81df\u816b\u5927\u7684\u75c7\u72c0\u3002\u5728\u6211\u5011\u7684\u7d93\u9a57\u4e2d\uff0c\u5c0d\u65bc\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u7684\u75c5\u60a3\u6709\u826f\u597d\u6548\u679c\u3002\u5c0d\u65bc\u975e\u60e1\u6027\u816b\u7624\u9020\u6210\u7684\u813e\u81df\u816b\u5927\uff0c\u813e\u81df\u7684\u653e\u5c04\u6cbb\u7642\u6548\u679c\u5247\u8f03\u5dee\uff0c\u9700\u8981\u9032\u4e00\u6b65\u7684\u7814\u7a76\u4f86\u8b49\u660e\u6b64\u4e00\u89c0\u9ede\u3002", "e": "Introduction: Splenic irradiation had been applied for many years as a treatment for various hematologic diseases. Its excellent effects, minimal side effects and low-cost make it as a reasonable treatment policy for palliation. We reviewed our experience of splenic irradiation and discussed its efficacy.\nMaterials and Methods: Thirteen cases received splenic irradiation at our department from January 2000 to August 2004, and twelve cases were eligible for analysis. Diseases included chronic myelogenous leukemia (4), liver cirrhosis (3), anaplastic anemia (2), acute lymphocytic leukemia (1), Hodgkin's lymphoma (1) and idiopathic myelofibrosis (1). Eighteen courses of radiotherapy were delivered. The radiation treatment techniques consisted of two opposed fields of Co60 and 6 or 15 MV photons targeting to the spleen. The cumulative doses ranged from 500 cGy to 2400 cGy with fraction size ranging from 50 to 160 cGy.\nResults: Good response was observed in four patients (3 cases of CML, 1 case of idiopathic myelofibrosis) and 7 courses of radiotherapy. Partial response was observed in six patients (2 cases were liver cirrhosis, the other 4 cases were CML, ALL, anaplatic anemia and Hodgkin's lymphoma) and 9 courses of radiotherapy. Two patients were not responsive to the treatment, who were suffering from liver cirrhosis and anaplastic anemia, respectively.\nDiscussion: Splenic irradiation can achieve good palliate effects for splenomegaly resulting from idiopathic myelofibrosis and hematological malignancies, especial CML. In non-malignant diseases, such as liver cirrhosis and anaplastic anemia, the symptom relief provided by splenic irradiation was not as good as for that of the malignant disease. However, it needs further investigation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-285-293-a", "title": "\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u904b\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u9a57\u8b49\u7247\u53ef\u884c\u6027\u8a55\u4f30", "keywords": "\u96fb\u8166\u653e\u5c04\u651d\u5f71;\u6cbb\u7642\u9a57\u8b49\u5e95\u7247;\u96fb\u5b50\u5f0f\u7167\u91ce\u5f71\u50cf\u7cfb\u7d71 Computed radiography;Verification film;EPID", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u6240\u63a1\u7528\u4e4b\u6cbb\u7642\u9a57\u8b49\u5e95\u7247\uff0c\u88ab\u5ee3\u6cdb\u904b\u7528\u65bc\u8a55\u4f30\u63a5\u53d7\u6cbb\u7642\u75c5\u60a3\u4e4b\u5b9a\u4f4d\u6e96\u78ba\u5ea6\u53ca\u76f8\u95dc\u914d\u4ef6\u8a2d\u5b9a\u88fd\u4f5c\u4e4b\u6b63\u78ba\u6027\u3002\u4f46\u5132\u5b58\u7a7a\u9593\u3001\u7ba1\u7406\u4e0d\u6613\u3001\u6613\u907a\u5931\u53ca\u74b0\u4fdd\u7b49\u554f\u984c\u4e5f\u9020\u6210\u4e9b\u8a31\u56f0\u64fe\u3002\u9452\u65bc\u6578\u4f4d\u5316\u5f71\u50cf\u70ba\u672a\u4f86\u767c\u5c55\u4e4b\u8da8\u52e2\u53ca\u91dd\u5c0d\u4e0a\u8ff0\u60c5\u6cc1\uff0c\u672c\u7814\u7a76\u8a66\u5716\u4ee5\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u904b\u7528\u65bc\u89c0\u5bdf\u9a57\u8b49\u7247\u6548\u679c\u8a55\u4f30\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6c7a\u5b9a\u6cbb\u7642\u9a57\u8b49\u5f71\u50cf\u54c1\u8cea\u512a\u826f\u8207\u5426\u7684\u56e0\u7d20\uff0c\u5728\u65bc\u5f71\u50cf\u662f\u5426\u80fd\u8868\u73fe\u4e0d\u540c\u5bc6\u5ea6\u53ca\u539a\u5ea6\u4e4b\u7269\u8cea\u7684\u76f8\u5c0d\u5c0d\u6bd4\u5ea6\u3002\u672c\u7814\u7a76\u5206\u5225\u4ee5\u968e\u68af\u5f0f\u6954\u578b\u6ffe\u7247\u53ca\u4eba\u578b\u5047\u9ad4\uff0c\u5206\u5225\u4ee5\u7167\u5c04\u9a57\u8b49\u7247\u6a21\u5f0f\u7167\u5c04\u9a57\u8b49\u5e95\u7247\u3001\u96fb\u5b50\u5f0f\u7167\u91ce\u5f71\u50cf\u7cfb\u7d71\u8207\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\uff0c\u4e26\u89c0\u5bdf\u6240\u5f97\u5f71\u50cf\u7684\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u5728\u968e\u68af\u5f0f\u6954\u578b\u6ffe\u7247\u5f71\u50cf\u8868\u73fe\uff0c\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u5728\u6700\u4f4e\u689d\u4ef6\u6642\u5373\u53ef\u5b8c\u5168\u5448\u73fe\u51fa\u6240\u6709\u968e\u68af\u5c64\u6b21\u3002\u5728\u4eba\u578b\u5047\u9ad4\u5f71\u50cf\u8868\u73fe\uff0c\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u5728\u4efb\u4f55\u90e8\u4f4d\uff0c\u5176\u53ef\u8996\u7070\u968e\u8868\u73fe\u7bc4\u570d\u53ca\u4e0d\u540c\u4ecb\u8cea\u4e4b\u76f8\u5c0d\u5c0d\u6bd4\u5ea6\u5747\u8f03\u6cbb\u7642\u9a57\u8b49\u5e95\u7247\u70ba\u9ad8\u3002\n\u8a0e\u8ad6\uff1a\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u7531\u65bc\u63a1\u7528\u6578\u4f4d\u6280\u8853\uff0c\u52d5\u614b\u7bc4\u570d\u5ee3\uff0c\u6709\u8f03\u5bec\u7684\u66dd\u5149\u5bec\u5bb9\u5ea6\uff0c\u5373\u4f7f\u5728\u4e00\u4e9b\u50b3\u7d71\u66dd\u5149\u689d\u4ef6\u96e3\u4ee5\u638c\u63e1\u7684\u90e8\u4f4d\u5982\u9aa8\u76c6\u8154\u5074\u4f4d\u4e5f\u80fd\u8abf\u6574\u51fa\u8f03\u597d\u7684\u5f71\u50cf\u3002\u5c0d\u653e\u5c04\u6cbb\u7642\u91ab\u5e2b\u800c\u8a00\uff0c\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\u80fd\u6e05\u695a\u5340\u5206\u76f8\u5c0d\u89e3\u5256\u4f4d\u7f6e\uff0c\u4ee5\u8a55\u4f30\u6cbb\u7642\u8a08\u5283\u7d66\u4e88\u5291\u91cf\u8207\u5be6\u969b\u6cbb\u7642\u6642\u7684\u7b26\u5408\u7a0b\u5ea6\u3002\u96fb\u8166\u653e\u5c04\u651d\u5f71\u7cfb\u7d71\uff0c\u4f3c\u4e4e\u662f\u89e3\u6c7a\u653e\u5c04\u6cbb\u7642\u9a57\u8b49\u5e95\u7247\u554f\u984c\u4e4b\u672a\u4f86\u8da8\u52e2\u3002", "e": "Purpose: The conventional verification films and electronic portal images are widely used in the verification of patients' position and the reproducibility of the multi-leaf collimator and block, custom block or cerroben block. The use of verification film is often accompanied by the inconvenience of storing and retrieving. In addition, the importance of using digital images cannot be overemphasized in the modem radiotherapy. We intended to compare digital portal images obtained from computed radiography (CR) system with conventional portal films and the images from electronic portal imaging devices (EPID).\nMaterials & Methods: The quality of the verification images was based on the contrast of different thickness or density. We took conventional portal films and digital images of a step wedge and an anthropomorphic RANDO Phantom under a 21 EX Varian linear accelerator. Those images were then compared by visual inspection and quantitative analysis method.\nResults: Based on the step wedge study, CR system could obtain the full gray-scale of images with least MU. In each treatment site (i.e. Head & Neck, Chest & Pelvis), the quality of the CR images was judged to be superior to conventional portal films.\nConclusion: The operation for the CR system is similar to the tradition verification film. Since they are digital images, they ca be post processed and the anatomic structure can be enhanced in different ways, especially in the lateral fields of pelvis. It provides a better quality of image to verify the accuracy of the treatment position. It seems that the CR system ca provide a better solution for the radiation treatment of cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-295-300-a", "title": "\u653e\u5c04\u816b\u7624\u79d1\u57f7\u884cTG-40\u5efa\u8b70\u4e4b\u6bcf\u9031\u75c5\u6b77\u6aa2\u95b1\u5236\u5ea6\uff1a\u516d\u5e74\u7d50\u679c\u5206\u6790", "keywords": "\u75c5\u6b77\u67e5\u6838;\u54c1\u8cea\u4fdd\u8b49;\u653e\u5c04\u6cbb\u7642\u59d4\u54e1\u6703\u5de5\u4f5c\u7fa440\u865f\u5831\u544a Chart checking;Quality assurance;TG-40", "c": "\u76ee\u7684\uff1a\u672c\u6587\u5167\u5bb9\u4e3b\u8981\u91dd\u5c0d\u672c\u79d1\u516d\u5e74\u4f86\u57f7\u884c\u6bcf\u9031\u75c5\u6b77\u67e5\u6838\u6240\u767c\u73fe\u7684\u7f3a\u5931\u4e88\u4ee5\u5206\u985e\u3001\u7d71\u8a08\uff0c\u4e26\u5206\u6790\u6aa2\u8a0e\u5176\u767c\u751f\u539f\u56e0\uff0c\u5c0b\u6c42\u6539\u5584\u65b9\u6cd5\u4ee5\u964d\u4f4e\u932f\u8aa4\u7387\uff0c\u9032\u800c\u63d0\u5347\u91ab\u7642\u54c1\u8cea\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f9d\u64da\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5e2b\u5b78\u6703\u653e\u5c04\u6cbb\u7642\u59d4\u54e1\u6703\u5de5\u4f5c\u7fa440\u865f\u5831\u544a(TG-40)\uff0c\u5c0d\u65bc\u81e8\u5e8a\u6cbb\u7642\u54c1\u8cea\u4fdd\u8b49\u8a08\u5283\u7684\u5efa\u8b70\uff0c\u5c0d\u65bc\u6bcf\u4f4d\u653e\u5c04\u6cbb\u7642\u75c5\u60a3\u7642\u7a0b\u4e2d\uff0c\u7531\u5291\u91cf\u5e2b\u8207\u5168\u9ad4\u91ab\u4e8b\u653e\u5c04\u5e2b\u5c0d\u5176\u75c5\u6b77\u5be6\u65bd\u6bcf\u9031\u4e00\u6b21\u7684\u75c5\u6b77\u67e5\u6838\u3002\u672c\u7814\u7a76\u81ea1999\u5e741\u6708\u8d77\u81f32004\u5e7412\u6708\u6b62\u5171\u516d\u5e74\u9593\uff0c\u65bc\u6bcf\u9031\u4e00\u6b21\u5be6\u65bd\u75c5\u6b77\u67e5\u6838\u6240\u767c\u73fe\u7684\u932f\u8aa4\u4e88\u4ee5\u7d71\u8a08\uff0c\u4e26\u5c07\u5176\u932f\u8aa4\u9805\u76ee\u5206\u985e\u70ba\u5291\u91cf\u8a08\u7b97\u932f\u8aa4\u3001\u586b\u5beb\u932f\u8aa4\u3001\u6cbb\u7642\u5e2b\u672a\u7c3d\u540d\u3001\u57f7\u884c\u8aa4\u5dee\u3001\u7e3d\u5291\u91cf\u52a0\u932f\u8207\u5176\u4ed6\u985e\u5404\u9805\uff0c\u4e26\u5206\u6790\u5176\u767c\u751f\u539f\u56e0\uff0c\u63d0\u51fa\u6539\u5584\u7684\u5c0d\u7b56\uff0c\u4ee5\u671f\u9010\u6b65\u6e1b\u5c11\u4eba\u70ba\u56e0\u7d20\u7684\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a\u57286\u5e74\u9593\u5171\u57f7\u884c304\u6b21\u67e5\u6838\u52d5\u4f5c\uff0c\u5171\u6aa2\u95b154418\u6b21\u75c5\u6b77\u6578\uff0c\u5176\u4e2d\u767c\u73fe936\u6b21\u7684\u932f\u8aa4\uff0c\u767c\u751f\u932f\u8aa4\u7684\u6bd4\u7387\u70ba1.72%(936/54418)\u3002\u5c6c\u65bc\u5291\u91cf\u8a08\u7b97\u932f\u8aa4\u4f540.56%(307/54418)\u3001\u6cbb\u7642\u8a18\u9304\u9805\u5beb\u932f\u8aa4\u4f540.54%(292/54418)\u3001\u6cbb\u7642\u5e2b\u672a\u7c3d\u540d\u4f540.2%(110/54418)\u3001\u57f7\u884c\u8aa4\u5dee\u4f540.08%(46/54418)\u3001\u7e3d\u5291\u91cf\u52a0\u932f0.30%(165/54418)\u8207\u5176\u4ed6\u5404\u9805\u4f540.03%(16/54418)\u3002\n\u7d50\u8ad6\uff1a\u6bcf\u9031\u75c5\u6b77\u67e5\u6838\u5236\u5ea6\u7684\u5be6\u65bd\u53ef\u5145\u5206\u77ad\u89e3\u6cbb\u7642\u75c5\u6b77\u8a18\u9304\u8207\u6cbb\u7642\u57f7\u884c\u7684\u6b63\u78ba\uff0c\u4e26\u4e14\u53ef\u85c9\u7531\u932f\u8aa4\u6578\u64da\u63a2\u8a0e\u5176\u767c\u751f\u7684\u539f\u56e0\u4e26\u5c07\u932f\u8aa4\u5373\u65e9\u52a0\u4ee5\u6539\u5584\u8207\u4fee\u6b63\uff0c\u9032\u800c\u63d0\u5347\u653e\u5c04\u6cbb\u7642\u90e8\u9580\u91ab\u7642\u54c1\u8cea\u3002", "e": "Purpose: The aim of this study was to classify, calculate and analyze the errors identified by weekly chart review during the past 6 years.\nMaterials and Methods: According to the guidelines recommended by the Task Group-40 report, AAPM, and recommendation by clinical quality assurance protocol, a weekly chart review program was initiated by dosimetrists and radiation therapists for each patient receiving radiation therapy Patients and their charts seen and treated between January 1999 and December 2004 were routinely reviewed once every Thursday during their treatment course. Errors, once identified, were documented, and categorized as calculation, recording, no signature, execution, summation or others errors. We abs analyze the errors with documentation containing an explanation of the error as well as a plan to avoid errors of this type in the future.\nResults: A total of 54418 charts were reviewed by 304 chart checking execution during the past 6 years. Of these, 936 errors were identified, accounting for a incidence of 1.72% (936/54418). Of these, 0.56%(307/54418), 0.54%(292/54418), 0.2%(110/54418), 0.08%(46/54418), 0.30%(165/54418), 0.03%(16/54418) errors were due to calculation, recording, no signature, execution, summation and others respectively.\nConclusion: A weekly chart review program can verify that all parameters are consistent from treatment plan to the daily treatment record to the treatment execution. A substantial proportion of treatment errors ca be effectively detected with aid of this program and thus weekly chart review program is an integrated part of quality assurance in a modem radiation oncology department."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-301-312-a", "title": "Intracranial Germ Cell Tumors and Pineal Tumors: Suboptimal Treatment with Radiosurgery alone Report of Four Cases and Review of Literature", "keywords": "\u4e2d\u6a1e\u795e\u7d93\u80da\u7d30\u80de\u7624;\u9871\u5167\u751f\u6b96\u7d30\u80de\u7624;\u677e\u679c\u9ad4\u816b\u7624;\u653e\u5c04\u624b\u8853 CNS germinoma;Intracranial germ cell tumors;Pineal tumors;Radiosurgery", "c": "\u5c0d\u65bc\u4e2d\u6a1e\u795e\u7d93\u751f\u6b96\u7d30\u80de\u7624\u4e4b\u6cbb\u7642\u76ee\u524d\u4ecd\u7121\u7d71\u4e00\u5171\u8b58\uff0c\u5f9e\u5168\u8166\u810a\u9ad3\u7167\u5c04\u6216\u662f\u5c40\u90e8\u75c5\u7076\u7167\u5c04\uff0c\u5230\u5316\u5b78\u6cbb\u7642\u7684\u4f7f\u7528\u8207\u5426\u76ee\u524d\u4ecd\u6709\u6b67\u898b\u3002\u81f3\u4eca\u6587\u737b\u4e0a\u6709\u6578\u7bc7\u75c5\u4f8b\u5831\u544a\u5efa\u8b70\u5c07\u653e\u5c04\u624b\u8853\u61c9\u65bc\u7528\u4e2d\u6a1e\u795e\u7d93\u751f\u6b96\u7d30\u80de\u7624\u7684\u6cbb\u7642\u4e0a\u3002\u800c\u672c\u7bc7\u6587\u7ae0\u63d0\u51fa\u56db\u540d\u81e8\u5e8a\u4e0a\u8a3a\u65b7\u4e2d\u6a1e\u795e\u7d93\u80da\u7d30\u80de\u7624(germinoma)\u7684\u75c5\u4f8b\u4f7f\u7528\u653e\u5c04\u624b\u8853\u6cbb\u7642\u4e4b\u7d50\u679c\u3002\u7b2c\u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u60a3\u63a5\u53d715Gy\u4f3d\u508c\u5200\u653e\u5c04\u624b\u8853\u6cbb\u7642\uff0c\u6cbb\u7642\u5f8c6\u500b\u6708\u767c\u73fe\u6709\u810a\u9ad3\u8154\u8f49\u79fb\uff0c\u4e4b\u5f8c\u63a5\u53d7\u5168\u8166\u810a\u9ad3\u7167\u5c04\uff0c\u81f3\u4eca\u8ffd\u8e646\u5e74\u75c5\u6cc1\u7a69\u5b9a\u4f46\u7559\u6709\u7b2c\u56db\u5c0d\u8166\u795e\u7d93\u529f\u80fd\u53d7\u640d\u7684\u5f8c\u907a\u75c7\u3002\u7b2c\u4e8c\u4f4d14\u6b72\u7537\u6027\u75c5\u60a3\uff0c\u5176\u75c5\u7076\u4f4d\u65bc\u57fa\u5e95\u6838\uff0c\u63a5\u53d710Gy\u4f3d\u508c\u5200\u5f8c\u62d2\u7d55\u63a5\u53d7\u5f8c\u7e8c\u5b89\u6392\u7684\u5168\u8166\u5ba4\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f3d\u508c\u5200\u5f8c7\u500b\u6708\u767c\u73fe\u7167\u91ce\u5167\u5fa9\u767c\uff0c\u4e4b\u5f8c\u7d93\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u529f\u63a7\u5236\u75be\u75c5\uff0c\u4f46\u7559\u6709\u8f15\u5fae\u5de6\u5074\u80a2\u9ad4\u7121\u529b\u7684\u795e\u7d93\u5b78\u5f8c\u907a\u75c7\u3002\u7b2c\u4e09\u4f4d30\u6b72\u5973\u6027\u75c5\u60a3\u5176\u75c5\u7076\u4f4d\u65bc\u677e\u679c\u9ad4\uff0c\u7d9310Gy\u4f3d\u508c\u5200\u6cbb\u7642\u5f8c\u816b\u7624\u5927\u5c0f\u4ecd\u7121\u660e\u986f\u6539\u5584\uff0c\u56e0\u6b64\u53c8\u63a5\u53d7\u7b2c\u4e8c\u6b219.5Gy\u4f3d\u508c\u5200\u6cbb\u7642\uff0c\u81f3\u4eca\u5169\u5e74\u591a\u8ffd\u8e64\u7121\u5fa9\u767c\u60c5\u6cc1\u767c\u751f\u3002\u7b2c\u56db\u4f4d18\u6b72\u7537\u6027\u75c5\u60a3\u5176\u75c5\u7076\u4f4d\u70ba\u677e\u679c\u9ad4\uff0c\u63a5\u53d715Gy\u4f3d\u508c\u5200\u6cbb\u7642\uff0c\u81f3\u4eca\u4e09\u5e74\u816b\u7624\u63a7\u5236\u4ecd\u7a69\u5b9a\u3002\u7d93\u7531\u4e0a\u8ff0\u56db\u4f8b\u7684\u7d9c\u5408\u7d50\u679c\u4f86\u770b\uff0c\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u624b\u8853\u4e26\u4e0d\u9069\u5408\u7576\u4f5c\u4e2d\u6a1e\u795e\u7d93\u751f\u6b96\u7d30\u80de\u7624\u7684\u4e3b\u8981\u6cbb\u7642\u3002", "e": "The therapeutic approaches to intracranial germ cell tumors (GCTs) vary from craniospinal irradiation (CSI) to focal irradiation with or without chemotherapy. There were several cases reports in favor of the application of radiosurgery in the management of intracranial GCTs. In this report, four cases of presumed germinomas treated with Gamma Knife radiosurgery (GKRS) were presented. The first patient, a 25 years old gentleman with presumed pineal germinoma, had spinal seeding at 6 months after 15 Gy of GKRS. After salvage CSI, 4th cranial nerve radiation injury developed. The second patient, a 14 years old boy with basal ganglion germinoma and elevated serum \u03b2-HCG, received a 10 Gy upfront GKRS boost but declined the scheduled periventricular irradiation. In-field local recurrence developed at 7 months after the GKRS. After salvage periventricular irradiation, the patient suffered from mild neurological deficit with poor left limb coordination. The third patient, a 30 years old lady with presumed pineal germinoma, had a poor response to therapeutic trial of 10 Gy GKRS. She was given a second course of 9.5 Gy GKRS. The fourth patient, an 18 years old gentleman with presumably pineal germinoma, had tumor control at 3 years after 15 Gy of GKRS. Based on the outcome of these 4 cases, radiosurgery alone is not recommended as the primary treatment for intracranial GCTs."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200512-12-4-313-318-a", "title": "Craniopharyngioma in a 70-Year-Old Male: Case Report and Review of Literature", "keywords": "\u9871\u54bd\u7624;\u8001\u5e74\u4eba;\u624b\u8853;\u653e\u5c04\u6cbb\u7642 Craniopharyngioma;Elderly;Surgery;Radiotherapy", "c": "\u9871\u54bd\u7624\u662f\u4f4d\u65bc\u4e0b\u8996\u4e18\uff0d\u8166\u4e0b\u5782\u9ad4\u5340\u57df\u7684\u7f55\u898b\u8166\u90e8\u816b\u7624\uff0c\u901a\u5e38\u767c\u751f\u5728\u5152\u7ae5\u8207\u9752\u5c11\u5e74\u3002\u672c\u6587\u5831\u544a\u4e86\u4e00\u4f4d\u63a5\u53d7\u624b\u8853\u8207\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u4e03\u5341\u6b72\u7537\u6027\u9871\u54bd\u7624\u60a3\u8005\uff0c\u4e26\u4e14\u56de\u9867\u95dc\u65bc\u9871\u54bd\u7624\u7684\u6587\u737b\u8cc7\u6599\u3002", "e": "Craniopharyngiomas are rare brain tumors in the hypothalamo-pituitary region. They are most commonly diagnosed in the young age. We report a 70-year-old man with craniopharyngioma treated with surgery and radiotherapy, and also reviewed the literatures of craniopharyngiomas."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-167-180-a", "title": "Brain Stem Doses for Patients of T3/T4 Nasopharyngeal Carcinoma Treated by Bid Irradiation and Concomitant Chemotherapy", "keywords": "\u9f3b\u54bd\u764c;\u8166\u5e79\u653e\u5c04\u6cbb\u7642\u8010\u53d7\u5ea6;\u4e00\u5929\u5169\u6b21\u653e\u5c04\u6cbb\u7642 Nasopharyngeal carcinoma;Brain stem tolerance;Hyperfractionation radiation", "c": "\u76ee\u7684\uff1a\u6839\u64da\u6211\u5011\u904e\u53bb\u7684\u7d93\u9a57\u767c\u73fe\uff0c\u5c0d\u65bc\u5c40\u90e8\u56b4\u91cd\u6027\u7b2c\u4e09\u671f\u53ca\u7b2c\u56db\u671f\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u65bc\u9871\u5e95\u9aa8\u65b9\u5411\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u7bc4\u570d\u5b89\u5168\u8ddd\u96e2\u5fc5\u9808\u5927\u65bc\u4e00\u516c\u5206\u624d\u80fd\u9054\u5230\u826f\u597d\u4e4b\u5c40\u90e8\u63a7\u5236\u3002\u70ba\u4e86\u9054\u5230\u6b64\u76ee\u7684\uff0c\u90e8\u4efd\u8166\u5e79\u4e5f\u6703\u63a5\u53d7\u8207\u539f\u767c\u816b\u7624\u76f8\u8fd1\u4e4b\u9ad8\u5291\u91cf\uff1b\u70ba\u4e86\u6e1b\u5c11\u9ad8\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u5c0d\u8166\u5e79\u4e4b\u50b7\u5bb3\uff0c\u672c\u9662\u8a2d\u8a08\u4f7f\u7528\u4e00\u5929\u4e8c\u6b21\u653e\u5c04\u6cbb\u7642\u914d\u5408\u5316\u5b78\u6cbb\u7642\uff0c\u4ee5\u671f\u9054\u5230\u63d0\u9ad8\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u800c\u4e0d\u9020\u6210\u9577\u671f\u8166\u5e79\u53d7\u50b7\u4e4b\u7814\u7a76\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65bc1991\u5e749\u6708\u81f31998\u5e7412\u6708\uff0c\u7e3d\u5171\u670969\u4f4dT3\u3001T4\u9f3b\u54bd\u764c\u75c5\u4eba\u65bc\u548c\u4fe1\u91ab\u9662\u63a5\u53d7\u4e00\u5929\u4e8c\u6b21\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u3002\u539f\u767c\u816b\u7624\u63a5\u53d7\u4e00\u5929\u4e8c\u6b21\u653e\u5c04\u6cbb\u7642\uff0c\u4e00\u6b211.2 Gy\uff0c\u6bcf\u9031\u6cbb\u7642\u4e94\u5929\uff0c\u7e3d\u517174.4 Gy\u520662\u6b21\u7d66\u4e88\u3002\u5c0d\u65bc\u6bcf\u4e00\u500b\u75c5\u4eba\u4e4b\u653e\u5c04\u6cbb\u7642\u7bc4\u570d\u4e4b\u8a2d\u8a08\uff0c\u65bc\u4e00\u958b\u59cb\u4e4b\u5927\u7bc4\u570d\u6cbb\u7642\u81f340.8\u81f343.2 Gy\uff1b\u5b89\u5168\u8ddd\u96e2\u70ba15 mm\uff0c\u7b2c\u4e00\u6b21\u7e2e\u5c0f\u4e4b\u6cbb\u7642\u7bc4\u570d\u6cbb\u7642\u5291\u91cf\u81f360 Gy\uff0c\u5b89\u5168\u8ddd\u96e2\u5247\u964d\u70ba7 mm\u81f310 mm\u3002\u800c\u6700\u5f8c\u52a0\u5f37\u7167\u5c04\u4e4b14.4 Gy\uff0c\u5247\u5b89\u5168\u8ddd\u96e2\u964d\u70ba3\u81f37 mm\u300269\u4f4d\u75c5\u4eba\u670925\u4f4d\u75c5\u4eba\u65bc1996\u5e74\u4e4b\u5f8c\u63a5\u53d7\u6cbb\u7642\uff0c\u5176\u539f\u59cb\u6cbb\u7642\u8a08\u756b\u53ef\u4ee5\u7528\u76ee\u524d\u6211\u5011\u4e09\u5ea6\u7a7a\u9593\u7684\u6cbb\u7642\u8a08\u756b\u4f86\u5206\u6790\u5176\u8166\u5e79\u7684\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u3002\u901925\u4f4d\u75c5\u4eba\u4e2d\u5176\u4e2d5\u4f4d\u75c5\u4eba\u65bc\u4e09\u5e74\u5167\u56e0\u75be\u75c5\u6b7b\u4ea1\uff0c\u6240\u4ee5\u4e0d\u5217\u5165\u7d71\u8a08\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u81f3\u5c1149\u500b\u6708\u4ee5\u53ca\u8ffd\u8e64\u6642\u9593\u4e2d\u4f4d\u503c97\u500b\u6708\u7684\u8ffd\u8e64\uff0c\u901920\u4f4d\u75c5\u4eba\u7684\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba93.8%\uff0c\u6211\u5011\u53ea\u89c0\u5bdf\u5230\u5176\u4e2d\u4e00\u4f4d\u75c5\u4eba\u6709\u8f15\u5fae\u7684\u7b2c\u4e8c\u7d1a\u540c\u5074\u4e0a\u80a2\u9ebb\u75fa\u3002\u9019\u4e9b\u75c5\u4eba\u6c92\u6709\u4eba\u56e0\u8166\u5e79\u53d7\u50b7\u800c\u5c0e\u81f4\u6b7b\u4ea1\u3002\u5e73\u5747\u8166\u5e79\u63a5\u53d7\u6700\u9ad8\u5291\u91cf\u70ba75.12 Gy\u3002\u5e73\u5747\u8166\u5e79\u63a5\u53d7\u5927\u65bc50 Gy\u300155 Gy\u300160 Gy\u300165 Gy\u53ca70 Gy\u7684\u9ad4\u7a4d\u5206\u5225\u70ba10.32 ml\u30017.72 ml\u30015.67 ml\u30013.58 ml\u53cal.72 ml\u3002\n\u7d50\u8ad6\uff1a\u7531\u6211\u5011\u7684\u7d93\u9a57\uff0c\u4e00\u5929\u4e8c\u6b21\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u7d66\u4e88\u5c40\u90e8\u56b4\u91cd\u6027\u9f3b\u54bd\u764c\u4e4b\u75c5\u4eba\u8db3\u5920\u4e4b\u653e\u5c04\u7dda\u5291\u91cf\u4ee5\u9054\u826f\u597d\u5c40\u90e8\u63a7\u5236\u800c\u4e0d\u9020\u6210\u9577\u671f\u8166\u5e79\u529f\u80fd\u4e4b\u640d\u50b7\u3002", "e": "Purpose: Our prior study revealed that at least 1 cm safe margin at clivus direction is necessary to obtain good local control of nasopharyngeal carcinoma (NPC). We retrospectively studied whether hyperfractionation irradiation to treat T3/T4 NPC patients could decrease the long-term side effect to the brain stem.\nPatients and Methods: Sixty-nine patients with T3/T4 (American Joint Committee on Cancer, 1997 staging system) NPC were treated with concomitant chemotherapy and twice a day radiation followed by adjuvant chemotherapy between September 1991 and December 1998 in Koo Foundation Sun Yat-Sen Cancer Center, Taipei. The planning dose of radiation was 74.4 Gy in 62 fractions, twice a day, 5 days per week. Every patient had 15 mm safe margin at clivus direction in the initial field to 40.8-43.2 Gy, 7mm to 10 mm to 60Gy at the 2nd boost field, and 3-7 mm at the final boost field to a total dose of 74.4 Gy. Twenty-five patients were treated between 1996 and 1998; their previous treatment plan data could be retrieved for analysis in our current CMS (Computerized Medical Systems, INC) three dimension treatment planning system for dose volume histogram calculation of brain stem. Five patients died from disease within 3 years after completion of treatment were excluded from the analysis.\nResults: With a minimal and median follow-up of 49 and 97 months, respectively, 5-year local control rate of the 20 patients was 93.8%. Brain stem toxicity was observed in one of 20 patients with the manifestation of grade \u2161 sensory loss at ipsilateral upper limb. There was no treatment related death. The average maximal dose to brain stem was 75.12 Gy and mean dose was 35.56 Gy. The average volumes of brain stem dose more than 50 Gy, 55 Gy, 60 Gy, 65 Gy, and 70 Gy were 10.32 ml, 7.72 ml, 5.67 ml, 3.58 ml, and 1.72 ml, respectively.\nConclusion: Our data indicated that adequate irradiation dose could be given safely with hyperfractionation for T3/T4 NPC patients to achieve good local tumor control without significant long-term side effect to brain stem."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-181-189-a", "title": "\u7b2c\u4e00\u671f\u4e0b\u671f\u8207\u7b2c\u4e8c\u671f\u4e0a\u671f\u4e4b\u5b50\u5bae\u9838\u764c\u7d93\u4e0d\u540c\u6cbb\u7642\u6a21\u5f0f\u5f8c\u7684\u9577\u671f\u751f\u6d3b\u54c1\u8cea\u6bd4\u8f03", "keywords": "EORTC;\u751f\u6d3b\u54c1\u8cea;\u653e\u5c04\u6cbb\u7642;\u5b50\u5bae\u9838\u764c EORTC;Quality of life;Radiotherapy;Uterine cervical cancer", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u662f\u6bd4\u8f03\u4ee5\u4e0d\u540c\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u5c0d\u7b2c\u4e00\u671f\u4e0b\u671f\u6216\u7b2c\u4e8c\u671f\u4e0a\u671f\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u9577\u671f\u7684\u526f\u4f5c\u7528\u8207\u751f\u6d3b\u54c1\u8cea\u4e4b\u5dee\u7570\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7e3d\u5171\u6709\u5169\u6a5f\u69cb\u7684336\u4f4d\u7b2c\u4e00\u671f\u4e0b\u671f\u6216\u7b2c\u4e8c\u671f\u4e0a\u671f\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u88ab\u9080\u8acb\u53c3\u8207\u7814\u7a76\u3002\u75c5\u60a3\u5747\u5728\u6cbb\u7642\u7d50\u675f\u5f8c\u5169\u5e74\u4ee5\u4e0a\uff08\u4ecb\u65bc25\u81f3218\u500b\u6708\uff09\uff0c\u9078\u64c745-74\u6b72\u7684261\u4f4d\u4e2d\u3001\u8001\u5e74\u70ba\u7814\u7a76\u5c0d\u8c61\u3002\u4f9d\u6cbb\u7642\u65b9\u5f0f\u4e4b\u4e0d\u540c\u5340\u5206\u70ba\u624b\u8853\u6cbb\u7642\u3001\u653e\u5c04\u6cbb\u7642\u8207\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4e09\u7d44\u3002\u75c5\u60a3\u9808\u9805\u5bebEORTC QLQ C-30\u751f\u6d3b\u54c1\u8cea\u91cf\u8868\u53ca\u5b50\u5bae\u9838\u764c\u6cbb\u7642\u5f8c\u7684\u526f\u4f5c\u7528\u91cf\u8868\uff0c\u4e26\u4ee5\u6b64\u4f5c\u70ba\u751f\u6d3b\u54c1\u8cea\u8a55\u4f30\u4e4b\u4f9d\u64da\u3002\n\u7d50\u679c\uff1a\u5171\u6709\u516b\u9805\u526f\u4f5c\u7528\u5728\u7d71\u8a08\u4e0a\u9054\u5230\u986f\u8457\u5dee\u7570\uff0c\u5305\u62ec\uff1a\u8179\u75db\u3001\u8179\u7009\u3001\u4fbf\u79d8\u3001\u8840\u4fbf\u3001\u6392\u5c3f\u56f0\u96e3\u3001\u5c3f\u5931\u7981\u3001\u4e0b\u80a2\u6c34\u816b\u53ca\u81c9\u6f6e\u7d05\u3002\u5176\u4e2d\uff0c\u624b\u8853\u7d44\u65bc\u4fbf\u79d8\u6392\u5c3f\u56f0\u96e3\u53ca\u81c9\u6f6e\u7d05\u4e4b\u526f\u4f5c\u7528\u660e\u986f\u9ad8\u65bc\u5176\u4ed6\u5169\u7d44\uff0c\u653e\u7642\u7d44\u65bc\u8179\u7009\u53ca\u8840\u4fbf\u5169\u9805\u986f\u8457\u8f03\u9ad8\uff0c\u8853\u5f8c\u653e\u7642\u7d44\u5247\u6709\u8f03\u9ad8\u7684\u8179\u7009\u3001\u8840\u4fbf\u3001\u5c3f\u5931\u7981\u53ca\u4e0b\u80a2\u6c34\u816b\u4e4b\u526f\u4f5c\u7528\u3002\u4ee5EORTC QLQ-C30\u751f\u6d3b\u54c1\u8cea\u4f86\u6bd4\u8f03\uff0c\u9664\u4e86\u529f\u80fd\u6027\u5c3a\u5ea6\u4e0a\u7684\u8a8d\u77e5\u529f\u80fd\u548c\u793e\u6703\u529f\u80fd\u5169\u9805\uff0c\u4ee5\u53ca\u75c7\u72c0\u5c3a\u5ea6\u4e4b\u75b2\u5026\u3001\u5641\u5fc3\uff0f\u5614\u5410\u3001\u98df\u617e\u4e0d\u632f\u3001\u4fbf\u79d8\u548c\u7d93\u6fdf\u56f0\u96e3\u4e94\u9805\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u986f\u8457\u6c34\u6e96\u5916\uff0c\u5176\u9918\u591a\u9805\u751f\u6d3b\u54c1\u8cea\u6307\u6a19\u65bc\u4e09\u7d44\u9593\u5dee\u7570\u4e0d\u5927\uff0c\u5747\u672a\u9054\u986f\u8457\u610f\u7fa9\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\u7b2c\u4e00\u671f\u4e0b\u671f\u6216\u7b2c\u4e8c\u671f\u4e0a\u671f\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u4e0d\u540c\u6cbb\u7642\u6a21\u5f0f\u7684\u526f\u4f5c\u7528\u6709\u6240\u4e0d\u540c\uff0c\u4f46\u9577\u671f\u4e4b\u6574\u9ad4\u751f\u6d3b\u54c1\u8cea\u5dee\u7570\u4e0d\u5927\u3002\u672c\u6587\u6709\u52a9\u65bc\u81e8\u5e8a\u91ab\u5e2b\u8003\u91cf\u75c5\u60a3\u63a5\u53d7\u6cbb\u7642\u5f8c\u4e4b\u751f\u6d3b\u54c1\u8cea\u7684\u6539\u8b8a\uff0c\u4e5f\u53ef\u5c0d\u75c5\u60a3\u6cbb\u7642\u5f8c\u7684\u5fa9\u5065\u8207\u652f\u6301\u7167\u8b77\u4e0a\u6709\u6240\u5e6b\u52a9\u3002", "e": "Purpose: To compare the difference treatment modalities for complications and long-term quality of life (QoL) in patients with stage IB and stage IIA uterine cervical carcinoma.\nMaterials and Methods: Three hundred and thirty-six patients of two institutions were invited to participate in this study. Inclusive patients were follow-up at least 2 years after the completion of the treatment (follow-up periods: 25-218 months) and were between ages 45-74 years. According to the treatment modalities, they were divided into 3 groups: surgery (OP), radiation therapy (RT), and surgery with postoperative radiation therapy (OP+RT). All patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ C-30) and complications Questionnaire for the assessment of QoL.\nResults: Total 8 items of complicatons were statistically significant, including abdominal pain, diarrhea, constipation, blood stools, dysuria, urine incontience, edema of lower extremities and hot flush. Constipation, dysuria, and hot flush were statistically higher in OP group; diarrhea and blood stools were highter in RT group. Significant higher complications treated by OP+RT were: diarrhea, blood stools, urine incontience and edema of lower extremities. Comparison of EORTC QLQ-C30, the majority of items showed little difference among these three treatment modalities, except cognitive functioning and social functioning in functional scales and fatique, nausea/vomiting, poor appetite, constipation and economical difficult in symptoms scales.\nConclusion: Our study revealed the different complications in stage IB and Stage IIA uterine cervical cancer patients treated by different modalities, whereas long-term QoL seem little difference among these three different modalities. These data were helpful for clinical physician not only for selecting treatment modalities when concerning with QoL changes of the patients, but also for rehabilitation and supportive care of the patients after treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-191-198-a", "title": "Treatment Results and Prognostic Factors of Esthesioneuroblastoma (ENB)", "keywords": "\u77e5\u89ba\u795e\u7d93\u6bcd\u7d30\u80de\u7624;\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642 Esthesioneuroblastoma;Olfactory neuroblastoma;Radiotherapy", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u6709\u95dc\u65bc\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u4e4b\u6cbb\u7642\u6210\u679c\u8207\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1989\u5e74\u81f32004\u5e74\u5171\u670921\u4f4d\u8a3a\u65b7\u70ba\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u65bc\u672c\u79d1\u6cbb\u7642\uff0c\u5305\u62ec14\u4f4d\u7537\u6027\u82077\u4f4d\u5973\u6027\u3002\u75c5\u60a3\u5e74\u9f61\u5206\u5e03\u81ea17\u6b72\u81f388\u6b72\u3002\u6211\u5011\u5206\u6790\u4e86\u75c5\u60a3\u4e4b\u521d\u671f\u75c7\u72c0\u3001\u816b\u7624\u5927\u5c0f\u3001\u6cbb\u7642\u65b9\u5f0f\u3001\u8207\u5b58\u6d3b\u6642\u9593\u300210\u4f4d\u75c5\u60a3(48%)\u63a5\u53d7\u4e86\u50b3\u7d71\u5b9a\u4f4d\u65b9\u5f0f\u7684\u653e\u5c04\u6cbb\u7642\uff0c11\u4f4d\u75c5\u60a3(52%)\u63a5\u53d7\u4e86\u7acb\u9ad4\u5b9a\u4f4d\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u60a3\u4e4b\u751f\u6d3b\u6d3b\u52d5\u7a0b\u5ea6\u8a55\u4f30\u4f9d\u7167Karnofsky Performance Scale (KPS)\u7d00\u9304\u3002\u816b\u7624\u4e4b\u5206\u671f\u4f9d\u64daKadish\u5206\u671f\u3002\n\u7d50\u679c\uff1a\u5728\u5206\u6790\u768421\u4f4d\u75c5\u60a3\u4e2d2\u4f4d\u75c5\u60a3\u70baA\u671f\uff0c3\u4f4d\u70baB\u671f\uff0c16\u4f4d\u70baC\u671f\u3002\u572835\u500b\u6708\u7684\u5e73\u5747\u8ffd\u8e64\u6642\u9593\u5f8c\uff0c\u67094\u4f4d\u75c5\u60a3\u5b58\u6d3b\uff0c\u53e64\u4f4d\u5b58\u6d3b\u4f46\u6709\u816b\u7624\u30026\u4f4d\u75c5\u60a3\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c\u53e6\u67095\u4f4d\u75c5\u60a3\u7522\u751f\u9060\u7aef\u8f49\u79fb\u3002\u572815\u4f4d\u767c\u75c5\u521d\u671f\u6c92\u6709\u9838\u90e8\u6dcb\u5df4\u816b\u5927\u4e26\u6c92\u6709\u63a5\u53d7\u9810\u9632\u6027\u9838\u90e8\u7167\u5c04\u7684\u75c5\u60a3\u4e2d\uff0c3\u4f4d(20%)\u767c\u751f\u4e86\u9838\u90e8\u5fa9\u767c\u3002\u6574\u9ad45\u5e74\u5b58\u6d3b\u7387\u70ba42%\uff0c5\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba17%\u3002\u5728\u55ae\u8b8a\u6578\u5206\u6790\u4e2d\u767c\u73fe\uff0c\u75c5\u60a3\u5e74\u9f61\u8207\u767c\u75c5\u521d\u671f\u4e4bKPS\u70ba\u5f71\u97ff\u5b58\u6d3b\u7387\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7814\u7a76\u6210\u679c\u8207\u5148\u524d\u6587\u737b\u4e2d\u5831\u544a\u904e\u7684\u6210\u679c\u76f8\u8fd1\u3002\u6211\u5011\u767c\u73fe\u75c5\u60a3\u5e74\u9f61\u8207KPS\u70ba\u5f71\u97ff\u5b58\u6d3b\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u7531\u65bc\u9838\u90e8\u5fa9\u767c\u7387\u5728\u55c5\u795e\u7d93\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u4e2d\u76f8\u5c0d\u751a\u9ad8\uff0c\u9810\u9632\u6027\u7684\u9838\u90e8\u7167\u5c04\u4f3c\u4e4e\u5c0d\u75c5\u60a3\u6709\u5e6b\u52a9\u3002", "e": "Purpose: To analyze treatment results and prognostic factors of esthesioneuroblastoma (ENB).\nMaterials and methods: Twenty-one patients with diagnosis of ENB treated between 1989 and 2004 were reviewed. There were 14 men and 7 women. Patients' age ranged from 17 to 88. Presenting symptoms/signs, tumor extent, treatment modalities, survival time, and disease-free survival time were recorded. Ten patients (48%) were treated with conventional two-dimensional technique and 11 (52%) with three-dimensional conformal radiotherapy (3D-CRT). Patient's performance status was scored with Karnofsky performance scale (KPS). Tumor extent was staged using Kadish system.\nResults: Of the 21 patients, 2 were Stage A, 3 Stage B, and 16 Stage C. After a mean follow-up time of 35 months, 4 patients are alive with disease and 4 are alive without disease Locoregional failure occurred in 6 patients and distant metastases were noted in 5 patients. Of the 15 initially node-negative patients who did not receive elective neck irradiation, 3 (20%) failed in the neck. Five-year overall survival rate was 42% and 5-year disease free survival rate was 17%. In univariate analysis, age (\u226660 vs. \uff1e60) and KPS (\u226780 vs. \uff1c80) were significant prognostic factors for overall survival (p=0.019, p=0.000, respectively) and disease-free survival (p=0.021, p=0.001, respectively).\nConclusion: Treatment results in our series are compatible with others. We find that age and KPS are significant prognostic factors in predicting the outcome. Due to relatively high incidence of neck failure, elective neck irradiation seems worthy to be considered in selective patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-199-206-a", "title": "Radiotherapy in the Management of Localized Classic Kaposi", "keywords": "\u50b3\u7d71\u6027\u5361\u6ce2\u897f\u6c0f\u8089\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u5291\u91cf;\u6cbb\u7642\u53cd\u61c9 Classic Kaposi", "c": "\u76ee\u7684\uff1a\u50b3\u7d71\u6027\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u662f\u7de9\u6162\u9032\u5c55\u7684\u816b\u7624\uff0c\u5176\u76db\u884c\u5728\u6771\u6b50\u53ca\u5730\u4e2d\u6d77\u6cbf\u5cb8\u4eba\u7a2e\uff0c\u4f46\u662f\u751a\u5c11\u767c\u751f\u65bc\u5176\u4ed6\u7a2e\u65cf\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u50c5\u6709\u5c40\u90e8\u5c11\u6578\u75c5\u7076\u7684\u75c5\u4eba\u53ef\u4ee5\u63d0\u4f9b\u89e3\u9664\u75c7\u72c0\u53ca\u816b\u7624\u63a7\u5236\uff0c\u4f46\u662f\u5c0d\u65bc\u5927\u7bc4\u570d\u7684\u6cbb\u7642\u4e26\u4e0d\u5bb9\u6613\u3002\u672c\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u5728\u8a55\u4f30\u50b3\u7d71\u6027\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u5c0d\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u5c40\u90e8\u63a7\u5236\u53ca\u75c7\u72c0\u89e3\u9664\u7684\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1994\u5e748\u6708\u81f32004\u5e7411\u6708\u9593\uff0c\u5f9e\u672c\u9662\u764c\u767b\u5ba4\u7684\u8cc7\u6599\uff0c48\u4f4d\u6709\u7d44\u7e54\u5b78\u8b49\u660e\u70ba\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u7684\u75c5\u60a3\u88ab\u9078\u51fa\u56de\u9867\u3002\u7b26\u5408\u8cc7\u683c\u7684\u670911\u4f4d\u75c5\u60a3\uff0c\u7686\u975e\u4eba\u985e\u514d\u75ab\u4e0d\u5168\u75c5\u6bd2\u967d\u6027\u53ca\u63a5\u53d7\u5668\u5b98\u79fb\u690d\u8005\u3002\u5c40\u90e8\u6cbb\u7642\u7684\u65b9\u5f0f\u5229\u7528\u923760\uff0c\u767e\u842c\u96fb\u5b50\u4f0f\u7279\u80fd\u91cf\u7684\u5149\u5b50\u6216\u96fb\u5b50\u5c04\u7dda\u3002\u7531\u81e8\u5e8a\u72c0\u6cc1\u6c7a\u5b9a\u7167\u91ce\u7684\u7bc4\u570d\uff0c\u7167\u5c04\u7684\u6b21\u6578\u53ca\u7e3d\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u7e3d\u517111\u4f4d\u75c5\u60a3\u670920\u500b\u75c5\u7076\u9032\u5165\u9019\u500b\u7814\u7a76\u3002\u5176\u4e2d9\u4f4d\u662f\u7537\u6027\uff0c2\u4f4d\u662f\u5973\u6027\uff0c\u5e73\u5747\u5e74\u9f61\u70ba66\u6b72\u3002\u5b58\u6d3b\u75c5\u4eba\u7684\u8ffd\u8e64\u671f\u70ba4\u81f344\u500b\u6708\uff08\u4e2d\u4f4d\u6578\u70ba17\u500b\u6708\uff09\u3002\u6cbb\u7642\u7684\u76ee\u6a19\u5291\u91cf\u5f9e30 Gy/10\u6b21\u523040 Gy/20\u6b21\uff0c\u4f46\u662f\u67094\u500b\u75c5\u7076\uff082\u4f4d\u75c5\u60a3\uff09\u6709\u4f8b\u5916\u60c5\u5f62\u3002\u5728\u6240\u6709\u768420\u500b\u6cbb\u7642\u75c5\u7076\u4e2d\uff0c\u670915\u500b\u6cbb\u7642\u75c5\u7076\u6709\u5b8c\u5168\u6d88\u9000\u53cd\u61c9(75%)\uff0c\u800c\u5176\u4ed6\u7686\u70ba\u90e8\u5206\u6d88\u9000\u53cd\u61c9\u3002\u7121\u5fa9\u767c\u671f\u9593\u7684\u4e2d\u4f4d\u6578\u81f3\u76ee\u524d\u70ba\u6b62\u5c1a\u672a\u7372\u5f97\u30023\u500b\u6708\uff0c6\u500b\u6708\u53ca\u4e00\u5e74\u534a\u7684\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba95%\uff0c74%\u548c74%\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u9054\u5230\u75c7\u72c0\u89e3\u9664\uff0c\u800c\u6162\u6027\u7684\u526f\u4f5c\u7528\u5305\u542b\u6ef2\u6db2\u6027\u76ae\u819a\u708e\u6216\u5404\u7a2e\u7a0b\u5ea6\u7684\u6c34\u816b\u662f\u5f88\u5c11\u767c\u751f\u548c\u8f15\u5fae\u7684\u3002\n\u7d50\u8ad6\uff1a\u5118\u7ba1\u6709\u8f15\u5fae\u7684\u6c34\u816b\u548c\u8272\u7d20\u6c88\u8457\u7684\u6162\u6027\u526f\u4f5c\u7528\uff0c\u5c40\u90e8\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u50b3\u7d71\u6027\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u662f\u8010\u53d7\u6027\u4f73\u7684\u4e14\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u672c\u7bc7\u8cc7\u6599\u5efa\u8b70\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u5c40\u90e8\u7684\u975e\u4eba\u985e\u514d\u75ab\u4e0d\u5168\u75c5\u6bd2\u76f8\u95dc\u7684\u50b3\u7d71\u6027\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u662f\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: Classic Kaposi's sarcoma (CKS) is a prevalent indolent neoplasm among Eastern European and Mediterranean origin, but is rare in the other ethnic groups.\nRadiotherapy may provide symptom relief and tumor control in patients who have a few lesions in a limited area. This study was to assess the effectiveness of radiotherapy in the local control and the symptom relief of the CKS.\nMaterials and Methods: Between August 1994 and November 2004, 48 patients with histologically proven Kaposi's sarcoma were selected for review from the Cancer Registry of National Taiwan University Hospital, eleven patients were both human immunodeficiency virus (HIV)-negative and non organ-transplant recipients. These patients received radiotherapy and were eligible for this study. Treatment methods consisted of local radiotherapy using Cobalt-60 teletherapy, megavoltage photon beam or electron beam. The treatment fields, fractionation, and total dose of radiation were determined on the clinical basis.\nResults: A total of 11 patients (20 lesions) were enrolled into this study. There were 9 men and 2 women, with a mean age of 66 years. Median follow-up for surviving patients ranged from 4 to 44 months (median, 17 months). Target dose ranged from 30 Gy in ten fractions to 40 Gy in twenty fractions, with the exceptions in four lesions (2 patients). The complete response rate was 75% (15 lesions), and the partial response was evident in the remaining lesions. Median free from recurrence interval has not been reached. The 3-month, 6-month and 1.5-year local regional control rates were 95%, 74% and 74%, respectively. Symptom relief was achieved in all patients. Chronic complications including exudative dermatitis and variable degrees of edema were rare and mild.\nConclusion: With the few late complication of mild edema and hyperpigmentation, local radiotherapy to CKS was well tolerated and effective. These data suggest that the local radiotherapy remains the effective treatment modality for non-HIV related localized classic Kaposi's sarcoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-207-213-a", "title": "Long-Term Survival with No Evidence of Brain Metastasis in 6 Patients of Limited-Stage Small Cell Lung Cancer Receiving Prophylactic Cranial Irradiation", "keywords": "\u5c0f\u7d30\u80de\u80ba\u764c;\u9810\u9632\u6027\u8166\u90e8\u653e\u5c04\u7dda\u7167\u5c04;\u9577\u671f\u8ffd\u8e64;\u8166\u90e8\u8f49\u79fb Small Cell Lung Cancer;Prophylactic Cranial Irradiation;Long-term Follow-up;Brain Metastasis", "c": "\u76ee\u7684\uff1a\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u5728\u521d\u59cb\u6cbb\u7642\u4e4b\u5f8c\u82e5\u9054\u5230\u5c40\u90e8\u5b8c\u5168\u7de9\u89e3\uff0c\u901a\u5e38\u6703\u5efa\u8b70\u63a5\u53d7\u9810\u9632\u6027\u8166\u90e8\u653e\u5c04\u7dda\u7167\u5c04\u3002\u5728\u672c\u6587\u4e2d\uff0c\u6211\u5011\u5831\u544a\u4e866\u4f4d\u4fb7\u9650\u578b\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u63a5\u53d7\u9810\u9632\u6027\u8166\u90e8\u7167\u5c04\u5f8c\uff0c\u6301\u7e8c3\u5e74\u4ee5\u4e0a\u7121\u8166\u90e8\u8f49\u79fb\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1998\u5e7411\u6708\u81f32002\u5e74l\u6708\uff0c\u67096\u4f4d\u8a3a\u65b7\u70ba\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u75c5\u4eba\u3002\u5176\u4e2d5\u4f4d(83%)\u662f\u7537\u6027\uff0cl\u4f4d(17%)\u662f\u5973\u6027\u3002\u75c5\u4eba\u7684\u5e73\u5747\u5e74\u9f61\u662f61\u6b72\u3002\u6240\u6709\u75c5\u4eba\u7684\u764c\u75c7\u671f\u5225\u7686\u70ba\u4fb7\u9650\u671f\u5c0f\u7d30\u80de\u80ba\u764c\u3002\u6839\u64daECOG (Eastern Cooperative Oncology Group) performance status\u72c0\u614b\u4f86\u8a55\u5206\uff0cl\u4f4d\u75c5\u4eba(17%)\u662fECOG 0\uff0c4\u4f4d(66%)\u662fECOG 1\uff0cl\u4f4d(17%)\u662fECOG 2\u3002\u6240\u6709\u75c5\u4eba\u7686\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5316\u5b78\u6cbb\u7642\u7684\u85e5\u7269\u70baCisplatin\u8207Etoposide\u3002\u80ba\u90e8\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba54 Gy\u3002\u6240\u67096\u4f4d\u75c5\u4eba\u7686\u9054\u5230\u5c40\u90e8\u5b8c\u5168\u7de9\u89e3\uff0c\u4e26\u4e14\u63a5\u53d7\u7e3d\u5291\u91cf\u4e2d\u4f4d\u6578\u70ba36 Gy\u7684\u9810\u9632\u6027\u8166\u90e8\u653e\u5c04\u7dda\u7167\u5c04\u3002\n\u7d50\u679c\uff1a\u6240\u67096\u4f4d\u75c5\u4eba\u5728\u6700\u8fd1\u4e00\u6b21\u8ffd\u8e64\u4e2d\u7686\u5b58\u6d3b\uff0c\u4e26\u4e14\u6301\u7e8c3\u5e74\u4ee5\u4e0a\u7121\u8166\u90e8\u8f49\u79fb\u3002\u6700\u9577\u7684\u8ffd\u8e64\u6642\u9593\u70ba75\u500b\u6708\u30023\u4f4d\u75c5\u4eba(50%)\u6709\u8166\u90e8\u4ee5\u5916\u7684\u8f49\u79fb\uff0c\u5305\u62ec\u4e862\u4f4d\u75c5\u4eba\u6709\u9aa8\u8f49\u79fb\uff0cl\u4f4d\u75c5\u4eba\u6709\u814e\u81df\u8f49\u79fb\u3002\n\u7d50\u8ad6\uff1a\u4fb7\u9650\u578b\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u5728\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u82e5\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u4e26\u4e14\u63a5\u53d7\u9810\u9632\u6027\u8166\u90e8\u7167\u5c04\uff0c\u53ef\u4ee5\u9054\u5230\u9577\u671f\u5b58\u6d3b\u4e14\u7121\u8166\u90e8\u8f49\u79fb\u7684\u7d50\u679c\u3002\u4e0d\u904e\uff0c\u4e00\u534a\u4ee5\u4e0a\u7684\u75c5\u4eba\u4ecd\u820a\u6709\u8166\u90e8\u4ee5\u5916\u7684\u9060\u7aef\u8f49\u79fb\u3002\u76f8\u5c0d\u65bc\u5176\u4ed6\u90e8\u4f4d\u7684\u8f49\u79fb\uff0c\u9810\u9632\u6027\u8166\u90e8\u653e\u5c04\u7dda\u7167\u5c04\u80fd\u5920\u6709\u6548\u907f\u514d\u8166\u90e8\u8f49\u79fb\u7684\u767c\u751f\u3002", "e": "Background: Prophylactic cranial irradiation (PCI) is generally suggested for limited-staged small cell lung cancer (SCLC) patients with complete local response to initial therapies. We presented 6 patients with no evidence of brain metastasis for more than 3-year follow-up after receiving PCI.\nMaterials and Methods: From November 1998 through January 2002, 6 patients were diagnosed as SCLC in our institution. Five patients (83%) were male and 1 (17%) was female. The median age at diagnosis was 61 years. All patients were classified as limited stage. According to ECOG (Eastern Cooperative Oncology Group) performance status, 1 patient (17%) was scaled to 0, 4 patients (66%) were 1, and 1 patient (17%) was 2. All patients were treated with concurrent chemoradiotherapy (CCRT). Chemotherapy regimens consisted of cisplatin and etoposide. The median cumulative thoracic irradiation dose was 54Gy. All 6 patients achieved complete local response after CCRT, and then they received PCI with median cumulative dose of 36Gy.\nResults: All patients were alive and had a long-term follow-up more than 3 years with no evidence of brain metastasis. The longest follow-up duration was 75 months. Three patients (50%) had metastasis to distant sites other than brain, including 2 patients with bone and one patient with kidney metastases.\nConclusions: In our study, long-term survival with no evidence of brain metastasis was achieved in patients of SCLC receiving PCI after complete local response to initial treatments of CCRT. Distant metastases to other sites still developed in half of these patients. PCI might have benefits in preventing distant metastasis to brain on the respect of failures to other distant sites with long-term follow-up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-215-226-a", "title": "\u52d5\u614b\u6e96\u76f4\u5100\u8449\u7247\u65bc\u865b\u64ec\u6954\u5f62\u6ffe\u677f\u4e4b\u7814\u7a76", "keywords": "\u6e96\u76f4\u5100\u8449\u7247;\u6954\u5f62\u6ffe\u677f Multileaf;Wedge", "c": "\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u7684\u5747\u52fb\u5f71\u97ff\u764c\u75c7\u60a3\u8005\u7684\u816b\u7624\u63a7\u5236\u7387\u548c\u6b63\u5e38\u7d44\u7e54\u526f\u4f5c\u7528\u767c\u751f\u7387\uff0c\u6240\u4ee5\u6cbb\u7642\u8a08\u5283\u7684\u64ec\u5b9a\u662f\u4ee5\u9ad8\u5291\u91cf\u5340\u5747\u52fb\u5206\u5e03\u65bc\u6cbb\u7642\u9776\u5340\u4e14\u5468\u570d\u6b63\u5e38\u7d44\u7e54\u7684\u5291\u91cf\u6108\u4f4e\u70ba\u52aa\u529b\u7684\u76ee\u6a19\u3002\u4f46\u7531\u65bc\u4eba\u9ad4\u5404\u90e8\u4f4d\u7d44\u7e54\u53ca\u8f2a\u5ed3\u7684\u5dee\u7570\u6027\u5f80\u5f80\u9020\u6210\u5291\u91cf\u7684\u4e0d\u5747\u52fb\u5206\u5e03\u3002\u5728\u50b3\u7d71\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u85c9\u7531\u5be6\u9ad4\u7684\u6954\u5f62\u6ffe\u677f\u4ee5\u88dc\u511f\u5291\u91cf\u7684\u4e0d\u5747\u52fb\u3002\u7136\u800c\u5be6\u9ad4\u7684\u6954\u5f62\u6ffe\u677f\u6709\u6954\u5f62\u89d2\u5ea6\u3001\u7167\u91ce\u5927\u5c0f\u7684\u9650\u5236\u4e26\u50c5\u6709\u4e00\u7dad\u7684\u88dc\u511f\u6548\u679c\u3002\u672c\u8ad6\u6587\u7814\u7a76\u7684\u76ee\u7684\u5373\u5728\u767c\u5c55\u51fa\u4e00\u500b\u4e8c\u7dad\u7684\u52d5\u614b\u6954\u5f62\u6ffe\u677f\uff0c\u4e14\u89d2\u5ea6\u8207\u7167\u91ce\u53f2\u8f03\u50b3\u7d71\u6ffe\u677f\u5bec\u5ee3\uff0c\u4ee5\u5229\u653e\u5c04\u6cbb\u7642\u9700\u8981\uff0c\u4f7f\u60a3\u8005\u53ef\u4ee5\u63a5\u53d7\u5230\u53f2\u5747\u52fb\u7684\u5291\u91cf\u3002\n\u85c9\u7531\u8a08\u7b97\u7684\u6954\u5f62\u5291\u91cf\u5716\u8b5c\u8f49\u63db\u6210\u6cbb\u7642\u8a08\u5283\u6a5f\u7684\u901a\u91cf\u5716\u8b5c\u7522\u751f\u8449\u7247\u79fb\u52d5\u7684\u57f7\u884c\u6a94\uff0c\u672c\u8ad6\u6587\u5229\u7528\u52d5\u614b\u6e96\u76f4\u5100\u7684\u8449\u7247\u79fb\u52d5\u5f62\u6210\uff0d\u975e\u5be6\u9ad4\u7684\u52d5\u614b\u6954\u5f62\u6ffe\u677f\uff0c\u4e26\u4ee5\u5047\u9ad4\u9a57\u8b49\u5176\u5291\u91cf\u66f2\u7dda\u8207\u7d55\u5c0d\u5291\u91cf\u7684\u6e96\u78ba\u6027\u3002\u7d50\u679c\u8a3c\u5be6\u5728X\u8ef8\u541145\u00b0\u300115\u00b038\u00b0Y\u8ef8\u541120\u00b0\u300130\u00b0\u7684\u52d5\u614b\u6954\u5f62\u6ffe\u677f\u5291\u91cf\u66f2\u7dda\u7684\u6700\u5927\u8aa4\u5dee\u5206\u5225\u662f1.8%\u30011.7%\u3001-1.8%\u3001-2.6%\u3001-2.3%\u3002\u540c\u6642\u5177X\u8ef8\u541145\u00b0Y\u8ef8\u541115\u00b0\u7684\u4e8c\u7dad\u52d5\u614b\u6954\u5f62\u6ffe\u677f\uff0c\u5176\u4e8c\u7dad\u7684\u7b49\u5291\u91cf\u66f2\u7dda\u8aa4\u5dee\u4e5f\u5c0f\u65bc2%\u53ca2 mm\u3002\u7d55\u5c0d\u5291\u91cf\u9a57\u8b49\u5728\u5404\u89d2\u5ea6\u7684\u52d5\u614b\u6954\u5f62\u6ffe\u677f\u7d66\u4e88\u5291\u91cf\u8aa4\u5dee\u4e5f\u90fd\u4e0d\u5927\u65bc3%\u3002\n\u52d5\u614b\u6954\u5f62\u6ffe\u677f\u53ef\u4ee5\u914d\u5408\u73fe\u884c\u7684CadPlan\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u6a5f\u9032\u884c\u5291\u91cf\u66f2\u7dda\u6a21\u64ec\uff0c\u70ba\u60a3\u8005\u63d0\u4f9b\u4e00\u66f4\u597d\u4e14\u6e96\u78ba\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u3002", "e": "Dose uniformity is directly related to tumor control probability (TCP) and normal tissue complication probability (NTCP). An ideal situation is one in which a uniform high dose is focused on the tumor target region and normal tissue surrounding the target volume receives minimal radiation. Dose distribution and uniformity must take into account the irregular contours and density changes within the body, especially the head, neck, and breast. A physical wedge has been used to compensate for irregular contours during traditional treatment, but a physical wedge is limited by its fixed angle and size. In addition, it cannot compensate for two dimensions simultaneously. We have developed a two-dimensional dynamic wedge to overcome these limitations.\nA wedge-shaped dose map was calculated for this study. The dose map was transferred to a fluence map in a CadPlan treatment planning program to generate a multileaf motion file. We created 6 dynamic wedges and verified them by phantom measurements. The maximum differences in the beam profiles between the calculated values and the measured values were 1.8%, 1.7%, and -1.8% when measured for wedges at 45 degrees, 15 degrees, and 38 degrees in the X direction, and -2.6% and -2.3% when measured for wedges at 20 and 30 degrees in the Y direction. The differences between the isodose curves for the two-dimensional dynamic wedges were less than 2% and 2mm. Absolute doses also showed good agreement between calculated and measured values in this study such that all differences were less than 3%.\nThe two-dimensional dynamic wedge developed in this study may be valuable for simulating isodose curves and can be used for CadPlan treatment planning which is currently used in many hospitals."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-227-233-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u9a57\u8b49", "keywords": "IMRT;\u6cbb\u7642\u8a08\u756b\u9a57\u8b49;\u54c1\u8cea\u4fdd\u8b49;\u81a0\u7247\u5291\u91cf\u91cf\u6e2c IMRT;Treatment verification;Quality assurance;Film dosimetry", "c": "\u76ee\u7684\uff1a\u5f37\u5ea6\u8abf\u63a7\u5f0f\u653e\u5c04\u6cbb\u7642(Intensity-modulated radiation therapy\uff0cIMRT)\u662f\u4e00\u9805\u5168\u65b0\u7684\u6cbb\u7642\u6280\u8853\uff0c\u85c9\u7531\u9006\u5411\u5f0f\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u53ca\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u7684\u5bc6\u5207\u914d\u5408\uff0c\u53ef\u4ee5\u88fd\u9020\u51fa\u524d\u6240\u672a\u6709\u7684\u6cbb\u7642\u5291\u91cf\u5206\u4f48\uff0c\u4f7f\u5371\u6025\u5668\u5b98\u5728\u653e\u5c04\u6cbb\u7642\u7684\u904e\u7a0b\u4e2d\u63a5\u53d7\u5230\u8f03\u4f4e\u7684\u5291\u91cf\u3002\u6b64\u5916\uff0c\u5728\u4fdd\u8b77\u6b63\u5e38\u7d44\u7e54\u7684\u540c\u6642\uff0c\u4e26\u4e0d\u6703\u5f71\u97ff\u5230\u816b\u7624\u6240\u8a72\u63a5\u53d7\u7684\u5291\u91cf\u3002\u4f46\u662f\u5728\u6b64\u8907\u96dc\u7684\u6280\u8853\u4e0b\uff0c\u5291\u91cf\u5206\u4f48\u7684\u9a57\u8b49\u4fbf\u6210\u70ba\u6975\u70ba\u95dc\u9375\u7684\u5de5\u4f5c\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u4fbf\u662f\u898f\u5283\u4e00\u5957\u5291\u91cf\u9a57\u8b49\u7684\u65b9\u6cd5\uff0c\u4ee5\u78ba\u4fdd\u6cbb\u7642\u7684\u54c1\u8cea\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4f7f\u7528Varian 21EX\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u642d\u914d120\u7247\u591a\u8449\u5f0f\u6e96\u76f4\u5100\uff0c\u53ef\u7522\u751f6 MV\u53ca10 MV\u5c04\u675f\u3002\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u662f\u4f7f\u7528Varian Eclipse system (Ver. 7.1)\u3002\u5291\u91cf\u9a57\u8b49\u7a0b\u5e8f\u5206\u4e09\u968e\u6bb5\u9032\u884c\uff0c\u4e00\u3001\u75c5\u60a3\u6cbb\u7642\u8a08\u756b\u5b8c\u6210\u5f8c\u5229\u7528\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u7684\u9a57\u8b49\u8a08\u756b\u529f\u80fd(create verification plan)\u8f49\u690d\u5230\u56fa\u614b\u6c34\u5047\u9ad4\uff0830\u00d730\u00d720\u516c\u5206\uff09\u3002\u5206\u70ba\u9ede\u5291\u91cf\u9a57\u8b49\u53ca\u5e73\u9762\u5291\u91cf\u5206\u4f48\u9a57\u8b49\u3002\u9ede\u5291\u91cf\u9a57\u8b49\u8207\u5be6\u969b\u8a08\u756b\u6709\u76f8\u540c\u7684\u5c04\u675f\u5b89\u6392\uff0c\u800c\u5e73\u9762\u5291\u91cf\u5206\u4f48\u9a57\u8b49\u5247\u5c07\u6240\u6709\u5c04\u675f\u7686\u8a2d\u5b9a\u5728\u5782\u76f4\u5411\u4e0b\u7684\u89d2\u5ea6\u4f86\u7d66\u4e88\u5291\u91cf\u3002\u4e8c\u3001\u5206\u6790\u6b64\u8a08\u756b\u5728\u5047\u9ad4\u5167\u7684\u5291\u91cf\u5206\u4f48\uff0c\u9078\u64c7\u5291\u91cf\u8b8a\u5316\u68af\u5ea6\u8f03\u70ba\u7de9\u548c\u7684\u5340\u57df\u4f5c\u70ba\u9ede\u5291\u91cf\u91cf\u6e2c\u7684\u53c3\u8003\u9ede\u3002\u5e73\u9762\u5291\u91cf\u5206\u4f48\u9a57\u8b49\u7684\u53c3\u8003\u5e73\u9762\u5247\u9078\u64c7\u5728\u7b49\u4e2d\u5fc3\u9ede\u7684\u4f4d\u7f6e\u3002\u4e09\u3001\u4ee5\u6e38\u96e2\u8154\u5291\u91cf\u91cf\u6e2c\u7cfb\u7d71\u5be6\u969b\u91cf\u6e2c\u9a57\u8b49\u8a08\u756b\u7684\u53c3\u8003\u9ede\u5291\u91cf\u503c\uff0c\u4e26\u4e14\u8207\u96fb\u8166\u8a08\u7b97\u503c\u505a\u6bd4\u8f03\u3002\u4ee5\u81a0\u7247\u3001\u96f7\u5c04\u6383\u7784\u5100\u53caDoselab\u81a0\u7247\u5291\u91cf\u5206\u6790\u8edf\u9ad4\uff0c\u5206\u6790\u53ca\u6bd4\u8f03\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u8a08\u7b97\u7684\u4e8c\u5ea6\u7a7a\u9593\u5e73\u9762\u5291\u91cf\u5206\u4f48\u8207\u5be6\u969b\u7684\u5291\u91cf\u5206\u4f48\u7684\u5dee\u7570\u3002\n\u7d50\u679c\uff1a\u5728\u9ede\u5291\u91cf\u91cf\u6e2c\u65b9\u9762\uff0c\u5206\u6790124\u4f4d\u75c5\u60a3\u7684\u8cc7\u6599\uff0c\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u6bd4\u8f03\uff0c\u5176\u5dee\u7570\u7686\u5728\u00b16%\u4e4b\u5167\uff0c\u5176\u4e2d89%\u7684\u75c5\u60a3\u5291\u91cf\u5dee\u7570\u5c0f\u65bc\u00b14%\u3002\u5728\u4e8c\u5ea6\u7a7a\u9593\u5e73\u9762\u5291\u91cf\u5206\u4f48\u65b9\u9762\uff0c\u6bcf\u55ae\uff0d\u7167\u91ce\u7684\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u4f48\uff0c\u6e2c\u91cf\u503c\u8207\u8a08\u7b97\u503c\u7686\u6709\u826f\u597d\u543b\u5408\u3002\n\u7d50\u8ad6\uff1a\u55ae\u9ede\u5291\u91cf\u91cf\u6e2c\u53ef\u4ee5\u63d0\u4f9b\u6e96\u78ba\u7684\u5291\u91cf\u5dee\u7570\u6bd4\u8f03\uff0c\u78ba\u4fdd\u6cbb\u7642\u5291\u91cf\u7684\u6e96\u78ba\u3002\u4e8c\u5ea6\u7a7a\u9593\u5e73\u9762\u5291\u91cf\u5206\u4f48\u7684\u6bd4\u8f03\uff0c\u53ef\u4ee5\u78ba\u8a8dIMRT\u6cbb\u7642\u5728\u5c04\u675f\u5e73\u9762\u5f37\u5ea6\u7684\u5206\u4f48\u3002\u672c\u7814\u7a76\u7684\u7d50\u679c\u8b49\u5be6\u6240\u4f7f\u7528\u7684\u65b9\u6cd5\u53ef\u4ee5\u7528\u65bc\u6821\u9a57IMRT\u6cbb\u7642\u8a08\u756b\uff0c\u4f46\u662f\u5c0d\u65bc\u9ad4\u5167\u4e0d\u5747\u8cea\u7d44\u7e54\uff0c\u5982\u80ba\u81df\u3001\u7a7a\u8154\u53ca\u9aa8\u9abc\u7b49\u90e8\u4f4d\u4e4b\u5291\u91cf\uff0c\u5c1a\u6709\u5f85\u9032\u4e00\u6b65\u767c\u5c55\u5291\u91cf\u9a57\u8b49\u4e4b\u65b9\u6cd5\u3002", "e": "Purpose: Intensity modulated radiation therapy (IMRT) represents one of the most significant technical advances in radiation therapy. By using the inverse treatment planning system and mulitileaf collimator, it allows the clinical implementation of highly conformal dose distributions for target coverage and adjacent normal tissues sparing. However, these advances do not come without a risk. The clinical success or failure of each institution's IMRT program depends on the correct delivery of 3D dose distributions calculated by the planning system to the correct location in the patient. The objective of this study is to establish a dose verification procedure for IMRT planning.\nMaterials and Methods: A Varian 21EX linac with the 120 leaf multileaf collimator operated in 6 MV and 10 MV x-ray modes using dynamic and step and shoot delivery at 300 MU/min was used for all irradiations. Varian Eclipse planning system (Ver. 7.1) was used also. The procedure was designed for 3 steps. Step 1. Hybridize the patient plan to a solid water phantom using the \u201dcreate verification plan\u201d in the Eclipse. Step 2. Recalculate the dose distribution in the phantom. Find area of low dose gradient and select points in this area for point dose verification. 2D dose distribution at isocenter for each portal are calculated for comparison. Step 3. The phantom is then irradiated according to this plan. The point doses are measured using CC01 ion chamber and the 2D dose distributions are measured using Kodak XV film or EDR2 film. Kodak LS75 laser scanner and DoseLab film analysis system are used for 2D dose comparison.\nResults: The variations of point dose of 124 patients are within 6%. The calculated dose distributions are consistent to the measurements for the 2D dose comparison.\nConclusions: CC01 chamber is suitable for IMRT point dose verification. Film dosimetry system in this study can be used for IMRT 2D dose distribution comparison. IMRT dose verification can be done by this procedure."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-235-239-a", "title": "\u9237\uff0d60\u8f3b\u5c04\u6c61\u67d3\u92fc\u7b4b\u5efa\u7269\u5c45\u6c11\u8f3b\u5c04\u98a8\u96aa\u56e0\u5b50\u4e4b\u7814\u7a76", "keywords": "\u8f3b\u5c04\u98a8\u96aa\u56e0\u5b50;\u5916\u63a8\u6cd5;\u76f8\u52a0;\u76f8\u4e58\u6a21\u5f0f;\u8d85\u984d\u6b7b\u4ea1\u7387;\u8d77\u59cb\u98a8\u96aa\u4fc2\u6578;\u7d55\u5c0d\u53ca\u8d85\u984d\u76f8\u5c0d\u98a8\u96aa\u4fc2\u6578;\u5291\u91cf\u53ca\u5291\u91cf\u7387\u6548\u61c9\u56e0\u5b50 Radiation risk factor;Extrapolation methods;Additive model and multiplicative model;Excess fatality rate;Initial risk factor;Absolute and excess relative risk factor;Dose and dose rate effectiveness f", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u5167\u5bb9\u70ba\u9237\uff0d60\u6c61\u67d3\u92fc\u7b4b\u5efa\u7269\u4e4b\u5c45\u6c11\u4f4e\u5291\u91cf\u7387\u8f3b\u5c04\u81f4\u6b7b\u764c\u75c5\u98a8\u96aa\u4e4b\u63a2\u8a0e\u3002\n\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u65e5\u672c\u539f\u7206\u751f\u9084\u8005\u7684\u8d77\u59cb\u98a8\u96aa\u4fc2\u6578\uff0c\u900f\u904e\u4eba\u7fa4\u5916\u63a8\u3001\u6642\u9593\u5916\u63a8\uff08\u76f8\u52a0\u3001\u76f8\u4e58\u6a21\u5f0f\uff09\u8207\u5291\u91cf\u5916\u63a8\uff0c\u4f30\u7b97\u51fa\u9069\u5408\u8f3b\u5c04\u5c4b\u5c45\u6c11\u5c07\u4f86\u764c\u75c5\u81f4\u6b7b\u7684\u98a8\u96aa\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u8a55\u4f30\u7d50\u679c\u8f3b\u5c04\u5c4b\u5c45\u6c11\u5c07\u4f86\u764c\u75c5\u81f4\u6b7b\u4e4b\u98a8\u96aa\u56e0\u5b50\u4ecb\u65bc12.15\u00d710^(-2)Sv^(-1)\u81f30.55\u00d710^(-2)Sv^(-1)\u4e4b\u9593\u3002", "e": "Purpose: This research is to study the risk of gamma radiation induced cancer mortalities at low dose rate exposure for residents living in 60Co-contaminated rebar buildings.\nMethods: The risk factor for residents living in radiation contaminated buildings were evaluated by extrapolation methods of population, time (additive model and multiplicative model) and dose based on the primary risk coefficient of Japanese A-bomb survivor.\nResults: The derived risk factor is between 12.15\u00d710^(-2)Sv^(-1) and 0.55\u00d710^(-2)Sv^(-1)"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200509-12-3-241-246-a", "title": "Metastatic Cardiac Tumor from Primary Tongue Cancer: A Case Report", "keywords": "\u820c\u764c;\u5fc3\u81df\u8f49\u79fb;\u5fc3\u5305\u819c\u586b\u585e Tongue cancer;Cardiac metastasis;Cardiac tamponade", "c": "\u76ee\u7684\uff1a\u539f\u767c\u6027\u820c\u764c\u4f34\u96a8\u5fc3\u81df\u8f49\u79fb\u7684\u75c5\u4f8b\u975e\u5e38\u7f55\u898b\uff0c\u6211\u5011\u5831\u544a\u4e00\u75c5\u60a3\u4ee5\u5fc3\u5305\u819c\u586b\u585e\u70ba\u8868\u73fe\u7684\u75c5\u4f8b\uff0c\u7d93\u958b\u5200\u5f8c\u8b49\u5be6\u662f\u8f49\u79fb\u6027\u9c57\u72c0\u4e0a\u76ae\u764c\u3002\n\u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u4f4d\u5e74\u7d0067\u6b72\u7684\u7537\u6027\u60a3\u8005\uff0c\u57282004\u5e743\u6708\u6642\u88ab\u78ba\u5b9a\u8a3a\u65b7\u51fa\u5de6\u5074\u9c57\u72c0\u4e0a\u76ae\u820c\u764c\uff0c\u7576\u6642\u764c\u75c7\u5206\u671f\u70baT2N0M0\u3002\u75c5\u4eba\u5728\u5916\u9662\u63a5\u53d7\u4e86\u5c40\u90e8\u820c\u5207\u9664\u5f8c\uff0c\u7121\u4f50\u4ee5\u5176\u4ed6\u8f14\u52a9\u6cbb\u7642\u3002\u4e0d\u5e78\u7684\uff0c\u57282004\u5e7410\u6708\u6642\uff0c\u5de6\u5074\u4e0b\u9837\u9aa8\u6dcb\u5df4\u7bc0\u5fa9\u767c\uff0c\u75c5\u4eba\u81ea\u884c\u8f49\u8a3a\u81f3\u672c\u9662\uff0c\u7d93\u6aa2\u67e5\u5f8c\u78ba\u5b9a\u7121\u9060\u8655\u8f49\u79fb\u3002\u75c5\u4eba\u572810\u6708\u6642\u63a5\u53d7\u4e86\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642\uff0c\u5f9e2004\u5e7410\u6708\u81f32004\u5e7412\u6708\uff0c\u7e3d\u5171\u63a5\u53d7\u4e866\u6b21\u5316\u5b78\u6cbb\u7642\u53ca79.8 Gy\u8a1838\u6b21\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6cbb\u7642\u671f\u9593\uff0c\u9664\u4e86\u6709WHO Grade \u2161\u7684\u9ecf\u819c\u53cd\u61c9\u5916\uff0c\u6cbb\u7642\u582a\u7a31\u5e73\u9806\u3002\u7136\u800c\u4e0d\u5e78\u7684\uff0c2005\u5e742\u6708\u75c5\u4eba\u6709\u9811\u56fa\u6027\u5fc3\u5305\u819c\u6ef2\u6db2\u7522\u751f\u4e26\u5c0e\u81f4\u5fc3\u5305\u819c\u586b\u585e\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u80f8\u90e8\u65b7\u5c64\u6383\u7784\u5747\u767c\u73fe\u5728\u53f3\u5fc3\u5ba4\u6709\u4e00\u816b\u7624\u53ca\u5fc3\u5305\u819c\u6ef2\u6db2\uff1b\u7531\u65bc\u6301\u7e8c\u6027\u5fc3\u81df\u529f\u80fd\u60e1\u5316\uff0c\u70ba\u4e86\u6539\u5584\u5fc3\u81df\u529f\u80fd\uff0c\u5fc3\u81df\u5916\u79d1\u91ab\u5e2b\u57282\u670824\u65e5\u65bd\u884c\u816b\u7624\u6458\u9664\u624b\u8853\uff0c\u5f9e\u53f3\u5fc3\u5ba4\u53d6\u51fa\u4e00\u500b3.3\u00d72.7\u00d72.0\u516c\u5206\u5927\u5c0f\u7684\u816b\u7624\u3002\u7d93\u75c5\u7406\u78ba\u5b9a\u8a3a\u65b7\u70ba\u8f49\u79fb\u6027\u9c57\u72c0\u4e0a\u76ae\u764c\u3002\n\u7d50\u679c\uff1a\u8853\u5f8c\u6211\u5011\u65bd\u4e88\u52a0\u5f37\u6027\u652f\u6301\u7642\u6cd5\uff0c\u7136\u800c\u75c5\u4eba\u4ecd\u65bc2005\u5e743\u67087\u65e5\u56e0\u5fc3\u8870\u7aed\u901d\u4e16\u3002\n\u7d50\u8ad6\uff1a\u96d6\u7136\u8f49\u79fb\u6027\u5fc3\u81df\u816b\u7624\u7684\u75c5\u4f8b\u6975\u70ba\u5c11\u898b\uff0c\u4f46\u5728\u982d\u9838\u90e8\u816b\u7624\u4e2d\uff0c\u820c\u764c\u7b97\u662f\u8f03\u5e38\u898b\u7684\u3002\u7531\u65bc\u816b\u7624\u5fc3\u81df\u8f49\u79fb\u6642\u4e26\u7121\u7279\u5b9a\u8868\u73fe\u7684\u75c5\u5fb5\uff1b\u4e14\u8f49\u79fb\u5f8c\uff0c\u75c5\u4eba\u901a\u5e38\u8655\u65bc\u5371\u6025\u72c0\u614b\uff0c\u6240\u4ee5\u81e8\u5e8a\u8981\u8a3a\u65b7\u8f49\u79fb\u6027\u5fc3\u81df\u816b\u7624\u5f88\u56f0\u96e3\u3002\u6211\u5011\u5fc5\u9808\u6ce8\u610f\u7684\u662f\uff0c\u820c\u764c\u60a3\u8005\uff0c\u4e00\u65e6\u51fa\u73fe\u65b0\u7684\u5fc3\u81df\u75be\u75c5\uff0c\u5fc3\u81df\u8f49\u79fb\u7684\u8a3a\u65b7\u4e0d\u53ef\u88ab\u5ffd\u7565\u3002", "e": "Purpose: To report a case of cardiac metastasis from primary squamous cell carcinoma of tongue presented as malignant pericardial effusion causing cardiac tamponade. This case was proven by pathologic evidence.\nCase report: This 67 years old male patient was diagnosed of left tongue carcinoma with initial staging of T2N0M0 and received local excision in March 2004 in another hospital. However, left submandibular lymph node recurrence occurred in October 2004. Restaging work-up was arranged and no evidence of distant metastasis was found. Then he received salvage treatment of concurrent chemo-radiotherapy (CCRT) since October 28, 2004. For radiotherapy, the total dose to recurrent LN and primary tumor bed with whole lymphatic chain were 79.8 Gy and 62.4 Gy, respectively. The regimen of chemotherapy was taxotere (12 mg/m2) plus cisplatin (30 mg/m2) weekly for 6 cycles. The total treatment course was completed smoothly on December 24, 2004 except for WHO Grade \u2161 mucositis that developed during treatment period. Unfortunately, pericardiac effusion occurred as diagnosed by cardiac echography in February 2005. Refractory pericardiac effusion caused cardiac tamponade was still persistent despite of repeated pericardiocentesis. Chest computed tomography (CT) showed that a mass within the right ventricle and massive pericardiac effusion. Surgery was performed owing to progressive degradation of cardiac function on February 24, 2005.\nResult: The myocardiac tumor biopsy proved metastatic squamous cell carcinoma. Unfortunately, this patient died of heart failure even after intensive supportive treatment,\n12 days after surgery.\nConclusion: Although primary tongue cancer is frequent in head and neck tumor, metastatic cardiac cancer is a rare occurrence. The diagnosis of metastasis to heart is difficult because of various cardiac symptoms. Most importantly, the diagnosis of cardiac metastasis should be kept in mind if a new onset of cardiac disease occurred in cancer patient."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-83-91-a", "title": "Outcome of Salvage Irradiation for Breast Cancer Patients with Locoregional Recurrence", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u4e73\u623f\u816b\u7624;\u5c40\u90e8\u5fa9\u767c Radiotherapy;Breast cancer;Locoregional recurrence", "c": "Purpose: This study aimed to investigate the outcome of salvage radiotherapy for post-mastectomy breast cancer patients with locoregional recurrence (LRR).\nMaterials and Methods: This study comprised 63 patients who completed allocated radiation treatment for LRR after mastectomy from October 1989 to December 2000. The distribution of initial American Joint Committee on Cancer (AJCC) 6th staging, 2002, included 4 stage I patients, 8 stage ha patients, 22 stage IIb patients, 23 stage IIIa patients, and 6 stage IIIb patients. The recurrent sites (including 40 in the ipsilateral chest wall, 16 in the axillary fossa, and 22 in the supraclavicular fossa) were treated with either electron beam or combined photon-electron beam therapy. The median prescribed dose was 60 Gy (range, 40-66 Gy). The overall survival (OS), disease free survival (DFS), locoregional free survival (LRFS), and distant metastasis free survival (DMFS) rates were compared by Kaplan-Meier method (Log-rank test); Cox regression model was used for a multivariate analysis.\nResults: After a median follow-up of 36 months (range, 3-93 months), 35 patients (55.6%) had developed distant metastasis at the time of the most recent follow-up. The most common sites were lung (41.7%) and bone (44.4%). The 3-year OS rate was 54%. The overall 3-year DFS rate was 31.7%. The overall 3-year LRFS rate was 50.8%. The overall 3-year DMFS rate was 34.9%. The 3-year OS for single site and multiple site recurrence was 60.4% and 20% (p=0.02), while the 3-year OS for small recurrent tumor (\uff1c=3cm) and large tumor/multiple lesions was 71.9% and 35.5%, respectively (p\uff1c0.01). Analysis of initial nodal status revealed that the 3-year OS for patients with no node metastasis was 78.6% and that for patients with positive node metastasis was 46.9% (p=0.04). In addition, the 3-year OS for patients with long latent period (\uff1e24 months) and short latent period was 81.5% and 33.3% (p\uff1c0.01), respectively. The 3-year OS for patients with and without surgery for recurrent tumor was 63.8% and 25% (p\uff1c0.01), respectively.\nConclusion: Salvage radiotherapy is effective in achieving satisfactory local control in patients with early stage disease and no lymph node metastasis who developed LRR. For patients with multiple or large recurrent tumors, as well as advanced initial lymph node metastasis, it is imperative to incorporate more aggressive systemic treatment to improve treatment outcome.", "e": "Purpose: This study aimed to investigate the outcome of salvage radiotherapy for post-mastectomy breast cancer patients with locoregional recurrence (LRR).\nMaterials and Methods: This study comprised 63 patients who completed allocated radiation treatment for LRR after mastectomy from October 1989 to December 2000. The distribution of initial American Joint Committee on Cancer (AJCC) 6th staging, 2002, included 4 stage I patients, 8 stage ha patients, 22 stage IIb patients, 23 stage IIIa patients, and 6 stage IIIb patients. The recurrent sites (including 40 in the ipsilateral chest wall, 16 in the axillary fossa, and 22 in the supraclavicular fossa) were treated with either electron beam or combined photon-electron beam therapy. The median prescribed dose was 60 Gy (range, 40-66 Gy). The overall survival (OS), disease free survival (DFS), locoregional free survival (LRFS), and distant metastasis free survival (DMFS) rates were compared by Kaplan-Meier method (Log-rank test); Cox regression model was used for a multivariate analysis.\nResults: After a median follow-up of 36 months (range, 3-93 months), 35 patients (55.6%) had developed distant metastasis at the time of the most recent follow-up. The most common sites were lung (41.7%) and bone (44.4%). The 3-year OS rate was 54%. The overall 3-year DFS rate was 31.7%. The overall 3-year LRFS rate was 50.8%. The overall 3-year DMFS rate was 34.9%. The 3-year OS for single site and multiple site recurrence was 60.4% and 20% (p=0.02), while the 3-year OS for small recurrent tumor (\uff1c=3cm) and large tumor/multiple lesions was 71.9% and 35.5%, respectively (p\uff1c0.01). Analysis of initial nodal status revealed that the 3-year OS for patients with no node metastasis was 78.6% and that for patients with positive node metastasis was 46.9% (p=0.04). In addition, the 3-year OS for patients with long latent period (\uff1e24 months) and short latent period was 81.5% and 33.3% (p\uff1c0.01), respectively. The 3-year OS for patients with and without surgery for recurrent tumor was 63.8% and 25% (p\uff1c0.01), respectively.\nConclusion: Salvage radiotherapy is effective in achieving satisfactory local control in patients with early stage disease and no lymph node metastasis who developed LRR. For patients with multiple or large recurrent tumors, as well as advanced initial lymph node metastasis, it is imperative to incorporate more aggressive systemic treatment to improve treatment outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-93-101-a", "title": "Experiences of Radiotherapy on Extrapulmonary Small Cell Carcinoma", "keywords": "\u975e\u80ba\u90e8\u5c0f\u7d30\u80de\u764c;\u653e\u5c04\u6cbb\u7642;\u81e8\u5e8a\u6cbb\u7642\u6210\u679c Extrapulmonary small cell carcinoma;Radiotherapy;Clinical Outcome", "c": "\u76ee\u7684\uff1a\u4ee5\u56de\u6eaf\u6027\u7684\u65b9\u5f0f\u5831\u544a\u975e\u80ba\u90e8\u5c0f\u7d30\u80de\u764c\u4e4b\u653e\u5c04\u6cbb\u7642\u7d93\u9a57\u3002\n\u6751\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1991\u5e74\u52302004\u5e74\uff0c\u5171\u670921\u4f4d\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u70ba\u975e\u80ba\u90e8\u5c0f\u7d30\u80de\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u7d0d\u5165\u7814\u7a76\u4e4b\u689d\u4ef6\u70ba\u5728\u80ba\u90e8\u4e4b\u5916\u7684\u816b\u7624\u4ee5\u75c5\u7406\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u70ba\u5c0f\u7d30\u80de\u764c\u3001\u4e14\u5728\u8a3a\u65b7\u6642\u75c5\u4eba\u7684\u80f8\u90e8X\u5149\u548c\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u5fc5\u9808\u70ba\u6b63\u5e38\u3001\u5176\u75f0\u6db2\u7d30\u80de\u5b78\u5316\u9a57\u6216\u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\u5fc5\u9808\u6c92\u6709\u7570\u5e38\u767c\u73fe\uff0c\u4ee5\u56de\u6eaf\u6027\u7684\u75c5\u6b77\u8abf\u95b1\u65b9\u5f0f\u6bd4\u8f03\u5176\u81e8\u5e8a\u6cbb\u7642\u6548\u679c\u3002\n\u7d50\u679c\uff1a\u975e\u80ba\u90e8\u5c0f\u7d30\u80de\u764c\u7684\u539f\u767c\u75c5\u7076\u70ba\uff1a\u5a66\u79d1\u90e8\u4f4d7\u4f4d\u3001\u9f3b\u8154\u526f\u9f3b\u7ac7\u548c\u553e\u6db2\u817a6\u4f4d\u3001\u8180\u80f13\u4f4d\u3001\u80c3\u8178\u6d88\u5316\u9053\u81df\u56683\u4f4d\u3001\u4e73\u623f\u548c\u9396\u9aa8\u4e0b\u8edf\u7d44\u7e54\u5404\u4e00\u4f4d\u75c5\u4eba\u3002\u5176\u4e2d5\u4f4d\u75c5\u4eba\u70ba\u5728\u8a3a\u65b7\u4e4b\u969b\u70ba\u64f4\u6563\u578b\uff0c16\u4f4d\u70ba\u5c40\u9650\u578b\u3002\u5728\u901916\u4f4d\u539f\u5148\u70ba\u5c40\u9650\u578b\u7684\u75c5\u4eba\u4e2d\uff0c11\u4f4d\u4e00\u958b\u59cb\u5c31\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u53e6\u5916\u67095\u4f4d\u75c5\u4eba\u5247\u7b49\u5230\u75be\u75c5\u5fa9\u767c\u6216\u8f49\u79fb\u6642\u624d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u4eba\u7684\u4e8c\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5728\u64f4\u6563\u578b\u75c5\u4eba\u70ba0%\uff0c\u5728\u5c40\u9650\u578b\u75c5\u4eba\u70ba49.2%\u3002\u7d93\u904e\u8ffd\u8e64\uff0c\u7e3d\u517117\u4f4d\u75c5\u4eba(81%)\u767c\u751f\u9060\u7aef\u8f49\u79fb\u3002\u653e\u5c04\u6cbb\u7642\u5c0d\u64f4\u6563\u578b\u548c\u672c\u70ba\u5c40\u9650\u578b\u5f8c\u4f86\u7522\u751f\u75be\u75c5\u5fa9\u767c\u6216\u8f49\u79fb\u7684\u75c5\u4eba\u670960%\u7684\u53cd\u61c9\u7387\uff0c\u5c0d11\u4f4d\u5c40\u9650\u578b\u521d\u59cb\u5c31\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u5176\u4e2d6\u4f4d\u5148\u63a5\u53d7\u624b\u8853\u518d\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff08\u6216\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff09\uff0c\u5f8c\u4f86\u6709\u4e00\u4f4d\u75c5\u4eba\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff1b\u53e6\u59165\u4f4d\u521d\u59cb\u5c31\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff08\u6216\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff09\u7684\u75c5\u4eba\uff0c\u5176\u653e\u5c04\u6cbb\u7642\u7684\u53cd\u61c9\u7387\u70ba100%\uff0c\u4e0d\u904e\u5f8c\u4f86\u5176\u4e2d4\u4f4d\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff08\u4e2d\u6578\uff1a8\u500b\u6708\uff09\u3002\u901911\u4f4d\u75c5\u4eba\u7684\u4e8c\u5e74\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u548c\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba53%\u548c27%\u3002\n\u7d50\u8ad6\uff1a\u975e\u80ba\u90e8\u5c0f\u7d30\u80de\u764c\u5c0d\u653e\u5c04\u6cbb\u7642\u7684\u53cd\u61c9\u5f88\u597d\uff0c\u9019\u500b\u75be\u75c5\u5bb9\u6613\u65e9\u671f\u5373\u767c\u751f\u9060\u7aef\u8f49\u79fb\u548c\u5c40\u90e8\u5fa9\u767c\uff0c\u9700\u8981\u66f4\u591a\u66f4\u7a4d\u6975\u7684\u5408\u4f75\u6cbb\u7642\u3002", "e": "Purpose: To report our institution's experience of radiotherapy (RT) on extrapulmonary small cell carcinoma (EPSCCA).\nMaterials and Methods: Between 1991 and 2004, 21 patients with tissue-proven EPSCCA received RT in our hospital with either curative or palliative intents. Study eligibility required that the patients had pathologically-proven small cell carcinoma in sites other than the lung, a normal chest radiograph and/or computed tomography of the chest, and a normal sputum cytology or negative bronchoscopic findings at diagnosis. The medical records of each patient were reviewed retrospectively and clinical outcomes were compared.\nResults: Primary sites of EPSCCA in our series included: 7 patients in the gynecological system, 6 in head and neck regions, 3 in urinary bladder, 3 in the gastrointestinal system, 1 in the breast, and 1 in the infra-clavicular soft tissue. Five patients had extended disease (ED) and 16 had limited disease (LD) at initial work-up. RT was delivered to 11 of 16 patients with LD as part of the initial primary therapy, and to 5 with relapse or metastasis as salvage or palliation. The 2-year overall survival for ED and LD EPSCCA were 0% and 49.2%, respectively. During follow-up, a total of 17 (81%) of the 21 patients developed distant metastases. There was a 60% response rate for those patients with ED at diagnosis or LD with relapse or metastasis when RT initiated. For the 11 patients with LD and receiving RT as part of the initial primary therapy, one of six patients receiving surgery followed by adjuvant RT (with or without chemotherapy) developed local recurrence. The remaining five who received RT alone or chemotherapy and RT had a 100% response rate. However, four of them developed local relapses at a median duration of 8 months. The 2-year local relapse-free and disease-free survivals for patients with LD were 53% and 27%, respectively.\nConclusion: EPSCCA was sensitive to radiotherapy. Easily distant metastasis and local recurrence of the disease warrant more aggressive combination therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-103-111-a", "title": "The Effect and Safety of Transdermal Fentanyl for Concurrent Chemoradiation Therapy-Induced Mucositis Pain in Head and Neck Cancer Patients", "keywords": "\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291;\u7c98\u819c\u708e;\u982d\u9838\u90e8\u764c\u75c7;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642 Transdermal fentanyl;Mucositis;Head and neck cancer;Concurrent chemoradiation therapy (CCRT)", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u662f\u63a2\u8a0e\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291(transdermal fentanyl)\u65bc\u6cbb\u7642\u982d\u9838\u90e8\u764c\u75c7\u75c5\u4eba\u56e0\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u6240\u5f15\u767c\u7684\u56b4\u91cd\u53e3\u8154\u7c98\u819c\u708e\u75bc\u75db\u6642\uff0c\u5176\u6548\u679c\u548c\u5b89\u5168\u6027\u7684\u8a55\u4f30\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e4b\u4e3b\u8981\u5c0d\u8c61\u70ba\u88ab\u8a3a\u65b7\u70ba\u982d\u9838\u90e8\u764c\u75c7\u4e26\u4ee5\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u3002\u7576\u60a3\u8005\u65bc\u6cbb\u7642\u904e\u7a0b\u4e2d\u7522\u751f\u56b4\u91cd\u7684\u53e3\u8154\u9ecf\u819c\u708e\u75bc\u75db\uff08\u5373numeric rating scale [NRS]\u22677\uff09\u4e14\u7121\u6cd5\u4ee5\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u5291(nonsteroid anti-inflammatory drugs)\u53ca\u985e\u56fa\u9187\u85e5\u818f\u9054\u5230\u63a7\u5236\u6642\uff0c\u6703\u7d66\u4e88\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u529125\u03bcg/h\u3002\u5176\u5f8c\u6bcf\u4e00\u500b\u661f\u671f\u6703\u505a\u75bc\u75db\u5f37\u5ea6\u7684\u8a55\u4f30\uff0c\u5982\u679cNRS\u4ecd\u5927\u65bc7\u5206\uff0c\u5247\u518d\u7d66\u4e88\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u529125\u03bcg/h\u4e00\u7247\u3002\u6b21\u5916\uff0c\u6bcf\u661f\u671f\u6703\u6839\u64daCommon Toxicity\uff0cCriteria (CTC) Version 2.0\u8a18\u9304\u56e0\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291\u9020\u6210\u7684\u526f\u4f5c\u7528\u3002\n\u7d50\u679c\uff1a\u81ea2002\u5e7410\u6708\u81f32003\u5e743\u6708\u671f\u9593\uff0c\u5171\u670921\u4f4d\u7537\u6027\u53ca1\u4f4d\u5973\u6027\u982d\u9838\u90e8\u764c\u75c7\u4e26\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u4e4b\u75c5\u60a3\u88ab\u6536\u5165\u81f3\u6b64\u7814\u7a76\u4e2d\u3002\u5e73\u5747NRS\u5728\u4f7f\u7528\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291\u4e00\u9031\u5f8c\u7531\u539f\u4f86\u76847.65\u00b10.99\uff08\u57fa\u6e96\u503c\uff09\u964d\u81f33.9\u00b11.29\u3002\u800c\u5728\u7b2c\u4e94\u9031\u6642\uff0c\u5e73\u5747NRS\u96d6\u4e0a\u5347\u5230\u4e864.79\u00b11.18\uff0c\u4f46\u4ecd\u6709\u610f\u7fa9\u7684\u4f4e\u65bc\u57fa\u6e96\u503c(p=0.003)\u3002\u9054\u5230\u9069\u7576\u7684\u75bc\u75db\u63a7\u5236\u5291\u91cf\u5206\u5225\u70ba\uff0c25\u03bcg/h\u670915\u4eba\uff0c50\u03bcg/h\u67095\u4eba\uff0c100\u03bcg/h\u5247\u67091\u4eba\u3002\u4e00\u4f4d\u60a3\u8005\u56e0\u70ba\u7121\u6cd5\u5fcd\u53d7\u7684\u76ae\u819a\u75b9\u5b50\u53ca\u5614\u5410\u800c\u5728\u7b2c\u4e8c\u9031\u6642\u505c\u6b62\u4f7f\u7528\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291\u3002\u5176\u5b83\u4e26\u6c92\u6709\u767c\u73fe\u547c\u5438\u6291\u5236\u3001\u610f\u8b58\u6539\u8b8a\uff0c\u6216\u8005\u7b2c\u4e09\u6216\u7b2c\u56db\u7d1a\u7684\u8178\u80c3\u9053\u526f\u4f5c\u7528\u3002\n\u7d50\u8ad6\uff1a\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291\u5c0d\u65bc\u63a7\u5236\u982d\u9838\u90e8\u764c\u75c7\u75c5\u4eba\u56e0\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u6240\u9020\u6210\u7684\u56b4\u91cd\u53e3\u8154\u7c98\u819c\u708e\u75bc\u75db\u662f\u6709\u6548\u4e14\u5b89\u5168\u7684\u3002\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u4ea6\u6e1b\u5c11\u4e86\u9019\u4e9b\u541e\u56a5\u75bc\u75db\u6216\u541e\u56a5\u56f0\u96e3\u7684\u75c5\u4eba\u541e\u98df\u85e5\u7269\u7684\u9700\u8981\u6027\uff0c\u540c\u6642\u4e5f\u6e1b\u5c11\u4e86\u8abf\u6574\u50b3\u7d71\u6b62\u75db\u85e5\u7269\u6240\u9700\u7684\u6642\u9593\u3002\u672a\u4f86\u9700\u8981\u66f4\u5927\u578b\u7684\u81e8\u5e8a\u96a8\u6a5f\u7814\u7a76\u4ee5\u518d\u8a55\u4f30\u5429\u5766\u5c3c\u7a7f\u76ae\u8cbc\u7247\u5291\u5c0d\u65bc\u53e3\u8154\u7c98\u819c\u708e\u75bc\u75db\u7684\u6548\u50f9\u548c\u5b89\u5168\u6027\u3002", "e": "Purpose: This prospective, longitudinal study was to evaluate the efficacy and the safety of using TTS-fentanyl for severe oral mucositis pain induced by concurrent chemoradiotherapy (CCRT) in head and neck cancer (HNC) patients.\nMaterials and Methods: Patients diagnosed as HNC and scheduled for concurrent chemoradiotherapy were eligible for this study. TTS-fentanyl was given with the initial dose of 25 \u03bcg/h when severe mucositis pain (numeric rating scale [NRS]\u22677) occurred in spite of nonsteroid anti-inflammatory drugs (NSAID) and topical steroidal ointment use. The pain intensity was assessed every week and if severe pain persisted, another dose of 25 \u03bcg/h TTS-fentanyl was given. The adverse effects were recorded every week according to Common Toxicity Criteria (CTC) Version 2.0.\nResults: From October 2002 to March 2003, 21 male and 1 female receiving CCRT with HNC were recruited to this study. The mean NRS for pain significantly decreased from 7.65\u00b10.99 (baseline) to 3.9\u00b11.29 within the first week. In the fifth week, the NRS raised to 4.79\u00b11.18 but was still lower than the baseline (p=0.003). The sufficient analgesia was achieved in 15 cases with a dose of 25 \u03bcg/h, in 5 cases with a dose of 50 \u03bcg/h, and in 1 case with a dose of 100 \u03bcg/h. One patient withdrew the TTS-fentanyl due to intolerable skin rash and vomiting in the second week. Besides, no one developed respiratory depression, mental clouding, or grade \u2162/IV gatrointestinal toxicities.\nConclusion: TTS-fentanyl is effective and safe in the treatment of mucositis-induced pain which is resistant to NSAID in HNC patients receiving CCRT. TTS-fentanyl also spares the need to swallow pain killers in these patients suffering from odynophagia and/or dysphagia, as well as the time for titration of conventional analgesic drugs. Further larger series with randomized setting is warranted to evaluate the efficacy and safety of TTS-fentanyl for oral mucositis pain."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-113-123-a", "title": "\u63a2\u8a0e\u982d\u9838\u90e8\u764c\u5408\u4f75\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\u7684\u75c5\u60a3\u4f7f\u7528\u4e8c\u6b21IMRT\u6cbb\u7642\u8a08\u5283\u4e4b\u5fc5\u8981\u6027", "keywords": "\u4e8c\u6b21\u96fb\u8166\u65b7\u5c64\u5b9a\u4f4dIMRT\u6cbb\u7642\u8a08\u5283;\u982d\u9838\u90e8\u764c;\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927;\u5f71\u50cf\u878d\u5408;\u816e\u817a;\u5305\u8986\u9806\u5f62\u5ea6 Dual-phase IMRT;Head and neck cancer;Cervical lymph nodes;Image fusion;The conformal index;Parotid gland", "c": "Purpose: To discuss the differences of dose distribution between the dual-phase IMRT and one-phase IMRT in the patients of head-and-neck (H&N) cancers with enlarged cervical lymph nodes.\nMaterials and Methods: From April 2003 to June 2004, we collected 6 patients of H&N cancers with enlarged cervical lymph nodes. Initially, we arranged first simulation by CT-MRI fusion for one-phase IMRT awl prescribed 4500 cGy on GTV including enlarged lymph nodes (Plan A). Five weeks later, we arranged the second simulation by the same method to design dual-phase IMRT and prescribed 2700 cGy on GTV (Plan B). All 6 patients received concurrent chemoradiotherapy (CCRT) with cisplatin 30 mg/wk intravenously. The IMRT technique was simultaneous intensity boost (SIB). Furthermore, we combined two CT images and superimposed the fluence map of Plan A onto the second CT images to get the Plan C. Finally, we compared Plan B with Plan C.\nResult: When we compared two CT images, we found that those enlarged lymph nodes already regressed or disappeared after plan A treatment, which made the skin and parotid gland fall into the high dose area. From the comparison of both plans, B had a much better conformal index than C for CTV. Using t test to analyze the D(subscript 50%), D(supbscript 30%) and D(subscript mean) of Plan B and C for the sparing of parotid glands, B had better results than C (p\uff1c0.001). Therefore, the dual-phase IMRT treatment planning can provide another way to significantly decrease the irradiation doses to parotid glands.\nConclusion This study indicate that if the patient's contour changes without modifying the prior IMRT treatment planning, the doses of parotid glands and the skin will increase and the conformity of dose distribution will decrease, which affect the result of IMRT.", "e": "Purpose: To discuss the differences of dose distribution between the dual-phase IMRT and one-phase IMRT in the patients of head-and-neck (H&N) cancers with enlarged cervical lymph nodes.\nMaterials and Methods: From April 2003 to June 2004, we collected 6 patients of H&N cancers with enlarged cervical lymph nodes. Initially, we arranged first simulation by CT-MRI fusion for one-phase IMRT awl prescribed 4500 cGy on GTV including enlarged lymph nodes (Plan A). Five weeks later, we arranged the second simulation by the same method to design dual-phase IMRT and prescribed 2700 cGy on GTV (Plan B). All 6 patients received concurrent chemoradiotherapy (CCRT) with cisplatin 30 mg/wk intravenously. The IMRT technique was simultaneous intensity boost (SIB). Furthermore, we combined two CT images and superimposed the fluence map of Plan A onto the second CT images to get the Plan C. Finally, we compared Plan B with Plan C.\nResult: When we compared two CT images, we found that those enlarged lymph nodes already regressed or disappeared after plan A treatment, which made the skin and parotid gland fall into the high dose area. From the comparison of both plans, B had a much better conformal index than C for CTV. Using t test to analyze the D(subscript 50%), D(supbscript 30%) and D(subscript mean) of Plan B and C for the sparing of parotid glands, B had better results than C (p\uff1c0.001). Therefore, the dual-phase IMRT treatment planning can provide another way to significantly decrease the irradiation doses to parotid glands.\nConclusion This study indicate that if the patient's contour changes without modifying the prior IMRT treatment planning, the doses of parotid glands and the skin will increase and the conformity of dose distribution will decrease, which affect the result of IMRT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-125-135-a", "title": "Localized Three Dimensional Conformal Hyperfractionated Radiotherapy in Glioblastoma Multiforme Patients-CGH Experience", "keywords": "\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624;\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642;\u6539\u8b8a\u5206\u6b21\u653e\u5c04\u6cbb\u7642 Glioblastoma multiforme;Hyperfractionation;Altered fractionation", "c": "\u76ee\u7684\uff1a\u570b\u6cf0\u7d9c\u5408\u91ab\u9662\u91dd\u5c0d\u8fd1\u516d\u5e74\u5167\u70ba\u8853\u5f8c\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u9032\u884c\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u4f5c\u56de\u9867\u6027\u7684\u5206\u6790\uff0c\u8a55\u4f30\u6b64\u985e\u6539\u8b8a\u5206\u6b21\u7684\u653e\u5c04\u6cbb\u7642\u5c0d\u9810\u5f8c\u7684\u6210\u6548\uff0c\u4e26\u7d9c\u5408\u5176\u4ed6\u6587\u7ae0\u4f5c\u8a0e\u8ad6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1999\u81f32004\u5e74\uff0c\u5171\u670927\u4f4d\u8853\u5f8c\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u5728\u672c\u79d1\u63a5\u53d7\u5f8c\u7e8c\u7684\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u3002\u9664\u4e86\u4e00\u4f4d\u5c0f\u5b69\u4ee5\u5916\uff0c\u6bcf\u4f4d\u75c5\u60a3\u7d66\u4e86\u6bcf\u5929\u5169\u6b21\uff0c\u6bcf\u6b211.2Gy\uff0c\u7e3d\u5291\u91cf\u7d66\u523072Gy\u3002\u552f\u4e00\u7684\u4e00\u4f4d\u5c0f\u5b69\uff0c\u6bcf\u6b21\u4ee51.08Gy\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u7d66\u523064.8 Gy\u3002\u800c\u6bcf\u4f4d\u7686\u4ee5\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\u6cd5\u4f86\u5b9a\u4f4d\u4f5c\u6cbb\u7642\u8a08\u756b\u3002\u6240\u6709\u7684\u75c5\u60a3\u4e26\u6c92\u6709\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\u5176\u4e2d\u53c8\u6709\u56db\u4f4d\u75c5\u60a3\u56e0\u816b\u7624\u5fa9\u767c\u63a5\u53d7\u4e86\u7b2c\u4e8c\u6b21\u5168\u7a0b\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u662f\u4ee5\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u6216\u4e00\u5929\u4e00\u6b21\u7684\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u3002\u75c5\u60a3\u7684\u5b58\u6d3b\u7387\u4ee5Kaplan-Meier\u65b9\u6cd5\u8a08\u7b97\uff0c\u4e26\u8a55\u4f30\u5e74\u9f61\u3001\u6027\u5225\u3001Karnofsky Peformance Score\u3001\u816b\u7624\u6700\u5927\u7684\u76f4\u5f91\u53ca\u624b\u8853\u65b9\u5f0f\u5c0d\u5b58\u6d3b\u7387\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u4e2d\u4f4d\u5b58\u6d3b\u7387\u70ba12\u500b\u6708\uff0c\u4e00\u5e74\u53ca\u5169\u5e74\u7684\u5b58\u6d3b\u7387\u5206\u5225\u662f44%\u820719%\u3002\u90a3\u56db\u4f4d\u63a5\u53d7\u4e86\u7b2c\u4e8c\u6b21\u5168\u7a0b\u7684\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\uff0c\u4ed6\u5011\u7684\u5b58\u6d3b\u7387\u76f8\u7576\u9577\uff0c\u5f9e12\u500b\u6708\u81f3\u500b41\u500b\u6708\u3002Karnofsky Performance Score\u70ba70\u81f3100\u7684\u75c5\u60a3\u5b58\u6d3b\u6642\u9593\u8f0370\u4ee5\u4e0b\u8005\u9577\uff1b\u5206\u5225\u70ba12\u500b\u6708\u53ca10\u500b\u6708(p=0.0443)\uff0c\u7d71\u8a08\u5b78\u4e0a\u662f\u5177\u6709\u610f\u7fa9\u7684\u3002\u800c55\u6b72\u4ee5\u4e0b\u8f03\u5e74\u8f15\u7684\u75c5\u60a3\uff0c\u96d6\u770b\u8d77\u4f86\u6d3b\u5f97\u8f0355\u6b72\u5305\u542b\u53ca\u4ee5\u4e0a\u7684\u75c5\u60a3\u4e45\uff0813\u500b\u6708\u6bd4\u4e0a11\u500b\u6708\uff09\uff0c\u4f46\u7d71\u8a08\u5b78\u4e0a\u662f\u4e0d\u5177\u6709\u610f\u7fa9\u7684\u3002\u5176\u4ed6\u7684\u8b8a\u6578\u4e26\u6c92\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u5dee\u7570\u3002\n\u7d50\u8ad6\uff1a\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u7684\u597d\u8655\u662f\u5728\u53ef\u4ee5\u63d0\u9ad8\u5c0d\u816b\u7624\u7684\u653e\u5c04\u5291\u91cf\u60c5\u6cc1\u4e0b\uff0c\u5c0d\u6b63\u5e38\u7d44\u7e54\u7684\u50b7\u5bb3\u4e26\u4e0d\u6703\u76f8\u5c0d\u7684\u589e\u52a0\u592a\u591a\uff0c\u800c\u4e14\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624\u7684\u75c5\u60a3\u666e\u904d\u80fd\u8010\u53d7\u6b64\u7a2e\u6cbb\u7642\u65b9\u5f0f\uff0c\u6cbb\u7642\u671f\u9593\u53ca\u4e4b\u5f8c\u4e26\u672a\u767c\u751f\u56b4\u91cd\u7684\u4f75\u767c\u75c7\u3002\u672c\u79d1\u7684\u75c5\u60a3\uff0c\u4e2d\u4f4d\u5b58\u6d3b\u7387\u8207\u5176\u4ed6\u5831\u544a\u76f8\u8fd1\u3002\u5728\u6b64\u7814\u7a76\u4e2d\uff0cKarnofsky Performance Score\u662f\u552f\u4e00\u5728\u7d71\u8a08\u4e0a\u5177\u6709\u5f71\u97ff\u5b58\u6d3b\u7387\u7684\u56e0\u7d20\u3002", "e": "Purpose: To evaluate the outcome of post-operative hyperfractionated radiation therapy in patients with glioblastoma multiforme in terms of overall survival and prognostic factors.\nMaterial and Methods: From September 1999 to April 2004, 27 post-operative glioblastoma multiforme patients received hyperfractionated radiation therapy with twice daily fractions of 1.2 Gy at a dose of 72 Gy, except one child who received twice daily 1.08 Gy fraction at a dose of 64.8 Gy. No adjuvant chemotherapy was applied. All patients were irradiated locally after 3-dimensional conformal treatment planning. There were 4 patients who received 2 courses of radiation therapy to the same region of the brain for tumor recurrence, in which the first course was hyperfractionated treatment and the second course were either hyperfractionation or conventional fractionation. Patient and tumor factors were investigated for survival differences using Kaplan-Meier method and Log-Rank test. These include age, sex, Karnofsky Performance Score, tumor maximum diameter, and types of surgery.\nResults: Median survival of our 27 patients was 12 months, with 1 year and 2-year survival probabilities of 44% and 19%, respectively. The group of patients who received two full courses of radiation treatment did fairly well in survival ranged 12 to 41 months. Patients with Karnofsky Performance Score equal or greater than 70 had longer median survival than patients less than 70 (12 months and 10 months, respectively). This difference is statistically significant (p=0.0443). Although patients younger than 55 years seemed to do better than those older or equal to 55 years (median survival of 13 months versus 11 months), no significant survival difference was noted. Patients who received total resection had better median survival (12 months) than patients who received inadequate resection (7 months), but this difference did not reach statistical significance either. Other tumor or patient factors showed no survival difference.\nConclusion: The advantage of hyperfractionation radiation treatment is to escalate total tumor dose without increasing toxicity in normal tissues. Total dose of 72 Gy is well tolerated by glioblastoma multiform patients given in hyperfractionated fashion. Overall survival rate and median survival of our patients are comparable to other studies of altered fractionation treatment regime. Karnofsky Performance Score is the most important prognostic factors in our study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-137-142-a", "title": "XV\u8207EDR2\u5e95\u7247\u4e4b\u5291\u91cf\u8868\u73fe\u8207\u53ef\u80fd\u7684\u5f71\u97ff\u53c3\u6578", "keywords": "XV\u5e95\u7247;EDR2\u5e95\u7247;\u5291\u91cf;\u5149\u5bc6\u5ea6 XV film;EDR2 film;Dose;Photographic density", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u653e\u5c04\u6cbb\u7642\u5e38\u7528\u4e4bXV\u548cEDR2\u4e8c\u7a2e\u5291\u91cf\u9a57\u8b49\u5e95\u7247\u7684\u7279\u6027\u8207\u7dda\u6027\u5291\u91cf\u53cd\u61c9\u7bc4\u570d\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u7531\u5149\u5bc6\u5ea6\u5291\u91cf\u5716\u5206\u6790\u6700\u9069\u5291\u91cf\u5340\u7684\u7bc4\u570d\uff0c\u4e26\u5efa\u8b70\u53ef\u61c9\u7528\u4e4b\u6700\u9069\u5291\u91cf\u53cd\u61c9\u5340\u3002\u53e6\u5916\u8a55\u4f30\u5291\u91cf\u7387\u3001\u7167\u91ce\u3001\u6df1\u5ea6\u3001\u53caX\u5149\u80fd\u91cf\uff0c\u5c0dXV\u548cEDR2\u5e95\u7247\u5149\u5bc6\u5ea6\u7684\u5f71\u97ff\u7a0b\u5ea6\u3002\n\u7d50\u679c\uff1a\u7531H&D\u66f2\u7dda\u5716\u77e5XV\u6bd4EDR2\u5e95\u7247\u7684\u659c\u7387\u5927\uff0c\u800c\u4e14\u9054\u5230\u98fd\u548c\u9ede\u7684\u5291\u91cf\u503c\u8f03\u5c0f\uff0c\u9019\u8aaa\u660e\u6b64\u5e95\u7247\u53ef\u6e2c\u91cf\u7684\u5291\u91cf\u7bc4\u570d\u8f03\u7a84\u3002\u5728\u4e0d\u540c\u7684\u5291\u91cf\u7387\u7167\u5c04\u4e0b\uff0cEDR2\u5e95\u7247\u8207XV\u5e95\u7247\u7684\u5149\u5bc6\u5ea6\u5291\u91cf\u66f2\u7dda\u4e26\u7121\u660e\u986f\u5dee\u7570\u3002\u7167\u91ce\u75315\u00d75\u5e73\u65b9\u516c\u5206\u8b8a\u5316\u81f320\u00d720\u5e73\u65b9\u516c\u5206\uff0c\u5c0d\u4e8c\u7a2e\u5e95\u7247\u5149\u5bc6\u5ea6\u4e4b\u5f71\u97ff\u8b8a\u5316\u5747\u5c0f\u65bc1.5%\u300220\u516c\u5206\u7684\u6df1\u5ea6\u8b8a\u5316\uff0c\u5c0d\u4e8c\u7a2e\u5e95\u7247\u5149\u5bc6\u5ea6\u4e4b\u5f71\u97ff\u5c0f\u65bc2.3%\u3002X\u5149\u80fd\u91cf\u5f9e4 MV\u589e\u81f310MV\uff0cXV\u4e4b\u5149\u5bc6\u5ea6\u589e\u52a08.9%\uff1b\u800cEDR2\u4e4b\u5149\u5bc6\u5ea6\u589e\u52a08.2%\u3002\n\u7d50\u8ad6\uff1a\u572810MV\u7684X\u5149\u66dd\u9732\u689d\u4ef6\u4e0b\uff0c\u5efa\u8b70XV\u5e95\u7247\u7684\u6700\u9069\u5291\u91cf\u53cd\u61c9\u7bc4\u570d\u572820~90 cGy\uff1b\u800cEDR2\u5e95\u7247\u4e4b\u6700\u9069\u5291\u91cf\u53cd\u61c9\u7bc4\u570d25~400 cGy\u3002\u5728\u5149\u5bc6\u5ea6\u5291\u91cf\u5716\u4e4b\u6700\u9069\u5291\u91cf\u5340\uff0cEDR2\u5e95\u7247\u7684\u7dda\u6027\u5ea6\u8f03XV\u5e95\u7247\u4f73\u3002\u5728XV\u548cEDR2\u5e95\u7247\u7684\u6700\u9069\u5291\u91cf\u5340\u5167\uff0c\u5291\u91cf\u7387\u3001\u7167\u91ce\u3001\u6df1\u5ea6\u5c0d\u5149\u5bc6\u5ea6\u7684\u5f71\u97ff\u5c0f\u53ef\u5ffd\u7565\u3002\u4f46\u80fd\u91cf\u5c0d\u5149\u5bc6\u5ea6\u7684\u6e2c\u5b9a\uff0c\u5176\u5f71\u97ff\u4e0d\u5bb9\u5ffd\u8996\u3002", "e": "Purpose: To study the characteristics of two radiographic films and their linearly response ranges.\nMethods and Materials: Measurement and using the sensitometric curves to analyze the dose performance and recommend the best responsive range for XV and EDR2 films. The parameters of dose rate, field size, depth, and energy of x-ray were applied to evaluate the change in photographic density.\nResults Comparing the responsive region in sensitometric curves, the slope of XV film is larger than EDR2 film and the saturation dose of XV film is less than EDR2 film. It means responsive range of XV film is smaller than that of EDR2 film. The photographic density was lot changed with the dose rate. As the field size changed from 5\u00d75 to 20\u00d720 cm^2, the variation of four photographic densities was less than 1.5%. The change of photographic density was less than 2.3% within a depth form 5 cm to 20 cm. Replacing the energy of 4 MV with 10 MV, the density increased 8.9% for XV film and 8.2% for EDR2 film.\nConclusion: We recommend the responsive range of XV film is from 20 to 90 cGy and EDR2 film is from 25 to 400 cGy, at the exposure of 10 MV x-ray. EDR2 film has a better linear relationship between photographic density and dose than XV film. No dose rate effect and a little change ill field size and depth were found. But, the x-ray clergy is an important parameter to the measurement of photographic density."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-143-151-a", "title": "Evaluation of Two Types of Digitizers for Film Dosimetry", "keywords": "\u8edf\u7247\u5291\u91cf\u9a57\u8b49;\u6383\u63cf\u5668;\u87a2\u5149\u71c8\u5149\u6e90;\u96f7\u5c04\u5149\u6e90 Film dosimetry;Digitizer;Fluorescent light source;Laser beam source", "c": "\u76ee\u7684\uff1a\u61c9\u7528\u8edf\u7247\u65bc\u5291\u91cf\u9a57\u8a3c\uff0c\u5728\u8edf\u7247\u6578\u4f4d\u5316\u4e4b\u904e\u7a0b\u6703\u56e0\u4f7f\u7528\u5100\u5668\u7684\u5149\u6e90\u3001\u6a5f\u68b0\u52d5\u4f5c\u5f71\u97ff\uff0c\u9020\u6210\u6578\u4f4d\u5316\u5f71\u50cf\u9593\u5b58\u5728\u5dee\u7570\u3002\u5148\u524d\u7814\u7a76\u66fe\u5229\u7528ROC(receiver operator characteristics)\u65b9\u5f0f\u6bd4\u8f03\u5169\u7a2e\u4e0d\u540c\u5149\u6e90\u6383\u63cf\u5668\u5f97\u5230\u6c92\u660e\u986f\u5dee\u7570\u4e4b\u7d50\u679c\uff1b\u7136\u800c\uff0c\u4e0a\u8ff0\u65b9\u5f0f\u4f9d\u8cf4\u8996\u529b\u4f86\u5224\u5225\u5f71\u50cf\u5dee\u7570\u4e4b\u65b9\u6cd5\u4e26\u4e0d\u9069\u7528\u65bc\u5291\u91cf\u9a57\u8a3c\u4e4b\u9700\u6c42\u3002\n\u6211\u5011\u8a55\u4f30\u5169\u53f0\u4e0d\u540c\u578b\u614b\u4e4b\u6383\u63cf\u5668\uff0c\u61c9\u7528\u65bc\u8edf\u7247\u5291\u91cf\u9a57\u8a3c\u7684\u7279\u6027\uff1b\u6b64\u4e8c\u53f0\u6383\u63cf\u5668\u5c6c\u65bc\u540c\u4e00\u5bb6\u91ab\u9662\u6240\u64c1\u6709\uff0c\u8cfc\u8cb7\u65bc\u76f8\u540c\u5e74\u4efd\uff081998\u5e74\uff09\uff0c\u4e26\u5229\u7528\u4f5c\u70ba\u65e5\u5e38\u6a5f\u5668\u54c1\u8cea\u4fdd\u8b49\u5de5\u5177\u4e4b\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u8907\u88fd\u7247(Kodak\uff0cRA Duplicating Film)\u8907\u88fd\u6a19\u6e96\u5149\u5bc6\u5ea6\u7247(Kodak photographic step tablet no.3\uff0c21 steps\uff0cO. D. range 0.05~3.05)\u53ca\u5176\u4ed6\u5be6\u9a57\u7528\u4e4b\u8edf\u7247\uff0c\u5c07\u6e2c\u8a66\u7247\u5206\u5225\u7d93\u904e\u5169\u7a2e\u4e0d\u540c\u6383\u63cf\u5668\u6578\u4f4d\u5316\uff0c\u4e00\u53f0\u70ba\u87a2\u5149\u71c8\u5149\u6e90(Vidar VXR-12 PLUS)\uff0c\u53e6\u4e00\u53f0\u6383\u63cf\u5668\u70ba\u96f7\u5c04\u5149\u6e90 (Lumiscan-50)\u3002\n\u5be6\u9a57\u7528\u4e4b\u8edf\u7247\uff0c\u8a2d\u8a08\u7528\u4f86\u6bd4\u8f03\u4e26\u91cf\u5316\u5169\u8005\u4e4b\u6696\u6a5f\u6548\u61c9\uff0c\u8a0a\u865f\u53ca\u96dc\u8a0a\u6bd4\uff0c\u767e\u5206\u6a19\u6e96\u8aa4\u5dee\uff0c\u5149\u5bc6\u5ea6\u7bc4\u570d\uff0c\u7a7f\u900f\u6027\u5047\u5f71\uff0c\u53ca\u5e72\u6d89\u6027\u5047\u5f71(Moir\u00e9 artifact)\u7b49\u7279\u6027\uff0c\u4e0a\u8ff0\u7279\u6027\u5c07\u9020\u6210\u50cf\u6578\u503c(pixel value)\u7684\u8b8a\u52d5\uff0c\u56e0\u800c\u9020\u6210\u5291\u91cf\u8f49\u63db\u6642\u7684\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a\u6383\u63cf\u5668\u7684\u8a0a\u865f\u5c0d\u96dc\u8a0a\u6bd4\u3001\u767e\u5206\u6a19\u6e96\u8aa4\u5dee\u53ca\u5149\u6e90\u7a7f\u900f\u80fd\u529b\uff0c\u6703\u6839\u64da\u4e0d\u540c\u5149\u5bc6\u5ea6\u503c\u8b8a\u5316\u800c\u5f71\u97ff\uff0c\u96f7\u5c04\u5149\u6e90\u6383\u63cf\u5668\u5728\u4e0a\u8ff0\u60c5\u6cc1\u6709\u8f03\u7a69\u5b9a\u7684\u8868\u73fe\uff1b\u53e6\u4e00\u65b9\u9762\uff0c\u87a2\u5149\u5149\u6e90\u6383\u63cf\u5668\u5247\u7522\u751f\u8f03\u5c11\u7684\u7a7f\u900f\u6027\u5047\u5f71\uff0c\u4e14\u4e0d\u6703\u6709\u5e72\u6d89\u6027\u5047\u5f71\u7522\u751f\u3002\n\u7d50\u8ad6\uff1a\u61c9\u7528\u6383\u63cf\u5668\u5728\u8edf\u7247\u5291\u91cf\u9a57\u8a3c\u9700\u8003\u616e\u5176\u4f7f\u7528\u76ee\u7684\uff0c\u87a2\u5149\u5149\u6e90\u6383\u63cf\u5668\u80fd\u63d0\u4f9b\u8f03\u9ad8\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\uff0c\u9069\u7528\u65bc\u5149\u7167\u91ce\u53ca\u8f3b\u5c04\u7167\u91ce\u4e00\u81f4\u6027\u6216\u661f\u72c0\u7167\u5c04(star shoot)\u7b49\u6aa2\u67e5\uff0c\u800c\u5229\u7528\u4f5c\u70ba\u5291\u91cf\u6aa2\u67e5\u6642\uff0c\u96f7\u5c04\u5149\u6e90\u6383\u63cf\u5668\u5247\u63d0\u4f9b\u76f8\u5c0d\u8f03\u5bec\u7684\u5291\u91cf\u5206\u6790\u7bc4\u570d\u53ca\u8f03\u4f4e\u7684\u96dc\u8a0a\u7522\u751f\u3002", "e": "Purpose: In radiographic dosimetry, the performance of the digitizing system is highly dependent on the illumination mechanism or characteristics of light source. Previous analysis of the two types of digitizers by ROC (receiver operator characteristics) method has shown no significant differences. However, ROC method by visual determination is not sensitive for dosimetry purpose.\nWe evaluated and compared the distinctive features between two digitizers that were purchased in the same particular year (1998's) by the same hospital. They have been routinely used for QA tools and film dosimetry.\nMaterials and Methods: The duplicate films (Kodak, RA Duplicating Film) were made to be replicas of standard O.D. strip (Kodak photographic step tablet no.3, 21 steps, O.D. range 0.05\uff5e3.05) and other test films. Two digitizers were used to digitize those films. One digitizer was the Vidar VXR-12 PLUS with fluorescent light source and the other was Lumiscan-50 with laser beam source.\nTest films were made in order to investigate their warm-up effect, signal-to-noise ratio, percentage standard deviation, optical density range, transmission artifact and Moir\u00e9 artifacts. Those features might be affected when films were converted into corresponding value through the above-mentioned digitizers.\nResults: Varying in O.D. range influence the feature of signal-to-noise ratio, percentage standard deviation, and transmitting capacity that performed by digitizers. The digitizer with a laser beam source was shown more stable in such circumstances. On the other hand, the digitizer with a broadband fluorescent light source had a minor transmission artifact and no Moir\u00e9 artifacts than the previous one.\nConclusions: Selection of a digitizer for film dosimetry depends on what kind of data one would want to acquire. A fluorescence light digitizer has a higher spatial resolution and is more suitable for radiation field-light field coincident and star shoot check. On the other hand, a laser beam digitizer offers wilder dose range and less noise."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-153-159-a", "title": "Paraganglioma of Head and Neck Treated with Surgery and Local Radiotherapy: Case Report and Reviews of Literature", "keywords": "\u526f\u795e\u7d93\u7bc0\u7624;\u982d\u9838\u90e8;\u5916\u79d1\u624b\u8853;\u653e\u5c04\u6cbb\u7642 Paraganglioma;Head and neck;Surgery;Radiotherapy", "c": "\u982d\u9838\u90e8\u526f\u795e\u7d93\u7bc0\u7624\u662f\u4e00\u7f55\u898b\u5076\u767c\u7684\u75be\u75c5\uff0c\u76db\u884c\u7387\u7d04\u4f54\u6240\u6709\u982d\u9838\u90e8\u816b\u7624\u7684\u4e09\u842c\u5206\u4e4b\u4e00\u3002\u5927\u90e8\u5206\u526f\u795e\u7d93\u7bc0\u7624\u7684\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\u662f\u5916\u79d1\u624b\u8853\u5207\u9664\u3002\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u4ee5\u6e1b\u7de9\u6b98\u5b58\u816b\u7624\u7684\u60e1\u5316\u3002\u5728\u672c\u6587\u4e2d\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f4d\u4ee5\u5916\u79d1\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u7dda\u6cbb\u7642\u7684\u982d\u9838\u90e8\u526f\u795e\u7d93\u7bc0\u7624\u7684\u60a3\u8005\uff0c\u4e26\u4e14\u56de\u9867\u95dc\u65bc\u526f\u795e\u7d93\u7bc0\u7624\u7684\u6587\u737b\u3002", "e": "Paragangliomas of head and neck are rare tumors that occur sporadically with the prevalence of about 1 in 30,000 of head and neck tumors. The treatment of choice is often surgical resection for most paragangliomas. Postoperative irradiation may be beneficial in slowing the progression of residual disease. We reported a case of paraganglioma of head and neck with the treatment of surgery plus postoperative irradiation and reviewed the literatures of paraganglioma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200506-12-2-161-165-a", "title": "Gingival Metastasis from Rectal Cancer: A Case Report", "keywords": "\u9f52\u9f66\u8f49\u79fb;\u76f4\u8178\u764c;\u653e\u5c04\u6cbb\u7642 Gingival metastasis;Rectal cancer;Radiotherapy", "c": "\u5f9e\u975e\u53e3\u8154\u90e8\u4f4d\u7684\u60e1\u6027\u816b\u7624\u8f49\u79fb\u81f3\u9f52\u9f66\u662f\u975e\u5e38\u7f55\u898b\u3002\u7d04\u4f54\u6240\u6709\u8f49\u79fb\u53e3\u8154\u75c5\u4f8b\u6bd4\u7387\u767e\u5206\u4e4b\u56db\u4ee5\u4e0b\u3002\u9060\u7aef\u764c\u75c7\u8f49\u79fb\u5230\u53e3\u8154\u8edf\u7d44\u7e54\uff0c\u4ee5\u80ba\u764c\u548c\u4e73\u764c\u6700\u5e38\u898b\u3002\u9664\u9838\u90e8\u8207\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7d50\u4e4b\u5916\uff0c\u76f4\u8178\u764c\u8f49\u79fb\u81f3\u53e3\u8154\u6975\u70ba\u5c11\u898b\u3002\u672c\u6587\u5831\u544a\u4e00\u4f4d\u7531\u76f4\u8178\u817a\u764c\u8f49\u79fb\u81f3\u9f52\u9f66\u7684\u7f55\u898b\u75c5\u4f8b\u3002\u96d6\u7136\u9f52\u9f66\u8f49\u79fb\u7684\u9810\u5f8c\u76f8\u7576\u5dee\uff0c\u4f46\u662f\u7d66\u4e88\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u662f\u5c0d\u65bc\u9019\u56b4\u91cd\u75be\u75c5\u7684\u9060\u7aef\u8f49\u79fb\u4e4b\u4e00\u7a2e\u6709\u6548\u7684\u59d1\u606f\u6027\u7642\u6cd5\u3002", "e": "Metastatic tumors to gingival from non-oral malignancies are very uncommon. It accounts only for less than 4% of all metastatic tumors to the oral cavity. The lung and breast are the most common distant primary sites for metastasis to oral soft tissue. Metastases from the rectal cancer to oral cavity and neck region are extremely rare, except to neck and supraclavicular lymph node. We will describe a rare case of primary adenocarcinoma of rectum with metastasis to the gingiva of the mouth. Although the prognosis of patients with gingival metastasis is felt to be poor, regional radiotherapy is effective for the palliative purpose to the local metastatic lesion of the advanced disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-1-7-a", "title": "\u65e9\u671f\u651d\u8b77\u817a\u764c\u4e4b\u624b\u8853\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642\u53ca\u5176\u9810\u5f8c\u56e0\u5b50", "keywords": "\u5c40\u90e8\u651d\u8b77\u817a\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u651d\u8b77\u817a\u6839\u9664\u6027\u6458\u9664\u624b\u8853;\u651d\u8b77\u817a\u7279\u7570\u6297\u539f Local prostate cancer;Radiotherapy;Radical prostatecomy;PSA", "c": "\u76ee\u7684\uff1a\u4ee5\u651d\u8b77\u817a\u7279\u7570\u6297\u539f(prostate specific antigen, PSA)\uff0c\u56de\u6eaf\u5206\u6790(retrospective analysis)\uff0c\u6bd4\u8f03\u81e8\u5e8a\u5206\u671f\u70baTl-T2\u7684\u5c40\u90e8\u651d\u8b77\u817a\u764c\uff0c\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642(radiation therapy)\u8207\u651d\u8b77\u817a\u6839\u9664\u6027\u6458\u9664\u624b\u8853(radical prostatectomy)\u7684\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1991\u5e747\u6708\u81f32003\u5e747\u6708\uff0c\u5171\u6709235\u4f4d\u81e8\u5e8a\u5206\u671f\u70baT1-T2\u7684\u65e9\u671f\u651d\u8b77\u817a\u764c\u75c5\u4eba\uff0c\u5728\u672c\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u651d\u8b77\u817a\u6839\u9664\u6027\u6458\u9664(radical prostatectomy)\u6cbb\u7642\u3002\u6240\u6709\u7684\u75c5\u4eba\u90fd\u6709\u6cbb\u7642\u524d\u7684\u8840\u4e2dPSA\u6fc3\u5ea6\u3001\u5207\u7247\u7684\u683c\u91cc\u68ee\u5206\u6578(Gleason score)\u3001\u6cbb\u7642\u524d\u7684\u8cc0\u723e\u8499\u6cbb\u7642\u4e0d\u8d85\u904e\u516d\u500b\u6708\uff0c\u5c40\u90e8\u6cbb\u7642\u5f8c\u6c92\u6709\u518d\u7d66\u4e88\u5176\u4ed6\u7684\u8f14\u52a9\u6cbb\u7642\u3002\u5171\u6709119\u4f4d(50.6%)\u63a5\u53d7\u5fb9\u5e95\u6839\u9664\u624b\u8853\uff0c\u624b\u8853\u5f8c\u908a\u7de3\u6709\u6b98\u9918\u75c5\u7076\u8005\u4e0d\u5217\u5165\u672c\u7814\u7a76\u7684\u5c0d\u8c61\uff1b\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u5c0f\u65bc70Gy\u8005\u5171\u670952\u4f4d(22.1%)\uff1b\u5927\u65bc\u7b49\u65bc70Gy\u8005\u5171\u670938\u4f4d(16.2%)\uff1b\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u5408\u4f75\u8fd1\u63a5\u6cbb\u7642\u8005\u5171\u670919\u4f4d(8.1%)\uff1b\u53e6\u5916\u67097\u4f4d(3%)\u63a5\u53d7\u7d93\u5c3f\u9053\u651d\u8b77\u817a\u5207\u9664\u624b\u8853\u5f8c\u52a0\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u5c0f\u65bc70Gy\u8207\u5927\u65bc70Gy\u7684\u4e2d\u503c\u5291\u91cf\u5206\u5225\u662f65.6Gy\u53ca70.2Gy\u3002\u6240\u6709\u75c5\u4eba\u7684\u4e2d\u503c\u8ffd\u8e64\u6642\u9593\u70ba41.9\u500b\u6708\u3002PSA\u503c\u53ef\u4f5c\u70ba\u5c0d\u6cbb\u7642\u53cd\u61c9\u7684\u6307\u6a19\uff0c\u6cbb\u7642\u5f8cPSA\u503c\u591a\u6703\u4e0b\u964d\uff0c\u5982\u679c\u4e0d\u6b63\u5e38\u7684\u6607\u9ad8\uff0c\u6709\u53ef\u80fd\u5c40\u90e8\u5fa9\u767c\u6216\u75be\u75c5\u60e1\u5316(disease progression)\u3002\u81e8\u5e8a\u4e0a\u90fd\u4ee5PSA\u503c\u5224\u65b7\u651d\u8b77\u817a\u764c\u9810\u5f8c\u4e4b\u597d\u58de\u6216\u6cbb\u7642\u5f8c\u8ffd\u8e64\u6aa2\u67e5\u75be\u75c5\u6709\u7121\u6301\u7e8c\u5b58\u5728(persistent disease)\u6216\u5fa9\u767c(relapse)\u3002\n\u672c\u7814\u7a76\u662f\u4ee5\u81e8\u5e8aT\u5206\u671f\u3001\u6cbb\u7642\u524d\u7684\u8840\u4e2dPSA\u6fc3\u5ea6\u3001Gleason\u5206\u6578\u3001\u6cbb\u7642\u6a21\u5f0f\u7b49\u8b8a\u6578\u5c0d\u751f\u5316\u6027\u7121\u5fa9\u767c\u5b58\u6d3b\u7387(biochemical relapse free survival, bRFS)\uff0c\u4f5c\u591a\u9805\u8b8a\u6578\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u624b\u8853\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u76845\u5e74bRFS(5-year biochemical relapse free survival)\u5206\u5225\u662f53.5%\u820759.0%\uff0c7\u5e74bRFS\u5206\u5225\u662f21.3%\u820745.0%\uff0c\u591a\u8b8a\u6578\u5206\u6790\u986f\u793a\u624b\u8853\u524d\u7684\u8840\u4e2dPSA\u6fc3\u5ea6(p=0.029)\u8207Gleason\u5206\u6578(p=0.006)\u662f\u7368\u7acb\u7684\u5fa9\u767c\u9810\u5f8c\u56e0\u5b50\uff0c\u6cbb\u7642\u6a21\u5f0f(p=0.025)\u8207\u81e8\u5e8aT\u5206\u671f(p=0.53)\u4e0d\u662fPSA\u5fa9\u767c\u7684\u7368\u7acb\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1aT1-T2\u7684\u5c40\u90e8\u651d\u8b77\u817a\u764c\uff0c\u8207\u6839\u9664\u6027\u6458\u9664\u624b\u8853\u6bd4\u8f03\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u4e5f\u6709\u76f8\u7576\u7684\u6cbb\u7642\u7d50\u679c\uff0c\u5c0d\u65bcPSA\u5fa9\u767c\u7684\u5f71\u97ff\u6c92\u6709\u7d71\u8a08\u4e0a\u7684\u610f\u7fa9\u3002", "e": "Purpose: This retrospective analysis reviewed the biochemical relapse free survival rates after treatment with radiotherapy or radical prostatectomy (RP) for clinical stage Tl-T2 localized prostate cancer.\nMethods and Materials: The study population comprised 235 patients treated at either Urology section or Radiation Oncology section in our institution. All patients had pretreatment prostate-specific antigen (iPSA) levels and biopsy Gleason scores (bGSs) Neoadjuvant androgen block treatment was given for less than 6 months. No adjuvant therapy was given after local therapy. 119 patients (50.6%) had undergone radical prostacteomy (RP). 52 patients (22.1%) received EBRT\uff1c70Gy, 38 patients (16.2%) received EBRT\u226570Gy, 7 patients (3%) were treated with post TURP radiotherapy and combined interstitial and radiotherapy was delivered for 19 patients (8.1%). Only patients with free surgical margin were enrolled in the group of RP, The median radiation doses in EBRT\uff1c70Gy and EBRT\u226570Gy was 65.6Gy and 70.2Gy, respectively. The median follow-up time for all patients was 41.9 months. Biochemical relapse was defined as two consecutive PSA\uff1e0.2ng/ml for RP and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases. Cox regression multivariate analysis was performed using clinical T stage, bGS, iPSA and treatment modality.\nResults: The 5-year bRFS (biological relapse free survival) for RP and radiotherapy was 53.5% and 59% respectively. The 7-year bRFS for RP and radiotherapy was 21.3% and 45% respectively. Multivariate analysis showed iPSA (p=0.029) and bGS (p=0.006) to be independent predictors of relapse. Treatment modality and clinical T stage were not independent predictors of relapse.\nConclusion: There was no significant difference between RP and radiotherapy in the view of biochemical relapse for stage T1-T2 prostate cancer"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-9-16-a", "title": "Surgery Followed by Concurrent Chemoradiation with Weekly Cisplatin and Adjuvant Systemic Chemotherapy for Locally Advanced Esophageal Cancer-A Pilot Study", "keywords": "\u98df\u9053\u764c;\u624b\u8853;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642;\u6bcf\u9031cisplatin;\u8f14\u52a9\u5316\u5b78\u6cbb\u7642 Esophageal cancer;Surgery;Chemoradiation,Weekly cisplatin;Adjuvant chemotherapy", "c": "\u76ee\u7684\uff1a\u98df\u9053\u764c\u662f\u4e00\u7a2e\u975e\u5e38\u60e1\u6027\u53ca\u5e38\u5e38\u5728\u75be\u75c5\u5f8c\u671f\u624d\u8a3a\u65b7\u51fa\u4f86\u7684\u75be\u75c5\u3002\u5373\u4f7f\u7d93\u904e\u7a4d\u6975\u7684\u5916\u79d1\u624b\u8853\u6cbb\u7642\uff0c\u5b58\u6d3b\u7387\u4ecd\u7136\u4e0d\u76e1\u7406\u60f3\u3002\u4e00\u4e9b\u7814\u7a76\u6a5f\u69cb\u5df2\u7d93\u8b49\u5be6\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u4ee5\u589e\u52a0\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u3002\u9451\u65bc\u570b\u5916\u8a2d\u8a08\u7684\u5316\u5b78\u85e5\u7269\u5291\u91cf\u5c0d\u65bc\u672c\u570b\u4eba\u4f86\u8aaa\u53ef\u80fd\u526f\u4f5c\u7528\u592a\u5927\u800c\u4e0d\u9069\u5408\uff0c\u6211\u5011\u8a2d\u8a08\u4e86\u4e00\u5957\u8853\u5f8c\u9031\u671f\u6027\u53ca\u4f4e\u5291\u91cf\u7684\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u4f86\u6cbb\u7642\u5c40\u90e8\u9032\u5c55\u6027\u7684\u98df\u9053\u764c\u3002\u9664\u6b64\u4e4b\u5916\uff0c\u9060\u7aef\u8f49\u79fb\u5e38\u662f\u6cbb\u7642\u5931\u6557\u7684\u4e3b\u56e0\u4e4b\u4e00\u3002\u56e0\u6b64\uff0c\u9664\u4e86\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5916\uff0c\u6211\u5011\u518d\u52a0\u4e0a\u5168\u8eab\u6027\u7684\u5316\u5b78\u6cbb\u7642\u7576\u4f5c\u6211\u5011\u6cbb\u7642\u98df\u9053\u764c\u7684\u8a08\u756b\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1999\u5e746\u6708\u52302003\u5e742\u6708\u5171\u670936\u4f4d\u5c40\u90e8\u9032\u5c55\u6027\u7684\u75c5\u4eba\u3002\u7d93\u904e\u624b\u8853\u4e4b\u5f8c\uff0c\u5176\u4e2d18\u4f4d\u75c5\u4eba\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5168\u8eab\u6027\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u5176\u991818\u4f4d\u75c5\u4eba\u53ea\u55ae\u7368\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u5169\u7d44\u7684\u8a2d\u8a08\u5291\u91cf\u76f8\u540c\uff0c\u70ba60 Gy\u3002\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u70ba\u6bcf\u9031\u4e00\u6b21\u4f4e\u5291\u91cf\u7684cisplatin (30 mg/(\u5e73\u65b9\u516c\u5c3a))\uff0c\u51716\u6b21\u3002\u9593\u96943\u52304\u9031\u5f8c\uff0c\u7d66\u65bc\u5168\u8eab\u6027\u7684\u5316\u5b78\u6cbb\u7642\u3002\u8a2d\u8a08\u5291\u91cf\u70ba\u6bcf\u6708\u4e00\u6b21\uff0c\u6bcf\u6b21cisplatin (20 mg/(\u5e73\u65b9\u516c\u5c3a)) D1~D5\uff0c\u51714\u6b21\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u7d50\u679c\u5728\u9019\u5169\u500b\u7d44\u5225\u5c0d\u65bc\u4e2d\u503c\u5b58\u6d3b(17.5 months vs. 10 months)\u53ca2\u5e74\u5b58\u6d3b\u7387(77% vs. 44%, p=0.02)\u3002\u8840\u6db2\u53ca\u975e\u8840\u6db2\u6027\u526f\u4f5c\u7528\u5728\u9019\u5169\u500b\u7d44\u5225\u662f\u76f8\u7576\u7684\u3002\n\u7d50\u8ad6\uff1a\u5728\u9019\u500b\u7814\u7a76\u8a2d\u8a08\u4e4b\u4e0b\uff0c\u8853\u5f8c\u9031\u671f\u6027\u53ca\u4f4e\u5291\u91cf\u7684\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u5408\u4f75\u5168\u8eab\u6027\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u5c0d\u65bc\u5c40\u90e8\u9032\u5c55\u6027\u7684\u98df\u9053\u764c\uff0c\u4e0d\u4f46\u5728\u526f\u4f5c\u7528\u4e0a\u662f\u53ef\u4ee5\u63a5\u53d7\u7684\uff0c\u800c\u4e14\u5728\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u4e0a\u662f\u6709\u5e6b\u52a9\u7684\u3002", "e": "Purpose: Carcinoma of the esophagus is a virulent malignancy with poor survival despite aggression resection. This pilot study was conducted to evaluate the efficacy and toxicity of a three-step combination therapy for locally advanced esophageal cancer.\nMaterial and Methods: We retrospectively reviewed patients with esophageal carcinoma treated at our institution from July 1999 to February 2003. Patients were included in the study if they had T3 to T4, N0/N1, and M0 stage disease. All patients underwent a curative resection with a margin negative for malignant cells. There were i8 patients who then had adjuvant concurrent chemoradiation (CCRT group) and systemic adjuvant chemotherapy and i8 had surgery followed by radiation alone (RT group). Total doses of 60 Gy for both groups were given. In addition to RT, the CCRT group received concurrent chemotherapy consisting of 6 weekly doses of cisplatin (CDDP) (30 mg/m^2). CCRT was followed by adjuvant chemotherapy consisting of 4 monthly cycles of CDDP (20 mg/m^2/day) plus 5-fluorouracil (1000 mg/m^2/day) for 5 consecutive days. This study looked at survival, toxicity, and patterns of failure.\nResults: The CCRT group had significantly better median survival (17.5 months vs. 10 months) and 2-year survival (77% vs. 44%, p=0.02). Hematologic and non-hematologic toxicities were generally comparable in both groups.\nConclusion: In this preliminary study, we have demonstrated that surgery followed by CCRT improves survival and locoregional control and decreases distant metastasis in local advanced esophageal cancer with acceptable toxicity. A large-scale, prospective randomized trial of this regimen is warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-17-25-a", "title": "Treatment Outcomes for Epidermoid Carcinoma of the Anal Canal in a Single Institution", "keywords": "\u809b\u9580\u764c;\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642 Anal cancer;Treatment;Radiotherapy", "c": "\u76ee\u7684\uff1a\u56de\u6eaf\u6027\u5206\u6790\u672c\u9662\u5c0d\u300e\u809b\u9580\u985e\u4e0a\u76ae\u764c\u300f\u4e4b\u6cbb\u7642\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1989\u5e7411\u6708\u81f32002\u5e743\u6708\uff0c\u5171\u670933\u7d93\u75c5\u7406\u5207\u7247\u8b49\u5be6\u4e14\u65b0\u8a3a\u65b7\u4e4b\u809b\u9580\u985e\u4e0a\u76ae\u764c\u75c5\u4eba\uff0c\u65bc\u672c\u9662\u63a5\u53d7\u4ee5\u6cbb\u7652\u70ba\u76ee\u7684\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d\u7b2c\u4e00\u3001\u7b2c\u4e8c\u671f\u7684\u75c5\u4eba\u4f5473%\uff0c\u800c\u7b2c\u4e09\u7b2c\u56db\u671f\u7684\u75c5\u4eba\u5247\u4f5427%\u3002\u653e\u5c04\u7dda\u7684\u4e2d\u4f4d\u6578\u5291\u91cf\u70ba54\u683c\u96f7(10-66.6 Gy)\u3002\u5176\u4e2d\u670930\u4f4d\u75c5\u4eba\u540c\u6642\u63a5\u53d72\u500b\u7642\u7a0b\u542b5-fluorouracil\u7684\u5316\u5b78\u6cbb\u7642\uff081000mg/(\u5e73\u65b9\u516c\u5c3a)/\u4e00\u5929\uff0c\u9023\u7e8c\u6ef4\u6ce8\u65bc\u7b2c1-4\u5929\uff0c\u7b2c29-32\u5929\uff09\uff0c\u4f75\u7d66\u4e88mitomyci-C\uff0810-15 mg\u65bc\u7b2c\u4e00\u5929\uff09\u4ea6\u6216cisplatin\uff0875mg/(\u5e73\u65b9\u516c\u5c3a)\uff0c3\u5c0f\u6642\u6ef4\u6ce8\uff0c\u65bc\u7b2c1\u5929\u548c\u7b2c29\u5929\uff09\u3002\u6240\u6709\u75c5\u4eba\u65bc\u6cbb\u7642\u958b\u59cb\u6642\u7686\u7121\u5b89\u6392\u8a08\u756b\u6027\u6cbb\u7642\u4e2d\u65b7\u6216\u4f11\u606f\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u4e4b\u4e2d\u4f4d\u6578\u70ba3\u5e74\uff080.1-14.1\u5e74\uff09\u3002\u65bc\u6b6433\u4f4d\u75c5\u4eba\u4e2d\uff0c\u670982%\u5b8c\u6210\u539f\u5148\u8a08\u756b\u7d66\u4e88\u7684\u653e\u5c04\u7dda\u5291\u91cf\uff0c\u4f46\u670948%\u7684\u75c5\u4eba\u56e0\u56b4\u91cd\u6703\u9670\u90e8\u6216\u809b\u9580\u5468\u570d\u7684\u76ae\u819a\u53cd\u61c9\u9700\u4e2d\u65b7\u6cbb\u7642\u90541\u661f\u671f\u4ee5\u4e0a\u30023\u5e74\u7684\u5be6\u969b\u300e\u5c40\u90e8\u63a7\u5236\u7387\u300f\uff0c\u300e\u5c40\u90e8\u5340\u57df\u63a7\u5236\u7387\u300f\u548c\u300e\u7121\u9808\u6c38\u4e45\u6027\u4eba\u5de5\u809b\u9580\u7387\u300f\u70ba71%\uff0c66%\uff0c79%\uff1b\u800c3\u5e74\uff085\u5e74\uff09\u4e4b\u300e\u7121\u75c5\u5b58\u6d3b\u7387\u300f\uff0c\u300e\u75be\u75c5\u5c08\u4e00\u6027\u5b58\u6d3b\u7387\u300f\u548c\u300e\u7e3d\u9ad4\u5b58\u6d3b\u7387\u300f\u5247\u5206\u5225\u70ba41%(41%)\uff0c77%(72%)\uff0c66%(53%)\u3002\n\u7d50\u8ad6\uff1a\u96d6\u672c\u9662\u4e4b\u300e\u809b\u9580\u985e\u4e0a\u76ae\u764c\u300f\u6cbb\u7642\u6210\u679c\u5206\u6790\u5176\u5404\u9805\u89c0\u5bdf\u53c3\u6578\u7565\u905c\u65bc\u65b0\u8fd1\u570b\u5916\u4e4b\u6587\u737b\u5831\u544a\uff0c\u4f46\u4ecd\u5728\u53ef\u63a5\u53d7\u4e4b\u7bc4\u570d\u5167\uff1b\u4e14\u53ef\u6b78\u56e0\u65bc\u8f03\u5c11\u7684\u7e3d\u75c5\u4eba\u6578\uff0c\u548c\u5305\u542b\u8f03\u591a\u8eab\u9ad4\u72c0\u6cc1\u5dee\u6216\u672a\u5b8c\u6210\u6cbb\u7642\u7684\u75c5\u4eba\u3002\u4ee5\u540c\u6b65\u653e\u7642\u53ca\u5316\u7642\u53ef\u4ee5\u4fdd\u7559\u809b\u9580\u4e26\u63a7\u5236\u816b\u7624\uff0c\u4f46\u76ae\u819a\u6bd2\u6027\u662f\u9020\u6210\u6cbb\u7642\u4e2d\u65b7\u7684\u4e3b\u8981\u4f75\u767c\u75c7\u3002\u672a\u4f86\u5180\u4ee5\u65b0\u5f0f\u4e4b\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4ee5\u6e1b\u5c11\u6bd2\u6027\u548c\u4e0d\u5fc5\u8981\u7684\u6cbb\u7642\u4e2d\u65b7\u4e26\u6539\u9032\u6210\u679c\u3002", "e": "Purpose: To retrospectively analyze treatment outcomes for epidermoid carcinoma of the anal canal in a single institution.\nMaterials and Methods: Between November 1989 and March 2002, thirty-three patients with biopsy-proven epidermoid carcinoma of the anal canal (Stage I-\u2161(73%), \u2162-\u2163(27%)) were treated by curative intent radiotherapy (RT). The median dose was 54 Gy (10-66.6 Gy). Two cycles of 5-fluorouracil-based chemotherapy (1000 mg/m^2/day, continuous infusion, days 1-4 and 29-32) either with mitomycin-C (10-15mg, bolus, day 1) or cisplatin (75mg/m^2, three hour infusion, day 1 and 29) were given concurrently to 30 patients. There were no scheduled breaks for any patients.\nResults: The median follow-up time was three years (0.1-14.1 years). Of the 33 patients, 82% completed their planned RT doses, and 48% had a RT interruption of more than one week due to severe skin reactions. The median interval for RT was 8 weeks (1-14 weeks). The 3-year actuarial local control (LC), locoregional control (LRC) and permanent colostomy-free survival (CFS) were 71%, 66%, 79%, whereas the 3-year (estimated 5-year) disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) were 41% (41%), 77% (72%), 66% (53%) respectively.\nConclusions: Outcomes at our institution with conventional anal cancer treatment were not outstanding, but were still comparable to other clinical trials. Organ preservation and durable local control can be obtained by concurrent chemoradiotherapy though significant skin toxicity is the major complication interrupting treatment. Innovative RT techniques and chemotherapy regimens certainly warrant further evaluation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-27-37-a", "title": "Treatment Results of Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer", "keywords": "\u5c0f\u7d30\u80de\u80ba\u764c;\u4fb7\u9650\u671f;\u5316\u5b78\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642 Small cell lung cancer;Limited stage;Chemotherapy;Radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u6587\u65e8\u5728\u7814\u7a76\u4fb7\u9650\u671f\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\u7d50\u679c\uff0c\u4e26\u5206\u6790\u5f71\u97ff\u6cbb\u7642\u7d50\u679c\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1997\u5e741\u6708\u81f32003\u5e749\u6708\uff0c\u5171\u670927\u4f4d\u75c5\u4eba\u5728\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u8a3a\u65b7\u70ba\u4fb7\u9650\u671f\u5c0f\u7d30\u80de\u80ba\u764c\uff0c\u4e26\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642\u3002\u5176\u4e2d22\u4f4d(82%)\u662f\u7537\u6027\uff0c5\u4f4d(18%)\u662f\u5973\u6027\u3002\u8a3a\u65b7\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f61\u6b72\u3002\u6839\u64daECOG (Eastern Cooperative Oncology Group) performance status\u72c0\u614b\u4f86\u8a55\u5206\uff0c3\u4f4d\u75c5\u4eba(11%)\u662fECOG 0\uff0c20\u4f4d(74%)\u662fECOG 1\uff0c4\u4f4d(15%)\u662fECOG 2\u3002\u6cbb\u7642\u65b9\u91dd\u5305\u62ec\u4e86\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642(CCRT)\u6216\u8005\u662f\u5316\u5b78\u6cbb\u7642\u4e4b\u5f8c\u518d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u5316\u5b78\u6cbb\u7642\u7684\u85e5\u7269\u662fcisplatin\u8207etoposide\uff0c\u653e\u5c04\u6cbb\u7642\u7684\u5291\u91cf\u4e2d\u4f4d\u6578\u662f55.80 Gy\u3002\n\u7d50\u679c\uff1a15\u4f4d\u75c5\u4eba(55%)\u816b\u7624\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff0c4\u4f4d\u75c5\u4eba(15%)\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff0c\u6574\u9ad4\u7de9\u89e3\u7387\u662f70%\u3002\u572815\u4f4d\u816b\u7624\u9054\u5230\u5b8c\u5168\u7de9\u89e3\u7684\u75c5\u4eba\u7576\u4e2d\uff0c\u53ea\u6709\u4e00\u4f4d\u75c5\u4eba(7%)\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u60c5\u5f62\u3002\u5728\u9060\u7aef\u8f49\u79fb\u65b9\u9762\uff0c\u670913\u4f4d\u75c5\u4eba(48%)\u6709\u9060\u7aef\u8f49\u79fb\uff0c\u5728\u4ed6\u5011\u7576\u4e2d\u67099\u4f4d(69%)\u6700\u5f8c\u6b7b\u4ea1\u3002\u6240\u670927\u4f4d\u75c5\u4eba\u7684\u5e73\u5747\u5b58\u6d3b\u6642\u9593\u662f28\u500b\u6708\u3002\u5728\u5b58\u6d3b\u7387\u65b9\u9762\uff0c1\u5e74\u30012\u5e74\u82075\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u662f67%\u300154%\u820743%\u30021\u5e74\u30012\u5e74\u82075\u5e74\u7684\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u662f68%\u300136%\u820722%\u30021\u5e74\u30012\u5e74\u82075\u5e74\u7684\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\u5206\u5225\u662f67%\u300158%\u8207465\u3002\u5728\u9810\u5f8c\u56e0\u5b50\u5206\u6790\u65b9\u9762\uff0c\u653e\u5c04\u6cbb\u7642\u7e3d\u5291\u91cf(p=0.018)\u662f\u5f71\u97ff\u816b\u7624\u7de9\u89e3\u7684\u91cd\u8981\u56e0\u5b50\u3002\u9ad4\u91cd\u662f\u5426\u6e1b\u8f15(p=0.010)\u3001\u5316\u5b78\u6cbb\u7642\u7684\u6b21\u6578(0.007)\u4ee5\u53ca\u816b\u7624\u662f\u5426\u6709\u7de9\u89e3(p=0.032)\u5247\u662f\u5f71\u97ff\u6574\u9ad4\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u9ad4\u91cd\u662f\u5426\u6e1b\u8f15(p=0.037)\u3001\u5316\u5b78\u6cbb\u7642\u7684\u6b21\u6578(0.001)\u4ee5\u53ca\u662f\u5426\u6709\u9060\u7aef\u8f49\u79fb(p=0.001)\u662f\u5f71\u97ff\u7121\u75c5\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u9ad4\u91cd\u662f\u5426\u6e1b\u8f15(p=0.004)\u3001\u5316\u5b78\u6cbb\u7642\u7684\u6b21\u6578(0.030)\u4ee5\u53ca\u816b\u7624\u662f\u5426\u6709\u7de9\u89e3(p=0.050)\u5247\u662f\u5f71\u97ff\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u7528cisplatin\u8207etoposide\u7684\u5316\u5b78\u6cbb\u7642\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u5c0d\u65bc\u4fb7\u9650\u671f\u7684\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u4f86\u8aaa\u662f\u4e00\u500b\u53ef\u884c\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u53ef\u4ee5\u9054\u523070%\u7684\u816b\u7624\u7de9\u89e3\u7387\uff0c2\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5247\u70ba54%\u3002\u7136\u800c\uff0c\u9060\u7aef\u8f49\u79fb\u4ecd\u820a\u662f\u5f71\u97ff\u5b58\u6d3b\u7387\u7684\u95dc\u9375\u3002\u572815\u4f4d\u6700\u5f8c\u6b7b\u4ea1\u7684\u75c5\u4eba\u7576\u4e2d\uff0c\u67099\u4f4d(60%)\u5c31\u662f\u56e0\u70ba\u9060\u7aef\u8f49\u79fb\u800c\u6b7b\u4ea1\u3002\u672a\u4f86\u61c9\u8a72\u6709\u66f4\u5927\u578b\u7684\u7814\u7a76\u91dd\u5c0d\u4fb7\u9650\u671f\u7684\u5c0f\u7d30\u80de\u80ba\u764c\u4f86\u63a2\u8a0e\u65b0\u7684\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u8207\u653e\u5c04\u6cbb\u7642\u6280\u8853\uff0c\u4ee5\u671f\u7814\u64ec\u51fa\u6700\u9069\u5408\u7684\u6cbb\u7642\u65b9\u5f0f\u4e26\u9054\u5230\u4ee4\u4eba\u6eff\u610f\u7684\u6cbb\u7642\u7d50\u679c\u3002", "e": "Purpose: The purpose of our study was to evaluate the treatment results and to analyze the prognostic factors affecting the outcome of limited-stage small cell lung cancer patients treated with combined chemotherapy and radiotherapy.\nMaterials and Methods: From January 1997 through September 2003, there were 27 patients diagnosed as limited-stage small cell lung cancer in Changhua Christian Hospital, Taiwan. Among the 27 patients treated with chemotherapy and radiotherapy, 22 (82%) were male and 5 (18%) were female. The median age of diagnosis was 61 years. According to the ECOG (Eastern Cooperative Oncology Group) performance status scaling system, 3 patients (11%) were ECOG 0, 20 patients (74%) were ECOG 1, and 4 patients (15%) were ECOG 2. The treatments consisted of either concurrent chemoradiotherapy (CCRT) or chemotherapy followed by radiotherapy. Chemotherapy regimens were cisplatin and etoposide. The median thoracic irradiation dose was 55.8 Gy (range: 45-64.8 Gy).\nResults: There were 15 patients (55%) achieving complete response, and 4 patients (15%) having partial response, with a total local response rate of 70%. Only one patient (7%) had local relapse out of 15 patients with complete tumor response. A total of 14 patients achieved local regional control (52%, 14 out of total 27 patients). Thirteen patients (48%) had distant metastasis, and 9 patients (69%) died of their diseases during the follow-up periods. The mean survival time was 28 months. In survival analysis, the 1- year, 2-year and 5-year overall survival rates were 67%, 54% and 43%, respectively. The 1-year, 2-year and 5-year disease-free survival rates were 68%, 36% and 22%, respectively. The 1-year, 2-year and 5-year disease-specific survival rates were 67%, 58% and 46%, respectively. In prognostic factors analysis, cumulative irradiation dose (p=0.018) was a predictor for local response. Body weight loss (p=0.010), cycles of chemotherapy (p=0.007) and local response (p=0.032) were prognostic factors for overall survival. Body weight loss (p=0.037), cycles of chemotherapy (p=0.001) and distant metastasis (p=0.001) were prognostic factors for disease-free survival. Body weight loss (p=0.004), cycles of chemotherapy (p=0.030) and local response (p=0.050) were prognostic factors for disease-specific survival.\nConclusion: Chemotherapy of cisplatin and etoposide combined with radiotherapy is a feasible treatment modality for patients of limited-stage small cell lung cancer. A local response rate of 70%, and a 2-year overall survival of 54% were achieved. However, distant failure is still the major concern affecting survival in our present study. Among the 15 patients died of their diseases, 9 patients (60%) were dead due to distant metastasis. The modifications of chemotherapy regimens and radiotherapy techniques in further clinical trials are warranted to explore an optimal treatment and to achieve a satisfactory out- come for limited-stage small cell lung cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-39-45-a", "title": "Radiotherapy for Squamous Cell Carcinoma of the Maxillary Sinus", "keywords": "\u4e0a\u9837\u7ac7;\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c;\u653e\u5c04\u6cbb\u7642 Maxillary sinus;Squamous cell carcinoma;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5728\u6240\u6709\u982d\u9838\u764c\u4e2d\uff0c\u6e90\u81ea\u4e0a\u984e\u7ac7\u7684\u60e1\u6027\u816b\u7624\u76f8\u5c0d\u8f03\u7f55\u898b\u3002\u672c\u56de\u6eaf\u6027\u7814\u7a76\u7684\u76ee\u7684\u662f\uff0c\u5206\u6790\u4e00\u500b\u91ab\u5b78\u4e2d\u5fc332\u4f8b\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u5c04\u6cbb\u7642\u4e4b\u4e0a\u984e\u7ac7\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u75c5\u6b77\u3001\u653e\u5c04\u6cbb\u7642\u8cc7\u6599\u3001\u4ee5\u53ca\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u5747\u7d93\u4ed4\u7d30\u5206\u6790\u3002\u5176\u4e2d\u7537\u6027\u670924\u4eba\uff0c\u5973\u60278\u4eba\u3002\u5e74\u9f61\u5206\u5e03\u5f9e33\u523076\u6b72\uff0c\u4e2d\u4f4d\u657863\u6b72\u3002\u5927\u90e8\u5206\u75c5\u4eba(84.4%)\u8a3a\u65b7\u6642\u5df2\u5c6c\u5c40\u90e8\u56b4\u91cd\u4fb5\u72af(T4)\u3002\u6cbb\u7642\u7684\u65b9\u5f0f\u6709\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u6cbb\u7642(20\u4f8b)\u3001\u653e\u5c04\u6cbb\u7642\u5408\u4f75(7\u4f8b)\u6216\u4e0d\u5408\u4f75(5\u4f8b)\u5316\u5b78\u6cbb\u7642\u3002\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u7bc4\u570d\u5f9e50~90Gy\uff0c\u4e2d\u4f4d\u6578\u70ba70Gy\uff0c\u5927\u591a\u4ee5\u50b3\u7d71\u5206\u6b21\u65b9\u5f0f\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba57.0%\uff0c\u4e94\u5e74\u7e3d\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba12.5%\u53ca40.7%\u3002\u5176\u4e2d\u670913\u4f4d\u75c5\u4eba(40.6%)\u816b\u7624\u5fa9\u767c\u6216\u9060\u8655\u9060\u79fb\uff0c\u5305\u62ec8\u4f8b\u5c40\u90e8\u5fa9\u767c\u30011\u4f8b\u9838\u90e8\u8f49\u79fb\u30011\u4f8b\u9060\u8655\u9060\u79fb\u30011\u4f8b\u5c40\u90e8\u5fa9\u767c\u5408\u4f75\u9060\u8655\u8f49\u79fb\u3001\u4ee5\u53ca2\u4f8b\u5c40\u90e8\u5fa9\u767c\u5408\u4f75\u9838\u90e8\u53ca\u9060\u8655\u8f49\u79fb\u3002Kaplan-Meier\u5b58\u6d3b\u66f2\u7dda\u5206\u6790\u986f\u793a\uff1a\u5e74\u9f61\u662f\u7121\u75c5\u5b58\u6d3b\u7387(P=0.018)\u53ca\u7e3d\u5b58\u6d3b\u7387(P=0.059)\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u7d20\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u8cc7\u6599\u986f\u793a\uff0c\u6cbb\u7642\u5931\u6557\u8655\u4ee5\u5c40\u90e8\u5fa9\u767c\u6700\u5e38\u898b\uff0c\u9664\u4e86\u9069\u7576\u7684\u624b\u8853\u5207\u9664\uff0c\u672a\u4f86\u52a0\u5f37\u653e\u5c04\u6cbb\u7642\u6548\u679c\u7684\u65b9\u5f0f\uff08\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6216\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u3001\u6539\u8b8a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\uff09\u3001\u4ee5\u53ca\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u7b49\u503c\u5f97\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Purpose: Malignant tumors arising from the maxillary sinus are relatively rare among head and neck cancer. The aim of this retrospective study is to analyze clinical outcome of 32 patients with squamous cell carcinoma of maxillary sinus treated by curative intent in a medical center.\nMaterials and Methods: Chart, radiotherapy data, and CT scan were reviewed in detail. There were 24 males and 8 females. Their age ranged from 33 to 76 (median 63) years old. Most patients (84.4%) presented with T4 disease. Treatment modalities were radical surgery + postoperative radiotherapy (20 cases), radiotherapy with (7 cases) or without (5 cases) chemotherapy. The range of radiation dose was 50-90 Gy with a median of 70 Gy by conventional fractionation.\nResults: The estimated local control rate at 5 years was 57.0%. The 5-year overall and disease-free survival rates were 12.5% and 40.7% respectively. Thirteen of 32 (40.6%) patients developed tumor recurrence or metastasis. The failure pattern illustrated 8 local recurrences, 1 neck metastasis, 1 distant metastasis, 1 local recurrence with distant metastasis, and 2 local recurrences with neck and distant metastasis. Kaplan-Meier survival analyses and log-rank test showed that age was the most important prognostic factor affecting disease-free survival (P=0.018) and overall survival (P=0.059).\nConclusion: Our data suggest that primary recurrence is the major site of failure. Except for adequate surgical resection, approaches that can enhance radiation effect (3-D conformal or intensity-modulated radiotherapy and altered fractionated radiotherapy) and concurrent chemotherapy deserve to be tried in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-47-58-a", "title": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u7684\u7c21\u5316\u8499\u5730\u5361\u7f85\u6a21\u64ec", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u8499\u5730\u5361\u7f85\u65b9\u53bb IMRT;Monte Carlo method", "c": "\u76ee\u7684\uff1a\u70ba\u589e\u52a0\u4ee5\u8499\u5730\u5361\u7f85\u6cd5\u9032\u884c\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6a21\u64ec\u6642\u7684\u6548\u7387\uff0c\u672c\u6587\u4ee5OMEGA/BEAM\u7a0b\u5f0f\u7cfb\u7d71\u70ba\u57fa\u790e\uff0c\u5efa\u7acb\u4e00\u7c21\u5316\u4e4b\u6a21\u64ec\u7a0b\u5e8f\uff0c\u4e26\u52a0\u4ee5\u9a57\u8b49\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4e0d\u76f4\u63a5\u6a21\u64ec\u591a\u8449\u6e96\u76f4\u5100\u79fb\u52d5\u7247\u6bb5(segment)\u7684\u7d30\u7bc0\uff0c\u800c\u662f\u63a1\u7528\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u6240\u63d0\u4f9b\u7684fluence map\u4f5c\u70ba\u6b0a\u91cd(weighting)\uff0c\u4fee\u6539\u958b\u653e\u7167\u91ce\u4e0b\u7684\u76f8\u7a7a\u9593\u5c04\u6e90\u7c92\u5b50(phase-space source particle)\uff0c\u4f7f\u5f97\u7531\u6578\u500bMLC\u79fb\u52d5\u7247\u6bb5\u6240\u69cb\u6210\u7684\u7167\u91ce\u53ef\u5728\u4e00\u6b21\u8499\u5730\u5361\u7f85\u6a21\u64ec\u4e2d\u904b\u8dd1\u5b8c\u6210\u3002\u5176\u4e2d\u6211\u5011\u4fee\u6539\u4e86DOSXYZ\u7a0b\u5f0f\uff0c\u4f7f\u5176\u5177\u5099\u8b80\u5165fluence map\u4ee5\u53ca\u8abf\u6574\u76f8\u7a7a\u9593\u5c04\u6e90\u7c92\u5b50\u6b0a\u91cd\u7b49\u529f\u80fd\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u5728\u672c\u6587\u4e2d\u6240\u63a1\u7528\u7684\u7c21\u5316\u6a21\u64ec\u7a0b\u5e8f\u9996\u5148\u91dd\u5c0dMLC dynamic wedge\u6848\u4f8b\u9032\u884c\u9a57\u8b49\u3002\u91dd\u6a3915\u300130\u300145\u820760\u5ea6\u7684MLC dynamic wedge\uff0c\u7c21\u5316\u7684\u8499\u5730\u5361\u7f85\u8a08\u7b97\u7d50\u679c\u8207\u5be6\u9a57\u503c(profiler)\u53ca\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71(CadPlan (\u4e0a\u6a19 TM))\u543b\u5408\u826f\u597d\u3002\u8a72\u65b9\u6cd5\u9032\u4e00\u6b65\u91dd\u5c0d\u4e94\u7167\u91ce\u7684\u8166\u7624\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u6848\u4f8b\u9032\u884c\u9a57\u8b49\uff0c\u8a08\u7b97\u7d50\u679c\u8207\u5e95\u7247\u91cf\u6e2c\u53ca\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u7684\u6bd4\u8f03\u4ea6\u986f\u793a\u543b\u5408\u826f\u597d\u3002\n\u7d50\u8ad6\uff1a\u672c\u6587\u4e2d\u6240\u63a1\u7528\u7684\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7c21\u5316\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5e8f\u53ef\u7701\u7565\u6a21\u64ecMLC\u5143\u4ef6\u672c\u8eab\u8207\u5176\u79fb\u52d5\u7247\u6bb5\u7684\u7d30\u7bc0\u7b49\u5de5\u4f5c\uff0c\u5176\u7d50\u679c\u986f\u793a\u8207\u5be6\u9a57\u503c\u543b\u5408\u826f\u597d\uff0c\u53ef\u5927\u5e45\u589e\u52a0\u61c9\u7528\u8499\u5730\u5361\u7f85\u6cd5\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u7167\u91ce\u4e0b\u6548\u61c9\u7684\u7814\u7a76\u3002", "e": "Purpose: To improve the efficiency of the Monte Carlo simulation on IMRT, the simplified method based on OMEGA/BEAM system was performed in this stud.\nMaterials and Methods: Instead of modeling the detailed segments of MLC movements, the fluence map provided by the treatment planning system was applied to modify the weights of the phase-space source particles. Therefore, an IMRT portal comprised of several sub-fields could be condensed as a single field in the Monte Carlo simulation. The DOSXYZ code used in this study has bed modified with the capabilities of reading the fluence map file awl adjusting the weights of the phase-space particles correspondingly.\nResults and Discussion: The simplified method proposed ill this study was verified with the MLC dynamic wedge cases first. The calculated dose profiles of 15-, 30-, 45-, and 60-degree MLC dynamic wedge cases show good agreements with the measurements of the profiler and results of the treatment planning system. Furthermore, this method has also bed used to calculate a 5-portal brain tumor IMRT case and the results were compared with the film measurements and treatment planning system. Our results were generally in good agreement with the film and treatment planning system.\nConclusion: The method of the simplified Monte Carlo simulation on IMRT described ill this study could save a lot of efforts on modeling the detailed segments of MLC movements and shows good agreement with measurements. It would be a good improvement of the efficiency and could be a simple and yet accurate method for applying Monte Carlo methods on the studies corresponding to the influences of IMRT in clinical tasks."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-59-65-a", "title": "\u653e\u5c04\u6cbb\u7642\u4e4b\u60e1\u6027\u8166\u7624\u60a3\u8005\u63a5\u53d7\u53e6\u985e\u7642\u6cd5\u8207\u98df\u7269\u89c0\u5ff5\u7684\u8abf\u67e5\u5206\u6790", "keywords": "\u8166\u7624;\u53e6\u985e\u7642\u6cd5;\u98df\u7269\u7981\u5fcc Brain tumor;Alternative treatment;Attitude towards food", "c": "Background: To gain a understanding of the degree to which malignant brain tumor patients choose to turn to alternative treatment and abstain from certain food, and to find out what factors play a role ill this preference.\nMethods: The study was carried out from November 1 1997 to July 15 1999. One hundred and twenty-six patients were enrolled in the study, being malignant brain tumor patients undergoing radiotherapy. Admission was based on a questionnaire that had to be filled ill by the malignant brain tumor patients. This questionnaire had to be filled in twice, the first time ill the first week after starting radiotherapy and the second time within 6 months after completion of the treatment.\nResults: Seventy-nine patients thought that nutrition would accelerate tumor growth, and 108 patients believed that cancer would lot be contracted through the sharing of food. Ninety-seven patients chose to abstain from certain food after being diagnosed with cancer. Generally more than one type of food was abstained from.\nConclusion: The patient's confidence in the treatment affected his inclination to turn to alternative treatment during radiotherapy. If alternative treatment was effective, the patients tended to recommend it to other patients.", "e": "Background: To gain a understanding of the degree to which malignant brain tumor patients choose to turn to alternative treatment and abstain from certain food, and to find out what factors play a role ill this preference.\nMethods: The study was carried out from November 1 1997 to July 15 1999. One hundred and twenty-six patients were enrolled in the study, being malignant brain tumor patients undergoing radiotherapy. Admission was based on a questionnaire that had to be filled ill by the malignant brain tumor patients. This questionnaire had to be filled in twice, the first time ill the first week after starting radiotherapy and the second time within 6 months after completion of the treatment.\nResults: Seventy-nine patients thought that nutrition would accelerate tumor growth, and 108 patients believed that cancer would lot be contracted through the sharing of food. Ninety-seven patients chose to abstain from certain food after being diagnosed with cancer. Generally more than one type of food was abstained from.\nConclusion: The patient's confidence in the treatment affected his inclination to turn to alternative treatment during radiotherapy. If alternative treatment was effective, the patients tended to recommend it to other patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200503-12-1-67-72-a", "title": "Radiotherapy for the Treatment of Giant Cell Tumor of the Spine: A Report of 3 Cases and Review of the Literature", "keywords": "\u5de8\u7d30\u80de\u7624;\u810a\u690e;\u653e\u5c04\u7dda\u6cbb\u7642 Giant cell tumor;Spine;Radiation therapy", "c": "\u810a\u690e\u5de8\u7d30\u80de\u7624\u7684\u6700\u4f73\u6cbb\u7642\u5728\u76ee\u524d\u4ecd\u9817\u5177\u6311\u6230\u6027\uff0c\u624b\u8853\u5207\u9664\u662f\u6700\u512a\u5148\u9078\u64c7\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u662f\u5176\u53ef\u80fd\u9020\u6210\u810a\u9ad3\u50b7\u5bb3\uff0c\u4e5f\u56e0\u6b64\u9650\u5236\u4e86\u624b\u8853\u7684\u7bc4\u570d\u3002\u5f9e2001\u81f32003\u5e74\u6211\u5011\u5171\u6cbb\u7642\u4e09\u4f8b\u810a\u690e\u5de8\u7d30\u80de\u7624\u75c5\u60a3\uff0c\u4ed6\u5011\u7686\u63a5\u53d7\u90e8\u4efd\u816b\u7624\u5207\u9664\uff0c\u518d\u91dd\u5c0d\u53d7\u5f71\u97ff\u7684\u810a\u690e\u9032\u884c\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u653e\u5c04\u5291\u91cf\u70ba4500\u81f36120cGy\u4e4b\u9593\uff0c\u4e09\u4f4d\u75c5\u60a3\u90fd\u80fd\u627f\u53d7\u6574\u500b\u6cbb\u7642\u904e\u7a0b\uff0c\u4e26\u4e14\u7121\u56b4\u91cd\u6027\u7684\u526f\u4f5c\u7528\u3002\u76ee\u524d\u6709\u4e8c\u4f8b\u5b58\u6d3b\uff0c\u4e14\u4e26\u7121\u75be\u75c5\u5fa9\u767c\u8b49\u64da\uff0c\u53e6\u5916\u4e00\u4f8b\u65bc\u6cbb\u7642\u5f8c24\u500b\u6708\uff0c\u7d93\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u8b49\u5be6\u70ba\u5c40\u90e8\u5fa9\u767c\uff0c\u8a72\u75c5\u60a3\u76ee\u524d\u4ecd\u7136\u5b58\u6d3b\u4e14\u7121\u660e\u986f\u7684\u81e8\u5e8a\u8a3c\u72c0\u3002\u6211\u5011\u7684\u7d93\u9a57\u986f\u793a\uff0c\u91dd\u5c0d\u7121\u6cd5\u5b8c\u5168\u5207\u9664\u7684\u816b\u7624\u6216\u958b\u5200\u5207\u9664\u6703\u9020\u6210\u56b4\u91cd\u5668\u5b98\u50b7\u5bb3\u7684\u75c5\u60a3\uff0c\u4fdd\u5b88\u6027\u624b\u8853\u5408\u4f75\u8f14\u52a9\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u4e00\u500b\u5408\u7406\u7684\u9078\u64c7\u3002\u96d6\u7136\u6c92\u6709\u660e\u78ba\u7684\u5291\u91cf\u8207\u81e8\u5e8a\u53cd\u61c9\u95dc\u4fc2\uff0c\u4f46\u662f\u6587\u737b\u4e2d\u5efa\u8b703500\u81f34500cGy\u7bc4\u570d\u4e4b\u5167\u7684\u5291\u91cf\u662f\u5b89\u5168\u7684\uff0c\u800c\u4e14\u53ef\u4ee5\u6709\u6548\u5730\u63a7\u5236\u810a\u690e\u5de8\u7d30\u80de\u7624\u3002", "e": "Optimal treatment for giant cell tumors of the spine remains challenging. Surgical excision remains the initial treatment of choice, but the potential spinal cord injury may limit the extent of resection. Between 2001 and 2003, we report 3 patients diagnosed with giant cell tumor of spine treated with post-operative radiotherapy. Surgery consisted of subtotal resection of tumor. The involved vertebrae were then irradiated with doses ranging from 4500 to 6120 cGy. All patients tolerated the treatment well with no severe or chronic complications. Two of the 3 patients are alive with no evidence of disease. One is alive with recurrent disease upon regular MRI follow-up 24 months after treatment, although it is not clinically apparent. Our experience shown adjuvant radiotherapy after conservative surgery is a reasonable treatment alternative for tumors that cannot be completely excised or in which surgery would result in significant morbidity. Although there is no clear dose response, review of the literature suggest doses ranged from 3500 to 4500 cGy are safe and effective in controlling giant cell tumor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-133-140-a", "title": "Bile Duct Cancer, Its Survival and Local-Control after Radiotherapy", "keywords": "\u81bd\u9053\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50;\u5b58\u6d3b Bile duct cancer;Radiotherapy;Prognostic factor;Survival", "c": "\u76ee\u7684\uff1a\u6b64\u7bc7\u5831\u544a\u63d0\u4f9b\u4e86\u672c\u9662\u904e\u53bb17\u5e74\u4f86\u7684\u81bd\u9053\u764c\u75c5\u60a3\u653e\u5c04\u7dda\u6cbb\u7642\u7d50\u679c\u7684\u56de\u6eaf\u6027\u5206\u6790\u3002\u6b64\u7814\u7a76\u4e43\u662f\u6839\u64da\u4ed6\u5011\u7684\u81e8\u5e8a\u75c7\u72c0\uff0d\u5831\u544a\u3001\u624b\u8853\u4e2d\u767c\u73fe\u4ee5\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u7d66\u4e88\u7684\u65b9\u6cd5\u7b49\u53bb\u5206\u6790\u5b58\u6d3b\u7387\u4ee5\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u897f\u51431985\u5e74\u81f32003\u5e74\uff0c\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u5171\u6709228\u4f4d\u8f49\u8a3a\u7684\u81bd\u9053\u764c\u75c5\u60a3\u3002\u5728\u6b64\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u53ea\u9078\u64c7\u5176\u4e2d78\u4f4d\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb\u3001\u4e26\u4e14\u63a5\u53d7\u4e86\u81bd\u9053\u7cfb\u7d71\u5c40\u90e8\u75c5\u7076\u6cbb\u7642\u7684\u75c5\u60a3\u4f86\u52a0\u4ee5\u5206\u6790\u3002\u5176\u4e2d5\u4f4d\u75c5\u60a3\u53ea\u63a5\u53d7\u4e86\u8154\u5167\u653e\u5c04\u7dda\u6cbb\u7642\uff08ILRT\uff09\uff0c15\u4f4d\u540c\u6642\u63a5\u53d7\u4e86\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\uff08EBRT\uff09\u548c\u8154\u5167\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u800c58\u4f4d\u75c5\u60a3\u53ea\u63a5\u53d7\u4e86\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u3002\n\u6b64\u7814\u7a76\u5206\u6790\u4e86\u5f71\u97ff\u5b58\u6d3b\u7387\u548c\u5c40\u90e8\u63a7\u5236\u7387\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u9019\u4e9b\u56e0\u5b50\u5305\u62ec\u4ed6\u5011\u7684\u81e8\u5e8a\u75c7\u72c0\uff0d\u5fb5\u8c61\uff08\u9ec3\u75b8\u53ca\u75bc\u75db\uff09\u3001\u904e\u53bb\u6709\u7121\u809d\u81bd\u75be\u75c5\u75c5\u53f2\u3001\u6d3b\u52d5\u80fd\u529b\uff08performance status\uff0c\u5373 Karnofsky scale\uff09\u3001\u624b\u8853\u4e2d\u7684\u767c\u73fe\uff08\u5982\u6dcb\u5df4\u817a\u9ad4\uff0c\u795e\u7d93\u5468\u570d\u3001\u4ee5\u53ca\u9580\u975c\u8108\u6709\u7121\u4fb5\u72af\uff09\u3001\u7d44\u7e54\u75c5\u7406\u5831\u544a\u3001CEA\u503c\u4ee5\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u65b9\u6cd5\u8207\u5291\u91cf\u7b49\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u671f\u5f9e1\u500b\u6708\u5230160\u500b\u6708\u4e0d\u7b49\uff08\u4e2d\u4f4d\u657817\u500b\u6708\uff09\u3002\u901978\u500b\u75c5\u60a3\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba11.3%\uff0c\u800c\u5b58\u6d3b\u4e2d\u4f4d\u6578\u70ba7\u500b\u6708\uff0895%\u4fe1\u8cf4\u5340\u9593\u70ba4.4\u52309.9\u500b\u6708\uff09\u3002\u5c0d\u5b58\u6d3b\u7387\u6709\u8ca0\u9762\u5f71\u97ff\u7684\u56e0\u7d20\u5305\u62ec\uff1a\u795e\u7d93\u5468\u908a\u548c\u6dcb\u5df4\u817a\u9ad4\u7684\u4fb5\u72af\u3001\u8f03\u5dee\u7684\u6d3b\u52d5\u80fd\u529b\u3001\u4f34\u6709\u75bc\u75db\u4ee5\u53ca\u9ec3\u75b8\u3001\u7d44\u7e54\u5b78\u7d30\u80de\u5206\u5316\u4e0d\u826f\u3001\u55ae\u4e00\u65b9\u6cd5\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u4ee5\u53ca\u8f03\u4f4e\u7684\u653e\u5c04\u7dda\u5291\u91cf\u7b49\u3002\u800c\u5f71\u97ff\u5c40\u90e8\u63a7\u5236\u7387\u6700\u4e3b\u8981\u7684\u56e0\u7d20\u70ba\u624b\u8853\u5f8c\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u524d\uff0c\u6709\u7121\u6b98\u5b58\u7684\u81bd\u9053\u764c\u75c5\u7076\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u81bd\u9053\u764c\u75c5\u60a3\uff0c\u5efa\u8b70\u8f03\u9ad8\u7684\u653e\u5c04\u7dda\u5291\u91cf\u4ee5\u5f97\u5230\u8f03\u597d\u7684\u5b58\u6d3b\u7387\u3002\u800c\u55ae\u7368\u7d66\u4e88\u8154\u5167\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u679c\u4ecd\u6709\u722d\u8b70\u3002\u65e2\u7136\u624b\u8853\u5f8c\u6709\u7121\u6b98\u5b58\u7684\u81bd\u9053\u764c\u75c5\u7076\u5c0d\u65bc\u5c40\u90e8\u63a7\u5236\u76f8\u7576\u95dc\u9375\uff0c\u624b\u8853\u82e5\u80fd\u5b8c\u5168\u5c07\u816b\u7624\u5207\u9664\u662f\u5fc5\u8981\u7684\uff1b\u82e5\u80fd\u65e9\u671f\u8a3a\u65b7\u81bd\u9053\u764c\uff0c\u4e5f\u5c07\u80fd\u9054\u5230\u66f4\u597d\u7684\u6cbb\u7642\u6548\u679c\u3002", "e": "Purpose: This report retrospectively reviewed bile duct cancer cases at the authors\u2019 institution over the past 17 years. Statistical methods have been employed to analyze overall survival and local-control rates of these cases, and to identify the correlations between different panameters such as the presenting symptoms and signs, surgical findings, radiotherapy (RT) dose, and the RT modality.\nMaterials and Methods: Between 1985 and 2003, the Department of Radiation Oncology at the Chang Gung Memorial Hospital, Linkou, had 228 patients with bile duct cancer referred for RT. Only the 78 patients with no distant organ metastases who underwent treatment for localized biliary system lesions were included in this study. Five patients received intra-luminal RT (ILRT) alone, 15 had external beam RT (EBRT) plus\nILRT, and 58 patients received EBRT alone. Statistical methods were employed to identify factors that affected overall survival and local-control rates. These factors include patients\u2019 presenting symptoms and signs (jaundice and pain), a past history of hepatobiliary disease, pre-operative performance status (Karnofsky score), surgical findings (lymph node, perineural, and portal vein involvement), histological and pathological classification, CEA level, the radiation modality and the radiation dose.\nResults : The follow-up periods ranged from 1-160 months (median 17 months). The 78 patients had a 5-year overall survival rate of 11.3% after RT, and the median survival was 7.0 months (95% CI, 4.4- 9.9 months). Peri-neural and lymph node involvement, poor performance status, presence of pain and/ or jaundice, poorly differentiated histology, single RT modality and lower radiation doses were factors that correlated negatively with\nsurvival. The local control rate was most significantly affected by the presence of residual disease prior to RT.\nConclusion: Higher doses RT offers a better survival to patients with bile duct cancers. The benefit of ILRT given alone remains unclear. Since residual disease appears to be critical for local control, complete resection of the tumor is essential; which reinforces the importance of early diagnosis of bile duct cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-141-149-a", "title": "An Evaluation of the Contents and Quality of Radiation Oncology Homepages in Taiwan", "keywords": "\u7db2\u9801\u54c1\u8cea;\u7db2\u9801\u5167\u5bb9;\u653e\u5c04\u816b\u7624\u79d1;HONcode;\u91ab\u7642\u76f8\u95dc\u7db2\u7ad9 Quality of website;Contents of homepage;Radiation oncology;HONcode;Health-related website", "c": "\u76ee\u7684\uff1a\u7db2\u969b\u7db2\u8def\u7684\u5feb\u901f\u767c\u5c55\u4f7f\u6c11\u773e\u80fd\u66f4\u6709\u6548\u7387\u7372\u5f97\u76f8\u95dc\u7684\u91ab\u5b78\u77e5\u8b58\u3002\u6709\u9451\u65bc\u6b64\uff0c\u8a55\u4f30\u53f0\u7063\u76ee\u524d\u73fe\u6709\u7684\u653e\u5c04\u816b\u7624\u79d1\u7db2\u9801\u7684\u5167\u5bb9\u548c\u54c1\u8cea\u662f\u6211\u5011\u7814\u7a76\u7684\u91cd\u9ede\uff0c\u800c\u7814\u7a76\u7d50\u679c\u5c07\u53ef\u4f9b\u73fe\u6709\u7db2\u9801\u7dad\u8b77\u8005\u505a\u70ba\u7db2\u9801\u6539\u9032\u7684\u53c3\u8003\uff0c\u4e26\u63d0\u4f9b\u672a\u4f86\u7db2\u9801\u8a2d\u8a08\u8005\u4f5c\u70ba\u8a2d\u8a08\u7684\u5efa\u8b70\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2003\u5e745\u670829\u65e5\u81f36\u67085\u65e5\uff0c\u6211\u5011\u8a55\u4f30\u4e86\u53f0\u7063\u57f7\u696d\u4e2d\u768449\u500b\u653e\u5c04\u816b\u7624\u79d1\u90e8\u3002\u8a55\u4f30\u5167\u5bb9\u5305\u62ec\u7db2\u9801\u4e4b\u7db2\u9801\u898f\u6a21\u3001\u53ef\u8fd1\u6027\u3001\u6709\u6548\u6027\u3001\u6db5\u84cb\u6027\u4ee5\u53ca\u4e92\u52d5\u6027\u3002\u53e6\u5916\u4e26\u63a1\u7528Health On the Net Foundation Code\uff08HONcode\uff09\u539f\u5247\u4f86\u8a55\u4f30\u7db2\u9801\u7684\u5167\u5bb9\u53ca\u54c1\u8cea\u3002\n\u7d50\u679c\uff1a\u53f0\u706349\u500b\u653e\u5c04\u816b\u7624\u90e8\u9580\u4e2d\u670930\u500b\uff0861.2%\uff09\u8a2d\u7acb\u7db2\u9801\u3002\u572830\u500b\u8a2d\u7acb\u7684\u7db2\u7ad9\u4e2d\uff0c\u670916\u500b\uff0853.3%\uff09\u7db2\u7ad9\u5728\u7db2\u9801\u898f\u6a21\u65b9\u9762\u88ab\u8a55\u70ba\u5b8c\u6574\u3002\u67098\u500b\uff0826.7%\uff09\u7db2\u9801\u5728\u53ef\u8fd1\u6027\u4e0a\u662f\u5c6c\u65bc\u5bb9\u6613\u641c\u5c0b\u3002\u5728\u6709\u6548\u6027\u65b9\u9762\uff0c\u53ea\u67095\u500b\uff0816.7%\uff09\u7db2\u7ad9\u65bc\u7db2\u9801\u4e0a\u986f\u793a\u6700\u5f8c\u66f4\u65b0\u6642\u9593\uff0c\u4e26\u65bc\u4e00\u500b\u7db2\u9801\u4e2d\u767c\u73fe\u4e86\u5169\u500b\u932f\u8aa4\u9023\u7d50\u3002\u95dc\u65bc\u6db5\u84cb\u6027\u65b9\u9762\uff0c\u5de5\u4f5c\u4eba\u54e1\u4e4b\u4ecb\u7d39\u3001\u6cbb\u7642\u6a5f\u5668\u4e4b\u4ecb\u7d39\u548c\u885b\u751f\u6559\u80b2\u65b9\u9762\uff0c\u5206\u5225\u670915\uff0850.0%\uff09\uff0c8\uff0826.7%\uff09\u548c7\uff0823.3%\uff09\u500b\u7db2\u9801\u5f97\u5230\u6700\u9ad8\u5206\u3002\u5728\u4e92\u52d5\u6027\u65b9\u9762\uff0c\u5e7e\u4e4e\u6240\u6709\u7684\u7db2\u9801\uff0896.7%\uff09\u53ef\u4ee5\u5728\u7db2\u8def\u4e0a\u627e\u5230\u9580\u8a3a\u6642\u9593\u8868\uff0c\u4e09\u500b\uff0810.0%\uff09\u7db2\u7ad9\u8a2d\u7acb\u6709\u8a0e\u8ad6\u7248\u4ee5\u53ca7\u500b\uff0823.3%\uff09\u7db2\u7ad9\u63d0\u4f9b\u8aee\u8a62\u96fb\u5b50\u90f5\u4ef6\u4fe1\u7bb1\u3002\u5728HONcode\u65b9\u9762\uff0c\u5f97\u5206\u5e73\u5747\u6578\u53ca\u4e2d\u4f4d\u6578\u5206\u5225\u70ba3.1\u53ca2.5\uff0c\u53ea\u6709\u4e00\u500b\u7db2\u7ad9\u5f97\u5230\u6eff\u52068\u5206\u3002\u4f9d\u64da\u91ab\u9662\u8a55\u9451\u7b49\u7d1a\u4f86\u8a55\u4f30HONcode\u4e2d\u7684\u4f5c\u8005\u7684\u900f\u660e\u6027\uff08p = 0.000\uff09\uff08\u5305\u62ec\u986f\u793a\u7db2\u9801\u6700\u5f8c\u66f4\u65b0\u6642\u9593\u53ca\u63d0\u4f9b\u6709\u6548\u7684\u96fb\u5b50\u4fe1\u7bb1\uff09\u4ee5\u53ca\u8d0a\u52a9\u8005\u7684\u900f\u660e\u6027\uff08p = 0.020\uff09\u7b49\u9805\u76ee\u4e2d\uff0c\u7686\u767c\u73fe\u6709\u660e\u986f\u7684\u7d71\u8a08\u4e0a\u7684\u5dee\u7570\u3002\n\u7d50\u8ad6\uff1a\u7db2\u969b\u6539\u8b8a\u4e86\u6211\u5011\u50b3\u7d71\u7372\u5f97\u77e5\u8b58\u7684\u65b9\u5f0f\u3002\u5728\u6211\u5011\u7684\u7814\u7a76\u4e2d\u986f\u793a\u53f0\u7063\u7684\u7db2\u9801\u5167\u5bb9\u548c\u54c1\u8cea\u9084\u9700\u8981\u4e00\u756a\u52aa\u529b\u4f86\u9054\u5230\u570b\u969b\u6a19\u6e96\u3002\u70ba\u4e86\u9806\u61c9\u9019\u500b\u8da8\u52e2\uff0c\u91ab\u7642\u5065\u5eb7\u76f8\u95dc\u9ad4\u7cfb\u6709\u7fa9\u52d9\u53ca\u8cac\u4efb\u70ba\u6c11\u773e\u63d0\u4f9b\u5feb\u901f\u4e14\u9ad8\u54c1\u8cea\u7684\u7db2\u8def\u8cc7\u8a0a\u3002", "e": "Purpose : Internet is a very powerful technology tool that enables the public having more efficient and varied ways to access health information. Regarding to this change, this study was performed in order to evaluate the content and quality of current radiation oncology homepages in Taiwan. Then make suggestions on the maintenance and the future homepage design. Materials and Methods : From May 29 to June 5, 2003, the websites of 49 practicing\ndepartments of radiation oncology were examined for their dimensions, accessibility, validity, coverage and interaction. The Site-Checker of the Health On the Net Foundation Code (HONcode) principles was also used to evaluate these websites.\nResults : Thirty of 49 (61.2%) practicing departments had homepages. In 30 established homepages, sixteen (53.3%) sites had full dimensions. Eight (26.7%) homepages revealed the last-update time and 2 error-links were detected in one homepage. On coverage category, the numbers of homepages which received the highest score of 2, were as following, introduction for treatment 15 (50%), introduction for treatment machines 8 (26.7%) and health education 7 (23.3%). There were 29 (96.7%) websites, which had the service table for outpatient, 3 (10%) had discussion board, and 7 (23.3%) provided valid email address. The mean and median of HONcode was 3.1 and 2.5. There was only one website, which received a perfect score of 8. Using. hospital grade as a variable, the displaying the date of last-update and providing valid email, and on transparency of sponsorship (p = 0.02) showed significant statistic difference on transparency of authorship (p = 0.000).\nConclusion : The Internet changes the ways of information acquisition. From the study result, the contents and quality of homepages on radiation oncology in Taiwan still require a great effort to reach the international standard. While on the trend of this change, the health related institutions must have conscience and responsibility to provide a rapid access, and high-quality information for the public."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-151-156-a", "title": "\u764c\u75c7\u60a3\u8005\u653e\u5c04\u6cbb\u7642\u5f8c\u8ff4\u8a3a\u8ffd\u8e64\u4e2d\u65b7\u7684\u539f\u56e0\u53ca\u5206\u6790", "keywords": "\u653e\u5c04\u6cbb\u7642;\u764c\u75c5\u767b\u8a18;\u8ffd\u8e64\u4e2d\u65b7 Radiotherapy;Cancer registry;Follow-up interrupation", "c": "\u76ee\u7684\uff1a\u96a8\u8457\u764c\u75c7\u6cbb\u7642\u65b9\u5f0f\u7684\u6539\u5584\u8207\u6574\u5408\uff0c\u764c\u75c7\u60a3\u8005\u5b58\u6d3b\u7387\u5927\u70ba\u63d0\u5347\uff1b\u7136\u800c\u9664\u4e86\u5b8c\u6574\u6cbb\u7642\u4e4b\u5916\uff0c\u5b9a\u671f\u8ff4\u8a3a\u8ffd\u8e64\u4e5f\u662f\u764c\u75c7\u7167\u8b77\u7684\u91cd\u8981\u4e00\u74b0\uff1b\u672c\u7814\u7a76\u85c9\u7531\u5206\u6790\u653e\u5c04\u6cbb\u7642\u5f8c\u764c\u75c7\u60a3\u8005\u8ff4\u8a3a\u4e2d\u65b7\u7684\u539f\u56e0\uff0c\u8a66\u5716\u89e3\u6c7a\u53ca\u6539\u5584\uff0c\u5354\u52a9\u60a3\u8005\u63a5\u53d7\u66f4\u5b8c\u6574\u7684\u7167\u8b77\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5947\u7f8e\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u81ea\u5f9e2001\u5e7410\u670827\u65e5\u52302002\u5e7410\u670819\u65e5\u6b62\uff0c\u91dd\u5c0d199 \u4f4d\u653e\u5c04\u6cbb\u7642\u5f8c\u8ff4\u8a3a\u4e2d\u65b7\u7684\u60a3\u8005\u9032\u884c\u4e2d\u65b7\u539f\u56e0\u5206\u6790\u3002\u8cc7\u6599\u4f86\u6e90\u4e43\u4f9d\u64da\u75c5\u6b77\u8a18\u8f09\u53ca\u96fb\u8a71\u6703\u8ac7\u9023\u7e6b\u8ffd\u8e64\u8cc7\u6599\u70ba\u6e96\u3002\n\u7d50\u679c\uff1a199\u4f4d\u8ff4\u8a3a\u4e2d\u65b7\u60a3\u8005\u4e2d\uff0c\u670939\u4f4d\uff0819.6%\uff09\u56e0\u75c5\u60c5\u8b8a\u5316\uff0c\u5305\u62ec\u6b7b\u4ea114.1%\u53ca\u60e1\u53165.5%\uff1b68\u4f4d\uff0834.2%\uff09\u8f49\u81f3\u4ed6\u79d1\uff08\u9662\uff09\u5c31\u91ab\uff0c\u5305\u542b\u81f3\u4ed6\u79d1\u5c31\u8a3a26.1%\u53ca\u8f49\u9662\u6cbb\u76428.1%\uff1b41\u4f4d\uff0820.6%\uff09\u56e0\u5916\u5728\u74b0\u5883\u56e0\u7d20\uff0c\u5305\u542b\u5bb6\u5ead\u56e0\u7d204%\u3001\u7d93\u6fdf\u56e0\u7d201%\u53ca\u5de5\u4f5c\u592a\u5fd915.6%\uff1b7\u4f4d\uff083.5%\uff09\u5c0d\u91ab\u7642\u4e0d\u6eff\uff1b\u56e0\u5c0d\u75be\u75c5\u932f\u8aa4\u8a8d\u77e5\u8005\u670925\u4f4d\uff0812.6%\uff09\uff0c\u5305\u542b\u4e0d\u77e5\u75c5\u60c51%\u3001\u81ea\u89ba\u7121\u65481.5%\u53ca\u81ea\u89ba\u5065\u5eb7\u826f\u597d\uff0c\u4e0d\u7528\u8ff4\u8a3a10.1%\uff1b\u5176\u4ed619\u4f4d\uff089.5%\uff09\u3002\n\u7d50\u8ad6\uff1a\u9664\u56e0\u75c5\u60c5\u60e1\u5316\u6216\u6b7b\u4ea1\uff0c\u8f49\u81f3\u4ed6\u79d1(\u9662)\u5c31\u91ab\u662f\u653e\u5c04\u6cbb\u7642\u5f8c\u60a3\u8005\u8ff4\u8a3a\u4e2d\u65b7\u7684\u6700\u5927\u539f\u56e0\u4f5434.2%\uff0c\u653e\u5c04\u816b\u7624\u79d1\u91ab\u5e2b\u61c9\u52a0\u5f37\u8207\u4ed6\u79d1\u91ab\u5e2b\u5408\u4f5c\uff0c\u5408\u529b\u7167\u9867\u60a3\u8005\u3002\u90e8\u4efd\u60a3\u8005\u56e0\u74b0\u5883\u56e0\u7d20\u9020\u6210\u8ff4\u8a3a\u4e2d\u65b7\uff0c\u6545\u9664\u4e86\u91ab\u7642\u5916\uff0c\u61c9\u63d0\u4f9b\u60a3\u8005\u793e\u6703\u7d93\u6fdf\u7b49\u652f\u63f4\u53ca\u5354\u52a9\uff0c\u5354\u52a9\u60a3\u8005\u6392\u9664\u56f0\u96e3\u3002\u53e6\u6709\u60a3\u8005\u56e0\u672a\u5c0d\u75be\u75c5\u6709\u6b63\u78ba\u8a8d\u77e5\uff0c\u6240\u4ee5\u61c9\u52a0\u5f37\u60a3\u8005\u6559\u80b2,\u4ffe\u4f7f\u5176\u80fd\u63a5\u53d7\u5b8c\u6574\u8ffd\u8e64\u3002", "e": "Purpose : The survival of cancer patients improved after the combination of multi-modality treatment and advance in the facility of radiotherapy. Besides, completion of treatment is essential for cancer patients, and regular follow-up is also an important part of cancer cares. The purposes of this study are, first, to explore the causes of interruption of regular follow-up and, second, to assess the role of onphone medical education as the first-line tool for follow-up course.\nMaterials and Methods : During the period from 2001/10/27 to 2002/10/19, there are 199 patients who did not come back on the day we had dated for follow-up course. The survey from hospital records, telephone were used to analyze the causes why these patients escaped from the regular follow-up course. \nResults : A total of 199 patients were eligible for analysis. Among these patients, 39 patients (19.6%) could not return back due to disease progression and 68 patients (34.2%) were transferred to other hospital / department for further management. Forty-one patients (20.6%) escaped from follow-up due to familial or economic problems. Twenty-five patients (12.6%) had psychologically ignorance of the disease. Seven patients were unsatisfied with our medical service. Nineteen patients were with unknown reasons.\nConclusion : In addition to disease progression, transferring and follow-up by other hospital or department are the major reasons causing follow up interruption. The radiation oncologist should cooperate with doctors of other hospital or department to follow up cancer patients. Other causes of follow-up interruption include economic or family problems, social workers maybe can offer some kind of support for these patients. The on-phone medical education is a useful tool in the follow-up of post treatment patients, but its role should be further evaluated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-157-172-a", "title": "\u9810\u9632\u52d5\u975c\u8108\u763b\u7ba1\u963b\u585e\u4e4b\u72f9\u9577\u578b\u96fb\u5b50\u5c04\u675f\u5291\u91cf\u5206\u6790", "keywords": "\u96fb\u5b50\u5c04\u7dda;\u52d5\u975c\u8108\u763b\u7ba1;\u72f9\u9577\u578b\u7167\u91ce Electron beam;Arteriovenous fistula;Small and elongated fields", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u662f\u60f3\u77ad\u89e3\u96fb\u5b50\u5c04\u675f\u5728\u72f9\u9577\u578b\u7167\u91ce\u4e2d\u6240\u7522\u751f\u7684\u5291\u91cf\u7279\u6027\uff0c\u91cf\u6e2c\u5176 (1) \u4e2d\u5fc3\u8ef8\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\uff08percent depth dose of central axis\uff09\u3001(2) \u7167\u91ce\u56e0\u5b50\uff08output factor\uff09\u3001(3) \u5291\u91cf\u5206\u4f48\uff08isodose distribution\uff09\uff0c\u63d0\u4f9b\u4e00\u5957\u5291\u91cf\u53c3\u8003\u7cfb\u7d71\uff0c\u4e0d\u50c5\u5c0d\u65bc\u672a\u4f86\u52d5\u975c\u8108\ue0b3\u7ba1\u653e\u5c04\u7dda\u9810\u9632\u963b\u585e\u4e0a\u80fd\u6709\u6240\u52a9\u76ca\uff0c\u4e5f\u53ef\u63d0\u4f9b\u5c0f\u7bc4\u570d\u7684\u76ae\u819a\u6216\u982d\u9838\u90e8\u75c5\u7076\u4e4b\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u78ba\u5207\u7684\u5291\u91cf\u9075\u5faa\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u91dd\u5c0d\u81e8\u5e8a\u4e0a\u8f03\u5e38\u4f7f\u7528\u7684\u516b\u7a2e\u7167\u91ce\u4f86\u505a\u91cf\u6e2c\u8207\u5206\u6790\uff0c\u5305\u542b2\u00d75\u30013\u00d75\u30014\u00d75\u30015\u00d75\u30012\u00d710\u30013\u00d710\u30014\u00d710\u30015\u00d710\u339d2\uff0c\u6240\u9078\u64c7\u7684\u80fd\u91cf\u70ba\u52d5\u975c\u8108\ue0b3\u7ba1\u8f03\u5e38\u4f7f\u7528\u7684\u4e09\u7a2e\u80fd\u91cf\uff0c\u5305\u542b6\u30018\u300110 MeV\uff0c\u800c\u4f7f\u7528\u7684\u76f4\u7dda\u52a0\u901f\u5668\u70baSiemens KDS-2\u4e26\u642d\u914d95\u339d \u768410\u00d710\u339d2\u96fb\u5b50\u9310\u7b52\uff08electron cone\uff09\uff0c\u800c\u5c04\u6e90\u5230\u5047\u9ad4\u8868\u9762\u8ddd\u96e2\uff08source-to-surface distance, SSD\uff09\u70ba100\u339d\u3002\u91cf\u6e2c\u5176 (1) \u4e2d\u5fc3\u8ef8\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\uff08percent depth dose of central axis\uff09\u3001(2) \u7167\u91ce\u56e0\u5b50\uff08output factor\uff09\u3001(3) \u5291\u91cf\u5206\u4f48\uff08isodose distribution\uff09\u3002\u70ba\u4e86\u7522\u751f\u72f9\u5c0f\u7167\u91ce\uff0c\u5fc5\u9808\u5229\u7528\u96fb\u5b50\u5c04\u675f\u906e\u64cb\u584a\uff08electron block\uff09\u4f86\u9054\u5230\u76ee\u7684\uff0c\u800c\u906e\u64cb\u584a\u653e\u7f6e\u7684\u4f4d\u7f6e\u6703\u5f71\u97ff\u96fb\u5b50\u5c04\u675f\u7684\u5291\u91cf\u5206\u4f48\uff0c\u6240\u4ee5\u5728\u672c\u7814\u7a76\u4e2d\u4e5f\u6bd4\u8f03\u5169\u7a2e\u906e\u64cb\u584a\u4f4d\u7f6e\uff08\u7f6e\u65bc\u96fb\u5b50\u9310\u7b52\u53ca\u5047\u9ad4\u8868\u9762\uff09\u4e0d\u540c\u6240\u9020\u6210\u7684\u5291\u91cf\u5206\u4f48\u3001\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\u53ca\u7167\u91ce\u56e0\u5b50\u7684\u6539\u8b8a\uff0c\u4ee5\u63d0\u4f9b\u65e5\u5f8c\u81e8\u5e8a\u4f7f\u7528\u6642\u53c3\u8003\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u5728\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u65b9\u9762\u53ef\u4ee5\u89c0\u5bdf\u51fa\u7576\u6df1\u5ea6\u5c0f\u65bcdmax\u6642\uff0c\u72f9\u9577\u578b\u7167\u91ce\u76f8\u5c0d\u65bc\u6b63\u65b9\u5f62\u7167\u91ce\u6709\u8f03\u9ad8\u7684\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\uff1b\u800c\u6df1\u5ea6\u5927\u65bcdmax\u6642\uff0c\u537b\u6709\u76f8\u53cd\u7684\u8da8\u52e2\u3002\u6b64\u5916\uff0c\u91dd\u5c0d\u906e\u64cb\u584a\u4f4d\u65bc\u96fb\u5b50\u9310\u7b52\u4e0b\u65b9\u8207\u5047\u9ad4\u8868\u9762\u7684\u7814\u7a76\u986f\u793a\uff0c\u7576\u906e\u64cb\u584a\u4f4d\u65bc\u96fb\u5b50\u9310\u7b52\u4e0b\u65b9\u6642\u6709\u8f03\u5c11\u7684\u4f4e\u80fd\u91cf\u6563\u5c04\u96fb\u5b50\uff0c\u4f7f\u5f97\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u503c\u7684\u8868\u73fe\u4ecb\u65bc\u6b63\u65b9\u5f62\u7167\u91ce\u8207\u906e\u64cb\u584a\u4f4d\u65bc\u5047\u9ad4\u8868\u9762\u4e8c\u8005\u4e4b\u9593\u3002\u5728\u7167\u91ce\u56e0\u5b50\u65b9\u9762\uff0c\u7576\u7167\u91ce\u8f03\u5c0f\u6642\uff0c\u7167\u91ce\u56e0\u5b50\u4e5f\u8f03\u5c0f\uff0c\u6b64\u5916\uff0c\u7576\u906e\u64cb\u584a\u4f4d\u65bc\u96fb\u5b50\u9310\u7b52\u4e0b\u65b9\u6642\uff0c\u7167\u91ce\u56e0\u5b50\u6bd4\u6c92\u6709\u906e\u64cb\u925b\u584a\u6709\u66f4\u5287\u70c8\u7684\u8b8a\u5316\u3002\u5728\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u4f48\u65b9\u9762\u7576\u906e\u64cb\u584a\u4f4d\u65bc\u96fb\u5b50\u9310\u7b52\u4e0b\u65b9\u6642\uff0c\u7b49\u5291\u91cf\u66f2\u7dda\u5448\u73fe\u8f03\u70ba\u9b06\u6563\u7684\u5206\u4f48\u3002\u56e0\u6b64\u81e8\u5e8a\u4e0a\uff0c\u906e\u64cb\u584a\u7684\u4f4d\u7f6e\u61c9\u5118\u53ef\u80fd\u7684\u63a5\u8fd1\u9ad4\u8868\u3002\u7b49\u5291\u91cf\u66f2\u7dda\u5728\u9ad8\u5291\u91cf\u5340\u6709\u660e\u986f\u5167\u7e2e\u60c5\u5f62\uff0c\u7576\u80fd\u91cf\u6108\u5927\u53ca\u7167\u91ce\u6108\u5c0f\u6642\uff0c\u5176\u5167\u7e2e\u60c5\u6cc1\u6108\u56b4\u91cd\u3002\u56e0\u6b64\uff0c\u7531\u672c\u5be6\u9a57\u53ef\u63d0\u4f9b\u4e00\u5957\u91dd\u5c0d\u5c0f\u800c\u72f9\u9577\u578b\u96fb\u5b50\u5c04\u675f\u7167\u91ce\u7684\u5291\u91cf\u53c3\u8003\u7cfb\u7d71\uff0c\u4e0d\u50c5\u5c0d\u65bc\u672a\u4f86\u52d5\u975c\u8108\ue0b3\u7ba1\u653e\u5c04\u7dda\u9810\u9632\u518d\u963b\u585e\u4e0a\u80fd\u6709\u6240\u52a9\u76ca\uff0c\u4e5f\u53ef\u61c9\u7528\u65bc\u5c0f\u7bc4\u570d\u7684\u76ae\u819a\u7167\u5c04\u6216\u982d\u9838\u90e8\u75c5\u7076\u4e4b\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u8a08\u7b97\u6240\u53c3\u8003\u3002", "e": "Purpose : The purpose of this study is to evaluate dose distribution of small and elongated electron beam fields for further reference in arterio-venous fistula treatment. The percent depth dose, isodose curve, and output factor were measured as a function of electron energies and field sizes to provide a practical reference dose system.\nMaterial and Methods : According to clinical practices , eight field sizes were measured (including 2 \u00d75, 3 \u00d75, 4 \u00d75, 5 \u00d75, 2 \u00d710, 3 \u00d710, 4 \u00d710, 5 \u00d710 cm2) and energy of 6, 8, 10 MeV generated by SIEMENS KDS-2 Linac were used in this study. The distance from source to surface (SSD) is 100cm. To generate small and elongated field, the electron blocks were used in our study, and percent depth dose, isodose curves, and output factor were also compared with blocks on electron cone and on phantom surface.\nResult and Discussion : The percent depth dose, isodose curve, and output factor were measured as a function of electron energies and field sizes. The Dmax shifts towards the surface as the electron beam field size reduced. The smaller the field sizes, the greater the surface dose, and the dose fall-off region becomes more gradual. If the mean size of arterio-venous fistula is 1.5 cm in length and 5mm in width, the safe margin should add 8mm more for long and short axis to cover treatment target adequately. The closer between cerrobend blocks and skin, the better the dose distribution will be.\nConclusion : The dialysis accesses (arterio-venous fistula) are suitable for electron-beam therapy because of their superficial location. The electron fields for arterio-venous fistula are usually small and elongated, dose distribution are usually unpredictable by conventional calculation table. The study provides a practical reference dose system for small and elongated field size electron beam dose calculation not only for arterio-venous fistula therapy, but also for skin, head and neck area treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-173-184-a", "title": "\u982d\u9838\u90e8\u653e\u5c04\u6cbb\u7642\u7684\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49", "keywords": "\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49;\u4e8c\u6975\u9ad4\u5075\u6aa2\u5668;\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u54c1\u8cea\u4fdd\u8b49 in vivo dosimetry;diodes;TLD;quality assurance", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u9054\u5230\u653e\u5c04\u6cbb\u7642\u7684\u76ee\u7684\uff0c\u5fc5\u9808\u78ba\u4fdd\u8655\u65b9\u5291\u91cf\u6b63\u78ba\u5730\u7d66\u4e88\u75c5\u60a3\u3002\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49\u70ba\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e2d\u7684\u6700\u5f8c\u4e00\u9053\u54c1\u8cea\u4fdd\u8b49\u95dc\u5361\uff0c\u5b83\u53ef\u5075\u6e2c\u51fa\u500b\u5225\u75c5\u60a3\u5728\u6cbb\u7642\u7a0b\u5e8f\u4e0a\u7684\u932f\u8aa4\uff0c\u4e5f\u53ef\u8a55\u4f30\u51fa\u7279\u6b8a\u6cbb\u7642\u8a08\u756b\u7684\u75c5\u60a3\u5291\u91cf\u3002\u672c\u5be6\u9a57\u7684\u76ee\u7684\uff0c\u5728\u65bc\u5efa\u7acb\u9f3b\u54bd\u764c\u60a3\u8005\u4e4b\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49\u7a0b\u5e8f\uff0c\u7814\u7a76\u6cbb\u7642\u8a08\u756b\u4e4b\u5291\u91cf\u5206\u5e03\u8207\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49\u7d50\u679c\u7684\u5dee\u5225\uff0c\u4ee5\u53ca\u6bd4\u8f03\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49\u5be6\u9a57\u6240\u7528\u4e4b\u5291\u91cf\u8a08\u7684\u512a\u7f3a\u9ede\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u8a08\u756b\u5c07\u5b8c\u6574\u6821\u6b63\u5f8c\u4e4b\u4e8c\u6975\u9ad4\u5075\u6aa2\u5668\u548c\u71b1\u767c\u5149\u5291\u91cf\u8a08\uff0c\u5206\u5225\u4f48\u7f6e\u5728\u5404\u500b\u7167\u91ce\u4e2d\u5fc3\u8ef8\u4e0a\u7684\u5c04\u5165\u548c\u5c04\u51fa\u76ae\u819a\u4f4d\u7f6e\u4e0a\uff0c\u7136\u5f8c\u5c07\u9019\u4e9b\u5291\u91cf\u8a08\u7684\u8b80\u6578\u7d93\u904e\u9069\u7576\u7684\u6821\u6b63\u8207\u4fee\u6b63\u53c3\u6578\uff08\u5305\u62ec\u7167\u91ce\u3001\u6954\u578b\u6ffe\u5668\u3001\u8207\u5c04\u675f\u963b\u64cb\u7269\u7b49\uff09\u8f49\u63db\u6210\u5c04\u5165\u5291\u91cf\u8207\u5c04\u51fa\u5291\u91cf\uff0c\u518d\u5229\u7528\u4ee5\u56fa\u614b\u6c34\u5047\u9ad4\u53ca\u6e38\u96e2\u8154\u5efa\u7acb\u7684\u7a7f\u900f\u7387\u66f2\u7dda\uff0c\u63a8\u7b97\u51fa\u75c5\u60a3\u8eab\u9ad4\u4e2d\u8ef8\u4e4b\u7d44\u7e54\u5291\u91cf\u3002\u6700\u5f8c\u5c07\u6b64\u5be6\u6e2c\u63a8\u7b97\u5f97\u4e4b\u4e2d\u7dda\u5291\u91cf\u8207\u8655\u65b9\u5291\u91cf\u6bd4\u8f03\u5206\u6790\u5176\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a\u4ee5\u4e8c\u6975\u9ad4\u5075\u6aa2\u5668\u8207\u71b1\u767c\u5149\u5291\u91cf\u8a08\u5206\u5225\u91cf\u6e2c\u4e8667\u500b\u7167\u91ce\uff0c\u5206\u5225\u5c6c\u65bc20\u820722\u4f4d\u75c5\u60a3\u3002\u4ee5\u4e8c\u6975\u9ad4\u5075\u6aa2\u5668\u91cf\u6e2c\u6d3b\u9ad4\u5291\u91cf\uff0c\u7d50\u679c\u67098.96%\u7167\u91ce\u7684\u816b\u7624\u5291\u91cf\u5927\u65bc5%\u7684\u8655\u65b9\u5291\u91cf\uff0c\u800c\u6240\u6709\u4e4b\u5291\u91cf\u8aa4\u5dee\u90fd\u5c11\u65bc10%\uff1b\u4ee5\u71b1\u767c\u5149\u5291\u91cf\u8a08\u5ea6\u91cf\u7684\u7d50\u679c\uff0c\u670943.28%\u7167\u91ce\u7684\u816b\u7624\u5291\u91cf\u8aa4\u5dee\u5927\u65bc5%\u7684\u8655\u65b9\u5291\u91cf\uff0c\u5927\u65bc10%\u7684\u5291\u91cf\u8aa4\u5dee\u5247\u67094.47%\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u672c\u5be6\u9a57\u5efa\u7acb\u4e00\u5957\u5305\u62ec\u6821\u6b63\u5291\u91cf\u8a08\u3001\u4fee\u6b63\u5404\u6cbb\u7642\u689d\u4ef6\u3001\u8207\u5be6\u969b\u75c5\u60a3\u91cf\u6e2c\u4e4b\u5b8c\u6574\u6d3b\u9ad4\u5291\u91cf\u9a57\u8b49\u65b9\u5f0f\uff0c\u4e5f\u7d93\u7531\u8aa4\u5dee\u5206\u6790\uff0c\u77ad\u89e3\u6cbb\u7642\u6d41\u7a0b\u4e2d\u53ef\u80fd\u767c\u751f\u8aa4\u5dee\u4e4b\u7a0b\u5e8f\uff0c\u5728\u6c7a\u5b9a\u6cbb\u7642\u8a08\u756b\u6642\u61c9\u7279\u5225\u6ce8\u610f\uff0c\u4ee5\u907f\u514d\u5291\u91cf\u8aa4\u5dee\uff0c\u9054\u5230\u54c1\u8cea\u4fdd\u8b49\u4e4b\u76ee\u7684\u3002", "e": "Purpose : Many national and international associations encourage the extension of in vivo dosimetry as an effective tool for an ultimate check of the treatment in external radiotherapy. In vivo dose measurements will be standardized in the QA procedure to avoid minor errors that might cause severe radiation damage. The aim of this study is to establish an in vivo dose verification procedure for head and neck patients and to ensure that they are treated optimally in radiotherapy.\nMaterials and Methods : To detect and analyze errors that could affect the therapy, we employed well calibrated diodes and thermoluminescence dosimeters (TLDs) for in vivo dosimetry to trace the dose delivery. The detectors were positioned on the patient\u2019s skin and behind the patient. Then, the entrance or exit dose was measured with appropriate correction factors (taking field size, wedge and block into account), and by combining the two dose mentioned above, the dose inside the patient was obtained using transmission curve. In external radiotherapy for head and neck patients where a very accurate dose delivery to the tumor is required, the experimental and prescribed midline dose values were compared.\nResults : From measurements obtained for external radiotherapy for head and neck patients, 8.96% of the diodes measurements showed a discrepancy more than 5% when compared with prescribed dose, while 43.28% was detected from TLDs. Difference of 10% or more were found in 4.47% of the TLDs measurements.\nConclusion : In this study we report on our experience with in vivo dosimetry. It shows that systematic in vivo dosimetry is a valid tool for quality assurance. Cancer centers can define an appropriate action level concerning the deviation between measured and prescribed dose; if the action level is exceeded, treatment parameters have to be checked and generally, in vivo dosimetry has to be repeated until the cause of the deviation is found and, if possible, eliminated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-185-192-a", "title": "Treatment Results of Langerhans Cell Histiocytosis: A Long Term Follow-Up", "keywords": "\u862d\u683c\u6f22\u6c0f\u7d44\u7e54\u7d30\u80de\u589e\u591a\u75c7;\u7d44\u7e54\u7d30\u80de\u589e\u591a\u75c7X Langerhans cell histiocytosis;Histiocytosis X", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u862d\u683c\u6f22\u6c0f\u7d44\u7e54\u7d30\u80de\u589e\u591a\u75c7\u60a3\u8005\u6cbb\u7642\u5f8c\u7684\u9577\u671f\u8ffd\u8e64\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1978\u5e741\u6708\u81f32002\u5e7412\u6708\u6b62\uff0c\u5171\u670920\u4f4d\u862d\u683c\u6f22\u6c0f\u7d44\u7e54\u7d30\u80de\u589e\u591a\u75c7\u60a3\u8005\u65bc\u4e09\u8ecd\u7e3d\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\u3002\u60a3\u8005\u5e74\u9f61\u7684\u4e2d\u4f4d\u503c\u70ba12\u6b72\u3002\u6cbb\u7642\u65b9\u6cd5\u5305\u62ec\u624b\u8853\u3001\u5316\u5b78\u6cbb\u7642\u3001\u653e\u5c04\u6cbb\u7642\u3001\u5408\u4f75\u591a\u7a2e\u6cbb\u7642\u65b9\u5f0f\u53ca\u89c0\u5bdf\u3002\u8ffd\u8e64\u6642\u9593\u7684\u4e2d\u4f4d\u503c\u70ba 87\u500b\u6708\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u9032\u5c55\u5b58\u6d3b\u7387\u5206\u5225\u70ba100%\u53ca92%\u3002\u4e94\u5e74\u7121\u75be\u75c5\u9032\u5c55\u5b58\u6d3b\u7387\u5728\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u53ca\u6c92\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u4e2d\uff0c\u5206\u5225\u70ba100%\u53ca83%\uff08p = 0.317\uff09\u3002\u4e94\u5e74\u7684\u6574\u9ad4\u5c40\u90e8\u63a7\u5236\u7387\u70ba87%\uff0c\u5176\u4e2d\u7b2c\u4e00\u671f\u3001\u7b2c\u4e8c\u671f\u3001\u7b2c\u4e09\u671f\u53ca\u7b2c\u56db\u671f\u60a3\u8005\u7684\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba100%\u3001100%\u300175%\u53ca50%\uff08p = 0.695\uff09\u3002\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u53ca\u6c92\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u662f75%\u8207100%\uff08p = 0.065\uff0c\u4f46\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u5c40\u90e8\u75c7\u72c0\u7de9\u89e3\u6548\u679c\u4f73\uff09\u3002\u5e74\u7d00\u5c0f\u65bc25\u6b72\u53ca\u5927\u65bc25\u6b72\u7684\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba100%\u53ca50%\uff08p = 0.0007\uff09\u3002\n\u8a0e\u8ad6\uff1a\u4e0d\u8ad6\u662f\u4f55\u7a2e\u6cbb\u7642\u65b9\u5f0f\uff0c\u862d\u683c\u6f22\u6c0f\u7d44\u7e54\u7d30\u80de\u589e\u591a\u75c7\u60a3\u8005\u7686\u6709\u975e\u5e38\u597d\u7684\u5b58\u6d3b\u7387\uff0c\u56e0\u6b64\u6211\u5011\u5efa\u8b70\u5c0d\u65bc\u9019\u985e\u60a3\u8005\u7684\u6cbb\u7642\u61c9\u76e1\u91cf\u907f\u514d\u7522\u751f\u526f\u4f5c\u7528\uff0c\u4e26\u5c31\u75be\u75c5\u4fb5\u72af\u7684\u7a0b\u5ea6\u4f86\u9078\u64c7\u6cbb\u7642\u65b9\u5f0f\u3002\u591a\u8655\u9aa8\u9abc\u4fb5\u72af\u6216\u795e\u7d93\u4fb5\u72af\u4f3c\u4e4e\u4e0d\u6703\u660e\u986f\u7684\u5f71\u97ff\u5b58\u6d3b\u7387\u3002\u7b2c\u4e00\u671f\u53ca\u7b2c\u4e8c\u671f\u60a3\u8005\u7684\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u548c\u5b58\u6d3b\u7387\u6c92\u6709\u5dee\u7570\u3002", "e": "Purpose : To investigate the long-term treatment outcome of patients of Langerhans cell\nhistiocytosis (LCH).\nMaterials and Methods : Twenty patients with the diagnosis of LCH between January 1978 and December 2002 were included in our study. Median age was 12 years. Treatment included surgery, chemotherapy, radiotherapy, combination of multiple modalities and observation. The median follow-up is 87 months.\nResults : The 5-year overall and progression-free survival rates for all patients were 100% and 92%, respectively. The 5-year progression-free survival rates for patients treated with and without radiotherapy were 100% and 83%, respectively (p = 0.317). The overall local control rate was 87% at five years. Of these, the 5-year local control rates for stage 1, 2, 3, and 4 were 100%, 100%, 75%, and 50%, respectively (p = 0.695). The 5-year local control rates for patients treated with and without radiotherapy were 75% and 100%, respectively (p= 0.065, despite a good response to local radiotherapy). The 5-year local control rates for age \u2264 25 and \uff1e 25 years were 100% and 50%, respectively (p = 0.0007).\nConclusion : All of our LCH patients had a very high survival regardless of the treatment modalities. This suggests that less aggressive treatments may be the reasonable initial therapy to avoid side effects. The choice of treatment depends on the extent of disease. It seems that multiple bone or neurological involvement did not significantly influence survival. There is no difference in the 5-year local control and survival rates between stage 1 and 2."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-193-199-a", "title": "Granulocytic Sarcoma of the Uterine Cervix: A Case Report and Review of the Literature", "keywords": "\u5b50\u5bae\u9838;\u9846\u7c92\u6027\u767d\u8840\u7403\u8089\u7624;\u7da0\u8272\u7624 Uterine cervix;Granulocytic sarcoma;Chloroma", "c": "\u5b50\u5bae\u9838\u539f\u767c\u6027\u8840\u6db2\u60e1\u6027\u75be\u75c5\u76f8\u7576\u7f55\u898b\u3002\u9846\u7c92\u6027\u767d\u8840\u7403\u8089\u7624\u4e5f\u7a31\u70ba\u9aa8\u9ad3\u80da\u7d30\u80de\u7624\u6216\u7da0\u8272\u7624\uff0c\u662f\u4e00\u7a2e\u5c11\u898b\u7684\u75be\u75c5\u3002\u9019\u7a2e\u8089\u7624\u542b\u6709\u4e0d\u6210\u719f\u7684\u9846\u7c92\u7d30\u80de\u3002\u672c\u75c5\u4f8b\u66fe\u60a3\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\uff0c\u4e26\u7d93\u6cbb\u7642\u4e14\u75be\u75c5\u7de9\u89e3\u5341\u4e8c\u5e74\u5f8c\uff0c\u5728\u5b50\u5bae\u9838\u4e0a\u767c\u751f\u9846\u7c92\u6027\u767d\u8840\u7403\u8089\u7624\uff0c\u56e0\u6b64\u66f4\u986f\u6b64\u75c5\u4f8b\u7279\u6b8a\u4e4b\u8655\u3002\u82e5\u80fd\u65e9\u671f\u78ba\u8a3a\u9019\u7a2e\u7f55\u898b\u7684\u75be\u75c5\u4e26\u7d93\u9069\u7576\u6cbb\u7642\uff0c\u5176\u9810\u5f8c\u4ecd\u4f73\u3002", "e": "Hematological malignant diseases rarely affect the uterine cervix as primary malignancies. Granulocytic sarcoma (GS), also known as extramedullary myeloblastoma or chloroma is an unusual manifestation and represent soft tissue masses composed of immature cells of the granulocytic series. We reported a case of GS of the uterine cervix. This GS case is unusual because of the disease happened after 12 years of AML remission in a patient considered to have been in remission of acute myelogenous leukemia (AML) for twelve years. The recognition of this rare entity is as important as early treatment to improve the prognosis of this dismal disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200409-11-3-201-206-a", "title": "Metaplastic Carcinoma of the Breast: One Case Report and Literature Review", "keywords": "\u4e73\u764c;\u8f49\u5f62\u6027\u764c\u7624;\u653e\u5c04\u6cbb\u7642;\u500b\u6848\u5831\u544a Breast Cancer;Metaplastic Carcinoma;Radiotherapy;Case Report", "c": "\u8f49\u5f62\u6027\u4e0a\u76ae\u764c\u4e4b\u4e73\u764c\u5728\u4e73\u623f\u816b\u7624\u75c5\u4f8b\u4e0a\u5f88\u5c11\u898b\u3002\u4e00\u4f4d41\u6b72\u5973\u6027\u4e73\u764c\u75c5\u60a3\uff0c\u521d\u671f\u8a3a\u65b7\u70ba\u6d78\u6f64\u6027\u4e73\u7ba1\u764c\uff0c\u7d93\u816b\u7624\u5207\u9664,\u540c\u6642\u505a\u76ae\u74e3\u8f49\u79fb\u91cd\u5efa\u8853\uff0c\u53ca\u814b\u4e0b\u6dcb\u5df4\u7d50\u6458\u9664\uff08pT2N1M0\uff09\uff0c\u4e5d\u500b\u6dcb\u5df4\u7d50\u4e2d\u6709\u4e00\u500b\u8f49\u79fb\uff0c\u9ec3\u9ad4\u7d20\u53d7\u9ad4\u53ca\u96cc\u6fc0\u7d20\u53d7\u9ad4\u5747\u70ba\u9670\u6027\uff1b\u8853\u5f8c\u7d93\u516d\u7642\u7a0bTaxetere\u5316\u5b78\u6cbb\u7642\u3001\u8377\u723e\u8499\u6cbb\u7642\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff082 Gy/fr.,50 Gy\uff09\u5f8c\uff0c\u5b9a\u6642\u9580\u8a3a\u8ffd\u8e64\uff1b\u4f46\u65bc\u624b\u8853\u5f8c\u4e8c\u5341\u500b\u6708\uff0c\u65bc\u624b\u8853\u75a4\u75d5\u4e0a\u7de3\u767c\u73fe\u816b\u7624\u5fa9\u767c\uff0c\u7d93\u816b\u7624\u5207\u9664\uff0c\u75c5\u7406\u8a3a\u65b7\u70ba\u8f49\u5f62\u6027\u4e0a\u76ae\u764c\uff1b\u4e00\u500b\u6708\u5f8c\uff0c\u767c\u73fe\u80ba\u90e8\u8f49\u79fb\uff0c\u516d\u500b\u7642\u7a0b\uff08Taxol + Navelbine\uff09\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u4ecd\u767c\u73fe\u8166\u90e8\u53ca\u9aa8\u982d\u8f49\u79fb\uff1b\u5f9e\u8a3a\u65b7\u70ba\u4e73\u764c\u81f3\u6b7b\u4ea1\uff0c\u671f\u9593\u50c5\u4e8c\u5341\u516d\u500b\u6708\u3002\u6211\u5011\u5831\u544a\u6b64\u4e00\u7f55\u898b\u75c5\u4f8b\u4e26\u91dd\u5c0d\u8f49\u5f62\u6027\u4e73\u764c\u505a\u4e00\u6587\u737b\u56de\u9867\u53ca\u6574\u7406\u3002", "e": "Metaplastic carcinoma is a rare form of breast carcinoma. Herein we reported a breast cancer patient with metaplastic carcinoma which mimicked infiltrating ductal carcinoma in the initial pathological diagnosis. She received modified radical mastectomy, adjuvant chemotherapy and radiotherapy to the chest wall and loco-regional lymphatic area.  Eight months after radiotherapy, a 3 x 2 cm hard mass over the right upper margin of incision was noted. The pathology revealed metaplastic carcinoma. Sequentially multi-organ metastases to the bones, lung and brain developed. The survival period was only 26 months from the diagnosis of breast cancer. The pathology pictures and literature of metaplastic breast carcinoma were reviewed and discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-71-79-a", "title": "Postoperative Radiation Therapy in Patients with Pathologic Risks of Stage IB to IIA Cervical Carcinoma", "keywords": "\u5b50\u5bae\u9838\u764c;\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Cervical cancer;Postoperative radiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u521d\u671f\u5b50\u5bae\u9838\u764c\u4e4b\u7d50\u679c\u53ca\u75c5\u7406\u9810\u5f8c\u56e0\u5b50\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1991\u5e744\u6708\u81f32000\u5e7412\u6708\uff0c\u5171\u6709130\u4f4d\u7f79\u60a3\u5b50\u5bae\u9838\u764c\u4e4b\u75c5\u60a3\u63a5\u53d7\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u5408\u4f75\u9aa8\u76c6\u6dcb\u5df4\u817a\u6458\u9664\u8853\u8207\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d19\u4f4d\u75c5\u60a3\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\u6240\u6709\u75c5\u60a3\u65bc\u8853\u5f8c\u75c5\u7406\u6aa2\u67e5\u767c\u73fe\u81f3\u5c11\u6709\u4e0b\u8ff0\u4e00\u9805\u5371\u96aa\u56e0\u5b50\uff1a1. \u9aa8\u76c6\u6dcb\u5df4\u8f49\u79fb\u30012. \u6dcb\u5df4\u8f49\u79fb\u500b\u6578\u8d85\u904e1\u500b\u30013. \u5b50\u5bae\u65c1\u7d44\u7e54\u4fb5\u72af\u30014. \u8840\u7ba1\u9593\u9699\u4fb5\u72af\u30015. \u624b\u8853\u5207\u7de3\u4e0d\u8db3\u30016. \u539f\u767c\u816b\u7624\u5927\u65bc4\u516c\u5206\u30017. \u591a\u65bc\u4e00\u9805\u5371\u96aa\u56e0\u5b50\u3002\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u7d66\u4e88\u6bcf\u4e00\u4f4d\u75c5\u60a3\u5168\u9aa8\u76c6\u815441-54 Gy\u4e4b\u816b\u7624\u5291\u91cf\uff0c\u5206\u6b21\u5291\u91cf\u70ba1.8 Gy\u3002\u5176\u4e2d124\u4f4d\u75c5\u60a3\u5229\u7528\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u7d66\u4e88\u9670\u9053\u7e2b\u5408\u7de32.5-21.5 Gy\u4e4b\u8ffd\u52a0\u5291\u91cf\u3002 \u7d50\u679c\uff1a\u4e94\u5e74\u5168\u90e8\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba76.5%\u548c76.1%\u30026\u4f4d\u75c5\u60a3\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c16\u4f4d\u75c5\u60a3\u767c\u751f\u9060\u7aef\u8f49\u79fb\uff0c7 \u4f4d\u75c5\u60a3\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u53ca\u9060\u7aef\u8f49\u79fb\u3002\u55ae\u8b8a\u6578\u5206\u6790\u7684\u7d50\u679c\u6307\u51fa\uff1a\u53ea\u6709\u8840\u7ba1\u9593\u9699\u4fb5\u72af\u5c0d\u5b58\u6d3b\u7387\u6709\u986f\u8457\u6027\u7684\u5f71\u97ff\uff08p = 0.05\uff09\u3002\u8840\u7ba1\u9593\u9699\u4fb5\u72af\u53ca\u591a\u65bc\u4e00\u9805\u5371\u96aa\u56e0\u5b50\u8207\u9ad8\u9060\u7aef\u8f49\u79fb\u767c\u751f\u6a5f\u7387\u76f8\u95dc\uff08p = 0.05\u53cap = 0.02\uff09\u3002\u4ee5\u591a\u56e0\u5b50\u5206\u6790\u800c\u8a00\uff0c\u53ea\u6709\u8840\u7ba1\u9593\u9699\u4fb5\u72af\u4ecd\u7136\u70ba\u5b58\u6d3b\u7387\u7684\u5f71\u97ff\u56e0\u5b50\u300220\u4f4d\uff0815%\uff09\u75c5\u60a3\u6cbb\u7642\u5f8c\u51fa\u73fe\u5f8c\u907a\u75c7\uff1a\u80c3\u8178\u9053\u65b9\u9762\u670912\u4f4d\uff089%\uff09\uff0c\u6ccc\u5c3f\u7cfb\u7d71\u65b9\u9762\u67098\u4f4d\uff086%\uff09\u3002\u4e94\u5e74\u7121\u767c\u751f\u5f8c\u907a\u75c7\u6a5f\u7387\u70ba91%\uff0c\u5176\u4e2d10\u4f4d\uff088%\uff09\u75c5\u60a3\u67093-4\u7d1a\u7684\u5f8c\u907a\u75c7\u3002 \u7d50\u8ad6\uff1a\u6b64\u7814\u7a76\u7d50\u679c\uff0c\u5c0d\u65bc\u521d\u671f\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u63a5\u53d7\u6839\u9664\u6027\u5b50\u5bae\u5207\u9664\u8853\u5408\u4f75\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u80fd\u7d66\u4e88\u75c5\u60a3\u5408\u7406\u7684\u5b58\u6d3b\u7387\u3002\u4f46\u5982\u679c\u75c5\u60a3\u5177\u6709\u8840\u7ba1\u9593\u9699\u4fb5\u72af\u6216\u591a\u65bc\u4e00\u9805\u5371\u96aa\u56e0\u5b50\uff0c\u5176\u5b58\u6d3b\u6642\u9593\u8f03\u77ed\u4e14\u9060\u7aef\u8f49\u79fb\u767c\u751f\u7387\u8f03\u9ad8\u3002", "e": "Purpose : To investigate the prognostic impact of pathologic risk factors and failure patterns in patients with stage IB to IIA cervical carcinoma treated with postoperative adjuvant pelvic irradiation. Material and Method : Between April 1991 to December 2000, 130 patients with FIGO IB to IIA carcinoma of the cervix were treated with radical hysterectomy, bilateral pelvic lymphadenectomy and postoperative radiation therapy. Nineteen patients received systemic chemotherapy. All the patients had at least one of the following pathologic risk factors: 1. positive pelvic nodal metastasis, 2. multiple positive lymph nodes, 3. parametrial invasion, 4. vascular space invasion, 5. positive surgical margin, 6. bulky tumor size \uff1e 4 cm, 7. multiple pathologic risk factors. The radiation dose delivered to the whole pelvis range from 41-54 Gy in 1.8 Gy fractions. One hundred twenty-four patients received 2.5-21.5 Gy intracavitary brachytherapy. Results : The patients were followed for a median of 57.9 months (range: 4.1 - 129.9). The 5-year overall survival and disease free survival rate were 76.5% and 76.1%, respectively. A total of 29 (22.3%) patients developed recurrence. Six recurrences were in the pelvis alone. Sixteen patients recurred only at sites outside the pelvis. Seven patients had both pelvic and distant recurrences. We demonstrated that only vascular space invasion had significant effect on disease free survival by univariate analysis (p = 0.05). Vascular space invasion and multiple pathologic risk factors were significantly correlated with higher incidence of distant metastasis. (p = 0.05 and p = 0.02, respectively). In multivariate analysis of these factors showed that only vascular space invasion remained significant risk factors (p = 0.05). Therapeutic complications occurred in 20 (15%) patients, including gastrointestinal in 12 (9%) patients or genitourinary in 8 (6%) patients. The overall 5-year complication-free rate was 91%. Ten (8%) of those patients had grade 3 and 4 late morbidity. Conclusion : Our study suggested that postoperative radiotherapy after radical hysterectomy give reasonable survival in early stage carcinoma of the cervix. Poor survival and higher incidence of distant metastasis were observed if presence of vascular space invasion or multiple pathologic risk factors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-81-89-a", "title": "Outcome of Radiotherapy in Histologically Confirmed Neoplasms of the Pancreas", "keywords": "\u80f0\u81df\u764c;\u653e\u5c04\u6cbb\u7642;\u81e8\u5e8a\u6cbb\u7642\u6210\u679c Pancreatic neoplasms;Radiotherapy;Clinical outcome", "c": "\u76ee\u7684\uff1a\u5927\u591a\u6578\u7684\u80f0\u81df\u764c\u5728\u75be\u75c5\u8a3a\u65b7\u4e4b\u521d\u5373\u70ba\u5c40\u90e8\u4fb5\u72af\u53b2\u5bb3\u7684\u665a\u671f\u75c5\u4eba\uff0c\u80fd\u9078\u64c7\u7684\u6cbb\u7642\u65b9\u6cd5\u4e26\u4e0d\u591a\uff0c\u6211\u5011\u4ee5\u56de\u6eaf\u6027\u7684\u65b9\u5f0f\u5831\u544a\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u70ba\u80f0\u81df\u764c\u4e4b\u653e\u5c04\u6cbb\u7642\u6210\u679c\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1992\u5e74\u52302002\u5e746\u6708\uff0c\u5171\u670932\u4f4d\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u70ba\u80f0\u81df\u764c\u7684\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u653e\u5c04\u7dda45\u523064 Gy\u7684\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff08\u4e2d\u4f4d\u6578\u70ba50.4 Gy\uff09\u3002\u5176\u4e2d8\u4f4d\u75c5\u4eba\u70ba\u53ef\u5207\u9664\u4e4b\u816b\u7624\uff0c\u56e0\u70ba\u624b\u8853\u7121\u6cd5\u5207\u9664\u4e7e\u6de8\u6216\u662f\u6709\u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u800c\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u7167\u5c04\uff1b8\u4f4d\u75c5\u4eba\u5728\u75be\u75c5\u8a3a\u65b7\u4e4b\u521d\u5373\u9060\u7aef\u8f49\u79fb\u81f3\u809d\u3001\u80ba\u548c\u9838\u90e8\u6dcb\u5df4\u7d50\uff1b\u53e6\u591616\u4f4d\u5247\u70ba\u5c40\u90e8\u816b\u7624\u4fb5\u72af\u53b2\u5bb3\u7121\u6cd5\u624b\u8853\u5207\u9664\u4e4b\u60a3\u8005\u3002\u7d44\u7e54\u578b\u614b\u5247\u4ee5\u817a\u764c\uff0828\u4f4d\u75c5\u4eba\uff09\u70ba\u6700\u5e38\u898b\uff0c\u5176\u9918\u4f9d\u6b21\u70ba\u60e1\u6027\u795e\u7d93\u5167\u5206\u6ccc\u7624\uff082\u4eba\uff09\u3001\u56ca\u817a\u764c\uff081\u4eba\uff09\u548c\u9ecf\u6db2\u6027\u764c\uff081\u4eba\uff09\u300228\u4f4d\u75c5\u4eba\uff0888%\uff09\u63a5\u53d7\u542b5-FU\u6216\u662fgemcitabine\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u591a\u8207\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u540c\u6642\u7d66\u4e88\u3002 \u7d50\u679c\uff1a\u75c5\u4eba\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u7b2c\u4e00\u5e74\u70ba31.3%\uff0c\u7b2c\u4e8c\u5e74\u70ba10.7%\u3002\u817a\u764c\u6bd4\u975e\u817a\u764c\u7684\u75c5\u4eba\u6709\u8f03\u5dee\u7684\u5b58\u6d3b\u7387\uff08\u4e2d\u4f4d\u6578\u70ba7.6\u6708\u548c22.2\u6708\uff1bP\u503c\u70ba0.04\uff09\u3002\u572828\u4f4d\u817a\u764c\u7684\u75c5\u4eba\u4e2d\uff0c\u63a5\u53d7\u624b\u8853\u5207\u9664\u816b\u7624\u8005\uff0c\u6bd4\u816b\u7624\u7121\u6cd5\u624b\u8853\u5207\u9664\u8005\u6216\u9060\u7aef\u816b\u7624\u8f49\u79fb\u8005\uff0c\u6709\u8f03\u4f73\u7684\u5b58\u6d3b\u7387\uff08\u4e2d\u4f4d\u6578\u70ba10.9\u6708\u6bd48.3\u6708\u6bd4 2.8\u6708\uff1bP\u503c\u70ba0.003\uff09\uff0c\u809d\u81df\u70ba\u6700\u6613\u597d\u767c\u4e4b\u9060\u7aef\u8f49\u79fb\u8655\uff0811\u4f4d\u75c5\u4eba\uff0c35%\uff09\u3002 \u7d50\u8ad6\uff1a\u5373\u4f7f\u653e\u5c04\u6cbb\u7642\u5c0d\u624b\u8853\u53ef\u5207\u9664\u4e4b\u80f0\u81df\u764c\u6709\u76f8\u5c0d\u8f03\u4f73\u7684\u81e8\u5e8a\u6cbb\u7642\u6210\u679c\uff0c\u80f0\u81df\u764c\u7684\u653e\u5c04\u6cbb\u7642\u6548\u679c\u4ecd\u7136\u5f88\u5dee\uff0c\u672a\u4f86\u5c0d\u9019\u500b\u75be\u75c5\u9700\u8981\u66f4\u591a\u65b0\u85e5\u548c\u65b0\u7684\u6cbb\u7642\u6a21\u5f0f\u7684\u5408\u4f75\u6cbb\u7642\u3002", "e": "Purpose : Treatment options for pancreatic cancer remain limited due to the large proportion of patients presenting with advanced disease at the time of diagnosis. This retrospective study is to report our result in treating pancreatic cancer with radiotherapy. Material and Methods : From 1992 to June 2002, 32 patients with tissue-proven neoplasms of the pancreas were treated with external-beam radiotherapy to a dose of 45 to 64 Gy (median, 50.4 Gy). Eight patients with resectable tumors received post-operative radiotherapy for margin or node positive. Eight had initial metastatic disease in the liver, lung or neck lymph nodes. The remaining 16 patients had unresectable, locally advanced tumors. Adenocarcinoma was the most common histologic type (28 patients), followed by neuroendocrine tumor (2), cystadenocarcinoma (1) and mucinous carcinoma (1). Chemotherapy with 5-FU or gemcitabine base was given to 28 (88%) patients, most concurrently. Result : The overall survival rate for all patients was 31.3% at 1 year and 10.7% at 2 years. Those with adenocarcinomas had a poorer survival than those with non-adenocarcinomatous tumors (median: 7.6 vs. 22.2 months, P = 0.04). Among the 28 adenocarcinoma patients, survival was significantly better for those with resectable tumors, as compared to unresectable and metastatic tumors (median: 10.9 vs. 8.3 vs. 2.8 months, P = 0.0003). The liver was the most common site of distant metastasis in 11 patients (35%). Conclusion : Despite the relatively favorable prognosis of radiotherapy for resectable compared with unresectable and metastatic pancreatic cancers, the survival of patients after radiotherapy is still dismal. New approaches using novel agents and combined treatment modalities are necessary to change the dismal outlook of the disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-91-97-a", "title": "Postoperative Chemoradiotherapy in Locally Advanced Esophageal Carcinoma: Low-Dose and Standard-Dose Radiotherapy Compared", "keywords": "\u98df\u9053\u764c;\u624b\u8853;\u8f14\u52a9\u6027\u5316\u7642\u653e\u5c04\u6cbb\u7642 Esophageal cancer;Surgery; Adjuvant chemoradiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u6b32\u63a2\u8a0e\u4e0d\u540c\u653e\u5c04\u5291\u91cf\u5c0d\u65bc\u98df\u9053\u764c\u624b\u8853\u5f8c\u65bd\u884c\u8f14\u52a9\u6027\u540c\u6b65\u5316\u7642\u653e\u5c04\u6cbb\u7642\u4e4b\u7642\u6548\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u56de\u6eaf\u5206\u6790\u81ea1990\u5e741\u6708\u81f31998\u5e7412\u670878\u4f4d\u63a5\u53d7\u624b\u8853\u5f8c\u5316\u7642\u653e\u5c04\u6cbb\u7642\u4e4b\u98df\u9053\u764c\u60a3\u8005\uff0c\u5176\u75c5\u7406\u5206\u671f\u70baTxN1, T3-4Nx\u3002\u75c5\u60a3\u5747\u63a5\u53d7\u98df\u9053\u5207\u9664\u8853\u70ba\u9996\u8981\u6cbb\u7642\u3002\u624b\u8853\u5f8c\u56db\u9031\u958b\u59cb\uff0c\u75c5\u60a3\u63a5\u53d7\u8f14\u52a9\u6027\u5316\u7642\u653e\u5c04\u6cbb\u7642\uff0c\u653e\u5c04\u6cbb\u7642\u6bcf\u6b21 1.8 Gy\uff0c\u671f\u9593\u4e26\u9032\u884c\u540c\u6b65\u5316\u7642\u4e00\u81f3\u4e8c\u6b21\uff0c\u6bcf\u6b21\u4ee5cisplatin 20 mg/m2, 5-Fu 500 mg/m2, leucovorin 90 mg/m2\uff0c\u9023\u7e8c\u6ef4\u6ce896\u5c0f\u6642\u3002\u6240\u6709\u75c5\u60a3\u4f9d\u653e\u5c04\u5291\u91cf\u5206\u6210\u4e8c\u7d44\uff0c\u4f4e\u5291\u91cf\u7d4425\u4eba\u70ba40\u81f349.99 Gy\uff0c\u6a19\u6e96\u5291\u91cf\u7d4453\u4eba\u70ba50 Gy\u4ee5\u4e0a\u3002 \u7d50\u679c\uff1a\u4f4e\u5291\u91cf\u7d44\u3001\u6a19\u6e96\u5291\u91cf\u7d44\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba40.00%\u300128.30%\uff08p = 0.43\uff09\uff0c\u4e94\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba28.00%\u300124.53%\uff08p = 0.36\uff09\uff0c\u4e94\u5e74\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u5206\u5225\u70ba36.00%\u300128.30%\uff08p = 0.44\uff09\uff0c\u4e94\u5e74\u7121\u8f49\u79fb\u5b58\u6d3b\u7387\u5206\u5225\u70ba38.77%\u300124.53%\uff08p = 0.61\uff09\u3002 \u7d50\u8ad6\uff1a\u5c40\u90e8\u6027\u98df\u9053\u764c\u60a3\u8005\u63a5\u53d7\u624b\u8853\u5f8c\u540c\u6b65\u5316\u7642\u653e\u5c04\u6cbb\u7642\uff0c\u8f03\u9ad8\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u4e26\u672a\u9054\u5230\u986f\u8457\u5ef6\u9577\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u3002\u4f4e\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u53ef\u80fd\u5c0d\u8f03\u65e9\u671f\u7684\u98df\u9053\u764c\u662f\u8db3\u5920\u7684\uff0c\u7136\u800c\u8f03\u9ad8\u5291\u91cf\u5c0d\u8f03\u665a\u671f\u98df\u9053\u764c\u7684\u6548\u679c\u4ecd\u672a\u660e\u3002\u6211\u5011\u5efa\u8b70\u9032\u884c\u96a8\u6a5f\u5be6\u9a57\uff0c\u4ee5\u63a2\u8a0e\u653e\u5c04\u5291\u91cf\u5728\u624b\u8853\u5f8c\u540c\u6b65\u5316\u7642\u653e\u5c04\u6cbb\u7642\u4e4b\u5f71\u97ff\u3002", "e": "Purpose : To compare overall survival rate, disease-free survival rate, local recurrence-free survival rate, distant metastasis-free survival rate of adjuvant chemoradiotherapy (CRT) after curative en-bloc esophagectomy using different doses of radiotherapy for locally advanced esophageal cancer (LAEC).  Materials and Methods : We conducted a retrospective analysis of 78 patients with pathologically staged LAEC (TxN1, T3-4Nx) with adjuvant CRT after surgery between January 1990 and December 1998. Patients received curative esophagectomy as the primary treatment. Four weeks later, patients received adjuvant CRT at 1.8 Gy/fraction and infusional chemotherapy (1-2 cycles) with regimens of cisplatin 20 mg/m2, fluorouracil 500 mg/m2, leucovorin 90 mg/m2 during radiotherapy. The patients were divided into two groups with the total doses of 40-49.99 Gy (low-dose) for AJCC stage II and over 50 Gy (standard-dose) for stage III.  Results : Twenty-five patients received low-dose radiotherapy and 53 patients received standard-dose radiotherapy. Five-year overall survival rate was 40.00% and 28.30% for the low- and standard- dose group (p = 0.43). Five-year disease-free survival rate was 28.00% (low-dose) and 24.53% (standard-dose) (p = 0.36). Five-year local recurrence-free survival rate was 40.00% and 28.30 % (p = 0.44). Five-year distal metastasis-free survival rate was 38.77% and 24.53 % (p = 0.61). There was no significant difference between the two treatment groups.  Conclusion : The higher radiation dose did not increase survival or local control in LAEC. Low-dose radiotherapy was sufficient whereas standard-dose radiotherapy was controversial for CCRT in LAEC. Randomized trails are recommended to further determine the effects of radiation dose in postoperative chemoradiotherapy in LAEC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-99-104-a", "title": "Radiation Therapy for Malignant Pheochromocytoma: Two Case Report and Review of the Literature", "keywords": "\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;131I-MIBG Malignant pheochromocytoma;Radiotherapy;Chemotherapy;131I-MIBG", "c": "\u55dc\u927b\u7d30\u80de\u7624\u70ba\u4e00\u7f55\u898b\u4e4b\u816b\u7624\uff0c\u7d040.1%\u4e4b\u9ad8\u8840\u58d3\u75c5\u4eba\u53ef\u767c\u73fe\u6709\u6b64\u816b\u7624\u3002\u8f49\u79fb\u6027\u4e4b\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u7d04\u4f54\u5168\u9ad4\u55dc\u927b\u7d30\u80de\u7624\u4e4b10-15%\u3002\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u9810\u5f8c\u76f8\u7576\u4e0d\u826f\uff0c\u5176\u4e94\u5e74\u5b58\u6d3b\u7387\u50c5\u7d0440%\u3002\u5118\u7ba1\u539f\u767c\u6027\u4e4b\u624b\u8853\u5207\u9664\u662f\u9996\u8981\u4e4b\u6cbb\u7642\u65b9\u5f0f\uff0c\u5728\u67d0\u4e9b\u60c5\u6cc1\u4e0b\uff0c\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u4ecd\u4e0d\u5931\u70ba\u66ff\u4ee3\u6027\u4e4b\u6cbb\u7642\u65b9\u6cd5\u3002\u672c\u7814\u7a76\u63d0\u51fa\u5169\u4f8b\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u75c5\u60a3\u5206\u5225\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u6216\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u91dd\u5c0d\u904e\u53bb\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u7d50\u679c\u9032\u884c\u6587\u737b\u56de\u9867\u3002", "e": "Pheochromocytomas are rare tumors that occur in approximately 0.1% of patients with hypertension. About 10-15% of pheochromocytomas presents with metastasis. Patients with malignant pheochromocytoma have a poor prognosis with an average 5-year survival of about 40%. Primary surgical resection is the treatment of choice whenever possible. External beam radiation may also be the alternative treatment modality for some situations. We reported two cases of malignant pheochromocytomas who received radiotherapy as postoperative adjuvant treatment and palliation. Relevant literatures are also reviewed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-105-111-a", "title": "Brain Metastasis from Small Cell Cervical Carcinoma with Long-Term Survival - A Case Report", "keywords": "\u5b50\u5bae\u9838\u816b\u7624;\u5c0f\u7d30\u80de\u764c;\u8166\u90e8\u79fb\u8f49;\u653e\u5c04\u6cbb\u7642;\u52a0\u99ac\u5200\u653e\u5c04\u624b\u8853 Cervical neoplasm;Small cell carcinoma;Brain metastasis;Radiotherapy;Gamma knife radiosurgery", "c": "\u5b50\u5bae\u9838\u5c0f\u7d30\u80de\u764c\u4fc2\u5c6c\u5b50\u5bae\u9838\u4e4b\u7f55\u898b\u60e1\u6027\u816b\u7624\uff0c\u4f54\u6240\u6709\u5b50\u5bae\u9838\u60e1\u6027\u816b\u7624\u4e4b\u6bd4\u4f8b\u70ba0.5-5%\uff0c\u5176\u7d30\u80de\u6700\u4e3b\u8981\u4e4b\u8868\u73fe\u7279\u5fb5\u70ba\u9ad8\u5ea6\u4fb5\u72af\u6027\uff0c\u53ca\u6613\u9060\u7aef\u79fb\u8f49\uff0c\u6545\u5176\u6709\u8f03\u5dee\u4e4b\u9810\u5f8c\u53ca\u9ad8\u65bc\u4e00\u822c\u5b50\u5bae\u9838\u764c\u4e4b\u6bd4\u4f8b\u6703\u6709\u8166\u90e8\u79fb\u8f49\u7684\u53ef\u80fd\u6027\u3002\u6211\u5011\u5831\u544a\u4e00\u5b50\u5bae\u9838\u5c0f\u7d30\u80de\u764c\u7684\u75c5\u4f8b\uff08\u539f\u59cb\u671f\u5225FIGO stage: Ib\uff09\uff0c\u5728\u7d93\u904e\u4e00\u822c\u50b3\u7d71\u5b50\u5bae\u6839\u9664\u624b\u8853\u53ca\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u65bc\u4e09\u5e74\u5f8c\u5728\u8166\u90e8\uff08\u5de6\u9802-\u6795\u8449\u4ea4\u754c\u8655\uff09\u9996\u5ea6\u767c\u73fe\u55ae\u4e00\u79fb\u8f49\u6027\u75c5\u7076\uff0c\u4e26\u7121\u5c40\u90e8\u5fa9\u767c\u53ca\u4ed6\u8655\u8f49\u79fb\u3002\u75c5\u4eba\u9996\u5148\u63a5\u53d7\u958b\u9871\u624b\u8853\u6458\u9664\u8f49\u79fb\u75c5\u7076\uff0c\u518d\u4f9d\u6839\u6cbb\u6027\u6cbb\u7642\u5291\u91cf\u7d66\u4e88\u8853\u5f8c\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u764246 Gy\uff0c23\u6b21\u6cbb\u7642\uff0c\u4e26\u52a0\u5f37\u5c40\u90e8\u7167\u5c04\u81f3\u7e3d\u5291\u91cf\u70ba56 Gy\u3002\u5169\u5e74\u5f8c\uff0c\u8a3a\u65b7\u53e6\u6709\u5169\u500b\u4f4d\u65bc\u5de6\u5074\u8166\u5ba4\u6795\u89d2\u5340\u4e4b\u65b0\u75c5\u7076\uff0c\u7531\u65bc\u75c5\u7076\u9ad4\u7a4d\u8f03\u5c0f\uff08\u7e3d\u9ad4\u7a4d8 cm3\uff09\uff0c\u75c5\u4eba\u6539\u63a1\u7528\u52a0\u99ac\u5200\u4e4b\u653e\u5c04\u624b\u8853\u6cbb\u7642\u65b9\u5f0f\uff0c\u65bc\u5c40\u90e8\u7d66\u4e8816.5 Gy\uff08\u53d655%\u4e4b\u7b49\u6548\u5291\u91cf\u5340\u6db5\u84cb\uff09\u3002\u6cbb\u7642\u5f8c\u5c40\u90e8\u63a7\u5236\u826f\u597d\u3002\u75c5\u4eba\u5f9e\u6700\u521d\u8a3a\u65b7\u6cbb\u7642\u81f3\u4eca\uff0c\u5b58\u6d3b\u6b77\u7d93\u4e5d\u5e74\u6642\u9593\uff0c\u5c0d\u65bc\u9ad8\u5ea6\u4fb5\u72af\u6027\u53ca\u9810\u5f8c\u4e0d\u4f73\u4e4b\u5c0f\u7d30\u80de\u764c\uff0c\u5be6\u5c6c\u7f55\u898b\uff0c\u8b49\u660e\u55ae\u4e00\u8166\u90e8\u79fb\u8f49\u4e4b\u75c5\u4eba\uff0c\u5728\u539f\u767c\u75c5\u7076\u63a7\u5236\u7a69\u5b9a\uff0c\u4e14\u6c92\u6709\u5176\u4ed6\u90e8\u4f4d\u79fb\u8f49\u7684\u60c5\u6cc1\u4e0b\uff0c\u5373\u4f7f\u816b\u7624\u578b\u614b\u60e1\u6027\u5ea6\u9ad8\uff0c\u90fd\u61c9\u7d66\u4e88\u75c5\u4eba\u7a4d\u6975\u6027\u7684\u6cbb\u7642\uff0c\u5c0d\u65bc\u5176\u5c40\u90e8\u63a7\u5236\u53ca\u6574\u9ad4\u5b58\u6d3b\u671f\u4e0a\u53ef\u6709\u8f03\u660e\u986f\u4e4b\u6539\u5584\u3002", "e": "Small cell carcinoma of the uterine cervix is a rare type of malignant tumor. It is characterized by its aggressive behaviors and potentially high metastatic rate. Herein, we present a 49-year-old female who was a victim of small cell cervical carcinoma with FIGO stage Ib. She initially underwent a radical surgery for tumor removal. Six courses of adjuvant chemotherapy were given thereafter with etoposide and cisplatin. Three years later, a solitary brain metastasis in the left parieto-occipital area was noted in magnetic resonance imaging (MRI) study. Craniotomy with metastatic tumor removal was performed. Post-operative whole brain radiotherapy with 46 Gy/23 fractions and a boost of 10 Gy/ 5 fractions to tumor bed were delivered. However, two small recurrent lesions were found in the left occipital horn of the periventricular regions 25 months later. Due to small tumor volumes (total 8 cm3), the new lesion sites were treated by Gamma knife radiosurgery with 16.5 Gy. The follow-up brain MRI disclosed tumor regression but some necrotic change were also noted around the re-irradiated area. She was then put on steroid and symptomatic treatment. By now, she has been alive with no local recurrence or other systemic disease. We think aggressive treatment for solitary brain metastasis from small cell cervical carcinoma can achieve long-term survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-113-117-a", "title": "Non-AIDS Kaposi", "keywords": "\u5361\u6ce2\u897f\u6c0f\u8089\u7624;\u5f8c\u5929\u514d\u75ab\u4e0d\u5168\u75c7\u5019\u7fa4;\u653e\u5c04\u7dda\u6cbb\u7642 Classic kapos", "c": "\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u662f\u5f8c\u5929\u514d\u75ab\u4e0d\u5168\u75c7\u5019\u7fa4\uff08AIDS\uff0c\u611b\u6ecb\u75c5\uff09\u6700\u5e38\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u4f46\u662f\u4e26\u4e0d\u662f\u6240\u6709\u7684\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u90fd\u6709\u5f8c\u5929\u514d\u75ab\u4e0d\u5168\u75c7\u5019\u7fa4\u3002\u6211\u5011\u5831\u544a\u4e86\u4e00\u4f8b\u5361\u6ce2\u897f\u6c0f\u8089\u7624\uff0c\u4f46\u662f\u611b\u6ecb\u75c5\u75c5\u6bd2\u611f\u67d3\u9670\u6027\u7684\u75c5\u60a3\u3002\u56e0\u70ba\u75c5\u60a3\u4e4b\u524d\u540c\u4e00\u4f4d\u7f6e\u7d93\u904e\u4e86\u5169\u6b21\u5207\u9664\u4ecd\u7136\u5fa9\u767c\u3002\u7d93\u904e\u8a0e\u8ad6\u4e4b\u5f8c\uff0c\u5728\u7b2c\u4e09\u6b21\u624b\u8853\u5207\u9664\u4e4b\u5f8c\uff0c\u8ffd\u52a0\u653e\u5c04\u7dda\u6cbb\u7642\u4ee5\u589e\u52a0\u5c40\u90e8\u63a7\u5236\u3002\u6211\u5011\u4f7f\u7528\u4e865040 cGy\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5169\u5e74\u7684\u8ffd\u8e64\u4e26\u6c92\u6709\u816b\u7624\u7684\u5fa9\u767c\u3002\u6839\u64da\u6211\u5011\u7684\u7d93\u9a57\u53ca\u6587\u737b\u56de\u9867\uff0c\u5c40\u90e8\u7684\u5361\u6ce2\u897f\u6c0f\u8089\u7624\u5c0d\u653e\u5c04\u7dda\u7167\u5c04\u662f\u76f8\u7576\u654f\u611f\u4e14\u6709\u6548\u7684\u3002", "e": "Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). However, not every patient with KS has AIDS. The classic form of KS is a rare disease. We present a 50-year-old Taiwanese with KS who was seronegative for human immunodeficiency virus (HIV). Because the tumor recurred twice after surgery, we used radiotherapy as the adjuvant therapy after the third surgical procedure yielded a specimen with unclear margins. The patient received a total of 5040 cGy in 28 fractions with a special designed water bolus. There was no evidence of recurrence 24 months later. According to the literature and our experience, radiotherapy is useful for localized KS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-119-126-a", "title": "Postirradiation Malignant Fibrous Histiocytoma of the Breast: A Case Report and Review of the Literature", "keywords": "\u4e73\u764c;\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642\u8853\u5f8c\u5f15\u767c\u8089\u7624;\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624 Breast cancer;Radiotherapy;Postirradiation sarcoma;Malignant fibrous histiocytoma", "c": "\u653e\u5c04\u6cbb\u7642\u8853\u5f8c\u5f15\u767c\u4e4b\u8089\u7624\u70ba\u4e00\u7f55\u898b\u4f46\u5df2\u5ee3\u70ba\u78ba\u5b9a\u4e4b\u764c\u75c7\u6cbb\u7642\u665a\u671f\u6548\u61c9\u3002\u4e00\u4f4d37\u6b72\u5a66\u5973\u65bc7.8\u5e74\u524d\u56e0\u4e73\u764c\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u65bc\u53f3\u5074\u814b\u4e0b\u767c\u751f\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u3002\u7531\u5176\u816b\u7624\u4f4d\u7f6e\u3001\u7d44\u7e54\u75c5\u7406\u53ca\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u8868\u73fe\u3001\u6700\u521d\u6cbb\u7642\u7d50\u675f\u81f3\u767c\u75c5\u6642\u9593\u9593\u9694\u7b49\u7279\u6027\u5206\u6790\uff0c\u6b64\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u53ef\u80fd\u8207\u5148\u524d\u4e4b\u653e\u5c04\u6cbb\u7642\u6709\u5bc6\u5207\u95dc\u4fc2\u3002\u7531\u65bc\u653e\u5c04\u6cbb\u7642\u8853\u5f8c\u5f15\u767c\u8089\u7624\u4e4b\u6a5f\u7387\u751a\u4f4e\uff0c\u56e0\u6b64\u4e0d\u61c9\u5217\u5165\u4e73\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u8207\u5426\u4e4b\u4e3b\u8981\u53c3\u8003\u56e0\u7d20\u3002\u5c0d\u65bc\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u4e4b\u5f8c\u7e8c\u8655\u7406\uff0c\u5ee3\u6cdb\u6027\u4e4b\u624b\u8853\u5207\u9664\u662f\u76ee\u524d\u76f8\u7576\u6709\u6548\u4e4b\u65b9\u6cd5\u3002", "e": "Postirradiation sarcomas are an unusual but well-recognized late effect of cancer therapy. A 37-year-old female patient presented with malignant fibrous histiocytoma (MFH) of the right axilla, occurring 7.8 years after radiation treatment for infiltrating duct carcinoma of right breast. The location, the histopathologic and immunohistochemical appearance of the tumor, and the time elapsed since the initial treatment make it probable that this tumor is associated with prior radiation treatment. The possibility of postirradiation sarcoma after radiation therapy should not be a major factor influencing treatment decision in the patient with breast cancer. Wide surgical resection of the tumor seems to be an efficient means in the management of this tumor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200406-11-2-127-132-a", "title": "Primary Breast Lymphoma Treated with Chemotherapy and Local Radiotherapy: Case Report and Review of Literature", "keywords": "\u539f\u767c\u6027\u4e73\u623f\u6dcb\u5df4\u7624;\u5316\u5b78\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642 Primary breast lymphoma;Chemotherapy;Radiotherapy", "c": "\u539f\u767c\u6027\u4e73\u623f\u6dcb\u5df4\u7624\u662f\u4e00\u7f55\u898b\u7684\u75be\u75c5\uff0c\u5728\u6240\u6709\u5973\u6027\u7684\u4e73\u623f\u60e1\u6027\u816b\u7624\u4e2d\u53ea\u5360\u4e860.12%\u81f30.30%\u3002\u75c5\u4f8b\u5831\u544a\u5e38\u5e38\u662f\u96f6\u661f\u51fa\u73fe\u3002\u56e0\u70ba\u7f3a\u4e4f\u75c5\u4eba\u8cc7\u6599\uff0c\u76ee\u524d\u70ba\u6b62\u5c0d\u65bc\u539f\u767c\u6027\u4e73\u623f\u6dcb\u5df4\u7624\u5c1a\u672a\u7d50\u8ad6\u51fa\u6a19\u6e96\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u672c\u6587\u5831\u544a\u4e86\u4e8c\u4f4d\u539f\u767c\u6027\u4e73\u623f\u6dcb\u5df4\u7624\u7684\u75c5\u60a3\uff0c\u6cbb\u7642\u65b9\u5f0f\u662f\u4ee5\u5316\u5b78\u6cbb\u7642\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u3002\u5728\u6cbb\u7642\u5b8c\u6210\u5f8c\uff0c\u6dcb\u5df4\u7624\u5b8c\u5168\u6d88\u5931\u4e26\u4e14\u6c92\u6709\u6b98\u5b58\u816b\u7624\u3002\u5728\u8ffd\u8e64\u904e\u7a0b\u4e2d\u4e5f\u6c92\u6709\u816b\u7624\u518d\u767c\u7684\u60c5\u5f62\u3002\u9019\u7bc7\u6587\u7ae0\u540c\u6642\u4e5f\u56de\u9867\u4e86\u6587\u737b\u4e0a\u6709\u95dc\u539f\u767c\u6027\u4e73\u623f\u6dcb\u5df4\u7624\u7684\u5831\u544a\uff0c\u4e26\u5c0d\u6cbb\u7642\u7d50\u679c\u8207\u9810\u5f8c\u4f5c\u4e00\u8a0e\u8ad6\u3002", "e": "Primary breast lymphoma is a rare disease. It represents only 0.12% to 0.30% of all female breast malignancies. Few cases were sporadically reported. Due to the paucity of patient data, there is no standard treatment protocol for primary breast lymphoma. We reported two cases of primary breast lymphoma treated with chemotherapy followed by radiotherapy. Tumor regression with no residual disease was achieved after treatments. No relapse was developed in the follow-up period. We also reviewed the literatures on primary breast lymphoma to evaluate treatment outcome and prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-1-7-a", "title": "\u9f3b\u54bd\u764c\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u5f71\u97ff\u8033\u4e0b\u817a\u529f\u80fd\u7684\u56e0\u5b50", "keywords": "\u9f3b\u54bd\u764c;\u53e3\u4e7e\u75c7;\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642;\u553e\u6db2\u817a\u9583\u720d\u651d\u5f71 nasopharyngeal carcinoma;xerostomia;intensity modulated radiotherapy;sialoscintigraphy", "c": "\u76ee\u7684\uff1a\u5831\u544a\u9f3b\u54bd\u764c\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\uff08IMRT\uff09\u7684\u7d93\u9a57\u4ee5\u53ca\u5229\u7528\u553e\u6db2\u817a\u9583\u720d\u651d\u5f71\u6aa2\u67e5\u4f86\u8a55\u4f30\u5f71\u97ff\u7167\u5c04\u5f8c\u8033\u4e0b\u817a\u529f\u80fd\u7684\u56e0\u5b50\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5305\u62ec\u4e86\u516c\u51432000\u5e748\u6708\u81f32001\u5e745\u6708\uff0c\u517119\u540d\u4e3b\u8981\u4ee5\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7642\u6cd5\u6cbb\u7642\u7684\u9f3b\u54bd\u764c\u75c5\u60a3\u3002\u5176\u4e2d12\u540d\u671f\u5225\u662f\u5c6c\u65bc\u7b2c\u4e00\u81f3\u7b2c\u4e8c\u671f\uff0c\u53e6\u59167\u540d\u5247\u662f\u5c6c\u65bc\u7b2c\u4e09\u81f3\u7b2c\u56db\u671f\u7684\u60a3\u8005\uff081997 AJCC\uff09\u3002\u5728\u6cbb\u7642\u8a08\u756b\u8a2d\u5b9a\u5291\u91cf\u65b9\u9762\uff0c\u53ef\u8996\u816b\u7624\u9ad4\u7a4d\u7684\u5916\u52a0\u8a08\u756b\u9ad4\u7a4d\uff08GTV-PTV\uff09\u3001\u53ef\u8996\u816b\u5927\u8f49\u79fb\u6dcb\u5df4\u817a\u3001\u8207\u81e8\u5e8a\u6a19\u9776\u9ad4\u7a4d\u7684\u5916\u52a0\u8a08\u756b\u9ad4\u7a4d\uff08CTV-PTV\uff09\u5404\u70ba70\u300165-70\u3001\u820755-60 Gy\uff1b\u5176\u5206\u6b21\u5291\u91cf\u5247\u5404\u70ba2.12\u30012.0-2.12\u3001\u53ca1.7-1.8 Gy\u3002\u67096\u4f4d\u75c5\u60a3\u5728\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u63a5\u53d7\u4e869.0\u81f318.0 Gy\u7684\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3002\u9664\u4e86\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u670918\u4f4d\u75c5\u60a3\u63a5\u53d7\u4e86\u9f3b\u54bd\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\uff0c\u5291\u91cf\u70ba7.0 Gy\u5206\u5169\u6b21\u6cbb\u7642\u3002\u6240\u6709\u7b2c\u4e8c\u81f3\u56db\u671f\u7684\u60a3\u8005\u7576\u4e2d\u9664\u4e00\u4f4d\u5916\u5747\u63a5\u53d7\u4e86\u5169\u6b21\u85e5\u7269cisplatin\u82075-FU\u7684\u540c\u6b65\u5316\u5b78\u6cbb\u7642\uff0c\u653e\u7642\u5f8c\u5247\u63a5\u53d7\u4e86\u5169\u5230\u56db\u6b21\u5316\u5b78\u6cbb\u7642\u3002\u5e73\u5747\u8ffd\u8e64\u671f\u70ba13\u500b\u6708\uff088 \u81f318\u500b\u6708\uff09\u3002\u60a3\u8005\u5728\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u53ca\u6cbb\u7642\u4e4b\u5f8c\u4e00\u3001\u4e09\u3001\u8207\u516d\u500b\u6708\u4ee5\u553e\u6db2\u817a\u9583\u720d\u651d\u5f71\u6aa2\u67e5\u4f86\u8a55\u4f30\u8033\u4e0b\u817a\u529f\u80fd\u7684\u5f71\u97ff\uff0c\u8a55\u4f30\u5f71\u97ff\u6cbb\u7642\u5f8c\u553e\u6db2\u5206\u6ccc\u6bd4\u7387\u56e0\u5b50\u7684\u65b9\u6cd5\u70baMann-Whitney rank-sum test\u3002 \u7d50\u679c\uff1a\u5e73\u5747GTV-PTV\u8207CTV-PTV\u7684\u5291\u91cf\u5404\u70ba70.9\u53ca63.2 Gy\uff1b\u5e73\u5747\u53f3\u5074\u8207\u5de6\u5074\u8033\u4e0b\u817a\u5291\u91cf\u5404\u70ba38.1\u53ca38.6 Gy\u3002\u5728\u516b\u5230\u5341\u516b\u500b\u6708\u8ffd\u8e64\u671f\u9593\u6240\u670919\u4f4d\u75c5\u60a3\u539f\u767c\u90e8\u4f4d\u8207\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u7624\u5747\u5b8c\u5168\u6d88\u5931\u3002\u6cbb\u7642\u7576\u4e2d\u767c\u751f\u6025\u6027\u9830\u9ecf\u819c\u767c\u708e\u53cd\u61c9\u5c6c RTOG\u7b2c\u4e09\u7b49\u8005\u670915\u4f4d\uff0879%\uff09\uff0c\u81e8\u5e8a\u5206\u985e\u7b2c\u4e00\u7d1a\u81f3\u7b2c\u4e09\u7d1a\u53e3\u4e7e\u75c7\u5404\u67099\u30019\u53ca1\u4f4d\u3002\u6cbb\u7642\u524d\u5f8c\u7684\u553e\u6db2\u5206\u6ccc\u6bd4\u7387\u9054\u5230\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u5dee\u5225\uff08p = 0.002\uff09\uff0c\u4e0d\u5229\u4fdd\u7559\u8033\u4e0b\u817a\u529f\u80fd\u7684\u56e0\u5b50\u6709N\uff08+\uff09\u671f\u5225\uff08p = 0.03\uff09\u3001\u8033\u4e0b\u817a\u4e2d\u503c\u5291\u91cf\u5927\u65bc35 Gy\uff08p = 0.038\uff09\u3001\u8033\u4e0b\u817a\u767e\u5206\u4e4b\u4e94\u5341\u9ad4\u7a4d\u5291\u91cf\u5927\u65bc35 Gy\uff08p = 0.032\uff09\u4ee5\u53ca\u5403\u6ab3\u6994\u6642\u9593\u8d85\u904e\u4e94\u5e74\u8005\uff08p = 0.029\uff09\u3002 \u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\u5c0d\u65bc\u9f3b\u54bd\u764c\u800c\u8a00\u540c\u6b65\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u8207\u5316\u5b78\u6cbb\u7642\u662f\u4e00\u5b89\u5168\u4e14\u6709\u6548\u7684\u6cbb\u7642\u65b9\u6cd5\u3002\u9838\u90e8\u6dcb\u5df4\u817a\u8f49\u79fb\u3001\u8033\u4e0b\u817a\u4e2d\u503c\u5291\u91cf\u3001\u8033\u4e0b\u817a\u767e\u5206\u4e4b\u4e94\u5341\u9ad4\u7a4d\u5291\u91cf\u4ee5\u53ca\u5403\u6ab3\u6994\u7fd2\u6163\u7b49\u56e0\u5b50\u6703\u5f71\u97ff\u6cbb\u7642\u5f8c\u7684\u8033\u4e0b\u817a\u529f\u80fd\u3002", "e": "Purpose : To report the experience with intensity-modulated radiotherapy (IMRT) in the treatment of nasopharyngeal carcinoma and to determine the factors influencing post-irradiation parotid gland function measured by sialoscintigraphy.  Methods and Materials : This study included 19 patients with NPC treated mainly with IMRT between August 2000 and May 2001. Twelve of these patients had Stage I-II disease and seven had Stage III-IV disease (1997 AJCC). The planning target volume of gross target volume (GTV-PTV), visible lymph node and planning target volume of clinical target volume (CTV-PTV) were designed to receive 70, 65-70 and 55-60 Gy with daily fraction of 2.12, 2.0-2.12 and 1.7-1.8 Gy, respectively. Six patients received 9-18 Gy 3D conformal radiotherapy prior to IMRT. Except from external beam, there were eighteen patients received intracavitary brachytherapy with the dose of 7.0 Gy in two fractions. All Stage II to IV cases except one received two courses of concurrent chemo-radiotherapy with cisplatin and 5-FU during radiotherapy and two to four cycles thereafter. The mean follow-up time was 13.0 months (range: 8-18 months). Objective parotid gland function was assessed by sialoscintigraphy pre-irradiation and at one, three and six months post-irradiation. Mann-Whitney rank-sum test was used to determine the factors associated with the changes in post-irradiated secretion ratio (SR).  Results :The mean dose administered to the GTV-PTV and CTV-PTV were 70.9 and 63.2 Gy, respectively. The mean dose administered to the right and left parotid glands was 38.1 and 38.6 Gy, respectively. All of the 19 patients had complete response of primary and lymph node disease at follow-up ranging from 8 to 18 months after radiotherapy (mean, 13 months). Acute side-effects which developed during this concurrent chemo-radiotherapy were RTOG Grade III mucositis in 15 (79%) patients. Clinical xerostomia of Grade I was noted in 9 patients, Grade II in 9, and Grade III in one. There was a significant difference between the pre- and post-irradiation parotid gland SR (p= 0.002). Poor prognostic factors for the preservation of parotid gland function were N (+) Stage (p= 0.03), median dose of parotid gland greater than 35 Gy (p = 0.038), 50% volume of parotid gland greater than 35 Gy (p = 0.032) and the habit of betel quid chewing for longer than 5 years (p = 0.029).  Conclusions :This study demonstrated that the combination of IMRT and chemotherapy is an effective and safe method for the treatment of nasopharyngeal cancer. The N stage, median dose of parotid gland, 50% volume dose to the parotid glands and the habit of betel quid chewing were correlated with post-irradiated parotid gland function."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-9-15-a", "title": "Concurrent Weekly Cisplatin and Radiotherapy Plus Adjuvant Chemotherapy for Nasopharyngeal Cancer \u2013A Preliminary Study", "keywords": "\u9f3b\u54bd\u764c;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u8f14\u52a9\u6027\u5316\u7642 nasopharyngeal carcinoma;concurrent chemoradiotherapy;adjuvant chemotherapy", "c": "\u76ee\u7684\uff1a\u5df2\u6709\u7814\u7a76\u986f\u793a\u5728\u5c40\u90e8\u665a\u671f\u7684\u9f3b\u54bd\u764c\u75c5\u60a3\u4e2d\uff0c\u63a5\u53d7\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u8005\u6bd4\u55ae\u7d14\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u8005\u6709\u8f03\u597d\u7684\u5b58\u6d3b\u7387\u3002\u70ba\u4e86\u5f37\u5316\u653e\u5c04\u7dda\u7684\u6548\u679c\uff0c\u540c\u6642\u6e1b\u5c11\u5316\u5b78\u6cbb\u7642\u5f15\u8d77\u7684\u6bd2\u6027\uff0c\u6211\u5011\u4f7f\u7528\u4f4e\u5291\u91cf\u7684cisplatin\u4f5c\u70ba\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u85e5\u7269\u4e26\u8a55\u4f30\u5176\u529f\u6548\u8207\u6bd2\u6027\u3002 \u65b9\u6cd5\uff1a\u5171\u670914\u500b\u7b26\u5408\u689d\u4ef6\u7684\u75c5\u60a3\u63a5\u53d7\u539f\u767c\u90e8\u4f4d70~72 Gy\u7684\u9060\u9694\u53ca3.5 Gy\u7684\u8154\u5167\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u540c\u6642\u6bcf\u9031\u7d66\u4e88\u4e00\u6b21\u4f4e\u5291\u91cf\u7684cisplatin\uff0830 mg/m2\uff09\uff0c\u51717\u52308\u9031\uff1b\u5728\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5f8c\u7d66\u4e884\u6b21\u7684\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u6bcf\u6b21\u6bcf\u500b\u6708\u6ce8\u5c04CDDP 20 mg/m2/day\u548c5-FU 1000 mg/m2/24hs\u9023\u7e8c\u6ce8\u5c045\u5929\uff0c\u4e26\u5206\u6790\u816b\u7624\u53cd\u61c9\u8207\u6bd2\u6027\u3002 \u7d50\u679c\uff1a11\u4f4d\u75c5\u60a3\u57288~10\u9031\u4e4b\u9593\uff0c3\u4f4d\u5ef6\u5f8c\u81f311\u9031\u5b8c\u6210\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4e00\u534a\u7684\u75c5\u60a3\u63a5\u53d7\u5b8c\u65744\u9031\u671f\u7684\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u300210\u500b\u75c5\u60a3\uff0871.4%\uff09\u5728\u5b8c\u6210\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5f8c\u6709\u5b8c\u5168\u53cd\u61c9\uff0c\u53e6\u5916\u4e09\u500b\u5728\u63a5\u53d7\u5b8c\u6574\u500b\u6cbb\u7642\u8a08\u5283\uff0c\u5305\u542b\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u8207\u8f14\u52a9\u6027\u5316\u7642\u5f8c\u9054\u5230\u5b8c\u5168\u53cd\u61c9\u3002\u5728\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u671f\u9593\uff0c3\u500b\u75c5\u4eba\uff0821.4%\uff09\u67093\u62164\u7d1a\u7684\u53e3\u54bd\u9ecf\u819c\u708e\uff0c8\u500b\u75c5\u4eba\uff0857.1%\uff09\u67093 \u62164\u7d1a\u7684\u653e\u5c04\u6027\u76ae\u819a\u708e\uff1b\u5728\u9019\u500b\u6cbb\u7642\u4e2d\uff0c\u6c92\u6709\u767c\u751f\u56b4\u91cd\u7684\u814e\u81df\u6216\u81f4\u547d\u7684\u6bd2\u6027\u3002\u572819.5\u500b\u6708\u7684\u4e2d\u4f4d\u6578\u8ffd\u8e64\u671f\u4e2d\uff0c1\u500b\u75c5\u60a3\u4ecd\u6709\u6b98\u9918\u816b\u7624\uff0c1\u500b\u5fa9\u767c\uff0c2\u500b\u6709\u5168\u8eab\u6027\u8f49\u79fb\u3002 \u7d50\u8ad6\uff1a\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u914d\u5408\u8f14\u52a9\u6027\u5316\u7642\u7684\u6cbb\u7642\u8a08\u5283\u5c0d\u65bc\u9f3b\u54bd\u764c\u75c5\u60a3\u6709\u52a9\u76ca\uff0c\u4e14\u5176\u6025\u6027\u6bd2\u6027\u662f\u53ef\u63a5\u53d7\u800c\u4e14\u662f\u53ef\u56de\u5fa9\u7684\uff0c\u9019\u7a2e\u6cbb\u7642\u8a08\u5283\u7684\u521d\u6b65\u7d50\u679c\u503c\u5f97\u9032\u4e00\u6b65\u7528\u96a8\u6a5f\u5206\u6d3e\u7684\u81e8\u5e8a\u8a08\u5283\u8b49\u5be6\u4e4b\u3002", "e": "Purpose : It has been shown that concurrent chemoradiotherapy (CCRT) confers significantly better survival in locally advanced nasopharyngeal carcinoma (NPC) compared with radiotherapy. We conducted a prospective pilot study to evaluate the efficacy and toxicity of a CCRT regimen using low-dose cisplatin (CDDP) for treatment of NPC to see if it enhanced radiation response and reduced chemotherapy-induced toxicity. Materials and Methods : A total of 14 patients were enrolled. The CCRT regimen consisted of radiotherapy (RT), 70~72 Gy to the primary tumor with concurrent CDDP 30 mg/m2 administered once a week for 7 to 8 weekly doses. After CCRT, 4 cycles of adjuvant CDDP, 20 mg/m2/day, and 5-FU, 1000 mg/m2 infused over 24 hours for 5 consecutive days were given monthly. Tumor response and toxicity were analyzed. Results : Eleven patients completed CCRT in 8 to 10 weeks, 3 patients delayed up to eleven weeks, and half (50%) received 4 complete courses of adjuvant chemotherapy. Ten (71.4%) patients had a complete response (CR) after CCRT, with an additional 3 achieving a CR after adjuvant chemotherapy, for a total of 13 (92.9%) out of 14. Adverse effects of CCRT included grade 3 or 4 oropharyngeal mucositis in 3 (21.4%) and grade 3 or 4 radiation dermatitis in 8 (57.1%). There was no severe renal or fatal toxicity from the treatment. At a median follow-up of 19.5 months, 1 patient still had residual tumor, 1 had recurrence and 2 had systemic metastases. Conclusion : CCRT followed by adjuvant chemotherapy was effective in a small series of NPC patients, with acceptable and reversible acute toxicity. This protocol deserves further investigation in randomized prospective trials."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-17-25-a", "title": "\u4e73\u623f\u4e73\u7ba1\u539f\u4f4d\u764c\u60a3\u8005\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff1a\u9810\u5f8c\u56e0\u5b50\u5206\u6790", "keywords": "\u4e73\u7ba1\u539f\u4f4d\u764c;\u4e73\u764c;\u4e73\u623f\u4fdd\u7559\u624b\u8853;\u653e\u5c04\u7dda\u6cbb\u7642 ductal carcinoma in situ;breast cancer;partial mastectomy;radiation therapy", "c": "\u76ee\u7684\uff1a\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u4e73\u623f\u4e73\u7ba1\u539f\u4f4d\u764c\u7684\u60a3\u8005\u4f86\u8aaa\u662f\u4e00\u500b\u6a19\u6e96\u7684\u6cbb\u7642\u65b9\u6cd5\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u5206\u6790\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5c0d\u65bc\u4e73\u623f\u4e73\u7ba1\u539f\u4f4d\u764c\u60a3\u8005\u7684\u6cbb\u7642\u7d50\u679c\uff0c\u4ee5\u53ca\u63a2\u8a0e\u5f71\u97ff\u9810\u5f8c\u7684\u56e0\u5b50\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1992\u5e7412\u6708\u81f32003\u5e747\u6708\uff0c\u5171\u670929\u4f4d\u5973\u6027\u5728\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u88ab\u8a3a\u65b7\u70ba\u4e73\u623f\u7684\u4e73\u7ba1\u539f\u4f4d\u764c\uff0c\u4e26\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u75c5\u4eba\u7684\u5e74\u9f61\u4e2d\u4f4d\u6578\u662f46\u6b72\u3002\u4e73\u623f\u816b\u7624\u662f\u7d93\u7531\u7406\u5b78\u6aa2\u67e5\uff0817%\uff09\u3001\u4e73\u623f\u8d85\u97f3\u6ce2\uff0828%\uff09\uff0c\u4ee5\u53ca\u4e73\u623f\u651d\u5f71\uff0855%\uff09\u6240\u5075\u6e2c\u5230\u3002\u816b\u7624\u7684\u5927\u5c0f\u4e2d\u4f4d\u6578\u662f2.0\u516c\u5206\u3002\u816b\u7624\u5927\u90e8\u5206\u4f4d\u65bc\u5de6\u5074\u4e73\u623f\uff0866%\uff09\uff0c\u4e14\u4ee5\u5916\u4e0a\u56db\u5206\u4e4b\u4e00\u7684\u4f4d\u7f6e\u5c45\u591a\uff0859%\uff09\u3002\u67098\u4f4d\u75c5\u4eba\uff0828%\uff09\u63a5\u53d7\u4e86\u814b\u4e0b\u54e8\u5175\u6dcb\u5df4\u7d50\u7684\u5207\u7247\u6aa2\u67e5\u3002\u5728\u624b\u8853\u5207\u9664\u908a\u7de3\u60c5\u6cc1\u65b9\u9762\uff0c14\u4f4d\u75c5\u4eba\uff0848%\uff09\u7684\u908a\u7de3\u6c92\u6709\u816b\u7624\u7d30\u80de\uff0c6\u4f4d\u75c5\u4eba\uff0821%\uff09\u5247\u5728\u5207\u9664\u908a\u7de3\u767c\u73fe\u6709\u6b98\u7559\u7684\u816b\u7624\u7d30\u80de\u3002\u5728\u75c5\u7406\u5831\u544a\u7684\u6b21\u9805\u5206\u985e\u65b9\u9762\uff0c13\u4f4d\u75c5\u4eba\uff0845%\uff09\u662f comedo type\uff0c4\u4f4d\u75c5\u4eba\uff0814%\uff09\u662fpapillary type\uff0c3\u4f4d\u75c5\u4eba\uff0810%\uff09\u662fcribriform type\uff0c2\u4f4d\u75c5\u4eba\uff087%\uff09\u662fsolid type\uff0c7\u4f4d\u75c5\u4eba\uff0824%\uff09\u5247\u662f\u6c92\u6709\u63d0\u5230\u6b21\u9805\u5206\u985e\u300210\u4f4d\u75c5\u4eba\uff0835%\uff09\u662f\u5c6c\u65bc\u9ad8\u5ea6\u60e1\u6027\uff08high-grade\uff09\u7684\u4e73\u7ba1\u539f\u4f4d\u764c\u300216\u4f4d\u75c5\u4eba\uff0855%\uff09\u5728\u75c5\u7406\u5831\u544a\u767c\u73fe\u6709\u816b\u7624\u58de\u6b7b\uff08tumor necrosis\uff09\u60c5\u5f62\u3002\u60a3\u5074\u4e73\u623f\u7684\u653e\u5c04\u7dda\u5291\u91cf\u4e2d\u4f4d\u6578\u662f46 Gy\u3002\u816b\u7624\u90e8\u4f4d\u7684\u52a0\u5f37\uff08boost\uff09\u653e\u5c04\u7dda\u5291\u91cf\u4e2d\u4f4d\u6578\u662f16 Gy\u3002\u5728\u5b8c\u6210\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7642\u7a0b\u4e4b\u5f8c\uff0c\u670913\u4f4d\u75c5\u4eba\uff0845%\uff09\u63a5\u53d7\u8377\u723e\u8499\u6cbb\u7642\uff08tamoxifen\uff0c\u6bcf\u592920 mg\uff09\u3002\u5728\u7d71\u8a08\u65b9\u9762\uff0c\u5b58\u6d3b\u7387\u5206\u6790\u4f7f\u7528Kaplan-Meier\uff0c\u55ae\u8b8a\u9805\u5206\u6790\u4f7f\u7528log rank test\u3002 \u7d50\u679c\uff1a\u901929\u4f4d\u75c5\u4eba\u7684\u8ffd\u8e64\u671f\u9593\u5f9e3\u500b\u6708\u81f3127\u500b\u6708\u4e0d\u7b49\uff0c\u4e2d\u4f4d\u6578\u662f25\u500b\u6708\u3002\u5168\u90e829\u4f4d\u75c5\u4eba\u5728\u6700\u8fd1\u4e00\u6b21\u7684\u8ffd\u8e64\u90fd\u4ecd\u7136\u5b58\u6d3b\u8457\u3002\u572828\u4f4d\u6c92\u6709\u4efb\u4f55\u816b\u7624\u5fa9\u767c\u6216\u662f\u9060\u7aef\u8f49\u79fb\u7684\u75c5\u4eba\u4e2d\uff0c11\u4f4d\u75c5\u4eba\u5b58\u6d3b\u4e8630\u500b\u6708\u4ee5\u4e0a\u3002\u5176\u4e2d\u6709\u4e00\u4f4d\u75c5\u4eba\u5b58\u6d3b\u9577\u905410\u5e74\u4e26\u4e14\u6301\u7e8c\u5b9a\u671f\u8ffd\u8e64\u7576\u4e2d\u3002\u5728\u5168\u90e829\u4f4d\u75c5\u4eba\u7576\u4e2d\uff0c\u53ea\u6709\u4e00\u4f4d\uff083%\uff09\u5728\u8ffd\u8e64\u4e864.5\u5e74\u4e4b\u5f8c\u767c\u73fe\u6709\u816b\u7624\u5fa9\u767c\u3002\u5728\u5b58\u6d3b\u7387\u65b9\u9762\uff0c\u4e09\u5e74\u8207\u4e94\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\uff08overall survival\uff09\u7686\u70ba100%\u3002\u4e09\u5e74\u8207\u4e94\u5e74\u7684\u7121\u75c5\u5b58\u6d3b\u7387\uff08disease-free survival\uff09\u5206\u5225\u662f 100%\u820780%\u3002\u4e09\u5e74\u8207\u4e94\u5e74\u7684\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\uff08disease-specific survival\uff09\u7686\u70ba100%\u3002\u5728\u7f8e\u89c0\u6eff\u610f\u5ea6\u65b9\u9762\uff0c25\u4f4d\u75c5\u4eba\uff0886%\uff09\u6709\u512a\u79c0\uff08excellent\uff09\u7684\u7f8e\u89c0\u6eff\u610f\u5ea6\uff0c\u5176\u99184\u4f4d\u75c5\u4eba\uff0814%\uff09\u5247\u70ba\u826f\u597d\uff08good\uff09\u7684\u7f8e\u89c0\u6eff\u610f\u5ea6\u3002\u4ee5log rank test\u5c0d\u6240\u6709\u8b8a\u6578\u4f5c\u55ae\u8b8a\u9805\u5206\u6790\u4e4b\u5f8c\uff0c\u767c\u73fe\u816b\u7624\u662f\u5426\u58de\u6b7b\uff08tumor necrosis\uff0cp = 0.0455\uff09\uff0c\u816b\u7624\u60e1\u6027\u7a0b\u5ea6\uff08tumor grade\uff0cp = 0.0455\uff09\uff0c\u624b\u8853\u5207\u9664\u908a\u7de3\u662f\u5426\u4e7e\u6de8\uff08resection margin\uff0cp = 0.0455\uff09\uff0c\u5c0d\u65bc\u7121\u75c5\u5b58\u6d3b\u7387\u4f86\u8aaa\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002 \u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba100%\uff0c\u5fa9\u767c\u7387\u70ba3%\u3002\u9810\u5f8c\u8b8a\u6578\u7576\u4e2d\uff0c\u816b\u7624\u662f\u5426\u58de\u6b7b\uff0c\u816b\u7624\u60e1\u6027\u5ea6\uff0c\u624b\u8853\u5207\u9664\u908a\u7de3\u662f\u5426\u4e7e\u6de8\uff0c\u5c0d\u65bc\u7121\u75c5\u5b58\u6d3b\u7387\u4f86\u8aaa\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6b64\u4e09\u9805\u56e0\u5b50\u7684\u6709\u7121\u5c31\u500b\u5225\u6bd4\u8f03\u4e0a\u5c0d\u75c5\u4eba\u7684\u7121\u75c5\u5b58\u6d3b\u7387\u5728\u7d71\u8a08\u4e0a\u6709\u5dee\u7570\uff0c\u81f3\u65bc\u662f\u5426\u70ba\u7368\u7acb\uff08independent\uff09\u9810\u5f8c\u56e0\u5b50\u5247\u9700\u66f4\u591a\u8cc7\u6599\u8207\u6578\u64da\u4f5c\u591a\u8b8a\u6578\u5206\u6790\u624d\u80fd\u5f97\u77e5\u3002\u9019\u4e9b\u5206\u6790\u7d50\u679c\u53ef\u4ee5\u5728\u5c0d\u65bc\u6709\u9ad8\u5371\u96aa\u56e0\u5b50\u7684\u4e73\u7ba1\u539f\u4f4d\u764c\u662f\u5426\u61c9\u8a72\u63a5\u53d7\u66f4\u7a4d\u6975\u7684\u6cbb\u7642\u6642\uff0c\u63d0\u4f9b\u66f4\u591a\u7684\u53c3\u8003\u8cc7\u8a0a\u3002\u672a\u4f86\u61c9\u8a72\u8981\u6709\u66f4\u5927\u578b\u7684\u7814\u7a76\u8207\u66f4\u9577\u7684\u8ffd\u8e64\u6642\u9593\uff0c\u91dd\u5c0d\u4ee5\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u4e73\u7ba1\u539f\u4f4d\u764c\u75c5\u60a3\u4f5c\u66f4\u9032\u4e00\u6b65\u7684\u5206\u6790\u3002", "e": "Purpose : Partial mastectomy and radiation therapy is a treatment option for patients with ductal carcinoma in situ (DCIS) of breast. The aim of our study is to evaluate the outcome and analyze prognostic factors in patients with DCIS of breast treated with partial mastectomy and radiation therapy. Materials and Methods : From December 1992 through July 2003, there were 29 women diagnosed with DCIS of breast receiving the treatment of partial mastectomy and radiation therapy at our institution. The median age of diagnosis was 46 years. The median tumor size was 2.0 cm. The tumor was predominantly at left-side breast (66%), and the outer upper quadrant was the main location (59%). Sentinel axillary lymph node biopsy was performed in 8 patients (28%). The resection margin was free in 14 patients (48%), and positive in 6 patients (21%). The subtypes of pathological report were comedo type in 13 patients (45%), papillary type in 4 patients (14%), cribriform type in 3 patients (10%), solid type in 2 patients (7%), and not specified in 7 patients (24%). Ten patients had high-grade DCIS (35%). Necrosis of tumor was found in 16 patients (55%). The median radiation dose to the breast was 46Gy. The median dose of tumor bed boost was 16Gy. After completion of radiation therapy, hormone therapy with tamoxifen 10mg twice daily was administered to 13 patients (45%). Results : All 29 patients were alive until the latest follow-up. The median duration of follow-up was 25 months (range: 3 to 127 months). Among 28 patients without any regional recurrence or distant metastasis, 11 patients survived for more than 30 months. Only one out of 29 patient (3%) had regional recurrence after follow-up for 4.5 years. Three-year overall survival rate was 100%, and five-year overall survival rate was 100%. Three-year disease free survival rate was 100%, and five-year disease free survival rate was 80%. Three-year disease specific survival rate was 100%, and three-year disease specific survival rate was 100%. Twenty-five patients (86%) had excellent cosmetic results, and 4 patients (14%) had good cosmetic results. In univariate analysis of variables with log rank test, tumor necrosis, tumor grade, and resection margin were significant in predicting disease free survival. Conclusion : The good survival outcome and low local recurrence rate suggested the treatment with partial mastectomy and radiation therapy was a good option of treatment for DCIS of breast. Tumor necrosis, tumor grade, and resection margin were prognostic factors on disease free survival. Larger study series with longer follow-up period should be warranted to make advanced analysis in patients with DCIS receiving treatments of partial mastectomy and radiation therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-27-34-a", "title": "Primary Tracheal Malignancy: Our Experience", "keywords": "\u6c23\u7ba1\u539f\u767c\u60e1\u6027\u816b\u7624;\u653e\u5c04\u7dda\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 tracheal malignancy;radiotherapy;prognostic factor", "c": "\u76ee\u7684\uff1a\u6c23\u7ba1\u539f\u767c\u60e1\u6027\u816b\u7624\u5728\u81e8\u5e8a\u4e0a\u6bd4\u8f03\u5c11\u898b\uff0c\u5176\u76db\u884c\u7387\u7d04\u662f\u547c\u5438\u9053\u816b\u7624\u76840.2-0.5%\u3002\u5c0d\u65bc\u65e9\u671f\u7684\u6c23\u7ba1\u816b\u7624\uff0c\u624b\u8853\u6cbb\u7642\u662f\u7b2c\u4e00\u9078\u64c7\u3002\u5c0d\u65bc\u4e2d\u665a\u671f\u7684\u75c5\u4eba\uff0c\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u662f\u55ae\u7d14\u653e\u5c04\u6cbb\u7642\u662f\u5fc5\u8981\u7684\uff0c\u4e26\u4e14\u80fd\u63d0\u4f9b\u4e0d\u932f\u7684\u6cbb\u7642\u6548\u679c\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1985\u5e74\u81f32000\u5e74\uff0c\u5171\u6709\u5341\u4e8c\u4f4d\u6c23\u7ba1\u539f\u767c\u60e1\u6027\u816b\u7624\u7684\u75c5\u60a3\u5728\u53f0\u4e2d\u69ae\u7e3d\u63a5\u6536\u6cbb\u7642\uff0c\u5176\u4e2d\u4e03\u4f4d\u662f\u4e0a\u76ae\u764c\uff0c\u4e09\u4f4d\u662f\u817a\u56ca\u72c0\u764c\uff0c\u4e00\u4f4d\u662f\u9ed1\u8272\u7d20\u764c\uff0c\u4e00\u4f4d\u662f\u795e\u7d93\u5167\u5206\u6ccc\u764c\u3002\u6240\u6709\u7d50\u679c\u4ee5Kaplan-Meier log rank\u7684\u7d71\u8a08\u65b9\u6cd5\u52a0\u4ee5\u5206\u6790\u3002 \u7d50\u679c\uff1a\u6709\u516b\u4f4d\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d\u4e00\u4f4d\u662f\u63a5\u53d7\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5341\u4f4d\u75c5\u4eba\u7684\u8cc7\u6599\u53ef\u4f9b\u5206\u6790\u3002\u9019\u4e9b\u75c5\u4eba\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba33\u500b\u6708\uff0c\u7b2c\u4e00\u5e74\u548c\u7b2c\u4e8c\u5e74\u7684\u5b58\u6d3b\u7387\u70ba70%\u548c60%\u3002\u7d93\u904e\u5206\u6790\u9810\u5f8c\u56e0\u5b50\uff0c\u767c\u73fe\u5c40\u90e8\u7d44\u7e54\u4fb5\u72af\u4ee5\u53ca\u521d\u59cb\u75c7\u72c0\u671f\u9593\u9577\u77ed\u7b49\u4e09\u56e0\u5b50\u70ba\u751f\u5b58\u6642\u9593\u53ef\u80fd\u7684\u986f\u8457\u9810\u5f8c\u56e0\u5b50\u3002\u53e6\u5916\uff0c\u5c40\u90e8\u7d44\u7e54\u4fb5\u72af\u4ee5\u53ca\u521d\u59cb\u75c7\u72c0\u671f\u9593\u9577\u77ed\u7b49\u4e8c\u56e0\u5b50\u4ea6\u70ba\u7121\u75c5\u751f\u5b58\u671f\u53ef\u80fd\u7684\u986f\u8457\u9810\u5f8c\u56e0\u5b50\u3002\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\u4ee5\u53ca\u816b\u7624\u7d44\u7e54\u578b\u614b\u96d6\u7136\u5c0d\u65bc\u9810\u5f8c\u6709\u5f71\u97ff\uff0c\u4f46\u662f\u672a\u9054\u5230\u986f\u8457\u610f\u7fa9\u3002 \u7d50\u8ad6\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u80fd\u662f\u4e00\u7a2e\u5b89\u5168\u800c\u6709\u6548\u7684\u6cbb\u7642\u6c23\u7ba1\u539f\u767c\u60e1\u6027\u816b\u7624\u7684\u65b9\u5f0f\u3002\u7531\u65bc\u539f\u767c\u6027\u6c23\u7ba1\u60e1\u6027\u816b\u7624\u6bd4\u8f03\u5c11\uff0c\u52a0\u4e0a\u6211\u5011\u7684\u75c5\u4eba\u6578\u5c11\uff0c\u7d71\u8a08\u5b78\u4e0a\u7684\u7fa9\u610f\u8f03\u5c0f\u3002\u9019\u7bc7\u6587\u7ae0\u4e3b\u8981\u662f\u5206\u4eab\u6211\u5011\u7684\u65bc\u6cbb\u7642\u539f\u767c\u6027\u6c23\u7ba1\u60e1\u6027\u816b\u7624\u7684\u7d93\u9a57\uff0c\u4ee5\u53ca\u63a2\u8a0e\u53ef\u80fd\u7684\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose : Tracheal malignancy was not often seen in clinical practice. Its prevalence was about 0.2-0.5% of all respiratory tract malignancies, with 1:100 ratio of tracheal to bronchial tumors in reported series. Prognosis of patients with tumor of the trachea remains poor. The treatment choice for early stage disease is surgery because extensive resection provides better control. For patients with advanced stage disease definitive radiotherapy has shown modest gain. Several studies have demonstrated the value of radiotherapy in controlling primary tumor in the trachea.  Material and Method : From 1985 to 2000, there were twelve patients with primary tracheal malignancy found in Taichung Veterans General Hospital. Seven patients were squamous cell carcinoma, three were adenoid cystic carcinoma, one was melanoma and one was neuroendocrine carcinoma. Among them, two patients?details were not available anymore. One died of surgical complication within two months after resection. Thus nine of ten evaluable patients entered into the analysis of possible prognostic factors for primary tracheal malignancy. Univariate analyses of prognostic factors were carried out by Kaplan-Meier log rank method.  Results : Seven of ten evaluable patients received definitive radiotherapy as curative purpose and one for palliation. The estimated median survival time for all ten patients was 33 months (CI: 0~66 months), with the survival rate at one and two years being 70% and 60%. Local invasion and duration of initial symptoms were possible significant prognostic factors for poor survival. Besides, we also identified the same factors as the possible significant prognostic factors for disease-free survival time. Local lymph node involvement and histological type of cancer showed effects in both survival and disease-free survival but didn\u6390 reach the significant level. Conclusion : From our experience, radiotherapy either as a curative or palliative purpose seems to be safe and effective for tracheal cancer. However, due to rarity of primary tracheal malignancy, there was small group in our series. We offered our experience of radiotherapy for tracheal cancer and discuss possible prognostic factors, although less statistic meanings."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-35-42-a", "title": "Primary Central Nervous System Lymphoma: A Meta-Analysis Study", "keywords": "\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624;\u7d71\u5408\u5206\u6790 primary central nervous system lymphoma;meta-analysis", "c": "\u76ee\u7684\uff1a\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u662f\u4e00\u7a2e\u5c11\u898b\u7684\u75be\u75c5\u3002\u56e0\u70ba\u75c5\u4eba\u6578\u5c11\u548c\u8cc7\u6599\u7f3a\u4e4f\uff0c\u8981\u505a\u5927\u578b\u7684\u7814\u7a76\u975e\u5e38\u56f0\u96e3\uff0c\u6240\u4ee5\u6211\u5011\u63a1\u7528\u7d71\u5408\u5206\u6790\u7684\u65b9\u5f0f\uff0c\u8a66\u8457\u627e\u51fa\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7684\u7406\u60f3\u6cbb\u7642\u65b9\u6cd5\u548c\u5176\u9810\u5f8c\u56e0\u5b50\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528PUBMED\u548cMEDLINE\uff0c\u5f9e2003\u5e749\u6708\u4e4b\u524d\u767c\u8868\u7684\u6587\u7ae0\u4e2d\uff0c\u627e\u51fa\u6a19\u984c\u542b\u6709\u201c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u201d\u6216\u201c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u201d\u7684\u8ad6\u6587\u3002\u7e3d\u5171\u627e\u523016\u7bc7\u6587\u7ae0\u7684\u6a19\u984c\u542b\u6709\u4e0a\u8ff02\u9805\u5176\u4e2d\u4e4b\u4e00\uff0c\u4f46\u53ea\u6709\u5176\u4e2d4\u7bc7\uff0885\u4f4d\u75c5\u4eba\uff09\u7b26\u5408\u7be9\u9078\u689d\u4ef6\u800c\u9078\u9032\u7814\u7a76\u4e2d\u3002\u6cbb\u7642\u65b9\u5f0f\u5305\u62ec\u53ea\u6709\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642\u5176\u4e2d\u4e4b\u4e00\uff0c\u6216\u5408\u4f75\u653e\u5c04\u7dda\u548c\u5316\u5b78\u6cbb\u7642\u3002\u5c0d\u65bc\u75c5\u4eba\u6cbb\u7642\u5f8c\u521d\u59cb\u53cd\u61c9\u548c\u9810\u5f8c\u7684\u5206\u6790\uff0c\u672c\u7814\u7a76\u5206\u6790\u7684\u8b8a\u56e0\u5305\u62ec\uff1a\u5e74\u9f61\u3001\u6027\u5225\u3001\u6cbb\u7642\u65b9\u5f0f\u7b49\uff0c\u800c\u4e14\u63a1\u7528\u55ae\u4e00\u8b8a\u9805\u5206\u6790\u548c\u591a\u8b8a\u9805\u5206\u6790\u3002\u55ae\u4e00\u8b8a\u9805\u5206\u6790\u662f\u63a1\u7528log rank test\uff0c\u800c\u591a\u8b8a\u9805\u5206\u6790\u662f\u63a1\u7528Cox proportional hazards model\uff0c\u5b58\u6d3b\u7387\u662f\u4ee5Kaplan-Meier\u8a08\u7b97\u3002 \u7d50\u679c\uff1a6\u4f4d\u75c5\u4eba\uff087.1%\uff09\u53ea\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c38\u4f4d\u75c5\u4eba\uff0844.7%\uff09\u53ea\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c41\u4f4d\u75c5\u4eba\uff0848.2%\uff09\u63a5\u53d7\u5408\u4f75\u653e\u5c04\u7dda\u548c\u5316\u5b78\u6cbb\u7642\u3002\u5728\u5b58\u6d3b\u7387\u65b9\u9762\uff0c3\u5e74\u548c5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\uff08overall survival\uff09\u5206\u5225\u70ba47.8%\u548c28.9%\u3002\u4e09\u5e74\u548c\u4e94\u5e74\u7684\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\uff08disease-specific survival\uff09\u5206\u5225\u70ba 49.1%\u548c34.0%\u3002\u5728\u55ae\u4e00\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u767c\u73fe\u5e74\u9f61\uff08p = 0.0129\uff09\u3001\u662f\u5426\u6709\u65bd\u884c\u5316\u5b78\u6cbb\u7642\uff08p = 0.0141\uff09\u53ca\u5316\u5b78\u6cbb\u7642\u662f\u5426\u6709 3 \u6b21\u4ee5\u4e0a\uff08p = 0.0003\uff09\u5c0d\u6574\u9ad4\u5b58\u6d3b\u7387\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u53e6\u5916\u5c0d\u65bc\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\uff0c\u662f\u5426\u6709\u65bd\u884c\u5316\u5b78\u6cbb\u7642\uff08p = 0.0077\uff09\u53ca\u5316\u5b78\u6cbb\u7642\u662f\u5426\u67093\u6b21\u4ee5\u4e0a\uff08p = 0.0001\uff09\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u5728\u591a\u8b8a\u9805\u5206\u6790\u4e2d\uff0c\u5316\u5b78\u6cbb\u7642\u662f\u5426\u6709 3 \u6b21\u4ee5\u4e0a\u662f\u552f\u4e00\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u548c\u75be\u75c5\u76f8\u95dc\u5b58\u6d3b\u7387\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\uff08p = 0.018, 0.007\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u63a5\u53d73\u6b21\u4ee5\u4e0a\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\u5176\u5b58\u6d3b\u7387\u8f03\u4f73\uff0c\u6545\u5efa\u8b70\u5728\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7684\u6cbb\u7642\u4e2d\uff0c\u61c9\u5305\u542b3\u6b21\u4ee5\u4e0a\u7684\u5316\u5b78\u6cbb\u7642\u3002", "e": "Purpose : Primary CNS lymphoma is a rare disease. Owing to small number of patients and lack of data, large-series studies become difficult. We use a meta-analysis to evaluate the treatment of primary CNS lymphoma and prognostic factor. Materials and Methods : Articles published before September 2003 were searched through PUBMED (National Library of Medicine) and MEDLINE and by the terms of \u70e2rimary CNS lymphoma? \u70cbon-Hodgkin\u6387 lymphoma of CNS? Sixteen potentially suitable articles were found. Among them, four articles matched the selective criteria and were collected into this meta-analysis. There were 85 patient entered the study. The treatment included single and combined modalities of radiotherapy and chemotherapy. The variables, such as age, sex, methods of treatment were analyzed about their influence upon initial response and prognosis. Univariate and multivariate analyses were used. Univariate analysis using the log rank test and multivariate analysis using the Cox proportional hazards model were performed. Overall survival and disease-specific survival were calculated with the method of Kaplan and Meier. Results : Forty-one patients (48.2%) were male, and 44 patients (51.8%) were female. The median age was 62 years. Six patients (7.1%) received radiotherapy alone. Thirty-eight patients (44.7%) received chemotherapy alone. Forty-one patients (48.2%) received combination of radiotherapy and chemotherapy. The rate of initial response were 82.4%. During the time of following up, 35 patients (41.2%) were alive, and 50 patients (58.8%) were expired. The 3-year and 5-year overall survival rates were 47.8% and 28.9%, respectively. The 3-year and 5-year disease-specific survival rates were 49.1% and 34.0%, respectively. In the univariate analysis, age was a significant prognostic factor of overall survival rate (p = 0.0129). Chemotherapy was a significant prognostic factor of overall survival rate and disease-specific survival rate (p = 0.0141, 0.0077 respectively). The number of cycle of chemotherapy was another significant prognostic factor of overall survival rate and disease-specific survival rate (p = 0.0003, 0.0001 respectively). In the multivariate analysis, the number of cycle of chemotherapy is the only significant prognostic factor of overall survival rate and disease-specific survival rate (p = 0.018, 0.007 respectively).  Conclusion : In this study, patients who received chemotherapy with 3 cycles or more had better survival outcome. Chemotherapy with 3 cycles or more is recommended in treatment of primary CNS lymphoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-43-53-a", "title": "\u61c9\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u4e4b\u81ea\u52d5\u98df\u9053\u908a\u7de3\u5206\u5272\u6f14\u7b97\u6cd5", "keywords": "\u6cbb\u7642\u4e0d\u78ba\u5b9a\u6027;\u5668\u5b98\u79fb\u52d5;\u5f71\u50cf\u908a\u7de3\u5206\u5272 treatment uncertainty;organ motion;image boundary extraction", "c": "\u76ee\u7684\uff1a\u7531\u65bc\u6cbb\u7642\u6280\u8853\u7684\u9032\u6b65\uff0c\u53ef\u52a0\u5f37\u816b\u7624\u548c\u6b63\u5e38\u7d44\u7e54\u9593\u5291\u91cf\u7684\u5dee\u7570\uff0c\u63d0\u6607\u6cbb\u7642\u7642\u6548\uff0c\u56e0\u6b64\u6cbb\u7642\u8a08\u756b\u5c0d\u65bc\u6cbb\u7642\u4e0d\u78ba\u5b9a\u6027\u7684\u654f\u611f\u5ea6\u4e5f\u96a8\u4e4b\u4e0a\u5347\u3002\u5728\u5404\u7a2e\u5f71\u97ff\u6cbb\u7642\u4e0d\u78ba\u5b9a\u6027\u7684\u56e0\u7d20\u4e2d\uff0c\u76ee\u524d\u4ee5\u5668\u5b98\u79fb\u52d5\u8a55\u4f30\u7684\u6e96\u78ba\u6027\u7279\u5225\u53d7\u5230\u91cd\u8996\u3002 \u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u662f\u5229\u7528\u6a21\u64ec\u651d\u5f71\u4e2d\uff0c\u85c9\u7531\u541e\u98df\u92c7\u5291\u5f8c\u4e4b\u900f\u8996\u5f71\u50cf\uff0c\u5229\u7528\u5f71\u50cf\u524d\u7f6e\u8655\u7406\u3001\u908a\u7de3\u5075\u6e2c\u3001\u548c\u908a\u7de3\u5b9a\u4f4d\u4f86\u81ea\u52d5\u641c\u5c0b\u98df\u9053\u5f71\u50cf\u908a\u7de3\u3002 \u7d50\u679c\uff1a\u7d93\u7531\u672c\u7814\u7a76\u6240\u63d0\u51fa\u81ea\u52d5\u98df\u9053\u908a\u7de3\u5206\u5272\u6f14\u7b97\u6cd5\uff0c\u5c0d\u65bc\u56e0\u53d7\u816b\u7624\u58d3\u8feb\u800c\u5f62\u6210\u7684\u92c7\u5291\u805a\u7a4d\u8655\uff0c\u53ef\u63cf\u7e6a\u51fa\u5b8c\u6574\u7684\u908a\u7de3\uff0c\u4e26\u9054\u5230\u4ee5\u98df\u9053\u908a\u7de3\u4e4b\u79fb\u52d5\u4ee3\u8868\u816b\u7624\u5728\u6cbb\u7642\u4e2d\u7684\u79fb\u52d5\u3002 \u7d50\u8ad6\uff1a\u79fb\u52d5\u8a55\u4f30\u7684\u7d50\u679c\uff0c\u6709\u5229\u65bc\u6cbb\u7642\u8a08\u756b\u4e2d\u5b89\u5168\u908a\u8ddd\u7684\u7e2e\u5c0f\uff0c\u5728\u816b\u7624\u6cbb\u7642\u5291\u91cf\u589e\u52a0\u6642\u4ecd\u80fd\u6709\u6548\u63a7\u5236\u6b63\u5e38\u7d44\u7e54\u6240\u63a5\u53d7\u4e4b\u5291\u91cf\uff0c\u964d\u4f4e\u6b63\u5e38\u7d44\u7e54\u526f\u4f5c\u7528\u767c\u751f\u6a5f\u7387\u53ca\u5176\u767c\u751f\u7684\u56b4\u91cd\u7a0b\u5ea6\u3002", "e": "Propose : As the prescribed dose difference between tumor cells and normal tissues increases, treatment planning becomes more sensitive to treatment uncertainties. Among various treatment uncertainties, accurate evaluation of organ motion plays an important role in quality improvement of treatment planning.  Materials and Methods : In this study, we describe an automatic segmentation algorithm to extract contrast medium enhanced esophagus in X-ray fluoroscopy. The algorithm is based on image pre-processing, image edge detection, and boundary extraction to identify the esophageal boundary in a fully automatic manner. Results and Conclusion : The extracted esophageal boundary variations between adjacent time frame sequences can be applied to estimate the tumor motions as well as the required safe margins."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-55-58-a", "title": "Recurrent Pigmented Villonodular Synovitis of Knee Treated with Surgery and Adjuvant Radiotherapy: A Case Report", "keywords": "\u8272\u7d20\u7d68\u6bdb\u7d50;\u7bc0\u72c0\u6ed1\u819c\u708e;\u653e\u5c04\u6cbb\u7642;\u75c5\u4f8b\u5831\u544a pigmented villonodular synovitis;radiotherapy;case report", "c": "\u8272\u7d20\u7d68\u6bdb\u7d50\u7bc0\u72c0\u6ed1\u819c\u708e\u70ba\u4e00\u7a00\u6709\u75be\u75c5\uff0c\u4e3b\u8981\u5f71\u97ff\u95dc\u7bc0\u6ed1\u819c\u4e26\u7522\u751f\u985e\u4f3c\u95dc\u7bc0\u708e\u7684\u75c7\u72c0\u3002\u7030\u6f2b\u6027\u8272\u7d20\u7d68\u6bdb\u7d50\u7bc0\u72c0\u6ed1\u819c\u708e\u5728\u63a5\u53d7\u624b\u8853\u6cbb\u7642\u4e4b\u5f8c\uff0c\u5fa9\u767c\u7684\u60c5\u6cc1\u4e26\u4e0d\u5c11\u898b\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d\u5728\u521d\u6b21\u6ed1\u819c\u5207\u9664\u8853\u5f8c\u4e00\u5e74\u53c8\u5341\u500b\u6708\u5fa9\u767c\u7684\u7537\u6027\u75c5\u60a3\u3002\u4ed6\u5728\u7b2c\u4e8c\u6b21\u624b\u8853\u5f8c39\u5929\u958b\u59cb\u63a5\u53d7\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u70ba34.5 Gy\uff0c\u4ee515\u6b21\u5206\u6b21\u7167\u5c04\u7d66\u4e88\u3002\u653e\u5c04\u6cbb\u7642\u7de9\u89e3\u4e86\u75be\u75c5\u76f8\u95dc\u7684\u75c7\u72c0\uff0c\u4f46\u8ffd\u8e64\u7684\u6838\u78c1\u5171\u632f\u5f71\u50cf\u4ecd\u6709\u75be\u75c5\u5b58\u5728\u7684\u8b49\u64da\u3002\u653e\u5c04\u6cbb\u7642\u5c0d\u67d0\u4e9b\u7030\u6f2b\u6027\u8272\u7d20\u7d68\u6bdb\u7d50\u7bc0\u72c0\u6ed1\u819c\u708e\u75c5\u4eba\u53ef\u80fd\u6703\u6709\u6cbb\u7642\u4e0a\u7684\u76ca\u8655\u3002", "e": "Pigmented villonodular synovitis (PVS) is a rare disease involving the synovial membrane and causing symptoms similar to arthritis. In diffuse PVS, recurrence is not uncommon after surgery. We report a male patient with PVS of the knee that recurred 1 year and 10 months after initial synovectomy. He was again operated on and then given adjuvant radiation therapy (RT) with a total dose of 34.5 Gy in 15 fractions beginning 39 days postoperatively. RT relieved his symptoms even though an MRI revealed persistent disease. RT may be beneficial for selected patients with diffuse PVS."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-59-64-a", "title": "Primary Central Nervous System Fibrosarcoma: Case Report and Literature Review", "keywords": "\u60e1\u6027\u7e96\u7dad\u8089\u7624;\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71;\u653e\u5c04\u6cbb\u7642 fibrosarcoma;central nervous system;radiotherapy", "c": "\u60e1\u6027\u8edf\u7d44\u7e54\u8089\u7624\u53ef\u767c\u751f\u65bc\u5168\u8eab\u5404\u90e8\u4f4d\uff0c\u4e26\u5e38\u898b\u65bc\u56db\u80a2\u3001\u8179\u819c\u8154\u53ca\u5f8c\u8179\u819c\u8154\u3002\u539f\u767c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u70ba\u7f55\u898b\u816b\u7624\uff0c\u7d04\u4f54\u9871\u5167\u816b\u7624\u76841.5%\uff0c\u6b64\u816b\u7624\u88ab\u8a8d\u70ba\u6e90\u751f\u65bc\u8166\u5be6\u8cea\u53ca\u8166\u819c\u4e4b\u9593\u8449\u7d30\u80de\uff0c\u6700\u5e38\u898b\u8005\u5305\u62ec\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u3001\u60e1\u6027\u7e96\u7dad\u8089\u7624\u3001\u60e1\u6027\u5e73\u6ed1\u808c\u7624\u3001\u60e1\u6027\u6a6b\u7d0b\u808c\u7624\u3001\u60e1\u6027\u8840\u7ba1\u7624\u53ca\u672a\u5206\u5316\u7624\u3002\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u5728\u7d44\u7e54\u5b78\u4e0a\u5e38\u8f03\u60e1\u6027\uff0c\u4e26\u5728\u81e8\u5e8a\u4e0a\u6709\u8f03\u9ad8\u5fa9\u767c\u6a5f\u7387\uff0c\u5176\u6613\u6709\u8166\u819c\u53ca\u9060\u7aef\u8f49\u79fb\u4e4b\u7279\u6027\u5247\u53ef\u8207\u795e\u7d93\u81a0\u6e90\u816b\u7624\u5340\u5206\u3002 \u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u8f03\u7f55\u898b\uff0c\u81f4\u4f7f\u6587\u737b\u8cc7\u6599\u53ca\u6cbb\u7642\u7d93\u9a57\u5747\u8f03\u7f3a\u4e4f\uff1b\u56e0\u5176\u6613\u65bc\u5c40\u90e8\u5fa9\u767c\u53ca\u9060\u7aef\u8f49\u79fb\uff0c\u6240\u4ee5\u5fc5\u9808\u4ee5\u591a\u79d1\u6574\u5408\u6a21\u5f0f\u6cbb\u7642\u3002\u5982\u540c\u56db\u80a2\u53ca\u8ec0\u5e79\u7684\u8edf\u7d44\u7e54\u8089\u7624\uff0c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u4e3b\u8981\u6cbb\u7642\u9700\u4ef0\u8cf4\u624b\u8853\u5207\u9664\uff0c\u4f46\u56e0\u8166\u90e8\u624b\u8853\u6709\u5176\u9650\u5236\u6027\uff0c\u96e3\u57f7\u884c\u5927\u7bc4\u570d\u5207\u9664\uff0c\u6240\u4ee5\u5fc5\u9808\u7d66\u4e88\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u65b9\u53ef\u63a7\u5236\u6b98\u9918\u816b\u7624\u7d30\u80de\u3002 \u6211\u5011\u5831\u544a\u4e00\u539f\u767c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u6848\u4f8b\uff0c\u5176\u81e8\u5e8a\u4e0a\u4ee5\u53f3\u5074\u504f\u7671\u53ca\u9ebb\u75fa\u8868\u73fe\uff1b\u8a72\u75c5\u60a3\u63a5\u53d7\u816b\u7624\u5168\u5207\u9664\u8853\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u65bc\u8ffd\u8e64\u4e00\u5e74\u671f\u9593\u672a\u6709\u5c40\u90e8\u5fa9\u767c\u6216\u9060\u7aef\u8f49\u79fb\u3002\u6587\u4e2d\u53e6\u63a2\u8a0e\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u60e1\u6027\u7e96\u7dad\u8089\u7624\u4e4b\u6700\u9069\u5207\u6cbb\u7642\u65b9\u5f0f\u53ca\u9810\u5f8c\u3002", "e": "Soft tissue sarcomas can occur in any site throughout the body and are more frequently found in the limbs, peritoneal cavity and retroperitoneum. Primary central nervous system sarcomas are rare and account for only 1.5% of all intracranial tumors. These tumors are thought to arise from mesenchymal elements within the brain parenchyma or its meningeal coverings. Histopathologically, the most common tumor types included malignant fibrous histiocytoma, fibrosarcoma, leimyosarcoma, rhabdomyosarcoma, angiosarcoma and undifferentiated sarcoma. Primary central nervous system fibrosarcomas are usually of high histological grade, with a high rate of recurrence. Their propensity for meningeal and distant relapse distinguishes them from tumors of glial origin. The rare occurrence of primary central nervous system fibrosarcomas leads to a paucity of data in the literature and experience regarding the therapeutic management of these tumors. Because soft tissue sarcomas are aggressive tumors capable of local recurrence and distant metastasis, the need for a multidisciplinary approach is indicated in treating these tumors. As for soft tissue sarcomas of the extremity and trunk, the mainstay of treatment of primary central nervous system sarcomas is surgical excision. While brain surgery must be limited due to the proximity of critical structures, en bloc resections cannot be achieved and adjuvant radiotherapy should be given to control residual disease. We report a case of 30-year-old man who had primary central nervous system fibrosarcoma over left frontal lobe with presentation of progressive right-sided numbness and weakness. The patient was treated with total excision of the tumor followed by adjuvant radiotherapy via cone-down wedged-pair technique. Neither local recurrence nor distant metastasis was identified during a follow-up of 1 year. The optimal treatment and prognosis were discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200403-11-1-65-69-a", "title": "Spinal Cord Drop Metastasis of Intracranial Oligodendroglioma: A Case Report", "keywords": "\u5be1\u6a39\u7a81\u795e\u7d93\u81a0\u8cea\u7624;\u810a\u9ad3\u8f49\u79fb;\u653e\u5c04\u7dda\u6cbb\u7642 oligodendroglioma;spinal cord metastasis;radiotherapy", "c": "\u76ee\u7684\uff1a\u9871\u5167\u5be1\u6a39\u7a81\u795e\u7d93\u81a0\u8cea\u7624\u4f34\u96a8\u4e0b\u79fb\u6027\u810a\u9ad3\u8f49\u79fb\u662f\u4e0d\u5e38\u898b\u7684\u75c5\u4f8b\uff0c\u6211\u5011\u5831\u544a\u4e00\u4f8b\u75c5\u60a3\u53ca\u5176\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u679c\u3002 \u75c5\u4f8b\u5831\u544a\uff1a\u4e00\u4f4d\u5e74\u9f6149\u6b72\u7684\u7537\u6027\u7f79\u60a3\u5de6\u5927\u8166\u9873\u8449\u5be1\u6a39\u7a81\u795e\u7d93\u81a0\u8cea\u7624\uff0c\u65bc1999\u5e74\u63a5\u53d7\u5927\u8166\u816b\u7624\u5207\u9664\u624b\u8853\u53ca\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u4e0d\u5e78\u7684\uff0c\u57282002\u5e74\u6642\uff0c\u65bc\u5c0f\u8166\u8693\u90e8\u53ca\u5ef6\u9ad3\u8655\u767c\u73fe\u5c40\u90e8\u5fa9\u767c\u7684\u60c5\u5f62\u3002\u4e4b\u5f8c\uff0c\u91dd\u5c0d\u8166\u90e8\u5fa9\u767c\u90e8\u4f4d\uff0c\u4ed6\u63a5\u53d7\u4e86\u4e00\u500b\u7642\u7a0b\u7684\u7d93\u52d5\u8108\u6ce8\u5165\u4e4b\u5316\u5b78\u6cbb\u7642\u3002\u5728\u90a3\u540c\u6642\uff0c\u75c5\u4eba\u4e5f\u81ea\u8a34\u6709\u6301\u7e8c\u5341\u500b\u591a\u6708\u56b4\u91cd\u7684\u4e0b\u80cc\u75bc\u75db\u4f34\u96a8\u5de6\u5074\u5750\u9aa8\u795e\u7d93\u75db\u3002\u96a8\u5f8c\u5728\u75c5\u4eba\u7684\u8170\u690e\u90e8\u4f4d\u767c\u73fe\u816b\u7624\uff0c\u75c5\u7406\u8a3a\u65b7\u70ba\u8f49\u79fb\u6027\u5be1\u6a39\u7a81\u795e\u7d93\u81a0\u8cea\u7624\u3002\u65bc\u662f\u5207\u9664\u4e86\u8f49\u79fb\u7684\u816b\u7624\uff0c\u4e26\u5728\u8170\u690e\u7b2c\u4e8c\u7bc0\u81f3\u85a6\u690e\u7b2c\u4e09\u7bc0\u7d66\u4e88\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5f9e2003\u5e741\u6708\u81f32003\u5e742\u6708\uff0c\u5171\u63a5\u53d7\u4e8655 Gy\u8a0851\u6b2141\u5929\u7167\u5c04\u3002 \u7d50\u679c\uff1a\u5728\u63a5\u53d7\u4e86\u5b8c\u6574\u7684\u653e\u5c04\u7dda\u7642\u7a0b\u4e4b\u5f8c\uff0c\u75c5\u4eba\u7684\u4e0b\u80cc\u75bc\u75db\u53ca\u5de6\u5074\u5750\u9aa8\u795e\u7d93\u75db\u7b49\u75c7\u72c0\u90fd\u7372\u5f97\u4e86\u660e\u986f\u7684\u6539\u5584\u3002\u6301\u7e8c7\u500b\u6708\u7684\u8ffd\u8e64\u64bf\u67e5\uff0c\u8170\u85a6\u690e\u7684\u60a3\u8655\u4e26\u7121\u4efb\u4f55\u660e\u986f\u7684\u60e1\u5316\u60c5\u5f62\u3002 \u7d50\u8ad6\uff1a\u5f9e1942\u5e74\u52302002\u5e74\uff0c\u4e16\u754c\u6587\u737b\u4e0a\u50c5\u53ea\u67098\u500b\u9871\u5167\u5be1\u6a39\u7a81\u795e\u7d93\u81a0\u8cea\u7624\u4e4b\u4e0b\u79fb\u6027\u810a\u9ad3\u8f49\u79fb\u75c5\u4f8b\u88ab\u5831\u544a\u3002\u7531\u6211\u5011\u5831\u544a\u75c5\u4f8b\u7684\u7d93\u9a57\u4e2d\u53ef\u77e5\uff0c\u8f49\u79fb\u816b\u7624\u6240\u9020\u6210\u7684\u795e\u7d93\u58d3\u8feb\u75c7\u72c0\u53ef\u7d93\u7531\u653e\u5c04\u7dda\u6cbb\u7642\u7372\u7684\u826f\u597d\u7684\u6539\u5584\u3002", "e": "Purpose : To report a case of malignant oligodendroglioma with drop metastasis to spinal cord. We report the treatment result of this case.  Case report : This 49 years old male patient is a case of left temporal oligodendroglioma, high grade. He received brain tumor excision and post -operative radiotherapy in 1999. Unfortunately, regional recurrence was found at vermis and cervicomedullar region in 2002. Then he received a course of intraarterial chemotherapy for brain recurrence. At the same time, low back pain with left sciatica was found for 10 months. Then spinal tumor was found and the tissue diagnosis was metastatic oligodendroglioma. Adjuvant radiation therapy to the L2-S3 region was given for 55 Gy/51 fraction 41 days from January, 2003. Result : After completion of radiotherapy, the symptom of low back pain had great improvement. At least 7 months up to recent follow up., this lesion did not show any obvious progression. Conclusion : There were only 8 cases of intracranial oligodendroglioma with spinal cord drop metastasis reported since 1942 to 2002. Base on this case, the compression symptom by tumor could be well controlled by radiation therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-189-195-a", "title": "\u4ee5\u8ff7\u4f60\u8c6c\u4f5c\u70ba\u816e\u817a\u8f3b\u5c04\u53cd\u61c9\u7814\u7a76\u4e4b\u6a21\u5f0f\u53ca\u521d\u6b65\u7d50\u679c", "keywords": "\u553e\u6db2\u817a;\u653e\u5c04\u7dda\u50b7\u5bb3;\u553e\u6db2\u817a\u4fdd\u8b77\u5291 Salivary glands;Radiation damage;Radiation protectors", "c": "\u76ee\u7684\uff1a\u553e\u6db2\u817a\u5177\u6975\u9ad8\u4e4b\u8f3b\u5c04\u654f\u611f\u5ea6\uff0c\u9f3b\u54bd\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u553e\u6db2\u817a\u906d\u7834\u58de\uff0c\u9020\u6210\u75c5\u4eba\u4e4b\u553e\u6db2\u5206\u6ccc\u5927\u5e45\u964d\u4f4e\u3002\u5982\u4f55\u5728\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e2d\u4fdd\u8b77\u553e\u6db2\u817a\uff0c\u65b9\u6cd5\u4e4b\u4e00\u662f\u4f7f\u7528\u80fd\u6e1b\u4f4e\u553e\u6db2\u8f3b\u5c04\u50b7\u5bb3\u7684\u4fdd\u8b77\u5291\u5982pentoxifylline\u3001amifostine\u7b49\u3002\u6b64\u5916\u6709\u8a31\u591a\u85e5\u7269\u53ef\u80fd\u5177\u553e\u6db2\u4fdd\u8b77\u7684\u6548\u679c\u5982\u7dad\u5b83\u547dC\u3001\u814e\u4e0a\u817a\u7d20\u6fc0\u6027\u85e5\u7269\uff08adrenergic agonist\uff09\u53ca\u81bd\u7d20\u523a\u6fc0\u6027\uff08cholinergic\uff09\u85e5\u7269\u3002\u672c\u7814\u7a76\u4f7f\u7528\u89e3\u5256\u3001\u751f\u7406\u8207\u4eba\u985e\u8fd1\u4f3c\u4e4b\u8ff7\u4f60\u8c6c\uff0c\u76ee\u7684\u70ba1. \u5efa\u7acb\u8ff7\u4f60\u8c6c\u553e\u6db2\u817a\u7814\u7a76\u7684\u52d5\u7269\u6a21\u5f0f\u30022. \u6e2c\u8a66\u7be9\u9078\u80fd\u6709\u6548\u523a\u6fc0\u8ff7\u4f60\u8c6c\u553e\u6db2\u5206\u6ccc\u7684\u6700\u9069\u7576\u65b9\u6cd5\u30023. \u5f97\u5230\u521d\u6b65\u8ff7\u4f60\u8c6c\u816e\u817a\u653e\u5c04\u53cd\u61c9\u8cc7\u6599\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u63a1\u7528\u53f0\u5927\u755c\u7522\u6240\u9ad4\u91cd\u7d0410-15\u516c\u65a4\u4e4b\u674e\u5b8b\u7cfb\u8ff7\u4f60\u8c6c\u3002\u7d93\u9ebb\u9189\u3001\u63d2\u7ba1\u5f8c\uff0c\u518d\u884c\u553e\u6db2\u6536\u96c6\u3001\u85e5\u7269\u6ce8\u5c04\u3001\u653e\u5c04\u7dda\u7167\u5c04\u6216\u624b\u8853\u3002\u553e\u6db2\u523a\u6fc0\u63a1\u85e5\u7269\u8207\u96fb\u523a\u6fc0\u65b9\u5f0f\u627e\u51fa\u6700\u4f73\u523a\u6fc0\u65b9\u5f0f\u3002\u81bd\u7d20\u523a\u6fc0\u6027\u85e5\u7269Carbachol\u53caa-\u814e\u4e0a\u817a\u7d20\u6fc0\u6027\u85e5\u7269Cyclocytidine\u8207Norepinephrine\u5747\u5728\u6e2c\u8a66\u4e4b\u5217\u3002\u653e\u5c04\u817a\u7167\u5c04\u4ee56MV\u76f4\u7dda\u52a0\u901f\u5668\u70ba\u4e4b\u3002\u6574\u500b\u5be6\u9a57\u67b6\u69cb\u5982\u4e0b\uff1a\u4e00\u3001\u52d5\u7269\u6a21\u5f0f\u5efa\u7acb\u3002\u5efa\u7acb\u5c0f\u8c6c\u9ebb\u9189\u65b9\u6cd5\uff0c\u9078\u64c7\u553e\u6db2\u523a\u6fc0\u65b9\u6cd5\uff08\u795e\u7d93\u523a\u6fc0\u6216\u85e5\u7269\u523a\u6fc0\uff09\uff0c\u6c7a\u5b9a\u553e\u6db2\u6536\u96c6\u65b9\u6cd5\u3002\u4e8c\u3001\u816e\u817a\u7167\u5c04\u524d\u5f8c\u4e4b\u553e\u6db2\u5206\u6ccc\u529f\u80fd\u3002\u6536\u96c6\u672a\u7167\u5c04\u524d\u5169\u5074\u816e\u817a\u553e\u6db2\uff0c\u53f3\u5074\u816e\u817a\u7167\u5c041000 cGy x 2\u3001300 cGy x 15\u3001\u8207400 cGy x 12\u5f8c\u65bc\u4e00\u9031\u3001\u4e00\u500b\u6708\u8207\u56db\u500b\u6708\u6642\u4ee5\u85e5\u7269\u523a\u6fc0\u5f8c\uff0c\u6536\u96c6\u553e\u6db2\u6bd4\u8f03\u7167\u5c04\u8207\u672a\u7167\u5c04\u5074\u816e\u817a\u5206\u6ccc\u91cf\u4e4b\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u7d93\u6e2c\u8a66Carbachol 0.2 mg/kg\u6700\u70ba\u9069\u7576\uff0c\u53ef\u523a\u6fc0\u553e\u6db2\u5927\u91cf\u5206\u6ccc\uff0c\u4e14\u53ef\u91cd\u8907\u9a57\u8b49\uff0c\u518d\u73fe\u6027\u6975\u4f73\u3002\u4f46\u4f7f\u7528carbachol\u4ecd\u53ef\u80fd\u5c0e\u81f4\u5fc3\u8df3\u505c\u6b62\uff0c\u5e38\u9808\u9032\u884c\u5fc3\u81df\u6309\u6469\u6436\u6551\u5c0f\u8c6c\u3002\u6b64\u60c5\u6cc1\u65bc\u975c\u6ce81cc atropine\u5f8c\u5fc3\u8df3\u5747\u53ef\u7acb\u5373\u6062\u5fa9\u3002\u96fb\u523a\u6fc0\u65b9\u5f0f\u5247\u7121\u6cd5\u523a\u6fc0\u553e\u6db2\u5206\u6ccc\u3002\u5728\u553e\u6db2\u6536\u96c6\u65b9\u9762\uff0c\u767c\u73fe\u4ee5\u4e7e\u71e52 x 2 cm\u7d17\u5e03\u585e\u65bc\u816e\u817a\u553e\u6db2\u7ba1\u4e73\u982d\u8655\u4e4b\u6536\u96c6\u6cd5\uff0c\u6700\u70ba\u53ef\u9760\u53ca\u7a69\u5b9a\u3002\u7d93\u7167\u5c041000 cGy x 2\u5f8c\u4e00\u9031\u53ca\u4e00\u500b\u6708\u553e\u6db2\u5206\u6ccc\u70ba2.93 ml/min\uff0c\u672a\u7167\u5c04\u816e\u817a\u5206\u6ccc\u91cf\u70ba3.0ml/min\u3002\u7167\u5c044500 cGy\u82074800 cGy\u4e00\u9031\u53ca\u4e00\u500b\u6708\u5f8c\uff0c\u672a\u7167\u5c04\u4e4b\u5de6\u816e\u817a\u53ca\u7167\u5c04\u4e4b\u53f3\u816e\u817a\u553e\u6db2\u5206\u6ccc\u91cf\u4ea6\u7121\u5dee\u5225\u3002\u7167\u5c044500 cGy\u82074800 cGy\u56db\u500b\u6708\u5f8c\uff0c\u672a\u7167\u5c04\u8207\u7167\u5c04\u816e\u817a\u5206\u6ccc\u91cf\u5206\u5225\u70ba2.56/1.08\u82076.83/1.99 ml/min\uff0c\u7167\u5c04\u904e\u4e4b\u816e\u817a\u8868\u73fe\u660e\u986f\u5206\u6ccc\u91cf\u7684\u6e1b\u5c11\u3002\u6b64\u6642\u7167\u5c04\u5f8c\u816e\u817a\u660e\u986f\u840e\u7e2e\uff0c\u5169\u96bb\u63a5\u53d74500 cGy\u82074800 cGy\u5c0f\u8c6c\u4e4b\u672a\u7167\u5c04\u8207\u7167\u5c04\u5074\u816e\u817a\u4e4b\u91cd\u91cf\u5206\u5225\u70ba127.9/26.9\u514b\u3001125.7/22.1\u514b\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u8ff7\u4f60\u8c6c\u70ba\u6750\u6599\uff0c\u53d6\u5176\u89e3\u5256\u8207\u751f\u7406\u8f03\u5927\u9f20\u66f4\u8fd1\u4f3c\u4eba\u985e\uff0c\u553e\u6db2\u91cf\u5920\u5927\u7b49\u512a\u9ede\u3002\u60df\u8207\u5927\u9f20\u76f8\u8f03\uff0c\u8ff7\u4f60\u8c6c\u6210\u672c\u9ad8\u51fa\u8a31\u591a\uff0c\u4ee5\u81f4\u5be6\u9a57\u898f\u6a21\u7121\u6cd5\u8207\u4f7f\u7528\u8001\u9f20\u6642\u76f8\u6bd4\u3002\u672c\u7814\u7a76\u5efa\u7acb\u4e4b\u52d5\u7269\u6a21\u5f0f\uff0c\u80fd\u53ef\u9760\u91cd\u8907\u523a\u6fc0\u8ff7\u4f60\u8c6c\u4e4b\u816e\u817a\u553e\u6db2\u5206\u6ccc\u3002Carbachol\u70ba\u4e00\u6709\u6548\u4e4b\u553e\u6db2\u523a\u6fc0\u85e5\u7269\uff0c\u4f46\u6709\u5fc3\u81df\u505c\u6b62\u8df3\u52d5\u7684\u7f3a\u9ede\u3002\u76f8\u53cd\u7684Adrenergic\u985e\u85e5\u7269norepinephrine\u5247\u4e0d\u7528\u64d4\u5fc3\u5fc3\u8df3\u505c\u6b62\uff0c\u4f46\u553e\u6db2\u523a\u6fc0\u6548\u7387\u4e0d\u597d\uff0c\u4f46\u82e5\u63d0\u9ad8norepinephrine\u7684\u5291\u91cf\u80fd\u5426\u589e\u5f37\u5176\u553e\u6db2\u523a\u6fc0\u6548\u679c\uff0c\u4ecd\u6709\u5f85\u9032\u4e00\u6b65\u7814\u7a76\u3002\u553e\u6db2\u817a\u5728\u4eba\u985e\u70ba\u65e9\u671f\u5373\u51fa\u73fe\u4e4b\u53cd\u61c9\uff0c\u4f46\u53c8\u6709\u665a\u671f\u53cd\u61c9\u7d44\u7e54\u7684\u7279\u8272\u3002\u672c\u7814\u7a76\u5247\u767c\u73fe\u8ff7\u4f60\u8c6c\u816e\u817a\u672a\u51fa\u73fe\u65e9\u671f\u53cd\u61c9\uff0c\u6b64\u9ede\u767c\u73fe\u8207\u4eba\u985e\u553e\u6db2\u817a\u7d93\u7167\u5c04360-720 cGy\u5f8c\u5373\u660e\u986f\u51fa\u73fe\u553e\u6db2\u5206\u6ccc\u964d\u4f4e\u6709\u986f\u8457\u5dee\u7570\uff0c\u5176\u9020\u6210\u4e4b\u539f\u56e0\u6709\u5f85\u9032\u4e00\u6b65\u7684\u7814\u7a76\u3002\u672c\u7814\u7a76\u4e4b\u7d50\u679c\u5c07\u53ef\u4f5c\u70ba\u5f8c\u7e8c\u52d5\u7269\u5be6\u9a57\u4e4b\u57fa\u790e\uff0c\u6700\u7d42\u5e0c\u671b\u80fd\u7528\u65bc\u6cbb\u7642\u6216\u9810\u9632\u9f3b\u54bd\u764c\u75c5\u4eba\u553e\u6db2\u817a\u50b7\u5bb3\u4e4b\u526f\u4f5c\u7528\u3002", "e": "Purpose : Salivary glands are extremely radiosensitive organs, and are inevitably destroyed during the course of radiotherapy in NPC patients. One of the possible preventive approaches for radiation-induced salivary gland damage is the use of parotid-protecting drugs including pentoxifylline and amifostine. A few other drugs including adrenergic and cholinergic agonists have been tested for their salivary protection effect. The goals for this study are: 1. To establish an animal model using miniature pigs for study of radiation protection of parotid gland. 2. To find out an effective agent for saliva stimulation. 3. To conduct a preliminary study of radiation effect on parotid gland using this animal model.\nMethods & Materials : Lee-Song species of miniature pigs 3-4 months old weighing about 10-15 kg were used.  They were anaesthetized and intubated followed by salivary collection, drug stimulation, irradiation or surgery.  Drugs including cholinergic stimulant carbachol, adrenergic agonists cyclocytidine and norepinephrine were tested for their efficacy in saliva-stimulation. Electric stimulation was also tested. The entire study structure was as follows: 1. For animal model establishment: anaesthesia procedure, optimization of salivary gland stimulation (physical and chemical approach), optimization of saliva collection.  2. For dose-response study of parotid glands: parotid secretion of unirradiated pigs, right parotid irradiation with 1000 cGy x 2, 300 cGy x 15, and 400 cGy x 12 and assayed for parotid function 1 week, 1 month and 4 months after completion of irradiation. \nResults : Carbachol 0.2 mg/kg was most efficient for stimulating salivary secretion in a reproducible way. Yet this drug induced cardiac arrest and cardiac massage was needed sometimes. However, this can be reversed immediately after iv bolus of 1 ml of atropine. For saliva collection, using dry, 2 x 2 inch gauze to suck the secretion proves to be accurate and feasible. One week and 1 month after 1000 cGy x 2 the control versus irradiated parotid secretion is 3.0/2.93 ml/min. The difference between control and irradiated glands was also insignificant 1 week and 1 month after 4500 cGy and 4800 cGy.  However, at 4 months, a marked difference in parotid secretion occurred with the control/irradiated of 2.56/1.08 and 6.83/1.99 ml/min, respectively. At 4 months, the irradiated gland was also markedly atrophic and the weight for control/irradiated parotids in 2 experiments was 127.9/26.9 gm after 4500 cGy and and 125.7/22.1 gm after 4800 cGy, respectively.\nConclusion : Advantages using minipig as the model include the higher similarity with humans than rodents in terms of physiology and anatomy and the much larger salivary secretion volume. The only disadvantage is the higher cost that limits the sample size of the experiment. The animal model we have established is feasible for salivary stimulation and saliva collection that can be reproduced consistently. Carbachol proves to be very efficient for saliva stimulation and cardiac arrest is the only shortcoming. On the contrary, norepinephrine is less efficient for saliva stimulation but is free of the side effect of cardiac arrest. Salivary gland damage appears acutely in humans and persists for many years after completion of radiotherapy. In contrast to humans, minipig parotid gland did not show an evaluable early effect up to 1 month after radiotherapy. The nature of this discrepancy is interesting and requires further exploration. The result of this study may be used for future experiments aiming at prevention of radiation damage to the parotid glands."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-197-208-a", "title": "\u809d\u764c\u60a3\u8005\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u671f\u9593\u75b2\u5026\u53ca\u8840\u6db2\u6578\u503c\u8b8a\u5316\u4e4b\u63a2\u8a0e", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642;\u75b2\u5026;\u8840\u6db2\u6578\u503c Stereotactic radiotherapy;Fatigue;Laboratory data", "c": "\u76ee\u7684\uff1a\u5728\u53f0\u7063\uff0c\u809d\u764c\u662f\u5e38\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u8fd1\u5e74\u4f86\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u6cbb\u7642\u809d\u764c\u7684\u65b0\u65b9\u5f0f\u4e4b\u4e00\u3002\u5c0d\u65bc\u6cbb\u7642\u671f\u9593\u75c5\u60a3\u6240\u51fa\u73fe\u7684\u75b2\u5026\u554f\u984c\uff0c\u76ee\u524d\u5c1a\u672a\u6709\u7814\u7a76\u63a2\u8a0e\uff0c\u56e0\u6b64\u672c\u7814\u7a76\u4e3b\u8981\u63a2\u8a0e\u809d\u764c\u60a3\u8005\u5728\u63a5\u53d7\u809d\u81df\u816b\u7624\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u671f\u9593\u6240\u7522\u751f\u7684\u75b2\u5026\u7a0b\u5ea6\u53ca\u8840\u6db2\u6578\u503c\u4e4b\u8b8a\u5316\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u63a1\u524d\u77bb\u6027\u7e31\u8cab\u5f0f\u7814\u7a76\u8a2d\u8a08\uff0c\u65bc\u5317\u5e02\u4e8c\u6240\u6559\u5b78\u91ab\u9662\u53d6\u6a23\u6536\u6848\uff0c\u6536\u6848\u6642\u9593\u81ea\u6c11\u570b90\u5e7412\u6708\u81f391\u5e745\u6708\u9593\uff0c\u5171\u6536\u96c645\u4f4d\u7b26\u5408\u689d\u4ef6\u4e4b\u809d\u764c\u60a3\u8005\u70ba\u6536\u6848\u5c0d\u8c61\uff0c\u5176\u4e2d5\u4f4d\u60a3\u8005\u5206\u5225\u56e0\u6b7b\u4ea1\u6216\u4e2d\u9014\u9000\u51fa\u800c\u4e2d\u6b62\u8a2a\u8ac7\uff0c\u6545\u5b8c\u6210\u9023\u7e8c\u4e03\u9031\u7814\u7a76\u8005\u5171\u8a0840\u540d\uff1b\u6bcf\u9031\u4ee5\u75b2\u5026\u75c7\u72c0\u91cf\u8868\u9032\u884c\u75b2\u5026\u5f37\u5ea6\u3001\u6301\u7e8c\u6642\u9593\u53ca\u5c0d\u751f\u6d3b\u5e72\u64fe\u7a0b\u5ea6\u4e4b\u6e2c\u91cf\u3002\u8840\u6db2\u6578\u503c\u65b9\u9762\u6bcf\u9031\u9032\u884cHb\u3001Ht\u3001WBC\u53caPlatelet\u4e4b\u6aa2\u9a57\uff0c\u5171\u8a08\u4e03\u6b21\uff1b\u6b64\u5916\u5206\u5225\u65bc\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u524d\u4e00\u9031\u3001\u653e\u5c04\u6cbb\u7642\u4e2d\u7b2c\u4e8c\u3001\u56db\u53ca\u7b2c\u516d\u9031\u4f86\u8ffd\u8e64AST\u3001ALT\u53caAlbumin\u4e4b\u8b8a\u5316\u3002\u7d71\u8a08\u65b9\u6cd5\u4ee5SPSS\u5957\u88dd\u8edf\u9ad4\u9032\u884c\u8cc7\u6599\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u6240\u6709\u7814\u7a76\u5c0d\u8c61\u65bc\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u524d\u5373\u5b58\u5728\u75b2\u5026\u73fe\u8c61\uff0c\u9664\u7b2c\u4e09\u9031\u7565\u70ba\u6539\u5584\u5916\uff0c\u75b2\u5026\u7a0b\u5ea6\u65bc\u7b2c\u4e94\u9031\u9054\u9ad8\u5cf0\uff0c\u7b2c\u516d\u9031\u4fbf\u6539\u5584\uff08p\uff1c0.01\uff09\uff0c\u4f46\u6574\u500b\u6cbb\u7642\u671f\u9593\u75b2\u5026\u7a0b\u5ea6\u4ecd\u5c6c\u8f15\u5ea6\u7bc4\u570d\u3002\u7814\u7a76\u5c0d\u8c61\u65bc\u6cbb\u7642\u524d\u4e00\u9031\u7684\u8840\u6db2\u5b78\u6578\u503c\u9664Ht\u504f\u4f4e\u5916\uff0c\u5176\u4ed6\u6578\u503c\u7686\u5728\u6b63\u5e38\u7bc4\u570d\u5167\uff0c\u4f46\u7d93\u653e\u5c04\u6cbb\u7642\u5f8c\uff0cHb\u3001Ht\u3001WBC\u3001platelet\u96a8\u653e\u5c04\u6cbb\u7642\u800c\u9010\u6f38\u4e0b\u964d\uff08p\uff1c0.05\uff09\uff0c\u4e14\u7686\u4f4e\u65bc\u6b63\u5e38\u503c\u3002\u6b64\u5916\uff0c\u6cbb\u7642\u524d\u60a3\u8005\u4e4bAST\u3001ALT\u6578\u503c\u7686\u9ad8\uff0c\u4e14\u96a8\u6cbb\u7642\u7642\u7a0b\u800c\u6301\u7e8c\u5347\u9ad8\uff0c\u65bc\u7b2c\u516d\u9031\u9054\u9ad8\u5cf0\uff1bAlbumin\u6578\u503c\u5247\u96a8\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u800c\u9010\u6f38\u4e0b\u964d\uff08p\uff1c0.01\uff09\uff0c\u4f46\u6cbb\u7642\u524d\u5f8c\u5747\u8655\u65bc\u6b63\u5e38\u7bc4\u570d\u5167\u3002\u800c\u75b2\u5026\u7a0b\u5ea6\u7684\u9ad8\u4f4e\u8207\u8840\u6db2\u6578\u503c \uff08WBC\u3001Platelet\u3001AST\u3001ALT\u53caAlbumin\uff09\u4e4b\u9593\u4e26\u7121\u986f\u8457\u76f8\u95dc\uff08p\uff1e0.05\uff09\u3002\n\u7d50\u8ad6\uff1a\u96d6\u7136\u75b2\u5026\u662f\u809d\u764c\u60a3\u8005\u65bc\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u7dda\u6cbb\u7642\u671f\u9593\u5e38\u898b\u7684\u554f\u984c\uff0c\u4f46\u6240\u5448\u73fe\u7684\u7a0b\u5ea6\u5c6c\u8f15\u5ea6\u7bc4\u570d\uff0c\u800c\u8840\u6db2\u4e2d\u4ee3\u8868\u809d\u529f\u80fd\u4e4b\u751f\u5316\u6578\u503c\u6703\u96a8\u6cbb\u7642\u7642\u7a0b\u90e8\u5206\u6709\u6539\u8b8a\u3002\u672c\u7814\u7a76\u7d50\u679c\u53ef\u63d0\u4f9b\u81e8\u5e8a\u91ab\u7642\u4eba\u54e1\u5728\u7167\u8b77\u6b64\u985e\u75c5\u60a3\u6642\u6709\u66f4\u591a\u7684\u53c3\u8003\u8a0a\u606f\uff0c\u9069\u6642\u63d0\u4f9b\u76f8\u95dc\u91ab\u8b77\u8655\u7f6e\uff0c\u4ee5\u5354\u52a9\u75c5\u60a3\u6e21\u904e\u4e0d\u9069\u7684\u968e\u6bb5\u3002", "e": "Purpose : Hepatocellular carcinoma is a common malignancy in Taiwan.  Recently, stereotactic radiotherapy is one of the new treatment modality for this disease.  However, there still do not have study focused on the changes of fatigue level in patients receiving this treatment.  The purpose of this study was to evaluate the changes of fatigue and hematology index in hepatocellular cancer patients receiving stereotactic radiotherapy. \nMaterials and methods : Prospective longitudinal research design was developed to examine the changes of fatigue and hematology index during and after stereotactic radiotherapy.  Data were collected from December 2001 to May 2002.  A total of 45 eligible subjects were recruited from two teaching hospitals in Taipei. Five patients were excluded due to expire or dropout from this study.  Forty eligible patients finished the seven weeks study.  Fatigues index were evaluated by questionnaire of Fatigue Symptom Inventory (FSI) which measured the fatigue intensity, fatigue duration and fatigue interference weekly. Hb, Ht, WBC and Platelet were measured weekly for 7 weeks.  Besides, AST, ALT and albumin blood index were measured one week before radiation therapy and at week 2, week 4 and week 6 during treatment. Data were analyzed by SPSS computer program. \nResults : All the subjects in this study had mild fatigue in the beginning of the treatment.  Their fatigue intensity, fatigue duration and fatigue interference were significantly increased from pre-treatment to the 5th week except the 3rd week. The peak level of fatigue occurred in the 5th week and it decreased since the 6th week (p \uff1c 0.01).  Blood Hb, Ht, WBC and platelet level descended gradually to abnormal along with treatment (p \uff1c 0.05), but the blood AST and ALT level rise along with the treatment.  Though the blood albumin level decreased, it was in normal range. Nonsignificant correlations between fatigue level and laboratory data were found.\nConclusion : Fatigue was a commonly experienced problem in hepatocellular cancer patients receiving stereotactic radiotherapy, but the fatigue scores were at minimal level.  Part of the hematology study data change during treatment.  The results of this study can provide the clinical personnel information about the change of fatigue level in hepatocellular cancer patients receiving stereotactic radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-209-218-a", "title": "Preliminary Results of Three-Dimensional Conformal Radiotherapy and Thalidomide for Advanced Hepatocellular Carcinoma", "keywords": "\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u809d\u764c Conformal radiotherapy;Hepatocellular carcinoma;Thalidomide", "c": "\u80cc\u666f\uff1a\u672c\u6587\u76ee\u7684\u6b32\u4ee5\u8a55\u4f30\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u53cathalidomide\u5c0d\u665a\u671f\u809d\u764c\u4e4b\u53cd\u61c9\u8207\u6cbb\u7642\u6210\u6548\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1999\u5e7410\u6708\u81f32002\u5e749\u6708\uff0c33\u4f4d\u665a\u671f\u809d\u764c\u75c5\u60a3\u65bd\u884c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u53cathalidomide\u6cbb\u7642\u3002\u75c5\u60a3\u5e73\u5747\u5e74\u9f61\u70ba61.36\u6b72\uff0836\u81f380\u6b72\uff09\u3002\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5229\u75286\u6216 10\u767e\u842c\u4f0f\u7279\u5149\u5b50\u5c04\u7dda\uff0c\u4ee5\u6bcf\u90315\u5929\uff0c\u6bcf\u59292\u6b21\uff0c\u6bcf\u6b211.5 Gy\u4e4b\u65b9\u5f0f\u65bd\u884c\uff0c\u7e3d\u5291\u91cf\u70ba45\u81f375 Gy\u3002\u5e73\u5747\u6cbb\u7642\u9ad4\u7a4d369.59\u6beb\u5347\uff0832.54\u81f32094.82\u6beb\u5347\uff09\u3002Thalidomide\u7684\u6cbb\u7642\u5291\u91cf\uff1a\u6bcf\u5929200 \u6beb\u514b\uff0c25\u4eba\uff1b300\u6beb\u514b\uff0c5\u4eba\uff1b 400\u6beb\u514b\uff0c3\u4eba\u3002\n\u7d50\u679c\uff1a\u670964%\u75c5\u60a3\uff0821/33\uff1b1\u5b8c\u5168\u53cd\u61c9\uff0c20\u90e8\u5206\u53cd\u61c9\uff09\u5c0d\u653e\u5c04\u6cbb\u7642\u7bc4\u570d\u5167\u6709\u53cd\u61c9\uff0c\u670912.1%\u75c5\u60a3\uff084/33\uff1b4\u90e8\u5206\u53cd\u61c9\uff09\u5c0d\u975e\u653e\u5c04\u6cbb\u7642\u75c5\u7076\u6709\u53cd\u61c9\u3002\u5982\u679c\u5c07\u6cbb\u7642\u7642\u6548\u4ee5\u4e0d\u540c\u816b\u7624\u578b\u614b\u5340\u5206\uff0c\u5fa9\u767c\u6027\u816b\u7624\u3001\u5de8\u5927\u816b\u7624\u3001\u809d\u764c\u5408\u4f75\u8f49\u79fb\u75c5\u7076\u53ca\u591a\u767c\u6027\u75c5\u7076\u5c0d\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7bc4\u570d\u5167\u7684\u53cd\u61c9\u5206\u5225\u70ba80.0%\uff088/10\uff1b1\u5b8c\u5168\u53cd\u61c9\uff0c7\u90e8\u5206\u53cd\u61c9\uff09\u300171.4%\uff085/7\uff1b5\u90e8\u5206\u53cd\u61c9\uff09\u300161.5%\uff088/13\uff1b8\u90e8\u5206\u53cd\u61c9\uff09\u548c0%\uff080/3\uff1b2\u75c5\u60c5\u7a69\u5b9a\u30011\u75c5\u60c5\u9032\u5c55\uff09\uff08p = 0.234\uff09\u3002\u5fa9\u767c\u6027\u816b\u7624\u3001\u5de8\u5927\u816b\u7624\u3001\u809d\u764c\u5408\u4f75\u8f49\u79fb\u75c5\u7076\u53ca\u591a\u767c\u6027\u75c5\u7076\u5c0d\u975e\u653e\u5c04\u6cbb\u7642\u75c5\u7076\u7684\u53cd\u61c9\u5206\u5225\u70ba10.0%\uff081/10\uff1b1\u90e8\u5206\u53cd\u61c9\uff09\u300114.3%\uff081/7\uff1b1\u90e8\u5206\u53cd\u61c9\uff09\u300115.4%\uff082/13\uff1b2\u90e8\u5206\u53cd\u61c9\uff09\u548c0%\uff080/3\uff1b\u6240\u6709\u5747\u70ba\u75c5\u60c5\u9032\u5c55\uff09\uff08p = 0.778\uff09\u3002\u5e73\u5747\u53ca\u4e2d\u4f4d\u5b58\u6d3b\u65e5\u6578\u5206\u5225\u70ba327\u53ca242\u5929\u3002\u6cbb\u7642\u5f8c\u526f\u4f5c\u7528\uff0c\u5305\u62ec\uff1a\u4fbf\u79d8\uff0826/33\uff0c78.8%\uff09\u3001\u56f0\u5026\u53ca\u55dc\u7761\uff0815/33\uff0c45.5%\uff09\u3001\u76ae\u75b9\uff0811/33\uff0c33.3%\uff09\u3001\u4e0b\u80a2\u6c34\u816b\uff0820/33\uff0c60.6%\uff09\u3001\u5468\u908a\u795e\u7d93\u75c5\u8b8a\uff082/33\uff0c6.1%\uff09\u3001\u7729\u6688\uff081/33\uff0c3.0%\uff09\u8d77\u7acb\u6027\u4f4e\u8840\u58d3\uff081/33\uff0c3.0%\uff09\u3001\u767d\u8840\u7403\u964d\u4f4e\uff085/33\uff0c15.2%\uff09\u3001\u66ab\u6642\u6027\u809d\u529f\u80fd\u969c\u7919\uff089/33\uff0c27.3%\uff09\u548c\u4e0a\u8179\u75db\uff088/33\uff0c24.2%\uff09\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u7d93\u9a57\u6307\u51fa\u5c0d\u816b\u7624\u7121\u6cd5\u5207\u9664\u4e4b\u809d\u764c\u75c5\u60a3\uff0c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5408\u4f75thalidomide\u6cbb\u7642\u662f\u5b89\u5168\u6709\u6548\u4e4b\u6cbb\u7642\u6a21\u5f0f\u3002\u521d\u6b65\u8cc7\u6599\u986f\u793a\u7814\u7a76\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5408\u4f75thalidomide\u6cbb\u7642\u5728\u4e0d\u540c\u671f\u5225\u4e4b\u809d\u764c\u7684\u6cbb\u7642\u7b56\u7565\u6240\u626e\u6f14\u7684\u89d2\u8272\u662f\u6975\u5177\u50f9\u503c\u4e14\u6709\u6210\u529f\u7684\u5e0c\u671b\u3002", "e": "Purpose : The purpose of this study was to evaluate the response and therapeutic results of advanced hepatocellular carcinoma (HCC) treated with three-dimensional conformal radiotherapy (3D-CRT) and thalidomide.   \nMaterials and Methods : From October 1999 to September 2002, thirty-three advanced HCC patients who had been treated with 3D-CRT and thalidomide were reviewed. The mean age was 61.36 years old (range:  36-80 years old). Three-dimensional CRT was delivered at 1.5 Gy per fraction using 6 or 10 MV photons, twice a day and 5 days a week for a total dose of 45- 75 Gy. The mean treatment volume was 369.59 ml (range:  32.54-2094.82 ml). The dosage of thalidomide was 200 mg/day in 25 patients, 300 mg/day in 5 patients, and 400 mg/day in 3 patients.\nResults : Sixty-four percent [21/33; 1 complete response (CR), 20 partial response (PR)] of patients responded in \u6defT field?and 12.1% (4/33; 4 PR) of patients responded in  \u70cbon-irradiated lesion? When therapeutic outcome was determined by the different tumor patterns, the responses of \u6defT field?for the recurrent tumor, huge mass, HCC with metastatic lesions and multiple lesions were 80.0% (8/10; 1 CR, 7 PR), 71.4% (5/7; 5 PR), 61.5% (8/13; 8 PR), and 0% (0/3; 2 SD and 1 PD), respectively (p = 0.234). Furthermore, the responses of \u70cbon-irradiated lesion?for the recurrent tumor, huge mass, HCC with metastatic lesions and multiple lesions were 10.0% (1/10; 1 PR), 14.3% (1/7; 1 PR), 15.4% (2/13; 2 PR), and 0% (0/3; all 3 PD), respectively (p = 0.778). The mean and median survival times were 327 and 242 days, respectively. The adverse effects of 3D-CRT and thalidomide include constipation (26/33, 78.8%), drowsiness and sedation (15/33, 45.5%), skin rash (11/33, 33.3%), lower extremity edema (20/33, 60.6%), peripheral neuropathy (2/33, 6.1%), dizziness (1/33, 3.0%), orthostatic hypotension (1/33, 3.0%), leukopenia (5/33, 15.2%), transient elevation in liver function tests (9/33, 27.3%), and epigastralgia (8/33, 24.2%).\nConclusions : Our experience concluded that 3D-CRT combined with thalidomide might be a safe and effective treatment modality for unresectable HCC patients. The preliminary data showed quite promising result. It is valuable to study the potential role of 3D-CRT combined with thalidomide in the treatment strategy for HCC at various stages."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-219-228-a", "title": "\u5c0f\u65bc\u56db\u5341\u6b72\u7684\u820c\u764c\u60a3\u8005\u4e4b\u6cbb\u7642\u7d50\u679c", "keywords": "\u820c\u764c;\u5e74\u8f15;\u653e\u5c04\u6cbb\u7642 Tongue cancer;Young age;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u672c\u9662\u904e\u53bb\u5c0d\u65bc\u5e74\u9f61\u5c0f\u65bc40\u6b72\u7684\u820c\u764c\u60a3\u8005\u5176\u6cbb\u7642\u7d50\u679c\u3002\n\u65b9\u6cd5\u548c\u6750\u6599\uff1a\u81ea1990\u5e74\u4e00\u6708\u81f31999\u5e749\u6708\u671f\u9593\uff0c\u5171\u670935\u540d\u5e74\u9f61\u5c0f\u65bc40\u6b72\u7684\u820c\u764c\u75c5\u60a3\u5728\u6797\u53e3\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u6240\u6709\u5b58\u6d3b\u7684\u75c5\u4eba\u90fd\u81f3\u5c11\u8ffd\u8e643\u5e74\u4ee5\u4e0a\uff0c\u800c\u6240\u6709\u75c5\u4eba\u5e73\u5747\u7684\u8ffd\u8e64\u6642\u9593\u70ba1.35\u5e74\u3002\n\u6240\u6709\u7684\u75c5\u4eba\u90fd\u63a5\u53d7\u4e86\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\uff08\u81f3\u5c1160 Gy\uff09\uff0c\u5176\u4e2d28\u4f4d\u662f\u5c6c\u65bc\u624b\u8853\u5f8c\u8ffd\u52a0\u6cbb\u7642\u3002\u5176\u4e2d\u6709\u516d\u4f4d\u75c5\u4eba\u56e0\u62d2\u7d55\u958b\u5200\u6216\u662f\u56e0\u6545\u4e0d\u80fd\u958b\u5200\uff0c\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u4e00\u4f4d\u5247\u662f\u5728\u653e\u5c04\u6cbb\u7642\u5f8c\u5fa9\u767c\uff0c\u518d\u5ea6\u63a5\u53d7\u958b\u5200\u6cbb\u7642\u3002\u6cbb\u7642\u7684\u7d50\u679c\u7528\u4e0b\u5217\u56e0\u5b50\u5206\u6790: \u6cbb\u7642\u524d\u7684\u7fd2\u6027\uff0c\u816b\u7624\u5206\u671f\uff0c\u4ee5\u53ca\u6cbb\u7642\u65b9\u5f0f\u7b49\u3002\n\u7d50\u679c\uff1a\u5168\u90e8\u75c5\u4eba\u7684\u4e09\u5e74\u7684\u7e3d\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba42.8%\u53ca48.2%\u3002\u5728\u6392\u9664\u6c92\u6709\u4ee5\u958b\u5200\u70ba\u7b2c\u4e00\u6cbb\u7642\u7684\u75c5\u4eba\u5f8c\uff0c\u4e09\u5e74\u7684\u7e3d\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba50%\u53ca57.6%\u3002\u6240\u6709\u75c5\u4eba\u53ca\u5148\u4ee5\u5916\u79d1\u958b\u5200\u6cbb\u7642\u4e4b\u75c5\u4eba\u5169\u8005\u7684\u5b58\u6d3b\u6642\u9593\u4e2d\u4f4d\u6578\u5404\u70ba1.42\u53ca3.26\u5e74\u3002\u4e03\u4f8b\u672a\u5c07\u5916\u79d1\u958b\u5200\u5217\u70ba\u9996\u9078\u6cbb\u7642\u8005\uff0c\u6709\u516d\u4f8b\u672a\u80fd\u9054\u5230\u6210\u529f\u7684\u5c40\u90e8\u63a7\u5236\uff0c\u800c\u4e14\u90fd\u572816\u500b\u6708\u5167\u6b7b\u4ea1\u3002\u53e6\u4e00\u4f8b\u5728\u63a5\u53d7\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u53ca\u540c\u6b65\u653e\u5c04\u53ca\u5316\u5b78\u6cbb\u7642\u5f8c\u5f97\u5230\u5b8c\u5168\u7de9\u89e3\uff0c\u4f463.7\u5e74\u5f8c\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u3002\u55ae\u8b8a\u6578\u5206\u6790\u986f\u793a\u4ee5\u958b\u5200\u70ba\u7b2c\u4e00\u6cbb\u7642\uff0c\u816b\u7624\u5206\u671f\u665a\u671f\uff08\u7b2c\u4e09\u6216\u7b2c\u56db\u671f\uff09\uff0c\u4ee5\u53ca\u75c5\u7406\u7d44\u7e54\u578b\u614b\u6703\u5f71\u97ff\u75c5\u4eba\u7684\u9810\u5f8c\u3002\u4f46\u662f\u591a\u8b8a\u6578\u5206\u6790\u50c5\u6709\u5206\u5316\u4e0d\u826f\u7684\u7d44\u7e54\u578b\u614b\u6709\u986f\u8457\u610f\u7fa9\u3002\n\u7d50\u8ad6\uff1a\u548c\u6587\u737b\u4e0a\u4e00\u822c\u75c5\u4eba\u65cf\u7fa4\u7684\u6cbb\u7642\u7d50\u679c\u6bd4\u8f03\u5f8c\uff0c\u6211\u5011\u7684\u6cbb\u7642\u7d50\u679c\u4e26\u6c92\u6709\u986f\u8457\u7684\u5dee\u7570\u3002\u53e6\u5916\uff0c\u624b\u8853\u61c9\u662f\u5c0f\u65bc\u56db\u5341\u6b72\u820c\u764c\u60a3\u8005\u7684\u7b2c\u4e00\u512a\u5148\u6cbb\u7642\u9078\u64c7\u3002", "e": "Purpose : To evaluate treatment outcomes in patients under 40 years of age with cancer of the mobile tongue.\nMethod and Materials : Between January 1990 and September 1999, 35 patients under 40 years of age suffering from mobile tongue cancers were treated at the LinKou Chang-Gung Memorial Hospital (LK-CGMH). External beam radiotherapy was used as either adjuvant management after surgery or primary treatment. All patients were followed for at least three years or until death. Median follow-up was 1.35 years.\nExternal radiotherapy of at least 60 Gy was administered to all patients. Twenty-eight patients received adjuvant radiotherapy. Six people who refused or were unsuitable for surgery were treated with radiotherapy only. One patient underwent radiotherapy as primary therapy but required surgical salvage after recurrence. The treatment results were analyzed, as were pre-treatment habits, tumor staging, and treatment modalities.\nResults : The three-year overall survival and disease-specific survival rates for the group were 42.8%, and 48.2%, respectively. After excluding patients who chose not to undergo surgery as primary treatment, the rates were 50% and 57.6%. The median survival of all patients and patients who received primary surgery was 1.42 and 3.26 years, respectively. In all patients who did not undergo surgery as primary treatment, tongue tumor control was not achieved, and all died within 16 months, except for one who experienced complete remission after induction chemotherapy and concurrent chemo-radiation. Univariate analysis indicated that primary surgery, 1997 AJCC staging group III or IV and histological differentiation significantly affected overall survival. Multivariate analysis found that poor histological differentiation was the only significant factor affecting overall survival.\nConclusions : These findings concur with those of other series for the age group studied. Surgery continues to be the first-line, primary treatment for patients under 40 years of age with cancer of the mobile tongue."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-229-236-a", "title": "Concurrent Chemoradiation with Weekly Cisplatin plus Systemic Adjuvant Chemotherapy for Locally Advanced Esophageal Cancer: A Pilot Study", "keywords": "\u98df\u9053\u764c;\u540c\u6b65\u5316\u5b78\u653e\u5c04\u7dda\u6cbb\u7642;\u6bcf\u9031cisplatin;\u8f14\u52a9\u5316\u5b78\u6cbb\u7642 Esophageal cancer;Chemoradiation;Weekly cisplatin;Adjuvant chemotherapy", "c": "Purpose : Carcinoma of the esophagus is a virulent malignancy often diagnosed in its late stage. Despite aggressive surgical resection, the overall 5-year survival reported is poor. Several researchers have investigated the use of concurrent chemoradiotherapy (CCRT) in the management of esophageal cancer and demonstrated a significant survival improvement. We conducted a pilot study to evaluate the efficacy and toxicity of an outpatient CCRT regimen using weekly cisplatin as a radiosensitizer. \nMaterials and Methods : We retrospectively reviewed the charts of patients with esophageal carcinoma treated at our institution from July 1999 to February 2003. Patients were included in the study if they had T3 to T4, N0, and M0 stage disease. There were sixteen patients enrolled into definite concurrent chemoradiotherapy (CCRT) with systemic adjuvant chemotherapy group whereas eleven patients into radiation alone (RT) group. RT for both groups was delivered with total dose of 60 Gy. In addition to RT, the CCRT group received concurrent chemotherapy consisting of 6 weekly doses of CDDP (30 mg/m2). CCRT was followed by adjuvant chemotherapy consisting of 4 monthly cycles of CDDP (20 mg/m2/day) plus 5-FU (1000 mg/m2/day) for 5 consecutive days. This study looked at survival, treatment response, toxicity and pattern of failure in enrolled patients.\nResults : A total of 27 patients fulfilled the study criteria. The most frequent symptom, present in over 90%, was progressive dysphagia. During therapy, 88% (14/16) of patients on CCRT and 81% (9/11) receiving RT had symptom relief. There are significant differences between the two groups (CCRT vs. RT) in terms of median survival (15 months vs. 5 months), 2-year survival (57% vs. 18%, p = 0.003) and local regional failure rate (43% vs. 100%, p = 0.003). Both the hematological and non-hematological toxicities developed in the two groups are generally comparable and acceptable. \nConclusion : In this preliminary study, we have demonstrated that a weekly outpatient CCRT regimen using low-dose cisplatin, followed by 4 cycles of adjuvant chemotherapy with cisplatin and 5-FU, improves survival and locoregional control of locally advanced esophageal cancer with acceptable toxicity. Large-scale, prospective randomized trials of this regimen are warranted.", "e": "Purpose : Carcinoma of the esophagus is a virulent malignancy often diagnosed in its late stage. Despite aggressive surgical resection, the overall 5-year survival reported is poor. Several researchers have investigated the use of concurrent chemoradiotherapy (CCRT) in the management of esophageal cancer and demonstrated a significant survival improvement. We conducted a pilot study to evaluate the efficacy and toxicity of an outpatient CCRT regimen using weekly cisplatin as a radiosensitizer. \nMaterials and Methods : We retrospectively reviewed the charts of patients with esophageal carcinoma treated at our institution from July 1999 to February 2003. Patients were included in the study if they had T3 to T4, N0, and M0 stage disease. There were sixteen patients enrolled into definite concurrent chemoradiotherapy (CCRT) with systemic adjuvant chemotherapy group whereas eleven patients into radiation alone (RT) group. RT for both groups was delivered with total dose of 60 Gy. In addition to RT, the CCRT group received concurrent chemotherapy consisting of 6 weekly doses of CDDP (30 mg/m2). CCRT was followed by adjuvant chemotherapy consisting of 4 monthly cycles of CDDP (20 mg/m2/day) plus 5-FU (1000 mg/m2/day) for 5 consecutive days. This study looked at survival, treatment response, toxicity and pattern of failure in enrolled patients.\nResults : A total of 27 patients fulfilled the study criteria. The most frequent symptom, present in over 90%, was progressive dysphagia. During therapy, 88% (14/16) of patients on CCRT and 81% (9/11) receiving RT had symptom relief. There are significant differences between the two groups (CCRT vs. RT) in terms of median survival (15 months vs. 5 months), 2-year survival (57% vs. 18%, p = 0.003) and local regional failure rate (43% vs. 100%, p = 0.003). Both the hematological and non-hematological toxicities developed in the two groups are generally comparable and acceptable. \nConclusion : In this preliminary study, we have demonstrated that a weekly outpatient CCRT regimen using low-dose cisplatin, followed by 4 cycles of adjuvant chemotherapy with cisplatin and 5-FU, improves survival and locoregional control of locally advanced esophageal cancer with acceptable toxicity. Large-scale, prospective randomized trials of this regimen are warranted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-237-246-a", "title": "Is Melanin a Radioprotector or Radiosensitizer? It", "keywords": "\u9ed1\u8272\u7d20;\u8f3b\u5c04\u4fdd\u8b77\u5291;\u8f3b\u5c04\u81f4\u654f\u5291;\u653e\u5c04\u6cbb\u7642;\u60e1\u6027\u9ed1\u8272\u7d20\u7624 Eumelanin;Pheomelanin;Radioprotector;Radiosensitizer;Radiotherapy;Malignant melanoma", "c": "\u9ed1\u8272\u7d20\u5c0d\u65bc\u4eba\u985e\u76ae\u819a\u7d30\u80de\u662f\u5149\u7167\u4fdd\u8b77\u5291\uff08Photoprotector\uff09\u6216\u5149\u7167\u81f4\u654f\u5291\uff08Photosensitizer\uff09\uff0c\u9577\u4e45\u4ee5\u4f86\u4ecd\u5b58\u6709\u8a31\u591a\u722d\u8b70\u3002\u6d41\u884c\u75c5\u5b78\u7684\u7814\u7a76\u986f\u793a\uff1a\u6df1\u819a\u8272\u4eba\u7a2e\u8207\u767d\u7a2e\u4eba\u76f8\u8f03\uff0c\u56e0\u7d2b\u5916\u7dda\u5f15\u767c\u76ae\u819a\u640d\u50b7\uff0c\u5305\u62ec\u9ed1\u8272\u7d20\u7624\u6216\u5176\u4ed6\u76ae\u819a\u816b\u7624\u7684\u6a5f\u6703\u8f03\u5c11\u3002\u7136\u800c\uff0c\u904e\u53bb\u7684\u7814\u7a76\u4e5f\u767c\u73fe\uff1a\u9ed1\u8272\u7d20\u53ca\u5176\u4e2d\u9593\u7522\u7269\u8207\u524d\u9a45\u7269\u5728\u63a5\u53d7\u7d2b\u5916\u7dda\u7167\u5c04\u5f8c\u6703\u7522\u751f\u53cd\u61c9\u6027\u6c27\u5316\u7269\u8cea\uff08reactive-oxygen species\uff09\uff0c\u56e0\u6b64\u986f\u793a\u9ed1\u8272\u7d20\u4e5f\u662f\u6709\u6548\u7684\u5149\u7167\u81f4\u654f\u5291\u3002\n\u3000\u3000\u7d93\u904e\u5341\u5e74\u4f86\u4e0d\u65b7\u5275\u65b0\u8207\u524d\u6240\u672a\u6709\u7684\u7814\u7a76\uff0c\u4f7f\u6211\u5011\u66f4\u52a0\u64f4\u5c55\u5c0d\u9ed1\u8272\u7d20\u7684\u8a8d\u77e5\u8207\u77ad\u89e3\u3002\u9ed1\u8272\u7d20\u662f\u7531\u9165\u80fa\u9178\uff08tyrosine\uff09\u6c27\u5316\u6240\u5f62\u6210\u4e4b\u55ae\u5143\u9ad4\u6240\u5efa\u69cb\u4e4b\u9ad8\u5ea6\u4e0d\u898f\u5247\u7570\u5316\u4e4b\u805a\u5408\u7269\uff0c\u5176\u5305\u542b\u5169\u7a2e\u69cb\u578b\uff1aeumelanin\u53capheomelanin\u3002\u76ee\u524d\u8b49\u5be6\uff1aeumelanin \u662f\u5177\u6709\u5149\u7167\u4fdd\u8b77\u6548\u679c\u7684\u8272\u7d20\uff0c\u800c pheomelanin\u5728\u7d2b\u5916\u7dda\u7167\u5c04\u5f8c\u6703\u7522\u751f\u7d30\u80de\u6bd2\u6027\u3002\n\u3000\u3000\u9ed1\u8272\u7d20\u8207\u6e38\u96e2\u8f3b\u5c04\u4e5f\u5b58\u5728\u6709\u985e\u4f3c\u7684\u6548\u61c9\uff1aeumelanin \u4e0d\u50c5\u6709\u5149\u7167\u4fdd\u8b77\u6548\u679c\uff0c\u540c\u6642\u4e5f\u6709\u8f3b\u5c04\u4fdd\u8b77\u6548\u679c\uff0c\u9019\u8207\u81e8\u5e8a\u4e0a\u6240\u89c0\u5bdf\u5230\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u7d30\u80de\u4e4b\u8f3b\u5c04\u62b5\u6297\u6027\u7684\u73fe\u8c61\u76f8\u7b26\u5408\u3002\u56e0\u6b64\u82e5\u80fd\u963b\u65b7 eumelanin \u8272\u7d20\u7684\u5408\u6210\u904e\u7a0b\uff0c\u5c0d\u65bc\u589e\u9032\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u7684\u653e\u5c04\u6cbb\u7642\u6548\u679c\u7576\u6709\u6f5b\u5728\u7684\u610f\u7fa9\u3002", "e": "It continues to be debated whether melanins are photoprotecting or photosensitizing in human skin cells. Epidemiologic studies have demonstrated that dark-skinned people are much less susceptible than Caucasians to ultraviolet (UV)-induced skin damage including both non-melanoma and melanoma skin cancer. On the other hand, melanin, its intermediates and precursors can generate reactive-oxygen species when irradiated with UV irradiation and have been shown to be effective photosensitizers. \nThe last decade has witnessed a renewed and unprecedented impetus in melanin research that has significantly expanded our knowledge of this field. Melanin is a highly irregular heteropolymer consisting of monomeric units derived from the enzymatic oxidation of the amino acid tyrosine. There are two distinct types of melanin, eumelanin and pheomelanin. Now, it is proved that eumelanins are the main photoprotective pigment in the epidermis and pheomelanins are phototoxic upon irradiation. \nThe same situation is also true for ionizing radiation that eumelanin not only possesses radiation protective effect but also contains photoprotective ability. Since malignant melanoma is resistant to radiation therapy, therapeutic strategies targeted to the melanogenesis of eumelanin may have potential benefit for the radiation therapy of malignant melanoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-247-255-a", "title": "\u5728\u4e0d\u540c\u6df1\u5ea6\u4e0b\u91cf\u6e2c\u96fb\u5b50\u5c04\u675f\u4e4b\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2\u4ee5\u904b\u7528\u65bc\u81e8\u5e8a", "keywords": "\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2;\u5c04\u675f\u4e2d\u8ef8\u5291\u91cf Effective SSD;Central beam axis dose", "c": "\u76ee\u7684\uff1a\u96fb\u5b50\u5c04\u675f\u662f\u6cbb\u7642\u8868\u6dfa\u816b\u7624\u6700\u6709\u5229\u7684\u6b66\u5668\uff0c\u56e0\u70ba\u96fb\u5b50\u5c04\u675f\u53ef\u4ee5\u4f9d\u816b\u7624\u75c5\u7076\u6df1\u5ea6\u4f86\u9078\u64c7\u9069\u5408\u7684\u80fd\u91cf\uff0c\u800c\u66f4\u6df1\u5c64\u7684\u6b63\u5e38\u7d44\u7e54\u6240\u63a5\u53d7\u5230\u7684\u5291\u91cf\uff0c\u5247\u9060\u6bd4\u5149\u5b50\u6cbb\u7642\u65b9\u5f0f\u6240\u63a5\u53d7\u5291\u91cf\u5c11\u4e86\u5f88\u591a\u3002\u96fb\u5b50\u5c04\u675f\u4e5f\u88ab\u7528\u5728\u5168\u8eab\u9aa8\u9ad3\u79fb\u690d\u75c5\u4eba\u80f8\u58c1\u5291\u91cf\u7684\u88dc\u5f37\uff1b\u5c0d\u65bc\u9ad4\u8868\u6dcb\u5df4\u764c\u4e5f\u53ef\u7528\u5168\u8eab\u7684\u96fb\u5b50\u5c04\u675f\u591a\u7167\u91ce\u7684\u65b9\u5f0f\u6cbb\u7642\uff0c\u8fd1\u5e74\u4f86\u96fb\u5b50\u5c04\u675f\u5728\u81e8\u5e8a\u61c9\u7528\u4e0a\u66f4\u5f62\u5ee3\u6cdb\u3001\u4e14\u91cd\u8981\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6b64\u6b21\u4ee5\u76f4\u7dda\u52a0\u901f\u5668\u3001\u5e73\u884c\u677f\u6e38\u96e2\u8154\u3001\u96fb\u91cf\u5668\uff0c\u5229\u7528\u56fa\u614b\u6c34\u5047\u9ad4\uff0c\u4f9d\u4e0d\u540c\u96fb\u5b50\u9310\u7b52\u3001\u4e0d\u540c\u80fd\u91cf\u91cf\u6e2c\u5728\u8868\u9762\u3001\u6700\u5927\u5291\u91cf\u6df1\u5ea6\u3001\u767e\u5206\u4e4b\u4e5d\u5341\u5291\u91cf\u6df1\u5ea6\u3001\u767e\u5206\u4e4b\u516b\u5341\u5291\u91cf\u6df1\u5ea6\u3001\u767e\u5206\u4e4b\u4e94\u5341\u5291\u91cf\u6df1\u5ea6\u7b49\u7684\u5291\u91cf\u8b8a\u5316\uff0c\u4e26\u63a2\u8a0e\u4e0d\u540c\u80fd\u91cf\u4e0b\u3001\u4e0d\u540c\u9593\u9694\u8f38\u51fa\u7684\u5291\u91cf\u8b8a\u5316\u53ca\u61c9\u7528\u3002\n\u7d50\u679c\uff1a\u7531\u5be6\u9a57\u5f97\u77e5\uff0c\u96fb\u5b50\u9310\u7b52\u6108\u5927\uff0c\u96fb\u5b50\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2\u6108\u5927\uff1b\u80fd\u91cf\u6108\u9ad8\uff0c\u96fb\u5b50\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2\u4e5f\u6108\u5927\u3002\u96fb\u5b50\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2\u5728\u6700\u5927\u5291\u91cf\u6df1\u5ea6\u3001\u767e\u5206\u4e4b\u4e5d\u5341\u5291\u91cf\u6df1\u5ea6\u3001\u767e\u5206\u4e4b\u516b\u5341\u5291\u91cf\u6df1\u5ea6\u6240\u6e2c\u5f97\u7684\u6578\u503c\u76f8\u7576\u63a5\u8fd1\uff0c\u8aa4\u5dee\u90fd\u57282%\u4ee5\u5167\uff1b\u800c\u5728\u8868\u9762\u548c\u767e\u5206\u4e4b\u4e94\u5341\u5291\u91cf\u6df1\u5ea6\u76f8\u5dee\u8f03\u5927\uff0c\u8aa4\u5dee\u9054+5.04%\u3002\n\u7d50\u8ad6\uff1a\u4e00\u822c\u4f7f\u7528\u96fb\u5b50\u6709\u6548\u5c04\u6e90-\u8868\u9762\u8ddd\u96e2\u5e73\u65b9\u53cd\u6bd4\u7684\u65b9\u6cd5\u4fee\u6b63\u5c04\u675f\u4e2d\u8ef8\u4e4b\u5291\u91cf\u6642\uff0c\u7686\u4ee5\u6700\u5927\u5291\u91cf\u6df1\u5ea6\u5291\u91cf\u70ba\u53c3\u8003\u9ede\uff0c\u6b64\u6b21\u5206\u5225\u505a\u4e0d\u540c\u767e\u5206\u6bd4\u7684\u4f4d\u7f6e\u6df1\u5ea6\u7684\u91cf\u6e2c\uff0c\u4e26\u88fd\u6210\u5716\u8868\uff0c\u4e3b\u8981\u5e0c\u671b\u81e8\u5e8a\u4f7f\u7528\u76f4\u7dda\u52a0\u901f\u5668\u6642\uff0c\u80fd\u66f4\u6e05\u695a\u5176\u7279\u6027\uff0c\u9032\u800c\u4e86\u89e3\u5176\u5291\u91cf\u5206\u5e03\u60c5\u5f62\uff0c\u4f7f\u75c5\u4eba\u7684\u6cbb\u7642\u66f4\u81fb\u5b8c\u5099\u3002", "e": "Purpose : Electron beam radiation therapy is one of the most potential treatment modality for treatment of superficial tumor. As the electron energy used in the treatment is chosen based on the depth, the underlying normal tissues can be spared more compared to photon beam therapy. Furthermore, electron beam has become frequently employed in total body irradiation to boost chest wall for treatment of bone marrow transplant, leukemia. Hence, radiation therapy using electron beams have shown increasing important role and applications in clinical use. \nMaterials and Methods : In this study, the effective SSD of different electron energies at various depths were investigated using linear accelerator, parallel plate ion chamber, electrometer and solid water phantom. The dosimetric properties of different electron cones and energies were measured at surface, and maximum, 90%, 80%, 50% dose depth. The dosimetric variations and applications under varied energies and output period were then discussed. \nResults : The results showed that: the larger the electron cone size and energy, the larger the electron effective SSD. The results of effective SSD measured at maximum, 90%, 80% dose depth showed negligible difference within 2%. The effective SSD measured at surface and 50% dose depth showed a larger difference about +5.04%.\nConclusions : In general, the central beam axis dose correction for the electron effective SSD applied with inverse square law uses the maximum depth as reference point. In this study, the measurements at different percentage depth dose point were tabulated to clearly state the dosimetry characteristics of electron beams and improve understanding of the dosimetric distributions, thus perfecting the patient treatment plans."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-257-264-a", "title": "\u55ae\u7ba1\u5713\u67f1\u72c0\u8fd1\u63a5\u88dd\u7642\u5668\u5291\u91cf\u5206\u4f48\u6700\u4f73\u5316\u7684\u5f71\u97ff\u56e0\u7d20", "keywords": "\u8fd1\u63a5\u6cbb\u7642;\u9670\u9053;\u5713\u67f1\u72c0\u88dd\u7642\u5668;\u6700\u4f73\u5316 Brachytherapy;Vagina;Cylindrical applicator;Optimization", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4f7f\u7528\u4e0d\u540c\u76f4\u5f91\u7684\u5713\u67f1\u72c0\u88dd\u7642\u5668\u3001\u9078\u64c7\u4e0d\u540c\u7684\u5c04\u6e90\u4f4d\u7f6e\u53ca\u6700\u4f73\u5316\u5291\u91cf\u9ede\uff0c\u5728\u4f5c\u9670\u9053\u8fd1\u63a5\u6cbb\u7642\u8a08\u5283\u6642\u5c0d\u5291\u91cf\u5206\u4f48\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f9d\u64daABS\uff08American Brachytherapy Society\uff09\u5831\u544a\uff0c\u5728\u4f7f\u7528\u5713\u67f1\u72c0\u88dd\u7642\u5668\u65bd\u884c\u8fd1\u63a5\u6cbb\u7642\u6642\uff0c\u5efa\u8b70\u63a1\u7528\u9670\u9053\u9ecf\u819c\u53ca\u9ecf\u819c\u4e0b5.0 mm\u70ba\u8868\u9762\u53ca\u5916\u5074\u5291\u91cf\u8a55\u4f30\u9ede\u3002\u8a55\u4f30\u5291\u91cf\u8a08\u7b97\u7684\u56e0\u7d20\u6709\u5713\u67f1\u72c0\u88dd\u7642\u5668\u76f4\u5f91\u7684\u5927\u5c0f\uff081.5 cm vs. 3.5 cm\uff09\u3001\u6539\u8b8a\u5c04\u6e90\u9ede\u505c\u7559\u9593\u8ddd \uff082.5, 5, 7.5, and 10 mm\uff09\u53ca\u6700\u4f73\u5316\u5291\u91cf\u9ede\u7684\u5b89\u6392\uff0c\u4ea4\u53c9\u5206\u6790\u5176\u5f71\u97ff\u5291\u91cf\u5206\u4f48\u7684\u7d50\u679c\u3002\n\u7d50\u679c\uff1a\u76f4\u5f911.5 cm\u88dd\u7642\u5668\u8f03\u76f4\u5f913.5 cm\u88dd\u7642\u5668\u6709\u8f03\u9ad8\u7684\u8868\u9762\u5e73\u5747\u5291\u91cf\uff08173.6 cGy vs.127.3 cGy\uff09\uff0c\u8207\u8f03\u4e0d\u5747\u52fb\u7684\u5291\u91cf\u5206\u4f48\uff08\u6a19\u6e96\u5dee31.8 cGy vs. 11.7 cGy\uff09\u3002\u5728\u6700\u4f73\u5316\u904e\u7a0b\u4e2d\uff0c\u62c9\u5927\u6700\u4f73\u5316\u5291\u91cf\u9ede\u9593\u8ddd\uff08\u75312.5 mm\u81f310.0 mm\uff09\uff0c\u76f4\u5f913.5 cm\u88dd\u7642\u5668\u8868\u9762\u9802\u9ede\u5291\u91cf\u6703\u589e\u52a028\uff05\u3002\u589e\u52a0\u5c04\u6e90\u505c\u7559\u4f4d\u7f6e\u7684\u9593\u8ddd\uff0c\u4ea6\u9020\u6210\u9802\u9ede\u5291\u91cf\u7684\u589e\u52a0\u3002\u82e5\u6539\u8b8a\u6700\u4f73\u5316\u5291\u91cf\u9ede\u7684\u5b89\u6392\u65b9\u5f0f\uff0c\u5916\u5074\u9802\u9ede\u6703\u9ad8\u905470\uff05\u7684\u5291\u91cf\u589e\u52a0\u3002\n\u7d50\u8ad6\uff1a\u81e8\u5e8a\u4e0a\u82e5\u4f7f\u7528\u55ae\u7ba1\u88dd\u7642\u5668\u4f5c\u9670\u9053\u8fd1\u63a5\u6cbb\u7642\uff0c\u76f4\u5f91\u8f03\u5927\u7684\u5713\u67f1\u72c0\u88dd\u7642\u5668\u53ef\u5f97\u5230\u8f03\u5747\u52fb\u7684\u5291\u91cf\u5206\u4f48\u3002", "e": "Purpose : To evaluate the dose distribution of vaginal brachytherapy with different diameters of cylindrical applicator, source positions and optimized dose points.\nMaterials and Methods : When using cylindrical applicator for vaginal brachytherapy, ABS (American Brachytherapy Society) recommended treatment report with the vaginal surface dose and the dose at 5 mm beneath mucosa. The affecting factors for dose optimization is this study include: diameter of vaginal cylinder, source positions and optimized dose points.\nResults : Vaginal applicator with smaller diameter (1.5 cm) has a higher average surface dose (173.6 cGy vs. 127.3 cGy) and a more inhomogeneous dose distribution (standard deviation 31.8 cGy vs. 11.7 cGy) than a larger one (3.5 cm). When the interval of optimized dose points was increasing to 10 mm, the dose at surface apex point increased 28% with the larger diameter applicator. Increasing interval of source dwelling positions resulted in a rise of dose at apex point. There was a 70% dose enhancement at off-surface dose point when optimized dose points were re-arranged.\nConclusions : When utilizing single-channeled applicator for vaginal brachytherapy, a cylinder with larger diameter will result in more homogenous dose distribution."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200312-10-4-265-273-a", "title": "Brain Necrosis as a Consequence of Reirradiation in Meningeal Hemangiopericytoma: A Case Report and Review of the Literature", "keywords": "\u8166\u7d30\u80de\u58de\u6b7b;\u91cd\u8907\u653e\u5c04\u6cbb\u7642;\u8166\u819c\u8840\u7ba1\u5916\u76ae\u7d30\u80de\u7624 Brain necrosis;Reirradiation;Meningeal hemangiopericytoma", "c": "\u8166\u819c\u8840\u7ba1\u5916\u76ae\u7d30\u80de\u7624\u662f\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u5167\u7f55\u898b\u7684\u816b\u7624\u4e4b\u4e00\uff0c\u5176\u767c\u751f\u6a5f\u7387\u5c0f\u65bc\u4e00\u767e\u5206\u6bd4\u3002\u6b64\u816b\u7624\u7684\u7279\u6027\u662f\u767c\u5c55\u6162\uff0c\u4f46\u5fa9\u767c\u7387\u9ad8\uff0c\u4e14\u6613\u65bc\u795e\u7d93\u7cfb\u8ef8\u5167\u751a\u81f3\u9060\u8655\u8f49\u79fb\u3002\u672c\u6848\u4f8b\u56e0\u591a\u6b21\u7684\u816b\u7624\u5fa9\u767c\uff0c\u6545\u63a5\u53d7\u4e86\u5169\u6b21\u5b8c\u6574\u5291\u91cf\u4e4b\u653e\u5c04\u6cbb\u7642\uff0c\u9593\u9694\u6642\u9593\u70ba\u4e94\u5e74\uff0c\u7d2f\u7a4d\u65bc\u8166\u90e8\u91cd\u758a\u7684\u5c40\u90e8\u5340\u57df\u5927\u65bc\u4e00\u767e\u683c\u96f7\u3002\u65bc\u7b2c\u4e8c\u6b21\u653e\u5c04\u6cbb\u7642\u4e03\u500b\u6708\u5f8c\uff0c\u75c5\u60a3\u767c\u751f\u9032\u5c55\u5f0f\u7684\u795e\u7d93\u75c7\u72c0\u53ca\u9871\u5167\u58d3\u5347\u9ad8\uff0c\u7d93\u518d\u6b21\u7684\u5916\u79d1\u624b\u8853\u5f8c\u767c\u73fe\u539f\u56e0\u70ba\u8166\u7d30\u80de\u58de\u6b7b\uff0c\u75c5\u7406\u4e26\u4e14\u8a3c\u5be6\u7121\u4efb\u4f55\u816b\u7624\u7d30\u80de\u3002\u7d93\u624b\u8853\u5f8c\u75c5\u60a3\u75c7\u72c0\u6e1b\u8f15\uff0c\u81f3\u4eca\u4ecd\u5b58\u6d3b\u3002\u81ea\u7b2c\u4e00\u6b21\u767c\u73fe\u9871\u5167\u816b\u7624\u81f3\u4eca\u75c5\u60a3\u5df2\u5b58\u6d3b\u4e86\u5341\u56db\u5e74\u3002\u91cd\u8907\u8166\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u9810\u671f\u53ef\u80fd\u767c\u751f\u8166\u7d30\u80de\u58de\u6b7b\uff0c\u4f46\u7d93\u6587\u737b\u56de\u9867\u5f8c\uff0c\u543e\u4eba\u7684\u7d50\u8ad6\u70ba\u4e26\u975e\u6240\u6709\u7684\u75c5\u4f8b\u7d93\u91cd\u8907\u653e\u5c04\u6cbb\u7642\u5f8c\u4e00\u5b9a\u767c\u5c55\u6210\u4e0d\u53ef\u9006\u7684\u795e\u7d93\u75c7\u72c0\uff0c\u82e5\u8003\u616e\u53ef\u80fd\u5ef6\u9577\u75c5\u60a3\u7684\u751f\u547d\u6642\uff0c\u91cd\u8907\u8166\u90e8\u7684\u653e\u5c04\u6cbb\u7642\u662f\u6709\u610f\u7fa9\u7684\u3002", "e": "Meningeal hemangiopericytoma is a rare tumor in central nervous system (CNS), consisting of less than one percent in incidence. It has distinctive characteristics of being slow in tumor progression and high in tumor recurrence. Unlike other CNS tumor, there exists also risk of neuroaxis and distant metastasis. Due to repeated recurrence, the presented case had received two full courses of irradiation to tumor bed with an interval of five years. The cumulative dose in the overlapped region of brain is greater than 100Gy, overt brain necrosis developed with progressive neurologic symptoms at seven months after second radiotherapy. After surgical decompression and removal of necrotic mass, the patient is still alive at present with improved neurologic symptoms. As a matter of fact, this patient has been alive for over 14 years since the first time that she found out about her brain tumor. After review of papers, we conclude that radiation induced brain necrosis may be expected in reirradiation, but not every case reirradiated results in brain necrosis with clinically severe neurologic deficit or mortality. If there is survival benefit and/or symptomatic improvement, reirradiation in the CNS may be considered in selected case."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-119-126-a", "title": "Gamma Knife Radiosurgery for Recurrent Nasopharyngeal Cancer", "keywords": "\u9f3b\u54bd\u764c;\u5fa9\u767c;\u653e\u5c04\u624b\u8853;\u5408\u4f75\u7642\u6cd5 Nasopharyngeal cancer;Recurrence;Radiosurgery;Combined treatment", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4ee5\u52a0\u99ac\u5200\u6cbb\u7642\u653e\u7642\u5f8c\u5fa9\u767c\u4e4b\u9f3b\u54bd\u764c\u7684\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1993\u81f31997\u5e74\uff0c\u5171\u6709\u5341\u4e00\u4f4d\uff08\u516d\u7537\u4e94\u5973\uff09\u653e\u7642\u5f8c\u5fa9\u767c\u7684\u9f3b\u54bd\u764c\u75c5\u60a3\u63a5\u53d7\u52a0\u99ac\u5200\u653e\u5c04\u624b\u8853\u6cbb\u7642\uff0c\u9996\u6b21\u653e\u7642\u8207\u52a0\u99ac\u5200\u7684\u9593\u9694\u6642\u9593\u662f\u4e00\u81f3\u5341\u4e8c\u5e74\uff08\u4e2d\u4f4d\u503c\u4e8c\u5e74\uff09\u3002\u52a0\u99ac\u5200\u7684\u6cbb\u7642\u5291\u91cf\u662f12.5\u81f320 Gy\uff08\u4e2d\u4f4d\u503c15 Gy\uff09\uff0c\u816b\u7624\u9ad4\u7a4d\u662f\u5f9e\u5c0f\u65bc1\u81f333 cc\uff08\u4e2d\u4f4d\u503c11 cc\uff09\uff0c\u653e\u7642\u6240\u7167\u9ad4\u7a4d\uff08Radiation Volume\uff09\u662f6\u81f348 cc\uff08\u4e2d\u4f4d\u503c20.9 cc\uff09\u7d93\u7531\u56de\u6eaf\u7814\u7a76\u9019\u4e9b\u75c5\u4eba\u6839\u64da\u6cbb\u7642\u7a2e\u985e\u7684\u4e0d\u540c\u800c\u5206\u70ba\u5169\u7d44\uff1a\u6709\u56db\u4f4d\u75c5\u4eba\u50c5\u63a5\u53d7\u52a0\u99ac\u5200\u800c\u7121\u63a5\u53d7\u50b3\u7d71\u653e\u7642\uff08A\u7d44\uff09\u3002\u53e6\u4e03\u540d\u75c5\u4eba\u9664\u52a0\u99ac\u5200\u5916\u63a5\u53d7\u50b3\u7d71\u7684\u5206\u6b21\u9ad4\u5916\u653e\u7642\uff08\u5291\u91cf30\u81f347 Gy\uff0c\u4e2d\u4f4d\u503c38 Gy\uff09\uff0c\u53ca\u540c\u6b65\u5316\u7642\uff08Cisplatin\uff0c5FU\u53caMitomycin C\uff09\uff0c\u662f\u70baB\u7d44\u3002\n\u7d50\u679c\uff1a\u6240\u6709\u75c5\u4eba\u90fd\u80fd\u5b8c\u6210\u52a0\u99ac\u5200\u6cbb\u7642\u800c\u7121\u660e\u986f\u4e4b\u6025\u6027\u526f\u4f5c\u7528\u3002\u5728\u4e5d\u4f4d\u6709\u505aMRI\u6aa2\u67e5\u7684\u75c5\u4eba\u4e2d\u6709\u516b\u4f4d\u90fd\u770b\u5230\u816b\u7624\u7e2e\u5c0f\u3002\u5728A\u7d44\u75c5\u4eba\u4e2d\u53ea\u6709\u4e00\u4f4d\u75c5\u4eba\u6b7b\u65bc\u540c\u6b65\u5316\u7642\u5f15\u8d77\u4e4b\u6557\u8840\u75c7\uff0c\u4e00\u4f4d\u5728\u516d\u500b\u6708\u5167\u6b7b\u4ea1\uff0c\u53e6\u5169\u4f4d\u75c5\u4eba\u5728\u5341\u4e94\u500b\u6708\u5167\u5fa9\u767c\u3002\u5728B\u7d44\u75c5\u4eba\u4e2d\uff0c\u6709\u4e94\u4f4d\u75c5\u4eba\u816b\u7624\u9577\u671f\u63a7\u5236\u826f\u597d\u3002\u4f46\u9019\u5176\u4e2d\u6709\u4e09\u4f4d\u75c5\u4eba\u5728\u6cbb\u7642\u5f8cMRI\u4e0a\u767c\u73fe\u6709\u660e\u986f\u7684\u8166\u90e8\u640d\u50b7\u3002\u6240\u6709\u75c5\u4eba\u7684\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba48.8\u500b\u6708,\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba36.4%\u3002\n\u7d50\u8ad6\uff1a\u52a0\u99ac\u5200\u5408\u4f75\u5206\u6b21\u653e\u7642\u53ca\u540c\u6b65\u5316\u7642\u5c0d\u5fa9\u767c\u9f3b\u54bd\u764c\u4f3c\u4e4e\u53ef\u4ee5\u6bd4\u55ae\u7368\u52a0\u99ac\u5200\u9054\u5230\u8f03\u597d\u7684\u7642\u6548\u3002\u5206\u6b21\u653e\u7642\u5b9c\u907f\u514d\u7528\u5169\u5074\u5c0d\u7167\u7684\u7167\u91ce\u4ee5\u514d\u8166\u90e8\u640d\u50b7\u3002", "e": "Purpose : To report the results of salvage treatment of recurrent nasopharyngeal cancers (NPC) using Gamma Knife radiosurgery (GK) alone or combined with conventional radiotherapy.\nMaterials and methods : From 1993 to 1997, eleven patients (6 males and 5 females) were diagnosed to have recurrent tumors over the primary site of nasopharynx and/or skull base at our hospital after initial radiotherapy. The time interval between the primary radiotherapy and salvage GK was 1 to 12 years (median = 2.0 years). All patients received single fraction of Gamma Knife radiosurgery was performed with peripheral doses of 12.5 to 20 Gy (median = 15 Gy) to cover the recurrent tumor as conformal as possible. The tumor volumes (TV) were less than 1 to 33 cc (median = 11cc) whereas radiation volumes (RV) were 6 to 48 cc (median = 20.9 cc). Retrospectively the patients were divided into two groups according to their treatment. Four patients received GK without further radiotherapy (Group A). The other 7 patients received hyperfractionated external beam radiotherapy of 30 to 47 Gy (median = 38 Gy) and concurrent chemotherapy (cisplatin, 5-FU, mitomycin C) for further boost of the tumor (Group B).\nResult : All patients tolerated GK well without significant acute toxicity. The first MRI after GK showed tumor regression for eight out of nine patients receiving this examination. One patient died of sepsis induced by concurrent chemotherapy, not receiving fractionated RT. For the other 3 patients receiving GK without combined RT (group A), 2 tumors recurred 7 and 15 months later and one patient lost to image follow-up and expired within 6 months after GK. Five out of seven patients of group B remained local control at the last image follow-up (6 to 62 months after GK). However, three patients of this group of had prominent brain damage shown by MRI and PET scan after salvage irradiation. The median survival of all our patients is 48.8 months. The five-year survival rate is 36.4%.\nConclusion : Combined fractionated RT, GK radiosurgery and concurrent chemotherapy seem to achieve better local control for intracranially recurrent NPC than GK alone. It is not recommended to use single-fraction radiosurgery to salvage a newly diagnosed skull base recurrent NPC. Bilateral opposing fields in fractionated RT should be avoided to lower the incidence of late complications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-127-136-a", "title": "\u9f3b\u54bd\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u5f8c\u751f\u6d3b\u54c1\u8cea\u4e4b\u7814\u7a76", "keywords": "\u751f\u6d3b\u54c1\u8cea;\u653e\u5c04\u6cbb\u7642;\u9f3b\u54bd\u764c Quality of life;Radiotherapy;Nasopharyngeal carcinoma;EORTC", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u662f\u8a55\u4f30\u9f3b\u54bd\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u751f\u6d3b\u54c1\u8cea\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea2001\u5e743\u6708\u81f32002\u5e7412\u6708\uff0c\u7e3d\u5171\u6709\u5169\u6a5f\u69cb\u7684\u4e09\u767e\u4e09\u5341\u4e8c\u4f4d\u9f3b\u54bd\u764c\u75c5\u60a3\u88ab\u9080\u8acb\u53c3\u8207\u7814\u7a76\u3002\u75c5\u60a3\u5728\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\u4e09\u500b\u6708\u4ee5\u4e0a\uff0c\u586b\u5bebEORTC QLQ C-30\u53caEORTC QLQ-H&N35\u7684\u751f\u6d3b\u54c1\u8cea\u91cf\u8868\uff0c\u4ee5\u6b64\u4f5c\u70ba\u8a55\u4f30\u4e4b\u4f9d\u64da\u3002\n\u7d50\u679c\uff1a\u4ee5\u7c21\u55ae\u76f8\u95dc\u5206\u6790\u800c\u8a00\uff0c\u300c\u6cbb\u7642\u5f8c\u6642\u9593\u9593\u9694\u300d\u8207\u300c\u75bc\u75db\u300d\uff08r = -0.194***\uff09\u5f62\u6210\u8ca0\u76f8\u95dc\uff0c\u662f\u6240\u6709\u76f8\u95dc\u8b8a\u9805\u4e2d\u6700\u986f\u8457\u7684\uff1b\u5176\u6b21\u70ba\u9ad4\u91cd\u6e1b\u8f15\uff08r = -0.165**\uff09\u3001\u53e3\u4e7e\uff08r = -0.155**\uff09\uff1b\u6b64\u5916\uff0c\u6027\u56f0\u64fe\uff08r = -0.138*\uff09\u3001\u553e\u6db2\u9ecf\u7a20\uff08r = -0.130*\uff09\u3001\u793e\u4ea4\u98f2\u98df\u554f\u984c\uff08r = -0.108*\uff09\u3001\u9ad4\u91cd\u589e\u52a0\uff08r = 0.107*\uff09\u53ca\u5f35\u5634\u554f\u984c\uff08r = 0.105*\uff09\u4e5f\u9054\u5230\u986f\u8457\u5dee\u7570\u3002\u672c\u7814\u7a76\u70ba\u4e86\u77ad\u89e3\u975e\u7dda\u6027\u7c21\u55ae\u95dc\u4fc2\u4e4b\u6548\u679c\uff0c\u9032\u4e00\u6b65\u5c07\u6642\u9593\u9593\u9694\u5206\u985e\u70ba\u300c\u6cbb\u7642\u5f8c\u4e09\u81f3\u516d\u500b\u6708\u300d\u3001\u300c\u6cbb\u7642\u5f8c\u516d\u500b\u6708\u81f3\u5341\u4e8c\u500b\u6708\u300d\u3001\u300c\u6cbb\u7642\u5f8c\u4e00\u5e74\u81f3\u4e94\u5e74\u300d\u53ca\u300c\u6cbb\u7642\u5f8c\u4e94\u5e74\u4ee5\u4e0a\u300d\uff0c\u5229\u7528\u55ae\u56e0\u6578\u8b8a\u7570\u6578\u5206\u6790\uff0c\u7d50\u679c\u767c\u73fe\u9664\u4e86\u300c\u5f35\u5634\u554f\u984c\u300d\u3001\u300c\u4f7f\u7528\u6b62\u75db\u85e5\u300d\u53ca\u300c\u9ad4\u91cd\u589e\u52a0\u300d\u4e09\u9805\u5916\uff0c\u5176\u9918\u5168\u90e8\u6709\u986f\u8457\u610f\u7fa9\u3002\u56e0\u6b64\uff0c\u672c\u7814\u7a76\u518d\u9032\u4e00\u6b65\u5c07\u751f\u6d3b\u54c1\u8cea\u5404\u9805\u6307\u6a19\u4f9d\u5176\u4e0d\u540c\u6642\u9593\u968e\u6bb5\u7684\u8b8a\u5316\uff0c\u4e88\u4ee5\u5340\u5206\u70ba\u56db\u7a2e\u985e\u578b\uff0c\u5373\u300c\u905e\u589e\u578b\u300d\u3001\u300c\u905e\u6e1b\u578b\u300d\u3001\u300cU\u578b\u300d\u53ca\u300cW\u6ce2\u6d6a\u578b\u300d\uff0c\u4e26\u5206\u6790\u4e0d\u540c\u985e\u578b\u4e4b\u751f\u6d3b\u54c1\u8cea\u6539\u8b8a\u7684\u73fe\u8c61\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\u4f9d\u4e0d\u540c\u6642\u9593\u968e\u6bb5\u7684\u751f\u6d3b\u54c1\u8cea\u6307\u6a19\u8b8a\u5316\u4e4b\u8a73\u76e1\u8cc7\u6599\u6709\u52a9\u65bc\u6211\u5011\u8207\u75c5\u60a3\u6e9d\u901a\u75c5\u60c5\uff0c\u4e26\u53ef\u9032\u4e00\u6b65\u8a2d\u8a08\u8457\u91cd\u65bc\u9f3b\u54bd\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u5f8c\u4e4b\u652f\u63f4\u7642\u6cd5\u53ca\u5fa9\u5065\u65b9\u9762\u7684\u4ecb\u5165\u6027\u7814\u7a76\u3002", "e": "Purpose : The purpose of this study is to evaluate the quality of life of patients with nasopharyngeal carcinoma after treatment with radiotherapy.\nMaterials and Methods : From March 2001 to November 2002, three hundred and thirty-two nasopharyngeal cancer patients in two institutions were invited to participation. Health- related quality of life was assessed 3 months or later after the completion of the treatment by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ C-30) and the EORTC head and neck cancer-specific questionnaire (QLQ H&N-35). \nResults : Pain (r = -0.194***), weight loss (r = -0.165**), dry mouth (r = -0.155**), sexuality (r = \n-0.138*), sticky saliva (r = -0.130*), social eating (r = -0.108*), gain weight (r = 0.107*) and problem of open mouth (r = 0.105*) revealed significance with changes over time by simple correlation analysis. In order to understand the effects of non-linear simple correlation, the periods between completion of radiotherapy and patients filling in the questionnaire were divided to 4 groups: 3-6 months, 6-12 months, 1-5 years and more than 5 years. All items but three (problem of open mouth, administration of painkiller and gain weight) showed statistical significance by one-way ANOVA analysis. Hence, all items and symptoms changing over time were divided into four types: increasing, decreasing, U type, and W wave type. \nConclusions : Our study suggest that detailed information about the changes over time may help us in communication with patients and in design of intervention studies focusing on improvement of the supportive care and rehabilitation of patients with nasopharyngeal carcinoma after radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-137-140-a", "title": "\u653e\u5c04\u6cbb\u7642\u4e4b\u764c\u60a3\u5c0d\u98df\u7269\u7981\u5fcc\u7684\u8abf\u67e5", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u98df\u7269\u7981\u5fcc Radiotherapy;Food taboo", "c": "Purpose : to evaluate factors related to tabooed foods in cancer patients and to study the motivation and concept of tabooed foods from patients?view point so that patients may accept correct knowledge about diet control and nutritional support via a positive communication skill.\nMaterials and Methods : From November of 1997 to October of 1999, data from 872 irradiated cancer patients were collected at Dept. of Radiation Oncology, Lin-Kou Chang Gung Memorial Hospital. Patients were requested to answer a series of questions from well-designed questionnaire. This was done twice , namely, first week at the beginning and 6 months after the entire course of radiotherapy.\nResults : prior to cancer attack, 24 cases (2.8%) had no tabooed food while 651 cases (74.7%) had this taboo after experiencing malignancy. Tabooed food were usually of several kinds. Of these, 325 cases (37.3%) considered that nutritional supplements may help the growing of tumor masses while 140 cases (16.1%) suspected that cancer is communicable via taking food together with one another. From patients unable to prove a statistically significant correlation between a special subset of patients and the development of above-mentioned misconcepts toward the effect of certain food intake on the growing of malignant tumors (p \uff1e 0.05). However, patients with age above 60 year old regarded that meats were toxic to normal human body and related to cancer development (p \uff1c 0.05).\nDiscussion : During radiotherapy, each patient received nutrition education from dietitian and nursing staff concerning balanced diets. Yet, patients may still adopt their own view point of diet control. The chance for a curative attempt of management may be compromised provided that patients failed to receive adequate nutritional support during radiotherapy which may cause loss of body weight, impairment of general immunity or toxicity related interruption of treatment. Health professionals should, therefore, try their best to offer patients accurate knowledge of nutrition and to clarify the inappropriate taboos of foods.", "e": "Purpose : to evaluate factors related to tabooed foods in cancer patients and to study the motivation and concept of tabooed foods from patients?view point so that patients may accept correct knowledge about diet control and nutritional support via a positive communication skill.\nMaterials and Methods : From November of 1997 to October of 1999, data from 872 irradiated cancer patients were collected at Dept. of Radiation Oncology, Lin-Kou Chang Gung Memorial Hospital. Patients were requested to answer a series of questions from well-designed questionnaire. This was done twice , namely, first week at the beginning and 6 months after the entire course of radiotherapy.\nResults : prior to cancer attack, 24 cases (2.8%) had no tabooed food while 651 cases (74.7%) had this taboo after experiencing malignancy. Tabooed food were usually of several kinds. Of these, 325 cases (37.3%) considered that nutritional supplements may help the growing of tumor masses while 140 cases (16.1%) suspected that cancer is communicable via taking food together with one another. From patients unable to prove a statistically significant correlation between a special subset of patients and the development of above-mentioned misconcepts toward the effect of certain food intake on the growing of malignant tumors (p \uff1e 0.05). However, patients with age above 60 year old regarded that meats were toxic to normal human body and related to cancer development (p \uff1c 0.05).\nDiscussion : During radiotherapy, each patient received nutrition education from dietitian and nursing staff concerning balanced diets. Yet, patients may still adopt their own view point of diet control. The chance for a curative attempt of management may be compromised provided that patients failed to receive adequate nutritional support during radiotherapy which may cause loss of body weight, impairment of general immunity or toxicity related interruption of treatment. Health professionals should, therefore, try their best to offer patients accurate knowledge of nutrition and to clarify the inappropriate taboos of foods."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-141-150-a", "title": "Optimization of 3D Wedged-Pair Radiation Therapy Planning: Geometrical Alignment of Wedge Orientation", "keywords": "\u6954\u5f62\u6ffe\u677f;\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642;\u6700\u4f73\u5316 Wedge;3D radiotherapy treatment planning;Optimization;Non-coplanar", "c": "\u6210\u5c0d\u6954\u5316\uff08wedged-pair\uff09\u7167\u91ce\u662f\u4e00\u7a2e\u5e38\u88ab\u4f7f\u7528\u7684\u653e\u5c04\u6cbb\u7642\u6280\u8853\u3002\u9019\u662f\u56e0\u70ba\u5229\u7528\u6210\u5c0d\u6954\u5316\u7167\u91ce\u7684\u65b9\u4f4d\u8a2d\u8a08\uff0c\u53ef\u4ee5\u5f97\u5230\u5728\u816b\u7624\u90e8\u4f4d\u5747\u52fb\u7684\u653e\u5c04\u5291\u91cf\u5206\u5e03\uff0c\u800c\u4e14\u9060\u7aef\u7684\u653e\u5c04\u5291\u91cf\u53ea\u6709\u816b\u7624\u5291\u91cf\u7684\u4e00\u534a\u4ee5\u4e0b\u3002\u6210\u5c0d\u6954\u5316\u7167\u91ce\u4f7f\u7528\u7684\u6954\u5f62\u6ffe\u677f\u4e4b\u89d2\u5ea6\u53d6\u6c7a\u65bc\u6b64\u6210\u5c0d\u7167\u91ce\u4e4b\u9593\u7684\u593e\u89d2\uff08hinge angle\uff09\u3002\u5728\u50b3\u7d71\u7684\u4e8c\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u4e2d\uff0c\u6cbb\u7642\u5e8a\u5927\u591a\u56fa\u5b9a\u57280\u5ea6\u300190\u5ea6\u6216270\u5ea6\u7684\u65b9\u4f4d\uff0c\u6210\u5c0d\u7167\u91ce\u4e4b\u9593\u7684\u593e\u89d2\u4e5f\u56e0\u6b64\u5f88\u5bb9\u6613\u8a08\u7b97\u5f97\u77e5\u3002\u4f46\u6b64\u7406\u60f3\u72c0\u6cc1\u5728\u8907\u96dc\u7684\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u4e2d\uff0c\u56e0\u70ba\u6cbb\u7642\u5e8a\u7684\u4efb\u610f\u89d2\u5ea6\u4e4b\u65cb\u8f49\u6240\u9020\u6210\u7684\u975e\u540c\u9762\u6027\uff08non-coplanar\uff09\u7167\u91ce\u65b9\u4f4d\u8a2d\u8a08\uff0c\u5df2\u4e0d\u5fa9\u9069\u7528\u3002\u9664\u4e86\u6210\u5c0d\u975e\u540c\u9762\u6027\u7167\u91ce\u4e4b\u9593\u7684\u593e\u89d2\u4e0d\u5bb9\u6613\u8a08\u7b97\uff0c\u53e6\u5916\u6954\u5f62\u6ffe\u677f\u539a\u8584\u4e4b\u65b9\u5411\u4e5f\u4e26\u4e0d\u5728\u540c\u4e00\u5e73\u9762\u4e0a\u5f62\u6210\u76f8\u5c0d\u7684\u6700\u4f73\u4f4d\u7f6e\u3002\u5982\u8981\u4f7f\u6954\u5f62\u6ffe\u677f\u539a\u8584\u4e4b\u65b9\u5411\u5728\u540c\u4e00\u5e73\u9762\u4e0a\u5f62\u6210\u76f8\u5c0d\u7684\u6700\u4f73\u4f4d\u7f6e\uff0c\u5fc5\u9808\u5148\u5c07\u6210\u5c0d\u975e\u540c\u9762\u6027\u7167\u91ce\u5404\u81ea\u65cb\u8f49\u6e96\u503c\u5100\uff08collimator\uff09\u81f3\u67d0\u4e00\u89d2\u5ea6\uff0c\u800c\u6b64\u89d2\u5ea6\u53d6\u6c7a\u65bc\u6210\u5c0d\u975e\u540c\u9762\u6027\u7167\u91ce\u4e09\u5ea6\u7a7a\u9593\u5165\u5c04\u65b9\u4f4d\u4e92\u76f8\u95dc\u4fc2\u3002\u672c\u7814\u7a76\u63a8\u5c0e\u6f14\u7b97\u51fa\u6210\u5c0d\u6954\u5316\u7167\u91ce\u6700\u4f73\u5316\u5e7e\u4f55\u53ca\u5411\u91cf\u65b9\u7a0b\u5f0f\uff1b\u4e26\u5c07\u6b64\u6700\u4f73\u5316\u5e7e\u4f55\u53ca\u5411\u91cf\u65b9\u7a0b\u5f0f\u64b0\u5beb\u6210\u96fb\u8166\u7a0b\u5f0f\uff0c\u4ee5\u4fbf\u81e8\u5e8a\u61c9\u7528\u3002\u6b64\u6700\u4f73\u5316\u7a0b\u5f0f\u50c5\u9700\u5169\u7d44\u53c3\u6578\uff1a\u6210\u5c0d\u6954\u5316\u7167\u91ce\u7684\u6cbb\u7642\u5e8a\u65cb\u8f49\u89d2\u5ea6\u53ca\u6cbb\u7642\u982d\u65cb\u8f49\u89d2\u5ea6\u3002\u7d93\u6700\u4f73\u5316\u6f14\u7b97\u5f8c\uff0c\u6b64\u7a0b\u5f0f\u6703\u63d0\u4f9b\uff08\u4e00\uff09\u500b\u5225\u7167\u91ce\u6e96\u503c\u5100\u61c9\u65cb\u8f49\u4e4b\u89d2\u5ea6\uff0c\u4f7f\u5f97\u6954\u5f62\u6ffe\u677f\u7684\u65b9\u5411\u6703\u4e92\u76f8\u5c0d\u4f4d\u5728\u4e09\u5ea6\u7a7a\u9593\u7684\u67d0\u4e00\u5e73\u9762\u4e0a\uff1b\uff08\u4e8c\uff09\u5169\u6210\u5c0d\u6954\u5316\u7167\u91ce\u4e4b\u9593\u5728\u4e09\u5ea6\u7a7a\u9593\u7684\u593e\u89d2\uff0c\u4ee5\u53ca\u6700\u4f73\u5316\u4e4b\u6954\u5f62\u6ffe\u677f\u89d2\u5ea6\u3002\u6b64\u6700\u4f73\u5316\u7a0b\u5f0f\u53ef\u4ee5\u6e1b\u5c11\u4e92\u52d5\u5f0f\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u6642\u5690\u8a66\u932f\u8aa4\u3001\u4fee\u6539\u6b63\u78ba\u6240\u9700\u7684\u6642\u9593\uff0c\u9032\u800c\u63d0\u6607\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u7684\u6548\u7387\u8207\u54c1\u8cea\u3002", "e": "A wedged-pair setup of two cross-fired radiation fields is a common practice in radiation therapy to achieve a homogeneous dose distribution over the irradiation volume.     It is a simple way to keep the radiation dose to the distal normal tissue below one half of the tumor dose.  The optimum wedge angle depends on the hinge angle between the wedged-pair fields.  The hinge angle can be easily determined in conventional 2D radiation planning, because the two wedged-pair fields are usually coplanar with treatment couch set at 0? 90?or 270?  In non-coplanar 3D radiation planning, hinge angle is difficult to be calculated.  In addition, the wedge orientations are most likely not opposed to one another.  An accurate mathematics formula to align two wedged-pair fields into coplanar orientation in 3D space is derived and implemented into a computer program.  The optimization program requires only two parameters, gantry angle and couch angle, for each of the wedged-pair fields.  It calculates the collimator angles of the wedged-pair fields and aligns the wedge direction and the isocenter on a single plane.  It also calculates the hinge angle of the wedged-pair fields and suggests a wedge angle for optimal dose distribution.  Through the reduction of the try-and-error optimization of collimator angle/wedge angle setting, this program increases the efficiency and throughput of an interactive 3D radiation therapy planning."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-151-157-a", "title": "Preliminary Study of an Image Archiving System With Monte Carlo Simulation", "keywords": "\u8499\u5730\u5361\u7f85\u6a21\u64ec DICOM;Monte Carlo Simulation;BEAMnrc", "c": "\u76ee\u7684\uff1a\u5c07\u5f71\u50cf\u5b58\u53d6\u7cfb\u7d71\u6574\u5408\u65bc\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0f\u4e2d\uff0c\u4ee5\u7c21\u5316\u8f49\u63db\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e26\u5efa\u7acb\u5047\u9ad4\u7684\u6b65\u9a5f\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5BEAMnrc\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7cfb\u7d71\u4f5c\u70ba\u5291\u91cf\u8a08\u7b97\u4e4b\u8edf\u9ad4\u3002\u85c9\u52a9\u958b\u653e\u6e90\u78bc\u8edf\u9ad4\uff0c\u53ca\u914d\u5408\u81ea\u884c\u958b\u767c\u7684\u7a0b\u5f0f\uff0c\u65bc\u5e73\u50f9\u7684\u500b\u4eba\u96fb\u8166\u4e0a\u5be6\u4f5c\u51fa\u76f8\u5bb9\u65bcDICOM\u6a19\u6e96\u4e4b\u5f71\u50cf\u5b58\u53d6\u7cfb\u7d71\uff0c\u4e26\u53ef\u900f\u904e\u8f03\u5bb9\u6613\u4f7f\u7528\u7684\u7db2\u9801\u64cd\u4f5c\u65b9\u5f0f\uff0c\u5c07\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u8f49\u63db\u6210\u5291\u91cf\u8a08\u7b97\u6642\u6240\u9700\u7684\u5047\u9ad4\u3002\n\u7d50\u679c\uff1a\u672c\u5f71\u50cf\u5b58\u53d6\u7cfb\u7d71\u63a1\u7528\u958b\u653e\u67b6\u69cb\uff0c\u53ef\u4ee5\u9023\u63a5\u4efb\u4f55\u5177DICOM\u529f\u80fd\u4e4b\u81e8\u5e8a\u9020\u5f71\u8a2d\u5099\uff0c\u6210\u70ba\u5177\u6709\u5f71\u50cf\u6aa2\u7d22\u53ca\u64f7\u53d6\u529f\u80fd\u7684\u5f71\u50cf\u8cc7\u6599\u5eab\u3002\u4f7f\u7528\u8005\u80fd\u5728\u700f\u89bd\u5668\u88e1\u9762\u67e5\u770b\u6240\u9700\u7684\u5f71\u50cf\uff0c\u6216\u900f\u904e\u7db2\u9801\u64cd\u4f5c\u4ecb\u9762\u9032\u884c\u5f71\u50cf\u50b3\u8f38\u53ca\u8f49\u63db\u8655\u7406\u3002\n\u7d50\u8ad6\uff1a\u6b64\u5f71\u50cf\u5b58\u53d6\u7cfb\u7d71\u904b\u4f5c\u826f\u597d\uff0c\u80fd\u7dca\u5bc6\u6574\u5408\u65bc\u73fe\u6709\u7684\u9020\u5f71\u8a2d\u5099\u3001\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u4ee5\u53ca BEAMnrc\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0f\u4e4b\u4e2d\u3002", "e": "Purpose : This study is to improve the laborious process of converting CT data sets into the simulation phantom via integrating a DICOM-compliant image archiving system with Monte Carlo Simulation.\nMaterials & Methods : The BEAMnrc Monte Carlo code is used for dose calculations in this study. A DICOM-compliant image archiving system is implemented using open-source software with inexpensive personal computers. Web-base software has been developed in-house to provide a user-friendly console to build the 3D patient phantom from CT data.\nResults : The architecture of this image archiving system is open and any modalities supporting specific DICOM services may be attached. This system acts as a central node for query and retrieval of information stored in DICOM databases. These retrieved images can be viewed inside a Web browser or distributed among DICOM-compliant modalities. The user can also issue the command to convert these images into CT based phantoms inside the Web-based console.\nConclusion : This system works well, and integrates seamlessly with existing systems including image modalities, treatment planning systems, and BEAMnrc Monte Carlo code system."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-159-166-a", "title": "Dose Calculation for Tissue Inhomogeneity in Lung Cancer Based on 6 MV Photon Beams", "keywords": "\u4e0d\u5747\u52fb\u5ea6;\u4e8c\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b;\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b;\u7d44\u7e54\u7a7a\u6c23\u6bd4\u6cd5;\u7d66\u4e88\u5291\u91cf;\u71b1\u767c\u5149\u5291\u91cf\u8a08 Inhomogeneity;2D-RT;3D-CRT;Power Law Method;Prescribe dose;TLDs", "c": "\u76ee\u7684\uff1a\u85c9\u7531\u4e8c\u5ea6\u53ca\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u4e2d\u7d44\u7e54\u4e0d\u5747\u52fb\u5ea6\u7684\u8003\u91cf\u8207\u5426\uff0c\u4f86\u8a55\u4f30\u80ba\u90e8\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u7684\u7cbe\u78ba\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4ee5\u6cbb\u7642\u5c08\u7528\u4eba\u9ad4\u5047\u9ad4\u70ba\u4eba\u9ad4\u80ba\u7d44\u7e54\u53c3\u8003\uff0c\u5168\u7a0b\u4f7f\u7528\u56fa\u5b9a\u6a21\u5177\u5305\u8986\u5047\u9ad4\uff0c\u4f7f\u5176\u7dad\u6301\u4e00\u81f4\u59ff\u52e2\u518d\u73fe\u6027\uff0c\u5c07\u71b1\u767c\u5149\u5291\u91cf\u8a08\u7f6e\u65bc\u816b\u7624\u6240\u5728\u4f4d\u7f6e\u4f5c\u5291\u91cf\u6e2c\u8b80\u4e26\u5229\u7528Varian C-Series 600C 6 MV\u52a0\u901f\u5668\u7167\u5c04\uff0c\u6240\u7167\u5c04\u7684\u5291\u91cf\u5206\u5225\u4f86\u81ea\u65bc\u4e8c\u5ea6\u3001\u7d44\u7e54\u7a7a\u6c23\u6bd4\u6cd5\u4fee\u6b63\u5f8c\u3001\u53ca\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\uff0c\u816b\u7624\u7684\u7d66\u4e88\u5291\u91cf\u70ba180 cGy\u3002\n\u7d50\u679c\uff1a\u5be6\u9a57\u7d50\u679c\u986f\u793a\uff0c\u7d93\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u53ca\u7d44\u7e54\u7a7a\u6c23\u6bd4\u6cd5\u4fee\u6b63\u5f8c\u6240\u6e2c\u51fa\u7684\u5291\u91cf\u8f03\u63a5\u8fd1\u816b\u7624\u7684\u7d66\u4e88\u5291\u91cf\uff08173 cGy\u8207172 cGy\u65bc5\u00d75 cm2\u7167\u91ce\uff0c175 cGy\u8207174 cGy\u65bc10\u00d710 cm2\u7167\u91ce\uff09\uff0c\u800c\u4e8c\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u7531\u65bc\u672a\u8003\u91cf\u7d44\u7e54\u4e0d\u5747\u52fb\u5ea6\uff0c\u56e0\u6b64\u6240\u6e2c\u51fa\u7684\u5291\u91cf\u5f88\u660e\u986f\u7684\u8d85\u51fa\u816b\u7624\u7684\u7d66\u4e88\u5291\u91cf\uff09212 cGy\u8207216 cGy\u5206\u5225\u65bc6\u00d76\u53ca10\u00d710 cm2\u7684\u7167\u91ce\uff09\u3002\n\u7d50\u8ad6\uff1a\u7531\u65bc\u80ba\u90e8\u7d44\u7e54\u5bc6\u5ea6\u7684\u591a\u5143\u5316\uff0c\u4e0d\u540c\u7684\u8a08\u7b97\u8003\u91cf\u65b9\u5f0f\u5c07\u7522\u751f\u4e0d\u540c\u7684\u7167\u5c04\u5291\u91cf\uff0c\u96d6\u7136\u4e00\u822c\u60c5\u6cc1\u4e0b\u5229\u7528\u7d44\u7e54\u7a7a\u6c23\u6bd4\u6cd5\u4fee\u6b63\u7d44\u7e54\u4e0d\u5747\u52fb\u5ea6\u6709\u4e00\u5b9a\u6548\u679c\uff0c\u4f46\u6b64\u65b9\u6cd5\u4e26\u672a\u8003\u91cf\u4e0d\u5747\u52fb\u5ea6\u7d44\u7e54\u7684\u5f62\u72c0\u53ca\u5074\u6563\u5c04\u7dda\uff0c\u800c\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u8f03\u4e8c\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u66f4\u80fd\u8003\u91cf\u80ba\u90e8\u7d44\u7e54\u5bc6\u5ea6\u7684\u4e0d\u5747\u52fb\u5ea6\u53ca\u6574\u9ad4\u7d50\u69cb\uff0c\u63d0\u4f9b\u8f03\u7cbe\u78ba\u7684\u5291\u91cf\u4e26\u6e1b\u5c11\u6cbb\u7642\u4e2d\u7684\u8ca0\u4f5c\u7528\u3002", "e": "Purpose : To evaluate the accuracy of dose calculation in lung cancer treatment planning using Two-dimensional radiotherapy (2D-RT) without inhomogeneity correction, with inhomogeneity correction by use of Power Law Tissue-Air Ratio Method (Power Law Method), and Three-dimensional conformal radiotherapy (3D-CRT) with inhomogeneity correction. The latter method takes into account in convolution algorithm. \nMaterials and Methods : Treatment was planned based on Alderson-Rando phantom held in an immobilization device. Doses were calculated on FOCUS release 2.0 planning system both for 2D-RT and 3D-CRT, and irradiation were performed on Varian C-Series 600C linear accelerator, 6MV x-ray. Thermoluminescent dosimeters (TLDs) were placed inside the target to compare the dose based on each method. The prescribed dose was180 cGy in isocenter.\nResults : The delivered doses by using 3D-CRT planning and 2D with Power Law Method correction were closer to the prescribed dose (173 cGy, 172 cGy in a 5 x 5 cm2 field and 175 cGy, 174 cGy in a 10 x 10 cm2 field). The delivered dose by using 2D-RT planning without heterogeneity correction was significantly higher (212 cGy and 216 cGy). \nConclusion : Dose variation between measurement and calculation is due to tissue inhomogenity, especially in the lung. Power Law Method accounts with tissue inhomogeneity but not with the 3D shape of inhomogeneity tissue. 3-D treatment planning with inhomogeneity correction based on CT image, delivers more accurate dose. Use of 3-D planning in lung cancer should reduce the risk of radiation side effects while optimizing delivery to the tumor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-167-173-a", "title": "\u5229\u7528\u5916\u52a0\u5ef6\u4f38\u5f0f\u925b\u5c4f\u853d\u584a\u964d\u4f4e\u8f3b\u5c04\u7167\u91ce\u5916\u5291\u91cf\u4e4b\u7814\u7a76", "keywords": "\u6cbb\u7642\u7167\u91ce\u5916\u7684\u8f3b\u5c04\u5291\u91cf;\u925b\u5408\u91d1\u584a;\u4e0d\u5c0d\u7a31\u7167\u91ce Peripheral dose;Block;Asymmetry field", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u76ee\u7684\u5728\u5229\u7528\u81ea\u884c\u7814\u767c\u7684\u925b\u5408\u91d1\u7d50\u69cb\u8a2d\u8a08\uff0c\u4ee5\u4e00\u7cfb\u5217\u5be6\u9a57\u4f86\u8a55\u4f30\u5176\u5c0d\u6cbb\u7642\u7167\u91ce\u5916\u8f3b\u5c04\u5291\u91cf\uff08Peripheral Dose\uff0cPD\uff09\u5c4f\u853d\u7684\u6548\u679c\u5982\u4f55\uff0c\u4e26\u63a2\u8a0e\u8f3b\u5c04\u7167\u91ce\u5916\u5291\u91cf\u8207\u6df1\u5ea6\u3001\u8ddd\u7167\u91ce\u908a\u7de3\u8ddd\u96e2\u53ca\u80fd\u91cf\u7684\u95dc\u4fc2\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u4e0d\u540c\u9577\u5ea6\u4e4b\u7c97\u87ba\u7d72\u91d8\u88fd\u4f5c\u9577\u5bec\u5206\u5225\u70ba12\u30018 cm\uff0c\u539a\u5ea6\uff08t\uff09\u5206\u5225\u70ba4\u30017.5\u53ca15 \u339d\uff0c\u4e14\u6258\u76e4\u8207\u925b\u5408\u91d1\u584a\u8868\u9762\u8ddd\u96e2\uff08Block Surface-Tray Distance\uff0cBSTD\uff09\u70ba15\u300120\u300125 \u339d\u4e4b\u5404\u7d44\u925b\u5408\u91d1\u584a\u3002\u6574\u500b\u7814\u7a76\u4f7f\u7528SIEMENS MEVATRON KDS-2\u76f4\u7dda\u52a0\u901f\u5668\u7522\u751f6\u548c10 MV\u4e8c\u7a2e\u80fd\u91cf\u7684\u5149\u5b50\u5c04\u675f\uff0c\u4e26\u91dd\u5c0d\u7b49\u6548\u7167\u91ce\u70ba10 x 10 \u339d2\u7684\u4e0d\u5c0d\u7a31\u7167\u91ce\u505a\u63a2\u8a0e\u3002\u5229\u75280.6 c.c. Farmer\u578b\u5f0f\u6e38\u96e2\u8154\u3001Victoreen 500\u96fb\u91cf\u8a08\u548cAcrylic\u56fa\u614b\u5047\u9ad4\u91cf\u6e2c\u6c34\u7b49\u6548\u6df1\u5ea6\u70ba1.5\u30012.5\u30015 \u339d\uff0c\u80fd\u91cf\u70ba6\u548c10 MV\u6642\uff0c\u5404\u7d44\u925b\u5408\u91d1\u584a\u5c0d\u964d\u4f4ePD\u7684\u6548\u679c\u70ba\u4f55\u3002\u6b64\u5916\uff0c\u70ba\u8a55\u4f30\u4e0d\u540c\u6df1\u5ea6\u53ca\u8ddd\u7167\u91ce\u908a\u7de3\u9060\u8fd1\u5c0dPD\u4e4b\u5f71\u97ff\uff0c\u5247\u5229\u7528NWP\u6c34\u5047\u9ad4\u7cfb\u7d71\uff08Nucletron Water-Phantom System\uff09\u642d\u914d0.12 c.c. RK\u6e38\u96e2\u8154\u505a\u6e2c\u91cf\uff0c\u57286\u548c10 MV\u6642\uff0c\u8ddd\u7167\u91ce\u908a\u7de31\u30012\u30013\u30014\u30015\u53ca7 \u339d\uff0c\u4e14\u6df1\u5ea6\u5f9e0~20 \u339d\uff0c\u67b6\u4e0a\u9577\u5bec\u9ad8\u5206\u5225\u70ba12\u30018\u30017.5 \u339d\uff0c\u800cBSTD\uff1d25 \u339d\u4e4b\u925b\u5408\u91d1\u584a\u518d\u6e2c\u91cf\u4e00\u6b21\uff0c\u5373\u53ef\u5f97PD\u7d93\u5c4f\u853d\u5f8c\u7684\u7d50\u679c\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u7d93\u5be6\u9a57\u5f97\u77e5\u925b\u5408\u91d1\u584a\u4e4bBSTD\uff1d25 \u339d\u6642\u5176\u5c0dPD\u7684\u5c4f\u853d\u6548\u679c\u6700\u4f73\uff0c\u4ee56 MV X-\u5c04\u7dda\u3001\u6df1\u5ea65 cm\u3001\u7167\u91ce\u5916\u8ddd\u908a\u7de35 cm\u7684\u6e2c\u91cf\u7d50\u679c\u800c\u8a00\uff0c\u5728\u7121\u5c4f\u853d\u7684\u60c5\u6cc1\u4e0b\uff0c\u6b64\u7167\u91ce\u5916\u5291\u91cf\u8207\u7167\u91ce\u5e7e\u4f55\u4e2d\u5fc3\u8ef8dmax\u8655\u7684\u5291\u91cf\u4e4b\u6bd4\u503c\u70ba1.74%\uff1b\u52a0\u4e0a\u925b\u5408\u91d1\u584a\u5f8c\u6bd4\u503c\u964d\u70ba0.86%\u3002\u540c\u6a23BSTD\uff1d25 \u339d\uff0c\u5247\u4ee5t\uff1d15 \u339d\u90a3\u7d44\u925b\u5408\u91d1\u584a\u5c0dPD\u7684\u8870\u6e1b\u6548\u679c\u6700\u597d\uff0c\u4ee5\u4e0a\u8ff0\u76f8\u540c\u7684\u9ede\u505a\u6e2c\u91cf\u5176PD\u70ba0.45%\u3002\u4e0d\u8ad6\u662f6\u621610 MV\uff0c\u7576\u91cf\u6e2c\u4f4d\u7f6e\u63a5\u8fd1\u7167\u91ce\u908a\u7de3\uff0c\u4e14\u4f4d\u65bc\u8f03\u8868\u6dfa\u7684\u5730\u65b9\uff0cPD\u6f38\u589e\uff0c\u4e26\u6703\u96a8\u6df1\u5ea6\u589e\u52a0\u9010\u6f38\u4e0b\u964d\u5230\u8a72\u80fd\u91cf\u4e4b\u5149\u5b50\u5c04\u675f\u5176dmax\u5de6\u53f3\u9054\u5230\u6700\u5c0f\u503c\u3002\u4e4b\u5f8c\uff0c\u96a8\u8457\u6df1\u5ea6\u7684\u589e\u52a0PD\u6703\u518d\u6b21\u8f15\u5fae\u5347\u9ad8\uff1b\u82e5\u8ddd\u96e2\u7167\u91ce\u908a\u7de3\u6108\u4f86\u6108\u9060\u6642\uff0cPD\u5c31\u96a8\u6df1\u5ea6\u8b8a\u5316\u7684\u60c5\u5f62\u5c07\u4e0d\u660e\u986f\uff1b\u800c\u8207\u7167\u91ce\u908a\u7de3\u8ddd\u96e2\u4e4b\u95dc\u4fc2\u662f\u96a8\u4e4b\u589e\u52a0\u800c\u9010\u6f38\u4e0b\u964d\u3002\n\u7d50\u8ad6\uff1a\u7531\u5be6\u9a57\u7d50\u679c\u767c\u73fe\uff0c\u6b64\u7a2e\u7279\u88fd\u925b\u5408\u91d1\u584a\u5c0d\u7167\u91ce\u5916\u5291\u91cf\u7684\u964d\u4f4e\u78ba\u5be6\u6709\u660e\u986f\u8ca2\u737b\uff0c\u4e14\u5176\u6709\u4f7f\u7528\u7c21\u4fbf\u3001\u88fd\u4f5c\u5bb9\u6613\u3001\u6210\u672c\u4f4e\u4e4b\u512a\u9ede\uff0c\u6709\u52a9\u65bc\u81e8\u5e8a\u4e0a\u7684\u4f7f\u7528\u3002\u4f46\u5176\u7f3a\u9ede\u70ba\u50c5\u9650\u7528\u65bc\u5c0f\u7bc4\u570d\u4e4b\u7167\u91ce\uff0c\u56e0\u6b64\uff0c\u5c07\u5176\u6539\u826f\u7684\u66f4\u597d\u3001\u61c9\u7528\u66f4\u5ee3\uff0c\u662f\u6211\u5011\u65e5\u5f8c\u52aa\u529b\u7684\u76ee\u6a19\u3002", "e": "Purpose : The main purpose of this study is to estimate the attenuate effect for peripheral dose (PD) with a special designed block overhung between blocking tray and phantom surface, and find out of PD on depth , distance from field edge, and energy.\nMaterials and methods : Blocks with different thickness, 4, 7.5 and 15 cm, and equal length and width were made by putting different length of screws into the blocks. The distance from block surface to tray (BSTD) is 10, 15 and 25 cm for the blocks. High energy photon beams of 6 and 10 MV generated by SIEMENS KDS-2 Linac were used in this study. Asymmetric field with equivalent field size of 10 ?10 cm2 was used for all the measurements. Peripheral doses were measured by using a Farmer type chamber and Acrylic solid phantom. Ionization charges were collected by a Victoreen 500 electrometer. PD for different depth, BSTD, and block thickness were evaluated. Nucletron water phantom system with 0.12 c.c. R K chamber was used for measuring the variations of PD with distances from field edge and depth. PD with and without block were measured also. \nResult and Discussion : We find that block with BSTD equal to 25 cm decrease the PD most. When distance from field edge is 5 cm and depth at 5 cm, the PD relative to Dmax (dose at dmax) at central axis is 1.74% without block, and is 0.86% with block for 6 MV. The block with thickness of 15 cm has the best attenuation effect, and reduce the PD to 0.45% relative to Dmax . The PD decreases as the distance from field edge increases. Close to the field edge, the PD drops initially with depth, the minimum apperance at the depth that deeper than the dmax (depth of maximum dose) of the central ray 0.5 cm. Behind the dmax, the PD increases gradually with depth and then become nearly constant farther. The qualitative behavior of the PD is similar for 6 and 10 MV.\nConclussion : From the results, we know that the blocks have obvious contribution for reducing the PD, and that advantage is used conviently, made easily, low cost, but shortcoming is just suitable for small treatment field. To improve the equipment for better is our object in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-175-179-a", "title": "Small Cell Neuroendocrine Carcinoma of Ethmoid Sinus: Case Report and Literature Review", "keywords": "\u5c0f\u7d30\u80de\u795e\u7d93\u5167\u5206\u6ccc\u764c;\u7be9\u9aa8\u8154;\u653e\u5c04\u6cbb\u7642 Small cell neuroendocrine carcinoma;Ethmoid sinus;Radiotherapy", "c": "\u526f\u9f3b\u7ac7\u8154\u60e1\u6027\u816b\u7624\u4f54\u4eba\u985e\u6240\u6709\u60e1\u6027\u816b\u7624\u76840.2\u52300.8%\uff0c\u9c57\u72c0\u7d30\u80de\u764c\u662f\u6700\u5e38\u898b\u7684\u7d44\u7e54\u578b\u614b\uff0c\u539f\u767c\u7be9\u9aa8\u8154\u5c0f\u7d30\u80de\u795e\u7d93\u5167\u5206\u6ccc\u764c\u662f\u4e00\u7f55\u898b\u4e14\u60e1\u6027\u4e4b\u816b\u7624\uff0c\u5176\u7d44\u7e54\u578b\u614b\u53ca\u514d\u75ab\u5316\u5b78\u67d3\u8272\u7279\u5fb5\u8207\u80ba\u5c0f\u7d30\u80de\u764c\u76f8\u4f3c\uff1b\u81e8\u5e8a\u4e0a\u9700\u4f75\u7528\u624b\u8853\u6216\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u7b49\u65b9\u5f0f\u8655\u7406\u3002\n\u6211\u5011\u5831\u544a\u4e00\u4f4d\u539f\u767c\u7be9\u9aa8\u8154\u5c0f\u7d30\u80de\u795e\u7d93\u5167\u5206\u6ccc\u764c\u7684\u6848\u4f8b\uff0c\u816b\u7624\u4fb5\u72af\u81f3\u53f3\u773c\u7aa9\u5167\u5074\u53ca\u4e0a\u984e\u9f3b\u7ac7\u8154\uff1b\u65bc\u816b\u7624\u6458\u9664\u8853\u5f8c\u8f14\u4ee5\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u3002\u8ffd\u8e64\u81f3\u4eca\u7d04\u516d\u500b\u6708\uff0c\u4e26\u7121\u5c40\u90e8\u5fa9\u767c\u6216\u9060\u7aef\u8f49\u79fb\u60c5\u6cc1\u767c\u751f\u3002\u6587\u4e2d\u53e6\u63a2\u8a0e\u5c0f\u7d30\u80de\u795e\u7d93\u5167\u5206\u6ccc\u764c\u4e4b\u6700\u9069\u7576\u8655\u7406\u6a21\u5f0f\u53ca\u5176\u514d\u75ab\u5316\u5b78\u67d3\u8272\u7279\u5fb5\u3002", "e": "Malignant tumors arising in the paranasal sinuses account for 0.2 to 0.8% of all cancers. Squamous cell carcinoma is by far the most common malignant tumor. Primary small cell neuroendocrine carcinoma of ethmoid sinus is an uncommon and distinctive tumor with an aggressive clinical behavior. Besides, its morphological and immuno-histo-chemical features are similar to those of small cell carcinoma of lung. The need for a multi-disciplinary treatment approach combining surgery or radiotherapy and chemotherapy is indicated in treating these aggressive tumors.\nWe report a case of 40-year-old man who has small cell neuroendocrine carcinoma of ethmoid sinus with invasion of upper aspect of right maxillary sinus and medial aspect of right orbit. The patient was treated with surgery and adjuvant radiotherapy followed by systemic chemotherapy. Neither local recurrence nor distant metastasis was noted during follow-up of 6 months. The optimal treatment and the immuno-histo-chemical characteristics are discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200309-10-3-181-187-a", "title": "Pre-operative Low Dose Radiotherapy of Rectal Cancer with Fournier", "keywords": "\u798f\u5c3c\u8033\u58de\u75bd;\u76f4\u8178\u764c;\u653e\u5c04\u6cbb\u7642;\u75c5\u4f8b\u5831\u544a Fournier", "c": "\u798f\u5c3c\u8033\u58de\u75bd\u5728\u76f4\u8178\u764c\u75c5\u60a3\u5f88\u5c11\u898b\u537b\u7d93\u5e38\u81f4\u547d\u3002\u6211\u5011\u5831\u544a\u4e00\u4f4d\u9157\u9152\u4e4b\u7537\u6027\u75c5\u60a3\uff0c\u4ed6\u7f79\u60a3\u81f3\u5c11\u662f\u816b\u7624\u7b2c\u4e09\u671f\u4e4b\u76f4\u8178\u764c\u53ca\u798f\u5c3c\u8033\u58de\u75bd\u3002\u6211\u5011\u5b89\u6392\u4e86\u816b\u7624\u5207\u9664\u524d\u4e4b\u4f4e\u5291\u91cf\u653e\u7642\uff0c\u800c\u4e0d\u662f\u4f9d\u7167\u6709\u4e9b\u6587\u737b\u4e0a\u6240\u4e3b\u5f35\uff0c\u8981\u628a\u653e\u7642\u6574\u500b\u7642\u7a0b\u5ef6\u5f8c\u5230\u50b7\u53e3\u7a69\u5b9a\u7652\u5408\u5f8c\u518d\u958b\u59cb\u3002\u5c31\u7b97\u653e\u7642\u4e3b\u8981\u4e4b\u6cbb\u7642\u5291\u91cf\u61c9\u5728\u816b\u7624\u5207\u9664\u5f8c\u518d\u65bd\u4e88\uff0c\u6211\u5011\u76f8\u4fe1\u8853\u524d\u4f4e\u5291\u91cf\u4e4b\u653e\u7642\u5c0d\u5e6b\u52a9\u75c5\u60a3\u816b\u7624\u4e4b\u5207\u9664\u548c\u81e8\u5e8a\u6574\u9ad4\u7d50\u679c\u6709\u6b63\u9762\u6548\u76ca\u3002\u9019\u7bc7\u6587\u7ae0\u540c\u6642\u4e5f\u56de\u9867\u4e86\u6587\u737b\u4e0a\u6709\u95dc\u540c\u6642\u6709\u76f4\u8178\u764c\u4f75\u767c\u798f\u5c3c\u8033\u58de\u75bd\u4e4b\u75c5\u4f8b\uff0c\u4e26\u5c0d\u653e\u7642\u4e4b\u6642\u6a5f\u4f5c\u4e00\u8a0e\u8ad6\u3002", "e": "Fournier's gangrene is a rare but often fatal manifestation of rectal cancer. We report a case of at least T3 stage adenocarcinoma of rectum with Fournier's gangrene in a male alcoholic abuser. Instead of postponing radiation therapy as suggested by some literature, we arranged low dose pre-operative radiation therapy and found the following operation was smoother than expected. Whereas full dose radiation therapy of the cancer should be performed after resection as suggested by the literature, we believe pre-operative low-dose radiation therapy may help the execution of tumor resection and thus the general outcome of the patient. This report also summarizes a review of the literature on the management of de novo Fournier\u6387 gangrene cases with rectal cancers and discusses the role and timing of radiation therapy in such cases."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-63-68-a", "title": "\u9f3b\u54bd\u764c\u75c5\u60a3\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u2500\u5c40\u90e8\u6cbb\u7642\u5291\u91cf4500cGy\u4ee5\u4e0b\u7d50\u679c\u4e4b\u63a2\u8a0e", "keywords": "\u9f3b\u54bd\u764c,\u653e\u5c04\u6cbb\u7642,\u6cbb\u7642\u5291\u91cf\u4e0d\u8db3 Undertreatment,Nasopharyngeal carcinoma,Radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u5728\u5206\u6790\u9f3b\u54bd\u764c\u75c5\u60a3\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f46\u5c40\u90e8\u6cbb\u7642\u5291\u91cf\u57284500cGy\u4e0b\u4e4b\u60c5\u5f62\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1979\u5e744\u6708\u81f31997\u5e7412\u6708\uff0c\u5171\u6709138\u4f4d\u9f3b\u54bd\u764c\u75c5\u60a3\u5728\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u5291\u91cf4500cGy\u4ee5\u4e0b\uff0c\u4e14\u4e4b\u5f8c\u4e26\u672a\u65bc\u4ed6\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u5316\u5b78\u6cbb\u7642\u7b49\u3002\u5176\u4e2d\u7537\u6027103\u4eba\u3001\u5973\u602735\u4eba\uff0c\u5e74\u9f61\u5206\u5e03\u653e18\u6b72\u81f385\u6b72\u4e4b\u9593\uff0c\u7b85\u54bd\u7684\u6cbb\u7642\u5291\u91cf\u4ecb\u65bc180cGy\u81f34500cGy\u9593\uff1b\u4e2d\u4f4d\u5291\u91cf(median dose)\u70ba2500cGy\u3002\u4f7f\u7528Kaplan-Meier\u4e4b\u65b9\u6cd5\u4f86\u6c7a\u5bb6\u5176\u751f\u5b58\u671f\u3002\n\u7d50\u679c\uff1a\u9019138\u4f4d\u75c5\u4eba\u7684\u8ffd\u8e64\u671f\u9593\u5f9e3\u5e74\u81f314.7\u5e74\u4e0d\u7b49\uff0c\u5176\u8ffd\u8e64\u4e4b\u4e2d\u4f4d\u6578\u70ba7.1\u5e74\u3002\u76f4\u81f32001\u5e7412\u6708\u5e95\u6b62\uff0c\u4ecd\u5b58\u6d3b\u8005\u5171\u67097\u4eba\uff0c\u5176\u4e2d5\u4eba\u662f\u7121\u75c5\u5b58\u6d3b\uff1b130\u4eba\u5df2\u6b7b\u4ea1\uff0c\u800c\u5176\u4e2d77\u4eba(56%)\u6b7b\u65bc\u5c40\u90e8\u816b\u7624\uff0c38\u4eba(27.5%)\u6b7b\u65bc\u9060\u8655\u8f49\u79fb\uff0c14\u4eba(10%)\u6b7b\u65bc\u60e1\u75c5\u8cea\uff0c1(0.7%)\u4eba\u6b7b\u65bc\u8166\u4e2d\u98a8\uff1b1\u4eba\u5931\u53bb\u806f\u7d61\u4e00\u5e74\u53ca\u4e94\u5e74\u4e4b\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba52%\u53ca11%\uff1b\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba1.06\u5e74\uff0c\u800c\u5927\u90e8\u5206\u4e4b\u75c5\u4eba\u90fd\u65bc\u4e2d\u65b7\u6cbb\u7642\u5f8c2\u5e74\u5167\u6b7b\u4ea1\u3002\n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793a\u9f3b\u54bd\u764c\u75c5\u60a3\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u53ea\u67094500cGy\u4ee5\u4e0b\u8005\u5176\u9810\u5f8c\u662f\u5f88\u5dee\u7684\uff0c\u5927\u90e8\u5206\u75c5\u60a3\u65bc\u6cbb\u7642\u4e2d\u65b7\u5f8c\u4e4b2\u5e74\u5167\u6b7b\u4ea1\uff0c\u800c\u9020\u6210\u75c5\u60a3\u6cbb\u7642\u4e2d\u65b7\u4e3b\u8981\u5c0e\u56e0\u4e43\u662f\u75c5\u60a3\u7121\u6cd5\u5fcd\u53d7\u653e\u5c04\u6cbb\u7642\u6240\u5f15\u8d77\u6025\u6027\u526f\u4f5c\u7528\u4e4b\u6545\u3002", "e": "Purpose: To study the outcome of undertreated nasopharyngeal carcinomas (NPC) in patients who received external beam radiation doses of no more than 4500 cGy. \nMaterials and Methods: Form April 1979 to December 1997, 138 NPC patients receiving radiotherapy with external beam radiation (EBRT) doses of no more than 4500 cGy at the Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou, were included in this study. Total doses ranged from 189 cGy to 4500 cGy with a median dose of 2520 cGy. The survivals were calculated by Kaplan-Miere method. The median follow-up time was7 years. \nResults: At the time of last follow-up, the 1\u2013 and 5-year survival rates for the 138 undertreated NPC patients, derived using the Kaplan-Miere method, were 52% and 11%, respectively. One hundred and twenty-nine patients had died of the disease. One patient had died of intercurrent disease. Five patients were alive without disease. Two patients were alive with disease. One patient was loss of follow-up. The median survival of these patients was 1.06 years (range from 0.03 ~ 19.7 year). At the end of study, local recurrent or persistent tumors were determined for 94 patients (68%). Forty-nine patients (35.5%)subsequently developed distant metastases. The causes of death were: locoregional disease: 56% (n=77),distant metastasis:27.5%(n=38), cachexia:11% (n=15), cerebrovascular accident:0.7% (n=1). Bone. Liver and lung were the most common metastatic sites. Most of the patients died within two years after interruption of treatment. Death was the only outcome evaluated. Less than 5% patients (n=5) were alive without disease till the time of analysis. \nDiscussion: The prognosis has been dismal for undertreated NPC patients. Our study confirmed that long-term survival is rare in patients with NPC receiving EBRT doses not more than 4500 cGy. The majority of patients died within 2 years after interruption of radiotherapy (RT). The acute side effects and complications of RT were the primary factors influencing the patient\u2019s decisions to drop out of the treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-69-78-a", "title": "THREE DIMENSIONAL CONFORMAL RADIOTHERAPY FOR PORTAL VEIN TUMOR THOMBOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA", "keywords": "\u809d\u9580\u975c\u8108\u963b\u585e,\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642,\u809d\u52d5\u8108\u6813\u585e,\u809d\u764c Three-dimensional conformal radiotherapy,Portal vein tumor thrombosis,Hepatocellular carcinoma", "c": "\u76ee\u7684\uff1a\u809d\u764c\u5408\u4f75\u809d\u9580\u975c\u8108\u816b\u7624\u690e\u585e\u7684\u9810\u5f8c\u5f88\u5dee\uff0c\u81f3\u4eca\u5c1a\u672a\u5f97\u5230\u6709\u6548\u4e14\u4e00\u81f4\u6027\u7684\u6cbb\u7642\u65b9\u6cd5\u3002\u672c\u6587\u63a2\u8a0e\u5229\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\u7684\u65b9\u5f0f\uff0c\u6cbb\u7642\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u3002\u5c0d\u7121\u6cd5\u5207\u9664\u7684\u809d\u764c\u75c5\u4eba\u4e4b\u5b58\u6d3b\u53ca\u5f8c\u7e8c\u6cbb\u7642\u7684\u5f71\u97ff\uff0c\u4e26\u5206\u6790\u5176\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1998\u81f32001\u5e74\uff0c\u5171\u670931\u4f4d\u5ee3\u6cdb\u6027\u809d\u764c\u5408\u4f75\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u7684\u75c5\u4eba\u81f3\u672c\u79d1\u63a5\u53d7\u809d\u9580\u975c\u8108\u4e4b\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d23\u4f4d\u75c5\u4eba\u5b8c\u6210\u6cbb\u7642\u8a08\u756b\u4e26\u6709\u5b8c\u6574\u7684\u5f8c\u7e8c\u8ffd\u8e64\u3002\u9019\u4e9b\u75c5\u4eba\u7d66\u4e88\u7684\u5291\u91cf\u5e73\u5747\u70ba47.6\u00b14.4Gy \uff0c\u6bcf\u6b211.8-2.2Gy\u3002\u6cbb\u7642\u7d50\u675f\u5f8c2\u81f34\u9031\uff0c\u4ee5\u8179\u90e8\u8d85\u97f3\u6ce2\u6216\u96fb\u8166\u65b7\u5c64\u4f86\u8a55\u4f30\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u7684\u53cd\u61c9\uff0c\u4e4b\u5f8c\u4e26\u5b9a\u671f\u8ffd\u8e64\u3002\u75c5\u4eba\u7684\u5b58\u6d3b\u6642\u9593\u81ea\u8a3a\u65b7\u51fa\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u7b97\u8d77\u81f3\u7d71\u8a08\u7d50\u675f\u3002\n\u7d50\u679c\uff1a\u67099\u4f4d\u75c5\u4eba(39%)\u7684\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u6d88\u5931\u6216\u7e2e\u5c0f\uff0c\u90199\u4f4d\u75c5\u4eba\u5168\u90e8\u63a5\u53d7\u5f8c\u7e8c\u7684\u809d\u52d5\u8108\u6813\u585e\u6216\u9152\u7cbe\u6ce8\u5c04\u6cbb\u7642\uff0c\u9019\u7fa4\u75c5\u4eba\u7684\u5b58\u6cbb\u6642\u9593\u4e5f\u660e\u986f\u8d85\u904e\u53e6\u591614\u4f4d\u75c5\u4eba\u3002\u591a\u8b8a\u9805\u5206\u6790\u986f\u793a\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u7684\u53cd\u61c9\u53ca\u5f8c\u7e8c\u7684\u6cbb\u7642\u662f\u5f71\u97ff\u5b58\u6d3b\u6642\u9593\u7684\u8b8a\u9805\uff0c\u800c\u5f71\u97ff\u809d\u9580\u975c\u8108\u6813\u585e\u53cd\u61c9\u7684\u8b8a\u9805\u5247\u5305\u62ec\u653e\u5c04\u6cbb\u7642\u524d\u7684\u8840\u7d05\u7d20(Hb)\u3001\u8840\u6e05\u767d\u86cb\u767d(serum albumin)\u3002\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\u6d88\u5931\u6216\u7e2e\u5c0f\u7684\u4e2d\u4f4d\u6642\u9593\u70ba17\u5929(10-255\u5929)\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\u7684\u65b9\u5f0f\u6cbb\u7642\u809d\u9580\u975c\u8108\u816b\u7624\u6813\u585e\uff0c\u5728\u7279\u5b9a\u60c5\u6cc1\u4e0b\uff0c\u53ef\u4ee5\u63d0\u4f9b\u75c5\u4eba\u63a5\u53d7\u5f8c\u7e8c\u6cbb\u7642\u7684\u6a5f\u6703\uff0c\u9032\u800c\u5ef6\u9577\u5b58\u6d3b\u6642\u9593\u3002\u7a4d\u6975\u63d0\u9ad8\u75c5\u4eba\u7684\u8840\u7d05\u7d20\u4e26\u6539\u5584\u71df\u990a\u72c0\u614b\uff0c\u53ef\u63d0\u5347\u6cbb\u7642\u6548\u679c\u3002", "e": "Purpose: Hepatocellular carcinoma (HCC)with portal vein tumor thrombosis(PVTT)has poor prognosis. The aim of this study was to investigate the efficacy and prognostic factors of conformal radiotherapy for PVTT in unresectable HCC. The primary endpoint of this study is the overall survival of patients. The secondary endpoint is the overall response of tumors. \nPatients and Methods: form June 1998 to December 2001, 23 patients of advanced HCC with PVTT enrolled into the study. Mean treatment dose was 47.6 \u00b14.4 Gy, in a daily fraction of 1.8-2.2 Gy. Response was assessed by enhanced computer tomography (CT) scan and/or color Doppler abdominal ultrasonography 2-4 weeks following completion of the treatment and then in a 2-4 month interval. Survival was calculated from the diagnosis of PVTT using the Kaplan-Meier method. \nResults: An objective response was observed in 9 patients, giving a response rate of 39%. The survival rate of the responder patients was significant higher than non-responders(median survival 13 vs. 5 months, p=0.0027). All of the 9 responders received sub-sequent transcatheter arterial chemoembolization (TACE) or percutaneous ethanol injection (PEI). Multivariate analysis showed that the response of PVTT and the subsequent treatments were the prognostic factors of the survival, while the pre-treatment hemoglobin and serum albumin level were the factors that affected response. The intervals from the completion of radiotherapy to response ranged from 10 to 255 days(median 17 days).\nConclusion: Local conformal irradiation to PVTT is sometimes feasible and effective. Better nutritional status reflected by the hemoglobin and serum albumin levels improves response rates and prolongs survival consequent to subsequent TACE or PEI."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-79-88-a", "title": "\u9ad8\u5bc6\u5ea6\u91d1\u5c6c\u7269\u8cea\u5728\u76f4\u7dda\u52a0\u901f\u5668\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u64fe\u52d5\u6548\u61c9\u7684\u8499\u5730\u5361\u7f85\u6a21\u64ec", "keywords": "\u8499\u5730\u5361\u7f85\u65b9\u6cd5,\u76f4\u7dda\u52a0\u901f\u5668 Monte Carlo method,LINAC", "c": "\u76ee\u7684\uff1a\u4ee5\u8499\u5730\u5361\u7f85\u6cd5\u7a0b\u5f0f\u6a21\u64ec\u9ad8\u5bc6\u5ea6\u91d1\u5c6c\u7269\u8cea\u5728\u653e\u5c04\u6cbb\u7642\u6642\u5c0d\u5291\u91cf\u64fe\u52d5\u7684\u6548\u61c9\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5OMEGA/BEAM \u7a0b\u5f0f\u70ba\u4e3b\uff0c\u9032\u884c\u76ee\u524d\u81e8\u5e8a\u4f7f\u7528Varian 21 EX \u6a5f\u578b\u76f4\u7dda\u52a0\u901f\u5668\u7684\u6a21\u64ec\uff0c\u9996\u5148\u91dd\u5c0d6MV\uff0c40 \u00d7 40 \u339d2\u7167\u91ce\uff0cSSD=100\u339d\u8a2d\u5b9a\u5728\u5747\u52fb\u6c34\u5047\u9ad4\u4e2d\u9032\u884c\u6a21\u64ec\uff0c\u8207\u5be6\u9a57\u91cf\u6e2c\u4e4b\u6df1\u5ea6\u5291\u91cf\u4ee5\u53ca\u5291\u91cf\u5256\u9762\u7b49\u7d50\u679c\u9a57\u8b49\u6bd4\u8f03\uff0c\u4e26\u9032\u884c\u53c3\u6578\u8abf\u6574\uff0c\u78ba\u8a8d\u5404\u9805\u6a21\u64ec\u53c3\u6578\u6b63\u78ba\u7121\u8aa4\u5f8c\uff0c\u518d\u91dd\u5c0d6MV\uff0c10 \u00d7 10 \u339d2\u7167\u91ce\uff0cSAD=100\u339d\u8a2d\u5b9a\u9032\u884c\u9ad8\u5bc6\u5ea6\u91d1\u5c6c\u6750\u8cea\u5c0d\u5291\u91cf\u64fe\u52d5\u6548\u61c9\u4e4b\u6a21\u64ec\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u7d93\u4ee5\u5be6\u9a57\u91cf\u6e2c\u7684\u6df1\u5ea6\u5291\u91cf\u8207\u5291\u91cf\u5256\u9762\u9a57\u8b49\u6c42\u5f97\u4e4b\u52a0\u901f\u5668\u53c3\u6578( 6 MV \u7167\u91ce\u5927\u5b50\u70ba40 \u00d7 40 \u339d2\u300110 \u00d7 10 \u339d2)\uff0c\u5176\u6a21\u64ec\u7d50\u679c\u5747\u8207\u91cf\u6e2c\u503c\u7684\u8aa4\u5dee\u57282%\u4ee5\u5167\uff0c\u8b49\u5be6\u5404\u9805\u63a8\u6e2c\u4e4b\u53c3\u6578\u6b63\u78ba\u7121\u8aa4\uff0c\u986f\u793a\u5df2\u5efa\u7acbVarian 21 EX \u6a5f\u578b\u52a0\u901f\u5668\u6a21\u64ec\u4e4b\u904b\u8dd1\u80fd\u529b\u3002\u4ee5\u5047\u7259\u91d1\u5c6c\u6a23\u54c1\u70ba\u4f8b\uff0c\u9032\u884c6MV\u7167\u91ce\u5927\u5c0f\u70ba10 \u00d7 10 \u339d2 \uff0cSAD=100 \u339d \uff0c\u6a23\u54c1\u4f4d\u65bc\u6c34\u5047\u9ad4\u5167 5 \u339d \u6df1\u4e4b\u6a21\u64ec\uff0c\u7d50\u679c\u986f\u793a\u5291\u91cf\u64fe\u52d5\u7684\u7bc4\u570d\uff0c\u5728\u6df1\u5ea6\u5291\u91cf\u65b9\u9762\u524d\u5f8c\u7d04\u70ba 1 \u339d \uff0c\u6a23\u54c1\u524d\u7684\u96fb\u5b50\u56de\u6563\u5c04\u6548\u61c9\u9020\u6210\u7d0440%\u7684\u5291\u91cf\u589e\u52a0\uff0c\u6a23\u54c1\u5f8c\u7684\u906e\u853d\u6548\u61c9\u7d04\u57280.2 \u81f3 0.6 MeV \u4e4b\u9593\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u4e2d\u6240\u63a1\u7528\u7684\u91d1\u5c6c\u6a23\u54c1\u9ad4\u7a4d\u96d6\u5c0f\u4f46\u5bc6\u5ea6\u751a\u9ad8\uff0c\u64fe\u52d5\u6548\u61c9\u76f8\u7576\u986f\u8457\uff0c\u4f46\u7531\u653e\u64fe\u52d5\u7684\u7bc4\u570d\u8f03\u5c0f\uff0c\u56e0\u6b64\u5c07\u5728\u5be6\u9a57\u91cf\u6e2c\u4e0a\u986f\u5f97\u8f03\u70ba\u56f0\u96e3\u3002\u5728\u672c\u7814\u7a76\u4e2d\u900f\u904e\u8499\u5730\u5361\u7f85\u6a21\u64ec\u63d0\u4f9b\u6df1\u5ea6\u5291\u91cf\u3001\u5291\u91cf\u5256\u9762\u3001\u4ee5\u53ca\u76f8\u95dc\u4f4d\u7f6e\u7684\u5149\u5b50\u80fd\u8b5c\u5206\u5e03\u5f71\u97ff\u4e4b\u8cc7\u8a0a\uff0c\u53ef\u4f5c\u70ba\u5be6\u9a57\u91cf\u6e2c\u8a2d\u8a08\u4e4b\u53c3\u8003\uff0c\u4ee5\u9032\u4e00\u6b65\u7814\u7a76\u63a2\u8a0e\u5728\u81e8\u5e8a\u4e0a\u6b64\u985e\u6750\u8cea\u6240\u9020\u6210\u7684\u5be6\u969b\u5f71\u97ff\u3002", "e": "Purpose: This study performed the simulation of the dose distribution around the embedded high-den-sity metal material.\nMaterials and Mathods: The simulation is focused on the Varian 21EX LINAC machine and imple-mented by the OMEGA/BEAM code system. For modeling the linear accelerator, the simulation para-meters are adjusted by comparing the results of the depth doses and the setup of 6 MV, 40 \u00d7 40 cm2, SAD= 100 cm in a homogeneous water phantom. Then, the dose disturbance has been investigated for the setup of 6 MV, 10 \u00d7 10 cm2 SAD= 100 cm with a denture sample.\nResults and Discussion: The adjusted LINAC parameters have been proved by the verifications of the depth doses and dose profiles calculated by DOSXYZ with the measurement setup of 6 MV, 40 \u00d7 40 cm2, SSD = 100 cm. It shows that the capability of simulating the Varian 21EX  LINAC has been established. For the Degubond 4 denture sample at a depth of 5 cm with a setup of 6 MV, 10 \u00d7 10 cm2, SAD = 100 cm, the dose disturbance range in depth dose is around 2 cm. The back scattering electrons cause a 40% dose increment in front of the sample and the shielding effect decreases the dose of about 20% behind the sample. Maximum range disturbs the dose profile is about 1.2 cm. The energy range of the back scattering photons is between 0.2 and 0.6 MeV.\nConclusion: The size of the denture sample used in the study is small, but the density is quite high, hence the perturbation effect is still significant. Besides, the spatial range of the perturbation is relative-ly small; it is difficult to be measured. In this study, it shows that the detailed information includes depth dose, dose profile at several depth, and the photon/electron spectrums could be obtained by Monte Carlo simulation, and could provide for the further study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-89-96-a", "title": "\u6dec\u53d6\u5927\u8166\u5f71\u50cf\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u9032\u884c\u4e09\u7dad\u96fb\u8166\u65b7\u5c64\u8207\u78c1\u632f\u9020\u5f71\u7684\u5c0d\u6e96\u8207\u878d\u5408", "keywords": "\u6b63\u4e2d\u77e2\u72c0\u5207\u9762,\u8ff4\u6b78,\u7a7a\u9593\u5e7e\u4f55\u8f49\u63db,\u4e09\u6b21\u66f2\u7dda\u5167\u63d2,\u6700\u4f73\u5316\u6cd5,\u5f71\u50cf\u5c0d\u6e96,\u5f71\u50cf\u878d\u5408 Mid-sagittal plane,Regression,Geometric transformation,Cubic spline interpolation,Optimization,Image registration,Image fusion", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u4e3b\u8981\u662f\u8457\u91cd\u65bc\u5229\u7528\u5927\u8166\u7684\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u9032\u884c\u4e09\u7dad\u96fb\u8166\u65b7\u5c64\u8207\u78c1\u632f\u9020\u5f71\u7684\u5f71\u50cf\u5c0d\u6e96\u8207\u878d\u5408\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7531\u65bc\u96fb\u8166\u65b7\u5c64\u4ee5\u53ca\u78c1\u632f\u9020\u5f71\u7684\u5f71\u50cf\u5747\u6703\u5448\u73fe\u51fa\u5de6\u53f3\u5c0d\u7a31\u7684\u5927\u8166\u534a\u7403\uff0c\u5229\u7528\u4eba\u70ba\u9ede\u9078\u7684\u65b9\u5f0f\u627e\u51fa\u5927\u8166\u8ef8\u5207\u5f71\u50cf\u7684\u5c0d\u7a31\u4e2d\u7dda\uff0c\u900f\u904e\u6bcf\u4e00\u5f35\u8ef8\u5207\u5f71\u50cf\u4e0a\u7684\u4e2d\u7dda\u524d\u5f8c\u5169\u9ede\uff0c\u56de\u6b78\u51fa\u5169\u7d44\u5f71\u50cf\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u6240\u5728\u7684\u5e73\u9762\u65b9\u7a0b\u5f0f\uff0c\u518d\u85c9\u7531\u7a7a\u9593\u5e7e\u4f55\u8f49\u63db\u4f7f\u5169\u7d44\u5f71\u50cf\u7684\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u5c0d\u61c9\u5230\u540c\u4e00\u5e73\u9762(Z= 0)\u4e0a\u3002\u7531\u65bc\u6bcf\u4e00\u5f35\u5f71\u50cf\u7684\u4e2d\u7dda\u524d\u7684\u5169\u9ede\u662f\u4f4d\u65bc\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u4e0a\uff0c\u56e0\u6b64\u9019\u4e9b\u9ede\u4e5f\u6703\u88ab\u8f49\u63db\u5230\u76f8\u540c\u5e73\u9762(Z=0)\u4e0a\uff0c\u5229\u7528\u4e09\u6b21\u66f2\u7dda\u5167\u63d2(cubic spline interpolation)\u6cd5\u5c07\u9019\u4e9b\u9ede\u5167\u63d2\u51fa\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u7684\u908a\u754c\uff0c\u4e26\u5229\u7528POWELL \u6700\u4f73\u5316\u6cd5\u9032\u884c\u5169\u7d44\u5f71\u50cf\u7684\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u5716\u5f62\u7684\u5c0d\u6e96\uff0c\u6700\u5f8c\u518d\u5c07\u5f71\u50cf\u505a\u878d\u5408\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u8a55\u4f30\u4e86\u5169\u7d44\u5f71\u50cf\uff0c\u7d50\u679c\u986f\u793a\u5728x-y\u65b9\u5411\u7684\u8aa4\u5dee\u70ba1~3mm\uff0c\u800c\u5728z\u65b9\u5411\u7684\u8aa4\u5dee\u5927\u7d04\u70ba4mm\u3002\n\u7d50\u8ad6\uff1a\u672c\u65b9\u6cd5\u5229\u7528\u76f8\u540c\u7684\u6b63\u4e2d\u77e2\u72c0\u5207\u9762\u4ee5\u9032\u884c\u5f71\u50cf\u5c0d\u6e96\uff0c\u964d\u4f4e\u4e86\u5c0d\u6e96\u7684\u81ea\u7531\u5ea6\uff0c\u4e26\u4e14\u4e5f\u964d\u4f4e\u4e86\u5c0d\u6e96\u7684\u6642\u9593\u3002", "e": "Objective: The Purpose of this study is to register 3D MR images with corresponding CT images by using mid-sagittal plane of the brain. \nMaterials and Methods: We manually select the end points of each mid-line from each slice from MRI and CT, respectively. From those coordinates we obtain estimated parameters for an equation of a plane using statistical regression method for MRI and CT, respectively. With the usage of geometric transformation, we transform the two sets of image points to fit the same plane with z = 0. Then, we exert cubic spline interpolation to find the edge of the sagittal slices of the two (MRI and CT) images. Finally, we put forth POWELL optimization method to register the two sagittal slices.\nResults: In our study, we test two sets of MRI and CT images with some part of the brain to evaluate the accuracy of out method. The registration error is 1~3 mm in the x and y direction, and about 4 mm in the z direction.\nConclusions: We find that the degree of freedom in registration has been decreased in out method, and it is more time saving by using the same mid-sagittal plane for registration has been decreased in out method, and it is more time saving by using the same mid-sagittal plane for registration."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-97-105-a", "title": "188Re\u6db2\u9ad4\u8c9d\u4ed6\u5c04\u6e90\u65bc\u8840\u7ba1\u8fd1\u63a5\u6cbb\u7642\u4e4b\u5291\u91cf\u8a55\u4f30\u8207\u91cf\u6e2c\u6280\u8853", "keywords": "\u518d\u72f9\u7a84,\u8fd1\u63a5\u6cbb\u7642,\u9338-188,\u8499\u5730\u5361\u7f85\u6cd5 Restenosis,Brachytherapy,Rhenium-188,Monte Carlo", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u5efa\u7acb188Re\u6db2\u9ad4\u8c9d\u5316\u5c04\u6e90\u65bc\u8840\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u4e4b\u5291\u91cf\u8a55\u4f30\u8207\u91cf\u6e2c\u6280\u8853\uff0c\u4e26\u61c9\u7528\u65bc\u8840\u7ba1\u518d\u72f9\u75c7\u5e45\u5c04\u6cbb\u7642\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5b8c\u6210\u4e8c\u7d446 mm \u7ba1\u5f91\u8840\u7ba1\u5047\u9ad4\u3001\u4e00\u7d444mm\u7ba1\u5f91\u8840\u7ba1\u5047\u9ad4\u8207\u4e00\u7d443 mm \u7ba1\u5f91\u8840\u7ba1\u5047\u9ad4\u7684\u7406\u8ad6\u8a55\u4f30\u8207\u5be6\u9a57\u91cf\u6e2c\u7d50\u679c\u6bd4\u8f03\uff0c\u7406\u8ad6\u8a55\u4f30\u4f7f\u7528\u8499\u5730\u5361\u7f85\u6cd5MCNP4C \u7a0b\u5f0f\uff0c\u5be6\u9a57\u91cf\u6e2c\u5247\u4f7f\u7528GafChromic MD-55 \u81a0\u7247\u3002\n\u7d50\u679c\uff1a\u5be6\u9a57\u91cf\u6e2c\u8207\u7406\u8ad6\u8a55\u4f30\u7684\u5e73\u5747\u5dee\u7570\u4ecb\u65bc3.7% - 6.1%\u4e4b\u9593\uff0c\u843d\u65bc\u4e0d\u78ba\u5b9a\u5ea6\u7bc4\u570d\u5167\uff0c\u8b49\u660e\u5169\u7a2e\u7814\u7a76\u65b9\u6cd5\u8207\u7d50\u679c\u7684\u4e00\u81f4\u6027\uff0c\u8a08\u7b97\u7d50\u679c\u986f\u793a\uff0c\u8981\u5f97\u5230\u6e96\u78ba\u7684\u5291\u91cf\u5206\u4f48\uff0c\u9700\u6a21\u64ec\u64f4\u5f35\u6c23\u7403\u4e2d\u5fc3\u5c0e\u7ba1\u5be6\u969b\u5c3a\u5bf8\u3002\u8840\u7ba1\u5047\u9ad4\u6a21\u64ec\u8a08\u7b97\u5247\u986f\u793a\uff0c\u64f4\u5f35\u6c23\u7403\u5916\u96a8\u5176\u548c\u6c23\u7403\u8868\u9762\u8ddd\u96e2\u7684\u589e\u52a0\u800c\u8fc5\u901f\u964d\u4f4e\uff0c\u4e14\u8f03\u5927\u7ba1\u5f91\u8840\u7ba1\u4e4b\u5291\u91cf\u964d\u4f4e\u901f\u5ea6\u7a0d\u5c0f\u65bc\u8f03\u5c0f\u7ba1\u5f91\u8840\u7ba1\u4e4b\u5291\u91cf\u964d\u4f4e\u901f\u5ea6\uff0c\u5c0d 6 mm \u3001 4 mm\u82073 mm \u76f4\u5f91\u4e4b\u64f4\u5f35\u6c23\u7403\u800c\u8a00\uff0c\u96e2\u958b\u6c23\u7403\u8868\u97620.5mm\u8ddd\u96e2\u8655\u4e4b\u5291\u91cf\u5206\u5225\u70ba\u64f4\u5f35\u6c23\u7403\u8868\u9762\u5291\u91cf\u768456.1%\u300152.4%\u820750.9%\uff0c\u7576\u96e2\u958b\u6c23\u7403\u8868\u9762\u8ddd\u96e2\u81f33 mm \u6642\uff0c\u5291\u91cf\u5247\u50c5\u5206\u5225\u70ba\u6c23\u7403\u8868\u9762\u5291\u91cf\u76846.1%\u30015.5%\u82075.2%\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u78ba\u8a8d\u4e86\u8499\u5730\u5361\u7f85\u6cd5MCNP4C\u7a0b\u5f0f\u61c9\u7528\u65bc\u8840\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u5291\u91cf\u8a55\u4f30\u7d50\u679c\u7684\u6b63\u78ba\u6027\uff0c\u540c\u6642\u4e5f\u521d\u6b65\u5efa\u7acb\u7c21\u6613\u5291\u91cf\u8a55\u4f30\u4ecb\u9762\u7a0b\u5f0f\u3001\u53ef\u63d0\u4f9b\u7b26\u5408188 Re\u5c04\u6e90\u8655\u65b9\u5291\u91cf\u6240\u9700\u4e4b\u7167\u5c04\u6642\u9593\u3002", "e": "Purpose: This study performed the simulation of the dose distribution around the embedded high-den-sity metal material.\nMaterials and Mathods: The simulation is focused on the Varian 21EX LINAC machine and imple-mented by the OMEGA/BEAM code system. For modeling the linear accelerator, the simulation para-meters are adjusted by comparing the results of the depth doses and the setup of 6 MV, 40 \u00d7 40 cm2, SAD= 100 cm in a homogeneous water phantom. Then, the dose disturbance has been investigated for the setup of 6 MV, 10 \u00d7 10 cm2 SAD= 100 cm with a denture sample.\nResults and Discussion : The adjusted LINAC parameters have been proved by the verifications of the depth doses and dose profiles calculated by DOSXYZ with the measurement setup of 6 MV, 40 \u00d7 40 cm2, SSD = 100 cm. It shows that the capability of simulating the Varian 21EX  LINAC has been established. For the Degubond 4 denture sample at a depth of 5 cm with a setup of 6 MV, 10 \u00d7 10 cm2, SAD = 100 cm, the dose disturbance range in depth dose is around 2 cm. The back scattering electrons cause a 40% dose increment in front of the sample and the shielding effect decreases the dose of about 20% behind the sample. Maximum range disturbs the dose profile is about 1.2 cm. The energy range of the back scattering photons is between 0.2 and 0.6 MeV.\nConclusion : The size of the denture sample used in the study is small, but the density is quite high, hence the perturbation effect is still significant. Besides, the spatial range of the perturbation is relative-ly small; it is difficult to be measured. In this study, it shows that the detailed information includes depth dose, dose profile at several depth, and the photon/electron spectrums could be obtained by Monte Carlo simulation, and could provide for the further study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-107-112-a", "title": "RADIOTHERAPY FOR EXTRAMAMMARY PAGET", "keywords": "\u975e\u4e73\u817a\u6027\u67cf\u54f2\u6c0f\u816b\u7624,\u5973\u6027\u5916\u9670\u764c,\u653e\u5c04\u7dda\u6cbb\u7642 Extramammary paget", "c": "\u76ee\u7684\uff1a\u5973\u6027\u5916\u90e8\u67cf\u54f2\u6c0f\u7624\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u816b\u7624\uff0c\u597d\u767c\u65bc\u767d\u7a2e\u4eba\u505c\u5f8c\u7d93\u5f8c\u4e4b\u5a66\u5973\uff0c\u6b64\u985e\u75be\u75c5\u57fa\u672c\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u5916\u79d1\u624b\u8853\u5927\u7bc4\u570d\u5207\u9664\uff0c\u4f46\u6709\u4e9b\u75c5\u60a3\u7121\u6cd5\u627f\u53d7\u6b64\u7a2e\u624b\u8853\u7642\u6cd5\u3002\u6211\u5011\u5831\u544a\u4e8c\u4f8b\u5973\u6027\u5916\u9670\u90e8\u67cf\u5fb7\u6c0f\u816b\u7624\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u7d50\u679c\u3002\n\u75c5\u4f8b\u5831\u544a\uff1a\u4e8c\u540d\u9ad8\u9f6181\u6b72\u7684\u5a66\u5973\u7f79\u60a3\u5916\u9670\u90e8\u67cf\u54f2\u6c0f\u816b\u7624\uff0c\u5728\u672c\u9662\u63a5\u53d7\u96fb\u5b50\u5408\u4f75\u5149\u5b50\u5c04\u7dda\u4e4b\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d\u4e00\u4f4d\uff08\u75c5\u60a3\u4e00\uff09\u63a5\u53d7 40 Gy\uff0f20 \u6b21\u7167\u5c04\uff0c\u53e6\u4e00\u4f4d\uff08\u75c5\u60a3\u4e8c\uff09\u63a5\u53d750Gy\uff0f25\u6b21\u7167\u5c04\u7684\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u75c5\u60a3\u5728\u653e\u5c04\u6cbb\u7642\u671f\u9593\u5747\u4f75\u767c\u5c40\u90e8\u816b\u8139\u3001\u6fd5\u6027\u812b\u76ae\u3001\u7d05\u816b\u53ca\u75bc\u75db\u4e4b\u526f\u4f5c\u7528\uff0c\u4f46\u75c5\u60a3\u5c0d\u6574\u500b\u7642\u7a0b\u7684\u8010\u53d7\u6027\u826f\u597d\u3002\u4e8c\u540d\u75c5\u60a3\u5728\u6cbb\u7642\u5f8c\u75be\u4e19\u5747\u9054\u5230\u5b8c\u7de9\u89e3\uff0c\u65bc\u539f\u7167\u91ce\u5167\u7121\u5c40\u90e8\u5fa9\u767c\u4ea6\u7121\u5176\u4ed6\u81df\u5668\u4e4b\u60e1\u6027\u816b\u7624\u7522\u751f\u3002\u75c5\u60a3\u4e00\u5728\u7167\u5c04\u5b8c10\u500b\u6708\u5f8c\u5728\u4e14\u9580\u9644\u8fd1\u76ae\u819a\u53c8\u767c\u73fe\u65b0\u7684\u67cf\u54f2\u6c0f\u816b\u7624\u75c5\u7076\uff0c\u4f46\u5728\u63a5\u53d750 Gy\uff0825\u6b21\u7167\u5c04\uff09\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u7372\u5f97\u826f\u597d\u7684\u5c40\u90e8\u63a7\u5236\uff0c\u81ea\u7b2c\u4e8c\u6b21\u7167\u5c04\u81f3\u4eca\u53c8\u8ffd\u8e64\u90545\u500b\u6708\u3002\u75c5\u60a3\u4e8c\u8ffd\u8e64\u81f3\u4eca\u5df212\u500b\u6708\uff0c\u7121\u5c40\u90e8\u5fa9\u767c\u4e4b\u8de1\u8c61\u3002\n\u7d50\u8ad6\uff1a\u653e\u5c04\u7dda\u6cbb\u7642\u662f\u5c0d\u65bc\u5927\u7bc4\u570d\u6216\u4e0d\u9069\u5408\u5916\u79d1\u624b\u8853\u4e4b\u5973\u6027\u5916\u9670\u90e8\u67cf\u54f2\u6c0f\u816b\u7624\u7684\u6709\u6548\u6cbb\u7642\u65b9\u6cd5\u3002", "e": "Background: Extramammary Paget\u2019s disease (EMPD) of the vulva is an uncommon tumor which frequently affecting postmenopausal Caucasian women. Wide local excision is the recommended treatment, although this may not always be feasible. Wu report out experience in treating EMPD of the vulva by radiotherapy in two patients.\nCases: Two 81-year-old women with EMPD in the vulvar region were treated using appositional electrons mixed with photon beams. One patient received 40 Gy in 20 fractions (patient 1), and the other one received 50 Gy in 25 fractions (patient 2).Both patients developed local swelling, focal moist desquamation, erythema and pain during the treatment course, but were tolerated well. Complete regression of EMPD was observed in both patients and neither local recurrences nor internal malignancies have been documented. Patient 1 developed new lesions over peri-anal region 10 months afterwards and was irradiated for another 50 Gy in 25 fractions with good local control. She was followed up for another 5 months with no evidence of disease. Patient 2 was followed up for 12 months without recurrence.\nConclusion: Radiation therapy potentially could be a curative treatment in selected cases of EMPD disease affecting large areas of the vulva region or elderly and clinically inoperable patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200306-10-2-113-118-a", "title": "RADIOTHERAPY OF GERM CELL TUMOR IN BASAL GANGLION:CASE REPORT AND REVIEW OF LITERATURE", "keywords": "\u9871\u5167\u80da\u7d30\u80de\u7624,\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u7dda\u6cbb\u7642 Intracranial germinoma,3D-conformal radiation therapy", "c": "\u4e00\u540d\u5341\u4e94\u6b72\u7537\u6027\u56e0\u7a81\u767c\u6027\u53f3\u5074\u7121\u529b\u4f4f\u9662\u3002\u7d93\u8166\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u7784\u65bc\u5de6\u8166\u57fa\u5e95\u6838\u767c\u73fe\u4e00\u5de8\u5927\u56ca\u72c0\u816b\u7624\u3002\u56e0\u7121\u6cd5\u4ee5\u6838\u78c1\u5171\u632f\u6383\u7784\u53ca\u8166\u90e8\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\u6392\u9664\u70ba\u52d5\u975c\u8108\u7578\u5f62\u7624\uff0c\u65bc\u662f\u958b\u5200\u53d6\u6a23\u5316\u9a57\u3002\u7d93\u75c5\u7406\u5831\u544a\u5be6\u70ba\u9871\u5167\u80da\u7d30\u80de\u5f8c\uff0c\u65bd\u4ee5\u5291\u91cf\u5168\u8166\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4e26\u65bc\u539f\u75c5\u7076\u4ee5\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u7dda\u6cbb\u7642\u65b9\u5f0f\u88dc\u5f37\u5291\u91cf\u3002\u75c5\u4eba\u8853\u5f8c\u8840\u4e2dHCG\u53caAFP\u6fc3\u5ea6\u504f\u9ad8\uff0c\u65bc\u653e\u5c04\u6cbb\u7642\u5f8c\u7686\u4e0b\u964d\u81f3\u4f4e\u65bc\u6b63\u5e38\u503c\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u4e09\u500b\u6708\u65bc\u75c5\u4eba\u7684\u8166\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u7784\u4e2d\u4e26\u672a\u767c\u73fe\u6b98\u9918\u816b\u7624\u3002\u75c5\u4eba\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u5176\u53f3\u5074\u7121\u529b\u4e4b\u73fe\u8c61\u5df2\u660e\u986f\u6539\u5584\u3002\u75c5\u4eba\u65bc\u6cbb\u7642\u4e2d\u4e26\u7121\u6025\u6027\u526f\u4f5c\u7528\uff0c\u8ffd\u8e64\u81f3\u4eca\u7121\u660e\u986f\u795e\u7d93\u6027\u5f8c\u907a\u75c7\u3002\u672c\u6587\u85c9\u6b64\u7f55\u898b\u75c5\u4f8b\u5206\u4eab\u6cbb\u7642\u7d93\u9a57\u53ca\u56de\u9867\u8fd1\u671f\u6587\u737b\u8a18\u9304\u3002", "e": "A 15 year-old boy was sent to our Neurologic Department because of severe headache and sudden onset of right hemiparesis. Neurologic exarmination showed motor dysfunction of right upper limb, bilateral temporal visual field deficits and impaired visual acuity. Computer tomographic scan and magnetic resonance imaging showed a mass lesion in the left basal ganglion region. He received craniotomy for partial resection of the tumor and the nature of the tumor was proved to be germinoma, histologically. He was then treated by radiotherapy with a mean dose of 21 Gy to the whole brain and an additional boosting dose of 20 Gy to the tumor bed by three-dimensional conformal radiotherapy. There was an elevation in the serum concentration of beta-human chorionic gonadotropin (B-HCG) and alfa-fetoprotein (AFP) after the operation which suggested the possibility of other germ cell components in the tumor. However, the response of radiotherapy was good. No acute radiation toxicity was noted during irradiation and the muscle power of his right arm improved after follow-up for one year until the present. Long-term follow-up and further clinical studies are needed to determine the benefit of this moderate dose radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-1-9-a", "title": "Definitive Radiotherapy for the Patients with Prostatic Adenocarcinoma: Analysis of Short-Term Outcome and Prognostic Factors", "keywords": "\u817a\u764c,\u651d\u8b77\u817a,\u653e\u5c04\u6cbb\u7642 Adenocarcinoma, Prostate, Radiotherapy, Gleason score", "c": "Purpose: This study is a retrospective analysis to evaluate the short-term outcome and prognostic factors of patients with prostatic adenocarcinoma and receiving definitive radiotherapy (RT).\nMethods and Materials: From 1994 through 2001, 67 patients with adenocarcinoma of prostate underwent definitive RT with or without neoadjuvant hormone therapy or adjuvant hormone therapy at Koo Foundation Sun Yat-Sen Cancer Center. Taipei, Taiwan. One 83-year-old patient was excluded for the grade 3 gastrointestinal toxicity and incomplete RT. The median dose to whole pelvis or seminal vesicle/prostate was 46 Gy in a daily fraction of 1.8-2.0 Gy. The median dose to the prostate was 70 Gy. The neoadjuvant hormone therapy was given to 49 patients, usually starting 1-3 months before the initial date of RT. The survival outcome was estimated by Kaplan-Meier method, The analysis of prognostic factors on survival was calculated by Log-ran k test. \nResults: The median follow-up interval of 66 patients was 36 months. The univariate analysis of overall survival, disease-free survival and biochemical failure-free survival showed only Gleason score with statistical significance. The 3-year overall survival, disease-free survival and biochemical failure-free survival were 97 % and 55%, 97 % and 27%, and 97 % and 35% in patients with Gleason Score \uff1c 8 and Gleason Score\u22678, respectively (p\uff1c0.0001 for each  comparison). The 3-year overall survival, disease-free survival and biochemical failure-free survival were 86%, 78%, and 80%, respectively, in patients with stage T2-T4 disease and receiving neoadjuvant hormone therapy followed by definitive RT. Treatment-related acute and [ate toxicity were all less than or equal to grade 2. \nConclusion: For our patients with adenocarcinoma of prostate undergoing definitive RT and short-term follow-up, we found no statistically significant difference in T stage, nodal status and pretreatment PSA level, except the significance in Gleason score. Our out-come of patients who received RT and neoadjuvant hormone therapy indicated the acceptable quality of care in our department The lager series with long-term follow-up is needed to further delineate the prognostic factors and confirmed outcome.", "e": "Purpose: This study is a retrospective analysis to evaluate the short-term outcome and prognostic factors of patients with prostatic adenocarcinoma and receiving definitive radiotherapy (RT).\nMethods and Materials: From 1994 through 2001, 67 patients with adenocarcinoma of prostate underwent definitive RT with or without neoadjuvant hormone therapy or adjuvant hormone therapy at Koo Foundation Sun Yat-Sen Cancer Center. Taipei, Taiwan. One 83-year-old patient was excluded for the grade 3 gastrointestinal toxicity and incomplete RT. The median dose to whole pelvis or seminal vesicle/prostate was 46 Gy in a daily fraction of 1.8-2.0 Gy. The median dose to the prostate was 70 Gy. The neoadjuvant hormone therapy was given to 49 patients, usually starting 1-3 months before the initial date of RT. The survival outcome was estimated by Kaplan-Meier method, The analysis of prognostic factors on survival was calculated by Log-ran k test. \nResults: The median follow-up interval of 66 patients was 36 months. The univariate analysis of overall survival, disease-free survival and biochemical failure-free survival showed only Gleason score with statistical significance. The 3-year overall survival, disease-free survival and biochemical failure-free survival were 97 % and 55%, 97 % and 27%, and 97 % and 35% in patients with Gleason Score \uff1c 8 and Gleason Score\u22678, respectively (p\uff1c0.0001 for each  comparison). The 3-year overall survival, disease-free survival and biochemical failure-free survival were 86%, 78%, and 80%, respectively, in patients with stage T2-T4 disease and receiving neoadjuvant hormone therapy followed by definitive RT. Treatment-related acute and [ate toxicity were all less than or equal to grade 2. \nConclusion: For our patients with adenocarcinoma of prostate undergoing definitive RT and short-term follow-up, we found no statistically significant difference in T stage, nodal status and pretreatment PSA level, except the significance in Gleason score. Our out-come of patients who received RT and neoadjuvant hormone therapy indicated the acceptable quality of care in our department The lager series with long-term follow-up is needed to further delineate the prognostic factors and confirmed outcome."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-11-18-a", "title": "\u96d9\u76f2\u5c0d\u7167\u5be6\u9a57\u8a55\u4f30\u53e3\u670dpilocarpine\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u5f15\u8d77\u982d\u9838\u90e8\u764c\u75c7\u75c5\u60a3\u53e3\u4e7e\u75c7\u65bc\u99ac\u5055\u91ab\u9662\u4e4b\u4f7f\u7528\u4e3b\u89c0\u6548\u679c\u53ca\u5b89\u5168\u6027\u5831\u544a", "keywords": "\u53e3\u4e7e\u75c7,\u982d\u9838\u90e8\u764c\u75c7,\u653e\u5c04\u7dda\u6cbb\u7642 Xerostomia, Head and neck cancer, Radiotherapy, Pilocarpine", "c": "\u201d\u76ee\u7684\uff1a\u8a31\u591a\u982d\u9838\u90e8\u764c\u75c7\u7684\u75c5\u4eba\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u591a\u534a\u6703\u906d\u9047\u53e3\u4e7e\u75c7(xerostomia)\u7684\u56f0\u64fe\uff0c\u800c\u4e00\u822c\u50b3\u7d71\u7684\u6cbb\u7642\u5982\uff1a\u4eba\u5de5\u553e\u6db2\uff0c\u6297\u83cc\u88fd\u5291\uff0c\u6c1f\u5316\u7269\u7b49\u901a\u5e38\u4e26\u4e0d\u80fd\u63d0\u4f9b\u4e00\u6eff\u610f\u7684\u7d50\u679c\u3002\u4e00\u4e9b\u8fd1\u4f86\u7684\u5916\u570b\u5be6\u9a57\u767c\u73fe\u53e3\u670dPilocarpine\u53ef\u4ee5\u7d66\u75c5\u60a3\u4e00\u500b\u6709\u6548\u800c\u5b89\u5168\u7684\u6cbb\u7642\uff0c\u4f46\u76ee\u524d\u4ecd\u7121\u53f0\u7063\u75c5\u60a3\u4e4b\u81e8\u5e8a\u8cc7\u6599\uff0c\u6240\u4ee5\u6211\u5011\u8a2d\u8a08\u4e86\u4e00\u500b\u81e8\u5e8a\u96d9\u76f2\u5c0d\u7167\u5be6\u9a57\u53bb\u8a55\u4f30\u53e3\u670dPilocarpine\u5c0d\u53f0\u7063\u56e0\u653e\u5c04\u7dda\u6cbb\u7642\u800c\u5f15\u767c\u4e4b\u53e3\u4e7e\u75c7\u75c5\u4eba\u7684\u7642\u6548\u53ca\u5b89\u5168\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u9019\u4e00\u6b21\u7684\u5be6\u9a57\u4e2d\u5171\u670948\u4f4d\u7684\u60a3\u8005\u53c3\u8207\uff0c\u5404\u670924\u4f4d\u60a3\u8005\u65bc\u5be6\u9a57\u7d44\u53ca\u5c0d\u7167\u7d44\u4e2d\u3002\u60a3\u8005\u5fc5\u9808\u662f\u66fe\u7d93\u63a5\u53d7\u904e40Gy\u4ee5\u4e0a\u7684\u982d\u9838\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u65bc\u670d\u85e5\u524d\u4e8c\u500b\u6708\u5373\u5df2\u505c\u6b62\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u3002\u60a3\u8005\u4e00\u65e5\u670d\u75285 mg\u7684Pilocarpin\u4e09\u6b21\u5171\u5341\u4e8c\u9031\uff0c\u4e26\u65bc\u670d\u85e5\u671f\u9593\u4f7f\u7528\u8996\u89ba\u985e\u6bd4\u8a55\u91cf\u8868(visual analog scale)\u70ba\u8a55\u91cf\u53e3\u4e7e\u75c7\u4e4b\u5de5\u5177\u3002\u6240\u8a55\u4f30\u7684\u9805\u76ee\u5305\u62ec\u6574\u9ad4\u60c5\u6cc1\u3001\u53e3\u4e7e\u7a0b\u5ea6\u3001\u53e3\u8154\u53ca\u820c\u982d\u7684\u8212\u9069\u5ea6\u3001\u8aaa\u8a71\u4e4b\u6d41\u66a2\u5ea6\u3001\u53e3\u8154\u6ebc\u6f64\u5291\u4e4b\u4f7f\u7528\u7a0b\u5ea6\u3001\u5480\u56bc\u53ca\u541e\u56a5\u80fd\u529b\u548c\u7761\u7720\u54c1\u8cea\u7b49\u4e03\u9805\u3002\u800c\u5b89\u5168\u6027\u5247\u4ee5\u4e0d\u826f\u53cd\u61c9\u7522\u751f\u60c5\u5f62\u53ca\u5be6\u9a57\u6578\u64da\u70ba\u8a55\u91cf\u6a19\u6e96\u3002\u6240\u6709\u7d50\u679c\u4ee5Cochran-Mantel-Haenzel's test\u505a\u70ba\u8b8a\u7570\u6027\u5206\u6790\u4e4b\u5de5\u5177\u3002\n\u7d50\u679c\uff1a\u65bc\u5be6\u9a57\u4e2d\u5171\u670925\u4f4d\u60a3\u8005\u5b8c\u6210\u5341\u4e8c\u9031\u7684\u6e2c\u8a66\uff0c\u5176\u4e2d\u5be6\u9a57\u7d44\u4f5411\u4eba\u3002\u65bc\u670d\u85e5\u5f8c\u7684\u7b2c\u56db\u9031\uff0c\u7b2c\u516b\u9031\u53ca\u7b2c\u5341\u4e8c\u9031\u5206\u5225\u6536\u96c6\u60a3\u8005\u8cc7\u6599\u4ee5\u5206\u6790\u6bd4\u8f03\u3002\u65bc\u8cc7\u6599\u4e2d\u986f\u793a\uff0c\u7121\u8ad6\u662f\u5be6\u9a57\u7d44\u6216\u662f\u5c0d\u7167\u7d44\u7684\u60a3\u8005\u5c0d\u65bc\u53e3\u4e7e\u75c7\u4e4b\u60c5\u5f62\u7686\u6709\u6539\u5584(18.2-63.6%)\uff0c\u800c\u5c0d\u65bc\u6240\u8a00\u5e73\u4f30\u7684\u516d\u500b\u9805\u76ee\u4e2d\uff0c\u53ea\u6709\u7761\u7720\u54c1\u8cea\u5177\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u5dee\u7570(p\uff1d0.026)\u3002\u5c0d\u65bc\u85e5\u7269\u5b89\u5168\u6027\u7684\u8a55\u4f30\u4e2d\uff0c\u9664\u4e86\u589e\u52a0\u6d41\u6c57\u53ca\u983b\u5ea6\u4e4b\u60c5\u5f62\u5916\uff0c\u4e26\u6c92\u6709\u767c\u73fe\u5177\u7d71\u8a08\u610f\u7fa9\u4e4b\u4e0d\u826f\u53cd\u61c9\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u56e0\u653e\u5c04\u7dda\u6cbb\u7642\u800c\u5f15\u767c\u4e4b\u53e3\u4e7e\u75c7\uff0cPilocarpine\u5728\u90e8\u5206\u75c5\u4eba\u4f3c\u4e4e\u53ef\u4ee5\u9054\u5230\u6cbb\u7642\u7684\u6548\u679c\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u7761\u7720\u54c1\u8cea\u7684\u6539\u5584\uff1b\u4e14\u65bc\u4f7f\u7528\u4e0a\u9664\u4e86\u589e\u52a0\u983b\u5c3f\u53ca\u6d41\u6c57\u4ee5\u5916\uff0c\u4e26\u7121\u5b89\u5168\u4e0a\u4e4b\u865e\u616e\uff1b\u4f46\u7d50\u679c\u89e3\u8b80\u53d7\u9650\u65bc\u500b\u6848\u6578\u592a\u5c11\u53ca\u534a\u6578\u7814\u7a76\u5c0d\u8c61\u672a\u80fd\u5b8c\u6210\u7642\u7a0b\uff0c\u56e0\u800c\u4e00\u4e9b\u66f4\u5ba2\u89c0\u7684\u7814\u7a76\uff0c\u5982\u4e0d\u540c\u7684\u653e\u5c04\u5291\u91cf\u3001\u85e5\u91cf\u3001\u670d\u7528\u6642\u9593\u9ede\u53ca\u553e\u6db2\u6d41\u91cf\u7684\u5ba2\u89c0\u6e2c\u91cf\u662f\u9700\u8981\u7684\u3002\u201d", "e": "\u201dPurpose: Many head and neck cancer patients suffer from xerostomia after irradiation. General treatments such as saliva substitutes, antimicrobial rinses and fluoride application do not provide a satisfactory result. Some current studies showed that oral pilocarpine improves the condition of xerostomia in these patients, We designed a double-blinded, placebo-controlled study to evaluate the efficacy and safety of this drug in our hospital. \nMaterials and Methods : The were 48 patients in this study divided equally into study or control cohort by a randomized way. All of them underwent more than 40 Gray of radiation and stopped the treatment, including radiation and chemotherapy, two months before getting into this study, Patients were administer Pilocarpine 5 mg three times a day for 12 weeks and weeks evaluated for overall condition, oral dryness, mouth and tongue comfort, speaking without fluid, the need for oral comfort agent, chewing and swallowing, and the ability to sleep, by visual analog scale questionnaire, The safety was evaluated by examining adverse events and laboratory results. Data were compared using Cochran-Mantel-Haenzel's test and analysis of variance.  Results: Twenty-five patients completed the experiment in this study, including eleven persons in the study group. We collected the data in the 4th, 8th, and 12th weeks after administration of drug to evaluate the efficacy of pilocarpine. The data showed that both groups got improvement in xerostomia (18.2 ~63.6% ) though it only showed the statiscally significant difference in the component of ability to sleep (p= 0.026). There was no statistical difference in adverse events between the two groups, except increased sweating and urinary frequency in study group. \nConclusion: Oral pilocarpine may be effective to treat radiation induced xerostomia in some head and neck cancer patients, especially to improve the ability to sleep, and it is also a safe drug for these patients. The results are limited for interpretation due to few numbers of patients in both arms and half patients excluded from the study with incomplete treatment. Further objective evaluations such as different radiation dose, different drug dose, the timing of administration, and saliva amount remain necessary.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-19-26-a", "title": "Preperative Radiotherapy Concurrent with Chemotherpy for Locally Advaced Rectal Cancer", "keywords": "\u76f4\u8178\u764c,\u8853\u524d\u5316\u5b78\u653e\u5c04\u6cbb\u7642 Rectal cancer, Preoperative chemoradiation", "c": "\u201d\u76ee\u5730\uff1a\u5206\u6790\u5c40\u90e8\u4fb5\u72af\u6027\u76f4\u8178\u764c\u75c5\u4eba\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff0c \u5c0d\u816b\u7624\u671f\u5225\u4e0b\u964d\u548c\u809b\u9580\u4fdd\u7559\u7684\u5e6b\u52a9\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u57281999\u5e746\u6708\u52302002\u5e742\u6708\u9593\uff0c\u672c\u9662\u5171\u670922\u540d\u76f4\u8178\u764c\u75c5\u4eba\u63a5\u53d7\u8853\u524d\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u518d\u884c\u624b\u8853\u5207\u9664\u3002\u5176\u4e2d\u5305\u62ec16\u4f4d\u7537\u6027\u548c6\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u5206\u4f48\u5f9e28\u523076\u6b72\uff0c\u5e74\u9f61\u4e2d\u4f4d\u657861\u6b72\u3002\u5316\u5b78\u6cbb\u7642\u4f7f\u7528\u9ad8\u5291\u91cf5-Fluorouracil(5-FU)\u5408\u4f75Leucovorin\uff1b\u653e\u5c04\u6cbb\u7642\u4e2d\u4f4d\u5291\u91cf\u70ba50AGy (45Gy - 50AGy)\u91dd\u5c0d\u9aa8\u76c6\u8154\u3002\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\u5e73\u57476\u9031(1\u81f311.7\u9031)\u63a5\u53d7\u6cbb\u764c\u6027\u624b\u8853\u3002\u6bd4\u8f03\u624b\u8853\u5f8c\u75c5\u7406\u671f\u5225\u548c\u6cbb\u7642\u524d\u81e8\u5e8a\u89c0\u5225\u4e4b\u9593\u7684\u5dee\u7570\uff0c\u53ca\u809b\u9580\u4fdd\u7559\u5728\u9019\u4e9b\u75c5\u4eba\u7684\u6bd4\u4f8b\u3002\n\u7d50\u679c\uff1a22\u4f4d\u75c5\u4eba\u4e2d\u670912\u4f4d(55%)\u6709\u671f\u5225\u4e0b\u964d\uff0c\u5176\u4e2d\u6709\u4e09\u4f4d\uff0814%\uff09\u7684\u5f97\u5230\u5b8c\u5168\u7de9\u89e3\uff0c\u5728\u5207\u4e0b\u7d44\u7e54\u6a19\u672c\u4e2d\u6c92\u6709\u6b98\u5b58\u7684\u816b\u7624\u7d30\u80de\u3002\u53e6\u59165\u4f4d\u5247\u662f\u75c5\u7406\u671f\u5225\u548c\u81e8\u5e8a\u671f\u5225\u4e00\u6a23\u3002\u9084\u6709\u5169\u4f4d\u5247\u662f\u6cbb\u7642\u524d\u8a55\u4f30\u70baNl\uff0c\u4f46\u75c5\u7406\u671f\u5225\u986f\u793aN2\u3002\u670918\u4f4d(82%)\u75c5\u4eba\u65bd\u884c\u809b\u9580\u4fdd\u7559\u6027\u624b\u518a\u3002\n\u7d50\u8ad6\uff1a\u8853\u524d\u540c\u6b65\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\u518d\u52a0\u4e0a\u624b\u8853\u80fd\u6709\u6548\u4f7f\u816b\u7624\u671f\u5225\u4e0b\u964d\uff0c \u4e26\u80fd\u4f7f\u5927\u90e8\u5206\u5c40\u90e8\u665a\u671f\u76f4\u8178\u764c\u75c5\u4eba\u4fdd\u7559\u809b\u9580\u3002 \u201d", "e": "\u201dPurpose: This study is to present the rates of tumor down-staging and sphincter-preservation with pre-operative concurrent chemo-radiation therapy (CCRT) in locally advanced rectal cancer \nMethods and Materials: Between June1999 and February 2002, twenty-two patients with advanced rectal cancer were treated with preoperative CCRT, followed by surgical resection of disease, The patient population consisted of 16 males and 6 females that had a median age of 61 year (range 28 to 76 years). Most of patients received high dose 5-Fluorouracil (5-FU) and Leucovorin, concurrent with pelvic irradiation 50.40Gy(45-50.4 Gy) in 28 fractions over 5.5 weeks. The median interval between completion of radiotherapy and surgery was 6 weeks (range 1-11.7 weeks). The retreatment and post-treatment stages were compared and rates of sphincter preservation were evaluated. \nResults: Twelve (55%) out of 22 patients achieved tumor downstaging, and 3 (14%) patients had pathologic complete remission. Five patients remained the same stage as pretreatment clinical stage. Two patients had clinical N1 disease but pathologic N2 stage. Sphincter- preserving surgery can achieve in 18(82%) patients. \nConclusion: Pre-operative CCRT followed by surgery can be effective for tumor shrink-age, tumor downstaging, and achieving sphincter preservation in most of patients.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-27-36-a", "title": "Preoperative Radiotherapy and Chemotherapy for Low or Locally Advaced Rectal Cancer", "keywords": "\u76f4\u8178\u764c,\u624b\u8853\u524d\u653e\u5c04\u6cbb\u7642,\u62ec\u7d04\u808c\u4fdd\u5b58 Rectal cancer, Preoperative radiotherapy, Sphincter preservation", "c": "\u201d\u76ee\u7684\uff1a\u5c0d\u4f4e\u4f4d\u6216\u5c40\u90e8\u4fb5\u72af\u53b2\u5bb3\u76f4\u8178\u764c\u7684\u75c5\u4eba\u4ee5\u624b\u8853\u524d\u653e\u5c04\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u65b9\u5f0f\uff0c\u8a55\u4f30\u5176\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u5b58\u7387\u53ca\u964d\u4f4e\u75be\u75c5\u5206\u671f\u4e4b\u6cbb\u7642\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1999\u5e74\u52302001\u5e74\uff0c\u5171\u670915\u4f4d\u76f4\u8178\u764c\u7684\u75c5\u4eba(13\u4f4d\u7537\u6027\u30012\u4f4d\u5973\u6027)\u5728\u672c\u5340\u63a5\u53d7\u624b\u8853\u524d\u653e\u5c04\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u65b9\u5f0f\u3002\u5176\u4e2d\u4e09\u4f4d\u60a3\u6709\u5c40\u90e8\u4fb5\u72af\u53b2\u5bb3\u76f4\u8178\u764c\uff0c\u53e6\u591612\u4f4d\u5247\u60a3\u6709\u816b\u7624\u8ddd\u96e2\u809b\u9580\u62ec\u7d04\u808c6\u516c\u5206\u4ee5\u5167\u7684\u4f4e\u4f4d\u76f4\u8178\u764c\u3002\u75c5\u4eba\u5e74\u7d00\u5206\u4f48\u7bc4\u5718\u81ea27\u523073\u6b72\u4e0d\u7b49\u3002\u4f9d\u64da\u6cbb\u7642\u524d\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u53ca\u809b\u9580\u89f8\u8a3a\u5408\u4f5c\u70ba\u81e8\u5e8a\u5206\u671f\u7684\u6a19\u6e96\uff0c\u5247\u8a08\u67092\u4f4dAJCC\u5206\u671fT2NO\u300110\u4f4dT3NO\u30011\u4f4dT3Nl\u30012\u4f4dT4NO\u7684\u75c5\u4eba\u3002\u9019\u4e9b\u75c5\u4eba\u5747\u63a5\u53d7\u6bcf\u65e5\u5206\u6b21\u5291\u91cf1.8\uff27y\uff0c\u9aa8\u76c6\u8154\u7e3d\u5291\u91cf\u768445Gy\u7684\u50b3\u7d71\u591a\u7167\u91ce\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u540c\u6642\u5408\u4f75\u4ee55-FU \u70ba\u4e3b\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u4e26\u5728\u6545\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u5b8c\u6210\u63a56\u52308\u9031\u63a5\u53d7\u624b\u8853\u3002\n\u7d50\u679c\uff1a\u670910\u4f4d\u75c5\u4eba(67%)\u7d93\u624b\u8853\u5f8c\u75c5\u7406\u5831\u544a\u8b49\u5be6\u816b\u7624\u75be\u75c5\u5206\u671f\u78ba\u6709\u964d\u4f4e\uff0c\u5176\u4e2d\u5305\u62ec3\u4f4d\u816b\u7624\u5b8c\u5168\u6d88\u5931\u30011\u4f4dTINO\u30014\u4f4dT2NO\uff0c\u548c2\u4f4dT3NO\u7684\u75c5\u4eba\u3002\u572812\u4f4d\u4f4e\u4f4d\u76f4\u8178\u764c\u7684\u75c5\u4eba\u4e2d\u67098\u4f4d(67% )\u53ef\u4ee5\u9054\u5230\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u5b58\u7684\u76ee\u7684\u300215 \u4f4d\u75c5\u4eba\u7684\u8853\u5f0f\u5206\u5225\u70ba\uff1a\u76f4\u8178\u5207\u9664\u53ca\u5927\u8178\u809b\u9580\u543b\u6cbb\u8853(7\u4f4d)\u3001\u4f4e\u524d\u4f4d\u5207\u969c\u8853(4\u4f4d)\u3001\u7d93\u8179\u90e8\u6703\u9670\u5207\u9664\u8853(4 \u4f4d)\u3002\u6cbb\u7642\u904e\u7a0b\u4e2d\u4e26\u6c92\u6709\u767c\u751f\u56b4\u91cd\u6cbb\u7642\u526f\u4f5c\u7528\u7684\u60c5\u5f62\uff1b\u540c\u6642\uff0c\u5230\u76ee\u524d\u70ba\u6b62\u5b58\u6d3b\u7684\u75c5\u4eba\u4e2d\u5747\u6c92\u6709\u75be\u75c5\u5c40\u90e8\u5fa9\u767c\u3002\u7d50\u8ad6\uff1a\u624b\u8853\u524d\u653e\u5c04\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u65b9\u5f0f\u5c0d\u4f4e\u4f4d\u6216\u5c40\u90e8\u4fb5\u72af\u53b2\u5bb3\u76f4\u8178\u764c\u7684\u60c5\u4eba\u670967%\u53ef\u4ee5\u5f97\u5230\u964d\u4f4e\u816b\u7624\u5206\u671f\u7684\u6548\u679c\uff0c\u5728\u4f4e\u4f4d\u76f4\u8178\u764c\u7684\u75c5\u4eba\u670967%\u4ea6\u53ef\u4ee5\u9054\u5230\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u5b58\u7684\u76ee\u7684\uff0c\u540c\u6642\u75c5\u4eba\u6709\u5f88\u597d\u7684\u8010\u53d7\u6027\uff0c\u81e8\u5e8a\u4e0a\u662f\u4e00\u500b\u53ef\u884c\u7684\u65b9\u5f0f\u3002\u201d", "e": "\u201dPurpose: To evaluate the rates of tumor down-staging and sphincter -paring surgery for low or locally advanced rectal cancers after preoperative radiotherapy and chemotherapy.\nMethods and Materials: During the period between 1999 and 2001, 15 patients (13 males and 2 males) received preoperative radiotherapy and chemotherapy followed by surgery for localized adenocarcinoma of the rectum. Three of them had locally advanced unresectable rectal cancer and 12 patients had low-lying rectal cancer (within 6 cm from the anal verge). Patients' age ranged from 27 to 73 years (median, 48). Pretreatment tumor stages, determined by the CT scan, included 2 with T2NO, 10 with T3NO, 1 with T3N1, and 2 with T4NO. The preoperative treatment procedure consisted of convention-ally fractionated irradiation of 45 Gy in 25 fractions to the pelvis with concomitant 5FU-based chemotherapy 6-8 weeks before surgery. \nResults: Tumor down-staging was pathologically confirmed in 10 (67%) of 15 patients, including 3 with complete response (CR), 1 T1 NO, 4 T2NO, and 2 T3NO disease. Sphincter preservation was accomplished in 8 (67%) of 12 of low rectal cancer patients. The surgical procedures included proctectomy and coloanal anastomosis (n = 7), lowanterior resection (n = 4), and abdominoperineal resection (n = 4) All patients tolerated the combined chemoradiotherapy approach well without grade 3 or 4 toxicity. There was no pelvic disease recurrence till now. \nConclusion: The combination of preoperative pelvic radiation and 5-FU infusional chemotherapy in the management of low or locally advanced rectal cancers was well tolerated. Preoperative chemoradiotherapy resulted in significant tumor down-staging, allowing sphincter-sparing surgery in 67% of patients whose tumors was located within 6 cm from the anal verge and who otherwise would have required a colostomy.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-37-44-a", "title": "\u56fa\u5b9a\u6df1\u5ea6\u6cbb\u7642\u5c0d\u76f4\u8178\u809b\u9580\u764c\u653e\u5c04\u6cbb\u7642\u7684\u5f71\u97ff", "keywords": "\u56fa\u5b9a\u6df1\u5ea6,\u653e\u5c04\u7dda\u6cbb\u7642,\u76f4\u8178\u809b\u9580\u764c,\u8aa4\u5dee Fixed couch-isocenter distance, Radiotherapy, Rectal cancer, Anal caner", "c": "\u201d\u524d\u8a00:\u70ba\u6e1b\u5c11\u76f4\u8178\u809b\u9580\u764c\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u6642\uff0c\u56e0\u75c5\u4eba\u56fa\u5b9a\u6027\u4e0d\u4f73\u800c\u9020\u6210\u816b\u7624\u6cbb\u7642\u5291\u91cf\u4e0d\u8db3\u6216\u6b63\u5e38\u7d44\u7e54\u63a5\u53d7\u5291\u91cf\u904e\u9ad8\u7684\u60c5\u5f62\u3002\u6211\u5011\u63a1\u7528\u65b0\u7684\u6cbb\u7642\u4e2d\u5fc3\u8a2d\u5b9a\u65b9\u6cd5\uff0c\u85c9\u7531\u9a57\u8b49\u7247\u53ca\u6a21\u64ec\u651d\u5f71\u7247\u7684\u6bd4\u8f03\u53ca\u6e2c\u91cf\uff0c\u6e2c\u5b9a\u6b64\u4e00\u65b9\u6cd5\u4e4b\u7cbe\u78ba\u6027\u3002\n\u65b9\u6cd5\uff1a\u75c5\u4eba\u4ee5\u4ef0\u81e5\u59ff\u52e2\uff0c\u9664\u982d\u6795\u53ca\u8173\u8e1d\u56fa\u5b9a\u5668\u5916\u4e0d\u4f7f\u7528\u5176\u4ed6\u7684\u56fa\u5b9a\u6750\u6599\u3002\u75c5\u4eba\u65bc\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6642\uff0c\u5c07\u6cbb\u7642\u4e2d\u5fc3\u56fa\u5b9a\u5728\u7531\u6cbb\u7642\u5e8a\u8868\u9762\u5f80\u8179\u90e87\u516c\u5206\u7684\u9ad8\u5ea6\u3002\u6cbb\u7642\u4e2d\u5fc3\u5b9a\u597d\u4e4b\u5f8c\uff0c\u4f9d\u7167\u96f7\u5c04\u6295\u5f71\u5728\u75c5\u4eba\u8eab\u4e0a\u7684\u4f4d\u7f6e\u505a\u8a18\u865f\uff0c\u4e26\u8cbc\u4e0aX \u5149\u53ef\u986f\u5f71\u4e4b\u81a0\u7ba1\uff0c\u5728\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u7247\u4e0a\u986f\u793a\u6cbb\u7642\u4e2d\u5fc3\u3002\u7b2c\u4e00\u6b21\u6cbb\u7642\u6642\u62cd\u4e0b\u9a57\u8b49\u7247\uff0c\u548c\u6a21\u64ec\u651d\u5f71\u7247\u6bd4\u8f03\u5f8c\uff0c\u6e2c\u91cf\u5169\u8005\u7684\u8aa4\u5dee\uff0c\u5305\u62ec\u4f4d\u79fb\u53ca\u65cb\u8f49\u89d2\u5ea6\u7684\u5dee\u7570\u3002\n\u7d50\u679c\uff1a\u982d\u8173\u65b9\u5411\u7684\u5e73\u5747\u4f4d\u79fb\u70ba1.3 \u00b13.3 mm\u5de6\u53f3\u65b9\u54111.9 \u00b13.8 mm\uff0c\u524d\u5f8c\u65b9\u5411\u70ba0.2 \u00b12.0mm\u3002\u51a0\u72c0\u9762\u5e73\u5747\u65cb\u8f49\u89d2\u5ea6\u70ba0.76 \u00b12.84 \u5ea6\uff0c\u77e2\u72c0\u9762\u81e80.52 \u00b1 0.76 \u5ea6\uff0c\u6a6b\u65b7\u9762\u70ba0.04 \u00b1 0.33\u5ea6\u3002\n\u7d50\u8ad6\uff1a\u56fa\u5b9a\u9aa8\u76c6\u8154\u7684\u5f8c\u524d\u6cbb\u7642\u6df1\u5ea6\u662f\u4e00\u500b\u53ef\u9760\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u5728\u5404\u65b9\u5411\u7684\u4f4d\u79fb\u5e7e\u4e4e\u90fd\u5c11\u65bc5mm\uff0c\u5176\u4e2d\u96d6\u7136\u4ee5\u51a0\u72c0\u9762\u7684\u65cb\u8f49\u8aa4\u5dee\u8f03\u5927\uff0c\u4f46\u662f\u4ecd\u5728\u826f\u597d\u7684\u7bc4\u570d\u5167\uff0c\u56e0\u6b64\u3001\u6b64\u7a2e\u5b9a\u4f4d\u6cbb\u7642\u6cd5\u662f\u7c21\u55ae\u4e14\u53ef\u9760\u7684\u65b9\u5f0f\u3002\u201d", "e": "\u201dPurpose: To improve the reproducibility of irradiated volume in treating rectal cancer patients with fractionations, we have developed a new isocenter determination method and tested its accuracy by comparison of portal and simulation films. \nMaterials and Methods : Patients were placed in the supine position with only a head restraint and feet immobilizer, During Computerized Tomography (CT), the isocenter was fixed at 7cm from the bed surface in the direction of the abdomen, after which the position was marked on the patient's body by means of laser projection. A rubber tube was attached for visualization on x-ray films. The isocenter was thus indicated on the CT scan. During the first treatment, a portal film was made for comparison with the simulation film, and displacement and rotation errors of the two were measured. Results: Mean head-to-toe displacement was 1.3\u00b13.3 mm, left-right displacement was 1.9 \u00b13.8 mm and anteroposterior displacement was 0.2\u00b1 2.0 mm. The man coronal rotation was 0.76\u00b12.84\u00b0, sagittal rotation was 0.52\u00b10.76\u00b0 and transverse rotation was 0.04\u00b10.33\u00b0. \nConclusion: Stabilizing the position of the pelvis on the treatment couch is a reliable method for treatment. Displacement in almost all directions was less than 5mm. The error for coronal rotation was slightly greater, but nonetheless within acceptable range. Therefore, this type of treatment localization method is a simple and reliable method.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-45-52-a", "title": "AAPMTG-51\u865f\u8b70\u5b9a\u66f8\u5149\u5b50\u8207\u96fb\u5b50\u5291\u91cf\u8a08\u7b97\u7a0b\u5f0f", "keywords": "TG-51,\u5291\u8cb4\u5ea6\u91cf,\u6821\u6b63,\u8a08\u7b97\u7a0b\u5f0f TG-51, Dosimetry, Calibration, Calculation Program", "c": "\u201d\u76ee\u7684\uff1a\u7f8e\u570b\u7269\u7406\u5e2b\u5b78\u6703\u65bc1999\u5e74\u767c\u8868\u4e86\u5ea6\u91cf\u9060\u9694\u6cbb\u7642\u9ad8\u80fd\u5149\u5b50\u53ca\u96fb\u5b50\u5c04\u675f\u81e8\u5e8a\u53c3\u8003\u5291\u91cf\u7684TG-51\u865f\u65b0\u8b70\u5b9a\u66f8\u4ee5\u53d6\u4ee31983 \u5e74\u767c\u8868\u7684TG-21\u865f\u8b70\u5b9a\u66f8\u3002TG-51 \u7684\u7279\u8272\u662f\u4f7f\u7528\u9237-60\u6c34\u4e2d\u5438\u6536\u5291\u91cf\u6a19\u6e96\u6821\u6b63\u6e38\u96e2\u8154\uff0c\u6e38\u96e2\u8154\u7684\u6821\u6b63\u56e0\u5b50\u7a31\u70baN\u3002\u53e6\u4e00\u500b\u7279\u8272\u5247\u662f\u5927\u5927\u7c21\u5316\u5291\u91cf\u8a08\u8349\u6240\u9700\u8981\u7684\u53c3\u6578\uff0c\u4e14\u4ee5kQ \u503c\u4f5c\u70ba\u5149\u5b50\u5c04\u6771\u54c1\u8cea\u8f49\u63db\u56e0\u5b50\uff0cP\uff0ck \uff0ck\u4f5c\u70ba\u96fb\u5b50\u5c04\u675f\u54c1\u8cea\u8f49\u63db\u56e0\u5b50\u3002\u672c\u7bc7\u7814\u7a76\u7684\u76ee\u7684\u5728\u65bc\u64b0\u5beb\u5b8c\u6574\u7684TG-51\u5291\u91cf\u8a08\u7b97\u7a0b\u5f0f\uff0c\u4ee5\u6e1b\u5c11\u53ca\u8a08\u7b97\u6240\u9020\u6210\u7684\u932f\u8aa4\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7bc7\u7814\u7a76\u4f7f\u7528\u5fae\u8edf\u516c\u53f8\u7684Visual Basic 6.0 \u8a9e\u8a00\u64b0\u5bebTG-51\u5291\u91cf\u8a08\u7b97\u7a0b\u5f0f\u3002\u6574\u500b\u7a0b\u5f0f\u8a2d\u8a08\u67b6\u69cb\u4f9d\u7167TG-51\u865f\u8b70\u5b9a\u66f8\u88e1\u9762\u6240\u63d0\u4f9b\u7684worksheet\u8868\u683c\u6d41\u7a0b\u5b89\u6392\uff0c\u4e26\u4f7f\u7528AAPM \u653e\u5c04\u7269\u7406\u4e2d\u5fc3\u63d0\u4f9b\u7684TG-51Workshop\u88e1\u7684\u8cc7\u6599\u9032\u884c\u7a0b\u5f0f\u6b63\u78ba\u6027\u7684\u9a57\u8b49\u3002\n\u7d50\u679c\uff1a\u8207AAPM\u6240\u63d0\u4f9b\u7684\u8cc7\u6599\u9a57\u8b49\u6bd4\u8f03\uff0c\u5149\u5b50\u5291\u91cf\u4e4b\u8a08\u7b97\u5dee\u7570\u70ba-0.0269%\uff0c\u96fb\u5b50\u5291\u91cf\u4e4b\u8a08\u7b97\u5dee\u7570\u70ba0.0429%\u3002\u7d50\u8ad6\uff1a\u6b64\u7a0b\u5f0f\u63d0\u4f9b\u4e86\u65b9\u4fbf\u3001\u6b63\u78ba\u800c\u4e14\u5b8c\u6574\u7684TG-51\u865f\u8b70\u5b9a\u66f8\u5291\u91cf\u8a08\u7b97\u5de5\u5177\uff0c\u4e26\u53ef\u6e1b\u5c11\u4eba\u70ba\u67e5\u5716\u6240\u9020\u6210\u7684\u8aa4\u5dee\u53ca\u5be6\u969b\u61c9\u7528\u65bc\u81e8\u5e8a\u53c3\u8003\u5291\u91cf\u7684\u5ea6\u91cf\u3002\u201d", "e": "\u201dPurpose: In 1999, American Association of Physicists in Medicine (AAPM) published the TG-51 protocol giving \u201d\u201dclinical reference dosimetry of high-energy photon and electron beams\u201d\u201d to replace theTG-21 protocol published by AAPM in 1983. One of the characteristics of TG-51 is being based on the use of the ion chambers calibrated in terms of absorbed dose to water in a 60Co beam. The calibration factors of are defined as N. The other is that the parameters needed for dose calculation are much more simplified than in TO-21 The conversion factor for beam quality of photon in TG-51 is kQ, for electron are P, k'R50'k, k.The purpose of this paper is to development complete TG-51 dose calculation program to decrease the errors arising from looking up tables and doing calculations. \nMaterials and Methods: We use Visual Basic 6.0 produced by Microsoft to develop a does calculation program of TG-15. The flowchart of this program follows the procedure of worksheet in TG-51. We verified the accuracy of this program by putting in the data in TO-51 Workshop provided by AAPM Radiological Physics Center. Results: Compared with the data provided by AAPM, the differences of photon and electron dos calculations are within 0.0269% and 0.0429%, respectively. \nConclusion: This program is a convenient, accurate and simple tool for dose calculation. Medical physicists can implement it to decrease the errors arising from looking up tables, and apply it in the clinical reference dosimetry practically.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200303-10-1-53-62-a", "title": "\u6539\u826f\u5f0f\u8edf\u7247\u5291\u91cf\u9a57\u8b49\u61c9\u7528\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5148\u671f\u7814\u7a76", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642,\u5291\u91cf\u9a57\u8b49,\u985e\u795e\u7d93\u7db2\u8def,\u8edf\u7247\u5291\u91cf\u91cf\u6e2c IMRT, Dose verification, Neural-net, Film dosimetry", "c": "\u201d\u76ee\u7684\uff1a\u70ba\u4e86\u4f7f\u8edf\u7247\u9069\u7528\u65bc\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u591a\u91cd\u89d2\u5ea6\u5165\u5c04\uff0c\u53ca\u52d5\u614b\u6027\u7167\u91ce\u8b8a\u5316\u7684\u5291\u91cf\u9a57\u8b49\u7279\u6027\uff0c\u672c\u7814\u7a76\u91dd\u5c0d\u5c04\u675f\u8207\u8edf\u7247\u5e73\u884c\u6392\u5217\u6642\uff0c\u7167\u91ce\u8207\u6df1\u5ea6\u6539\u8b8a\u7684\u60c5\u6cc1\u4e0b\uff0c\u5982\u4f55\u6b63\u78ba\u5c07\u8edf\u7247\u5149\u5bc6\u5ea6\u503c\u6b63\u78ba\u8f49\u63db\u5291\u91cf\uff0c\u63d0\u4f9b\u4e00\u5957\u53ef\u884c\u7684\u8fa6\u6cd5\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u6578\u7a2e\u6750\u8cea\u7684\u6ffe\u7247\u8207\u8edf\u7247\u4e4b\u7d44\u5408\u63a5\u53d7X\u5149\u7684\u7167\u5c04\uff0c\u518d\u4ee5\u985e\u795e\u7d93\u7db2\u8def\u5c07\u4e0d\u540c\u80fd\u8b5c\u8207\u5291\u91cf\u4e4b\u9593\u7684\u95dc\u4fc2\u627e\u51fa\u4f86\uff0c\u53ef\u4ee5\u5f97\u5230\u5be6\u969b\u7684\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u7d93\u672c\u7cfb\u7d71\u8f49\u63db\u7684\u5291\u91cf\u503c\uff0c\u5728\u6df1\u5ea6\u53ca\u7167\u91ce\u8b8a\u5316\u7684\u60c5\u6cc1\u4e0b\uff0c\u4ecd\u80fd\u6709\u6548\u8f49\u63db\u5291\u91cf\u81f3\u6700\u5927\u8aa4\u5dee\u5c0f\u65bc\u00b14%\uff0c\u5e73\u5747\u8aa4\u5dee2%\u5de6\u53f3\uff0c\u6b64\u70ba\u81e8\u5e8a\u4e0a\u53ef\u63a5\u53d7\u4e4b\u8aa4\u5dee\u7bc4\u570d\u3002\n\u7d50\u8ad6\uff1a\u672c\u5be6\u9a57\u6240\u63d0\u51fa\u4e4b\u5291\u91cf\u8f49\u63db\u65b9\u5f0f\uff0c\u5df2\u80fd\u6b63\u78ba\u8f49\u63db\u5291\u91cf\u65bc\u5c04\u675f\u548c\u8edf\u7247\u5e73\u884c\u6392\u5217\u53ca\u7167\u91ce\u8b8a\u5316\u7684\u60c5\u6cc1\uff0c\u9032\u4e00\u6b65\u5c07\u5be6\u969b\u8a55\u4f30\u672c\u7cfb\u7d71\u5728\u81e8\u5e8a\u61c9\u7528\u53ca\u591a\u91cd\u7167\u91ce(multiple field)\u4e0b\u7684\u8868\u73fe\u3002\u201d", "e": "\u201dPurpose: Intensity Modulation Radiation Therapy (IMRT) is implemented using multiple beam orientations and varius field sizes, X-ray film can't be used as a dosimetry tool in such situation because of its serious energy dependent problem. We present and develop an improved method to overcome the circumstances. \nMaterials and Methods: We used the combination of film with various filters (None, Pb, Cu, and AI) so that each film is irradiated to different energy spectrum. A neural-network is employed to relate the actual dose and energy spectra. After calibration and training, the optical densities of the four films can be input to the network to yield the actual dose at any location. \nResults: The PDD of a 20 x 20 field size and the dose distribution of an off-axis location at 5cm are estimated using this trained neural network. The maximum differences between the measurements of this film system and ionization chamber were less than \u00b14%, and less than 2% for the mean error in our investigation. \nConclusion: Optical density and dose relationship can be found and converted by our neural-net system. For the future studies, we will focus on clinical application of these experimental results and extend the concept to multiple beam orientations.\u201d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-1-12-a", "title": "Analysis on the Variation of Respiratory organ motion and a Preliminary Feasibility Study for a Voice Coaching Technique to Improve the Reproducibility of Respiratory Cycle between Tteatiments", "keywords": "\u6cbb\u7642\u4e2d;\u6cbb\u7642\u9593;\u547c\u5438\u5668\u5b98\u904b\u52d5 Intrafraction;Interfraction;Respiratory organ motion", "c": "\u76ee\u7684\uff1a\u653e\u5c04\u6cbb\u7642\u7684\u9032\u6b65\u5141\u8a31\u816b\u7624\u5291\u91cf\u7684\u63d0\u6607\uff0c\u5f9e\u800c\u4fc3\u9032\u66f4\u9ad8\u7684\u816b\u7624\u63a7\u5236\u7387\uff0c\u7136\u800c\u5176\u8907\u96dc\u6027\u4e5f\u9700\u76f8\u5c0d\u7684\u56b4\u683c\u63a7\u5236\u5668\u5b98\u904b\u52d5\u9020\u6210\u4e4b\u4e0d\u78ba\u5b9a\u5ea6\u3002\u5668\u5b98\u904b\u52d5\u9020\u6210\u4e4b\u4e0d\u78ba\u5b9a\u5ea6\u4e3b\u8981\u53ef\u5206\u70ba\uff08\u4e00\uff09\u9ad4\u5167\u5668\u5b98\u904b\u52d5\u5f62\u6210\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e4b\u5047\u5f71\uff1b\uff08\u4e8c\uff09\u5668\u5b98\u904b\u52d5\u5f71\u97ff\u6cbb\u7642\u4e2d\u4e4b\u5291\u91cf\u5206\u5e03\uff1b\uff08\u4e09\uff09\u5668\u5b98\u904b\u52d5\u5f71\u97ff\u5206\u6b21\u6cbb\u7642\u9593\u4e4b\u5291\u91cf\u3002\u5c0d\u6a6b\u9694\u819c\u4e0a\u4e0b\u4e4b\u816b\u7624\uff0c\u547c\u5438\u662f\u5f71\u97ff\u9ad4\u5167\u5668\u5b98\u904b\u52d5\u4e4b\u4e3b\u8981\u56e0\u7d20\u3002\u70ba\u4e86\u9032\u4e00\u6b65\u77ad\u89e3\u547c\u5438\u9020\u6210\u5668\u5b98\u904b\u52d5\u4e4b\u5927\u5c0f\uff0c\u672c\u6587\u63a2\u8a0e\uff08\u4e00\uff09\u81ea\u7531\u547c\u5438\u8207\u9589\u6c23\u547c\u5438\u816b\u7624\u8207\u91cd\u8981\u5668\u5b98\u4e4b\u5f62\u72c0\u5927\u5c0f\u5dee\u7570\uff1b\uff08\u4e8c\uff09\u547c\u5438\u5668\u5b98\u5728\u982d\u5c3e\u65b9\u5411\u4e4b\u4f4d\u79fb\u5927\u5c0f\uff1b\uff08\u4e09\uff09\u7814\u7a76\u4ee5\u547c\u5438\u5c0e\u5f15\u6280\u8853\u6539\u5584\u6cbb\u7642\u9593\u547c\u5438\u9031\u671f\u8207\u5668\u5b98\u904b\u52d5\u4e4b\u8b8a\u7570\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u8cc7\u6599\u4f86\u6e90\u70ba\u897f\u51432001\u5e743\u6708\u81f310\u6708\u9593\u65bc\u672c\u9662\u5f9e\u4e8b\u80f8\u8179\u90e8\u653e\u5c04\u6cbb\u7642\u4e4b\u75c5\u60a3\uff0c\u4f7f\u7528\u6750\u6599\u8207\u65b9\u6cd5\u5305\u62ec\u87ba\u65cb\u5f0f\u96fb\u8166\u65b7\u5c64\u6383\u7784\u6a5f\u5404\u53d6\u5169\u7d44\u5f71\u50cf\u53ca\u904b\u7528\u7acb\u5373\u5f0f\u547c\u5438\u540c\u6b65\u900f\u8996\u5f71\u50cf\u89c0\u5bdf\u9ad4\u5167\u5668\u5b98\u904b\u52d5\u3002\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u672c\u5206\u6790\u986f\u793a\u81ea\u7531\u547c\u5438\u5f71\u50cf\u8207\u9589\u6c23\u5f71\u50cf\u5dee\u5225\u751a\u5927\u3002\u6a6b\u9694\u819c\u5728\u982d\u5c3e\u65b9\u5411\u4e4b\u4f4d\u79fb\u53ef\u905415.5\u00b13.5 mm\uff0c\u80f0\u81df\u5247\u670913.7\u00b12.4 mm\u3002\u672c\u5be6\u9a57\u986f\u793a\u547c\u5438\u5c0e\u5f15\u6280\u8853\u53ef\u6539\u5584\u67d0\u4e9b\u547c\u5438\u4e0d\u7a69\u5b9a\u60a3\u8005\u4e4b\u547c\u5438\u9031\u671f\uff0c\u5f9e\u800c\u80fd\u6709\u6548\u7684\u5c0b\u6c42\u9032\u4e00\u6b65\u63a7\u5236\u5176\u9ad4\u5167\u547c\u5438\u5668\u5b98\u904b\u52d5\uff0c\u81f3\u65bc\u67d0\u4e9b\u75c5\u60a3\u5176\u547c\u5438\u539f\u672c\u5373\u5df2\u898f\u5f8b\u8005\uff0c\u547c\u5438\u5c0e\u5f15\u5c0d\u5176\u53cd\u800c\u4e0d\u5229\u3002", "e": "Purpose: New advances in radiotherapy technology enable us to attain higher dose delivery to tumor region, resulting in greater tumor control probability, with this sophistication there is more demand to control the uncertainties contributed by organ motion. The organ motion related uncertainties can be mainly classified into three main categories: (I) the blurring of planning images due to internal organ motion during CT scan acquisition; (II) intrafractional organ motion that affect the dose distribution within a single treatment delivery; (III) interfractional organ motion that affect the dose distribution between treatments. For patients with supradiagphragmatic and infradiagphragmatic tumor, respiration is a major factor that causes the displacement of the internal organ. For further under standing the magnitude of the respiratory organ motion, we endeavor to investigate: (I) the geometrical differences in spatial displacement of the tumor and critical organ while in free breathing status and breath holding status; (II) measures the magnitude of the respiratory organ motion in the cranio-caudal direction; (III) makes a preliminary feasibility study of the coaching breathing technique to improve the reproducibility of the respiratory cycle and hence reduce the variation of organ motion in between treatment. Results and Methods: The data were collected between March 2001 to October 2001in our department from subjects undergoing radiation therapy of the thoracic and abdominal regions using our spiral CT and real time Respiratory Gating system to measure and analyze the variation of respiratory organ motion. A voice coaching technique is designed to improve the consistency of the respiration cycles. Results and Conclusions: Our analysis shows a significant variation of tumor and organ geometry between free breathing and breath holding state. The cranio-caudal displacement are 15.5\u00b13.5 mm for diaphragm and 13.7\u00b12.4 mm for pancreas, respectively. For patients in our study, coaching technique may improve the reproducibility for those patient whose breathing cycles is not consistent within intrafraction treatment, but not for those with consistent cycles."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-13-21-a", "title": "Post-Operative Combination of Radiotherapy and Chemotherapy in Esophageal Cancer", "keywords": "\u98df\u9053\u764c;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u624b\u8853\u5f8c\u5408\u62fc\u6cbb\u7642 Esophageal cancer;Radiotherapy;Chemotherapy;Post-operative combination therapy", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u624b\u8853\u5f8c\u4e4b\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u65bc\u98df\u9053\u764c\u7684\u6548\u7528\uff0c\u4e26\u5c0b\u627e\u5f71\u97ff\u75c5\u60a3\u9810\u5f8c\u7684\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1991\u5e7410\u6708\u81f32000\u5e7411\u6708\u5171\u670956\u4f4d\u98df\u9053\u764c\u60a3\u8005\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d23\u4f4d\u75c5\u60a3\u63a5\u53d7\u55ae\u7368\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5291\u91cf\u7d04\u70ba50Gy\uff0c\u53e6\u591633\u4f4d\u4e26\u63a5\u53d7\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f7f\u7528\u7684\u85e5\u7269\u70bacisplatin\u82075-FU\u3002\u5169\u7d44\u75c5\u4eba\u9664\u816b\u7624\u9577\u5ea6\u5916\u4e26\u7121\u660e\u986f\u5dee\u7570\u3002\u6211\u5011\u6bd4\u8f03\u5169\u7d44\u75c5\u60a3\u4e4b\u5b58\u6d3b\u7387\u4ee5\u8a55\u4f30\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u7528\uff0c\u4e26\u5206\u6790\u5e74\u9f61\u3001\u816b\u7624\u7684\u671f\u5225\u3001\u9577\u5ea6\u3001\u4fb5\u72af\u60c5\u5f62\u8207\u967d\u6027\u6dcb\u5df4\u7684\u72c0\u614b\u7b49\u5c0d\u9810\u5f8c\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u4e2d\u503c\u6642\u9593\u70ba16\u500b\u6708\u300256\u4f4d\u75c5\u60a3\u7684\u4e94\u5e74\u5168\u90e8\u5b58\u6d3b\u7387\u70ba20.2%\uff0c\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba19.1%\u3002\u5176\u4e2d14.3%\u7684\u60a3\u8005\u767c\u751f\u5c40\u90e8\u5fa9\u767c\uff0c35.7%\u7684\u75c5\u60a3\u6709\u9060\u7aef\u8f49\u79fb\u3002\u63a5\u53d7\u55ae\u7368\u653e\u5c04\u7dda\u6cbb\u7642\u75c5\u60a3\u76842\u53ca5\u5e74\u5b58\u6d3b\u7387\u70ba42.7%\u53ca23.7%\uff0c\u800c\u5408\u4f75\u6cbb\u7642\u7684\u75c5\u60a3\u5247\u70ba41.0%\u53ca16.0%\uff0c\u5169\u7d44\u65bc\u5168\u90e8\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u4e26\u7121\u7d71\u8a08\u5b78\u4e0a\u7684\u5dee\u7570\uff08p\uff1d0.694\u53ca0.875)\u3002\u5c0d\u65bc\u6709\u6dcb\u5df4\u8f49\u79fb\u7684\u60a3\u8005\u800c\u8a00\uff0c\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u5728\u5168\u90e8\u5b58\u6d3b\u7387\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u4e0a\u4e26\u7121\u512a\u65bc\u55ae\u7368\u653e\u5c04\u7dda\u6cbb\u7642\uff08p\uff1d0.273\u53ca0.486\uff09\u3002\u5c0d\u5408\u4f75\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u4e09\u6b21\u6216\u4e09\u6b21\u4ee5\u4e0a\u4e4b\u5316\u5b78\u6cbb\u7642\u5176\u5168\u90e8\u53ca\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u4e26\u7121\u512a\u65bc\u8f03\u5c11\u6b21\u6578\u4e4b\u75c5\u60a3\uff08p\uff1d0.968\u53ca0.406\uff09\u3002\u5c31\u55ae\u8b8a\u6578\u5206\u6790\u800c\u8a00\uff0c\u795e\u7d93\u4fb5\u72af\u3001\u967d\u6027\u6dcb\u5df4\u7684\u6578\u76ee\u3001\u7bc4\u570d\u8207\u6bd4\u4f8b\u662f\u5168\u90e8\u5b58\u6d3b\u7387\u8207\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u7684\u5f71\u97ff\u56e0\u5b50\u3002\u4ee5\u591a\u56e0\u5b50\u5206\u6790\u800c\u8a00\uff0c\u53ea\u6709\u967d\u6027\u6dcb\u5df4\u7684\u7bc4\u570d\u5f71\u97ff\u5b58\u6d3b\u7387\u3002\n\u8a0e\u8ad6\uff1a\u6839\u64da\u6211\u5011\u75c5\u60a3\u7684\u6578\u64da\uff0c\u624b\u8853\u5f8c\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u7dda\u6cbb\u7642\u4e26\u7121\u589e\u52a0\u5b58\u6d3b\u7387\u7684\u6548\u61c9\u3002\u795e\u7d93\u4fb5\u72af\u3001\u967d\u6027\u6dcb\u5df4\u7684\u6578\u76ee\u3001\u7bc4\u570d\u8207\u6bd4\u4f8b\u662f\u5f71\u97ff\u8853\u5f8c\u75c5\u60a3\u9810\u5f8c\u7684\u91cd\u8981\u56e0\u5b50\u3002", "e": "Purpose: To evaluate the effect of post-operative concurrent chemoradiotherapy (CCRT) and to determine the prognostic factors in esophageal cancer. \nMaterials and Methods: From October 1991 to November 2000, fifty-six patients with esophageal cancer received post-operative radiotherapy at VGH-KS. Twenty-three patients were treated with radiotherapy (RT) alone at 50 Gy and others underwent RT combined with chemotherapy (C/T) consisting of cisplatin plus 5-flurouracil (5-FU). There was no significant difference in patient characteristics between two groups, except in tumor length. We compared overall, disease-free, loco-regional-free and distant-metastasis-free survival rates between two groups. We also analyzed various prognostic factors including age, tumor length, tumor stage, status of surgical margin, lymph node (LN) metastasis, vascular or neural invasion, and the time interval between operation and radiotherapy.\nResults: The median follow-up time was 16 months. For all patients, the overall survival (OS) at 5 years was 20.2%, and the disease-free survival (DFS) was 19.1 %. Loco regional failure occurred in 14.3% of patients and 35.7% of patients developed distant metastasis. The 2-year and 5-year overall survival rates were 42.7% and 23.7% for RT group and 41.0% and 16.0% for CCRT group. There was no significant difference in as and DFS between two groups (p= 0.694 and 0.875). In lymph node metastatic patients, overall and disease-free survivals of CCRT group were not superior to those of RT group (p= 0.273 and 0.486). In CCRT group, there was also no significant difference in as and DFS between the patients receiving less than 3 cycles of C/T and those receiving more (p= 0.968 and 0.406, respectively). By the uni-variate analysis, we found that neural invasion, numbers of LN metastases and involved LN levels, and the percentage of positive dissected LN affected the survival rates. The only prognostic factor of survivals in the multi-variate analysis was the involvement of more than one LN level. \nConclusion: Based on our analysis, post-operative combination therapy is no better than adjuvant radiotherapy alone in disease control. The most important prognostic factors affecting the post-operative survival rate of patients are the number of positive lymph node and LN levels involved, the percentage of positive dissected LN and neural invasion."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-23-30-a", "title": "\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u61c9\u7528\u65bc\u5168\u8166\u810a\u690e\u7167\u5c04\u7167\u91ce\u4e4b\u8a2d\u8a08\u8207\u8a55\u4f30", "keywords": "\u653e\u5c04\u6cbb\u7642;\u5168\u8166\u810a\u690e\u7167\u5c04;\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71 Radiotherapy;Craniospinal irradiation;Computed tomography simulation", "c": "\u76ee\u7684\uff1a\u5c0d\u65bc\u5168\u8166\u810a\u690e\u7167\u5c04\u75c5\u60a3\u800c\u8a00\uff0c\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u7684\u4f7f\u7528\uff0c\u4e0d\u50c5\u7e2e\u77ed\u75c5\u60a3\u76f8\u5c0d\u65bc\u6a21\u64ec\u651d\u5f71\u6240\u9700\u8981\u7684\u6642\u9593\uff0c\u66f4\u91cd\u8981\u7684\u662f\u63d0\u4f9b\u7cbe\u78ba\u7684\u5de5\u5177\u8b93\u91ab\u5e2b\u66f4\u80fd\u6709\u4fe1\u5fc3\u53bb\u6c7a\u5b9a\u7167\u91ce\u4f4d\u7f6e\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6797\u53e3\u9577\u5e9a\u91ab\u5b78\u4e2d\u5fc3\u653e\u5c04\u816b\u7624\u79d1\u81ea\u6c11\u570b89\u5e74\u5f15\u9032PQ5000\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u4ee5\u4f86\uff0c\u5229\u7528VOXEL Q\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u53caACQ sim\u865b\u64ec\u6a21\u64ec\u651d\u5f71\u7cfb\u7d71\u5c0d\u53d6\u5f97\u81ea\u75c5\u60a3\u7684\u65b7\u9762\u5f71\u50cf\u9032\u884c\u8655\u7406\u3002\u91cd\u7d44\u6210\u4e09\u5ea6\u7a7a\u9593\u5f71\u50cf\u5f97\u77e5\u816b\u7624\u7684\u6df1\u90e8\u4f4d\u7f6e\u3001\u5927\u5c0f\uff0c\u800c\u5f8c\u80fd\u6c7a\u5b9a\u51fa\u6cbb\u7642\u7684\u7167\u91ce\u5927\u5c0f\u3001\u7bc4\u5713\u3001\u89d2\u5ea6\u3001\u963b\u64cb\u7269\u7b49\u6cbb\u7642\u53c3\u6578\u3002\u7d50\u679c\uff1a\u50b3\u7d71\u4e0a\u5168\u8166\u810a\u690e\u7167\u5c04\u7684\u6a21\u64ec\u651d\u5f71\u9808\u8017\u6642\u8f03\u4e45\uff0c\u6240\u6709\u7684\u4f5c\u696d\u6d41\u7a0b\u7d04\u9700\u898130~50\u5206\u9418\uff0c\u4e14\u75c5\u60a3\u63a1\u7528\u4ee5\u4e0b\u5df4\u548c\u9f3b\u6a11\u4f86\u652f\u6490\u982d\u90e8\u91cd\u91cf\u7684\u4fef\u81e5\u59ff\u52e2\u9032\u884c\u6a21\u64ec\u651d\u5f71\u3002\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6642\u63a1\u7528\u4ef0\u81e5\u7684\u65b9\u5f0f\u9032\u884c\u5168\u8166\u810a\u690e\u7167\u5c04\u6a21\u64ec\u651d\u5f71\uff0c\u4f7f\u75c5\u60a3\u5f97\u5230\u8212\u670d\u7684\u6cbb\u7642\u59ff\u52e2\uff0c\u7e2e\u77ed\u6a21\u64ec\u651d\u5f71\u4f5c\u696d\u7684\u6642\u9593\uff0c\u53ea\u9700\u898110~15\u5206\u937e\u7684\u6642\u9593\u800c\u4e14\u53ef\u4ee5\u63d0\u4f9b\u8f03\u6e96\u78ba\u7684\u7167\u91ce\u8a2d\u5b9a\u3002\u7d50\u8ad6\uff1a\u4f7f\u7528\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u5728\u5168\u8166\u810a\u690e\u7167\u5c04\u6a21\u64ec\u651d\u5f71\u4f5c\u696d\u65b9\u9762\u7684\u52a9\u76ca\uff0c\u5728\u4f7f\u75c5\u60a3\u6a21\u64ec\u651d\u5f71\u6240\u9700\u82b1\u8cbb\u7684\u6642\u9593\u53ea\u9700\u50b3\u7d71\u6a21\u64ec\u651d\u5f71\u7684\u4e09\u5206\u4e4b\u4e00\u3002\u5c0d\u91ab\u5e2b\u800c\u8a00\u5c04\u675f\u8207\u7167\u91ce\u7684\u8a2d\u5b9a\u66f4\u6e96\u78ba\u3002\u66f4\u91cd\u8981\u7684\u662f\u75c5\u60a3\u56e0\u70ba\u6a21\u64ec\u651d\u5f71\u6240\u9700\u82b1\u8cbb\u7684\u6642\u9593\u6e1b\u5c11\uff0c\u964d\u4f4e\u4e86\u6a21\u64ec\u651d\u5f71\u671f\u9593\u56e0\u75c5\u60a3\u79fb\u52d5\u6240\u9020\u6210\u7684\u8aa4\u5dee\uff0c\u63d0\u9ad8\u4e86\u6a21\u64ec\u651d\u5f71\u53ca\u6cbb\u7642\u7684\u6e96\u78ba\u6027\u3002", "e": "Purpose: An important issue for cancer patients, who are destined to receive craniospinal irradiation (CSI), is how to reduce the overall time needed for simulation. Furthermore, it is necessary that more accurate tools are designed and adapted so that there is increased accuracy in the determination of the optimal irradiation position and field. This will increase the level of confidence of radiation oncologists with respect to these factors. In this study, we investigated and evaluated simulation techniques that utilize computed tomography (CT) for simulation of craniospinal irradiation. Material and Methods: A PQ5000 computed tomography simulator (CT-sim) has been available since 2000 at the Department of Radiation Oncology of Linkou Chang-Gung Memorial Hospital. The VOXEL Q treatment planning system and the ACQ-sim virtual simulation software were employed to access images for processing to allow the reconstruction of three-dimensional images and the accurate identification of the location and size of the tumor. Subsequently, the treatment-related parameters such as field size, the angles of gantry and collimator, and the customized block could be decided. Result: Conventional CSI simulation, which is similar to traditional X-ray simulation, is rather time consuming, requiring thirty to fifty minutes to accomplish all the processes. In addition, the patient must assume an uncomfortable prone position during which the chin and nose inevitably has to bear the weight of the head. In CT-sim, the patient adopts a supine position for CSI. With this simulation technique and position, not only does the patient feels much more comfortable as well as the simulation time needed being reduced to ten to fifteen minutes, but it also seems to be a more accurate method for determining the treatment parameters. Discussion: The benefits of CT-sim, when utilized for CSI, include a reduction in the simulation time to only one third of that needed for conventional X-ray simulation, an increased level of confidence for the radiation oncologist with respect to the determination of the radiation beam and field size and, most important of all, a decrease in treatment errors caused by patient motion during the simulation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-31-39-a", "title": "Rarely Reported Liver Toxicity in Patients Who Were Hepatitis B Carrier and Underwent Chemoirradiation for Gastric Cancer", "keywords": "\u809d\u81df\u6bd2\u6027;\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642;\u80c3\u764c Hepatic toxicity;Concurrent chemoirradiation;Gastric cancer", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u5728\u5831\u544a6\u4f4dB\u578b\u809d\u708e\u5e36\u539f\u8005\u53ca\u540c\u6642\u7f79\u60a3\u80c3\u764c\u75c5\u4eba\u5728\u63a5\u53d7\u8853\u5f8c\u8f14\u52a9\u6216\u5168\u7a0b\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u5f8c\u7522\u751f\u7b2c\u4e09\u6216\u56db\u7d1a\u809d\u81df\u6bd2\u6027\u7684\u81e8\u5e8a\u53ca\u5291\u91cf\u5b78\u6578\u64da\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a1993\u5e7412\u6708\u81f32001\u5e747\u6708\u9593\uff0c82\u4f4d\u7d93\u5207\u7247\u8b49\u5be6\u70ba\u80c3\u817a\u764c\u75c5\u4eba\u63a5\u53d7\u624b\u8853\u5f8c\u8f14\u52a9\u6216\u5168\u7a0b\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\uff0c\u5176\u4e2d10\u4f4d\u75c5\u4eba\u7d93\u8840\u6e05\u5b78\u6aa2\u67e5\u70baB\u578b\u809d\u708e\u5e36\u539f\u8005\uff0c10\u4f4d\u4e2d\u76846\u4f4d\u75c5\u4eba\u5728\u63a5\u53d7\u624b\u8853\u5f8c\u8f14\u52a9\u6216\u5168\u7a0b\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u5f8c\u7522\u751f\u7b2c\u4e09\u6216\u56db\u7d1a\u809d\u81df\u6bd2\u6027\uff0c\u70ba\u672c\u7814\u7a76\u7684\u4e3b\u8981\u5c0d\u8c61\u30025\u4f4d\u75c5\u4eba\u63a5\u53d745Gy\uff0f1.8Gy\uff0f25\u6b21\uff0c1\u4f4d\u75c5\u4eba\u63a5\u53d750.4Gy\uff0f1.8Gy\uff0f28\u6b21\u768418 MV\u5149\u5b50\u5c04\u675f\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u65bc\u816b\u7624\u5207\u9664\u5340\u57df\u53ca\u9644\u8fd1\u6dcb\u5df4\u5340\u57df\u3002\u540c\u6b65\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u4f7f\u7528\u6bcf\u90311\u6b21\u975c\u8108\u9023\u7e8c\u6ce8\u5c0424\u5c0f\u6642\u76845-fluorouracil 2 gm/m2\u53caleucovorin 300 mg/m2\uff0c\u5171\u63a5\u53d73-6\u7642\u7a0b\uff08\u4e2d\u4f4d\u6578\uff1a5\u7642\u7a0b\uff09\uff0c3\u4f4d\u75c5\u4eba\u53e6\u63a5\u53d71\u6b21\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u958b\u59cb\u524d3\u9031\u7684etoposide\uff0c5-fluorouracil\uff0cleucovorin\u524d\u5c0e\u5316\u5b78\u6cbb\u7642\u3002\u7b2c\u4e09\u6216\u7b2c\u56db\u7d1a\u809d\u81df\u6bd2\u6027\u6839\u64da\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u4e2d\u5fc3\u4e4b\u5e38\u898b\u6bd2\u6027\u6a19\u6e96\u5b9a\u7fa9\u70ba\u975e\u60e1\u6027\u8179\u6c34\u5f62\u6210\u53ca\u9e7c\u6027\u78f7\u9178\u92c2\u4e0a\u66072\u500d\u4ee5\u4e0a\uff0c\u6216\u809d\u6307\u6578\uff08GOT/GPT\uff09\u4e0a\u5347\u81f3\u6b63\u5e38\u503c\u4e0a\u9650\u6216\u6cbb\u7642\u524d\u76845\u500d\u4ee5\u4e0a\u3002\u75c5\u4eba\u5b8c\u6210\u6cbb\u7642\u63a5\u53d7\u6bcf\u67081\u6b21\u7684\u8eab\u9ad4\u6aa2\u67e5\u53ca\u8840\u6db2\u8840\u7403\u8a08\u6578\u8207\u751f\u5316\u6aa2\u67e5\u3002\u5291\u91cf\u9ad4\u7a4d\u5716\u4f7f\u7528\u65bc\u6b63\u5e38\u5668\u5b98\u5291\u91cf\u53c3\u6578\u7684\u5206\u6790\u5de5\u5177\u3002\u7d50\u679c\uff1a6\u4f4d\u75c5\u4eba\u653e\u5c04\u6cbb\u7642\u5f8c\u4e2d\u4f4d\u657838\u5929\u767c\u751f\u7b2c\u4e09\u6216\u7b2c\u56db\u7d1a\u809d\u81df\u6bd2\u6027\uff0c5\u4f4d\u75c5\u4eba\u5b8c\u5168\u5eb7\u5fa9\uff0c1\u4f4d\u75c5\u4eba\u6b7b\u65bc\u6b64\u4f75\u767c\u75c7\u30025\u4f4d\u75c5\u4eba\u75c5\u767c\u6642\u6709\u8840\u6e05\u5b78\u6216\u75c5\u7406\u5b78\u7684\u6162\u6027\u809d\u708e\u6025\u6027\u767c\u4f5c\u8b49\u64da\u3002\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u7642\u7a0b\u4e2d\u7684\u6700\u5927\u8840\u6db2\u7cfb\u7d71\u6bd2\u6027\u70ba\u7b2c1\u7d1a1\u4f4d\uff0c\u7b2c2\u7d1a4\u4f4d\uff0c\u7b2c3\u7d1al\u4f4d\u75c5\u4eba\u30026\u4f4d\u75c5\u4eba\u7684\u5e73\u5747\u809d\u81df\u5291\u91cf\u7bc4\u570d\u70ba10.4Gy\u523022.9Gy\uff08\u5e73\u5747\u657817.2Gy\uff09\uff0c\u809d\u81df\u63a5\u53d7\u8d85\u904e30Gy\u5291\u91cf\u7684\u9ad4\u7a4d\u6bd4\u4f8b\u7bc4\u570d\u70ba7%\u523037%\uff08\u5e73\u5747\u657824%\uff09\uff0c\u5e73\u5747\u7684\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u70ba3.3%\uff0c\u7bc4\u570d\u70ba0.03%\u52306.8%\uff0c\u9019\u4e09\u9805\u53c3\u6578\u7684\u5e73\u5747\u6578\u986f\u8457\u4f4e\u65bc\u53e6\u591612\u4f4d\u809d\u764c\u75c5\u4eba\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u5f8c\u767c\u751f\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u81df\u75c5\u8b8a\u7684\u5291\u91cf\u53c3\u6578\u5e73\u5747\u6578\u3002\u7d50\u8ad6\uff1a B\u578b\u809d\u708e\u5e36\u539f\u8005\u7f79\u60a3\u80c3\u764c\u63a5\u53d7\u5408\u4f75\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u5f8c\u767c\u751f\u809d\u81df\u6bd2\u6027\u7684\u73fe\u8c61\uff0c\u662f\u6587\u737b\u4e0a\u5c11\u898b\u4e14\u503c\u5f97\u7279\u5225\u6ce8\u610f\u7684\u3002\u5728\u7d66\u4e88\u5316\u5b78\u6cbb\u7642\u7684\u540c\u6642\uff0c\u809d\u81df\u5c0d\u653e\u5c04\u7dda\u7684\u5fcd\u53d7\u5ea6\u66f4\u5f62\u4e0b\u964d\u3002\u9032\u4e00\u6b65\u5c0d\u809d\u81df\u50b7\u5bb3\u5f62\u6210\u6a5f\u8f49\u7684\u7814\u7a76\u662f\u6025\u5207\u9700\u8981\u7684\u3002", "e": "Purpose: This study is to report the clinical and dosimetric parameters of six patients who were carriers of type B chronic hepatitis and developed grade 3 or 4 hepatic toxicity after adjuvant or definitive concurrent chemoirradiation for gastric cancer. Materials and Methods: From December 1993 through July 2001, 82 patients with gastric adenocarcinoma underwent radiotherapy as adjuvant or definitive treatment. Ten patients were carriers of type B chronic hepatitis on serology test. Six of 10 patients who developed grade 3 or 4 hepatic toxicity within 4 months after radiotherapy, formed the basis of this study. Five patients underwent external-beam radiotherapy with 45 Gy/1.8 Gy/25 fractions and 18 MV photons delivered to the tumor bed and regional lymphatics Over 5 weeks. One patient had the radiotherapy with 50.4 Gy/28 fractions. Concurrent chemotherapy consisted of 3-6 (median: 5) weekly cycles of intravenous infusion with 5fluorouracil 2 gm/m2 and leucovorin 300mg/m2 for 24 hours. Dose-volume histograms of the critical organs were used for the dosimetric factors in these patients.  Results: Six patients developed grade 3 or 4 hepatic toxicity, with a median interval of 38 days from completion of radiotherapy. One patient died of this complication and five patients recovered. All but one patient had either serologic or histological evidence of reactivation of chronic viral hepatitis. Mean dose of liver of the 6 patients ranged from 10.4 Gy to 22.9 Gy (mean: 17.2 Gy), while the percent volume receiving more than 30 Gy of radiation (V3o Gy) ranged from 7% to 37% (mean: 24%). Mean normal tissue complication probability (NTCP) was 3.3%, ranging from 0.03% to 6.8%. Mean hepatic dose, V30GY, and NTCP were all significantly lower than those of the 12 patients with hepatocelular carcinoma and radiation-induced liver disease after three-dimensional conformal radiotherapy. Conclusion: Hepatic toxicity after concurrent chemoirradiation, in patients who were carriers of type B chronic hepatitis and underwent treatment for gastric cancer, deserves special attention and was rarely reported in the literature. The tolerance of liver to radiation was even lower than expected in the presence of concurrent chemotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-41-51-a", "title": "A Dosimetric Comparison of the Predictive Value of Two Rectal Reference Points for Late Rectal Complications Following the Treatment of Cervical Cancer by High-Dose-Rate Brachytherapy", "keywords": "\u5b50\u5bae\u9838\u764c;\u8fd1\u63a5\u6cbb\u7642;\u76f4\u8178\u5f8c\u907a\u75c7;\u653e\u5c04\u5291\u91cf Cervical cancer;Brachytherapy;Rectal sequelae;Radiation dose", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u5728\u6bd4\u8f03\u5169\u7a2e\u76f4\u8178\u5291\u91cf\u53c3\u8003\u9ede\u5c0d\u5b50\u5bae\u9838\u764c\u653e\u5c04\u7dda\u6cbb\u7642\u5f15\u767c\u4e4b\u76f4\u8178\u51fa\u8840\u5f8c\u907a\u75c7\u7684\u9810\u6e2c\u50f9\u503c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1992\u5e749\u6708\u81f31997\u5e7412\u6708\uff0c\u5171\u6709181\u4f4d\u5728\u65b0\u5149\u53ca\u4e2d\u570b\u91ab\u85e5\u5b78\u9662\u9644\u8a2d\u91ab\u9662\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u4e4b\u5b50\u5bae\u9838\u764c\u75c5\u4eba\uff08\u7b2cIB\uff0cIIA\uff0cIIB\uff0cIIIA\uff0cIIIB\u671f\u5206\u5225\u670932\uff0c23\uff0c102\uff0c3\uff0c21\u4eba)\u9032\u5165\u5206\u6790\u3002\u6240\u6709\u75c5\u4eba\u7686\u5b58\u6d3b\u4e00\u5e74\u4ee5\u4e0a\uff0c\u4e14\u9577\u671f\u5b58\u6d3b\u8005\u9808\u7d93\u81f3\u5c11\u4e09\u5e74\u4e4b\u8ffd\u8e64\u6aa2\u67e5\u3002\u653e\u5c04\u6cbb\u7642\u7bc4\u570d\u6db5\u84cb\u6574\u500b\u5b50\u5bae\uff0c\u9670\u9053\u53ca\u4e0b\u8179\u8154\u6dcb\u5df4\u817a\uff0c\u7d93\u7167\u5c0444Gy\u81f345Gy\u5f8c\uff0c\u816b\u7624\u671f\u5225\u8d85\u904eIIB\u7684\u75c5\u4eba\uff0c\u7167\u91ce\u7e2e\u5c0f\u81f3\u5169\u5074\u7684\u5b50\u5bae\u65c1\u7d44\u7e54\uff08parametrium\uff09\uff0c\u518d\u7d66\u820714Gy\u3002\u9ad8\u5291\u91cf\u7387\uff08HDR\uff09\u5b50\u5bae\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u9593\u9694\u4e00\u9031\uff0c\u5176\u4e2d51\u4f4d\u75c5\u4eba\u6cbb\u7642\u6b21\u65783\u6b21\uff0c\u6bcf\u6b21\u7d66\u4e88\u53c3\u8003\u9edeA\uff08Point A\uff097.2Gy\u7684\u5291\u91cf\uff1b\u53e6130\u4f4d\u75c5\u4eba\u6cbb\u7642\u6b21\u65784\u6b21\uff0c\u6bcf\u6b21\u7d66\u4e88\u53c3\u8003\u9edeA\uff08Point A\uff096.0Gy\u7684\u5291\u91cf\uff0c\u6bcf\u6b21\u8fd1\u63a5\u6cbb\u7642\u6642\u7686\u4ee5ICRU\u53ca\u50b3\u7d71\u65b9\u5f0f\u5169\u7a2e\u65b9\u6cd5\u4f86\u8a08\u7b97\u6bcf\u4f4d\u75c5\u4eba\u4e4b\u76f4\u8178\u5291\u91cf\uff0c\u7e3d\u5171\u4e4b\u653e\u5c04\u6cbb\u7642\u6642\u959347\u81f390\u5929\uff08\u4e2d\u4f4d\u657860\u5929\uff09\u3002\u7531\u591a\u8b8a\u6578\u5206\u6790\u4f86\u5206\u6790\u75c5\u4eba\u672c\u8eab\u3001\u8fd1\u63a5\u6cbb\u7642\u53ca\u76f4\u8178\u5291\u91cf\u7b49\u53ef\u80fd\u5f71\u97ff\u76f4\u8178\u5f8c\u907a\u75c7\u4e4b\u56e0\u5b50\uff0c\u4ee5\u627e\u51fa\u767c\u751f\u5f8c\u907a\u75c7\u4e4b\u9ad8\u5371\u96aa\u7fa4\u3002\n\u7d50\u679c\uff1a181\u4f4d\u75c5\u60a3\u7d93\u904e38\u81f3110\u500b\u6708\u7684\u8ffd\u8e64\u6aa2\u67e5\uff08\u4e2d\u4f4d\u503c58\u500b\u6708\uff09\uff0c45\u4eba(24.9% )\u767c\u751fRTOG\u7b2c\u4e00\u81f3\u7b2c\u56db\u7d1a\u4e4b\u76f4\u8178\u5f8c\u907a\u75c7\uff08\u7b2c\u4e00\u3001\u7b2c\u4e8c\u3001\u7b2c\u4e09\u81f3\u56db\u7d1a\u5206\u5225\u670927\u300113\u53ca5\u4eba\uff09\u3002\u76f4\u8178\u5f8c\u907a\u75c7\u767c\u751f\u7684\u6a5f\u7387\u8207\u7d2f\u7a4d\u4e4bICRU\u76f4\u8178\u5291\u91cf\u53c3\u8003\u9ede\u5291\u91cf\u6709\u8f03\u660e\u986f\u7684\u76f8\u95dc\u6027\u3002\u591a\u8b8a\u6578\u5206\u6790\u5f8c\u767c\u73fe\u7b2cIIB-III\u671f\uff08p\uff1d0.002\uff09\u53ca\u7d2f\u7a4d\u4e4bICRU\u76f4\u8178\u5291\u91cf\u53c3\u8003\u9ede\u5291\u91cf\u5927\u65bc20Gy\uff08p\uff1d0.005\uff09\u70ba\u5f15\u767c\u76f4\u8178\u5f8c\u907a\u75c7\u4e4b\u9ad8\u5371\u96aa\u7fa4\u3002\n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u78ba\u5b9aICRU\u76f4\u8178\u5291\u91cf\u53c3\u8003\u9ede\u5c0d\u9810\u6e2c\u76f4\u8178\u5f8c\u907a\u75c7\u7684\u50f9\u503c\uff0c\u800c\u4ee5\u50b3\u7d71\u65b9\u5f0f\u8a08\u7b97\u4e4b\u76f4\u8178\u5291\u91cf\u8207\u76f4\u8178\u5f8c\u907a\u75c7\u7684\u767c\u751f\u4e26\u6c92\u6709\u5f88\u597d\u7684\u76f8\u95dc\u6027\u3002\u672c\u7814\u7a76\u5efa\u8b70\uff0c\u5728\u4e0d\u5f71\u97ff\u6cbb\u7642\u7d50\u679c\u7684\u524d\u63d0\u4e0b\uff0c\u91dd\u5c0d\u76f4\u8178\u5f8c\u907a\u75c7\u4e4b\u9ad8\u5371\u96aa\u7fa4\uff0c\u61c9\u8abf\u6574\u6cbb\u7642\u8a08\u5283\uff0c\u4ee5\u6e1b\u5c11\u5f8c\u907a\u75c7\u767c\u751f\u7684\u6a5f\u7387\u3002", "e": "Purpose: This study aimed to compare the predictive value of ICRU (International Committee on Radiation Units and Measurements) and conventional rectal reference point with the risk of late rectal sequelae in patients with carcinoma of the uterine cervix treated with high-dose-rate intracavitary brachytherapy (HDRICB). Materials and Methods: From September 1992 to December 1997, 181 cases (32 IB, 23 IIA, 102 IIB, 3IIIA, 2IIIB) who survived more than 12 months after treatment and the long-term survivors should receive a minimum 3 years of follow-up, were entered in our study. Initially, they were treated with 10 MV X-rays for 44 - 45 Gy / 22 - 25 fractions over 4-5 weeks to whole pelvis Radiation dose for patients with FIGO Stage IIB-III bilateral parametrial disease was boosted to 54-58 Gy, with a central shielding. After the completion of whole-pelvis radiotherapy, HDRICB was performed using an Ir-192 remote after loading technique at one-week intervals. Fifty-one patients received three insertions, while 130 patients had four insertions. The prescribed dose for each HDRICB was 7.2 Gy to Point A for three insertions (before July 1995), or 6.0 Gy for four insertions (after July 1995). HDRICB dosimetry was calculated using orthogonal films exposed during each insertion. Doses to both ICRU and conventional rectal reference points were calculated for each patient. The overall duration of treatment ranged from 47-90 days (median, 60). Patient and treatment related factors were evaluated for late rectal complication using logistic regression model. Results: Median follow-up of these patients was 58 months (range: 38-110 months). Forty-five patients (24.9%) had late rectal complications (27 Grade 1, 13 Grade 2, 5 Grade 3-4). The probability of rectal complications shows a better correlation of doseresponse with increasing total brachytherapy ICRU rectal dose. Multivariate logistic regression analysis demonstrated a high risk of late rectal sequelae in patients who had Stage IIB-III disease (p = 0.002, relative risk, 3.66, 95% CI 1.82-6.45) and total ICRU rectal dose greater than 20 Gy (p = 0.005, relative risk, 1.62, 95% CI1.03-3.21). Conclusions: This study confirms the value of ICRU rectal reference point in the prediction of late rectal sequelae. Patients who have Stage IIB-III disease, or a total ICRU rectal dose greater than 20 Gy, have a higher risk of late rectal sequelae."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-53-63-a", "title": "\u5b50\u5bae\u9838\u764c\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u75c5\u4eba\u7d44\u7e54\u75c5\u7406\u5b78\u9810\u5f8c\u56e0\u5b50\u4e4b\u591a\u8b8a\u6578\u5206\u6790", "keywords": "\u5b50\u5bae\u9838\u764c;\u9810\u5f8c\u56e0\u5b50;\u591a\u8b8a\u6578\u5206\u6790 Cervical cancer;Prognostic factors;Multivariate analysis", "c": "\u76ee\u7684\uff1a\u672c\u6587\u7814\u7a76\u7684\u76ee\u7684\u662f\u5f9e\u5b50\u5bae\u9838\u764c\u4f5c\u904e\u5b50\u5bae\u5207\u9664\u624b\u8853\u53ca\u8853\u5f8c\u653e\u7642\u7684\u75c5\u4eba\u4e2d\u6aa2\u8996\u5176\u75c5\u7406\u5831\u544a\uff0c\u5f9e\u5176\u4e2d\u4e03\u9805\u75c5\u7406\u767c\u73fe\uff0c\u5229\u7528\u7d71\u8a08\u65b9\u6cd5\u5206\u6790\u90a3\u4e9b\u662f\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u5357\u90ed\u91ab\u5b78\u4e2d\u5fc3\u653e\u5c04\u816b\u7624\u79d1\uff0c\u81ea\u6c11\u570b\u4e03\u5341\u56db\u5e74\u5341\u4e8c\u6708\u4e00\u65e5\u8fc4\u6c11\u570b\u516b\u5341\u5e74\u5341\u4e8c\u6708\u4e09\u5341\u4e00\u65e5\uff0c\u5171\u8a08\u6709126\u4f8b\u7d93\u75c5\u7406\u8a3a\u65b7\u8b49\u5be6\u4e4b\u7b2c\u4e00\u8207\u7b2c\u4e8c\u671f\u5b50\u5bae\u9838\u764c\u75c5\u4eba\uff0c\u63a5\u53d7\u904e\u6839\u6cbb\u6027\u5b50\u5bae\u5207\u9664\u8853\u5408\u4f75\u9aa8\u76c6\u8154\u6dcb\u5df4\u817a\u6458\u9664\u8853\uff08\u5305\u62ec\u5168\u5b50\u5bae\u5207\u9664\u8853\u5728\u5167\uff09\u8207\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u4e3b\u8981\u4f86\u81ea\u8853\u5f8c\u75c5\u7406\u6aa2\u67e5\u767c\u73fe\u6709\u6dcb\u5df4\u817a\u8f49\u79fb\uff0c\u624b\u8853\u908a\u7de3\u6709\u764c\u7d30\u80de\u4fb5\u72af\uff0c\u6dcb\u5df4\u8840\u7ba1\u6d78\u6f64\uff0c\u539f\u767c\u816b\u7624\u5927\u65bc\u6216\u7b49\u65bc3.0\u516c\u5206\uff0c\u5b50\u5bae\u65c1\u7d44\u7e54\u4fb5\u72af\uff0c\u5b50\u5bae\u9ad4\u64f4\u6563\u6216\u50c5\u4f5c\u55ae\u7d14\u5b50\u5bae\u5207\u9664\u8853\u7b49\u56e0\u7d20\u3002\u9ad4\u5916\u653e\u5c04\u7dda\u5291\u91cf\u901a\u5e38\u5168\u9aa8\u76c6\u8154\u63a5\u53d739.6\u81f361.2 Gy\u4e4b\u816b\u7624\u5291\u91cf\uff0c\u53e6\u5916\u5728\u9670\u9053\u7e2b\u5408\u7de3\u518d\u8ffd\u52a0\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u3002\u6240\u6709\u63a5\u53d7\u904e\u5b8c\u6574\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u60a3\u5176\u8ffd\u8e64\u671f\u6700\u77ed\u70ba8\u500b\u6708\uff0c\u6700\u9577\u7684\u70ba256\u500b\u6708\uff08\u4e2d\u503c\u8ffd\u8e64\u671f\uff1a113\u500b\u6708\uff09\u3002\u8207\u9810\u5f8c\u76f8\u95dc\u4e4b\u75c5\u7406\u7d44\u7e54\u5b78\u53c3\u6578\u5982\u75c5\u7406\u5b78\u5206\u985e\u3001\u816b\u7624\u5206\u5316\u7a0b\u5ea6\u3001\u816b\u7624\u7e31\u6df1\u5f91\u3001\u6dcb\u5df4\u8840\u7ba1\u9593\u9699\u4fb5\u72af\u3001\u5b50\u5bae\u9ad4\u64f4\u6563\u3001\u5b50\u5bae\u65c1\u7d44\u7e54\u4fb5\u72af\u3001\u9670\u9053\u4fb5\u72af\u53ca\u9aa8\u76c6\u6dcb\u5df4\u817a\u8f49\u79fb\u7b49\uff0c\u7686\u7d93\u641c\u96c6\u5206\u985e\u4e26\u4ee5\u7d71\u8a08\u8edf\u9ad4\u4f5c\u55ae\u8b8a\u6578\u8207\u591a\u8b8a\u6578\u5206\u6790\u3002\u7d50\u679c\uff1a\u6240\u6709\u7684126\u4f8b\u500b\u6848\u7686\u7d93\u904e\u5be9\u614e\u7684\u8a55\u4f30\uff0c\u5206\u6790\u8207\u8ffd\u8e64\u4e00\u76f4\u5230\u7814\u7a76\u7d50\u675f\uff08\u6c11\u570b\u4e5d\u5341\u5e74\u516d\u6708\u5e95\uff09\u3002\u5230\u76ee\u524d\u5df2\u6709\u534a\u6578\u75c5\u4eba\uff0863\u4f8b\uff09\u6b7b\u4ea1\u3002\u5b58\u6d3b\u671f\u9593\u7684\u8a08\u7b97\u662f\u7531\u75c5\u7406\u8a3a\u65b7\u65e5\u7b97\u8d77\u76f4\u5230\u6700\u5f8c\u8ffd\u8e64\u65e5\u671f\u6216\u6b7b\u4ea1\u65e5\u671f\u3002\u4f9d\u64da\u5916\u79d1\u5206\u671f\u7684\u7d50\u679c\uff0cIB\uff0cIIA\uff0cIIB\u5404\u671f\u4e4b\u4f30\u8a08\u4e94\u5e74\u8207\u5341\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba65%\uff0c75%\uff0c62%\u820759%\uff0c 49%\uff0c53% \uff08p\uff1e0.05\uff09\u3002\u55ae\u8b8a\u6578\u5206\u6790\u7d50\u679c\u6307\u51fa\uff0c\u9aa8\u76c6\u8154\u6dcb\u5df4\u817a\u8f49\u79fb\u3001\u7d44\u7e54\u75c5\u7406\u5b78\u5206\u985e\u3001\u816b\u7624\u5927\u5c0f\u8207\u5b50\u5bae\u9ad4\u4fb5\u72af\u56db\u500b\u8b8a\u9805\uff0c\u5c0d\u5b58\u6d3b\u7387\u6709\u986f\u8457\u6027\u7684\u5f71\u97ff\uff08p\uff1c0.05\uff09\u3002\u7d93\u904eCox regression model\u9032\u884c\u591a\u8b8a\u6578\u5206\u6790\u4ee5\u5f8c\uff0c\u50c5\u6709\u7d44\u7e54\u75c5\u7406\u5b78\u5206\u985e\u8207\u9aa8\u76c6\u8154\u6dcb\u5df4\u817a\u8f49\u79fb\u4e8c\u8b8a\u9805\uff0c\u88ab\u9451\u5b9a\u70ba\u5f71\u97ff\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u6cbb\u7642\u5f8c\u4e94\u5e74\u53ca\u5341\u5e74\u5b58\u6d3b\u7387\u4e4b\u7368\u7acb\u4e14\u986f\u8457\u4e4b\u9810\u5f8c\u56e0\u5b50\uff08p\uff1c0.005\uff09\u3002\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5f9e\u5b50\u5bae\u9838\u764c\u4f5c\u904e\u5b50\u5bae\u5207\u9664\u8853\u53ca\u8853\u5f8c\u653e\u7642\u7684126\u4f8b\u75c5\u4eba\uff0c\u7d93Cox\u6c0f\u6a21\u578b\u7684\u7d71\u8a08\u5206\u6790\u5f8c\uff0c\u767c\u73fe\u7d44\u7e54\u75c5\u7406\u5b78\u5206\u985e\u70ba\u975e\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u8207\u9aa8\u76c6\u8154\u6dcb\u5df4\u7d50\u8f49\u79fb\u500b\u6578\u57282\u4ee5\u4e0a\uff0c\u5176\u4e94\u5e74\u53ca\u5341\u5e74\u7684\u5b58\u6d3b\u7387\u6700\u5dee\uff0c\u4e14\u662f\u5169\u500b\u7368\u7acb\u800c\u610f\u7fa9\u986f\u8457\u4e4b\u9810\u5f8c\u8b8a\u6578\u3002", "e": "Purpose: The purpose of this investigation is to evaluate the histopathologic reports from cervical cancer patients who had undergone hysterectomy and post-operative irradiation, and, from seven major pathologic findings, to analyze what are important prognostic factors by statistical methods. Materials and Methods: Between 1st, Dec. 1985 and 31, Dec. 1991, 126 patients with pathology proven stages I and II carcinoma of the uterine cervix were treated by radical hysterectomy and pelvic lymphadenectomy (some of them underwent abdominal total hysterectomy) (ATH) followed with post operative irradiation at Department of Radiation Oncology, Chang-hua Christian Hospital. The indications for radiotherapy were based on pathologic findings including lymph node metastasis, positive Surgical margins, lymphovascular permeation, primary tumor size\u22673.0 cm, parametrial involvement, corpus invasion, previous inadequate surgery (ATH) or more than one combination of the above. Patients usually received external beam irradiation 39.6 Gy to 61.2 Gy to the whole pelvis, and the vaginal cuff were boosted by intravaginal brachytherapy. All patients who received complete course of radiotherapy had follow-up period between 8 and 256 months (median: 113 months). The prognosis related histologic parameters including histologic subtypes, tumor grade, longitudinal tumor dimension, lymphovascular space invasion, corpus invasion, parametrial extension, vaginal invasion and pelvic lymph node(s) (PLN) metastases were collected and evaluated with univariate and multivariate analysis. Results: All the 126 cases were evaluated, analyzed and followed until closure of this study (Jun. 2001). Half(63) of all the cases died. The survival duration was calculated from time of histologic diagnosis to the time of last follow-up or death. The estimated 5- and 10-year survival rate of surgical stages IB, IIA and IIB were 65%, 75%, 62% and 59%, 49%, 53%respectively (p \uff1e 0.05). Univariate analysis revealed that PLN metastases, histologic subtype, tumor size and corpus invasion were significant in survival (p \uff1c 0.05). Among these variables, we found that histologic subtype and PLN metastases were identified as the most independent and significant prognostic factors (p \uff1c 0.005) which have major analysis using Cox regression model. Conclusions: In the current study, which enrolled 126 cases of cervical cancer patients having hysterectomy and post-operative irradiation, we found that histologic subtype (non-See from pathologic classification) and PLN metastases (number of metastatic nodes more than 2) have the worst 5- and 10year survival rate, and were recognized as two independent and significant prognostic variables by Cox's model."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200203-9-1-65-70-a", "title": "\u80f8\u90e8\u56fa\u5b9a\u5668\u8a2d\u8a08\u8207\u81e8\u5e8a\u4e0a\u4e4b\u61c9\u7528", "keywords": "\u80f8\u90e8\u56fa\u5b9a\u5668;\u6a21\u5177;\u6a21\u64ec\u5b9a\u4f4d\u7247;\u9a57\u8b49\u7247 Chest holder;Aquaplast;Portal film;Verification film", "c": "\u76ee\u7684\uff1a\u672c\u79d1\u70ba\u4f7f\u80f8\u90e8\u75c5\u60a3\u6cbb\u7642\u90e8\u4f4d\u7cbe\u78ba\u5ea6\u63d0\u9ad8\uff0c\u6bcf\u5929\u6cbb\u7642\u4e4b\u518d\u73fe\u6027\u4e00\u81f4[9,13]\uff0c\u7279\u5225\u7814\u767c\u9069\u5408\u570b\u4eba\u80f8\u90e8\u56fa\u5b9a\u4e4b\u5668\u5177\uff0c\u80fd\u9069\u7528\u65bc\u98df\u9053\u764c\u3001\u80ba\u764c\u3001\u4e73\u623f\u764c\u7b49\u7b49\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9996\u5148\u9078\u5b9a\u6a21\u5177\uff08aquaplast\uff09\uff0c\u5c07\u5176\u6d78\u5165\u71b1\u6c34\u69fd\u7bb1\uff0c\u5f85\u5176\u8edf\u5316\u5f8c\uff0c\u81ea\u71b1\u6c34\u69fd\u7bb1\u4e2d\u53d6\u51fa\u4e26\u8986\u84cb\u5728\u75c5\u60a3\u9ad4\u8868\uff0c\u914d\u5408\u81ea\u884c\u7814\u767c\u4e4b\u80f8\u90e8\u56fa\u5b9a\u5668\uff08chest holder\uff09\uff0c\u5b8c\u6210\u5177\u6709\u56fa\u5b9a\u6548\u679c\u4e4b\u56fa\u5b9a\u6a21\u578b\u3002\u518d\u4f7f\u7528\u6a21\u64ec\u651d\u5f71\u6a5f\u5c0d\u75c5\u60a3\u5be6\u65bd\u6a21\u64ec\u5b9a\u4f4d\u651d\u5f71\uff0c\u53d6\u5f97\u6a21\u64ec\u5b9a\u4f4d\u7247\uff08portal film\uff09\uff0c\u53ca\u5b89\u6392\u75c5\u60a3\u5be6\u65bd\u96fb\u8166\u65b7\u5c64\u651d\u5f71\uff0c\u53d6\u5f97\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4ee5\u88fd\u4f5c\u75c5\u60a3\u4e4b\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u3002\u7d93\u91ab\u5e2b\u78ba\u8a8d\u6cbb\u7642\u7bc4\u570d\u548c\u6a21\u64ec\u9a57\u8b49\u7686\u7b26\u5408\u6cbb\u7642\u8a08\u5283\u53ca\u6cbb\u7642\u76ee\u6a19\u5f8c\uff0c\u5373\u53ef\u81f3\u76f4\u7dda\u52a0\u901f\u5668\u4e0a\u5be6\u65bd\u9a57\u8b49\u7247\uff08verification film\uff09\u4e4b\u5de5\u4f5c\uff0c\u6700\u5f8c\u7531\u91ab\u5e2b\u6839\u64da\u6a21\u64ec\u5b9a\u4f4d\u7247\u548c\u9a57\u8b49\u7247\u7684\u5668\u5b98\u5f71\u50cf\u89e3\u5256\u7684\u4f4d\u7f6e\uff0c\u4f86\u6bd4\u8f03\u5169\u8005\u4e4b\u5dee\u7570\uff0c\u5f97\u77e5\u56fa\u5b9a\u6a21\u578b\u4e4b\u56fa\u5b9a\u6548\u679c\u53ca\u6e96\u78ba\u5ea6\u3002\n\u7d50\u679c\uff1a\u672c\u79d1\u5f9e87\u5e7412\u6708\u81f390\u5e7412\u6708\u88fd\u4f5c\u904e200\u500b\u80f8\u90e8\u56fa\u5b9a\u6a21\u5177\u4e4b\u75c5\u60a3\uff0c\u7d93\u7531\u6a21\u64ec\u5b9a\u4f4d\u7247\u8207\u9a57\u8b49\u7247\u6bd4\u8f03\u7d50\u679c\uff0c\u5169\u8005\u8aa4\u5dee\u7686\u57281~3 mm\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u672c\u79d1\u88fd\u4f5c\u7684\u80f8\u90e8\u56fa\u5b9a\u6a21\u5177\u512a\u9ede\u662f\u6bcf\u5929\u6cbb\u7642\u53ef\u6b63\u78ba\u3001\u5feb\u901f\u5c0d\u6e96\u6cbb\u7642\u90e8\u4f4d\uff0c\u800c\u4e14\u53ef\u907f\u514d\u6240\u4f5c\u8a18\u865f\u756b\u5728\u75c5\u60a3\u9ad4\u8868\u4e0a\uff0c\u9020\u6210\u75c5\u60a3\u7f8e\u89c0\u4e0a\u7684\u554f\u984c\uff0c\u4e26\u9632\u6b62\u67d0\u4e9b\u75c5\u60a3\u76ae\u819a\u5c0d\u81a0\u5e03\u6216\u5947\u7570\u7b46\u6240\u91cf\u7684\u8a18\u865f\u6703\u9020\u6210\u76ae\u819a\u7684\u904e\u654f\uff0c\u9032\u800c\u5f71\u97ff\u6cbb\u7642\u54c1\u8cea\u3002", "e": "Purpose: In order to increase the accuracy of radiotherapeutic treatment in the chest region and ensure the reproducibility of precise daily treatment portals [9,13], we design a chest immobilization device that better fits Chinese people and this is appropriate in the application for the treatment for esophageal cancer, lung cancer, breast cancer and so on. \nMaterials and Methods: To design the chest holder, we measure the width of patient's body and the length of patient's head, shoulders, and weight. The material of the chest holder is the acrylic. The CT number of the acrylic is the same with the muscle tissue of our body. We use the aquaplast on patients for immobilizing and marking. \nResults: To verify the feasibility and quality of the chest holder, we compare the treatment portals taken in portal films and verification films. The discrepancy of the two figures are within 1~3 mm, which is clinically acceptable. \nConclusion: The advantage of the chest holder is the assurance of a daily accurate treatment and also the avoidance of placing the markers on patient's skin, which may produce the allergic reaction in convenience in daily living and patient's outlook change."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-1-14-a", "title": "Three Dimensional Conformal Radiation Therapy to Portal Vein Thrombosis Area as the Initial Treatment for Hepatocellular Carcinoma With Portal Vein Thrombosis: Prognostic Factors and Outcome for Patie", "keywords": "\u809d\u764c;\u9580\u975c\u8108\u6813\u585e;\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642 Hepatocellular carcinoma;Portal vein thrombosis;Three-dimensional conformal radiotherapy", "c": "\u7814\u7a76\u80cc\u666f\u53ca\u76ee\u7684\uff1a\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u6813\u585e\u4e4b\u9810\u5f8c\u4e0d\u4f73\uff0c\u4e26\u4e14\u662f\u505a\u7d93\u76ae\u809d\u52d5\u8108\u8840\u7ba1\u6813\u585e\u6cbb\u7642\uff08TAE\uff09\u7684\u7981\u5fcc\u75c7\u3002\u96d6\u7136\u904e\u53bb\u5df2\u7d93\u8b49\u5be6\u50b3\u7d71\u7684\u809d\u764c\u653e\u5c04\u6cbb\u7642\u65b9\u6cd5\u6548\u679c\u4e0d\u5f70\uff0c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u537b\u53ef\u80fd\u662f\u53e6\u4e00\u500b\u53ef\u9078\u64c7\u7684\u66ff\u4ee3\u65b9\u6848\u3002\u5728\u9019\u500b\u7814\u7a76\u7576\u4e2d\uff0c\u6211\u5011\u5c07\u5206\u6790\u4ee5\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u9580\u975c\u8108\u6813\u585e\u70ba\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u6813\u585e\u70ba\u521d\u59cb\u7642\u6cd5\u4e4b\u9810\u5f8c\u56e0\u5b50\u8207\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1997\u5e74\u4e5d\u6708\u52301999\u5e74\u516b\u6708\uff0c\u5171\u670942\u4f4d\u75c5\u4eba\u88ab\u8f49\u4ecb\u81f3\u672c\u79d1\u5176\u521d\u59cb\u8a3a\u65b7\u70ba\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u6813\u585e\u4e26\u4e14\u6c92\u6709\u63a5\u53d7\u904e\u4efb\u4f55\u6cbb\u7642\u4ee5\u53ca\u897f\u65b9\u764c\u75c5\u806f\u5408\u7d44\u7e54\uff08ECOG\uff09\u529f\u80fd\u72c0\u614b\u512a\u65bc\u4e8c\u7d1a\uff0c\u9019\u4e9b\u75c5\u4eba\u5373\u70ba\u6211\u5011\u7814\u7a76\u7684\u5c0d\u8c61\u3002\u4ed6\u5011\u4f9d\u7167\u500b\u4eba\u4e0d\u540c\u7684\u60c5\u5f62\u91dd\u5c0d\u9580\u975c\u8108\u6813\u585e\u5340\u57df\u4ee5\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7d66\u4e8850\u523061.3\u683c\u96f7\u7684\u5291\u91cf\uff0c\u6bcf\u65e5\u5206\u6b21\u5291\u91cf\u70ba1.8\u81f32.5\u683c\u96f7\u3002\u5e74\u9f61\u3001\u6027\u5225\u3001ECOG\u529f\u80fd\u72c0\u614b\u3001Child-Pugh\u5206\u7d1a\u3001\u816b\u7624\u4f4d\u7f6e\u3001\u816b\u7624\u578b\u614b\u3001\u9580\u975c\u8108\u6813\u585e\u4f4d\u7f6e\u3001\u653e\u5c04\u6cbb\u7642\u7167\u5c04\u9ad4\u7a4d\u3001\u7532\u578b\u80ce\u5152\u86cb\u767d\u3001\u4e0a\u6d88\u5316\u9053\u51fa\u8840\u75c5\u53f2\u3001B\u578b\u53caC\u578b\u809d\u708e\u6a19\u8a18\u4ee5\u53ca\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u524d\u3001\u6cbb\u7642\u4e2d\u3001\u6cbb\u7642\u5f8c\u7684\u809d\u529f\u80fd\u6307\u6578\uff0c\u5305\u62ec\u4e86\u9ea9\u8349\u918b\u9178\u6c28\u57fa\u8f49\u79fb?\uff08AST\uff09\u3001\u6c28\u57fa\u4e19\u9178\u8f49\u6c2b?\uff08ALT\uff09\u53ca\u7e3d\u9ec3\u75b8\u6307\u6578\uff08Bil-T\uff09\uff0c\u7686\u88ab\u7d00\u9304\u4e0b\u4f86\u4ee5\u4f9b\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u5171\u670924\u4f4d\uff0857%\uff09\u75c5\u60a3\u5b8c\u6210\u4e86\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\uff0c\u5176\u4ed6\u5247\u662f\u56e0\u70baECOG\u529f\u80fd\u72c0\u614b\u60e1\u5316\u505c\u6b62\u6cbb\u7642\uff0c\u5176\u4e2d\u67097\u500b\u75c5\u4eba\u5728\u6cbb\u7642\u5f8c\u5931\u53bb\u8ffd\u8e64\u3002\u5728\u8ffd\u8e64\u768417\u4f4d\u75c5\u60a3\u7576\u4e2d\u67099\u4f4d\uff0853%\uff09\u5c0d\u653e\u5c04\u6cbb\u7642\u6709\u53cd\u61c9\uff0c\u5176\u4e2d\u53c8\u67097\u4f4d\uff0841%\uff09\u75c5\u60a3\u5728\u6cbb\u7642\u5f8c\u53ef\u7e7c\u7e8c\u63a5\u53d7TAE\u6cbb\u7642\u3002\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u7684\u75c5\u60a3\u51763\u500b\u6708\u53ca6\u500b\u6708\u5b58\u6d3b\u7387\u70ba63%\u53ca34%\u3002\u800c\u672a\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u7684\u75c5\u60a3\u5247\u70ba24%\u53ca8%\u3002\u5728\u5b8c\u6210\u53ca\u672a\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u7684\u75c5\u4eba\u4e4b\u9593\uff0c\u5176\u5b58\u6d3b\u7387\u6709\u660e\u986f\u7d71\u8a08\u4e0a\u7684\u5dee\u7570\uff08p= 0.022\uff09\u3002\u75c5\u60a3\u6cbb\u7642\u524d\u3001\u4e2d\u3001\u5f8c\u7684AST\uff0cALT\u53caBil-T\u7121\u660e\u986f\u7d71\u8a08\u4e0a\u7684\u5dee\u7570\uff0c\u53ea\u67096\u4f4d\u75c5\u60a3\uff0835%\uff09\u6709\u7591\u4f3c\u80c3\u90e8\u4f75\u767c\u75c7\u4e4b\u5831\u544a\u3002Bil-T\u662f\u5728\u7d71\u8a08\u5b78\u4e0a\u552f\u4e00\u5c0d\u9810\u6e2c\u75c5\u60a3\u53ef\u5426\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u6709\u610f\u7fa9\u4e4b\u56e0\u5b50\uff08p = 0.028\uff09\u3002\n\u7d50\u8ad6\uff1a\u6b64\u7814\u7a76\u7684\u75c5\u60a3\u9078\u64c7\u8207\u9810\u5f8c\u4e0d\u4f73\uff0c\u53ea\u6709\u5c11\u65bc\u4e00\u534a\u7684\u75c5\u4eba\u53ef\u4ee5\u5b8c\u6210\u653e\u5c04\u6cbb\u7642\u8207\u5b8c\u6574\u7684\u75c5\u7a0b\u8ffd\u8e64\u3002\u56e0\u6b64\uff0c\u9032\u4e00\u6b65\u524d\u81bd\u6027\u63a7\u5236\u4e14\u9078\u64c7\u75c5\u60a3\u826f\u597d\u7684\u7814\u7a76\u662f\u5fc5\u9808\u7684\uff0c\u4f8b\u5982\u9078\u64c7\u4f4eBil-T\u4e4b\u75c5\u4eba\uff0c\u4f86\u8a55\u4f30\u6b64\u7a2e\u6cbb\u7642\u7684\u53ef\u884c\u6027\uff0c\u6cbb\u7642\u5931\u6557\u5fa9\u767c\u7684\u578b\u614b\uff0c\u4ee5\u53ca\u63a1\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u4f5c\u70ba\u809d\u764c\u5408\u4f75\u9580\u975c\u8108\u6813\u585e\u4e4b\u521d\u59cb\u7642\u6cd5\u7684\u771f\u6b63\u6548\u76ca\u3002", "e": "Background and Purpose: Hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) indicated poor prognosis and is the contraindication for transcatheter hepatic arterial embolization (TAE). Although the conventional method of external irradiation to HCC has been proven not effective, three-dimensional conformal radiation therapy (3D-CRT) may be an alternative choice. In this study, the prognostic factors and results of 3D-CRT to PVT area as the initial treatment for HCC with PVT patients who could not receive other treatments was investigated. \nMaterials and Methods : From September 1997 to August 1999, 42 patients who were initially diagnosed as HCC with PVT without any previous treatment and Eastern Cooperative Oncology Group (ECOG) performance status superior to Grade II were enrolled into the study. Radiation therapy (RT) was given via 3D-CRT technique to PVT area with 50 Gy to 61.3 Gy in daily fraction of 1.8 Gy to 2.5 Gy by individual condition. Age, sex, ECOG performance status, Child-Pugh classification, tumor location, tumor type, invaded PVT area, radiation treatment volume, alpha-fetoprotein (AFP), upper gastrointestinal (UGI) bleeding history, viral hepatitis markers for B and C, and pre-treatment liver function, on-treatment liver function, post-treatment liver function, including Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Total Bilirubin (Bil-T), were recorded for analysis. \nResults: Twenty-four patients (57%) completed the RT course and others withdrew from RT due to worsened ECOG performance status. Seven complete RT patients were lost to follow-up. Nine of 17 followed patients (53%) had positive response to RT. Seven patients (41%) underwent further TAE after RT. In the patients who could complete RT, overall survival for 3 months and 6 months were 63% and 34%. Survival rate for incomplete RT patients was 24% and 8% for 3 months and 6 months respectively. There was statistically significant difference (p = 0.022) in survival between patients who completed RT and their counterpart. There were no significant difference in pre-treatment, on-treatment and post-treatment AST, ALT and Bil-T level. Only 6 patients (35%) were reported to have suspicious gastric complications. Bil-T was the only significant factor for predicting whether RT could be completed or not (p = 0.028). \nConclusions : Less than half of the patients completed the planned RT and were adequately followed, indicating the poor prognosis and selection of patients in this study. Further prospective control studies with appropriate patient enrollment, such as low bilirubin level, is required to verify the feasibility, patterns of failure, and the possible benefit of 3D-CRT as the initial treatment of HCC with PVT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-15-24-a", "title": "Prognostic Factors and Results of Radiotherapy for Brain Stem Gliomas", "keywords": "\u8166\u5e79\u795e\u7d93\u81a0\u8cea\u7624;\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Brain stem glioma;Radiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u5206\u6790\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u8166\u5e79\u795e\u7d93\u81a0\u8cea\u7624\u7684\u75c5\u60a3\u5176\u9810\u5f8c\u56e0\u5b50\u53ca\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1986\u5e74\u81f32000\u5e74\u9593\uff0c\u5171\u670944\u4f4d\u8166\u5e79\u795e\u7d93\u81a0\u8cea\u7624\u7684\u75c5\u60a3\u70ba\u7814\u7a76\u5c0d\u8c61\u3002\u5305\u62ec27\u4f4d\u7537\u6027\u548c17\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u81ea3\u6b72\u81f374\u6b72\uff0c\u4e2d\u9593\u503c\u70ba26.5\u6b72\u3002\u5176\u4e2d19\u4f4d\u7d93\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u70ba\u795e\u7d93\u81a0\u8cea\u7624\uff0c\u63a5\u53d7\u8166\u816b\u7624\u90e8\u5206\u5207\u9664\u624b\u8853\u670913\u4f4d\u3002\u6240\u6709\u75c5\u60a3\u5747\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u6216\u5408\u4f75\u5916\u79d1\u624b\u8853\u3002\u653e\u5c04\u6cbb\u7642\u7d66\u4e88\u7e3d\u5291\u91cf\u7684\u4e2d\u9593\u503c\u572855.9 Gy\uff0c\u6bcf\u6b211.8 - 2.0 Gy\u3002\u5b58\u6d3b\u75c5\u60a3\u4e2d\u4f4d\u8ffd?\u671f\u70ba3\u5e74\u3002\n\u7d50\u679c\uff1a\u670916\uff0f44\u500b\u75c5\u60a3\u9054\u5230\u660e\u986f\u5730\u795e\u7d93\u5b78\u75c7\u72c0\u7684\u6539\u5584\u3002\u57284\uff0f44\u500b\u75c5\u60a3\u5f71\u50cf\u6aa2\u67e5\u4e2d\u986f\u793a\u816b\u7624\u9ad4\u7a4d\u6e1b\u5c11\uff0c\u572828\u500b\u75c5\u60a3\u4e2d\u816b\u7624\u9ad4\u7a4d\u7dad\u6301\u4e0d\u8b8a\uff0c\u800c\u670912\u500b\u75c5\u60a3\u5176\u816b\u7624\u9ad4\u7a4d\u7e7c\u7e8c\u8b8a\u5927\u3002\u81ea\u6cbb\u7642\u7d50\u675f\u5230\u816b\u7624\u60e1\u5316\u671f\u9593\u7684\u4e2d\u4f4d\u503c\u70ba13.2\u500b\u6708\uff0c\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba17.9\u500b\u6708\uff0c1\u5e74\u5b58\u6d3b\u7387\u70ba53%\uff0c2\u5e74\u5b58\u6d3b\u7387\u70ba37%\uff0c5\u5e74\u5b58\u6d3b\u7387\u70ba27%\u3002 Karnofsky performance score\u5927\u65bc70%\u7684\u75c5\u60a3\u5176\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba31.6\u500b\u6708\uff0c\u76f8\u8f03\u65bcKarnofsky performance score\u5c0f\u65bc70%\u7684\u75c5\u60a3\u5176\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba7.9\u500b\u6708\uff08p=0.037\uff09\u3002\u4ee5\u591a\u8b8a\u6578\u5206\u6790\u8a55\u4f30\u5176\u4ed6\u4e00\u4e9b\u53ef\u80fd\u7684\u9810\u5f8c\u56e0\u5b50\uff08\u5305\u62ec\u75c5\u60a3\u5e74\u9f61\u3001\u6027\u5225\u3001\u816b\u7624\u7684\u5206\u5316\u7a0b\u5ea6\u3001\u816b\u7624\u4f4d\u7f6e\u3001\u662f\u5426\u63a5\u53d7\u624b\u8853\u5207\u9664\u3001\u6709\u7121\u8166\u795e\u7d93\u9ebb\u75fa\u3001\u653e\u5c04\u6cbb\u7642\u7e3d\u5291\u91cf\u3001\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u3001\u75c7\u72c0\u7684\u6301\u7e8c\u6642\u9593\u3001\u6216\u5f71\u50cf\u5b78\u4e0a\u816b\u7624\u662f\u5426\u8b8a\u5927\uff09\u5747\u4e0d\u5f71\u97ff\u75c5\u60a3\u5b58\u6d3b\u7387\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u7814\u7a76\u4e2dKarnofsky performance score\u662f\u5f71\u97ff\u5b58\u6d3b\u7387\u7684\u6700\u91cd\u8981\u56e0\u5b50\u3002\u8166\u5e79\u795e\u7d93\u81a0\u8cea\u7624\u7684\u653e\u5c04\u6cbb\u7642\u7d50\u679c\u4ecd\u4e0d\u76e1\u7406\u60f3\uff0c\u9700\u7e7c\u7e8c\u5c0b\u627e\u66f4\u6709\u6548\u7684\u6cbb\u7642\u6a21\u5f0f\u3002", "e": "Purpose:To analyze the prognostic factors and treatment results in patients with brainstem gliomas following radiotherapy. \nMaterials and Methods:Between 1986 and 2000, 44 patients with brain stem gliomas were evaluated retrospectively. Included were 27 males and 17 females ranging in age from 3 to 74 years (median, 26.5 years). Out of 19 patients with histologically proven glioma, 13 had a partial tumor resection. These patients were treated with various combinations of surgery and radiotherapy. A median total tumor dose of 55.9 Gy was given in daily fractions of 1.8-2.0 Gy. The median follow up time of survivors was 3years.\nResults: Neurological improvement was achieved in 16/44 patients. Reduction of tumor size was reported in 4/44, in 28 patients the lesion was unchanged, and 12 patients progressed radiologically. Median time to progression was 13.2 months, and median overall survival time was 17.9 months with an actuarial survival of 53% at 1 year, 37% at 2 years and 27% at 5 years. For patients who had Karnofsky performance score\u226770%, their median overall survival was 31.6 months compared to 7.9 months for those who had Karnofsky performance score \uff1c 70% (p = 0.037). None of the other potential prognostic factors evaluated (including patient age, gender, tumor grade, tumor location, subtotal resection, presence or absence of cranial nerve palsies, total dose, 3D conformal radiotherapy, duration of symptoms, or radiological response) were associated with patient overall survival in multivariate analysis.\nConclusions:Karnofsky performance score is the most important prognostic factor in this study. The result of radiotherapy for brain stem glioma is still disappointed. It is necessary to continue to search for more effective treatment methods."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-25-32-a", "title": "Effect of Low Dose Irradiation on the Induction of Sister-Chromatid Exchange in V-79 Cells", "keywords": "\u4e2d\u570b\u7070\u9f20\u7e96\u7dad\u6bcd\u7d30\u80de;\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db;\u653e\u5c04\u7dda\u7167\u5c04 V-79 cells;Sister-chromatid exchange;Irradiation", "c": "\u76ee\u7684\uff1a\u4ee5\u4f4e\u5291\u91cf\u7684\u92ab-137\u52a0\u99ac\u5c04\u7dda\u7167\u5c04\u4e2d\u570b\u7070\u9f20\u7e96\u7dad\u6bcd\u7d30\u80de\uff08V-79\uff09\uff0c\u4e26\u5c31\u5176\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\uff08SCE\uff09\u3001\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u4e4b\u767e\u5206\u6bd4\u5206\u4f48\u60c5\u5f62\u3001\u6709\u7d72\u5206\u88c2\u6307\u6578\u3001\u8907\u88fd\u4fc2\u6578\u7b49\u9805\u76ee\u52a0\u4ee5\u5206\u6790\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4e2d\u570b\u7070\u9f20\u7e96\u7dad\u6bcd\u7d30\u80de\u4ee5\u4f4e\u5291\u91cf\u7684\u92ab-137\u52a0\u99ac\u5c04\u7dda\u7167\u5c04\uff0c\u5291\u91cf\u7387\u70ba\u6bcf\u5206\u94180.1 Gy\uff0c\u5be6\u9a57\u7d44\u7684\u7167\u5c04\u5291\u91cf\u5206\u5225\u70ba0.01\uff0c0.05\uff0c0.1\uff0c0.25\u53ca0.5 Gy\u4e94\u7d44\u3002\u4ee5\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u5c0d\u6bd4\u67d3\u8272\u6cd5\u9023\u7e8c\u8a08\u6578\u4e00\u767e\u500b\u7b2c\u4e8c\u5206\u88c2\u4e2d\u671f\u7d30\u80de\u7684\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u6bd4\u7387\uff0c\u9032\u4e00\u6b65\u4ee5\u7d10\u9580\u57fa\u6e2c\u8a66\u6cd5\uff08Newman-Keuls test\uff09\u4f5c\u7d44\u9593\u7684\u4ea4\u4e92\u914d\u5c0d\u6bd4\u8f03\u3002\u53e6\u5916\u4ea6\u5206\u6790\u7167\u5c04\u5f8c\u6709\u7d72\u5206\u88c2\u6307\u6578\u548c\u8907\u88fd\u4fc2\u6578\u7684\u6539\u8b8a\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a\u5be6\u9a57\u6578\u64da\u986f\u793a\uff0c\u5f9e\u63a7\u5236\u7d44\u82070.01\u30010.05 Gy\u5169\u7d44\u6bd4\u8f03\uff0c\u5176\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u6bd4\u7387\u5206\u5225\u589e\u52a0\u81f336%\u548c40%\u3002\u5291\u91cf\u5347\u9ad8\u52300.25\u30010.5 Gy\u5169\u7d44\u5247\u8f03\u63a7\u5236\u7d44\u589e\u52a0\u523050%\u548c53%\u7684\u767e\u5206\u6bd4\uff0c\u986f\u793a\u52a0\u99ac\u5c04\u7dda\u8a98\u589e\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u6bd4\u7387\u96a8\u5291\u91cf\u589e\u52a0\u6709\u8da8\u65bc\u98fd\u548c\u4e4b\u73fe\u8c61\u3002\u66f4\u9032\u4e00\u6b65\u5c07\u6bcf\u500b\u7d30\u80de\u7522\u751f\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u6578\u5340\u5206\u70ba\u56db\u7d44\u5340\u57df\uff1a\u5340\u57dfI\uff08\u22665\uff09\u3001\u5340\u57dfII\uff086-8\uff09\u3001\u5340\u57dfIII\uff089-11\uff09\u4ee5\u53ca\u5340\u57dfIV\uff08\u226712\uff09\u3002\u7d50\u679c\u986f\u793a\u7167\u5c04\u7d44\u5291\u91cf\u8655\u7406\u7684\u7d30\u80de\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u767e\u5206\u6bd4\u4e3b\u8981\u5206\u4f48\u65bc\u5340\u57dfII\u548c\u5340\u57dfIII\uff0c\u4e14\u9019\u4e8c\u5340\u57df\u5408\u8d77\u4f86\u7684\u767e\u5206\u6bd4\u70ba66-71%\u5de6\u53f3\uff0c\u7136\u800c\u63a7\u5236\u7d44\u7684\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u767e\u5206\u6bd4\u4e3b\u8981\u662f\u5206\u4f48\u65bc\u5340\u57dfI\u3002\n\u7d50\u8ad6\uff1a\u672c\u5be6\u9a57\u7d50\u679c\u660e\u767d\u6307\u51fa\u4f4e\u5291\u91cf\u98fd-137\u52a0\u99ac\u5c04\u7dda\uff0c\u80fd\u8a98\u589e\u4e2d\u570b\u7070\u9f20\u7e96\u7dad\u6bcd\u7d30\u80de\u7684\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\uff0c\u4e14\u5291\u91cf\u8d8a\u9ad8\u5247\u8d8a\u8da8\u65bc\u98fd\u548c\u72c0\u614b\u3002\u4f4e\u5291\u91cf\u52a0\u99ac\u5c04\u7dda\u7684\u7167\u5c04\u4e0d\u50c5\u63d0\u9ad8\u4e86\u59d0\u59b9\u67d3\u8272\u5206\u9ad4\u4ea4\u63db\u7387\uff0c\u540c\u6642\u4e5f\u6539\u8b8a\u4e86\u5176\u5206\u4f48\u7684\u5340\u9593\uff0c\u7167\u5c04\u5f8c\u4e3b\u8981\u96c6\u4e2d\u65bc\u4ea4\u63db\u6578\u9ad8\u4e4b\u5340\u6bb5\u3002", "e": "Purpose: Chromosomal changes, chromosome aberrations and sister-chromatid exchanges are widely used as indicators of chromosomal DNA damage. The relationship between numbers of SCE and low dose irradiation in V-79 cells was investigated. \nMaterials and Methods: The Chinese hamaster cells, V-79 cell line, were grown and irradiated by low doses of 137Cs \u03b3-ray at an exposure dose rate of 0.1 Gy/min. The sister-chromatid exchanges were stained by Sorensen's buffer containing Hoechst and Giemsa. Newman-Keuls test was employed to analyze the difference of SCEs between one group and others. The replication index and mitotic index of cells after the treatment of low dose \u03b3-ray were also analyzed. \nResults: The frequency of sister-chromatid exchange in the 0.01 Gy and 0.05 Gy groups comparing to control group were 36% and 40%, respectively. While the ratios of SCE in higher treated dose for 0.25 and 0.5 Gy were 50% and 53%, respectively. With dose increasing, ratios of SCE became saturated. In addition, the data were analyzed by dividing into four sections (\u22665, 6-8, 9-11, and\u226712) based on SCE numbers in each cell. The results demonstrated that SCE numbers in all treated groups were mainly in 6~8 and 9~11 sections, and percentages were about 66~68 %. It was only 46% for control group and 52% fall down in the section of\u22665. The section of \u226712 in control group has only 2%. \nConclusions: Low dose irradiation of 137Cs indeed induced SCE in V79 cells as low as 0.01 Gy, but not increase linearly. In this study, SCE numbers increased quickly at first division from 0 to 0.01 Gy, and the increased frequency in second part was slow down. Low dose irradiation not only increase SCE numbers, but also change the distribution of SCE numbers."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-33-41-a", "title": "Intracavity Brachytherapy for Nasopharyngeal Carcinoma With Rotterdam Nasopharyngeal Applicator", "keywords": "\u9f3b\u54bd\u764c;\u8fd1\u63a5\u6cbb\u7642;\u9e7f\u7279\u4e39\u7f6e\u5165\u5668 Nasopharyngeal carcinoma;Brachytherapy;Rotterdam applicator", "c": "\u76ee\u7684\uff1a\u85c9\u7531\u8207\u5176\u4ed6\u4e0d\u540c\u578b\u5f0f\u7684\u300c\u9ad8\u5291\u91cf\u7387\u9f3b\u54bd\u8154\u5167\u7f6e\u5165\u5668\u300d\uff08High dose rate intracavitary nasopha-ryngeal applicator\u4e4b\u6bd4\u8f03\u4ee5\u8a55\u4f30\u300c\u9e7f\u7279\u4e39\u9f3b\u54bd\u7f6e\u5165\u5668\u300d\uff08Rotterdam Nasopharyngeal Applicator\uff09\u4e4b\u512a\u9ede\u8207\u9650\u5236\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u6bd4\u8f03\u4e86\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u6797\u53e3\u5206\u9662\u70ba\u9f3b\u54bd\u764c\u300c\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\u300d\u6240\u4f7f\u7528\u7684\u4e09\u7a2e\u4e0d\u540c\u578b\u5f0f\u4e4b\u300c\u9f3b\u54bd\u8154\u5167\u7f6e\u5165\u5668\u300d\u6b64\u4e09\u7a2e\u5206\u5225\u662f\uff1a\u55ae\u7ba1\u91d1\u5c6c\u7f6e\u5165\u5668\uff08Single metal tandem\uff09\uff1b\u6c23\u7403\u7f6e\u5165\u5668\uff08Balloon applicator\uff09\u548c\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\uff08Rotterdam applicator\uff09\u3002\u6211\u5011\u4ee5\u4e00\u4f4dAJCC stage T1\u4e4b\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u5206\u5225\u7f6e\u5165\u4e09\u7a2e\u4e0d\u540c\u578b\u5f0f\u4e4b\u7f6e\u5165\u5668\uff0c\u4ee5\u7372\u5f97\u4e00\u7d44\u7528\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\u6240\u7522\u751f\u4e4b\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5f71\u50cf\uff0c\u548c\u53e6\u5169\u7a2e\u7f6e\u5165\u5668\u6240\u7522\u751f\u7684x\u5149\u7d20\u7247\u6a21\u64ec\u5f71\u50cf\u3002\u53e6\u627e\u4e94\u500b\u4e0d\u540c\u7a0b\u5ea6\u539f\u767c\u816b\u7624\u4fb5\u72af \uff08tumor extent\uff09\u7684\u75c5\u4eba\uff0c\u6b64\u4e94\u4f4d\u75c5\u4eba\u7684\u816b\u7624\u4fb5\u72af\u5206\u5225\u662fT2o\uff1a\u816b\u7624\u4fb5\u72af\u5230\u53e3\u54bd\u8154\uff08oropharynx\uff09T2n\uff1a\u816b\u7624\u4fb5\u72af\u5230\u9f3b\u8154\uff08nasal cavity\uff09T2b\uff1a\u4fb5\u72af\u5230\u54bd\u65c1\u5340\uff08parapharyngeal space\uff09T3\uff1a\u4fb5\u72af\u5230\u9871\u5e95\uff08skull base\uff09T4\uff1a\u4fb5\u72af\u5230\u9871\u5167\uff08brain\uff09\uff0c\u5c07\u6b64\u4e94\u4f4d\u75c5\u4eba\u7684\u78c1\u632f\u9020\u5f71\uff08MRI\uff09\u75c5\u7076\u756b\u5728\u5546\u696d\u7528\u7684\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u8a08\u5283\u8edf\u9ad4\u4e0a\uff0c\u4ee5\u6a21\u64ec\u8a08\u7b97\u6b64\u9e7f\u7279\u4e39\u653e\u7f6e\u5668\u5728\u516d\u7a2e\u75c5\u7076\u60c5\u5f62\u6240\u5206\u5225\u7522\u751f\u7684\u653e\u5c04\u5291\u91cf\u5206\u4f48\u3002\u6b64\u5916\uff0c\u8a72\u4f4dAJCC stage T1\u9f3b\u54bd\u764c\u75c5\u4eba\u4ee5\u55ae\u7ba1\u91d1\u5c6c\u7f6e\u5165\u5668\uff08Single metal tandem\uff09\uff1b\u6c23\u7403\u7f6e\u5165\u5668\uff08Balloon applicator\uff09\u6240\u7522\u751f\u7684\u653e\u5c04\u5291\u91cf\u5206\u5e03\u4e5f\u88ab\u62ff\u4f86\u8207\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\u6240\u7522\u751f\u7684\u8a08\u91cf\u5206\u5e03\u76f8\u6bd4\u8f03\u3002\u800c\u6b64\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\u7684\u9069\u7528\u6027\uff08feasibility\uff09\uff0c\u518d\u73fe\u6027\uff08reproducibility\uff09\uff0c\u548c\u8212\u9069\u5ea6\uff08comfort\uff09\u4e5f\u540c\u6642\u52a0\u4ee5\u8a55\u4f30\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u767c\u73fe\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\uff08Rotterdam applicator\uff09\u5177\u6709\u518d\u73fe\u6027\uff0c\u4e26\u4e14\u8f03\u4e4b\u65bc\u5176\u4ed6\u5169\u7a2e\u7f6e\u5165\u5668\uff0c\u65bc\u9f3b\u54bd\u9ecf\u819c\u6216\u9ecf\u819c\u4e0b\u816b\u7624\u5340\u57df\uff08Mucosa or submucosa tumor area\uff09\uff0c\u5177\u6709\u6700\u597d\u7684\u653e\u5c04\u5291\u91cf\u5206\u5e03\uff08radiation dose distribution\uff09\u3002\u4e14\u5176\u7d66\u4e88T1\u75c5\u7076\u5340\u57df\u8655\u65b9\u5291\u91cf\uff08prescribed dose\uff09\u6642\u4e26\u4e0d\u6703\u589e\u52a0\u592a\u591a\u7684\u904e\u591a\u5291\u91cf\uff08hot spot\uff09\u3002\u4f46\u56e0\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\u9700\u653e\u7f6e\u65bc\u75c5\u4eba\u9f3b\u54bd\u8154\u5167\u70ba\u6642\u7d04\u4e8c\u81f3\u6578\u5929\u4e4b\u4e45\uff0c\u6240\u4ee5\u9700\u7d66\u4e88\u975c\u8108\u93ae\u75db\u8f38\u6db2\u4ee5\u7de9\u548c\u5c0d\u75c5\u4eba\u6240\u9020\u6210\u7684\u7684\u4e0d\u9069\u3002\u6b64\u5916\uff0c\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\u4e4b\u6cbb\u7642\u7bc4\u570d\u5f88\u96e3\u6db5\u84cb\u592a\u5927\u4e4b\u54bd\u65c1\u5340\uff08huge parapharyngeal space\uff09\u53ca\u9871\u5167\u816b\u7624\uff0c\u5426\u5247\u5247\u9700\u4ed8\u51fa\u6975\u9ad8\u904e\u591a\u5291\u91cf\uff08hot spot\uff09\u4e4b\u4ee3\u50f9\u548c\u9aa8\u982d\u56b4\u91cd\u58de\u6b7b\u6216\u7a7f\u5b54\uff08necrosis or perforation\uff09\u7684\u98a8\u96aa\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u5efa\u8b70\u5c0f\u7684\u9f3b\u54bd\u8154\u816b\u7624\uff08small nasopharyngeal tumor\uff09\u53ef\u4ee5\u9e7f\u7279\u4e39\u7f6e\u5165\u5668\uff08Rotterdam applicator\uff09\u4f5c\u70ba\u8ffd\u52a0\u5291\u91cf\u4e4b\u7528\uff0c\u7136\u800c\u6b64\u7f6e\u5165\u5668\u5728\u5916\u5f62\u7d50\u69cb\u4e0a\u4ecd\u6709\u5f88\u5927\u7684\u4fee\u98fe\u7a7a\u9593\u4ee5\u66f4\u9032\u4e00\u6b65\u6539\u5584\u5176\u5728\u9f3b\u54bd\u5340\u57df\u4e4b\u653e\u5c04\u5291\u91cf\u5206\u5e03\u3002", "e": "Purpose: To use Rotterdam nasopharyngeal applicator to examine its results on radiation dose distribution and investigate the possible indications for the treatment of nasopharyngeal tumor. \nMaterials and Methods: We compared three types of HDR nasopharyngeal brachytherapy applicators that were used in Chang Gung Memorial Hospital-Linkou. The three types of applicators were: single metal tandem, balloon applicator and Rotterdam applicator. Three types of applicators were tested in one patient with AJCC stage T1 nasopharyngeal cancer. We further selected five patients with different tumor extension as representative to compare the radiation dose distribution. The five repre-sentative case included T2o: tumor extended to oropharynx, T2n: tumor to nasal cavity, T2b: tumor to parapharynx space, T3: tumor to skull base and T4: tumor to brain. We use MRI to define the tumor, CT scan and commercial software to calculate the radiation dose. The feasibility, reproducibility and patients' comfort were also be evaluated. \nResults: We found that Rotterdam applicator was more reproducible and best radiation dose distribution to nasopharyngeal mucosa or submucosa tumor area compared to the other 2 applicators. The Rotterdam applicator can deliver prescribed dose to the lesion area without too much hot spot in the treatment of T1-T2a NPC. However, when Rotterdam applicator was placed to the nasopharynx for few days during the treatment, patients would feel much discomfort. It therefore needed intravenous medication or fluid to relieve patients' discomfort. Besides, Rotterdam applicator also has the limitation in coverage of tumor with huge parapharyngeal space extension or to intracranial area. For the treatment of advanced NPC, it may still be at the price of very high radiation hot spot and face the risk of severe necrosis or bone perforation.\nConclusion : With the treatment of small nasopharyngeal tumor, we will suggest Rotterdam applicator to be the choice as an aid of brachytherapy boost. However, there will be a great potential to improve the shape of the Rotterdam applicator to fit better in our patients in order to be common use for the improvement of the radiation dose distribution to the nasopharyngeal area."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-43-53-a", "title": "\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0f\u5206\u6790\u92a5192\u8fd1\u63a5\u6cbb\u7642\u5c04\u6e90\u5728\u9aa8\u548c\u80ba\u7d44\u7e54\u4e2d\u7684\u5291\u91cf\u5206\u4f48", "keywords": "\u8fd1\u63a5\u6cbb\u7642;\u92a5192\u5c04\u6e90;\u4e0d\u5747\u52fb\u7d44\u7e54;\u8499\u5730\u5361\u7f85\u8a08\u7b97 Brachytherapy;Iridium-192;Heterogeneity;Monte Carlo simulation", "c": "\u76ee\u7684\uff1a\u904e\u53bb\u8a31\u591a\u5b78\u8005\u66fe\u63d0\u51fa\u95dc\u65bc192Ir\u5c04\u6e90\u5728\u6c34\u4e2d\u7684\u5291\u91cf\u5206\u4f48\uff0c\u4f46\u662f\u5c0d\u65bc\u4e00\u4e9b\u7d44\u7e54\u5bc6\u5ea6\u4e0d\u5747\u52fb\u7684\u5340\u57df\uff0c\u5982\u9aa8\u982d\u3001\u9f3b\u54bd\u8154\u3001\u652f\u6c23\u7ba1\u53ca\u80ba\u81df\u7b49\u90e8\u4f4d\u5247\u9bae\u6709\u63a2\u8a0e\u3002\u672c\u7814\u7a76\u7684\u4e3b\u8981\u76ee\u7684\u5373\u70ba\u63a2\u8a0e192Ir\u5c04\u6e90\u5728\u9aa8\u53ca\u80ba\u7d44\u7e54\u4e2d\u7684\u5291\u91cf\u5206\u4f48\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u91dd\u5c0d\u76ee\u524d\u81e8\u5e8a\u4f7f\u7528\u6700\u5ee3\u6cdb\u7684\u92a5192\u5c04\u6e90\uff0c\u4ee5\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0f\u8a08\u7b97\u5728\u6c34\u3001\u9aa8\u548c\u80ba\u7d44\u7e54\u4e2d\u7684\u5291\u91cf\u5206\u4f48\u3002\u8a08\u7b97\u7d50\u679c\u9664\u4e86\u8207\u904e\u53bb\u5176\u4ed6\u5b78\u8005\u7684\u7814\u7a76\u6bd4\u8f03\u5916\uff0cTLD\u6e2c\u91cf\u4e5f\u540c\u6642\u9032\u884c\u4ee5\u4fbf\u9a57\u8b49\u8499\u5730\u5361\u7f85\u6a21\u64ec\u7a0b\u5f0f\u7684\u6e96\u78ba\u6027\u3002\n\u7d50\u679c\uff1a\u6c34\u4e2d\u7684\u8a08\u7b97\u7d50\u679c\u8207JF Williamson\u57281995\u5e74\u7684\u7d50\u679c\u76f8\u6bd4\u8aa4\u5dee\u5c0f\u65bc1.6%\u3002\u800c\u5728\u9aa8\u7d44\u7e54\u4e2d\u5f91\u5411\u5291\u91cf\u7387\uff08radial dose rate\uff09\u5247\u96a8\u8457\u6df1\u5ea6\u964d\u4f4e\u7684\u6bd4\u6c34\u4e2d\u591a\uff0c\u5728\u534a\u5f910.1-12cm\u8ddd\u96e2\u5167\u8207\u6c34\u4e2d\u5dee\u7570\u905421%\u3002\u9aa8\u7d44\u7e54\u4e2d\u975e\u5747\u5411\u51fd\u6578\uff08anisotropy function\uff09\u5728\u8f03\u9060\u96e2\u5c04\u6e90\u8655\u53ef\u80fd\u56e0\u6563\u5c04\u7dda\u8f03\u6c34\u4e2d\u70ba\u591a\u800c\u8868\u73fe\u7684\u8f03\u63a5\u8fd1\u9ede\u5c04\u6e90\u3002\u5728\u80ba\u7d44\u7e54\u5247\u662f\u76f8\u53cd\u7684\u60c5\u6cc1\uff0c\u5f91\u5411\u5291\u91cf\u7387\u96a8\u8457\u6df1\u5ea6\u964d\u4f4e\u60c5\u6cc1\u660e\u986f\u5730\u6bd4\u6c34\u4e2d\u5c11\u3002\u975e\u5747\u5411\u51fd\u6578\u5728\u534a\u5f91\u8f03\u8fd1\u8655\u8207\u6c34\u4e2d\u6c92\u6709\u660e\u986f\u5dee\u7570\uff0c\u5728\u534a\u5f91\u8f03\u9060\u8655\u5247\u8207\u6c34\u4e2d\u6709\u660e\u986f\u5dee\u7570\u3002TLD\u6e2c\u91cf\u7d50\u679c\u5728\u63a5\u8fd1\u5c04\u6e901-cm\u5167\u6642\u6709\u8f03\u5927\u8aa4\u5dee\uff0c\u800c\u534a\u5f913-cm\u4ee5\u4e0a\u7684\u7d50\u679c\u5247\u76f8\u7576\u7b26\u5408EGS4\u6a21\u64ec\u7a0b\u5f0f\u7684\u8a08\u7b97\u7d50\u679c\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u4ee5EGS4\u6a21\u64ec\u7a0b\u5f0f\u6240\u8a08\u7b97\u51fa\u7684\u6c34\u4e2d\u7684\u5291\u91cf\u53c3\u6578\u8207\u904e\u53bb\u7814\u7a76\u4e4b\u5dee\u7570\u5c0f\u65bc2%\uff0c\u9aa8\u8207\u80ba\u7d44\u7e54\u4e2d\u7684\u8a08\u7b97\u503c\u8207TLD\u7684\u9a57\u8b49\u7d50\u679c\u4e5f\u76f8\u7576\u7b26\u5408\u3002\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0c\u92a5192\u5c04\u6e90\u5728\u8fd1\u63a5\u6cbb\u7642\u7684\u5291\u91cf\u8a55\u4f30\u4e0a\u4ecd\u6709\u6539\u5584\u7a7a\u9593\u3002\u672c\u7814\u7a76\u6240\u6a21\u64ec\u7684\u72c0\u6cc1\u8207\u5be6\u969b\u81e8\u5e8a\u8fd1\u63a5\u6cbb\u7642\u4ecd\u6709\u4e00\u6bb5\u5dee\u8ddd\uff0c\u4f46\u4e0d\u5931\u70ba\u5c0d\u92a5192\u5c04\u6e90\u7279\u6027\u9032\u4e00\u6b65\u4e86\u89e3\u7684\u53c3\u8003\u3002", "e": "Purpose: Many authors have discussed radiation dose distributions of an192Ir source in Water. The purpose of our study is to analyze dose distribution of 192Ir in heterogeneity, such as bone and lung tissue, using Monte Carlo calculation and TLD measurements. \nMaterial and Methods : An EGS4 Monte Carlo simulation program, incorporating with detailed source construction, has been used to investigate the dose distribution in water, bone and lung phantoms. TLD measurements were also performed to verify the calculating accuracy. The small size (1mm x 1mm x 1mm cube) TLD-100H LiF dosimeter is chosen to minimize the influence of dose gradient in measurement. The compositions of bone and lung phantoms are referred to ICRU report 44. \nResults: The radial dose function and anisotropy function in water agree with published data in less than 1%. The radial dose function in bone decreases with depth much more than those in water and the difference can be up to 21%. In contrast, the dose distribution in lung shows less attenuation and scatter than in water and the difference can be up to 16%. The TLD measurements and Monte Carlo results agree within statistical uncertainty (approximately +/- 5%) when the radial distance is larger than 1 cm. At 0.5-cm radial distance, the extreme high dose gradient causes the measurement uncertainty to become too large to estimate the consistency. \nConclusions: Most of previous studies focused on the dosimetry around an Iridium-192 in water. Through this study, we obtain a better understanding of the dose distributions in heterogeneities, bone and lung tissue."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-55-59-a", "title": "Choroid Plexus Carcinoma of the Lateral Ventricle: Case Report and Review", "keywords": "\u8108\u7d61\u53e2\u60e1\u6027\u816b\u7624;\u5074\u8166\u5ba4\u8108;\u653e\u5c04\u7dda\u6cbb\u7642 Choroid plexus carcinoma;Lateral ventricle;Radiation therapy", "c": "\u539f\u767c\u8166\u5ba4\u8108\u7d61\u53e2\u60e1\u6027\u816b\u7624\u662f\u4e00\u7a2e\u76f8\u7576\u7f55\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u5e38\u767c\u751f\u65bc\u5c0f\u5b69\u3002\u5c0f\u5b69\u7684\u539f\u767c\u8108\u7d61\u53e2\u764c\u5e38\u767c\u751f\u65bc\u5074\u8166\u5ba4\uff0c\u6210\u4eba\u7684\u5247\u767c\u751f\u5728\u7b2c\u56db\u8166\u5ba4\u3002\u6211\u5011\u63d0\u51fa\u7684\u75c5\u4f8b\u70ba53\u6b72\u7684\u7537\u6027\u75c5\u60a3\uff0c\u8a3a\u65b7\u70ba\u5074\u8166\u5ba4\u7684\u539f\u767c\u8108\u7d61\u53e2\u764c\uff0c\u5408\u4f75\u8166\u810a\u9ad3\u6db2\u7684\u8f49\u79fb\uff1b\u7d93\u624b\u8853\u5207\u9664\u5f8c\uff0c\u518d\u8ffd\u52a0\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff1b\u6cbb\u7642\u7684\u7bc4\u570d\u5305\u62ec\u5168\u8166\u53ca\u810a\u9ad3\u3002\u672c\u6587\u7684\u4e3b\u65e8\u5728\u63a2\u8a0e\u6b64\u75c5\u7684\u53ef\u80fd\u6cbb\u7642\u65b9\u5f0f\u53ca\u5176\u9650\u5236\u3002", "e": "Primary carcinoma of choroid plexus are rare and found most frequently in children than in adults. In children, the choroid plexus carcinoma are located predominantly in the lateral ventricles, while adults in the fourth ventricle. This report is about a 53 year old male with primary carcinoma located in the lateral ventricle with CSF metastases, which was treated with total tumor excision of choroids plexus followed by post-operative cranial spinal irradiation. This paper aims at the possibilities and limitations of the treatment of primary carcinoma of choroids plexus."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200103-8-1-61-65-a", "title": "Rare Brain Metastasis From Papillary Thyroid Carcinoma at the Cerebellopotine Angle: a Case Report and Review of the Literature", "keywords": "\u7532\u72c0\u817a\u816b\u7624;\u60e1\u6027\u4e73\u7a81\u7624;\u8166\u90e8\u8f49\u79fb;\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u5b9a\u4f4d\u9806\u5f62\u653e\u5c04\u6cbb\u7642 Thyroid cancer;Papillary carcinoma;Intracranial metastasis;3D-conformal radiotherapy", "c": "\u7532\u72c0\u817a\u60e1\u6027\u4e73\u7a81\u7624\u662f\u7532\u72c0\u817a\u60e1\u6027\u816b\u7624\u4e2d\u6700\u5e38\u898b\u7684\u4e00\u7a2e\u75c5\u7406\u578b\u614b\uff0c\u901a\u5e38\u816b\u7624\u751f\u9577\u901f\u5ea6\u548c\u81e8\u5e8a\u9032\u7a0b\u7de9\u6162\u3002\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\u4e26\u4e0d\u5e38\u898b\u3002\u5982\u679c\u75c5\u7406\u5206\u671f\u986f\u793a\u6709\u5c40\u90e8\u6dcb\u5df4\u8f49\u79fb\uff0c\u5176\u5c40\u90e8\u5fa9\u767c\u7387\u8f03\u9ad8\u3002\u5176\u9810\u5f8c\u548c\u5e74\u9f61\u3001\u816b\u7624\u5927\u5c0f\u3001\u6027\u5225\u3001\u624b\u8853\u5207\u9664\u7bc4\u570d\uff0c\u6709\u7121\u7532\u72c0\u817a\u5916\u4fb5\u72af\u3001\u6709\u7121\u591a\u75c5\u7076\u4ee5\u53ca\u6709\u7121\u9060\u8655\u8f49\u79fb\u7b49\u56e0\u5ea6\u6709\u95dc\u3002\u5408\u4f75\u9060\u8655\u8f49\u79fb\u4e0d\u5e38\u898b\uff0c\u5c24\u5176\u8166\u90e8\u8f49\u79fb\u76f8\u7576\u5c11\u898b\u3002\u6839\u64da\u91ab\u5b78\u6587\u737b\u8cc7\u6599\uff0c\u8166\u90e8\u8f49\u79fb\u7d04\u4f540.1-5%\u5de6\u53f3\u3002\u5728\u8166\u90e8\u8f49\u79fb\u7684\u75c5\u4f8b\u4e2d\uff0c\u8f49\u79fb\u75c5\u7076\u6700\u5e38\u898b\u65bc\u5169\u5074\u5927\u8166\u534a\u7403\u3002\u5728\u6b64\uff0c\u6211\u5011\u5831\u544a\u4e00\u7532\u72c0\u817a\u60e1\u6027\u4e73\u7a81\u7624\u5408\u4f75\u5de6\u5074\u5c0f\u8166\u6a4b\u8166\u4ea4\u754c\u8655\u8f49\u79fb\u7684\u7f55\u898b\u75c5\u4f8b\uff0c\u6210\u529f\u7684\u4ee5\u5408\u4f75\u624b\u8853\u5207\u9664\u816b\u7624\u3001\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4ee5\u53ca\u653e\u5c04\u6027\u7898\u6cbb\u7642\u7684\u6574\u5408\u6027\u7642\u6cd5\u6cbb\u7642\uff0c\u4e26\u4e14\u5206\u4eab\u6211\u5011\u6cbb\u7642\u9019\u75c5\u4f8b\u7684\u7d93\u9a57\u3002", "e": "Papillary thyroid carcinoma (PTC), representing the most common type of the thyroid cancer, is usually slow-growing and runs an indolent clinical course. Metastasis to regional lymph nodes is a common finding. Patients with initial N1 stage or higher have higher local recurrence rate. The prognosis had been related to the age at initial diagnosis, tumor size, sex, extent of surgical resection, presence of extrathyroid invasion, multi centricity and presence of distant metastasis [4]. Distant metastasis is uncommon, especially intracranial metastasis that is rare with a frequency of 0.1-5% in reported series Cerebral hemispheres are the most common site of intracranial metastasis in reported series. We report a case of papillary carcinoma of the thyroid with metastasis to a very unusual location of left cerebellopotine angle and present our experience of successful management for this case with combined modalities including surgery, post-operative adjuvant radiotherapy and radioiodine therapy. Literature reviews of this unusual clinical presentation are also discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-221-231-a", "title": "Outcome Of Radiotherapy For Primary Operable Invasive Breast Cancer AT A Medical Center", "keywords": "\u653e\u5c04\u6cbb\u7642;\u4e73\u764c;\u81e8\u5e8a\u6cbb\u7642\u6210\u679c Radiotherapy;Breast neoplasms;Clinical Outcome", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u539f\u767c\u4e73\u764c\u75c5\u4eba\u5728\u4e00\u91ab\u5b78\u4e2d\u5fc3\u516c\u51431998\u5e74\u52302000\u5e74\u63a5\u53d7\u5b8c\u6574\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u5f8c\u7684\u81e8\u5e8a\u6cbb\u7642\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1988\u5e74\u52302000\u5e74\u9593\uff0c\u5728\u4f5c\u8005\u670d\u52d9\u4e4b\u91ab\u5b78\u4e2d\u5fc3\u7684\u653e\u5c04\u816b\u7624\u90e8\u5171\u9023\u7e8c\u6709341\u4f4d\u53ef\u624b\u8853\u4e4b\u4fb5\u8972\u6027\u4e73\u764c\u7684\u75c5\u4eba\u63a5\u53d7\u5b8c\u6574\u7642\u7a0b\u4e4b\u653e\u5c04\u6cbb\u7642\u3002\u5c0d\u90a3\u4e9b\u63a5\u53d7\u4e73\u623f\u5207\u9664\u8853\u7684\u75c5\u4eba\uff0c\u653e\u5c04\u6cbb\u7642\u4e3b\u8981\u7167\u5c04\u5176\u524d\u80f8\u58c1\u53ca\u5176\u9644\u8fd1\u4e4b\u6dcb\u5df4\u7d50\uff1b\u5176\u7167\u5c04\u5291\u91cf\u7684\u4e2d\u6578\u70ba50 Gy\u5171\u8a0825\u4e4b\u7167\u5c04\uff1b\u5c0d\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u7684\u75c5\u7684\u4eba\uff0c\u653e\u5c04\u6cbb\u7642\u5247\u53e6\u5916\u8ffd\u52a015\u523020Gy \u7684\u5291\u91cf\u4f7f\u5176\u7e3d\u5291\u91cf\u9054\u5230 65 - 70 Gy \u3002\u672c\u7814\u7a76\u7531\u56de\u9867\u75c5\u6b77\u53d6\u5f97\u6bcf\u4f4d\u75c5\u4eba\u7684\u76f8\u95dc\u8cc7\u6599\uff0c\u4e26\u6bd4\u8f03\u81e8\u5e8a\u7684\u6cbb\u7642\u6210\u679c\u3002\n\u7d50\u679c\uff1a\u9019341\u4f4d\u75c5\u4eba\u7684\u8ffd\u8e64\u671f\u9593\u81ea7\u500b\u6708\u81f313.1\u5e74\u4e0d\u7b49\uff0c\u5176\u4e2d\u6578\u70ba\u8ffd\u8e642.6\u5e74\u3002\u5176\u4e2d142\u4f4d\u75c5\u4eba\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\uff0c199\u4f4d\u75c5\u4eba\u63a5\u53d7\u4e73\u623f\u5207\u9664\u8853\uff1b\u6709264\u4f4d\u75c5\u4eba(77%) \u63a5\u53d7\u8f14\u52a9\u6027\u7684\u5316\u5b78\u6cbb\u7642\u3002\u5176\u4e94\u5e74\u7684\u75be\u75c5\u5c40\u90e8\u63a7\u5236\u7387\u70ba90.5%\uff0c\u5176\u4e94\u5e74\u7684\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u70ba71.8%\uff0c\u5176\u4e94\u5e74\u7684\u5168\u90e8\u5b58\u6d3b\u7387\u70ba81.4%\u3002\u4ee5\u75be\u75c5\u7684\u5206\u671f\u4f86\u770b\uff0c\u5176\u4e94\u5e74\u7684\u7121\u75be\u75c5\u5b58\u6d3b\u7387\u548c\u75be\u75c5\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba\uff1a\u7b2c\u4e00\u671f95.5%\u548c100%\uff0c\u7b2c\u4e8cA\u671f93.2%\u548c98%\uff0c\u7b2c\u4e8cB\u671f62.4%\u548c92.1%\uff0c\u7b2c\u4e09A\u671f58.8%\u548c80.5%\uff0c\u7b2c\u4e09B\u671f43.7%\u548c75.4%\u3002\u5168\u90e8\u5171\u670924\u4f4d\u75c5\u4eba(7.1%)\u57285\u500b\u6708\u52305.5\u5e74\u5f8c\u767c\u751f\u5c40\u90e8\u5fa9\u767c(\u4e2d\u6578\u70ba1.6\u5e74)\uff0c\u4f46\u5c0d142\u4f4d\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u81f3\u4eca\u53ea\u6709\u4f4d\u6709\u5c40\u90e8\u5fa9\u767c(\u4e2d\u6578\u70ba2.1\u5e74)\u3002\n\u7d50\u8ad6\uff1a\u4e73\u764c\u7684\u653e\u5c04\u6cbb\u7642\u70ba\u4e00\u975e\u5e38\u6709\u6548\u7684\u5c40\u90e8\u63a7\u5236\u75be\u75c5\u7684\u6cbb\u7642\u65b9\u6cd5\uff0c\u6211\u5011\u7684\u6cbb\u7642\u6210\u679c\u548c\u5176\u4ed6\u91ab\u5b78\u4e2d\u5fc3\u4e0d\u76f8\u4e0a\u4e0b\uff0c\u5c0d\u63a5\u53d7\u4e73\u623f\u4fdd\u7559\u624b\u8853\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u4f86\u8aaa\uff0c\u6211\u5011\u76ee\u524d\u6709\u5f88\u4f4e\u7684\u5c40\u90e8\u5fa9\u767c\u7387\u3002", "e": "Purpose: To evaluate the treatment outcome of patients with primary operable invasive breast cancer who received radiotherapy at a medical center from 1998 to 2000.\nMaterials and Methods: We recruited 341 consecutive patients of primary operable invasive breast cancer who received radiotherapy in the department of radiation oncology of the authors\u2019 medical center from 1998 to 2000. A median dose of 50 Gy in 25 fractions was delivered to the chest wall and/or regional lymph nodes of patients who had received mastectomy. For those who had received breast-conserving surgery, another tumor boost dose of 15 to 20 Gy (total dose: 65 to 70 Gy) was given. Information on each patient was collected by reviewing the medical records, and clinical outcome was compared.\nResults: The median follow-up time for the 341 patients was 2.6 years (range, 7 months to 13.1 years). Among them, 142 received breast-conserving surgery and 199 received mastectomy. Systemic chemotherapy was used on 264 patients (77%) as a neoadjuvant of adjuvant treatment. The local-control rate at 5 years was 81.4%. The disease-free survival and local control at 5 years by stage were 95.5% and 100% for stage I, 93.2% and 98% for stage IIA, 62.4% and 92.1% for stage IIB, 58.8% and 80.5% for stage IIIA, and 43.7% and 75.4% for stage IIIB, respectively. A total of 24 patients (7.1%) had locoregional recurrence, which occurred at 5 months to 5.5 years (median, 1.6 years). But for the 142 BCS patients, only one of them developed local recurrence till now (median, 2.1 years).\nConclusion: Radiotherapy is a very effective adjuvant treatment on local control in breast cancer patients. Survival and local recurrence rates were comparable to other series. Our results also showed a very low rate of recurrence for patients receiving breast-conserving surgery followed by radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-233-242-a", "title": "Clinical Studies OF 283 Patients With Undifferentiated Carcinoma OF THE Nasopharynx (UCN) Treated BY Radiotherapy", "keywords": "\u672a\u5206\u5316\u9f3b\u54bd\u764c\u7d30\u80de\u578b\u614b;\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642 Undifferentiated carcinoma of the nasopharynx;Nasopharyngeal carcinoma;Radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u6a19\uff0c\u662f\u5c0d\u65bc\u672a\u5206\u5316\u9f3b\u54bd\u764c\u7d30\u80de\u578b\u614b(UCN)\u4e4b\u75c5\u60a3\u5011\u5728\u7d93\u904e\u653e\u5c04\u6cbb\u7642\u7684\u7d50\u679c\u505a\u4e00\u63a2\u8a0e\uff0c\u5176\u76ee\u7684\u662f\u5728\u85c9\u7531\u5c40\u90e8\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u65b9\u9762\uff0c\u5c0d\u65bc\u4e0d\u540c\u4e4b\u75c5\u4eba\u76f8\u95dc\u56e0\u5b50\u548c\u6cbb\u7642\u76f8\u95dc\u53c3\u6578\u3001\u4f86\u8a55\u4f30\u5176\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1984\u5e74\u52301997\u5e74\u9593\uff0c\u6709283\u4f4d\u5728\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\uff0c\u63a5\u53d7\u904e\u6cbb\u7642\u4e4bUCN\u75c5\u60a3\u7684\u8ffd\u8e64\u3002\u6240\u6709\u9f3b\u54bd\u764c\u4e4b\u75c5\u4f8b\u5747\u4f9d\u7167WHO\u4e4b\u6a19\u6e96\u4f86\u5206\u985e\uff0c\u540c\u6642\u4f9d\u7167\u7b2c\u56db\u7248AJCC (the 4the American Joint Committee on Cancer, 1992)\u5206\u671f\u7cfb\u7d71\uff0c\u91cd\u65b0\u5206\u671f\u3002\u5c0d\u65bc\u539f\u767c\u816b\u7624\u7d66\u4e887020 cGy \u7684\u653e\u5c04\u6cbb\u7642\uff0c\u4e26\u4f9d\u816b\u7624\u53cd\u61c9\u800c\u5b9a\uff0c\u7d66\u4e88\u984d\u5916\u4e4b\u8ffd\u52a0\u5291\u91cf\u3002\u5c40\u90e8\u6dcb\u5df4\u817a\u63a5\u53d7 5040 cGy \u5230 7020 cGy \u4e4b\u653e\u5c04\u7dda\u5291\u91cf\uff0c\u4f9d\u5176\u6dcb\u5df4\u7d50\u5927\u5c0f\u800c\u5b9a\u3002\u653e\u5c04\u6cbb\u7642\u4e3b\u8981\u662f\u4f7f\u7528\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u62166 MV x-ray \u897f\u9580\u5b50\u52a0\u901f\u5668\uff0c\u6240\u6709\u75c5\u60a3\u5747\u63a5\u53d7\u5b9a\u671f\u8ffd\u8e64\uff0c\u76f4\u81f3\u6b7b\u4ea1\u70ba\u6b62\u3002\u4f7f\u7528Kaplan-Meier \u4e4b\u65b9\u6cd5\u4f86\u6c7a\u5b9a\u5176\u751f\u5b58\u671f\uff0c\u8207\u4f7f\u7528Logrank test \u53caCox \u56de\u6b78\u503c\u4e4b\u65b9\u6cd5\u4f86\u6bd4\u8f03\u548c\u6c7a\u5b9a\u5176\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u4e2d\u5171\u6709\u4e94\u5341\u4f4d\u75c5\u60a3\u7531\u65bc\u672a\u5b8c\u6210\u6cbb\u7642\uff0c\u56e0\u6b64\u7531283\u7684\u75c5\u60a3\u4e2d\u79fb\u9664\u3002\u9019\u4e9b\u75c5\u60a3\u6240\u63a5\u53d7\u4e4b\u5747\u503c\u5291\u91cf\u70ba2709 cGy (\u7bc4\u570d\uff1a 300 cGy - 4750 cGY )\uff0c\u8d85\u904e\u4e94\u5e74\u5b58\u6d3b\u671f\u50c5\u670916.1%\uff0c\u5176\u751f\u5b58\u4e2d\u503c\u70ba\u5341\u56db\u500b\u6708\u3002\u5176\u6b7b\u4ea1\u7387\u70ba74% (37/50)\uff0c\u75c5\u60a3\u4e3b\u8981\u90fd\u6b7b\u65bc\u9060\u7aef\u8f49\u79fb\u3002\u5728\u6211\u5011\u6240\u5206\u6790\u7684233\u75c5\u60a3\u7576\u4e2d\uff0c\u5176\u7537\u5973\u6bd4\u70ba2.4\uff1a1\uff1b\u670928\u4f8b\u75c5\u60a3\u7522\u751f\u5c40\u90e8\u5fa9\u767c\uff0c\u5176\u5c40\u90e8\u63a7\u5236\u7387\u70ba87.9%\uff0cCox \u56de\u6b78\u503c\u5206\u6790\u5f97\u51fa\u6dcb\u5df4\u5206\u671f\u70ba\u6709\u610f\u7fa9\u7684\u5c40\u90e8\u63a7\u5236\u9810\u5f8c\u56e0\u5b50\u3002\u6709\u516d\u5341\u4f4d\uff0826%\uff09\u75c5\u60a3\u7522\u751f\u9060\u7aef\u9aa8\u982d\u3001\u809d\u81df\u53ca\u80ba\u81df\u8f49\u79fb\uff0c\u6b64\u4e09\u8655\u70ba\u6700\u6613\u8f49\u79fb\u90e8\u4f4d\u3002\u672c\u7814\u7a76\u5206\u6790\u5f97\u51fa\u6dcb\u5df4\u5206\u671f\uff0cWHO\u5206\u985e\u4ee5\u53ca\u81e8\u5e8a\u5206\u671f\u70ba\u6709\u610f\u7fa9\u7684\u9060\u7aef\u8f49\u79fb\u9810\u5f8c\u56e0\u5b50\u3002\u4e94\u5e74\u5b58\u6d3b\u671f\u5c0d\u65bc\u7b2c\u4e00\u53ca\u4e8c\u3001\u4e09\u3001\u56db\u671f\u75c5\u60a3\uff0c\u5206\u5225\u70ba80%\uff0c65.7% and 49.7%\u3002\u672c\u7814\u7a76\u5206\u6790\u986f\u793a\u6dcb\u5df4\u5206\u671f\uff0c\u8f49\u79fb\u5206\u671f\u4ee5\u53caWHO\u5206\u985e\u671f\u70ba\u6709\u610f\u7fa9\u7684\u75c5\u60a3\u5b58\u6d3b\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u672a\u5206\u5316\u9f3b\u54bd\u764c\u7d30\u80de\u578b\u614b(UCN)\u4e4b\u75c5\u60a3\uff0c\u4ecd\u662f\u6700\u7d42\u7684\u9078\u64c7\u3002\u96d6\u7136\u5982\u6b64\uff0c\u7531\u65bc\u6709\u5f88\u9ad8\u7684\u9060\u7aef\u8f49\u79fb\u6a5f\u7387\uff0c\u56e0\u6b64\u9664\u4e86\u653e\u5c04\u6cbb\u7642\u5916\u4ecd\u9808\u85c9\u52a9\u5316\u5b78\u85e5\u7269\u6cbb\u7642\uff0c\u61c9\u662f\u65e5\u5f8c\u81e8\u5e8a\u8a66\u9a57\u7684\u7814\u7a76\u65b9\u5411\u3002", "e": "Purpose: Our objective in this study is to review the results of radiotherapy for patients of undifferentiated carcinoma of nasopharynx (UCN), in terms of local control and overall survival. We also evaluated different prognostic factors for patient survival.\nMaterials and Methods: A retrospective review was done on 283 patients with UNC patients treated at the department of radiation oncology, Changhua Christian Hospital from 1984 to 1997. All cases were classified histologically according to the WHO criteria for nasopharyngeal tumor, and were then re-staged according to the 4th American joint Committee on Cancer (AJCC, 1992) staging system. Radiotherapy (RT) consisted of 70.2 Gy to the primary tumor with optional boost dose depending on tumor response. Regional lymphatics were irradiated with a dose ranging from 50.4Gy to 70.2 Gy, based on the size of the involved lymph nodes. A cobalt-60 or 6 MV X-ray linear accelerator (Seimens Mevatron) was used for radiotherapy. All patients were then followed-up regularly until death. The Kaplan-Meier method was used to determine actuarial survival. Logrank test and Cox regression analysis were used for comparison and determination of prognostic factors.\nResults: Among the 283 patients, a total of 50 patients were excluded from our study due to incomplete treatment. The mean dose received by these patients were 27.09 Gy (range: 3 Gy \u2013 47.5 Gy). Their overall 5-year actuarial survival was only 16.1 %, with a median survival of 14 months. Thirty-seven of 50 patients died. The mortality rate was 74% (37/50), with most of them dying from systemic disease. The remaining 233 patients were analyzed. The male to female ratio was 2.4:1. Three were 28 patients with local recurrence, reflecting a local control rate of 87.9%. Cox regression analysis revealed that N stage was the only significant factor for local control. Sixty (26%) patients developed distant metastasis, mainly to the bone, the lung, and the liver. Analysis revealed that N stage, WHO type and stage were significant factors affecting distant metastasis. The 5-year survival for stage I / II , III, and IV patients were 80% , 65.7% and 49.7%, respectively .Our analysis revealed that N stage were significant prognostic factors for overall survival.\nConclusion: Radiotherapy remains the treatment of choice for undifferentiated carcinoma of the nasopharyns (UCN). However, due to a high rate of distant metastasis, chemotherapy in addition to radiotherapy should be the direction for future clinical trial."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-243-251-a", "title": "Prophylactic Para-Aortic Radiotherapy AND Concomitant Chemotherapy FOR Patients With Cervical Carcinoma:Preliminary Analysis OF Outcome AND Toxicity", "keywords": "\u5b50\u5bae\u9838\u764c;\u9810\u9632\u6027\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u5340\u653e\u5c04\u6cbb\u7642;\u540c\u6b65\u5316\u5b78\u6cbb\u7642;\u6cbb\u7642\u6bd2\u6027 Cervical carcinoma;Prophylactic para-aortic irradiation;Concurrent chemotherapy;Toxicity", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u76ee\u7684\u5728\u5206\u6790\u7b2c\u4e8c\u671fB\u8207\u7b2c\u4e09\u671fB\u5b50\u5bae\u9838\u764c\u75c5\u4eba\u63a5\u53d7\u5168\u653e\u5c04\u6cbb\u7642\u4e2d\uff0c\u52a0\u5165\u9810\u9632\u6027\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u5340\u7167\u5c04\u8207\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7684\u521d\u671f\u5b58\u6d3b\u6210\u679c\u8207\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u5206\u6790\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a1998\u5e746\u6708\u81f32001\u5e746\u6708\u9593\uff0c20\u4f4d\u7b2c\u4e8c\u671fB\u6216\u7b2c\u4e09\u671fB\u5b50\u5bae\u9838\u764c\u4e14\u7121\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u817a\u8f49\u79fb\u7684\u75c5\u4eba\uff0c\u88ab\u7d0d\u5165\u672c\u7814\u7a76\u5206\u6790\u4e2d\u3002\u6cbb\u7642\u7d44\u5408\u5305\u62ec\u5168\u7a0b\u9aa8\u76c6\u8154\u653e\u5c04\u6cbb\u7642\uff0c\u9810\u9632\u6027\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u5340\u653e\u5c04\u6cbb\u7642\uff0c\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u4e2d\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u8207\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u7d50\u675f\u5f8c\u7684\u5316\u5b78\u6cbb\u7642\u3002\u653e\u5c04\u6cbb\u7642\u8a2d\u8a08\u670945 Gy/25\u6b21\u7684\u4e3b\u52d5\u6d3e\u65c1\u6dcb\u5df4\u5340\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c50.4Gy/28\u6b21\u7684\u9aa8\u76c6\u8154\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c9 Gy/5\u6b21\u7684\u5b50\u5bae\u9838\u65c1\u8edf\u7d44\u7e54\u7684\u52a0\u5f37\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u4ee5\u53caPoint A 4-5\u6b21\u5171\u8a0822-30 Gy\u7684\u9ad4\u8154\u5167\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u3002\u5316\u5b78\u6cbb\u7642\u5305\u62ec\u653e\u5c04\u7642\u7a0b\u4e2d\u7b2c1\u53ca29\u5929\u5171\u5169\u6b21\u7684cisplatinum 60-80 mg/m2 \uff0c\u4ee5\u53ca\u653e\u5c04\u7642\u7a0b\u5f8c1\u53ca2\u500b\u6708\u7684cisplatinum 60-80 mg/m2\u548c\u9023\u7e8c\u6ce8\u5c04 5 \u65e5\u7684 5-fluorouracil 600- 800 mg/m2 \uff0c\u75c5\u4eba\u6cbb\u7642\u7d50\u675f\u5f8c\u5b9a\u671f\u8fd4\u56de\u9580\u8a3a\u8ffd\u8e64\u6aa2\u67e5\u3002\u5b58\u6d3b\u6210\u679c\u5206\u6790\u4ee5Kaplan-Meier \u65b9\u6cd5\u5206\u6790\uff0c\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u4ee5RTOG\u6a19\u6e96\u8a55\u5b9a\uff0c\u4e2d\u4f4d\u6578\u8ffd\u8e64\u6642\u9593\u70ba15\u500b\u6708\u3002\n\u7d50\u679c\uff1a\u6240\u6709\u75c5\u4eba\u7686\u5b8c\u6210\u539f\u5b9a\u7684\u653e\u6cbb\u7642\u53ca\u653e\u5c04\u7642\u7a0b\u4e2d\u7684\u5169\u6b21\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c16\u4f4d\u75c5\u4eba\uff0880%\uff09\u53e6\u5b8c\u6210\u4e86\u653e\u5c04\u7642\u7a0b\u5f8c\u7684\u5169\u6b21\u5316\u5b78\u6cbb\u7642\uff0c\u5176\u4e2d4\u4f4d\u75c5\u4eba\u5728\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u4e0a\u6709\u6240\u8abf\u6574\u30021\u4f4d\u75c5\u4eba\u8ffd\u8e64\u6642\u51fa\u73fe\u5c40\u90e8\u5fa9\u767c\uff0c2\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba83%\uff0c\u53e6\u4e00\u4f4d\u75c5\u4eba\u51fa\u73fe\u80ba\u90e8\u8f49\u79fb\uff0c\u6c92\u6709\u75c5\u4eba\u51fa\u73fe\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u5fa9\u767c\uff0c\u6240\u6709\u75c5\u4eba\u5747\u4ecd\u5b58\u6d3b\uff0c2\u5e74\u5b58\u6d3b\u7387\u70ba100%\u3002\u6240\u6709\u75c5\u4eba\u7686\u6c92\u6709\u7b2c\u56db\u5ea6\u7684\u6025\u6027\u526f\u4f5c\u7528\uff0c\u5927\u591a\u6578\u7684\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u70ba\u8178\u80c3\u9053\u53ca\u8840\u6db2\u7cfb\u7d71\u7684\u53cd\u61c9\uff0c\u56db\u4f4d\u75c5\u4eba\uff0820%\uff09\u51fa\u73fe\u7b2c3\u5ea6\u8178\u80c3\u9053\u526f\u4f5c\u7528\uff0c\u4e94\u4f4d\u75c5\u4eba\uff0825%\uff09\u51fa\u73fe\u7b2c3\u5ea6\u8840\u6db2\u7cfb\u7d71\u526f\u4f5c\u7528\uff0c\u50c5\u67092\u4f4d\u75c5\u4eba\u51fa\u73fe\u8d85\u904e2\u5ea6\u4ee5\u4e0a\u7684\u9577\u671f\u4f75\u767c\u75c7\u3002\u6c92\u6709\u75c5\u4eba\u56e0\u70ba\u6cbb\u7642\u526f\u4f5c\u7528\u800c\u9020\u6210\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u5ef6\u8aa4\u6216\u4e2d\u65b7\u3002\n\u7d50\u8ad6\uff1a\u5168\u7a0b\u653e\u5c04\u6cbb\u7642\u4e2d\u52a0\u5165\u9810\u9632\u6027\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u5340\u653e\u5c04\u6cbb\u7642\u53ca\u5408\u4f75\u5316\u5b78\u6cbb\u7642\uff0c\u5c0d\u7b2c\u4e8c\u671fB\u53ca\u7b2c\u4e09\u671fB\u7684\u5b50\u5bae\u9838\u764c\u75c5\u4eba\u662f\u5b89\u5168\u4e14\u53ef\u5fcd\u53d7\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u521d\u671f\u5b58\u6d3b\u6210\u679c\u662f\u8db3\u4ee5\u63a5\u53d7\u7684\uff0c\u672c\u7814\u7a76\u9700\u8981\u66f4\u9577\u6642\u9593\u7684\u8ffd\u8e64\uff0c\u4ee5\u78ba\u8a8d\u9019\u7a2e\u5f37\u5ea6\u7684\u7d44\u5408\u6cbb\u7642\u65b9\u5f0f\u7684\u63a7\u5236\u6210\u6548\u548c\u6cbb\u7642\u526f\u4f5c\u7528\u3002", "e": "Purpose: This study was to analyze the preliminary survival outcomes and treatment-related toxicities of definitive radiotherapy with prophylactic para-aortic irradiation and concurrent chemotherapy for patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB/IIIB cervical carcinoma.\nMaterials and Methods: From June 1998 to June 2001, 20 patients with FIGO stage IIB or IIIB cervical carcinoma with no lymph node metastasis to the para-aortic area were included in the study. Patients were treated with definitive pelvic and prophylactic para-aortic radiotherapy, concomitant chemotherapy, and post-radiation chemotherapy Radiation treatments included external radiation to the para-aortic area with 45 Gy in 25 fractions and to the whole pelvis with 50.4 Gy in 28 fractions, additional boost to the parametrium with 9 Gy in 5 fractions, and the intracavitary brachytherapy with point A doses of 22-30 Gy in 4-5 fractions. Chemotherapy included 2 cycles of cisplatinum 60-80 mg/m2 on day 1 and day 29 during radiotherapy , and 2 cycles of cisplatinum 60-80 mg/m2 and 5-fluorouracil 600-800 mg/m2/day for 5 days, at 1 and 2 months after completion of radiotherapy. Patients were followed on a regular basis. The survival outcome was calculated by Kaplan-Meier method, and the treatment-related side effects were evaluated by RTOG criteria. The median follow-up interval was 15 months. \nResults: All patients completed the planned radiotherapy and the planned 2 cycles of chemotherapy during radiotherapy. Sixteen patients (80%) underwent 2 cycles of the post-radiation chemotherapy, while 4 of them had modification of chemotherapy regimens. One patient had local recurrence, with the 2-year local control rate of 83%. None of the 20 patients had para-aortic recurrence, but one patient developed lung metastasis. All patients were alive and the 2-year survival rate was 100%. Most treatment-related side effects were gastrointestinal and hematological reactions. No patient had grade IV acute toxicity. For gastrointestinal toxicity, there were four patient(20%) with grade III reaction. For hematological toxicity, there were five patients (25%) with grade III reaction. All but 2 patients had the late toxicities less than or equal to grade II. No patient had the interruption of radiation therapy due to the treatment-related adverse effects. \nConclusion: Definitive radiotherapy with prophylactic para-aortic irradiation and concur-rent chemotherapy are safe and well tolerated for patients with FIGO stage IIB-IIIB cervical carcinoma. The preliminary survival results were acceptable. Long-term follow-up is needed to evaluate the side effects and outcome with this intensive treatment combination."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-253-257-a", "title": "Local Recurrence After Postmastetomy Irradiation IN Breast Cancer", "keywords": "\u5c40\u90e8\u5fa9\u767c;\u653e\u5c04\u7dda\u6cbb\u7642;\u4e73\u764c Local recurrence;Radiotherapy;Breast cancer", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e3b\u8981\u76ee\u7684\u5728\u63a2\u8a0e\u4e73\u764c\u75c5\u60a3\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u5176\u80f8\u58c1\u5c40\u90e8\u5fa9\u767c\u53ca\u518d\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1978\u5e741\u6708\u81f31996\u5e7412\u6708\uff0c\u517117\u4f4d\u7d93\u75c5\u7406\u5207\u7247\u8b49\u5be6\u70ba\u80f8\u58c1\u5fa9\u767c\u7684\u4e73\u764c\u75c5\u60a3\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u6211\u5011\u4f7f\u75284\u62166\u767e\u842c\u4f0f\u7279\u5149\u5b50\u62169\u767e\u842c\u4f0f\u7279\u96fb\u5b50\uff0c\u6bcf\u9031\u6cbb\u7642\u4e94\u5929\uff0c\u6bcf\u5929\u5291\u91cf\u70ba 2 Gy\uff0c\u7e3d\u5291\u91cf\u70ba20 \u81f3 Gy \uff0c\u5e73\u5747\u5291\u91cf\u70ba48 Gy\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\u670914\u500b\u75c5\u60a3\uff0882%\uff09\u767c\u751f\u9060\u8655\u8f49\u79fb\uff0c\u4ee5\u80ba\u8f49\u79fb\u6700\u5e38\u898b\uff0c\u80f8\u58c1\u5fa9\u767c\u5f8c\u5b58\u6d3b\u671f\u70ba3\u500b\u6708\u81f33\u5e746\u500b\u6708\uff0c\u5e73\u5747\u5b58\u6d3b\u671f\u70ba15\u500b\u6708\u3002\u80f8\u58c1\u5fa9\u767c\u591a\u767c\u751f\u5728\u8853\u5f8c\u7167\u5c04\u5f8c\u5169\u5e74\u5167\uff08\u4f5490%\uff09\uff0c71%\u5fa9\u767c\u90e8\u4f4d\u767c\u751f\u8853\u5f8c\u7167\u5c04\u7684\u7bc4\u570d\u5167\u3002\n\u7d50\u8ad6\uff1a\u7531\u653e\u4e73\u764c\u75c5\u60a3\u80f8\u58c1\u5f8c\u767c\u5f8c\u6709\u5f88\u9ad8\u7684\u9060\u8655\u8f49\u79fb\u7387\uff0c\u800c\u653e\u5c04\u6cbb\u7642\u50c5\u6709\u5c40\u90e8\u63a7\u5236\u7684\u6548\u679c\uff0c\u56e0\u6b64\u91dd\u5c0d\u9060\u8655\u8f49\u79fb\u7684\u5168\u8eab\u6027\u6cbb\u7642\u5fc5\u9808\u66f4\u9032\u4e00\u6b65\u7684\u7814\u7a76\u3002", "e": "Purpose: The purpose of this study was to investigate the failure patterns of chest wall recurrence after postmastectomy radiotherapy (RT) in the patients with locally advanced breast cancer and the outcome of re-irradiaton.\nMaterials and Methods: From January 1978 to December 1996, 17 patients with pathology confirmed recurrent breast cancer were included in this study. The recurrent chest wall was treated with 4 or 6 MV photon through tangential field technique or 9 MeV electron beam through anterior or oblique portal, in a daily dose of 2 Gy, 5 days per week. Total dose ranged from 20 to 60 Gy with the average dose of 48 Gy.\nResults: The median survival time from chest wall recurrence was 16 mouths, ranged from 3 months to 3.5 years. There was 90% of recurrence occurred within 2 years after postmastectomy irradiation, and 71% recurrent site occurred in the previous RT field. Fourteen patients (82%) developed distant metastases. Lung was the most common site.\nConclusion: Re-irradiation to the chest wall played only a palliative role. Further systemic management should be investigated and recommended due to high incidence of distant metastases."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-259-265-a", "title": "Treatment OF Nasopharyngeal Carcinoma With Unusual Histological Features", "keywords": "\u9f3b\u54bd\u764c;\u7f55\u898b\u75c5\u7406\u7d44\u7e54\u578b\u614b;\u653e\u5c04\u6cbb\u7642 Nasopharyngeal carcinoma;Unusual histological features;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5206\u6790\u7f55\u898b\u75c5\u7406\u7d44\u7e54\u578b\u614b\u9f3b\u54bd\u764c\u7684\u653e\u5c04\u6cbb\u7642\u6210\u679c\u53ca\u5fa9\u767c\u578b\u614b\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5341\u4e94\u5e74\u5167\uff081983-1997\uff09\u5171\u6709\u4e5d\u4f4d\u7f55\u898b\u75c5\u7406\u7d44\u7d71\u578b\u614b\u9f3b\u54bd\u764c\u4e4b\u75c5\u60a3\u65bc\u6797\u53e3\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff1b\u5176\u75c5\u7406\u7d44\u7e54\u578b\u614b\u5206\u5225\u70ba\u817a\u6a23\u56ca\u72c0\u4e0a\u76ae\u764c(adenoid cystic carcinoma) \uff0c\u4f54\u56db\u4f4d\u75c5\u4eba\uff1b\u5206\u5316\u4e0d\u826f\u817a\u764c(poorly differentiated adenocarcinoma)\uff0c\u4f54\u4e09\u4f4d\u75c5\u4eba\uff1b\u53ca\u9ecf\u6db2\u985e\u4e0a\u76ae\u764c(mucoepidermoid carcinoma)\uff0c\u4f54\u5169\u4f4d\u75c5\u4eba\u3002\u5e74\u9f61\u5206\u5e03\u81ea15\u81f372\u6b72\uff1b\u7537\u3001\u5973\u6027\u75c5\u60a3\u5206\u4f54\u4e03\u3001\u4e8c\u4f4d\u3002\u5169\u4f4d\u9ecf\u6db2\u76ae\u764c\u75c5\u4eba\u53ca\u4e00\u4f4d\u817a\u6a23\u56ca\u72c0\u4e0a\u76ae\u764c\u75c5\u4eba\u5728\u653e\u5c04\u6cbb\u7642\u524d\u63a5\u53d7\u624b\u8853\u5207\u9664(transpalate excision of tumor )\u3002\u6240\u6709\u75c5\u4eba\u7686\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff1b\u9f3b\u54bd\u7684\u653e\u5c04\u5291\u91cf\u70ba6480 cGy\u81f3 7280 cGy \uff1b\u4e2d\u4f4d\u5291\u91cf(median dose)\u70ba7080cGy\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u53ca\u5341\u5e74\u7684\u6574\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u70ba44.4%\u53ca29.6%\uff1b\u4e2d\u4f4d\u5b58\u6d3b\u671f\u70ba2.73\u5e74\u3002\u5171\u6709\u516d\u4f4d\u75c5\u4eba(66%)\u5c40\u90e8\u5fa9\u767c\uff1b\u6cbb\u7642\u5f8c\u81f3\u5c40\u90e8\u5fa9\u767c\u7684\u6642\u9593\u6700\u77ed\u70ba\u5341\u4e8c\u500b\u6708\uff0c\u6700\u9577\u70ba\u4e00\u767e\u4e00\u5341\u4e09\u500b\u6708(\u4e2d\u4f4d\u6578\u70ba\u4e09\u5341\u4e09\u500b\u6708)\u3002\u5171\u6709\u4e8c\u4f4d\u75c5\u4eba\u767c\u751f\u9060\u8655\u8f49\u79fb\uff0c\u5206\u5225\u8f49\u79fb\u81f3\u80ba\u90e8\u53ca\u809d\u81df\u3002\n\u7d50\u8ad6\uff1a\u7f55\u898b\u75c5\u7406\u7d44\u7e54\u578b\u614b\u4e4b\u9f3b\u54bd\u764c\u5728\u81e8\u5e8a\u4e0a\u78ba\u5c6c\u5c11\u898b\uff1b\u6545\u75c5\u4f8b\u6578\u9650\u5236\u4e86\u672c\u7814\u7a76\u7684\u4ee3\u8868\u6027\u3002\u672c\u7814\u7a76\u89c0\u5bdf\u5230\u6b64\u65cf\u7fa4\u6709\u76f8\u5c0d\u8f03\u591a\u7684\u665a\u671f\u75c5\u60a3\u4ee5\u53ca\u653e\u5c04\u6cbb\u7642\u5f8c\u5c40\u90e8\u5fa9\u767c\uff0c\u9019\u4e9b\u7279\u6027\u6216\u53ef\u89e3\u91cb\u70ba\u4f55\u7f55\u898b\u75c5\u7406\u7d44\u7e54\u578b\u614b\u9f3b\u54bd\u764c\u76f8\u8f03\u65bc\u4e00\u822c\u9f3b\u54bd\u764c\uff0c\u5176\u5b58\u6d3b\u7387\u8f03\u5dee\u3002", "e": "Purpose: To evaluate the treatment results and relapse patterns for nasopharyngeal carcinomas (NPCs) with unusual histological features.\nMaterials and Methods: From Dec 1983 to April 1997, nine cases of carcinoma occur-ring in the nasopharynx, which were characterized by unusual histological presentations, underwent radiotherapy at the Department of Radiation Oncology, Chang Gung Memorial Hospital-Linkou. The histological diagnoses for these patients were adenoid cystic carcinoma (n= 4), poorly differentiated adenocarcinoma (n= 3), and mucoepider-moid carcinoma (n= 2). This group consisted of two females and seven males, with a median age of 41 years (range, 15 to 72). Two patients with mucoepidermoid carcinoma and one with the adenoid cystic variant underwent transpalate excision of the tumor before irradiation. All patients were treated with definite irradiation, with total dose to the nasopharynx ranging from 6480 to 7280 cGy (median, 7080).\nResults: The five and ten-year overall survival rates, derived using the Kaplan-Meier method, were 44.4% and 29.6%, respectively. Median survival was 2.73 years. Local recurrence occurred for six of the patients (66%). The duration to local recurrence varied from 12 to 113 months, with a median of 33 months. Two patients developed distant metastasis to lung or liver.\nConclusion: Nasopharyngeal carcinomas with unusual histological features are rare. As a result, the small number of such cases diagnosed during the study period limited the statistical power of this study. Relatively advanced stage distribution and a greater proportion of local relapse after definite radiotherapy were observed, with these features probably accounting for the poor survival rate for NPC cases which are characterized by unusual histological features."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-267-274-a", "title": "Comparision OF Treatment Plans FOR Nasopharyngeal Carcinoma: Bil-Lateral Opposing, 3D Conformal AND Intensity Modulated Radiotherapy", "keywords": "\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642;\u9f3b\u54bd\u764c;\u9ad4\u5291\u91cf\u9577\u689d\u5716 IMRT;Nasopharyngeal carcinoma;DVH", "c": "\u76ee\u7684\uff1a\u5728\u4e0d\u540c\u5206\u671f\u4e4b\u9f3b\u54bd\u764c\u6bd4\u8f03\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642(IMRT)\u6cbb\u7642\u8a08\u756b\u8207\u9806\u5f62\u6cbb\u7642\u8a08\u756b\u4e4b\u5dee\u7570\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u4ee5\u4e09\u500b\u4e0d\u540c\u5206\u671f\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u5176\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u9664\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642(IMRT)\u6280\u8853\u5916\u3001\u4e5f\u4f7f\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\u6280\u8853\u53ca\u50b3\u7d71\u5169\u5074\u76f8\u5c0d\u7167\u91ce\u6280\u8853\u3002\u6211\u5011\u5229\u7528\u4e0d\u540c\u7684\u6280\u8853\u7d44\u5408\u904b\u7528\u65bc\u8d77\u521d\u6cbb\u7642\u7bc4\u570d\u53ca\u52a0\u5f37\u6cbb\u7642\u7bc4\u570d\uff0c\u5176\u91cd\u9ede\u5728\u65bc\u5291\u91cf\u66f2\u7dda\u5206\u5e03(dose conformality)\u3001\u9ad4\u7a4d\u5291\u91cf\u9577\u689d\u5716(dose-volume histogram, DVH)\u53ca\u5291\u91cf\u5c0d\u8f03\u654f\u611f\u6b63\u5e38\u7d44\u7e54\u7684\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u4ee5\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u6280\u8853\u5b8c\u6210\u4e4b\u8a08\u756b\u5176\u5291\u91cf\u66f2\u7dda\u5206\u5e03\u8f03\u80fd\u8cbc\u8fd1\u816b\u7624\u9ad4\u7a4d\uff0c\u70ba\u4e86\u9054\u5230\u4fdd\u8b77\u816e\u817a\u548c\u773c\u775b\u7b49\u5668\u5b98\u7684\u76ee\u7684\uff0c\u5fc5\u9808\u65bc\u653e\u5c04\u6cbb\u7642\u4e00\u958b\u59cb\u5373\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u6280\u8853\u3002\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u9806\u6cbb\u7642\u6280\u8853\u80fd\u7d66\u4e88\u816b\u7624\u66f4\u9ad8\u6cbb\u7642\u5291\u91cf\uff0c\u4e5f\u9020\u6210\u773c\u7403\u5668\u5b98\u7684\u50b7\u5bb3\u9ad8\u65bc\u7be9\u7ac7\u63a5\u8fd1\u773c\u7aa9\u8655\u4f4d\u7f6e\u3002\u6240\u7d66\u4e88\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u53ca\u5291\u91cf\u66f2\u7dda\u5206\u4f48\u5c07\u6703\u5f71\u97ff\u65e5\u5f8c\u773c\u7403\u7d44\u7e54\u7684\u90e8\u5206\u529f\u80fd\u3002\n\u7d50\u8ad6\uff1a\u4e0d\u540c\u5206\u671f\u7684\u816b\u7624\u53ca\u51f9\u9762\u5f62\u72c0\u7684\u816b\u7624\uff0c\u63a1\u7528\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u6280\u8853\u5c0d\u816e\u817a\u90e8\u5206\u5c07\u589e\u52a0\u4e9b\u8a31\u597d\u8655\u3002\u4f46\u7121\u8ad6\u5982\u4f55\uff0c\u4f7f\u7528\u5f37\u5ea6\u8abf\u63a7\u9806\u5f62\u6cbb\u7642\u6280\u8853\u63a1\u5171\u9762\u65b9\u5f0f\u5b8c\u6210\u4e4b\u6cbb\u7642\u8a08\u756b\u5728\u6cbb\u7642\u4f4d\u65bc\u4e2d\u592e\u90e8\u4f4d\u7d44\u7e54\uff1b\u4f8b\u5982\u4e0a\u7be9\u7ac7\u5340\u57df(upper ethmoid sinus area)\u6642\u5c0e\u81f4\u5c0d\u773c\u7403\u90e8\u5206\u7d50\u69cb\u50b7\u5bb3\u3002", "e": "Purpose: To compare intensity-modulated radiotherapy (IMRT) treatment plans with conventional treatment plans for different stage of nasopharyngeal carcinoma. \nMaterials and Methods: We used 3 cases of different T stage of nasopharyngeal cancer using IMRT techniques, as well as three-dimensional conformal radiotherapy technique (3D-CRT), and traditional bil-opposing fields technique. We use different combinations of techniques in initial and boost fields. These plans were compared with respect to dose conformality, dose-volume histogram (DVH) and dose to the sensitive normal tissue structures.\nResults: The planned dose distributions were more conformal to the rumor target volume by IMRT in T1 and T3 tumor but not in T4 lesion with extending to eye balls level. To achieve the parotid and ear organs preservation purpose, IMRT should be done from the beginning of radiotherapy. The IMRT technique may deliver more radiation dose to eye balls for the lesion over the ethmoid sinus nearing the orbit level. The radiation dosage and conformality will be lost after the limitation of the eye structure.\nConclusion: The IMRT will gain the benefit of parotid sparing in different stage of tumor and the concave shape tumor. However, the IMRT with co-planar treatment planning may cause some harm to eye structures for the lesion at the central such as upper ethmoid sinus area."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-275-281-a", "title": "\u8868\u5c64\u7d44\u7e54\u4e4b\u6df1\u5ea6\u767e\u5206\u7387\u5291\u91cf\u66f2\u7dda\u7684\u8499\u5730\u5361\u7f85\u6a21\u64ec", "keywords": "\u8499\u5730\u5361\u7f85\u65b9\u6cd5;\u76ae\u819a\u5291\u91cf Monte Carlo method;PDD;Skin dose", "c": "\u76ee\u7684\uff1a\u4ee5\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ec\u8868\u5c64\u7d44\u7e54\u7684\u6df1\u5ea6\u767e\u5206\u5291\u91cf(PDD)\u66f2\u7dda\uff0c\u4f5c\u70ba\u5f80\u5f8c\u6e96\u78ba\u76ae\u819a\u5291\u91cf\u8a55\u4f30\u4e4b\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5OMEGA/BEAM\u70ba\u4e3b\u8981\u6a21\u64ec\u8edf\u9ad4\uff0c\u6a21\u5f0f\u5316\u8abf\u6574\u5f8c\u4e4bSiemens PRIMUS \u4ee5BEAM\u6a21\u64ec\u4e26\u65bcSSD\u70ba100cm \u8655\u6536\u96c6\u7522\u751f\u7684\u7c92\u5b50\u7fa4\uff0c\u8a72\u7c92\u5b50\u7fa4\u4f5c\u70ba\u534a\u5f9130cm\uff0c\u539a 10 cm \u4e4b\u6c34\u5047\u9ad4\u8868\u9762\u5291\u91cf\u4e4b\u5c04\u6e90\u3002\u672c\u7814\u7a76\u4fc2\u5c0d6\u820715 MV \uff0c 10 \u00d7 10 \u3001 20 \u00d7 20 \u8207 30 \u00d7 30 cm2\u7b49\u7167\u91ce\u9032\u884c\u6a21\u64ec\uff0c\u5206\u5225\u653e\u6c34\u5047\u9ad4\u5713\u5fc3\u9078\u53d6\u534a\u5f911.0\u30012.0\u82073.0 cm\u7684\u5713\u5f62\u5340\u57df\u70ba 10 \u00d7 10 \u3001 20 \u00d7 20 \u8207 30 \u00d7 30 cm2 \u7167\u91ce\u4e2d\u5291\u91cf\u8a08\u7b97\u5340\u57df\uff0c\u7531\u6c34\u8868\u9762\u958b\u59cb\u5171\u5206\u5272\u539a 0.05 mm \u00d7 50\u03bcm)\u7684\u9ad4\u7a4d\u514320\u500b\uff0c\u4e26\u5728Dmax\u8655\u8a2d\u7f6e\u534a\u5f91\u8207\u4e0a\u8ff0\u9ad4\u7a4d\u5143\u9762\u7a4d\u4e00\u81f4\u4f46\u539a\u5ea6\u70ba0.1cm \u7684\u9ad4\u7a4d\u5143\uff0c\u6a21\u64ec\u8a08\u7b97\u5f8c\u5404\u9ede\u8207Dmax\u8655\u4e4b\u5291\u91cf\u6bd4\u503c\u5373\u70baPDD\u5206\u4f48\u5716\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u5404\u9ede\u6a21\u64ec\u4e4b\u767e\u5206\u8aa4\u5dee\u5927\u90fd\u63a7\u5236\u57281%\u4ee5\u5167\uff0c\u5c11\u90e8\u4efd 30 \u00d7 30 cm2\u7684\u8aa4\u5dee\u57282%\u4ee5\u5167\u3002\u6a21\u64ec\u6240\u5f97\u4e4b\u5404\u6c34\u8868\u9762\u9644\u8fd1PDD\u66f2\u7dda\uff0c\u7d93\u4e00\u5143\u56db\u6b21\u591a\u9805\u5f0f\u64ec\u5408\uff0c\u5f97\u77e5\u5728\u6c34\u8868\u9762\u8655( X=0) \u7684 6 MV \u4e4b 10 \u00d7 10 \u300120 \u00d7 20 \u820730 \u00d7 30 cm2\u7684PDD\u503c\u5206\u5225\u70ba 13.67 \u00b1 0.17% \u300123.07 \u00b10.35% \u820729.75\u00b1 0.52% \uff0c 15MV\u4e4b\u7d50\u679c\u5247\u70ba8.71 \u00b1 0.06 % \u3001 18.77 \u00b1 0.14% \u8207 27.06\u00b10.32%\u3002\u64ec\u5408\u7684x2\u503c\u7686\u5927\u65bc0.997\u3002\n\u7d50\u8ad6\uff1a\u6a21\u64ec\u6240\u5f97\u4e4b\u6c34\u8868\u9762\u8655PDD\u503c\u53ef\u4ee5\u4f5c\u70ba\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u6a21\u5f0f\u5316\u6642\u8abf\u6574\u64ec\u5408\u66f2\u7dda\u8868\u9762\u4e4b\u503c ( X=0)\u7684\u53c3\u8003\u3002\u672c\u7814\u7a76\u50c5\u5c0d6MV\u820715MV\u958b\u653e\u5f0f\u7684\u7167\u91ce\u4f5c\u6a21\u64ec\uff0c\u672a\u4f86\u4ea6\u5c07\u5617\u8a66\u5c0d\u56fa\u614b\u6954\u578b\u6ffe\u5668(physical wedge) \u8207\u52d5\u614b\u6954\u578b\u6ffe\u5668(dynamic wedge)\u4f5c\u6c34\u8868\u5c64PDD\u5206\u4f48\u4e4b\u6a21\u64ec\uff0c\u4ee5\u589e\u52a0\u5176\u81e8\u5e8a\u7684\u904b\u7528\u3002", "e": "Purpose: This study performed the Percent Depth Dose (PDD) curve simulation at surface region by Monte Carlo method for the accurately evaluating skin dose in the future.\nMaterials and Methods: Simulation in this study is carried out by the OMEGA/BEAM code. After modeling the Siemens PRIMUS linear accelerator, phase space data is collected at SSD= 100 cm for following dose distribution simulation in a water phantom. Dose distribution simulation is carried out for 6 MV and 15 MV, 10 \u00d7 10\u300120 \u00d7 20 and 30 \u00d730 cm2 fields in a water phantom. The phantom size in 30 cm in radius and 10 cm in thickness. The areas selected for dose calculation of 10 \u00d7 10\u300120 \u00d7 20 and 30 \u00d730 cm2 fields are 1.0, 2.0 and 3.0 cm in radius, respectively. Total twenty voxels of thickness 0.05mm (50\u03bcm) from water surface and 1 voxel of thickness 0.1cm at Dmax were selected for dose calculation. The dose ratios of voxels at surface region to voxel at Dmax form the PDD curve at surface region.\nResult and Discussion: The relative error of all voxels is within 1% with the exception of some voxels within 2% in 30 \u00d7 30 cm2 field. The PDD curves at surface region were fit with 4th order polynomial function. The x2 value of each fitting is better than 0.997. The PDD value at water surface ( X=0) for 6 MV, 10 \u00d7 10\u300120 \u00d7 20 and 30 \u00d7 30 cm2 fields are 13.67 \u00b1 0.17%\u300123.07 \u00b1 0.35% and 29.75 \u00b1 0.52%, respectively. For 15 MV, the values are 8.71\u00b1 0.06%\u300118.77 \u00b1 0.14% and 27.06 \u00b1 0.32%, respectively.\nConclusion: The PDD value at water surface can be taken as reference for modeling of treatment planning system. This study only carried out the simulation for 6 and 15 MV open fields. More efforts on surface PDD of physical wedge and dynamic wedge fields are needed to widen the clinical application."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200012-7-4-283-290-a", "title": "Management OF Soft Tissue Sarcoma OF Lower Limb - 2 Case Reports AND Review OF THE Literature", "keywords": "\u8edf\u7d44\u7e54\u8089\u7624;\u80a2\u9ad4\u4fdd\u7559\u7642\u6cd5;\u7d44\u7e54\u63d2\u7a2e\u8fd1\u63a5\u6cbb\u7642 Soft tissue sarcoma;Interstital brachytherapy;Limb-salvage therapy", "c": "\u4e8c\u540d\u7f79\u60a3\u4e0b\u80a2\u8edf\u7d44\u7e54\u8089\u7624\u75c5\u60a3\uff0c\u65bc\u53f0\u4e2d\u69ae\u7e3d\u63a5\u53d7\u624b\u8853\u53ca\u7d44\u7e54\u9593\u8fd1\u63a5\u6cbb\u7642\u3002\u6b64\u4e8c\u540d\u75c5\u4eba\u5230\u9662\u6642\u7686\u5df2\u70ba\u665a\u671f\u60a3\u8005\uff0c\u4f46\u662f\u75c5\u60a3\u7686\u6709\u5f37\u70c8\u610f\u9858\u4fdd\u7559\u5176\u60a3\u80a2\u3002\u65bc\u662f\u672c\u9662\u70ba\u5176\u6cbb\u7642\uff0c\u63a1\u80a2\u9ad4\u4fdd\u6301\u624b\u8853\u5373\u5be6\u65bd\u884c\u5927\u7bc4\u570d\u5207\u9664\u816b\u7624\uff0c\u4e26\u65bc\u624b\u8853\u4e2d\u65bc\u60a3\u90e8\u57cb\u8a2d\u8853\u5f8c\u8fd1\u63a5\u6cbb\u7642\u4e4b\u7ba1\u5b50\uff0c\u4ee51\u516c\u5206\u70ba\u9593\uff0c\u6392\u5217\u65bc\u816b\u7624\u6316\u53d6\u4e4b\u7a7a\u9593\u53ca\u5176\u9130\u8fd1\u7d44\u7e54\u3002\u624b\u8853\u5f8c\u4ee5\u67cf\u62c9\u5716\u8fd1\u63a5\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u9032\u884c\u5404\u5225\u6cbb\u7642\u8a08\u756b\u3002\u5728\u624b\u8853\u5f8c\u7b2c\u56db\u5929\u65bc\u60a3\u884c\u7d44\u7e54\u9593\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u3002\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u4e4b\u7e3d\u5291\u91cf\u5206\u5225\u70ba 2880 cGy\u53ca 2800 cGy\uff0c\u4e26\u4ee5\u4e00\u5929\u5169\u6b21\u5171\u5206\u516b\u6b21\u7d66\u4e88\u3002\u5176\u4e2d\u4e00\u4eba\u5916\u52a0\u9ad4\u5916\u7167\u5c04 4000 cGy\u3002\u53e6\u4e00\u4eba\u56e0\u60a3\u6709\u7cd6\u5c3f\u75c5\u9032\u63a5\u6cbb\u7642\u5f8c\u5ef6\u9072\u50b7\u53e3\u7652\u5408\uff0c\u56e0\u6b64\u6c92\u6709\u52a0\u7167\u9ad4\u5916\u7167\u5c04\uff0c\u6b64\u4e8c\u540d\u75c5\u60a3\u653e\u6cbb\u7642\u4e00\u4ef6\u5f8c\uff0c\u5c0d\u65bc\u5176\u4fdd\u7559\u4e0b\u4f86\u7684\u60a3\u80a2\u529f\u80fd\uff0c\u7686\u6709\u9ad8\u5ea6\u4e4b\u6eff\u610f\u5ea6\uff0c\u9664\u65bc\u60a3\u80a2\u6709\u5c40\u90e8\u808c\u8089\u7e96\u7dad\u5316\u4e26\u7121\u5176\u4ed6\u4f75\u767c\u75c7\uff0c\u8f49\u79fb\u6216\u5c40\u90e8\u5fa9\u767c\u4e4b\u767c\u73fe\u3002\n\u7d93\u7531\u6b64\u4e8c\u4f8b\u75c5\u60a3\u4e4b\u6cbb\u7642\u7d50\u679c\uff0c\u9664\u4e86\u4fdd\u7559\u4e86\u60a3\u8005\u7684\u4e0b\u80a2\uff0c\u4e5f\u589e\u52a0\u60a3\u8005\u5c0d\u6297\u75be\u75c5\u7684\u4fe1\u5fc3\uff0c\u9032\u800c\u6539\u5584\u60a3\u8005\u7684\u751f\u6d3b\u54c1\u8cea\u3002\u96d6\u7136\u6b64\u6cd5\u53ef\u6539\u5584\u767c\u751f\u65bc\u80a2\u9ad4\u4e4b\u8edf\u7d44\u7e54\u8089\u7624\u7684\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u4f46\u662f\u9019\u4e26\u4e0d\u4ee3\u8868\u53ef\u589e\u52a0\u60a3\u8005\u4e4b\u9577\u671f\u5b58\u6d3b\u7387\u3002\u65e5\u5f8c\u5c0d\u6b64\u4e8c\u4f8b\u75c5\u60a3\u4e4b\u9577\u671f\u8ffd\u8e64\u5be6\u70ba\u5fc5\u8981\u4e26\u5e0c\u671b\u6709\u597d\u7684\u9810\u5f8c\u7d50\u679c\u51fa\u73fe\u3002", "e": "Two cases of lower limb soft tissue sarcoma, one malignant fibrous histiocytoma and one liposarcoma, were treated by surgery and a postoperative high dose rate of interstitial brachytherapy with and without external beam irradiation in Taichung Veteran General Hospital. Both cases were advanced stage and high grade in histology at presentation and had a high concern for leg preservation. Conservative surgical treatments were performed by wide excision and marginal excision, respectively. The interstitial catheters were implanted with 1-cm spacing in a parallel array intra-operatively. High dose rate brachytherapy was planned by Plato Brachytherapy Planning System and was started 4 days after the operation by the application of the micro selection after loader using iridum-192 as the irradiation source. The total doses were 2880cGy and 2800 cGy respectively and were applied in 8 and 7 fractions was given to one case but was withheld in the second case due to delayed wound healing after brachytherapy. There were on significant wound complications in the first case. There was also no bone fracture or peripheral nerve damage in either case except muscle fibrosis occurred after the irradiation. Both of the patients were satisfied with the function of the preserved limbs during a follow up one year later. No local recurrence or distant metastasis was seen at present. For advanced lower limbs soft tissue sarcoma, wide excision plus interstitial brachytherapy may be an alternative management for the preservation of the limbs. Though we had a good initial local control of these two cases but it does not indicate there will be a good prognosis later on. However it did improve the patient\u2019s quality of life and their self-con-fidence in facing the disease. Further long-term follow-up is necessary and hopefully there will be good long-term survival in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-137-145-a", "title": "An Effective, Efficient and Safe Method to Deliver A Modified 3-D Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c,\u591a\u5206\u6b21\u653e\u5c04\u7dda\u6cbb\u7642 Nasopharyngeal carcinoma,DVH,Hyperfractionation radiotherapy", "c": "\u76ee\u7684\uff1a\u8a2d\u8a08\u4e00\u7a2e\u6539\u826f\u5f0f\u7684\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff0c\u4e0d\u50c5\u5bb9\u6613\u57f7\u884c\uff0c\u6e1b\u5c11\u8166\u5e79\u7167\u5c04\uff0c\u4e14\u4ecd\u53ef\u7d66\u4e88\u5c40\u90e8\u56b4\u91cd\u4fb5\u72af\u7684\u9f3b\u54bd\u764c\u8db3\u5920\u5291\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u9078\u64c7\u816b\u7624\u4fb5\u72af\u9760\u8fd1\u8166\u5e79\u800c\u7121\u9060\u8655\u8f49\u79fb\u7684T4\u9f3b\u54bd\u764c\u75c5\u4eba\u70ba\u6b64\u7a2e\u6cbb\u7642\u8a08\u5283\u7684\u6a19\u7684\u3002\u6b64\u8a08\u756b\u7684\u8a2d\u8a08\u4e43\u85c9\u7531CMS-Focus\u4e4b\u8edf\u9ad4\u7cfb\u7d71\uff0c\u4e26\u7d93\u7531\u897f\u9580\u5b50\u516c\u53f8\u4e4b\u52a0\u901f\u5668\u4f86\u57f7\u884c\u3002\u6cbb\u7642\u8a08\u5283\u7684\u53ef\u884c\u6027\u662f\u4ee5\u57f7\u884c\u7684\u5bb9\u6613\u5ea6\uff0c\u8981\u6c42\u5291\u91cf\u5206\u4f48\u4e4b\u9054\u6210\u5ea6\uff0c\u816b\u7624\u53ca\u6b63\u5e38\u7d44\u7e54\u4e4bDVH\u548cIMRT\u53ca3DCRT\u4e4b\u6bd4\u8f03\uff0c\u6f5b\u5728\u8f3b\u5c04\u751f\u7269\u7684\u6548\u679c\u548c\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u4e4b\u6bd2\u6027\u4f86\u8a55\u4f30\u3002\u5176\u6cbb\u7642\u7d50\u679c\u4e4b\u78ba\u5b9a\u4e43\u6bd4\u8f03\u6cbb\u7642\u524d\u5f8c\u4e4b\u6838\u78c1\u5171\u632f\u548c\u6838\u91ab\u6aa2\u67e5\u4e4b\u5f71\u50cf\u3002\n\u7d50\u679c\uff1a\u6b64\u6cbb\u7642\u8a08\u5283\u6bcf\u6b21\u53ea\u9700\u57f7\u884c2\u81f34\u7167\u91ce\u5373\u53ef\uff0c\u6700\u7d42\u9054\u5230\u816b\u7624\u81f4\u6b7b\u5291\u91cf\u800c\u6b63\u5e38\u7d44\u7e54\u6240\u63a5\u53d7\u7684\u5291\u91cf\u4ecd\u5728\u6b63\u5e38\u7bc4\u570d\u5167\uff0c\u816b\u7624\u4e4bDVH\u76f8\u4f3c\u65bcIMRT\u4e4b\u7d50\u679c\uff0c\u800c\u6b63\u5e38\u7d44\u7e54\u4e4bDVH\u5247\u76f8\u4f3c\u65bc3DCRT\u4e4b\u7d50\u679c\uff0c\u5728\u816b\u7624\u5bc6\u5ea6\u6108\u5927\u4e4b\u5340\uff0c\u5176\u6240\u53d7\u5291\u91cf\u4e4b\u6108\u9ad8\uff0c\u800c\u6b63\u5e38\u7d44\u7e54\u5167\u4e26\u7121\u71b1\u9ede(hot spot)\uff0c\u5373\u4f7f\u5408\u4f75\u540c\u6b65\u5316\u5b78\u6cbb\u7642\uff0c\u75c5\u4eba\u4ecd\u53ef\u8010\u53d7\u800c\u7121\u91cd\u5927\u6bd2\u6027\u3002\u85c9\u7531\u6cbb\u7642\u5b8c\u6210\u5f8c\u7684\u7b2c\u4e09\u500b\u6708\u7684\u6838\u78c1\u5171\u632f\u53ca\u6838\u5b50\u91ab\u5b78\u7684\u6383\u63cf\u5f71\u50cf\uff0c\u8b49\u5be6\u816b\u7624\u5b8c\u5168\u6d88\u5931\u3002\n\u7d50\u8ad6\uff1a\u6b64\u6539\u826f\u5f0f\u7684\u4e09\u5ea6\u7a7a\u9593\u653e\u5c04\u6cbb\u7642\u662f\u4e00\u6709\u6548\u7387\u53ca\u5b89\u5168\u7684\u65b9\u6cd5\uff0c\u53ef\u4ee5\u6709\u6548\u7684\u6cbb\u7642\u5c40\u90e8\u56b4\u91cd\u4fb5\u72af\u7684\u9f3b\u54bd\u764c\uff0c\u4f46\u4ecd\u9700\u9577\u671f\u8ffd\u8e64\u89c0\u5bdf\uff0c\u4ee5\u78ba\u7acb\u81e8\u5e8a\u4e0a\u4e4b\u771f\u6b63\u76ca\u8655\u3002", "e": "Purpose: To generate a modified 3-D radiotherapy planning that can be delivered easily and safely, and treat the targets adequately in locally advanced nasopharyngeal carcinoma.\nMaterials and Methods: The stage 14 NPC patients without distant metastasis, especially with a huge tumor approaching or close to the brain stem, were selected for this Treatment planning under curative intent. The CMS.FOCUS planning system was used to generate these 3-D radiotherapy plans. The plans were evaluated with respect to daily treatment time and ease of treatment delivery, achievement of dose requirement to tumor with normal tissue sparing, dose-volume histograms of gross target volume and critical normal structures, potential radiobiological effects and toxicity of concurrent chemotherapy. The treatment responses were defined by the serial follow-up MRI and Tc-99mnuclear scans.\nResults: Each time only 2-4 portals were needed to deliver a tumoricidal dose (200 cGyonce a day to 7000 cGy, or 120 cGy twice a day to 7440 cGy) to 100% of the primary tumor target volume while still keeping the doses of the adjacent critical normal structures within safety limits. The DVH of GTV is similar to that of IMRT but the DVHs of spinal cord and mandible are similar to those of 3DCRT. The highest dose was centered to the heavy tumor burden area. There was no any hot spot in normal tissue. This treatment was well tolerated and showed only moderate toxicity, even with concurrent chemotherapy. The complete response was confirmed by serial MRI and Tc.99m nuclear scans after treatment.\nConclusion: This modified 3-D radiotherapy was effective, efficient, and safe in treating locally advanced nasopharyngeal carcinoma. Longer follow-up and more patients are needed to establish the true clinical advantage."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-147-159-a", "title": "Fractiona Stereotactic Radiotherapy for Malignant Glioma", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642,\u60e1\u6027\u81a0\u72c0\u7624,\u5b58\u6d3b\u7387 Stereotactic radiotherapy,Glioma,survival", "c": "Purpose: This study is a retrospective analysis to evaluate the impact of fractionated stereotactic radiotherapy (FSRT) on malignant glioma.\nMaterial and Methods: Between June 1996 and May 1998, 37 patients with histology-cally proven WHO grade III or IV glioma (17 Anaplastic astrocytoma, 20 Glioblastoma multiforme) were treated at Taipei Medical University hospital with FSRT. External beam radiotherapy (EBRT) delivered a median dose of 46 Gy which is followed by stereotactic radiotherapy. A frameless fractionated stereotactic radiotherapy was used to boost the tumor bed, using daily fraction of 2.0 -3.0 Gy for 5 to 12 fractions. Non-coplanar arcs (4-8 arcs, median 4 arcs) with 1 to 2 isocenters were mostly used. Survival curves were calculated using the Kaplan-Meier method. Prognostic factors and different treatment variables were tested by univariate and multivariate analysis.\nResults: Overall median survival was 22 months. One year and 2-year survival rate were 60% and 30% respectively. Follow up imaging study showed tumor reduction greater than 50% in 6 patients (16%), reduction less than 50% or unchanged in 14 patients (38%) and progression in 17 of the 37 patients (46%). On analysis of different prognostic factors, patient's age (\uff1c50 years and\u226750 years), extent of surgical resection, and tumor volume (\uff1c20 ml) were correlated with survival in univariate analysis (p\uff1c0.05). Tumor volume and extent of surgical resection remained significant in multivariate analysis. The performance status remained stable for all patients during FSRT and only 5 patients (13%) suffered from treatment related acute toxicity with good medication control.\nConclusion: Fractionated stereotactic radiotherapy provides a safe and feasible technique in the primary treatment of malignant gliomas. Although the overall survival and 1 year survival is encouraging, we did not observe a significant dose-effect relationship on overall and progression-free survival. Large series study with long term fallow-up is indicated.", "e": "Purpose: This study is a retrospective analysis to evaluate the impact of fractionated stereotactic radiotherapy (FSRT) on malignant glioma.\nMaterial and Methods: Between June 1996 and May 1998, 37 patients with histology-cally proven WHO grade III or IV glioma (17 Anaplastic astrocytoma, 20 Glioblastoma multiforme) were treated at Taipei Medical University hospital with FSRT. External beam radiotherapy (EBRT) delivered a median dose of 46 Gy which is followed by stereotactic radiotherapy. A frameless fractionated stereotactic radiotherapy was used to boost the tumor bed, using daily fraction of 2.0 -3.0 Gy for 5 to 12 fractions. Non-coplanar arcs (4-8 arcs, median 4 arcs) with 1 to 2 isocenters were mostly used. Survival curves were calculated using the Kaplan-Meier method. Prognostic factors and different treatment variables were tested by univariate and multivariate analysis.\nResults: Overall median survival was 22 months. One year and 2-year survival rate were 60% and 30% respectively. Follow up imaging study showed tumor reduction greater than 50% in 6 patients (16%), reduction less than 50% or unchanged in 14 patients (38%) and progression in 17 of the 37 patients (46%). On analysis of different prognostic factors, patient's age (\uff1c50 years and\u226750 years), extent of surgical resection, and tumor volume (\uff1c20 ml) were correlated with survival in univariate analysis (p\uff1c0.05). Tumor volume and extent of surgical resection remained significant in multivariate analysis. The performance status remained stable for all patients during FSRT and only 5 patients (13%) suffered from treatment related acute toxicity with good medication control.\nConclusion: Fractionated stereotactic radiotherapy provides a safe and feasible technique in the primary treatment of malignant gliomas. Although the overall survival and 1 year survival is encouraging, we did not observe a significant dose-effect relationship on overall and progression-free survival. Large series study with long term fallow-up is indicated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-161-168-a", "title": "Radiotherapy of Conjunctival Lymphoma with A Specially Designed Lens Block", "keywords": "\u7d50\u819c\u6dcb\u5df4\u7624,\u60e1\u6027\u816b\u7624,\u653e\u5c04\u6cbb\u7642,\u6c34\u6676\u9ad4 Conjunctival lymphoma,neoplasm,radiotherapy,lens", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4e26\u8a0e\u8ad6\u7d50\u819c\u6dcb\u5df4\u7624\u653e\u5c04\u6cbb\u7642\u4e4b\u6210\u679c\u548c\u6280\u8853\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6b64\u56de\u6eaf\u6027\u7814\u7a76\u4e43\u91dd\u5c0d\u81ea1988\u5e74\u81f31996\u5e74\uff0c10\u4f4d\u5728\u53f0\u5927\u91ab\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u7d50\u819c\u6dcb\u5df4\u7624\u60a3\u8005\u3002\u5176\u4e2d8\u4f4d\u7537\u6027\uff0c2\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u81ea32\u6b72\u81f375\u6b72\uff0c\u5e73\u5747\u5e74\u9f61\u70ba59.1\u6b72\u3002\u591a\u6578\u75c5\u60a3\u4ee5\u7d50\u819c\u816b\u584a\u3001\u773c\u775b\u767c\u7d05\u53ca\u7570\u7269\u611f\u70ba\u81e8\u5e8a\u8868\u73fe\u3002\u75c5\u60a3\u4e4b\u7d50\u819c\u75c5\u7076\u5747\u4ee5\u55ae\u4e00\u524d\u65b9\u7167\u91ce\u5305\u542b\u6574\u500b\u7d50\u819c\u7d44\u7e54\u4f86\u6cbb\u7642\uff0c\u96fb\u5b50\u80fd\u91cf\u75313MeV\u81f310MeV\u4e0d\u7b49\u3002\u653e\u5c04\u6cbb\u7642\u7e3d\u5291\u91cf30 Gy\u523050 Gy \uff0c\u520615\u81f3 25\u6b21\u7d66\u4e88\uff0c\u6cbb\u7642\u6642\u9593\u9593\u8ddd\u70ba23\u81f333\u5929\u3002\u6240\u6709\u75c5\u60a3\u5747\u4f7f\u7528\u7279\u6b8a\u8a2d\u8a08\u4e4b\u5408\u91d1\u6a21\u584a\u4ee5\u4fdd\u8b77\u6c34\u6676\u9ad4\u3002\u8ffd\u8e64\u6642\u9593\u905424\u81f3124\u500b\u6708\u3002\n\u7d50\u679c\uff1a\u6240\u6709\u75c5\u60a3\u5728\u8ffd\u8e64\u6642\u9593\u5167\u5747\u7121\u5c40\u90e8\u6216\u8f49\u79fb\u75c5\u7076\u3002\u800c\u653e\u5c04\u6cbb\u7642\u7684\u4f75\u767c\u75c7\uff0c\u5305\u542b\u8996\u529b\u4e0b\u964d\u3001\u767d\u5167\u969c\u53ca\u754f\u5149\u5747\u5c6c\u8f15\u5fae\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u7e3d\u5291\u91cf30Gy\u81f340Gy\u7684\u653e\u5c04\u6cbb\u7642\u53ef\u6709\u6548\u7528\u5728\u5c40\u9650\u65bc\u7d50\u819c\u7684\u6dcb\u5df4\u7624\u60a3\u8005\u3002\u85c9\u7531\u719f\u7df4\u7684\u6cbb\u7642\u6280\u8853\u53ca\u826f\u597d\u4fdd\u8b77\u5177\u9ad8\u653e\u5c04\u7dda\u654f\u611f\u5ea6\u7684\u6c34\u6676\u9ad4\u53ef\u964d\u4f4e\u653e\u5c04\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u3002", "e": "Purpose:To evaluate and discuss the therapeutic results and technique of conjunctival lymphoma. \nMaterials and Methods: This retrospective study was to review the 10 patients with conjunctival lymphoma treated at National Taiwan University Hospital from 1988 to 1996. There were 8 men and 2 women. The range of age was 32 - 75 years old, mean: 59.1 years old. Most of the patients presented with conjunctival mass, reddish eyes and forelgn body sensation. The conjunctival lesions in all patients were treated with a single anterior field which covered the entire conjunctiva, using 3 MeV to 10 MeV electron beam. Total dose of 30 Gy to 50 Gy was delivered in 15 to 25 fractions over 23 to 33 days. In all cases, a specially designed lead shield was used to protect the lens. The follow-up time ranged from 24 months to 124 months.\nResults: All patients were doing well with no sign of active localized or distant disease till the closing date of the study. Moreover, the complications, including decreased visual acuity, cataract and photophobia, were minimal.\nConclusion: Lymphoma clinically localized to conjunctiva as the initial presentation can be cured by radiation therapy with a dosage of 30 Gy to 40 Gy. The complications of radiation therapy can be minimized with sophisticated treatment technique and well protection of the highly radiosensitive lens."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-169-176-a", "title": "\u96fb\u8166\u8f14\u52a9\u8a2d\u8a08\u4e09\u5ea6\u7a7a\u9593\u771f\u5be6\u8868\u9762\u6578\u5b78\u6a21\u5f0f\u65bc\u653e\u5c04\u6cbb\u7642\u5b9a\u4f4d\u5f71\u50cf\u4e4b\u61c9\u7528", "keywords": "\u96fb\u8166\u8f14\u52a9\u8a2d\u8a08,\u6578\u4f4d\u651d\u5f71\u6e2c\u91cf\u6280\u8853,\u653e\u5c04\u6cbb\u7642 Computer Aided Design (CAD),Digital Photogrammetry,Radiation Therapy", "c": "\u76ee\u7684\uff1a\u6574\u5408\u6578\u4f4d\u5316\u5f71\u50cf\u651d\u5f71\u6280\u8853\u53ca\u96fb\u8166\u8f14\u52a9\u8a2d\u8a08(CAD)\u4e09\u5ea6\u7a7a\u9593(3D)\u771f\u5be6\u8868\u9762(Real-world surface)\u6578\u5b78\u6a21\u5f0f\uff0c\u9032\u800c\u767c\u5c55\u4e00\u5be6\u7528\u7684\u91ab\u7528\u96fb\u8166\u4eba\u9ad43D\u771f\u5be6\u8868\u9762\u5f71\u50cf\u7684\u6578\u4f4d\u5316\u53ca\u6210\u5f62\u6280\u8853\uff0c\u4e26\u671f\u671b\u7d93\u7531\u4ecb\u9762\u7684\u6574\u5408\u82073D\u653e\u5c04\u6cbb\u7642\u7cfb\u7d71\u7d50\u5408\uff0c\u4ee5\u6eff\u8db3\u653e\u5c04\u6cbb\u7642\u904e\u7a0b\u4e2d\u5b9a\u4f4d\u5f71\u50cf\u53ca\u5291\u91cf\u8a08\u7b97\u4e4b\u9700\u6c42\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e2d\u5229\u7528\u6578\u4f4d\u651d\u5f71\u6e2c\u91cf\u6280\u8853\u91cf\u6e2c\u76ee\u6a19\u7269\uff0c\u4ee5\u91cd\u758a\u4e4b\u6578\u4f4d\u5f71\u50cf\u69cb\u6210\u7acb\u9ad4\u50cf\u5c0d\uff0c\u914d\u5408\u4e8b\u5148\u8a2d\u8a08\u4e4b\u651d\u5f71\u5e73\u53f0\u8207\u7cbe\u78ba\u91cf\u6e2c\u4e4b\u63a7\u5236\u9ede\u5ea7\u6a19\uff0c\u5efa\u69cb\u5f71\u50cf\u4e4b\u7acb\u9ad4\u6a21\u578b\u3002\n\u7d50\u8ad6\uff1a\u672c\u6b21\u8a66\u9a57\u91cf\u6e2c\u4e4b\u6a21\u5177\u5305\u62ec\u5713\u67f1\u9ad4\u3001\u9577\u65b9\u9ad4\u3001\u4e09\u89d2\u9ad4\u3001\u534a\u5713\u5f62\u67f1\u9ad4\u7b49\uff0c\u91cf\u6e2c\u4e4b\u7d50\u679c\u8207\u5be6\u7269\u91cf\u6e2c\u4e4b\u7d50\u679c\u8aa4\u5dee\u4ecb\u65bc3-8%\u3002\n\u7d50\u8ad6\uff1a\u6578\u4f4d\u5f71\u50cf\u4e4b\u6676\u8cea\u826f\u597d\u8207\u5426\u95dc\u4fc2\u6e2c\u91cf\u7d50\u679c\u4e4b\u7cbe\u5ea6\u751a\u9245\uff0c\u56e0\u6b64\u64f7\u53d6\u5f71\u50cf\u4e4b\u8a2d\u5099\u61c9\u59a5\u5584\u898f\u756b\uff0c\u76f8\u6a5f\u93e1\u982d\u4e4b\u89e3\u50cf\u529b\u3001\u7126\u8ddd\u3001\u651d\u5f71\u5e73\u53f0\u3001\u76f8\u6a5f\u67b6\u8a2d\u3001\u651d\u5f71\u8ddd\u96e2\u3001\u5149\u7dda\u7b49\u5747\u61c9\u8a73\u7d30\u898f\u5283\uff0c\u4ee5\u7372\u5f97\u8f03\u4f73\u4e4b\u651d\u5f71\u7d50\u679c\u3002", "e": "Purpose: The objective of this research is to integrate digital image processing techniques, computer aided design (CAD), and 3-dimension mathematical model to develop a 3-D real-world surface model imaging system for medical applications. \nMaterials and Methods: In this study, digital photogrammetry technique was used to measure target objects. Digital image pairs with appropriate overlap were used to form stereo image pairs. With properly designed photographic platform and precisely measured control points, stereo models can be built from digital images and coordinates of target objects can be measured.\nResults: The results indicate that digital photogrammetry can be used in acquiring information about target objects.\nConclusion: With properly designed photographic equipment and procedure, and appropriate software and hardware facilities, the technique can meet the requirements of various medical applications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-177-185-a", "title": "\u4e0d\u540c\u9aa8\u76c6\u8154\u56fa\u5b9a\u5668\u5728\u651d\u8b77\u817a\u764c\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u8a55\u4f30", "keywords": "\u9aa8\u76c6\u8154\u56fa\u5b9a\u5668,\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6280\u8853,\u64fa\u8a2d\u4f4d\u7f6e\u8aa4\u5dee,\u9a57\u8b49\u7247,\u6a21\u64ec\u5b9a\u4f4d\u7247 Pelvic immobilization devices,Three-dimensional conformal radiotherapy (3D-CRT),Setup error,Portal film,Simulation film", "c": "Purpose: To determine the variability of patient setup errors during three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer treatment without immobilization or with different immobilization devices.\nMaterials and Methods : Forty-eight prostate cancer patients treated with 3D-CRT were prospective evaluated. They were treated by the same physician, technician and  machine. Five groups of patients and technique were compared: (A) supine position without immobilization; (B) prone position without immobilization, but with belly-board; (C) prone position with belly-board and cast immobilization; (D) supine position with alpha cradle from waist to below knee immobilization; (E) supine position with stereotactic body frame immobilization. Serial portal films were recorded and compared with simulation films. The deviation in each axis and rotation angle were compared.\nResults: Group A has the least deviation in X-axis of anterior-posterior view CAP-X; p = 0.044); group B has the least deviation in Z-axis of anterior-posterior view (AP-Z; p = 0.065); group 0 has the least deviation in rotation angle of anterior-posterior view (AP-Ang.; p = 0.067); group E has the least deviation in rotation angle of lateral view (Lat-Ang. ; p = 0.078). There is no significant difference in deviation both in each directions and angles according to body habitus as normal or obese. Heavier weight has less AP-Z and Lat-Z deviation (p = 0.011 and p = 0.108); the deviation of Lat-Z has positive correlation with AP-Z (p \uff1c 0.001), deviation AP-X has positive correlation with deviation Lat-Z and Lat-Ang. (p = 0.037 and p = 0.05 ). For patients with thickness of pelvic circumference (PC-AP) \uff1c 19.0 cm have the least deviation in AP-Z (p = 0.034), Lat-Ang. (p = 0.034) in group B and the least AP-Ang. (p = 0.031) in group D; for patients with width of pelvic circumference (PC-Lat) \uff1c 35.0 cm have the least deviation in AP-X (p = 0.013) in group A, Lat-Z in group C; for patients with body weight \uff1c 67.5 kg have the least deviation in AP-X (p = 0.039) in group A. \nConclusion: Group A has better setup error in AP-X and Lat-Z with statistics significant (p \uff1c 0.05), group B has better setup error in AP-Z; group D and E have better setup error in rotation angle; group C has less setup error in Lat-Y, but without statistical significance. We conclude supine position without immobilization fixation technique seems to be a suitable method for treating patients with localized prostate cancer either in accuracy or conveniency.", "e": "Purpose: To determine the variability of patient setup errors during three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer treatment without immobilization or with different immobilization devices.\nMaterials and Methods : Forty-eight prostate cancer patients treated with 3D-CRT were prospective evaluated. They were treated by the same physician, technician and  machine. Five groups of patients and technique were compared: (A) supine position without immobilization; (B) prone position without immobilization, but with belly-board; (C) prone position with belly-board and cast immobilization; (D) supine position with alpha cradle from waist to below knee immobilization; (E) supine position with stereotactic body frame immobilization. Serial portal films were recorded and compared with simulation films. The deviation in each axis and rotation angle were compared.\nResults: Group A has the least deviation in X-axis of anterior-posterior view CAP-X; p = 0.044); group B has the least deviation in Z-axis of anterior-posterior view (AP-Z; p = 0.065); group 0 has the least deviation in rotation angle of anterior-posterior view (AP-Ang.; p = 0.067); group E has the least deviation in rotation angle of lateral view (Lat-Ang. ; p = 0.078). There is no significant difference in deviation both in each directions and angles according to body habitus as normal or obese. Heavier weight has less AP-Z and Lat-Z deviation (p = 0.011 and p = 0.108); the deviation of Lat-Z has positive correlation with AP-Z (p \uff1c 0.001), deviation AP-X has positive correlation with deviation Lat-Z and Lat-Ang. (p = 0.037 and p = 0.05 ). For patients with thickness of pelvic circumference (PC-AP) \uff1c 19.0 cm have the least deviation in AP-Z (p = 0.034), Lat-Ang. (p = 0.034) in group B and the least AP-Ang. (p = 0.031) in group D; for patients with width of pelvic circumference (PC-Lat) \uff1c 35.0 cm have the least deviation in AP-X (p = 0.013) in group A, Lat-Z in group C; for patients with body weight \uff1c 67.5 kg have the least deviation in AP-X (p = 0.039) in group A. \nConclusion: Group A has better setup error in AP-X and Lat-Z with statistics significant (p \uff1c 0.05), group B has better setup error in AP-Z; group D and E have better setup error in rotation angle; group C has less setup error in Lat-Y, but without statistical significance. We conclude supine position without immobilization fixation technique seems to be a suitable method for treating patients with localized prostate cancer either in accuracy or conveniency."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-187-192-a", "title": "\u5229\u7528\u6c23\u6ce1\u5075\u6aa2\u5668\u91cf\u6e2c\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u5149\u4e2d\u5b50\u7814\u7a76", "keywords": "\u4e2d\u5b50\u7b49\u6548\u5291\u91cf,\u6c23\u6ce1\u5075\u6aa2\u5668 Neutron dose equivalent,Bubble detectors", "c": "\u76ee\u7684\uff1a\u5229\u7528\u6c23\u6ce1\u5075\u6aa2\u5668\u91cf\u6e2cSiemens PRIMUS\u76f4\u7dda\u52a0\u901f\u566815MV\u5149\u5b50\u8207\u4e0d\u540c\u80fd\u91cf\u96fb\u5b50\u4e4b\u4e2d\u5b50\u6c61\u67d3\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4e0d\u540c\u9748\u654f\u5ea6\u7684\u6c23\u6ce1\u5075\u6aa2\u5668\u5206\u5225\u4f48\u9ede\u65bc\u6cbb\u7642\u5ba4\u5167\u75c5\u4eba\u5e73\u9762\u7684\u4f4d\u7f6e\uff0c\u8ddd\u96e2\u7b49\u4e2d\u5fc3\u8655\u4e0d\u540c\u8ddd\u96e2\u3002\u91cf\u6e2c15 MV\u5149\u5b5040\u00d740cm2\u82070\u00d70 cm2\u53ca15\u300118\u820721 MeV\u96fb\u5b5025\u00d725 cm2\u96fb\u5b50\u9310\u7167\u5c04\u4e0b\u6cbb\u7642\u5ba4\u5167\u4e4b\u4e2d\u5b50\u7b49\u6548\u5291\u91cf\u5206\u4f48\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u5ba4\u5167\u4e2d\u5b50\u7b49\u6548\u5291\u91cf\u91cf\u6e2c\u7d50\u679c\u767c\u73fe\u8a72\u91cf\u96a8\u8ddd\u96e2\u7b49\u4e2d\u5fc3\u8d8a\u9060\u800c\u905e\u6e1b\uff0c\u6700\u5927\u503c\u767c\u751f\u5728\u7b49\u4e2d\u5fc3\u8655\uff0c\u5c0d15 MV\u5149\u5b5040\u00d740 cm2\u82070\u00d70 cm2\u5206\u5225\u70ba184.3\u00b19.0\u53ca16.99\u00b15.99 mRem per Gy x-ray\uff0c\u5c0d 15\u300118\u820721 MeV\u96fb\u5b5025 x 25 cm2\u96fb\u5b50\u9310\u7167\u5c04\u4e0b\uff0c\u8a72\u503c\u5206\u5225\u70ba10.00 \u00b12.04\u300126.27 \u00b16.12\u53ca34.90 \u00b12.96 mRem per Gy -electron\u3002\u80fd\u91cf\u5c0f\u65bc12 MeV\u4e4b\u96fb\u5b50\u7684\u4e2d\u5b50\u6c61\u67d3\u5c0f\u65bc\u6c23\u6ce1\u5075\u6aa2\u5668\u4e4b\u5075\u6e2c\u6975\u9650\u3002\n\u7d50\u8ad6\uff1a\u6c23\u6ce1\u5075\u6aa2\u5668\u65bc\u672c\u91cf\u6e2c\u7814\u7a76\u4e2d\u5448\u73fe\u7a69\u5b9a\u3001\u65b9\u4fbf\u8207\u6e96\u78ba\u4e4b\u7279\u6027\uff0c\u9069\u5408\u65bc\u6b64\u91cf\u6e2c\u6240\u9700\u3002\u4e2d\u5b50\u7b49\u6548\u5291\u91cf\u96a8\u8ddd\u96e2\u7b49\u4e2d\u5fc3\u8d8a\u9060\u800c\u905e\u6e1b\uff0c\u4e26\u96a8\u96fb\u5b50\u80fd\u91cf\u589e\u52a0\u800c\u905e\u589e\u3002\u672c\u91cf\u6e2c\u7d50\u679c\u5c1a\u4e0d\u8db3\u505a\u70ba\u75c5\u4eba\u6cbb\u7642\u6642\u4e2d \u5b50\u6c61\u67d3\u8a55\u4f30\u4e4b\u7528\uff0c\u5f8c\u7e8c\u5047\u9ad4\u5167\u4e4b\u91cf\u6e2c\u5de5\u4f5c\u662f\u5fc5\u9808\u7684\u3002", "e": "Purpose: Measuring the photoneutron contamination of 15 MV X-ray and various electrons emitted from Siemens PRIMUS linear accelerator by using bubble detector. \nMaterials and Methods: Various bubble detectors are arranged around the linac head with the interval of 1m and the same height of isocenter to measure the dose equivalent distribution in the treatment room. The measurements were perform for 15 MV x-rays with 40\u00d740 cm2 and 0\u00d70 cm2 fields and for 15, 18, and 21 MeV electrons with 25\u00d725 cm2 electron cone.\nResults: Neutron dose equivalent rate in the points of measurement in the treatment room decreased with increased distance to isocenter. The maximum neutron dose equivalent are at isocenter, and its values for 15 MV 40\u00d740 cm2 and 0\u00d70 cm2 are 184.3\u00b19.0 and 16.99\u00b15.99 mRem per Gy x-ray, respectively. The values for 15, 18 and 21 MeV electrons with 25\u00d725 cm2 cones are 10.00\u00b12.04,26.27\u00b16.12 and 34.90\u00b12.96 mRem per Gy-electron, respectively. The neutron contamination of electron less than 12 MeV is under detection limit.\nConclusion: Bubble detector performs the stable, convenient and accuracy properties in this photoneutron measurement. The neutron dose equivalent decreased with increased distance to isocenter. With electron energy increased, the neutron contamination also increased. Further studies of in-phantom measurements are required for the evaluation of the neutron dose equivalent in the patient."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-193-200-a", "title": "\u653e\u5c04\u6cbb\u7642\u6a5f\u52a0\u503c\u578b\u7db2\u8def\u5291\u91cf\u54c1\u8cea\u4fdd\u8b49\u7cfb\u7d71", "keywords": "\u52a0\u503c\u578b\u7db2\u8def,\u54c1\u8cea\u4fdd\u8b49\u7cfb\u7d71,\u985e\u6c34\u56fa\u614b\u5047\u9ad4 Value-Added Intranet,Quality assurance system,Solid water phantom", "c": "\u76ee\u7684\uff1a\u5efa\u7acb\u5feb\u901f\u6e96\u78ba\u7684\u8f38\u51fa\u6821\u6b63\u6b65\u9a5f\uff0c\u4ee5\u7bc0\u7701\u6642\u9593\u4e26\u78ba\u4fdd\u6cbb\u7642\u6a5f\u7684\u6e96\u78ba\u5ea6\uff0c\u66f4\u9032\u800c\u638c\u63e1\u6574\u9ad4\u6cbb\u7642\u54c1\u8cea\u7684\u7cbe\u6e96\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a1.\u8a2d\u8a08\u4e00\u985e\u6c34\u6e2c\u8a66\u56fa\u614b\u5047\u9ad4\uff0c\u4e26\u4f9d\u64da\u653e\u5c04\u6cbb\u7642\u6a5f\u8f38\u51fa\u80fd\u91cf\u6c7a\u5b9a\u653e\u7f6e\u6e2c\u8a66\u6e38\u96e2\u8154\u7684\u6df1\u5ea6\uff1b\u5b54\u5f91\u5927\u5c0f\u4f9d\u64da\u6e2c\u8a66\u6e38\u96e2\u8154\u7684\u589e\u5efa\u8b77\u5957\u5c3a\u5bf8\u6c7a\u5b9a\uff0c\u5b54\u8207\u5b54\u7684\u4e2d\u5fc3\u8ddd\u96e2\u70ba6 cm\u30022. X\u5149\u80fd\u91cf\u7528\u589e\u5efa\u985e\u6c34\u56fa\u614b\u5047\u9ad4\u5c3a\u5bf8\u5927\u5c0f\u70ba30\u00d730 cm\uff0c\u539a\u5ea6\u70ba5cm\u30012cm\u30011cm\u30010.5 cm\u30010.2 cm\u30010.1 cm\u7b49\u3002\u4f9d\u64da\u6b64\u7c21\u6613\u88dd\u7f6e\u53ef\u57f7\u884c\u591a\u9805\u6e2c\u8a66\u6aa2\u9a57\u5305\u62ec\uff1a\u6bcf\u65e5\u8f3b\u5c04\u5291\u91cf\u8f38\u51fa\u7a69\u5b9a\u5ea6\u6e2c\u8a66\u3001X\u5149\u80fd\u91cf\u7a69\u5b9a\u5ea6\u3001\u5c04\u675f\u5e73\u5766\u6027\u53ca\u5c0d\u7a31\u6027\u3001\u5149\u5b78\u5c3a\u53ca\u5c0f\u7167\u91ce\u6e96\u78ba\u5ea6\u7684\u6aa2\u9a57\uff0c\u4e5f\u53ef\u4f5c\u96f7\u5c04\u5c04\u675f\u6c34\u5e73\u7684\u6821\u6b63\u30023.\u8a2d\u8a08\u4e0a\u8ff0\u6e2c\u8a66\u9805\u76ee\u7684\u986f\u793a\u9801( display form)\u4e26\u64b0\u5beb\u7a0b\u5f0f\u8a9e\u8a00\u3002\n\u7d50\u679c\uff1a\u7a0b\u5f0f\u5df2\u901a\u904e\u6e2c\u8a66\uff0c\u80fd\u9806\u5229\u5c07\u6240\u5f97\u7684\u5404\u9805\u6578\u64da\u8cc7\u6599\uff0c\u7d93\u7531\u7db2\u8def\u50b3\u9001\u81f3\u4e3b\u96fb\u8166\u5132\u5b58\u4e26\u4ee5\u65e5\u3001\u6708\u548c\u5e74\u70ba\u55ae\u4f4d\u532f\u6574\uff1b\u4e26\u914d\u5408\u500b\u4eba\u96fb\u8166\u6574\u5408\u6578\u64da\uff0c\u96c6\u7d50\u5b8c\u6210\u5404\u5f0f\u5831\u8868\uff0c\u9032\u800c\u7e6a\u88fd\u6210\u5716\u8868\uff0c\u85c9\u6b64\u53ef\u5efa\u7acb\u6cbb\u7642\u6a5f\u5b89\u96aa\u54c1\u8cea\u4fdd\u8b49\u53ca\u5b8c\u6574\u8cc7\u6599\u7684\u6027\u80fd\u5206\u6790\u3002\n\u7d50\u8ad6\uff1a\u5728\u5f37\u8abf\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u7684\u540c\u6642\uff0c\u6cbb\u7642\u4e4b\u6a5f\u5668\u54c1\u8cea\u4fdd\u8b49\u7d55\u5c0d\u662f\u6700\u91cd\u8981\u7684\u8ab2\u984c\uff0c\u85c9\u7531\u96fb\u8166\u7db2\u8def\u7684\u50b3\u8f38\u53ef\u5feb\u901f\u4e14\u5b8c\u6574\u7684\u5c0d\u653e\u5c04\u6cbb\u7642\u6a5f\u9054\u5230\u6709\u6548\u76e3\u63a7\u53ca\u6cbb\u7642\u54c1\u8cea\u4e4b\u4fdd\u8b49\u3002", "e": "Purpose: To assure the radiation treatment accuracy, the quality assurance of radiotherapy machines is an important issue. Currently, in VGHTPE Hospital, daily manually calibration and documentation on each radiotherapy machine have been used on quality assurance, which is time consuming while performing data integration and transfermation inter machines. Therefore, we set up an intranet system to perform automatic calibration and integrate database to shorten the processing time of quality assurance meanwhile acquire up dated and complete report after all the procedures have been done.\nMaterials and Methods: 1. Design WebPages in data transfermation and integration, use Microsoft visual basic 6.0 and Borland C++ builder 4.0 to design intranet webpages for treatment machines. There are two modules (therapeutic technique and mechanical quality assurance) installed on each treatment station, and the tolerance tables are well defined. 2. In running the daily calibration, design a virtual water solid phantom (water-equivalent) to acquire the energy distribution and decide the depth of the ion chamber. According to the size of the build up cap of the tested ion chamber to decide the size of the cylinder. The size of build up phantom is 30 cm by 30 cm and the depths are varied. By using these devises, we can run the tests on the daily radiation output stability, x-ray stability, beam flatness and asymmetry, optical range-finder, portal accuracy and laser beam alignment and all the data are recorded. \nResult: Obtaining and transferring all of the data mentioned above from various treatment machines to the main sever, we could integrate data and formulate reports at daily, weekly, monthly and annually bases and further plot histograms according to different requirements. By performing these procedures, we could assure the quality of the treatment machines and build detailed database for property analysis. \nConclusion: While we emphasize the quality assurance of radiotherapy, the quality assurance of treatment machines becomes the most important issue. Therefore, via practically use computer network system in quality assurance of radiotherapy machines is the most effective way to reach the goal of better quality assurance."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-201-205-a", "title": "Primary Central Nervous system Lymphoma - 3 Cases Report", "keywords": "\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624,\u6cbb\u7642 Primary CNS lymphoma,Treatment", "c": "\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u7d04\u4f54\u7bc0\u5916\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u4e4b1-2% \uff1b\u8fd1\u5e74\u4f86\u5831\u544a\u75c5\u4f8b\u6709\u589e\u52a0\u8da8\u52e2\u3002\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u901a\u5e38\u4ee5B\u7d30\u80de\u6dcb\u5df4\u7624\u591a\uff0cCT\u6216MR\u7684\u8868\u73fe\u7279\u5fb5\u5728\u5927\u8166\u534a\u7403\u8166\u5ba4\u65c1\u6210\u55ae\u4e00\u6216\u591a\u767c\u6027\u816b\u584a\u3002\u5176\u6cbb\u7642\u4ee5methotraxate\u70ba\u57fa\u790e\u4e4b\u7d44\u5408\u5f0f\u5316\u5b78\u6cbb\u7642\u4f75\u5168\u816640 Gy - 50 Gy\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u52a0\u4e0a\u816b\u7624\u90e8\u52061400 cGy - 1440 cGy\u52a0\u5f37\uff0c\u7d50\u679c\u53ef\u7372\u5f97\u8f03\u9577\u751f\u5b58\u671f\u3002\u4f46\u665a\u671f\u795e\u7d93\u6bd2\u6027\u75c7\u72c0\u4ea6\u76f8\u5c0d\u589e\u52a0\u3002\u672c\u6587\u63d0\u4f9b\u4e09\u4f8b\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\u4e4b\u8a3a\u65b7\u53ca\u6cbb\u7642\uff0c\u5169\u4f4d\u5973\u6027\uff0c\u4e00\u4f4d\u7537\u6027\u611b\u6ecb\u75c5\u4f75\u767c\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u6dcb\u5df4\u7624\uff0c\u8a3a\u65b7\u53ca\u6cbb\u7642\u6642\u5e74\u9f61\u7686\u4f4e\u65bc50\u6b72\uff0c\u5169\u4f4d\u9810\u5f8c\u8f03\u4f73\u8005\u5206\u5225\u5b58\u6d3b8 \u5e74\u53ca6\u5e74\uff0c\u611b\u6ecb\u75c5\u60a3\u5247\u9810\u5f8c\u4e0d\u4f73\uff0c\u53ea\u751f\u5b588\u500b\u591a\u6708\u3002", "e": "Primary central nervous system lymphoma (PCNSL) comprised 2% of extranodal non-Hodgkin's lymphoma and 1-2% of primary intracranial tumor. The main pathohistologic type was high grade B-cell origin. PCNSL presented multifocal parenchymal lesions or leptomeningeal infiltration in the brain. The incidence increased in the patients associated with immunocompromised condition.\nWe presented 3 cases with pathologically-proved PCNSL, one of whom is a young man with AIDS and the others are female, age below 50. They received chemotherapy and brain irradiation of 5000 - 5440 cGy. The methotrexate-based regimen was the effective chemotherapy. The patient with AIDS died at 8 months after completion of radiotherapyand another 2 were alive for 8 and 6 years respectively until last follow-up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-207-213-a", "title": "Alveolar Soft Part Sarcoma: Clinical Outcome of Two Patients and Review of the Literature", "keywords": "\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624,\u8edf\u7d44\u7e54\u8089\u7624,\u653e\u5c04\u6cbb\u7642 Alveolar soft part sarcoma,Soft tissue tumor,Radiation therapy", "c": "\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624\u70ba\u4e00\u7f55\u898b\u7684\u60e1\u6027\u8edf\u7d44\u7e54\u8089\u7624\uff0c\u597d\u767c\u65bc\u5e74\u8f15\u6210\u4eba\u7684\u4e0b\u80a2\u3002\u6211\u5011\u5831\u5c0e\u5169\u500b\u5178\u578b\u7684\u75c5\u4f8b\u53ca\u56de\u9867\u6587\u737b\u5831\u544a\uff0c\u4e26\u5c0d\u6b64\u75be\u75c5\u7684\u81e8\u5e8a\u8868\u73fe\u53ca\u6cbb\u7642\u9810\u5f8c\u505a\u4e00\u8a0e\u8ad6\u3002\n\u75c5\u60a3\u4e00\u662f33\u6b72\u5973\u6027\uff0c\u767c\u73fe\u5de6\u5927\u817f\u6709\u4e00\u7121\u75db\u816b\u7624\uff0c\u7d93\u624b\u8853\u5207\u9664\u8b49\u5be6\u662f\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624\u5f8c\uff0c\u75c5\u60a3\u63a5\u53d7\u4e86\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u4e94\u5e74\u5f8c\u80f8\u90e8X\u5149\u767c\u73fe\u80ba\u90e8\u6709\u591a\u767c\u6027\u816b\u7624\uff0c\u7d93\u5207\u7247\u8b49\u5be6\u70ba\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624\u8f49\u79fb\uff0c\u4e09\u500b\u6708\u5f8c\u8166\u90e8\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u4e5f\u767c\u73fe\u8f49\u79fb\u816b\u7624\uff0c\u75c5\u4eba\u5728\u5916\u9662\u63a5\u53d7\u52a0\u99ac\u5200\u653e\u5c04\u624b\u8853\uff0c\u516d\u500b\u6708\u5f8c\u56e0\u5fa9\u767c\u53ca\u51fa\u73fe\u65b0\u8f49\u79fb\u75c5\u7076\u800c\u63a5\u53d7\u4e86\u8166\u90e8\u8f49\u79fb\u816b\u7624\u4e4b\u5207\u9664\uff1b\u63a5\u8457\u75c5\u4eba\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c\u516d\u500b\u6708\u5f8c\u7684\u8166\u90e8\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u4ecd\u767c\u73fe\u591a\u767c\u6027\u816b\u7624\uff0c\u75c5\u60a3\u9042\u63a5\u53d7\u5168\u8166\u653e\u5c04\u6cbb\u7642\uff0c\u4f46\u662f\u7121\u6cd5\u63a5\u53d7\u5b8c\u6574\u7684\u7642\u7a0b\u800c\u65bc\u4e00\u500b\u6708\u5f8c\u53bb\u4e16\u3002\u75c5\u60a3\u4e8c\u70ba26\u6b72\u7537\u6027\uff0c\u81e8\u5e8a\u8868\u73fe\u70ba\u4e0b\u80cc\u75db\uff0c\u80f8\u90e8X\u5149\u767c\u73fe\u80ba\u53e4\u5df4\u6709\u591a\u767c\u6027\u816b\u7624\uff0c\u80f8\u8170\u690e\u7684\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u767c\u73fe\u6709\u591a\u8655\u9aa8\u9abc\u75c5\u8b8a\u5408\u4f75\u810a\u9798\u56ca\u58d3\u8feb\uff0c\u7d93\u624b\u8853\u5207\u9664\u5f8c\u8b49\u5be6\u70ba\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624\uff0c\u75c5\u4eba\u4e26\u63a5\u53d7\u80f8\u8170\u690e\u9aa8\u7684\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u986f\u793a\u51fa\u539f\u767c\u9ad4\u7624\u4f4d\u65bc\u75c5\u60a3\u7684\u5de6\u817f\uff0c\u63a5\u4e0b\u4f86\u75c5\u60a3\u96d6\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u4f46\u662f\u7642\u6548\u4e0d\u4f73\uff0c\u65bc\u767c\u75c5\u5f8c\u7b2c\u5341\u4e94\u500b\u6708\u53bb\u4e16\u3002\n\u80ba\u6ce1\u72c0\u8edf\u7d44\u7e54\u8089\u7624\u6975\u6613\u65bc\u75be\u75c5\u7684\u65e9\u671f\u6216\u665a\u671f\u51fa\u73fe\u9060\u7aef\u8f49\u79fb\uff0c\u624b\u8853\u5207\u9664\u70ba\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u63d0\u9ad8\u75be\u75c5\u7684\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u4e5f\u662f\u5728\u75be\u75c5\u51fa\u73fe\u8f49\u79fb\u6642\u53ef\u9054\u5230\u5c40\u90e8\u75c7\u72c0\u7de9\u89e3\u7684\u6709\u6548\u59d1\u606f\u7642\u6cd5\u3002", "e": "Alveolar soft part sarcoma (ASPS) is a very rare soft tissue tumor which usually occurs in the lower extremity of young adults. We described two cases of ASPS in terms of natural history and clinical outcome.\nThe first case was a female patient who noticed a painless swelling in her left thigh at the age of 33. She underwent total removal of the tumor followed by post-operative radiation therapy for 50 Gy in 25 fractions. The diagnosis was ASPS. Five years after surgery, CXR showed multiple nodules which were proved to be metastasis by open lung biopsy. Brain metastasis developed three months later and was irradiated by Gamma-knife. Six months after radiosurgery for metastatic brain lesion, the patient underwent surgical excision for recurrent and newly developed metastatic brain lesions, followed by chemotherapy with Epirubicin, Ifosfamide and Mesna. Follow-up brain CT scan 6 months later revealed multiple nodules. The patient received radiation therapy to the whole brain but could not complete the course. She died of lung and brain metastases one month later. The second case was a 26-yearold man presented with low back pain. MRI of T-L spine revealed multiple lesions in the vertebral bodies with thecal sac compression at T11. ASPS was confirmed by a surgical decompression with partial removal of the extradural tumor. Routine CXR revealed multiple lung nodules. A meticulous clinical search led to find the primary tumor located at lateral aspect of the left thigh. He underwent T-L spine irradiation for 40.5 Gy in 17 fractions and systemic chemotherapy with Epirubicin and Cyclophosphamide for 3 months. However, no response was shown. The patient died of the disease 15 months after diagnosis. \nASPS tends to metastasize both early and late. Surgical excision is the mainstay of therapy. Radiation therapy may enhance local control after surgery or provide meaningful palliation for metastasis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200009-7-3-215-220-a", "title": "Radiotherapy is Effective in the Treatment of Hepatocellular Carcinoma with Right Atrium Invasion - Report of A Case", "keywords": "\u809d\u7d30\u80de\u764c,\u53f3\u5fc3\u623f,\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u7642 Hepatocellular carcinoma,Right atrium,Three-dimensional conformal radiotherapy", "c": "\u809d\u7d30\u80de\u764c\u662f\u6771\u4e9e\u5e38\u898b\u7684\u764c\u75c7\u4e4b\u4e00\uff0c\u5177\u6709\u8840\u7ba1\u4fb5\u72af\u7684\u7279\u6027\uff0c\u4e3b\u8981\u662f\u4fb5\u72af\u809d\u9580\u8108\u7cfb\u7d71\u3002\u7136\u800c\uff0c\u6975\u5c11\u6578\u7684\u60c5\u6cc1\u4e0b\uff0c\u809d\u7d30\u80de\u764c\u4e5f\u53ef\u80fd\u85c9\u7531\u4fb5\u72af\u809d\u975c\u8108\u800c\u8f49\u79fb\u81f3\u53f3\u5fc3\u623f\uff0c\u901a\u5e38\u9019\u985e\u75c5\u4eba\u7684\u9810\u5f8c\u90fd\u975e\u5e38\u5dee\u3002\u624b\u8853\u5207\u9664\u5fc3\u623f\u5167\u816b\u7624\u662f\u9019\u985e\u75c5\u4eba\u7684\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u5c0d\u9019\u985e\u75c5\u4eba\u7684\u75c5\u6cc1\u800c\u8a00\uff0c\u901a\u5e38\u9019\u6a23\u7684\u6cbb\u7642\u537b\u53c8\u592a\u904e\u4fb5\u8972\u6027\u3002\u672c\u6587\u5831\u544a\u4e00\u540d58\u6b72\u7684\u809d\u7d30\u80de\u764c\u75c5\u4eba\uff0c\u5176\u816b\u7624\u5177\u6709\u809d\u975c\u8108\u3001\u4e0d\u8154\u975c\u8108\u53ca\u53f3\u5fc3\u623f\u4fb5\u72af\u7684\u73fe\u8c61\uff0c\u56e0\u4e0d\u9069\u65bc\u63a5\u53d7\u5176\u4ed6\u8f03\u5177\u4fb5\u5165\u6027\u4e4b\u6cbb\u7642\uff0c\u56e0\u6b64\u5b89\u6392\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642(\u517160 Gy \uff0c\u520633\u6b21\u7167\u5c04) \uff0c\u53ca\u4e00\u500b\u7642\u7a0b\u7684\u809d\u52d5\u8108\u5167\u5316\u5b78\u6cbb\u7642( cisplatin 65 mg/m2\u9023\u7e8c\u6ef4\u6ce8 6\u5c0f\u6642\u4e4b\u5f8c\u63a5\u84575-fluorouracil 2200 mg/m2\u9023\u7e8c\u6ef4\u6ce824\u5c0f\u6642)\u3002\u8840\u6e05\u4e2d\u7532\u7a2e\u80ce\u5152\u86cb\u767d\u6307\u6578\u986f\u8457\u964d\u4f4e\uff0c\u540c\u6642\u4f34\u96a8\u8457\u5fc3\u623f\u5167\u816b\u7624\u7e2e\u5c0f\u3002\u6b64\u75c5\u4eba\u81ea\u8a3a\u65b7\u8d77\u5b58\u6d3b\u8d85\u904e15\u500b\u6708\u3002\u5c31\u6b64\u75c5\u4f8b\u7684\u89c0\u5bdf\uff0c\u543e\u4eba\u53ef\u4ee5\u8aaa\uff0c\u5c0d\u65bc\u4f75\u6709\u53f3\u5fc3\u623f\u8f49\u79fb\u7684\u809d\u7d30\u80de\u764c\u75c5\u4eba\uff0c\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u52a0\u4e0a\u5316\u5b78\u6cbb\u7642\u6216\u53ef\u4ee5\u4f5c\u70ba\u4e0d\u9069\u65bc\u624b\u8853\u7684\u75c5\u4eba\u53e6\u4e00\u7a2e\u66ff\u4ee3\u7642\u6cd5\u3002", "e": "Hepatocellular carcinoma (HCC) is a common malignant neoplasm in East Asia. HCC has the tendency to invade vessels, mainly the portal venous system. Right atrium metastasis through venous invasion is a rare condition with grave prognosis. Surgical resection of intra-atrial tumors is technically difficult and it is too invasive for the seriously ill patients. Here, we present a 58-year-old male patient of HCC with hepatic veins, inferior vena cava, and right atrium invasion, who received well-designed three-dimensional conformal radiotherapy (totally 60 Gy 33 fractions), followed by one course of intra-arterial chemotherapy with cisplatin (65 mg/m2 infusion for 6 hours) and 5-fluorouracil (2,200 mg/m2 infusion for 24 hours). Serum alpha-fetoprotein was markedly decreased, and size of tumor thrombus was shrinkage. This patient survived for 15 more months. Therefore, for HCC patients with right atrium metastasis, three-dimensional conformal radiotherapy plus chemotherapy may be an effective salvage treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-77-87-a", "title": "Junction Techniques for Pharynx and Neck Treatment", "keywords": "\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853,\u4ea4\u63a5\u79fb\u52d5\u6280\u8853,\u586b\u5145\u7269 Monoisocentric technique,Moving junction technique,Bolus", "c": "\u76ee\u7684\uff1a\u6e2c\u91cf\u8207\u6bd4\u8f03\u7167\u91ce\u4ea4\u63a5\u6280\u8853(field junction)\u5728\u982d\u9838\u90e8\u816b\u7624\u4f75\u5de8\u5927\u9838\u90e8\u6dcb\u5df4\u7d50\u7684\u61c9\u7528\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u53d6\u5047\u9ad4(Alderson Rando phanton)\u4f5c\u6a21\u64ec\u651d\u5f71\u8a02\u5b9a\u51fa\u7167\u91ce\u7684\u4e2d\u5fc3\u548c\u7bc4\u570d\uff0c\u4e26\u4f5c\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u53d6\u5f97\u5047\u9ad4\u5f71\u50cf\u3002\u672c\u5be6\u9a57\u6240\u8981\u63a2\u8a0e\u7684\u662f\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853(monoisocentric technique)\u548c\u4ea4\u63a5\u79fb\u52d5\u6280\u8853(moving junction technique)\uff0c\u4e26\u914d\u5408\u4e0a\u5169\u7a2e\u4e0d\u540c\u7684\u9838\u90e8\u7279\u88fd\u586b\u5145\u7269(bolus)\u3002\u4e00\u865f\u586b\u5145\u7269\u53ea\u7528\u4f86\u8abf\u6574\u524d\u5f8c\u5f91\u5dee\u5225\uff0c\u800c\u4e8c\u865f\u586b\u5145\u7269\u662f\u7528\u4f86\u8abf\u6574\u524d\u5f8c\u5f91\u53ca\u5169\u5074\u5f91\u5dee\u5225\u7684\u7279\u88fd\u586b\u5145\u7269\u3002\u7528\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853\u6216\u4ea4\u63a5\u79fb\u52d5\u6280\u8853\u518d\u914d\u5408\u4e0a\u6709\u7121\u586b\u5145\u7269\uff0c\u6240\u4ee5\u5171\u6709\u516d\u7a2e\u7684\u4e0d\u540c\u7684\u7d44\u5408\u3002\u9996\u5148\u7528\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71(ADAC computer treatment planning system)\uff0c\u6a21\u64ec\u5404\u7a2e\u4e0d\u540c\u6cbb\u7642\u65b9\u5f0f\uff0c\u53bb\u8a08\u7b97\u51fa\u5404\u7a2e\u6cbb\u7642\u65b9\u5f0f\u7684\u5291\u91cf\u5206\u4f48\u66f2\u7dda\uff0c\u4ee5\u4f5c\u70ba\u8a55\u4f30\u64fa\u653e\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD)\u7684\u8003\u91cf\u3002\u7136\u5f8c\uff0c\u5be6\u5730\u6a21\u64ec\u5404\u7a2e\u5be6\u969b\u6cbb\u7642\u60c5\u6cc1\u53bb\u7167\u5c04\u5167\u542b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u7684\u5be6\u9a57\u5047\u9ad4\u5404\u4e09\u6b21\uff0c\u4ee5\u7372\u5f97\u8f03\u63a5\u8fd1\u5be6\u969b\u6cbb\u7642\u6240\u5f97\u5230\u7684\u5438\u6536\u5291\u91cf\u7684\u5e73\u5747\u503c\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u6821\u6b63\uff0c\u6240\u6709\u71b1\u767c\u5149\u8a08\u91cf\u5291\u7684\u8aa4\u5dee\u7686\u57283%\u4ee5\u5167\u3002\u4e0d\u8ad6\u662f\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853\u6216\u4ea4\u63a5\u79fb\u52d5\u6295\u8853\uff0c\u53ea\u8981\u914d\u5408\u4e0a\u9838\u90e8\u7279\u88fd\u586b\u5145\u7269\u90fd\u53ef\u7372\u5f97\u5747\u52fb\u7684\u5291\u91cf\u5206\u4f48\u3002\u4f46\u662f\u5982\u679c\u6c92\u6709\u914d\u5408\u9838\u90e8\u7279\u88fd\u586b\u5145\u7269\u7684\u8a71\uff0c\u8f03\u8584\u7684\u9838\u90e8\u6703\u7522\u751f\u4e0d\u53ef\u63a5\u53d7\u7684\u9ad8\u5291\u91cf\u5340\u3002\u7136\u800c\u4e0d\u53ef\u907f\u514d\u7684\uff0c\u9084\u662f\u6709\u5c11\u6578\u5340\u57df\u6703\u6709\u5291\u91cf\u5206\u4f48\u4e0d\u5747\u7684\u73fe\u8c61\uff0c\u5982\u9ad8\u5291\u91cf\u5340\u843d\u5728\u524d\u9838\u6dfa\u8655\u53ca\u5074\u9838\u90e8\uff0c\u4f4e\u5291\u91cf\u5340\u843d\u5728\u5f8c\u9838\u90e8\u3002\u4e0d\u904e\u4f3c\u4e4e\u9084\u662f\u4ee5\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853'\u914d\u5408\u4e0a\u4e8c\u865f\u7279\u88fd\u586b\u5145\u7269\uff0c\u80fd\u7522\u751f\u6700\u7406\u60f3\u7684\u5291\u91cf\u5206\u4f48\u3002\u56de\u982d\u6bd4\u8f03\u7528TLD\u5be6\u969b\u6e2c\u91cf\u51fa\u4f86\u548c\u96fb\u8166\u6240\u9810\u6e2c\u51fa\u4f86\u7684\u503c\uff0c\u767c\u73fe\u5927\u90e8\u4efd\u7684\u8aa4\u5dee\u4e0d\u6703\u8d85\u904e\u7684\uff0c\u7136\u800c\u5728\u67d0\u4e9b\u5730\u65b9\uff0c\u5c24\u5176\u5728\u7167\u91ce\u7bc4\u5468\u908a\u7de3(-19~-22%)\uff0c\u7167\u91ce\u4ea4\u63a5\u8655(\u00b19%)\u53ca\u8868\u6dfa\u8655(-5~-7%)\u3002\n\u7d50\u8ad6\uff1a\u55ae\u4e00\u4e2d\u5fc3\u7167\u91ce\u6280\u8853\u6216\u4ea4\u63a5\u79fb\u52d5\u6280\u8853\uff0c\u914d\u5408\u4e0a\u826f\u597d\u7684\u9838\u90e8\u7279\u88fd\u586b\u5145\u7269\uff0c\u53ef\u61c9\u7528\u65bc\u81e8\u5e8a\u5be6\u969b\u6cbb\u7642\u982d\u9838\u90e8\u816b\u7624\u4f75\u5de8\u5927\u9838\u90e8\u6dcb\u5df4\u7d50\u7684\u75c5\u4eba\uff0c\u65e2\u7c21\u55ae\u65b9\u4fbf\uff0c\u53c8\u6709\u5747\u53e5\u7684\u5291\u91cf\u5206\u4f48\u3002\u81f3\u65bc\u6700\u9069\u5408\u7684\u7136\u800c\uff0c\u8981\u914d\u5408\u4e0a\u826f\u597d\u7684\u9838\u90e8\u7279\u88fd\u586b\u5145\u7269\uff0c\u624d\u80fd\u4f7f\u5291\u91cf\u5206\u5e03\u66f4\u70ba\u5747\u52fb\u3002", "e": "Purpose: To probe into junction fields techniques of radiotherapy in head and neck cancer patients who need radical radiotherapy to whole pharyngeal wall and whole neck lymphatics.\nMaterial and Methods : We get a simulation film and CT scan image of an Alderson Rando phantom for defining field size and lsocenter, and for computer planning system In this study, we showed dose distribution data of monoisocentric technique and moving junction technique with or without bolus. Two different bolus were used: bolus 1 emphasized only AP depth, bolus 2 emphasized both AP and bilateral depth. So there were six various combinations by either monoisocentric or moving junction with or without bolus. First, isodose distribution by computer planning system was generated to decide where to place TLDs. The average radiation dose in different techniques were obtained by irradiating the phantom packed with TLDs.\nResults: Both monoisocentric techniques and moving junction techniques with adequate bolus could generate homogenous dose distributions. But if there were no bolus, there was hot area over neck. However there were still uneven dose distribution areas, such as hot areas in anterior superficial neck and lateral neck; cold areas in posterior lower neck. In comparison, monoisocentric technique with bolus 2 tended to create better dose distribution. After comparing data from TLDs and computer planning system, we found most differences were within 4%. However, inconsistency still existed in some locations such as field margins (underestimate 19-22%); junction areas (over/underestimate 9%); superficial areas (underestimate 5-7%).\nConclusion: Both monoisocentric techniques and moving junction techniques combined with well-designed bolus can be satisfactorily applied in treating head and neck cancer patients with huge neck lymphadenopathy. There are not only good reproducibili\ufe52 ty but also good homogeneity. How to choose the optimal technique depends on patients' clinical status and individual hospital equipments. We suggest that the monoisocentric technique is a more convenient technique in junction fields. However, an well designed bolus is also very important to get a good dose distribution."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-89-97-a", "title": "\u6cbb\u7642\u7528\u96fb\u5b50\u5c04\u675f\u5728\u5747\u52fb\u7269\u8cea\u4e2d\u80fd\u91cf\u640d\u5931\u7684\u6578\u503c\u65b9\u6cd5\u6a21\u64ec", "keywords": "\u6578\u503c\u65b9\u6cd5,\u5291\u91cf\u8a08\u7b97,\u7b49\u6a5f\u7387\u5206\u6016 Numerical algorithm,Dose calculation,Equal probability", "c": "\u76ee\u7684\uff1aMcLellan\u65bc1992\u5e74\u767c\u8868\u4e86\u96fb\u5b50\u5291\u91cf\u8a08\u7b97\u7684\u6578\u503c\u6f14\u7b97\u65b9\u6cd5\uff0c\u5728\u6578\u503c\u6a21\u64ec\u65b9\u6cd5\u4e0a\u63a1\u7528\u7b49\u7a7a\u9593\u53d6\u6a23\u6cd5(equal spacing)\u505a\u6a5f\u7387\u5206\u6016\u7684\u53d6\u6a23\uff0c\u5176\u7f3a\u9ede\u662f\u5728\u8a08\u7b97\u6642\u975e\u5e38\u8017\u6642\u3002\u672c\u7814\u7a76\u4e2d\u5728\u6578\u503c\u65b9\u6cd5\u4e0a\u63a1\u7528\u4e00\u500b\u7a31\u505a\u7b49\u6a5f\u7387\u5206\u4f48(equal probability)\u7684\u65b9\u6cd5\uff0c\u671f\u671b\u80fd\u6e1b\u5c11\u53d6\u6a23\u6578\u76ee\u4e26\u7dad\u6301\u540c\u6a23\u7684\u8a08\u7b97\u6e96\u78ba\u5ea6\u3002\u5728\u9019\u7bc7\u5831\u544a\u4e2d\uff0c\u6211\u5011\u5c07\u9a57\u8b49\u6b64\u6578\u503c\u7a0b\u5f0f\u65bc\u80fd\u91cf\u640d\u5931\u6a21\u64ec\u65b9\u9762\u7684\u6e96\u78ba\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u65b0\u7684\u6578\u503c\u8a08\u7b97\u7a0b\u5f0f\u63a1\u7528Moliere\u7684\u7406\u8ad6\u4f86\u6a21\u64ec\u50b3\u64ad\u904e\u7a0b\u4e2d\u96fb\u5b50\u7684\u89d2\u5ea6\u6563\u5c04\u6a5f\u7387\u5206\u4f48'\u80fd\u91cf\u640d\u5931\u5206\u4f48\u5247\u662f\u4ee5Landau\u7684\u6e38\u96e2\u80fd\u91cf\u640d\u5931\u7406\u8ad6\u4f86\u8655\u7406\u3002\u7531\u5236\u52d5\u807d\u5c04\u6240\u9020\u6210\u7684\u80fd\u91cf\u640d\u5931\u5247\u66ab\u672a\u5305\u542b\u5728\u672c\u7814\u7a76\u4e2d\u3002\u672c\u5831\u544a\u91dd\u5c0d20MeV\u300110MeV\u4ee5\u53ca6MeV\u7684\u55ae\u80fd\u96fb\u5b50\u5c04\u675f\u5728\u7c21\u5316\u7684\u4e00\u5ea6\u7a7a\u9593\u689d\u4ef6\u4e0b(\u672a\u5305\u542b\u89d2\u5ea6\u6563\u5c04)\uff0c\u9032\u884c\u6c34\u4e2d\u7684\u78b0\u649e\u8cea\u91cf\u963b\u64cb\u672c\u9818\u8a08\u7b97\u3001\u4e26\u5728\u76f8\u540c\u689d\u4ef6\u4e0b\u6a21\u64ec\u96fb\u5b50\u65bc\u6c34\u4e2d\u7684\u50b3\u64ad\u904e\u7a0b\u3002\u70ba\u9a57\u8b49\u6578\u503c\u8a08\u7b97\u7a0b\u5f0f\u7684\u6b63\u78ba\u6027\uff0c\u6211\u5011\u63a1\u7528EGS4\u8499\u5730\u5361\u7f85\u7a0b\u5f0f\u4f5c\u70ba\u8a08\u7b97\u9a57\u8b49\u7684\u5de5\u5177\u3002\n\u7d50\u679c\uff1a\u5728\u672a\u5305\u542b\u89d2\u5ea6\u6563\u5c04\u7684\u689d\u4ef6\u4e0b\uff0c\u6578\u503c\u7a0b\u5f0f\u6240\u8a08\u7b97\u7684\u78b0\u649e\u8cea\u91cf\u963b\u64cb\u672c\u9818\u8207ICRU\u63d0\u4f9b\u7684\u8cc7\u6599\u6bd4\u8f03\uff0c\u5176\u8aa4\u5dee\u65bc\u9ad8\u4f4d\u91cf(20MeV\u300110MeV)\u4e0b\u5c0f\u65bc2%\uff1b\u4f4e\u80fd\u91cf(6MeV)\u4e0b\u5247\u7d04\u57283%\u5de6\u53f3\u3002\u800c\u61c9\u7528\u65bc\u7d55\u5c0d\u6df1\u5ea6\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u8a08\u7b97\u4e2d\uff0c50%\u5291\u91cf\u6df1\u5ea6\u8aa4\u5dee\u5411\u57283mm\u4ee5\u5167\uff1b\u7c92\u5b50\u5c04\u7a0b(practical range)\u8aa4\u5dee\u5247\u5747\u57282mm\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u8b49\u5be6landau\u7684\u7406\u8ad6\u53ef\u4ee5\u6e96\u78ba\u7684\u6a21\u64ec\u96fb\u5b50\u5728\u6c34\u4e2d\u7684\u6e38\u96e2\u80fd\u91cf\u640d\u5931\uff0c\u4e14\u7b49\u6a5f\u7387\u53d6\u6a23\u65b9\u6cd5\u4e26\u4e0d\u6703\u5728\u5291\u91cf\u8a08\u7b97\u4e0a\u7522\u751f\u592a\u5927\u7684\u8aa4\u5dee\u3002", "e": "Purpose: A numerical electron dose calculation algorithm was introduced in 1992 by McLellan who used equal space sampling method to simulate electron energy loss and angular scattering distribution. The drawback of this numerical algorithm was its long calculation time. In our study, an equal probability sampling method was adopted in hope that less sampling points were necessary while the same calculation accuracy can still be maintained. Calculation results for electron energy loss process in homogeneous media were reported.\nMaterial and Methods: The multiple scattering theory of Moliere was used in the modified numerical algorithm to simulate electron angular scattering; while Landau's ionizational energy loss theory was used to simulate electron energy loss process. At present, energy loss due to bremsstrahlung production was not included in the algorithm. Test calculation of collisional stopping power for 20, 10 and 6 MeV electrons incident into water under simplified condition (excluding electron multiple scattering) was performed. The energy loss process for the same setup was also simulated. In order to verify the calculation accuracy of the numerical code, EGS4 Monte Carlo code was adopted to perform benchmark calculation.\nResults: When excluding electron multiple scattering, the calculation of collisional stopping power shows discrepancy of less than 2% between numerical calculation and ICRU reports for high energy electrons (20 and 10 MeV). For low electrons (6 MeV), this discrepancy is close to 3%. The calculation esults of absolute depth-dose distribution demonstrate that the calculated depths of 50% dose agree with EGS4 to within 3 mm and the calculated electron ranges to within 2 mm.\nConclusion: Landau's theory is suitable for simulating electron ionizational energy loss in homogeneous media and the error due to equal probability sampling of electron energy loss distribution is acceptable."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-99-107-a", "title": "\u4f7f\u7528\u8499\u5730\u5361\u7f85\u6cd5EGS4\u7a0b\u5f0f\u8a08\u7b97\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668\u5167\u92a5-192\u5c04\u6e90\u5468\u570d\u4e09\u7dad\u5291\u91cf\u5206\u4f48\u8207\u5efa\u7acb\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u96db\u5f62", "keywords": "\u8499\u5730\u5361\u7f85\u6cd5,\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668,\u92a5-192 Monte Carlo method,EGS4,Shielded cylindrical applicator,Iridium-192,lDLTM", "c": "\u76ee\u7684\uff1a\u5229\u7528\u8499\u5730\u5361\u7f85\u6cd5EGS4\u7a0b\u5f0f\u8655\u7406\u4e09\u7dad\u4e14\u5177\u975e\u5747\u8cea\u4ecb\u8cea\u554f\u984c\u4e4b\u5f37\u5927\u80fd\u529b\uff0c\u5efa\u7acb\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668\u5167\u92a5-192\u5c04\u6e90\u4e4b\u4e09\u5ea6\u7a7a\u9593\u5291\u91cf\u8a55\u4f30\u6a21\u5f0f\uff0c\u4e26\u5617\u8a66\u4ee5\u8499\u5730\u5361\u7f85\u6cd5\u65bc\u9810\u6e2c\u5be6\u969b\u81e8\u5e8a\u61c9\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528EGS4\u7a0b\u5f0f\u5efa\u7acb\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668\u5167\u92a5-192\u5c04\u6e90\u4e09\u7dad\u5291\u91cf\u5206\u6790\u8a55\u4f30\u6a21\u5f0f\uff0c\u4e26\u8207\u4ee5\u5f80\u7814\u7a76\u4ee5\u53ca\u76ee\u524d\u6240\u63a1\u7528\u4e4b\u6cbb\u7642\u8a08\u756b\u8a55\u4f30\u7d50\u679c\u9032\u884c\u6bd4\u8f03\u9a57\u8b49\u3002\u9032\u4e00\u6b65\u91dd\u5c0d\u5404\u7a2e\u5c04\u6e90\u5f37\u5ea6\u3001\u4f4d\u7f6e\u3001\u8207\u906e\u853d\u60c5\u5f62\u7d44\u5408\u9032\u884c\u8a08\u7b97\uff0c\u4e26\u5c07\u7d50\u679c\u5132\u5b58\u5efa\u7acb\u8cc7\u6599\u5eab\u3002\u4f7f\u7528IDLTM\u7a0b\u5f0f\u8a9e\u8a00(Interactive Data Language)\u64b0\u5beb\u8cc7\u6599\u5eab\u4eba\u6a5f\u754c\u9762\uff0c\u5efa\u7acb\u4f7f\u7528\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668\u8fd1\u63a5\u6cbb\u7642\u4e4b\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u96db\u5f62\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u4e2d\u5efa\u7acb\u4e4b\u4e09\u7dad\u5291\u91cf\u8a55\u4f30\u6a21\u5f0f\u8207\u4ee5\u5f80\u63a1\u7528\u6e38\u96e2\u8154\u5be6\u9a57\u7d50\u679c\u6bd4\u5c0d\u986f\u793a\u543b\u5408\u826f\u597d\uff0c\u800c\u8207\u76ee \u524d\u6240\u63a1\u7528\u4e4b\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8a08\u7b97\u7d50\u679c\u6bd4\u5c0d\uff0c\u986f\u793a\u7121\u906e\u853d\u60c5\u5f62\u6642\uff0c\u5728\u5f91\u5411\u65b9\u5411\u7684\u7d66\u4e88\u5291\u91cf\u7d50\u679c\u543b\u5408\u826f\u597d\uff0c\u800c\u9760\u8fd1\u8ef8\u5411\u7684\u90e8\u5206\u5247\u6709\u5dee\u7570\u3002\u6b64\u5dee\u7570\u4e3b\u8981\u4f86\u81ea\u76ee\u524d\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5ffd\u7565\u906e\u853d\u5f0f\u5713\u7b52\u72c0\u5c04\u6e90\u7f6e\u5165\u5668\u4e2d\u975e\u5747\u8cea\u6548\u61c9\uff0c\u5982\u92a5-192\u5c04\u6e90\u5305\u5c01\u6750\u8cea\u4ee5\u53ca\u5c04\u6e90\u901a\u9053\u7b49\u6240\u9020\u6210\u3002\n\u8a0e\u8ad6\uff1a\u63a1\u53d6\u9810\u5148\u8a08\u7b97\u5404\u7a2e\u5c04\u6e90\u8207\u906e\u853d\u60c5\u5f62\u7d44\u5408\u4e26\u5efa\u7acb\u8cc7\u6599\u5eab\u7684\u65b9\u6cd5\uff0c\u900f\u904e\u4eba\u6a5f\u754c\u9762\u53ef\u4ee5\u5728\u5e7e\u79d2\u9418 \u5167\u7372\u5f97\u8499\u5730\u5361\u7f85\u6cd5\u8a08\u7b97\u7d50\u679c\uff0c\u4e26\u53ef\u4ee5\u4e00\u3001\u4e8c\u3001\u4e09\u7dad\u7684\u5404\u7a2e\u5713\u5f62\u986f\u793a\u8a08\u7b97\u7d50\u679c\uff0c\u5982\u6b64\u53ef\u514b\u670d\u8499\u5730\u5361 \u7f85\u6cd5\u8a08\u7b97\u8017\u6642\u7684\u7f3a\u9ede\uff0c\u800c\u5c07\u5617\u8a66\u4ee5\u8499\u5730\u5361\u7f85\u6cd5\u65bc\u9810\u6e2c\u5be6\u969b\u81e8\u5e8a\u61c9\u7528\u4e4b\u8a08\u7b97\u7d50\u679c\u3002", "e": "Purpose: The purpose of this work is to apply EGS4 code to calculate the 3D spatial dose distribution around a shielded cylindrical applicator set and propose a way to implement the results based on Monte Carlo method into clinical applications. \nMaterials and Methods : The simulation model of 3D spatial dose distribution was established by using EGS4 code and was compared with the results measured in our previous study and evaluated by existing commercial treatment planning system. Furthermore, the dose distributions for unit intensity lr-l92 source of each probable combination of source and shielding situations were pre-calculated and sayed as a database. A graphical user interface for accessing this database was developed by using IDLTM (Interactive Data Language).\nResults: The results calculated by the 3D-simulation model established in this work show good agreement with the results measured in our previous study. The comparison of the existing commercial treatment planning system also show good agreement at prescribed dose in radial direction, but same discrepancy in Source axis. This discrepancy is due to the commercial treatment planning system that neglected the heterogeneity effect, such as the encapsulated material of source and the guide tube.\nDiscussions: Through the interactive graphical user interface to access the database pre-calculated by EGS4, users could generate and display the dose distribution around the shielded cylindrical applicator set with Ir-192 source under any probable combination of source and shielding situations in 1, 2, or 3D plot. It seems to be a prototype of our treatment planning system based on Monte Carlo method for the shielded cylindrical applicator set."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-109-112-a", "title": "Extraskeletal Osteosarcoma: A Case Report", "keywords": "\u9aa8\u9abc\u5916\u9aa8\u8089\u7624,\u653e\u5c04\u6cbb\u7642,\u5316\u5b78\u6cbb\u7642 Extraskeletal osteosarcoma (ESOS),Radiotherapy,Chemotherapy", "c": "\u9aa8\u9abc\u5916\u9aa8\u8089\u7624( extraskeletal osteosarcoma, ESOS )\u662f\u4e00\u7a2e\u7f55\u898b\u7684\u60e1\u6027\u9593\u8cea\u816b\u7624\uff0c\u5927\u7d04\u4f54\u6240\u6709\u8edf\u7d44\u7e54\u8089\u76241%\u3002\u4e0d\u540c\u65bc\u751f\u9577\u81ea\u9aa8\u9abc\u7684\u9aa8\u8089\u7624\uff0c\u9aa8\u9abc\u5916\u9aa8\u8089\u7624\u4e00\u822c\u8f03\u5c11\u4fb5\u72af\u5341\u5e7e\u6b72\u7684\u5e74\u8f15\u4eba\uff0c\u53cd\u800c\u662f\u4ee5\u56db\u4e94\u5341\u6b72\u7684\u6210\u5e74\u60a3\u8005\u5c45\u591a\u3002\u591a\u6578\u5831\u544a\u4e2d\u986f\u793a\u7537\u6027\u60a3\u8005\u6bd4\u4f8b\u7565\u9ad8\u65bc\u5973\u6027\u60a3\u8005\u3002\u5148\u524d\u5728\u767c\u75c5\u90e8\u4f4d\u6709\u904e\u53d7\u50b7\u53ca\u63a5\u53d7\u904e\u8f3b\u5c04\u7dda\u66b4\u9732\u7684\u7d93\u9a57\u53ef\u80fd\u662f\u6210\u56e0\u4e4b\u4e00\u3002\u5927\u817f\u53ca\u81c0\u90e8\u662f\u70ba\u6700\u6613\u88ab\u4fb5\u72af\u7684\u90e8\u4f4d\u3002\u5e7e\u4e4e\u6240\u6709\u9019\u985e\u816b\u7624\u90fd\u662f\u5c6c\u65bc\u9ad8\u5ea6\u60e1\u6027\u5316\u4e4b\u816b\u7624\u3002\u4e00\u822c\u800c\u8a00\uff0c\u9aa8\u9abc\u5916\u9aa8\u8089\u7624\u7684\u9810\u5f8c\u4e26\u4e0d\u597d\u3002\u6cbb\u7642\u5931\u6557\u7684\u539f\u56e0\u4e0d\u5728\u65bc\u534a\u6578\u7684\u75c5\u60a3\u6703\u5c40\u90e8\u8907\u767c\uff0c\u800c\u5728\u65bc\u767c\u751f\u7387\u66f4\u9ad8\u7684\u9084\u7aef\u8f49\u79fb\uff0c\u5c24\u5176\u662f\u80ba\u90e8\u8f49\u79fb(\u5927\u65bc80%)\u3002\u6b7b\u4ea1\u7387\u4ecb\u65bc55.4%\u81f381%\u4e4b\u9593\uff0c\u4e94\u5e74\u5b58\u6d3b\u7387\u5c0f\u65bc25%\u3002\n\u5c0d\u65bc\u9aa8\u9abc\u5916\u9aa8\u8089\u7624\u7684\u6cbb\u7642\uff0c\u4e00\u822c\u5efa\u8b70\u4ee5\u622a\u80a2\u6216\u6839\u9664\u6027\u5207\u9664\u518d\u52a0\u4e0a\u653e\u5c04\u6cbb\u7642\u70ba\u4e3b\u8981\u65b9\u5f0f\uff0c\u800c\u5316\u5b78\u6cbb\u7642\u7684\u89d2\u8272\u5247\u8f03\u591a\u7570\u8b70\u3002\u7136\u800c\uff0c\u6b64\u500b\u6848\u6211\u5011\u63a1\u53d6\u4e86\u5c0d\u75c5\u8d74\u5ee3\u6cdb\u6027\u5207\u9664\u5f8c\uff0c\u518d\u52a0\u4e0a\u5229\u7528\u7e2e\u5c0f\u7167\u91ce\u65b9\u5f0f\u7d66\u4e88\u9ad8\u5291\u91cf\u7684\u653e\u5c04\u6cbb\u7642( 7020 cGy)\u53ca6\u6b21\u4ee5epirubicin\u70ba\u4e3b\u7684\u5316\u5b78\u6cbb\u7642\u3002\u5728\u9019\u7a2e\u6cbb\u7642\u6a21\u5f0f\u4e0b\uff0c\u6574\u500b\u904e\u7a0b\u4e2d\u7684\u526f\u4f5c\u7528\u4e26\u4e0d\u56b4\u91cd\uff0c\u800c\u4e14\u60a3\u8005\u53ef\u4ee5\u7e7c\u7e8c\u5b78\u696d\u800c\u6c92\u6709\u5ef6\u8aa4\u3002\n\u76f4\u5230\u73fe\u4eca\uff0c\u4f3c\u4e4e\u6c92\u6709\u4e00\u7a2e\u7279\u5b9a\u7684\u6cbb\u7642\u65b9\u5f0f\u53ef\u4ee5\u6539\u8b8a\u9aa8\u9abc\u5916\u9aa8\u8089\u7624\u7684\u5b58\u6d3b\u7387\u3002\u7136\u800c\uff0c\u5728\u77ed\u77ed\u7684\u4e00\u5e74\u8ffd\u8e64\u7576\u4e2d\uff0c\u9019\u500b\u63a1\u7528\u8907\u5408\u5f0f\u7642\u6cd5\u7684\u500b\u6848\uff0c\u7121\u8ad6\u5728\u5c40\u90e8\u6216\u5168\u8eab\u65b9\u9762\u90fd\u9054\u5230\u521d\u6b65\u7684\u63a7\u5236\u3002\u56e0\u6b64\uff0c\u5118\u53ef\u80fd\u5730\u5ee3\u6cdb\u6027\u624b\u8853\u5207\u9664\u5f8c\uff0c\u7a4d\u6975\u5730\u7d66\u4e88\u9ad8\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u4ecd\u61c9\u5617\u8a66\uff0c\u4ee5\u6c42\u66f4\u597d \u7684\u6cbb\u7652\u6a5f\u6703\u53ca\u5ef6\u9577\u751f\u547d\u7684\u53ef\u80fd\u6027\u3002", "e": "Extraskeletal osteosarcoma (ESOS) is a rare malignancy that accounts for about 1 % of all soft tissue sarcomas. In contrast to osteosarcoma of bone which occurs most frequently in children and adolescents, ESOS primarily affects adults in their fourth and fifth decades. The thigh and buttocks are the most common primary tumor sites. There is a slight male to female predominance observed in most series. Generally, wide resection followed by radiotherapy and/or chemotherapy is recommended. Local recurrence usually occurs in more than half of the patients, but distant metastasis, most common to the lung (\uff1e80% of cases), is more common than local recurrence. The mortality rate ranges from 55.4% to 81 % and the median 5 years survival rate is less than 25%.\nHere we represent a case of ESOS, which had been recurred many times after primary resection. We gave a high adjuvant radiation dose (7020 cGy) using the conedown fields technique and 6 cycles of epirubicin after wide excision of the recurrent tumor. Treatment related toxicities were limited to the treatment course and this student was able to continue his schooling while undergoing treatment.\nTo date, no particular method of treatment seems to alter the survival rate of ESOS. After a short period of follow up, however, the combined modalities therapy, in our experience, has attained the object of initial local and systemic disease control."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-113-119-a", "title": "Intraoperative Extracorporeal Irradiation and RE-Implantation in Treatment of  Osteogenic Sarcoma--Two Cases Experience", "keywords": "\u624b\u8853\u4e2d,\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642,\u518d\u79fb\u690d,\u9aa8\u8089\u7624,\u81ea\u9ad4\u79fb\u690d Intraoperative,Extracorporeal irradiation,Re-implantation,Osteogenic sarcoma,Autograft", "c": "\u62dc\u81e8\u5e8a\u5316\u5b78\u6cbb\u7642\u4e4b\u9032\u6b65\uff0c\u80a2\u9ad4\u4fdd\u7559\u624b\u8853\u6cbb\u7642\u9aa8\u8089\u764c\u5df2\u6210\u70ba\u76ee\u524d\u7684\u624b\u8853\u8da8\u52e2\u3002\u816b\u7624\u4eba\u5de5\u95dc\u7bc0\u79fb\u690d\uff0c\u7570\u9ad4\u9aa8\u79fb\u690d\uff0c\u81ea\u9ad4\u9aa8\u79fb\u690d\u5747\u88ab\u904b\u7528\u4f5c\u70ba\u9aa8\u91cd\u5efa\u4e4b\u8981\u4ef6\u3002\u5176\u4e2d\u816b\u7624\u4eba\u5de5\u95dc\u7bc0\u79fb\u690d\u7684\u7f3a\u9ede\u70ba\u7f3a\u4e4f\u8edf\u7d44\u7e54\u4f7f\u816b\u7624\u4eba\u5de5\u95dc\u7bc0\u56fa\u5b9a\u56f0\u96e3\uff0c\u53e6\u5916\u6703\u56e0\u9577\u6642\u9593\u4f7f\u7528\u800c\u767c\u751f\u9b06\u812b\u73fe\u50cf\u3002\u7570\u9ad4\u9aa8\u79fb\u690d\u7684\u554f\u984c\u5728\u65bc\u5bb9\u6613\u767c\u751f\u611f\u67d3\uff0c\u9aa8\u9abc\u7652\u5408\u4e0d\u826f\u548c\u9aa8\u8cea\u5438\u6536\u3002\u4ee5\u81ea\u9ad4\u9aa8\u79fb\u690d\u4e0d\u6703\u767c\u751f\u4e0a\u8ff0\u554f\u984c\uff0c\u56e0\u6b64\u6240\u5f97\u5230\u7684\u7d50\u679c\u6700\u597d\u3002\u4f46\u662f\u7d93\u7531\u80a2\u9ad4\u4fdd\u7559\u624b\u8853\u6240\u5207\u9664\u4e4b\u9aa8\u6bb5\u751a\u9577\uff0c\u5e7e\u4e4e\u4e0d\u53ef\u80fd\u5728\u540c\u4e00\u4eba\u8eab\u4e0a\u627e\u5230\u540c\u7b49\u9577\u5ea6\u4e4b\u9aa8\u6bb5\u53ef\u4f5c\u70ba\u81ea\u9ad4\u9aa8\u79fb\u690d\u3002\u7d93\u7531\u624b\u8853\u4e2d\u9ad4\u5916\u653e\u5c04\u7dda\u7167\u5c04\u542b\u816b\u7624\u4e4b\u9aa8\u6bb5\uff0c\u53ef\u4fdd\u7559\u9aa8\u6bb5\u4e4b\u8edf\u7d44\u7e54\u53ca\u53bb\u816b\u7624\u4e4b\u6b7b\u9aa8\u67b6\u4f5c\u70ba\u80a2\u9ad4\u91cd\u5efa\u7684\u81ea\u9ad4\u79fb\u690d\u6750\u6599\u3002\u7531\u65bc\u63a1\u9ad4\u5916\u7167\u5c04\uff0c\u56e0\u6b64\u6c92\u6709\u5291\u91cf\u63d0\u5347\u4e4b\u9650\u5236\u4e14\u4e0d\u9808\u8003\u616e\u65e5\u5f8c\u6703\u9020\u6210\u9130\u8fd1\u8edf\u7d44\u7e54\u7684\u8089\u7624\u8b8a\u5316\u3002\u6211\u5011\u5617\u8a66\u4ee5\u9019\u7a2e\u65b0\u65b9\u6cd5\u6cbb\u7642\u5169\u4f4d\u60a3\u6709\u4e0b\u80a2\u9aa8\u8089\u764c\u7684\u75c5\u4eba\u3002\u4ee5\u8853\u4e2d\u9ad4\u5916\u653e\u5c04\u7dda30000 cGy\u5291\u91cf\u7167\u5c04\u5e36\u816b\u7624\u9aa8\uff0c\u4e26\u65bc\u7167\u5c04\u5f8c\u7acb\u5373\u7a2e\u56de\u539f\u4f86\u6240\u53d6\u4e0b\u4f86\u7684\u4f4d\u7f6e(\u81ea\u9ad4\u79fb\u690d)\u3002\u6b64\u4e8c\u4f8b\u75c5\u60a3\u65bc\u8853\u5f8c\u516d\u500b\u6708\u5747\u53ef\u4e0d\u7528\u62d0\u6756\u81ea\u884c\u884c\u8d70\u3002\u4e0d\u5e78\u9019\u5169\u4f8b\u75c5\u60a3\u5747\u65bc\u624b\u8853\u5f8c\u4e00\u5e74\u5167\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u3002\u6211\u5011\u8a8d\u70ba\u624b\u8853\u524d\u5316\u5b78\u6cbb\u7642\u5291\u91cf\u4e0d\u8db3\u53ca\u624b\u8853\u6642\u7121\u6cd5\u65bd\u884c\u5927\u7bc4\u570d\u5207\u9664\u8853\u662f\u5c0e\u81f4\u6b64\u4e8c\u4f8b\u75c5\u60a3\u65e9\u671f\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u7684\u4e3b\u56e0\u3002\u624b\u8853\u4e2d\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u96d6\u7136\u53ef\u63d0\u4f9b\u826f\u597d\u7684\u81ea \u9ad4\u79fb\u690d\u6750\u6599\uff0c\u4f46\u662f\u5728\u5c0d\u75c5\u60a3\u65bd\u884c\u80a2\u9ad4\u4fdd\u7559\u624b\u8853\u524d\u61c9\u56b4\u683c\u7be9\u9078\u8853\u524d\u5c0d\u5316\u5b78\u6cbb\u7642\u53cd\u61c9\u826f\u597d\u53ca\u624b\u8853\u6642\u8f03\u53ef\u80fd\u65bd\u884c\u5927\u7bc4\u570d\u5207\u9664\u816b\u7624\u7684\u75c5\u60a3\uff0c\u624d\u53ef\u964d\u4f4e\u624b\u8853\u5f8c\u7684\u5c40\u90e8\u5fa9\u767c\u7387\u4ee5\u9054\u5230\u80a2\u9ad4\u4fdd\u7559\u624b\u8853\u7684\u76ee\u7684\u3002", "e": "Limb salvage surgery is currently used in treatment of osteogenic sarcoma in extremities by the advances in chemotherapy. Tumor prosthesis, allograft and autograft had been used for bone defect reconstruction. The use of autograft avoids some disadvantages of tumor prosthesis such as difficulty of soft tissue attachment and implant loosening after a period of time and decreases the probabilities of wound infection and nonunion as what might happen with allograft. So autograft provides the best result in bone reconstruction. However, it is impossible to find exactly the same length of autograft as what we had resected in the operation from our body. By the use of intraoperative extracorporeal irradiation to the tumor bearing bone segment, the soft tissue is preserved and the dead bone can be used to re-implant and substitute the bone defect. There is no limitation in dose escalation for irradiation of bone extracorporeally. The sarcomatous change of the adjacent normal soft tissue induced by radiation need not to be considered. In this paper, we tried to use this new method to provide a tumor free autograft for limb salvage surgery in two cases of locally advanced osteogenic sarcoma in lower limbs. A tumor dose of 30000 cGy was applied to the tumor bearing bone segment resected from both cases. The heavily irradiated specimen was sent back to the operation room immediately for re\ufe52implantation. The initial functional result was encouraging after six months of immobilization. Intraoperative extracorporeal irradiation with no dose limitation plays an important role in providing a sterile tumor free autograft with good bone union of the diseased leg. Unfortunately both cases had local tumor recurrence within one year after operation, inadequate neoadjuvant chemotherapy and inadequate (marginal) resection for locally advanced disease may be the main reasons for these early recurrences. We think that limb salvage surgery is a potential method only for some highly selected patients with good neoadjuvant chemotherapeutic response. Moreover, the tumor bearing bone segment should be resected with wide surgical margin to achieve a better long-term local tumor control."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-121-127-a", "title": "\u81e8\u5e8a\u5149\u5b50\u5c04\u675f\u4e4b\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ec\u7814\u7a76", "keywords": "\u8499\u5730\u5361\u7f85\u65b9\u6cd5 Monte Carlo,EGS4,OMEGA/BEAM,DOSXYZ", "c": "\u76ee\u7684\uff1a\u4ee5\u8499\u5730\u5361\u7f85\u65b9\u6cd5\u6a21\u64ecSiemens Primus\u76f4\u7dda\u52a0\u901f\u5668\u6a5f\u982d\uff0c\u4f5c\u70ba\u5f8c\u7e8c\u75c5\u4eba\u9ad4\u5167\u5291\u91cf\u8a08\u7b97\u4e4b\u524d\u9a45\u6b65\u9a5f\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5EGS4\u70ba\u57fa\u790e\u7684OMEGA/BEAM code\u70ba\u6a21\u64ec\u8a08\u7b97\u4e4b\u8edf\u9ad4\uff0c\u5229\u7528\u5ee0\u5546\u63d0\u4f9b\u4e4b\u8a73\u7d30\u52a0\u901f\u5668\u6a5f\u982d\u69cb\u9020\u6a21\u64ec6\u820715 MV\u5149\u5b5010 x 10 em2\u820720 x 20 em2\u7167\u91ce\u3002\u5148\u65bc\u7db2\u93e1\u4e0b\u8a2d\u6536\u96c6\u5e73\u9762\u6536\u96c6\u7531\u52a0\u7a7f\u8f2a\u4e0b\u4e4b\u7c92\u5b50\u8a0a\u606f\uff0c\u518d\u4ee5\u6b64\u5e73\u9762\u7576\u4f5cDOSXYZ\u4e4b\u5165\u5c04\u5c04\u6e90\uff0c\u8a08\u7b97\u572830 x 30 x 30 cm 3\u6c34\u5047\u9ad4\u4e2d\u4e0d\u540c\u6df1\u5ea6\u7684\u5291\u91cf\u5206\u4f48\u8207\u6df1\u5ea6\u767e\u5206\u7387\u5291\u91cf\u66f2\u7dda\uff0c\u8a08\u7b97\u7d50\u679c\u5c07\u8207Wellhofer\u6c34\u5047\u9ad4\u7cfb\u7d71\u91cf\u6e2c\u7d50\u679c\u6bd4\u8f03\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a6\u820715 MV\u6a21\u64ec\u7d50\u679c\u5728\u7167\u91ce\u5167\u8207\u7167\u91ce\u5916\u8207\u91cf\u6e2c\u7d50\u679c\u5951\u5408\u826f\u597d\uff0c\u4f46\u65bc\u7167\u91ce\u908a\u754c\u8655\u6a21\u64ec\u7d50\u679c\u7565\u9ad8\u65bc\u91cf\u6e2c\u7d50\u679c\uff0c\u4f46\u8aa4\u5dee\u7686\u57283 %\u4ee5\u5167\u3002\u6df1\u5ea6\u767e\u5206\u7387\u5291\u91cf\u66f2\u7dda6 MV\u6a21\u7db4\u7d50\u679c\u8207\u91cf\u6e2c\u7d50\u679c\u5404\u9ede\u8aa4\u5dee\u5747\u57281.5 %\u4ee5\u5167. 15 MV\u5247\u57281%\u4ee5\u5167\u3002 \n\u7d50\u8ad6\uff1a\u8499\u5730\u5361\u7f85\u6a21\u51dd\u7d50\u679c\u8207\u91cf\u6e2c\u7d50\u679c\u5951\u5408\u826f\u597d\uff0c\u56e0\u70ba\u6a21\u64ec\u8a08\u7b97\u6240\u9700\u6642\u9593\u904e\u9577\uff0c\u76ee\u524d\u4e0d\u7b26\u81e8\u5e8a\u6240\u9700\uff0c\u53ef\u8003\u616e\u4ee5\u5e73\u884c\u8a08\u7b97\u6216\u6a21\u5f0f\u5316\u65b9\u6cd5\u6539\u5584\u3002", "e": "Purpose: Monte Carlo simulation of the head of Siemens PRIMUS for the following step of patient dose calculation.\nMaterial and Methods: EGS4 based user code, OMEGA/BEAM, was used in this study. With detailed, linac head structure, 6 and 15 MV of l0\u00d710 cm2 and 20\u00d720 cm2 fields were simulated. Particles were collected in scored plane, which is set under retied, and treat as phase space source in DOSXYZ. With simulating in 30 x 30 x 30 em3 water phantom via DOSXYZ, dose profiles at various depth and percent depth dose curve were gained. The simulation results will compare with Wellhofer scan system measurement.\nResults and Discussion: The dose profiles of 6 and 15 MV in- and out- field fit quite well with measured data. However, simulation data encountered less than 3% larger than measured one at penumbra region. Percent depth dose curves were within 1.5% error of each point of simulation and measurement in 6 MY while within 1 %in 15 MV.\nConclusion: Monte Carlo simulation results fit quite well with Wellhofer scan data of dose profiles and percent depth dose curve. However, Monte Carlo simulation is time consuming and is not feasible for clinics so far. Parallel computing and modeling may considered for improvement."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200006-7-2-129-135-a", "title": "\u8d85\u8584\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u91cf\u6e2c\u81e8\u5e8a\u7684\u76ae\u819a\u5291\u91cf", "keywords": "\u76ae\u819a\u5291\u91cf,\u71b1\u767c\u5149\u5291\u91cf\u8a08,\u57fa\u5e95\u5c64\u50be\u659c\u56e0\u5b50 Skin dose,TLO,Basal layer oblique factor", "c": "\u76ee\u5f97\uff1a\u76ae\u819a\u526f\u4f5c\u7528\u662f\u653e\u5c04\u6cbb\u7642\u4e2d\u4e3b\u8981\u7684\u4f75\u767c\u75c7\uff0c\u5e38\u9020\u6210\u5fc5\u9808\u4e2d\u65b7\u7642\u7a0b\uff0c\u662f\u4ee5\u5c0d\u5176\u505a\u5b9a\u91cf\u5316\u7684\u91cf\u6e2c\u662f\u91cd\u8981\u4e14\u5fc5\u9808\u7684\u3002\u672c\u7814\u7a76\u5229\u7528\u8d85\u8584\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u91cf\u6e2c\u5728\u81e8\u5e8a\u4e0d\u540c\u7167\u5c04\u60c5\u6cc1\u4e0b\u7684\u76ae\u819a\u5291\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5229\u7528\u8d85\u8584\u578b\u71b1\u767c\u5149\u5291\u91cf\u8a08( GR-200F\uff0c\u9762\u7a4d0.5\u00d70.5 cm2\uff0c\u654f\u611f\u5c64\u539a\u5ea65 mg\uff0ecm-2)\u91cf\u6e2c6-15 MV\u5149\u5b50\u53ca6-21 MeV\u96fb\u5b50\uff0c\u5728\u4e0d\u540c\u7167\u91ce\u9762\u7a4d( 10\u00d710 cm2\u523040\u00d740 cm2)\u53ca\u4e0d\u540c\u5c04 \u675f\u5165\u5c04\u89d2\u5ea6( 0\u00b0 \u5230 80\u00b0 )\u4e0b\u7684\u76ae\u819a\u5291\u91cf\u3002\u5c0d\u5047\u9ad4\u5728\u8986\u84cb0 mm\u30013 mm\u30015 mm\u300110 mm\u539a\u7684\u64ec\u7d44\u7e54\u6750\u6599 ( bolus)\u4e0b\u7684\u76ae\u819a\u5291\u91cf\u4ea6\u5728\u91cf\u6e2c\u4e4b\u5217\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u5c0d6\u300110\u820715 MV\u5149\u5b5010\u00d710 cm2\u7167\u91ce\uff0c\u5047\u9ad4\u8868\u9762\u5e73\u5747\u5291\u91cf\u8207\u5047\u9ad4\u5167\u6700\u5927\u5291\u91cf\u7684\u6bd4 \u503c\u5206\u5225\u70ba16.10\u00b10.68%\u300114.03\u00b11.04%\u820710.59\u00b10.64%\uff0c\u540c\u6642\u96a8\u7167\u91ce\u589e\u52a0\u800c\u589e\u52a0\u3002\u5c0d6\u30019\u3001 12\u300115\u300118\u820721 MeV\u96fb\u5b50\uff0c\u8a72\u503c\u5206\u5225\u70ba72.59\u00b11.72%\u300178.52\u00b12.99%\u300178.89\u00b12.86%\u300186.08\u00b1 2.62%\u300187.75 \u00b1 1.94%\u820786.33 \u00b1 3.0\u9593\uff0c\u96a8\u7167\u91ce\u589e\u52a0\u8a72\u503c\u4ea6\u589e\u52a0\u3002\u6b64\u5916\uff0c\u57fa\u5e95\u5c64\u50be\u659c\u56e0\u5b50\u96a8\u5c04\u675f\u5165\u5c04\u89d2\u5ea6\u589e\u52a0\u800c\u589e\u52a0\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u5149\u5b50\u8207\u96fb\u5b50\u5047\u9ad4\u8868\u9762\u5e73\u5747PDD 1\u76f4\u96a8\u7167\u91ce\u589e\u52a0\u800c\u589e\u52a0\u3002\u57fa\u5e95\u5c64\u50be\u659c\u56e0\u5b50\u96a8\u5c04\u675f\u5165\u5c04\u89d2\u5ea6\u589e \u52a0\u800c\u589e\u52a0\u3002\u64ec\u7d44\u7e54\u6750\u6599(bolus)\u6703\u589e\u52a0\u76ae\u819a\u5291\u91cf\u540c\u6642\u964d\u4f4e\u50be\u659c\u56e0\u5b50\u3002", "e": "Purpose: Skin complication is the main event of radiation therapy that interrupts the treatment schedule and is of important to quantify. This study measured the skin dose at some clinical setups by using ultra-thin TLDs.\nMaterials and Methods: Measurements were performed for 6-15 MV photons and 6-21 MeV electrons with ultra-thin TLDs (GR-200F, surface area 0.5 x 0.5 cm2, nominal thickness 5 mg. cm-2 of sensitive layer). The skin dose of various field sizes, ranging from 10 x 10 cm2 to 40 x 40 cm2, and incident angle )f beam, from 0\u00b0to 80\u00b0, were measured. The measurements were also performed for the skin dose on phantom with 0 mm, 3 mm, 5 mm and 10 mm bolus covered.\nResults and Discussion: The ratios of mean surface dose to maximum dose in phantom for 10 x 10 cm2 are 16.1O\u00b10.68%, 14.03\u00b1 1.04% and 10.59\u00b10.64% for 6, 10 and 15 MY respectively, increasing with increased field size. For electrons, the ratios are 72.59\u00b1 1.72%, 78.52\u00b1 2.99%, 78.89 \u00b1 2.86%, 86.08\u00b1 2.62%, 87.75\u00b1 1.94% and 86.33\u00b1 3.09% for 6, 9, 12, 15, 18 and 21 MeV respectively, increasing with increased field size. The basal layer oblique factors increase with increased incident angle. \nConclusion: The mean PDD value of skin increases with increased field size for both photons and electrons. The basal layer oblique factor increases with increased incident angle. The bolus will increase the skin dose and eliminate the oblique factor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-1-8-a", "title": "\u653e\u5c04\u7dda\u7167\u5c04\u53caBSO\u8655\u7406\u5f8c\u591a\u5f62\u6027\u795e\u7d93\u81a0\u6bcd\u7624\u7d30\u80de\u5167\u9ea9\u6c28\u57fa\u786b\u542b\u91cf\u8b8a\u5316\u4e4b\u7814\u7a76", "keywords": "\u9ea9\u6c28\u57fa\u786b,\u591a\u5f62\u6027\u795e\u7d93\u81a0\u6bcd\u7624,\u653e\u5c04\u6cbb\u7642 Glutathione ([GSH]),Glioblastoma muItiforme (GBM),BSO (D, L-buthionine-S, R-sulfoximine),Radiation", "c": "\u76ee\u7684\uff1a\u5206\u6790\u653e\u5c04\u7dda\u7167\u5c04\u53caBSO\u8655\u7406\u5c0d\u65bc\u591a\u5f62\u6027\u795e\u7d93\u81a0\u6bcd\u7624\u7d30\u80de(glioblastoma multiforme, GSM)\u5167GSH\u542b\u91cf\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u63a1\u7528GBM\u7d30\u80de\u682a\u70ba\u5be6\u9a57\u5c0d\u8c61\uff0c\u9996\u5148\u9032\u884cGBM\u7d30\u80de\u682a\u5167\u9ea9\u57fa\u786b(glutathione\uff0cGSH)\u542b\u91cf\u4e4b\u6e2c\u5b9a\uff0c\u63a5\u8457\u4ee5Lowrymethod\u6e2c\u5b9a\u7d30\u80de\u5167\u86cb\u767d\u8cea\u4e4b\u6fc3\u5ea6\uff0c\u7136\u5f8c\u4ee5\u653e\u5c04\u7dda\u7167\u5c04\u53ca/\u6216BSO(D\uff0cL-buthionine-S\uff0cR-sulfoximine)\u8655\u7406\u7d30\u80de\uff0c\u7814\u7a76\u5728\u6709\u6c27\u53ca\u7f3a\u6c27\u74b0\u5883\u4e0b\uff0c\u4e0d\u540c\u5291\u91cf\u653e\u5c04\u7dda\u7167\u5c04\u53ca/\u6216BSO\u8655\u7406\u5f8c\u7d30\u80deGSH\u542b\u91cf\u6539\u8b8a\u4e4b\u60c5\u5f62\u3002\n\u7d50\u679c\uff1aGBM\u7d30\u80de\u5167GSH\u4e4b\u6fc3\u5ea6([GSH])\u7d04\u70ba9.93\u00b10.46(ug/mg of cellular protein\uff0c\u4ee5\u4e0b\u55ae\u4f4d\u76f8\u540c\u6545\u7701\u7565)\uff0c\u7d93\u904e2-14Gy\u4e4b\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e0d\u540c\u6642\u9593\uff0c\u96a8\u8457\u653e\u5c04\u5291\u91cf\u7684\u589e\u52a0[GSH]\u6709\u4e0a\u5347\u7684\u8da8\u52e2\u3002\u7d30\u80de\u7d93BSO\u8655\u982d\u9f8d\u4e4b\u6fc3\u5ea6\u77ef8.78\u00b10.05\uff0c\u7d93BSO\u8655\u7406\u53ca\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e0d\u540c\u6642\u9593\u4e4b[GSH]\u96a8\u8457\u653e\u5c04\u7dda\u5291\u91cf\u4e4b\u589e\u52a0\u4e5f\u6709\u4e0a\u5347\u7684\u8da8\u52e2\u3002\u7f3a\u6c27GBM\u7d30\u80de\u5167[GSH]\u7d04\u70ba32.45\u00b10.25\uff0c\u7d93BSO\u8655\u7406\u5f8c\u4e4b\u6fc3\u5ea6\u70ba13.36\u00b10.47\uff0c\u7d93\u653e\u5c04\u7dda\u7167\u5c04/\u6216BSO\u8655\u7406\u53ca\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e0d\u540c\u6642\u9593\u4e4b[GSH]\u96a8\u8457\u7167\u5c04\u5291\u91cf\u4e4b\u589e\u52a0\u591a\u6709\u5347\u9ad8\u7684\u73fe\u8c61\u3002\u6709\u6c27\u4e4bGBM\u7d30\u80de\u7d93BSO\u8655\u7406\u5f8c\u7d30\u80de\u5167[GSH]\u6709\u4e0b\u964d\u4e4b\u60c5\u5f62\uff0c\u4f46\u662f\u7f3a\u6c27GSM\u7d30\u80de\u53ea\u6709\u5728\u7167\u5c04\u5f8c\u7acb\u5373\u81f3\u5206\u6790\u9019\u4e00\u7d44[GSH]\u6e1b\u5c11\uff0c\u7d93\u904e24\u53ca48\u5c0f\u6642\u518d\u5206\u6790\u4e4b\u5169\u7d44[GSH]\u7121\u660e\u986f\u8b8a\u5316\u3002\u9664\u4e86\u5728\u6709\u6c27\u72c0\u614b\u7167\u5c04\u5f8c\u7acb\u5373\u5206\u6790\u7d44\uff0c\u5176\u9918\u7d44\u4e4b\u7d30\u80de\u7d93\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\uff0c\u96a8\u8457\u653e\u5c04\u5291\u91cf\u7684\u589e\u52a0[GSH]\u6709\u4e0a\u5347\u7684\u8da8\u52e2\uff0c\u4e14\u6b64\u4e0a\u5347\u8da8\u52e2\u7d93\u904eBSO\u8655\u7406\u5f8c\u66f4\u70ba\u660e\u986f\u3002\u6b64\u5916\uff0c\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e4bGBM\u7d30\u80de\u5167(GSH)\u8b8a\u5316\u5177\u6709\u6c27\u6216\u7f3a\u6c27\u72c0\u614b\u7121\u986f\u8457\u95dc\u4fc2\u3002\n\u7d50\u8ad6\uff1a\uff08\u4e00\uff09\u6709\u6c27GBM\u7d30\u80de\u7d93BSO\u8655\u7406\u5f8c\u7d30\u80de\u5167[GSH]\u6709\u4e0b\u964d\u4e4b\u60c5\u5f62\uff0c\u4f46\u662f\u7f3a\u6c27GBM\u7d30\u80de\u53ea\u6709\u5728\u7167\u5c04\u5f8c\u7acb\u5373\u5206\u6790\u9019\u4e00\u7d44[GSH]\u6e1b\u5c11\u3002\u4ec1)\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e4bGSM\u7d30\u80de\u5167(GSH)\u8b8a\u5316\u5177\u8207\u6709\u6c27\u6216\u7f3a\u6c27\u72c0\u614b\u7121\u986f\u8457\u95dc\u4fc2\u3002\u4e00\u822c\u800c\u8a00\uff0cGBM\u7d30\u80de\u7d93\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\uff0c\u96a8\u8457\u653e\u5c04\u5291\u91cf\u7684\u589e\u52a0[GSH]\u6709\u76ca\u6f38\u4e0a\u5347\u7684\u8da8\u52e2\uff0c\u4e14\u6b64\u4e0a\u5347\u8da8\u52e2\u7d93BSO\u8655\u7406\u6216\u5728\u7167\u5c04\u5f8c24~48\u5c0f\u6642\u66f4\u70ba\u660e\u986f\u3002\u6b64\u7a2e[GSH]\u9010\u6f38\u4e0a\u5347\u53ef\u80fd\u8868\u793a\u96a8\u8457\u653e\u5c04\u5291\u91cf\u589e\u52a0\u7d30\u80de\u4fee\u5fa9\u6108\u4e0d\u660e\u986f\u4e14\u8f3b\u5c04\u751f\u7269\u9f13\u61c9\u4ea6\u6108\u52a0\u986f\u8457\u3002", "e": "Purpose: To evaluate the efficacy of radiation and BSO on the GSH concentration of GBM cells.\nMaterials and Methods : Exponentially growing cultures of GBM/8401 cells were used for this study. The GSH concentrations in GBM cells treated with radiation and/or BSO (D, L-buthionine-S, R-sulfox-imine) were determined. Cells were irradiated with dosage ranged from 0 to 14 Gy with gamma radiation using a cobalt 60 machine. The concentration of GSH in irradiated GBM cells treated with or without BSO was evaluated under aerobic and hypoxic conditions.\nResult: The intracellular concentration of glutathione ([GSH]) was 9.93\u00b1 0.46 ug/mg of cellular protein. In general, the [GSH] increased gradually after irradiated by cobalt-60 with 2~14 Gy. The [GSH] in OBM cells were 8.78\u00b10.05 after treated with BSO. Also, [GSH] increased gradually after irradiated from low to high dose of irradiation. The [GSH] in hypoxic GBM cells were 32.45\u00b10.25. It was 13.36\u00b10.47 after treated with BSO. In general, the cellular [GSH] after irradiated from low to high dose of radiation increased gradually no matter treated with BSO or not. BSO is able to deplete the intracellular [GSH] but this is not significant in hypoxic cells 24 and 48 hours after treatment. Change of intracellular [GSH] is also not closely related with the present of oxygen or not.\nConclusion: (1). In aerobic group, the GSH concentrations in OBM cells decrease after treated with BSO. In hypoxic group, the GSH concentration decreased only in cells analyzed immediately after irradiation. (2). There is no significant association between GSH concentrations of irradiated GBM cells and various oxygenated conditions. (3). In general, GSH concentration increase in proportional to radiation dose. This is more evident after treated the cells with BSO or 24~48 hours after irradiation Gradually increased concentration of GSH represents less repair of the damaged cells from radiation and more biologic effects in accordance with high radiation dose."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-9-14-a", "title": "Effect of Lomustine on N-Acetyltransferase Activity in RAT Glioma in Vitro Cultured Cells", "keywords": "\u82b3\u9999\u80fa\u5316\u5408\u7269,N \u57fa\u4e59\u91af\u8f49\u79fb\u9176,\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624 Arylamine,N-acetyltransferase,Glioma,Lomustine", "c": "\u76ee\u7684\uff1a\u82b3\u9999\u80fa\u5316\u5408\u7269\u7d93N\u57fa\u4e59\u91af\u8f49\u79fb?( N-acetyltransferase )\u4e4bN \u57fa\u4e59\u91af\u5316\u53ef\u8a98\u767c\u764c\uff0clomustine\u662f\u5e38\u7528\u65bc\u6cbb\u7642\u8166\u7624\u7684\u4e00\u7a2e\u6297\u764c\u7269\u85e5\uff0c\u672c\u7814\u7a76\u662fin vitro \u63a2\u8a0elomustine \u5c0d\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de\u4e2d\u4e59\u91af\u8f49\u79fb\u81e8\u6d3b\u6027\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u53d6\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de( n = 12)\u7528\u4e59\u91af\u5316\u8f14?A \u4f5c\u4e59\u91af\u57fa\u800c\u518d\u5229\u7528\u9ad8\u58d3\u6db2\u76f8\u5c64\u6790\u5100\u5206\u6790\u4e59\u91af\u8f49\u79fb?\u7684\u6d3b\u6027\u53calomustine\u5c0d\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de\u4e2d\u4e59\u91af\u8f49\u79fb\u7531\u6d3b\u6027\u7684\u5f71\u97ff\uff0c\u4ee52-aminofluorene (2-AF)\u548c p-minobenzoic acid (PABA)\u4f5c\u53d7\u8cea\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u986f\u793a\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de\u5c0dAF\u53caPABA \u53d7\u8cea\u7686\u6709\u4e59\u91af\u8f49\u79fb?\u6d3b\u6027\u5b58\u5728\uff0c\u5176\u5c0dAF\u53caPABA \u7684\u6d3b\u6027\u5e73\u5747\u503c\u5404\u70ba1.08\u00b10.18\u53ca0.96\u00b10.16 nmol/min/mg protein\u3002\u57280.8\u03bcM\uff0c8\u03bcM and 80\u03bcM \u7684lomustine \u6fc3\u5ea6\u4e2d\uff0c\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de\u4e2dAF-NAT\u6d3b\u6027\u964d\u4f4e\u7d0417.6%\uff0c31.5% and 45.4%\uff0cPABA-NAT\u6d3b\u6027\u964d\u503c\u7d0410.4%\uff0c27.1 % and 45\uff0c8%\u3002\n\u7d50\u8ad6\uff1aLomustine\u53ef\u964d\u4f4e\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u9ad4\u5916\u57f9\u990a\u7d30\u80de\u4e2d\u4e59\u91af\u8f49\u79fb?\u7684\u6d3b\u6027\u3002", "e": "Purpose: Arylamine N-acetylation capacity by the N-acetyltransferase (NAT) may be an important causative factor in the initiation of cancer. Lomustine is a commercially avail-able nitrosourea derivative and chloroethyl nitrosourea compound which applied in antineopstic therapy especially in central nervous system. The aaffect of lomustine on the activity of NAT in rat glioma in vitro cultured cells were investigated. \nMaterials and Methods: Rat glioma in vitro cultured cell cytosol (n=12) were used to investigate for the effect of lomustine on the activity of NAT toward 2-amniofluorene (AF) and p-aminiobenzoic acid (PABA) using an acetyl coenzyme A (AcCoA) recycling assay and high pressure liquid chromatography (HPLC).\nResults: Activity of N-acetyltransferase in rat glioma in vitro cultured cell cytosol is found to be inhibited by lomustine. Its presence in the assay medium shows an inhibition in aminofluorene-N-acetyltransferase (AF-NAT) activity about of 17.6%, 31.5% and 45.4% in rat glioma in vitro cultured cells at 0.8 \u03bcM, 8 \u03bcM and 80 \u03bcM of lomustine concentrations respectively; while as p-aminobenzoic acid-N-acetyltransferase (PABA-NAT) activity decreased about 10.4%, 27.1% and 45.8% in rat glioma cells with 0.8\u03bcM,8\u03bcM and 80(M of lomustine concentrations respectively.\nConclusion: The results of this study show that the NAT activity of rat glioma cultured cells are decreased by lomustine."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-15-20-a", "title": "\u6210\u4eba\u8edf\u7d44\u7e54\u8089\u7624\u75c5\u4eba\u4e4b\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642", "keywords": "\u6210\u5e74\u8edf\u7d44\u7e54\u8089\u7624,\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642 Adult soft tissue sarcoma,Adjuvant postoperative radiotherapy", "c": "\u80cc\u666f\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u5728\u5206\u6790\u6210\u4eba\u8edf\u7d44\u7e54\u8089\u7624\u4e4b\u75c5\u4eba\u5728\u65b0\u5149\u91ab\u9662\u63a5\u53d7\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u4e4b\u5b58\u6d3b\u60c5\u5f62\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1993\u52301996\u5171\u6709\u768416\u4f4d\u6210\u5e74\u75c5\u60a3\u5728\u65b0\u5149\u91ab\u9662\uff0c\u56e0\u8edf\u7d44\u7e54\u8089\u7624\u63a5\u53d7\u624b\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d\u7537\u60277\u4eba\u5973\u60279\u4eba\u3002\u81e8\u5e8aTNM\u5206\u671f\u4fc2\u4f9d\u7167\u91ab\u9662\u4e4b\u75c5\u6b77\u7d00\u9304\uff0c11\u4f4d\u75c5\u60a3\u5728\u6cbb\u7642\u5f8c\u63a5\u53d7\u5b9a\u671f\u9580\u8a3a\u8ffd\u8e64\uff0c5\u4f4d\u75c5\u60a3\u5728\u63a5\u53d7\u5b9a\u671f\u9580\u8a3a\u8ffd\u8e64\u4e00\u6bb5\u6642\u9593\u5f8c\uff0c\u6700\u5f8c\u4ee5\u96fb\u8a71\u8ffd\u8e64\u5408\u4f75\u5168\u570b\u6b7b\u4ea1\u767b\u8a18\u4f86\u78ba\u8a8d\u5b58\u6d3b\u60c5\u5f62\u3002\u5176\u56e0\u75c5\u5b58\u6d3b\u7387(OS=overall cause specific survival)\uff0c\u5c40\u90e8\u7121\u5fa9\u767c\u5b58\u6d3b\u7387(LRRF8=local regional relapse free survival)\uff0c\u9060\u7aef\u7121\u8f49\u79fb\u5b58\u6d3b\u7387(MFS=distant metastasis free survival)\uff0c\u7121\u75c5\u5b58\u6d3b\u7387(DFS=disease free survival)\u4fc2\u4f9dKaplan-Meier\u65b9\u6cd5\u8a08\u7b97\u3002\n\u7d50\u679c\uff1a\u5728\u8ffd?7-81\u500b\u6708\u5f8c(\u4e2d\u4f4d\u6578\uff1a55)\uff0c\u4e00\u4f4d\u75c5\u4eba\u6b7b\u65bc\u5c40\u90e8\u5fa9\u767c\uff0c\u5169\u4f4d\u75c5\u4eba\u6b7b\u65bc\u9060\u7aef\u80ba\u8f49\u79fb\uff0c\u4e00\u4f4d\u75c5\u4eba\u6b7b\u65bc\u5176\u4ed6\u75be\u75c5(\u809d\u764c)\uff0c\u5176\u9918\u75c5\u4eba\u7121\u5fa9\u767c\u60c5\u5f62\u3002\u4e09\u5e74\u53ca\u4e94\u5e74\u56e0\u75c5\u5b58\u6d3b\u7387(OS)\u5206\u5225\u70ba87.5\uff05\u53ca80\uff05\u3002\u4e09\u5e74\u53ca\u4e94\u5e74\u5c40\u90e8\u7121\u75c5\u767c\u5b58\u6d3b\u7387(LRRFS)\u5747\u70ba92.3\uff05\u3002\u4e09\u5e74\u53ca\u4e94\u5e74\u9060\u7aef\u7121\u8f49\u79fb\u5b58\u6d3b\u7387(DMFS)\u5747\u70ba84%\u3002\u4e09\u5e74\u53ca\u4e94\u5e74\u7121\u75c5\u5b58\u6d3b\u7387(DFS)\u5747\u70ba77%\u3002\u4f75\u767c\u75c7\u5171\u5169\u4f8b\uff1a\u76f4\u8178\u51fa\u8840\u4e00\u4f8b(RTOG\u7b2c\u4e09\u7d1a)\uff0c\u50b7\u53e3\u7652\u5408\u4e0d\u826f\u4e00\u4f8b(RTOG\u7b2c\u56db\u7d1a)\u3002\n\u7d50\u8ad6\uff1a\u4f9d\u672c\u9662\u4e4b\u7d93\u9a57\uff0c\u6210\u4eba\u8edf\u7d44\u7e54\u8089\u7624\u75c5\u4eba\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u53ef\u63a5\u81f4\u9ad8\u5ea6\u5c40\u90e8\u63a7\u5236\uff0c\u800c\u4f75\u767c\u75c7\u4e26\u4e0d\u5e38\u898b\u3002", "e": "Background: The aim of this study is to analyze the survival status of adult patients with soft tissue sarcoma who received postoperative adjuvant radiotherapy at Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.\nMaterials and Methods: From 1993 through 1996, 16 adult patients (M: 7, F: 9) were diagnosed with soft tissue sarcoma (STS) to be treated with postoperative adjuvant radiotherapy in our institute. TNM staging was based on the hospital medical records. The survival status was based on regular follow-up (11/16) and interrupted follow-up combined with national mortality registry and telephone visits (5/16). The overall cause specific survival (OS), local-regional relapse free survival (LRRFS), and distant metastasis free survival (DMFS), and disease free survival (DFS) were analyzed using the Kaplan-Meier method.\nResults: After a median follow-up of 55 (7-81) months, 12 patients are survivors without disease, one died of local relapse, two died of distant metastases, and one died of concurrent disease (HCC). The OS, LRRFS, DMFS, and DFS at 3 years and 5 years were 87.5% and 80%, 92.3% and 92.3%, 84% and 84%, and 77% and 77% respectively. The complications included one rectal bleeding (RTOG grade III) and one poor wound healing (RTOG grade IV).\nConclusion: In our experience, postoperative adjuvant radiotherapy can achieve high local controlled rate in adult soft tissue sarcoma with acceptable complication."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-21-26-a", "title": "Hodgkin", "keywords": "\u4f55\u6770\u91d1\u6c0f\u75c5,\u7d50\u7bc0\u786c\u5316,\u6df7\u5408\u7d30\u80de Hodgkin", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u8fd126\u5e74\u4f86\u4f55\u6770\u91d1\u6c0f\u75c5\u4e4b\u7d44\u7e54\u5206\u985e\u8207\u5e74\u9f61\u5206\u4f48\u7684\u6539\u8b8a\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1970\u5e74\u81f31995\u5e74\uff0c\u5728\u53f0\u5317\u69ae\u7e3d\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u4f55\u6770\u91d1\u6c0f\u75c5\u75c5\u4f8b\uff0c\u5171\u6709240\u540d\u3002\u5206\u6790\u5176\u5e74\u9f61\u3001\u6027\u5225\u8207\u7d44\u7e54\u5206\u7a4e\u7684\u5206\u4f48\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a\u4f55\u6770\u91d1\u6c0f\u75c5\u4e4b\u5e74\u9f61\u5206\u6016\u51fa\u73fe\u96d9\u6ce2\u5cf0\uff0c\u572815\u81f324\u6b72\u820755\u81f364\u6b72\u9593\u4e4b\u767c\u751f\u7387\u6700\u9ad8\u3002\u82e5\u518d\u4ee5\u8a3a\u65b7\u7684\u6642\u9593\u7d30\u5206\uff0c\u53ef\u767c\u73fe\u57281970\u81f31979\u5e74\u959315\u81f324\u6b72\u4e4b\u9ad8\u5cf0\u4e26\u4e0d\u660e\u986f\uff0c\u800c1990\u81f31995\u5e74\u9593\u8a3a\u65b7\u7684\u75c5\u4f8b\u6b64\u4e00\u9ad8\u5cf0\u5341\u5206\u660e\u986f\uff0c\u56e0\u6b64\u4f55\u6770\u91d1\u6c0f\u75c5\u7684\u767c\u751f\u6709\u5e74\u8f15\u5316\u4e4b\u50be\u5411\u3002\u7537\u6027\u8207\u5973\u6027\u4e4b\u6bd4\u7387\u70ba3.2\uff1a1\u3002\u7d44\u7e54\u5206\u985e\u4ee5\u6df7\u5408\u7d30\u80de(mixed cellularity)\u70ba\u6700\u591a\uff0c\u7d50\u7bc0\u786c\u5316(nodular sclerosis)\u6b21\u4e4b\u3002\u82e5\u518d\u4ee5\u5e74\u4ee3\u7d30\u5206\uff0c\u767c\u73fe\u7d50\u7bc0\u786c\u5316\u9010\u5e74\u589e\u52a0\uff0c\u800c\u6df7\u5408\u7d30\u80de\u5247\u9023\u5e74\u6e1b\u5c11\u3002\n\u7d50\u8ad6\uff1a\u53f0\u5317\u69ae\u7e3d\u8fd126\u5e74\u7684\u4f55\u6770\u91d1\u6c0f\u75c5\u7684\u75c5\u4f8b\u6709\u4e8c\u500b\u7279\u6027\uff1a\u4e00\u3001\u75c5\u4eba\u5e74\u8f15\u5316\u3002\u4e8c\u3001\u7d50\u7bc0\u786c\u5316\u75c5\u4f8b\u984d\u589e\u52a0\u3002\u672c\u7814\u7a76\u7684\u671f\u9593\u53f0\u7063\u7d93\u6fdf\u6709\u6975\u5927\u7684\u9032\u6b65\uff0c\u5728\u570b\u5916\u6587\u737b\u4e2d\u4ea6\u6709\u5831\u544a\uff0c\u4f55\u6770\u91d1\u6c0f\u75c5\u7684\u767c\u751f\u5e74\u9f61\u8207\u7d44\u7e54\u5206\u985e\u6703\u96a8\u8457\u793e\u6703\u7d93\u6fdf\u5730\u4f4d\u7684\u6539\u5584\u800c\u6539\u8b8a\u3002", "e": "Purpose: To evaluate the change in histology subgroups and age distribution of Hodgkin's disease over the past twenty-six years.\nMaterial and Method: We reviewed medical records of Hodgkin's disease diagnosed and treated in Veterans General Hospital-Taipei from 1970 to 1995. The age distribution, sex, and histology subgroupings, are analyzed.\nResults: There is a bimodal age distribution, peaked at 15 to 24 and 55 to 64.When age distribution was further analyzed according to the time of diagnosis, there is an increasing frequency of patients at the 15 to 24 age group and decreasing frequency of the 55 to 64 age group. Male to female ratio is 3.2: 1. For histological proved cases, mixed cellularity Hodgkin's disease (MCHD) is the predominant type during 1970 to 1989. The incidence of nodular sclerosis Hodgkin's disease (NSHD) is increasing during the study period. It has become the most prevalent histology type during 1990 to 1995.\nConclusion: There are two significant changes in the demographic data of Hodgkin's disease at the time of diagnosis during the study period. First, the incidence of young adult patients is increasing. Second, the frequency of MCHD is decreasing and that of NSHD is increasing. These two changes are consistent with previous reports that economical status correlates with the age and histology subgroup distribution of Hodgkin's disease. Thus, our observations are consistent with the hypothesis that environmental or infectious agents are contributing factors in the pathogenesis of HD. Further multi-institutional study is warranted to confirm the significance of our observation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-27-33-a", "title": "\u5168\u8eab\u7167\u5c04\u6cbb\u7642\u7684\u5291\u91cf\u6e2c\u5b9a\u8207\u5169\u5074\u5e73\u884c\u5c0d\u7167\u6280\u8853\u7684\u61c9\u7528", "keywords": "\u5168\u8eab\u7167\u5c04\u6cbb\u7642,\u9aa8\u9ad3\u79fb\u690d,\u80ba\u90e8\u5291\u91cf Total body irradiation,Bone marrow transplant,Lung dose", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u80fd\u7e2e\u77ed\u75c5\u4eba\u63a5\u53d7\u5168\u8eab\u7167\u5c04\u6cbb\u7642\u4f4d\u7f6e\u64fa\u8a2d\u6642\u9593\u53ca\u63d0\u9ad8\u6bcf\u6b21\u6cbb\u7642\u7684\u518d\u73fe\u6027\uff0c\u898f\u5283\u8eba\u81e5\u5f0f\u5de6\u53f3\u5169\u5074\u5e73\u884c\u5c0d\u7167\u7684\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u4f86\u6cbb\u7642\u9aa8\u9ad3\u79fb\u690d\u75c5\u4eba\uff0c\u4e26\u64da\u6b64\u65b9\u5f0f\u642d\u914d\u76f8\u95dc\u6cbb\u7642\u8f14\u52a9\u8a2d\u5099\u4f86\u57f7\u884c\u76f8\u95dc\u5291\u91cf\u6e2c\u91cf\u53ca\u5c04\u675f\u6578\u64da\u91cf\u5de5\u4f5c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u5c0f\u578b\u6c34\u5047\u9ad4(35\u516c\u5206(\u9577)\u00d735\u516c\u5206(\u5bec)\u00d737\u516c\u5206(\u9ad8)\u5074\u9762\u70ba\u9ea5\u62c9\u6750\u8cea\u7684\u8996\u7a97(Mylar window)\u5167\u7f6e\u8fb2\u592b\u578b\u6e38\u96e2\u8154(Farmer type0.6cc\uff0cPR06C)\u53ca\u84b8\u993e\u6c34\u4e26\u5728\u4e0b\u9762\u914d\u7f6e\u6607\u964d\u5e73\u53f0\uff0c\u53ef\u8abf\u6574\u9069\u7576\u9ad8\u5ea6\u3002\u6cbb\u7642\u80fd\u91cf\u9084\u7528\u897f\u9580\u5b50PRIMUS\u578b\u76f4\u7dda\u901f\u5668\u516d\u767e\u842c\u4f0f\u7279\u5149\u5b50\uff0c\u7167\u91ce\u958b\u5230\u6700\u5927(\u96e2\u5c04\u6e90100\u516c\u5206\u8655\u70ba40\u00d740\u516c\u5206)\uff0c\u6e96\u76f4\u5100\u65cb\u8f4945\u5ea6\uff0c\u65cb\u8f49\u81c2\u8a2d\u5728270\u5ea6\u7b49\u689d\u4ef6\u4e0b\uff0c\u5728\u8ddd\u96e2\u5c04\u6e90400~500\u516c\u5206\u4e4b\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u5206\u4f48\u3001\u5291\u91cf\u5256\u9762\u3001\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u3001\u88dc\u511f\u5668\u53ca\u6563\u5c04\u5c4f\u4e4b\u8870\u6e1b\u56e0\u5b50\u6e2c\u91cf\u3002\u6211\u5011\u4e26\u81ea\u5df1\u88fd\u4f5c\u6607\u964d\u5e8a\u53ca\u58d3\u514b\u529b\u6563\u5c04\u5c4f\u98a8\uff0c\u5982\u6b64\u75c5\u4eba\u6cbb\u7642\u6642\u4f4d\u7f6e\u7684\u64fa\u8a2d\u53ef\u76f8\u5c0d\u7684\u5bb9\u6613\u8207\u6e96\u78ba\u3002\n\u7d50\u679c\uff1a\u96e2\u5c04\u6e90400-500\u516c\u5206\u4e4b\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u6bd4\uff0c\u4ee510\u516c\u5206\u820720\u516c\u5206\u6df1\u5ea6\u7684\u6bd4\u503c\u4f86\u8aaa\uff0c\u5c0f\u65bc0.5%\uff0c\u5c04\u675f\u7684\u5e73\u5766\u5ea6\u572820\u516c\u5206\u6df1\u5ea6\u4e0b\u7684\u5256\u9762\u5291\u91cf\u5206\u4f48\uff0c\u5728\u5c0d\u89d2\u7dda\u7167\u91ce\u9577\u5ea6\u767e\u5206\u4e4b\u4e03\u5341\u7bc4\u570d\u5167\u70ba\u00b10.5%\uff1b\u7531\u65bc\u8ddd\u96e2\u751a\u9060\uff0c\u8f38\u51fa\u5291\u91cf\u9664\u4e86\u53ef\u7528\u5e73\u65b9\u53cd\u6b64\u5b9a\u5f8b\u63a8\u7b97\uff0c\u4e5f\u53ef\u4f9d\u5be6\u6e2c\u503c\u7e6a\u88fd\u8868\u683c\u4ee5\u5e73\u81e8\u5e8a\u6cbb\u7642\u4f7f\u7528\uff0c\u540c\u6642\u56e0\u70ba\u8eab\u9ad4\u5074\u9762\u4e0d\u540c\u4f4d\u7f6e\u7684\u539a\u5ea6\u5dee\u7570\u8f03\u5927\uff0c\u9700\u8981\u88fd\u4f5c\u7d44\u7e54\u88dc\u511f\u5668\u4f86\u6539\u5584\u5291\u91cf\u5747\u52fb\u5ea6\u3002\u81f3\u65bc\u8868\u9762\u5291\u91cf\u5247\u53ef\u75281\u516c\u5206\u58d3\u514b\u529b\u5c4f\u98a8\u7f6e\u65bc\u75c5\u4eba\u524d\u65b910\u516c\u5206\u4ee5\u9054\u5230\u8db3\u5920\u7684\u6cbb\u7642\u5291\u91cf\u3002\n\u7d50\u8ad6\uff1a\u5229\u7528\u982d\u9838\u90e8\u816b\u7624\u6cbb\u7642\u666e\u904d\u4f7f\u7528\u7684\u5de6\u53f3\u5169\u5074\u5e73\u884c\u5c0d\u7167\u7684\u5168\u8eab\u7167\u5c04\u6cbb\u7642\u65b9\u5f0f\uff0c\u9069\u7576\u7684\u5229\u7528\u75c5\u4eba\u7684\u624b\u81c2\u53d6\u4ee3\u4e0d\u6613\u6e96\u78ba\u64fa\u8a2d\u7684\u80ba\u90e8\u906e\u6a94\u925b\u584a\uff0c\u65e2\u4e0d\u72a7\u7272\u5291\u91cf\u6e96\u78ba\u6027\uff0c\u4e14\u80fd\u63d0\u9ad8\u75c5\u4eba\u6cbb\u7642\u6642\u7684\u8212\u9069\u5ea6\uff0c\u96d6\u4e0d\u7b97\u5275\u65b0\uff0c\u4f46\u53ef\u63d0\u4f9b\u570b\u5167\u9078\u64c7\u5168\u8eab\u7167\u5c04\u6cbb\u7642\u65b9\u5f0f\u7684\u53c3\u8003\u3002", "e": "Purpose: In an attempt to shorten patient setup time and increase setup reproducibility, we developed a supplemental system for a bilateral opposed technique of total body irradiation. We completed the dosimetry study and beam data measurement for clinical application.\nMaterials and Methods: A small-size water phantom, (35 cm (L) x 35 cm (W) x 37 cm (H? with a lateral Mylar window, built in a farmer type chamber, was used for this measurement. The measurement was performed with 6 MV photon at 270\u00b0 gantry angle, 45\u00b0 and 135\u00b0 collimator angle with maximum field size, and at 400~500 cm source-phantom distance. The measured items were dose rates, beam profiles, percent depth dose, and transmission factors for both tissue compensator and beam spoiler. \nResults: The ratio of percent depth doses at 10 cm and 20 cm depth with in 400~500 cm SSD was 0.5%. The flatness of beam profiles was within (5% under the same conditions. The dose output ratios were also measured for clinical treatment. We measured the attenuation coefficient for the compensator material. Besides, we found that a 1 cm thick Lucite screen at 10 cm from the patient was enough to build up the surface dose.\nConclusions: Our bilateral opposed technique for total body irradiation can achieve more comfortable and reproducible levels than that of conventional anterior/posterior technique. There is an advantage of using the arms of patients to shield the lungs, and it can reduce the lung dose effectively. Although this technique is not new, it can be a choice of total body irradiation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-35-44-a", "title": "\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u5b78", "keywords": "\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642,\u516d\u5c0d\u7167\u91ce\u6cd5,\u5291\u91cf\u5b78 Total skin electron radiation therapy (TSET),Six-dual-field technique,Dosimetry", "c": "\u76ee\u7684\uff1a\u63cf\u8ff0\u672c\u79d1\u8003\u91cf\u5ba2\u89c0\u8a2d\u5099\u689d\u4ef6\uff0c\u53c3\u914c\u300c\u516d\u5c0d\u7167\u91ce\u6cd5\u300d\u9032\u884c\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642\u4e4b\u5291\u91cf\u5b78\u5be6\u52d9\u7d93\u737b\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2(SSD)\u662f323cm\uff0c\u4e26\u5728\u6cbb\u7642\u5e73\u9762\u524d15cm\u8655\u67b6\u8a2d-0.8cm\u539a\u5ea6\u4e4b\u58d3\u514b\u529b\u677f\u4ee5\u767c\u6563\u5c04\u675f\u4e26\u8870\u6e1b\u521d\u80fd\u91cf\u70ba6MeV\u7684\u96fb\u5b50\u80fd\u91cf\u3002\u9996\u5148\u6e2c\u5b9a\u80fd\u4f7f\u5782\u76f4\u65b9\u5411\u9054\u5230\u6700\u4f73\u5291\u91cf\u5747\u52fb\u5ea6\u7684\u6210\u5c0d\u7167\u91ce\u89d2(dual-field angle)\uff0c\u4e26\u91cf\u6e2c\u6c34\u5e73\u548c\u5782\u76f415\u65b9\u5411\u7684\u7167\u91ce\u5e73\u5766\u5ea6\u3002\u63a5\u8457\u5229\u7528X\u5149\u7247\u5291\u91cf\u6cd5\u6c42\u51fa\u96fb\u5b50\u5728\u6cbb\u7642\u5e73\u9762\u7684\u5291\u91cf\u53ca\u76f8\u95dc\u6578\u64da\uff0c\u64da\u4ee5\u6821\u6b63\u76f4\u7dda\u52a0\u901f\u5668\u7684output\u3002\u518d\u5229\u7528\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD)\u6e2c\u91cf\u4eba\u5f62\u5047\u9ad4\u4e0a\u4ee5\u516d\u500bdual-fields\u548c\u4e00\u500bdual-field\u7167\u5c04\u7684\u5438\u6536\u5291\u91cf\u4e4b\u6bd4\u503c\u4ee5\u6c7a\u5b9a\u500d\u6578\u56e0\u5b50(multiplication factor\uff0c\u7c21\u7a31MF)\uff0c\u4fbf\u53ef\u6c42\u5f97\u6cbb\u7642\u6bcf\u55ae\u4e00\u7167\u91ce\u6240\u5fc5\u9808\u7d66\u4e88\u7684\u5291\u91cf\u3002\u518d\u5b8c\u5168\u6a21\u64ec\u5be6\u969b\u6cbb\u7642\u689d\u4ef6\uff0c\u4ee5TLD\u9032\u884cin vivo dosimetry\uff0c\u78ba\u8a8d\u75c5\u4eba\u9ad4\u8868\u5291\u91cf\u4e26\u8a55\u4f30\u5404\u9ede\u7684\u5291\u91cf\u5dee\u7ffc(dose variation)\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u6240\u5be6\u9a57\u6216\u6e2c\u91cf\u5f97\u5230\u7684duel-field angle(20\u00b0)\u548cmultiplication factor(2.68)\u7b49\u53c3\u6578\uff0c\u8207\u4ed6\u4eba\u7d93\u9a57\u76f8\u7b26\u3002\u96fb\u5b50\u7684\u5291\u91cf\u5b50\u5206\u4f48\u53caX-ray back ground(0.75\u514b)\u4ea6\u4ee4\u4eba\u6eff\u610f\u3002\u76f4\u7dda\u52a0\u901f\u5668\u7684output\u96d6\u5927\u5e45\u6e1b\u5c0f(0.0684cGy/MU)\uff0c\u4f46\u85c9\u8457\u63d0\u9ad8\u5291\u91cf\u7387(600MU/min)\u4f7f\u6bcf\u6b21\u6cbb\u7642\u6642\u9593\u4e0d\u81f4\u904e\u9577\u3002\u75c5\u4eba\u9ad4\u8868\u7684dose variation\u5927\u81f4\u8207\u6587\u737b\u5831\u544a\u76f8\u7b26\u5408\u3002\u60df\u6c34\u5e73\u65b9\u5411\u7684\u7167\u91ce\u5e73\u5766\u5ea6\u7565\u70ba\u4e0d\u8db3(60cm\u7684\u7bc4\u570d\u5167\u662f\u00b110%)\u3002\n\u7d50\u8ad6\uff1a\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642\u7684\u6280\u8853\u6975\u7e41\u5fa9\uff0c\u5c0d\u6bcf\u4f4d\u75c5\u4eba\u7684\u5291\u91cf\u5b78\u8003\u616e\u9808\u517c\u9867\u500b\u6027\u3001\u7cfb\u7d71\u6027\u8207\u5b8c\u6574\u6027\u3002", "e": "Purpose: Dependent on the equipment and facilities available, we adopted \u201csix-dual-field technique\u201d to administer total skin electron radiation therapy (TSET). Our experience with dosimetric measurements for this modality is reported.\nMaterials and Methods: The source-to-surface distance (SSD) was extended to be 323 cm, and an 0.8 cm-thick acrylic screen was installed at 15 cm in front of the treatment plane to scatter the beam and attenuate the electron energy. At first, the optimal dual-field angle was determined in order to achieve feasible dose uniformity in the vertical dimension, and then field flatness could be assured. Film dosimetry was applied to define depth dose distribution profile of electron beam at treatment plane. Accordingly, the output of the linear accelerator could be calibrated. Multiplication factor was deter-mined to be 2.68, represented as the ratio of the absorbed dose from all six dual-fields to that from one dual-field measured with thermoluminescent dosimeters (TLDs) taped at Rando phantom. Thus, the value of MU for each field could be calculated. TLDs were used for in vivo dosimetry to verify the skin dose and evaluate dose variation at different anatomic sites.\nResults: The determined dual-field angle (20 ) and multiplication factor (2.68) were comparable to those described in the literature. Depth dose distribution and beam penetration were satisfying, and X-ray background level (0.75%) was also acceptable. Markedly decreased output of the Linac (0.0684 cGy/MU) could be partially compensated with the escalation of dose rate (600 MU/min). Thus, each treatment would not cost too much time. Does variation among different sites at skin is compatible with the experience of other institutions. Instead, field flatness in the horizontal dimension (\u00b11O% within 60 cm) did not meet the requirement given by AAPM.\nConclusion: The technique of TSET is complex. Dosimetry for this modality should be studied case by case systematically and thoroughly."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-45-66-a", "title": "\u81e8\u5e8a\u5291\u91cf\u6e2c\u5b9a\u65b9\u6cd5\u7684\u6700\u65b0\u767c\u5c55\uff0dTG-51\u8b70\u5b9a\u66f8", "keywords": "\u8a8d\u8b49\u901a\u904e\u5291\u91cf\u6821\u6b63\u7684\u5be6\u9a57\u5ba4,\u963b\u64cb\u672c\u9818\u6bd4\u503c,\u6c34\u4e2d\u5438\u6536\u5291\u91cf\u6821\u6b63\u56e0\u5b50 Accredited Dosimetry Calibration Laboratory\uff1b Stopping power ratios\uff1b Absorbe dose-to-water calibration factors", "c": "\u76ee\u7684\uff1a\u672c\u6587\u9996\u5148\u4ecb\u7d39TG-51\u8b70\u5b9a\u66f8\u7684\u5167\u5bb9\uff0c\u6aa2\u8a0e\u6b77\u5e74\u4f86\u81e8\u5e8a\u5291\u6e2c\u91cf\u65b9\u6cd5\u7684\u6f14\u9032\uff0c\u4e26\u4e14\u5206\u5225\u4f9d\u7167TG-21\u3001TG-51\u8b70\u5b9a\u66f8\u7684\u65b9\u6cd5\u91cf\u6e2c\u80fd\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u6bd4\u8f03\u8f38\u51fa\u5291\u91cf\u503c\u7684\u6539\u8b8a\uff0c\u6700\u5f8c\u63d0\u51fa\u66f4\u65b0\u5291\u91cf\u6e2c\u91cf\u65b9\u6cd5\u6642\u61c9\u8a72\u5be9\u614e\u8003\u91cf\u7684\u4e8b\u9805\uff0c\u907f\u514d\u9020\u6210\u81e8\u5e8a\u7684\u885d\u64ca\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u8a8d\u8b49\u901a\u904e\u7684\u5291\u91cf\u6821\u6b63\u5be6\u9a57\u5ba4(Accredited Dosimehy Calibration Laboratory\uff0cADCL)\u6821\u6b63\u7684\u6e2c\u91cf\u5668\u6750\uff0cKeithley 35617E85\u96fb\u91cf\u8a08\uff0c\u914d\u5408NE2571 0.6c.c.\u8fb2\u592b\u578b\u5713\u67f1\u5f0f\u6e38\u96e2\u8154\u3001PTWN23343 0.04c.c.\u5e73\u884c\u677f\u5f0f\u6e38\u96e2\u8154\uff0c\u5c0dVarian\u9ad8\u80fd\u76f4\u7dda\u52a0\u901f\u5668Clinic6/100(\u5149\u5b50\u80fd\u70ba6MV)\u8207Clinic1800(\u5149\u5b50\u80fd\u91cf\u70ba\u300118MV\uff0c\u96fb\u5b50\u80fd\u91cf\u70ba6\u30019\u300112\u300116\u300120MeV)\u91cf\u6e2c\u8f38\u51fa\u5291\u91cf\uff0c\u767c\u5225\u4f9d\u7167TG-21\u3001TG-51\u8b70\u5b9a\u66f8\u7684\u65b9\u6cd5\u6e2c\u91cf\u9ad8\u80fd\u76f4\u7dda\u52a0\u901f\u5668\u7684\u8f38\u51fa\u5291\u91cf\uff0c\u4ee5\u6bd4\u8f03\u6bcf\u76e3\u8996\u55ae\u4f4d\u7684\u5438\u6536\u5291\u91cf(cGy/MU)\u8b8a\u5316\u60c5\u6cc1\u3002\n\u7d50\u679c\uff1a\u57286MV\u5149\u5b50\u7684\u8b8a\u5316\u91cf\u81f3\u5206\u5225\u70ba0.7%\u30011.4%\uff0c18MV\u5149\u5b50\u7684\u8b8a\u5316\u91cf\u70ba2.2\uff05\uff0c\u5e73\u5747\u70ba1.43\uff05\uff0c\u80fd\u91cf\u8d85\u9ad8\u8b8a\u5316\u91cf\u8d8a\u5927\uff0c\u53ef\u80fd\u7531\u65bc\u80fd\u8b5c\u5206\u5e03\u8f03\u5ee3\uff0c\u4e14\u9ad8\u80fd\u5149\u5b50\u6709\u8f03\u5927\u7684\u6563\u5c04\uff0c\u4f7f\u5f97TG-21\u8207TG-51\u5728\u4f30\u7b97\u8f38\u51fa\u5291\u91cf\u4e4b\u7d50\u679c\u6709\u8f03\u5927\u7684\u5dee\u5225\uff1b\u96fb\u5b50\u7684\u8b8a\u5316\u91cf\u57281.5-2.2\uff05\u4e4b\u9593\uff0c\u5c0d\u80fd\u91cf\u7684\u6539\u8b8a\u4e26\u6c92\u6709\u660e\u986f\u7684\u8da8\u87c4\uff0c\u5e73\u5747\u7684\u8b8a\u5316\u91cf\u70bal.84%\uff0c\u8f03\u5149\u5b50\u7565\u9ad8\uff0c\u53ef\u80fd\u539f\u56e0\u70baTG-51\u8b70\u5b9a\u66f8\u5728\u96fb\u5b50\u5c04\u675f\u5291\u6e2c\u91cf\u65b9\u9762\uff0c\u7531\u65bc\u6e2c\u91cf\u4f4d\u7f6e\u8207TG-21\u8b70\u5b9a\u66f8\u4e0d\u540c\uff0c\u800c\u4e14\u4f7f\u7528\u8f03\u6e96\u78ba\u7684\u904e\u7a0b\u4f86\u63cf\u8ff0\u5be6\u969b\u81e8\u5e8a\u7684\u96fb\u5b50\u5c04\u675f\u8207\u963b\u64cb\u672c\u9818\u6bd4\u503c\u7684\u95dc\u4fc2\uff0c\u4e26\u5c07\u4f7f\u7528\u5e73\u884c\u677f\u6e38\u96e2\u8154\u7d0d\u5165\u8a55\u4f30\uff0c\u4f7f\u5f97\u96fb\u5b50\u5c04\u675f\u5728\u5291\u91cf\u6e2c\u91cf\u6642\uff0c\u6703\u6709\u7a0d\u505a\u5927\u4e00\u9ede\u7684\u6539\u8b8a\u3002\n\u7d50\u8ad6\uff1a\u7531\u65bcTG-51\u8b70\u5b9a\u66f8\u4e0d\u9700\u8981\u4f7f\u7528\u963b\u64cb\u672c\u9818\u6bd4\u503c(stopping-power ratios)\u8207\u8cea\u91cf\u80fd\u91cf\u5438\u6536\u4fc2\u6578(mass-energy absorption coefficients)\u7b49\u9f90\u5927\u3001\u7e41\u7463\u7684\u8868\u683c\uff0c\u4f7f\u7528\u8005\u4e5f\u4e0d\u9700\u8981\u8a08\u7b97\u4efb\u4f55\u7406\u8ad6\u4e0a\u7684\u5291\u91cf\u56e0\u5b50\uff0c\u4f7f\u5f97TG-51\u8b70\u5b9a\u66f8\u5728\u89c0\u5ff5\u4e0a\u6216\u4f7f\u7528\u4e0a\u90fd\u8f03TG-21\u8b70\u5b9a\u66f8\u55ae\u7d14\u3001\u5bb9\u6613\u8a31\u591a\uff0c\u8aa4\u5dee\u4e5f\u76f8\u5c0d\u5730\u964d\u4f4e\uff0c\u66f4\u70ba\u5de5\u4f5c\u65b9\u4fbf\uff0c\u5c07\u6e2c\u91cf\u904e\u7a0b\u7c21\u8981\u5730\u6b78\u7d0d\u6210\u5de5\u4f5c\u55ae(worksheets).\u4f7f\u7528\u8005\u53ea\u8981\u4f9d\u5faa\u8457\u5de5\u4f5c\u55ae\u7684\u6b65\u9a5f\uff0c\u5c31\u53ef\u4ee5\u5f88\u7c21\u55ae\u5730\u5c07\u5291\u91cf\u6e96\u78ba\u5730\u6e2c\u91cf\u51fa\u4f86\u3002\u70ba\u964d\u4f4e\u81e8\u5e8a\u5291\u91cf\u6e2c\u5b9a\u6642\u6240\u6709\u53ef\u80fd\u7684\u8aa4\u5dee\uff0c\u4e26\u7b26\u5408\u65e5\u76ca\u7cbe\u9032\u7684\u6cbb\u7642\u6280\u8853\u8207\u5291\u91cf\u6e96\u78ba\u5ea6\u7684\u8981\u6c42\uff0c\u5728\u6b64\u7c72\u8acb\u570b\u5bb6\u539f\u7d1a\u6a19\u6e96\u5be6\u6230\u5ba4\u5ee3\u6cdb\u63d0\u4f9b\u6e38\u96e2\u8154\u7684\u6c34\u4e2d\u5438\u6536\u5291\u91cf\u6821\u6b63\u56e0\u5b50(absorbed-dose-to-water calibration factors)\uff0cN\u3002", "e": "Purpose: This article introduces and compares the latest TO-51 clinical dosimetry protocol to the earlier protocol, TG-21. Based on the methodology of TG-21 and TG-51, the differences in clinical dosimetry measurements for both protocols are described and performed. Finally, precautions in performing the latest protocol were listed to avoid errors in clinic.\nMaterials and Methods: The electrometer (Keithley 35617EBS) with 0.6 c.c. Farmer type cylindricalion chamber (NE2571) and 0.04 C.c. plane parallel ion chamber were employed for the measurements. The electrometer and ion chambers were authenticated by the Accredited Dosimetry Calibration Laboratory (ADCL) in University of Texas. Varian linear accelerators Clinic6/100s/n: 358 (Photon beam energy with 6 MV) and Clinic1800 s/n:180 (Photon beam energies with 6 and 18 MV, electron beam with energies 6, 9, 12, 16 and 20 MeV) were used for output measurements. The measurement protocols were based on TG-21 and TG-51 respectively, with output doses obtained to observe the variations in the monitor unit of the absorbed dose (cGy/MU).\nResults: The variations of monitor unit in 6 MV photon were within 0.7% and 1.4%, 18 MV photon was 2.2%, and the average for photon energies was 1.43%. The higher the photon energy, the larger the variation, suggesting that higher photon energies produce more scatter radiation due to wider distributed energy spectrum. For the electron beam, the variations in monitor units were within 1.5 - 2.2% with the average of 1.84%, showing no dependency with the electron beam energies. The variations in electron beam output were slightly higher than the photon beam, possible reasons are the measurement points in TO-51 protocol for electron beam is different from earlier protocl, a more precise method to prescribe the relationship between the clinical beam quality and stopping power ratio of the electron beam and the plane parallel ion chamber is considered for the electron beam measurements.\nConclusion: The TG-51 protocol is simple campared to TG-21 protocol as large tables of stopping power ratios and mass-energy absorption coefficients are omitted and the user does not need to calculate any theoretical dosimetry factors, hence reduces calculation errors. For convenience, worksheets encompass the measurement steps and required equipment is provided. In Taiwan, it is strongly recommended that national primary standards laboratory should be established to provide the absorbed-dose-to-water calibration factor (N)for ion chambers to avoid clinical errors and to meet the accuracy in advanced radiation therapy and dosimetry."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-200003-7-1-67-75-a", "title": "\u6839\u64daTG-51\u8b70\u5b9a\u66f8\u4ee5\u4e0d\u540c\u6e38\u96e2\u8154\u91cf\u6e2c\u76f4\u7dda\u52a0\u901f\u5668\u96fb\u5b50\u8f38\u51fa\u5291\u91cf\u4e4b\u6bd4\u8f03", "keywords": "\u96fb\u5b50\u5438\u6536\u5291\u91cf\u6821\u6b63,TG-21\u8b70\u5b9a\u66f8,TG-51\u8b70\u5b9a\u66f8 Electron calibration,TG-21 protocol,TG-51 protocol", "c": "\u76ee\u7684\uff1a\u672c\u6587\u76ee\u7684\u4e3b\u8981\u6709\u4e8c\uff1a(1)\u6307\u51faTG-21\u8207TG-51\u5169\u7a2e\u8b70\u5b9a\u66f8\u5728\u6821\u6b63\u5291\u91cf\u8f38\u51fa\u65b9\u6cd5\u4e0a\u7684\u4e0d\u540c\u53ca\u5dee\u7570\uff1a\u53ca(2)\u4f9d\u64daTG-51\u9032\u884c\u96fb\u5b50\u5c04\u675f\u8f38\u51fa\u5291\u91cf\u4e4b\u6821\u6b63\uff0c\u5728\u4e0d\u540c\u96fb\u5b50\u80fd\u91cf\u53ca\u6e38\u96e2\u8154\u4e0b\u6bd4\u8f03\u5176\u7d50\u679c\u4e4b\u5dee\u7570\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u91dd\u5c0dSiemens PRIMUS\u8a62\u554f\u76f4\u7dda\u52a0\u901f\u5668\u76846\u30019\u300112\u300115\u300118\u300121MeV\u7b49\u96fb\u5b50\u80fd\u91cf\uff0c\u5206\u5225\u4f7f\u7528NE2581\u3001IC15\u5713\u67f1\u578b\u6e38\u96e2\u8154\u53caRoos\u578b\u7684PPC35\u5e73\u677f\u5f0f\u6e38\u96e2\u8154\u7b49\uff0c\u5728Wellhofer\u6c34\u5047\u9ad4\u4e2d\u9032\u884c\u8f38\u51fa\u5291\u91cf\u91cf\u6e2c\uff0c\u6839\u64daTG-51\u8b70\u5b9a\u66f8\u6821\u6b63\u8f38\u51fa\u5291\u91cf\uff0c\u6bd4\u8f03\u6240\u5f97\u4e4b\u5c0d\u6c34\u5438\u6536\u5291\u91cf\u503c\u3002\n\u7d50\u679c\uff1a\u6839\u64daTG-51\u8b70\u5b9a\u66f8\u4f7f\u7528\u4e0d\u540c\u6e38\u96e2\u8154\u6821\u6b63\u5728\u5291\u91cf\u6700\u5927\u8655\u4e4b\u96fb\u5b50\u8f38\u51fa\u5291\u91cf\uff0c\u8b8a\u5316\u5dee\u7570\u7a0b\u5ea6\u96a8\u96fb\u5b50\u80fd\u91cf\u5927\u5c0f\u4e0d\u540c\u800c\u6709\u4e0d\u540c\u7d50\u679c(-1.4%-0.67%)\uff0c\u5728\u96fb\u5b50\u80fd\u91cf\u70ba9MeV\u6642\u7684\u6821\u6b63\u7d50\u679c\u5dee\u7570\u6700\u5927\u3002NE2581\u8207PPC35\u5dee -1.4%\uff0cIC15\u8207PPC\u7684\u5dee\u7570\u503c\u70ba -1.26\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u7528\u4e0d\u540c\u6e38\u96e2\u8154\u6240\u9020\u6210\u7684\u7d50\u679c\u5dee\u7570\u6240\u5728\uff0c\u9664\u4e86\u5713\u67f1\u578b\u6e38\u96e2\u8154(NE2581\uff0cIC15)\u548c\u5e73\u677f\u5f0f\u6e38\u96e2\u8154(PPC35)\u672c\u8eab\u7684\u6e38\u96e2\u8154\u69cb\u9020\u3001\u6750\u8cea\u4e0d\u540c\u5916\uff0c\u5c0d\u6c34\u5438\u6536\u5291\u91cf\u6821\u6b63\u56e0\u5b50(absorbed-dose to water calibration factor\uff0cN)\u7684\u53d6\u5f97\u4ea6\u662f\u4e00\u91cd\u8981\u56e0\u7d20\u3002\u5176\u4e2dTG-21\u8b70\u5b9a\u66f8\u662f\u57fa\u65bc\u66b4\u9732(\u7a7a\u6c23\u514b\u99ac)\u65b9\u6cd5\uff0c\u8207\u8a31\u591a\u6821\u6b63\u56e0\u5b50\u7684\u63db\u7b97\u53bb\u9032\u884c\u5291\u91cf\u6821\u6b63\uff0c\u800cTG-51\u8b70\u5b9a\u66f8\u5247\u662f\u6839\u64da\u5c0d\u6c34\u5438\u6536\u5291\u91cf\u4fee\u6b63\u56e0\u5b50N\u548c\u5c04\u675f\u54c1\u8cea\u8f49\u63db\u56e0\u5b50kQ\u7684\u89c0\u5ff5\uff0c\u6240\u5f97\u4e4b\u53c3\u8003\u8f38\u51fa\u5291\u91cf\u6821\u6b63\u503c\u76f4\u63a5\u70ba\u6c34\u7684\u5438\u6536\u5291\u91cf\uff0c\u5176\u57fa\u790e\u6982\u5ff5\u8f03TG-21\u6613\u77ad\u89e3\uff0c\u4e14\u4e0d\u7528\u7d93\u904e\u5982TG-21\u7684\u8907\u96dc\u67e5\u8868\u8a08\u7b97\u3002", "e": "Purpose: The purpose of this paper is two-fold: (1)to indicate specific differences in the techniques between TO-21 and TG-51; and (2) to show the magnitude of the discrepancies in results when following the TG-51 protocol. The discrepancies are compared by different electron energies and chamber types.\nMaterials and Methods: We use three different ionization chambers ( NE 2581, IC 15 and PPC 35) to measure the output of electron beams.\nTo compare the values of absorbed dose to water determined according the newest AAPM TO-51 protocol for electron beams of energies from 6 to 21 MeV. The incident electron beams are from the Siemens PRIMUS3008 linear accelerator.\nResults: The results are found that differences in determined absorbed dose at Dmax by TO-51 protocol vary with electron beam energies and ion chambers. The discrepancies of the ratios are -1.4 %~0.67 %. The dose determined by the NE 2581 chamber is found to be the largest discrepancies than that of the PPC 35 chamber by -1.4 % at 9 MeV. The corresponding results for the IC 15 chamber are -1.26 % at 9 MeV.\nConclusions: We find that at difference s in determined absorbed dose at dmax according to the TG-51 protocol vary with the characteristics of ion chambers. The absorbed-dose to water calibration factor, N, is an important parameter, too. AAPM TO-21 protocol is based on an exposed (air-kerma) standard and multiple energy-dependent correction factors. The TG-51 protocol is based on an absorbed dose to water calibration factor (ND.IV) and an energy-dependent correction factor, kQ. The quantity of interest is absorbed dose to water in this TO-51 protocol. The overall TG-51 protocol is simpler and easier to understand than the TG-21 protocol."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-239-245-a", "title": "\u9aa8\u9abc\u8f49\u79fb\u7684\u55ae\u6b21\u8207\u5206\u6b21\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642\u7684\u6bd4\u8f03\uff1a\u4e00\u500b\u524d\u77bb\u6027\u96a8\u6a5f\u8a66\u9a57", "keywords": "\u9aa8\u8f49\u79fb;\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642;\u55ae\u6b21\u6cbb\u7642;\u5206\u6b21\u6cbb\u7642 Bone metastases;Palliative radiotherapy;Fractionation", "c": "\u524d\u8a00\uff1a\u5c0d\u89e3\u9664\u9aa8\u8f49\u79fb\u6240\u5f15\u8d77\u7684\u75bc\u75db\uff0c\u6700\u9069\u5207\u7684\u7de9\u548c\u6027\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u4ecd\u672a\u6709\u5b9a\u8ad6\u3002\u672c\u7814\u7a76\u76ee\u7684\u5728\u6bd4\u8f03\u5169\u7a2e\u4e0d\u540c\u7684\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u5c0d\u9aa8\u8f49\u79fb\u6027\u75bc\u75db\u7684\u6cbb\u7642\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5171\u670936\u4f4d\u56e0\u9aa8\u8f49\u79fb\u800c\u5f15\u8d77\u75bc\u75db\u7684\u764c\u75c7\u60a3\u8005\u9032\u5165\u672c\u524d\u81bd\u6027\u96a8\u6a5f\u8a66\u9a57\u3002\u75c5\u4eba\u96a8\u6a5f\u5206\u6d3e\u6210\u5169\u7d44\uff0c\u7b2c\u4e00\u7d44\u75286Gy\u7684\u55ae\u6b21\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u3002\u7b2c\u4e8c\u7d44\u75c5\u4eba\u752830Gy\u5206\u621010\u6b21\u7684\u5206\u6b21\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u3002\u6bcf\u4f4d\u75c5\u4eba\u5171\u8ffd\u8e64\u4e09\u6b21\uff0c\u6cbb\u7642\u958b\u59cb\u524d\u4e00\u6b21\u3001\u6cbb\u7642\u5b8c\u6210\u5f8c\u4e09\u5929\u53ca\u4e00\u500b\u6708\u5f8c\u5404\u4e00\u6b21\u3002\u7531\u75c5\u4eba\u4f9d\u4e3b\u89c0\u7684\u611f\u53d7\u7d66\u5206\uff0c\u85c9\u4ee5\u8a55\u4f30\u6b64\u5169\u7a2e\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u7684\u6cbb\u7642\u6548\u679c\u3002\n\u7d50\u679c\uff1a\u6b64\u5169\u7a2e\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u5728\u75bc\u75db\u7de9\u89e3\u7684\u7a0b\u5ea6\u3001\u75bc\u75db\u7de9\u89e3\u5f8c\u6240\u80fd\u6301\u7e8c\u7684\u6642\u554f\u3001\u65e5\u5e38\u751f\u6d3b\u56e0\u9aa8\u75bc\u75db\u800c\u53d7\u9650\u5236\u7684\u7a0b\u5ea6\u3001\u4ee5\u53ca\uff08\u53e3\u60e1\uff09\u5fc3\u5614\u5410\u7684\u72c0\u6cc1\u4e0a\u3002\u4e26\u7121\u986f\u8457\u7684\u5dee\u7570\u3002\u4f46\u57286Gy\u7684\u55ae\u6b21\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u5f8c\u4e09\u5929\uff0c\u75bc\u75db\u767c\u4f5c\u7684\u983b\u7387\u4fbf\u6709\u986f\u8457\u7684\u964d\u4f4e(p=0.001)\uff0c\u4e26\u6301\u7e8c\u5230\u6cbb\u7642\u5f8c\u4e00\u500b\u6708(p=0.003)\uff1b\u4e14\u75c5\u60a3\u89ba\u5f97\u75b2\u618a\u7684\u7a0b\u5ea6\uff0c\u8f03\u5206\u6b21\u5291\u91cf\u653e\u5c04\u6cbb\u7642\u8f15(p=0.003)\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u5b58\u6d3b\u671f\u4e0d\u9577\u7684\u764c\u75c7\u672b\u671f\u75c5\u4eba\uff0c\u4e00\u6b216Gy\u7684\u55ae\u6b21\u5291\u91cf\u653e\u5c04\u6cbb\u7642\uff0c\u63d0\u4f9b\u4e86\u6cbb\u7642\u9aa8\u8f49\u79fb\u75bc\u75db\u4e00\u500b\u66f4\u5b89\u5168\u6709\u6548\uff0c\u800c\u53c8\u5feb\u901f\u7684\u65b9\u5f0f\u3002", "e": "Introduction: The most optimal radiotherapy schedule for palliative irradiation of painful bony metastases remains controversial. This study compares the therapeutic efficacy of two radiotherapy schedules in the management of painful bony metastases.\nMaterials and Methods: Thirty-six patients with painful bony metastases entered the prospective randomized trial. They were randomized to receive either a single 6Gy treatment (Group 1) or a course of 30Gy in ten daily fractions (Group 2). Every patient had three follow-up visits which included at the beginning of treatment, three days, and one month after completion of the treatment. The efficacy of theses two radiotherapy schedules was evaluated by each visit using a self-scoring questionnaire.\nResults: There were no significant differences between the two treatment regimens in the degree of pain relief, the duration of pain relief, and the limitation of movement due to metastatic bone pain nor nausea or vomiting. Three days after single 6Gy radiotherapy treatment, the frequency of pain episodes can be reduced significantly (p=0.001) and so do one month later (p=0.003); in addition, these patients had less fatique than patients treated with fractionated radiotherapy (p=0.033).\nConclusion: A single 6Gy radiotherapy offers a safer, easier, and more effective way to manage metastatic bone pain in a terminal patient with a very short life expectancy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-247-252-a", "title": "Preliminary Results of Fractionated Stereotactic Radiotherapy in Patients with Advanced Hepatocellular Carcinoma", "keywords": "\u665a\u671f\u809d\u764c;\u591a\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6027\u50b7\u5bb3 Advanced hepatocellular carcinoma;Fractionated stereotactic radiotherapy;Radiation toxicity", "c": "\u76ee\u7684\uff1a\u6813\u585e\u5931\u6557\u5f8c\u5fa9\u767c\u7684\u665a\u671f\u809d\u764c\u7684\u6cbb\u7642\u7d50\u679c\u901a\u5e38\u5f88\u5dee\uff0c\u70ba\u4e86\u5c07\u809d\u81df\u653e\u5c04\u6cbb\u7642\u7684\u65e9\u671f\u548c\u665a\u671f\u50b7\u5bb3\u6e1b\u81f3\u6700\u4f4e\uff0c\u4e26\u4fdd\u5b58\u6700\u591a\u6b63\u5e38\u809d\u81df\u7d44\u7e54\u3002\u6211\u5011\u5617\u8a66\u4f7f\u7528\u591a\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u4f86\u6cbb\u7642\u6813\u585e\u5931\u6557\u5f8c\u5fa9\u767c\u7684\u665a\u671f\u809d\u764c\u3002\n\u65b9\u6cd5\u53ca\u6750\u6599\uff1a\u4e8c\u5341\u4e09\u4f4d\u665a\u671f\u809d\u764c\u75c5\u4eba\u63a5\u53d7\u4e86\u4e8c\u5341\u4e8c\u5206\u6b21\u7e3d\u5291\u91cf55Gy\u7684\u591a\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff0c\u6240\u6709\u75c5\u4eba\u7684\u526f\u4f5c\u7528\u53ca\u53cd\u61c9\u5747\u7d93\u904e\u8a55\u4f30\u3002\n\u7d50\u679c\uff1a\u6cbb\u7642\u7d50\u675f\u5f8c\u4e00\u500b\u6708\u5e73\u5747\u816b\u7624\u9ad4\u7a4d\u8b8a\u5c0f29%\uff0c\u4e8c\u500b\u6708\u9ad4\u7a4d\u5247\u70ba\u6e1b\u5c1141%\uff0c\u4e09\u500b\u6708\u5247\u70ba55%\uff0c\u518d\u8005\u5341\u4e03\u4f4d\u6cbb\u7642\u524d\u7532\u578b\u80ce\u5152\u86cb\u767d(AFP)\u5347\u9ad8\u7684\u75c5\u4eba\u4e2d\uff0c\u5341\u4e94\u4f4d(88 %)\u767c\u73fe\u5728\u6cbb\u7642\u5f8c\u7b2c\u4e00\u500b\u6708AFP\u5747\u964d\u4f4e\uff0c\u5176\u4e2d\u5341\u540d(59%)\u66f4\u65bc\u6cbb\u7642\u5f8c\u4e00\u500b\u6708\u6642AFP\u964d\u4f4e\u5230\u6cbb\u7642\u524d\u7684\u4e00\u534a\u4ee5\u4e0b\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u672b\u671f\u809d\u764c\u75c5\u60a3\u800c\u8a00\uff0c\u9019\u7a2e\u591a\u5206\u6b21\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u662f\u4e00\u7a2e\u53ef\u884c\u7684\u6cbb\u7642\u65b9\u5f0f\u3002", "e": "Purpose: The treatment result of advanced hepatocellular carcinoma failed from previous TACE is often unsatisfactory. To minimize the acute and late adverse effects of liver irradiation and preserve maximal normal liver tissue, fractionated stereotactic radiotherapy (R/T) is used in our institute.\nMaterials & Methods: Twenty-three patients with advanced hepatocellular carcinoma received fractionated stereotactic radiotherapy with 55Gy in 22 fractions. All patients were assessable for side effects and response.\nResults: The mean regression of turner volume was 29% at 1 month after completion of R?T, 41% at 2 months and 55% at 3 months. In 17 patients with elevated serum alpha-fetoptein (AFP), 15 (88%) were found to have response in the first month after R/T, 10 (59%) had regression of more than 50% of the original level at the first month after R/T. \nConclusion: For patients with advanced hepatocellular carcinoma, the fractionated stereotactic radiotherapy is a feasible modality and deserves further follow-up for outcome and toxicity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-253-260-a", "title": "3D-Conformal Radiotherapy of Unresectable and Unembolizable Advanced Hepatoma-A Pilot Study", "keywords": "\u809d\u764c;\u4e09\u7dad\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u5148\u5c0e\u7814\u7a76 Hepatoma;3D-conformal radiotherapy;Pilot study", "c": "Purpose: To conduct a pilot study on the feasibility of 3D-conformal radiotherapy on unresectable and unembolizable advanced hepatoma.\nMaterials and Methods: From November 1996 to March 1998, 16 patients of 15 males and 1 female with median age 62 (range 26-80) were enrolled in this pilot study. All the patients have varying degree of liver cirrhosis. According to Child's classification, 8 patients were in Child' A, 7 in Child's B and I in Child's C. Two patients had diffuse disease, 11 with massive-nodular lesion (\uff1e = 7cm), 4 with smaller nodular lesion (\uff1c7cm). All patients had their CT images taken at treatment position and contours of the tumor and normal tissues were defined. Tumor volume was bounded with 2cm margin bilaterally, 2.0 to 2.5cm in cranial and caudal direction depending on the extent of respiratory motion. The beam's eye view representation was used for treatment planning. Normal liver was maximally spared outside the target volume and irradiation was administered daily using 10 MV X-rays at 1.8-2Gy per fraction. The percent volume of normal liver irradiated by 50% of target dose or greater (% VNLD50) would determine total dose given.\nResults: Eight patients had % VNLD50 less than 40 and the median dose given was 60.1Gy (range 49-68Gy). There were 3 PR (partial response), 3 SD (stable disease), 1 CR (complete response) and 1 PD (progressive disease). There were two patients died of fatal radiation hepatitis. Six patients were in the group having 33 to 66 % VNLDSO and median dose was 49.4Gy (range 40-64Gy). There were 4 SD and 2 PD. Two patients suffered from non-fatal radiation hepatitis and 1 patient died of fatal hepatitis. Two patients had %VNLD50 greater than 66. One was SD and another one had PD. One patient died of fatal radiation hepatitis. Median follow-up time was 7 months. Overall response rate was 25%. Median survival was 7 months (range 1-16). Six-month survival rate was 50% and that of 1 2-month was 37.5%.\nConclusion: Selected cases of hepatoma that has %VNLDSO under 40 can be'considered for 3D-conformal radiotherapy but the correlation of radiation dose and radiation induced liver damage still need further investigation. For cases with % VNLD50 greater than 66, there is no clinical benefit of performing 3D-oonformal radiotherapy.", "e": "Purpose: To conduct a pilot study on the feasibility of 3D-conformal radiotherapy on unresectable and unembolizable advanced hepatoma.\nMaterials and Methods: From November 1996 to March 1998, 16 patients of 15 males and 1 female with median age 62 (range 26-80) were enrolled in this pilot study. All the patients have varying degree of liver cirrhosis. According to Child's classification, 8 patients were in Child' A, 7 in Child's B and I in Child's C. Two patients had diffuse disease, 11 with massive-nodular lesion (\uff1e = 7cm), 4 with smaller nodular lesion (\uff1c7cm). All patients had their CT images taken at treatment position and contours of the tumor and normal tissues were defined. Tumor volume was bounded with 2cm margin bilaterally, 2.0 to 2.5cm in cranial and caudal direction depending on the extent of respiratory motion. The beam's eye view representation was used for treatment planning. Normal liver was maximally spared outside the target volume and irradiation was administered daily using 10 MV X-rays at 1.8-2Gy per fraction. The percent volume of normal liver irradiated by 50% of target dose or greater (% VNLD50) would determine total dose given.\nResults: Eight patients had % VNLD50 less than 40 and the median dose given was 60.1Gy (range 49-68Gy). There were 3 PR (partial response), 3 SD (stable disease), 1 CR (complete response) and 1 PD (progressive disease). There were two patients died of fatal radiation hepatitis. Six patients were in the group having 33 to 66 % VNLDSO and median dose was 49.4Gy (range 40-64Gy). There were 4 SD and 2 PD. Two patients suffered from non-fatal radiation hepatitis and 1 patient died of fatal hepatitis. Two patients had %VNLD50 greater than 66. One was SD and another one had PD. One patient died of fatal radiation hepatitis. Median follow-up time was 7 months. Overall response rate was 25%. Median survival was 7 months (range 1-16). Six-month survival rate was 50% and that of 1 2-month was 37.5%.\nConclusion: Selected cases of hepatoma that has %VNLDSO under 40 can be'considered for 3D-conformal radiotherapy but the correlation of radiation dose and radiation induced liver damage still need further investigation. For cases with % VNLD50 greater than 66, there is no clinical benefit of performing 3D-oonformal radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-261-272-a", "title": "\u4ee5\u96fb\u8166\u65b7\u5c64\u70ba\u6a21\u64ec\u8a08\u756b\u57fa\u790e\u7684\u4e73\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u6210\u679c\u5831\u544a", "keywords": "\u653e\u5c04\u6cbb\u7642;\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71;\u4e73\u764c;\u80ba\u90e8\u7e96\u7dad\u5316 Radiotherapy;CT-based simulation;Breast cance;Lung fibrosis", "c": "\u76ee\u7684\uff1a\u4ee5\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u4f5c\u70ba\u4e73\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u524d\u4e4b\u6a21\u64ec\u651d\u5f71\uff0c\u53ef\u589e\u9032\u6cbb\u7642\u6e96\u78ba\u5ea6\u671f\u671b\u80fd\u6e1b\u5c11\u80ba\u7e96\u7dad\u5316\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u6c11\u570b83\u5e747\u6708\u81f3\u6c11\u570b88\u5e741\u6708\u6b62\uff0c\u4ee5\u5728\u672c\u79d1\u63a5\u53d7\u5b8c\u6574\u653e\u5c04\u6cbb\u7642\u6cbb\u7642\u4e26\u5b9a\u671f\u8ffd\u8e64\u7684\u4e73\u764c\u75c5\u60a3\u70ba\u7814\u7a76\u5c0d\u8c61\uff0c\u5171\u670995\u4eba\uff0c\u5e73\u5747\u5e74\u9f61\u70ba49\u6b72\uff0c\u5e73\u5747\u8ffd\u8e64\u6642\u9593\u70ba26.74\u500b\u6708\u3002\u6240\u6709\u7684\u75c5\u4eba\u5747\u5148\u4ee5Alpha Cradle\u56fa\u5b9a\uff0c\u6a21\u64ec\u5b9a\u4f4d\u5f8c\uff0c\u63a5\u53d7\u8a3a\u65b7\u7528\u7684\u96fb\u8166\u65b7\u5c64\u6383\u7784\uff0c\u4e26\u5c07\u5f71\u50cf\u50b3\u81f3\u5de5\u4f5c\u7ad9\u4e4b\u96fb\u8166\uff0c\u505a\u6a21\u64ec\u8a08\u756b\u8a02\u51fa\u5207\u7dda\u7167\u91ce\u90e8\u4f4d\u3002\u78ba\u5b9a\u5f8c\uff0c\u518d\u65bc\u6a21\u64ec\u5b9a\u4f4d\u5ba4\u4f9d\u96fb\u8166\u6a21\u64ec\u7684\u7d50\u679c\u5be6\u969b\u6a21\u64ec\u4e00\u6b21\uff0c\u4e26\u8a02\u51fa\u5176\u4ed6\u6cbb\u7642\u90e8\u4f4d\uff0c\u5b8c\u6210\u5f8c\u65b9\u958b\u59cb\u6cbb\u7642\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u9808\u5b9a\u671f\u56de\u8a3a\u4e26\u4ee5\u80f8\u90e8X\u5149\u7247\u6aa2\u8996\u80ba\u90e8\u72c0\u6cc1\uff0c\u4ee5\u89c0\u5bdf\u5176\u80ba\u7e96\u7dad\u5316\u60c5\u5f62\u3002\u6b64\u5916\uff0c\u61c9\u75283-D\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u6aa2\u8996\u6240\u6709\u75c5\u60a3\u5176\u5207\u7dda\u7167\u91ce\u4e4b\u80ba\u90e8\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u72c0\u6cc1\uff0c\u8207\u80ba\u7e96\u7dad\u5316\u505a\u6bd4\u8f03\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u6cbb\u7642\u524d\u5f8c\u80f8\u90e8X\u5149\u7247\u8207\u653e\u5c04\u90e8\u4f4d\u4e4b\u6bd4\u5c0d\u6aa2\u8996\uff0c\u80ba\u7e96\u7dad\u5316\u5171\u67095\u4f8b(526%)\uff0c\u800c\u5c40\u90e8\u5fa9\u767c\u8005\u67093\u4f8b(3.16%)\u3002\u5c31\u80ba\u9435\u7dad\u5316\u76845\u4f8b\u75c5\u60a3\u800c\u8a00\uff0c\u5176\u96fb\u8166\u65b7\u5c64\u5716\u4e0a\u7684\u6700\u5927\u5782\u76f4\u8ddd\u96e2(greatest perpendicular distance, GPD)\u5e73\u5747\u70ba1.75cm\u3002\u63a5\u53d7\u5207\u7dda\u7167\u91ce\u7167\u5c04\u7684\u80ba\u90e8\u9ad4\u7a4d\u5e73\u5747\u70ba122.25ml\uff0c\u800c\u5176\u63a5\u53d7\u7167\u5c04\u7684\u80ba\u90e8\u9ad4\u7a4d\u4f54\u540c\u5074\u80ba\u9ad4\u7a4d\u4e4b\u767e\u5206\u6bd4\u5e73\u5747\u70ba7%,3\u4f8b\u5c40\u90e8\u5fa9\u767c\u75c5\u60a3\u5176GPD\u5e73\u5747\u70ba1.5cm\uff1b\u63a5\u53d7\u5207\u7dda\u7167\u91ce\u7167\u5c04\u7684\u80ba\u90e8\u9ad4\u7a4d\u5e73\u5747\u70ba155.48ml\uff1b\u800c\u5176\u7167\u5c04\u7684\u80ba\u9ad4\u7a4d\u4f54\u540c\u5074\u80ba\u9ad4\u7a4d\u4e4b\u767e\u5206\u6bd4\u5e73\u5747\u70ba6.12%\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u96fb\u8166\u65b7\u5c64\u70ba\u6a21\u64ec\u8a08\u756b\u57fa\u790e\u7684\u4e73\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u589e\u52a0\u6cbb\u7642\u8a08\u756b\u7684\u6e96\u78ba\u5ea6\u3002\u5b83\u6bd4\u50b3\u7d71\u6cbb\u7642\u66f4\u7cbe\u78ba\u7684\u539f\u56e0\u5728\u65bc\u80fd\u7cbe\u78ba\u5730\u638c\u63e1\u89e3\u5256\u5b78\u4e0a\u7684\u4f4d\u7f6e\uff0c\u5982\u810a\u9ad3\uff0c\u5fc3\u81df\uff0c\u6dcb\u5df4\u7d50\uff0c\u53ca\u539f\u767c\u816b\u7624\u4f4d\u7f6e\uff0c\u6240\u4ee5\u66f4\u80fd\u638c\u63e1\u8981\u6cbb\u7642\u7684\u90e8\u4f4d\u53ca\u8981\u4fdd\u8b77\u7684\u7d44\u7e54\u3002\u6211\u5011\u5e0c\u671b\u85c9\u6b64\u53ef\u4ee5\u5b89\u5168\u5730\u7d66\u4e88\u8f03\u9ad8\u5291\u91cf\uff0c\u4ee5\u63d0\u6607\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u53ca\u6e1b\u5c11\u80ba\u90e8\u7167\u5c04\u4ee5\u964d\u4f4e\u80ba\u7e96\u7dad\u5316\u7684\u767c\u751f\u3002", "e": "Purpose: Using CT-based simulation as an aid for breast cancer radiotherapy to increase the accuracy of treatment and hope to decrease the rate of lung fibrosis.\nMaterials and Methods: From July 1994 to January 1999, we retrospectively analyzed 95 patients who received full course radiotherapy with regular follow-up at our department. The average age of the patients was 49 years old, and the median follow-up interval was 26.7 months. A method was devised to simulate patients with breast cancer in the actual treatment position by using a diagnostic CT spiral scanner and a workstation for virtual simulation. It was desired to produce non-divergent tangential beams through the lung at the matching line for tangential and supraclavicular fields. Bach patient was immobilized in an Alpha Cradle cast. Radio-opaque markers were placed on the margins of the fields decided by simulation and CT scan was performed. The data set was transferred to the workstation. After reconstruction of all the images, we performed virtual simulation from computer. When treatment parameters were decided, we would resimulate patient before treatment started. Patients received regular follow-up after completion of radiotherapy. Chest X-ray films were taken to detect lung metastasis and fibrosis while physical examination and chest CT were performed to evaluate local recurrence.\nResults: All the chest X-ray films were rechecked and 5 patients (5.26%) with lung fibrosis were noted. According to the chart records and CT images, local recurrence was noted in 3 patients (3.16%). Among the 5 patients with lung fibrosis, the average greatest perpendicular distance (GPD) measured from the CT image was 1.75cm, the average irradiated lung volume of the tangential fields was 122.25 mlthat occupied 7% of the ipsilateral lung volume. For the 3 patients with local recurrence, the average GPD was 1.5cm, the average irradiated lung volume within the tangential fields was 155.48 ml, and the average irradiated lung volume was 6.12% of the ipsilateral lung.\nConclusion: Using CT-based simulation as an aid for breast cancer radiation treatment was more accurate than traditional treatment planning. It provided us the accurate relationship between the position of the target and critical organs. We decrease irradiated lung volume and hope to reduce the chance of lung fibrosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-273-283-a", "title": "Evaluation of Tumor Markers in the Follow-Up of Breast Cancer Patients after Treatment", "keywords": "CEA;TPA;CA153;\u816b\u7624\u76f8\u95dc\u6297\u539f;\u4e73\u764c;\u816b\u7624\u6307\u6578 CEA;TPA;CA153;Tumor-associated antigen;Breast cancer;Tumor markers", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u7814\u7a76\u91dd\u5c0d\u63a5\u53d7\u904e\u624b\u8853\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642\u4ee5\u53ca\u8cc0\u723e\u8499\u6cbb\u7642\u7684\u4e73\u764c\u60a3\u8005\uff0c\u5075\u6e2c\u5176\u8840\u6db2\u4e2d\u4e4bCEA\u3001TPA\u4ee5\u53caCA153\u6fc3\u5ea6\uff0c\u63a2\u8a0e\u55ae\u7368\u6216\u8907\u5408\u4f7f\u7528\u6642\u8207\u65e9\u671f\u6aa2\u6e2c\u5fa9\u767c\u7684\u95dc\u4fc2\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5f9e332\u4f4d\u4e73\u764c\u60a3\u8005\uff08\u5e73\u5747\u8ffd\u8e6448.9\u500b\u6708\uff09\u53d6\u5f97\u7cfb\u5217CEA\u3001TPA\u4ee5\u53caCA153\u7684\u8840\u6db2\u6fc3\u5ea6\u503c\u3002\u5728\u8ffd\u8e64\u904e\u7a0b\u4e2d\uff0c\u6709195\u500b\u5fa9\u767c\u7684\u4e8b\u4ef6\uff1b\u6211\u5011\u6bd4\u8f03\u4e86\u816b\u7624\u6307\u6578\u81e8\u754c\u503c\u300120%\u4ee5\u53ca30%\u52d5\u614b\u8b8a\u5316\u7b49\u4e09\u7a2e\u65b9\u6cd5\uff0c\u5c0d\u65bc\u9810\u6e2c\u764c\u75c7\u5fa9\u767c\u7684\u512a\u52a3\u9ede\u3002\n\u7d50\u679c\uff1a\u7531\u81e8\u754c\u503c\u7684\u6bd4\u8f03\u6240\u7372\u5f97\u7684\u654f\u611f\u6027\u53ca\u5c08\u4e00\u6027\u5206\u5225\u70ba\uff1aCEA (27.91%, 94.38%)\u3001TPA(63.37% 5313%)\u4ee5\u53caCA153 (31.40 %, 92.50%)\u3002\u800c\u85c9\u753120%\u9023\u7e8c\u52d5\u614b\u8b8a\u5316\u7684\u65b9\u6cd5\u6240\u53d6\u5f97\u7684\u654f\u611f\u6027\u53ca\u5c08\u4e00\u6027\u5247\u70ba\uff1aCEA (59.30%,18.75%)\u3001TPA (55.23%, 38.13%)\u3001\u4ee5\u53caCA153 (17.44%, 99.38%)\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u7bc7\u5be6\u9a57\u4e2d\uff0c\u8f49\u79fb\u7684\u5730\u9ede\u88ab\u5206\u985e\u6210\u81df\u5668\u3001\u9aa8\u982d\u4ee5\u53ca\u5c40\u90e8\u5fa9\u767c\u7b49\u4e09\u5927\u985e\u3002\u816b\u7624\u6307\u6578\u7684\u654f\u611f\u6027\u548c\u5fa9\u767c\u5730\u9ede\u6709\u5f88\u597d\u7684\u95dc\u9023\u6027\uff1a\u4e00\u822c\u4f86\u8aaa\u5c0d\u65bc\u5c40\u90e8\u5fa9\u767c\u7684\u654f\u611f\u6027\u8f03\u5dee\u4f46\u5c0d\u65bc\u81df\u5668\u8655\u5247\u8f03\u597d\u3002\u7576\u4f7f\u7528\u81e8\u754c\u503c\u7684\u65b9\u6cd5\u6642\uff0cCA153\u6bd4CEA\u6709\u66f4\u9ad8\u7684\u654f\u611f\u6027\uff1b\u4f46\u662f\u82e5\u6539\u7528\u9023\u7e8c\u52d5\u614b\u6578\u503c\u6642\uff0c\u5247\u5169\u8005\u525b\u597d\u76f8\u53cd\u3002\u5c0d\u65bc\u55ae\u4e00\u816b\u7624\u6307\u6578TPA\u4f86\u8aaa\uff0c\u4f7f\u7528\u81e8\u754c\u503c\u7684\u65b9\u6cd5\u5c0d\u65bc\u6240\u6709\u7684\u8f49\u79fb\u8655\u800c\u8a00\u90fd\u6709\u6700\u597d\u7684\u654f\u611f\u5ea6\uff0c\u4f46\u82e5\u6539\u7528\u9023\u7e8c\u52d5\u614b\u6578\u503c\uff0c\u5247\u5728\u81df\u5668\u8f49\u79fb\u8655\uff0cCEA\u6709\u6700\u9ad8\u7684\u654f\u611f\u6027\u3002\u816b\u7624\u6307\u6578\u7570\u5e38\u5347\u9ad8\u901a\u5e38\u9810\u6e2c\u4e86\u6cbb\u7652\u5f8c\u7684\u518d\u767c\u73fe\u8c61\uff0c\u800c\u7576\u8907\u5408\u4f7f\u7528CEA\u3001TPA\u548cCA153\u6642\uff0c\u5247\u6709\u52a9\u65bc\u63d0\u9ad8\u9810\u6e2c\u7684\u654f\u611f\u6027\u3002", "e": "Purpose: This study evaluates the usefulness of serial CEA, TPA, CA153 and combined modalities in serum levels for screening recurrence in patients with primary breast cancer after surgery, chemotherapy, radiotherapy and hormone therapy.\nMaterials and Methods: CEA, TPA, and CA153 serial serum determinations were performed on 332 patients (median follow-up: 48.9 months) with primary breast cancer. Within the group, there were 195 clinically diagnosed episodes of relapse during follow- up. Comparison among groups by cut-off value, and dynamic changes of 20% and 30% were done.\nResults: The sensitivity and specificity, determined for circulating tumor markers by cutoff levels were (for CEA)27.91%, 94.38%; (TPA) 63.37%, 53.13%; and (CM 53) 31.40%, 92.50%, respectively. Utilizing 20% dynamic change methods, CEA, TPA and CA1S3 showed sensitivities of 59.30%, 55.23% and 17.44%, and specificities of 18.75%, 38.13% and 99.38%, respectively.\nConclusions: In this study, metastatic patients were classified into three categories of sites: viscera, bones and locoregional. Tumor marker sensitivity was clearly related to the site of recurrence; the lowest sensitivity was found in locoregional relapse and the highest was in patients with visceral metastasis, CA153 was more sensitive than CEA in monitoring breast cancer recurrence under cut-off methods but the results were reversed when serum concentration was evaluated by dynamic changes. For single markers, TPA presented the best sensitivity in all fields under cut-off methods, but was surpassed by CEA under dynamic changes for the detection of visceral metastasis. Unlike the other categories, when serum TPA values were determined by dynamic changes, the highest sensitivity was obtained for visceral metastasis detection. Significant elevation predicted new recurrence or tumor regrowth after complete remission. The combined use of CEA, TPA, and CA153 increased the overall sensitivity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-285-293-a", "title": "Radiotherapy in Graves Ophthalmopathy at National Taiwan University Hospital", "keywords": "\u683c\u96f7\u592b\u53f8\u6c0f\u773c\u75c5;\u653e\u5c04\u6cbb\u7642;\u6c34\u6676\u9ad4 Graves", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4e26\u8a0e\u8ad6\u53f0\u5927\u91ab\u9662\u683c\u96f7\u592b\u53f8\u6c0f\u773c\u75c5\u653e\u5c04\u6cbb\u7642\u4e4b\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1992\u5e74\u81f31997\u5e74\u5171\u670916\u4f4d\u683c\u96f7\u592b\u53f8\u6c0f\u773c\u75c5\u4e4b\u60a3\u8005\u65bc\u53f0\u5927\u91ab\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u5176\u4e2d8\u4f4d\u7537\u6027\uff0c8\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u81ea14\u6b72\u81f363\u6b72\uff0c\u5e73\u5747\u5e74\u9f61\u70ba42.9\u6b72\u3002\u591a\u6578\u75c5\u60a3\u4ee5\u773c\u7403\u7a81\u51fa\u3001\u8edf\u7d44\u7e54\u75c7\u72c0\u53ca\u773c\u808c\u904b\u52d5\u969c\u7919\u70ba\u4e3b\u3002\u75c5\u60a3\u5747\u63a5\u53d7\u55ae\u6b21\u5291\u91cf2Gy\uff0c\u7e3d\u5291\u91cf20Gy\u4e4b\u653e\u5c04\u6cbb\u7642\uff0c\u6cbb\u7642\u7bc4\u570d\u5305\u542b\u6240\u6709\u7570\u5e38\u90e8\u4f4d\uff0c\u7d93\u5e38\u7531\u5f8c\u773c\u7403\u5ef6\u4f38\u81f3\u524d\u5e8a\u7a81\u3002\n\u7d50\u679c\uff1a\u7e3d\u8a08625% (10/16)\u7684\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u6709\u7642\u6548\uff0c\u5176\u4e2d\u8edf\u7d44\u7e54\u75c7\u72c0\u7684\u6539\u5584\u70ba62.5% (10/16)\u3002\u773c\u7403\u7a81\u51fa\u7684\u6539\u5584\u70ba83.3% (5/6)\uff0c\u773c\u808c\u904b\u52d5\u969c\u7919\u7684\u6539\u5584\u70ba400% (4/10)\uff0c\u6709600% (3/5)\u7684\u75c5\u60a3\u5728\u8996\u529b\u4e0a\u7372\u5f97\u6539\u5584\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u7e3d\u5291\u91cf20Gy\u7684\u653e\u5c04\u6cbb\u7642\u53ef\u6709\u6548\u7528\u65bc\u907f\u514d\u683c\u96f7\u592b\u53f8\u6c0f\u773c\u75c5\u6d3b\u52d5\u671f\u4e4b\u52a0\u5287\u53ca\u6e1b\u5c11\u985e\u56fa\u9187\u6cbb\u7642\u5ef6\u9577\u4f7f\u7528\u6240\u5e36\u4f86\u4e4b\u526f\u4f5c\u7528\u3002\u683c\u96f7\u592b\u53f8\u6c0f\u773c\u75c5\u653e\u5c04\u6cbb\u7642\u7684\u9069\u61c9\u75c7\u5305\u62ec\uff1a\u985e\u56fa\u9187\u7642\u6cd5\u5931\u6557\u6216\u75c5\u60a3\u5c0d\u4f7f\u7528\u985e\u56fa\u9187\u6709\u7981\u5fcc\u8005\u3002\u624b\u8853\u6cbb\u7642\u5982\u773c\u7403\u6e1b\u58d3\uff0c\u53ef\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u5f8c\u773c\u7403\u7a81\u51fa\u6301\u7e8c\u9032\u5c55\u6216\u7121\u6548\u4e4b\u75c5\u60a3\u3002", "e": "Purpose: To evaluate and discuss the radietion therapeutic results of Graves' ophthamopathy treated at National Taiwan University Hospital (NTUH).\nMaterials & Methods: This retrospective study was to review the 16 patients with Graves' ophthalmopathy whom treated with radiation therapy at National Taiwan University Hospital from 1992 to 1997. There were Smen and 8 women, aged from 14 to 63 years old, with a mean age of 42.9 years old. Most of the patients presented with soft tissue signs, eye muscle impairment and proptosis. Patients received 20Gy in 2Gy per fraction to volume that included the entire area of abnormality and usually extended from the posterior globe to the anterior clinoids process.\nResults: Sixty-three percent (10/16) of the patients responded successfully to radiotherapy. There was 62.5% (10/16) of the patients presenting with these signs demonstrated significant improvement. Patients with proptosis improved after treatment was 83.3% (5/6), respectively. Only 40.0% (4/10) of the patients showed improvement in the restriction of eye movement. Improvement of visual acuity was found in 60.0% (3/5) of the patients.\nConclusion: Radiotherapy with a dosage of 20Gy is effective in preventing exacerbation of active inflammatory ophthalmopathy in patients with Graves' disease and eliminates the side effects associated with protracted use of corticosteroid. It is recommended that radiotherapy can be considered to treat patients who fail after steroid administration or have a contraindication to steroid. Surgical management such as orbit decompression may reserved for patients who have progressing or disabling proptosis after radiation therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-295-300-a", "title": "\u653e\u5c04\u6cbb\u7642\u4e4b\u764c\u60a3\u63a5\u53d7\u53e6\u985e\u7642\u6cd5\u7684\u8abf\u67e5", "keywords": "\u53e6\u985e\u7642\u6cd5;\u764c\u75c7\u6cbb\u7642;\u653e\u5c04\u7dda\u6cbb\u7642 Alternative treatment;Cancer treatment;Radiotherapy", "c": "Purpose: This study was designed to gain an understanding of the degree to which cancer patients choose to turn to alternative treatment methods, to find out what factors play a role in this preference, and to encourage medical personnel to open their mind to the ergonomic and educational aspects of this tendency towards alternative treatment methods. Consequently, this should lead to a more positive approach to convincing patients to submit to scientific medical treatment and increase their familiarity therewith, so that they can take advantage of both types of treatment when carried out simultaneously.\nMaterials and Methods The study was carried out at the Linkou Chang Sung Memorial Hospital from November 1, 1997 to November 30, 1999. Eight hundreds and seventy-two patients were entered in the study, being cancer patients undergoing radiotherapy at the hospital's Radiation Oncology Department. Admission was based on a questionnaire that had to be filled in by each patient, in which they were assisted by senior nursing staff of the Radiation Oncology Department. This questionnaire had to be filled in twice, the first time within the first week during radiotherapy and the second time within 6 months after completion of the treatment.\nResults There were various types of alternative treatments that the studied patients received before or during the radiotherapy course, including folk recipe, breathing exercises, massage, vegetarian food. Among the various types of alternative treatments, diet alternative treatments were most significantly increased during radiotherapy. Therefore, it was understood that the cancer patients thought diet was closely associated with cancer diseases. Of those patients who turned to alternative treatment methods either before or during radiotherapy, most would choose more than one alternative, but mostly in the form of popular treatment methods primarily being the administering of medicinal herbs. One hundred sixty and one patients would recommend such treatments to other patients. Whether or not alternative treatment methods were effective directly influenced the patient's inclination to recommend such treatments to other patients (p\uff1c0.0001). After local radiotherapy, the majority of the studied patients would design health care programs themselves and modify their life styles.\nConclusion: The intent of the cancer patients to accept the standard treatments such as radiotherapy did not conflict with the intent for them to turn to alternative treatments. Although taking alternative treatments is not recommended, it is not practical to prohibit their use. Considering the vast cost turning to alternative treatments must result in, the medical and nursing staff should help the patients select their alternative treatments seriously in order to lead to economic difficulties and psychophysical affliction. Further large-scale clinical investigations are needed to study whether alternative treatments would influence the effectiveness of the recommended standard treatments or not.", "e": "Purpose: This study was designed to gain an understanding of the degree to which cancer patients choose to turn to alternative treatment methods, to find out what factors play a role in this preference, and to encourage medical personnel to open their mind to the ergonomic and educational aspects of this tendency towards alternative treatment methods. Consequently, this should lead to a more positive approach to convincing patients to submit to scientific medical treatment and increase their familiarity therewith, so that they can take advantage of both types of treatment when carried out simultaneously.\nMaterials and Methods The study was carried out at the Linkou Chang Sung Memorial Hospital from November 1, 1997 to November 30, 1999. Eight hundreds and seventy-two patients were entered in the study, being cancer patients undergoing radiotherapy at the hospital's Radiation Oncology Department. Admission was based on a questionnaire that had to be filled in by each patient, in which they were assisted by senior nursing staff of the Radiation Oncology Department. This questionnaire had to be filled in twice, the first time within the first week during radiotherapy and the second time within 6 months after completion of the treatment.\nResults There were various types of alternative treatments that the studied patients received before or during the radiotherapy course, including folk recipe, breathing exercises, massage, vegetarian food. Among the various types of alternative treatments, diet alternative treatments were most significantly increased during radiotherapy. Therefore, it was understood that the cancer patients thought diet was closely associated with cancer diseases. Of those patients who turned to alternative treatment methods either before or during radiotherapy, most would choose more than one alternative, but mostly in the form of popular treatment methods primarily being the administering of medicinal herbs. One hundred sixty and one patients would recommend such treatments to other patients. Whether or not alternative treatment methods were effective directly influenced the patient's inclination to recommend such treatments to other patients (p\uff1c0.0001). After local radiotherapy, the majority of the studied patients would design health care programs themselves and modify their life styles.\nConclusion: The intent of the cancer patients to accept the standard treatments such as radiotherapy did not conflict with the intent for them to turn to alternative treatments. Although taking alternative treatments is not recommended, it is not practical to prohibit their use. Considering the vast cost turning to alternative treatments must result in, the medical and nursing staff should help the patients select their alternative treatments seriously in order to lead to economic difficulties and psychophysical affliction. Further large-scale clinical investigations are needed to study whether alternative treatments would influence the effectiveness of the recommended standard treatments or not."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-301-308-a", "title": "\u5be6\u9ad4\u8207\u589e\u5f37\u52d5\u614b\u578b\u6954\u5f62\u6ffe\u7247\u5c0d\u5c04\u675f\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u8abf\u8b8a\u4e4b\u6e2c\u91cf\u8207\u7814\u7a76", "keywords": "\u9ad8\u80fdX\u5149;\u5be6\u9ad4\u578b\u6ffe\u7247;\u589e\u5f37\u578b\u52d5\u614b\u6ffe\u7247;\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u8abf\u8b8a High energy x-ray beam;Physical wedge;Enhanced dynamic wedge;PDD modification effect", "c": "Purpose: The percentage depth dose of physical and enhanced dynamic wedge fields of Varian CL-2100 CD linear accelerators were measured. According to the variation of the PDD values, PDD modification effect of both type wedges will be observed and discussed.\nMaterials and Methods: The PDD curves of open and physical wedged fields were measured with Nucletron 3D water phantom equipped with 0.12 cc Scanditronix RK ionization chamber. The PDD values of enhanced dynamic wedged fields were measured with Keithley 35040 dosimeter connected to Wellhofer Focus PPC-35 parallel plate ionization chamber. The beam energies are 6 and 10 MV. The measured field sizes are 5\u00d75, 10\u00d710, 15\u00d715, 20\u00d720cm^2. The wedge angles are 15\u00b0, 30\u00b0, 45\u00b0 and 60\u00b0. The depths are surface, the dm, 5, 10, 15, 20cm. Each value were normalized to it's own D(subscript max) to compare the PDD variation.\nResults: The beam hardening effect of physical wedged field were inverse to beam energy and field size. But increase when the depth and wedge angle increased. The maximum PDD increment (2.23%) is located at 6 MV, 5\u00d75cm^2 field size, 60\u00b0 wedge angle and depth equal to 20cm. The PDD modification effect of enhanced dynamic wedged field was inverse with beam energy, but increased when the field size, the depth and the wedge angle increased. The maximum PDD increment (1.14%) is located at 6MV, 20\u00d720cm^2 field size, 60\u00b0 wedge angle and depth equal to 20cm.\nConclusions: The PDD modification effect of enhanced dynamic wedged field are really exist. The effect from the physical wedge is due to the filtering effect of the wedge material. The effect from the enhanced dynamic wedge is due to the dose-gradient effect.", "e": "Purpose: The percentage depth dose of physical and enhanced dynamic wedge fields of Varian CL-2100 CD linear accelerators were measured. According to the variation of the PDD values, PDD modification effect of both type wedges will be observed and discussed.\nMaterials and Methods: The PDD curves of open and physical wedged fields were measured with Nucletron 3D water phantom equipped with 0.12 cc Scanditronix RK ionization chamber. The PDD values of enhanced dynamic wedged fields were measured with Keithley 35040 dosimeter connected to Wellhofer Focus PPC-35 parallel plate ionization chamber. The beam energies are 6 and 10 MV. The measured field sizes are 5\u00d75, 10\u00d710, 15\u00d715, 20\u00d720cm^2. The wedge angles are 15\u00b0, 30\u00b0, 45\u00b0 and 60\u00b0. The depths are surface, the dm, 5, 10, 15, 20cm. Each value were normalized to it's own D(subscript max) to compare the PDD variation.\nResults: The beam hardening effect of physical wedged field were inverse to beam energy and field size. But increase when the depth and wedge angle increased. The maximum PDD increment (2.23%) is located at 6 MV, 5\u00d75cm^2 field size, 60\u00b0 wedge angle and depth equal to 20cm. The PDD modification effect of enhanced dynamic wedged field was inverse with beam energy, but increased when the field size, the depth and the wedge angle increased. The maximum PDD increment (1.14%) is located at 6MV, 20\u00d720cm^2 field size, 60\u00b0 wedge angle and depth equal to 20cm.\nConclusions: The PDD modification effect of enhanced dynamic wedged field are really exist. The effect from the physical wedge is due to the filtering effect of the wedge material. The effect from the enhanced dynamic wedge is due to the dose-gradient effect."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-309-315-a", "title": "\u897f\u9580\u5b50\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u8207\u5be6\u9ad4\u6954\u578b\u6ffe\u5668\u7a7f\u900f\u56e0\u5b50\u4e4b\u6bd4\u8f03\u8a55\u4f30", "keywords": "\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668;\u5be6\u9ad4\u6954\u578b\u6ffe\u5668;\u7a7f\u900f\u56e0\u5b50 Virtual wedge;Physical wedge;Transmission factor", "c": "\u76ee\u7684\uff1a\u6e2c\u91cf\u897f\u9580\u5b50PRIMUS\u76f4\u7dda\u52a0\u901f\u5668\u4e2d\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u548c\u5be6\u9ad4\u6954\u578b\u6ffe\u5668\u5728\u4e0d\u540c\u7684\u7167\u91ce\u4e0b\uff0c\u5c0d\u65bc\u6ffe\u5668\u7a7f\u900f\u56e0\u5b50\u7684\u6bd4\u8f03\u5206\u6790\uff0c\u4ee5\u77ad\u89e3\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u7279\u6027\u8207\u5be6\u969b\u61c9\u7528\u4e0a\u6240\u61c9\u8003\u91cf\u7684\u56e0\u7d20\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5Wellh\u00f6fer IC15,0.13cc\u9632\u6c34\u904a\u96e2\u8154\u56fa\u5b9a\u65bcWellh\u00f6fer (48 \u00d748\u00d740\u7acb\u65b9\u516c\u5206\u6c34\u5047\u9ad4\u4e2d\uff0c\u5c07\u5c04\u6e90\u5230\u6c34\u5047\u9ad4\u6c34\u9762\u7684\u4f4d\u7f6e(SSD)\u8abf\u81f3100\u516c\u5206\uff0c\u904a\u96e2\u8154\u64fa\u653e\u65bc\u4e2d\u5fc3\u8ef8\u6df1\u5ea6\u4e0b5\u516c\u5206(6MV)\u621610\u516c\u5206(15MV)\u8655\uff0c\u5206\u5225\u6e2c\u91cf\u5be6\u9ad4\u548c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u572815\u00b0\u300130\u00b0\u300145\u00b0\u548c 60\u00b0\u56db\u7a2e\u4e0d\u540c\u89d2\u5ea6\u4e4b\u5728\u7167\u91ce\u75314\u00d74cm^2\u523025\u00d725cm^2\u8b8a\u5316\u4e0b\u4e4b\u8f38\u51fa\u5291\u91cf\uff0c\u7136\u5f8c\u6bd4\u8f03\u5be6\u9ad4\u548c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u5728\u7167\u91ce\u4e0d\u540c\u7684\u60c5\u6cc1\u4e0b\uff0c\u5176\u7a7f\u900f\u56e0\u5b50\u7684\u8b8a\u5316\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a\u5be6\u9ad4\u6954\u578b\u6ffe\u5668\u548c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u4e4b\u7a7f\u900f\u56e0\u5b50\u5c0d\u65bc\u7167\u91ce\u5927\u5c0f\u7684\u8b8a\u5316\u622a\u7136\u4e0d\u540c\u3002\u5be6\u9ad4\u6954\u578b\u6ffe\u5668\u4e4b\u7a7f\u900f\u56e0\u5b50\u96a8\u7167\u91ce\u8b8a\u5927\u6709\u7de9\u6162\u4e0a\u5347\u7684\u8da8\u52e2\uff0c\u5e73\u5747\u589e\u52a0\u7387\u70ba\u89c0\uff0c\u6700\u5927\u589e\u52a06%\u4e4b\u591a\uff0c\u4e14\u4e0d\u540c\u89d2\u5ea6\u4e4b\u6954\u578b\u6ffe\u5668\u6709\u4e0d\u540c\u7684\u7a7f\u900f\u56e0\u5b50\u3002\u4f46\u5728\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u4e2d\u56db\u7a2e\u4e0d\u540c\u89d2\u5ea6\u7684\u7a7f\u900f\u56e0\u5b50\u5e73\u5747\u5206\u4f48\u5728\u6578\u503c1.0\u9644\u8fd1\uff0c\u6b64\u8207\u52d5\u614b\u5f0f\u6954\u578b\u6ffe\u5668\u622a\u7136\u4e0d\u540c\uff0c\u53e6\u5916\uff0c\u96d6\u7136\u5176\u7a7f\u900f\u56e0\u5b50\u4e5f\u6703\u96a8\u8457\u7167\u91ce\u8b8a\u5316\u6709\u7de9\u6162\u4e0a\u5347\u7684\u8da8\u52e2\u3002\u5e73\u5747\u589e\u52a0\u7387\u70ba1.7%\uff0c\u6700\u5927\u589e\u52a03%\uff0c\u4f46\u5728\u5291\u91cf\u8a08\u7b97\u96a8\u6a5f\u8aa4\u5dee\u4e0a\uff0c\u8996\u70ba\u53ef\u5bb9\u5fcd\u5ffd\u7565\u7bc4\u570d\u5167\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u7a7f\u900f\u56e0\u5b50\u7686\u5206\u4f48\u5728\u6578\u503c1.0\u9644\u8fd1\uff0c\u4ee3\u8868\u4e86\u5728\u7167\u91ce\u5782\u76f4\u4e2d\u5fc3\u8ef8\u4f4d\u7f6e\uff0c\u6709\u52a0\u6ffe\u5668\u6642\u7684\u5291\u91cf\u8f38\u51fa\u503c\u7b49\u65bc\u6c92\u6709\u52a0\u6ffe\u5668\u6642\u7684\u5291\u91cf\u8f38\u51fa\u503c\uff0c\u800c\u9019\u8868\u793a\u5728\u81e8\u5e8a\u7684\u61c9\u7528\u4e0a\uff0c\u5c0d\u65bc\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u4e4b\u7a7f\u900f\u56e0\u5b50\u6240\u4f54\u6709\u7684\u5f71\u97ff\u56e0\u7d20\u5f88\u5c0f\u3002", "e": "Purpose: The transmission factors of virtual wedges and physical wedges were measured on different field sizes for a Siemens PRIMUS 3008 linear accelerator to assess and analyze characteristics of virtual wedges.\nMaterials and Methci4.: The Wellh\u00f6fer 1C15, 0.13 cc chamber was setup on the chamber frame of Wellh\u00f6fer water phantom (48\u00d748\u00d740 cm^3). The distance between the source and the surface of water is 100 cm. Transmission factors in water were measured at 5cm depth (6 MV) and 10cm depth (15 MV) of the central axis for four wedge angles (15\u00b0, 30\u00b0, 45\u00b0, 60\u00b0) at field sizes ranging from 4.0 to 25.0 cm. Results The transmission factors of physical wedges increase slowly as filed size increase. The mean increment is 4% and the maximum increment is 6%. However, the transmission factors of virtual wedges remain almost constant (1.0) for all the wedge angles. The mean increment is 1.7%, and the maximum increment is 3%.\nConclusion Transmission factors of all virtual wedges are almost constant It means that the output without a wedge is almost equal to the output with a wedge at the central axis. This tells us the transmission factors are not the primary influence factor on clinical applications of virtual wedge."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199912-6-4-317-323-a", "title": "\u975e\u4fb5\u5165\u6027\u8166\u7acb\u9ad4\u653e\u5c04\u6cbb\u7642\u5b9a\u4f4d\u67b6\u4e4b\u6280\u8853\u8207\u518d\u73fe\u6027\u7814\u7a76", "keywords": "\u975e\u4fb5\u5165\u6027;\u8166\u7acb\u9ad4\u5b9a\u4f4d\u67b6;\u518d\u73fe\u6027 Non-invasive;Stereoadapter;Reproducibility", "c": "\u76ee\u7684\uff1a\u672c\u6587\u5c07\u7814\u7a76\u65b0\u578b\uff0c\u591a\u529f\u80fd\u975e\u4fb5\u5165\u6027\u8166\u7acb\u9ad4\u5b9a\u4f4d\u67b6\u64cd\u4f5c\u6d41\u7a0b\u4e4b\u6280\u8853\u4e0a\u7684\u7d30\u7bc0\u4f5c\u4ecb\u7d39\uff0c\u4ee5\u53ca\u6b64\u5b9a\u4f4d\u67b6\u91cd\u8907\u56fa\u5b9a\u5f8c\u4e4b\u81e8\u5e8a\u6cbb\u7642\u518d\u73fe\u6e96\u78ba\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6b64\u975e\u4fb5\u5165\u6027\u7acb\u9ad4\u5b9a\u4f4d\u67b6\u70bastereoadaPter5000\uff0c\u7531\u589e\u5f37\u5851\u81a0\u8207\u4e0d\u7522\u751f\u5047\u5f71\u7684\u92c1\u5408\u91d1\u7d44\u6210\u3002\u5b9a\u4f4d\u67b6\u85c9\u7531\u5169\u5074\u8033\u585e\u8207\u9f3b\u6a11\u652f\u63f4\u5668\u56fa\u5b9a\u65bc\u75c5\u60a3\u982d\u90e8\u2018\u5b9a\u4f4d\u67b6\u4e4b\u7dca\u5ea6\u53ef\u7531\u9f3b\u6a11\u652f\u6301\u5668\u4e0a\u7684\u87ba\u65cb\u687f\uff0c\u9f3b\u6a11\u652f\u6301\u81c2\u8207\u4e09\u89d2\u7269\u4ef6\u76f8\u63a5\u7684\u9f52\u8f2a\uff0c\u4ee5\u53ca\u9023\u63a5\u91d1\u5c6c\u677f\u8207\u4e09\u89d2\u7269\u4ef6\u4ea4\u63a5\u7684\u9f52\u8f2a\u6240\u8abf\u6574\u8207\u63a7\u5236\uff0c\u672c\u6587\u7531\u4e03\u4f4d\u5065\u5eb7\u7684\u81ea\u9858\u8005\u9032\u884c\u6e2c\u8a66\uff0c\u77ad\u89e3\u5b9a\u4f4d\u67b6\u56fa\u5b9a\u65bc\u982d\u90e8\u7684\u6d41\u7a0b\u8207\u82b1\u8cbb\u7684\u6642\u9593\uff0c\u4ee5\u53ca\u8a66\u6234\u5f8c\u7684\u611f\u89ba\u3002\u95dc\u65bc\u518d\u73fe\u6027\u7684\u7814\u7a76\uff0c\u662f\u4ee5\u81ea\u9858\u8005\u91cd\u8907\u6234\u4e0a\u5b9a\u4f4d\u67b6\u4e09\u6b21\uff0c\u6bcf\u6b21\u76f8\u96945\u5206\u9418\uff0c\u65bc\u540c\u6a23\u7684\u53c3\u8003\u9ede\u4e0a\u6a19\u9ede\uff0c\u6700\u5f8c\u4ee5\u6beb\u7c73\u523b\u5ea6\u5c3a\u91cf\u6e2c\u5dee\u7570\u503c\u3002\n\u7d50\u679c\uff1a\u5c07\u975e\u4fb5\u5165\u6027\u5b9a\u4f4d\u67b6\u56fa\u5b9a\u65bc\u81ea\u9858\u8005\u982d\u90e8\u6240\u82b1\u8cbb\u6642\u554f\u5927\u7d04\u70ba3\u5206\u9418\uff0c\u81ea\u9858\u8005\u4e09\u6b21\u8a66\u6234\u7d50\u679c\uff0c\u5bb9\u5fcd\u5ea6\u826f\u597d\uff0c\u7121\u56b4\u91cd\u7684\u4e0d\u8212\u9069\u611f\uff0c\u5176\u4e2d\u7684\u4e0d\u8212\u9069\u611f\u5305\u62ec\u9f3b\u6a11\u8207\u5916\u8033\u9053\u53d7\u5230\u58d3\u8feb\uff0c\u8033\u6735\u7531\u65bc\u8033\u585e\u7684\u63a9\u853d\u73fe\u8c61\u800c\u6709\u807d\u4e0d\u592a\u6e05\u695a\u7684\u60c5\u6cc1\u7522\u751f\uff0c\u95dc\u65bc\u518d\u73fe\u6027\u7684\u7814\u7a76\uff0c\u5de6\u53f3\u5169\u5074\u5404\u6709\u4e00\u500b\u53c3\u8003\u9ede\uff0c\u53f3\u5074\u5e73\u5747\u5dee\u75700.74mm\uff08\u6a19\u6e96\u5dee0.47mm\uff0c\u6700\u5927\u5dee\u75701.5mm)\uff0c\u5de6\u5074\u5e73\u5747\u5dee\u75700.89 mm\uff08\u6a19\u6e96\u5dee0.24mm\uff0c\u6700\u5927\u5dee\u75701.25mm\uff09\u3002\n\u7d50\u679c\uff1a\u6b64\u8166\u7acb\u9ad4\u5b9a\u4f4d\u67b6\u70ba\u4e00\u7a2e\u975e\u4fb5\u5165\u6027\uff0c\u53ef\u5bb9\u6613\u4e14\u5feb\u901f\u7684\u56fa\u5b9a\u65bc\u75c5\u60a3\u7684\u982d\u90e8\uff0c\u4ee5\u53ca\u5176\u91cd\u8907\u7684\u518d\u73fe\u6027\u9ad8\u3002\u56e0\u6b64\u5c0d\u65bc\u6b64\u5b9a\u4f4d\u67b6\u4e0d\u518d\u4fb7\u9650\u65bc\u55ae\u6b21\u7684\u6cbb\u7642\u6a21\u5f0f\uff0c\u800c\u53ef\u61c9\u7528\u65bc\u751f\u7269\u6548\u61c9\u8f03\u597d\u7684\u5206\u6b21\u6cbb\u7642\u6280\u8853\u3002", "e": "Purpose: In this study, we will describe the technique details of mounting the new, versatile stereoadapter. In addition, we will research the reproducibility of repeated mounting of that.\nMaterials and Methods: The stereoadapter5000 is a non-invasive frame made of reinforced plastic and aluminum alloy. It is mounted to patient's head by means of two ear plugs and nasion support. The tight intensity of this frame is modify by a threaded screw at the nasion support, two cogwheel cases joined the lateral triangle components to the nasion support arm, and two ones joined the connector plate to the lateral triangle components. To achieve maximum accuracy and confidence with the stereoadapter, we should repeat the mounting procedure several times to become familiar with all the features of the frame. Besides, the reproducibility of repeat fixations of the frame to the head was tested in 7 healthy volunteers. The differences in location of the marking were measured.\nResults: The mountings of the frame to the head took 3 mm. All subjects tolerated well the three mountings of the frame. Some complaints were unpleasant pressure on the bridge of the nose and on the external auditory canal and not hear well due to the occlusion of the canal by the ear plugs. About reproducibility of repeat fixation of this frame, the differences in the position of the blocks on the right side was 0.74 mm (SD 0.47 mm, range 1.5 mm), and on the left side was 0.89 mm (SD 0.24 mm, range 1.25).\nConclusion: This stereoadapter is easy and quick to mount on the patient's head, and reproducibility of repeated mountings is very 4gh. So not limited to single session, the stereotactic irradiation can be fractionated, according to radidbiological principles, in several sessions. In addition to combine with CT and MRI system, this frame is also suitable for open stereotactic surgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-159-165-a", "title": "\u653e\u5c04\u6027\u6c2b\u6c27\u57fa\u78f7\u7070\u77f3\u5fae\u7c92\u88fd\u5099\u53ca\u5176\u7528\u65bc\u809d\u764c\u6cbb\u7642\u4e4b\u9ad4\u5916\u5be6\u9a57", "keywords": "\u653e\u5c04\u6027\u9676\u74f7\u5fae\u7c92;\u9ad4\u5167\u8f3b\u5c04\u6cbb\u7642;\u809d\u764c Radioactive ceramic particles;Internal radiotherapy;Liver cancer", "c": "Purpose: The radioactive hydroxyapatite micron-sized particles (RHMP) were prepared for internal radiotherapy of hepatoma. The interaction of hydroxyapatite micron-sized particles (HMP) and the cytotoxicity of RHMP to the hepatoma cells were also studied.\nMaterials and Methods: The RHMP were synthesized using biocompatible hydroxyapatite and neutron irradiated in Tsing-Hua open pool reactor. Human hepatoma HepG2 cell line was employed for in-vitro evaluation.\nResults: The main nuclide of the RHMP is P-32. Cell culture tested reveals that hepatoma cells have high affinity to HMP. Tested with 70-100\u03bcm HMR the hepatoma cells climbed and surrounded the particles within 3 days. Testing with sub-micron HMP, the particles were endocytosised by hepatoma cells. Cells treated with higher dosages of RHMP showed lower surviving fraction, and cells seemed to have less morphological changes. Meanwhile, cells were treated with lower dosages, changes were observed and the RHMP could be endocytosised by hepatoma cells.\nConclusion: In-vitro evaluation reveals that the RHMP are highly cytotoxic and are an effective internal radio-therapeutic agent for hepatoma. These results may have major clinical significance in the development of future research in internal radiotherapy.", "e": "Purpose: The radioactive hydroxyapatite micron-sized particles (RHMP) were prepared for internal radiotherapy of hepatoma. The interaction of hydroxyapatite micron-sized particles (HMP) and the cytotoxicity of RHMP to the hepatoma cells were also studied.\nMaterials and Methods: The RHMP were synthesized using biocompatible hydroxyapatite and neutron irradiated in Tsing-Hua open pool reactor. Human hepatoma HepG2 cell line was employed for in-vitro evaluation.\nResults: The main nuclide of the RHMP is P-32. Cell culture tested reveals that hepatoma cells have high affinity to HMP. Tested with 70-100\u03bcm HMR the hepatoma cells climbed and surrounded the particles within 3 days. Testing with sub-micron HMP, the particles were endocytosised by hepatoma cells. Cells treated with higher dosages of RHMP showed lower surviving fraction, and cells seemed to have less morphological changes. Meanwhile, cells were treated with lower dosages, changes were observed and the RHMP could be endocytosised by hepatoma cells.\nConclusion: In-vitro evaluation reveals that the RHMP are highly cytotoxic and are an effective internal radio-therapeutic agent for hepatoma. These results may have major clinical significance in the development of future research in internal radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-167-172-a", "title": "\u958b\u767c\u4e0a\u76ae\u96c6\u843d\u9451\u5b9a\u7cfb\u7d71\u4ee5\u8a55\u4f30\u8c6c\u76ae\u819a\u4e4b\u653e\u5c04\u7dda\u654f\u611f\u5ea6", "keywords": "\u8c6c\u76ae\u819a;\u4e0a\u76ae\u5fae\u5c0f\u96c6\u843d;\u653e\u5c04\u7dda Pig skin;Epidermal microcolony;Radiation", "c": "\u76ee\u7684\uff1a\u5229\u7528\u8207\u4eba\u985e\u76ae\u819a\u975e\u5e38\u76f8\u8fd1\u4e4b\u8c6c\u76ae\u819a\u3002\u767c\u5c55\u6700\u70ba\u7cbe\u78ba\u53ef\u9760\u4e14\u5177\u6709\u91cf\u5316\u529f\u80fd\u7684\u8c6c\u4e0a\u76ae\u5fae\u5c0f\u96c6\u843d\u9451\u5b9a\u6280\u8853\uff0c\u4ee5\u63d0\u4f9b\u76ae\u819a\u653e\u5c04\u7dda\u50b7\u5bb3\u4e4b\u826f\u597d\u7814\u7a76\u6a21\u5f0f\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5e73\u5747\u9ad4\u91cd\u7d04\u70ba30\u516c\u65a4\u4e4b\u767d\u8272\u96c4\u6027Landrace\u8c6c\u96bb\u65bc\u9069\u61c9\u98fc\u990a\u74b0\u58832\u5468\u4ee5\u4e0a\uff0c\u4e26\u540c\u6642\u65bc\u5de6\u5074\u8179\u9762\u5229\u7528\u523a\u9752\u65b9\u6cd5\u5283\u51fa4\u00d74\u516c\u5206\u7bc4\u570d\uff0c\u65bc\u6bcf\u4e00\u7167\u91ce\u9593\u96945\u516c\u5206\u60c5\u6cc1\u4e0b\uff0c\u5148\u884c\u7d66\u4e88\u5438\u5165\u9ebb\u9189\u4e26\u5206\u5225\u7167\u5c04 22.5,25.0\u53ca27.5Gy\u4e4b3MeV\u96fb\u5b50\u5c04\u7dda\u5291\u91cf\u3002\u7167\u5c04\u5f8c\u7b2c14\u5929\u8d77\u5229\u7528\u8272\u5dee\u8a08(chromometer)\u6e2c\u5b9a\u7d05\u6591\u53cd\u61c9\u7a0b\u5ea6\u4e26\u65bc\u25b3E\u503c\u9054\u5230\u9ad8\u5cf0\u4e4b\u5f8c\u4e00\u5929\u9032\u884c\u76ae\u819a\u53d6\u6a23\u3002\u5207\u4e0b\u4e2d\u95932\u00d72\u516c\u5206\u7d44\u7e54\u7d93\u904e\u56fa\u5b9a\u3001\u6c34\u89e3\u3001DNA\u67d3\u8272\u3002\u6e05\u9664\u771f\u76ae\u5c64\u5167\u6240\u542b\u7d50\u7de0\u7d44\u7e54\u5f8c\u3002\u5c07\u50c5\u5269\u7684\u4e0a\u76ae\u5c64\u4e88\u4ee5\u5c01\u7247\uff0c\u4e26\u5229\u7528\u5149\u5b78\u986f\u5fae\u93e1\u8a08\u6578\u6bcf\u5e73\u65b9\u516c\u5206\u5927\u65bc50\u500b\u7d30\u80de\u7684\u96c6\u843d\u6578\u76ee\uff0c\u4e26\u9032\u4e00\u6b65\u6c42\u5f97\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\u53caD(\u4e0b\u6a19 0)\u503c\u3002\n\u7d50\u679c\uff1a\u5229\u7528\u8272\u5dee\u8a08\u6240\u6e2c\u5f97\u4e4b\u503c\u53ef\u898b\uff0c\u76ae\u819a\u7d05\u6591\u53cd\u61c9\u9ad8\u5cf0\u671f\u7684\u25b3E\u503c\u7d04\u4ecb\u65bc5\u81f38\u5de6\u53f3\uff0c\u4e14\u6b64\u9ad8\u5cf0\u503c\u50c5\u5b58\u5728\u7d042\u5929\u6642\u554f\u3002\u591a\u6578\u8c6c\u96bb\u25b3E\u503c\u4e4b\u9ad8\u5cf0\u671f\u7d04\u4ecb\u65bc\u7167\u5c04\u5f8c\u73b2\u81f321\u5929\u4e4b\u554f\u3002\u672c\u6280\u8853\u7372\u53d6\u4e4b\u96c6\u843d\u5f71\u50cf\u5448\u73fe\u51fa\u7d30\u80de\u6838\u67d3\u8272\u6df1\uff0c\u6392\u5217\u898f\u5247\u800c\u7dca\u5bc6\u3002\u540c\u6642\u53ef\u898b\u5206\u88c2\u7d30\u80de\u5b83\u8207\u5468\u570d\u5e02\u7d30\u80de\u5f62\u6210\u5f37\u70c8\u5c0d\u6bd4\uff0c\u56e0\u6b64\u8a08\u8b80\u5bb9\u6613\u3002\u6240\u7372\u53d6\u4e4b\u6d3b\u5b58\u66f2\u7ddaD(\u4e0b\u6a19 0)\u3002\u503c\u70ba3.05\u00b10.38Gy\u3002\n\u7d50\u8ad6\uff1b\u5927\u8c6c\u96bb\u76ae\u819a\u653e\u5c04\u7dda\u7814\u7a76\u4e4b\u91cd\u8981\u6027\u4eba\u4eba\u7686\u77e5\uff0c\u4f46\u57fa\u65bc\u4eba\u529b\u3001\u7269\u529b\u3001\u6642\u554f\u53ca\u7cbe\u78ba\u6027\u4e4b\u8003\u6688\uff0c\u4ecd\u820a\u5fc5\u9808\u91dd\u5c0d\u7167\u5c04\u5291\u91cf\u6e96\u78ba\u5ea6\uff0c\u6700\u9069\u5408\u7684\u53d6\u6a23\u6642\u6a5f\uff0c\u76ae\u819a\u7d44\u7e54\u4e4b\u56fa\u5b9a\uff0c\u67d3\u8272\u53ca\u4e0a\u76ae\u7d44\u7e54\u4e4b\u5206\u96e2\u3002\u7b49\u505a\u6700\u4f73\u7684\u7d44\u5408\u3002 \u65b9\u80fd\u6210\u70ba\u826f\u597d\u7684\u50b7\u5bb3\u9451\u5b9a\u6a21\u5f0f\u3002\u7814\u7a76\u7d50\u679c\u8b49\u5be6\u672c\u6280\u8853\u4e4b\u512a\u8d8a\u6027\u53ca\u5be6\u7528\u9678\u3002\u76f8\u4fe1\u5c0d\u65bc\u76ae\u819a\u65e9\u3001\u665a\u671f\u653e\u5c04\u7dda\u50b7\u5bb3\u4e4b\u7814\u7a76\u5fc5\u5c07\u5f15\u8d77\u5ee3\u6cdb\u7684\u6ce8\u610f\u6216\u61c9\u7528\u3002", "e": "Purpose: To develop an accurate and quantitative measurement technique of the pig epidermal micro-colonies as an ideal model system for radiation research on the skin.\nMaterials and Methods: White male pigs weighing about 30kg were kept in a separate cage indoors and quarantined for at least 2 weeks before irradiation. All animals were tattooed on the left flank with Indian ink at size of 4\u00d74 cm and a gap of 5cm between the fields. Prior to irradiation the animals were anaesthetized with a gas mixture. Radiation dose was given at 22.5, 25.0 and 27.5Gy using 3MeV electrons. At 14 days after irradiation, a chromometer was used to determined the degree of erythema, the skin samples were taken on the next day after erythema reached the maximum. Only 2\u00d72cm skin samples were cutted, fixed, hydrolysed, stained, connective tissues removed, epidermal sheets prepared and mounted for final colony counting under the microscope. Furthermore, a dose..response curve and D(subscript 0) value were obtained.\nResults: The maximum AR value were between 5 to 8, this peak value only lasts for about 2 days. Normally the maximum SE value appeared between days 18 to 21. The pattern of the present epidermal microcolonies appears to have dark nuclear stain, regular and compact cellular arrangement with few mitotic cells, which forms strong contrast to the surrounding cells. The D(subscript o) value deduced from the surviving curve was 3.05\u00b10.38Gy.\nConclusions: The importance of pig skin in radiation research is known for many years by many experts. However, the development of an optimal assay system has to rely on the best combination of the accuracy of radiation dose delivery, optimal sampling time, skin fixation, staining and epidermal sheet separation etc. The present results proved it's superiority and applicability in terms of the assay technique. We believe that this technique will draw much attention to the people who study early and late radiation injury on the skin."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-173-177-a", "title": "2-Aminofluorene-Dna Adducts Formation in Rat Glial Cultured Tumor Cells", "keywords": "\u82b3\u9999\u80fa\u5316\u5408\u7269;\u53bb\u6c27\u6838\u7cd6\u6838\u9178\u91a3;\u795e\u7d93\u81a0\u8cea\u7624 Arylamine;DNA;Glioma", "c": "\u76ee\u7684\uff1a\u82b3\u9999\u80fa\u5316\u5408\u7269\u7d93N\u57fa\u4e59\u91af\u8f49\u79fb\u9175\u7d20N\u57fa\u4e59\u91af\u5316\u5f8c\u53ef\u8a98\u767c\u764c\u9176\u75c7\uff0c\u672c\u7814\u7a76\u662fin vitro\u3002\u63a2\u8a0e\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u57f9\u990a\u816b\u7624\u7d30\u80de\u4e2d2-AF-DNA\u7684\u5f62\u6210\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u53d6\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u57f9\u990a\u816b\u7624\u7d30\u80de\u5229\u7528\u4e59\u917c\u5316\u8f14\u9176A\u4f5c\u4e59\u91b1\u57fa\u53ca\u03b3-[(\u4e0a\u6a19 32)p]-dATP\u800c\u518d\u5229\u7528\u9ad8\u58d3\u5c64\u6790\u5100\u5206\u67902-AF-DNA\u7684\u5f62\u6210\u6027\uff0c\u4ee5aminofluorene(AF)\u4f5c\u53d7\u8cea\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u57f9\u990a\u816b\u7624\u7d30\u80de\u6709\u4e59\u917c\u8f49\u79fb\u9175\u7d20\u7684\u6d3b\u6027\u5b58\u5728\uff0c\u5176\u5c0d\u6fc3\u5ea630\u03bcM and 60\u03bcM AF\u70ba\u53d7\u8cea\u5f62\u62102-AF-DNA adducts\u5404\u70ba 0.48\u00b10.16 and 0.70\u00b10.12pmol/mg DNA\u3002\n\u7d50\u8ad6\uff1a\u7d50\u679c\u767c\u73fe\u5927\u767d\u9f20\u795e\u7d93\u81a0\u8cea\u57f9\u990a\u816b\u7624\u7d30\u80de\u4e2d\u4e59\u917c\u8f49\u79fb\u9175\u7d20\uff0c\u53ef\u5c072-AF\u4e59\u917c\u5316\u62102-AAF\u8207\u7d30\u80de\u4e2d\u53bb\u6c27\u6838\u7cd6\u6838\u9178\u9176\u7d50\u5408\u70ba2-AF-DNA\u3002\u672c\u7814\u7a76\u5831\u544a\u662fin vitro\u63a2\u8a0e\u7684\u521d\u6b65\u5831\u544a\uff0c\u672a\u4f86\u9700\u9032\u4e00\u6b65\u4ee5in vivo\u7684\u5be6\u9a57\u78ba\u8a8d\u3002", "e": "Purpose: Arylamine N-acetylation capacity by the N- acetyltransferase (NAT) may be an important causative factor in the initiation of cancer. Most carcinogens have been demonstrated to react with cellular DNA to form covalent DNA adducts. Arylamine-DNA adducts formation have been correlated with the carcinogenic effect of heterocyclic aromatic amines. 2-AF-DNA formation in rat glial cultured tumor cell line was investigated.\nMaterials and Methods: 2-aminofluorene-ONA (2-AF-DNA) adducts formation in rat glial cultured tumor cell line was investigated by \u03b3-[(superscript 32)p]-dATP and HPLC, using 2-amino- fluorene as substrates.\nResults: 2-AF-DNA adducts formation in rat glial cultured tumor cell with 30uM and 60uM AF were 0.48\u00b10.16 and 0.70\u00b10.12pmol/mg DNA, respectively.\nConclusion: The results indicate that rat glial cultured tumor cells activate AF to a metabolite able to bind covalently with DNA, and also induced dose-dependent effect."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-179-186-a", "title": "\u76f4\u8178\u764c\u75c5\u4eba\u63a5\u53d7\u8853\u5f8c\u55ae\u7368\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u6cbb\u7642\u7d50\u679c\u53ca\u9810\u5f8c\u56e0\u5b50", "keywords": "\u76f4\u8178\u764c;\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642;\u653e\u5c04\u7dda\u6cbb\u7642 Rectal cancer;Postoperative radiotherapy;Irradiation", "c": "Purpose: To analyze the treatment results and prognostic factors in rectal cancer patients receiving postoperative radiotherapy after radical resection.\nMaterials and Methods: From October 1987 through August 1997, ninety-five patients with stage II or III (AJCC1997) rectal cancer were treated with complete surgical resection and postoperative adjuvant pelvic irradiation without chemotherapy. The radiation was delivered with 10 or 15 MV X-ray given 5 days per week at 1.8 to 2Gy per fraction. Total doses ranged from 52 to 60Gy. All patients had at least 2 years of follow-up.\nResults: The 5-year local control rate (LC), overall survival rate (OS), distant metastasis-free rate (DMF) and disease-free survival rate (DFS) for the 95 patients were 49%, 43%, 46% and 35%, respectively. In univariate analysis, the stage (\u2161 vs. \u2162), T stage (T3 vs. T4), N stage (N0 vs. N1 vs. N2) and preoperative CEA (\uff1c5 vs. \u22655ng/ml) were the significant prognostic factors in LC, OS, DMF and DFS. In multivariate analysis, the N stage was the only statistically significant predictor of LC (p=0.0124), OS (p=0.0014), DMF (p=0.0012) and DFS (p=0.0010).\nConclusion: N stage (the number of involved nodes) is the most important prognostic factor in rectal cancer patients receiving postoperative radiotherapy alone. Patients with more than 3 involved nodes had significantly poor treatment outcome. The optimal adjuvant treatment for rectal cancer is still controversial. Further investigation of various treatment modalities is needed.", "e": "Purpose: To analyze the treatment results and prognostic factors in rectal cancer patients receiving postoperative radiotherapy after radical resection.\nMaterials and Methods: From October 1987 through August 1997, ninety-five patients with stage II or III (AJCC1997) rectal cancer were treated with complete surgical resection and postoperative adjuvant pelvic irradiation without chemotherapy. The radiation was delivered with 10 or 15 MV X-ray given 5 days per week at 1.8 to 2Gy per fraction. Total doses ranged from 52 to 60Gy. All patients had at least 2 years of follow-up.\nResults: The 5-year local control rate (LC), overall survival rate (OS), distant metastasis-free rate (DMF) and disease-free survival rate (DFS) for the 95 patients were 49%, 43%, 46% and 35%, respectively. In univariate analysis, the stage (\u2161 vs. \u2162), T stage (T3 vs. T4), N stage (N0 vs. N1 vs. N2) and preoperative CEA (\uff1c5 vs. \u22655ng/ml) were the significant prognostic factors in LC, OS, DMF and DFS. In multivariate analysis, the N stage was the only statistically significant predictor of LC (p=0.0124), OS (p=0.0014), DMF (p=0.0012) and DFS (p=0.0010).\nConclusion: N stage (the number of involved nodes) is the most important prognostic factor in rectal cancer patients receiving postoperative radiotherapy alone. Patients with more than 3 involved nodes had significantly poor treatment outcome. The optimal adjuvant treatment for rectal cancer is still controversial. Further investigation of various treatment modalities is needed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-187-196-a", "title": "\u665a\u671f\u9f3b\u54bd\u764c\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u8207\u55ae\u7368\u653e\u5c04\u6cbb\u7642\u81e8\u5e8a\u7d50\u679c\u4e4b\u6bd4\u8f03\u2014\u96a8\u6a5f\u5206\u7d44\u8a66\u9a57\u521d\u6b65\u5831\u544a", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642 Nasopharyngeal carcinoma;Radiotherapy;Chemotherapy", "c": "Purpose: To compare the effect and toxicity of concomitant chemoradiotherapy (CRT) and radiotherapy alone (RT) for advanced nasopharyngeal carcinoma (NPC).\nMaterials and Methods: A phase III randomized trial was conducted since December 1993. Patients with previously untreated and pathologic diagnosis of NPC were eligible. These included 1)1992 AJCC stage \u2162/\u2163; 2)Karnofsky scale \uff1e50%; 3)age \uff1c80 years old; 4)normal liver, renal, and bone marrow function; 5)no distant metastasis; 6)obtaining informed consent. Radiotherapy was administered in both arms with total dose of 70-75 Gy/6-8 weeks using a similar fractionation and technique. The concomitant chemotherapy consisted of cisplatin + 5-FU continuous intravenous infusion during the first and fifth weeks of radiotherapy.\nResults: This preliminary analysis included 120 patients who were followed at least 3 years after treatment. It was compatible between the two groups in patients' characteristics. Tumor response were evaluated 2 months after treatment which showed no difference between CRT and RT. Acute toxicity was similar except for leucopenia which occurred more frequently and more severe in CRT arm. But most patients in both arms tolerated the treatment course smoothly. The 4-year primary disease-free, regional disease-free and distant metastasis disease-free survival rates were 91.6% vs. 75.5%, 93.7% vs. 88.8%, and 73.4% vs. 70.7%, respectively in CRT and RT groups. CRT has better local control than RT with a borderline significant difference (P=0.0753). The 4-year overall survival and progression-free survival rates were 68.6% vs. 53.5% and 70.1% vs. 55.1% respectively, favored CRT groups but the difference was not statistically significant. Distant metastasis was the predominant site of failure in both arms.\nConclusion: Concomitant chemoradiotherapy is better than radiotherapy alone in local control rate for advanced NPC. However, most patients failed at distant site(s). Adequate and effective neoadjuvant or adjuvant chemotherapy before or after radiotherapy to eradicate subclinical micrometastasis should be further consideration.", "e": "Purpose: To compare the effect and toxicity of concomitant chemoradiotherapy (CRT) and radiotherapy alone (RT) for advanced nasopharyngeal carcinoma (NPC).\nMaterials and Methods: A phase III randomized trial was conducted since December 1993. Patients with previously untreated and pathologic diagnosis of NPC were eligible. These included 1)1992 AJCC stage \u2162/\u2163; 2)Karnofsky scale \uff1e50%; 3)age \uff1c80 years old; 4)normal liver, renal, and bone marrow function; 5)no distant metastasis; 6)obtaining informed consent. Radiotherapy was administered in both arms with total dose of 70-75 Gy/6-8 weeks using a similar fractionation and technique. The concomitant chemotherapy consisted of cisplatin + 5-FU continuous intravenous infusion during the first and fifth weeks of radiotherapy.\nResults: This preliminary analysis included 120 patients who were followed at least 3 years after treatment. It was compatible between the two groups in patients' characteristics. Tumor response were evaluated 2 months after treatment which showed no difference between CRT and RT. Acute toxicity was similar except for leucopenia which occurred more frequently and more severe in CRT arm. But most patients in both arms tolerated the treatment course smoothly. The 4-year primary disease-free, regional disease-free and distant metastasis disease-free survival rates were 91.6% vs. 75.5%, 93.7% vs. 88.8%, and 73.4% vs. 70.7%, respectively in CRT and RT groups. CRT has better local control than RT with a borderline significant difference (P=0.0753). The 4-year overall survival and progression-free survival rates were 68.6% vs. 53.5% and 70.1% vs. 55.1% respectively, favored CRT groups but the difference was not statistically significant. Distant metastasis was the predominant site of failure in both arms.\nConclusion: Concomitant chemoradiotherapy is better than radiotherapy alone in local control rate for advanced NPC. However, most patients failed at distant site(s). Adequate and effective neoadjuvant or adjuvant chemotherapy before or after radiotherapy to eradicate subclinical micrometastasis should be further consideration."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-197-202-a", "title": "Treatment Results of Carcinoma of the Nasal Cavity", "keywords": "\u9f3b\u764c;\u8853\u5f8c\u653e\u5c04\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642;\u624b\u8853 Carcinoma of the nasal cavity;Post-operative radiotherapy;Radiotherapy;Surgery", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9f3b\u764c\u4e4b\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u5f9e1977\u81f31991\uff0c40\u4f4d\u7d93\u75c5\u7406\u5207\u7247\u8b49\u5be6\u9f3b\u764c\u4e4b\u75c5\u4eba\u5728\u672c\u9662\u63a5\u53d7\u78ba\u5b9a\u4e4b\u958b\u5200\u3001\u653e\u5c04\u6cbb\u7642\u3001\u53ca\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u6839\u64da\u4f5b\u7f85\u88cf\u9054\u5927\u5b78\u5206\u671f\u65b9\u6cd5\u8a08\u7b97\u5176\u5b58\u6d3b\u7387\uff0c\u6b7b\u56e0\u5b58\u6d3b\u7387\uff0c\u5c40\u90e8\u63a7\u5236\u7387\u548c\u9838\u90e8\u63a7\u5236\u7387\u3002\n\u7d50\u679c\uff1a\u5f9e\u7b2c\u4e00\u81f3\u4e09\u671f\u4e4b\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba76%,84%,55%\u3002\u4e94\u5e74\u5b58\u6d3b\u7387\u53ca\u6b7b\u56e0\u5b58\u6d3b\u7387\u5206\u5225\u70ba54%\u53ca64%\u3002\u5f9e\u7b2c\u4e00\u81f3\u4e09\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba88%,60%,38%\u3002\u5408\u4f75\u624b\u8853\u53ca\u653e\u5c04\u6cbb\u7642\uff0c\u50c5\u4f5c\u653e\u5c04\u6cbb\u7642\u548c\u50c5\u4f5c\u624b\u8853\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba63%,45%,75%\u3002\n\u7d50\u8ad6\uff1a\u671f\u5225\u3001\u9838\u90e8\u6dcb\u5df4\u8f49\u79fb\u70ba\u4e3b\u8981\u4e4b\u9810\u5f8c\u56e0\u6578\u3002\u6cbb\u7642\u65b9\u5f0f\u3001\u5e74\u9f61\u3001\u6027\u5225\u3001\u75c5\u7406\u578b\u614b\u3001\u6e90\u8d77\u90e8\u4f4d\u5c0d\u9810\u5f8c\u4e26\u7121\u986f\u8457\u5f71\u97ff\u3002\u9810\u9632\u6027\u9838\u90e8\u653e\u5c04\u6cbb\u7642\u5c0d\u9810\u9632\u9838\u90e8\u5fa9\u767c\u53ef\u80fd\u7121\u660e\u986f\u76ca\u8655\u3002", "e": "Purpose: To evaluate the treatment results of carcinoma of the nasal cavity in one single institution.\nMaterials and Methods Forty patients with pathologically-proved carcinoma of nasal cavity received definite treatment such as surgery alone (4 cases, 10%), radiotherapy alone (22 cases, 55%), or post-operative radiotherapy (14 cases, 35%). Staging system of the Florida University was used in this study. Absolute survival, cause-specific survival, local control, and regional neck control were calculated.\nResults The 5-year local control rates for stage \u2160 through stage \u2162 were 76%, 84% and 55%, respectively. The overall 5-year and cause-specific survival were 54% and 64%, respectively. Overall five-year survival for stage \u2160 through \u2162 were 88%, 60% and 30%, respectively. Five-year survival of different treatment methods by operation and postoperative radiotherapy, radiotherapy alone, and operation alone revealed 63%, 45% and 75%, respectively.\nConclusion: Initial stage and neck nodal status were significant prognostic factors. Treatment methods, age, gender, histology, and sites of tumor origin were not significant factors. Elective neck irradiation might have no significant benefit for the prevention of neck failure."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-203-214-a", "title": "\u76f4\u7dda\u52a0\u901f\u5668\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u4e4b\u91cf\u6e2c\u2014\u6ffe\u5668\u89d2\u5ea6\u8207\u5256\u9762\u5291\u91cf\u5206\u4f48", "keywords": "\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668;\u671f\u671b\u89d2\u5ea6;\u5256\u9762\u5291\u91cf\u5206\u4f48\u66f2\u7dda Virtual wedge;Desired wedge angle;Beam profile", "c": "\u76ee\u7684\uff1aSIEMENS Primus\u76f4\u7dda\u52a0\u901f\u5668\u7684\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\uff0c\u662f\u7167\u5c04\u671f\u9593\u5229\u7528\u76e3\u63a7\u55ae\u4f4d\u5291\u91cf\u7387\u7684\u8b8a\u5316\u8207\u6e96\u76f4\u5100\u64cb\u584a\u7684\u79fb\u52d5\uff0c\u4f86\u6a21\u64ec\u56fa\u5b9a\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u5256\u9762\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u3002\u672c\u6587\u4e3b\u8981\u662f\u91dd\u5c0d\u6ffe\u5668\u671f\u671b\u89d2\u5ea6\u8207\u5256\u9762\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u5169\u90e8\u4efd\uff0c\u4f86\u6bd4\u8f03\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u8207\u56fa\u5b9a\u5f0f\u6954\u578b\u6ffe\u5668\u4e4b\u554f\u7684\u5dee\u7570\u6027\uff0c\u4e26\u8a55\u4f30\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u5728\u81e8\u5e8a\u61c9\u7528\u4e4b\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u6587\u4f7f\u7528Memorial 1.0c.c\u5e73\u884c\u677f\u5f0f\u904a\u96e2\u8154\u3001\u91cf\u6e2c\u6bcf\u4e00\u76e3\u63a7\u55ae\u4f4d\u5c0d\u5291\u91cf\u4e4b\u6821\u6b63\u6bd4\u4f8b(MU/dose)\uff0c\u4ee5\u9a57\u8a3c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u5c0d\u81e8\u5e8a\u61c9\u7528\u7684\u5291\u91cf\u8a2d\u5b9a\uff1b\u4f7f\u7528WELLHOFER WP700\u6c34\u5047\u9ad4\u7cfb\u7d71\uff0c\u91cf\u6e2c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u671f\u671b\u89d2\u5ea6\uff1b\u4e26\u4ee5Sun Nuclear The Profiler\u9663\u5217\u5f0f\u56fa\u614b\u5075\u6aa2\u7cfb\u7d71\u91cf\u6e2c\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\uff0c\u8207\u56fa\u5b9a\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u5256\u9762\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u3002\n\u7d50\u679c\uff1a\u5c0d\u65bc\u56fa\u5b9a\u5f0f\u6954\u578b\u6ffe\u5668\u5e38\u7528\u7684\u56db\u7a2e\u89d2\u5ea615\u00b0\u300130\u00b0\u300145\u00b0\u53ca60\u00b0\u800c\u8a00\uff0c6MV\u53ca18MV\u7684\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u76f8\u5c0d\u671f\u671b\u89d2\u5ea6\u7684\u504f\u5dee\u503c\u5747\u5728\u00b11.5\u00b0\u4ee5\u5167\uff1b\u5256\u9762\u5291\u91cf\u5206\u4f48\u90e8\u4efd\uff0c6MV\u7684\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u8207\u56fa\u5b9a\u5f0f\u6954\u578b\u6ffe\u5668\u6700\u5927\u504f\u5dee\u503c\u70ba\uff1a\u6ffe\u5668\u89d2\u5ea660\u00b0\uff0c\u6df1\u5ea65cm\u8655\u7167\u91ce15\u00d715 cm^2\u70ba5.0%\uff1b\u800c18MV\u5728\u6df1\u5ea6\u8d85\u904e5cm\u5f8c\uff0c\u6ffe\u5668\u89d2\u5ea660\u00b0\uff0c\u6df1\u5ea610cm\u8655\u7167\u91ce20\u00d720cm^2\u70ba5.7%\uff0c\u4f4618MV\u6df1\u5ea6\u82e5\u672a\u8d77\u904e5cm\u5247\u6700\u5927\u504f\u5dee\u503c\u6703\u9054\u523011.1%\u3002\n\u7d50\u8ad6\uff1a\u57fa\u65bc\u6b64\u4e00\u8a2d\u5099\u4e0d\u540c\u65bc\u4ee5\u5f80\u7684\u89c0\u5ff5\u53ca\u6cbb\u7642\u65b9\u5f0f\uff0c\u56e0\u6b64\u5728\u81e8\u5e8a\u653e\u5c04\u6cbb\u7642\u4e4b\u524d\u9808\u6709\u5b8c\u6574\u7684\u9a57\u8b49\u5831\u544a\u53ca\u5b8c\u5584\u7684\u6e2c\u8a66\u63aa\u65bd\uff0c\u4e26\u914d\u5408\u5b9a\u671f\u7684\u54c1\u8cea\u9a57\u8b49\u5de5\u4f5c\u4ee5\u78ba\u4fdd\u91ab\u7642\u4e4b\u54c1\u8cea\u3002", "e": "Purpose: The virtual wedge which is equipped in Primus uses dose rate variation and collimator jaw motion to simulate the isodose distribution of hard wedge. The purpose of this report are to compare the differences between virtual wedge and hard wedge for desired wedge angles and beam profiles, and to evaluate the feasibility of virtual wedge clinical application.\nMaterials and Methods: The Memorial 1.0 c.c. parallel plate chamber was used to measure the ratio of MU/dose, to verify the clinic dosimetry sets of virtual wedge. The WELLHOFER WP700 water phantom system with ion chamber was applied to measure the desired angle (\u03b1.) of VW. The beam profile data was measured by the Sun Nuclear The Profiler linear array of solid-state detectors.\nResults: Compared with the 4 commonly-used wedge angles, namely, 15\u00b0, 30\u00b0, 45\u00b0 and 60\u00b0, the deviation of desired virtual wedge angle for 6 MV and 18 MV photon beam are all within one-and-half degree. For beam profiles, the maximum deviation between VW and HW for 6 MV was 5.0% with wedge angle of 60\u00b0, depth of 5cm, and field size of 15\u00d715cm^2. For depth beyond 5cm the maximum deviation between virtual wedge and hard wedge for 18 MV was 5.7% with wedge angle of 60\u00b0, depth of 10cm, and field size of 20\u00d720cm^2. However, for depth less than 5cm, the maximum deviation for 18 MV will be as high as 11.1%.\nConclusions: Due to the different concept and the clinical application of virtual wedge, we need a comprehensive verification data before we apply the virtual wedge technique in the clinics. We also need to set up and practice a quality assurance program for virtual wedge system to assure the treatment quality."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-215-224-a", "title": "\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u81e8\u5e8a\u7269\u7406\u7279\u6027\u5206\u6790", "keywords": "\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668;\u9663\u5217\u5f0f\u904a\u96e2\u8154;\u7a7f\u900f\u56e0\u5b50 Virtual wedge;Chamber array;Transmission factor", "c": "\u76ee\u7684\uff1a\u70ba\u77ad\u89e3\u591a\u529f\u80fd\u897f\u9580\u5b50PRIMUS 3008\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u5728\u81e8\u5e8a\u61c9\u7528\u4e0a\u4e4b\u7269\u7406\u7279\u6027\uff0c\u91dd\u5c0d\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u89d2\u5ea6\u3002\u7a7f\u900f\u56e0\u5b50\uff0c\u53ca\u5176\u8207\u5be6\u9ad4\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u76f8\u5c0d\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u505a\u4e00\u6bd4\u8f03\u5206\u6790\uff0c\u4ee5\u4f5c\u70ba\u5728\u81e8\u5e8a\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u4f7f\u7528\u4e0a\u80fd\u6709\u6548\u7684\u57f7\u884c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528IC 15\u904a\u96e2\u8154\u5728Wellh\u00f6fer48\u00d748\u00d740cm^3\u7684\u6c34\u5047\u9ad4\u4e2d\uff0c\u5728SSD 90\u516c\u5206\uff0c\u8ddd\u4e2d\u5fc3\u8ef8\u6c34\u9762\u4e0b10\u516c\u5206\u8655\uff0c\u6e2c\u91cf\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u89d2\u5ea6\uff1b\u5728\u4e2d\u5fc3\u8ef8\u6c34\u9762\u4e0b5\u516c\u5206(6MV)\u548c10\u516c\u5206 (15MV)\u8655\u6e2c\u91cf\u7a7f\u900f\u56e0\u6578\uff0c SSD\u70ba100\u516c\u5206\u3002\u53e6\u5916\u4f7f\u7528Wellh\u00f6fer CA24\u9663\u5217\u5f0f\u904a\u96e2\u8154\uff0c\u5728\u4e0d\u540c\u7684\u6df1\u5ea6\uff086MV\u6642\u6df1\u5ea6\u5206\u5225\u70bad(\u4e0b\u6a19 max)\u30015\u300115\u300120\u516c\u5206\uff1b 15MV\u6642\u70bad(\u4e0b\u6a19 max)\u300110\u300115\u300120\u516c\u5206\uff09\u548c\u4e0d\u540c\u7684\u6ffe\u5668\u89d2\u5ea6\uff0815\u300130\u300145\u300160\u5ea6\uff09\u4e0b\uff0c\u91cf\u6e2c\u865b\u64ec\u5f0f\u548c\u5be6\u9ad4\u5f0f\u6954\u578b\u6ffe\u5668\u7684\u76f8\u5c0d\u5291\u91cf\u66f2\u7dda\u5206\u4f48\u5716\u3002\n\u7d50\u679c\uff1a\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u89d2\u5ea6\u5728\u6a5f\u5668\u8a2d\u5b9a\u503c\u8207\u5be6\u969b\u91cf\u6e2c\u8a08\u7b97\u6240\u5f97\u4e4b\u554f\u7684\u8aa4\u5dee\u572815\u5ea6\u7bc4\u570d\u5167\uff0c\u800c\u7a7f\u900f\u56e0\u6578\u8da8\u8fd1\u65bc\u5b9a\u503c\uff08\u7d04\u70ba1\uff09\u3002\u7531\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u548c\u5be6\u9ad4\u5f0f\u6954\u578b\u6ffe\u5668\u5728\u4e0d\u540c\u6df1\u5ea6\u3001\u89d2\u5ea6\u6642\u7684\u76f8\u5c0d\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u8b8a\u5316\uff0c\u767c\u73fe\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u6240\u5f62\u6210\u7684\u5291\u91cf\u66f2\u7dda\u5206\u4f48\u4e26\u975e\u5b8c\u5168\u8207\u5be6\u9ad4\u5f0f\u6954\u578b\u6ffe\u5668\u76f8\u540c\u3002\n\u7d50\u8ad6\uff1a\u865b\u64ec\u5f0f\u6954\u578b\u6ffe\u5668\u64c1\u6709\u6bd4\u5be6\u9ad4\u5f0f\u6954\u578b\u6ffe\u5668\u66f4\u9748\u6d3b\u7684\u61c9\u7528\u3002\u4f46\u5fc5\u9808\u5c0d\u65bc\u6cbb\u7642\u6a5f\u7684\u7269\u7406\u7279\u6027\u6709\u5145\u5206\u7684\u77ad\u89e3\uff0c\u95dc\u65bc\u6cbb\u7642\u6a5f\u7684\u54c1\u8cea\u9a57\u8b49\u66f4\u662f\u4e00\u5927\u91cd\u9ede\uff0c\u5982\u5291\u91cf\u7387\u7684\u8b8a\u5316\u3001\u9023\u7e8c\u6027\u7684\u89d2\u5ea6\u8b8a\u5316\u3002\u5982\u6b64\u624d\u80fd\u771f\u6b63\u7684\u78ba\u4fdd\u4e26\u63d0\u9ad8\u6cbb\u7642\u54c1\u8cea\u3002", "e": "Purpose: The purposes of this paper are to analyze the clinical physical characteristics of virtual wedges for the Siemens PRIMUS 3008 linear acceleratot We focus on the wedge angles, transmission factors and the discrepancies of relative dose distributions between physical and virtual wedges. The data will be used to set up the computer treatment planning database.\nMaterials and Methods We measure virtual wedge angles and transmission factors by Wellh\u00f6fer IC 15, 0.13 cc chamber. The wedge angles are measured at 10cm depth of the central axis, and SSD is 90cm. Transmission factors are measured at 5cm (6 MV) and 10cm (15 MV) depth of central axis, and SSD is 100cm. The relative dose profiles of virtual and physical wedges are measured by Wellh\u00f6fer CA24 chamber array. We measure four depths of the central axis (the depth are d(subscript max), 5, 15, 20cm for 6 MV, and d(subscript max), 10, 15, 20cm for 15 MV) for four wedge angles. The chamber is installed on the chamber frame of Wellh\u00f6fer water phantom (48\u00d748\u00d740cm^3).\nResults The different range of virtual wedge angles is below 1.5 degrees between the machine setup and the results measured by ion chamber. The transmission factors of virtual wedges remain almost constant. The relative dose profiles of virtual and physical wedges were not completely the same.\nConclusion The clinical applications of virtual wedge have convenience for treatment setup, and various arbitrary angle. In order to promote the quality of treatment, the QA program beccmes very important."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-225-231-a", "title": "\u6a21\u64ec\u5b9a\u4f4d\u7247\u8207\u6cbb\u7642\u524d\u9a57\u8b49\u7247\u9593\u7167\u91ce\u4e2d\u5fc3\u4f4d\u79fb\u91cf\u8aa4\u5dee\u63a2\u8a0e", "keywords": "\u6a21\u64ec\u5b9a\u4f4d\u7247;\u6cbb\u7642\u524d\u9a57\u8b49\u7247;\u6e96\u78ba\u6027 Simulation film;Port film;Accuracy", "c": "\u76ee\u7684\uff1a\u7c4d\u8457\u6bd4\u8f03\u6a21\u64ec\u5b9a\u4f4d\u7247\u8207\u6cbb\u7642\u524d\u9a57\u8b49\u7247\u7167\u91ce\u4e2d\u5fc3\u9ede\u7684\u4f4d\u79fb\u91cf\u8a55\u4f30\u5f9e\u6a21\u64ec\u5b9a\u4f4d\u5230\u5be6\u969b\u9032\u884c\u653e\u5c04\u6cbb\u7642\u4e4b\u554f\u5176\u6cbb\u7642\u90e8\u4f4d\u518d\u73fe\u6027\u7684\u7a0b\u5ea6\uff0c\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u7531\u672c\u79d1\u81ea87\u5e74\u5ea6110\u4f4d\u60a3\u6709\u5b50\u5bae\u9838\u764c\u7684\u6848\u4f8b\u4e2d\uff0c\u62bd\u53d635\u540d\u75c5\u60a3\u8cc7\u6599\uff0c\u4ee5\u6065\u9aa8\u806f\u5408\u8655\u548c\u75c5\u4eba\u5de6\u53f3\u5074\u9ad6\u81fc\u9802\u7684\u4f4d\u7f6e\u70ba\u89e3\u5256\u53c3\u8003\u9ede\uff0c\u4ee5\u9019\u4e9b\u90e8\u4f4d\u6bd4\u8f03\u5176\u6a21\u64ec\u5b9a\u4f4d\u7247\u8207\u6cbb\u7642\u524d\u9a57\u8b49\u7247\u7684\u7167\u91ce\u4e2d\u5fc3\u9ede\u4f4d\u79fb\u91cf\u9032\u884c\u7d71\u8a08\u5206\u6790\uff0c\n\u7d50\u679c\uff1a35\u500b\u60a3\u6709\u5b50\u5bae\u9838\u764c\u75c5\u60a3\u7684\u75c5\u4f8b\u4e2d\uff0c\u5728X\u8ef8\u65b9\u5411\u8aa4\u5dee\u5c0f\u65bc2mm\u7684\u670991.42%\uff1bY\u8ef8\u65b9\u5411\u8aa4\u5dee\u5c0f\u65bc4mm\u4f54\u670985.72%\uff0c\u986f\u793a\u51fa\u5728Y\u8ef8\u65b9\u5411\u4e0a\u8aa4\u5dee\u6bd4X\u8ef8\u65b9\u5411\u4e0a\u5927\u3002\n\u7d50\u8ad6\uff1a\u5728\u6a21\u64ec\u5b9a\u4f4d\u7247AP\u4f4d\u7f6e\u548c\u6cbb\u7642\u524d\u9a57\u8b49\u7247\u537b\u4f4d\u7f6e\u6240\u5f97\u6578\u64da\u4e2d\uff0c\u53ef\u767c\u73fe\u7167\u91ce\u4e2d\u5fc3\u9ede\u7684\u4f4d\u79fb\u8aa4\u5dee\u5927\u591a\u7686\u5728\u53ef\u63a5\u53d7\u7684\u7a0b\u5ea6\u5167\uff0c\u4e14\u5176\u8aa4\u5dee\u7bc4\u570d\u591a\u57280~1mm\u4e4b\u9593\uff0c\u8868\u793a\u51fa\u5f9e\u6a21\u64ec\u5b9a\u4f4d\u5ba4\u5230\u6cbb\u7642\u5ba4\uff0c\u6cbb\u7642\u90e8\u4f4d\u7684AP\u4f4d\u7f6e\u6e96\u78ba\u6027\u5f88\u9ad8\uff0c\u9019\u5c0d\u65bc\u6574\u500b\u653e\u5c04\u6cbb\u7642\u7684\u54c1\u8cea\u4fdd\u8b49\u800c\u8a00\u662f\u6975\u91cd\u8981\u7684\u4e00\u74b0\u3002", "e": "Purpose: The objective of this study is to evaluate and compare patient setup errors using simulation film and port film in radiation therapy for cervical cancer.\nMaterials and Methods: Simulation films and port films of 35 patients with cervical cancer are analyzed. Two anatomical landmarks, roof of the acetabulum and symphysis pubis, are used to evaluate the difference between simulation film and port film.\nResults: Errors in X axis of 31 cases are less than 2mm. Errors in Y axis of 30 cases are less than 4mm. In other words, the error in Y axis is larger than that in X axis.\nConclusion: Based on the analysis of the data of AP simulation films and AP port films, most of the radiation field deviations are within the range of 0 to 1mm. Therefore, setup errors in our department are acceptable."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199909-6-3-233-238-a", "title": "\u6bcf\u9031\u75c5\u6b77\u67e5\u6838\u5236\u5ea6\u7684\u57f7\u884c\u8207\u7d50\u679c\u5206\u6790\u5831\u544a", "keywords": "\u54c1\u8cea\u4fdd\u8b49;\u6bcf\u9031\u75c5\u6b77\u67e5\u6838 Quality assurance;Weekly chart review", "c": "\u76ee\u7684\uff1a\u672c\u6587\u5167\u5bb9\u4e3b\u8981\u91dd\u5c0d\u6bcf\u5468\u75c5\u6b77\u67e5\u6838\u6240\u767c\u73fe\u7f3a\u5931\u4e88\u4ee5\u5206\u985e\u3001\u7d71\u8a08\u5206\u6790\u5176\u767c\u751f\u539f\u56e0\u3002\u4e26\u4ecb\u7d39\u672c\u79d1\u57f7\u884c\u6bcf\u5468\u75c5\u6b77\u67e5\u6838\u5236\u5ea6\u7684\u65b9\u6cd5\u53ca\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f9d\u64da\u7f8e\u570b\u91ab\u5b78\u7269\u7406\u5e2b\u5b78\u6703\u653e\u5c04\u6cbb\u7642\u59d4\u54e1\u6703\u5de5\u4f5c\u7fa440(TG-40)\u7684\u5831\u544a\uff0c\u5c0d\u81e8\u5e8a\u6cbb\u7642\u54c1\u8cea\u4fdd\u8b49\u8a08\u5283\u7684\u5efa\u8b70\u3002\u65bc\u6bcf\u4e00\u4f4d\u75c5\u60a3\u6cbb\u7642\u7642\u7a0b\u4e2d\uff0c\u5c0d\u5176\u75c5\u6b77\u5be6\u65bd\u6bcf\u5468\u4e00\u6b21\u7684\u75c5\u6b77\u67e5\u6838\u3002\u672c\u6587\u5171\u8a18\u9304\u81ea1998\u5e747\u6708\u8d77\u52301999\u5e746\u6708\u6b62\u4e00\u5e74\u9593\uff0c\u65bc\u6bcf\u5468\u4e94\u5be6\u65bd\u75c5\u6b77\u67e5\u6838\u6240\u767c\u73fe\u7684\u8aa4\u5dee\uff0c\u5c0d\u65bc\u6240\u767c\u73fe\u7f3a\u5931\u5206\u985e\u70ba\u5291\u91cf\u8a08\u7b97\u932f\u8aa4\u3001\u6cbb\u7642\u8a18\u9304\u586b\u5beb\u932f\u8aa4\u3001\u6cbb\u7642\u8a2d\u5b9a\u932f\u8aa4\u6216\u5176\u4ed6\u932f\u8aa4\u3002\u540c\u6642\u4e5f\u5206\u6790\u932f\u8aa4\u7684\u767c\u751f\u548c\u6cbb\u7642\u6a5f\u5668\u3001\u6cbb\u7642\u6642\u6bb5\u4e4b\u95dc\u4fc2\uff0c\u6b64\u5916\u5c0d\u65bc\u5291\u91cf\u57f7\u884c\u8aa4\u5dee\u7684\u75c5\u6b77\uff0c\u4f9d\u8aa4\u5dee\u7a0b\u5ea6\u7d71\u8a08\u4e26\u5206\u6790\u767c\u751f\u539f\u56e0\uff0c\n\u7d50\u679c\uff1a\u5728\u51719425\u672c\u6b21\u6578\u7684\u75c5\u6b77\u67e5\u6838\u4e2d\u767c\u73fe172\u672c\u6709\u932f\u8aa4\u7684\u75c5\u6b77\uff0c\u767c\u751f\u932f\u8aa4\u6bd4\u7387\u70ba18% (172/9425)\u3002\u5176\u4e2d\u5c6c\u65bc\u5291\u91cf\u8a08\u7b97\u932f\u8aa4\u5360453% (78/172)\u53ca\u6cbb\u7642\u8a18\u9304\u586b\u5beb\u932f\u8aa4\u70ba52.3% (90/172) , \u800c\u6cbb\u7642\u8a2d\u5b9a\u932f\u8aa4\u6216\u5176\u4ed6\u932f\u8aa4\u53602.4% (4/172)\uff0c\u5728\u6240\u6709\u5291\u91cf\u57f7\u884c\u8aa4\u5dee\u7684\u75c5\u6b77\u4e2d\u3002\u55ae\u6b21\u57f7\u884c\u5291\u91cf\u8207\u8655\u65b9\u5291\u91cf\u8aa4\u5dee\u7387\u5c0f\u65bc\u6216\u7b49\u65bc5%\u8005\u5360\u5927\u591a\u657878% (64/82)\uff1b\u800c\u5c31\u6240\u767c\u73fe\u932f\u8aa4\u5728\u5404\u6cbb\u7642\u6a5f\u5668\u5206\u4f48\u60c5\u5f62\uff0cL4\u5360255% (49/172)\u3002L1\u53caL2\u5404\u5360235% (41/172),L3\u70ba169% (29/172), L5\u53607% (12/172)\uff1b\u5f9e\u6240\u767c\u73fe\u932f\u8aa4\u75c5\u6b77\u5728\u5404\u6cbb\u7642\u6642\u554f\u5206\u4f48\u4e0a\uff0c\u6700\u9ad8\u8005\u70ba\u4e0b\u53483\u81f34\u9ede\uff0c\u5360\u6240\u6709\u932f\u8aa4\u75c5\u6b7720% (34/172)\u3002\n\u7d50\u8ad6\uff1a\u6bcf\u5468\u75c5\u6b77\u67e5\u6838\u5236\u5ea6\u7684\u5be6\u65bd\u70ba\u653e\u5c04\u6cbb\u7642\u90e8\u9580\u54c1\u8cea\u4fdd\u8b49\u8a08\u5283\u4e0d\u53ef\u5ffd\u8996\u7684\u91cd\u8981\u8ab2\u984c\u3002\u53ef\u85c9\u6b64\u767c\u73fe\u6cbb\u7642\u932f\u8aa4\uff0c\u4e26\u5118\u65e9\u66f4\u6b63\u3002", "e": "Purpose: To initiate and conduct a weekly chart review program in a radiation oncology department. Its results were analyzed and reported.\nMethods and Materials: According to the guidelines recommended by the Task Group-40 report, AAPM, a weekly chart review program was initiated. Patients and their charts seen and treated between June 1998 and July 1999 were routinely reviewed once every Friday during their treatment course. Errors, once identfied, were documented, and categorized as calculation (summation), recording, or execution errors. Analyses were also made according to treatment machines and time allocations. Calculation errors were rated according to the discrepancy between the dose actually delivered and prescribed.\nResults: A total of 9425 charts were reviewed. Of these, 172 errors were identified, accounting for an incidence of 1.8% (172/9425). Of these, 45.3% (78/172), 52.3% (90/172), 2.4% (4/172) errors were due to calculation, recording, and execution, respectively. Dose discrepancy in 78% of patients was less than or equal to 5%. Error distributions by treatment machine were 23.8%, 23.8%, 16.9%, 28.5%, and 7%, for Li through L5, respectively. The most frequent time allocation that errors occurred was 3-4 PM, accounting for 20% of total errors.\nConclusion: A weekly chart review program is an integrated part of quality assurance in a modem radiation oncology department. A substantial proportion of treatment errors can be effectively detected with aid of this program."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-73-82-a", "title": "5-\u6c1f\u5c3f\u5627\u5576\u55ae\u7368\u6216\u4f75\u7528\u904a\u96e2\u8f3b\u5c04\u6cbb\u7642\u4eba\u985e\u7d50\u8178\u76f4\u8178\u764c\u7d30\u80de\u4e4b\u6548\u679c", "keywords": "5-\u6c1f\u5c3f\u5627\u5576;\u4eba\u985e\u7d50\u8178\u76f4\u8178\u764cSW480\u7d30\u80de;\u904a\u96e2\u8f3b\u5c04;\u5408\u4f75\u6cbb\u7642;\u5354\u540c\u4f5c\u7528 5-Fluorouracil;Human colorectal adenocarcinoma SW480 cells;Ionizing radiation;Combined treatment;Synergistic effect", "c": "Purpose: In this study 5-fluorouracil (5FU), ionizing radiation or combination of both was applied on human colorectal adenocarcinoma cells (SW480) in order to establish a better therapeutic strategy for clinical use.\nMaterials and Methods: Log-phase SW480 cells were used for all experiments. For 5FU treatment alone, cells were treated with 0, 0.1, 0.5, 1-0, 1.5 and 2.0mM 5FU for 3 hours. For radiation treatment alone, cells were irradiated for 0, 1, 1.5, 2, 4 and 6Gy. For combined treatment, cells were treated with 0.2mM 5FU and graded radiation doses using concurrent treatments or different order of sequence. Surviving fractions of cells were assayed by 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl-terazolium bromide (MTT) method. Activity of thymidylate synthase and intracellular glutathione contents were also measured.\nResults: The surviving fractions of SW480 cells were about 40% after three-hour treatments of 0.5mM, 1mM or 2mM 5FU. The 50% inhibition concentration (IC50) obtained from survival curve is about 0.4mM. Pre-irradiation 0.2mM 5FU treatment, post-irradiation 0.2mM 5FU treatment, and concurrent treatment of 0.2mM 5FU and radiation all had synergistic effect. However, the concurrent treatment of 5FU and radiation was found with the highest killing effect among the three different combined treatments. After 1mM and 2mM 5FU treatments for three hours, contents of reduced glutathione were 6.2\u00b11.5nmole/mg and 5,2\u00b12.6nmole/mg, respectively, and were significantly reduced (p\uff1c 0.05) as compared to 12\u00b10.4nmole/mg of the control group. Contents of oxidized glutathione were 29.6\u00b15.5nmole/mg and 29.8\u00b12.7nmole/mg, respectively, and were significantly increased (p\uff1c0.05) as compared to 20.5\u00b13.0 amok/mg of the control group. Also, activities of thymidylate synthase were reduced to 0.59 \u00b1 0.04pmole/min/mg and 0.36\u00b10.15pmole/min/mg, respectively, as compared to 2.7\u00b10.76pmole/min/mg of the control group, p\uff1c0.01.\nConclusions: Concurrently combined 5FU with ionizing radiation showed the highest killing effect on SW480 human colorectal carcinoma cells. Reduced glutathione was significantly decreased in 5W480 cells after 1mM and 2mM 5FU treatments for 3 hours. The finding that the treatment of low concentration (0.2mM) 5FLJ with low doses of ionizing radiation (1Gy, 1.5Gy and 2Gy) still showed synergistic killing effect may have feasible clinical application in fractionated radiotherapy combined with chemotherapy for human colorectal carcinoma.", "e": "Purpose: In this study 5-fluorouracil (5FU), ionizing radiation or combination of both was applied on human colorectal adenocarcinoma cells (SW480) in order to establish a better therapeutic strategy for clinical use.\nMaterials and Methods: Log-phase SW480 cells were used for all experiments. For 5FU treatment alone, cells were treated with 0, 0.1, 0.5, 1-0, 1.5 and 2.0mM 5FU for 3 hours. For radiation treatment alone, cells were irradiated for 0, 1, 1.5, 2, 4 and 6Gy. For combined treatment, cells were treated with 0.2mM 5FU and graded radiation doses using concurrent treatments or different order of sequence. Surviving fractions of cells were assayed by 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl-terazolium bromide (MTT) method. Activity of thymidylate synthase and intracellular glutathione contents were also measured.\nResults: The surviving fractions of SW480 cells were about 40% after three-hour treatments of 0.5mM, 1mM or 2mM 5FU. The 50% inhibition concentration (IC50) obtained from survival curve is about 0.4mM. Pre-irradiation 0.2mM 5FU treatment, post-irradiation 0.2mM 5FU treatment, and concurrent treatment of 0.2mM 5FU and radiation all had synergistic effect. However, the concurrent treatment of 5FU and radiation was found with the highest killing effect among the three different combined treatments. After 1mM and 2mM 5FU treatments for three hours, contents of reduced glutathione were 6.2\u00b11.5nmole/mg and 5,2\u00b12.6nmole/mg, respectively, and were significantly reduced (p\uff1c 0.05) as compared to 12\u00b10.4nmole/mg of the control group. Contents of oxidized glutathione were 29.6\u00b15.5nmole/mg and 29.8\u00b12.7nmole/mg, respectively, and were significantly increased (p\uff1c0.05) as compared to 20.5\u00b13.0 amok/mg of the control group. Also, activities of thymidylate synthase were reduced to 0.59 \u00b1 0.04pmole/min/mg and 0.36\u00b10.15pmole/min/mg, respectively, as compared to 2.7\u00b10.76pmole/min/mg of the control group, p\uff1c0.01.\nConclusions: Concurrently combined 5FU with ionizing radiation showed the highest killing effect on SW480 human colorectal carcinoma cells. Reduced glutathione was significantly decreased in 5W480 cells after 1mM and 2mM 5FU treatments for 3 hours. The finding that the treatment of low concentration (0.2mM) 5FLJ with low doses of ionizing radiation (1Gy, 1.5Gy and 2Gy) still showed synergistic killing effect may have feasible clinical application in fractionated radiotherapy combined with chemotherapy for human colorectal carcinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-83-87-a", "title": "The Combined Effect of Colchicine and Radiation of Human Hepatoma HA22T/VGH Cells", "keywords": "\u653e\u5c04\u7dda;\u79cb\u6c34\u4ed9\u7d20;\u809d\u764c\u7d30\u80de Radiation;Colchicine;Hepatoma HA22T/VGH cell", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u65e8\u5728\u6e2c\u8a66\u5176\u662f\u5426\u53ef\u964d\u4f4e\u4eba\u985eHA22T/VGH\u809d\u764c\u7d30\u80de\u63a5\u53d7\u653e\u5c04\u7dda\u5f8c\u4e4b\u5b58\u6d3b\u7387\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1aHA22T/VGH\u7d30\u80de\u7d93\u79cb\u6c34\u4ed9\u7d20\u8655\u740624\u5c0f\u6642\u5f8c\uff0c\u63a5\u53d7\u4e0d\u540c\u5291\u91cf\u653e\u5c04\u7dda\uff0c75\u5c0f\u6642\u5f8c\u7528MTT\u65b9\u6cd5\u6e2c\u8a66\u7d30\u80de\u6d3b\u5ea6\uff1b\u4e26\u8a08\u6578\u7167\u5c04\u524d\u7684\u6709\u7d72\u5206\u88c2\u767e\u5206\u6bd4\u53ca\u89c0\u5bdf\u5176\u5f62\u614b\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u79cb\u6c34\u4ed9\u7d20\u5728\u6975\u4f4e\u5291\u91cf\u4e0b(8ng/ml)\u5373\u53ef\u964d\u4f4e\u4eba\u985eHA22T/VGH\u809d\u764c\u7d30\u80de\u63a5\u53d7\u653e\u5c04\u7dda\u5f8c\u4e4b\u5b58\u6d3b\u7387\uff1b\u4f34\u96a8\u6b64\u73fe\u8c61\u53ef\u898b\u5230\u79cb\u6c34\u4ed9\u7d20\u589e\u52a0\u7d30\u80de\u7684\u6709\u7d72\u5206\u88c2\u767e\u5206\u6bd4\u3002\u53e6\u5916\uff0cHA22T/VGH\u7d30\u80de\u7d93\u79cb\u6c34\u4ed9\u7d20\u8655\u7406\u5f8c\uff0c\u5728\u5f62\u614b\u4e0a\u8b8a\u6210\u5713\u5f62\u3001\u6d6e\u8d77\u4e14\u5448\u73fe\u660e\u986f\u7684\u5206\u88c2\u505c\u6eef\u73fe\u8c61\u3002\n\u7d50\u8ad6\uff1a\u4e0a\u8ff0\u7d50\u679c\u986f\u793a\u79cb\u6c34\u4ed9\u7d20\u53ef\u964d\u4f4e\u4eba\u985eHA22T/VGH\u809d\u764c\u7d30\u80de\u63a5\u53d7\u653e\u5c04\u7dda\u5f8c\u4e4b\u5b58\u6d3b\u7387\u3002", "e": "Purpose: We studied colchicine to determine whether or not it can reduce the survival of irradiated human hepatoma HA22T/VGH cells.\nMaterials and Methods: Twenty four hours after treatment of 0-8ng/ml colchicine, HA22T/VGH cells were irradiated with various doses. Seventy five hours later, the MTT[(3-(4,5-dimethylthiazol-2-y-2,5-diphenyl tetrazolium bromide)] assay was performed to assess cell viability. Before radiation, the percentage of mitosis was calculated and micrographs were taken for morphological observation.\nResults: Colohicine at a low concentration of 8ng/ml enhanced the growth-inhibiting effect of radiation (up to 10-folds compared to 2Gy radiation alone). We also noted a parallel effect of colchicine on increasing the percentage of mitosis of cells before radiation. Cells treated with colchicine became rounded, floated up and showed mitotic features under observation by an inverted light microscope.\nConclusion: These findings suggest that colchicine has potential as an adjunct to radiotherapy for hepatoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-89-96-a", "title": "\u4ee5\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6cbb\u7642\u8166\u52d5\u975c\u8108\u7578\u5f62\uff1a\u9ad8\u96c4\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u4e4b\u521d\u6b65\u7d50\u679c", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u52d5\u975c\u8108\u7578\u5f62;\u6d88\u9000\u7387 Stereotactic radiosurgery;Arteriovenous malformation;Obliteration rate", "c": "Purpose: For reporting the preliminary result of brain arteriovenous malformation (AVM) treated with single fraction stereotactic radiosurgery.\nMaterials and Methods: From June 1994 through April 1998, 26 patients with brain AVM received stereotactic radiosurgery. The age of patients ranged from 12 to 77 years old (median: 28.5). We used 6 MV X-ray Siemens linear accelerator. The median prescribed dose was 15 Gy (range: 10-18.73 Gy) to the nidus margin. The minimal dose ranged from 4.62 to 15.13 Gy (median 11.88 Gy). The maximal dose ranged from 13.33 to 27.95 Gy (median 18.84 Gy). The mean target volume was 6.85 cm^3 (range: 0.63-25.76). Twenty-two patients were treated with one isocenter (4-6 arcs), 4 patients with 2 isoeenters (6-10 arcs). We evaluated the response rate and radiation-induced complication.\nResults: The follow-up angiogram or MRI studies in 21 patients revealed the complete obliteration rates in 1 and 2 years were 33% and 41%, respectively. With the minimal dose of\u226413 and\uff1e 13 Gy, the 2-year complete obliteration rate was 17% and 60%, respectively (p = 0.0067). The 2-year complete obliteration rate was 44% and 34% with target volume \u22646 and \uff1e 6 cm^3 (p = 0.6507), respectively. Higher ratio (\uff1e85%) of minimal dose to prescribed dose was noted in 73% (11/15) and 27% (3/11) of the patients whose target volume was \u22646 and \uff1e6 cm^3 (p = 0.02), respectively. In multivariate analysis, minimal dose was an only significant factor for complete obliteration (p = 0.0495). One patient had hemorrhage 5 months after radiosurgery. Two patients had radiation-induced complications on MRI 14 to 21 months later after radiosurgery.\nConclusion: Target volume and minimal dose may influence the obliteration rate of brain AVM. According to literature review, the complete obliteration rates in our series were lower than some reports. Lower prescribed doses may be the cause. Higher doses may improve the response rate.", "e": "Purpose: For reporting the preliminary result of brain arteriovenous malformation (AVM) treated with single fraction stereotactic radiosurgery.\nMaterials and Methods: From June 1994 through April 1998, 26 patients with brain AVM received stereotactic radiosurgery. The age of patients ranged from 12 to 77 years old (median: 28.5). We used 6 MV X-ray Siemens linear accelerator. The median prescribed dose was 15 Gy (range: 10-18.73 Gy) to the nidus margin. The minimal dose ranged from 4.62 to 15.13 Gy (median 11.88 Gy). The maximal dose ranged from 13.33 to 27.95 Gy (median 18.84 Gy). The mean target volume was 6.85 cm^3 (range: 0.63-25.76). Twenty-two patients were treated with one isocenter (4-6 arcs), 4 patients with 2 isoeenters (6-10 arcs). We evaluated the response rate and radiation-induced complication.\nResults: The follow-up angiogram or MRI studies in 21 patients revealed the complete obliteration rates in 1 and 2 years were 33% and 41%, respectively. With the minimal dose of\u226413 and\uff1e 13 Gy, the 2-year complete obliteration rate was 17% and 60%, respectively (p = 0.0067). The 2-year complete obliteration rate was 44% and 34% with target volume \u22646 and \uff1e 6 cm^3 (p = 0.6507), respectively. Higher ratio (\uff1e85%) of minimal dose to prescribed dose was noted in 73% (11/15) and 27% (3/11) of the patients whose target volume was \u22646 and \uff1e6 cm^3 (p = 0.02), respectively. In multivariate analysis, minimal dose was an only significant factor for complete obliteration (p = 0.0495). One patient had hemorrhage 5 months after radiosurgery. Two patients had radiation-induced complications on MRI 14 to 21 months later after radiosurgery.\nConclusion: Target volume and minimal dose may influence the obliteration rate of brain AVM. According to literature review, the complete obliteration rates in our series were lower than some reports. Lower prescribed doses may be the cause. Higher doses may improve the response rate."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-97-104-a", "title": "\u52a0\u99ac\u5200\u55ae\u4e00\u5c04\u675f\u5291\u91cf\u5206\u4f48\u6a21\u64ec\u7814\u7a76", "keywords": "\u653e\u5c04\u624b\u8853;\u8499\u5730\u5361\u7f85\u65b9\u6cd5;\u52a0\u99ac\u5200;\u5291\u91cf\u5206\u4f48 Radiosurgery;Monte Carlo;Gamma Knife;Dose distribution", "c": "\u76ee\u7684\uff1a\u6a21\u64ec\u52a0\u99ac\u5200\u653e\u5c04\u624b\u8853\u55ae\u4e00\u5c04\u675f\u6df1\u5ea6\u8207\u5f91\u5411\u5291\u91cf\u5206\u4f48\uff0c\u4e26\u8207\u52a0\u99ac\u5200\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u4e00\u52a0\u99ac\u8a08\u756b(GammaPlan \uff08\u4e0a\u6a19 \u00ae\uff09)\u9032\u884c\u6bd4\u8f03\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528EGS4\u8499\u5730\u5361\u7f85\u8a08\u7b97\u6a5f\u7a0b\u5f0f\uff0c\u6a21\u64ec\u52a0\u99ac\u5200\u653e\u5c04\u624b\u8853\u6cbb\u7642\u6a5f18 mm\u5b54\u5f91\u55ae\u4e00\u5c04\u675f\u901a\u904e\u805a\u82ef\u4e59\u70ef\u5747\u8cea\u5047\u9ad4\u3002\n\u7d50\u679c\uff1a\u6a21\u64ec\u904e\u7a0b\u4e2d\uff0c\u9ad4\u5c04\u6e90\u6a21\u64ec\u9664\u5c04\u6e90\u81ea\u6211\u906e\u7f69\u964d\u4f4e\u7d55\u5c0d\u6df1\u5ea6\u5291\u91cf\u5916\uff0c\u5176\u4ed6\u76f8\u5c0d\u5291\u91cf\u5206\u4f48\u8a08\u7b97\u7d50\u679c\u8207\u9ede\u5c04\u6e90\u6a21\u64ec\u5927\u81f4\u76f8\u540c\uff0c\u6545\u5229\u7528\u9ede\u5c04\u6e90\u5c04\u675f\u6a21\u64ec\u5be6\u969b\u60c5\u5f62\uff0c\u53ef\u5927\u5e45\u6e1b\u77ed\u7a0b\u5f0f\u8a08\u7b97\u6642\u9593\u3002\u52a0\u99ac\u8a08\u756b\u9664\u8868\u9762\u5291\u91cf\u589e\u5efa\u5340\u7121\u6cd5\u8a08\u7b97\u5916\uff0c\u76f8\u5c0d\u6df1\u5ea6\u5291\u91cf\u8a08\u7b97\u53ef\u8b02\u76f8\u7576\u6e96\u78ba\uff1b\u5f91\u5411\u5291\u91cf\u65b9\u9762\uff0c\u52a0\u99ac\u8a08\u756b\u5229\u7528\u7126\u9ede\u5e73\u9762\u76f8\u5c0d\u5f91\u5411\u5291\u91cf\u5206\u4f48\u53d6\u4ee3\u5176\u4ed6\u5e73\u9762\u5291\u91cf\u5206\u4f48\uff0c\u4ea6\u7121\u4e0d\u59a5\u3002\n\u7d50\u8ad6\uff1a\u5747\u8cea\u5047\u9ad4\u4e2d\uff0c\u52a0\u99ac\u8a08\u756b\u5291\u91cf\u8a55\u4f30\u9664\u6df1\u5ea6\u5291\u91cf\u5206\u4f48\u4e4b\u8868\u9762\u589e\u5efa\u73fe\u8c61\u7121\u6cd5\u8a08\u7b97\u5916\uff0c\u5176\u9918\u6df1\u5ea6\u8207\u5f91\u5411\u5291\u91cf\u5206\u4f48\u53ef\u8b02\u76f8\u7576\u6e96\u78ba\u3002", "e": "Purpose: To simulate the single beam depth and radial dose distribution for the 18 mm collimator of a Gamma Knife radiosurgery unit.\nMaterials and Methods: EGS4 Monte Carlo code was used to simulate the single beam passing a polystyrene phantom.\nResults: Simulation results show no difference in the relative dose distributions for point and body sources, it is desirable to use a point source to replace the real body source for all the simulations in this study to reduce computation time. The simulated relative depth dose distribution show good agreement with that calculated by the treatment planning system (GammaPlan (superscript \u00ae)) provided by the manufacturer except at the region adjacent to phantom surface. The simulated relative radial dose distributions at various depths also indicate that the assumption made by the GammaPlan to use the radial dose distribution at the focus to replace those at other depths generates only minimum errors.\nConclusions: Excluding the build up effect on depth dose distribution at the surface region, GanmiaPlan (superscript \u00ae) show a good agreement with EGS4 simulation both on depth and radial dose distribution in a homogeneous phantom for single beam of gamma knife."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-105-112-a", "title": "\u6838\u91ab\u85e5\u7269\u653e\u5c04\u6027\u6838\u7a2e\u6cbb\u7642\u88fd\u5291\u9338-188\uff0d\u932b-1,1\u6c2b\u6c27\u4e9e\u4e59\u57fa\u4e8c\u78f7\u9178\u9e7d\u4e4b\u7279\u6027\u7814\u7a76", "keywords": "\u653e\u5c04\u6838\u7a2e\u6cbb\u7642\u88fd\u5291;Re-188-Sn-HEDP;\u9aa8\u8f49\u79fb Radionuclide therapy;Rhenium-188-Sn-1, 1-hydroxy ethylidene Diphosphonate;Bone metastasis", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u6b32\u6df1\u5165\u7814\u7a76\u6838\u91ab\u85e5\u7269\u653e\u5c04\u6838\u7a2e\u6cbb\u7642\u88fd\u5291\u9338-188\uff0d\u932b-1,1-\u6c2b\u6c27\u4e9e\u4e59\u57fa\u4e8c\u78f7\u9178\u9e7d(Re-188-HEDP)\u4e4b\u7279\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6838\u7a2e\u7522\u751f\u5668Re-188\u5b73\u751f\u5668\u662f\u6838\u80fd\u7814\u7a76\u6240\u540c\u4f4d\u7d20\u7d44\u8207\u570b\u969b\u9593\u5408\u4f5c\u7531\u7f8e\u570bOak Ridge National Laboratory\u63d0\u4f9b\u3002\u9996\u5148\u9032\u884cRe-188-Ligand\u932f\u5408\u7269\u4e4b\u5408\u6210\u53ca\u9451\u5b9a\uff0c\u4e26\u9032\u884cRe-188-Ligand\u88fd\u5291\u4e2d\u5f62\u6210\u4e4b\u932f\u5316\u5408\u7269\u6210\u4efd\u5206\u6790\uff0c\u4e26\u63a2\u8a0e\u88fd\u5291\u4e2d\u914d\u4f4d\u5b50(ligand)\u3001\u9084\u539f\u5291(SnCl2.2H2O)\u3001\u6297\u6c27\u5316\u5291(gentisic acid)\u53caPH\u503c\u5927\u5c0f\u7b49\u56e0\u7d20\u5c0d\u932f\u5316\u5408\u7269\u5404\u6210\u4efd\u542b\u91cf\u4e4b\u5f71\u97ff\u3002\u5176\u6b21Re-188-Sn-HEDP\u5728\u5404\u689d\u4ef6\u4e0b\u88fd\u5099\u4e4b\u914d\u5291\u5728\u9ad4\u5916(in vitro)\u9032\u884c\u7279\u6027\u6e2c\u5b9a\u3001\u5305\u542b\u8207\u8840\u4e2d\u86cb\u767d\u8cea\u7684\u9375\u7d50\u91cf\u53ca\u8f9b\u9187\u7de9\u885d\u6db2(1-octanoy/buffer solution)\u4e4b\u5206\u5360\u4fc2\u6578\u4e4b\u6e2c\u5b9a\uff0c\u4e26\u9032\u884cRe-18-Ligand\u932f\u5316\u5408\u7269\u88fd\u5291\u4e4b\u751f\u7269\u5206\u4f48\u6e2c\u5b9a\u3002\n\u7d50\u679c\uff1a\u7531\u5be6\u9a57\u7d50\u679c\u767c\u73fe\u653e\u5c04\u6027\u6838\u7a2e\u6cbb\u7642\u88fd\u5291\u9338\u9178\u9e7dRe-188-Sn-HEDP\u914d\u5291\u4f7f\u7528TSK G2000 PW size exclusion gel\u7ba1\u67f1\u5206\u6790\u53ef\u5f97\u4e94\u500b\u4e3b\u6210\u4efd\u96fb\u8377\u7bc4\u570d\u5728-1\u81f3-3\u4e4b\u554f\uff0c\u4f7f\u7528Amine A28\u9670\u96e2\u5b50\u4ea4\u63db\u6a39\u916f\u7ba1\u67f1\u5206\u6790\u53ef\u5f97\u4e94\u500b\u4e3b\u6210\u4efd\u96fb\u8377\u7bc4\u570d\u5728-3\u81f3-12\u4e4b\u9593\u3002\u7576\u914d\u5291\u689d\u4ef6\u6539\u8b8a\u6642\u653e\u5c04\u6027\u6838\u7a2e\u6cbb\u7642\u88fd\u5291\u9338\u9178\u9e7dRe-188-Sn-HEDP\u4e3b\u8981\u6210\u4efd\u4ea6\u6709\u5f88\u5927\u7684\u8b8a\u5316\u3002\u7576PH\u503c\u9ad8\u65bc11\u4ee5\u4e0a\u4e3b\u6210\u4efd\u5e7e\u4e4e\u53ea\u5448\u73fe\u4e00\u7a2e\u4e3b\u6210\u4efd\uff0cPH\u503c\u6108\u4f4e\u9178\u6027\u6108\u5f37\u6642\u914d\u5291\u4e2d\u4e3b\u6210\u4efd\u5c31\u6709\u6108\u591a\u7a2e\u3002\u3000\n\u7d50\u8ad6\uff1a\u56e0\u6b64PH\u964d\u4f4e\u53ef\u5206\u96e2\u51fa\u7f6e\u7559\u6642\u554f\u6bd4\u8f03\u9577\u7684\u4e3b\u6210\u4efd\u51fa\u4f86\uff0c\u81f3\u65bc\u914d\u4f4d\u5b50\u5728\u914d\u5291\u4e2d\u5c0d\u4e3b\u6210\u4efd\u4e4b\u5f71\u9957\u672c\u7814\u7a76\u767c\u73fe\u914d\u4f4d\u5b50HEDP\u8207\u9084\u539f\u5291SnCl2.2H2O\u4e4b\u6bd4\u4f8b\u503c\u4e0d\u540c\u6642\u4e3b\u6210\u4efd\u4e4b\u542b\u91cf\u4e5f\u6703\u4e0d\u540c\u3002", "e": "Objective: The goal of this study was to analysis and characterize the agent of rhenium-188-Sn-1, 1-hydroxyethylidene diphosphonate in radionuclide therapy for Nuclear Medicine.\nMaterials and Methods: We use the generator of W-188/Re-188 to do some research, because we cooperated with researchers of Institute of Nuclear Energy Research. There are the generators of W-188/Re-188 from Oak Ridge National Laboratory in U.S.A.. First, We synthesize and identify the rhenium-186-1, 1-hydroxyethylidene diphosphonate in different condition, then to analyte (including in different conditions) and proceed the biodistribution of the agent of rhenium-188-Sn-1, 1-hydroxyethylidcnc diphosphonate. Results and Discussions: In this study, we found that the main components were five peaks by the analytical method of TSK G2000 PW size exclusion gel in HPLC and their charge is between -1 and -3. The same main components are five peaks by the analytical method of Amine A28 in HPLC and their charge is between -3 and -12 in different proportions.\nConclusion: We found that the component was only one in the high pH of the rhenium-188-Sn-l, 1-hydroxyethylidene diphosphonate, and the components increased more and more when the concentration of hydrogen ion increased. The contents of the components are also dependent on the ratio of the ligand and reduced agent."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-113-119-a", "title": "Siemens PRIMUS\u76f4\u7dda\u52a0\u901f\u5668\u4e4b\u4e2d\u5b50\u91cf\u6e2c\u7814\u7a76", "keywords": "\u4e2d\u5b50\u7b49\u6548\u5291\u91cf\u7387;Siemens PRIMUS;\u53ef\u651c\u5f0f\u4f96\u76ee\u5100;BF3\u6bd4\u4f8b\u8a08\u6578\u5668;\u4e94\u6c27\u5316\u4e8c\u78f7 Neutron dose equivalent rate;Siemens PRIMUS;Portable remmeter;BF3 proportional counter;P2O5", "c": "\u76ee\u7684\uff1a\u91cf\u6e2c\u76ee\u524d\u570b\u969b\u4e0a\u5c1a\u7f3a\u4e4f\u4e4bSiemens PRIMUS\u76f4\u7dda\u52a0\u901f\u5668\u80fd\u91cf15 MV\u5149\u5b50\u6240\u7522\u751f\u4e4b\u5149\u4e2d\u5b50\u6c61\u67d3\u91cf\uff0c\u4ee5\u4f5c\u70ba\u906e\u7f69\u8a2d\u8a08\u4e4b\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1b\u672c\u7814\u7a76\u4e4b\u91cf\u6e2c\u5206\u70ba\u56db\u90e8\u4efd\u5305\u62ec(l)\u53ef\u651c\u5f0f\u4e2d\u5b50\u4f96\u76ee\u5100(Harwell Co. N91)\uff0c\u8a72\u5075\u6aa2\u5668\u7d93\u5f71\u9310\u6cd5\u6821\u6b63\uff0c\u4f5c\u70ba\u6cbb\u7642\u5ba4\u5468\u570d\u74b0\u5883\u4e2d\u5b50\u91cf\u6e2c\u5de5\u5177\u3002(2)\u4e2d\u5b50\u5075\u6aa2\u6838\u5100\u6a21\u7d44\uff0c\u70baBF3\u6bd4\u4f8b\u8a08\u6578\u5668\u5916\u5957\u76f4\u5f919\u540b\u82073\u540b\u7dca\u4e59\u70ef(PE)\u7403\uff0c\u4f5c\u70ba\u6cbb\u7642\u5ba4\u5167\u5c04\u675f\u5916\u4e2d\u5b50\u80fd\u91cf\u5206\u4f48\u91cf\u6e2c\u5de5\u5177\u3002(3)\u91d1\u7247\uff0c\u505a\u70ba\u4e2d\u5b50\u6d3b\u5316\u5206\u6790\u5de5\u5177\uff0c\u5229\u7528\u4e2d\u5b50\u6d3b\u5316\u5206\u6790\u4e4b\u9ad8\u9748\u654f\u5ea6\u78ba\u5b9a\u52a0\u901f\u5668\u7167\u91ce\u5167\u6709\u7121\u4e2d\u5b50\u91cf\u3002(4)\u7c89\u72c0\u4e94\u6c27\u5316\u4e8c\u78f7(P2O5)\u7528\u4ee5\u5ea6\u91cf\u7167\u91ce\u5167\u4e2d\u5b50\u5291\u91cf\u4e4b\u5de5\u5177\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u7d93\u53ef\u651c\u5f0f\u4e2d\u5b50\u4f96\u76ee\u5100\u91cf\u6e2c\uff0c\u6cbb\u7642\u5ba4\u5916\u4e2d\u5b50\u7b49\u6548\u5291\u91cf\u7387\u7686\u8207\u80cc\u666f\u503c\u76f8\u7576(\u22660.04\u03bcSv/h)\u3002\u6cbb\u7642\u5ba4\u5167\u4e2d\u5b50\u5e73\u5747\u80fd\u91cf\u5206\u4f48\u8ddd\u96e2\u7b49\u4e2d\u5fc3\u86551\u30012\u30013\u53ca5\u516c\u5c3a\u8655\u5206\u5225\u70ba0.05\u30010.20\u30010.18\u53ca0.17 MeV\uff0c\u5feb\u4e2d\u5b50\u901a\u91cf\u7387\u5728\u7b49\u4e2d\u5fc3\u8655\u70ba1.745\u00d710^4n cm^(-2)s^(-1)\uff0c\u6162\u4e2d\u5b50\u901a\u91cf\u7387\u70ba1.258\u00d710^5n cm(-2)s(-1)\uff0cQ\u503c\u7d93\u8a08\u7b97\u70ba\u5c0f\u65bc2.17\u00d710^11, neutron per Gy\u3002\n\u7d50\u8ad6\uff1aSiemens PRIMUS\u76f4\u7dda\u52a0\u901f\u5668\u80fd\u91cf15 MV\u4e4b\u5149\u5b50\u7522\u751f\u4e4b\u5149\u4e2d\u5b50\u91cf\u70ba\u4e0d\u53ef\u5ffd\u7565\u91cf\uff0c \u906e\u7f69\u8a2d\u8a08\u6642\u9700\u52a0\u4ee5\u8003\u91cf\u3002\u8a72\u6cbb\u7642\u5ba4\u4e4b\u906e\u7f69\u5de5\u7a0b\u80fd\u6709\u6548\u9632\u8b77\u6cbb\u7642\u6642\u7522\u751f\u4e4b\u5149\u4e2d\u5b50\u6c61\u67d3\u3002", "e": "Purpose: Measuring the photoncutron contamination of 15 MV X-ray emitted from Siemens PRIMUS linear accelerator as to be the reference of radiation safety management.\nMaterials and Methods: This research includes four parts of measurements. (1) Portable neutron remmeter (Harwell Co. N91) which calibrated through shadow cone method is used for environmental survey in the vicinity of treatment room. (2) Neutron detection module, including BF3 proportional counter encased by 9 inch or 3 inch diameter polystyrene (Ph) sphere, is used for mean neutron energy distribution measurement in treatment room. (3) Neutron activation analysis of gold (Au) foil which is irradiated in the X rays field is administrated to determinate neutron contamination. (4) Powder P205 is used to measure the thermal and fast neutron flux in the X rays field.\nResults and Discussion: Neutron dose equivalent rate in the points of measurement near the treatment room is under the detection limit and is in the range of\u22660.04\u03bcSv/h. The distribution of mean energy of neutrons from the isocenter of 1, 2, 3 and 5 m are 0.50, 0.20, 0.18 and 0.17 MeV, respectively in treatment room. Thermal and fast neutron flux at isocenter are 1.258 \u00d710^5 n cm^(-2) s^(-1)and 1.745\u00d7 l0^4 n cm^(-2) s^(-1), respectively. The Q value is less than 2.17\u00d710^11 neutron per Gy.\nConclusion: The quantity of photoneutron in the 15 MV X-ray beam of Siemen PRIMUS linear accelerator is not negligible and is in considerable level of shielding design. The shielding structure of this treatment room is effective for photoneutron shielding."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-121-129-a", "title": "\u7db2\u773c\u6280\u8853\u5c0d\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u7684\u76ae\u819a\u514d\u9664\u6548\u61c9\u7814\u7a76", "keywords": "\u7db2\u773c\u6280\u8853;\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u675f;\u76ae\u819a\u514d\u9664\u6548\u61c9 Grid technique;Electron radiotherapy;Skin sparing effect", "c": "\u524d\u8a00\uff1a\u7814\u7a76\u7db2\u773c\u6280\u8853\u61c9\u7528\u5728\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u4e0a\u5c0d\u76ae\u819a\u514d\u9664\u6548\u61c9\u4e4b\u5f71\u97ff\uff0c\u4ee5\u671f\u85c9\u6b64\u589e\u52a0\u76ae\u819a\u5c0d\u8f3b\u5c04\u7684\u8010\u53d7\u5ea6\uff0c\u89e3\u6c7a\u4f7f\u7528\u96fb\u5b50\u5c04\u675f\u6cbb\u7642\u6642\u7f3a\u5c11\u76ae\u819a\u514d\u9664\u6548\u61c9\u7684\u554f\u984c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u5e95\u7247\u6e2c\u91cf\u8853\u7684\u65b9\u6cd5\uff0c\u89c0\u5bdf\u757615\u00d715cm^2\u925b\u5408\u91d1\u7db2\u773c\u677f\u4e0a\u7684\u7db2\u773c\u5b54\u5f91\u5927\u5c0f(d=0.45, 1.0, 1.5 cm)\u3001 \u7db2\u773c\u4e4b\u9593\u7684 \u9593\u9694\u5bec\u5ea6(s=0.4, 0.2cm)\u4e0d\u540c\u6642\uff0c\u4ee5\u4e0d\u540c\u80fd\u91cf\u7684\u96fb\u5b50\u5c04\u675f(6\u30018\u300110\u300112\u300114 MeV)\u7167\u5c04\u5291\u91cf50 M.U.\uff0c\u5c0d\u5e95\u7247\u7684\u76f8\u5c0d\u8868\u9762\u5e73\u5747\u5149\u5bc6\u5ea6\u53ca\u6df1\u5ea6\u7b49\u5149\u5bc6\u5ea6\u66f2\u7dda\u5206\u4f48\u60c5\u5f62\u6240\u5f15\u8d77\u7684\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u5728\u4e0d\u540c\u96fb\u5b50\u80fd\u91cf\u4e0b\u4f7f\u7528\u7db2\u773c\u6280\u8853\u7686\u80fd\u6e1b\u5c11\u76f8\u5c0d\u8868\u9762\u5e73\u5747\u5149\u5bc6\u5ea6\uff0c\u5176\u6e1b\u5c11\u7684\u7a0b\u5ea6\u8207\u7db2\u773c\u677f\u4e0a\u958b\u53e3\u90e8\u5206\u6240\u4f54\u767e\u5206\u6bd4\u76f8\u95dc\uff0c\u4e14\u6df1\u5ea6\u5291\u91cf\u7684\u5206\u4f48\u4ea6\u53d7\u9019\u4e9b\u56e0\u7d20\u5f71\u97ff\u3002\u5176\u4e2d\u7db2\u773c\u9593 s=0.2cm\uff0c\u7db2\u773c\u5b54\u5f91d=1.5cm\u7684\u898f\u683c\u8a2d\u8a08\u65e2\u80fd\u540c\u6642\u6e1b\u5c11\u8868\u9762\u6240\u53d7\u5291\u91cf\uff0c\u53c8\u80fd\u5728\u76ae\u4e0b\u7d93\u904e\u4e00\u6bb5\u8ddd\u96e2\u5f8c\u5f62\u6210\u5e73\u5766\u7684\u5291\u91cf\u5206\u4f48 \uff0c\u4f7f\u816b\u7624\u63a5\u53d7\u5747\u52fb\u5291\u91cf\uff0c\u7b26\u5408\u5be6\u969b\u81e8\u5e8a\u7684\u9700\u6c42\u3002\n\u7d50\u8ad6\uff1a\u96d6\u7136\u6703\u6709\u5291\u91cf\u6ce2\u52d5\u7684\u73fe\u8c61\u767c\u751f\uff0c\u4f46\u7db2\u773c\u6280\u8853\u78ba\u5be6\u80fd\u6e1b\u5c11\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u4e0b\u7684\u8868\u9762\u5291\u91cf\uff0c\u5982\u80fd\u627e\u51fa\u9069\u7576\u7684\u7db2\u773c\u898f\u683c\u8a2d\u8a08\uff0c\u6216\u53ef\u5229\u7528\u7db2\u773c\u6280\u8853\u89e3\u6c7a\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u7f3a\u4e4f\u76ae\u819a\u514d\u9664\u6548\u61c9\u7684\u554f\u984c\uff0c\u5728\u7d66\u4e88\u9ad8\u5291\u91cf\u96fb\u5b50\u653e\u5c04\u6cbb\u7642\u7684\u540c\u6642\u4e0d\u6703\u9020\u6210\u5c0d\u76ae\u819a\u7684\u50b7\u5bb3\u3002", "e": "Purpose: The aim of this experiment is to solve the problem of lack of skin sparing in electron beam therapy and to increase the tolerance of skin to radiation by using grid technique.\nMaterials and methods: The method of the electron grid therapy is to place a cerrobend grid on the end of an electron cone. Film dosimetry was used to measure the relative surface optical density and depth profile of grided electron beam with energies of 6 to 14 MeV. Different grid hole diameters (d=0.45, 1.0, 1.5 cm) and grid spaces (s=0.4, 0.2 cm) were investigated for each electron energy.\nResults: Our results indicate that electron grid therapy can decrease the relative surface optical density at various electron energies. The degradations of the relative surface optical density depend on the percentage of open area of the grid portal. The cerrobend grid with 1.5 cm diameter holes and grid space 0.2 cm could conform to the demands of clinical radiotherapy. With this design we could decrease the surface dose and the range of nonhomogeneous dose be limited to a depth so that the target volume could receive a homogeneous dose.\nDiscussion: Grid technique can lessen the surface dose in electron beam radiotherapy indeed. We would delivery of high radiation dose with electron beams without damaging the skin by grid technique."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-131-140-a", "title": "Mycosis Fungoides: A Case Report", "keywords": "\u8548\u6a23\u9ef4\u83cc\u75c5;\u8868\u76aeT-\u7d30\u80de\u6dcb\u5df4\u764c;\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642;\u516d\u5c0d\u7167\u91ce\u6cd5 Mycosis fungoides;Cutaneous T-cell lymphoma;Total skin electron beam radiation therapy;Six-dual-field technique", "c": "\u8548\u6a23\u9ef4\u83cc\u75c5\u662f\u4e00\u7f55\u898b\u7684T-\u7d30\u80de\u6dcb\u5df4\u764c\uff0c\u7136\u800c\u7d04\u4f54\u6240\u6709\u8868\u76aeT-\u7d30\u80de\u6dcb\u5df4\u764c\u75c5\u4f8b\u7684\u534a\u6578\u3002\u9577\u4e45\u4ee5\u4f86\u653e\u5c04\u7dda\u88ab\u7528\u65bc\u6cbb\u7642\u9019\u500b\u751a\u5177\u8f3b\u5c04\u654f\u611f\u6027\u4e4b\u75be\u75c5\uff0c\u4e0d\u904e\u76f8\u7576\u6bd4\u4f8b\u7684\u75c5\u4eba\u6709\u5ee3\u6cdb\u7684\u76ae\u819a\u75c5\u8b8a\uff0c\u6216\u662f\u75c5\u7076\u5728\u5148\u524d\u7167\u5c04\u904e\u7684\u7bc4\u570d\u4ee5\u5916\u751a\u6216\u4e4b\u4e2d\u5fa9\u767c\uff0c\u56e0\u6b64\u6578\u5341\u5e74\u4f86\u653e\u5c04\u6cbb\u7642\u5de5\u4f5c\u8005\uff0c\u4e00\u76f4\u63a2\u5c0b\u80fd\u5920\u4f7f\u76ae\u819a\uff08\u201c\u5713\u67f1\u201d\u72c0\u7684\u4eba\u9ad4\u4e4b\u8868\u5c64\uff09\u63a5\u53d7\u8f03\u5927\u7bc4\u570d\u8207\u8f03\u9ad8\u5291\u91cf\u7167\u5c04\u4e14\u53c8\u80fd\u63a5\u53d7\u5176\u6bd2\u6027\u7684\u6280\u8853\u3002\u4f7f\u7528\u73fe\u4ee3\u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f\u7684\u4f4e\u80fd\u91cf\u96fb\u5b50\uff0c\u5728\u6709\u9650\u6df1\u5ea6\u5167\u91cb\u51fa\u80fd\u91cf\uff0c\u5f97\u4ee5\u907f\u514d\u8f03\u6df1\u90e8\u7684\u7d44\u7e54\u53d7\u5230\u8f3b\u5c04\uff0c\u52a0\u4ee5\u4e09\u5341\u591a\u5e74\u524d\u53f2\u4e39\u4f5b\u5927\u5b78\u767c\u5c55\u4e00\u7a2e\u201c\u516d\u5c0d\u7167\u91ce\u63a5\u201d\uff0c\u80fd\u5728\u7b26\u5408\u4e0a\u8ff0\u8981\u6c42\u4e0b\u9054\u5230\u8f03\u4f73\u7684\u5291\u91cf\u5206\u4f48\uff0c\u81ea\u6b64\u63a5\u53d7\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u6709\u8f03\u597d\u7684\u81e8\u5e8a\u53cd\u61c9\u8207\u8f03\u5c0f\u7684\u6bd2\u6027\u3002\n\u6211\u5011\u63a1\u7528\u9019\u7a2e\u201c\u516d\u5c0d\u7167\u91ce\u6cd5\u201d\u6cbb\u7642\u4e00\u4f4d\u6709\u5ee3\u6cdb\u76ae\u819a\u75c5\u8b8a\u768449\u6b72\u7537\u6027\u75c5\u60a3\u201c\u5c04\u6e90\u81f3\u8868\u9762\u7684\u8ddd\u96e2\u62c9\u9577\u70ba323\u516c\u5206\uff0c\u4e26\u67b6\u8a2d\u4e00\u584a\u58d3\u514b\u529b\u677f\u4ee5\u767c\u6563\u5c04\u675f\u53ca\u8870\u6e1b\u96fb\u5b50\u80fd\u91cf\u3002\u5f9e\u76f4\u7dda\u52a0\u901f\u5668\u6240\u7522\u751f6 MeV\u521d\u80fd\u91cf\u7684\u96fb\u5b50\u5c07\u8b8a\u70ba2.62 MeV\u3002\u52a0\u901f\u5668\u7684\u8f38\u51fa\u6e1b\u70ba0.0648 cGy/Mu \uff08\u5728\u6700\u9ad8\u5291\u91cf\u6df1\u5ea6\u8655\uff09\uff0c\u6e96\u76f4\u5100\u5168\u958b\u81f340\u4e58\u4ee540\u5e73\u65b9\u516c\u5206\uff0c\u4e14\u4e0d\u52a0\u9310\u5b54\u3002\u6bcf\u4e00\u6210\u5c0d\u7167\u91ce\u7684\u5c04\u675f\u5404\u8207\u6c34\u6e96\u8ef8\u6210\u4e0a\u6216\u4e0b20\u5ea6\u4e4b\u593e\u89d2\uff0c\u500d\u7387\u4fc2\u6578(multiplication factor) \u7d93\u6e2c\u91cf\u70ba2.68\uff0c\u816b\u7624\u5291\u91cf\u5b9a\u65bc\u76ae\u819a\u8868\u9762\u4e0b5\u6beb\u7c73\u8655\uff08\u4f4d\u65bc90%\u7b49\u5291\u91cf\u66f2\u7dda\uff09\uff0c\u7e3d\u8a08\u6bcf\u55ae\u4e00\u7167\u91ce\u7684\u7167\u5c04\u5fc5\u98081212 MU\u3002\u5c04\u675f\u5e73\u5766\u5ea6\u5728\u5782\u76f4\u53ca\u6c34\u6e96\u65b9\u5411\u5206\u5225\u70ba\u00b15%\u8207\u00b110%\u4e4b\u5167\uff0c\u4f7f\u7528\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD)\u7684\u6e2c\u91cf\u503c\u4f86\u8a55\u4f30\u9ad4\u886845\u500b\u90e8\u4f4d\u7684\u5291\u91cf\u5747\u52fb\u5ea6\uff0c\u662f\u5426\u8ffd\u52a0\u7167\u5c04\u6216\u906e\u7f69\u5247\u4f9d\u500b\u5225\u60c5\u6cc1\u800c\u5b9a\u3002\u6bcf\u9031\u6cbb\u76424\u500b\u9023\u7e8c\u65e5\uff0c\u6bcf2\u65e5\u70ba\u4e00\u9031\u671f\uff0c\u6bcfl\u5929\u6cbb\u7642\u534a\u6578\u7684\u6210\u5c0d\u7167\u91ce\uff0c\u55ae\u6b21\u5291\u91cf\u662f2 Gy\uff0c\u5171\u7167\u5c0418\u500b\u9031\u671f\uff0c\u9054\u523036 Gy\u7684\u7e3d\u5291\u91cf\uff0c\u4f46\u5728\u7642\u7a0b\u7684\u6b63\u4e2d\u6bb5\u4f11\u606f10\u5929\u3002\u76ae\u819a\u75c5\u7076\u5c0d\u6b64\u7642\u6cd5\u53cd\u61c9\u826f\u597d\uff0c\u6414\u7662\u5728\u524d\u534a\u7642\u7a0b\u7d50\u675f\u524d\u5df2\u5b8c\u5168\u7de9\u89e3\uff0c\u526f\u4f5c\u7528\uff08\u624b\u638c\u548c\u8173\u638c\u7684\u76ae\u819a\u708e\u548c\u982d\u9aee\u5b8c\u5168\u812b\u843d\uff09\u4ea6\u53ef\u63a5\u53d7\uff0c\u7136\u800c\u8a72\u75c5\u4eba\u62d2\u7d55\u5f8c\u7e8c\u7684\u8f14\u52a9\u6cbb\u7642\u3002\n\u5118\u7ba1\u5168\u8eab\u76ae\u819a\u96fb\u5b50\u675f\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u9054\u5230\u826f\u597d\u7684\u521d\u671f\u81e8\u5e8a\u6548\u679c\uff0c\u81f3\u4eca\u5c0d\u65bc\u8548\u6a23\u9ef4\u83cc\u75c5\u75c5\u4eba\u7684\u8655\u7406\u4f9d\u7136\u662f\u500b\u6311\u6230\u3002\u6b64\u75be\u75c5\u6709\u6975\u9ad8\u7684\u5fa9\u767c\u50be\u5411\uff0c\u76ee\u524d\u8981\u5b8c\u5168\u6cbb\u7652\u75c5\u8b8a\u5df2\u8d85\u8d8a\u5c40\u90e8\u7bc4\u570d\u7684\u75c5\u4eba\uff0c\u6a5f\u6703\u4f9d\u7136\u6e3a\u832b\u3002\u9664\u4e86\u653e\u5c04\u6cbb\u7642\uff0c\u5c1a\u6709\u8a31\u591a\u7642\u6cd5\u5df2\u5728\u81e8\u5e8a\u61c9\u7528\u6216\u7814\u7a76\u4e2d\uff0c\u6211\u5011\u5efa\u8b70\u5c0d\u9019\u985e\u75c5\u4eba\u63a1\u53d6\u8907\u5408\u5f0f\u6cbb\u7642\u4ee5\u63d0\u6607\u9577\u671f\u7642\u6548\u3002", "e": "Mycosis fungoides is a rare T-cell lymphoma, but it accounts for about half of all cases of cutaneous 7-cell lymphoma. Radiation has long been used to treat patients with this radiosensitive disease. However, a significant proportion of patients present with generalized plaques or recurrence of lesions outside or even within the previously irradiated area, it challenged radiotherapists for decades how to irradiate skin (the superficial layer of a somewhat \u201dcylinder-like\u201d human body) with not only larger field and higher dose but also tolerable toxicity. Radiation with low energy electrons generated by modern linear accelerators, depositing their energy within limited depth could spare deeper tissues. The six-dual-field technique, which provide more satisfying dose distribution for these requirements was developed at Stanford University three decades ago. Since then, the patients treated with total skin electron beam radiation would have better clinical response and minor toxicity.\nWe adopted the six-dual-field technique to treat a 49-year-old male with generalized plaques. The source-to-surface distance was extended to be 323 cm, and an acrylic beam spoiler was installed to scatter the beam and attenuate the electron energy. The resulting electron energy was 2.62 MeV, generated by a 6 MeV Linac, the output of which was degraded to deliver 0.0648 cGy/MU (at the depth of maximum dose, d(subscript max). The collimator was fully opened to 40\u00d740 cm^2 without a cone. The hinge angle of the dual-field was determined to be 20 degrees. The measured multiplication factor was 2.68. We prescribed a tumor dose at 5 mm depth beneath the skin surface (90% isodose profile). Overall, 1212 MU were required for each field. Beam flatness was within \u00b15% and \u00b110% in the vertical and horizontal dimensions, respectively. Thermoluminescent dosimeters (TLD) were used to evaluate dose homogeneity at 45 sites. Individualized boost or shielding was used at appropriate sites. Radiation therapy was administered for 4 consecutive days per week, with 2 days constituting a treatment cycle. On the first day of a cycle, half of the 6 dual-fields were irradiated, with the other half treated the other day A total dose of 36 Gy over 18 cycles was given with a fraction dose of 2 Gy. A 10-day midway break was given. The skin lesions responded well to this regimen, and itching was completely relieved prior to completion of the first half of the treatment course. Side effects (marked dermatitis of palms and soles and total hair loss) were acceptable. The patient refused subsequent adjuvant therapy.\nDespite total skin radiation can achieve good initial clinical outcome, the management of patients with mycosis fungoides is still challenging. This disease has a predisposition to relapse, and the chance is dismal to cure patients with the disease beyond limited plaque stage for the time being. In additicn to radiation therapy, a variety of modalities have been in clinical use or in investigation. We suppose combination treatment should be administered in these patients to improve long-term control."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-141-148-a", "title": "Preliminary Experience of Reducing Bowel Irradiation Volume in the Treatment of Rectal Cancer: Two Cases Study", "keywords": "\u5c0f\u8178;\u76f4\u8178\u764c;\u8179\u90e8\u652f\u6301\u5668;\u7d44\u7e54\u5291\u91cf\u5206\u4f48\u5716 Bowel;Rectal cancer;Belly board;Dose volume histogram", "c": "\u76ee\u7684\uff1a\u9aa8\u76c6\u8154\u90e8\u4f4d\u653e\u5c04\u6cbb\u7642\u5e38\u53d7\u9650\u65bc\u5c0f\u8178\u7684\u8010\u53d7\u5291\u91cf\u3002\u672c\u7bc7\u4e43\u8a55\u4f30\u76f4\u8178\u764c\u75c5\u60a3\u5728\u4ef0\u81e5\u8207\u4fef\u81e5\u59ff\u52e2\u4e0b\uff0c\u85c9\u7531\u7d44\u7e54\u5291\u91cf\u5206\u4f48\u5716(dose-volume histogram)\u7684\u5206\u6790\uff0c\u986f\u793a\u8178\u9053\u53d7\u7167\u9ad4\u7a4d\u5728\u5169\u7a2e\u59ff\u52e2\u4e0b\u7684\u6539\u8b8a\u60c5\u5f62\uff0c\u4e26\u5c0d\u80d6\u7626\u4e0d\u540c\u9ad4\u578b\u75c5\u60a3\u9032\u884c\u8a55\u4f30\u3002\n\u6751\u6599\u8207\u65b9\u6cd5\uff1a\u6bcf\u4f4d\u75c5\u60a3\u5747\u63a5\u53d7\u5169\u7d44\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u5176\u4e2d\u4e00\u7d44\uff0c\u75c5\u60a3\u4ee5\u4fef\u81e5\u59ff\u52e2\u8eba\u5728\u8179\u90e8\u652f\u6301\u5668(belly board)\u4e0a\uff0c\u53e6\u4e00\u7d44\u5247\u63a1\u4ef0\u8eba\u59ff\u52e2\u9032\u884c\u6383\u63cf\u3002\u5c07\u5f71\u50cf\u8f38\u5165\u6cbb\u7642\u8a08\u756b\u96fb\u8166\u4e2d\uff0c\u5206\u6790\u7a4d\u5206(cumulatlve)\u8207\u5fae\u5206(differential)\u7d44\u7e54\u5291\u91cf\u5206\u4f48\u5716\uff0c\u8a55\u4f30\u5c0f\u8178\u7167\u5c04\u9ad4\u7a4d\u8207\u5291\u91cf\u7684\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u7a4d\u5206\u7d44\u7e54\u5291\u91cf\u5206\u4f48\u5716\u53ef\u88ab\u7528\u4ee5\u8868\u793a\u6b63\u5e38\u7d44\u7e54\u53ef\u80fd\u53d7\u5230\u7684\u50b7\u5bb3\uff0c\u6b64\u5206\u6790\u8868\u793a\u5728\u4fef\u81e5\u59ff\u52e2\u664270%\u81f395%\u7684\u767e\u5206\u5291\u91cf\u7bc4\u570d\u5167\uff0c\u5c0f\u8178\u53d7\u7167\u5c04\u9ad4\u7a4d\u6bd4\u4ef0\u8eba\u59ff\u52e2\u6e1b\u5c1115%~18%\u3002\u800c\u8a55\u4f30\u816b\u7624\u53ca\u7d44\u7e54\u63a5\u53d7\u5291\u91cf\u5747\u52fb\u5ea6\u7684\u5fae\u5206\u7d44\u7e54\u5291\u91cf\u5206\u4f48\u5716\uff0c\u53ef\u4ee5\u770b\u5230\u5c0f\u8178\u6240\u53d7\u5291\u91cf\u7531\u8f03\u9ad8\u7684\u5291\u91cf\u7bc4\u570d\u5206\u4f48\u79fb\u5230\u8f03\u4f4e\u7684\u5291\u91cf\u7bc4\u570d\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u8179\u90e8\u652f\u6301\u5668\u7684\u4f7f\u7528\uff0c\u4f7f\u5c0f\u8178\u79fb\u51fa\u7167\u5c04\u7bc4\u570d\u4e4b\u5916\u662f\u5341\u5206\u53ef\u884c\u7684\uff0c\u7121\u8ad6\u80d6\u6216\u7626\u7684\u75c5\u4eba\u5747\u53ef\u85c9\u6b64\u6e1b\u4f4e\u8178\u9053\u7167\u5c04\u9ad4\u7a4d\u3002\u4ee5\u6b64\u65b9\u5f0f\u6cbb\u7642\u6642\uff0c\u4e00\u500b\u56fa\u5b9a\u6a21\u5177\u662f\u4e0d\u53ef\u6216\u7f3a\u7684\uff0c\u53ef\u4f7f\u75c5\u4eba\u5728\u6574\u500b\u6cbb\u7642\u904e\u7a0b\u4e2d\uff0c\u5177\u6709\u76f8\u540c\u7684\u4f4d\u7f6e\u53ca\u59ff\u52e2\uff0c\u78ba\u4fdd\u6cbb\u7642\u90e8\u4f4d\u7684\u6b63\u78ba\u6027\u3002", "e": "Purpose: The dosage of radiotherapy to the pelvis is always limited by the tolerance of small bowel. This study is to evaluate the dose volume histogram (DVH) of the irradiated bowel volume by prone position with belly board in comparison to treatment in supine position technique. Two patients with rectal cancer were analyzed.\nMaterials and Methods: Two groups of sequential computerized tomography (CT) scans were performed with 8-mm slice thickness for each patient. One group of the scans was obtained for patient with a belly board in a prone position, and the other one was in a supine position for comparing the bowel irradiation volume with the previous scan. Hard copies of CT scan slices for both patients were produced. The contours of small bowel volumes were outlined on each CT slice hard copy and the information was then digitized and entered into treatment planning computer. The cumulative and the differential DVHs were performed for evaluating the bowel irradiation volume.\nResults: The cumulative DVH, which is used in assessing potential damage to normal tissue, shows that from 70% to 95% of the percentage dose in prone position has a 15% to 18% volume reduction compared to supine position. The differential DVH, which is useful in assessing uniformity of dose to tumors. shows that the irradiated bowel volume has been moved to a region of rower percentage dose.\nConclusion: Displacement of bowel loops out of the true pelvis is done by using a belly board in the prone position for thin and obese patients instead of supine position to decrease the volume of the intestine under irradiation because of external compression. The pelvic board and a half-body cast can be applied to immobilize patient for precise positioning and repositioning throughout the entire treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199906-6-2-149-154-a", "title": "\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5c0d\u8166\u5e79\u90e8\u4f4d\u4e0d\u6210\u719f\u7578\u80ce\u7624\u4e4b\u6cbb\u7642\u6548\u679c\uff0d\u75c5\u4f8b\u5831\u544a", "keywords": "\u4e0d\u6210\u719f\u7578\u80ce\u7624;\u653e\u5c04\u6cbb\u7642;\u8166\u5e79\u816b\u7624;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642 Immature teratoma;Radiotherapy;Brainstem tumor;Stereotectic radiotherapy", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4e00\u7f55\u898b\u8166\u5e79\u90e8\u4f4d\u4e0d\u6210\u719f\u7578\u80ce\u7624\uff0c\u8853\u5f8c\u7d93\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u53ca\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u7684\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a-21 \u6b72\u5973\u6027\u56e0\u5438\u5165\u6027\u80ba\u708e\u5165\u9662\uff0c\u7d93\u6aa2\u67e5\u70ba\u8166\u5e79\u816b\u7624\u5f15\u8d77\u54bd\u53cd\u5c04(gag reflex)\u529f\u80fd\u7f3a\u5931\uff0c\u5c0e\u81f4\u98df\u7269\u5438\u5165\u6027\u80ba\u708e\u7684\u53cd\u8986\u767c\u751f\u3002\u4e26\u5169\u6b21\u51fa\u73fe\u7a81\u767c\u6027\u547c\u5438\u8870\u7aed\u3001\u8840\u58d3\u4e0b\u964d\u4e4b\u5371\u8c61\u3002\u56e0\u816b\u7624\u4f4d\u65bc\u8166\u5e79\u751f\u547d\u4e2d\u6a1e\uff0c\u8166\u90e8\u986f\u5fae\u624b\u8853\u50c5\u80fd\u90e8\u4efd\u6458\u9664\u3002\u75c5\u7406\u5831\u544a\u986f\u793a\u70ba\u4e0d\u6210\u719f\u7578\u80ce\u7624(immature teratoma)\u3002\u8853\u5f8c\u4e4b\u5316\u5b78\u6cbb\u7642\u56e0\u518d\u5ea6\u767c\u751f\u547c\u5438\u505c\u6b62\u3001\u8840\u58d3\u4e0b\u964d\u800c\u534a\u9014\u4e2d\u6b62\u3002\u70ba\u7dad\u6301\u751f\u547d\u4e2d\u6a1e\u7684\u6b63\u5e38\u904b\u4f5c\uff0c\u4e88\u4ee5\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\uff0c\u517139.6 Gy \u81f3\u8a08\u5283\u6a19\u7684\u7269\u9ad4\u7a4d\u3002\u4e4b\u5f8c\u4e26\u4ee5\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\uff0c\u5c0d\u5c40\u90e8\u816b\u7624\u8ffd\u52a0\u81f3\u7e3d\u5291\u91cf54.6 Gy\u3002\u653e\u5c04\u6cbb\u7642\u5b8c\u6210\u5f8c\u5169\u9031\u958b\u59cb\u6bcf\u6708\u4e00\u6b21\u7684\u5316\u5b78\u6cbb\u7642\uff0c\u81f3\u4eca\u56db\u6b21\u3002\n\u7d50\u679c\uff1a\u5728\u6574\u500b\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u8840\u6e05\u53ca\u8166\u810a\u6db2\u4e2d\u7684\u963f\u767c\uff0d\u80ce\u5152\u86cb\u767d(alpha fetoprotein, AFP)\u3001\u8c9d\u4ed6\uff0d\u4eba\u985e\u7d68\u6bdb\u819c\u6027\u7dda\u6fc0\u7d20(\u03b2-HCG)\u5747\u7531\u653e\u5c04\u6cbb\u7642\u524d\u7684\u4e0d\u6b63\u5e38\u504f\u9ad8\u56de\u5fa9\u6b63\u5e38\u503c\u3002\u54bd\u53cd\u5c04\u7684\u529f\u80fd\u9010\u6f38\u6062\u5fa9\uff0c\u4e0d\u9700\u518d\u85c9\u9f3b\u80c3\u7ba1\u9032\u98df\uff0c \u4ea6\u4e0d\u518d\u6709\u55c6\u5230(chocking)\u6216\u5438\u5165\u6027\u80ba\u708e\u7684\u767c\u751f\u3002\u751f\u547d\u4e2d\u6a1e\u7684\u904b\u4f5c\u81ea\u958b\u59cb\u653e\u5c04\u6cbb\u7642\u8d77\u5373\u6301\u7e8c\u7a69\u5b9a\uff0c\u4e0d\u518d\u6709\u547c\u5438\u4e2d\u6b62\u3001\u8840\u58d3\u6539\u8b8a\u4e4b\u5371\u8c61\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u8166\u5e79\u90e8\u4f4d\u4e4b\u4e0d\u6210\u719f\u7578\u80ce\u7624\uff0c\u672c\u6587\u6709\u9650\u7684\u7d93\u9a57\u4e0b\u986f\u793a\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u5c0d\u816b\u7624\u5c40\u90e8\u63a7\u5236\u53ca\u8fc5\u901f\u7de9\u89e3\u81f4\u547d\u75c7\u72c0\u5747\u6709\u6b63\u9762\u7684\u6548\u679c\u3002", "e": "Purpose: To report a rare case of brainstem immature teratoma treated by post-operative limited-field radiotherapy and stereotactic radiotherapy.\nMaterials and Methods: A 21-year-old female presented with symptoms and signs of recurrent aspiration pneumonia that was caused by dysphagia. She had two episodes of acute respiratory arrest and hypotension while in the hospital. Computed tomography (CT) of the brain revealed a heterogenous mass at lower brain stem region. Microscopic surgery only could yielded a piece of tumor that disclosed the entity of immature teratoma. Adjuvant chemotherapy with the regimen of cisplatin, etoposide, and bleomycin was administered, but was interrupted due to sudden onset of respiratory arrest. In order to maintain brainstem function, limited-field irradiation with 39.6 Gy to planning target volume followed by a boost dose to the primary site by stereotactic radiotherapy were performed with a total dose of 54.6 Gy. Two weeks after radiotherapy, the patient began receiving monthly adjuvant chemotherapy for 4 cycles up to the time of this report.\nResults: Previously elevated serum and cerebrospinal fluid (CSF) levels of both alpha-fetoprotein and beta human-chorionic gonadotropin returned to a normal range after irradiation. The swallowing reflex gradually improved and the patient did not develop aspiration pneumonia again even after the NG tube was removed. Brainstcm function has remained stable following irradiation.\nConclusion: Our limited experience suggests that limited field radiotherapy followed by a boost dose with stereotactic radiotherapy is very effective in treating brainstem immature teratoma for both local tumor control and relief of life-threatening symptoms."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-1-7-a", "title": "Effect of Vitamin E on Arylamine N-Acetyltransferase Activity in Colon Cancer Tissues", "keywords": "\u82b3\u9999\u80fa\u5316\u5408\u7269;N\u57fa\u4e59\u91af\u8f49\u79fb\u9175\u7d20;\u5927\u8178\u764c;\u7dad\u751f\u7d20E Arylamine;N-acetyltransferase;Colon cancer;Vitamin E", "c": "\u76ee\u7684\uff1a\u82b3\u9999\u80fa\u5316\u5408\u7269\u7d93N\u57fa\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u4e4bN\u57fa\u4e59\u91af\u5316\u5f8c\u53ef\u8a98\u767c\u5927\u8178\u764c\uff0c\u672c\u7814\u7a76\u662fin vitro\u63a2\u8a0e\u6b63\u5e38\u5927\u8178\u7d44\u7e54\u53ca\u5927\u8178\u764c\u7d44\u7e54\u4e2d\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u7684\u6d3b\u6027\u53caVitamin E\u5c0d\u6b63\u5e38\u5927\u8178\u7d44\u7e54\u53ca\u5927\u8178\u764c\u764c\u7d44\u7e54\u4e2d\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u6d3b\u6027\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u53d640\u500b\u6b63\u5e38\u5927\u8178\u7d44\u7e54\u53ca\u5927\u8178\u764c\u7d44\u7e54\u5229\u7528\u4e59\u91af\u5316\u8f14\u81bd\u4f5c\u4e59\u91af\u57fa\u800c\u518d\u5229\u7528\u9ad8\u58d3\u5c64\u6790\u5100\u5206\u6790\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u7684\u6d3b\u6027\u53caVitamin E\u5c0d\u6b63\u5e38\u5927\u8178\u7d44\u7e54\u53ca\u5927\u8178\u764c\u764c\u7d44\u7e54\u4e2d\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u6d3b\u6027\u7684\u5f71\u97ff\uff0c\u4ee5aminofluorene\u548cp-aminobenzoic acid\u4f5c\u53d7\u8cea\u3002\n\u7d50\u679c\uff1a\u7d50\u679c\u5927\u8178\u764c\u7d44\u7e54\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u6d3b\u6027\u8f03\u6b63\u5e38\u7d44\u7e54\u4e2d\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u6d3b\u6027\u9ad8\uff0cVitamin E\u5c0d\u6b63\u5e38\u5927\u8178\u7d44\u7e54\u53ca\u5927\u8178\u764c\u764c\u7d44\u7e54\u4e2d\u4e59\u91af\u8f49\u79fb\u9175\u7d20\u7684\u6d3b\u6027\u6709\u964d\u4f4e\u7684\u4f5c\u7528\u3002\n\u7d50\u8ad6\uff1aVitamin E\u5c0d\u5927\u8178\u764c\u7684\u6cbb\u7642\u53ca\u9810\u9632\u6709\u53ef\u80fd\u5177\u81e8\u5e8a\u7684\u50f9\u503c\u3002\u672c\u5be6\u9a57\u5831\u544a\u662fin vitro\u63a2\u8a0e\u7684\u521d\u6b65\u5831\u544a\uff0c\u7576\u7136\u9808\u518d\u9032\u4e00\u6b65in vivo\u7684\u7814\u7a76\u78ba\u8a8d\u3002", "e": "Purpose: Arylamine N-acetylation capacity by the N-acetyltransferase (NAT) may be an important causative factor in the initiation of colorectal cancer. Vitamin E (aipha-tocopherol) has been known for many years as an antioxidant and act as an important component of anticancer regimens. The activity of NAT and the effect of vitamin E on NAT activity in healthy colon and colon cancerous tissues (in vitro) were investigated.\nMaterials and Methods\uff1a Forty human healthy colon and colon cancerous tissue cytosol (subcellular fraction) were investigated for NAT activity. The effect of vitamin E on the activity of NAT was also examined by high pressure liquid chromatography (HPLC) using 2-aminofluorene and p-aminobenzoic acid as substrates in this study.\nResults: NAT activity are higher in colon cancerous tissue cytosol than in healthy colon tissue cytosol and vitamin E could decrease NAT activity in healthy colon and colon cancerous tissue cytosol.\nConclusion: The results may suggest a clue to the use of vitamin E in treatment and prevention of human colon cancer. In future, in vivo study will be investigated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-9-15-a", "title": "Effects of Cobalt-60 Irradiation on Trabecular Bone", "keywords": "\u653e\u5c04\u6027\u9237\u516d\u5341\u7167\u5c04;\u9020\u9aa8\u7d30\u80de;\u7834\u9aa8\u7d30\u80de;\u9aa8\u8cea\u6d41\u5931 Cobalt-60 irradiation;Osteoblast;Osteoclast;Osteopenia", "c": "\u76ee\u7684\uff1a\u5229\u7528\u751f\u5316\u548c\u5b8c\u6574\u7684\u9aa8\u7d44\u7e54\u5f62\u614b\u5b78\u5b9a\u91cf\u5206\u6790\u6cd5\uff0c\u63a2\u8a0e\u5c40\u90e8\u6027\u9237\u516d\u5341\u653e\u5c04\u7dda\u7167\u5c04\u5c0d\u9aa8\u7d44\u7e54\u7684\u5f71\u97ff\u548c\u5176\u5c0e\u81f4\u9aa8\u8cea\u6d41\u5931\u7684\u6a5f\u8f49\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e2d\u4f7f\u752840\u96bb8\u5468\u5927\u96c4\u6027SD\u5927\u767d\u9f20\uff0c\u6309\u96a8\u6a5f\u62bd\u6a23\u6cd5\u5206\u6210\u5c0d\u7167\u7d44\u548c\u653e\u5c04\u7dda\u7167\u5c04\u7d44\u3002\u5728\u9237\u516d\u5341\u653e\u5c04\u7dda(12 Gy)\u5c40\u90e8\u7167\u5c04\u65bc\u5927\u767d\u9f20\u53f3\u5074\u80a1\u9aa8\u548c\u811b\u9aa8\u3002\u52d5\u7269\u5206\u5225\u65bc\u7167\u5c04\u5f8c1\u30017\u300114\u621628\u5929\u72a7\u7272\u3002\u52d5\u7269\u72a7\u7272\u5f8c\uff0c\u5229\u7528\u8840\u6db2\u751f\u5316\u5206\u6790\u6cd5\uff08\u9e7c\u6027\u78f7\u9178\u9176\u548c\u6297\u9152\u77f3\u9178\u9e7d\u9178\u6027\u78f7\u9178\u9176\u6fc3\u5ea6\u7684\u6e2c\u5b9a\uff09\u548c\u975c\u614b\u8207\u52d5\u614b\u9aa8\u7d44\u7e54\u5f62\u614b\u5b78\u8a08\u91cf\u6cd5\u7b49\u9032\u884c\u653e\u5c04\u7dda\u5c40\u90e8\u7167\u5c04\u5f8c\uff0c\u9aa8\u751f\u6210\u548c\u9aa8\u5438\u6536\u5404\u9805\u53c3\u6578\u7684\u8a08\u91cf\u8207\u5206\u6790\uff0c\u4ee5\u53ca\u65ce\u5c0d\u7dda\u7167\u5c04\u5c0d\u9aa8\u7d44\u7e54\u5f71\u97ff\u6a5f\u8f49\u7684\u63a2\u8a0e\u3002\n\u7d50\u679c\uff1a\u9237\u516d\u5341\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\u4e03\u5929\u6642\u767c\u73fe\u6297\u9152\u77f3\u9178\u9e7d\u9178\u6027\u78f7\u9178\u9176\u6d3b\u6027\uff0c\u7834\u9aa8\u7d30\u80de\u5e73\u5747\u542b\u6838\u6578\u548c\u9aa8\u5438\u6536\u8868\u9762\u986f\u8457\u5730\u589e\u52a0\uff0c\u800c\u55ae\u4f4d\u9762\u7a4d\u9020\u9aa8\u7d30\u80de\u6578\u76ee\u3001\u786c\u7d44\u7e54\u767e\u5206\u6bd4\u3001\u9aa8\u767e\u5206\u6bd4\u3001\u9aa8\u5c0f\u6a11\u539a\u5ea6\u3001\u9aa8\u5c0f\u6a11\u7926\u7269\u8cea\u6c88\u7a4d\u901f\u7387\u53ca\u9aa8\u5c0f\u6a11\u9aa8\u751f\u6210\u901f\u7387\u5247\u660e\u986f\u5730\u964d\u4f4e\uff0c\u5728\u7167\u5c04\u5f8c28\u5929\u5247\u767c\u73fe\u4e0a\u8ff0\u53c3\u6578\u6709\u9010\u6f38\u56de\u5fa9\u6b63\u5e38\u4e4b\u8da8\u52e2\u3002\n\u7d50\u8ad6\uff1a\u5c40\u90e8\u6027\u9237\u516d\u5341\u653e\u5c04\u7dda\u7167\u5c04\u6703\u5c0e\u81f4\uff1a1\uff09\u7834\u9aa8\u7d30\u80de\u5e73\u5747\u542b\u6838\u6578\u3001\u6297\u9152\u77f3\u9178\u9e7d\u9178\u6027\u78f7\u9178\u9176\u6d3b\u6027\u548c\u9aa8\u5438\u6536\u8868\u9762\u660e\u986f\u905e\u589e\u52a0\u548c2\uff09\u9020\u9aa8\u539f\u59cb\u7d30\u80de\u589e\u751f\u3001\u9020\u9aa8\u7d30\u80de\u7684\u6d3b\u6027\u53ca\u7926\u7269\u5316\u4f5c\u7528\u660e\u986f\u5730\u6e1b\u5c11\u3002\u56e0\u6b64\uff0c\u5c40\u90e8\u6027\u653e\u5c04\u7dda\u9237\u516d\u5341\u7167\u5c04\u6703\u5c0e\u81f4\u9aa8\u8cea\u6d41\u5931\u4e4b\u767c\u751f\u3002", "e": "Purpose: To investigate the quantitative changes in bone after localized Cobalt-60 irradiation (IR) using biochemical assay and well-established histomorphometric analysis and the mechanisms of irradiation-induced bone loss.\nMaterials and Methods: Forty 8-week old male Sprague-Dawley rats were randomly assigned into control and irradiated (IR) groups. Five rats of each group were sacrified at 1, 7, 14 or 28 days after 12 Gy of localized Cobalt-60 irradiation on right femur and tibia. The parameters of bone formation and bone resorption, and the mechanism of IR on bone were evaluated using biochemical bone marker assay [measuring the concentrations of serum-alkaline phosphatase and tartrate resistant acid phosphatase (TRAP)], and the static and dynamic bone histomorphometry.\nResults: Seven days after localized cobalt-60 irradiation, there were significant increases in TRAP, nuclei/OC and resorption surface, and decreases in OB/mm^2. A significant decrease in OC/mm^2 occurred 14 days after irradiation. In addition, OC/mm^2, nuclei/OC and resorption surface returned to normal on day 28. No significant difference were found in percent hard tissue, percent bone, trabecular thickness, trabecular mineral apposition and trabecular bone formation between the irradiated and untreated normal control group one day after irradiation. However, they became significantly less on day 7 and began to resume on the day 28 after irradiation.\nConclusion: Localized Cobalt-60 irradiation could significantly increase nuclei/osteoclast, TRAP activity and resorption space. In addition, it significantly decrease osteoprogenitor cell proliferation, osteoblastic activity and mineralization, and induce dramatic bone loss. In conclusion, Cobalt-60 irradiation could result in osteopenia."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-17-23-a", "title": "\u4fb5\u72af\u6027\u4e0a\u6ccc\u5c3f\u9053\u79fb\u5f62\u4e0a\u76ae\u7d30\u80de\u764c\u4e4b\u6cbb\u7642", "keywords": "\u79fb\u5f62\u4e0a\u76ae\u7d30\u80de\u764c;\u4e0a\u6ccc\u5c3f\u9053;\u8f38\u5c3f\u7ba1\u816b\u7624;\u7b2c\u4e8c\u500b\u6ccc\u5c3f\u9053\u816b\u7624 Transitional cell carcinoma;Upper urinary tract;Ureteral tumor;Second location tumor", "c": "\u76ee\u7684\uff1a\u56de\u9867\u9ad8\u96c4\u69ae\u6c11\u7e3d\u91ab\u9662\u4fb5\u72af\u6027\u4e0a\u6ccc\u5c3f\u9053\u79fb\u5f62\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u6cbb\u7642\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1991\u5e743\u6708\u81f31996\u5e7412\u6708\u5171\u670946\u4f4d\u4fb5\u72af\u6027\u4e0a\u6ccc\u5c3f\u9053\u79fb\u5f62\u4e0a\u76ae\u7d30\u80de\u764c\u7684\u75c5\u60a3\u63a5\u53d7\u6839\u9664\u6027\u624b\u8853\uff0c\u5176\u4e2d\u7537\u6027\u670931\u4f4d\uff0c\u5973\u6027\u670915\u4f4d\uff0c\u5e74\u9f61\u5206\u4f48\u70ba43\u81f382\u6b72\uff08\u4e2d\u4f4d\u657867\uff09\u3002\u5176\u4e2d\u670916\u4f4d\u63a5\u53d7\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u7bc4\u570d\u662f48.6\u81f360 Gy\uff08\u4e2d\u4f4d\u657855\uff09\uff1b14\u4f4d\u63a5\u53d7\u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\uff0c\u4f7f\u7528MVEC (methotrexate\uff0cvinblastine\uff0cepirubicin\uff0ccisplatin)\u6216 MCV(methotrexate\uff0ccisplatin\uff0cvinblastine)2\u81f312\u500b\u7642\u7a0b\uff08\u4e2d\u4f4d\u65784\uff09\u3002T2\u3001T3\u3001T4(AJCC\uff0c1992)\u5404\u670920\u300121\u30015\u4f8b\uff0c\u624b\u8853\u6642\u5df2\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\u8005\u67094\u4f8b\uff0c\u8f38\u5c3f\u7ba1\u816b\u7624\u8005\u670924\u4f8b\u3002\n\u7d50\u679c\uff1a\u7d93\u904e5-65\u500b\u6708\u7684\u8ffd\u8e2a\uff08\u4e2d\u4f4d\u657832\uff09\uff0c\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u8005\u67097\u4f8b(15%)\uff0c\u767c\u751f\u9060\u7aef\u8f49\u79fb\u8005\u670916\u4f8b(35%)\u3002\u6240\u6709\u75c5\u60a3\u76845\u5e74\u5b58\u6d3b\u7387\u662f19%\uff0c5\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u662f16%\u3002\u9810\u5f8c\u56e0\u5b50\u4e2d\uff0c\u624b\u8853\u6642\u6c92\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\u53ca\u539f\u767c\u90e8\u4f4d\u70ba\u8f38\u5c3f\u7ba1\u816b\u7624\u5c0d5\u5e74\u5b58\u6d3b\u7387\u82075\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u800c\u8a00\u662f\u9810\u5f8c\u8f03\u4f73\u56e0\u5b50\u4e14\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u5dee\u7570\u3002\u55ae\u7368\u624b\u8853\u8005\u3001\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u8005\u53ca\u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\u8005\u4e4b5\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u662f16%\u300112%\u53ca37%(p\uff1d0.43)\uff0c\u800c5\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u662f15%\u300110%\u300127% (p\uff1d0.37)\u3002\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u8005\u7121\u56b4\u91cd\u4f75\u767c\u75c7\u767c\u751f\u3002\u624b\u8853\u6642\u5df2\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\u8005\u67094\u4f8b\u3002\u5176\u4e2d3\u4f8b\u767c\u751f\u9060\u7aef\u8f49\u79fb\u800c\u4e14\u5df2\u6b7b\u4ea1\u3002\u767c\u751f\u7b2c\u4e8c\u500b\u6ccc\u5c3f\u9053\u816b\u7624\u8005\u67098\u4f8b\u3002\u767c\u751f\u90e8\u4f4d\u5747\u5728\u8180\u80f1\u3002\n\u9237\u8ad6\uff1a\u4e0d\u8ad6\u662f\u5426\u7d66\u4e88\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u5316\u5b78\u6cbb\u7642\uff0c\u5747\u6709\u76f8\u7576\u9ad8\u6bd4\u4f8b\u7684\u75c5\u4eba\u767c\u751f\u9060\u7aef\u8f49\u79fb\u3002\u624b\u8853\u6642\u6c92\u6709\u6dcb\u5df4\u7d50\u8f49\u79fb\u53ca\u539f\u767c\u90e8\u4f4d\u70ba\u8f38\u5c3f\u7ba1\u816b\u7624\u5c0d5\u5e74\u5b58\u6d3b\u7387\u82075\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u800c\u8a00\u662f\u9810\u5f8c\u8f03\u4f73\u56e0\u5b50\u3002\u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\u8005\u76845\u5e74\u5b58\u6d3b\u7387\u82075\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u8f03\u55ae\u7368\u624b\u8853\u8005\u8207\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u8005\u70ba\u4f73\uff0c\u96d6\u672a\u9054\u5230\u7d71\u8a08\u4e0a\u7684\u610f\u7fa9\uff0c\u4f46\u503c\u5f97\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Purpose: To review the treatment results of invasive transitional cell carcinoma of upper urinary tract at Veterans General Hospital-Kaohsiung.\nMaterials and Methods: From March 1991 to December 1996, 46 patients with invasive transitional cell carcinoma of the upper urinary tract received radical surgery. There were 31 male and 15 female patients. Patient's age ranges between 43 and 82 years. (median: 67). Sixteen patients received postoperative radiotherapy with dosages of 48.6 to 60 Gy (median: 55) to the tumor bed. Fourteen patients received 2 to 12 courses (median: 4) of post-operative chemotherapy using regimens of MVEC (methotrexate, vinblastine, epirubicin, cisplatin) or MCV (methotrexate, cisplatin, vinblastine). Twenty, 21, 5 patients were pathologically staged as T2, T3, T4 (AJCC, 1992), respectively. Four patients had lymph node metastasis pathologically. Twenty four patients had tumor confined to ureter only.\nResults: Follow-up duration ranges from 5 to 65 months (median: 32). Overall, 7 patients (15%) developed local recurrence and 16 patients (35%) developed distant metastasis. Overall 5-year survival rate (5 YSR) was 19%, and 5-year disease-free survival rate (5 DFS) was 16%. Negative lymph nodes metastasis and the ureteral tumor only were statistically significant good factors for 5 YSR and 5 DFS. 5 YSR for surgery alone group, post-operative radiotherapy group and post-operative chemotherapy group were 16%, 12% and 37% respectively (p=0.43). 5 DFS for the aforementioned treatment arms were 15%, 10% and 27% respectively (p=0.37). No severe complications were observed in patients with post-operative radiotherapy. Three out of the 4 patients with lymph node metastasis developed distant metastasis and died. Eight patients had second location tumors, all of which occurred in the bladder.\nConclusions: This study showed relative high incidences of patients developing distant metastasis regardless of treatment arms was given. Negative lymph node metastasis and the ureteral tumor only were good factors for 5 YSR and 5 DFS. The post-operative chemotherapy group had a higher 5 YSR and 5 DFS than the other treatment groups, and the results need further confirmation although it was not statistically significant."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-25-32-a", "title": "Treatment Results of Polymorphic Reticulosis at Veterans General Hospital-Taipei", "keywords": "\u591a\u5f62\u6027\u7db2\u7d30\u80de\u589e\u591a\u75c7;\u653e\u5c04\u6cbb\u7642;\u60e1\u6027\u6dcb\u5df4\u816b\u7624 Polymorphic reticulosis;Radiotherapy;Malignant lymphoma.", "c": "Purpose: Retrospectively review the treatment results of polymorphic reticulosis (now called angiocentric T-cell lymphoma) patients at Veterans General Hospital-Taipei over the past fifteen years (1982-1997).\nMaterials and Methods: From December 1982 to December 1997, there were 40 patients diagnosed of polymorphic reticulosis at Veterans General Hospital-Taipei. There were 35 male patients and 5 female patients. The age of the patients ranged from 14 to 78 years old. The follow-up period ranged from 1 to 172 months. Medical histories, laboratory and X-ray examinations and modalities of treatment from medical records of each patient were reviewed. Five patients received chemotherapy alone, 19 patients received radiotherapy alone and 16 patients received radiotherapy combined with chemotherapy or surgery.\nResults: The 5-year disease-free survival rate of all patients was 35%. The 5-year disease-free survival rate for patients receiving radiotherapy alone was 57%. It was 19% for patients treated with radiotherapy plus surgery, chemotherapy or both; and 8% only for patients received surgery combined with other treatments. Number of involved sites (=1), Karnofsky scale (\uff1e70), non-surgery treatment are positive statistical prognostic factors. There were 23 patients died and 9 of them have evidence of disease progression (5 cases of distant metastasis and 4 cases of locoregional recurrence). There were 2 patients relapsed in 15 patients who received chemotherapy, and there were 7 patients relapsed in 25 patients who without chemotherapy.\nConclusion: Polymorphic reticulosis had excellent local control rate by radiotherapy. Chemotherapy may be benefit for prevention of distant metastasis and local recurrence. Number of involved site(s), good Karnofsky scale, and non-surgical treatment are associated better prognosis.", "e": "Purpose: Retrospectively review the treatment results of polymorphic reticulosis (now called angiocentric T-cell lymphoma) patients at Veterans General Hospital-Taipei over the past fifteen years (1982-1997).\nMaterials and Methods: From December 1982 to December 1997, there were 40 patients diagnosed of polymorphic reticulosis at Veterans General Hospital-Taipei. There were 35 male patients and 5 female patients. The age of the patients ranged from 14 to 78 years old. The follow-up period ranged from 1 to 172 months. Medical histories, laboratory and X-ray examinations and modalities of treatment from medical records of each patient were reviewed. Five patients received chemotherapy alone, 19 patients received radiotherapy alone and 16 patients received radiotherapy combined with chemotherapy or surgery.\nResults: The 5-year disease-free survival rate of all patients was 35%. The 5-year disease-free survival rate for patients receiving radiotherapy alone was 57%. It was 19% for patients treated with radiotherapy plus surgery, chemotherapy or both; and 8% only for patients received surgery combined with other treatments. Number of involved sites (=1), Karnofsky scale (\uff1e70), non-surgery treatment are positive statistical prognostic factors. There were 23 patients died and 9 of them have evidence of disease progression (5 cases of distant metastasis and 4 cases of locoregional recurrence). There were 2 patients relapsed in 15 patients who received chemotherapy, and there were 7 patients relapsed in 25 patients who without chemotherapy.\nConclusion: Polymorphic reticulosis had excellent local control rate by radiotherapy. Chemotherapy may be benefit for prevention of distant metastasis and local recurrence. Number of involved site(s), good Karnofsky scale, and non-surgical treatment are associated better prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-33-39-a", "title": "Definitive Radiotherapy with or Without Chemotherapy for Resectable Head and Neck Cancer", "keywords": "\u53ef\u5207\u9664\u4e4b\u982d\u9838\u90e8\u816b\u7624;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u5408\u4f75\u6cbb\u7642 Resectable head and neck cancers;Radiotherapy;Chemotherapy;Concurrent", "c": "\u76ee\u7684\uff1a\u56de\u9867\u6027\u5206\u6790\u4ee5\u653e\u5c04\u6cbb\u7642\u6216\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u4e4b\u65b9\u5f0f\u6cbb\u7642\u53ef\u5207\u9664\u4e4b\u982d\u9838\u90e8\u816b\u7624\u7684\u53ef\u884c\u6027\u3001\u6cbb\u7642\u526f\u4f5c\u7528\u53ca\u5b58\u6d3b\u7387\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4e09\u5341\u4f4d\u8a3a\u65b7\u70ba\u53ef\u5207\u9664\u4e4b\u982d\u9838\u90e8\u816b\u7624\u75c5\u4eba\u63a5\u53d7\u6839\u6cbb\u6027\u653e\u5c04\u6cbb\u7642\u6216\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u3002\u4e00\u4f4d\u75c5\u4eba\u70ba\u7b2c\u4e00\u671f\uff0c\u56db\u4f4d\u7b2c\u4e8c\u671f\uff0c\u4e09\u4f4d\u7b2c\u4e09\u671f\uff0c\u4e8c\u5341\u4e8c\u4f4d\u7b2c\u56db\u671f\u75be\u75c5\u3002\u653e\u5c04\u6cbb\u7642\u70ba\u4e00\u65e5\u4e00\u6b21\u6216\u4e00\u65e5\u5169\u6b21\uff0c\u7e3d\u5291\u91cf\u70ba68-74Gy\u3002\u5316\u5b78\u6cbb\u7642\u4f7f\u7528CDDP\u82075-FU\uff0c\u5305\u62ec\u5169\u6b21\u653e\u5c04\u6cbb\u7642\u4e2d\u7684\u5408\u4f75\u6cbb\u7642\uff0c\u8207\u5169\u6b21\u653e\u5c04\u6cbb\u7642\u5f8c\u7684\u6cbb\u7642\u3002\u4ee5 Kaplan-Meier method\u5206\u6790\u5b58\u6d3b\u7387\uff0c\u4ee5log-rank test\u5206\u6790\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e64\u6642\u9593\u4e4b\u4e2d\u4f4d\u6578\u70ba50.8\u500b\u6708\u3002\u56db\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75c5\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u5206\u5225\u70ba55.7%\u300164.9%\u53ca75.8%\u3002\u6cbb\u7642\u76f8\u95dc\u7684\u526f\u4f5c\u7528\u5c6c\u53ef\u5fcd\u53d7\u3002Tl/T2\u816b\u7624\u7684\u75c5\u4eba\u5728\u7d71\u8a08\u4e0a\u5177\u6709\u610f\u7fa9\u7684\u8f03\u4f73\u5c40\u90e8\u63a7\u5236\u7387(p=0.03)\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\u7684\u6838\u78c1\u5171\u632f\u6216\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u4e2d\u82e5\u6709\u6b98\u5b58\u75be\u75c5\u7684\u75c5\u4eba\uff0c\u5177\u7d71\u8a08\u4e0a\u6709\u610f\u7fa9\u7684\u8f03\u5dee\u6574\u9ad4\u5b58\u6d3b\u7387(p=0.05)\u3001\u7121\u75c5\u5b58\u6d3b\u7387(p\uff1d0.009)\u53ca\u5c40\u90e8\u7121\u518d\u767c\u5b58\u6d3b\u7387(p\uff1d0.0001)\u3002\n\u7d50\u8ad6\uff1a\u653e\u5c04\u6cbb\u7642\u6216\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u4e4b\u65b9\u5f0f\u6cbb\u7642\u53ef\u5207\u9664\u4e4b\u982d\u9838\u90e8\u816b\u7624\u53ef\u8003\u616e\u70ba\u6839\u9664\u624b\u8853\u5916\u7684\u4e00\u7a2e\u9078\u64c7\u3002\u5b83\u5177\u6709\u53ef\u63a5\u53d7\u7684\u6cbb\u7642\u76f8\u95dc\u526f\u4f5c\u7528\u53ca\u5b58\u6d3b\u7387\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\u7684\u6838\u78c1\u5171\u632f\u6216\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u4e2d\u82e5\u6709\u6b98\u5b58\u75be\u75c5\u7684\u75c5\u4eba\uff0c\u61c9\u63a5\u53d7\u9032\u4e00\u6b65\u63a2\u67e5\u8207\u6cbb\u7642\u3002", "e": "Purpose: To retrospectively analyze the feasibility, toxicity and outcome of definitive radiotherapy with or without chemotherapy for patients with resectable head and neck cancers.\nMaterials and Methods: Thirty patients with resectable head and neck cancers were treated with definitive split-course radiotherapy with or without concurrent chemotherapy. One patient had stage I, 4 stage II, 3 stage \u2162 and 22 stage IV diseases. Radiotherapy was given once daily or twice daily with total dose of 68-74 Gy. Chemotherapy included 2 cycles with CDDP+/-SFIJ during radiotherapy, and 2 cycles with CDDP+5FU after radiation treatment. Survival outcome was calculated by the Kaplan-Meier method. Prognostic factors were determined by log-rank test.\nResults: The median follow-up time was 50.8 months. The 4-year overall survival, disease-free survival and locoregional control rates were 55.7%, 64.9% and 75.8%, respectively. Treatment-related toxicities were tolerable. T1/T2 diseases were associated with heifer locoregional control (p=0.03). The presence of residual disease on post-treatment MRI or CT was the prognostic factor for overall survival (p=0.05), disease-free survival (p=0.009) and locoregional recurrence-free survival (p=0.0001).\nConclusion: Definitive radiotherapy with or without chemotherapy can be an alternative to radical surgery for patients with resectable head and neck cancers, with acceptable toxicity and outcome. The presence of residual disease on post-treatment imaging studies demands further investigation and possibly salvage treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-41-48-a", "title": "\u9f3b\u54bd\u764c\u653e\u5c04\u6cbb\u7642\u5f8c\u76ae\u819a\u6ebc\u6027\u812b\u5c51\u7684\u8655\u7406\u8207\u5206\u6790", "keywords": "\u76ae\u819a\u6fd5\u6027\u812b\u5c51\u53cd\u61c9;\u6c34\u81a0\u6027\u6577\u6599;\u985e\u56fa\u9187\u85e5\u818f Wet desquamation;Gel formula dressing;Steroid ointment", "c": "\u76ee\u7684\uff1a\u6bd4\u8f03\u958b\u653e\u6027\u5305\u7d2e\u8207\u5c01\u9589\u6027\u5305\u7d2e\u61c9\u7528\u65bc\u9f3b\u54bd\u764c\u60a3\u8005\u76ae\u819a\u6fd5\u6027\u80a1\u5c51\u53cd\u61c9\u4e4b\u8b77\u7406\u65b9\u6848\uff0c\u4ee5\u8a55\u4f30\u653e\u5c04\u6cbb\u7642\u5f15\u8d77\u76ae\u819a\u50b7\u5bb3\u7652\u5408\u7684\u901f\u7387\uff0c\u89c0\u5bdf\u50b7\u53e3\u8b8a\u5316\u4e4b\u76f8\u4e92\u95dc\u4fc2\uff0c\u4e86\u89e3\u662f\u5426\u6703\u5f15\u8d77\u4e8c\u5ea6\u611f\u67d3\u4e4b\u6a5f\u7387\uff0c\u9032\u800c\u767c\u5c55\u8212\u9069\u53ca\u65b9\u4fbf\u5feb\u901f\u7684\u8b77\u7406\u65b9\u6cd5\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a100\u4f4d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u5f15\u8d77\u6e05\u6ebc\u6027\u76ae\u819a\u812b\u5c51\u53cd\u61c9\u4e4b\u9f3b\u54bd\u764c\u500b\u6848\u9032\u884c\u8b77\u7406\u3002\u81e8\u5e8a\u4e0a\u63a1\u4e8c\u7a2e\u8b77\u7406\u65b9\u5f0f\uff1a\uff08A\uff09\u985e\u56fa\u9187\u85e5\u818f\uff0c\uff08B\uff09\u6c34\u81a0\u6027(hydrocolloid)\u6577\u6599\u3002\u800c\u8b77\u7406\u904e\u7a0b\u4e2d\u4e43\u57fa\u65bc\uff08l\uff09\u50b7\u53e3\u7652\u5408\u7684\u6642\u9593\uff0c\uff082\uff09\u7d30\u83cc\u751f\u9577\u7684\u60c5\u5f62\uff0c\uff083\uff09\u50b7\u53e3\u7684\u6eab\u5ea6\u8b8a\u5316\uff0c\uff084\uff09\u8212\u9069\u6027\uff0c\u4f86\u8a55\u4f30\u6548\u679c\u4e4b\u597d\u58de\u3002\n\u7d50\u679c\uff1a100\u4f4d\u500b\u6848\u76ae\u819a\u50b7\u53e3\u7686\u7652\u5408\u4e14\u7121\u7d30\u83cc\u4e4b\u611f\u67d3\u3002\u4e8c\u7a2e\u8b77\u7406\u65b9\u5f0f\u4e4b\u50b7\u53e3\u6eab\u5ea6\u8b8a\u5316\uff0c\u7686\u96a8\u8457\u76ae\u819a\u6f38\u9032\u7652\u5408\u3001\u8868\u76ae\u5316\u800c\u964d\u4f4e\uff0c\u5e73\u5747\u4e0b\u964d1\u2103\u3002\u4e00\u59292\u6b21\u653e\u5c04\u6cbb\u7642\u8207\u4e00\u5929\u653e\u5c04\u6cbb\u76421\u6b21\u7b49\uff0c\u5e73\u5747\u50b7\u53e3\u7652\u5408\u6642\u9593\uff1a\uff08l\uff09\u985e\u56fa\u9187\u85e5\u818f\u7d44\u70ba29-42\u5929\uff0c\uff082\uff09\u6c34\u81a0\u6027\u6577\u6599\u7d44\u70ba6-13\u5929\u3002\u6c34\u81a0\u6027\u6577\u6599\u7d44\u670994%\u7684\u75c5\u60a3\u611f\u89ba\u8212\u9069\uff0c\u75bc\u75db\u611f\u5b8c\u5168\u6e1b\u8f15\uff1b\u800c\u540c\u6642\u985e\u56fa\u9187\u85e5\u818f\u7d44\u670922%\u7684\u75c5\u4eba\u611f\u89ba\u75bc\u75db\u6e1b\u8f15\u53ca\u8212\u9069\u3002\n\u8a0e\u8ad6\uff1a\u6c34\u81a0\u6027\u6577\u6599\u80fd\u5b8c\u5168\u6e1b\u8f15\u653e\u5c04\u7dda\u6cbb\u7642\u5f15\u8d77\u7684\u6025\u6027\u76ae\u819a\u53cd\u61c9\u4e0d\u9069\u53ca\u75bc\u75db\uff0c\u7e2e\u77ed\u7642\u7a0b\uff0c\u589e\u5f37\u75c5\u4eba\u5c0d\u6cbb\u7642\u7684\u5fcd\u53d7\u529b\u53ca\u81ea\u4fe1\u5fc3\uff0c\u907f\u514d\u4e2d\u65b7\u6cbb\u7642\u4e4b\u6a5f\u7387\uff0c\u589e\u52a0\u6cbb\u7642\u4e4b\u6548\u679c\uff1b\u964d\u4f4e\u611f\u67d3\u7684\u5371\u96aa\uff0c\u53ef\u4f7f\u50b7\u53e3\u5feb\u901f\u7652\u5408\uff1b\u4e26\u4e14\u80fd\u6e1b\u5c11\u63db\u85e5\u6b21\u6578\uff0c\u964d\u4f4e\u8b77\u7406\u5de5\u6642\u53ca\u7d93\u6fdf\u6210\u672c\uff0c\u63d0\u6607\u91ab\u7642\u670d\u52d9\u54c1\u8cea\u3002", "e": "Purpose: To evaluate the efficacy of gel formula dressing in the wound care of acute skin damage by radiation in nasopharyngeal cancer patients.\nMaterials and Methods: One hundred nasopharyngeal cancer patients developing acute skin reaction at middle neck region due to the effect of irradiation were enrolled into the study and divided into two groups. The first group was applied with (A) 0.5% soluble hydrocortisone plus neomycin ointment and the second group with (B) DuoDERM (Bristol-Meyers) - a gel formula dressing to the skin wound. The end points set for evaluating of skin healing process were (1). Bacterial growth, (2). Healing time, (3). Change in wound temperature and (4). Pain relief.\nResults: No local infection was recognized in both groups. Skin temperature lowers lo C as the skin healing is in progress. The healing time was 29-42 days in the steroid ointment group and 6-13 days in the wet dressing group. Ninety-four percentages of patients in the gel formula dressing group were satisfied with the effect of pain relief, in contrast to only 22% in the hydrocortisone ointment group.\nConclusion: Gel formula dressing did relieve the uncomfortable sensation and shorten the healing time of wet desquamation caused by local irradiation in nasopharyngeal cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-49-54-a", "title": "Assessment of Dose Perturbation Due to Air Cavity Effects under Megavoltage Photon Beams", "keywords": "\u7a7a\u6c23\u8154;\u5291\u91cf\u64fe\u52d5;\u6a39\u8102;\u754c\u9762\u6548\u61c9;\u96fb\u5b50\u5e73\u8861 Air cavity;Dose perturbation;Resin;Interface effect;Electron equilibrium", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u5728\u4f7f\u7528\u767e\u842c\u4f0f\u7279\u5149\u5b50\u5c04\u7dda\u6642\uff0c\u56e0\u7a7a\u6c23\u8154\u8207\u7d44\u7e54\u9593\u7570\u8cea\u6027\u6548\u61c9\u800c\u7522\u751f\u4e4b\u5291\u91cf\u64fe\u52d5\uff0c\u52a0\u4ee5\u5206\u6790\u5176\u5f71\u97ff\u7a0b\u5ea6\u53ca\u76f8\u95dc\u56e0\u7d20\uff0c\u4e26\u63a2\u8a0e\u6a39\u8102\u6750\u6599\u5b78\u5229\u7528\u65bc\u586b\u5145\u5668\u6216\u5f4c\u88dc\u7269\u4e4b\u4e3b\u6210\u4efd\uff0c\u5728\u5291\u91cf\u5b78\u4e0a\u4e4b\u7279\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5b9a\u7fa9\u7570\u8cea\u6027\u5291\u91cf\u6821\u6b63\u56e0\u5b50HDCF\u7b49\u65bcDi/Dh\uff0c\u5176\u4e2dDi\u70ba\u7570\u8cea\u6027\u6750\u8cea\u5b58\u5728\u6642\u6e2c\u51fa\u4e4b\u5291\u91cf\uff0c\u800cDh\u70ba\u6750\u8cea\u5747\u52fb\u6642\u6e2c\u51fa\u4e4b\u5291\u91cf\u3002\u5229\u75286MV\u53ca10MV\u5149\u5b50\u5c04\u7dda\u7167\u5c04\u5404\u7a2e\u4e0d\u540c\u7167\u91ce\u5927\u5c0f\uff0c\u4ee5\u7a7a\u6c23\u6216\u6a39\u8102\u586b\u5145\u4e4b\u7a7a\u8154\uff0c\u5728\u8154\u58c1\u4e4b\u5169\u5074\uff0c\u6e2c\u91cf\u5176\u8b8a\u5316\u4e4b\u7a0b\u5ea6\u3002\n\u7d50\u679c\uff1a\u7576\u7167\u91ce\u9762\u7a4d\u7b49\u65bc\u6216\u5c0f\u65bc\u7a7a\u6c23\u8154\u9762\u7a4d\u6642\uff0c\u5728\u5c04\u7dda\u9060\u7aef\u754c\u9762\u51fa\u73fe\u660e\u986f\u5291\u91cf\u4e0d\u8db3\u73fe\u8c61\uff08\u53ef\u80fd\u591a\u65bc30%\uff09\uff0c\u5c24\u5176\u5728\u4f7f\u7528\u8f03\u9ad8\u80fd\u91cf\u5c04\u7dda\u60c5\u6cc1\u4e0b\u3002\u7576\u7167\u91ce\u9762\u7a4d\u589e\u5927\u6642\uff0cHDCF\u4e5f\u96a8\u4e4b\u589e\u52a0\uff0c\u751a\u81f3\u6703\u5927\u65bc1\uff0c\u4e5f\u5c31\u662f\u53ef\u80fd\u51fa\u73fe\u5291\u91cf\u904e\u9ad8\u73fe\u8c61\uff0c\u4f46\u4e4b\u5f8c\u6703\u4fdd\u6301\u4e00\u500b\u56fa\u5b9a\u6578\u503c\u3002\u5728\u8154\u5f8c\u58c1\u6e2c\u91cf\u6642\uff0c\u5247\u767c\u73fe\u5b58\u5728\u6709\u518d\u589e\u5efa\u5340\u3002\u81f3\u65bc\u8fd1\u7aef\u754c\u9762\u7522\u751f\u4e4b\u5291\u91cf\u4e0d\u8db3\u73fe\u8c61\uff0c\u5247\u96a8\u7167\u91ce\u9762\u7a4d\u589e\u5927\u800c\u4ecd\u7136\u5b58\u5728\uff0c\u4f46\u5176\u7a0b\u5ea6\u8f03\u4e0d\u986f\u8457\uff08\u5c0f\u65bc10%\uff09\u3002\u5229\u7528\u6a39\u8102\u4f86\u4f5c\u70ba\u7a7a\u8154\u586b\u88dc\u7269\u6703\u660e\u986f\u964d\u4f4e\u5291\u91cf\u64fe\u52d5\u60c5\u5f62\uff0c\u548c\u6750\u8cea\u5747\u52fb\u6642\u6bd4\u8f03\u8d77\u4f86\uff0c\u9060\u8fd1\u7aef\u5dee\u7570\u7686\u572825%\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u7576\u6cbb\u7642\u5340\u57df\u5167\u6709\u7a7a\u6c23\u8154\u5b58\u5728\uff0c\u4e14\u8154\u524d\u4ecb\u8cea\u53ef\u9054\u5230\u96fb\u5b50\u5e73\u8861\u6642\uff0c\u5728\u754c\u9762\u53ca\u5176\u5f8c\u7d44\u7e54\u6240\u6e2c\u5f97\u5291\u91cf\u4e4b\u5f71\u97ff\u56e0\u7d20\uff0c\u6709\u7167\u91ce\u53ca\u8154\u5f91\u5927\u5c0f\u76f8\u95dc\u60c5\u6cc1\u3001\u8154\u5f62\u72c0\u53ca\u5c04\u7dda\u80fd\u91cf\u5f37\u5ea6\u7b49\u3002\u6563\u5c04\u96fb\u5b50\u6e1b\u5c11\uff0c\u53ca\u672a\u88ab\u8870\u6e1b\u4e4b\u5149\u5b50\u5c04\u7dda\u6703\u589e\u52a0\uff0c\u9019\u5169\u8005\u5c07\u6709\u5e73\u8861\u4f5c\u7528\u3002\u5728\u9019\u4e9b\u60c5\u6cc1\u4e0b\u9078\u64c7\u9069\u7576\u80fd\u91cf\u4e4b\u5c04\u7dda\uff0c\u7d93\u7531\u5b8c\u5584\u8a08\u5283\u914d\u5408\u8db3\u5920\u5927\u5c0f\u4e4b\u7167\u91ce\uff0c\u5c07\u662f\u5fc5\u9700\u7684\u3002\u7531\u65bc\u6a39\u8102\u5176\u65b9\u4fbf\u6027\u53ca\u5728\u5291\u91cf\u5b78\u4e0a\u4e4b\u7406\u60f3\u7279\u6027\uff0c\u6211\u5011\u5efa\u8b70\u53ef\u4ee5\u4f7f\u7528\u65bc\u586b\u5145\u7a7a\u8154\u5167\uff0c\u5927\u5e45\u6539\u5584\u5291\u91cf\u5206\u4f48\u4e4b\u5747\u52fb\u5ea6\u3002", "e": "Purpose: To evaluate the magnitude and corresponding factors of dose perturbation due to air to tissue inhomogeneity for megavoltage photon beams. The dosimetric property of resin, a major component of obturator or prosthesis, is investigated.\nMaterials and Methods: The heterogeneity dose correction factor (HDCF) is introduced and defined as Di/Dh where Di is the dose at heterogeneous condition and Dh is dose of the same point in a homogenous phantom. Dose perturbation for varying sizes of cubic air-filled and resin-filled cavity were examined for 6 and 10 MV photon beams along the beam direction for both proximal side (entering the cavity) and distal side (leaving the cavity).\nResults: Significant underdosage (more than 30%) can occur on the distal interface when the field size is equal to or less than the air cavity size, especially for higher energy photon beams. The HDCF increases with the increase in field sizes and can be greater than 1 unity, which indicates the possibility of overdosage, but it will remain constant afterwards. A buildup region is observed at the downstream measurements. Underdose phenomenon at the proximal air-phantom interface remains over a wide range of field sizes, but it is less significant (\uff1c10%). The use of resin as the cavity tilling material will dramatically reduce the dose perturbation to within 2.5% on both interfaces, compared with a homogeneous condition.\nConclusion: With an air cavity embedded in the treatment volume and under the condition of electron equilibrium of pre-cavity medium, the dose measured at interface and subsequent tissue is influenced by the relationship between the field size and cavity size, and also between the cavity shape and photon beam energy. Loss of scattered electron and increase of unattenuated photon beam balance it. Well designed planning with sufficient field size from proper energy beam is recommended. Resin can be used to fill the cavity for improving the dose distribution."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-55-61-a", "title": "Dose-Volume Analysis for 4 Patients with Radiation-Induced Liver Disease after 3-Dimensional Conformal Radiotherapy for Hepatocellular Carcinoma", "keywords": "\u809d\u7d30\u80de\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a Hepatocellular carcinoma;Radiotherapy;Radiation-induced liver disease", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u76ee\u524d\u767c\u8868\u4e4b\u5e7e\u7a2e\u809d\u81df\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u9810\u6e2c\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a\u7684\u6a5f\u7387\u6a21\u5f0f\uff0c\u8a55\u4f30\u5176\u5be6\u7528\u6027\u8207\u6e96\u78ba\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a1994\u5e744\u6708\u81f31998\u5e7410\u6708\uff0c\u56db\u4f4d\u809d\u7d30\u80de\u764c\u75c5\u4eba\u63a5\u53d7\u4e09\u5ea6\u7a7a\u9593\u96a8\u5f62\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\uff0c\u4e09\u500b\u6708\u5167\u7522\u751f\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a\u3002\u56db\u4f4d\u75c5\u4eba\u6cbb\u7642\u524d\u7686\u63a5\u53d7\u4e86\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u5b9a\u4f4d\uff0c\u4e14\u5f71\u50cf\u8cc7\u8a0a\u5747\u6db5\u84cb\u6574\u500b\u809d\u81df\u3002\u7531\u5291\u91cf\uff0d\u79ae\u7a4d\u95dc\u4fc2\u5716\u4e2d\u6c42\u5f97V(\u4e0b\u6a19 30Gy)\uff0cV(\u4e0b\u6a19 50%)\uff0cV(\u4e0b\u6a19 off)\u8207PS\u5e7e\u9805\u53c3\u6578\uff0c\u518d\u7531\u5e7e\u7a2e\u9810\u6e2c\u6a21\u5f0f\u63db\u7b97\u51fa\u7522\u751f\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u81df\u75c5\u8b8a\u6a5f\u7387\u3002\n\u7d50\u679c\uff1a\u56db\u4f4d\u767c\u751f\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a\u75c5\u4eba\u4e2d\uff0c\u4e8c\u4f4d\u6b7b\u65bc\u6b64\u4f75\u767c\u75c7\uff0c\u53e6\u4e8c\u4f4d\u5fa9\u539f\u3002\u4e8c\u4f4d\u6b7b\u65bc\u4f75\u767c\u75c7\u7684\u75c5\u4eba\u6b63\u5e38\u809d\u81df\u8d85\u904e30Gy\u7684\u9ad4\u7a4d\u5747\u5c0f\u65bc50%\uff0c\u800c\u5b58\u6d3b\u7684\u4e8c\u4f4d\u75c5\u4eba\u8d85\u904e30Gy\u7684\u809d\u81df\u5247\u5927\u65bc50%\u3002\u56db\u4f4d\u75c5\u4eba\u4e2d\u7684\u4e09\u4f4d\u5176\u653e\u5c04\u7dda\u5291\u91cf\u7686\u7b26\u5408\u5bc6\u897f\u6839\u5927\u5b78\u91ab\u5b78\u4e2d\u5fc3\u4f9d\u64daV(\u4e0b\u6a19 50%)\u7684\u5efa\u8b70\u5291\u91cf\u3002\u4f9d\u64da\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387\u6a21\u5f0f\u5206\u6790\uff0c\u82e5\u61c9\u75280.69\u70ba\u9ad4\u7a4d\u6548\u61c9\u53c3\u6578\uff0c\u56db\u4f4d\u75c5\u4eba\u7684\u4f75\u767c\u75c7\u6a5f\u7387\u5747\u57285%\u4ee5\u4e0b\uff0c\u82e5\u61c9\u75280.32\u70ba\u53c3\u6578\uff0c\u5247\u6a5f\u7387\u70ba5-20%\u3002\n\u7d50\u8ad6\uff1a\u76ee\u524d\u767c\u8868\u7684\u5e7e\u7a2e\u5c0d\u653e\u5c04\u7dda\u5f15\u8d77\u4e4b\u809d\u75c5\u8b8a\u7684\u6a5f\u7387\u9810\u6e2c\u6a21\u5f0f\uff0c\u5747\u4e0d\u80fd\u6e96\u78ba\u8a55\u4f30\u53f0\u7063\u809d\u7d30\u80de\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u5f8c\u7684\u4f75\u767c\u75c7\u6a5f\u7387\u3002\u5229\u7528\u76ee\u524d\u4f7f\u7528\u7684\u653e\u5c04\u6cbb\u7642\u7642\u7a0b\u8a2d\u8a08\u53ca\u5291\u91cf\uff0d\u79ae\u7a4d\u8cc7\u6599\uff0c\u5efa\u7acb\u4e00\u5957\u9069\u5408\u53f0\u7063\u809d\u7d30\u80de\u764c\u75c5\u4eba\u4f75\u767c\u75c7\u9810\u6e2c\u6a21\u5f0f\uff0c\u662f\u6709\u5176\u5fc5\u8981\u6027\u7684\u3002", "e": "Purpose: To evaluate the feasibility and accuracy of the currently documented models for prediction of radiation -induced liver disease (RILD), for patients with hepatocellular carcinoma (HCC) treated with 3-dimensional conformal radiotherapy.\nMaterials and Methods: From September 1994 to October 1998, four patients with HCC developed FOLD within 3 months after completion of 3-dimensional conformal radiotherapy. All patients had CT simulation with the images including the entire liver. The detailed information from the dose-volume histogram (DVH), including V(subscript 30Gy), V(subscript 50%) V (subscript off) and prediction score (PS), were calculated and assessed. The complication probabilities were compared with several documented models.\nResults: Two patients died of RILD-related hepatic failure and 2 recovered. Two patients had more than half of the liver with \uff1e 30 cay survived but the other 2 patients died of RILD with 40% and 23% of the liver receiving \uff1e 30 Gy. Three of 4 patient had the recommended doses of radiation based on the calculated V(subscript 60%). According to the normal tissue complication probability (NTCP) model, the complication probabilities were less than 5% and within 5-20% if 0.69 and 0.32 were applied for the volume effect parameters, respectively.\nConclusion: All the currently documented models fail to accurately estimate the probability of FOLD for the 4 patients with HCC treated with 3-dimensional conformal radiotherapy. It is indicated to establish a model for patients with HCC in Taiwan, using the currently available fractionation and the information from the DVH."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199903-6-1-63-72-a", "title": "\u9060\u9694\u6cbb\u7642\u6a5f\u4e4b\u5c4f\u853d\u8f3b\u9632\u5b89\u5168\u8a55\u4f30", "keywords": "\u4e3b\u5c04\u675f;\u4e8c\u6b21\u8f3b\u5c04;\u5291\u91cf\u9650\u5236 Primary beam;Secondary radiation;Dose constraint", "c": "\u672c\u90e8\u9580\u70ba\u63d0\u6607\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\u8207\u91ab\u7642\u54c1\u8cea\uff0c\u65b0\u6dfb\u4e59\u90e8Siemens PRIMUS\u76f4\u7dda\u52a0\u901f\u5668\uff0810/15MV\u96d9\u5149\u5b50\u80fd\u91cf\uff09\uff0c\u56e0\u7a7a\u554f\u53ca\u6cbb\u7642\u6d41\u7a0b\u8003\u91cf\uff0c\u539f\u9237\u516d\u5341\u6cbb\u7642\u5ba4(LAI)\u64ec\u88dd\u8a2d\u79fb\u5165\u539fLAII\u4e4b6/10MV\u96d9\u5149\u5b50\u80fd\u91cf\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u539f\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u5247\u4e88\u79fb\u5165\u9694\u9130\u7a7a\u9593\u3002\u820a\u6709\u6309\u9237\u516d\u5341\u80fd\u91cf(LAI)\u53ca10MV\u5149\u5b50(LAII)\u8a08\u7b97\u7684\u5c4f\u853d\u5efa\u69cb\u7269\uff0c\u5305\u62ec\u5c4f\u853d\u539a\u5ea6\u3001\u8ff7\u5bae\u9577\u5ea6\u3001\u925b\u9580\u8a2d\u8a08\u2026\u7b49\uff0c\u7531\u65bc\u653e\u5c04\u7dda\u80fd\u91cf\u63d0\u6607\u53ca\u7a7a\u9593\u91cd\u65b0\u898f\u756b\u7b49\u56e0\u7d20\uff0c\u5fc5\u9808\u91cd\u65b0\u8a08\u7b97\u8207\u8a55\u4f30\u3002\u672c\u8ad6\u6587\u6839\u64daNCRP49\u300151\u300133\u3001102\u865f\u5831\u544a\u66f8\u53caICRP60\u865f\u5831\u544a\u66f8\u8207\u884c\u653f\u9662\u539f\u5b50\u80fd\u59d4\u54e1\u6703\u6e38\u96e2\u8f3b\u5c04\u9632\u8b77\u5b89\u5168\u6a19\u6e96\uff0c\u8003\u616e\u6574\u9ad4\u7a7a\u9593\u4e4b\u4e3b\u5c04\u675f\u8207\u4e8c\u6b21\u8f3b\u5c04\u91cf\u53ca\u6cd5\u898f\u5291\u6688\u9650\u5236\u5f8c\uff0c\u9700\u88dc\u5f37\u5c4b\u9802\u539a\u5ea6\u3001\u8ff7\u5bae\u9577\u5ea6\u53ca\u925b\u9580\u539a\u5ea6\u3002\u8a08\u7b97\u7684\u904e\u7a0b\u53ca\u76f8\u95dc\u5c4f\u853d\u554f\u984c\u5c07\u5728\u6587\u4e2d\u8a0e\u8ad6\u3002", "e": "For upgrade radiotherapy techniques and medical quality, our department replaces Co-60 unit (room LAI) with the linear accelerator (6/10 MV dual energy, moved from room LA II) and set up an new Siemens PRIMUS linear accelerator (linac, 10/15 MV dual energy) in LAII. The Co-60 unit will move to another compartment. Since the higher radiation energy of linacs and new arrangement of the treatment room, the previous shielding including the thickness of barriers and lead door, the length of maze ....etc, need be re-evaluated. Calculations are based on NCRP49, 51, 33, 102, ICRP60 and AEC dose constraint, and the results show the shielding deficiency on ceiling, maze and lead door. The process of the calculation and relative shielding problems will be discussed in this paper."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-233-243-a", "title": "\u651d\u8b77\u817a\u764c\u4e4b\u50b3\u7d71\u653e\u5c04\u7dda\u6cbb\u7642\u2014\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u5341\u56db\u5e74\u4e4b\u7d93\u9a57", "keywords": "\u651d\u8b77\u817a\u764c;\u653e\u5c04\u6cbb\u7642;\u526f\u4f5c\u7528 Prostate cancer;Radiotherapy;Complication", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u63a2\u8a0e\u50b3\u7d71\u653e\u5c04\u7dda\u6cbb\u7642\u651d\u8b77\u817a\u764c\u7684\u7d50\u679c\uff0c\u56e0\u6b64\u56de\u6eaf\u5206\u679014\u5e74\u4f86\u65bc\u672c\u79d1\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u651d\u8b77\u817a\u764c\u75c5\u4f8b\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1982\u81f31996\u5e74\uff0c\u5171\u6709240\u4f4d\u651d\u8b77\u817a\u764c\u75c5\u60a3\u88ab\u8f49\u4ecb\u81f3\u672c\u79d1\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\u50c5\u6709\u816b\u7624\u5c40\u9650\u5728\u9aa8\u76c6\u8154\uff08\u5206\u671fA-D1\uff09\u4e14\u5b8c\u6210\u6cbb\u7642\u768473\u4f4d\u75c5\u60a3\u624d\u9032\u5165\u6700\u5f8c\u5206\u6790\u3002\u901973 \u4f4d\u75c5\u60a3\u4e2d\u67091\u4f4d\u70baA\u671f\u300123\u4f4d\u70baB\u671f\u300135\u4f4d\u70baC\u671f\u300112\u4f4d\u70baD1\u671f\u30012\u4f4d\u672a\u77e5\u3002\u75c5\u60a3\u7684\u4e2d\u503c\u5e74\u9f61\u70ba67\u6b72\uff08\u7bc4\u570d53-78\u6b72\uff09\uff0c\u4e2d\u503c\u8ffd\u8e64\u671f\u70ba38.5\u500b\u6708\uff08\u7bc4\u570d7.8-124\u500b\u6708\uff09\u3002\u70ba\u4e86\u4fbf\u65bc\u5206\u6790\uff0c\u6211\u5011\u5c07\u75c5\u60a3\u5206\u70ba\u4e8c\u7d44\uff1aGroup \u2160-\u63a5\u53d7\u6cbb\u7652\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5171\u670964\u4f4d\uff1bGrouP \u2161-\u63a5\u53d7\u6839\u9664\u6027\u651d\u8b77\u817a\u5207\u9664\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5171\u67099\u4f4d\u3002\u539f\u5247\u4e0a\u653e\u5c04\u7dda\u6cbb\u7642\u65b9\u5f0f\u662f\u63a1\u50b3\u7d71\u4e8c\u5ea6\u7a7a\u554f\u6cbb\u7642\u8a08\u5283\u65b9\u5f0f\uff0c\u7528\u9ad8\u80fd\u653e\u5c04\u7dda(10-15MV)\u5148\u7167\u5c04\u9aa8\u76c6\u8154\u81f34400cGy \uff0c\u518d\u7e2e\u5c0f\u7bc4\u570d\u7167\u5c04\u8caf\u7cbe\u56ca\u53ca\u651d\u8b77\u817a\u3002 Group \u2160\u7e3d\u5291\u91cf\u90544400-8400 cGy\uff08\u5e73\u5747\u503c6638 cGy\uff09, Group \u2161 \u5291\u91cf\u5247\u81f35600-6800 cGy\uff08\u5e73\u5747\u503c5956 cGy\uff09\u3002\u5171\u670935\u4f4d\u75c5\u60a3\uff0c\u63a5\u53d7\u8f14\u52a9\u6027\u7684\u8377\u723e\u8499\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u901973\u4f4d\u75c5\u60a3\u6cbb\u7642\u7684\u65e9\u671f\u526f\u4f5c\u7528\uff1a28 (38%)\u4f4d\u6709\u7b2c\u4e8c\u7d1a\u7684\u8178\u80c3\u9053\u75c7\u72c0\uff0c18\u4f4d(25%)\u6709\u7b2c\u4e8c\u7d1a\u7684\u6ccc\u5c3f\u9053\u75c7\u72c0\u30021\u4f4d\u6709\u7b2c\u4e09\u7d1a\u7684\u8178\u80c3\u9053\u75c7\u72c0\uff0c1\u4f4d\u6709\u7b2c\u4e09\u7d1a\u7684\u6ccc\u5c3f\u9053\u75c7\u72c0\u3002\u5728\u6cbb\u7642\u7684\u665a\u671f\u4f5c\u7528\u65b9\u9762\uff1b\u7522\u751f\u56b4\u91cd\u4f75\u767c\u75c7\u5305\u62ec\u5c62\u7ba1\u3001\u5c3f\u9053\u72f9\u7a84\u3001\u8180\u80f1\u708e\u3001\u76f4\u8178\u708e\u51719\u4f4d(14%)\uff1b\u5176\u4e2d5\u4f4d\u70baGroup \u2160(5/55,9%),4\u4f4d\u70baGrouP\u2161(4/9, 44%)\uff0c\u8207\u570b\u5916\u6587\u737b\u76f8\u6bd4\u660e\u986f\u8f03\u9ad8\u3002\u63a5\u53d7\u958b\u5200\u6c92\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\u7522\u751f\u665a\u671f\u56b4\u91cd\u4f75\u767c\u75c7\u7684\u6bd4\u4f8b\uff0c\u660e\u986f\u8f03\u55ae\u7d14\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u70ba\u9ad8\uff08\u03c1=0.004\uff0c\u5361\u65b9\u7d71\u8a08\uff09\uff0c\u901973\u4f4d\u75c5\u60a35\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba67%\uff0c10\u5e74\u70ba36%\uff1b5\u5e74\u75be\u75c5\u5c08\u5c6c\u5b58\u6d3b\u7387\u70ba66%\uff0c10\u5e74\u70ba34%\u3002 Group \u2160\u4e2d\u5206\u671fA\u3001B\u8005\u5c40\u90e8\u63a7\u5236\u7387\u70ba83%\uff0c\u5206\u671fC\u70ba90%\uff0c\u5206\u671fD1\u70ba50%\uff1bGrouP\u2161\u5247\u70ba100%\u3002\u5206\u671f\u3001\u5e74\u9f61\u3001\u75c5\u7406\u5206\u7d1a\u3001\u8377\u723e\u8499\u6cbb\u7642\u3001\u653e\u5c04\u7dda\u6cbb\u7642\u7e3d\u5291\u91cf\u5728\u55ae\u8b8a\u56e0\u5206\u6790\u4e2d\u767c\u73fe\uff0c\u5c0d\u75be\u75c5\u5c08\u5c6c\u5b58\u6d3b\u7387\u7686\u6c92\u6709\u7d71\u8a08\u5b78\u4e0a\u6709\u610f\u7fa9\u7684\u5f71\u97ff\u3002\n\u7d50\u8ad6\uff1a\u672c\u7bc7\u7814\u7a76\u986f\u793a\u6cbb\u7652\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u6839\u9664\u6027\u651d\u8b77\u817a\u5207\u9664\u52a0\u4e0a\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5c0d\u651d\u8b77\u817a\u764c\u53ef\u5f97\u5230\u826f\u597d\u4e4b\u5c40\u90e8\u63a7\u5236\uff1b\u4f46\u63a1\u7528\u50b3\u7d71\u4e8c\u5ea6\u7a7a\u9593\u6cbb\u7642\u8a08\u5283\u65b9\u5f0f\uff0c\u526f\u4f5c\u7528\u660e\u986f\u504f\u9ad8\u3002\u56e0\u6b64\u5efa\u8b70\u651d\u8b77\u817a\u764c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u5b9c\u63a1\u7528\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\uff0c\u4ee5\u6e1b\u5c11\u5176\u526f\u4f5c\u7528\u3002", "e": "Purpose: To evaluate the result of conventional radiation treatment for prostate cancer, we performed a retrospective analysis of patients referred to our department from 1982 to 1996.\nMaterial and Methods: From 1982 to 1996, a total of 240 prostate cancer patients were referred to our department for radiotherapy (RT). Only 73 patients who had disease confined to the pelvis (stage A-D1) and completed the RT treatment were entered into this analysis. The median age was 67 years (range 53-78) and the median follow-up time was 38.5 months (range 7.8 -124.3). For convenience for comparison, we divided those patients into two groups for final analysis: group I - curative RT alone, 64 patients; group II - radical prostatectomy followed by adjuvant RT, 9 patients. Radiotherapy was delivered by conventional two-dimensional treatment plan. External irradiation was usually given by 10 or 15 MV X-ray to the pelvis and then coned down to the prostate and seminal vesicle, yielding a total dose of 4400 to 8400 cGy (mean 6638 cGy) for group I patients and 5600 to 6800 cGy (mean 5956 cGy) for group II patients. Adjuvant or neoadjuvant hormone therapy was given in 33 patients.\nResults: Grade II acute gastrointestinal (01) and genitourinary (GU) toxicity were observed in 28 (38%) and 18 (25%) patients, respectively. There were one patient with acute grade III 01 toxicity and another patient with acute grade III GU toxicity. Late morbidity analysis was only available in 66 patients. Severe late complications including fistula formation, urethral stricture, cystitis, proctitis were found in 9 patients (14%) which is higher than other reported series. Those patients who received RT after radical prostatectomy experienced a significant higher severe late complication rate than those who received RT alone. (44% vs 9%, p\uff1c0.05). The overall survival rates for all patients are 67% at 5 years and 36% at 10 years. The cause-specific survivals for all patients are 66% at 5 years and 34% at 10 years. The local control rates are 83% for stage A and B, 90% for stage C and 50% for stage Dl patients in group I. The local control rate for group II patients is 100%. In univariate analysis, age, stage, pathology grading, hormone therapy and RT dose didn\u2019t show significant impact on cause specific survivals.\nConclusion: This study showed the local control rates after curative RT or radical prostatectomy followed by adjuvant RT are good. However, the complication rates after conventional two-dimensional RT are high. Further efforts in three-dimensional conformal RT for prostate cancer is highly recommended in term of decreasing toxicity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-245-252-a", "title": "Preoperative Radiotherapy in Patients with Lower Rectal Cancer: Results of Sphincter-Preservation, Treatment Outcome and Morbidities", "keywords": "\u8853\u524d\u653e\u5c04\u6cbb\u7642;\u5668\u5b98\u4fdd\u7559;\u76f4\u8178\u764c;\u5f8c\u907a\u75c7 Preoporative radiotherapy;Sphincter preservation;Rectal cancer;Morbidity", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u8853\u524d\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u65bc\u4f4e\u4f4d\u76f4\u8178\u764c\u60a3\u8005\uff0c\u5728\u4fc3\u9032\u5668\u5b98\u4fdd\u7559\u4e4b\u89d2\u8272\uff0c\u4e26\u8a55\u4f30\u5176\u6cbb\u7642\u7d50\u679c\u53ca\u5f8c\u907a\u75c7\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u5f9e1992\u5e744\u6708\u81f31996\u5e7412\u6708\uff0c\u5171\u670943\u4f4d\u76f4\u8178\u764c\u60a3\u8005\u56e0\u816b\u7624\u4f4d\u7f6e\u904e\u65bc\u63a5\u8fd1\u809b\u9580\uff0c\u7d93\u5916\u79d1\u91ab\u5e2b\u5224\u65b7\u7121\u6cd5\u540c\u6642\u5207\u9664\u816b\u7624\u4e26\u4fdd\u7559\u809b\u9580\uff0c\u70ba\u4e86\u63d0\u9ad8\u75c5\u60a3\u63a5\u53d7\u816b\u7624\u5207\u9664\u4e26\u4fdd\u7559\u809b\u9580\u4e4b\u6a5f\u6703\uff0c\u65bc\u672c\u79d1\u63a5\u53d7\u8853\u524d\u653e\u5c04\u6cbb\u7642\u3002\u7167\u5c04\u7bc4\u570d\u70ba\u9aa8\u76c6\u8154\uff0c\u5291\u91cf\u70ba37.5 Gy\uff0c\u8a0815\u6b21\uff0c\u6bcf\u9031\u6cbb\u7642\u4e94\u5929\u3002\n\u7d50\u679c\uff1a\u653e\u5c04\u6cbb\u7642\u5f8c\u670930\u4f4d(70%)\u60a3\u8005\u53ef\u63a5\u53d7\u4fdd\u5b58\u809b\u9580\u4e4b\u4f4e\u524d\u4f4d\u5207\u9664\u8853\u3002\u4e09\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u3001\u7121\u75c5\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u63a7\u5236\u7387\u5404\u70ba60%\u300162%\u3001\u53ca89%\u3002\u55ae\u8b8a\u6578\u5206\u6790\u767c\u73fe\u75c5\u7406\u5206\u671f\u53ca\u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u5c0d\u65bc\u6574\u9ad4\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u70ba\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u5c0d\u65bc\u5c40\u90e8\u63a7\u5236\u7387\u5247\u53ea\u6709\u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u70ba\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u63a5\u53d7\u4fdd\u5b58\u809b\u9580\u4e4b\u4f4e\u524d\u4f4d\u5207\u9664\u8853\u4e26\u4e0d\u5f71\u97ff\u60a3\u8005\u4e4b\u5b58\u6d3b\u7387\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u3002\u4ee5\u591a\u8b8a\u6578\u5206\u6790\u767c\u73fe\u75c5\u7406\u5206\u671f\u70ba\u5f71\u97ff\u7121\u75c5\u5b58\u6d3b\u7387\u4e4b\u7368\u7acb\u56e0\u5b50\uff0c\u800c\u5c40\u90e8\u6dcb\u5df4\u7d50\u8f49\u79fb\u70ba\u5f71\u97ff\u5c40\u90e8\u63a7\u5236\u7387\u4e4b\u7368\u7acb\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u8853\u524d\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u65bc\u4f4e\u4f4d\u76f4\u8178\u764c\u60a3\u8005\uff0c\u53ef\u4f7f\u75c5\u60a3\u6709\u76f8\u7576\u6a5f\u6703\u63a5\u53d7\u4fdd\u7559\u809b\u9580\u4e4b\u5207\u9664\u8853\u3002\u540c\u6642\uff0c\u7d93\u7531\u8853\u524d\u653e\u5c04\u6cbb\u7642\u800c\u4fdd\u5b58\u4e4b\u809b\u9580\uff0c\u5176\u62ec\u7d04\u808c\u529f\u80fd\u5728\u5927\u90e8\u4efd\u75c5\u4eba\u7686\u70ba\u6b63\u5e38\u3002\u5982\u4f55\u6539\u9032\u6cbb\u7642\u6280\u8853\uff0c\u4ee5\u6e1b\u5c11\u653e\u5c04\u6cbb\u7642\u4e4b\u526f\u4f5c\u7528\uff0c\u4ecd\u6709\u5f85\u52aa\u529b\u3002", "e": "Purpose: To study the impact of preoperative irradiation on enhancing sphincter preservation and to evaluate the treatment outcome in patients with lower rectal cancer. The results were analyzed for the endpoints of sphincter preservation, sphincter function, pelvic control, disease-free survival, overall survival and treatment-related morbidities.\nMaterials and Methods: From 1992 to 1996, 43 patients with clinically resectable rectal cancer received preoperative radiotherapy at our department. All of these patients had undergone a prospective clinical assessment by their surgeons and were declared to require an abdominoperineal resection due to the proximity of the tumor to the anal sphincter. The whole pelvis received 37.5 Gy in daily fraction of 2.5 Gy with parallel opposed anterior-posterior portals.\nResults: Thirty of the forty-three patients (70%) were able to undergo low anterior resection. The majority (88%) of patients had good sphincter function after sphincter-preserving surgery. The pathologic stage was T2 in 11 patients and T3 in 32 patients. The 3- year overall survival rate, disease-tree survival rate, and local control rate of the 43 patients were 60%, 62%, and 89%, respectively. In univariate analysis, pathologic stage and the presence of regional lymphadenopathy were noted as significant prognostic factors for both overall survival and disease-free survival. With regard to local control, only the presence of regional lymphadenopathy showed prognostic significance for local control. No difference in survival rate and local control rate was observed between patients undergoing low anterior resection and those undergoing abdominoperineal resection. In multivariate analysis, pathologic stage was noted as the only independent prognostic factor for disease-free survival; likewise, only the presence of lymphadenopathy was demonstrated as an independent predictor for local control. No clinical and pathologic parameters were proved to be independent prognostic factors for overall survival. Acute intestinal toxicity included grade 1 in 10 (23%) patients, grade 2 in 18 (42%) patients, and grade 3 in 2 patients (5%). No patients had acute urological toxicity.\nConclusion: With the help of preoperative radiotherapy, a significant proportion of patients would have a chance to receive sphincter-preserving surgery. Furthermore, the preserved sphincter functioned well in most of the patients. Further efforts should be made to reduce the treatment-related morbidities."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-253-259-a", "title": "Comparison of Clinical Outcome in Hypopharyngeal Cancer Treated with Radiotherapy Alone or Surgery Combined with Adjuvant Radiotherapy- 10 Years, Experience in Mackay Memorial Hospital", "keywords": "\u4e0b\u54bd\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u624b\u8853 Hypopharyngeal cancer;Radiotherapy;Surgery", "c": "\u76ee\u7684\uff1a\u91dd\u5c0d\u4e0b\u54bd\u764c\u63a5\u53d7\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u8a55\u4f30\u5176\u6cbb\u7642\u7d50\u679c\uff0c\u4e26\u5206\u6790\u7d44\u7e54\u5b78\u4e0a\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1987\u5e741\u6708\u81f31997\u5e7412\u6708\uff0c\u5728\u672c\u9662\u63a5\u53d7\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u768481\u4f4d\u4e0b\u54bd\u764c\u75c5\u60a3\uff0c\u4f5c\u56de\u6eaf\u6027\u7684\u5206\u6790\uff0c\u5176\u4e2d\u7537\u6027\u536079\u4f4d\uff0c\u5973\u60272\u4f4d\uff0c\u5e74\u9f61\u4ecb\u65bc24\u81f380\u6b72\uff08\u4e2d\u9593\u503c54\uff09\u3002\u5176\u816b\u7624\u7b2c\u4e00\u671f\u81f3\u56db\u671f\u5206\u5225\u70ba0\uff0c3\uff0c22\u53ca56\u4f4d\uff0c\u9019\u5169\u7d44\u75c5\u60a3\u4e4bT-\u671f\u8207N-\u671f\u5206\u4f48\u4e0a\u4e26\u7121\u660e\u986f\u5dee\u7570\uff0c\u5176\u4e2d18\u4f4d\u75c5\u60a3\u63a5\u53d7\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u6bcf\u59291.8Gy\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u5e73\u5747\u5291\u91cf\u70ba63.9 Gy\uff08\u4ecb\u65bc34.2\u81f375.6 Gy\uff09\uff0c\u53e6\u591663\u4f4d\u75c5\u60a3\u63a5\u53d7\u5168\u5589\u5207\u9664\u8853\u5408\u4f75\u90e8\u5206\u54bd\u5589\u5207\u9664\u6216\u98df\u9053\u5207\u9664\u8853\uff0c\u9019\u4e9b\u75c5\u60a3\u7686\u63a5\u53d7\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5e73\u5747\u5291\u91cf\u70ba60.4 Gy\uff08\u4ecb\u65bc36\u81f3738 Gy\uff09\u3002\n\u7d50\u679c\uff1a\u63a5\u53d7\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u75c5\u60a3\u76845\u5e74\u5b58\u6d3b\u7387\u70ba33% \uff0c\u63a5\u53d7\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u75c5\u60a3\u76845\u5e74\u5b58\u6d3b\u7387\u70ba30%\uff0c\u9019\u5169\u7d44\u5b58\u6d3b\u7387\u7121\u660e\u986f\u5dee\u7570\u3002\u63a5\u53d7\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u75c5\u60a3\u76845\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba52% \uff0c\u800c\u63a5\u53d7\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u75c5\u60a3\u76845\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba40% \uff0c\u5176\u6709\u7d71\u8a08\u5b78\u4e0a\u5dee\u7570(p=0.015)\u3002\u591a\u56e0\u5b50\u5206\u6790\u78ba\u8a8d\u795e\u7d93\u4fb5\u72af\u8207\u58de\u6b7b\u70ba\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u624b\u8853\u5408\u4f75\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u6bd4\u55ae\u7368\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u6709\u8f03\u597d\u7684\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u4f46\u5c0d\u5b58\u6d3b\u7387\u7121\u660e\u986f\u5dee\u7570\uff0c\u795e\u7d93\u4fb5\u72af\u8207\u58de\u6b7b\u70ba\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002", "e": "Purpose: To evaluate treatment results and analyze pathological prognostic factors in surgery plus postoperative radiotherapy and radiotherapy alone for hypopharyngeal cancer.\nMaterials and Methods: This retrospective analysis is based on the clinical outcome of 81 patients with hypopharyngeal cancer treated with surgery plus adjuvant radiotherapy and radiotherapy alone from January 1987 to December 1997. There were 79 males and 2 females, between 24 and 80 years old (median: 54). The numbers of patients in stages I to IV were 0, 3, 22 and 56, respectively. There were no significant difference in T- and N-distributions between the two treatment groups. Radiotherapy alone was used in 18 patients with 1.8 Gy pen fraction per day to a mean total dose of 63.9 Gy (range 34.2 to 75.6 Gy). Surgical treatment for 63 patients consisted of total laryngectomy with partial or total pharyngectomy and esophagectomy when indicated. These patients received ad]uvant radiotherapy to a mean dose of 60.4Gy (range 36 to 73.8 Gy).\nResults: The 5-year survival rates were 33% for patients treated with surgery plus adjuvant radiotherapy and 30% for patients treated with radiotherapy alone. There was no significant difference in survival between the two treatment groups. The local control rate at 5 years was 52% for patients treated with surgery plus adjuvant radiotherapy, compared with 40% for patients treated with radiotherapy alone with a significant difference (p = 0.015). Multivariate analysis identified that perineural invasion and necrosis are the significant predictors of poorer survival.\nConclusion: The combination of surgery plus radiotherapy results in a better locoregional control than radiotherapy alone, but dose not yield a better survival. Perineural invasion and necrosis are associated with poorer survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-261-268-a", "title": "A Phase \u2161 Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx", "keywords": "\u5e72\u64fe\u7d20;\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642 interferon;NPC;Radiotherapy", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u540c\u6642\u80fd\u8a55\u4f30\u5408\u6210\u5e72\u64fe\u7d20\u6cbb\u7642\u5206\u5316\u4e0d\u826f\u9f3b\u54bd\u764c\u60a3\u8005\u4e4b\u7642\u6548\uff0c\u6211\u5011\u57f7\u884c\u4e86\u4e00\u500b\u7b2c\u4e8c\u671f\u81e8\u5e8a\u8a08\u5283\uff0c\u5c07\u5ee3\u6c3e\u6027\u9f3b\u54bd\u764c\u60a3\u8005\u5148\u4ee5\u5e72\u64fe\u7d20\u6cbb\u7642\u6578\u9031\u4ee5\u6e96\u5099\u653e\u5c04\u6cbb\u7642\uff0c\u518d\u540c\u6b65\u9032\u884c\u653e\u5c04\u6cbb\u7642\u8207\u5e72\u64fe\u7d20\u6ce8\u5c04\uff0c\u89c0\u5bdf\u5e72\u64fe\u7d20\u5728\u9f3b\u54bd\u764c\u6cbb\u7642\u4e4b\u89d2\u8272\u3002\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5171\u670914\u4f4d\u60a3\u8005\u9032\u5165\u6b64\u7814\u7a76\u63a5\u53d7\u5e72\u64fe\u7d20300\u842c\u55ae\u4f4d\uff0c\u4e00\u9031\u4e09\u6b21\u7684\u76ae\u4e0b\u6ce8\u5c04\u7684\u6cbb\u7642\uff0c\u5e73\u5747\u6cbb\u7642\u516d\u9031\u5f8c\uff0c\u521d\u6b65\u8a55\u4f30\u5176\u7642\u6548\uff0c\u800c\u5f8c\u75c5\u60a3\u63a5\u53d7\u6bcf\u5929180\u81f3200cGy\u4e0d\u7b49\u7684\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u5171\u8a087000cGy\u3002\u5176\u9593\u75c5\u60a3\u4ecd\u7136\u63a5\u53d7\u76f8\u540c\u5291\u91cf\u7684\u5e72\u64fe\u7d20\u76ae\u4e0b\u6ce8\u5c04\u3002\n\u7d50\u679c\uff1a\u5171\u8a08\u670913\u4f4d\u60a3\u8005\u5f97\u4ee5\u8a55\u4f30\u55ae\u7528\u5e72\u64fe\u7d20\u7684\u7642\u6548\uff0c\u7121\u75c5\u60a3\u53ef\u89c0\u5bdf\u5230\u660e\u986f\u7684\u816b\u7624\u6291\u5236\u4f5c\u7528\uff0c7\u4f4d\u60a3\u8005\u816b\u7624\u53cd\u800c\u6709\u7e7c\u7e8c\u589e\u9577\u7684\u8da8\u52e2\u3002\u5176\u4e2d\u670912\u4f4d\u60a3\u8005\u63a5\u53d7\u4f75\u7528\u5e72\u64fe\u7d20\u8207\u653e\u5c04\u6cbb\u7642\u7684\u6cbb\u7642\uff0c\u5168\u90e8\u60a3\u8005\u7686\u80fd\u6709\u660e\u986f\u800c\u5feb\u901f\u7684\u816b\u7624\u7e2e\u5c0f\uff0c83%\u75c5\u7076\u5b8c\u5168\u6d88\u5931\uff0c\u7136\u800c100%\u7684\u60a3\u8005\u6709\u7b2c\u4e09\u5ea6\u5de6\u53f3\u7684\u54bd\u5589\u7c98\u819c\u708e\u4e14\u9700\u66ab\u6642\u4e2d\u65b7\u653e\u5c04\u6cbb\u7642\u3002\u5176\u5b83\u7684\u6bd2\u6027\u53cd\u61c9\u5982\u767c\u71d2\u3001\u75b2\u5026\u3001\u9aa8\u9abc\u9178\u75db\u7b49\u5168\u8eab\u7684\u75c7\u72c0\u591a\u5c6c\u8f15\u5fae\uff0c\u80fd\u4ee5\u89e3\u71b1\u9000\u71d2\u5291\u6709\u6548\u7684\u63a7\u5236\u3002\u7d93\u904e\u9577\u671f\u7684\u8ffd\u8e64\uff08\u6700\u9577\u8d85\u904e10\u5e74\uff09\uff0c\u8a08\u6709\u516d\u4f4d\u60a3\u8005\u6b7b\u65bc\u9060\u7aef\u8f49\u79fb\uff0c\u4e8c\u4f8b\u60a3\u8005\u6709\u5c40\u90e8\u5fa9\u767c\u7684\u73fe\u8c61\u3002\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba26\u500b\u6708\u3002\n\u7d50\u8ad6\uff1a\u55ae\u7528\u5e72\u64fe\u7d20\u5728\u9f3b\u54bd\u764c\u70ba\u4e00\u7121\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u7136\u800c\u537b\u6709\u660e\u986f\u7684\u653e\u5c04\u589e\u654f\u4f5c\u7528\uff0c\u96d6\u7136\u5b58\u6d3b\u671f\u8207\u5c40\u90e8\u63a7\u5236\u7387\u4e26\u672a\u6709\u7a81\u51fa\u4e4b\u8655\uff0c\u672c\u7814\u7a76\u63d0\u4f9b\u4e86\u5e72\u64fe\u7d20\u589e\u5f37\u653e\u5c04\u6cbb\u7642\u6548\u679c\u7684\u4e00\u500b\u81e8\u5e8a\u4f50\u8b49\uff0c\u5c0d\u672a\u4f86\u767c\u5c55\u4f75\u7528\u5e72\u64fe\u7d20\u8207\u653e\u5c04\u6cbb\u7642\uff0c\u6211\u5011\u4ecd\u6301\u6a02\u89c0\u7684\u614b\u5ea6\u3002", "e": "Purpose: To determine the efficacy of recombinant interferon alfa-2b (Intron A) (rIFN) in the treatment of primary untreated undifferentiated nasopharyngeal carcinoma (NPC) before radiotherapy and to determine the efficacy and feasibility of combined rIFN and radiotherapy concomitantly.\nMaterial and Patients: Fourteen patients enrolled in this study. All of them had histologically proved locally advanced NPC. Patients received rIFN subcutaneous injection with dose of 3 x 10^8 U/body, three times a week for a median of 6 weeks. Then rIFN was continued during the following 7 weeks\u2019 radiotherapy period with the same dose and schedule. Radiotherapy consisted of 70 Gy of boo-regional irradation with conventional fractionation. Toxicities and response were evaluated. A long follow-up report was performed.\nResults: There was no observed response from neoadjuvant rIEN treatment in 13 evaluable patients. Twelve of them received scheduled radiotherapy as well as rIFN treatment. All of them had rapid tumor shrinkage, 10 of them (83%) had complete response after radiotherapy. The oropharyngeal mucositis (\u2267grade 3) toxicity was quite substantial, and most patients had been forced to interrupt to radiotherapy course. There were two patients with locally failure and 6 had distant metastases. The median survival for those 12 patients who received complete course of treatment was 26 months (range: 20-140+months).\nDiscussion: Interferon single agent is not effective in NPC therapy. The combined use of rlFN and radiotherapy has resulted in a higher oropharyngeal mucositis rate from the radiosensitization effect of rIFN, but it does not translate to a higher local control rate nor lower distant failure rate. The benefit of adjunctive use of rIFN is not evident from this small series of study. In viewing of the better tolerance of rIFN than chemotherapy by most patients, the radiosensitization effect of rIFN can be further studied and explored."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-269-276-a", "title": "\u6210\u4eba\u4f4e\u60e1\u6027\u5ea6\u9871\u5167\u661f\u72c0\u7d30\u80de\u7624\u4e4b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642", "keywords": "\u9871\u5167\u661f\u72c0\u7d44\u80de\u7624;\u9810\u5f8c\u56e0\u5b50;\u653e\u5c04\u6cbb\u7642;\u5b58\u6d3b\u7387 Intracranial low grade astrocytoma;Radiotherapy;Survival", "c": "\u76ee\u7684\uff1a\u4f4e\u60e1\u6027\u5ea6\u8166\u7624\u7684\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u5c24\u5176\u662f\u661f\u72c0\u7d30\u80de\u7624\u7684\u8655\u7406\u662f\u500b\u722d\u8b70\u6027\u7684\u8ab2\u984c\uff0c\u672c\u7814\u7a76\u63a2\u8a0e\u4f4e\u60e1\u6027\u5ea6\u661f\u72c0\u7d30\u80de\u8166\u7624\u7684\u9810\u5f8c\u56e0\u5b50\u4e26\u5c0d\u5176\u6cbb\u7642\u505a\u4e00\u500b\u56de\u9867\u8207\u8a55\u4f30\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a1979\u5e74\u81f31988\u5e74\u9593\uff0c\u5171\u670946\u4f4d\u4f4e\u60e1\u6027\u5ea6\u661f\u72c0\u7d30\u7528\u5305\u8166\u7624\u7684\u6210\u4eba\u60a3\u8005\u5728\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u5b8c\u6210\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u3002\u4ed6\u5011\u5e74\u7d00\u5f9e15\u6b72\u81f363\u6b72\uff0c\u4e2d\u9593\u503c\u662f32\u6b72\u3002\u670925\u4f4d\u7537\u6027\uff0c21\u4f4d\u5973\u6027\u3002\u6839\u64daKernohan\u7684\u75c5\u7406\u5206\u671f\u6a19\u6e96\uff0c\u9019\u4e9b\u75c5\u4eba\u670910\u4f4d\u60a3\u8005\u5c6c\u7b2c\u4e00\u7d1a\uff0c36\u4f4d\u5c6c\u7b2c\u4e8c\u7d1a\u3002\u5176\u4e2d11\u4f4d\u75c5\u4eba\u63a5\u53d7\u816b\u7624\u5b8c\u5168\u5207\u9664\u8853\uff0c17\u4f4d\u63a5\u53d7\u90e8\u4efd\u5207\u9664\u8853\uff0c\u800c\u53e618\u4f4d\u53ea\u63a5\u53d7\u5207\u7247\u6aa2\u67e5\uff0c\u4e26\u6c92\u6709\u5207\u9664\u816b\u7624\u3002\u958b\u5200\u5f8c\uff0c46\u4f4d\u60a3\u8005\u90fd\u6709\u5f88\u597d\u7684\u884c\u52d5\u6307\u6a19(Performance status)\u3002\u6bcf\u4f4d\u75c5\u4eba\u90fd\u63a5\u53d7Co-60\u6216\u767e\u842c\u96fb\u5b50\u4f0f\u7279\u4ee5\u4e0a\u7684\u5149\u5b50\u5c04\u7dda\u6cbb\u7642\u3002\u6cbb\u7642\u5291\u91cf\u5f9e44-66Gy\u4e0d\u7b49\uff0c\u5291\u91cf\u7684\u4e2d\u9593\u503c\u662f60Gy\u3002\u6c92\u6709\u60a3\u8005\u5728\u4e00\u958b\u59cb\u4fbf\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u7684\u5b58\u6d3b\u7387\u662f49%\uff0c\u5973\u6027\u6bd4\u7537\u6027\u60a3\u8005\u6709\u8f03\u597d\u7684\u5b58\u6d3b\u7387(54% vs. 24%, P=0.015)\uff1b\u5e74\u9f61\u5c0f\u65bc\u6216\u7b49\u65bc30\u6b72\u8005\u6bd4\u5e74\u7d00\u5927\u7684\u75c5\u4eba\u6709\u8f03\u597d\u7684\u6cbb\u7642\u7d50\u679c(47% vs. 30%, P=0.035)\uff1b\u75c5\u7406\u5206\u671f\u5c6c\u7b2c\u4e00\u7d1a\u8005\u6bd4\u7b2c\u4e8c\u7d1a\u8005\u9810\u5f8c\u8f03\u597d(69% vs. 30%, P=0.04)\uff1b\u958b\u5200\u7bc4\u570d\u7684\u5927\u5c0f\u4e26\u4e0d\u5f71\u97ff\u9810\u5f8c\uff0c\u4f46\u6709\u958b\u5200\u5207\u9664\u8005\u6bd4\u53ea\u505a\u5207\u7247\u8005\u6709\u8f03\u597d\u7684\u4e94\u5e74\u5b58\u6d3b\u7387(44% vs. 32%, P=0.05) \uff1b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u7684\u9ad8\u4f4e\u5c0d\u9810\u5f8c\u4e26\u7121\u5be6\u8cea\u7684\u5f71\u97ff\u3002\n\u7d50\u8ad6\uff1a\u6839\u64da\u6211\u5011\u6cbb\u7642\u7684\u7d50\u679c\u767c\u73fe\u4f4e\u60e1\u6027\u5ea6\u661f\u72c0\u7d30\u80de\u7624\u75c5\u4eba\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u7d50\u679c\u4e26\u4e0d\u4f73\uff0c\u5176\u4e2d\u66f4\u4ee5Kemohan\u7b2c\u4e8c\u7d1a\u75c5\u4eba\u7684\u8868\u73fe\u8f03\u5dee\u3002\u56e0\u6b64\u5c0b\u6c42\u66f4\u7a4d\u6975\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\u61c9\u662f\u512a\u5148\u8003\u91cf\u7684\u8ab2\u984c\u3002", "e": "Purpose: It got no consensus about the therapy of low grade glioma, especially for the low grade astrocytoma. We have retrospectively reviewed the results of radiotherapy for low grade astrocytoma, and define the role of postoperative radiotherapy in the treatment of low grade astrocytoma. Materials and Methods: From 1979 to 1988, 46 adult patients with low grade astrocytoma received postoperative radiotherapy in Chang Gung Memorial Hospital-Linkou Medical Center. The median age of these patients was 32 years old with the range from 15 to 63. There were 25 male and 21 female. According to the Kernohan's grading system, 10 patients' tumors belonged to grade 1 and the others belonged to grade 2. Eleven patients received total removal of tumors, 17 patients received subtotal excision of tumors, and 18 patients received biopsy only. All patients had good performance status (Karnofsky scale \uff1e 70) after operation. For radiotherapy, the median total dose was 6000 cGy on each patient, ranging from 4400 to 6600 cGy. No patient received chemotherapy at the beginning.\nResult: The overall 5 year survival was 49%. Female had better survival than male (54% vs 24%, p=O.O15). Younger patients had better results than older patients (47% vs 30%, p0.04). Patients with grade I tumors had better survival than patients with grade Ii tumors (69% vs 30%, p=O.O4). Patients received excision surgery had better survival rate (44% vs 32 %, p=0.05), but the extent of surgery did not make the difference. Total radiation dose did not significantly change the survival result. \nDiscussion: The low grade astrocytoma patients showed poor survival rate after radiotherapy, especially for patients with grade II tumor. To properly treat patients with low-grade astrocytorma is a more important issue than to consider the incidence of radiation complications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-277-283-a", "title": "The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer", "keywords": "\u5b58\u6d3b\u7387;\u653e\u5c04\u6cbb\u7642;\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c Survival;Radiotherapy;Advanced non-small cell lung cancer", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u4e4b\u9069\u7576\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5171\u670989\u540d\u75c5\u60a3\u65bc1992\u5e747\u6708\u81f31997\u5e746\u9593\u5230\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u6c42\u8a3a\u3002\u5176\u4e2d63\u4f4d\u66fe\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u53e6\u591623\u4f4d\u5247\u5426\u3002\u5c0d\u65bc\u7b2c\u4e09\u671f\u4e4b\u75c5\u60a3\u5c07\u7d66\u4e88\u80f8\u8154\u653e\u5c04\u6cbb\u7642\uff0c\u800c\u7b2c\u56db\u671f\u4e4b\u75c5\u60a3\u5247\u53ea\u91dd\u5c0d\u8f49\u79fb\u90e8\u4f4d\u6216\u5f15\u8d77\u4e4b\u75c7\u72c0\u7d66\u4e88\u653e\u5c04\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u76f8\u5c0d\u65bc\u6c92\u6709\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u4eba\u6bd4\u8f03\u8d77\u4f86\uff0c\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e26\u6c92\u6709\u5b58\u6d3b\u7387\u589e\u52a0\u4e4b\u512a\u9ede\u3002\n\u7d50\u8ad6\uff1a\u80f8\u8154\u653e\u5c04\u6cbb\u7642\u4e26\u4e0d\u80fd\u589e\u52a0\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u4eba\u4e4b\u5b58\u6d3b\u7387\u3002", "e": "Purpose: To re-evaluate the appropriateness of thoracic radiotherapy (AT) for patients with advanced non-small coil lung cancer (NSCLC).\nMaterials and Methods: This retrospective study included 89 patients with advanced NSCLC registered in Mackay Memorial Hospital from July 1992 to Juno 1997. Thoracic RT was given with radical or palliative intent depending on the stage and/or performance status at diagnosis to 63 (the AT group) but had withheld in 26 (the non-AT group). The total dose to the primary tumor was in the range of 5000-6000 cGy at 180 cGy per fraction over 5-6.5 weeks. Tumor control was strictly defined as complete disappearance of tumor on all radiographic examinations and/or no evidence of disease clinically at the last follow up.\nResults: No survival advantage was noted in the AT group compared to the non-AT group (median 3.0 vs. 5.5 months). The mean survival time of patients with stage Ill disease was 11.37 \u00b1 1.94 months and median survival time was 8 months. The control rate in the AT group was poor with only 4 of 63 (6%) disease-free on the last follow up. One of four patients who were disease-free died of radiation pneumonitis about 3 months after complete of AT. In addition, one patient with stage lllb was still alive, undergoing chemotherapy for distant metastasis.\nConclusion: Thoracic RT did not prolong survival for patients with locally advanced NSCLC."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-285-291-a", "title": "\u809d\u764c\u6cbb\u7642\u6838\u91ab\u85e5\u7269[(\u4e0a\u6a19 125)I/(\u4e0a\u6a19 131)I]Iododeoxyuridine\u4e4b\u5408\u6210\u8207\u914d\u65b9\u7814\u7a76", "keywords": "\u6838\u91ab\u85e5\u7269;\u816b\u7624\u6cbb\u7642;5-iodo-2", "c": "\u76ee\u7684\uff1a\u809d\u764c\u662f\u76ee\u524d\u53f0\u7063\u7537\u6027\u60e1\u6027\u816b\u7624\u6b7b\u4ea1\u7387\u6700\u9ad8\u7684\u764c\u75c7\uff0c\u672c\u6587\u6558\u8ff0\u809d\u764c\u653e\u5c04\u6cbb\u7642\u85e5\u7269\u5c11[(\u4e0a\u6a19 125)I]IUdR\u4e4b\u6cbb\u7642\u6a5f\u5236\u3001\u88fd\u5099\u65b9\u6cd5\u53ca\u5b89\u5b9a\u6027\u5206\u6790\u3002\n\u6750\u6599\u8207\u53bb\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u81ea\u884c\u5408\u6210\u4e4b5-tributylstannyl-2'-deoxyuridine(Bu3SnUdR) \u70ba\u524d\u9a45\u7269\u9032\u884c\u653e\u5c04\u6027\u7898\u6a19\u5e5f\uff0c\u53cd\u61c9\u5b8c\u6210\u5f8c\u52a0\u5165\u9069\u91cfgentlsic acid\uff0c\u518d\u7d93\u51b7\u51cd\u6fc3\u7e2e\u7d14\u5316\u5373\u5f97\u5230[(\u4e0a\u6a19 125)I/(\u4e0a\u6a19 131)I]lUdR\u51cd\u6676\u5c0f\u74f6\u6210\u54c1\u3002\n\u7d50\u679c\uff1a\u81ea\u88fd\u4e4b[(\u4e0a\u6a19 125)I/(\u4e0a\u6a19 131)I]IUdR \u51cd\u6676\u5c0f\u74f6\uff0c\u65bc\u4f7f\u7528\u524d\u52a0\u5165\u9069\u91cf\u751f\u7406\u98df\u9e7d\u6c34\u6216lipiodol\u6eb6\u6db2\u914d\u6210\u6240\u9700\u4e4b\u653e\u5c04\u6d3b\u6027\u6fc3\u5ea6\uff0c\u5373\u53ef\u4f9b\u809d\u764c\u6216\u5176\u4ed6\u60e1\u6027\u816b\u7624\u6cbb\u7642\u7814\u7a76\u4e4b\u7528\u3002\u4e8c\u7a2e\u914d\u65b9\u4e4b\u6eb6\u6db2\u653e\u5c04\u5316\u5b78\u7d14\u5ea6\u5747\u53ef\u905497%\u4ee5\u4e0a\u3002\u672c\u7814\u7a76\u9032\u884c\u4e00\u7cfb\u5217\u4e4b[(\u4e0a\u6a19125)I/(\u4e0a\u6a19 131)I]IUdR\u5b89\u5b9a\u6027\u8a66\u9a57\uff0c\u7d50\u679c\u986f\u793a\u6dfb\u52a0gntsic acid\u5c0d[(\u4e0a\u6a19 125)I/(\u4e0a\u6a19 131)l]IUdR\u6eb6\u6db2\u6216\u51cd\u6676\u6210\u54c1\u5747\u53ef\u660e\u986f\u589e\u52a0\u5176\u8caf\u5b58\u5b89\u5b9a\u6027\uff0c\u800c\u51cd\u6676\u6210\u54c1\u4e4b\u5b89\u5b9a\u6027\u9060\u64fe\u65bc\u6eb6\u6db2\u6210\u54c1\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u88fd\u5099\u5b8c\u6210\u4e4b[(\u4e0a\u6a19 125)I/(\u4e0a\u6a19 131)I]IUdR \u6838\u91ab\u85e5\u7269\uff0c\u653e\u5c04\u5316\u5b78\u7d14\u5ea6\u9ad8\u4e14\u5b89\u5b9a\u6027\u4f73\uff0c\u53ef\u63d0\u4f9b\u570b\u4eba\u9032\u884c\u809d\u764c\u6216\u5176\u4ed6\u60e1\u6027\u816b\u7624\u6cbb\u7642\u7814\u7a76\u4e4b\u7528\u3002", "e": "Purpose: Hepatoma is one of the most prevalent male cancers in Taiwan. This paper investigates the interaction mechanism, preparation, formulation and stability of 5-[(superscript 125)I/(superscript131)I]-iodo-2'-deoxyuridine as a potential radiopharmaceutical for hepatoma and cancers treatment.\nMaterials and Methods: The self-synthesized 5-ributylstannyl-2\u2019-deoxyuridine (Bu3SnUdR), used as a precursor, was radioiodinated to produce [(superscript 125)I/(superscript 131)I]IUdR. After adding the stabilizer, gentisic acid, the resultant reaction mixture was dispensed and lyophilized to give the [(superscrip 125)I/(superscrip 131)I]IUdR hot kits.\nResults: The lyophilized [(superscript 125)I/(superscript 131)I]IUdR hot kit was added with an appropriate amount of normal saline or lipiodol prior to preclinieal hepatoma treatment studies. The radiochemical purity for the studied formulation was higher than 97%. When gentisic acid was used as a stabilizer, the stability of [(superscript 125)I/(superscript 131)I]IUdR was significantly increased, and the stability of lyophilized form is far better than that of solution form.\nConclusion: A stable radiopharmaceutical [(superscript 125)I/(superscript 131)I]IUdR with high radioehemical purity and specific activity was prepared in this study. Its use for preclinieal and clinical studies on hepatoma and cancers therapy will be carried out in the further investigation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-293-302-a", "title": "Study of Treatment Variation in the Radiotherapy of Pelvic Tumors Using a New Custom-Made Immobilization Cast and On-Line Electronic Portal Imaging", "keywords": "\u56fa\u5b9a\u88dd\u7f6e;\u4e09\u5ea6\u7a7a\u554f\u9806\u5f62\u6cbb\u7642;\u7167\u91ce\u5f71\u50cf;\u64fa\u8a2d\u8aa4\u5dee;\u71b1\u7194\u5851\u81a0\u6a21\u5177 Immobilization;Three-dimensional conformal radiotherapy;Portal imaging;Setup errors;Thermoplastic cast", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u672c\u79d1\u6240\u7814\u767c\u9aa8\u76c6\u8154\u56fa\u5b9a\u88dd\u7f6e\u4f7f\u7528\u65bc\u653e\u5c04\u6cbb\u7642\u7684\u60c5\u5f62\u53ca\u5176\u6e96\u78ba\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6700\u65b0\u81ea\u88fd\u5f0f\u9aa8\u76c6\u8154\u56fa\u5b9a\u88dd\u7f6e\u80fd\u63d0\u4f9b\u75c5\u4eba\u7a69\u5b9a\u53ca\u8212\u670d\u7684\u59ff\u52e2\uff0c\u6b64\u88dd\u7f6e\u5305\u62ec\u4e00\u5e73\u5766\u5805\u56fa\u7684\u58d3\u514b\u529b\u5e95\u677f\u53ca\u71b1\u7194\u5851\u81a0\u6a21\u5177\u3002\u6709\u516b\u4f4d\u75c5\u4eba\u4f7f\u7528\u6b64\u88dd\u7f6e\u57285-8\u65e5\u5167\u6bcf\u5929\u5229\u7528\u96fb\u5b50\u5f0f\u7167\u91ce\u5f71\u50cf\u7cfb\u7d71(EPI)\u4f5c\u6cbb\u7642\u4e2d\u7684\u5373\u6642\u53d6\u6a23\uff0c\u53e6\u6709\u5341\u4f4d\u75c5\u60a3\u6c92\u6709\u4f7f\u7528\u56fa\u5b9a\u5668\uff0c\u505a\u70ba\u5c0d\u7167\u7d44\uff0c\u7e3d\u5171\u53d6221\u5f35\u7684EPI\u5f71\u50cf\u3002\u7d93\u96fb\u8166\u5f71\u50cf\u8655\u7406\u8edf\u9ad4\u7684\u5354\u52a9\u8207\u4f7f\u7528\u8005\u4e92\u52d5\u7684\u65b9\u5f0f\uff0c\u53ef\u4ee5\u7531\u5f71\u50cf\u4e2d\u5f97\u5230\u7167\u91ce\u64fa\u8a2d\u7684\u5e7e\u4f55\u8aa4\u5dee\uff0c\u4e26\u9032\u4e00\u6b65\u8a08\u7b97\u51fa\u6bcf\u4e00\u4f4d\u75c5\u4eba\u7684\u7cfb\u7d71\u8aa4\u5dee\u53ca\u4efb\u610f\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a\u63a1\u7528\u6b64\u56fa\u5b9a\u88dd\u7f6e\u78ba\u5be6\u660e\u986f\u6539\u9032\u6bcf\u65e5\u7684\u75c5\u4eba\u64fa\u8a2d\u8aa4\u5dee\uff0c\u82e5\u662f\u6bd4\u8f03\u5728\u75c5\u4eba\u524d\u5f8c(A-P)\uff0c\u5de6\u53f3(L-R)\uff0c\u8173\u982d(I-S)\u5411\u7684\u8aa4\u5dee\uff0c\u6709\u4f7f\u7528\u56fa\u5b9a\u88dd\u7f6e\u5206\u5225\u70ba-0.1\u00b12.2\u5e73\u65b9\u516c\u5398\uff0c-0.4\u00b11.2\u5e73\u65b9\u516c\u5398\uff0c3.6\u00b12.3\u5e73\u65b9\u516c\u5398\uff0c\u6c92\u6709\u4f7f\u7528\u56fa\u5b9a\u88dd\u7f6e\u5206\u5225\u70ba-0.4\u00b12.4\u5e73\u65b9\u516c\u5398\uff0c1.2\u00b11.9\u5e73\u65b9\u516c\u5398\uff0c-1.1\u00b13.8\u5e73\u65b9\u516c\u5398 \u3002\u6839\u64da\u6bcf\u4f4d\u75c5\u4eba\u8a08\u7b97\u51fa\u4f86\u7684\u524d\u5f8c(AP)\u6216\u5f8c\u524d(PA)\u53ca\u5de6\u53f3(LR)\u7167\u91ce\u4f4d\u7f6e\u8aa4\u5dee\uff0c\u6709\u8d85\u904e5\u5e73\u65b9\u516c\u5398\u8aa4\u5dee\u4ee5\u4e0a\u7684\u5728\u4f7f\u7528\u56fa\u5b9a\u88dd\u7f6e\u5206\u5225\u70ba14%\u53ca33%\uff1b\u6c92\u4f7f\u7528\u56fa\u5b9a\u88dd\u7f6e\u5247\u5206\u5225\u70ba60%\u53ca89%\uff08\u524d\u5f8c\u7167\u91ce\u53ca\u5de6\u53f3\u7167\u91ce\u6bd4\u8f03\u4e4bp\u503c\u5206\u5225\u70ba0.065\u53ca0.024\uff09\u3002\n \u7d50\u8ad6\uff1a\u6b64\u81ea\u88fd\u5f0f\u9aa8\u76c6\u8154\u56fa\u5b9a\u88dd\u7f6e\uff0c\u5c0d\u65bc\u9aa8\u76c6\u8154\u816b\u7624\u7684\u653e\u5c04\u6cbb\u7642\u80fd\u6539\u9032\u75c5\u4eba\u64fa\u8a2d\u7684\u91cd\u8907\u6027\u3002\u6b64\u7a2e\u88dd\u7f6e\u81ea\u524d\u5df2\u4f8b\u884c\u6027\u4f7f\u7528\u65bc\u672c\u79d1\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u6cbb\u7642\u6280\u8853\uff0c\u6211\u5011\u4e5f\u5efa\u8b70\u80fd\u5920\u4f7f\u7528\u65bc\u6240\u6709\u9aa8\u76c6\u8154\u7684\u653e\u5c04\u6cbb\u7642\u3002", "e": "Purpose: To evaluate and quantify the accuracy using a new custom-made pelvis immobilization device during the course of radiotherapy.\nMaterials and Methods: A new custom-made pelvic immobilization cast had been developed to provide a stable and comfort position of the patients. It consists of a flat and rigid acrylic plate and thermoplastic cast. Eight patients with pelvic cast were evaluated by on line electronic portal imaging during daily radiotherapy treatment for 5 to 8 consecutive days. While another 10 patients without pelvic casts were used as a control. A total of 221 electronic portal imaging (EPI) were reviewed. Under the assistance of image registration software, the geometric errors from the EPI was identified by interactive techniques. The systematic and random setup errors for each patient were determined.\nResults: Daily set-up variation was markedly improved using the cast. The total directed setup errors for all patients in anterior-posterior (AP), left-right (LR) and inferior-superior (IS) directions were -0.1\u00b12.2 mm, -0.4\u00b11.2 mm and -0.3 \u00b12.0 mm respectively with cast as compared to -0.4\u00b12.4 mm, 1.2\u00b11.9 mm and -1.1\u00b13.8 mm respectively without cast. The suggested margin, which was calculated according to the total undirected setup error for each patient, in AP/PA and lateral fields for more than 5 mm were found in 14% and 33% of patients with casts as compared to 60% and 89% of patients without immobilization cast. (p value = 0.065 for AP/PA fields and p value = 0.024 for lateral fields)\nConclusion: This custom-made pelvic immobilization cast appears to improve the reproducibility of patient setup during radiotherapy for pelvic tumors. In application to 3-D conformal radiotherapy, this type of immobilization is now routinely used in our department and is recommended for all patients receiving pelvic radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-303-310-a", "title": "\u4e09\u5ea6\u7a7a\u9593\u96fb\u8166\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u4e4b\u9a57\u6536\u8207\u6e2c\u8a66", "keywords": "\u4e09\u5ea6\u7a7a\u554f\u96fb\u8166\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71;\u9a57\u6536\u904e\u7a0b;\u5c04\u675f\u8cc7\u6599;\u81e8\u5e8a\u61c9\u7528 3-D RTP;ATP;Beam data;Clinical application", "c": "\u76ee\u7684\uff1a\u5982\u4f55\u4f7f\u4e09\u5ea6\u7a7a\u9593\u96fb\u8166\u653e\u5c04\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71(3-D radiotherapy Treatment Planning System, 3-D RTP)\u8a08\u7b97\u6240\u5f97\u4e4b\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u4f48\u8207\u6c34\u5047\u9ad4\u91cf\u6e2c\u51fa\u4f86\u4e4b\u7d50\u679c\u53d6\u5f97\u5408\u7406\u7684\u4e00\u81f4\u6027\uff0c\u662fRTP\u9a57\u6536\u904e\u7a0b(Acceptance Test Procedure, ATP)\u4e2d\u91cd\u8981\u7684\u8ab2\u984c\uff0c\u4e5f\u662f\u75c5\u4eba\u63a5\u53d7\u9ad8\u54c1\u8cea\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u91cd\u8981\u56e0\u7d20\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u6587\u4fc2\u91dd\u5c0dComputerized Medicals System-Focus 1.4.0 \u53caHelax-TMS 4.0\u7248\u7cfb\u7d71\u9010\u9805\u4f5c\u4e00\u9a57\u6536\u6e2c\u8a66\uff0c\u4e26\u4e14\u8a55\u4f30\u5176\u9593\u4e4b\u8aa4\u5dee\u503c\u662f\u5426\u5408\u7406\u4ee5\u53ca\u904b\u7528\u65bc\u81e8\u5e8a\u4e0a\u4e4b\u6cbb\u7642\u662f\u5426\u53ef\u884c\u3002ATP\u5206\u6210\u786c\u9ad4\u53ca\u8edf\u4f11\u5169\u90e8\u4efd\uff0c\u786c\u9ad4\u5305\u62ec\u7db2\u8def\u4e4b\u9023\u7d50\u53ca\u5f71\u50cf\u4e4b\u50b3\u8f38\u529f\u80fd\uff0c\u5c6c\u65bc3-D RTP\u672c\u8eab\u6578\u4f4d\u677f(digitizer)\u7684\u6e96\u78ba\u6027\uff0c\u7e6a\u5716\u6a5f\u7684\u653e\u5927\u7387\u53ca\u6e96\u78ba\u5ea6\u53ca\u75c5\u4eba\u8cc7\u6599\u4fdd\u5b58(backup)\u4e4b\u5b8c\u6574\u6027\u8207\u65b9\u4fbf\u6027\u3002\u8edf\u9ad4\u90e8\u4efd\u6709\u5149\u5b50\u53ca\u96fb\u5b50\u5c04\u675f\u7684\u767e\u5206\u6df1\u5ea6\u5291\u91cf(Percentage Depth Dose)\u3001\u7b49\u5291\u91cf\u66f2\u7dda\u5206\u4f48(isodose distribution)\u53ca\u5c04\u675f\u5256\u9762\u5716(beam profile)\u7684\u6bd4\u5c0d\uff1b\u4ee5\u53ca\u91dd\u5c0d\u5149\u5b50\u5c04\u6771\u7684\u958b\u653e\u6027\u7167\u91ce(open-field)\u3001\u6954\u5f62\u6ffe\u677f(wedge)\u3001\u7d44\u7e54\u586b\u5145\u7269(bolus)\u3001\u975e\u5747\u52fb\u5bc6\u5ea6\u7d44\u7e54(inhomogenities)\u3001\u925b\u64cb\u584a(block)\u53ca\u591a\u8449\u578b\u6e96\u76f4\u5100(Multi-Leaf collimator, MLC)\u4fee\u6b63\u5f8c\u7684\u5291\u91cf\u6bd4\u5c0d\uff1b\u53e6\u5916\u96fb\u5b50\u7684\u659c\u89d2\u5ea6\u5291\u91cf\u5206\u4f48(oblique incidence)\u4e5f\u662f\u9a57\u6536\u9805\u76ee\u3002\u7531\u65bc\u6cbb\u7642\u8a08\u756b\u662f\u4ee5\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u70ba\u57fa\u790e\uff0c\u56e0\u6b64\u9662\u5167\u653e\u5c04\u6cbb\u7642\u7db2\u8def\u7cfb\u7d71(SIEMENS LANTIS)\u4e4b\u9023\u7d50\u53ca\u5f71\u50cf\u50b3\u8f2a\u7cfb\u7d71\u4e4b\u8a2d\u65bd\u4ea6\u9700\u91dd\u5c0d\u5176\u7279\u9ede\u9010\u4e00\u9a57\u6536\u6e2c\u8a66\uff0c\u4ee5\u5229\u65bc\u6574\u9ad4\u4e4b\u61c9\u7528\u64cd\u4f5c\u3002\n\u7d50\u679c:\u4ee5Helax-TMS\u800c\u8a00\uff0c\u958b\u653e\u6027\u7167\u91ce\u90e8\u4efd\uff0c\u82e5\u7167\u91ce\u5927\u65bc\u529f 20\u00d720\u5247\u89ed\u89d2\u6548\u61c9(horn effect)\u6703\u660e\u986f\u589e\u5927\uff0c\u6700\u5927\u7d042%\u7684\u5291\u91cf\u8aa4\u5dee\u3002\u800c\u6954\u5f62\u6ffe\u677f\u90e8\u4efd\u7167\u91ce\u4e0d\u5b9c\u904e\u5927\uff0c\u82e5\u7167\u91ce\u5927\u65bc10\u00d710\u524745\u00b0\u53ca60\u00b0\u6954\u5f62\u6ffe\u677f\u6703\u6709\u7d043%\u4e4b\u5291\u91cf\u8aa4\u5dee\u3002\u925b\u64cb\u584a\u53ca\u591a\u8449\u578b\u6e96\u76f4\u5100\u7684\u534a\u5f71\u5340\u5247\u8f03\u6c34\u5047\u4f11\u6240\u91cf\u6e2c\u4e4b\u503c\u6709\u5927\u7d042~3 \u5e73\u65b9\u516c\u5398\u4e4b\u8aa4\u5dee\u3002\u5c0dCMS-Focus\u800c\u8a00\uff0c\u5728\u958b\u653e\u6027\u7167\u91ce\u90e8\u4efd\uff0c\u89ed\u9ce5\u6548\u61c9\u4e26\u4e0d\u6703\u96a8\u7167\u91ce\u4e4b\u5927\u5c0f\u800c\u6709\u6240\u6539\u8b8a\uff0c\u5176\u5291\u91cf\u8aa4\u5dee\u503c\u67092%\u3002\u6954\u5f62\u6ffe\u677f\u4e4b\u5291\u91cf\u8aa4\u5dee\u503c\u7d04\u57282%\uff0c\u7167\u91ce\u9069\u7528\u7bc4\u570d\u53ef\u958b\u81f3\u6700\u5927\u503c20 cm \u3002\u800c\u925b\u6a94\u584a\u53ca\u591a\u8449\u578b\u6e96\u76f4\u5100\u4e4b\u534a\u5f71\u5340\u5247\u6709 1~2 mm \u4e4b\u8aa4\u5dee\u3002\n\u8a0e\u8ad6\uff1a\u5c0d\u65bc\u4ee5\u4e0a\u9a57\u6536\u6e2c\u8a66\u7684\u7d50\u679c\uff0c\u7db2\u8def\u4e4b\u9023\u7d50\u53ca\u5f71\u50cf\u4e4b\u50b3\u8f38\u7686\u53ef\u6b63\u5e38\u4e4b\u904b\u4f5c\uff0c\u800c\u5291\u91cf\u5206\u4f48\u4e4b\u8aa4\u5dee\u503c\u7686\u5728\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u63a5\u53d7\u7684\u7bc4\u570d\u5167\uff0c\u56e0\u6b64\u4e5f\u78ba\u5b9a\u672c\u9662\u5169\u59573\uff0dD RTP\u53ef\u61c9\u7528\u65bc\u81e8\u5e8a\u653e\u5c04\u7dda\u4e4b\u6cbb\u7642\u3002", "e": "Purpose: The important subject of 3-D radiotherapy treatment planning system (3-D RTP) acceptance test procedure (ATP) is to get the reasonable agreement between the calculated isodose distribution of 3-D RTP and the measured results of water phantom, before the clinical use of 3-D RTP system.\nMaterials & Methods: This report is a acceptance test results of Computerized Medical System - Focus 1.4.0 and Helax-TMS 4.0. Acceptance test procedure includes hardware and software. Hardware includes the function of the link of Network system, the function of the image transfer system, the accuracy of the digitizer, the magnification and accuracy of the plotter, the function of the printer and the patient data backup facility. Software includes the comparison of percentage depth dose for photon beam and for electron beam, isodose distribution check and beam profile check. The comparisons of photon beam include open-field, wedge-field, half-beam, asymmetric jaws, irregular-field, bolus, inhomogeneities, block-field and Multi-Leaf Collimator MLC). The electron oblique incidence is also one of the test items.\nResults: For Helax-TMS, if the field size is more than 20\u00d720, the open-field horn effect will be increased, the maximum dose deviation about 2%. It's about 3% dose deviation of 45\u00b0 and 60\u00b0 wedge filter of the field size more than 10\u00d710. The penumbra error of block and MLC is 2-3 mm compared with water phantom data, For CMS-Focus, the horn effect is independent of field size and the dose deviation about 2%. The field size of wedge filter can open to a maximum of 20 cm and the dose deviation is 2%. The penumbra error of block and MLC, compared to water phantom, about 1-2 mm.\nConclusion: In conclusion, the functions of network and include image-transfer are acceptable and the isodose distribution discrepancies are also acceptable for the clinical radiotherapy treatment application."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199812-5-4-311-316-a", "title": "\u96fb\u5b50\u5c04\u675f\u906e\u64cb\u7167\u91ce\u4e4b\u5291\u91cf\u7279\u6027", "keywords": "\u96fb\u5b50\u5c04\u675f\u6cbb\u7642;Cerrobend\u906e\u64cb\u925b\u584a;\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u66f2\u7dda Electron beam therapy;Cerrobend cutout blocks;Percentage depth dose curves", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4ee5CERROBEND\u925b\u5408\u91d1\uff0c\u91dd\u5c0dCL-2100CD\u76f4\u7dda\u52a0\u901f\u5668\u958b\u58c1\u5f0f\u5404\u9650\u5149\u7b52\u5c3a\u5bf8\uff0c\u88fd\u6210\u908a\u9577\u4ee51cm\u70ba\u7d1a\u6578\u8b8a\u5316\u4e4b\u6b63\u65b9\u5f62\u906e\u6a94\u584a\uff0c\u6e2c\u91cf\u5728\u5c04\u6e90\u81f3\u76ae\u819a\u8868\u9762\u70ba 100 cm\u6642\uff0c\u5404\u7e2e\u5c0f\u7167\u91ce\u4e4b\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u66f2\u7dda\uff0c\u4ee5\u89c0\u5bdf\u4e26\u63a2\u8a0e\u7e2e\u5c0f\u7167\u91ce\u9762\u7a4d\u7684\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u66f2\u7dda\u8b8a\u5316\u4e4b\u60c5\u5f62\u53ca\u81e8\u5e8a\u61c9\u6ce8\u610f\u7684\u4e8b\u9805\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5CERROBEND\u925b\u5408\u91d1\uff0c\u4f9d\u5404\u9650\u5149\u7b52\u5c3a\u5bf8\u88fd\u4f5c\u908a\u9577\u4ee51cm\u70ba\u7d1a\u6578\u4e4b\u6b63\u65b9\u5f62\u4e2d\u7a7a\u906e\u64cb\u584a\uff0c\u4f9d\u6b21\u7f6e\u65bcVarian CL\uff0d210OCD\u76f4\u7dda\u52a0\u901f\u5668\u96fb\u5b50\u9650\u5149\u7b52\u5e95\u90e8\uff0c\u4ee5Nucletron\u4e09\u5ea6\u7a7a\u554f\u6c34\u5047\u9ad4\u9023\u63a5Scanditronix p\u578b\u534a\u5c0e\u9ad4\u5075\u6e2c\u5668\uff0c\u6e2c\u6688\u5404\u6a94\u584a\u7167\u91ce\u96fb\u5b50\u5c04\u675f\u80fd\u91cf\u5206\u5225\u70ba6\uff0c9\uff0c12\uff0c16\uff0c20 Mev\u5c04\u675f\u4e4b\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u66f2\u7dda\uff0c\u89c0\u5bdf\u5404\u80fd\u91cf\u5404\u7167\u91ce\u4e4b\u6700\u9ad8\u5291\u91cf\u9ede(D(\u4e0b\u6a19 max))\uff0c90%\uff0c80%\u5291\u91cf\u9ede\u4e4b\u6df1\u5ea6\uff0c\u53ca\u96fb\u5b50\u675f\u5c04\u7a0b(Rp)\u4e4b\u8b8a\u5316\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a\u6700\u9ad8\u5291\u91cf\u9ede(D(\u4e0b\u6a19 max))\uff0c90%\uff0c80%\u5291\u91cf\u9ede\u6df1\u5ea6\u4e4b\u8b8a\u5316\u60c5\u5f62\u70ba\uff1a\u7576\u7167\u91ce\u9762\u7a4d\u7e2e\u5c0f\u52301x1cm^2\u6642\uff0c\u6240\u6709\u80fd\u91cf\u5c04\u6771\u4e4b\u6700\u9ad8\u5291\u91cf\u9ede\u7686\u4f4d\u65bc0.5~0.8cm\u4e4b\u9593\uff0c\u4e0d\u8ad6\u9650\u5149\u7b52\u5927\u5c0f\u70ba\u4f55\uff0c90%\u5291\u91cf\u9ede\u6df1\u5ea6\u7684\u8b8a\u5316\u60c5\u5f62\u70ba\uff1a6 MeV\u5f9e\u7167\u91ce3x3cm^2, 9MeV\u5f9e4.5x4.5cm^2\uff0c12 MeV\u5f9e6x6cm^2\uff0c16 MeV\u5f9e8x8cm^2\uff0c20 MeV\u5247\u5f9e10.5xl0.5cm^2\u4ee5\u4e0b\u958b\u59cb\u964d\u4f4e\u3002\n\u7d50\u8ad6\uff1a\u81e8\u5e8a\u4e0a\u4ee5\u4e0d\u898f\u5247\u5f62CERROBEND\u925b\u5408\u91d1\u57f7\u884c\u5c0f\u7167\u91ce\u96fb\u5b50\u5c04\u675f\u6cbb\u7642\u6642\uff0c\u5176\u6700\u9ad8\u5291\u91cf\u9ede\uff0c90%\uff0c80%\u5291\u91cf\u9ede\u4e4b\u6df1\u5ea6\u5c07\u6703\u8b8a\u5c0f\uff0c\u56e0\u6b64\uff0c\u81e8\u5e8a\u4e0a\u5728\u6c7a\u5b9a\u5c04\u675f\u80fd\u91cf\u6642\uff0c\u82e5\u7167\u91ce\u9762\u7a4d\u5c0f\u65bc\u5404\u80fd\u91cf\u3001\u5404\u5291\u91cf\u7684\u964d\u4f4e\u9ede\u6642\uff0c\u61c9\u5148\u6ce8\u610f\u6cbb\u7642\u64cb\u584a\u4e4b\u5927\u5c0f\uff0c\u67e5\u5f97\u517690%\uff0c80%\u5291\u91cf\u9ede\u6df1\u5ea6\uff0c\u518d\u6c7a\u5b9a\u80fd\u91cf\u3002", "e": "Purpose: The percentage depth dose changes of high energy electron beams generated from Varian CL2100C/D linear accelerator collerated with various sizes of cutout blocks were measured at 100cm source-to-surface distance. The clinical significance was discussed.\nMaterials and Methods: CERROBEND cutout blocks were made for open-wall MLC type applicators. The step size of the square cutout is 1 cm. The percentage depth dose curve were scanned with Nucletron 3-D water phantom system connected with Scanditronix p-type semiconductor chamber. The electron energies were ranged from 6, 9, 12, 16 and 20 MeV. The depths of D(subscript max), D90, D80 and R(subscript p) were measured to observed its variation with cutout size.\nResults: The depths of D(subscript max) were located at 0.5 to 0.8cm at the cutout size equal to 1x1 cm^2 for all energies. The decrement points of the four parameters for each energy were the same in all cone sizes. The decrement cutout sizes were 3x3 cm^2 for 6 MeV, 4.5x4.5 cm^2 for 9 MeV, 6x6 cm^2 for 12 MeV 8x8 cm^2 for 16 MeV and 10.5x10.5 cm^2 for 20 MeV.\nConclusions: The depth of 90% and 80% depth dose will shift to surface direction when the irradiate area was decreased. It is mentioned clinically that the 90% depth should be examined before energy selection for tumor treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-149-156-a", "title": "\u9ad4\u5916\u653e\u5c04\u7dda\u5c0d\u672a\u7d93\u7528\u8853\u7684\u8996\u7db1\u819c\u6bcd\u7d30\u80de\u7624\u4e4b\u6cbb\u7642\u6548\u679c\uff1a\u4e00\u56de\u6eaf\u6027\u7814\u7a76\u5831\u544a", "keywords": "\u8996\u7db1\u819c\u6bcd\u7d30\u80de\u7624;\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642 Retinoblastoma;External beam radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u56de\u6eaf\u6027\u7814\u7a76\u5831\u544a\u4e43\u91dd\u5c0d\u672a\u7d93\u624b\u8853\u4e4b9\u4f4d\u517113\u500b\u773c\u775b\u7684\u8996\u7db1\u819c\u6bcd\u7d30\u80de\u7624\u75c5\u4eba\uff0c\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1988\u5e74\u4e94\u6708\u81f31997\u5e74\u4e8c\u6708\uff0c\u4e00\u5171\u67099\u4f4d\u517113\u500b\u773c\u775b\u7684\u8996\u7db1\u819c\u6bcd\u7d30\u80de\u7624\u75c5\u4eba\uff0c\u65bc\u672c\u9662\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d\u5305\u62ec\u4e866\u540d\u7537\u5b69\u548c3\u4f4d\u5973\u5b69\u3002\u96d9\u4f8b\u75c5\u7076\u7684\u67094\u4f4d\u75c5\u4eba\uff0c\u55ae\u5074\u75c5\u7076\u7684\u67095\u4f4d\u75c5\u4eba\u3002\u5e73\u5747\u8a3a\u65b7\u7684\u5e74\u5e7b\u70ba25.8\u500b\u6708\uff08\u4e2d\u4f4d\u6578\uff1a24.3\u500b\u6708\uff09\u3002\u653e\u5c04\u6cbb\u7642\u662f\u4ee5\u767e\u842c\u4f0f\u7279\u9ad4\u5916\u7167\u5c04(Maga-vollage external beam radiation)\uff0c\u5149\u5b50\u80fd\u91cf\u81ea6\u81f315\u767e\u842c\u4f0f\u7279(MV)\u3002\u653e\u5c04\u7dda\u5291\u91cf\u70ba30GY\u81f360GY\uff08\u5e73\u5747\u503c\uff1a47.1GY\uff1b\u4e2d\u4f4d\u6578\uff1a51.0GY\uff09\uff0c\u6bcf\u5929\u7167\u5c04\u4e00\u6b21\uff0c\u6bcf\u6b211.8\u81f32.0GY\u3002\u75be\u75c5\u7684\u5206\u671f\u662f\u63a1\u7528St.Jude Children's Research Hospital \u6240\u63d0\u51fa\u7684\u5206\u671f\u6cd5\u3002\u5176\u4e2d\u67098\u4f4d\u75c5\u60a3\u56e0\u6cbb\u7642\u524d\u5df2\u6709\u5c40\u90e8\u773c\u7403\u5916\u4fb5\u72af\u6216\u9060\u7aef\u8f49\u79fb\uff0c\u800c\u8f49\u4ee5\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u8ffd\u8e647.1\u81f3115.5\u500b\u6708\u5f8c\uff08\u4e2d\u4f4d\u6578\uff1a20.5\u500b\u6708\uff09\uff0c13\u500b\u773c\u775b\u67093\u500b\u75c5\u7076\u5c40\u90e8\u6cbb\u7642\u5931\u6557(3/13;23.1%)\u3002\u9060\u7aef\u8f49\u79fb\u67095\u4f4d\u75c5\u4eba(5/9;55.6%)\uff0c3\u5e74\u7e3d\u5b58\u6d3b\u7387\u70ba56.3%(5/9)\uff0c3\u5e74\u7121\u75c5\u5b58\u6d3b\u7387(disease-free survival rate)\u70ba25.9%(3/9)\u3002\u67095\u500b\u773c\u775b\uff084\u4f4d\u75c5\u4eba\uff09\u7dad\u6301\u8996\u529b\uff08\u65bc\u4e00\u516c\u5c3a\u8655\u53ef\u898b\u624b\u90e8\u6416\u52d5\uff09\u3002\u66f4\u67094\u500b\u773c\u775b\uff083\u4f4d\u75c5\u4eba\uff09\u7dad\u6301\u81f3\u5c11\u80fd\u8fa8\u8b58\u624b\u6307\u7684\u8996\u529b\u3002\n\u7d50\u679c\uff1a\u65e9\u671f\u8a3a\u65b7\u548c\u6cbb\u7642\u4ecd\u662f\u7372\u5f97\u9ad8\u6cbb\u7642\u7387\u6700\u6709\u6548\u7684\u8fa8\u6cd5\uff0c\u5373\u4f7f\u662f\u5c40\u90e8\u56b4\u91cd\u4e4b\u8996\u7db1\u819c\u6bcd\u7d30\u80de\u7624\uff0c\u6211\u5011\u5efa\u8b58\u4ecd\u4ee5\u9ad4\u5916\u653e\u5c04\u7dda\u4f5c\u70ba\u7b2c\u4e00\u7dda\u7684\u6cbb\u7642\uff0c\u662f\u5426\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u7aef\u8996\u816b\u7624\u4fb5\u72af\u7684\u7a0b\u5ea6\u53ca\u662f\u5426\u6709\u9060\u7aef\u8f49\u79fb\u3002\u800c\u773c\u7403\u525c\u9664\u8853(enucleation)\u5247\u7559\u5f85\u70ba\u5c40\u90e8\u816b\u7624\u5fa9\u767c\u4e4b\u63f4\u6551\u6027\u6cbb\u7642\u3002\u7136\u800c\u5c0d\u5f8c\u907a\u75c7\u7684\u8a55\u4f30\u5247\u9700\u66f4\u9577\u671f\u7684\u8ffd\u8e64\u3002", "e": "Purpose: To determinate the effects of external beam radiation alone for patients with retinoblastoma.\nMaterials and Methods: Between May 1988 to February 1997, 9 patients (13 eyes) with non-operative retinoblastoma (St. Jude Children's Research Hospital Classification) received external beam radiotherapy alone. The mean age at diagnosis was 25.8 months with 6 males and 3females. Four of 9 patients had bilateral retinoblastoma. Radiation doses ranged from 30 GY-60 GY (mean 47.1 GY, median 51.0 Gy) in 1.8-2.0 GY fractions by using electron or photon beam. Eight patients had been received chemotherapy.\nResults: At median follow up of 20.5 months (range 7.1-115.5 months), the local failure rate, 3-year disease free survival rate and 3-year overall survival rate of 23.1%, 25.9%, and 56.3% were obtained.\nConclusion: We concluded that external beam radiotherapy alone is an efficient treatment in local control for local advanced non-operative retinoblastoma. In our series, the tumor was locally controlled in 10 eyes (7 patients). Distant metastasis was the major failure in these patients. Primary radiotherapy was used to maintain normal vision, salvage treatment by enucleation is suggested. But longer follow-up time is needed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-157-162-a", "title": "\u982d\u9838\u90e8\u816b\u7624\u65bc\u5de6\u53f3\u5169\u5074\u7167\u91ce\u6642\uff0c\u5291\u91cf\u5206\u4f48\u4e0d\u5747\u52fb\u5ea6\u7684\u5206\u6790\u53ca\u7c21\u6613\u5957\u88dd\u7d44\u7e54\u88dc\u511f\u5668\u7684\u904b\u7528", "keywords": "\u653e\u5c04\u6cbb\u7642;\u5291\u91cf\u5206\u4f48\u4e0d\u5747\u52fb;\u7d44\u7e54\u88dc\u511f\u5668 Radiotherapy;Dose nonuniformity;Tissue compensator", "c": "\u76ee\u7684\uff1a\u5de6\u53f3\u5169\u5074\u7167\u91ce\u7684\u653e\u5c04\u6cbb\u7642\u5728\u982d\u9838\u90e8\u816b\u7624\u7684\u6cbb\u7642\u4e0a\u76f8\u7576\u666e\u904d\u3002\u56e0\u982d\u90e8\u8207\u524d\u7de3\u7684\u6cbb\u7642\u6df1\u5ea6\u6709\u5dee\u7570\uff0c\u6240\u4ee5\u8a55\u4f30\u8a08\u5283\u76ee\u6a19\u9ad4\u7a4d\u5167\u5291\u91cf\u5206\u4f48\u4e0d\u5747\u52fb\u7684\u73fe\u8c61\uff0c\u4e26\u767c\u5c55\u4e00\u7a2e\u7c21\u6613\u7684\u5957\u88dd\u7d44\u7e54\u88dc\u511f\u5668\u7684\u904b\u7528\u65b9\u5f0f\uff0c\u4ee5\u6539\u5584\u6cbb\u7642\u6642\u7684\u4e0d\u5747\u52fb\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9996\u5148\u5206\u679012\u4f8b\u56e0\u982d\u9838\u90e8\u816b\u7624\u800c\u63a5\u53d7\u5de6\u53f3\u5169\u5074\u7167\u91ce\u4e4b\u75c5\u4eba\uff0c\u5176\u4e2d\u820c\u764c4\u4f8b\uff0c\u4e0b\u54bd\u764c4\u4f8b\uff0c\u9f3b\u54bd\u764c4\u4f8b\u3002\u9019\u4e9b\u75c5\u4eba\u7684\u982d\u90e8\u53ca\u9838\u90e8\u5bec\u5ea6\u4ee5\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u5206\u6790\uff0c\u5176\u4e2d\u9838\u90e8\u5bec\u5ea6\u7684\u53c3\u8003\u9ede\u5b9a\u5728\u7167\u91ce\u7684\u4e2d\u5fc3(field center)\uff0c\u800c\u9838\u90e8\u5bec\u5ea6\u7684\u53c3\u8003\u9ede\u5b9a\u5728\u9838\u690eC3\u53caC4\u4ea4\u754c\u8655\u4e4b\u6cbb\u7642\u622a\u9762\u5411\u524d\u5ef6\u4f38\u96e2\u9838\u90e8\u524d\u7de32CM\uff08\u53c3\u8003\u9edeA\uff09\u53ca3cm\uff08\u53c3\u8003\u9edeB\uff09\u3002\u65bc\u6a21\u64ec\u651d\u5f71\u6642\u5c07\u7167\u91ce\u4e2d\u9838\u90e8\u5bec\u5ea6\u660e\u986f\u6e1b\u5c11\u5340\u57df\u6a19\u793a\u65bc\u7247\u5b50\u4e0a\uff0c\u7d93\u7531\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u5206\u6790\u6a19\u793a\u5340\u7684\u9838\u90e8\u843d\u5dee\u60c5\u6cc1\uff0c\u4ee5\u6a19\u793a\u5340\u5404\u622a\u9762\u4e4b\u810a\u690e\u9aa8\u690e\u9ad4\u524d\u7de3\u7576\u4f5c\u4e09\u89d2\u578b\u7684\u5e95\u908a\u7684\u53c3\u8003\u7dda\uff0c\u53ef\u91cf\u51fa\u6bcf\u500b\u6848\u4f8b\u9838\u90e8\u4e09\u89d2\u578b\u5340\u57df\u7684\u89d2\u5ea6\u03b8\u4ee5\u03b8\u4e4b\u5e73\u5747\u503c\u88c2\u4f5c\u4e86\u5e7e\u5957\u55ae\u4e00\u659c\u5ea6\u7684\u7d44\u7e54\u88dc\u511f\u5668\u3002\n\u7d50\u679c\uff1a\u82e5\u4ee5\u7167\u91ce\u7684\u4e2d\u5fc3\u70ba\u57fa\u6e96\uff0c\u524d\u9838\u90e8\u5291\u91cf\u904e\u9ad8\u7684\u60c5\u6cc1\u5982\u4e0b\uff0c\u53c3\u8003\u9edeA\u9ad8\u51fa\u6cbb\u7642\u4e2d\u5fc3\u4e4b\u8655\u65b9\u5291\u91cf(prescribed dose)\u7684\u5e73\u5747\u503c\u5206\u5225\u662f\u820c\u764c13.7%(10.0~16.6%)\uff0c\u4e0b\u54bd\u764c7.4%(5.8~9.9%)\uff0c\u9f3b\u54bd\u764c\u70ba13.6%(12.4~14.4%)\uff1b\u800c\u9838\u90e8\u53c3\u8003\u9edeB\u9ad8\u51fa\u6cbb\u7642\u4e2d\u5fc3\u9ede\u4e4b\u8655\u65b9\u5291\u91cf\u7684\u5e73\u5747\u503c\u5206\u5225\u820c\u764c11.7%(9.5~14.7%)\uff0c\u4e0b\u54bd\u764c5.4%(4.0~6.7%)\uff0c\u9f3b\u54bd\u764c\u70ba10.1%(7.4~13.1%)\u3002\u75c5\u4eba\u9838\u90e8\u6a19\u793a\u5340\u4e0d\u540c\u622a\u9762\u4e0d\u03b8\u89d2\u5ea6\u6578\u90fd\u843d\u572835\u81f355\u5ea6\u4e4b\u9593\uff0c\u82e5\u4ee55\u5ea6\u70ba\u9593\u9694\u55ae\u4f4d\uff0c\u5176\u4e2d\u67099\u4f8b\u03b8\u89d2\u5e73\u5747\u503c\u70ba45\u5ea6\uff0c2\u4f8b\u5e73\u5747\u503c\u70ba50\u5ea6\uff0c1\u4f8b\u5e73\u5747\u503c\u70ba40\u5ea6\u3002\u800c\u500b\u5225\u4f7f\u7528\u4e86\u55ae\u4e00\u659c\u5ea6\uff08\u5206\u5225\u70ba40,45\u53ca50\u5ea6\uff09\u7684\u5957\u88dd\u7d44\u7e54\u88dc\u511f\u5668\u5f8c\uff0c\u767c\u73fe\u9838\u90e8\u5291\u91cf\u904e\u9ad8\u7684\u60c5\u6cc1\u5df2\u6709\u5f88\u5927\u7684\u6539\u5584\u3002\n\u7d50\u8ad6\uff1a\u982d\u9838\u90e8\u816b\u7624\u7576\u9032\u884c\u5927\u7bc4\u570d\u7684\u5de6\u53f3\u5169\u5074\u7167\u91ce\u6642\uff0c\u5fc5\u9808\u8a55\u4f30\u7167\u91ce\u5167\u524d\u9838\u90e8\u6cbb\u7642\u5291\u91cf\u662f\u5426\u8f03\u4e2d\u5fc3\u9ede\u7d66\u4e88\u5291\u91cf\u70ba\u9ad8\u3002\u5982\u679c\u7121\u6cd5\u91dd\u5c0d\u6bcf\u4e00\u500b\u6848\u88fd\u4f5c\u4e00\u500b\u7d44\u7e54\u88dc\u511f\u5668\uff0c\u672c\u6587\u6240\u4ecb\u7d39\u4e4b\u7c21\u6613\u7684\u5957\u88dd\u7d44\u7e54\u88dc\u511f\u5668\u7684\u904b\u7528\u65b9\u5f0f\uff0c\u4f5c\u70ba\u6539\u5584\u524d\u9838\u7642\u5291\u91cf\u4e0d\u5747\u52fb\u7684\u4e00\u7a2e\u53c3\u8003\u3002", "e": "Purpose: For the radiotherapy of many head and neck tumors, bilateral parallel opposed fields have been used for initial treatment. Because the thickness of head and anterior portion of neck may be different, our study is to evaluate the dose nonuniformity within target volume and to introduce a simple application model of tissue compensator to improve the dose nonuniformity for the bilateral treatment.\nMaterials and methods: We analyzed the data of twelve cases with head and neck tumors (4 tongue cancers, 4 hypopharyngeal cancers, and the rest are nasopharyngeal cancer). They received bilateral parallel opposed fields or initial treatment. The thickness of head and neck was estimated from CT scan, the reference point of the thickness of head was defined at field center, and the reference points of the thickness of were defined at cross-section of C3-C4 interface, 2 cm from anterior margin of neck (reference point A), 3 cm anterior margin (reference point B). During simulation, the area with significant deficit was delineated, and was analyzed on CT scan. If the line along the anterior border of vertebral body was defined as the base of a triangle, we can find the base angle \u03b8 of anterior neck. Following measurcment and analysis of angle \u03b8 of different sections on CT scan, several sets of compensator were made.\nResults: If the given dose was normalized at the center of radiation field, the average percentage of overdose of anterior neck was as following: reference point A, 13.7% (10.0~166.6) for tongue cancer, 7.4% (5.8~9.9) for hypopharyngeal cancer, 13.6% (12.4~14.4) for nasopharyngeal cancer; reference point B, 11.7% (9.5~14.7), 5.4% (4.0~6.7), and 10.1% (7.4~13.1) respectively. The degree of angle \u03b8 at different cross-sections of anterior neck were all within the range of 35\u00b0 to 55\u00b0. With the interval of 5 degree as a unit, the mean degree of angle \u03b8 is 45\u00b0for 9cases, 50\u00b0for 2 cases, and 40\u00b0for one case. After the application of compensator with simple slope(40\u00b0, 45\u00b0, and 50\u00b0), the overdose of anterior neck has been substantially improved.\nConclusion: When bilateral parallel opposed fields are used for the initial treatment of head neck tumors, the dose nonuniformity of anterior portion of neck should be assessed. If significant overdose was noted and it is impossible to make tissue compensator case by case, the simple application model of tissue compensator for anterior neck can be considered."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-163-170-a", "title": "Prlmary Radiotherapy Treatment Results of Maxillary Sinus Squamous Cell Carcinoma", "keywords": "\u653e\u5c04\u6cbb\u7642;\u5408\u4f75\u6cbb\u7642;\u4e0a\u9837\u7ac7;\u6241\u5e73\u7d30\u80de\u764c Radiotherapy;Combined treatment;Maxillary sinus;Squamous cell carcinoma", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u4e0a\u9837\u7ac7\u764c\u7528\u4e0d\u540c\u6cbb\u7642\u65b9\u5f8c\u7684\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1977\u81f31991\u5e7461\u500b\u4e0a\u9837\u7ac7\u6241\u5e73\u7d30\u80de\u4e2d\uff0c\u670911\u500b\u75c5\u4eba(18%)\u662fT3\uff0c50\u500b\u75c5\u4eba(82%)\u662fT4\u3002\u5176\u4e2d18\u500b\u75c5\u4eba\u53ea\u4f5c\u653e\u5c04\u6cbb\u7642\uff0c32\u500b\u75c5\u4eba\u8853\u5f8c\u8ffd\u52a0\u653e\u5c04\u6cbb\u7642\uff0c11\u500b\u75c5\u4eba\u5408\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u7ac7\u9020\u53e3\u8853\u53ca\u52d5\u8124\u5167\u6ce8\u5c04\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u4ee5\u4e0a\u4e09\u7d44\u75c5\u4eba\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba5.6%,34.4%\u53ca54.5\uff0c\u5177\u6709\u660e\u986f\u7d71\u8a08\u5dee\u5225\u3002\u5728\u8a3a\u65b7\u6642\u6709\u6dcb\u5df4\u8f49\u79fb\u7684\u75c5\u4eba\uff0c\u5176\u4e94\u5e74\u5b58\u6d3b\u7387\u8f03\u7121\u6dcb\u5df4\u8f49\u79fb\u75c5\u4eba\u660e\u986f\u504f\u4f4e\uff087.1%\u6bd436.2%\uff09\u3002\u591a\u8b8a\u6578\u5206\u6790\u5f97\u51fa\u6027\u5225\uff0c\u6cbb\u7642\u65b9\u5f0f\uff0c\u6dcb\u5df4\u5206\u671f\u70ba\u986f\u8457\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u5408\u4f75\u6cbb\u7642\u6bd4\u53ea\u4f5c\u653e\u5c04\u6cbb\u7642\u6709\u8f03\u597d\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u3002", "e": "Purpose: Evaluating 5-year survival rates of maxillary sinus squamous cell carcinoma treated by different methods.\nMaterials and Methods: From 1997 to 1991, 61 patients of maxillary sinus squamous cell carcinoma were included in our study. There were 11 patients with T3 (18%) disease and 50 patients with T4 (82%) disease. Eighteen patients (29.5%) were treated by radiotherapy alone (RT), 32 patients (52.5%) by combined surgery and radiotherapy (SRT) and 11 patients (18.0%) by combined radiotherapy with intra-arterial 5-FU infusion chemotherapy and antrostomy drainage (CRT).\nResults: Five-year survival rates were 5.6%, 34.4% and 54.5% in RT, SRT and CRT groups, respectively. Statistical significant difference (p\uff1c0.05) of survival rates was noted. Regional neck nodal metastasis at initial diagnosis carried significant worse survival results than initial NO state (7.1% vs. 36.2%, p=0.0003). Multivariate analysis revealed that treatment methods, sex and N stages significantly influenced the 5-year survival rate.\nConclusion: Combined treatment was superior to radiotherapy alone in 5-year survival rates."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-171-177-a", "title": "Radiotherapy in the Treatment of Paranasal Sinuses Cancer\uff0dThe Experience of Tri-Service General Hospital", "keywords": "\u526f\u9f3b\u7ac7\u764c;\u653e\u5c04\u6cbb\u7642;\u5b58\u6d3b Paranasal sinuses cancer;Radiotherapy;Survival", "c": "\u76ee\u7684\uff1a\u5831\u544a\u672c\u9662\u653e\u5c04\u816b\u7624\u90e8\u81ea\u6210\u7acb\u4ee5\u4f86\u6cbb\u7642\u526f\u9f3b\u7ac7\u764c\u4e4b\u6210\u6548\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u6536\u96c61968\u81f31996\u517183\u4f8b\u65bc\u672c\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u526f\u9f3b\u7ac7\u764c\u75c5\u60a3\uff0c\u591a\u6578\u75c5\u60a3\u63a5\u53d7\u923760\u7167\u5c04\uff0c\u816b\u7624\u5291\u91cf\u5f9e60~130\u845b\u96f7\uff0c\u4e2d\u657870\u845b\u96f7\uff0c\u63a1\u7528\u50b3\u7d71\u7167\u5c04\u65b9\u6cd5\u3002\u5b58\u6d3b\u7387\u5206\u6790\u63a1\u7528Kaplan-Meier\uff0c\u76f8\u95dc\u9810\u5f8c\u56e0\u5b50\u63a1\u7528Log-rank test \u6bd4\u8f03\u5176\u5dee\u7570\u4e4b\u986f\u8457\u7a0b\u5ea6\u3002\n\u7d50\u679c\uff1a\u672c\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u526f\u9f3b\u7ac7\u764c\u75c5\u60a3\uff0c5\u5e74\u5b58\u6d3b\u7387\u70ba53.0%\uff0c10\u5e74\u5b58\u6d3b\u7387\u70ba30.9%\uff1b\u653e\u5c04\u6cbb\u7642\u524d\u63a5\u53d7\u6839\u9664\u5207\u9664\u624b\u8853\u8005\u986f\u793a\u51fa\u8f03\u4f73\u4e4b5\u5e74\u5b58\u6d3b\u7387\uff1b\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u5f8c\u816b\u7624\u5b8c\u5168\u6d88\u5931\u4f5430%\uff0c\u90e8\u5206\u6d88\u5931\u4f5422%\uff1b\u5c40\u90e8\u5fa9\u767c\u7387\u70ba35%\uff0c\u9060\u8655\u8f49\u79fb\u7387\u70ba13%\uff1b\u85c9\u7531\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u4e4b\u5e6b\u52a9\uff0c\u53ef\u5ef6\u9577\u51765\u5e74\u53ca10\u5e74\u5b58\u6d3b\u7387\uff0c\u4f46\u672a\u9054\u7d71\u8a08\u5b78\u4e4b\u610f\u7fa9(p=0.2867)\u3002\u665a\u671f\u4f75\u767c\u75c7\u5305\u62ec\uff1a\u53e3\u4e7e\u75c7\uff0c\u7259\u95dc\u7dca\u9589\uff0c\u982d\u75db\uff0c\u5c40\u90e8\u75bc\u75db\u816b\u8139\uff0c\u6d41\u9f3b\u8840\uff0c\u7d50\u819c\u5145\u8840\uff0c\u773c\u76f2\u7b49\uff0c\u81e8\u5e8a\u4e0a\u4e0d\u5e38\u898b\u5230\u3002\n\u7d50\u8ad6\uff1a\u7531\u65bc\u89e3\u5256\u5b78\u4e0a\u7684\u7279\u6b8a\u4f4d\u7f6e\uff0c\u672c\u7814\u7a76\u6240\u6709\u526f\u9f3b\u7ac7\u764c\u5747\u4fb5\u72af\u4e00\u8655\u4ee5\u4e0a\u4e4b\u90e8\u4f4d\u3002\u5176\u539f\u767c\u90e8\u4f4d\u4ee5\u4e0a\u9837\u7ac7\u53ca\u7be9\u7ac7\u6700\u70ba\u5e38\u898b\uff1b\u5206\u5225\u4f54\uff0881.7%\u53ca16.4%\uff09\u3002\u4ee5\u55ae\u7368\u653e\u5c04\u6cbb\u7642\u4f5c\u70ba\u4e3b\u8981\u6cbb\u7642\u7684\u60a3\u8005\u5f80\u5f80\u517c\u5177\u8f03\u5dee\u4e4b\u9810\u5f8c\u56e0\u5b50\u4e5f\u8f03\u4e0d\u6613\u610f\u55ae\u7368\u4ee5\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u9054\u5230\u6cbb\u7652\u3002\u4e14\u7531\u65bc\u665a\u671f\u7121\u6cd5\u4ee5\u624b\u8853\u5207\u9664\u4e4b\u526f\u9f3b\u7ac7\u764c\uff0c\u55ae\u7368\u4ee5\u50b3\u7d71\u653e\u5c04\u6cbb\u7642\u5176\u5c40\u90e8\u63a7\u5236\u7387\u4ecd\u4e0d\u7406\u60f3\uff0c\u672c\u9662\u63a1\u7528\u591a\u7a2e\u65b0\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u5982\u6bcf\u65e5\u5169\u6b21\u591a\u5206\u6b21\u7167\u5c04\u6cd5\u4f75\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u4ee5\u63d0\u9ad8\u816b\u7624\u8a08\u91cf\uff0c\u964d\u4f4e\u5468\u908a\u6b63\u5e38\u7d44\u7e54\u526f\u4f5c\u7528\uff0c\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\uff1b\u85c9\u7531\u9019\u4e9b\u65b0\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u61c9\u53ef\u7372\u5f97\u66f4\u4f73\u6cbb\u7642\u6548\u679c\u3001\u6e1b\u5c11\u77ed\u671f\u53ca\u9577\u671f\u4e4b\u526f\u4f5c\u7528\u3001\u63d0\u6607\u751f\u6d3b\u54c1\u8cea\u3002", "e": "Purpose: To present our experience in the treatment of paranasal sinuses cancer using radiotherapy.\nMaterials and Methods: Between 1968 and 1996, 83 patients with cancer of paranasal sinuses received radiotherapy in the Radiation Oncology department of the Tri-Service General Hospital. Most of the patients were treated using Co-60 gamma irradiation. A Cs-137 teletherapy unit was used in 7% of the patients in the 60's. The median prescribed tumor dose was 70 GY with a range of 60~130 GY and the daily fraction size was 1.8-2.0 Gy, 5 fractions per week. Survival was calculated using the Kaplan-Meier actuarial method. Differences between survival curves were compared using the log rank test.\nResults: The 5- and 10-year survivals are 53.0% and 30.9%, respectively. Patients receiving radical surgery before radiotherapy showed a better 5-year survival. The complete response rate is 30% and partial response rate is 22% in our study after radiotherapy. The overall local failure and distant metastasis rate are about 35% and 13%. No correlation could be made between the survival and histology, staging group, and sex in our study. The magnitude of improved survival by the aid of CT scanning is not significant in our study (p=0.2867). Late complications are not common, including xerostomia, trismus, headache, local tenderness and swelling, epistaxis, conjunctival congestion, and blindness.\nConclusion: All of the patients in our study had the tumor involving more than one site. The maxillary and ethmoid sinuses were the most common primary tumor sites in our study (81.7% and 14.6%). Patients receiving radiotherapy alone had relative poor prognostic factors and the cure was not achieved by conventional radiotherapy alone in most patients. In view of the poor local control for advanced unresectable paranasal sinuses cancer and relative low morbidity with standard-dose irradiation, we have conducted cancer and relative low morbidity with standard-dose irradiation, we have conducted dose escalation using hyperfractionation regiment and CT based 3-D conformal treatment planning in recent years. Concurrent chemo-irradiation may be a reasonable approach."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-179-186-a", "title": "Lymphoma with Intraspinal Extramedullary Involvement as Initial Presentation", "keywords": "\u6e1b\u58d3\u624b\u8853;\u786c\u819c\u4e0a\u6dcb\u5df4\u7624;\u786c\u819c\u5167\u6dcb\u5df4\u7624 Decompression surgery;Epidural lymphoma;Intradural lymphoma", "c": "\u76ee\u7684\uff1a\u56de\u9867\u810a\u690e\u6216\u795e\u7d93\u6839\u58d3\u8feb\u70ba\u521d\u59cb\u75c7\u72c0\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u6cbb\u7642\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1977\u81f31996\u5e74\u4e8c\u5341\u5e74\u9593\uff0c\u672c\u9662\u5171\u67099\u4f8b\u4ee5\u810a\u690e\u6216\u795e\u7d93\u6839\u58d3\u8feb\u70ba\u521d\u59cb\u75c7\u72c0\u4e4b\u6dcb\u5df4\u7624\u60a3\u8005\u3002\u5176\u4e2d\u53ea\u67096\u4f8b\u539f\u767c\u7684\u786c\u819c\u5916\u4fb5\u72af\u5c6c\u7b2c\u4e00\u671f\uff0c\u800c\u7b2c\u4e8c\u3001\u4e09\u3001\u56db\u671f\u54041\u4f8b\u3002\u9664\u4e861\u4f8b\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u53ca1\u4f8b\u6dcb\u5df4\u8089\u7624\u5916\uff0c\u5176\u9918\u75c5\u60a3\u7686\u662f\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\uff0c\u4ee5\u5de5\u4f5c\u5206\u985e\u4f86\u5206\u591a\u5c6c\u4e2d\u9593\u7d1a\u3002\u6e1b\u58d3\u624b\u8853\u5f8c\uff0c\u5169\u4f4d\u75c5\u4f8b\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff1b1\u4f4d\u75c5\u4f8b\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff1b\u5176\u99186\u4f8b\u63a5\u53d7\u5408\u4f75\u653e\u5c04\u53ca\u5316\u5b78\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u75c5\u60a3\u65bc\u524d\u9a45\u671f\u6703\u5148\u67091\u523010\u500b\u6708\u7684\u80cc\u75db\uff0c\u63a5\u8457\u767c\u751f\u6025\u907d\u60e1\u5316\u4e4b\u810a\u9ad3\u58d3\u8feb\u75c7\u72c0\u3002\u6cbb\u7642\u5f8c\uff0c5\u4f4d\u75c5\u60a3\u7684\u816b\u7624\u5b8c\u5168\u7de9\u89e3\uff0c\u723e\u5f8c\u5176\u4e2d1\u4f4d\u6b7b\u65bc\u5316\u7642\u4e4b\u526f\u4f5c\u7528\uff0c1\u4f4d\u6b7b\u65bc\u5176\u4ed6\u75be\u75c5\uff0c1\u4f4d\u8f49\u79fb\uff0c\u53ea\u67092\u4f4d\u81f3\u4eca\u7121\u75be\u75c5\u5fa9\u767c\u8de1\u8c61\u3002\u800c4\u4f4d\u90e8\u5206\u7de9\u89e3\u7684\u75c5\u60a3\u5247\u5168\u56e0\u6b64\u75be\u75c5\u4ea1\u6545\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u786c\u819c\u4e0a\u6216\u786c\u819c\u5167\u58d3\u8feb\u70ba\u521d\u59cb\u75c7\u72c0\u4e4b\u6dcb\u5df4\u7624\u662f\u4e00\u7a2e\u9032\u884c\u5feb\u901f\u7684\u75be\u75c5\u3002\u7a4d\u6975\u7684\u8655\u7406\u5408\u4f75\u624b\u8853\u3001\u653e\u5c04\u53ca\u5316\u5b78\u6cbb\u7642\uff0c\u4ee5\u7372\u5f97\u8f03\u597d\u7684\u5c40\u90e8\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u662f\u4e00\u822c\u7684\u5efa\u8b70\u3002", "e": "Purpose: To review the treatment results of lymphoma with initial presentation of spinal cord or cauda equina compression.\nMaterials and Methods: Lymphoma with cord or cauda equina compression as initial presentation were seen in 9 patients in our hospital between 1977 to 1996. Among them, six patients presented with stage IE primary spinal epidurl involvement, whereas the others has stage \u2161E, \u2162E and \u2163E disease (1 patient each). Except for one Hodgkin's lymphoma and one lymphosarcoma, all of the other patients were non-Hodgkin's lymphoma with unfavorable histologic grading, mostly were the intermediate grade classification according to the Warking Formulation. After decompression surgery, the subsequent treatments of these patients were radiotherapy (2 patients), chemotherapy (1 patient), and combination of both treatment modalities (6 patients).\nResults: A prodromal phase of local back pain occurred in all patients, with duration from 1 to 10 months, followed by a second phase of rapidly progressive signs of cord compression. After treatment, 5 patients achieved complete remission: among with, one died of chemotherapy complication, one died of intercurrent disease, one had distant metastasis, and only 2 patients remained disease free. The other 4 patients who got partial remission were all dead of this disease.\nConclusion: Lymphoma with spinal epidural or intradural involvement at initial presentation is an aggressive disease. An intensive treatment combination with irradiation, chemotherapy, and surgery, is suggested in order to achieve good local control and longterm survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-187-191-a", "title": "\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u5f71\u50cf\u89e3\u6790\u5ea6\u53ca\u96dc\u8a0a\u7684\u91cf\u6e2c", "keywords": "\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f;\u7a7a\u9593\u89e3\u6790\u5ea6;\u5c0d\u6bd4\u89e3\u6790\u5ea6;\u96dc\u8a0a\u7a0b\u5ea6 Computed tomography simulation;Spatial resolution;Contrast resolution;Noise", "c": "\u76ee\u7684\uff1a\u70ba\u786e\u4fdd\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u5f71\u50cf\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\uff0c\u5c0d\u6bd4\u89e3\u6790\u5ea6\u53ca\u96dc\u8a0a\u7a0b\u5ea6\uff0c\u4ee5\u9054\u5230\u7a4d\u786e\u653e\u5c04\u6cbb\u7642\u7684\u6a19\u6e96\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528Elscint HeliCAT II\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u6a5f\u3001\u6a19\u6e96\u982d\u90e8\u53ca\u8eab\u9ad4\u5047\u9ad4\u4f86\u505a\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u89e3\u6790\u5ea6\u53ca\u96dc\u8a0a\u7684\u91cf\u6e2c\u3002\u7a7a\u9593\u89e3\u6790\u5ea6\u4f7f\u7528\u6a19\u6e96\u982d\u90e8\u5047\u9ad4\u591a\u5c64\u91dd\u72c0\u5c64\u4e2d\u4e03\u5217\u4e0d\u540c\u534a\u5f91\u7684\u6a6b\u6392\u5b54\u6d1e\uff0c\u53ca\u7d93\u904e\u6a5f\u5668\u6383\u63cf\u5f8c\u5f97\u51fa\u7684\u5f71\u50cf\u53c3\u6578\u8207\u6a19\u6e96\u503c\u4f5c\u6bd4\u8f03\u3002\u5c0d\u6bd4\u89e3\u6790\u5ea6\u4f7f\u7528\u982d\u90e8\u5047\u9ad4\u591a\u5c64\u91dd\u72c0\u5c64\u4e2d\u4e94\u500b\u4e0d\u540c\u6750\u8cea\u91cf\u6e2c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u503c\u8207\u6e96\u6a19\u503c\u4f5c\u6bd4\u3002\u96dc\u8b80\u4e43\u662f\u4f7f\u7528\u982d\u90e8\u53ca\u8eab\u9ad4\u5047\u9ad4\uff0c\u5229\u7528\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u4e0a\u7684\u529f\u80fd\u9375\u6e2c\u51fa\u6a19\u6e96\u504f\u5dee\uff0c\u7d93\u904e\u904b\u7b97\u5f97\u5230\u4e4b\u503c\uff0c\u662f\u5426\u843d\u65bc\u6a19\u6e96\u7bc4\u570d\u5167\u3002\n\u7d50\u679c\uff1a\u7a7a\u9593\u89e3\u6790\u5ea6\u7684\u8aa4\u5dee\u57280.8mm\u4ee5\u5167\uff0c\u5c0d\u6b64\u89e3\u6790\u5ea6\u8aa4\u5dee\u9664\u9435\u6c1f\u9f8d\u4ee5\u5916CT\u8aa4\u5dee\u503c\u572818\u4ee5\u5167\uff0c\u800c\u96dc\u8a0a\u7684\u91cf\u6e2c\u7d93\u904e\u8a08\u7b97\u6240\u5f97\u4e4bCT\u503c\u57283%\u4ee5\u5167\u3002\n\u7d50\u8ad6\uff1a\u6839\u64da\u91cf\u6e2c\u6240\u5f97\u6578\u64da\uff0c\u986f\u793a\u6b64\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5100\u7684\u7a7a\u9593\u89e3\u6790\u5ea6\u3001\u5c0d\u6bd4\u89e3\u6790\u5ea6\u53ca\u96dc\u8a0a\u5728\u6a19\u6e96\u503c\u4e4b\u5167\u4e26\u5408\u65bc\u7cbe\u6e96\u653e\u5c04\u6cbb\u7642\u4e4b\u7528\u3002\u82e5\u8981\u4fdd\u8b49\u6b64\u90e8\u6a5f\u5668\u7684\u54c1\u8cea\u9700\u8981\u5b9a\u671f\u7684\u6e2c\u8a66\u8207\u6821\u6b63\u3002", "e": "Purpose: To measure and evaluate the spatial resolution, contrast resolution and noise of computed tomography simulation image in order to meet the requirement of precision radiation therapy.\nMaterials and methods: Elscint HeliCAT \u2161 CT scanner head and body phantom were used to measure and evaluate the image quality of computed tomography simulator. We used the head phantom includes seven rows of different diameter perspex layer (multipin layer) to do the spatial resolution comparisons, and another five different material layer of this head phantom were also used to do the contrast resolution comparisons. The noise was used the head and body phantom through the \u201dROI\u201d function key to find its percentage errors in order to meet the requirement of precision radiation therapy.\nConclusions: The quality assurance procedure of this computed tomography simulation imaging system had been setup before formally using. It all met the requirement of precision radiation therapy. To assure the image quality, it also needs measurement periodically."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-193-199-a", "title": "\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u9664\u5f79\u8655\u7f6e\u53ca\u4eba\u54e1\u5291\u91cf\u8a55\u4f30", "keywords": "\u8f3b\u9632\u5c08\u54e1;\u8a08\u76e1\u7279\u5225\u66dd\u9732;\u5408\u7406\u6291\u4f4e Radiation Protection Commissioner;Planned special exposures;As low as reasonable achievable(ALARA)", "c": "\u76ee\u7684\uff1a\u5f70\u5316\u57fa\u7763\u6559\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u898f\u5283\u5c07\u539f\u6709\u4e4b\u9237\u516d\u5341\u9060\u9694\u6cbb\u7642\u6a5f\u9664\u5f79\uff0c\u4ee5\u7a7a\u51fa\u6cbb\u7642\u5ba4\u505a\u70ba\u5b89\u88dd\u65b0\u76f4\u7dda\u52a0\u901f\u5668\u6cbb\u7642\u6a5f\u4e4b\u7528\u3002\u6b32\u64a4\u9664\u4e4b\u820a\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u4fc2\u5c6c\u91ab\u7528\u5bc6\u5c01\u653e\u5c04\u6027\u7269\u8cea\uff0c\u61c9\u7531\u5408\u683c\u8f3b\u9632\u5c08\u54e1\u76e3\u7763\u57f7\u884c\u6574\u500b\u9664\u5f79\u62c6\u6a5f\u53ca\u904b\u9001\u5b89\u5168\u7a0b\u5e8f\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5728\u7d93\u884c\u653f\u9662\u539f\u5b50\u80fd\u59d4\u54e1\u6703\u6838\u6e96\u505c\u7528\u5f8c\uff0c\u6574\u500b\u9664\u5f79\u904e\u7a0b\u5728\u8f49\u5c04\u5b89\u5168\u3001\u61c9\u6ce8\u610f\u4e8b\u9805\u53ca\u8655\u7406\u6b65\u9a5f\u4e0a\u7686\u4f9d\u7167\u539f\u80fd\u6703\u6240\u9812\u8a02\u4e4b\u300c\u653e\u5c04\u6027\u7269\u8cea\u5b89\u5168\u904b\u9001\u898f\u5247\u300d\u53ca\u300c\u6e38\u96e2\u8f3b\u5c04\u9632\u8b77\u5b89\u5168\u6a19\u6e96\u300d\u8fa8\u7406\uff0c\u4e26\u4e14\u91dd\u5c0d\u62c6\u6a5f\u671f\u9593\u5de5\u4f5c\u4eba\u54e1\u6240\u53d7\u4e4b\u8f3b\u5c04\u66dd\u9732\u64ec\u5b9a\u8a08\u5283\u7279\u5225\u66dd\u9732\u548c\u8a55\u4f30\u5176\u6240\u53d7\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u65bc\u505a\u904e\u56b4\u8b39\u7684\u6c99\u76e4\u6f14\u7df4\u5f8c\uff0c\u5728\u6574\u500b\u62c6\u6a5f\u3001\u8f3b\u9632\u4f5c\u696d\u898f\u5283\u53ca\u7ba1\u5236\u63a1\u53d6\u5408\u7406\u6291\u4f4e\u7684\u539f\u5247\u4e0b\uff0c\u9806\u5f97\u5730\u5b8c\u6210\u6574\u500b\u5831\u5ee2\u79fb\u6a5f\u624b\u7e8c\u3002\n\u7d50\u8ad6\uff1a\u672c\u6587\u5373\u91dd\u5c0d\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u7684\u9664\u5f79\u3001\u904b\u9001\u904e\u7a0b\u4e2d\u6240\u9700\u8981\u505a\u7684\u6e96\u5099\u53ca\u5176\u5291\u91cf\u8a55\u4f30\u6d41\u7a0b\u7d93\u9a57\u505a\u4e00\u8a73\u5be6\u7684\u63cf\u8ff0\u3002", "e": "Purpose: The Department of Radiation Oncology at the Changhua Christian Hospital plans to retire the original cobalt-60 machine, and empty out the treatment room to install a new linear accelerator. The old cobalt-60 machine that will be removed is a sealed source for medical use. There should be a qualified radiation protection commissioner to supervise all procedures of dismantling the machine and the safety of transportation.\nMaterials and Methods: After gaining the approval of the Atomic Energy Council (AEC) at the executive yuan, all procedures concerning radiation protection, works should be considered and in line with the steps according to \u201dRegulations about the Security of Transporting Radioactive Materials\u201d and \u201dRules of Ionizing Radiation Security\u201d which are issued by AEC. Aiming at the workers who received radiation exposures during the dismantling gauge planned special exposures and extimating the doses.\nResults: After conscientious and careful practices, planning and controlling of radiation protection obey the rule of ALARA (as low as reasonable achievable) whole dismantling and transportation of the cobalt-60 machine was smoothly accomplished.\nConclusion: This paper describes the procedure about how to handle the retiring of a cobalt-60 machine and estimate personal dose fully and accurately."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-201-206-a", "title": "\u4ee5Plexiglass\u5047\u9ad4\u6821\u6b63Ir-192\u8fd1\u63a5\u6cbb\u7642\u5c04\u6e90\u6d3b\u5ea6", "keywords": "\u8fd1\u63a5\u6cbb\u7642;Ir-192\u5c04\u6e90\u6d3b\u5ea6;\u56fa\u614b\u5047\u9ad4 Brachytherapy;Ir-192 source activity;Plexiglass phantom", "c": "\u672c\u6587\u4ee5PTW N23333\u6e38\u96e2\u8154\u5728\u7a7a\u6c23\u4e2d\u6e2c\u5f97Ir-192\u5c04\u6e90\u7684\u66dd\u9732\u7387\u70ba\u57fa\u6e96\uff0c\u63a2\u8a0eGammamed\u5f8c\u8377\u8fd1\u63a5\u6cbb\u7642\u6a5f\u7d44\u63d0\u4f9b\u7684\u6709\u9650\u9ad4\u7a4d\u5713\u67f1\u578bplexiglass\u5047\u9ad4\u7528\u65bc\u6821\u6b63Ir-192\u5c04\u6e90\u6d3b\u5ea6\u6642\u61c9\u4fee\u6b63\u7684\u53c3\u6578\u53ca\u6b64\u5047\u9ad4\u7684\u81e8\u5e8a\u61c9\u7528\u4e0a\u7684\u512a\u9ede\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5148\u4ee5PTW N23333\u6e38\u96e2\u8154\uff0c\u6839\u64daAAPM Report 41\u7684\u5831\u544a\u6240\u6558\u8ff0\u7684\u53c3\u6578\u4fee\u6b63\u5f8c\uff0c\u6e2c\u5f97\u8ddd\u5c04\u6e908\u516c\u5206\u8655\u4e4b\u7a7a\u6c23\u4e2d\u66dd\u9732\u7387\uff0c\u52a0\u5165\u7814\u7a76\u4e2d\u984d\u5916\u53c3\u6578\u7684\u4fee\u6b63\u5f8c\uff0c\u6c42\u5f97\u4ecb\u8cea\u5167\u4e4b\u5291\u91cf\u7387\uff1b\u518d\u6e2c\u91cf\u4f4d\u65bcPiexiglass\u5047\u9ad4\u5167\uff0c\u6709\u7121\u9644\u52a0\u56de\u6563\u5c04\u6c34\u5047\u9ad4\u4e4b\u66dd\u9732\u7387\uff0c\u6c42\u5f97\u6b64\u5047\u9ad4\u4e4b\u56de\u6563\u5c04\u56e0\u5b50\uff0c\u4ee5\u63a2\u8a08\u5728plexiglass\u5047\u9ad4\u5167\u6e2c\u91cf\u61c9\u505a\u7684\u4fee\u6b63\u3002\n\u7d50\u679c\uff1a\u4f7f\u7528Plexiglass\u5047\u9ad4\u6642\uff0c\u5176\u56de\u6563\u5c04\u4fee\u6b63\u56e0\u5b50(BSF)\u7d93\u6e2c\u5448\u61c9\u70ba1.081\u3002\u5291\u5448\u68af\u5ea6\u6821\u6b63\u56e0\u5b50(Cgrad)\u5728\u5c04\u6e90\u81f3\u6e38\u96e2\u8154\u7684\u8ddd\u96e2(SCD)\u7b49\u65bc8\u516c\u5206\u8655\u4e4b\u4fee\u6b63\u503c\u70ba1.158\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u7528Plexiglass\u5047\u9ad4\u6821\u6b63Ir-192\u5c04\u6e90\u6d3b\u5ea6\uff0c\u5728\u81e8\u5e8a\u61c9\u7528\u4e0a\u6bd4\u5728\u7a7a\u6c23\u4e2d\u6e2c\u91cf\u6709\u8f03\u9ad8\u7684\u7a69\u5b9a\u6027\uff0c\u91cd\u73fe\u6027\u53ca\u65b9\u4fbf\u6027\uff0c\u7136\u800c\u5728\u4f7f\u7528\u524d\u9700\u5148\u8207\u5176\u4ed6\u6e2c\u91cf\u65b9\u6cd5\u76f8\u4e92\u5370\u8b49\uff0c\u6c42\u5f97\u5176\u56de\u6563\u5c04\u7b49\u56e0\u5b50\u624d\u80fd\u6e96\u786e\u7528\u65bc\u5b9a\u671f\u5c04\u6e90\u6d3b\u5ea6\u4e4b\u6aa2\u6e2c\u3002", "e": "Purpose: In this paper, the PTW N23333 ionization chamber was used to calibrate the in air exposure rate of IR-192 HDR brachytherapy source in a Gammamed 12I remote afterloading machine. The exposure rate of the source in finite cylinder plexiglass phantom that was equipped with the system was measured. The calibration factor of the plexiglass phantom for IR-192 source activity calibration is discussed and the clinical advantages of the phantom is summarized.\nMaterials and Methods: The in air exposure rate of the source was measured with the PTW N2333 ionization chamber connected to the Capintec electrometer at SCD equal to 8 cm. Source activity was calculated from the measured exposure according to the suggested parameters of AAPM Report 41. The in phantom exposure rate were measured with and without water phantom to calculated the back-scatter-factor of the plexiglass phantom.\nResults: The back-scatter-factor is equal to 1.081 and the factor Cgrad=1.158 should be considered to calibrate the scatter from the upper and button side of the phantom which was less due to the lack of scatter and dose gradient correction.\nConclusion: Calibrations in plexiglass phantom of Ir-192 HDR brachy-therapy source allow more stability and reproducibility. The calibration factors of the plexiglass phantom needs to be considered in routine source calibration."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-207-216-a", "title": "\u4f55\u6770\u91d1\u6c0f\u75c5\u7684\u653e\u5c04\u6cbb\u7642\u65b9\u6cd5\uff1a\u63a2\u8a0e\u8207\u5206\u6790", "keywords": "\u4f55\u6770\u91d1\u6c0f\u75c5;Clarkson \u65b9\u6cd5 Hodgkin", "c": "\u76ee\u7684\uff1a\u8a73\u7d30\u8a0e\u8ad6\u4f55\u6770\u91d1\u6c0f\u75c5\u653e\u5c04\u6cbb\u7642\u65b9\u6cd5\u8207\u5291\u91cf\u8a08\u7b97\u904e\u7a0b\uff0c\u4e26\u8a0e\u8ad6\u5176\u81e8\u5e8a\u4e0a\u5be6\u7528\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u91dd\u5c0d\u672c\u9662\uff0d18\u6b72\u4f55\u6770\u91d1\u6c0f\u75c5\u7537\u6027\u75c5\u4eba\uff0c\u8a0e\u8ad6\u6597\u84ec\u7167\u91ce\u3001\u5012Y\u578b\u7167\u91ceClarkson\u5291\u91cf\u8a08\u7b97\u65b9\u6cd5\uff0c\u4e26\u5229\u7528\u6cbb\u7642\u8a08\u76e1\u505a\u8ffd\u52a0\u7167\u5c04(boost)\u5291\u91cf\u63a8\u5b9a\uff0c\u53ca\u4f30\u7b97\u5169\u7167\u91ce\u9593\u8ddd\u82e5\u5e72\u3002\n\u8a08\u8ad6\uff1a\u5291\u91cf\u8a08\u7b97\u4e4b\u8aa4\u5dee\u4e3b\u8981\u4f86\u81ea\u9ad4\u8868\u4e0d\u5e73\u6574\u6027\uff0c\u8aa4\u5dee\u7d046%\u3002\u800c\u6597\u84ec\u7167\u91ce\u4e2d\u4e4b\u80ba\u8207\u5176\u4ed6\u7d44\u7e54\u4e4b\u5747\u52fb\u6027\uff0c\u7531\u65bc\u80ba\u90e8\u7d93\u7d66\u6a94\u584a\u906e\u6a94\uff0c\u5c0d\u65bc\u7167\u91ce\u7bc4\u570d\u5167\u4e4b\u5291\u91cf\u8a08\u7b97\u4e0d\u9020\u6210\u4efb\u4f55\u5f71\u97ff\u3002\u9ad4\u8868\u808b\u9aa8\u4e4b\u5f71\u97ff\uff0c\u8aa4\u5dee\u57281%\u4ee5\u5167\uff0c\u53ef\u4ee5\u5ffd\u7565\u3002\n\u7d50\u8ad6\uff1aClarkson \u65b9\u6cd5\u70ba\u8a08\u7b97\u4e0d\u898f\u5247\u7167\u91ce\u5291\u91cf\u4e4b\u53ef\u884c\u65b9\u6cd5\uff0c\u552f\u5176\u8cbb\u6642\u8cbb\u529b\uff0c\u6545\u96fb\u8166\u5316\u6216\u88fd\u4f5c\u63db\u7b97\u6a23\u7248\u4ee5\u63d0\u9ad8\u81e8\u5e8a\u5be6\u7528\u6027\u662f\u5fc5\u9808\u7684\u3002", "e": "Purpose: Discussing the dose evaluation process for Hodgkin's disease radiotherapy and the clinical practice. \nMaterials and Methods: Using the Clarkson's method to evaluate mantle and inverse Y fields dosimetry for a eighteen-year-old Hodgkin's disease patient in our hospital, and estimate the boost dose from treatment planning, otherwise, calculate the gap between two adjacent fields.\nDiscussion: The main error of dose evaluation came from the non-flatteness of body, which up to 6%. Since lung was blocked, the inhomogeneity between lung and adjacent tissue in the mantle field caused on effect to dose evaluation. The rib's effect which within 1% is negligible.\nConclusion: Clarkson's method is a useful way to evaluate the dose of irregular fields, but it is time wasting and laborious. Computerization or equivalent squares template may be applied to increase clinical practice."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199809-5-3-217-220-a", "title": "A Left Lower Lung Mass in a Hodgkin", "keywords": "\u653e\u5c04\u7dda\u80ba\u708e;\u4f55\u6770\u91d1\u6c0f\u75c7;\u813e\u81d3 Radiation pneumonitis;Hodgkin", "c": "\u653e\u5c04\u6cbb\u7642\u5728\u4f55\u6770\u91d1\u6c0f\u75c7\u7684\u6cbb\u7642\u4e0a\u5177\u6709\u50b3\u7d71\u7684\u89d2\u8272\u3002\u672c\u6587\u5831\u544a\u4e00\u4f4d\u7b2c\u4e8c\u671f\u4f55\u6770\u91d1\u6c0f\u75c7\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u5169\u500b\u6708\uff0c\u5de6\u4e0b\u80ba\u51fa\u73fe\u816b\u584a\u75c5\u8b8a\uff0c\u8a72\u816b\u584a\u4f4d\u65bc\u5fc3\u81df\u5de6\u5916\u5074\u4e0b\u7de3\uff0c\u4e26\u4e14\u9020\u6210\u6a6b\u9694\u819c\u5074\u5f71\u7684\u6a21\u7cca\u3002\u56e0\u70ba\u8a72\u816b\u584a\u7684\u75c5\u8b8a\u4f4d\u7f6e\u8207\u4e00\u822c\u6240\u8a8d\u77e5\u7684\u56e0\u201c\u6597\u84ec\u7167\u5c04\u201d\u5f8c\u5f15\u8d77\u5f9e\u9694\u8154\u65c1\u7684\u653e\u5c04\u7dda\u80ba\u708e\u4e26\u4e0d\u543b\u5408\uff0c\u4ee5\u81f4\u65bc\u8a72\u816b\u584a\u4e00\u5ea6\u88ab\u5224\u8b80\u70ba\u816b\u7624\u6216\u80ba\u7d50\u6838\u816b\u584a\u3002\u4f46\u662f\u7d93\u904e\u6211\u5011\u6bd4\u5c0d\u6a6b\u9694\u819c\u4e0b\u7167\u91ce\u5f8c\u767c\u73fe\uff0c\u5176\u4f4d\u7f6e\u8207\u8a72\u7167\u5c04\u4f4d\u7f6e\u543b\u5408\uff0c\u61c9\u662f\u813e\u81df\u7167\u5c04\u5f8c\u5f15\u8d77\u7684\u653e\u5c04\u7dda\u80ba\u708e\u3002\u7d93\u904e\u6aa2\u67e5\u53ca\u50c5\u75c7\u72c0\u4e0a\u7684\u6cbb\u7642\u5f8c\uff0c\u8a72\u816b\u584a\u5728\u4e09\u500b\u6708\u5f8c\u81ea\u884c\u6d88\u5931\u3002\u9019\u500b\u5c11\u898b\u7684\u6848\u4f8b\u986f\u793a\uff0c\u4e86\u89e3\u653e\u5c04\u7dda\u7167\u91ce\u7684\u5b89\u6392\uff0c\u5c0d\u65bc\u6b63\u786e\u5730\u5224\u8b80\u4f55\u6770\u91d1\u6c0f\u75c7\u75c5\u4eba\u6cbb\u7642\u5f8c\u7684\u80f8\u90e8X\u5149\u7247\u7684\u91cd\u8981\u6027\u3002", "e": "Radiation therapy played a classic role in the radical treatment of localized Hodgkin's disease. We described a Hodgkin's disease patient, stage \u2161A, who was found a left lung mass on a chest film 2 months after irradiation. The mass was near the left lower heart border and obliterated the left diaphragm silhouette. Because the location was quite different from the commonly recognized paramediastinal radiation pneumonitis following mantle-field irradiation, the lesion has been mistakenly interpreted as a recurrent tumor or tuberculoma. After reviewing and comparing the chest radiograph with the subdiaphragmatic port-film, a diagnosis of radiation pneumonitis due to spleen irradiation was suspected. Given only symptomatic treatment, the mass spontaneously resolved 3 months later. The unusual case highlighted the importance of knowledge of the radiationport arrangement on the correct interpretation of a follow-up chest radiograph in Hodgkin's disease patients receiving radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-65-71-a", "title": "\u4e0d\u540c\u65b9\u5f0f\u653e\u5c04\u7dda\u7167\u5c04\u6cd5\u5c0d\u9f3b\u54bd\u764c\u75c5\u4eba\u553e\u6db2\u817a\u529f\u80fd\u4e4b\u5f71\u97ff", "keywords": "\u653e\u5c04\u6cbb\u7642;\u553e\u6db2;\u9f3b\u54bd\u764c Radiotherapy;Saliva;Nasopharyngeal carcinoma", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u9f3b\u54bd\u764c\u75c5\u4eba\u653e\u5c04\u6cbb\u7642\u524d\u5f8c\u5168\u553e\u6db2\u6d41\u91cf\u4e4b\u8b8a\u5316\uff0c\u53ca\u6aa2\u9a57\u591a\u5206\u6b21\u653e\u5c04\u7dda\u7167\u5c04\u6cd5\uff0c\u662f\u5426\u5982\u7406\u8ad6\u6240\u9810\u671f\uff0c\u53ef\u4ee5\u964d\u4f4e\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u553e\u6db2\u817a\u4e4b\u50b7\u5bb3\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e00\u5171\u5c0d30\u4f8b\u63a5\u53d7\u50b3\u7d71\u7167\u5c04\u820717\u4f8b\u591a\u5206\u6b21\u7167\u5c04\u4e4b\u75c5\u4eba\uff0c\u5b9a\u91cf\u5730\u6e2c\u91cf\u9f3b\u54bd\u764c\u75c5\u4eba\u6cbb\u7642\u524d\u3001\u63a5\u53d7\u4e0d\u540c\u5291\u91cf\u7167\u5c04\u5f8c\u3001\u53ca\u6cbb\u7642\u7d50\u675f\u5f8c\u4e00\u3001\u4e09\u53ca\u516d\u500b\u6708\u6642\uff0c\u975c\u6b62\u614b\u8207\u523a\u6fc0\u614b\u6642\u553e\u6db2\u7e3d\u6d41\u91cf\u7684\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u767c\u73fe\u6b63\u5e38\u672a\u7167\u5c04\u4e4b\u553e\u6db2\u6d41\u91cf\u500b\u5225\u5dee\u7570\u6975\u5927\uff0c\u975c\u6b62\u72c0\u614b\u7bc4\u570d\uff1a0.01-0.83 ml/min\uff1b\u523a\u6fc0\u72c0\u614b0.08-2.83 ml/min\u3002\u800c\u4e14\u553e\u6db2\u817a\u5c0d\u65bc\u653e\u5c04\u7dda\u6975\u5ea6\u654f\u611f\uff0c\u7167\u5c04\u50c5360-720 cGy\u4e4b\u5f8c\uff0c\u975c\u6b62\u72c0\u614b\u7e3d\u553e\u6db2\u6d41\u91cf\u5df2\u6e1b\u5c1150\uff05\uff0c\u5c11\u6578\u75c5\u4eba\u66f4\u5df2\u6e1b\u5c11\u81f3\u539f\u4f86\u4e4b10\uff05\u4ee5\u4e0b\uff1b\u800c\u523a\u6fc0\u72c0\u614b\u4e0b\u7684\u7e3d\u6d41\u91cf\uff0c\u4e5f\u6025\u5287\u964d\u81f3\u539f\u4f86\u768430-50\uff05\u3002\u800c\u4e14\u5728\u7167\u5c043600 cGy\u4e4b\u5f8c\uff0c\u5927\u90e8\u4efd\u75c5\u4eba\u553e\u6db2\u6d41\u91cf\u5df2\u9054\u6700\u4f4e\u9ede\u3002\u81f3\u65bc\u4f7f\u7528\u591a\u5206\u6b21\u7167\u5c04\u6cd5\u662f\u5426\u8f03\u50b3\u7d71\u7167\u5c04\u6cd5\u80fd\u6e1b\u8f15\u553e\u6db2\u817a\u4e4b\u653e\u5c04\u50b7\u5bb3\uff0c\u7d93\u4ee5GEE\u4e4b\u7d71\u8a08\u5b78\u5206\u6790\uff0c\u767c\u73fe\u57fa\u672c\u4e0a\u5169\u7a2e\u7167\u5c04\u6cd5\u5c0d\u65bc\u5168\u553e\u6db2\u6d41\u91cf\u4e26\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e0d\u904e\u4e0d\u8ad6\u662f\u975c\u6b62\u614b\u6216\u523a\u6fc0\u614b\u6642\uff0c\u5728\u7167\u5c04\u7d50\u675f\u81f3\u534a\u5e74\u671f\u9593\uff0c\u591a\u5206\u6b21\u7167\u5c04\u6cd5\u6709\u8f03\u597d\u5275\u9803\u5411\uff08p\u503c\u5206\u5225\u70ba0.039\u53ca0.04\uff09\u3002\u6b64\u5916\uff0c\u5206\u6790\u767c\u73fe\u5973\u6027\u3001\u672a\u7167\u5c04\u524d\u4e4b\u553e\u6db2\u6d41\u91cf\u9ad8\u3001\u4ee5\u53ca\u5e74\u9f61\u8d8a\u5927\u8005\uff0c\u553e\u6db2\u817a\u7d93\u7167\u5c04\u5f8c\u5176\u6d41\u91cf\u6e1b\u5c11\u8d8a\u660e\u986f\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u9996\u5ea6\u5c31\u570b\u4eba\u553e\u6db2\u6d41\u91cf\u4e4b\u6b63\u5e38\u503c\u63d0\u51fa\u5177\u9ad4\u6578\u64da\uff0c\u767c\u73fe\u500b\u5225\u5dee\u7570\u6975\u5927\u3002\u553e\u6db2\u817a\u5c0d\u65bc\u653e\u5c04\u7dda\u6975\u5ea6\u654f\u611f\uff0c\u7167\u5c04\u50c5360-720 cGy\u4e4b\u5f8c\uff0c\u975c\u6b62\u8207\u523a\u6fc0\u72c0\u614b\u7e3d\u553e\u6db2\u6d41\u91cf\u5df2\u6e1b\u5c1130-50%\u3002\u7167\u5c043600 cGy\u4e4b\u5f8c\uff0c\u5927\u90e8\u4efd\u75c5\u4eba\u553e\u6db2\u6d41\u91cf\u5df2\u9054\u6700\u4f4e\u9ede\uff0c\u4e14\u76f4\u5230\u7167\u5c04\u7d50\u675f\u5f8c\u516d\u500b\u6708\u5747\u4e0d\u898b\u6062\u5fa9\u3002\u4f7f\u7528\u591a\u5206\u6b21\u7167\u5c04\u6cd5\uff0c\u5728\u553e\u6db2\u817a\u50b7\u5bb3\u65b9\u9762\uff0c\u4f3c\u672a\u6bd4\u50b3\u7d71\u7167\u5c04\u6cd5\u597d\u3002", "e": "Purpose: To evaluate the change of whole salivary flow rates of nasopharyngeal carcinoma patients before and after radiotherapy, and to examine whether hyperfractionated regimen may induce less damage to the salivary glands than conventional technique. \nMaterials and Methods: This study included 30 and 17 patients irradiated using conventional and hyperfractionated radiotherapy. Whole salivary flow rates were measured both at resting and stimulated status before, during, 1, 3 and 6 months after radiotherapy. \nResults: A large variation in unirradiated salivary flow rate was noted with the range for resting and stimulated rates of 0.01-0.83 ml/min and 0.08-2.83 ml/min, respectively. After 360-720 cGy, the resting and stimulated salivary flow rate had already decreased by 30-50%. The nadir was reached in many patients after 3600 cGy. Statistical analysis did not show significant difference between the hyperfractionated and conventional groups. However, after completing radiotherapy and up to 6 months' follow-up, a marginal difference favoring hyperfractionated group was noted both for resting and stimulated flow (p=0.039 & 0.04, respectively). In addition, female, high initial salivary flow rate, and older age might predict more salivary flow rate reduction after radiotherapy. \nConclusions: Salivary glands were highly radiosensitive, and saliva excretion dropped by 30-50% after 360-720 cGy. The present study did not show a significant reduction of damage to the salivary glands using hyperfractionated radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-73-80-a", "title": "\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\uff1a\u6797\u53e3\u9577\u5e9a\u7d00\u5ff5\u91ab\u9662\u7684\u521d\u6b65\u7d93\u9a57", "keywords": "\u624b\u8853\u4e2d\u96fb\u5b50\u5c04\u7dda\u653e\u5c04\u6cbb\u7642;\u624b\u8853\u4e2d\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642;\u9ad4\u5916\u653e\u5c04\u6cbb\u7642 Intraoperative electron radiotherapy (IOERT);Intraoperative brachytherapy (IOBRT);External beam radiotherapy (EBRT)", "c": "\u76ee\u7684\uff1a\u5c0d\u65bc\u5c40\u90e8\u4fb5\u72af\u76f8\u7576\u56b4\u91cd\u6216\u767c\u751f\u5c40\u90e8\u5fa9\u767c\u4e4b\u8179\u90e8\u3001\u9aa8\u76c6\u8154\u5167\u7684\u60e1\u6027\u816b\u7624\u800c\u8a00\uff0c\u50c5\u9760\u55ae\u4e00\u7a2e\u6cbb\u7642\u65b9\u5f0f\u8981\u4f86\u9054\u5230\u9577\u671f\u7684\u75be\u75c5\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u662f\u76f8\u7576\u56f0\u96e3\u7684\u3002\u672c\u7814\u7a76\u4e3b\u8981\u662f\u5831\u544a\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u5c0d\u65bc\u4e0a\u8ff0\u60c5\u6cc1\u7684\u816b\u7624\u63a1\u7528\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u7684\u521d\u6b65\u7d93\u9a57\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1996\u5e743\u6708\u8d77\uff0c\u672c\u9662\u958b\u59cb\u91dd\u5c0d\u4e0b\u5217\u60c5\u6cc1\u7684\u816b\u7624\u63a1\u7528\u624b\u8853\u4e2d\u5408\u4f75\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u7684\u65b9\u5f0f\u3002\u4e00\u985e\u662f\u91dd\u5c0d\u539f\u767c\u4f46\u5c1a\u672a\u7d93\u904e\u5176\u5b83\u65b9\u5f0f\u6cbb\u7642\u7684\u816b\u7624\uff08\u5982\u80f0\u81df\u764c\u3001\u80c3\u764c\uff09\uff1b\u53e6\u4e00\u985e\u5247\u662f\u5c0d\u5fa9\u767c\u7684\u9aa8\u76c6\u8154\u5167\u816b\u7624\uff08\u5982\u76f4\u8178\u764c\u3001\u5b50\u5bae\u9838\u764c\uff09\u505a\u6551\u63f4\u6027\u7684\u6cbb\u7642\u3002\u81f31997\u5e7411\u6708\u6b62\uff0c\u5171\u6cbb\u7642\u4e8648\u4f4d\u6210\u4eba\u60a3\u8005\uff0c\u5e74\u9f61\u5206\u5e03\u5f9e324\u81f375.7\u6b72\uff08\u4e2d\u4f4d\u6578\uff1a60.5\u6b72\uff09\u3002\u6cbb\u7642\u7684\u60a3\u8005\u8a08\u670919\u4f8b\u80f0\u81df\u764c\u30016\u4f8b\u81bd\u9053\u764c\u30016\u4f8b\u5191\u764c\u30019\u4f8b\u5927\u8178\u76f4\u8178\u764c\u30011\u4f8b\u5fa9\u767c\u7684\u7a7a\u8178\u5e73\u6ed1\u808c\u8089\u7624(jejunal leiomyosarcoma)\u3001\u53ca7\u4f8b\u5fa9\u767c\u7684\u5a66\u79d1\u60e1\u6027\u816b\u7624\u3002\n\u7d50\u679c\uff1a58%\u7684\u60a3\u8005\u81f3\u4eca\u4ecd\u5b58\u6d3b\uff0c\u5305\u62ec7\u4f8b\u80f0\u81df\u764c\u30014\u4f8b\u81bd\u9053\u764c\u30013\u4f8b\u80c3\u764c\u30018\u4f8b\u5927\u8178\u76f4\u8178\u764c\u3001\u53ca5\u4f8b\u5a66\u79d1\u60e1\u6027\u816b\u7624\u201d\u9664\u4e86\u80fd\u5920\u63a5\u53d7\u9aa8\u76c6\u8154\u5668\u5b98\u5168\u6458\u9664\u7684\u9aa8\u76c6\u8154\u816b\u7624\u4e4b\u5916\uff0c\u5176\u5b83\u75c5\u4f8b\u5728\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u4e4b\u6642\u4ecd\u6709\u6b98\u7559\u7684\u816b\u7624\u6216\u751a\u81f3\u6839\u672c\u7121\u6cd5\u5207\u9664\u8a72\u816b\u7624\u300274%\u4e4b\u80f0\u81df\u764c\u60a3\u8005\u5728\u8853\u524d\u56e0\u816b\u7624\u58d3\u8feb\u5230\u4e3b\u52d5\u8108\u65c1\u795e\u7d93\u53e2\u5f15\u8d77\u7684\u6975\u5ea6\u75bc\u75db\u5728\u63a5\u53d7\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u4e4b\u5f8c\u5373\u523b\u5f97\u5230\u76f8\u7576\u597d\u7684\u7de9\u89e3\u3002\u8207\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u7684\u9ad8\u5291\u91cf\u6709\u95dc\u4e4b\u4f75\u767c\u75c7\u81f3\u76ee\u524d\u70ba\u6b62\u67091\u4f8b\u767c\u751f(2%)\u3002\n\u7d50\u8ad6\uff1a\u5c0d\u65bc\u5c40\u90e8\u6709\u6975\u9ad8\u5fa9\u767c\u5371\u96aa\u6027\u4e4b\u8179\u90e8\uff0d\u9aa8\u76c6\u8154\u60e1\u6027\u816b\u7624\u800c\u8a00\uff0c\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u662f\u500b\u5b89\u5168\u4e14\u53ef\u884c\u7684\u6cbb\u7642\u65b9\u5f0f\u4e4b\u4e00\u3002\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u6e1b\u8f15\u80f0\u81df\u816b\u7624\u6240\u5f15\u8d77\u7684\u75bc\u75db\u76f8\u7576\u6709\u6548\u3002\u9032\u4e00\u6b65\u7684\u8a55\u4f30\u9808\u8981\u66f4\u9577\u6642\u9593\u7684\u8ffd\u7d9c\u3002", "e": "Purpose: In patients with locally recurrent or advanced abdominal/pelvic malignancies, long-term disease control and survival are difficult to achieve with single modality therapy. This report presents the preliminary results of intraoperative radiotherapy (IORT) in our hospital. \nMaterials and Methods: In our hospital, TORT has been utilized either as part of the initial management in some previously untreated primary malignancies (e.g., pancreatic carcinoma, gastric carcinoma) or part of the salvage or adjuvant treatment in other malignancies (e.g., recurrent rectal or cervical cancer) since March 1996. Up to November 1997, 48 adult patients underwent this treatment modality with age ranging from 32.4 to 75.7 years old (median: 60.5). The malignancies treated by IORT consisted of 19 pancreatic cancers, 6 cholangiocarcinomas, 6 gastric cancers, 9 colorectal cancers, one case of recurrent jejunal leiomyosarcoma, and 7 gynecologic cancers. \nResult: Twenty-eight of 48 patients (58%) were alive (including 7/19 pancreatic cancers, 4/6 cholangiocarcinoma, 3/6 gastric cancers, 8/9 colorectal cancers, 5/7 gynecologic cancers). Except for some patients with pelvic malignancies receiving pelvic exenteration, all of the other patients had either gross residual or unresectable disease. Seventy-four percent of the patients with pancreatic cancer suffering from epigastralgia or back pain before treatment had achieved good symptomatic relief after surgery and IORT. TORT-related complications due to high dose irradiation occurred in two patients (4%). \nConclusion: The preliminary results suggested that IORT was a safe and feasible modality for abdominal pelvic malignancies at high risk for local recurrence. It was especially effective in relieving tumor pain caused by pancreatic cancer. Longer follow-up should be needed to evaluate the toxicity and efficacy of this approach."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-81-88-a", "title": "Treatment Results of Rectal Adenocarcinoma after Curative Surgery and Recurrent Disease after Salvage Treatment", "keywords": "\u76f4\u8178\u817a\u764c;\u6839\u9664\u624b\u8853;\u62ef\u6551\u6027\u6cbb\u7642 Rectal adenocarcinoma;Curative surgery;Salvage treatment", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4e3b\u8981\u5206\u6790\u539f\u767c\u76f4\u8178\u817a\u764c\u7684\u7d93\u6839\u9664\u624b\u8853\u6cbb\u7642\u7684\u7d50\u679c\u4ee5\u53ca\u8a0e\u8ad6\u5fa9\u767c\u76f4\u8178\u817a\u764c\u4e4b\u62ef\u6551\u6027\u6cbb\u7642\u626e\u6f14\u7684\u89d2\u8272\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u53f0\u4e2d\u69ae\u6c11\u7e3d\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u81ea1980\u5e74\u81f31995\u5e74\u764c\u75c5\u767b\u8a18\u670990\u4f4d\u539f\u767c\u76f4\u8178\u817a\u764c\u60a3\u8005\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u767b\u8a18\u8cc7\u6599\uff0c\u4f46\u624b\u8853\u904e\u7a0b\u4e2d\u767c\u73fe\u6709\u9aa8\u76c6\u8154\u4ee5\u5916\u64f4\u6563\u7684\u7684\u60a3\u8005\u3001\u78ba\u5b9a\u8a3a\u65b7\u6642\u63a5\u53d7\u59d1\u606f\u6027\u624b\u8853\u8005\u3001\u53ca\u6cbb\u7642\u8a18\u9304\u4e0d\u5b8c\u6574\u8005\u7686\u4e0d\u5217\u5165\u672c\u6587\u5206\u6790\uff0c\u6709\u6548\u5206\u6790\u8005\u5171\u670960\u4f4d\u60a3\u8005\uff0c\u6240\u6709\u75c5\u60a3\u5747\u63a5\u53d7\u4e86\u6839\u9664\u624b\u8853\uff0c\u8f14\u52a9\u6cbb\u7642\u63a1\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u6216\u5316\u5b78\u6cbb\u7642\u5247\u4e3b\u8981\u7531\u5916\u79d1\u91ab\u5e2b\u6c7a\u5b9a\uff1b\u816b\u7624\u5fa9\u767c\u85c9\u7531\u7406\u5b78\u6aa2\u67e5\u3001\u5f71\u50cf\u6aa2\u67e5\u5982\u96fb\u8166\u65b7\u5c64\u6216\u78c1\u632f\u9020\u5f71\u3002\u5927\u8178\u93e1\u6aa2\u3001\u764c\u80da\u6297\u539f(CEA)\u3001\u6216\u662f\u8d85\u97f3\u6ce2\u6aa2\u67e5\u7684\u7d50\u679c\u4f86\u78ba\u5b9a\u3002\u672c\u6587\u4f7f\u7528Kaplan-Meier\u65b9\u6cd5\u81ea\u624b\u8853\u65e5\u958b\u59cb\u7b97\u8d77\u5206\u6790\u5b58\u6d3b\u7684\u6642\u9593\u3002\n\u7d50\u679c\uff1a\u901960\u4f4d\u60a3\u8005\u4e4b\u5169\u5e74\u53ca\u4e94\u5e74\u7684\u5168\u9ad4\u5b58\u6d3b\u7387\u5206\u5225\u662f63\u53ca33%\uff0c\u4e00\u822c\u5fa9\u767c\u7387\u662f88%\uff0c\u8853\u5f8c\u5230\u5c40\u90e8\u5fa9\u767c\u5e73\u5747\u6642\u9593\u662f26\u500b\u6708\uff0c\u8853\u5f8c\u5230\u9060\u8655\u8f49\u79fb\u5e73\u5747\u6642\u554f\u662f21\u500b\u6708\u3002\u50c5\u67095\u4f4d\u60a3\u8005\u7684\u55ae\u7368\u9aa8\u76c6\u8154\u5fa9\u767c\u80fd\u5920\u63a5\u53d7\u518d\u5ea6\u6cbb\u7652\u6027\u7684\u624b\u8853\u5207\u9664\u3002\u76f4\u8178\u764c\u5fa9\u767c\u63a5\u53d7\u59d1\u606f\u6027\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u4e2d\u503c\u5b58\u6d3b\u6642\u9593\u662f6\u500b\u6708\uff0c7\u4f4d\u76f4\u8178\u764c\u5fa9\u767c\u7684\u60a3\u8005\u50c5\u63a5\u53d7\u62ef\u6551\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u81ea\u8a3a\u65b7\u51fa\u816b\u7624\u5fa9\u767c\u65e5\u7b97\u8d77\uff0c\u63a5\u53d7\u62ef\u6551\u6027\u624b\u8853\u7684\u60a3\u8005\u4e4b\u5b58\u6d3b\u4e2d\u503c\u6642\u554f\u70ba16\u500b\u6708\uff0c\u5c0d\u65bc\u50c5\u63a5\u53d7\u62ef\u6551\u6027\u653e\u5c04\u6cbb\u7642\u7684\u60a3\u8005\uff0c\u5176\u5b58\u6d3b\u4e2d\u503c\u6642\u9593\u70ba85\u500b\u6708\u3002\n\u7d50\u8ad6\uff1a\u539f\u767c\u76f4\u8178\u817a\u764c\u7684\u60a3\u8005\u50c5\u63a5\u53d7\u6839\u9664\u6027\u624b\u8853\uff0c\u4ecd\u6709\u5f88\u9ad8\u7684\u5fa9\u767c\u7387\uff0c\u6709\u5c11\u6578\u5c40\u90e8\u5fa9\u767c\u7684\u60a3\u8005\u53ef\u518d\u6b21\u65bd\u884c\u6839\u9664\u6027\u7684\u624b\u8853\u800c\u7372\u5f97\u8f03\u9577\u7684\u5b58\u6d3b\u6642\u9593\u3002", "e": "Purpose: This study was to analyze the treatment results of our patients with rectal adenocarcinoma receiving curative surgery \u00b1 radiotherapy and discuss the role of salvage treatment for recurrence. \nMaterials and Methods: A total of 90 patients with rectal adenocarcinoma who received radiotherapy from 1980 to 1995 were registered at Department of Radiation Oncology, Taichung Veteran General Hospital. The patients who were found to have extrapelvic extension at operation, palliative surgery at diagnosis, and incomplete data were excluded. Sixty patients were analyzable. All these 60 patients received potentially curative surgery at diagnosis. Adjuvant therapy with radiotherapy or chemotherapy was mainly decided by the surgeon. Recurrence of tumor was documented by physical examination, imaging studies such as CT scan or MRI, colonosoopy, CEA, or sonography. The salvage treatment of recurrent tumor included reoperation with curative or palliative intent, radiotherapy alone or with chemotherapy. Analysis of survival was calculated from the date of operation using Kaplan-Meier method. \nResults: Of these 60 patients 2- and 5-year overall survival rate were 63% and 33%, respectively. Overall recurrence rate was 88%. The mean loco-regional recurrence time was 26 months vs. 21 months for distant metastasis. Only 5 patients with isoloated pelvic recurrence can be salvaged by reoperation with curative intent. The patients with recurrent cancer receiving palliative surgery survived at a median of 6 months. Seven patients with recurrent disease were salvaged with radiotherapy only. The patients with salvage surgery survived at a median of 16 months after diagnosis of recurrence vs. 8.5 months for patients with salvage radiotherapy only. Clinical variables such as age, gender, stage, tumor location, and tumor size had no statistically significant impact on survival. \nConclusion: There was substantially high recurrence rate for patients with even potentially curative resection of primary rectal adenocarcinoma. A minority of patients with isolated local recurrence can be salvaged by aggressive reoperation with a relatively long survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-89-99-a", "title": "A Radiotherapy Survey on the Institutional Manpowers, Patients, and Treatment Characteristics in the Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital between 1987-1996", "keywords": "\u653e\u5c04\u816b\u7624\u5b78;\u91ab\u7642\u7167\u9867\u6a21\u5f0f\u7814\u7a76;\u4eba\u529b\u8cc7\u6e90;\u75c5\u60a3\u8ca0\u8f09 Radiation oncology;Patterns of Care Study;Manpower;Patient load", "c": "\u76ee\u7684\uff1a\u8abf\u67e5\u9ad8\u96c4\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d11987\u81f31996\u5341\u5e74\u671f\u9593\u4e4b\u4eba\u529b\u9700\u6c42\u3001\u75c5\u60a3\u3001\u53ca\u6cbb\u7642\u7279\u5fb5\u3002\u90e8\u5206\u9805\u76ee\u548c\u7f8e\u570b\u7684Patterns of Care Study (PCS)\u505a\u6bd4\u8f03\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1987\u81f31996\u5b58\u653e\u5728\u500b\u4eba\u96fb\u8166\u764c\u767b\u7cfb\u7d71\u7684\u8cc7\u6599\u6a94\u6848\u9032\u884c\u56de\u9867\u6027\u7684\u5206\u6790\u3002\u4e3b\u8981\u9805\u76ee\u5305\u62ec\uff1a\u6bcf\u5e74\u65b0\u75c5\u4eba\u6578\u3001\u764c\u60a3\u8f49\u8a3a\u3001\u5404\u5de5\u4f5c\u4eba\u54e1\u53ca\u6cbb\u7642\u6a5f\u7684\u5e73\u5747\u8ca0\u8377\u3001\u75be\u75c5\u578b\u614b\u3001\u6cbb\u7642\u5b8c\u6210\u7387\u3001\u5206\u6b21\u65b9\u5f0f\u3001\u6cbb\u7642\u76ee\u7684\u3001\u53ca\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7684\u4f7f\u7528\u60c5\u5f62\u3002\n\u7d50\u679c\uff1a(l)\u6bcf\u5e74\u65b0\u75c5\u4eba\u6578\u5f9e458-1265\u4eba\uff08\u5e73\u57471087)\uff0c\u6578\u76ee\u5448\u9010\u5e74\u7de9\u548c\u4e0a\u5347\uff0c\u4f46\u8fd14\u5e74\u5247\u5448\u6c34\u5e73\u72c0\u614b\u3002\u764c\u60a3\u8f49\u4ecb\u7387\u7d0430%\uff0c\u6b64\u8f49\u4ecb\u7387\u5728\u524d\u671f(1987-1991)\u70ba26%\uff0c\u5f8c\u671f(1992-1996)\u70ba33%\uff0c\u5448\u5fae\u5e45\u6210\u9577\uff0c\u4f46\u6574\u9ad4\u800c\u8a00\uff0c\u4ecd\u6bd4PCS\u7684\u5831\u544a\u70ba\u4f4e\u3002(2)\u5404\u5de5\u4f5c\u4eba\u54e1\u53ca\u6cbb\u7642\u6a5f\u7684\u5e73\u5747\u8ca0\u8377\uff08\u75c5\u4eba\u6578\u5e74\uff09\u5982\u4e0b\uff1a\u91ab\u5e2b281(177-339)\uff0c\u7269\u7406\u5e2b350(280-466)\uff0c\u6280\u8853\u5e2b123(86-157)\uff0c\u6cbb\u7642\u6a5f428(298-705)\uff0c\u5404\u5de5\u4f5c\u4eba\u54e1\u53ca\u6cbb\u7642\u6a5f\u7684\u5e73\u5747\u8ca0\u8377\u5448\u9010\u5e74\u4e0b\u964d\u7684\u8da8\u52e2\u3002(3)\u6700\u5e38\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u4e94\u7a2e\u764c\u75c5\u4f9d\u6b21\u662f\uff1a\u80ba\u764c(15.9%)\u3001\u5b50\u5bae\u9838\u764c(14.5%)\u3001\u9f3b\u54bd\u764c(13.1%)\u3001\u982d\u9838\u90e8\u816b\u7624(12.2%)\u3001\u53ca\u76f4\u8178\u764c(72%)\u3002\u55ae\u7d14\u826f\u6027\u75be\u75c5\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5247\u4f54l%\u3002(4)1\u81f315\u6b72\u5c0f\u5152\u816b\u7624\u4f541.8%\u3002(5) 57\uff05\u7684\u75c5\u60a3\u5176\u6cbb\u7642\u76ee\u7684\u662f\u6cbb\u6108\u6027\uff0c12\uff05\u7684\u75c5\u60a3\u56e0\u624b\u8853\u5f8c\u5fa9\u767c\u800c\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002(6)\u6574\u9ad4\u7684\u6cbb\u7642\u5b8c\u6210\u7387\u70ba76\uff05\u3002(7)\u4f7f\u7528\u50b3\u7d71\u7684\u5206\u6b21\u65b9\u5f0f\u4f5469%\uff0c\u4e00\u5929\u5169\u6b21\u7684\u5206\u6b21\u4f541%\uff0c\u4e26\u4e14\u5927\u90e8\u5206\u662f\u982d\u9838\u90e8\u816b\u7624\u3002(8)\u4f7f\u7528\u96fb\u8166\u505a\u6cbb\u7642\u8a08\u5283\u5247\u5448\u9010\u5e74\u6fc0\u589e\u7684\u8da8\u52e2\uff0c3D\u7684\u6cbb\u7642\u5728\u6700\u8fd1\u4e00\u5e74\u5df2\u8d85\u8d8a2D\u7684\u6cbb\u7642\u7e3d\u6578\u3002\n\u7d50\u8ad6\uff1a\u5404\u5de5\u4f5c\u4eba\u54e1\u53ca\u6cbb\u7642\u6a5f\u7684\u5e73\u5747\u8ca0\u8377\u6709\u9010\u5e74\u964d\u4f4e\u7684\u8da8\u52e2\uff0c\u9019\u500b\u8da8\u52e2\u548cPCS\u985e\u4f3c\u3002\u672c\u9662\u7684\u764c\u60a3\u8f49\u8a3a\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u6bd4\u4f8b\u504f\u4f4e\uff0c\u9019\u7a2e\u73fe\u50cf\u5728\u5341\u5e74\u671f\u9593\u4e26\u672a\u6709\u592a\u5927\u7684\u6539\u5584\u3002\u4e00\u5929\u5169\u6b21\u7684\u6cbb\u7642\u5728\u6574\u500b\u8abf\u67e5\u671f\u9593\u6975\u5c11\u4f7f\u7528\u3002\u6cbb\u7642\u5b8c\u6210\u7387\u53ca\u4ee5\u6cbb\u7652\u70ba\u76ee\u6a19\u7684\u6bd4\u4f8b\uff0c\u5247\u5927\u81f4\u4ee4\u4eba\u6eff\u610f\u4e26\u4e14\u548cPCS\u76f8\u8fd1\u3002", "e": "Purpose: To conduct a survey on the institutional manpower, patients, and treatment characteristics at the Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital between 1987-1996. Some of the survey items were compared with results of Patterns of Care Study (PCS) in the United States. \nMethods and Materials: The database of 9785 radiotherapy (RT) patients registered in a personal computer-based cancer registry system between 1987 and 1996 was reviewed and analyzed. Major items of the survey included: new cases per annum (NCPA), patient referral, average patient load and its trends over time, disease patterns, treatment intent, treatment completion, fractionation patterns, and application of computer in the assistance of radiotherapy treatment planning. \nResults: (1) The NCPA ranged from 458 to 1264, the mean being 1087. The number increased by year, and reached a plateau during the last four years. The crude rate of patient referral for RT was 30%. The referral rate in the two treatment periods, 1987-1991 and 1992-1996, increased mildly from 26% to 33%, respectively. (2) The average patient load (NCPA per personnel or machine) was as follows: radiation oncologist: 281 (range, 177-339); physicist: 350 (range, 280-466); technologist: 123 (range, 86-157); machine: 428 (range, 298-705). The patient load for personnel and machine declined overtime. (3) The five diseases most commonly treated were cancers of the lung (15.9%), cervix (14.5%), nasopharynx (13.1%, NPC), head/neck (12.2%, exclude NPC), recto-sigmoid (7.2%). Purely benign disorders accounted for about 1% of cases. (4) Pediatric patients of age \uff1c 15 years accounted for 1.8% of cases. (5) Fifty-seven percent of patients were treated with curative-intent (definitive plus adjuvant). Twelve percent of patients were treated with salvage FIT for postsurgical recurrence. (6) The overall treatment completion rate was 76%. (7) Conventional fraction, 1.8-2 Gy/day, was used in 69% of patients. Twice-a-day (BID) scheme accounted for 1% of cases. (8) The application of computerized treatment planning increased by sixfold in the two treatment peroids, 1987-1992 and 1992-1996, respectively. There was an obvious trend toward a decreased use of two-dimensional planning and an increase of three-dimensional planning. \nConclusion: Compared with the PCS survey, there was a similar trend toward a decline of average patient load for personnel and machine over time. The rate of cancer patients referral for radiotherapy was significantly lower than the PCS survey in the United States. Regarding the treatment, the BID scheme was rarely used throughout the period of the survey. The treatment completion rate and percentage of patients treated with curative intent appeared satisfactory and comparable with the result of PCS survey."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-101-109-a", "title": "\u7dad\u751f\u7d20K3\u55ae\u7368\u6216\u4f75\u7528\u6e38\u96e2\u8f3b\u5c04\u5c0d\u4eba\u985e\u809d\u764c\u7d30\u80de\u7684\u5f71\u97ff", "keywords": "\u7dad\u751f\u7d20K3;Hep3B\u809d\u764c\u7d30\u80de;\u5408\u4f75\u6cbb\u7642;\u5354\u540c\u4f5c\u7528 Menadione;Hep3B hepatoma cell;Combined treatment;Synergistic effect", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u7684\u76ee\u7684\u5728\u63a2\u8a0e\u7dad\u751f\u7d20K3(menadione)\u55ae\u7368\u6216\u4f75\u7528\u6e38\u96e2\u8f3b\u5c04\u5c0d\u65bc\u4eba\u985e\u809d\u764cHep3B\u7d30\u80de\u4e4b\u6bba\u50b7\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u5206\u5225\u63a2\u8a0eHep3B\u7d30\u80de\u4ee5\u7dad\u751f\u7d20K3\uff0c\u6e38\u96e2\u8f3b\u5c04\u55ae\u7368\u8655\u7406\u6216\u5408\u4f75\u8655\u7406\u6642\u4e4b\u5b58\u6d3b\u66f2\u7dda\uff0c\u5408\u4f75\u8655\u7406\u4e4b\u65b9\u5f0f\u5982\u4e0b\uff1a\u5148\u7d66\u4e8835\u00b5M\u7dad\u751f\u7d20K3\u4e09\u5c0f\u6642\u518d\u8f3b\u5c04\u7167\u5c04\uff1b\u6216\u5148\u8f3b\u5c04\u7167\u5c04\u518d\u7d66\u4e88\u7dad\u751f\u7d20K3\uff1b\u6216\u5728\u7dad\u751f\u7d20K3\u5b58\u5728\u4e0b\uff0c\u540c\u6642\u7d66\u5b50\u8f3b\u5c04\u7167\u5c04\u3002\n\u7d50\u679c\uff1a\u7814\u7a76\u7d50\u679c\u767c\u73fe\u7dad\u751f\u7d20K3\u5c0d\u65bcHep3B\u7d30\u80de\u4e4b\u751f\u9577\u6709\u6291\u5236\u4f5c\u7528\uff0c\u5176\u4f7f50%\u7d30\u80de\u6b7b\u4ea1\u4e4b\u6fc3\u5ea6(IC50)\u7d04\u70ba60 \u00b5M\u3002\u4ee510-100 \u00b5M\u7dad\u751f\u7d20K3\u8655\u7406Hep3B\u7d30\u80de\u4e09\u5c0f\u6642\u5f8c\uff0c\u7d30\u80de\u5167\u9084\u539f\u614b\u9ea9\u80f1\u7518\u80bd\u986f\u8457\u964d\u4f4e\u3002\u4ee52 Gy\u4ee5\u4e0a\u5291\u91cf\u8207\u7dad\u751f\u7d20K3\u5408\u4f75\u8655\u7406\u6642\uff0cHep3B\u4e4b\u5b58\u6d3b\u5206\u7387\u5927\u90e8\u4efd\u90fd\u964d\u81f315\uff05\u4ee5\u4e0b\uff0c\u986f\u8457\u589e\u52a0\u764c\u672a\u7530\u80de\u6b7b\u4ea1\u7684\u6548\u679c\u3002\n\u7d50\u8ad6\uff1a\u4ee5\u6e38\u96e2\u8f3b\u5c04\u548c\u7dad\u751f\u7d20K3\u5408\u4f75\u8655\u7406\u7d30\u80de\u6642\uff0c\u4ee5\u2018\u5148\u7167\u5c04\u5f8c\u7d66\u4e88\u7dad\u751f\u7d20K3\u2019\u6216\u8005\u2018\u7dad\u751f\u7d20K3\u5b58\u5728\u7684\u540c\u6642\u7d66\u4e88\u8f3b\u5c04\u7167\u5c04\u2019\u5169\u7a2e\u60c5\u6cc1\u6700\u597d\uff0c\u5177\u6709\u5354\u540c\u6bba\u50b7\u764c\u7d30\u80de\u7684\u4f5c\u7528(Synergism)\u3002\u81f3\u65bc\u2018\u5148\u7d66\u4e88\u7dad\u751f\u7d20K3\u518d\u8f3b\u5c04\u7167\u5c04\u2019\uff0c\u96648 Gy\u5916\uff0c\u5176\u9918\u90fd\u53ea\u6709\u52a0\u6210\u4f5c\u7528\u3002\u6b64\u7a2e\u6cbb\u7642\u9806\u5e8f\u7684\u5dee\u5225\u5c0e\u81f4\u764c\u7d30\u80de\u6b7b\u4ea1\u7387\u7684\u5dee\u7570\uff0c\u53ef\u80fd\u6709\u52a9\u65bc\u7dad\u751f\u7d20K3\u5728\u5408\u4f75\u6cbb\u7642\u4e0a\u7684\u61c9\u7528\u3002", "e": "Purpose: To study the killing effects of menadione alone or combined with ionizing radiation on human hepatoma Hep3B cell. \nMaterials and Methods: log-phase Hep3B cells were treated with menadione, ionizing radiation or the combination of both agents. Three protocols for combined treatments: first, cells were pre-treated with 35 \u00b5M menadione for 3 hours then irradiated; second, cells were irradiated followed by the menadione treatment; third, cells were concurrently treated with both agents. \nResults: The menadione inhibited the Hep3B tumor cells growth, the IC50 was around 60 \u03bcM. The intracellular reduced glutathione was significantly decreased after menadione treatment for 3 hours. After combined treatment most surviving fractions were less than 15%. \nConclusions: Both 'pre-irradiation followed by menadione' and 'concurrent treatment' have synergistic effect. However, 'pre-treatment of menadione followed by irradiation' only has the addition effect. This finding may be useful for clinical application of menadione when combined with ionizing radiation to treat cancers."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-111-117-a", "title": "\u4e73\u9178\u687f\u83cc\u79d1\u83cc\u682a\u63d0\u9ad8\u514d\u75ab\u529b\u53ca\u6297\u764c\u65b9\u9762\u7684\u7814\u7a76", "keywords": "\u4e73\u9178\u687f\u83cc\u79d1;\u514d\u75ab\u589e\u5f37\u4f5c\u7528;\u6297\u764c;\u9072\u767c\u6027\u904e\u654f\u53cd\u61c9;\u4f50\u5291 Lactobacteriaceae;Immunopotentiation;Anti-tumor;Delayed type hypersensitivity;Adjnvant", "c": "\u76ee\u7684\uff1a\u6e2c\u8a66\u4e73\u9178\u687f\u83cc\u79d1\u83cc\u682a\u63d0\u9ad8\u514d\u75ab\u529b\u4e4b\u6548\u679c\u53ca\u5176\u6297\u764c\u65b9\u9762\u7684\u8868\u73fe\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u4e0d\u540c\u4f86\u6e90\u4e4b\u4e73\u9178\u634d\u83cc\u79d1\u6b7b\u83cc\u9ad4\u53ca\u9748\u829d\u8403\u53d6\u6db2\uff0c\u80fd\u5426\u5728\u9ad4\u5916\u523a\u6fc0\u8001\u9f20\u813e\u81df\u7d30\u80de\u7522\u751f\u03b3\uff0d\u64fe\u7d20\uff0c\u505a\u70ba\u5176\u589e\u5f37\u514d\u75ab\u529b\u7684\u6307\u6a19\uff1b\u518d\u4ee5\u9072\u767c\u6027\u904e\u654f\u53cd\u61c9(Delayed Type Hypersensitlvity; DTH) \u6e2c\u8a66\u4e73\u9178\u634d\u83cc\u79d1\u83cc\u682a\u7684\u4f50\u5291\u4f5c\u7528\u53ca\u5176\u5f15\u767c\u7684T\u7d30\u80de\u8a18\u61b6\u53cd\u61c9\uff1b\u6700\u5f8c\u4ee5\u540c\u6642\u6ce8\u5c04\u65b9\u5f0f\uff0c\u6e2c\u5b9a\u4e73\u9178\u687f\u83cc\u79d1\u6b7b\u83cc\u9ad4\u6291\u5236\u8089\u7624\u7d30\u80de(CT-26)\u7684\u751f\u9577\u60c5\u5f62\uff0c\u4e26\u8207BCG\u6bd4\u8f03\u4e4b\u3002\n\u7d50\u679c\uff1a\u5c0d\u9ad4\u5916\u57f9\u990a\u7684\u8001\u9f20\u813e\u81df\u7d30\u80de\uff0c\u6240\u6709\u7684\u4e73\u9178\u687f\u83cc\u79d1\u6b7b\u83cc\u9ad4\u5728\u523a\u6fc0\u03b3\uff0d\u64fe\u7d20\u7684\u751f\u6210\u4f5c\u7528\u4e0a\u90fd\u6bd4\u9748\u829d\u5f37\uff0c\u800c\u6bd4Con A\u7a0d\u5dee\u3002\u540c\u6642\u65bd\u6253\u7f8a\u7d05\u8840\u7403(SRBC)\u548c\u4e73\u9178\u634d\u83cc\u79d1\u6b7b\u83cc\u9ad4\u6642\uff0c\u53ef\u4ee5\u7a0d\u5fae\u589e\u52a0\u76ae\u819a\u7684\u816b\u8139\u7a0b\u5ea6\uff0c\u8868\u793a\u5b83\u5c0d\u9072\u767c\u6027\u904e\u654f\u53cd\u61c9\u6709\u8f15\u5ea6\u7684\u4f50\u5291\u4f5c\u7528\u3002\u800c\u5148\u6253\u6b7b\u83cc\u9ad4\u523a\u6fc0\u5c40\u90e8\u7684\u514d\u75ab\u7cfb\u7d71\uff0c\u518d\u4ee5SRBC\u514d\u75ab\u6642\uff0c\u5c40\u90e8\u7684\u9072\u8972\u6027\u904e\u654f\u53cd\u61c9\u8981\u6bd4\u672a\u6253\u6b7b\u83cc\u9ad4\u7684\u5c0d\u7167\u7d44\u5f37\u3002\u53e6\u5916\u540c\u6642\u6ce8\u5c04\u6b7b\u83cc\u9ad4\u8207\u816b\u7624\u7d30\u80de\u6642\uff0c\u6b7b\u83cc\u9ad4\u6bd4BCG\u6d3b\u83cc\u66f4\u80fd\u6291\u5236\u8089\u7624\u7d30\u80de\u7684\u751f\u9577\u3002\n\u7d50\u8ad6\uff1a\u7d93\u672c\u5be6\u9a57\u7372\u5f97\u521d\u6b65\u7684\u8b49\u5be6\uff0c\u4e73\u9178\u687f\u83cc\u79d1\u83cc\u682a\u53ef\u589e\u5f37\u514d\u75ab\u53cd\u61c9\u4e26\u6291\u5236\u764c\u7d30\u80de\u7684\u751f\u9577\uff0c\u4f46\u5176\u5b8c\u6574\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u9084\u9808\u9032\u4e00\u6b65\u6df1\u5165\u7814\u7a76\u3002", "e": "Purpose: To examine the immunopotentiating ability of Lactobacteriaceae with Ganoderma lucidum in vitro and compare the anti-tumor ability of Lactobactcriaceac with that of BCG using a mouse model injected with sarcoma cells. \nMaterials and Methods: The immunopotentiating ability was tested in vitro using the stimulation of interferon- gamma production by mouse spleen cells. The delayed type hypersensitivity shown by foot swelling scale was chosen as an index of adjuvant effect. Anti-tumor ability was examined by simultaneously injected bacteria cells with sarcoma cells on mouse left hind leg. \nResults: The concentrations of interferon-gamma proliferation by various heat-killed Lactobateriaceae cells were higher than four tested Ganoderma lucidum products, but slightly lower than Con A. Simultaneously injected SRBC with heat-killed Lactobacteriaceae cells showed an adjuvant effect on foot swelling in mouse model. Mice immunized with heat-killed Lactobacteiraceae cells had higher foot swelling scale when challenged with SRBC three weeks later. Heat-killed Lactobateriaceae cells demonstrated a better inhibition of tumor growth than viable BCG. \nConclusion: The immunopotentiating and anti-tumor abilities of Lactobacteriaceae are initially verified, further studies should be carried on."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-119-125-a", "title": "\u9aa8\u76c6\u56fa\u5b9a\u5668\u5c0d\u64fa\u4f4d\u8aa4\u5dee\u7684\u5f71\u97ff", "keywords": "\u9aa8\u76c6\u56fa\u5b9a\u5668;\u9aa8\u76c6\u8154;\u653e\u5c04\u6cbb\u7642;\u54c1\u8cea\u7ba1\u5236 Pelvic immobilization device;Pelvic cavity;Radiotherapy;Quality assurance", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9aa8\u76c6\u56fa\u5b9a\u5668\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u64fa\u4f4d\u8aa4\u5dee\u7684\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u9078\u64c7\u4e09\u7a2e\u9aa8\u76c6\u90e8\u4f4d\u7684\u60e1\u6027\u816b\u7624\u4f5c\u70ba\u5206\u6790\u6bd4\u8f03\u7684\u5c0d\u8c61\uff1a\u5305\u62ec\u4e86\u5b50\u5bae\u9838\u764c10\u4f8b\uff0c\u651d\u8b77\u817a\u764c4\u4f8b\uff0c\u53ca\u76f4\u8178\u764c2\u4f8b\u3002\u5728\u57f7\u884c\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u4e4b\u524d\u5373\u4ee5\u96a8\u6a5f\u62bd\u6a23\u7684\u65b9\u5f0f\u5340\u5206\u70ba\u50b3\u7d71\u672a\u52a0\u9aa8\u76c6\u56fa\u5b9a\u5668\u8207\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u5169\u7d44\u60a3\u8005\u3002\u958b\u59cb\u6cbb\u7642\u5f8c\u6bcf\u5468\u62cd\u651d\u5169\u5f35\u7167\u91ce\u7247\uff0c\u7167\u91ce\u7247\u62cd\u651d\u7684\u65b9\u5411\u662f\u524d\u5f8c\u6216\u5169\u5074\u9762\u65b9\u5411\u3002\u672c\u7814\u7a76\u5171\u53d6\u5f9734\u5f35\u6a21\u64ec\u651d\u5f71\u7247\u8207149\u5f35\u7167\u91ce\u7247\u3002\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u5728\u5169\u7d44\u4e4b\u554f\u6c92\u6709\u4efb\u4f55\u5dee\u7570\uff0c\u9664\u76f4\u8178\u764c\u662f\u4ee5\u4e09\u7167\u91ce\u6cbb\u7642\u5916\u5176\u9918\u5747\u662f\u56db\u7167\u91ce\u65b9\u5f0f\u6cbb\u7642\u3002\u8a18\u9304\u653e\u5c04\u6cbb\u7642\u64fa\u4f4d\u8aa4\u5dee\u7684\u65b9\u6cd5\u70ba\u6bd4\u8f03\u6a21\u64ec\u651d\u5f71X\u5149\u7247\u8207\u7167\u91ce\u7247\u7684\u5de6\u53f3\u3001\u982d\u8173\u3001\u524d\u5f8c\u3001\u4ee5\u53ca\u65cb\u8f49\u7b49\u8ef8\u7684\u8aa4\u5dee\u3002\u5206\u6790\u64fa\u4f4d\u8aa4\u5dee\u7684\u65b9\u6cd5\u662f\u4ee5t-test\uff08\u5169\u5c3e\uff09\u53cachi-square\u65b9\u6cd5\u5206\u5225\u8a55\u4f30\u8aa4\u5dee\u5e73\u5747\u503c\u53ca\u8aa4\u5dee\u8d85\u904e5mm \u6bd4\u4f8b\u7b49\u6578\u503c\u6709\u7121\u7d71\u8a08\u5b78\u4e0a\u7684\u5dee\u7570\u3002\n\u7d50\u679c\uff1a\u50b3\u7d71\u672a\u52a0\u9aa8\u76c6\u56fa\u5b9a\u5668\u8207\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u5169\u7d44\u4e4b\u9593\u7684\u8aa4\u5dee\u578b\u614b\u4e26\u4e0d\u76f8\u540c\u3002\u4ee5\u8aa4\u5dee\u5e73\u5747\u503c\u65b9\u5f0f\u8a55\u4f54\uff0c\u5169\u8005\u5de6\u53f3(p=0.445)\u3001\u982d\u8173(p=0.092)\u3001\u8207\u65cb\u8f49\u8ef8(p=0.337)\u5747\u672a\u6709\u660e\u986f\u5dee\u5225\u3002\u552f\u6709\u6a5f\u982d270\u5ea6\u6642\u7684\u524d\u5f8c\u8ef8\u9054\u5230\u7d71\u8a08\u5dee\u7570(p=0.016)\uff1b\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u60a3\u8005\u7684\u5e73\u5747\u8aa4\u5dee(0.21mm, SD=1.11mm)\u660e\u986f\u5c0f\u65bc\u672a\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u60a3\u8005\u7684\u5e73\u5747\u8aa4\u5dee(1.54mm, SD=2.58mrn)\uff0c\u4ee5\u8aa4\u5dee\u8d85\u904e5mm\u6bd4\u4f8b\u7684\u65b9\u6cd5\u4f5c\u8a55\u4f30\uff0c\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u53ef\u6e1b\u5c11\u524d\u5f8c\u8ef8\u7684\u8aa4\u5dee(p=0.046)\uff0c\u4f46\u53cd\u800c\u4f7f\u982d\u8173\u8ef8\u7684\u8aa4\u5dee\u52a0\u5927(p=0.018)\uff1b\u5de6\u53f3\u8ef8\u5247\u672a\u6709\u986f\u8457\u5dee\u5225(p=0.359)\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u53ef\u4ee5\u986f\u8457\u7684\u6e1b\u5c11\u524d\u5f8c\u8ef8\u65b9\u5411\u7684\u8aa4\u5dee\uff0c\u4f46\u5c0d\u64fa\u4f4d\u8aa4\u5dee\u8d85\u904e5mm\u7684\u6bd4\u4f8b\u800c\u8a00\u5b83\u53cd\u800c\u4f7f\u982d\u8173\u8ef8\u65b9\u5411\u7684\u8aa4\u5dee\u52a0\u5927\uff1b\u5c0d\u65bc\u5de6\u53f3\u8ef8\u65b9\u5411\u7684\u8aa4\u5dee\u4e26\u672a\u6709\u660e\u986f\u7684\u5f71\u97ff\u3002\u6240\u4ee5\u7576\u4f7f\u7528\u9aa8\u76c6\u56fa\u5b9a\u5668\u6642\u61c9\u6ce8\u610f\u982d\u8173\u8ef8\u65b9\u5411\u7684\u56fa\u5b9a\u65b9\u6cd5\u4ee5\u6e1b\u5c11\u6b64\u65b9\u5411\u8ef8\u7684\u8aa4\u5dee\u3002", "e": "Purpose: To evaluate the extent of influence of setup deviation by pelvic immobilization device. \nMaterials and Methods: This prospective randomized study composed of two study groups that were with or without pelvic immobilization device. We included three kinds of malignant diseases that originated in pelvic cavity; these were 10 cases of cervical cancer, 4 cases of prostate cancer, and 2 cases of rectal cancer. Except from the two patients of rectal cancer, all of them were treated with four-field box technique and the principle of radiation technique was all the same in both groups. The portal films were taken from anterior-posterior and bilateral directions with the frequency of twice per week. There were 34 simulation films and 149 portal films to be evaluated. The setup error was recorded by comparison the iso-center shift between simulation and portal films of four individual axes, that were latero-lateral, caudo-cranial, anterior-posterior axis and degree of rotation. The statistic methods for evaluation the results were two-tall t-test and chi-square methods for mean value of setup deviation and ratio of iso-center shift exceeded 5-mm, respectively. \nResults: The patterns of setup error were different between non-immobilization and immobilization groups. When evaluated by mean setup error, there were no significant differencer between the two groups of the laterolateral (p=0.44S) and caudo-cranial (p=0.092) axes, the degree of rotation was also no difference at all (p=0.337). In anterior-posterior axis evaluated by gantry 270 degree, the mean setup error of the immobilization group (0.21-mm, SD=l.llmm) was significant smaller than non-immobilization group (1.54-mm, SD=2.SSmm) (p=0.016). Evaluation by the ratio of iso-center shift exceeded 5-mm, the immobilized group showed significant reduction in the error of anterior-posterior axis (p=0.046), but this group had opposed behavior of the caudocranial axis (p=0.0l8). The latero-lateral (p=0.359) and rotational (p=0.803) axes did not show any significant difference between the two groups. \nConclusion: With the immobilization device, there has significant improvement of the anterior-posterior axis, but the caudo-cranial axis has opposed effect when we evaluated by the ratio of setup error exceeded 5-mm. The iso-center shift in latero-lateral axis has no significant difference despite of the used of this immobilization device. So, we must pay more effort to avoid the inter-treatment variation of the caudo-cranial axis when we use this kind of pelvic immobilization device."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-127-133-a", "title": "\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u7684\u8f3b\u5c04\u5291\u91cf\u8207\u54c1\u8cea\u4e4b\u7814\u7a76", "keywords": "\u4e2d\u5b50\u6cbb\u7642;\u787c\u4e2d\u5b50\u6355\u7372;\u6709\u6548\u5c04\u8cea\u56e0\u6578 Neutron therapy;Boron neutron capture therapy;Effective quality factor", "c": "\u76ee\u7684\uff1a\u8fd1\u5e74\u4f86\uff0c\u764c\u75c5\u5df2\u6210\u70ba\u4eba\u985e\u6b7b\u4ea1\u7684\u4e3b\u8981\u75c5\u56e0\uff0c\u56e0\u6b64\u79d1\u5b78\u5bb6\u6b63\u9803\u5168\u529b\u7814\u7a76\u764c\u75c5\u7684\u8d77\u56e0\u3001\u9632\u6cbb\u3001\u8207\u8a3a\u7642\u3002\u76ee\u524d\u6e05\u83ef\u5927\u5b78\u6b63\u5229\u7528\u6e05\u83ef\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668\uff0c\u9032\u884c\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u6cd5(Boron Neutron Capture Therapy\uff0c\u7c21\u7a31BNCT)\u4e4b\u4e2d\u5b50\u5c4f\u853d\u3001\u85e5\u7269\u7814\u767c\u3001\u751f\u7269\u5be6\u9a57\u3001\u5291\u91cf\u8a55\u4f30\u7b49\u7814\u7a76\u3002\u672c\u6587\u4e4b\u76ee\u7684\uff0c\u5373\u5728\u65bc\u8a55\u4f30\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u7684\u8f3b\u5c04\u5291\u91cf\u8207\u54c1\u8cea\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u6cd5\u662f\u5229\u7528\u85e5\u7269\u5c07\u787c10\u540c\u4f4d\u7d20\u5e36\u5165\u4eba\u9ad4\uff0c\u4f7f\u4e4b\u7d2f\u7a4d\u5728\u816b\u7624\u7d44\u7e54\u4e2d\uff0c\u518d\u4ee5\u71b1\uff08\u6216\u8d85\u71b1\uff09\u4e2d\u5b50\u675f\u7167\u5c04\uff0c\u4f7f\u4e2d\u5b50\u548c\u787c\u767c\u751f\u6838\u53cd\u61c9\uff0c\u91cb\u51fa\u9ad8\u6e38\u96e2\u5bc6\u5ea6\u8207\u77ed\u5c04\u7a0b\u7684\u7c92\u5b50\u8f3b\u5c04\uff0c\u6709\u6548\u6bba\u6b7b\u816b\u7624\u7d44\u7e54\u800c\u4e0d\u5f71\u97ff\u6b63\u5e38\u7d44\u7e54\u3002\u5176\u6240\u9020\u6210\u5438\u6536\u5291\u91cf\u7684\u4e3b\u8981\u8ca2\u737b\u6709a\u7c92\u5b50\u5291\u91cf\u53ca\u93d7-7\u91cd\u6838\u7c92\u5b50\u5291\u91cf\uff0c\u82e5\u4ee3\u5165\u7b49\u6548\u5291\u91cf\u7684\u5b9a\u7fa9\uff0c\u53ef\u6c42\u5f97\u816b\u7624\u7d44\u7e54\u7684\u6709\u6548\u5c04\u8cea\u56e0\u6578Q\uff1b\u82e5\u4ee3\u5165\u7b49\u503c\u5291\u91cf\u7684\u5b9a\u7fa9\uff0c\u5373\u53ef\u6c42\u5f97\u6b63\u5e38\u7d44\u7e54\u53ca\u816b\u7624\u7d44\u5fae\u7684\u6709\u6548\u8f3b\u5c04\u52a0\u6b0a\u56e0\u6578W\uff08\u4e0b\u6a19\u3000R\uff09\n\u7d50\u662f\uff1a\u7576\u9ad4\u5167\u816b\u7624\u7d44\u7e54\u542b\u787c\u6fc3\u5ea6\u589e\u52a0\u6642\uff0c\u5728\u4f4e\u6fc3\u5ea6\u7b49\u6548\u5291\u91cf\u8207\u542b\u787c\u6fc3\u5ea6\u5448\u975e\u7dda\u6027\u6bd4\u4f8b\u7684\u95dc\u4fc2\uff0c\u5728\u9ad8\u6fc3\u5ea6\u6642\u5247\u5448\u7dda\u6027\u6b63\u6bd4\u7684\u95dc\u4fc2\u3002\u7576\u816b\u7624\u7d44\u7e54\u542b\u787c\u6fc3\u5ea6\u592a\u4f4e\u6642\uff0c\u6709\u6548\u5c04\u8cea\u56e0\u6578\u6703\u964d\u4f4e\uff0c\u4f7f\u5f97\u816b\u7624\u7d44\u7e54\u8207\u6b63\u5e38\u7d44\u7e54\u7684\u8f3b\u5c04\u81f4\u6b7b\u6548\u61c9\u76f8\u7576\uff0c\u800c\u6e1b\u4f4eBNCT\u7684\u6cbb\u7642\u6548\u76ca\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5df2\u958b\u767c\u5b8c\u6210\u7b49\u6548\u5291\u91cf(dose equivalent)\u3001\u6709\u6548\u5c04\u8cea\u56e0\u6578(effective qualify factor)\u3001\u7b49\u503c\u5291\u91cf(equivalent dose)\uff0c\u6709\u6548\u8f3b\u5c04\u52a0\u6b0a\u56e0\u6578(effective radiation weighting factor)\u7684\u8a55\u4f30\u7a0b\u5f0f\uff0c\u7531\u5916\u90e8\u8f38\u5165\u6216\u5229\u7528\u7cfb\u7d71\u5167\u5efa\u7684\u4e2d\u5b50\u80fd\u8b5c\u3001\u4e2d\u5b50\u901a\u91cf\u7387\u201c\u53ca\u816b\u7624\u7d44\u7e54\u4e4b\u542b\u787c\u6fc3\u5ea6\u7b49\u689d\u4ef6\uff0c\u9032\u884c\u5404\u7a2e\u6838\u53cd\u61c9\u5f15\u8d77\u7684\u8f3b\u5c04\u5291\u91cf\u8207\u8f3b\u5c04\u54c1\u8cea\u7684\u63a2\u8a0e\u3002", "e": "Purpose: A beam port of epithermal neutrons at Tsing Hua Open Pool Reactor (THOR) was recently built. This port was designed for basic research on boron neutron capture therapy (BNCT). The research team consisted of radiobiologists, pharmaceutical chemists, medical scientists, nuclear engineers, and health physicists. The dosimetry group took the responsibility for the assessment of tumor/normal tissue biological doses. Radiation dose and quality were assessed in this work, \nMaterials and Methods: The basic principle of BNCT is to deliver (superscript 10)B-laheled drug to the patient. (superscript 10)B isotope will accumulate in tumor mostly. Following the irradiation of an epithermal (thermal) neutron beam, (superscript 10)B(n,\u03b1)^7Li nuclear reactions occur and short-range and high LET particles emit. These particles kill the tumor cells but unharm the normal tissues. We focus our study on equivalent doses, effective quality factors (Q) and effective radiation weighting factors (W(subscript R) ) by the dosimetric model. \nResult: In low boron concentration, the relation between equivalent dose and boron concentration was nonlinear. At such concentration, when decreased, the radiation effects for tumor and normal tissues were approximately the same. The therapeutic effectiveness by BNCT was decreased. As boron concentration increased the relation became linear and the therapeutic effectiveness was better. \nConclusion: A computer code was developed to calculate the dosimetric quantities from input of boron concentration, neutron flux and energy, irradiation geometry and time. Results were analyzed as a function of separate and combined input factors. Optimal irradiation conditions were recommended for future clinical application."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-135-142-a", "title": "\u71b1\u767c\u5149\u5291\u91cf\u8a08\u5c0d\u8cea\u5b50\u7684\u56de\u61c9", "keywords": "\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u8cea\u5b50\u52a0\u901f\u5668;\u76f4\u7dda\u80fd\u6688\u8f49\u79fb;\u8f1d\u5149\u66f2\u7dda;\u5f91\u8de1\u7d50\u69cb\u7406\u8ad6;\u6df1\u9677\u9631\u7af6\u722d\u6a21\u578b Thermoluminescent dosimeter;Cockroft-Walton accelerator;Linear energy transfer (LET);Glow curve;Track structure theory (TST);Deep trap competition model", "c": "\u76ee\u7684\uff1a\u77ad\u89e3\u71b1\u767c\u5149\u5291\u91cf\u8a08\u5c0d\u4f4e\u80fd\u91cf\u8cea\u5b50\u7684\u56de\u61c9\uff0c\u4ee5\u4f9b\u5c07\u4f86\u5efa\u7acb\u5e03\u62c9\u683c\u5c16\u5cf0\u8655\u5291\u91cf\u91cf\u6e2c\u6280\u8853\u6240\u9700\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c07\u4ee5\u6700\u4f73\u56de\u706b\u689d\u4ef6\u56de\u706b\u5b8c\u6210\u4e4bCaF2\uff1aDy (TLD-200)\u53caCaF2: Tm (TLD-300)\uff0c\u78ba\u4fdd\u5176\u8868\u9762\u6027\u8cea\u53ca\u771f\u7a7a\u56de\u706b\u5f8c\u51b7\u537b\u904e\u7a0b\u5c0d\u71b1\u767c\u5149\u53cd\u61c9\u7121\u5f71\u97ff\u5f8c\uff0c\u5c07\u5176\u7f6e\u65bc\u771f\u7a7a\u8154\u5167\u4e4b\u4e00\u58d3\u514b\u529b\u7f6e\u88dd\u5668\u5167\u3002\u7531Cockroft-Walton\u52a0\u901f\u5668\u63d0\u4f9b\u4e4b\u8cea\u5b50\u6e90\uff0c\u80fd\u91cf\u572830~100keV\u9593\uff0c\u7d93\u6e96\u76f4\u5f8c\u901a\u904e\u4e0010 \u00b5g/\u5e73\u65b9\u516c\u5206\u4e4b\u78b3\u819c\u505a\u62c9\u585e\u798f\u6563\u5c04(Rutherford scattering)\uff0c\u6563\u5c04\u5f8c\u4e4b\u8cea\u5b50\u5747\u52fb\u6253\u5728\u7f6e\u65bc\u5176\u5f8c20\u00b0\u7684\u58d3\u514b\u529b\u7f6e\u88dd\u5668\u5167\u7684\u71b1\u767c\u5149\u5291\u91cf\u8a08\uff0c\u5229\u7528\u58d3\u514b\u529b\u7f6e\u88dd\u5668\u5f8c\u4e4b\u4e00\u96fb\u5b50\u500d\u589e\u5668(channeltron)\u4f5c\u70ba\u91cf\u6e2c\u8cea\u5b50\u5de5\u5177\u3002\u7167\u5c04\u5b8c\u4e4b\u71b1\u767c\u5149\u5291\u91cf\u8a08\u7d93\u8a08\u8b80\u5f8c\u5206\u6790\u8f1d\u5149\u66f2\u7dda\u8207\u8cea\u5b50\u80fd\u91cf\u4e4b\u95dc\u4fc2\uff0c\n\u7d50\u679c\uff1aTLD-200\u3001TLD-300\u7167\u5c0430~100 keV\u8cea\u5b50\uff0c\u7d50\u679c\u986f\u793aTLD-200\u3001TLD-300\u71b1\u767c\u5149\u9748\u654f\u5ea6\u96a8\u8cea\u5b50\u80fd\u91cf\u4e0b\u964d\uff08\u76f4\u7dda\u80fd\u91cf\u8f49\u79fb\u5dde(linear energy transfer, LET)\u4e0b\u964d\uff09\u800c\u4e0a\u5347\uff0c\u7b26\u5408\u5f91\u8de1\u7d50\u69cb\u7406\u8ad6(track structure theory, TST) \u3002\u800cTLD-300\u4e4b\u8f1d\u5149\u66f2\u7dda\u5206\u6790\uff0c\u4ea6\u8b49\u660e\u5176\u7b26\u5408\u6df1\u9677\u9631\u7af6\u722d\u6a21\u578b\u4e4b\u63a8\u8ad6(deep trap competition model)\u3002\u540c\u6642\u5176\u5404\u8f1d\u5149\u5cf0\uff08\u7b2c\u4e8c\u3001\u7b2c\u4e09\u3001\u7b2c\u4e94\u8f1d\u5149\u5cf0\uff09\u8207\u8cea\u5b50\u80fd\u91cf\u5177\u76f8\u95dc\u6027\u3002\n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793a\uff0cTLD-200\u3001TLD-300\u6709\u8db3\u5920\u7684\u9748\u654f\u5ea6\u53ef\u4f5c\u70ba\u91cf\u6e2c\u8cea\u5b50\u5291\u91cf\u4f7f\u7528\uff0c\u552f\u5176\u4e26\u975e\u7d44\u7e54\u7b49\u6548\u6750\u6599\uff0c\u9700\u7d93\u4e00\u4e9b\u6821\u6b63\u56e0\u6578\u4fee\u6b63\uff0c\u540c\u6642\u5c1a\u9700\u66f4\u591a\u4e0d\u540c\u80fd\u91cf\u8cea\u5b50\u7684\u9748\u654f\u5ea6\u6821\u6b63\u56e0\u6578\u7684\u91cf\u6e2c\u914d\u5408\uff0c\u65b9\u53ef\u4f7f\u8cea\u5b50\u5291\u91cf\u91cf\u6e2c\u6280\u8853\u66f4\u70ba\u5b8c\u6574\u6e96\u78ba\u3002", "e": "Purpose: To understand the TLD response for low energy proton in order to establish the proton dose measurement technique at Bragg peak in the future. \nMaterials and Methods: Under the best annealing condition treatment and making sure the surface characteristics and cooling process after vacuum annealing had no significant effects to thermoluminescent response, TLD samples were put into the ABS TLD holder in the vacuum chamber. Proton generated from a Cockroft-Walton accelerator in the energy range of 30-100 keV were appropriately collimated and made to pass through a 10 \u00b5g/cm^2 carbon foil. After Rutherford scattering, proton uniformly irradiated TLDs which were placed at the 20\u00b0 behind and 20 cm away from the carbon foil. We used a channeltron behind TLD holder as the proton detector. After irradiation, readout of the TLD samples was done with a TLD reader and comparison of the glow curve under different proton energies was initiated. \nResults: The result showed that the TLD-200, TLD-300 sensitivities increased while proton energy decreased (LET decreased), which was consistent with track structure theory. While TLD-300 glow curve analysis conformed to the deep trap competition model, it also showed that the glow peaks (P2, P3, P5) of TLD-300 depended on proton energy in the range of 30-100 key. \nConclusion: TLD-200, TLD-300 have sufficient sensitivity to be proton detectors, but they are not a tissue equivalent material and need some calibration process. Furthermore, it still needs more sensitivity calibration factor measurements for different energies of proton to makes proton dose evaluation complete."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199806-5-2-143-148-a", "title": "\u4f7f\u7528\u4e0d\u540c\u96fb\u5b50\u9310\u6642\u7684\u96fb\u5b50\u5c04\u675f\u7279\u6027\u8b8a\u5316\u63a2\u8a0e", "keywords": "\u96fb\u5b50\u5c04\u675f;\u96fb\u5b50\u9310;\u7a7a\u6c23\u9593\u9699;\u5e73\u5766\u5ea6 Electron beam;Electron cone;Air gap;Flatness", "c": "\u524d\u8a00\uff1a\u5728\u81e8\u5e8a\u7684\u653e\u5c04\u6cbb\u7642\u4e2d\u4f7f\u7528\u96fb\u5b50\u5c04\u675f\u6642\uff0c\u6703\u4f9d\u64da\u4e0d\u540c\u60c5\u5f62\u800c\u4f7f\u7528\u4e0d\u540c\u7684\u96fb\u5b50\u9310\uff0c\u800c\u5728\u4f7f\u7528\u96fb\u5b50\u9310\u4e4b\u5f8c\uff0c\u4ee5\u53ca\u96fb\u5b50\u9310\u548c\u5047\u9ad4\u8868\u9762\u4e4b\u9593\u6709\u7121\u7a7a\u6c23\u554f\u9699\u7684\u5b58\u5728\uff0c\u96fb\u5b50\u5c04\u675f\u7684\u7279\u6027\u90fd\u6703\u6709\u6240\u6539\u8b8a\uff0c\u6545\u672c\u7bc7\u91dd\u5c0dsiemens Linac MD-2 \u76f4\u7dda\u52a0\u901f\u5668\u4f7f\u7528\u4e0d\u540c\u7684\u96fb\u5b50\u9310\u6642\uff0c\u6240\u5f97\u5230\u7684\u96fb\u5b50\u5c04\u675f\u7279\u6027\u8b8a\u5316\u505a\u4e00\u7814\u7a76\u63a2\u8a0e\u3002\n\u8015\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u752810\u00d710\u5e73\u65b9\u516c\u5206\u6b63\u65b9\u5f62\u7167\u91ce\u7684\u96fb\u5b50\u9310\u3001\u88dd\u6709\u76f4\u5f915 cm \u5713\u5f62\u7167\u91ce\u906e\u6a94\u925b\u584a\u768410\u00d710\u5e73\u65b9\u516c\u65b9\u4e4b\u96fb\u5b50\u9310\u4ee5\u53ca\u76f4\u5f915 cm\u7684\u5713\u5f62\u7167\u91ce\u96fb\u5b50\u9310\u7b49\u4e09\u7a2e\u4e0d\u540c\u7684\u96fb\u5b50\u9310\u88dd\u7f6e\u572812 MeV\u300180 MU\u7684\u689d\u4ef6\u4e0b\uff0c\u5206\u5225\u65bc\u96fb\u5b50\u9310\u548c\u5047\u9ad4\u8868\u9762\u4e4b\u554f\u6c92\u6709\u7a7a\u6c23\u9593\u9699(air gap=0 cm)\uff0c\u4ee5\u53ca\u7a7a\u6c23\u9593\u9699\u7b49\u65bc10 cm\u7684\u689d\u4ef6\u4e0b\u9032\u884c\u7167\u5c04\uff0c\u4e26\u91dd\u5c0d\u5176\u6240\u5f97\u7d50\u679c\u76f8\u4e92\u505a\u4e00\u6bd4\u8f03\u3002\n\u7d50\u679c\uff1a\u4f7f\u752810\u00d710\u5e73\u65b9\u516c\u5206\u6b63\u65b9\u5f62\u7167\u91ce\u7684\u96fb\u5b50\u9310\uff0c\u6240\u5f15\u8d77\u7684\u7d50\u679c\u662f\u80cc\u666f\u7684X\u5c04\u7dda\u8f03\u5927\uff0c\u5747\u4e00\u5316\u7684\u5291\u91cf\u68af\u5ea6(Go) \u548cd(\u4e0b\u6a19 max)\u4ea6\u8f03\u5927\uff0c\u800c\u4e14\u5747\u52fb\u5ea6\u8f03\u597d\u3002\u5982\u679c\u662f\u4f7f\u7528\u88dd\u6709\u76f4\u5f915 cm\u5713\u5f62\u7167\u91ce\u906e\u6a94\u925b\u584a\u768410\u00d710 cm^2\u96fb\u5b50\u9310\u6642\uff0c\u6240\u9020\u6210\u7684\u5747\u52fb\u5ea6\u6bd4\u8f03\u5dee\uff0c\u5747\u4e00\u5316\u7684\u5291\u91cf\u68af\u5ea6(Go)\u548cd(\u4e0b\u6a19 max)\u4ea6\u8f03\u5c0f\uff0c\u4f46\u662f\u80cc\u666fX\u5c04\u7dda\u548c\u8868\u9762\u5291\u91cf\u6703\u8f03\u5c0f\u3002\u7576\u96fb\u5b50\u9310\u548c\u5047\u9ad4\u8868\u9762\u4e4b\u9593\u7684\u7a7a\u6c23\u9593\u9699\u589e\u52a0\u6642(air gap=0 cm \u2192 air gap=10 cm)\uff0c\u534a\u5f71\u5340\u7684\u5bec\u5ea6\u947e\u5927\uff0c\u80cc\u666fX\u5c04\u7dda\u548c\u6563\u5c04\u4e5f\u589e\u52a0\u4e86\u3002\u4e26\u4e14\u767c\u73fe\u7a7a\u6c23\u9593\u9699\u7684\u5b58\u5728\u8207\u5426\uff0c\u5c0d\u4f7f\u752810\u00d710\u5e73\u65b9\u516c\u5206\u6b63\u65b9\u5f62\u7167\u91ce\u7684\u96fb\u5b50\u9310\uff0c\u6240\u9020\u6210\u7684\u5f71\u97ff\u8f03\u5927\u3002\n\u7d50\u8ad6\uff1a\u4f7f\u752810\u00d710\u5e73\u65b9\u516c\u5206\uff0c\u6b63\u65b9\u5f62\u7167\u91ce\u7684\u96fb\u5b50\u9310\uff0c\u6240\u5f62\u6210\u7684\u96fb\u5b50\u5c04\u675f\u7279\u6027\u53ef\u7528\u4f86\u6cbb\u7642\u8f03\u5927\u7684\u816b\u7624\uff1b\u5982\u679c\u662f\u4f7f\u7528\u88dd\u6709\u76f4\u5f915cm \u5713\u5f62\u7167\u91ce\u906e\u6a94\u925b\u584a\u768410\u00d710\u5e73\u65b9\u516c\u5206\u96fb\u5b50\u9310\u6642\uff0c\u7528\u4f86\u6cbb\u7642\u5c0f\u4e00\u9ede\u7684\u816b\u7624\u6bd4\u8f03\u9069\u7576\u3002\u800c\u4f7f\u7528\u88dd\u6709\u76f4\u5f915 cm\u5713\u5f62\u7167\u91ce\u906e\u6a94\u925b\u584a\u768410\u00d710\u5e73\u65b9\u516c\u5206\u96fb\u5b50\u9310\u6240\u5f97\u4e4b\u96fb\u5b50\u5c04\u675f\u7684\u5747\u52fb\u5ea6\u548c\u6709\u6548\u6cbb\u7642\u9762\u7a4d\uff0c\u6bd4\u4f7f\u7528\u76f4\u5f915 cm\u7684\u5713\u5f62\u7167\u91ce\u96fb\u5b50\u9310\u4f86\u5f97\u597d\u3002", "e": "Introduction: When electron beams are used for radiotherapy, the treatment portals are often shaped to fit the treatment area. In some clinical application, a larger nominal gap is necessary. For these different applicator effects, we most determine empirically these effects for the applicator system employed. \nMaterials and Methods: In this paper, a 10\u00d710 cm^2 open cone, a 10 x 10 cone with 5 cm diameter circular cutout, and a 5 cm diameter open cane for 12 MeV, 80 MU electrons will be studied. Change the air gap between the collimator and the phantom surface from 0 cm to 10 cm. We measure parameters and compare these differences. \nResults: When applicator is a 10\u00d710 cm^2 open cone resulting in larger X-ray background, larger D(subscript max), G0 and flatness is better. If the applicator is a 10\u00d710 cm^2 cone with 5 cm diameter circular cutout, the X-ray background is smaller. As the air gap between the collimator and the phantom surface increases the penumbra increases, X-ray background and scatters increase, too. We also find that the 10\u00d710 cm^2 open cone for the effect of the air gap is larger. \nConclusion: Electron beams with a 10\u00d710 cm^2 open cone can be used to treat larger tumors. To treat smaller tumors, a 10 x 10 cm2 cone with 5 cm diameter circular cutout will be better. The flatness and effective treatment size of electron beams with a 10\u00d710 cm^2. cone with 5 cm diameter circular cutout are better than with a 5 cm diameter open cone."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-1-10-a", "title": "Establishment and Characterization of Genetically Modified Cancer Cells for Experimental Cancer Therapy", "keywords": "\u9846\u7c92\u7403\u5de8\u566c\u7d30\u80de\u751f\u9577\u56e0\u5b50;\u80f8\u5627\u5576\u6fc0\u6d3b\u9175\u7d20;\u57fa\u56e0\u8f49\u67d3\u4e4b\u764c\u7d30\u80de;\u816b\u7624\u75ab\u82d7 GM-CSF;Thymidine kinase;Genetically modified cancer cells;Tumor vaccine", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u89e3\u4e0d\u540c\u7a2e\u985e\u7684\u7d30\u80de\u682a\u5728\u5e36\u6709\u76b0\u75b9\u75c5\u6bd2\u4e4b\u80f8\u5580\u776b\u6fc0\u6d3b\u9175\u7d20(HSVtk)\u6216\u9846\u7c92\u7403\u5de8\u566c\u7d30\u80de\u751f\u9577\u56e0\u5b50(GM-CSF)\u6642\uff0c\u80fd\u5426\u4f5c\u70ba\u764c\u75c7\u6cbb\u7642\u4e4b\u7d30\u80de\u75ab\u82d7\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5617\u8a66\u5c07HSVtk\u57fa\u56e0\u6216\u8001\u9f20\u4e4bGM-CSF\u57fa\u56e0\u5206\u5225\u6216\u5171\u540c\u8f49\u67d3\u81f3\u4eba\u985e\u5b50\u5bae\u9838\u764c\u7d30\u80de\u682aHela\u3002\u7d93\u904e\u4e00\u7cfb\u5217\u7be9\u9078\uff0c\u56e0\u800c\u5efa\u7acb\u4e09\u7a2e\u7d30\u80de\u682a\uff0c\u547d\u540d\u70baH-tk, H-gm\uff0c\u53caH-tk/gm\u3002\u6211\u5011\u6240\u6e2c\u8a66\u4e4b\u816b\u7624\u6a21\u5f0f\u70baK-BALB sarcoma\u53ca\u5176\u540c\u6e90\u4e4bBALB/C\u9f20\u3002\u5206\u5225\u628a\u7b49\u91cf(lx10^6)\u7684K-BALB\u7d30\u80de\u8207H-tk, H-gm\uff0c\u6216H-tk/gm\u7d30\u80de\u6df7\u5408\uff0c\u800c\u5f8c\u6ce8\u5c04\u5165BALB/C\u9f20\u4e4b\u53f3\u8170\uff1b\u6bcf\u4e00\u6e2c\u8a66\u7d44\u4e4bBALB/C\u9f20\u5de6\u8170\u4ea6\u6ce8\u51651x10^6\u7684K-BALB\u7d30\u80de\uff1b\u518d\u7d66\u4e88ganciclovir (GCV)\u6216PBS\u6ce8\u5c04\uff0c\u6bcf\u9031\u6e2c\u91cf\u816b\u7624\u4e4b\u76f4\u5f91\u5404\u4e8c\u6b21\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u9078\u6b96\u52302\u682a\u542b\u6709HSVtk\u57fa\u56e0\u7684HeLa\u7d30\u80de\uff0c\u5206\u5225\u547d\u540d\u70baH-tk 3-2\u53caH-tk 12-2\u3002\u96a8\u5f8c\u5efa\u7acb\u4e4bH-tk/gm\u7d30\u80de\u682a\u4ea6\u5206\u6cccGM-CSF\u800c\u80fd\u652f\u6301GM-CSF\u4f9d\u8cf4\u6027\u7d30\u80de\u682aNSF60\u4e4b\u751f\u9577\u3002\u96a8\u5f8c\u4e4b\u6d3b\u9ad4\u5167\u816b\u7624\u6e2c\u8a66\u6642\u986f\u793a\uff0c\u7576H-tk\u8207K-BALB\u7d30\u80de\u6df7\u5408\u5728\u690d\u5165\u8001\u9f20\u5f8c\uff0c\u518d\u7d66\u4e88GCV\u6642\uff0c\u4e26\u4e0d\u80fd\u5ef6\u7de9K-BALB \u816b\u7624\u4e4b\u751f\u9577\u3002\u53cd\u4e4b\uff0cK-BALB\u7d30\u80de\u8207\u542b\u6709GM-CSF\u4e4b\u7d30\u80de\u682a\u6df7\u5408\u518d\u690d\u5165\u8001\u9f20\u6642\uff0c\u80fd\u6291\u5236\u5927\u90e8\u4efd\u7684\u8001\u9f20\u53f3\u8170\u90e8\u816b\u7624\u7684\u751f\u9577\u3002\u9032\u4e00\u6b65\u7684\u5be6\u9a57\u986f\u793aH-tk\u7d30\u80de\u5728\u6ce8\u5c04\u5165\u8001\u9f203\u5929\u5f8c\u4ecd\u6703\u8868\u9054H-SVtk\uff0c\u4f46\u8207\u540c\u6e90\u7d30\u80deHeLa\u4e4b\u554f\u7121\u6cd5\u6e2c\u8a66\u5230\u65c1\u89c0\u8005\u6548\u61c9(bystander effect)\u3002\u7136\u800c\uff0c\u6bcf\u4e00\u5be6\u9a57\u7d44\u4e4b\u8001\u9f20\u5176\u5de6\u8170\u90e8\u816b\u7624\u4e4b\u6291\u5236\u6548\u679c\u4e0d\u660e\u3002\n\u7d50\u8ad6\uff1aH-tk\u7d30\u80de\u96d6\u7136\u5728\u6d3b\u9ad4\u5167\u4ecd\u6703\u8868\u9054HSVtk\u57fa\u56e0\uff0c\u4f46\u4e0d\u80fd\u5f15\u8d77\u7570\u7a2e\u764c\u7d30\u80de\u7684\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u53ef\u80fd\u8207HeLa\u7d30\u80de\u672c\u8eab\u5c0d\u4ee3\u8b1d\u5408\u4f5c\u5177\u6709\u62b5\u6297\u6027\u6709\u95dc\u3002\u53cd\u4e4b\uff0c\u5c40\u90e8\u4e4bGM-CSF\u5206\u6ccc\u80fd\u58d3\u6291\u7570\u7a2e\u764c\u7d30\u80de\u5f62\u6210\u816b\u7624\uff0c\u4f46\u537b\u4e0d\u8db3\u5f15\u8d77\u5f37\u70c8\u7684\u816b\u7624\u514d\u75ab\u53cd\u61c9\u4ee5\u6291\u5236\u9060\u7aef\u816b\u7684\u751f\u9577\u3002", "e": "Purpose: To study whether a xenogeneic cell line engineered to express the herpes simplex virus thymidine kinase (HSVtk) and/or granulocyte-macrophage colony-stimulating factor (GM-CSF) can be used as cellular vaccine to repress tumor growth.\nMaterials and Methods: The HSVtk gene, murine GM-CSF gene, or both were stably transfected into the human cervix cancer cell line HeLa, thus creating three different cell lines designated as H-tk, H-gm, and H-tk/gm. The tumor model we tested was the KBALB sarcoma cells in syngenic BALB/c mice. For in vivo studies, equal number of KBALB cells and H-tk, H-gm, or H-tk/gm cells were premixed and injected into the right flanks of mice. The tumor growth was monitored after ganciclovir (GCV) administration.\nResults: Two HSVtk-expressing clones (H-tk 2-3 and H-tk 12-2) were isolated. The established H-tk/gm or H-gm cell line was confirmed to express GM-CSF by supporting the growth of a GM-CSF-dependent cell line NSF6O. The right flank tumors in mice injected with premixed K-BALB and H-tk cells showed no definite growth retardation upon GCV administration. Further studies implied that the H-tk cells expressed HSVtk in the injection sites, but failed to confer bystander effect between homologous cells by in vitro studies. The right flanks of mice injected with premixed K-BALB and H-tk/gm or Hgm showed no detectable or much delayed tumor growth either with or without GCV administration; however, the left flank K-BALB tumor progressed with similar growth curve in each study group.\nConclusion: Cur studies suggest that though HeLa cells can express HSVtk gene in vivo, they can not confer bystander killing effect to xenogeneic tumor (sarcoma) cells upon GCV administration. This might be because the HeLa cells are intrinsically resistant to metabolic cooperation with other cells. Local production of GM-CSF is able to suppress local tumor growth, but not potent enough to induce distant antitumor immunity. This inability might be related to insufficient duration or amount of GM-CSF action."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-11-18-a", "title": "\u5b50\u5bae\u9838\u764c\u653e\u5c04\u6cbb\u7642\u7684\u7d50\u679c\u53ca\u76f4\u8178\u5f8c\u907a\u75c7\u7684\u5206\u6790\uff08\u65b0\u5149\u91ab\u9662\u7684\u4e94\u5e74\u7d93\u9a57\uff09", "keywords": "\u5b50\u5bae\u9838\u764c;\u653e\u5c04\u6cbb\u7642;\u9ad8\u5291\u91cf\u7387(HDR)\u5b50\u5bae\u8154\u5167\u8fd1\u63a5\u6cbb\u7642;\u76f4\u8178\u5f8c\u9063\u75c7 Carcinoma of the uterine cervix;Radiotherapy;HDR brachytherapy;Late rectal complications", "c": "\u76ee\u7684\uff1a\u5b50\u5bae\u9838\u764c\u662f\u76ee\u524d\u53f0\u7063\u5a66\u5973\u767c\u751f\u7387\u6700\u9ad8\u7684\u764c\u75c7\uff0c\u672c\u7814\u7a76\u4e3b\u8981\u5728\u6aa2\u8a0e\u65b0\u5149\u91ab\u9662\u4e94\u5e74\u4f86\u653e\u5c04\u7dda\u6cbb\u7642\u5b50\u5bae\u9838\u764c\u7684\u521d\u6b65\u7d50\u679c\uff0c\u4e26\u5206\u6790\u56e0\u6cbb\u7642\u800c\u5f15\u767c\u4e4b\u76f4\u8178\u526f\u4f5c\u7528\u7684\u53ef\u80fd\u56e0\u7d20\u800c\u6539\u5584\u5c07\u4f86\u7684\u6cbb\u7642\u8a08\u5283\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1992\u5e749\u6708\u81f31994\u5e7412\u6708\uff0c\u5171\u6709109\u4f4d\u5b50\u5bae\u9838\u764c\u75c5\u4eba\u5728\u65b0\u5149\u91ab\u9662\u5b8c\u6210\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u5305\u62ec\u9060\u9694\u6cbb\u7642\u8207\u5b50\u5bae\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u3002\u958b\u59cb\u7684\u6cbb\u7642\u7bc4\u570d\u6db5\u84cb\u6574\u500b\u5b50\u5bae\uff0c\u9670\u9053\u53ca\u4e0b\u8179\u8154\u6dcb\u5df4\u817a\uff0c\u7d93\u7167\u5c0440 Gy\u81f344 Gy\u5f8c\uff0c\u4f9d\u816b\u7624\u671f\u5225\u7e2e\u5c0f\u7bc4\u570d\u81f3\u5169\u5074\u7684\u5b50\u5bae\u65c1\u7d44\u5fae(parametrium)\u5b50\u5bae\u8154\u5167\u6cbb\u7642\u6b21\u65783\u6b21\uff0c\u9593\u9694\u4e00\u5468\uff0c\u6bcf\u6b21\u7d66\u4e88\u53c3\u8003\u9edeA (point A) 72 Gy\u7684\u5291\u91cf\uff0c\u91dd\u5c0d\u5e74\u7d00\u8f03\u5927\u53ca\u76f4\u8178\u7d2f\u7a4d\u653e\u5c04\u5291\u91cf\u8f03\u9ad8\u7684\u75c5\u60a3\u5247\u4f9d\u60c5\u6cc1\u8abf\u6574point A\u5291\u91cf\u81f35 Gy\u62166 Gy\u3002109\u4f4d\u75c5\u606f\u4e2d\u6709102\u4f8b(FIGO stage lb-lla 24\u4eba\uff0cllb 48\u4eba\uff0cllla-ll1b26\u4eba\uff0c1Va-b 4\u4eba)\u63a5\u53d7\u8ffd\u8dcc\u6aa2\u67e5\u800c\u9032\u5165\u5206\u6790\u3002\u7d50\u679c\uff1a102\u4f4d\u75c5\u60a3\u7d93\u904e30\u81f354\u500b\u6708\u7684\u8ffd\u8e64\u6aa2\u67e5\uff08\u4e2d\u4f4d\u503c39\u500b\u6708\uff09\uff0c\u81f31997\u5e7412\u6708\u5e95\u6b62\uff0c\u4ecd\u5b58\u6d3b\u8005\u5171\u670965\u4eba\uff08\u5176\u4e2d\u4e00\u4eba\u5df2\u6709\u9060\u8655\u8f49\u79fb\uff09,37\u4eba\u5df2\u6b7b\u4ea1\uff0c\u5176\u4e2d8\u4eba\u6b7b\u65bc\u5c40\u90e8\u5fa9\u767c\uff0c16\u4eba\u6b7b\u65bc\u9060\u8655\u8f49\u79fb\uff0c1\u4eba\u6b7b\u5c40\u90e8\u5fa9\u767c\u5408\u4f75\u9060\u8655\u8f49\u79fb\uff0c3\u4eba\u6b7b\u65bc\u6cbb\u7642\u6240\u5f15\u767c\u7684\u5f8c\u9063\u75c7\uff0c9\u4eba\u6b7b\u65bc\u5176\u5b83\u75be\u75c5\u3002\u4e09\u5e74\u5b58\u6d3b\u7387\u8207\u4e0b\u8179\u8154\u816b\u7624\u63a7\u5236\u7387\u5206\u5225\u70balb-lla 95%/95%, llb 84%/92%, llla-lllb50%/78%\uff0c\u2163 25%/50%)\u3002\u91dd\u5c0d86\u4f4d\u5b58\u6d3b\u6642\u554f\u8d85\u904e\u4e00\u5e74\u7684\u75c5\u60a3\u9032\u884c\u5927\u8178\u5f8c\u907a\u75c7\u7684\u5206\u6790\uff0c\u5176\u7d50\u679c\u986f\u793a\u5171\u670926\u4eba(30.2%)\u767c\u751f\u76f4\u8178\u5f8c\u907a\u75c7\uff08RTOG grade I 14\u4eba\uff0cgrade II 18\u4eba\uff0cgrade III-IV 4\u4eba\uff09\uff0c\u7d93\u5206\u6790\u5f8c\u767c\u73feFIGO stage IIb-IV\uff0c\u76f4\u8178\u653e\u5c04\u5291\u91cf\uff08\u9060\u9694\u6cbb\u7642+\u6240\u6709\u8fd1\u63a5\u6cbb\u7642\u7684ICRU\u76f4\u8178\u5291\u91cf\uff09\u5927\u65bc65 Gy\uff0c\u4ee5\u53ca\u7e3d\u6cbb\u7642\u6642\u554f\u8d85\u904e70\u5929\u8005\u70ba\u9ad8\u5371\u96aa\u7fa4\u3002\n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793astage IIIa-IIIb\u75c5\u60a3\u7684\u6cbb\u7642\u7d50\u679c\u4ecd\u9808\u9032\u4e00\u6b65\u52a0\u4ee5\u6539\u5584\u3002\u56e0\u670918\u4f8b(17.6%)\u7684\u75c5\u606f\u767c\u751f\u9060\u8655\u8f49\u79fb\uff0c\u61c9\u8a55\u4f30\u9078\u5b9a\u9ad8\u5371\u96aa\u7684\u75c5\u4eba\u9032\u884c\u5316\u5b78\u6cbb\u7642\u4e4b\u81e8\u5e8a\u7814\u7a76\u3002\u4ee5\u76ee\u524d\u8fd1\u63a5\u6cbb\u7642\u7684\u65b9\u5f0f\uff0c\u7d04\u670930%\u6703\u767c\u751f\u4e0d\u540c\u7a0b\u5ea6\u7684\u653e\u5c04\u7dda\u76f4\u8178\u708e\uff0c\u672a\u4f86\u61c9\u7e7c\u7e8c\u5206\u6790\u5f15\u767c\u76f4\u8178\u5f8c\u9063\u75c7\u7684\u56e0\u7d20\uff0c\u5728\u4e0d\u5f71\u97ff\u6cbb\u7642\u7d50\u679c\u7684\u524d\u63d0\u4e0b\uff0c\u7531\u6cbb\u7642\u8a08\u5283\u7684\u8abf\u6574\uff0c\u9032\u800c\u6e1b\u5c11\u5f8c\u9063\u75c7\u767c\u751f\u7684\u6a5f\u7387\u3002", "e": "Introduction: Cancer of the uterine cervix is the most prevalent female cancer in Taiwan. Our study is to analyse the treatment outcome of cervical cancer in the past five years at Shin Kong Memorial Hospital. In order to refine future treatment protocol, the possible risk factors of late rectal complications will also be analysed.\nMaterials & Methods: From September 1992 to December 1994, 109 patients with uterine cervical cancer completed planned radiotherapy (RT) at Shin Kong Memorial Hospital. Treatment consisted of external beam RT followed by HDR (high dose rate) intracavitary brachytherapy. After external RT dose of 40~44 Gy to whole pelvis, bilateral parametrium of stage (IIb cases were further boosted to 54~58 Gy with central shielding. Intracavitary brachytherapy consisted of three to four insertions with intervals of one week. The prescribed dose of each insertion was 7.2 Ely to point A, while in some circumstances (old age or high cumulative rectal dose), point A dose had been modified to 5-6 Gy. One hundred and two cases (24 Iv-IIa, 48 IIb, 26 IIIa-b, 4 IVa) received follow-up and were enrolled for the study.\nResults: After 30 to 54 months of follow-up (median 39 months), 65 cases was alive (one was noted to have distant metastasis), 37 cases died of disease (8 for local reurrence, 16 for distant metastasis, one for both), 3 cases died of complication, while 9 cases were dead due to intercurrent disease. The 3-year cause-specific survival and local control rates are 95%/95% for Ib-IIa, 84%/92% for IIb, 50%/78% for IIIa-b, 25%/50% for stage IV, respectively. A total of 86 cases who survived more than one year were further analysed to define the risk factors of late gastrointestinal complication. Twenty-six patients (30.2%) was noted to have late rectal sequale (RTOG gradeI 14, gradeI 8, gradeIII-IV 4), while four cases (4.6%) developed ileus. Logistic regression analysis demonstrated a high risk of late rectal sequale in those who were stage IIb-IV cases, total rectal dose (external RT+total ICRU rectal dose)\uff1e65 Gy, and overall treatment time\uff1e70 days.\nConclusion: Our current study show the treatment outcome of Figo IIIa-tub cases is not satisfactory. Because 18 patients (17.6%) were noted to have distant metastases, it might be recommended to select high risk patients to undergo adjuvant chemotherapy. With our present tratment proctocol, there will be about 30% of cases to have different extent of radiation proctitis. We will continue to analyse possible risk factors of late rectal complications and promote the therapeutic gain of HDR brachytherapy based treatment planning."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-19-25-a", "title": "Outpatient Continuous Infusional Chemotherapy with Ambulatory Infusional Puma-The Early Experience of Outpatient Chemotherapy Unit at the Veterans General Hospital-Taipei", "keywords": "\u5316\u5b78\u6cbb\u7642;\u9023\u7e8c\u6027\u704c\u6ce8\u5316\u5b78\u6cbb\u7642;Hickman", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9580\u8a3a\u75c5\u4eba\u4f7f\u7528\u4e2d\u592e\u975c\u8108\u5c0e\u7ba1\u8207\u53ef\u651c\u5e36\u5f0f\u704c\u6ce8\u5e6b\u6d66\u9032\u884c\u9023\u7e8c\u6027\u704c\u6ce8\u5316\u5b78\u6cbb\u7642\u7684\u4f75\u767c\u75c7\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u81ea1990\u5e749\u6708\u81f31991\u5e746\u6708\u5171\u6536\u96c6\u4e8690\u4f8b\u75c5\u4eba\uff0c\u4e2d\u592e\u975c\u8108\u5c0e\u7ba1\u88dd\u7f6e\u5305\u62ecPort-A\u5c0e\u7ba1\uff0c\u6216\u662fHickman\u5c0e\u7ba1\u3002\u4f7f\u7528\u704c\u6ce8\u5e6b\u6d66\u70baWalkmed 430\u578b\u7cfb\u5217\uff0c\u6839\u64da\u75c5\u6b77\u53ca\u8b77\u7406\u8a18\u9304\u4f5c\u56de\u6eaf\u6027\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u7e3d\u5171\u6cbb\u7642666\u4eba\u6b21\u4e2d\uff0c27\u4eba\u6b21(4.1%)\u6709\u4f75\u767c\u75c7\u4e4b\u8a18\u9304\u3002\u67091\u4eba\u6b21\u56e0Hickman\u5c0e\u7ba1\u5f15\u8d77\u6557\u8840\u75c7\u800c\u4f4f\u9662\u5c07\u5c0e\u7ba1\u62d4\u9664\uff0c\u67095\u4eba\u6b21\u56e0\u5c0e\u7ba1\u548c\u85e5\u888b\u806f\u7d50\u812b\u843d\uff0c5\u4eba\u6b21\u56e0\u5e6b\u6d66\u64cd\u4f5c\u4e0d\u7576\u800c\u6545\u969c\uff0c 4 \u4eba\u6b21\u56e0\u5c0e\u7ba1\u963b\u585e\u800c\u9700\u4f7f\u7528urokinase\u6c96\u704c\uff0c4\u4eba\u6b21\u56e0\u96fb\u6c60\u8017\u76e1\u800c\u6545\u969c\uff0c4\u4eba\u6b21\u56e0Hickman\u5c0e\u7ba1\u812b\u51fa\u800c\u9700\u91cd\u88dd\uff0c3\u4eba\u6b21\u85e5\u888b\u7834\u88c2\u800c\u85e5\u7269\u6ef2\u51fa\uff0c\u6709l\u4eba\u6b21\u4e0d\u660e\u539f\u56e0\u56de\u8840\u5c0e\u81f4\u6545\u969c\u3002\u5176\u4ed6\u6c92\u6709\u4e3b\u8981\u7684\u4e0d\u826f\u4f75\u767c\u75c7\u3002\n\u7d50\u8ad6\uff1a\u9580\u8a3a\u75c5\u4eba\u4f7f\u7528\u4e2d\u592e\u975c\u8108\u5c0e\u7ba1\u8207\u53ef\u651c\u5e36\u5f0f\u704c\u6ce8\u5e6b\u6d66\uff0c\u9032\u884c\u9023\u7e8c\u6027\u704c\u6ce8\u5316\u5b78\u6cbb\u7642\u662f\u4e00\u7a2e\u5b89\u5168\u7684\u3001\u65b9\u4fbf\u7684\u53ca\u4f4e\u4f75\u767c\u75c7\u7684\u6cbb\u7642\u6a21\u5f0f\u3002", "e": "Purpose: We plan to evaluate the patterns of complication, and conveniences of outpatient ambulatory continuous infusional chemotherapy delivery system through implantable semipermanent central vein catheter and portable infusional pump in the treatment of cancer patients at the outpatient chemotherapy unit of VGH-Taipei.\nMaterials and Methods: From September 1990 to June 1991, we collected ninety cancer patients who received chemotherapy through either Hickman's catheter or Port-A Cath and Walkmed 430 iv infusion pump for outpatient infusional chemotherapy. Patients' chart and nursing records were analyzed retrospectively.\nResults: In a total of 666 treatment courses, there were 27 (4.1%) complications recorded. One patient developed catheter related sepsis who needed hospitalization and catheter removal thereafter. There were 5 courses (5 patients) with bag and tube disconnection, 5 courses (5 patients) with pump malfunction from improper operation, 4 courses (4 patients) of catheter obstruction which need urokinase salvage, 4 courses (4 patients) of pump failure from battery exhaustion, 4 courses ( 4 patients) of Hickman's catheter dislodged, 3 courses ( 3 patients) of drug leakage from reservoir, 1 course (1 patient) of machine malfunction from unknown reason. No other major morbidity were noted.\nConclusion: Outpatient continuous infusional chemotherapy with implantable central vein catheter and portable infusional pump is a safe, convenient with low complication treatment modality."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-27-36-a", "title": "Palliative Radiotherapy for Synchronous Brain Metastases from Lung Cancer", "keywords": "\u540c\u6642\u6027\u8166\u8f49\u79fb;\u80ba\u764c;\u7de9\u89e3\u6027\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Synchronous brain metastases;Lung cancer;Palliative radiotherapy;Prognostic factors", "c": "\u76ee\u7684\uff1a\u5728\u521d\u8a3a\u65b7\u80ba\u764c\u6642\u82e5\u540c\u6642\u5408\u4f75\u8166\u8f49\u79fb\uff0c\u5247\u8868\u793a\u5df2\u7d93\u662f\u7b2c\u56db\u671f\u7684\u80ba\u764c\uff0c\u5b58\u6d3b\u6642\u554f\u4e5f\u6bd4\u8f03\u6709\u9650\u3002\u5c0d\u65bc\u6b64\u7a2e\u75c5\u4eba\u7684\u6cbb\u7642\uff0c\u662f\u4ee5\u6e1b\u8f15\u75c5\u4eba\u7684\u75db\u82e6\u70ba\u4e3b\u8981\u76ee\u7684\u3002\u672c\u6587\u5206\u6790\u6b64\u7a2e\u75c5\u4eba\u63a5\u53d7\u7de9\u89e3\u6027\u653e\u5c04\u6cbb\u7642\u7684\u7d50\u679c\u4e26\u8a55\u4f30\u5176\u7642\u6548\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u79d1\u5f9e\u897f\u51431987\u5e74\u81f31994\u5e74\uff0c\u7e3d\u5171\u6709102\u4f4d\u75c5\u4eba\u5728\u521d\u8a3a\u65b7\u80ba\u764c\u6642\u5373\u540c\u6642\u5408\u4f75\u6709\u8166\u90e8\u96fb\u8166\u65b7\u5c64\u8b49\u5be6\u7684\u8166\u8f49\u79fb\u3002\u9019102\u4f4d\u75c5\u4eba\u90fd\u6709\u63a5\u53d7dexamethasone\u6cbb\u7642\u53ca\u8166\u90e8\u653e\u5c04\u6cbb\u7642\uff08\u653e\u5c04\u5291\u91cf\u4e2d\u9593\u503c\u662f30 Gy\uff09\u3002\u5176\u4e2d\u670930\u4f4d\u75c5\u4eba\u4e5f\u6709\u63a5\u53d7\u80ba\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u53e6\u5916\u5206\u5225\u670914\u4f4d\u75c5\u4eba\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c9\u4f4d\u75c5\u4eba\u63a5\u53d7\u8166\u90e8\u624b\u8853\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u8166\u8f49\u79fb\u6700\u5e38\u898b\u7684\u795e\u7d93\u75c7\u72c0\u662f\u7121\u529b(67.6%)\u53ca\u982d\u75db(55.9%)\u3002\u8166\u90e8\u653e\u5c04\u6cbb\u7642\u5e73\u5747\u70ba\u671f15.2\u5929\u300274.3%\u7684\u75c5\u4eba\u5728\u6cbb\u7642\u5f8c\u5176\u795e\u7d93\u75c7\u72c0\u6709\u6539\u5584\u3002\u5b58\u6d3b\u6642\u9593\u7684\u4e2d\u554f\u503c\u662f4.2\u500b\u6708\uff0c\u4e00\u5e74\u5b58\u6d3b\u7387\u662f14.7%\u3002\u591a\u8b8a\u9805\u5b58\u6d3b\u5206\u6790\u7684\u7d50\u679c\u986f\u793a\u826f\u597d\u7684\u6d3b\u52d5\u72c0\u614b\u3001\u8f03\u9ad8\u7684\u8166\u90e8\u653e\u5c04\u5291\u91cf\u3001\u6709\u63a5\u53d7\u8166\u90e8\u624b\u8853\u6cbb\u7642\u3001\u6c92\u6709\u5927\u5c0f\u4fbf\u5931\u7981\u7b49\u56db\u500b\u8b8a\u6578\u70ba\u826f\u597d\u7684\u9810\u5f8c\u56e0\u5b50\u3002\n\u7d50\u8ad6\uff1a\u56e0\u70ba\u80ba\u764c\u540c\u6642\u5408\u4f75\u8166\u8f49\u79fb\u75c5\u4eba\u7684\u5b58\u6d3b\u6642\u9593\u6709\u9650\uff0c\u800c\u4e14\u5176\u795e\u7d93\u75c7\u72c0\u4e5f\u76f8\u7576\u4e0d\u9069\uff1b\u826f\u597d\u7684\u59d1\u606f\u6027\u6cbb\u7642\u4ee5\u6539\u5584\u751f\u6d3b\u54c1\u8cea\u662f\u975e\u5e38\u91cd\u8981\u7684\u3002\u7531\u672c\u6587\u7d50\u679c\u767c\u73fe\u8166\u90e8\u653e\u5c04\u6cbb\u7642\u53ef\u4ee5\u6e1b\u8f1574.3%\u75c5\u4eba\u7684\u795e\u7d93\u75c7\u72c0\uff0c\u800c\u4e14\u5176\u5e73\u5747\u70ba\u671f\u53ea\u670915.2\u5929\uff1b\u6240\u4ee5\u653e\u5c04\u6cbb\u7642\u662f\u5f88\u597d\u7684\u7de9\u89e3\u6027\u6cbb\u7642\u3002\u80ba\u90e8\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u5b58\u6d3b\u4e26\u6c92\u6709\u986f\u8457\u7684\u5f71\u97ff\uff0c\u5176\u89d2\u8272\u4e3b\u8981\u5728\u7de9\u89e3\u75c5\u4eba\u7684\u80ba\u90e8\u75c7\u72c0\u3002", "e": "Purpose: Synchronous brain metastases (SM) of lung cancer patients indicate advanced stage and limited survival. The treatment intent is to relieve the agonizing symptoms. We analyzed the results of radiotherapy for these patients to evaluate the effects of palliative treatment.\nMaterials and Methods: From 1987 to 1994, 102 lung cancer patients with CT-documented synchronous SM were reviewed. All patients received cranial irradiation (median dose 30 Gy) and dexamethasone. Chemotherapy and neurosurgery were performed in 14 and 9 cases respectively. Thirty patients also underwent lung irradiation.\nResults: The two leading neurological symptoms were motor weakness (67.6%) and headache (55.9%). The mean duration of cranial irradiation was 15.2 days. After treatment, overall neurological symptomatic response rate was 74.3%. Median survival was 4.2 months and 1-year survival rate was 14.7%. The multivariate survival analysis showed that good performance status, higher total cranial radiation dose, neurosurgery, and absence of urine/stool incontinence were favorable prognostic factors.\nConclusions: Owing to short life expectancy and neurological morbidity of lung cancer patients with synchronous SM, a good palliative treatment to improve life quality is required in supportive care of these patients. Radiotherapy appears as an effective means of palliation with 74.3% neurological symptomatic response rate while the median duration of cranial irradiation is only 15 days. Lung irradiation has no significant effect on survival; instead, it should be used for palliation of symptoms."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-37-44-a", "title": "Retrospective Study of Pediatric Acute Leukemia", "keywords": "\u767d\u8840\u75c5;\u9810\u9632\u6027\u5168\u8166\u7167\u5c04;\u4e2d\u6a1e\u6027\u767d\u8840\u75c5\u5fa9\u767c Leukemia;Prophylactic cranial irradiation;CNS relapse", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u6709\u95dc\u672c\u9662\u5152\u7ae5\u6025\u6027\u767d\u8840\u75c5\u9810\u9632\u6027\u5168\u8166\u7167\u5c04\u7684\u6cbb\u7642\u7d50\u679c\u4ee5\u53ca\u9019\u4e9b\u75c5\u7ae5\u7684\u9810\u5f8c\u5f71\u97ff\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1987\u5e749\u6708\u81f31996\u5e743\u6708\uff0c\u5171\u670922\u4f4d\u60a3\u6709\u6025\u6027\u767d\u8840\u75c5\u5152\u7ae5\uff0817\u4f4d\u70ba\u6025\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5\uff0c5\u4f4d\u70ba\u6025\u6027\u975e\u6dcb\u5df4\u6027\u767d\u8840\u75c5\uff09\u65bc\u672c\u79d1\u63a5\u53d7\u9810\u9632\u6027\u5168\u8166\u7167\u5c04\u3002\u5176\u4e2d\u7537\u5b69\u4f549\u4f4d\uff0c\u5973\u5b69\u4f5413\u4f4d\uff0c\u5e74\u9f61\u4ecb\u65bc1.6\u81f317.4\u6b72\u4e4b\u9593\uff0c\u5c0d\u65bc\u5b58\u6d3b\u75c5\u7ae5\u7684\u5e73\u5747\u8ffd\u7d9c\u6642\u9593\u70ba48\u5e74\uff08\u7bc4\u570d\u5f9e2.7\u52307.16\u5e74\uff09\u3002\u653e\u5c04\u6cbb\u7642\u7e3d\u5291\u91cf\u70ba1800 cGy\u3002\u7d93\u7531\u56de\u6eaf\u6574\u7406\u5176\u6cbb\u7642\u8a18\u9304\u8207\u75c5\u6b77\u8cc7\u6599\u4f86\u7814\u7a76\u5176\u5404\u9805\u9810\u5f8c\u56e0\u5b50\u8207\u5b58\u6d3b\u60c5\u6cc1\u3002\n\u7d50\u679c\uff1a\u672c\u6587\u5206\u6790\u76f8\u95dc\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u767c\u73fe\u6dcb\u5df4\u817a\u816b\u70ba\u5f71\u97ff\u9810\u5f8c\u7684\u4e3b\u8981\u56e0\u7d20\u3002\u6240\u6709\u75c5\u7ae5\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba50%\uff0c\u800c\u76ee\u524d\u5b58\u6d3b\u7684\u75c5\u7ae5\u5df2\u7d93\u7d50\u675f\u5316\u5b78\u6cbb\u7642\u7642\u7a0b\u8d85\u904e\u4e09\u5e74\u4ee5\u4e0a\u3002\u653e\u5c04\u6cbb\u7642\u4e2d\u4e3b\u8981\u7684\u53cd\u61c9\u70ba\u5614\u5410\u3001\u982d\u75db\u3002\u6240\u6709\u75c5\u7ae5\u53ea\u6709\u4e00\u4eba\u5728\u9810\u9632\u6027\u5168\u8166\u7167\u5c04\u5341\u4e00\u500b\u6708\u5f8c\u767c\u751f\u4e2d\u6a1e\u6027\u7684\u767d\u8840\u75c5\u5fa9\u767c\u3002\u800c\u6b7b\u4ea1\u75c5\u7ae5\u7684\u4e3b\u8981\u81f4\u6b7b\u539f\u56e0\u70ba\u6557\u8840\u75c5\u3002\n\u7d50\u8ad6\uff1a\u767d\u8840\u75c5\u7ae5\u82e5\u767c\u751f\u4e2d\u6a1e\u6027\u767d\u8840\u75c5\u6703\u5f71\u97ff\u5230\u767d\u8840\u75c5\u7684\u6cbb\u7642\u8207\u9810\u5f8c\uff0c\u800c\u4e14\u7531\u65bc\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u5167\u7684\u767d\u8840\u7403\u6bcd\u7d30\u80de\u6709\u6a5f\u6703\u518d\u5ea6\u690d\u5165\u5df2\u7d93\u5316\u5b78\u6cbb\u7642\u7de9\u89e3\u7684\u9aa8\u9ad3\u4e2d\uff0c\u7d50\u679c\u4e5f\u53ef\u80fd\u6703\u5c0e\u81f4\u767d\u8840\u75c5\u7684\u8840\u6db2\u5fa9\u767c\u3002\u800c\u6839\u64da\u672c\u6587\uff0c\u9810\u9632\u6027\u5168\u8166\u7167\u5c04\u53ef\u7372\u5f97\u5f88\u597d\u7684\u4e2d\u6a1e\u6027\u767d\u8840\u75c5\u9810\u9632\u7d50\u679c\u3002\u767d\u8840\u75c5\u6cbb\u7642\u7684\u6a21\u5f0f\u4e2d\uff0c\u65bc\u5316\u5b78\u6cbb\u7642\u7a0b\u4e2d\u5747\u61c9\u52a0\u5165\u5168\u8166\u9810\u9632\u6027\u7167\u5c04\u662f\u503c\u5f97\u8003\u616e\u7684\u65b9\u5f0f\u3002\u81f3\u65bc\u5176\u4ed6\u9810\u5f8c\u56e0\u5b50\u4e4b\u5206\u6790\u5247\u6709\u5f85\u672a\u4f86\u66f4\u591a\u8cc7\u6599\u75c5\u6b77\u7684\u6536\u96c6\u3002", "e": "Purpose: To evaluate the therapeutic result and analyze the prognostic variables of pediatric acute leukemia treated with chemotherapy and prophylactic cranial irradiation (PCI) at KMCH over the past 10 years.\nMaterials and Methods: From September 1987 to March 1996, twenty-two patients with acute leukemia received PCI at Kaohsiung Medical College Hospital. There were 9 boys and 13 girls between 1.6 and 17.4 years of age at diagnosis. According to French- American-British (FAB) classification, seventeen patients had acute lymphoblastic leukemia (ALL) and 5 patients had acute non-lymphoblastic leukemia (ANLL). The radiation dose was 1800 cGy given in 10 to 15 fractions. Prognostic factors such as leukemia subtype, age, sex, hemogram, hepatosplenomegaly, lymphoadenopathy and radiotherapy fraction were analyzed by retrospective review of the medical records. All patients were followed up regularly. The median follow-up time for patients still alive were 4.8 years (range 2.7 to 7.16 years).\nResults: The common acute reactions were vomiting and headache. The 5-year disease-free survival rate was 50%. Overall median survival time was 6 years; ALL was 6.16 years and ANLL was 2 years. Only one patient (5%) suffered from CNS relapse 1 year after PCI. The major cause of death was sepsis (55%). Adenopathy was the significant prognostic factors in this study.\nConclusion: Leukemia involvement of the CNS remains a major clinical problem despite the improved disease control provided by mordern treatment regimens. In this study, excellent CNS prophylactic result (95%) was achieved in our cases, and we recommend that PCI should be incorporated in the management of pediatric acute leukemia. Besides, the most significant prognostic factor was adenopathy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-45-49-a", "title": "\u4ee5\u7b49\u4e2d\u5fc3\u9ede\u76f8\u5207\u7167\u91ce\u6280\u8853\u6cbb\u7642\u4e73\u764c\u60a3\u8005\u6642\u4e4b\u5c0d\u5074\u4e73\u623f\u5291\u91cf\u8a55\u4f30\u53ca\u5c4f\u853d\u6548\u61c9", "keywords": "\u4e73\u764c;\u76f8\u5207\u7167\u91ce\u6cbb\u7642\u6280\u8853;\u5c0d\u5074\u4e73\u623f\u5291\u91cf;\u586b\u5145\u7269 Breast cancer;Tangential field;Contralateral breast;Bolus", "c": "\u76ee\u7684\uff1a\u6e2c\u91cf\u4ee5\u7b49\u4e2d\u5fc3\u9ede\u76f8\u5207\u7167\u91ce\u6280\u8853\u6cbb\u7642\u4e73\u764c\u60a3\u8005\u6642\u4e4b\u5c0d\u5074\u4e73\u623f\u5291\u91cf\uff0c\u4e26\u89c0\u5bdf\u6dfb\u52a0\u925b\u76ae\u53ca\u6a23\u76ae\u6751\u8cea\u586b\u5145\u7269\u7684\u5c4f\u853d\u6548\u679c\uff0c\u53ca\u8a55\u4f30\u5be6\u969b\u6cbb\u7642\u6642\u4e4b\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u4e0d\u5c0d\u7a31\u7167\u91ce(asymmetric Jaws)\u63a1\u4e09\u500b\u7167\u91ce\u7684\u7b49\u4e2d\u5fc3\u9ede\u76f8\u5207\u7167\u91ce\u6280\u8853(mono-isocenter tangential technique)\uff0c\u4ee5\u5169\u500b\u76f8\u5207\u7167\u91ce(tangential fields)\u4f86\u6cbb\u7642\u4e73\u623f\u3001\u80f8\u8154\u58c1\u3001\u5167\u4e73\u6dcb\u5df4\u7d50\u53ca\u814b\u4e0b\u6dcb\u5df4\u7d50\uff0c\u518d\u7d50\u5408\u4e00\u500b\u4e0a\u9396\u9aa8\u7167\u91ce(supraclavicular field)\u4f86\u6cbb\u7642\u9396\u9aa8\u4e0a\u6dcb\u5df4\u7d50\u3002\u5171\u670911\u540d\u5c6c\u65bc\u4e09\u81f3\u56db\u671f\u4e73\u764c\u4e26\u5df2\u505a\u904e\u4e73\u623f\u5207\u9664\u624b\u8853\u7684\u4e73\u764c\u60a3\u8005\u63a5\u53d7\u4e73\u623f\u5291\u91cf\u8a55\u4f30\uff0c\u5176\u5e74\u9f61\u5f9e40-51\u6b72\uff08\u5e73\u574746\u6b72\uff09\u3002\u6211\u5011\u5728\u5176\u5c0d\u5074\u4e73\u623f\u8cbc\u4e0a\u71b1\u767c\u5149\u5291\u91cf\u8a08(TLD)\uff0c\u65bc\u6bcf\u6b21\u6cbb\u7642\u6642\u5206\u5225\u6dfb\u52a0\u4e0d\u540c\u539a\u5ea6\u7684\u925b\u76ae\u53ca\u6a61\u76ae\u6750\u8cea\u586b\u5145\u7269\u4e88\u4ee5\u5c4f\u853d\uff0c\u6cbb\u7642\u5f8c\u8b80\u53d6TLD\u503c\u3002\n\u7d50\u679c\uff1a\u5728\u55ae\u6b21\u6cbb\u7642\u7d66\u4e88180 cGy\uff0c\u672a\u6dfb\u52a0\u4efb\u4f55\u5c4f\u853d\u6642\uff0c\u5c0d\u5074\u4e73\u623f\u5e73\u5747\u63a5\u53d711\u00b11.9 cGy\u7684\u5291\u91cf\uff0c\u5728\u6dfb\u52a00.5cm\u30011cm\u30011.5cm\u30012cm\u586b\u5145\u7269\u5f8c\uff0c\u5c0d\u5074\u4e73\u623f\u7684\u5291\u91cf\u5206\u5225\u6e1b\u5c11\u70ba4.6\u00b10.5 cGy\u30013.2\u00b10.3 cGy\u30013.0\u00b10.2 cGy\u53ca2.8\u00b10.1 cGy\uff1b\u800c\u5728\u6dfb\u52a00.3cm\u53ca0.5cm\u925b\u76ae\u5f8c\uff0c\u5c0d\u5074\u4e73\u623f\u5291\u91cf\u5206\u5225\u6e1b\u70ba2.7\u00b10.2 cGy\u53ca2.6\u00b10.2 cGy\u3002\u56e0\u6b64\uff0c\u5728\u6cbb\u764228\u6b21\u7e3d\u5291\u91cf\u90545040 cGy\u5f8c\uff0c\u4f30\u8a08\u5c0d\u5074\u4e73\u623f\u5c07\u63a5\u53d7\u7d04332 cGy\u7684\u6563\u5c04\u5291\u91cf\uff1b\u5728\u6dfb\u52a02cm\u7684\u586b\u5145\u7269\u53ca0.5cm\u7684\u925b\u76ae\u5c4f\u853d\u5f8c\uff0c\u53ef\u4f7f\u5c0d\u5074\u4e73\u623f\u8868\u9762\u5291\u91cf\u5206\u5225\u6e1b\u5c11\u70ba80 cGy\u53ca73 cGy\uff0c\u6e1b\u5c11\u7d0475%\u7684\u6563\u5c04\u5291\u91cf\u3002\n\u7d50\u8ad6\uff1a\u6a61\u76ae\u6750\u8cea\u586b\u5145\u7269\u5728\u653e\u5c04\u6cbb\u7642\u4e0a\u4e00\u822c\u88ab\u61c9\u7528\u65bc\u63d0\u6607\u8eab\u9ad4\u6dfa\u90e8\u5291\u91cf\uff0c\u7531\u672c\u7814\u7a76\u5f97\u77e5\uff0c\u5176\u540c\u6642\u53ef\u7528\u4ee5\u964d\u4f4e\u6cbb\u7642\u4e73\u764c\u6642\u4e4b\u5c0d\u5074\u4e73\u623f\u5291\u91cf\u201c\u7531\u65bc\u586b\u5145\u7269\u5728\u5404\u653e\u5c04\u6cbb\u7642\u90e8\u9580\u7686\u6613\u8cfc\u5f97\u6216\u5bb9\u6613\u88fd\u4f5c\uff0c\u4e14\u6613\u65bc\u56fa\u5b9a\u53ca\u7dca\u8cbc\u65bc\u60a3\u8005\u8eab\u4e0a\uff0c\u56e0\u6b64\u503c\u5f97\u52a0\u4ee5\u904b\u7528\u4ee5\u6e1b\u5c11\u75c5\u60a3\u4e4b\u6563\u5c04\u5291\u91cf\u3002", "e": "Purpose: To measure the doses of contralateral breast from mono-isocenter tangential fields. To investigate the shielding effect of lead sheet and rubber bolus and evaluate the availability on practical treatment.\nMaterials and Methods: We develop mono-isocenter tangential technique. Two tangential fields was applied to treat patient's breast, chest wall, internal mammary chain and axillary lymph nodes. The supraclavicular lymph nodes were treated with a supraclavicular field. 11 stage III, IV post-mastectomy patients were enrolled in our study. TLDs were placed on their contralateral breast for dosage evaluation with the following condition: (1) without rubber bolus or lead sheet, (2) with lead sheet, (3) with rubber bolus. The prescribe dose was 180 cGy daily.\nResults: We found that the to contralateral breast was 11\u00b11.9 cGy daily, when there is no shielding. By adding 0.5cm, 1cm, 1.5cm and 2cm bolus on contralateral breast, the doses decreased to 4.6\u00b10.5 cGy, 3.2\u00b10.3 cGy, 3.0\u00b10.2 cGy and 2.8\u00b10.1 cGy, respectively. While 0.3cm and 0.5cm lead sheet were added, the doses decreased to 2.7\u00b10.2 cGy and 2.6\u00b10.2 cGy, respectively. Therefore, while the total dose reach 5040 cGy, the dose to contralateral breast was estimated as 332 cGy. Adding a 2cm bolus or 0.5cm lead sheet will effectively reduce the dose to 80 cGy and 73 cGy, respectively, which eliminate approximately 75% scatter radiation doses.\nConclusion: Rubber bolus is usually used for increasing body surface dose during radiation therapy. This study indicated that rubber bolus can decrease the doses to contralateral breast when a tangential field technique is applied. Rubber bolus is a material which can be easily available, and proved to effectively reduce the dose of contralateral breast, it is also easy to fix on patient's chest wall, so we encourage the usage of bolus during radiation therapy for breast cancer."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-51-55-a", "title": "Inverted Papilloma with Sarcomatoid Carcinoma in the Nasal Cavity: A Case Report", "keywords": "\u5012\u751f\u6027\u4e73\u982d\u72c0\u7624;\u8089\u764c\u985e\u764c;\u653e\u5c04\u7dda\u6cbb\u7642 Inverted papilloma;Sarcomatoid carcinoma;Radiotherapy", "c": "\u5012\u751f\u6027\u4e73\u982d\u72c0\u7624\u8207\u8089\u764c\u985e\u764c\u5728\u4e0a\u547c\u5438\u8178\u80c3\u9053\u4e26\u4e0d\u5e38\u898b\uff0c\u800c\u5176\u6cbb\u7642\u65b9\u5f0f\u4e5f\u672a\u5b8c\u5168\u6709\u5b9a\u8ad6\u3002\u672c\u6587\u4e2d\u63d0\u51fa\u4e0080\u6b72\u60a3\u6709\u9f3b\u8154\u5167\u816b\u7624\u4e4b\u7537\u6027\u75c5\u4eba\uff0c\u7d93\u529f\u80fd\u6027\u5167\u8996\u93e1\u9f3b\u7ac7\u624b\u8853\u5207\u9664\u5f8c\uff0c\u75c5\u7406\u5831\u544a\u986f\u793a\u6b64\u816b\u7624\u4f75\u6709\u5012\u751f\u6027\u4e73\u982d\u72c0\u7624\u8207\u8089\u764c\u985e\u764c\u5169\u7a2e\u75c5\u7406\u7d44\u7e54\u3002\u56e0\u672c\u75c5\u4f8b\u70ba\u4e00\u4fb5\u72af\u6027\u816b\u7624\u4e14\u5177\u7279\u6b8a\u7684\u75c5\u7406\u7279\u5fb5\uff0c\u8853\u5f8c\u75c5\u4eba\u63a5\u53d7\u4ee5\u4e09\u7167\u91ce\u65b9\u5f0f\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u7e3d\u5291\u91cf\u70ba5940 cGy\u3002\u81f3\u76ee\u524d\u816b\u7624\u4e26\u7121\u5fa9\u767c\u8de1\u8c61\uff0c\u56e0\u6b64\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u4f5c\u70ba\u5c0d\u6b64\u7279\u6b8a\u75be\u75c5\u7684\u8f14\u52a9\u7642\u6cd5\u53ef\u671b\u6709\u52a9\u65bc\u589e\u52a0\u5c0d\u816b\u7624\u7684\u5c40\u90e8\u63a7\u5236\u3002", "e": "Inverted papilloma and sarcomatoid carcinoma are both uncommon tumors of the upper aerodigestive tract, and the treatment modalities are controversial. We report a case of an 80-year-old male patient with a nasal cavity tumor. Functional endoscopic sinus surgery was performed and the pathology revealed inverted papilloma and sarcomatoid carcinoma. This combination has not previously been reported. Radiotherapy was administrated because of advanced disease, inadequate surgical margins, and the unique pathological findings. A 3-field technique was used, with a total dose to 5940 cGy. No recurrence was noted. This suggests that radiotherapy may be a useful adjuvant therapy for improving local control of this disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199803-5-1-57-62-a", "title": "Relief of Dysphagia by Palliative Intracavitary Brachytherapy for Recurrent Esophageal Cancer Two Cases Report", "keywords": "\u8154\u5167\u8fd1\u63a5\u6cbb\u7642;\u98df\u9053\u764c Intracavitary brachytherapy;Esophageal cancer", "c": "\u76ee\u7684\uff1a\u7528\u59d1\u606f\u6027\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u6539\u5584\u98df\u9053\u764c\u5c40\u90e8\u5fa9\u767c\u7684\u541e\u56a5\u56f0\u96e3\u5831\u544a\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1996\u5e741\u6708\u5169\u540d\u98df\u9053\u764c\u5c40\u90e8\u5fa9\u767c\u60a3\u8005\u56e0\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\uff0c\u5229\u7528a microSelectron-HDR afterloading device, Iridium-192\u5c04\u6e90\u8207\u4e00\u7279\u5225\u70ba\u98df\u9053\u8a2d\u8a08\u7684\u5c0e\u7ba1\u4f86\u6cbb\u7642\u3002\u7b2c\u4e00\u4f8b\u7d66\u4e88\u6cbb\u7642\u7bc4\u570d\u662f\u9577\u5ea6\u4e5d\u516c\u5206\uff0c\u534a\u5f91\u662f\u4e00\u516c\u5206\uff0c\u7e3d\u5291\u91cf\u662f2000 cGy\u520610 fractions\uff0c\u5728\u5169\u5468\u5b8c\u6210\u3002\u7b2c\u4e8c\u4f8b\u7d66\u4e88\u6cbb\u7642\u7bc4\u570d\u662f\u9577\u5ea6\u4e8c\u516c\u5206\uff0c\u534a\u5f91\u662f\u4e00\u516c\u5206\uff0c\u7e3d\u5291\u91cf\u662f2000 cGy\u52064 fractions, \u5728\u5341\u4e8c\u65e5\u5167\u5b8c\u6210\u3002\n\u7d50\u679c\uff1a\u7b2c\u4e00\u4f8b\u63a5\u53d75 fraction\u5f8c\uff0c\u5df2\u7d93\u53ef\u4ee5\u559d\u6d41\u8cea\u5be6\u7269\uff0c\u5728\u5169\u5468\u5b8c\u6210\u5f8c\uff0c\u7121\u6025\u6027\u526f\u4f5c\u7528\uff0c\u4e0d\u904e\u60a3\u8005\u5728\u6cbb\u7642\u5f8c\u7b2c\u4e09\u500b\u6708\u56e0\u816b\u7624\u51fa\u8840\u53ca\u60e1\u8cea\u9ad4\u53bb\u4e16\u3002\u7b2c\u4e8c\u4f8b\u7d93\u8fd1\u63a5\u6cbb\u7642\u5f8c\uff0c\u60a3\u8005\u611f\u5230\u5410\u53e3\u6c34\u5c11\u5f88\u591a\uff0c\u751f\u6d3b\u54c1\u8cea\u6709\u6539\u5584\uff0c\u7121\u6025\u6027\u526f\u4f5c\u7528\uff0c\u4e0d\u904e\u60a3\u8005\u5728\u6cbb\u7642\u5f8c\u7b2c\u4e8c\u500b\u6708\u56e0\u80ba\u708e\u53ca\u60e1\u8cea\u9ad4\u53bb\u4e16\u3002\u6b64\u7a2e\u6cbb\u7642\u80fd\u6539\u5584\u60a3\u8005\u751f\u6d3b\u54c1\u8cea\uff0c\u4e14\u7121\u660e\u986f\u526f\u4f5c\u7528\uff0c\u9664\u4e86\u8f15\u5fae\u98df\u9053\u708e\u3002\n\u7d50\u8ad6\uff1a\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u53ef\u4ee5\u4f7f\u66fe\u63a5\u53d7\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u800c\u5c40\u90e8\u5fa9\u767c\u98df\u9053\u764c\u60a3\u8005\u7684\u541e\u56a5\u56f0\u96e3\u75c7\u72c0\u7372\u5f97\u6539\u5584\u3002", "e": "Purpose: To report the result of palliative intracavitary brachytherapy in recurrent esophageal cancer patient.\nMaterials and Methods Since January 1996, there were two recurrent esophageal cancer patients with symptoms of severe dysphagia who received intracavitary brachytherapy as palliative treatment. The treatment were carried out by a microSelectron-HDR afterloading device with lridium-192 radiation source and a special catheter which was  designed for esophageal applications. One patient was treated by a treatment volume including the middle third of the esophagus, 9cm in length, the prescribed dose point was one cm in depth from the central axis of the source. The total treatment dose was 2000 cGy in 10 fractions within 2 weeks. The brachytherapy for another patient was arranged to cover the upper part of the esophageal tumor with 2cm in length and the prescribed dose point was one cm in depth. The total treatment dose was 2000 cGy in 4 fractions within 12 days.\nResults The symptoms of the first patient had improved after the first 5 fractions of HDR treatments. He could eat liquid diet after this treatment but odynophagia occurred. Two months later, he expired due to tumor bleeding and cachexia. After 2 fractions of intracavitary brachytherapy, the second patient could swallow some saliva, and the NO tube could be inserted more deeply. He felt better due to less production of saliva after treatment. He expired due to pneumonia in two months. The purpose of improving quality of life could be reached via this kind of treatment without severe acute toxicity except for grade one esophagitis.\nConclusion; Palliative intracavitary brachytherapy can be a successful treatment for relief of dysphagia for patients with recurrent esophageal cancer patients with previous external beam radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-243-249-a", "title": "\u52a0\u901f\u5f0f\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u65bc\u9f3b\u54bd\u764c\u4e4b\u7d93\u9a57", "keywords": "\u52a0\u901f\u5f0f;\u653e\u5c04\u6cbb\u7642;\u9f3b\u54bd\u764c Accelerated;Radiotherapy;Nasopharyngeal carcinoma", "c": "\u76ee\u7684\uff1a\u6539\u8b8a\u5206\u6b21\u7684\u653e\u5c04\u6cbb\u7642\u5df2\u88ab\u8b49\u5be6\u53ef\u4ee5\u63d0\u9ad8\u816b\u7624\u63a7\u5236\u7387\uff0c\u672c\u524d\u77bb\u6027\u7814\u7a76\u4fc2\u63a2\u8a0e\u6bcf\u5929\u7167\u5c04\u4e8c\u6b21\u4e4b\u52a0\u901f\u5f0f\u653e\u5c04\u6cbb\u7642\u5c0d\u9f3b\u54bd\u764c\u4e4b\u53ef\u884c\u6027\u3001\u7642\u6548\u53ca\u526f\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u6c11\u570b\u516b\u5341\u4e00\u5e74\u5341\u4e8c\u6708\u81f3\u516b\u5341\u56db\u5e74\u5341\u4e8c\u6708\uff0c\u5171\u670943\u4f4d\u9f3b\u54bd\u764c\u75c5\u4eba\u9032\u5165\u672c\u7814\u7a76\uff0c\u5176\u4e2d\u7537\u602732\u4f8b\u3001\u5973\u6027u\u4f8b\uff0c\u5e74\u9f61\u4ecb\u65bc28\u81f378\u6b72\uff0c\u5927\u591a\u6578\u75c5\u4eba\u75c5\u7406\u5207\u7247\u5c6c\u65bc\u5206\u5316\u5f88\u5dee\u6216\u672a\u5206\u5316\u764c\uff0c\u6839\u64da1958\u5e74AJCC\u5206\u671f\u7cfb\u7d71\uff0c\u7b2c\u4e8c\u671f\u4e00\u4f8b\uff0c\u7b2c\u4e09\u671f\u4e94\u4f8b\uff0c\u4e09\u5341\u4e03\u4f8b\uff0886.1%\uff09\u5c6c\u65bc\u7b2c\u56db\u671f\u3002\u52a0\u901f\u5f0f\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\u5982\u4e0b\uff1a\u6bcf\u5929\u7167\u5c04\u4e8c\u6b21\uff0c\u6bcf\u6b211.5Gy\uff0c\u4e0a\u4e0b\u5348\u6cbb\u7642\u81f3\u5c11\u9694\u516d\u5c0f\u6642,\u6bcf\u9031\u7167\u5c04\u4e94\u5929\u2022\u7e3d\u5291\u91cf\u70ba72Gy/4\u5206\u6b21/5\u9031\u3002\n\u7d50\u679c\uff1a\u75c5\u4eba\u7684\u6025\u6027\u526f\u4f5c\u7528\uff0c\u4e3b\u8981\u662f\u53e3\u8154\u9ecf\u819c\u767c\u708e\u53cd\u61c9\uff0856%\u9054\u7b2c\u4e09\u3001\u56db\u7d1a\uff09\u548c\u76ae\u819a\u53cd\u61c9\uff0860%\u9054\u7b2c\u4e09\u3001\u56db\u7d1a\uff5d\u3002\u670911\u4f8b\u56e0\u6bd2\u6027\u53cd\u61c9\u5728\u63a5\u53d7\u7d04\u4e09\u9031\u52a0\u901f\u5f0f\u653e\u5c04\u6cbb\u7642\u5f8c\u2022\u8981\u6c42\u6539\u70ba\u50b3\u7d71\u5206\u6b21\u6cbb\u7642\uff0c\u6bcf\u5929\u53ea\u7167\u5c04\u4e00\u6b21\uff0c\u53e6\u67092\u4f8b\u5206\u5225\u4f11\u606f\u4e8c\u548c\u56db\u9031\u4e4b\u4e45\u3002\u96d6\u7136\u5982\u6b64\uff0c\u6240\u6709\u75c5\u4eba\u90fd\u80fd\u5b8c\u6210\u8db3\u91cf\u7684\u653e\u5c04\u6cbb\u7642\uff0c\u5e73\u5747\u6bcf\u4eba\u63a5\u53d772Gy/47\u5206\u6b21\uff0867.5\u81f379Gy)\uff0c\u5e73\u5747\u6cbb\u7642\u6642\u959338\u5929\u3002\u8fc4\u4eca\u8ffd\u8e2a\u6642\u554f\u5df224\u81f360\u500b\u6708\uff08\u4e2d\u503c\u8ffd\u8dcc\u6642\u959341\u500b\u6708\uff09\uff0c\u76ee\u524d\u6cbb\u7642\u5931\u6557\u8005\u670915\u4f8b\uff0c\u55ae\u7368\u9f3b\u54bd\u90e8\u5fa9\u767c4\u4f8b\uff0c\u9f3b\u54bd\u90e8\u5408\u4f75\u9060\u8655\u8f49\u79fb\u80051\u4f8b\uff0c1\u4f8b\u5148\u767c\u751f\u9060\u8655\u8f49\u79fb\u5f8c\u53c8\u767c\u751f\u9f3b\u54bd\u90e8\u53ca\u9838\u90e8\u6dcb\u5df4\u5fa9\u767c\uff0c\u5176\u4ed69\u4f8b\u90fd\u662f\u9060\u8655\u8f49\u79fb\uff0c\u4e09\u5e74\u9f3b\u54bd\u90e8\u63a7\u5236\u7387\u90b5\u991b\uff0c\u9838\u90e8\u63a7\u5236\u738797.3%\uff0c\u9060\u8655\u8f49\u79fb\u63a7\u5236\u738771.2%, \u4e09\u5e74\u7e3d\u5b58\u6d3b\u738754.1%\uff0c\u4e09\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u710965.7%\u3002\n\u7d50\u8ad6\uff1a\u52a0\u901f\u5f0f\u653e\u5c04\u6cbb\u7642\u5c0d\u665a\u671f\u9f3b\u54bd\u764c\u662f\u53ef\u884c\u4e14\u6839\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u9060\u8655\u8f49\u79fb\u662f\u6cbb\u7642\u5931\u6557\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u653e\u7642\u5f8c\u518d\u8ffd\u52a0\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u4ee5\u6e1b\u5c11\u9060\u8655\u8f49\u79fb\u767c\u751f\uff0c\u63d0\u9ad8\u5b58\u6d3b\u7387\uff0c\u503c\u5f97\u9032\u4e00\u6b65\u7814\u7a76\u201c\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997;4:243-249\uff3d", "e": "Purpose: Altered fractionated radiotherapy can enhance the local control in many types of tumor when compared with conventional radiotherapy, especially for head and neck cancer. The purpose of this prospective phase II study is to evaluate the feasibility, response and toxicities of accelerated radiotherapy for nasopharyngeal carcinoma (NPC).\nMaterials and Methods: Through December 1992 to December 1995, 43 patients with pathologically documented NPC were entered. There were 32 male and 11 female with a median age of 51 years (range 28-78). The pathology of most patients (91%) belongs to WHO type II and III. According to 1988 AJCC staging system, 37 patients (86.1%) were stage IV, 5 (11.6%) stage III, and 1(2.3%) stage II. The accelerated radiotherapy consists of 1.5 Gy/fraction, two fractions per day, with at least a 6-hour interval. The total dose is usually 72 Gy/48 fractions in 5 weeks.\nResults: The major toxicities were mucositis and skin reaction. Grade 3/4 mucositis occurred in 24 patients (55.8%) and grade 3/4 skin reaction in 26 patients (60.5%). Eleven patients asked to change to conventional radiotherapy (1.8-2.0 Gy/fraction, one fraction per day) during the later part of radiotherapy, and 2 patients had interruption for 2 and 4 weeks. Although the original accelerated schedule in 13 patients were modified, all patients completed the treatment with average dose 72 Gy/47 fractions/38 days (range 67.5-79 Gy). After a median follow-up time of 41 months (range 24-60), the nasopharynx disease-free, neck disease-free, and distant metastasis disease-free survivals are 86.6%, 97.3%, and 71.2% respectively. The 3-year overall survival and disease-free survival are 54.1% and 65.7%. Most patients failed due to distant metastases.\nConclusion: Our data indicate that accelerated radiotherapy for advance NPC is both feasible and effective, with acceptable toxicities. Post-radiation adjuvant chemotherapy to eradicate subclinical micrometastasis should be further studied.\n\uff3bTherapeut Radiol Oncol 1997; 4:243-249\uff3d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-251-257-a", "title": "\u9f3b\u54bd\u764c\u75c5\u60a3\u653e\u5c04\u6cbb\u7642\u4e2d\u65b7\u7684\u539f\u56e0\u53ca\u5206\u6790", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u4e2d\u65b7\u6cbb\u7642 Nasopharyngeal cancer;Radiotherapy;Treatment interruption", "c": "\u76ee\u7684\uff1a\u96a8\u8457\u91ab\u7642\u79d1\u6280\u7684\u9032\u6b65\uff0c\u8a31\u591a\u9f3b\u54bd\u764c\u764c\u75c7\u60a3\u8005\u7d93\u6cbb\u7642\u4fca\u5b58\u6d3b\u4e0b\u6765\u3002\u7136\u800c\u9047\u53bb\u6570\uff0b\u5e74\u7684\u91ab\u7642\u7814\u7a76\uff0c\u91cd\u9eef\u653e\u5728\u9759\u65ad\u53ca\u71ce\u6548\u4e0a\uff1b\u5c01\u9f3b\u54bd\u764c\u75c5\u60a3\u672a\u5b8c\u6210\u5168\u7a0b\u6cbb\u7634\u7684\u539f\u56e0\u53ca\u5176\u751f\u6d3b\u54c1\u77cd\u5247\u5f88\u5c11\u88ab\u7814\u7a76\u3001\u63a2\u5c09\u3002\u672c\u6587\u85c9\u7531\u4e86\u89e3\u9f3b\u54bd\u764c\u75c5\u4eba\u4e2d\u65ad\u6cbb\u7642\u7684\u56e0\u7d20\uff0c\u8a66\u5716\u89e3\u8bc0\u6216\u6539\u5584\u7121\u6cd5\u5168\u7a0b\u6cbb\u7642\u7684\u539f\u56e0\uff0c\u5354\u52a9\u75c5\u4eba\u589e\u52a0\u6cbb\u7642\u7684\u6a5f\u6703\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u81ea1979\u81f31994\u5e74\u517116\u5e74\u5185\uff0c 259\u4f4d\u9f3b\u54bd\u764c\u60a3\u8005\u672a\u5b8c\u6210\u5168\u7a0b\u653e\u5c04\u7ce0\u6cbb\u7642\uff0c\u9032\u884c\u539f\u56e0\u6b4c\u67e5\u53ca\u5206\u6790\u3002\u8cc7\u6599\u6765\u6e90\u4e43\u6839\u64da\u75c5\u5c55\u8a18\u8f7d\u3001\u96fb\u8a71\u6703\u8ac7\u9023\u805a\u53ca\u4fe1\u4ef6\u901a\u8a0a\u8ffd\u8e2a\u7109\u4f9d\u64da\u3002\n\u7d50\u679c\uff1a259\u4f4d\u4e2d\u65ad\u6cbb\u7642\u4e4b\u9f3b\u54bd\u764c\u75c5\u60a3\u6709115\u4f4d(44.4%\uff09\u500b\u6848\u7121\u6cd5\u5fcd\u53d7\u6cbb\u7642\u5f9e\u5f15\u8d77\u7684\u526f\u4f5c\u7528\u53ca\u5bb3\u6015\u6cbb\u7642\u5408\u4f75\u75c7\u3002 52\u4f4d(20.1%\uff09\u56e0\u75c5\u60c5\u56b4\u91cd\u3001\u865a\u5f31\u3001\u81ea\u89ba\u6cbb\u7642\u7121\u6548\u4e14\u5c0d\u662f\u5426\u60a3\u75c5\u4ecd\u5b58\u7591\u3002\u63a1\u7528\u504f\u65b9\u7642\u6cd5\u670948\u4f4d\uff0818.5%\uff09\u300217\u4f4d\uff086.6%\uff09\u75c5\u60a3\u6709\u793e\u6703\u8207\u7d93\u6fdf\u554f\u9898\u3002\u56e0\u8def\u9014\u9065\u9060\u53ca\u4ea4\u901a\u4e0d\u4fbf\uff0c\u6545\u5c0d\u9662\u6cbb\u7642\u670913\u4f4d\uff085%\uff09\u3002\u67097\u4f4d\uff082.7%\uff09\u500b\u6848\u4e43\u56e0\u5176\u5b83\u79d1\u91ab\u5e08\u8a8d\u70ba\u4e0d\u9069\u5408\u7e7c\u7e8c\u653e\u5c04\u6cbb\u7642\uff0c\u6539\u7528\u624b\u8853\u6216\u5316\u5b78\u6cbb\u7642\u3002\u800c\u56e0\u5bb6\u5ead\u56e0\u7d20\u53cd\u5c0d\u4efb\u4f55\u6b63\u7d71\u6cbb\u7642\uff0c\u4ee5\u6c42\u795e\u62dc\u4f5b\u3001\u5403\u9999\u7070\u4ed9\u4e39\u8005\u51717\u4f4d\uff082.7%\uff09\u3002\n\u7d50\u8ad6\uff1a\u653e\u5c04\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u53ca\u5408\u4f75\u75c7\uff0c\u662f\u75c5\u60a3\u7121\u6cd5\u5b8c\u6210\u5168\u7a0b\u6cbb\u7642\u7684\u6700\u5927\u56e0\u7d20\uff0c\u4f5444.4%\uff1b\u91ab\u7642\u4eba\u54e1\u61c9\u52a0\u5f3a\u5c0d\u653e\u5c04\u6cbb\u7642\u5f15\u8d77\u4e4b\u526f\u4f5c\u7528\u7684\u7167\u987e\u53ca\u4e8b\u5148\u7eb7\u75c5\u4eba\u7684\u6559\u9752\uff0c\u90e8\u4efd\u75c5\u60a3\u5c0d\u53e6\u985e\u7642\u6cd5\u62b1\u6301\u6975\u5927\u5e0c\u671b\uff0c\u9700\u63a2\u8a0e\u53e6\u985e\u7642\u6cd5\u5c0d\u4e8e\u764c\u75c5\u4e0a\u4e4b\u529f\u6548\u3002\u6545\u81e8\u5e8a\u91ab\u7642\u5c0f\u7d44\u9700\u52a0\u5f3a\u764c\u60a3\u793e\u6703\u3001\u7d93\u6fdf\u3001\u5fc3\u7406\u3001\u6559\u80b2\u7b49\u7684\u652f\u63f4\u53ca\u5efa\u6bb7\uff0c\u4ffe\u4f7f\u75c5\u60a3\u6392\u9664\u56f0\u96e3\uff0c\u9f13\u52f5\u75c5\u60a3\u63a5\u53d7\u5168\u7a0b\u6cbb\u7634\u4e1a\u5b8c\u6210\u4e4b\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997\uff1b4:251-257\uff3d", "e": "Purpose: The survival of nasopharyngeal cancer (NPC) patient improved after the advance in the diagnostic technology and in megavoltage facility of radiotherapy. Radiotherapy has become the standard local treatment for NPC, and failure in completion of the treatment will almost lose the chance for cure. There are few articles to explore and analyze the reasons why NPC patients interrupted or even refused the radiotherapy treatment. The aim of this study is to investigate the problem.\nMaterial and Methods: There are 2,860 NPC cases registered in Radiation Oncology Department of Chang Gung Memorial Hospital from 1979 to 1994. Two hundred and fifty-nine patients did not complete their treatment after registration. The survey from hospital records, telephone or mail contacts were used to analyze the reasons why these patients escaped from the treatment of local irradiation.\nResults: One hundred and fifteen (44.4%) in these 259 patients cannot tolerate the acute reactions of the treatment or fear for the thought of the expected long-term sequels. Fifty-two patients (20.1%) had poor general condition, or psychologically ignored the disease. Forty-eight patients tried alternative treatments instead of the radiotherapy and seventeen suffered from economic problem. The last 14 patients either lacked the support from family or converted to have chemotherapy only by the referring physician.\nConclusion: Adverse effect of radiation therapy in NPC is one of the important reasons to causing the cessation of the treatment. Alternative treatments are another motivation causing interruption of local treatment. Fail to have faith on the curable by radiotherapy and fear for the complications remained the main causes of interruption. It is important to encourage and help the NPC patients and their family to go through the local treatment.\n[Therapeut Radiol Oncol 1997; 4:251-257]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-259-264-a", "title": "Relationship of CD44 and Bcl-2 Expression to Nodal Radiation Resistance in Non-hodgkin", "keywords": "CD44;bCI-2;\u975e\u4f55\u6770\u6c0f\u6dcb\u5df4\u7624;\u653e\u5c04\u6cbb\u7642\u62b5\u6297\u6027 CD44;bcl-2;Non-Hodgkin", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u60a3\u8005\u4e4b\u7279\u6027\u53ca\u816b\u7624\u57fa\u56e0\u8868\u73fe\u8207\u5176\u6dcb\u5df4\u7d50\u5fa9\u767c\u75c5\u7076\u5c0d\u653e\u5c04\u6cbb\u7642\u6548\u679c\u4e4b\u95dc\u4fc2\uff0c\u4ee5\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u8a55\u4f30\u653e\u5c04\u6cbb\u7642\u6548\u679c\u4e4b\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a16\u4f8b\u5316\u5b78\u6cbb\u7642\u5f8c\u767c\u751f\u6dcb\u5df4\u7d50\u5fa9\u767c\u7684\u60a3\u8005\uff0c\u7d93\u75c5\u7406\u5207\u7247\u8a3c\u5be6\u8a3a\u65b7\u5f8c\uff0c\u5176\u4e2d10\u4f8b\u60a3\u8005\u4e4b\u7d44\u7e54\u5207\u7247\u881f\u584a\u4ecd\u53ef\u4f9b\u61c9\u5404\u7a2e\u816b\u7624\u57fa\u56e0\u7522\u7269\u4e4b\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u3002\u65bc\u662f\u5c07\u5404\u7a2e\u67d3\u8272\u7d50\u679c\u8207\u75c5\u60a3\u5fa9\u767c\u8655\u6dcb\u5df4\u7d50\u7d93\u7167\u5c04\u5f8c\u7684\u6548\u679c\uff0c\u7528\u55ae\u8b8a\u6578\u53ca\u591a\u8b8a\u6578\u7d71\u8a08\u65b9\u6cd5\u8a55\u4f30\u5176\u76f8\u95dc\u6027\uff0c\u4e26\u8207\u75c5\u60a3\u57fa\u672c\u8cc7\u6599\u4e00\u4f75\u6bd4\u8f03\u4e4b\u3002\n\u7d50\u679c\uff1a\u5728\u55ae\u8b8a\u7570\u6578\u5206\u6790\u65b9\u9762\uff0c\u767c\u73feCD44\u8868\u73fe\u8207\u653e\u5c04\u6cbb\u7642\u62b5\u6297\u6027\u6709\u986f\u8457\u76f8\u95dc\u6027(p=0.011)\uff0c\u591a\u8b8a\u7570\u6578\u5206\u6790\u7d50\u679c\u5247\u986f\u793aCD44\u53cabCI-2\u904e\u5ea6\u8868\u73fe\u4ea6\u5177\u6709\u4e0a\u8ff0\u76f8\u95dc\u6027\u3002 \n\u7d50\u8ad6\uff1a\u7814\u7a76\u7d50\u679c\u986f\u793aCD44\u53cabCI-2\u57fa\u56e0\u8868\u73fe\u5728\u9810\u6e2c\u975e\u4f55\u6770\u6c0f\u6dcb\u5df4\u7624\u60a3\u8005\u4e4b\u653e\u5c04\u6cbb\u7642\u6548\u679c\u4e0a\u5177\u6709\u4e00\u5b9a\u7684\u89d2\u8272\uff0c\u60df\u4ecd\u9700\u66f4\u591a\u75c5\u4f8b\u53ca\u524d\u77bb\u6027\u7814\u7a76\u505a\u9032\u4e00\u6b65\u8b49\u5be6\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997;4:259-264\uff3d", "e": "Purpose: To examine the relationship of patient characteristics, oncogenes expression with one another and assess their correlation to nodal RT resistance in non-Hodgkin\u2019s lymphoma (NHL) patients.\nMaterials and Methods: 16 NHL patients after chemotherapy with nodal relapse were eligible in this study. Immunohistochemical stain with various monoclonal antibodies was applied to stored fixed-paraffin-embeded nodal biopsy specimen from 10 available patients. Univariate and multivariate analysis of relationship between variables were performed using Fisher\u2019s exact test and logistic regression model, respectively.\nResults: We find that expression of CD44 is significant associated with nodal AT resistance in univariate analysis (p=0.011). Moreover, multivariate analysis of all variables by a logistic regression model reveals the significant association of CD44 and bcl-2 overexpression to nodal RT resistance (p=0.01 12 and 0.0455, respectively).\nConclusion: The results suggest an important role of CD44 and bcl-2 in a clinical predictive model of nodal RT responses in NHL patients.\n[Therapeut Aadiol Onool 1997; 4:259-264]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-265-270-a", "title": "Neutron Dose Measurement for Medical Linear Accelerator", "keywords": "\u6d3b\u5316;\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668;\u4e2d\u5b50\u5438\u6536\u5291\u91cf Activation;Medical linear accelerator;Neutron absored dose", "c": "\u76ee\u7684\uff1a\u5efa\u7acb\u4e2d\u5b50\u5291\u91cf\u91cf\u6e2c\u6280\u8853\u4ee5\u8a55\u4f30\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7522\u751f\u4e4bX\u5149\u4e2d\u4e4b\u4e2d\u5b50\u5291\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c0732\u516c\u514b\u7d14\u5ea698\uff05\u4ee5\u4e0a\u7684\u4e94\u6c27\u5316\u4e8c\u78f7\uff08P2\u25cb5\uff09\u88dd\u5165\u5c0f\u73bb\u7483\u74f6\u5167\uff0c\u4e26\u7f6e\u65bc\u5c04\u67f1\u5167\u8ddd\u96e2X\u5c04\u7dda\u9776l\u516c\u5c3a\u8655\uff0c\u7167\u91ce\u9762\u7a4d40\u516c\u5206\u00d740\u516c\u5206\uff0c\u7167\u5c04\u5291\u91cf\u70ba40\u6208\u96f7\uff0810-18MV\uff09\u3002\u4e94\u6c27\u5316\u4e8c\u78f7\u7d93\u904e\u5149\u5b50\u8207\u4e2d\u5b50\u6df7\u5408\u5834\u7167\u5c04\u5f8c\u800c\u7522\u751f\u6d3b\u5316\u53cd\u61c9\uff0c\u598231^P (n,y)^32P\u53can,p)^31Si\u3002\u6d3b\u5316\u7269\u7528\u84b8\u993e\u6c34\u6eb6\u89e3\u5f8c\uff0c\u4ee5\u8a08\u6e2c\u6548\u7387\u8da8\u8fd1100\uff05\u4e4b\u6db2\u9ad4\u9583\u720d\u5668\u8a08\u6e2c\u3002\u6700\u5f8c\u5229\u7528\u6d3b\u5316\u7269\u98fd\u548c\u6d3b\u5ea6\u53ca\u5291\u91cf\u8f49\u63db\u56e0\u5b50\u4e4b\u4e58\u7a4d\uff0c\u5247\u53ef\u6c7a\u5b9a\u5feb\u4e2d\u5b50\u8207\u71b1\u4e2d\u5b50\u7684\u5438\u6536\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u52a0\u901f\u5668\u7522\u751f\u4e2d\u5b50\u8f3b\u5c04\u7684\u591a\u5be1\u8207\u52a0\u901f\u5668\u7684\u7167\u91ce\u6709\u95dc\uff0c\u7576\u7167\u91ce\u9762\u7a4d\u6108\u5927\u6642\u7522\u751f\u7684\u4e2d\u5b50\u8f3b\u5c04\u4e5f\u6108\u591a\u3002\u7167\u91ce40\u516c\u5206\u00d740\u516c\u5206\uff0c\u7167\u5c04\u5291\u91cf40\u6208\u96f7\u7684\u689d\u4ef6\u4e0b\uff0c\u5c0d10MV\u81f318MV\u4e4bX\u5c04\u7dda\u6240\u7522\u751f\u7684\u4e2d\u5b50\u901a\u91cf\u7387\u7bc4\u570d\u572810^5\u81f310^6ncm^-2s^-l\u4e4b\u9593\u3002\n\u7d50\u8ad6\uff1a\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7522\u751f\u4e4b\u4e2d\u5b50\u8207\u75c5\u4eba\u6cbb\u7642\u5291\u91cf\u7684\u6bd4\u503c\u57280.02\uff05\u81f30.071%\u4e4b\u9593\u3002\u6b64\u7d50\u679c\u7b26\u5408\u539f\u5b50\u80fd\u59d4\u54e1\u6703\u898f\u5b9a\u4e2d\u5b50\u5291\u91cf\u8207\u75c5\u4eba\u6cbb\u7642\u5291\u91cf\u7684\u6bd4\u503c\u5fc5\u9808\u5c0f\u65bc0.1\uff05\u4e4b\u8981\u6c42\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997; 4:265-70\uff3d", "e": "Purpose\uff1aTo develop a technique to measure neutron dose in a high-energy photon field generated by a linear accelerator.\nMaterials and Methods: Approximately 3.2g of phosphorus pentoxide P205 powder with purity over 98% was placed into a 5 mL. glass vial and capped. The vial was then placed in the radiation beam at 1m against the target and irradiated to 40 Gy for 10MV to 18MV x-ray under the field size of 40cm\u00d740cm. Samples of P205 were exposed to a mixed photon-neutron field with the reactions of ^31P(n,y)^32P and ^31P(n,p)^31Si. The irradiated samples were then dissolved in distilled water and the activation products were counted using the liquid scintillation counting techique with a counting efficiency approaching 100%. The decay characteristics of the sample was then analyzed to determine the fast and thermal neutron absorbed dose.\nResults\uff1aMeasurements for neutron contribution related to field size showed that the larger field size for irradiation, the more neutron contamination was generated. The total neutron fluence rate generated by five accelerators were in the range from 10^5 to 10^6ncm^-2 s^-1 for 10MV to 18MV x-ray machines with photon dose of 40Gy and field size 40cmX40cm.\nConclusion\uff1aThe total neutron absorbed dose was about 0.002% to 0.071% compared with treatment x-ray dose to the patient. It meets the criteria as set by the Atomic Energy Council. The requirement is that the neutron dose due to neutron contamination produced by a linear accelerator with voltage above 7MV should be less than 0.1% of radio-therapeutical dose to the patient.\nfTherapeut Radiol Oncol 1997; 4: 265-270]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-271-279-a", "title": "\u76f4\u7dda\u52a0\u901f\u5668\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7cfb\u7d71", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u6cbb\u7642;\u591a\u91cd\u975e\u5171\u9762\u5f27\u5f62\u7167\u5c04;\u5291\u91cf\u6025\u901f\u4e0b\u964d\u68af\u5ea6;\u4e8c\u7d1a\u6e96\u76f4\u6a5f;\u7b49\u5291\u91cf\u5206\u4f48\u5716 Stereotactic radiosurgery;Non-coplanar;Steep gradient dose;Secondary collimator;Isodose curve", "c": "\u524d\u8a00\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\uff0c\u70ba\u5728\u81fa\u5317\u69ae\u6c11\u7e3d\u91ab\u9662\u767c\u5c55\u5229\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7d66\u4e88\u9871\u5167\u5c0f\u816b\u7624\u55ae\u6b21\u9ad8\u5291\u91cf\u4e4b\u7167\u5c04\u65b9\u6cd5\u3002\u5176\u7167\u5c04\u7cbe\u6e96\u5ea6\u5728\u6a5f\u68b0\u5e7e\u4f55\u4e0a\u53ef\u90541mm\uff0c\u800c\u5728\u5291\u91cf\u4e4b\u6e96\u78ba\u5ea6\u53ef\u90543\uff05\u4e4b\u8aa4\u5dee\u7bc4\u570d\u5167\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u8a2d\u5099\u662f\u63a1\u7528varian CL-1800\u76f4\u7dda\u52a0\u901f\u5668\u8207Leksell\u7acb\u9ad4\u5b9a\u4f4d\u7cfb\u7d71\u3002\u6cbb\u7642\u6280\u8853\u5247\u4f7f\u7528\u591a\u91cd\u975e\u5171\u9762\u5f27\u5f62\u7167\u5c04\u4e26\u914d\u5408\u9644\u52a0\u65bc\u925b\u64cb\u677f\u6e9d\u69fd\u4e4b\u4e8c\u7d1a\u6e96\u76f4\u5100\uff0c\u5176\u5167\u90e8\u4e4b\u5713\u67f1\u5f62\u6e96\u76f4\u5668\u4e4b\u6750\u8cea\u723210cm\u539a\u4e4b\u4e0d\u8a98\u92fc\uff0c\u5176\u7167\u91ce\u76f4\u5f91\u753115mm\u523030mm \uff0c\u53ef\u6e96\u78ba\u7684\u9650\u5236\u5291\u91cf\u50c5\u843d\u65bc\u7167\u5c04\u9ede\u4e0a\uff0c\u800c\u5c0d\u65bc\u7167\u5c04\u5340\u4e4b\u5916\uff0c\u5247\u5291\u91cf\u5c07\u6703\u6025\u901f\u7684\u5411\u5916\u4e0b\u964d\uff1b\u75c5\u60a3\u56fa\u5b9a\u7cfb\u7d71\u5247\u5305\u542b\u7acb\u9ad4\u5b9a\u4f4d\u56fa\u5b9a\u74b0\u8207\u56fa\u5b9a\u65bc\u6cbb\u7642\u5e8a\u7684\u7acb\u9ad4\u5b9a\u4f4d\u5e95\u5ea7\uff1b\u5b9a\u4f4d\u6846\u53ca\u7b49\u4e2d\u5fc3\u9ede\u6307\u793a\u5668\u5247\u7528\u65bc\u5b9a\u51fa\u7167\u5c04\u9776\u64ca\u4e2d\u5fc3\u4f4d\u7f6e\uff1b\u6df1\u5ea6\u91cf\u5c3a\u53ef\u7528\u4f86\u6e2c\u91cf\u816b\u7624\u8ddd\u5404\u4e0d\u540c\u65b9\u5411\u8207\u622a\u9762\u4e4b\u7167\u5c04\u6df1\u5ea6\u3002\n\u7d50\u679c\uff1a\u6b64\u7cfb\u7d71\u6e2c\u8a66\u4e4b\u6a19\u6e96\u9808\u9054\u52301mm\u4e4b\u6a5f\u68b0\u5e7e\u4f55\u4e4b\u6e96\u78ba\u5ea6\uff0c\u5728\u5291\u91cf\u4e4b\u6e96\u78ba\u5ea6\u9808\u9054\u5230 3%\uff1b\u6e96\u76f4\u7cfb\u7d71\u4e4b\u6f0f\u5c04\u91cf\u9808\u5c0f\u65bc7\uff05\u3002\u5291\u91cf\u8f38\u51fa\u7387\u53ca\u7d44\u7e54\u8207\u5047\u9ad4\u6bd4\u8868\u683c\u5df2\u5efa\u7acb\u53ef\u4f9b\u8a08\u7b97\u5291\u91cf\uff0c\u7b49\u5291\u6688\u5206\u4f48\u5716\u4e5f\u5df2\u5229\u7528\u6c34\u5047\u9ad4\u6e2c\u8a66\u7cfb\u7d71\u5efa\u7acb\u5b8c\u6210\uff0c\u4e26\u7d93LiF\u71b1\u767c\u5149\u6676\u7247\u9a57\u8b49\u3002\n\u8a0e\u8ad6\uff1a\u4e09\u5ea6\u7a7a\u9593\u982d\u90e8\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5728\u6574\u4f43\u8a08\u756b\u4e2d\u626e\u6f14\u8457\u4e00\u500b\u4e0d\u53ef\u6216\u7f3a\u7684\u89d2\u8272\u3002\u800c\u53ef\u7528\u65bc\u6e2c\u91cf\u81f35mm \u76f4\u5f91\u5927\u5c0f\u7167\u91ce\u9762\u7a4d\u4e4b\u5075\u6e2c\u5668\u4ee5\u53ca\u7cbe\u5bc6\u5ea6\u9054\u52301mm\u4ee5\u4e0b\u7684\u5149\u5bc6\u5ea6\u5100\uff0c\u4ea6\u70ba\u5f9e\u4e8b\u653e\u5c04\u624b\u8853\u54c1\u8cea\u7ba1\u5236\u4e2d\u5fc5\u5099\u7684\u5100\u5668\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u4e4b\u8a2d\u5099\u8207\u57fa\u790e\u5291\u91cf\u7814\u7a76\u90fd\u5df2\u5b8c\u6210\uff0c\u6b64\u6280\u8853\u5df2\u53ef\u4f9b\u65e5\u5f8c\u81e8\u5e8a\u4f7f\u7528\u8207\u8a55\u4f30\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b78 1997; 4:271-279\uff3d", "e": "Purpose\uff1aThe aim of this study is to develop a technique at Veterans General Hospital-Taipei to irradiate small lesion in the brain to a high dose per fraction with 1mm geometric accuracy and 3% dosimetric accuracy. \nMaterials and Methods: The technique employs Varian CL-1800 linear accelerator with 10MV X-Ray and the Leksell stereotactic system. This treatment technique combines with multiple non-coplanar arc irradiation and secondary rigid collimator mouhting to the slot of block tray. The cylindrical collimator inserts are made by stainless steel with 10cm thickness. Their field size opening range from 15mm to 30mm in diameter and confine the accurate dose to the target and steep dose fall-off outside the target volume. The patient fixation system consists of stereotactic base ring and head fixing posts that can be directly mounted on the treatment couch. The target position frame and isocenter front pointer are used for adjusting the target point of isocenter. A ruler is used for measuring depth of tumor at various planes and directions.\nResults\uff1aThis system was systematically tested within 1-mm mechanical geometric and 2% dosimetric accuracy respectively. All of collimator inserts showed no flaw and the radiation leakage was less than 7%. Dose rate and tissue-phantom-ratio table had been setup for dosimetry purpose. Isodose curve were established by water phantom and verified by radiation sensitive films and TLD dosimetry.\nDiscussion\uff1aA three-dimensional computerized treatment planning system is essential for stereotactic radio-surgery device. Dosimetry detetors capable of measuring 5-mm diameter field and film dosimetry with 1mm accuracy are indispensable equipment for quality control of this radiosurgery procedure.\nConclusion: Apparatus test and basic dosimetry study had been complied; The technique is ready for future pre-clinical study and evaluation.\n\uff3bTherapeot Radiol Oncol 1997; 4:27 1-279\uff3d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-281-284-a", "title": "\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u65bd\u653e\u5668\u4e4b\u8a2d\u8a08", "keywords": "\u958b\u5200\u4e2d\u653e\u5c04\u6cbb\u7642;\u9310\u9ad4\u6e96\u76f4\u5100;\u9310\u9ad4 Intraoperative radiotherapy;Applicator adapter;Applicator", "c": "\u76ee\u7684:\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u4e3b\u8981\u662f\u91dd\u5c0d\u8179\u8154\u816b\u7624\uff0c\u5982\u80c3\u764c\u3001\u80f0\u81df\u764c\u3001\u5b50\u5bae\u9838\u764c\u3001\u76f4\u8178\u764c\u7b49\u90e8\u4f4d\u65bd\u4ee5\u76f4\u63a5\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u63a1\u9ad8\u5291\u91cf\u96c6\u4e2d\u65bc\u9700\u6cbb\u7642\u4e4b\u90e8\u4f4d\uff0c\u4e26\u907f\u958b\u9130\u8fd1\u6b63\u5e38\u7d44\u7e54\u88ab\u6d89\u53ca\u800c\u6e1b\u5c11\u6cbb\u7642\u526f\u4f5c\u7528\uff0c\u4ee5\u5f97\u5230\u9060\u9694\u6cbb\u7642\u6240\u7121\u6cd5\u9054\u5230\u4e4b\u6548\u679c\u3002\u624b\u8853\u4e2d\u653e\u5c04\u6cbb\u7642\u4e4b\u6cbb\u7642\u90e8\u4f4d\uff0c\u9700\u653e\u7f6e\u4e00\u9310\u9ad4\u6e96\u76f4\u5100\u53ca\u9310\u9ad4\uff0c\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u91dd\u5c0d\u6b64\u8a2d\u5099\u52a0\u4ee5\u8a2d\u8a08\u53ca\u88fd\u4f5c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u8a2d\u8a08\u53ca\u88fd\u4f5c\u4e4b\uff1a[\u4e00]\u9310\u9ad4\u6e96\u76f4\u5100\uff1a\uff081\uff09\u5149\u6b04\u9023\u63a5\u8a2d\u5099\uff1a\u7f6e\u65bc\u76f4\u7dda\u52a0\u901f\u5668\u6e96\u76f4\u5100\u4e0b\uff0c\u6b64\u5100\u5668\u6709\u5c0d\u6b63\u9310\u9ad4\u4e4b\u8a2d\u5099\u3002\uff082\uff09\u5f62\u72c0\u5927\u5c0f\u63a7\u5236\u90e8\u4efd\uff1a\u6b64\u90e8\u4efd\u7f6e\u65bc\u9310\u9ad4\u6e96\u76f4\u5100\u4e0b\u4e4b\u63a7\u5236\u677f\uff0c\u53ef\u4f9d\u9310\u9ad4\u5f62\u72c0\u5927\u5c0f\u88fd\u4f5c\u4e0d\u540c\u63a7\u5236\u677f\uff0c\u5176\u539a\u5ea6\u70ba1.4\u516c\u5206\u7684\u925b\u5408\u91d1\uff0c\u8db3\u4ee5\u963b\u6a94\u96fb\u5b50\u5c04\u7dda\u4e4b\u4e3b\u5c04\u7dda\u3002[\u4e8c]\u9310\u9ad4\u90e8\u4efd\uff1a\u56e0\u6cbb\u7642\u7167\u91ce\u8207\u4eba\u9ad4\u5167\u90e8\u5668\u5b98\u53ca\u816b\u7624\u5f62\u72c0\u4e0d\u76e1\u76f8\u540c\uff0c\u672c\u79d1\u76ee\u524d\u8a2d\u8a08\u51fa\u516d\u7a2e\u9310\u9ad4, \uff081\uff09\u5713\u9310\u9ad4\u3001\uff082\uff09\u99ac\u8e44\u9310\u9ad4\u3001\uff083\uff09\u4e94\u89d2\u9310\u9ad4\u3001\uff084\uff09\u659c15\u5ea6\u5713\u9310\u9ad4\u3001\uff085\uff09\u659c\u5de7\u5ea6\u99ac\u8def\u9310\u9ad4\u3001\uff086\uff09\u659c15\u5ea6\u4e94\u89d2\u9310\u9ad4\u3002 [\u4e09]\u9632\u6b62\u9310\u9ad4\u672b\u7aef\u8f3b\u5c04\u6f0f\u5c04\u4e4b\u8a2d\u8a08\uff1a\u56e0\u9310\u9ad4\u672b\u7aef\u76f4\u63a5\u63a5\u89d2\u89f8\u816b\u7624\uff0c\u800c\u9310\u9ad4\u5916\u70ba\u6b63\u5e38\u7d44\u7e54\uff0c\u6545\u5728\u8ab0\u9ad4\u672b\u7aef\u52a0\u4e00\u9285\u7247,\u4ee5\u6e1b\u5c11\u6563\u5c04\u5230\u6b63\u5e38\u7d44\u7e54\u4e4b\u5291\u91cf\u3002\n\u7d50\u679c\uff1a\u4f7f\u7528\u9ad8\u7cbe\u5bc6\u5ea6\u4e4b\u6578\u4f4d\u5f0f\u6c34\u5e73\u5100\uff0c\u4e0d\u7ba1\u9310\u9ad4\u6c34\u5e73\u8207\u5426\u6216\u50be\u659c\uff0c\u7686\u53ef\u4f9d\u64da\u6b64\u8a2d\u5099\u8b80\u51fa\u6b63\u78ba\u89d2\u5ea6\uff0c\u4e26\u4f5c\u9069\u5ea6\u8abf\u6574\uff0c\u4f7f\u9310\u9ad4\u8207\u9310\u9ad4\u6e96\u76f4\u5100\u5448\u73fe\u6c34\u5e73\u4e00\u81f4\u3002\n\u8a0e\u8ad6\uff1a\u75c5\u60a3\u7684\u8f49\u9001\u3001\u4e0a\u4e0b\u6cbb\u7642\u5e8a\u3001\u9310\u9ad4\u56fa\u5b9a\u3001\u75c5\u60a3\u7684\u8a2d\u5b9a\u53ca\u6cbb\u7642\uff0c\u6240\u82b1\u8cbb\u7684\u6642\u9593\u7d04\u970030\u81f340\u5206\u9418\u3002\u6b64\u8a2d\u5099\u4e4b\u8a2d\u8a08\u76ee\u7684\u70ba\u6c42\u5feb\u6377\u8207\u65b9\u4fbf\uff0c\u4ee5\u671f\u9054\u5230\u7e2e\u77ed\u6cbb\u7642\u6642\u554f\u4e4b\u76ee\u6a19\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b78 1997; 4:281-284\uff3d", "e": "Purpose: It is dangerous to deliver high dose from external irradiation to the tumor or tumor bed in the abdominal cavity without the consideration of the tolerance limitation of adjacent normal tissues. Intraoperative radiotherapy (IORT) then was developed to deliver high dose to the target in the hope of increasing local control and sparing the damage to adjacent critical organs. The adapter to linear accelerator fur IORT and the electron cone application were the key to the IORT procedure and were developed in our department.\nMaterial and Methods: An IORT adapter and a set of applicator - electron cone were designed and made in Radiation Oncology Department of Chang Gung Memorial Hospital. The apparatus consists of several items; (I) IORT adapter: including [a] docking adapter, [b] beam shaping apparatus: made by 1-4cm thickness of lead that matched the electron cone shapes. (2) Applicators: different electron cones were designed, including circular, horseshoe and pentagonal shapes. The applicators had either flat or 15-degree oblique at the end facing the patient. (3) A copper of 2cm high and 0.5cm thick was mounted at the end of the applicator to reduce the scattering of electron beam.\nResults: By using the digital level to measure the inclination of the electron cone, and then to determine the set up angles of the applicator, the electron cone can be aligned to the adapter without any diffculty.\nConclusion: This design can be applied for the IORT without any difficulty, and it takes only 30 to 40 minutes to complete the whole procedures, including setting up of the intraoperative applicators and the treatment time. \n\uff3bTherapeut Radiol Oncol 1997; 4:281-284\uff3d"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-285-289-a", "title": "\u53f0\u7063\u653e\u5c04\u816b\u7624\u79d1\u8b77\u7406\u6a21\u5f0f\u4e4b\u8abf\u67e5\u8207\u65b9\u5411", "keywords": "\u653e\u5c04\u816b\u7624\u8b77\u7406\u6a21\u5f0f Radiation oncology nurse model", "c": "\u76ee\u7684\uff1a\u73fe\u4ee3\u764c\u75c5\u91ab\u7642\uff0c\u653e\u5c04\u816b\u7624\u90e8\u9580\u4f54\u6709\u975e\u5e38\u91cd\u8981\u7684\u5730\u4f4d\uff0c\u7136\u800c\u76ee\u524d\u570b\u5167\u91ab\u754c\u5c0d\u653e\u5c04\u816b\u7624\u79d1\u8b77\u7406\u4eba\u54e1\u5de5\u4f5c\u8077\u638c\u8a8d\u8b58\u4e0d\u6e05\uff0c\u4ee5\u81f4\u7121\u6240\u9075\u5faa\uff0c\u6545\u85c9\u7531\u672c\u6587\u63a2\u8a0e\uff0c\u5206\u6790\u76ee\u524d\u4e4b\u73fe\u6cc1\uff0c\u4f5c\u70ba\u65e5\u5f8c\u653e\u5c04\u816b\u7624\u79d1\u8b77\u7406\u4eba\u54e1\u89d2\u8272\u78ba\u5b9a\u4e4b\u53c3\u8003\uff0c\u4ee5\u63d0\u5347\u8b77\u7406\u54c1\u8cea\uff0c\u5609\u60e0\u75c5\u60a3\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c0d\u8c61\u4fc2\u570b\u516711\u5bb6\u91ab\u5b78\u4e2d\u5fc3\u653e\u5c04\u816b\u7624\u79d1\u4e4b\u4e3b\u7ba1\uff0c\u4f9d85\u5e745\u6708\u554f\u767c\u51fa\u4e4b\u554f\u5377\u5167\u5bb9\uff0c\u63a1\u4e0d\u8a18\u540d\u65b9\u5f0f\u56de\u7b54\uff0c\u4f9d\u6b64\u8cc7\u6599\u505a\u6574\u7406\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u767c\u51fa11\u4efd\u4fe1\u4ef6\uff0c\u6709\u6548\u56de\u653610\u4ef6\u3002\u653e\u5c04\u816b\u7624\u79d1\u8b77\u7406\u4eba\u54e1\u5de5\u4f5c\u8077\u638c\uff0c\u5305\u62ec\u8ddf\u8a3a\u3001\u5354\u52a9\u8fd1\u63a5\u6cbb\u7642\u3001\u5354\u8ac7\u3001\u764c\u75c5\u767b\u8a18\u3001\u8ffd\u8e2a\u3001\u7167\u8b77\u5316\u5b78\u6cbb\u7642\u3001\u71df\u990a\u885b\u6559\u3001\u5b89\u6392\u75c5\u60a3\u6cbb\u7642\u4f5c\u696d\u6d41\u7a0b\u7b49\u3002\u5176\u4e2d\u5168\u8077\u8b77\u7406\u4eba\u54e1\u6700\u591a\u7684\u90e8\u9580\u670912\u4eba\uff0c\u6700\u5c11\u7684\u53ea\u67092\u4eba\uff1b\u67095\u5bb6\u91ab\u9662\u8b77\u7406\u4eba\u54e1\u8981\u517c\u505a\u5316\u5b78\u6cbb\u7642\u3002\u6bcf\u5e74\u6709\u8b77\u7406\u4eba\u54e1\u5347\u7b49\u8003\u8a66\u7684\u53ea\u67092\u5bb6\u3002\n\u8a0e\u8ad6\uff1a\u591a\u6578\u653e\u5c04\u816b\u7624\u79d1\u4e3b\u7ba1\u7686\u8a8d\u70ba\u8b77\u7406\u4eba\u529b\u4e0d\u8db3\uff0c\u70ba\u76ee\u524d\u4e9f\u5f85\u89e3\u6c7a\u4e4b\u554f\u984c\u3002\u570b\u5167\u8b77\u7406\u816b\u7624\u5b78\u6703\u6216\u653e\u5c04\u816b\u7624\u5b78\u6703\u61c9\u8a2d\u7acb\u653e\u5c04\u816b\u7624\u8b77\u7406\u6a19\u6e96\uff0c\u914d\u5408\u9069\u7576\u7684\u8a13\u7df4\u8ab2\u7a0b\uff0c\u4f7f\u653e\u5c04\u816b\u7624\u8b77\u7406\u4eba\u54e1\u89d2\u8272\u66f4\u660e\u78ba\uff0c\u624d\u80fd\u8b93\u9662\u65b9\u4e3b\u7ba1\u91cd\u8996\uff0c\u4f7f\u6709\u8db3\u5920\u8b77\u7406\u4eba\u54e1\uff0c\u9032\u800c\u63d0\u5347\u8b77\u7406\u54c1\u8cea\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997;4;285-289\uff3d", "e": "Purpose\uff1aRadiation therapy has an important role in cancer management. However, the responsibilities of nursing care in the department of radiation oncology are still controversy. In this study, we investigated, analyzed the current situation of the role of radiation oncology nurses in order to raise the quality of nursing care in this aspect.\nMaterials and Methods\uff1aOn May, 1997, we designed a questionnaires for 11 medical centers and analyzed the different duties of radiation oncology nurses in their departments.\nResults\uff1a10 questionnaires had been returned for analysis. The duties of radiation oncology nurse included outpatient clinic service, brachytherapy care, patient education, cancer registration, chemotherapy service, nutritional consultation, patient's treatment arrangement etc. The number of full time nurses in the departments ranged from 2 to 12. The nurses have the duty of chemotherapy service in 5 hospitals. Only two departments have annual qualified examination for the nurses.\nConclusion\uff1aMost of the department chairmen have complained the manpower of nurses are not enough for the daily duties. The Oncology Nursing Society and Radiation Oncology Society should have the responsibility to establish the standard of nursing care in the department of radiation oncology. Hence, the hospital administrators will conform to this standard to adjust the manpowers in the department of radiation oncology.\n[Therapeut Radiol Oncol 1997\uff1b4:285-289]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-291-297-a", "title": "\u570b\u969b\u8cea\u5b50\u52a0\u901f\u5668\u91ab\u5b78\u6cbb\u7642\u8a2d\u5099\u53c3\u8a2a\u5831\u544a", "keywords": "\u8cea\u5b50\u52a0\u901f\u5668;\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u898f\u683c;\u7f8e\u65e5\u73fe\u4ee3\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099 Proton accelerators;Proton therapy performance specifications;Modern proton therapy facilities in USA and Japan", "c": "\u76ee\u7684\uff1a\u53f0\u7063\u79d1\u6280\u53ca\u91ab\u5b78\u5c08\u5bb6\u65bc\u4e00\u4e5d\u4e5d\u516d\u5e74\u5b8c\u6210\u4e86\u300c\u8cea\u5b50\u52a0\u901f\u5668\u91ab\u5b78\u53ca\u79d1\u5b78\u61c9\u7528\u8a2d\u5099\u300d\u7684\u53ef\u884c\u6027\u8a55\u4f30\uff0c\u672c\u6587\u5c6c\u672c\u8a08\u756b\u4e2d\u53c3\u8a2a\u7f8e\u3001\u65e5\u6700\u65b0\u8cea\u5b50\u52a0\u901f\u5668\u8a2d\u5099\u7684\u90e8\u4efd\uff0c\u7d93\u6574\u7406\u5f8c\u520a\u51fa\u4ee5\u4f9b\u53c3\u8003\u3002\u8aaa\u670b\uff1a\u9ad8\u80fd\uff0870-300Mev\uff09\u8cea\u5b50\u61c9\u7528\u5728\u5c40\u90e8\u6027\u764c\u816b\u7624\u53ca\u8166\u90e8\u8840\u7ba1\u7578\u5f62\u75c7\u662f\u5eff\u4e16\u7d00\u96c6\u5408\u7269\u7406\u3001\u751f\u7269\u3001\u5de5\u7a0b\u61c9\u7528\u65bc\u91ab\u5b78\u7684\u4e00\u5927\u6210\u5c31\u3002\u5728\u904e\u53bb\uff0c\u8cea\u5b50\u6cbb\u7642\u662f\u76f4\u63a5\u5229\u7528\u9ad8\u80fd\u7269\u7406\u52a0\u901f\u5668\u5728\u5bc5\u9a57\u5ba4\u4f5c\u6cbb\u7642\uff0c\u5176\u7d50\u679c\u5df2\u666e\u53d7\u91ab\u5b78\u754c\u4e4b\u80af\u5b9a\u3002\u8fd1\u5e74\u4f86\u7684\u767c\u5c55\u662f\u628a\u52a0\u901f\u5668\u5168\u5957\u6cbb\u7642\u8a2d\u5099\u5efa\u9020\u5728\u91ab\u9662\u5167\uff0c\u65b0\u7684\u5de5\u7a0b\u53ef\u542b\u65cb\u8f49\u578b\u8cea\u5b50\u6e90\u96c6\u7126\u67b6\uff0c\u4f7f\u8cea\u5b50\u6cbb\u7642\u7684\u7acb\u9ad4\u5291\u91cf\u5206\u914d\u9054\u5230\u6700\u9ad8\u5883\u754c\u3002\u672c\u6587\u4ee5\u4eca\u65e5\u7f8e\u3001\u65e5\u6700\u65b0\u7a4e\u7684\u8a2d\u5099\u4ecb\u7d39\u5404\u7a2e\u52a0\u901f\u5668\u7a2e\u985e\u53ca\u76f8\u95dc\u8a2d\u5099\u3002\n\u7d50\u8ad6\uff1a\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u4e2d\u52a0\u901f\u5668\u5927\u81f4\u53ef\u5206\u70ba\u7dda\u578b\u3001\u8ff4\u65cb\u578b\u53ca\u540c\u6b65\u74b0\u578b\u4e09\u7a2e\uff0c\u5176\u4e2d\u4ee5\u8ff4\u65cb\u578b\u53ca\u540c\u6b65\u74b0\u578b\u70ba\u9078\u64c7\u5c0d\u8c61\uff0c\u4f46\u4ecd\u5404\u6709\u5229\u5f0a\u3002\u9664\u52a0\u901f\u5668\u672c\u8eab\u4e4b\u5916\uff0c\u5c1a\u6709\u8cea\u5b50\u5c04\u675f\u50b3\u8f38\u7cfb\u7d71\u3001\u5c04\u675f\u50b3\u9001\u7cfb\u7d71\u3001\u53ca\u75c5\u60a3\u5b9a\u4f4d\u7cfb\u7d71\u5747\u5c6c\u6cbb\u7642\u8a2d\u5099\u91cd\u8981\u90e8\u4efd\u3002\u6b64\u5916\uff0c\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u3001\u54c1\u8cea\u7ba1\u5236\u53ca\u8f3b\u5c04\u9632\u8b77\u7684\u5efa\u7acb\u90fd\u662f\u4e0d\u53ef\u6216\u7f3a\u7684\u6cbb\u7642\u63aa\u65bd\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b78 1997\uff1b4:291-297\uff3d", "e": "Purpose: A task force consisting of scientists, accelerator engineers and radiation oncologists in Taiwan has completed a feasibility study to establish a proton accelerator facility for medical and scientific applications; this report is an excerpt of the accelerator (and related beam hardwares) part of the study. The information is mostly derived from site visits to several modern facilities in the United States and Japan.\nDescription: The use of accelerating proton beams to effectively control solid tumors and arteriovenous malformations is one of the major breakthroughs that combine physics, biology and engineering for medicine in the twentieth century. In the past, the clinical outcomes of proton therapy by use of proton beams at physics laboratories have already been recognized by the medical community. More recent advances including the building of accelerator facility within a hospital and the development of isocentric beam delivery gantry permit the 3D physical dose distribution to reach its ever optimum status.\nConclusions: The accelerator of a proton therapy facility can be selected from a linear accelerator, a cyclotron, or a synchrotron. The latter two kinds of accelerators are the current choices for hospital use and each has its own advantages and disadvantages. In addition to an accelerator, beam extraction and transport system, beam delivery system, and patient positioning system are all integral parts of the facility. Further, treatment planning system, quality control and radiation safety measures are essential for the operation.\n[Therapeut Radiol Oncol 1997; 4:291-297]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199712-4-4-299-303-a", "title": "Combined Radiotherapy and Chemotherapy for Gastric Schwannoma with Gross Residual Tumor-case Report", "keywords": "\u80c3\u60e1\u6027\u795e\u7d93\u9798\u7624;\u653e\u5c04\u6cbb\u7642;\u5316\u5b78\u6cbb\u7642;\u5408\u4f75\u7642\u6cd5 Gastric schwannoma;Radiotherapy;Chemotherapy;Combined treatment", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u4e00\u4f8b\u80c3\u60e1\u6027\u795e\u7d93\u9798\u7624\u4f7f\u7528\u764c\u75c7\u591a\u91cd\u7642\u6cd5\u7684\u6548\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a1997\u5e74\u5143\u6708\uff0c\u4e00\u4f8b76\u6b72\u7537\u6027\u56e0\u6025\u6027\u8179\u75db\u5408\u4f75\u80c3\u51fa\u8840\u5c31\u91ab\u3002\u7dca\u6025\u8179\u90e8\u63a2\u8a0e\u8853\u767c\u73fe\u51fa\u8840\u8655\u662f\u56e0\u80c3\u9ad4\u7a7f\u5b54\u6027\u816b\u7624\u5f15\u8d77\u3002\u624b\u8853\u4e2d\u4e5f\u767c\u73fe\u80c3\u5e95\u6709\u5de8\u5927\u816b\u7624\u3002\u51fa\u8840\u6027\u80c3\u9ad4\u816b\u7624\u7d93\u5207\u9664\u5f8c\u6709\u660e\u986f\u6b62\u8840\u6548\u679c\u3002\u8853\u5f8c\u7684\u7b2c\u4e09\u9031\u75c5\u4eba\u63a5\u53d7\u6b98\u7559\u816b\u7624\u7684\u653e\u5c04\u6cbb\u7642\u3002\u4f7f\u7528\u7684\u6a5f\u5668\u662f6\u532f\u5831MV\u76f4\u7dda\u52a0\u901f\u5668\u5149\u5b50\u5c04\u7dda\u3002\u7e3d\u5291\u91cf\u662f5000cGy\u5206\u621028\u6b21\u7167\u5c04\u3002\u5728\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u75c5\u4eba\u63a5\u53d7\u4e00\u6b21\u7684\u5408\u4f75\u5316\u5b78\u6cbb\u7642\u3002\u4f7f\u7528\u7684\u85e5\u7269\u542b\uff1a5-FU (500mg/m^2) , Leucovorin (200mg/m^2)\uff0c\u7b2c\u4e00\u5929\u81f3\u7b2c\u4e94\u5929\u3002\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u75c5\u4eba\u518d\u5ea6\u63a5\u53d7\u4e94\u6b21\u7684\u540c\u6a23\u5316\u7642\u3002\n\u7d50\u679c\uff1a\u653e\u5c04\u6cbb\u7642\u524d\uff0c\u75c5\u4eba\u6709\u6301\u7e8c\u7684\u8179\u75db\u53ca\u8840\u4fbf\u3002\u653e\u5c04\u6cbb\u7642\u7684\u7b2c\u4e09\u9031\u52a0\u4e0a\u7b2c\u4e00\u6b21\u7684\u5316\u7642\u5f8c\uff0c\u75c5\u4eba\u89ba\u5f97\u75bc\u75db\u6709\u6539\u5584\u3002\u75c5\u4eba\u53ef\u4ee5\u541e\u6771\u897f\u800c\u4e14\u4e0d\u6703\u5f15\u8d77\u8179\u6f32\u53ca\u8179\u75db\u3002\u653e\u5c04\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u75c5\u4eba\u53ef\u4ee5\u81ea\u5df1\u884c\u52d5\u3002\u5316\u5b78\u6cbb\u7642\u7d50\u675f\u5f8c\uff0c\u80c3\u5e95\u816b\u7624\u5b8c\u5168\u6d88\u5931\u3002\u75c5\u4eba\u76ee\u524d\u5df2\u5b58\u6d3b11\u500b\u6708\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u6587\u6709\u9650\u7684\u7d93\u9a57\u4e0b\u53ef\u986f\u793a\u51fa\u764c\u75c7\u591a\u91cd\u7642\u6cd5\u5c0d\u6b64\u75c5\u4eba\u4e4b\u6548\u679c\u53ca\u5e6b\u52a9\u3002\n\uff3b\u653e\u5c04\u6cbb\u7642\u8207\u816b\u7624\u5b781997\uff1b4:299-303\uff3d", "e": "Purpose\uff1aTo evaluate the effect of using combined radiotherapy and chemotherapy in a case of gastric schwannoma with gross residual tumor.\nMaterials and Methods\uff1aIn January 1997, a 76-year-old male, presenting with acute abdomen with signs of gastrointestinal breeding, received emergent exploratory laparotomy. Bleeding site was determined to be due to a perforated tumor in the body of stomach. Other operative findings revealed huge massive necrotic tumors in the gastric fundus. The peroforated tumor in the body was resected. However, the huge fundal tumor was left intact. Three weeks after surgery, the residual tumor was irradiated using the 6MV linear accelerator photon beams. Total dose of 5,000 cGy in 28 fractions was given. One course of chemotherapy using 5-Fluorouracil (500mg/rn^2), Leucovorin (200mg/m^2) Day 1 to Day 5 was given concurrently. Five more courses of chemotherapy using the same regimen were given after completion of radiotherapy.\nResults\uff1aBefore radiotherapy was started, patient complained of abdominal pain and giddiness. Tarry stool was still noted. Three weeks after concurrent chemoradiotherapy patient claimed that pain and distension had improved a lot. He was able to swallow solid foods without much abdominal discomfort. After completion of radiotherapy, patient was completely ambulatory and able to come to OPD for chemotherapy regulary by himself. After completion of chemotherapy, repeated endoscopy revealed complete regression of the tumor. Patient at present is alive without evidence of disease and is in his eleventh month of follow up.\nConclusion\uff1aIn our limited experience, the use of combined modality seemed to have provided excellent result to this patient.\n[Therapeut Radiol Oncol 1997; 4:299-303]"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-179-184-a", "title": "\u7dad\u751f\u7d20\u4e19\u5c0d\u65bc\u9ad8\u5291\u91cf\u7167\u5c04CHO\u53caGBM\u7d30\u80de\u4e4b\u751f\u7269\u6548\u61c9", "keywords": "\u7dad\u751f\u7d20\u4e19(AA);\u4e2d\u570b\u5927\u9830\u9f20\u5375\u5de2(CHO)\u7d30\u80de;\u591a\u5f62\u6027\u795e\u7d93\u81a0\u8cea\u6bcd\u7d30\u80de\u7624(GBM8401)\u7d30\u80de;\u9ad8\u5291\u91cf\u653e\u5c04\u7dda\u7167\u5c04;\u03b1/\u03b2\u503c Ascorbic acid;Chinese hamster ovary (CHO) cells;Glioblastoma multiformi (GBM8401) cells;High dose irradiation;\u03b1/\u03b2", "c": "\u76ee\u7684\uff1a\u4e86\u89e3\u9ad8\u5291\u91cf\u653e\u5c04\u7dda\u7167\u5c04\u6642\uff0c\u7dad\u751f\u7d20\u4e19(ascorbic acid, AA)\u5c0d\u65bc\u4e2d\u570b\u5927\u9830\u9f20\u5375\u5de2(CHO)\u53ca\u591a\u5f62\u6027\u795e\u7d93\u81a0\u8cea\u6bcd\u7d30\u80de\u7624(GBM8401)\u7d30\u80de\u8f3b\u5c04\u751f\u7269\u6548\u61c9\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4ee5\u9ad4\u5916\u7e7c\u4ee3\u57f9\u990a\u4e4bCHO\u7d30\u80de\u53caGBM8401\u7d30\u80de\u7232\u5c0d\u8c61\uff0c\u5c07\u7d30\u80de\u5404\u5206\u7232\u5c0d\u7167\u53ca\u5be6\u9a57\u7d44\uff0c\u5c0d\u7167\u7d44\u7d30\u80de\u53ea\u63a5\u53d7\u653e\u5c04(8~16Gy)\uff0c\u5be6\u9a57\u7d44\u7d30\u80de\u5148\u4ee5AA\u8655\u7406\u5f8c\u518d\u63a5\u53d7\u8207\u5c0d\u7167\u7d44\u76f8\u540c\u4e4b\u653e\u5c04\u7dda\u7167\u5c04\u3002\u7167\u5c04\u5f8c\u7684\u7d30\u80de\u7d93\u904e\u5341\u5929\u7684\u57f9\u990a\u5f8c\u4ee5\u7fa4\u843d\u5206\u6790\u6cd5\u8a08\u7b97\u51fa\u5176\u751f\u5b58\u5206\u6578\uff0c\u4e26\u4ee5\u7d71\u8a08\u8edf\u9ad4\u4e2d\u7684\u7dda\u6027\u5e73\u65b9\u6a21\u5f0f(Linear-Quadratic model)\u7e6a\u51fa\u751f\u5b58\u66f2\u7dda\uff0c\u540c\u6642\u8a08\u7b97\u5176\u03b1\uff0c\u03b2\u53ca\u03b1/\u03b2\u503c\u3002\u7136\u5f8c\u4ee5\u9019\u4e9b\u8f3b\u5c04\u751f\u7269\u53cd\u61c9\u4e4b\u53c3\u6578\u5206\u6790AA\u5c0d\u65bc\u9019\u4e9b\u7d30\u80de\u7684\u8f3b\u5c04\u751f\u7269\u6548\u61c9\u3002\n\u7d50\u679c\uff1a\u4ee58~16Gy\u9ad8\u5291\u91cf\u7167\u5c04CHO\u53caGBM8401\u7d30\u80de\u6240\u9020\u6210\u4e4b\u751f\u5b58\u5206\u6578(survival fraction)\u96a8\u8457\u653e\u5c04\u5291\u91cf\u4e4b\u589e\u52a0\u800c\u5feb\u901f\u905e\u6e1b\u3002\u4ee5\u9ad8\u5291\u91cf\u7167\u5c04CHO\u7d30\u80de\u4e4b\u03b1/\u03b2\u503c\u72324.43\u3002\u800c\u5148\u4ee5AA(0.025mg/ml)\u8655\u7406\u4e8c\u5c0f\u6642\u518d\u63a5\u53d7\u9ad8\u5291\u91cf\u7167\u5c04\u4e4bCHO\u7d30\u80de\u03b1/\u03b2\u503c\u72329.28\u3002\u540c\u6a23\u7684\uff0c\u4ee58~16Gy\u9ad8\u5291\u91cf\u7167\u5c04GBM8401\u7d30\u80de\u4e4b\u03b1/\u03b2\u503c\u72329.41\u3002\u800c\u5148\u4ee5AA\u8655\u7406\u518d\u63a5\u53d7\u9ad8\u5291\u91cf\u7167\u5c04\u4e4bBM8401\u7d30\u80de\u03b1/\u03b2\u503c\u723219.65\u3002\u7d93\u7531AA\u8655\u7406\u5f8c\uff0c\u5169\u7a2e\u7d30\u80de\u4e4b\u751f\u5b58\u66f2\u7dda\u659c\u7387\u90fd\u964d\u4f4e\uff0c\u5176\u4e2d\u4ee5CHO\u7d30\u80de\u8f03\u660e\u986f\uff0c\u6b64\u7a2e\u8f3b\u5c04\u4fdd\u8b77\u6548\u61c9\u57288~16Gy\u4e4b\u7167\u5c04\u5291\u91cf\u7bc4\u570d\u5167\u96a8\u8457\u5291\u91cf\u589e\u52a0\u800c\u6108\u660e\u986f\u3002\u6b64\u5916\uff0c\u7d93AA\u8655\u7406\u5f8c\uff0c\u7167\u5c04\u5291\u91cf\u6108\u9ad8\u540c\u4e00\u7d30\u80de\u4e4b\u8f3b\u5c04\u654f\u611f\u5ea6\u4e5f\u964d\u7684\u6108\u4f4e\u3002\u5169\u7d44\u7d30\u80de\u4e4b\u03b1/\u03b2\u503c\u90fd\u986f\u8457\u589e\u52a0\u3002\n\u7d50\u8ad6\uff1a\u5728\u9ad8\u5291\u91cf\u653e\u5c04\u7dda\u7167\u5c04\u4e0b\uff0cAA\u6703\u964d\u4f4eCHO\u53caGBM8401\u7d30\u80de\u7684\u8f3b\u5c04\u751f\u7269\u6548\u61c9\uff0c\u4e14\u5291\u91cf\u6108\u9ad8\u6bd4\u73fe\u8c61\u6108\u660e\u986f\u3002", "e": "Purpose: Study of the influence of ascorbic acid (AA) on the radiobiologic effects of high dose radiation on CHO and 0BM8401 cells.\nMaterials and Methods: CHO and GBM84O1 cells grown in plateau phase were used in all experiments. Each cell line was further divided into control and experimental groups, respectively. Cells of control group received irradiation (8~16Gy) only. Cells of experimental group were treated with AA and then irradiated. After 10 days in culture, survival fractions of irradiated cells were analyzed by clonogenic assay. The survival curves and related parameters including \u03b1/\u03b2, and \u03b1/\u03b2 were analyzed by Linear-Quadratic model.\nResults: The \u03b1/\u03b2 values of irradiated CHO cells treated with and without AA were 9.28 and 4.43, respectively. Similarly, The \u03b1/\u03b2 values of irradiated GBM8401 cells treated with and without AA were 19.65 and 9.41, respectively. Slopes of survival curves for both cells decreased after treatment with AA. However, it was more significant for CHO cells than GBM8401 cells. In addition, the higher the dose of radiation, the greater radio- protective effect of AA on cells.\nConclusion: AA decreased the radiobiologic effects of CHO and GBM840I cells under high dose irradiation. The radioprotective effects of AA on these cells were proportional to radiation dose in the range of 8~16Gy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-185-193-a", "title": "Ho-166-Acetylacetonate-Lipiodol\u6838\u91ab\u85e5\u7269\u7814\u5236\u53ca\u5176\u505a\u7232\u809d\u764c\u9ad4\u5167\u8f3b\u5c04\u6cbb\u7642\u4e4b\u7d30\u80de\u5be6\u9a57\u8a55\u4f30", "keywords": "Ho-166-AcAc-lipiodol;\u809d\u764c\u7d30\u80de;\u6838\u91ab\u85e5\u5291 Ho-166-AcAc-lipiodol;Hepatoma cells;Radiopharmaceuticals", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u662f\u4ee5\u4e2d\u5b50\u6d3b\u5316\u4e4bHo-166 \u7814\u88fd\u809d\u764c\u6cbb\u7642\u6838\u91ab\u85e5\u5291\uff0c\u6e2c\u8a66\u85e5\u7269\u4e4b\u7a69\u5b9a\u6027\u53ca\u5c0d\u809d\u764c\u7d30\u80de\u4e4b\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c07\u7814\u88fd\u4e4bHo-165-acetylacetonate (Ho-165-AcAc)\u85e5\u7269\u65bc\u6e05\u83ef\u5927\u5b78\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668\u9032\u884c\u4e2d\u5b50\u7167\u5c04\uff0c\u4f7fHO-165\u8f49\u63db\u6210\u91cb\u653e\u9ad8\u80fd\u03b2\u8f3b\u5c04\u4e4bHo-156\u6838\u7a2e\uff0c\u4ee5\u591a\u983b\u9053\u80fd\u8b5c\u5206\u6790\u5100\u5206\u6790\u85e5\u7269\u6838\u7a2e\u5f37\u5ea6\u53ca\u7d14\u5ea6\u3002\u6240\u5f97\u4e4bHo-166-AcAc \u4ee5\u7898\u5316\u7f4c\u7c9f\u6cb9\u651c\u5e36\u4e4b\uff0c\u4e26\u65bc\u8840\u6e05\u4e2d\u6e2c\u8a66\u5176\u7a69\u5b9a\u6027\uff0c\u4ee5\u57f9\u990a\u4e4b\u4eba\u985e\u809d\u764c\u7d30\u80de(HepG2 cells)\u63a2\u8a0e\u85e5\u7269\u5c0d\u809d\u764c\u7d30\u80de\u4e4b\u4f5c\u7528\u3002\n\u7d50\u679c\uff1aHo-165-AcAc\u7f6e\u65bc\u53cd\u61c9\u5668\u4e4b\u5782\u76f4\u7167\u5c04\u7ba1\u4e2d\u7167\u5c0410\u5c0f\u6642\uff0c\u6240\u751f\u6210\u4e4bHo-165-AcAc\u653e\u5c04\u6bd4\u6d3b\u6027\u53ef\u905416-18 mCl/50 mg\uff0c\u7d93120\u5c0f\u6642\u8840\u6e05\u4e2d\u4e2d\u8a66\u7d50\u679c\u986f\u793aHo-166-AcAc-lipiodol\u4e2d\u7d04\u670998\uff05\u7684Ho-166\u4fdd\u5b58\u5728\u5176\u6cb9\u76f8\u4e4b\u4e2d\u3002HepG2\u3001\u7d30\u80de\u5728Ho-165-AcAc-lipiodol\u8655\u740624\u5c0f\u6642\u5f8c\uff0c\u986f\u5fae\u93e1\u4e0b\u53ef\u898b\u6709\u5927\u91cfHo-165-AcAc-liplodol\u8102\u7403\u7a4d\u805a\u5176\u4e2d\uff0c\u6b64\u6642\u7d30\u80de\u5167\u7684Ho-165-AcAc\u91cf\u70ba1.3\u00b5g/10^6 cells\u3002\u7531\u65bd\u85e5\u6642Ho-166-AcAc-lipiodol\u4e4b\u653e\u5c04\u6bd4\u6d3b\u6027\u53ef\u4ee5\u4f30\u7b97\u5f97\u7d30\u80de\u4e2dHo-166-AcAc-lipiodol\u4e4b\u653e\u5c04\u6d3b\u6027\u3002\n\u7d50\u8ad6\uff1aHo-166-acetylacetonate-lipiodol\u651c\u5e36\u9ad8\u80fd\u03b2\u8f3b\u5c04\u91cb\u51fa\u6838\u7a2e\uff0c\u65bc\u8840\u6e05\u4e4b\u7a69\u5b9a\u6027\u9ad8\uff0c\u7d30\u80de\u5be6\u9a57\u7d50\u679c\u986f\u793a\uff0cHo-165AcAclipiodol\u53ef\u70ba\u809d\u764c\u7d30\u80de\u6240\u5927\u91cf\u651d\u5165\uff0c\u6b64\u9ad4\u5916\u7814\u7a76\u63d0\u4f9b\u672a\u4f86\u9ad4\u5167\u5be6\u9a57\u4e4b\u57fa\u672c\u8cc7\u6599\uff0c\u6b64Ho-166AcAc-lipiodol\u85e5\u7269\u61c9\u53ef\u63d0\u4f9b\u809d\u764c\u4e00\u65b0\u7684\u9ad4\u5167\u8f3b\u5c04\u6cbb\u7642\u6a5f\u6703\u3002", "e": "Objective: The objective of this research was to synthesize and prepare radiopharmaceuticals containing neutron-activated Ho 166. The in vitro stability of Ho-166-radiopharmaceuticals was tested, and the interaction of the radiopharmaceuticals with hepatoma cells was investigated.\nMaterials and Methods: In order to generate Ho 166, the non-radioactive Ho-165-acetylacetonate (Ho-165-AcAc) was prepared and irradiated in the Tsing Hua Open-Pool Reactor. Multiple channel analyzer was used for analysis of the radioactivity and the purity of the Ho-166-AcAc. Lipiodol was used as a carrier of Ho-166-AcAc. The stability of Ho-166-AcAc-lipiodol in serum was tested. The interaction of Ho-l65-AcAc lipiodol with human hepatoma cells (HepG2 cells) was investigated.\nResult: In this study, the prepared Ho-l65-AcAc samples were irradiated in the nuclear reactor for up to 10 hr and yielded 16-l8mCi/SOmg of specific activity. In addition, in vitro analysis of the stability of Ho-166-AcAc-lipiodol in plasma revealed a 98% retention of Ho-166 in the Ho-l66-AcAc-lipiodol after 120 hr. In vitro treatment of HepG2 cells for 24 hr with Ho-165-AcAc-lipiodol resulted in a retention of 1.3\u00b5g of Ho-165-AcAc in 106 cells. Thus, from the specific activity of Ho-166-AcAc-lipiodol the potential radioactivity of Ho-166 in HepG2 cells can be evaluated.\nConclusion: Ho I 66-AcAc-lipiodol contained sufficient high energy J3 emitter and has a high stability in serum. in vitro cell culture analysis showed that large amount of I-lo-165-AcAc-lipiodol can be uptake by hepatoma cells. Results of this in vitro study provided important basic information for future development and in vitro tests. The Ho-I 66-AcAc-lipiodol has potential for future hepatoma therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-195-201-a", "title": "Postoperative Concurrent Chemotherapy and Radiotherapy for Resectable Locally Advanced Gastric Cancer Patients\uff0dA Preliminary Report", "keywords": "\u5c40\u90e8\u5ee3\u6cdb\u6027\u80c3\u764c;\u8f14\u52a9\u6cbb\u7642 Locally advanced gastric cancer;Adjuvant therapy", "c": "\u76ee\u7684\uff1a\u65bc1993\u5e749\u6708\u81f31995\u5e7412\u6708\u9593\uff0c13\u4f4d\u80c3\u764c\u9ad8\u5371\u96aa\u7fa4\u75c5\u4eba\u65bc\u8f9c\u516c\u4eae\u57fa\u91d1\u6703\u5b6b\u9038\u4ed9\u91ab\u9662\u63a5\u53d7\u624b\u8853\u5f8c\u5408\u4f75\u5316\u7642\u53ca\u653e\u7642\u4e4b\u8f14\u52a9\u6cbb\u7642\u3002\u672c\u7814\u7a76\u76ee\u7684\u5728\u8a55\u4f30\u65bc\u5c40\u90e8\u5ee3\u6cdb\u6027\u80c3\u764c\u75c5\u4eba\u9032\u884c\u8853\u5f8c\u5408\u4f75\u5316\u7642\u53ca\u653e\u7642\u8f14\u52a9\u6cbb\u7642\u4e4b\u53ef\u884c\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u653e\u5c04\u6cbb\u7642\u65bc\u624b\u8853\u5f8c4\u81f36\u9031\u9032\u884c\uff0c\u65bc4\u81f35\u5468\u9593\u6295\u4e88\u80c3\u90e8\u53ca\u4e0a\u8179\u6dcb\u5df4\u5f15\u6d41\u53403440\u81f34320 cGy \u653e\u5c04\u6cbb\u7642\u3002\u6bcf\u4f4d\u75c5\u4eba\u7686\u6709\u96fb\u8166\u65b7\u5c64\u6cbb\u7642\u8a08\u756b\u53ca\u7279\u88fd\u925b\u584a\uff0c\u5316\u5b78\u6cbb\u7642\u4e43\u540c\u6642\u9032\u884c\uff0c\u8655\u65b9\u70ba 5-FU\u70ba\u4e3b\u6bcf\u6708\u6216\u6bcf\u9031\u9023\u7e8c\u5f0f\u7d66\u4e88\u3002\n\u7d50\u679c\uff1a\u56db\u4f4d\u75c5\u4eba\u767c\u751f3\u7d1a\u5614\u5410\u53ca\u60e1\u5fc3\uff0c\u5176\u4e2d\u4e00\u4eba\u65bc3440 cGy \u6642\u63d0\u524d\u7d50\u675f\u6cbb\u7642\uff0c\u5168\u90e8\u75c5\u4eba\u5e73\u5747\u8ffd\u8e6420\u500b\u6708(11\u81f348\u500b\u6708)\uff0c\u6c92\u6709\u75c5\u4eba\u767c\u751f\u55ae\u7368\u6027\u5c40\u90e8\u5fa9\u767c\uff0c\u50c5\u6709\u4e00\u4f4d\u75c5\u4eba\u65bc\u6b98\u7559\u80c3\u5c40\u90e8\u5fa9\u767c\uff0c\u4f46\u540c\u6642\u5408\u4f75\u8179\u8154\u5fa9\u767c\uff0c\u6709\u4e09\u4f4d\u75c5\u4eba\u767c\u751f\u9060\u7aef\u8f49\u79fb\u3002\n\u7d50\u8ad6\uff1a\u5728\u5c40\u90e8\u5ee3\u6cdb\u6027\u80c3\u764c\u75c5\u4eba\u9032\u884c\u8853\u5f8c\u5408\u4f75\u5316\u7642\u53ca\u653e\u7642\u8f14\u52a9\u6cbb\u7642\uff0c\u5176\u6025\u6027\u671f\u526f\u4f5c\u7528\u662f\u53ef\u63a5\u53d7\u7684\uff0c\u77ed\u671f\u4e4b\u75be\u75c5\u63a7\u5236\u53ca\u5b58\u6d3b\u7387\u8207\u5176\u4ed6\u985e\u4f3c\u7814\u7a76\u7d50\u679c\u76f8\u540c\uff0c\u5408\u4f75\u5316\u7642\u53ca\u653e\u7642\u6700\u6070\u7576\u7684\u8655\u65b9\u8207\u5291\u91cf\uff0c\u4ecd\u9808\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Purpose: To evaluate the feasibility of postoperative adjuvant concurrent chemotherapy and radiotherapy for locally advanced gastric cancer patients\nMaterials and Methods: From September 1993 to December 1995, 13 patients who had locally advanced gastric cancer were treated with postoperative concurrent chemotherapy and radiotherapy (CCRT) at the Koo Foundation Sun Yat-Sen Cancer Center. Radiotherapy was given in the range of 3440 cGy to 4320 cGy in 4 to 5 weeks to the gastric bed and upper abdominal nodal draining regions beginning 4 to 6 weeks after surgery. All patients had computerized tomography treatment planning and customized shaping blocks. 5-Fluorouraoil based chemotherapy with either monthly or weekly continuous infusion were prescribed concomitantly.\nResults: Four patients developed grade 3 nausea and vomiting. One of them discontinued the CCRT earlier after the dose of 3440 cGy. At the median follow up interval of 20 months (ranged from 11 to 48 months), 10 patients were free of disease. Three patients developed recurrence.\nConclusion: Our preliminary results suggest that the acute toxicity were moderate for patients with locally advanced gastric cancer who underwent postoperative CCRT using 5-FU based chemotherapy and radiotherapy up to 4000 cGy in standard fractionation. The short term disease control and survival are promising as compared with those reported by other institutions with adjuvant treatment in resected gastric patients. We suggest gastric cancer patients with T3, 4 or N1, 2 disease should be enrolled into clinical trial of adjuvant therapy postoperatively. The most appropriate radiation dosage and chemotherapy regimen needs further investigation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-203-210-a", "title": "Adding Radiation Dose to Incomplete-Regressed Cervical Cancer after Definitive Radiotherapy-Chang Gung Memorial Hospital", "keywords": "\u5b50\u5bae\u9838\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u6b98\u9918\u75c5\u7076;\u589e\u6dfb\u653e\u5c04\u7dda\u51b6\u7642\u5291\u91cf cervical cancer;radiotherapy;residual lesion;additional radiation dose", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u589e\u6dfb\u653e\u5c04\u7dda\u6cbb\u7642\u5291\u91cf\u5c0d\u5b50\u5bae\u9838\u764c\u653e\u5c04\u5f8c\u6b98\u9918\u816b\u7624\u4e4b\u6548\u679c\u53ca\u9810\u5f8c\u5206\u6790\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1979\u81f31988\u5e74\u9593\uff0c\u672c\u9662\u6709552\u4f4d\u5b50\u5bae\u9838\u764c\u60a3\u8005\u63a5\u53d7\u5b8c\u6574\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c79\u4f4d\u7684\u75c5\u7076\u5728\u6cbb\u7642\u7d50\u675f\u6642\u6c92\u6709\u5b8c\u5168\u6d88\u5931\uff1b\u5176FIGO\u5206\u671f\u7232\uff1a1\u4f4dIB\uff0c21\u4f4d\u2161B\uff0c3\u4f4d\u2162A\uff0c41\u4f4d\u2162B\u53ca13\u4f4dIVA\uff1b\u75c5\u7406\u5206\u985e\uff0c74\u4f4d\u5c6c\u4e0a\u76ae\u7d30\u80de\u764c\uff0c4\u4f4d\u662f\u817a\u764c\u53ca1\u4f4d\u817a\u6027\u4e0a\u76ae\u7d30\u80de\u764c\u3002\u816b\u7624\u4e4b\u4e0d\u5b8c\u5168\u6d88\u5931\u662f\u4ee5\u75c5\u4eba\u5728\u7642\u7a0b\u4e2d\u7684\u6bcf\u9031\u53ca\u7642\u5f8c4\u9031\u4e4b\u8ffd\u8e64\u6aa2\u67e5\u7232\u4f9d\u64da\u3002\u6b6479\u4f4d\u75c5\u60a3\uff0c30\u4eba\u63a5\u53d7\u4e86\u589e\u6dfb\u653e\u5c04\u7dda\u5291\u91cf\u6cbb\u7642(ART)\u5269\u4e0b\u4e4b49\u4f4d\u5247\u53ea\u7e7c\u7e8c\u8ffd\u8e64\u53ca\u89c0\u5bdf(NRT)\u3002ART\u7684\u65b9\u6cd5\u662f\u63a1\u53d6\u4e00\u822c\u4e4b\u9ad4\u5916\u6cbb\u7642\u3001\u8fd1\u63a5\u6cbb\u7642\u6216\u96fb\u5b50\u4f38\u5c55\u9310\u6cbb\u7642\u3002\u5291\u91cf\u5f9e5Gy\u523040Gy\u4e0d\u7b49(\u4e2d\u9593\u503c18Gy)\u3002\n\u7d50\u679c\uff1aART\u53caNRT\u7684\u5c40\u90e8\u5931\u6557\u7387\u5206\u5225\u662f93%\u548c94%\uff0c\u9060\u7aef\u8f49\u79fb\u5247\u662f20%\u53ca33%(p=0.241)\u3002\u5169\u5e74\u5b58\u6d3b\u7387NRT\u67092%\uff0cART\u662f17%(p=0.354)\u3002ART\u75c5\u4eba\u4e2d\u67092\u4f4d\u767c\u751fGrade \u2162\u53ca1\u4f4dGrade IV\u4e4b\u75c5\u767c\u75c7\u3002\u5176\u6b7b\u4ea1\u7686\u8207\u4f75\u767c\u75c7\u7121\u95dc\u3002ART\u53ef\u5ef6\u7de9\u5b50\u5bae\u9838\u6b98\u9918\u816b\u7624\u4e4b\u60e1\u5316\uff0cp\u503c\u72320.007\u3002\u4f46\u5b58\u6d3b\uff0c\u5c40\u90e8\u53ca\u9060\u7aef\u4e4b\u63a7\u5236\u5247\u7121\u660e\u986f\u6548\u679c\u3002\n\u7d50\u8ad6\uff1a\u5b50\u5bae\u9838\u764c\u653e\u5c04\u6cbb\u7642\u5f8c\u4ecd\u6709\u6b98\u9918\u816b\u7624\u6642\u3002ART\u4e26\u4e0d\u80fd\u6539\u5584\u5176\u9810\u5f8c\u3002\u4f46\u5c0d\u75c5\u7076\u4e4b\u6301\u7e8c\u60e1\u5316\u6709\u5ef6\u7de9\u4f5c\u7528\u3002\u56e0\u6b64\u589e\u6dfb\u653e\u5c04\u7dda\u5291\u91cf\u4f86\u5c0d\u4ed8\u5b50\u5bae\u9838\u6b98\u9918\u816b\u7624\u65b9\u6cd5\uff0c\u4ecd\u6709\u5f85\u6539\u9032\u3002", "e": "Purpose: This study is to analyze the prognosis and evaluate the effect of additional radiation dose to incomplete-regressed cervical cancer after definitive radiotherapy.\nMaterials and Methods: From 1979-1988, 552 cervical carcinoma patients were treated with definitive radiotherapy at Chang Sung Memorial Hospital (CGMH), Taiwan. After the completion of treatment, 79 lesions showed incomplete regression; among them, 74 were squamous cell carcinoma, 4 were adenocarcinoma, and 1 was adenosquamous carcinoma. There were one stage \u2161A, 21 \u2161B, 3 \u2162A, 41 \u2162B, and 13 IVA. Incomplete regression of tumor was defined as having palpable or visible disease noted through out the treatment course and at the time of follow-up four weeks after the completion of treatment. Thirty patients received additional radiotherapy (ART), and 49 received no further therapy (NRT). ART was delivered by external beam, brachytherapy or electron cone. Dose ranged from 5 Gy to 40 Gy, (median 18 Gy). Minimal follow-up was one year.\nResults: We observed similar local failures in ART and NRT groups (93% and 94%, respectively). The incidence of distant metastasis were 20% and 33% respectively for ART and NAT (p=0.24l). Overall survival at 2 years was 2% for NRT, and 17% for patients received ART (p=0.354). There were two grade \u2162 and one grade IV complications in patients received ART, but their death was due to cancer, not to complication. ART did delay the progression of residual tumor with a p-value of 0.007, yet it had no beneficial gain in terms of survival, local and distal control.\nConclusions: For incomplete-regressed cervical cancer after standard radiotherapy, ART cannot improve their outcome of survivals and tumor control but may delay the residual tumor's progression. Therefore the ultimal ways of ART to treat incomplete-regressed cervical cancer deserve further investigation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-211-214-a", "title": "Effect of the Air Gap between the Skin Surface and Bolus Material on the Relative Surface Dose in Electron Beam Therapy", "keywords": "\u96fb\u5b50\u7dda\u6cbb\u7642;\u7a7a\u6c23\u9593\u9694 Electron beam therapy;Air gap;Bolus", "c": "\u76ee\u7684\uff1a\u5728\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u4e2d\uff0c\u4f7f\u7528\u7684Bolus\u8207\u75c5\u60a3\u9ad4\u8868\u5e38\u7121\u6cd5\u5bc6\u5408\u800c\u7522\u751f\u7a7a\u6c23\u9593\u9694\u3002\u6b64\u7814\u7a76\u5373\u63a2\u8a0e\u4e0d\u540c\u7684\u7a7a\u6c23\u9593\u9694\u5c0d\u76ae\u819a\u8868\u9762\u5291\u91cf\u6240\u9020\u6210\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u4f7f\u7528\u5e73\u884c\u677f\u6e38\u96e2\u8154\u6e2c\u91cf\u9ad4\u8868\u76f8\u5c0d\u5291\u91cf\uff0c\u7a7a\u6c23\u9593\u9694\u75310\u516c\u5206\u81f32\u516c\u5206\uff0c\u96fb\u5b50\u5c04\u7dda\u80fd\u91cf\u70ba6\u30019\u300112\u300116\u53ca20\u767e\u842c\u96fb\u5b50\u4f0f\u7279\u7b49\u4e94\u7a2e\uff0c\u7167\u5c04\u7bc4\u570d\u67096\u00d76\u300110\u00d7l0\u53ca20\u00d720 \u5e73\u65b9\u516c\u5206\u65a4\u7b49\u4e09\u7a2e\uff0cBolus\u7684\u539a\u5ea6\u67090.5\u548c1.0\u516c\u5206\u4e8c\u7a2e\u3002\n\u7d50\u679c\uff1a\u7576\u7167\u5c04\u7bc4\u570d\u70ba6\u00d76\u5e73\u65b9\u516c\u5206\u6642\uff0c\u9ad4\u8868\u76f8\u5c0d\u5291\u91cf\u6703\u96a8\u4e0d\u540c Bolus \u539a\u5ea6\uff0c\u7a7a\u6c23\u9593\u9694\u53ca\u96fb\u5b50\u5c04\u7dda\u80fd\u91cf\u7531100\uff05\u6e1b\u70ba852\uff05\u3002\u7576\u7167\u5c04\u7bc4\u570d\u70bal0\u00d710\u5e73\u65b9\u516c\u5206\u6642\uff0c\u9ad4\u8868\u76f8\u5c0d\u5291\u91cf\u7531100\uff05\u6e1b\u70ba937\uff05\u3002\u7576\u7167\u5c04\u7bc4\u570d\u70ba20\u00d720\u5e73\u65b9\u516c\u5206\u6642\uff0c\u9ad4\u8868\u76f8\u5c0d\u5291\u91cf\u7531100\uff05\u6e1b\u70ba97.1%\u3002\n\u7d50\u8ad6\uff1a\u6839\u64da\u5be6\u9a57\u7d50\u679c\uff0c\u6211\u5011\u767c\u73fe\u7576\u96fb\u5b50\u5c04\u7dda\u80fd\u91cf\u6108\u4f4e\uff0c\u7167\u5c04\u7bc4\u570d\u6108\u5c0f\uff0c\u9ad4\u8868\u8207 Bolus \u7684\u7a7a\u6c23\u9593\u9694\u6108\u5927\uff0c\u53caBolus\u6108\u539a\uff0c\u6703\u5c0d\u96fb\u5b50\u5c04\u7dda\u76f8\u5c0d\u8868\u9762\u5291\u91cf\u7684\u5f71\u97ff\u6108\u5927\uff0c\u500b\u5225\u7684\u6e2c\u91cf\u505a\u9069\u5ea6\u7684\u4fee\u6b63\u662f\u5fc5\u8981\u7684\u3002", "e": "Purpose: The existence of an air gap between the bolus material and the skin surface is often encountered in electron beam therapy. This study investigated the perturbation effect of air gaps under bolus material on the surface dose.\nMaterials and Methods: The surface dose was measured for air gaps from a distance of 0.0cm to 2.0cm using 6, 9, 12, 16 and 20 MeV electron beams and various available cone sizes from 6\u00d76, 10\u00d7l0, and 20\u00d720 cm^2 on a linear accelerator\nResults: In the case of 6\u00d76 cm^2 cone size with different thickness of boluses and electron energy, the relative surface dose decreased from 100% to 85.2% as the air gap was increased. In l0\u00d7l0 cm^2cone size the relative surface dose decreased from 100% to 93.7%. In 20\u00d720 cm^2 cone size the relative surface dose decreased from 100% to 97.1%. \nConclusions: These measurements showed that there was a tendency of relatively decreasing surface dose by lower electron energies, smaller field sizes, larger air gaps, and thicker boluses. It is necessary to correct the problem with individual dosimetry."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-215-221-a", "title": "\u4f4e\u8f3b\u5c04\u5291\u91cf\u4e0bTLD-100H\u4e4b\u8f03\u6b63\u8207\u7dda\u6027\u6e2c\u8a66", "keywords": "\u71b1\u767c\u5149\u5291\u91cf\u8a08;\u5438\u6536\u5291\u91cf;\u6821\u6b63\u4fc2\u6578 Thermoluminescence dosimeter;Absorbed dose;Calibration factor", "c": "\u76ee\u7684\uff1a\u5728\u653e\u5c04\u6cbb\u7642\u671f\u9593\uff0c\u9130\u8fd1\u6cbb\u7642\u90e8\u4f4d\u4e4b\u6b63\u5e38\u7d44\u7e54\u6703\u63a5\u53d7\u8f03\u4f4e\u5291\u91cf\u4e4b\u6563\u5c04\uff0c\u70ba\u4e86\u80fd\u6e96\u78ba\u5730\u8a55\u4f54\u9130\u8fd1\u7d44\u7e54\u7684\u5438\u6536\u5291\u91cf\uff0c\u5fc5\u9808\u4e8b\u5148\u5c0d\u71b1\u767c\u5149\u5291\u91cf\u8a08\u9032\u884c\u7be9\u9078\u3001\u6821\u6b63\u8207\u7dda\u6027\u6e2c\u8a66\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u63a1\u7528\u4e0bTLD-100H\u4f86\u9032\u884c\u5291\u91cf\u5075\u6e2c\uff0c\u4e26\u5efa\u7acb\u5728\u8f3b\u5c04\u5291\u91cf\u5c0f\u65bc1 cGy\u6642\uff0cTLD-100H\u5c0d\u4f4e\u5291\u91cf\u4e4b\u7be9\u9078\u8207\u6821\u6b63\u4fc2\u6578\u7684\u6c42\u6cd5\u3002\u540c\u6642\u4e5f\u6c42\u51fa\u5176\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\uff0c\u4ee5\u5224\u5b9a\u8a08\u8b80\u96fb\u91cf\u8207\u7167\u5c04\u5291\u91cf\u4e4b\u9593\u7684\u95dc\u4fc2\uff0c\u6700\u5f8c\u518d\u505a\u4e0d\u6e96\u5ea6\u6e2c\u8a66\u4ee5\u9a57\u8b49\u5176\u8aa4\u5dee\u5ea6\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u7531\u7814\u7a76\u7684\u7be9\u9078\u7d50\u679c\u53ef\u77e5\uff0c\u672c\u6b21\u4f7f\u7528\u768425\u9846TLD\u4e2d\uff0c\u67095\u9846\u5728\u9810\u6e2c\u5291\u91cf\u6642\uff0c\u7121\u6cd5\u5c07\u8aa4\u5dee\u5ea6\u63a7\u5236\u57283%\u4ee5\u5167\uff0c\u56e0\u6b64\u5c07\u5176\u522a\u9664\u3002\u7531\u7dda\u6027\u5ea6\u6e2c\u8a66\u53ef\u77e5\uff0c\u5291\u91cf\u57280\u52300.9cGy\u6642\uff0c\u8a08\u8b80\u96fb\u91cf\u8207\u7167\u5c04\u5291\u91cf\u4e4b\u9593\u70ba\u7dda\u6027\u95dc\u4fc2\uff0c\u4e14\u5224\u5b9a\u4fc2\u6578(R^2)\u70ba0.9999\u3002\n\u7d50\u8ad6\uff1aTLD-100H \u5728\u4f4e\u5291\u91cf\u6642\uff0c\u6709\u975e\u5e38\u9ad8\u4e4b\u9748\u654f\u5ea6\uff0c\u4e26\u4e14\u76f8\u7576\u7a69\u5b9a\uff0c\u5341\u5206\u9069\u5408\u4f4e\u5291\u91cf\u8f3b\u5c04\u5075\u6e2c\u3002\u6700\u5f8c\uff0c\u7d93\u904e\u672c\u7814\u7a76\u7684\u7be9\u9078\u8207\u6821\u6b63\uff0cTLD-100H\u5373\u5728\u9810\u6e2c\u5291\u91cf\u6642\uff0c\u53ef\u5c07\u4e0d\u6e96\u5ea6\u63a7\u5236\u57283\uff05\u4ee5\u5167\u3002", "e": "Purpose: It is clinically necessary to evaluate scatter radiation dose to the adjacent normal organs in most radiation therapy procedures. One must perform the calibration and linearity test for TLD in advance so that the scattered dose can be accurately determined.\nMaterial and Method: The TLD-100H is used for dose measurement in the study. A method for selection and calibration of TLD in low-level radiation exposure is proposed, and their dose response curves are also determined. To verify the linear relationship between collected charges and received doses, a blind test is also presented to ensure that the overall uncertainty is under 3% of error.\nResult: Five out of 25 TLD-100H, failed to report their predict doses within 3% error rate and therefore were eliminated from the study. The test of TLDs verified that the linearity performance is satisfactory with determination coefficient of 0.9999 in the range of 0~0.9 cGy.\nConclusion: The TLD-100H is very stable and sensitive, and is especially useful in low-level radiation detection. If the TLD-100H us carefully selected and calibrated, then the overall error rate is controlled within 3%, which is applicable for clinical studies."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-223-228-a", "title": "Cf-252\u901f\u4e2d\u5b50\u4e4b\u53e3\u8154\u764c\u6cbb\u7642\u7d93\u9a57\u8207\u4e2d\u5b50\u6cbb\u7642\u4e4b\u5c55\u671b", "keywords": "\u4e2d\u5b50;\u53e3\u8154\u764c;\u9272 Neutron;Oral cavity cancer;Cf-252", "c": "\u653e\u5c04\u7dda\u6cbb\u7642\u4ecd\u662f\u76ee\u524d\u8a31\u591a\u60e1\u6027\u816b\u7624\u7684\u91cd\u8981\u6cbb\u7642\u65b9\u6cd5\u4e4b\u4e00\uff0c\u7531\u65bc\u6cbb\u7642\u6280\u8853\u4e4b\u9032\u6b65\u8207\u6539\u5584\uff0c\u653e\u5c04\u7dda\u5c0d\u65bc\u60e1\u6027\u816b\u7624\u4e4b\u6cbb\u7642\u6548\u679c\u8207\u6210\u7e3e\u7e7c\u7e8c\u5728\u63d0\u6607\u3002\u4f46\u662f\u5c0d\u65bc\u6709\u4e9b\u8f03\u5927\u7684\u816b\u7624\u6216\u662f\u6d78\u6f64\u8f03\u6df1\u4e4b\u816b\u7624\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u6548\u679c\u4ecd\u7136\u6709\u9650\uff0c\u6839\u6cbb\u6cbb\u7642\u76f8\u7576\u7684\u56f0\u96e3\u3002\u70ba\u4e86\u63d0\u9ad8\u764c\u7d30\u80de\u5c0d\u653e\u5c04\u7dda\u4e4b\u654f\u611f\u6027\uff0c\u4ee5\u53ca\u6e1b\u5c11\u5c0d\u6b63\u5e38\u7d44\u7e54\u4e4b\u5f71\u97ff\uff0c\u4f7fRRE\u589e\u52a0\uff0cOER\u964d\u4f4e\uff0c\u4f86\u63d0\u9ad8\u6cbb\u7642\u6548\u679c\u6bd4(TR)\uff0c\u662f\u653e\u5c04\u7dda\u816b\u7624\u5b78\u6240\u671f\u5f85\u7684\u3002\u56e0\u800c\u4e2d\u5b50\u7dda\u8207\u91cd\u7c92\u5b50\u7dda\u7b49\u9ad8LET\u4e4b\u653e\u5c04\u7dda\u7684\u81e8\u5e8a\u61c9\u7528\uff0c\u5373\u70ba\u8a31\u591a\u5b78\u8005\u5c08\u5bb6\u6240\u6ce8\u76ee\u548c\u7814\u7a76\u7684\u5c0d\u8c61\u3002\nCalifornium-252\uff08\u4ee5\u4e0b\u7c21\u7a31Ci-252\uff09\u4e4bOER\u503c\u5728\u4f4e\u5291\u91cf\u7387(20 rad/hr)\u6642\u7d04\u70ba1.45 \uff0c\u9ad8\u5291\u91cf\u7387 (100-500 rad/hr)\u7d041.82\uff0c\u8207Radium\u4e4b23\u6bd4\u662f\u975e\u5e38\u7684\u4f4e\u3002\u800c Cf-252\u4e4bRBE\u5728\u5291\u91cf\u7387\u70ba10-20 rad/hr\u6642\u7d04\u70ba5-7\uff0c\u4f46\u5982\u5176\u5291\u91cf\u7387\u8d85\u904e200 rad/hr\u6642\uff0c\u5247\u96d6\u7136\u5176\u503c\u4e26\u4e0d\u662f\u5b9a\u503c\uff0c\u4f46\u537b\u8f03\u5927\u3002\u5feb\u901f\u4e2d\u5b50\u4e4bOER\u6bd4X\u7dda\u4f4e\uff0c\u5728\u7d30\u80de\u6c27\u6fc3\u5ea6\u8f03\u4f4e\u7684\u72c0\u614b\u4e0b\u4ea6\u80fd\u9054\u5230\u6cbb\u7642\u7684\u6548\u679c\uff1b\u53c8\u5176RBE\u8f03\u9ad8\uff0c\u56e0\u6b64\u5c0d\u65bc\u81e8\u5e8a\u6240\u9700\u6c42\u4e4b\u6539\u5584\u6cbb\u7642\u6548\u679c\u6bd4\u975e\u5e38\u7684\u7406\u60f3\uff0c\u4f7f\u7528\u8f03\u5c0f\u4e4b\u653e\u5c04\u5291\u91cf\u5373\u53ef\u7372\u5f97\u8f03\u5927\u7684\u6cbb\u7642\u6548\u679c\uff0c\u800c\u4e14\u5c0d\u65bc\u8edf\u7d44\u7e54\u7684\u5f71\u97ff\u6bd4\u786c\u7d44\u7e54\u3001\u9aa8\u3001\u7259\u9f52\u7b49\u5927\uff0c\u56e0\u6b64\u53ef\u4ee5\u6e1b\u5c11\u9aa8\u58de\u6b7b\u7b49\u526f\u4f5c\u7528\u3002\u5c0d\u65bc\u518d\u767c\u764c\u4e4b\u91cd\u8907\u7167\u5c04\u6240\u9020\u6210\u6b63\u5e38\u7d44\u7e54\u7684\u5f71\u97ff\u8f03\u5c0f\uff0c\u7406\u8ad6\u4e0a\u5728\u4e00\u822c\u6cbb\u7642\u7684\u5291\u91cf\u4e0b\u61c9\u8a72\u6bd4\u8f03\u4e0d\u6703\u5f15\u8d77\u56b4\u91cd\u7684\u526f\u4f5c\u7528\u3002\n\u4e00\u822cCf-252\u662f\u88fd\u6210\u53ef\u4ee5\u653e\u51fa\u4e2d\u5b50\u7dda\u4e4b\u5c0f\u5c04\u6e90\uff0c\u800c\u61c9\u7528\u65bc\u8154\u5167\u6216\u7d44\u7e54\u5167\u4e4b\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u70ba\u4e3b\u3002\u7531\u65bcCf-252\u4e4b\u901f\u4e2d\u5b50\u7dda\u6709\u9ad8LET\u653e\u5c04\u7dda\u4e4b\u7279\u5fb5\uff0c\u6240\u9020\u6210\u764c\u7d30\u80de\u7684\u50b7\u5bb3\u5176\u6062\u5fa9\u6bd4\u00d7\u7dda\u62167\u7dda\u5c11\uff0c\u56e0\u6b64\u5c0d\u65bc\u6cbb\u7642\u6548\u679c\u6bd4(therapeutic ratio)\u4e4b\u6539\u5584\u662f\u53ef\u671f\u5f85\u7684\u3002\n\u7531\u65bc\u8fd1\u5e74\u4f86\u5728\u53f0\u7063\u5730\u5340\uff0c\u5927\u5bb6\u5c0d\u65bc\u4e2d\u5b50\u6cbb\u7642\u8207\u91cd\u7c92\u5b50\u6cbb\u7642\u6709\u5f88\u5927\u7684\u8208\u8da3\uff0c\u56e0\u6b64\u4f5c\u8005\u5229\u7528\u672c\u6587\uff0c\u5831\u544a\u8457\u8005\u5229\u7528Cf-252\u4e4b\u9060\u9694\u5f8c\u8377\u5f0f\u88dd\u7f6e\u4f86\u6cbb\u7642\u518d\u767c\u6027\u53e3\u8154\u764c\u4e4b\u7d93\u9a57\uff0c\u4ee5\u63d0\u4f9b\u5b78\u8005\u3001\u5c08\u5bb6\u4e4b\u53c3\u8003\u3002", "e": "Radiotherapy is one of the most effective methods in treament of malignant tumors. But in some conditions, such as advanced tumors, hypoxic tumors, success of radiotherapy is limited, peoples seeking for high RBE, and low OER radiation for such radioresistant tumors.\nCf-252 is the only one man-made radioisotope emitted neutrons. high RBE and lower OER are characteristics of Neutron Beam.\nIn this paper we have experienced some cases of oral cancer, treatment with Cf252 remote after loading system intra oral brachytherapy. Both cases are well responded to neutron therapy, but one case recurrent 10 months later died with disease, and the other one died 14 months later without evidence of disease. According to our experiences, We know, oral cancer patients can tolerate neutron therapy well and have good response to it, but fur her studies about the Neutron therapy for malignant disease in dosimetry and radiobiological response is necessary."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-229-236-a", "title": "\u892a\u9ed1\u6fc0\u7d20\uff1a\u65b0\u63d0\u51fa\u7684\u6297\u764c\u8377\u723e\u8499", "keywords": "\u892a\u9ed1\u6fc0\u7d20;\u6297\u816b\u7624\u5291;\u8377\u723e\u8499 Melatonin;Anti-cancer agent;Hormone", "c": "\u892a\u9ed1\u6fc0\u7d20\uff0c\u7531\u677e\u679c\u9ad4\u5206\u6ccc\u7684\u8377\u723e\u8499\uff0c\u4e00\u5411\u88ab\u7528\u65bc\u8abf\u6574\u6642\u5dee\u8207\u6539\u5584\u7761\u7720\uff0c\u96d6\u7136\u5728\u6297\u8001\u5316\u6548\u679c\u4e0a\u88ab\u5a92\u9ad4\u904e\u5ea6\u5439\u5653\uff0c\u5c1a\u7121\u6cd5\u88ab\u5217\u70ba\u6307\u793a\u7528\u85e5\uff0c\u4f46\u537b\u6709\u76f4\u63a5\u3001\u9593\u63a5\u7684\u5be6\u9a57\u8b49\u64da\u986f\u793a\u892a\u9ed1\u6fc0\u7d20\u5177\u6709\u76f4\u63a5\u8abf\u7bc0\u751f\u9577\u8377\u723e\u8499\u7684\u529f\u80fd\uff0c\u4e26\u6709\u5f88\u5f37\u7684\u6297\u6c27\u5316\u529b\u53ca\u514d\u75ab\u589e\u5f37\u529b\uff0c\u53ef\u6e1b\u5c11\u53ca\u9810\u9632\u764c\u75c5\u7684\u767c\u751f\u6216\u60e1\u5316\u3002\u81e8\u5e8a\u767c\u73fe\u5f88\u591a\u764c\u75c5\u60a3\u8005\u90fd\u6709\u892a\u9ed1\u6fc0\u7d20\u5206\u6ccc\u4e0d\u6b63\u5e38\u7684\u73fe\u8c61\uff0c\u5728\u88dc\u5145\u892a\u9ed1\u6fc0\u7d20\u5f8c\uff0c\u53ef\u89c0\u5bdf\u5230\u816b\u7624\u6291\u5236\u4f5c\u7528\uff0c\u75c5\u60a3\u7684\u7cbe\u795e\u72c0\u6cc1\u4e5f\u7372\u5f97\u6539\u5584\u3002\u8207Tamoxifen\u6216\u4ecb\u767d\u7d20\u4e8c\u865f\u5408\u4f75\u6cbb\u7642\uff0c\u9664\u6709\u76f8\u8f14\u76f8\u6210\u7684\u6548\u679c\u4e4b\u5916\uff0c\u66f4\u53ef\u964d\u4f4e\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u3002\u672c\u6587\u505a\u4e86\u6587\u737b\u6eaf\u95b1\uff0c\u4e26\u5c0d\u5176\u6a5f\u8f49\u505a\u4e9b\u63cf\u8ff0\uff0c\u76ee\u7684\u662f\u63d0\u9192\u91ab\u5e2b\u6b63\u8996\u892a\u9ed1\u6fc0\u7d20\u5728\u764c\u75c5\u6cbb\u7642\u4e0a\u53ef\u80fd\u7684\u6548\u679c\uff0c\u4e0d\u8981\u56e0\u70ba\u574a\u9593\u7684\u6feb\u7528\u800c\u5ffd\u7565\u5b83\u771f\u6b63\u7684\u50f9\u503c\u3002", "e": "Melatonin, an over exaggerated anti aging hormone used widely around the world for improving sleep quality, has now shown great potential in fighting against cancers. Many laboratory and clinical evidences support its oncostatic action, anti-oxidization effect and immune enhancement ability. Cancer patients have altered rhythm of melatonin secretion as compared with healthy people. Clinical trials provide evidences of improving quality of life, increase disease free survival rates and overall survival rates by supplement with melatonin in pharmacological dose. Melatonin can reduce the toxicity from chemotherapy and immunotherapy. It has synergistic effect when combines with Interlukin-2 or tamoxifen. Melatonin may be a newly proposed anti-cancer hormonl for anti-cancer therapy. It should not be overlooked."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199709-4-3-237-241-a", "title": "\u5b50\u5bae\u9838\u764c\u9ad8\u5291\u91cf\u7387\u8207\u4f4e\u5291\u91cf\u7387\u9ad4\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u4e4b\u73fe\u6cc1\u8207\u6bd4\u8f03", "keywords": "\u9ad4\u8154\u5167\u8fd1\u63a5\u6cbb\u7642;\u9ad8\u5291\u91cf\u7387;\u5b50\u5bae\u9838\u764c Intracavitary brachytherapy;High-dose-rate;Cervical carcinoma", "c": "\u5b50\u5bae\u9838\u764c\u9ad4\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\u7684\u6280\u8853\u8207\u8da8\u52e2\uff0c\u5728\u904e\u53bb\u7684\u5341\u5e74\u6709\u6975\u986f\u8457\u7684\u8f49\u8b8a\uff1a\u9ad8\u5291\u91cf\u7387(HDR)\u6280\u8853\u6b63\u9010\u6f38\u7684\u53d6\u4ee3\u904e\u53bb\u4f7f\u7528\u8fd1\u534a\u4e16\u7d00\u7684\u4f4e\u5291\u91cf\u7387(LDR)\u6280\u8853\u3002\u81e8\u5e8a\u7684\u5831\u544a\u986f\u793a\uff0cHDR\u7684\u7d50\u679c\u8207LDR\u76f8\u7576\u3001\u6216\u6bd4LDR\u7565\u597d\uff0c\u66f4\u91cd\u8981\u7684\u662f\u56b4\u91cd\u7684\u4f75\u767c\u75c7\u6709\u660e\u986f\u7684\u6e1b\u5c11\uff0c\u9019\u5176\u4e2d\u5fc5\u9808\u6b78\u56e0\u65bcHDR\u5c04\u6e90\u7684\u6539\u9032\u8207\u96fb\u5b50\u6a5f\u68b0\u8a2d\u5099\u7684\u73fe\u4ee3\u5316\uff0c\u4ee5\u53caHDR\u9069\u7576\u7684\u5206\u6b21\u6cbb\u7642\uff0cHDR\u8207LDR\u7684\u96a8\u6a5f\u6bd4\u8f03\u3001\u6700\u9069\u7576\u5206\u6b21\u539f\u5247\u3001\u76f4\u8178\u4f75\u767c\u75c7\u7684\u6e1b\u5c11\u662fHDR\u5c07\u4f86\u91cd\u8981\u7684\u8b70\u984c\u3002", "e": "Over the past one decade, there was a significant reverse in clinical attitude to the high-dose-rate (HDR) intracavitary brachytherapy for treatment of cervical carcinoma. Cumulative data from both meta-analysis and a few available randomized studies have shown that results of HDR were comparable with, or slightly superior to, that of the existing low-dose-rate (LDR) results. The improvement of treatment results, parallel with a significant reduction of severe rectal complication rate (Grade 3 and 4), has been attributed mainly to the improved physical/mechanical characteristics of HDR facility and the use of appropriately fractionated treatment. Prospective randominzed comparison of HDR vs. LDR, optimal dose-fractionation study, and prediction/prevention of rectal complication are the three central issues of HDR in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-77-84-a", "title": "Radiation Therapy in Extranodal Non-Hodgkin", "keywords": "\u9810\u5f8c\u56e0\u5b50;\u6025\u6027\u526f\u4f5c\u7528 Prognostic factors;Acute radiation toxicities", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u5404\u9805\u6709\u95dc\u982d\u9838\u90e8\u6dcb\u5df4\u7d50\u5916\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u764c\u4e4b\u9810\u5f8c\u56e0\u6578\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1984\u5e746\u6708\u81f31992\u5e744\u6708\uff0c\u5171\u670922\u4f4d\u7f79\u60a3\u6dcb\u5df4\u7d50\u5916\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u764c\u4e4b\u75c5\u60a3\u65bc\u672c\u79d1\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d\u7537\u602716\u4f4d\uff0c\u5973\u60276\u4f4d\uff0c\u5e74\u9f61\u4ecb\u65bc14\u81f379\u6b72\u4e4b\u9593\uff0c\u8ffd\u7d9c\u671f\u9593\u70ba6\u81f3133\u500b\u6708\u3002\u4f7f\u7528\u4e4b\u6a5f\u5668\u70ba\u9237\u516d\u5341\u9060\u9694\u6cbb\u7642\uff0c6\u621610\u767e\u842c\u4f0f\u7279\u4e4b\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u653e\u5c04\u6cbb\u7642\u7e3d\u5291\u91cf\u70ba2998\u81f37001 cGy\u3002\u7d93\u7531\u56de\u6eaf\u6574\u7406\u5176\u6cbb\u7642\u8a18\u9304\u53ca\u75c5\u6b77\u4f86\u7814\u7a76\u5404\u9805\u9810\u5f8c\u56e0\u6578\u3002\n\u7d50\u679c\uff1a\u672c\u6587\u5206\u6790\u76f8\u95dc\u4e4b\u9810\u5f8c\u56e0\u6578\uff0c\u767c\u73fe\u816b\u7624\u4e4b\u5206\u671f(Ann Arbor stage)\u70ba\u5f71\u97ff\u9810\u5f8c\u4e4b\u4e3b\u8981\u56e0\u7d20\u3002\u6574\u9ad4\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba57\uff05\u3002\u6cbb\u7642\u5931\u6557\u5305\u62ec\u6709\u516b\u540d\u75c5\u60a3\u767c\u751f\u9060\u7aef\u5fa9\u767c\uff0c\u4e09\u540d\u75c5\u60a3\u5728\u539f\u767c\u90e8\u4f4d\u5fa9\u767c\uff0c\u4ee5\u53ca\u4e00\u540d\u75c5\u60a3\u5728\u9130\u8fd1\u4e4b\u6dcb\u5df4\u7d50\u5fa9\u767c\u3002\u4e3b\u8981\u6b7b\u56e0\u70ba\u9060\u7aef\u5fa9\u767c\u3002\u816b\u7624\u5206\u671f\u7b2c\u4e00\u671f\u4e4b\u4e94\u5e74\u5b58\u6d3b\u671f\u53ef\u9054\u523088%\uff0c\u7b2c\u4e8c\u3001\u4e09\u3001\u56db\u671f\u4e4b\u4e94\u5e74\u5b58\u6d3b\u671f\u5247\u5206\u5225\u70ba53%,0%,0\uff05\u3002\u653e\u5c04\u6cbb\u7642\u4e4b\u6025\u6027\u526f\u4f5c\u7528\u4ee5\u9ecf\u819c\u53ca\u553e\u6db2\u817a\u70ba\u4e3b\u3002\n\u7d50\u8ad6\uff1a\u65e9\u671f\u982d\u9838\u90e8\u6dcb\u5df4\u7d50\u5916\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u764c\u4e4b\u6cbb\u7642\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u4ee5\u7372\u5f97\u76f8\u7576\u4e0d\u932f\u7684\u7d50\u679c\u3002\u81f3\u65bc\u5176\u4ed6\u9810\u5f8c\u56e0\u6578\u4e4b\u5206\u6790\u5247\u6709\u5f85\u672a\u4f86\u66f4\u591a\u8cc7\u79d1\u6536\u96c6\u3002", "e": "Purpose: To evaluate a variety of disease- and treatment-related variables that influence the prognosis of extranodal non-Hodgkin's lymphoma of the head and neck.\nMaterials and Methods: From June 1984 to April 1992, 22 patients with extranodal non-Hodgkin's lymphoma of the hoad and neck area had received radiotherapy at Taichung Veterans General Hospital. There were 16 males and 6 females between 14 and 79 years of age. The follow-up period ranged from 6 to 133 months. All patients were treated with Co-60 teletherapy machine, 6 MV or 10 MV linear accelerator. The radiation dose ranged from 2998 to 7001 cGy (mean: 4609 cGy). Prognostic factors such as the Ann Arbor stage, pathologic grading, number of involved sites, Waldeyer's ring involvement, age, sex, extent of radiation field, radiation dose, and LDH level were analyzed by retrospective review of the medical records.\nResults: The most common acute radiation reactions occurred at mucous membrane and salivary gland. The overall 5-year disease-specific survival rate was 57%. Treatment failures included distant relapse (8 patients), relapse in primary site (3 patients) and regional LN (1 patient). The major cause of death was distant relapse. The Ann Arbor stage was the only significant prognostic factor in this study. The 5-year disease-specific survival was excellent for stage I disease (88%) and the survival rates for stage II, Ill, and IV were 53%, 0%, and 0%, respectively.\nConclusion: Non-Hodgkin's lymphoma arising from extranodal sites in the head and neck area was uncommon. The most significant prognostic factor was extent of the disease (Ann Arbor stage). Proper management of patients with early stage non-Hodgkin's lymphoma of the head and neck area remains controversial. However, excellent survival for stage I non-Hodgkin's lymphoma in the head and neck arising from extranodal sites was achievable by radiation therapy in this study."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-85-91-a", "title": "Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital", "keywords": "\u9f3b\u54bd;\u6dcb\u5df4\u7624;\u816b\u7624;\u653e\u5c04\u6cbb\u7642;\u4e94\u5e74\u5b58\u6d3b\u7387 Nasopharynx;Lymphoma;Neoplasm;Radiotherapy;Five-year survival rate", "c": "\u76ee\u7684\uff1a\u56de\u9867\u904e\u53bb\u5341\u4e94\u5e74(1977-1993)\u5728\u81fa\u5927\u91ab\u9662\u60e1\u6027\u9f3b\u54bd\u6dcb\u5df4\u7624\u4e4b\u6cbb\u7642\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9019\u5341\u4e94\u5e74\u4e2d\u81fa\u5927\u91ab\u9662\u5171\u670940\u4f4d\u60e1\u6027\u9f3b\u54bd\u6dcb\u5df4\u7624\u4e4b\u75c5\u60a3\u3002\u5e74\u9f61\u5206\u4f48\u81ea13\u81f381\u6b72\uff0c\u7537\u3001\u5973\u6027\u75c5\u60a3\u540420\u4f4d\u3002\u7b2c\u4e00\u3001\u4e8c\u671f\u5404\u670918\u53ca22\u500b\u75c5\u4f8b\u3002\u4ee5\u7d44\u7e54\u75c5\u7406\u5b78\u800c\u8a00\uff0c\u4f4e \u3001\u4e2d\u3001\u9ad8\u7d1a\u5404\u670910\u300126\u53ca4\u4f4d\u30027\u4f4d\u75c5\u60a3\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c15\u4f4d\u75c5\u606f\u53ea\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c10\u4f4d\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u53ca\u5316\u5b78\u5408\u4f75\u6cbb\u7642\uff0c8\u4f4d\u75c5\u60a3\u672a\u63a5\u53d7\u4efb\u4f55\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u7b2c\u4e00\u4e8c\u671f\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba65.7\uff05\u53ca2.73\uff05\u3002\u4ee5Rappaport\u5206\u985e\u6cd5\u6642\uff0c\u7d50\u7bc0\u6027\u8207\u7030\u6f2b\u6027\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba 72.7%\u53ca33.5%\uff1b\u4ee5working formulation\u5206\u985e\u6642\uff0c\u4f4e\u3001\u4e2d\u3001\u9ad8\u7d1a\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba80.0%,39.0\uff05\u53ca50.0%\u3002\u653e\u5c04\u6cbb\u7642\uff0c\u5316\u5b78\u6cbb\u7642\u53ca\u5408\u4f75\u7642\u6cd5\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba100.0%,58.7%\u53ca30.0%\u3002\n\u7d50\u8ad6\uff1a\u6dcb\u5df4\u7624\u5c40\u9650\u65bc\u9f3b\u54bd\u4e4b\u6dcb\u5df4\u7624\u53ef\u7528\u653e\u5c04\u6cbb\u7642\u52a0\u4ee5\u63a7\u5236\u3002\u4ee5\u7d44\u7e54\u75c5\u7406\u5b78\u5206\u985e\u6642\uff0c\u4f4e\u7d1a\u6216\u7d50\u7bc0\u6027\u4e4b\u60e1\u6027\u9f3b\u54bd\u6dcb\u5df4\u7624\u53ef\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u3002\u800c\u4e2d\u7d1a\u6216\u7030\u6f2b\u6027\u4e4b\u60e1\u6027\u9f3b\u54bd\u6dcb\u5df4\u7624\u4f7f\u7528\u5316\u5b78\u6cbb\u7642\u6216\u5408\u4f75\u7642\u6cd5\uff0c\u5c0d\u75c5\u60a3\u4e4b\u5b58\u6d3b\u7387\u5247\u6709\u6240\u4ffe\u76ca\u3002", "e": "Purpose: To evaluate the therapeutic results of nasopharyngeal malignant lymphoma treated at NTUH over the past fifteen years (1979-1993).\nMaterials & Methods: Forty patients with malignant lymphoma of nasopharynx visited our hospital in the past fifteen years and their data were analyzed. The age of the patients ranged from 13 to 81 years old. There were 20 male patients and 20 female patients. Stage I and LI patients were 18 and 22, respectively. According to histopathologic classification, patients with low grade, intermediate grade and high grade malignant lymphoma were 10, 26 and 4, respectively. Seven patients received radical radiotherapy and 15 patients received chemotherapy. The remaining 10 patients were treated by combined chemotherapy and irradiation. Eight patients did not receive any treatment.\nResults: The actuarial five-year survival rates for nasopharyngeal malignant lymphoma patients with Stage I, II were 65.7% and 27.3%, respectively. When classified by the Rappaport classification, the actuarial five-year survival rates for patients of nodular type and diffuse type were 72.7% and 33.5%, respectively. The actuarial five-year survival rates for patients of Low grade, intermediate grade and high grade nasopharyngeal malignant lymphoma were 80.0%, 39.0%, and 50.0%, respectively. The actuarial five- year survival rates for patients treated with radiotherapy, chemotherapy and combined treatment modalities were 100.0%, 58.7%, and 30.0%, respectively.\nConclusion: Lymphoma clinically localized to nasopharynx can be cured by radiotherapy. When classified by histopathology, patients with low grade or nodular type can be successfully treated using local radiotherapy alone. Chemotherapy used as primary treatment (with or without adjuvant radiotherapy) may be benefit for intermediate grade or diffuse type patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-93-100-a", "title": "\u665a\u671f\u9f3b\u54bd\u764c\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u4e4b\u7814\u7a76\uff0d\u81fa\u4e2d\u69ae\u7e3d\u4e4b\u7d93\u9a57", "keywords": "\u540c\u6b65\u7684;\u5316\u5b78\u653e\u5c04\u6cbb\u7642;\u9f3b\u54bd\u764c Concurrent;Chemoradiotherapy;Nasopharyngeal carcinoma", "c": "\u76ee\u7684\uff1a\u9f3b\u54bd\u764c\u662f\u4e00\u7a2e\u597d\u767c\u65bc\u4e2d\u570b\u5357\u65b9\u7684\u764c\u75c7\uff0c\u50b3\u7d71\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e94\u5e74\u5b58\u6d3b\u7387\u7d045%\uff0c\u8fd1\u5e74\u4f86\u764c\u75c7\u6cbb\u7642\u8da8\u52e2\u662f\u5408\u4f75\u5f0f\u7642\u6cd5\uff0c\u9f3b\u54bd\u764c\u5c0d\u653e\u5c04\u7dda\u548c\u5316\u5b78\u6cbb\u7642\u90fd\u5f88\u654f\u611f\uff0c\u672c\u7814\u7a76\u63a2\u8a0e\u540c\u6b65\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u5c0d\u665a\u671f\u9f3b\u54bd\u764c\u7684\u4e4b\u53ef\u884c\u6027\u3001\u7642\u6548\u53ca\u526f\u4f5c\u7528\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5171\u6536\u96c680\u4f4d\u665a\u671f\u9f3b\u54bd\u764c\uff0c\u5176\u4e2d76\u4f8b(95%)\u5e7c\u5c6c\u65bc\u7b2c\u56db\u671f\u3002\u6700\u521d19\u4f8b\u63a5\u53d7\u50b3\u7d71\u5f0f\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\uff0c\u5373\u6bcf\u5929\u7167\u5c04\u4e00\u6b21\uff0c\u6bcf\u6b211.8-2.0 Gy\uff0c\u6bcf\u9031\u7167\u5c04\u4e94\u6b21\uff1b\u5176\u6b2161\u4f8b\u63a5\u53d7\u6211\u5011\u81ea\u884c\u8a2d\u8a08\u7684\u90e8\u4efd\u9ad8\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u65b9\u5f0f\uff1a\u7b2c\u4e00\u4e94\u3001\u516d\u9031\u6bcf\u5929\u4e0a\u4e0b\u5348\u5404\u7167\u4e00\u6b211.5 Gy\uff0c\u7b2c\u4e8c\u3001\u4e09\u3001\u56db\u9031\u6bcf\u5929\u7167\u5c04\u4e00\u6b21\uff0c\u6bcf\u6b211.8 Gy\uff0c\u7e3d\u5291\u91cf\u70ba72 Gy/45\u5206\u6b21\uff0f6\u9031\uff0c\u5982\u679c\u9047\u5230\u5047\u65e5\u6216\u6a5f\u5668\u6545\u969c\uff0c\u5247\u5229\u7528\u9031\u516d\u88dc\u7167\u6216\u5c07\u5291\u91cf\u5206\u6524\u65bc\u5176\u4ed6\u6cbb\u7642\u65e5\uff0c\u52d9\u5fc5\u65bc\u516d\u9031\u5167\u7d66\u4e8872 Gy\u3002\u540c\u6b65\u5316\u5b78\u6cbb\u7642\u63a1\u7528cisplatin\u548c5-FU\uff0c\u5728\u653e\u7642\u4e2d\u7b2c\u4e00\u548c\u7b2c\u4e94\u9031\u540c\u6642\u7d66\u4e88\u4e8c\u6b21\u5316\u7642\u3002\n\u7d50\u679c\uff1a80\u4f8b\u4e2d\u670977\u4f8b(96%)\u816b\u7624\u5b8c\u5168\u7de9\u89e3\uff0c3\u4f8b\u816b\u7624\u90e8\u4efd\u7de9\u89e3\u4f544% \uff0c\u816b\u7624\u53cd\u61c9\u7387\u9ad8\u9054100%\uff01\u75c5\u4eba\u7684\u6025\u6027\u526f\u4f5c\u7528\uff0c\u4e3b\u8981\u662f\u767d\u8840\u7403\u964d\u4f4e\u3001\u53e3\u8154\u9ecf\u819c\u767c\u708e\u53cd\u61c9\uff0856\uff05\u9054\u7b2c\u4e09\u7d1a\uff09\u3001\u9ad4\u91cd\u6e1b\u8f15\u2026\u7b49\u3002\u67095\u4f8b\u7b2c\u4e8c\u6b21\u5316\u7642\u56e0\u6bd2\u6027\u53cd\u61c9\u9808\u5ef6\u5f8c\u4e00\u9031\u7d66\u4e88\uff0c\u67092\u4f8b\u7b2c\u4e8c\u6b21\u5316\u7642\u53ea\u6253\u4e00\u534a\uff0c\u67092\u4f8b\u62d2\u7d55\u7b2c\u4e8c\u6b21\u5316\u7642\u3002\u653e\u5c04\u6cbb\u7642\u56e0\u6bd2\u6027\u53cd\u61c9\u4e2d\u65b7\u8d85\u904e\u4e00\u9031\u4ee5\u4e0a\u8005\u67097\u4f8b\uff0c\u5176\u4e2d1\u4f8b\u53ea\u7167\u5c04\u81f355.5 Gy\u5f8c\uff0c\u5c31\u62d2\u7d55\u7e7c\u7e8c\u653e\u7642\u3002\u8fc4\u4eca\u8ffd\u8e64\u6642\u9593\u5df239\u81f366\u500b\u6708\uff08\u4e2d\u503c\u8ffd\u8e64\u6642\u959348\u500b\u6708\uff09\uff0c\u7d50\u679c23\u4f8b\u5df2\u6b7b\u4ea1\uff0c57\u4eba\u4ecd\u5b58\u6d3b\u3002\u6b7b\u4ea1\u75c5\u4f8b\u4e2d\uff0c17\u4f8b\u56e0\u9f3b\u54bd\u764c\u800c\u6b7b\uff0816\u4f8b\u6b7b\u65bc\u9060\u8655\u8f49\u79fb\uff09\uff0c\u7e3d\u8a08\u76ee\u524d\u6cbb\u7642\u5931\u6557\u8005\u670924\u4f8b\uff0c\u55ae\u7368\u9f3b\u54bd\u90e8\u5fa9\u767c3\u4f8b\uff0c\u9f3b\u54bd\u90e8\u548c\u9838\u90e8\u6dcb\u5df4\u540c\u6642\u5fa9\u767c\u80054\u4f8b\uff0c1\u4f8b\u767c\u751f\u9838\u90e8\u6dcb\u5df4\u5fa9\u767c\u5408\u4f75\u9060\u8655\u8f49\u79fb\uff0c\u5176\u4ed616\u4f8b\u90fd\u662f\u9060\u8655\u8f49\u79fb\uff0c\u56db\u5e74\u9f3b\u54bd\u90e8\u63a7\u5236\u738787.5%\u5462\uff0c\u9838\u90e8\u63a7\u5236\u738791.86%\uff0c\u9060\u8655\u8f49\u79fb\u63a7\u5236\u738776.2%\uff0c\u56db\u5e74\u7e3d\u5b58\u6d3b\u7387\u70ba71.9%\uff0c\u56db\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba66.3\uff05\u3002\n\u7d50\u8ad6\uff1a\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642\u5c0d\u665a\u671f\u9f3b\u54bd\u764c\u662f\u53ef\u884c\u4e14\u5f88\u6709\u6548\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u9060\u8655\u8f49\u79fb\u662f\u6cbb\u7642\u5931\u6557\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u653e\u7642\u5f8c\u518d\u8ffd\u52a0\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u4ee5\u6e1b\u5c11\u9060\u8655\u8f49\u79fb\u767c\u751f\uff0c\u63d0\u9ad8\u5b58\u6d3b\u7387\uff0c\u503c\u5f97\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Purpose: Nasopharyngeal carcinoma (NPC) is a radio- and chemosensitive tumor. We evaluate the feasibility, response and toxicities of concurrent chemoradiotherapy for advanced NPC.\nMaterials and Methods: A total of 80 patients with advanced NPC (95% belong to AJCC stage IV) were treated by concurrent chemoradiotherapy. Radiotherapy was delivered using a telecobalt unit and 10 MV X-rays and by conventional fractionation (1.8-2.0 Gy/fraction, 5 fractions a week) for 19 patients and partially hyperfractionated accelerated schedule (1.5 Gy B.I.D. x 1 week+ 1.8 Gy Q.D. x 3 weeks + 1.5 Gy B. I. D. x 2 weeks) for 61 patients. Chemotherapy with cisplatin and 5-FU were given concurrently during the first and fifth weeks of radiotherapy.\nResults: The major toxicities were mucositis, leucopenia, weight loss, and skin reaction. The 2nd cycle concurrent chemotherapy should be delayed for one week in 5 patinets. Two patients refused the 2nd cycle chemotherapy and another 2 patients received incomplete dose of 2nd cycle chemotherapy. Seven patients interrupted radiotherapy for more than one week doe to toxicities. One patient refused further radiotherapy after 55.5 Gy. Complete response was noted in 77 cases (96%) and partial response 4%, with an overall response rate of 100%. After a median follow-up time of 4 years (39-66 months), the nasopharynx disease-free, neck disease- free, and distant metastasis disease-free survivals are 87.5%, 9 1.8%, and 76.2% irrespectively. The 4-year over-alt survival and disease-free survival are 71.9% and 66.3%. Patients who failed were due to distant metastases.\nConclusion: Our data indicated that concurrent chemoradiotherapy for advanced NPC is both feasible and effective, with acceptable toxicities. Post-radiation adjuvant chemotherapy to eradicate subclinical micrometastasis should be further studied."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-101-107-a", "title": "\u9f3b\u54bd\u764c\u8207\u6cbb\u7642\u524dEB\u75c5\u6bd2VCA\u6297\u9ad4\u6307\u6578\u7684\u95dc\u4fc2", "keywords": "\u9f3b\u54bd\u764c;EB\u75c5\u6bd2;VCA\u6297\u9ad4;\u9810\u5f8c Nasopharyngeal carcinoma;Eli virus;Viral capsid antigen;Prognosis", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u653e\u5c04\u7dda\u6cbb\u7642\u524dEB\u75c5\u6bd2VCA\u6297\u9ad4\u6307\u6578\u548c\u9f3b\u54bd\u764c\u60a3\u8005\u81e8\u5e8a\u8868\u5fb5\u7684\u95dc\u4fc2\uff0c\u4e26\u5206\u6790\u6297\u9ad4\u6307\u6578\u9ad8\u4f4e\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u81ea1991\u5e744\u6708\u81f31995\u5e749\u6708\uff0c\u6709101\u4f4d\u60a3\u8005\u65bc\u6cbb\u7642\u524d\u4e00\u500b\u6708\u5167\u66fe\u63a5\u53d7EB\u75c5\u6bd2VCA\u6297\u9ad4\u7684\u6e2c\u8a66\u3002\u6211\u5011\u4f5c\u6297\u9ad4\u5e7e\u4f55\u5e73\u5747\u6307\u6578\u53ca\u8840\u6e05\u967d\u6027\u7387\u5c0d\u6027\u5225\u3001\u5e74\u9f61\u3001WHO\u7d44\u7e54\u5b78\u5f62\u614b\u548c\u81e8\u5e8a\u5206\u671f\u7b49\u81e8\u5e8a\u56e0\u7d20\u95dc\u4fc2\u7684\u5206\u6790\uff0c\u4e26\u5206\u6790\u9f3b\u54bd\u764c\u4e4b\u9810\u5f8c\u56e0\u5b50\u53caEB\u75c5\u6bd2VCA\u6297\u9ad4\u503c\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\n\u7d50\u679c\uff1a101\u4f4d\u60a3\u8005VCA-IgA\u53caIgG\u6297\u9ad4\u7684\u5e7e\u4f55\u5e73\u5747\u6307\u6578\u5206\u5225\u70ba102\u53ca1316 \uff0c\u800c\u8840\u6e05\u967d\u6027\u7387\u5206\u5225\u70ba87.00\uff05\u53ca91.70%\u3002 VCA-lgA\u5e7e\u4f55\u5e73\u5747\u6307\u6578\u5728\u5973\u6027\u660e\u986f\u8f03\u9ad8(p=0.040), IgA\u8840\u6e05\u967d\u6027\u7387\u5247\u65bc\u5e74\u9577\u53ca\u75be\u75c5\u671f\u5225\u9ad8\u7684\u60a3\u8005\u6709\u660e\u986f\u504f\u9ad8(p=0.047\u53ca0.015)\u3002\u800cVCA-IgG\u6297\u9ad4\u548c\u9019\u4e9b\u81e8\u5e8a\u8868\u5fb5\u4e26\u7121\u5bc6\u5207\u95dc\u4fc2\u3002\u9f3b\u54bd\u764c\u9810\u5f8c\u548c\u6027\u5225\u53ca\u75be\u75c5\u671f\u5225\u6709\u95dc\u3002\u800cVCA\u6297\u9ad4\u967d\u6027\u8207\u5426\u548c\u6297\u9ad4\u9ad8\u4f4e\u7686\u8207\u9810\u5f8c\u7121\u95dc\u3002\n\u7d50\u8ad6\uff1a\u96d6\u7136\u6cbb\u7642\u524d\u7684VCA\u6297\u9ad4\u5e7e\u4f55\u5e73\u5747\u6307\u6578\u6709\u96a8\u671f\u5225\u589e\u52a0\u800c\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u4f46\u7121\u660e\u986f\u5dee\u7570\u3002\u800cVCA-IgA\u8840\u6e05\u967d\u6027\u7387\u548c\u5e74\u9f61\u3001\u4e0b\u671f\u5225\u53caAJCC\u5206\u671f\u6709\u76f8\u967d\u6027\uff0c\u6b64\u5916\uff0cVCA\u6297\u9ad4\u503c\u4e26\u4e0d\u53ef\u4f5c\u70ba\u63a8\u6e2c\u9810\u5f8c\u7684\u56e0\u7d20\u3002", "e": "-Purpose: To assess the relationship between the pre-RJT EBV VCA titers and the characteristics of the patients with NPC and to analyze the prognostic value of the titers\nMaterials and Methods: From April 1991 to September 1995, 101 patients with nasopharyngeal carcinoma who received the examination of EBV VGA titers before radiotherapy were reviewed. We analyzed the correlation between titers and clinical characteristics, including genders, age, WHO histologic types and stages. We also tried to find the role of these titers in predicting prognosis.\nResults: We found that the geometric mean titers of EBV VCA-IgA and IgG of these 101 patients were 102 and 1136 and the seropositive rates were 87% and 91.7%, respectively. The GMTs of IgA and IgG trended to be increased in advanced stages, but no significant difference in statistics. There is no significant difference of GMT5 in other clinical features, except IgA titer in sex. The seropositive rates were higher in elders, higher T stage and advanced stage. The role in predicting prognosis was not found.\nConclusions: The pre-treatment EBV VGA GMTs increased in advanced stages, but the difference was not significant and they were not proper factors in predicting prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-109-115-a", "title": "Postoperative Radiotherapy for Malignant Parotid Gland Tumors", "keywords": "\u60e1\u6027\u816e\u817a\u816b\u7624;\u624b\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642 Malignant parotid gland tumors;Postoperative radiotherapy", "c": "Purpose: To evaluate the treatment results and analyze the prognostic factors of postoperative radiotherapy for malignant parotid gland tumors.\nMaterials and Methods: From January 1984 to December 1993, 42 patients with malignant parotid gland tumors received a complete course of radiotherapy at Taichung Veterans General Hospital. Twenty-eight of the 42 patients were treated with postoperative radiotherapy. There were 12 males and 16 females, between 15 and 78 years old (median: 46). The numbers of the patients in stage I to IV were 8, 6, 3, and 11, respectively. The types of cancer included mucoepidermoid carcinoma,8; adenocarcinoma,6; epidermoid caroinoma,3; adenoid cystic carcinoma,3; malignant mixed tumor,2; adenosquamous cell caroinoma,2; undifferentiated caroinoma,2; acinic cell carcinoma,1; and lymphoepithelioma-like carcinoma, 1. Most patients were treated with Go-60 using unilateral wedge pair fields and an electron beam local boost. The dose of radiotherapy was 57 to 72 Gy (median: 60 Gy).\nResults: The patients were followed up till January 1997. The 5-year and 10-year overall survival rates were 78% and 65%, respectively. The 5-year local control rate was 89%. Three patients developed local recurrences at 3-12 months, 6 patients developed distant metastases at 3-69 months, and 2 had combined local recurrences and distant metastases. Most failure occurred in the first year after surgery. Five-year survival rates for stage Ito IV were 100%, 83%, 100%, and 55%, respectively. Lymph node involvement, stage, and histology were the significant prognostic factors (P\uff1c0.05).\nConclusions: Postoperative radiotherapy was effective in eradicating microscopic residual tumors and yielded a good local control rate. Lymph node involvement, stage, and histology were the significant prognostic factors. Lymph node involvement, stage IV tumors, and adenocarcinoma indicated a relatively poor prognosis.", "e": "Purpose: To evaluate the treatment results and analyze the prognostic factors of postoperative radiotherapy for malignant parotid gland tumors.\nMaterials and Methods: From January 1984 to December 1993, 42 patients with malignant parotid gland tumors received a complete course of radiotherapy at Taichung Veterans General Hospital. Twenty-eight of the 42 patients were treated with postoperative radiotherapy. There were 12 males and 16 females, between 15 and 78 years old (median: 46). The numbers of the patients in stage I to IV were 8, 6, 3, and 11, respectively. The types of cancer included mucoepidermoid carcinoma,8; adenocarcinoma,6; epidermoid caroinoma,3; adenoid cystic carcinoma,3; malignant mixed tumor,2; adenosquamous cell caroinoma,2; undifferentiated caroinoma,2; acinic cell carcinoma,1; and lymphoepithelioma-like carcinoma, 1. Most patients were treated with Go-60 using unilateral wedge pair fields and an electron beam local boost. The dose of radiotherapy was 57 to 72 Gy (median: 60 Gy).\nResults: The patients were followed up till January 1997. The 5-year and 10-year overall survival rates were 78% and 65%, respectively. The 5-year local control rate was 89%. Three patients developed local recurrences at 3-12 months, 6 patients developed distant metastases at 3-69 months, and 2 had combined local recurrences and distant metastases. Most failure occurred in the first year after surgery. Five-year survival rates for stage Ito IV were 100%, 83%, 100%, and 55%, respectively. Lymph node involvement, stage, and histology were the significant prognostic factors (P\uff1c0.05).\nConclusions: Postoperative radiotherapy was effective in eradicating microscopic residual tumors and yielded a good local control rate. Lymph node involvement, stage, and histology were the significant prognostic factors. Lymph node involvement, stage IV tumors, and adenocarcinoma indicated a relatively poor prognosis."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-117-124-a", "title": "Endocrine Dysfunction in Patients with Nasopharyngeal Carcinoma after Radiotherapy -A Prospective Study with 10 Years Follow-Up", "keywords": "\u653e\u5c04\u6cbb\u7642;\u9f3b\u54bd\u764c;\u5167\u5206\u6ccc\u529f\u80fd\u5931\u8abf Radiotherapy;Nasopharyngeal carcinoma;Endocrine dysfunction", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u63a2\u8a0e\u9f3b\u54bd\u764c\u75c5\u4eba\u5176\u5167\u5206\u6ccc\u529f\u80fd\u5728\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u4e4b\u5f8c\u7684\u9577\u671f\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u70ba\u4e00\u524d\u77bb\u6027\u7814\u7a76\uff0c\u6e2c\u91cf5\u4f4d\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u5305\u62ec\u4e09\u4f4d\u7537\u6027\u53ca\u4e8c\u4f4d\u5973\u6027\u606f\u8005\uff0c\u65bc\u653e\u5c04\u6cbb\u7642\u524d\u3001\u653e\u7642\u5f8c1\u5e74\u534a\u53ca\u653e\u7642\u5f8c10\u5e74\u7684\u5167\u5206\u6ccc\u529f\u80fd\u3002\u4f30\u8a08\u4e0b\u8996\u4e18\u3001\u8166\u4e0b\u5782\u9ad4\u53ca\u7532\u72c0\u817a\u6240\u63a5\u53d7\u7684\u653e\u7642\u5291\u91cf\u5404\u70ba49.4-66.6 Gy\u300150.9-70.2 Gy\u300146.8 Gy\u3002\u5167\u5206\u6ccc\u529f\u80fd\u6e2c\u9a57\u5305\u62ec\u751f\u9577\u6fc0\u7d20\u3001\u814e\u4e0a\u817a\u76ae\u8cea\u7d20\u5c0d\u80f0\u5cf6\u7d20\u8010\u53d7\u6027\u6e2c\u9a57\uff0c\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u5c0dTRH\uff0c\u6027\u817a\u6fc0\u7d20\u5c0dLHRH\u7b49\u523a\u6fc0\u8a66\u9a57\uff0c\u53ca\u6ccc\u4e73\u6fc0\u7d20\u3001\u776a\u56fa\u916e\u3001\u52d5\u60c5\u6fc0\u7d20\u3001\u7532\u72c0\u817a\u7d20\u7b49\u4e4b\u5f8c\u57fa\u790e\u6fc3\u5ea6\u3002\n\u7d50\u679c\uff1a\u5728\u653e\u764210\u5e74\u5f8c\u7684\u5167\u5206\u6ccc\u529f\u80fd\u6e2c\u8a66\u4e2d\uff0c5\u4f4d\u75c5\u4eba\u751f\u9577\u6fc0\u7d20\u7686\u6709\u660e\u986f\u6e1b\u9000\uff0c2\u4f4d\u75c5\u4eba\u6709\u8f03\u9ad8\u7684\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u53ca\u81e8\u5e8a\u7684\u4f4e\u7532\u72c0\u817a\u7d20\u75c7\u72c0\uff0c\u800c\u5728TRH\u8a66\u9a57\u4e2d\uff0c\u4e09\u4f4d\u6709\u8f03\u9ad8\u7684\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u7684\u53cd\u61c9\uff0c\u800c\u4e00\u4f4d\u6709\u5ef6\u9072\u7684\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u7684\u53cd\u61c9\u3002\u6709\u4e00\u4f4d\u5973\u6027\u60a3\u8005\u5728\u653e\u7642\u5f8c\u767c\u751f\u7121\u6708\u7d93\u75c7\u72c0\uff0c\u4f75\u6709\u4f4e\u814e\u4e0a\u76ae\u8cea\u7d20\u53cd\u61c9\u3002\n\u7d50\u8ad6\uff1a\u5167\u5206\u6ccc\u529f\u80fd\u5931\u8abf\uff0c\u5728\u7d93\u904e\u653e\u7642\u4e4b\u5f8c\u7684\u9f3b\u54bd\u764c\u75c5\u4eba\u662f\u76f8\u7576\u5e38\u898b\u7684\uff0c\u653e\u5c04\u6cbb\u7642\u61c9\u76e1\u91cf\u907f\u514d\u50b7\u5bb3\u5230\u4e0b\u8996\u4e18\u3001\u8166\u4e0b\u5782\u9ad4\u53ca\u7532\u72c0\u817a\u3002\u9069\u6642\u7684\u6aa2\u6e2c\u5167\u5206\u6ccc\u529f\u80fd\u53ca\u88dc\u5145\u6fc0\u7d20\u662f\u9f3b\u54bd\u764c\u75c5\u4eba\u6cbb\u7642\u5f8c\u7684\u8ffd\u8e64\u6642\u8a72\u6ce8\u610f\u7684\u4e8b\u9805\u3002", "e": "Purpose: To investigate the late endocrine dysfunction in patients with nasopharyngeal carcinoma (NPC) following radiotherapy (RT).\nMaterials & Methods: The endocrine function in 5 NPC patients (3 male and 2 female) treated with RT alone was analyzed in this study. Estimated doses to the hypothalamus, pituitary, and thyroid were 49.4-66.6 Gy, 50.9-70.2 Gy and 46.8 Gy, respectively. Growth hormone (GH), cortisol response to insulin tolerance test (In), thyroid-stimulating hormone (TSH) response to TRH and gonadotropin response to LHRH were measured before, at 1.5 years and at 10 years after RT. The basal levels of prolactin, estradiol or testosterone, total triiodothyronine, and thyroxine were also measured at these time points.\nResults: The pre-treatment endocrine function was normal in all patients. All of them developed GH deficiency and 2 patients with clinical symptoms of hypothyroidism had increased basal level of TSH at 10 years after RT. TSH responses to TRH were increased in 3 patients and delayed in 1 patient. One female patient developed amenorrhea and had decreased cortisol response to ITT. No hyperprolactinemia was observed in these patients.\nConclusion: Endocrine dysfunction is a common complication in NPC patients following RT. The hypothalamic-pituitary region and thyroid gland should be shielded as much as possible if the possibility of cure is not compromised. Regular endocrine assessment and replacement of deficient hormone might be indicated in NPC patients following RT."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-125-131-a", "title": "\u5a66\u5973\u8179\u80a1\u6dcb\u5df4\u7d50\u4e4b\u653e\u5c04\u6cbb\u7642\u6280\u8853", "keywords": "\u8179\u80a1\u6dcb\u5df4\u7d50;\u653e\u5c04\u6cbb\u7642 Inguinal lymph node;Radiotherapy", "c": "\u524d\u8a00\uff1a\u665a\u671f\u7684\u6703\u9670\u90e8\u816b\u7624\u5e38\u6703\u5408\u4f75\u6709\u8179\u80a1\u6dcb\u5df4\u7d50\u7684\u8f49\u79fb\uff0c\u56e0\u6b64\u8179\u80a1\u6dcb\u5df4\u7d50\u7684\u6cbb\u7642\u5c0d\u8655\u7406\u665a\u671f\u7684\u6703\u9670\u90e8\u816b\u7624\u4f54\u6709\u975e\u5e38\u91cd\u8981\u7684\u89d2\u8272\u3002\u82e5\u653e\u5c04\u6cbb\u7642\u7d66\u4e88\u8179\u80a1\u6dcb\u5df4\u7d50\u8db3\u5920\u7684\u8f3b\u5c04\u5291\u91cf\u53ca\u6df1\u5ea6\uff0c\u63a7\u5236\u7387\u5e7e\u4e4e\u6703\u548c\u624b\u8853\u6709\u4e00\u6a23\u7684\u6548\u679c\u4e14\u526f\u4f5c\u7528\u8f03\u5c0f\u3002\u4f46\u6cbb\u7642\u592a\u6df1\u4ee5\u81f4\u65bc\u8179\u80a1\u6e9d\u7684\u5291\u91cf\u592a\u9ad8\u6642\u537b\u53c8\u6709\u589e\u52a0\u80a1\u95dc\u7bc0\u9aa8\u6298\u7684\u5371\u96aa\u3002\u56e0\u6b64\u5982\u4f55\u62ff\u634f\u6cbb\u7642\u6548\u7528(therapeutic ratio)\uff0c\u662f\u7528\u653e\u5c04\u7dda\u4f86\u6cbb\u7642\u8179\u80a1\u6e9d\u6dcb\u5df4\u7d50\u7684\u91cd\u8981\u8ab2\u984c\u3002\u6211\u5011\u505a\u4e86\u5a66\u5973\u8179\u80a1\u6dcb\u5df4\u7d50\u6df1\u5ea6\u7684\u5206\u6790\uff0c\u4e26\u63a2\u8a0e\u53ef\u80fd\u8f03\u597d\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\n\u6750\u6599\u53ca\u65b9\u6cd5\uff1a\u6211\u5011\u96a8\u6a5f\u62bd\u9a5765\u4f4d\u5728\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u653e\u5c04\u6cbb\u7634\u7684\u5a66\u764c\u60a3\u8005\uff0c\u6aa2\u8996\u5176\u56db\u689d\u80a1\u8840\u7ba1\u7684\u6df1\u5ea6\u4f86\u4ee3\u8868\u8179\u80a1\u6dcb\u5df4\u7d50\u7684\u53ef\u80fd\u6df1\u5ea6\u3002\u53e6\u5916\u6211\u5011\u4f7f\u7528\u96fb\u8166\u8a08\u5283\u7cfb\u7d71\u4f86\u8a08\u7b97\u4e0d\u540c\u80fd\u91cf\u7684\u5149\u5b50\u5c04\u7dda\u3001\u96fb\u5b50\u5c04\u7dda\u53ca\u4e0d\u7b49\u6bd4\u91cd\u4e4b\u5149\u5b50\u3001\u96fb\u5b50\u4e4b\u7d44\u5408\u6240\u5f97\u4e4b\u5291\u91cf\u5206\u5e03\u60c5\u6cc1\u3002\n\u7d50\u679c\uff1a\u7d93\u904e\u6e2c\u91cf\uff0c65\u4f4d\u5973\u75c5\u4eba\u7684\u8179\u80a1\u6dcb\u5df4\u7d50\u53ef\u80fd\u7684\u6df1\u5ea6\uff0c\u5f9e1\u81f36.5\u516c\u5206\uff0c\u5e73\u5747\u662f2.49\u516c\u5206\u3002\u4e2d\u9593\u503c\u70ba3.75\u516c\u5206\u3002\u6700\u6df1\u8655\u5f9e2.5\u81f38.8\u516c\u5206\uff0c\u5e73\u5747\u662f4.46\u516c\u5206\uff0c\u4e2d\u9593\u503c\u662f5.65\u516c\u5206\u3002\u5728\u6cbb\u76423\u516c\u5206\u4ee5\u4e0b\u7684\u6df1\u5ea6\uff0c\u96fb\u5b50\u5c04\u7dda\u6216\u8a31\u662f\u4e0d\u932f\u7684\u9078\u64c7\u3002\u8981\u6cbb\u76425\u516c\u5206\u7684\u539a\u5ea6\u4ee5\u4e0a\u6642\uff0c\u4f7f\u752810-12 MeV\u96fb\u5b50\u5c04\u7dda\u5408\u4f756 MV\u5149\u5b50\u5c04\u7dda\uff0c\u53ef\u4ee5\u57285\u516c\u5206\u5f8c\uff0c\u5291\u91cf\u4fbf\u4e0b\u964d\u4e8620%\u4ee5\u4e0a\u7684\u80fd\u91cf\uff0c\u800c\u80fd\u4f7f\u80a1\u95dc\u7bc0\u7684\u8f3b\u5c04\u5291\u91cf\u4e0d\u6703\u592a\u9ad8\u3002\n\u7d50\u8ad6\uff1a\u8179\u80a1\u6e9d\u6dcb\u5df4\u7d50\u7684\u653e\u5c04\u6cbb\u7642\u9700\u8981\u505a\u500b\u5225\u7684\u8003\u91cf\uff0c\u56e0\u4e0d\u540c\u7684\u539a\u5ea6\u505a\u4e0d\u540c\u65b9\u5f0f\u7684\u6cbb\u7642\uff0c\u4ee5\u671f\u9054\u5230\u6700\u4f73\u7684\u6cbb\u7642\u6548\u679c\uff0c\u540c\u6642\u80fd\u6709\u6700\u5c0f\u7684\u526f\u4f5c\u7528\u3002", "e": "Purpose: irradiation to inguinal lymph node had a very important role to treat advanced stage perineal tumor for it had high incideoce of inguinal lymph node metastasis. It needs great caution to irradiate the ingoinal area. To irradiate with inadequate depth will cause poor control rate but too deep will lead risk of femoral head or neck fracture. We evaluate the depth of inguinal lymph nodes and propose the possible better irradiation method.\nMaterial and Methods: We reviewed the CT films of sixty-five gynecological cancer patients who received radiotherapy to find the possible depth of inguinal nodes - the depth of four femoral vessels. We also calculated the irradiation dose distribotion by using different energy of photon beam, electron beam and various combination of photon and electron beams.\nResults: The most superficial depth of inguinal lymph node ranged from 1 cm to 6.5 cm; the median was 3.75 and the mean was 2.49 cm. The most deep depth of inguinal lymph node ranged from 2.5 to 8.8 cm; the median was 5.65 cm and the mean was 4.46 cm. Using the photon beam to treat the inguinal will cause too much radiation dose to femoral head area. High energy electron was a good choice to treat the lesion with 3 cm depth without too much hot spot. To treat the depth of 5 cm, using the combination of 6 MV photon beam and high energy electron beam can get much homogenous dose distribution but also can reduce more than 20 % of dose to the femoral head area.\nConclusion: It needs individual treatment plan according to the different depth to irradiate the inguinal lymph node area. To treat with appropriate depth with proper radiation modality not only can get good control but also to reduce the complication as much as possible."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-133-137-a", "title": "Leipzig Applicators\u4e4b\u5291\u91cf\u7279\u6027", "keywords": "\u8fd1\u63a5\u6cbb\u7642;Leipzig Applicator;\u5291\u91cf\u5b78 Brachytherapy;Leipzig applicator;Dosimetry", "c": "\u76ee\u7684\uff1aLeipzig Applicators\u70baNucletron Micro-selectron^192 lr\u9ad8\u5291\u91cf\u7387\u5f8c\u8377\u6cbb\u7642\u6a5f\u914d\u4ef6\u4e4b\u4e00\uff0c\u4f9d\u5c04\u6e90\u4e4b\u65b9\u4f4d\u53ef\u5206\u70ba\u76f4\u7acb\u5f0f\u53ca\u6c34\u5e73\u5f0f\u4e8c\u7a2e\u578b\u5f0f\uff0c\u53c8\u4f9d\u5176\u53e3\u5f91\u5927\u5c0f\u5404\u53ef\u5206\u70ba\u4e00\u3001\u4e8c\u53ca\u4e09\u516c\u5206\u4e4b\u88dd\u7642\u7ba1\u3002\u70ba\u4e86\u89e3\u6b64\u578b\u88dd\u7642\u7ba1\u7684\u81e8\u5e8a\u5291\u91cf\u5b78\u7279\u6027\uff0c\u672c\u5be6\u9a57\u5c07\u91cf\u6e2c\u4e94\u7a2e\u7279\u6027\uff0c\u5206\u5225\u70ba\uff1a\u5e7e\u4f55\u7d50\u69cb\u3001\u76f8\u5c0d\u8f38\u51fa\u3001\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u3001\u7b49\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u53ca\u771f\u5be6\u77e2\u72c0\u9762\u8f3b\u5c04\u6d29\u6f0f\u60c5\u5f62\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5\u9ad8\u7cbe\u5bc6\u5ea6\u6e38\u6a19\u5c3a\u91cf\u53d6\u5404\u88dd\u7642\u7ba1\u4e4b\u5e7e\u4f55\u7d50\u69cb\u3002\u76f8\u5c0d\u8f38\u51fa\u5247\u4ee5HN.E.0.03 cc\u5e73\u677f\u578b(type:2534)\u6e38\u96e2\u8154\u9023\u63a5lonex Dosemaster 5590\u96fb\u4f4d\u8a08\uff0c\u52a0\u4e0a3 mm\u589e\u5efa\u5c64\u4e88\u4ee5\u6e2c\u91cf\uff0c\u4e26\u6b78\u4e00\u5230\u5728\u5168\u5047\u9ad4\u5167\u76f8\u7b49\u8ddd\u96e2\u6240\u6e2c\u5f97\u7684\u8f38\u51fa\u3002\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u53ca\u7b49\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u5247\u4ee5Scanditronix RFA-300\u6c34\u5047\u9ad4\u9023\u63a5p-\u578b\u96fb\u5b50\u5c04\u675f\u534a\u5c0e\u9ad4\u5075\u6e2c\u5668\u5728\u6c34\u4e2d\u6e2c\u91cf\u800c\u5f97\uff0c\u8f3b\u5c04\u6d29\u6f0f\u91cf\u7684\u6e2c\u91cf\u5247\u65bcKodak V-tilm\u4e2d\u9593\uff0c\u4f9d\u88dd\u7642\u7ba1\u4e4b\u5916\u5f62\u6316\u7a7a\uff0c\u5c07\u5e95\u7247\u7f6e\u65bc\u88dd\u7642\u7ba1\u77e2\u72c0\u9762\uff0c\u4e0a\u4e0b\u5404\u7f6e0.5 cm bolus\u4f5c\u589e\u5efa\uff0c\u4ee5\u6e2c\u91cf\u771f\u5be6\u77e2\u72c0\u9762\u4e4b\u8f3b\u5c04\u6d29\u6f0f\u91cf\u3002\n\u7d50\u679c\uff1a\u6c34\u5e73\u5f0f\u88dd\u7642\u7ba1\u4e4b\u8f38\u51fa\u589e\u52a0\u7d0410%\uff0c\u76f4\u7acb\u5f0f\u88dd\u7642\u7ba1\u5247\u964d\u4f4e\u7d049%\u3002\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2\uff1a\u6c34\u5e73\u5f0f\u88dd\u7642\u7ba1\u70ba1.93cm\uff0c\u76f4\u7acb\u5f0f\u5247\u70ba1.74cm\u3002\u76f4\u7acb\u5f0f\u88dd\u7642\u7ba1\u4e4b\u7b49\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u4e2d\u5fc3\u8ef8\u6709\u51f9\u9677\u60c5\u5f62\uff0c\u6c34\u5e73\u5f0f\u88dd\u7642\u7ba1\u4e4b\u8f3b\u5c04\u6d29\u6f0f\u91cf\u70ba\u6700\u9ad8\u5291\u91cf\u9ede\u4e4b30\uff05\u3002\u4f4d\u65bc\u88dd\u7642\u7ba1\u7684\u9802\u90e8\uff0c\u800c\u76f4\u7acb\u5f0f\u4e4b\u8f3b\u5c04\u6d29\u6f0f\u91cf\u70ba\u6700\u9ad8\u5291\u91cf\u9ede\u4e4b20%\uff0c\u4f4d\u65bc\u88dd\u7642\u7ba1\u7684\u5074\u90e8\u3002\n\u7d50\u8ad6\uff1aLeipzig applicators\u7531\u65bc\u9ad4\u7a4d\u5c0f\uff0c\u9069\u5408\u65bc\u4e00\u4e9b\u5c0f\u7bc4\u570d\u76ae\u819a\u764c\uff0c\u53e3\u8154\u764c\u3002\u53ca\u5176\u4ed6\u764c\u75c7\u4e4b\u6cbb\u7642\u3002\u7531\u6e2c\u91cf\u7684\u7d50\u679c\u767c\u73fe\uff1a\u767e\u5206\u6df1\u5ea6\u5291\u91cf\u53ef\u7528\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2\u4e88\u4ee5\u6e96\u78ba\u4f30\u7b97\u81f320\uff05\u5291\u91cf\u6df1\u5ea6\uff0c\u76f4\u7acb\u5f0f\u8207\u6c34\u5e73\u5f0f\u88dd\u7642\u7ba1\u7684\u8f38\u51fa\u8b8a\u5316\u905420%\uff0c\u6295\u4e88\u5291\u91cf\u6642\u61c9\u7279\u5225\u6ce8\u610f\u3002\u8f3b\u5c04\u6d29\u6f0f\u91cf\u7684\u6e2c\u91cf\u63d0\u4f9b\u4f7f\u7528\u8005\u4e86\u89e3\u88dd\u7642\u7ba1\u7684\u9632\u8b77\u80fd\u529b\u53ca\u71b1\u9ede\u6240\u5728\u4f4d\u7f6e\uff0c\u4ee5\u4f9b\u81e8\u5e8a\u61c9\u7528\u6642\u4e4b\u53c3\u8003\u3002", "e": "Purpose: Leipzig applicators are one kind of accessories of Nucletron (superscript 192)1r High-Dose Rate remote afterloading system. According to the orientation of the source axis in the applicator, it can be divided into two kinds: horizontal and vertical ones. There are three kinds of diameter for each type of applicator: 1, 2 and 3 cm. Five characteristics of the applicator will be measured for clinical application. They are geometric structure, relative output, percent depth dose, isodose curve distributions and real sagittal plane radiation leakage test.\nMaterials and Methods: High accuracy calipers was used to measure the geometric structure of the applicator The relative outputs were measured with N.E. 0.03 cc. parallel-plate ionization chamber connected to Ionex Dosemaster 2590 in RMI solid phantom with 3 mm build-up layer The outputs were normalized to the dose in full phantom that was measured at the same source-to-chamber distance. The percentage depth dose and isodose curve distributions were measured with Scanditronix RFA300 water phantom connected to p-type electron beam semiconductor chamber The measurement was performed in water along the side Mylar window. The real sagittal plane radiation leakage of the applicator was measured with Kodak V film that was cut according to the shape of the applicator.\nResults: The relative outputs of the horizontal type were increased 10%, while the vertical ones were decreased 9%. The effective source-to-surface distance of the horizontal type is equal to 1.93 cm and 1.74 cm for the vertical ones. The isodose curves are attenuated in the central axis of vertical type applicators due to the attenuation from catheter and source tip. The hot spots of the horizontal type applicators are located at the top of the applicator and at the sides for the vertical ones. The leakage is 30% for the horizontal types and 20% for the vertical types.\nConclusion: Leipzig applicators can be used to treat some small volume cancer such as skin cancer, oral cancer and for other dose boost treatment. The dose can be estimated with BSSD to approximately 20% depth accurately. The hot spots of the applicators allow the user to avoid unnecessary exposure."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-139-145-a", "title": "\u786b\u9178\u4e9e\u9435\u81a0\u9ad4\u5291\u91cf\u8a08\u5728\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u4e4b\u539f\u7406\u8207\u63a2\u8a0e", "keywords": "\u786b\u9178\u4e9e\u9435\u81a0\u9ad4;\u653e\u5c04\u5291\u91cf\u8a08;\u653e\u5c04\u6cbb\u7642 Ferrous sulphate agarosc gel;Radiation dosimeter;Radiation therapy", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u786b\u9178\u4e9e\u9435\u5291\u91cf\u8a08\u4e4b\u539f\u7406\uff0c\u4e26\u7814\u7a76\u5176\u78c1\u632fT1\u9b06\u5f1b\u7387\u8207\u5438\u6536\u5291\u91cf\u4e4b\u9593\u7684\u95dc\u4fc2\uff0c\u4e26\u5206\u6790\u5176\u5728\u4eba\u9ad4\u7d44\u7e54\u5167\u5438\u6536\u5291\u91cf\u53cd\u61c9\u8207\u5206\u4f48\u7684\u60c5\u5f62\uff0c\u6700\u5f8c\u4e5f\u91dd\u5c0d\u5176\u5728\u81e8\u5e8a\u653e\u5c04\u6cbb\u7642\u61c9\u7528\u4e0a\u4e4b\u53ef\u884c\u6027\u505a\u4e00\u5617\u8a66\u8207\u6bd4\u8f03\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u914d\u88fd\u786b\u9178\u4e9e\u9435\u6eb6\u6db2\u65bc\u6d0b\u83dc\u7c89\u672b\u4e2d\uff0c\u9694\u591c\u4e26\u5f85\u51dd\u56fa\u5f8c\uff0c\u7f6e\u5165\u7dda\u6027\u52a0\u901f\u5668\u7167\u5c04\uff0c\u6700\u5f8c\u7d93\u7531\u78c1\u632f\u9020\u5f71\u6c42\u51fa\u5176T1\u9b06\u5f1b\u7387\uff0c\u4e26\u9032\u800c\u7814\u7a76\u5176T1\u9b06\u5f1b\u7387\u8207\u5438\u6536\u5291\u91cf\u4e4b\u9593\u7684\u95dc\u4fc2\u3002\u540c\u6642\u4e5f\u88fd\u4f5c\u4e73\u623f\u76f8\u4f3c\u5047\u9ad4\u8207\u975e\u5747\u8cea\u7d44\u7e54\u4f86\u6a21\u64ec\u80ba\u90e8\u7a7a\u8154\u5047\u9ad4\uff0c\u4ee5\u5206\u6790\u5176\u5291\u91cf\u5206\u4f48\u7684\u60c5\u5f62\uff0c\u4e5f\u8207\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u505a\u4e00\u6bd4\u8f03\u53ca\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u786b\u9178\u4e9e\u9435\u5291\u91cf\u81a0\u9ad4\u5728\u78c1\u632fT1\u9b06\u5f1b\u7387\u8207\u5291\u91cf\u53cd\u61c9\u3002\u5728\u5291\u91cf\u905430 Gy\u6642\u4ecd\u5448\u76f4\u7dda\u95dc\u4fc2\u3002\u4f46\u7531\u65bc\u78c1\u632f\u4e3b\u78c1\u5834\u4e0d\u5747\u52fb\u3001\u81a0\u9ad4\u5167\u96e2\u5b50\u64f4\u6563\u53ca\u964d\u89e3\u4f5c\u7528\u7b49\u56e0\u7d20\u4f7f\u5f97\u5176\u4fe1\u865f\u8207\u96dc\u8a0a\u6bd4\u4ecd\u672a\u5341\u5206\u6eff\u610f\u3002\n\u7d50\u8ad6\uff1a\u786b\u9178\u4e9e\u9435\u5291\u91cf\u8a08\u5728\u4e09\u5ea6\u7a7a\u9593\u7acb\u9ad4\u5291\u91cf\u5206\u4f48\u4e0a\u975e\u5e38\u6709\u7528\uff0c\u5c24\u5176\u5728\u4e73\u623f\u8207\u80f8\u8154\u58c1\u9593\u4e4b\u5291\u91cf\u5206\u4f48\u3001\u7d44\u5fae\u5bc6\u5ea6\u4e0d\u5747\u52fb\u4e4b\u4ecb\u9762\u5291\u91cf\u5206\u6790\u4e0a\uff0c\u6709\u5176\u81e8\u5e8a\u4e0a\u61c9\u7528\u7684\u50f9\u503c\u3002\u4f46\u5728\u63d0\u6607\u5f71\u50cf\u89e3\u6790\u5ea6\u3001\u4fe1\u865f\u8207\u96dc\u8a0a\u6bd4\u65b9\u9762\uff0c\u4ecd\u6709\u5f85\u66f4\u9032\u4e00\u6b65\u7684\u7814\u7a76\u3002", "e": "Purpose: To study how the ferrous sulphate agarose gel reports the dose response and distribution to the mediums. The potential applications to clinical radiation therapy are also introduced.\nMaterial and Method: Ferrous sulphate agarose gel containing ferrous ammonium sulfate, sodium chloride, sulfuric acid and triple distilled water was employed to measure dose distribution in the mediums. The change for T1 of the spin-lattice relaxation rates of ferric ions with an MRI scanner was studied as a function of absorbed dose given to the gels. Breast-mimic gel phantom and inhomogeneous layer phantom were constructed to compare the 3D dose distributions in the gel phantoms with treatment planning dose distributions in these phantoms.\nResult: The dose response of the gel is linear up to 30 Gy. The degree of homogeneity of the magnetic field, chemical diffusion and degradation of the gel are the major factors affecting the signal to noise ratio of the gel imaging.\nConclusion: The gel may he applicable to 3D dose verification in the areas of bone and air interface, breast and chest wall. However, the signal strength and resolution of the gel images are still not clinically satisfactory. Further studies to improve the above insufficiencies are needed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199706-4-2-147-153-a", "title": "\u7d44\u7e54\u633f\u690d\u5f0f\u5fae\u6ce2\u5929\u7dda\u9663\u5217\u71b1\u7642\u7cfb\u7d71\u4e4b\u5047\u9ad4\u7814\u7a76", "keywords": "\u5fae\u6ce2\u5929\u7dda\u9663\u5217;\u6eab\u5ea6\u5206\u4f48;\u5047\u9ad4;\u7a69\u614b;\u6c34\u6d41\u6d41\u901f Microwave antenna array;Temperature distribution;Phantom;Steady state;Flow rate", "c": "\u76ee\u7684\uff1a\u5728\u63a2\u8a0e\u4f7f\u7528\u7d44\u7e54\u633f\u690d\u5f0f\u5fae\u6ce2\u71b1\u7642\u7cfb\u7d71\u65bc\u5047\u9ad4\u5167\u6eab\u5ea6\u5206\u4f48\u4e4b\u72c0\u6cc1\uff0c\u4ee5\u8a55\u4f30\u8a72\u7cfb\u7d71\u4e4b\u767c\u5c55\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u4e43\u63a1\u7528\u4e00\u7a2e\u65b0\u8a2d\u8a08\u7684\u5fae\u6ce2\u5929\u7dda-\u5957\u7ba1\u5f0f\u540c\u8ef8\u72f9\u7e2b\u5929\u7dda\u4f86\u505a\u70ba\u5be6\u9a57\u4e2d\u7684\u52a0\u71b1\u6e90\uff0c\u4e26\u5229\u7528\u516d\u6839\u5929\u7dda\u6240\u7d44\u6210\u7684\u5929\u7dda\u9663\u5217\uff0c\u4ee5\u671f\u80fd\u65bc\u9663\u5217\u6240\u6db5\u84cb\u4e4b\u7bc4\u570d\u5167\u4f5c\u5340\u57df\u6027\u52a0\u71b1\u3002\u5047\u9ad4\u7684\u5be6\u9a57\u5206\u5169\u90e8\u5206\u5b8c\u6210\uff0c\u7b2c\u4e00\u90e8\u4efd\u5728\u4e0d\u8003\u616e\u8840\u6db2\u5faa\u74b0\u5c0d\u65bc\u6eab\u5ea6\u5206\u4f48\u6240\u7522\u751f\u7684\u5f71\u97ff\u4e0b\uff0c\u5229\u7528\u7d44\u7e54\u633f\u690d\u5f0f\u5fae\u6ce2\u71b1\u6cbb\u7642\u7cfb\u7d71\u5148\u91dd\u5c0d\u4eba\u9ad4\u5747\u8cea\u5047\u9ad4\u9032\u884c\u52a0\u71b1\u3002\u70ba\u4e86\u80fd\u5920\u6e2c\u5f97\u5047\u9ad4\u4e2d\u4e0d\u540c\u6df1\u5ea6\u7684\u6eab\u5ea6\u5206\u4f48\u60c5\u5f62\uff0c\u56e0\u6b64\u65bc\u52a0\u71b1\u4e00\u6bb5\u6642\u9593\u4e14\u5047\u9ad4\u4e4b\u6eab\u5ea6\u5206\u4f48\u5230\u9054\u7a69\u614b\u5f8c\uff0c\u5373\u958b\u59cb\u4ee5\u6bcf\u6b215mm\u7684\u8ddd\u96e2\u8abf\u6574\u6eab\u5ea6\u8a08\u633f\u5165\u4e4b\u6df1\u5ea6\uff0c\u4ee5\u91cf\u6e2c\u591a\u500b\u6df1\u5ea6\u5e73\u9762\u7684\u6eab\u5ea6\u5206\u4f48\u7d50\u679c\u3002\u7b2c\u4e8c\u90e8\u4efd\uff0c\u5247\u5229\u7528\u76f8\u540c\u7684\u71b1\u6cbb\u7642\u7cfb\u7d71\u4e26\u914d\u5408\u81ea\u884c\u8a2d\u8a08\u7684\u6a21\u64ec\u8840\u6db2\u5faa\u74b0\u7cfb\u7d71\uff0c\u5c0d\u808c\u8089\u5047\u9ad4\u9032\u884c\u52a0\u71b1\u8a66\u9a57\uff0c\u8207\u7b2c\u4e00\u90e8\u4efd\u4e0d\u540c\u7684\u662f\u53e6\u52a0\u4e00\u6c34\u7ba1\u8cab\u7a7f\u808c\u8089\u5047\u9ad4\u7684\u4e2d\u5fc3\u4f4d\u7f6e\uff0c\u85c9\u6c34\u6eab36\u2103\u7684\u5faa\u74b0\u6db2\u6d41\u904e\u4ee5\u6a21\u64ec\u8840\u6db2\u6d41\u52d5\u72c0\u614b\uff0c\u4e26\u5206\u5225\u4ee5\u4e94\u7a2e\u4e0d\u540c\u6c34\u6d41\u901f\u5ea6\uff0825\u300150\u300175\u3001100\u548c125ml/min\uff09\u4f86\u8a0e\u8ad6\u5176\u6eab\u5ea6\u5206\u4f48\u72c0\u614b\u3002\n\u7d50\u679c\uff1a\u7b2c\u4e00\u90e8\u4efd\u7684\u5be6\u9a57\u7d50\u679c\u986f\u793a\u6b64\u4e00\u5929\u7dda\u9663\u5217\u52a0\u71b1\u6642\u5728\u5929\u7dda\u65b9\u5411\u4e0a\u6240\u7522\u751f\u7684\u6eab\u5ea6\u5206\u4f48\u60c5\u5f62\uff0c\u5176\u6700\u9ad8\u6eab\u5ea6\u662f\u51fa\u73fe\u65bc\u63a5\u8fd1\u5929\u7dda\u524d\u7aef\u4e4b\u72f9\u7e2b\u5340\u57df\uff0c\u540c\u6642\u5728\u5929\u7dda\u9802\u7aef\u8655\u4ea6\u80fd\u9054\u5289\u6709\u6548\u7684\u6cbb\u7642\u6eab\u5ea643\u2103\u3002\u7b2c\u4e8c\u90e8\u4efd\u7814\u7a76\u5247\u986f\u793a\u5728\u6709\u6c34\u6d41\u7684\u72c0\u614b\u4e0b\uff0c\u5176\u6eab\u5ea6\u4e0a\u5347\u4e4b\u659c\u7387\u660e\u986f\u4f4e\u65bc\u7121\u6c34\u6d41\u7684\u72c0\u614b\uff0c\u56e0\u800c\u8b49\u5be6\u8840\u6d41\u5c0d\u65bc\u5047\u9ad4\u5728\u52a0\u71b1\u6642\u5176\u80fd\u91cf\u7684\u5438\u6536\u78ba\u5be6\u6709\u6240\u5f71\u97ff\uff0c\u800c\u4e14\u96a8\u8457\u6c34\u6d41\u6d41\u901f\u7684\u589e\u5927\uff0c\u5176\u5f71\u97ff\u4ea6\u5448\u73fe\u9010\u6f38\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u4f46\u662f\u7576\u6c34\u6d41\u6d41\u901f\u5230\u9054\u4e00\u5b9a\u7a0b\u5ea6\u6642(100ml/min)\uff0c\u6c34\u6d41\u5c0d\u65bc\u80fd\u91cf\u4e4b\u5f71\u97ff\u5c07\u5448\u73fe\u4e00\u7a69\u5b9a\u72c0\u614b\uff0c\u6b64\u6642\u5047\u9ad4\u7684\u80fd\u91cf\u6d41\u5931\u7387\u4e0d\u518d\u96a8\u8457\u6c34\u6d41\u6d41\u901f\u7684\u589e\u52a0\u800c\u589e\u52a0\u3002\n\u7d50\u8ad6\uff1a\u5728\u672c\u7cfb\u7d71\u6eab\u5ea6\u76e3\u63a7\u8edf\u9ad4\u7684\u81ea\u52d5\u63a7\u5236\u4e0b\uff0c\u5c0d\u65bc\u76ee\u524d\u8003\u616e\u8840\u6d41\u7684\u5047\u9ad4\u5be6\u9a57\u8a2d\u8a08\u800c\u8a00\uff0c\u5229\u7528\u6b64\u4e00\u71b1\u7642\u7cfb\u7d71\u4f86\u9032\u884c\u52a0\u71b1\uff0c\u5c07\u53ef\u4f7f\u6574\u500b\u5929\u7dda\u9663\u5217\u6240\u570d\u6210\u7684\u5340\u57df\u5176\u6eab\u5ea6\u5206\u4f48\u7dad\u6301\u65bc43-45\u2103\uff0c\u800c\u6b64\u4e00\u5be6\u9a57\u7d50\u679c\u5c07\u6709\u52a9\u65bc\u672a\u4f86\u52d5\u7269\u5be6\u9a57\u7684\u63a8\u5c55\u3002", "e": "Purpose: To test the performance of interstitial microwave antenna array hyperthermia system using a phantom model with or without flow effect\nMaterial and Method: The heating device was a custom-made interstitial microwave antenna array hyperthermia system. Six 2450-MHz antennas which were implanted on the corners of a hexagon with intercather spacing of 15 mm were used in this system. A phantom with flow was designed, namely, one silicone tube inserted into a homogenons muscle phantom. The temperature data from four fibrooptic thermometers were fed to the personal computer which could record and analyze the data, also could control the output power of microwave source. To test the system performance, we devided the study into two stages. In the first stage, the thermal distribution in a phantom without flow was conducted. In the second stage, the experiments in a phantom with different flow rates (25, 50, 75, 100 and 125 ml/min) were designed. The flow rates of water through silicone tubes were controlled by a microtube pump.\nResult: Using the automatic temperature and power control in this interstitial microwave antenna array hyperthermia system, the temperature distribution in phantom can be maintained uniformly in the range of 43-45 DC. The first-stage study showed that there was a tendency that the temperature was concentrated around the antennas. For the flow effect on thermal distribution, the results demonstrated that the faster flow rate would take more energy away in the transient period. However, the rate of energy loss caused by flowing water became constant when the flow rate was faster than l00ml/min.\nConclusions: An interstitial microwave antenna array hyperthermia system for deep-seated heating was developed. The superior ability of this system in maintaining uniform temperature distribution around the heating area was also clearly demonstrated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-1-8-a", "title": "\u7b2c\u56db\u671f\u9f3b\u54bd\u764c\u7684\u9810\u5f8c\u56e0\u5b50", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c\u56e0\u5b50 Nasopharyngeal cancer;Radiotherapy;Prognostic factor", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u7b2c\u56db\u671f\u9f3b\u54bd\u764c\u7684\u6cbb\u7642\u6210\u6548\u8207\u5176\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1991\u5e744\u6708\u81f31995\u5e746\u6708\u9593\uff0c\u9ad8\u96c4\u69ae\u6c11\u7e3d\u91ab\u9662\u5171\u670989\u540d\u53ef\u8a55\u4f30\u7684T1-4N2-3MO\u9f3b\u54bd\u764c\u60a3\u8005\u3002\u6240\u670989\u540d\u60a3\u8005\u90fd\u63a5\u53d7\u4e86\u6cbb\u7642\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff1b\u5176\u4e2d\u50c5\u5291\u91cf\u70ba7200cGy\u5728\uff08\u7bc4\u570d\u70ba6800\u81f37670cGyl\uff09.\u672c\u7814\u7a76\u9664\u8a08\u7b97\u6cbb\u7642\u5f8c\u4e4b\u5b58\u6d3b\u7387\u5916\uff0c\u4ea6\u5206\u6790T\u53caN\u671f\u5225\u8207\u5931\u6557\u578b\u614b\u7684\u95dc\u7cfb\u3002\u53ef\u80fd\u5f71\u97ff\u9810\u5f8c\u7684\u56e0\u5b50\u5747\u5148\u4ee5\u55ae\u8b8a\u7570\u6578\u65b9\u6cd5\u5206\u6790\uff1b\u6709\u610f\u7fa9\u7684\u9810\u5f8c\u56e0\u5b50\u518d\u4ee5\u591a\u8b8a\u7570\u6578\u65b9\u6cd5\u5206\u6790\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u5b58\u6d3b\u7387\u3001\u5c40\u90e8\u63a7\u5236\u5b58\u6d3b\u7387\u8207\u75be\u75c5\u63a7\u5236\u5b58\u6d3b\u7387\u5206\u5225\u70ba43.7%\u300144.6%\u53ca40.3%\u3002\u4ee5\u55ae\u8b8a\u7570\u6578\u65b9\u6cd5\u5206\u6790\uff0c\u672c\u7814\u7a76\u767c\u73feT\u671f\u5225\u3001T4\u816b\u7624\u4fb5\u72af\u7279\u5fb5\u3001\u7e3d\u6cbb\u7642\u6642\u9593\u3001\u6dcb\u5df4\u7d50\u653e\u7642\u53cd\u61c9\u3001T/N\u671f\u5225\u7d44\u5408\u3001\u6027\u5225\u53ca\u8840\u5c0f\u677f\u7b49\u5747\u70ba\u6709\u610f\u7fa9\u4e4b\u9810\u5f8c\u56e0\u5b50\u3002\u4ee5\u591a\u8b8a\u7570\u6578\u65b9\u6cd5\u5206\u6790\uff0c\u5247\u53ea\u6709T4\u816b\u7624\u4fb5\u72af\u7279\u5fb5\u6703\u5f71\u97ff\u5b58\u6d3b\u7387\uff0cT/N\u671f\u5225\u7e43\u5e36\u3000\u5408\u6703\u5f71\u97ff\u5c40\u90e8\u63a7\u5236\u5b58\u6d3b\u7387\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u767c\u73fe\u7b2c\u56db\u671f\u9f3b\u54bd\u764c\u60a3\u8005\u7684\u6cbb\u7642\u6210\u679c\u6703\u96a8\u4e0d\u540c\u9810\u5f8c\u56e0\u5b50\u800c\u6709\u6240\u5dee\u7570\u3002\u4ee5\u5f8c\u5728\u6c7a\u5b9a\u6b64\u671f\u764c\u75c5\u7684\u6cbb\u7642\u65b9\u91dd\u6642\uff0c\u53ef\u6537\u616e\u4f9d\u7167\u4e0d\u540c\u7684\u9810\u5f8c\u56e0\u5b50\u4f86\u898f\u5283\u8207\u8a2d\u8a08\u4e0d\u540c\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4ee5\u63d0\u9ad8\u6cbb\u7642\u6210\u6548\u3002", "e": "Purpose: To evaluate the results and prognostic factors of Stage IV nasopharyngeal cancer.\nMethods and Materials: From April 11191 to June 1995, 89 patients with Tl-4 N2-3M0 nasopharyngeal cancer treated at the Veteran General Hospital-Kaohsiung were evaluated. All these patients had received definitive radiotherapy to a median dose of 7200 cGy (range from 6800 to 7670 cGy). The failure patterns according to different T and N stages were evaluated. The possible prognostic factors were analysed by univariate analysis first, then those have significant p values were further eveluated by multivariate analysis.\nResults: The survival rate, local failure free survival and disease-free survival at 5 years were 43.7%, 44.6% and 40.3%, respectively. The factors including T stage, characteristics of T4 invasion, total treatment time, lymph node response rate, T and N grouping, sex and platelet counts all showed statistically significance by univariate analysis. The multivariate analysis revealed both the characteristics of T4 invasion and T/N grouping are significant to the overall survival and local failure free survival, respectively.\nConclusion: This study disclosed that the patients with Stage IV nasopharyngeal cancer have different prognosis according to different factors. In the future, we might design treatment policies according to different prognostic factors in an attempt to improve the treatment results."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-9-15-a", "title": "\u5168\u7403\u8cc7\u8a0a\u7db2(World Wide Web)\u4e0a\u7684\u653e\u5c04\u6cbb\u7642Home Page\uff1a\u4e00\u5e74\u4f86\u7684\u7d93\u9a57\u8207\u672a\u4f86\u7684\u5c55\u671b", "keywords": "\u7db1\u969b\u7db1\u8def;\u5168\u7403\u8cc7\u8a0a\u7db1;\u653e\u5c04\u6cbb\u7642 Internet;World Wide Web;Radiation Oncology", "c": "\u76ee\u7684\uff1a\u96a8\u8457\u7db1\u969b\u7db1\u8def(Internet)\u8207\u5168\u7403\u8cc7\u8a0a\u7db2(World Wide Web)\u7684\u91cd\u8981\u6027\u8207\u65e5\u4ff1\u589e\uff0c\u7db2\u8def\u4e0a\u7684\u8cc7\u8a0a\u4ea4\u6d41\u9010\u6f38\u6210\u70ba\u73fe\u4ee3\u901a\u8a0a\u7684\u4e3b\u8981\u5de5\u5177\u3002\u800c\u5168\u7403\u8cc7\u8a0a\u7db2\u7531\u65bc\u5176\u89aa\u5207\u7684\u4f7f\u7528\u754c\u9762\u53ca\u591a\u5a92\u9ad4\u7684\u5167\u5bb9\u5448\u73fe\uff0c\u66f4\u5c55\u73fe\u4e86\u9a5a\u4eba\u7684\u6210\u9577\u3002\u672c\u6587\u8a55\u4f30\u672c\u79d1Home Page\u6210\u7acb\u4e00\u5e74\u4f86\u7684\u6210\u6548\uff0c\u5c0d\u7db2\u8def\u91ab\u5b78\u7684\u53ef\u884c\u6027\u53ca\u672a\u4f86\u5c55\u671b\u505a\u4e00\u500b\u521d\u6b65\u7684\u63a2\u8a0e\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u79d1\u65bc\u96f2\u5e74\u8a2d\u7acb\u6709\u95dc\u653e\u5c04\u6cbb\u7642\u7684Home Page\uff0c\u5728Home Page\u4e2d\u63d0\u4f9b\u4e86\u764c\u75c7\u653e\u5c04\u6cbb\u7642\u76f8\u95dc\u8cc7\u8a0a\u53ca\u7dda\u4e0a\u764c\u75c7\u54a8\u8a62\u8207\u89e3\u7b54\u3002\u672c\u6587\u5206\u6790\u9019\u4e00\u5e74\u4f86\u7684\u8a2a\u5ba2\u4eba\u6578\u8cc7\u6599\u53ca\u7dda\u4e0a\u764c\u75c7\u5e38\u554f\u96c6\u7684\u554f\u984c\u3002\n\u7d50\u679c\u53ca\u7d50\u8ad6\uff1a\u7531\u672c\u6587\u7684\u7d50\u679c\u986f\u793a\uff0c\u5168\u7403\u8cc7\u8a0a\u7db2\u7684\u653e\u5c04\u6cbb\u7642Home Page\u53ef\u4ee5\u9054\u5230\u670d\u52d9\u764c\u75c7\u75c5\u4eba\u548c\u4e00\u822c\u6c11\u8846\u7684\u76ee\u7684\uff0c\u800c\u4e14\u672a\u4f86\u9084\u6709\u5f88\u5927\u7684\u767c\u5c55\u6f5b\u529b\u3002", "e": "Purpose: As the importance of the Internet, and specifically the WWW (World Wide Web) escalates, the information transfer over network becomes the mainstream of communication. The WWW shows the most striking expansion because its friendly user interface and its multimedia capacity. In this paper, we intend to evaluate the efficacy of the WWW home page of our department and investigate the feasibility of medical consultation over Internet.\nMaterials and Methods: The home page of department of radiation oncology in Chang Gung Memorial Hospital-Kaohsiuag was set up one year ago. Our WWW home page provides comprehensive information about radiotherapy of cancers and on-line medical consultation. We analyze the number of visitors and the on-line medical questions within this year.\nResults and Conclusion: The results indicate that the WWW home page of radiation oncology is an effective way to serve the cancer patients and the public. Also, the potential of WWW home page will be tremendous in the future."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-17-22-a", "title": "\u65e9\u671f\u5b50\u5bae\u5167\u819c\u764c\u7684\u6cbb\u7642\u8207\u9810\u5f8c\u56e0\u5b50", "keywords": "\u5371\u96aa\u56e0\u5b50;\u653e\u5c04\u7dda\u6cbb\u7642;\u5b50\u5bae\u5167\u819c\u764c Risk Factor;Radiotherapy;Endometrial Carcinoma", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u65e9\u671f\u5b50\u5bae\u5167\u819c\u764c\u624b\u8853\u8207\u624b\u8853\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7684\u5b58\u6d3b\u7387\u53ca\u5404\u7a2e\u9810\u5f8c\u56e0\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u5c071984\u5e746\u6708\u81f31996\u5e747\u6708\u9593\u5728\u99ac\u5055\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\u7684143\u4f4d\u65e9\u671f\u5b50\u5bae\u5167\u819c\u764c\u7684\u75c5\u60a3\u505a\u56de\u6eaf\u6027\u7684\u7814\u7a76\uff0c\u4e26\u4e14\u518d\u6839\u64daFIGO\u5206\u671f\u7cfb\u7d71\u91cd\u65b0\u5206\u671f\uff0c\u4e73\u7a81\u72c0\u6f3f\u6db2\u764c\u548c\u900f\u660e\u7d30\u80de\u764c\u90fd\u6392\u968a\u8a0e\u8ad6\uff0c\u5171\u8a08135\u4f4d\u75c5\u60a3\u9032\u5165\u672c\u7814\u7a76\u4e4b\u5206\u6790\u3002\u5982\u679c\u60a3\u8005\u5177\u6709\u4e0b\u5217\u4e00\u9805\u4ee5\u4e0a\u5371\u96aa\u56e0\u5b50\uff0c\u5247\u8996\u70ba\u9ad8\u5371\u96aa\u7fa4\uff0c\u5426\u5247\u8996\u70ba\u4f4e\u5371\u96aa\u7fa4\u3002\u9019\u4e9b\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u2460\u5b50\u5bae\u808c\u5c64\u88ab\u4fb5\u72af\u6df1\u5ea6\u5927\u65bc\u4e8c\u5206\u4e4b\u4e00\u2461\u7d30\u80de\u5206\u5316\u7b2c3\u7d1a(G3)\u2462\u5b50\u5bae\u9838\u4fb5\u72af\u2463\u817a\u9c57\u764c\u3002\u5728\u9019135\u4f4d\u75c5\u60a3\u4e2dA\u7d44\u670999\u4f4d\u75c5\u60a3\u63a5\u53d7\u624b\u8853\u6cbb\u7642\uff0c\u5176\u4e2d8\u4f4d\u75c5\u60a3(8%)\u70ba\u9ad8\u5371\u96aa\u7fa4\uff0cB\u7d44\u670936\u4f4d\u75c5\u60a3\u63a5\u53d7\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d30\u4f4d\u75c5\u60a3(83%)\u70ba\u9ad8\u5371\u96aa\u7fa4\uff0c\u5927\u90e8\u4efd\u63a5\u53d7\u624b\u8853\u5f8c\u9aa8\u76c6\u5916\u7167\u5c04\u6216\u914d\u5408\u9670\u9053\u6b98\u7aef\u8154\u5167\u6cbb\u7642\uff0c\u5176\u9aa8\u76c6\u5916\u7167\u5c04\u7dda\u5291\u91cf\u70ba4000-5400\u5398\u845b\u96f7(cGy)\uff08\u5e73\u5747\u70ba5013\u5398\u845b\u96f7\uff09\uff0c\u81f3\u65bc\u9670\u9053\u6b98\u7aef\u8154\u5167\u6cbb\u7642\uff0c\u6bcf\u6b21\u5291\u91cf\u70ba\u81f3\u9ecf\u819c\u4e0b0.5\u516c\u5206\u8655\u7d66\u4e88500\u5398\u845b\u96f7\uff0c\u7e3d\u5291\u91cf\u70ba1000-3000\u5398\u845b\u96f7\uff08\u5e73\u5747\u70ba2933\u5398\u845b\u96f7\uff09\u3002\n\u7d50\u679c\uff1a\u7d93\u904e6-147\u500b\u6708\u8ffd\u8e64\uff08\u4e2d\u4f4d\u6578\u70ba62\uff09\uff0c\u4e94\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387A\u7d44\u70ba96.9%\uff0cB\u7d44\u70ba89.3%\u3002\u7d93\u7531\u55ae\u8b8a\u6578\u56e0\u5b50\u5206\u6790\u81e8\u5e8a\u4e0a\u5f71\u97ff\u5b58\u6d3b\u56e0\u7d20\u4ee5\u5e74\u9f61\u5927\u65bc55\u6b72\u3001\u5b50\u5bae\u808c\u8089\u5c64\u4fb5\u72af\u7a0b\u5ea6\u5927\u65bc\u4e8c\u5206\u4e4b\u4e00\u53ca\u505c\u7d93\u70ba\u5b58\u6d3b\u7387\u964d\u4f4e\u4e4b\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\uff0c\u800c\u591a\u8b8a\u6578\u56e0\u5b50\u5206\u6790\u4e0a\uff0c\u5b50\u5bae\u808c\u8089\u5c64\u4fb5\u72af\u7a0b\u5ea6\u5927\u65bc\u4e8c\u5206\u4e4b\u4e00\u70ba\u5b58\u6d3b\u7387\u964d\u4f4e\u4e4b\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\uff0c\u800c\u5176\u4ed6\u56e0\u5b50\u5247\u7686\u7121\u7d71\u8a08\u5b78\u4e0a\u7684\u610f\u7fa9\u3002\u5728A\u7d4499\u4f4d\u75c5\u60a3\u4e2d\u67092\u4f4d\u5fa9\u767c\uff0c\u5176\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba98%\uff1b\u5728B\u7d4436\u4f4d\u75c5\u60a3\u4e2d\u67094\u4f4d\u5fa9\u767c\uff0c\u5176\u4e94\u5e74\u5c40\u90e8\u63a7\u5236\u7387\u70ba88%\u3002\n\u7d50\u8ad6\uff1a\u5728\u7d93\u904e\u6211\u5011\u56de\u6eaf\u6027\u7684\u7814\u7a76\u986f\u793a\uff0c\u5c0d\u65bc\u65e9\u671f\u5b50\u5bae\u5167\u819c\u764c\u7684\u6cbb\u7642\u4e0a\uff0c\u9078\u64c7\u6027\u5c0d\u65bc\u9ad8\u5371\u96aa\u7fa4\u7684\u75c5\u60a3\uff0c\u7d66\u4e88\u624b\u8853\u5408\u4f75\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u81e8\u5e8a\u4e0a\u6709\u4ee4\u4eba\u6eff\u610f\u7684\u6548\u679c\u53ca\u767c\u73fe\u91cd\u8981\u9810\u5f8c\u56e0\u5b50\uff0c\u503c\u5f97\u505a\u70ba\u9032\u4e00\u6b65\u524d\u77bb\u6027\u7814\u7a76\u7684\u53c3\u6537\u3002", "e": "Aims: To evaluation prognostic factors and treatment outcome for early stage endometrial cancer patients treated with surgery or combined surgery and radiation therapy (RT)\nMaterial and Methods: We desinged a retrospective study for 143 patients with StageI/II endometrial cancer treated at Mackay Memorial Hospital between 1984 and 1996. Patients were restaged according to the 1988 EGO staging system. Patients with papillary serous, and clear cell histologies were excluded. Patients were considered as high risk group if they had one or more of the following factors: grade 3 tumor differentiation, depth of myometrial invasion\uff1e1/2, pathologic cervical involvement, or adenosquamous histology. Of these 135 patients, 99 patients was treated with surgery alone (Group A) and the other 36 patients were treated with combined surgery and RT (Group B). Eight (8%) patients in group A and thirty (82%) patients in group B were defined high risk group. The main treatment modality consisted of total abdominal hysterectomy and bilateral salpingo-oophorectomy and/or postoperative external pelvic RT with/without intracavitary brachytherapy. The total dose of external pelvic irradiation is 4000-5400 cGy (median: 5013 cGy). Intracavity brachytherapy was given with 500 cGy per fraction prescribed to a depth of 0.5 cm under mucosal surface and the total dose was 1000-3000 cOy (median: 2933 cGy).\nResults: Follow- up duration ranged from 6 to 147 months (median: 62 months). The 5-year overall survival rate in group A and group 13 were 96.9% and 89.3%, respectively. Univariate analysis identified the following significant prognostic factors: age, menopausal status and myometrial invasion. Multivariate analysis revealed myometrial invasion more than half of the thickness to be the only factor significant for reduce overall survival. Two of the 99 patients of group A had tumor relapse. The local control rate is 98%. Four of the 36 patients of group 13 had tumor relapse. The local control rate is 88%. Conclusion: Our retrospective study revealed good outcome associated with selective treatment combing surgery and RT for high risk patients. We also confirmed some important prognostic factors associated with survival. Base on the results of our study, further prospective study for the role of adjuvant radiation therapy for early stage endometrial cancer patient can be designed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-23-30-a", "title": "Treatment Results of Oral Tongue Cancer", "keywords": "\u820c\u764c;\u539f\u767c\u8207\u9838\u90e8\u816b\u7624\u63a7\u5236\u7387;\u4f75\u767c\u75c7;\u4e94\u5e74\u5b58\u6d3b\u7387 Oral Tongue Cancer;Primary and Neck Control;Com-Plications of Treatment;Five-year Survival Rate", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u820c\u764c\u75c5\u60a3\u5728\u53f0\u5927\u91ab\u9662\u6cbb\u7642\u4e4b\u7d50\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5171\u8490\u96c6\u4e86\u81ea1977\u81f31994\u5e74\u9593161\u4f4d\u820c\u764c\u75c5\u60a3\u9032\u884c\u5206\u6790\u3002\u6cbb\u7642\u65b9\u5f0f\u5305\u62ec\u624b\u8853\u6cbb\u7642\uff0885\u4f4d\uff09\u3001\u653e\u5c04\u6cbb\u7642\uff0840\u4f4d\uff09\u548c\u5408\u4f75\u624b\u8853\u53ca\u653e\u5c04\u6cbb\u7642\uff0836\u4f4d\uff09\u3002\u5c6c\u65bc\u7b2c\u4e00\u671f33\u4f4d\uff0820%\uff09\uff1b\u7b2c\u4e8c\u671f53\u4f4d\uff0833%\uff09\uff1b\u7b2c\u4e09\u671f37\u4f4d\uff0823%\uff09\uff1b\u7b2c\u56db\u671f38\u4f4d\uff0824%\uff09\u3002\u5168\u90e8\u75c5\u60a3\u7686\u7d93\u904e\u75c5\u7406\u8a3a\u65b7\u70ba\u6241\u5e73\u7d30\u80de\u764c\uff1b\u7537\u5973\u6bd4\u4f8b4\uff1a1\u3002\u6211\u5011\u5206\u6790\u6bd4\u8f03\u816b\u7624\u539f\u767c\u8655\u8207\u9838\u90e8\u6dcb\u5df4\u7d50\u7684\u63a7\u5236\u6548\u679c\u3001\u9810\u5f8c\u548c\u4f75\u767c\u75c7\u3002\n\u7d50\u679c\uff1a\u8d85\u904e\u4e94\u5206\u4e4b\u56db\u7684\u816b\u7624\u4f4d\u65bc\u820c\u908a\uff0c\u5c11\u65bc5%\u4f4d\u65bc\u820c\u8868\u9762\u8207\u820c\u8179\u3002T1\u3001T2\u63a5\u53d7\u624b\u8853\u7684\u75c5\u60a3\uff0c\u539f\u767c\u816b\u7624\u63a7\u5236\u7387\u5f88\u597d\uff0c\u5206\u5225\u662f90%\u548c86%\u3002T3\u4ee5\u5408\u4f75\u6cbb\u7642\u7684\u6548\u679c\u8f03\u597d\uff0c\u63a7\u5236\u7387\u662f67%\uff1bT4\u7684\u6cbb\u7642\u6548\u679c\u90fd\u5f88\u5dee\u3002\u5373\u4f7f\u662f\u65e9\u671f\u75c5\u60a3\uff0c\u53ea\u63a5\u53d7\u624b\u8853\u5207\u9664\u816b\u7624\u800c\u7121\u9032\u4e00\u6b65\u8655\u7406\u9838\u90e8\u6dcb\u5df4\u7d50\uff0c\u5247\u6613\u5728\u9838\u90e8\u5fa9\u767c\u3002\u7b2c\u4e09\u671f\u75c5\u60a3\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u662f\uff1a\u624b\u8853\u6cbb\u764224\uff05\uff0c\u653e\u5c04\u6cbb\u764217%\uff0c\u5408\u4f75\u624b\u8853\u8207\u653e\u5c04\u6cbb\u764261%\u3002T3\u3001T4\u5fa9\u767c\u7684\u75c5\u60a3\u7576\u4e2d\uff0c\u5fa9\u767c\u65bc\u4e00\u5e74\u5167\u7684\u4f5484%\uff1bT1\u3001T2\u5fa9\u767c\u7684\u75c5\u60a3\u7576\u4e2d\uff0c\u5fa9\u767c\u65bc\u4e00\u5e74\u5167\u7684\u4f5472\uff05\u3002\u5168\u90e8\u5fa9\u767c\u7684\u75c5\u60a3\u4e2d\uff0c86%\u5fa9\u767c\u65bc\u5169\u5e74\u5167\u3002\u5171\u6709\u5341\u4f4d\u516d\u75c5\u60a3(10%)\u9060\u7aef\u8f49\u79fb\uff0c\u80ba\u8f49\u79fb\u4f54\u6700\u591a(75%)\u3002\u767c\u751f\u9aa8\u8cea\u7cdc\u721b\u5728\u5408\u4f75\u6cbb\u7642\u7d44(6%)\u7684\u5371\u96aa\u6027\u8207\u653e\u5c04\u6cbb\u7642\u7d44(3%)\u76f8\u4f3c\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u7684\u5206\u6790\u7d50\u679c\uff1a\u624b\u8853\u6cbb\u7642\u80fd\u6709\u6548\u63a7\u5236T1\u3001T2\u7684\u539f\u767c\u816b\u7624\u3002T3\u3001T4\u55ae\u4ee5\u624b\u8853\u6216\u653e\u5c04\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\uff0c\u6700\u597d\u5408\u4f75\u6cbb\u7642\u3002\u7b2c\u4e09\u671f\u7684\u75c5\u60a3\u7576\u4e2d\uff0c\u5408\u4f75\u6cbb\u7642\u7d44\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u512a\u65bc\u5176\u4ed6\u5169\u7d44(P\uff1c0.05)\u3002\u820c\u90e8\u7684\u6dcb\u5df4\u8c50\u5bcc\uff0c\u6240\u4ee5\u816b\u7624\u6613\u8f49\u79fb\u5230\u5c40\u90e8\u6dcb\u5df4\u7d50\u3002\u5982\u679c\u53ea\u63a5\u53d7\u624b\u8853\u5207\u9664\u816b\u7624\uff0c\u8981\u6ce8\u610f\u9838\u90e8\u7684\u8ffd\u8e64\u6aa2\u67e5\u4ee5\u9632\u5fa9\u767c\uff1b\u529f\u80fd\u6027\u9838\u90e8\u6dcb\u5df4\u6458\u9664\u6216\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4e5f\u662f\u5f88\u597d\u7684\u9078\u64c7\u3002\u4ecd\u670914%\u7684\u5fa9\u767c\u65bc\u5169\u5e74\u5f8c\u624d\u767c\u73fe\uff0c\u6240\u4ee5\u9577\u671f\u8ffd\u8e64\u5f88\u91cd\u8981\u3002", "e": "Purpose: To evaluate the therapeutic results of oral tongue cancer patients treated with curative intent at the National Taiwan University Hospital.\nMaterials and Methods: From 1977 to 1994, 161 oral tongue cancer patients were treated by different modalities, including surgery alone (85 patients), radiotherapy alone (40 patients) and surgery followed by radiotherapy (36 patients). Patients were grouped according to the American Joint Committee on Cancer (AJCC) staging system. Among these 161 patients, 33 (20%) were categorized as stage I; 53 (33%) stage II; 37 (23%) stage III and 38 (24%) stage IV. All of them were squamous cell carcinoma with a male to female ratio of approximately 4:1. The treatment results of primary control, neck node control, outcomes and complications were analyzed.\nResults: More than four fifths of the lesions were located on the lateral border of the tongue and less than 5% were either on the dorsum or undersurface. Primary control rates of Ti and T2 diseases in the OP alone group were 90% and 86%, respectively. The T3 patients of OP+REF group had better primary control rate as 67%. Primary control of T4 disease was very poor hi our three treatment groups. Even for the early disease, patients receiving surgical resection of primary tumor without further neck treatment have a higher risk (28%) of neck failure. Five-year survival rates of stage \u2162 patients were: R/T alone, 17%; OP alone, 24%; OP+R/T, 61%. Eighty-four percent and 72% recurrence in T3/T4 and T1/T2, respectively, occurred within one year after treatment. Overall, 86% recurrence occurred within the first 2 years. Sixteen patients (10%) showed evidence of distant metastasis; most commonly presented in the lung (75%). The risk of osteonecrosis was similar between OP+R/T group (6%) and R/T alone group (3%).\nConclusion: In our study, surgery can control primary tumors effectively in Ti and T2 lesions. Advanced (T3 and T4) disease is unlikely to be cured by radiation therapy or surgery alone and therefore is best managed by a planned combination of surgery and radiation therapy. For stage\u2162 group, five-year survival rate was significantly improved (p\uff1cO.O5) for patients who were treated with surgery and postoperative radiotherapy. When the primary lesion is treated by simple excision, neck failure is not uncommon and adjuvant radiotherapy to the neck lymphatics may decrease its occurrence. There was 14% of recurrence occurred beyond the first 2 years which indicated that a long period of follow-up was important for tongue cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-31-38-a", "title": "Treatment Results of Hodgkin", "keywords": "\u4f55\u6770\u91d1\u6c0f\u75c5;\u5316\u5b78\u6cbb\u7642;\u653e\u5c04\u6cbb\u7642;\u5408\u4f75\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642;\u5b58\u6d3b\u7387;\u514d\u65bc\u5fa9\u767c\u7387 Hodgkin", "c": "Purpose: To evaluate the response and outcome of patients of Hodgkin's disease undergoing different treatment modalities.\nMaterials and Methods: We reviewed clinical records of Hodgkin's disease who received chemotherapy (C/T), radiotherapy (R/T) or combined chemotherapy and radiotherapy (CRT) from 1977 to 1991 in National Taiwan University Hospital ( NTUH). The 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) in different stages were calculated and classified by different treatment modalities.\nResult: The overall 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) were summarized for stage I+\u2161, \u2162 and IV diseases. In stage I+\u2161 diseases, the SR of CIT, RIT and CRT groups were 50%, 60% and 89%; the FFR were 33%, 100% and 67% respectively. In stage \u2162disease, the SR of C/T and CRT groups were 72% and 90%; the FFR were 59% and 90% respectively. In stage IV disease, the SR of C/T and CRT groups were 45% and 38%; the FFR both were 38%. No statistical significance of SR was noted between CT, R/T and CRT groups in different stages. However, the FFR between C/T and R/T groups in the early stage showed statistical significance (p\uff1cO.OS). Patients with histologic subtype of lymphocyte depletion had the worst prognosis than the other 3 histologic subtypes. C/T and CRT groups bad some complications while no complication was seen in the HIT group within the 5-year follow-up.\nConclusion: In our study, Hodgkin's disease was potentially curable by using either C/T, R/T, or CRT. For stage \u2162and IV diseases, no statistical significance was noted by C/T or CRT groups. However, for early stage disease, R/T is a better treatment of choice because R/T group had better FFR and no late complication.", "e": "Purpose: To evaluate the response and outcome of patients of Hodgkin's disease undergoing different treatment modalities.\nMaterials and Methods: We reviewed clinical records of Hodgkin's disease who received chemotherapy (C/T), radiotherapy (R/T) or combined chemotherapy and radiotherapy (CRT) from 1977 to 1991 in National Taiwan University Hospital ( NTUH). The 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) in different stages were calculated and classified by different treatment modalities.\nResult: The overall 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) were summarized for stage I+\u2161, \u2162 and IV diseases. In stage I+\u2161 diseases, the SR of CIT, RIT and CRT groups were 50%, 60% and 89%; the FFR were 33%, 100% and 67% respectively. In stage \u2162disease, the SR of C/T and CRT groups were 72% and 90%; the FFR were 59% and 90% respectively. In stage IV disease, the SR of C/T and CRT groups were 45% and 38%; the FFR both were 38%. No statistical significance of SR was noted between CT, R/T and CRT groups in different stages. However, the FFR between C/T and R/T groups in the early stage showed statistical significance (p\uff1cO.OS). Patients with histologic subtype of lymphocyte depletion had the worst prognosis than the other 3 histologic subtypes. C/T and CRT groups bad some complications while no complication was seen in the HIT group within the 5-year follow-up.\nConclusion: In our study, Hodgkin's disease was potentially curable by using either C/T, R/T, or CRT. For stage \u2162and IV diseases, no statistical significance was noted by C/T or CRT groups. However, for early stage disease, R/T is a better treatment of choice because R/T group had better FFR and no late complication."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-39-43-a", "title": "Estimation of Complication Probability for Non-Uniform Normal Tissue Irradiation Using the Effective Volume Method and Normal Distribution", "keywords": "\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5713;\u6709\u6548\u9ad4\u7a4d\u6cd5;\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387 Dose volume histogram;Effective volume method;Normal tissue complication probability", "c": "\u76ee\u7684\uff1a\u4f30\u7b97\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387(NTCP)\u4ee5\u8a55\u4f30\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff0c\u7279\u5225\u662f\u4e09\u5ea6\u7a7a\u9593\u6cbb\u7642\u8a08\u5283\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716\u53ef\u7531\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u8cc7\u6599\u8207\u653e\u5c04\u5291\u91cf\u5206\u4f48\u8a08\u7b97\u800c\u5f97\u3002\u6709\u6548\u9ad4\u7a4d\u6cd5\u662f\u4e00\u7a2e\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716\u4e4b\u8f49\u63db\u6280\u8853\u3002\u53ef\u5c07\u975e\u5747\u52fb\u7167\u5c04\u76f4\u65b9\u5716\u8f49\u63db\u6210\u5747\u52fb\u7167\u5c04\u76f4\u65b9\u5716\uff0c\u4f7f\u6b64\u5716\u4e4b\u9ad4\u7a4d\u70ba\u6709\u6548\u9ad4\u7a4d\u800c\u5291\u91cf\u5247\u7b49\u65bc\u6700\u5927\u5291\u91cf\u3002\u975e\u5747\u52fb\u7167\u5c04\u4e4b\u6b63\u5e38\u7d44\u7e54\u4f75\u767c\u75c7\u6a5f\u7387(NTCP)\u53ef\u7531\u5df2\u77e5\u4e4b\u5747\u52fb\u7167\u5c04\u5168\u90e8\u53ca\u90e8\u5206\u5668\u5b98\u4e4b\u4f75\u767c\u75c7\u6a5f\u7387\u5229\u7528\u516c\u5f0f\u8a08\u7b97\u800c\u5f97\u3002\n\u7d50\u679c\uff1a\u5404\u5668\u5b98\u4e4b\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716\u7531Render-Plan\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u8a08\u7b97\u800c\u5f97\u3002\u5404\u5668\u5b98\u4e4b\u6709\u6548\u9ad4\u7a4d\u7528 Kutcher\u6709\u6548\u9ad4\u7a4d\u6cd5\u8a08\u7b97\u800c\u5f97\u3002\u5229\u7528Lyman\u516c\u5f0f\u8207\u5e38\u614b\u5206\u914d\u8868\u53ef\u4f30\u7b97\u5f97\u5404\u5668\u5b98\u4e4bNTCP\u3002\n\u7d50\u8ad6\uff1a NTCP\u7684\u4f30\u7b97\u5c0d\u653e\u5c04\u6cbb\u7642\u8a08\u5283\uff0c\u7279\u5225\u662f\u4e09\u5ea6\u7a7a\u9593\u6cbb\u7642\u8a08\u5283\u7684\u8a55\u4f30\u5341\u5206\u91cd\u8981\u3002\u5728\u8a55\u4f30\u6cbb\u7642\u8a08\u5283\u6642\uff0c\u9664\u4e86\u5be9\u8996\u5291\u91cf\u5206\u4f48\u5716\u8207\u5291\u91cf\u9ad4\u7a4d\u76f4\u65b9\u5716\u5916\uff0c\u6700\u597d\u52a0\u4e0aNTCP\u4e4b\u4f30\u7b97\uff0c\u4ee5\u4fbf\u8a08\u5283\u8a55\u4f30\u66f4\u70ba\u6709\u6548\u8207\u6b63\u78ba\u3002", "e": "Purpose: To estimate normal tissue complication probability (NTCP) for nonuniform irradiation.\nMaterials and Methods: Before calculation of NTCP, dose volume histograms are calculated for the organs of interest and tolerance doses for uniform whole and partial organ irradiation are obtained from published data. The calculation of dose volume histograms is straightforward if there are an adequate number of CT scans and dose distributions for organs of interest. The effective volume method transforms the histogram into a uniform one of height (effective volume) and dose (D(subscript max))equal to the maximum dose in the histogram. NTCP can be obtained using Lyman's model and table of the normal distribution.\nResults: Dose volume histograms for various organs are obtained by calculation with Render-Plan treatment planning system. Effective volumes for these organs are obtained by calculation with Kutcher's effective volume method. Calculation using Lyman's model and table of the normal distribution, we obtained the NTCP values for these organs.\nConclusion During radiotherapy normal tissues are irradiated along with the tumor. Radiation oncologists try to minimize the dose to normal tissues while delivering a high dose to the tumor. Often this is difficult and complications arise due to irradiation of normal tissues. Estimation of NTCP is important for evaluation of 3-dimensional treatment plans. It is preferable to use NTCP as an additional tool for plan evaluation, in conjunction with a review of graphical dose distributions and dose volume histograms."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-45-48-a", "title": "\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u7a7f\u900f\u56e0\u5b50\u4e4b\u6e2c\u91cf", "keywords": "\u653e\u5c04\u6cbb\u7642;\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f;\u7a7f\u900f\u56e0\u5b50;\u5291\u91cf\u5b78 Radiation therapy;Dynamic wedge filter;Transmission factor", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u4e3b\u8981\u6e2c\u91cf Varian CL\uff0d2100C/D sn:481 \u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5728\u4e0d\u540c\u7167\u91ce\u7684\u7a7f\u900f\u56e0\u5b50\uff0c\u4ee5\u505a\u70ba\u5efa\u7acb\u81e8\u5e8a\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5291\u91cf\u5b78\u8cc7\u6599\u4e4b\u4e00\u74b0\uff0c\u4e26\u8207\u56fa\u5b9a\u5f0f\u6954\u5f62\u6ffe\u677f\u56e0\u5b50\u505a\u6bd4\u8f03\uff0c\u4ee5\u4e86\u89e3\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5291\u91cf\u4e0a\u4e0d\u540c\u65bc\u56fa\u5b9a\u5f0f\u6954\u5f62\u6ffe\u677f\u7684\u7279\u6027\uff0c\u589e\u52a0\u5c0d\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5291\u91cf\u5b78\u4e0a\u7684\u4e86\u89e3\u53ca\u4f7f\u7528\u4e0a\u61c9\u8003\u91cf \u7684\u56e0\u7d20\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4ee5 N.E.0.6cc Farmer Type\u6e38\u96e2\u8154\u7f6e\u65bcScanditronix RFA-300 \u6c34\u5047\u9ad4\u5c04\u675f\u4e2d\u5fc3\u8ef8\u6df1\u5ea65cm(6MV)\u53ca 10cm(15 MV)\u8655\uff0c\u5c07\u6c34\u5047\u9ad4\u8868\u9762\u7f6e\u65bc100cm\u8655\uff0c\u6e38\u96e2\u8154\u9577\u8ef8\u8207\u6ffe\u677f\u6a6b\u5207\u9762\u5448\u5782\u76f4\uff0c\u5206\u5225\u6e2c\u91cf15\u00b0\u300130\u00b0\u300145\u00b0\u300160\u00b0\u3002\u56fa\u5b9a\u5f0f\u53ca\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5404\u6b63\u65b9\u5f62\u7167\u91ce\u4e4b\u7a7f\u900f\u56e0\u5b50\uff0c\u4ee5\u89c0\u5bdf\u4e26\u6bd4\u8f03\u5176\u8b8a\u5316\u3002\n\u7d50\u679c\uff1a\u56fa\u5b9a\u5f0f\u6954\u5f62\u6ffe\u677f\u4e4b\u7a7f\u900f\u56e0\u5b50\u96a8\u7167\u91ce\u8b8a\u5927\u6709\u589e\u5927\u4e4b\u8da8\u52e2\uff0c\u5e73\u5747\u7d04\u589e\u52a03%\uff1b\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u7a7f\u900f\u56e0\u5b50\u4e00\u822c\u8f03\u56fa\u5b9a\u5f0f\u6954\u5f62\u6ffe\u677f\u4e4b\u7a7f\u900f\u56e0\u5b50\u5927\uff0c\u8207\u7167\u91ce\u5927\u5c0f\u4e4b\u8b8a\u5316\u95dc\u4fc2\u5247\u5448\u4e0d\u898f\u5247\u4e4b\u8b8a\u5c0f\u8da8\u52e2\uff0c\u76f8\u5dee\u6700\u5927\u905435%\u3002\n\u7d50\u8ad6\uff1a\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u5728\u570b\u5167\u61c9\u7528\u4e4b\u7d93\u9a57\u5c1a\u6dfa\uff0c\u5c0d\u5176\u5291\u91cf\u5b78\u4e0a\u4e4b\u7279\u6027\u61c9\u4e88\u591a\u65b9\u4e86\u89e3\uff0c\u6bd4\u5982\u7b49\u5291\u91cf\u5206\u4f48\u66f2\u7dda\uff0c\u7a7f\u900f\u56e0\u5b50\u8207\u7167\u91ce\u4e4b\u95dc\u4fc2\u7b49\uff0e\u7531\u672c\u6587\u4e4b\u7d50\u679c\u5f97\u77e5\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u7a7f\u900f\u56e0\u5b50\u8207\u7167\u91ce\u4e4b\u95dc\u4fc2\u4e0d\u5448\u898f\u5247\u6027\u8b8a\u5316\uff0c\u5c0d\u81e8\u5e8a\u61c9\u7528\u4e0a\uff0c\u7531\u65bc\u8b8a\u5316\u6975\u5927\uff0c\u5291\u91cf\u8a08\u7b97\u6642\u61c9\u8996\u5176\u7167\u91ce\u5927\u5c0f\u6b63\u78ba\u67e5\u5f97\u5176\u56e0\u5b50\uff0c\u4ee5\u6c42\u5f97\u6b63\u78ba\u4e4b\u76e3\u6e2c\u55ae\u4f4d\uff1b\u53e6\u5916\uff0c\u6b32\u5c0d\u4e00\u822c\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5efa\u7acb\u52d5\u614b\u5f0f\u6954\u5f62\u6ffe\u677f\u8cc7\u6599\u5eab\u6642\uff0c\u4ea6\u61c9\u5c0d\u7a7f\u900f\u56e0\u5b50\u7684\u4e0d\u898f\u5247\u8b8a\u5316\u4ed4\u7d30\u8003\u616e\u5176\u5291\u91cf\u5b78\u7684\u6e96\u78ba\u6027\u3002", "e": "Purpose: The transmission factors of each dynamic and fixed wedge were measured for Varian CL-2100C/D Sn: 481 linear accelerator. The factors were used to set-up the clinical treatment data tables for clinical dosimetry for dynamic wedges utilization. The data will be used to set-up the computer treatment planning database also.\nMaterials and Methods: The N.E.0.6cc Farmer type chamber (Type: 2571) connected to lonex Dosemaster 2590 was installed on the chamber frame of Scanditronix RFA-300 water phantom with water prove protector. The axis of the chamber is perpendicular to the transverse plane of the wedge. Output factors in water were measured on the central axis of each field at 5-cm depth for 6 MV and 10-cm depth for 15 MV X-rays. The phantom was positioned with the water surface at 100 cm SSD. Measurements were performed for field sizes ranging from 4.0-20.0 cm and for equivalent square field to 25 cm. The measurements were performed for open, for fixed and dynamic wedge angles. The transmission factor of each field size was calculated from the output with/without wedge.\nResults: The transmission factors of each fixed wedges were increased as field size increase. The increment is around 3%. The factors of the dynamic wedge were larger than the fix ones, but the factors were decreased irregularly when field size increase. The maximum decrement is 35%. Conclusion Transmission factor is an important parameter in clinical applications of wedge filters. The variation of the factors of dynamic wedges verse field size is not the same as fixed ones and more complex. Due to the variation of the factors, one should take more attention in the application and the data input of the planning system."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-49-56-a", "title": "\u665a\u671f\u5b50\u5bae\u5167\u819c\u764c", "keywords": "\u5b50\u5bae\u5167\u819c\u764c;\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c Endometrial cancer;Post-operative radiotherapy;Prognosis", "c": "\u76ee\u7684\uff1a\u672c\u6587\u4ee5\u56de\u6eaf\u6027\u7814\u7a76\u5c07\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u5341\u4e00\u5e74\u4f86\u7684\u75c5\u60a3\u91cd\u65b0\u75c5\u7406\u5206\u671f\u70ba\u665a\u671f\u5b50\u5bae\u5167\u819c\u764c\u75c5\u60a3\u7684\u5b58\u6d3b\u8207\u6cbb\u7642\u7684\u72c0\u6cc1\u505a\u4e00\u5206\u6790\u6574\u7406\uff0c\u4ee5\u63d0\u4f9b\u672a\u4f86\u6cbb\u7642\u65b9\u5411\u7684\u4f9d\u64da\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1985\u5e746\u6708\u52301996\u5e747\u6708\uff0c \u5728\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u764c\u75c7\u767b\u8a18\u4e2d\u5171\u6709174\u540d\u5b50\u5bae\u5167\u819c\u764c\u7684\u75c5\u60a3\uff0c\u91cd\u65b0\u5c07\u624b\u8853\u5f8c\u75c5\u7406\u5831\u544a\u53ca\u8179\u8154\u764c\u7d30\u80de\u6aa2\u67e5\u7d50\u679c\u4ee5\u570b\u969b\u5a66\u7522\u79d1\u806f\u76df\u671f\u5225\u7cfb\u7d71\u5206\u671f\u5f8c\uff0c25\u540d\u75c5\u60a3\u70ba\u7b2c\u2162\u671f\u5b50\u5bae\u5167\u819c\u764c\u60a3\uff0c4\u540d\u70ba\u7b2c\u56db\u671f\u75c5\u4eba\uff1b\u5e74\u9f61\u753140\u6b72\u523079\u6b72\uff0c\u4e2d\u4f4d\u6578\u70ba 56 \u6b72\uff1b\u81e8\u5e8a\u8868\u73fe\u75c7\u72c0\u4e2d\u4ee5\u4e0d\u6b63\u5e38\u51fa\u8840\u6700\u70ba\u5e38\u898b\uff0c\u4f5421/29; 28\u540d\u75c5\u60a3\u7d93\u904e\u624b\u8853\u63a2\u67e5\uff0c\u670918\u4f4d\u75c5\u60a3\u63a5\u53d7\u624b\u8853\u5f8c\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u5305\u62ec\u9ad4\u5916\u7167\u5c04\u53ca\u9670\u9053\u6b98\u7aef\u8154\u5167\u6cbb\u7642\uff0c\u7167\u5c04\u7e3d\u5291\u91cf\u5206\u5225\u70ba5040cGy \u5230 5940c \u53e5\u8207 2000cGy\u52303000cGy\uff1b\u8ffd\u8e64\u671f\u70ba2.5\u500b\u6708\u5230161.3\u500b\u6708\uff08\u4e2d\u503c\u70ba37.3\u500b\u6708\uff09\uff0c\u5be6\u969b\u7684\u7d2f\u8a08\u5b58\u6d3b\u66f2\u7dda\u5247\u4f9d\u7167Kaplan-Meier\u5206\u6790\u6cd5\u6c42\u5f97\uff0c\u4e26\u63a1\u7528Gehans Generalized wilcoxon\u3000test\u4f86\u6aa2\u6e2c\u4e0d\u540c\u5b58\u6d3b\u66f2\u7dda\u7684\u5dee\u7570\u6027\u3002\n\u7d50\u679c\uff1a\u91cd\u65b0\u75c5\u7406\u5206\u671f\u5f8c\u670914\u540d\u60a3\u8005\u70ba\u7b2c\u2162A \u671f\u300111\u540d\u60a3\u8005\u70ba\u7b2c\u2163C\u671f\u30011 \u540d\u70ba\u7b2c\u2163A\u671f\u3001 3\u540d\u70ba\u7b2c\u2163B\u671f\uff0c\u5168\u90e8\u75c5\u60a3\u4e94\u5e74\u6574\u9ad4\u7684\u5b58\u6d3b\u7387\u70ba48.3%\uff1b\u7b2c\u4e09\u671f\u75c5\u60a3\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba52%\uff1b\u800c4\u540d\u7b2c\u56db\u671f\u7684\u60a3\u8005\u67093\u540d\u6b7b\u4ea1\uff1b\u4e94\u5e74\u5b58\u6d3b\u7387\u5728\u7d30\u80de\u5206\u5316\u5ea6\u4f73\u3001\u6dfa\u808c\u5c64\u4fb5\u72af\u3001\u8f14\u52a9\u653e\u7642\u7b49\u60c5\u5f62\u4e0b\u6709\u986f\u8457\u5dee\u7570\uff1b\u9ad8\u9f61\u75c5\u606f\u4ea6\u53ef\u898b\u4f4e\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\uff0c\u4f46\u672a\u9054\u986f\u8457\u5dee\u7570\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u5206\u6790\u53ef\u77e5\u5c0d\u665a\u671f\u5b50\u5bae\u5167\u819c\u764c\u624b\u8853\u5f8c\u653e\u7642\u7684\u7d66\u8207\u53ef\u63d0\u9ad8\u5b58\u6d3b\u7387\uff1a\u5e74\u9f61\u5927\u8005\uff0c\u75c5\u7406\u671f\u5225\u8207\u7d30\u80de\u5206\u5316\u5ea6\u5dee\u7684\u6bd4\u7387\u5747\u8f03\u9ad8\uff0c\u56e0\u800c\u53ef\u80fd\u6709\u8f03\u5dee\u7684\u5b58\u6d3b\u7387\uff1b\u6df1\u90e8\u5b50\u5bae\u808c\u5c64\u4fb5\u72af\u6703\u660e\u986f\u5f71\u97ff\u5b58\u6d3b\u7387\uff0c\u4f46\u53ef\u80fd\u8207\u9ad8\u6bd4\u7387\u7684\u5dee\u7d30\u80de\u5206\u5316\u5ea6\u8207\u6dcb\u5df4\u8f49\u79fb\u6709\u95dc\uff1b\u5c0d\u65bc\u55ae\u7368\u7684\u8f38\u5375\u7ba1\u6234\u5375\u5de2\u4fb5\u72af\u7684\u75c5\u60a3\uff0c\u61c9\u9f13\u52f5\u5176\u5b8c\u6210\u9aa8\u76c6\u8154\u653e\u7642\u4ee5\u53d6\u5f97\u8f03\u4f73\u7684\u5b58\u6d3b\u6a5f\u6703\uff1b\u4f46\u662f\u82e5\u6709\u5de8\u89c0\u7684\u5b50\u5bae\u65c1\u7d44\u7e54\u7684\u4fb5\u72af\uff0c\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u7d50\u8f49\u79fb\uff0c\u7b2c\u4e09\u7d1a\u5206\u5316\u5ea6\u8207\u900f\u660e\u7d30\u80de\u764c\u6216\u4e73\u7a81\u72c0\u6f3f\u6db2\u764c\uff0c\u66f4\u7a4d\u6975\u7684\u8f14\u52a9\u6027\u6cbb\u7642\u5982\u66f4\u5927\u7bc4\u570d\u7684\u653e\u7642\u6216\u5316\u5b78\u6cbb\u7642\u7b49\u61c9\u5373\u65e9\u4f7f\u7528\u3002", "e": "Purpose: To evaluate the therapeutic results of stage \u2162 and IV advanced endometrial carcinoma treated at Mackay Memorial Hospital over the past ten years. To address the future direction in the management of this disease.\nMaterials and methods: From July 1985 to June 1996, 174 patients with pathologically proven endometrial cancer were registered. All patients were staged according to the 1988 FIGO staging system. There were 25 cases with stage \u2162 disease and 4 patients with stage IV disease. The median age was 57 years with a range of 40-79 years. Abnormal vaginal bloody discharge (21/29) was the most common symptom. Twenty-eight patients received a surgical approach initially. Seventeen patients received adjuvant radiotherapy to the whole pelvis with doses ranging from 5040 cGy to 5940 cGy and vaginal cuff irradiation with doses ranging from 2000 cGy to 3000 cGy, respectively. The follow-up period ranged from 2.5 months to 161.3 months. The acturial five-year cumulative survival rate was evaluated according to the Kaplan-Meier method and significance was calculated according to the Gehans General Wilcoxan test.\nResults: Restaging showed 14 cases with stage \u2162A disease, 11 with stage \u2162C, 1 with stage IVA and 3 with stage IVB. The overall 5-year survival for all patients was 48.3%, and for stage \u2162 patients was 52%. There were four patients with stage IV disease, three of them died during the follow-up. In addition, the overall 5- year survival rate was statistically higher in grade 1 and 2 than in grade 3 in superficial myometrial invasion and in the radiation group. Older aged patients did have a lower 5-year survival rate but it was not statistically significant.\nConclusion: In patients with solitary extrauterine involvement, whole pelvis irradiation results in better survival. Gross adaexic involvement, para-aortic lymph node metastases and poordifferentiation or clear cell or papillary serous carcinoma have a more aggressive character, and so pelvic irradiation only as adjuvant therapy is inadequate. Therefore further aggressive therapy including extended-field irradiation, whole abdominal irradiation, hormonal therapy and chemotherapy should be considered."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-57-63-a", "title": "Evaluation of Major Salivary Gland Function by Sialoscintigraphy in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy", "keywords": "\u553e\u6db2\u817a\u6838\u91ab\u9020\u5f71;\u553e\u6db2\u817a;\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642 sialoscintigraphy;salivary gland;nasopharyngeal cancer;radiotherapy", "c": "Purpose: To evaluate the major salivary gland functions by sialoscintigraphy in nasopharyngeal carcinoma patients treated by radiotherapy.\nMaterials and Methods: This analysis includes 28 nasopharyngeal cancer (NPC) patients and 31 sialoscintigraphies. The sialoscintigraphies were grouped as pre-radiotherapy (pre-RT), low dose (\uff1c1050 cGy), and high dose (\uff1e1050 cGy) according to the radiation dose given to the patients when the scanning was performed. Apart from 3 patients who received 2scannings, the other 26 patients received only one test. Another 8 normal adult sialoscintigraphics were included as controls. Patients, noa-irradiated or irradiated with high or low doses, were given 10mCi(superscript 99m) Tc-pertechnetate and scanned immediately. Twenty minutes later 200 ml of lemon juice was given by month and the patient was scanned again for another 20 minutes. Time-activity curves and the cumulative gland (superscript 99m)Tc-pertechnetate uptake of each gland were plotted and calculated. The stimulated secretion is defined as: stimnlated secretion (SS)=[1-(min/max)]\u00d7100%. The downward slope was also obtained from the post-stimnlation curve of the time-activity curve to describe the secretory function.\nResults: A strong positive excretion response after lemon juice stimulation of both parotid and submandibular glands was noted in non-irradiated patients. After irradiation of 1050 cGy or less, a significant impairment in secretion of all major salivary glands was noted. The trapping of (superscript 99m)Tc-pertechnetate was not affected as compared with the normal controls and pre-RT scannings. After a larger dose of radiations, no curves displayed excretory response after stimulation. In terms of qualitative measurement, the 99mTc-pertechnetate uptake is not different among the four groups of patients in either parotid or submandibular glands except in the group after high dose radiations. The down slopes and stimulated secretion are statistically different between the non-irradiated and the irradiated groups.\nConclusion: The salivary gland secretion was totally or partially disturbed in all patients after high dose radiation . Cumulative uptake of (superscript 99m)Tc-pertechnetate after high dose is statistically higher than pre-RT patients. Stimulated secretion was markedly retarded after high dose radiation. The data imply that the mechanism of dry mouth after high dose irradiation was mainly excretory dysfunction rather than uptake disturbance of metabolic substances. This observation is valuable in the understanding of the underlying mechanism of radiation-induced salivary gland dysfunction, and may contribute to the future resolution of this difficult side effect.", "e": "Purpose: To evaluate the major salivary gland functions by sialoscintigraphy in nasopharyngeal carcinoma patients treated by radiotherapy.\nMaterials and Methods: This analysis includes 28 nasopharyngeal cancer (NPC) patients and 31 sialoscintigraphies. The sialoscintigraphies were grouped as pre-radiotherapy (pre-RT), low dose (\uff1c1050 cGy), and high dose (\uff1e1050 cGy) according to the radiation dose given to the patients when the scanning was performed. Apart from 3 patients who received 2scannings, the other 26 patients received only one test. Another 8 normal adult sialoscintigraphics were included as controls. Patients, noa-irradiated or irradiated with high or low doses, were given 10mCi(superscript 99m) Tc-pertechnetate and scanned immediately. Twenty minutes later 200 ml of lemon juice was given by month and the patient was scanned again for another 20 minutes. Time-activity curves and the cumulative gland (superscript 99m)Tc-pertechnetate uptake of each gland were plotted and calculated. The stimulated secretion is defined as: stimnlated secretion (SS)=[1-(min/max)]\u00d7100%. The downward slope was also obtained from the post-stimnlation curve of the time-activity curve to describe the secretory function.\nResults: A strong positive excretion response after lemon juice stimulation of both parotid and submandibular glands was noted in non-irradiated patients. After irradiation of 1050 cGy or less, a significant impairment in secretion of all major salivary glands was noted. The trapping of (superscript 99m)Tc-pertechnetate was not affected as compared with the normal controls and pre-RT scannings. After a larger dose of radiations, no curves displayed excretory response after stimulation. In terms of qualitative measurement, the 99mTc-pertechnetate uptake is not different among the four groups of patients in either parotid or submandibular glands except in the group after high dose radiations. The down slopes and stimulated secretion are statistically different between the non-irradiated and the irradiated groups.\nConclusion: The salivary gland secretion was totally or partially disturbed in all patients after high dose radiation . Cumulative uptake of (superscript 99m)Tc-pertechnetate after high dose is statistically higher than pre-RT patients. Stimulated secretion was markedly retarded after high dose radiation. The data imply that the mechanism of dry mouth after high dose irradiation was mainly excretory dysfunction rather than uptake disturbance of metabolic substances. This observation is valuable in the understanding of the underlying mechanism of radiation-induced salivary gland dysfunction, and may contribute to the future resolution of this difficult side effect."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199703-4-1-65-69-a", "title": "\u653e\u5c04\u624b\u8853\u8207\u591a\u7167\u91ce\u653e\u5c04\u6cbb\u7642\u65e9\u671f\u5fa9\u767c\u6027\u9f3b\u54bd\u764c\u4e4b\u81e8\u5e8a\u75c5\u4f8b\u5831\u544a", "keywords": "\u5fa9\u767c\u9f3b\u54bd\u764c;\u7acb\u9ad4\u5b9a\u4f4dX\u5149\u5200;\u653e\u5c04\u6cbb\u7642 Recurrent nasopharyngeal cance;Stereotactic radiosurgery;Radiotherapy", "c": "\u76ee\u7684\uff1a\u5fa9\u767c\u9f3b\u54bd\u764c\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4dX\u5149\u5200\u53ca\u540c\u5e73\u9762\u4e03\u7167\u91ce\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u8ffd\u8e64\u905432\u500b\u6708\u4e4b\u75c5\u4f8b\u5831\u544a\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u75c5\u4f8b\u70ba\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5f8c\u4e00\u5e74\u767c\u751f\u5fa9\u767c\u4e4b\u9f3b\u5614\u764c\u60a3\u8005\uff0c\u5176\u63a5\u53d7\u4e86\u4e8c\u5ea6\u7a7a\u9593\u540c\u5e73\u9762\u4e03\u7167\u91ce\u4e4b\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff0c\u5291\u91cf\u70ba504 Gy\u3002\u518d\u63a5\u53d7\u7acb\u9ad4\u5b9a\u4f4dX\u5149\u5200\uff0c\u53d62\u500b\u7b49\u5291\u91cf\u4e2d\u5fc3\uff0c\u6cbb\u7642\u9ad4\u7a4d\u70ba41.75\u7acb\u65b9\u516c\u5206\uff0c\u7d66\u5b50\u5291\u91cf\u65bc80%\u7b49\u5291\u91cf\u66f2\u7dda\u8655\u70ba10Gy\u3002\n\u7d50\u679c\uff1a\u5fa9\u767c\u816b\u7624\u6cbb\u7642\u5f8c\u8ffd\u8e6432\u500b\u6708\u4ecd\u7121\u5c40\u90e8\u816b\u7624\u9032\u884c\u7684\u8de1\u8c61\uff0c\u4ee5\u53ca\u76f8\u95dc\u5f8c\u9063\u75c7\u7684\u7522\u751f\u3002\n\u7d50\u8ad6\uff1a\u5728\u8ffd32\u500b\u6708\u5f8c\uff0c\u4ecd\u7dad\u6301\u5c40\u90e8\u816b\u7624\u7684\u63a7\u5236\uff0c\u4ea6\u7121\u76f8\u95dc\u5f8c\u907a\u75c7\u7522\u751f\uff0c\u6bd4\u8d77\u5c0d\u5fa9\u767c\u9f3b\u54bd\u764c\u50b3\u7d71\u7684\u6cbb\u7642\uff0c\u5305\u62ec\u624b\u8853\u3001\u5316\u5b78\u6cbb\u7642\u3001\u653e\u5c04\u8fd1\u63a5\u6cbb\u7642\u53ca\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u800c\u8a00\uff0c\u591a\u7167\u91ce\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u5408\u4f75\u4e4b\u7acb\u9ad4\u5b9a\u4f4d\u00d7\u5149\u5200\u624b\u8853\uff0c\u5728\u4e0d\u964d\u4f4e\u5c40\u90e8\u816b\u7624\u4e4b\u63a7\u5236\u4e0b\u53ef\u6e1b\u5c11\u5f8c\u907a\u75c7\u3002\u4f46\u4ecd\u9700\u8981\u9577\u671f\u8a55\u4f30\u5c0d\u672b\u671f\u53cd\u61c9\u7d44\u7e54\u4e4b\u5f71\u9957\u3002", "e": "Purpose: To report a case of locally recurrent nasopharyngeal cancer (NPC) remaining disease-free 32 months after 7 portals of co-planar external beams re-irradiation and LINAC-based stereotactic radio-surgery.\nMaterials and Methods: A NPC patient recurred at one year after the first local irradiation. He then was treated with a dose of 50.4 Gy external radiotherapy delivered by 7 portals of co-planar beams and followed by 10 Gy LINAC-based stereotactic radiosurgery. In radiosurgery, the dose was delivered by using of 2 isocenters and prescribed at the 80% isodose curve. The treatment volume was 41.75 cubic centimeter.\nResults: After 32 months of follow up, no local recurrence or adverse effect is recognized.\nConclusion: Multiple portals of co-planar external beam radiotherapy and radiosurgery in treating recurrent NPC is successful in local control and less complication than single treatment modality such as operation, chemotherapy, brachytherapy and regular external radiotherapy. Long-term follow up is necessary for further evaluation in late effect on critical organs of this kind of combined treatment modalities."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-215-220-a", "title": "\u4ee5\u4eba\u985e\u809d\u764c\u7d30\u80de\u6e2c\u8a66\u787c\u7898\u5316\u6cb9\u5728\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u4e0a\u4e4b\u751f\u7269\u6548\u61c9", "keywords": "\u787c\u7898\u5316\u6cb9;\u809d\u764c\u7d30\u80de;\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642 B-lipiodol;Hepatoma cell;Boron neutron capture therapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u70ba\u7814\u88fd\u542b\u787c\u7898\u5316\u6cb9(B-lipiodol)\uff0c\u63a2\u8a0e\u4eba\u985e\u809d\u764c\u7d30\u80de(HepG2 Cells)\u5c0dB-lipiodol\u4e4b\u7a4d\u805a\u6548\u679c\u53ca\u4e2d\u5b50\u7167\u5c04\u5f8c\u4e4b\u7d30\u80de\u6bd2\u6027\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u57f9\u990a\u4e2d\u4e4b\u4eba\u985e\u809d\u764c\u7d30\u80de\u6e2c\u8a66\u5176\u5c0dB-lipiodol\u4e4b\u651d\u5165\u53ca\u7a4d\u805a\u3002\u4ee5\u5149\u5b78\u986f\u5fae\u93e1\u6aa2\u8996B-lipiodol\u8207\u809d\u764c\u7d30\u80de\u9593\u4e4b\u4ea4\u4e92\u4f5c\u7528\u3002\u4ee5\u611f\u61c9\u5076\u5408\u96fb\u6f3f\u539f\u5b50\u767c\u5c04\u5149\u8b5c\u5206\u6790\u5100\u5206\u6790\u787c\u542b\u91cf\u3002\u7d93B-lipiodol\u8655\u7406\u4e4b\u809d\u764c\u7d30\u80de\u65bc\u6e05\u83ef\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668\u4e2d\u63a5\u53d7\u4e2d\u5b50\u7167\u5c04\u3002\n\u7d50\u679c\uff1a\u8840\u6e05\u4e2d\u7a69\u5b9a\u6027\u6e2c\u8a66\uff0c\u7d50\u679c\u986f\u793a\u787c\u53ef\u7a69\u5b9a\u5b58\u65bcB-lipiodol\u4e2d\u3002\u809d\u764c\u7d30\u80de\u53ef\u5927\u91cf\u651d\u5165\u3001\u7a4d\u805aB-lipiodol\u3002\u5728\u6211\u5011\u7684\u6e2c\u8a66\u689d\u4ef6\u4e0b\uff0c\u4e2d\u5b50\u6355\u7372\u5c0dB-lipiodol\u8655\u7406\u4e4b\u809d\u764c\u7d30\u80de\u5177\u6709\u6975\u9ad8\u4e4b\u7d30\u80de\u6bd2\u6027\u3001\u5291\u91cf\u53cd\u61c9\u66f2\u7dab\u76f8\u7576\u9661\u3002\n\u7d50\u8ad6\uff1a\u53d7\u6e2c\u4eba\u985e\u809d\u764c\u7d30\u80de\u6703\u651d\u5165B-lipiodol\uff0c\u4e14\u6709\u8db3\u591f\u91cf\u4e4b\u787c\u6703\u6eef\u7559\u65bc\u7d30\u80de\u4e2d\u4ee5\u4f9b\u4e2d\u5b50\u6355\u7372\u53cd\u61c9\u7528\u3002B-lipiodol\u61c9\u7528\u65bc\u4eba\u985e\u809d\u764c\u7d30\u80de\u4e4b\u787c\u4e2d\u5b50\u6355\u7372\u6bba\u50b7\u4e0a\u662f\u4e00\u5177\u9ad8\u7d30\u80de\u6bd2\u6027\u85e5\u7269\u3002", "e": "Objective: The objective of this study was designed to preparation of the boron containing lipiodol (B-lipiodol) for boron neutron capture therapy, and evaluation of the cytotoxicity of B-lipiodol on hepatoma cells after neutron irradiation.\nMaterials and Methods: HepG2 cell culture was used to examine of the uptake and retention of B-lipiodol. Light microscopes were used for examination of the interaction and retention of 8-lipiodol droplets in the individual cell. Boron concentration was determined by ICPASS analysis. THOR was used for irradiation of the B-lipiodol treated HepG2 cells.\nResults: Stability test showed that boron was stably retained in lipiodol contrast medium. HepG2 cells appeared proficiently at internalization and retention of B-lipiodol. Under our tested condition, boron neutron capture was highly cytotoxic in B-lipiodol treated HepG2 cells. There was a steep dose response relationship.\nConclusion: Hepatoma cells are capable of active uptake of B-lipiodol and enough amount of boron was retention inside the cells for neutron capture reaction. B-lipiodol is a highly cytotoxic and effective drug for the neutron-capture killing of FIepG2 cells."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-221-228-a", "title": "Dose Calculation Algorithm for Proton Beam Radiotherapy at the Indiana University Cyclotron Facility (IUCF)", "keywords": "\u8cea\u5b50\u653e\u5c04\u6cbb\u7642;\u5291\u91cf\u8a08\u7b97;\u6cbb\u7642\u8a08\u756b;\u8cea\u5b50\u5c04\u6771\u767c\u6563\u6cd5 Proton radiotherapy;Dose calculation;Treatment planning;Ray-tracing", "c": "\u76ee\u7684\uff1a\u4ecb\u7d39\u5370\u7b2c\u5b89\u90a3\u5927\u5b78;\u56de\u65cb\u52a0\u901f\u5668\u8cea\u5b50\u6cbb\u7642\u8a2d\u65bd\u53ca\u5176\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u8a08\u7b97\u7a0b\u5f0f\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5370\u7b2c\u5b89\u90a3\u5927\u5b78\u8ff4\u65cb\u52a0\u901f\u5668\u8cea\u5b50\u6cbb\u7642\u8a2d\u65bd\u5177\u6709\u4e00\u53ef\u8b8a\u80fd\u91cf(45-200MeV)\u7684\u8cea\u5b50\u6cbb\u7642\u5c04\u675f\u3002\u5176\u7d44\u6210\u5305\u542b\u5c04\u675f\u622a\u9762\u64f4\u6563\u88dd\u7f6e\uff0c\u5c04\u675f\u80fd\u91cf\u64f4\u6563\u88dd\u7f6e\u53ca\u7d66\u65bc\u5291\u91cf\u76e3\u8996\u6a21\u64ec\u88dd\u7f6e\u3002\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u8207\u50b3\u7d71\u5149\u5b50\u8207\u96fb\u5b50\u6cbb\u7642\u985e\u4f3c\u3002\u5176\u5291\u91cf\u8a08\u7b97\u7a0b\u5f0f\u5247\u63a1\u7528\u76f4\u7dda\u5c04\u675f\u767c\u6563\u6cd5\u4e26\u5047\u8a2d\u8cea\u5b50\u5728\u7269\u8cea\u5167\u4ee5\u76f4\u7dda\u7684\u8def\u5f91\u524d\u9032\u3002\u8cea\u5b50\u7684\u591a\u78b0\u649e\u6563\u5c04\u6548\u61c9\u662f\u7531\u6e2c\u91cf\u800c\u5f97\u7684\u5074\u9762\u5291\u91cf\u5206\u5e03\u4f86\u8655\u7406\uff1b\u800c\u5176\u96a8\u6df1\u5ea6\u589e\u52a0\u7684\u80fd\u91cf\u640d\u5931\u5247\u7531\u53e6\u4e00\u6e2c\u91cf\u5f97\u5230\u7684\u6df1\u5ea6\u5291\u91cf\u5206\u4f48\u4f86\u5305\u542b\uff0c\u5728\u5291\u91cf\u8a08\u7b97\u4e0a\u5f88\u91cd\u8981\u7684\u4e0d\u5747\u8cea\u6821\u6b63\u662f\u5229\u7528\u6e2c\u5f97\u7684CT\u6578\u8207\u7269\u8cea\u96fb\u5b50\u5bc6\u5ea6\u4e4b\u554f\u7684\u6821\u6b63\u66f2\u7dab\u800c\u5f97\u3002\n\u7d50\u679c\u8207\u8a0e\u8ad6\uff1a\u7d93\u7531\u6e2c\u91cf\u7d50\u679c\u986f\u793a\uff0c\u5be6\u9a57\u6240\u7528\u7269\u8cea\u7684CT\u6578\u8207\u96fb\u5b50\u5bc6\u5ea6\u4e4b\u9593\u5b58\u5728\u4e00\u6b63\u6bd4\u7684\u7dda\u6027\u95dc\u4fc2\u3002\u91c7\u7528\u76f4\u7dab\u5c04\u675f\u767c\u6563\u6cd5\u505a\u5291\u91cf\u8a08\u7b97\u7684\u597d\u8655\u5728\u4e8e\u5176\u5feb\u901f\u7684\u8a08\u7b97\u6642\u9593\u5e77\u80fd\u7dad\u6301\u81e8\u5e8a\u53ef\u63a5\u53d7\u7684\u6e96\u78ba\u5ea6\u3002\u672c\u6587\u4ee5\u4e00\u500b\u4e09\u7167\u91ce\u5171\u5e73\u9762\u7684\u6cbb\u7642\u8a08\u756b\u7232\u4f8b\uff0c\u5728\u5de5\u4f5c\u7ad9\u7d1a\u7684\u96fb\u8166\u4e0a(Sun Sparc 10)\u5176\u6240\u9700\u8a08\u7b97\u6642\u9593\u53ef\u5c11\u65bc\u5169\u5206\u9418\u3002\n\u7d50\u8ad6\uff1a\u5f9e\u4e00\u500b\u4e09\u7167\u91ce\u5171\u5e73\u9762\u7684\u6cbb\u7642\u8a08\u756b\u5291\u91cf\u5206\u5e03\u53ef\u77e5\u76f4\u7dab\u5c04\u675f\u767c\u6563\u6cd5\u7232\u4e00\u6e96\u78ba\u5e77\u9069\u7528\u4e8e\u81e8\u5e8a\u4e0a\u7684\u8cea\u5b50\u6cbb\u7642\u5291\u91cf\u8a08\u7b97\u65b9\u6cd5\u3002\u5176\u5feb\u901f\u7684\u5291\u91cf\u8a08\u7b97\u6700\u9069\u5408\u5728\u7e41\u5fd9\u7684\u81e8\u5e8a\u74b0\u5883\u4e2d\u61c9\u7528\u3002", "e": "Purpose: To describe the treatment facility and the proton treatment planning algorithm at the Indiana University Cyclotron Facility (IUCF) for patient dose calculation.\nMaterials and Methods: A 45-200 MeV proton beam line is available at IUCF for cancer patient treatments. The treatment beam line consists of a beam spreading system, range modulator and beam and dose monitoring diagnostics. Treatment planning is similar to conventional 3-D photon and electron radiotherapy. The dose calculation algorithm used is based on a ray-tracing method which assumes that protons penetrate dense media following straight paths. The proton multiple scattering effects are implicitly included in the algorithm by incorporating measured lateral beam data. Measured central axis depth dose data is also incorporated into the algorithm to model the energy loss process along defined proton ray paths. The well-known relationship between CT number and electron density (i.e. stopping power) of tissues was measured for our CT scanner and the data were then used to connect the input depth dose for tissue heterogeneities along proton ray paths. \nResults and Discussion: A linear relationship between CT number and electron density over the range of interest was defined by direct measurements. The advantage of the chosen ray-tracing method lies in its short calculation time while maintaining a clinically acceptable point dose accuracy. An example calculation for a coplanar three field treatment technique was demonstrated. Calculation time for this plan took less than two minutes on a Sun Spare 10 workstation.\nConclusion: An example calculation for a coplanar three field treatment technique demonstrated the ray tracing method to be an accurate and clinically feasible proton dose calculation algorithm. Its fast dose calculation time makes it an ideal candidate for proton treatment planning dose calculation in a busy clinical environment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-229-232-a", "title": "\u9f3b\u54bd\u764c\u7684\u9060\u7aef\u8f49\u79fb", "keywords": "\u9f3b\u54bd\u764c;\u9060\u7aef\u8f49\u79fb Nasopharyngeal cancer;Distant metastases", "c": "\u76ee\u7684\uff1a\u9019\u662f\u4e00\u7bc7\u6709\u95dc\u65bc\u9f3b\u54bd\u764c\u6cbb\u7642\u5f8c\u767c\u751f\u9060\u7aef\u8f49\u79fb\u7684\u56de\u6eaf\u6027\u5206\u6790\u3002\u91dd\u5c0d252\u4f4d\u5728\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u904e\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\u5f8c\u7522\u751f\u9060\u7aef\u8f49\u79fb\u7684\u9f3b\u54bd\u764c\u75c5\u60a3\uff0c\u4f86\u89c0\u5bdf\u9f3b\u54bd\u764c\u9060\u7aef\u8f49\u79fb\u7684\u6642\u9593\u6027\u3001\u8f49\u79fb\u5340\u57df\u7684\u597d\u767c\u6027\u3001\u53ca\u5c0d\u9810\u5f8c\u5f71\u97ff\u7b49\u56e0\u7d20\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5f9e1979\u5e744\u6708\u52301990\u5e7412\u6708\u671f\u9593\uff0c\u5171\u6709l195\u4f4d\u9f3b\u54bd\u764c\u75c5\u60a3\u63a5\u53d7\u6839\u9664\u6027\u653e\u5c04\u6cbb\u7642\uff0c\u4e4b\u5f8c\u6709252\u4f4d\u60a3\u8005\u5728\u8ffd\u8e64\u6aa2\u67e5\u767c\u73fe\u6709\u9060\u7aef\u8f49\u79fb\u7684\u8de1\u8c61\u3002\n\u7d50\u679c\uff1a\u5728\u767c\u751f\u8f49\u79fb\u7684\u90e8\u4f4d\u4e0a\uff0c\u4ee5\u9aa8\u9abc\u3001\u809d\u81df\u3001\u53ca\u80ba\u81df\u8f49\u79fb\u6700\u70ba\u5e38\u898b\u3002\u670948%\u7684\u75c5\u4eba\u5728\u6cbb\u7642\u5f8c\u4e00\u5e74\u5167\u88ab\u767c\u73fe\u8f49\u79fb\uff0c\u5169\u5e74\u5167\u88ab\u767c\u73fe\u7684\u6bd4\u7387\u662f73%\uff0c\u800c\u4e94\u5e74\u5f8c\u767c\u751f\u9060\u7aef\u8f49\u79fb\u7684\u6a5f\u6703\u5247\u4f4e\u65bc5%\u3002\u767c\u73fe\u8f49\u79fb\u5f8c\u7684\u5b58\u6d3b\u6642\u554f\uff0c\u4e2d\u4f4d\u6578\u70ba8\u500b\u6708\uff0c1\u5e74\u5f8c\u5b58\u6d3b\u7387\u70ba35%\uff0c\u800c2\u5e74\u70ba12%\u3002\n\u7d50\u8ad6\uff1a\u9f3b\u54bd\u764c\u60a3\u8005\u5728\u767c\u73fe\u9060\u7aef\u8f49\u79fb\u4e4b\u5f8c\u7684\u5b58\u6d3b\u6642\u9593\uff0c\u5927\u591a\u6578\u90fd\u57282\u5e74\u4e4b\u5167\u3002\u5728\u767c\u751f\u8f49\u79fb\u7684\u90e8\u4f4d\u4e0a\uff0c\u4ee5\u9aa8\u9abc\u8f49\u79fb\u6700\u70ba\u5e38\u898b\u3002", "e": "Purpose: To study the interval between the incident of distant metastases and radical radiotherapy, the preferable metastatic sites, and the survival after metastases in nasopharyngeal carcinoma (N PC) patients.\nMaterials and Methods: One thousand one hundred and ninety-five (1195) NPC patients had completed local treatment of radiotherapy in radiation oncology department at Chang Gung Memorial Hospital from April 1979 to Dcecember 1990. Two hundred fifty-two patients (21%) were found to have distant metastases by the end of August 1996.\nResults: Bone, liver, and lung were the most common metastatic sites. Forty-eitht percent metastases happened within 1 year and 73% within 2 years. Less than 5% of distant metastases occurred 5 years after primary nasopharyngeal irradiation. Most of the patients died within one year (8 months median survival) after distant metastases had been diagnosed. The post distant mestastases survival rates in one and two years were 35% and 12% respectively.\nDiscussion: The majority of patients died within 2 years after distant metastases were diagnosed. Most of the distant metastases happened within 2 years after radiotherapy, skeletal metastases were the most common site."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-233-237-a", "title": "16\u5e74\u9f3b\u54bd\u764c\u764c\u75c5\u767b\u8a18", "keywords": "\u764c\u75c5\u767b\u8a18;\u764c\u75c5\u8ffd\u8e64;\u9f3b\u54bd\u764c Cancer registry;Follow up;Nasopharyngeal cancer", "c": "\u76ee\u7684\uff1a\u53f0\u7063\u5730\u5340\u8fd1\u5e74\u4f86\u764c\u75c7\u5df2\u8e8b\u8eab\u65bc\u5341\u5927\u6b7b\u56e0\u4e4b\u9996\u3002\u9f3b\u54bd\u764c\u5728\u53f0\u7063\u8207\u4e2d\u570b\u5357\u90e8\u7684\u7f79\u60a3\u7387\u6bd4\u4e16\u754c\u5176\u5b83\u5730\u65b9\u7232\u9ad8\uff0c\u6240\u4ee5\u77ad\u89e3\u9f3b\u54bd\u764c\u5c0d\u570b\u4eba\u5065\u5eb7\u7684\u5f71\u97ff\u662f\u975e\u5e38\u91cd\u8981\u7684\u8ab2\u984c\u3002\u672c\u7814\u7a76\u5229\u7528\u9f3b\u54bd\u764c\u764c\u75c5\u767b\u8a18\u4e4b\u8cc7\u6599\u5206\u6790\u53ca\u63a2\u8a0e\u9f3b\u54bd\u764c\u7684\u767c\u75c5\u9f61\u5206\u5e03\u3001\u5c45\u4f4f\u5730\u8207\u8077\u696d\u74b0\u5883\u56e0\u5b50\u4e4b\u5f71\u97ff\u3001\u76f4\u7cfb\u5bb6\u65cf\u764c\u75c5\u53f2\u7684\u6bd4\u7387\u3001\u6b7b\u4ea1\u539f\u56e0\u53ca\u8f49\u79fb\u90e8\u4f4d\u4e4b\u5206\u5e03\u3001\u75c5\u60a3\u8ffd\u8e2a\u65b9\u5f0f\u53ca\u6bd4\u7387\u6210\u6548\uff0c\u4f5c\u7232\u65e5\u5f8c\u8b77\u7406\u4e0a\u4e4b\u6539\u9032\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6797\u53e3\u9577\u5e9a\u91ab\u9662\u653e\u5c04\u816b\u7624\u79d1\u5f9e1979\u81f31994\u5e74\uff0c\u572816\u5e74\u5167\uff0c\u5171\u767b\u9304\u67092860\u4f4d\u9f3b\u54bd\u764c\u60a3\u8005\uff0c\u9032\u884c\u764c\u75c5\u767b\u8a18\u5206\u6790\u3002\u8cc7\u6599\u4f86\u6e90\u4e43\u6839\u64da\u75c5\u6b77\u8a18\u8f09\u8207\u8a72\u79d1\u764c\u75c5\u8cc7\u6599\u5e77\u9032\u884c\u96fb\u8a71\u9023\u7e6b\uff0c\u4fe1\u4ef6\u53ca\u6236\u653f\u901a\u8a0a\u7b49\u8ffd\u8e2a\u3002\n\u7d50\u679c\uff1a2860\u4f4d\u9f3b\u54bd\u764c\u75c5\u60a3\u4e4b\u767c\u75c5\u9f61\u4ee541-50\u6b72\u70ba\u6700\u591a\uff1b\u8077\u696d\u7684\u5206\u5e03\u4ee5\u5f9e\u4e8b\u5de5\u3001\u8fb2\u3001\u5bb6\u7ba1\u7232\u6688\u591a\uff1b\u75c5\u60a3\u5c45\u4f4f\u5730\u4e4b\u5206\u4f48\u4ee5\u6843\u5712\u7e23\u70ba\u6700\u9ad8\u30025\u5e74\u5b58\u6d3b\u7387\u70ba43%\uff0c\u4e2d\u9593\u5b58\u6d3b\u5e74\u4efd\u70ba3.83\u5e74\u30022860\u4f4d\u9f3b\u54bd\u764c\u75c5\u606f\u4e2d\u6709\u5bb6\u65cf\u764c\u75c5\u53f2\u8005\u5171226\u4f4d(7.9%)\uff0c\u6709\u5169\u7a2e\u6216\u5169\u7a2e\u4ee5\u4e0a\u764c\u75c5\u8005\u517144\u4f4d(l.5%)\u3002\u572816\u5e74\u5167\uff0c2860\u4f4d\u9f3b\u54bd\u764c\u75c5\u60a3\u5df2\u67091415\u4f4d(49.5%)\u500b\u6848\u6b7b\u4ea1\u3002\u6b7b\u4ea1\u539f\u56e0\u4e2d\uff0c1002\u4f4d(70.8%)\u4e43\u56e0\u9f3b\u54bd\u764c\u5c40\u90e8\u5fa9\u767c\u6216\u4e0d\u80fd\u63a7\u5236\u53bb\u4e16\uff1b\u6709300\u4f4d(21.2%)\u56e0\u9060\u8655\u8f49\u79fb\u6b7b\u4ea1\uff1bl13\u4f4d(8.0%)\u56e0\u764c\u75c5\u4ee5\u5916\u4e4b\u5176\u4ed6\u75be\u75c5\u800c\u6b7b\u4ea1\u3002\n\u7d50\u8ad6\uff1a\u9f3b\u54bd\u764c\u597d\u767c\u4e8e\u72c0\u5e74\u6642\u671f\uff0c\u5c0d\u5404\u65b9\u9762\u7523\u751f\u6df1\u5207\u5f71\u97ff\uff0c\u61c9\u7a4d\u6975\u63a8\u52d5\u9632\u764c\u6559\u80b2\u4ee5\u4fbf\u65e9\u671f\u8a3a\u65b7\u3001\u65e9\u671f\u6cbb\u7642\u3002\u7531\u5c08\u696d\u91ab\u5e2b\u3001\u8b77\u7406\u5e2b\u5171\u540c\u53c3\u8207\u5efa\u7acb\u7cfb\u7d71\u5316\u7684\u764c\u75c5\u767b\u8a18\u8207\u8ffd\u8e2a\u662f\u764c\u75c5\u7814\u7a76\u6240\u5fc5\u9700\u7684\u3002", "e": "Purpose: Malignancy is the leading cause of death in Taiwan. High prevalence of nasopharyngeal cancer (NPC) is recognized in Taiwan and Southern China compared to the rest of the world. The aim of this study is to improve the role of nursing in management of NPC patients by analyzing the age, living places, employment, family history, site of metastases, follow-up patterns and causes of death.\nMaterial and Methods: Radiation Oncology Department in Chang Gung Memorial Hospital has registered 2860 NPC cases in sixteen years, from 1979 to 1994. The age, living places, employment, family history, site of metastases, follow up patterns and causes of death were examined.\nResults: Thirty percentages of patients diagnosed in the age from 41 to 50. Two hundred and twenty-six (7.9%) of them have cancer family history, and 44patients have second primary malignancy, other than NPC. The median survival time was 3.83 years and survival rate at five years was 43%. In these 2860 patients, almost half of them (1415 cases) deceased, one thousand and two died of uncontrollable local disease or local recurrence, and 300 patients died of distant metastases. The remaining 113 cases (8%) died of intercurrent diseases.\nConclusion: NPC mainly occurred at middle age that causing a great impact on the family and society, so early detection and treatment is essential. Good follow-up and organizing cancer registry in cancer patients is substantial in cancer research and investigation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-239-244-a", "title": "Nucletron Micro-Seletron\u5c04\u6e90\u63a5\u6536\u6e2c\u8a66\u2015\u6210\u5927\u91ab\u9662\u4e4b\u7d93\u9a57", "keywords": "\u8fd1\u63a5\u6cbb\u7642;\u5c04\u6e90\u6d3b\u5ea6;\u5c04\u6e90\u4f4d\u7f6e;\u8f3b\u5c04\u6d29\u6f0f Brachytherapy;Source strength;Source position;Radiation leakage", "c": "\u76ee\u7684\uff1a\u5c04\u6e90\u6d3b\u5ea6\u6e2c\u91cf\u70ba\u66f4\u63db\u5c04\u6e90\u6642\u4e0d\u53ef\u6216\u7f3a\u7684\u5de5\u4f5c\u3002\u672c\u7bc7\u91dd\u5c0dNucletron Micro-Selectron\u5f8c\u8377\u6cbb\u7642\u6a5f\u66f4\u65b0\u5c04\u6e90\u6642\uff0c\u5206\u5225\u4ee50.6c.c.\u5957\u7ba1\u53ca\u4e95\u578b\u6e38\u96e2\u8154\u6e2c\u91cf\u5176\u6d3b\u5ea6\uff0c\u63a2\u8a0e\u5e77\u6bd4\u8f03\u6b64\u4e8c\u65b9\u6cd5\u4e4b\u7cbe\u78ba\u5ea6\uff0c\u4f9b\u65e5\u5f8c\n\u4f8b\u884c\u6e2c\u91cf\u5c04\u6e90\u6d3b\u5ea6\u4e4b\u4f9d\u64da\uff1b\u4ee5\u96d9\u91cd\u66dd\u5149\u65b9\u6cd5\u6aa2\u6e2c\u5c04\u6e90\u8207\u865b\u64ec\u5c04\u6e90\u4f4d\u7f6e\u4e4b\u4e00\u81f4\u6027\uff1b\u540c\u6642\u4e26\u6e2c\u91cf\u6cbb\u7642\u6a5f\u982d\u4e4b\u8f3b\u5c04\u6d29\u6f0f\u91cf\uff0c\u4ee5\u78ba\u4fdd\u8f3b\u5c04\u5b89\u5168\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f9dAAPM TG-40\u4e4b\u5efa\u8b70\uff0c\u4f7f\u7528Kodak V-films\u4ee5\u91cd\u8986\u66dd\u5149\u65b9\u5f0f\u6aa2\u9a57\u5c04\u6e90\u6295\u4e88\u81f3\u6307\u5b9a\u865b\u64ec\u5c04\u6e90\u4f4d\u7f6e\u4e4b\u6e96\u78ba\u6027\uff1b\u4ee5lonex Dosemaster 2590\u9023\u63a50.6 c.c.\u5957\u7ba1\u6e38\u96e2\u8154\u53caPRM\u4e95\u578b\u6e38\u96e2\u8154\u9023\u63a5CNMC\u96fb\u4f4d\u8a08\uff0c\u7d93\u6eab\u5ea6\u3001\u58d3\u529b\u4fee\u6b63\u5f8c\uff0c\u6e2c\u91cf\u5176\u6d3b\u5ea6\uff0c\u4ee5\u9a57\u8b49\u539f\u5ee0\u63d0\u4f9b\u4e4b\u6d3b\u5ea6\uff1b\u6cbb\u7642\u6a5f\u982d\u8f3b\u5c04\u6d29\u6f0f\u6e2c\u91cf\u4ee5Victoreen 450P survey meter\u9032\u884c\u91cf\u6e2c\u3002\n\u7d50\u679c\uff1a\u6295\u4e88\u5c04\u6e90\u4f4d\u7f6e\u8207\u5404\u865b\u64ec\u5c04\u6e90\u9593\u4e4b\u8aa4\u5dee\u53ef\u6e96\u78ba\u81f31mm\u4ee5\u5167\uff1b\u5c04\u6e90\u6d3b\u5ea6\u4ee50.5c.c.\u5957\u7ba1\u6e38\u96e2\u8154\u5728\u8ddd\u5c04\u6e9020cm\u8655\u6240\u91cf\u5f97\u6d3b\u5ea6\u8aa4\u5dee\u53ef\u5c0f\u65bc3%\uff0c\u5e77\u8f03\u4e95\u578b\u6e38\u96e2\u8154\u6240\u91cf\u5f97\u4e4b\u503c\u8f03\u63a5\u8fd1\u539f\u5ee0\u4e4b\u5831\u8868\u6578\u503c\uff1b\u6cbb\u7642\u6a5f\u982d\u4e4b\u8f3b\u5c04\u6cc4\u6f0f\u91cf\u6700\u9ad8\u9ede\u5728\u53f3\u5074\u8868\u9762\u8655\uff0c\u5176\u6578\u503c\u5c0f\u65bc0.03mSv/hr\uff0c\u6eff\u8db3\u7f8e\u570bNRC\u4e4b\u8981\u6c42\u3002\n\u7d50\u8ad6\uff1a\u5c04\u6e90\u4f4d\u7f6e\uff0c\u5c04\u6e90\u6d3b\u5ea6\u4e4b\u6e96\u78ba\u6027\u5c07\u56b4\u91cd\u5f71\u97ff\u5291\u91cf\u4e4b\u6295\u4e88\uff0c\u552f\u6709\u6b63\u78ba\u638c\u63e1\u6b64\u4e8c\u9805\u91cd\u9ede\uff0c\u8fd1\u63a5\u6cbb\u7642\u4e4b\u54c1\u8cea\u624d\u80fd\u6709\u6240\u4f9d\u64da\uff0c\u6cbb\u7642\u4e4b\u6548\u679c\u624d\u80fd\u63d0\u5347\u3002", "e": "Purpose: The quality assurance procedures for Nucletron Micro-Selectron source renew were performed when the (superscript 192)Ir source changed. The basic items are source strength measurement, source position alignment and head radiation protection ability survey. \nMaterials and Methods: According to the suggestions of AAPM TG-40, 0.6cc Farmer type ionization chamber and PRM well chambers were used to measure the source strength. Kodak V-films were used to check the source position alignment according to the autoradiography method. The head radiation protection ability was surveyed by Victoreen 450P. \nResults: The source strength was over estimated from 0.6 cc Farmer type ionization chamber (around +1.5%) while the PRM chamber's reading appear under estimated. The source position can be accurated within 1mm and the head radiation protection is satisfied to the NRC and The Council of Atomic Energy's regulation.\nConclusion: The source strength and source position affect the treatment quality greatly. The PRM well type chamber is convenient for the routine source strength calibration. The head protection ability satisfies the regulation and is safe to the staffs."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-245-250-a", "title": "\u624b\u8853\u4e2d\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642", "keywords": "\u624b\u8853\u4e2d\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642;\u5927\u8178\u764c;\u5f8c\u8179\u8154\u764c Intraoperative brachytherapy;Colorectal cancers;Retroperitoneum cancers", "c": "\u76ee\u7684\uff1a\u4ecb\u7d39\u4e00\u7a2e\u8fd1\u63a5\u6cbb\u7642\u65bc\u653e\u5c04\u6cbb\u7642\u7684\u7279\u6b8a\u61c9\u7528\uff0d\u624b\u8853\u4e2d\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u5099\u6709\u8f3b\u5c04\u9632\u8b77\u7246\u58c1\uff0c\u76e3\u8996\u5668\u53ca\u96fb\u8166\u63a7\u5236\u4e4b\u9ebb\u9189\u5668\u68b0\u7684\u624b\u8853\u623f\u3001\u9ad8\u5291\u7387\u9060\u7aef\u63a7\u5236\u7684\u8fd1\u63a5\u6cbb\u7642\u6a5f\u53ca\u7279\u6b8a\u8a2d\u8a08\u7684\u8d85\u8edf\u61c9\u7528\u5668\uff0c\u8b93\u8f3b\u5c04\u5291\u91cf\u53ef\u4ee5\u5f88\u5747\u52fb\u5730\u5206\u4f48\u5728\u8eab\u9ad4\u5167\u8154\u7684\u7684\u4efb\u4f55\u8868\u9762\u4e0a\uff0c\u5c24\u5176\u662f\u5177\u6709\u5f4e\u66f2\u5f27\u5ea6\u7684\u9aa8\u76c6\u8154\u6216\u5f8c\u8179\u8154\u4e2d\u3002\u7531\u65bc\u9019\u662f\u4e00\u7a2e\u624b\u8853\u4e2d\u7684\u6cbb\u7642\uff0c\u6240\u4ee5\u80fd\u628a\u53ef\u80fd\u6703\u9020\u6210\u8f3b\u5c04\u50b7\u5bb3\u7684\u91cd\u8981\u5668\u5b98\uff0c\u5982\u5c0f\u8178\u3001\u814e\u81df\u3001\u809d\u81d3\u7b49\uff0c\u5728\u653e\u5c04\u6cbb\u7642\u6642\u9694\u96e2\u3002\u56e0\u6b64\uff0c\u80fd\u964d\u4f4e\u8f3b\u5c04\u6cbb\u7642\u5291\u91cf\u800c\u907f\u514d\u7522\u751f\u8f3b\u5c04\u50b7\u5bb3\u3002\n\u7d50\u679c\uff1a\u624b\u8853\u4e2d\u7684\u8fd1\u63a5\u6cbb\u7642\u914d\u5408\u4e2d\u5ea6\u5291\u91cf\u7684\u9ad4\u5916\u7167\u5c04(40-45Gy)\uff0c\u5c0d\u65bc\u539f\u767c\u76f4\u8178\u764c\uff0c\u5f8c\u767c\u76f4\u8178\u764c\u53ca\u5f8c\u8179\u8154\u7684\u816b\u7624\uff0c\u5728\u4e8c\u5e74\u7684\u816b\u7624\u63a7\u5236\u7387\u5831\u544a\u4e2d\uff0c\u670980-90%\u7684\u6548\u679c\u3002\n\u7d50\u8ad6\uff1a\u624b\u8853\u4e2d\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\uff0c\u63d0\u4f9b\u96e3\u4ee5\u7528\u50b3\u7d71\u6cbb\u7642\u4f86\u9054\u6210\u7406\u60f3\u63a7\u5236\u7684\u816b\u7624\uff0c\u5982\u9aa8\u76c6\u8154\u6216\u8179\u8154\u816b\u7624\uff0c\u4e00\u500b\u65b0\u7684\u6cbb\u7652\u6a5f\u6703\u3002", "e": "Introduction: This is to introduce a special brachytherapy application in radiotherapy intraoperative high-dose-rate brachytherapy.\nMaterials and Methods: Using an operation room possessing radiation-protection walls, monitors and computer-controlled anesthesia instruments, combined with remote-controlled high-dose-rate after-loading brachytherapy modality and a special designed super-flab or super-mould applicator, let radiation dose distribute very evenly on any surface of body inner cavity, especially on the arch surface, such as the cavity of pelvis or retroperitoneum. Since this is a radiotherapy during surgery, the possible radiation-damaged organs, such as intestine, kidney and liver can be blocked as much as possible. Hence, the effective radiotherapy dose can be reduced and avoid radiation-inducing damage.\nResult: Combination of intraoperative high-dose-rate brachytherapy and moderate dose (40-45Gy) of external radiotherapy in the treatment of primary and recurrent colorectal cancers and retroperitoneum cancers has significantly improved tumor control. For these tumors, there were reported of 80-90% of two-year tumor control rate.\nConclusion: Intraoperative high-dose-rate brachytherapy provides a novel curable opportunity for those tumors difficult to reach optimally tumor-controlled by traditional treatment methods, such as the tumors in pelvis or retroperitoneum cavity."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-251-256-a", "title": "\u6a21\u64ec\u651d\u5f71\u7167\u5c04\u65b9\u5411\u4e4b\u4e00\u4e9b\u8003\u91cf", "keywords": "\u6a21\u64ec\u651d\u5f71;\u7167\u91ce;\u767c\u6563\u6548\u61c9 Simulation;Field;Divergency effect", "c": "\u81e8\u5e8a\u4e0a\uff0c\u5c0d\u65bc\u653e\u5c04\u6cbb\u7642\u7167\u91ce\u5927\u5c0f\u4e4b\u53d6\u6c7a\uff0c\u5f80\u5f80\u5f97\u5148\u501f\u52a9\u6a21\u64ec\u651d\u5f71(simulation)\u4e4b\u6280\u8853\u65bc\u6cbb\u7642\u524d\u62cd\u651d\u6a21\u64ec\u651d\u5f71\u7247\uff0c\u518d\u7531\u7247\u4e0a\u6e05\u6670\u4e4b\u89e3\u5256\u76f8\u95dc\u4f4d\u7f6e\u6c7a\u5b9a\u6cbb\u7642\u7684\u7bc4\u570d\uff0c\u4e26\u5728\u75c5\u60a3\u8eab\u4e0a\u6216\u6a21\u5177(cast)\u4e0a\u505a\u597d\u9ad4\u8868\u4e4b\u76f8\u5c0d\u56db\u5468\u8207\u4e2d\u5fc3\u9ede\u7684\u8a18\u865f\u3002\u4f46\u6709\u6642\u60f3\u7167\u5c04\u4e4b\u67d0\u4e9b\u90e8\u4f4d\uff08\u5982\u809b\u9580\uff0c\u9838\u90e8\u6dcb\u5df4\u7d50\uff09\uff0c\u6216\u662f\u60f3\u907f\u958b\u4e4b\u67d0\u4e9b\u5340\u57df\uff08\u5982\u773c\u7403\u4e4b\u6c34\u6676\u9ad4\uff0c\u8178\u9020\u53e3\uff09\uff0c\u4e26\u975e\u5728\u7167\u91ce\u9ad4\u539a\u4e00\u534a\u4e4b\u4e2d\u5fc3\u6df1\u5ea6\u4e14\u9060\u96e2\u5c04\u675f\u4e4b\u4e2d\u5fc3\u9ede\uff08\u63a5\u8fd1\u7167\u91ce\u4e4b\u56db\u5468\u908a\u7de3\uff09\uff0c\u5247\u6b64\u6642\u61c9\u6e05\u6670\u5730\u6a19\u660e\u51fa\u4f86\uff0c\u4e26\u7279\u5225\u8003\u616e\u6a21\u51dd\u651d\u5f71\u7167\u5c04\u4e4b\u65b9\u5411\uff0c\u4ee5\u514d\u5728\u7167\u91ce\u908a\u7da0\u56e0\u5c04\u675f\u4e4b\u767c\u6563\u6548\u61c9(divergency)\u800c\u9020\u6210\u6db5\u84cb\u4e0d\u5920\u6216\u904e\u591a\uff0c\u5f15\u8d77\u6cbb\u7642\u4e4b\u5931\u6557\u3002", "e": "Simulation is a technique to determine the treatment field via diagnostic films before radiotherapy. By radiographic visualization of internal organs, the correct position of fields can be obtained by physicians in relation to external landmarks. Some of areas we would like to include in treatment fields (eg. anus, neck lymph node) or to spare (eg. lens, colostomy) by cerrobend block are not located exactly at the midline of body thickness and are far from the central beam axis (near the field margin). Because of the beam divergency effect, the field margin may be too extended or too limited by different beam directions. Therefore, those areas should be marked clearly and we should especially consider the direction of simulation beam. It may be one of the crucial factors of marginal failure of treatment if we do not pay attention to it."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-257-264-a", "title": "\u91ab\u9662\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u7c4c\u5efa\u898f\u5283\uff0d\u2160\uff0e\u540c\u6b65\u8ff4\u65cb\u52a0\u901f\u5668", "keywords": "\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099;\u540c\u6b65\u8ff4\u65cb\u52a0\u901f\u5668;\u898f\u5283 Proton therapy facility;Synchrotron;Planning", "c": "\u76ee\u7684\uff1a\u53d9\u8ff0\u91ab\u9662\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u540c\u6b65\u8ff4\u65cb\u52a0\u901f\u5668\u7684\u69cb\u9020\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u53c3\u8003\u7f8e\u570b\u5fb7\u5dde\u5730\u5340\u91ab\u5b78\u6280\u8853\u4e2d\u5fc3\u81ea\u884c\u7121\u5efa\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u7684\u89c0\u5ff5\u8a2d\u8a08\uff0c\u6a21\u64ec\u548c\u53d9\u8ff0\u81fa\u7063\u5728\u91ab\u9662\u5167\u7c4c\u5efa\u540c\u6b65\u8ff4\u65cb\u52a0\u901f\u5668\u7684\u69cb\u9020\uff0c\u4f5c\u7232\u8cea\u5b50\u5c04\u7dab\u6cbb\u7642\u764c\u60a3\u4e4b\u7528\u3002\n\u7d50\u679c\uff1a\u91ab\u9662\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u6db5\u84cb\u6280\u8853\u7cfb\u7d71\u548c\u50b3\u7d71\u8a2d\u65bd\u5169\u5927\u985e\uff0c\u800c\u4ee5\u7c4c\u5efa\u6280\u8853\u7cfb\u7d71\u6700\u5177\u6311\u6230\u6027\u3002\u6280\u8853\u7cfb\u7d71\u5305\u62ec\u7528\u4f5c\u5165\u5c04\u5668\u7684\u52a0\u901f\u5668\u3001\u9ad8\u80fd\u52a0\u901f\u5668\uff08\u53ef\u91c7\u7528\u540c\u6b65\u8ff4\u65cb\u52a0\u901f\u5668\uff09\u3001\u5c04\u675f\u8f38\u9001\u7ba1\u3001\u65cb\u8f49\u67b6\u8cea\u5b50\u8f38\u9001\u548c\u5c04\u7dab\u7ba1\u53e3\u3001\u6cbb\u7642\u5e8a\u3001\u7ba1\u5236\u6b21\u7cfb\u7d71\u7b49\u3002\u50b3\u7d71\u8a2d\u65bd\u5247\u5305\u62ec\u5efa\u7bc9\u3001\u8a3a\u65b7\u91ab\u5b78\u5f71\u50cf\u8207\u653e\u5c04\u816b\u7624\u5b78\u7684\u4eba\u9ad4\u56fa\u5b9a\u7cfb\u7d71\u3001\u6a21\u64ec\u651d\u5f71\u3001\u6cbb\u7642\u8a08\u756b\u53ca\u5176\u4ed6\u5468\u908a\u8a2d\u5099\u3002\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u9019\u6a23\u7684\u8a2d\u8a08\uff0c\u5c0d\u764c\u60a3\u6cbb\u7642\u6700\u7cbe\u78ba\u3001\u6709\u6548\u8207\u8212\u9069\u3002\n\u7d50\u8ad6\uff1a\u91ab\u9662\u7528\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u662f\u9ad8\u80fd\u7269\u7406\u5de5\u7a0b\u548c\u653e\u5c04\u7684\u7d50\u5408\uff0c\u5c0d\u81fa\u7063\u7684\u79d1\u5b78\u8207\u91ab\u5b78\u754c\u662f\u4e00\u7a2e\u6311\u6230\uff0c\u4e5f\u662f\u4e00\u9805\u6a5f\u6703\u3002\u5982\u5c0d\u7c4c\u5efa\u8cea\u5b50\u6cbb\u7642\u8a2d\u5099\u7684\u5167\u5bb9\u6709\u5145\u5206\u7684\u8a8d\u8b58\uff0c\u7576\u6703\u66f4\u6210\u719f\u7684\u63a8\u52d5\u662f\u9805\u8de8\u4e16\u7d00\u7684\u91ab\u5b78\u5de5\u7a0b\uff0c\u4f7f\u5f97\u591a\u764c\u60a3\u53d7\u76ca\u3002", "e": "Purpose: To describe the structure of a hospital-based proton therapy facility.\nMaterials and methods: We take the conceptual design of the Texas Regional Medical Technology Center for construction of a hospital-based proton therapy facility as a reference and describe the structure of a synchrotron for cancer patient treatment in Taiwan.\nResults: Hospital-base proton facility consists of technical system and the traditional facilities. Technical system includes the injector and the accelerator subsystem, synchrotron, beam transport, gantry with beam transport and nozzle, treatment couch and control subsystems etc. Traditional facilities consist of building, medical imaging and equipment, other supportive facilities of radiation oncology such as patient position fixation, simulation, treatment planning, etc. so that the protn therapy facility will be most accurate, efficient and convenient to the operators, and effective and comfortable fir the cancer patients.\nConclusion: A hospital-based proton therapy facility is the combination of high energy physics engineering and radiation medicine. This is a great challenge but also an unprecedent opportunity for scientists and physicians in Taiwan. An inept understanding of the structure of the proton therapy facility will ensure a more mature planning and implementation of such a medical engineering program across the century and many cancer patients can be benefited."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-265-274-a", "title": "\u7d30\u80de\uff0c\u7d44\u7e54\uff0c\u816b\u7624\u4e4b\u52d5\u614b\u5b78\u53ca\u5176\u81e8\u5e8a\u61c9\u7528", "keywords": "\u7d30\u80de\u9031\u671f;\u751f\u9577\u5206\u7387;\u6f5b\u5728\u816b\u7624\u500d\u589e\u6642\u9593;\u7d30\u80de\u640d\u5931\u56e0\u7d20 Cell cycle;Growth fraction;Potential tumor doubling time;Cell loss", "c": "\u5b78\u7fd2\u816b\u7624\u52d5\u614b\u5b78\u7684\u5169\u500b\u4e3b\u8981\u76ee\u7684\u70ba\u75c5\u4eba\u4e4b\u9810\u5f8c\u53ca\u7d66\u4e88\u75c5\u4eba\u6700\u597d\u4e4b\u6cbb\u7642\u65b9\u5f0f\u3002\u816b\u7624\u5167S\u671f\u7d30\u80de\u5206\u7387\u548c\u67d3\u8272\u9ad4\u500d\u6578\u7d93\u5e38\u4f5c\u70ba\u81e8\u5e8a\u4e0a\u7684\u6cbb\u7642\u6307\u6a19\u3002\u816b\u7624\u5167\u7d30\u80de\u5728\u6cbb\u7642\u524d\u5f8c\u4e4b\u52d5\u614b\u8b8a\u5316\u727d\u6d89\u5230\u6cbb\u7642\u6210\u6557\u751a\u9245\u3002\u4f8b\u5982S/M\u671f\u6216\u5faa\u74b0\u671f\u7d30\u80de\u8f03\u591a\u4e4b\u816b\u7624\uff0c\u61c9\u63a1\u7528\u5c0d\u9019\u7a2e\u7d30\u80de\u6709\u8f03\u4f73\u6bd2\u6bba\u6027\u4e4b\u5316\u7642\u85e5\u7269\u6216\u52a0\u901f\u653e\u5c04\u6cbb\u7642\u3002\u76ee\u524d\u5316\u5b78\u6cbb\u7642\u4f7f\u7528\u4e4b\u85e5\u7269\u4e0d\u5916\u5169\u7a2e\u3002\u4e00\u7a2e\u662f\u6291\u5236DNA\u8907\u88fd\u6642\u6240\u9700\u4e4b\u9175\u7d20\uff0c\u4f8b\u59825-FU\u6291\u5236\u80f8\u817a\u5627\u5576\u5408\u6210\u9175\u7d20\u800c\u6bba\u6b7bS\u671f\u7d30\u80de\u3002\u7b2c\u4e8c\u7a2e\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u5247\u70ba\u7834\u58de\u7d30\u80de\u5206\u88c2\u671f\u4e4b\u80de\u5668\uff0c\u5982vinblastine\u6703\u7834\u58detubulin\u7684\u805a\u5408\uff1bcyclophosphamide\u6703\u5c0e\u81f4synaptonemal complex\u7834\u788e\u800c\u6bba\u6b7bM\u671f\u7d30\u80de\u3002\u653e\u5c04\u6cbb\u7642\u5247\u5c0d\u65bcG2/M\u671f\u7d30\u80de\u6709\u8f03\u4f73\u4e4b\u6bba\u50b7\u529b\uff0c\u5c0d\u65bcS\u671f\u7d30\u80de\u4e4b\u6bba\u50b7\u6548\u679c\u5247\u8f03\u5dee\u3002\u56e0\u6b64\u81e8\u5e8a\u764c\u75c7\u5e38\u9700\u914d\u5408\u591a\u7a2e\u6cbb\u7642\u65b9\u5f0f\u3002\u81f3\u65bc\u5e73\u5747\u4f54\u816b\u7624\u5167\u9ad8\u905415%\u4e4b\u7f3a\u6c27\u7d30\u80de\u53caG1/G0\u671f\u7d30\u80de\uff0c\u5247\u4e0a\u8ff0\u5169\u7a2e\u6cbb\u7642\u65b9\u5f0f\u5747\u6548\u679c\u4e0d\u4f73\u3002\u56e0\u6b64\u5c0d\u65bc\u816b\u7624\u5167\u7d30\u80de\u4e4b\u52d5\u614b\u8b8a\u5316\uff0c\u6709\u5fc5\u8981\u505a\u6df1\u5165\u63a2\u8a0e\u3002\u672c\u6587\u5c31\u7d30\u80de\u9031\u671f\u53ca\u5176\u6e2c\u5b9a\u6280\u8853\uff0c\u751f\u9577\u5206\u7387\uff0c\u6f5b\u5728\u816b\u7624\u500d\u589e\u6642\u9593\uff0c\u7d30\u80de\u640d\u5931\u53ca\u6b64\u7b49\u6280\u8853\u6216\u89c0\u5ff5\u4e4b\u81e8\u5e8a\u61c9\u7528\u5206\u5225\u8a0e\u8ad6\u3002\u5c0d\u65bc\u751f\u9577\u5206\u7387\uff0c\u6f5b\u5728\u816b\u7624\u500d\u589e\u6642\u9593\u53ca\u7d30\u80de\u640d\u5931\u56e0\u7d20\u5247\u6709\u8f03\u6df1\u5165\u4e4b\u63a2\u8a0e\u3002", "e": "The purpose of studying tumor kinetics are for the prognosis of patients and for the choice of the optimal treatment. S-phase fraction (SPF) as well as ploidy status of a tumor, for example, has been used frequently for prognosis and treatment guidance in clinic. The kinetics of a tumor before and after the treatment plays an important role which may affect the outcome of the therapy. For a tumor with high SPF, either the cytotoxic drugs specific for S- or M-phase cells should be used in chemotherapy or the accelerated treatment should be adopted in radiotherapy. There are two kinds of drugs currently used for clinical chemotherapy. One of which can inhibit the activity of the enzyme required for DNA replication, such as 5-fluorouracil which kills S-phase cells by inhibiting the activity of thymydylate synthetase. The second one killed M-phase cells by destructing the organelle required for mitotic processes, such as vinblastine which breaks tubulin assembly and cyclophosphamide which results in fragmentation of synaptonemal complex. Radiotherapy, on the other way, is more effective in killing G2/M cells but less effective for S-phase cells. Both treatments, however, are not very effective for hypoxic cells, which in average accounts for 15% of solid tumors, and those cells in the GJG0 stage. The more one understands the tumor kinetics, the higher control rate one may obtain. The following four subjects and their clinical applications were discussed: cell cycle and its measuring techniques, growth fraction, potential tumor doubling time and cell loss."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199612-3-4-275-280-a", "title": "\u4f96\u7434\u4e8b\u696d\u7684\u5960\u57fa\u548c\u98db\u63da", "keywords": "\u4f96\u7434;\u4e8b\u696d Wilhelm C. Roentgen;Career", "c": "\u4f96\u7434\u65bc1869\u5e7424\u6b72\u6642\u5728\u745e\u58eb\u8607\u9ece\u4e16\u7406\u5de5\u5b78\u9662\u7372\u54f2\u5b78\u535a\u58eb\uff0c\u5f8c\u96a8\u5b54\u5fb7\u5148\u751f\u5728\u6bcd\u6821\u4efb\u5be6\u9a57\u7269\u7406\u5b78\u7814\u7a76\u52a9\u7406\u30021872\u5e741\u6708\u5728\u5fb7\u570b\u70cf\u8332\u5821\u5927\u5b78\u77ed\u671f\u4efb\u8077\u6642\u8207\u9678\u535a\u838e\u5728\u5152\u6642\u9577\u5927\u7684\u8377\u862d\u7d50\u5a5a\u3002\u540c\u5e74\u96a8\u5b54\u5fb7\u8f49\u5f80\u53f2\u67e5\u65af\u5821\u5927\u5b78\u4efb\u8077\uff0c\u7d93\u5169\u5e74\u52aa\u529b\u5de5\u4f5c\uff0c\u59cb\u7372\u8b1b\u5e2b\u8077\u929c\u3002\u5f9e\u6b64\u7236\u6bcd\u642c\u4f86\u540c\u4f4f\u3002 1875\u5e74\u8058\u70ba\u8fb2\u696d\u7814\u7a76\u6240\u7269\u7406\u548c\u6578\u5b78\u7cfb\u4e3b\u4efb\u3002\u56e0\u79d1\u5b78\u8207\u5de5\u9918\u751f\u6d3b\u74b0\u5883\u4e0d\u826f\uff0c\u7fcc\u5e74\u56de\u53f2\u67e5\u65af\u5821\u5927\u5b78\u64d4\u4efb\u7406\u8ad6\u7269\u7406\u5b78\u526f\u6559\u6388\u3002\u7531\u65bc\u5b78\u8853\u8868\u73fe\u512a\u7570\uff0c\u5169\u5e74\u4e4b\u5f8c\u88ab\u8058\u70ba\u5409\u68ee\u5927\u5b78\u7269\u7406\u5b78\u6559\u6388\u517c\u7cfb\u4e3b\u4efb\uff0c\u5728\u8077\u4e5d\u5e74\uff0c\u751f\u6d3b\u8207\u6210\u5c31\u5747\u751a\u53ef\u89c0\uff0c\u6bcd\u8207\u7236\u5247\u76f8\u7e7c\u65bc74\u548c83\u9ad8\u9f61\u53bb\u4e16\u3002\u56e0\u535a\u838e\u591a\u5e74\u4e0d\u5b55\u4e43\u6536\u990a\u5176\u5144\u4e4b\u5973\u7d04\u745f\u82ac\u30021888\u5e74\u7d42\u56e0\u8072\u8b7d\u5d07\u9686\uff0c\u88ab\u70cf\u8332\u5821\u5927\u5b78\u8058\u70ba\u7269\u7406\u5b78\u6559\u6388\u517c\u7269\u7406\u7814\u7a76\u9662\u9662\u9577\uff0c\u4e03\u5e74\u4e4b\u5f8c\u5c31\u5728\u6b64\u8077\u767c\u73feX\u5149\u3002", "e": "Mr. Wilhelm Conrad Roentgen was awarded his Doctorate of Philosophy degree in 1869 in the Graduate School of Zurich Polytechnic, Switzerland when he was 24 years old. He worked as a research assistant for two years in the same school with his professor Mr. August Kundt. Roentgen followed professor Kundt and left Zurich for a short term at the University of Wurzburg. During this time, Roentgen married with Miss Bertha Ludwig on January 19, 1872 in Apeldoorn, Holland where he spent many years in his childhood. Roentgen followed professor Kundt again to work as his assistant in the University of Strasbourg in 1872. After two years of successful work, he was promoted to be an instructor, his first academic position, while his parents lived with them. Within a year, Roentgen accepted to chair the Department of Physics and Mathematics at the Agricultural Academy in Wurttemberg where the scientific and social lives were not quite satisfy, so in 1876 he returned to the University of Strasbourg and worked as an associate professor of the orectic physics. During this period Roentgen began to establish his reputation in physics. Two year later he was recruited to be professor and chairman of physics at the University of Giessen where Roentgens spent nine extremely happy years. However, his mother and father died respectively at their age of 74 and 83. Because of childless, Roentgens adopted Josephine Bertha, the daughter of Bertha's brother. Roentgen acquired a high reputation in the academic circles, in 1888 he was offered and willingly accepted the post of professor of physics and director of the new Physical Institute. It was there seven years later, Roentgen discovered x-rays."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-151-156-a", "title": "EB\u75c5\u6bd2\u8207\u4fc3\u764c\u7269\u5354\u540c\u4f5c\u7528\u80fd\u8a98\u767c\u88f8\u9f20\u9ad4\u5167\u4eba\u7684\u9f3b\u54bd\u764c", "keywords": "EB\u75c5\u6bd2;\u4fc3\u764c\u7269;\u9f3b\u54bd\u764c Epstein-Barr virus;Tumor promoter;Nasopharyngeal carcinoma", "c": "\u7dd2\u8a00\uff1a\u9f3b\u54bd\u764c\u6d3b\u6aa2\u7d44\u7e54\u4e2d\u5b58\u5728EB\u75c5\u6bd2\u57fa\u56e0\u7d44\u548c\u9f3b\u54bd\u764c\u60a3\u8005\u7684\u8840\u6e05\u5b78\u8b49\u64da\u8b49\u660eEB\u75c5\u6bd2\u5728\u9f3b\u54bd\u764c\u7684\u767c\u751f\u4e2d\u8d77\u91cd\u8981\u4f5c\u7528\uff0c\u4f46\u4e26\u6c92\u6709\u76f4\u63a5\u7684\u8b49\u64da\u8b49\u660eEB\u75c5\u6bd2\u5c31\u662f\u9f3b\u54bd\u764c\u7684\u75c5\u56e0\u3002\u5728\u9f3b\u54bd\u764c\u9ad8\u767c\u5340\u7684\u5927\u91cf\u4e2d\u8349\u85e5\u548c\u98df\u7269\u4e2d\u542b\u6709EB\u75c5\u6bd2\u8a98\u5c0e\u7269\u548c\u4fc3\u764c\u7269\uff0c\u5b58\u5728\u65bc\u6b63\u5e38\u4eba\u9f3b\u54bd\u90e8\u7684\u53ad\u6c27\u83cc\u53ef\u4ee5\u7522\u751f\u4e01\u9178\uff0c\u5b83\u5011\u8207EB\u75c5\u6bd2\u5354\u540c\u5728\u9f3b\u54bd\u764c\u767c\u751f\u4e2d\u8d77\u91cd\u8981\u4f5c\u7528\u3002\n\u65b9\u6cd5\uff1a\u61c9\u7528\u539f\u4f4d\u96dc\u4ea4\uff0cPCR\u64f4\u589e\u3001\u55ae\u682a\u57f9\u990a\u53ca\u6838\u82f7\u9178\u5e8f\u5217\u5206\u6790\u65b9\u6cd5\uff0c\u6aa2\u6e2c\u4e86\u9f3b\u54bd\u764c\u7d30\u80de\u682aCNE1\u548cCNE3\u4e2d\u7684EB\u75c5\u6bd2\u6f5b\u4f0f\u819c\u86cb\u767d(LMP1)\u57fa\u56e0\u3002\u7528CR23\u8f49\u67d3\u6c38\u751f\u5316293\u7d30\u80de\uff0c\u7136\u5f8c\u611f\u67d3\u5b8c\u6574EB\u75c5\u6bd2\uff0c\u63a5\u7a2e\u65bc\u88f8\u9f20\u76ae\u4e0b\uff0c\u6bcf\u5468\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c0450ng TPA\u3002\u5728\u53e6\u4e00\u5be6\u9a57\u4e2d\uff0c\u5c07EB\u75c5\u6bd2\u611f\u67d3\u7684\u4eba\u80ce\u5152\u9f3b\u54bd\u7cbe\u819c\u79fb\u690d\u65bc\u88f8\u9f20\u76ae\u4e0b\uff0c\u6bcf\u5468\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4e01\u9178200ug\u548cTPA 50ng\u5c0d\u8a98\u767c\u7684\u816b\u7624\u9032\u884c\u7d44\u7e54\u75c5\u7406\u5b78\u6aa2\u67e5\u3001EB\u75c5\u6bd2LMP1\u57fa\u56e0\u7684PCR\u64f4\u589e\u3001\u539f\u4f4d\u96dc\u4ea4\u548c\u6838\u82f7\u9178\u5e8f\u5217\u5206\u6790\u3002\n\u7d50\u679c\uff1a CNE1\u7d30\u80de\u4e2dLMP1\u57fa\u56e0\u5b58\u5728\u65bc\u7d30\u80de\u6838\u5167\uff0c\u6574\u5408\u65bc\u7b2c\u4e00\u865f\u67d3\u8272\u9ad4\u4e0a\uff1bCNE3\u4e2dLMP1\u57fa\u56e0\u5247\u96a8\u6a5f\u5b58\u5728\u65bc\u7d30\u80de\u6838\u5167\u53ca\u591a\u689d\u67d3\u8272\u9ad4\u4e0a\u3002\u6838\u82f7\u9178\u5e8f\u5217\u5206\u6790\u8b49\u660e\uff0c\u7528PCR\u65b9\u6cd5\u5206\u5225\u5f9eCNE1\u53caCNE3\u4e2d\u64f4\u589e\u5f97\u5230\u4e86LMP1\u57fa\u56e0\u7247\u6bb5\uff08\u5916\u986f\u5b503\uff09\uff0c\u6838\u82f7\u9178\u5e8f\u5217\u5206\u6790\u8b49\u660e\uff0c\u4f86\u81eaCNE1\u7684LMP1\u8207\u4f86\u81eaB95-8 \u7d30\u80de\u7684LMP1\u6838\u82f7\u9178\u5e8f\u5217\u540c\u6e90\u6027\u6975\u9ad8\u905499.5%\uff0c\u800cCNE3\u7684LMP1\u57fa\u56e0\u8207B95-8\u7684LMP1\u56e0\u540c\u6e90\u6027\u70ba93%\u3002\u7528EB\u75c5\u6bd2\u611f\u67d3\u7684293 \u7d30\u80de\u63a5\u7a2e\u65bc\u88f8\u9f20\uff0c\u5728TPA\u4f5c\u7528\u4e0b\uff0c\u8a98\u767c\u51fa\u4f4e\u5206\u5316\u764c\u3002\u7528EB\u75c5\u6bd2\u611f\u67d3\u7684\u4eba\u80ce\u5152\u9f3b\u54bd\u7c98\u819c\u79fb\u690d\u65bc\u88f8\u9f20\uff0c\u5728TPA\u548cT\u9178\u5354\u540c\u4f5c\u7528\u4e0b\uff0c\u8a98\u767c\u51fa\u672a\u5206\u5316\u9f3b\u54bd\u764c\uff0cEB\u75c5\u6bd2\u5b58\u5728\u65bc\u6240\u6709\u9019\u4e9b\u764c\u7d30\u80de\u4e2d\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u7d50\u679c\u9996\u6b21\u8b49\u660e\u5b8c\u6574\u7684EB\u75c5\u6bd2\u548c\u4fc3\u764c\u7269\u5354\u540c\u4f5c\u7528\u53ef\u4ee5\u8a98\u767c\u9f3b\u54bd\u764c\u3002\u6211\u5011\u7684\u8cc7\u6599\u4e5f\u8b49\u8cd3EB\u75c5\u6bd2\u5728\u9f3b\u54bd\u764c\u7684\u767c\u751f\u4e2d\u8d77\u75c5\u56e0\u5b78\u4f5c\u7528\u3002", "e": "Introduction: The presence of Epstein-Barr virus (EBV) genome in dispose of nasopharyngeal carcinoma (NPC) and serological evidence in NPC patients indicated that ED virus plays an important role in the development of NPC. However, there is no direct evidence that EB virus is the etiological cause of NPC. There are many Chinese medicinal herbs and foods containing ES virus inducers and tumor promoters in NPC high risk areas. Many anaerobic bacteria producing butyric acid could also be found in the nasopharynces. Both of them together with ED virus may play an important role in the development of NPC.\nMethods: The latent membrane protein 1 (LMP1) gene of RB virus contained in the nasopharyngeal carcinoma cell line (CNE1, CNE3) was detected by in situ hybridization, PCR amplification, cloning and nucleotide sequence analysis.Immortalized 293 (human fetal kidney cells) transfected with CR2 were infected with B95-8 REV. These cells were transplanted into nude mice sub cutaneously. A week later, each mouse was injected with 5Ong TPA subcutaneously. In another experiment, nude mice were subcutaneously transplanted with human fetal nasopharygeal mucosa infected with REV. 200ug butyrate and 50ng TPA were injected subcutaneously once a week following the tramplantation. Tumors were examined histopathologcally. The presence of EBV DNA were determined by PCR, in situ hybridization, and nucleotide sequence analysis of EBV LMP-1 gene.\nResults: LMP1 gene is integrated into the No.1 chromosome in CNE1, and into several chromosomes in CNE3. The exon 3 of LMP1 gene was amplified by PCR and cloned from CNE1 and CNE3. Sequence analyses of these PCR products revealed a high homology of 99.5% between B95-8 strain and CNE1, and a lower homology of 93% between B95-8 and CNE3. Poorly differentiated carcinoma was found in nude mice transplanted with EBV infected 293 cells under the influence of TPA. Undifferentiated nasopharyngeal carcinoma was also found in nude mice transplanted with RBV-infected human fetal nasopharyngeal mucosa by synergistic effect of TPA and butyrate. EB virus existed in all of these carcinoma cells.\nConclusion: The present data demonstrated for the first time that the synergistic effect of RB virus and tumor promoter can induce nasopharyngeal carcinoma. Our data also confirmed that EU virus could play an etiological role in the development of nasopharyngeal carcinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-167-172-a", "title": "\u9f3b\u54bd\u764c\u75c5\u4eba\u4f7f\u7528\u4e00\u65e5\u5169\u6b21\u591a\u5206\u6b21\u7167\u5c04\u4e4b\u6025\u6162\u6027\u526f\u4f5c\u7528\u5206\u6790", "keywords": "\u591a\u5206\u6b21\u7167\u5c04;\u9f3b\u54bd\u764c;\u526f\u4f5c\u7528 Hyperfractionated radiotherapy;Nasopharyngeal carcinoma;Radiation toxicities", "c": "\u76ee\u7684\uff1a\u672c\u6587\u64ec\u5831\u544a\u9f3b\u54bd\u764c\u75c5\u4eba\u4ee5\u591a\u5206\u6b21\u653e\u5c04\u7167\u5c04\u6cd5\u6cbb\u7642\u5f8c\uff0c\u6240\u767c\u751f\u7684\u6025\u6162\u6027\u526f\u4f5c\u7528\uff0c\u4ee5\u4f5c\u70ba\u81e8\u5e8a\u91ab\u5e2b\u9078\u64c7\u6cbb\u7642\u6cd5\u6642\u4e4b\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea\u6c11\u570b\u516b\u5341\u5e74\u5341\u6708\u8d77\u81f3\u516b\u5341\u4e94\u5e74\u516d\u6708\u6b62\uff0c\u5171\u7d66\u4e88\u4e94\u5341\u4f8b\u9f3b\u54bd\u764c\u75c5\u4f8b\u4f7f\u7528\u591a\u5206\u6b21\u653e\u5c04\u7167\u5c04\u6cd5\uff0c\u5176\u4e2d\u7537\u75c5\u4eba35\u4f8b\u3001\u5973\u75c5\u4eba15\u4f8b\u3002\u9664\u5169\u4f8b\u5916\u5747\u70baAJCC\u7b2c\u4e09\u6216\u7b2c\u56db\u671f\u3002\u5e74\u9f61\u81ea17\u81f379\u6b72\u4e0d\u7b49\uff0c\u4e2d\u503c\u70ba51\u6b72\u3002\u6cbb\u7642\u63a1\u6bcf\u65e5\u5169\u6b21\u9593\u9694\u516d\u5c0f\u6642\u3002\u539f\u767c\u816b\u7624\u4e00\u822c\u572855-60\u5929\u5167\u7d66\u82077500-8000 cGy\u3002\u6cbb\u7642\u4e2d\u75c5\u4eba\u6bcf\u9031\u81f3\u5c11\u56fa\u5b9a\u6aa2\u67e5\u4e00\u6b21\uff0c\u4e26\u5c07\u6025\u6027\u526f\u4f5c\u7528\u8a73\u7d30\u4f5c\u6210\u8a18\u9304\u8a18\u8f09\u65bc\u7279\u5225\u4e4b\u8868\u683c\u3002\u6cbb\u7642\u7d50\u675f\u5f8c\u6bcf\u6b21\u56de\u8a3a\uff0c\u5747\u8a73\u7d30\u8a18\u9304\u75c5\u4eba\u4e4b\u5ef6\u767c\u6027\u665a\u671f\u526f\u4f5c\u7528\u3002\u6240\u6709\u526f\u4f5c\u7528\u4e4b\u5206\u7d1a\u5747\u6309RTOG/EORTC\u4e4b\u6a19\u6e96\u3002\n\u7d50\u679c\uff1a\u6025\u6027\u526f\u4f5c\u7528\u65b9\u9762\uff0c\u53e3\u4e7e\u6700\u666e\u904d\uff0c\u6c92\u6709\u4e00\u4eba\u5016\u514d\u3002\u53e3\u8154\u9ecf\u819c\u708e\u5247\u51fa\u73fe\u572896%\u7684\u75c5\u4eba\uff0c\u5176\u4e2d\u670962%\u70ba\u7b2c\u4e09\u7d1a\u300220\u4f8b\u51fa\u73fe\u60e1\u5fc3\u5614\u5410\uff0c\u9664\u4e00\u4f8b\u70ba\u56b4\u91cd\u7684\u7b2c\u4e09\u7d1a\u4e4b\u5916\uff0c\u5176\u9918\u5c6c\u8f15\u5fae\u3002\u9838\u90e8\u7167\u5c04\u90e8\u4f4d\u76ae\u819a\u6f70\u721b\u51fa\u73fe\u57288\u4f8b\u3002\u767d\u8840\u7403\u6e1b\u5c11\u4e26\u4e0d\u5e38\u898b\u800c\u4e14\u5927\u591a\u70ba\u8f15\u5fae\u964d\u4f4e\u3002\u9ad4\u91cd\u6e1b\u8f15\u5e73\u5747\u964d\u5e45\u70ba8.2\u00b10.6%\u3002\u665a\u671f\u526f\u4f5c\u7528\u4ecd\u4ee5\u53e3\u4e7e\u6700\u5e38\u898b\uff0c\u6240\u6709\u75c5\u4eba\u5747\u53d7\u5176\u82e6\u3002\u982d\u90e8\u8edf\u7d44\u7e54\u7e96\u7dad\u5316\u7684\u670913\u4eba(26%)\uff0c\u4e0d\u904e\u5927\u591a\u70ba\u8f15\u5fae\u4e4b\u7b2c\u4e00\u7d1a\uff0c\u51fa\u73feLhermitte's sign\u7684\u670912\u500b\u75c5\u4eba\uff0c\u6b64\u5916\u4e26\u6c92\u6709\u51fa\u73fe\u5176\u5b83\u795e\u7d93\u75c7\u72c0\u3002\u807d\u529b\u6e1b\u9000\u8207\u4e2d\u8033\u708e\u53ca\u9f3b\u585e\u4e5f\u6709\u7d04\u4e94\u5206\u4e4b\u4e00\u5de6\u53f3\u7684\u75c5\u4eba\u51fa\u73fe\uff0c\u7259\u95dc\u7dca\u9589\u6709\u5169\u4f8b\u3002\u53e6\u5916\u6709\u4e00\u4f8b\u51fa\u73fe\u53f3\u4e0b\u9f52\u69fd\u9aa8\u58de\u6b7b\u3002\n\u7d50\u8ad6\uff1a\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u7528\u65bc\u9f3b\u54bd\u764c\u75c5\u4eba\uff0c\u5f15\u767c\u7684\u6025\u6027\u53e3\u8154\u9ecf\u819c\u708e\u6bd4\u7387\u9817\u9ad8\uff0c\u4f46\u4e26\u4e0d\u81f4\u56e0\u6b64\u59a8\u7919\u4e86\u6cbb\u7642\u9032\u884c\u3002\u5176\u5b83\u7684\u6025\u6027\u526f\u4f5c\u7528\uff0c\u57fa\u672c\u4e0a\u5747\u5c6c\u8f15\u5fae\uff0c\u6216\u8005\u8207\u50b3\u7d71\u6cbb\u7642\u6cd5\u76f8\u7576\uff0c\u75c5\u4eba\u6240\u627f\u53d7\u56e0\u6cbb\u7642\u5e36\u4f86\u7684\u58d3\u529b\uff0c\u4f3c\u4e26\u4e0d\u6bd4\u50b3\u7d71\u7167\u5c04\u9ad8\u3002\u5728\u665a\u671f\u526f\u4f5c\u7528\u65b9\u9762\uff0c\u9664\u4e00\u4eba\u767c\u751f\u9aa8\u58e4\u6b7b\u5c6c\u8f03\u56b4\u91cd\u7684\u4f8b\u5b50\uff0c\u5176\u9918\u7684\u526f\u4f5c\u7528\u5747\u5c6c\u4e00\u822c\u50b3\u7d71\u7167\u5c04\u7684\u7bc4\u570d\u3002\u4e0d\u904e\u4ecd\u9700\u9032\u4e00\u6b65\u8ffd\u8e64\uff0c\u624d\u80fd\u5c0d\u65bc\u665a\u671f\u526f\u4f5c\u7528\uff0c\u4f5c\u66f4\u6e96\u78ba\u7684\u7d50\u8ad6\u3002\u5728\u76ee\u524d\u7684\u968e\u6bb5\uff0c\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642\u7406\u8ad6\u4e0a\u61c9\u4e0d\u6703\u589e\u52a0\u665a\u671f\u526f\u4f5c\u7528\u3001\u4f46\u6703\u589e\u52a0\u65e9\u671f\u53cd\u61c9\uff08\u53ca\u816b\u7624\u63a7\u5236\u7387\uff09\u7684\u512a\u9ede\uff0c\u82e5\u8b39\u614e\u4f7f\u7528\uff0c\u4e0d\u5931\u70ba\u9f3b\u54bd\u764c\u75c5\u4eba\u5728\u50b3\u7d71\u7167\u5c04\u6cd5\u4e4b\u5916\u7684\u53e6\u4e00\u9078\u64c7\u3002", "e": "Purpose: To analyze the treatment-related acute and late toxicities of NPC patients after hyperfractionated radiotherapy.\nMaterials and Methods: During the period from Oct. 1991 to June 1996, 50 patients were treated using hyperfractionated radiotherapy with 120 cGy bid and 6-hour intervals. There were 35 males and 15 females with the age range of 17-79. All except 2 cases were of AJCC stage III & IV. During the treatment period, acute toxicities were recorded once a week. Late toxicities were also evaluated on every follow-up visit after completion of radiotherapy. RTOG/EORTC criteria are used to grade toxicities.\nResults: Dry mouth was the most commonly found acute side effect affecting all patients. Acute mucositis developed in 96% of the patients, with 62% of grade 3. Nausea/vomiting occurred in 20 cases and were mostly mild except one. Moist desquamation was noted in 8 patients. Leukopenia was not frequent and mild. Body weight loss was 8.2\u00b10.6%. For late toxicities, xerostomia was again the most common and affected all patients. Neck fibrosis was found in 13 patients (26%), mostly mild. Twelve patients developed Lhermitte's sign. No other neurological dysfunction has been noted. Hearing impairment was often associated with otitis media and occurred in about 1/ 5 of patients. Two patients had trismus, and one had radionecrosis at the posterior alveolar bone of the right mandible.\nConclusions: Hyperfractionated radiotherapy induced a high proportion of mucositis. However, the patient tolerance was not compromised by this. Other acute toxicities resembled that after conventional radiotherapy both in frequency and severity. This also applied to late complications except one case with radionecrosis. Longer follow-up is needed before any definite conclusion can he made. At the present stage, hyperfractionated radiotherapy, with its theoretical advantages, appears to be a reasonable alternative to conventional radiotherapy for NPC patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-173-178-a", "title": "\u7dad\u751f\u7d20C\u5c0d\u65bcKB\u53caCHO\u7d30\u80de\u653e\u5c04\u7dda\u654f\u611f\u5ea6\u4e4b\u5f71\u97ff", "keywords": "\u7dad\u751f\u7d20C;\u751f\u5b58\u5206\u6578;KB\u53e3\u8154\u764c\u7d30\u80de;\u4e2d\u570b\u5009\u9f20\u5375\u5de2\u7d30\u80de;\u8f3b\u5c04\u4fdd\u8b77 Ascorbic acid (AA);Survival Fraction (SF);KB cells;CHO cells;Radioprotection", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u5728\u63a2\u8a0e\u7dad\u751f\u7d20C(vitamin C, ascorbic acid, AA)\u5c0d\u65bc\u53e3\u8154\u764c(KB)\u53ca\u4e2d\u570b\u5009\u9f20\u5375\u5de2(CHO)\u7d30\u80de\u653e\u5c04\u7dda\u654f\u611f\u5ea6\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u5c07\u7d30\u80de\u5171\u5206\u70ba\u4e09\u7d44\uff1aA\u7d44\u70ba\u6b63\u5e38\u5c0d\u7167\u7d44\uff0cB\u7d44\u70baAA\u7d66\u8207\u5f8c\u7acb\u5373(0\u5c0f\u6642)\u63a5\u53d7\u653e\u5c04\u7dda\u7167\u5c04\uff0cC\u7d44\u70baAA\u8655\u7406\u5f8c24\u53ca48\u5c0f\u6642\u518d\u63a5\u53d7\u653e\u5c04\u7dda\u7167\u5c04\u3002\n\u7d50\u679c\uff1b\u7814\u7a76\u767c\u73feAA\u5c0d\u65bcKB\u53caCHO\u7d30\u80de\u4e4b\u751f\u9577\u6709\u6291\u5236\u4f5c\u7528\u3002AA\u5c0d\u65bcKB\u53caCHO\u7d30\u80de\u4e4bID50\u503c\u5206\u5225\u70ba2.48\u53ca2.11 mg/ml\uff08\u57f9\u990a\u6db2\uff09\uff0c\u5169\u8005\u975e\u5e38\u63a5\u8fd1\u3002\u5728KB\u7d30\u80de\u57f9\u990a\u4e2d\u52a0\u5165AA\u5f8c0,24\u53ca48\u5c0f\u6642\uff0c\u5206\u5225\u7d66\u4e88\u55ae\u4e00\u653e\u5c04\u5291\u91cf800 cGy\u7167\u5c04\uff0c\u53ef\u767c\u73feKB\u7d30\u80de\u4e4b\u751f\u5b58\u5206\u6578(survival fraction, SF)\u96a8\u8457\u6642\u9593\u589e\u52a0\u800c\u589e\u52a0\uff0c\u4e14CHO\u7d30\u80deSF\u4e4b\u8b8a\u5316\u4e5f\u6709\u76f8\u540c\u8da8\u52e2\u3002\u4e00\u822c\u8aaa\u4f86\u57f9\u990a\u5f8c\u6108\u4e45\u6642\u9593\uff0c\u63a5\u53d7\u653e\u5c04\u7dda\u7167\u5c04\u4e4bSF\u503c\u4e5f\u6108\u9ad8\u3002\u4f46\u82e5\u5206\u5225\u8207B\u7d44\u7d30\u80de\u4e4bSF\u503c\u76f8\u6bd4\uff0cAA\u52a0\u5165\u5f8c24\u53ca48\u5c0f\u6642\u518d\u5206\u5225\u63a5\u53d7\u653e\u5c04\u7dda\u7167\u5c04\u4e4bKB\u7d30\u80de\u5176SF\u503c\u589e\u52a0\u500d\u6578\u7121\u986f\u8457\u8b8a\u5316\u3002\u986f\u793aAA\u5c0d\u65bcKB\u7d30\u80de\u6c92\u6709\u660e\u986f\u7684\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u3002\u76f8\u53cd\u7684\uff0c\u8207B\u7d44\u7d30\u80de\u4e4bSF\u503c\u76f8\u6bd4\uff0cCHO\u7d30\u80de\u4e4bSF\u589e\u52a0\u500d\u6578\u6709\u6975\u986f\u8457\u7684\u589e\u52a0\uff0c\u8868\u793aAA\u5c0dCHO\u7d30\u80de\u6709\u660e\u986f\u7684\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u3002\u7d50\u8ad6\uff1a\u7576CHO\u7d30\u80de\u57f9\u990a\u6db2\u5167\u52a0\u5165AA\u5f8c\uff0c\u5728\u57f9\u990a\u5f8c48\u5c0f\u6642\u5167\uff0c\u96a8\u8457\u6642\u9593\u7684\u589e\u52a0AA\u80fd\u63d0\u4f9b\u4e4b\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u4e5f\u6108\u660e\u986f\u3002\u6b64\u7a2e\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u5728KB\u7d30\u80de\u4e26\u4e0d\u986f\u8457\uff0c\u5728CHO\u7d30\u80de\u5247\u975e\u5e38\u660e\u986f\u3002\u800c\u6b64\u7a2e\u5dee\u5225\u6027\u7684\u4fdd\u8b77\u6b63\u5e38\u7d30\u80de\u53ef\u80fd\u6709\u52a9\u80fdAA\u5728\u653e\u5c04\u6cbb\u7642\u4e0a\u7684\u61c9\u7528\u3002", "e": "Purpose: The goal of this study is to realize the radioprotective effects of vitamin C (ascorbic acid, AA) on KB and CHO cells.\nMaterials and Methods: The experimental cells were assigned to divide into three groups: group A was the normal control; Cells in group C were irradiated at 24 or 48 hrs respectively after AA treatment.\nResults: There is an inhibitory effect of AA on the growth of KB and CHO cells. The ID50 data of AA on KB and CHO cells are 2.48 and 2.11 mg/ml of culture medium respectively, roughly the same of them. The survival fractions (SF) of KB cells increased gradually after delivered AA to their culture medium at 0, 24 and 48 hrs, and then irradiated with a single fraction of 800 cGy. Similar results were also noted in CHO cells. In general, the longer of the culture period, the higher of the SF after irradiation at that culture time. Compared to the SF of group B (0 hr), there was no significant increase of SF at 24 and 48 hrs in CHO treated KB cells. It showed that there was no radioprotective effect of AA on KB cells. On the contrary, the SF of CHO cells treated with AA at 24 and 48 hrs respectively increased significantly compared to the SF of group B.\nConclusion: The radioprotective effects of AA on CHO cell were proportional to culture time within 48 hrs after AA treatment. This radioprotective effect was not significant in KB cells, but was significant in CHO cells. The differential radioprotective effect of AA on normal cells may be used in clinical radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-179-185-a", "title": "\u7d44\u7e54\u9593\u633f\u690d\u71b1\u6cbb\u7642\u4f7f\u7528\u71b1\u900f\u5c0e\u7ba1\u7cfb\u7d71\u4e4b\u7814\u7a76", "keywords": "\u7d44\u7e54\u9593\u633f\u63d2\u690d\u71b1\u6cbb\u7642;\u71b1\u900f\u5c0e\u7ba1 Interstitial hyperthermia;Thermofuse", "c": "\u76ee\u7684\uff1a\u4ee5\u7d44\u7e54\u633f\u690d\u65b9\u5f0f\uff0c\u7c4d\u4e00\u6b21\u65bc\u816b\u7624\u7684\u91dd\u7ba1\u633f\u690d\uff0c\u53ef\u7cbe\u78ba\u4e14\u8db3\u5920\u5730\u7d66\u4e88\u653e\u5c04\u6cbb\u7642\u53ca\u71b1\u6cbb\u7642(hyperthermia)\u5169\u7a2e\u76f8\u8f14\u76f8\u6210\u7684\u6cbb\u7642\uff0c\u63d0\u9ad8\u5c40\u90e8\u6cbb\u7642\u7387\u3002\u4ee5\u96fb\u78c1\u6ce2\u6216\u5c04\u983b(radiofrequency)\u70ba\u71b1\u6e90\uff0c\u52a0\u6eab\u53ca\u6e2c\u6eab\u6613\u53d7\u5176\u7269\u7406\u6027\u4e4b\u5e72\u64fe\u3002\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u4e43\u5728\u65bc\u7814\u7a76\u4ee5\u71b1\u900f\u5f0f\u5c0e\u7ba1(thermofuse)\u71b1\u6cbb\u7642\u5100\u4f7f\u7528\u7d44\u7e54\u633f\u690d\u6eab\u5ea6\u5206\u4f48\u7684\u60c5\u5f62\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4f7f\u7528\u71b1\u900f\u5c0e\u7ba1\u71b1\u6cbb\u7642\u5100\uff0c\u5206\u5225\u65bc\u71b1\u6cbb\u7642\u4e4b\u5047\u9ad4\uff0c\u8c6c\u8089\u53ca\u6d3b\u9ad4\u8c6c\uff0c\u4f9d\u4e09\u81f3\u4e94\u5c64\u9762(plane), \u4ee5\u7a4d\u9ad4\u5f0f(voiume)\u5f0f\u633f\u690d\u91dd\u7ba1\uff0c\u6bcf\u5c64\u9762\u4e94\u6839\uff0c\u6bcf\u6839\u4f9d10,12, 15mm \u9593\u8ddd\u5171\u4e09\u7d44\u3002\u4ee5\u71b1\u5076(thermocouple)\u5be6\u6e2c\u633f\u690d\u5340\u5167\u3001\u5916\u4e0d\u540c\u4f4d\u7f6e\u6eab\u5ea6\u4e4b\u5206\u4f48\u53ca\u8b8a\u5316\u60c5\u5f62\uff0c\u5206\u6790\u4e26\u76f8\u4e92\u6bd4\u8f03\u3002\n\u7d50\u679c\uff1a\u65bc\u5047\u9ad4\u3001\u8c6c\u8089\u8207\u6d3b\u9ad4\u8c6c\u7686\u53ef\u85c9\u8abf\u6574\u5faa\u74b0\u524d\u4e4b\u6c34\u6eab\uff0c\u4f7f10\u53ca12 mm\u9593\u8ddd\u4e4b\u633f\u690d\u5340\u5167\u9054\u5230\u7406\u60f3\u4e4b\u6cbb\u7642\u6709\u6548\u6eab\u5ea6\uff0c\u65bc\u6d3b\u9ad4\u8c6c\u516715mm\u90e8\u4efd\u9593\u8ddd\uff0c\u633f\u503c\u5340\u5167\u5247\u672a\u9054\u71b1\u6cbb\u7642\u7406\u60f3\u7684\u6eab\u5ea6\u3002\u6d3b\u9ad4\u8c6c\u5167\u6e2c\u6eab\u986f\u793a\u8fd1\u8840\u7ba1\u5340\u57df\uff0c\u6eab\u5ea6\u986f\u8457\u4e0b\u964d1.4~2.0\u2103\u3002\n\u7d50\u8ad6\uff1a\u672c\u7814\u7a76\u986f\u793a\uff0c\u4f7f\u7528\u71b1\u900f\u5c0e\u7ba1\u7cfb\u7d71\u4f5c\u7d44\u7e54\u9593\u633f\u690d\u71b1\u6cbb\u7642\uff0c\u80fd\u65bc\u816b\u7624\u5340\u57df\u85c9\u91dd\u7ba1\u4e4b\u633f\u690d\u53ca\u4e0d\u53d7\u7269\u7406\u6027\u56e0\u7d20\u689d\u4ef6\u5e72\u64fe\u4e4b\u6e2c\u91cf\uff0c\u7cbe\u78ba\u5730\u7d66\u4e88\u53ca\u5be6\u6e2c\u6709\u6548\u6cbb\u7642\u6eab\u5ea6, \u5176\u52a0\u71b1\u8207\u6e2c\u6eab\u4e4b\u6e96\u78ba\u6027\u70ba\u76ee\u524d\u5176\u4ed6\u9ad4\u5916\u71b1\u6cbb\u7642\uff0c\u6240\u7121\u6cd5\u6bd4\u64ec\u3002\u4f30\u8a08\u8207\u653e\u5c04\u6cbb\u7642\u5408\u7528\u53ef\u63d0\u6607\u7642\u6548\uff0c\u5c0d\u5b58\u6d3b\u671f\u9577\u4e4b\u5be6\u8cea\u7624(solid tumor)\uff0c\u52a9\u76ca\u5c24\u591a\u3002", "e": "Purpose: Using intersitial implantation, one needle implantation procedure provides for two complimentary treatment modalities of radiotherapy and hyperthermia with adequate dose and temperature distribution, subsequently improving the local control. Problems of interference of heat delivery and temperature measurement exist when we use microwave or radiofrequency as the heating source, This study aims at investigating the heat distribution using interstitial thermofuse system.\nMaterial and Methods: Thermofuse hyperthermia system was used to study on phantom, pork and alive pigs. Volume needle implantation with 3-5 planes, 5 needles per plane were implanted. They were devided into 3 groups with 10, 12 and 15mm needle spacing. Thermocouples were used to measure the temperature distribution inside and outside implantation areas. The data were analyzed and compared.\nResults: In the study of phantom, pork and alive pigs, the implantation volume could achieve ideal and effective hyperthermia temperatures at 10, 12 mm spacing through the adjustment of water temperature before circulation. In alive pigs, with a 15 mm needle spacing, the implanted volume could not achieve ideal temperatures. The temperatures were significantly decreased by 1.4-2.0\u2103in the areas near the vessels.\nConclusion: This study shows that interstitial hyperthermia using thermofuse system is able to precisely provide effective hyperthermia temperature without the interference of physics parameters in thermo-measurement in implanted tumor areas. The accuracy of heat delivery and temperature measurement is better than other external hyperthermia systems. We estimate that the combination with radiotherapy can improve the treatment effect of solid tumors. It is expected more beneficial, especially for those solid tumors with relatively long survivals."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-187-192-a", "title": "\u8154\u5167\u5c04\u983b\u71b1\u6cbb\u7642\u6642\u5047\u9ad4\u5167\u6eab\u5ea6\u5206\u4f48\u4e4b\u7814\u7a76", "keywords": "\u5c04\u983b\u96fb\u6ce2;\u71b1\u5206\u4f48;\u8154\u5167\u5f0f\u96fb\u6975 Radiofrequency;Thermal distribution;Intracavitary electrode", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u8154\u5167\u5f0f\u5c04\u983b\u71b1\u6cbb\u7642\u6642\uff0c\u5be6\u969b\u6e2c\u91cf\u5047\u9ad4\u5167\u6eab\u5ea6\u5206\u4f48\u4e4b\u72c0\u6cc1\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u5c04\u983b\u52a0\u71b1\u6cbb\u7642\u7cfb\u7d71\uff0c\u4e26\u63a1\u7528\u8154\u5167\u5f0f\u96fb\u6975\u5c0d\u808c\u8089\u5047\u9ad4\u9032\u884c\u52a0\u71b1\u8a66\u9a57\u3002\u5148\u5c07\u6a21\u64ec\u4eba\u9ad4\u7684\u808c\u8089\u5047\u9ad4\u5099\u88fd\u5b8c\u5168\uff0c\u5728\u5c1a\u672a\u586b\u88dd\u65bc\u58d3\u514b\u529b\u67b6\u5167\u524d\uff0c\u5148\u628a\u4e00\u96fb\u5bb9\u677f\u5f0f\u96fb\u6975\uff0c\u7f6e\u65bc\u58d3\u514b\u529b\u67b6\u5e95\u90e8\uff0c\u518d\u5c07\u5047\u9ad4\u586b\u88dd\u5b8c\u6210\uff0c\u63a5\u8457\u5c07\u8154\u5167\u5f0f\u96fb\u6975\u7a7f\u904e\u58d3\u514b\u529b\u67b6\u4e0a\u9810\u5148\u6240\u947d\u7684\u5713\u5b54\u4e26\u5c07\u4e4b\u57cb\u5165\u5047\u9ad4\u4e2d\u592e\u4f4d\u7f6e\u5f8c\u56fa\u5b9a\u4e4b\uff0c\u4e26\u4ee5\u5c0e\u7ba1\u5c07\u6eab\u5ea6\u8a08\u63a2\u91dd\u56fa\u5b9a\u65bc\u91cf\u6e2c\u9ede\u4ee5\u6e2c\u91cf\u6eab\u5ea6\u4e4b\u8b8a\u5316\uff0c\u52a0\u71b1\u4e4b\u96fb\u78c1\u529f\u7387\u70ba150\u74e6\u3001\u52a0\u71b1\u6642\u9593\u70ba30\u5206\u9418\u3002\n\u7d50\u679c\uff1a\u672c\u5be6\u9a57\u7531\u5047\u9ad4\u4e2d\u592e\u7e31\u5411\u5e73\u9762\u7b49\u6eab\u5716\u986f\u793a\u9760\u8fd1\u96fb\u6975\u52a0\u71b1\u7aef\u6eab\u5ea6\u8f03\u9ad8\uff0c\u96a8\u8457\u8ddd\u96e2\u589e\u52a0\uff0c\u6eab\u5ea6\u6108\u4f4e\uff0c\u53e6\u5916\u5c31\u4e2d\u592e\u7e31\u5411\u5e73\u9762\u4e0d\u540c\u4f4d\u7f6e\u5728Y\u8ef8\u65b9\u5411\u4e4b\u6eab\u5ea6\u5206\u4f48\u800c\u8a00\uff0c\u5728\u52a0\u71b1\u524d\u7aef\u6eab\u5ea6\u7686\u6bd4\u540c\u4e00\u65b9\u5411\u5404\u4f4d\u7f6e\u70ba\u9ad8\uff0c\u6eab\u5ea6\u5206\u4f48\u96e2\u4e2d\u5fc3\u9ede\u6108\u9060\u6108\u4f4e\uff0c\u4e14\u8ddd\u96e2\u4e2d\u5fc3\u9ede\u76f8\u540c\u4f4d\u7f6e\u8655\uff0c\u8154\u5167\u5f0f\u96fb\u6975\u8154\u633f\u5165\u7684\u4e00\u5074\u8f03\u53e6\u4e00\u5074\u6eab\u5ea6\u70ba\u9ad8\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u5be6\u969b\u7684\u91cf\u6e2c\uff0c\u6211\u5011\u5c0d\u8154\u5167\u5f0f\u5c04\u983b\u71b1\u7642\u7cfb\u7d71\u672c\u8eab\u5728\u5047\u9ad4\u5167\u80fd\u91cf\u5206\u4f48\u7684\u72c0\u6cc1\uff0c\u5df2\u6709\u76f8\u7576\u7a0b\u5ea6\u7684\u4e86\u89e3\uff0c\u5be6\u9a57\u7d50\u679c\u4ea6\u8a3c\u5be6\u5176\u80fd\u91cf\u96c6\u4e2d\u5728\u8154\u5167\u5f0f\u96fb\u6975\u9644\u8fd1\uff0c\u5c31\u81e8\u5e8a\u61c9\u7528\u800c\u8a00\uff0c\u662f\u4e00\u7a2e\u53ef\u884c\u7684\u6cbb\u7642\u6a21\u5f0f\uff0c\u7136\u800c\u6211\u5011\u4e5f\u767c\u73fe\u9ad4\u8154\u5167\u52a0\u71b1\u6642\uff0c\u6700\u9ad8\u6eab\u5ea6\u767c\u751f\u5728\u9760\u8fd1\u96fb\u6975\u52a0\u71b1\u7ba1\u6700\u524d\u7aef\u90e8\u5206\uff0c\u56e0\u6b64\u82e5\u5c07\u6b64\u6280\u8853\u61c9\u7528\u5728\u4eba\u9ad4\u4e0a\uff0c\u5247\u5fc5\u9808\u975e\u5e38\u5c0f\u5fc3\u76e3\u6e2c\u8a72\u8655\u7684\u6eab\u5ea6\uff0c\u4ee5\u514d\u7522\u751f\u904e\u71b1\u73fe\u8c61\u50b7\u5bb3\u6b63\u5e38\u7d44\u7e54\u3002", "e": "Purpose: To evaluate the temperature distribution in a phantom using a radiofrequency intracavitary heating system.\nMaterial and Method: The heating device is a 13.56 MHz radiofrequency hyperthermia system. A homogenous muscle phantom was used. Before heating, one capacitive plate electrode was placed under the phantom and another intracavitary electrode was inserted horizontally to the center of the phantom. The temperatures were measured by thin-coated thermocouples which were placed into the phantom through angiocatheters. The catheters were arranged with the aid of a custom-made holder. Simultaneously, thermogram was performed via a computerized system.\nResult: The result showed that the temperatures around the intracavitary device were higher than the points elsewhere in the phantom. The farther away from the intracavitary electrode a point was, the less temperature was measured. The highest temperature appeared at the anterior part of the intracavitary electrode.\nConclusion The study revealed that the energy would concentrate around the intracavitary electrode. It may be reasonable applying an intracavitary heating device into the body cavity to treat the malignancy of vagina, cervix, esophagus, prostate, etc. However, it must be very careful to monitor the temperature around the intracavitary electrode for prevention of normal tissue injury by overheating."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-193-198-a", "title": "\u96fb\u5b50\u5c04\u675f\u906e\u64cb\u7167\u91ce\u5291\u91cf\u8f38\u51fa\u4e4b\u7814\u7a76", "keywords": "\u96fb\u5b50\u5c04\u675f;\u5c0f\u7167\u91ce\u5291\u91cf\u8f38\u51fa;\u5291\u91cf\u8a08\u7b97 Electron beam;Cutout field output;Dosimetry", "c": "\u76ee\u7684\uff1a\u96fb\u5b50\u5c04\u675f\u4e0d\u898f\u5247\u5f62\u906e\u6a94\u7167\u91ce\u7684\u5291\u91cf\u8f38\u51fa\u5c1a\u7121\u6cd5\u4ee5\u4efb\u4f55\u6578\u5b78\u516c\u5f0f\u4e88\u4ee5\u6b63\u78ba\u9810\u4f30\u53ca\u8a08\u7b97\uff0c\u672c\u7bc7\u91dd\u5c0dVarian CL-1800 sn:164\u76f4\u7dda\u52a0\u901f\u5668\u5404\u96fb\u5b50\u9650\u5149\u7b52\uff0c\u5404\u80fd\u91cf\u96fb\u5b50\u5c04\u675f\u5206\u5225\u6e2c\u91cf\u7531\u5168\u958b\u52301\u00d71cm^2\u6b63\u65b9\u5f62\u7167\u91ce\u7684\u8f38\u51fa\uff0c\u89c0\u5bdf\u5176\u8f38\u51fa\u8207\u906e\u64cb\u9762\u7a4d\u4e4b\u8b8a\u5316\u95dc\u4fc2\uff0c\u9032\u800c\u5efa\u8b70\u81e8\u5e8a\u96fb\u5b50\u5c04\u675f\u4e0d\u898f\u5247\u5f62\u7167\u91ce\u5291\u91cf\u4e4b\u4fee\u6b63\u65b9\u6cd5\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u63a1\u7528CERROBEND\u925b\u5408\u91d1\u88fd\u4f5c\u9762\u7a4d\u4e0d\u540c\uff0c\u7bc4\u570d\u70ba1\u00d71cm^2\u81f310\u00d710cm^2\uff0cstep size=1cm\u53ca15\u00d715cm^2\u4e4b\u6b63\u65b9\u5f62\u906e\u6a94\u925b\u584a\uff0c\u7f6e\u65bcVarian CL-1800 sn:164\u4e4b\u9650\u5149\u7b52\u5e95\u90e8\uff0c\u4ee5N.E. 0.03 c.c.\u5e73\u677f\u578b\u6e38\u96e2\u8154(Type:2534)\u7f6e\u65bcRMI PMMA\u56fa\u614b\u5047\u9ad4\u5c04\u675f\u4e2d\u5fc3\u8ef8\u6700\u9ad8\u5291\u91cf\u9ede\u6df1\u5ea6\uff0c\u5c0d20\u00d720cm^2\uff0c15\u00d715cm^2, 10\u00d710cm^2\u53ca6\u00d76cm^2\u96fb\u5b50\u9650\u5149\u7b52\u53ca\u80fd\u91cf\u70ba4,6,9,12,15 MeV\u7684\u96fb\u5b50\u5c04\u675f\u6e2c\u91cf\u5176\u8f38\u51fa\uff0c\u4e26\u5c07\u5176\u6578\u503c\u6b78\u4e00\u5230\u5168\u958b\u7167\u91ce\u7684\u8f38\u51fa\uff0c\u4ee5\u89c0\u5bdf\u96fb\u5b50\u5c04\u7dda\u5728\u540c\u4e00\u9650\u5149\u7b52\u4e2d\uff0c\u56e0\u7167\u91ce\u7e2e\u5c0f\u5f8c\u5176\u5291\u91cf\u7684\u8b8a\u5316\u60f0\u5f62\uff1b\u4e26\u4ee5\u6578\u584a\u81e8\u5e8a\u75c5\u60a3\u4e4b\u925b\u584a\u7d93\u6e2c\u91cf\u53ca\u8a08\u7b97\u4e92\u76f8\u6bd4\u5c0d\u5176\u8aa4\u5dee\u3002\n\u7d50\u679c\uff1a20\u00d720\u53ca15\u00d715cm^2\u7684\u9650\u5149\u7b52\uff0c\u5c0d\u5404\u80fd\u91cf\u800c\u8a00\uff0c\u7167\u91ce\u9762\u7a4d\u5c0f\u65bc5\u00d75cm^2\u4ee5\u4e0b\u6642\u8f38\u51fa\u660e\u986f\u964d\u4f4e\uff1b10\u00d710cm^2\u7684\u9650\u5149\u7b52\uff0c\u7167\u91ce\u9762\u7a4d\u5c0f\u65bc4\u00d74cm^2\u4ee5\u4e0b\uff1b6\u00d76cm^2\u7684\u9650\u5149\u7b52\uff0c\u7167\u91ce\u9762\u7a4d\u5c0f\u65bc3\u00d73cm^2\u4ee5\u4e0b\u8f38\u51fa\u4ea6\u660e\u986f\u964d\u4f4e\uff0c\u82e5\u906e\u64cb\u7167\u91ce\u4e0d\u5c0f\u65bc\u4ee5\u4e0a\u6578\u503c\u5247\u5176\u8f2a\u51fa\u4e0d\u5fc5\u7279\u5225\u4fee\u6b63\u3002\n\u7d50\u8ad6\uff1a\u4e0d\u898f\u5247\u5f62\u7167\u91ce\u96fb\u5b50\u5c04\u675f\u5291\u91cf\u8f38\u51fa\u7684\u8b8a\u5316\u7121\u6cd5\u5982\u5149\u5b50\u5c04\u675f\u4e00\u822c\u53ef\u7528SAR\u503c\u53caClarkson\u6cd5\u5b50\u4ee5\u7cbe\u78ba\u8a08\u7b97\uff0c\u7531\u672c\u5be6\u9a57\u7684\u7d50\u679c\u53ef\u77e5\uff1a\u82e5\u906e\u64cb\u9762\u7e3e\u4e0d\u8d85\u904e\u5291\u91cf\u8870\u6e1b\u9ede\u5247\u5176\u8f38\u51fa\u4e0d\u5fc5\u7279\u5225\u4fee\u6b63\uff1a\u82e5\u906e\u64cb\u9762\u7e8c\u8d85\u904e\u5291\u91cf\u8870\u6e1b\u9ede\u5247\u53ef\u7528 M D Mills\u6240\u63d0\u51fa\u7684\u65b9\u6cd5\u9032\u884c\u5291\u91cf\u8a08\u7b97\u3002", "e": "Purpose: Computer summation algorithms for irregular electron fields are not widely available. In this study, we measured the output factors of each electron energy and each electron cone (except 25\u00d7 25 cm^2 applicator) of Varian Cl-l800 sn: 164 linear accelerator. The cut-out size is ranging from l\u00d71 cm^2 to l0\u00d710 cm^2 stepped by 1 cm for l0\u00d710 cm^2 and 6\u00d76 cm^2 electron cones and 15\u00d715 cm^2 for 20\u00d720 cm^2 cone. According to the measured data, we will observed the variation of the output factors and suggest the method for irregular electron field output correction. Materials & Methods: Cut-out BSBs(Beam-Shaping-Blocks) were made of CERROBEND alloy to put into the frame of each applicator. The output was measured with 0.0 3cc parallel plate ionization chamber be setted at the dmax of RMI PMMA solid phantom and connected to lonex Dosemaster 2590 electrometer. The readings were corrected with temperature, pressure and be normalized to its full open cone output.\nResults: For each energy and 15\u00d715 cm^2, 20\u00d720 cm^2 electron cones, the output factors decreases rapidly when the cut-out size is less than 5\u00d75 cm^2. For 10 \u00d710 cm^2 cone, the output is not decrease when the cut-out size is larger than 4\u00d74 cm^2. For 6\u00d76 cm^2 cone, the output is the same when the cut-out size is not less than 3\u00d73 cm^2.\nConclusion: There is no simple mathematical function just like the SAR method and Clarkson mehtod that allows us to predict the output for a given field size and electron energy. According to the results of this measurement, the output of the irregular field can be corrected by Mills method if the cutout area less than the point of curve decreasing."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-199-204-a", "title": "\u4e0d\u5c0d\u7a31\u6e96\u76f4\u5100\u5728\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e0a\u4e4b\u904b\u7528", "keywords": "\u4e0d\u5c0d\u7a31\u6e96\u76f4\u5100;\u767c\u6563\u6548\u61c9;\u5207\u5272\u7167\u91ce;\u96e2\u4e2d\u5fc3\u8ef8;\u4e2d\u5fc3\u9ede Asymmetric jaws;Divergence effect;Tangential field;Off axis;Center", "c": "\u76ee\u7684\uff1a\u73fe\u4ee3\u7684\u653e\u5c04\u6cbb\u7642\u5728\u6280\u8853\u548c\u5291\u91cf\u8a55\u4f30\u65b9\u9762\u6108\u6c42\u7cbe\u6e96\u3002\u96a8\u8457\u4e00\u4e9b\u7279\u6b8a\u75c5\u60a3\u53ca\u6280\u8853\u4e4b\u9700\u8981\uff0c\u5728\u6a5f\u5668\u65b9\u9762\u6709\u5f88\u591a\u65b0\u7a4e\u3001\u5148\u9032\u7684\u8a2d\u8a08\uff0c\u4e0d\u5c0d\u7a31\u6e96\u76f4\u5100(asymmetric jaws)\u5c31\u662f\u4e00\u660e\u986f\u7684\u4f8b\u8a3c\uff0c\u672c\u6587\u5373\u91dd\u5c0d\u4e0d\u5c0d\u7a31\u6e96\u76f4\u5100\u5728\u5291\u91cf\u8f38\u51fa\u548c\u81e8\u5e8a\u4e0a\u4e4b\u7279\u6b8a\u7167\u91ce\u6280\u8853\u61c9\u7528\u505a\u4e00\u4ecb\u7d39\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6211\u5011\u4f7f\u7528Vorian -2100C\u76f4\u7dda\u52a0\u901f\u5668\uff0c\u8a72\u6a5f\u5668\u5177\u6709\u5169\u5c0d\u6e96\u76f4\u5100\uff08\u4e0a\u3001\u4e0b\u5404\u4e00\u5c0d\uff09\uff0c\u53ef\u4f5c\u4e0d\u5c0d\u7a31\u6027\u958b\u95dc\uff0c\u5c07\u4e0a\u6e96\u76f4\u5100(upper jaw)\u7684\u4e00\u908a\u95dc\u81f3\u4e2d\u5fc3\u8ef8(central axis)\uff0c\u53e6\u4e00\u908a\u5206\u5225\u958b\u62105,10,15\u516c\u5206\uff0c\u800c\u4e0b\u6e96\u76f4\u5100(low jaw)\u5247\u70ba10\u516c\u5206\uff0c\u4f7f\u5176\u7167\u91ce\u5206\u5225\u70ba(5, 0)\u00d710, (10,0)\u00d710 (15, 0)\u00d710\uff08\u516c\u5206\u00d7\u516c\u5206\uff09\uff0c\u5373\u7167\u91ce\u7684\u4e2d\u5fc3\u8ef8\u504f\u96e2\u539f\u6a5f\u5668\u4e4b\u4e2d\u5fc3\u8ef8(off-axis)\u5404\u70ba2.5,5,7.5\u516c\u5206\uff0c\u518d\u5c07\u6a5f\u5668\u7684\u6e96\u76f4\u5100\u958b\u6210\u5c0d\u7a31\u6027\u7167\u91ce\u5206\u5225\u70ba5\u00d710,10\u00d710, 15\u00d7l0\uff08\u516c\u5206\u00d7\u516c\u5206\uff09\uff0c\u7136\u5f8c\u75280.6\u7acb\u65b9\u516c\u5206\u7684\u5713\u67f1\u9ad4\u6e38\u96e2\u8154(PTW, 0.66cc cylindrical ionization chamber)\u6e2c\u91cf\u5176\u4e0d\u540c\u7167\u91ce\u4e2d\u5fc3\u9ede\u7684\u66dd\u9732\u91cf\u3002\n\u7d50\u679c\uff1a\u5206\u6790\u6bd4\u8f03\u5169\u7a2e\u76f8\u540c\u7167\u91ce\u4e0d\u540c\u72c0\u6cc1\u4e0b\u4e4b\u5291\u91cf\uff0c\u767c\u73fe\u5176\u7167\u91ce\u4e2d\u5fc3\u9ede(center)\u4e4b\u5291\u91cf\u5dee\u7d04\u5728 1~2-5%\u5de6\u53f3\u3002\u6240\u4ee5\u5728\u81e8\u5e8a\u4e0a\u5176\u5291\u91cf\u56e0\u7d20\u8f03\u7121\u9808\u8003\u616e\uff0c\u53ef\u591a\u52a0\u5229\u7528\u6b64\u7279\u6b8a\u88dd\u5099\u914d\u5408\u65b0\u6280\u8853\u6cbb\u7642\u75c5\u60a3\u3002\n\u7d50\u8ad6\uff1a\u5728\u81e8\u5e8a\u65b9\u9762\uff0c\u982d\u9838\u90e8\u4e4b\u60a3\u8005\u5982\uff1a\u9f3b\u54bd\u764c\u3001\u53e3\u8154\u764c\u2026\u2026\u7b49\u7b49\uff0c\u5176\u6cbb\u7642\u7bc4\u570d\u751a\u5ee3\uff0c\u9808\u5305\u542b\u4e0b\u9838\u90e8\u548c\u4e0a\u9396\u9aa8\u6dcb\u5df4\u7d44\u8b58\uff0c\u800c\u7531\u65bc\u653e\u5c04\u7dda\u5177\u767c\u6563\u6548\u61c9(divergence)\u4e4b\u95dc\u4fc2\uff0c\u6240\u4ee5\u5728\u9838\u90e8\u5169\u5074\u548c\u4e0b\u9838\u90e8\u524d\u9762\u7167\u91ce\u63a5\u5408\u7684\u90e8\u4f4d\uff0c\u5176\u5291\u91cf\u4e0d\u662f\u904e\u591a\u5c31\u662f\u904e\u5c11\uff1b\u5176\u4ed6\u50cf\u4e73\u623f\u5207\u5272\u7167\u91ce(tangential field)\u4e5f\u662f\u6709\u985e\u4f3c\u540c\u6aac\u4e4b\u554f\u984c\u767c\u751f\u3002\u56e0\u6b64\uff0c\u5169\u76f8\u63a5\u7167\u91ce\u5176\u63a5\u5408\u8655\u4e4b\u5291\u91cf\u78ba\u9808\u4ed4\u7d30\u8a55\u4f30\uff0c\u800c\u4f7f\u7528\u4e0d\u5c0d\u7a31\u6e96\u76f4\u5100\u6b63\u53ef\u89e3\u6c7a\u4e0a\u8ff0\u4e4b\u5291\u91cf\u554f\u984c\u3002", "e": "Purpose: For specific treatment site and precision technique in modern radiation therapy, the advance design of asymmetric jaws in linear accelerator is being used currently. The technical application of asymmetric jaws and it output measurement were introduced in this article.\nMethods and Materials: There are two pairs of collimators in Varian-2100 C which can travel asymmetrically. Asymmetric fields of 5\u00d710, l0\u00d710, 15\u00d710 cm were opened with one of the upper jaws moved to the central axis and the lower jaws opened at 10 cm symmetrically to the central axis. The output of each field was measured by a PTW-23333, 0.6 cc cylindrical ionization chamber along the off-axis center and was compared to the output of the symmetric field of the same field size along the central axis.\nResults: The PTW-23333 Farmer chamber was used to measure the central axis dose for both symmetric and asymmetric fields. We found that the discrepancies were about 1 to 2.5% for the same field sizes. This is acceptable for clinical consideration.\nConclusion: Many head and neck cancer patients, such as nasopharyngeal or oral cavity cancers, are treated by external radiation. The divergent effect of field-to-field junction, between bilateral opposing field in upper neck and anterior lower neck, are always noted. Over (under) dosage in junction area is always concerned by physicians. Further more, supraclavicular and tangential field junction in breast cancer treatments also encounter the same problem. The use of asymmetric jaws can overcome the divergent effect and improve dose uniformity near the junction area."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199609-3-3-205-210-a", "title": "The Use Factor for Protective Barrier in a Medical Linear Accelerator Installation", "keywords": "\u4e3b\u5c4f\u853d;\u5229\u7528\u56e0\u6578;\u8870\u6e1b\u56e0\u6578 Primary barrier;Use factor;Atteunation factor", "c": "\u76ee\u7684\uff1a\u7814\u7a76\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u88dd\u7f6e\u7684\u9632\u8b77\u5c4f\u853d\u4e4b\u5229\u7528\u56e0\u6578\u3002\n\u65b9\u6cd5\uff1a\u672c\u6587\u7d71\u8a08\u81ea\u6c11\u570b70\u81f379\u5e74\u4e2d\uff0c\u9ad8\u96c4\u91ab\u5b78\u9662\u653e\u5c04\u7dda\u6cbb\u7642\u79d1\u5171\u9032\u884c88,949\u9580\u7684\u7167\u5c04\u6cbb\u7642\uff0c\u7e3d\u8f3b\u5c04\u5291\u91cf\u70ba17,050,249 cGy\uff0c\u5e73\u5747\u6bcf\u9580\u7167\u5c04\u7684\u8f3b\u5c04\u5291\u91cf\u70ba1.92\u6208\u96f7\uff0c\u4e26\u4ee5\u6b64\u6578\u64da\u8a08\u7b97\u6b64\u90e8\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u88dd\u7f6e\u7684\u9632\u8b77\u5c4f\u853d\u4e4b\u5229\u7528\u56e0\u6578\u3002\n\u7d50\u679c\uff1a\u82e5\u4ee5\u6bcf\u5e74\u5de5\u4f5c50\u9031\uff0c\u6bcf\u9031\u5de5\u4f5c5\u5929\u4f86\u8a08\u7b97\u5247\u6bcf10\u5e74\u4f86\u6b64\u90e8\u52a0\u901f\u5668\u5e73\u5747\u6bcf\u5929\u7684\u7167\u5c04\u5291\u91cf\u70ba68.2\u6208\u96f7\u3002\u5c0d\u76ee\u524d\u7684\u653e\u5c04\u6cbb\u7642\u6a5f\u4e4b\u9632\u8b77\u5c4f\u853d\u8a08\u7b97\u800c\u8a00\uff0c\u4e3b\u5c4f\u853d\u7684\u5229\u7528\u56e0\u6578(U)\u8207\u5c4f\u853d\u6240\u7522\u751f\u7684\u8870\u6e1b\u56e0\u6578(A)\u662f\u6210\u6b63\u6bd4\u95dc\u4fc2\u3002\u7d71\u8a08\u6b64\u90e8\u52a0\u901f\u5668\u7684\u4e3b\u5c4f\u853d\u7167\u5c04\u65b9\u5411\uff0c\u767c\u73fe\u5927\u7d04\u670940%\u7684\u958b\u6a5f\u6642\u9593\u662f\u5411\u4e0b\uff0c20%\u5411\u4e0a\uff0c\u6c34\u5e73\u65b9\u5411\u5404\u70ba20%\uff0c\u800c\u8207NCRP No.49\u7684\u6578\u64da\u6709\u76f8\u7576\u5927\u7684\u51fa\u5165\u3002\n\u7d50\u8ad6\uff1a\u672c\u6587\u7684\u7d50\u679c\u53ef\u4ee5\u63d0\u9192\u570b\u5167\u653e\u5c04\u6cbb\u7642\u5b78\u754c\u6709\u95dc\u653e\u5c04\u6cbb\u7642\u7684\u4e3b\u5c4f\u853d\u8a2d\u8a08\u8207\u5be9\u6838\u5747\u8207\u570b\u5916\u7684\u6709\u4e9b\u4e0d\u540c\uff0c\u56e0\u6b64\u5c0d\u65bc\u5229\u7528\u56e0\u6578\u503c\u5f97\u9032\u4e00\u6b65\u63a2\u8a0e\u3002", "e": "Purpose: To Study the use factors for primary barrier design using a medical LINAC.\nMaterials and Methods: Upon determining the use factors of a medical LINAC, a total of 88,949 treatment portals and 17,050,249 cGy output doses were calculated in detail during 1981-1990 at Kaohsiung Medical College Hospitals. The use factors were studied by determining the fraction of the time that the primary beam was directed at the primary barrier.\nResults: The average output doses was 192 cGy per treatment portal and 68Gy per day. The primary beam is pointed downward about 40% of the time, upward about 20% of the time, and about 20% in each of the horizontal directions. Upon determining the use factor of this LINAC, it revealed a great difference from the data recommended by NCRP.\nConclusions: The use factor should be taken as an important factor when calculating the thickness of the primary barrier."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-93-99-a", "title": "Technique of Total Body Irradiation Used in NCKUH", "keywords": "\u9aa8\u9ad3\u79fb\u690d;\u5168\u8eab\u7167\u5c04\u8853;\u75c5\u60a3\u4f4d\u7f6e\u7684\u56fa\u5b9a Bone marrow transplant;Total body irradiation;Patient immobilization", "c": "\u76ee\u7684\uff1a\u70ba\u4e86\u7e2e\u77ed\u75c5\u60a3\u5728\u63a5\u53d7\u5168\u8eab\u7167\u5c04\u6cbb\u7642\u6642\u7684\u4f4d\u7f6e\u64fa\u8a2d\u6642\u9593\u53ca\u589e\u9032\u81e8\u5e8a\u6cbb\u7642\u7684\u518d\u8907\u88fd\u53ef\u80fd\u6027\uff0c\u6211\u5011\u63d0\u51fa\u6210\u5927\u91ab\u9662\u6240\u7528\u7684\u5168\u8eab\u7167\u5c04\u65b9\u6cd5\u3002\n\u6750\u6599\u548c\u65b9\u6cd5\uff1a\u6211\u5011\u81ea\u5df1\u88fd\u505a\u4e86\u4e00\u500b\u53ef\u4f9b\u75c5\u4eba\u7ad9\u7acb\u7684\u67b6\u5b50\uff0c\u4e0a\u9762\u6709\u4e00\u500b\u985e\u4f3c\u8173\u8e0f\u8eca\u5ea7\u588a\u7684\u6905\u5b50\u548c\u56fa\u5b9a\u982d\u53ca\u8eab\u9ad4\u7684\u88dd\u7f6e\uff0c\u5982\u6b64\u75c5\u4eba\u6cbb\u7642\u6642\u4f4d\u7f6e\u7684\u64fa\u8a2d\u53ef\u4ee5\u5f88\u8f15\u6613\u5730\u64fa\u597d\u3002\u70ba\u4e86\u907f\u514d\u80ba\u90e8\u63a5\u53d7\u5230\u8d85\u904e\u6b63\u5e38\u5fcd\u53d7\u7684\u5291\u91cf\uff0c\u6bcf\u500b\u75c5\u4eba\u90fd\u7279\u5225\u88fd\u505a\u4e86\u80ba\u90e8\u906e\u64cb\u7684\u925b\u584a\uff0c\u9019\u925b\u584a\u662f\u56fa\u5b9a\u5728\u4e00\u4ef6\u70ba\u75c5\u4eba\u91cf\u8eab\u88fd\u505a\u7684\u9444\u6210\u54c1\u4e0a\uff0c\u4ee5\u52a0\u71b1\u53ef\u5851\u9020\u51b7\u537b\u5373\u5b9a\u578b\u7684\u6750\u6599(Aquaplast(\u4e0a\u6a19 TM) Thermoplastics)\u505a\u6210\uff0c\u75c5\u4eba\u7a7f\u5728\u8eab\u4e0a\u597d\u50cf\u7a7f\u4e86\u4e00\u4ef6\u8cbc\u8eab\u7684\u80cc\u5fc3\u3002\u85c9\u8457\u6bd4\u5be6\u969b\u7167\u5c04\u6642\u7684\u7167\u91ce\u7247\u5b50\u548c\u6a21\u64ec\u651d\u5f71\u7247\u5b50\u6709\u7121\u4e00\u81f4\u4f86\u8a55\u4f30\u75c5\u60a3\u7684\u80ba\u90e8\u906e\u64cb\u925b\u584a\u662f\u5426\u5728\u6b63\u78ba\u4f4d\u7f6e\uff0c\u4ee5\u53ca\u4ed6\u7684\u59ff\u52e2\u662f\u5426\u6b63\u78ba\uff0c\u4f50\u4ee5\u534a\u5c0e\u9ad4\u5075\u6aa2\u5668\u4f86\u6e2c\u91cf\u751f\u7269\u6d3b\u9ad4\u7167\u5c04\u6642\u7684\u5291\u91cf\u6e2c\u91cf\uff0c\u4e26\u4ee5\u5168\u7a0b\u7167\u5c04\u7684\u78ba\u8a8d\u7247\u4f86\u5c0d\u6574\u500b\u7167\u5c04\u904e\u7a0b\u505a\u76e3\u6e2c\u3002\n\u7d50\u679c\uff1a\u5c0d\u8eab\u9ad4\u6b63\u9762\u7684\u7167\u91ce\u4f86\u8aaa\uff0c\u80ba\u90e8\u906e\u64cb\u925b\u584a\u7684\u5e73\u5747\u6c34\u5e73\u8207\u5782\u76f4\u504f\u79fb\u70ba4.8\u00b11.1mm\u548c4.3\u00b11.3mm; \u5c0d\u8eab\u9ad4\u80cc\u9762\u7684\u7167\u91ce\u4f86\u8aaa\uff0c\u5176\u5e73\u5747\u6c34\u5e73\u8207\u5782\u76f4\u504f\u79fb\u70ba3.1\u00b11.1mm\u548c3.4\u00b10.9mm\u3002\u80ba\u90e8\u6240\u53d7\u5230\u7684\u5e73\u5747\u5291\u91cf\u70ba936\u00b121 cGy\uff0c\u6bcf\u6b21\u6cbb\u7642\u7684\u6642\u9593\u82e5\u4f7f\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7d04\u970030\u00b15\u5206\u9418\uff0c\u82e5\u7528\u9237\u516d\u5341\u5247\u970055\u00b15\u5206\u9418\u3002\n\u7d50\u8ad6\uff1a\u6211\u5011\u4ee5\u9019\u6a23\u7684\u65b9\u602f\u53ef\u4ee5\u9054\u5230\u4e00\u500b\u4ee4\u4eba\u6eff\u610f\u7684\u7d50\u679c\uff0c\u4e0d\u4f46\u75c5\u60a3\u81e8\u5e8a\u6cbb\u7642\u6642\u4e0d\u9ebb\u7169\uff0c\u800c\u4e14\u53ef\u4ee5\u63d0\u9ad8\u75c5\u60a3\u5728\u6cbb\u7642\u6642\u7684\u8212\u9069\u5ea6\u3002", "e": "Purpose: We developed a system for total body irradiation (TBI) in an attempt to shorten patient setup and increase the reproducibility.\nMaterials and Methods: A special homemade stand with a quasi-saddle shaped chair and an additional immobilization system for the head and body help to position patient in a reproducible manner. Customized lung shields are used to protect the lung from excess tolerance dose. The blocks are screwed in a customized Aquaplast(superscript TM) Thermoplasties cast which the patient wears like a vest. The reproducibility of the patient's positioning and lung shielding was evaluated by comparing the verification films with the simulation films. In vivo dosimetry was performed by placing diodes in the central axis and in several off-axis sites. Full-course verification of the lung shields was also performed.\nResults: The mean horizontal and vertical deviations were 4.8\u00b11.1mm and 4.3\u00b11.3mm for the anterior fields, and 3.1\u00b11.1mm and 3.4\u00b10.9mm for the posterior fields. The average lung dose was 936\u00b121 cGy. The mean duration per fraction was about 30\u00b15min for linear accelerator and 55\u00b15min for (superscript 60)Co.\nConclusions: Our technique can reach a satisfactory level of reproducibility. It can also increase patient comfort during the treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-101-104-a", "title": "\u9f3b\u54bd\u764c\u75c5\u4eba\u653e\u5c04\u7dda\u9ecf\u819c\u708e\u4e4b\u6291\u5236\uff0d\u6bd4\u8f03Salcoat\u8207Dexaltin\u4e4b\u96a8\u6a5f\u53d6\u6a23\u8a66\u9a57", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642;\u9ecf\u819c\u708e;Salcoat Nasopharyngeal cancers;Radiation therapy;Mucositis;Salcoat", "c": "\u653e\u5c04\u7dda\u53e3\u8154\u9ecf\u819c\u708e\u662f\u653e\u5c04\u7dda\u6cbb\u7642\u982d\u9838\u90e8\u764c\u7684\u4e00\u9805\u9650\u5236\u56e0\u7d20\uff0c\u9ecf\u819c\u708e\u56b4\u91cd\u7684\u6642\u5019\uff0c\u5e38\u4f7f\u653e\u5c04\u7dda\u6cbb\u7642\u4e2d\u65b7\uff0c\u70ba\u4e86\u7814\u7a76\u5674\u9727\u5291Beclomethasone dipropionate (salcoat)\u662f\u5426\u6709\u6548\u6291\u5236\u653e\u5c04\u7dda\u9ecf\u819c\u708e\uff0c\u5c0750\u4f8b\u672a\u63a5\u53d7\u6cbb\u7642\u7684\u9f3b\u54bd\u764c\u60a3\u8005\uff0c\u7d93\u96a8\u6a5f\u53d6\u6a23\u5206\u914d\u6210\u8a66\u9a57\u7d44\uff0825\u4f8b\u7528Salcoat 50\u03bcg QD\uff09\u53ca\u5c0d\u7167\u7d44\uff0825\u4f8b\u7528Dexaltin 120\u03bcg QD\uff09\u3002\u6240\u6709\u60a3\u8005\u5747\u81ea\u7b2c\u516d\u6b21\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u958b\u59cb\u6bcf\u5929\u63a5\u53d7\u5c40\u90e8\u7528\u85e5\u4e00\u6b21\uff0c\u6548\u679c\u7684\u8a55\u4f30\u4f9d1\uff0e\u9ecf\u819c\u708e\u75bc\u75db\u7684\u7a0b\u5ea6\u3001\u6642\u95932\uff0e\u9ecf\u819c\u708e\u7684\u90e8\u4f4d\u591a\u5be1\u53ca\u767c\u751f\u6642\u95933\uff0e\u9ecf\u819c\u708e\u7a0b\u5ea6\u53ca\u767c\u751f\u7684\u6642\u95934\uff0e\u9ecf\u819c\u708e\u75bc\u75db\u7684\u6d88\u5931\u3001\u9ecf\u819c\u708e\u7a0b\u5ea6\u3001\u90e8\u4f4d\u548c\u6d88\u5931\u6642\u9593\u65e9\u665a\u7b49\u4f86\u91cf\u5ea6\u6bd4\u8f03\u3002\u7d93\u904e\u7d71\u8a08\u5206\u6790\u767c\u73fe\uff0cSalcoat\u8f03Dexaitin\u5728\u6e1b\u8f15\u75bc\u75db\u7684\u7a0b\u5ea6\u3001\u6e1b\u8f15\u75bc\u75db\u6240\u9700\u7684\u6642\u9593\u3001\u9ecf\u819c\u708e\u75bc\u75db\u7684\u6d88\u5931\u6642\u9593\u3001\u9ecf\u819c\u708e\u90e8\u4f4d\u591a\u5be1\u3001\u9ecf\u819c\u708e\u6d88\u5931\u6642\u9593\u7b49\uff0c\u5728\u7d71\u8a08\u5b78\u4e0a\u5747\u5c6c\u6709\u610f\u7fa9\u7684\u512a\u8d8a\u6027\u3002", "e": "Radiation-induced oral mucositis is a restricting factor while treating head and neck cancers. It is well known that radiation therapy (R/T) often been interruped while oral mucositis aggravated. To study if Beclomethasone dipropionate an effective drug in the suppression of radiation mucositis. Fifty untreated nasopharyngeal cancer (NPC) patients were randomized into experimental group: (25 NPC patients used Salcoat Cap 50 \u03bcg QD) and controlled group (25 NPC patients use Dexaltin l20\u03bcg QD). Local treatment have been applied to all patients since the 6th time of R/T. The efficacy was evaluated by 1. Onset and degree of pain sensation of mucositis. 2. Onset and sites of mucositis. 3. Onset and degree of mucositis. 4. Disappearance time of pain sensation and mucositis.\nSalcoat is superior to Dexaltin for relief the degree of pain sensation (P\uff1c0.05), time for relief of pain sensation (P\uff1c0.01) and time for recovery of mucositis (P\uff1c0.001)."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-105-111-a", "title": "Findings of Persistent Microscopic Hematuria in a Cancer Prevention and Early Detection Program", "keywords": "\u986f\u5fae\u8840\u5c3f;\u65e9\u671f\u764c\u75c5;\u814e\u7d30\u80de\u764c;\u5b50\u5bae\u5167\u819c\u764c Microscopic hematuria;Early cancers;Renal cell carcinoma;Endometrial carcinoma", "c": "\u76ee\u7684\uff1a\u8a55\u4f30\u9632\u764c\u6aa2\u5bdf\u4e2d\uff0c\u6301\u7e8c\u986f\u5fae\u8840\u5c3f\u7684\u81e8\u5e8a\u610f\u7fa9\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u81ea1987\u5e749\u6708\u81f31993\u5e744\u6708\uff0c\u53f0\u5317\u69ae\u6c11\u7e3d\u91ab\u9662\u764c\u75c5\u6cbb\u7642\u4e2d\u5fc3\u9632\u764c\u5ba4\u5c0d3476\u4f8b\u6c11\u773e\u5f9e\u4e8b\u9632\u764c\u5075\u6aa2\u3002\u51e1\u6709\u986f\u5fae\u8840\u5c3f\u8005\u91cd\u8986\u5c3f\u6db2\u6aa2\u67e5\u3002\u82e5\u75c5\u4eba\u6709\u6301\u7e8c\u986f\u5fae\u8840\u5c3f\u8005\u5247\u8f49\u4ecb\u81f3\u9069\u7576\u79d1\u5225\u63a5\u6388\u5c3f\u6db2\u57f9\u990a\u3001\u6392\u5c3f\u651d\u5f71\u3001\u8180\u80f1\u93e1\u3001\u5c3f\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\u3001\u8d85\u97f3\u6ce2\u6216\u96fb\u8166\u65b7\u5c64\u7b49\u6aa2\u67e5\u3002\n\u7d50\u679c\uff1a\u767e\u5206\u4e4b\u5341\u4e8c(420/3476)\u53c3\u8207\u6aa2\u67e5\u8005\u88ab\u767c\u73fe\u6709\u7121\u75c7\u72c0\u7684\u986f\u5fae\u8840\u5c3f\uff0c\u767e\u5206\u4e4b\u4e03(243/3476)\u7684\u53c3\u8207\u8005\u6709\u6301\u7e8c\u986f\u5fae\u8840\u5c3f\u3002199\u4eba\u5b8c\u6210\u4e86\u9032\u4e00\u6b65\u7684\u6aa2\u67e5\u3002\u7d50\u679c\u767c\u73fe\u5169\u4f8b\u65e9\u671f\u764c\u75c5\u60a3\u8005\uff08\u814e\u7d30\u80de\u764c\u4e00\u4f8b\u3001\u5b50\u5bae\u5167\u819c\u764c\u4e00\u4f8b\uff09\uff1b\u5176\u4ed6\u767c\u73fe\u4e00\u4e9b\u826f\u6027\u75be\u75c5\u5982\u651d\u8b77\u817a\u80a5\u5927\u5345\u4e03\u4f8b\u3001\u6ccc\u5c3f\u9053\u767c\u708e\u56db\u5341\u4e5d\u4f8b\u3001\u814e\u7d50\u77f3\u4e5d\u4f8b\u3001\u8f38\u5c3f\u7ba1\u7d50\u77f3\u4e5d\u4f8b\u3001\u8180\u80f1\u4e73\u7a81\u7624\u4e00\u4f8b\uff0c\u8a8d\u70ba\u8207\u6301\u7e8c\u986f\u5fae\u8840\u5c3f\u6709\u95dc\u3002\n\u7d50\u8ad6\uff1a\u5728\u6b643476\u4eba\u53c3\u8207\u7684\u9632\u764c\u6aa2\u67e5\u4e2d\uff0c\u767e\u5206\u4e4b\u4e03\u7684\u53c3\u8207\u8005\u6709\u6301\u7e8c\u6027\u7684\u986f\u5fae\u8840\u5c3f\u3002\u9032\u4e00\u6b65\u7684\u6aa2\u67e5\u767c\u73fe\u4e86\u5169\u4f8b\u65e9\u671f\u764c\u75c5\u53ca\u4e00\u767e\u5345\u4e00\u4f8b\u826f\u6027\u75be\u75c5\uff0c\u5305\u62ec\u651d\u8b77\u817a\u80a5\u5927\u3001\u6ccc\u5c3f\u9053\u767c\u708e\u3001\u814e\u548c\u8f38\u5c3f\u7ba1\u7d50\u77f3\uff0c\u4ee5\u53ca\u8180\u80f1\u4e73\u7a81\u7624\u3002", "e": "Purpose: To evaluate the significance of microscopic hematuria detected in participants of Cancer Prevention and Early Detection Program.\nMaterials and Methods: From September 1987 through April 1993, a total of 3 476 individuals completed the first-line assessment of the Cancer Prevention and Early Detection Program in the Cancer Center of Veterans General Hospital-Taipei. For those who showed microscopic hematuria would repeat the urine examination, if the persons demonstrated persistent microscopic hematuria, further work-up procedures consisting of urine culture, excretory urography, cystoscopy, urine cytology, sonography or CT scan will be performed.\nResults: Twelve percent (420/3476) of the participants showed asymptomatic microscopic hematuria, 7% (242/3 476) showed persistent microhematuria. 199 persons completed the further work-up procedures. 2 early cancers (1 renal cell carcinoma, 1 endometrial carcinoma) were detected. In addition, other benign diseases such as benign prostate hypertrophy (37), inflammatory lesions (49), renal stones (9), ureteral stones (9) and urinary bladder papilloma (1) were associated with persistent microscopic hematuria.\nConclusion: Among 3 476 individuals participating cancer detection program, 7% showed persistent microscopic hematuria. Further examination detected two early cancers and 131 benign diseases including benign prostate hypertrophy, inflammatory lesions, renal and ureteral stones and urinary bladder papilloma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-113-120-a", "title": "Varian\u76f4\u7dda\u52a0\u901f\u5668\u96fb\u5b50\u5c04\u675f\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2\u4e4b\u6e2c\u91cf\u7814\u7a76", "keywords": "\u653e\u5c04\u6cbb\u7642;\u96fb\u5b50\u5c04\u675f;\u865b\u64ec\u5c04\u6e90\u4f4d\u7f6e;\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2 Radiation therapy;Electron beam therapy;Virtual source position;Effective source-to-surface distance", "c": "\u76ee\u7684\uff1a\u672c\u7bc7\u6e2c\u91cf\u4e09\u90e8\u4e0d\u540c\u578b\u865f\u4e4bVarian\u96d9\u80fd\u91cf\u9ad8\u80fd\u76f4\u7dda\u52a0\u901f\u5668\u96fb\u5b50\u5c04\u675f\u4e4b\u865b\u64ec\u5c04\u6e90\u4f4d\u7f6e\uff0c\u6c42\u51fa\u5176\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2\uff0c\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u4ee5\u5ef6\u9577SSD\u65b9\u5f0f\u6cbb\u7642\u6642\u8a08\u7b97\u5291\u91cf\u53ca\u76e3\u6e2c\u55ae\u4f4d\u4e4b\u7528\uff0c\u540c\u6642\u89c0\u5bdf\u4e26\u6bd4\u8f03\u6b64\u4e09\u90e8\u6a5f\u7d44\u56e0\u8a2d\u8a08\u53ca\u914d\u5099\u4e0d\u540c\u9020\u6210\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u8ddd\u96e2\u4e0d\u540c\u4e4b\u8655\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5c07Scanditronix RFA-300\u6c34\u5047\u9ad4\u7d44\u5b89\u88dd\u65bc\u52a0\u901f\u5668\u96fb\u5b50\u9650\u5149\u7b52\u4e0b\u65b9\uff0c\u518d\u5c07N.E. 0.03c.c.\u5e73\u677f\u578b\u6e38\u96e2\u8154\u56fa\u5b9a\u65bc\u6c34\u7bb1\u5075\u6e2c\u5668\u652f\u67b6\u4e0a\uff0c\u5c07\u6e38\u96e2\u8154\u8868\u9762\u8abf\u6574\u81f3\u5c04\u6771\u4e2d\u5fc3\u8ef8\u6700\u9ad8\u5291\u91cf\u9ede\u8655\uff0c\u4ee5lonex Dosemaster 2590\u96fb\u4f4d\u8a08\uff0c\u5206\u5225\u65bc\u5149\u8ddd\u96e2\u6307\u793a\u5668\u70ba100\u3001110\u53ca120cm\u8655\uff0c\u5c31\u5404\u80fd\u91cf\uff0c\u5404\u96fb\u5b50\u9650\u5149\u7b52\u6e2c\u91cf\u5176\u8b80\u503c\uff0c\u6700\u5f8c\u5c07\u6e2c\u91cf\u503c\u4f9d\u53cd\u5e73\u65b9\u5b9a\u5f8b\u6c42\u5f97\u5176\u6709\u6548\u5c04\u6e90\u81f3\u8868\u9762\u4e4b\u8ddd\u96e2\u3002\n\u7d50\u679c\uff1a\u5c04\u675f\u80fd\u91cf\u6108\u4f4e\uff0c\u9650\u5149\u7b52\u6108\u5c0f\uff0cESSD\u6108\u77ed\uff1b\u5c04\u675f\u80fd\u91cf\u76f8\u540c\uff0c\u9650\u5149\u7b52\u6108\u5927\uff0cESSD\u6108\u5927\u4e14\u6108\u63a5\u8fd1100cm\uff1b\u76f8\u540c\u7684\u96fb\u5b50\u9650\u5149\u7b52\uff0c\u80fd\u91cf\u6108\u9ad8\uff0cESSD\u4e26\u4e0d\u6210\u6bd4\u4f8b\u95dc\u4fc2\u8b8a\u5316\uff1bMLC \u578b\u9650\u5149\u7b52\u5f62\u6210\u7684ESSD\u8b8a\u5316\u8f03\u5c0f\uff1b\u4f7f\u7528Kapton\u578b\u76e3\u6e2c\u6e38\u96e2\u8154\u4e4b\u6a5f\u578b\u5f62\u6210\u7684ESSD\u6bd4\u7531Mica\u578b\u6e38\u96e2\u8154\u6240\u5f62\u6210\u7684ESSD\u8f03\u70ba\u63a5\u8fd1100cm\u3002\n\u7d50\u8ad6\uff1a\u672c\u91cf\u6e2c\u4e4b\u7d50\u679c\u53ef\u61c9\u7528\u65bc\u81e8\u5e8a\u4e0a\u4ee5\u5ef6\u9577SSD\u65b9\u5f0f\u6cbb\u7642\u75c5\u60a3\u6642\uff0c\u5291\u91cf\u8a08\u7b97\u4e4b\u4fee\u6b63\u53c3\u6578\u4e4b\u4e00\uff1b\u53c8\u7531\u672c\u91cf\u6e2c\u53ef\u77e5\uff1a\u5c31Varian\u76f4\u7dda\u52a0\u901f\u5668\u800c\u8a00\uff0c\u6a5f\u578b\u76f8\u540c\uff0c\u96fb\u5b50\u5c04\u6771\u80fd\u91cf\u76f8\u540c\uff0c\u9650\u5149\u7b52\u4e0d\u540c\uff0c\u5f62\u6210\u7684ESSD\u4e0d\u540c\u4e0d\u6a5f\u578b\u4e0d\u540c\uff0c\u80fd\u91cf\u76f8\u540c\uff0c\u9650\u5149\u7b52\u76f8\u540c\uff0c\u5f62\u6210\u7684ESSD\u4e0d\u540c\uff1b\u6a5f\u578b\u4e0d\u540c\uff0c\u80fd\u91cf\u76f8\u540c\uff0c\u9650\u5149\u7b52\u4e0d\u540c\uff0c\u6240\u5f62\u6210\u7684ESSD\u4ea6\u4e0d\u540c\uff1a\u96fb\u5b50\u5c04\u675f\u4e4bESSD\u61c9\u96a8\u6a5f\u91cf\u6e2c\uff0c\u4e26\u7121\u4e00\u5b9a\u7684\u8b8a\u5316\u7d50\u679c\u53ca\u5b8c\u5168\u76f8\u540c\u7684\u6578\u503c\u3002", "e": "Purpose: The ESSD of three different types of Varian linear accelerators have been measured for electron beams in extended SSD treatment. The ESSD values were supplied the dosimetry calculation for routine patient treatments. According to the results, we compare and discuss the differences among the three different types of Varian linear accelerators.\nMaterials and Methods: The N.E. 0.03 c.c. parallel plate ionization chamber was installed on the chamber frame of Scanditronix RFA-300 3D water phantom and was connected to Ionex Dosemaster 2590 for dose measurement. The proximal electrode surface was placed at the depth of D(subscript max) to measure the delivered dose of each energy, each electron cone at SSD=100, 110, 120cm respectively. The ESSD of each electron cone and each energy was calculated according to the inverse-square-law using the data of SSD 100 and 120cm.\nResults: The lower beam energies and the smaller electron cone, the ESSD become shorter. The same nominal energy, the larger cone size, the ESSD get more close to 100cm. The same electron cone size, the larger electron energy, the ESSD did not change regularly. The ESSD formed by MLC type electron cone varies smoothly. The scatter from Kapton type ion chamber is smaller than that from Mica type ones. Thus, the ESSD formed from the Kapton type machine is closed to 100cm.\nConclusion: The measured ESSDs of the three linear accelerators will be used to calculate the monitor units in the extend SSD electron beam treatment. From this study, for Varian linear accelerators, no any two machines got the same ESSD whether the same nominal energies or the same type of electron cones."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-121-127-a", "title": "\u6bd4\u8f03\u805a\u5408\u5e95\u7247\u548c\u50b3\u7d71\u611f\u5149\u9a57\u8b49\u7247\u65bc\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u4e4b\u5291\u91cf\u5206\u4f48", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853;\u805a\u5408\u5e95\u7247;\u5291\u91cf\u5206\u4f48;\u5291\u91cf\u53cd\u61c9\u66f2\u7dda Stereotactic radiosurgery;Radiochromic film;Dose distribution;Dose response curve", "c": "\u76ee\u7684\uff1a\u5229\u7528\u805a\u5408\u5e95\u7247\u548c\u611f\u5149\u9a57\u8b49\u5e95\u7247\u4f86\u63a2\u8a0e\u5728\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7684\u5291\u91cf\u5206\u4f48\u60c5\u5f62\u53ca\u5176\u5c0d\u653e\u5c04\u7dda\u7684\u9748\u654f\u5ea6\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u4e00\u7a2e\u65b0\u4e14\u5177\u6709\u9ad8\u5ea6\u5747\u52fb\u5ea6\u7684\u76f4\u63a5\u9020\u5f71\u5e95\u7247radiochromic film,\u5176\u611f\u61c9\u5c64\u7684\u539a\u5ea6\u70ba7\u03bcm\u3002\u7d93\u653e\u5c04\u7dda\u7167\u5c04\u5f8c\uff0c\u805a\u5408\u4f5c\u7528\u6703\u4f7f\u5176\u7247\u5b50\u7531\u7121\u8272\u8b8a\u70ba\u6df1\u85cd\u8272\u800c\u7121\u9700\u984d\u5916\u8655\u7406\u3002\u5229\u7528\u6a21\u6a5f\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u7684\u56db\u500b\u591a\u5f27\u975e\u5171\u5e73\u9762\u4e4b\u7167\u5c04\uff0c\u5206\u6790\u5176\u5728\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\u8207\u7167\u5c04\u5f8c\u5291\u91cf\u5206\u4f48\u7684\u7d50\u679c\uff0c\u4e26\u8207\u50c5\u9700250 cGy\u5291\u91cf\u5927\u5c0f\u7684\u50b3\u7d71\u611f\u5149\u81a0\u7247\u505a\u4e00\u6bd4\u8f03\u3002\n\u7d50\u679c\uff1a\u6211\u5011\u767c\u73fe\u805a\u5408\u5e95\u7247\u4e0d\u6703\u6709\u50b3\u7d71\u611f\u5149\u9a57\u8b49\u7247\u9700\u8981\u5f8c\u8655\u7406\u7684\u8aa4\u5dee\u7522\u751f\uff0c\u5982\u5149\u5bb3\u3001\u986f\u5f71\u548c\u5b9a\u5f71\u904e\u7a0b\u53ca\u5176\u6fc3\u5ea6\u7121\u6cd5\u4fdd\u6301\u4e00\u5b9a\u7b49\u56e0\u7d20\uff0c\u56e0\u6b64\u662f\u53ef\u4ee5\u7528\u4f86\u505a\u70ba\u4e0d\u932f\u7684\u5291\u91cf\u91cf\u6e2c\u6750\u8cea\u3002\u7136\u800c\u70ba\u4e86\u9054\u5230\u5408\u7406\u7684\u5149\u5ea6\u503c\uff0c\u6240\u7528\u7684\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853\u6a21\u64ec\u7e3d\u5291\u91cf\u9ad8\u905410Gy\uff0c\u800c\u5728\u81e8\u5e8a\u4e0a\u662f\u5f88\u5c11\u7528\u5230\u5982\u6b64\u9ad8\u5291\u91cf\u3002\u5728\u5291\u91cf\u5206\u4f48\u7684\u6bd4\u8f03\u4e0a\uff0c\u53ef\u4ee5\u5f97\u5230\u8207\u50b3\u7d71\u611f\u5149\u9a57\u8b49\u7247\u7684\u5e73\u5747\u504f\u5dee\u4e0d\u5927\u65bc0.5mm\u3002\n\u7d50\u8ad6\uff1a\u53ef\u4ee5\u5f97\u77e5\u805a\u5408\u5e95\u7247\u80fd\u63d0\u4f9b\u81e8\u5e8a\u7684\u7cbe\u78ba\u5ea6\u57281mm\u4ee5\u5167\u3002\u5c0d\u65bc\u653e\u5c04\u624b\u8853\u7684\u54c1\u8cea\u78ba\u8a8d\u548c\u6cbb\u7642\u6642\u7684\u5291\u91cf\u8f38\u51fa\u63d0\u4f9b\u4e86\u53e6\u4e00\u7cbe\u78ba\u7684\u91cf\u6e2c\u5de5\u5177\u3002", "e": "Purpose: To study the dose distribution and sensitivity with radiochromic (Gafchromic) film and silver halide (Kodak X-Omat V-film) on stereotactic radiosurgery.\nMaterial and Method: A new radiochromic film, with highly uniform, thin and sensitive layer (7\u03bcm thick), is employed in the study. The film changes from colorless to blue by dye polymerization without processing, upon exposure to ionization from 0-50 Gy. The dose distribution patterns of 4 non-coplanar irradiation with the Gafchromic film were compared with the ones from the verification film which was only exposed with 250 cGy.\nResult: The Gafchromic film appears to be a better choice for actual dose measurement in the medium with avoiding potential uncertainties found in most of silver halide films such as light exposure, processing time, developer concentration etc. However, to obtain reasonable good optical densities in the Gafchromic film, there is a need to offer irradiation about 10 Gy that is not practically achievable in the clinical settings. The accuracy study of the chromic film was found to be less 0.5% in error comparing with the one from the verification film.\nConclusion: It is clinically possible to obtain an accuracy of 1mm on determining the physical center in the linac-based radiosurgery. For actual dose measurement in the body, the chromic film offers a good test tool for dosimetry and quality assurance."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-129-134-a", "title": "\u57fa\u56e0\u6cbb\u7642\u7684\u56f0\u5883\uff1a1996\u5e74\u7684\u56de\u9867\u8a55\u8ad6", "keywords": "\u57fa\u56e0\u6cbb\u7642;\u907a\u50b3\u6027\u75be\u75c5;\u5148\u5929\u6027\u514d\u75ab\u7f3a\u5931\u75c7;\u817a\u82f7\u9178\u53bb\u80fa\u9175\u7d20 Gene therapy;Genetic diseases;Severe combined immunodeficiency;Adenosine deaminase", "c": "\u57fa\u56e0\u6cbb\u7642\u96d6\u7136\u6709\u5176\u6f5b\u529b\uff0c\u53ef\u662f\u57fa\u56e0\u6cbb\u7642\u5728\u79d1\u5b78\u548c\u91ab\u5b78\u4e0a\u7684\u80fd\u529b\u4ecd\u7136\u662f\u975e\u5e38\u6709\u9650\u3002\u57fa\u56e0\u6cbb\u7642\u7684\u4eba\u9ad4\u8a66\u9a57\u53ef\u5206\u70ba\u907a\u50b3\u6027\u75be\u75c5\u7684\u77ef\u6b63\u8207\u975e\u907a\u50b3\u6027\u75be\u75c5\u7684\u6cbb\u7642\u4e8c\u5927\u985e\uff0c\u57fa\u56e0\u6cbb\u7642\u7684\u7b2c\u4e00\u500b\u4f8b\u5b50\u662f\u7a69\u6027\u6b63\u67d3\u8272\u9ad4\u907a\u50b3\u75be\u75c5\u4e2d\u7684\u5148\u5929\u6027\u514d\u75ab\u7f3a\u5931\u75c7\uff0c\u5176\u53ef\u80fd\u75c5\u56e0\u662f\u817a\u82f7\u9178\u53bb\u80fa\u9175\u7d20\u7684\u7f3a\u5931\u3002\u50b3\u7d71\u6cbb\u7642\u662f\u5b9a\u671f\u6ce8\u5c04\u653e\u5c04\u7dda\u8655\u7406\u904e\u7684\u7d05\u8840\u7403\uff0c\u6216\u662f\u806f\u7d50\u5728\u805a\u4e59\u70ef\u7518\u9187\u4e0a\u7684\u9175\u7d20\u4f86\u7de9\u89e3\u75c7\u72c0\uff0c\u57fa\u56e0\u6cbb\u7642\u537b\u662f\u4ee5\u542b\u6709\u6b63\u5e38\u9175\u7d20\u57fa\u56e0\u7684\u53cd\u8f49\u9304\u75c5\u6bd2\u8f09\u9ad4\u611f\u67d3\u75c5\u4eba\u7684T\u7d30\u80de\u5f8c\uff0c\u518d\u6253\u56de\u75c5\u4eba\u8840\u4e2d\u3002\u75c5\u4eba\u5247\u7e7c\u7e8c\u63a5\u53d7\u50b3\u7d71\u6cbb\u7642\u4ee5\u5f37\u5316\u7642\u6548\u3002\u5f37\u5316\u4f5c\u7528\u4f7f\u57fa\u56e0\u6cbb\u7642\u7684\u7642\u6548\u7522\u751f\u554f\u984c\uff0c\u7a76\u7adf\u9019\u4e9b\u75c5\u4eba\u75c7\u72c0\u7684\u7de9\u89e3\uff0c\u662f\u5426\u56e0\u70ba\u57fa\u56e0\u6cbb\u7642\u800c\u5f97\u4ee5\u6539\u5584\uff0c\u7d50\u8ad6\u503c\u5f97\u5546\u69b7\u3002\u672c\u6587\u5c31\u6700\u8fd1\u57fa\u56e0\u6cbb\u7642\u7684\u7d50\u679c\u4f86\u8a0e\u8ad6\u57fa\u56e0\u6cbb\u7642\u5fc5\u9808\u8003\u616e\u7684\u5e7e\u500b\u91cd\u8981\u689d\u4ef6\u3001\u76ee\u524d\u4f7f\u7528\u7684\u65b9\u6cd5\u8208\u53ef\u80fd\u7684\u526f\u4f5c\u7528\uff0c\u53ca\u4e00\u822c\u6c11\u773e\u5c0d\u57fa\u56e0\u6cbb\u7642\u7684\u770b\u6cd5\u3002", "e": "Although gene therapy is potentially available, the accomplishment in scientific and medical application is still limited. Human clinical trial of gene therapy could be divided into two categories: correction of genetic diseases and treatment of non-genetic diseases. The first example of gene therapy is to treat patients with severe combined immunodeficiency, an autosomal recessive disease. The possible cause of the disease is the deficiency of adenosine deaminase. The traditional treatment is to inject the irradiated red blood cells or the polyethylene glycol-conjugated adenosine deaminase. The strategy of gene therapy is to transfect human T cells with retroviral vector that contains normal perspective gene and then to deliver these transfected human T cells back into the patient's circulation. Patient receives PEG-ADA continuously for the disease control. The belt-and-brace approach may be medically sensible. However, the call of success by gene therapy is in question. In this paper, we discuss several important issues of gene therapy, including the recent application methods and the plausible complications."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-135-141-a", "title": "\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u63a2\u8a0e", "keywords": "\u9806\u5f62\u653e\u5c04\u6cbb\u7642 Conformal radiotherapy", "c": "\u4e09\u5ea6\u7a7a\u9593\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u662f\u8fd1\u5e74\u4f86\u4ee5\u9060\u9694\u7167\u5c04\u816b\u7624\u7684\u4e00\u7a2e\u65b0\u6280\u8853\uff0c\u5176\u65b9\u6cd5\u662f\u5728\u4e0d\u540c\u89d2\u5ea6\u7167\u5c04\u6642\uff0c\u7167\u91ce\u53ef\u9806\u8457\u816b\u7624\u5f62\u72c0\u800c\u6539\u8b8a\u3002\u5176\u76ee\u7684\u662f\u53ef\u63d0\u9ad8\u816b\u7624\u7684\u7167\u5c04\u5291\u91cf\uff0c\u6e1b\u5c11\u6b63\u5e38\u7d44\u7e54\u6240\u63a5\u53d7\u7684\u7167\u5c04\u3002\u96a8\u8457\u96fb\u5b50\u6280\u8853\u7684\u9032\u6b65\uff0c\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7684\u4e0d\u65b7\u66f4\u65b0\uff0c\u591a\u8449\u5f0f\u6e96\u76f4\u5100\u7684\u767c\u5c55\uff0c\u91ab\u7642\u5f71\u50cf\u7684\u89e3\u6670\u5ea6\u4e0d\u65b7\u63d0\u9ad8\u3002\u56e0\u6b64\uff0c\u653e\u5c04\u816b\u7624\u79d1\u540c\u4ec1\u8ffd\u6c42\u7684\u5148\u9032\u9806\u5f62\u6cbb\u7642\u6280\u8853\uff0c\u5f97\u4ee5\u5be6\u73fe\uff1b\u5c0d\u764c\u75c7\u5c40\u90e8\u63a7\u5236\u7684\u6210\u529f\u7387\u5f97\u4ee5\u63d0\u5347\uff0c\u800c\u7167\u5c04\u5f15\u8d77\u7684\u526f\u4f5c\u7528\u76f8\u5c0d\u5730\u6e1b\u5c11\u3002\u672c\u6587\u91cd\u9ede\u662f\u4ecb\u7d39\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u6280\u8853\u53ca\u5176\u9700\u8981\u6ce8\u610f\u7684\u689d\u4ef6\uff0c\u6cbb\u7642\u9078\u64c7\u7684\u5c0d\u8c61\uff0c\u66f4\u56de\u9867\u8fd1\u5e74\u570b\u5916\u6cbb\u7642\u7684\u7d50\u679c\uff0c\u505a\u4e00\u6574\u7406\u6027\u5831\u5c0e\u3002", "e": "3-dimensional conformal radiotherapy is a new technique for cancer treatment by using external radiation fields. The multi-field approach is made to conform radiation dose closely to the tumor shape. The dose escalation for the tumors is the main purpose, and the normal tissue dose can relatively be reduced. With the currently advance electronic technology, the improvement of computer planning system, the development of multileaf collimator and the high resolution of the oncologic images, they achieve the dream of conformal technique for radiation oncologists. Furthermore, the local tumor control rate becomes better and the complication rate of normal tissues reduced or at least the same as conventional treatments. This report was to introduce the technical aspects and the indications of patient selection for conformal radiotherapy. The treatment results of recent years had been reviewed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199606-3-2-143-147-a", "title": "\u4f96\u7434\u7684\u5c11\u58ef\u6b72\u6708", "keywords": "\u4f96\u7434;\u5e74\u9752 Wilhelm C. Roentgen;Young", "c": "\u4f96\u7434\u65bc1845\u5e743\u670827\u65e5\u51fa\u751f\u5728\u666e\u9b6f\u58eb\u738b\u570b\u9023\u7d0d\u666e\u5e02\u7684\u5546\u4eba\u5bb6\u5ead\u3002\u56e0\u570b\u5bb6\u52d5\u4e82\uff0c\u4e09\u6b72\u6642\u96a8\u7236\u6bcd\u79fb\u6c11\u81f3\u8377\u862d\uff0c\u5ea6\u904e\u5e73\u975c\u800c\u5feb\u6a02\u7684\u7ae5\u5e74\u548c\u5c11\u5e74\uff0c\u5f9e\u5c0f\u751f\u6d3b\u548c\u5b78\u6821\u7684\u74b0\u5883\u57f9\u990a\u4ed6\u9177\u611b\u5927\u81ea\u7136\u3002\u9752\u5e74\u6642\u5bc4\u4f4f\u5728\u6559\u5316\u5b78\u7684\u6839\u5be7\u6559\u6388\u5bb6\uff0c\u5c0d\u4ed6\u65e5\u5f8c\u5f9e\u4e8b\u9ad8\u6df1\u5b78\u554f\u6709\u91cd\u5927\u7684\u5f71\u97ff\u3002\u5341\u4e03\u6b72\u6642\u66fe\u88ab\u5b78\u6821\u958b\u9664\u5b78\u7c4d\uff0c\u65b7\u9001\u4e86\u4ed6\u5728\u570b\u5167\u5c31\u8b80\u5927\u5b78\u7684\u9014\u5f91\uff0c\u5167\u5fc3\u5275\u75db\u751a\u6df1\u3002\u5e78\u800c\u52aa\u529b\u4e0d\u61c8\uff0c\u8003\u5165\u745e\u58eb\u8607\u9ece\u4e16\u7406\u5de5\u5b78\u9662\u6a5f\u68b0\u5de5\u7a0b\u5b78\u7cfb\uff0c\u4e26\u7d50\u8b58\u672a\u4f86\u7684\u59bb\u5b50\u9678\u535a\u838e\u5c0f\u59d0\u3002\u7562\u696d\u5f8c\u7e7c\u7e8c\u9032\u4fee\uff0c1869\u5e74\u4ee5\u201c\u6c23\u9ad4\u7684\u7814\u7a76\u201d\u8ad6\u6587\u7372\u5f97\u54f2\u5b78\u535a\u58eb\u5b78\u4f4d\uff0c\u4e26\u7559\u5728\u6bcd\u6821\u96a8\u5be6\u9a57\u7269\u7406\u5b78\u5bb6\u5b54\u5fb7\u5148\u751f\u4efb\u7814\u7a76\u52a9\u7406\u3002", "e": "Wilhelm Conrad Roentgen was born on March 27, 1845 in a merchant family in Lennep of Prussia. While Wilhelm was three year-old, because of turmoil in Prussia the family emigrated to Holland where he enjoyed a peaceful and happy childhood that he acquired a love of outdoor life. In 1862, Roentgen registered at the Utrecht Technical School and lived in the pleasant home of J. W. Gunning, professor of chemistry. This cultured family provided the young Roentgen with good inspiration and direction to the right path of life. Unfortunately, Roentgen was expelled from the school at his 17 and that would prevent him entering the university. After two years of struggle, he was admitted to the Zurich Polytechnic, Switzerland where he acquainted with his future wife Anna Bertha Ludwig and then graduated with the Diploma in Mechanical Engineering. 1869 Roentgen was awarded his Doctorate of Philosophy degree with a thesis \u201dStudies on Gases\u201d. Afterward, he remained in the graduate school as research assistant of Mr. August Kundt, a physics experimentalist."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-5-11-a", "title": "National Taiwan University Hospital Pilot Study of Chemoradiotherapy for Esophageal Carcinoma", "keywords": "\u98df\u9053\u764c;\u4f75\u7528\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642;\u6bd2\u6027 Esophageal cancer;Chemoradiotherapy;Toxicity", "c": "\u5c0d\u65bc\u98df\u9053\u764c\uff0c\u4f75\u7528\u5316\u5b78\u8207\u653e\u5c04\u6cbb\u7642\u7684\u65b9\u6cd5\u5df2\u986f\u793a\u6709\u5176\u6548\u679c\uff0c\u4f46\u5c11\u898b\u6cbb\u7652\u6027\u7684\u7d50\u679c\u3002\u70ba\u4fc3\u9032\u98df\u9053\u6241\u5e73\u7d30\u80de\u764c\u7684\u5c40\u90e8\u63a7\u5236\u548c\u6e1b\u5c11\u9060\u8655\u8f49\u79fb\uff0c\u6211\u5011\u7684\u9818\u822a\u7814\u7a76\u662f\u4f7f\u7528\u4f4e\u5291\u91cf\u9023\u7e8c\u6ce8\u8f385-FU\u548c\u6bcf\u65e5\u4f4e\u5291\u91cfcisplatin (CDDP)\u6ce8\u8f38\u4f75\u7528\u653e\u5c04\u6cbb\u7642\u518d\u52a0\u4e0a\u624b\u8853\u5207\u9664\uff0c\u5176\u9593\u7642\u7a0b\u51714\u5468\u3002\u6cbb\u7642\u8a08\u5283\u5305\u62ec\uff1a\u57284\u5468\u5167\u7d66\u4e88\u7e3d\u5291\u91cf5000 cGy \u7684\u653e\u5c04\u6cbb\u7642\uff1b\u9023\u7e8c28\u5929\u6ce8\u8f385-FU(225mg/\u5e73\u65b9\u516c\u5c3a/day)\uff1a\u5728\u958b\u59cb\u653e\u5c04\u6cbb\u7642\u524d\u768430\u5206\u9418\u975c\u8108\u6ce8\u8f38CDDP (6mg/\u5e73\u65b9\u516c\u5c3a/day)\u3002\u75c5\u60a3\u5728\u5b8c\u6210\u56db\u5468\u7684\u7642\u7a0b\u4e4b\u5f8c\uff0c\u5c07\u63a5\u53d7\u98df\u9053\u651d\u5f71\u3001\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u548c\u5167\u8996\u93e1\u6aa2\u67e5\u4ee5\u4fbf\u91cd\u65b0\u5206\u671f\u3002\u5728\u5b8c\u6210\u653e\u7642\u8207\u5316\u7642\u76843\u52305\u5468\u5f8c\uff0c\u6211\u5011\u70ba\u75c5\u60a3\u9032\u884c\u98df\u9053\u5207\u9664\u624b\u8853\u3002\u7d50\u679c\uff1a\u5f9e1993\u5e7410\u6708\u52301994\u5e748\u6708\uff0c\u670913\u4f4d\u7537\u6027\u53ca3\u4f4d\u5973\u6027\u75c5\u60a3\u63a5\u53d7\u6b64\u6cbb\u7642\u8a08\u5283\u3002\u6211\u5011\u8a73\u7d30\u7684\u8a18\u9304\u75c5\u60a3\u7684\u6cbb\u7642\u6548\u679c\u8207\u6bd2\u6027\u3002\u75c5\u60a3\u5e74\u9f61\u7684\u4e2d\u9593\u503c\u70ba62\u6b72\uff0c\u6cbb\u7642\u524d\u9ad4\u91cd\u6e1b\u8f15\u7684\u4e2d\u9593\u503c\u662f6\u516c\u65a4\uff0c\u8840\u6db2\u4e2d\u767d\u86cb\u767d\u7684\u4e2d\u9593\u503c\u662f3.7mg\uff05\u3002\u767c\u751f\u7b2c\u4e09\u7d1a\u767d\u8840\u7403\u904e\u5c11\u75c7\u7684\u67097\u4eba\u800c\u7b2c\u56db\u7d1a\u7684\u67092\u4eba\uff1a\u767c\u751f\u7b2c\u56db\u7d1a\u8840\u5c0f\u677f\u904e\u5c11\u75c7\u7684\u67093\u4eba\u3002\u5728\u91cd\u65b0\u5206\u671f\u6aa2\u67e5\u6642\uff0c\u67097\u4eba(44%)\u539f\u816b\u7624\u5df2\u6d88\u9664\u3002\u5168\u90e8\u75c5\u60a3\u7684\u4e8c\u5e74\u5b58\u6d3b\u7387\u662f37\uff05\u3002\u7d50\u8ad6\uff1a\u6b64\u7a2e\u6cbb\u7642\u8a08\u5283\u5c0d\u65bc\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7684\u6548\u679c\u5f88\u597d\uff0c\u4f46\u662f\u6cbb\u7642\u6240\u7522\u751f\u7684\u6bd2\u6027\u5f88\u9ad8\uff0c\u8d85\u51fa\u4e86\u6211\u5011\u53ef\u4ee5\u63a5\u53d7\u7684\u7bc4\u570d\u3002", "e": "Introduction: Chemoradiotherapy has demonstrated efficacy in esophageal cancer but with poor result. Combined ehemo-radiotherapy and surgery may further increase the local control rate. A pilot study was initiated by using low dose continuous infusion (CI) of 5-FU and daily low dose cisplatin (CDDP) injection with radiotherapy (RT) followed by surgery in patients with locoregional squamous cell carcinoma of the esophagus. \nMethods: The treatment consisted of RT to the esophagus 5000 cGy in 4 weeks, CI of 5-FU (225 mg/m^2/day) over 28 days and CDDP (6mg/m^2/day) iv injection 30 minutes before RT. Patients were then restaged by esophagogram, panendoscopy and CT scan. Esophagectomy will be performed on approximately three to five weeks after completion of concurrent chemoradiotherapy.\nResults: From October 1993 to August 1994, 13 men and 3 women were en rolled. All were evaluated for toxicity and response. The median age was 62 years old, the median pretreatment weight loss was 6 kilograms, and the median serum albumin level was 3.7 gm/dl. Grade III and IV leukopenia were noted in 7 patients and 2 patients, respectively. Three patients had Grade IV thrombocytopenia. Seven patients (44%) showed complete remission on restaging. The 2-year survival rate is 37%.\nConclusion: This treatment regimen provides a high local tumor control. However, the toxicity of the treatment was unacceptably high."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-13-19-a", "title": "\u7dad\u751f\u7d20C\u53caDesmethylmisonidazole \u5c0d\u65bcCHO \u7d30\u80de\u653e\u5c04\u7dda\u6548\u61c9\u4e4b\u7814\u7a76", "keywords": "\u7dad\u751f\u7d20C;Desmethylmisonidazole;\u4e2d\u570b\u5927\u9830\u9f20\u5375\u5de2\u7d30\u80de;\u751f\u5b58\u5206\u6578 Vitamin C;Desmethylmisonidazole;CHO cells;Survival fraction", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u7dad\u751f\u7d20C(vitamin C, ascorbic acid, AA)\u53cadesmethylmisonidazole (DMM)\u5c0d\u65bcCHO\u7d30\u80de\u4e4b\u8f90\u5c04\u6548\u61c9\uff0c\u4ee5\u505a\u7232\u982d\u982d\u90e8\u816b\u7624\u75c5\u4eba\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u81e8\u5e8a\u53c3\u8003\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u5be6\u9a57\u5206\u7232\u4e09\u90e8\u4efd\uff0c\u7b2c\u4e00\u90e8\u4efd\u5206\u5225\u63a2\u8a0eAA\u6216DMM\u5c0d\u65bcCHO\u7d30\u80de\u4e4b\u8f3b\u5c04\u6548\u61c9\u3002\u7b2c\u4e8c\u90e8\u5206\u7814\u7a76\u5728\u76f8\u540c\u6fc3\u5ea6DMM\u4f5c\u7528\u60c5\u6cc1\u4e0b\uff0c\u4e0d\u540c\u6fc3\u5ea6\u4e4bAA\u5c0d\u65bcCHO\u7d30\u80de\u4e4b\u8f3b\u5c04\u6548\u61c9\u3002\u7b2c\u4e09\u90e8\u5206\u63a2\u8a0e\u5728\u76f8\u540c\u6fc3\u5ea6AA\u4f5c\u7528\u4e0b\uff0c\u4e0d\u540c\u6fc3\u5ea6\u4e4bDMM\u5c0d\u65bcCHO\u7d30\u80de\u8f3b\u5c04\u6548\u61c9\u4e4b\u5f71\u97ff\u3002\n\u7d50\u679c\uff1a\u7814\u7a76\u986f\u793a\uff0cAA\u5c0d\u65bcCHO\u7d30\u80de\u6709\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\uff0c\u800cDMM\u5c0dCHO\u7d30\u80de\u5177\u6709\u8f3b\u5c04\u654f\u611f\u4f5c\u7528\uff0c\u4f46\u5169\u8005\u5408\u4f75\u4f7f\u7528\u6642\u5c0dCHO\u7d30\u80de\u7684\u654f\u611f\u4f5c\u7528\u986f\u8457\u5927\u65bc\u4fdd\u8b77\u4f5c\u7528\u3002\u7576DMM\u6fc3\u5ea6\u56fa\u5b9a\u6642\uff0c\u6108\u9ad8\u6fc3\u5ea6\u4e4bAA\u5c0d\u7d30\u80de\u4e4b\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u4e5f\u6108\u660e\u986f\u3002\u53cd\u4e4b\uff0c\u7576AA\u6fc3\u5ea6\u56fa\u5b9a\u6642\uff0cDMM\u6fc3\u5ea6\u6108\u9ad8\u5176\u5c0d\u7d30\u80de\u4e4b\u8f3b\u5c04\u654f\u611f\u6548\u61c9\u4e5f\u6108\u986f\u8457\u3002\n\u7d50\u8ad6\uff1a\u5408\u4f75AA (0.025mg/ml)\u53caDMM(0.5-10mM)\u8868\u73fe\u51fa\u4f86\u7684\u662f\u5c0dCHO\u7d30\u80de\u4e4b\u8f3b\u5c04\u654f\u611f\u6548\u61c9\uff0c\u800cAA\u5c0dCHO\u7d30\u80de\u4e4b\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u53ea\u6709\u7576DMM\u4e0d\u5b58\u5728\u6642\u624d\u6703\u986f\u8457\u8868\u73fe\u3002", "e": "Purpose: The goal of this research is to study the influence of vitamin C (ascorbic acid, AA) and desmethylmisonidazole (DMM) on the radiobiological effects of CHO cells and then as a basis of radiotherapy for head and neck cancer patients.\nMaterials and Methods: This study was designed to investigate the influence of AA and DMM on radiobiological effects of CHO cells. Combination of AA (with different concentration) and DMM (with constant concentration) was also used to evaluate their radiobiological effects. In the same way, the radiobiological effects of combined DMM (with different concentration) and AA (with constant concentration) was also evaluated.\nResults: The results showed that there are radioprotective effects of AA and radiosensitizing effects of DMM on CHO cells. However, the radiosensitizing effect is significantly greater than radioprotective effect when both drugs were combined used. In addition, the higher concentrations of AA were, the greater it protected CHO cells from radiation under constant concentrations of DMM. On the contrary, the higher concentration of DMM was, the greater it sensitized CHO cells to radiation under constant concentrations of AA.\nConclusion: The effect of combined AA (0.025 mg/ml) and DMM (0.5-10 mM) on CHO cells is radiosensitization. When DMM is absent, the radioprotective effect of AA is expressed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-21-32-a", "title": "Treatment Results of Laryngeal Cancer by Badiotherapy with or Without Surgery", "keywords": "\u54bd\u5589;\u816b\u7624;\u653e\u5c04\u6cbb\u7642;\u6551\u63f4\u624b\u8853;\u4e94\u5e74\u5b58\u6d3b\u7387 Larynx;Neoplasm;Radiotherapy;Salvage operation;Five-year  survival rate", "c": "\u76ee\u7684\uff1a\u56de\u9867\u904e\u53bb\u5341\u5e74(1981-1990)\u5728\u81fa\u5927\u91ab\u9662\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u7684\u5589\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\u6210\u679c\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u9019\u5341\u5e74\u4e2d\u5171\u6709133\u4f4d\u521d\u6b21\u5728\u81fa\u5927\u63a5\u53d7\u5168\u7a0b\u653e\u5c04\u6cbb\u7642\u7684\u75c5\u60a3\uff0c\u75c5\u7406\u4e0a\u5c6c\u65bc\u9c57\u72c0\u7d30\u80de\u764c\u3002\u5e74\u9f61\u5206\u5e03\u81ea34\u523084\u6b72\uff0c\u5c24\u4ee560-69\u6b72\u7684\u60a3\u8005\u6700\u591a\u3002\u7537\u6027\u75c5\u60a3\u5171128\u4f4d\uff0c\u5973\u6027\u75c5\u60a3\u5247\u53ea\u67095\u4f4d\uff0c\u6bd4\u4f8b\u7d04\u723226:1\u3002\u7b2c\u4e00\u671f\u5230\u7b2c\u56db\u671f\u5404\u670925\u300121\u300122\u300165\u500b\u75c5\u4f8b\uff0c\u7b2c\u56db\u671f\u4f54\u4e86\u4e00\u534a\u5de6\u53f3\uff0c\u4ee5\u90e8\u4f4d\u800c\u8a00\uff0c\u4e0a\u8072\u9580\u764c\u670951\u4f4d\uff0c\u8072\u9580\u764c\u670972\u4f4d\uff0c\u4e0b\u8072\u9580\u764c\u670910\u4f4d\uff0c\u8072\u9580\u764c\u7684\u75c5\u60a3\u8d85\u904e\u4e00\u534a\u300257\u4f4d\u75c5\u60a3\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4ed676\u4f4d\u75c5\u60a3\u5247\u5148\u63a5\u53d7\u624b\u8853\uff0c\u518d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u3002\n\u7d50\u679c\uff1a\u5168\u9ad4\u4e94\u5e74\u5b58\u6d3b\u7387\u662f54.9%\u3002\u7b2c\u4e00\u671f\u5230\u7b2c\u56db\u671f\u4e4b\u4e94\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u723278.8%\u300158.3%\u300154%\u300144.4%\u3002\u4ee5\u90e8\u4f4d\u800c\u8a00\uff0c\u5247\u7232\u4e0a\u8072\u9580\u764c34.7%\u3001\u8072\u9580\u764c70.5%\u3001\u4e0b\u8072\u9580\u764c38.9%\u3002\n\u7d50\u8ad6\uff1a\u521d\u671f\u75c5\u60a3\u5927\u591a\u6578\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u723e\u5f8c\u82e5\u5fa9\u767c\u4ecd\u53ef\u7528\u6551\u63f4\u624b\u8853\u633d\u6551\uff0c\u4f46\u4e09\u3001\u56db\u671f\u60a3\u8005\u82e5\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u5247\u5176\u9810\u5f8c\u8f03\u5dee\uff0c\u4e14\u5fa9\u767c\u5f8c\u5373\u4f7f\u518d\u63a5\u53d7\u4e8c\u5ea6\u6cbb\u7642\u4ecd\u7136\u4e0d\u6613\u63a7\u5236\u3002\u6240\u4ee5\u653e\u5c04\u6cbb\u7642\u5f8c\u61c9\u9577\u671f\u8ffd\u8e64\uff0c\u4ffe\u80fd\u65e9\u671f\u767c\u73fe\u518d\u767c\u800c\u4e88\u4ee5\u6cbb\u7642\u3002", "e": "Purpose: To evaluate the therapeutic results of laryngeal cancer patients treated at Department of Radiation Oncology of NTUII over the past ten years (1981-1990).\nMaterials & Methods: One hundred and thirty-three laryngeal cancer patients treated at our clinic were analyzed clinically. All of them were squamous cell carcinoma. The age of the patients ranged from 34 to 84 years old with the highest incidence at the 60-69 age group. There were 128 male patients and 5 female patients with male to female ratio as 26:1. The numbers of patients in stage I to IV were 25, 21, 22, and 65, respectively. Stage IV patients accounted for about half of the cases. The numbers of supraglottic, glottic, and subglottic cancers were 51, 72, and 10, respectively. Glottic type accounted for more than half of the cases. Fifty-seven patients received primary radiotherapy. The other 76 patients received surgery before radiotherapy.\nResults: The overall actuarial five-year survival rate was 54.7%. The actuarial five-year survival rates for patients of stages \u2160, \u2161,\u2162 and \u2163 were 78.7%, 58.3%, 54%, and 44.4%, respectively. The five-year survival rates for supraglottic, glottic and subglottic cancers were 34.7%, 70.5%, and 38.9%, respectively.\nConclusion: Recurrence after radiotherapy was salvaged by surgery satisfactorily in stages I and II, but the prognosis was poor for recurrent patients with initial stages III and IV. A life-long follow-up after radical radiotherapy is essential for early detection of recurrence and earlier salvage to improve the therapeutic result."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-33-40-a", "title": "\u7b2c\u4e8c\u53ca\u7b2c\u4e09\u671f\u4e73\u764c\u8853\u5f8c\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u4e4b\u7d50\u679c", "keywords": "\u4e73\u764c;\u4e73\u623f\u5207\u9664\u5f8c;\u96fb\u5b50\u5c04\u7dda;\u653e\u5c04\u6cbb\u7642;\u591a\u8b8a\u6578\u5206\u6790 Breast cancer;Postmastectomy;Electron beam;Radiotherapy;Multivariate analysis", "c": "Purpose: To evaluate the results of postoperative electron beam irradiation for stage \u2161 and \u2162 breast cancer.\nMaterials and methods: From August 1987 to June 1992, we retrospectively analyzed the results of electron beam irradiation for 87 women with primary breast cancer treated by modified radical mastectomy. Adjuvant chemotherapy and hormone therapy were also given to 55 and 40 patients, respectively.\nResults: The 5-year disease-free survival rates for stage \u2161 and \u2162 patients were 80% and 31%, respectively. The 5-year local control rates for stage \u2161 and \u2162 patients were 98% and 72%, respectively. Thirty-seven patients had distant rnetastases. Bone was the most common site. Thirteen percent of grade 1 and 18% of grade 2 late skin complication were noted. Late grade 1 complication of lung was noted in 6% of patients. In patients of high risk group (tumor size of larger than 5 cm and more than 3 positive axillary nodes metastases), the 5-year disease-free survival and local control rates were 10% and 37%, respectively. In multivariate analysis, more than 3 positive axillary nodes metastases was a strong prognostic factor for disease. free survival rates (p\uff1c0.0001) and local control rates (p=0.0096). Tumor size of larger than 5 cm was also recognized as independent prognostic factors for local control rates (p=0.0213).\nConclusion: Electron beam irradiation for postmastectomy of breast cancer has been proven with good local control in this study. It is compatible with the study in many reports. This technique has the advantages of easy setup, homogeneous dose distribution, and less pulmonary complication. The outcomes of high risk group patients are poor, more aggressive management may be needed for these patients.", "e": "Purpose: To evaluate the results of postoperative electron beam irradiation for stage \u2161 and \u2162 breast cancer.\nMaterials and methods: From August 1987 to June 1992, we retrospectively analyzed the results of electron beam irradiation for 87 women with primary breast cancer treated by modified radical mastectomy. Adjuvant chemotherapy and hormone therapy were also given to 55 and 40 patients, respectively.\nResults: The 5-year disease-free survival rates for stage \u2161 and \u2162 patients were 80% and 31%, respectively. The 5-year local control rates for stage \u2161 and \u2162 patients were 98% and 72%, respectively. Thirty-seven patients had distant rnetastases. Bone was the most common site. Thirteen percent of grade 1 and 18% of grade 2 late skin complication were noted. Late grade 1 complication of lung was noted in 6% of patients. In patients of high risk group (tumor size of larger than 5 cm and more than 3 positive axillary nodes metastases), the 5-year disease-free survival and local control rates were 10% and 37%, respectively. In multivariate analysis, more than 3 positive axillary nodes metastases was a strong prognostic factor for disease. free survival rates (p\uff1c0.0001) and local control rates (p=0.0096). Tumor size of larger than 5 cm was also recognized as independent prognostic factors for local control rates (p=0.0213).\nConclusion: Electron beam irradiation for postmastectomy of breast cancer has been proven with good local control in this study. It is compatible with the study in many reports. This technique has the advantages of easy setup, homogeneous dose distribution, and less pulmonary complication. The outcomes of high risk group patients are poor, more aggressive management may be needed for these patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-41-47-a", "title": "\u8166\u5782\u9ad4\u817a\u7624\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642", "keywords": "\u8166\u90e8\u816b\u7624;\u8166\u5782\u9ad4\u817a\u7624;\u653e\u5c04\u6cbb\u7642\u5b78 Brain neoplasm;Pituitary adenoma;Radiation therapy", "c": "\u76ee\u7684\uff1a\u8166\u5782\u9ad4\u817a\u7624\u7684\u6cbb\u7642\u6709\u4e09\u7a2e\u57fa\u672c\u65b9\u6cd5\uff0c\u5408\u4f75\u4f7f\u7528\u624b\u8853\u548c\u653e\u5c04\u6cbb\u7642\u5e38\u7528\u65bc\u6cbb\u7642\u8f03\u5927\u7684\u817a\u7624\u53ca\u816b\u7624\u5fa9\u767c\u4e4b\u6551\u63f4\u3002\u672c\u6587\u7684\u76ee\u7684\u5728\u63a2\u8a0e\u5408\u4f75\u4f7f\u7528\u624b\u8853\u548c\u653e\u5c04\u6cbb\u7642\u7684\u5b58\u6d3b\u7387\uff0c\u4ee5\u53ca\u5404\u7a2e\u9810\u5f8c\u56e0\u5b50\u5c0d\u5b58\u6d3b\u7387\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\ufe30\u81ea1983\u81f31993 \u5e74\u9593\uff0c\u7e3d\u8a0847\u4f4d\u7d93\u75c5\u7406\u5831\u544a\u8b49\u5be6\u70ba\u8166\u5782\u9ad4\u817a\u7624\u7684\u60a3\u8005\u5728\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5176\u4e2d\u5171\u670925\u4f4d\u7537\u6027\u53ca22\u4f4d\u5973\u6027\uff0c\u5e74\u9f61\u7bc4\u570d\u753121\u81f371\u6b72\uff08\u4e2d\u503c\u70ba42.5\u6b72\uff09\u3002\u6700\u5e38\u898b\u7684\u75c7\u72c0\u70ba\u8996\u529b\u969c\u7919(\u4f5472%)\u548c\u982d\u75db(\u4f5460%)\u3002\u653e\u5c04\u7dda\u662f\u7d93\u75316MV \u5149\u5b50\u6216\u923760\u5c04\u7dda\uff0c\u6bcf\u5468\u7167\u5c045\u6b21\uff0c\u6bcf\u6b21\u7d66\u4e88180\u81f3200 cGy(\u4e2d\u503c\u70ba5800 cGy)\uff0c\u5168\u90e8\u8ffd\u8e64\u6642\u9593\u75312\u81f311\u5e74\uff08\u4e2d\u503c\u70ba5.6\u5e74\uff09\u3002\n\u7d50\u679c\uff1a47\u4f4d\u75c5\u4eba\u5206\u6210(A)\u53ca(B)\u5169\u7d44\u3002(A)\u7d44\u670942\u4f4d\u60a3\u8005\u662f\u63a5\u53d7\u975e\u6839\u9664\u6027\u624b\u8853\u5f8c\u52a0\u4e0a\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d\u67094\u4f4d\u4e2d\u9014\u5931\u53bb\u8ffd\u8e64\u30013\u4f4d\u5fa9\u767c\u53ca5\u4f4d\u6b7b\u4ea1\u3002\u6b7b\u4ea1\u7684\u539f\u56e0\u67094\u4f4d\u662f\u56e0\u816b\u7624\u58d3\u8feb\uff0c\u53e61\u4f4d\u70ba\u8166\u8840\u7ba1\u6897\u585e\u3002\u624b\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4e4b5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba87%\uff0c\u7121\u5fa9\u767c\u5b58\u6d3b\u7387\u70ba93%\u3002(B)\u7d44\u67095\u4f4d\u75c5\u4eba\u4ee5\u653e\u5c04\u7dda\u6cbb\u7642\u4f86\u8655\u7406\u624b\u8853\u5f8c\u5fa9\u767c\u4e4b\u816b\u7624\u3002\u5176\u4e2d\u76841\u4f4d\u5728124\u500b\u6708\u5f8c\u56e0\u816b\u7624\u58d3\u8feb\u81f4\u6b7b\uff0c\u5176\u99184\u4f4d\u60c5\u6cc1\u6b63\u5e38\u3002\n\u7d50\u8ad6\uff1a\u5229\u7528log-rank test \u4f86\u5206\u6790\u9810\u5f8c\u56e0\u5b50\uff0c\u767c\u73fe\u5e74\u9f61\u3001\u6027\u5225\u53ca\u5291\u91cf\u5c0d\u5b58\u6d3b\u7387\u5f71\u97ff\u4e4b\u5dee\u7570\u7686\u4e0d\u5177\u6709\u7d71\u8a08\u5b78\u4e0a\u610f\u7fa9\u3002\u4f46\u6574\u9ad4\u800c\u8a00\uff0c\u5c0d\u65bc\u8f03\u5927\u7684\u8166\u5782\u9ad4\u817a\u7624\uff0c\u6211\u5011\u767c\u73fe\u624b\u8853\u5f8c\u52a0\u4e0a\u653e\u5c04\u7dda\u6cbb\u7642\u53ef\u5f97\u5230\u4e0d\u932f\u7684\u816b\u7624\u63a7\u5236\u7387,\u4e5f\u8a31\u53ef\u4ee5\u53d6\u4ee3\u6839\u9664\u624b\u8853\u6210\u70ba\u8f03\u5927\u7684\u8166\u5782\u9ad4\u817a\u7624\u4e4b\u6a19\u6e96\u6cbb\u7642\u65b9\u6cd5\u3002", "e": "Aims: Patients with pituitary adenoma can be managed by three effective modes of treatments. Combined surgery and radiotherapy were used to treat pituitary macroadenoma and recurrent pituitary adenoma. The object of this study was to investigate the survival rate and prognostic factors using combined surgery and radiotherapy.\nMaterials and Methods: Between 1983 and 1993, 47 patients with pathologically proven pitiuitary adenoma received radiation therapy at Mackay Memorial Hospital. Of these patients, 25 were males and 22 were females. The median age was 42.5 years with a range of 21 to 71 years. Visual disturbance (72%) and headache (60%) were the most common symptoms. Irradiation was delivered with 6-MV photon or Co-60 gamma ray, 5 days per week, at a dose of 180 to 200 cGy per fraction. The total tumor dose ranged from 4140 cGy to 6500 cGy with a median dose of 5800 cGy. The follow-up period ranged from 2 to 11 years with a median time of 5.6 years.\nResults: 47 patients were divided into two groups by their tumor status before radiation therapy. Group A patients, consisting of 42 patients were underwent incomplete resection and radiation therapy as the primary treatment. Among these patients, 4 patients were lost during follow-up, and 3 patients experienced recurrence of the tumor. Five patients died during the follow-up period, 4 patients for uncontrolled disease and one patient for CVA. The overall 5-year survival rate was 87% and the relapse-free survival rate was 93%. Group (B) patients, cansisting of 5 patients were treated for recurrence after surgery. Of these patients, one died due to tumor compression 124 months after radiotherapy, but the remaining 4 cases are still doing well.\nConclusions: Using the Log-rank test, gender, age and dose are not significant prognostic factors. In brief, we found that appropriate surgery and postoperative radiation therapy could achieve good local control and may replace radical surgery as the standard treatment for pituitary macroadenoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-49-61-a", "title": "Prognostic Parameters in Malignant gliomas", "keywords": "\u9000\u884c\u6027\u661f\u72c0\u7d30\u80de\u7624;\u591a\u578b\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624;\u5b58\u6d3b;\u653e\u5c04\u7dda\u6cbb\u7642 Anaplastic astrocytoma;Glioblastoma multiforme;Survival;Radiotherapy", "c": "\u76ee\u7684\uff1a\u672c\u7814\u7a76\u63a2\u8a0e\u8166\u5167\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u4e4b\u75c5\u60a3\uff0c\u5176\u5b58\u5728\u4e4b\u7279\u6b8a\u8b8a\u7570\u56e0\u5b50\uff0c\u5c0d\u65bc\u6cbb\u7642\u9810\u5f8c\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5171\u641c\u96c6\u4e86\u81ea\u6c11\u570b74\u5e744\u6708\u81f3\u6c11\u570b84\u5e744\u6708\u9593\uff0c\u65bc\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\uff0c\u7d93\u624b\u8853\u5f8c\u8a3a\u65b7\u70ba\u8166\u5167\u60e1\u6027\u795e\u7d93\u81a0\u7624\u4e4b42\u4f4d\u75c5\u60a3\u3002\u5176\u4e2d17\u4f4d\u60a3\u6709\u9000\u884c\u6027\u661f\u72c0\u7d30\u80de\u7624\uff0c\u53e625\u4f4d\u75c5\u4eba\u60a3\u6709\u591a\u578b\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\u3002\u9019\u4e9b\u75c5\u60a3\u7686\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u7814\u7a76\u91dd\u5c0d17\u4f4d\u81e8\u5e8a\u56e0\u5b50\u53ca2\u9805\u7d44\u7e54\u5b78\u56e0\u5b50\uff0c\u5305\u62ec\u5e74\u9f61\u3001\u6027\u5225\u3001\u51fa\u73fe\u982d\u75db\u3001\u7cbe\u795e\u6539\u8b8a\u3001\u7672\u75c5\u3001\u8996\u529b\u6539\u8b8a\u3001\u904b\u52d5\u80fd\u529b\u7f3a\u5931\u3001\u611f\u89ba\u6539\u8b8a\u3001\u8a00\u8a9e\u56f0\u96e3\u3001\u8853\u524d\u884c\u70ba\u72c0\u614b\u3001\u958b\u5200\u7bc4\u570d\u3001\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u5291\u91cf\u3001\u8166\u6c34\u816b\u3001\u8166\u4e2d\u817a\u79fb\u52d5\u3001\u8840\u816b\u5f62\u6210\u3001\u816b\u7624\u90e8\u4f4d\u3001\u75c7\u72c0\u6301\u7e8c\u6642\u9593\u3001\u7d44\u7e54\u5b78\u5206\u671f\u53ca\u816b\u7624\u56ca\u816b\u5f62\u6210\uff0c\u5206\u6790\u9019\u4e9b\u56e0\u5b50\u5c0d\u65bc\u5b58\u6d3b\u671f\u8a55\u4f30\u7684\u91cd\u8981\u6027\u3002\n\u7d50\u679c\uff1a\u672c\u7814\u7a76\u5206\u6790\u4e4b\u7e3d\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba18.7\u6708\uff0c\u9000\u884c\u6027\u661f\u72c0\u7d30\u80de\u7624\u75c5\u60a3\u4e4b\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba25.4\u6708\uff0c\u591a\u578b\u6027\u81a0\u8cea\u6bcd\u7d30\u80de\u7624\u75c5\u60a3\u4e4b\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba14.2\u6708\u3002\u5206\u6790\u7d50\u679c\u5229\u7528Cox multivariate regession model \u53ca Chisquare test \u986f\u793a\uff0c\u7d44\u7e54\u5206\u671f\u3001\u624b\u8853\u5207\u9664\u4e4b\u7bc4\u570d\u3001\u5e74\u9f61\u3001\u6027\u5225\u53ca\u75c5\u60a3\u8868\u73fe\u982d\u75db\u548c\u904b\u52d5\u6a5f\u80fd\u7f3a\u5931\uff0c\u7686\u6703\u5f71\u97ff\u6cbb\u7642\u4e4b\u9810\u5f8c\u3002\n\u7d50\u8ad6\uff1a\u7d93\u7531\u7814\u7a76\u5206\u6790\u51fa\u60e1\u6027\u795e\u7d93\u81a0\u8cea\u7624\u4e4b\u9810\u5f8c\u53c3\u6578\uff0c\u53ef\u5229\u7528\u4f86\u4f5c\u70ba\u75c5\u60a3\u4e4b\u5206\u7d44\u6cbb\u7642\u3002\u91dd\u5c0d\u4e0d\u540c\u9810\u5f8c\u56e0\u5b50\uff0c\u63d0\u4f9b\u75c5\u60a3\u66f4\u5408\u9069\u4e4b\u6cbb\u7642\u3002", "e": "Aim: Despite recent advances in neuro-imaging, neurosurgieal techniques, and aggressive approach using combined modalities, the prognosis for patients with malignant gliomas remains dismal. The goal of this study was to increase our understanding of the relative influence that specific variables have on the outcome of patients.\nMethods and Materials: Forty-two patients with intracranial malignant gliomas (17 with anaplastic astrocytomas and 25 with glioblastoma multiforme), treated by surgery and postoperative radiotherapy at Mackay Memorial Hospital from April 1985 through April 1995, were retrospectively reviewed. Twenty-six men and 16 women with a median age of 44 years (range, 10 to 70 years) were entered in the study. Seventeen clinical factors (age at surgery; sex; initial presenting symptoms of headaches, mental changes, seizure, visual changes, motor deficits, sensory changes, and speech difficulties; preoperative performance status based on the Karnofsky scale; the extent of surgical removal; postoperative radiotherapy dose; the presence of brain edema, brain midline shift, and hematoma formation; tumor she; duration of initial symptoms), and 2 histological factors (histological grade; tumor cystic formation) were analyzed to investigate their importance in predicting length of survival. Data were analyzed using the Cox proportional harzards analysis or Chi-square test.\nResults: The overall median survival time was 18.7 months. The median survival time was 25.4 months for anaplastic astrocytoma and 14.2 months for glioblastoma multiforme Four pretreatment variables including histological grade, age, sex and the extent of tumor resection (subtotal or total) were found to have a statistically significant effect on survival when analyzed together by the Cox multivariate regression model. Univariate analysis by the Chi-square test identified the presenting neurological symptoms of mental changes and motor deficits as having an adverse effect on survival.\nConclusions: The authors conclude that histological grade, age, sex, extent of tumor resection, and the presenting symptoms of mental changes or motor deficits were important prognostic parameters in malignant gliomas. By stratifying patients into more homogeneous subgroups with favorable or unfavorable prognostic factors, treatment can be specially tailored for different subgroups."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-63-69-a", "title": "\u4e0d\u540c\u6c34\u6d41\u901f\u5ea6\u5c0d\u5047\u9ad4\u5167\u71b1\u6cbb\u7642\u6eab\u5ea6\u5206\u5e03\u4e4b\u7814\u7a76", "keywords": "\u5c04\u983b;\u71b1\u5206\u5e03 Radiofrequency;Thermal distribution", "c": "\u76ee\u7684\uff1a\u63a2\u8a0e\u6df1\u90e8\u71b1\u6cbb\u7642\u6642\uff0c\u6c34\u6d41\u6d41\u901f\u5c0d\u5047\u9ad4\u5167\u71b1\u5206\u5e03\u4e4b\u5f71\u97ff\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u5229\u7528\u96fb\u5bb9\u677f\u5f0f\u96fb\u6975\u52a0\u71b1\u6cbb\u7642\u7cfb\u7d71\u914d\u5408\u81ea\u884c\u8a2d\u8a08\u7684\u6a21\u64ec\u8840\u6db2\u5faa\u74b0\u7cfb\u7d71\uff0c\u5c0d\u808c\u8089\u5047\u9ad4\u9032\u884c\u52a0\u71b1\u8a66\u9a57\u3002\u7b2c\u4e00\u90e8\u4efd\u5148\u5229\u7528\u96fb\u78c1\u529f\u7387400\u74e6\u3001\u76f4\u5f91\u5927\u5c0f\u76f8\u540c(20\u516c\u5206)\u7684\u96fb\u6975\u5c0d\u5047\u9ad4\u65bd\u71b1\uff0c\u4e26\u91cf\u6e2c\u5176\u7e31\u5411\u548c\u6a6b\u5411\u7684\u6eab\u5ea6\u5206\u5e03\u3002\u7b2c\u4e8c\u90e8\u4efd\u5247\u53e6\u52a0\u4e00\u6c34\u7ba1\u8cab\u7a7f\u808c\u8089\u5047\u9ad4\u7684\u4e2d\u5fc3\u4f4d\u7f6e\uff0c\u4ee5\u5faa\u74b0\u6db2\u6d41\u904e\u4ee5\u6a21\u64ec\u8840\u6db2\u6d41\u52d5\u72c0\u614b\uff0c\u5206\u5225\u4ee5\u4e0d\u540c\u7684\u6c34\u6d41\u901f\u5ea6(9.45, 18.9, 75.15\u548c150.3ml/min)\u4f86\u8a0e\u8ad6\u5176\u4e2d\u592e\u7e31\u5411\u6eab\u5ea6\u5206\u5e03\u72c0\u614b\u3002\n\u7d50\u679c\uff1a\u7b2c\u4e00\u90e8\u4efd\u7684\u5be6\u9a57\u7d50\u679c\u986f\u793a\uff0c\u7531\u4e2d\u592e\u7e31\u5411\u6eab\u5ea6\u5206\u4f48\u72c0\u614b\u986f\u793a\u6eab\u5ea6\u5f9e\u4e2d\u5fc3\u9ede\u5411\u5916\u905e\u6e1b\uff0c\u4f46\u662f\u9760\u8fd1\u5169\u96fb\u5bb9\u677f\u96fb\u6975\u8655\u7686\u6709\u904e\u71b1\u73fe\u8c61\uff0c\u4e14\u5047\u9ad4\u4e0b\u65b9\u4e4b\u6eab\u5ea6\u8f03\u4e0a\u65b9\u9ad85-6\u2103\u5de6\u53f3\uff1b\u800c\u4e2d\u592e\u6a6b\u5411\u6eab\u5ea6\u5206\u5e03\u72c0\u614b\u5247\u986f\u793a\u9760\u8fd1\u71b1\u6cbb\u7642\u52a0\u71b1\u96fb\u6975\u7684\u4e00\u5074\u6eab\u5ea6\u6bd4\u5c0d\u5074\u7aef\u9ad83-4\u2103\u5de6\u53f3\u3002\u7b2c\u4e8c\u90e8\u4efd\u7814\u7a76\u986f\u793a\uff1a\u6c34\u6d41\u901f\u5ea6\u6108\u5feb\uff0c\u71b1\u50b3\u5c0e\u901f\u5ea6\u589e\u52a0\uff0c\u80fd\u91cf\u6d41\u5931\u767e\u5206\u6bd4\u4e5f\u589e\u52a0\uff0c\u6545\u6eab\u5ea6\u6bd4\u8f03\u4f4e\u3002\u4f46\u662f\u7576\u6c34\u6d41\u901f\u5ea6\u589e\u81f3150.3ml/min\uff0c\u80fd\u91cf\u6d41\u5931\u53cd\u800c\u6210\u7a69\u5b9a\u72c0\u614b\uff0c\u6eab\u5ea6\u8b8a\u5316\u4e0d\u660e\u986f\u3002\n\u7d50\u8ad6\uff1a\u7576\u5047\u9ad4\u5167\u52a0\u5165\u6c34\u6d41\u7684\u56e0\u7d20\u5f8c\uff0c\u6c34\u6d41\u6d41\u901f\u7684\u5927\u5c0f\u78ba\u80fd\u5f71\u97ff\u71b1\u5206\u5e03\u7684\u72c0\u6cc1,\u4f7f\u6eab\u5ea6\u964d\u4f4e\u3002\u4f46\u7576\u6c34\u6d41\u901f\u5ea6\u589e\u81f3150.3ml/min\uff0c\u80fd\u91cf\u6d41\u5931\u53cd\u800c\u6210\u7a69\u5b9a\u72c0\u614b\uff0c\u6eab\u5ea6\u8b8a\u5316\u4e0d\u660e\u986f\u3002", "e": "Purpose: To evaluate the effects of velocity of water flow on temperature distribution in a phantom.\nMaterial and Method: The beating device is the 13.56 MHz radiofrequency capacitive hyperthermia system. A phantom with flow is designed, namely, one silicone tube inserted into a homogenous muscle phantom. The temperature to be achieved is 43\u2103. It was measured by thin- coated thermocouples which are inserted into phantom through angiocatheter. The catheters were arranged with the aid of self-design holder. Simutaneously, thermogram was done via the computerized system.\nWe compare the thermal distribuation in two different enviorments: 1. Phantom without flow as a control arm, 2. Phantom with single silicone tube. The flow rates of water through silicone tubes are controlled by a microtube pump.\nResult: The control arm demonstrated there was a tendency that the temperature of upper part of the phantom was lower than lower part. In experimental group, progressively increased velocity of the flow will also increase the ability of heat conduction. This phenomenon was not observed when the flow rate reached 150.3 ml/mm.\nConclusion: Water flow played an important role in thermal distribution. The higher the velocity of the flow, the more increased ability of heat conduction was noted."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-71-76-a", "title": "\u570b\u7acb\u6e05\u83ef\u5927\u5b78\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668\u61c9\u7528\u65bc\u787c\u4e2d\u5b50\u6355\u6349\u6cbb\u7642\u7684\u8d85\u71b1\u4e2d\u5b50\u675f\u8a2d\u8a08\u4e4b\u73fe\u6cc1", "keywords": "\u787c\u4e2d\u5b50\u6355\u6349\u6cbb\u7642;\u8d85\u71b1\u4e2d\u5b50\u7167\u5c04\u7ba1;\u6e05\u83ef\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668 Boron neutron capture therapy (BNCT);Epithermal neutron beam;Tsing Hua Open-pool Reactor", "c": "\u8fd1\u5e74\u4f86\uff0c\u787c\u4e2d\u5b50\u6355\u6349\u6cbb\u7642\u4e4b\u7814\u7a76\u50be\u5411\u65bc\u63a1\u7528\u8d85\u71b1\u4e2d\u5b50\u675f\u4ee5\u907f\u514d\u5207\u958b\u982d\u84cb\u9aa8\u4e4b\u624b\u8853\u53ca\u9032\u884c\u8f03\u6df1\u5c64\u4e4b\u816b\u7624\u6cbb\u7642\u3002\u672c\u6587\u5c07\u4ecb\u7d39\u4e16\u754c\u5404\u570b\u5728\u8a2d\u8a08\u5efa\u9020\u8d85\u71b1\u4e2d\u5b50\u7167\u5c04\u7ba1\u4e4b\u73fe\u6cc1\uff0c\u4ee5\u53ca\u76ee\u524d\u5728\u570b\u5167\u6e05\u83ef\u6c34\u6c60\u5f0f\u53cd\u61c9\u5668\u5efa\u9020\u8d85\u71b1\u4e2d\u5b50\u7167\u5c04\u7ba1\u4e4b\u9032\u5c55\u53ca\u8a08\u5283\u3002", "e": "In recent years, study of boron neutron capture therapy has been aimed at the establishment of epithermal neutron beams in order to avoid the open-skull surgury and for the treatment of deep-seated tumors. In this article, the current status of epithermal neutron beams in the world is reviewed and also the design and construction plan of the epithermal neutron beam at the Tsing Hua Open-pool Reactor is reported."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199603-3-1-77-82-a", "title": "Primary Malignant Fibrous Histiocytoma of The Breast a Case Report and Review of The Literature", "keywords": "\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624;\u4e73\u623f;\u653e\u5c04\u7dda\u6cbb\u7642 Malignant fibrous histiocytoma;Breast;Radiotherapy", "c": "\u4e00\u500b38\u6b72\u7684\u5973\u6027\u75c5\u4eba\u5728\u5176\u53f3\u5074\u4e73\u623f\u767c\u73fe\u6709\u4e0010\u00d74\u00d78\u516c\u5206\u786c\u4e14\u56fa\u8457\u7684\u816b\u584a\u3002\u75c5\u4eba\u5728\u99ac\u5055\u7d00\u5ff5\u91ab\u9662\u63a5\u53d7\u6539\u826f\u5f0f\u6839\u9664\u6027\u4e73\u623f\u5207\u9664\u8853\u3002\u75c5\u7406\u5831\u544a\u986f\u793a\u70ba\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u3002\u816b\u7624\u5728\u958b\u5200\u5f8c\u4e00\u5e74\u5fa9\u767c\u3002\u75c5\u4eba\u65bc\u672c\u79d1\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5728\u53f3\u5074\u80f8\u58c1\u3001\u814b\u7aa9\u3001\u9396\u9aa8\u4e0a\u51f9\u7aa9\u3001\u53ca\u4e0b\u9838\u90e8\uff0c\u5206\u5225\u63a5\u53d75040 cGy \u7684\u5291\u91cf\u3002\u76f4\u5230\u76ee\u524d\u70ba\u6b62\u4e26\u672a\u767c\u73fe\u6709\u6b64\u75c5\u5b58\u5728\u7684\u8de1\u8c61\u3002\u672c\u6587\u4e2d\u5206\u6790\u5f9e1964\u5e74\u52301992\u5e74\u6240\u767c\u8868\u768435\u500b\u4e73\u623f\u60e1\u6027\u7e96\u7dad\u7d44\u7e54\u7d30\u80de\u7624\u7684\u75c5\u4eba\uff0c\u767c\u73fe\u63a5\u53d7\u5c40\u90e8\u5207\u9664\u3001\u7c21\u55ae\u4e73\u623f\u5207\u9664\u6216\u90e8\u4efd\u4e73\u623f\u5207\u9664\u7684\u75c5\u4eba\u6bd4\u63a5\u53d7\u6839\u9664\u6027\u4e73\u623f\u5207\u9664\u7684\u75c5\u4eba\u6709\u8f03\u9ad8\u7684\u5c40\u90e8\u5fa9\u767c\u7387\u3002\u653e\u5c04\u7dda\u6cbb\u7642\u5c0d\u65bc\u53ea\u63a5\u53d7\u5c40\u90e8\u5207\u9664\u3001\u7c21\u55ae\u4e73\u623f\u5207\u9664\u6216\u90e8\u4efd\u4e73\u623f\u5207\u9664\u7684\u75c5\u4eba\u53ef\u80fd\u6709\u52a9\u65bc\u5c40\u90e8\u75be\u75c5\u7684\u63a7\u5236\u3002", "e": "Aim: Present a rare case of primary malignant fibrous histiocytoma of the breast and review the reported cases in the literature.\nMaterial and method: A 38 year-old female patient who ivitially complained of a l0\u00d74\u00d78 cm hard, fixed mass in her right breast underwent modified radical mastectomy at Mackay Memorial Hospital in May 1991. The pathology report revealed malignant fibrous histiocytoma. Tumor recurrence was noted one year later. Radiotherapy was administrated with a total dose of 5040 cGy to the right chest wall, axilla, supraclavicular fossa and lower neck.\nResult: No evidence of disease has been noted up to now (Sep. 1995).\nDiscussion: Thirty five cases reported from 1964 to 1992 in article reviews show that the local recurrence rate is higher in patients who receive local excision, simple mastectomy or partial mastectomy than in those who receive radical mastectomy. If adequate surgery is not performed, radiotherapy can play a role of increasing local control for this disease."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-317-327-a", "title": "\u5c40\u90e8\u91cd\u5ea6\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u591a\u7a2e\u578b\u5f0f\u6cbb\u7642", "keywords": "\u591a\u7a2e\u578b\u5f0f\u6cbb\u7642;\u80ba\u764c;\u975e\u5c0f\u7d30\u80de\u6027\u80ba\u764c Multimodality treatment;Lung cancer;NSCLC", "c": "\u5c0d\u65bc\u65e9\u671f\u5c40\u9650\u6027\u7684\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff0c\u7531\u65bc\u5316\u7642\u6548\u679c\u4e0d\u592a\u7406\u60f3\uff0c\u56e0\u6b64\u5916\u79d1\u5207\u9664\u662f\u4e3b\u8981\u7684\u9078\u64c7\u3002\u4f46\u5df2\u6709\u8f49\u79fb\u8005\uff0c\u5247\u53ea\u597d\u4ee5\u5316\u7642\u4f5c\u59d1\u606f\u6027\u6216\u8a66\u9a57\u6027\u7684\u6cbb\u7642\u3002\u5982\u679c\u662f\u5c40\u90e8\u91cd\u5ea6\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff0c\u5c0d\u65bc\u5982\u4f55\u6cbb\u7642\uff0c\u5247\u4ecd\u6709\u722d\u8b70\u3002\u56e0\u70ba\u55ae\u4e00\u5916\u79d1\u5207\u9664\u6216\u653e\u7642\uff0c\u6548\u679c\u90fd\u4e0d\u7406\u60f3\uff0c\u6240\u4ee5\u61c9\u8003\u616e\u591a\u578b\u5f0f\u7642\u6cd5\u3002\u554f\u984c\u662f\u5982\u4f55\u914d\u5408\u624b\u8853\u3001\u653e\u7642\u53ca\u5316\u7642\uff0c\u800c\u5316\u7642\u4e2d\u61c9\u4ee5\u4f55\u7a2e\u85e5\u7269\uff0c\u5247\u662f\u5404\u6709\u4e0d\u540c\u610f\u898b\u3002\u672c\u6587\u5c31\u4ee5\u6b64\u4e00\u554f\u984c\uff0c\u4f5c\u4e00\u7c21\u8981\u7684\u7d9c\u5408\u8a0e\u8ad6\uff0c\u4ee5\u4f9b\u53c3\u8003\u3002\u76ee\u524d\u5404\u65b9\u9762\u7684\u81e8\u5e8a\u8a66\u9a57\u7d50\u679c\uff0c\u8b49\u660e\u591a\u578b\u5f0f\u6cbb\u7642\uff0c\u5c0d\u5c40\u90e8\u91cd\u5ea6\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8001\u662f\u53ef\u884c\u800c\u53c8\u6709\u597d\u8655\u7684\uff0c\u5c24\u5176\u662f\u5c0d\u4e00\u822c\u72c0\u6cc1\u8f03\u597d\u7684\u75c5\u60a3\u3002\u6240\u4ee5\u61c9\u8a72\u5f80\u6b64\u65b9\u5411\u767c\u5c55\uff0c\u540c\u6642\u66f4\u8b93\u6211\u5011\u611f\u89ba\u5230\uff0c\u4f75\u7528\u5316\u7642\u8207\u653e\u7642\u5c0d\u5c40\u90e8\u63a7\u5236\u6709\u597d\u8655\uff0c\u800c\u4f9d\u5e8f\u5316\u7642\u8207\u653e\u7642\uff0c\u53ef\u6e1b\u5c11\u8f49\u79fb\u3002\u7136\u800c\u8ddd\u96e2\u6211\u5011\u7684\u7406\u60f3\u9084\u9060\u3002\u56e0\u6b64\uff0c\u671f\u5f85\u65b0\u85e5\u7684\u958b\u767c\u3002", "e": "Surgical resection is the main treatment for stage I, II non-small cell lung cancer (NSCLC). Combination chemotherapy programs or others are the principle palliative treatment for metastatic stage IV disease. Controversies exist in localized advanced stage III a and III b NSCLC. Different approaches including neoadjuvant chemotherapy followed by surgery, induction chemotherapy with sequential radiotherapy, different schedules of primary radiotherapy, concomitant chemotherapy and radiotherapy have been reviewed in this article. The optimal treatment for stage III b NSCLC may be concomitant chemotherapy and radiotherapy than either radiotherapy alone or sequential chemotherapy and radiotherapy. However, more clinical trials is warrant."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-329-335-a", "title": "\u982d\u9838\u90e8\u764c\u75c7\u75c5\u60a3\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\u6642\u7684\u6027\u817a\u5291\u91cf\u7814\u7a76", "keywords": "\u6027\u817a\u5291\u91cf;\u6563\u5c04\u8f3b\u5c04 Gonad dose;Scattering radiation", "c": "\u76ee\u7684\uff1a\u982d\u9838\u90e8\u764c\u75c7\u60a3\u8005\u5728\u63a5\u53d7\u5168\u7a0b\u7684\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u6027\u817a\u96d6\u672a\u88ab\u76f4\u63a5\u7167\u5c04\uff0c\u4f46\u4ea6\u6703\u63a5\u53d7\u5230\u5fae\u91cf\u7684\u8f3b\u5c04\u5291\u91cf\u3002\u9019\u4e9b\u7531\u6563\u5c04\u5149\u5b50\u6240\u9020\u6210\u7684\u5fae\u91cf\u8f3b\u5c04\uff0c\u4e3b\u8981\u4f86\u81ea\u6e96\u503c\u5100\u7684\u6563\u5c04\u8f3b\u5c04\u3001\u6cbb\u7642\u6a5f\u982d\u7684\u6d29\u6f0f\u8f3b\u5c04\u548c\u60a3\u8005\u81ea\u982d\u9838\u90e8\u7d93\u7531\u9ad4\u5167\u6563\u5c04\u5230\u6027\u817a\u5340\u7684\u5149\u5b50\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u672c\u7814\u7a76\u5148\u4ee5\u4eba\u5047\u9ad4(Rando phantom)\u70ba\u6e2c\u91cf\u7684\u5c0d\u8c61\uff0c\u6cbb\u7642\u6240\u7528\u7684\u7167\u91ce\uff0c\u653e\u5c04\u7dda\u7167\u7684\u89d2\u5ea6\u53ca\u6cbb\u7642\u7684\u816b\u7624\u5291\u91cf\u7686\u4ee5\u9f3b\u54bd\u764c\u7684\u653e\u5c04\u6cbb\u7642\u65b9\u6cd5\u70ba\u6e96\u3002\u4f7f\u7528Farmer\u5f0f\u5291\u91cf\u5100\uff08\u6e38\u96e2\u8154\uff09\u53ca\u71b1\u87a2\u5149\u5291\u91cf\u5100\uff08TLD;HARSHAW 2000\u578b\uff09\u4f86\u8a08\u6e2c\u982d\u9838\u90e8\u63a5\u53d7\u653e\u5c04\u7dda\u7167\u5c04\u6642\uff0c\u6027\u817a\u6240\u63a5\u53d7\u5230\u7684\u6563\u5c04\u91cf\uff1bFarmer\u5291\u91cf\u5100\u70baNE 2502/3\u578b\u53ca0.6 c. c\u6e38\u96e2\u8154\uff0cTLD\u5247\u70ba\u6c1f\u5316\u92f0\u7c89\u672b\u3002\n\u7d50\u679c\uff1a\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u65bc\u4eba\u5047\u9ad4\u7684\u982d\u9838\u90e8\u816b\u7624\u7167\u5c04\u5291\u91cf\u9054\u52301800 cGy\uff0c\u4e14\u672a\u52a0\u4efb\u4f55\u5c4f\u853d\u6642\uff0c\u6027\u817a\u6240\u91cf\u6e2c\u5230\u7684\u5291\u91cf\u70ba2.18 cGy\uff1b\u5982\u5728\u4eba\u5047\u9ad4\u8179\u90e8\u5468\u570d\u4ee56\u516c\u5206\u539a\u7684\u925b\u584a\u570d\u6210\u5c4f\u853d\uff0c\u5247\u7d50\u679c\u53ea\u67090.54 cGy\uff0c\u6bd4\u672a\u52a0\u5c4f\u853d\u6642\u7684\u5291\u91cf\u5c11\u4e86\u7d0475%\u3002\u82e5\u4ee5\u9f3b\u54bd\u764c\u7684\u816b\u7624\u6cbb\u7642\u5291\u91cf\u70ba7000 cGy\uff0c\u7d93\u7531\u5be6\u969b\u65bc\u75c5\u60a3\u6027\u817a\u8655\u6240\u6e2c\u5f97\u7684\u6578\u64da\u548c\u8a08\u7b97\uff0c\u6027\u817a\u6240\u63a5\u53d7\u5230\u7684\u5291\u91cf\u7d04\u70ba5.83 cGy\u3002", "e": "Purpose: Although the gonad is located far away from the primary radiation beam for head and neck cancer patients receiving radiotherapy, the gonad will inevitably be exposured to scattered radiations. The scattered radiations are resulted from scattering from the collimators and modifiers, photon leakage through the treatment head of the machine, and scattering within the patient from the treatment beams. \nMaterial & Methods: The Rando phantom is irradiated according the treatment protocol of nasopharyngeal cancer patients. The Farmer dosimeter and Thermoluminescent dosimeter are used to measure the gonad dose. The Farmer dosineler in NE 2503/3 with 0.6 c.c. lonizing chamber and the material of TLD is HF power. \nResult: Using the Rando phantom measurements, the gonad dose is about 2.18 cGy when a dose of 1800 cGy is given to the head and neck area. The gonad dose may be reduced by 75% (from 2.18 cGy to 0.54 cGy) when the abdomen of the Rando phantom is shielded by 6 cm lead bolcks. According to the measured data and calculation, the gonad dose is about 5.38 cGy if the head and neck area is irradiated to 7000 cGy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-337-344-a", "title": "\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u5c0d\u6b63\u5e38\u7d44\u7e54\u7684\u5f71\u97ff", "keywords": "\u4e73\u764c\u653e\u5c04\u6cbb\u7642;\u6b63\u5e38\u5668\u5b98;\u816b\u7624\u5291\u91cf;\u6563\u5c04\u5291\u91cf Breast cancer radiotherapy;Normal tissue;Tumor dose;Scatter dose", "c": "\u76ee\u7684\uff1b\u5728\u653e\u5c04\u6cbb\u7642\u671f\u9593\uff0c\u7167\u5c04\u7bc4\u570d\u5916\u7684\u6b63\u5e38\u5668\u5b98\u53ca\u7d44\u7e54\uff0c\u4e0d\u53ef\u907f\u514d\u5730\u5fc5\u5b9a\u6703\u63a5\u53d7\u5230\u4e00\u4e9b\u6563\u5c04\u5291\u91cf\u3002\u70ba\u4e86\u4f5c\u70ba\u81e8\u5e8a\u4e0a\u8a55\u4f30\u7684\u9700\u8981\u3002\u6211\u5011\u4ee5\u4eba\u5f62\u5047\u9ad4\u4f5c\u70ba\u5be6\u9a57\u75c5\u4eba\uff0c\u91dd\u5c0d\u4e73\u764c\u653e\u5c04\u6cbb\u7642\u6642\uff0c\u5176\u4ed6\u6b63\u5e38\u5668\u5b98\u6240\u63a5\u53d7\u7684\u5291\u91cf\u9032\u884c\u6e2c\u91cf\u3002\n\u6750\u6599\u8207\u65b9\u6cd5\uff1a\u6240\u4f7f\u7528\u7684\u6a5f\u5668\u5305\u62ec\u76f4\u7dda\u52a0\u901f\u5668(6MV)\u548c\u9237\u516d\u5341\u6cbb\u7642\u6a5f\uff0c\u6e2c\u91cf\u7684\u5668\u5b98\u6709\u8166\u3001\u773c\u7403\u3001\u553e\u6db2\u817a\u3001\u7532\u72c0\u817a\u3001\u80ba\u3001\u80c3\u3001\u80f0\u81df\u3001\u814e\u3001\u5375\u5de2\u3001\u776a\u4e38\u53ca\u5c0d\u5074\u4e73\u623f\u7b49\u3002\n\u7d50\u679c\uff1a\u6e2c\u91cf\u7684\u7d50\u679c\u986f\u793a\uff1b\u7576\u4e00\u5074\u4e73\u623f\u4ee56MV\u7684X\u5c04\u7dda\u7167\u5c045000 Gy\u7684\u816b\u7624\u5291\u91cf\u6642\uff0c\u9664\u4e86\u5c0d\u5074\u4e73\u623f\u4e4b\u5916\u5176\u5b83\u5668\u5b98\u7684\u6563\u5c04\u5291\u91cf\u57286~246 cGy\u4e4b\u9593\u3002\u5c0d\u5074\u4e73\u623f\u5247\u5206\u5225\u4ee5\u76f4\u7dda\u52a0\u901f\u5668(6MV)\u548c\u9237\u516d\u5341\u6cbb\u7642\u6a5f\u53ca\u52a0\u4e0a\u4e0d\u540c\u89d2\u5ea6\u7684\u6954\u5f62\u6ffe\u7247(wedge)\u5728\u5341\u7a2e\u4e0d\u540c\u60c5\u6cc1\u4e0b\u4f5c\u6e2c\u91cf\uff0c\u5176\u6563\u5c04\u5291\u91cf\u7d04\u572864~425 cGy\u4e4b\u9593\uff0c\u800c\u4e14\u4f7f\u7528\u7684wedge\u89d2\u5ea6\u8d8a\u5927\u5c0d\u5074\u4e73\u623f\u7684\u5291\u91cf\u5c31\u8d8a\u9ad8\u3002\n\u7d50\u8ad6\uff1a\u5f9e\u672c\u5be6\u9a57\u7684\u7d50\u679c\u6211\u5011\u6709\u4ee5\u4e0b\u7d50\u8ad6\uff1a1)\u8d8a\u9060\u96e2\u7167\u5c04\u90e8\u4f4d\u7684\u5668\u5b98\u63a5\u53d7\u7684\u6563\u5c04\u5291\u91cf\u8d8a\u4f4e\u30022)\u4f7f\u7528\u6954\u6ffe\u7247\u5c07\u6703\u589e\u52a0\u5c0d\u5074\u4e73\u623f\u7684\u6563\u5c04\u5291\u91cf\u30023)\u4f7f\u7528\u7684\u6954\u5f62\u6ffe\u7247\u89d2\u5ea6\u8d8a\u5927\u3002\u5c0d\u5074\u4e73\u623f\u7684\u6563\u5c04\u5291\u91cf\u4e5f\u8d8a\u9ad8\u3002", "e": "Purpose: Incidental radiation, outside of the treatment field, is an unavoidable consequence of radiotherapy. For the use of clinical evaluation, scatter radiation to normal tissue was measured with an Alderson anthromorphic phantom simulating breast cancer radiotherapy. \nMaterial and method: Treatment machines included a Mitsubishi linear accelerator (6 MV) and a AECL Cobalt-60 teletherapy unit. The scatter dose to the brain, eye, salivary gland, thyroid gland, lung, stomach, pancreas, kidney, ovary, testis, and opposite breast was measured. Result: Measurement results indicated that if the affected breast received 5000 cGy tumor dose by irradiation with 6 MV X-ray then the other organs except the opposite breast would absorb a scatter dose ranging between 6 cGy to 246 cGy. Incidental radiation to the opposite breast was measured under 10 different situations using diverse wedges on the linear accelerator (6 MV) and a Cobalt.60 teletherapy unit. The measured scatter dose to the opposite breast ranged from 64 cGy to 425 cGy. We also found out that larger wedge angles deliver a higher scatter dose to the opposite breast. \nConclusion: From the result of our experiment, we conclude: 1) The scatter dose outside of the primary beam decreased with increasing distance from the irradiated site. 2) When wedges were used, the scatter dose to opposite breast increased, 3) Using the larger wedge angle would deliver the higher scatter dose to opposite breast."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-345-351-a", "title": "The Effect of Megestrol Acetate on Nutritional Improvement for the Head and Neck Cancer Patients during Radiotherapy", "keywords": "megestrol acetate;\u9ad4\u91cd;\u98df\u617e;\u653e\u5c04\u6cbb\u7642 Megestrol acetate;Body weight;Appetite;Irradiation", "c": "Purpose: To determine the effect of megestrol acetate on nutritional improvement for the head and neck cancer patients during radiotherapy. \nMaterials and Methods: Sixty-five consecutive patients of head and neck cancer treated between July, 1993 and June, 1994 were prospectively randomized to receive megestrol acetate, Megace, 40mg qid, (Megace group) or placebo treatment (control group) during radiotherapy. Before radiotherapy, body weight (kg), appetite score, performance status, biochemical parameters and hematological parameters were evaluated. The above clinical and biochemical parameters were assessed and recorded every other week. All patients received 6 MV X-ray or Co60-ray for full course of radiotherapy, 64.8-75.6 Gy/7-9 weeks. \nResult: Thirty-five patients were enrolled in Megace group and 30 patients in control group. At the 4th, 6th and 8th week, as radiation dose escalated, the Megace group had less body weight loss, than the control group (p=0.0l2, 0.003, 0.008, respectively). Significant lower appetite score was noted in control group as compared with Megace group (p=0.03, 0.01, 0.004, respectively). However, there were no significant difference in the change of prealbumin and albumin level between these two groups at the 2nd, 4th, 6th and 8th week (p\uff1e0.005, respectively). \nConclusion: Low dose megestrol acetate can significantly decrease the degree of body weight loss and deterioration of the appetite status for the head and neck cancer patients receiving conventional radiotherapy.", "e": "Purpose: To determine the effect of megestrol acetate on nutritional improvement for the head and neck cancer patients during radiotherapy. \nMaterials and Methods: Sixty-five consecutive patients of head and neck cancer treated between July, 1993 and June, 1994 were prospectively randomized to receive megestrol acetate, Megace, 40mg qid, (Megace group) or placebo treatment (control group) during radiotherapy. Before radiotherapy, body weight (kg), appetite score, performance status, biochemical parameters and hematological parameters were evaluated. The above clinical and biochemical parameters were assessed and recorded every other week. All patients received 6 MV X-ray or Co60-ray for full course of radiotherapy, 64.8-75.6 Gy/7-9 weeks. \nResult: Thirty-five patients were enrolled in Megace group and 30 patients in control group. At the 4th, 6th and 8th week, as radiation dose escalated, the Megace group had less body weight loss, than the control group (p=0.0l2, 0.003, 0.008, respectively). Significant lower appetite score was noted in control group as compared with Megace group (p=0.03, 0.01, 0.004, respectively). However, there were no significant difference in the change of prealbumin and albumin level between these two groups at the 2nd, 4th, 6th and 8th week (p\uff1e0.005, respectively). \nConclusion: Low dose megestrol acetate can significantly decrease the degree of body weight loss and deterioration of the appetite status for the head and neck cancer patients receiving conventional radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-353-356-a", "title": "\u65bc\u5168\u7403\u8cc7\u8a0a\u7db1\u8def(World-Wide-Web)\u4e0a\u5982\u4f55\u8a2d\u7acb\u764c\u75c7\u4e4b\u8aee\u8a62\u7cfb\u7d71\u53ca\u5176\u61c9\u7528", "keywords": "\u6d32\u969b\u7db1\u8def;\u5168\u7403\u8cc7\u8a0a\u7db1;\u764c\u75c7\u8aee\u8a62 Internet;World-Wide-Web;Cancer consultation", "c": "\u6d32\u969b\u7db1\u8def(Internet)\u5728\u9032\u5165\u4e00\u4e5d\u4e5d\u96f6\u5e74\u4ee3\u5f8c\u5df2\u7d93\u84ec\u52c3\u767c\u5c55\uff0c\u4ee5\u5e7e\u4f55\u500d\u6578\u6210\u9577\u3002\u800c\u8eab\u7232Internet\u4e00\u74b0\u7684\u5168\u7403\u8cc7\u8a0a\u7db1(WWW)\u56e0\u5176\u89aa\u548c\u7684\u4f7f\u7528\u8005\u4ecb\u9762\uff0c\u66f4\u662f\u5448\u73fe\u7206\u70b8\u6027\u7684\u6210\u9577\u3002\u672c\u6587\u63a2\u8a0e\u53f0\u5927\u91ab\u9662\u653e\u5c04\u6cbb\u7642\u90e8\u5982\u4f55\u5728\u6d32\u969b\u7db1\u8def\u7684\u4e00\u500b\u7bc0\u9ede\uff0c\uff0c\u5efa\u7acb\u8d77\u4e00\u500b\u5168\u7403\u8cc7\u8a0a\u7db1\u4f3a\u670d\u5668\uff0c\u4f7f\u9019\u5957\u8cc7\u8a0a\u7cfb\u7d71\u61c9\u7528\u65bc\u764c\u75c7\u4e4b\u8cc7\u8a62\u670d\u52d9\u4e0a\u3002", "e": "Internet has grown exuberantly, almost exponentially in the 1990s. One of the application of Internet--World-Wide-Web, owing to its friendly operational interface, shows explosively development. \nThis article reviewed how the staffs of Department of Radiation Oncology in National Taiwan University Hospital setup a World-Wide-Web server on the Internet in the purpose on cancer consultation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-357-361-a", "title": "\u764c\u75c5\u653e\u7642\u6280\u8853\u7684\u91cd\u8981\u767c\u5c55\u65b9\u5411\uff0d\u7121\u5275\u50b7\u624b\u8853", "keywords": "\u7121\u5275\u50b7\u624b\u8853;\u52a0\u99ac\u5200;\u7126\u76ae\u6bd4;\u5feb\u4e2d\u5b50\u6cbb\u7642\u6a5f;\u8fd1\u8ddd\u5f8c\u88dd\u4e2d\u5b50\u6cbb\u7642\u6a5f;\u8cea\u5b50\u6cbb\u7642\u6a5f Non-traumatic surgery;Gamma knife;Focal skin dose ratio;Fast neutron accelerator;Neutron brachytherapy machine;Proton therapy cyclotron", "c": "\u5916\u79d1\u7684\u6700\u65b0\u767c\u5c55\u662f\u4f4e\u5275\u50b7\u624b\u8853\u3002\u73fe\u4ee3\u91ab\u5b78\u653e\u5c04\u7dda\u6cbb\u7642\u764c\u75c5\u7684\u767c\u5c55\uff0c\u5be6\u969b\u4e0a\u662f\u7121\u5275\u50b7\u624b\u8853\u3002\u745e\u5178Elekta\u516c\u53f8\u751f\u7522\u7684\u52a0\u99ac\u5200\uff0c\u5176\u7126\u76ae\u6bd4\u70ba100:1\uff0c\u6df1\u5733\u5967\u6c83\u516c\u53f8\u751f\u7522\u65cb\u8f49\u5f0f\u52a0\u99ac\u5200\uff0c\u7126\u76ae\u6bd4\u81ea100:l\u6539\u5584\u70ba500:1\u3002\u5967\u6c83\u516c\u53f8\u6b63\u5728\u7814\u88fd\u5168\u8eab\u7684\u52a0\u99ac\u5200\u548cX\u5200\uff0c\u90fd\u662f\u7121\u5275\u50b7\u624b\u8853\u7684\u5229\u5668\u3002\u5967\u6c83\u516c\u53f8\u6b63\u5728\u7814\u767c\u4e2d\u7684\u653e\u5c04\u6cbb\u7642\u6a5f\u5c1a\u6709\u65cb\u8f49\u805a\u7126\u5feb\u4e2d\u5b50\u6cbb\u7642\u6a5f\uff0c\u7126\u76ae\u6bd4\u53ef\u905460:l\uff0c\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u7cfb\u7d71\uff0c(\u4e0a\u6a19\u3000252)\u9272\u8fd1\u8ddd\u5f8c\u88dd\u4e2d\u5b50\u6cbb\u7642\u6a5f\uff1b200 Me V\u8cea\u5b50\u6cbb\u7642\u6a5f\u7b49\uff0c\u4f7f\u7121\u5275\u50b7\u624b\u8853\u9010\u6b65\u666e\u53ca\u3002", "e": "The recent trend of surgical development is minimal traumatic operation. However, moden cancer radiotherapeutic development is non-traumatic surgery, such as radiosurgery with Sweden mode (Elekta) gamma knife or rotation gamma knife mode by OUR Company of China, the focal skin dose ratio improves from 100:1 to 500:1. Other radiotherapy equipment under developed by OUR Company include whole body gamma knife, X knife, focal rotation fast neutron accelerator, boron neutron capture treatment system, afterloading neutron brachytherapy machine, 200 MeV proton therapy cyclotron etc."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199512-2-4-363-367-a", "title": "\u9272\uff0d252\u4e2d\u5b50\u8fd1\u8ddd\u96e2\u6cbb\u7642", "keywords": "(\u4e0a\u6a19 252)\u9272;\u4e2d\u5b50\u8fd1\u8ddd\u96e2\u6cbb\u7642 Californium-252;Neutron brachytherapy", "c": "(\u4e0a\u6a19\u3000252)\u9272\u662f\u552f\u4e00\u653e\u5c04\u4e2d\u5b50\u7684\u4eba\u9020\u653e\u5c04\u6027\u540c\u4f4d\u5143\u7d20\uff0c\u5728\u81e8\u5e8a\u4e0a\u7528\u4f5c\u77ed\u8ddd\u96e2\u653e\u7642\u3002(\u4e0a\u6a19\u3000252)\u9272\u7684\u534a\u8870\u671f\u662f265\u5e74\uff0c3\uff05\u7684\u8870\u8b8a\u70ba\u81ea\u7136\u88c2\u8b8a\uff0c\u767c\u51fa\u03b3\u548c\u4e2d\u5b50\u5c04\u7dda\uff0c\u5176\u5e73\u5747\u80fd\u91cf\u70ba2.35 MeV\uff0cn/\u03b3\u5c04\u7dda\u5291\u91cf\u6bd4\u70ba840/740 cGy, OER\u503c\u70bal.4~l.9\uff0c\u96a8\u5291\u91cf\u7387\u52a0\u5927\u800c\u5347\u9ad8\u3002(\u4e0a\u6a19\u3000252)\u9272\u7684RSE\u503c\u70ba3.5~7.5\uff0c\u5291\u91cf\u7387\u4f4e\uff0c\u5247RBE\u9ad8\u3002\u7531\u65bc(\u4e0a\u6a19\u3000252)\u9272\u767c\u51fa\u4e2d\u5b50\u548c\u52a0\u99ac\u5c04\u7dda\uff0c\u81e8\u5e8a\u4f7f\u7528\u6642\uff0c\u5c0d\u5de5\u4f5c\u4eba\u54e1\u7684\u8f3b\u5c04\u5c4f\u853d\u4fbf\u986f\u5f97\u7279\u5225\u91cd\u8981\uff0c\u904e\u53bb\u4e8c\u5e74\u672b\u6587\u737b\u7684\u81e8\u5e8a\u7d93\u9a57\u986f\u793a\uff0c (\u4e0a\u6a19\u3000252)\u9272\u53ef\u7528\u4f5c\u5b50\u5bae\u9838\u764c\u8154\u5167\u6cbb\u7642\uff0c\u901a\u5e38\u5408\u4f75\u9ad4\u5916X\u7dda\u5168\u9aa8\u76c6\u8154\u7167\u5c04\u6216\u624b\u8853\u5207\u9664\uff0c\u5c40\u90e8\u816b\u7624\u63a7\u5236\u7387\u53ef\u905477\u81f394\uff05\u30022 \u7d39\u92d2\u4ea6\u53ef\u7528\u65bc\u820c\u764c\u7684\u53cd\u5411\u904b\u52d5\u633f\u690d\u6cbb\u7642\uff0c\u5c0d\u65e9\u671f\u820c\u764c\u7684\u5fa9\u767c\u7387\u70ba6%, \u665a\u671f\u820c\u764c\u5fa9\u767c\u7387\u7d04\u4e09\u5206\u4e4b\u4e00\uff0c(\u4e0a\u6a19\u3000252)\u9272\u4ea6\u53ef\u7528\u65bc\u4e73\u764c\u3001\u982d\u9838\u764c\u6216\u76f4\u8178\u764c\u7684\u633f\u690d\u6cbb\u7642\uff0c\u77ed\u671f\u816b\u7624\u6d88\u9000\u7387\u905475\u81f3100%\uff0c\u5fa9\u767c\u738714\u81f325%\u3002", "e": "(superscript 525) Californium is the only one man-made radiosotope emitted neutrons which can be used clinically for brachytherapy. The halflife of (superscript 525)Cf is 2.65 years, 3% of decay are natural nuclear fission emitting gamma and neutron radiations, the mean energy of radiation is 2.35 MeV, n/\u03b3 dose ratio is 840/740 cGy. OER value is 1.4~4.9, it is higher when the dose rate is higher. The RBE value of 252Cf vary between 3.5 and 7.5, it is higher when dose rate is lower. Since 252Cf emits both gamma and neutron radiations, radiation protection for the personnel become very important. Literature reviewed indicated that intracavitary brachytherapy with 252Cf combined with external beam whole pelvis irradiation or plus surgery provided 77 to 94% local tumor control rate. \nImplantation of 255Cf in early as well advanced tongue cancer showed 6% and 33% recurrent rates respectively. 252Cf implantation could be used for cancer of breast, head and neck and rectum etc, the immediate tumor regression rate could be as high as 75 to 100%, the tumor recurrent rate varied between 14 to 25%."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-181-186-a", "title": "\u7dad\u751f\u7d20\u4e19\u5c0d\u9f37\u9f20\u653e\u5c04\u7dda\u53e3\u8154\u9ecf\u819c\u708e\u4fee\u5fa9\u8207\u9810\u9632\u6548\u61c9\u4e4b\u7814\u7a76", "keywords": "\u7dad\u751f\u7d20\u4e19;\u653e\u5c04\u7dda\u9ecf\u819c\u708e;\u5291\u91cf\u8abf\u6574\u56e0\u5b50 Vitamin C;Radiation mucositis;Dose modification factor", "c": "\u672c\u7814\u7a76\u4e4b\u76ee\u7684\u5728\u89c0\u5bdfBALB/c\u9f37\u9f20\u53e3\u8154\u9ecf\u819c\u63a5\u53d7\u653e\u5c04\u7dab\u7167\u5c04\u5f8c\u4e4b\u75c5\u7406\u8b8a\u5316\uff0c\u5e77\u5206\u6790\u7dad\u751f\u7d20\u4e19\uff08\u6297\u58de\u8840\u9178\uff0cascorbic acid. AA\uff09\u6539\u8b8a\u9019\u4e9b\u75c5\u7406\u8b8a\u5316\u4e4b\u7a0b\u5ea6\uff0c\u4ee5\u9032\u4e00\u6b65\u77ad\u89e3\u5728\u6d3b\u9ad4\u60c5\u51b5\u4e0b\uff0cAA\u8207\u653e\u5c04\u7dda\u9ecf\u819c\u708e(radiation mucositis)\u4e4b\u95dc\u4fc2\u3002\u7d9c\u5408\u5404\u7d44\u9f37\u9f20\u4e4b\u75c5\u7406\u8b8a\u5316\u53ef\u77e5\uff0c\u63a5\u53d7\u55ae\u6b21\u7167\u5c04850cGy(2000cGy/10 Fr/2 wks)\u81f3 1050cGy (3000 cGy/15 Fr/3ks)\u4e4b\u9f37\u9f20\uff0c\u53e3\u8154\u5207\u7247\u5167\u51fa\u73fe\u8f15\u5fae\u591a\u5f62\u6838\u7d30\u80de(polymor-phonuclear cells, PMN)\u6d78\u6f64\u3002\u4e0a\u76ae\u90e8\u4efd\u812b\u843d\u53ca\u4e0a\u76ae\u4e0b\u6c34\u6ce1\u5f62\u6210\u57281250cGy (4000cGy/20 Fr/4 wks)\u7167\u5c04\u91cf\u6642\u5f62\u6210\u3002\u800c\u80de\u6838\u5167\u7a7a\u6ce1\u53ca\u56b4\u91cd\u8840\u7ba1\u5468\u570d\u53ca\u808c\u7d30\u80de\u9593\u5145\u8840\u5728\u7167\u5c04\u91cf\u9054\u52301579cGy(5000 cGy/25 Fr/5 wks)\u958b\u59cb\u51fa\u73fe\u3002\u81f3\u65bc\u66f4\u56b4\u91cd\u7684\u4e0a\u76ae\u5168\u90e8\u812b\u843d\u5247\u662f\u5728\u7167\u5c04\u91cf\u9054\u52301772cGy(6000cGy/30 Fr/6 wks) \u958b\u59cb\u51fa\u73fe\u3002\u6240\u6709\u9019\u4e9b\u653e\u5c04\u7dab\u7167\u5c04\u5f15\u8d77\u7684\u75c5\u7406\u8b8a\u5316\u7a0b\u5ea6\u5982\u679c\u5728\u7167\u5c04\u524d\u52a0\u5165AA\u5f8c\u90fd\u6703\u660e\u986f\u6e1b\u8f15\u3002\u672c\u7814\u7a76\u7d50\u679c\u4ea6\u986f\u793a\uff1aAA\u5c0d\u9f37\u9f20\u53e3\u8154\u9ecf\u819c\u53ca\u5176\u4e0b\u5c64\u808c\u8089\u7d50\u7de0\u7d44\u7e54\u80fd\u51cf\u5c11\u8f3b\u5c04\u7167\u5c04\u7523\u751f\u4e4b\u767c\u708e\u6548\u61c9\uff0c\u5176\u5291\u91cf\u8abf\u6574\u56e0\u5b50(dose modification factor: DMF)\u503c\u7bc4\u570d\u75311.28\u81f31.66\u3002", "e": "The histological effects of radiations on mouse oral mucosa and its modification by ascorbic acid were studied. At a single dose range between 850cGy (equivalent to 2000cGy/10 Fr/2 wks) and 1050cGy (equivalent to 3000cGy/15 Fr/3 wks), the pathological change in oral mucosa of the BALB/c mice showed mild degree infiltration of polymorphonuclear cells (PMN). Partial epidermal drop and subepidermal blisters formation were noted at 1250cGy (4000cGy/20 Fr/4 wks).\nNuclear vacuolization, severe perivascular and intermuscle cell congestion were noted after exposure to a dose of 1579cGy (5000cGy/ 25 Fr/S wks) irradiation. Furthermore, complete drop of the keratin layer was noted after 1772cGy (6000cGy/30 Fr/6 wks). All these histological effects were ameliorated when ascorbic acid was added before irradiation. It also showed that AA reduced the severity of radiation inflammation in the oral mucosa, submucosal muscle and connective tissues of mice, and the modification factor of range from 1.28 to 1.66."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-187-192-a", "title": "Curative Radiotherapy for Vocal Cord Carcinoma", "keywords": "\u5589\u764c;\u653e\u5c04\u6cbb\u7642 Vocal cord carcinoma;Radiotherapy", "c": "\u653e\u5c04\u6cbb\u7642\u5c0d\u5589\u764c\u60a3\u8005\u4e0d\u50c5\u6709\u597d\u7684\u5c40\u90e8\u6cbb\u7642\u6548\u679c\uff0c\u5c24\u5176\u80fd\u826f\u597d\u4fdd\u6301\u60a3\u8005\u7684\u8aaa\u8a71\u529f\u80fd\u3002\u5f9e1983\u5e742\u6708\u52301992\u5e7412\u6708\uff0c\u5171\u670975\u4f4d\u5589\u764c\u60a3\u8005\u5728\u53f0\u4e2d\u69ae\u7e3d\u55ae\u7368\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d\u7537\u602769\u4f4d\uff0c\u5973\u60276\u4f4d\uff0c\u5e73\u5747\u5e74\u9f6164\u6b72\u3002\n75\u4f4d\u60a3\u8005\u4e2d\uff0c40\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c1\u671f\uff0c22\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c2\u671f\uff0c8\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c3\u671f\uff0c\u548c5\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c4\u671f\u3002\u53e6\u591675\u4e94\u4f4d\u60a3\u8005\u4e2d\u67095\u4f4d\u6709\u9838\u90e8\u6dcb\u5df4\u8f49\u79fb\uff0c\u5176\u4e2d\u6709\u4e00\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c1\u671f\uff0c\u4e00\u4f4d\u539f\u4f4d\u662f\u816b\u7624\u7b2c2\u671f\uff0c\u4e00\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c3\u671f\uff0c\u4e8c\u4f4d\u662f\u539f\u4f4d\u816b\u7624\u7b2c4\u671f\u3002\n\u5927\u90e8\u5206\u60a3\u8005\u653e\u5c04\u6cbb\u7642\u662f\u4ee5\u6bcf\u65e5200\u81f3220cGy\uff0c\u5169\u5074\u5c0d\u7167\uff0c\u7e3d\u5291\u91cf\u72326,000\u81f36,600cGy\u3002\u67098\u4f4d\u60a3\u8005\u662f\u4ee5\u6bcf\u65e5\u653e\u5c04\u6cbb\u7642\u5169\u6b21\uff0c\u6bcf\u6b21150\u81f3170cGy\uff0c\u5169\u5074\u5c0d\u7167\uff0c\u7e3d\u5291\u91cf5,800\u81f37,400cGy\u3002\u4ee5\u53ca\u53e6\u4e00\u4f4d\u60a3\u8005\u662f\u4ee5\u5169\u6bb5\u5f0f\u653e\u5c04\u6cbb\u7642\uff0c\u6bcf\u65e5\u662f\u4ee5300cGy\uff0c\u5169\u5074\u5c0d\u7167\uff0c\u6bcf\u4e00\u968e\u6bb5\u7167\u5c0410\u6b21\uff0c\u4e2d\u9593\u4f11\u60a3\u5169\u9031\uff0c\u7e3d\u5291\u91cf\u5171\u70ba6,000cGy\u3002\n\u5e7e\u4e4e\u6240\u6709\u60a3\u8005\u90fd\u80fd\u5f88\u5feb\u5f9e\u653e\u5c04\u6cbb\u7642\u6025\u6027\u53cd\u61c9\u4e2d\u6062\u5fa9\uff0c\u9664\u4e86\u4e00\u4f4d\u60a3\u8005\u6cbb\u7642\u5f8c\u5169\u500b\u6708\u5167\u767c\u751f\u56b4\u91cd\u8072\u5e36\u6d6e\u816b\uff0c\u53ca\u53e6\u5169\u4f4d\u60a3\u8005\u5728\u6cbb\u7642\u6700\u5f8c\u5169\u9031\u56e0\u80ba\u764c\u904e\u901d\u3002\n\u7d93\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u767c\u8072\u529f\u80fd\u4fdd\u7559\u7387\u723296%\u3002\u539f\u4f4d\u816b\u7624\u7b2c\u4e00\u671f5\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba86%\uff0c\u7b2c\u4e8c\u671f\u70ba80%,\u7b2c\u4e09\u671f\u70ba75%\uff0c\u800c\u7b2c\u56db\u671f\u60a3\u8005\u90fd\u572818\u500b\u6708\u5167\u904e\u901d\uff0c\u5176p\u503c\u5c0f\u65bc0.001\u3002\u5c0d\u65bc\u7121\u6dcb\u5df4\u8f49\u79fb\u4e4b\u60a3\u80055\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\u70ba82%\uff0c\u800c\u6709\u6dcb\u5df4\u8f49\u79fb\u4e4b\u60a3\u8005\u90fd\u572830\u500b\u6708\u5167\u904e\u901d\uff0c\u5176p\u503c\u5c0f\u65bc0.001\u3002\u56e0\u6b64\u539f\u4f4d\u816b\u7624\u7b2c\u56db\u671f\u8207\u6709\u6dcb\u5df4\u8f49\u79fb\u4e4b\u60a3\u8005\u7684\u9810\u5f8c\u5341\u5206\u5dee\u3002\u53e6\u5916\u91dd\u5c0d\u6027\u5225\u548c\u5e74\u9f61\u5340\u5206\u4f86\u63a2\u8a0e\u60a3\u80055\u5e74\u7121\u75c5\u5b58\u6d3b\u7387\uff0c\u5247\u7121\u660e\u986f\u5dee\u5225\u3002\n5\u4f4d\u63a5\u53d7\u6bcf\u65e5\u653e\u5c04\u6cbb\u7642\u5169\u6b21\u7684\u65e9\u671f\u60a3\u8005\uff0c\u7d93\u6cbb\u7642\u5f8c\uff0c\u76ee\u524d\u8ffd\u8e2a\u5169\u5e74\u4ee5\u4e0a\uff0c\u66ab\u7121\u75c5\u75c7\uff0c\u521d\u671f\u7642\u6548\u4e0d\u932f\uff0c\u4f46\u9700\u9032\u4e00\u6b65\u89c0\u5bdf\u3002", "e": "Radiotherapy for vocal cord carcinoma plays an important role in controlling the primary tumors and regional lymph nodes and preserving the voice. From February 1983 to December 1992, 75 patients with vocal cord carcinoma were treated by curative radiotherapy alone at VGHTC. 69 patients were male and 6 patients were female. The median age was 64 years old.\nThere were 40 of 75 patients with Ti, 22 with T2, 8 with T3 and 5 with T4. 5 of 75 patients had positive lymph node metastases (1 of 5 patients with TI, 1 with T2, 1 with T3, and 2 with T4).\nExternal beam radiotherapy was mostly delivered with bilateral opposing portals and a single daily fraction between 200cGy and 220cCy per day, up to a total dose between 6000cGy and 6600cGy. 8 patients were treated with bilateral opposing portals and hyperfractionation using 150cGy to 170cGy bid per day, up to a total dose between 5800cGy to 7400cGy. 1 patient was treated with bilateral opposing portals and split course technique of 300cGy per day with two weeks interval, up to 6000cGy.\nAlmost all patients recovered from acute reactions of radiotherapy soon except one patient with acute laryngeal edema in 2 months post radiotherapy and two patients with acute pneumonia due to cachexia in the last days of radiotherapy.\nThe vocal function preservation rate is about 96%. The 5-year disease- free survival rates in stage Ti, T2 and T3 were 86%, 80% and 75% respectively and T4 patients all died in 18 months. The P value is less than 0.001. The 5-year disease-free survival rate in stage N0 was 82% but N positive patients died in 30 months post radiotherapy. The P value is less than 0.001. Therefore T4 stage and N positive were obviously poorly prognostic factors. No significant differences of 5-year disease-free survival rates between male and female or younger and older age were noted and P values were 0.36 and 0.98 respectively.\n5 patients with early stage were treated by hyperfractionation radiotherapy from 1991 to 1992. They have had good local control with a minimum follow-up of 24 months but it needs more time to follow up."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-193-201-a", "title": "Results of Radiation Therapy for Regional Stage T4 Nasopharyngeal Carcinoma", "keywords": "\u9f3b\u54bd\u764c;\u653e\u5c04\u6cbb\u7642 Nasopharyngeal Carcinoma;Radiotherapy", "c": "A retrospective analysis of 142 eases of stage T4 nasopharyngeal carcinoma (NPC) treated with radiotherapy between Jan. 1970 and Dec. 1988 was undertaken. Ninety patients completed radiotherapy while 52 patients were excluded due to incomplete radiotherapy (18 pt) or systemic disease within 2 months after radiotherapy (34 pt). The mean dose given to the primary tumor was 73Gy while neck node metastasis received a dose ranging from 50Gy to 70Gy depending on nodal size. The patients were subclassified into stage T4b for skull base invasion (37pt), T4a for cranial nerve palsy (23pt) and T4bn for bone and nerve involvement (30 pt). Analysis showed that local control was associated with the number of cranial nerve involved, tumor grade and biological dose equivalent (BED). Actuarial survival was significantly influenced by tumor grade, T stage with T4b showing the best survival (5-year 49.5%), and site of tumor invasion with middle cranial fossa involvement showing a higher 5 year survival compared with posterior and middle-posterior cranial fossa involvement (48% vs. 19.6% vs. 29.2% respectively, p\uff1c0.05). The overall 5-year survival for these 90 stage T4 regional NPC patients was 56.5%, the local recurrence rate was 34.4% with a median -disease free interval of 15 months.", "e": "A retrospective analysis of 142 eases of stage T4 nasopharyngeal carcinoma (NPC) treated with radiotherapy between Jan. 1970 and Dec. 1988 was undertaken. Ninety patients completed radiotherapy while 52 patients were excluded due to incomplete radiotherapy (18 pt) or systemic disease within 2 months after radiotherapy (34 pt). The mean dose given to the primary tumor was 73Gy while neck node metastasis received a dose ranging from 50Gy to 70Gy depending on nodal size. The patients were subclassified into stage T4b for skull base invasion (37pt), T4a for cranial nerve palsy (23pt) and T4bn for bone and nerve involvement (30 pt). Analysis showed that local control was associated with the number of cranial nerve involved, tumor grade and biological dose equivalent (BED). Actuarial survival was significantly influenced by tumor grade, T stage with T4b showing the best survival (5-year 49.5%), and site of tumor invasion with middle cranial fossa involvement showing a higher 5 year survival compared with posterior and middle-posterior cranial fossa involvement (48% vs. 19.6% vs. 29.2% respectively, p\uff1c0.05). The overall 5-year survival for these 90 stage T4 regional NPC patients was 56.5%, the local recurrence rate was 34.4% with a median -disease free interval of 15 months."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-203-208-a", "title": "\u63a5\u53d7\u8f3b\u5c04\u6cbb\u7642\u4e4b\u9f3b\u54bd\u816b\u7624\u60a3\u8005\u5176\u8996\u7db1\u819c\u75c5\u8b8a\u4e4b\u8a55\u4f30", "keywords": "\u8f3b\u5c04\u6027\u8996\u7db2\u819c\u75c5\u8b8a;\u9f3b\u54bd\u816b\u7624;\u653e\u5c04\u7dab\u6cbb\u7642 Radiation Retinopathy;Nasopharyngeal tumor;Radiotherapy", "c": "\u6211\u5011\u56de\u986715\u4f4d\u9f3b\u54bd\u816b\u7624\uff0c\u7d93\u773c\u5e95\u87a2\u5149\u651d\u5f71\u8a3a\u65b7\u6709\u8f3b\u5c04\u8996\u7db1\u819c\u75c5\u8b8a\u7684\u75c5\u4eba\uff0c\u5206\u6790\u4ed6\u5011\u6240\u63a5\u53d7\u7684\u653e\u5c04\u5291\u91cf\u53ca\u76f8\u95dc\u7684\u5371\u96aa\u56e0\u5b50\u3002\n\u81ea1984\u5e74\u81f31992\u5e74\u5171\u670915\u4f4d\u75c5\u60a3\uff0826\u96bb\u773c\u775b\uff09\u88ab\u8a3a\u65b7\u6709\u8f3b\u5c04\u6027\u8996\u7db2\u819c\u75c5\u8b8a\u3002\u6f5b\u4f0f\u671f\u5f9e10\u500b\u6708\u81f372\u500b\u6708\uff0c\u4e2d\u554f\u503c\u662f24\u500b\u6708\uff0c\u5e73\u5747\u503c\u70ba23\u500b\u6708\u3002\u7d93\u5206\u6790\u8a08\u7b97\u5f8c\u5176\u6240\u63a5\u53d7\u5230\u7684\u8f3b\u5c04\u5291\u91cf\u5f9e2262cGy\u81f35963cGy\uff0c\u4e2d\u9593\u503c\u662f3658cGy\u3002\u5e73\u5747\u503c\u70ba3795cGy\u3002\u67093\u4f4d\u75c5\u4eba\u4e94\u96bb\u773c\u775b\u9664\u4e86\u8996\u7db1\u819c\u7684\u8840\u7ba1\u75c5\u8b8a\u5916\u53e6\u6709\u767d\u5167\u969c\u7684\u7523\u751f\u3002\u65bc\u9577\u671f\u7684\u8ffd\u8e64\u671f\u554f\uff0c26\u96bb\u773c\u775b\u4e2d\uff0c\u8996\u529b\u6709\u8b8a\u5316\u7684\u670915\u96bb\u773c\u775b\uff0c14\u96bb\u773c\u775b\u6709\u8996\u7db2\u819c\u75c5\u8b8a\u60e1\u5316\u7684\u60c5\u6cc1\u3002\u4e94\u4f4d\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u7684\u75c5\u4eba\u5176\u5291\u91cf\u53ca\u6f5b\u4f0f\u671f\u548c\u5176\u4ed6\u75c5\u4eba\u4e26\u7121\u986f\u8457\u5dee\u7570\u3002\u6709\u4e8c\u4f4d\u75c5\u4eba\u5f8c\u4f86\u767c\u73fe\u9ad8\u8840\u58d3\u800c\u63a5\u53d7\u5167\u79d1\u6cbb\u7642\u3002\n\u6211\u5011\u5728\u6587\u4e2d\u5c0d\u8f3b\u5c04\u8996\u7db2\u819c\u75c5\u8b8a\u7684\u8f3b\u5c04\u751f\u7269\u6a5f\u8f49\u505a\u4e00\u53ef\u80fd\u63a2\u8a0e\u5e77\u56de\u9867\u6587\u737b\u3002", "e": "With retrospective methods, 15 patients of radiation retinopathy were diagnosed by fluores. cein angiography in ophthalmology department in those patients who received radiotherapy because of nasopharyngeal tumor. We analyze the retina irradiation dose and the relative risk factors.\nFifteen patients, 26 eyes of radiation retinopathy were found from 1984 to 1992.The median latent period was 20 months with the range of 10 to 72 months and the mean was 24 months. The median retina irradiation dose was 3688cGy ranging from 2262cGy to 5963cGy and the mean was 3795cGy after retrospective treatment plan computer analyses. Three patients, 5 eyes had cataract formation in addition to the radiation retinopathy. Visual acuity change in 15 eyes and progressive retinopathy in 14 eyes were found after long term follow-up. Five patients with additional chemotherapy showed no significant difference from other patients in term of the latent period anal irradiation dose for retinopathy. Hypertension was found in two patients who took the medication in the later follow-up period.\nWe discussed the possible mechanism in radiation biology and a review of the literature."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-209-215-a", "title": "Postoperative Low Dose Single Fraction Irradiation for Prevention of Heterotopic Bone Formation after Hip Surgery", "keywords": "\u9ad6\u95dc\u7bc0;\u7570\u4f4d\u9aa8\u5316;\u653e\u5c04\u6cbb\u7642 Hip joints;Heterotopic ossification;Radiotherapy", "c": "\u9ad6\u95dc\u7bc0\u7570\u4f4d\u9aa8\u5316\u662f\u9ad6\u95dc\u7bc0\u624b\u8853\u5f8c\u5e38\u898b\u4e4b\u5e77\u767c\u75c7\uff0c\u800c\u6709\u9ad8\u5371\u96aa\u56e0\u5b50\u7684\u75c5\u60a3\u767c\u751f\u7684\u6bd4\u7387\u66f4\u9ad8\uff0c\u53ef\u9ad8\u905450%\u3002\u6240\u8b02\u9ad8\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u50f5\u76f4\u6027\u810a\u690e\u708e\u3001\u9aa8\u95dc\u7bc0\u708e\u3001\u9ad6\u95dc\u7bc0\u9aa8\u6298\u3001\u9ad6\u95dc\u7bc0\u591a\u6b21\u624b\u8853\uff0c\u7570\u4f4d\u9aa8\u5316\u4e4b\u65e2\u5f80\u6b77\u3002\u800c\u9810\u9632\u9ad8\u5371\u96aa\u7fa4\u75c5\u60a3\u624b\u8853\u5f8c\u767c\u751f\u9ad6\u95dc\u7bc0\u7570\u4f4d\u9aa8\u5316\u7684\u65b9\u6cd5\u6709\u624b\u8853\u6539\u826f\uff0c\u85e5\u7269\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642\u7b49\u4e09\u7a2e\u65b9\u5f0f\u3002\u624b\u8853\u6539\u826f\u5c1a\u672a\u8b49\u5be6\u6709\u6548\uff0c\u85e5\u7269\u6cbb\u7642\u96d6\u7136\u6709\u6548\u4f46\u9700\u9577\u671f\u670d\u7528\u4e14\u6613\u7523\u751f\u526f\u4f5c\u7528\uff0c\u7136\u800c\u653e\u5c04\u6cbb\u7642\u4e0d\u50c5\u6709\u6548\u4e14\u8017\u6642\u77ed\u800c\u7232\u81e8\u5e8a\u4e0a\u5e38\u7528\u4e4b\u65b9\u5f0f\u3002\u5f9e1989\u5e74\u81f31994\u5e74\uff0c\u81fa\u5317\u69ae\u7e3d\u5171\u6cbb\u7642\u4e8615\u4f4d\u75c5\u4eba\uff0818\u8655\u9ad6\u95dc\u7bc0\uff09\uff0c\u9019\u4e9b\u75c5\u4eba\u5305\u62ec\u4e86\u50f5\u76f4\u6027\u810a\u690e\u708e\uff0812\u4f8b\uff09\u3001\u9aa8\u95dc\u7bc0\u708e\uff081\u4f8b\uff09\u3001\u9ad6\u90e8\u9aa8\u6298\uff082\u4f8b\uff09\u3001\u9ad6\u95dc\u7bc0\u591a\u6b21\u624b\u8853\uff083\u4f8b\uff09\uff0c\u6709\u7570\u4f4d\u9aa8\u5316\u4e4b\u65e2\u5f80\u6b77\uff081\u4f8b\uff09\uff0c\u67093\u4f8b\u5371\u96aa\u56e0\u5b50\u8d85\u904e2\u500b\u4ee5\u4e0a\u3002\u901915\u4f8b\u5747\u70ba\u7537\u6027\uff0c\u5e74\u9f61\u5206\u4f48\u5f9e24\u81f370\u6b72\uff0c\u6240\u4f5c\u4e4b\u624b\u8853\u5305\u62ec\u5168\u95dc\u7bc0\u7f6e\u63db\uff0814\u8655\u95dc\u7bc0\uff09\u3001\u4eba\u5de5\u95dc\u7bc0\u4fee\u88dc\uff083\u8655\u95dc\u7bc0\uff09\u3001\u9aa8\u6298\u63a5\u5408\u8853\uff081\u8655\u95dc\u7bc0\uff09\u3001\u653e\u5c04\u6cbb\u7642\u5247\u5728\u624b\u8853\u5f8c6\u5929\u5167\u5be6\u65bd\u3002\u5229\u7528\u52a0\u99ac\u7dda\u53ca\u4e00\u5343\u842c\u4f0f\u7279X\u5149\u4ee5\u524d\u5f8c\u5c0d\u7a31\u7167\u91ce\u65bd\u4ee5\u55ae\u6b21\u7167\u5c04\uff0c\u7167\u5c04\u7bc4\u570d\u5305\u62ec\u9ad6\u81fc\uff0c\u80a1\u9aa8\u982d\u4e0a\u534a\u90e8\u53ca\u5468\u570d\u8edf\u7d44\u7e54\uff0c\u7167\u5c04\u5291\u91cf\u662f5\u62167\u683c\u96f7\u3002\u6cbb\u7642\u5f8c\u8feb\u8e644\u523066\u500b\u6708\uff0c\u671f\u9593\u67092\u8655\u9ad6\u95dc\u7bc0\u767c\u751f\u7570\u4f4d\u9aa8\u5316\uff0c\u53e6\u67091\u8655\u5df2\u767c\u751f\u7570\u4f4d\u9aa8\u5316\u4e4b\u95dc\u7bc0\u5247\u672a\u7e7c\u7e8c\u60e1\u5316\u3002\u6b64\u5916\u71211\u4f8b\u767c\u751f\u5e77\u767c\u75c7\u53ca\u7570\u4f4d\u9aa8\u5316\u5f15\u8d77\u4e4b\u529f\u80fd\u4e0d\u826f\u3002\u6211\u5011\u4e4b\u7d93\u9a57\u986f\u793a\u624b\u8853\u5f8c\u55ae\u5291\u91cf\u7167\u5c04\u5c0d\u9810\u9632\u9ad6\u95dc\u7bc0\u7570\u4f4d\u9aa8\u5316\u662f\u6709\u6548\u800c\u5b89\u5168\u7684\u6cbb\u7642\u3002", "e": "Purpose: To investigate retrospectively the effects of postoperative low-dose single fraction irradiation in prevention of ectopic bone formation after hip surgery in high-risk patients.\nMaterials and Methods: From 1989 to 1994 fifteen patients (18 hips) were treated with single-dose irradiation to hip joints after hip surgery in an attempt to prevent heterotopic bone formation. Of these patients, there were 12 patients with ankylosing spondilitis, 1 patient with osteoarthritis, 2 patients with bony fractures, 3 patients post multiple surgical procedures, and 1 patient with past history of ectopic bone formation. These patients received surgical procedures of primary total-hip arthroplasty (14 hips), revision of arthroplasty (3 hips), or open reduction of acetabular fracture (1 hip). Radiotherapy was delivered with either Cobalt-60 gamma ray (4 patients) or 10 MV X-ray (11 patients) at midplane doses of 5 or 7 Gy several hours to 6 days after operation.\nResults: New ectopic bone formation was found in 2 patients (2 hips), while 1 patient (1 hip) has stable disease, with a follow-up time from 4 to 66 months (median=31 months). Neither functional disability nor complication related to heterotopic ossification and irradiation developed.\nConclusion: Postoperative low-dose single fraction irradiation with 5 or 7 Gy is an effective and safe procedure to prevent heterotopic bone formation in high-risk patients after hip surgery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-217-225-a", "title": "Patterns of Pelvic Recurrence and Results of Salvage Treatment with Radiation Therapy for Recurrent Rectal Carcinoma", "keywords": "\u653e\u5c04\u6cbb\u7642;\u76f4\u8178\u764c\u5fa9\u767c Radiation therapy;Recurrent rectal carcinoma", "c": "\u7232\u4e86\u5c0d\u76f4\u8178\u764c\u624b\u8853\u5f8c\u5fa9\u767c\u7684\u578b\u614b\u53ca\u4f7f\u7528\u653e\u5c04\u7dab\u4f86\u4f5c\u633d\u6551\u6027\u6cbb\u7642\u7684\u6548\u679c\u53ca\u75c5\u60a3\u5b58\u6d3b\u60c5\u5f62\u6709\u6240\u77ad\u89e3\uff0c\u672c\u6587\u56de\u9867\u6027\u5206\u6790\u4e8656\u500b\u81ea1987\u5e7411\u6708\u81f31991\u5e7412\u6708\u6cbb\u7642\u7684\u75c5\u4f8b\u3002\u5fa9\u767c\u7684\u75c7\u72c0\u6216\u8868\u5fb5\u4ee5\u5c3e\u690e\u5e95\u90e8\u75bc\u75db\u6700\u5e38\u898b(66%)\uff0c\u5176\u6b21\u5247\u662f\u5c3f\u8def\u963b\u585e(45%)\u3002\u539f\u59cb\u5206\u671f\u4ee5B3\u3001C3\u6700\u591a\uff0c\u5169\u8005\u5408\u8a08\u536064%\u3002\u5fa9\u767c\u7684\u6642\u554f\u4ee5\u624b\u8853\u5f8c\u7b2c\u4e00\u5e74\u6700\u591a\u536070% , 96%\u7684\u5fa9\u767c\u767c\u751f\u5728\u624b\u8853\u5f8c\u7684\u524d\u4e09\u5e74\uff0c\u53ea\u67094%\u7684\u5fa9\u767c\u662f\u624b\u8853\u5f8c3\u5e74\u767c\u751f\u300242%\u7684\u75c5\u4f8b\u5728\u5fa9\u767c\u6642\u6709CEA\u503c\u7684\u5347\u9ad8\u3002\u816b\u7624\u7d93\u653e\u5c04\u6cbb\u7642\u5f8c\uff0c\u572838\u4f8b\u53ef\u8a55\u4f30\u75c5\u4eba\u4e2d\uff0c4\u4f8b(11%)\u9054\u5b8c\u5168\u6d88\u5931\uff0c18\u4f8b(47%)\u816b\u7624\u7e2e\u5c0f\u8d85\u904e\u4e00\u534a\uff0c10\u4f8b(26%)\u816b\u7624\u7e2e\u5c0f\u672a\u9054\u4e00\u534a\uff0c6\u4f8b(16%)\u816b\u7624\u6c92\u6709\u53cd\u61c9\u3002\u5c40\u90e8\u75bc\u75db\u6539\u5584\u65b9\u9762\uff0c\u572831\u4f8b\u55ae\u7368\u653e\u5c04\u6cbb\u7642\u4e14\u4ee5\u5c40\u90e8\u75bc\u75db\u8868\u73fe\u8005\uff0c10\u4f8b(32%)\u81ea\u89ba\u6709\u826f\u597d\u6539\u5584\uff0c14\u4f8b(45%)\u81ea\u89ba\u6709\u6539\u5584\u4f46\u75bc\u75db\u4ecd\u5b58\u5728\uff0c7\u4f8b(23%)\u81ea\u89ba\u6c92\u6709\u6539\u5584\u3002\u6574\u9ad4\u5b58\u6d3b\u7387\u70ba2\u5e7419%,3\u5e747%\uff0c\u5148\u884c\u624b\u8853\u518d\u653e\u5c04\u6cbb\u7642\u548c\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u5169\u8005\u5b58\u6d3b\u7387\u5e77\u6c92\u6709\u7d71\u8a08\u4e0a\u7684\u5dee\u5225(12%\u82075%)\uff0c\u6709\u9451\u65bc\u76f4\u8178\u764c\u624b\u8853\u5f8c\u5fa9\u767c\u7684\u4e0d\u826f\u9810\u5f8c\uff0c\u6cbb\u7642\u7684\u76ee\u6a19\u61c9\u8457\u624b\u65bc\u5c40\u90e8\u5fa9\u767c\u7684\u9810\u9632\u6cbb\u7642\u3002", "e": "Patterns of pelvic recurrence and results of salvage with radiation therapy in 56 patients with postsurgical recurrent rectal carcinoma treated between November 1987 and December 1991 were retrospectively analyzed. The common presenting symptoms/signs were sacral pain (66%), following by obstructive uropathy (45%). In modified Astler-Coller classification, stage B3 and C3 are the most common initial stage of the patients, comprising 64% of cases. Presacral area was the most common site of recurrence (30%). 70% of patients recurred at the first year of surgery. Cumulative rate of recurrence at 3 years was 96%. Only 4% of patients recurred beyond 3 years after surgery. 42% of cases had CEA elevation at the time of recurrence. There were 38 patients evaluable for tumor response to radiation therapy alone. Of them, 4 cases (11%) achieved complete tumor regression, 18 cases (47%) had partial tumor regression, 10 cases (26%) had tumor regression less than 50%, and 6 cases (16%) had no objective tumor regression. In 31 ItT-alone patients with sacral pain, 10 cases (32%) achieved good pain relief, 14 cases (45%) achieved moderate pain relief, and 7 cases (23%) had no pain relief at all. Overall survival in 56 patients was 19% at 2years, and 7% at 3 years. No statistically significant difference of survival existed between surgery plus radiation therapy and radiation-alone group. In viewing the grave outcome of recurrent patients, treatment strategy must be aimed at prevention of local recurrence for high risk group of patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-227-234-a", "title": "Postoperative Radiotherapy for Malignant Gliomas", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;\u9000\u5316\u661f\u7d30\u80de\u7624;\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624 Radiation therapy;Anaplastic astrocytoma;Glioblastoma multiforme", "c": "\u81ea1988\u5e741\u6708\u81f31993\u5e7410\u6708\uff0c\u5171\u670945\u4f4d\u7d93\u7d44\u7e54\u75c5\u7406\u5207\u7247\u8b49\u5be6\u4e4b\u8166\u90e8\u60e1\u6027\u795e\u7d93\u81a0\u7624\u60a3\u8005\u65bc\u672c\u79d1\u63a5\u53d7\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u672c\u6587\u5206\u6790\u76f8\u95dc\u4e4b\u9810\u5f8c\u56e0\u5b50\uff0c\u767c\u73fe\u8853\u524d\u4e4b\u75c5\u7076\u7232\u55ae\u4e00\u6216\u591a\u767c\uff0c\u624b\u8853\u7bc4\u570d\uff0c\u53ca\u8853\u5f8c\u4e4b\u884c\u7232\u72c0\u614b(Karnofsky performance status)\u7686\u6703\u5f71\u97ff\u6cbb\u7642\u4e4b\u9810\u5f8c\u3002\u800c\u6cbb\u7642\u4e4b\u7d50\u679c\u7b2c\u4e09\u7d1a\u60e1\u6027\u795e\u7d93\u81a0\u7624\uff08\u9000\u5316\u661f\u7d30\u80de\u7624\uff09\u4e4b\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba11.9\u500b\u6708\uff0c\u7b2c\u56db\u7d1a\u60e1\u6027\u795e\u7d93\u81a0\u7624\uff08\u591a\u5f62\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624\uff09\u4e4b\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba11.5\u500b\u6708\u3002", "e": "From January 1988 to October 1993, forty-five patients with histologically confirmed intracranial malignant gliomas were treated with post-operative radiation therapy in our department. They were subjected to this analysis according to the extent of surgery, postoperative Karnofsky performance status, age, histology grading, sex, radiation doses, and presence or absence of seizures. There were 26 males and 19 females between 11 and 67 years of age. The median survival for patients with anaplastic astrocytoma and glioblastoma multiforme was 11.9 and 11.5 months, respectively. The postoperative Karnofsky performance status, extent of surgery, and the multiplicity of lesions were identified as significant prognostic factors."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-235-242-a", "title": "Study on Radiation Safety of High Dose Rate Multiple Cobalt-60 Sources Teletherapy Machine", "keywords": "\u805a\u7126\u7167\u5c04;\u653e\u5c04\u7dab\u624b\u8853;\u52a0\u99ac\u5200 Focusing irradiation;Radiosurgery;Gamma Knife", "c": "\u591a\u5c04\u6e90\u9ad8\u5291\u91cf\u9237\u516d\u5341\u9060\u9694\u805a\u7126\u6cbb\u7642(stereotactic focusing irradiation)\u662f\u5728X\u5c04\u7dda\u7acb\u9ad4\u5b9a\u4f4d\u4e0b\uff0c\u4ee5\u591a\u5c04\u675fX\u5149\u6216\u52a0\u99ac\u5c04\u7dab\u96c6\u4e2d\u7167\u5c04\u75c5\u7076\u90e8\u4f4d\u7684\u653e\u5c04\u7dab\u6cbb\u7642\u6280\u8853\u4ea6\u7a31\u653e\u5c04\u7dab\u624b\u8853(radiosurgery)\u3002Gamma Unit \uff08\u4ea6\u7a31\u70baGamma Knife\uff09\u70ba\u5177\u6709201 \u9846\u9237\u516d\u5341\u8f3b\u5c04\u6e90\u4e4b\u805a\u7126\u653e\u5c04\u6cbb\u7642\u6a5f\uff0c\u5728\u745e\u5178\u5df2\u767c\u5c55\u591a\u5e74\uff0c\u8fd1\u5341\u5e74\u4f86\u76f8\u7e7c\u5728\u7f8e\u65e5\u767c\u5c55\u3002\u56e0201\u9846\u9ad8\u6d3b\u6027\u5f3a\u5ea6\u5c04\u6e90\u5177\u65b0\u7642\u6cd5\u53ca\u6280\u8853\u4e4b\u9237\u516d\u5341\u6cbb\u7642\u6a5f\uff0c\u5176\u69cb\u9020\u3001\u5b89\u88dd\u3001\u5c04\u675f\u65b9\u5411\u3001\u53ef\u80fd\u7684\u8f3b\u5c04\u6ef2\u6f0f\u8207\u50b3\u7d71\u7684\u9237\u516d\u5341\u9060\u9694\u6cbb\u7642\u6a5f\u6709\u6240\u4e0d\u540c\uff0c\u570b\u5167\u5c1a\u672a\u6709\u6b64\u7d93\u9a57\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u70ba\u91dd\u5c0d\u6b64\u7279\u6b8a\u653e\u5c04\u6cbb\u7642\u8a2d\u5099\u65bc\u6cbb\u7642\u5ba4\u4e2d\u8f3b\u5c04\u5b89\u5168\u5c4f\u853d\u9632\u8b77\u4e4b\u8a55\u4f30\u53ca\u6ef2\u6f0f\u4e4b\u5be6\u6e2c\uff0c\u5efa\u7acb\u8f3b\u5b89\u54c1\u7ba1\u4e4b\u8cc7\u6599\uff0c\u4ee5\u589e\u52a0\u5de5\u4f5c\u4eba\u54e1\u3001\u75c5\u4eba\u53ca\u966a\u4f34\u5bb6\u5c6c\u4e4b\u5b89\u5168\u6027\u3002\u6211\u5011\u4f7f\u7528Laksell Gamma Unit (B\u578b)\u5177\u56db\u5957\u4e0d\u540c\u5927\u5c0f\u3001\u53ef\u66f4\u63db\u4e4b\u6e96\u76f4\u5100(collimator)\u982d\u76d4\u3001\u5404\u5225\u4e4b\u6e96\u76f4\u5100\u6813(plug)\u53ca\u4e0d\u540c\u4e4b\u5075\u6aa2\u5100\u5305\u62ec\u6e38\u96e2\u8154\u3001\u6c1f\u5316\u92f0\u71b1\u87a2\u5149\u5291\u91cf\u8a08\u8b80\u7247\u3001\u9a57\u8b49\u7247\u3001\u805a\u82ef\u4e59\u70ef(polystyrene)\u7403\u5f62\u5047\u9ad4\uff0c\u5229\u7528\u5075\u6aa2\u5100\u4f86\u91cf\u89d2\u5ea6\u53ca\u6cbb\u7642\u5ba4\u4e0d\u540c\u5340\u57df\u7684\u5438\u6536\u5291\u91cf\u53ca\u6cbb\u7642\u5ba4\u5916\u7684\u66dd\u9732\u91cf\uff0c\u65bc\u6cbb\u7642\u5ba4\u5916\u570d\u3001\u4e0a\u3001\u4e0b\u5340\u57df\u7d93\u6e2c\u91cf\u986f\u793a\u8f3b\u5c04\u66dd\u9732\u91cf\u7686\u7232\u80cc\u666f\u503c\u5747\u4e8e\u570b\u969b\u8f3b\u5c04\u9632\u8b77\u7d44\u7e54(NCRP) 49\u865f\u5831\u544a\u4e4b\u8981\u6c42\u503c\u7684\u7bc4\u570d\u5167\u3002\u6b64\u6210\u679c\u9664\u63d0\u4f9b\u672c\u4e2d\u5fc3\u9075\u5faa\u5ef6\u7528\u5916\uff0c\u672a\u4f86\u4ea6\u53ef\u4f9b\u570b\u5167\u5176\u4ed6\u91ab\u9662\u6dfb\u88dd\u985e\u4f3c\u8a2d\u5099\u53c3\u8003\u3002", "e": "Stereotactic focusing irradiation (radiosurgery) by applying multiple beam from linear accelerator or multiple cobalt sources has been used in the treatment of brain tumors. Gamma Unit (Gamma Knife) containing 201 cobalt sources has been developed and used in Sweden for decades and it also has gradually become popular in the treatment of deep-located brain tumors or abnormalities in the recent 10 years. Owing to the high activity of its 201 cobalt sources, the internal structure, installation, beam direction, possible radiation leakage and operations of this new treatment modality and techniques of Gamma Unit are quite different from those of traditional cobalt teletherapy machines. So far, there is no such therapeutic experience in Taiwan. This study is to set up the quality assurance program and to evaluate our own data about radiation protection, shielding, possible radiation leakage and measurement to increase the radiation safety for patients as well as staffs. Laksell Gamma Unit (Model B) with 4 different sized interchangable collimator helmets, individual collimator plugs and different detector including ion chambers, LiF thermoluminescent dosimeter chips, verification films, spherical polystyrene phantom and survey meters were used for exposure and absorbed dose measurement, The radiation leakage measurements around, above and beneath the treatment room were background readings which were below the limits established by NCRP Report 49. This study will provide not only the data and rules to follow for the radiation safety in our center, but also the reference data for other hospitals when they install similar facilities in the coming days."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-243-260-a", "title": "The Role of Epstein-Barr Virus Infection and the Immunocompetence of Patients with Nasopharyngeal Cancer", "keywords": "EB\u75c5\u6bd2;\u9f3b\u54bd\u764c;\u4ecb\u767d\u7d20;\u514d\u75ab\u80fd\u529b EBV;NPC;Interleukins;Immunocomprimise", "c": "\u9f3b\u54bd\u764c\u60a3\u8005\u8840\u6e05\u4e2d\u5c0dEB\u75c5\u6bd2IgA\u6ef4\u5ea6\u666e\u904d\u5347\u9ad8\uff0c\u800c\u4e14\u764c\u5de2\u5167\u53ca\u9644\u8fd1\u6dcb\u5df4\u7d30\u80de\u6d78\u6f64\u5927\u91cf\u589e\u52a0\u3002\u53ef\u662f\u75c5\u4eba\u7684\u514d\u75ab\u529b\u537b\u53cd\u800c\u8870\u9000\u3002\n\u56e0\u70ba\u4ecb\u767d\u7d20\u5341\u865f(IL-10)\u6709\u58d3\u6291\u7d30\u80de\u6027\u514d\u75ab\u53cd\u61c9\uff08\u4f8b\u5982\u6bba\u624b\u7d30\u80de\u53ca\u541e\u566c\u7d30\u80de\uff09\uff0c\u537b\u63d0\u6607\u9ad4\u6db2\u6027\u514d\u75ab\u53cd\u61c9\uff08\u4f8b\u5982\u6297\u9ad4\u7684\u7522\u751f\uff09\u7684\u4f5c\u7528\uff0c\u800cEB\u75c5\u6bd2\u665a\u671f\u57fa\u56e0BCRF 1\u8207\u4ecb\u767d\u7d20\u5341\u865f\u6709\u76f8\u4f3c\u7684\u57fa\u56e0\u5e8f\u5217\uff08\u53c8\u7a31vIL-10\uff09\uff0c\u4e5f\u53ef\u80fd\u5177\u6709\u76f8\u4f3c\u7684\u529f\u80fd\u3002\u518d\u8005\u53ef\u6eb6\u6027\u4ecb\u767d\u7d20\u4e8c\u865f\u53d7\u9ad4(IL-2R)\u4e5f\u53ef\u80fd\u58d3\u6291\u7d30\u80de\u6027\u514d\u75ab\u53cd\u61c9\uff0c\u56e0\u6b64\uff0c\u672c\u6587\u5c31\u91dd\u5c0d\u9019\u4e9bEB\u75c5\u6bd2\u611f\u67d3\u8207\u9f3b\u54bd\u764c\u75c5\u4eba\u7684\u514d\u75ab\u529b\u7b49\u554f\u984c\u63d0\u51fa\u4e00\u4e9b\u6211\u5011\u7684\u770b\u6cd5\uff0c\u85c9\u8457\u5206\u6790\u8207EB\u75c5\u6bd2\u6709\u95dc\u7684\u75be\u75c5\uff0cEB\u75c5\u6bd2\u7684\u81f4\u764c\u6a5f\u8f49\uff0c\u7d30\u80de\u8207\u75c5\u6bd2\u7684\u76f8\u4e92\u4f5c\u7528\uff0c\u7d30\u80de\u57f9\u990a\u7684\u6a21\u5f0f\uff0c\u75c5\u6bd2\u56e0\u7d20\u8207\u5176\u4ed6\u81f4\u75c5\u56e0\u7d20\u7684\u4f5c\u7528\uff0c\u9032\u800c\u8a0e\u8ad6\u75c5\u6bd2\u5728\u764c\u7d30\u80de\u4e2d\u7a76\u7adf\u662f\u6f5c\u4f0f\u6027\u611f\u67d3\u6216\u662f\u518d\u6fc0\u6d3b\u611f\u67d3\uff0c\u4e5f\u7531\u6b64\u63a2\u8a0e\u75c5\u4eba\u514d\u75ab\u529b\u7684\u51cf\u5f31\u548c\u75be\u75c5\u7684\u60e1\u5316\u3002\u5e0c\u671b\u80fd\u7531\u79d1\u5b78\u4e0a\u7684\u89c0\u5bdf\u5e6b\u52a9\u77ad\u89e3\u75c5\u4eba\u514d\u75ab\u529b\u964d\u4f4e\u7684\u53ef\u80fd\u539f\u56e0\uff0c\u5c0d\u81e8\u5e8a\u7684\u73fe\u8c61\u6709\u66f4\u597d\u7684\u89e3\u91cb\uff0c\u5e77\u7232\u672a\u4f86\u7684\u514d\u75ab\u6cbb\u7642\u3001\u57fa\u56e0\u6cbb\u7642\u6216\u514d\u75ab\u57fa\u56e0\u6cbb\u7642\u7684\u8a2d\u8a08\uff0c\u63d0\u4f9b\u4e00\u500b\u7406\u8ad6\u57fa\u790e\u3002", "e": "Seral IgA titer to gene products of Epstein-Barr virus is prevalently elevated in patients with nasopharyngeal carcinoma, an indication of EBV infection. Pathologically, tumor infiltrating lymphocytes that could be attracted by the presence of EBY in the NPC cells also increased immensely in the neighborhood of tumor nest. In a glance, EBV seemed to induce both cellular and humoral immune response. However, the immunocompetence of patients inversely decreased following the progression of the disease.\nInterleukin-l0 (IL-l0), a potent cytokine synthesis inhibitory factor, suppresses function of T cells and NK cells ns well as that of monocytes and macrophages, the major components of cellular immune response. Besides its suppression on cellular immunity, IL-b stimulates B cells to enhance their viability, cell proliferation, class II MHC expression and immunoglobulin secretion, a hallmark of humoral immune response. Interestingly, sequence of a EBV late gene, UCIIF1, is highly homologous to that of both mouse and human IL-10(BCRF1 gene product is now designated as vIL-10). It may exert a similar function like that of JL-10. The activity of vIL-10 may explain the unusual seral phenomena and the aggregated non-functional lymphocytes surrounding the tumor nest. Anthor factor affecting the cellular immunity is the presence of soluble interleukin-2 receptor (sIL-2R) that will compete with the membrane-bound IL-2R and desensitize the immune response. With these leads, the authors will discuss the subject \u201dthe role of Epstein-Barr virus infection and the immunocompetence of patients with nasopharyngeal cancer\u201d in the following catogories: EBV-associated diseases and oncogenesis, virus-cell interaction, cell culture model, synergistic effect between viral and other risk factors, latent infection or the reactivated infection, and abrogation of immunocompetence and tumor progression. Hopefully, the discussion will delineate the plausible reason for the decreasing immunocompetence in patients with NPC and will provide a better explanation for the clinical phenomena as well as the theoretical base for the future design of immunotherapy, gene therapy and immuno-gene therapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199509-2-3-261-266-a", "title": "\u5982\u4f55\u4f7f\u7528\u6a21\u64ec\u651d\u5f71\u6a5f\u4e4b\u64cb\u5f71\u6258\u76e4(shadow tray)\u786e\u8a8d\u64cb\u584a\u4f4d\u7f6e", "keywords": "\u653e\u5c04\u6cbb\u7642\u6280\u8853;\u6a21\u51dd\u651d\u5f71\u6a5f;\u54c1\u8cea\u4fdd\u8b49 Radiotherapeutic technique;Simulator;Quality assurance", "c": "\u5728\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e0a\uff0c\u4e00\u822c\u7686\u4ee5\u7167\u91ce\u7247(portal film)\u800c\u4f86\u78ba\u8a8d\u6cbb\u7642\u4f4d\u7f6e\u53ca\u9a57\u8b49\u88fd\u4f5c\u7684\u906e\u64cb\u925b\u584a\u5c0d\u91cd\u8981\u5668\u5b98\u548c\u816b\u7624\u5916\u6b63\u5e38\u7d44\u7e54\u7684\u4fdd\u8b77\u60c5\u5f62\u3002\u4f46\u7167\u91ce\u7247\u7684\u54c1\u8cea\uff0c\u5e38\u4e0d\u80fd\u6eff\u8db3\u7cbe\u78ba\u7684\u8981\u6c42\u3002\n\u672c\u79d1\u73fe\u64c1\u6709Theratron 780c\u9237\u516d\u5341\u9060\u9694\u6cbb\u7642\u6a5f\u53caToshiba LX-40A \u6a21\u64ec\u651d\u5f71\u6a5f\u3002\u4f46Toshiba LX-40A\u539f\u5ee0\u6240\u9644\u4e4b\u64cb\u5f71\u6258\u76e4\u8207\u6cbb\u7642\u6a5fSTD(source-axis-distance)\u53ca\u64cb\u584a\u6258\u76e4(block tray)\u5927\u5c0f\u4e0d\u7b26\u3002\u6545\u8a2d\u8a08\u8a02\u88fd\u7b26\u5408\u9700\u8981\u7684\u64cb\u5f71\u6258\u76e4\uff0c\u5e77\u6e2c\u91cf\u5176\u6e96\u78ba\u6027\uff0c\u767c\u73feSTD\u8207\u539f\u8a2d\u8a08\u77ed\u5c110.4cm\u3002\u6545\u65bc\u7b49\u4e2d\u5fc3\u8ef8SAD(source-axis-distance)80cm \u8655\uff0c\u9020\u6210\u5e95\u7247\u4e0a\u64cb\u584a\u9670\u5f71\u8f03\u5be6\u969b\u7d04\u653e\u59270.8%\u3002\n\u5c07\u88fd\u4f5c\u597d\u7684\u64cb\u584a\uff0c\u76f4\u63a5\u7f6e\u65bc\u6a21\u64ec\u651d\u5f71\u6a5f\u7684\u64cb\u5f71\u6258\u76e4\u4e0b\u78ba\u8a8d\uff0c\u6709\u4ee5\u4e0b\u512a\u9ede\uff1a(l)\u64cb\u584a\u4f4d\u7f6e\u6613\u78ba\u8a8d\u3002\u5373\u4f7f\u6709\u5fae\u5c0f\u8aa4\u5dee\uff0c\u7686\u6e05\u6670\u53ef\u8fa8\u3002(2)\u60a3\u8005\u53ef\u51cf\u5c11\u56e0\u64cb\u584a\u88fd\u4f5c\u932f\u8aa4\uff0c\u800c\u91cd\u8986\u7167\u91ce\u7247\u7684\u8f3b\u5c04\u66b4\u9732\u3002(3)\u78ba\u4fdd\u6cbb\u7642\u54c1\u8cea\u3002(4)\u64cd\u4f5c\u65b9\u4fbf\u3002", "e": "The primary purpose of portal film is to verify the treatment volume and shielding block position under the actual condition of treatment. However, the quality of portal film is rarely satisfactory.\nWe have a Theratron 780c Co-60 teletherapy machine and a Toshiba LX-40A simulator in our department. However, the orginal specification of the size and STD (source-tray-distance) of the shadow tray in the simulator are totally different from those of the Co-60 unit. There fore we have to modify the shadow tray to make it suitable to our daily practice. The STD of the modified shadow tray is only 0.4cm shorter than our original design. This result in about 0.8% magnifying imaging of block shadow on films in the position of SAD=80cm. With the use of the modified shadow tray, we can verify the shielding block in the simulator directly with the following advantages: (1) clear anatomical field boundaries to prevent geographic marginal miss. (2) the avoidance of the repeat portal films due to wrong position of shielding block.(3) therapeutic quality assurance. (4) user-friendly."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-95-97-a", "title": "The Interplay of Chemotherapy and Radiation Therapy in Pediatric Oncology Risks Versus Benefits", "keywords": "\u5c0f\u5152\u764c;\u653e\u5c04\u5316\u5b78\u6cbb\u7642;\u6cbb\u7642\u526f\u4f5c\u7528 Childhood cancer;Chemo-radiotherapy;Iatrogenic complications", "c": "\u8fd1\u5e74\u4f86\u91ab\u5b78\u754c\u5728\u5c0f\u5152\u764c\u75c5\u4eba\u6cbb\u7642\u4e0a\u80fd\u7372\u5f97\u9577\u8db3\u7684\u9032\u6b65\uff0c\u4e3b\u8981\u5728\u65bc\u6709\u5916\u79d1\u624b\u8853\u53ca\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u4e0a\u4e4b\u5bc6\u4e00\u5207\u914d\u5408\u3002\u96d6\u7136\u653e\u5c04\u5316\u5b78\u6cbb\u7642\u5c0d\u65bc\u624b\u8853\u5f8c\u4e4b\u6b98\u9918\u816b\u7624\u80fd\u5c04\u6cbb\u7642\u554f\u4e4b\u589e\u5f37\u4f5c\u7528\u6709\u53ef\u80fd\u5c0e\u81f4\u56b4\u91cd\u7684\u6cbb\u7642\u526f\u4f5c\u7528\u3002\u6709\u6975\u4f73\u7684\u7642\u6548\uff0c\u4f46\u7121\u53ef\u8af1\u8a00\u7684\uff0c\u67d0\u4e9b\u5316\u5b78\u85e5\u7269\u8207\u653e\u6545\u5728\u5c0f\u5152\u764c\u4e4b\u806f\u5408\u6cbb\u7642\u4e0a\u60f3\u8981\u6709\u6700\u4f73\u7684\u7642\u6548\uff0c\u53c8\u60f3\u907f\u514d\u56b4\u91cd\u7684\u6cbb\u7642\u526f\u4f5c\u7528\uff0c\u4e00\u500b\u719f\u7df4\u3001\u5c08\u696d\u800c\u53c8\u5bcc\u7d93\u9a57\u7684\u6cbb\u7642\u5c0f\u7d44\u662f\u7d55\u5c0d\u9700\u8981\u7684\u3002", "e": "Major advances in pediatric oncology have been made since surgery, radiation therapy, and chemotherapy have been integrated in the management of children with cancer. Combined chemo-radiotherapy can be used successfully to control minimal residual disease after resections. However, particularly with certain drugs, radiation reactions can be augmented severely so as to produce crippling if not lethal damage. The skill and expertise of an experienced team is needed if the benefits of combined care are to be maximized, and the risks minimized."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-99-106-a", "title": "Long-Term Follow-Up of Cervical Cancer Patients Treated with Preloaded Radium Brachytherapy from 1977 to 1983", "keywords": "\u5b50\u5bae\u9838\u764c;\u524d\u8377\u5f0f\u9433\u9320;\u8154\u5167\u653e\u5c04\u6cbb\u7642 Cervical cancer;Preloaded radium;Intracavitary radiation therapy", "c": "\u5728\u5f8c\u8377\u6cbb\u7642\u6280\u8853\u767c\u5c55\u4e4b\u524d\uff0c\u5b50\u5bae\u9838\u764c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u4e00\u76f4\u4ee5\u524d\u8377\u5f0f\u9433\u9320\u6cbb\u7642\u70ba\u4e3b\uff0c\u5373\u4f7f\u5728\u6578\u5341\u5e74\u5f8c\u7684\u4eca\u5929\uff0c\u9019\u4e9b\u7d93\u9a57\u4ecd\u662f\u5c07\u4f86\u767c\u5c55\u9032\u6b65\u7684\u53c3\u8003\u3002\u672c\u6587\u8a0e\u8ad6\u81ea1977\u52301983\u5e74\u9593\u6211\u5011\u4ee5\u524d\u8377\u5f0f\u9433\u9320\u6cbb\u7642\u505a\u5b50\u5bae\u9838\u764c\u8154\u5167\u8fd1\u63a5\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7d50\u679c\uff0c\u4ee5\u4fbf\u8207\u4ee5\u5f8c\u7684\u5f8c\u8377\u5f0f\u6cbb\u7642\u6709\u6240\u6bd4\u8f03\u3002\u9019\u7bc7\u56de\u6eaf\u6027\u7684\u5206\u6790\u5171\u6709347\u500b\u75c5\u4f8b\uff0c\u5176\u4e94\u5e74\u548c\u5341\u5e74\u7684\u4fdd\u96aa\u5b58\u6d3b\u7387\u5206\u5225\u70ba\uff1a\u7b2c\u4e00\u671f\uff1a89.2%\u548c456%\uff0c\u7b2c\u4e8c\u671f\uff1a67.8%\u548c53.5%\uff0c\u7b2c\u4e09\u671f\uff1a48.9%\u548c40.3%\u3002\u5171\u67098\u500b\u75c5\u4f8b\u6709\u5c3f\u9053\u548c\u76f4\u8178\u65b9\u9762\u7684\u5f8c\u907a\u75c7\uff0c\u5b83\u5011\u767c\u751f\u5728\u6cbb\u7642\u5f8c\u4e00\u5e74\u81f3\u6578\u5e74\u4e0d\u7b49\u3002\u67095\u500b\u75c5\u4f8b\u5728\u7167\u5c04\u5f8c1\u523011\u5e74\u767c\u751f\u4e86\u7b2c\u4e8c\u500b\u816b\u7624\uff0c\u5206\u5225\u70ba\uff1a2\u500b\u4e73\u764c\uff0c1\u500b\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff0c1\u500b\u80ba\u90e8\u9c57\u72c0\u7d30\u80de\u764c\uff0c1\u500b\u8179\u58c1\u4e0a\u7684\u8edf\u7d44\u7e54\u8089\u7624\u3002\u5728\u5f8c\u8377\u6cbb\u7642\u6280\u8853\u767c\u5c55\u4e4b\u524d\uff0c\u5b50\u5bae\u9838\u764c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u4e00\u76f4\u4ee5\u524d\u8377\u5f0f\u9433\u9320\u6cbb\u7642\u70ba\u4e3b\uff0c\u5373\u4f7f\u5728\u6578\u5341\u5e74\u5f8c\u7684\u4eca\u5929\uff0c\u9019\u4e9b\u7d93\u9a57\u4ecd\u662f\u5c07\u4f86\u767c\u5c55\u9032\u6b65\u7684\u53c3\u8003\u3002\u672c\u6587\u8a0e\u8ad6\u81ea1977\u52301983\u5e74\u9593\u6211\u5011\u4ee5\u524d\u8377\u5f0f\u9433\u9320\u6cbb\u7642\u505a\u5b50\u5bae\u9838\u764c\u8154\u5167\u8fd1\u63a5\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u7d50\u679c\uff0c\u4ee5\u4fbf\u8207\u4ee5\u5f8c\u7684\u5f8c\u8377\u5f0f\u6cbb\u7642\u6709\u6240\u6bd4\u8f03\u3002\u9019\u7bc7\u56de\u6eaf\u6027\u7684\u5206\u6790\u5171\u6709347\u500b\u75c5\u4f8b\uff0c\u5176\u4e94\u5e74\u548c\u5341\u5e74\u7684\u4fdd\u96aa\u5b58\u6d3b\u7387\u5206\u5225\u70ba\uff1a\u7b2c\u4e00\u671f\uff1a89.2%\u548c456%\uff0c\u7b2c\u4e8c\u671f\uff1a67.8%\u548c53.5%\uff0c\u7b2c\u4e09\u671f\uff1a48.9%\u548c40.3%\u3002\u5171\u67098\u500b\u75c5\u4f8b\u6709\u5c3f\u9053\u548c\u76f4\u8178\u65b9\u9762\u7684\u5f8c\u907a\u75c7\uff0c\u5b83\u5011\u767c\u751f\u5728\u6cbb\u7642\u5f8c\u4e00\u5e74\u81f3\u6578\u5e74\u4e0d\u7b49\u3002\u67095\u500b\u75c5\u4f8b\u5728\u7167\u5c04\u5f8c1\u523011\u5e74\u767c\u751f\u4e86\u7b2c\u4e8c\u500b\u816b\u7624\uff0c\u5206\u5225\u70ba\uff1a2\u500b\u4e73\u764c\uff0c1\u500b\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff0c1\u500b\u80ba\u90e8\u9c57\u72c0\u7d30\u80de\u764c\uff0c1\u500b\u8179\u58c1\u4e0a\u7684\u8edf\u7d44\u7e54\u8089\u7624\u3002", "e": "Before the afterloading technique was available, preloaded radium was the mainstay for radiotherapy of carcinoma of the uterine cervix. After many decades of clinical practice, the experience is still useful as references in t he developments of brachytherapy for cervical cancer. This study reports our results during 1977 through 1983 when preloaded radium was used for intracavitary brachytherapy. Comparison is made with results treated with afterloading technique in later years. Three hundred and forty seven cases were in eluded in this retrospective analysis. The 5-year and 10-year actuarial survival rates were: stage I 89.2% and 45.6%; stage II 67.8% and 53.5%; and stage III 48.9% and 40.3%, respectively. There were 8 cases of major complications of the urinary tract and rectum which occurred one or more years after treatment. Five patients were diagnosed to have second malignant tumor 1-11 years after irradiation. These tumors include 2 breast cancers, 1 multiple myeloma, I squamous cell carcinoma of the lung, and 1 soft tissue sarcoma of the abdominal wall."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-107-113-a", "title": "Induction Chemotherapy Followed by Radiotherapy in Locally Advanced Cervical Cancer: A Review", "keywords": "\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642;\u542bcisplatin\u7684\u85e5\u7269\u7d44\u5408 Induction chemotherapy;Cisplatin-based regimens", "c": "\u8fd130\u5e74\u4f86\uff0c\u5ee3\u6cdb\u4fb5\u72af\u6027\u5b50\u5bae\u9838\u764c\u7684\u9810\u5f8c\u4e26\u672a\u660e\u986f\u6539\u5584\uff0c\u7136\u800c\u653e\u5c04\u6cbb\u7642\u4ecd\u70ba\u6cbb\u7642\u7684\u4e3b\u529b\u3002\u76ee\u524d\u4ecd\u5f85\u7a81\u7834\u7684\u6cbb\u7642\u91cd\u9ede\u4e0d\u5916\u4e4e\u6539\u5584\u5c40\u90e8\u63a7\u5236\u7387\u53ca\u6709\u6548\u6cbb\u7642\u96b1\u533f\u6027\u8f49\u79fb\u75c5\u7076\u201c\u904e\u53bb\u66fe\u6709\u52a0\u5165\u624b\u8853\u3001\u7f3a\u6c27\u7d30\u80de\u81f4\u654f\u5291\u3001\u9ad8\u58d3\u6c27\uff0c\u6216\u4e2d\u5b50\u6cbb\u7642\u7b49\u65b9\u5f0f\uff0c\u7136\u5927\u90fd\u56e0\u7642\u6548\u6709\u9650\u6216\u56e0\u660e\u986f\u526f\u4f5c\u7528\u800c\u81f4\u6210\u6548\u4e0d\u5f70\u3002\u76ee\u524d\u5247\u4ee5\u5408\u4f75\u5316\u5b78\u85e5\u7269\u7684\u65b9\u5f0f\u88ab\u7814\u7a76\u6700\u591a\uff0c\u5176\u4e2d\u300c\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u300d\u7684\u4f5c\u6cd5\u662f\u4e00\u9805\u8f03\u65b0\u7684\u5690\u8a66\uff0c\u5176\u5316\u5b78\u85e5\u7269\u7684\u7d44\u6210\u5927\u90fd\u662f\u4ee5\u542b\u6709cisplatin\u7684\u591a\u7a2e\u85e5\u7269\u7d44\u5408\u201c\u56de\u9867\u6587\u737b\u9b22\u73fe\u90e8\u4efd\u7814\u7a76\u8005\u63d0\u51fa\u80af\u5b9a\u7684\u5831\u544a\uff0c\u4f46\u4ea6\u6709\u4e9b\u5b78\u8005\u6307\u51fa\u9019\u7a2e\u6cbb\u7642\u65b9\u5f0f\u8207\u55ae\u7368\u4f7f\u7528\u653e\u5c04\u6cbb\u7642\u4f5c\u6bd4\u8f03\uff0c\u4e26\u7121\u6cd5\u6709\u6548\u63d0\u9ad8\u5c40\u90e8\u63a7\u5236\u6216\u5b58\u6d3b\u7387\u3002\u56e0\u6b64\uff0c\u524d\u5c0e\u6027\u5316\u5b78\u6cbb\u7642\u5408\u4f75\u653e\u5c04\u6cbb\u7642\u7684\u5be6\u969b\u50f9\u503c\u5982\u4f55\uff0c\u5247\u6709\u8cf4\u66f4\u9032\u4e00\u6b65\u7684\u7814\u7a76\u3002", "e": "The prognosis for locally advanced cervical cancer has not improved in the past 3 decades. The strategies for improving the outcome include better local control as well as effective management of occult metastases already present at diagnosis. Radiotherapy has always been the standard treatment for these stages. The addition of other modalities including surgery, hypoxic cell sensitizer, hyperbaric oxygen, or neutron therapy has met with limited or no success, or has been associated with an increased morbidity. The role of chemotherapy, either as single agent or in combination, has been extensively evaluated in advanced or recurrent disease.\nInduction or neoadjuvant chemotherapy is one of the novel therapeutic approaches. Various regimens have been used, mostly cisplatin-based combinations. Several investigators conducted phase II trials of neoadjuvant chemotherapy. Some of these trials showed positive result. Nevertheless, some failed to demonstrate any benefit in terms of locoregional relapse and/or survival\nAt present, the optimum regimen that lends to a maximum efficacy and a minimum toxicity remains to be determined. We have to learn whether the induction chemotherapy eventually improves survivals or is yet another approach that just demonstrates good responses without impact on survival."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-115-121-a", "title": "Fractionated High-Dose-Rate Stereotactic Brachytherapy in the Management of Malignant Gliomas", "keywords": "\u81a0\u8cea\u7d30\u80de\u7624;\u8fd1\u63a5\u6cbb\u7642;\u9ad8\u5291\u91cf\u7387;\u7acb\u9ad4\u5b9a\u4f4d Glioma;Brachytherapy;High-dose-rate;Stereotactic", "c": "\u9ad8\u5291\u91cf\u7387\u7acb\u9ad4\u5b9a\u4f4d\u8fd1\u63a5\u6cbb\u7642\u6280\u8853\u5df2\u6210\u529f\u88ab\u5f15\u9032\uff0c\u7528\u65bc\u6cbb\u7642\u60e1\u6027\u81a0\u8cea\u7d30\u80de\u7624\u4e4b\u75c5\u60a3\u3002\u9996\u5148\uff0c\u5148\u5c07CRW\u9435\u74b0\u56fa\u5b9a\u65bc\u75c5\u4eba\u982d\u4e0a\uff0c\u6234\u4e0a\u96fb\u8166\u65b7\u5c64\u5b9a\u4f4d\u6846\u5f8c\uff0c\u75c5\u4eba\u63a5\u53d7\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u3002\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u7d93\u7531\u5149\u789f\u7247\u50b3\u9001\u81f3\u4e09\u5ea6\u7a7a\u9593\u6cbb\u7642\u8a08\u5283\u8edf\u9ad4(BrainSCAN)\u3002\u5148\u524d\u4e4b\u6cbb\u7642\u8a08\u5283\uff0c\u7d93\u7531\u5c0e\u7ba1\u6578\u76ee\u3001\u4f4d\u7f6e\u53ca\u5404\u5c0e\u7ba1\u5167\u5c04\u6e90\u505c\u7559\u7684\u4f4d\u7f6e\u53ca\u6642\u9593\u7684\u6c7a\u5b9a\u800c\u7522\u751f\u3002\u6700\u4e3b\u8981\u7684\u76ee\u6a19\u662f\u4f7f\u6a19\u7684\u9ad4\u7a4d\u5167\u9054\u5230\u6700\u5747\u52fb\u7684\u5291\u91cf\uff0c\u800c\u5728\u6a19\u7684\u9ad4\u7a4d\u5916\u7684\u5291\u91cf\u5feb\u901f\u905e\u6e1b\u3002\u4e00\u65e6\u6c7a\u5b9a\u597d\u6cbb\u7642\u8a08\u5283\uff0c\u75c5\u4eba\u518d\u9001\u81f3\u958b\u5200\u623f\u3002\u4f9d\u64da\u5148\u524d\u7684\u6cbb\u7642\u8a08\u5283\uff0c\u8166\u795e\u7d93\u5916\u79d1\u91ab\u5e2b\u4f7f\u7528\u624b\u947d\u5728\u982d\u6bbc\u4e0a\u6253\u4e00\u500b\u5c0f\u6d1e\uff0c\u518d\u5c07\u5c0e\u7ba1\u7f6e\u5165\u9810\u5b9a\u4f4d\u7f6e\u4e2d\u3002\u85c9\u8457\u4e92\u76f8\u5782\u76f4\u65b9\u5411\u7167\u5f97\u7684X\u5149\u7247\uff0c\u53ef\u4ee5\u9a57\u8b49\u771f\u738b\u5c0e\u7ba1\u53ca\u5148\u524d\u6cbb\u7642\u8a08\u5283\u5c0e\u7ba1\u4f4d\u7f6e\u7684\u5dee\u7570\u3002\u7d93\u904e\u9069\u7576\u5730\u8abf\u6574\u5c04\u6e90\u4f4d\u7f6e\u53ca\u505c\u7559\u6642\u554f\u4ee5\u5f4c\u88dc\u5c0e\u7ba1\u4f4d\u7f6e\u7684\u8aa4\u5dee\uff0c\u518d\u5c07\u75c5\u4eba\u4ee5MicroSelectron\u5f8c\u8377\u6cbb\u7642\u6a5f\u65bd\u884c\u6cbb\u7642\u3002\u6839\u64da\u6211\u5011\u7684\u521d\u6b65\u7d93\u9a57\uff0c\u5df2\u958b\u59cb\u9032\u884c\u7b2c\u4e00/\u4e8c\u76f8\u7684\u7814\u7a76\u8a66\u9a57\u3002", "e": "A stereotactic high-dose-rate brachytherapy technique has recently been implemented for the treatment of malignant gliomas. A Cosman-Roberts-Wells (CRW) base ring is attached to the patient's skull with a CT localization frame attached to the base ring. The patient undergoes a contrast enhanced CT scanning. The CT images are transferred to the three-dimensional stereotactic brachytherapy treatment planning system (Brain-SCAN) through optical disc. Then the pre-plan is generated to determine the number of catheters, the location of each catheter, the source positions in each catheter and the implant time. The goal is to provide a steep dose fall off outside the target volume while providing the best possible dose homogeneity within the target volume. Once the plan is approved, the patient is taken to the operation room. According to the pre-plan data, neurosurgeons make a small hole by twist-drill on the skull and then place the catheters into the desired location. Later on, the real positions of catheters in the brain are verified by orthogonal radiographics and compare with the preplanned positions. After adjusting the implant time and position of each seed to compromise the position deviation of catheters, the patient is treated with MicroSelectron unit. High activity Ir-192 source is afterloaded into the catheters by remote-control system. Based on our preliminary experience, a phase I/II clinical study has been initiated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-123-129-a", "title": "Hyperfractionated Radiotherapy of Lung Cancer: Report of a Pilot Study", "keywords": "\u80ba\u764c;\u591a\u5206\u6b21\u653e\u5c04\u6cbb\u7642 Lung cancer;Hyperfractionated radiotherapy", "c": "\u672c\u6587\u76ee\u7684\uff0c\u5728\u65bc\u8a55\u4f30\u4ee5\u591a\u5206\u6b21\u653e\u5c04\u7dda\u7167\u5c04\u6cd5\u6cbb\u7642\u5c40\u90e8\u665a\u671f\u6216\u4e0d\u80fd\u624b\u8853\u4e4b\u80ba\u764c\u75c5\u4eba\u662f\u5426\u53ef\u884c\u3001\u75c5\u4eba\u662f\u5426\u53ef\u4ee5\u8010\u53d7\u8a72\u7a2e\u653e\u7642\u3002\u76ee\u524d\u6709\u5341\u4e09\u500b\u75c5\u4eba\u63a5\u53d7\u6b64\u7a2e\u7167\u5c04\u65b9\u5f0f\uff0c\u9664\u4e00\u4f8b\u70ba\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u5916\uff0c\u9918\u7686\u70ba\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3002\u5e74\u9f61\u4ecb\u65bc37\u81f384\u6b72\u4e4b\u554f\uff0c\u5341\u4e09\u4eba\u4e2d\u4fbf\u6709\u5341\u4e8c\u4eba\u5927\u65bc60\u6b72\u3002\u9664\u4e86\u4e00\u4f8b\u70baT2N0M0\u7684\u65e9\u671f\u75c5\u4eba\u662f\u7531\u65bc\u5167\u79d1\u7406\u7531\u7121\u6cd5\u624b\u8853\u4e4b\u5916\uff0c\u5176\u4ed6\u75c5\u4f8b\u5747\u70ba\u5c40\u90e8\u665a\u671f\u6216\u5fa9\u767c\u201d\u7167\u5c04\u65b9\u6cd5\u70ba120 cGy bid\uff0c\u7e31\u8188\u8154\u63a5\u53d74,200-4,500 cGy\uff0c\u539f\u767c\u816b\u7624\u70ba7,000 cGy\u3002\u6700\u77ed\u53ca\u6700\u9577\u8ffd\u8e64\u671f\u5206\u5225\u70ba1\u53ca34\u500b\u6708\u3002\u4e03\u500b\u75c5\u4eba\u65bc\u7167\u5c04\u4e2d\u767c\u751f\u541e\u56a5\u75bc\u75db\u6216\u5589\u56a8\u75db\uff1a\u555e\u5fc3\u5614\u5410\u50c5\u5076\u723e\u51fa\u73fe\u4e14\u5747\u751a\u8f15\u5fae\u3002\u653e\u5c04\u6027\u80ba\u708e\u662f\u60df\u4e00\u7d93\u5e38\u51fa\u73fe\u7684\u665a\u671f\u526f\u4f5c\u7528\uff0c\u6709\u5341\u4e00\u500b\u75c5\u4eba\u65bc\u7167\u5c04\u7d50\u675f\u5f8c\u9700\u8981\u85e5\u7269\u6cbb\u7642\u56b4\u91cd\u54b3\u55fd\u6216\u547c\u5438\u4e0d\u66a2\u3002\u5171\u6709\u5341\u500b\u75c5\u4eba\u9700\u8981\u4f7f\u7528\u985e\u56fa\u9187\u3002\u6709\u516d\u500b\u75c5\u4eba\u51fa\u73fe\u6301\u7e8c\u8d85\u904e\u516d\u500b\u6708\u4e4b\u4e45\u7684\u808b\u819c\u7a4d\u6c34\u3002\u6240\u6709\u4ee5\u4e0a\u526f\u4f5c\u7528\u5747\u80fd\u8655\u7406\uff0c\u4e14\u4e26\u7121\u75c5\u4eba\u56e0\u653e\u5c04\u6027\u80ba\u708e\u800c\u4f4f\u9662\u201c\u5728\u816b\u7624\u5c0d\u7167\u5c04\u7684\u53cd\u61c9\u65b9\u9762\uff0c\u5169\u4f8b\u70ba\u5b8c\u5168\u53cd\u61c9\u3001\u5341\u4e00\u4f8b\u70ba\u90e8\u4efd\u53cd\u61c9\u6216\u7a69\u5b9a\u3002\u76ee\u524d\u5c40\u90e8\u5fa9\u767c\u7684\u6709\u5169\u4f8b\u3001\u5df2\u767c\u751f\u9060\u8655\u8f49\u79fb\u7684\u6709\u4e94\u4f8b\u3002\n\u7e3d\u7d50\u800c\u8a00\uff0c\u4f7f\u7528120 cGy bid\u53ca7,000 cGy\u7684\u7167\u5c04\u6cd5\uff0c\u75c5\u4eba\u8010\u53d7\u529b\u53ca\u5c40\u90e8\u63a7\u5236\u7387\u5747\u4f73\uff0c\u4e14\u5728\u81e8\u5e8a\u4e0a\u4e5f\u65b9\u4fbf\u6613\u884c\u3002", "e": "The purpose of the present paper is to evaluate the feasibility and patient tolerance of hyperfractionated radiotherapy in advanced or inoperable lung cancer patients. Thirteen patients, all of non-small cell lung cancer (NSCLC) except one, were treated with 120 cGy bid hyperfractionated radiotherapy. The age range were between 37 and 84 years, with 12 of them older than 60. Except one medically inoperable T2N0M0 patient, all the remaining 11 NSCLC patients were either locally advanced or had local-regional recurrence. Patients received 4200-4500 cGy to the mediastinum and 7000 cGy to the primary lesion. Minimum and maximum follow-up was 1 and 34 months, respectively. Seven patients developed dysphagia/sore throat during irradiation. Nausea/vomiting was infrequent and mild. Radiation pneumonitis was the single significant chronic side effect up to the time of analysis. Eleven patients required some medication during the post-radiotherapy period for either severe cough or dyspnea. Ten needed steroid. Chronic pleural effusion that persisted for more than 6 months was observed in 6 patients. This was manageable in all patients. No patient was hospitalized because of radiation-induced pneumonitis. There were 2 CR and 11 PR/SD. Local recurrence has developed in 2. Distant metastasis has been documented in 5 patients who were initially MO. Patient tolerance and local control were good. Hyperfractionated radiotherapy, 120 cGy bid, with a total dose of 4500 cGy to the mediastinum and 7000 cGy to the primary lesion, is a feasible and tolerable regimen for lung cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-131-139-a", "title": "\u4ee5\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u70ba\u5f71\u50cf\u57fa\u790e\u7684\u9806\u5f62\u653e\u5c04\u6cbb\u7642\uff1a\u6280\u8853\u7d30\u7bc0\u8207\u521d\u6b65\u7d93\u9a57", "keywords": "\u9806\u5f62\u653e\u5c04\u6cbb\u7642;\u6cbb\u7642\u8a08\u5283 Conformal radiation therapy;Treatment planning", "c": "\u672c\u6587\u63cf\u8ff0\u76ee\u524d\u672c\u79d1\u6709\u95dc\u65bc\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u7684\u6280\u8853\u7d30\u7bc0\uff0c\u4e26\u5831\u544a\u4e5d\u500b\u75c5\u4f8b\u7684\u521d\u6b65\u7d93\u9a57\u3002\u4f7f\u7528\u6b65\u9a5f\u5305\u62ec\uff1a\uff08\u4e00\uff09\u59ff\u52e2\u8a2d\u5b9a\u3001\u56fa\u5b9a\u53ca\u521d\u6b21\u6a21\u64ec\u651d\u5f71\uff08\u4e8c\uff09\u96fb\u8166\u65b7\u5c64\u6a21\u64ec\u651d\u5f71\u53ca\u5f71\u50cf\u53d6\u5f97\uff08\u4e09\uff09\u6cbb\u7642\u76ee\u6a19\u53ca\u91cd\u8981\u5668\u5b98\u7684\u754c\u5b9a\uff08\u56db\uff09\u5c04\u675f\u7684\u754c\u5b9a\u3001\u7167\u91ce\u7684\u5b89\u6392\u53ca\u5291\u91cf\u7684\u8a08\u7b97\uff08\u4e94\uff09\u8a08\u5283\u7684\u8a55\u4f30\u8207\u6bd4\u8f03\u56e0\u6cbb\u7642\u7684\u9a57\u8b49\u8207\u57f7\u884c\u7b49\u516d\u90e8\u4efd\u3002\u570b\u5167\u9806\u5f62\u653e\u5c04\u6cbb\u7642\u6b63\u5728\u8d77\u6b65\u968e\u6bb5\uff0c\u76ee\u524d\u6211\u5011\u5f90\u4e86\u5c07\u66f4\u7cbe\u7c21\u6574\u500b\u6d41\u7a0b\u6b65\u9a5f\u5916\uff0c\u4e5f\u9810\u5099\u64ec\u5b9a\u4e00\u4e9b\u6cbb\u7642\u8a08\u5283\u8b93\u9069\u7576\u7684\u75c5\u4eba\u9032\u5165\u9019\u9805\u6cbb\u7642\u3002", "e": "Technical details and early experiences of nine patients treated with conformal radiation therapy were described and discussed. Techniques based on CT images reconstruction and incorporating beam's eye view-assisted blocks design were used. General procedures currently apply at this department including: patient positioning, immobilization, first x-ray simulation, CT simulation and image acquisition, target and critical organ definition, beam definition, fields arrangement, dose calculation, plan evaluation, treatment verification and delivery. Technical refinement and protocol setup for conformal radiation therapy at this department are now in progress."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-141-149-a", "title": "\u80f8\u8154\u90e8\u4f4d\u653e\u5c04\u6cbb\u7642\u4e4b\u80fd\u91cf\u9078\u64c7\uff0d\u7269\u7406\u8003\u91cf", "keywords": "\u653e\u5c04\u6cbb\u7642;\u534a\u5f71\u5340;\u80ba\u81df;\u9ad8\u80fd\u5149\u5b50 Radiotherapy;Penumbra;Lung;High-energy photon", "c": "\u5229\u7528\u9ad8\u80fd\u653e\u5c04\u7dda\u4ee5\u6cbb\u7642\u80f8\u8154\u5167\u60e1\u6027\u816b\u7624\uff0c\u4f8b\u5982\u80ba\u764c\u3001\u98df\u9053\u764c\u3001\u80f8\u817a\u764c\u3001\u53caHodgkin\u6c0f\u75c5\u7b49\u5747\u662f\u5f9e\u4e8b\u653e\u5c04\u816b\u7624\u5de5\u4f5c\u8005\u6642\u5e38\u6703\u9047\u5230\u4e4b\u6311\u6230\u3002\u7531\u65bc\u80f8\u8154\u5167\u4e0d\u540c\u7d44\u7e54\u7684\u5bc6\u5ea6\u8b8a\u5316\u592a\u5927\uff0c\u53ef\u80fd\u6703\u56e0\u6b64\u5f71\u97ff\u653e\u5c04\u7dda\u5728\u80ba\u81df\u5167\u7684\u7269\u7406\u7279\u6027\uff0c\u751a\u81f3\u5f71\u97ff\u653e\u5c04\u7dda\u80fd\u91cf\u4e4b\u9078\u64c7\u3002\u672c\u6587\u4ee5\u7269\u7406\u5be6\u9a57\u65b9\u6cd5\u3001\u6e2c\u8a66\u9237\u516d\u5341\u3001\u516d\u3001\u53ca\u5341\u767e\u842c\u4f0f\u7279X\u5149\u4e09\u7a2e\u80fd\u6688\uff0c\u5728\u6a21\u64ec\u80f8\u8154\u7d44\u8b58\u5047\u9ad4\u5167\u4e4b\u534a\u5f71\u5340\u3001\u6df1\u5ea6\u5291\u91cf\u3001\u53ca\u7167\u91ce\u5167\u5916\u7de3\u7b49\u8b8a\u5316\uff0c\u7528\u4ee5\u63a2\u6c42\u4e0a\u8ff0\u7591\u554f\u3002\u672c\u5be6\u9a57\u4ee5\u9a57\u8b49\u8edf\u7247\u5206\u5225\u7f6e\u65bc\u5047\u9ad4\u6df1\u5ea62\u30014\u30016\u30018\u53ca10\u516c\u5206\u8655\u4f86\u8a18\u9304\u653e\u5c04\u7dda\u7684\u8b8a\u5316\u3002\u5728\u534a\u5f71\u5340\u7684\u8b8a\u5316\u65b9\u9762\uff0c\u5f9e\u5747\u8cea\u5047\u9ad4\u63db\u6210\u6a21\u64ec\u80ba\u81df\u5bc6\u5ea6\u5047\u9ad4\uff0c\u9237\u516d\u5341\u30016-\u3001\u53ca10-MVX\u5149\u5206\u5225\u8b8a\u5bec\u4e86-5.4%\uff5e-30.9%\u3001-9.7~28.3%\u3001\u53ca-2.7~91.8%\u3002\u76f8\u540c\u689d\u4f34\u4e0b\uff0c\u52a0\u5165\u6a21\u64ec\u7e31\u9694\u8154\u4e4b\u90e8\u4efd\u5c0d\u65bc\u534a\u5f71\u5340\u7684\u5f71\u97ff\u4e26\u4e0d\u5927\u3002\u5728\u80ba\u81df\u5167\u6df1\u5ea6\u5291\u91cf\u65b9\u9762\uff0c\u9237\u516d\u5341\u30016-\u53ca10-MVX\u5149\u6703\u6bd4\u5747\u8cea\u5047\u9ad4\u589e\u52a0-l.0%~23.0%\u30010.5~14.0%\u3001\u53ca0.5~7.5%\u3002\u4ee5\u7269\u7406\u89c0\u9ede\u800c\u8a00\uff0c\u80fd\u91cf\u6108\u9ad8\uff08\u5982-10-MVX\uff09\u5728\u80ba\u81df\u5167\u7684\u534a\u5f71\u5340\u6703\u5bec\u65bc\u5e73\u5e38\u5728\u5747\u8cea\u5047\u9ad4\u6240\u6e2c\u91cf\u4e4b\u6578\u64da\uff0c\u81e8\u5e8a\u82e5\u8981\u4f7f\u7528\u5fc5\u9808\u7559\u6709\u8f03\u5bec\u4e4b\u5b89\u5168\u908a\u7de3\u3002\u800c\u80fd\u91cf\u6108\u4f4e\u8005\uff08\u5982\u9237-60\u62166-MVX\u5149\uff09\u96d6\u7a0b\u5ea6\u4e0a\u8f03\u8f15\u5fae\uff0c\u4f46\u80ba\u81df\u5167\u7684\u6df1\u5ea6\u5291\u91cf\u537b\u9060\u6bd4\u672a\u6821\u6b63\u4e4b\u8a08\u7b97\u70ba\u9ad8\u3002", "e": "Radiotherapy have an important role for treating the intra-thoracic malignant disease. The depth dose distribution and the width of the penumbra within the lung tissue are quite different from ordinary soft tissue owing to the entity of extra low density of the lung parenchyma. This experiment was designed to study three most popular energies which including Co-60, 6-, and 10-MV X-rays. Film dosimetry method had been used with different phantoms. There are three different kinds of phantom to simulate unit-density soft tissue, chest wall with lung, & chest wall with lung and mediastinum, respectively. The definition of penumbra is 20% to 80% dosage of the dose profile in the central plane. We used Kodak V films for recording the different layers of depth in test phantom, that were 2,4,6,8,& 10 cm, respectively. Comparing the size of penumbra between unit-density and lung-density phantom, the Co-60, 6-, and 10-MV X-rays increased -5.4% to -30.9%, -9.7% to 28.3%, and -2.7% to 91.8%, respectively. In the same condition, there is not too much different with and without the part of mediastinum simulator. The depth dose of lung parenchyma will increase -1.0% to 23.0% for Co-60, 0.5% to 14.0% for 6-MV X-rays, and 0.5% to 7.5% for 10-MV X-rays. In physical point of view, when the energies getting higher (ex. 10-MVX), the size of penumbra within the lung will be more widened than ordinary data. Clinically, if we wanted to use these kinds of energy, we must reserve a larger safe margin around the tumor. Although the lower energy (ex. Co-60) does not have above problem, but the absorbed dose within the lung will get higher than expected if correction does not apply to the calculation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-151-156-a", "title": "\u9f3b\u54bd\u764c\u659c\u4f4d\u773c\u7736\u4e0b\u7167\u5c04\u90e8\u4f4d\u4e4b\u554f\u63a5\u9a57\u8b49", "keywords": "\u9593\u63a5\u9a57\u8b49;\u659c\u4f4d\u773c\u7736\u4e0b\u7167\u91ce;\u9f3b\u54bd\u764c;\u4f9d\u64da\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u4e4b\u6a21\u64ec\u5b9a\u4f4d Indirect verification;Oblique infraorbital portal;Nasopharyngeal carcinoma;CT based simulation", "c": "\u5229\u7528\u773c\u7736\u4e0b\u653e\u5c04\u6cbb\u7642\u90e8\u4f4d\u65bc\u9f3b\u54bd\u764c\u4e4b\u653e\u5c04\u6cbb\u7642\u53ef\u6e1b\u5c11\u5927\u8166\u986f\u8449\u3001\u4e2d\u8033\u3001\u5167\u8033\u3001\u986f\u984e\u95dc\u7bc0\u7b49\u6b63\u5e38\u7d44\u5fae\u4e4b\u5291\u91cf\uff0c\u56e0\u6b64\u53ef\u6e1b\u5c11\u5176\u5f8c\u907a\u75c7\u201c\u50b3\u7d71\u4e4b\u9a57\u8b49\u7247\u5411\u4f86\u8a8d\u70ba\u4e0d\u6613\u9a57\u8b49\u6b64\u659c\u4f4d\u6cbb\u7642\u90e8\u4f4d\uff0c\u6b64\u7814\u7a76\u7684\u76ee\u7684\u4e43\u5728\u767c\u5c55\u4e00\u554f\u63a5\u65b9\u6cd5\u53ef\u6b63\u78ba\u9a57\u8b49\u6b64\u659c\u4f4d\u773c\u7736\u4e0b\u7167\u5c04\u90e8\u4f4d\u3002\u6211\u5011\u4f7f\u7528\u4e8b\u5148\u505a\u597d\u75c5\u4eba\u6a21\u64ec\u651d\u5f71\u4f4d\u7f6e\u6642\u56fa\u5b9a\u4e4b\u8a2d\u65bd\u8207\u9762\u5177\uff0c\u7136\u5f8c\u9001\u75c5\u4eba\u505a\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u3002\u53d6\u9f3b\u54bd\u90e8\u4f4d\u8655\u4e4b\u4e00\u7cfb\u5217\u6a6b\u8ef8\u5207\u9762\u5f71\u50cf\uff0c\u754c\u5b9a\u51fa\u816b\u7624\u4e4b\u7bc4\u570d\uff0c\u540c\u6642\u4e26\u756b\u51fa\u6240\u6709\u5f71\u50cf\u7e31\u5411\u4e2d\u7dda\u3002\u6211\u5011\u4f7f\u7528\u4e00\u8207\u5f71\u50cf5\u516c\u5206\u5bec\u540c\u6a23\u653e\u5927\u7387\u4e4b\u7d19\u689d\uff0c\u5118\u91cf\u80fd\u6db5\u84cb\u9f3b\u54bd\u53ca\u54bd\u65c1\u5340\uff0c\u7136\u5f8c\u4ee5\u6b64\u90e8\u4f4d\u4e4b\u4e2d\u8ef8\u8207\u6a6b\u8ef8\u96fb\u8166\u65b7\u5c64\u4e4b\u4e2d\u7dda\u4ea4\u53c8\u9ede\u70ba\u65cb\u8f49\u8ef8\u4e2d\uff0c\u9078\u53d640\u00b0~50\u00b0\u5411\u5de6\u53f3\u5169\u5074\u65cb\u8f49\uff0c\u4f7f\u80fd\u6db5\u84cb\u5c0d\u5074\u4e4b\u9f3b\u54bd\u53ca\u54bd\u65c1\u5340\uff0c\u540c\u5074\u5927\u90e8\u4efd\u4e4b\u9f3b\u54bd\u53ca\u54bd\u65c1\u5340\u800c\u4e0d\u76f4\u63a5\u7167\u5c04\u5230\u810a\u9ad3\uff0c\u518d\u5c07\u6b64\u7d19\u689d\u65cb\u8f49\u81f3\u6c34\u5e73\uff08\u5074\u4f4d\uff09\uff0c\u7136\u5f8c\u5c07\u6b64\u90e8\u4f4d\u4e4b\u5f8c\u7da0\u505a\u8a18\u865f\u65bc\u6b64\u7cfb\u5217\u5f71\u50cf\u4e0a\uff0c\u518d\u9023\u63a5\u9019\u4e9b\u8a18\u865f\u6210\u4e00\u7dda\uff0c\u5373\u70ba\u6b64\u5074\u4f4d\u7167\u91ce\u4e4b\u5f8c\u7da0\u3002\u82e5\u6e96\u76f4\u5100\u518d\u914d\u5408\u4ee5\u9069\u7576\u89d2\u5ea6\u7684\u65cb\u8f49\u53ca\u963b\u64cb\u925b\u584a\u7684\u88fd\u4f5c\uff0c\u5373\u53ef\u5f97\u659c\u4f4d\u7167\u91ce\u4e4b\u554f\u63a5\u9a57\u8b49\uff0c\u65bc\u9f3b\u54bd\u764c\u659c\u4f4d\u76ee\u5247\u5321\u4e0b\u90e8\u4f4d\u4e4b\u6cbb\u7642\u662f\u9069\u7576\u4e14\u53ef\u4fe1\u8cf4\u7684\u3002\u672c\u6587\u7684\u7d50\u8ad6\u8a8d\u70ba\u5728\u4e09\u7dad\u96fb\u8166\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u666e\u904d\u4f7f\u7528\u4e4b\u524d\uff0c\u6b64\u6cd5\u70ba\u4e00\u7c21\u55ae\u65b9\u4fbf\u6709\u6548\u4e4b\u6b63\u78ba\u9a57\u8b49\u65b9\u6cd5\uff0c\u53ef\u6e1b\u5c11\u6cbb\u7642\u4e4b\u665a\u671f\u526f\u4f5c\u7528\uff0c\u9054\u5230\u63d0\u6607\u6cbb\u7642\u6548\u76ca(therapeutic gain)\u7684\u76ee\u7684\u3002", "e": "Using the infra orbital portals in the treatment of the nasopharyngeal carcinoma allows radiation oncologists to reduce the dosage to the temporal lobes, middle and inner ears, and temporomandibular joints, therefore, the morbidities of normal tissues can he minimized. It has been thought difficult to verify these portals by using the traditional simulation techniques and films. This study is to develop an indirect method to accurately verify the oblique infraobital portals. We sent the NPC patient for CT scan with a mask and immobilization devices as in simulation position. Serial axial cuts are used to delineate the tumor margin. A midline is drawn at all cuts of images at the nasopharynx level. Use a paper strip with same magnification rate of 5cm as CT image's as the portal width covering the most nasopharyngeal and parapharyngeal areas, then get the cross point of the portal central line and the midline of axial cuts as the rotation center. Rotate the paper strip in the angle of 40-50 degree bilaterally to cover the nasopharyngeal and parapharyngeal areas on the contralateral side and the most nasopharyngeal and parapharyngeal areas on the ipsilateral side without irradiating the spinal cord. Then rotate the paper strip again to the horizontal (true lateral) position. Mark the posterior margin of the treatment portals on the image of axial cuts. Connect these markers into a line as the posterior margin of true lateral portal. With a suitable collimator angulation and the necessary block making, an indirect method for verification of this position is obtained. This technique allows us to correctly irradiate the oblique infraorbital portal with reliable verification. Applying indirect verification of oblique infraorbital portal in nasopharyngeal carcinoma, is feasible and reliable. This study shows that indirect verification for delivering the oblique infraorbital portal is not only a simple, convenient procedure for the patients, technologists and physicians, but also an effective way to achieve the therapeutic gain in the treatment of nasopharyugeal carcinoma."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-157-160-a", "title": "\u570b\u7acb\u53f0\u7063\u5927\u5b78\u9644\u8a2d\u91ab\u9662\u653e\u5c04\u6cbb\u7642\u79d1\u7684\u767c\u5c55", "keywords": "\u653e\u5c04\u6cbb\u7642;\u767c\u5c55\u53f2 Radiotherapy;History", "c": "\u53f0\u5927\u91ab\u9662\u65bc\u6230\u5f8c\u8cfc\u9032\u5169\u90e8250 kVP\u6df1\u90e8X-\u5c04\u7dda\u6cbb\u7642\u6a5f\u53ca\u4e00\u90e8100 kVp\u6dfa\u90e8\u6cbb\u7642\u6a5f\uff0c\u6700\u521d\u7531\u674e\u6587\u8208\u91ab\u5e2b\u8ca0\u8cac\uff0c\u5f8c\u4f86\u4ea4\u7531\u653e\u5c04\u8a3a\u65b7\u90e8\u7684\u91ab\u5e2b\u8f2a\u6d41\u57f7\u884c\u653e\u5c04\u6cbb\u7642\u7684\u5de5\u4f5c\u3002\u4e00\u4e5d\u4e94\u516b\u5e74\u4e09\u6708\u555f\u7528\u5168\u53f0\u7063\u7b2c\u4e00\u90e8\u9237-60\u6cbb\u7642\u6a5f\uff0c\u9ec3\u6dd1\u73cd\u6559\u6388\u752b\u65bc\u540c\u5e74\u8d74\u82f1\u9032\u4fee\u5169\u5e74\u4e26\u8003\u53d6\u82f1\u570b\u653e\u5c04\u6cbb\u7642\u5c08\u79d1\u91ab\u5e2b\u57f7\u7167\uff0c\u7e7c\u8d74\u65e5\u672c\u4fee\u7fd2\u540c\u4f4d\u7d20\u5b78\u4e00\u5e74\uff0c\u65cb\u65bc\u4e00\u4e5d\u516d\u25cb\u5e74\u8fd4\u56de\u53f0\u5927\u91ab\u9662\u8a2d\u7acb\u653e\u5c04\u6cbb\u7642\u79d1\uff0c\u5148\u5f8c\u8cfc\u7f6e\u76f4\u7dda\u52a0\u901f\u5668\u3001\u6a21\u64ec\u651d\u5f71\u6a5f\u3001\u96fb\u8166\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u53ca\u9059\u63a7\u5f8c\u8377\u5f0f\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\u6a5f\uff0c\u4e26\u5c0d\u5c08\u79d1\u91ab\u5e2b\u7684\u8a13\u7df4\u4e0d\u907a\u9918\u529b\uff0c\u4f7f\u653e\u5c04\u6cbb\u7642\u79d1\u5f97\u4ee5\u65e5\u76ca\u5065\u58ef\u3002", "e": "After Second World War, Dr. Lee was the one who operated cancer therapy with two 250 kVp deep X-ray machines and one 100 kVp superficial X ray machine at National Taiwan University Hospital (NTUH). Since lacking the knowledge of radiation protection, he quitted this job due to leukopenia. It was taken over by other radiologists in a rotating basis. The first Co-60 machine in Taiwan was equipped in March 1958 at NTUH. Professor Shu-Chen Huang got a chance to study therapeutic radiology in London for two years and achieved D.M.R.T. She then went to Japan for one year to learn nuclear medicine. In 1960, she was back to NTUH and established the Department of Radiation Oncology and further development was carried out."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199506-2-2-161-167-a", "title": "\u8d6b\u6fdf\u6642\u7684\u57fa\u790e\u6559\u80b2\u4e00\u4f4d\u5c0d\u4e2d\u570b\u5927\u9678\u8207\u53f0\u7063\u653e\u5c04\u7dda\u5b78\u6709\u9245\u5927\u8ca2\u737b\u7684\u6559\u6388\u65e9\u5e74\u7d93\u6b77", "keywords": "\u8d6b\u6fdf\u6642;\u653e\u5c04\u7dda\u5b78;\u6b77\u53f2 Paul C. Hodges;Radiology;History", "c": "\u8d6b\u6fdf\u6642\uff0c\u7f8e\u570b\u4eba\uff0c1893\u5e741\u67086\u65e5\u51fa\u751f\uff0c\u7236\u89aa\u548c\u59e8\u7236\u90fd\u662f\u91ab\u5e2b\uff0c\u4e94\u6b72\u6642\u4fbf\u81ea\u7236\u57f7\u8f29\u91ab\u9662\u898b\u904e\u65b0\u767c\u660e\u7684X\u5149\u651d\u5f71\u6a5f\u3002\u4e0d\u5e78\u516b\u6b72\u55aa\u7236\uff0c\u96a8\u59e8\u7236\u7fd2\u91ab\u8207X\u5149\u651d\u5f71\u53ca\u50cf\u7247\u6c96\u6d17\uff0c\u559c\u611b\u624b\u4f5c\u5de5\u85dd\uff0c\u4ee5\u80fd\u5145\u7576X\u5149\u5320\u70ba\u50b2\u3002\u5f9e\u5c0f\u5b78\u5230\u5927\u5b78\uff0c\u90fd\u9760\u534a\u5de5\u534a\u8b80\u6c42\u5b78\u3002\u5538\u5927\u5b78\u91ab\u9810\u79d1\u6642\uff0c\u5fd7\u8da3\u5728\u91ab\u5b78\u8207\u751f\u7406\u5b78\u4e4b\u9593\u6416\u64fa\u3002\u5927\u5b78\u7b2c\u4e09\u5e74\u59e8\u7236\u53bb\u901d\uff0c\u4e00\u5ea6\u653e\u68c4\u91ab\u5b78\u800c\u5c31\u751f\u7406\u5b78\u30021915\u5e74\u5927\u5b78\u7562\u696d\u524d\u5915\uff0c\u6b32\u6295\u5165\u6b50\u6d32\u6230\u5834\u7f8e\u570b\u7d05\u5341\u5b57\u6703\u6551\u707d\u968a\uff0c\u537b\u9806\u5f9e\u6307\u5c0e\u6559\u6388\u7684\u5b89\u6392\uff0c\u524d\u5f80\u4e0a\u6d77\u91ab\u5b78\u9662\u6559\u6388\u751f\u7406\u5b78\u3002\u56e0\u64cd\u4f5cX\u5149\u6a5f\u5f9e\u65b0\u63a5\u89f8\u81e8\u5e8a\u5de5\u4f5c\uff0c\u6c7a\u610f\u56de\u7f8e\u570b\u5b8c\u6210\u91ab\u5b78\u6559\u80b2\u3002\u56e0\u8207\u6d1b\u514b\u83f2\u52d2\u57fa\u91d1\u6703\u63a8\u5c55\u4e2d\u570b\u91ab\u5b78\u6559\u80b2\u8a08\u756b\u4e3b\u6301\u4eba\u63a5\u89f8\uff0c\u5960\u5b9a\u4e86\u65e5\u5f8c\u5728\u5317\u5e73\u5354\u548c\u91ab\u5b78\u9662\u3001\u829d\u52a0\u54e5\u5927\u5b78\u548c\u5728\u53f0\u7063\u7684\u570b\u9632\u91ab\u5b78\u9662\u3001\u69ae\u6c11\u7e3d\u91ab\u9662\u653e\u5c04\u7dda\u5b78\u63a8\u5ee3\u6559\u80b2\u7684\u5951\u6a5f\u3002", "e": "Paul C. Hodges, an American, was born on January 6, 1893. His father and uncle were physicians, he observed the newly invented X-ray machine as early as 5 years old in his uncle's hospital. Unfortunately Paul\u2019s father died 3 years later, so he followed his uncle to learn medicine, X-ray exposure, film development and mechanics and was proud of the appellation as X-ray man. From grade school to university, Paul had to work hard for schooling and living. His interesting swung between medicine and physiology in the University of Wisconsin but concentrated in physiology after his uncle expired. A few months before graduation from the university, Mr. Hodges attempted to join the relief expedition of the American Red Cross in Europe but eventually went to Shanghai to teach physiology in the Harvard Medical School of China in 1915 by the recommendation of Dr. Percy Dawson, the professor of physiology. X-ray machine operation and reestablishment of clinical contacts in China convinced Mr. Hodges that he should finish his medical education in the United States. With the acquaintance of the members of the Rockefeller Foundation such as Simon Flexner and Roger Green and the future medical program in China, opportunities were harbored that one day Mr. Hodges would go to mainland China (Peking Union Medical School), University of Chicago, and later to Taiwan (National Defense Medical Center and Veterans General Hospital-Taipei) for teaching and the development of radiology."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-1-10-a", "title": "\u653e\u5c04\u7dda\u8a3a\u65b7\u548c\u6cbb\u7642\u5b78\u5728\u4e2d\u570b\u5927\u9678\u548c\u53f0\u7063\u7684\u767c\u5c55\u53f2", "keywords": "\u6b77\u53f2;\u90dd\u6fdf\u6642;\u653e\u5c04\u8a3a\u65b7;\u653e\u5c04\u816b\u7624 History;P.C. Hodges;Diagnostic radiology;Radiation oncology", "c": "\u4e00\u767e\u5e74\u524d\uff0c\u53731895\u5e74\uff0c\u7269\u7406\u5b78\u5bb6\u4f96\u7434\u767c\u73fe\u4e86X\u5149\u3002\u540c\u4e00\u5e74\u6e05\u671d\u7532\u5348\u6230\u6557\uff0c\u901a\u5546\u5927\u81e3\u674e\u9d3b\u7ae0\u524d\u5f80\u65e5\u672c\u99ac\u95dc\u8b70\u548c\uff0c\u537b\u906d\u65e5\u4eba\u958b\u9397\u6697\u6bba\uff0c\u5b50\u5f48\u7559\u5728\u9ad4\u5167\uff0c\u7c3d\u4e0b\u99ac\u95dc\u689d\u7d04\uff0c\u5c07\u53f0\u7063\u548c\u6f8e\u6e56\u7fa4\u5cf6\u5272\u8b93\u7d66\u65e5\u672c\u3002\u6578\u6708\u5f8c\u674e\u9d3b\u7ae0\u62cd\u4e86\u53ef\u80fd\u662f\u4e2d\u570b\u4eba\u7b2c\u4e00\u5f35\u7684X\u5149\u7247\uff0c\u986f\u793a\u5f48\u982d\u5728\u9ad4\u5167\u7684\u4f4d\u7f6e\u3002\u7f8e\u570b\u91ab\u5e2b\u3001\u751f\u7406\u5b78\u535a\u58eb\u3001\u653e\u5c04\u7dda\u5b78\u6559\u6388\u90dd\u6fdf\u6642\uff0c1915\u81f31927\u5e74\u5728\u5927\u9678\uff08\u4e0a\u6d77\u91ab\u5b78\u9662\u548c\u5317\u5e73\u91ab\u5b78\u9662\uff09\u30021960\u81f31962\u5e74\u5728\u53f0\u7063\uff08\u570b\u9632\u91ab\u5b78\u9662\u548c\u69ae\u6c11\u7e3d\u91ab\u9662\uff09\u4ecb\u7d39\u548c\u767c\u5c55\u653e\u5c04\u7dda\u8a3a\u65b7\u548c\u6cbb\u7642\u5b78\u6709\u6975\u5927\u7684\u8ca2\u737b\u3002\u56db\u5341\u5e74\u4f86\u5433\u975c\u6559\u6388\u548c\u591a\u4f4d\u5b78\u8005\u5e36\u9818\u53f0\u7063\u7684\u91ab\u5b78\u9662\u548c\u91ab\u5b78\u4e2d\u5fc3\u5982\u53f0\u5927\u91ab\u9662\uff0c\u570b\u9632\u91ab\u5b78\u9662\uff0f\u4e09\u8ecd\u7e3d\u91ab\u9662\u548c\u570b\u7acb\u967d\u660e\u5927\u5b78\uff0f\u53f0\u5317\u69ae\u6c11\u7e3d\u91ab\u9662\u7b49\u5728\u653e\u5c04\u816b\u7624\u5b78\u7684\u6280\u8853\u548c\u6559\u80b2\u84ec\u52c3\u767c\u5c55\uff0c\u5176\u7d93\u904e\u8207\u91cd\u5927\u4e8b\u4ef6\uff0c\u5728x\u5149\u767c\u73fe\u767e\u5468\u5e74\u7d00\u5ff5\u4e4b\u969b\uff0c\u6df1\u503c\u8ffd\u8ff0\u3002", "e": "In 1995 there will be a great number of centennial celebration world-wide for discovery of X-rays by a German physicist Wilhelm Conrad Roentgen in 1895, the very year that the Chinese northern navy of Ching Dynasty defeated by the Japanese who eventually annexed Taiwan and Pescadores Islands for 51 years according to the Sino-Japanese Treaty of Shimonoseki! Statesman of Chinese government Hung-Chang Li, the delegate for negotiation of the Treaty who received a gun shot injury in Shimonoseki, was probably the first Chinese to have the X-ray examination to show the bullet in the body. Dr. Paul C. Hodges, M.D., Ph. D. in physiology and professor of radiology was an American who made the greatest contribution to introduce diagnostic and therapeutic radiology to mainland China (Shanghai Harvard Medical School of China, Peking Union Medical College) from 1915 to 1927 and to Taiwan (National Defense Medical Center and Veterans General Hospital-Taipei) from 1960 to 1962. The other pioneers, important events and development of technology and training of modern radiotherapy in Taiwan in the medical schools and major medical centers such as National Taiwan University Hospital, the National Defense Medical Center/Tri-Service General Hospital and National Yang Ming University/Veterans General Hospital-Taipei in the last forty years were very dynamic and fascinating worthwhile to mention on this centennial occasion."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-11-18-a", "title": "\u6297\u764c\u85e5Taxol\u8207\u653e\u5c04\u7dda\u7684\u653e\u5c04\u589e\u654f\u4f5c\u7528\uff1a\u5c0b\u627e\u6700\u4f73\u914d\u5408\u7684\u7406\u8ad6\u57fa\u790e", "keywords": "Taxol;\u653e\u5c04\u589e\u654f;\u51cb\u4ea1 Taxol;Radiosensitization;Apoptosis", "c": "\u7814\u7a76\u4ee5\u7d30\u80de\u51cb\u4ea1\u73fe\u8c61\u4f5c\u70ba\u85e5\u7269\u653e\u5c04\u589e\u654f\u73fe\u8c61\u7684\u7406\u8ad6\u8207\u65b9\u6cd5\u8a55\u4f30\u3002\u540c\u6642\u627e\u5c0b\u6700\u4f73\u7684\u6297\u764c\u85e5Taxol\u8207\u653e\u5c04\u7dda\u7167\u5c04\u7684\u6700\u4f73\u914d\u5408\u65b9\u5f0f\u3002\u6e2c\u5b9a\u5b50\u5bae\u9838\u764c\u7d30\u80deHeLas3\u5c0d\u65bcTaxol\u7684\u751f\u9577\u6291\u5236\u6fc3\u5ea6\uff0c\u7fa4\u843d\u751f\u5b58\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\uff0c\u627e\u5c0b\u6700\u4f73\u7684Taxol\u4f7f\u7528\u6cd5\u3002\u4ee5\u7531\u4f4e\u81f3\u9ad8\u4e09\u7a2e\u5291\u91cfTaxol\u8655\u74062\u5c0f\u6642\u621624\u5c0f\u6642\uff0c\u653e\u5c04\u7dda\u5c07\u57282\u5c0f\u6642Taxol\u8655\u7406\u5f8c\u5373\u523b\u6216\u662f\u518d\u7b4924\u5c0f\u6642\u5f8c\u7d66\u5b502Gy\u7167\u5c04\uff0c\u6216\u662fTaxol\u8655\u740624\u5c0f\u6642\u5f8c\u96a8\u5373\u7167\u5c04\u3002\u5404\u7a2e\u689d\u4ef6\u7684\u7d30\u80de\u7e3d\u6688\u5168\u6578\u6536\u96c6\u5f8c\uff0c\u4ee5\u87a2\u5149\u93e1\u6aa2\u51cb\u4ea1\u7d30\u80de\u7684\u6bd4\u7387\uff0c\u4ee5\u53ca\u5229\u7528\u6d41\u91cf\u7d30\u80de\u5100\u6e2c\u91cf\u6b21G1\u671f\u53caG2M\u671f\u7d30\u80de\u4e4b\u6bd4\u7387\u3002Taxol\u9020\u6210\u7d30\u80de\u51cb\u4ea1\u73fe\u8c61\u4ee5\u53ca\u6b21G1\u671f\u7d30\u80de\u589e\u52a0\uff0c2Gy\u7684\u7167\u5c04\u6703\u589e\u52a0\u8a72\u73fe\u8c61\u3002\u51cb\u4ea1\u6bd4\u7387\u96a8Taxol\u5291\u91cf\u8207\u6642\u9593\u800c\u589e\u52a0\u3002\u4ee5\u8a72\u5169\u7a2e\u6307\u6a19\u53ef\u4ee5\u770b\u51fa\u6700\u5927\u653e\u5c04\u589e\u654f\u73fe\u8c61\u5728Taxol\u4ee5\u4f4e\u5291\u91cf\u8655\u74062\u5c0f\u6642\u5f8c\uff0c\u518d\u904e24\u5c0f\u6642\u624d\u7167\u5c04\u70ba\u6700\u660e\u986f\u3002\u589e\u654f\u7684\u539f\u56e0\u662f\u6709\u66f4\u591a\u7684\u7d30\u80de\u505c\u7559\u5728G2M\u671f\u3002\u7d30\u80de\u51cb\u4ea1\u73fe\u8c61\u4ee5\u53ca\u6b21G1\u671f\u6bd4\u7387\u53ef\u4ee5\u7528\u4f86\u4f5c\u70ba\u653e\u5c04\u589e\u654f\u4f5c\u7528\u7684\u6307\u6a19\u3002\u5efa\u8b70\u6700\u4f73Taxol\u4f7f\u7528\u6cd5\u70ba\u6bcf\u5929\u4f4e\u5291\u91cfTaxol 2-3\u5c0f\u6642\u975c\u6ce8\uff0c\u6bcf\u5929\u5728\u6ce8\u5c04\u4e4b\u5f8c\u7167\u5c042Gy\u76f4\u5230\u7167\u5c04\u7d50\u675f\u3002", "e": "Taxol is active in many types of human tumors, and is a potent radiosensitization drug. Because clonogenic assay in studying drug-radiation interaction is not sensitive enough to detect the viability change caused by low dose radiation, an in vitro apoptotic assay is used to evaluate the synergistic effect of taxol and low dose radiation as well as to arrange the optimal schedule for using taxol in radiotherapy. The growth inhibition curve and radiation survival curve were determined with or without taxol on HeLa cells. HeLa cells were treated with various doses of taxol for 2 or 24 hrs. Radiation of 2Gy was given at various time intervals following taxol treatment. Percentages of apoptotic cells were calculated according to nucleus morphology after propidium iodide staining was counted by fluorescence microscope. The proportion of cell cycle distribution was determined by flow cytometry. Cytotoxicity of taxol is not dose-dependent with killing efficiency most obvious at low dose. However, the increase of apoptotic cells and cells at sub-G1 phase following taxol treatment are correlated with the taxol concentration and the timing to irradiation. The maximal effect of taxol-2Gy combination assessed by percentage of apoptosis and sub-G1 phase proportion was resulted from low dose (IC10) taxol for 2hr and then radiation 24hr later. Under such condition, taxol functioned as a cell-cycle selective radiosensitizer. (Partial supported by VGH 83-158 and D0H84-HR-202)"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-19-23-a", "title": "\u7dad\u751f\u7d20\u4e19\u5c0d\u65bc\u653e\u5c04\u7dda\u50b7\u5bb3\u4e4b\u4fee\u5fa9\u8207\u9810\u9632\u6548\u61c9\u7684\u9ad4\u5916\u7814\u7a76", "keywords": "\u7dad\u751f\u7d20\u4e19;\u653e\u5c04\u7dda\u9ecf\u819c\u708e;\u4e2d\u570b\u5927\u9830\u9f20\u5375\u5de2\u7d30\u80de;\u81a0\u539f\u7e96\u7dad Vitamin C;Radiation mucositis;CHO cells;Collagen fibers", "c": "\u4ee5\u4e0d\u540c\u6fc3\u5ea6\u4e4b\u7dad\u751f\u7d20\u4e19(ascorbic acid, AA)\u52a0\u65bc\u57f9\u990a\u4e2d\u4e4b\u4e2d\u570b\u5927\u9830\u9f20\u5375\u5de2\u7d30\u80de(Chinese hamster ovary cells, CHO\u7d30\u80de)\uff0c\u89c0\u5bdfAA\u5c0d\u65bc\u7d30\u80de\u4e4b\u6bd2\u6027\u53ca\u63a5\u53d7\u9237\uff0d\u516d\u5341\u7167\u5c04\u7684\u7d30\u80de\u5728\u8f3b\u5c04\u751f\u7269\u8207\u81a0\u539f\u7e96\u7dad(collagen fibers)\u5408\u6210\u65b9\u9762\u7684\u6548\u61c9\u3002\u7d50\u679c\u986f\u793a\u7576AA\u6fc3\u5ea6\u90540.025mg/ml\u6642\uff0c\u958b\u59cb\u5c0dCHO\u7d30\u80de\u4e4b\u751f\u9577\u7522\u751f\u6291\u5236\u4f5c\u7528\uff1b\u7576\u6fc3\u5ea6\u9054\u52300.25mg/ml\u6642\uff0c\u53ef\u6291\u523680% CHO\u7d30\u80de\uff1b\u7576\u6fc3\u5ea6\u9054\u52302.5mg/ml\u6642\uff0c100%\u7d30\u80de\u88ab\u6bba\u6b7b\u3002\u6b64\u5916\uff0c\u7576AA\u6fc3\u5ea6\u589e\u52a0\uff0c\u5247CHO\u7d30\u80de\u5c0d\u81a0\u539f\u7e96\u7dad\u524d\u9a45\u7269\u8cea\u812f\u80fa\u9178(proline)\u4e4b\u651d\u53d6\u4ea6\u589e\u52a0\uff0c\u7576AA\u6fc3\u5ea6\u70ba0.25mg/ml\u6642\uff0c\u5176\u651d\u53d6\u4e4b\u91cf\u7d04\u662f\u4e0d\u52a0AA\u4e4b\u4e00\u500d\uff0c\u5176\u5408\u6210\u81a0\u539f\u7e96\u7dad\u4e4b\u80fd\u529b\u4e5f\u5c31\u589e\u52a0\u4e86\u4e00\u500d\u3002\u7814\u7a76\u7d50\u679c\u4ea6\u986f\u793aCHO\u7d30\u80de\u751f\u5b58\u5206\u6578\u96a8\u8457\u653e\u5c04\u7dda\u5291\u91cf\u589e\u52a0\u800c\u6e1b\u5c11\u3002\u7136\u800c\uff0c\u7576\u7d30\u80de\u57f9\u990a\u6db2\u4e2d\u7dadAA\u7684\u6fc3\u5ea6\u70ba0.025 -0.25mg/ml\u6642\uff0cAA\u5c0dCHO\u7d30\u80de\u6709\u7a0b\u5ea6\u4e0d\u7b49\u7684\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\uff0c\u4e14\u6b64\u4fdd\u8b77\u4f5c\u7528\u96a8AA\u6fc3\u5ea6\u4e4b\u589e\u52a0\u800c\u8da8\u660e\u986f\uff0c\u9019\u7a2e\u73fe\u8c61\u5728\u7d30\u80de\u63a5\u53d7400\u6216800 cGy\u7167\u5c04\u6642\u7121\u986f\u8457\u5dee\u7570\uff0c\u4f46\u662f\u7576\u7d30\u80de\u63a5\u53d71200\u62161600 cGy\u7167\u5c04\u6642\uff0cAA (0.25mg/ml)\u5c0d\u65bcCHO\u7d30\u80de\u7684\u8f3b\u5c04\u4fdd\u8b77\u4f5c\u7528\u6700\u660e\u986f\uff0c\u5176\u7a0b\u5ea6\u7d04\u662f\u4e0d\u52a0AA\u7d44\u76843.5-4.0\u500d\u3002", "e": "The effects of various concentrations of ascorbic acid (AA) on the cell growth, the systhesis of collagen fibers and radiosensitivity of irradiated CFIO cells were tested. When the concentration reached 0.025mg/ml, inhibition of cell growth appeared. At 0.25mg/ml, 80% of the CHO cells were inhibited. All cells were killed at the concentration of 2.5mg/ml. The uptake of the collagen precursor, proline, was increased as a function of AA concentration. Proline uptake doubled at the concentration of 0.25mg/ml compared with cells that were without AA, implying a 2-fold increased in collagen systhesis. A radioprotection effect of AA was also noted as a function of AA concentration in the range of 0.025-0.25mg/ml. This effect was not apparent between the dose of 400 and 800 cGy; it was most prominent when dose of 1200 or 1600 cGy was given to the cells at an AA concentration of 0.25mg/ml where a protective factor of 3.5-4.0 was observed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-25-34-a", "title": "Medulloblastoma: The Treatment Results and Literature Review", "keywords": "\u795e\u7d93\u7ba1\u80da\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642;\u9810\u5f8c Medulloblastoma;Radiation therapy;Prognosis", "c": "\u81ea1982\u5e74\u5143\u6708\u52301991\u5e7412\u6708\uff0c\u5171\u670924\u4f8b\uff08\u7537\uff1a\u5973=13:11\uff09\u5e74\u9f61\u4ecb\u65bc10\u500b\u6708\u523013\u6b72\uff08\u4e2d\u503c\u5e74\u9f61\u662f6\u6b72\uff09\u7d93\u7d44\u7e54\u5207\u7247\u8b49\u5be6\u4e4b\u795e\u7d93\u7ba1\u80da\u7d30\u80de\u7624\u75c5\u60a3\u65bc\u99ac\u5055\u91ab\u9662\u63a5\u53d7\u6cbb\u7642\uff1b\u5168\u90e8\u75c5\u60a3\u5747\u63a5\u53d7\u624b\u8853\u5207\u9664\u816b\u7624\u53ca\u8f14\u52a9\u6027\u8166\u810a\u9ad3\u8ef8\u653e\u5c04\u6cbb\u7642\u548c\u5f8c\u9871\u7aa9\u52a0\u5f37\u6cbb\u7642\u3002\u982d\u75db\uff0c\u5614\u5410\u53ca\u6b65\u614b\u4e0d\u7a69\u70ba\u672c\u6587\u75c5\u60a3\u6700\u4e3b\u8981\u7684\u81e8\u5e8a\u8868\u73fe\uff1b\u75be\u75c5\u4e4b\u7a0b\u5ea6\u5247\u4f9d\u7167Chang\u6c0f\u5206\u7d1a\u7cfb\u7d71\u52a0\u4ee5\u5340\u5206\uff1b\u5176\u5168\u9ad45\u5e74\u751f\u5b58\u7387\u70ba58%\uff1b\u6b64\u5916\u5973\u6027\u76845\u5e74\u751f\u5b58\u7387\u6bd4\u7537\u6027\u4f73\uff0873%\u53ca46%, P=0.03\uff09\uff0c\u65e9\u671f\u60a3\u8005\uff08T1\u53caT2\uff09\u6bd4\u665a\u671f\uff08T3\u53caT4\uff09\u6709\u8f03\u597d\u76845\u5e74\u751f\u5b58\u7387\uff0871%\u53ca40%, P =0.016\uff09 \uff0c\u5f8c\u9871\u7aa9\u4e4b\u5291\u91cf\u81f350 Gy\u4ee5\u4e0a\u7684\u6709\u8f03\u9ad8\u76845\u5e74\u751f\u5b58\u7387\uff0873%\u53ca33%, P=0.05\uff09\uff1b\u800c\u624b\u8853\u5207\u9664\u7684\u5b8c\u6574\u6027\u4e26\u4e0d\u5f71\u97ff5\u5e74\u751f\u5b58\u7387(P=0.13) \uff0c\u4e14\u5e74\u7d00\u5927\u65bc5\u6b72\u8005\u96d6\u71365\u5e74\u751f\u5b58\u7387\u8f03\u9ad8\u4f46P\u503c\u70ba0.066\uff0871%\u53ca40%\uff09\u3002\u672c\u5831\u544a\u4e4b\u5fa9\u767c\u7387\u905450%(12/24)\uff0c\u5176\u4e2d\u53ea\u67093\u500b\u75c5\u4f8b\u65bc\u8ffd\u8e64\u4e2d\u5c1a\u5b58\u6d3b\u3002\n\u7531\u6587\u737b\u4e4b\u56de\u9867\u53ca\u672c\u6587\u4e2d\u5206\u6790\u53ef\u77e5\u7531\u65bc\u5f8c\u9871\u7aa9\u8d85\u904e50 Gy\u7684\u7167\u5c04\u53ca\u8a3a\u65b7\u6280\u8853\u6539\u9032\uff0c\u5168\u9ad4\u751f\u5b58\u7387\u5df2\u6709\u5f88\u5927\u4e4b\u9032\u6b65\uff0c\u56e0\u800c\u665a\u671f\u7684\u5f8c\u907a\u75c7\u5df2\u6210\u70ba\u91cd\u8981\u4e3b\u984c\uff1b\u7136\u800c\uff0c\u5728\u665a\u671f\u6216\u5fa9\u767c\u75c5\u4f8b\u5176\u9810\u5f8c\u4ecd\u7136\u4e0d\u4f73\u3002\u6545\u8a02\u5b9a\u9069\u7576\u8981\u4ef6\u4ee5\u964d\u4f4e\u9577\u671f\u526f\u4f5c\u7528\u53ca\u9032\u4e00\u6b65\u6539\u5584\u6cbb\u7642\u7d50\u679c\u662f\u5fc5\u9808\u7684\u3002", "e": "Twenty-four children (M:F=13:11) whose ages ranged from 10 months to 13 years (median age 6 years) with histologically confirmed medulloblastomas were treated at Mackay Memorial Hospital from January 1982 to December 1991. All 24 patients were to undergo extensive resection and then to receive a primary course of adjuvant craniospinal axis irradiation with a local posterior fossa boost. The anatomical extent of the disease was classified according to the Chang staging system. Headache, vomiting and an unsteady gait were the major presentations in this series. The overall 5-year survival rate was 58% respectively. In addition, the overall 5-year survival rate was statistically higher in females than in males (73% vs 46%, P=0.03), in early-stage tumors (T1 & T2) than in late-stage tumors (T3 & T4) (71% vs 40%, P=0.066), and in patients who received a dose of 50 Gy or more to the posterior fossa than in those who received a lower dose (73% vs 33%, P=0.05). The extent of surgery had no impact on the survival rate (P=0.13). Patients older than 5-years of age had a higher 5-year survival rate but it was not statistically significant (71% vs 40%, P=0.066). The overall relapse rate was 50% in our series with only 3 eases survived in the follow-up.\nFrom the literature review and the results of this series, we can conclude that by more than 50 Gy posterior fossa irradiation, the overall survival rate has much improved, so the late sequellae have become an important subject. However, there is still poor outcome in advanced disease and recurrent disease. The optimal selection criteria are urgently required to reduce long-term complications and to increase survival in poor outcome groups."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-35-39-a", "title": "Conservation Therapy of Breast Cancer", "keywords": "\u4e73\u623f\u4fdd\u5b88\u6cbb\u7642\u6cd5;\u653e\u5c04\u6cbb\u7642;\u4e73\u764c Breast conservation therapy;Radiotherapy;Breast Cancer", "c": "\u5f9e1987\u81f31994\u5e74\uff0c21\u4f4d\u65e9\u671f\u4e73\u764c\u75c5\u4eba\uff08\u7b2c\u4e00\u671f\u548c\u7b2c\u4e8c\u671f\uff09\u5728\u672c\u9662\u63a5\u53d7\u4fdd\u5b88\u816b\u7624\u5207\u9664\u624b\u8853\uff0c\u4e26\u4fdd\u5b58\u4e86\u5b8c\u597d\u7684\u4e73\u623f\u5916\u578b\uff0c\u4ea6\u7a31\u4e73\u623f\u4fdd\u5b88\u6cbb\u7642\uff0c\u624b\u8853\u5f8c\u518d\u5230\u653e\u5c04\u816b\u7624\u79d1\u63a5\u53d7\u5c40\u90e8\u653e\u5c04\u6cbb\u7642\u3002\u9237\uff0d\u516d\u5341\u6cbb\u7642\u6a5f(Theratron Cobalt-60 unit)\u62166-MV\u5149\u5b50\u76f4\u7dda\u52a0\u901f\u5668(6-MV Linear Accelerator unit)\u4f5c\u70ba\u6cbb\u7642\u5de5\u5177\uff0c\u4e26\u7528\u5207\u9762\u7167\u91ce(Tangential Field)\u7167\u5c04\u60a3\u5074\u4e73\u623f\u81f35040 cGy\u5206\u70ba28\u6b21\u7167\u5c04\uff0c\u53e6\u5916\u5728\u958b\u5200\u75a4\u75d5\u8655\u518d\u7528180 cGy\u5206\u6b21\u91cf\u4e4b\u96fb\u5b50\u5c04\u7dda(6-MeV or 9-MeV Electron beam)\uff0c\u5c40\u90e8\u7167\u5c041000 cGy\u81f32000 cGy\u3002\u9664\u53bb\u5169\u4f4d\u5931\u53bb\u8ffd\u8e64\u4e4b\u75c5\u60a3\uff0c\u5341\u4e5d\u4f4d\u75c5\u60a3\u4e4b\u6578\u64da\u5206\u6790\u7d50\u679c\u5f97\u51fa\uff0c\u4e94\u5e74\u5b58\u6d3b\u7387\u70ba80%\uff0c\u4ee5\u53ca\u767e\u5206\u4e4b\u767e\u7684\u5c40\u90e8\u63a7\u5236\u7387\uff0c\u6210\u6548\u5be6\u5728\u4ee4\u4eba\u9f13\u821e\u3002\u7e3d\u800c\u8a00\u4e4b\uff0c\u4e73\u623f\u4fdd\u5b88\u6cbb\u7642\u8f14\u52a0\u653e\u5c04\u7dda\u5c40\u90e8\u7167\u5c04\u4e4b\u65b9\u6cd5\uff0c\u7528\u65bc\u65e9\u671f\u4e73\u764c\u75c5\u60a3\u662f\u503c\u5f97\u9f13\u52f5\u7684\uff0c\u56e0\u70ba\u5b83\u9664\u4e86\u53ef\u4ee5\u5f97\u5230\u826f\u597d\u4e4b\u5c40\u90e8\u63a7\u5236\u5916\uff0c\u9084\u4fdd\u5b58\u4e86\u75c5\u60a3\u4e73\u623f\u4e4b\u5b8c\u6574\u7f8e\u89c0\uff0c\u53ef\u8b02\u5b8c\u7f8e\u4e4b\u81f3\u3002", "e": "From 1987 to 1994, twenty-one cases of early breast cancer (stage I or II) received conservative operation to preserve breasts. They were referred to the Department of the Radiation Oncology for radiotherapy. Tangential field irradiation using a Theratron Cobalt-60 unit or a 6-MV Linear Accelerator unit was given to the involved breast with a dose of 5040 cGy in 28 fractions, followed by surgical sear boost of 1000 to 2000 cGy in 180 cGy per fraction with 6-MeV or 9-MeV electron beam. With two patients lost to follow-up after radiotherapy excluded, nineteen patients were analysed with an encouraging results showing an 80% 5-year overall survival rate and a 100% local control rate.\nIn conclusion, Breast Conservation Therapy (BCT) with adjuvant irradiation should be encouraged for early stage breast cancer because it has the benefits of a good local tumor control and superior breast cosmetic result."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-41-45-a", "title": "Optimization of Position and Exposure Time of Radioactive Source in High-Dose-Rate Afterloading Brachytherapy", "keywords": "\u5f8c\u8377\u5f0f\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642;\u6cbb\u7642\u8a08\u756b;\u6700\u4f73\u5316 Afterloading high-dose-rate;brachytherapy;Treatment planning;Optimization", "c": "\u5f8c\u8377\u5f0f\u9ad8\u5291\u91cf\u7387\u8fd1\u63a5\u6cbb\u7642\u92a5\uff0d\u4e5d\u4e8c\u55ae\u4e00\u5c04\u6e90\uff0c\u95773.5\u5398\u7c73\uff0c\u76f4\u5f911.1\u5398\u7c73\uff0c\u53ef\u9060\u8ddd\u96e2\u7a0b\u5f0f\u5316\u79fb\u52d5\u5230\u9810\u8a2d\u7684\u4f4d\u7f6e\uff0c\u5728\u56fa\u5b9a\u7684\u6642\u7a0b\u5167\u67092.5\u62165.0\u5398\u7c73\u5169\u7a2e\u9593\u8ddd\u7684\u79fb\u52d5\u65b9\u5f0f\u3002\u7406\u8ad6\u4e0a\u5c0d\u4e00\u56fa\u5b9a\u6cbb\u7642\u65b9\u5f0f\u5c04\u6e90\u4f4d\u7f6e\u53ca\u66b4\u9732\u6642\u805e\u6709\u7121\u9650\u591a\u7684\u6392\u5217\u65b9\u5f0f\u3002\u70ba\u7372\u5f97\u6eff\u610f\u7684\u5291\u91cf\u66f2\u7dda\u5fc5\u9808\u5148\u6c7a\u5b9a\u6700\u7406\u60f3\u7684\u5c04\u6e90\u4f4d\u7f6e\u53ca\u66b4\u9732\u6642\u9593\u7684\u7d44\u5408\uff0c\u53ef\u7528\u7dda\u6027\u65b9\u7a0b\u7d44\u4f86\u8a08\u7b97\uff0c\u4f46\u5927\u591a\u6578\u4f4d\u7f6e\u7684\u66b4\u9732\u6642\u554f\u70ba\u8ca0\u6578\u503c\uff0c\u672c\u7814\u7a76\u662f\u767c\u5c55\u4e00\u5957\u6578\u5b78\u65b9\u6cd5\u8a08\u7b97\u5c04\u6e90\u6578\u76ee\u4f4d\u7f6e\u53ca\u66b4\u9732\u6642\u554f\u7684\u6700\u4f73\u7d44\u5408\uff0c\u4e26\u4e14\u5229\u7528CMS\u6cbb\u7642\u8a08\u756b\u7cfb\u7d71\u5c07\u5291\u91cf\u5206\u4f48\u756b\u51fa\u4f86\uff0c\u5be6\u969b\u7684\u8003\u91cf\u5247\u5efa\u7acb\u5713\u67f1\u5f62\u5291\u91cf\u6cbb\u7642\u6642\u9593\u53ca\u4f4d\u7f6e\u8868\uff0c\u5291\u91cf\u7684\u8aa4\u5dee\u5747\u57284%\u4ee5\u5167\u3002\u9032\u4e00\u6b65\u80fd\u8a08\u7b97\u55ae\u4e00\u5e73\u9762\u4e09\u6839\u63d2\u91dd\u8fd1\u63a5\u6cbb\u7642\uff0c\u6b64\u539f\u7406\u80fd\u61c9\u7528\u5728\u66f4\u8907\u96dc\u7684\u6cbb\u7642\u8a08\u756b\u3002", "e": "In the high-dose-rate afterloading brachytherapy unit, the 3.5 mm in length and 1.1 mm in diameter Ir-192 single source is remotely and programmably moved into thc preset positions which can be 2.5 or 5.0 mm apart for a certain period of time. Theoretically, there are infinite arrangements of position and exposure time of the radioactive source for a given treatment. In order to produce satisfactory isodose curves, the best number and allocation of the source position and exposure time must be predetermined. Optimization of number, location and exposure time of the source can be calculated involving linear equations. Unfortunately, by direct calculation the exposure time can be negative for some positions. In this study, a mathematical method is developed to calculate the number and proper positions of the source and the exposure time in each position, the dose distribution can be plotted out by a plotter of CMS treatment planning system, By this algorithm we match the dose requirement as clinically needed. For practical consideration, a table of source dwelling-time for cylindrical dose contour is constructed. The dose distributions were found to corresponding within 4% as initially requested. Furthermore, using the multiple linear equation one can determine the position and exposure time for up to three needles on single plane brachytherapy. This principles can be applied to more complicated treatment plannings."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-47-55-a", "title": "Estimation of High-Energy Primary Photon-Induced Doses for Non Charged Particle Equilibrium Conditions", "keywords": "\u5149\u5b50\u5291\u91cf;\u589e\u5efa\u5291\u91cf Photon dose;Buildup dose", "c": "\u7576\u4e00\u675f\u9ad8\u80fd\u91cf\u7684\u5149\u5b50\u7167\u5c04\u5230\uff0d\u7269\u8cea\u4e0a\u6642\uff0c\u901a\u5e38\u5728\u81e8\u63a5\u65bc\u7269\u8cea\u8868\u9762\u4e0b\u7684\u4e00\u5c0f\u90e8\u4efd\u5340\u57df\u5167\u6240\u7522\u751f\u7684\u96fb\u5b50\uff0c\u4e26\u4e0d\u6703\u9054\u5230\uff0d\u5e73\u8861\u7a69\u5b9a\u7684\u72c0\u614b\u3002\u672c\u7814\u7a76\u8a08\u5283\u5229\u7528\u6240\u5c0e\u51fa\u4f86\u7684\u6b21\u7d1a\u96fb\u5b50\u80fd\u91cf\u5206\u4f48\u66f2\u7dda\u65b9\u7a0b\u5f0f\u4f86\u8a08\u7b97\u5728\u4e0d\u540c\u5149\u5b50\u80fd\u91cf\u5c04\u675f\u4e0b\u7684\u6b21\u7d1a\u96fb\u5b50\u5206\u4f48\u66f2\u7dda\u60c5\u5f62\uff0c\u518d\u4ee5\u6240\u7522\u751f\u7684\u6b21\u7d1a\u96fb\u5b50\u80fd\u91cf\u5149\u8b5c\u52a0\u4e0aSPencer\u7684\u96fb\u5b50\u5728\u7269\u8cea\u4e2d\u4e4b\u80fd\u91cf\u6d88\u6563\u5206\u4f48\u66f2\u7dda\u6578\u64da\uff0c\u4f86\u63a8\u7b97\u5728\u589e\u5efa\u5340\u57df\u5167\u5f9e\u76ae\u819a\u8868\u9762\u5230\u6975\u5927\u5291\u91cfDmax\u4e0b\u4e4b\u5149\u5b50\u5291\u91cf\uff0c\u6700\u5f8c\u4ee5\u6240\u5f97\u5230\u7684\u589e\u5efa\u5340\u57df\u5167\u5149\u5b50\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u6578\u64da\u63a8\u6f14\u51fa\u4e00\u500b\u4ee5\u81ea\u7136\u6307\u6578\u70ba\u5e95\u7684\u65b9\u7a0b\u5f0f\uff0c\u4f86\u4ee3\u8868\u4e0d\u540c\u80fd\u91cf\u7684\u5149\u5b50\u5728\u589e\u5efa\u5340\u57df\u5167\u4e4b\u5291\u91cf\u5206\u4f48\u66f2\u7dda\u60c5\u5f62\u3002\u6240\u8a08\u7b97\u7684\u5149\u5b50\u80fd\u91cf\u5f9e\u9237\u516d\u5341\u76841.25 MeV\uff08\u767e\u842c\u96fb\u5b50\u4f0f\u7279\uff09\u523025 MV\u7684\u76f4\u7dda\u52a0\u901f\u5668\u7b49\u3002", "e": "This research used derived equations for secondary electron energy distributions in water irradiated by gamma rays in conjunction with generated electron spectra for different incident photon energies to estimate primary photon-induced absorbed doses for non charged particle equilibrium conditions in the dose buildup regions. The pair production contribution was added to the Compton spectrum for 2 MeV to 30 MeV photons. The generated electron spectral data were combined with Spencer's electron energy dissipation distribution data to calculate the buildup dose from the skin surface up to the depth of maximum dose under non charged particle equilibrium conditions. We then fit our calculated results to exponential and polynomial forms and obtained the final buildup dose in one exponential form. The computed results for 1.25 MeV, 5 MeV and 10 MeV monoenergetic photons are presented and compared to experimental results for (superscript 60)Co gamma radiation, and 10 MV and 25 MV accelerator produced radiations."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-57-62-a", "title": "Quality Assurance in Modern Sophisticated LINAC Radiotherapy", "keywords": "\u54c1\u8cea\u4fdd\u8b49;\u91ab\u7528\u52a0\u901f\u5668;\u653e\u5c04\u6cbb\u7642 Quality assurance;LINAC;Radiotherapy", "c": "\u8fd1\u5e7e\u5e74\u4f86\uff0c\u7531\u65bc\u653e\u5c04\u6cbb\u7642\u79d1\u6280\u7684\u9ad8\u5ea6\u767c\u5c55\uff0c\u5df2\u5927\u5e45\u63d0\u6607\u4e86\u5c40\u90e8\u816b\u7624\u7684\u63a7\u5236\u7387\u3002\u653e\u5c04\u6cbb\u7642\u54c1\u8cea\u4fdd\u8b49\u5728\u65bc\u76e3\u7763\u548c\u63d0\u6607\u764c\u75c7\u75c5\u4eba\u7684\u5be6\u969b\u6cbb\u7642\u54c1\u8cea\uff0c\u6240\u4ee5\u9700\u8981\u5468\u8a73\u7684\u54c1\u8cea\u4fdd\u8b49\u8a08\u5283\u4f86\u78ba\u4fdd\u764c\u75c7\u6cbb\u7642\u7684\u6548\u679c\u3002\u4e3b\u8981\u7684\u54c1\u8cea\u4fdd\u8b49\u9805\u76ee\u5305\u62ec\u6709\u75c5\u4eba\u548c\u6cbb\u7642\u4eba\u54e1\u7684\u5e45\u5c04\u9632\u8b77\u3001\u91ab\u7528\u76f4\u7dda\u52a0\u901f\u5668\u7684\u5b89\u5168\u64cd\u4f5c\u548c\u7dad\u8b77\u4ee5\u53ca\u6e96\u78ba\u7684\u816b\u7624\u7167\u5c04\u5291\u91cf\u3002\u4e09\u5ea6\u7a7a\u9593\u201c\u96a8\u5f62\u201d\u6cbb\u7642\u5c0d\u65bc\u6cbb\u7642\u7167\u5c04\u7684\u7cbe\u78ba\u5ea6\u8981\u6c42\u975e\u5e38\u9ad8\uff0c\u6240\u4ee5\u5fc5\u9808\u8981\u6709\u66f4\u5468\u8a73\u7684\u54c1\u8cea\u4fdd\u8b49\u7a0b\u5e8f\u4ee5\u78ba\u4fdd\u91ab\u5e2b\u8655\u65b9\u8207\u5be6\u969b\u6cbb\u7642\u6642\u7684\u4e00\u81f4\u6027\u3002\u7531\u65bc\u6cbb\u7642\u8a08\u5283\u7cfb\u7d71\u548c\u6cbb\u7642\u6a5f\u5668\u7684\u7cbe\u5bc6\u5ea6\u548c\u8907\u96dc\u6027\u8207\u65e5\u4ff1\u589e\uff0c\u6240\u4ee5\u6211\u5011\u9700\u8981\u66f4\u5468\u8a73\u7684\u54c1\u8cea\u4fdd\u8b49\u8a08\u5283\u4f86\u78ba\u4fdd\u6cbb\u7642\u7684\u54c1\u8cea\u548c\u6548\u679c\u3002", "e": "The tremendous developments in radiation therapy technology open a new prospect for improvements in local tumor control. Quality assurance in radiation treatment attempts to monitor and improve the quality of cancer patient therapy. The major quality assurance programs include radiation protection of personnel and patients, safe operations, maintenance of the medical accelerator, and an accurate dose delivery to the target volume. Three dimensional conformal therapy puts greater attention in the treatment delivery precision, and hence greater efforts should be made in quality assurance to ensure uniformity between the radiation treatment prescription and the actual treatment delivered. With the increasingly complex treatment planning systems and treatment machines, extra and more stringent quality assurance programs are needed to ensure safety of the patients and personnel, and the accuracy of the dose delivery."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-63-67-a", "title": "\u5168\u982d\u76ae\u653e\u5c04\u6cbb\u7642\u6280\u8853\u4e4b\u5291\u91cf\u8853\u8a55\u4f30", "keywords": "\u5168\u982d\u76ae\u7167\u5c04;\u5149\u5b50;\u96fb\u5b50;\u4e0d\u898f\u5247\u7167\u91ce Total scalp irradiaion;Photon;Electron;Irregular field", "c": "\u7531\u65bc\u982d\u9871\u7684\u5f62\u72c0\u548c\u9760\u8fd1\u6b63\u5e38\u8166\u7d44\u7e54\u7684\u56e0\u7d20\u4f7f\u5f97\u5168\u982d\u76ae\u653e\u5c04\u6cbb\u7642\u6280\u8853\u8207\u5291\u91cf\u8853\u4e0a\u5b58\u5728\u4e00\u4e9b\u56f0\u96e3\u6027\uff0c\u672c\u6587\u5c07\u4ecb\u7d39\u5229\u7528\u5169\u76f8\u5c0d\u50746 MV\u5149\u5b50\u5c04\u7dda\u6cbb\u7642\u8166\u908a\u7de3\u5340\u518d\u4ee5 6MeV\u96fb\u5b50\u5c04\u7dda\u6cbb\u7642\u8166\u5074\u908a\u5e73\u5766\u5340\u7684\u6280\u8853\uff0c\u982d\u90e8\u56fa\u5b9a\u65b9\u5f0f\u3001\u96fb\u5b50\u53ca\u5149\u5b50\u7167\u91ce\u925b\u584a\u88fd\u4f5c\u3001\u586b\u5145\u7269\u7684\u61c9\u7528\u4e5f\u5217\u5165\u8a0e\u8ad6\u3002\u53e6\u5916\u518d\u6df1\u5165\u63a2\u8a0e\u5291\u91cf\u5206\u4f48\u60c5\u5f62\u3002\u5149\u5b50\u5c04\u7dda\u8208\u96fb\u5b50\u5c04\u7dda\u6240\u9020\u6210\u5168\u982d\u76ae\u53ca\u7167\u91ce\u4ea4\u754c\u5340\u7684\u5291\u91cf\u5206\u4f48\u662f\u5229\u7528\u77f3\u881f\u982d\u5f62\u5047\u9ad4\u8207\u5e95\u7247\u4f5c\u8a55\u4f30\uff0c\u5be6\u9a57\u4e2d\u53ef\u770b\u5230\u7167\u91ce\u4ea4\u754c\u8655\u6703\u9020\u6210\u5291\u91cf\u7684\u4e0d\u8db3\u6216\u904e\u91cf\u7684\u554f\u984c\uff0c\u82e5\u662f\u91cd\u758a\u4ea4\u754c\u8655\u80fd\u4ee5\u79fb\u52d5\u65b9\u5f0f(moving junction)\u8655\u7406\u5247\u53ef\u4ee5\u907f\u514d\u5291\u91cf\u904e\u4efd\u96c6\u4e2d\u7684\u554f\u984c\uff0c\u6b64\u5916\u5229\u7528\u71b1\u767c\u5149\u5291(TLD)\u4f86\u9a57\u8b49\u4e0d\u898f\u5247\u7167\u91ce\u7684\u96fb\u5b50\u5c04\u7dda\u8207\u5149\u5b50\u5c04\u7dda\u5291\u91cf\u7d66\u4e88\u7684\u6e96\u78ba\u6027\u3002", "e": "The radiation treatment of the total scalp present some technical and dosimetric problems due to the curvature of the scalp and close proximity of the scalp to the adjacent normal tissues. We introduce the technique that involves lateral apposed 6 MV photon fields to cover the outer area of the scalp and adjoining lateral 6 MeV electron fields to irradiate the inner flat area. The purpose of this report is to evaluate the dosimetric results in this technique. We also discuss the technique procedures including the head immobolization, electron and photon block making and bolus setting. Wax head phantom with film were used to evaluate the dose distribution around the scalp. In fields junction area showed the problems of underdosage or overdosage. The moving junction will be recommended as a way to solve the problem. TLD dosimeter was used as a tool to check the accuracy of dose given by irregular electron and photon field."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199503-2-1-69-77-a", "title": "Characteristics, Advantages and Limitations of a Treatment Planning System for Gamma Knife Radiosurgery", "keywords": "\u653e\u5c04\u624b\u8853;\u52a0\u99ac\u5200;\u6cbb\u7642\u8a08\u756b;KULA Radiosurgery;Gamma Knife;Treatment planning;KULA", "c": "\u672c\u6587\u4e3b\u65e8\u5728\u4ecb\u7d39\u52a0\u99ac\u5200\u6cbb\u7642\u8a08\u756bKULA\u7cfb\u7d71\u7684\u7279\u8272\uff0c\u4e26\u4ee5\u4e00\u5fa9\u767c\u9f3b\u54bd\u70ba\u4f8b\uff0c\u8a0e\u8ad6\u81e8\u5e8a\u4e0a\u4f7f\u7528\u8a72\u7cfb\u7d71\u4e4b\u512a\u7f3a\u9ede\u3002\n\u81ea1993\u5e743\u6708\u8d77\u672c\u9662\u958b\u59cb\u4ee5\u7acb\u9ad4\u5b9a\u4f4d\u52a0\u99ac\u624b\u8853\u5200\u6cbb\u7642\u8166\u5167\u4e4b\u52d5\u975c\u8108\u7578\u578b\uff0c\u807d\u795e\u7d93\u7624\u53ca\u5176\u4ed6\u9871\u5167\u826f\u6027\u6216\u60e1\u6027\u816b\u7624\u3002\u70ba\u8a08\u7b97201\u500b\u9237\u516d\u5341\u5c04\u6e90\u7684\u5408\u6210\u5291\u91cf\uff0c\u6b64\u7a2e\u653e\u5c04\u624b\u8853\u61c9\u7528\u4e86\u7279\u5225\u8a2d\u8a08\u7684\u6cbb\u7642\u8a08\u756b\u96fb\u8166\u8edf\u9ad4(KULA)\u3002\u6cbb\u7642\u7684\u539f\u7406\u662f\u5806\u7a4d\u4e0d\u540c\u5927\u5c0f\u4e4b\u7167\u5c04\u805a\u7126\u4e2d\u5fc3(shots)\u4f86\u6db5\u84cb\u816b\u7624\u7bc4\u570d\u3002KULA\u4f7f\u7528\u4e09\u5ea6\u7a7a\u9593\u5291\u91cf\u8a08\u7b97\uff0c\u4e26\u4ee5\u6c34\u5e73\u9762\u3001\u51a0\u72c0\u5207\u9762\u3001\u77e2\u72c0\u5207\u9762\u7b49\u4e8c\u5ea6\u7a7a\u9593\u7684\u65b9\u5f0f\u5448\u73fe\u5291\u91cf\u5206\u5e03\u5716\u3002\u4e0d\u4f46\u53ef\u4ee5\u7528\u55ae\u4e00\u805a\u7126\u4e2d\u5fc3\u6cbb\u7642\u8f03\u5c0f\u7684\u816b\u7624\uff0c\u5806\u7a4d\u6700\u591a\u9054\u5341\u4e8c\u500b\u805a\u7126\u4e2d\u5fc3\u4e5f\u53ef\u6cbb\u7642\u8f03\u5927\u7684\u816b\u7624\u3002\u8a08\u7b97\u7d50\u679c\u53ef\u7372\u5f97\u76f8\u7576\u826f\u597d\u7684\u7cbe\u78ba\u5ea6\u53ca\u4ee4\u4eba\u6eff\u610f\u7684\u5291\u91cf\u5206\u4f48\uff0c\u4f46\u5c0d\u65bc\u9ad4\u7a4d\u8f03\u5927\u4e14\u5f62\u72c0\u4e0d\u898f\u5247\u7684\u816b\u7624\uff0c\u4f8b\u5982\u5fa9\u767c\u65bc\u9871\u5e95\u7684\u9f3b\u54bd\u764c\uff0c\u6cbb\u7642\u8a08\u756b\u6240\u82b1\u7684\u6642\u554f\u76f8\u7576\u5197\u9577\u3002\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00\u662fKULA\u7cfb\u7d71\u5728\u8f38\u5165\u6307\u4ee4\uff0c\u57f7\u884c\u8a08\u7b97\u53ca\u986f\u793a\u7b49\u5291\u91cf\u66f2\u7dda\u5716\u7684\u529f\u80fd\u4e0a\uff0c\u6548\u7387\u4e0d\u4f73\u3002\u5b83\u672a\u80fd\u5c07\u5f71\u50cf\u6aa2\u67e5\u8cc7\u6599\u7d0d\u5165\u8a08\u756b\u7cfb\u7d71\u5167\uff0c\u4e5f\u6c92\u6709\u63d0\u4f9b\u4f7f\u7528\u8005\u8207\u5716\u5f62\u7684\u4ecb\u9762\u3002\u96d6\u7136\u7d93\u904e\u591a\u6b21\u7684\u4fee\u6b63\u5f8c\u4ecd\u80fd\u5f97\u5230\u6eff\u610f\u610f\u7684\u5291\u91cf\u5206\u5e03\uff0c\u4f46\u6240\u8cbb\u7684\u6642\u805e\u76f8\u7576\u4e0d\u7d93\u6fdf\u3002\u5728\u65b0\u4e00\u4ee3\u7684\u6cbb\u7642\u8a08\u756b\u8edf\u9ad4\u5c1a\u672a\u555f\u7528\u524d\uff0c\u719f\u6089KULA\u7cfb\u7d71\u7684\u7279\u6027\u53ca\u805a\u7126\u4e2d\u5fc3\u7684\u914d\u7f6e\u7d44\u5408\u539f\u5247\uff0c\u662f\u9032\u884c\u9ad8\u6548\u7387\u6cbb\u7642\u8a08\u756b\u7684\u552f\u4e00\u9014\u5f91\u3002", "e": "Stereotactic radiosurgery refers to the use of small, well-collimated beams of ionizing radiation to ablate intracranial lesions. In our hospital radiosurgery with the Leksell Gamma Knife was used to treat AVM, acoustic neuroma, meningioma, glioma and other benign or malignant brain tumors. To deal with 201 cobalt-60 sources of the Gamma Knife, the complex dosimetry was performed using specially developed computer software (KULA). The treatment planning with KULA for a recurrent nasopharyngeal cancer after external beam radiotherapy is presented. After initial rough planning with 12 shots to cover the tumor, repeated revisions of coordinates and weights of most shots resulted in a 50% isodose curve matching the tumor contour in 3 dimensions. The possibility of neurological complication is low due to the relative low dose (\uff1c30%) to the neighboring optic nerve and brain stem. Though the result of this laborious and prolonged treatment planning is good, the amenity and efficiency of using KULA are unsatisfactory for this large and irregular shaped tumor. When stacking of multiple isocenters or shots in 3 dimensions to fill the tumor volume, the melded isodose curves can be very differnt from the simple combination of individual curves and trials and errors are inevitable. For efficient planning of large and irregular shaped tumors with KULA, it is essential to be familiar with the principle of allocation and methods of fine adjustment of parameters of shots."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-301-307-a", "title": "\u6bcf\u65e5\u5169\u6b21\u5c0f\u5291\u91cf\u534a\u8eab\u653e\u5c04\u6cbb\u7642\u5c0d\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6cbb\u7642\u8a55\u4f30", "keywords": "\u6bcf\u65e5\u5169\u6b21\u653e\u5c04\u6cbb\u7642;\u534a\u8eab\u653e\u5c04\u6cbb\u7642;\u591a\u767c\u6027\u9aa8\u9ad3\u7624 Twice Daily Radiotherapy Half Body Radiotherapy Multiple Myeloma", "c": "\u4e09\u8ecd\u7e3d\u91ab\u9662\u5f9e\u6c11\u570b79\u5e746\u6708\u81f382\u5e745\u6708\uff0c\u4ee5\u534a\u8eab\u653e\u5c04\u6cbb\u7642(HBRT)\u4e00\u5171\u6cbb\u7642\u4e8610\u4f4d\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u75c5\u4eba\uff0c\u6240\u6709\u7684\u75c5\u4eba\u7686\u6709\u9aa8\u9abc\u75bc\u75db\u7684\u75c7\u72c0\u3002\u5176\u4e2d7\u4f4d\u6709\u8ca7\u8840\uff0c5\u4f4d\u6709lgG\u514d\u75ab\u7403\u86cb\u767d\u5347\u9ad8\u7684\u60c5\u5f62\uff0c4\u4f4d\u6709lgA\u5347\u9ad8\uff0c\u53ea\u6709\u4e00\u4f4d\u5c3f\u4e2d\u6709Bence Jones Protein\u3002\n\u6211\u5011\u4f7f\u7528\u6bcf\u65e5\u5169\u6b21\u5c0f\u5291\u91cf(120cGy bid)\u7684HBRT\uff0c\u4f86\u6cbb\u7642\u75c5\u4eba\u3002\u7e3d\u5291\u91cf\u70ba120cGy\uff0c\u901a\u5e38\u4ee5\u6709\u75c7\u72c0\u6216\u75c7\u72c0\u8f03\u56b4\u91cd\u7684\u534a\u8eab\u5148\u958b\u59cb\u6cbb\u7642\uff0c\u4f11\u606f6\u661f\u671f\u5f8c\u518d\u6cbb\u7642\u53e6\u4e00\u534a\u8ec0\u9ad4\u3002\n\u6cbb\u7642\u7684\u7d50\u679c\u67096\u4f4d\u75c5\u4eba\u75c7\u72c0\u6709\u660e\u986f\u7684\u6539\u5584\uff0c\u5176\u5e73\u5747\u5b58\u6d3b\u671f\u5728\u6cbb\u7642\u4ee5\u5f8c\u70ba14.4\u500b\u6708\uff1b\u800c\u5176\u4ed64\u4f4d\u53ea\u6709\u8f15\u5ea6\u75c7\u72c0\u6e1b\u8f15\u7684\u75c5\u4eba\uff0c\u5176\u5e73\u5747\u5b58\u6d3b\u671f\u70ba3.9\u500b\u6708\u3002\u6cbb\u7642\u7684\u6bd2\u6027\u7686\u53ef\u5fcd\u53d7\uff0c\u800c\u4e14\u5728\u4f11\u606f\u6216\u8f38\u8840\u5f8c\u7686\u53ef\u6062\u5fa9\u5230\u6cbb\u7642\u524d\u7684\u72c0\u6cc1\u3002\n\u6240\u4ee5\u6bcf\u65e5\u5169\u6b21\u5291\u91cf\u7684\u534a\u8eab\u653e\u5c04\u6cbb\u7642\u5c0d\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u662f\u5b89\u5168\u4e14\u6709\u6548\u7684\u65b9\u6cd5\u3002", "e": "Ten patients with multiple myeloma were referred for hemibody irradiation from June 1990 to May 1993. MI patients had bone pain, 7 cases had anemia, 5 cases had elevation of lgG immunoglobulin, 4 cases had elevation of lgA level and only one patient had urine Bence-Jones protein.\nAll patients received hemibody irradiation of l200cGy in 10 fractions with 2 fractions per day. Usually, the more severe half side body was treated first and then the other half side body was treated with the same method after 6 weeks rest.\nSix patients had obvious symptom relief and their average survival time was 14.4 months after treatment. The other 4 cases had mild symptom relief and their average survival time was only 3.9 months after treatment.\nThe toxicities related to hemibody treatment were tolerable. All patients recovered after rest or blood transfusion. Our twice daily small dose hemibody irradiation is a safe and effective method."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-309-319-a", "title": "The Role of Teleradiotherapy in the Management of Craniopharygioma", "keywords": "\u9871\u54bd\u7ba1\u7624;\u653e\u5c04\u6cbb\u7642;\u5168\u5207\u9664;\u90e8\u4efd\u5207\u9664;\u5fa9\u767c;\u5f8c\u63f4\u6cbb\u7642 Craniopharyngioma;Radiotherapy;Total removal;Subtotal removal;Recurrence;Salvage;Progression free survival;Local control", "c": "\u76ee\u7684\uff1a\u5c31\u672c\u9662\u6cbb\u7642\u9871\u54bd\u7ba1\u7624\u4e4b\u7d93\u9a57\u4f5c\u4e00\u5206\u6790\uff0c\u540c\u6642\u6bd4\u8f03\u5404\u6cbb\u7642\u65b9\u6cd5\u4e4b\u7d50\u679c\u3002\n\u65b9\u6cd5\u8207\u6750\u6599\uff1a\u65bc1980\u81f31991\u5e74\u9593\uff0c\u7e3d\u8a08\u670941\u4f4d\u9871\u54bd\u7ba1\u60a3\u8005\u65bc\u53f0\u5317\u69ae\u6c11\u7e3d\u9662\u63a5\u53d7\u6cbb\u7642\u3002\u670925\u4f4d\u60a3\u8005\u63a5\u53d7\u5168\u5207\u9664\u624b\u8853\uff08\u7b2c\u4e00\u7d44\uff09,6\u4f4d\u63a5\u53d7\u90e8\u4efd\u5207\u9664\uff08\u7b2c\u4e8c\u7d44\uff09,6\u4f4d\u63a5\u53d7\u90e8\u4efd\u5207\u9664\u53ca\u653e\u5c04\u6cbb\u7642\uff08\u7b2c\u4e09\u7d44\uff09,4\u4f4d\u53ea\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff08\u7b2c\u56db\u7d44\uff09\uff0c\u6b64\u5916\u670916\u4f4d\u5fa9\u767c\u606f\u8005\u63a5\u53d7\u5f8c\u63f4\u653e\u5c04\u6cbb\u7642-\u653e\u5c04\u6cbb\u7642\u662f\u7d93\u753110MV\u5149\u5b50\u6216\u923760\u5c04\u7dda\u7d66\u4e88\uff0c\u6bcf\u9031\u4e94\u6b21\uff0c\u6bcf\u6b212Gy\uff0c\u7e3d\u816b\u7624\u8f3b\u5c04\u5291\u91cf\u70ba49-63Gy\uff08\u4e2d\u503c\u70ba60Gy\uff09\u3002\n\u7d50\u679c\uff1a\u4e94\u5e74\u7121\u75be\u75c5\u9032\u884c\u5b58\u6d3b\u7387\u70ba41.3%\uff0c\u5206\u5225\u662f25.8%\uff08\u4e00\u7d44\uff09,13.3%\uff08\u4e8c\u7d44\uff09,100%\uff08\u4e09\u7d44\uff09\uff0c\u53ca75%\uff08\u56db\u7d44\uff09(p=0.0231)\u3002\u5fa9\u767c\u60a3\u8005\u5f8c\u63f4\u6cbb\u7642\u4e4b\u4e94\u5e74\u63a7\u5236\u7387\u70ba81.3%\u3002\u5176\u4e2d\u7b2c\u4e09\u7d44\uff0c\u7b2c\u56db\u7d44\u53ca\u5fa9\u767c\u60a3\u8005\u4e4b\u816b\u7624\u8f3b\u5c04\u5291\u91cf\u5206\u5225\u70ba52,60\u53ca53cGy\u3002\u7b2c\u4e00\uff0c\u4e8c\uff0c\u4e09\u53ca\u56db\u7d44\u60a3\u8005\u4e4b\u4e2d\u503c\u816b\u7624\u63a7\u5236\u671f\u70ba11,8,50\u53ca82\u500b\u6708\u800c\u5c3f\u5d29\u4f75\u767c\u75c7\u5247\u5206\u5225\u70ba56%,50%,33%\u53ca0%\u3002\n\u7d50\u8ad6\uff1a\u7e3d\u7d50\u4f86\u8aaa\uff0c\u5728\u9871\u54bd\u7ba1\u7624\u4e4b\u6cbb\u7642\u4e0a\uff0c\u653e\u5c04\u7dda\u6cbb\u7642\u7121\u8ad6\u662f\u5728\u8853\u5f8c\u6cbb\u7642\uff0c\u5fa9\u767c\u5f8c\u4e4b\u5f8c\u63f4\u6cbb\u7642\u6216\u662f\u4e3b\u8981\u6cbb\u7642\u4e0a\u7686\u626e\u6f14\u8457\u91cd\u8981\u7684\u89d2\u8272\u3002\u800c\u90e8\u4efd\u5207\u9664\u624b\u8853\u52a0\u4e0a\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u4e0d\u4f46\u6709\u6975\u4f73\u7684\u6cbb\u7642\u6548\u679c\u4e14\u6709\u4f4e\u4f75\u767c\u75c7\u7387\u3002", "e": "Purpose: The purpose of this study was to evaluate the effectiveness of teleradiotherapy in the treatment of primary and recurrent craniopharygioma patients treated at the Veterans General Hospital-Taipei.\nMaterials and Methods: Between 1980 and 1991, 41 patients received primary management of craniopharyngioma in the VGH-Taipei. Gross total removal of tumor was performed in 25 patients (Group \u2160). Six patients had subtotal removal of tumor (Group \u2161), 6 patients had subtotal removal with postoperative radiotherapy (Group \u2162). Four patients had teleradiotherapy alone Group \u2163). Sixteen patients out of the 19 patients from Group \u2160 and Group \u2161 with recurrent tumors received salvage radiotherapy. Median tumor dose prescribed at the 90% isodose volume were 52, 60 and 53 Gy for Group \u2162, \u2163 and recurrent tumors, respectively. The fraction size was 2.0 Gy. Either 10 MV or cobalt 60 was used.\nResult: Of five-year progression-free survival was 41.3% for the whole series, and 25.8%, 13.3%, 100%, 75% for Groups \u2160, \u2161, \u2162 and \u2163, respectively (p-0.0231). The actuarial five-year local control rate after salvage radiotherapy for recurrent disease was 81.3%. The median tumor control duration were 11, 8, 50, 82 months. Rates of diabetes insipidus were 56%, 50%, 33%, 0% for Group \u2160, \u2161, \u2162 and \u2163, respectively.\nConclusion: This study shows that definitive, adjuvant and salvage radiotherapy all lead to significant improvement in local control of craniopharyngioma with few complications. Postoperative radiotherapy is also highly recommended for patients treated with subtotal resection of tumor."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-321-327-a", "title": "\u7b2c\u4e09\u671f\u5f8c\u671f\u5b50\u5bae\u9838\u764c\u63a5\u53d7\u55ae\u7368\u653e\u5c04\u7dda\u6cbb\u7642\u4e4b\u7d50\u679c", "keywords": "\u5b50\u5bae\u9838\u764c;\u653e\u5c04\u7dda\u6cbb\u7642;\u7b2c\u4e09\u671f\u5f8c\u671f cervical neoplasms;radiotherapy;stage \u2162 B", "c": "\u81ea1987\u5e7410\u6708\u81f31992\u5e746\u6708\uff0c\u5171\u670974\u4f4d\u7d93\u7d44\u7e54\u75c5\u7406\u5207\u7247\u8a3c\u5be6\u4e4b\u7b2c\u4e09\u671f\u5f8c\u671f\u5b50\u5bae\u9838\u764c\u60a3\u8005\u65bc\u672c\u79d1\u63a5\u53d7\u6839\u9664\u6027\u7684\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u75c5\u7406\u5831\u544a\u70ba\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\u8005\u4f5497%\uff0c\u800c2\u5e74\u30015\u5e74\u4e4b\u5b58\u6d3b\u7387\u5206\u5225\u70ba58%\u300137%\u3002 \u6b6474\u4f4d\u75c5\u4eba\u4e2d\u670917\u540d\u53ea\u63a5\u53d7\u4e86\u9ad4\u5916\u9aa8\u76c6\u8154\u7167\u5c04\uff0c\u53e657\u540d\u5247\u63a5\u53d7\u4e86\u9ad4\u5916\u9aa8\u76c6\u8154\u7167\u5c04\u4f75\u5b50\u5bae\u8154\u5167\u8fd1\u63a5\u6cbb\u7642\uff0c\u51765\u5e74\u5b58\u6d3b\u7387\u5206\u5225\u70ba7%\u300144%\u3002\n\u672c\u6587\u4ea6\u5206\u6790\u76f8\u95dc\u7684\u9810\u5f8c\u56e0\u5b50\uff0c\u767c\u73fe\u6cbb\u7642\u524d\u82e5\u5df2\u6709\u9aa8\u76c6\u8154\u5167\u6dcb\u5df4\u7d50\u8f49\u79fb\u8005\uff08\u6839\u64da\u96fb\u8166\u65b7\u5c64\u7247\u5224\u8b80\uff09\uff0c\u5176\u9810\u5f8c\u8f03\u7121\u8f49\u79fb\u8005\u70ba\u5dee\uff0c5\u5e74\u4fdd\u96aa\u7d71\u8a08\u5b58\u6d3b\u7387\u5206\u5225\u70ba9%\u300143%(p=0.008)\u3002\u800c\u814e\u6c34\u816b(hydronephrosis)\u7684\u6709\u7121\u4e5f\u70ba\u4e00\u9810\u5f8c\u56e0\u5b50\uff0c\u6709\u814e\u6c34\u816b\u8005\uff08\u5305\u62ec\u55ae\u6216\u96d9\u5074\uff09\u5176\u9810\u5f8c\u8f03\u7121\u814e\u6c34\u816b\u8005\u70ba\u5dee\uff0c5\u5e74\u4fdd\u96aa\u7d71\u8a08\u5b58\u6d3b\u7387\u5206\u5225\u70ba8%\u300147% (p=0.001)\u3002\n\u53e6\u7d71\u8a08\u670936\u540d\u75c5\u4eba\u6cbb\u7642\u5931\u6557\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u7bc4\u570d\u5167\uff0c\u5176\u5c40\u90e8\u5340\u57df\u6027\u5931\u6557\u7387\u70ba49%;26\u540d\u75c5\u4eba\u767c\u751f\u9060\u8655\u8f49\u79fb\uff0c\u4ee5\u80ba\u90e8\u70ba\u6700\u591a\u3002\u95dc\u65bc\u6cbb\u7642\u6240\u751f\u4e4b\u4f75\u767c\u75c7\uff0c\u517131\u540d\u75c5\u4eba\u767c\u751f\u7a0b\u5ea6\u4e0d\u4e00\u4e4b\u4f75\u767c\u75c7\uff0c\u5176\u4e2d\u767c\u751f\u653e\u5c04\u7dda\u76f4\u8178\u708e\u800519\u4eba\uff0c\u8180\u80f1\u708e\u80054\u4eba\uff0c\u9670\u9053\u72f9\u7a84\u80059\u4eba\uff0c\u90e8\u4efd\u6027\u5c0f\u8178\u963b\u585e\u80052\u4eba\uff0c\u4f46\u767c\u751f\u7b2c\u4e09\u7d1a\u6216\u7b2c\u56db\u7d1a\u4f75\u767c\u75c7\u8005\u5247\u67097\u4eba\u3002\n\u96d6\u7136\u5c0d\u65bc\u5c40\u90e8\u665a\u671f\u7684\u5b50\u5bae\u9838\u764c\uff0c\u672c\u79d1\u4e4b\u6cbb\u7642\u7d50\u679c\u8207\u570b\u5916\u76f8\u53bb\u4e0d\u9060\uff0c\u4f46\u6211\u5011\u5be6\u61c9\u767c\u5c55\u66f4\u591a\u7684\u81e8\u5e8a\u914d\u5408\u6cbb\u7642\u6a21\u5f0f\uff0c\u4ee5\u9054\u66f4\u4f73\u7684\u6cbb\u7642\u6548\u679c\u3002", "e": "From October 1987 through June 1992, 74 patients with histologically proven carcinoma of the uterine cervix, stage \u2162 B, were treated with radical radiation therapy in our department. Squamous cell carcinoma comprised 97% of the cases. The actuarial survival rate at 2 and 5 years was 58% and 37%, respectively. Seventeen patients were treated with external beam therapy only, and 57 received external beam and brachytherapy. The 5-year actuarial survival rate in these two groups was 7% vs. 44%.\nPelvic lymph nodes involvement (by computed tomography) at initial diagnosis was shown to be a strong prognostic factor. Patients with pelvic lymph nodes involvement had a 5-year actuarial survival rate of 9% whereas in those without involvement was 43% (p0.008). Hydronephrosis was also proved to be a prognostic factor. The 5-year actuarial survival rate for patients with hydronephrosis (including unilateral or bilateral sides) was lower than those without hydronephrosis (8% vs. 47%, p=0.001).\nThirty-six patients experienced pelvic failure within the irradiation field, the locoregional failure rate was 49%. Distant metastases was found in 26 patients. Lung was the most common site. Thirty-one patients developed complications attributable to radiotherapy (19 radiation proctitis, 4 cystitis, 9 vagina stenosis, 2 partial intestinal obstruction). Seven out of 31 patients were in grade 3 or 4 complications.\nAlthough our result in the management of advanced carcinoma of the uterine cervix is compatible with most of the foreign reports, more aggressive multiple treatment modalities may need further development."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-329-333-a", "title": "\u9f3b\u54bd\u764c\u4e4b\u9aa8\u9abc\u8f49\u79fb\u5206\u6790", "keywords": "\u9f3b\u54bd\u764c;\u9aa8\u9abc;\u9060\u8655\u8f49\u79fb nasopharynx;head and neck cancer;bone distant metastasis", "c": "This is a restrospective study of skeletal metastases in nasopharyngeal cancer. Between November 1987 and December 1992, 90 cases out of 630 nasopharyngeal cancer patients was found to have skeletal metastases. Multiple sites of abnormal radioisotope uptake in skeletal scintigraphy were found in all patients (100%). Radiologically, the lesions were osteolytic in 60%, mixed osteolytic and osteoblastic in 11% and osteoblastic in 29%. The spine was the most common site of bone metastasis. The distribution of metastatic sites was as follows: thoracic spine (74%), ribs (66%), lumbar spine (22%), pelvic bone (60%), sternum (28%), cervical spine (11%). There were 20 cases of spinal cord compression due to skeletal metastases. Thoracic spine was the most common site (60%), followed by lumbar spine (35%) and cervical spine (5%). In the timing of skeletal metastases, fifty-seven cases (63%) were found to have distant metastases at diagnosis or before completion of radiotherapy. The skeletal metastases of the other 33 cases occurred within 3 years after the completion of radiotherapy, the incidence in the first, second and third year were 64%, 18% and 18% respectively. The survival period for patients with skeletal metastases ranged from 1 to 44 months (median 9.5 months). The 1-year and 2-year actuarial survival rate were 48% and 16% respectively. The group receiving radiotherapy and chemotherapy had a longer survival than radiation alone or supportive treatment group. (p\uff1c0.05)", "e": "This is a restrospective study of skeletal metastases in nasopharyngeal cancer. Between November 1987 and December 1992, 90 cases out of 630 nasopharyngeal cancer patients was found to have skeletal metastases. Multiple sites of abnormal radioisotope uptake in skeletal scintigraphy were found in all patients (100%). Radiologically, the lesions were osteolytic in 60%, mixed osteolytic and osteoblastic in 11% and osteoblastic in 29%. The spine was the most common site of bone metastasis. The distribution of metastatic sites was as follows: thoracic spine (74%), ribs (66%), lumbar spine (22%), pelvic bone (60%), sternum (28%), cervical spine (11%). There were 20 cases of spinal cord compression due to skeletal metastases. Thoracic spine was the most common site (60%), followed by lumbar spine (35%) and cervical spine (5%). In the timing of skeletal metastases, fifty-seven cases (63%) were found to have distant metastases at diagnosis or before completion of radiotherapy. The skeletal metastases of the other 33 cases occurred within 3 years after the completion of radiotherapy, the incidence in the first, second and third year were 64%, 18% and 18% respectively. The survival period for patients with skeletal metastases ranged from 1 to 44 months (median 9.5 months). The 1-year and 2-year actuarial survival rate were 48% and 16% respectively. The group receiving radiotherapy and chemotherapy had a longer survival than radiation alone or supportive treatment group. (p\uff1c0.05)"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-335-343-a", "title": "\u9ad8\u71b1\u6cbb\u7642\u6240\u7522\u751f\u4e4b\u6eab\u5ea6\u5206\u4f48", "keywords": "\u9ad8\u71b1\u6cbb\u7642(hyperthermia);\u71b1\u8026\u5f0f\u6eab\u5ea6\u8a08 Hyperthermia;Thermocouple thermometer", "c": "\u81ea\u897f\u51431912\u5e74\uff0c\u7531Lambert\u63d0\u51fa\u71b1\u6cbb\u7642\u7406\u8ad6\u5f8c\uff0c\u96a8\u8457\u79d1\u6280\u7684\u65e5\u76ca\u767c\u9054\uff0c\u9ad8\u71b1\u6cbb\u7642(hyperthermia)\u8fd1\u5e74\u4f86\u5728\u764c\u75c7\u6cbb\u7642\u4e0a\uff0c\u5df2\u65e5\u6f38\u767c\u5c55\u70ba\u53e6\u4e00\u7a2e\u8f14\u52a9\u6cbb\u7642\u65b9\u6cd5\uff0c\u5176\u8207\u653e\u5c04\u6cbb\u7642\u6216\u5316\u5b78\u6cbb\u7642\u5408\u4f75\u4f7f\u7528\u6642\uff0c\u53ef\u4e92\u88dc\u5176\u4e0d\u8db3\u4e4b\u8655\uff0c\u4f7f\u764c\u75c7\u7684\u6cbb\u7652\u7387\u6709\u986f\u8457\u7684\u4e0a\u6607\u3002\u4e09\u8ecd\u7e3d\u91ab\u9662\u653e\u5c04\u816b\u7624\u90e8\u65bc\u6c11\u570b78\u5e74\u81ea\u65e5\u672c\u5f15\u9032OMRON\u5ee0\u751f\u7522\u7684HEH-500C,RF\u96fb\u5bb9\u677f\u5f0f\u96fb\u6975\u9ad8\u71b1\u6cbb\u7642\u7cfb\u7d71\uff0c\u4ee5\u5f9e\u4e8b\u9ad8\u71b1\u6cbb\u7642\u65b9\u9762\u7684\u7814\u7a76\u3002\u6b64\u7cfb\u7d71\u63a1\u7528\u71b1\u8026\u5f0f\u6eab\u5ea6\u8a08\u4f86\u91cf\u6e2c\u6eab\u5ea6\u4e4b\u8b8a\u5316\uff0c\u6b64\u6eab\u5ea6\u6e2c\u91cf\u7cfb\u7d71\u7684\u6821\u9a57\u7d50\u679c\u986f\u793a\uff0c\u5176\u7a69\u5b9a\u6027\u3001\u7cbe\u5bc6\u6027\u548c\u7cbe\u78ba\u6027\u7b49\u5747\u5728\u00b10.1\u2103\u4e4b\u5167\u3002\u6211\u5011\u4ea6\u91dd\u5c0d\u5747\u8cea\u7684\u808c\u8089\u5047\u9ad4(TX-150)\u3001\u52d5\u7269\uff08\u72d7\uff09\u53ca\u4eba\u9ad4\uff08\u5c4d\u9ad4\uff09\u505a\u4e86\u4e00\u7cfb\u5217\u7684\u52a0\u71b1\u5be6\u9a57\uff0c\u671f\u80fd\u77ad\u89e3\u5404\u7a2e\u72c0\u6cc1\u4e0b\uff0c\u6eab\u5ea6\u7684\u5206\u4f48\u60c5\u5f62\u3002", "e": "Since Dr. Lambert presented the theory of hyperthermia in 1912, the technology of hyperthermia has been improved and developed as a new modality for cancer therapy. Hyperthermia which is combined with radiotherapy or chemotherapy increases the cancer cure rate significantly. The OMRON HEH-500C RE Capacitive Plate Electrode Hyperthermia System was insatlled at the Department of Radiation Oncology of TSGH in 1989 for the clinical research of hyperthermia. The thermocouple thermometry is used for the temperature measurement in this system. In our acceptance test, the stability, precision, and accuracy, ect. of those thermocouple thermometers are all within \u00b10.1\u2103. These results agree with the acceptability criteria of the hyperthermia quality assurance guidelines."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-345-351-a", "title": "\u9237-60\u9060\u9694\u6cbb\u7642\u6a5f\u4e4btimer error\u5206\u6790", "keywords": " timer error;single/multiple exposure method", "c": "\u4f7f\u7528\u923760\u9060\u9694\u6cbb\u7642\u6a5f\u4f86\u505a\u653e\u5c04\u7dda\u6cbb\u7642\u6642\uff0c\u4e3b\u8981\u662f\u4f9d\u64da\u5c04\u6e90\u5728beam on\u4f4d\u7f6e\u4e4b\u6642\u9593\u9577\u77ed\u4f86\u9054\u5230\u6b32\u7d66\u4e88\u4e4b\u5291\u91cf\u3002\u7531\u65bc\u5c04\u6e90\u9032\u51fa\u7d14\u7cb9\u662f\u6a5f\u68b0\u52d5\u4f5c\uff0c\u6240\u4ee5\u5fc5\u7136\u6703\u7d93\u6b77\u4e00\u6bb5\u6642\u9593\u3002\u6b64\u6bb5\u6642\u9593\u5167\u7531\u65bc\u8f38\u51fa\u5291\u91cf\u7387\u662f\u8655\u65bc\u4e0d\u7a69\u5b9a\u72c0\u614b\u4e26\u975e\u5e38\u6578\u3002\u56e0\u6b64\u5728\u5291\u91cf\u6642\u9593\u8a08\u7b97\u904e\u7a0b\u5fc5\u9808\u52a0\u4ee5\u8003\u616e\uff0c\u6b64\u56e0\u5b50\u5373timer error\u3002\u76ee\u524d\u88ab\u8a8d\u70ba\u8f03\u6e96\u78ba\u4e26\u5ee3\u6cdb\u4f7f\u7528\u4f86\u6e2c\u91cftimer error\u7684\u65b9\u6cd5\u662fsingle/mustiple exposure method[1,2,3]\uff0c\u7136\u800c\u5176\u6240\u4f7f\u7528\u4e4b\u516c\u5f0f\u70ba\u89c0\u5ff5\u6027\u4e4b\u5b9a\u7fa9\uff0c\u8981\u5f9e\u5176\u4e2d\u6df1\u5165\u77ad\u89e3timer error\u4e4b\u610f\u7fa9\u4e26\u4e0d\u5bb9\u6613\u3002\u672c\u7bc7\u6587\u7ae0\u5617\u8a66\u4ee5\u8f03\u8a73\u7d30\u7684\u6578\u5b78\u5206\u6790\uff0c\u4f86\u66f4\u660e\u78ba\u5448\u73fetimer error\u4e4b\u610f\u7fa9\u3002", "e": "When we treat patient by Co-60 teletherapy unit, we give the dose depend on the time that source is on. Because that the source transits between the position of beam on and beam off is mechanical action, we can't switch the source position instantly. In the period of time, the dose rate is instable and is not constant, so we must consider the factor in dose time calculation. At present, the method used widely to calculate timer error is single/multiple exposure method[1,2,3], but it is difficult for us to completely understand the meaning of timer error. Therefore, this article will clearty describe the meaning of timer error by mathematical analysis in details."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-353-361-a", "title": "\u53f0\u7063\u5730\u5340\u6ccc\u5c3f\u9053\u764c\u7684\u8da8\u52e2", "keywords": "\u6ccc\u5c3f\u9053\u764c;\u767c\u751f\u7387;\u53f0\u7063;\u8da8\u52e2 Genitourinary tract carcinoma;incidence;Taiwan;trands", "c": "\u672c\u7814\u7a76\u5206\u6790\u53f0\u7063\u5730\u5340\u6ccc\u5c3f\u9053\u764c\u767c\u751f\u7387\u7684\u8b8a\u5316\uff0c\u9996\u5148\u81ea\u885b\u751f\u7f721979\u5e74\u81f31986\u5e74\u6240\u767c\u8868\u7684\u8cc7\u6599\uff0c\u767c\u73fe\u6ccc\u5c3f\u9053\u764c\u4e4b\u767c\u751f\u7387\u75311979\u5e74\u6bcf\u5341\u842c\u5206\u4e4b5.2\u589e\u81f31986\u5e74\u6bcf\u5341\u842c\u5206\u4e4b9.3\u3002\u5e74\u589e\u7387\u70ba8.8%\u3002\u6ccc\u5c3f\u9053\u764c\u5305\u62ec\u8180\u80f1\u764c\u3001\u814e\u764c\u53ca\u7537\u6027\u6ccc\u5c3f\u9053\u764c\u3002\u516b\u5e74\u4f86\u5206\u5225\u589e\u52a084%\u300156%\u300190%\uff0c\u5176\u5e74\u589e\u7387\u5206\u5225\u70ba9.1%\u30016.6%\u30019.6%\uff0c\u7537\u6027\u6ccc\u5c3f\u9053\u764c\u53c8\u53ef\u7d30\u5206\u70ba\u651d\u8b77\u817a\u764c\u3001\u776a\u4e38\u764c\u53ca\u9670\u8396\u764c\uff0c\u5e74\u589e\u7387\u5206\u5225\u70ba13%\u30015%\u3001-3%\u3002\n\u5206\u6790\u53f0\u5317\u69ae\u6c11\u7e3d\u91ab\u96621970\u5e74\u81f31991\u5e74\u4e4b\u764c\u8cc7\u6599\u767c\u73fe21\u5e74\u4f86\u8180\u80f1\u764c\u3001\u814e\u764c\u3001\u7537\u6027\u6ccc\u5c3f\u9053\u764c\uff0c\u6bcf\u5e74\u5206\u5225\u589e\u529b6%\u300110.5%\u53ca8.2%\u3002\u7537\u6027\u6ccc\u5c3f\u9053\u764c\u7d30\u5206\u70ba\u651d\u8b77\u817a\u764c\u3001\u776a\u4e38\u764c\u3001\u9670\u8396\u764c\uff0c\u5176\u5e74\u589e\u7387\u5206\u5225\u70ba11%\u30011.4%\u30010.9%\u3002\n\u5206\u6790\u99ac\u5055\u91ab\u96621984\u5e74\u81f31990\u5e74\u4e4b\u764c\u8cc7\u6599\u767c\u73fe\uff0c\u8180\u80f1\u764c\u3001\u814e\u764c\u3001\u7537\u6027\u6ccc\u5c3f\u9053\u764c\uff0c\u4e03\u5e74\u4f86\u6bcf\u5e74\u5206\u5225\u589e\u52a011%\u30016.3%\u53ca-0.9%\uff0c\u7537\u6027\u6ccc\u5c3f\u9053\u764c\u4e2d\u651d\u8b77\u817a\u764c\u3001\u776a\u4e38\u764c\u53ca\u9670\u8396\u764c\u5e74\u589e\u7387\u5206\u5225\u70ba-7%\u30019.1%\u30015.7%\u3002\n\u7531\u53f0\u7063\u5730\u5340\u53ca\u53f0\u5317\u69ae\u7e3d\u7684\u8cc7\u6599\uff0c\u5716\u5f62\u986f\u793a\u51fa\u651d\u8b77\u817a\u764c\u662f\u6240\u6709\u6ccc\u5c3f\u9053\u764c\u4e2d\u589e\u52a0\u6700\u5feb\u7684\u3002\u4f46\u99ac\u5055\u91ab\u9662\u53ef\u80fd\u56e0\u4eba\u6578\u8f03\u5c11\uff0c\u5176\u8cc7\u6599\u986f\u793a\u4e0d\u540c\u7684\u7d50\u679c\u3002", "e": "This study investigated the changing trends of the genitourinary tract cancers in Taiwan, From 1979 to 1986, the G-U cancers incidence rate increased from 5.2 in 1979 to 9.3 per 100,000 persons in 1986 or increased 8.8% annually. G-U cancers include uriary bladder cancer, kindney cancer and male genital cancer. The incidence of these three types of cancer increased 84%, 56%, 90% respectively from 1979 to 1986 or increased 9.1%, 6.6%, 9.6% annually. The male genital cancers may be further classified into prostate cancer, testis cancer and penis cancer, the annual increasing rate equivalent to 13%, 5%, -3% respectively.\nAnalysis of the cancer data of Veterans General Hospital-Taipei from 1970 to 1991 revealed that the number of bladder cancer, kindney cancer, male genital cancer, increased 6%, 10.5%, and 8.2% annually in 21 years. The male genital cancer may be further classified into prostate cancer, testis cancer and penis cancers, their annual increasing rate were 11%, 1.4%, 0.9% respectively.\nAnalysis of the cancer data of MacKay Memorial Hospital from 1984 to 1990. We found that the number of bladder cancer, kindey cancer and male genital cancer increased 11%, 6.3%, and -0.9% annually in 7 years. The male genital cancer may be further classified into prostate cancer, testis cancer and penis cancer1 their annual increasing rate were -7.1%, 9.1%, 5.7% respectively.\nFrom both the hospital and population based figures, carcinoma of the prostate was probably increased most rapidly in Taiwan, even though this may not be seen in the data from the Mackay Memorial Hospital."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199412-1-4-363-368-a", "title": "\u764c\u75c5\u7684\u57fa\u56e0\u6cbb\u7642", "keywords": "\u764c\u75c5;\u57fa\u56e0\u6cbb\u7642;\u8f09\u9ad4;\u653e\u5c04\u7dda cancer;gene therapy;vector;radiation", "c": "\u764c\u75c5\u7684\u50b3\u7d71\u7642\u6cd5\u9084\u6709\u7f3a\u9ede\uff0c\u65b0\u7684\u6cbb\u764c\u65b9\u6cd5\u5c1a\u5f85\u958b\u767c\uff0c\u57fa\u56e0\u6cbb\u7642\u662f\u503c\u5f97\u7814\u767c\u7684\u6cbb\u764c\u65b0\u6cd5\u3002\u6309\u57f7\u884c\u7d30\u80de\u7684\u9078\u64c7\uff0c\u57fa\u56e0\u6cbb\u7642\u6709\u751f\u6b96\u7d30\u80de\u548c\u9ad4\u7d30\u80de\u6cbb\u7642\u5169\u985e\uff0c\u800c\u4ee5\u9ad4\u7d30\u80de\u57fa\u56e0\u6cbb\u7642\u8f03\u70ba\u793e\u6703\u6240\u63a5\u53d7\uff0c\u57fa\u56e0\u6cbb\u7642\u7684\u65b9\u6cd5\u6709\u4e8c\uff0c\u4e00\u70ba\u57fa\u56e0\u7f6e\u63db\u6cbb\u7642\uff0c\u53e6\u4e00\u70ba\u57fa\u56e0\u589e\u5f37\u6cbb\u7642\u3002\u57fa\u56e0\u7684\u8f09\u904b\u7cfb\u7d71\u5247\u6709\u75c5\u6bd2\u8f09\u904b\u8207\u975e\u75c5\u6bd2\u8f09\u904b\u5169\u7a2e\u3002\u524d\u8005\u767c\u5c55\u8f03\u65e9\uff0c\u5f8c\u8005\u6f38\u88ab\u91cd\u8996\u3002\u57fa\u56e0\u6cbb\u7642\u7684\u6548\u61c9\uff0c\u8981\u900f\u904e\u5206\u5b50\u7684\u4f5c\u7528\uff0c\u9019\u4e9b\u5206\u5b50\u5305\u62ec\u91cd\u7d44\u85e5\u3001\u751f\u7269\u8a0a\u606f\u5206\u5b50\u3001\u514d\u75ab\u8abf\u63a7\u5206\u5b50\u3001\u964d\u6bd2\u5206\u5b50\u3001\u5c0e\u5411\u578b\u85e5\u7269\u548c\u88ab\u7f6e\u63db\u7684\u57fa\u56e0\u3002\u653e\u5c04\u7dda\u7167\u5c04\u6703\u8a98\u5c0e\u591a\u7a2e\u57fa\u56e0\u7684\u8868\u73fe\uff0c\u5982jun, fos, NF(\u4e0b\u6a19 x)\u3001B,Egr-1,PKC \u53ca\u591a\u7a2e\u7d30\u80de\u7d20\uff0c\u6709\u4e9b\u53ef\u52a0\u5f37\u764c\u7d30\u80de\u7684\u6bd2\u6bba\u80fd\u529b\uff0c\u6709\u4e9b\u5c0d\u6b63\u5e38\u7d30\u80de\u6709\u4fdd\u8b77\u4f5c\u7528\uff0c\u6545\u653e\u5c04\u7dda\u7167\u5c04\u7684\u57fa\u56e0\u6cbb\u7642\u6b63\u5728\u7814\u767c\u4e2d\u3002\u57fa\u56e0\u6cbb\u7642\u4e26\u975e\u7d55\u5c0d\u5b89\u5168\uff0c\u6f5b\u5728\u7684\u5371\u96aa\u5305\u62ec\u6b63\u5e38\u7d30\u80de\u764c\u5316\u3001\u74b0\u5883\u70ba\u91cd\u7d44\u75c5\u6bd2\u6240\u6c61\u67d3\u3001\u75c5\u6bd2\u8840\u75c7\u3001\u4eba\u9ad4\u70ba\u4e0d\u826f\u75c5\u6bd2\u6216\u5fae\u751f\u7269\u6c61\u67d3\uff0c\u5f15\u9032\u9ad4\u5916\u907a\u50b3\u7269\u8cea\u7b49\u3002\u56e0\u6b64\u5728\u9ad4\u5167\u5c0d\u764c\u7d30\u80de\u4f5c\u57fa\u56e0\u8f49\u6b96\uff0c\u5fc5\u9808\u6548\u7387\u9ad8\u800c\u7a69\u5b9a\uff0c\u4fdd\u8b77\u75c5\u4eba\u548c\u5de5\u4f5c\u4eba\u54e1\u7684\u5b89\u5168\u3002", "e": "Gene therapy may involve germ cells or somatic cells and the latter is more acceptable to the society. In therapy, the genes can be either replaced or gene augmented. Gene transfer techniques are either viral or non-viral. The former has developed earlier and has become more popular; the latter is gaining more momentum in the research because of its safety. Elements involoved in gene therapy are recombinant drugs, informational molecules, genetic immunomodulation, detoxified molecules, targeting drugs and replacement genes. Radiation may induce expression of certain genes such as jun, fos, NFkB, Egr-1, PKC and several cytokines, some may enhance killing effect of cancer cells while some may protect normal cells. Radiation-associated gene therapy is under development. Gene therapy is not risk-free. Potential risks include insertional mutagenesis leading to cancer, environmental pollution of infectious recombinant virus, toxic shock caused by viremia, contamination of human body with deleterious viruses or microorganisms and transfer of nonviral exogenous genetic materials. Therefore, in the study of gene therapy, gene transfer into tumor cells in vivo should be efficent and stable and should ensure safety for both patients and staff."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-217-227-a", "title": "A Pilot Study of Taxol Treatment in Carcinoma of Unknown Primary Site: Preliminary Results", "keywords": "Taxol;\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u764c\u75c7 Taxol;Carcinoma of Unknown Primary Site", "c": "\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u764c\u75c7\uff08\u4e0d\u660e\u764c\uff09\u4f75\u6709\u5ee3\u6cdb\u809d\u8f49\u79fb\u7684\u9810\u5f8c\u975e\u5e38\u5dee\u3002\u8fd1\u5341\u5e74\uff0c\u5728\u6297\u764c\u85e5\u7269\u7684\u767c\u5c55\u4e0a\uff0cTaxol\u662f\u6700\u6709\u5c55\u671b\u7684\u5176\u4e2d\u4e4b\u4e00\u3002\u7136\u800cTaxol\u5c0d\u4e0d\u660e\u764c\u7684\u6297\u764c\u6548\u679c\uff0c\u65e5\u524d\u4ecd\u5c6c\u672a\u77e5\u3002\u6b64\u524d\u5c0e\u6027\u7814\u7a76\u7684\u76ee\u7684\u5728\u63a2\u8a0eTaxol\u6cbb\u7642\u4e0d\u660e\u764c\u7684\u53ef\u884c\u6027\u3002\u7814\u7a76\u65b9\u6cd5\u662f\u9078\u64c7\u4e0d\u660e\u764c\u4f75\u809d\u8f49\u79fb\u75c5\u60a3\u4ee5\u6bcf3\u661f\u671f\u70ba\u4e00\u7642\u7a0b\uff0c\u7d66\u4e88Taxol\u6bcf\u5e73\u65b9\u516c\u5c3a\u9ad4\u8868\u9762\u7a4d175\u6beb\u514b\u975c\u8108\u6ce8\u5c043\u5c0f\u6642\uff0c\u4e26\u8a55\u4f30\u6cbb\u7642\u53cd\u61c9\u53ca\u6bd2\u6027\u53cd\u61c9\u3002\u7d50\u679c\uff0c\u5171\u67093\u4f4d\u75c5\u4eba\uff0c\u524d2\u4f4d\u66fe\u63a5\u53d7\u904e\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642\u3002\u7b2c1\u4f4d\u60a3\u8005\u5c0dTaxol\u6709\u90e8\u4efd\u7de9\u89e3\u53cd\u61c9\uff0c\u8010\u53d7\u5ea6\u76f8\u7576\u597d\u4e14\u5291\u91cf\u5728\u4e0d\u4f9d\u9760\u4efb\u4f55\u767d\u8840\u7403\u523a\u6fc0\u751f\u9577\u56e0\u5b50\u4e4b\u4e0b\uff0c\u53ef\u63d0\u9ad8\u5230\u6bcf\u5e73\u65b9\u516c\u5c3a\u9ad4\u8868\u9762\u7a4d230\u6beb\u514b\u3002\u7b2c2\u4f4d\u60a3\u8005\u672c\u8eab\u662fB\u578b\u809d\u708e\u5e36\u539f\u8005\uff0c\u4ed6\u53ea\u63a5\u53d7\u904e\u4e00\u500b\u7642\u7a0b\u76ee\u524d\u5c1a\u5f85\u8a55\u4f30\u6cbb\u7642\u53cd\u61c9\uff0c\u4f46\u5c0dTaxol\u6cbb\u7642\u7684\u8010\u53d7\u6027\u76f8\u7576\u597d\u3002\u6574\u500b\u4f86\u8aaa\uff0cTaxol\u5f15\u8d77\u7684\u6bd2\u6027\u53cd\u61c9\u662f\u76f8\u7576\u53ef\u5fcd\u53d7\u7684\uff0c\u4e3b\u8981\u6bd2\u6027\u662f\u9aa8\u9ad3\u6291\u5236\uff0c\u5291\u91cf\u9650\u5236\u7684\u6bd2\u6027\u5728\u9996\u4f4d\u60a3\u8005\u662f\u808c\u8089\u75bc\u75db\u3002\u7121\u53ad\u98df\u3001\u5614\u5410\u3001\u809d\u814e\u6bd2\u6027\u3001\u5fc3\u5f8b\u4e0d\u6574\u6216\u904e\u654f\u53cd\u61c9\u3002\n\u7d50\u8ad6\uff0c\u6b64\u524d\u5c0e\u6027\u7814\u7a76\u7684\u521d\u5831\u63d0\u793a\uff1a\u7528Taxol\u6cbb\u7642\u66fe\u7d93\u5316\u5b78\u6cbb\u7642\u6216\u653e\u5c04\u6cbb\u7642\u4e14\u4f75\u809d\u8f49\u79fb\u7684\u4e0d\u660e\u764c\uff0c\u4ee53\u661f\u671f\u70ba\u4e00\u7642\u7a0b\uff0c\u4f7f\u7528\u6bcf\u5e73\u65b9\u516c\u5c3a\u9ad4\u8868\u9762\u7a4d175\u6beb\u514b\uff0c3\u5c0f\u6642\u975c\u8108\u6ce8\u5c04\u65b9\u5f0f\uff0c\u662f\u53ef\u884c\u7684\uff0c\u6b64\u6cbb\u7642\u4e0d\u50c5\u8010\u53d7\u6027\u76f8\u7576\u597d\uff0c\u800c\u4e14\u9996\u4f4d\u60a3\u8005\u66f4\u662f\u7b2c\u4e00\u4f4d\u88ab\u5831\u544a\u4f7f\u7528Taxol\u6cbb\u7642\u9811\u56fa\u6027\u4e0d\u660e\u764c\u6709\u6548\u7684\u75c5\u4f8b\u3002", "e": "Background: Patients with carcinoma of unknown primary site (CUPS) and massive liver metastasis have a poor prognosis. Taxol is one of the most promising anticancer agent developed in the last decade. The anticancer activity of Taxol in CUPS is unknown. The objective of this pilot study is to investigate the feasibility of Taxol treatment in CUPS.\nMethod: Patients with CUPS with massive liver metastases were eligible. Taxol 175 mg/m^2 was administered by 3-hour intravenous infusion every three weeks. Patients were evaluated for response and toxicity.\nResults: Three patients were studied. The first two patients had failed previous chemotherapy and radiotherapy. The first patient had partial response to Taxol therapy. He tolerated Taxol well. Taxol was escalated to 230 mg/m^2 without G.CSF support. The second patient, a hepatitis B carrier, received one course of Taxol treatment and had stable disease. He tolerated treatment well but developed reactivation of hepatitis B virus with ful-minant hepatitis. The third patient tolerated treatment well but response was too early to be evaluated. The overall toxicities of Taxol treatment were tolerable. The major toxicity was myelosuppression. The dose-limiting toxicity was myalgia in one patient. No nausea, vomiting, major organ toxicity, hypersensitivity reaction or heart block was noted.\nConclusions: The preliminary results of this pilot study suggest that it is feasible to administer Taxol with full dose of 175 mg/m^2 in 3-hour intravenous infusion every 3 weeks to CUPS patients. Taxol treatment was well tolerated. The anticancer response observed in this study was the first report of effectiveness of taxol in the treatment of CUPS patient with massive liver metastases, and refractory to chemotherapy and radiotherapy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-229-234-a", "title": "A Pilot Study of Concomitant Cisplatin and Radiotherapy as Organ Preservative Treatment for Invasive Urinary Bladder Cancer", "keywords": "\u4fb5\u72af\u6027\u8180\u80f1\u764c;\u9251\u5291;\u5316\u653e\u5408\u4f75\u6cbb\u7642;\u5668\u5b98\u4fdd\u5b58\u7642\u6cd5 Invasive bladder cancer;cisplatin;concomitant radio-chemotherapy;organ preservative treatment", "c": "\u5f9e1989\u5e746\u6708\u81f31991\u5e748\u6708\u6b62\uff0c\u6709\u5341\u4f4d\u75c5\u4eba\uff08\u5176\u4e2d\u503c\u5e74\u9f61\u70ba74\u6b72\uff09\u56e0\u7f79\u60a3\uff08\u808c\u8089\u5c64\uff09\u4fb5\u72af\u6027\u8180\u80f1\u764c\u5728\u505a\u5b8c\u7d93\u5c3f\u9053\u8180\u80f1\u522e\u9664\u8853\u522e\u9664\u816b\u7624\u5f8c\uff0c\u7e7c\u7e8c\u63a5\u53d7\u653e\u5c04\u7dda\u5408\u4f75\u9251\u5291\u7642\u6cd5\u4ee5\u4fdd\u7559\u5668\u5b98\u3002\u5728\u4e2d\u503c\u8ffd\u8e64\u671f33\u500b\u6708\u5167\uff08\u7bc4\u570d\u753117\u81f340\u500b\u6708\uff09\uff0c\u5341\u4f8b\u5747\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff0c\u5176\u4e2d\u4e00\u4f8b7\u500b\u6708\u5f8c\u5c40\u90e8\u5fa9\u767c\uff0c\u56e0\u6b64\u5c40\u90e8\u63a7\u5236\u7387\u905490%\u3002\u6b64\u5916\u7121\u4e00\u4f8b\u56e0\u5c40\u90e8\u5fa9\u767c\u6216\u526f\u505a\u7528\u63a5\u53d7\u8180\u80f1\u5207\u9664\u8853\uff0c\u6545\u6240\u6709\u75c5\u4eba\u7686\u4fdd\u7559\u8180\u80f1\u3002\u6709\u5169\u4f8b\u767c\u751f\u9060\u7aef\u8f49\u79fb\uff0c\u58f9\u5728\u8166\uff0c\u58f9\u5728\u9aa8\u982d\u3002\u6cbb\u7642\u671f\u554f\u7121\u75c5\u4eba\u56e0\u6025\u6027\u4f75\u767c\u75c7\u5fc5\u9808\u4f4f\u9662\u6cbb\u7642\uff0c\u4f46\u6709\u56db\u4f8b\u56e0\u6cbb\u7642\u800c\u767c\u751f\u665a\u671f\u4f75\u767c\u75c7\uff0c\u4e00\u4f8b\u70ba\u51fa\u8840\u6027\u8180\u80f1\u708e\uff1b\u53e6\u4e09\u4f8b\u56e0\u8f38\u5c3f\u7ba1\u72f9\u7a84\u767c\u751f\u5169\u5074\u814e\u6c34\u816b\u3002\u9019\u5341\u4f4d\u75c5\u4eba\u4e4b\u58f9\u5e74\u671f\u53ca\u8cb3\u5e74\u671f\u7cbe\u7b97\u5b58\u6d3b\u7387\u5404\u70ba100%\u53ca89%\u3002\u6211\u5011\u7684\u7d50\u8ad6\u662f\u5316\u653e\u5408\u4f75\u6cbb\u7642\u4e0d\u50c5\u5c0d\u7f79\u60a3\u4fb5\u72af\u6027\u8180\u80f1\u764c\u7684\u9ad8\u5e74\u75c5\u4eba\u662f\u58f9\u7a2e\u6613\u8010\u53d7\u7684\u6cbb\u7642\uff0c\u4e14\u80fd\u6709\u6548\u9054\u5230\u9ad8\u5c40\u90e8\u63a7\u5236\u7387\u53ca\u8180\u80f1\u4fdd\u5b58\u7387\u3002", "e": "From June 1989 to August 1991, ten patients with invasive bladder cancers (6 were inoperable and 4 refused surgery) were treated with concomitant cisplatin (25mg/m^2 weekly for 6 cycles) and irradiation (median 61.5 Gy) after transurethral resection. Their median age was 74 years old. The complete response rate was 100% within median follow-up time of 33 months (range: 17 to 40 months). One out of the ten treated patients had local recurrence 7 months after treatment. The overall local tumor control rate was 90%. All the patients preserved their bladders. Two patients developed distant metastasis, one in bone and one in brain. No significant acute toxic effects related to irradiation and chemotherapy occurred. Four patients had late sequelae from treatment. One had hemorrhagic cystitis and the other three developed bilateral hydronephrosis due to ureter stenosis. The one-year and two-year actuarial survival rates were 100%and 89% respectively. Our results demonstrate that concomitant cisplatin and irradiation is a tolerable, effective treatment for old-aged patients with invasive bladder cancer. High local control rate and bladder preservation rate can also be achieved by this combined-modality treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-235-240-a", "title": "Concurrent Chemotherapy and Radiotherapy of Anal Cancer", "keywords": "\u809b\u9580\u764c;\u5316\u653e\u5408\u5e77\u6cbb\u7642;\u809b\u9580\u62ec\u7d04\u808c\u4fdd\u5b58;5-Fluorouracil;Mitomycin-C Anal cancer;concurrent chemoradiotherapy;anal sphincter preservation;5-Fluorouracil;Mitomycin-C", "c": "\u5f9e1985\u5e742\u6708\u52301992\u5e7412\u6708\u6b62\uff0c\u670917\u4f4d\u75c5\u4eba\u56e0\u60a3\u809b\u9580\u764c\u63a5\u53d7\u5316\u653e\u5408\u5e77\u6cbb\u7642\u3002\u816b\u7624\u5206\u671f\u70baT13\u4f4d\uff0cT28\u4f4d\uff0cT33\u4f4d\u53caT43\u4f4d\u3002\u4e5d\u4f8b\u6709\u8179\u80a1\u6e9d\u6dcb\u5df4\u816b\u5927\u300216\u4f8b\u5728\u653e\u7642\u671f\u9593\u63a5\u53d75-Fluorouracil(SFU)\u548cMitomycin-C(MMC)\u7684\u5316\u7642\uff0c\u53e6\u4e00\u4f8b\u63a5\u53d7 Cisplatin\uff0cSFU\u548cLeucovorin\u3002\u9060\u8ddd\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u6bcf\u65e5\u5291\u91cf1.8\u52302.0Gy\uff0c\u4e2d\u503c\u5291\u91cf55Gy\u300215\u4f8b\u65bc\u6cbb\u7642\u5f8c\u816b\u7624\u5b8c\u5168\u6d88\u5931\uff0c12\u4f8b\u6301\u7e8c\u816b\u7624\u63a7\u5236\uff0c\u6b6412\u4f4d\u75c5\u4eba\uff0c\u67098\u4eba\u5b58\u6d3b\u4e14\u672a\u6709\u816b\u7624\u5fa9\u767c\uff0c3\u4f8b\u6709\u9060\u7aef\u8f49\u79fb\uff0c\u53e6\u4e00\u4f8b\u56e0\u5176\u5b83\u75be\u75c5\u6b7b\u4ea1\u3002\u5c40\u90e8\u672a\u63a7\u5236\u76845\u4f8b\uff0c\u67093\u4f8b\u63a5\u53d7\u8179\u6703\u9670\u5207\u9664(Abdomino-perineal resection)\uff0c\u7d50\u679c2\u4f8b\u56e0\u5c40\u90e8\u816b\u7624\u6b7b\u4ea1\uff0c2\u4f8b\u56e0\u5c40\u90e8\u53ca\u9060\u7aef\u816b\u7624\u6b7b\u4ea1\uff0c\u53e6\u4e00\u4f8b\u5c40\u90e8\u63a7\u5236\u4f46\u6b7b\u65bc\u9060\u7aef\u8f49\u79fb\u3002\u5169\u5e74\u7684\u7cbe\u7b97\u5b58\u6d3b\u7387\u70ba68%\uff0c\u572812\u4f4d\u5c40\u90e8\u63a7\u5236\u75c5\u60a3\uff0c\u670910\u4f4d\u4fdd\u5b58\u809b\u9580\u529f\u80fd\u3002\u6211\u5011\u8a8d\u7232\u653e\u5c04\u6cbb\u7642\u5408\u5e77\u5316\u5b78\u6cbb\u7642\u5c0d\u809b\u9580\u764c\u75c5\u60a3\u80fd\u63d0\u4f9b\u597d\u7684\u5c40\u90e8\u63a7\u5236\u53ca\u4fdd\u7559\u809b\u9580\u529f\u80fd\u3002", "e": "From February 1985 to December 1992, 17 patients with carcinoma of anal canal were treated by concurrent radiotherapy and chemotherapy There were 3patients with TI, 8 with T2, 3 with T3, and 3 with T4 lesions. Nine patients had palpable inguinal lymph nodes. One to two courses of chemotherapy with 5-fluorouracil and mitomycin-C were given during radiotherapy in 16 patients and cisplatin, 5-fluorouracil and leucovorin combination in one patient. External beam radiotherapy was delivered with single daily fraction between 1.8 and 2.0Gy up to a median total dose of 55Gy. Fifteen patients (88%) achieved complete response and 12 of them remain local recurrence free with a median follow-up time of 32 months (range:9-95 months). Eight of this 12 patients were alive without evidence of disease, 3 developed distant metastasis and one died of intercurrent disease. Five patients did not achieve local contral, three of them received abdomino-perineal resection. Two died of local tumor relapse and one died of distant metastasis but with local control. The other 2 patients without local contral died of local and distant diseases. The overall 2-year actuarial survival rate is 68%. Twelve of 17 patients was colostomy-free and anal function was preserved in 10 of 12 patients with local control. We conclude that concurrent chemoradiotherapy can provide good local control and preserve the anal sphincter function in most of anal cancer patients."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-241-248-a", "title": "\u975c\u8108\u4e45\u7f6e\u6027\u6ce8\u5c04\u8154\u5c0d\u653e\u5c04\u5291\u91cf\u5206\u5e03\u7684\u5f71\u97ff", "keywords": "\u6ce8\u5c04\u8154;\u653e\u5c04\u6548\u61c9;\u5149\u5b50;\u96fb\u5b50;\u5316\u5b78\u6cbb\u7642 Injection ports;Radiation effect;Photons;Electrons;Chemotherapy", "c": "\u5316\u5b78\u6cbb\u7642\u662f\u6cbb\u7642\u60e1\u6027\u816b\u7624\u7684\u4e00\u7a2e\u76f8\u7576\u91cd\u8981\u7684\u65b9\u6cd5\uff0c\u81e8\u5e8a\u4e0a\uff0c\u75c5\u4eba\u5728\u7d93\u904e\u591a\u6b21\u975c\u8109\u6ce8\u5c04\u6297\u764c\u85e5\u7269\u4ee5\u5f8c\uff0c\u5e38\u6703\u906d\u9047\u5230\u56e0\u7232\u975c\u8109\u840e\u7e2e\u6c92\u6709\u6dfa\u5c64\u975c\u8109\u53ef\u4f9b\u7d66\u85e5\u7684\u56f0\u64fe\uff1b\u8fd1\u5e74\u4f86\uff0c\u56e0\u7232\u975c\u8109\u4e45\u7f6e\u6027\u6ce8\u5c04\u8154\u5728\u81e8\u5e8a\u4e0a\u7684\u5ee3\u6cdb\u4f7f\u7528\uff0c\u89e3\u51b3\u4e86\u9019\u65b9\u9762\u7684\u96e3\u984c\u3002\u7531\u65bc\u6ce8\u5c04\u8154\u5e38\u5e38\u690d\u65bc\u524d\u80f8\u58c1\u76ae\u4e0b\uff0c\u4ee5\u4fbf\u5176\u5c0e\u7ba1\u63d2\u5165\u9396\u9aa8\u4e0b\u975c\u8109\u4e2d\uff1b\u5047\u5982\u9019\u500b\u75c5\u4eba\u540c\u6642\u5728\u6b64\u90e8\u4f4d\u63a5\u53d7\u653e\u5c04\u6cbb\u7642\uff0c\u90a3\u9ebd\u6ce8\u5c04\u8154\u5e95\u4e0b\u7d44\u7e54\u7684\u653e\u5c04\u5291\u91cf\uff0c\u5c07\u6703\u4e0d\u5747\u52fb\u53ca\u964d\u4f4e\u3002\u672c\u5be6\u9a57\u7528\u4e0d\u540c\u7a2e\u985e\u53ca\u4e0d\u540c\u80fd\u91cf\u7684\u653e\u5c04\u7dda\u675f\uff0c\u5305\u62ec 6MV\u53ca10MV X\u5149\uff0c\u82079\u202212\u202215\u2022\u53ca18MeV\u96fb\u5b50\u675f\uff0c\u6e2c\u91cf\u91d1\u5c6c\u8207\u77fd\u81a0\u5169\u7a2e\u4e0d\u540c\u6750\u8cea\u6ce8\u5c04\u8154\u5e95\u4e0b\u4e0d\u540c\u6df1\u5ea6\u7684\u5291\u91cf\u5206\u5e03\uff0c\u4f86\u77ad\u89e3\u6ce8\u5c04\u8154\u6240\u9020\u6210\u7684\u5f71\u97ff\u3002\u5be6\u9a57\u7684\u7d50\u679c\u986f\u793a\u6ce8\u5c04\u8154\u6703\u6539\u8b8a\u5291\u91cf\u5206\u5e03\u7684\u5747\u52fb\uff0c\u5e77\u4e14\u4f7f\u6df1\u5ea6\u5291\u91cf\u964d\u4f4e\uff1b\u4f8b\u5982\u4ee59MeV\u96fb\u5b50\u675f\u7232\u4f8b\uff0c\u65bc\u91d1\u5c6c\u6ce8\u5c04\u8154\u5b58\u5728\u4e0b\uff0c\u6ce8\u5c04\u8154\u4e0b\u65b92.5cm\u8655\u7684\u4e2d\u5fc3\u8ef8\u5291\u91cf\u6703\u964d\u4f4e\u81f337%\u3002\u7531\u672c\u7814\u7a76\u7684\u767c\u73fe\uff0c\u5efa\u8b701.\u5c07\u6ce8\u5c04\u8154\u88dd\u7f6e\u65bc\u53ef\u80fd\u7684\u653e\u5c04\u7167\u91ce\u4e4b\u5916\u30022.\u8a2d\u8a08\u653e\u5c04\u6cbb\u7642\u6280\u8853\u6642\uff0c\u5c07\u7167\u91ce\u907f\u958b\u6ce8\u5c04\u8154\u30023.\u9078\u7528\u77fd\u81a0\u88fd\u7684\u6ce8\u5c04\u8154\u30024 \u907f\u514d\u4f7f\u7528\u96fb\u5b50\u675f\u3002", "e": "Chemotherapy is a very important method in cancer treatment. Clinically, the patient would suffer from lack of adequate venous access for administration of chemotherapeutic agents after multiple courses of chemotherapy. The problem is resolved by the extensive use of venous injection ports. Injection ports are usually implanted in the anterior chest wall, with their catheter inserted into the subclavian vein. If the patient must receive radiotherapy over these areas, the radiation dose under injection ports would be lower. This paper trys to find out the influence of metallic or silicon injection ports on the dose distribution of K-rays and electron beams. Two different kinds of radiation beams, with different energy levels, were used in these experiments. They were 6MV and 10 MV K-rays, and 9, 12, 15 and 18MeV eletron beams. In order to understand the influence of injection ports, all dose measurements were made at different depths under the ports. The data revealed that the presence of injection ports alters the dose uniformity and decreased the depth dose. For example, the dose underlying metal injection portals at 2.5cm depth reduced to 37% when 9MeV electrons are used. This paper recommends that 1.The injection port should be implanted outside the potential irradiation field. 2. Avoid irradiation of the injection port whenever possible. 3. Use silicon-made injections port. 4. Avoid selecting electron beams for treatment."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-249-254-a", "title": "\u652f\u6c23\u7ba1\u5167\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\uff0d\u53f0\u5317\u69ae\u7e3d\u7684\u521d\u6b65\u7d93\u9a57\u5831\u544a", "keywords": "\u975e\u5c0f\u7d30\u80de\u80ba\u764c;\u8fd1\u63a5\u6cbb\u7642;\u652f\u6c23\u7ba1\u93e1 Non-small cell lung cancer;brachytherapy;bronchoscopy", "c": "\u81ea1992\u5e7411\u6708\u8d77\u81f31994\u5e742\u6708\u6b62\uff0c\u5171\u67098\u4f8b\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u63a5\u53d7\u652f\u6c23\u7ba1\u5167\u8fd1\u63a5\u653e\u5c04\u6cbb\u7642\uff0c\u5176\u4e2d7\u4f8b\u70basatge \u2162A (3)\u8207statge \u2162 B(4)\uff0c\u53e6\u4e00\u4f8b\u539f\u70bastage\u2160\uff0c\u7d93\u624b\u8853\u6cbb\u7642\u5f8c\u5c40\u90e8\u5fa9\u767c\u3002\u6240\u6709\u75c5\u4f8b\u7686\u540c\u6642\u63a5\u53d7\u9ad4\u5916\u7167\u5c04\uff0c\u8996\u6cbb\u7642\u76ee\u7684\u7d66\u4e8840\u81f360Gy\u7684\u5291\u91cf\uff0c\u8fd1\u63a5\u6cbb\u7642\u5247\u5728\u7642\u7a0b\u4e2d\u554f\u53ca\u7d50\u675f\u6642\u5404\u4e88\uff0d\u6b21\uff0c\u7d66\u4e88\u5291\u91cf\u5728\u8ddd\u5c04\u6e90\u8f38\u9001\u7ba1\u4e2d\u8ef8\u5916l\u516c\u5206\u86558\u81f310Gy\u3002\u4f7f\u7528\u92a5-192\u9ad8\u5291\u91cf\u7387\u9059\u63a7\u5f8c\u8377\u5f0f\u7cfb\u7d71(lr-192 High-dose-rate: emote afterloading system)\uff0c\u6bcf\u6b21\u6cbb\u7642\u7d04\u970010\u5206\u9418\u3002\u6bcf\u4f4d\u75c5\u4eba\u5728\u6cbb\u7642\u7d50\u675f\u5f8c\u56db\u5468\u63a5\u53d7\u652f\u6c23\u7ba1\u93e1\u8907\u67e5\uff0c\u5e77\u5b9a\u671f\u8ffd\u8e2a\u80f8\u90e8x\u5149\u7247\u6216\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\u3002\u7d50\u679c\u57288\u4f8b\u4e2d\u67095\u4f8b\u5176\u652f\u6c23\u7ba1\u93e1\u6aa2\u986f\u793a\u816b\u7624\u963b\u585e\u7bc4\u570d\u670950%\u4ee5\u4e0a\u4e4b\u6539\u5584\uff0c\u67096\u4f8b\u5176\u4e3b\u89c0\u75c7\u72c0\u6539\u5584\uff0c\u4f46\u662f\u50c52\u4f8b\u76ee\u524d\u75c5\u51b5\u7a69\u5b9a\u3002\n\u652f\u6c23\u7ba1\u5167\u8fd1\u63a5\u6cbb\u7642\u5c0d\u65bc\u56e0\u8fd1\u7aef\u652f\u6c23\u7ba1\u5167\u7684\u816b\u7624\u75c5\u7076\u6240\u9020\u6210\u7684\u5835\u585e\u53ca\u76f8\u95dc\u75c7\u72c0\u6709\u4ee4\u4eba\u6eff\u610f\u7684\u6548\u679c\u3002\u6cbb\u7642\u904e\u7a0b\u4e2d\u4e26\u7121\u986f\u8457\u7684\u526f\u4f5c\u7528\u3002\u5c0d\u65bc\u5c40\u90e8\u816b\u7624\u63a7\u5236\u53ca\u66f4\u7cbe\u78ba\u7684\u6548\u679c\u8a55\u4f30\u7cfb\u7d71\u5247\u9808\u9032\u4e00\u6b65\u7814\u7a76\u3002", "e": "Between November 1992 and Feburary 1994, eight patients with primary non-small cell lung cancer were treated with endobronchial brachytherapy with Iridium-192 high dose rate remote afterloading system after teletherapy. Seven patients were previously untreated stage III A (3) and stage III B (4), and one was recurrent after surgery. All patients presented with intraluminal tumor, and received external radiation ranging 40 to 60Gy regarding the therapeutic intents. Brachytherapies were usually performed twice at the median and end of the course of teletherapy, with prescribed dose 8 to 10Gy at 1cm off the cather center. Bronchoscopies were performed 4 weeks after treatments to follow up pulmonary conditions. Five of eight patients obtained more than 50% improvement of endobronchial obstruction; six patients got subjective improvement of previous symptoms; but only two patients were stable conditions to date.\nEndobronchial brachytherapy is an effective method to relieve intraluminal obstruction by lung cancer in the proximal bronchial trees without significant acute toxicities. Development of more precise quantatative criteriae is needed to document the treatment response. Effectiveness of tumor control and survival will be investigated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-255-262-a", "title": "Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients", "keywords": "Cisplatin;5-Fluorouracil;Leucovorin\u9811\u56fa\u6027\u80c3\u764c Refractory Gastric Cancer;Cisplatin;Fluorouracil;Leucovorin", "c": "\u7f79\u60a3\u665a\u671f\u80c3\u764c\u4e14\u5c0d\u7b2c\u4e00\u7dda\u5316\u5b78\u6cbb\u7642\u5931\u6557\u5f8c\u7684\u9810\u5f8c\u975e\u5e38\u5dee\u3002\u7136\u800c\uff0c\u537b\u5c11\u898b\u6709\u6548\u7684\u5316\u5b78\u6cbb\u7642\u53ef\u7528\u4f86\u5c0d\u6297\u9019\u7a2e\u665a\u671f\u9811\u56fa\u6027\u80c3\u764c\u3002\u57fa\u65bcPFL\u7642\u6cd5\u5728\u80c3\u764c\u3001\u9f3b\u54bd\u764c\u7b49\u764c\u75c5\u6709\u4ee4\u4eba\u9f13\u821e\u7684\u7642\u6548\uff0c\u6211\u5011\u5c0e\u5f15\u6b64\u524d\u671f\u7814\u7a76\u4f86\u8a55\u4f30PFL\u5728\u665a\u671f\u9811\u56fa\u6027\u80c3\u764c\u7684\u7642\u6548\u3002\u7814\u7a76\u65b9\u6cd5\u662f\u9078\u64c7\u53ef\u6e2c\u91cf\u4e4b\u665a\u671f\u9811\u56fa\u6027\u80c3\u764c\u75c5\u4eba\uff0c\u6bcf\u4e09\u661f\u671f\u70ba\u4e00\u7642\u7a0b\uff0c\u7d66\u4e88\u6bcf\u5929\u6bcf\u5e73\u65b9\u516c\u5c3a\u9ad4\u8868\u9762\u7a4d\u6df7\u5408\u4e4bCisplatin20\u6beb\u514b\uff0c5-FU 800\u6beb\u514b\uff0cLeucovorin 90\u6beb\u514b\uff0c\u7d93\u975c\u8108\u6ef4\u6ce896\u5c0f\u6642\uff0c\u4e26\u8a55\u4f30\u6cbb\u7642\u53cd\u61c9\u3001\u5b58\u6d3b\u671f\u53ca\u6bd2\u6027\u53cd\u61c9\u3002\u7d50\u679c\uff0c\u5171\u670920\u4f4d\u75c5\u4eba\u9032\u5165\u6b64\u7814\u7a76\uff0c\u53ea\u670915\u4f4d\u53ef\u8a55\u4f30\u6cbb\u7642\u53cd\u61c9\uff0c\u7121\u4e00\u4f8b\u5b8c\u5168\u7de9\u89e3\uff0c\u6709\u56db\u4f4d\u9054\u90e8\u4efd\u7de9\u89e3\uff0c\u7de9\u89e3\u7387\u905427%\u3002\u5168\u90e8\u7684\u6bd2\u6027\u4e4b\u8010\u53d7\u5ea6\u76f8\u7576\u597d\uff0c\u4e3b\u8981\u7684\u6bd2\u6027\u662f\u53e3\u8154\u9ecf\u819c\u708e\u53ca\u767d\u8840\u7403\u7f3a\u4e4f\u3002\u7121\u7b2c\u56db\u7d1a\u6bd2\u6027\u6216\u6cbb\u7642\u76f8\u95dc\u4e4b\u6b7b\u4ea1\u3002\u7d50\u8ad6\uff1a\u7528PFL\u6cbb\u7642\u9811\u56fa\u6027\u80c3\u764c\u662f\u5b89\u5168\u4e14\u53ef\u80fd\u6709\u6548\u7684\u7642\u6cd5\uff0c\u4f46\u4ecd\u9700\u9032\u4e00\u6b65\u7684\u8a55\u4f30\u3002", "e": "Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.\nMethod: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.\nResults: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.\nConclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-263-268-a", "title": "A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer", "keywords": "Cisplatin;5FU;Leucovorin;\u982d\u9838\u764c\u6cbb\u7642\u3002 Cisplatin;5-FU;leucovorin;head and neck cancer", "c": "Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary.\nMethods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity.\nResults: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred.\nConclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.", "e": "Cisplatin\u30015-FU\u53ca\u9ad8\u5291\u91cfleucovorin\u5316\u7642\u5831\u5c0e\u986f\u793a\u5c0d\u982d\u9838\u764c\u75c5\u60a3\u6cbb\u7642\u5177\u9ad8\u5ea6\u7642\u6548\u3002\u7e3d\u9ad4\u800c\u8a00\uff0c\u6bd2\u6027\u662f\u9ad8\u7684\u3002\u570b\u5167\u5728\u8003\u616e\u9032\u884c\u7b2c\u4e09\u671f\u7684\u9ad8\u5291\u91cfPFL\u5316\u7642\u7814\u7a76\u4e4b\u524d\uff0c\u61c9\u5148\u5f9e\u4e8b\u524d\u671f\u7684PFL\u5316\u7642\u7814\u7a76\u3002\u7814\u7a76\u65b9\u6cd5\uff1a\u9078\u5b9a\u7f79\u60a3\u7f8e\u570b\u764c\u75c7\u59d4\u54e1\u6703(AJCC)\u7b2c\u56db\u671f\u3001\u4e14\u672a\u66fe\u63a5\u53d7\u6cbb\u7642\u4e4b\u982d\u9838\u7d44\u7e54\u9c57\u7247\u7d30\u80de\u764c\u7684\u75c5\u60a3\uff0c\u65bd\u4ee5\u6bcf\u5929\u6bcf\u5e73\u65b9\u516c\u5c3a\u9ad4\u8868\u9762\u7a4d\u6df7\u5408\u4e4bcisplatin 20\u6beb\u514b\u30015-FU 500\u6beb\u514b\u3001leucovorin 500\u4eb3\u514b\uff0c\u7d93\u9023\u7e8c\u975c\u8109\u6ef4\u6ce896\u5c0f\u6642\uff0c\u6bcf28\u5929\u70ba\u4e00\u7642\u7a0b\uff0c\u8a55\u4f30\u5176\u6cbb\u7642\u53cd\u61c9\u3001\u6bd2\u6027\u53cd\u61c9\u3002\u7d50\u679c\uff1a\u5171\u670914\u4f4d\u75c5\u4eba\u9032\u5165\u6b64\u7814\u7a76\u3002\u9054\u5b8c\u5168\u7de9\u89e3\u80051\u4f4d(7%)\u90e8\u5206\u7de9\u89e3\u80058\u4f4d(57%) \uff0c\u7de9\u89e3\u7387\u905464%\u3002\u4e3b\u8981\u7684\u6bd2\u6027\u53cd\u61c9\u662f\u53e3\u8154\u7c98\u819c\u708e\u53ca\u767d\u8840\u7403\u7f3a\u4e4f\u3002\u5176\u4e2d\u53e3\u8154\u9ecf\u819c\u708e\u9054\u7b2c\u4e09\u3001\u56db\u5ea6\u6bd2\u6027\u53cd\u61c9\u4e4b\u60a3\u8005\u670935%\u3002\u7121\u6cbb\u7642\u76f8\u95dc\u4e4b\u6b7b\u4ea1\u767c\u751f\u3002\u7d50\u8ad6\uff1a\u96d6\u7136\u7528\u9ad8\u5291\u91cfPFL\u6cbb\u7642\u982d\u9838\u764c\u662f\u6709\u6548\u7684\u7642\u6cd5\uff0c\u4f46\u5176\u6bd2\u6027\u53cd\u61c9\u8868\u73fe\u904e\u5ea6\u3002\u5efa\u8b70\u5728\u672a\u4f86\u7814\u7a76\u4e2d\u4ee5\u5177\u6709\u76f8\u540c\u7642\u6548\u4f46\u6bd2\u6027\u51cf\u5c11\u5f88\u591a\u7684\u5176\u5b83PFL\u7642\u6cd5\u4f86\u4f5c\u9032\u4e00\u6b65\u7684\u8a55\u4f30\u3002"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-269-279-a", "title": "\u4e2d\u897f\u91ab\u5c0d\u764c\u75c7\u8a3a\u7642\u7684\u8a8d\u8b58", "keywords": " ", "c": "\u5728\u81fa\u7063\uff0c\u764c\u75c5\u5df2\u9010\u6f38\u6210\u70ba\u56b4\u91cd\u5371\u5bb3\u4eba\u985e\u5065\u5eb7\u7684\u4e00\u7a2e\u75be\u75c5\uff0c\u6b7b\u4ea1\u7387\u66f4\u5c45\u5341\u5927\u6b7b\u4ea1\u539f\u56e0\u7684\u7b2c\u4e00\u4f4d\uff0c\u6b7b\u4ea1\u4eba\u6578\u7d04\u4f54\u5168\u5e74\u6b7b\u4ea1\u7e3d\u4eba\u6578\u7684\u4e94\u5206\u4e4b\u4e00\u3002\u764c\u75c7\u5c0d\u793e\u6703\u7684\u5f71\u97ff\u66f4\u9054\u201c\u8ac7\u764c\u8272\u8b8a\u201d\u7684\u5730\u6b65\uff0c\u5c24\u5176\u662f\u7d93\u6fdf\u72c0\u51b5\u4e0d\u751a\u597d\u7684\u5bb6\u5ead\uff0c\u4e0d\u4f46\u5f97\u8003\u616e\u662f\u5426\u8ca0\u64d4\u5f97\u8d77\u91ab\u85e5\u8cbb\uff0c\u9084\u5f97\u8003\u616e\u5982\u4f55\u9762\u5c0d\u548c\u8655\u7406\u764c\u75c7\u75c5\u4eba\u7684\u7d55\u671b\u3001\u6050\u61fc\u6b7b\u4ea1\u7684\u5fc3\u60c5\u3002\n\u73fe\u4ee3\u91ab\u5b78\u5c0d\u764c\u75c5\u7684\u7814\u7a76\u5df2\u9577\u671f\u6295\u5165\u76f8\u7576\u5927\u7684\u4eba\u529b\u548c\u7269\u529b\uff0c\u5c0d\u65bc\u764c\u75c5\u7684\u8d77\u56e0\u5df2\u6709\u9010\u6f38\u7684\u8a8d\u8b58\u548c\u77ad\u89e3\uff1b\u5c0d\u65bc\u764c\u75c5\u7684\u8a3a\u65b7\uff0c\u7531\u65bc\u79d1\u6280\u7684\u9032\u6b65\uff0c\u66f4\u6709\u9577\u8db3\u7684\u9032\u5c55\uff1b\u53ef\u662f\u5728\u6cbb\u7642\u4e0a\u9762\uff0c\u96d6\u7136\u73fe\u4ee3\u79d1\u5b78\u6587\u660e\u767c\u9054\uff0c\u73fe\u5b58\u7684\u65b9\u6cd5\u5982\u624b\u8853\u6cbb\u7642\u3001\u8cc0\u723e\u8499\u6cbb\u7642\u3001\u653e\u5c04\u6cbb\u7642\u3001\u5316\u5b78\u6cbb\u7642\u548c\u514d\u75ab\u6cbb\u7642\u7b49\uff0c\u4e5f\u53ea\u80fd\u6cbb\u6108\u7d04\u767e\u5206\u4e4b\u4e94\u5341\u7684\u764c\u75c7\u75c5\u4eba\uff0c\u9019\u4e9b\u75c5\u4eba\u9084\u9808\u662f\u764c\u75c7\u65e9\u671f\u7684\u75c5\u4eba\uff0c\u5927\u591a\u6578\u764c\u75c7\u7684\u665a\u671f\u75c5\u4eba\u4ecd\u6b7b\u65bc\u764c\u75c7\u3002\n\u7531\u65bc\u7642\u6548\u548c\u9810\u5f8c\u504f\u4f4e\uff0c\u6cbb\u7642\u8cbb\u7528\u9ad8\u6602\uff0c\u4ee5\u53ca\u6cbb\u7642\u904e\u7a0b\u7684\u75db\u82e6\uff0c\u5927\u90e8\u5206\u7684\u75c5\u4eba\uff0c\u5c24\u5176\u662f\u665a\u671f\u764c\u75c7\u7684\u75c5\u4eba\uff0c\u4fbf\u6703\u8f49\u800c\u6c42\u52a9\u65bc\u504f\u65b9\u3001\u79d8\u65b9\u3001\u8349\u85e5\u3001\u4e2d\u85e5\u6216\u5176\u4ed6\u975e\u50b3\u7d71\u7684\u65b9\u6cd5\u3002\u5176\u5be6\uff0c\u50b3\u7d71\u4e2d\u570b\u91ab\u5b78\u5728\u764c\u75c5\u7684\u6cbb\u7642\u65b9\u9762\u6709\u7368\u7279\u7684\u770b\u6cd5\uff0c\u4e2d\u8349\u85e5\u7684\u6297\u764c\u6210\u4efd\uff0c\u5df2\u6709\u8a31\u591a\u88ab\u5206\u6790\u51fa\u4f86\uff1b\u50b3\u7d71\u4e2d\u570b\u91ab\u5b78\u201c\u56fa\u672c\u57f9\u5143\u201d\u7684\u91ab\u7642\u6982\u5ff5\uff0c\u5c0d\u65bc\u51cf\u8f15\u764c\u75c7\u75c5\u4eba\u6cbb\u7642\u904e\u7a0b\u7684\u75db\u82e6\uff0c\u548c\u9632\u6b62\u6cbb\u7642\u904e\u7a0b\u5c0d\u75c5\u4eba\u8eab\u9ad4\u3001\u5668\u5b98\u7684\u50b7\u5bb3\uff0c\u66f4\u662f\u4e0d\u53ef\u5ffd\u8996\u7684\u3002\u672c\u6587\u5c31\u73fe\u884c\u764c\u75c7\u7684\u75c5\u56e0\u3001\u8a3a\u65b7\u8207\u6cbb\u7642\u4ee5\u897f\u91ab\u7684\u7406\u8ad6\u8207\u4e2d\u91ab\u7684\u89c0\u5ff5\u505a\u4e00\u5206\u6790\u548c\u6bd4\u8f03\u3002", "e": "In Taiwan, the death rate of cancer patients has become the highest in the top ten lists of the death cause. The number of the death is about 20% of the total death toll. The influence of the cancer to the society, besides the death itself has almost reached the panic level. Because of its chronic property, the family afflicted not only has to consider the medical cost, but also has to face how to deal with the psychological despair and the thrill of the death.\nModern medicine has already invested a great deal of man power and money into the investigation of cancer and the cause of the cancer has been gradually unveiled. Also, because of the advances of modern technology, the diagnostic method of cancer has progressed enormously. However, in concern of the cancer treatment, the present methods such as surgery, radiation therapy, chemotherapy, hormonal therapy and immunotherapy, can only beneifit about 50% of the patients. These patients also have to be the patients of whom the tumors were luckily discovered at the earlier stages. Those at the advanced stage were usually ended up with death.\nBecause the treatment efficacy and prognosis are low, the treatment cost is high and the procedure of the treatment is painful, a great portion of patients, especially those at the terminal stage, will then turn to seek help from the other way including the untraditional folk medicine. In fact, traditional Chinese medicine has its unique feature. The ingredients of many Chinese medicinal herbs have been purified and characterized. The treatment strategy and treatment plan that aimed at how to \u201dsolidify the basis and nourish the origin\u201d were novel to that of the modern medicine. Actually, the idea is wholesome and should be helpful for improving the effect of the modern treatment. The purpose of this paper is to compare and to describle the differences between the modern medicine and the Chinese herbal medicine, in hope to find a complementary way to the advances of the cancer research."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-281-285-a", "title": "Graphical Calculation of the Target Plane Magnification Factor in Radiosurgery of Arteriovenous Malformation", "keywords": "\u7acb\u9ad4\u5b9a\u4f4d\u982d\u67b6;\u6b63\u4ea4\u653e\u5c04\u7dda\u5f71\u50cf;\u653e\u5927\u7387;\u7acb\u9ad4\u5b9a\u4f4d\u653e\u5c04\u624b\u8853 stereotactic frame;orthogonal biplane radiography;magnification factor, stereotactic radiosurgery", "c": "\u4e00\u500b\u7c21\u55ae\u53c8\u6b63\u78ba\u7684\u653e\u5927\u7387\u5716\u5f62\u8a08\u7b97\u6cd5\u88ab\u767c\u5c55\u51fa\u4f86\u61c9\u7528\u65bc\u52d5\u975c\u8109\u7578\u578b\u7624\u7682\u653e\u5c04\u624b\u8853\u3002\u9019\u500b\u5716\u5f62\u8a08\u7b97\u6cd5\u9069\u7528\u65bc\u4e0d\u540c\u65b9\u4f4d\u7684\u6b63\u4ea4\u8840\u7ba1\u651d\u5f71\u3002\u672c\u7bc7\u4ecb\u7d39\u6b64\u5716\u5f62\u8a08\u7b97\u6cd5\u7684\u6578\u5b78\u6a21\u5f0f\u53ca\u8a2d\u8a08\u65b9\u6cd5\u3002\u6211\u5011\u5efa\u8b70\u5229\u7528\u6b64\u5716\u5f62\u8a08\u7b97\u6cd5\u4f86\u8907\u67e5\u96fb\u8166\u8a08\u7b97\u6240\u5f97\u4e4b\u653e\u5927\u7387\u6578\u64da\u3002", "e": "A simple and accurate graphical method for calculating the magnification factors of a target lesion on stereotactic-framed orthogonal angiographic films has been developed for radiosurgery of arteriovenous malformation. This graphical method can be accurately applied to different orientations of the orthogonal angiography and can be used as a routine double-check tool against computer program."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199409-1-3-287-291-a", "title": "Radiotherapy for Peyronie", "keywords": "\u653e\u5c04\u7dda\u6cbb\u7642;Peyronie", "c": "Peyronie's disease, an idiopathic disease, is associated with painful sexual dysfunction, penile deformity and single or multiple indurated plaques. Many methods of treatment have been tried but results are still unsatisfactory. We present here 2 cases of Peyronie's disease treated with a combination of natural vitamin E, corticosteroid and radiotherapy at a total dose of 2000 cGy in 10 fractions in 2 weeks. Lead shields were used to protect the testes and pubic hair. Good response was achieved and patients seemed very satisfactory. Long-term follow-up is necessary for the evaluation of cancer risk.", "e": "Peyronie\u2019s\u75c5\u662f\u4e00\u7a2e\u539f\u56e0\u4e0d\u660e\u7684\u9670\u8396\u75be\u75c5\uff0c\u81e8\u5e8a\u4e0a\u4ee5\u9670\u8396\u75bc\u75db\u81f4\u4f7f\u6027\u529f\u80fd\u8b8a\u5dee\uff0c\u9670\u8396\u8b8a\u5f62\u4ee5\u53ca\u9670\u8396\u4e0a\u51fa\u73fe\u55ae\u4e00\u6216\u591a\u767c\u7684\u786c\u7d50\u7bc0\u7232\u8868\u73fe\u3002\u96d6\u7136\u6709\u8a31\u591a\u7684\u65b9\u6cd5\u5617\u8a66\u7528\u4f86\u6cbb\u7642\uff0c\u4f46\u7d50\u679c\u4ecd\u7136\u7121\u6cd5\u4ee4\u4eba\u6eff\u610f\u3002\u6211\u5011\u5728\u9019\u7bc7\u5831\u544a\u63d0\u51fa\u5169\u500b\u7d93\u7531\u5929\u7136\u7dad\u5b83\u547dE\uff0c\u985e\u56fa\u9187\u53ca\u5169\u5468\u5167\u7d66\u5341\u6b21\u7e3d\u5291\u91cf2000cGy\u653e\u5c04\u7dda\u6cbb\u7642\u7684\u75c5\u4f8b\uff0c\u925b\u5c4f\u969c\u88ab\u7528\u4f86\u4fdd\u8b77\u776a\u4e38\u53ca\u6065\u6bdb\uff0c\u6cbb\u7642\u53cd\u61c9\u826f\u597d\uff0c\u800c\u4e14\u75c5\u4eba\u5c0d\u65bc\u7d50\u679c\u4f3c\u4e4e\u76f8\u7576\u6eff\u610f\u3002\u9577\u6642\u9593\u8ffd\u8e2a\u81f4\u764c\u7684\u5371\u96aa\u6027\u662f\u6709\u5fc5\u8981\u7684\u3002"}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-109-114-a", "title": "\u653e\u5c04\u816b\u7624\u7684\u4eba\u529b\u9700\u6c42\u8207\u8a2d\u5099\u5206\u4f48\uff0d\u81fa\u7063\u5730\u5340\u7684\u6982\u7565\u8a55\u4f30", "keywords": "\u653e\u5c04\u816b\u7624;\u4eba\u529b;\u8a2d\u5099 Radiation oncology;manpower;facilities", "c": "\u8a2d\u5099\u5206\u4f48\u4e0d\u5747\uff0c\u4eba\u529b\u4e4b\u57f9\u990a\u7f3a\u4e4f\u91cd\u9ede\uff0c\u5e38\u5c0e\u81f4\u764c\u75c7\u75c5\u60a3\u7121\u6cd5\u63a5\u53d7\u5230\u65b9\u4fbf\u53c8\u9ad8\u54c1\u8cea\u4e4b\u653e\u5c04\u6cbb\u7642\u3002\u672c\u6587\u5c07\u91dd\u5c0d\u8a2d\u5099\u53ca\u4eba\u529b\u5169\u65b9\u9762\uff0c\u6982\u7565\u6027\u5730\u8a55\u4f30\u81fa\u7063\u5730\u5340\u653e\u5c04\u816b\u7624\u7684\u73fe\u6cc1\u3002\u5728\u81fa\u7063\u5730\u5340\uff0c\u76ee\u524d\u8a2d\u6709\u653e\u5c04\u816b\u7624\u79d1\u7684\u91ab\u9662\u670928\u5bb6\u3002\u5171\u6709\u91ab\u7528\u9ad8\u80fd\u76f4\u7dda\u52a0\u901f\u566829\u90e8\uff0c\u9237\u516d\u5341\u9060\u9694\u6cbb\u7642\u6a5f25\u90e8\uff0c\u5c08\u79d1\u91ab\u5e2b77\u4f4d\uff1b\u572816\u500b\u7e23\u5e02\u4e2d\uff0c\u4e0a\u524d\u4ecd\u67098\u500b\u7e23\u5e02\u7121\u4efb\u4f55\u653e\u5c04\u6cbb\u7642\u7684\u8a2d\u5099\u3002\u6709\u95dc\u5176\u4ed6\u5404\u9805\u4eba\u529b\u8cc7\u6e90\u8a2d\u5099\u5206\u4f48\uff0c\u6587\u5167\u6709\u8a73\u8ff0\u3002\n\u7531\u4e8e\u6709\u95dc\u81fa\u7063\u5730\u5340\u764c\u75c7\u4e4b\u6d41\u884c\u75c5\u5b78\u7d71\u8a08\u8cc7\u6599\u76f8\u7576\u4e0d\u5168\uff0c\u6839\u64da\u9019\u4e9b\u8cc7\u6599\uff0c\u5e76\u7121\u6cd5\u6e96\u786e\u5730\u8a55\u4f30\u81fa\u7063\u5730\u5340\u653e\u5c04\u816b\u7624\u6240\u9700\u4e4b\u4eba\u529b\u8207\u8a2d\u5099\u3002\u672c\u6587\u7576\u8a66\u5f15\u7528\u6587\u737b\u4e0a\u6709\u95dc\u7f8e\u570b\u3001\u52a0\u62ff\u5927\u7684\u8cc7\u6599\u5e76\u8207\u73fe\u6709\u4e4b\u8cc7\u6599\u76f8\u6bd4\u8f03\uff0c\u4f86\u52a0\u4ee5\u5206\u6790\u8207\u8a55\u4f30\u3002", "e": "An uneven distribution of facilities and manpower in Taiwan contributed to the diverse standards among departments of radiation oncology. Cancer patients in various locations cannot receive convenience and quality treatment due to either improper facilities and lack of well- trained oncology staff. This article is to focus on the facilities and manpower evaluation of the current situation in Taiwan. Presently, there are 28 hospitals which have radiation oncology department with a total of 29 high energy linear accelerators and 25 Co-60 machines around the island. There are 77 certified radiation oncologists servicing a population of 20 millions. Currently, there are eight out of 16 counties that do not have radiotherapy service. The distribution of machines and manpower and other related figures will be discussed in the context.\nDue to the deficiency of epidemiological data on cancer incidence in Taiwan, we are unable to precisely project the required manpower and facilities needed. However, we can evaluate the current situation and the future requirement by comparing the data from the USA and Canada."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-115-123-a", "title": "\u5375\u5de2\u751f\u6b96\u7d30\u80de\u7624", "keywords": "\u5375\u5de2\u816b\u7624;\u751f\u6b96\u7d30\u80de\u7624;\u653e\u5c04\u6cbb\u7642 Ovarian cancer;Dysgerminoma;Radiotherapy;Chemotherapy", "c": "\u5375\u5de2\u751f\u6b96\u7d30\u80de\u7624\u662f\u7a2e\u5c11\u898b\uff0c\u5c0d\u653e\u5c04\u6cbb\u7642\u53ca\u5316\u5b78\u6cbb\u7642\u654f\u611f\u7684\u816b\u7624\uff0c\u8f03\u5e38\u898b\u65bc\u5e74\u8f15\u5973\u6027\u3002\u81fa\u5317\u53ca\u9ad8\u96c4\u69ae\u7e3d\u81ea1971\u5e74\u81f31993\u5e74\u5171\u670915\u4f8b\u5375\u5de2\u751f\u6b96\u7d30\u80de\u7624\uff1b\u5e73\u5747\u5e74\u9f61\u662f23\u6b72\uff0c\u5176\u4e2d\u670913\u4f8b\u662f\u539f\u767c\u6027\u816b\u7624\uff0c\u7b2c\u4e00\u3001\u4e8c\u3001\u4e09\u3001\u56db\u671f\u7684\u75c5\u4eba\u5206\u5225\u6709\u56db\u3001\u4e09\u3001\u56db\u53ca\u4e00\u4f4d\u3002\u9664\u4e00\u4f4d\u80ba\u90e8\u8f49\u79fb\u7684\u75c5\u4eba\u5916\uff0c\u5176\u9918\u7684\u90fd\u6703\u63a5\u53d7\u624b\u8853\u6cbb\u7642\uff1b\u5316\u5b78\u6cbb\u7642\u6216\u662f\u653e\u5c04\u6cbb\u7642\u7684\u5206\u5225\u6709\u5341\u4f4d\u53ca\u516b\u4f4d\u3002\u6709\u4e00\u4f8b\u5931\u53bb\u8ffd\u8e64\uff0c\u5176\u9918\u7684\u75c5\u4eba\u81f3\u5c11\u8ffd\u8e64\u4e09\u500b\u6708\uff0c\u6700\u9577\u7684\u5df2\u8ffd\u8e6416\u5e74\u3002\u53e6\u6709\u4e09\u4f8b\uff0c\u5206\u5225\u660c\u56e0\u70ba\u80ba\u90e8\u8f49\u79fb\uff0c\u6dcb\u5df4\u8f49\u79fb\u8207\u5c40\u90e8\u5fa9\u767c\u4f86\u6c42\u8a3a\u7684\u75c5\u4eba\u5df2\u7d93\u6b7b\u4ea1\u3002\u7b2c\u4e00\u3001\u4e8c\u671f\u75c5\u4eba\u7684\u75be\u75c5\u63a7\u5236\u7387\u662f100%\uff0c\u53e6\u5916\u624b\u8853\u52a0\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u7684\u75be\u75c5\u63a7\u5236\u7387\u4ea6\u9ad8\u9054100%\u3002\u7531\u672c\u7814\u7a76\u7684\u5206\u6790\u53ef\u767c\u73fe\uff0c\u7b2c\u4e8c\u671f\u4ee5\u4e0a\u7684\u75c5\u4eba\u536066%\uff0c\u76ee\u524d\u6d41\u884c\u7684\u4fdd\u5b88\u7642\u6cd5\u5e76\u4e0d\u9069\u5408\u5927\u90e8\u5206\u7684\u75c5\u4eba\u3002\u6b64\u5916\uff0c\u624b\u8853\u5408\u5e76\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u662f\u5426\u53ef\u4ee5\u53d6\u4ee3\u624b\u8853\u52a0\u4e0a\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\uff0c\u4ecd\u9700\u66f4\u9577\u6642\u9593\u7684\u8ffd\u8e64\u3002\u6240\u4ee5\u5728\u76ee\u524d\u9ad8\u671f\u5225\u75c5\u4eba\u5360\u591a\u6578\u7684\u60c5\u6cc1\u4e0b\uff0c\u7d93\u7531\u4fdd\u5b88\u7642\u6cd5\u4f86\u63a7\u5236\u75be\u75c5\u53ca\u4fdd\u7559\u751f\u80b2\u80fd\u529b\u662f\u4e0d\u6070\u7576\u7684\uff1b\u5728\u5316\u5b78\u6cbb\u7642\u7684\u6548\u679c\u9084\u6c92\u6709\u5145\u5206\u7684\u75c5\u4f8b\u652f\u6301\u4e4b\u524d\uff0c\u4ee5\u69ae\u7e3d\u7684\u6709\u9650\u7d93\u9a57\u800c\u8a00\uff0c\u624b\u8853\u5408\u5e76\u8853\u5f8c\u653e\u5c04\u6cbb\u7642\u662f\u6709\u4e0d\u932f\u7684\u6548\u679c\u3002", "e": "Ovarian dysgerminoma is a rare, highly radiosensitive and chemosensitive tumor, occurring mostly in young females. There were 15 cases of ovarian dysgerminoma treated at Taipei and Kaohsiung Veteran General Hospitals from 1971to 1993. The mean age is 23 years old. Among them, 13 patients were primary tumors and the other 2 patients were recurrent ones. Four patients were in Stage \u2160, three patients Stage \u2161, four patients Stage \u2162 and one patient Stage \u2163. All patients except the one with pulmonary metastases received surgery. Eight patients received postoperative radiotherapy and ten patients received chemotherapy respectively. Only one patient was lost for follow-up. The other patients were followed up regularly for at least 3 months. The longest follow.up duration was 16 years. Three patieuts who initially presented with pulmonary metastases, lymphatic metastases or local recurrent disease had died. The local control rates were 100% for Stage I-Il diseases and for diseases treated by post-operative radiother. apy. According to this analysis, current conservative treatment seems not suitable for most patients because 66% of them were in Stage II or beyond. In addition, it still needs longer follow- up to evaluate whether adjuvant chemotherapy can take the place of post-operative radiotherapy. Therefore, it seems not appropriate to adapt conservative treatments for the control of disease and conservation of fertility under such condition that the patients are mostly in higher stages. Before there are sufficient cases to support the effects of chemotherapy, to treat ovarian dysgerminoma with surgery and post-operative radiotherapy still works quiet well according to the experiences of Veteran General Hospital."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-125-128-a", "title": "\u9871\u9802\u7167\u91ce\u5728\u653e\u5c04\u6cbb\u7642\u7684\u61c9\u7528\u53ca\u9a57\u8b49\u6280\u8853", "keywords": "\u9871\u9802\u7167\u91ce;\u653e\u5c04\u6cbb\u7642;\u9a57\u8b49\u7247;\u540c\u4e2d\u5fc3 Vertex fieled;Radiotherapy;Verification Film;Isocenter", "c": "\u5728\u9032\u884c\u653e\u5c04\u6cbb\u7642\u7684\u904e\u7a0b\u4e2d\uff0c\u70ba\u4e86\u907f\u958b\u4e00\u4e9b\u91cd\u8981\u5668\u5b98\uff0c\u6e1b\u5c11\u6b63\u5e38\u7d44\u7e54\u7684\u7167\u5c04\u5291\u91cf\uff0c\u6211\u5011\u6703\u61c9\u7528\u540c\u4e2d\u5fc3\u591a\u91cd\u7167\u91ce\u7684\u6280\u8853\u4f86\u63d0\u6607\u816b\u7624\u5291\u91cf\u3002\u7531\u4e8e\uff0c\u8a31\u591a\u8166\u90e8\u816b\u7624\u4f4d\u7f6e\u8f03\u9760\u8fd1\u9871\u9802\uff0c\u56e0\u6b64\uff0c\u9871\u9802\u7167\u91ce\u4e4b\u61c9\u7528\u4e5f\u5c31\u65e5\u76ca\u589e\u591a\uff0c\u4f46\u5728\u5be6\u65bd\u6b64\u6280\u8853\u6642\uff0c\u50b3\u7d71\u96d9\u91cd\u66dd\u5149\u7684\u9a57\u8b49\u65b9\u5f0f\u537b\u7121\u6cd5\u9054\u5230\u9871\u9802\u7167\u91ce\u7684\u9a57\u8b49\u76ee\u7684\u3002\u56e0\u6b64\uff0c\u672c\u7bc7\u4e43\u91dd\u5c0d\u6b64\u554f\u984c\uff0c\u5229\u7528\u7b49\u4e2d\u5fc3\u9ede\u7684\u539f\u7406\uff0c\u4ee5\u4e09\u91cd\u66dd\u5149\u7684\u6280\u8853\uff0c\u4f86\u7372\u5f97\u4e00\u5f35\u5171\u6709\u4e09\u5ea6\u7a7a\u9593\u95dc\u7cfb\u7684\u5f71\u50cf\uff0c\u4ee5\u9054\u5230\u9a57\u8b49\u7684\u76ee\u7684\uff0c\u4f7f\u5f97\u5728\u6cbb\u7642\u904e\u7a0b\u4e2d\u66f4\u53ef\u4ee5\u786e\u5b9a\u6cbb\u7642\u7167\u91ce\u4e4b\u6e96\u786e\u6027\uff0c\u4ee5\u53ca\u63d0\u6607\u6cbb\u7642\u54c1\u8cea\u3002", "e": "In order to preserve some critical organs and reduce the radiation dosage in normal tissue, we usually apply the multi-field technique with isocenter during radiation therapy in order to escalate the maximal radiation dose to the tumor.\nIt is because many tumor is applicahe locate near the upper portion of brain with the vertex field irradiation. Meanwhile, it is difficult to verify the vertex field if we use the traditional verification technique. In this study, we made an exposure film with 3-dimension relationship through the three fold exposure technique, in order to verify the treatment area, and ensure the treatment accuracy."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-129-134-a", "title": "\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u8d85\u71b1\u4e2d\u5b50\u5c04\u67f1\u5148\u5c0e\u5be6\u9a57", "keywords": "1)\u787c\u6349\u4e2d\u5b50\u7642\u6cd5;2)\u8d85\u71b1\u4e2d\u5b50\u5c04\u67f1;3)\u4e2d\u5b50\u6ffe\u5c4f Boron Neutron Capture Therapy(BNCT);Epithermal Neutron Beam;Neutron Filter", "c": "\u4ee5\u91cd\u6c34\u548c\u92c1\u7684\u9ad4\u7a4d\u6bd4\u70ba13.6/86.4\u8207\u924d\u3001\u9398\u7b49\u91d1\u5c6c\u7d44\u5408\u6210\u4e2d\u5b50\u6ffe\u5c4f\u7684\u963b\u79bb\u7279\u6027\uff0c\u5728\u6e05\u83ef\u6c34\u6c60\u5f0f\u6838\u5b50\u53cd\u61c9\u5668E-1\u5be6\u9a57\u7ba1\u5167\u9032\u884c\u5be6\u9a57\u63a2\u8a0e\u3002\u8d85\u71b1\u4e2d\u5b50\u7684\u7a7f\u900f\u7387\u70ba8.43x10^(-4)\u70ba\u71b1\u4e2d\u5b50\u768477\u500d\uff0c\u8d85\u71b1\u4e2d\u5b50\u8207\u71b1\u5442\u5b50\u901a\u7387\u6bd4\u70ba74/26\uff0c\u5feb\u4e2d\u5b50\u901a\u7387\u5df2\u5728\u53ef\u5075\u6e2c\u6975\u9650\u7684\u7bc4\u570d\u4e0b\u3002\u4f3d\u99ac\u7b49\u6548\u5291\u91cf\u8207\u4e2d\u5b50\u901a\u7387\u6bd4\u70ba1.13pSv\u00b7n^(-1)\u00b7cm^2\u6dfa\u764c\u5291\u91cf\uff0c\u53ca0.905 pSv\u00b7n^(-1)\u00b7cm^2\u6df1\u90e8\u5291\u91cf\u3002", "e": "Characterization studies of a neutron filter of a combination of D2O, aluminum,bismuth and cadmium were carride out experimentally for a neutron beam at the E-1 beam port of THOR. The volume ratio of D2O to Al was 13.6/86.4. The epithermal neutron flux vs thermal is 74/26 at outlet of the beam port, but the fast neutron flux at the same point is far below the detection limit. The rate of gamma dose equivalent vs neutron flux is 1.13pSv\u00b7n^(-1)\u00b7cm^2 for skin dose and 0.905 pSv\u00b7n^(-1)\u00b7cm^2 for depth dose."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-135-139-a", "title": "(\u4e0a\u6a19 10)B(n,a)^7Li\u3001(\u4e0a\u6a19 14)N(n,p)^14C\u5291\u91cf", "keywords": "(1)\u787c\u6349\u4e2d\u5b50\u7642\u6cd5;(2)\u56fa\u614b\u6838\u5f91\u8de1\u5075\u6aa2\u5668;(3)\u5438\u6536\u5291\u91cf Boron Neutron Capture Therapy;BNCT;Solid State Nuclear Track Detector;SSNTD;Absorbed Dose", "c": "\u70ba\u914d\u5408\u5229\u7528\u8d85\u71b1\u4e2d\u5b50\u61c9\u7528\u65bc\u787c\u6349\u4e2d\u5b50\u6cbb\u764c\u5728\u5438\u6536\u5291\u91cf\u8a55\u4f30\u4e0a\u7684\u9700\u6c42\uff0c\u4e43\u958b\u767c\u4ee5\u76f4\u63a5\u91cf\u6e2c\u4e2d\u5b50\u5f15\u767c(\u4e0a\u6a19 10)B(n,a)^7Li\u53ca(\u4e0a\u6a19 14)N(n,p)^14C\u6240\u7522\u751f\u5438\u6536\u5291\u91cf\u7684\u91cf\u6e2c\u6280\u8853\u3002\u6b64\u9805\u7814\u7a76\u5171\u91c7\u7528\u56db\u7a2e\u4e0d\u540c\u578b\u614b\u7684\u56fa\u614b\u6838\u5f91\u8e64\u5075\u6aa2\u5668\uff0c\u5373CR-39\u3001Lexan\u3001LR-15\u53caCN-106\uff0c\u5e76\u5728\u6e05\u83ef\u5927\u5b78\u6c34\u6c60\u6838\u5b50\u53cd\u61c9\u5668\u7684\u71b1\u4e2d\u5b50\u5ba4\u5167\u9032\u884c\u6821\u9a57\u5de5\u4f5c\u3002\u7d50\u679c\u986f\u793a\uff0c\u5169\u7a2e\u785d\u9178\u7e54\u7dad\u7247\uff0c\u5728\u9069\u7576\u7684\u8150\u523b\u63a7\u5236\u689d\u4ef6\u4e0b\uff0c\u5c0d(\u4e0a\u6a19 14)N(n,p)^14C\u7684\u53cd\u61c9\u9072\u920d\uff0c\u5f91\u8de1\u96e3\u4ee5\u986f\u73fe\u3002\u56db\u7a2e\u5075\u6aa2\u5668\u5c0d\u5f91\u8de1\u8a18\u9304\u7684\u6548\u7387\u53ca\u5075\u6e2c\u9748\u654f\u5ea6\uff0c\u5728\u6587\u4e2d\u5c07\u4e88\u8a0e\u8ad6\u3002", "e": "In order to evalution the absorbed dose from the epithermal neutron field adequate for BNET, the experiments were carried out to intend to develope a measuring technique directly for the absorbed dose due to the neutron inducd (superscript 10)B(n,a)(superscript 7)Li and (superscript 14)N(n,p)^14C nuclear reactions. Four types of solid state nuclear track detector were used in this work, such as CR-39, Lexan, LR-115 and CN-106. The calibrations were workde out at the thermal column of THOR to determine the detection sensitivities of these detectors. The results show that two types of cellulose nitrate plastic are insensitive to the (superscript 14)N(n,p)^14C reaction under certain controlled etching condition. The track registration efficiency and its detection sensitivity of the detectors were discussed."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-151-157-a", "title": "\u4e2d\u5b50\u6355\u7372\u6cbb\u764c\u4e4b\u56de\u9867\u8207\u524d\u77bb", "keywords": " ", "c": "\u672c\u6587\u8a0e\u8ad6\u5229\u7528\u539f\u5b50\u6355\u7372\u4e2d\u5b50\u91cb\u653e\u51fa\u8377\u96fb\u7c92\u5b50\u4f86\u6cbb\u764c\u7684\u65b9\u6cd5\u3002\u4e3b\u8981\u662f\u5c07\u5177\u6709\u5de8\u5927\u4e2d\u5b50\u6355\u7372\u622a\u9762\u7684\u6838\u7a2e\u4ee5\u7279\u6b8a\u5316\u5b78\u54c1\u7684\u5f62\u5f0f\u6ce8\u5165\u4eba\u9ad4\uff0c\u4f7f\u5176\u8207\u816b\u7624\u7d30\u80de\u7d50\u5408\uff0c\u518d\u5229\u7528\u4e2d\u5b50\u7167\u5c04\u816b\u7624\u90e8\u4f4d\u3002\u85e5\u54c1\u4e2d\u7684\u7279\u5b9a\u6838\u7a2e\u5438\u6536\u4e2d\u5b50\u5f8c\u5206\u88c2\u6210\u5169\u500b\u8f03\u5c0f\u7684\u7834\u7247\u540c\u6642\u653e\u51fa\u80fd\u91cf\uff0c\u5176\u5c04\u7a0b\u5c0f\u65bc10\u5fae\u7c73\uff0c\u56e0\u6b64\u50c5\u7834\u58de\u816b\u7624\u7d30\u80de\u8207\u5176\u9130\u8fd1\u7684\u7d30\u80de\uff0c\u800c\u9054\u5230\u6cbb\u7642\u7684\u76ee\u7684\u3002\u4e2d\u5b50\u6355\u7372\u6cbb\u764c\u4e3b\u8981\u61c9\u7528\u65bc\u6cbb\u7642\u8166\u816b\u7624\u8207\u9ed1\u8272\u7d20\u764c\uff0c\u6700\u8fd1\u4ea6\u6709\u6cbb\u7642\u809d\u764c\u7684\u7814\u7a76\u3002\u95dc\u4e8e\u6838\u7a2e\u7684\u9078\u64c7\u3001\u85e5\u54c1\u914d\u88fd\u3001\u4e2d\u5b50\u6e90\u7684\u7522\u751f\u3001\u8f3b\u5c04\u5291\u91cf\u8a55\u4f30\u4ee5\u53ca\u53ef\u61c9\u7528\u6b64\u6cd5\u6cbb\u7642\u7684\u764c\u75c5\u5747\u8a0e\u8ad6\u65bc\u6b64\u3002", "e": "In this paper we review treatments of tumors by neutron capture therapy (NCT). Nuclides with very large neutron capture cross section are introduced into a special chemical form and are admitted into a tumor patient. This compound will penetrate into the tumor and tumor cells and will stay there for a sufficient long time. The tumor is then irradiated with a neutron beam. The special nuclide in the chemical will capture the neutron and will split into two smaller fragments then release energy. The range of the fragment is smaller than 10 pm. So only the tumor cell and its nearest neighbor cells will be damaged, and the tumor is cured. The main application of NCT is the treatment of brain tumors and malignant melanomas. Recently there are some studies on NCT for hepatomas. We discuss the choice of nuclides suitable chemical compounds, neutron beams and radiation dosimetry."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199406-1-2-159-164-a", "title": "\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u767c\u5c55\u8da8\u52e2", "keywords": "\u787c\u6349\u4e2d\u5b50\u6cbb\u7642;\u542b\u787c\u5c0b\u764c\u85e5;\u4e2d\u5b50\u5c04\u675f;\u767c\u5c55 (superscript 10)B-Neutron Capture Therapy(BNCT);tumor-localizing boron compounds;neutron beams;development", "c": "\u81ea1950\u5e74\u4ee3\u52301980\u5e74\u4ee3\uff0c\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u6a21\u5f0f\u7d93\u904e\u7a2e\u7a2e\u7684\u8a66\u9a57\u968e\u6bb5\uff0c\u5176\u81e8\u5e8a\u5be6\u7528\u6027\u7d42\u65bc\u5728\u67d0\u4e9b\u764c\u75c5\u7684\u6cbb\u7642\u4e0a\u7372\u5f97\u521d\u6b65\u8b49\u5be6\u3002\u76ee\u524d\u9019\u7a2e\u6cbb\u7642\u65b9\u5f0f\u6b63\u9010\u6f38\u5f97\u5230\u4e16\u754c\u5404\u5148\u9032\u570b\u5bb6\u7684\u91cd\u8996\uff0c\u5c24\u5176\u662f\u6838\u80fd\u6280\u8853\u767c\u9054\u7684\u5730\u5340\uff0c\u83ab\u4e0d\u6295\u6ce8\u4eba\u529b\u7269\u529b\u9032\u884c\u7814\u7a76\uff1b\u5176\u4e3b\u8981\u7684\u539f\u56e0\uff0c\u8981\u6b78\u529f\u65bc1960\u5e74\u4ee3\u5728\u65e5\u672c\u60e1\u6027\u8166\u7624\u81e8\u5e8a\u8a66\u9a57\u7684\u6210\u679c\u3002\u7531\u65bc\u787c\u5341\u539f\u5b50(10B)\u5148\u5929\u4e0a\u7684\u5316\u5b78\u7279\u6027\u4f7f\u5b83\u53ef\u4ee5\u88ab\u7d0d\u5165\u8a31\u591a\u7a2e\u5316\u5408\u7269\u7d50\u69cb\u88e1\uff0c\u5404\u5f0f\u5404\u6a23\u7684\u542b\u787c\u5316\u5408\u7269\u73fe\u4eca\u90fd\u53ef\u4ee5\u5408\u6210\u51fa\u4f86\uff0c\u8003\u616e\u7528\u5728\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u4e0a\u3002\u53e6\u4e00\u65b9\u9762\uff0c\u6838\u80fd\u6280\u8853\u7684\u9032\u6b65\u4e5f\u4fc3\u4f7f\u4e2d\u5b50\u5c04\u675f\u7684\u54c1\u8cea\u6709\u6240\u6539\u9032\uff1b\u914d\u5408\u542b\u787c\u5c0b\u764c\u85e5\u7684\u767c\u5c55\uff0c\u787c\u6349\u4e2d\u5b50\u6cbb\u7642\u7684\u6548\u679c\u61c9\u8a72\u53ef\u4ee5\u66f4\u597d\uff0c\u65bc\u764c\u75c5\u6cbb\u7642\u4e0a\u7684\u61c9\u7528\u7bc4\u570d\u53ef\u4ee5\u66f4\u5ee3\u3002\u8655\u5728\u9019\u6a23\u7684\u767c\u5c55\u771f\u646f\u88e1\uff0c\u6709\u4e9b\u5fc5\u9808\u4e8b\u5148\u77ad\u89e3\u7684\u89c0\u5ff5\u548c\u5b78\u7406\uff0c\u5c07\u5728\u672c\u7bc7\u6587\u7ae0\u88f9\u6709\u8f03\u8a73\u76e1\u7684\u6558\u8ff0\u3002", "e": "From 1950s to 1980s, the (superscript 10)B-Neutron Capture Therapy(BNCT) has been considered as an effective and useful treatment modality for some kinds of cancer through a series of testing work. Owing to the success of malignant brain tumor trial in Japan 1960s, today, more and more countries spend resources to develop this treatment modality. For the extensive chemistry of boron is such that it can be incorporated into a multitude of different chemical structures, there have been many kinds of boron compounds synthesized for potential use in BNCT. Otherwise the progressing nuclear engineering makes it possible to improve the quality of neutron beams; and combined with the developing tumor-localizing boron compounds, BNCT will be more effective and more useful for cancer treatment. About the development of BNCT, there is more detail of concept & mechanism analysis in this paper."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-1-12-a", "title": "A Dose Response Analysis For Cytotxic Drugs (\u2160) Alpha,Beta,Gamma Model", "keywords": " Anticancer;antineoplastic;drugs;chemotherapy;pharmacodynamics; linearquadratic model", "c": "\u50b3\u7d71\u4e0a\u5316\u5b78\u6297\u764c\u85e5\u7269\u7684\u7d66\u6cd5\u5e38\u662f\u9593\u9694\u6027\u7684\u7d66\u4e88\u4e00\u500b\u5927\u5291\u91cf\uff0c\u5f85\u6cbb\u7642\u7684\u526f\u4f5c\u7528\u6062\u5fa9\u5f8c\u518d\u7d1a\u4e88\u4e0b\u4e00\u5291\u91cf\uff0c\u5176\u9593\u9694\u591a\u70ba3\u81f36\u9031\u4e0d\u7b49\uff0c\u8996\u85e5\u7269\u4e0d\u540c\u800c\u7570\u3002\u7136\u800c\uff0c\u81e8\u5e8a\u5831\u544a\u767c\u73fe\u6709\u8a31\u591a\u85e5\u7269\u7684\u7642\u6548\u4ee5\u53ca\u5176\u526f\u4f5c\u7528\uff0c\u6703\u56e0\u7d66\u85e5\u7684\u9593\u9694\u65b9\u6cd5\u800c\u5927\u6709\u4e0d\u540c\u3002\u5982\u4f55\u80fd\u4e8b\u5148\u9810\u6e2c\u67d0\u4e00\u85e5\u7269\u4ee5\u90a3\u4e00\u7a2e\u7d66\u85e5\u65b9\u6cd5\u80fd\u7522\u751f\u6700\u5927\u7684\u6bd2\u6bba\u4f5c\u7528\uff0c\u662f\u672c\u7814\u7a76\u7684\u76ee\u7684\u3002\n\u9996\u5148\u4ee5\u80aa\u80f1\u764c\u7d30\u80de\u682a\u4f5c\u70ba\u5be6\u9a57\u7d30\u80de\uff0c\u4f5c\u51fa5\u7a2e\u5316\u5b78\u85e5\u7269CDDP\uff0cTDDP\uff0cBLM\uff0cVP-16\u53caBCNU\u7684\u7d30\u80de\u2014\u2014\u85e5\u7269\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\u3002\u518d\u4ee5\u6578\u5b78\u6a21\u5f0fS=exp [-(\u03b1D+\u03b2D^2+rD^3)]\uff0c\u7531\u96fb\u8166\u7b97\u51fa\u5404\u500b\u53c3\u6578\u53ca\u6a21\u64ec\u5716\u5f62\uff0c\u4e26\u5c0e\u51fa\u4e00\u7cfb\u5217\u7684\u6578\u5b78\u6f14\u7b97\u4f86\u89e3\u91cb\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\u7684\u52d5\u529b\u610f\u7fa9\u3002\u6b64\u6a21\u5f0f\u4e0d\u50c5\u53ef\u6a21\u64ec\u85e5\u7269\u7684\u5291\u91cf\u53cd\u61c9\u66f2\u7dda\uff0c\u66f4\u67b6\u8d77\u4e86\u5316\u5b78\u6cbb\u7642\u8207\u653e\u5c04\u6cbb\u7642\u4e4b\u9593\u7684\u6865\u6a11\u3002\u672c\u6587\u5148\u5831\u544a\u6b64\u7814\u7a76\u7684\u7b2c\u4e00\u90e8\u5206\u2014\u2014\u6a21\u5f0f\u7684\u5275\u7acb\u3002", "e": "We tentatively investigate the hypothesis that the effect of repeated small doses of chemotherapeutic drugs can be estimated from the shape of in vitro cell survival curves of human cancer cells, provided that this shape is the same for each dose administered. Drugs with different shapes of survival curves will require differently planned dose scheduling. A human bladder cancer cell line (647V) was used in these preliminary experiments.\nThe clonogenic survival curves for 5 different anticancer drugs (CDDP, TDDP, BLM, VP-16, BCNU) for 647V cells were determined experimentally and found to fit a polynomial survival curve model over a limited range, the \u03b1, \u03b2, \u03b3 model, with s=exp[-(\u03b1D+\u03b2D2 +\u03b3D3)], where D is dose, and is a function of both concentration and time. Equations are derived for schedule changes and clonogenic kill calculations. This approach provides a new method of optimizing dosage schedules. It also provides a common language between medical oncologists and radiation oncologists in survival curve analysis. Although these preliminary experiments were limited to one human cancer cell line and five chemotherapeutic drugs, the concept appears to be worth testing further. We are now reporting the first psrt of this research work-the modeling."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-13-16-a", "title": "\u591a\u5f62\u6027\u795e\u7d93\u81a0\u6bcd\u7d30\u80de\u7624\u4e00\u65e5\u591a\u6b21\u52a0\u901f\u5ea6\u7167\u5c04\u4e4b\u6587\u737b\u56de\u9867\u53ca\u500b\u4eba\u7d93\u9a57", "keywords": " ", "c": "Clioblastorna multiforme(GBM) is one of the most malignant brain tumor in adults. Clinically, this tumor is characterized by its rapid deteriorated course with reported 2-year survival rate rarely exceeding 15%. From the biological viewpoint, GBM is well-known by its rapid proliferating activity, short doubling time, and intrinsic radioresistence. With the recent advances in radiation biology, a new altered fraction treatment called multiple daily fractionated radiation therapy (MDF-RT) by shortening the overall treatment time, is therefore designed to counteract the rapid proliferating characteristics of GBM.\nWe initiated a prospective trial of MDF-RT in patients with GBM at Chang Gung Memorial Hospital between January 1981 and June 1988. Twenty one patients were treated with MDF-RT schedule, consisting of 28-35Gy whole brain irradiation in 14 fr (2-2.5Gy per fr) given 3 fr per day with 4-hour split intervals. The treatment had a break of 3-4 weeks and followed by cone-down boost 6-20Gy in normal fraction. Another 34 patients, referred to as control group, were treated with conventional daily fraction, consisting of 50Gy whole brain irradiation and l0Gy cone-down boost. The actuarial 1-year and 2-year suryival rate were 32% and 5% respectively for MDF-RT group, 38% and 4% respectively for control group. There was no observable survival difference between the two treatment groups. We concluded that the currently designed MDF-RT schedule had not yielded a superior result than that of normal control group.", "e": "Clioblastorna multiforme(GBM) is one of the most malignant brain tumor in adults. Clinically, this tumor is characterized by its rapid deteriorated course with reported 2-year survival rate rarely exceeding 15%. From the biological viewpoint, GBM is well-known by its rapid proliferating activity, short doubling time, and intrinsic radioresistence. With the recent advances in radiation biology, a new altered fraction treatment called multiple daily fractionated radiation therapy (MDF-RT) by shortening the overall treatment time, is therefore designed to counteract the rapid proliferating characteristics of GBM.\nWe initiated a prospective trial of MDF-RT in patients with GBM at Chang Gung Memorial Hospital between January 1981 and June 1988. Twenty one patients were treated with MDF-RT schedule, consisting of 28-35Gy whole brain irradiation in 14 fr (2-2.5Gy per fr) given 3 fr per day with 4-hour split intervals. The treatment had a break of 3-4 weeks and followed by cone-down boost 6-20Gy in normal fraction. Another 34 patients, referred to as control group, were treated with conventional daily fraction, consisting of 50Gy whole brain irradiation and l0Gy cone-down boost. The actuarial 1-year and 2-year suryival rate were 32% and 5% respectively for MDF-RT group, 38% and 4% respectively for control group. There was no observable survival difference between the two treatment groups. We concluded that the currently designed MDF-RT schedule had not yielded a superior result than that of normal control group."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-17-26-a", "title": "Radiotherapy of Nasopharyngeal Carcinoma in the Young Age Group: a Review From Mackay Memorial Hospital", "keywords": "\u9f3b\u54bd\u764c;\u5e74\u9752\u75c5\u4eba;\u653e\u5c04\u7dda\u6cbb\u7642 NPC;young patients;radiotherapy", "c": "\u9f3b\u54bd\u764c\u901a\u5e38\u597d\u767c\u65bc\u4e2d\u5e74\u4eba\uff0c\u8f03\u5c11\u767c\u751f\u5728\u5c0f\u5b69\u53ca\u9752\u5e74\u4e4b\u75c5\u4eba\u3002\u672c\u9662\u5c0d\u65bc37\u4f8b\u5c0f\u65bc30\u6b72\u4e4b\u5e74\u9752\u9f3b\u54bd\u764c\u75c5\u4eba\u4f5c\u56de\u6eaf\u6027\u5206\u6790\uff0c\u5176\u4e2d\u670925\u4f8b\u7537\u6027\uff0c12\u4f8b\u5973\u6027\u81e8\u5e8a\u5206\u671f\u75281988AJC\u4e4b\u5206\u671f\u7cfb\u7d71\uff0c11\u4f8b(30%)\u5c6c\u65bcT4\uff0c25\u4f8b(68%)\u5c6c\u65bcN2\u4ee5\u4e0a\u4e4b\u665a\u671f\u6dcb\u5df4\u8f49\u79fb\uff0c\u67092\u4f8b(6%)\u65bc\u8a3a\u65b7\u6642\u5373\u6709\u9060\u7aef\u8f49\u79fb\uff0c\u6240\u6709\u75c5\u4eba\u90fd\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u90e8\u5206\u75c5\u4eba\u4e26\u4e14\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u4f5c\u70ba\u8f14\u52a9\u6027\u6cbb\u7642\u6216\u9060\u7aef\u8f49\u79fb\u4e4b\u5168\u8eab\u6cbb\u7642\uff0c\u5168\u9ad4\u75c5\u4eba5\u5e74\u4e4b\u5b58\u6d3b\u7387\u53ca\u7121\u75c5\u5b58\u6d3b\u7387\u5206\u5225\u70ba56%\u53ca48%\u3002\u672c\u9662\u4e4b\u7d93\u9a57\u986f\u793a\uff0c\u653e\u5c04\u6cbb\u7642\u5c0d\u65bc\u5c40\u90e8\u75c5\u7076\u4e4b\u63a7\u5236\u76f8\u7576\u6709\u6548\uff0c\u800c\u6f5b\u5728\u6027\u4e4b\u9060\u7aef\u8f49\u79fb\u662f\u6cbb\u7642\u5931\u6557\u53ca\u5c0e\u81f4\u75c5\u4eba\u6b7b\u4ea1\u4e4b\u4e3b\u8981\u539f\u56e0\uff1b\u56e0\u6b64\uff0c\u5c0b\u627e\u6709\u6548\u63a7\u5236\u9060\u7aef\u8f49\u79fb\u4e4b\u8f14\u52a9\u6027\u6cbb\u7642\u5c0d\u65bc\u6cbb\u7642\u7d50\u679c\u4e4b\u63d0\u6607\u662f\u5fc5\u8981\u7684\u3002", "e": "Nasopharyngeal carcinoma (NPC) most often occurs in middle age; it is rarely found in children and young adults. The clinical findings and treatment results in 37 patients with NPC under 30 years of age were retrospectively analyzed. There were 25 males and 12 females. The anatomical extent of disease was described using 1988 AJC classification. Eleven patients (30%) presented with T4lesions, 25 patients (68%) with advanced neck lymphadenopathy (N2+N3), and two patients (6%) with distant metastases. All pateints received radiotherapy, some patients also received chemotherapy as an adjuvant treatment or salvage when distant metastases developed. The overall 5-year survival and disease free survival rates were 56% and 48%, respectively. Radiotherapy is effective in controlling local disease. Occult distant metastases, increasing with more advanced N-stage disease, is the major cause of death and the chief obstacle to successful treatment. The search for an effective adjuvant treatment for systemic control is urgently needed to improve the therapeutic result."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-27-32-a", "title": "\u60e1\u6027\u8166\u90e8\u661f\u7d30\u80de\u7624\u7684\u653e\u5c04\u6cbb\u7642\u8fd1\u6cc1", "keywords": " ", "c": "\u60e1\u6027\u8166\u90e8\u661f\u7d30\u80de\u7624\uff0c\u5305\u62ecanaplastic astrocytoma(AAF)\u53caglioblastoma multiforme (GBM)\uff0c\u662f\u6240\u6709\u60e1\u6027\u8166\u7624\u4e2d\u6700\u5e38\u898b\u4e5f\u6700\u96e3\u8655\u7406\u7684\u764c\u75c5\u3002\u50b3\u7d71\u7684\u6cbb\u7642\u7686\u662f\u5148\u624b\u8853\u5207\u9664\u518d\u5408\u4f75\u7528\u8853\u5f8c\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4ee5\u4e09\u7e3d\u70ba\u4f8b\uff0c\u5728\u904e\u53bb10\u5e74\u4e2d\uff0c\u4e00\u5171\u670956\u4f8b\uff0c\u5176\u4e2dAAF\u4f54\u4e8636\u4f8b\uff0c\u800cGBM\u70ba20\u4f8b\uff0c\u6240\u6709\u75c5\u4eba\u7686\u5148\u63a5\u53d7\u624b\u8853\u5168\u90e8\u6216\u90e8\u4efd\u5207\u9664\u518d\u52a0\u4e0a5,000-6500cGy/5-7wk\u5c0e\u7684\u5149\u5b50\u5c04\u675f\u6cbb\u7642\u3002AAF\u7684\u5e73\u5747\u5b58\u6d3b\u671f\u7d0430\u500b\u6708\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba20\u500b\u6708\uff0c5\u5e74\u5b58\u6d3b\u7387\u70ba30%\uff0c\u800cGBM\u7684\u5e73\u5747\u5b58\u6d3b\u671f\u70ba9\u500b\u6708\uff0c\u4e2d\u503c\u5b58\u6d3b\u671f\u70ba8\u500b\u6708\uff0c\u5b58\u6d3b\u8d85\u904e2\u5e74\u7684\u53ea\u67093\u4f4d\uff0c\u5176\u5e74\u9f61\u5206\u5225\u70ba6\u6b72\u300117\u6b72\u53ca48\u6b72\uff0c\u7d50\u679c\u975e\u5e38\u4e0d\u7406\u60f3\u3002\u5206\u6790\u5176\u5931\u6557\u7684\u539f\u56e0\uff0c\u5927\u90e8\u4efd\u7686\u56e0\u5c40\u90e8\u5fa9\u767c\u800c\u6b7b\u4ea1\uff0c\u4e5f\u5c31\u662f\u816b\u7624\u4e2d\u7684\u7f3a\u6c27\u7d30\u80de\u5f71\u97ff\u5149\u5b50\u5c04\u675f\u7684\u6cbb\u7642\u6548\u679c\u3002\u76ee\u524d\u570b\u5916\u6709\u8a31\u591a\u5c0d\u7f3a\u6c27\u7d30\u80de\u6240\u63d0\u51fa\u7684\u6539\u5584\u8fa8\u6cd5\u4f86\u5c0d\u4ed8AAF\u53caGBM\u7b49\u5169\u7a2e\u60e1\u6027\u8166\u764c\uff0c\u5305\u62ec\u9ad8\u58d3\u6c27\u5408\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u653e\u5c04\u81f4\u7642\u5291\u5408\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u5316\u5b78\u85e5\u7269\u5408\u4f75\u653e\u5c04\u6cbb\u7642\uff0c\u6bcf\u65e5\u591a\u6b21\u653e\u5c04\u6cbb\u7642\uff0c\u91cd\u7c92\u5b50\u653e\u5c04\u6cbb\u7642(heavy particle)\uff0c\u7d44\u7e54\u63d2\u7a2e\u653e\u5c04\u6cbb\u7642\u6216\u5408\u4f75\u9ad8\u719f\u6cbb\u7642\u53ca\u787c\u4e2d\u5b50\u6355\u7372\u6cbb\u7642\u7b49\uff0c\u5c07\u2014\u5206\u5225\u5728\u6587\u4e2d\u8a08\u8ad6\u3002", "e": "Malignant astrocytoma, including Anaplastic astrocytoma(AAF) and Glioblastma Multiforme(GBM), are the most common primary intracranial tumor with high mortality. Conventionally, malignant astrocytoma are treated with surgical resection and postoperative radiotherapy. In past ten years, fifty-six cases of malignant astrocytoma including 36 cases of AAF and 20 cases of GBM were treated with complete or incomplete resection first then followed by postoperative cranial irradiation at Tri-Service General Hospital. The mean and medial survival for AAF were 30 and 20 months, with 30% of 5-y-s-r. For GEM, the mean and median survival were 9 and 8 months, only three cases survived over 2 years. The treatment result was not good. Most of the causes of failure were local recurrence and the attempts to improve disease control with irradiation have focused on the known hypoxic regions of malignant astrocytoma. Several new approaches to improving the efficacy of irradiation on the hypoxic cells of AAF and GBM have been utilized in other countries, it included hyperbaric oxygen, radiosensitizers, hyperfractionation, heavy particle radiotherapy, interstitial brachytherapy, hyperthermia and boron neutron capture therapy. I will discuss the above approaches in this paper."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-33-37-a", "title": "Hyperfractionation for Head & Neck Cancer: a Preliminary Report From Chang-Hua Christian Hospital", "keywords": "\u6bcf\u65e5\u591a\u6b21\u653e\u5c04\u6cbb\u7642 Hyperfractionation", "c": "\u6bcf\u65e5\u7167\u5c04\u5169\u6b21\u4e4b\u7406\u8ad6\u57fa\u790e\u662f\u5728\u665a\u671f\u53cd\u61c9\u7d44\u7e54\u7684\u5fcd\u53d7\u7bc4\u570d\u5167\u6bcf\u6b21\u7d66\u4e88\u8f03\u5c0f\u7684\u5291\u91cf\uff0c\u800c\u63d0\u9ad8\u7e3d\u5291\u91cf\u7684\u653e\u5c04\u6cbb\u7642\u3002\u5176\u4ed6\u7684\u7406\u8ad6\u57fa\u790e\u662f\u7d93\u7531\u518d\u5206\u914d\u8a18\u73fe\u8c61\uff0c\u4f7f\u7d30\u80de\u653e\u5c04\u654f\u611f\u6027\u589e\u52a0\uff0c\u53ca\u5c0d\u6c27\u6548\u61c9\u7684\u4f9d\u5b58\u5ea6\u964d\u4f4e\u3002\u5728 1992 \u5e74 7 \u6708\u81f3 1993 \u5e74 6 \u6708\u9593\uff0c\u6709 19 \u4f8b\u982d\u9838\u90e8\u764c\u75c7\u60a3\u8005\u63a5\u53d7\u6bcf\u65e5\u5169\u6b21\u7167\u5c04\u6cbb\u7642\u3002\u816b\u7624\u539f\u767c\u90e8\u4f4d\u53ca\u9838\u90e8\u6bcf\u6b21\u7167\u5291\u91cf\u70ba 115cGy\u3002\u5169\u6b21\u7167\u5c04\u76f8\u9694\u7d04\u516d\u5c0f\u6642\u3002\u4f7f\u7528 6MV \u7684 X \u5c04\u7dda\uff0c\u6bcf\u5468\u6cbb\u7642\u4e94\u5929\u3002\u5728 6.5 \u5468\u9593\u5206 64-66 \u6b21\uff0c\u7d66\u4e88\u7e3d\u5291\u91cf 7360 cGy-7590cGy . 18 \u4f4d\u60a3\u8005\u816b\u7624\u5b8c\u5168\u6d88\u9000\uff0c\u4e00\u4f4d N3 \u7684\u60a3\u8005\uff0c\u9838\u90e8\u816b\u7624\u90e8\u4efd\u6d88\u9000\u3002\u7d93\u624b\u8853\u5207\u9664\u5f8c\uff0c\u75c5\u7406\u5831\u544a\u8a3c\u5be6\u5df2\u7121\u764c\u7d30\u80de\u5b58\u5728\u3002\u516d\u4f4d\u75c5\u4eba\u767c\u751f\u4e8c\u5ea6\u9ecf\u819c\u708e\uff0c\u5176\u9918 13 \u4f4d\u767c\u751f\u4e09\u5ea6\u9ecf\u819c\u708e\uff0c\u5176\u4e2d\u5169\u4f4d\u9700\u4e2d\u65b7\u62ac\u7642\u4e00\u5468\u3002\u901a\u5e38\u9ecf\u819c\u708e\u5728\u7167\u5c04\u7d50\u675f\u5f8c 1-2 \u5468\u5373\u6d88\u9000\u3002", "e": "The rationale of hyperfraetionation is that the use of smaller dose per fraction allows higher total dose to be administered within the tolerance of late-responding tissues, Other rationales for hyper- fractionation are radiosensitization through redistribution and lesser dependence on oxygen effect. Between July 1992 and June 1993, 19 patients of previously untreated head and neck cancer received treatment with twice-a-day irradiation. A dose of 115 cGy was administered to the primary site and neck at each treatment session. The interfraction interval was usually 6 hours. Treatments were administered 5 days a week using 6 MV x-ray. The total dose was 7360 cGy/64 - 7590 cGy/66 fractions over 6.5 weeks. Complete response achieved in 18 patients. One patient with large neck node (N3) achieved partial response. The residual node was excised, pathological examination showed no evidence of cancer. Six patients developed Grade 2 mucositis, the remaining 13 deve- loped Grade 3 mucositis, two of them necessitated a treatment interruption of one week. Usually the mucositis subsided 1 - 2 weeks after completion of irradiation."}, {"url": "http://www.airitilibrary.com/Publication/Index?DocID=1023988x-199403-1-1-43-46-a", "title": "\u5a66\u764c\u75c5\u4eba\u4e00\u5929\u7167\u5c04\u5169\u6b21\u4e4b\u6587\u737b\u56de\u9867\u53ca\u500b\u4eba\u7d93\u9a57", "keywords": " ", "c": "\u4e00\u5929\u7167\u5c04\u5169\u6b21\u4e4b\u653e\u5c04\u7dda\u6cbb\u7642\u6280\u8853\uff0c\u5c0d\u8f03\u665a\u671f\u4e4b\u986f\u9838\u90e8\u764c\uff0c\u5df2\u6709\u8a31\u591a\u6587\u737b\u5831\u544a\uff0c\u53ef\u4ee5\u589e\u52a0\u5c40\u90e8\u4e4b\u816b\u7624\u63a7\u5236\u7387\uff0c\u800c\u5df2\u5ee3\u6c3e\u5730\u88ab\u4f7f\u7528\u3002\u4f46\u904b\u7528\u5728\u5a66\u79d1\u816b\u7624\u5982\u5b50\u5bae\u764c\u5247\u5f88\u5c11\uff0c\u672c\u9662\u65bc81\u5e74\u6703\u4ee5\u6b64\u65b9\u6cd5\u6cbb\u7642\u5169\u500b\u75c5\u4f8b\uff0c\u4e00\u4f8b\u70ba\u5fa9\u767c\u6027\u5b50\u5bae\u9838\u764c\uff0c\u4e00\u4f8b\u70ba11B\u671f\u5b50\u5bae\u9838\u764c\uff0c\u5747\u4ee5\u4e00\u5929\u7167\u5c04\u5169\u6b21\u6bcf\u6b21\u9593\u96946\u5c0f\u6642\u4ee5\u4e0a\uff0c\u65e9\u4e0a\u7167\u5c04\u524d\u5f8c\u7167\u91ce1.8\u845b\u96f7\uff0c\u4e0b\u5348\u7167\u5c04\u5169\u5074\u7167\u91ce1.2\u845b\u96f7\u3002\u5171\u7167\u5c0415\u5929\uff0c45\u845b\u96f7\uff0c\u7136\u5f8c\u6539\u7528\u4e00\u822c\u6cbb\u7642\u65b9\u6cd5\uff0c\u7b2c\u4e8c\u4f8b\u6709\u52a03\u5929\u4e4bcisplatin \u4f5c\u70ba\u653e\u5c04\u654f\u611f\u5291\uff0c\u5169\u4f8b\u4e4b\u816b\u7624\u63a7\u5236\u90fd\u5f88\u597d\uff0c\u5df2\u7dad\u630117\u500b\u6708\uff0c\u4f46\u5169\u4f8b\u5747\u6709\u8f03\u660e\u986f\u4e4b\u6025\u6027\u53cd\u61c9\u5305\u62ec\u8179\u7009\uff0c\u88e1\u6025\u5f8c\u91cd\uff0c\u767d\u8840\u7403\u964d\u4f4e\u7b49\uff0c\u9700\u4f11\u606f\u4e00\u81f3\u4e8c\u5468\u3002\u6587\u737b\u5831\u544a\u65b9\u9762\uff0c\u53ea\u6709\u5169\u7bc7\u7528\u6b64\u6280\u8853\u6cbb\u7642\u5b50\u5bae\u9838\u764c\uff0c\u7d50\u679c\u816b\u7624\u63a7\u5236\u4e26\u6c92\u6709\u6bd4\u4e00\u822c\u6cbb\u7642\u65b9\u6cd5\u589e\u52a0\uff0c\u800c\u6025\u6027\u53cd\u61c9\u5247\u6709\u5f88\u660e\u986f\u7684\u589e\u52a0\u3002\u7531\u65bc\u7528\u4e00\u5929\u7167\u5c04\u5169\u6b21\u4e4b\u6280\u8853\u61c9\u7528\u5728\u5a66\u764c\u65b9\u9762\u53ef\u80fd\u589e\u52a0\u4e00\u4e9b\u6025\u6027\u526f\u4f5c\u7528\uff0c\u800c\u816b\u7624\u63a7\u5236\u7387\u4e26\u6c92\u6709\u660e\u986f\u589e\u52a0\uff0c\u6545\u5f88\u5c11\u4f7f\u7528\u3002", "e": "That the radiotherapy with hyperfractionation technique can improve the local tumor control rate has been reported in lots of literature in therapy for advanced head and neck cancers and other cancers but little in gynecological cancers. In 1992 we treated 2 cases with carcinoma of the uterine cervix by two fractions per day. Case I had recurrent tumor in the vaginal cuff and case II had FIGO stage IIB disease. Both cases received hyperfractionation with 1.8 Gy from AP and PA portals in the morning and 1.2 Gy from bilateral opposing portals in the afternoon at interval of at least 6 hours. We delivered up to 45 Gy in lsdays, rested for 1-2 weeks, and then changed the dose as in the conventional radiotherapy with 2 Gy per day. Case I totally received 72.6 Gy in 43 fractions in 59 days. Case II received 65 Gy in 40 fractions in 45 days. Case II also received concomitant chemotherapy with 30 mg cisplatin for 3 days in the second week of radiotherapy as a radiation sensitizer and intracavitary brachytherapy to the uterine cavity with 500 cGy to point A for each treatment and totally for 5 treatments after external radiotherapy. After radiotherapy both cases developed moderate to severe acute reactPons including diarrhea, tenesmus and low white count in 2 weeks of the hyperfractionation treatment. But the acute reactions were soon recovered after a rest of 1-2 weeks. In our follow-up as of July 1993, there was no late complication and the case were with good local controland without distant metastasis up to 17 months. The literature, review demonstrated only 2 reports regarding hyperfractionation of the gynecological cancershad been reported. The local tumor control in is 2 reports did not show any significant improvement and the increased acute normal tissue reactions showed in one report. In conclusion, hyperfractionation technique for gynecological cancers may induce more acute reactions but may not increase the local control rate, so, it is not frequently applied in the therapy for gynecological cancers."}]